<SEC-DOCUMENT>0000875045-19-000006.txt : 20190206
<SEC-HEADER>0000875045-19-000006.hdr.sgml : 20190206
<ACCEPTANCE-DATETIME>20190206172115
ACCESSION NUMBER:		0000875045-19-000006
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		188
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190206
DATE AS OF CHANGE:		20190206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		19572382

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>biib-20181231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sAD2358921284584CB1C4DD7A5181E334"></a></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:14pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">Washington,&#160;D.C. 20549</font></div><div style="line-height:100%;text-align:center;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;font-weight:bold;">Form&#160;10-K</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">For the fiscal year ended December 31, 2018</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">or</font></div><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Commission file number:&#160;0-19311</font></div><div style="line-height:120%;text-align:center;"><img src="biogenlogoa04.jpg" alt="biogenlogoa04.jpg" style="height:41px;width:126px;"></div><div style="line-height:100%;text-align:center;font-size:24pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:24pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">33-0112644</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(State or other jurisdiction of incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(I.R.S. Employer Identification No.)</font></div></td></tr></table></div></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">225 Binney Street, Cambridge, Massachusetts 02142</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(617)&#160;679-2000</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-style:italic;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Common Stock, $0.0005&#160;par value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">The Nasdaq Global Select Market</font></div></td></tr></table></div></div><div style="line-height:100%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act:</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">None</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section 15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;padding-top:4px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K is not contained herein, and will not be contained, to the best of the registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:100%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:38%;"></td><td style="width:24%;"></td><td style="width:38%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Large&#160;accelerated&#160;filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accelerated&#160;filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-accelerated&#160;filer </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Emerging growth company&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) computed by reference to the price at which the common stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58,267,511,287</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the registrant had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">196,708,784</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock, $0.0005&#160;par value, outstanding.</font></div><div style="line-height:100%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:100%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Portions of the definitive proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Annual Meeting of Stockholders are incorporated by reference into Part&#160;III of this report.</font></div><div style="line-height:100%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s3C1ADEED17A553A5BA51EF8AA48A0BF1"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">ANNUAL REPORT ON FORM&#160;10-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">For the Year Ended December 31, 2018</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">TABLE OF CONTENTS</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:76%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#sD31DCEF7FF455441AC964949646A016C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;I</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s36DA7FAF4FB95D31A42FA1DE7F4A7048"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s36DA7FAF4FB95D31A42FA1DE7F4A7048"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s36DA7FAF4FB95D31A42FA1DE7F4A7048">1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s022B08E42B265BE8A0F8842ACF5078F0"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;1A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s022B08E42B265BE8A0F8842ACF5078F0"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s022B08E42B265BE8A0F8842ACF5078F0">34</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5D0C6888D8895790B56EC9590AF1F523"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 1B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5D0C6888D8895790B56EC9590AF1F523"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s5D0C6888D8895790B56EC9590AF1F523">47</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0EB35F22F75B5B3EA9585C21A9E8FB22"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 2.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0EB35F22F75B5B3EA9585C21A9E8FB22"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0EB35F22F75B5B3EA9585C21A9E8FB22">47</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s14E4E2157A4F53D8A155CA297B50FF0C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 3.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s14E4E2157A4F53D8A155CA297B50FF0C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s14E4E2157A4F53D8A155CA297B50FF0C">48</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s7A5F84AB4804540A907D9546E5A9683C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 4.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s7A5F84AB4804540A907D9546E5A9683C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s7A5F84AB4804540A907D9546E5A9683C">48</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s69F1031EA97551128CD40642A48F4AD5"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;II</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1F9B5B7DB082508A8FFA50D2978EA272"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 5.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1F9B5B7DB082508A8FFA50D2978EA272"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1F9B5B7DB082508A8FFA50D2978EA272">49</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0B9D923A3D235F1A8A4C01BDA429E13D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 6.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0B9D923A3D235F1A8A4C01BDA429E13D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0B9D923A3D235F1A8A4C01BDA429E13D">51</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s9D7322C2A1975C1EBBECDC47FFCD4CEF"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 7.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s9D7322C2A1975C1EBBECDC47FFCD4CEF"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s9D7322C2A1975C1EBBECDC47FFCD4CEF">54</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1AAD106F9942510EA9D1ED17127FC3BD"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 7A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1AAD106F9942510EA9D1ED17127FC3BD"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s1AAD106F9942510EA9D1ED17127FC3BD">91</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s707669BEDD62597F890CB2C96561EF2E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 8.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s707669BEDD62597F890CB2C96561EF2E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s707669BEDD62597F890CB2C96561EF2E">93</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA44DEFFC3AE759329E20668C2428D25C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA44DEFFC3AE759329E20668C2428D25C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sA44DEFFC3AE759329E20668C2428D25C">93</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s685EB8586ABF5521B00BA9CE09EE9B2C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9A.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s685EB8586ABF5521B00BA9CE09EE9B2C"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s685EB8586ABF5521B00BA9CE09EE9B2C">93</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBECF0D29E08A56B1B9896105AF82ABFA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 9B.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBECF0D29E08A56B1B9896105AF82ABFA"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBECF0D29E08A56B1B9896105AF82ABFA">94</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s20A44D7D03C353008B5ED16E08178407"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;III</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s759E1402DD4D53A2B9692EBE1D0C1AE6"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 10.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s759E1402DD4D53A2B9692EBE1D0C1AE6"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s759E1402DD4D53A2B9692EBE1D0C1AE6">95</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD05F9BB43BA95FAA93131247B9576039"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 11.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD05F9BB43BA95FAA93131247B9576039"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Compensation</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD05F9BB43BA95FAA93131247B9576039">95</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0862E8EC77275FD4A6A1E9B40F4BD221"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 12.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0862E8EC77275FD4A6A1E9B40F4BD221"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0862E8EC77275FD4A6A1E9B40F4BD221">95</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD77AE4903CB557C099CADD03CAD43FE3"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 13.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD77AE4903CB557C099CADD03CAD43FE3"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sD77AE4903CB557C099CADD03CAD43FE3">95</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCED3B1F81C4653039612D625277168CC"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 14.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCED3B1F81C4653039612D625277168CC"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Principal Accountant Fees and Services</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sCED3B1F81C4653039612D625277168CC">95</a></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;" href="#s37EDD5FDE9AC550FBA3E16DEDCD24B7E"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PART&#160;IV</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0D23296250B4568CA1D49B383D8835B6"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item&#160;15.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0D23296250B4568CA1D49B383D8835B6"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exhibits and Financial Statement Schedules</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s0D23296250B4568CA1D49B383D8835B6">96</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s268CC2A2702357C9ADD89AFC28D3704B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Item 16.</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s268CC2A2702357C9ADD89AFC28D3704B"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form 10-K Summary</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s268CC2A2702357C9ADD89AFC28D3704B">96</a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBDDF3826BF6950A9A1BA42CCC959AD8F"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#sBDDF3826BF6950A9A1BA42CCC959AD8F">100</a></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s4493835284205B3683A1DE1DFEFFA63D"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;" href="#s4493835284205B3683A1DE1DFEFFA63D">F- 1</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="s2DDEB1D6B66E532AB05BC9276A2337F3"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated amount, timing and accounting of revenues; contingent, milestone, royalty and other payments under licensing, collaboration or acquisition agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expenses; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expectations, plans and prospects relating to sales, pricing, growth and launch of our marketed and pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of increased product competition in the markets in which we compete, including increased competition from generics, biosimilars, prodrugs and other products approved under alternative regulatory pathways;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our plans and investments in our core and emerging growth areas, as well as implementation of our 2017 corporate strategy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the drivers for growing our business, including our plans and intent to commit resources relating to research and development programs and business development opportunities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to finance our operations and business initiatives and obtain funding for such activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the costs and timing of potential clinical trials, filings and approvals, and the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse safety events involving our marketed products or generic or biosimilar products marketed by others;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact of healthcare reform in the United States (U.S.) and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our manufacturing capacity, use of third-party contract manufacturing organizations and plans and timing relating to the expansion of our manufacturing capabilities, including anticipated investments and activities in new manufacturing facilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated benefits and the potential costs and expenses related to our current or future initiatives to streamline our operations and reallocate resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe and our collection of accounts receivable in such countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the potential impact on our results of operations and liquidity of the United Kingdom's (U.K.) intent to voluntarily depart from the European Union (E.U.);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the impact of new laws, regulatory requirements, judicial decisions and accounting standards; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:9px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the anticipated costs and tax treatment of the spin-off of our hemophilia business as well as the timeline for selling substantially all remaining hemophilia related inventory.</font></div></td></tr></table><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These forward-looking statements involve risks and uncertainties, including those that are described in Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report and elsewhere in this report that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</font></div><div><a name="s15102290540B5EBCB4EB2FFC9F5FD40B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in this report to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">"ELOCTATE" refers to both ELOCTATE (the trade name for Antihemophilic Factor (recombinant), Fc Fusion Protein in the U.S., Canada and Japan) and ELOCTA (the trade name for Antihemophilic Factor (recombinant), Fc Fusion Protein in the E.U.).</font></div></td></tr></table><div><a name="s2D463BFF895A5AAD9604CD8B41BA66BD"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">NOTE&#160;REGARDING TRADEMARKS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and ZINBRYTA&#174; are registered trademarks of Biogen. BENEPALI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FLIXABI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, FUMADERM</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and IMRALDI</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM </sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">are trademarks of Biogen. ALPROLIX&#174;, ELOCTATE&#174;, ENBREL&#174;, FAMPYRA</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, GAZYVA&#174;, HUMIRA&#174;, OCREVUS&#174;, REMICADE&#174; and other trademarks referenced in this report are the property of their respective owners.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="sD31DCEF7FF455441AC964949646A016C"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;I</font></div><div><a name="s36DA7FAF4FB95D31A42FA1DE7F4A7048"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;1. &#160;&#160;&#160;&#160;Business</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&#8217;s disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also manufacture and commercialize biosimilars of advanced biologics.</font><img src="biogenbubbles.jpg" alt="biogenbubbles.jpg" style="height:157px;width:682px;"></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), Parkinson's disease, ALS, stroke, epilepsy, cognitive impairment associated with schizophrenia (CIAS) and pain.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilar products through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U. For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s37A6ED8D5C0D5A37856D6EA76AF449BD"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Key Business Developments</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of key developments affecting our business since the beginning of 2018. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisitions, collaborative and other relationships discussed below, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and Note 27, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions, Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB100 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired BIIB100 (formerly known as KPT-350) from Karyopharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 ready investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XP01, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB104 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we acquired BIIB104 (formerly known as PF-04958242) from Pfizer Inc. (Pfizer). BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for CIAS, representing our first program in neurocognitive disorders. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2018 we made a $50.0 million payment to Neurimmune SubOne AG (Neurimmune) under the terms of our amended collaboration and license agreement with Neurimmune (as amended, the Neurimmune Agreement) to reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, our anti-amyloid beta antibody candidate for the treatment of AD, by 5%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, will now range from the high single digits to sub-teens.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we closed a 10-year exclusive agreement with Ionis Pharmaceuticals, Inc. (Ionis) to develop novel antisense oligonucleotide (ASO) drug candidates for a broad range of neurological diseases (the 2018 Ionis Agreement). We have the option to license therapies arising out of the 2018 Ionis Agreement and will be responsible for the development and potential commercialization of such therapies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TMS Co., Ltd. Option Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we entered into an exclusive option agreement with TMS Co., Ltd. (TMS) granting us the option to acquire TMS-007, a plasminogen activator with a novel mechanism of action (MOA) associated with breaking down blood clots, which is in Phase 2 development in Japan, and backup compounds for the treatment of stroke.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement with Samsung BioLogics to increase our ownership percentage in Samsung Bioepis from approximately 5% to approximately 49.9%. The share purchase transaction was completed in November 2018.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB110 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we acquired BIIB110 (formerly known as ALG-801) (Phase 1a) and ALG-802 (preclinical) from AliveGen Inc. (AliveGen). BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 in multiple neuromuscular indications, including SMA and ALS.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB067 Option Exercise</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), an investigational treatment for ALS with superoxide dismutase 1 (SOD1) mutations. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">C4 Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we entered into a collaborative research and license agreement with C4 Therapeutics (C4T) to investigate the use of C4T&#8217;s novel protein degradation platform to discover and develop potential new treatments </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">for neurological diseases, such as AD and Parkinson&#8217;s disease. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk&#8217;s SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration. </font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Key Developments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ZINBRYTA Withdrawal</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 we and AbbVie Inc. (AbbVie) announced the voluntary worldwide withdrawal of ZINBRYTA for RMS.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we began to recognize revenues on sales of IMRALDI, an adalimumab biosimilar referencing HUMIRA, to third parties in the E.U. We and Samsung Bioepis previously entered into an agreement with AbbVie for the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. </font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2018 Share Repurchase Program</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to $3.5 billion of our common stock (2018 Share Repurchase Program). Our 2018 Share Repurchase Program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s518947E3EFC85397A3D6C07D238A575F"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product and Pipeline Developments</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Core Growth Areas</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Multiple Sclerosis and Neuroimmunology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">TECFIDERA (dimethyl fumarate)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we presented new real-world data that demonstrated that people with RMS treated with TECFIDERA early in the course of their disease may experience better long-term outcomes. These data were presented at the 70</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of the American Academy of Neurology (AAN) in Los Angeles, CA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we presented clinical and real-world evidence that further support the long-term efficacy and well characterized safety of TECFIDERA early within the disease course. These data were presented at the 34</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Berlin, Germany.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">TYSABRI (natalizumab)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018, at the 70</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of the AAN in Los Angeles, CA, we presented new real-world data that demonstrated that people with RMS treated with TYSABRI early in the course of their disease may experience better long-term outcomes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we presented observational data that demonstrated that extended interval dosing with TYSABRI is associated with a significant reduction in the risk of progressive multifocal leukoencephalopathy (PML), a serious brain injury, compared with standard interval dosing in the TOUCH prescribing program. These data were presented at the 70</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of the AAN in Los Angeles, CA. In November 2018 we initiated the Phase 3b NOVA study evaluating the efficacy and safety of extended interval dosing (every six weeks) for natalizumab compared to standard interval dosing in patients with RMS and enrolled the first patient in December 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we presented clinical and real-world evidence that further support the long-term efficacy and well characterized safety of TYSABRI early within the disease course. These data were presented at the 34</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Congress of ECTRIMS in Berlin, Germany.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">PLEGRIDY (peginterferon beta-1a)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we dosed the first patient in a bioequivalence study to test whether exposure levels of PLEGRIDY are maintained with intramuscular administration.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">ZINBRYTA (daclizumab)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 we and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for RMS.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB098 (formerly known as ALKS 8700) (diroximel fumarate; DRF)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 MRI and relapse results from the Phase 3 EVOLVE-MS-1 study for diroximel fumarate in patients with relapsing remitting MS (RRMS) were presented at the 70</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of the AAN in Los Angeles, CA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for diroximel fumarate. Alkermes is seeking approval of diroximel fumarate under the 505(b)(2) regulatory pathway. If approved, we intend to market diroximel fumarate under the brand name VUMERITY. This name has been conditionally accepted by the FDA and will be confirmed upon approval.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Opicinumab (anti-LINGO)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 we completed enrollment of the Phase 2b AFFINITY study, evaluating opicinumab as an add-on therapy in MS patients who are adequately controlled on their anti-inflammatory disease-modifying therapy (DMT), versus the DMT alone.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neuromuscular Disorders</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">SPINRAZA (nusinersen)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2018 the end of study results from CHERISH, the Phase 3 study evaluating SPINRAZA for the treatment of individuals with later-onset SMA, were published in The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">New England Journal of Medicine</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Results from CHERISH demonstrated meaningful motor function and upper limb improvements in individuals with later-onset SMA rarely seen in the natural course of the disease, which is typically a continued decline in motor function over time.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 we presented new interim Phase 2 results from NURTURE, the ongoing open-label, single-arm study evaluating the efficacy and safety of SPINRAZA among pre-symptomatic infants with SMA. In NURTURE, all infants treated with SPINRAZA were alive, did not require permanent ventilation and showed improvement in motor function and motor milestone achievements as of July 5, 2017, compared to the disease's natural history. We also presented a case series demonstrating SPINRAZA's effectiveness among teens and young adults. These data were presented at the Muscular Dystrophy Association Clinical Conference in Arlington, VA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we presented data from the CS2/CS12 studies that demonstrated that with SPINRAZA treatment, older patients were able to walk longer distances while experiencing stable or less fatigue at the same time, in contrast to natural history. The study participants have Type 2 or Type 3 SMA and were ages 12 to 15 years at study enrollment.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:54px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also presented data on part one of the Phase 2 EMBRACE study as well as an interim analysis of the SHINE open-label extension study, which examined the longer-term safety and efficacy of SPINRAZA in infantile-onset SMA patients.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:54px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These data were presented at the 70</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of the AAN in Los Angeles, CA.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we presented data from our SPINRAZA clinical development program for SMA at the Cure SMA 2018 Annual SMA Conference in Dallas, TX. Platform and poster presentations highlighted interim analyses from the SHINE and NURTURE studies, which assess SPINRAZA's safety and efficacy among those with infantile-onset SMA, and data on the utility of plasma phosphorylated neurofilament heavy chain (pNF-H) as a potential biomarker for SMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we presented new interim results from NURTURE, an ongoing open-label, single-arm efficacy and safety study of SPINRAZA in 25 presymptomatic infants with SMA at the Annual Congress of the World Muscle Society held in Mendoza, Argentina. As of May 2018 all NURTURE study participants were alive and none required permanent ventilation, in contrast to the natural history of SMA. In addition, 100% of study participants achieved the motor milestone of sitting independently, 88% were able to walk with assistance and 77% were able to walk independently. All NURTURE study participants were older than 15 months at the time of the analysis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 we were awarded the 2018 International Prix Galien as Best Biotechnology Product for SPINRAZA. The prestigious honor marks the seventh Prix Galien for SPINRAZA, following country recognitions in the U.S., Germany, Italy, Belgium-Luxembourg, the Netherlands, and the U.K. The International Prix Galien is given every two years by Prix Galien International Committee members in recognition of excellence in scientific innovation to improve human health.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB089 - SMA</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2018 we submitted an Investigational New Drug Application for BIIB089 in SMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we announced that the FDA had placed BIIB089 on a clinical hold.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB078 (IONIS-C9</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">) - ALS</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 we enrolled the first patient in the Phase 1 study evaluating BIIB078, an ASO drug candidate, in adults with C9ORF72-associated ALS.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB067 (IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">) - ALS</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we and Ionis announced results from a positive interim analysis of the ongoing Phase 1 study of BIIB067 in ALS with SOD1 mutations. The interim analysis showed that, over a three month period, </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:54px;padding-top:6px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BIIB067 resulted in a statistically significant lowering of SOD1 protein levels in the cerebrospinal fluid and a numerical trend towards slowing of clinical decline as measured by the ALS Functional Rating Scale Revised, both compared to placebo.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Alzheimer's Disease and Dementia</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Aducanumab (A&#946; mAb)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2018 we announced that, following a pre-planned blinded sample size review of the data per study protocol and based on variability in the primary endpoint that was greater than study protocol assumed, we increased the sample size of ENGAGE and EMERGE, the Phase 3 studies of aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 we presented data from the long-term extension (LTE) of the Phase 1b PRIME study of aducanumab at the Advances in Alzheimer's and Parkinson's Therapies (AAT-AD/PD) Focus Meeting in Torino, Italy. The data presentation included the Centiloid scale, a method used to standardize the aducanumab Phase 1b PRIME study amyloid-PET (positron emission tomography) results as previously measured by the composite Standardized Uptake Value Ratio.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we presented 36-month data and 24-month titration data from the Phase 1b PRIME study of aducanumab at the 70</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of the AAN in Los Angeles, CA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we completed enrollment of ENGAGE and EMERGE, the Phase 3 studies of aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we presented a new analysis from the Phase 1b PRIME study of aducanumab at the Alzheimer's Association International Conference (AAIC) 2018 in Chicago, IL. These data included a poster presentation on the 24-month analysis of APOE &#949;4 carriers in the Phase 1b PRIME study and a platform presentation on the 24-month clinical dementia rating scale analysis of the Phase 1b PRIME study.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 we and our collaboration partner Eisai Co., Ltd. (Eisai) announced results from a recent analysis of the ongoing LTE of the Phase 1b PRIME study of aducanumab. The updated analyses include data from the placebo-controlled period and LTE for patients treated with aducanumab up to 36 months in the titration cohort and up to 48 months in the fixed dose cohorts. The results are generally consistent with previous interim analyses, and there were no changes to the risk-benefit profile of aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we presented data on the efficacy of aducanumab and the cumulative safety data from the LTE of the Phase 1b PRIME study of patients with prodromal and mild Alzheimer's disease. These data were presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual meeting in Barcelona, Spain. These results are generally consistent with previous interim analyses, and there were no changes to the risk-benefit profile of aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 we initiated a Phase 2 study of aducanumab to assess the clinical relevance of asymptomatic amyloid related imaging abnormalities (ARIA). This Phase 2 study was not required by regulators and is not necessary for registration.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BAN2401 (A&#946; mAb)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2017 we and our collaboration partner Eisai announced that the Phase 2 study of BAN2401, a monoclonal antibody that targets amyloid beta aggregates, an Eisai product candidate for the treatment of AD, did not meet the criteria for success based on a Bayesian analysis at 12 months as the primary endpoint in an 856-patient Phase 2 clinical study, an endpoint that was designed to enable a potentially more rapid entry into Phase 3 development. In July 2018, based upon the final analysis of the data at 18 months, we and Eisai announced that the topline results from the Phase 2 study demonstrated a statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain. The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer&#8217;s Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured using amyloid-PET. In July 2018 Eisai presented this data in an oral session at AAIC 2018 in Chicago, IL.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 our collaboration partner Eisai presented clinical and biomarker updates from the Phase 2 study of BAN2401 at the CTAD annual meeting in Barcelona, Spain.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Elenbecestat (E2609)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we and our collaboration partner Eisai announced that elenbecestat, the oral BACE (beta amyloid cleaving enzyme) inhibitor, demonstrated an acceptable safety and tolerability profile in the Phase 2 study, and the results demonstrated a statistically significant difference in amyloid-beta levels in the brain measured by amyloid-PET. A numerical slowing of decline in functional clinical scales of a potentially clinically important difference was also observed, although this effect was not statistically significant. In July 2018 the data were featured in an Eisai poster presentation at AAIC 2018 in Chicago, IL.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 our collaboration partner Eisai presented safety and efficacy data for elenbecestat from the Phase 2 study in mild cognitive impairment-to-moderate AD at the CTAD annual meeting in Barcelona, Spain.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB092 (anti-tau mAb)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2018 we initiated a Phase 2 study of BIIB092 for AD.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Movement Disorders</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB054 (&#945;-synuclein antibody) - Parkinson's Disease</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we dosed the first patient in the Phase 2 SPARK study of BIIB054 in Parkinson's disease.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we presented Phase 1 study results for BIIB054 in Parkinson's disease at the 70</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of the AAN in Los Angeles, CA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we presented an overview of the design of the Phase 2 SPARK study of BIIB054 in Parkinson's disease at the International Congress of Parkinson's Disease and Movement Disorders in Hong Kong.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB092 (anti-tau mAb) - PSP</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 we presented data regarding details about the design of the ongoing Phase 2 PASSPORT study of BIIB092 for PSP at the AAT-AD/PD Focus Meeting in Torino, Italy.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we presented Phase 1 study results of BIIB092 for PSP as well as details about the design of the ongoing Phase 2 PASSPORT study of BIIB092 for PSP at the 70</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of the AAN in Los Angeles, CA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 we completed enrollment of the Phase 2 PASSPORT study of BIIB092 for PSP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 the FDA granted BIIB092 fast track designation for PSP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we presented safety data from the Phase 1 LTE study of BIIB092 for PSP and baseline demographics from the Phase 2 PASSPORT study of BIIB092 for PSP at the International Congress of Parkinson's Disease and Movement Disorders in Hong Kong.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Emerging Growth Areas</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acute Neurology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB093 (glibenclamide IV) - Large Hemispheric Infarction</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 we enrolled the first patient in the Phase 3 CHARM study of BIIB093 in large hemispheric infarction (LHI), a severe form of ischemic stroke.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Natalizumab (&#945;4-integrin inhibitor) - Epilepsy</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 we dosed the first patient in the Phase 2 OPUS study of natalizumab in drug-resistant focal epilepsy.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurocognitive Disorders</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB104 (AMPA) - CIAS</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we dosed the first patient in our Phase 2b study of BIIB104 in CIAS.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Pain</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">Vixotrigine (BIIB074) - Small Fiber Neuropathy</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2018 we initiated a Phase 2 study of BIIB074 in small fiber neuropathy (SFN).</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">BIIB095 (Nav 1.7) - Neuropathic Pain</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 we initiated a Phase 1 study of BIIB095, a Nav 1.7 inhibitor for neuropathic pain.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Samsung Bioepis - Biogen's Joint Venture with Samsung BioLogics</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we and Samsung Bioepis announced pooled analysis results from three separate Phase 3 studies comparing the efficacy and safety of BENEPALI in reference to etanercept, FLIXABI in reference to infliximab and IMRALDI in reference to adalimumab in patients with moderate to severe rheumatoid arthritis. The data indicated that the incidence of anti-drug antibodies was comparable between the biosimilars and their reference products and that radiographic progression of disease was minimal and comparable across all treatment groups. The data were presented at the Annual European Congress of Rheumatology (EULAR 2018) in Amsterdam, Netherlands.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">IMRALDI (Adalimumab)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we and Samsung Bioepis launched IMRALDI, an adalimumab biosimilar referencing HUMIRA, in Europe. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Genentech Relationship</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-CD20 Therapies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">OCREVUS (ocrelizumab)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 the European Commission (EC) granted a marketing authorization for OCREVUS for the treatment of RMS and PPMS.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;">RITUXAN (rituximab)</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 the FDA approved RITUXAN for the treatment of adult patients with moderate to severe pemphigus vulgaris. Subsequently, the FDA confirmed orphan-drug exclusivity associated with this approval.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BG00011 (STX-100) - Idiopathic Pulmonary Fibrosis</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 we dosed the first patient in the Phase 2b study of BG00011 in idiopathic pulmonary fibrosis (IPF), a chronic irreversible and ultimately fatal disease characterized by a progressive decline in lung function.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Dapirolizumab Pegol (anti-CD40L) - Systemic Lupus Erythematosus</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we and our collaboration partner UCB announced top-line results from the Phase 2b study evaluating the safety and efficacy of dapirolizumab pegol (DZP), an anti-CD40L pegylated Fab, in adults with moderately-to-severely active systemic lupus erythematosus (SLE) despite receiving standard-of-care treatment such as corticosteroids, anti-malarials and non-biological immunosuppressants. The primary endpoint of the study, which was to demonstrate a dose response at 24 weeks on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA), was not met (p=0.06). The study did demonstrate consistent and potentially meaningful improvements for the majority of clinical endpoints in patients treated with DZP compared with placebo. In addition, biomarker data demonstrated evidence of proof of biology and DZP demonstrated an acceptable safety profile.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Discontinued Programs</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2018 we announced that the Phase 2b dose-ranging ACTION study investigating natalizumab in individuals with acute ischemic stroke (AIS) did not meet its primary endpoint. Based on these results, we have discontinued development of natalizumab in AIS. The results of the Phase 2b ACTION study do not impact the benefit-risk profile of natalizumab in approved indications, including MS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we announced that we completed the Phase 2b study of vixotrigine (BIIB074) for the treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:54px;padding-top:6px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">efficacy endpoints and we have discontinued development of vixotrigine for the treatment of PLSR. The safety data were consistent with the safety profile reported in previous studies.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we notified Applied Genetic Technologies Corporation (AGTC) of the termination of our collaboration agreement with AGTC. The termination of this collaboration agreement will be effective in March 2019. As a result, we will have no further involvement in the development of BIIB087, an investigational adeno-associated virus (AAV)-based gene therapy for the treatment of X-linked Retinoschisis (XLRS), BIIB088, an investigational AAV-based gene therapy for the treatment of X-linked Retinitis Pigmentosa (XLRP), and early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we notified the University of Pennsylvania (UPenn) that we will be terminating certain programs under our collaboration and alliance with UPenn, including the development of therapeutic approaches that target the eye, skeletal muscle and central nervous system and research and validation of next generation gene transfer technology using AAV gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform. The termination of these programs will be effective in May 2019. This termination did not impact our collaboration with UPenn for the development of BIIB089 for the treatment of SMA.</font></div></td></tr></table><div><a name="s78FA52EE07975A4EAAB28C7396437511"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Marketed Products</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following graph shows our revenues by product and revenues from anti-CD20 therapeutic programs for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;"><img src="marketedproducts18.jpg" alt="marketedproducts18.jpg" style="height:508px;width:666px;"></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Interferon includes product revenues from AVONEX and PLEGRIDY.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">For 2018, 2017 and 2016 other includes product revenues from FAMPYRA, FUMADERM, BENEPALI, FLIXABI and ZINBRYTA. For 2018 other also includes product revenues from IMRALDI, which was launched in Europe in October 2018. For 2017 </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">and 2016 other also includes product revenues from ALPROLIX and ELOCTATE through January 31, 2017. No product revenues for ELOCTATE and ALPROLIX were recognized subsequent to February 1, 2017, the effective date of the spin-off of our hemophilia business.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Anti-CD20 therapeutic programs includes revenues from RITUXAN, RITUXAN HYCELA, GAZYVA and OCREVUS.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product sales for TECFIDERA, AVONEX and TYSABRI as well as our share of pre-tax profits in the U.S. for RITUXAN each accounted for more than 10% of our total revenues for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Product sales for SPINRAZA also accounted for more than 10% of our total revenues for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional financial information about our product and other revenues and geographic areas where we operate, please read Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and Note&#160;25, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report and Item&#160;6. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Selected Financial Data </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Item 7. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management's Discussion and Analysis of Financial Condition and Results of Operations </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">included in this report. A discussion of the risks attendant to our operations is set forth in Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis and Neuroimmunology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve cells, leading to a loss of muscle control, paralysis and, in some cases, death. Patients with active RMS experience an uneven pattern of disease progression characterized by periods of stability that are interrupted by flare-ups of the disease after which the patient returns to a new baseline of functioning. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our MS products and major markets are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="tecfidera.jpg" alt="tecfidera.jpg" style="height:37px;width:172px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS in the U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RRMS in the E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="avonex.jpg" alt="avonex.jpg" style="height:49px;width:134px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="plegridy.jpg" alt="plegridy.jpg" style="height:77px;width:128px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS in the U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RRMS in the E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="tysabri.jpg" alt="tysabri.jpg" style="height:62px;width:114px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RRMS in the E.U.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Crohn's disease in the U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="fampyra.jpg" alt="fampyra.jpg" style="height:37px;width:133px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Walking ability for patients with MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acorda Therapeutics, Inc. (Acorda)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Neuromuscular Disorders</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SMA is characterized by loss of motor neurons in the spinal cord and lower brain stem, resulting in severe and progressive muscular atrophy and weakness. Ultimately, individuals with the most severe type of SMA can become paralyzed and have difficulty performing the basic functions of life, like breathing and swallowing. Due to a loss of, or defect in, the SMN1 gene, people with SMA do not produce enough survival motor neuron (SMN) protein, which is critical for the maintenance of motor neurons. The severity of SMA correlates with the amount of SMN protein. People with Type 1 SMA, the most severe life-threatening form, produce very little SMN protein and do not achieve the ability to sit without support or live beyond two years without respiratory support. People with Type 2 and Type 3 SMA produce greater amounts of SMN protein and have less severe, but still life-altering, forms of SMA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our SMA product and major markets are as follows: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><img src="spinrazalogonewa01.jpg" alt="spinrazalogonewa01.jpg" style="height:80px;width:160px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SMA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brazil</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Turkey</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars are a group of biologic medicines that are similar to currently available biologic therapies known as originators. Under our agreement with Samsung Bioepis, we manufacture and commercialize three anti-tumor necrosis factor (TNF) biosimilars in certain countries in the E.U.: BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our biosimilar products and major markets are as follows: </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="benepalia04.jpg" alt="benepalia04.jpg" style="height:74px;width:173px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Moderate to severe rheumatoid arthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Progressive psoriatic arthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Axial spondyloarthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Moderate to severe plaque psoriasis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Norway</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sweden</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.K</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="flixabi.jpg" alt="flixabi.jpg" style="height:85px;width:162px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis<br>Moderate to severe Crohn's disease<br>Severe ulcerative colitis<br>Severe ankylosing spondylitis<br>Psoriatic arthritis<br>Moderate to severe plaque psoriasis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="imraldi.jpg" alt="imraldi.jpg" style="height:89px;width:173px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Axial spondyloarthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Psoriatic arthritis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Psoriasis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paediatric plaque psoriasis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hireadenitis suppurativa</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Crohn's disease</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Paediatric Crohn's disease</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ulcerative colitis</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Uveitis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have agreements with Genentech that entitle us to certain business and financial rights with respect to RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS and other potential anti-CD20 therapies. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current anti-CD20 therapeutic programs and major markets are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="rituxan.jpg" alt="rituxan.jpg" style="height:46px;width:128px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-Hodgkin's lymphoma</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CLL</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rheumatoid arthritis</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Two forms of ANCA-associated vasculitis</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pemphigus vulgaris</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="rituxanhycelalogo300x87.jpg" alt="rituxanhycelalogo300x87.jpg" style="height:48px;width:165px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-Hodgkin's lymphoma</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CLL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="gazyva.jpg" alt="gazyva.jpg" style="height:73px;width:97px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In combination with chlorambucil for previously untreated CLL</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Follicular lymphoma</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In combination with chemotherapy followed by GAZYVA alone for previously untreated follicular lymphoma</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="ocrevus.jpg" alt="ocrevus.jpg" style="height:49px;width:165px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RMS</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PPMS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australia</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Genentech, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Indication</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Collaborator</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Major Markets</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;"><img src="fumaderm.jpg" alt="fumaderm.jpg" style="height:45px;width:116px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Moderate to severe plaque psoriasis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><a name="s0CD49000A664572E908209DCA1A5F3A2"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Patient Support and Access</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We interact with patients, advocacy organizations and healthcare societies in order to gain insights into unmet needs. The insights gained from these engagements help us support patients with services, programs and applications that are designed to help patients lead better lives. Among other things, we provide customer service and other related programs for our products, such as disease and product specific websites, insurance research services, financial assistance programs and the facilitation of the procurement of our marketed products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are dedicated to helping patients obtain access to our therapies. Our patient representatives have access to a suite of financial assistance tools. With those tools, we help patients understand their insurance coverage and, if needed, help patients compare and select new insurance options and programs. In the U.S., we have established programs that provide co-pay assistance or free marketed product for qualified uninsured or underinsured patients, based on specific eligibility criteria. We also provide charitable contributions to independent charitable organizations that assist patients with out-of-pocket expenses associated with their therapy.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Marketing and Distribution</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales Force and Marketing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We promote our products worldwide, including in the U.S., most of the major countries of the E.U. and Japan, primarily through our own sales forces and marketing groups. In some countries, particularly in areas where we continue to expand into new geographic areas, we partner with third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN, RITUXAN HYCELA, GAZYVA and OCREVUS are marketed by the Roche Group and its sublicensees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We co-promote BENEPALI, FLIXABI and IMRALDI with Samsung Bioepis in certain countries in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We focus our sales and marketing efforts on specialist physicians in private practice or at major medical centers. We use customary industry practices to market our products and to educate physicians, such as sales representatives calling on individual physicians, advertisements, professional symposia, direct mail, public relations and other methods. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Distribution Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We distribute our products in the U.S. principally through wholesale distributors of pharmaceutical </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">products, mail order specialty distributors or shipping service providers. In other countries, the distribution of our products varies from country to country, including through wholesale distributors of pharmaceutical products and third-party distribution partners who are responsible for most marketing and distribution activities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN, RITUXAN HYCELA, GAZYVA and OCREVUS are distributed by the Roche Group and its sublicensees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We distribute BENEPALI, FLIXABI and IMRALDI in certain countries in the E.U.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our product sales to two wholesale distributors, AmerisourceBergen and McKesson, each accounted for more than 10% of our total revenues for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and on a combined basis, accounted for approximately 50%, 56% and 57% of our gross product revenues for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information, please read Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div><a name="s163B497619835246BD13A7293E151CC4"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Patents and Other Proprietary Rights</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patents are important to obtaining and protecting exclusive rights in our products and product candidates. We regularly seek patent protection in the U.S.&#160;and in selected countries outside the U.S.&#160;for inventions originating from our research and development efforts. In addition, we license rights to various patents and patent applications. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.&#160;patents, as well as most foreign patents, are generally effective for 20&#160;years from the date the earliest application was filed; however, U.S.&#160;patents that issue on applications filed before June&#160;8, 1995,&#160;may be effective until 17&#160;years from the issue date, if that is later than the 20-year date. In some cases, the patent term may be extended to recapture a portion of the term lost during regulatory review of the claimed therapeutic or, in the case of the U.S., because of U.S.&#160;Patent and Trademark Office (USPTO) delays in prosecuting the application. Specifically, in the U.S., under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, a patent that covers a drug approved by the FDA may be eligible for patent term extension (for up to 5 years, but not beyond a total of 14 years from the date of product approval) as compensation for patent term lost during the FDA regulatory review process. The duration and extension of the term of foreign patents varies, in accordance </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">with local law. For example, supplementary protection certificates (SPCs) on some of our products have been granted in a number of European countries, compensating in part for delays in obtaining marketing approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory exclusivity, which may consist of regulatory data protection and market protection, also can provide meaningful protection for our products. Regulatory data protection provides to the holder of a drug or biologic marketing authorization, for a set period of time, the exclusive use of the proprietary pre-clinical and clinical data that it created at significant cost and submitted to the applicable regulatory authority to obtain approval of its product. After the applicable set period of time, third parties are then permitted to rely upon such data to file for approval of their abbreviated applications for, and to market (subject to any applicable market protection), their generic drugs and biosimilars referencing such data. Market protection provides to the holder of a drug or biologic marketing authorization the exclusive right to commercialize its product for a set period of time, thereby preventing the commercialization of another product containing the same active ingredient(s) during that period. Although the World Trade Organization's agreement on trade-related aspects of intellectual property rights (TRIPS) requires signatory countries to provide regulatory exclusivity to innovative pharmaceutical products, implementation and enforcement varies widely from country to country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely upon other forms of unpatented confidential information to remain competitive. We protect such information principally through confidentiality agreements with our employees, consultants, outside scientific collaborators, </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">scientists whose research we sponsor and other advisers. In the case of our employees, these agreements also provide, in compliance with relevant law, that inventions and other intellectual property conceived by such employees during their employment shall be our exclusive property.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our trademarks are important to us and are generally covered by trademark applications or registrations in the USPTO and the patent or trademark offices of other countries. We also use trademarks licensed from third parties, such as the trademark FAMPYRA, which we license from Acorda. Trademark protection varies in accordance with local law, and continues in some countries as long as the trademark is used and in other countries as long as the trademark is registered. Trademark registrations generally are for fixed but renewable terms.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our Patent Portfolio </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes our patents in the U.S. and Europe that we currently consider of primary importance to our marketed products, including the territory, patent number, general subject matter and expected expiration dates. Except as otherwise noted, the expected expiration dates include any granted patent term extensions and issued SPCs. In some instances, there are later-expiring patents relating to our products directed to, among other things, particular forms or compositions, methods of manufacturing or use of the drug in the treatment of particular diseases or conditions. We also continue to pursue additional patents and patent term extensions in the U.S. and other territories covering various aspects of our products that may, if issued, extend exclusivity beyond the expiration of the patents listed in the table.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Patent No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">General Subject Matter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Patent </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Expiration</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,619,001</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,399,514</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2028</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1131065</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Formulations of dialkyl fumarates and their use for treating autoimmune diseases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2137537</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of use</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2028</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">AVONEX and PLEGRIDY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,588,755</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Use of recombinant beta interferon for immunomodulation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">PLEGRIDY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,446,173</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon beta-1a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2022</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,524,660</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,017,733</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon beta-1a</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1656952</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon-beta-1a and uses thereof</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1476181</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Polymer conjugates of interferon-beta-1a and uses thereof</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(4)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TYSABRI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">6,602,503</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Humanized recombinant antibodies; nucleic acids and host cells; processes for production; therapeutic compositions; methods of use</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,807,167</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,493,567</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of treatment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">0804237</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Humanized immunoglobulins; nucleic acids; pharmaceutical compositions; medical uses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2020</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(5)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1485127</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Methods of use </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">FAMPYRA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1732548</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Sustained-release aminopyridine compositions for increasing walking speed in patients with MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(6)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2377536</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Sustained-release aminopyridine compositions for treating MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(7)</sup></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">SPINRAZA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,101,993</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Oligonucleotides containing 2&#8217;-O-modified purines</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">7,838,657</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">SMA treatment via targeting of SMN2 splice site inhibitory sequences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2027</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,110,560</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">SMA treatment via targeting of SMN2 splice site inhibitory sequences</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2025</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,361,977</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">8,980,853</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,717,750</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">9,926,559</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2034</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">1910395</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(8)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2548560</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(9)</sup></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">3305302</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2030</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">3308788</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2472b9;">Compositions and methods for modulation of SMN2 splicing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Footnotes follow on next page.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">In addition to patent protection, certain of our products are entitled to regulatory exclusivity in the U.S. and the E.U. expected until the dates set forth below:</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:20%;"></td><td style="width:2%;"></td><td style="width:21%;"></td><td style="width:2%;"></td><td style="width:55%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Territory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Expected Expiration</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">PLEGRIDY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2026</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2024</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">FAMPYRA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2021</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">SPINRAZA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2023</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">E.U.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;color:#2573ba;">2029</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2024. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent was revoked in a European opposition. This decision is being appealed. This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2029.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2028.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Reflects SPCs granted in most European countries and pediatric extension in some countries.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(6)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(7)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent was revoked in a European opposition. This decision is being appealed. This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2026.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(8)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2031.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(9)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">This patent is subject to granted SPCs in certain European countries, which extended the patent term in those countries to 2031.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The existence of patents does not guarantee our right to practice the patented technology or commercialize the patented product. Patents relating to pharmaceutical, biopharmaceutical and biotechnology products, compounds and processes, such as those that cover our existing products, compounds and processes and those that we will likely file in the future, do not always provide complete or adequate protection. Litigation, interferences, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews or other proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our patents, regulatory exclusivities or other proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patents, regulatory exclusivities or other proprietary rights covering our products by manufacturers of generics, biosimilars, prodrugs and other products approved under alternative regulatory pathways. A discussion of certain risks and uncertainties that may affect our patent position, regulatory exclusivities or other proprietary rights is set forth in Item 1A.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report, and a discussion of legal proceedings related to certain patents described above is set forth in Note&#160;21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><a name="s8D68B15BF9A15885A7F8FFC9812708BC"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition in the biopharmaceutical industry is intense and comes from many sources, including specialized biotechnology firms and large pharmaceutical companies. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. Certain of these companies have substantially greater financial, marketing and research and development resources than we do.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that competition and leadership in the industry is based on managerial and technological excellence and innovation as well as establishing patent and other proprietary positions through research and development. The achievement of a leadership position also depends largely upon our ability to maximize the approval, acceptance and use of products resulting from research and the availability of adequate financial resources to fund facilities, equipment, personnel, clinical testing, manufacturing and marketing. Another key aspect of remaining competitive within the industry is recruiting and retaining leading scientists and technicians. We believe that we have been successful in attracting and retaining skilled and experienced scientific personnel.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition among products approved for sale may be based, among other things, on patent position, product efficacy, safety, convenience/delivery devices, reliability, availability and price. In addition, early entry of a new pharmaceutical product into the market may have important advantages in gaining product acceptance and market share. Accordingly, the relative speed with which we can develop products, complete the testing and approval process and supply commercial quantities of products will have a significant impact on our competitive position.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The introduction of new products or technologies, including the development of new processes or technologies by competitors or new information about existing products or technologies, may result in increased competition for our marketed products or pricing pressure on our marketed products. It is also possible that the development of new or improved treatment options or standards of care or cures for the diseases our products treat could reduce or eliminate the use of our products or may limit the utility and application of ongoing clinical trials for our product candidates. We may also face increased competitive pressures as a result of generic versions, prodrugs of existing therapies, biosimilars of existing products, other products approved under alternative regulatory pathways or other technologies. If a generic, prodrug, biosimilar or </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other product approved under alternative regulatory pathways of one of our products were approved, it could reduce our sales of that product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional information about the competition that our marketed products face is set forth below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA, AVONEX, PLEGRIDY and TYSABRI each compete with one or more of the following products as well as generic and biosimilar versions of such products: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:2%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Competing Product</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Competitor</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AUBAGIO (teriflunomide)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sanofi Genzyme</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">BETASERON/BETAFERON (interferon-beta-1b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Bayer Group</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">COPAXONE </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(glatiramer acetate)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Teva Pharmaceuticals Industries Ltd.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">EXTAVIA </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(interferon-beta-1b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">GILENYA (fingolimod)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">GLATOPA (glatiramer acetate)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sandoz, a division of Novartis AG</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">LEMTRADA (alemtuzumab)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Sanofi Genzyme</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">OCREVUS (ocrelizumab)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Genentech</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">REBIF </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(interferon-beta-1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">EMD Serono</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA is indicated as a treatment to improve walking in adult patients with MS who a have walking disability and is the first treatment that addresses this unmet medical need with demonstrated efficacy in people with all types of MS. FAMPYRA is currently the only therapy approved to improve walking in patients with MS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Competition in the MS market is intense.&#160;Along with us, a number of companies are working to develop additional treatments for MS that may in the future compete with our MS products. One such product that was approved in the U.S. in 2017 and in the E.U. in 2018 is OCREVUS, a treatment for RMS and PPMS that was developed by Genentech. While we have a financial interest in OCREVUS, future sales of our MS products may be adversely affected if OCREVUS continues to gain market share, or if other MS products that we or our competitors are developing are commercialized</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Future sales may also be negatively impacted</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">by</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of generics, prodrugs of existing therapeutics, biosimilars of existing products, other products approved under alternative regulatory pathways or other technologies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA is the only approved treatment for SMA. We are aware of other products in development that, if successfully developed and approved, may </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compete with SPINRAZA in the SMA market, including a potential gene therapy product for the treatment of SMA Type 1, which could come to market in the U.S. in 2019. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Psoriasis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM competes with several different types of therapies in the psoriasis market within Germany, including oral systemics such as methotrexate and cyclosporine.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI, FLIXABI and IMRALDI, the three biosimilars we currently manufacture and commercialize in the E.U. for Samsung Bioepis, compete with their reference products, ENBREL, REMICADE and HUMIRA, respectively, as well as other biosimilars of those reference products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech Relationships in Other Indications</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN, RITUXAN HYCELA and GAZYVA in Oncology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN, RITUXAN HYCELA and GAZYVA compete with a number of therapies in the oncology market, including TREANDA (bendamustine HCL), ARZERRA (ofatumumab), IMBRUVICA (ibrutinib) and ZYDELIG (idelalisib). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also expect that over time RITUXAN HYCELA and GAZYVA will increasingly compete with RITUXAN in the oncology market. In addition, we are aware of anti-CD20 molecules, including biosimilars, in development that, if successfully developed and approved, may compete with RITUXAN, RITUXAN HYCELA and GAZYVA in the oncology market. In 2018 the FDA approved a rituximab biosimilar in the U.S. A biosimilar of RITUXAN could come to market in the U.S. in 2019, which may adversely affect the pre-tax profits of our collaboration arrangements with Genentech, which would, in turn adversely affect our co-promotion profits in the U.S. in future years.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN in Rheumatoid Arthritis</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RITUXAN competes with several different types of therapies in the rheumatoid arthritis market, including, among others, traditional disease-modifying anti-rheumatic drugs such as steroids, methotrexate and cyclosporine, TNF inhibitors, ORENCIA (abatacept), ACTEMRA (tocilizumab) and XELJANZ (tofacitinib).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also aware of other products, including biosimilars, in development that, if successfully developed and approved, may compete with RITUXAN in the rheumatoid arthritis market. </font></div><div><a name="sE5FBF6D86DEC50CCB1213AD8FE4C7A47"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Research and Development Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A commitment to research is fundamental to our mission. Our research efforts are focused on better understanding the underlying biology of diseases so we can discover and deliver treatments that have the potential to make a real difference in the lives of patients with high unmet medical needs. By applying our expertise in biologics and our growing capabilities in small molecule, antisense, gene therapy, gene editing and other technologies, we target specific medical needs where we believe new or better treatments are needed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities. As part of our ongoing research and development efforts, we have devoted significant resources to conducting clinical studies to advance the development of new pharmaceutical products and technologies and to explore the utility of our existing products in treating disorders beyond those currently approved in their labels.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our research and development expense included in our consolidated statements of income, please read Item 7. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management's Discussion and Analysis of Financial Condition and Results of Operations </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The table below highlights our current research and development programs that are in clinical trials and the current phase of such programs. Drug development involves a high degree of risk and investment, and the status, timing and scope of our development programs are subject to change. Important factors that could adversely affect our drug development efforts are discussed in Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:8%;"></td><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:3%;"></td><td style="width:6%;"></td><td style="width:6%;"></td></tr><tr><td rowspan="27" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Core Growth Areas</font></div></td><td rowspan="5" style="vertical-align:middle;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">MS and Neuroimmunology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB098 (diroximel fumarate)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">*</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Opicinumab (anti-LINGO) - MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB061 (oral remyelination) - MS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="11" style="vertical-align:middle;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Alzheimer's Disease and Dementia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Aducanumab (A&#946; mAb)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">*</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Elenbecestat (E2609)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">*</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BAN2401 (A&#946; mAb)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">*</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB092 (anti-tau mAb) - Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB076 (anti-tau mAb) - Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB080 (IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- Alzheimer's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Parkinson's Disease and </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Movement Disorders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB092 (anti-tau mAb) - PSP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#b1cbeb;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB054 (&#945;-synuclein mAb) - Parkinson's</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Neuromuscular Disorders, </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">including SMA and ALS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB067 (IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">*</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- ALS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB078 (IONIS-C9</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- ALS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB110 (ActRIIA/B ligand trap) - SMA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="13" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Emerging Growth Areas</font></div></td><td rowspan="5" style="vertical-align:middle;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Acute Neurology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB093 (glibenclamide IV) - LHI Stroke</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#1c5a7d;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">TMS-007</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">#</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- Acute Ischemic Stroke</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Natalizumab - Epilepsy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Neurocognitive Disorders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#8fc46e;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB104 (AMPA) - CIAS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="5" style="vertical-align:middle;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Pain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB074 (Vixotrigine) - Trigeminal Neuralgia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB074 (Vixotrigine) - Small Fiber Neuropathy</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#bbdc7f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB095 (Nav 1.7) - Neuropathic Pain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#77afe4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td rowspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="5" style="vertical-align:middle;background-color:#cecece;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cecece;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BIIB059 (anti-BDCA2) - SLE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">^</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cecece;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">BG00011 (STX-100) - IPF</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">@</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cecece;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Dapirolizumab pegol (anti-CD40L)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">*</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;- SLE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">^</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#2573ba;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#ffffff;">Phase 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Collaboration programs</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"># Option agreements</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">^ Systemic Lupus Erythematosus (SLE)</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">@ Idiopathic Pulmonary Fibrosis (IPF)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For information about certain of our agreements with collaborators and other third parties, please read the subsection entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Business Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;below and Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="s17A72E649C3F57EE8C831EEF34F135EC"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Business Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As part of our business strategy, we establish business relationships, including joint ventures and collaborative arrangements with other companies, universities and medical research institutions, to assist in the clinical development and/or commercialization of certain of our products and product candidates and to provide support for our research programs. We also evaluate opportunities for acquiring products or rights to products and technologies that are complementary to our business from other companies, universities and medical research institutions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Below is a brief description of certain business relationships and collaborations that expand our pipeline and provide us with certain rights to existing and potential new products and technologies. For additional information on certain of these relationships, including their ongoing financial and accounting impact on our business, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and Note 27, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie for the development and commercialization of ZINBRYTA in MS, which was approved for the treatment of RMS in the U.S. in May 2016 and in the E.U. in July 2016. In March 2018 we and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for RMS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we and AbbVie conducted ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories, and we were responsible for all manufacturing and research and development activities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Acorda to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we notified AGTC of the termination of our collaboration agreement with AGTC to develop gene-based therapies for multiple ophthalmic diseases. This collaboration focused on the development of BIIB087, an investigational AAV-based gene therapy for the treatment of XLRS, and BIIB088, an investigational AAV-based gene therapy </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">for the treatment of XLRP. This collaboration also provided us with options to early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition. The termination of this collaboration agreement will be effective in March 2019 and we will have no further involvement in the development of any of these programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Alkermes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive license and collaboration agreement with Alkermes to develop and commercialize diroximel fumarate (BIIB098), a novel oral fumarate in Phase 3 development for the treatment of RMS. Under this agreement, we received an exclusive, worldwide license to develop and commercialize diroximel fumarate. Alkermes will maintain responsibility for regulatory interactions with the FDA through the potential approval of the NDA for diroximel fumarate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092, a phase 2 investigational therapy with potential in AD and PSP. Under this agreement, we received worldwide rights to BIIB092 and are responsible for the full development and potential commercialization of BIIB092 in AD and PSP. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">C4 Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we entered into a collaborative research and license agreement with C4T to investigate the use of C4T&#8217;s novel protein degradation platform to discover and develop potential new treatments for neurological diseases, such as AD and Parkinson&#8217;s disease. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai to jointly develop and commercialize BAN2401 and elenbecestat, two Eisai product candidates for the treatment of AD.&#160;Eisai serves as the global operational and regulatory lead for BAN2401 and elenbecestat and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai. Upon marketing approval in major markets, we and Eisai will co-promote BAN2401 and elenbecestat and share profits equally. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have a collaboration agreement with Eisai to jointly develop and commercialize aducanumab (the Aducanumab Collaboration Agreement). Under the Aducanumab Collaboration </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Agreement, the two companies will co-promote aducanumab with a region-based profit split and we will continue to lead the ongoing Phase 3 development of aducanumab. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech, Inc. (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have collaboration arrangements with Genentech which entitle us to certain business and financial rights with respect to RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS and other potential anti-CD20 therapies. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive, worldwide option and collaboration agreement with Ionis relating to the development and commercialization of up to three gene targets, and an exclusive, worldwide option and collaboration agreement with Ionis under which both companies are responsible for the development and commercialization of SPINRAZA for the treatment of SMA. We also have the 2018 Ionis Agreement, which is a 10-year exclusive collaboration agreement with Ionis to develop novel ASO drug candidates for a broad range of neurological diseases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we have research collaboration agreements with Ionis, under which both companies perform discovery level research and will develop and commercialize new ASO drug candidates for the treatment of SMA and additional antisense and other therapeutics for the treatment of neurological diseases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the treatment of AD, including aducanumab (as amended, the Neurimmune Agreement). Under the Neurimmune Agreement, we are responsible for the development, manufacturing and commercialization of all licensed products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Samsung BioLogics established a joint venture, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;We also have an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-TNF biosimilar product candidates in Europe and, in the case of BENEPALI, Japan.&#160;Under this agreement, we are manufacturing and commercializing BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our joint venture and commercialization agreements with Samsung Bioepis, we license certain of our proprietary technology to Samsung Bioepis in connection with Samsung Bioepis' development, manufacture and commercialization of its biosimilar products. We also provide technical development and technology transfer services to Samsung Bioepis and manufacture clinical and commercial quantities of bulk drug substance of Samsung Bioepis' biosimilar products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Skyhawk Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services arrangement with Skyhawk pursuant to which the companies will leverage Skyhawk&#8217;s SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TMS Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have an exclusive option agreement with TMS granting us the option to acquire TMS-007 and backup compounds for the treatment of stroke.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">University of Pennsylvania</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and alliance with UPenn to advance gene therapy and gene editing technologies. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we notified UPenn that we will be terminating certain programs under this collaboration, including the development of therapeutic approaches that target the eye, skeletal muscle and central nervous system and research and validation of next generation gene transfer technology using AAV gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform. The termination of these programs will be effective in May 2019. This termination did not impact our collaboration with UPenn for the development of BIIB089 for the treatment of SMA.</font></div><div><a name="sAB7DCC607590583E87F44A8FA70F055C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Regulatory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current and contemplated activities and the products, technologies and processes that result from such activities are subject to substantial government regulation.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation of Pharmaceuticals</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Approval and Post-Approval Regulation in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">APPROVAL PROCESS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Before new pharmaceutical products may be sold in the U.S., preclinical studies and clinical trials of the products must be conducted and the results submitted to the FDA for approval. With limited exceptions, the FDA requires companies to register both pre-approval and post-approval clinical trials and disclose clinical trial results in public databases. Failure to register a trial or disclose study results within the required time periods could result in penalties, including civil monetary penalties. Clinical trial programs must establish efficacy, determine an appropriate dose and dosing regimen and define the conditions for safe use. This is a high-risk process that requires stepwise clinical studies in which the candidate product must successfully meet predetermined endpoints. The results of the preclinical and clinical testing of a product are then submitted to the FDA in the form of a Biologics License Application (BLA) or a NDA. In response to a BLA or NDA, the FDA may grant marketing approval, request additional information or deny the application if it determines the application does not provide an adequate basis for approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development and receipt of regulatory approval takes a number of years, involves the expenditure of substantial resources and depends on a number of factors, including the severity of the disease in question, the availability of alternative treatments, potential safety signals observed in preclinical or clinical tests and the risks and benefits of the product as demonstrated in clinical trials. The FDA has substantial discretion in the product approval process, and it is impossible to predict with any certainty whether and when the FDA will grant marketing approval. The agency may require the sponsor of a BLA or NDA to conduct additional clinical studies or to provide other scientific or technical information about the product, and these additional requirements may lead to unanticipated delays or expenses. Furthermore, even if a product is approved, the approval may be subject to limitations based on the FDA's interpretation of the existing pre-clinical or clinical data. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA has developed four distinct approaches intended to make therapeutically important drugs available as rapidly as possible, especially when the drugs are the first available treatment or have advantages over existing treatments: accelerated approval, fast track, breakthrough therapy and priority review.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Accelerated Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant &#8220;accelerated approval&#8221; status to products that treat serious or life-threatening illnesses and that provide meaningful therapeutic benefits to patients over existing treatments. Under this pathway, the FDA may approve a product based on surrogate endpoints, or clinical endpoints other than survival or irreversible morbidity. When approval is based on surrogate endpoints or clinical endpoints other than survival or morbidity, the sponsor will be required to conduct additional post-approval clinical studies to verify and describe clinical benefit. Under the FDA's accelerated approval regulations, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it may require certain post-marketing restrictions to assure safe use. In addition, for products approved under accelerated approval, sponsors may be required to submit all copies of their promotional materials, including advertisements, to the FDA at least 30 days prior to initial dissemination. The FDA may withdraw approval under accelerated approval after a hearing if, for instance, post-marketing studies fail to verify any clinical benefit, it becomes clear that restrictions on the distribution of the product are inadequate to ensure its safe use, or if a sponsor fails to comply with the conditions of the accelerated approval.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fast Track</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant "fast track" status to products that treat a serious condition and have data demonstrating the potential to address an unmet medical need or a drug that has been designated as a qualified infectious disease product.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Breakthrough Therapy</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: The FDA may grant &#8220;breakthrough therapy&#8221; status to drugs designed to treat, alone or in combination with another drug or drugs, a serious or life-threatening disease or condition and for which preliminary clinical evidence suggests a substantial improvement over existing therapies. Such drugs need not address an unmet need, but are nevertheless eligible for expedited review if they offer the potential for an improvement. Breakthrough therapy status entitles the sponsor to earlier and more frequent meetings with the FDA regarding the development of nonclinical and clinical data and permits the FDA to offer product development or regulatory advice for the purpose of shortening the time to product approval. Breakthrough therapy status does not guarantee that a product will be reviewed more quickly and does not ensure FDA approval.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Priority Review</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: &#8220;Priority review&#8221; only applies to applications (original or efficacy supplement) for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, diagnosis or prevention of a serious condition when compared to standard applications. Priority review may also be granted for any supplement that proposes a labeling change due to studies completed in response to a written request from the FDA for pediatric studies, for an application for a drug that has been designated as a qualified infectious disease product or for any application or supplement for a drug submitted with a priority review voucher.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 the FDA issued us a rare pediatric disease priority review voucher in connection with the approval of SPINRAZA. </font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">POST-MARKETING STUDIES</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of the approval pathway employed, the FDA may require a sponsor to conduct additional post-marketing studies as a condition of approval to provide data on safety and effectiveness. If a sponsor fails to conduct the required studies, the FDA may withdraw its approval. In addition, if the FDA concludes that a drug that has been shown to be effective can be safely used only if distribution or use is restricted, it can mandate post-marketing restrictions to assure safe use. In such a case, the sponsor may be required to establish rigorous systems to assure use of the product under safe conditions. These systems are usually referred to as Risk Evaluation and Mitigation Strategies (REMS). The FDA can impose financial penalties for failing to comply with certain post-marketing commitments, including REMS. In addition, any changes to an approved REMS must be reviewed and approved by the FDA prior to implementation.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">ADVERSE EVENT REPORTING</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor information on side effects and adverse events reported during clinical studies and after marketing approval and report such information and events to regulatory agencies. Non-compliance with the FDA's safety reporting requirements may result in civil or criminal penalties. Side effects or adverse events that are reported during clinical trials can delay, impede or prevent marketing approval. Based on new safety information that emerges after approval, the FDA can mandate product labeling changes, impose a new REMS or the addition of elements to an existing REMS, require new post-marketing studies (including additional clinical trials) or suspend or withdraw approval of the product. These requirements may affect our ability to maintain marketing approval of our products or require us to </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">make significant expenditures to obtain or maintain such approvals.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">APPROVAL OF CHANGES TO AN APPROVED PRODUCT</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we seek to make certain types of changes to an approved product, such as adding a new indication, making certain manufacturing changes or changing manufacturers or suppliers of certain ingredients or components, the FDA will need to review and approve such changes in advance. In the case of a new indication, we are required to demonstrate with additional clinical data that the product is safe and effective for a use other than what was initially approved. FDA regulatory review may result in denial or modification of the planned changes, or requirements to conduct additional tests or evaluations that can substantially delay or increase the cost of the planned changes.</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">REGULATION OF PRODUCT ADVERTISING AND PROMOTION</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA regulates all advertising and promotion activities and communications for products under its jurisdiction both before and after approval. Pursuant to FDA guidance, a company can make safety and efficacy claims from data either in or consistent with the label. However, physicians may prescribe legally available drugs for uses that are not described in the drug's labeling. Such off-label uses are common across medical specialties, and often reflect a physician's belief that the off-label use is the best treatment for patients. The FDA does not regulate the behavior of physicians in their choice of treatments, but FDA regulations do impose stringent restrictions on manufacturers' communications regarding off-label uses. Failure to comply with applicable FDA requirements may subject a company to adverse publicity, enforcement action by the FDA, corrective advertising and the full range of civil and criminal penalties available to the government.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Regulation of Combination Products</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Combination products are defined by the FDA to include products comprising two or more regulated components (e.g., a biologic and a device). Biologics and devices each have their own regulatory requirements, and combination products may have additional requirements. Some of our marketed products meet this definition and are regulated under this framework and similar regulations outside the U.S., and we expect that some of our pipeline product candidates may be evaluated for regulatory approval under this framework as well. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Approval and Post-Approval Regulation Outside the U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We market our products in numerous jurisdictions outside the U.S. Most of these jurisdictions have product approval and post-approval regulatory processes that are similar in principle to those in the U.S. In Europe, for example, where a substantial part of our ex-U.S. efforts are focused, there are several tracks for marketing approval, depending on the type of product for which approval is sought. Under the centralized procedure, a company submits a single application to the European Medicines Agency (EMA). The marketing authorization application is similar to the NDA or BLA in the U.S. and is evaluated by the Committee for Medicinal Products for Human Use (CHMP), the expert scientific committee of the EMA responsible for human medicines. If the CHMP determines that the marketing authorization application fulfills the requirements for quality, safety and efficacy and that the medicine has a positive benefit risk balance, it will adopt a positive opinion recommending the granting of the marketing authorization by the EC. The CHMP opinion is not binding, but is typically adopted by the EC. A marketing application approved by the EC is valid in all member states of the E.U. The centralized procedure is required for all biological products, orphan medicinal products and new treatments for neurodegenerative disorders, and it is available for certain other products, including those which constitute a significant therapeutic, scientific or technical innovation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the centralized procedure, the European regulatory framework includes the following options for regulatory review and approval in E.U. member states: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a national procedure, which requires an application to the competent authority of an E.U. country (if an application is to be made in more than one E.U. country, following approval in the first country, the applicant must submit applications in the other countries using the mutual recognition procedure); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a decentralized procedure, whereby applicants submit identical applications to several countries and receive simultaneous approval, if the medicine has not yet been authorized in any E.U. country; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a mutual recognition procedure, where applicants that have a medicine authorized in one E.U. country can apply for mutual recognition of this authorization in other E.U. countries. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As in the U.S., the E.U. also has distinct approaches intended to optimize the regulatory pathways for therapeutically important drugs, </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">including the Priority Medicines Evaluation Scheme (PRIME), accelerated assessment and conditional authorization. PRIME is intended to provide additional support to medicine developers throughout the development process. Regulatory review timelines in the E.U. may be truncated under accelerated assessment for products that address an unmet medical need. In addition, conditional authorizations may be granted for such products in the interest of public health, where the benefit of immediate availability outweighs the risk of less comprehensive data than normally required. Conditional authorizations are valid for one year and can be renewed annually. The marketing authorization holder is required to complete specific obligations (ongoing or new studies and, in some cases, additional activities) with a view to providing comprehensive data confirming that the benefit risk balance is positive. Once comprehensive data on the product have been obtained, the marketing authorization may be converted into a standard marketing authorization.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. there is detailed legislation on pharmacovigilance and extensive guidance on good pharmacovigilance practices. A failure to comply with the E.U. pharmacovigilance obligations may result in significant financial penalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of the approval process employed, various parties share responsibilities for the monitoring, detection and evaluation of adverse events post-approval, including national competent authorities, the EMA, the EC and the marketing authorization holder. The EMA&#8217;s Pharmacovigilance Risk Assessment Committee is responsible for assessing and monitoring the safety of human medicines and makes recommendations on product safety issues. Marketing authorization holders have an obligation to inform regulatory agencies of any new information which may influence the evaluation of benefits and risks of the medicinal product concerned. In the U.S., E.U. and other jurisdictions, regulatory agencies, including the FDA, conduct periodic inspections of NDA and BLA holders to assess their compliance with pharmacovigilance obligations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In some regions, it is possible to receive an &#8220;accelerated&#8221; review whereby the national regulatory authority will commit to truncated review timelines for products that meet specific medical needs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Good Manufacturing Practices</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory agencies regulate and inspect equipment, facilities and processes used in the manufacturing and testing of pharmaceutical and biologic products prior to approving a product. If, after receiving approval from regulatory agencies, a company makes a material change in manufacturing </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">equipment, location or process, additional regulatory review and approval may be required. We also must adhere to current Good Manufacturing Practices (cGMP) and product-specific regulations enforced by regulatory agencies following product approval. The FDA, the EMA and other regulatory agencies also conduct periodic visits to re-inspect equipment, facilities and processes following the initial approval of a product. If, as a result of these inspections, it is determined that our equipment, facilities or processes do not comply with applicable regulations and conditions of product approval, regulatory agencies may seek civil, criminal or administrative sanctions or remedies against us, including significant financial penalties and the suspension of our manufacturing operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Good Clinical Practices</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FDA, the EMA and other regulatory agencies promulgate regulations and standards for designing, conducting, monitoring, auditing and reporting the results of clinical trials to ensure that the data and results are accurate and that the rights and welfare of trial participants are adequately protected (commonly referred to as current Good Clinical Practices (cGCP)). Regulatory agencies enforce cGCP through periodic inspections of trial sponsors, principal investigators and trial sites, contract research organizations (CROs) and institutional review boards. If our studies fail to comply with applicable cGCP guidelines, the clinical data generated in our clinical trials may be deemed unreliable and relevant regulatory agencies may require us to perform additional clinical trials before approving our marketing applications. Noncompliance can also result in civil or criminal sanctions. We rely on third parties, including CROs, to carry out many of our clinical trial-related activities. Failure of such third parties to comply with cGCP can likewise result in rejection of our clinical trial data or other sanctions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2014 the EC adopted a new Clinical Trial Regulation, which was effective in June 2014 but is not expected to apply until early 2020. The regulation harmonizes the procedures for assessment and governance of clinical trials throughout the E.U. and will require that information on the authorization, conduct and results of each clinical trial conducted in the E.U. be publicly available.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Approval of Biosimilars </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Patient Protection and Affordable Care Act (PPACA) amended the Public Health Service Act (PHSA) to authorize the FDA to approve biological products, referred to as biosimilars or follow-on biologics that are shown to be highly similar to previously approved biological products based upon potentially abbreviated data packages.&#160;The biosimilar must show it has no clinically meaningful differences </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">in terms of safety and effectiveness from the reference product, and only minor differences in clinically inactive components are allowable in biosimilars products. The approval pathway for biosimilars does, however, grant a biologics manufacturer a 12-year period of exclusivity from the date of approval of its biological product before biosimilar competition can be introduced. There is uncertainty, however, as the approval framework for biosimilars originally was enacted as part of the PPACA. There have been, and there are likely to continue to be, federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. If the PPACA is repealed, substantially modified or invalidated, it is unclear what, if any, impact such action would have on biosimilar regulation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A biosimilars approval pathway has been in place in the E.U. since 2003. The EMA has issued a number of scientific and product specific biosimilar guidelines, including requirements for approving biosimilars containing monoclonal antibodies. In the E.U., biosimilars are generally approved under the centralized procedure. The approval pathway allows sponsors of a biosimilar to seek and obtain regulatory approval based in part on reliance on the clinical trial data of an innovator product to which the biosimilar has been demonstrated, through comprehensive comparability studies, to be &#8220;similar.&#8221; In many cases, this allows biosimilars to be brought to market without conducting the full complement of clinical trials typically required for novel biologic drugs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Orphan Drug Act</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the U.S.&#160;Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a &#8220;rare disease or condition,&#8221; which generally is a disease or condition that affects fewer than 200,000 individuals in the U.S.&#160;If a product which has an orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, i.e., the FDA may not approve any other applications to market the same drug for the same indication for a period of seven years following marketing approval, except in certain very limited circumstances, such as if the later product is shown to be clinically superior to the orphan product. Legislation similar to the U.S.&#160;Orphan Drug Act has been enacted in other countries to encourage the research, development and marketing of medicines to treat, prevent or diagnose rare diseases. In the E.U., medicinal products that receive an orphan designation are entitled to 10 years of market exclusivity following approval, protocol assistance and access to the centralized procedure for marketing authorization. SPINRAZA has been granted orphan drug designation in the U.S., E.U. and Japan.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation Pertaining to Pricing and Reimbursement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In both domestic and foreign markets, sales of our products depend, to a significant extent, on the availability and amount of reimbursement by third-party payors, including governments, private health plans and other organizations. Substantial uncertainty exists regarding the pricing and reimbursement of our products, and drug prices continue to receive significant scrutiny. Governments may regulate coverage, reimbursement and pricing of our products to control cost or affect utilization of our products. Challenges to our pricing strategies, by either government or private stakeholders, could harm our business. The U.S.&#160;and foreign governments have enacted and regularly consider additional reform measures that affect health care coverage and costs. Private health plans may also seek to manage cost and utilization by implementing coverage and reimbursement limitations. Other payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities and private health insurers, seek price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, may impose restrictions on access, coverage or pricing of particular drugs based on perceived value.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Within the U.S.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Medicaid</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. Under the Medicaid Drug Rebate Program, we are required to pay a rebate for each unit of product reimbursed by the state Medicaid programs. The amount of the rebate is established by law and is adjusted upward if the average manufacture price (AMP) increases more than inflation (measured by the Consumer Price Index&#160;- Urban). The rebate amount is calculated each quarter based on our report of current AMP and best price for each of our products to the Centers for Medicare&#160;&amp; Medicaid Services (CMS). The requirements for calculating AMP and best price are complex. We are required to report any revisions to AMP or best price previously reported within a certain period, which revisions could affect our rebate liability for prior quarters. In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the statute governing the Medicaid Drug Rebate Program provides for civil monetary penalties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Medicare</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Medicare is a federal program that is administered by the federal government. The program covers individuals age&#160;65 and over as </font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">well as those with certain disabilities. Medicare Part&#160;B generally covers drugs that must be administered by physicians or other health care practitioners, are provided in connection with certain durable medical equipment or are certain oral anti-cancer drugs and certain oral immunosuppressive drugs. Medicare Part B pays for such drugs under a payment methodology based on the average sales price (ASP) of the drugs. Manufacturers, including us, are required to provide ASP information to the CMS on a quarterly basis. The manufacturer-submitted information is used to calculate Medicare payment rates. If a manufacturer is found to have made a misrepresentation in the reporting of ASP, the governing statute provides for civil monetary penalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicare Part D provides coverage to enrolled Medicare patients for self-administered drugs (i.e., drugs that are not administered by a physician). Medicare Part D is administered by private prescription drug plans approved by the U.S. government. Each drug plan establishes its own Medicare Part D formulary for prescription drug coverage and pricing, which the drug plan may modify from time-to-time. The prescription drug plans negotiate pricing with manufacturers and pharmacies, and may condition formulary placement on the availability of manufacturer discounts. In addition, manufacturers, including us, are required to provide to the CMS a discount of up to 70% on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries reach the coverage gap in their drug benefits.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Federal Agency Discounted Pricing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: Our products are subject to discounted pricing when purchased by federal agencies via the Federal Supply Schedule (FSS). FSS participation is required for our products to be covered and reimbursed by the Veterans Administration (VA), Department of Defense, Coast Guard and Public Health Service (PHS). Coverage under Medicaid, Medicare and the PHS pharmaceutical pricing program is also conditioned upon FSS participation. FSS pricing is intended not to exceed the price that we charge our most-favored non-federal customer for a product. In addition, prices for drugs purchased by the VA, Department of Defense (including drugs purchased by military personnel and dependents through the TriCare retail pharmacy program), Coast Guard and PHS are subject to a cap on pricing equal to 76% of the non-federal average manufacturer price (non-FAMP). An additional discount applies if non-FAMP increases more than inflation (measured by the Consumer Price </font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Index&#160;- Urban). In addition, if we fail to provide information timely or we are found to have knowingly submitted false information to the government, the governing statute provides for civil monetary penalties.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">340B Discounted Pricing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">: To maintain coverage of our products under the Medicaid Drug Rebate Program and Medicare Part B, we are required to extend significant discounts to certain covered entities that purchase products under Section 340B of the PHS pharmaceutical pricing program. Purchasers eligible for discounts include hospitals that serve a disproportionate share of financially needy patients, community health clinics and other entities that receive certain types of grants under the PHSA. For all of our products, we must agree to charge a price that will not exceed the amount determined under statute (the &#8220;ceiling price&#8221;) when we sell outpatient drugs to these covered entities. In addition, we may, but are not required to, offer these covered entities a price lower than the 340B ceiling price. The 340B discount formula is based on AMP and is generally similar to the level of rebates calculated under the Medicaid Drug Rebate Program. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Outside the U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outside the U.S., our products are paid for by a variety of payors, with governments being the primary source of payment. Governments may determine or influence reimbursement of products and may also set prices or otherwise regulate pricing. Negotiating prices with governmental authorities can delay commercialization of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing and reference pricing (i.e., referencing prices in other countries and using those reference prices to set a price). Budgetary pressures in many countries are continuing to cause governments to consider or implement various cost-containment measures, such as price freezes, increased price cuts and rebates and expanded generic substitution and patient cost-sharing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Regulation Pertaining to Sales and Marketing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to various federal and state laws pertaining to health care &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a prescription drug manufacturer from soliciting, offering, receiving or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is therefore a possibility that our practices might be challenged under anti-kickback or similar laws. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented, for payment to third-party payors (including Medicare and Medicaid), claims for reimbursed drugs or services that are false or fraudulent, claims for items or services not provided as claimed or claims for medically unnecessary items or services. Our activities relating to the sale and marketing of our products may be subject to scrutiny under these laws. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions, including fines and civil monetary penalties, and exclusion from federal health care programs (including Medicare and Medicaid). In the U.S., federal and state authorities are paying increased attention to enforcement of these laws within the pharmaceutical industry and private individuals have been active in alleging violations of the laws and bringing suits on behalf of the government under the federal civil False Claims Act. If we were subject to allegations concerning, or were convicted of violating, these laws, our business could be harmed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Laws and regulations have been enacted by the federal government and various states to regulate the sales and marketing practices of pharmaceutical manufacturers. The laws and regulations generally limit financial interactions between manufacturers and health care providers or require disclosure to the government and public of such interactions. The laws include federal &#8220;sunshine&#8221; provisions. The sunshine provisions apply to pharmaceutical manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government (for re-disclosure to the public) certain payments made to physicians and certain other healthcare practitioners or to teaching hospitals. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Many of these laws and regulations contain ambiguous requirements. Given the lack of clarity in laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations. Outside the U.S., other countries have implemented requirements for disclosure of financial interactions with healthcare providers and additional countries may consider or implement such laws.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Regulations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Foreign Anti-Corruption</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to various federal and foreign laws that govern our international business practices with respect to payments to government officials. Those laws include the U.S.&#160;Foreign Corrupt Practices Act (FCPA), which prohibits U.S.&#160;companies and their </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect their transactions and to devise and maintain an adequate system of internal accounting controls.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The laws to which we are subject also include the U.K. Bribery Act 2010 (Bribery Act), which proscribes giving and receiving bribes in the public and private sectors, bribing a foreign public official and failing to have adequate procedures to prevent employees and other agents from giving bribes. U.S. companies that conduct business in the U.K. generally will be subject to the Bribery Act. Penalties under the Bribery Act include significant fines for companies and criminal sanctions for corporate officers under certain circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">NIH Guidelines</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We seek to conduct research at our U.S. facilities in compliance with the current U.S.&#160;National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines). By local ordinance, we are required to, among other things, comply with the NIH Guidelines in relation to our facilities in Research Triangle Park (RTP), NC and are required to operate pursuant to certain permits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Laws</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our present and future business has been and will continue to be subject to various other laws and regulations. Various laws, regulations and recommendations relating to data privacy and protection, safe working conditions, laboratory practices, the experimental use of animals and the purchase, storage, movement, import, export and use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research work are or may be applicable to our activities. Certain agreements entered into by us involving exclusive license rights may be subject to national or international antitrust regulatory control, the effect of which cannot be predicted. The extent of government regulation, which might result from future legislation or administrative action, cannot accurately be predicted.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The European Parliament and the Council of the European Union adopted a comprehensive general </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">data privacy regulation (GDPR) in 2016 to replace the current E.U. Data Protection Directive and related country-specific legislation. The GDPR took effect in May 2018 and governs the collection and use of personal data in the E.U. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the E.U. to the U.S., provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20.0 million or 4% of the annual global revenues of the infringer, whichever is greater.</font></div><div><a name="s419E1FCBA13E50229E11837A2F6F6221"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Environmental Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We strive to comply in all material respects with applicable laws and regulations concerning the environment. While it is impossible to predict accurately the future costs associated with environmental compliance and potential remediation activities, compliance with environmental laws is not expected to require significant capital expenditures and has not had, and is not expected to have, a material adverse effect on our operations or competitive position.</font></div><div><a name="sADC10E1D68CA5BDDACE290126AE39E7F"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Manufacturing</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are committed to ensuring an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. We believe that our manufacturing facilities, together with the third-party contract manufacturing organizations we outsource to, currently provide sufficient capacity for our products and the contract manufacturing services we provide to Samsung Bioepis, our joint venture that develops, manufactures and markets biosimilar products, and other strategic contract manufacturing partners. Due to the long lead times necessary for the expansion of manufacturing capacity, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing Facilities</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our drug substance manufacturing facilities include:</font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Facility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Drug Substance Manufactured</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">RTP, NC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">AVONEX</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">PLEGRIDY</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">TYSABRI</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Other*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Hiller&#248;d, Denmark</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">TYSABRI</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Biosimilars</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Other*</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-12px;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Other includes products manufactured for contract manufacturing partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to our drug substance manufacturing facilities, we have a drug product manufacturing facility and supporting infrastructure in RTP, NC, including a parenteral facility and an oral solid dose products manufacturing facility. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The parenteral facility adds capabilities and capacity for filling biologics into vials and is principally used for filling product candidates. The oral solid dose products facility supplements our outsourced small molecule manufacturing capabilities, including the manufacture of TECFIDERA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have an oligonucleotide synthesis manufacturing facility in RTP, NC. This facility gives us the capability to manufacture ASO drugs like SPINRAZA as well as our other ASO candidates currently in our clinical pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech is responsible for all worldwide manufacturing activities for bulk RITUXAN, RITUXAN HYCELA and GAZYVA and has sourced the manufacture of certain bulk RITUXAN, RITUXAN HYCELA and GAZYVA requirements to a third party. Acorda supplies FAMPYRA to us pursuant to its supply agreement with Alkermes, Inc. and Ionis supplies the active pharmaceutical ingredient (API) for SPINRAZA.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Third-Party Suppliers and Manufacturers</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We principally use third parties to manufacture the API and the final product for our small molecule products and product candidates, including TECFIDERA and FUMADERM, and the final drug product for our large molecule products and, to a lesser extent, product candidates. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We source all of our fill-finish and the majority of final product assembly and storage operations for our products, along with a substantial part of our packaging operations, to a concentrated group of third-party contract manufacturing organizations. We have internal label and packaging capability for clinical and commercial products at our Hiller&#248;d facility. Raw materials, delivery devices, such as syringes and auto-injectors, and other supplies required for the production of our products and product candidates are procured from various third-party suppliers and manufacturers in quantities adequate to meet our needs. Continuity of supply of such raw materials, devices and supplies is assured using a strategy of dual sourcing where possible or by a risk-based inventory strategy. Our third-party service providers, suppliers and manufacturers may be subject to routine cGMP inspections by the FDA or comparable agencies in other jurisdictions and undergo assessment and certification by our quality management group.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><a name="sB4895D8A5F6759DC8BE804C58B718177"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Our Employees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately 7,800 employees worldwide.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Our Executive Officers (as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">February&#160;6, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:7%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Current Position</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Age</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year Joined Biogen</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michel Vounatsos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Susan H. Alexander</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Chief Legal Officer and Secretary</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2006</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Jeffrey D. Capello</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michael D. Ehlers, M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Research and Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Ginger Gregory, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and Chief Human Resources Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Chirfi Guindo</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Daniel Karp</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Corporate Development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Robin C. Kramer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Chief Accounting Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Paul McKenzie, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Pharmaceutical Operations and Technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Alfred W. Sandrock, Jr., M.D., Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President and Chief Medical Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1998</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michel Vounatsos</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Vounatsos has served as our Chief Executive Officer since January 2017. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President and Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck &amp; Co., Inc. (Merck), a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line. In this role, he led Merck&#8217;s global primary care business unit, a role which encompassed Merck&#8217;s cardiology-metabolic, general medicine, women&#8217;s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company&#8217;s relationships with key constituents, including the most significant providers, payors and retailers and the world&#8217;s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Universite Victor Segalen, Bordeaux II, France, C.S.C.T. Certificate in Medicine</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">HEC School of Management - Paris, M.B.A.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Susan H. Alexander</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ms. Alexander has served as our Executive Vice President, Chief Legal Officer and Secretary since April 2018. Prior to that, from March 2017 to March 2018, Ms. Alexander served as our Executive Vice President, Chief Legal, Corporate Services and Secretary, from December 2011 to March 2017, as our Executive Vice President, Chief Legal Officer and Secretary and from 2006 to December 2011, as our Executive Vice President, General Counsel and Corporate Secretary. Prior to joining Biogen, Ms.&#160;Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation, a biopharmaceutical services company, from 2003 to January 2006. From 2001 to 2003 Ms.&#160;Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001 Ms.&#160;Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms.&#160;Alexander was a partner at the law firms of Hinckley, Allen&#160;&amp; Snyder and Fine&#160;&amp; Ambrogne. </font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Invacare Corporation, a medical and healthcare product company</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Wellesley College, B.A.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston University School of Law, J.D.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Jeffrey D. Capello</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Capello has served as our Executive Vice President and Chief Financial Officer since December 2017 and served as our Chief Accounting Officer from July 2018 to November 2018. Prior to joining Biogen, Mr. Capello served as the Chief Financial Officer of Beacon Health Options, Inc., a behavioral health company, with responsibility for finance, human resources, information technology, real estate and procurement, from October 2016 until November 2017. From July 2015 until September 2016 Mr. Capello was the founder and Chief Executive Officer of Monomoy Advisors, which focuses on helping companies drive shareholder value. From July 2014 until June 2015 Mr. Capello served as the Executive Vice President and Chief Financial Officer of Ortho-Clinical Diagnostics, an in-vitro diagnostics company that was acquired by the Carlyle Group from Johnson &amp; Johnson (J&amp;J), with responsibility for global finance and business development. From March 2010 to December 2013 Mr. Capello served as Chief Financial Officer and Executive Vice President of Boston Scientific Corporation (Boston Scientific), a medical device company, where he was responsible for the worldwide management of Boston Scientific&#8217;s finance, information systems, business development and corporate strategy functions. Mr. Capello joined Boston Scientific in June 2008 and served as Senior Vice President and Chief Accounting Officer until March 2010. From 2006 to 2008 he was the Senior Vice President and Chief Financial Officer with responsibilities for global finance and business development at PerkinElmer, Inc. (PerkinElmer), a life sciences tool company. Previously, he served as PerkinElmer&#8217;s Vice President of Finance, Corporate Controller, Treasurer and Chief Accounting Officer from 2001 to 2006. Prior to his tenure at PerkinElmer, Mr. Capello was a Partner at PricewaterhouseCoopers LLP, both in the U.S. and in the Netherlands.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Vermont, B.S. Business Administration</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard Business School, M.B.A.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Michael D. Ehlers, M.D., Ph.D.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Ehlers has served as our Executive Vice President, Research and Development since May 2016. Prior to joining Biogen, from August 2010 to April 2016, Dr. Ehlers served in leadership positions at Pfizer, a biopharmaceutical company, including Senior Vice President &amp; Head BioTherapeutics R&amp;D and Chief Scientific Officer, Neuroscience &amp; Pain. Prior to that, Dr. Ehlers was the George Barth Geller Professor of Neurobiology and an Investigator of the Howard Hughes Medical Institute at Duke University Medical Center. He is the recipient of numerous awards, including the Eppendorf &amp; Science Prize in Neurobiology, the John J. Abel Award in Pharmacology, the Society for Neuroscience Young Investigator Award, a National Institute of Mental Health MERIT Award, the National Alliance for Schizophrenia and Depression Distinguished Investigator Award and the Massachusetts Medical Society Honored Business Leader Award. In 2013 Dr. Ehlers became the 11</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;recipient of the Thudichum Medal of the Biochemical Society of the U.K. Past recipients include two Nobel laureates. Dr. Ehlers has authored over 100 scientific papers, has served on the Editorial Boards of Annual Reviews in Medicine, Annual Reviews in Pharmacology and Toxicology, the Journal of Neuroscience, the Journal of Biological Chemistry and the Journal of Molecular and Cellular Neuroscience and has sat on advisory committees of the National Institutes of Health.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Outside Affiliations</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">McKnight Endowment Fund for Neuroscience Board</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">American Society for Cell Biology</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">California Institute of Technology, B.S. Chemistry</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Johns Hopkins University School of Medicine, M.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Johns Hopkins University School of Medicine, Ph.D. Neuroscience</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Ginger Gregory, Ph.D.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Gregory has served as our Executive Vice President and Chief Human Resources Officer since July 2017. Prior to joining Biogen, Dr. Gregory served as Executive Vice President and Chief Human Resources Officer at Shire PLC, a global specialty biopharmaceutical company, from February 2014 to April 2017. Prior to that, Dr. Gregory held executive-level human resources positions for several multinational companies across a variety of industries, including Dunkin&#8217; Brands Group Inc., a restaurant holding company, where she served as Chief Human Resource Officer; Novartis, AG, a pharmaceutical company, where she was the division head of Human Resources for Novartis Vaccines and Diagnostics, Novartis Consumer Health and Novartis Institutes of BioMedical Research from 2005 to 2012; and Novo Nordisk A/S, a pharmaceutical company, where she served as Senior Vice President, Corporate People &amp; Organization at the company&#8217;s headquarters in Copenhagen, Denmark. Earlier in her career, Dr. Gregory held a variety of human resources generalist and specialist positions at BMS, a pharmaceutical company, and served as a consultant with Booz Allen &amp; Hamilton, an information technology consulting company, in the area of organization change and effectiveness.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Massachusetts, B.A. Psychology</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The George Washington University, Ph.D. Psychology</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Chirfi Guindo</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Guindo has served as our Executive Vice President and Head of Global Marketing, Market Access and Customer Innovation since November 2017. Prior to joining Biogen, Mr. Guindo has spent 27 years in the global pharmaceutical industry and has held several leadership positions at Merck, a pharmaceutical company, in Canada, the U.S., France, Africa and the Netherlands. He worked in several disciplines including Finance, Sales &amp; Marketing, General Management and Global Strategy/Product Development in specialty, acute and hospital care. Most recently Mr. Guindo was Vice President and Managing Director and President and Managing Director of Merck Canada from October 2014 to November 2017. From January 2011 to October 2014, he was Vice President and General Manager, Global HIV Franchise at Merck.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ecole Central de Paris (France), Engineering</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stern School of Business, New York University, M.B.A. Finance/Economics</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Daniel Karp</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mr. Karp has served as our Executive Vice President, Corporate Development since June 2018. Prior to joining Biogen, Mr. Karp held a number of positions of increasing responsibility at Pfizer, a biopharmaceutical company, including as Vice President, Worldwide Business Development and Head of Business Development for Worldwide Research and Development from May 2016 to June 2018, as Vice President, Worldwide Business Development and BD Lead for Pfizer Vaccines, Oncology and Consumer Healthcare from January 2014 to May 2016, as Senior Director, Worldwide Business Development from December 2010 to December 2013, as Director, Worldwide Business Development from January 2008 to December 2010, as Senior Manager, Worldwide Business Development from May 2007 to December 2007 and as Manager, U.S. Business Development from July 2006 to April 2007. Prior to that, Mr. Karp held roles in healthcare and life sciences strategy consulting.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Duke University, B.S. Biology</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Wharton School of the University of Pennsylvania, M.B.A.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Robin C. Kramer</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ms. Kramer has served as our Vice President, Chief Accounting Officer since November 2018. Prior to joining Biogen, Ms. Kramer served as the Senior Vice President and Chief Accounting Officer of Hertz Global Holdings, Inc., a car rental company, from May 2014 to November 2018. Prior to that, Ms. Kramer was an audit partner at Deloitte &amp; Touche LLP (Deloitte), a professional services firm, from 2007 to 2014, including serving in Deloitte's National Office Accounting Standards and Communications Group from 2007 to 2010. From 2005 to 2007, Ms. Kramer served as Chief Accounting Officer of Fisher Scientific International, Inc., a laboratory supply and biotechnology company, and from 2004 to 2005 Ms. Kramer served as Director, External Reporting, Accounting and Control for the Gillette Company, a personal care company. Ms. Kramer also held partner positions in the public accounting firms of Ernst &amp; Young LLP and Arthur Anderson LLP. Ms. Kramer is a licensed certified public accountant (CPA) in Massachusetts. She is a member of the Massachusetts Society of CPAs and the American Institute of CPAs and served as a Board Member for the Massachusetts State Board of Accountancy from September 2011 to December 2015.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Salem State University, B.B.A. Accounting</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Paul McKenzie, Ph.D.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. McKenzie has served as our Executive Vice President, Pharmaceutical Operations and Technology since July 2016. Prior to that, from February 2016 to June 2016, he served as our Senior Vice President for Global Biologics Manufacturing &amp; Technical Operations. Prior to joining Biogen, beginning in 2008, Dr. McKenzie held a number of positions of increasing responsibility at J&amp;J, including Vice President of R&amp;D for J&amp;J&#8217;s Ethicon business and Global Head of Pharmaceutical Manufacturing and Technical Operations, where he led the manufacturing and technical operations team responsible for internal and external manufacturing of Janssen&#8217;s pharmaceutical portfolio. He also ran global Development for Janssen R&amp;D, helping to manage pipeline activities from discovery through clinical development and commercialization. Prior to J&amp;J, Dr. McKenzie also held various R&amp;D and manufacturing positions at BMS and Merck, both of which are pharmaceutical companies.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">University of Pennsylvania, B.S. Chemical Engineering</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Carnegie Mellon University, Ph.D. Chemical Engineering</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:5%;"></td><td style="width:95%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">Alfred W. Sandrock, Jr., M.D., Ph.D.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Experience</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dr. Sandrock has served as our Executive Vice President and Chief Medical Officer since October 2017. Prior to that, Dr. Sandrock served as our Executive Vice President, Chief Medical Officer Neurology and Neurodegeneration from October 2015 to October 2017, as our Chief Medical Officer and Group Senior Vice President from April 2013 to October 2015 and as our Chief Medical Officer and Senior Vice President of Development Sciences from February 2012 to April 2013. Prior to that, Dr. Sandrock held several other senior executive positions since joining Biogen in 1998, including Senior Vice President of Neurology Research and Development and Vice President of Clinical Development, Neurology.</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Public Company Boards</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Neurocrine Biosciences, Inc., a life sciences company</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Education</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stanford University, B.A. Human Biology</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard Medical School, M.D. </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Harvard University, Ph.D. Neurobiology</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6pt;"><font style="font-family:Wingdings;font-size:6pt;">l</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts General Hospital, internship in Medicine, residency and chief residency in Neurology and clinical fellowship in Neuromuscular Disease and Clinical Neurophysiology (electromyography)</font></div></td></tr></table></div></div><div><a name="sA5C0858C8B935B5BA6968E833FD0AECC"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Available Information</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our principal executive offices are located at 225 Binney Street, Cambridge, MA 02142 and our telephone number is (617)&#160;679-2000. Our website address is www.biogen.com. We make available free of charge through the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;section of our website our Annual Reports on Form&#160;10-K, Quarterly Reports on Form&#160;10-Q, Current Reports on Form&#160;8-K and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission (SEC). We include our website address in this report only as an inactive textual reference and do not intend it to be an active link to our website. The contents of our website are not incorporated into this report.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><a name="s022B08E42B265BE8A0F8842ACF5078F0"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;1A. &#160;&#160;&#160;&#160;Risk Factors</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are substantially dependent on revenues from our principal products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our principal products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our principal products and our financial rights in our anti-CD20 therapeutic programs for many years. Further, following the completion of the spin-off of our hemophilia business on February 1, 2017, our revenues are further reliant and concentrated on sales of our MS products in an increasingly competitive market, revenues from sales of our product for SMA and our financial rights in our anti-CD20 therapeutic programs. Any of the following negative developments relating to any of our principal products or any of our anti-CD20 therapeutic programs may adversely affect our revenues and results of operations or could cause a decline in our stock price: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">safety or efficacy issues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction or greater acceptance of competing products, including lower-priced competing products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements, increased competition or changes in, or implementation of, reimbursement policies and practices of payors and other third parties; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">adverse legal, administrative, regulatory or legislative developments.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA has been approved by, among others, the FDA, the EC and the Japanese Ministry of Health, Labor and Welfare, and is in the early stages of commercial launch in certain markets.&#160;In addition to risks associated with new product launches and the other factors described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ability to successfully commercialize SPINRAZA may be adversely affected due to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our limited marketing experience within certain SMA markets, which may impact our ability to develop additional relationships with the associated medical and scientific community; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the lack of readiness of healthcare providers to treat patients with SMA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effectiveness of our commercial strategy for marketing SPINRAZA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to maintain a positive reputation among patients, healthcare providers and others in the SMA community, which may be impacted by pricing and reimbursement decisions relating to SPINRAZA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including potential gene therapy or oral products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenues and results of operations or could cause a decline or volatility in our stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pricing and reimbursement for our products may be adversely affected by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pressure by employers on private health insurance plans to reduce costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidation and increasing assertiveness of payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, seeking price discounts or rebates in connection with the placement of our </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:54px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value; and</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our value-based contracting pilot program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to set the price for our products varies significantly from country to country and as a result so can the price of our products. Certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may not only limit the revenues from our products within that country, but may also adversely affect our ability to secure acceptable prices in existing and potential new markets. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenues.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. In addition, competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products or treatments brought to market by our competitors could cause revenues for our products to decrease due to potential price reductions and lower sales volumes. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payors, including managed care organizations, health insurers, pharmacy benefit managers, government health administration authorities, private health insurers and other organizations, increasingly seek ways to reduce their costs. Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients. Such measures include more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Payors also increasingly seek price discounts or rebates in connection with the placement of our products on their formularies or those they manage and control costs by imposing restrictions on access to or usage of our products, such as by requiring prior authorization or step therapy. Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Ultimately, additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success depends in part on our ability to obtain and defend patent and other intellectual property rights that are important to the commercialization of our products and product candidates. The degree of patent protection that will be afforded to our products and processes in the U.S. and in other important markets remains uncertain and is dependent upon the scope of protection decided upon by the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to successfully obtain or preserve patent protection for the technologies incorporated into our products and processes, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business. Under the Hatch-Waxman Act, a manufacturer may file an Abbreviated New Drug Application, seeking approval of a generic copy of an approved innovator product, or a NDA under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act, which may be for a new or improved version of the original innovator product. The manufacturers are allowed to rely on the safety and efficacy data of the innovator's product, may not need to conduct clinical trials, can market a competing version of a product after the expiration or loss of patent exclusivity or the expiration or loss of regulatory exclusivity and often charge significantly lower prices. Upon the expiration or loss of patent protection or the expiration or loss of regulatory exclusivity for a product, especially a small molecule product, the major portion of revenues for that product may be dramatically reduced in a very short period of time. If we cannot prevent others from exploiting our inventions, we will not derive the expected benefit from them. Furthermore, our products may be determined to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">infringe patents or other intellectual property rights held by third parties, which could result in financial, legal, business or reputational harm to us.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also rely on regulatory exclusivity for protection of our products. Implementation and enforcement of regulatory exclusivity, which may consist of regulatory data protection and market protection, varies widely from country to country.&#160;Failure to qualify for regulatory exclusivity, or failure to obtain or maintain the extent or duration of such protections that we expect in each of the markets for our products due to challenges, changes or interpretations in the law or otherwise, could affect our revenues for our products or our decision on whether to market our products in a particular country or countries or could otherwise have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Litigation, interferences, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews, administrative challenges or other similar types of proceedings are, have been and may in the future be necessary in some instances to determine the validity and scope of certain of our proprietary rights, and in other instances to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;We may also face challenges to our patent and regulatory protections covering our products by third parties, including manufacturers of generics and biosimilars that may choose to launch or attempt to launch their products before the expiration of our patent or regulatory exclusivity.&#160;Litigation, interference, oppositions, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reviews, administrative challenges or other similar types of proceedings are unpredictable and may be protracted, expensive and distracting to management. The outcome of such proceedings could adversely affect the validity and scope of our patent or other proprietary rights, hinder our ability to manufacture and market our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. An adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits derived from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our long-term success depends upon the successful development of new products and additional indications for existing products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our long-term viability and growth will depend upon the successful development of additional indications for our existing products as well as the successful development of new products and technologies from our research and development activities, our biosimilars joint venture with Samsung BioLogics or licenses or acquisitions from third parties. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product development is very expensive and involves a high degree of risk. Only a small number of research and development programs result in the commercialization of a product. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to compete effectively, our business and market position would suffer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing and research and development and other resources and other technological or competitive advantages. One or more of our competitors may benefit from significantly greater sales and marketing capabilities, may develop products that are accepted more widely than ours or may receive patent protection that dominates, blocks or adversely affects our product development or business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generics, biosimilars, prodrugs and other products approved under alternative regulatory pathways.&#160;Generic versions of drugs, biosimilars, prodrugs and other products approved under alternative regulatory pathways are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the price that we receive for branded products and the volume of branded products that we sell, which will negatively impact our revenues.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the MS market, we face intense competition as the number of products and competitors continues to expand. Due to our significant reliance on sales of our MS products, including TECFIDERA, our business may be harmed if we are unable to successfully compete in the MS market. More specifically, our ability to compete, maintain and grow our share in the MS market may be adversely affected due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of more efficacious, safer, less expensive or more convenient alternatives to our MS products, including our own products and products of our collaborators; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the introduction of biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under other alternative regulatory pathways, which would be significantly less costly than our products to bring to market and would be offered for sale at lower prices, and could result in a significant percentage of the sales of our products being lost to such biosimilars, follow-on products, generic versions of branded MS products, prodrugs or products approved under other alternative regulatory pathways;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the off-label use by physicians of therapies indicated for other conditions to treat MS patients; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">patient dynamics, including the size of the patient population and our ability to attract and maintain new and current patients to our therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">damage to physician and patient confidence in any of our MS products or generic or biosimilars of our MS products, or to our sales and reputation as a result of label changes or adverse experiences or events that may occur with patients treated with our MS products or generic or biosimilars of our MS products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inability to obtain appropriate pricing and reimbursement for our MS products compared to our competitors in key international markets; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our ability to obtain and maintain patent, data or market exclusivity for our MS products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business may be adversely affected if we do not successfully execute our growth initiatives.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate growth through internal development projects, commercial initiatives and external opportunities, which may include the acquisition, partnering and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. While we believe we have a number of promising programs in our pipeline, failure of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. The availability of high quality, cost-effective development opportunities is limited and competitive, and we are not certain that we will be able to identify candidates that we and our shareholders consider suitable or complete transactions on terms that are acceptable to us and our shareholders. We may fail to complete transactions for other reasons, including if we are unable to obtain desired financing on favorable terms, if at all. Even if we are able to successfully identify and complete acquisitions and other strategic alliances and collaborations, we may face unanticipated costs or liabilities in connection with the transaction or we may not be able to integrate them, which may prove to be an expensive and time consuming procedure, or take full advantage of them or otherwise realize the benefits that we expect.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supporting our growth initiatives and the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. If we do not successfully execute our growth initiatives, then our business and financial results may be adversely affected and we may incur asset impairment or restructuring charges.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasingly dependent upon technology systems and data. Our computer systems continue to increase in multitude and complexity, making them potentially vulnerable to breakdown, malicious intrusion and random attack.&#160;Likewise, data privacy or security breaches by individuals authorized to access our technology systems or others may pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers or other business partners, may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with malicious </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">intent. Cyber-attacks could include the deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. In addition, even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or the processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated. These restrictions may include limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expenses, have an adverse effect on our business, financial condition and results of operations, and cause our stock price to decline or experience periods of volatility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Even if we are able to successfully develop new products or indications, sales of new products or products with additional indications may not meet investor expectations. We may also make a strategic decision to discontinue development of a product or indication if, for example, we believe commercialization will be difficult relative to the standard of care or other opportunities in our pipeline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with cGCP. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials. If this CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs. Although we believe there are a number of other CROs we could engage to continue these activities, the replacement of an existing CRO may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adverse safety events involving our marketed products or generic or biosimilar products marketed by others may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in liabilities, loss of revenues, material write-offs of inventory, material impairments of intangible assets, goodwill and fixed assets, material restructuring charges or other adverse impacts on our results of operations. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales or stock price to decline or experience periods of volatility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restrictions on use or significant safety warnings that may be required to be included in the label of our products, such as the risk of developing PML or liver injury in the label for certain of our products, may significantly reduce expected revenues for those products and require significant expense and management time. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We depend on relationships with collaborators and other third parties for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on a number of significant collaborative and other third-party relationships for revenues, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource to third parties certain aspects of our regulatory affairs and clinical development relating to our products and product candidates. Reliance on collaborative and other third-party relationships subjects us to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">we may be unable to control the resources our collaborators or third parties devote to our programs, products or product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">disputes may arise under an agreement, including with respect to the achievement and payment of milestones or ownership of rights to technology developed with our collaborators or other third parties, and the underlying agreement with our collaborators or other third parties may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators or third parties fail to perform; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the interests of our collaborators or third parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenues; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">third-party relationships and collaborations often require the parties to cooperate, and failure to do so effectively could adversely affect product sales, or the clinical development or regulatory approvals of products under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any failure on the part of our collaborators or other third parties to comply with applicable laws and regulatory requirements in the marketing, sale and maintenance of the marketing authorization of our products or to fulfill any responsibilities our collaborators or other third parties may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenues as well as involve us in possible legal proceedings; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">any improper conduct or actions on the part of our collaborators or other third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, and could adversely impact our ability to conduct business, our operating results and our reputation.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed or revenues from products could decline and/or we may not realize the anticipated benefits of the collaboration arrangements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our results of operations may be adversely affected by current and potential future healthcare reforms.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the PPACA have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and the expansion of the number of hospitals eligible for discounts under Section 340B of the PHSA. These changes have had and are expected to continue to have a significant impact on our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may face uncertainties as a result of federal and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The administration has also indicated an intent to address prescription drug pricing and recent Congressional hearings have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expenses may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenues and may continue to adversely affect our revenues and results of operations in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight both in the U.S.&#160;and in foreign jurisdictions. The FDA and comparable agencies in other jurisdictions directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting and product risk management. Our interactions in the U.S.&#160;or abroad with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies such as ours are facing heightened scrutiny of their relationships with health care providers from anti-corruption enforcement officials. In addition, health care companies such as ours have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. If we, or our vendors or donation recipients, are deemed to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with wage and hour laws and other employment practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the FDA and foreign regulatory approval processes that may delay or prevent the approval of new products and result in lost market opportunity; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S. government shutdowns, similar to the one that began in December 2018, may result in delays to the FDA's review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA&#8217;s clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Violations of governmental regulation may be punishable by criminal and civil sanctions against us, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. In addition to penalties for violation of laws and regulations, we could be required to repay amounts we received from government payors, or pay additional rebates and interest if we are found to have miscalculated the pricing information we have submitted to the government. We cannot ensure that our compliance controls, policies and procedures will in every instance protect us from acts committed by our employees, collaborators, partners or third-party providers that would violate the laws or regulations of the jurisdictions in which we operate. Whether or not we have complied with the law, an investigation into alleged unlawful conduct could increase our expenses, damage our reputation, divert management time and attention and adversely affect our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our sales and operations are subject to the risks of doing business internationally.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are increasing our presence in international markets, particularly emerging markets, subjecting us to many risks that could adversely affect our business and revenues, such as:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the inability to obtain necessary foreign regulatory or pricing approvals of products in a timely manner; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">uncertainties regarding the collectability of accounts receivable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">fluctuations in foreign currency exchange rates that may adversely impact our revenues, net income and value of certain of our investments; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">difficulties in staffing and managing international operations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of governmental controls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less favorable intellectual property or other applicable laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the Bribery Act, and elsewhere and escalation of investigations and prosecutions pursuant to such laws; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the effects of the implementation of the U.K.&#8217;s decision to voluntarily depart from the E.U., known as Brexit;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">compliance with complex import and export control laws;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">restrictions on direct investments by foreign entities and trade restrictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">greater political or economic instability; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in tax laws; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the imposition of tariffs or embargoes and other trade restrictions, including the recent tariffs imposed by the U.S. and China and the possibility of additional tariffs or other trade restrictions relating to trade between the two countries.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our international operations are subject to regulation under U.S. law. For example, the FCPA prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including: possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management and key personnel changes may disrupt our operations, and we may have difficulty retaining key personnel or attracting and retaining qualified replacements on a timely basis for management and other key personnel who may leave the Company.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have experienced changes in management and other key personnel in critical functions across our organization in recent years. Changes in management and other key personnel have the potential to disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. Further, new members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new business opportunities or reduce or change emphasis on our existing business programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract them, particularly at the executive level. We may face difficulty in attracting and retaining key talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more late stage programs or recruitment by competitors. We cannot ensure you that we will be able to hire or retain the personnel necessary for our operations or that the loss of any such personnel will not have a material impact on our financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We are expanding our manufacturing capacity for future clinical and commercial requirements for product candidates, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe we currently have sufficient large-scale manufacturing capacity to meet our near-term manufacturing requirements. However, due to the long lead times necessary for the expansion of manufacturing capacity, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required. In addition, we have made and expect to make significant investments in connection with the building of this manufacturing facility with no assurance that such investment will be recouped. If we are unable to adequately and timely manufacture and supply our products and product candidates or if we do not fully utilize our manufacturing facilities, our business may be harmed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks of Reliance on Third Parties and Single Source Providers.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:54px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risks Relating to Compliance with cGMP.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or the facilities or operations of third parties to pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Global Bulk Supply Risks. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rely on our principal manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk of Product Loss.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenues or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilars, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our success in commercializing biosimilars developed by Samsung Bioepis is subject to a number of risks, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Reliance on Third Parties.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;We are dependent on the efforts of Samsung Bioepis and other third parties over whom we have limited or no control in the development and manufacturing of biosimilars products. If Samsung Bioepis or such other third parties fail to perform successfully, we may not realize the anticipated benefits of our investment in Samsung Bioepis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Regulatory Compliance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intellectual Property and Regulatory Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:54px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Failure to Gain Market and Patient Acceptance.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Ability to Provide Adequate Supply.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Manufacturing biosimilars is complex.&#160;If we encounter any manufacturing or supply chain difficulties, we may be unable to meet higher than anticipated demand; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Competitive Challenges.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Biosimilar products face significant competition, including from innovator products and from biosimilar products offered by other companies. In some jurisdictions, local tendering processes may restrict biosimilar products from being marketed and sold in those jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If Samsung Bioepis is unsuccessful in the development, manufacture and commercialization of biosimilar products, we may not realize the anticipated benefits of our investment in Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, as Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis, may be limited and we may realize significantly less than the value of such investment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our operating results are subject to significant fluctuations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our quarterly revenues, expenses and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as well as the timing of charges and expenses that we may take. We have recorded, or may be required to record, charges that include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">impairments with respect to investments, fixed assets and long-lived assets, including in-process R&amp;D and other intangible assets; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">inventory write-downs for failed quality specifications, charges for excess or obsolete inventory and charges for inventory write downs relating to product suspensions, expirations or recalls; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent consideration;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">bad debt expenses and increased bad debt reserves; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">milestone payments under license and collaboration agreements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">payments in connection with acquisitions and other business development activities.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Although we have foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in the mix of our profitability from country to country, the results of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws, including the Tax Cuts and Jobs Act of 2017 (2017 Tax Act). Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as global intangible low-taxed income (GILTI), and includes base erosion prevention measures on non-U.S. earnings. These changes became effective in 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act also includes a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our estimates concerning the impact of the 2017 Tax Act on our accounting and on our business remain subject to developing interpretations of the provisions of the 2017 Tax Act and changes to certain estimates and amounts related to the earnings and profits of certain subsidiaries. U.S. Treasury regulations, administrative interpretations or court decisions interpreting the 2017 Tax Act may require further adjustments and changes in our estimates, which could have a material adverse effect on our business, results of operations or financial condition. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, the adoption of some or all of the recommendations set forth in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities in the countries in which we operate, could negatively impact our effective tax rate. These recommendations focus on payments from affiliates in high tax jurisdictions to affiliates in lower tax jurisdictions and the activities that give rise to a taxable presence in a particular country.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our investments in properties may not be fully realized.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. For strategic or other operational reasons, we may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate an owned or leased property, we may incur significant cost, including facility closing costs, employee separation and retention expenses, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our portfolio of marketable securities is subject to market, interest and credit risk that may reduce its value.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a portfolio of marketable securities for investment of our cash. Changes in the value of our portfolio of marketable securities could adversely affect our earnings. In particular, the value of our investments may decline due to increases in interest rates, downgrades of the bonds and other securities included in our portfolio, instability in the global financial markets that reduces the liquidity of securities included in our portfolio, declines in the value of collateral underlying the securities included in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time our Board of Directors authorizes share repurchase programs, including most recently our 2018 Share Repurchase Program, which is a program to repurchase up to $3.5 billion of our common stock that was </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">authorized by our Board of Directors in August 2018. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our agreements applicable to the repurchase of shares. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our 2018 Share Repurchase Program could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may not be able to access the capital and credit markets on terms that are favorable to us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets have experienced extreme volatility and disruption in the past, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse capital and credit market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">increase our vulnerability to general adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our ability to access capital markets and incur additional debt in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development efforts, research and development and mergers and acquisitions;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a competitive disadvantage compared to our competitors that have less debt.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. In addition, inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">The increasing use of social media platforms presents new risks and challenges.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face overly restrictive regulatory actions or incur other harm to our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders.&#160;Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">We may be exposed to claims and liabilities as a result of the spin-off of our hemophilia business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, in connection with the spin-off of our hemophilia business, we distributed all of the then outstanding shares of Bioverativ Inc. (Bioverativ) common stock to Biogen shareholders pursuant to a separation agreement. In March 2018 Bioverativ was acquired by Sanofi and is now an indirect wholly-owned subsidiary of Sanofi.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The spin-off of our hemophilia business was intended to qualify for tax-free treatment to Biogen and its shareholders under the Internal Revenue Code. Completion of the spin-off was conditioned upon, among other things, our receipt of a favorable opinion from our tax advisors with respect to the tax-free nature of the transaction. The opinion is not binding on the U.S. Internal Revenue Service (IRS) or the courts, and there can be no assurance that the IRS or the courts will not challenge the qualification of the spin-off as a tax-free transaction or that any such challenge would not prevail. If the spin-off is determined to be taxable, the full financial benefits expected to result from the separation may not be achieved and/or Biogen and its shareholders could incur significant tax liabilities, which could adversely affect our business, financial condition or results of operations and the value of our stock could be adversely impacted.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bioverativ agreed to indemnify us for certain potential liabilities that may arise, but we cannot guarantee that Bioverativ will be able to satisfy its indemnification obligations. Third parties could also seek to hold us responsible for any of these liabilities or obligations, and the indemnity rights we have under the separation agreement may not be sufficient to fully cover all of these liabilities and obligations. Even if we are successful in obtaining indemnification, we may have to bear costs temporarily. In addition, our indemnity obligations to Bioverativ may be significant. These risks could negatively affect our business, financial condition or results of operations.</font></div><div><a name="s5D0C6888D8895790B56EC9590AF1F523"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;1B. &#160;&#160;&#160;&#160;Unresolved Staff Comments</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div><div><a name="s0EB35F22F75B5B3EA9585C21A9E8FB22"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;2. &#160;&#160;&#160;&#160;Properties</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Below is a summary of our owned and leased properties as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Massachusetts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In Cambridge, MA, we own approximately 508,000&#160;square feet of real estate space, consisting of a building that houses a research laboratory and a cogeneration plant totaling approximately 263,000&#160;square feet and a building that contains research, development and quality laboratories totaling approximately 245,000&#160;square feet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we lease a total of approximately 1,157,000&#160;square feet in Massachusetts, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">800,000&#160;square feet in Cambridge, MA, which is comprised of offices for our corporate headquarters, and other administrative and development functions and laboratories, of which 289,000 square feet is subleased by multiple companies for general office space, laboratories and manufacturing facilities; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">357,000&#160;square feet of office space in Weston, MA, of which 174,000 square feet is subleased through the remaining term of our lease agreement.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Massachusetts lease agreements expire at various dates through the year 2028.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">North Carolina</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In RTP, NC, we own approximately 1,022,000&#160;square feet of real estate space, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">357,000&#160;square feet of laboratory and office space;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">188,000 square foot multi-purpose facility, including an ASO manufacturing suite and administrative space;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">175,000&#160;square feet related to a large-scale biologics manufacturing facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">105,000&#160;square feet related to a small-scale biologics manufacturing facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84,000&#160;square feet of warehouse space and utilities;&#160;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70,000 square feet related to a parenteral fill-finish facility; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43,000&#160;square feet related to a large-scale purification facility.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we own approximately 40,000 square feet of warehouse space in Durham, NC. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Denmark</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We own a large-scale biologics manufacturing facility totaling approximately 228,000&#160;square feet located in Hiller&#248;d, Denmark. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also own approximately 306,000&#160;square feet of additional space, which is summarized as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">139,000&#160;square feet of warehouse, utilities and support space;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70,000&#160;square feet related to a label and packaging facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50,000&#160;square feet related to a laboratory facility;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47,000&#160;square feet of administrative space.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we lease approximately 26,000 square feet of administrative space in Hiller&#248;d, Denmark.</font></div><div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Switzerland</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. Upon completion, the facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other International</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease office space in Baar, Switzerland, our international headquarters; Zug, Switzerland; the U.K.; Germany; France; Denmark and numerous other countries. Our international lease agreements expire at various dates through the year 2028.</font></div><div><a name="s14E4E2157A4F53D8A155CA297B50FF0C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;3. &#160;&#160;&#160;&#160;Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal matters as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report, which is incorporated into this item by reference.</font></div><div><a name="s7A5F84AB4804540A907D9546E5A9683C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;&#160;4. &#160;&#160;&#160;&#160;Mine Safety Disclosures</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><a name="s69F1031EA97551128CD40642A48F4AD5"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;II</font></div><div><a name="s1F9B5B7DB082508A8FFA50D2978EA272"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;5. &#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Market and Stockholder Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our common stock trades on The Nasdaq Global Select Market under the symbol &#8220;BIIB.&#8221; As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;1, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, there were approximately 600 shareholders of record of our common stock.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not paid cash dividends since our inception. While we historically have not paid cash dividends and do not have a current intention to pay cash dividends, we continually review our capital allocation strategies, including, among other things, payment of cash dividends, share repurchases and acquisitions.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Issuer Purchases of Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The following table summarizes our common stock repurchase activity under our 2018 Share Repurchase Program during the fourth quarter of 2018:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:18%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average&#160;Price</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Paid&#160;per&#160;Share</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">($)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares&#160;Purchased</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">as&#160;Part&#160;of&#160;Publicly</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Announced Programs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(#)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Maximum</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Approximate Dollar Value</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">of Shares That May Yet Be</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Purchased Under</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Our Programs ($ in millions)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">October 2018</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">762,633</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">309.42</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">762,633</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">3,264.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">November 2018</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,809,120</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">317.55</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,809,120</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,689.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December 2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,774,138</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">305.59</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,774,138</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">2,147.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">4,345,891</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">311.24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized our 2018 Share Repurchase Program, which is a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. Our 2018 Share Repurchase program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, 3.7 million and 3.3 million shares of common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, $1.0 billion and $1.0 billion during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, 2017 and 2016, respectively. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Performance Graph</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The performance graph below compares the five-year cumulative total stockholder return on our common stock, the S&amp;P 500 Index, the Nasdaq Pharmaceutical Index and the Nasdaq Biotechnology Index.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company. In connection with the spin-off, each Biogen shareholder received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The performance graph below assumes the investment of $100.00 on December&#160;31, 2013, in our common stock and each of the three indexes, with dividends being reinvested. Our stock prices have been adjusted for the effect of the spin-off of our hemophilia business. The five-year cumulative total stockholder return for Biogen does not reflect the reinvestment by Biogen shareholders of the distribution they received in connection with the spin-off of our hemophilia business or any subsequent increase or decrease in value of Bioverativ stock subsequent to the spin-off. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The stock price performance in the graph below is not necessarily indicative of future price performance.</font></div><div style="line-height:120%;text-align:left;"><img src="performancegraph.jpg" alt="performancegraph.jpg" style="height:480px;width:613px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2013</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$121.42</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.58</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$101.43</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$123.54</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$116.69</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nasdaq Pharmaceutical</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$121.82</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.44</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$127.04</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$151.33</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$163.37</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">S&amp;P 500 Index</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.69</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$115.26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$129.05</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$157.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.33</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nasdaq Biotechnology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$134.40</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$118.15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$143.74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$131.00</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information included under the heading </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Performance Graph</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;is &#8220;furnished&#8221; and not &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be &#8220;soliciting material&#8221; subject to Regulation&#160;14A or incorporated by reference in any filing under the Securities Act or the Securities Exchange Act.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><a name="s0B9D923A3D235F1A8A4C01BDA429E13D"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;6. &#160;&#160;&#160;&#160;Selected Financial Data</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SELECTED FINANCIAL DATA</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="20" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:18px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are summarized as follows:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">(a) (b) (c) (d) (e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(c) (d) (e) (f) </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Results of Operations (1)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,188.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,203.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,339.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,195.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">585.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">236.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">304.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13,452.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,273.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,448.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,763.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,703.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,564.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,928.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,297.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,872.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,747.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain on sale of rights</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,888.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,345.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,151.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,891.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,972.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(217.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(218.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(123.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(25.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,899.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,128.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,933.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,767.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,946.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,425.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,458.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,237.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,161.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">989.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,474.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,670.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,695.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,593.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,941.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to noncontrolling interests, net of tax (3)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,430.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,547.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,934.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Diluted Earnings Per Share (4)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">205.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">231.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">237.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="20" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Financial Condition (1)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,913.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,746.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,724.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,188.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,316.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25,288.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23,652.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22,876.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19,504.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14,314.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable, less current portion </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(5)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,936.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,935.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,512.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,521.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">580.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">(4)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13,039.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,612.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,140.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,372.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,809.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the following notes, the financial data included within the tables above should be read in conjunction with our consolidated financial statements and related notes and Item 7. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report and our previously filed Annual Reports on Form&#160;10-K.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">On February 1, 2017, we completed the spin-off of our hemophilia business. Our consolidated results of operations and financial position reflect the financial results of our hemophilia business for all periods through January 31, 2017. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Product revenues, net reflect the impact of the following product launches:</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Commercial sales of SPINRAZA in the U.S. began in the fourth quarter of 2016 and in rest of world markets beginning in the first quarter of 2017.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Under our collaboration agreement with AbbVie, we began to recognize revenues on sales of ZINBRYTA to third parties in the E.U. in the third quarter of 2016. In March 2018 we and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for RMS.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Under our commercial agreement with Samsung Bioepis, we began to recognize revenues on sales of BENEPALI and FLIXABI to third parties in the E.U. in the first and third quarters of 2016, respectively, and began to recognize revenues on sales of IMRALDI to third parties in the E.U. in the fourth quarter of 2018. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Commercial sales of ALPROLIX commenced in the second quarter of 2014 and commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014. We stopped recognizing product revenues from ALPROLIX and ELOCTATE effective February 1, 2017,upon the completion of the spin-off of our hemophilia business.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Net income (loss) attributable to noncontrolling interests, net of tax includes the following activity:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Pre-tax charges of $50.0 million and $150.0 million for the years ended December 31, 2018 and 2017, respectively, for payments made under the terms of the Neurimmune Agreement in exchange for reductions in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">A pre-tax charge of $60.0 million for the year ended December 31, 2015, for a milestone payment due to Neurimmune upon the enrollment of the first patient in a Phase 3 study for aducanumab.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:48px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">For additional information on our collaboration arrangement with Neurimmune, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, to our consolidated financial statements included in this report.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total Biogen Inc. shareholders' equity reflects the repurchase of approximately 40.0 million shares of our common stock at a cost of approximately $11.7 billion between December 31, 2014 and December 31, 2018:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">During 2018 we repurchased and retired approximately 4.3 million and 10.5 million shares of our common stock at a cost of approximately $1.4 billion and $3.0 billion under our 2018 and 2016 Share Repurchase Programs, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">During 2017 we repurchased and retired approximately 3.7 million shares of our common stock at a cost of approximately $1.0 billion under our 2016 Share Repurchase Program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">During 2017 we repurchased approximately 1.2 million shares of our common stock at a cost of $365.4 million under a program authorized by our Board of Directors in February 2011 for the repurchase of up to 20.0 million shares of our common stock (2011 Share Repurchase Program). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">During 2016 we repurchased and retired approximately 3.3 million shares of our common stock at a cost of approximately $1.0 billion under our 2016 Share Repurchase Program.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">During 2015 we repurchased and retired approximately 16.8 million shares of our common stock at a cost of $5.0 billion under a program authorized by our Board of Directors in May 2015 for the repurchase of up to $5.0 billion of our common stock.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(5)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Notes payable, less current portion reflect:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Our 2017 repayment of our 6.875% Senior Notes that were issued in 2008 with an aggregate principal amount of $550.0 million; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:46px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">The issuance of our senior unsecured notes for an aggregate principal amount of $6.0 billion in September 2015.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total cost and expenses for the year ended December 31, 2018, includes a pre-tax charge to research and development expense of $486.2 million upon the closing of the 2018 Ionis Agreement. Included in this amount was a charge of $162.1 million reflecting the premium paid above fair value for the purchase of approximately 11.5 million shares of Ionis' common stock upon the closing of the 2018 Ionis Agreement. This charge is partially offset by net gains totaling $100.9 million recognized in other income (expense), net for the year ended December 31, 2018, related to these shares. For further information on our collaboration arrangements with Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, to our consolidated financial statements included in this report.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total cost and expenses for the year ended December 31, 2018, includes the impact of impairment charges totaling $189.3 million related to certain in-process research and development (IPR&amp;D) assets associated with our vixotrigine (BIIB074) program. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total cost and expenses for the year ended December 31, 2018, includes pre-tax charges to acquired IPR&amp;D totaling $112.5 million for upfront payments made to AliveGen, Pfizer and Karyopharm upon the closing of our asset purchase </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:29px;padding-top:10px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">transactions for BIIB110, BIIB104 and BIIB100, respectively, as the underlying assets had not yet reached technological feasibility.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:29px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total cost and expenses for the year ended December 31, 2017, includes a pre-tax charge to acquired IPR&amp;D of $120.0 million for an upfront payment made to Remedy Pharmaceuticals Inc. (Remedy) upon the closing of our asset purchase transaction for BIIB093 in LHI.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income tax expense for the year ended December 31, 2017, includes a $1,173.6 million provisional estimate pursuant to SEC Staff Accounting Bulletin No. 118. Our provisional estimate included an amount of $989.6 million associated with the Transition Toll Tax and $184.0 million related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law. </font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:29px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Income tax expense for the year ended December 31, 2018, reflects a net increase to expense of approximately $125.0 million recognized upon finalization of our provisional estimates related to the Transition Toll Tax, the remeasurement of our deferred tax assets and liabilities, the impact of electing to record deferred taxes on GILTI and other aspects of the 2017 Tax Act. For additional information on the 2017 Tax Act, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, to our consolidated financial statements included in this report.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total cost and expenses for the year ended December 31, 2016, includes a pre-tax charge of $454.8 million related to our January 2017 settlement and license agreement with Forward Pharma A/S (Forward Pharma).</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:29px;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total cost and expenses for the years ended December 31, 2018 and 2017, includes $176.8 million and $328.2 million, respectively, of impairment charges related to our intangible asset associated with our U.S. license to Forward Pharma&#8217;s intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. For additional information on our settlement and license agreement with Forward Pharma and related intangible assets, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">, to our consolidated financial statements included in this report.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:29px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:5px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Total cost and expenses for the year ended December 31, 2017, includes pre-tax charge of $300.0 million for an upfront payment made to BMS upon entering into our agreement to exclusively license BIIB092 and a pre-tax charge of $60.0 million for a development milestone that became payable to the former shareholders of iPierian, Inc. (iPierian) upon the dosing of the first patient in the Phase 2 study of BIIB092 for PSP.</font></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;padding-left:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><a name="s9D7322C2A1975C1EBBECDC47FFCD4CEF"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;7. &#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following discussion should be read in conjunction with our consolidated financial statements and the accompanying notes beginning on page&#160;F-1 of this report. </font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Executive Summary</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Introduction</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of MS and neuroimmunology, AD and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including SMA and ALS. We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of PPMS and RMS and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our revenues depend upon continued sales of our principal products, as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our principal products and our financial rights in our anti-CD20 therapeutic programs for many years. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilar products through Samsung Bioepis, our joint venture with Samsung BioLogics. Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the E.U. For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent publicly traded company. Our consolidated results of operations and financial position included in our consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Environment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved MS products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing MS products. Our products may also face increased competitive pressures from the introduction of generic versions, prodrugs of existing therapies, biosimilars of existing products, other products approved under alternative regulatory pathways and other technologies. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Drug prices are under significant scrutiny in the markets in which our products are prescribed.&#160;We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis.&#160;</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenues and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products or could cause a decline or volatility in our stock price.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to&#160;the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures as well as the impact of the continued uncertainty of the credit and economic conditions in certain countries in Europe.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our competition and pricing risks that could negatively impact our product sales, please read Item 1A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Risk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and Item 7A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Brexit</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the U.K. electorate voted in a referendum to voluntarily depart from the E.U., known as Brexit. In March 2017 the U.K. government formally notified the European Council of its intention to leave the E.U. and began to negotiate the terms of the future relationship between the U.K. and the E.U. upon exit, which is expected to occur in March 2019.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The potential impact on our results of operations and liquidity resulting from Brexit remains unclear. The actual effects of Brexit will depend upon many factors and significant uncertainty remains with respect to the ultimate resolution of the Brexit negotiations. The final outcome of these negotiations may impact certain of our research, commercial and general business operations in the U.K. and the E.U., including the approval and supply of our products. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compliance with any resulting regulatory mandates may prove challenging and the macroeconomic impact on our sales and consolidated results of operations from these developments remains unknown. We do not, however, expect Brexit to have a material impact on our consolidated results of operations as approximately 2% of our total product revenues in each of 2018 and 2017 were derived from U.K. sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While we are in the process of implementing measures to meet E.U. legal requirements and to modify our business operations after the U.K. separates from the E.U., we cannot predict the direction Brexit-related developments will take nor the impact of those developments on our European operations and the economies of the markets where we operate. We will continue to monitor for developments and will assess the resulting potential impact on our business and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Financial Highlights</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;"><img src="financialhighlights18.jpg" alt="financialhighlights18.jpg" style="height:433px;width:317px;"></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc. were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.58</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of 81.0% over $11.92 in the same period in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Results of Operations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our net income and diluted earnings per share attributable to Biogen Inc. for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, compared to the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues were </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$13,452.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">9.6%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over $12,273.9 million in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$10,886.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.1%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over $10,354.7 million in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to higher revenues from SPINRAZA and our biosimilar products, partially offset by a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;net decrease in our MS product revenues, primarily resulting from a decrease in our Interferon product revenues. Product revenues, net, compared to the same period in 2017, further reflects the favorable impact of foreign currency exchange of $88.7 million. Net losses recognized in relation to the settlement of certain cash flow hedge instruments under our foreign currency hedging program for 2018 and 2017 were similar.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For 2018 compared to 2017, product revenues, net, were also negatively impacted by the elimination of worldwide ELOCTATE and ALPROLIX revenues resulting from the spin-off of our hemophilia business on February 1, 2017, as well as a decrease in ZINBRYTA revenues due to the voluntary worldwide withdrawal of ZINBRYTA, which was announced in the first quarter of 2018. Compared to 2017, these events negatively impacted revenues by $125.7 million.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,980.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">27.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over $1,559.2 million in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was due to higher royalty revenues on sales of OCREVUS as well as an increase on our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$585.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">62.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over $360.0 million in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to higher contract manufacturing revenues.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses totaled </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$7,564.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, representing an increase of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">9.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over $6,928.1 million in </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This increase was primarily due to a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">15.2%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in research and development, a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">11.4%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase </font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">in cost of sales and an </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">8.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase in selling, general and administrative expenses. These increases were partially offset by the net change in (gain) loss recognized on the fair value remeasurement of our contingent consideration obligations as well as a decrease in amortization and impairment of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in research and development was primarily due to the $482.6 million net charge recognized upon the closing of the 2018 Ionis Agreement, partially offset by charges recognized in the prior year period totaling $360.0 million related to our exclusive license agreement with BMS as well as increased spending related to our early and late stage pipeline candidates.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in cost of sales was primarily due to higher contract manufacturing shipments of drug product and drug substance production provided to our strategic partners, an increase in biosimilar sales volumes and increased royalties payable to Ionis on higher sales of SPINRAZA, partially offset by lower sales and costs associated with our MS products.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in selling, general and administrative expenses was primarily due to increases in operational spending on sales and marketing activities in support of our marketed products, primarily related to SPINRAZA as we continue to expand into new international markets and increased costs incurred in support of our business development transactions completed in the current period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. was favorably impacted by a decrease in our effective tax rate to 24.2% for the year ended December 31, 2018, from 47.9% for 2017. The reduction in tax rate was primarily due to the favorable impacts of the 2017 Tax Act on our 2018 tax rate and the Transition Toll Tax expense recognized on enactment in December 2017.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Condition, Liquidity and Capital Resources</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generated </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$6,187.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net cash flows from operations for </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were primarily driven by earnings. </font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash, cash equivalents and marketable securities totaled approximately </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$4,913.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We repurchased and retired approximately 14.8 million shares of our common stock at a cost of approximately $4.4 billion during 2018 under our 2018 and 2016 Share Repurchase Programs.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquisitions, Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB100 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired BIIB100 from Karyopharm. BIIB100 is a Phase 1 ready investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XP01, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Karyopharm.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB104 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we acquired BIIB104 from Pfizer. BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for CIAS, representing our first program in neurocognitive disorders. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Pfizer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2018 we made a $50.0 million payment to Neurimmune under the terms of the Neurimmune Agreement to reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by 5%. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, will now range from the high single digits to sub-teens.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ionis Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we closed the 2018 Ionis Agreement, which is a new 10-year exclusive agreement with Ionis to develop novel ASO drug candidates for a broad range of neurological diseases, and made a total payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Ionis. We have the option to license therapies arising out of the 2018 Ionis Agreement and will be responsible for the development and potential commercialization of such therapies.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TMS Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we entered into an exclusive option agreement with TMS granting us the option to acquire TMS-007, a plasminogen activator with a novel MOA associated with breaking down blood clots, which is in Phase 2 development in Japan, and backup compounds for the treatment of stroke. In exchange for the purchase option, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment to TMS.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement with Samsung BioLogics to increase our ownership percentage in Samsung Bioepis from approximately 5% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB110 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we acquired BIIB110 and ALG-802 from AliveGen. BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 in multiple neuromuscular indications, including SMA and ALS. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to AliveGen.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB067 Option Exercise</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067, an investigational treatment for ALS with SOD1 mutations. In connection with the option exercise, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Ionis.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">C4 Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we entered into a collaborative research and license agreement with C4T to investigate the use of C4T&#8217;s novel protein degradation platform to discover and develop potential new treatments for neurological diseases, such as AD and Parkinson&#8217;s disease. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration. In connection with this agreement, we made an upfront payment of $45.0 million to C4T. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Skyhawk Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk pursuant to which the companies will leverage Skyhawk&#8217;s SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">therapies resulting from this collaboration. In connection with this agreement, we made an upfront payment of $74.0 million to Skyhawk.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisitions of BIIB100, BIIB104 and BIIB110 and our exclusive option agreement with TMS, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Ionis, Samsung Bioepis and C4T, please read Note 19,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report. For additional information on our collaboration arrangement with Skyhawk, please read Note 27, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Subsequent Events</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Key Developments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ZINBRYTA Withdrawal</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 we and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for RMS.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with AbbVie, please read Note 19,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 we began to recognize revenues on sales of IMRALDI, an adalimumab biosimilar referencing HUMIRA, to third parties in the E.U. We and Samsung Bioepis previously entered into an agreement with AbbVie for the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2018 Share Repurchase Program</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized our 2018 Share Repurchase Program, which is a program to repurchase up to $3.5 billion of our common stock. Our 2018 Share Repurchase Program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div></div><div><a name="sDB93868B707E5CC9B6A57DE3202CE4BB"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018 compared to 2017</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017 compared to 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,800.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,017.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,050.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Rest of world</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,086.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,337.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">585.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">62.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13,452.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,273.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,448.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018 compared to 2017</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017 compared to 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,274.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,214.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,968.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,363.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,645.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,795.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,864.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,973.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,963.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(97.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">575.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: MS product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8,595.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,977.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,819.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,724.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">883.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">95.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19,110.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biosimilars:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">485.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">370.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">30.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">268.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">380.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,900.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IMRALDI</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Biosimilar product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">545.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">379.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">22.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(43.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">513.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(90.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">333.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(92.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal: Hemophilia product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">846.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(92.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total product revenues, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">* Interferon includes AVONEX and PLEGRIDY.</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><a name="s40FE6C54BC175BA38355376E5BAAD213"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Multiple Sclerosis (MS)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA</font></div><div style="line-height:120%;text-align:left;"><img src="tecfiderarev.jpg" alt="tecfiderarev.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. TECFIDERA revenues was primarily due to a decrease in unit sales volume of 5% and higher discounts and allowances, partially offset by price increases. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. TECFIDERA revenues was primarily due to price increases, partially offset by higher discounts and allowances and a decrease in unit sales volume of 3%.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume of 16% and the favorable impact of foreign currency exchange of $30.8 million. These increases were partially offset by higher discounts and allowances and pricing reductions in certain European countries. TECFIDERA rest of world revenues for 2018 also include net losses recognized in relation to the settlement of certain cash flow hedge instruments under our foreign currency hedging program totaling $11.8 million, compared to net losses recognized of $12.4 million for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TECFIDERA revenues was primarily due to increases in unit sales volume of 19% primarily in the E.U., partially offset by pricing reductions in certain European countries.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate continued increase in TECFIDERA demand on a global basis in 2019, compared to 2018, with increasing competition from additional treatments for MS. We expect sales volumes in the U.S. to stabilize in future periods. We also expect </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">moderate volume growth in our international markets with price reductions in certain European countries.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interferon</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX and PLEGRIDY</font></div><div style="line-height:120%;text-align:left;"><img src="interferonrev.jpg" alt="interferonrev.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. Interferon revenues was primarily due to a decrease in Interferon unit sales volumes of 15%, which was primarily attributable to patients transitioning to other MS therapies, partially offset by price increases. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. Interferon revenues was primarily due to an overall decrease in Interferon unit sales volumes of 12%, which was primarily attributable to patients transitioning to other MS therapies, partially offset by price increases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world Interferon revenues was primarily due to a decrease in Interferon unit sales volume of 6%, as patients transition to other MS therapies in the E.U., and pricing reductions in certain European countries. These decreases were partially offset by the favorable impact of foreign currency exchange of $21.9 million. Net losses recognized in relation to the settlement of certain cash flow hedge instruments under our foreign currency hedging program, and included in Interferon rest of world revenues, totaled $8.7 million for both </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world Interferon revenues was primarily due to an overall decrease in AVONEX unit sales volume of 14% primarily due to patients transitioning to other MS therapies in the E.U. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that Interferon revenues will continue to decline in both the U.S. and international markets </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">in 2019, compared to 2018, as a result of increasing competition from our other MS products as well as other treatments for MS, including biosimilars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">AVONEX</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;U.S. AVONEX revenues totaled $1,420.2 million, $1,593.6 million and $1,675.3 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;rest of world AVONEX revenues totaled $495.3 million, $557.9 million and $638.2 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">PLEGRIDY</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;U.S. PLEGRIDY revenues totaled $248.1 million, $295.5 million and $305.0 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;rest of world PLEGRIDY revenues totaled $199.4 million, $198.8 million and $176.7 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;text-align:left;"><img src="tysabrirev.jpg" alt="tysabrirev.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. TYSABRI revenues was primarily due to a decrease in unit sales volume of 9%, partially offset by price increases and lower discounts and allowances. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in U.S. TYSABRI revenues was primarily due to higher discounts and allowances and a decrease in unit sales volume of 4%, partially offset by price increases.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in rest of world TYSABRI revenues was primarily due to the recognition in the prior year period of approximately $45.0 million of previously deferred </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">revenues in Italy relating to the pricing agreement with the Italian National Medicines Agency (Agenzia Italiana de Farmaco or AIFA), as discussed below, and pricing reductions in certain European countries. These decreases were partially offset by an increase in unit sales volumes of 1% and the favorable impact of foreign currency exchange of $27.8 million.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TYSABRI rest of world revenues for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;also include net losses recognized in relation to the settlement of certain cash flow hedge instruments under our foreign currency hedging program totaling $10.5 million, compared to net losses recognized of $10.7 million for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world TYSABRI revenues was primarily due to the recognition of approximately $45.0 million of previously deferred revenues in Italy relating to the pricing agreement with AIFA, as discussed below, and a 12% increase in unit sales volume primarily in our international partner markets, partially offset by a prior year favorable adjustment of approximately $20.0 million to previous reserves estimates related to a government price reimbursement program included in our discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2011 Biogen Italia SRL, our Italian subsidiary, received notice from AIFA that sales of TYSABRI after mid-February 2009 through mid-February 2011 exceeded a reimbursement limit pursuant to a Price Determination Resolution granted by AIFA in December 2006. Since being notified in the fourth quarter of 2011 that AIFA believed a reimbursement limit was still in effect, we deferred revenue on sales of TYSABRI as if the reimbursement limit were in effect for each biannual period beginning in mid-February 2009. In June 2014 AIFA approved a resolution affirming that there is no reimbursement limit from and after February 2013. In the first quarter of 2017 we reached an agreement with AIFA's Price and Reimbursement Committee resolving all of AIFA's claims relating to sales of TYSABRI in excess of the reimbursement limit for prior periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We anticipate a slight decline in TYSABRI demand on a global basis in 2019, compared to 2018, with expected volume declines in the U.S. due to increasing competition from additional treatments for MS, including OCREVUS, exceeding volume growth in our international markets.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">ZINBRYTA</font></div><div style="line-height:120%;text-align:left;"><img src="zinbrytarev.jpg" alt="zinbrytarev.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under our collaboration agreement with AbbVie, we began to recognize revenues on sales of ZINBRYTA to third parties in the E.U. in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in ZINBRYTA revenues was primarily due to the voluntary worldwide withdrawal of ZINBRYTA for RMS, which we and AbbVie announced in March 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in ZINBRYTA revenues was primarily due to an increase in unit sales volume.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spinal Muscular Atrophy</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;text-align:left;text-indent:18px;"><img src="spinrazarev.jpg" alt="spinrazarev.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We began to recognize revenues on sales of SPINRAZA in the U.S. in the fourth quarter of 2016 and in our rest of world markets beginning in the first quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. SPINRAZA revenues was primarily due to increases in unit sales volume of 32%, partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in rest of world SPINRAZA revenues was primarily due to increases in unit sales volumes as the product continued to be launched in new markets around the world, partially offset by the unfavorable impact of foreign currency exchange of $10.0 million.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S. and rest of world SPINRAZA revenues was primarily due to an increase in unit sales volume in new and existing markets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We expect that the rate at which SPINRAZA revenues will grow will moderate in 2019, compared to 2018, primarily due to a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we are aware of other products in development that, if successfully developed and approved, may compete with SPINRAZA in the SMA market, including a potential gene therapy product for the treatment of SMA Type 1, which could come to market in the U.S. in 2019. Future sales of SPINRAZA may be adversely affected by the commercialization of competing products. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Biosimilars</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">BENEPALI, FLIXABI and IMRALDI</font></div><div style="line-height:120%;"><img src="biosimilarrev.jpg" alt="biosimilarrev.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under our commercial agreement with Samsung Bioepis, we began to recognize revenues on sales of BENEPALI and FLIXABI to third parties in the E.U. in the first and third quarters of 2016, respectively, and began to recognize revenues on sales of IMRALDI to third parties in the E.U. in the fourth quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in biosimilar revenues was primarily due to an increase in BENEPALI unit sales volume of 45% and the launch of IMRALDI in the fourth quarter of 2018. These increases were partially offset by pricing reductions in certain European countries.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in biosimilar revenues was primarily due to an increase in BENEPALI unit sales volume in new and existing markets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2019 we expect strong revenue growth for our biosimilars business, primarily driven by the continued launch of IMRALDI.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s1C78C64B0F2751FDBE770F36792FB9BF"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech Inc. (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;"><img src="anticd20.jpg" alt="anticd20.jpg" style="height:366px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN, including RITUXAN HYCELA, and GAZYVA:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,484.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,206.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,941.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">669.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">755.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">744.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax profits in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,814.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,451.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,197.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,431.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,316.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN, including RITUXAN HYCELA, annual pre-tax co-promotion profits in the U.S. in excess of $50.0 million decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in February 2016 when GAZYVA was approved by the FDA as a new treatment for follicular lymphoma and further decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the third quarter of 2017 as gross sales of GAZYVA in the U.S. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">for the preceding 12-month period exceeded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues, net was primarily due to an increase in net sales of RITUXAN, including RITUXAN HYCELA, in the U.S. of 6%. This increase reflects selling price increases and an increase in unit sales volume of 1%, partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase in U.S. product revenues, net over 2017 also reflects an increase in GAZYVA unit sales volume of 22%, partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in U.S.&#160;product revenues, net was primarily due to selling price increases and an increase in RITUXAN, including RITUXAN HYCELA, and GAZYVA unit sales volume of 2% and 6%, respectively, partially offset by higher discounts and allowances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in collaboration costs and expenses was primarily due to lower Branded Pharmaceutical Drug fee expenses and decreases in GAZYVA and RITUXAN research and development costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in collaboration costs and expenses was primarily due to higher Branded Pharmaceutical Drug Fee expenses and an increase in RITUXAN selling and marketing costs, partially offset by a decrease in GAZYVA research and development costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are aware of anti-CD20 molecules, including biosimilars, in development that if successfully developed and approved, may compete with RITUXAN in the oncology market. In 2018 the FDA approved a rituximab biosimilar in the U.S. A biosimilar of RITUXAN could come to market in the U.S. in 2019, which may adversely affect the pre-tax profits of our collaboration arrangements with Genentech, which would, in turn, adversely affect our co-promotion profits in the U.S. in future years.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs consist of royalty revenues on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in other revenues from anti-CD20 therapeutic programs was primarily due to the launch of OCREVUS in the second quarter of 2017 and subsequent sales growth. Royalty revenues recognized on sales of OCREVUS for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled $478.3 million and $159.3 million, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, other revenues from anti-CD20 therapeutic programs increased primarily due to the launch of OCREVUS in the second quarter of 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">OCREVUS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FDA approved OCREVUS for the treatment of RMS and PPMS. Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24% if annual net sales exceed $900.0 million. There will be a 50% reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we receive a gross 3% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS has been approved for treatment of RMS and PPMS in the E.U. and certain other countries. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenues from anti-CD20 therapeutic programs, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><a name="s4E13562C784B57C9A95CB6974BF3714A"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For The Years </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018 compared to 2017</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017 compared to 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">140.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">498.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">323.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">277.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">54.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">585.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">62.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenues from Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships include revenues from our technical development services and manufacturing agreements with Samsung Bioepis and royalty revenues on biosimilar products from Samsung Bioepis. Revenues from collaborative and other relationships also include our 50% share of the co-promotion losses on sales of ZINBRYTA in the U.S. with AbbVie.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to the spin-off of our hemophilia business, other revenues from collaborative and other relationships also included revenues earned under our manufacturing services agreement with Swedish Orphan Biovitrum AB (Sobi) on shipments of ELOCTA and ALPROLIX to Sobi and royalties from Sobi on sales of ELOCTA and ALPROLIX in their territory, which included substantially all of Europe, Russia and certain markets in Northern Africa and the Middle East. Bioverativ assumed all of our rights and obligations under our agreement with Sobi on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in revenues from collaborative and other relationships was primarily due to higher revenues earned under our manufacturing agreement with Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in other revenues from collaborative and other relationships was primarily due to the impact of the spin-off of our hemophilia business on February 1, 2017, partially offset by higher revenues earned under our manufacturing agreement with Samsung Bioepis.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaborative and other relationships, including revenues recognized under our technical development services and manufacturing agreements with Samsung Bioepis and our share of co-promotion losses in the U.S. on the sale of ZINBRYTA, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Royalty and Corporate Revenues</font></div><div style="line-height:120%;text-align:left;"><img src="royaltyandcorprev.jpg" alt="royaltyandcorprev.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenues primarily from amounts earned under contract manufacturing agreements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty and other corporate revenues was primarily due to higher contract manufacturing revenues resulting from increased shipments of drug product and drug substance production provided to our strategic partners, partially offset by a reduction in royalty revenues due to the expiration of certain of our patents.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the adoption of the new revenue standards as of January 1, 2018, other corporate revenue and cost of sales, excluding amortization and impairment of acquired intangible assets were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;and $42.4 million, respectively, higher in the year ended December 31, 2018, compared to what </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">would have been reported under the previous revenue guidance, primarily due to the earlier recognition of revenue associated with our contract manufacturing agreements. Under the previous revenue guidance, these amounts would have been recognized in future periods upon shipment. The adoption of the new revenue standards did not have a material impact on any other balances within our consolidated financial statements as of and for the&#160;year ended&#160;December 31, 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty and other corporate revenues was primarily due to an increase in sales of the underlying products from which we receive royalties and higher contract manufacturing revenues related to the volume of shipments of drug substance production provided to our strategic partners, including Bioverativ.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the terms of the manufacture and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business, we expect to sell substantially all remaining hemophilia related inventory to Bioverativ during the first quarter of 2019, with a cost basis totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$180.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of December 31, 2018. </font></div><div><a name="s6AA153E28C9F5976A16B7E85894A2C4A"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reserves for discounts, contractual adjustments and returns that reduced gross product revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:center;"><img src="reserves.jpg" alt="reserves.jpg" style="height:328px;width:317px;"></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reserves for discounts and allowances as a percentage of gross product revenues were 23.7%, 22.0% and 21.3%, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Discounts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in discounts was primarily due to increases in rest of world product revenues, due in part to increases in SPINRAZA and biosimilar revenues, partially offset by the impact resulting from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in discounts was primarily driven by the impact from the spin-off of our hemophilia business on February 1, 2017, partially offset by an increase in rest of world product revenues, due in part to an increase in biosimilar revenues, as well as an increase in gross selling prices.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment assistance (copay), VA and PHS discounts, specialty pharmacy program fees and other government rebates or applicable allowances. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher managed care rebates in the U.S. as well as other governmental rebates and allowances in the U.S. and </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">rest of world, due in part to an increase in SPINRAZA sales volumes worldwide and an increase in gross selling prices in the U.S. These increases were partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in contractual adjustments was primarily due to higher managed care rebates and Medicaid and other governmental rebates and allowances in the U.S., due in part to an increase in gross selling prices and the launch of SPINRAZA in the U.S. in the fourth quarter of 2016, partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Returns</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in return reserves was primarily due to the voluntary worldwide withdrawal of ZINBRYTA for RMS, which we and AbbVie announced in March 2018. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, return provisions were relatively consistent.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenue reserves, please read Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><div><a name="sBF1B328551705028A9EFCCA3C1DB3294"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Cost and Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of total cost and expenses is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018 compared to 2017</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017 compared to 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,816.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,630.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,478.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,597.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,253.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,973.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,106.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,933.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,946.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">747.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">814.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">385.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">185.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">112.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">**</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(97.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(12.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(119.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">323.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA litigation settlement charge</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">**</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,564.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,928.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,297.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">** Percentage not meaningful.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><a name="sC65B5258EA1656EA8F8665B1F0C79D34"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets (Cost of Sales)</font></div><div style="line-height:120%;text-align:left;"><img src="costofsales2018.jpg" alt="costofsales2018.jpg" style="height:306px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily due to higher contract manufacturing shipments of drug product and drug substance production provided to our strategic partners and an increase in biosimilar sales volumes. These increases were partially offset by lower costs associated with our MS products and a decrease in inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in product cost of sales was primarily driven by higher unit sales volume related to our biosimilar product shipments, higher contract manufacturing shipments of drug substance production provided to our strategic partners, including Bioverativ, and an increase in inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons. These increases were partially offset by the impact from the spin-off of our hemophilia business on February 1, 2017, and the accelerated depreciation recorded in the second, third and fourth quarters of 2016 as a result of our decision to cease manufacturing in Cambridge, MA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product cost of sales for 2016 reflects the recognition of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of accelerated depreciation as a result of our decision to cease manufacturing in Cambridge, MA and vacate our small-scale biologics manufacturing facility in Cambridge, MA and warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reasons totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$76.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily due to increased royalties payable to Ionis on higher sales of SPINRAZA, partially offset by the expiration of certain third-party royalties payable on sales of TYSABRI and decreases in royalties payable due to lower sales of TYSABRI.</font></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in royalty cost of sales was primarily driven by the recognition of royalties payable to Ionis on sales of SPINRAZA and higher royalties on sales of AVONEX and PLEGRIDY in the U.S., as described below. These increases were partially offset by the elimination of royalties payable on sales of hemophilia products resulting from the spin-off of our hemophilia business on February 1, 2017, and lower royalties on sales of TYSABRI resulting from the expiration of certain third-party royalties.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On June 28, 2016, the USPTO issued to the Japanese Foundation for Cancer Research (JFCR) a patent related to recombinant interferon-beta protein. This patent, U.S. Patent No. 9,376,478, expires in June 2033. This patent was issued following an interference proceeding between JFCR and us. This patent is relevant to AVONEX and PLEGRIDY, and we will pay royalties in the mid-single digits in relation to this patent during the life of the patent. </font></div><div><a name="sBB86E2FBC43B5EFF939F6EA4DD584132"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;"><img src="rdpercentofrev.jpg" alt="rdpercentofrev.jpg" style="height:356px;width:317px;"></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;"><img src="researchanddev.jpg" alt="researchanddev.jpg" style="height:733px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily due to increases in milestone and upfront expenses, costs incurred in connection with our early and late stage programs and increased costs incurred in connection with research and discovery. These increases were partially offset by decreased costs incurred with our marketed products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in research and development expense was primarily related to milestone and upfront expenses and costs incurred in connection with our early stage and late stage programs, partially offset by decreased costs incurred in connection with our marketed products.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Milestone and Upfront Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;includes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$486.2 million net charge to research and development expense upon the closing of the 2018 Ionis Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.0 million charge to research and development expense upon the exercise of our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB067; and</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.0 million upfront charge recognized upon entering into a collaboration and research and development services agreement with C4T to investigate the use of C4T&#8217;s novel protein degradation platform to discover and develop potential new treatments for neurological diseases.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;includes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million upfront payment made to BMS upon entering into our agreement to exclusively license BIIB092;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million developmental milestone payment due to the former shareholders of iPierian, which became payable upon dosing of the first patient in the Phase 2 study of BIIB092 for PSP;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million upfront payment made to Alkermes upon entering into our agreement to exclusively license diroximel fumarate, representing our share of diroximel fumarate development costs already incurred in 2017;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million accrual based upon the expected continuation of our agreement with Alkermes to develop and commercialize diroximel fumarate; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million upfront payment recognized upon entering into a new collaboration agreement with Ionis to identify new ASO drug candidates for the treatment of SMA.  </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;includes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million license fee paid to Ionis as we exercised our option to develop and commercialize SPINRAZA from Ionis;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million milestone payment to Eisai related to the initiation of a Phase 3 study for elenbecestat; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:12px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million upfront payment recognized upon entering into a collaboration and alliance agreement with UPenn.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These payments are classified as research and development expense as the programs they relate to had not achieved regulatory approval as of the payment date.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information about these collaboration arrangements, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Early Stage Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in spending associated with our early stage programs was primarily due to the development of BIIB092 in AD and PSP pursuant to our license agreement with BMS, the development of BIIB054 in Parkinson's disease, the development of BIIB080 (IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) in AD, the development of opicinumab in MS and the development of BIIB093 in LHI, which we advanced to a late stage program in the third quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in spending associated with our early stage programs was primarily related to the development of BIIB092 in AD and PSP pursuant to our license agreement with BMS, vixotrigine for the treatment of trigeminal neuralgia (TGN) and BIIB076 (anti-tau mAb) in AD. These increases were partially offset by a reduction in costs resulting from our discontinuance of development of amiselimod in the third quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Late Stage Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in spending associated with our late stage programs was primarily due to the development of diroximel fumarate in MS pursuant to our license and collaboration agreement with Alkermes, the development of elenbecestat in AD pursuant to our collaboration agreement with Eisai and the development of BIIB093 in LHI, which we advanced to a late stage program in the third quarter of 2018. These increases were partially offset by a decrease in costs related to aducanumab reflecting Eisai's 15% reimbursement of aducanumab development expenses beginning April 1, 2018.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning January 1, 2019, Eisai began to reimburse us for 45% of aducanumab development expense incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in spending associated with our late stage programs was primarily related to the increased costs associated with the development of aducanumab in AD and costs incurred associated with the development of elenbecestat that was advanced to a late stage program in the fourth quarter of 2016. These increases were partially offset by advancement of SPINRAZA to marketed products following its approval in the U.S. in the fourth quarter of 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketed Products</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in spending associated with our marketed products was primarily due to decreases in costs associated with our MS related projects. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in spending associated with our marketed products was primarily due to a reduction in spending resulting from the spin-off of our hemophilia business on February 1, 2017, and a reduction in spending related to TECFIDERA. These decreases were partially offset by increased spending related to SPINRAZA following its approval in the U.S. in the fourth quarter of 2016.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;"><img src="sellinggeneralandadmin.jpg" alt="sellinggeneralandadmin.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in selling, general and administrative expenses was primarily due to increases in operational spending on sales and marketing activities in support of our marketed products, primarily related to increased commercialization costs of SPINRAZA as we continue to expand into new international markets and increased costs incurred in support of our business development activities completed during the current period. These increases were partially offset by the timing of certain spend, a decrease in operational spend on ZINBRYTA subsequent to the voluntary worldwide withdrawal of ZINBRYTA for RMS, which we and AbbVie announced in March 2018, and a reduction in the Branded Pharmaceutical Drug fee expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in selling, general and administrative expenses was primarily due to a reduction in operational spending resulting from the spin-off of our hemophilia business on February 1, 2017, the execution of targeted cost reduction initiatives and a reduction in costs resulting from the discontinuance of our TECFIDERA television advertising campaign in the second quarter of 2016. These decreases were offset by an increase in SPINRAZA commercialization costs and an increase in corporate giving.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s95FF1ADD9E2D584599A045A0C768E4B0"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Amortization and Impairment of Acquired Intangible Assets</font></div><div style="line-height:120%;"><img src="amortizationofintang.jpg" alt="amortizationofintang.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets, excluding impairment charges, totaled $381.2 million, $455.3 million and $373.4 million for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in amortization and impairment of acquired intangible assets reflects an overall net decrease in amortization and impairment charges related to our intangible assets associated with our U.S. and rest of world licenses for Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below, and the impact of higher expected lifetime revenues of TYSABRI. These decreases were partially offset by the impact of impairment charges related to certain IPR&amp;D assets associated with our vixotrigine program totaling $189.3 million, also discussed below. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in amortization and impairment of acquired intangible assets was primarily due to $444.2 million of amortization and impairment charges related to our intangible asset associated with our U.S. and rest of world licenses for Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. Amortization and impairment of acquired intangible asset for 2017 also includes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairment related to our acquired and in-licensed rights and patents intangible asset associated with ZINBRYTA after the initiation of an EMA review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">of fatal fulminant liver failure, as well as four cases of serious liver injury.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;$1.25 billion&#160;in cash, of which $795.2 million was recorded within intangible assets in the first quarter of 2017. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded a $328.2 million impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute and continued to amortize the remaining net book value of the U.S. intangible asset in our consolidated statements of income utilizing an economic consumption model. The U.S. Court of Appeals for the Federal Circuit upheld the USPTO's March 2017 ruling and in January 2019 denied Forward Pharma&#8217;s petition for rehearing. We evaluated the recoverability of the U.S. asset based upon these most recent developments recorded a $176.8 million impairment charge in the fourth quarter of 2018 to reduce the remaining net book value of the U.S. asset to zero.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the European Patent Office (EPO) revoked Forward Pharma&#8217;s European Patent No. 2 801 355. Forward Pharma has filed an appeal to the Technical Board of Appeal of the EPO and the appeal is pending. Based upon our assessment of this ruling, we continue to amortize the remaining net book value of the rest of world intangible asset in our consolidated statements of income utilizing an economic consumption model. The remaining net book value of the TECFIDERA rest of world intangible asset as of December 31, 2018, was $71.0 million.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these disputes, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the treatment of PLSR. The study did not meet its primary or secondary efficacy endpoints; therefore, we discontinued development of vixotrigine for the treatment of PLSR and we recognized an impairment charge of approximately $60.0 million during the third quarter of 2018 to reduce the fair value of the related IPR&amp;D intangible asset to zero. In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the treatment of TGN as we awaited the outcome of ongoing interactions with the FDA regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the treatment of PLSR and insights from the Phase 2 study of vixotrigine for the treatment of SFN. We reassessed the fair value of our vixotrigine program for the treatment of TGN using reduced expected lifetime revenues, higher expected clinical development costs and lower cumulative probabilities of success, and, as a result of that assessment, we recognized an impairment charge of $129.3 million during the third quarter of 2018 to reduce the fair value of the IPR&amp;D intangible asset associated with our vixotrigine program for the treatment of TGN to $41.8 million.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In late December 2018 we received feedback from the FDA regarding the design of the Phase 3 vixotrigine program for the treatment of TGN. Following this feedback, we are now planning to initiate the Phase 3 vixotrigine program for the treatment of TGN.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may recognize additional impairment charges in the future depending upon our ability to advance vixotrigine for the treatment of TGN or other indications.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenues and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies and changes in program economics and related impact of foreign currency exchange rates, and evaluating industry data regarding the productivity of clinical research and the development process. Changes in our estimates of these items may result in a significant change to our valuation of our IPR&amp;D assets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the amortization and impairment of acquired intangible assets, including our TECFIDERA settlement and license agreement and our IPR&amp;D intangible asset related to our vixotrigine program for the treatment of TGN, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Annually, during our long-range planning cycle, we perform an analysis of anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The results of our TYSABRI, AVONEX and TECFIDERA analyses were impacted by changes in the estimated timing and impact of other alternative MS formulations, including OCREVUS. The outcome of this most recent analysis resulted in a net overall decrease in our expected rate of amortization for acquired intangible assets, which was primarily related to higher expected lifetime revenues of TYSABRI. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:30%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">270.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">290.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The amounts in the table above are lower than the total amount of amortization recognized for the years ended December 31, 2018, 2017 and 2016, as </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a result of the impact of the impairment charges discussed above.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenues of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</font></div><div><a name="sC646D7443729513BA0F93353AFBF9D95"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Collaboration Profit (Loss) Sharing</font></div><div style="line-height:120%;"><img src="collabprofitshare.jpg" alt="collabprofitshare.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing includes our partner&#8217;s 50% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and our partner&#8217;s 50% share of the co-promotion profits or losses in the E.U. and Canada related to our collaboration agreement with AbbVie on the commercialization of ZINBRYTA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net profit-sharing expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$187.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis&#8217; </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration profits. The increase in profit-sharing expense for the comparative periods were primarily due to increased collaboration profits resulting from increased biosimilar sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we recognized net profit-sharing income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie&#8217;s 50% sharing of the net collaboration losses in the E.U. and Canada, compared to net profit-sharing expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie&#8217;s 50% sharing of the net collaboration profits in the E.U. and Canada, and net profit-sharing income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie&#8217;s 50% sharing of the net collaboration losses in the E.U. and Canada. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis and AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div><a name="s6E8983A49BF050278D6F1E384782E222"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired In-Process Research and Development</font></div><div style="line-height:120%;"><img src="acquirediprd.jpg" alt="acquirediprd.jpg" style="height:293px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB110 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we acquired BIIB110 and ALG-802 from AliveGen. BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. In connection with the closing of this transaction, we made an upfront payment of $27.5 million to AliveGen, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB110 has not yet reached technological feasibility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB104 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we acquired BIIB104 from Pfizer. BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for CIAS. In connection with the closing of this transaction, we made an upfront payment of $75.0 million to Pfizer, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB104 has not yet reached technological feasibility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB100 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired BIIB100 from Kayropharm. BIIB100 is a Phase 1 ready investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. In connection with the closing of this transaction, we made an upfront payment of $10.0 million to Karyopharm, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB100 has not yet reached technological feasibility.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BIIB093 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we acquired BIIB093 from Remedy. In connection with the closing of this transaction, we made an upfront payment of $120.0 million to Remedy, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB093 had not yet reached technological feasibility. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisitions of BIIB110, BIIB104, BIIB100 and BIIB093, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div><a name="s1C56C89599295C9B9FD73D6E43EDDDED"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Restructuring Charges</font></div><div style="line-height:120%;"><img src="restructuring2018.jpg" alt="restructuring2018.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2017 Corporate Strategy</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and capital expenditures of approximately $135.0 million in connection with this program and our goal is to redirect resources of up to $400.0 million annually by 2020 to prioritized research and development and other value creation opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Throughout 2018 we reallocated resources within our research and development organization to maximize our investment in what we believe are our highest-potential programs. As a result, we have terminated certain research and development programs and redesigned clinical trial protocols with the goal of driving efficiencies and savings to be reinvested in such efforts. Additionally, we have focused efforts on implementing improvements to our core business processes as well as refining our facility footprint, which allowed for the further reallocation of resources towards prioritized research and investment in our sales and marketing organizations to fortify our core business in MS and SMA and to prepare for the potential launch of future products. </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this effort, respectively, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are reflected as restructuring charges and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are included in selling, general and administrative expenses in our consolidated statements of income. These restructuring charges were primarily related to severance.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges incurred to date under this program have been substantially paid in cash as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2016 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin-off our hemophilia business, and to achieve further targeted cost reductions. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this effort. These amounts, which were substantially incurred and paid by the end of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cambridge, MA Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we decided to cease manufacturing and vacate our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and close and vacate our 46,000 square foot warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December&#160;2016 we subleased our rights to the Cambridge, MA manufacturing facility to Brammer Bio MA,&#160;LLC (Brammer). Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we closed and vacated our warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets&#8217; new shorter useful lives. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of this additional depreciation, which was recorded as cost of sales in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2016 we also recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for severance costs </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">related to certain employees separated from Biogen in connection with our departure from these facilities. These amounts were substantially incurred and paid by the end of first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2015 Restructuring Charges</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges for the year ended December 31, 2016, include $8.0 million of expense related to our 2015 restructuring program.</font></div><div><a name="sB710212C0DC655D7A6C7CDB672FDDF39"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</font></div><div style="line-height:120%;"><img src="gainlossonfvremeasurement.jpg" alt="gainlossonfvremeasurement.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The gain on fair value remeasurement of contingent consideration for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to delays in the expected timing of achievement of milestones related to our vixotrigine program for the treatment of TGN and an increase in discount rates used to revalue our contingent consideration liabilities, partially offset by the passage of time. For additional information on our IPR&amp;D intangible asset related to our vixotrigine program for the treatment of TGN, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The loss on fair value remeasurement of contingent consideration for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to the increase in the probability of achieving certain </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developmental milestones based upon the progression of the underlying clinical programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The loss on fair value remeasurement of contingent consideration for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was primarily due to changes in the probability of achieving certain developmental milestones based upon the progression of the underlying clinical programs and changes in the discount rate.</font></div><div><a name="sDE61BE63E682594CAEAD5B4680752496"></a></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TECFIDERA Litigation Settlement Charge</font></div><div style="line-height:120%;"><img src="teclitigation.jpg" alt="teclitigation.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As described above under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Amortization and Impairment of Acquired Intangible Assets - TECFIDERA License Rights, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">in January 2017 we entered into a settlement and license agreement with Forward Pharma pursuant to which we obtained U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property, including Forward Pharma&#8217;s intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;$1.25 billion&#160;in cash. During the fourth quarter of 2016, we recognized a pre-tax charge of&#160;$454.8 million&#160;and, in the first quarter of 2017, we recognized an intangible asset of&#160;$795.2 million&#160;related to this agreement. The pre-tax charge recognized in the fourth quarter of 2016 represented the fair value of our licenses to Forward Pharma&#8217;s intellectual property for the period April 2014, when we started selling TECFIDERA, through December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our TECFIDERA settlement and license agreement, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="sC9D7DD12D47C5517BF7581E2890FC250"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;"><img src="otherincomeexpnet.jpg" alt="otherincomeexpnet.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective January 1, 2018, other income (expense), net for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects the recognition of net gains (losses) recorded in relation to changes in the fair value of our strategic investments following our adoption of Accounting Standards Update (ASU) No. 2016-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Changes in the fair value of our strategic investments could have a significant impact on our results of operations in any given period. For 2018 net gains (losses) recognized in relation to the changes in fair value of our strategic investments totaled $128.0 million, which are reflected in the net gains discussed below. Prior to the adoption of this standard, we recognized changes in fair value of our strategic investment in accumulated other comprehensive income (loss), net. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to the recognition of net gains totaling $119.5 million recorded in 2018 in relation to our investment portfolio as compared to net losses totaling $36.3 million in 2017. The change in other income (expense), net for 2018, compared to 2017, was also due to a decrease in interest expense due to the redemption in November 2017 of our 6.875% Senior Notes due March 1, 2018, and an increase in capitalized interest costs, which was primarily related to the ongoing construction of our manufacturing facility in Solothurn, Switzerland as well as an increase in interest income primarily due to higher interest rates. These comparative net increases were partially offset by foreign exchange losses recognized in 2018 compared to gains recognized in 2017. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the change in other income (expense), net was primarily due to an increase in foreign currency exchange gains, an increase in interest income, primarily due to higher interest rates, and a decrease in interest expense </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">due to the redemption in November 2017 of our 6.875% Senior Notes due March 1, 2018. These comparative net increases were partially offset by other than temporary impairments recognized on strategic investments and marketable debt securities during 2017.</font></div><div><a name="sC6E4FF98663457B49369206D495A6B35"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Income Tax Provision</font></div><div style="line-height:120%;"><img src="taxexpense.jpg" alt="taxexpense.jpg" style="height:338px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, acquisitions and licensing transactions.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the enactment of the 2017 Tax Act. The effects of an overall reduction in the federal statutory rate in the U.S. were partially offset by the elimination of the manufacturing deduction, the imposition of the GILTI tax on international earnings, our recording of deferred taxes on GILTI in 2018, limits on the deductibility of certain benefits on executive compensation and a reduction in the tax benefit associated with the Orphan Drug Credit, all resulting from the 2017 Tax Act, and a change in accounting rules related to recording the tax impacts of intra-entity transactions. Included in our effective tax rate for 2018 was an increase of approximately 350 basis points related to the sale of inventory, the tax effect of which had been included within prepaid taxes at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at a higher effective tax rate. The effective tax rate for the year ended </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflected the impact of a favorable settlement related to a state tax matter in 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in our effective tax rate was primarily due to the effect of the 2017 Tax Act and the impairment of prepaid tax assets related to our ZINBRYTA program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Excluding the effect of these items, our income tax rate would have decreased due to a lower percentage of our earnings being recognized in the U.S., a higher tax jurisdiction. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we earned a lower benefit from the Orphan Drug Credit due to the FDA&#8217;s approval of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2017 Tax Act</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as GILTI, and includes base erosion prevention measures on non-U.S. earnings. These changes became effective in 2018. During the fourth quarter of 2018 we elected to recognize deferred taxes for basis differences expected to reverse as GILTI is incurred and have established initial deferred tax balances, as of the enactment date of the 2017 Tax Act, resulting in our recording of a $135.8 million income tax expense during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2017 we recognized within our provision for income taxes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;provisional estimate pursuant to SEC Staff Accounting Bulletin No. 118. Our provisional estimate included an amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries&#8217; previously untaxed foreign earnings, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$184.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended December 31, 2018, we recognized a net reduction of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our estimated Transition Toll Tax, an expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.7 </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to remeasure our deferred tax balances, an expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$135.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to establishing deferred taxes for GILTI and an expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect other aspects of the 2017 Tax Act. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The final determination of the Transition Toll Tax and remeasurement of our deferred assets and liabilities was completed in the fourth quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Article 20 Procedure of ZINBRYTA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the Article 20 Procedure of ZINBRYTA, for the year ended December 31, 2017, we recognized a net impairment charge on certain tax assets related to ZINBRYTA reflected within income tax expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This charge reflected the write-off of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to prepaid taxes, which was partially offset by the recognition of an unrecorded deferred tax benefit of $93.8 million. For additional information on our collaboration arrangement with AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, excluding the effect of the 2017 Tax Act and the ZINBRTYA impairment, our income tax rate would have decreased due to a lower percentage of our earnings being recognized in the U.S., a higher tax jurisdiction. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we earned a lower benefit from the Orphan Drug Credit due to the FDA&#8217;s approval of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our uncertain tax positions and income tax rate reconciliation for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to our consolidated financial statements included in this report.</font></div><div><a name="sC883C3EEE47F583982B715723A01E7B5"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Noncontrolling Interest</font></div><div style="line-height:120%;"><img src="nci2018.jpg" alt="nci2018.jpg" style="height:240px;width:317px;"></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;net income attributable to noncontrolling interests, net of tax, was primarily related to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;pre-tax payment made to Neurimmune to reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by 5%. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;net income attributable to noncontrolling interests, net of tax, was primarily related to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;pre-tax payment made to Neurimmune to reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by 15%.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Neurimmune, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><a name="s650553E84D6E5D139DCE90EBA0C17D50"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Condition, Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our financial condition is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">%&#160;Change</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2018 compared to 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,224.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,573.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,313.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,115.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities &#8212; non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,375.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,057.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(55.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,913.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,746.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(27.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Borrowings:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable and other financing arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(100.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable and other financing arrangements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,936.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,935.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,938.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working Capital:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,640.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,873.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3,295.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3,368.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total working capital</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,345.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,505.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s18803E0DF81B534D9455366E1CBBDFC5"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$6.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities, net of: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#32;in total net payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$375.0 million in an upfront payment made to Ionis upon the closing of the 2018 Ionis Agreement and a $162.1 million expense reflecting the premium paid for the purchase of Ionis</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8217;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#32;common stock; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$4.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$770.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment made to Samsung BioLogics upon the closing of the share purchase transaction increasing our ownership percentage in Samsung Bioepis to approximately 49.9%;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$462.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment made to Ionis reflecting the fair value of the common stock purchased upon the closing the 2018 Ionis Agreement; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$112.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in payments made for the acquisitions of BIIB100, BIIB104 and BIIB110.</font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, certain significant cash flows were as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$4.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in net cash flows provided by operating activities, net of:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.1 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total net payments for income taxes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$463.0 million in upfront and milestone payments made to BMS, iPierian, Eisai, Alkermes and Ionis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:42px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#9702;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">$454.8 million payment made to Forward Pharma for the litigation settlement charge that was accrued as of December 31, 2016;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for share repurchases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments made to former shareholders of Fumapharm AG and holders of their rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$867.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;used for purchases of property, plant and equipment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million payment made to Forward Pharma to license Forward Pharma&#8217;s intellectual property, including Forward Pharma&#8217;s intellectual property related to TECFIDERA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$557.7 million payment made for the redemption of our 6.875% Senior Notes due March 1, 2018, prior to their maturity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million net cash contribution made in connection with the spin-off of our hemophilia business;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$295.0 million in upfront and milestone payments made to Remedy, Ionis and Samsung Bioepis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$132.4 million payment, net of tax, made to Neurimmune in exchange for a 15% reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have historically financed our operating and capital expenditures primarily through cash flows earned through our operations. We expect to continue funding our current and planned operating requirements principally through our cash flows from operations, as well as our existing cash resources. We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Reform</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act resulted in significant changes to the U.S. corporate income tax system.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries&#8217; previously untaxed foreign earnings. The Transition Toll Tax was assessed on our share of our foreign corporations&#8217; accumulated foreign earnings that have not previously been taxed. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we considered none of our earnings to be permanently reinvested outside the U.S. and therefore recorded deferred tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. Other than for earnings, we are permanently reinvested for book/tax basis differences related to foreign subsidiaries. These differences are estimated to total approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and primarily arose through the impacts of purchase accounting. These basis differences could reverse through sales of the foreign subsidiaries, as well as various other events, </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">none of which are considered probable as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The residual U.S. tax liability, if these differences would reverse, would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, under the Transition Toll Tax. The decrease in this liability is primarily attributed to our 2018 Transition Toll Tax payment of $85.0 million, the application by the IRS of an approximately $150.0 million overpayment against the accrual and the net reduction of approximately $34.6 million in our estimated Transition Toll Tax. Of the amounts accrued as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to the overpayment discussed above. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest. For additional information on the 2017 Tax Act, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">After repatriating approximately $3.5 billion during the first quarter of 2018 as a result of the 2017 Tax Act, approximately 51% of our total cash, cash equivalents and marketable securities at the end of the year were held in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read Item 1A. R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">isk Factors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and Item 7A. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Quantitative and Qualitative Disclosures About Market Risk</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchase Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized our 2018 Share Repurchase Program, which is a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. Our 2018 Share Repurchase program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized our 2016 Share Repurchase Program, which is a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock. Our 2016 Share Repurchase Program was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and 3.3 million shares of common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and $1.0 billion during the </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and 2016, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized our 2011 Share Repurchase Program, which is a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock. Our 2011 Share Repurchase Program was completed as of March 31, 2017. Share repurchases under our 2011 Share Repurchase Program were principally used to offset common stock issuances under our share-based compensation programs. Under our 2011 Share Repurchase Program, we repurchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the year ended December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had cash, cash equivalents and marketable securities totaling approximately $4.9 billion compared to approximately $6.7 billion as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The net decrease in cash, cash equivalents and marketable securities at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was primarily due to cash used for share repurchases, contingent payments made to former shareholders of Fumapharm AG and holders of their rights, the payment made to Ionis upon the closing of the 2018 Ionis Agreement, net purchases of property, plant and equipment, payment made to Samsung BioLogics upon the closing of the share purchase transaction increasing our ownership percentage in Samsung Bioepis to approximately 49.9%, the upfront payments made to Karyopharm, Pfizer and AliveGen upon the acquisitions of BIIB100, BIIB104 and BIIB110, respectively, and the payment made to Ionis for the option exercise for BIIB067. These decreases were partially offset by cash flows from operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, investments and other assets in our consolidated balance sheet as of December 31, 2018, includes the carrying value of our investment in Samsung Bioepis of $680.6 million. As Samsung Bioepis is a privately-held entity, our ability to liquidate our investment in Samsung Bioepis, may be limited and we may realize significantly less than the value of </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">such investment. Investments in other assets, as of December 31, 2018, also includes an asset of $563.8 million reflecting the fair value of our investment in Ionis&#8217; common stock, which is subject to certain holding period restrictions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisitions of BIIB100, BIIB104 and BIIB110, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report. For additional information on the 2018 Ionis Agreement, the additional investment in Samsung Bioepis and the option exercise for BIIB067, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Borrowings</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These Senior Notes were issued at discount and are amortized as additional interest expense over the period from issuance through maturity.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2015 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica AG, we issued notes totaling 61.4 million Swiss Francs that were payable to Fumedica AG in varying amounts from June 2008 through June 2018. In June 2018 we redeemed our remaining note payable to Fumedica AG, which had a carrying value of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a summary of the fair values of our outstanding borrowings as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Working Capital</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Working capital is defined as current assets less current liabilities. The change in working capital at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects a decrease in total current assets of $232.4 million and a decrease in total current liabilities of $73.0 million. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net decrease in total current assets was primarily due to a decrease in prepaid taxes related to intra-entity inventory transactions, partially offset by an increase in accounts receivable, net related to our ongoing operations.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net decrease in total current liabilities was primarily due to a reduction in accrued expenses and other and a decrease in accounts payable. The net decrease in accrued expenses and other was due to a decrease in the accrual of contingent payments related to FUMADERM and TECFIDERA (together, the Fumapharm Products), a decrease in accrued contingent consideration due to the milestone payment made to the former shareholders of Stromedix Inc. (Stromedix) and a decrease in our derivative liabilities. These decreases were partially offset by an increase in our accrued revenue related rebates due primarily to an increase in SPINRAZA and biosimilars revenues and an increase in accrued collaboration expenses due to an increase in expenses related to our collaboration with Samsung Bioepis.</font></div></div></div><div><a name="s1C10346DE06B582EB1994BE98A8EEC4B"></a></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our cash flow activity:</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31,</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">% Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018 compared to 2017</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017 compared to 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except percentages)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,187.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,551.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,587.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">36.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,046.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,963.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,484.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(30.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,472.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,380.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,052.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">87.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">126.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s4C17FB975E0F5B1E8ABD11343125E596"></a></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Operating Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating cash flow is derived by adjusting our net income for:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">non-cash operating items such as depreciation and amortization, impairment charges, acquired IPR&amp;D and share-based compensation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For 2018 compared to 2017, the increase in net cash flows provided by operating activities was primarily due to an increase in net income, improved collections from customers and collaborators, higher relative accruals for revenue-related reserves and lower overall cash income taxes paid.&#160;These factors were partially offset by higher spending related to business development activities discussed below.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net cash flows provided by operating activities for the year ended December 31, 2018, were reduced by the $375.0 million upfront payment made to Ionis upon the closing of the 2018 Ionis Agreement and the $162.1 million charge reflecting the premium paid for the purchase of Ionis&#8217; common stock compared to payments totaling $463.0 million in 2017 to BMS, iPierian, Eisai, Alkermes and Ionis.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The net cash flows provided by operating activities for the year ended December 31, 2017, were reduced by the $454.8 million payment made to Forward Pharma for the litigation settlement charge in the first quarter of 2017 that was accrued as of December 31, 2016.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net cash flows provided by operations were relatively consistent. Higher sales and lower income tax payments were offset by the $454.8 million payment related to our settlement and license agreement with Forward Pharma, which had been accrued as of December 31, 2016, and the timing of customer payments, including amounts due in connection with anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net income was lower primarily due to the Transition Toll Tax under the 2017 Tax Act and higher depreciation and amortization.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in net cash flows used in investing activities was primarily due to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">higher net proceeds of marketable securities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the 2017 $795.2 million payment made to Forward Pharma to license Forward Pharma&#8217;s intellectual property, including Forward Pharma&#8217;s intellectual property related to TECFIDERA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a decrease in purchases of property, plant and equipment. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These changes were partially offset by the following increases to investing activity:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the $676.6 million payment made to Samsung BioLogics upon the closing of the share purchase transaction increasing our ownership percentage in Samsung Bioepis to approximately 49.9%;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the $462.9 million payment made to Ionis reflecting the fair value of the common stock purchased upon the closing of the 2018 Ionis Agreement; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">an increase in contingent payments made to former shareholders of Fumapharm AG and holders of their rights.</font></div></td></tr></table></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in investing activities was primarily due to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#32;$795.2 million payment made to Forward Pharma to license Forward Pharma</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8217;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">s intellectual property, including Forward Pharma</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8217;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">s intellectual property related to TECFIDERA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">an increase in purchases of property, plant and equipment primarily related to the construction of our Solothurn, Switzerland facility;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$175.0 million in milestone payments made to Ionis and Samsung Bioepis; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#0f243e;">the $120.0 million payment made to Remedy for the acquisition of BIIB093.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These increases were partially offset by an increase in net proceeds of marketable securities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in financing activities was primarily due to an increase in cash used for share repurchases. The effect of the increase in share repurchases was partially offset by lower repayment of outstanding debt, the contribution made in connection with the spin-off of our hemophilia business in the first quarter of 2017 and lower net distributions to noncontrolling interest reflecting the payments made to Neurimmune in October 2017 and May 2018. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the increase in net cash flows used in financing activities was primarily due to an increase in cash used for share repurchases, the payment made for the redemption of our 6.875% Senior Notes due March 1, 2018, prior to their maturity, the net cash contribution made in connection with the spin-off of our hemophilia business on February 1, 2017, and the net distributions to noncontrolling interest, including the payment made to Neurimmune in exchange for a  reduction of 15% in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><a name="sA9EC8BFA3334588DBDB9293B12ABC7D2"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Contractual Obligations and Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our contractual obligations as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Less&#160;than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1 Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">1 to 3</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">3 to 5</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">After</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">5&#160;Years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-cancellable operating leases (1), (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">418.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">107.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">94.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">156.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term debt obligations (3)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,185.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">241.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,939.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,360.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,643.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase and other obligations (4)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,114.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">327.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">132.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">234.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">420.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Defined benefit obligation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">93.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">93.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total contractual obligations</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,812.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">628.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,179.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,689.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,315.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s07D07EE7F4BB5AAEBFA08B9135C90BB5"></a></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We lease properties and equipment for use in our operations. Amounts reflected within the table above detail future minimum rental commitments under non-cancelable operating leases as of December&#160;31 for each of the periods presented. In addition to the minimum rental commitments, these leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Obligations are presented net of sublease income expected to be received for the vacated small-scale biologics manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term debt obligations are primarily related to our Senior Notes, including principal and interest payments. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase and other obligations primarily include our obligations to purchase direct materials, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$697.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the remaining payments on the Transition Toll Tax, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$111.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contractual commitments for the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$24.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the fair value of net liabilities on derivative contracts. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Payments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan Pharma International Ltd. (Elan), an affiliate of Elan Corporation plc, full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recognized as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013, and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the third quarter of 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payment to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11% and 15%, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence Pharmaceuticals Ltd. (Convergence), Stromedix and Biogen International Neuroscience GmbH (BIN), we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestones related to these acquisitions.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired FUMADERM and TECFIDERA (together, the Fumapharm Products). We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013 TECFIDERA was approved in the U.S. for MS by the FDA and we made the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment. We are also required to make additional contingent payments to former shareholders of Fumapharm AG and holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement, until such time as the cumulative sales level reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments are due. These payments are accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. Any portion of the payment that is tax deductible was recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level was reached. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2017 and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the first, second and third quarters of 2018, respectively. In the fourth quarter of 2018 we achieved the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales level threshold and accrued our last </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment related to the Fumapharm Products, which will be paid in the first quarter of 2019.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.7 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in development milestones, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in regulatory milestones and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Provided various development, regulatory or commercial milestones are achieved, we anticipate that we may pay approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of milestone payments in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$655.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$117.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net liabilities associated with uncertain tax positions. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, under the Transition Toll Tax. Of the amounts accrued as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to a $150.0 million overpayment of taxes in the current year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><a name="sFBB636C5502E5615982D57FD25633C72"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Legal Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of legal matters as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note&#160;21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Critical Accounting Estimates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(U.S.&#160;GAAP), requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates. Other significant accounting policies are outlined in Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the Financial Accounting Standards Board (FASB) issued ASU No. 2014-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2014-09 that have the same effective date and transition date: ASU No. 2016-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contract with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; and ASU No. 2016-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">result in a significant change to our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon adoption. However, the adoption of the new revenue standards will result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under ASU 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">components do not differ materially from our historical practices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to the discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our revenues, please read Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired Intangible Assets, including IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we purchase a business, the acquired IPR&amp;D is measured at fair value, capitalized as an intangible asset and tested for impairment at least annually, as of October 31, until commercialization, after which time the IPR&amp;D is amortized over its estimated useful life. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">research and development expense as they are incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have acquired, and expect to continue to acquire, intangible assets through the acquisition of biotechnology companies or through the consolidation of variable interest entities. These intangible assets primarily consist of technology associated with human therapeutic products and IPR&amp;D product candidates. When significant identifiable intangible assets are acquired, we generally engage an independent third-party valuation firm to assist in determining the fair values of these assets as of the acquisition date. Management will determine the fair value of less significant identifiable intangible assets acquired. Discounted cash flow models are typically used in these valuations, and these models require the use of significant estimates and assumptions including but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">estimating the timing of and expected costs to complete the in-process projects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">projecting regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">estimating future cash flows from product sales resulting from completed products and in process projects;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">developing appropriate discount rates and probability rates by project.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe the fair values assigned to the intangible assets acquired are based upon reasonable estimates and assumptions given available facts and circumstances as of the acquisition dates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If these projects are not successfully developed, the sales and profitability of the company may be adversely affected in future periods. Additionally, the value of the acquired intangible assets may become impaired. We believe that the foregoing assumptions used in the IPR&amp;D analysis were reasonable. No assurance can be given that the underlying assumptions used to estimate expected project sales, development costs or profitability, or the events associated with such projects, will transpire as estimated.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment and Amortization of Long-lived Assets and Accounting for Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Long-lived Assets Other than Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used include property, plant and equipment as well as intangible assets, including IPR&amp;D and trademarks. Property, plant and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We review our intangible assets </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">87</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquired Intangible Assets, including IPR&amp;D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Changes in the estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have previously been impaired, including our vixotrigine program for the treatment of neuropathic pain, such as TGN, could become further impaired in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most significant intangible assets are our acquired and in-licensed rights and patents and developed technology. Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan and obtaining the fair value of the U.S. and rest of world licenses to Forward Pharma&#8217;s intellectual property, including Forward Pharma&#8217;s intellectual property related to TECFIDERA. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of TYSABRI, AVONEX, SPINRAZA and TECFIDERA is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA or TECFIDERA products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the impairment charges related to our long-lived assets during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill relates largely to amounts that arose in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003 and amounts that are being paid in connection with the acquisition of Fumapharm AG. Our goodwill balances represent the difference between the purchase price and the fair value of the identifiable tangible and intangible net </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">assets when accounted for using the purchase method of accounting.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess our goodwill balance within our single reporting unit annually, as of October&#160;31, and whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We completed our required annual impairment test in the fourth quarters of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and determined in each of those periods that the carrying value of goodwill was not impaired. In each year, the fair value of our reporting unit, which includes goodwill, was significantly in excess of the carrying value of our reporting unit.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Investments, including Fair Value Measurements and Impairment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We invest in various types of securities, including short-term and long-term marketable securities, principally corporate notes, government securities including government sponsored enterprise mortgage-backed securities and credit card and auto loan asset-backed securities, in which our excess cash balances are invested. We also invest in equity securities of certain biotechnology companies and venture capital funds where the underlying investments are in equity securities of certain biotechnology companies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In accordance with the accounting standard for fair value measurements, we have classified our financial assets as Level 1, 2 or 3 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that we have the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, yield curves, foreign currency spot rates and option pricing valuation models. Fair values determined by Level 3 inputs utilize unobservable data points for the asset.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As discussed in Note 8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our consolidated financial statements included in this report, a majority of our financial assets have been classified as Level 2. These assets have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services use many observable market inputs to determine value, including reportable trades, </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events. We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in our fair value measurements could have a significant impact on our results of operations in any given period.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Impairment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected within earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security and are reflected within earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make certain assumptions in order to value and record expense associated with awards made under our share-based compensation arrangements. Changes in these assumptions may lead to variability with respect to the amount of expense we recognize in connection with share-based payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determining the appropriate valuation model and related assumptions requires judgment, and includes estimating the expected market price of our stock on vesting date and stock price volatility as well as the </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">term of the expected awards. Determining the appropriate amount to expense based on the anticipated achievement of performance targets requires judgment, including forecasting the achievement of future financial targets. The estimate of expense is revised periodically based on the probability of achieving the required performance targets and adjustments are made throughout the term as appropriate. The cumulative impact of any revision is reflected in the period of change.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also estimate forfeitures over the requisite service period when recognizing share-based compensation expense based on historical rates and forward-looking factors. These estimates are adjusted to the extent that actual forfeitures differ, or are expected to materially differ, from our estimates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions of a business completed after January&#160;1, 2009, we record contingent consideration resulting from a business combination at its fair value on the acquisition date. Each reporting period thereafter, we revalue these obligations and record increases or decreases in their fair value as an adjustment to contingent consideration expense in our consolidated statements of income. Changes in the fair value of our contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates and achievement and timing of any cumulative sales-based and development milestones or changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions described above, could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We prepare and file income tax returns based on our interpretation of each jurisdiction&#8217;s tax laws and regulations. In preparing our consolidated financial statements, we estimate our income tax liability in each of the jurisdictions in which we operate by estimating our actual current tax expense together with assessing temporary differences resulting from differing treatment of items for tax and financial </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">reporting purposes. These differences result in deferred tax assets and liabilities, which are included in our consolidated balance sheets. Upon our election in the fourth quarter of 2018 to record deferred taxes for GILTI, we have included amounts related to U.S. GILTI taxes within temporary difference. Significant management judgment is required in assessing the realizability of our deferred tax assets. In performing this assessment, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial accounting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and the effects of tax planning strategies. Our estimates of future taxable income include, among other items, our estimates of future income tax deductions related to the exercise of stock options. In the event that actual results differ from our estimates, we adjust our estimates in future periods and we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date.&#160;Upon adoption, we recognized additional deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, offset by a corresponding increase to deferred tax liabilities of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and an increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of $0.4 billion with a corresponding reduction to our retained earnings as these differences are related to inter-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on ASU 2016-16, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to our </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">consolidated financial statements included in this report.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Our liabilities for uncertain tax positions can be relieved only if the contingency becomes legally extinguished, through either payment to the taxing authority or the expiration of the statute of limitations, the recognition of the benefits associated with the position meet the &#8220;more-likely-than-not&#8221; threshold or the liability becomes effectively settled through the examination process. We consider matters to be effectively settled once the taxing authority has completed all of its required or expected examination procedures, including all appeals and administrative reviews, we have no plans to appeal or litigate any aspect of the tax position and we believe that it is highly unlikely that the taxing authority would examine or re-examine the related tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We earn a significant amount of our operating income outside the U.S.&#160;As a result, a portion of our cash, cash equivalents and marketable securities are held by foreign subsidiaries.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act resulted in significant changes to the U.S. corporate income tax system.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax, which is a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries&#8217; previously untaxed foreign earnings. The Transition Toll Tax was assessed on our share of our foreign corporations&#8217; accumulated foreign earnings that were not previously taxed.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of $697.0 million and $989.6 million, respectively, under the Transition Toll Tax. Of the amounts accrued as of December 31, 2018, no amounts are expected to be paid within one year due to a $150.0 million overpayment of taxes in the current year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90</font></div></div><hr style="page-break-after:always"><div><a name="s48EBE8B4D0B35959BDDD2489F1F420AC"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">New Accounting Standards</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For a discussion of new accounting standards and their expected impact on our consolidated financial statements or disclosures, please read Note&#160;1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.</font></div><div><a name="s1AAD106F9942510EA9D1ED17127FC3BD"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements, pricing pressures worldwide and weak economic conditions in the foreign markets in which we operate. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. We have operations or maintain distribution relationships in the U.S., Europe, Canada, Asia, and Central and South America. In addition, we recognize our share of pre-tax co-promotion profits on RITUXAN in Canada. As a result, our consolidated financial position, results of operations and cash flows can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Danish krone and Japanese yen.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenues will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expenses, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">value of the non-U.S. revenues and expenses will increase when reported in U.S. dollars.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by volatility in foreign currency exchange rates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100%, which indicated that Argentina&#8217;s economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of December 31, 2018, and is not expected to have a material impact on our results of operations or financial position in the future.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue and Operating Expense Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenues and operating expenses. We use foreign currency forward contracts to manage foreign currency risk, with the majority of our forward contracts used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to our consolidated financial statements included in this report.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our ability to mitigate the impact of foreign currency exchange rate changes on revenues and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flows from these contracts are reported as operating activities in our consolidated statements of cash flows.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Balance Sheet Risk Management Hedging Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flows from these contracts are reported as operating activities in our consolidated statements of cash flows.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a hypothetical adverse 10% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $290.0 million and $286.0 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Hedge Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our net investment hedging program is designed to mitigate currency fluctuations between the U.S. dollar and South Korean won as a result of exercising our option to increase our ownership percentage in Samsung Bioepis to approximately 49.9%. We entered into foreign currency forward contracts to manage the foreign currency risk with our forward contracts used to hedge changes in the spot rate over the next 10 months. As of December 31, 2018, a hypothetical adverse 10% movement would result in a hypothetical decrease in fair value of approximately $64.0 million. The estimated fair value was determined by measuring the impact of the hypothetical spot rate movement on outstanding forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $19.0 million and $50.0 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">To achieve a desired mix of fixed and floating interest rate debt, we entered into interest rate swap contracts during 2015 for certain of our fixed-rate debt. These derivative contracts effectively converted a fixed-rate interest coupon to a floating-rate LIBOR-based coupon over the life of the respective note. As </font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, a 100 basis-point adverse movement (increase in LIBOR) would increase annual interest expense by approximately $6.8&#160;million. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pricing Pressure</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governments in certain international markets in which we operate have implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. In addition, certain countries set prices by reference to the prices in other countries where our products are marketed. Thus, our inability to obtain and maintain adequate prices in a particular country may adversely affect our ability to secure acceptable prices in existing and potential new markets, which may limit market growth. The continued implementation of pricing actions throughout Europe may also lead to higher levels of parallel trade.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs and increasing pressure from social sources could significantly influence the way our products are prescribed and purchased. It is possible that additional federal health care reform measures will be adopted in the future, which could result in increased pricing pressure and reduced reimbursement for our products and otherwise have an adverse impact on our consolidated financial position or results of operations. There is also significant economic pressure on state budgets that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Managed care organizations are also continuing to seek price discounts and, in some cases, impose restrictions on the coverage of certain drugs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our products are also susceptible to increasing competition in many markets from generics, biosimilars, prodrugs and other products approved under alternative regulatory pathways.&#160;Generic versions of drugs, biosimilars and other products approved under alternative regulatory pathways are likely to be sold at substantially lower prices than branded products.&#160;Accordingly, the introduction of such products, as well as other lower-priced competing products, may significantly reduce both the </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">price that we receive for branded products and the volume of branded products that we sell, which will negatively impact our revenues.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are subject to credit risk from our accounts receivable related to our product sales. The majority of our accounts receivable arise from product sales in the U.S.&#160;and Europe with concentrations of credit risk limited due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. Our accounts receivable are primarily due from wholesale and other third-party distributors, public hospitals, pharmacies and other government entities. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We operate in certain countries where weakness in economic conditions can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit and economic conditions in the E.U. continue to remain uncertain, which has, from time to time, led to long collection periods for our accounts receivable and greater collection risk in certain countries. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We believe that our allowance for doubtful accounts was adequate as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. However, if significant changes occur in the availability of government funding or the reimbursement practices of these or other governments, we may not be able to collect on amounts due to us from customers in such countries and our results of operations could be adversely affected.</font></div><div><a name="s707669BEDD62597F890CB2C96561EF2E"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information required by this Item&#160;8 is contained on pages F-1 through F-83 of this report and is incorporated herein by reference.</font></div><div><a name="sA44DEFFC3AE759329E20668C2428D25C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div><a name="s685EB8586ABF5521B00BA9CE09EE9B2C"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</font></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Disclosure Controls and Procedures and Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that (a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and (b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There were no changes in our internal control over financial reporting during the quarter ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by a company&#8217;s board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with </font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">U.S.&#160;GAAP. Our internal control over financial reporting includes those policies and procedures that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S.&#160;GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our management assessed the effectiveness of our internal control over financial reporting as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its 2013 Internal Control&#160;&#8212; Integrated Framework.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our assessment, our management has concluded that, as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our internal control over financial reporting is effective based on those criteria.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The effectiveness of our internal control over financial reporting as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their attestation report, which is included herein.</font></div><div><a name="sBECF0D29E08A56B1B9896105AF82ABFA"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">None.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">94</font></div></div><hr style="page-break-after:always"><div><a name="s20A44D7D03C353008B5ED16E08178407"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;III</font></div><div style='display:inline-block; width:100%;'><div style='float:left; width:48%;'><div><a name="s759E1402DD4D53A2B9692EBE1D0C1AE6"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The information concerning our executive officers is set forth under the heading </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Our Executive Officers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in Item 1 of this report. The text of our code of business conduct, which includes the code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions, is posted on our website, www.biogen.com, under the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Corporate Governance</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; subsection of the &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; section of the site. We intend to make all required disclosures regarding any amendments to, or waivers from, provisions of our code of business conduct at the same location of our website. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to the remainder of this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Proposal&#160;1&#160;- Election of Directors,&#8221; &#8220;Corporate Governance at Biogen,&#8221; &#8220;Stock Ownership&#160;- Section&#160;16(a) Beneficial Ownership Reporting Compliance</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Miscellaneous&#160;- Stockholder Proposals</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><div><a name="sD05F9BB43BA95FAA93131247B9576039"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Executive Compensation Matters</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Corporate Governance at Biogen&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div></div><div style='width:4%; float:left;'>&#160;</div><div style='float:right; width:48%;'><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><a name="s0862E8EC77275FD4A6A1E9B40F4BD221"></a></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Stock Ownership&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Equity Compensation Plan Information&#8221;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><div><a name="sD77AE4903CB557C099CADD03CAD43FE3"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the sections entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Certain Relationships and Related Person Transactions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#8220;Corporate Governance at Biogen</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div><div><a name="sCED3B1F81C4653039612D625277168CC"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The response to this item is incorporated by reference from the discussion responsive thereto in the section entitled &#8220;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Proposal&#160;2&#160;- Ratification of the Selection of our Independent Registered Public Accounting Firm</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8221; contained in the proxy statement for our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annual meeting of stockholders.</font></div></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95</font></div></div><hr style="page-break-after:always"><div><a name="s37EDD5FDE9AC550FBA3E16DEDCD24B7E"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">PART&#160;IV</font></div><div><a name="s0D23296250B4568CA1D49B383D8835B6"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;15. &#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">a. &#160;&#160;&#160;&#160;(1)&#160;Consolidated Financial Statements:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following financial statements are filed as part of this report:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:37%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page&#160;Number</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-2</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-3</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-4</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-5</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-6</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-9</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-83</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certain totals may not sum due to rounding.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;(2) Exhibits</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The exhibits listed on the Exhibit&#160;Index beginning on page&#160;97, which is incorporated herein by reference, are filed or furnished as part of this report or are incorporated into this report by reference.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">(3) Financial Statement Schedules</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Schedules are omitted because they are not applicable, or are not required, or because the information is included in the consolidated financial statements and notes thereto.</font></div><div><a name="s268CC2A2702357C9ADD89AFC28D3704B"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">Item&#160;16. &#160;&#160;&#160;&#160;Form 10-K Summary</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">96</font></div></div><hr style="page-break-after:always"><div><a name="sCD48E5336A8E55B3891559BEB3E55BDB"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;-sec-extract:summary;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">EXHIBIT INDEX</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:7%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504513000010/apa.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset Purchase Agreement among Biogen Idec International Holding Ltd., Elan Pharma International Limited and Elan Pharmaceuticals, Inc., dated as of February 5, 2013. Filed as Exhibit 2.1 to our Current Report on Form 8-K/A filed on February 12, 2013.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000007/ex21_separationxagreement.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Separation Agreement between Biogen Inc. and Bioverativ Inc. dated as of January 31, 2017. Filed as Exhibit 2.1 to our Current Report on Form 8-K filed on February 2, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312512312222/d362642dex31.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amended and Restated Certificate of Incorporation, as amended. Filed as Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000008/biib-2015x327xexhibit31.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certificate of Amendment to the Certificate of Incorporation. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on March 27, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312517200127/d406783dex31.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fourth Amended and Restated Bylaws. Filed as Exhibit 3.1 to our Current Report on Form 8-K filed on June 9, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312512312222/d362642dex31.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reference is made to Exhibit 3.1 for a description of the rights, preferences and privileges of our Series A Preferred Stock and Series X Junior Participating Preferred Stock.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515320650/d78596dex41.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indenture between Biogen Inc. and U.S. Bank National Association, dated as of September 15, 2015. Filed as Exhibit 4.1 to our Current Report on Form 8-K filed on September 16, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515320650/d78596dex42.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">First Supplemental Indenture between Biogen Inc. and U.S. Bank National Association, dated September 15, 2015. Filed as Exhibit 4.2 to our Current Report on Form 8-K filed on September 16, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000028/creditagreement2015biogen.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credit Agreement between Biogen Inc., Bank of America, N.A., Goldman Sachs Bank USA and other lenders party thereto, dated August 28, 2015. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on September 1, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311009300/b83162exv10w5.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Second Amended and Restated Collaboration Agreement between Biogen Idec Inc. and Genentech, Inc., dated as of October 18, 2010. Filed as Exhibit 10.5 to our Annual Report on Form 10-K for the year ended December 31, 2010.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.3&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311009300/b83162exv10w6.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter Agreement regarding GA101 financial terms between Biogen Idec Inc. and Genentech, Inc., dated October 18, 2010. Filed as Exhibit 10.6 to our Annual Report on Form 10-K for the year ended December 31, 2010.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095015717000082/ex10-1.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement and License Agreement, dated January 17, 2017, between Biogen Swiss Manufacturing GmbH, Biogen International Holdings ltd., Forward Pharma A/S and other parties thereto. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on February 1, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312517139450/d43428ddef14a.htm#toc43428_63"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2017 Omnibus Equity Plan. Filed as Appendix B to our Definitive Proxy Statement on Schedule 14A filed on April 26, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.6*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit102.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of restricted stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit103.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.8*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit104.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.4 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.9*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504517000024/biib-2017630xexhibit105.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of cash-settled performance unit award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.5 to our Quarterly Report on Form 10-Q for the quarter ended June 30, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.10*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1010.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement (cash-settled) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.10 to our Annual Report on Form 10-K for the year ended December 31, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.11*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1011.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.11 to our Annual Report on Form 10-K for the year ended December 31, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.12*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000010/biib-2018331xex101.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</font></a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:16%;"></td><td style="width:7%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.13*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000010/biib-2018331xex102.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance stock units award agreement (cash settled) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.14*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000010/biib-2018331xex103.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of restricted stock unit award agreement (2018 one-time transition grant) under the Biogen Inc. 2017 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.15*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex101.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2008 Amended and Restated Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.16*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex102.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of performance unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.17*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000011/biib-2014331xex103.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of market stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.3 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2014.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.18*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508005246/b71469biexv10w1.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of restricted stock unit award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 1, 2008.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.19*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508005246/b71469biexv10w2.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of nonqualified stock option award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.2 to our Current Report on Form 8-K filed on August 1, 2008.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.20*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012310036233/b79987exv10w1.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of cash-settled performance shares award agreement under the Biogen Idec Inc. 2008 Omnibus Equity Plan. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2010.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.21*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504515000014/biib-2015331xex101.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2006 Non-Employee Directors Equity Plan, as amended. Filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.22*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000119312515159387/d786327ddef14a.htm#toc786327_57"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. 2015 Employee Stock Purchase Plan. Filed as Appendix A to our Definitive Proxy Statement on Schedule 14A filed on April 30, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.23*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508003542/b67068dfdefc14a.htm#152"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. 2008 Performance-Based Management Incentive Plan. Filed as Appendix B to our Definitive Proxy Statement on Schedule 14A filed on May 8, 2008.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.24*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013504001180/b48790biexv10w13.txt"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Voluntary Executive Supplemental Savings Plan, as amended and restated effective January 1, 2004. Filed as Exhibit 10.13 to our Annual Report on Form 10-K for the year ended December 31, 2003.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.25*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000042/biib-20151231xex1023.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Supplemental Savings Plan, as amended. Filed as Exhibit 10.23 to our Annual Report on Form 10-K for the year ended December 31, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.26*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000042/biib-20151231xex1024.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Voluntary Board of Directors Savings Plan, as amended. Filed as Exhibit 10.24 to our Annual Report on Form 10-K for the year ended December 31, 2015.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.27*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000004/biib-20131231xex1039.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy - U.S. Executive Vice President, as amended effective January 1, 2014. Filed as Exhibit 10.39 to our Annual Report on Form 10-K for the year ended December 31, 2013.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.28*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504514000004/biib-20131231xex1040.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy - International Executive Vice President, as amended effective January 1, 2014. Filed as Exhibit 10.40 to our Annual Report on Form 10-K for the year ended December 31, 2013.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.29*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013509000730/b73435biexv10w53.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy - U.S. Senior Vice President, as amended effective October 13, 2008. Filed as Exhibit 10.53 to our Annual Report on Form 10-K for the year ended December 31, 2008.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.30*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013509000730/b73435biexv10w54.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Inc. Executive Severance Policy - International Senior Vice President, as amended effective October 13, 2008. Filed as Exhibit 10.54 to our Annual Report on Form 10-K for the year ended December 31, 2008.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.31*+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20181231xex1031.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Annual Retainer Summary for Board of Directors.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.32*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012311057276/b86869exv10w1.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Form of indemnification agreement for directors and executive officers. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on June 7, 2011.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.33*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504516000076/biogenemploymentagreementf.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employment Agreement between Biogen Inc. and Michel Vounatsos dated December 18, 2016 and effective as of January 6, 2017. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on December 19, 2016.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.34*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1031.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Jeffrey Capello dated November 14, 2017. Filed as Exhibit 10.31 to our Annual Report on Form 10-K for the year ended December 31, 2017.</font></a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">98</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:17%;"></td><td style="width:6%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.35*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1032.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Gregory Covino dated February 25, 2012. Filed as Exhibit 10.32 to our Annual Report on Form 10-K for the year ended December 31, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.36*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000005/biib-20171231xex1033.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Michael Ehlers dated April 16, 2016. Filed as Exhibit 10.33 to our Annual Report on Form 10-K for the year ended December 31, 2017.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.37*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095012310010528/b77985exv10w58.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Susan Alexander dated December 13, 2005. Filed as Exhibit 10.58 to our Annual Report on Form 10-K for the year ended December 31, 2009.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.38*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504518000010/biib-2018331xex104.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement for Paul McKenzie dated December 14, 2015. Filed as Exhibit 10.4 to our Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.39*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504513000029/exhibit101amendedemploymen.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employment Agreement between Biogen Idec. Inc. and George A. Scangos amended as of August 23, 2013. Filed as Exhibit 10.1 to our Current Report on Form 8-K filed on August 26, 2013.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.40*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000095013508001029/b68103biexv10w49.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Paul J. Clancy dated August 17, 2007. Filed as Exhibit 10.49 to our Annual Report on Form 10-K for the year ended December 31, 2007.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.41*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/875045/000087504513000006/biib-20121231xex1049.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Letter regarding employment arrangement of Kenneth DiPietro dated December 12, 2011. Filed as Exhibit 10.49 to our Annual Report on Form 10-K for the year ended December 31, 2012.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20181231xex21.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subsidiaries. </font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20181231xex23.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.1+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20181231xex311.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.2+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20181231xex312.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.1++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="biib-20181231xex321.htm"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101++</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following materials from Biogen Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018, formatted in XBRL (Extensible Business Reporting Language): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Cash Flows, (v) the Consolidated Statements of Equity and (vi) Notes to Consolidated Financial Statements.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">^</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References to &#8220;our&#8221; filings mean filings made by Biogen Inc. and filings made by IDEC Pharmaceuticals Corporation prior to the merger with Biogen, Inc. Unless otherwise indicated exhibits were previously filed with the SEC under Commission File Number 0-19311 and are incorporated herein by reference.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management contract or compensatory plan or arrangement.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Confidential treatment has been granted or requested with respect to portions of this exhibit.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Filed herewith.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:2%;"></td><td style="width:4%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furnished herewith.</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99</font></div></div><hr style="page-break-after:always"><div><a name="sBDDF3826BF6950A9A1BA42CCC959AD8F"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div style="line-height:120%;font-size:18pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:18pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:316px;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:50px;"></td><td style="width:265px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">BIOGEN INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;M</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHEL</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;V</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OUNATSOS</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:42%;"></td><td style="width:3%;"></td><td style="width:34%;"></td><td style="width:3%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Capacity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;M</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHEL</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;V</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OUNATSOS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director&#160;and&#160;Chief&#160;Executive&#160;Officer (principal&#160;executive&#160;officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;J</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">EFFREY </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">APELLO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive&#160;Vice&#160;President and Chief Financial Officer (principal financial officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey D. Capello</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OBIN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;C. K</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RAMER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vice President, Chief Accounting Officer (principal accounting officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robin C. Kramer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TELIOS</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">APADOPOULOS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director&#160;and&#160;Chairman&#160;of&#160;the&#160;Board&#160;of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stelios Papadopoulos</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">LEXANDER </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">J</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ENNER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;Alexander J. Denner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">AROLINE</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;D. D</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ORSA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Caroline D. Dorsa</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;N</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ANCY</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;L. L</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">EAMING</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Nancy L. Leaming</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ICHARD </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">C</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">M</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ULLIGAN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Richard C. Mulligan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OBERT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;W. P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ANGIA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Robert W. Pangia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;B</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RIAN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;S. P</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OSNER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brian S. Posner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;E</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">RIC</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;K. R</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">OWINSKY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eric K. Rowinsky</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;L</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">YNN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">CHENK</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Lynn Schenk</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/&#160;&#160;&#160;&#160;S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TEPHEN</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;A. S</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">HERWIN</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stephen A. Sherwin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101</font></div></div><hr style="page-break-after:always"><div><a name="s4493835284205B3683A1DE1DFEFFA63D"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:37%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Page&#160;Number</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-2</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Comprehensive Income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-4</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-5</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Consolidated Statements of Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-6</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-9</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F-83</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:300px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 1</font></div></div><hr style="page-break-after:always"><div><a name="s37E54567146952E082EAC6E3F325173A"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions, except per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">585.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13,452.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,273.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,448.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost and expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cost of sales, excluding amortization and impairment of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,816.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,630.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,478.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,597.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,253.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,973.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,106.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,933.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,946.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairment of acquired intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">747.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">814.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">385.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration profit (loss) sharing</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">185.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">112.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">112.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Gain) loss on fair value remeasurement of contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(12.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">TECFIDERA litigation settlement charge</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">454.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,564.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,928.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,297.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,888.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,345.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,151.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(217.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(218.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax expense and equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,899.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,128.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,933.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,425.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,458.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,237.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity in loss of investee, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,474.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,670.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,695.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,430.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.94</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.96</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.93</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">205.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:120px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 2</font></div></div><hr style="page-break-after:always"><div><a name="s64F4B8C778F152B4ACAA6F7D5FBFC570"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,430.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on securities available for sale, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) recognized during the period, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">97.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(193.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">41.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on cash flow hedges, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">139.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(162.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedges:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) recognized during the period, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: reclassification adjustment for (gains) losses included in net income, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedges, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unrealized gains (losses) on pension benefit obligation, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(67.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">76.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,507.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,540.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,606.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">42.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Comprehensive income</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,550.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,671.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,599.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 3</font></div></div><hr style="page-break-after:always"><div><a name="sCAFE7EE68227511C9F86C99BBA918490"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions, except per share amounts)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,224.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,573.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,313.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,115.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,958.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,787.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">526.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">532.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">929.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">902.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">687.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">962.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,640.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,873.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,375.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,057.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,601.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,182.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,120.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,879.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,706.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,632.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax asset</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,153.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">595.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,690.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">431.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25,288.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23,652.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="8" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND EQUITY</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">63.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">370.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">395.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,861.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,295.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,368.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,936.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,935.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,636.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">122.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,389.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,628.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,257.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11,054.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Equity:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Preferred stock, par value $0.001 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock, par value $0.0005 per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">97.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(240.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(318.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retained earnings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16,257.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15,810.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total Biogen Inc. shareholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13,039.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,612.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Noncontrolling interests</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13,031.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,598.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total liabilities and equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25,288.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23,652.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 4</font></div></div><hr style="page-break-after:always"><div><a name="sE08EC068F1F2568EAAE7A1D9466912A2"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,474.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,670.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,695.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and impairments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,016.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,081.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">682.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">112.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">157.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">128.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">154.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">108.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(12.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(69.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">162.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">89.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in operating assets and liabilities, net:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(205.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(435.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(241.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(232.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(52.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(94.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(165.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(119.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(76.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">59.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">465.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(227.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">622.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax assets and liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">321.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,303.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(232.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows provided by operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,187.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,551.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,587.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,173.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,565.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,378.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7,694.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5,355.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7,913.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration related to Fumapharm AG acquisition</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,200.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,200.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired in-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(112.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(120.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of property, plant and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(770.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(867.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(616.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisitions of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(975.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(111.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchase of Ionis Pharmaceuticals, Inc. stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(462.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investment in Samsung Bioepis</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(676.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,046.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,963.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,484.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchases of treasury stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,352.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,365.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments related to issuance of stock for share-based compensation arrangements, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(5.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net distribution to noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(134.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repayments of borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(560.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash contribution to Bioverativ, Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(302.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(58.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(38.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(19.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net cash flows used in financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,472.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,380.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,052.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net increase (decrease) in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(330.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(792.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,049.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of exchange rate changes on cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(18.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(31.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, beginning of the year</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,573.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,326.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,308.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash and cash equivalents, end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,224.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,573.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,326.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 5</font></div></div><hr style="page-break-after:always"><div><a name="s3939D176103F52B1B41B91A890F9882E"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:97.91666666666666%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:10%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">235.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">97.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(318.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">15,810.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(23.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(2,977.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">12,612.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(14.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">12,598.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">4,430.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">4,430.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">43.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">4,474.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">76.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">76.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">76.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Capital contribution by noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">13.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">13.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Distribution to noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(50.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(50.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the 2018 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(1,352.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(1,352.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(1,352.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the 2018 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(92.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(1,259.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">4.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">1,352.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(10.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(3,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(3,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(3,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(10.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(171.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(2,828.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">10.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">3,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">41.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">41.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">41.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(43.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(43.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(43.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Compensation related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">168.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">168.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">168.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;">Adoption of new accounting guidance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">104.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">106.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">106.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;font-weight:bold;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">221.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(240.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">16,257.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(23.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">13,039.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">(8.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9.5pt;color:#2573ba;">13,031.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15,071.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,140.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,128.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">131.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,670.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital contribution by noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Distribution to noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(150.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(150.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(964.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2011 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(365.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(365.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(365.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(45.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(45.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">138.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">138.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">138.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia spin-off adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(852.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(852.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(852.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">97.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(318.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15,810.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,977.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,612.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,598.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">(In millions)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:11%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Retained</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">earnings</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Biogen Inc.</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">shareholders&#8217;</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Noncontrolling</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">interests</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">241.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,208.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,372.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,374.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,695.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss), net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquisition of noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capital contribution by noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deconsolidation of noncontrolling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(7.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Repurchase of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,000.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(164.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(835.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock option and stock purchase plans</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">43.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Issuance of common stock under stock award plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(47.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(52.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(52.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Compensation related to share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit from share-based payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15,071.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(22.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,611.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,140.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,128.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">See accompanying notes to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 8</font></div></div><hr style="page-break-after:always"><div><a name="sFFEB98F6AFD85DAC95AB8A4361992F11"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div><a name="s6A71CFACABD95F75A88520C7BF24AFEE"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">1. &#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&#8217;s disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), Parkinson's disease, ALS, stroke, epilepsy, cognitive impairment associated with schizophrenia (CIAS) and pain.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilar products through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these audited consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the spin-off of our hemophilia business, please read Note 3,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;to these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2014-09 that have the same effective date and transition date: ASU No. 2016-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; and ASU No. 2016-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not change our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon adoption. However, the adoption of the new revenue standards will result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under ASU 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the new revenue standards, other corporate revenue was higher by&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;and cost of sales, excluding amortization and impairment of acquired intangible assets was higher by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the year ended December 31, 2018, compared to what would have been reported under the previous revenue guidance, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">primarily due to the earlier recognition of revenue associated with our contract manufacturing agreements. Under the previous revenue guidance, these amounts would have been recognized in future periods upon shipment. The adoption of the new revenue standards did not have a material impact on any other balances within our consolidated financial statements as of and for the&#160;year ended&#160;December 31, 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the United States (U.S.), we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-left:54px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates, non-US pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration with Genentech is within the scope of Accounting Standards Codification (ASC) 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Agreements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">expenses incurred by Genentech, the Roche Group and us. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates that are based on information received from Genentech. These estimates are subject to change and actual results may differ. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Genentech, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with AbbVie Inc. (AbbVie), Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with AbbVie, Genentech and Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Corporate Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We provide reserves against trade receivables for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of the new revenue standards did not change our historical accounting methods for our accounts receivable.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities and Other Investments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities and Venture Capital Funds</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Equity Method of Accounting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also includes our U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired In-process Research and Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&#160;25, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions of a business completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cash Flow and Fair Value Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Translation of Foreign Currencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense, net of forfeitures, for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of PSUs that settle in stock are based upon the stock price on the date of grant and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes valuation model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;discount is recognized as compensation expense over the 90-day purchase period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. In December 2018 we elected to recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfers of assets other than inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset is transferred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Earnings per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued ASU 2014-09, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. For additional information on the adoption of the new revenue standards, please read the section titled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue Recognition </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">above, and Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, and recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;net increase to retained earnings as well as a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;increase to accumulated other comprehensive income reflecting the cumulative impact for the accounting changes made upon adoption. The adoption of this standard resulted in a change in the income statement classification with respect to where we recognize changes in fair value related to certain equity security investments. Prior to the adoption of ASU 2016-01, we recognized changes in fair value in accumulated other comprehensive income (loss), net. Upon the adoption of ASU 2016-01, we recognize changes in fair value in other income (expense), net. During the year ended December 31, 2018, we recognized net gains resulting from changes in fair value related to our equity security investments in other income (expense), net totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under this standard that would not have been recognized in other income (expense), net under the previous standard. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Leasing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This standard became effective for us on January 1, 2019. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB has subsequently issued the following amendments to ASU 2016-02, which have the same effective date and transition date of January 1, 2019, and which we collectively refer to as the new leasing standards: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-01,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that exist or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which amends certain narrow aspects of the guidance issued in ASU 2016-02.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvements for Lessors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which contains certain narrow scope improvements to the guidance issued in ASU 2016-02.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards on January 1, 2019, using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019. We have reviewed our existing lease contracts and the impact of the new leasing standards on our consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards, we expect to recognize a lease liability and related right-of-use asset on our consolidated balance sheet of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The impact of adoption of the new leasing standards will have an immaterial impact to our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Credit Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard will be effective for us on January 1, 2020. We are currently evaluating the potential impact that this standard may have on our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, offset by a corresponding net increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;with a corresponding reduction to our retained earnings as these differences are related to inter-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our income taxes, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Periodic Pension Cost</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Costs and Net Periodic Postretirement Benefit Cost.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;This standard requires that an employer disaggregate the service cost component from the other components of net benefit cost. This standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the statements of income and allows only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on our consolidated statements of income. We adopted this standard on January 1, 2018, using the retrospective method. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the adoption of this standard, the other components of net periodic benefit cost, which we previously presented as a component of operating income, are now classified in other income (expense), net in our consolidated statements of income. For the years ended December 31, 2017 and 2016, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.3 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reclassified from operating income to other income (expense), net in our consolidated statements of income to conform to our current year presentation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Debt Securities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. Based upon our marketable debt securities as of December 31, 2018, the adoption of this standard did not result in a significant adjustment to our marketable debt securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard provides guidance to better align an entity's risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. This standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this standard resulted in additional disclosures and a change in the income statement classification with respect to where we recognize cash flow hedge ineffective or excluded hedge transaction gains and losses. Prior to the adoption of ASU 2017-12 on January 1, 2018, to the extent ineffective or excluded, cash flow hedge transaction gains and losses were reported in other income (expense), net. Effective January 1, 2018, we recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of any cash flow hedge ineffectiveness or excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, in October 2018 the FASB issued ASU No. 2018-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will be effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;This standard makes targeted improvements for collaborative arrangements as follows: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Requires that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting that transaction together with revenue recognized under ASC 606 is precluded if the collaborative arrangement participant is not a customer. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will be effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. We are currently evaluating the potential impact that this standard may have on our consolidated financial position and results of operations.</font></div><div><a name="s7E9659B6D2A65EA59EC0E32CC4F1CB68"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB100 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired BIIB100 (formerly known as KPT-350) from Karyopharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 ready investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Karyopharm, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB100 has not yet reached technological feasibility. We may also pay Karyopharm up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$207.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestone payments as well as tiered royalties on potential net commercial sales in the mid-single digit to low-teen percentages. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB104 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we acquired BIIB104 (formerly known as PF-04958242) from Pfizer Inc. (Pfizer). BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for CIAS, representing our first program in neurocognitive disorders. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Pfizer, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB104 has not yet reached technological feasibility. We may also pay Pfizer up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$515.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the low to mid-teen percentages. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2018 we accrued a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment related to the Phase 2b trial for BIIB104, which is included in research and development expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TMS Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we entered into an exclusive option agreement with TMS Co., Ltd. (TMS) granting us the option to acquire TMS-007, a plasminogen activator with a novel mechanism of action associated with breaking down blood clots, which is in Phase 2 development in Japan, and backup compounds for the treatment of stroke. In exchange for the purchase option, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment to TMS, which was recorded as research and development expense in our consolidated statements of income as TMS-007 has not yet reached technological feasibility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we exercise the purchase option, we will make an additional payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon closing of the asset acquisition, which will be recorded as acquired IPR&amp;D expense in our consolidated statements of income as TMS-007 will not have reached technological feasibility at that time. In addition, we may pay TMS up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$335.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional development and commercialization milestone payments as well as tiered royalties on potential </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">net commercial sales in the high-single digit to low-teen percentages. If we exercise the purchase option, consummation of the asset acquisition may be subject to the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB110 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we acquired BIIB110 (formerly known as ALG-801) (Phase 1a) and ALG-802 (preclinical) from AliveGen Inc. (AliveGen).&#160;BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 in multiple neuromuscular indications, including SMA and ALS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to AliveGen, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB110 has not yet reached technological feasibility. We may also pay AliveGen up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$535.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional development and commercialization milestones.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB093 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we acquired BIIB093 (glibencamide IV) (formerly known as CIRARA) from Remedy Pharmaceuticals Inc. (Remedy). BIIB093 is a Phase 3 ready candidate for large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) granted BIIB093 orphan drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 Fast Track designation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are responsible for the future development and commercialization of BIIB093 and Remedy will share in the cost of development for the target indication for BIIB093 in LHI stroke.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Remedy, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB093 has not yet reached technological feasibility. We may also pay Remedy certain development and sales based milestone payments that are substantially payable upon or after regulatory approval, as well as royalties on potential net commercial sales. </font></div><div><a name="s60c0206c568146069685b52320c058d6"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">3.&#160;&#160;&#160;&#160;Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company, which was acquired by Sanofi in March 2018. In connection with the spin-off, each Biogen shareholder received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen and Bioverativ entered into a separation agreement and various other agreements, including a manufacturing and supply agreement, which govern the separation and distribution and the relationship between the two companies going forward. Under the separation agreement, Bioverativ is obligated to indemnify us for liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we distributed ALPROLIX and ELOCTATE on behalf of Bioverativ until Bioverativ obtained appropriate regulatory authorizations in certain countries, including a Biologics License Application transfer in the U.S., which was received in September 2017. Accordingly, commencing October 2017, we ceased distribution of ALPROLIX and ELOCTATE on behalf of Bioverativ under this arrangement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. The manufacturing and supply agreement has an initial term of five years, with a five-year extension at Bioverativ's sole discretion and a further five-year extension with Bioverativ's and our consent. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$206.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues in relation to contract manufacturing services provided to Bioverativ, which is reflected as a component of other royalty and corporate revenues in our consolidated statements of income. We also recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$180.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as cost of sales in relation to these services during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Additionally, pursuant to the terms of the manufacture and supply agreement, we expect to sell substantially all remaining hemophilia related inventory to Bioverativ during the first quarter of 2019, when Bioverativ will assume full control over its manufacturing processes. Hemophilia related inventory on hand as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totals approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$180.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items. These amounts, which were primarily reflected as a reduction to selling, general and administrative expenses in our consolidated statements of income, were not significant for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia related product revenues reflected in our consolidated statements of income for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$846.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Results for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, only reflect hemophilia-related product revenues through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Patents</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 27</font></div></div><hr style="page-break-after:always"><div><a name="s92E35692AFC45F929070CFB1C84E8888"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Restructuring, Business Transformation and Other Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2017 Corporate Strategy</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and capital expenditures of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$135.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in connection with this program and our goal is to redirect resources of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$400.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;annually by 2020 to prioritized research and development and other value creation opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to this effort, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are reflected as restructuring charges and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are included in selling, general and administrative expenses in our consolidated statements of income. These restructuring charges were primarily related to severance.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges incurred to date under this program have been substantially paid in cash as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2016 Organizational Changes and Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2016 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin-off our hemophilia business, and to achieve further targeted cost reductions. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to this effort. These amounts, which were substantially incurred and paid by the end of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cambridge, MA Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we decided to cease manufacturing and vacate our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and close and vacate our 46,000 square foot warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December&#160;2016 we subleased our rights to the Cambridge, MA manufacturing facility to Brammer Bio MA,&#160;LLC (Brammer). Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we closed and vacated our warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets' new shorter useful lives. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of this additional depreciation, which was recorded as cost of sales in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2016 we also recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for severance costs related to certain employees separated from Biogen in connection with our departure from these facilities. These amounts were substantially incurred and paid by the end of first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2015 Restructuring Charges</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, include </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of expense related to our 2015 restructuring program.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 28</font></div></div><hr style="page-break-after:always"><div><a name="sAD8D3EAC7F025EAA9FCD869E226764B0"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">5.&#160;&#160;&#160;&#160;Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36"></td></tr><tr><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,253.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,020.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">4,274.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,294.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">920.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4,214.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,169.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">798.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,968.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,668.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">694.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,363.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,889.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">756.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,645.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,980.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">814.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,795.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,025.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">839.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,864.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,113.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">859.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,973.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,182.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">780.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,963.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">92.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">92.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">91.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">91.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">52.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">52.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS Product Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">5,946.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,648.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">8,595.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,296.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,680.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,977.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,332.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,487.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,819.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">854.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">870.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,724.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">657.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">226.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">883.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">485.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">485.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">370.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">370.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">43.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">43.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">545.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">545.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">379.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">379.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">22.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">22.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">39.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">39.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">42.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">48.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">445.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">68.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">513.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">21.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">26.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">268.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">65.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">333.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Hemophilia product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">63.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">74.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">713.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">133.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">846.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">6,800.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">4,086.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7,017.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,337.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">10,354.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7,050.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.6%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net accounts receivable associated with our product sales, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">109.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">606.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">761.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">679.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,686.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">23.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,389.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(12.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(551.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,887.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,440.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(109.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(506.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(646.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">127.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">888.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">482.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,307.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,917.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(475.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,756.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,232.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(69.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(442.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(534.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">109.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">606.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">592.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,044.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,668.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(522.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,576.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,099.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(536.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(609.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">482.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">176.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">874.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,431.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,316.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our total revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">96.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Sobi and royalties from Sobi on sales of ELOCTA and ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">459.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">253.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">585.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with AbbVie and Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For additional information on our contract manufacturing agreements with Bioverativ, please read Note 3,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;to these consolidated financial statements.</font></div><div><a name="s813884A0B1035C47898859517F00D6A4"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">196.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">162.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">606.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">133.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">157.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">929.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">902.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the table above is hemophilia related inventory totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$180.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of December 31, 2018, which is expected to be sold to Bioverativ in the first quarter of 2019. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$76.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 31</font></div></div><hr style="page-break-after:always"><div><a name="s9A7738D2353354A785933E5CB4822770"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(542.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(535.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,734.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">270.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,689.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">476.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">476.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,638.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,330.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,308.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,971.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,160.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,811.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,727.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,607.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,120.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,264.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,385.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,879.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$747.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$814.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$385.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes the impact of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$176.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairment charge related to our intangible asset associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below. Amortization and impairment of acquired intangible assets for 2018 also reflects the impact of impairment charges related to certain IPR&amp;D assets associated with our vixotrigine (BIIB074) program totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$189.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes the impact of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$328.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairment charge related to our intangible assets associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. Amortization and impairment of acquired intangible assets for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;also includes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairment charge related to our acquired and in-licensed rights and patents intangible asset associated with ZINBRYTA after the initiation of an European Medicines Agency (EMA) review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the year ended December 31, 2016, included impairment charges of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;related to two of our IPR&amp;D intangible assets resulting from the termination of our collaboration agreements with Rodin Therapeutics, Inc. and Ataxion Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets, excluding impairment charges, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$381.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$455.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$373.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Out-licensed Patents</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset, as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$265.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired and had not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">useful life and amortize these amounts based upon an economic consumption method. The carrying value associated with our IPR&amp;D assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of Convergence Pharmaceuticals (Convergence), Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2015, 2012 and 2010, respectively. IPR&amp;D balances include adjustments related to foreign currency exchange rate fluctuations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long-range planning cycle, which was most recently updated in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Vixotrigine</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints; therefore, we discontinued development of vixotrigine for the treatment of PLSR and we recognized an impairment charge of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the third quarter of 2018 to reduce the fair value of the related IPR&amp;D intangible asset to zero. In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the treatment of TGN as we awaited the outcome of ongoing interactions with the FDA regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the treatment of PLSR and insights from the Phase 2 study of vixotrigine for the treatment of small fiber neuropathy. We reassessed the fair value of our vixotrigine program for the treatment of TGN using reduced expected lifetime revenues, higher expected clinical development costs and lower cumulative probabilities of success, and, as a result of that assessment, we recognized an impairment charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$129.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the third quarter of 2018 to reduce the fair value of the IPR&amp;D intangible asset associated with our vixotrigine program for the treatment of TGN to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In late December 2018 we received feedback from the FDA regarding the design of the Phase 3 vixotrigine program for the treatment of TGN. Following this feedback, we are now planning to initiate the Phase 3 vixotrigine program for the treatment of TGN.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The IPR&amp;D impairment charges that resulted from the developments in our vixotrigine program for the treatment of TGN, as discussed above, were included in amortization and impairment of acquired intangible assets. The fair value of the intangible assets were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may recognize additional impairment charges in the future depending upon our ability to advance vixotrigine for the treatment of TGN or other indications. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan. Acquired and in-licensed rights and patents also includes our U.S and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,027.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was recorded within intangible assets in the first quarter of 2017. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$328.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairment charge in the first quarter of 2017 to adjust the carrying value of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute and continued to amortize the remaining net book value of the U.S. intangible asset in our consolidated statements of income utilizing an economic consumption model. The U.S. Court of Appeals for the Federal Circuit upheld the U.S. Patent and Trademark Office&#8217;s (USPTO) March 2017 ruling and in January 2019 denied Forward Pharma's petition for rehearing. We evaluated the recoverability of the U.S. asset based upon these most recent developments recorded a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$176.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;impairment charge in the fourth quarter of 2018 to reduce the remaining net book value of the U.S. asset to zero.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the European Patent Office (EPO) revoked Forward Pharma&#8217;s European Patent No. 2 801 355. Forward Pharma has filed an appeal to the Technical Board of Appeal of the EPO and the appeal is pending. Based upon our assessment of this ruling, we continue to amortize the remaining net book value of the rest of world intangible asset in our consolidated statements of income utilizing an economic consumption model. The remaining net book value of the TECFIDERA intangible asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$71.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these disputes, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:81%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">270.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">290.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,632.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,669.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(314.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,080.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,267.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,706.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,632.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative enterprise fair value of our hemophilia business as of February 1, 2017. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase to goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$119.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$232.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in tax benefits), respectively, and payable to the former shareholders of Fumapharm AG and holders of their rights. In the fourth quarter of 2018 we achieved the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales level threshold and accrued our last </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment related to FUMADERM and TECFIDERA (together, the Fumapharm Products), which will be paid in the first quarter of 2019. For </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">additional information on contingent payments to the former shareholders of Fumapharm AG and holders of their rights, please read Note 22, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other includes changes related to foreign currency exchange rate fluctuations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;accumulated impairment losses related to goodwill. </font></div><div><a name="sA78FDD4E7DE15ADF90D52208D5BC0CFA"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,459.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,459.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">969.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">969.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">615.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">563.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,102.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,050.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">434.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,444.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,433.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;changes in valuation techniques or transfers between fair value measurement levels during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">new agreement with Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,489.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,517.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,745.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,851.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,802.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,077.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,037.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica AG, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs that were payable to Fumedica AG in varying amounts from June 2008 through June 2018. In June 2018 we redeemed our remaining note payable to Fumedica AG.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica AG, as of December 31, 2017, was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair value for each series of our Senior Notes was determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and BIN in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(12.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(101.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$265.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$279.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of achievement of milestones related to our vixotrigine program for the treatment of TGN and an increase in discount rates used to revalue our contingent consideration liabilities, partially offset by the passage of time. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, payments and other reflects a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment made to the former shareholders of Stromedix, as discussed below. For additional information on our IPR&amp;D intangible asset related to our vixotrigine program for the treatment of TGN, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations are primarily due to changes in the expected timing and probabilities of success related to the achievement of certain development milestones and changes in the discount rate.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Convergence Pharmaceuticals Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was based on probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was the estimated cost of debt financing for market participants. This liability reflected the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$246.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$259.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash flow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$400.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in our contingent consideration obligation was primarily due to delays in the expected timing of achievement of milestones related to our vixotrigine program for the treatment of TGN and an increase in discount rates used to revalue our contingent consideration liabilities, partially offset by the passage of time. Accrued expenses and other in our consolidated balance sheets include </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$144.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Stromedix Inc.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Stromedix in March 2012 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$122.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$83.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$162.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$306.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in our contingent consideration obligation was primarily due to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone paid to the former shareholders of Stromedix as we dosed our first patient in the Phase 2b study of BG00011 (STX-100) in idiopathic pulmonary fibrosis in September 2018, changes in the expected timing related to the achievement of certain remaining developmental milestones and an increase in discount rates, partially offset by the passage of time. No amounts are reflected as a current liability in our consolidated balance sheets as we do not expect to make a payment in the next year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen Idec International Neuroscience GmbH</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$335.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in our contingent consideration obligation was primarily due to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;development milestone paid in the first quarter of 2018 as we dosed our first patient in our Phase 2 SPARK study of BIIB054 (&#945;-synuclein mAb) in Parkinson's disease in January 2018 and an increase in discount rates, partially offset by the passage of time. No amounts are reflected as a current liability in our consolidated balance sheets as we do not expect to make a payment in the next year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we also allocated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the total purchase price to acquired IPR&amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. These assets will be tested for impairment annually until commercialization, after which time the acquired IPR&amp;D will be amortized over its estimated useful life using the economic consumption method. During the third quarter of 2018 we recognized impairment charges related to certain IPR&amp;D assets associated with our vixotrigine program totaling </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$189.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our IPR&amp;D intangible assets related to our vixotrigine program, including a discussion of our most significant assumptions, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div><a name="sAB0D2D612BF65F6B92FC6929FD48EA73"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">9.&#160;&#160;&#160;&#160;Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">279.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">948.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">194.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">247.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon the adoption of ASU 2016-01, our marketable equity securities gains (losses) are recorded in other income (expense), net in our consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,607.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,608.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">851.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">854.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">706.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">263.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">264.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">615.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">127.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">496.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,570.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,569.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">845.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,313.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,314.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,115.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,116.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,232.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,235.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;months and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;months, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,173.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,565.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,378.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to impairments recognized on certain of our available-for-sale marketable debt securities, sales of agency mortgage-backed securities, corporate bonds and government securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our consolidated balance sheets. The increase in our strategic investment portfolio is primarily a result of our investment in Ionis' common stock, as discussed below. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and venture capital funds where the underlying investments are in equity securities of certain biotechnology companies. Our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1 marketable equity securities within our disclosures included in Note 8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ionis Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we closed a new </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year exclusive agreement with Ionis to develop novel antisense oligonucleotide (ASO) drug candidates for a broad range of neurological diseases (the 2018 Ionis Agreement) for a total payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and the purchase of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of Ionis' common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$625.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Ionis' common stock is remeasured each reporting period and carried at fair value as a Level 2 marketable equity security due to certain holding period restrictions. The effect of these holding period restrictions are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis' common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the 2018 Ionis Agreement, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement with Samsung BioLogics to increase our ownership percentage in Samsung Bioepis from approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), which is classified as a component of investments and other assets within our consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div><a name="s15D595DB6C095BF3982874BC63BEC9FD"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">10.&#160;&#160;&#160;&#160;Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU 2017-12. We adopted this standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this standard resulted in additional disclosures and a change in the income statement classification with respect to where we recognize cash flow hedge ineffective or excluded hedge transaction gains and losses. For additional information on this standard, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect, as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. Prior to the adoption of ASU 2017-12 on January 1, 2018, to the extent ineffective or excluded, cash flow hedge transaction gains and losses were reported in other income (expense), net. Effective January 1, 2018, we recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of any cash flow hedge ineffectiveness or excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,701.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,875.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">131.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">98.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,239.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,198.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We expect the net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Year&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized Directly into Net Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Swap Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes, as described in Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate these currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as net investment hedges. Since the critical terms of the investment and the foreign currency forward contracts match, these contracts are assumed to be highly effective. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedge in our consolidated financial statements:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">For the Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net Gains/(Losses) Recognized in AOCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (Losses) on Net Investment Hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net Gains/(Losses) Reclassified from AOCI into Net Income </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$735.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$564.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to these contracts were recorded as a component of other income (expense), net, for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br>As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br>As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 42</font></div></div><hr style="page-break-after:always"><div><a name="sB6BB27242A515AC8B9153B86C7F50C55"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">11.&#160;&#160;&#160;&#160;&#160;&#160;Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">144.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">141.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,282.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,213.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">94.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,258.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,207.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">798.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">767.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,758.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,276.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,398.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,741.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,797.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,601.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,182.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation expense totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$269.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$266.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$309.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we capitalized interest costs related to construction in progress totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$54.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The increase in capitalized interest costs is primarily due to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, as discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. Upon completion, the facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility. </font></div><div><a name="s149922A84B795C77B39F1B45DAD5E99E"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">12.&#160;&#160;&#160;&#160;&#160;Indebtedness</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,480.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,482.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">995.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">994.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,737.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,736.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,722.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,722.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,935.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">6.875% Senior Notes due March 1, 2018</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 4, 2008, we issued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due March 1, 2018, at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99.184%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par. These notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these interest rate swap contracts, the carrying amount of these Senior Notes increased </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with this amount being amortized using the effective interest rate method over the remaining life of the Senior Notes and recognized as a reduction of interest expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we redeemed these Senior Notes prior to their maturity and recognized a net charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon the extinguishment of these Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our consolidated statements of income for the year ended December 31, 2017, reflects the payment of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;early call premium and the write-off of remaining unamortized original debt issuance costs and discount balances, partially offset by a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;gain related to the remaining unamortized balance of the interest rate swap liability discussed above.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Notes payable to Fumedica AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica AG, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Swiss Francs that were payable to Fumedica AG in varying amounts from June 2008 through June 2018. In June 2018 we redeemed our remaining note payable to Fumedica AG.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Senior Notes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with these offerings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations. These Senior Notes may be redeemed at our option at any time at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the principal amount plus accrued interest and a specified make-whole amount. These Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Senior Notes as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these contracts. For additional information on our interest rate contracts, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Maturity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments due under our debt arrangements are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,000.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our debt is disclosed in Note&#160;8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><a name="s12B5208C873159919C2D78F12F864B8B"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">13.&#160;&#160;&#160;&#160;&#160; Equity</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Preferred Stock authorized, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are authorized as Series A, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are authorized as Series X junior participating and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.25 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and 2016:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27"></td></tr><tr><td style="width:13%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">221.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">197.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2018 Share Repurchase Program). Our 2018 Share Repurchase program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock (2011 Share Repurchase Program), which was completed as of March 31, 2017. Share repurchases under our 2011 Share Repurchase Program were principally used to offset common stock issuances under our share-based compensation programs. Under our 2011 Share Repurchase Program, we repurchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts paid to repurchase shares in excess of their par value are allocated between additional paid-in capital and retained earnings, with payments in excess of our additional paid-in-capital balance recorded as a reduction to retained earnings.</font></div><div><a name="s2EBB1D5ED1D459589EAA6CD678B49634"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">14.&#160;&#160;&#160;&#160;&#160;&#160;Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(318.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU 2016-01</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(316.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">97.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(67.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">29.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">41.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">139.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(67.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">76.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(243.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(240.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(193.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(162.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(104.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(318.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(92.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s857B77BBF19B56CAA16861C0F88EB1D3"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">15.&#160;&#160;&#160;&#160;&#160;&#160;Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,430.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">205.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings per share for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects, on a weighted average basis, the repurchase of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of our common stock, respectively, under our 2018, 2016 and 2011 Share Repurchase Programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.</font></div><div><a name="s46B2ECD6378557EB8F33286110D93757"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">16.&#160;&#160;&#160;&#160;&#160;Share-Based Payments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">105.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">121.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">181.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(27.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">142.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">117.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">135.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">126.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">107.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">181.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, unrecognized compensation cost related to unvested share-based compensation was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$188.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spin-off Related Equity Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing share-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, RSUs, CSPUs and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen's and Bioverativ's equity awards with the outstanding awards continuing to vest over </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">their respective original vesting periods. Outstanding equity awards for employees transferring to Bioverativ were converted to unvested Bioverativ equity awards.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume-weighted average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Directors Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2006 our shareholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Omnibus Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017, or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017, are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;ratio.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a 10-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;grants of stock options made in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all outstanding options were exercisable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility or both, we have </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&#160;1, 2006, were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">42,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.82</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total intrinsic values of options exercised in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The weighted average remaining contractual term for options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Market Stock Units (MSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees prior to 2014 vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees in 2014 and thereafter vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">171,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">370.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">129,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">378.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(91,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">365.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(29,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">376.51</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">180,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">371.32</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted during 2018 include awards granted in conjunction with our annual awards made in February 2018 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2018 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2017, 2016 and 2015.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price on the date of grant for MSUs, expected volatility of our stock price, risk-free rates of return and expected dividend yield.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assumptions used in our valuation are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:44%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.5% - 32.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.0% - 35.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.2% - 40.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.9% - 2.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9% - 1.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6% - 0.9%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$279.47 - $346.76</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$263.18 - $267.88</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.67 - $304.86</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$378.85</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.59</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$328.03</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of MSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Settled Performance Units (CSPUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CSPUs awarded to employees vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs are classified as liability awards and will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">105,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(51,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">These shares reflect the CSPUs issued in 2018 based upon the attainment of performance criteria set for 2017 in relation to CSPUs granted in 2017.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cash paid in settlement of CSPUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance-vested Restricted Stock Units (PUs)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(52,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">These shares reflect the PUs issued in 2018 based upon the attainment of performance criteria set for 2017 in relation to PUs granted in 2017.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance Stock Units (PSUs)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018 we began granting awards for performance-vested RSUs that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of cumulative three-year performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in stock activity:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:73%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">317.09</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">315.70</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">317.26</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PSUs settled in stock granted in 2018 include awards granted in conjunction with our annual awards made in February 2018 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Cash</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018 we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have three performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of three annual performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs are classified as liability awards and will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;calendar day average closing stock price through the vesting date, once the actual vested and earned number of PSUs is determined. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in cash activity:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:83%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">45,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PSUs settled in cash granted in 2018 include awards granted in conjunction with our annual awards made in February 2018 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Time-Vested Restricted Stock Units (RSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs awarded to employees generally vest no sooner than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one-third per year over three years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:67%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">832,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">291.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">581,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.32</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(376,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">299.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(134,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">298.81</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">903,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">303.18</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2018 primarily represent RSUs granted in conjunction with our annual awards made in February 2018 and awards made in conjunction with the hiring of new employees. RSUs granted in 2018 also include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">9,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#32;RSUs granted to our Board of Directors.</font></div></td></tr></table><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs granted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;had weighted average grant date fair values of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$293.41</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$268.52</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of RSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015 our shareholders approved the 2015 ESPP. The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP, which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">167,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">190,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="sAAD34AC3668E5CD4A402F208D541F8F6"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">17.&#160;&#160;&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Tax Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,877.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,540.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,655.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,022.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,588.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,277.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,899.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,128.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,933.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,131.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,201.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,304.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">45.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">140.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">108.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,317.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,367.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,412.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(62.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">241.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">177.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(159.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(45.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">108.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,425.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,458.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,237.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2017 Tax Act</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as GILTI, and includes base erosion prevention measures on non-U.S. earnings. These changes became effective in 2018. During the fourth quarter of 2018 we elected to recognize deferred taxes for basis differences expected to reverse as GILTI is incurred and have established initial deferred tax balances, as of the enactment date of the 2017 Tax Act.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2017 we recognized within our provision for income taxes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;provisional estimate pursuant to the U.S. Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 118. Our provisional estimate included an amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;associated with a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax), as discussed below, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$184.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended December 31, 2018, we recognized a net reduction of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our estimated Transition Toll Tax, an expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to remeasure our deferred tax balances, an expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$135.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to establishing deferred taxes for GILTI and an expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect other aspects of the 2017 Tax Act.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Transition Toll Tax</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax. The Transition Toll Tax was assessed on our share of our foreign corporations' accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and all other earnings were taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, under the Transition Toll Tax. The decrease in this liability is primarily attributed to our 2018 Transition Toll Tax payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the application by the U.S. Internal Revenue Service (IRS) of an approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;overpayment against the accrual and the impact of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;net reduction described above. Of the amounts accrued as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to the overpayment discussed above. The Transition Toll Tax will be paid in installments over an eight--year period, which started in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Status of our Assessment</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The final determination of the Transition Toll Tax and the remeasurement of our deferred assets and liabilities was completed during the fourth quarter of 2018 under SEC Staff Accounting Bulletin No. 118. Throughout 2018 proposed regulations were issued by the IRS, which are expected to be finalized in 2019 and may have an impact on our income tax provision. We will assess the impact of any additional guidance when it is issued.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Unremitted Earnings</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we considered none of our earnings to be permanently reinvested outside the U.S. and therefore recorded deferred tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. Other than for earnings, we are permanently reinvested for book/tax basis differences related to foreign subsidiaries. These differences are estimated to total approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and primarily arose through the impacts of purchase accounting. These basis differences could reverse through sales of the foreign subsidiaries, as well as various other events, none of which are considered probable as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The residual U.S. tax liability, if these differences would reverse, would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Article 20 Procedure of ZINBRYTA</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the Article 20 Procedure of ZINBRYTA, for the year ended December 31, 2017, we recognized a net impairment charge on certain tax assets related to ZINBRYTA reflected within income tax expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.8 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This charge reflected the write-off of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to prepaid taxes, which was partially offset by the recognition of an unrecorded deferred tax benefit of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our collaboration arrangement with AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">102.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">163.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,298.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">378.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">209.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,823.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">831.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(232.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(250.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(544.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,425.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(102.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(107.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,305.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(358.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intra-entity transactions. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total deferred charges and prepaid taxes were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$239.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$617.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU 2016-16. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date.&#160;Upon adoption, we recognized additional deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;offset by a corresponding increase to deferred tax liabilities, related to an expected reduction in future U.S. foreign tax credits of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and an increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;with a corresponding reduction to our retained earnings as these differences are related to inter-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:55%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 Tax Act</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment of ZINBRYTA related tax assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Changes in Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the enactment of the 2017 Tax Act. The effects of an overall reduction in the federal statutory rate in the U.S. were partially offset by the elimination of the manufacturing deduction, the imposition of the GILTI tax on international earnings, our recording of deferred taxes on GILTI in 2018, limits on the deductibility of certain benefits on executive compensation and a reduction in the tax benefit associated with the Orphan Drug Credit, all resulting from the 2017 Tax Act, and a change in accounting rules related to recording the tax impacts of intra-entity transactions. Included in taxes on foreign earnings in the above rate reconciliation for 2018 was an increase of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">350</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;basis points related to the sale of inventory, the tax effect of which had been included within prepaid taxes at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at a higher effective tax rate. The effective tax rate for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflected the impact of a favorable settlement related to a state tax matter in 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the most significant factors contributing to the increase in our effective tax rate was the effect of the enactment of the 2017 Tax Act and the impairment of certain ZINBRYTA related tax assets, both of which are discussed above. Excluding the effect of these items, our income tax rate would have decreased due to a lower percentage of our earnings being recognized in the U.S., a higher tax jurisdiction. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we earned a lower benefit from the Orphan Drug Credit due to the FDA's approval of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Attributes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which begin to expire in 2022. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;that begin to expire in 2020. For state income tax purposes, we also had research and investment credit carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$133.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;that begin to expire in 2019. For foreign income tax purposes, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of net operating loss carryforwards that begin to expire in 2024.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">58.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement refund (payment)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(64.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">114.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our 2017 activity above reflects a refund received from a state, related to the settlement of an uncertain tax position.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the balance of unrecognized tax benefits as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;(net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, 2017 and 2016 we recognized a net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We have accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the payment of interest and penalties as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">International Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to the Danish Tax Authority (SKAT) for assessments received for 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid. It is reasonably possible that we will adjust the value of our uncertain tax positions related to Danish withholding taxes based on potential European court decisions expected in 2019 on similar matters.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Federal and State Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 58</font></div></div><hr style="page-break-after:always"><div><a name="s668D49B593435220BA8A409C7DF4DE1A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">18.&#160;&#160;&#160;&#160;&#160;&#160;Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Supplemental Cash Flow Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:51%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">243.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,007.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,066.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,642.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-cash Operating, Investing and Financing Activity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2018 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of the Fumapharm Products, which will be paid in the first quarter of 2019. In the fourth quarter of 2017 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total cumulative sales of the Fumapharm Products, which was paid in the first quarter of 2018. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. For additional information on the contingent payments to the former shareholders of Fumapharm AG and holders of their rights, please read Note 22, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our consolidated balance sheets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read Note 11,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Property, Plant and Equipment,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the settlement and license agreement with Forward Pharma. For additional information on the settlement and license agreement with Forward Pharma, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">112.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(200.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(250.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(260.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">119.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(18.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(217.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(218.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, gain (loss) on investments, net, as reflected in the table above, substantially relate to marketable equity securities held at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$687.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$962.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and include prepaid taxes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$271.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$657.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Investments and other assets</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,690.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$563.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to our investments in Samsung Bioepis and Ionis, respectively. For additional information on </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our collaboration arrangements with Samsung Bioepis and Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">874.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">444.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">320.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">297.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">224.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">206.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">125.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">159.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">261.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">609.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">636.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,861.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,389.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,628.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and include accrued income taxes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$791.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$979.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div><a name="s6263F44B2A9B5928A66E14B7E6998847"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">19.&#160;&#160;&#160;&#160;&#160;&#160;Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depending on the collaborative arrangement, we may record funding receivable or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech, Inc. (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of PPMS and RMS and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration arrangements will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN, as well as all development and commercialization activities as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Canada</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">OCREVUS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FDA approved OCREVUS for the treatment of RMS and PPMS. Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and increasing up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if annual net sales exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. There will be a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we receive a gross </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11 years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS has been approved for the treatment of RMS and PPMS in the E.U. and certain other countries. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Profit-sharing Formulas</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">RITUXAN Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN pre-tax profits in the U.S. decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in February 2016 when GAZYVA was approved by the FDA as a new treatment for follicular lymphoma and further decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12-month period exceeded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on certain events.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GAZYVA Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax profit-sharing formula for GAZYVA provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of operating profits earned each calendar year. Our share of annual profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:82%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;GAZYVA profit-sharing threshold was met during the third quarter. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;our share of operating profits on GAZYVA was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,431.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,316.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;RITUXAN profit-sharing threshold was met during the first quarter. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;profit-sharing threshold was met during the first quarter and further decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12-month period exceeded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;profit-sharing threshold was met during the first quarter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Collaborations </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis to develop and commercialize SPINRAZA for the treatment of SMA. SPINRAZA was approved for the treatment of SMA in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized product revenues of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,724.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$883.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, on our sales of SPINRAZA. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$238.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$112.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, upon the exercise of our option to develop and commercialize SPINRAZA, we paid a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;license fee to Ionis, which was recorded as research and development expense in our consolidated statements of income. In addition, during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we made milestone payments to Ionis totaling&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;related to the marketing approvals discussed above, which were capitalized in intangible assets, net in our consolidated balance sheets.  </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;no clinical trial payments were made to Ionis due to the completion of study activities. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we made clinical trial payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the advancement of the program, which were recorded in investments and other assets in our consolidated balance sheets as they represented prepaid research and development expenditures. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these prepaid research and development amounts were fully expensed as the services were provided.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$285.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$234.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$257.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in total costs and expenses in our consolidated statements of income related to the advancement and commercialization of the program. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Antisense Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three therapeutic targets. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, Ionis is responsible for global development of any product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to another </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Ionis and agreed to make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;developmental milestone upon the selection of BIIB080 (also known as IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), which is currently in Phase 1 development for the treatment of AD. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Research Collaborations</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">2018 Ionis Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we closed the 2018 Ionis Agreement, which is a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year exclusive agreement with Ionis to develop novel ASO drug candidates for a broad range of neurological diseases for a total payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and the purchase of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of Ionis' common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$625.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon closing, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment as prepaid services in our consolidated balance sheets and recognized the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$324.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as research and development expense in our consolidated statements of income. The amount recorded as prepaid services represented the value of the employee resources committed to the arrangement to provide research and discovery services over the term of the agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of Ionis' common stock were purchased at a premium to their fair value at the transaction closing date. The premium consisted of acquiring the shares at a price above the fair value based on the trailing 10-day weighted-average close price prior to entering into the 2018 Ionis Agreement in April 2018 and the effect of certain holding period restrictions. We recorded an asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$462.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in investments and other assets in our consolidated balance sheets reflecting the fair value of the common stock as of the purchase date and a charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$162.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to research and development expense in our consolidated statements of income in the second quarter of 2018 reflecting the premium paid for the common stock. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Ionis' common stock is remeasured each reporting period. Changes in the fair value of our investment in Ionis' common stock, including the effect of the holding period restrictions, are reflected in other income (expense), net in our consolidated statements of income. For additional information on the fair value of our investment in Ionis' common stock, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have the option to license therapies arising out of this agreement and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$125.0 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$270.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for each program, depending on the indication plus an annual license fee, as well as royalties on potential net commercial sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">2017 SMA Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2017 we entered into a new collaboration agreement with Ionis to identify new ASO drug candidates for the treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of these therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment to Ionis and we may pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional development and regulatory milestone payments if new drug candidates advance to marketing approval. Upon commercialization, we may also pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$800.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">2013 Long-term Strategic Research Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2013 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the treatment of neurological diseases.&#160;Under this agreement, Ionis performs research on a set of neurological targets identified within the agreement. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis is eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us under the terms of the 2013 agreement. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), an investigational treatment for ALS with superoxide dismutase 1 (SOD1) mutations. In connection with the option exercise, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Ionis. Future payments may include potential post-licensing milestone payments of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$55.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and royalties in the low to mid-teen percentages on potential annual worldwide net sales. We are solely responsible for the costs and expenses related to the development, manufacturing and commercialization of BIIB067 following the option exercise. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we incurred milestones of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of BIIB067 and other neurological targets identified.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the treatment of AD (the BAN2401 and Elenbecestat Collaboration). Eisai serves as the global operational and regulatory lead for BAN2401 and elenbecestat and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai; and, if applicable, upon marketing approval in major markets, such as the U.S., the E.U. and Japan, we and Eisai will co-promote BAN2401 and elenbecestat and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for the treatment of AD (Aducanumab Option), </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, a separate collaboration agreement would be entered into with Eisai on terms and conditions that mirror the BAN2401 and Elenbecestat Collaboration agreement. Eisai has not yet exercised its Anti-Tau Option.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 and elenbecestat in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. The two companies will co-promote aducanumab with a region-based profit split and we will continue to lead the ongoing Phase 3 development of aducanumab.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration were immaterial. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">232.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">146.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">116.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, during the fourth quarter of 2016 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment related to the initiation of a Phase 3 trial for elenbecestat, which is included in research and development expense in our consolidated statements of income. We could pay Eisai up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$625.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;under the BAN2401 and Elenbecestat Collaboration based on the future achievement of certain development, regulatory and commercial milestones.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of aducanumab development expense incurred and beginning January 1, 2019, is reimbursing us for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of aducanumab development expense incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the potential profits (losses) in the U.S., a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the potential profits (losses) in the E.U. and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The two companies will continue to share equally in the potential profits (losses) in rest of world markets. Sales and marketing expense incurred before commercialization are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">264.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">268.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">209.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">268.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">209.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">27.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-Tau Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Alkermes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), for diroximel fumarate (BIIB098), a novel fumarate in Phase 3 development for the treatment of RMS. In December 2018 Alkermes submitted a New Drug Application (NDA) to the FDA for diroximel fumarate. Alkermes is seeking approval of diroximel fumarate under the 505(b)(2) regulatory pathway. If approved, we intend to market diroximel fumarate under the brand name VUMERITY. This name has been conditionally accepted by the FDA and will be confirmed upon approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received an exclusive, worldwide license to develop and commercialize diroximel fumarate and will pay Alkermes a mid-teens percentage royalty on potential worldwide net commercial sales of diroximel fumarate. Royalties payable on net commercial sales of diroximel fumarate are subject, under certain circumstances, to tiered minimum payment requirements for a period of five years following FDA approval. Alkermes is eligible to receive royalties in the high-single digits to sub-teen double digits of annual net commercial sales upon successful development and commercialization of new product candidates other than diroximel fumarate, developed under the exclusive license from Alkermes. Alkermes will maintain responsibility for regulatory interactions with the FDA through the potential approval of the NDA for diroximel fumarate. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment to Alkermes representing our share of diroximel fumarate development costs already incurred in 2017. Beginning in 2018 we became responsible for all development expenses related to diroximel fumarate. In December 2017 we also recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;expense, which was paid to Alkermes in 2018, enabling the continuation of the agreement to develop diroximel fumarate. Both the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;continuation payment were recorded as research and development expense in our consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may also pay Alkermes an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;milestone payment upon a regulatory achievement related to diroximel fumarate under this agreement. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in research and development expense in our consolidated statements of income related to this collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the license and collaboration agreement, we may also enter into a supply agreement with Alkermes for the commercial supply of diroximel fumarate and other products developed under the license and collaboration agreement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092, a Phase 2 investigational therapy with potential in AD and PSP. BIIB092 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received worldwide rights to BIIB092 and are responsible for the full development and potential commercialization of BIIB092 in AD and PSP. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to BMS and we may pay BMS up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$410.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestone payments, and potential royalties. We also assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&#8217;s acquisition of iPierian in 2014. In June 2017 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;developmental milestone payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 study of BIIB092 for PSP and we may pay the former shareholders of iPierian up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$490.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestone payments as well as potential royalties on net commercial sales. Both the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;developmental milestone payment were recorded as research and development expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$97.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in research and development expense in our consolidated statements of income related to this collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and we may pay potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone would be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due if ex-U.S. net sales reach </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;over a period of four consecutive quarters. Royalty payments are recognized in cost of sales within our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$36.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie for the development and commercialization of ZINBRYTA, which was approved for the treatment of RMS in the U.S. in May 2016 and in the E.U. in July 2016. In March 2018 we and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for RMS.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we and AbbVie conducted ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits were shared equally. Outside of the Collaboration Territory, we were solely responsible for development and commercialization of ZINBRYTA and paid a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We were responsible for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and recorded these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&#160;For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the collaboration incurred </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$32.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for research and development activities, respectively, for which we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense recognized in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;charge recognized in the first quarter of 2018 related to the termination of research and development contracts and clinical trials as a result of the voluntary worldwide withdrawal of ZINBRYTA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we also recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of pre-commercialization expenses within our selling, general and administrative expense, which represented </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the collaboration's pre-commercialization costs for 2016. After ZINBRYTA was approved by the FDA and the EMA in 2016, we began to recognize our share of the collaboration activities within the Collaboration Territories as described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Co-promotion Profits and Losses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognized revenues on sales to third parties and we recognized our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The collaboration began selling ZINBRYTA in the U.S. in the third quarter of 2016 and ceased selling ZINBRYTA in the U.S. in March 2018 in connection with the voluntary worldwide withdrawal of ZINBRYTA for RMS. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenues from collaborative and other relationships, a component of other revenues, of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect our share of the overall net losses within the collaboration for each of those years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we recognized revenues on sales to third parties in product revenues, net in our consolidated statements of income. We began to recognize net product revenues on sales of ZINBRYTA in the E.U. and Canada in the third quarter of 2016 and first quarter of 2017, respectively, and ceased selling ZINBRYTA in the E.U. and Canada in March 2018 in connection with the voluntary worldwide withdrawal of ZINBRYTA for RMS. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net product revenues on the sales of ZINBRYTA in the E.U. and Canada of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$52.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We also recorded the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income as these costs were incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reimbursed AbbVie for their </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement was recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration losses in the E.U. and Canada, as compared to net profit-sharing expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and net profit-sharing income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 68</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">C4 Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we entered into a collaborative research and license agreement with C4 Therapeutics (C4T) to investigate the use of C4T&#8217;s novel protein degradation platform to discover and develop potential new treatments for neurological diseases, such as AD and Parkinson&#8217;s disease.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the agreement, C4T will provide expertise and research services in targeted protein degradation and we will provide neuroscience expertise and drug development capabilities. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to C4T, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was recorded as research and development expense in our consolidated statements of income and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;was recorded as prepaid research and development expenditures within investments and other assets in our consolidated balance sheets. We may also pay C4T up to a total of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$370.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestone payments as well as potential royalties on net commercial sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">University of Pennsylvania</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and alliance with the University of Pennsylvania (UPenn) to advance gene therapy and gene editing technologies. In December 2018 we notified UPenn that we will be terminating certain programs under our collaboration and alliance with UPenn, including the development of therapeutic approaches that target the eye, skeletal muscle and central nervous system and research and validation of next generation gene transfer technology using adeno-associated virus (AAV) gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform. The termination of these programs will be effective in May 2019. This termination did not impact our collaboration with UPenn for the development of BIIB089 for the treatment of SMA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to UPenn, which was recorded as research and development expense in our consolidated statements of income, and made prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded in investments and other assets in our consolidated balance sheets. During 2017 we made additional prepaid research and development expenditures to UPenn of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the advancement of the programs under this agreement. These prepaid research and development amounts were expensed as the services were provided, of which no amounts remain as a prepaid asset as of December 31, 2018. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may be required to make future payments of over </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$137.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in research funding, options and milestone payments in relation to the BIIB089 program if we are successful and exercise our related options under this agreement. UPenn is also eligible to receive royalties in the mid-single digit percentages of annual net commercial sales upon successful development and commercialization of BIIB089. UPenn is no longer entitled to any potential future research funding, options and milestone payments from us in relation to the development of programs other than BIIB089.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$33.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in research and development expense in our consolidated statements of income related to this collaboration.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). This collaboration focused on the development of BIIB087, an investigational AAV-based gene therapy for the treatment of X-linked Retinoschisis (XLRS), and BIIB088, an investigational AAV-based gene therapy for the treatment of X-Linked Retinitis Pigmentosa (XLRP). This collaboration also provided us with options to early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we notified AGTC of the termination of our collaboration agreement with AGTC. The termination of this collaboration agreement will be effective in March 2019 and we will have no further involvement in the development of any of the programs under this collaboration. Accordingly, AGTC is no longer entitled to any potential development, regulatory and commercial milestone payments from us in relation to the development of these programs.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we also received a manufacturing license under which we received an exclusive license to use AGTC&#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&#8217;s discretion, in exchange for payment of milestones and royalties. Our termination of the collaboration agreement does not impact our rights under the manufacturing license.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into the collaboration agreement we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to AGTC. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upfront payment reflected a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equity investment in AGTC, including a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;premium on our equity investment, prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and total licensing and other fees of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in total licensing and other fees and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;premium on our equity investment were recorded as a charge to research and development expense in our consolidated statements of income. The remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;equity investment and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets. These prepaid research and development amounts were expensed as the services were provided. No amounts remain as a prepaid asset as of December 31, 2018. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which were reflected in research and development expense in our consolidated statements of income related to this collaboration. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into several research, discovery and other related arrangements that resulted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, recorded as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis Co., Ltd.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;Samsung BioLogics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;stake in Samsung Bioepis and we contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;ownership interest.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflected the effect of previous equity financings in which we did not participate, to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics.&#160;As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remains approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019, depending on the results of Samsung Bioepis, we expect to restart recognizing our share of Samsung Bioepis' income (losses) and we will begin recognizing the amortization of certain basis differences resulting from our November 2018 investment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), which is classified as a component of investments and other assets within our consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2013 pursuant to our rights under the joint venture agreement with Samsung BioLogics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of BENEPALI, Japan.&#160;Under this agreement, we have made upfront and clinical development milestone payments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 70</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">biosimilar referencing ENBREL, received regulatory approval in the E.U. in August 2017, May 2016 and January 2016, respectively, and we capitalized the related milestone payments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as intangible assets, net in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we and Samsung Bioepis announced an agreement with AbbVie related to the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. We began to recognize revenues on sales of IMRALDI to third parties in the E.U. in the fourth quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of IMRALDI, FLIXABI and BENEPALI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net profit-sharing expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$187.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;sharing of the net collaboration profits. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under our license, technical development services and manufacturing agreements, which is reflected in revenues from collaborative and other relationships, as a component of other revenues in our consolidated statements of income. </font></div><div><a name="s8126B947CBE754B0BE1ABCAA71E1BD3B"></a></div><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">20.&#160;&#160;&#160;&#160;&#160;Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2007 we entered into a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD, including aducanumab, our anti-amyloid beta antibody candidate for the treatment of AD. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 71</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. Under this agreement, we are also required to pay royalties on net sales of any resulting commercial products and make payments upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of our collaboration and license agreement with Neurimmune (as amended, the Neurimmune Agreement). Under the Neurimmune Agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.&#160;In May 2018 we made an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, will now range from the high single digits to sub-teens.&#160;As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interest in the fourth quarter of 2017 and the second quarter of 2018, as applicable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts. </font></div><div><a name="sCB27BCBD650B5BBEB6D9EDAE1FA5E156"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">21.&#160;&#160;&#160;&#160;Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in March 2035. In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the Dusseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. No hearing has yet been set in these proceedings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom counterpart of the '510 Patent. Fresenius Kabi has filed a counterclaim asserting infringement of the '510 Patent and seeking damages and an injunction to restrain infringement if the patent is found valid and infringed. A trial has been set for July 2019.&#160;In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &#8216;510 Patent.&#160;A trial has been set for October 2019. An estimate of the possible loss or range of loss in the above matters cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Gedeon Richter PLC asserted to Biogen and Samsung Bioepis UK Limited that IMRALDI infringes European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035.&#160;We dispute the assertion. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2018 we were served with a qui tam action filed by SMSF, LLC on behalf of the U.S. and certain states in the U.S. District Court for the District of Massachusetts alleging activities by nurse-educators in violation of the federal False Claims Act and state law counterparts. The government declined to intervene, and we, other defendants and the U.S. moved to dismiss. In December 2018 the court dismissed the case with prejudice against the relator and without prejudice as to the U.S. and states. The period for an appeal has lapsed and we consider the matter closed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case alleges agreements with pharmacy benefit managers in violation of the Federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. We, the other defendants and the U.S. have moved to dismiss the case and the motions are pending. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 73</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In March 2018 the court dismissed the complaint with prejudice. The plaintiff's appeal is pending. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June and July 2017, January, March, April, August and December 2018 and January 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Caribe Holdings (Cayman) Co. Ltd.&#160;DBA Puracap&#160;Caribe, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shipla Medicare Limited, Slayback Pharma LLC, Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial has been set for December 2019 in the Delaware actions, and a trial date has been set for February 2020 in the West Virginia action. A trial date has not been set in the case against Banner Life Sciences LLC or the case against Hetero USA Inc. that was filed in January 2019.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review filed by Mylan Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals, Inc. filed a petition with the U.S. Patent Trial and Appeal Board seeking </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. On February 6, 2019, the U.S. Patent Trial and Appeal Board instituted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;review of the '514 Patent.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the USPTO declared an interference between Forward Pharma&#8217;s U.S. Patent Application No. 11,576,871 and the '514 Patent. The U.S. Court of Appeals for the Federal Circuit affirmed the March 2017 ruling of the USPTO in favor of Biogen and in January 2019 denied Forward Pharma's petition for rehearing. For additional information regarding this matter, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the EPO revoked our European patent number 2 137 537 (the '537 Patent). We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. The '537 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. The settlement and license agreement that we entered into with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination. For additional information regarding this matter, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action to the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish '263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU '127 Patent) ("Administration of agents to treat inflammation"). The </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Polish '263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent was issued in 2013 and expires in February 2023. Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which was issued in 2011 and also concerns administration of natalizumab (TYSABRI) to treat MS. The EU '127 Patent expires in February 2023. The Dutch and German counterparts were ruled invalid and we have appealed. No date for a hearing on the merits has been set in the Polish and Italian actions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018, following a trial against EMD Serono and Pfizer, the court granted Biogen's motion for judgment as a matter of law that the '755 Patent is infringed and valid and ordered a new trial on all damages issues. The court has not yet scheduled the trial on damages or a trial against Bayer and Novartis. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;including interest and penalties. We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending. We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 75</font></div></div><hr style="page-break-after:always"><div><a name="sA7B55130B12E55E99EA3D5CE9C980F2B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">22.&#160;&#160;&#160;&#160;Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Payments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recorded as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013, and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the third quarter of 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payment to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in remaining milestones related to these acquisitions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired the Fumapharm Products. We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013 TECFIDERA was approved in the U.S. for MS by the FDA and we made the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment. We are also required to make additional contingent payments to former shareholders of Fumapharm AG and holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement, until such time as the cumulative sales level reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments are due. These payments are accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. Any portion of the payment that is tax deductible was recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level was reached. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2017 and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales levels related to the Fumapharm Products in the first, second and third quarters of 2018, respectively. In the fourth quarter of 2018 we achieved the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;cumulative sales level threshold and accrued our last </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;contingent payment related to the Fumapharm Products, which will be paid in the first quarter of 2019.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.7 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in development milestones, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in regulatory milestones and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$655.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$117.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;of liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and 2017, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, under the Transition Toll Tax. Of the amounts accrued as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;overpayment of taxes in the current year. The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest. For additional information on the Transition Toll Tax, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the construction of this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense, net of sublease income under these leases, which terminate at various dates through 2028, amounted to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$65.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">87.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">601.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(26.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(25.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(58.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(182.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">156.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">418.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 77</font></div></div><hr style="page-break-after:always"><div><a name="s26DB6B669CCC5ABCBADC3C6EF8440717"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">23.&#160;&#160;&#160;&#160;&#160;&#160;Guarantees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not have significant liabilities recorded for guarantees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div><a name="s54CC2451319356888D8D047B225C6A94"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">24.&#160;&#160;&#160;&#160;&#160;&#160;Employee Benefit Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">401(k) Savings Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense related to our 401(k) Savings Plan totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Compensation Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pension Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.00%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary and gender. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the Swiss plan had an unfunded net pension obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and plan assets that totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$83.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized expense totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our Swiss plan, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, was included in other income (expense), net.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The obligations under the German plans are unfunded and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net periodic pension cost related to the German plans totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, was included in other income (expense), net.</font></div><div><a name="sC977C8B2DFE35811A62D34F19BC65196"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">25.&#160;&#160;&#160;&#160;&#160;&#160;Segment Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Geographic Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,800.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,370.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">281.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">434.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,903.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">76.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">457.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">96.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">585.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,152.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,442.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,601.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,017.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,844.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">332.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,475.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,226.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,948.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,182.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,050.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,237.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">313.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">224.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,272.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,221.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,748.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,215.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$545.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$646.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$707.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$643.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to these consolidated financial statements.</font></div><div><a name="s1AF12F0195615A48845B88DCBB93EC06"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">26.&#160;&#160;&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b) (c) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b) (e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (f) (g) (h) (i)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,523.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,757.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,780.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,825.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">443.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">490.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">511.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">534.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">164.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">108.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">147.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">165.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">585.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,131.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,356.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,439.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,526.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13,452.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,685.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,935.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,978.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,037.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,636.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,171.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">915.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,442.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">944.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,474.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,172.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">866.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,444.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">946.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,430.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.55</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.18</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.17</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.74</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.63</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.54</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.18</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.15</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.73</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.58</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">201.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">199.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">201.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">200.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">205.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(j) (k) (l)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(m) (n) (o) (p)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,380.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,639.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,622.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,712.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">340.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">397.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">406.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">415.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">179.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,810.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,078.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,077.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,307.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,273.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,426.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,712.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,707.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,797.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,643.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">862.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,226.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(166.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,670.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">862.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,226.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(297.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.47</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.07</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.94</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.46</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.07</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.92</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the first, second, third and fourth quarters of 2018 includes pre-tax charges related to (losses) gains recorded in relation to changes in the fair value of our strategic investments of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$(6.4) million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$5.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$141.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$(12.2) million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the first, second and third quarters of 2018 include pre-tax charges to acquired IPR&amp;D of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$27.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, for upfront payments to Karyopharm, Pfizer and AliveGen, respectively, upon closing of the asset purchase transactions for BIIB100, BIIB104 and BIIB110, respectively, as the underlying assets had not yet reached technological feasibility.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2018 includes pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$486.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;upon the closing of the 2018 Ionis Agreement. Included in this amount was a charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$162.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflecting the premium paid above fair value for the purchase of approximately </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;shares of Ionis' common stock upon the closing of the 2018 Ionis Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. for the second quarter of 2018 includes a pre-tax charge to noncontrolling interest of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for a payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2018 includes the impact of impairment charges totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$189.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to certain IPR&amp;D assets associated with our vixotrigine program and an adjustment to the value of our contingent consideration obligations related to our vixotrigine program for the treatment of TGN to reflect the lower cumulative probabilities of success, which resulted in a gain of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$89.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the third quarter of 2018. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In late December 2018 we received feedback from the FDA regarding the design of the Phase 3 vixotrigine program for the treatment of TGN. Following this feedback, we are now planning to initiate the Phase 3 vixotrigine program for the treatment of TGN and, as a result, we adjusted the fair value of our contingent consideration obligations related to our vixotrigine program for the treatment of TGN to reflect the increased probabilities of success and recognized a loss of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$80.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the fourth quarter of 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 and the first quarter of 2017 includes </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$176.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$328.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of impairment charges related to our intangible asset associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 includes a net increase to income tax expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$135.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reflecting the impact of electing to record deferred taxes on GILTI.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 includes an upfront payment of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Ionis, as we exercised our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB067.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(j)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for an upfront payment made to BMS upon entering into our agreement to exclusively license BIIB092.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(k)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to acquired IPR&amp;D of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for an upfront payment to Remedy upon closing of the asset purchase transaction for BIIB093.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(l)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for a developmental milestone that became payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 study of BIIB092 for PSP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(m)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to noncontrolling interest of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for a payment made to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;reduction in the </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">BIOGEN INC. AND SUBSIDIARIES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS &#8212; (Continued)</font></div></div><div><br></div><div style="line-height:120%;padding-left:30px;padding-top:12px;text-align:left;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(n)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for an upfront payment and a continuation payment, respectively, to Alkermes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(o)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;for an upfront payment to Ionis upon entering into a new collaboration agreement to identify new ASO drug candidates for the treatment of SMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(p)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;related to the provisions of the 2017 Tax Act, including a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;expense under the Transition Toll Tax.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisitions of BIIB100, BIIB104, BIIB110 and BIIB093, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For additional information on our collaboration arrangements with Ionis, BMS and Alkermes, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For additional information on our collaboration arrangement with Neurimmune, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For additional information on the amortization and impairment of acquired intangible assets, including our IPR&amp;D intangible asset related to our vixotrigine program for the treatment of TGN and our TECFIDERA settlement and license agreement, please read Note 7,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">&#32;Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For additional information on the 2017 Tax Act, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div><a name="s437EB023E35957BDB7CCDB7E9DEE6463"></a></div><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">27.&#160;&#160;&#160;&#160;&#160;&#160;Subsequent Events</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Skyhawk Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk&#8217;s SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;to Skyhawk. We may also pay Skyhawk up to a total of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in additional milestone payments as well as potential royalties on net commercial sales. We expect to record research and development expense of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;in the first quarter of 2019 related to this collaboration.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 82</font></div></div><hr style="page-break-after:always"><div><a name="s9ED41FEC351F53C3B6C09582D3A25485"></a></div><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#1c5a7d;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">To the Board of Directors and Shareholders of Biogen Inc.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Opinions on the Financial Statements and Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Biogen Inc. and its subsidiaries</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(the &#8220;Company&#8221;) as of December 31, 2018 and 2017, and the related consolidated statements of income, comprehensive income, equity and cash flows for each of the three years in the period ended December 31, 2018, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;).</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also have audited the Company's internal control over financial reporting as of December 31, 2018, based on criteria established in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2013)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and 2017,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">and the results of its</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">operations and its</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">cash flows for each of the three years in the period ended December 31, 2018 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018, based on criteria established in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Internal Control - Integrated Framework</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2013)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">issued by the COSO.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Change in Accounting Principle</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As discussed in Note 1 to the consolidated financial statements, the Company changed the manner in which it accounts for income taxes for intra-entity transfers of assets other than inventory in 2018.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Basis for Opinions</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Management&#8217;s Annual Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.  </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#ff0000;font-weight:bold;">&#32;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Definition and Limitations of Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:8pt;"><a style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;" href="#s3C1ADEED17A553A5BA51EF8AA48A0BF1"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/PricewaterhouseCoopers LLP</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston, Massachusetts</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February&#160;6, 2019</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have served as the Company's auditor since 2003.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">F- 84</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>2
<FILENAME>biib-20181231xex1031.htm
<DESCRIPTION>EXHIBIT 10.31
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s6e360451317c4719b01681f3a5fde29b"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit 10.31</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Non-Employee Director Compensation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The following is a summary of the retainers and meeting fees payable to non-employee directors effective July 1, 2018:</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:79%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#aec2e4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Retainers</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#aec2e4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Annual Board Retainer</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$65,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Annual Retainers (in addition to Annual Board Retainer):</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Independent Chairman of the Board</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$75,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Audit Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$25,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Compensation and Management Development Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$20,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Corporate Governance Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$15,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Finance Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$15,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Risk Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$15,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Science and Technology Committee Chair</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$15,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Audit Committee Member (other than Chair)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$5,000</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#aec2e4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Meeting Fees</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#aec2e4;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Board of Directors Meetings (per meeting day):</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In-person attendance</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$2,500</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Telephonic attendance</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$1,500</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Committee Meetings (per meeting attended by each such committee member in person or telephonically)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$1,500</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attendance at Annual Science and Technology Committee Portfolio Review (per day)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$1,500</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Special service fee (for each full day of service other than in connection with Board or Committee meetings)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dbe5f1;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">$1,000</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>3
<FILENAME>biib-20181231xex21.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sd58189c286da4a28942181be6e129a8e"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 21</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;font-weight:bold;">BIOGEN INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a list of subsidiaries of Biogen Inc. as of December 31, 2018, omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SUBSIDIARY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Foundation Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen MA Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Realty Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Realty Limited Partnership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Limited Partnership</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Massachusetts</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (RTP) Realty LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Chesapeake LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding I LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding II LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Manufacturing Holding LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen New Ventures Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen SRO Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Therapeutics Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. Pacific LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen U.S. West Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Conforma Therapeutics Corporation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stromedix, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Argentina) SRL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Argentina</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Australia PTY Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Austria GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Austria</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Belgium N.V./S.A.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International Holding Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bermuda</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Brasil Produtos Farmaceuticos LTDA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Brazil</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Canada Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Chile Spa</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chile</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Biotechnology (Shanghai) Co., Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">China</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Colombia S.A.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Colombia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Czech Republic) s.r.o.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Czech Republic</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) A/S</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) Manufacturing ApS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Holding APS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Denmark) New Manufacturing ApS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Finland OY</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen France S.A.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Hong Kong Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hong Kong</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Hungary KFT</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hungary</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Biotech India Pvt. Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">India</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec (Ireland) Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Italia SRL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Italy</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Japan Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japan</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Korea</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Korea</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Luxembourg Holding SARL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Mexico S. DE R.L. DE C.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Mexico Servicios, S. DE R.L. DE C.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen NZ Biopharma Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">New Zealand</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Norway AS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Norway</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Poland Sp. z.o.o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Poland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Portugal Sociedade Farmaceutica, Unipessoal, Lda.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen (Singapore) Pte Ltd</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Slovakia s.r.o.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Slovak Republic</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Pharma, farmacevtska in biotehnoloska druzba d.o.o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Slovenia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Spain, S.L.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Sweden AB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen International Neuroscience GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Management Services GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Swiss Investments GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Swiss Manufacturing GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Switzerland AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Switzerland Holdings GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eidetica Biopharma GmbH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Taiwan Limited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taiwan</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen B.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Netherlands B.V.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Research Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Convergence Pharmaceuticals Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Convergence Pharmaceuticals Holdings Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Old Convergence Pharmaceuticals Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Panion Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Silver Acquisition Co. Ltd.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen Idec Uruguay SA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Uruguay</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>biib-20181231xex23.htm
<DESCRIPTION>EXHIBIT 23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sb589032b338e4869b94f79eb10135607"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 23</font></div><div style="line-height:120%;padding-bottom:32px;padding-top:32px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-218799, 333-205254, 333-128339, 333-152456, 333-140817 and 333-170133) of Biogen Inc. of our report dated February 6, 2019 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10&#8209;K.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ PricewaterhouseCoopers LLP </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Boston, Massachusetts</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">February 6, 2019</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>biib-20181231xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s008881AD0DAA50BAA1D31D24E33BC15A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Michel Vounatsos, certify that:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this annual report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">c) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:76%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: February&#160;6, 2019</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>biib-20181231xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sBDE3DA933A38511D85D930B4BC2C8948"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I, Jeffrey Capello, certify that:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">I have reviewed this annual report of Biogen Inc.;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#32;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">d) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5. </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">a) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">b) </font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:68%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Date: February&#160;6, 2019</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/&#160;Jeffrey Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Finance</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Financial Officer (principal financial officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>biib-20181231xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE3DC7F29EAC554CB948A40A8FA49EF4C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Annual Report on Form 10-K for the year ended December&#160;31, 2018 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: February&#160;6, 2019</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Michel Vounatsos &#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Michel Vounatsos</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal executive officer]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:75%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dated: February 6, 2019</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">/s/ Jeffrey Capello</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Jeffrey Capello</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Executive Vice President, Finance and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">[principal financial officer]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>biib-20181231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:267150F1167F549CAC1DBF154615F3ED,x:277e91d8a95f459cadc9bbbe0ab3a3cc-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2018-01-31" xmlns:ap="http://fasb.org/dis/ap/2018-01-31" xmlns:aro="http://fasb.org/dis/aro/2018-01-31" xmlns:bc="http://fasb.org/dis/bc/2018-01-31" xmlns:biib="http://www.biogenidec.com/20181231" xmlns:bsoff="http://fasb.org/dis/bsoff/2018-01-31" xmlns:cc="http://fasb.org/dis/cc/2018-01-31" xmlns:cce="http://fasb.org/dis/cce/2018-01-31" xmlns:codification-part="http://fasb.org/codification-part/2018-01-31" xmlns:com="http://fasb.org/stm/com/2018-01-31" xmlns:con="http://fasb.org/dis/con/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2018-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2018-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2018-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2018-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2018-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2017-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2017-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2017-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2017-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2018-01-31" xmlns:debt="http://fasb.org/dis/debt/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2018-01-31" xmlns:disops="http://fasb.org/dis/disops/2018-01-31" xmlns:dr="http://fasb.org/dis/dr/2018-01-31" xmlns:edco="http://fasb.org/dis/edco/2018-01-31" xmlns:ei="http://fasb.org/dis/ei/2018-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2018-01-31" xmlns:eps="http://fasb.org/dis/eps/2018-01-31" xmlns:equity="http://fasb.org/dis/equity/2018-01-31" xmlns:ero="http://fasb.org/dis/ero/2018-01-31" xmlns:eui="http://fasb.org/dis/eui/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2018-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2018-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2018-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2018-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2018-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2018-01-31" xmlns:foct="http://fasb.org/dis/foct/2018-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2018-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2018-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2018-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2018-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2018-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2018-01-31" xmlns:guar="http://fasb.org/dis/guar/2018-01-31" xmlns:hco="http://fasb.org/dis/hco/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2018-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2018-01-31" xmlns:ides="http://fasb.org/dis/ides/2018-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2018-01-31" xmlns:inv="http://fasb.org/dis/inv/2018-01-31" xmlns:invco="http://fasb.org/dis/invco/2018-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2018-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2018-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2018-01-31" xmlns:oi="http://fasb.org/dis/oi/2018-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2018-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2018-01-31" xmlns:pay="http://fasb.org/dis/pay/2018-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2018-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2018-01-31" xmlns:rd="http://fasb.org/dis/rd/2018-01-31" xmlns:re="http://fasb.org/dis/re/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2018-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2018-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2018-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2018-01-31" xmlns:ru="http://fasb.org/dis/ru/2018-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2018-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2018-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2018-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2018-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2018-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2018-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2018-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2018-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2018-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2018-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2018-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2018-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2018-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2018-01-31" xmlns:se="http://fasb.org/dis/se/2018-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2018-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2018-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2018-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2018-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2018-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2018-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2018-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2018-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2018-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2018-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2018-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2018-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2018-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2018-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2018-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2018-01-31" xmlns:soi="http://fasb.org/stm/soi/2018-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2018-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2018-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2018-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2018-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2018-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2018-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2018-01-31" xmlns:spc="http://fasb.org/stm/spc/2018-01-31" xmlns:sr="http://fasb.org/dis/sr/2018-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:srt-all="http://fasb.org/srt-all/2018-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2018-01-31" xmlns:srt-std="http://fasb.org/srt-std/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2018-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2018-01-31" xmlns:tin-part="http://fasb.org/tin-part/2018-01-31" xmlns:ts="http://fasb.org/dis/ts/2018-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2018-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2018-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2018-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="biib-20181231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4SharesOutstanding">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramYearToDateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_BalanceSheetLocationAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201707Member_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201707Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201707Member_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201707Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_IncomeStatementLocationAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredIncomeTaxChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DeferredIncomeTaxChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ProspectiveAdoptionOfNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_biib_DeferredtaxliabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:KaryopharmMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:AliveGenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:KaryopharmMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_RemedyPharmaceuticalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:RemedyPharmaceuticalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TMSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:AliveGenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:PfizerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Bioverativ">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_MajorCustomersAxis_biib_BioverativMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:BioverativMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017CorporateStrategyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017CorporateStrategyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017CorporateStrategyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2016RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017CorporateStrategyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017CorporateStrategyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017CorporateStrategyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2016RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2017CorporateStrategyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2015RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_FacilityLocationAxis_biib_CambridgeMAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:CambridgeMAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SobiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SobiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:SobiMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_MajorDistributorAxis_biib_DistributorOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:MajorDistributorAxis">biib:DistributorOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ALPROLIXMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ELOCTATEMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:HemophiliaProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q1_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EachAdditionalOneBillionUpToTwentyBillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_PLSRMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:PLSRMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_biib_CumulativeSalesLevelAxis_biib_TwentybillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:TwentybillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2006Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NotesPayableToFumedicaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2006-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:StromedixMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:BiogenIdecInternationalNeuroscienceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-10-01</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-02-01</xbrli:startDate>
			<xbrli:endDate>2015-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ConvergencePharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_FacilityLocationAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2008-03-04</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2008-12-01</xbrli:startDate>
			<xbrli:endDate>2008-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2011Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2011ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2011-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:SeriesXPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2018ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">biib:UndesignatedPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2016ShareRepurchaseProgramMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:StockOptionsAndEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:PerformanceUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2017OmnibusEquityPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:DirectorsPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:CashSettledPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">biib:A2015ESPPMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_BalanceSheetLocationAxis_biib_PrepaidtaxesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:PrepaidtaxesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredTaxAssetDomain">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:DeferredTaxAssetDomain</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_biib_DeferredtaxliabilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201616Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">biib:DeferredtaxliabilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_ForeignearningstypeAxis_biib_OtherForeignEarningsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:OtherForeignEarningsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:GeneralBusinessMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_ForeignearningstypeAxis_biib_ForeignearningsintheformofcashandcashequivalentsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ForeignearningstypeAxis">biib:ForeignearningsintheformofcashandcashequivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">biib:U.S.2017TaxActMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_FifteenbillionMemberMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:FifteenbillionMemberMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SixteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AducanumabMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:InLicensedPatentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q1_srt_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_srt_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q1Feb_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-02-01</xbrli:startDate>
			<xbrli:endDate>2012-02-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_us-gaap_TypeOfArrangementAxis_biib_C4TherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:C4TherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_StatementGeographicalAxis_us-gaap_ForeignCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_srt_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:AbbVieMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:NewAntiCd20Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-07-01</xbrli:startDate>
			<xbrli:endDate>2013-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SOD1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_srt_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_C4TherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:C4TherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2_us-gaap_TypeOfArrangementAxis_biib_IPerianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q2_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_ProductOrServiceAxis_biib_RituxanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_IPerianMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IPerianMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:GeographicDistributionForeignMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AlkermesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-02-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AbbVieMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AGTCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UniversityofPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:BristolMyersSquibbMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:AcordaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:BR</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2006-01-01</xbrli:startDate>
			<xbrli:endDate>2006-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:TysabriProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-04-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_biib_CumulativeSalesLevelAxis_biib_SeventeenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:SeventeenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q2_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:DevelopmentMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q3_biib_CumulativeSalesLevelAxis_biib_NineteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:NineteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q2_biib_CumulativeSalesLevelAxis_biib_EighteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:EighteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_biib_FutureContingentMilestoneTypesAxis_biib_CommercialMilestonesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:CommercialMilestonesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_biib_CumulativeSalesLevelAxis_biib_NineteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:CumulativeSalesLevelAxis">biib:NineteenbillionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TecfideraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:FumapharmAgMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_country_DE_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:DomesticPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_country_DE_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SegmentGeographicalGroupsOfCountriesGroupOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_srt_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_srt_StatementGeographicalAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_biib_SolothurnMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">biib:SolothurnMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_country_DK">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DK</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:VariableInterestEntitiesByClassificationOfEntityAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Skyhawk_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Skyhawk_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SkyhawkTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="KRW">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="chf">
		<xbrli:measure>iso4217:CHF</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Plan">
		<xbrli:measure>biib:Plan</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="Increment">
		<xbrli:measure>biib:Increment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>biib:segment</xbrli:measure>
	</xbrli:unit>
	<biib:AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax contextRef="FI2018Q4_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" decimals="-5" id="Fact-D19CAFDB692A30F63EA60F64887D8633" unitRef="usd">7300000</biib:AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax>
	<biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch contextRef="FI2018Q4" decimals="-5" id="Fact-93806BE66C26DB6AFC03FBB7C0D7BBF4" unitRef="usd">27000000</biib:AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch>
	<biib:AdditionalMilestonePayment contextRef="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-0B250CB6C235E11AD851FBB7C11574EA" unitRef="usd">10000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-ACC1117B758DF706B415FBB7C10547D1" unitRef="usd">25000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" decimals="-5" id="Fact-2FBB29B000E4DF58868519609B3EC655" unitRef="usd">410000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_C4TherapeuticsMember" decimals="-5" id="Fact-0D41ED6BD459EED759C519703D74E6D1" unitRef="usd">370000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-D2A6FDD358D9D6BA8410FBB7C163790C" unitRef="usd">625000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_IPerianMember" decimals="-5" id="Fact-F3257990646D30480E49195E6710585B" unitRef="usd">490000000</biib:AdditionalMilestonePayment>
	<biib:AdditionalMilestonePayment contextRef="I2019Q1Skyhawk_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" decimals="-8" id="Fact-3FFB0EC035D576AE953AAA9DACB92E70" unitRef="usd">2000000000</biib:AdditionalMilestonePayment>
	<biib:Additionalreductioninroyaltyratepayableoncommercialsales contextRef="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="2" id="Fact-B96E5500CC9EFD1DF03AF522B204EEAA" unitRef="number">0.05</biib:Additionalreductioninroyaltyratepayableoncommercialsales>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD" decimals="-5" id="Fact-29D103F93AC225BDFC4CFBB7C0B73111" unitRef="usd">16700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-C43739AB671CBA0B3333FBB7C0B7232E" unitRef="usd">-1500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-2961CE8A64B24FEF11DBFBB7C0B7BFC9" unitRef="usd">1400000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-0E4E8B85AEA9F430B203FBB7C0C7EDDD" unitRef="usd">16800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q4YTD" decimals="-5" id="Fact-19D0E0FDB1111787006FFBB7C115CF92" unitRef="usd">-6000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-BF374B7D3D45F7B594E2FBB7C0899781" unitRef="usd">-15000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-7FC38747B365718D6642FBB7C0C7D538" unitRef="usd">100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-2363D9713E796C8A9338FBB7C182455A" unitRef="usd">8900000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2018Q4YTD" decimals="-5" id="Fact-EB2D2C8CEEF975624ED9FBB7C0B7018E" unitRef="usd">12100000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-A263AA68081F55B8E7BEFBB7C098A40F" unitRef="usd">10000000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-C93295D7AEBBF7D7E399FBB7C153E879" unitRef="usd">300000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-4DD6583DEB8687359F66FBB7C115C40B" unitRef="usd">1800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
	<biib:AmortizationandImpairmentofAcquiredIntangibleAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AAC0922A784ED31E1933FBB7C0C7160B" unitRef="usd">385600000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
	<biib:AmortizationandImpairmentofAcquiredIntangibleAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-FCE74976A257EA71160FFBB7C0F691A0" unitRef="usd">814700000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
	<biib:AmortizationandImpairmentofAcquiredIntangibleAssets contextRef="FD2018Q4YTD" decimals="-5" id="Fact-653732C9C0FF33C9AA22FBB7C1155715" unitRef="usd">747300000</biib:AmortizationandImpairmentofAcquiredIntangibleAssets>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-95F1972A40868978C031FBB7C144D57D" unitRef="usd">327000000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost contextRef="FI2018Q4" decimals="-5" id="Fact-5E68F2DB48CF3657FC47FBB7C07906D9" unitRef="usd">143500000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-E161E394DD3A9E273022FBB7C144E858" unitRef="usd">327300000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue contextRef="FI2018Q4" decimals="-5" id="Fact-A812ACEFA14ACD49A0F8FBB7C1448161" unitRef="usd">143200000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2017Q4YTD" id="Fact-04D0501211902B779325FBB7C0D7B0B2">P17M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageMaturityOfMarketableSecurities contextRef="FD2018Q4YTD" id="Fact-21073938A806723CD405FBB7C0D7886B">P12M</biib:AverageMaturityOfMarketableSecurities>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-F238CCE36377B5AA2676FBB7C0C73908" unitRef="usd">304.86</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-38F5C9AF6EDD994E4118FBB7C0A88892" unitRef="usd">267.88</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMaximum contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-C6DC2545EE05ED1F69AFFBB7C098B6CC" unitRef="usd">346.76</biib:AverageStockPriceOnGrantDateInDollarsMaximum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-5BD26FB9205796B594E5FBB7C1721273" unitRef="usd">260.67</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-D71613174CE2AB399004FBB7C15330AC" unitRef="usd">263.18</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:AverageStockPriceOnGrantDateInDollarsMinimum contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-7BB9363AD848F9395E2CFBB7C1259E49" unitRef="usd">279.47</biib:AverageStockPriceOnGrantDateInDollarsMinimum>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="2" id="Fact-A0CD7808CA1197DA2EDBFBB7C13482A2" unitRef="number">0.20</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="2" id="Fact-3F8CF1A37BDE346F402DFBB7C182D1B0" unitRef="number">0.55</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="3" id="Fact-8E5A37988C86174A7AB0FBB7C1058DDA" unitRef="number">0.685</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:Biogenshareofcopromotionprofitsorlosses contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="INF" id="Fact-AE429A1A0BF5BE03023619662C5B85F6" unitRef="number">0.5</biib:Biogenshareofcopromotionprofitsorlosses>
	<biib:ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram contextRef="FD2017Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember" decimals="-5" id="Fact-400B31A913752FE1C1609520F0858C0D" unitRef="usd">19400000</biib:ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram>
	<biib:ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram contextRef="FD2018Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember" decimals="-5" id="Fact-70356E9C8325C0EBA97C95206001073A" unitRef="usd">22900000</biib:ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram>
	<biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-6CD34371AAC70AC40F17FBB7C115F9AF" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
	<biib:CollaborationProfitSharing contextRef="FD2016Q4YTD" decimals="-5" id="Fact-04B5436AA19810725188FBB7C0E6BAED" unitRef="usd">10200000</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-66E86CD1AD316A6C702FF18EDB88A862" unitRef="usd">15100000</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0672F46F8E82075AC660FBB7C0E663E3" unitRef="usd">112300000</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-69B5E5CDC148764D6917FBB7C18231A8" unitRef="usd">111000000</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2018Q4YTD" decimals="-5" id="Fact-7F6F806EC85D6CDB364EFBB7C144D78C" unitRef="usd">185000000</biib:CollaborationProfitSharing>
	<biib:CollaborationProfitSharing contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-A032CB98D6917DC8E289FBB7C18267F2" unitRef="usd">187400000</biib:CollaborationProfitSharing>
	<biib:Collaborationexpensesaccrual contextRef="FI2017Q4" decimals="-5" id="Fact-BB70748CEFB05D913BCDFBB7C125F5B6" unitRef="usd">183700000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationexpensesaccrual contextRef="FI2018Q4" decimals="-5" id="Fact-1BD8BFD28C6CFE0729D5FBB7C13499D2" unitRef="usd">261600000</biib:Collaborationexpensesaccrual>
	<biib:Collaborationprofitlosssharing contextRef="FD2016Q4YTD_srt_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-638A62D4DFBF30C53888F146C89AA750" unitRef="usd">4900000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-AC28BF4D90BA73294669FBB7C105E6C5" unitRef="usd">1300000</biib:Collaborationprofitlosssharing>
	<biib:Collaborationprofitlosssharing contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-5A904CFA6E4020246861FBB7C09859AE" unitRef="usd">2400000</biib:Collaborationprofitlosssharing>
	<biib:CompensationExpenseOverPurchasePeriod contextRef="FD2018Q4YTD" id="Fact-2EE6A67086EAD204AA52FBB7C172D1C1">The fair value of the look-back provision plus the 15% discount</biib:CompensationExpenseOverPurchasePeriod>
	<biib:ComputerSoftwareAndHardware contextRef="FI2017Q4" decimals="-5" id="Fact-290157F483F9DF8CAA77FBB7C0A8F970" unitRef="usd">767100000</biib:ComputerSoftwareAndHardware>
	<biib:ComputerSoftwareAndHardware contextRef="FI2018Q4" decimals="-5" id="Fact-4D6FAAC5B3B901277BB7FBB7C0F6635E" unitRef="usd">798700000</biib:ComputerSoftwareAndHardware>
	<biib:Copromotionprofitsandlosses contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-491E14723C13E57BE445852ED8B4F47D" unitRef="usd">43900000</biib:Copromotionprofitsandlosses>
	<biib:Copromotionprofitsandlosses contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-F4F52DA642D8AA9E6924852ED8A4A337" unitRef="usd">39500000</biib:Copromotionprofitsandlosses>
	<biib:Copromotionprofitsandlosses contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-214B05EB6F17D1178A6D852ED8952B14" unitRef="usd">17800000</biib:Copromotionprofitsandlosses>
	<biib:CumulativeSalesLevel contextRef="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_FifteenbillionMemberMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-ED8524D1B20DBF88611321475AFCD91C" unitRef="usd">15000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2017Q4_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-803D3F4CB31E79A55EB32145F989DE32" unitRef="usd">16000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2018Q1_biib_CumulativeSalesLevelAxis_biib_SeventeenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-515DA254FA75EF8EA0E0FBB7C0B79C94" unitRef="usd">17000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2018Q2_biib_CumulativeSalesLevelAxis_biib_EighteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-47890F5D5E060E2151AEF52FE7B628B1" unitRef="usd">18000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2018Q3_biib_CumulativeSalesLevelAxis_biib_NineteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-89D054C4071B17D2115AFBB7C0D71CD9" unitRef="usd">19000000000</biib:CumulativeSalesLevel>
	<biib:CumulativeSalesLevel contextRef="FI2018Q4_biib_CumulativeSalesLevelAxis_biib_EachAdditionalOneBillionUpToTwentyBillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-6F4CB535D35A2F7CD267820ED31EF0A6" unitRef="usd">20000000000</biib:CumulativeSalesLevel>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD" decimals="-5" id="Fact-80AE62F51FB141E3FFEAFBB7C0B77E05" unitRef="usd">2668000000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-EF11BC6A538CB38B26B9FBB7C0B7C010" unitRef="usd">2044500000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-763708F2DB3922A4D6A1FBB7C0C76A92" unitRef="usd">592600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-1AB9FD2C799BAE1615BAFBB7C0B7069A" unitRef="usd">30900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q4YTD" decimals="-5" id="Fact-02C60C1EBD073A7AD1D8FBB7C0C71B0D" unitRef="usd">2917300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-DB7B1ECA13ECA2D5930AFBB7C0C73CC4" unitRef="usd">2307400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-026F754C767F2C6E9DA9FBB7C0B789E4" unitRef="usd">583000000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-87DE220CF56B018AC1D9FBB7C105F481" unitRef="usd">26900000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2018Q4YTD" decimals="-5" id="Fact-C0027F77E8B728C54353FBB7C105D437" unitRef="usd">3389100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-BC3737170AD03A4CCFBEFBB7C134F3CB" unitRef="usd">2686700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-AF53F236C8079E58F962FBB7C172E1E5" unitRef="usd">679300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-F235097B86A92CEFC9EEFBB7C1341359" unitRef="usd">23100000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
	<biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage contextRef="FD2018Q4YTD" decimals="INF" id="Fact-CA62D8C1B09F2E7F26E5FBB7C1442E7E" unitRef="number">1.01</biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage>
	<biib:DeferredTaxLiabilitiesDecreaseDuetoOverpayment contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-0AEBDA388E41EE8453F4F0EA27107083" unitRef="usd">150000000</biib:DeferredTaxLiabilitiesDecreaseDuetoOverpayment>
	<biib:DeferredTaxLiabilitiesDepreciationAmortizationOther contextRef="FI2017Q4" decimals="-5" id="Fact-1DC25960667CC44D8A94FBB7C0C74D46" unitRef="usd">107900000</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
	<biib:DeferredTaxLiabilitiesDepreciationAmortizationOther contextRef="FI2018Q4" decimals="-5" id="Fact-1D950BADE32C4634F7C2FBB7C0B7E6B0" unitRef="usd">102300000</biib:DeferredTaxLiabilitiesDepreciationAmortizationOther>
	<biib:DeferredTaxLiabilitiesTaxCreditCarryforwards contextRef="FI2017Q4" decimals="-5" id="Fact-ABAEA748DD57BC61D5EA82486EF3D99E" unitRef="usd">0</biib:DeferredTaxLiabilitiesTaxCreditCarryforwards>
	<biib:DeferredTaxLiabilitiesTaxCreditCarryforwards contextRef="FI2018Q4" decimals="-5" id="Fact-3AC7DF344E2A0F735B47824849676326" unitRef="usd">-1425700000</biib:DeferredTaxLiabilitiesTaxCreditCarryforwards>
	<biib:DeferredtaxliabilitiesGILTItaxcalculation contextRef="FI2017Q4" decimals="-5" id="Fact-A0BB74EB60AD2B9070A582457AF3A961" unitRef="usd">0</biib:DeferredtaxliabilitiesGILTItaxcalculation>
	<biib:DeferredtaxliabilitiesGILTItaxcalculation contextRef="FI2018Q4" decimals="-5" id="Fact-FE7D77F90F34B6BD943782456577C10F" unitRef="usd">-544600000</biib:DeferredtaxliabilitiesGILTItaxcalculation>
	<biib:DeferredtaxliabilitiesGILTItaxcalculation contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-8B18271EBDB6CD2B48B6824113883315" unitRef="usd">135800000</biib:DeferredtaxliabilitiesGILTItaxcalculation>
	<biib:Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries contextRef="FI2018Q4" decimals="-8" id="Fact-BCE53DB95FE18F2F2D8A9F94259B677F" unitRef="usd">1500000000</biib:Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries>
	<biib:DevelopmentalMilestonePayment contextRef="FI2017Q2_us-gaap_TypeOfArrangementAxis_biib_IPerianMember" decimals="-5" id="Fact-AF412FCCAB0B0D70B5FF195C1C1869BC" unitRef="usd">60000000</biib:DevelopmentalMilestonePayment>
	<biib:DiscountRateRecognizedInCompensationExpense contextRef="FD2018Q4YTD" decimals="2" id="Fact-4B8D8456E4D6FB5C0534FBB7C115338C" unitRef="number">0.15</biib:DiscountRateRecognizedInCompensationExpense>
	<biib:DueFromUnconsolidatedJointBusiness contextRef="FI2017Q4" decimals="-5" id="Fact-0A278FDF7515872E9A4DFBB7C0E63D12" unitRef="usd">532600000</biib:DueFromUnconsolidatedJointBusiness>
	<biib:DueFromUnconsolidatedJointBusiness contextRef="FI2018Q4" decimals="-5" id="Fact-A3B289E22A95A8DCC684FBB7C134E072" unitRef="usd">526900000</biib:DueFromUnconsolidatedJointBusiness>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2016Q4YTD" decimals="3" id="Fact-C8F1276AA7C69B93C470FBB7C1053C56" unitRef="number">-0.019</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2017Q4YTD" decimals="3" id="Fact-B52BCEE776A68F8B1F2DFBB7C115493F" unitRef="number">-0.019</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction contextRef="FD2018Q4YTD" decimals="3" id="Fact-675981B0AD1426494B07FBB7C1631EE6" unitRef="number">0.000</biib:EffectiveIncomeTaxRateReconciliationManufacturingDeduction>
	<biib:EffectiveTaxRateReconciliationGILTItax contextRef="FD2016Q4YTD" decimals="3" id="Fact-B2F34CA92600245A9CB5824D31B46299" unitRef="number">0.000</biib:EffectiveTaxRateReconciliationGILTItax>
	<biib:EffectiveTaxRateReconciliationGILTItax contextRef="FD2017Q4YTD" decimals="3" id="Fact-EEA5B7DB563F6515A392824D101CA7D1" unitRef="number">0.000</biib:EffectiveTaxRateReconciliationGILTItax>
	<biib:EffectiveTaxRateReconciliationGILTItax contextRef="FD2018Q4YTD" decimals="3" id="Fact-47CB9E167085AEF544C2824CC961823C" unitRef="number">0.016</biib:EffectiveTaxRateReconciliationGILTItax>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-9D2F86E1A2463DCB8F8CFBB7C1633CD8" unitRef="number">0.35</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2016Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-9AE3E4FAB798866A6B87FBB7C163E2A4" unitRef="number">0.22</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-16084C4881BC7414F0E8FBB7C163AC23" unitRef="number">0.34</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2017Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-0FED537AE549585327A9FBB7C1635645" unitRef="number">0.21</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="2" id="Fact-C3D65B78B8D18E03C3B8FBB7C16367EB" unitRef="number">0.32</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="FD2018Q4YTD_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="2" id="Fact-E91146084C315F62332BFBB7C163BB11" unitRef="number">0.18</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
	<biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-C0AFC16B3BE01E45D3B716740BDBA134" unitRef="number">0.05</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
	<biib:EquityMethodInvestmentsExpectedProfitShare contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="INF" id="Fact-E398A9E6919D16E7103DFBB7C172E299" unitRef="number">0.5</biib:EquityMethodInvestmentsExpectedProfitShare>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FD2018Q4QTD_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember" decimals="-5" id="Fact-B7581D988A263D852A9711A5C18FBD60" unitRef="usd">10000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-363816A8CD0535441050F16B409FAFFF" unitRef="usd">55000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-305F5B7DBF54BFF7748CF15808C5D86C" unitRef="usd">270000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-BECEAE084759A8EB212AF157D6197A03" unitRef="usd">125000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember" decimals="-5" id="Fact-6654169B963045DF9B4D11A8410E1603" unitRef="usd">535000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember" decimals="-5" id="Fact-C94075AFD621033EE5AB11A4BA371DCB" unitRef="usd">207000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember" decimals="-5" id="Fact-D737B9E9ED7F3BF4916111A56584FC3C" unitRef="usd">515000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember" decimals="-5" id="Fact-38A0A8D97E2250521BB411A77D285A83" unitRef="usd">335000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-19A7333BE627D92721AFF159AE224E18" unitRef="usd">260000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
	<biib:EstimatedUsefulLivesOfLeaseholdImprovements contextRef="FD2018Q4YTD" id="Fact-BBB73D451BE48ECB2691FBB7C0A8CAFD">Lesser of the useful life or the term of the respective lease</biib:EstimatedUsefulLivesOfLeaseholdImprovements>
	<biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-8122207424B9C93B4592195EFF1545E9" unitRef="usd">15000000</biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold>
	<biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-6FE444C2D60D9A9C97C1F15A34B94028" unitRef="usd">800000000</biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold>
	<biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-57E59D2058EDAEED7DB0FBB7C1822FE0" unitRef="usd">130000000</biib:ExpectedLicenseFeeAndRegulatoryMilestonePayments>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-AE259229DD09FAC08585FBB7C0A89D71" unitRef="usd">48600000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-8E0C0FEAF69A3508B311FBB7C07956CC" unitRef="usd">95100000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-ADCDB0A456C7B33BBB1EFBB7C1156A72" unitRef="usd">39900000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-BDD3058187129CEC696EFBB7C07943D7" unitRef="usd">146200000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-69C755745EFE41942922FBB7C163C2C2" unitRef="usd">32400000</biib:ExpenseIncurredByCollaboration>
	<biib:ExpenseIncurredByCollaboration contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-B7C3B6AC6021FCC04C03FBB7C125B930" unitRef="usd">232000000</biib:ExpenseIncurredByCollaboration>
	<biib:Expenseincurredbythecollaboration contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-0C7A74A0B444947B7685F172DF03CF8F" unitRef="usd">209500000</biib:Expenseincurredbythecollaboration>
	<biib:Expenseincurredbythecollaboration contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-EB2231228AEFCC0C4220F172EA5848E1" unitRef="usd">18300000</biib:Expenseincurredbythecollaboration>
	<biib:Expenseincurredbythecollaboration contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-40ABF56C59985D8957CBF1729FAAA604" unitRef="usd">268700000</biib:Expenseincurredbythecollaboration>
	<biib:Expenseincurredbythecollaboration contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-5D7AF58241DA93C4B8B0F172AC971D49" unitRef="usd">23600000</biib:Expenseincurredbythecollaboration>
	<biib:Expenseincurredbythecollaboration contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-BF101032AFA2B3A33FCDF17249FBE8B0" unitRef="usd">264800000</biib:Expenseincurredbythecollaboration>
	<biib:Expenseincurredbythecollaboration contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-AAF857FBCA106E093037F1725C14F030" unitRef="usd">50600000</biib:Expenseincurredbythecollaboration>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-25DCDC3EC1AD11EE33F6F172E4499D46" unitRef="usd">209500000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-7221C1E98C0AA4B95AEAF172EFD17969" unitRef="usd">18300000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-60F9C76D4AB2C1E38DA6FBB7C16370BB" unitRef="usd">257800000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-2D6B01AAACC625A159A7851D9DDC58FA" unitRef="usd">22000000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-C50C42DF0BCE9E81F8AFFBB7C134C4BB" unitRef="usd">24300000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-FC4F68EBE6F0F59B5A1EFBB7C0984C2D" unitRef="usd">31500000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-76970B0585FD47C0FDF5FBB7C08940BB" unitRef="usd">50500000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-E806E8DB753FF393858CF172A55411A2" unitRef="usd">268700000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-F9E0D55923CEC1B0ABC3F172B2B40EF6" unitRef="usd">23600000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-45B706DA6038FEDFF27BFBB7C0E688E0" unitRef="usd">234500000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-714D4E240908E000F6AAFBB7C0B7BA91" unitRef="usd">19900000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-2471B5C1916A1FC68F13FBB7C1441593" unitRef="usd">34000000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-DDB04148A6F26B565395FBB7C0F61999" unitRef="usd">74300000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-32C19C78A5A8B3A135C9F17255383917" unitRef="usd">234600000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_AducanumabMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-962F56D8691BD76B4C84F17261FBF470" unitRef="usd">27300000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-A0CC4A352594A8958926FBB7C0696D19" unitRef="usd">285000000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-735967A92D63347A99A7FBB7C11559D3" unitRef="usd">16200000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-958970507852030CD7DBFBB7C09814E6" unitRef="usd">36500000</biib:Expensereflectedwithinstatementsofincome>
	<biib:Expensereflectedwithinstatementsofincome contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-9628856AB4379E0242B0FBB7C13429F6" unitRef="usd">116000000</biib:Expensereflectedwithinstatementsofincome>
	<biib:FairValueMeasurementInputs contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" id="Fact-6F2142BC6884806BACACFBB7C089F6AE">0.02</biib:FairValueMeasurementInputs>
	<biib:FairValueMeasurementInputs contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" id="Fact-982A3DF7761C5D412E44FBB7C14498AB">0.038</biib:FairValueMeasurementInputs>
	<biib:FairValueMeasurementInputs contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" id="Fact-7566268734930BAD353FFBB7C0A82A37">0.036</biib:FairValueMeasurementInputs>
	<biib:FairValueMeasurementInputs contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" id="Fact-F5057ACCEC0B85713708FBB7C1050B09">0.036</biib:FairValueMeasurementInputs>
	<biib:ForeignSalesRequiredToTriggerMilestone contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AcordaMember" decimals="-5" id="Fact-192FC159BE1134921700195F86392955" unitRef="usd">100000000</biib:ForeignSalesRequiredToTriggerMilestone>
	<biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="2" id="Fact-6C433C05920FA075CF6DFBB7C069CC38" unitRef="number">0.25</biib:FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion>
	<biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="2" id="Fact-5E59C8D15270404BFCBFFBB7C0B76C91" unitRef="number">0.18</biib:FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion>
	<biib:FutureContingentPaymentThreshold contextRef="I2013Q2SD_us-gaap_BusinessAcquisitionAxis_biib_TysabriProductMember" decimals="-8" id="Fact-27994CFE05501398C7D5FBB7C0D775B3" unitRef="usd">2000000000</biib:FutureContingentPaymentThreshold>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MaximumMember" decimals="2" id="Fact-006747F6AC955C4CFB24FBB7C0B7E2DB" unitRef="number">0.24</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_RangeAxis_srt_MinimumMember" decimals="3" id="Fact-8205B81758CB01C9294FFBB7C06983E7" unitRef="number">0.135</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember_srt_StatementGeographicalAxis_us-gaap_ForeignCountryMember" decimals="2" id="Fact-11C1AD17358299EEFF01FBB7C182BAB3" unitRef="number">0.03</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
	<biib:Futurepercentageofcopromotionoperatingprofits contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MaximumMember" decimals="3" id="Fact-3405815958FBC8149A36FBB7C163E3A8" unitRef="number">0.375</biib:Futurepercentageofcopromotionoperatingprofits>
	<biib:Futurepercentageofcopromotionoperatingprofits contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_NewAntiCd20Member_srt_RangeAxis_srt_MinimumMember" decimals="2" id="Fact-89F61DCF10651C305F1BFBB7C069990C" unitRef="number">0.30</biib:Futurepercentageofcopromotionoperatingprofits>
	<biib:Futureresearchanddevelopmentcommitment contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-5369593C3DF6F8041E9719602B6DAED5" unitRef="usd">137000000</biib:Futureresearchanddevelopmentcommitment>
	<biib:IncreasedCarryingAmountOfSeniorNotes contextRef="D2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-3691C5B4BE3CB34035EFF0A221676FB2" unitRef="usd">62800000</biib:IncreasedCarryingAmountOfSeniorNotes>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2018Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" id="Fact-A5CE0D80B9C589CF7A4DFBB7C0E6CCFA">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:IndefiniteLivedIntangibleAssetsUsefulLife contextRef="FD2018Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" id="Fact-1EFA893C17A7120EB8B6FBB7C0F6698A">Indefinite</biib:IndefiniteLivedIntangibleAssetsUsefulLife>
	<biib:InterestInSubsidiary contextRef="FD2018Q4YTD" decimals="2" id="Fact-0B472EE81E76E0295904FBB7C0697C41" unitRef="number">1.00</biib:InterestInSubsidiary>
	<biib:InventoryexpectedtobesoldtoBioverativ contextRef="FI2018Q4_srt_MajorCustomersAxis_biib_BioverativMember" decimals="-5" id="Fact-D4BB6BA02D5D086D8008F08A46263692" unitRef="usd">180000000</biib:InventoryexpectedtobesoldtoBioverativ>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-9AE8308D2FDD0907C255FBB7C079CB09" unitRef="usd">925500000</biib:Inventorynetcurrentandnoncurrent>
	<biib:Inventorynetcurrentandnoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-866D01F3FFF4A0D09A6EFBB7C0C7B5A7" unitRef="usd">936500000</biib:Inventorynetcurrentandnoncurrent>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2017Q4" decimals="-5" id="Fact-5B66C13C2EECA057CC7FFBB7C0E65023" unitRef="usd">48300000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="FI2018Q4" decimals="-5" id="Fact-D5259A52F65DD333E508FBB7C0F635D5" unitRef="usd">28700000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
	<biib:Investmentincommonstocksharespurchased contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-378A1B1AA1FA0F00196C16289448CF48" unitRef="shares">11500000</biib:Investmentincommonstocksharespurchased>
	<biib:Investmentincommonstockvalue contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-3B8D96DD921ADC212081F179EC71A85E" unitRef="usd">22500000</biib:Investmentincommonstockvalue>
	<biib:Investmentincommonstockvalue contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-E2C179FC48F19E5C1083F1576A5E2198" unitRef="usd">462900000</biib:Investmentincommonstockvalue>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-54BF82CD2D6294D41F2FFBB7C06919F9" unitRef="usd">250000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-54230C276B3DC641CD81FBB7C0690F86" unitRef="KRW">280500000000</biib:InvestmentsByThirdPartyInJointVentureAsPerAgreement>
	<biib:JointVentureOwnerShipPercentageByThirdParty contextRef="D2012Q1Feb_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-206924BBF3CFD11C960EFBB7C1153938" unitRef="number">0.85</biib:JointVentureOwnerShipPercentageByThirdParty>
	<biib:LicenseFee contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-202D616E570506809DC9FBB7C1639BC0" unitRef="usd">35600000</biib:LicenseFee>
	<biib:LicenseFee contextRef="FD2016Q3QTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-7DA422E8C4A23059CFA6F14FE25024A3" unitRef="usd">75000000</biib:LicenseFee>
	<biib:LicenseFee contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-7511289B48E9ADAFF42AFBB7C1346ED6" unitRef="usd">70000000</biib:LicenseFee>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-C509D77A36EF9ADB98CEFBB7C1537AC5" unitRef="number">1.50</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="2" id="Fact-C6391DA496DAAC7B1F7BFBB7C1442C0C" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-597F92D4F55BEFF9767AFBB7C1441E8C" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="2" id="Fact-2E1637E87FD43204527D1B5136678F53" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="2" id="Fact-B9557D19D9EBD39E978B1B47E38A5583" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="2" id="Fact-8644E0BBCEFA90902C94FBB7C153AFA4" unitRef="number">2.00</biib:MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumQualifyingAgeForEmployeeBenefitPlan contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" id="Fact-58ABB26547E2BA23C65AFBB7C079AD8D">P21Y</biib:MinimumQualifyingAgeForEmployeeBenefitPlan>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-07A8254816BAD8674006FBB7C153F177" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="2" id="Fact-5025486BDDE8A2CB2367FBB7C163F678" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-159212ACEF5664717695FBB7C1442644" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="2" id="Fact-B0FA9FE7D74DD55CC6671B50ED496E35" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="2" id="Fact-BE56986DA2FC4455E1D21B46CCA87C34" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="2" id="Fact-9DBA2804D880250EA3F0FBB7C153661A" unitRef="number">0.00</biib:MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent>
	<biib:NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" decimals="-5" id="Fact-D8FA84E4C03584EA3B56167E8830EA04" unitRef="usd">-3800000</biib:NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome>
	<biib:NetMinimumLeasePayments contextRef="FI2018Q4" decimals="-5" id="Fact-D5C9B0D31C980D6F3004FBB7C0D7256C" unitRef="usd">418800000</biib:NetMinimumLeasePayments>
	<biib:NetMinimumLeasePaymentsThereafter contextRef="FI2018Q4" decimals="-5" id="Fact-DD118F41DEFA96A45228FBB7C0C79B66" unitRef="usd">156900000</biib:NetMinimumLeasePaymentsThereafter>
	<biib:NetMinimumLeasePaymentsWithInFiveYear contextRef="FI2018Q4" decimals="-5" id="Fact-BADFF32BC6D92CDDD37CFBB7C0C73AEF" unitRef="usd">46700000</biib:NetMinimumLeasePaymentsWithInFiveYear>
	<biib:NetMinimumLeasePaymentsWithInFourYear contextRef="FI2018Q4" decimals="-5" id="Fact-9A3FFD9B8004555D752CFBB7C0D75FD2" unitRef="usd">47700000</biib:NetMinimumLeasePaymentsWithInFourYear>
	<biib:NetMinimumLeasePaymentsWithInOneYear contextRef="FI2018Q4" decimals="-5" id="Fact-1A16AF44544C4F2DFDDBFBB7C0C7A82A" unitRef="usd">60200000</biib:NetMinimumLeasePaymentsWithInOneYear>
	<biib:NetMinimumLeasePaymentsWithInThreeYear contextRef="FI2018Q4" decimals="-5" id="Fact-FB2BD20C3715C0358579FBB7C0D7B49B" unitRef="usd">52200000</biib:NetMinimumLeasePaymentsWithInThreeYear>
	<biib:NetMinimumLeasePaymentsWithInTwoYear contextRef="FI2018Q4" decimals="-5" id="Fact-CBAB6E65F1CE2C313788FBB7C0B771E2" unitRef="usd">55100000</biib:NetMinimumLeasePaymentsWithInTwoYear>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C09D51CE456BBF413C30FBB7C1346F34" unitRef="usd">1500000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-9901C62890D832B3D16FFBB7C0C791A9" unitRef="usd">1500000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-EDB0B2DD42332BC8D298FBB7C0C79A06" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2017Q4YTD" decimals="-5" id="Fact-EE7BFD0D6F57919CEBB3FBB7C0981AC9" unitRef="usd">15800000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-00FF60E4D2061EEC9208FBB7C0895E62" unitRef="usd">15800000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-F501AFB28A490126F165FBB7C1536C66" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2018Q4YTD" decimals="-5" id="Fact-CA99BABF0D67A4560FDBFBB7C1535263" unitRef="usd">13800000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-5F71A555E913A9CC8FBCFBB7C1537CE4" unitRef="usd">13800000</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:Noncontrollinginterestincreasedecreaseother contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-1B7D6E2DB4EA38EDCEC0FBB7C1726FAD" unitRef="usd">0</biib:Noncontrollinginterestincreasedecreaseother>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" id="Fact-441A22198B42DA42F7ABFBB7C144B867">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" id="Fact-0F27B93E4DE01A002E64FBB7C1446B28">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" id="Fact-43C1D4C5A15B4F090A131B5229BE0367">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfDaysForCalculationOfAverageClosingStockPrice contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" id="Fact-48D2A6F9CF3A65C81266FBB7C1533188">P30D</biib:NumberOfDaysForCalculationOfAverageClosingStockPrice>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2013Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-37996EEB4A596611A781FBB7C1537ADC" unitRef="Increment">4</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-37E5FDFBDBB56E4AF4B9FBB7C14492A8" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-961BD8815CB41B681E77FBB7C153D1DE" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfEqualAnnualIncrements contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-93EB25D161CBD95EAE94FBB7C15343FA" unitRef="Increment">3</biib:NumberOfEqualAnnualIncrements>
	<biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade contextRef="FD2018Q4YTD" decimals="INF" id="Fact-23229211BAD73F1CB921FBB7C144DDD2" unitRef="Plan">3</biib:NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade>
	<biib:NumberOfSharesOfCommonStockForIssuance contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember" decimals="-5" id="Fact-35B43353937AB2F13D58FBB7C153D429" unitRef="shares">1600000</biib:NumberOfSharesOfCommonStockForIssuance>
	<biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="FD2016Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-DFC126360B3BC5C42E2E122627937531" unitRef="usd">65000000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
	<biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-DBE7228F374AAABD1F5A1225FE768D39" unitRef="usd">242800000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
	<biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-2DC06EDB09EAC92609751221412F73F0" unitRef="usd">548300000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
	<biib:PaymentTermsOfAccountsReceivable contextRef="FD2018Q4YTD" id="Fact-9DD3E8630C738644E7CCFBB7C105A35B">30 to 90 days</biib:PaymentTermsOfAccountsReceivable>
	<biib:PaymentforTransitionTollTax contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-D7E4A4B402F6E6D9DE67F0E9B8A9F70E" unitRef="usd">85000000</biib:PaymentforTransitionTollTax>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD" decimals="-5" id="Fact-10F1A3588BF1D61B7440FBB7C153C362" unitRef="usd">2099500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-2CCED3A65907256D6877FBB7C153BB7E" unitRef="usd">1576000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-B2EC04080989FBBF695BFBB7C0B7BF48" unitRef="usd">522500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-7D58F177AC7A3DCBB730FBB7C153C805" unitRef="usd">1000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D77C380D7AD896BFF45AFBB7C172A1AE" unitRef="usd">2232800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-D41898B4E4F1819BF899FBB7C0A850DF" unitRef="usd">1756900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-5CDB9C2C77AF5E2D8CE0FBB7C0D7790E" unitRef="usd">475800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-C6AE749B2CE23E723125FBB7C15381B2" unitRef="usd">100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2018Q4YTD" decimals="-5" id="Fact-DC6292A8732EF2E3110DFBB7C1726E12" unitRef="usd">2440400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-2D07CEC5BB36569AD2F9FBB7C0E6726F" unitRef="usd">1887600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-8E791204E8CC91DF4F39FBB7C0C74362" unitRef="usd">551700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-34D70320AFB617D37FF9FBB7C0982CF0" unitRef="usd">1100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1502DBB9CF97F3085FA2FBB7C0B76129" unitRef="usd">609000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-4458F7A15752D876B99FFBB7C0C72646" unitRef="usd">536000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-65266316B0B04EBAC59AFBB7C15334F2" unitRef="usd">53200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2016Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-DF6D00BB698588DE025AFBB7C1535589" unitRef="usd">19800000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E27C7733F60FFF26E267FBB7C0C7E3D0" unitRef="usd">534400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-C73C1C6F035A725AF36BFBB7C1342079" unitRef="usd">442200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-772F429E970413BE6B82FBB7C115497D" unitRef="usd">69100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2017Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-A9441E45E699C9AA05EEFBB7C0D7B2E2" unitRef="usd">23100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2018Q4YTD" decimals="-5" id="Fact-1657E7263DC275AC5327FBB7C13446CA" unitRef="usd">646900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-715AE9F0FE030E326BDCFBB7C125867C" unitRef="usd">506300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-84CA4F81E6DD4041AECDFBB7C134057C" unitRef="usd">109100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="FD2018Q4YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-F4955669BAAEA2A3D370FBB7C0E61E8A" unitRef="usd">31500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
	<biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" decimals="2" id="Fact-9B0AC71794F136576734FBB7C115EBF2" unitRef="number">0.35</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-71F3CF4542C89B49696AFBB7C172E2D2" unitRef="number">0.30</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne contextRef="FI2015Q4_srt_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-8DFBF5D8B97860FEC3B4F0F95F7CDA94" unitRef="number">0.40</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-69E423F2F4EDA86A8F56FBB7C153E668" unitRef="number">0.400</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2016Q1_srt_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-1E98C7E42F441533BCC4F0F8D13E3C68" unitRef="number">0.39</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2016Q4_srt_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-2D2C104D9D3D95B2A7CBFBB7C1058AC4" unitRef="number">0.39</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2017Q4_srt_ProductOrServiceAxis_biib_RituxanMember" decimals="2" id="Fact-374550F223CCE7F48297BEC8DCDE8F6E" unitRef="number">0.39</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-094343A8D639EAB92ABEFBB7C163400B" unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-08944F987E8B99A43550FBB7C1536BE7" unitRef="number">0.390</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-EA9AF045C09DDD492A2AFBB7C163B2AB" unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-69B8E5B1939A69E02F1DFBB7C153A504" unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo contextRef="FI2017Q3_srt_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-D2D1CDDB41B5F1202221FBB7C115B4B2" unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo contextRef="FI2017Q4_srt_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-0A0D11BC53EDBDE1BDC4FBB7C182AB5D" unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_GAZYVAMember" decimals="3" id="Fact-E7B2820F0C56607DE3FB8512855E6AE2" unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
	<biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_RituxanMember" decimals="3" id="Fact-FF216F397B723DEBF617FBB7C163F629" unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
	<biib:PercentageOfMarketValuePerShareOfCommonStock contextRef="FD2018Q4YTD" decimals="2" id="Fact-215C159A006C4F111F39FBB7C1442E1A" unitRef="usdPerShare">0.85</biib:PercentageOfMarketValuePerShareOfCommonStock>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2016Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="4" id="Fact-FB4735A255E317396FBCFBB7C0790252" unitRef="number">0.0125</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="4" id="Fact-1C719DCD2D376A5378CBFBB7C079E479" unitRef="number">0.0100</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageOfMinimumInvestmentReturn contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="4" id="Fact-914076078111B0FBD13BFBB7C0799C75" unitRef="number">0.0100</biib:PercentageOfMinimumInvestmentReturn>
	<biib:PercentageOfRoyaltiesAsPerCollaboration contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="INF" id="Fact-1D3EEA24BAE6E6E71265FBB7C105994B" unitRef="number">0.15</biib:PercentageOfRoyaltiesAsPerCollaboration>
	<biib:PercentageOfRoyaltiesAsPerCollaboration contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="INF" id="Fact-F57558AA77E4153A2177FBB7C0A87A1A" unitRef="number">0.11</biib:PercentageOfRoyaltiesAsPerCollaboration>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-0006F4136099650E96EAFBB7C089198C" unitRef="number">0.99294</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-93835B7F5AB2827ED7B3FBB7C0E67513" unitRef="number">0.99764</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-AFB83FF3FD966B89015FFBB7C153C440" unitRef="number">0.9992</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-70E322F76451A33E1005FBB7C0F6BA67" unitRef="number">0.99792</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageParValueOfSeniorNotes contextRef="I2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="INF" id="Fact-EBB7731BF29FD7627F74F09FA8CA6347" unitRef="number">0.99184</biib:PercentageParValueOfSeniorNotes>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2017Q4_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="3" id="Fact-12DB00A3E6D390C2ACFDFBB7C10587A4" unitRef="number">0.265</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2017Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="3" id="Fact-8CD51BA9C22F07A7C921FBB7C1053553" unitRef="number">0.190</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorOneMember" decimals="3" id="Fact-F3BDC0E4D8D732D7C76AFBB7C10532DD" unitRef="number">0.277</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables contextRef="FI2018Q4_biib_MajorDistributorAxis_biib_DistributorTwoMember" decimals="3" id="Fact-A5ED46A560E4CAC82889FBB7C153DBAB" unitRef="number">0.156</biib:PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables>
	<biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="D2018Q2_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="INF" id="Fact-2BC361B91E7E37AB1D87FBB7C0B7EC8E" unitRef="number">0.15</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
	<biib:PercentageoffuturedevelopmentcostsrelatedtoEisai contextRef="D2019Q1_us-gaap_StatementScenarioAxis_us-gaap_ScenarioForecastMember_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="INF" id="Fact-84765763887AC885B8DCFBB7C172BF7D" unitRef="number">0.45</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
	<biib:PeriodOfCollaborationAgreement contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember" id="Fact-CEBE20FAEEB4E7A9E400FBB7C1635904">P11Y</biib:PeriodOfCollaborationAgreement>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-44793C0169BB7BE4268DFBB7C098B4F0" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4C2C19EE0D98D840D022FBB7C07945F5" unitRef="usd">28500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-39C5D61393706E5D6610FBB7C079BD50" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CF9BF77B029B6C28A73DFBB7C079EE98" unitRef="usd">28500000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C2A59168E5A0F5822514FBB7C089C199" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9F9E97AC48E6E7BE374CFBB7C0C798EF" unitRef="usd">25400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5B60B0C81B8978239B64FBB7C0A87033" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-36AE11B14956D0784386FBB7C0E623D8" unitRef="usd">25400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2018Q4" decimals="-8" id="Fact-2B84A62CB1210B40E3DFFBB7C0C77E17" unitRef="usd">5000000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2018Q4_biib_FutureContingentMilestoneTypesAxis_biib_CommercialMilestonesMember" decimals="-8" id="Fact-5007A53ABE10D8C1F69AFBB7C0C75468" unitRef="usd">2500000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2018Q4_biib_FutureContingentMilestoneTypesAxis_biib_DevelopmentMilestonesMember" decimals="-8" id="Fact-B14720BEE70C5EF5D6B7FBB7C0D77C06" unitRef="usd">700000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2018Q4_biib_FutureContingentMilestoneTypesAxis_biib_RegulatoryMilestonesMember" decimals="-8" id="Fact-3CD28D3E92F7F1078452FBB7C0E6228D" unitRef="usd">1800000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" decimals="-5" id="Fact-ABFC917F06B04CC0DF74FBB7C0E638F0" unitRef="usd">150000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
	<biib:Premiumonpurchaseofcommonstock contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-7AC610530936544A2984F176E47EFB90" unitRef="usd">7500000</biib:Premiumonpurchaseofcommonstock>
	<biib:Premiumonpurchaseofcommonstock contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-69C3E3306C1DD812EB8AF157964DCBF7" unitRef="usd">162100000</biib:Premiumonpurchaseofcommonstock>
	<biib:PurchasePriceOfCommonStockUnderEspp contextRef="FD2018Q4YTD" id="Fact-D03B74357F73114840FFFBB7C1637421">85% of the lower of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date</biib:PurchasePriceOfCommonStockUnderEspp>
	<biib:Purchaseofcommonstock contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-CF769BBDDB7030920F3AFBB7C09807DF" unitRef="usd">30000000</biib:Purchaseofcommonstock>
	<biib:Purchaseofcommonstock contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-C6428646A9CE896B15B01628F10FF673" unitRef="usd">625000000</biib:Purchaseofcommonstock>
	<biib:RatioOfNumberOfSharesReservedUnderPlan contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember" id="Fact-0D1E00F96C886089D887FBB7C1539DF8">1.5-to-1</biib:RatioOfNumberOfSharesReservedUnderPlan>
	<biib:RatioOfNumberOfSharesReservedUnderPlan contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_DirectorsPlanMember" id="Fact-62FF9E7435CCF9253CAAFBB7C1533EEB">1.5-to-1</biib:RatioOfNumberOfSharesReservedUnderPlan>
	<biib:Reductionindeferredtaxliabilityundistributedforeignearnings contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-56BB61574C4A4C087BD6F0E73C5E70CD" unitRef="usd">34600000</biib:Reductionindeferredtaxliabilityundistributedforeignearnings>
	<biib:Reductioninroyaltyrate contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember" decimals="INF" id="Fact-23CDDE77C9002D7279A4FBB7C069BAE8" unitRef="number">0.5</biib:Reductioninroyaltyrate>
	<biib:Reductioninroyaltyratepayableoncommercialsales contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="INF" id="Fact-1D79E0FD648E4FF164FCFBB7C0F656FC" unitRef="number">0.15</biib:Reductioninroyaltyratepayableoncommercialsales>
	<biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember" decimals="-8" id="Fact-AA17D590CA974214735E9F96FB52E3D7" unitRef="usd">400000000</biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting>
	<biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting contextRef="FI2018Q4_srt_RangeAxis_srt_MinimumMember" decimals="-8" id="Fact-020AD22768A09B99D08C9F96883F8EED" unitRef="usd">300000000</biib:ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting>
	<biib:ResourcesRedirectedthroughRestructuringProgram contextRef="FD2017Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember" decimals="-5" id="Fact-18F27EDBC9126167A9EEF06E842FDC34" unitRef="usd">400000000</biib:ResourcesRedirectedthroughRestructuringProgram>
	<biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms contextRef="FD2016Q4YTD" decimals="2" id="Fact-F0CC1167D7C7F09208C4FBB7C163BA75" unitRef="number">0.11</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
	<biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms contextRef="FD2017Q4YTD" decimals="2" id="Fact-880F8B98AADE95EA1B5EFBB7C163E4A1" unitRef="number">0.13</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
	<biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms contextRef="FD2018Q4YTD" decimals="2" id="Fact-747B16C3AEEB851BFE2CFBB7C1633441" unitRef="number">0.15</biib:RevenuesInPercentageFromAntiCD20TherapeuticPrograms>
	<biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OCREVUSMember" decimals="-5" id="Fact-36D9819AE7EB21F0DA95FBB7C163C166" unitRef="usd">900000000</biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage>
	<biib:SalesTriggerGrossSalesThreshold contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-6469B6B170DDE1DDBACDFBB7C0B7D21F" unitRef="usd">500000000</biib:SalesTriggerGrossSalesThreshold>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4431EDC4BC89BD653DEDFBB7C1729CB9" unitRef="usd">189800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2017Q4YTD" decimals="-5" id="Fact-6E90638C6A9B7BB95EC5FBB7C1255459" unitRef="usd">160100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="FD2018Q4YTD" decimals="-5" id="Fact-CAD5EB5D868FEA591017FBB7C0B74D8A" unitRef="usd">170100000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
	<biib:ShareOfCoPromotionProfits contextRef="FD2016Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-198BB8FD1A3C76B41E29122624E79BD3" unitRef="usd">1249500000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-4A1559CA16145AAD7B0E1225FC7627A5" unitRef="usd">1316400000</biib:ShareOfCoPromotionProfits>
	<biib:ShareOfCoPromotionProfits contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_RocheGroupGenentechMember" decimals="-5" id="Fact-2BB64B40BBC6DB03015912213D8C2A4D" unitRef="usd">1431900000</biib:ShareOfCoPromotionProfits>
	<biib:StrategicInvestmentPortfolio contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-8B7D9A7AE10B18B09C95FBB7C0F6169B" unitRef="usd">85800000</biib:StrategicInvestmentPortfolio>
	<biib:StrategicInvestmentPortfolio contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_StrategicInvestmentsMember" decimals="-5" id="Fact-F9371D6EE85501470DF2FBB7C0F67366" unitRef="usd">676300000</biib:StrategicInvestmentPortfolio>
	<biib:Termofcollaborationagreement contextRef="FD2013Q3QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" id="Fact-7BDBCD49DAFF17A7750BFBB7C134BBDC">P6Y</biib:Termofcollaborationagreement>
	<biib:Termofcollaborationagreement contextRef="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" id="Fact-E96FC4A9DAEBAF82264616271E1BA67B">P10Y</biib:Termofcollaborationagreement>
	<biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-4A9FC674A77CB7A7F8C0FBB7C125EDB2" unitRef="usd">150000000</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
	<biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_GAZYVAMember" decimals="-5" id="Fact-9564CAA74D57C176E390FBB7C1826306" unitRef="usd">150000000</biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne>
	<biib:Totaldeferredchargesandprepaidtaxes contextRef="FI2017Q4" decimals="-5" id="Fact-4F5D4558D36CF546B7C0FBB7C0C7015A" unitRef="usd">617700000</biib:Totaldeferredchargesandprepaidtaxes>
	<biib:Totaldeferredchargesandprepaidtaxes contextRef="FI2018Q4" decimals="-5" id="Fact-13D4896135E4DD647E1CFBB7C0C7A272" unitRef="usd">239200000</biib:Totaldeferredchargesandprepaidtaxes>
	<biib:Totalpaymenttoentercollaborationagreement contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-8" id="Fact-90E355AB2A9B1341ED6D16269A5E1A8F" unitRef="usd">1000000000</biib:Totalpaymenttoentercollaborationagreement>
	<biib:TransitionTollTaxRepatriationTaxRate contextRef="FI2017Q4_biib_ForeignearningstypeAxis_biib_ForeignearningsintheformofcashandcashequivalentsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="INF" id="Fact-00E7DB7D294B35FBFAE4FBB7C0C7FD19" unitRef="number">0.155</biib:TransitionTollTaxRepatriationTaxRate>
	<biib:TransitionTollTaxRepatriationTaxRate contextRef="FI2017Q4_biib_ForeignearningstypeAxis_biib_OtherForeignEarningsMember_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="INF" id="Fact-F6957A10F1A32D5A6B19FBB7C0D780E4" unitRef="number">0.08</biib:TransitionTollTaxRepatriationTaxRate>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="D2019Q1Skyhawk_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" decimals="-5" id="Fact-CA88786197878844B7B4197126D8D266" unitRef="usd">74000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FD2015Q3QTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-7351B8C3F6A41F2D1159FBB7C115B2D4" unitRef="usd">124000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" decimals="-5" id="Fact-216E7BBA444E997B6772FBB7C1632C41" unitRef="usd">28000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-026CDCA706521AEFFC5CF158DAEF42B9" unitRef="usd">25000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-3807CF1B2BFD297824C8F164605056FE" unitRef="usd">35000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
	<biib:Upfrontpaymentforcollaborationagreement contextRef="FI2012Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-E629823E503DF8EBE908FBB7C18258AF" unitRef="usd">30000000</biib:Upfrontpaymentforcollaborationagreement>
	<biib:Upfrontpaymentforcollaborationagreement contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_C4TherapeuticsMember" decimals="-5" id="Fact-E9AB27AF57AA3BDC7ECCA5E8A2DC31AD" unitRef="usd">45000000</biib:Upfrontpaymentforcollaborationagreement>
	<biib:Upfrontpaymentforcollaborationagreement contextRef="I2018Q2Ioniscollaboration_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-24549A78D3D2A0311B9A16284B6D3353" unitRef="usd">375000000</biib:Upfrontpaymentforcollaborationagreement>
	<biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards contextRef="FD2018Q4YTD" id="Fact-2C0EC0CE78F6896D6968FBB7C153A3FB">P1Y11M</biib:WeightedAveragePeriodToRecognizeCostOfNonvestedAwards>
	<dei:AmendmentFlag contextRef="FD2018Q4YTD" id="Fact-C0429EA15AD7FF46F45FFBB7C07987F4">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2018Q4YTD" id="Fact-EA3CCC0CBE251B70F650FBB7C0B77EAA">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2018Q4YTD" id="Fact-106D7C065528A6C636ACFBB7C182BE19">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2018Q4YTD" id="Fact-2DE4BEFD4381F429FB22FBB7C069DBEE">2018</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2018Q4YTD" id="Fact-E4B1020F355C7B70F2B7FBB7C1827BD7">2018-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2018Q4YTD" id="Fact-8FCF32556F3F39F2C110FBB7C0696CCF">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2018Q4YTD" id="Fact-5E4D573704798292E370FBB7C1822E81">0000875045</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q4SharesOutstanding" decimals="0" id="Fact-714BE484ED36322B4300FBB7C0C712D4" unitRef="shares">196708784</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2018Q4YTD" id="Fact-4D863B2CE74C2ED9EF57FBB7C0B73B6A">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2018Q4YTD" id="Fact-6F15C492846CEA5473B61D33C7363436">false</dei:EntityEmergingGrowthCompany>
	<dei:EntityFilerCategory contextRef="FD2018Q4YTD" id="Fact-07AFB5995294C2FC7FA0FBB7C182E05E">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2018Q2" decimals="0" id="Fact-86DDFFF63C8ACF1139BFFBB7C0C7838A" unitRef="usd">58267511287</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2018Q4YTD" id="Fact-F378A321F044DF0D7E30FBB7C089CA8B">BIOGEN INC.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2018Q4YTD" id="Fact-BA9425FBA8563A46D722BFA7A9D3B627">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2018Q4YTD" id="Fact-3C2BC3D281E0B54B350E1D33882CF56A">false</dei:EntitySmallBusiness>
	<dei:EntityVoluntaryFilers contextRef="FD2018Q4YTD" id="Fact-968A8BC0B618B1E0563BFBB7C182833C">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2018Q4YTD" id="Fact-D7090D756FD744A868F5FBB7C0898D11">Yes</dei:EntityWellKnownSeasonedIssuer>
	<invest:DerivativeNotionalAmount contextRef="FI2015Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-23DB9B54C720EEB2B05D166EC268CED8" unitRef="usd">675000000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-5235EA2724A8013D6FBAFBB7C08933B7" unitRef="usd">83500000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-6F49E6065C467FD79550FBB7C0894C09" unitRef="usd">88700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-27AC8DAAEDA2F5AF5FC4FBB7C0C762AA" unitRef="usd">1875600000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-D3D38380CA902EA5C1C1FBB7C1052EAB" unitRef="usd">150900000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-CDA4BC279C5C1A6309F28218F67E9E80" unitRef="usd">0</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-68C0CC82A5FB1B28B811FBB7C134C7D9" unitRef="usd">2198700000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2017Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-ED893D67142D53BEF476FBB7C0899539" unitRef="usd">564900000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_srt_CurrencyAxis_currency_CAD_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-32CFBAD36A35269E0047FBB7C07948A9" unitRef="usd">92200000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_srt_CurrencyAxis_currency_CHF_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-176AB589DA2B15D6A03AFBB7C0F6B34E" unitRef="usd">131400000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_srt_CurrencyAxis_currency_EUR_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-B9DD9A8F802C5C03B2B6FBB7C105AF81" unitRef="usd">1701400000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_srt_CurrencyAxis_currency_GBP_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-D02BE78948A02455751DFBB7C079FD03" unitRef="usd">215300000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_srt_CurrencyAxis_currency_JPY_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-B967C5B141AB0707EEA98218F33EA325" unitRef="usd">98800000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-FBEE979CCB01C115D0F0FBB7C0799632" unitRef="usd">2239100000</invest:DerivativeNotionalAmount>
	<invest:DerivativeNotionalAmount contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-137EC549F0030E78EF0EFBB7C1348D8C" unitRef="usd">735100000</invest:DerivativeNotionalAmount>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-BA5FFCEC02CB05CE7069FBB7C0A8528B" unitRef="usd">395500000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-FB2003F5F5529F04E175FBB7C13426D3" unitRef="usd">370500000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-94090335F246324816BFFBB7C0892920" unitRef="usd">1787000000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-CB3EA97DA1E5068D5DA3FBB7C098F5AC" unitRef="usd">1958500000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedIncomeTaxesNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-DC2BF96C7951749DCD12214D69A2BB21" unitRef="usd">979800000</us-gaap:AccruedIncomeTaxesNoncurrent>
	<us-gaap:AccruedIncomeTaxesNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-7DE76A505E430036F7B6214D34A987F5" unitRef="usd">791400000</us-gaap:AccruedIncomeTaxesNoncurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-8679DD9FBA1230393282FBB7C1821A98" unitRef="usd">206700000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccruedRoyaltiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-875904FD390DB6280362FBB7C0983B5F" unitRef="usd">224700000</us-gaap:AccruedRoyaltiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-5" id="Fact-0B654826596DFC08BD80FBB7C0B71E8A" unitRef="usd">1559100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-5" id="Fact-815283AD52407043E716FBB7C1726075" unitRef="usd">1797400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4" decimals="-5" id="Fact-5D3C5928C6B1EA95E761FBB7C0F6A902" unitRef="usd">-224000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-DB062B6C3AF83B3F7A0CFBB7C0E6DA70" unitRef="usd">-37800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-213C44C05AD7AFBBD9C3FBB7C11553E5" unitRef="usd">10200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-42650B701D2C61E330B5FBB7C1256743" unitRef="usd">-800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-2FC75A388FA7653F52371749585DDAEE" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-CE514012A1102C0A67E2FBB7C0D78D6F" unitRef="usd">-195600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4" decimals="-5" id="Fact-FF6138412D5C178EB1E9FBB7C098B035" unitRef="usd">-319900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-1CE759914ED7260A4B96FBB7C0B70B25" unitRef="usd">-32700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-C82C4D81058EF86F3E42FBB7C163CA84" unitRef="usd">57800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-4DA414B3782EDA49339BFBB7C115F943" unitRef="usd">-10800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-91890C2D85FA97C5A2F417496295A63A" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-259B991AF51CC50CFBB6FBB7C0B74F8D" unitRef="usd">-334200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4" decimals="-5" id="Fact-5C3A3C4C14D0E94A5E86FBB7C0985BE9" unitRef="usd">-318400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-B3BBFA9A582EE345A6D3FBB7C144C7E9" unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-2E150CAB1E7D6206E846FBB7C098E97D" unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-17CBCA237DE35E95E79DFBB7C098F35C" unitRef="usd">-1600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-66AE3778DC26F852F9831746DD2D66E1" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-FA4F085A4793AD6F4056FBB7C0B7C1A2" unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="-5" id="Fact-E617878AA139F550FB89FBB7C125FA80" unitRef="usd">-240400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-86DA1D202F92906D139EFBB7C14426D4" unitRef="usd">-31300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-D82F6C7A8398417A5F7BFBB7C15321F7" unitRef="usd">34700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-1ED365C4FCDB1D0F4EC9FBB7C14472AD" unitRef="usd">-4000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-5B092FA02720B7244F771747180BAE09" unitRef="usd">3500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-92B898B796A3693D306CFBB7C098E640" unitRef="usd">-243300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate" decimals="-5" id="Fact-72EF1018174888BA1BFE174693771085" unitRef="usd">-316900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-A380F70494732FD3CE9117468D741B4C" unitRef="usd">-36800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-6BD3AF43378B30E7F4CA174687D26CDA" unitRef="usd">-104500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-249349770E6A60792E44174685281B32" unitRef="usd">-100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="0" id="Fact-300D6B6DF23F0BC7561517468B147B1C" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="I2018Q1ASUadoptiondate_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-96691017B62EC9B406DE174690B9C843" unitRef="usd">-175500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q4" decimals="-5" id="Fact-46BB4EEC0195694EE249FBB7C098D085" unitRef="usd">97800000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2018Q4" decimals="-5" id="Fact-D075F26C14F04D7A61DBFBB7C0A836B9" unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1418D11FD149B15B3D23FBB7C0A8F238" unitRef="usd">600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-5CA62A3F87398CEF644DFBB7C0983A5F" unitRef="usd">-600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-FD933E4D01E823B517ADFBB7C0D75399" unitRef="usd">600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation>
	<us-gaap:AdvertisingExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F61D49CB28F3DA35DF0EFBB7C0C76B64" unitRef="usd">106300000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0D34C06FF8BBFD42B20EFBB7C115DB71" unitRef="usd">75200000</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-0F81FAF3C7E630B1D614FBB7C0B7583D" unitRef="usd">90200000</us-gaap:AdvertisingExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C0E3112677035B82ACFFFBB7C0C7AEB9" unitRef="usd">-169400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-884168C96879657513B4FBB7C153557B" unitRef="usd">135800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-FC941F1154A8A991DCF7FBB7C07964E0" unitRef="usd">84500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-3B28EAFD2390DD7B5A37FBB7C1449DF7" unitRef="usd">-1800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-85C72F0FE8FC3C0FF250FBB7C0F67296" unitRef="usd">121700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-264D0731F1C46A7EB130FBB7C134DD34" unitRef="usd">16300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-769B24B2D171F8883C10FBB7C0B71841" unitRef="usd">11100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-737A6177FF09260D9AA7FBB7C1254655" unitRef="usd">38400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-5" id="Fact-5592DD442207BBD8F7CBF0B4B56AE286" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-EDB837F37CEB8CD81F1FF0B4B2E12BC6" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" decimals="-5" id="Fact-2B75E5B940A9C2118952FBB7C134FABD" unitRef="usd">18600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-776A0C24A1A6D7033D90FBB7C172709F" unitRef="usd">120000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-813252807F5C2353127CFBB7C0D7D0C9" unitRef="usd">-169400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A8825843EAD5668BC3CAFBB7C0E6C664" unitRef="usd">138100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-9A9E021915F9E1B02025FBB7C0E67254" unitRef="usd">117300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-FABD5533803D69174269FBB7C153D33E" unitRef="usd">74000000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-9B9E9F50D578C50BA3C4FBB7C0E60B01" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-63B7E42E74FFB0A65B80FBB7C0E6CC15" unitRef="usd">95700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-A3922978D5E46FCD5C72FBB7C0A873EC" unitRef="usd">18400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-FAFC2B02E4AFC9ECD342FBB7C0A8BFD4" unitRef="usd">9300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-8F9A28B6908132C3FD46FBB7C1638916" unitRef="usd">22400000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-5" id="Fact-D1D4E6E107C3DC2E7FE9F0B48DC12BF1" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-FC311A5119086A05D447F0B48A3F4EA1" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" decimals="-5" id="Fact-466FA4F1692EB85F10EAFBB7C14461A2" unitRef="usd">12300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-D6BBAA5E173320AEE7B2FBB7C0A89E02" unitRef="usd">107300000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-E8BC86D0D24CF99480C0FBB7C0891197" unitRef="usd">138100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-EBBDF41D027E7E38F0C2FBB7C153327F" unitRef="usd">168700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ParentMember" decimals="-5" id="Fact-3CB1B2868E5E1A32C3E1FBB7C0E6BF6B" unitRef="usd">142600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-1E8F934EA8402577CB6EFBB7C10531A9" unitRef="usd">75800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember" decimals="-5" id="Fact-14359CA45BA388F1B29CFBB7C0D75424" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-5" id="Fact-5F0DD11A228A104BCF1EFBB7C0E69E69" unitRef="usd">105800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-BD638102D593E6EC7A4FFBB7C0B78B66" unitRef="usd">7800000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_EmployeeStockPurchasePlanMember" decimals="-5" id="Fact-DCA27224F0CE59DFB62FFBB7C12576E4" unitRef="usd">10500000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-67F982E02B3D3D77BC7DFBB7C144E9B2" unitRef="usd">27200000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-5" id="Fact-A42D5A298322CAC7384EF0B1ABCAB950" unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-0B0E8D22E3CE41C20964F0B1A9A24F23" unitRef="usd">4700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_PerformanceUnitsMember" decimals="-5" id="Fact-0D634796062E446180A3FBB7C163F132" unitRef="usd">3100000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-2EDEC6C69F42E0BBA6BAFBB7C0A8B30B" unitRef="usd">126600000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-21DFD41C82D582CB3A2AFBB7C163448A" unitRef="usd">168700000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-11F4547711F9D6A698F4FBB7C1826ABC" unitRef="usd">204400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BAB092B7675DB631AD78FBB7C1254416" unitRef="usd">169700000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-127481DF2C802E1B0323FBB7C134621D" unitRef="usd">181600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D34A9FB647A126F831E3954CFB39685E" unitRef="usd">373400000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-949CAED2162982E12C82FBB7C13470C2" unitRef="usd">328200000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-F3A0E0AF30124A79759E1DEEF9C6DA5E" unitRef="usd">328200000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-50739DD17C9A843198C4954CAF575BDC" unitRef="usd">455300000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_PLSRMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-FF90067A4F27D68C8991F0928193CFE9" unitRef="usd">60000000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-B91CD09AD86D2DA65C7E1DE84FF4E86E" unitRef="usd">129300000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-997F1C0438967A5F9DBEF56FB03A0BD5" unitRef="usd">189300000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-2669D747BFB9DC51101DFBB7C13498EA" unitRef="usd">176800000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-0011987200D7F266E989F093725EB1D5" unitRef="usd">176800000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q4YTD" decimals="-5" id="Fact-32CBB99A37BE0F461353954B26BA462C" unitRef="usd">381200000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-5" id="Fact-BC9C7625449DA9181ADDFBB7C0F637CC" unitRef="usd">23652600000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-5" id="Fact-E5A88BD37C2FE8D3377FFBB7C0C70E65" unitRef="usd">25288900000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-D49F1B34D5F854DF34F2FBB7C0799F36" unitRef="usd">7873300000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-0C8C05530AA26F3511F9FBB7C0B7B999" unitRef="usd">7640900000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0A00A11785ECEF5DB292FBB7C0C7A53B" unitRef="usd">11800000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B5A9DAC331C803075510FBB7C0D773DE" unitRef="usd">6433100000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-586C21558706BC3BD193FBB7C0C7D884" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D5B301CD4B29C076FDC3FBB7C0C75C7F" unitRef="usd">6444900000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-39D0BCEC8347CBEDA0B9FBB7C0D7C5B5" unitRef="usd">51700000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E98633BE018BC59335E2FBB7C0B7F867" unitRef="usd">5050800000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-175BD8BC5690D4506112FBB7C0895EF1" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0F7C2A98BD02F6F9C98BFBB7C0A88224" unitRef="usd">5102500000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="I2017Q1Bioverativ" decimals="-5" id="Fact-9A0099A6AEAF3AB0D01FF05F90557D57" unitRef="usd">1008300000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4" decimals="-5" id="Fact-F481FC18828675D9A809FBB7C10556CA" unitRef="usd">5173000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4" decimals="-5" id="Fact-919BF180F8CDDCCB91D3FBB7C1158A88" unitRef="usd">3694000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4" decimals="-5" id="Fact-D562540586B21F00F6C5FBB7C0A8BAC3" unitRef="usd">5172500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-050A3423A613CE401274FBB7C0B71A79" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-ABE4AD7F4AB93E708653FBB7C08965E5" unitRef="usd">643400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3175392BDADC92D239DFFBB7C0891794" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-09285436D35ADFF8D3A3FBB7C1720037" unitRef="usd">643400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-97929496D058076C71EDFBB7C1634BF8" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-31A2154F1FB688CBDF9EFBB7C079E025" unitRef="usd">2609800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6D3679FFE929397CD57CFBB7C0790609" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4F1190140016805F783CFBB7C08919B2" unitRef="usd">2609800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6EC797FB9AEF2602090FFBB7C0980657" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DD22D717897634DA3BA3FBB7C079C988" unitRef="usd">1919300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6E6FD80A885586ABB600FBB7C089EC4D" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-30F9D692999823B96F92FBB7C0896855" unitRef="usd">1919300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-80682B9DA24182E682F6FBB7C0A8F3CE" unitRef="usd">1039300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-E57D4DAD45086A419E93FBB7C0A89C3D" unitRef="usd">1570500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-6A15A203B8EE04FB6EB2FBB7C0984524" unitRef="usd">1075100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-F20D9A2494DD8E9A76F5FBB7C1155089" unitRef="usd">844200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-D093FA4BA5FC3FE88AADFBB7C0B77472" unitRef="usd">800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-8F16079484321B126973FBB7C0C71FFC" unitRef="usd">642600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-F529551175AD33EB54AAFBB7C0B711D5" unitRef="usd">11800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4" decimals="-5" id="Fact-5D3643F2C7DD20496C31FBB7C0B7EB86" unitRef="usd">3689300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-89D2FF380A5094ED53C8FBB7C0D77772" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4223A54202F8CDD4001DFBB7C134B0AB" unitRef="usd">260500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-40ED31BC916EEC73DD35FBB7C0A8EB1E" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_AssetBackedSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-70F303A8545E3B6FB9C1FBB7C089B04D" unitRef="usd">260500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-C12DBB53076EED22A54BFBB7C134B26F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1811C5026C506905BA14FBB7C0980AED" unitRef="usd">2459200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B6BD2F839921F9FE171EFBB7C163F506" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-DBDD66BF0B5CE74D9A16FBB7C1347C52" unitRef="usd">2459200000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5F8EEA7D6772F3997446FBB7C079A7F8" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-48C76B150580CDB75E00FBB7C0F63C54" unitRef="usd">969600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B0798DD9F6ACACC5E9AEFBB7C08937C4" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasuryAndGovernmentMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8D11B9205F5199157143FBB7C0A8953D" unitRef="usd">969600000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-82417F743FA6E47073B5FBB7C0A8D4B2" unitRef="usd">1607500000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-9B1E8FEEF8AE4DD49C72FBB7C1252B93" unitRef="usd">851700000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-2D124E925DA60DD274D3FBB7C0F68FBB" unitRef="usd">705800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-7CE9E995472EB9C59FFCFBB7C0A8AEEE" unitRef="usd">263800000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-63D528B8FD1357D2B87DFBB7C134358E" unitRef="usd">100000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-E5D0034DAEC9C4B57F64FBB7C0E663D9" unitRef="usd">260400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-5574BEE9F1B6F1EF34A9FBB7C1345284" unitRef="usd">615400000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4" decimals="-5" id="Fact-57586B06C1311F10EA8CFBB7C0A8487C" unitRef="usd">2300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-AB79E6A05B7B68097E61FBB7C098A94F" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-9FC597EFA80BDE19DB2CFBB7C0A8F058" unitRef="usd">900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-76A0C71D1CC405448518FBB7C105FD3E" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-D02C7876805626AC0D21FBB7C0983984" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-7F92C8F51FB7831C6188FBB7C0985901" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-974BEF02B54A25FEF2CBFBB7C115C9BE" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-4090AEBCA62FC0E621ACFBB7C09882BB" unitRef="usd">1800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4" decimals="-5" id="Fact-8787AE386F5C51BF9D7CFBB7C0E60266" unitRef="usd">1300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-D4E3782F8719EAC51FEAFBB7C0A88F39" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-EA85ADAA0AA8A43FC5FEFBB7C0A876BE" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-107DEF50632D614719B3FBB7C1343E5B" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-44781FA8D997237598AAFBB7C153CE41" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-F76D87D5B5AD5B7E1D17FBB7C0B74263" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-397BA23C55735BF67ACAFBB7C1253282" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-F6D0097CD5C90CADCB67FBB7C0A89BFC" unitRef="usd">127700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4" decimals="-5" id="Fact-BE608E0ACBA91C477C73FBB7C0B798DD" unitRef="usd">2800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-324D6C5924F67F7F0BF9FBB7C0A819DF" unitRef="usd">200000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-C62F8A89CFF5F2D6337CFBB7C1153E5E" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-03332EB6274991984676FBB7C0B79076" unitRef="usd">700000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-92AFF959B6EE822D3580FBB7C098C428" unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-DC975CDA1FCBD0A8C0EAFBB7C1154D6D" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-1C3E4315B7658C2B887EFBB7C1058868" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-A4050B41FF832F01B760FBB7C0A8B3C3" unitRef="usd">4400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4" decimals="-5" id="Fact-3912EEF11B242CEEA995FBB7C125667B" unitRef="usd">6000000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-A5FF43F33E8E28B0DFDFFBB7C0B7010D" unitRef="usd">900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-49F191971B07EE9767D9FBB7C0988DCE" unitRef="usd">3900000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-84ABD8D69CEA930C040CFBB7C0F61813" unitRef="usd">400000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-22DE1EB4B95DEDC7510EFBB7C0A83D51" unitRef="usd">300000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-16BEC3CB744CD625A5DBFBB7C1341955" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-44BD0892348A1DC31E87FBB7C0A8425D" unitRef="usd">500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-AD13E928C54590D0BE36FBB7C153C376" unitRef="usd">8500000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-9D6ACD331AE5411B11F5FBB7C115BB44" unitRef="usd">5173000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-DAA6BEAA18B4075AA82DFBB7C1050CCA" unitRef="usd">1039500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-EE55EC98EBDF15B54363FBB7C0A8F41F" unitRef="usd">1569600000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-9C70F10EEB669B845749FBB7C0A8B4F1" unitRef="usd">1075700000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-909E0F5EFA0995E1E9B7FBB7C0A866AE" unitRef="usd">845100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-9CC65F2A6DE8E09E7531FBB7C0A8CA5E" unitRef="usd">800000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-B6D9E480D4B1515DD4F8FBB7C09896B5" unitRef="usd">642300000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-2096AC0D2AEEC064C4EBFBB7C0A88DAE" unitRef="usd">14400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q4" decimals="-5" id="Fact-EC00FFF0AFBB30A2C78AFBB7C0E6FF1F" unitRef="usd">3694000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesCurrentMember" decimals="-5" id="Fact-D23F3ED41C195D3F1EC5FBB7C125694D" unitRef="usd">1608400000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_CorporateDebtSecuritiesNonCurrentMember" decimals="-5" id="Fact-80DE57C52C8F07699BACFBB7C153BC97" unitRef="usd">854900000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesCurrentMember" decimals="-5" id="Fact-DA845D1B99ED2403FA04FBB7C0E6BB24" unitRef="usd">706100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_GovernmentSecuritiesNonCurrentMember" decimals="-5" id="Fact-3F3933BE742365D63FD3FBB7C0E626F1" unitRef="usd">264000000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" decimals="-5" id="Fact-ADFA6C5DE0FDFBC81AD6FBB7C0D7337E" unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" decimals="-5" id="Fact-70A152D6B90EC68CFEC5FBB7C144953E" unitRef="usd">260500000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesAmortizedCost contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" decimals="-5" id="Fact-FB26148AA2FAE16B8ABEFBB7C0F65447" unitRef="usd">496200000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-CA4A06DD09168411DF08FBB7C079726F" unitRef="usd">2115200000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-5F8A8F64938B6F945895FBB7C0C7054C" unitRef="usd">2313400000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-D6FBC0341652CE6E3E44FBB7C1341091" unitRef="usd">2730000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2018Q4" decimals="-5" id="Fact-E73E7629A2C1797B4124FBB7C144AB83" unitRef="usd">1235900000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-33C1AB0A1D22C0148AA2FBB7C098B5FC" unitRef="usd">2730000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2018Q4" decimals="-5" id="Fact-C1BE833DBAB296A77455FBB7C079FE42" unitRef="usd">1232700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2017Q4" decimals="-5" id="Fact-F0F716D3EAF70C4E595CFBB7C11591DE" unitRef="usd">2116000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2018Q4" decimals="-5" id="Fact-0B8724B7AE7D392A0376FBB7C1251DF5" unitRef="usd">2314600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-D5AD1EF09FDB1D2C5984FBB7C144BD85" unitRef="usd">2115200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2018Q4" decimals="-5" id="Fact-4D414AAC0DFCC5C5CE76FBB7C0897E17" unitRef="usd">2313400000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6A2F50223369423B3294FBB7C13430BD" unitRef="usd">3300000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2017Q4YTD" decimals="-5" id="Fact-6648D668D69F54CAF050FBB7C0C7E817" unitRef="usd">3000000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedGains contextRef="FD2018Q4YTD" decimals="-5" id="Fact-F51FF27A1F3ECD86EE00FBB7C1538822" unitRef="usd">3200000</us-gaap:AvailableForSaleSecuritiesGrossRealizedGains>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1CB2CC7628B7844D90D2FBB7C0D7358C" unitRef="usd">4300000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E872AAAE248199FA820FFBB7C0C7A19B" unitRef="usd">22400000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses contextRef="FD2018Q4YTD" decimals="-5" id="Fact-5C9320D4C631C1E86D12FBB7C13486C0" unitRef="usd">11700000</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-2F1B92E45B6C40818F67FBB7C089C51D" unitRef="usd">3057300000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-388F164B3AB139E543A1FBB7C0D7DD7A" unitRef="usd">1375900000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:BuildingsAndImprovementsGross contextRef="FI2017Q4" decimals="-5" id="Fact-3FCE6EDA404DA7FDD7A6FBB7C069C17F" unitRef="usd">1213600000</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BuildingsAndImprovementsGross contextRef="FI2018Q4" decimals="-5" id="Fact-91761C2D26DCF81C41A2FBB7C17291A9" unitRef="usd">1282800000</us-gaap:BuildingsAndImprovementsGross>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2013Q2_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-DAB4C8351CD3A97B8C7EFBB7C105167A" unitRef="usd">15000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2018Q4" decimals="-8" id="Fact-B89B6EA7715194B6B170FBB7C105184E" unitRef="usd">1000000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-C19A87B2BE66BEBE2744FBB7C098BEE7" unitRef="usd">335000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-FC5BF4FF112B4D4E87E2FBB7C0E6E984" unitRef="usd">400000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-785DA07A49FD80234B9EFBB7C1151E30" unitRef="usd">306500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-7AED4F85193E9AE1CD0BFBB7C1051A8E" unitRef="usd">450000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2016Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-2A0DCACC3E7DC1E0D8C3FBB7C125B716" unitRef="usd">467600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-C392C3001DA1CF32C77CFBB7C0F674B3" unitRef="usd">102200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-5EA1447648F8C56B4712FBB7C098B0D7" unitRef="usd">259000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-8C393DC839FC19B6AE71FBB7C0D73CC2" unitRef="usd">162400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E51AEA602537C6F85EC0FBB7C0C735A4" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-405FE534D644DE5BBFCBFBB7C0B701AE" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F49E12CE9E9BF07D8D50FBB7C0B7A55D" unitRef="usd">523600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-92FF83175CF7BB9A6B91FBB7C0B7F9FC" unitRef="usd">523600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-D8B28B8C2BAC92CB8C3FFBB7C144810B" unitRef="usd">80200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-FCF45DF3BE77FB1F1CBBFBB7C0F6AC43" unitRef="usd">246600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_AccruedLiabilitiesMember" decimals="-5" id="Fact-C561111049DC3BD81697FBB7C0F6FE06" unitRef="usd">144800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-B0DBB801E94483C7935EFBB7C115A730" unitRef="usd">83000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-647FDE73CE29D1452840FBB7C1050452" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9475C08A4EEB49345F4EFBB7C0C7AA9C" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9F37354B814B0E998079FBB7C07987CD" unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3D20081FEDABB6556165FBB7C182C0C7" unitRef="usd">409800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-9C874B73EFD98ABD84CFFBB7C1153133" unitRef="usd">844600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-B23189462F8D0D6320CBFBB7C0D7634B" unitRef="usd">444800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2017Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember" decimals="-5" id="Fact-A9AAC01D45B7D2FEE5E8FBB7C098E68D" unitRef="usd">279000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="FI2018Q4_us-gaap_ContingentConsiderationByTypeAxis_us-gaap_OtherNoncurrentLiabilitiesMember" decimals="-5" id="Fact-8FA9019E4D856CD7F360FBB7C0E6AE99" unitRef="usd">265000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="I2015Q1ConvergencePharma_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-F541F4B3627E3DA6FEB0FBB7C0A84412" unitRef="usd">424600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-5" id="Fact-B8F30374DDEC6BB4E067FBB7C1720852" unitRef="usd">1308000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-5" id="Fact-80E9254E74B1D83271F3FBB7C1722A8D" unitRef="usd">2326500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-5" id="Fact-D12957DCA4FA50FB7FEDFBB7C0D79CA4" unitRef="usd">1573800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-5" id="Fact-844CC564ED02C3013377FBB7C0D7D333" unitRef="usd">1224600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-1509B1464319AC302C1AFBB7C0792946" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-33C6CED9F9BDC0E86833FBB7C0F6510E" unitRef="usd">1229400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-20FD23AC2D0309B8DC1CFBB7C079B7DF" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-74EB24B2321322D429A3FBB7C0C7BA34" unitRef="usd">1229400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-46CB7D6C8E407FA8E876FBB7C1255AF3" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-A64E9319DACED71D950CFBB7C1340FB0" unitRef="usd">705500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-E41C6F30D192D985C0ECFBB7C0D7883B" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3B2C07D48361D2BC66EFFBB7C0A80D87" unitRef="usd">705500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="FD2016Q4YTD" decimals="-5" id="Fact-D563D5A3D72CFC3FB844FBB7C1639DDD" unitRef="usd">1049800000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B200F8A458828E8006B6FBB7C17247B4" unitRef="usd">-792100000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="FD2018Q4YTD" decimals="-5" id="Fact-E61689FFB1E74AE03660FBB7C163B942" unitRef="usd">-330600000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-5" id="Fact-97FD612248A570F20F22FBB7C134AC9E" unitRef="usd">1229400000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-62DABE453B4AA5A8D535FBB7C1348A2C" unitRef="usd">30500000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-288921B7FAB0E83EE817FBB7C0F62E97" unitRef="usd">247300000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-4160390F0C7765BCB338FBB7C144246E" unitRef="usd">948000000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2017Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-48C4DFA49EBBDEAAB0C9FBB7C144429E" unitRef="usd">3600000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-5" id="Fact-CFDFCC5DF1D9F0962D06FBB7C0E60154" unitRef="usd">705500000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommercialPaperMember" decimals="-5" id="Fact-95F2ABEAF0AAFB819EBAFBB7C1346226" unitRef="usd">231200000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" decimals="-5" id="Fact-483A70989369834BD28AFBB7C0F61665" unitRef="usd">194800000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_MoneyMarketFundsMember" decimals="-5" id="Fact-8CC223F752168CFD6AEEFBB7C1257B46" unitRef="usd">279500000</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CashEquivalentsAtCarryingValue contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_RepurchaseAgreementsMember" decimals="-5" id="Fact-CDFED12D2F95EF9921EFFBB7C13412E7" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q4" id="Fact-199B96ADCBA95D923F25FBB7C105EF97" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-07D67F3AF13FE4A5884BFBB7C0897532" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="4" id="Fact-2BE3DF0D1D80E31ACAADFBB7C0C7D827" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="4" id="Fact-0EEB31C73CB09F089B0AFBB7C0B76B24" unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="-5" id="Fact-FA0094EF8417626939F5F0A92A366FCF" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="-5" id="Fact-EC0CC2ACA014E5D7134AFBB7C0897986" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="-5" id="Fact-ECA2EFB5D7D957BFC237FBB7C079C8A2" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="-5" id="Fact-B7786579F9BE63C434DBF0A92B4797D8" unitRef="shares">238500000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q4" decimals="-5" id="Fact-8AD6FFF0A2C75289003FFBB7C08982AE" unitRef="shares">235300000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="-5" id="Fact-02C0A1173C4489620AB8FBB7C089AFF1" unitRef="shares">221000000</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="-5" id="Fact-6B368401D6BFC8C1C40DF0A92C74FF47" unitRef="shares">215900000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="-5" id="Fact-5B10A4A7A37FC5F8FB3FFBB7C0890805" unitRef="shares">211500000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="-5" id="Fact-3E2314A24E23AA374BDCFBB7C089B905" unitRef="shares">197200000</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-5" id="Fact-3C65F6C6B679D3FD5A59FBB7C0E67196" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="-5" id="Fact-069BEBF64369FCA635D5FBB7C0C7944D" unitRef="usd">100000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F834D9AF60DD60C35F1AFBB7C0E6299E" unitRef="usd">3606900000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-527E3580DB551B4D7E01FBB7C1058602" unitRef="usd">2540600000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-03C767EAFBAA84CAA0FCFBB7C0C7EAE2" unitRef="usd">4507200000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1FD2F6D0CBC9E3AEAAAEFBB7C1346676" unitRef="usd">-7100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3D7DB8B3931FC12F9845FBB7C0E661B5" unitRef="usd">131000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="-5" id="Fact-791C7A37EDB5742B1581FBB7C10502CE" unitRef="usd">42900000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-137662030D99C669355DFBB7C0F60E8E" unitRef="usd">3599800000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-5" id="Fact-30BF930396F9A95DEB1FFBB7C11559DA" unitRef="usd">2671600000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="-5" id="Fact-4C423F2A103373EC4007FBB7C1441EFF" unitRef="usd">4550100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ConstructionInProgressGross contextRef="FI2017Q4" decimals="-5" id="Fact-20ED9D6FF5CD29253560FBB7C0A851E1" unitRef="usd">1276000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2017Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-8" id="Fact-2764C19ABE0238E9CE1CFBB7C1258963" unitRef="usd">1200000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2018Q4" decimals="-5" id="Fact-725D8C30CE428ECECAF3FBB7C0A8F699" unitRef="usd">1758500000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-8" id="Fact-114DF5C26E607D27F2AFFBB7C1250C1A" unitRef="usd">1600000000</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-04BA9FDD1381553D3D69FBB7C163241D" unitRef="usd">159700000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2017Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-299E487BC141986D34F1FBB7C134B13C" unitRef="usd">150000000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-5ED98C0EECEB7092D961FBB7C0B776A0" unitRef="usd">125200000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-0B43435C633130198D54FBB7C0D7A884" unitRef="usd">100000000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2016Q4YTD" decimals="-5" id="Fact-321018D1EC1238FECDCFFBB7C10548DB" unitRef="usd">1478700000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-B8AD0562C1D4FC630D01F14E89AD3AFF" unitRef="usd">500000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2017Q4YTD" decimals="-5" id="Fact-9E4B02CAB39A35D2E603FBB7C15306FD" unitRef="usd">1630000000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-20B41C254A4FC116C248FBB7C1342462" unitRef="usd">112400000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2017Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-E61A039C64B5C544F651F0666AC82132" unitRef="usd">15100000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2018Q4YTD" decimals="-5" id="Fact-EB145BFC6C63D588FDF2FBB7C0F601E3" unitRef="usd">1816300000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-4DC50905AAF86F4D0809FBB7C069C39A" unitRef="usd">238000000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2018Q4YTD_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-EAE08C5A308D8F9D4990F065749DFEB6" unitRef="usd">180400000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q4YTD" decimals="-5" id="Fact-801949D53B34648C1353FBB7C1055075" unitRef="usd">6297100000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-ECB5F9CAEA59A4712C39852CD16203E1" unitRef="usd">50000000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q4YTD" decimals="-5" id="Fact-839949431375DE8E9002FBB7C17215BB" unitRef="usd">6928100000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-D3601D54724D2C2DEF83852CD162693A" unitRef="usd">92600000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2018Q4YTD" decimals="-5" id="Fact-F880F936E5378CF9757EFBB7C0D79BEE" unitRef="usd">7564300000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-03DFAB7F6E31064CB506852CD162E10F" unitRef="usd">25300000</us-gaap:CostsAndExpenses>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="FI2018Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_biib_DeferredtaxliabilityMember" decimals="-8" id="Fact-BC0C6616BD4B3A5CFEB281C74AAC4A60" unitRef="usd">400000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member" decimals="-5" id="Fact-A2EBEE9DE2B086BB58CD174682339D27" unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_BalanceSheetLocationAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-31C06A29C13BCF7B17A2BAB53ED0EBBC" unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember" decimals="-8" id="Fact-2AB48D52AC983660F5651D39A47D49CE" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-8CB9358D28D530AFF86017467A989769" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-52AAAD14F434FB6702CE174670597D7D" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-D0386C7A1E8BC695EF9317466C37C985" unitRef="usd">1500000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-4443F3B93BD205D98D491746762D51DF" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-B7A3B7737A31F7F5A39717467ED216AE" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_biib_DeferredtaxliabilityMember" decimals="-8" id="Fact-2E2C374EB6AABC5FFA501B6F9AAEB636" unitRef="usd">1500000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredIncomeTaxChargesMember" decimals="-8" id="Fact-0FE509A18C12E322121CFBB7C0F68A55" unitRef="usd">500000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_DeferredTaxAssetDomain" decimals="-8" id="Fact-AFE51AC8237E7E2A2F7E1B6F3D72CA88" unitRef="usd">2000000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1ASUadoptiondate_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_BalanceSheetLocationAxis_us-gaap_RetainedEarningsMember" decimals="-8" id="Fact-804569D80DDD4B902CE6FBB7C0F6FBB9" unitRef="usd">500000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-FC83045A0F324231ACFFFBB7C0B7E37D" unitRef="usd">1304300000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-C9321CB024BCD644909EFBB7C0D769AB" unitRef="usd">2201400000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-AE7360E4FDA9E42262BBFBB7C1531416" unitRef="usd">1131800000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-835F45C399BFE66E0382FBB7C1723B38" unitRef="usd">52900000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BF26716B0E74A8C07551FBB7C0B740F2" unitRef="usd">108600000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-3719B2065ACD0F21A628FBB7C1446AE2" unitRef="usd">140000000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3F81619EAB6A76D32E16FBB7C098A2CE" unitRef="usd">1412300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B39676B984A4E97116B9FBB7C163F120" unitRef="usd">2367000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-FF03C348340CBDC974E0FBB7C0F674C4" unitRef="usd">1317300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A90FE54B88AEF114E2C8FBB7C0796E72" unitRef="usd">55100000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2FE7B7BC076052556735FBB7C0981128" unitRef="usd">57000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-9C6238979ABBF5DB47C8FBB7C1631D3F" unitRef="usd">45500000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-00818777C21D98A42D68FBB7C0D72CE0" unitRef="usd">3200000</us-gaap:DebtCurrent>
	<us-gaap:DebtCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-E46854F68164DC0D1045FBB7C1253EC1" unitRef="usd">0</us-gaap:DebtCurrent>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-7" id="Fact-D4183F5F6E4FA78F51FCFBB7C0F6DBB6" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-7" id="Fact-A3014875D2D7027B8E65FBB7C1448AC5" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-8" id="Fact-F350A5CC82545DBA5C05FBB7C0791BB1" unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-8" id="Fact-0D8C6DB950A787C11BECFBB7C1443C48" unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-957EB909DEF9A5BD2188F09E256A0897" unitRef="usd">550000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2017Q4" decimals="-5" id="Fact-AF5483D865399542DAA1FBB7C105D69A" unitRef="usd">6483300000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentFairValue contextRef="FI2018Q4" decimals="-5" id="Fact-605155C07B440D24DE63FBB7C182DD17" unitRef="usd">6037600000</us-gaap:DebtInstrumentFairValue>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-EE445A10475BEA5A631FFBB7C079D664" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-A6C271D16E438BC170CAFBB7C1530584" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-32F10B38935DBF233995FBB7C0799EF3" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2015Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="4" id="Fact-A7BC27FB25F6FF56E452FBB7C134429A" unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="INF" id="Fact-527289A3619F041E5C4BFBB7C153831E" unitRef="number">0.052</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="INF" id="Fact-CC25EB4676F456D1F05DFBB7C153214B" unitRef="number">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="INF" id="Fact-0154F911377FAC1801EAFBB7C153DAAC" unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="INF" id="Fact-310F10F8AF22345769C7FBB7C153F06D" unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2008Q1SD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="INF" id="Fact-9EE3FEBEDE8BCCD7AFD1F09D03BBFA4E" unitRef="number">0.06875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentMaturityDateDescription contextRef="FD2018Q4YTD" id="Fact-612120CB8B1C3526C1D1FBB7C0D7EF21">less than 90&#160;days</us-gaap:DebtInstrumentMaturityDateDescription>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="FD2018Q4YTD" decimals="INF" id="Fact-AE3AEE54FDCF3E870305FBB7C144E537" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" decimals="-5" id="Fact-07F1921EBFB53BD28FE5FBB7C0791DB8" unitRef="usd">109800000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
	<us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" decimals="-5" id="Fact-08683E0CB65C03CD6481FBB7C07974C1" unitRef="usd">109300000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7BC44E2D033C05A86047FBB7C163DF79" unitRef="usd">-125600000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-723875FF19A3B49F802FFBB7C0A8134E" unitRef="usd">241000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-7A246F6E05678D9C6C08FBB7C1341FD1" unitRef="usd">-62000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-90CFE5CCA0C6C2FA559AFBB7C1821D4B" unitRef="usd">-45600000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5F51DE35D9D7D11EF854FBB7C1150202" unitRef="usd">-159200000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-5963453C167FC4D24702FBB7C105A95D" unitRef="usd">177700000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6DDAB2D75BB4218A84F7FBB7C172373A" unitRef="usd">-175000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B9ED51AD97A0B49B144DFBB7C163DF55" unitRef="usd">91700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-36E6AEDFDCAB5336A50EFBB7C16319A3" unitRef="usd">108300000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A6D6B4AE43F04F8D531AFBB7C0F6080B" unitRef="usd">-3800000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-224CC7CA6FEE22F9CB2FFBB7C1723496" unitRef="usd">9900000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-CF071E42F10C7067DA28FBB7C0E6A8FB" unitRef="usd">-7400000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2017Q4" decimals="-5" id="Fact-72DB81F9C0E55672B497FBB7C0C77825" unitRef="usd">378800000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="FI2018Q4" decimals="-5" id="Fact-CCE4F3175F629CB158EBFBB7C0B784F8" unitRef="usd">2298600000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2017Q4" decimals="-5" id="Fact-32AEF8B33433D7814913FBB7C0B7E274" unitRef="usd">147800000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsInventory contextRef="FI2018Q4" decimals="-5" id="Fact-344FC8EF5915530D358EFBB7C0C7C9B5" unitRef="usd">163900000</us-gaap:DeferredTaxAssetsInventory>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-1E57B7A2AEEFEDA546FA11739328CB98" unitRef="usd">595900000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-025221A7B5C841F41EAD117360B30F73" unitRef="usd">2153900000</us-gaap:DeferredTaxAssetsLiabilitiesNetNoncurrent>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2017Q4" decimals="-5" id="Fact-D1CC0EF8CDE0332C1D4CFBB7C0C733C5" unitRef="usd">831800000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2018Q4" decimals="-5" id="Fact-EC4C08ED3E101EAFF1FDFBB7C0C71712" unitRef="usd">2823100000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2017Q4" decimals="-5" id="Fact-F2DE758699F1AE60C462FBB7C0C70D5D" unitRef="usd">209800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2018Q4" decimals="-5" id="Fact-C5EEC1149263AAB48243FBB7C0C7698E" unitRef="usd">213100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-65A59F6B631DC3409C7DFBB7C0D74100" unitRef="usd">4600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2017Q4" decimals="-5" id="Fact-17A5035D8DEDDE22A5AFFBB7C0B7BCDB" unitRef="usd">25100000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2018Q4" decimals="-5" id="Fact-D2954D7E42CD60DA4966FBB7C0C74940" unitRef="usd">38900000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2017Q4" decimals="-5" id="Fact-C242779319A71CB602FBFBB7C0B71960" unitRef="usd">60000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="FI2018Q4" decimals="-5" id="Fact-6E5124FE0948444F1E27FBB7C0B79E9B" unitRef="usd">102800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2017Q4" decimals="-5" id="Fact-4D8198097B6E946457C5FBB7C0C7A1CE" unitRef="usd">26900000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2018Q4" decimals="-5" id="Fact-67E171701498F3C99490FBB7C0B7DDEA" unitRef="usd">25800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="FI2017Q4" decimals="-5" id="Fact-5B0A9D5DADB07B000356FBB7C0C7EDD9" unitRef="usd">48800000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_biib_PrepaidtaxesMember" decimals="-5" id="Fact-9506BC065D47BCDC074BFBB7C0D7AD7D" unitRef="usd">142600000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-5" id="Fact-DDA8730586CF2728EA71FBB7C0B72495" unitRef="usd">16600000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2018Q4" decimals="-5" id="Fact-1B500C2E9450813DCC52FBB7C0C75614" unitRef="usd">20000000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2017Q4" decimals="-5" id="Fact-09901B4B599FB1F00F04FBB7C0C72BA1" unitRef="usd">358600000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2018Q4" decimals="-5" id="Fact-0D33B04920007DE91F8AFBB7C0C77F23" unitRef="usd">2305400000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2017Q4" decimals="-5" id="Fact-B71BCC16374709668CA5FBB7C0C7CFA0" unitRef="usd">250700000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2018Q4" decimals="-5" id="Fact-AB630353FDC680EE55DBFBB7C0B7C655" unitRef="usd">232800000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-EA6A46E37BD0D4F69469FBB7C0B78C8F" unitRef="usd">122600000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-06F2A373DF74B3892394FBB7C079A3DA" unitRef="usd">1636200000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
	<us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-768A63D256B0480E979A1B6AD2E236AE" unitRef="usd">989600000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
	<us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-A249F2DF152A0F5BC28F1B6BE2130CF5" unitRef="usd">697000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2017Q4_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-BC26356D3A4B53044871FBB7C079E3BC" unitRef="usd">83700000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2017Q4_srt_StatementGeographicalAxis_country_DE_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-6488396A98455ABEF3B9FBB7C079A204" unitRef="usd">43500000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2018Q4_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-C2F6F9FF7E56CA7B01B7FBB7C0790FB8" unitRef="usd">93100000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanBenefitObligation contextRef="FI2018Q4_srt_StatementGeographicalAxis_country_DE_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-3E121748DDA3850483A6FBB7C0798F2A" unitRef="usd">45300000</us-gaap:DefinedBenefitPlanBenefitObligation>
	<us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="FI2017Q4_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-4AC7C33EC5B80851092FFBB7C079E9B6" unitRef="usd">48300000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
	<us-gaap:DefinedBenefitPlanFundedStatusOfPlan contextRef="FI2018Q4_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-C0992A883C51F69391A3FBB7C0797977" unitRef="usd">48600000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2016Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-928636E45B1112F698EC855997CC9FD6" unitRef="usd">1100000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2016Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-62B1DCCEDA6BF351C406FBB7C07979A4" unitRef="usd">4200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-58EDFE023EE8EE4046548558F4925A39" unitRef="usd">1400000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-801F9D0F62420AA65067FBB7C079FA38" unitRef="usd">5200000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-84F5C0096B7BF2D8988885584AF07436" unitRef="usd">1500000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_DE_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-C03B694845A2F79DEE30FBB7C079EB68" unitRef="usd">5300000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2016Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" decimals="-5" id="Fact-40C773F6494C2CA77EABFBB7C07933CC" unitRef="usd">45200000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" decimals="-5" id="Fact-2A7943E023125C887970FBB7C079FDB2" unitRef="usd">42600000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_DomesticPlanMember" decimals="-5" id="Fact-F02C8048E99BADD09A02FBB7C079D5A3" unitRef="usd">42200000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:Depreciation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9284B71EB0ED6EBDBFC4FBB7C1255B0D" unitRef="usd">309300000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-91B873F873BD7EE84650FBB7C125ADF2" unitRef="usd">266300000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2018Q4YTD" decimals="-5" id="Fact-417C815AA4F31982733FFBB7C1256143" unitRef="usd">269400000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q4YTD" decimals="-5" id="Fact-191D1351200D694F92FBFBB7C172FCEB" unitRef="usd">682700000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q4YTD" decimals="-5" id="Fact-1ADC2D03372A4846153BFBB7C17245AF" unitRef="usd">1081000000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q4YTD" decimals="-5" id="Fact-58C782282051838D2C04FBB7C163EF04" unitRef="usd">1016600000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-DEB6D0C9ACDD76265393FBB7C1728C40" unitRef="usd">700000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-FA2D69CAD6A92C69D13AFBB7C17229E7" unitRef="usd">1800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherInvestmentsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-8F09657F916375533790FBB7C1724A30" unitRef="usd">200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" decimals="-5" id="Fact-7FC6B5038A60A169A43D8222DC4FB4D3" unitRef="usd">10100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-75BE52346896648B634DFBB7C0E6C343" unitRef="usd">65800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-9C2EC59B0E1EE65F311FFBB7C0E6A2EA" unitRef="usd">1100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" decimals="-5" id="Fact-F50002ECAB8D1A53E64EFBB7C1440A0A" unitRef="usd">14500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-73743927F44AF786731C169155BDF07A" unitRef="usd">84700000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-A7D3E6EFD62581FF8DBEFBB7C1820A0B" unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-72559CA750C1A72C5A39FBB7C17256BD" unitRef="usd">23600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-CF7372E6514ACFAC4384FBB7C0F6C638" unitRef="usd">6900000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccruedLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" decimals="-5" id="Fact-7CFF2DBB1777914DC5CFFBB7C0F64A34" unitRef="usd">3200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" decimals="-5" id="Fact-8ED01B45DE53E0CD24E1FBB7C0D7C004" unitRef="usd">14500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-65BB35B935A069E81CBAFBB7C153499B" unitRef="usd">-1500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-7C0458C5125B9D29184CFBB7C1447B5A" unitRef="usd">5300000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-885169066EB798C83E4AFBB7C1448ED4" unitRef="usd">600000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-0DCB281BEF3CAE49080EFBB7C144DDA4" unitRef="usd">-32500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-D2C2DD00773141F63C3816654D2644FA" unitRef="usd">200000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-F20F4A37BE5C79BB1FF81665462FB469" unitRef="usd">-42500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-25CE7233D9D93BCFD0E01688EF80E956" unitRef="usd">1500000</us-gaap:DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-EDB047673FA48C6C2C9AFBB7C125910D" unitRef="usd">100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2016Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-58584FA87013DCCB1774FBB7C1251FE2" unitRef="usd">2900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-520370E5D24D8200FB4AFBB7C153E9AC" unitRef="usd">-200000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-E1B66A045DA11F3C670FFBB7C153C1B2" unitRef="usd">8900000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsoperatingexpensesMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OperatingExpenseMember" decimals="-5" id="Fact-E5F3006E82D55075BF4D16660B9BF256" unitRef="usd">-100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_biib_CashflowsrevenueMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SalesMember" decimals="-5" id="Fact-4C99E81EA4D631CDBCFE166605DAFED0" unitRef="usd">10800000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-0BA70C8E989CDC2EF613FBB7C13478D2">P21M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-3C129F079F47BA840D91FBB7C1445CE0">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2018Q4YTD" id="Fact-2EC05F5D037F8EED0358FBB7C15376FE">P12M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-40576EC5B2F3A4D646D8FBB7C079CEBD">P12M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeRemainingMaturity1 contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-17626CFAEFE888DA99F9FBB7C1447F74">P1M</us-gaap:DerivativeRemainingMaturity1>
	<us-gaap:DerivativeTermOfContract contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" id="Fact-0A091D82F0CBA0E651B11E000DF1D9C7">P10M</us-gaap:DerivativeTermOfContract>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="I2017Q1Bioverativ" decimals="-5" id="Fact-9227230BD549867BDD48F05C18C57800" unitRef="usd">144700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent contextRef="I2017Q1Bioverativ" decimals="-5" id="Fact-6E9FEED5A1867C0F5986F05FD0D34021" unitRef="usd">87800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-A93E7C84639487D20FFCF053F2C500A8" unitRef="usd">302700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="FI2018Q4" decimals="-5" id="Fact-CB85F177EAB0735B233FFBB7C1349675" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="I2017Q1Bioverativ" decimals="-5" id="Fact-8FAE4D2B786EF986EA4AF05EFEA3BB98" unitRef="usd">314100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="I2017Q1Bioverativ_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-D9E12C4CCD2ADC1504BCFBB7C172D8FF" unitRef="usd">314100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="I2017Q1Bioverativ" decimals="-5" id="Fact-53AE7696DC3154BF3B44F05E98CA9628" unitRef="usd">56800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent contextRef="I2017Q1Bioverativ" decimals="-5" id="Fact-BE7797C2626AABAB9311F05CEBF31CC5" unitRef="usd">116100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets contextRef="I2017Q1Bioverativ" decimals="-5" id="Fact-9594CF868DE838A834C8F05F4EF041FE" unitRef="usd">53700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities contextRef="I2017Q1Bioverativ" decimals="-5" id="Fact-E66A71889E0BF5A0A96EF0600DD1A357" unitRef="usd">67700000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
	<us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="I2017Q1Bioverativ" decimals="-5" id="Fact-9FF95E8A2992C1CACB97F05E36D9D01F" unitRef="usd">20200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q4YTD" decimals="2" id="Fact-06511A78FA5F96803BEFFBB7C1532AE4" unitRef="usdPerShare">16.96</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q1QTD" decimals="2" id="Fact-FFCFF23C862B6196F895FBB7C089CED2" unitRef="usdPerShare">3.47</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q2QTD" decimals="2" id="Fact-EB6D11C64CF144DD46B2FBB7C0699CC2" unitRef="usdPerShare">4.07</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q3QTD" decimals="2" id="Fact-859C5716A16DAD7EAC2AFBB7C098C1F8" unitRef="usdPerShare">5.80</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q4QTD" decimals="2" id="Fact-0028FEED162A82672A56FBB7C079408D" unitRef="usdPerShare">-1.41</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q4YTD" decimals="2" id="Fact-E01DD0AB9CA5FF241F55FBB7C12516C6" unitRef="usdPerShare">11.94</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q1QTD" decimals="2" id="Fact-9D33C096A620E3F98617FBB7C0A87FBF" unitRef="usdPerShare">5.55</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q2QTD" decimals="2" id="Fact-8407DC3E4AFC339BC05FFBB7C098F2A9" unitRef="usdPerShare">4.18</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q3QTD" decimals="2" id="Fact-7343E0C5798CC6BFFD0FFBB7C0D76483" unitRef="usdPerShare">7.17</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q4QTD" decimals="2" id="Fact-F322BBD0A36A62A24F35FBB7C098E0E1" unitRef="usdPerShare">4.74</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q4YTD" decimals="2" id="Fact-02E28A24F8D232989CE0FBB7C10549E3" unitRef="usdPerShare">21.63</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-DCC98BF64E59701666FCFBB7C1530A14" unitRef="usdPerShare">16.93</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q1QTD" decimals="2" id="Fact-2486F75EBF1EA41E6F54FBB7C079FC3D" unitRef="usdPerShare">3.46</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q2QTD" decimals="2" id="Fact-D14D9695E0D9289BAC94FBB7C0A8C716" unitRef="usdPerShare">4.07</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-27F861A09FD86941093CFBB7C0890F7A" unitRef="usdPerShare">5.79</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q4QTD" decimals="2" id="Fact-CD2F267F79E57DCD8917FBB7C07974AA" unitRef="usdPerShare">-1.40</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-9BF409B4017C54018D15FBB7C0E63168" unitRef="usdPerShare">11.92</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q1QTD" decimals="2" id="Fact-DBA119DD72A6525D2A8BFBB7C0D7A486" unitRef="usdPerShare">5.54</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q2QTD" decimals="2" id="Fact-9FA8758F39CFA5CA4EC5FBB7C098256E" unitRef="usdPerShare">4.18</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q3QTD" decimals="2" id="Fact-DFF76D6D05BA9B9C5B28FBB7C098ADCD" unitRef="usdPerShare">7.15</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q4QTD" decimals="2" id="Fact-161250C5423CF1E135F6FBB7C0694C87" unitRef="usdPerShare">4.73</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q4YTD" decimals="2" id="Fact-2B9B285E9AA4D3415780FBB7C1053ABB" unitRef="usdPerShare">21.58</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2016Q4YTD" decimals="-5" id="Fact-BF2728FA9C21D27E4236FBB7C172892E" unitRef="usd">-31300000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2017Q4YTD" decimals="-5" id="Fact-759093A374FBBF266F79FBB7C163D324" unitRef="usd">39400000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="FD2018Q4YTD" decimals="-5" id="Fact-5E2E071DBBC47BE1406CFBB7C1720A2B" unitRef="usd">-18600000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2016Q4YTD" decimals="3" id="Fact-8CC1165D676FB188FE0AFBB7C1155902" unitRef="number">0.251</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2017Q4YTD" decimals="3" id="Fact-D060CA7ECD17EC5B1CF8FBB7C11580E1" unitRef="number">0.479</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="FD2018Q4YTD" decimals="3" id="Fact-8DEF7001D20AD702AC3BFBB7C1159286" unitRef="number">0.242</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="3" id="Fact-A8FB771E987608928996FBB7C115B75F" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="3" id="Fact-E939F4E7C2F66DB2A9BBFBB7C0F67AF2" unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q4YTD" decimals="3" id="Fact-7C9620C153726796D650FBB7C105336C" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="2" id="Fact-045863EA55FA80914C8AFBB7C0D7D5F2" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2016Q4YTD" decimals="3" id="Fact-55570DBA91CBF6A04F87FBB7C125FBD3" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="3" id="Fact-49ACA73AD2FD8504A110FBB7C1057B56" unitRef="number">0.229</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="FD2018Q4YTD" decimals="3" id="Fact-1A6F1001B2D47581FB5BFBB7C1050BD0" unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2016Q4YTD" decimals="3" id="Fact-B8A8CC6BF483C58C5A4EFBB7C115AF8E" unitRef="number">-0.096</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2017Q4YTD" decimals="3" id="Fact-EFD437C7A0A06E26DF90FBB7C115139A" unitRef="number">-0.111</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2018Q4YTD" decimals="3" id="Fact-1DD3B5F037200BCAD3F9FBB7C1053F9B" unitRef="number">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="0" id="Fact-1D2161149F2624618358A5E9D96874F0" unitRef="number">350</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2016Q4YTD" decimals="3" id="Fact-3037A40BFA42E408727EFBB7C1058FF6" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2017Q4YTD" decimals="3" id="Fact-CFC1122D5D8D37BF466AFBB7C1151EA5" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="FD2018Q4YTD" decimals="3" id="Fact-CA2849938F5A9DC87820FBB7C115D859" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses contextRef="FD2016Q4YTD" decimals="3" id="Fact-79D1E924C51120BCABAAFBB7C115082E" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses contextRef="FD2017Q4YTD" decimals="3" id="Fact-8D16EB198CD76B324E0CFBB7C1158976" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses contextRef="FD2018Q4YTD" decimals="3" id="Fact-2F634FB9131587AD5822FBB7C115F07E" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2016Q4YTD" decimals="3" id="Fact-D5376AA9F4EA6C00692BFBB7C1054927" unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2017Q4YTD" decimals="3" id="Fact-F2F3EA45534B08A36581FBB7C115F3A9" unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="FD2018Q4YTD" decimals="3" id="Fact-9D539177D68BC604DE60FBB7C163FA8D" unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2016Q4YTD" decimals="3" id="Fact-2E431DD0A4D83CF60A53FBB7C163E109" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2017Q4YTD" decimals="3" id="Fact-9BFB9F37E434878808D1FBB7C1055237" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="FD2018Q4YTD" decimals="3" id="Fact-8449999313411AFA69B4FBB7C10573A0" unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="3" id="Fact-68B41D715492C27641A5FBB7C1158AE7" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="3" id="Fact-30BBDB995F9B03809811FBB7C11589B8" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="FD2018Q4YTD" decimals="3" id="Fact-37076568A6820336E437FBB7C115A435" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2016Q4YTD" decimals="3" id="Fact-FC7BAEB8062EBA40DF61FBB7C1055088" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2017Q4YTD" decimals="3" id="Fact-5667377AF548277177C2FBB7C125F48F" unitRef="number">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="FD2018Q4YTD" decimals="3" id="Fact-9657BA5666296D99C64DFBB7C115A064" unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-225350B7EA273852E460FBB7C14487AD" unitRef="usd">297700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-057EF1271031F690E7C8FBB7C0E64374" unitRef="usd">320900000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2016Q4YTD" decimals="-5" id="Fact-178DD7D6A116DA08B504FBB7C0A8B399" unitRef="usd">14600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-48941DBD550EABCEA110FBB7C0A8E4C6" unitRef="usd">9600000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="FD2018Q4YTD" decimals="-5" id="Fact-07BE23CA01F7EF4F84AEFBB7C1637D6E" unitRef="usd">11500000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-EA000C4B06E188D5CA99FBB7C1441A9B" unitRef="usd">31900000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-0D5C7B2DA365BC9FD8EFFBB7C144EFD4" unitRef="usd">8100000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-5DADAC030509EC3FD946FBB7C144F5DE" unitRef="usd">16600000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-2C7D584F6497C8608D671B4162EF5ED0" unitRef="usd">11500000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="-5" id="Fact-A0F62E39F6B152F4B937FBB7C1444974" unitRef="usd">15100000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="-5" id="Fact-CCE08EE8499154623F03FBB7C1536AC2" unitRef="usd">17000000</us-gaap:EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q4" decimals="-5" id="Fact-210C911E21FCACA57C0DFBB7C144CB9C" unitRef="usd">188500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8263672EA88E2DB374C6FBB7C0E62892" unitRef="usd">54000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-78822CB9CBF45414BEE4FBB7C0D79C62" unitRef="usd">42800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-851F4A08C102AB9DAA9CFBB7C0899297" unitRef="usd">27500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7257D6F3AEF659369F21FBB7C115CD7A" unitRef="usd">4000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0ED0CB87DF8BCF966672FBB7C1152881" unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="FD2018Q4YTD" decimals="-5" id="Fact-5672FE7C2439D25147A7FBB7C11530A6" unitRef="usd">2200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="3" id="Fact-233DC9502858B9EDE08516744DECE6BC" unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="2" id="Fact-2CB846318BD823882A5EFBB7C0D7D115" unitRef="number">0.15</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestments contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-C68E0D80B7408E1A5F04F189A7A9871D" unitRef="usd">680600000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-434B455A884BE7A658AFF1892A5EEDE8" unitRef="KRW">759500000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-DC46736A58E5133039C6FBB7C0797DE1" unitRef="KRW">49500000000</us-gaap:EquityMethodInvestments>
	<us-gaap:EquityMethodInvestments contextRef="I2012Q1SD2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-F3B657717ABE0DF5AC24FBB7C163A8C2" unitRef="usd">45000000</us-gaap:EquityMethodInvestments>
	<us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="FD2017Q4QTD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-EEB7116EE288248F25C2F0A47495E0EB" unitRef="usd">5200000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
	<us-gaap:ExtinguishmentOfDebtGainLossNetOfTax contextRef="FD2017Q4QTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateSwapMember" decimals="-5" id="Fact-8F890D16D4D82B134BC8F0A6789590A4" unitRef="usd">2900000</us-gaap:ExtinguishmentOfDebtGainLossNetOfTax>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EF93E7BC7A4EFA6AA1D1FBB7C0F6F4D3" unitRef="usd">-14800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2017Q4YTD" decimals="-5" id="Fact-15545207642C8F1CD87FFBB7C0E648E5" unitRef="usd">-62700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2018Q3QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember" decimals="-5" id="Fact-64D85776AB75C193B2AD855CC12040A6" unitRef="usd">89600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2018Q4QTD_biib_ResearchanddevelopmentassetAxis_biib_TGNMember" decimals="-5" id="Fact-00E100FCCEF732FDF325855CEE2E0451" unitRef="usd">80600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2018Q4YTD" decimals="-5" id="Fact-9FBE47719F892C7F916DFBB7C134F39E" unitRef="usd">12300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="D2015Q1_us-gaap_BusinessAcquisitionAxis_biib_ConvergencePharmaceuticalsMember" decimals="-5" id="Fact-2D9E49067EA4E00539D3FBB7C06947B2" unitRef="usd">274500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2010Q4QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-E0E011DC854A86F5BA45FBB7C115F933" unitRef="usd">81200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2012Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-C0A68101154459618ED1FBB7C0F6FECA" unitRef="usd">122200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4015A15A1C0DA52580DDFBB7C0B740D8" unitRef="usd">6700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_BiogenIdecInternationalNeuroscienceMember" decimals="-5" id="Fact-4759CA85F9E14D7116D1821415078FA9" unitRef="usd">-20000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2018Q4YTD" decimals="-5" id="Fact-60B5661AB6A1772ADF88FBB7C0A82E91" unitRef="usd">101500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_StromedixMember" decimals="-5" id="Fact-E0DD6BEAEED545BCBC301DF593B1CC21" unitRef="usd">-81500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" id="Fact-9FF0183E193228946070FBB7C0F625EB">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" id="Fact-4A0FA54FCE27EB8C9300FBB7C0F68A0C">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" id="Fact-FCD14EF0A6C9A1D0B1F3FBB7C0D780B4">P23Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" id="Fact-30B52A5BAEEEF0597E53FBB7C0E651F9">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" id="Fact-326EFA385C1B74032DE6FBB7C0E64A8D">P13Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" id="Fact-D76D10FCF22246544760FBB7C0E60580">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4" decimals="-5" id="Fact-DCBEAA3734ECDB1A4F66FBB7C1151F3C" unitRef="usd">4385000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-8F9A3FC33D26694E41BAFBB7C1346AC5" unitRef="usd">1160400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-81529D4D194482568DB1FBB7C0A86676" unitRef="usd">535600000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-098517E9ADECB1CC7EB0FBB7C0A80405" unitRef="usd">2689000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-B05FB4D38F4DE8144C49FBB7C14469FC" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-0CA577B3F1EC167FB918FBB7C134C0DC" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4" decimals="-5" id="Fact-D1F2CB8EA278BEEDD427FBB7C0D75D3C" unitRef="usd">4607300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-CE330EBC02672D34E3B6FBB7C153C77F" unitRef="usd">1330200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-4E1A731E376EDCC82B96FBB7C0B7C2C3" unitRef="usd">542300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-3A974917D2011E5942F8FBB7C144E802" unitRef="usd">2734800000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-C7E0984A2B9DA3F3A572FBB7C0A8ECF7" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-DBE889CF77AAAEA78D92FBB7C0B78312" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2018Q4" decimals="-5" id="Fact-A68BCFC9C5CD7BB75D74FBB7C163DD3C" unitRef="usd">270000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2018Q4" decimals="-5" id="Fact-1001B6290EA109C22207FBB7C0E66470" unitRef="usd">230000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2018Q4" decimals="-5" id="Fact-D98E077FDA3EC7015390FBB7C0E6180A" unitRef="usd">250000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2018Q4" decimals="-5" id="Fact-1A398CAD86E4BDF54B47FBB7C0B7501C" unitRef="usd">250000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2018Q4" decimals="-5" id="Fact-7A61FB59765F833515E6FBB7C0D7B8E5" unitRef="usd">290000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-AFCEA705C871F439A915FBB7C098532A" unitRef="usd">3971400000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-71EA5CA47D21066F76B3FBB7C0B7FF22" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-2BC5CEE440BF07150EEDFBB7C0A8BD08" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-B3706778EAC18793C5F9FBB7C134EDFA" unitRef="usd">3638700000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-B1508916C39939E5121EFBB7C1443E0F" unitRef="usd">543300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-820472C8873BB0ED8041FBB7C0A80253" unitRef="usd">3005300000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q1_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-92C209A742936E6EA22B1DEE1FC7B334" unitRef="usd">795200000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-68A21C08A37681B68D85FBB7C1347E30" unitRef="usd">2811000000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-B0240639FFA2AEEA1876FBB7C0980B95" unitRef="usd">7700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2017Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-D77C3FEFAE1868DBF0D9FBB7C0D78F39" unitRef="usd">316300000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_AVONEXMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-8CE4B334BC6845AD0CA2FBB7C0899201" unitRef="usd">265000000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-63570978F03B58C6C25815E0CAC33CF2" unitRef="usd">71000000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_srt_ProductOrServiceAxis_biib_TysabriProductMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-F0235A41242C428F4DFFFBB7C1444B79" unitRef="usd">2027100000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember" decimals="-5" id="Fact-C91D9A9DB1A4102585EEFBB7C0C71F21" unitRef="usd">2308500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_OutLicensedPatentsMember" decimals="-5" id="Fact-63FFB813E1EE82EF1A6CFBB7C1346866" unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" decimals="-5" id="Fact-0A7A3570EF1058FBE95AFBB7C134C45E" unitRef="usd">270500000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-A497EB696548225D7EAEF18CD0F34D25" unitRef="usd">75000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_biib_InLicensedPatentsMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-1E8495FB8AB63CB33078FBB7C163C198" unitRef="usd">150000000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-78D098CED0B95063D73DFBB7C0D7298C" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F969B7439215D68D67A4FBB7C079086F" unitRef="usd">2700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4898D61E9E8292437FD9FBB7C089B8D2" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F885D8C3CE9ABA48918CFBB7C0B7A59C" unitRef="usd">2700000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EB079BDE70E0629E8BF6FBB7C0E6BFA9" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FFE64686C4F41711E53FFBB7C182FAA9" unitRef="usd">66900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D5DB1B09225186726FFBFBB7C1053175" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-626A27287C54BABF1568FBB7C098A265" unitRef="usd">66900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B058033B0C1B4E7D991DFBB7C134A02B" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-D841FE501CA256737672FBB7C1345331" unitRef="usd">111300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-0CBC56ED0CCA04686041FBB7C0C75FD8" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8728B04ECB9BC1C5B348FBB7C0791450" unitRef="usd">111300000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9DA973AA8990343FAAE5FBB7C0795EE8" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-7A8714BA21C941B72FCBFBB7C134AE4A" unitRef="usd">24600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-9EA7E21BBBE5A6E5C2E5FBB7C1342EDB" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-EE3AC2E581A684B4F073FBB7C069241D" unitRef="usd">24600000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2DD194AECF58DCEB20FBFBB7C0980CFF" unitRef="usd">-9800000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0A5DACFB9FE04AACE103FBB7C0E6E165" unitRef="usd">6300000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-AD7C7A2A9829686279C8FBB7C1639724" unitRef="usd">-9900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2017Q4" decimals="-5" id="Fact-6F98F460AC140231A2CBFBB7C0A8645E" unitRef="usd">55300000</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:FurnitureAndFixturesGross contextRef="FI2018Q4" decimals="-5" id="Fact-808D49FEFF4033718C80FBB7C08957E9" unitRef="usd">61600000</us-gaap:FurnitureAndFixturesGross>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions contextRef="FI2018Q4" decimals="-5" id="Fact-93A20EE668464F0801F8FBB7C0D7EF82" unitRef="usd">182800000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactions>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter contextRef="FI2018Q4" decimals="-5" id="Fact-3B68AEF8EDE0C25EF26BFBB7C0C7C914" unitRef="usd">58400000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears contextRef="FI2018Q4" decimals="-5" id="Fact-984625AE7C7FB99A4CF8FBB7C1059F3B" unitRef="usd">24300000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears contextRef="FI2018Q4" decimals="-5" id="Fact-05BFB29E6FD3DB68EC18FBB7C0C7D558" unitRef="usd">24000000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear contextRef="FI2018Q4" decimals="-5" id="Fact-19A9CE3DEA75728A1A29FBB7C105AA39" unitRef="usd">26800000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears contextRef="FI2018Q4" decimals="-5" id="Fact-B96F77A02B096DA3B896FBB7C0C717C4" unitRef="usd">23700000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears>
	<us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears contextRef="FI2018Q4" decimals="-5" id="Fact-833650F52D11774FBB15FBB7C134A041" unitRef="usd">25600000</us-gaap:FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-17FAE69A2EB68ADFEF04FBB7C0E64943" unitRef="usd">29200000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3D4A7F3142E2E469B112FBB7C134BCED" unitRef="usd">4500000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="FD2018Q4YTD" decimals="-5" id="Fact-0BA1E453C94F46E098F3FBB7C0F6F1C4" unitRef="usd">2000000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-82CD7D99CD3B248FF7B7FBB7C134AD01" unitRef="usd">6000000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2017Q4YTD" decimals="-5" id="Fact-56361C6388B407948FE2FBB7C1827439" unitRef="usd">-36300000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:GainLossOnSaleOfInvestments contextRef="FD2018Q4YTD" decimals="-5" id="Fact-0180C7B8174C775EBFF9FBB7C0980DAB" unitRef="usd">119500000</us-gaap:GainLossOnSaleOfInvestments>
	<us-gaap:Goodwill contextRef="FI2016Q4" decimals="-5" id="Fact-E540F6ACEF6A7026A141FBB7C1444FED" unitRef="usd">3669300000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2017Q4" decimals="-5" id="Fact-8A7C7DBF5A122DB8DB85FBB7C0A8030E" unitRef="usd">4632500000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2018Q4" decimals="-5" id="Fact-C1319D1045E5791C5574FBB7C105331D" unitRef="usd">5706400000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q4QTD_biib_CumulativeSalesLevelAxis_biib_SixteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-53D5939E07F3D6EA5F0E2147D40A7EE9" unitRef="usd">600000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D364C0864670D08CF871FBB7C182A5B4" unitRef="usd">1267300000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-573A27499E61C9E8AE7DFBB7C098EDDF" unitRef="usd">1500000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2018Q4QTD_biib_CumulativeSalesLevelAxis_biib_TwentybillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-7CA8693DCBC4B888A093FBB7C1342271" unitRef="usd">300000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2018Q4YTD" decimals="-5" id="Fact-71B11C3091A14924712AFBB7C125AC14" unitRef="usd">1080100000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2018Q4YTD_biib_CumulativeSalesLevelAxis_biib_NineteenbillionMember_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-BC95DB2A4519CCA89B6BFBB7C0F6F745" unitRef="usd">1500000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-8" id="Fact-D3457638C7B9AB211855FBB7C0A8F2A6" unitRef="usd">1200000000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="FI2018Q4" decimals="-6" id="Fact-EC46854B5883A5BD3A9FFBB7C134795F" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
	<us-gaap:GoodwillOtherIncreaseDecrease contextRef="FD2017Q4YTD" decimals="-5" id="Fact-6E225509A605B11F7FA5FBB7C17282E6" unitRef="usd">10000000</us-gaap:GoodwillOtherIncreaseDecrease>
	<us-gaap:GoodwillOtherIncreaseDecrease contextRef="FD2018Q4YTD" decimals="-5" id="Fact-426DFADE1BD5AC375375FBB7C172CFF6" unitRef="usd">-6200000</us-gaap:GoodwillOtherIncreaseDecrease>
	<us-gaap:GrossProfit contextRef="FD2017Q1QTD" decimals="-5" id="Fact-71C8A2D372E4122CF634FBB7C089D19A" unitRef="usd">2426100000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q2QTD" decimals="-5" id="Fact-C1E948B2D1E2E57480C2FBB7C069C85F" unitRef="usd">2712200000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q3QTD" decimals="-5" id="Fact-40DABB1511BD3C02C3B7FBB7C0A8BD32" unitRef="usd">2707800000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q4QTD" decimals="-5" id="Fact-8D43E09D68F48CDBC68BFBB7C0892C9D" unitRef="usd">2797800000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-051310FA795F315318C8FBB7C0898552" unitRef="usd">10643900000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2018Q1QTD" decimals="-5" id="Fact-5DEA0A52AC0E74840687FBB7C0983542" unitRef="usd">2685100000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2018Q2QTD" decimals="-5" id="Fact-3011AF50099A05D73CBFFBB7C0986916" unitRef="usd">2935500000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2018Q3QTD" decimals="-5" id="Fact-63FA38D8F484DC30B585FBB7C0D73BD6" unitRef="usd">2978200000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2018Q4QTD" decimals="-5" id="Fact-9F32D086C0DBB353F404FBB7C0D70991" unitRef="usd">3037800000</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-DA9C3E6BB315A7751A38FBB7C0F6468B" unitRef="usd">11636600000</us-gaap:GrossProfit>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1424AA8D6FA1FADB37EB9547CF2DBB74" unitRef="usd">12200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-CF0088645764CBB95596FBB7C17279D4" unitRef="usd">328200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2017Q4QTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-7E0569F3797E361A0132FBB7C134E577" unitRef="usd">31200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2018Q3QTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-2EFDCDA2FFE0AD1BECC81DE606C8E21F" unitRef="usd">189300000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-54243E6B7817EB80F228820AC71E0C4B" unitRef="usd">176800000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7334E2ABD4FBFCC3C0F0FBB7C0F65A46" unitRef="usd">3655400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4F8365C371DE80D2C00CFBB7C0F665D6" unitRef="usd">3540400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="FD2018Q4YTD" decimals="-5" id="Fact-6A9B2345F251476012E2FBB7C0E68B24" unitRef="usd">3877000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2016Q4YTD" decimals="-5" id="Fact-99FCC29D2903DEA0ACFBFBB7C1348C62" unitRef="usd">1277600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BD583649EA68AB6E42B3FBB7C0F6A815" unitRef="usd">1588400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="FD2018Q4YTD" decimals="-5" id="Fact-94D96E31B90D2E1B783EFBB7C1822D47" unitRef="usd">2022600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A716599642CB6928CF0FFBB7C0D7B110" unitRef="usd">4933000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2017Q4YTD" decimals="-5" id="Fact-98B28290AF198CD32BCCFBB7C0B7EF0F" unitRef="usd">5128800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="FD2018Q4YTD" decimals="-5" id="Fact-F9236BF22DA4DEEB4152FBB7C0F6BCDB" unitRef="usd">5899600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-48F8CDBE0DBB1C7853BBFBB7C0F6619B" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A75C817F43C7FE2059A1FBB7C134D246" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeLossFromEquityMethodInvestments contextRef="FD2018Q4YTD" decimals="-5" id="Fact-B30CAF69F4ACE061A7F6FBB7C1342852" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember" decimals="-5" id="Fact-947BEED8FB5840085127FBB7C0D7E7FB" unitRef="usd">60000000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-5" id="Fact-450F9C1B3F4B80B37A75FBB7C0E6AD72" unitRef="usd">1237300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-422A7E640DFDB8EB7A47FBB7C1441F5A" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-B3DBAD2B8230A737426AFBB7C144741D" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-7209463555C4A186A687174B956968C0" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-5" id="Fact-6A19AA1BBD0859DFBD99FBB7C1348940" unitRef="usd">2458700000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-8C6315B5F30337FE6AFBFBB7C089E293" unitRef="usd">232700000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-39A8A4A6F94E1F048C9FF573712D6668" unitRef="usd">1173600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-8" id="Fact-D7A052AD6C90F49045081B68AEA69CE6" unitRef="usd">1200000000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-D07CD396951B1CF16A06FBB7C0A85C60" unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-8490FE5577804262E7A4FBB7C15330F8" unitRef="usd">6800000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-4A79972170CE9A1643B0174B69897E73" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-5" id="Fact-6A04EC3D06E909BADF66FBB7C1155975" unitRef="usd">1425600000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-4A92A7A50E279E601511FBB7C13422D5" unitRef="usd">119900000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-96764171195E2D442608FBB7C153D6BE" unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-662105835DAA0C768AAEFBB7C1442887" unitRef="usd">1800000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-4D044444BB36E1464C0F174B42BBA7DA" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability contextRef="FD2017Q4QTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-D1C63F98338BA87ACE591B6A3F440CF1" unitRef="usd">184000000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
	<us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-739DB25E1D57DE533FE8F0E7B3C6720D" unitRef="usd">12700000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9706E754C2BDC5CB7305FBB7C163B68A" unitRef="usd">1642200000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3875F85749BB3123F285FBB7C1158875" unitRef="usd">1066400000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncomeTaxesPaidNet contextRef="FD2018Q4YTD" decimals="-5" id="Fact-2EF9FC836C1D76F98960FBB7C115C456" unitRef="usd">1007100000</us-gaap:IncomeTaxesPaidNet>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4535BEAD7FEC3B9813E7FBB7C1635D53" unitRef="usd">241400000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q4YTD" decimals="-5" id="Fact-06AA2F3D27E6FB1DC3ACFBB7C163DFCE" unitRef="usd">435600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q4YTD" decimals="-5" id="Fact-96B112A18BB4BF54C64BFBB7C16394A3" unitRef="usd">205200000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9B5587E79239642D19C3FBB7C1721013" unitRef="usd">-232600000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2017Q4YTD" decimals="-5" id="Fact-8666D5EDF71CA0AD03D5FBB7C1822925" unitRef="usd">1303900000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="FD2018Q4YTD" decimals="-5" id="Fact-FACE97647785993973BCFBB7C17230C3" unitRef="usd">321700000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AEBF303A7114B5004244FBB7C172D9C6" unitRef="usd">622300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-EC300D35CC0F0CD02218FBB7C163A405" unitRef="usd">-227400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-1848F1950419FB2F134EFBB7C1633303" unitRef="usd">465500000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5693DF6953482DC4D3A3FBB7C1630F63" unitRef="usd">165600000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2017Q4YTD" decimals="-5" id="Fact-DAB721010E5895D4FF73FBB7C172E6B4" unitRef="usd">94500000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2018Q4YTD" decimals="-5" id="Fact-5C25D27695BED2CF97A9FBB7C172FA3A" unitRef="usd">52100000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F76EDA17F54C7BC47C9EFBB7C172977B" unitRef="usd">-59100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-DCAF3BAB0E22A16CF4D2FBB7C182D3DA" unitRef="usd">76600000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2018Q4YTD" decimals="-5" id="Fact-7EC447AA52CD42E0FD7AFBB7C172BAFC" unitRef="usd">119100000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-967E5AFDBF51B555624EFBB7C172D4D5" unitRef="usd">-13900000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2017Q4YTD" decimals="-5" id="Fact-EBD00BCD49DB621F6B76FBB7C172E5C1" unitRef="usd">232000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="FD2018Q4YTD" decimals="-5" id="Fact-0DBDE54B8C6F1DC8D210FBB7C163EAD0" unitRef="usd">-5700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E6375B9501E2E9A78745FBB7C163507A" unitRef="usd">69500000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2758D4905B4906936402FBB7C182BF71" unitRef="usd">-2400000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-0907898D1209198459CDFBB7C17255C4" unitRef="usd">-16300000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-C65B108B010A3FF5F354FBB7C0A8DF9B" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-F774B3A48162D760909A174FBDD5218C" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-CACA260D6D05D3B26178FBB7C0A8BCF7" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-EBC309136E1166CC475DFBB7C0E61D57" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-F2A755C70163EE04A80DFBB7C0D7BE92" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-626C8CC85816ACA5FA1F174FA341C80C" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-D54A769599C08D428029FBB7C0D722CC" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-363D30E2DCE5451E152FFBB7C0E640C8" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-BF6DBC961DC7F5261682FBB7C0A87456" unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-5" id="Fact-54950E686F4752857F91174F7CFCE107" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_StockOptionsAndEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-470FE2BF581FF506D96AFBB7C0D7D0CC" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-4B0A0FEE0FCC32D41992FBB7C0A84BE1" unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-6ED6867E1C6F75C92FA6FBB7C098670D" unitRef="usd">680600000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2017Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-A3108313588449DBD041FBB7C0B7EDC5" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2018Q3_biib_ResearchanddevelopmentassetAxis_biib_TGNMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-E06B0D63915928FA85881DE8A9B0F687" unitRef="usd">41800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-5" id="Fact-35642E5D7F8DA6E1F2DCFBB7C0A8C177" unitRef="usd">476000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TrademarksAndTradeNamesMember" decimals="-5" id="Fact-4E5F90256A5CCAD87C11FBB7C0C724AE" unitRef="usd">64000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2017Q4" decimals="-5" id="Fact-51413700ABFEB61474AAFBB7C134E8BE" unitRef="usd">8264600000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="FI2018Q4" decimals="-5" id="Fact-68CC67A6FE69DA414BD0FBB7C0A87781" unitRef="usd">7727300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2017Q4" decimals="-5" id="Fact-AB996C44A9B9B52A795BFBB7C0A861EB" unitRef="usd">3879600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2018Q4" decimals="-5" id="Fact-BE78E9509DE2DB24EB92FBB7C1720571" unitRef="usd">3120000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestCostsCapitalized contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1290C8EFD5F1345FDA39FBB7C12569DE" unitRef="usd">12900000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2017Q4YTD" decimals="-5" id="Fact-77621A1E42DD2A4D8F31FBB7C098F766" unitRef="usd">30700000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestCostsCapitalized contextRef="FD2018Q4YTD" decimals="-5" id="Fact-C675D1D0E294E79E11E0FBB7C125626F" unitRef="usd">54000000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3726EC6164DB256E097DFBB7C13425D4" unitRef="usd">260000000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A99297643210A757C368FBB7C13435B4" unitRef="usd">250800000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-C5D561545A438F7AF8BCFBB7C0C70FB9" unitRef="usd">200600000</us-gaap:InterestExpense>
	<us-gaap:InterestPaidNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4CD412FD73CA87879298FBB7C1159404" unitRef="usd">281200000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0BDC8D6F6DD05DA4C001FBB7C115E035" unitRef="usd">281700000</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2018Q4YTD" decimals="-5" id="Fact-34A9C8023CF259E8FE2AFBB7C1052DFD" unitRef="usd">243200000</us-gaap:InterestPaidNet>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2017Q4" decimals="-5" id="Fact-2C2E370C63A50C5DB81BFBB7C1154321" unitRef="usd">157400000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="FI2018Q4" decimals="-5" id="Fact-658916CE19C27693E272FBB7C0D7D7C0" unitRef="usd">133500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
	<us-gaap:InventoryNet contextRef="FI2017Q4" decimals="-5" id="Fact-6A401A83D9178CC0526DFBB7C0E6104A" unitRef="usd">902700000</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2018Q4" decimals="-5" id="Fact-DE4D61E5FB7CF7A01E5EFBB7C144C37C" unitRef="usd">929900000</us-gaap:InventoryNet>
	<us-gaap:InventoryNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-DE16F3B7321EC7C370DAFBB7C0C70219" unitRef="usd">22800000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-792EC5AD5305724AA2DBFBB7C07923C3" unitRef="usd">6600000</us-gaap:InventoryNoncurrent>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2017Q4" decimals="-5" id="Fact-735762153D1AC648DED5FBB7C0D756D5" unitRef="usd">162400000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryRawMaterialsNetOfReserves contextRef="FI2018Q4" decimals="-5" id="Fact-A466EB2C8ADFFC1B4D6DFBB7C115DD1A" unitRef="usd">196300000</us-gaap:InventoryRawMaterialsNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2017Q4" decimals="-5" id="Fact-EFC99EE5B638CF389172FBB7C1057241" unitRef="usd">605700000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWorkInProcessNetOfReserves contextRef="FI2018Q4" decimals="-5" id="Fact-16FA805934BD97D8C887FBB7C1055E91" unitRef="usd">606700000</us-gaap:InventoryWorkInProcessNetOfReserves>
	<us-gaap:InventoryWriteDown contextRef="FD2016Q4YTD" decimals="-5" id="Fact-35CDCE5D2A66A7EBCA06FBB7C163919D" unitRef="usd">48200000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="FD2017Q4YTD" decimals="-5" id="Fact-01996A7DDB19EAAFD4BFFBB7C172E443" unitRef="usd">76900000</us-gaap:InventoryWriteDown>
	<us-gaap:InventoryWriteDown contextRef="FD2018Q4YTD" decimals="-5" id="Fact-FB2E71CD2600DA66DB65FBB7C1725F63" unitRef="usd">41900000</us-gaap:InventoryWriteDown>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B3322C94C5D59E2DC520FBB7C0E6C285" unitRef="usd">63400000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2017Q4YTD" decimals="-5" id="Fact-F990B52D800CEB9793B9FBB7C0E66C33" unitRef="usd">78500000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentIncomeInterest contextRef="FD2018Q4YTD" decimals="-5" id="Fact-AEEA114F0754050864D2FBB7C1345B5A" unitRef="usd">112500000</us-gaap:InvestmentIncomeInterest>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-5053DD7EEAECFB14A3FBFBB7C163507F" unitRef="usd">11800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-3580EAAAD99361DC0000FBB7C079E14E" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-88C051F43E5E24C3BD3DFBB7C0C7A586" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-37B26FF65FB21041944BFBB7C134049A" unitRef="usd">11800000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4F23361914EEEC337EF1FBB7C0D72017" unitRef="usd">51700000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-CB6A6A6F06E73951D152FBB7C125FD17" unitRef="usd">563700000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-F0531AA8A24C765FA437FBB7C0E6A2F1" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:InvestmentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-4A27696724AE486DEB24FBB7C0A8F491" unitRef="usd">615400000</us-gaap:InvestmentsFairValueDisclosure>
	<us-gaap:Land contextRef="FI2017Q4" decimals="-5" id="Fact-3DA96916540441564ACDFBB7C0B7FEB4" unitRef="usd">141200000</us-gaap:Land>
	<us-gaap:Land contextRef="FI2018Q4" decimals="-5" id="Fact-55BBFEA58F9E5E5CF98FFBB7C098A6A2" unitRef="usd">144500000</us-gaap:Land>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-26D7B091C7D780DB7ED4FBB7C0D78F55" unitRef="usd">68700000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BC580FB37ECA9C53C493FBB7C115A044" unitRef="usd">65300000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-E1BC2394D6865BCCB75DFBB7C0E6C964" unitRef="usd">64500000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseholdImprovementsGross contextRef="FI2017Q4" decimals="-5" id="Fact-9F204E738C015DAAFD13FBB7C0A80F23" unitRef="usd">80600000</us-gaap:LeaseholdImprovementsGross>
	<us-gaap:LeaseholdImprovementsGross contextRef="FI2018Q4" decimals="-5" id="Fact-38FF85CD9722C374C3F4FBB7C0A8D057" unitRef="usd">94400000</us-gaap:LeaseholdImprovementsGross>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-5" id="Fact-37F2A558A0EB961D3804FBB7C1634C57" unitRef="usd">11054500000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-5" id="Fact-31A2C039595069C014B7FBB7C09836DB" unitRef="usd">12257300000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-5" id="Fact-07A5CC390F01E94786E0FBB7C0A870A3" unitRef="usd">23652600000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-5" id="Fact-8CD008916F4A02193221FBB7C0E64BA2" unitRef="usd">25288900000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-9B897BBE7E24F88F81E5FBB7C105F359" unitRef="usd">3368200000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-FC14F7D082D549AF9268FBB7C0984761" unitRef="usd">3295200000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-FA9B7298C6C633E09C6BFBB7C0897513" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-426FFA29AC22F687973FFBB7C0C7A57C" unitRef="usd">111300000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-6E1E5ADB6BC817A47C7BFBB7C079BD73" unitRef="usd">523600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-B7DDC4F775B2CB8DEB74FBB7C089EA50" unitRef="usd">634900000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AE60F716B757F8179720FBB7C1347DB1" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-60A45A83B9C9BE6DAF14FBB7C0987431" unitRef="usd">24600000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-8777463D955DBB365E79FBB7C144D720" unitRef="usd">409800000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="-5" id="Fact-AF99AFAA32C557CAD4F6FBB7C0E679A8" unitRef="usd">434400000</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="I2017Q1Bioverativ" decimals="-5" id="Fact-B0D46C171C5D1E7B7F16F0604C479152" unitRef="usd">155500000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
	<us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-E1422D55361D5661F161FBB7C0D78967" unitRef="usd">117700000</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
	<us-gaap:LineOfCreditFacilityExpirationPeriod contextRef="FD2015Q4YTD" id="Fact-FDAEE94374BEE0CA0309FBB7C0895A25">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
	<us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding contextRef="FI2018Q4" decimals="0" id="Fact-2F025B9D902998F23B97FBB7C144D759" unitRef="usd">0</us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="FI2015Q4" decimals="-8" id="Fact-6A2A93C1B5E7136F6777FBB7C153ABA1" unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="FD2017Q1QTD" decimals="-7" id="Fact-1B8FC4E85FE6AB84D3C6FBB7C172D6AE" unitRef="usd">1250000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
	<us-gaap:LitigationSettlementExpense contextRef="FD2016Q4QTD" decimals="-5" id="Fact-98CA6DC9C93CE873BFB6FBB7C134AE1A" unitRef="usd">454800000</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-BB971CAA800712806914FBB7C1252F72" unitRef="usd">454800000</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-48FD3B2E6264DB22A8CCFBB7C14410C5" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
	<us-gaap:LitigationSettlementExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-1141EABE65C08F75D04DFBB7C1258828" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
	<us-gaap:LongTermDebt contextRef="FI2017Q4" decimals="-5" id="Fact-6195DFB79802D3ECA76FFBB7C134C500" unitRef="usd">5935000000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2018Q4" decimals="-5" id="Fact-B6274FDF66DC8FF89FC2FBB7C079468C" unitRef="usd">5936500000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="FI2018Q4" decimals="-5" id="Fact-8CA155C348A0E06A1082FBB7C0B7D24E" unitRef="usd">3500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2018Q4" decimals="-5" id="Fact-97398E60870BBAD9BB1BFBB7C0B71C10" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2018Q4" decimals="-5" id="Fact-3E25B3C1854473D489F7FBB7C0B71627" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2018Q4" decimals="-5" id="Fact-B90822D4DCB17841FD52FBB7C0B7AE0B" unitRef="usd">1000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2018Q4" decimals="-5" id="Fact-CD2385C7259D4F8AD765FBB7C0B75D71" unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2018Q4" decimals="-5" id="Fact-AB8C44A68FA041EEFBC5FBB7C0B7F901" unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-D3E0C7A1073683A441F4FBB7C079F537" unitRef="usd">1722000000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-FF574CFC32A02944E6F7FBB7C0798A91" unitRef="usd">1736300000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-A593B6EC7A814EB6DA1CFBB7C0793E14" unitRef="usd">994300000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-40FAB1593683AFC2A4F3FBB7C0894640" unitRef="usd">1482400000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2018Q4" decimals="-5" id="Fact-9E4BEB405FC9143D5C98FBB7C0B79D9A" unitRef="usd">6000000000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-BC9A53918D5D82E3CAB4FBB7C0793B6D" unitRef="usd">1722400000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-3782F14FF94EDB55BB94FBB7C07980E9" unitRef="usd">1737800000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-6788D424133030725C39FBB7C0795BE6" unitRef="usd">995500000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-1145869F1C7F7483AE88FBB7C079A5ED" unitRef="usd">1480800000</us-gaap:LongTermNotesPayable>
	<us-gaap:LossContingencyDamagesSought contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_country_BR" id="Fact-10ED4D49963E81A4D660F526934454DE">70.0</us-gaap:LossContingencyDamagesSought>
	<us-gaap:MachineryAndEquipmentGross contextRef="FI2017Q4" decimals="-5" id="Fact-9729F2AEFF74241CB733FBB7C0A86899" unitRef="usd">1207700000</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MachineryAndEquipmentGross contextRef="FI2018Q4" decimals="-5" id="Fact-E2541F541352BB8EA26EFBB7C0A8276C" unitRef="usd">1258100000</us-gaap:MachineryAndEquipmentGross>
	<us-gaap:MarketableSecuritiesNoncurrent contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-56677F91D560A582B1A1A984C7DA3E84" unitRef="usd">563800000</us-gaap:MarketableSecuritiesNoncurrent>
	<us-gaap:MinorityInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-E212100443698563EC70FBB7C125DB14" unitRef="usd">2100000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-DA966E4DF57AA7CDBD11FBB7C1250A6B" unitRef="usd">-11500000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2017Q4" decimals="-5" id="Fact-9564E51B6993CC455047FBB7C0E6C7DD" unitRef="usd">-14700000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-D92E11F49A1736FB9521FBB7C0E65D6F" unitRef="usd">-14700000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2018Q4" decimals="-5" id="Fact-0C61AAD4A6A88145F9B5FBB7C134C3EC" unitRef="usd">-8000000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-7E2C26E4C6E01F728292FBB7C089C5E4" unitRef="usd">-8000000</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2017Q4YTD" decimals="-5" id="Fact-688C75CA8320D5CFF416FBB7C0D78FB4" unitRef="usd">150000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-08E58681D318DA7C6CBFFBB7C15380C7" unitRef="usd">150000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-E622142309903AF51811FBB7C0E695B0" unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2018Q4YTD" decimals="-5" id="Fact-51A173F8CA9A91725B05FBB7C115BE98" unitRef="usd">50000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-F356DDD74C0B59BA57E0FBB7C07956D5" unitRef="usd">50000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-F3CAF2F8111E754040DCFBB7C0E63148" unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-394DBBDD60DBF28C0E47FBB7C1725BB1" unitRef="usd">-1052600000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-7B3382B6D44A21325151FBB7C1638F8D" unitRef="usd">-2380000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-25FDC565404E542175CEFBB7C163F5DD" unitRef="usd">-4472000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5D1DF8C678E1D0D26E67FBB7C172F198" unitRef="usd">-2484800000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A208BC3EB0DE3DE4EDD1FBB7C172F2DC" unitRef="usd">-2963100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-BE79F439DFACFF5FBF99FBB7C172E959" unitRef="usd">-2046300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6A2AF4F3A82BDBB95B9EFBB7C1723E72" unitRef="usd">4587200000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5E626DEDD6E76D3E5C40FBB7C16317DC" unitRef="usd">4551000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-7FA8418EB53D1EA3297EFBB7C172EDE2" unitRef="usd">6187700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7FD5DFF30D268D35E8D0FBB7C1721CF6" unitRef="usd">3702800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-48A24A8D297F0E40B574FBB7C1539642" unitRef="usd">3400000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-85C9EF8F7FAFDFEB0198FBB7C0C7A821" unitRef="usd">3702800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1QTD" decimals="-5" id="Fact-EBA9C4BC7F158CF609C7FBB7C0897630" unitRef="usd">747600000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2QTD" decimals="-5" id="Fact-F7AA64F6AE02C5F2D81EFBB7C079EF7D" unitRef="usd">862800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-5" id="Fact-7D5AA440A8BFD1AC8DA0FBB7C0895B5B" unitRef="usd">1226100000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4QTD" decimals="-5" id="Fact-4D0AFB48DCF9E129F21FFBB7C089ADA4" unitRef="usd">-297400000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B1186AEADC1323EC1FCFFBB7C125CB85" unitRef="usd">2539100000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-6EBC6F6D5EF20187F077FBB7C144EFF2" unitRef="usd">-44200000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-89F6658437BFBE4CDE37FBB7C1253F6E" unitRef="usd">2539100000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q1QTD" decimals="-5" id="Fact-B301C27BECD2DCEBCDE2FBB7C0D76EBA" unitRef="usd">1172900000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q2QTD" decimals="-5" id="Fact-D0744D0EC070FB368B20FBB7C098217C" unitRef="usd">866600000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q3QTD" decimals="-5" id="Fact-2BC1C982357DFD379E10FBB7C09816CE" unitRef="usd">1444400000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4QTD" decimals="-5" id="Fact-50729C24892486B73C25FBB7C098EBB8" unitRef="usd">946800000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD" decimals="-5" id="Fact-674B01E64C3B33F9A997FBB7C0B74E27" unitRef="usd">4430700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-C00DC940EB97BEB3DAC0FBB7C098BC61" unitRef="usd">-47000000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-72385BCD8A6160878B68FBB7C18262F9" unitRef="usd">4430700000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A9133CD435BB3C5F6A18FBB7C144362E" unitRef="usd">-7100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-73A6AE98AE4E17C82885FBB7C0B7B5F9" unitRef="usd">-7100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2017Q4QTD_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-59AF9DD56655BC1AA495FBB7C079C4B7" unitRef="usd">150000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A514096DCEC03D334872FBB7C0F68730" unitRef="usd">131000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-AA47B93DC55F82304A2AFBB7C0F63CDB" unitRef="usd">131000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="-5" id="Fact-5E057642CB3466B55053FBB7C0C79F6F" unitRef="usd">43300000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-1A390B8C5C39B5495806FBB7C1636962" unitRef="usd">43300000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_IncomeStatementLocationAxis_biib_OthercorporaterevenuesMember" decimals="-5" id="Fact-868DC91867B36A0EDCFD8194FE24464E" unitRef="usd">75800000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
	<us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" decimals="-5" id="Fact-C32CD422D109C396BCD8953B648B3873" unitRef="usd">42400000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
	<us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member" decimals="-5" id="Fact-B74112D4BD6A9F84D66D9544BED1E42D" unitRef="usd">128000000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
	<us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification contextRef="FD2018Q4YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-8" id="Fact-5CE5538D6E5AAC936A2581C551C3254D" unitRef="usd">500000000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification>
	<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-46B33E4C7663850D9DC11188B631AAD5" unitRef="usd">7500000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
	<us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="0" id="Fact-C6B43E2F33B86ADC7A751188B631226C" unitRef="usd">0</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2F4D9A56D34091A61A0DFBB7C0A888A4" unitRef="usd">600000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-F5CB898D04C0BD05DE63FBB7C1348E45" unitRef="usd">600000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" decimals="-5" id="Fact-2F3936D4359CB47A418BFBB7C0C7DF0D" unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4" decimals="-5" id="Fact-E6874C52B11100D0EE1BFBB7C08985D8" unitRef="usd">2501800000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-BC5161A776B45210B240FBB7C09834FE" unitRef="usd">1400000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_srt_StatementGeographicalAxis_biib_SolothurnMember" decimals="-5" id="Fact-94CF539A62B001E30581FBB7C1630442" unitRef="usd">545500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_srt_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-8D61AE7A6F60D9E0A03BFBB7C163832E" unitRef="usd">643600000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-EAEFD7C0DCF0D9BD7F70FBB7C0899885" unitRef="usd">1272300000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-0F4342ED38F0EECE1136FBB7C0895E58" unitRef="usd">7000000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2016Q4_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-71D881BBDA40C81FDB86FBB7C0895666" unitRef="usd">1221100000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4" decimals="-5" id="Fact-C62D5B7AF4C9F833D98EFBB7C0897DA5" unitRef="usd">3182400000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-A60A960CDDC08888F804FBB7C0892BB8" unitRef="usd">2100000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_srt_StatementGeographicalAxis_biib_SolothurnMember" decimals="-5" id="Fact-BACA273F33B6A7AAA7EEFBB7C1634CE4" unitRef="usd">1215700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_srt_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-E3E3C78C894994FA4DD6FBB7C1633B8F" unitRef="usd">707100000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-AABDDC81B8C6FF45CE65FBB7C089AD1D" unitRef="usd">1226900000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-F581D727264B4FB513EBFBB7C0898B5E" unitRef="usd">5200000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2017Q4_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-129FB4242AD6F62BEE28FBB7C0891940" unitRef="usd">1948200000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2018Q4" decimals="-5" id="Fact-4238804B4FC1D62A7A60FBB7C089848B" unitRef="usd">3601200000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2018Q4_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-4DB170FFC1648A3722C0FBB7C089A21A" unitRef="usd">1800000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2018Q4_srt_StatementGeographicalAxis_biib_SolothurnMember" decimals="-5" id="Fact-9D7E7915D74D5DC21821FBB7C163F86F" unitRef="usd">1748500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2018Q4_srt_StatementGeographicalAxis_country_DK" decimals="-5" id="Fact-A8F1F45D42DF9E379E8CFBB7C069D20D" unitRef="usd">646500000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2018Q4_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-DC1D874907602D737975FBB7C0895E69" unitRef="usd">1152700000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2018Q4_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-3A8BB4C91CD3A22D4FA4FBB7C08963E9" unitRef="usd">3900000</us-gaap:NoncurrentAssets>
	<us-gaap:NoncurrentAssets contextRef="FI2018Q4_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-E260D3267CA8DF324FC9FBB7C08943A7" unitRef="usd">2442800000</us-gaap:NoncurrentAssets>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1674BF5575FAA24EE43FFBB7C0D7BE66" unitRef="usd">-218700000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-28984E854696DAB2C267FBB7C153A781" unitRef="usd">200000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-374907373C843F7E2313174B90F7C9F4" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0945BF07549E07FBD40BFBB7C0F6596A" unitRef="usd">-217000000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-7ADCD8E6B2A2BA99C65DFBB7C1446175" unitRef="usd">300000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-D89BA4D46BCBA9982C28174B6640621E" unitRef="usd">0</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-286F1E376989549E186FFBB7C1058A46" unitRef="usd">11000000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-BBD9147EC8785BEA86E7FBB7C163841D" unitRef="usd">300000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-1434240D662CD44230C5174B3F4004A8" unitRef="usd">1500000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesPayable contextRef="I2006Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-930DB7C255407913B7E115EA88E248C8" unitRef="chf">61400000</us-gaap:NotesPayable>
	<us-gaap:NotesPayableCurrent contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-22F151F76B6532332957FBB7C079B2D8" unitRef="usd">3200000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-5" id="Fact-648280F5FD0AF48D17C7FBB7C0796F15" unitRef="usd">0</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-19BBD26A945757984872FBB7C1637A54" unitRef="usd">3200000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-245FCA5E10D6570CFB3DFBB7C105AAED" unitRef="usd">2077600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-D84D1DA91DE16D26D556FBB7C1722447" unitRef="usd">1851900000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-8A5AD514E79615BE8B4FFBB7C105A716" unitRef="usd">1032900000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-549A083B38DD3C47F093FBB7C105ED68" unitRef="usd">1517700000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_NotesPayableToFumedicaMember" decimals="-5" id="Fact-0EAE2E6EAD3E1BC80405FBB7C163857D" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" decimals="-5" id="Fact-6AA7A3977FEC5502E68BFBB7C115AAC5" unitRef="usd">1802600000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" decimals="-5" id="Fact-48DF6EA6D69B1B27A651FBB7C1723B2A" unitRef="usd">1745100000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" decimals="-5" id="Fact-8C7CDEE685CF6C83113AFBB7C0F6B0DC" unitRef="usd">1000400000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" decimals="-5" id="Fact-0C1C4633AF78EC8BC28CFBB7C1051D6C" unitRef="usd">1489500000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportableSegments contextRef="FD2018Q4YTD" decimals="0" id="Fact-B5B485F14B1128DF6476FBB7C16361E6" unitRef="segment">1</us-gaap:NumberOfReportableSegments>
	<us-gaap:OperatingExpenses contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-A72DD60E1AC887B1A84DFBB7C0A8A565" unitRef="usd">-1500000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-D1FBE46274926A148752FBB7C15356DF" unitRef="usd">600000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-ED72E4BC146D1A6BE93EFBB7C1440494" unitRef="usd">200000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6523BFF57BC14D40A60EFBB7C0D7E302" unitRef="usd">5151700000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="-5" id="Fact-EDE527F16DDDA1D8FECDFBB7C0D7E1FE" unitRef="usd">5345800000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q4YTD" decimals="-5" id="Fact-945D849AE49B9F8F9029FBB7C0890391" unitRef="usd">5888600000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2018Q4" decimals="-5" id="Fact-5DF56F9AE974904011A7FBB7C0C7C0D7" unitRef="usd">601600000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-D6BE4018A8D34D13BFCAFBB7C0D780DD" unitRef="usd">87000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2018Q4" decimals="-5" id="Fact-320EDF1EBF7DDF918693FBB7C0F66130" unitRef="usd">71000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2018Q4" decimals="-5" id="Fact-A20602EC934451E9A166FBB7C1443E35" unitRef="usd">71700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2018Q4" decimals="-5" id="Fact-399D320762C7A7CF6AF7FBB7C0C77E0B" unitRef="usd">75900000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2018Q4" decimals="-5" id="Fact-457113D3E8F992EB7FA8FBB7C0C7DBA0" unitRef="usd">80700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2018Q4" decimals="-5" id="Fact-138D37DA11792DF20956FBB7C105569F" unitRef="usd">215300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-B48E1764B4B381773980FBB7C0D783DA" unitRef="usd">1000000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-8" id="Fact-F7C6BB1900866F786C15FBB7C0F62041" unitRef="usd">2200000000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-A1A89F2425FF6004A505FBB7C0C74540" unitRef="usd">636900000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-DC611AF919E3B0D05873FBB7C089A496" unitRef="usd">609300000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-7E401C297249E1D83D26FBB7C0F6DD23" unitRef="usd">962000000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-393C45488E7968C2E4CAFBB7C0A83B70" unitRef="usd">687600000</us-gaap:OtherAssetsCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q2_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-CD3DDEA93569EC192779195CDED6B81A" unitRef="usd">15000000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-4DCD0ADCC9FDD9C6319EFBB7C0A8093E" unitRef="usd">431600000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-AF6FAA8DDE70435DE2BF195D607480CE" unitRef="usd">29100000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-BA093719BC57AD24481CFBB7C134B353" unitRef="usd">1690600000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4_us-gaap_TypeOfArrangementAxis_biib_C4TherapeuticsMember" decimals="-5" id="Fact-A26AFE374EDBC184183F853784F887C7" unitRef="usd">28000000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="I2019Q1Skyhawk_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_biib_SkyhawkTherapeuticsMember" decimals="-5" id="Fact-B9BD16779630858983A585658632BD97" unitRef="usd">35000000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherCommitment contextRef="FI2018Q4" decimals="-5" id="Fact-922454CDBA0A747339C2FBB7C0F6A33F" unitRef="usd">655000000</us-gaap:OtherCommitment>
	<us-gaap:OtherCommitment contextRef="FI2018Q4_biib_FacilityLocationAxis_biib_SolothurnMember" decimals="-5" id="Fact-49B189F0D0193EFBEC9FFBB7C0C79C81" unitRef="usd">111000000</us-gaap:OtherCommitment>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C401F75D2D474754FA08FBB7C0981994" unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-38071759331EF34057FFFBB7C0B7D1E0" unitRef="usd">9200000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-B4283CC2D18013053C8DFBB7C0D700A0" unitRef="usd">-3900000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-16D7C90E1AC99DDCDEA4FBB7C0F6A332" unitRef="usd">-92500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-EAECBAD3135534FC923BFBB7C098616E" unitRef="usd">5100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-A93162E86249D1F99EC0FBB7C0F6E879" unitRef="usd">51600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-FE31F0064207919673FFFBB7C0E69CC7" unitRef="usd">-10600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-9E260ED8A8FB21BEB36C17495AF22B98" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-76336D60C3FA1EDDC419FBB7C1823552" unitRef="usd">-138600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-113B7ABEBF6E86D284B0FBB7C172826E" unitRef="usd">-42700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-6F75CBB8C0552596B4BBFBB7C1538D39" unitRef="usd">-4100000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-09A5259A232EA6ECB541FBB7C144ADC3" unitRef="usd">-193800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-4C73D08BB53FB1E3F976FBB7C153FE51" unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-5AFB06AE27C757C819D1174892B5E83C" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-8DFB58657DEE1E12F378FBB7C1440962" unitRef="usd">158700000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-545A5855EE7F1945DC49FBB7C144740A" unitRef="usd">29500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-7CC6C9808285BA152CEDFBB7C1446081" unitRef="usd">5500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-94BF7BE3C8033EF89032FBB7C1446F35" unitRef="usd">97400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-3F389D53D7D331BD5B5AFBB7C0C7BC97" unitRef="usd">-10600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-0A7A8A23488883FF401E17471135933F" unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-86B098F067099869DA46FBB7C0A8BE51" unitRef="usd">-67800000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-FF7826247184C880003DF034A2969F13" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-75811306E33145C4BB81F03474D7ACC5" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-FD0F4BA74D4F025EF3DDF0333D771954" unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-BFEA300839AD62BDDC72F034A480CAEE" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0FA97035580A4F159874F03476CD2F93" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-DD491055BFD9E71A0AC8F02379CFFADD" unitRef="usd">3500000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6250F2E51B8E2C623796F034A1E740FD" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B453E198B00DB067652FF0347414FC99" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-536678AC2407413650D0F0235E1A113A" unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-00C76896E442E218A885FBB7C0E614B7" unitRef="usd">47600000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D9E5E14633FC97BB70F5FBB7C098A082" unitRef="usd">-162300000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-BCC32B48B91311F46932FBB7C144F8C5" unitRef="usd">139200000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8FBCF4ACF4308C35AED8FBB7C0E6A3CA" unitRef="usd">-138600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-CE332F3F1B1D194B97C9FBB7C0F6A015" unitRef="usd">158700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-CF7A70795A63361EC585FBB7C0798808" unitRef="usd">-67800000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EAEF801723F08903FC18FBB7C1252691" unitRef="usd">-95800000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-763009ADB75E7B4AFC3D17495FFDA938" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-5BAF6F09AA530AE6E7E6FBB7C0B7F6C3" unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-AD71427E20CD307691C1FBB7C0E69CFB" unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-3B098B1A620037E085B017489762643D" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-805228FD42B3C7AFC001FBB7C0E6DAF2" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-CC688E882FBDC71FB321FBB7C16327EA" unitRef="usd">76100000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-AE311D8DCA32A0C2E9E5174715B17FB1" unitRef="usd">3500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="-5" id="Fact-9ACD0B9B2BAAC74EB85CFBB7C0E69E0E" unitRef="usd">-400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1230F8EF5499FA22770DFBB7C115BF8C" unitRef="usd">-95900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-130E871D48CA16B7B649FBB7C0C7B613" unitRef="usd">5100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-9CD488C82AEAC82C5BE5FBB7C14481BC" unitRef="usd">47600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-36167AD5BAEF47EB0871FBB7C0A833A1" unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-3CD7069FDFA39D2F6355FBB7C0C79BAF" unitRef="usd">-95900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-921755FB491D5152ACC8FBB7C089483B" unitRef="usd">-138600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD" decimals="-5" id="Fact-93E44E4AD12FBBA4A27EFBB7C115DA9D" unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-95C6DCCEEDF62C3712F6FBB7C144DA1D" unitRef="usd">-4100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-5F2457A37DD8E24A82B3FBB7C1058808" unitRef="usd">-162300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-BC7659B278AE1F38C9F1FBB7C0C715C8" unitRef="usd">9200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-E07D5CA6555C8FC259EDFBB7C0E6B87F" unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-480ACAFC84F84C2D5BC2FBB7C1822587" unitRef="usd">158700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2018Q4YTD" decimals="-5" id="Fact-040585FB8E0E80892632FBB7C1349062" unitRef="usd">76500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-30783911B9599E111413FBB7C1532FB5" unitRef="usd">5500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-6A83A3942A1CA2833D7FFBB7C1446C3A" unitRef="usd">139200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-332E15940A7F75871D04FBB7C1448FF1" unitRef="usd">-3900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-5832209581548EC23EFFFBB7C1532612" unitRef="usd">76500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-931F90FAD052C30B13AEFBB7C153A3D3" unitRef="usd">-67800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-8A06A1166AC8A647DD45FBB7C1446D66" unitRef="usd">-5100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-AD2ED100E24353A311B5FBB7C0F6DB28" unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-88B3021EFD0E745D899FFBB7C144500A" unitRef="usd">-5500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A7A0362FEF96AFAAD46CFBB7C0F67FAE" unitRef="usd">-600000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-267D0D7A20949D9DA703FBB7C115E3E7" unitRef="usd">-12700000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-510978D516E6EE77F5AFFBB7C105A64C" unitRef="usd">-6700000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B977EC15BA6847E30EB6FBB7C0E68D5A" unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-9D969511ABF6B4538CD7FBB7C1254F85" unitRef="usd">-31500000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-78E191AF2C19025A3ABAFBB7C0A844A8" unitRef="usd">-41800000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-3C6EE50E0F31DF78BFD6FBB7C08924DC" unitRef="usd">51600000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-898BD32B6D5D52CE38B8FBB7C0B7A9FF" unitRef="usd">-193800000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-C93A4827A7F641AA12DEFBB7C125CD1D" unitRef="usd">97400000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-610E914EF21F27552BB6FBB7C11557AE" unitRef="usd">-10600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4958DCB6C783E74817BAFBB7C1056979" unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-2B0DBE879CAB4471E40DFBB7C0F6D378" unitRef="usd">-10600000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-817906281B5CD38D1A8CFBB7C115C845" unitRef="usd">2901300000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-5EAF0420396DCF375A4FFBB7C0E633B3" unitRef="usd">2861200000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q4" decimals="-5" id="Fact-FF7384FF330590CAC59FFBB7C0B76CE9" unitRef="usd">1628700000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2018Q4" decimals="-5" id="Fact-52BBEC23EB60E5619742FBB7C0B7FAA3" unitRef="usd">1389400000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7214BE24F65FE55367ABFBB7C1729544" unitRef="usd">-89000000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E78B890F8210F5C6EE76FBB7C1723833" unitRef="usd">-162100000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNoncashIncomeExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-8B0540005C9283D9D558FBB7C182A000" unitRef="usd">69100000</us-gaap:OtherNoncashIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A77896FA345923713D9CFBB7C0E6F46B" unitRef="usd">-18300000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-0378D789691669968BDCFBB7C0980832" unitRef="usd">-900000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B47FAB770D33654DD995FBB7C0E696B5" unitRef="usd">-14700000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-760113139EF3C5D51151FBB7C153CE7F" unitRef="usd">-19500000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-9C75C8EBDD9BB9E1381EFBB7C0A83E63" unitRef="usd">-10500000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-832C434820EF1EFC0106FBB7C1536329" unitRef="usd">-8500000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonrecurringExpense contextRef="FD2017Q4QTD_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember" decimals="-5" id="Fact-603E1DF85824B7FBECFFF06DD14015F1" unitRef="usd">135000000</us-gaap:OtherNonrecurringExpense>
	<us-gaap:OtherTaxExpenseBenefit contextRef="FD2018Q4YTD_us-gaap_IncomeTaxAuthorityAxis_biib_U.S.2017TaxActMember" decimals="-5" id="Fact-F4692B4431151A61B734F0E8A8848D04" unitRef="usd">11000000</us-gaap:OtherTaxExpenseBenefit>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5BFBE5AAFAACDF082FDCFBB7C1637BB5" unitRef="usd">22800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-05909431B9D7CFB6278BFBB7C1639B80" unitRef="usd">11000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-8935FDF84C7B02E70941FBB7C16374BB" unitRef="usd">-400000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2016Q4YTD" decimals="-5" id="Fact-93BCF1EBDDBF5D2435D0FBB7C17228D2" unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2016Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-8" id="Fact-A59C32C3AF80D9F0D152F0AA03AA5D76" unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A496E094BFB1D95142DAFBB7C182EF69" unitRef="usd">1365400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-D5DE2E618691D3682B9C1732388324FC" unitRef="usd">365400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-8" id="Fact-3618C606E79C028F867D17348C0C70F4" unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2018Q4YTD" decimals="-5" id="Fact-C919B7D401F7DB418615FBB7C16318B7" unitRef="usd">4352600000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-8" id="Fact-EBAB4B53BC1258C0EFA1FBB7C0B7D58D" unitRef="usd">3000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" decimals="-8" id="Fact-E277E3956BD92D0C86CF1737530434E6" unitRef="usd">1400000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2016Q4YTD" decimals="-5" id="Fact-7D18D6BE41C25F73FB64FBB7C1728DDE" unitRef="usd">0</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B82C677DB5B56485E590FBB7C17203BE" unitRef="usd">302700000</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsOfCapitalDistribution contextRef="FD2018Q4YTD" decimals="-5" id="Fact-E0FFD967EFF8DBAB7AF1FBB7C172EA30" unitRef="usd">0</us-gaap:PaymentsOfCapitalDistribution>
	<us-gaap:PaymentsOfDebtExtinguishmentCosts contextRef="FD2017Q4QTD_us-gaap_DebtInstrumentAxis_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" decimals="-5" id="Fact-286C048DDC2BF480E967F0A53B5C0429" unitRef="usd">7700000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
	<us-gaap:PaymentsOfFinancingCosts contextRef="FD2015Q4YTD" decimals="-5" id="Fact-75547877B54318F44419FBB7C079F9EC" unitRef="usd">47500000</us-gaap:PaymentsOfFinancingCosts>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5D4054C8B8A339305C33FBB7C18246C6" unitRef="usd">8500000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-09D05E190AE4E0C88EDCFBB7C1726ED4" unitRef="usd">5300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2018Q4YTD" decimals="-5" id="Fact-FF29B16F3FBEEBB6413DFBB7C172A143" unitRef="usd">2100000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5CD0470C162499FD0C01FBB7C172C65D" unitRef="usd">7913200000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-68CF6A38FFAAB15E0FB1FBB7C16307B2" unitRef="usd">5355200000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-7D0AD6DB5317BBDBA7ADFBB7C1639DFB" unitRef="usd">7694800000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
	<us-gaap:PaymentsToAcquireBusinessesGross contextRef="D2006Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_FumapharmAgMember" decimals="-5" id="Fact-179CBB62B098CD35839AFBB7C0F60557" unitRef="usd">220000000</us-gaap:PaymentsToAcquireBusinessesGross>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1EFF4B1C60AA8C7C83E581793F40CFE2" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4012B56DFFF91FD7767281791F9C693A" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-97E195116856B0AABA201674E68DBED0" unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="FD2018Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember" decimals="-8" id="Fact-6BB2A34DB7BC0F53023F1674A9618148" unitRef="KRW">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="FD2018Q4YTD" decimals="-5" id="Fact-D3DA1DF91B883B87EF928178D59043DA" unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2016Q4YTD" decimals="-5" id="Fact-39B79FEFE0E57044D64CFBB7C1726703" unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2017Q4YTD" decimals="-5" id="Fact-566FBEDE8E0E033A3D97FBB7C17213BC" unitRef="usd">120000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment contextRef="FD2018Q4YTD" decimals="-5" id="Fact-82C871A8BD8B6A1B3226FBB7C1722E58" unitRef="usd">112500000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-13B79C752C0C31A3FFFDFBB7C1639D32" unitRef="usd">111600000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-103087403C17790E3A3DFBB7C182145B" unitRef="usd">975400000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="FD2018Q4YTD" decimals="-5" id="Fact-A0B116A6E0A3530D3B50FBB7C1633D05" unitRef="usd">3000000</us-gaap:PaymentsToAcquireIntangibleAssets>
	<us-gaap:PaymentsToAcquireOtherInvestments contextRef="FD2016Q4YTD" decimals="-5" id="Fact-C2095F81968187131E0A1176DEEF54AE" unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
	<us-gaap:PaymentsToAcquireOtherInvestments contextRef="FD2017Q4YTD" decimals="-5" id="Fact-F70688C77181BDA0EE7F1176C5EE5930" unitRef="usd">0</us-gaap:PaymentsToAcquireOtherInvestments>
	<us-gaap:PaymentsToAcquireOtherInvestments contextRef="FD2018Q4YTD" decimals="-5" id="Fact-F46085364ACC9D45241A11769F732E90" unitRef="usd">462900000</us-gaap:PaymentsToAcquireOtherInvestments>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-53DF4B51DE5B9402233EFBB7C17211E7" unitRef="usd">1200000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E5D7039B8403A2599B86FBB7C172D27A" unitRef="usd">1200000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireOtherProductiveAssets contextRef="FD2018Q4YTD" decimals="-5" id="Fact-6107662D571F93CE623CFBB7C17200A9" unitRef="usd">1500000000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9382F652EED52EB56939FBB7C1638FD5" unitRef="usd">38600000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2017Q4YTD" decimals="-5" id="Fact-ED60691A9E5A075318AAFBB7C172289B" unitRef="usd">3000000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquireProductiveAssets contextRef="FD2018Q4YTD" decimals="-5" id="Fact-5E01889C51A196402BDBFBB7C1723E0B" unitRef="usd">58200000</us-gaap:PaymentsToAcquireProductiveAssets>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-5" id="Fact-77C7F2560640F35FF9CCFBB7C172FA3B" unitRef="usd">616100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-5" id="Fact-6F09E0AB0786B32A3481FBB7C1727222" unitRef="usd">867400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q4YTD" decimals="-5" id="Fact-F1D9445FA68918AE9CBAFBB7C172C5DE" unitRef="usd">770600000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToMinorityShareholders contextRef="D2017Q4_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-E5DF759FE5B7F08FB8C3FBB7C0F6488C" unitRef="usd">150000000</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PaymentsToMinorityShareholders contextRef="D2018Q2Neurimmune_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_biib_NeurimmuneMember" decimals="-5" id="Fact-AE4A5139DB53DE7F9457F521701173E8" unitRef="usd">50000000</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PaymentsToMinorityShareholders contextRef="FD2016Q4YTD" decimals="-5" id="Fact-6064E4BABE4DC3B0A9D8FBB7C1724613" unitRef="usd">0</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PaymentsToMinorityShareholders contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A77EE5775D1816026783FBB7C172FC66" unitRef="usd">134100000</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PaymentsToMinorityShareholders contextRef="FD2018Q4YTD" decimals="-5" id="Fact-9BEE2068D0D04F0B9727FBB7C172EE2E" unitRef="usd">36400000</us-gaap:PaymentsToMinorityShareholders>
	<us-gaap:PensionExpense contextRef="FD2016Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-3F690AC828C9F16BDECB85573F8F287F" unitRef="usd">2200000</us-gaap:PensionExpense>
	<us-gaap:PensionExpense contextRef="FD2016Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-C3FD1EFE4E1753A6F958FBB7C0790412" unitRef="usd">15300000</us-gaap:PensionExpense>
	<us-gaap:PensionExpense contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-2DC7671E38AD852B0EF6855691ED7CB8" unitRef="usd">1100000</us-gaap:PensionExpense>
	<us-gaap:PensionExpense contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-3A66C07CBBCDE27FAFAFFBB7C0799961" unitRef="usd">12300000</us-gaap:PensionExpense>
	<us-gaap:PensionExpense contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-EF4E6DB843CD05019B858555D7283F74" unitRef="usd">1300000</us-gaap:PensionExpense>
	<us-gaap:PensionExpense contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_CH_us-gaap_RetirementPlanTypeAxis_us-gaap_ForeignPlanMember" decimals="-5" id="Fact-350C76D0E0675FF3FF76FBB7C079F5AD" unitRef="usd">14800000</us-gaap:PensionExpense>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="3" id="Fact-372C290FC3AF081798F0FBB7C1345EEA" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="3" id="Fact-06EAD2A14EE40F370C13FBB7C105BF43" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="-5" id="Fact-ECC513BA4C4FD6C17F60FBB7C0A8E278" unitRef="shares">8000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_biib_SeriesXPreferredStockMember" decimals="-5" id="Fact-E503D430F25007572FF0FBB7C0A8A9EC" unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_biib_UndesignatedPreferredStockMember" decimals="-4" id="Fact-0C731490E0792EF16213FBB7C0A8A7E7" unitRef="shares">5250000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember" decimals="-4" id="Fact-7BEB579971B3FBD4AC25FBB7C0A8568F" unitRef="shares">1750000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockValue contextRef="FI2017Q4" decimals="-5" id="Fact-3E1BD9D142A44E619C99FBB7C0F68BF0" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="-5" id="Fact-29A3A2D15B335ED52C1FFBB7C105940B" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2015Q3_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-FBD60A25675BD43EFD5DFBB7C11503AB" unitRef="usd">58400000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidExpenseAndOtherAssets contextRef="FI2018Q2_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-4A52CFD039AF1A8D4EF7F1570A24F59D" unitRef="usd">50900000</us-gaap:PrepaidExpenseAndOtherAssets>
	<us-gaap:PrepaidTaxes contextRef="FI2017Q4" decimals="-5" id="Fact-233911C42FF40A1AE904FBB7C134D311" unitRef="usd">657600000</us-gaap:PrepaidTaxes>
	<us-gaap:PrepaidTaxes contextRef="FI2018Q4" decimals="-5" id="Fact-715D4BE691B978877B3AFBB7C134E7AE" unitRef="usd">271200000</us-gaap:PrepaidTaxes>
	<us-gaap:PriorPeriodReclassificationAdjustment contextRef="FD2016Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201707Member_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-A446086AEEF6EB905DBC1D48745F98B3" unitRef="usd">3300000</us-gaap:PriorPeriodReclassificationAdjustment>
	<us-gaap:PriorPeriodReclassificationAdjustment contextRef="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201707Member_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" decimals="-5" id="Fact-5C174359E4573901924B1D4834EB3271" unitRef="usd">2500000</us-gaap:PriorPeriodReclassificationAdjustment>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-950CCAA02FA69EF6318AFBB7C172D697" unitRef="usd">-2800000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-1A12C74586B5BEA4E1ECFBB7C1631818" unitRef="usd">-8600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-56BC5EB4570D5E9C43DEFBB7C163D778" unitRef="usd">-19500000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-BE43F02A0A68BC0A8F92FBB7C172CBF8" unitRef="usd">7378900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A38A58DAE086C169A17DFBB7C1633C0A" unitRef="usd">5565900000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-5BE93F5E33DD94560E2DFBB7C172AB0B" unitRef="usd">9173700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-5" id="Fact-32C728457F487AD129F6FBB7C115112B" unitRef="usd">2200000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-5" id="Fact-693B4EF8F162112FB616FBB7C115682B" unitRef="usd">700000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2018Q4YTD" decimals="-5" id="Fact-B9ED62CB7C771C456BE2FBB7C1157786" unitRef="usd">800000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProfitLoss contextRef="FD2016Q4YTD" decimals="-5" id="Fact-F69FB2D6DABC1F75B0B4FBB7C089BDA0" unitRef="usd">3695700000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q1QTD" decimals="-5" id="Fact-27A82EC2B9E68FEC401CFBB7C09835F4" unitRef="usd">747500000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q2QTD" decimals="-5" id="Fact-105E28AB715A4F16BDF7FBB7C0987C29" unitRef="usd">862800000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q3QTD" decimals="-5" id="Fact-ABD22E78271C7A5E1D1CFBB7C0795B8E" unitRef="usd">1226100000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q4QTD" decimals="-5" id="Fact-D09FD35BBD5A5E28387BFBB7C0695498" unitRef="usd">-166300000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q4YTD" decimals="-5" id="Fact-AE9376350A94D9E90B52FBB7C0D7329C" unitRef="usd">2670100000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q1QTD" decimals="-5" id="Fact-D24E19A27F1A59C44E38FBB7C0981BC1" unitRef="usd">1171200000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q2QTD" decimals="-5" id="Fact-5C21A40F5BF4AA92CA04FBB7C09876E9" unitRef="usd">915000000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q3QTD" decimals="-5" id="Fact-0FE7490548DA4C986F40FBB7C098628C" unitRef="usd">1442900000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q4QTD" decimals="-5" id="Fact-34C026D4FB75897A3EE2FBB7C0984E08" unitRef="usd">944900000</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q4YTD" decimals="-5" id="Fact-6B5CFB6F7FAF59FAFEECFBB7C134364E" unitRef="usd">4474000000</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4" decimals="-5" id="Fact-315F6DE5216E27EBE162FBB7C0A84609" unitRef="usd">4741500000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4" decimals="-5" id="Fact-E0CEED85B5C5520DE1E7FBB7C0A86954" unitRef="usd">5398600000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-5" id="Fact-4D09A2AAC0004C32D64DFBB7C079830D" unitRef="usd">3182400000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="-5" id="Fact-D13D0EEB702174ED3984FBB7C0E6E730" unitRef="usd">3601200000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" id="Fact-95112259B1BE2E1C30BAFBB7C0A8E65D">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" id="Fact-FAE61D1BE1448A285025FBB7C1051D58">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" id="Fact-8CC295A35E5B0C39639FFBB7C0795072">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" id="Fact-F4C46A84292E191F875CFBB7C1724E9C">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" id="Fact-4E6BCE408CA460B1DC5CFBB7C10561F8">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" id="Fact-E0BE89038C7E26B3D396FBB7C0F67593">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" id="Fact-D7FE2206AE91A144EF47FBB7C172457C">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" id="Fact-503D40105F07964A4E57FBB7C1447F3D">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-2CC11AC94B5AD64C2CA7FBB7C09832BA" unitRef="usd">-3400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-0252D8404796E28FEA3BFBB7C0E67676" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-75FA748E9E60E448F70BFBB7C1531551" unitRef="usd">-4000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-422ED855D83A11BC3051FBB7C1349A08" unitRef="usd">600000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-92E1FFE462EB46935AC917495D91839E" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-707346B9C28B26CA934AFBB7C1253019" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2EA482C217D1871947D5FBB7C098578D" unitRef="usd">44200000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-8628F8D6A0D3BF64EBC2FBB7C163DF9F" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-5F08307D867F3D7CBBD6FBB7C144E796" unitRef="usd">31500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-1DFE63EB00640A2F956EFBB7C09898FF" unitRef="usd">12700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-FE4BC2A61C4B47A969CF1748950DB6EA" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-1FDDD747ABB855D39C55FBB7C1532528" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-8F576A394EFFFF2BCF57FBB7C1442CD2" unitRef="usd">47000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" decimals="-5" id="Fact-F5C19FD4EDC0C11D7913FBB7C15389F2" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" decimals="-5" id="Fact-D2DA51FBD2001BE1B997FBB7C15390C5" unitRef="usd">41800000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" decimals="-5" id="Fact-8E9AC3DA8B9909D62668FBB7C0988F0A" unitRef="usd">6700000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" decimals="-5" id="Fact-E66257A6E963B93A045117471362873E" unitRef="usd">-1500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" decimals="-5" id="Fact-6B9940365A1D1D6A9EA8FBB7C153A9E2" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
	<us-gaap:RepaymentsOfDebt contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AABA3282A18A0C715626FBB7C163BC93" unitRef="usd">2700000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2017Q4YTD" decimals="-5" id="Fact-5B8D52E47342198D207EFBB7C172F3F1" unitRef="usd">560900000</us-gaap:RepaymentsOfDebt>
	<us-gaap:RepaymentsOfDebt contextRef="FD2018Q4YTD" decimals="-5" id="Fact-4B3023CD669B63A62C1BFBB7C163A7B7" unitRef="usd">3200000</us-gaap:RepaymentsOfDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember" decimals="-5" id="Fact-0DFF29D1DF4BB065B4F911A6BB5AD416" unitRef="usd">4000000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-2F8111132D59522AAC3DF56B7D4A7897" unitRef="usd">486200000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2013Q4QTD_us-gaap_TypeOfArrangementAxis_biib_SamsungBiosimilarAgreementMember" decimals="-5" id="Fact-FE0710414FB64901C0D2FBB7C0F69200" unitRef="usd">46000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2015Q4YTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-BBC89B7E2E419B2DFEAAFBB7C115B88C" unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q2QTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-FBF9C177AC780CF2D5C319611865B058" unitRef="usd">20000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4QTD_us-gaap_TypeOfArrangementAxis_biib_EisaiMember" decimals="-5" id="Fact-5CF4C9662F67972956E6FBB7C0E68948" unitRef="usd">50000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EF453E26A0DD23789E45FBB7C0E6D33F" unitRef="usd">1973300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-D3AD8F199CDBB966E335FBB7C115A205" unitRef="usd">5500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-A4C0475A8C9A046FBBC4FBB7C0D753F7" unitRef="usd">35300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-EAC575DFC0A66BB98048FBB7C098E6A7" unitRef="usd">26500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" decimals="-5" id="Fact-EE2258B4D43F76384CBF195DF730A159" unitRef="usd">10300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2016Q4YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-3CC75E334E943944D69BF18478982BB4" unitRef="usd">27800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q2QTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" decimals="-5" id="Fact-17D9E5CEEE6FF3DC79A21957B7534262" unitRef="usd">300000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4QTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" decimals="-5" id="Fact-C9AC2D8461ECC3678A54FBB7C182801B" unitRef="usd">50000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD" decimals="-5" id="Fact-49081054C7CD2B528128FBB7C0B7CC35" unitRef="usd">2253600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-F798E34EA60FA6A97E28FBB7C1826CF1" unitRef="usd">12000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-C4DCEA0FBA45217FC8EEFBB7C1157959" unitRef="usd">27500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" decimals="-5" id="Fact-0B6D8FEB8AA9EC5AA399FBB7C12508B5" unitRef="usd">80300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" decimals="-5" id="Fact-DACF11AFC2162C33FFD9195B91321992" unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-15907F64BA8BDCDC573EFBB7C0F68E5B" unitRef="usd">33000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-49B76AE3E46B35536CC7196330E01CC0" unitRef="usd">12800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q2QTD_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-D0E7E06D3A25F63DB637F1573B3DB52A" unitRef="usd">324100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q4QTD_us-gaap_TypeOfArrangementAxis_biib_C4TherapeuticsMember" decimals="-5" id="Fact-57A0383080FB92EFD019196C20993232" unitRef="usd">17000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q4YTD" decimals="-5" id="Fact-57661DADBD7353A2246AFBB7C1345507" unitRef="usd">2597200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SOD1Member_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-781EF859067A5933EAFEFBB7C115832F" unitRef="usd">53000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AGTCMember" decimals="-5" id="Fact-1D2E2B3395891A1DEDA8FBB7C0B734D2" unitRef="usd">39500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_AlkermesMember" decimals="-5" id="Fact-8410B7473B319AE2EBCEF17478CD7291" unitRef="usd">68700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_BristolMyersSquibbMember" decimals="-5" id="Fact-CBFE40DB62134D024ADF8517D04025A3" unitRef="usd">97000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_OtherresearchanddiscoveryMember" decimals="-5" id="Fact-F47E0EF7D927D68BE6BD195A35F4BF2E" unitRef="usd">5000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_biib_UniversityofPennsylvaniaMember" decimals="-5" id="Fact-6E28BAA757C29B82DF8EFBB7C182BD79" unitRef="usd">64000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2016Q4YTD" decimals="-5" id="Fact-DD5C328634DCC6EBFD5BFBB7C0F604FB" unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_RemedyPharmaceuticalMember" decimals="-5" id="Fact-C67F784CF18BBAFEA657FBB7C06989AB" unitRef="usd">120000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2017Q4YTD" decimals="-5" id="Fact-15C744C6E82CFABD5CD2FBB7C0F6FDFB" unitRef="usd">120000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_biib_KaryopharmMember" decimals="-5" id="Fact-0A5E771BCDD2709748EE11A4216E9518" unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2018Q2QTD_us-gaap_BusinessAcquisitionAxis_biib_PfizerMember" decimals="-5" id="Fact-F72C4B5D5F7CA14168A211A51B398997" unitRef="usd">75000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2018Q3QTD_us-gaap_BusinessAcquisitionAxis_biib_AliveGenMember" decimals="-5" id="Fact-5EFE63740B57AFEE79C911A7E380C499" unitRef="usd">27500000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2018Q4YTD" decimals="-5" id="Fact-A4C80723F60BBCC396B4FBB7C0F6E8C2" unitRef="usd">112500000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:ResearchAndDevelopmentInProcess contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_biib_TMSMember" decimals="-5" id="Fact-C076240DCDB6D1E6825011A729994773" unitRef="usd">18000000</us-gaap:ResearchAndDevelopmentInProcess>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4QTD_biib_FacilityLocationAxis_biib_CambridgeMAMember_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember" decimals="-5" id="Fact-14832161CA8770761DDFFBB7C0E61D93" unitRef="usd">7400000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD" decimals="-5" id="Fact-678C0F69E47E0AC5C4DBFBB7C11505CA" unitRef="usd">33100000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2015RestructuringChargesMember" decimals="-5" id="Fact-7CC505C5840A01CB1EEF95286058A7A7" unitRef="usd">8000000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2016Q4YTD_us-gaap_RestructuringPlanAxis_biib_A2016RestructuringChargesMember" decimals="-5" id="Fact-C716B8C58A67507C1EC9FBB7C105AC74" unitRef="usd">17700000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D9BFCA9C67158DA3B7F0FBB7C1058275" unitRef="usd">900000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember" decimals="-5" id="Fact-ECA57448E8C442530455FBB7C0E61CA6" unitRef="usd">900000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember" decimals="-5" id="Fact-5CA451E333D84C3722B8F0707A9D349A" unitRef="usd">18500000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q4YTD" decimals="-5" id="Fact-1E6ED7FBD6C190E890C2FBB7C134203A" unitRef="usd">12000000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_RestructuringChargesMember_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember" decimals="-5" id="Fact-3A5271DDDFB512403513FBB7C0F6F18F" unitRef="usd">12000000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringCharges contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_us-gaap_RestructuringPlanAxis_biib_A2017CorporateStrategyMember" decimals="-5" id="Fact-8111BC47A1E6D74D591281ECA8EFE3D8" unitRef="usd">10900000</us-gaap:RestructuringCharges>
	<us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="FD2016Q4YTD_biib_FacilityLocationAxis_biib_CambridgeMAMember" decimals="-5" id="Fact-55C5D14FF5D894B24AE1FBB7C125E47A" unitRef="usd">45500000</us-gaap:RestructuringReserveAcceleratedDepreciation>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-5" id="Fact-277F3A06837DD8CD1F7AFBB7C0B75912" unitRef="usd">15810400000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-5" id="Fact-9899B0E6150145E74146FBB7C1340358" unitRef="usd">16257000000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:Revenues contextRef="FD2016Q4YTD" decimals="-5" id="Fact-51B63FA61CB2A63FF3DAFBB7C0E664B9" unitRef="usd">11448800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-0B74B66068AC04CFBE961D5454133D79" unitRef="usd">-21900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-A5A13CE048A1A5EB2F29122BC28BD497" unitRef="usd">-21900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-331DA97C632C47072927122BC6A4203E" unitRef="usd">20200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-8FB2E6C623169A1525BB8207A3AAE349" unitRef="usd">41000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember" decimals="-5" id="Fact-169A7EA1FD01BB675507F081FB54480D" unitRef="usd">333700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-6D0BE282CEEF4F0956AB11F47B8C824B" unitRef="usd">268000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-420724845EABD69CAE2911F48036BA73" unitRef="usd">65700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-B335BA1E369F0DC4E03C11F4A48FAB85" unitRef="usd">100600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-A167D4257394E5A8766311F49901604B" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-E9E5AE10776948C63AA411F49E1868E0" unitRef="usd">100600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" decimals="-5" id="Fact-0183E6B49048A9EC14E7F0801F838723" unitRef="usd">100700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-764F8F0C6FDAD4283CE7F08014525485" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-D147B709CEF7150CF8B1F0801A34587D" unitRef="usd">100700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-1A5DA9EB76D76E700063F081F7621505" unitRef="usd">513200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-04776677B152B0D0C76311F46E60E7C4" unitRef="usd">445200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-8F29CBC80C40B76E53D511F473421D59" unitRef="usd">68000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-C39B8DEB83856A15511411F44D81DF78" unitRef="usd">84900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-7B07D77B30F5456E768011F443EBCE78" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-E0F07C83DBFC012E932E11F4488C3E0F" unitRef="usd">84900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-06C43A3078F5A4AD1A8D11F4B2F95DB4" unitRef="usd">100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-CD235B54A908DE61770B11F4A7C01C76" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-EBF7FB40186B1637887F11F4AD879F3C" unitRef="usd">100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-95CC78E033D55682EAA8F08147E597A9" unitRef="usd">45900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-027C1B5A59AB6980957E11F48B46FF99" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-4D1B7C875E1B98A9C1E211F4904D27B1" unitRef="usd">45900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember" decimals="-5" id="Fact-42C6C44E6D1EE159B987F069E150712A" unitRef="usd">846900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-F152A065EB629C04852DF0825933ADD9" unitRef="usd">713200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-CFC4EEBD0CF3D7EF4BDCF0825EFA62FD" unitRef="usd">133700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" decimals="-5" id="Fact-F997E1802E35AB661CF8F07FA4C6C64B" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-6FDC6D8226032B1FF837F07E7BB92070" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-FD175B39B5F11DD2A707F07F1B68CECC" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember" decimals="-5" id="Fact-5400931651F9AE13830F11F433D53004" unitRef="usd">2795200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-CA60F29E67CCC4387B7611F42A7BD9D3" unitRef="usd">1980300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-88BBE0B72EA78F9575D211F42F1A761B" unitRef="usd">814900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" decimals="-5" id="Fact-52FEC638A76849A3F8B0F07D578CD728" unitRef="usd">8819800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-C37FD3D2D126093CD066F07BF0817AAB" unitRef="usd">6332600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-A47694B43095B5D6D0B9F07CB18A8445" unitRef="usd">2487200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" decimals="-5" id="Fact-4132BFD1DE6F369F616A122BCE99DD71" unitRef="usd">230600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-4ACBABC1B856A311184EFBB7C0B70D8D" unitRef="usd">1314500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-0A26EFC83A5A3E7BC6A6FBB7C089022E" unitRef="usd">63100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-7EBEEC66D266E6DB9C67FBB7C0890954" unitRef="usd">1249500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-AD21C12AFBDAED512C3FFBB7C07944E2" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-9BB5F4F69BD4AD7C5A61FBB7C098B5F4" unitRef="usd">1900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-8DAD79985D3A6AFCDDB411F4690ED024" unitRef="usd">4600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-D2977293E00F7F612D5F11F45EEEAC15" unitRef="usd">4600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-6651AE28877443DCF0DEF14C26A27723" unitRef="usd">4600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-511E78F193D0F57A292411F463EBA9BA" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-EA55273721B80191164611F427255660" unitRef="usd">3968100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-693F8FB9E510AB6CC85311F41D534026" unitRef="usd">3169400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-B4D1D8AF0E446CBF519B11F42234D083" unitRef="usd">798700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" decimals="-5" id="Fact-EFB8040BEE105B13F69A11F44112D871" unitRef="usd">1963800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-82C1FFE98949DC63FF3C11F436E80CB8" unitRef="usd">1182900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-EE251472E55F8C1A60B311F43BF79D42" unitRef="usd">780900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-432D3D4F5D0B09DFA4E711F45997D5F4" unitRef="usd">7800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-A195C13AE81FCB5E26AD11F45050B557" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-E82F9A66025EF008E77E11F454DBE7BD" unitRef="usd">7800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-802918AF9F5539DAEB2AFBB7C0F6AEB5" unitRef="usd">316400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-390FEB5E8D35834FAEC7FBB7C0891C14" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-3E0DC54DBF81D9D7A2B6FBB7C089D425" unitRef="usd">224700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-CF8955DCBAF240D87FF5FBB7C089DDE4" unitRef="usd">20200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-E3E8173B8B2AFA659656FBB7C0894B72" unitRef="usd">71500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-E72459084F2840542DFDFBB7C115E5BF" unitRef="usd">9817900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-13D0DAE5B30AFEA6D511FBB7C08962D7" unitRef="usd">313000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-B77B3188FFB035092BA711F4B610F01C" unitRef="usd">7050400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-61A4104B09F6E902C6338528A36CF24C" unitRef="usd">6100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-F29BF0DBECFE5DC27766FBB7C0795FB9" unitRef="usd">217300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-E02229C4A9931475D410FBB7C0890E1E" unitRef="usd">2237200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-2BCF135341019C8EA9DC11F4BADD475F" unitRef="usd">2767500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" decimals="-5" id="Fact-EB52B81BA90A95FF8CB2122BCB4C9D56" unitRef="usd">46500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-0CD27E884D119B083CD9F1902CB1E0DC" unitRef="usd">20200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-BAA4CDBE07AE52DB4AD8852A55515BC0" unitRef="usd">-21900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_srt_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-8AFBEB1E5D791B4B4F741969631D4A2C" unitRef="usd">7800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-04133BC68B446DF7535DFBB7C0A811EA" unitRef="usd">-5300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1QTD" decimals="-5" id="Fact-38A02ED7534D83A3B57BFBB7C07975D1" unitRef="usd">2810700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-023EA3CA97D78D754BC2FBB7C0792A03" unitRef="usd">340600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-BFBC001CEBE55C8D4FC2FBB7C0897341" unitRef="usd">90000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-242EF07553CFF377D898FBB7C0796E31" unitRef="usd">2380100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD" decimals="-5" id="Fact-A56A59AE2135FD788B77FBB7C182B6F5" unitRef="usd">3078400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-2F1047A2351922AECC09FBB7C098F337" unitRef="usd">397100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-FC3FB85E3008668FF6F0FBB7C079CE64" unitRef="usd">41600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-D3003B2976E0DB76F203FBB7C079F7BA" unitRef="usd">2639700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q3QTD" decimals="-5" id="Fact-A740F3A5872CB587E482FBB7C098A312" unitRef="usd">3077800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-DFEBCA4851A0026BD7DBFBB7C0890925" unitRef="usd">406500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-EBC818446E2B7DE2CDA0FBB7C098BCDD" unitRef="usd">48800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-AB529AC730330034E655FBB7C0B785F2" unitRef="usd">2622500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4QTD" decimals="-5" id="Fact-4235C6AC9E76FDAE854FFBB7C069FC57" unitRef="usd">3307000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-8464D2B951E0BEF2F341FBB7C089F803" unitRef="usd">415000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-3FD00F7B1F0C6F362766FBB7C0794A1F" unitRef="usd">179600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-B88E3C5C8D1633F7AC1CFBB7C0794DA1" unitRef="usd">2712400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A6C43557EB96CCE8E29BFBB7C0E68F9C" unitRef="usd">12273900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-D047C1FF8C3CA223F958FBB7C144943C" unitRef="usd">-16900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-0A2D7162EA0E78DE54B6122B8D8A3EA7" unitRef="usd">-16900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-66A43AA9339F55C08755122B91A47350" unitRef="usd">42700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-8ED34069C8500FD7C0BB8207A007EA33" unitRef="usd">10700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember" decimals="-5" id="Fact-0EDCEA394F3E29615258F081D61B67F3" unitRef="usd">26000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-085689A87EFFB710671911F1A277D42E" unitRef="usd">21000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-0B6658160225EAE4BC1911F1A8FB62AA" unitRef="usd">5000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-E77621AFD047897053B511F1EB2C44E6" unitRef="usd">370800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-4957C089EBBA0AE3A54511F1C73B0296" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-FD95E32A7FB540D7BBCF11F1CE014E4A" unitRef="usd">370800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" decimals="-5" id="Fact-9B190ADE7731D3FB098CF080103ADC7E" unitRef="usd">379800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-F964C37C55D756F3B2BDF080057870EA" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-1BBE5E4C6A1A5BB0000DF0800AFF2675" unitRef="usd">379800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-FCEE11EC1C1102B51546F081D3063F60" unitRef="usd">48400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-9F389C1D5D4E32B971BB11F1925EEBE9" unitRef="usd">42200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-B0A044C8693834603F8C11F1986CA803" unitRef="usd">6200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-0D3EC83866F19F45113C11F16729D79D" unitRef="usd">91600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-AA688F45DFE890B11E9A11F15A80F6E0" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-6968AC3272BB1505563D11F15FC89C44" unitRef="usd">91600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-52AEC2739AFD37AE64BF11F20D9C63DE" unitRef="usd">9000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-D18E66952D4B93B90F4511F1FEE72281" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-CAF301CCD729CB949B0211F206E75BAC" unitRef="usd">9000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-6A3154943FC7B63516D6F081222DE5AE" unitRef="usd">39600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-2DAEA438484A9436EDF911F1B705206F" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-8BBB27FC3D865A8DCCC311F1BD032798" unitRef="usd">39600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember" decimals="-5" id="Fact-3D28540C7447A810F92EF0670F03A399" unitRef="usd">74400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-30DC2423F90DA0E94479F0824A4B4463" unitRef="usd">63200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-AD577023CBADE8F53BC6F0824FECBA61" unitRef="usd">11200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" decimals="-5" id="Fact-F7F04535E6529E5AB3D1F07F85F4732F" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-DD2A4C4E64B2256EF66CF07E56FB10A3" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-D910ED699B7B31517D80F07EF5EE5476" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember" decimals="-5" id="Fact-3A1D4D0224DFF6F52B7011F14AC1D74F" unitRef="usd">2645800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-F0590859457BABE5553C11F141504EE1" unitRef="usd">1889100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-CCF1699E541D06F1B40E11F145BD08CC" unitRef="usd">756700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" decimals="-5" id="Fact-D689405B176C334C056AF07D39C78033" unitRef="usd">8977200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-92169B9DB79A1C3E6DE1F07BBDA21A5C" unitRef="usd">6296900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-15571BC0B0AFFB107006F07C91813224" unitRef="usd">2680300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" decimals="-5" id="Fact-45752C2811BE7CE9EB3A122B98869957" unitRef="usd">253700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-1B4A54D60C87D3152D5AFBB7C0D7891A" unitRef="usd">1559200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-1FF22015EB5987BCCB85FBB7C0897B4C" unitRef="usd">83000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-2E4BD517F55F19424B43FBB7C0892160" unitRef="usd">1475600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-16112E14080FA141EBE1FBB7C0984356" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-5238AAFB6126F19031FCFBB7C089A09F" unitRef="usd">600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-B0FD59250920E622990911F18BDCF31B" unitRef="usd">883700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-F6652334719D2F75A87311F17DF35D2F" unitRef="usd">657000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-0C76920489217AC6BC2BFBB7C11580A4" unitRef="usd">883700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-B37A2D73029CACD0256C11F185C55370" unitRef="usd">226700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-431E8AD84189DAA66F9E11F13E63D44C" unitRef="usd">4214000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-469DFD5375CA145B973911F1349F000B" unitRef="usd">3294000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-82A7AC39B5D0DF48AE1A11F13981177A" unitRef="usd">920000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" decimals="-5" id="Fact-FF7933DF09FDF6D24ABC11F157A5EFB4" unitRef="usd">1973100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-0411F386D8710147869C11F14D855A8D" unitRef="usd">1113800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-CD5F7806077D89A17CFD11F152253971" unitRef="usd">859300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-CB28CC11A41AEEACFFA111F178072633" unitRef="usd">52700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-56F1E40A436D58B11C2E11F16B253CF5" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-EDF2CBD1121EA973D76611F1717E6A1B" unitRef="usd">52700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-F00F3C95E71C77914ABDFBB7C0E6F80F" unitRef="usd">360000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-436A44D069256BDE5893FBB7C0894392" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-15D6A98A90EFD5B86FA3FBB7C0895139" unitRef="usd">249500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-394E6C6F1237EB84361EFBB7C0894551" unitRef="usd">42700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-C175E6289685461192A7FBB7C079DF19" unitRef="usd">67800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-6F363E78FAAABB9EA6C2F061A1B8B1B7" unitRef="usd">64800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-FA7E9088FCD99B276F32FBB7C144865B" unitRef="usd">10354700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-710FCFF3EF14194FF280FBB7C098E5CC" unitRef="usd">332700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-1B749610727FC3F7FF5E11F213841DCC" unitRef="usd">7017100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-BE6AAE32C3AE090DA35B8528A35C5A41" unitRef="usd">53100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-9D6C167967B109A008AEFBB7C0897EC0" unitRef="usd">160100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-095E40FA592DC667CB61FBB7C0898172" unitRef="usd">2844800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-151401AFA04F062777AB11F21A6FA773" unitRef="usd">3337600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" decimals="-5" id="Fact-8FD52825B11BCAAB3377122B961CFAE7" unitRef="usd">69800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-5206D0329DBFDEAF11D6FBB7C0693CFF" unitRef="usd">42700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-DB935134326CFD06B590852A23067B5C" unitRef="usd">-16900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-1D33D77EF24B36D263881968CE1CDFCC" unitRef="usd">52700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-AB40ED13928665A79EE4FBB7C1449098" unitRef="usd">32500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1QTD" decimals="-5" id="Fact-23A561ED65CED6075917FBB7C098FB85" unitRef="usd">3131100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-748F16CD419737215D24FBB7C0989C00" unitRef="usd">443200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-64EF10137AAA5CC9CB1DFBB7C098364D" unitRef="usd">164400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-D3752433ADB11959F536FBB7C0B71485" unitRef="usd">2523500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q2QTD" decimals="-5" id="Fact-30F5220EB5EE8F50DD25FBB7C0A8F0D7" unitRef="usd">3356500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-88C5DEF7C81512BE7AF5FBB7C0A8862D" unitRef="usd">490400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-D6B8C15FBEF5A8E32FBDFBB7C098A032" unitRef="usd">108600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-FEAEDE2F5A3566E4FF95FBB7C0B7E32B" unitRef="usd">2757500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q3QTD" decimals="-5" id="Fact-60C639F42ED5A4F5F6E6FBB7C0D78B40" unitRef="usd">3439000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-C3EF9B7490C6A165F441FBB7C0983777" unitRef="usd">511700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-16B450CFDD09DA58BB1CFBB7C0985BD1" unitRef="usd">147200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-62F99B1B68A4EBE6EFA8FBB7C098270D" unitRef="usd">2780100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4QTD" decimals="-5" id="Fact-979AC4ED6E783B3C8ED9FBB7C098E574" unitRef="usd">3526300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-D9970C87FDCD6D950ADFFBB7C098CAC7" unitRef="usd">534900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-5B64C7AB2BDAB889A096FBB7C0D7BB1F" unitRef="usd">165700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-EB9178C1023430A26947FBB7C0980946" unitRef="usd">2825700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD" decimals="-5" id="Fact-D949D8023EAAFC0ABAE3FBB7C0D7AD8F" unitRef="usd">13452900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-5146F27FF0E0D0D75678FBB7C105CC20" unitRef="usd">-8600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_AbbVieMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-C41D0C81E48C412BDC37122982FE2434" unitRef="usd">-8600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-FFAB7CC4D67F00F6D90612298892765F" unitRef="usd">96400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_biib_SobiMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-B785709DBC367CE0446782079C2BBA4B" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember" decimals="-5" id="Fact-2E341B8FB6E4F5C6F933F0819F249F9A" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-D7907557C0957781E64211F08AB7B35B" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ALPROLIXMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-94EFF7EC483926C5A6B711F08F06D3FA" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember" decimals="-5" id="Fact-E8A4162C5C50384035CA11EF42689A34" unitRef="usd">485200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-8CD3345BB0DC75CE03A411EF392A43E2" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BENEPALIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-8F4AFD1421556683FC5411EF3D32CC0F" unitRef="usd">485200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember" decimals="-5" id="Fact-61B4A16F3FDD520B203EF08001C56A68" unitRef="usd">545100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-18A352D5CA23207EF25CF07FF6B3780B" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_BiosimilarsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-E50FF0DF970EBE477995F07FFC57BCE4" unitRef="usd">545100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember" decimals="-5" id="Fact-A66B3647A6C72629D21CF0819AE9FDEE" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-C172DF6CF14F042698E211F07E6652E5" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ELOCTATEMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-E53032DB587C7ED6F2BA11F08293D77A" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember" decimals="-5" id="Fact-DFC0B9A9EE81F28AA24511ED0EA4E813" unitRef="usd">92700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-C2BBA2C96317C3F4B5E211ED05B9EC08" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FAMPYRAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-21D98C8373687315DE6E11ED09664D05" unitRef="usd">92700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember" decimals="-5" id="Fact-4042F33C35400D23A46111EF4EC5D992" unitRef="usd">43200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-E402FD99A8877B320D1E11EF453F33FF" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FLIXABIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-8C873F53632B834937EB11EF4972C46B" unitRef="usd">43200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember" decimals="-5" id="Fact-A2863D1EFC971D1A7548F080D32CC1C9" unitRef="usd">22300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-1D4981A029C6BAC74FB211EF2C950A64" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_FUMADERMMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-2DD1B87DD694493A4F7111EF30EED6D3" unitRef="usd">22300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember" decimals="-5" id="Fact-4F285E1B9006E2220B3BF08246640FD1" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-54350CD1FA7D91E04E66F0823B302CB1" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_HemophiliaProductsMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-21E0D91FC4A108FE8B69F08240DA211C" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember" decimals="-5" id="Fact-1829C00A343CEC170E82F07F45DC7889" unitRef="usd">16700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-1D3A71A5A301B5A5C9B7F07DB09BB0BA" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_IMRALDIMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-09ECDC53AC7FFD317D2CF07EB54425FC" unitRef="usd">16700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember" decimals="-5" id="Fact-B7D4771C8685A0CBA60D11ECF7B7C6CD" unitRef="usd">2363000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-A37EDE66AAA132F879C911ECEE9CAAC7" unitRef="usd">1668300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_InterferonMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-70DCC24F0B9A70CFB09811ECF2F9CCEA" unitRef="usd">694700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember" decimals="-5" id="Fact-052AF9E7359F809E76DAF07CECE3A38E" unitRef="usd">8595200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-817B8C0F35C5813BF3DFF07AE40DAC2B" unitRef="usd">5946500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_MSProductRevenuesMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-12DB484A7B197D2AF415F07C3658A3E4" unitRef="usd">2648700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_OthercorporaterevenuesMember" decimals="-5" id="Fact-C0CE7703216EB095D9F512298C006EF5" unitRef="usd">459400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember" decimals="-5" id="Fact-A6F77814F9355345D528FBB7C0A88232" unitRef="usd">1980200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-C0FEEE48309C712E6697FBB7C089BAA2" unitRef="usd">76600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-FB29A10110748559FB05FBB7C0893A0A" unitRef="usd">1903400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-D9907FA89828AA6FCE81FBB7C0894C05" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_Revenuesfromanticd20therapeuticprogramsMember_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-6D25EB195F8854112403FBB7C0892315" unitRef="usd">200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember" decimals="-5" id="Fact-6CEFDA38087EDB323B6B11ED2AD5B060" unitRef="usd">1724200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-D372200A07384AF999EF11ED21344A51" unitRef="usd">854000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_IonisPharmaceuticalsMember" decimals="-5" id="Fact-3268906947840ABDACA0FBB7C1637EDC" unitRef="usd">1724200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_SPINRAZAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-7C1F6ED804F769017B5F11ED25C2C471" unitRef="usd">870200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember" decimals="-5" id="Fact-F929B4D502FAFF61AD7C11ECEAD933D7" unitRef="usd">4274100000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-4EA016CFC670231212EC11ECE0BEE5A8" unitRef="usd">3253200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TecfideraMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-3CCECBB5C0EFA191AC6C11ECE606F66A" unitRef="usd">1020900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember" decimals="-5" id="Fact-C98DE5AB8EDF9EFD025B11ED031EE864" unitRef="usd">1864000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-60E185CE17046D9985E511ECFA6D3786" unitRef="usd">1025000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_TysabriProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-BA889168A814ACAB247A11ECFE2328C4" unitRef="usd">839000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-95C64C214799CA89A7AA11ED1B566261" unitRef="usd">1400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-BF9C92A8FE44886DBB7011ED11903885" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-D3C7D0EBC57584880C8A11ED1654A057" unitRef="usd">1400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="-5" id="Fact-1944B65CF7ED19C03B7EFBB7C1447A4C" unitRef="usd">585900000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-0F480DB80D2EAFD45855FBB7C08964C9" unitRef="usd">0</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-965F83C73FB24D14E9C8FBB7C089B4FD" unitRef="usd">457000000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-B9803C7AABD61114338CFBB7C089F76B" unitRef="usd">96200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-B250CEC1CBA5F91DF6EDFBB7C08982C2" unitRef="usd">32700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_biib_BioverativMember" decimals="-5" id="Fact-99D640370691AF1C858CF062556B7BC8" unitRef="usd">206700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-5" id="Fact-621982259C963063CFFEFBB7C0F6FC71" unitRef="usd">10886800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" decimals="-5" id="Fact-3DF1315B6E74DB823A1CFBB7C08974C7" unitRef="usd">434800000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-F19CEB55ADAC147FDDFB11EF519829CF" unitRef="usd">6800500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-040F64937E71FEFCCF238528A34D0ECD" unitRef="usd">7500000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_AsiaMember" decimals="-5" id="Fact-78CE85E1A25A0172E40DFBB7C089DD2D" unitRef="usd">281200000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_srt_EuropeMember" decimals="-5" id="Fact-D9442330518BD908BFFCFBB7C0891DF5" unitRef="usd">3370300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-0D97291F992DB0E7945D11EF55F092F3" unitRef="usd">4086300000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_RoyaltyMember" decimals="-5" id="Fact-96C81FD5040542A00F7912298B56D119" unitRef="usd">38700000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_biib_SamsungBiosimilarAgreementMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-04DD76711755DE0867E1FBB7C0B709E4" unitRef="usd">96400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-B3137F1740C7B233908E8529F377B038" unitRef="usd">-8600000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_us-gaap_GeographicDistributionForeignMember_us-gaap_TypeOfArrangementAxis_biib_AbbVieMember" decimals="-5" id="Fact-29470CA45FACE2851D6C19680369B91C" unitRef="usd">1400000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2018Q4YTD_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" decimals="-5" id="Fact-0776062B4A4031EB0654FBB7C153D627" unitRef="usd">42500000</us-gaap:Revenues>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-CAE828108C8889860A03FBB7C0D745D7" unitRef="usd">1946600000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4AC3B6D7D5EA85C111D0FBB7C153636C" unitRef="usd">1933900000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-F0712C13861FCEE14976FBB7C0D75914" unitRef="usd">2106300000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs contextRef="FD2017Q4YTD" id="Fact-B791E0818D75A18CF3A2FBB7C1536724">0</us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs>
	<us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs contextRef="FD2018Q4YTD" id="Fact-B7710C58D55BFBE3934EFBB7C079614C">0</us-gaap:ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-65ACA306E0ADD95FD577FBB7C1636A17" unitRef="usd">154800000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-C0F938E61EC88A3A8F83FBB7C172B9FF" unitRef="usd">128000000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q4YTD" decimals="-5" id="Fact-660C29CDC7DAA05469CBFBB7C1725750" unitRef="usd">157500000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-1767B8B94B037A3014DAFBB7C1050DB1" unitRef="shares">16000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-3C36B0DBA019B536F906FBB7C0F6FFBB" unitRef="shares">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-3" id="Fact-FFC7A7FC68584157F7D582364BE05FCF" unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-3" id="Fact-2A19EC7E793F4DA9058E82350FABAAC7" unitRef="shares">7000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-74B77C1A8A90F822D24FFBB7C0D75BAF" unitRef="shares">134000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-64A29FEF9DC2D9B06F61FBB7C0A823E7" unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-8BCA8E9FE116E5BF5480FBB7C11534C1" unitRef="usdPerShare">376.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="2" id="Fact-880110A904EFB39F1F1082342D5A9364" unitRef="usdPerShare">315.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-CC48E0DE8BCBB8AAC62BFBB7C182B1AF" unitRef="usdPerShare">298.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-0BD60284F9324DDB51A7FBB7C1056BFB" unitRef="shares">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-ED3B0C68121C77143E7EFBB7C0F6D4EA" unitRef="shares">129000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-3" id="Fact-E0BF108443209ADC767982364BD136AA" unitRef="shares">45000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-3" id="Fact-EB0DAAD241843974165D82350FAB1205" unitRef="shares">67000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-8247015340EB4CE7B582FBB7C182613F" unitRef="shares">581000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember_us-gaap_TitleOfIndividualAxis_us-gaap_DirectorMember" decimals="INF" id="Fact-2103DC1E374417F9113FFBB7C163274F" unitRef="shares">9000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-1204D9D6F3D991DFA014FBB7C0A8CF3E" unitRef="shares">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-3D4F9148D855B98C0B91FBB7C105C698" unitRef="usdPerShare">328.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-36FF00057932F631F5DFFBB7C1446D50" unitRef="usdPerShare">268.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-4931E814F8BA5E0ACE8DFBB7C1051132" unitRef="usdPerShare">382.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-9B96F0DC5CD09CB6898CFBB7C16391E3" unitRef="usdPerShare">293.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-6E4D22D3F5313590F94FFBB7C10520ED" unitRef="usdPerShare">378.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="2" id="Fact-9F11857C25DC412E1B0482341FD9B703" unitRef="usdPerShare">317.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-1E0C5101C3C91BD8BA87FBB7C1634532" unitRef="usdPerShare">316.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-072A0143BFBF4FC1C790FBB7C105D6F1" unitRef="shares">105000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-3DBFB97F6351AC687177FBB7C1154898" unitRef="shares">171000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-3" id="Fact-D9B6ABADE4ACE74E59D482364BD12B1D" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-3" id="Fact-D3730FCFF3A77A15608E82350FBB24A2" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-E08307B103861C8AE702FBB7C1442D13" unitRef="shares">832000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-0C7E7A5D9F2AC288B2ECFBB7C0A8D2A1" unitRef="shares">91000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-69E9588A7FB174C150D3FBB7C105FD26" unitRef="shares">50000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-B23E2CF0BA69A2AFC7EAFBB7C115FCE2" unitRef="shares">180000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-3" id="Fact-BCB55176C563E6CA813E82364BD1DD87" unitRef="shares">40000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-3" id="Fact-7EE905BD51F10CD97CFF82350FAB6C37" unitRef="shares">60000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-ECE5DAD34A79D74BBC45FBB7C153BF94" unitRef="shares">903000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-612105F0183CE89556BDFBB7C0A86F96" unitRef="shares">48000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-730067379BB41DDAF612FBB7C0F64181" unitRef="usdPerShare">370.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="2" id="Fact-C5AC220C82977519B352823418A3FF54" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2017Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-5C6E24AA755F5EB6908DFBB7C0989722" unitRef="usdPerShare">291.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-24314802389E11403067FBB7C0F61AD2" unitRef="usdPerShare">371.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="2" id="Fact-39473DF5DBC5AB62AB0B823434C5E382" unitRef="usdPerShare">317.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-18ECA7943249F6A193ACFBB7C0B77B20" unitRef="usdPerShare">303.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_CashSettledPerformanceSharesMember" decimals="INF" id="Fact-2096A32D936080A1B3E7FBB7C11552FC" unitRef="shares">51000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="INF" id="Fact-8B002AD24947C86FDB11FBB7C0F665BD" unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinCashMember" decimals="-3" id="Fact-6C219B0B6B99B57F0D2A82364BE03864" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="-3" id="Fact-A878C5FEF992EA6F8FA982350FBB678C" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="INF" id="Fact-723A91030D955FB890DFFBB7C182310A" unitRef="shares">376000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" decimals="INF" id="Fact-5EBAFE94B31515DC58F2FBB7C0A8ED51" unitRef="shares">52000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-6C2A9DD03977F060F224FBB7C144BC23" unitRef="usd">39300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-C35929DD29BD2E7C13D3FBB7C1531D80" unitRef="usd">104600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-00EF29F25621CA2B68CFFBB7C1535081" unitRef="usd">31400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-318C313443C594C35E90FBB7C14482AD" unitRef="usd">100000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="-5" id="Fact-9C0EFC1047929A7BBA89FBB7C1535F03" unitRef="usd">26900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="-5" id="Fact-53FA532D565BCD308DDFFBB7C14422DD" unitRef="usd">111700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-2CEBBD6AF52569C15978FBB7C0F63BC0" unitRef="usdPerShare">365.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_PerformanceStockUnitsSettledinStockMember" decimals="2" id="Fact-6780CD3F6FE1E9E739BA82342711511C" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_TimeVestedRestrictedStockUnitsMember" decimals="2" id="Fact-0D8FDB298DE4ABC6A881FBB7C163FAC7" unitRef="usdPerShare">299.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-A09E0BFD9FF7ACD90AF8FBB7C105F3CF" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-BFC25299C349866646DAFBB7C105BEE8" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="2" id="Fact-A8663C4DF590ABBC5F37FBB7C115C15B" unitRef="number">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-B1CF57F0B81BEDB1B360FBB7C163BABF" unitRef="number">0.407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-32D7344B9851C44C8954FBB7C0A8961B" unitRef="number">0.382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-9C3EFED2D548C8177D5EFBB7C125F813" unitRef="number">0.356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-BA9E483CCF968CEB7B74FBB7C0E61EB6" unitRef="number">0.330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-04A9C2E4F909C192651BFBB7C15360AA" unitRef="number">0.324</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-94C460FB3CDB51ED1AFEFBB7C0D73326" unitRef="number">0.275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-29429172FBCC8403F9ECFBB7C0C79E8A" unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-72CF3954EA3F85D00580FBB7C144C2C9" unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-6A06C18BB4A92FB0BCFFFBB7C09883D6" unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2016Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-2ADD0904E069CF8D4D3CFBB7C0D74BD1" unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-05C13AF5A44A3CF45C54FBB7C1057778" unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_biib_MarketStockUnitsMember" decimals="3" id="Fact-6C3442F4612CDAD53642FBB7C0E6AC10" unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2017Q2_us-gaap_PlanNameAxis_biib_A2017OmnibusEquityPlanMember" decimals="-5" id="Fact-87594F1CFBCCF6D278BEFBB7C1537AAE" unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2016Q4" decimals="INF" id="Fact-90CEC9A55779CB10068DFBB7C1639857" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q4" decimals="INF" id="Fact-1C9FD979E07D72D307D4FBB7C163A5A1" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2018Q4" decimals="INF" id="Fact-3CD7BA010E0A898807A8FBB7C15387CD" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q4YTD" decimals="-5" id="Fact-372711AC17977C6A6022FBB7C1537119" unitRef="usd">10400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A9466C73B19BFB49F118FBB7C153612C" unitRef="usd">3400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2018Q4YTD" decimals="-5" id="Fact-0C94A966A3BF3AC0E6D9FBB7C144485A" unitRef="usd">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2018Q4YTD" decimals="INF" id="Fact-1BC2E0D9AA0AEEED8370FBB7C0C75366" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2018Q4YTD" decimals="INF" id="Fact-0D7D71D59B74461B217CFBB7C0C73617" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q4" decimals="-5" id="Fact-873E9E3DDA387ED54118FBB7C153674C" unitRef="usd">6700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4" decimals="INF" id="Fact-E7F23DC276DD6738E263FBB7C0C72ECD" unitRef="shares">42000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4" decimals="INF" id="Fact-E59F907C2EDD7CD3B488FBB7C0C75144" unitRef="shares">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-9DC95C7B53E2F9AED77FFBB7C0C78EA0" unitRef="usdPerShare">53.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-AE7D3A436811308D34D0FBB7C0D7EF8B" unitRef="usdPerShare">53.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD" decimals="2" id="Fact-04633D059260DDC0F6ECFBB7C0C75A58" unitRef="usdPerShare">53.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD" decimals="2" id="Fact-5DF840BA21D2CC4CB64CFBB7C0C7327F" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD" decimals="2" id="Fact-2CFC5C42CCC55338FF1BFBB7C0C79A8A" unitRef="usdPerShare">0.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q4YTD" id="Fact-24C8711EB157EFECFCDCFBB7C1537573">P0Y8M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-91A190C94EC75F0C778DFBB7C0D70165" unitRef="shares">241200000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-9EDA0FEF782929492F46FBB7C0C724AE" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-DBA5A25AB52963828481FBB7C0B705FD" unitRef="shares">22600000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-157E06187FC8E06BF088FBB7C0B7AA0B" unitRef="shares">238500000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-6659E3E08BC07EA47E32FBB7C0E67ABE" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-348FFC424BDF5BBA4C0FFBB7C0794406" unitRef="shares">22600000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-97122B531D921CB59AE8FBB7C0E60B8F" unitRef="shares">235300000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-6C5289EEE377909FBD78FBB7C0E6EDD3" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-DFE9DB8294F444765C70FBB7C134FBFB" unitRef="shares">23800000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-380CDAEA5EDB31B498D0FBB7C1441146" unitRef="shares">221000000</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-F941886D9FDF39578FBAFBB7C17252E0" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-20BF9D52060F953E89F8FBB7C098E94F" unitRef="shares">23800000</us-gaap:SharesIssued>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="INF" id="Fact-5E81BC6D42298180F60FFBB7C11569B2" unitRef="shares">190000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="INF" id="Fact-B4612ADBD6B0199A29B9FBB7C0988B48" unitRef="shares">167000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2018Q4YTD" decimals="-5" id="Fact-912B3C90FCC15891B7FDFBB7C1539862" unitRef="shares">6200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="INF" id="Fact-19154C4049DE3B4DE481FBB7C098611A" unitRef="shares">170000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-50ED89F038C4F5C02ECAFBB7C0A8A909" unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-9166C5023BE0C8B75882FBB7C07941A1" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q4YTD" decimals="INF" id="Fact-FD7ADC4D9FAB2F67F29CFBB7C0C7B1F1" unitRef="shares">15000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-C2D6C849247324DC4609FBB7C172917E" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-7840BE568E6DAA54D9C8FBB7C0983EA5" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-ACCA504F791D71A2CF9FFBB7C0E625E8" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-357E6893423ACBFB1830FBB7C15373DE" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2016Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="-5" id="Fact-3D13EFCBB586E2EA54AFFBB7C115158D" unitRef="usd">41500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="-5" id="Fact-4CBCB010245E3CEC0D55FBB7C1158B56" unitRef="usd">39800000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_biib_A2015ESPPMember" decimals="-5" id="Fact-8A823782C8B10BBF58A0FBB7C1153862" unitRef="usd">40500000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-5" id="Fact-CCE8A4F5813C6722ACFDFBB7C0D718C0" unitRef="usd">52100000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-193843507B5CD070A6E7FBB7C0D7DC3C" unitRef="usd">47600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-C4316635E3DE6FABB687FBB7C0C7065E" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-7207EEC54872AB3FA3A185F791C58618" unitRef="usd">4500000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-5" id="Fact-91C4D7A5158BA1ECA5C0FBB7C0C71C05" unitRef="usd">45800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-3B894C6058DDA5C692E8FBB7C0E6F0AD" unitRef="usd">44800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-698E52FB3CBC48A7615AFBB7C13467DA" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-205EE46C0C6DEEB6D5D5FBB7C1631344" unitRef="usd">1000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q4YTD" decimals="-5" id="Fact-B3E44F01B2DF3F93B6A6FBB7C1725298" unitRef="usd">43800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-19CB5578BC417A8364BEFBB7C153C780" unitRef="usd">43800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-67D75DD08D5ECF29253DFBB7C172BCD5" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2016Q4YTD" decimals="-5" id="Fact-DCADB699227C33101026FBB7C125F82B" unitRef="usd">43700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-E44804B9E5A1A48BC4EAFBB7C0C75D98" unitRef="usd">43700000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-57EF5D53F9BDB052644EFBB7C12585E2" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D6EFCDADB808A8A98EB0FBB7C144E9E6" unitRef="usd">40500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-5E28ED90007594118CA7FBB7C13458F6" unitRef="usd">40500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-F888A3E4D112F52DF729FBB7C0C71091" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2018Q4YTD" decimals="-5" id="Fact-76C37F42C484FBF7F9D0FBB7C17232EE" unitRef="usd">41200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-236BFC941804782FB1D9FBB7C1537A47" unitRef="usd">41200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-2AF4E6D888D427DA5F29FBB7C07976F5" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2016Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-8" id="Fact-FD329219A183CBDF510D17329FC21038" unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="FI2018Q3_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" decimals="-8" id="Fact-B79BCE58BE7AD55AC2F41734F959AF47" unitRef="usd">3500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
	<us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased contextRef="FI2011Q1_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-74685F7D429591B5480DFBB7C0A8049F" unitRef="shares">20000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-3AB443D16E03F85CC661FBB7C0B79137" unitRef="shares">3300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-ED76C2984229F028A85CFBB7C0A856DC" unitRef="shares">3300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-3556ED2543DE1D0ADD03FBB7C0E661C1" unitRef="shares">3700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-D0D718ACCFEF94523563FBB7C0F68EA2" unitRef="shares">3700000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-C731059D1C778E8A81C8FBB7C079E957" unitRef="shares">10500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-5A47FF8006B363BCC668FBB7C163253A" unitRef="shares">10500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-8109C9477E56199B3C9F1D3571B9B496" unitRef="shares">4300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockRepurchasedAndRetiredDuringPeriodShares contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-733D07D73247A1A460AC1D35795EEB2B" unitRef="shares">4300000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-5" id="Fact-9B4EF7FABE3CEC07DBFFFBB7C0986718" unitRef="usd">9372800000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-5" id="Fact-D78F189D530FD30F9DC4FBB7C1347C06" unitRef="usd">12140100000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-5" id="Fact-89A44FEE645DE85A123BFBB7C1342170" unitRef="usd">12612800000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="-5" id="Fact-AC893CE7F1752EEB6B49FBB7C134C8DB" unitRef="usd">13039600000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4" decimals="-5" id="Fact-56C8CAAAD2558BAFB137FBB7C1251547" unitRef="usd">9374900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-A1EC8E02FA6A27AF8C92FBB7C0B7E44E" unitRef="usd">-224000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-F4F613C77CBB29FAFE7DFBB7C125AF06" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-8E54061C49405B46D312FBB7C0D732FF" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-128F5D44FE1B75246A6AFBB7C0A8C313" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-86FAC77B8F1EC5BD07CAFBB7C0A8DE05" unitRef="usd">12208400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-FFE95EAEBEA438054626FBB7C0B74C6D" unitRef="usd">2611700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="-5" id="Fact-43F96B1D38F7C0497A9EFBB7C0E611AE" unitRef="usd">12128600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-E7C7FED450F8ABB7F4B2FBB7C1150CD6" unitRef="usd">-319900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-3996ED2A18E13B247D1EFBB7C115BF1C" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-D2AAF1656DFBF56CE707FBB7C0E6A9A6" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-0E5BD98DB60F1F34B3FEFBB7C0E6642F" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-9E3DB8C7554064DC10D2FBB7C0F62884" unitRef="usd">15071600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-7AF2BCB05CC3F47E80BFFBB7C0D7B3F9" unitRef="usd">-2611700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4" decimals="-5" id="Fact-4FC02FA89E40214C55D7FBB7C098AF01" unitRef="usd">12598100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-049004B014F05E8A2AAFFBB7C144936F" unitRef="usd">-318400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-8759CC1A7DD29671FEF0FBB7C0F69B72" unitRef="usd">97800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-CFB11D83432660B785C4FBB7C0D7C378" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-C9CC027B1F851F7A9D2DFBB7C0E6D0E5" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-C90E8BBDED6A9955E2BBFBB7C0D74321" unitRef="usd">15810400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-0B01B408C3E34CAC42D3FBB7C0F69578" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4" decimals="-5" id="Fact-AB1EAD5E90B9025FFB56FBB7C1441A0F" unitRef="usd">13031600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-5" id="Fact-006DA64A18230753A5CDFBB7C0E62514" unitRef="usd">-240400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-E78B87398A1E1F57BD2AFBB7C172C6CE" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-059ECF5D1C919C12C0F6FBB7C144D4F7" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-5" id="Fact-44FBC9029D725D2EE91CFBB7C1722514" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-23DF18AA85B3AD589D32FBB7C0B7FF3E" unitRef="usd">16257000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-6BF9D8910F4C8AF0B641FBB7C153A1E2" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="FD2017Q4YTD" decimals="-5" id="Fact-F203C4E7365C87663599117AFCA6C2D4" unitRef="usd">-852800000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
	<us-gaap:StockholdersEquityNoteSpinoffTransaction contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-13588E9E43AF244484681179B82876B7" unitRef="usd">-852800000</us-gaap:StockholdersEquityNoteSpinoffTransaction>
	<us-gaap:StockholdersEquityOther contextRef="FD2017Q4YTD" decimals="-5" id="Fact-FEBE007356E4B8369764FBB7C0C7275F" unitRef="usd">17500000</us-gaap:StockholdersEquityOther>
	<us-gaap:StockholdersEquityOther contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-608E0A9514E67AFB1D23117A427548F7" unitRef="usd">17500000</us-gaap:StockholdersEquityOther>
	<us-gaap:StockholdersEquityOther contextRef="FD2018Q4YTD" decimals="-5" id="Fact-2258A3CB3AB67EE7FB92FBB7C153882A" unitRef="usd">106100000</us-gaap:StockholdersEquityOther>
	<us-gaap:StockholdersEquityOther contextRef="FD2018Q4YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-DFE3527DFEFAFA8888A98507113F4095" unitRef="usd">1500000</us-gaap:StockholdersEquityOther>
	<us-gaap:StockholdersEquityOther contextRef="FD2018Q4YTD_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201616Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-AA53596BC4C7FDC2CBB3FBB7C0794490" unitRef="usd">104600000</us-gaap:StockholdersEquityOther>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_GeneralBusinessMember" decimals="-5" id="Fact-E1D4F271FE5B79E0EC77FBB7C0F631F0" unitRef="usd">1300000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2018Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-75CFBC15D4BBFF72682CFBB7C0D767FC" unitRef="usd">133100000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxesPayableCurrent contextRef="FI2017Q4" decimals="-5" id="Fact-F018B132EE6C11C77E03FBB7C079115C" unitRef="usd">68200000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TaxesPayableCurrent contextRef="FI2018Q4" decimals="-5" id="Fact-37C75E4F4B52A1400CCDFBB7C0F67E69" unitRef="usd">63500000</us-gaap:TaxesPayableCurrent>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD" decimals="-5" id="Fact-EC82F8E2868534F61758FBB7C0C7695B" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-5DF4BACF7CB05871B80BFBB7C0B77FDC" unitRef="usd">164900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-6F77AD95E624941B06DC117D7E41B65E" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-43E0307D2D2746CA7109FBB7C0B7DF46" unitRef="usd">835100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-A52757E42191F9236AE4FBB7C1343002" unitRef="usd">-1000000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-C0ED2146EDECCB8B7838FBB7C1446306" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-66279C7972549A4560DCFBB7C0F658BB" unitRef="usd">36000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-619F4F43987AF495CBAAFBB7C0D7DD29" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-309147E529309D94B51DFBB7C10564BB" unitRef="usd">964000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-A65B65DE8E1628BF84DDFBB7C0B7B3A8" unitRef="usd">1000000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-E733EAF75BAEEF208E94FBB7C0793545" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-1D7CBA2D2BBEDC01D0B3FBB7C079F623" unitRef="usd">171100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-4CFC5D549034BF910A33FBB7C172AB31" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-0BAF2BA021AAAC7E58FAFBB7C14482B6" unitRef="usd">2828900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-E5BDFB2A1AA3871F189FFBB7C144FDC9" unitRef="usd">3000000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" decimals="-5" id="Fact-9C9B3EDE1A9F479DE27A1D357CF52918" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-5" id="Fact-8EA62D91E5D83C569A691D3576AD719A" unitRef="usd">92800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-913F6F14B4EED57930EB1D35748870ED" unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-5" id="Fact-7EBB28B8E3CFD2043A071D35789150C0" unitRef="usd">1259800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockRetiredCostMethodAmount contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-1FFBFFC94E3395674B241D357A979FB9" unitRef="usd">1352600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
	<us-gaap:TreasuryStockShares contextRef="FI2017Q4" decimals="-5" id="Fact-9C256ECC7B15149C955EFBB7C0C7CF26" unitRef="shares">23800000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockShares contextRef="FI2018Q4" decimals="-5" id="Fact-F25822098E2185BA3086FBB7C0D7BB3E" unitRef="shares">23800000</us-gaap:TreasuryStockShares>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2016Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-C393381AEA836CB7CE9FF0A9C664C7C3" unitRef="shares">3300000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-71B07D43A106297FF362FBB7C0C75A7F" unitRef="shares">3300000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-F04853529FB798380096173417285A55" unitRef="shares">1200000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-30A743F2F88BE27384D2117AA325B44B" unitRef="shares">1200000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-EA7F197FE407FB1B90F8FBB7C0A805A2" unitRef="shares">3700000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-A9E8880CA873C0797A5DFBB7C1151813" unitRef="shares">3700000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramMember" decimals="-5" id="Fact-2C25497F8F82358D0ACEFBB7C0A82AE2" unitRef="shares">10500000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-BA98F0DB56B4D8AE0C3AFBB7C172C2CB" unitRef="shares">10500000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" decimals="-5" id="Fact-771270DE1C79C65EC91617368C125F9E" unitRef="shares">4300000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockSharesAcquired contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-E0F5EEBA24844EC487C21D35622A4A92" unitRef="shares">4300000</us-gaap:TreasuryStockSharesAcquired>
	<us-gaap:TreasuryStockValue contextRef="FI2017Q4" decimals="-5" id="Fact-9B212406515FA66EB908FBB7C0896076" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValue contextRef="FI2018Q4" decimals="-5" id="Fact-24CB97564B822FDDAEAAFBB7C1536A02" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1598AB2519AAA531812FFBB7C0C7CA35" unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-A57A7854E4EE9A3F306EFBB7C0D794E7" unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember" decimals="-5" id="Fact-65E40B606413680AF6BA117AA899EBB1" unitRef="usd">365400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2011ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-895B0AA7FF30046BF8D1117AA5FC9534" unitRef="usd">365400000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-5" id="Fact-BA20A461893245040F54FBB7C1443CDF" unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2017Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-9F1BFC53E100E35F5916FBB7C0E60013" unitRef="usd">1000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember" decimals="-5" id="Fact-430D01950606475BAF79FBB7C0E6CC31" unitRef="usd">3000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2016ShareRepurchaseProgramYearToDateMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-81D8D2A8EE6704992FBAFBB7C182F60D" unitRef="usd">3000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember" decimals="-5" id="Fact-2EFE7A559ECD5157F9981D356B62B58E" unitRef="usd">1352600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_biib_A2018ShareRepurchaseProgramMember_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-5" id="Fact-655307B153BA5E35E5D51D3566DCA40E" unitRef="usd">1352600000</us-gaap:TreasuryStockValueAcquiredCostMethod>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E9CCD6760BEB7A208A5AFBB7C134E859" unitRef="usd">49800000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2017Q4YTD" decimals="-5" id="Fact-EC7A0C1369D9FAF5F93FFBB7C089274B" unitRef="usd">-113000000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2018Q4YTD" decimals="-5" id="Fact-53A3CDCD19B27CA308B4FBB7C0F63F8E" unitRef="usd">27300000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember" decimals="-5" id="Fact-8C4AF19D4344B9882AF20F7C0F44A74D" unitRef="usd">3800000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
	<us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments contextRef="FD2018Q1QTD" decimals="-5" id="Fact-158947A64175BB28C426F569BA8897CE" unitRef="usd">-6400000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
	<us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments contextRef="FD2018Q2QTD" decimals="-5" id="Fact-196222B28F9B760A54D8F56A1EAE521D" unitRef="usd">5400000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
	<us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments contextRef="FD2018Q3QTD" decimals="-5" id="Fact-4462B14EDFDF1DE12067F56A427A02A3" unitRef="usd">141200000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
	<us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments contextRef="FD2018Q4QTD" decimals="-5" id="Fact-A5213FC88DAD260184CEF56A6367B9F0" unitRef="usd">-12200000</us-gaap:UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q4" decimals="-5" id="Fact-F5F16012EEB0278439BCFBB7C12516CB" unitRef="usd">67900000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-5" id="Fact-BCE2840E8D94B805F126FBB7C1347E45" unitRef="usd">32400000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-5" id="Fact-0AA4F53CA27BA379FFFBFBB7C1342530" unitRef="usd">66800000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2018Q4" decimals="-5" id="Fact-1B2694278DB9D418C4BDFBB7C1254821" unitRef="usd">114200000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-A1FB1E08DE88AF2488E7FBB7C12598A7" unitRef="usd">13300000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-5" id="Fact-967B0BC581B37335D9EAFBB7C134A82E" unitRef="usd">21800000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-5" id="Fact-742773A7D45ED0CDE485FBB7C1059964" unitRef="usd">13600000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1891CC4B18BEC9262897FBB7C1530F3A" unitRef="usd">64300000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2017Q4YTD" decimals="-5" id="Fact-694E4176778848166F6CFBB7C125D602" unitRef="usd">44600000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-EF772F0ECD552DDF9642FBB7C163BCA9" unitRef="usd">4700000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2016Q4YTD" decimals="-5" id="Fact-9F26ADACBA05F7AB4B9BFBB7C0C77488" unitRef="usd">9100000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-0969B939DFC70FAC0623FBB7C0C75724" unitRef="usd">4800000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2018Q4YTD" decimals="-5" id="Fact-734234F5C197D846363EFBB7C0D76ACB" unitRef="usd">2200000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-B398BD1920D748885E8CFBB7C0A8109F" unitRef="usd">7200000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-5" id="Fact-378B3C921C05322AE5CBFBB7C163FCE0" unitRef="usd">5700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-5" id="Fact-8CB9E7F5CAC802907614FBB7C134C189" unitRef="usd">500000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1FC64D998A4E4EA38B99FBB7C1251642" unitRef="usd">36300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-5" id="Fact-BD3BA091D0BF639AF851FBB7C1636D27" unitRef="usd">7300000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-5" id="Fact-D521B15C66267AE7BBB7FBB7C1251F76" unitRef="usd">58700000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="FI2017Q4" decimals="-5" id="Fact-C50FC1862E184502E00DFBB7C0C7DE43" unitRef="usd">16100000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
	<us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="FI2018Q4" decimals="-5" id="Fact-7D5789B48747D700A618FBB7C0D75245" unitRef="usd">13800000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
	<us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_biib_ZINBRYTAMember" decimals="-5" id="Fact-971DB45B5F88B2F7BCA11B6D265E29D9" unitRef="usd">93800000</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2016Q4YTD" decimals="-5" id="Fact-FBD0B5249805822119A0FBB7C1345C10" unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2017Q4YTD" decimals="-5" id="Fact-3528D611780968E2305DFBB7C1340715" unitRef="usd">1400000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="FD2018Q4YTD" decimals="-5" id="Fact-F8BAEA8B98ABF397C89AFBB7C153E0F8" unitRef="usd">2900000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2016Q4" decimals="-5" id="Fact-F246A9AA820F9AD7E54FFBB7C0C782D9" unitRef="usd">26900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2017Q4" decimals="-5" id="Fact-C38776C7E1BC004F7CC3FBB7C0C7A1EF" unitRef="usd">64300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2018Q4" decimals="-5" id="Fact-BE00C85634D5D6EF1DD2FBB7C0C7D5EC" unitRef="usd">109100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4" decimals="-5" id="Fact-4F78A5FFD23519567802FBB7C0C70F78" unitRef="usd">662700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-6ECF6080681531D0FE37FBB7C0C7315A" unitRef="usd">548700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-DBA103E9A0BBF8469894FBB7C0C7E8F7" unitRef="usd">56100000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2015Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-B941FE7055DAC31AEB73FBB7C1533F36" unitRef="usd">57900000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4" decimals="-5" id="Fact-8E3EBE1380BE80F6C861FBB7C0A8133C" unitRef="usd">605500000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-DD55B9513893D8EAB573FBB7C105597F" unitRef="usd">482700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-52919EA540EC2520C74CFBB7C144DFA7" unitRef="usd">71600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2016Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-D072FBE5C058E9CA19F9FBB7C11565FF" unitRef="usd">51200000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4" decimals="-5" id="Fact-951314CBC5D1504872DBFBB7C0F649DC" unitRef="usd">761600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-3E5C610799517DB6E103FBB7C08948D9" unitRef="usd">189600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-DF811852F0012DAEFE4DFBB7C0F646C6" unitRef="usd">572000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-94A7CA0DFA4F07BDDB16FBB7C0D7D4AD" unitRef="usd">606000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-09F279AE69A5D1D820F5FBB7C0A89E1B" unitRef="usd">109600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2017Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-43DD289851A8F2D0A167FBB7C0C719B7" unitRef="usd">46000000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4" decimals="-5" id="Fact-61A440F753314ED3AB02FBB7C1532C08" unitRef="usd">1051300000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" decimals="-5" id="Fact-C4539D4296225E1FF852FBB7C0C7CDE9" unitRef="usd">176600000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" decimals="-5" id="Fact-E2E26D75EFCEC6E78821FBB7C0E6547D" unitRef="usd">874700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ContractualAdjustmentsMember" decimals="-5" id="Fact-DE27001F15309C5BBB49FBB7C089CB79" unitRef="usd">888800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_biib_ReserveforCashDiscountsMember" decimals="-5" id="Fact-D201C31A8AFC1D9E213EFBB7C0C7EC40" unitRef="usd">127800000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:ValuationAllowancesAndReservesBalance contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_us-gaap_SalesReturnsAndAllowancesMember" decimals="-5" id="Fact-44F503CDEE7C10022BD3FBB7C1720409" unitRef="usd">34700000</us-gaap:ValuationAllowancesAndReservesBalance>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2016Q4YTD" decimals="-5" id="Fact-DA5679A7B0C95E2B630CFBB7C0B75BDE" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2017Q4YTD" decimals="-5" id="Fact-17D130972F4C6F9B7844FBB7C0D7C5E9" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="FD2018Q4YTD" decimals="-5" id="Fact-2AF287496AC00598A5D4FBB7C0B71775" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q4YTD" decimals="-5" id="Fact-602EAB37DB0481434EE1FBB7C125A640" unitRef="shares">218800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q1QTD" decimals="-5" id="Fact-1BF303D6879B886A76C0FBB7C089C4CD" unitRef="shares">215900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q2QTD" decimals="-5" id="Fact-79F28F19D13472384F33FBB7C098C2C3" unitRef="shares">212200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q3QTD" decimals="-5" id="Fact-1D4792A5936E2C1426AEFBB7C0793467" unitRef="shares">211800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q4QTD" decimals="-5" id="Fact-E9AE117A9814FDEFAE8EFBB7C089BC14" unitRef="shares">212000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q4YTD" decimals="-5" id="Fact-DBE89A17C98D5B36AC88FBB7C15329EE" unitRef="shares">213000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2018Q1QTD" decimals="-5" id="Fact-EF306B971C1A29B7344EFBB7C098AE31" unitRef="shares">211700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2018Q2QTD" decimals="-5" id="Fact-2DD6B1B58C00FA8BC81EFBB7C09866F6" unitRef="shares">207300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2018Q3QTD" decimals="-5" id="Fact-17E020A7145CD018A1C3FBB7C0B7B836" unitRef="shares">201900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2018Q4QTD" decimals="-5" id="Fact-1943CF28A5C29C42FA1AFBB7C098EC8E" unitRef="shares">200300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2018Q4YTD" decimals="-5" id="Fact-BE6579B0EDC95876A1ABFBB7C0E66384" unitRef="shares">205300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-34D762E8AA66524E6F55FBB7C144DBDE" unitRef="shares">700000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B247A34878B894D55D69FBB7C144ACA1" unitRef="shares">3700000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation contextRef="FD2018Q4YTD" decimals="-5" id="Fact-B6670190D670C648892CFBB7C144D9E7" unitRef="shares">14800000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5CA4D96DAB6454752838FBB7C0C799E4" unitRef="shares">218400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q1QTD" decimals="-5" id="Fact-6674E9660C7AE2CA7CE2FBB7C06926FF" unitRef="shares">215600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q2QTD" decimals="-5" id="Fact-412ADA19FFA464338531FBB7C0699030" unitRef="shares">211900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q3QTD" decimals="-5" id="Fact-65D2A06A82520D62D5A9FBB7C0A81AF3" unitRef="shares">211400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q4QTD" decimals="-5" id="Fact-BCD62A960DAC83CDB54DFBB7C069FBEA" unitRef="shares">211500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E14AD94BDFD9522388CEFBB7C163D34A" unitRef="shares">212600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2018Q1QTD" decimals="-5" id="Fact-6E74B1C977EB968019A6FBB7C098A6D1" unitRef="shares">211400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2018Q2QTD" decimals="-5" id="Fact-DAF9966C57645847D95CFBB7C098F04A" unitRef="shares">207100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2018Q3QTD" decimals="-5" id="Fact-E59A5F3DD784E4F2F64CFBB7C0B733C1" unitRef="shares">201400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2018Q4QTD" decimals="-5" id="Fact-8436048E55CA387F66E2FBB7C098817A" unitRef="shares">199800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2018Q4YTD" decimals="-5" id="Fact-439779ED1CFE754922BCFBB7C1444E0B" unitRef="shares">204900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-7A185D723AF62C3722EB11FED7939FFD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;109.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;606.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;679.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,686.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;23.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,389.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(12.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(551.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,887.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,440.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(109.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(506.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(646.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;127.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;888.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,051.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;583.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,307.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,917.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(475.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,756.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,232.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(69.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(442.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(534.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;109.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;606.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;592.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,044.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,668.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(522.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,576.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,099.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(53.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(536.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(609.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
	<biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-19CDC469F51ED5B6DE91FBB7C144BC09">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;he assumptions used in our valuation are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of expected stock price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;27.5% - 32.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.0% - 35.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.2% - 40.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of risk-free interest rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.9% - 2.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9% - 1.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6% - 0.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 calendar day average stock price on grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$279.47 - $346.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$263.18 - $267.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$260.67 - $304.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average per share grant date fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$378.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$382.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$328.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock>
	<biib:BusinessOverviewPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-89B9C3EDE59B5AD07359FBB7C098E332">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&amp;#8217;s disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also manufacture and commercialize biosimilars of advanced biologics.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), Parkinson's disease, ALS, stroke, epilepsy, cognitive impairment associated with schizophrenia (CIAS) and pain.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilar products through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
	<biib:CoPromotionProfitSharingFormulaTableTextBlock contextRef="FD2018Q4YTD" id="Fact-349254CFEE3472B64225FBB7C098D116">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share of annual co-promotion profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First Non-CLL GAZYVA FDA Approval&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the FDA&amp;#8217;s first approval of GAZYVA in an indication other than CLL.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the earlier of (i)&amp;#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or (ii)&amp;#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;Second GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$500.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:CoPromotionProfitSharingFormulaTableTextBlock>
	<biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="FD2018Q4YTD" id="Fact-810F67FF48CA0B4684D8FBB7C0793231">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(542.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(535.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;270.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,689.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;476.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;476.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks and trade names&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,638.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,330.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,308.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,971.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,160.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,811.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,727.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4,607.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,264.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4,385.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,879.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
	<biib:OtherrevenuesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-AE12AEAF5970A4806C551227EBB01F60">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;42.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Sobi and royalties from Sobi on sales of ELOCTA and ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;38.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;459.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;253.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;230.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;585.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;360.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with AbbVie and Samsung Bioepis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. For additional information on our contract manufacturing agreements with Bioverativ, please read Note 3,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;,&amp;#160;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
	<biib:PerformanceStockUnitsSettledinCashTableTextBlock contextRef="FD2018Q4YTD" id="Fact-E7D603F1DEECD33901B51B530BB9D632">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PSUs that settle in cash activity:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;45,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PerformanceStockUnitsSettledinCashTableTextBlock>
	<biib:PerformanceStockUnitsSettledinStockTableTextBlock contextRef="FD2018Q4YTD" id="Fact-78BAEB02689DD850A7011B4A882A7530">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PSUs that settle in stock activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;67,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;317.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(7,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;315.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;317.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PerformanceStockUnitsSettledinStockTableTextBlock>
	<biib:PerformanceunitsactivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-A8F63C3D635CB65460E1FBB7C1537761">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;91,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(52,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;48,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PerformanceunitsactivityTableTextBlock>
	<biib:PretaxProfitSharingFormulaTableTextBlock contextRef="FD2018Q4YTD" id="Fact-86283F7E3F79ABDDB877FBB7C105FE66">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share of annual profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:PretaxProfitSharingFormulaTableTextBlock>
	<biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-708482C392A4829A2427121E931A46E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,431.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;548.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,980.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,431.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;548.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,980.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
	<biib:RoyaltyCostofSalesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-AFBCC5AE84A756A474A7FBB7C0E6FA3F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&amp;#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</biib:RoyaltyCostofSalesPolicyTextBlock>
	<biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-9A9CD2EF0874794A2037FBB7C153FDF6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our CSPU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;105,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(51,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock>
	<biib:ScheduleOfMarketStockUnitsActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-46EA77970DA7E821850BFBB7C1539B17">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our MSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;171,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;370.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;129,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;378.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(91,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;365.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(29,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;376.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;180,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;371.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfMarketStockUnitsActivityTableTextBlock>
	<biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-4F5E09E461BC40FEBA8CFBB7C0B7C197">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
	<biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock contextRef="FD2018Q4YTD" id="Fact-C503C08159E94E49A90EFBB7C153A48D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our ESPP activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;167,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;190,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock>
	<biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock contextRef="FD2018Q4YTD" id="Fact-C15E297EDDCCC0A3D615FBB7C172DC82">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;232.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;146.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;116.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;74.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock>
	<biib:SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock contextRef="FD2018Q4YTD" id="Fact-EC1DADCEC0DA1094ABA08534A5D72E4C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Costs and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;92.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;17.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;43.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock>
	<biib:SummaryOfCommonStockTableTextBlock contextRef="FD2018Q4YTD" id="Fact-589AFF4AC55B66B8C4E1FBB7C0A868E5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table describes the number of shares authorized, issued and outstanding of our common stock as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="27" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;221.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;197.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;238.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfCommonStockTableTextBlock>
	<biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-EF2DF8B64011047CC04D1218C6464C30">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;176.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;874.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,051.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
	<biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock contextRef="FD2018Q4YTD" id="Fact-71BE7045358DFCEA8068F198E6B6F962">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;264.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;268.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;209.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;234.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;268.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;209.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;50.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;27.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
	<biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-AF510FAB9EAAF30763EDFBB7C153F0A5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our RSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;832,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;291.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;581,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;316.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(376,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;299.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(134,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;298.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;903,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;303.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</biib:TimeVestedRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-B9FB26778B3100FB3AB0FBB7C1152057">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Other Consolidated Financial Statement Detail&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Supplemental Cash Flow Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid during the year for:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;243.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;281.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;281.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,007.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,066.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,642.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-cash Operating, Investing and Financing Activity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2018 we accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of the Fumapharm Products, which will be paid in the first quarter of 2019. In the fourth quarter of 2017 we accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$600.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon reaching &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total cumulative sales of the Fumapharm Products, which was paid in the first quarter of 2018. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. For additional information on the contingent payments to the former shareholders of Fumapharm AG and holders of their rights, please read Note 22, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our consolidated balance sheets as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read Note 11,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Property, Plant and Equipment,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2016 we accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$454.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the settlement and license agreement with Forward Pharma. For additional information on the settlement and license agreement with Forward Pharma, please read Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Income (Expense), Net&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;112.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(200.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(250.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(260.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;119.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(36.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(18.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(217.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(218.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, gain (loss) on investments, net, as reflected in the table above, substantially relate to marketable equity securities held at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Current Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$687.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$962.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and include prepaid taxes totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$271.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$657.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,690.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, including &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$680.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$563.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to our investments in Samsung Bioepis and Ionis, respectively. For additional information on our collaboration arrangements with Samsung Bioepis and Ionis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accrued Expenses and Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;874.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;444.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;844.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;320.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;297.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;224.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;206.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;125.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;159.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;261.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;183.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;609.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;636.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,861.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,901.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Long-term Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,389.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,628.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and include accrued income taxes totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$791.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$979.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2018Q4YTD" id="Fact-D72B4715E0480D430757FBB7C0C79810">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,607.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,608.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;851.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;854.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;705.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;706.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;263.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;264.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;260.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,689.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,694.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;615.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;127.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;496.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,570.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,569.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,075.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,075.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;844.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;845.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;642.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;642.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-C4E796EA3D81FD350E12FBB7C079A701">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Acquisitions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;BIIB100 Acquisition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2018 we acquired BIIB100 (formerly known as KPT-350) from Karyopharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 ready investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Karyopharm, which was recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB100 has not yet reached technological feasibility. We may also pay Karyopharm up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$207.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments as well as tiered royalties on potential net commercial sales in the mid-single digit to low-teen percentages. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;BIIB104 Acquisition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2018 we acquired BIIB104 (formerly known as PF-04958242) from Pfizer Inc. (Pfizer). BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for CIAS, representing our first program in neurocognitive disorders. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Pfizer, which was recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB104 has not yet reached technological feasibility. We may also pay Pfizer up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$515.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the low to mid-teen percentages. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the fourth quarter of 2018 we accrued a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment related to the Phase 2b trial for BIIB104, which is included in research and development expense in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;TMS Co., Ltd.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2018 we entered into an exclusive option agreement with TMS Co., Ltd. (TMS) granting us the option to acquire TMS-007, a plasminogen activator with a novel mechanism of action associated with breaking down blood clots, which is in Phase 2 development in Japan, and backup compounds for the treatment of stroke. In exchange for the purchase option, we made a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment to TMS, which was recorded as research and development expense in our consolidated statements of income as TMS-007 has not yet reached technological feasibility. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we exercise the purchase option, we will make an additional payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$18.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon closing of the asset acquisition, which will be recorded as acquired IPR&amp;amp;D expense in our consolidated statements of income as TMS-007 will not have reached technological feasibility at that time. In addition, we may pay TMS up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$335.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the high-single digit to low-teen percentages. If we exercise the purchase option, consummation of the asset acquisition may be subject to the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;BIIB110 Acquisition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 we acquired BIIB110 (formerly known as ALG-801) (Phase 1a) and ALG-802 (preclinical) from AliveGen Inc. (AliveGen).&amp;#160;BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 in multiple neuromuscular indications, including SMA and ALS. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to AliveGen, which was recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB110 has not yet reached technological feasibility. We may also pay AliveGen up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$535.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development and commercialization milestones.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;BIIB093 Acquisition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2017 we acquired BIIB093 (glibencamide IV) (formerly known as CIRARA) from Remedy Pharmaceuticals Inc. (Remedy). BIIB093 is a Phase 3 ready candidate for large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) granted BIIB093 orphan drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 Fast Track designation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are responsible for the future development and commercialization of BIIB093 and Remedy will share in the cost of development for the target indication for BIIB093 in LHI stroke.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. In connection with the closing of this transaction, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Remedy, which was recorded as acquired IPR&amp;amp;D in our consolidated statements of income as BIIB093 has not yet reached technological feasibility. We may also pay Remedy certain development and sales based milestone payments that are substantially payable upon or after regulatory approval, as well as royalties on potential net commercial sales.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:BusinessCombinationsPolicy contextRef="FD2018Q4YTD" id="Fact-6639D6F32462F503C3BFFBB7C0F6E469">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions of a business completed after January&amp;#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-C0936261C14A44E6E617FBB7C1155EF2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="FD2018Q4YTD" id="Fact-681A6DCEE3528AF29EFCFBB7C0D75298">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;less than 90&amp;#160;days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;279.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;948.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;194.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;247.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon the adoption of ASU 2016-01, our marketable equity securities gains (losses) are recorded in other income (expense), net in our consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,607.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,608.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;851.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;854.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;705.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;706.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;263.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;264.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;260.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,689.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,694.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;615.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;127.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;496.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,039.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,570.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,569.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,075.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,075.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;844.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;845.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;642.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;642.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total marketable debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities, non-current&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Contractual Maturities: Available-for-Sale Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,313.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,314.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,115.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,116.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,232.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,235.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;143.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;143.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;327.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;327.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,689.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,694.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The average maturity of our marketable debt securities available-for-sale as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;months and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;17&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; months, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Proceeds from Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,173.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,565.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,378.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to impairments recognized on certain of our available-for-sale marketable debt securities, sales of agency mortgage-backed securities, corporate bonds and government securities. Realized losses for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Strategic Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our strategic investment portfolio was comprised of investments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$676.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$85.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which are included in investments and other assets in our consolidated balance sheets. The increase in our strategic investment portfolio is primarily a result of our investment in Ionis' common stock, as discussed below. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and venture capital funds where the underlying investments are in equity securities of certain biotechnology companies. Our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1 marketable equity securities within our disclosures included in Note 8, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Ionis Pharmaceuticals, Inc. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2018 we closed a new &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year exclusive agreement with Ionis to develop novel antisense oligonucleotide (ASO) drug candidates for a broad range of neurological diseases (the 2018 Ionis Agreement) for a total payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisting of an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$375.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and the purchase of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of Ionis' common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$625.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our investment in Ionis' common stock is remeasured each reporting period and carried at fair value as a Level 2 marketable equity security due to certain holding period restrictions. The effect of these holding period restrictions are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis' common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the 2018 Ionis Agreement, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2018 we exercised our option under our joint venture agreement with Samsung BioLogics to increase our ownership percentage in Samsung Bioepis from approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;759.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$676.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investment in Samsung Bioepis totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;759.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$680.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), which is classified as a component of investments and other assets within our consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
	<us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-799E4824DB08F31FBA04FBB7C1532F66">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax benefit realized for stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received from the exercise of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-F26C374D7C5EF7158F14FBB7C1639976">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depending on the collaborative arrangement, we may record funding receivable or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Genentech, Inc. (Roche Group)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of PPMS and RMS and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our collaboration arrangements will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&amp;#8217;s offer or purchase Genentech&amp;#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;RITUXAN&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN, as well as all development and commercialization activities as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Canada&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;GAZYVA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;OCREVUS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FDA approved OCREVUS for the treatment of RMS and PPMS. Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and increasing up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;24%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if annual net sales exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$900.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. There will be a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we receive a gross &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11 years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS has been approved for the treatment of RMS and PPMS in the E.U. and certain other countries. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Profit-sharing Formulas&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;RITUXAN Profit Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share on the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until GAZYVA First Non-CLL FDA Approval&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First Non-CLL GAZYVA FDA Approval&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the FDA&amp;#8217;s first approval of GAZYVA in an indication other than CLL.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;First GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the earlier of (i)&amp;#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or (ii)&amp;#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;"&gt;Second GAZYVA Threshold Date&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$500.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share of RITUXAN pre-tax profits in the U.S. decreased to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in February 2016 when GAZYVA was approved by the FDA as a new treatment for follicular lymphoma and further decreased to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12-month period exceeded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on certain events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;GAZYVA Profit Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our current pretax profit-sharing formula for GAZYVA provides for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share on the first &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of operating profits earned each calendar year. Our share of annual profits in excess of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; varies, as summarized in the table below, upon the following events:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Until First GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After First GAZYVA Threshold Date until Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;37.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;After Second GAZYVA Threshold Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; GAZYVA profit-sharing threshold was met during the third quarter. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; our share of operating profits on GAZYVA was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,431.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;548.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,980.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; RITUXAN profit-sharing threshold was met during the first quarter. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; profit-sharing threshold was met during the first quarter and further decreased to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;37.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12-month period exceeded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; profit-sharing threshold was met during the first quarter.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Ionis Pharmaceuticals, Inc. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Collaborations &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis to develop and commercialize SPINRAZA for the treatment of SMA. SPINRAZA was approved for the treatment of SMA in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized product revenues of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,724.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$883.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, on our sales of SPINRAZA. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$238.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$112.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, upon the exercise of our option to develop and commercialize SPINRAZA, we paid a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; license fee to Ionis, which was recorded as research and development expense in our consolidated statements of income. In addition, during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we made milestone payments to Ionis totaling&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;related to the marketing approvals discussed above, which were capitalized in intangible assets, net in our consolidated balance sheets.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; no clinical trial payments were made to Ionis due to the completion of study activities. During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we made clinical trial payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the advancement of the program, which were recorded in investments and other assets in our consolidated balance sheets as they represented prepaid research and development expenditures. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, these prepaid research and development amounts were fully expensed as the services were provided.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$285.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$234.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$257.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, were reflected in total costs and expenses in our consolidated statements of income related to the advancement and commercialization of the program. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Antisense Therapeutics&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three therapeutic targets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, Ionis is responsible for global development of any product candidate&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to another &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt; &lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;if we successfully develop the product candidate after option exercise. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis and agreed to make potential additional payments, prior to licensing, of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone upon the selection of BIIB080 (also known as IONIS-MAPT&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;Rx&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), which is currently in Phase 1 development for the treatment of AD. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Research Collaborations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;2018 Ionis Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2018 we closed the 2018 Ionis Agreement, which is a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year exclusive agreement with Ionis to develop novel ASO drug candidates for a broad range of neurological diseases for a total payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, consisting of an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$375.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and the purchase of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of Ionis' common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$625.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon closing, we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$375.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment as prepaid services in our consolidated balance sheets and recognized the remaining &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$324.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as research and development expense in our consolidated statements of income. The amount recorded as prepaid services represented the value of the employee resources committed to the arrangement to provide research and discovery services over the term of the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of Ionis' common stock were purchased at a premium to their fair value at the transaction closing date. The premium consisted of acquiring the shares at a price above the fair value based on the trailing 10-day weighted-average close price prior to entering into the 2018 Ionis Agreement in April 2018 and the effect of certain holding period restrictions. We recorded an asset of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$462.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in investments and other assets in our consolidated balance sheets reflecting the fair value of the common stock as of the purchase date and a charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$162.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to research and development expense in our consolidated statements of income in the second quarter of 2018 reflecting the premium paid for the common stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our investment in Ionis' common stock is remeasured each reporting period. Changes in the fair value of our investment in Ionis' common stock, including the effect of the holding period restrictions, are reflected in other income (expense), net in our consolidated statements of income. For additional information on the fair value of our investment in Ionis' common stock, please read Note 9, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have the option to license therapies arising out of this agreement and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$125.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$270.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for each program, depending on the indication plus an annual license fee, as well as royalties on potential net commercial sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;2017 SMA Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2017 we entered into a new collaboration agreement with Ionis to identify new ASO drug candidates for the treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of these therapies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment to Ionis and we may pay Ionis up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$260.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional development and regulatory milestone payments if new drug candidates advance to marketing approval. Upon commercialization, we may also pay Ionis up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$800.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;2013 Long-term Strategic Research Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2013 we entered into a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;six&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the treatment of neurological diseases.&amp;#160;Under this agreement, Ionis performs research on a set of neurological targets identified within the agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ionis is eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us under the terms of the 2013 agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$130.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&lt;sub style="vertical-align:bottom;line-height:120%;font-size:pt"&gt;Rx&lt;/sub&gt;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), an investigational treatment for ALS with superoxide dismutase 1 (SOD1) mutations. In connection with the option exercise, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis. Future payments may include potential post-licensing milestone payments of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$55.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and royalties in the low to mid-teen percentages on potential annual worldwide net sales. We are solely responsible for the costs and expenses related to the development, manufacturing and commercialization of BIIB067 following the option exercise. During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we incurred milestones of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$53.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to the advancement of BIIB067 and other neurological targets identified.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Eisai Co., Ltd. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;BAN2401 and Elenbecestat Collaboration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the treatment of AD (the BAN2401 and Elenbecestat Collaboration). Eisai serves as the global operational and regulatory lead for BAN2401 and elenbecestat and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai; and, if applicable, upon marketing approval in major markets, such as the U.S., the E.U. and Japan, we and Eisai will co-promote BAN2401 and elenbecestat and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for the treatment of AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, a separate collaboration agreement would be entered into with Eisai on terms and conditions that mirror the BAN2401 and Elenbecestat Collaboration agreement. Eisai has not yet exercised its Anti-Tau Option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 and elenbecestat in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. The two companies will co-promote aducanumab with a region-based profit split and we will continue to lead the ongoing Phase 3 development of aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration were immaterial. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;232.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;146.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;116.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;74.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, during the fourth quarter of 2016 we recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment related to the initiation of a Phase 3 trial for elenbecestat, which is included in research and development expense in our consolidated statements of income. We could pay Eisai up to an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$625.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under the BAN2401 and Elenbecestat Collaboration based on the future achievement of certain development, regulatory and commercial milestones.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Aducanumab Collaboration Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of aducanumab development expense incurred and beginning January 1, 2019, is reimbursing us for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;45%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of aducanumab development expense incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in the U.S., a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;68.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in the E.U. and a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The two companies will continue to share equally in the potential profits (losses) in rest of world markets. Sales and marketing expense incurred before commercialization are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab development expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;264.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;268.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;209.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;234.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;268.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;209.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total aducanumab sales and marketing expense incurred by the collaboration&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;50.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;27.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Anti-Tau Option&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Alkermes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), for diroximel fumarate (BIIB098), a novel fumarate in Phase 3 development for the treatment of RMS. In December 2018 Alkermes submitted a New Drug Application (NDA) to the FDA for diroximel fumarate. Alkermes is seeking approval of diroximel fumarate under the 505(b)(2) regulatory pathway. If approved, we intend to market diroximel fumarate under the brand name VUMERITY. This name has been conditionally accepted by the FDA and will be confirmed upon approval.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we received an exclusive, worldwide license to develop and commercialize diroximel fumarate and will pay Alkermes a mid-teens percentage royalty on potential worldwide net commercial sales of diroximel fumarate. Royalties payable on net commercial sales of diroximel fumarate are subject, under certain circumstances, to tiered minimum payment requirements for a period of five years following FDA approval. Alkermes is eligible to receive royalties in the high-single digits to sub-teen double digits of annual net commercial sales upon successful development and commercialization of new product candidates other than diroximel fumarate, developed under the exclusive license from Alkermes. Alkermes will maintain responsibility for regulatory interactions with the FDA through the potential approval of the NDA for diroximel fumarate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment to Alkermes representing our share of diroximel fumarate development costs already incurred in 2017. Beginning in 2018 we became responsible for all development expenses related to diroximel fumarate. In December 2017 we also recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; expense, which was paid to Alkermes in 2018, enabling the continuation of the agreement to develop diroximel fumarate. Both the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; continuation payment were recorded as research and development expense in our consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may also pay Alkermes an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment upon a regulatory achievement related to diroximel fumarate under this agreement. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$68.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$80.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in research and development expense in our consolidated statements of income related to this collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the license and collaboration agreement, we may also enter into a supply agreement with Alkermes for the commercial supply of diroximel fumarate and other products developed under the license and collaboration agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Bristol-Myers Squibb Company&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092, a Phase 2 investigational therapy with potential in AD and PSP. BIIB092 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we received worldwide rights to BIIB092 and are responsible for the full development and potential commercialization of BIIB092 in AD and PSP. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to BMS and we may pay BMS up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$410.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments, and potential royalties. We also assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&amp;#8217;s acquisition of iPierian in 2014. In June 2017 we recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 study of BIIB092 for PSP and we may pay the former shareholders of iPierian up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$490.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestone payments as well as potential royalties on net commercial sales. Both the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment and the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; developmental milestone payment were recorded as research and development expense in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$97.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in research and development expense in our consolidated statements of income related to this collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acorda Therapeutics, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&amp;#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and we may pay potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone would be &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, due if ex-U.S. net sales reach &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; over a period of four consecutive quarters. Royalty payments are recognized in cost of sales within our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$36.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$34.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;AbbVie Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration agreement with AbbVie for the development and commercialization of ZINBRYTA, which was approved for the treatment of RMS in the U.S. in May 2016 and in the E.U. in July 2016. In March 2018 we and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for RMS.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under this agreement, we and AbbVie conducted ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits were shared equally. Outside of the Collaboration Territory, we were solely responsible for development and commercialization of ZINBRYTA and paid a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We were responsible for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and recorded these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&amp;#160;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the collaboration incurred &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$32.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$39.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for research and development activities, respectively, for which we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$19.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$24.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development expense recognized in our consolidated statements of income for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; charge recognized in the first quarter of 2018 related to the termination of research and development contracts and clinical trials as a result of the voluntary worldwide withdrawal of ZINBRYTA. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to regulatory approval, we also recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$22.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of pre-commercialization expenses within our selling, general and administrative expense, which represented &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the collaboration's pre-commercialization costs for 2016. After ZINBRYTA was approved by the FDA and the EMA in 2016, we began to recognize our share of the collaboration activities within the Collaboration Territories as described below under &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Co-promotion Profits and Losses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Co-promotion Profits and Losses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the U.S., AbbVie recognized revenues on sales to third parties and we recognized our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The collaboration began selling ZINBRYTA in the U.S. in the third quarter of 2016 and ceased selling ZINBRYTA in the U.S. in March 2018 in connection with the voluntary worldwide withdrawal of ZINBRYTA for RMS. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net reduction in revenues from collaborative and other relationships, a component of other revenues, of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$21.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect our share of the overall net losses within the collaboration for each of those years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Costs and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;92.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;17.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;39.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;43.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of co-promotion losses in the U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;16.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the E.U. and Canada, we recognized revenues on sales to third parties in product revenues, net in our consolidated statements of income. We began to recognize net product revenues on sales of ZINBRYTA in the E.U. and Canada in the third quarter of 2016 and first quarter of 2017, respectively, and ceased selling ZINBRYTA in the E.U. and Canada in March 2018 in connection with the voluntary worldwide withdrawal of ZINBRYTA for RMS. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net product revenues on the sales of ZINBRYTA in the E.U. and Canada of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$52.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We also recorded the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income as these costs were incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We reimbursed AbbVie for their &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement was recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized net profit-sharing income of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect AbbVie's &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration losses in the E.U. and Canada, as compared to net profit-sharing expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and net profit-sharing income of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Research and Discovery Arrangements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;C4 Therapeutics&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2018 we entered into a collaborative research and license agreement with C4 Therapeutics (C4T) to investigate the use of C4T&amp;#8217;s novel protein degradation platform to discover and develop potential new treatments for neurological diseases, such as AD and Parkinson&amp;#8217;s disease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the agreement, C4T will provide expertise and research services in targeted protein degradation and we will provide neuroscience expertise and drug development capabilities. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this agreement we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to C4T, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as research and development expense in our consolidated statements of income and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded as prepaid research and development expenditures within investments and other assets in our consolidated balance sheets. We may also pay C4T up to a total of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$370.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments as well as potential royalties on net commercial sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;University of Pennsylvania&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration and alliance with the University of Pennsylvania (UPenn) to advance gene therapy and gene editing technologies. In December 2018 we notified UPenn that we will be terminating certain programs under our collaboration and alliance with UPenn, including the development of therapeutic approaches that target the eye, skeletal muscle and central nervous system and research and validation of next generation gene transfer technology using adeno-associated virus (AAV) gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform. The termination of these programs will be effective in May 2019. This termination did not impact our collaboration with UPenn for the development of BIIB089 for the treatment of SMA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into this agreement we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to UPenn, which was recorded as research and development expense in our consolidated statements of income, and made prepaid research and development expenditures of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was recorded in investments and other assets in our consolidated balance sheets. During 2017 we made additional prepaid research and development expenditures to UPenn of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the advancement of the programs under this agreement. These prepaid research and development amounts were expensed as the services were provided, of which no amounts remain as a prepaid asset as of December 31, 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may be required to make future payments of over &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$137.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in research funding, options and milestone payments in relation to the BIIB089 program if we are successful and exercise our related options under this agreement. UPenn is also eligible to receive royalties in the mid-single digit percentages of annual net commercial sales upon successful development and commercialization of BIIB089. UPenn is no longer entitled to any potential future research funding, options and milestone payments from us in relation to the development of programs other than BIIB089.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$64.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$33.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in research and development expense in our consolidated statements of income related to this collaboration.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Applied Genetic Technologies Corporation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). This collaboration focused on the development of BIIB087, an investigational AAV-based gene therapy for the treatment of X-linked Retinoschisis (XLRS), and BIIB088, an investigational AAV-based gene therapy for the treatment of X-Linked Retinitis Pigmentosa (XLRP). This collaboration also provided us with options to early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2018 we notified AGTC of the termination of our collaboration agreement with AGTC. The termination of this collaboration agreement will be effective in March 2019 and we will have no further involvement in the development of any of the programs under this collaboration. Accordingly, AGTC is no longer entitled to any potential development, regulatory and commercial milestone payments from us in relation to the development of these programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the collaboration and license agreement, we also received a manufacturing license under which we received an exclusive license to use AGTC&amp;#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&amp;#8217;s discretion, in exchange for payment of milestones and royalties. Our termination of the collaboration agreement does not impact our rights under the manufacturing license.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Upon entering into the collaboration agreement we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$124.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to AGTC. The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$124.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upfront payment reflected a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equity investment in AGTC, including a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; premium on our equity investment, prepaid research and development expenditures of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and total licensing and other fees of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in total licensing and other fees and the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; premium on our equity investment were recorded as a charge to research and development expense in our consolidated statements of income. The remaining &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$22.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equity investment and the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$58.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets. These prepaid research and development amounts were expensed as the services were provided. No amounts remain as a prepaid asset as of December 31, 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$39.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$26.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which were reflected in research and development expense in our consolidated statements of income related to this collaboration. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we entered into several research, discovery and other related arrangements that resulted in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, recorded as research and development expense in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Samsung Bioepis Co., Ltd.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Joint Venture Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&amp;#160;Samsung BioLogics contributed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;280.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for an &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; stake in Samsung Bioepis and we contributed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) for the remaining &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ownership interest.&amp;#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which reflected the effect of previous equity financings in which we did not participate, to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;759.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$676.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics.&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, our ownership percentage remains approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019, depending on the results of Samsung Bioepis, we expect to restart recognizing our share of Samsung Bioepis' income (losses) and we will begin recognizing the amortization of certain basis differences resulting from our November 2018 investment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investment in Samsung Bioepis totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;759.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$680.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;), which is classified as a component of investments and other assets within our consolidated balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Commercial Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December 2013 pursuant to our rights under the joint venture agreement with Samsung BioLogics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of BENEPALI, Japan.&amp;#160;Under this agreement, we have made upfront and clinical development milestone payments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$46.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which were recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, received regulatory approval in the E.U. in August 2017, May 2016 and January 2016, respectively, and we capitalized the related milestone payments totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as intangible assets, net in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2018 we and Samsung Bioepis announced an agreement with AbbVie related to the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. We began to recognize revenues on sales of IMRALDI to third parties in the E.U. in the fourth quarter of 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We reflect revenues on sales of IMRALDI, FLIXABI and BENEPALI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We share &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized a net profit-sharing expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$187.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$111.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, to reflect Samsung Bioepis' &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; sharing of the net collaboration profits. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&amp;#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$96.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues under our license, technical development services and manufacturing agreements, which is reflected in revenues from collaborative and other relationships, as a component of other revenues in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-F2474724541E31F1A226FBB7C10553DC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net sales up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on annual worldwide net sales that exceed &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Royalty payments to Elan and other third parties are recorded as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013, and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the third quarter of 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payment to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration related to Business Combinations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence, Stromedix and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As the acquisitions of Convergence, Stromedix and BIN occurred after January&amp;#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in remaining milestones related to these acquisitions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Fumapharm AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired the Fumapharm Products. We paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$220.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon closing of the transaction and agreed to pay an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; if a Fumapharm Product was approved for MS in the U.S.&amp;#160;or E.U. In the second quarter of 2013 TECFIDERA was approved in the U.S. for MS by the FDA and we made the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment. We are also required to make additional contingent payments to former shareholders of Fumapharm AG and holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement, until such time as the cumulative sales level reached &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, at which time no further contingent payments are due. These payments are accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. Any portion of the payment that is tax deductible was recorded as a reduction to goodwill. Payments are due within 60&amp;#160;days following the end of the quarter in which the applicable cumulative sales level was reached. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent payments as we reached the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2017 and the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$18.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$19.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cumulative sales levels related to the Fumapharm Products in the first, second and third quarters of 2018, respectively. In the fourth quarter of 2018 we achieved the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cumulative sales level threshold and accrued our last &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment related to the Fumapharm Products, which will be paid in the first quarter of 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Development, Regulatory and Commercial Milestone Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based on our development plans as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we could make potential future milestone payments to third parties of up to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, including approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.7 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in development milestones, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.8 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in regulatory milestones and approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Funding Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our consolidated balance sheet for expenditures incurred by CROs as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We have approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$655.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in cancellable future commitments based on existing CRO contracts as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Related Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$117.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of liabilities associated with uncertain tax positions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and 2017, we have accrued income tax liabilities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$697.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$989.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, under the Transition Toll Tax. Of the amounts accrued as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, no amounts are expected to be paid within one year due to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; overpayment of taxes in the current year. The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest. For additional information on the Transition Toll Tax, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had contractual commitments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$111.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the construction of this facility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense, net of sublease income under these leases, which terminate at various dates through 2028, amounted to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$64.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$65.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$68.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;87.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;80.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;601.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(26.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(182.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;52.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;46.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;156.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;418.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-6B29AA6C01EA8361C1ECFBB7C105D471">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&amp;#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&amp;#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
	<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-E9236C5AB5B142EB4594FBB7C089A3C1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&amp;#8217; vesting periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense, net of forfeitures, for RSUs is recognized straight-line over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of PSUs that settle in stock are based upon the stock price on the date of grant and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price of common stock under our ESPP is equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the lesser of (i)&amp;#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&amp;#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes valuation model. The fair value of the look-back provision plus the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; discount is recognized as compensation expense over the 90-day purchase period. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
	<us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="FD2018Q4YTD" id="Fact-FA0BADD5A43698CFF287FBB7C1156FCA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(318.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified, net of tax, upon adoption of ASU 2016-01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(316.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;97.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(67.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;29.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;41.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;139.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(67.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;76.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(243.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(240.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(193.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;158.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(42.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;44.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(162.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;158.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(318.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(92.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(95.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(44.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2018Q4YTD" id="Fact-B8592A8CBF9D1F793A3FFBB7C105AA53">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-CB59BCD8256EF18293A9FBB7C0982527">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-4DE739A3B66A7BF47D78FBB7C0F6F8E6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Indebtedness&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our indebtedness is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica AG&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of notes payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Non-current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,480.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,482.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;995.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;994.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,737.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,736.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,722.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,722.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of notes payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,935.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;6.875% Senior Notes due March 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On March 4, 2008, we issued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$550.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.875%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due March 1, 2018, at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;99.184%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par. These notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these interest rate swap contracts, the carrying amount of these Senior Notes increased by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$62.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, with this amount being amortized using the effective interest rate method over the remaining life of the Senior Notes and recognized as a reduction of interest expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 we redeemed these Senior Notes prior to their maturity and recognized a net charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the extinguishment of these Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our consolidated statements of income for the year ended December 31, 2017, reflects the payment of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; early call premium and the write-off of remaining unamortized original debt issuance costs and discount balances, partially offset by a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; gain related to the remaining unamortized balance of the interest rate swap liability discussed above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Notes payable to Fumedica AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our 2006 distribution agreement with Fumedica AG, we issued notes totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs that were payable to Fumedica AG in varying amounts from June 2008 through June 2018. In June 2018 we redeemed our remaining note payable to Fumedica AG.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2015 Senior Notes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following is a summary of our principal indebtedness as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2020, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.792%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;3.625%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2022, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.920%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.75 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;4.05%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15, 2025, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.764%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1.75 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;5.20%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes due September 15,&amp;#160;2045, valued at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;99.294%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of par.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The costs associated with these offerings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$47.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These notes are senior unsecured obligations. These Senior Notes may be redeemed at our option at any time at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued interest and a specified make-whole amount. These Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;101%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to changes in the fair value of these contracts. For additional information on our interest rate contracts, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Credit Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2015 we entered into a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; outstanding borrowings and were in compliance with all covenants under this facility.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Maturity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total gross payments due under our debt arrangements are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our debt is disclosed in Note&amp;#160;8, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-6B976EB2175AB307EC8FFBB7C1536F66">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2017 the FASB issued ASU 2017-12. We adopted this standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this standard resulted in additional disclosures and a change in the income statement classification with respect to where we recognize cash flow hedge ineffective or excluded hedge transaction gains and losses. For additional information on this standard, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies - New Accounting Pronouncements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&amp;#160;dollar. The value of revenues and operating expenses measured in U.S.&amp;#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign currency forward contracts in effect, as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. Prior to the adoption of ASU 2017-12 on January 1, 2018, to the extent ineffective or excluded, cash flow hedge transaction gains and losses were reported in other income (expense), net. Effective January 1, 2018, we recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of any cash flow hedge ineffectiveness or excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,701.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,875.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound sterling&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;131.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;88.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;98.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;92.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;83.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,239.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,198.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$113.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, and net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$49.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We expect the net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$27.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to be settled over the next &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&amp;#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, credit risk did not change the fair value of our foreign currency forward contracts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Year&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized Directly into Net Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Interest Rate Contracts - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interest Rate Swap Contracts&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the issuance of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes, as described in Note 12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements, we entered into interest rate swaps with an aggregate notional amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$675.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.90%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Net Investment Hedges - Hedging Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;49.9%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The share purchase transaction was completed in November 2018 and, upon closing, we paid &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;759.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; South Korean won (&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$676.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In order to mitigate these currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, had remaining durations of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10 months&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. These contracts have been designated as net investment hedges. Since the critical terms of the investment and the foreign currency forward contracts match, these contracts are assumed to be highly effective. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of our net investment hedge in our consolidated financial statements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:43%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;For the Year Ended December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net Gains/(Losses) Recognized in AOCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (Losses) on Net Investment Hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net Gains/(Losses) Reclassified from AOCI into Net Income &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The aggregate notional amount of these outstanding foreign currency contracts as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$735.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$564.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net gains of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and net losses of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$29.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to these contracts were recorded as a component of other income (expense), net, for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Summary of Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance&amp;#160;Sheet&amp;#160;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivative Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivative Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
	<us-gaap:DerivativesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-3F0DB56D413BB97EDFA0FBB7C0B724DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Cash Flow and Fair Value Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Net Investment Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our derivative instruments and hedging activities, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
	<us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="FD2018Q4YTD" id="Fact-154F5FCB5C5B8C7FE09211E8398B2000">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="36" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,253.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,020.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;4,274.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,294.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;920.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4,214.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,169.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;798.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,968.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interferon*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,668.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;694.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,363.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,889.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;756.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,645.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,980.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;814.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,795.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,025.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;839.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,864.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,113.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;859.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,973.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,182.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;780.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,963.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;92.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;92.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;91.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;91.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;52.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;52.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: MS Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;5,946.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,648.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;8,595.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;6,296.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,680.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;8,977.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;6,332.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,487.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;8,819.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Spinal Muscular Atrophy:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;854.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;870.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,724.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;657.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;226.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;883.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biosimilars:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;485.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;485.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;370.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;370.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;43.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;43.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;IMRALDI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Biosimilar product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;545.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;545.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;379.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;379.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;22.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;22.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;39.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;39.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Hemophilia:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ELOCTATE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;42.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;48.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;445.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;68.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;513.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;26.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;268.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;65.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;333.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Hemophilia product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;63.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;74.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;713.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;133.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;846.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;6,800.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;4,086.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;10,886.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7,017.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,337.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,767.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2018Q4YTD" id="Fact-AD841073217076393B8AFBB7C1530B84">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Share-Based Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;74.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;105.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;121.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;181.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;169.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;170.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(27.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(42.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(54.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;142.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;117.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;135.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;126.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;107.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;181.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;169.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;170.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, unrecognized compensation cost related to unvested share-based compensation was approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$188.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Spin-off Related Equity Adjustments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing share-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, RSUs, CSPUs and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen's and Bioverativ's equity awards with the outstanding awards continuing to vest over their respective original vesting periods. Outstanding equity awards for employees transferring to Bioverativ were converted to unvested Bioverativ equity awards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume-weighted average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; share-based compensation plans pursuant to which awards are currently being made: (i)&amp;#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&amp;#160;Directors Plan); (ii)&amp;#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&amp;#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Directors Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2006 our shareholders approved the 2006&amp;#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&amp;#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock for issuance under the 2006&amp;#160;Directors Plan. The 2006&amp;#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5-to-1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Omnibus Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017, or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017, are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5-to-1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;ratio.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a 10-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&amp;#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; grants of stock options made in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, all outstanding options were exercisable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&amp;#160;1, 2006, were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our stock option activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;42,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(15,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;27,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total intrinsic values of options exercised in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. The aggregate intrinsic values of options outstanding as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$6.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The weighted average remaining contractual term for options outstanding as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax benefit realized for stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received from the exercise of stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Market Stock Units (MSUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;MSUs awarded to employees prior to 2014 vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;four&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on actual stock performance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;MSUs awarded to employees in 2014 and thereafter vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on actual stock performance. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our MSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;171,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;370.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;129,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;378.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(91,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;365.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(29,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;376.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;180,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;371.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;MSUs granted during 2018 include awards granted in conjunction with our annual awards made in February 2018 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2018 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2017, 2016 and 2015.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price on the date of grant for MSUs, expected volatility of our stock price, risk-free rates of return and expected dividend yield.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assumptions used in our valuation are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of expected stock price volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;27.5% - 32.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;33.0% - 35.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.2% - 40.7%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Range of risk-free interest rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.9% - 2.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9% - 1.6%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6% - 0.9%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 calendar day average stock price on grant date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$279.47 - $346.76&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$263.18 - $267.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$260.67 - $304.86&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average per share grant date fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$378.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$382.59&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$328.03&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of MSUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$26.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$39.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Cash Settled Performance Units (CSPUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;CSPUs awarded to employees vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&amp;#160;31 of each year. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs are classified as liability awards and will be settled in cash based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our CSPU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;105,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;12,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(51,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(16,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;50,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;These shares reflect the CSPUs issued in 2018 based upon the attainment of performance criteria set for 2017 in relation to CSPUs granted in 2017.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The cash paid in settlement of CSPUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Performance-vested Restricted Stock Units (PUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:82%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;91,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(52,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;48,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;These shares reflect the PUs issued in 2018 based upon the attainment of performance criteria set for 2017 in relation to PUs granted in 2017.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;All PUs that vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; were settled in cash totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Performance Stock Units (PSUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;PSUs Settled in Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the first quarter of 2018 we began granting awards for performance-vested RSUs that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of cumulative three-year performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PSUs that settle in stock activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;67,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;317.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(7,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;315.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;317.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;PSUs settled in stock granted in 2018 include awards granted in conjunction with our annual awards made in February 2018 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;"&gt;PSUs Settled in Cash&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the first quarter of 2018 we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have three performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&amp;#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of three annual performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Participants may ultimately earn between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;200%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs are classified as liability awards and will be settled in cash based on the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; calendar day average closing stock price through the vesting date, once the actual vested and earned number of PSUs is determined. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our PSUs that settle in cash activity:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="3" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;45,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(5,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;PSUs settled in cash granted in 2018 include awards granted in conjunction with our annual awards made in February 2018 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Time-Vested Restricted Stock Units (RSUs)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;RSUs awarded to employees generally vest no sooner than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one-third per year over three years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our RSU activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Grant&amp;#160;Date&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;832,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;291.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted (a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;581,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;316.32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(376,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;299.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(134,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;298.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Unvested at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;903,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;303.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;RSUs granted in 2018 primarily represent RSUs granted in conjunction with our annual awards made in February 2018 and awards made in conjunction with the hiring of new employees. RSUs granted in 2018 also include approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:9pt;"&gt;9,000&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt; RSUs granted to our Board of Directors.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;RSUs granted in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; had weighted average grant date fair values of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$293.41&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$268.52&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of RSUs vested in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$111.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$104.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan (ESPP)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2015 our shareholders approved the 2015 ESPP. The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP, which expired on June&amp;#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our ESPP activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares issued under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;167,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;190,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash received under the 2015 ESPP&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;40.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;39.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-CCBF6C24F40309517664F0522266E253">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company, which was acquired by Sanofi in March 2018. In connection with the spin-off, each Biogen shareholder received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen and Bioverativ entered into a separation agreement and various other agreements, including a manufacturing and supply agreement, which govern the separation and distribution and the relationship between the two companies going forward. Under the separation agreement, Bioverativ is obligated to indemnify us for liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$302.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;302.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;56.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;53.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,008.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;87.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;67.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;155.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we distributed ALPROLIX and ELOCTATE on behalf of Bioverativ until Bioverativ obtained appropriate regulatory authorizations in certain countries, including a Biologics License Application transfer in the U.S., which was received in September 2017. Accordingly, commencing October 2017, we ceased distribution of ALPROLIX and ELOCTATE on behalf of Bioverativ under this arrangement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. The manufacturing and supply agreement has an initial term of five years, with a five-year extension at Bioverativ's sole discretion and a further five-year extension with Bioverativ's and our consent. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$206.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$64.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, in revenues in relation to contract manufacturing services provided to Bioverativ, which is reflected as a component of other royalty and corporate revenues in our consolidated statements of income. We also recorded &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$180.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as cost of sales in relation to these services during the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Additionally, pursuant to the terms of the manufacture and supply agreement, we expect to sell substantially all remaining hemophilia related inventory to Bioverativ during the first quarter of 2019, when Bioverativ will assume full control over its manufacturing processes. Hemophilia related inventory on hand as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, totals approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$180.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items. These amounts, which were primarily reflected as a reduction to selling, general and administrative expenses in our consolidated statements of income, were not significant for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Hemophilia related product revenues reflected in our consolidated statements of income for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$74.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$846.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Results for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, only reflect hemophilia-related product revenues through January 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;"&gt;Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-8D61B41702099A68BE58FBB7C0B72668">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2018Q4YTD" id="Fact-ACB2D029B8598C2813B8FBB7C1446243">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Earnings&amp;#160;per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,430.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,539.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,702.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;204.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;205.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Earnings per share for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, reflects, on a weighted average basis, the repurchase of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;14.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock, respectively, under our 2018, 2016 and 2011 Share Repurchase Programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:EquityMethodInvestmentsPolicy contextRef="FD2018Q4YTD" id="Fact-E43530F7809A5F03D9FCFBB7C0B76F49">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&amp;#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&amp;#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
	<us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="FD2018Q4YTD" id="Fact-82C2C1A698763AB58630FBB7C0B7441C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica AG&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,489.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,517.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,745.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,851.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,802.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,077.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,037.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,483.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2018Q4YTD" id="Fact-C9CE842A7841F7F32911FBB7C1053F3C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,459.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,459.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;969.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;969.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;615.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;51.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;563.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,102.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;51.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,050.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;434.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,444.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,433.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;634.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;There have been &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; changes in valuation techniques or transfers between fair value measurement levels during the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our new agreement with Ionis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies - Fair Value Measurements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Debt Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our debt instruments, which are Level&amp;#160;2 liabilities, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica AG&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,489.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,517.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,032.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,745.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,851.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,802.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,077.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,037.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,483.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our 2006 distribution agreement with Fumedica AG, we issued notes totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;61.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Swiss Francs that were payable to Fumedica AG in varying amounts from June 2008 through June 2018. In June 2018 we redeemed our remaining note payable to Fumedica AG.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair value of our notes payable to Fumedica AG, as of December 31, 2017, was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair value for each series of our Senior Notes was determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Indebtedness,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration Obligations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisitions of Convergence, Stromedix and BIN in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(12.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;62.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(101.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$265.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$279.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of achievement of milestones related to our vixotrigine program for the treatment of TGN and an increase in discount rates used to revalue our contingent consideration liabilities, partially offset by the passage of time. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, payments and other reflects a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$81.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone payment made to the former shareholders of Stromedix, as discussed below. For additional information on our IPR&amp;amp;D intangible asset related to our vixotrigine program for the treatment of TGN, please read Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, changes in the fair value of our contingent consideration obligations are primarily due to changes in the expected timing and probabilities of success related to the achievement of certain development milestones and changes in the discount rate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Convergence Pharmaceuticals Ltd.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$274.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This valuation was based on probability weighted net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$450.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which was the estimated cost of debt financing for market participants. This liability reflected the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$246.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$259.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon net cash flow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$400.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, probability weighted and discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.6%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net decrease in our contingent consideration obligation was primarily due to delays in the expected timing of achievement of milestones related to our vixotrigine program for the treatment of TGN and an increase in discount rates used to revalue our contingent consideration liabilities, partially offset by the passage of time. Accrued expenses and other in our consolidated balance sheets include &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$144.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as we expect to make the payment within one year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Stromedix Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Stromedix in March 2012 we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$122.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$83.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$162.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$306.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, probability weighted and discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.6%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net decrease in our contingent consideration obligation was primarily due to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$81.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; milestone paid to the former shareholders of Stromedix as we dosed our first patient in the Phase 2b study of BG00011 (STX-100) in idiopathic pulmonary fibrosis in September 2018, changes in the expected timing related to the achievement of certain remaining developmental milestones and an increase in discount rates, partially offset by the passage of time. No amounts are reflected as a current liability in our consolidated balance sheets as we do not expect to make a payment in the next year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Biogen Idec International Neuroscience GmbH&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$81.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the fair value of this contingent consideration obligation was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$80.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$102.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our most recent valuation was determined based upon net cash outflow projections of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$335.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, probability weighted and discounted using a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.8%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which is a measure of the credit risk associated with settling the liability. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the net decrease in our contingent consideration obligation was primarily due to a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; development milestone paid in the first quarter of 2018 as we dosed our first patient in our Phase 2 SPARK study of BIIB054 (&amp;#945;-synuclein mAb) in Parkinson's disease in January 2018 and an increase in discount rates, partially offset by the passage of time. No amounts are reflected as a current liability in our consolidated balance sheets as we do not expect to make a payment in the next year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Acquired IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with our acquisition of Convergence, we also allocated &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$424.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the total purchase price to acquired IPR&amp;amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. These assets will be tested for impairment annually until commercialization, after which time the acquired IPR&amp;amp;D will be amortized over its estimated useful life using the economic consumption method. During the third quarter of 2018 we recognized impairment charges related to certain IPR&amp;amp;D assets associated with our vixotrigine program totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$189.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our IPR&amp;amp;D intangible assets related to our vixotrigine program, including a discussion of our most significant assumptions, please read Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2018Q4YTD" id="Fact-E5653C529FFF6111CD45FBB7C089ED53">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;467.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Changes in fair value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(12.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;62.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(101.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Fair value, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2018Q4YTD" id="Fact-91BCA895E1FAC6DA3A26FBB7C0C7C0E7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&amp;#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&amp;#160;and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our financial assets have been classified as Level&amp;#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-BEE1E7043B7E9D447473FBB7C0C77EA5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&amp;#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-4810CBD903D47E9E7D38FBB7C089C665">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated Life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(542.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;543.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(535.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15-23 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,734.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;270.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,005.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,689.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In-process research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite until commercialization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;476.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;476.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;680.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Trademarks and trade names&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;64.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4-18 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,638.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,330.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,308.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,971.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,160.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,811.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7,727.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4,607.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8,264.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4,385.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,879.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization and impairments of acquired intangible assets totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$747.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$814.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$385.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization and impairments of acquired intangible assets for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes the impact of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$176.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charge related to our intangible asset associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below. Amortization and impairment of acquired intangible assets for 2018 also reflects the impact of impairment charges related to certain IPR&amp;amp;D assets associated with our vixotrigine (BIIB074) program totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$189.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, also discussed below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization and impairments of acquired intangible assets for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, includes the impact of a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$328.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charge related to our intangible assets associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. Amortization and impairment of acquired intangible assets for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; also includes a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$31.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charge related to our acquired and in-licensed rights and patents intangible asset associated with ZINBRYTA after the initiation of an European Medicines Agency (EMA) review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization and impairments of acquired intangible assets for the year ended December 31, 2016, included impairment charges of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;related to two of our IPR&amp;amp;D intangible assets resulting from the termination of our collaboration agreements with Rodin Therapeutics, Inc. and Ataxion Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amortization of acquired intangible assets, excluding impairment charges, totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$381.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$455.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$373.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Out-licensed Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Developed Technology&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset, as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$265.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IPR&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired and had not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. The carrying value associated with our IPR&amp;amp;D assets as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, relates to the various IPR&amp;amp;D programs we acquired in connection with our acquisitions of Convergence Pharmaceuticals (Convergence), Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2015, 2012 and 2010, respectively. IPR&amp;amp;D balances include adjustments related to foreign currency exchange rate fluctuations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long-range planning cycle, which was most recently updated in the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&amp;#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Vixotrigine&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints; therefore, we discontinued development of vixotrigine for the treatment of PLSR and we recognized an impairment charge of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the third quarter of 2018 to reduce the fair value of the related IPR&amp;amp;D intangible asset to zero. In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the treatment of TGN as we awaited the outcome of ongoing interactions with the FDA regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the treatment of PLSR and insights from the Phase 2 study of vixotrigine for the treatment of small fiber neuropathy. We reassessed the fair value of our vixotrigine program for the treatment of TGN using reduced expected lifetime revenues, higher expected clinical development costs and lower cumulative probabilities of success, and, as a result of that assessment, we recognized an impairment charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$129.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the third quarter of 2018 to reduce the fair value of the IPR&amp;amp;D intangible asset associated with our vixotrigine program for the treatment of TGN to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$41.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In late December 2018 we received feedback from the FDA regarding the design of the Phase 3 vixotrigine program for the treatment of TGN. Following this feedback, we are now planning to initiate the Phase 3 vixotrigine program for the treatment of TGN.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The IPR&amp;amp;D impairment charges that resulted from the developments in our vixotrigine program for the treatment of TGN, as discussed above, were included in amortization and impairment of acquired intangible assets. The fair value of the intangible assets were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We may recognize additional impairment charges in the future depending upon our ability to advance vixotrigine for the treatment of TGN or other indications. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired and In-licensed Rights and Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan. Acquired and in-licensed rights and patents also includes our U.S and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2,027.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;TECFIDERA License Rights&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.25 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;in cash, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$795.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was recorded within intangible assets in the first quarter of 2017. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$328.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute and continued to amortize the remaining net book value of the U.S. intangible asset in our consolidated statements of income utilizing an economic consumption model. The U.S. Court of Appeals for the Federal Circuit upheld the U.S. Patent and Trademark Office&amp;#8217;s (USPTO) March 2017 ruling and in January 2019 denied Forward Pharma's petition for rehearing. We evaluated the recoverability of the U.S. asset based upon these most recent developments recorded a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$176.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; impairment charge in the fourth quarter of 2018 to reduce the remaining net book value of the U.S. asset to zero.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2018 the European Patent Office (EPO) revoked Forward Pharma&amp;#8217;s European Patent No. 2 801 355. Forward Pharma has filed an appeal to the Technical Board of Appeal of the EPO and the appeal is pending. Based upon our assessment of this ruling, we continue to amortize the remaining net book value of the rest of world intangible asset in our consolidated statements of income utilizing an economic consumption model. The remaining net book value of the TECFIDERA intangible asset as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$71.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on these disputes, please read Note 21, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Litigation,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Estimated Future Amortization of Intangible Assets&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our most recent long-range planning cycle was completed in the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;270.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;290.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;250.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;250.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;230.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,632.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to our hemophilia business&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,080.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,267.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,706.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,632.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The elimination of goodwill represents an allocation based upon the relative enterprise fair value of our hemophilia business as of February 1, 2017. For additional information on the spin-off of our hemophilia business, please read Note 3, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The increase to goodwill during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; was related to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in contingent milestones achieved (exclusive of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$119.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$232.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in tax benefits), respectively, and payable to the former shareholders of Fumapharm AG and holders of their rights. In the fourth quarter of 2018 we achieved the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$20.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; cumulative sales level threshold and accrued our last &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; contingent payment related to FUMADERM and TECFIDERA (together, the Fumapharm Products), which will be paid in the first quarter of 2019. For additional information on contingent payments to the former shareholders of Fumapharm AG and holders of their rights, please read Note 22, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Commitments and Contingencies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other includes changes related to foreign currency exchange rate fluctuations. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; accumulated impairment losses related to goodwill.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="FD2018Q4YTD" id="Fact-16C71BC66C9B7E6958CCFBB7C079A295">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&amp;#160;25, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Segment Information,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="FD2018Q4YTD" id="Fact-D730574351B4113F2922FBB7C1151AA3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&amp;#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also includes our U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
	<us-gaap:GuaranteesTextBlock contextRef="FD2018Q4YTD" id="Fact-B0CB418601F5D5315584FBB7C079FC2D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Guarantees&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we did not have significant liabilities recorded for guarantees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GuaranteesTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-7FC2AD2071915394AB41FBB7C1051A3D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:InProcessResearchAndDevelopmentPolicy contextRef="FD2018Q4YTD" id="Fact-99D4338D80D08ED69BC8FBB7C11576D1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-1180975BEAAAAFC0CD01FBB7C0C7FE66">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Income Tax Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income before income tax provision and the income tax expense consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income before income taxes (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,877.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,540.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,655.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,022.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,588.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,277.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,899.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,128.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,933.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income tax expense (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,131.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,201.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,304.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;45.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;140.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;108.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;52.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,317.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,367.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,412.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(62.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;241.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(125.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;177.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(159.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(45.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;108.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;91.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(175.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,425.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,458.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,237.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2017 Tax Act&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as GILTI, and includes base erosion prevention measures on non-U.S. earnings. These changes became effective in 2018. During the fourth quarter of 2018 we elected to recognize deferred taxes for basis differences expected to reverse as GILTI is incurred and have established initial deferred tax balances, as of the enactment date of the 2017 Tax Act.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the fourth quarter of 2017 we recognized within our provision for income taxes a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; provisional estimate pursuant to the U.S. Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 118. Our provisional estimate included an amount of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$989.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; associated with a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax), as discussed below, and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$184.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the year ended December 31, 2018, we recognized a net reduction of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$34.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in our estimated Transition Toll Tax, an expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to remeasure our deferred tax balances, an expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$135.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to establishing deferred taxes for GILTI and an expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$11.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to reflect other aspects of the 2017 Tax Act.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Transition Toll Tax&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax. The Transition Toll Tax was assessed on our share of our foreign corporations' accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and all other earnings were taxed at a rate of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we have accrued income tax liabilities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$697.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$989.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, under the Transition Toll Tax. The decrease in this liability is primarily attributed to our 2018 Transition Toll Tax payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$85.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the application by the U.S. Internal Revenue Service (IRS) of an approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; overpayment against the accrual and the impact of the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$34.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; net reduction described above. Of the amounts accrued as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, no amounts are expected to be paid within one year due to the overpayment discussed above. The Transition Toll Tax will be paid in installments over an eight--year period, which started in 2018, and will not accrue interest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Status of our Assessment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The final determination of the Transition Toll Tax and the remeasurement of our deferred assets and liabilities was completed during the fourth quarter of 2018 under SEC Staff Accounting Bulletin No. 118. Throughout 2018 proposed regulations were issued by the IRS, which are expected to be finalized in 2019 and may have an impact on our income tax provision. We will assess the impact of any additional guidance when it is issued.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Unremitted Earnings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we considered none of our earnings to be permanently reinvested outside the U.S. and therefore recorded deferred tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. Other than for earnings, we are permanently reinvested for book/tax basis differences related to foreign subsidiaries. These differences are estimated to total approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and primarily arose through the impacts of purchase accounting. These basis differences could reverse through sales of the foreign subsidiaries, as well as various other events, none of which are considered probable as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The residual U.S. tax liability, if these differences would reverse, would be between &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.3 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.4 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Article 20 Procedure of ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of the Article 20 Procedure of ZINBRYTA, for the year ended December 31, 2017, we recognized a net impairment charge on certain tax assets related to ZINBRYTA reflected within income tax expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This charge reflected the write-off of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$142.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to prepaid taxes, which was partially offset by the recognition of an unrecorded deferred tax benefit of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$93.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. For additional information on our collaboration arrangement with AbbVie, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Deferred Tax Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Significant components of our deferred tax assets and liabilities are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;102.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory, other reserves and accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;163.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;147.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangibles, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,298.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;378.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;213.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;209.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;38.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,823.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;831.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(232.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(250.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(544.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,425.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation, amortization and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(102.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(107.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,305.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(358.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intra-entity transactions. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the total deferred charges and prepaid taxes were &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$239.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$617.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU 2016-16. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date.&amp;#160;Upon adoption, we recognized additional deferred tax assets of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; offset by a corresponding increase to deferred tax liabilities, related to an expected reduction in future U.S. foreign tax credits of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and an increase to retained earnings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.4 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; with a corresponding reduction to our retained earnings as these differences are related to inter-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017 Tax Act&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairment of ZINBRYTA related tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Changes in Tax Rate&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the decrease in our effective tax rate was primarily due to the enactment of the 2017 Tax Act. The effects of an overall reduction in the federal statutory rate in the U.S. were partially offset by the elimination of the manufacturing deduction, the imposition of the GILTI tax on international earnings, our recording of deferred taxes on GILTI in 2018, limits on the deductibility of certain benefits on executive compensation and a reduction in the tax benefit associated with the Orphan Drug Credit, all resulting from the 2017 Tax Act, and a change in accounting rules related to recording the tax impacts of intra-entity transactions. Included in taxes on foreign earnings in the above rate reconciliation for 2018 was an increase of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;350&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; basis points related to the sale of inventory, the tax effect of which had been included within prepaid taxes at &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, at a higher effective tax rate. The effective tax rate for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, also reflected the impact of a favorable settlement related to a state tax matter in 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the most significant factors contributing to the increase in our effective tax rate was the effect of the enactment of the 2017 Tax Act and the impairment of certain ZINBRYTA related tax assets, both of which are discussed above. Excluding the effect of these items, our income tax rate would have decreased due to a lower percentage of our earnings being recognized in the U.S., a higher tax jurisdiction. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we earned a lower benefit from the Orphan Drug Credit due to the FDA's approval of SPINRAZA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Tax Attributes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, which begin to expire in 2022. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; that begin to expire in 2020. For state income tax purposes, we also had research and investment credit carry forwards of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$133.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; that begin to expire in 2019. For foreign income tax purposes, we had &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of net operating loss carryforwards that begin to expire in 2024.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Uncertainty in Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at January&amp;#160;1,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions based on tax positions related to the current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;58.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reductions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statute expirations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlement refund (payment)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;44.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(64.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;114.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;66.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our 2017 activity above reflects a refund received from a state, related to the settlement of an uncertain tax position.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Included in the balance of unrecognized tax benefits as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, are &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$109.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$64.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$26.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, 2017 and 2016 we recognized a net interest expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$9.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. We have accrued &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$13.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$16.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the payment of interest and penalties as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;International Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have made payments totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to the Danish Tax Authority (SKAT) for assessments received for 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid. It is reasonably possible that we will adjust the value of our uncertain tax positions related to Danish withholding taxes based on potential European court decisions expected in 2019 on similar matters.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Federal and State Uncertain Tax Positions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-B2125434798CD514A91BFBB7C144F6AD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. In December 2018 we elected to recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfers of assets other than inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset is transferred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We account for uncertain tax positions using a &amp;#8220;more-likely-than-not&amp;#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-354DA06D69BCBAAB7806FBB7C172AA98">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;162.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;606.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;133.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;157.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;929.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;902.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Included in the table above is hemophilia related inventory totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$180.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of December 31, 2018, which is expected to be sold to Bioverativ in the first quarter of 2019. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$41.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$76.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-A01BBF187F0898DE3FB9FBB7C115E341">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Capitalization of Inventory Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Obsolescence and Unmarketable Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-85B559590BAEC1140FE9FBB7C105409A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Equity Securities and Venture Capital Funds&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Evaluating Investments for Other-than-Temporary Impairments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
	<us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="FD2018Q4YTD" id="Fact-193A05277540C7D9D7CBFBB7C0F6CD34">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160; Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,313.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,314.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,115.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,116.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after one year through five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,232.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,235.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,730.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Due after five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;143.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;143.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;327.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;327.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,689.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,694.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,172.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,173.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
	<us-gaap:LegalMattersAndContingenciesTextBlock contextRef="FD2018Q4YTD" id="Fact-E128B0DC6442B3DA50DCFBB7C08918A8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Summary of Significant Accounting Policies,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&amp;#8217; legal theories; and (v) the parties' settlement positions. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Loss Contingencies &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;IMRALDI Patent Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in March 2035. In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &amp;#8216;510 Patent, and against Biogen GmbH in the Dusseldorf Regional Court relating to the German counterpart of the &amp;#8216;510 Patent. No hearing has yet been set in these proceedings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom counterpart of the '510 Patent. Fresenius Kabi has filed a counterclaim asserting infringement of the '510 Patent and seeking damages and an injunction to restrain infringement if the patent is found valid and infringed. A trial has been set for July 2019.&amp;#160;In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &amp;#8216;510 Patent.&amp;#160;A trial has been set for October 2019. An estimate of the possible loss or range of loss in the above matters cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2018 Gedeon Richter PLC asserted to Biogen and Samsung Bioepis UK Limited that IMRALDI infringes European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035.&amp;#160;We dispute the assertion. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Qui Tam Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&amp;#8217; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2018 we were served with a qui tam action filed by SMSF, LLC on behalf of the U.S. and certain states in the U.S. District Court for the District of Massachusetts alleging activities by nurse-educators in violation of the federal False Claims Act and state law counterparts. The government declined to intervene, and we, other defendants and the U.S. moved to dismiss. In December 2018 the court dismissed the case with prejudice against the relator and without prejudice as to the U.S. and states. The period for an appeal has lapsed and we consider the matter closed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case alleges agreements with pharmacy benefit managers in violation of the Federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. We, the other defendants and the U.S. have moved to dismiss the case and the motions are pending. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Securities Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &amp;#167;78j(b) and &amp;#167;78t(a) and 17 C.F.R. &amp;#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In March 2018 the court dismissed the complaint with prejudice. The plaintiff's appeal is pending. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June and July 2017, January, March, April, August and December 2018 and January 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Caribe Holdings (Cayman) Co. Ltd.&amp;#160;DBA Puracap&amp;#160;Caribe, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&amp;#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shipla Medicare Limited, Slayback Pharma LLC, Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A trial has been set for December 2019 in the Delaware actions, and a trial date has been set for February 2020 in the West Virginia action. A trial date has not been set in the case against Banner Life Sciences LLC or the case against Hetero USA Inc. that was filed in January 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Petition for Inter Partes Review filed by Mylan Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2018 Mylan Pharmaceuticals, Inc. filed a petition with the U.S. Patent Trial and Appeal Board seeking &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. The petition is pending. February 6, 2019, the U.S. Patent Trial and Appeal Board instituted &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;inter partes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; review of the '514 Patent.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Interference Proceeding with Forward Pharma&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In April 2015 the USPTO declared an interference between Forward Pharma&amp;#8217;s U.S. Patent Application No. 11,576,871 and the '514 Patent. The U.S. Court of Appeals for the Federal Circuit affirmed the March 2017 ruling of the USPTO in favor of Biogen and in January 2019 denied Forward Pharma's petition for rehearing. For additional information regarding this matter, please read Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;European Patent Office Oppositions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In 2016 the EPO revoked our European patent number 2 137 537 (the '537 Patent). We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. The '537 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2018 the EPO revoked Forward Pharma&amp;#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. The settlement and license agreement that we entered into with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination. For additional information regarding this matter, please read Note 7, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Intangible Assets and Goodwill,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;TYSABRI Patent Revocation Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action to the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish '263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU '127 Patent) ("Administration of agents to treat inflammation"). The Polish '263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent was issued in 2013 and expires in February 2023. Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which was issued in 2011 and also concerns administration of natalizumab (TYSABRI) to treat MS. The EU '127 Patent expires in February 2023. The Dutch and German counterparts were ruled invalid and we have appealed. No date for a hearing on the merits has been set in the Polish and Italian actions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;'755 Patent Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May&amp;#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&amp;#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In September 2018, following a trial against EMD Serono and Pfizer, the court granted Biogen's motion for judgment as a matter of law that the '755 Patent is infringed and valid and ordered a new trial on all damages issues. The court has not yet scheduled the trial on damages or a trial against Bayer and Novartis. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Government Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&amp;#160;We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&amp;#160;We are cooperating with the government.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Tax Matter&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$70.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; including interest and penalties. We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending. We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Product Liability and Other Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-047EAA814D9071B7E036FBB7C0D76B3B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued ASU 2014-09, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. For additional information on the adoption of the new revenue standards, please read the section titled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue Recognition &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;above, and Note 5, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenues&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this standard on January 1, 2018, using the modified retrospective method, and recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; net increase to retained earnings as well as a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; increase to accumulated other comprehensive income reflecting the cumulative impact for the accounting changes made upon adoption. The adoption of this standard resulted in a change in the income statement classification with respect to where we recognize changes in fair value related to certain equity security investments. Prior to the adoption of ASU 2016-01, we recognized changes in fair value in accumulated other comprehensive income (loss), net. Upon the adoption of ASU 2016-01, we recognize changes in fair value in other income (expense), net. During the year ended December 31, 2018, we recognized net gains resulting from changes in fair value related to our equity security investments in other income (expense), net totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$128.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under this standard that would not have been recognized in other income (expense), net under the previous standard. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Leasing&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This standard became effective for us on January 1, 2019. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB has subsequently issued the following amendments to ASU 2016-02, which have the same effective date and transition date of January 1, 2019, and which we collectively refer to as the new leasing standards: &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2018-01,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that exist or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2018-10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which amends certain narrow aspects of the guidance issued in ASU 2016-02.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2018-20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Narrow-Scope Improvements for Lessors&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which contains certain narrow scope improvements to the guidance issued in ASU 2016-02.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the new leasing standards on January 1, 2019, using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019. We have reviewed our existing lease contracts and the impact of the new leasing standards on our consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards, we expect to recognize a lease liability and related right-of-use asset on our consolidated balance sheet of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The impact of adoption of the new leasing standards will have an immaterial impact to our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Credit Losses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard will be effective for us on January 1, 2020. We are currently evaluating the potential impact that this standard may have on our consolidated financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, offset by a corresponding net increase to retained earnings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.4 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; with a corresponding reduction to our retained earnings as these differences are related to inter-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our income taxes, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Net Periodic Pension Cost&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-07, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Costs and Net Periodic Postretirement Benefit Cost.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; This standard requires that an employer disaggregate the service cost component from the other components of net benefit cost. This standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the statements of income and allows only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on our consolidated statements of income. We adopted this standard on January 1, 2018, using the retrospective method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of the adoption of this standard, the other components of net periodic benefit cost, which we previously presented as a component of operating income, are now classified in other income (expense), net in our consolidated statements of income. For the years ended December 31, 2017 and 2016, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, were reclassified from operating income to other income (expense), net in our consolidated statements of income to conform to our current year presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. Based upon our marketable debt securities as of December 31, 2018, the adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2017 the FASB issued ASU No. 2017-12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard provides guidance to better align an entity's risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. This standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this standard resulted in additional disclosures and a change in the income statement classification with respect to where we recognize cash flow hedge ineffective or excluded hedge transaction gains and losses. Prior to the adoption of ASU 2017-12 on January 1, 2018, to the extent ineffective or excluded, cash flow hedge transaction gains and losses were reported in other income (expense), net. Effective January 1, 2018, we recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of any cash flow hedge ineffectiveness or excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additionally, in October 2018 the FASB issued ASU No. 2018-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our derivative instruments and hedging activities, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard will be effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; This standard makes targeted improvements for collaborative arrangements as follows: &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Requires that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting that transaction together with revenue recognized under ASC 606 is precluded if the collaborative arrangement participant is not a customer. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard will be effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. We are currently evaluating the potential impact that this standard may have on our consolidated financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-53552ED81AFF2E4A821FFBB7C079CCE5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Employee Benefit Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;401(k) Savings Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&amp;#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Expense related to our 401(k) Savings Plan totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Deferred Compensation Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, totaled approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$109.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$109.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Pension Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.00%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.25%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&amp;#8217;s contribution. Minimum employee contributions are based on the respective employee&amp;#8217;s age, salary and gender. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the Swiss plan had an unfunded net pension obligation of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, and plan assets that totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$93.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$83.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. In &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized expense totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$14.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$15.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to our Swiss plan, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, was included in other income (expense), net.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The obligations under the German plans are unfunded and totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$43.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Net periodic pension cost related to the German plans totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, was included in other income (expense), net.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-04D49CD2BADA2E416E02FBB7C12584B4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;144.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;141.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,282.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,213.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;94.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;80.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,258.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,207.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Computer software and hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;798.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;767.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;61.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,758.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,276.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,398.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,741.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,797.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,601.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,182.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation expense totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$269.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$266.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$309.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we capitalized interest costs related to construction in progress totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$54.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$30.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. The increase in capitalized interest costs is primarily due to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, as discussed below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. Upon completion, the facility will include 393,000&amp;#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we had approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.6 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.2 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, capitalized as construction in progress related to this facility.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-FC9531B4DBEAB6660272FBB7C0D73EAB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three to five years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2018Q4YTD" id="Fact-B1D6D7D532CA020DB0FBFBB7C125FE21">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of property, plant and equipment, net are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;144.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;141.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,282.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,213.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;94.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;80.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Machinery and equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,258.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,207.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Computer software and hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;798.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;767.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;61.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,758.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,276.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,398.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,741.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,797.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,559.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,601.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,182.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2018Q4YTD" id="Fact-B7CC982DCA735892B848FBB7C0A8E17E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Quarterly Financial Data (Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (b) (c) (d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (b) (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (f) (g) (h) (i)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,523.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,757.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,780.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,825.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,886.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;443.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;490.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;511.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;534.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,980.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;164.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;108.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;147.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;165.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;585.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,131.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,356.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,439.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,526.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13,452.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,685.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,935.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,978.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,037.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11,636.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,171.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;915.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,442.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;944.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,474.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,172.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;866.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,444.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;946.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,430.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;207.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;201.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;199.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;204.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;201.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;200.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;205.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(j) (k) (l)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(m) (n) (o) (p)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,380.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,639.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,622.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,712.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;340.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;397.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;406.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;415.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;90.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;48.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;179.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;360.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,810.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,078.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,077.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,307.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12,273.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,426.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,712.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,707.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,797.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10,643.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;747.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;862.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,226.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(166.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,670.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;747.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;862.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,226.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(297.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,539.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the first, second, third and fourth quarters of 2018 includes pre-tax charges related to (losses) gains recorded in relation to changes in the fair value of our strategic investments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$(6.4) million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$141.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$(12.2) million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the first, second and third quarters of 2018 include pre-tax charges to acquired IPR&amp;amp;D of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$27.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, for upfront payments to Karyopharm, Pfizer and AliveGen, respectively, upon closing of the asset purchase transactions for BIIB100, BIIB104 and BIIB110, respectively, as the underlying assets had not yet reached technological feasibility.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2018 includes pre-tax charges to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$486.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the closing of the 2018 Ionis Agreement. Included in this amount was a charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$162.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reflecting the premium paid above fair value for the purchase of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;11.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of Ionis' common stock upon the closing of the 2018 Ionis Agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc. for the second quarter of 2018 includes a pre-tax charge to noncontrolling interest of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a payment to Neurimmune in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the third quarter of 2018 includes the impact of impairment charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$189.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to certain IPR&amp;amp;D assets associated with our vixotrigine program and an adjustment to the value of our contingent consideration obligations related to our vixotrigine program for the treatment of TGN to reflect the lower cumulative probabilities of success, which resulted in a gain of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$89.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third quarter of 2018. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In late December 2018 we received feedback from the FDA regarding the design of the Phase 3 vixotrigine program for the treatment of TGN. Following this feedback, we are now planning to initiate the Phase 3 vixotrigine program for the treatment of TGN and, as a result, we adjusted the fair value of our contingent consideration obligations related to our vixotrigine program for the treatment of TGN to reflect the increased probabilities of success and recognized a loss of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$80.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the fourth quarter of 2018.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 and the first quarter of 2017 includes &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$176.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$328.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of impairment charges related to our intangible asset associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(h)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 includes a net increase to income tax expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$135.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reflecting the impact of electing to record deferred taxes on GILTI.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 includes an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$35.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis, as we exercised our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB067.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(j)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment made to BMS upon entering into our agreement to exclusively license BIIB092.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(k)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to acquired IPR&amp;amp;D of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment to Remedy upon closing of the asset purchase transaction for BIIB093.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(l)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a developmental milestone that became payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 study of BIIB092 for PSP.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(m)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to noncontrolling interest of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a payment made to Neurimmune in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(n)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes pre-tax charges to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment and a continuation payment, respectively, to Alkermes.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(o)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment to Ionis upon entering into a new collaboration agreement to identify new ASO drug candidates for the treatment of SMA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(p)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1,173.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the provisions of the 2017 Tax Act, including a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$989.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; expense under the Transition Toll Tax.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our acquisitions of BIIB100, BIIB104, BIIB110 and BIIB093, please read Note 2, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Acquisitions&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. For additional information on our collaboration arrangements with Ionis, BMS and Alkermes, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. For additional information on our collaboration arrangement with Neurimmune, please read Note 20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. For additional information on the amortization and impairment of acquired intangible assets, including our IPR&amp;amp;D intangible asset related to our vixotrigine program for the treatment of TGN and our TECFIDERA settlement and license agreement, please read Note 7,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Intangible Assets and Goodwill&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. For additional information on the 2017 Tax Act, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:RealizedGainLossOnInvestmentsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-EF6ABDE9B8733DB8DA8DFBB7C0F61CA8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Proceeds from maturities and sales&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;9,173.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,565.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,378.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Realized losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
	<us-gaap:ReceivablesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-A64CDF41B4D28A738FC1FBB7C089ACD6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 to 90 days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We provide reserves against trade receivables for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adoption of the new revenue standards did not change our historical accounting methods for our accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
	<us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="FD2018Q4YTD" id="Fact-28B33127456DBB4F634AFBB7C089E2EB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Income Statement Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Amounts Reclassified from&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Accumulated Other Comprehensive Income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on securities available for sale&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(8.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on cash flow hedges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (losses) on net investment hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other Income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax benefit (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total reclassifications, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(44.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
	<us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-E4141C3AA2F963A4221BFBB7C09867EE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
	<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-AF5D77CBD44371346048FBB7C0F6033A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Restructuring, Business Transformation and Other Cost Saving Initiatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2017 Corporate Strategy&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and capital expenditures of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$135.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in connection with this program and our goal is to redirect resources of up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$400.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; annually by 2020 to prioritized research and development and other value creation opportunities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized charges of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$22.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$19.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, related to this effort, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$12.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, are reflected as restructuring charges and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$10.9 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$18.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, are included in selling, general and administrative expenses in our consolidated statements of income. These restructuring charges were primarily related to severance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges incurred to date under this program have been substantially paid in cash as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;2016 Organizational Changes and Cost Saving Initiatives&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2016 Restructuring Charges&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;During the third quarter of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin-off our hemophilia business, and to achieve further targeted cost reductions. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$17.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to this effort. These amounts, which were substantially incurred and paid by the end of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, were primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Cambridge, MA Manufacturing Facility&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we decided to cease manufacturing and vacate our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and close and vacate our 46,000 square foot warehouse space in Somerville, MA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In December&amp;#160;2016 we subleased our rights to the Cambridge, MA manufacturing facility to Brammer Bio MA,&amp;#160;LLC (Brammer). Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we closed and vacated our warehouse space in Somerville, MA.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets' new shorter useful lives. For the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, we recognized approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$45.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of this additional depreciation, which was recorded as cost of sales in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the fourth quarter of 2016 we also recognized charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$7.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for severance costs related to certain employees separated from Biogen in connection with our departure from these facilities. These amounts were substantially incurred and paid by the end of first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;2015 Restructuring Charges&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges for the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, include &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of expense related to our 2015 restructuring program.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
	<us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="FD2018Q4YTD" id="Fact-76C81FCB47E251CDCB4711E3E2366DE5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues by product are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="36" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;United&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;States&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Rest of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;World&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Multiple Sclerosis (MS):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TECFIDERA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;3,253.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,020.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;4,274.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,294.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;920.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4,214.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,169.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;798.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,968.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Interferon*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,668.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;694.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,363.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,889.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;756.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,645.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,980.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;814.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,795.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;TYSABRI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,025.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;839.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,864.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,113.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;859.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,973.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,182.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;780.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;1,963.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FAMPYRA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;92.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;92.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;91.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;91.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;84.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ZINBRYTA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;52.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;52.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: MS Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;5,946.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;2,648.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;8,595.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;6,296.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,680.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;8,977.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;6,332.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,487.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;8,819.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Spinal Muscular Atrophy:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;SPINRAZA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;854.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;870.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;1,724.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;657.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;226.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;883.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;4.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Biosimilars:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;BENEPALI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;485.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;485.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;370.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;370.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FLIXABI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;43.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;43.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;IMRALDI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Biosimilar product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;545.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;545.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;379.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;379.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;100.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Other:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;FUMADERM&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;22.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;22.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;39.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;39.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;45.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Hemophilia:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ELOCTATE&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;42.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;48.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;445.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;68.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;513.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;26.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;268.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;65.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;333.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Subtotal: Hemophilia product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;63.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;11.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;74.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;713.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;133.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;846.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;Total product revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;6,800.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;4,086.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;"&gt;10,886.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7,017.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;3,337.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;2,767.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;*Interferon includes AVONEX and PLEGRIDY.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognized revenues from two wholesalers accounting for &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;34%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;21%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of gross product revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, two wholesale distributors individually accounted for approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;27.7%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.6%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of net accounts receivable associated with our product sales, as compared to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;19.0%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;109.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;606.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;679.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,686.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;23.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,389.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(12.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(551.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,887.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,440.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(109.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(506.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(646.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;127.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;888.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,051.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;583.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,307.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,917.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(475.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,756.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,232.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(69.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(442.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(23.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(534.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;109.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;606.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Discounts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Returns&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;56.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;548.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;662.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current provisions relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;592.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,044.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,668.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adjustments relating to prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in current year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(522.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1,576.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(2,099.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Payments/returns relating to sales in prior years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(53.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(536.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(19.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(609.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;482.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reduction of accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;176.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Component of accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;874.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenue-related reserves&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,051.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;761.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,431.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;548.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;242.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;65.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,980.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;13%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our total revenues in &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, are derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;"&gt;Other Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from collaborative and other relationships:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(8.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;96.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;42.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Sobi and royalties from Sobi on sales of ELOCTA and ALPROLIX&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other royalty and corporate revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalty&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;38.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;69.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;46.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;459.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;253.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;230.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;585.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;360.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with AbbVie and Samsung Bioepis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements. For additional information on our contract manufacturing agreements with Bioverativ, please read Note 3,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;,&amp;#160;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-B18C6EE4A9E409151624FBB7C0B72A30">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU 2014-09 that have the same effective date and transition date: ASU No. 2016-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; ASU No. 2016-10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; ASU No. 2016-12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; and ASU No. 2016-20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not change our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon adoption. However, the adoption of the new revenue standards will result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under ASU 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of the new revenue standards, other corporate revenue was higher by&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;and cost of sales, excluding amortization and impairment of acquired intangible assets was higher by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the year ended December 31, 2018, compared to what would have been reported under the previous revenue guidance, primarily due to the earlier recognition of revenue associated with our contract manufacturing agreements. Under the previous revenue guidance, these amounts would have been recognized in future periods upon shipment. The adoption of the new revenue standards did not have a material impact on any other balances within our consolidated financial statements as of and for the&amp;#160;year ended&amp;#160;December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the United States (U.S.), we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&amp;#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other governmental rebates, non-US pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our collaboration with Genentech is within the scope of Accounting Standards Codification (ASC) 808, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Agreements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(ii)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech, the Roche Group and us. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates that are based on information received from Genentech. These estimates are subject to change and actual results may differ. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our relationship with Genentech, please read Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our development and commercialization arrangements with AbbVie Inc. (AbbVie), Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with AbbVie, Genentech and Samsung Bioepis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Royalty Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Corporate Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-14B8728478E178E71097FBB7C1349090">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other consists of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenue-related reserves for discounts and allowances&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;874.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;572.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;444.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;844.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee compensation and benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;320.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;297.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Royalties and licensing fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;224.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;206.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;125.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;159.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Collaboration expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;261.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;183.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;609.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;636.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total accrued expenses and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,861.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,901.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2018Q4YTD" id="Fact-D5DA6384B1CD92CADAB8FBB7C098FEEF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(318.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified, net of tax, upon adoption of ASU 2016-01&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(316.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;97.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(67.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;29.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;41.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;139.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(67.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;76.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;34.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(31.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(243.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(240.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(193.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;158.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(42.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;31.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;44.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(162.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;158.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(104.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(36.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(175.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(318.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Securities Available for Sale, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Gains (Losses) on Net Investment Hedge, Net of Tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unfunded Status of Postretirement Benefit Plans, net of tax&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Currency Translation Adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(37.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(195.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(224.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other comprehensive income (loss) before reclassifications&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;51.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(92.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(4.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net current period other comprehensive income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(138.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(95.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance, December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(334.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(319.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-A5BBBF33CCD0E7A47BDFFBB7C0F6DB2E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our financial assets with maturities of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;less than 90&amp;#160;days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;231.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Overnight reverse repurchase agreements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;279.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;948.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Short-term debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;194.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;247.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
	<us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="FD2018Q4YTD" id="Fact-459600911677661F7FA4FBB7C13485D7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Supplemental disclosure of cash flow information for the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:51%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash paid during the year for:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;243.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;281.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;281.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,007.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,066.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,642.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
	<us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="FD2018Q4YTD" id="Fact-48524C765F37CA7D92E7FBB7C153238E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;27.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;38.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;126.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;107.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;120.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash settled performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;16.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;18.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;181.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;169.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;170.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2018Q4YTD" id="Fact-78ED15BBFC8317D92AF2FBB7C0C7424D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income before income tax provision and the income tax expense consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income before income taxes (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Domestic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,877.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,540.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,655.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,022.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,588.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,277.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,899.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,128.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,933.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income tax expense (benefit):&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,131.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,201.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,304.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;45.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;57.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;55.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;140.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;108.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;52.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,317.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,367.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,412.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(62.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;241.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(125.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(7.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;177.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(159.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(45.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;108.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;91.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(175.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total income tax expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,425.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,458.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,237.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2018Q4YTD" id="Fact-5BBF80D30CEDF0DEE46DFBB7C14487C0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our indebtedness is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Notes payable to Fumedica AG&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Current portion of notes payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Non-current portion:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.900% Senior Notes due September 15, 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,480.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,482.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.625% Senior Notes due September 15, 2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;995.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;994.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.050% Senior Notes due September 15, 2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,737.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,736.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.200% Senior Notes due September 15, 2045&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,722.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,722.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Non-current portion of notes payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5,935.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-1C1736CE8203ECBB3D9AFBB7C0C7F7A9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Significant components of our deferred tax assets and liabilities are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;102.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;60.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory, other reserves and accruals&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;163.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;147.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangibles, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,298.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;378.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net operating loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;213.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;209.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;26.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;38.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(20.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(16.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,823.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;831.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(232.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(250.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(544.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1,425.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Depreciation, amortization and other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(102.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(107.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2,305.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(358.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="FD2018Q4YTD" id="Fact-1D055E6C1C5F309ECAB9FBB7C0E632C8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Year&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized in Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(42.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="19" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:24%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Net Gains/(Losses)&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Recognized Directly into Net Income (in millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(32.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
	<us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="FD2018Q4YTD" id="Fact-6ACFDEA1FAEB6A0BC35FFBB7C0F6B32C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance&amp;#160;Sheet&amp;#160;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;65.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;14.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivative Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:33%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Balance Sheet Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fair Value&lt;br clear="none"/&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hedging Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;23.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Derivative Instruments:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Asset derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other current assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liability derivative instruments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued&amp;#160;expenses&amp;#160;and&amp;#160;other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
	<us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="FD2018Q4YTD" id="Fact-37569D9F331FD4E8A5C581DCA6DC3C67">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;302.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accounts receivable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;144.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;116.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;56.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;53.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Assets transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1,008.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Accrued expenses and other current liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;87.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other long-term liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;67.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Liabilities transferred, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;155.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2018Q4YTD" id="Fact-E00E86D8AEC28433D518FBB7C144A929">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic and diluted earnings per share are calculated as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For the Years Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,430.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,539.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,702.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted average number of common shares outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;204.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Stock options and employee stock purchase plan&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Time-vested restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Market stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Performance stock units settled in stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Shares used in calculating diluted earnings per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;205.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;218.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2018Q4YTD" id="Fact-CC57560CFED2869385BEFBB7C0C76F3B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation between the U.S.&amp;#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;35.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;State taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Taxes on foreign earnings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(11.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Credits and net operating loss utilization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(0.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Purchased intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Manufacturing deduction&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017 Tax Act&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;GILTI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Impairment of ZINBRYTA related tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Effective tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;47.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;25.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2018Q4YTD" id="Fact-DAABD8C69D0C838D2303FBB7C144AB44">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes share-based compensation expense included in our consolidated statements of income:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;74.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;84.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;105.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;95.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;121.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Restructuring charges&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Subtotal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;181.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;169.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;204.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Capitalized share-based compensation costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(11.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in total cost and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;170.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;189.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Income tax effect&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(27.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(42.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(54.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;142.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;117.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;135.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2018Q4YTD" id="Fact-7FA9C6E2307092C76E4CFBB7C115F2CF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;705.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,459.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,459.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;969.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;969.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;260.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;615.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;51.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;563.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;25.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,102.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;51.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,050.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;434.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;24.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;409.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quoted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;in&amp;#160;Active&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Observable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(Level 3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,229.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable debt securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,609.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Government securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,919.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Mortgage and other asset backed securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;643.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Marketable equity securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Plan assets for deferred compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;28.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,444.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6,433.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Derivative contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contingent consideration obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;634.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;111.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;523.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2018Q4YTD" id="Fact-C3335C9BB70B325699FBFBB7C0B754A0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Minimum lease payments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;87.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;80.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;75.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;71.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;601.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Less: income from subleases (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(26.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(25.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(23.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(24.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(58.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(182.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net minimum lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;60.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;55.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;52.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;47.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;46.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;156.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;418.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfGoodwillTextBlock contextRef="FD2018Q4YTD" id="Fact-8F371027FC69165E06A3FBB7C144E6F7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, beginning of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,632.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,669.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Elimination of goodwill allocated to our hemophilia business&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(314.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Increase to goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,080.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,267.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(6.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill, end of year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5,706.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4,632.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
	<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="FD2018Q4YTD" id="Fact-DBA768D4EE0EC6E192F7FBB7C172C5ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The components of inventory are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;196.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;162.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Work in process&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;606.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;605.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;133.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;157.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet Classification:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;929.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;902.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Investments and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;22.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total inventory&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;936.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;925.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2018Q4YTD" id="Fact-16C8621D7188C3C11717FBB7C1440CAA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The total gross payments due under our debt arrangements are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2024 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,500.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="FD2018Q4YTD" id="Fact-D226456DD5332E838E0416885A29A6FA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes the effect of our net investment hedge in our consolidated financial statements:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:43%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Location&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;For the Year Ended December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net Gains/(Losses) Recognized in AOCI&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gains (Losses) on Net Investment Hedge&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;(3.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net Gains/(Losses) Reclassified from AOCI into Net Income &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other income (expense)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;"&gt;1.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
	<us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="FD2018Q4YTD" id="Fact-7CAC73F14867524ADE68FBB7C125713E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Notional Amount&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As&amp;#160;of&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Foreign Currency: (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Euro&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,701.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,875.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;British pound sterling&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;215.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;150.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Swiss francs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;131.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;88.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Japanese yen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;98.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Canadian dollar&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;92.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;83.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total foreign currency forward contracts&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,239.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,198.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
	<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="FD2018Q4YTD" id="Fact-9C4D18855308A7EABECBFBB7C1441FE6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Components of other income (expense), net, are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;112.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;78.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(200.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(250.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(260.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gain (loss) on investments, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;119.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(36.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Foreign exchange gains (losses), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(9.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;6.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(9.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(10.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(14.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(18.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(217.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(218.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2018Q4YTD" id="Fact-5CE52B2C2C81FE09AE7CFBB7C0E65C93">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (b) (c) (d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (b) (e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(a) (f) (g) (h) (i)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,523.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,757.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,780.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,825.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,886.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;443.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;490.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;511.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;534.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,980.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;164.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;108.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;147.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;165.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;585.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,131.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,356.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,439.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,526.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;13,452.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,685.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,935.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,978.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,037.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;11,636.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,171.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;915.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,442.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;944.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,474.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,172.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;866.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,444.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;946.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4,430.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.55&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;7.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.73&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;21.58&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;207.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;201.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;199.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;204.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;211.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;207.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;201.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;200.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;205.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions, except per share amounts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;First&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Second&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Third&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Fourth&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(j) (k) (l)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(m) (n) (o) (p)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,380.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,639.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,622.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,712.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;340.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;397.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;406.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;415.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;90.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;41.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;48.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;179.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;360.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,810.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,078.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,077.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,307.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;12,273.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Gross profit (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,426.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,712.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,707.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,797.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10,643.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;747.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;862.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,226.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(166.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,670.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;747.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;862.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,226.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(297.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,539.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income per share:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.47&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.41&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.94&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.46&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;11.92&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Weighted-average shares used in calculating:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Diluted earnings per share attributable to Biogen Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;212.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;213.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"&gt;(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the first, second, third and fourth quarters of 2018 includes pre-tax charges related to (losses) gains recorded in relation to changes in the fair value of our strategic investments of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$(6.4) million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$5.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$141.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$(12.2) million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the first, second and third quarters of 2018 include pre-tax charges to acquired IPR&amp;amp;D of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$27.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, for upfront payments to Karyopharm, Pfizer and AliveGen, respectively, upon closing of the asset purchase transactions for BIIB100, BIIB104 and BIIB110, respectively, as the underlying assets had not yet reached technological feasibility.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2018 includes pre-tax charges to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$486.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; upon the closing of the 2018 Ionis Agreement. Included in this amount was a charge of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$162.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reflecting the premium paid above fair value for the purchase of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;11.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of Ionis' common stock upon the closing of the 2018 Ionis Agreement.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc. for the second quarter of 2018 includes a pre-tax charge to noncontrolling interest of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a payment to Neurimmune in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(e)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the third quarter of 2018 includes the impact of impairment charges totaling &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$189.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to certain IPR&amp;amp;D assets associated with our vixotrigine program and an adjustment to the value of our contingent consideration obligations related to our vixotrigine program for the treatment of TGN to reflect the lower cumulative probabilities of success, which resulted in a gain of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$89.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the third quarter of 2018. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(f)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In late December 2018 we received feedback from the FDA regarding the design of the Phase 3 vixotrigine program for the treatment of TGN. Following this feedback, we are now planning to initiate the Phase 3 vixotrigine program for the treatment of TGN and, as a result, we adjusted the fair value of our contingent consideration obligations related to our vixotrigine program for the treatment of TGN to reflect the increased probabilities of success and recognized a loss of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$80.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the fourth quarter of 2018.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(g)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 and the first quarter of 2017 includes &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$176.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$328.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of impairment charges related to our intangible asset associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(h)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 includes a net increase to income tax expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$135.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reflecting the impact of electing to record deferred taxes on GILTI.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 includes an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$35.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Ionis, as we exercised our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB067.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(j)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$300.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment made to BMS upon entering into our agreement to exclusively license BIIB092.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(k)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to acquired IPR&amp;amp;D of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$120.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment to Remedy upon closing of the asset purchase transaction for BIIB093.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(l)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$60.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a developmental milestone that became payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 study of BIIB092 for PSP.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(m)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to noncontrolling interest of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for a payment made to Neurimmune in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(n)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes pre-tax charges to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$28.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment and a continuation payment, respectively, to Alkermes.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(o)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to research and development expense of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$25.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for an upfront payment to Ionis upon entering into a new collaboration agreement to identify new ASO drug candidates for the treatment of SMA.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:30px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:6px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(p)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$1,173.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; related to the provisions of the 2017 Tax Act, including a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book;font-size:10pt;"&gt;$989.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; expense under the Transition Toll Tax.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock contextRef="FD2018Q4YTD" id="Fact-E73C8880E1B65726FB4BFBB7C163631B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables contain certain financial information by geographic area:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;December 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,800.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,370.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;281.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;434.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,886.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,903.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;76.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,980.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;457.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;96.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;585.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,152.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,442.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,601.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,017.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,844.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;332.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,475.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;83.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;42.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;360.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,226.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,948.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,182.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;217.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;313.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;224.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,272.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,221.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,501.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2018Q4YTD" id="Fact-089FD76B5AAB20B8C9D0FBB7C153FE9A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table summarizes our stock option activity:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;42,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(15,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Outstanding at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;27,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;53.82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="FD2018Q4YTD" id="Fact-27571CC92C9270A34010FBB7C0F6C4EC">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;For&amp;#160;the&amp;#160;Years&amp;#160;Ended&amp;#160;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at January&amp;#160;1,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;66.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions based on tax positions related to the current period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;58.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;36.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Reductions for tax positions of prior periods&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(13.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(21.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(13.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Statute expirations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;(2.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Settlement refund (payment)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;4.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;44.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(64.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Balance at December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;114.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;66.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;32.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2018Q4YTD" id="Fact-0DECA64205FD58CD0BC4FBB7C13404D2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:81%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;270.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;290.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;250.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;250.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;230.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SegmentReportingDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-274673CEC92D0D3F2C7BFBB7C1639064">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We operate as &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Geographic Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following tables contain certain financial information by geographic area:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="20" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;December 31, 2018 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;6,800.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,370.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;281.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;434.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;10,886.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,903.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;0.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;76.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,980.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;457.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;32.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;96.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;585.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,152.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;2,442.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3,601.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2017 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,017.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,844.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;160.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;332.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10,354.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,475.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;0.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;83.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,559.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;67.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;42.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;360.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,226.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,948.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3,182.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2016 (In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;U.S.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Europe&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Asia&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7,050.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,237.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;217.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;313.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;9,817.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,249.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;63.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,314.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other revenues from external customers&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;224.7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;71.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;316.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,272.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,221.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2,501.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,748.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1,215.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$545.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$646.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$707.1 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$643.6 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read Note 11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
	<us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="FD2018Q4YTD" id="Fact-41233506648EAC9FF7FFFBB7C11580B8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Advertising costs are expensed as incurred. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, advertising costs totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$90.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$106.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2018Q4YTD" id="Fact-D7DC353675DF26332B6DFBB7C1153929">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Business Overview&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&amp;#8217;s disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also manufacture and commercialize biosimilars of advanced biologics.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), Parkinson's disease, ALS, stroke, epilepsy, cognitive impairment associated with schizophrenia (CIAS) and pain.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilar products through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these audited consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on the spin-off of our hemophilia business, please read Note 3,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Hemophilia Spin-Off&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;,&amp;#160;to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB subsequently issued the following amendments to ASU 2014-09 that have the same effective date and transition date: ASU No. 2016-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; ASU No. 2016-10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; ASU No. 2016-12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;; and ASU No. 2016-20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not change our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon adoption. However, the adoption of the new revenue standards will result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under ASU 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of the new revenue standards, other corporate revenue was higher by&amp;#160;&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.8 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;and cost of sales, excluding amortization and impairment of acquired intangible assets was higher by &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$42.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; for the year ended December 31, 2018, compared to what would have been reported under the previous revenue guidance, primarily due to the earlier recognition of revenue associated with our contract manufacturing agreements. Under the previous revenue guidance, these amounts would have been recognized in future periods upon shipment. The adoption of the new revenue standards did not have a material impact on any other balances within our consolidated financial statements as of and for the&amp;#160;year ended&amp;#160;December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Product Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In the United States (U.S.), we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Reserves for Discounts and Allowances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&amp;#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Other governmental rebates, non-US pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenues from Anti-CD20 Therapeutic Programs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our collaboration with Genentech is within the scope of Accounting Standards Codification (ASC) 808, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Agreements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Revenues from anti-CD20 therapeutic programs consist of:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(i)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;(ii)&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech, the Roche Group and us. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates that are based on information received from Genentech. These estimates are subject to change and actual results may differ. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our relationship with Genentech, please read Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our development and commercialization arrangements with AbbVie Inc. (AbbVie), Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our collaboration arrangements with AbbVie, Genentech and Samsung Bioepis, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Royalty Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Other Corporate Revenues&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have certain financial assets and liabilities recorded at fair value which have been classified as Level&amp;#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;1&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;2&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&amp;#160;and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Level&amp;#160;3&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;&amp;#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our financial assets have been classified as Level&amp;#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Other Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;30 to 90 days&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&amp;#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We provide reserves against trade receivables for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The adoption of the new revenue standards did not change our historical accounting methods for our accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Marketable Securities and Other Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Marketable Equity Securities and Venture Capital Funds&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Non-Marketable Equity Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Evaluating Investments for Other-than-Temporary Impairments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&amp;#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Equity Method of Accounting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&amp;#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&amp;#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Capitalization of Inventory Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&amp;#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Obsolescence and Unmarketable Inventory&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;three to five years&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Asset Category&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Useful Lives&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Land&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Not depreciated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Buildings&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;15 to 40&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Leasehold Improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Lesser of the useful life or the term of the respective lease&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Furniture and Fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 7&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Machinery and Equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;5 to 20&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;Computer&amp;#160;Software&amp;#160;and&amp;#160;Hardware&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;3 to 5&amp;#160;years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&amp;#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also includes our U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Acquired In-process Research and Development (IPR&amp;amp;D)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&amp;#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&amp;#160;25, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Segment Information,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingent Consideration&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions of a business completed after January&amp;#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Derivative Instruments and Hedging Activities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Cash Flow and Fair Value Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Net Investment Derivative Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our derivative instruments and hedging activities, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Translation of Foreign Currencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&amp;#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Royalty Cost of Sales&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&amp;#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Accounting for Share-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&amp;#8217; vesting periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense, net of forfeitures, for RSUs is recognized straight-line over the applicable service period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The fair values of PSUs that settle in stock are based upon the stock price on the date of grant and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The purchase price of common stock under our ESPP is equal to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of the lesser of (i)&amp;#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&amp;#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes valuation model. The fair value of the look-back provision plus the &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; discount is recognized as compensation expense over the 90-day purchase period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&amp;#160;19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Selling, General and Administrative Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Advertising costs are expensed as incurred. For the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, advertising costs totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$90.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$75.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$106.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. In December 2018 we elected to recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfers of assets other than inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset is transferred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We account for uncertain tax positions using a &amp;#8220;more-likely-than-not&amp;#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&amp;#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&amp;#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Earnings per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;New Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Revenue recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In May 2014 the FASB issued ASU 2014-09, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. For additional information on the adoption of the new revenue standards, please read the section titled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue Recognition &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;above, and Note 5, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenues&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2016 the FASB issued ASU No. 2016-01, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this standard on January 1, 2018, using the modified retrospective method, and recognized a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; net increase to retained earnings as well as a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; increase to accumulated other comprehensive income reflecting the cumulative impact for the accounting changes made upon adoption. The adoption of this standard resulted in a change in the income statement classification with respect to where we recognize changes in fair value related to certain equity security investments. Prior to the adoption of ASU 2016-01, we recognized changes in fair value in accumulated other comprehensive income (loss), net. Upon the adoption of ASU 2016-01, we recognize changes in fair value in other income (expense), net. During the year ended December 31, 2018, we recognized net gains resulting from changes in fair value related to our equity security investments in other income (expense), net totaling approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$128.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; under this standard that would not have been recognized in other income (expense), net under the previous standard. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Leasing&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2016 the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This standard became effective for us on January 1, 2019. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The FASB has subsequently issued the following amendments to ASU 2016-02, which have the same effective date and transition date of January 1, 2019, and which we collectively refer to as the new leasing standards: &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2018-01,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt; Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that exist or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2018-10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which amends certain narrow aspects of the guidance issued in ASU 2016-02.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2018-11, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;ASU No. 2018-20, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Narrow-Scope Improvements for Lessors&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, which contains certain narrow scope improvements to the guidance issued in ASU 2016-02.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted the new leasing standards on January 1, 2019, using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019. We have reviewed our existing lease contracts and the impact of the new leasing standards on our consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards, we expect to recognize a lease liability and related right-of-use asset on our consolidated balance sheet of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. The impact of adoption of the new leasing standards will have an immaterial impact to our consolidated statements of income. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Credit Losses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In June 2016 the FASB issued ASU No. 2016-13, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard will be effective for us on January 1, 2020. We are currently evaluating the potential impact that this standard may have on our consolidated financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2016 the FASB issued ASU No. 2016-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, offset by a corresponding net increase to retained earnings of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$0.4 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; with a corresponding reduction to our retained earnings as these differences are related to inter-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our income taxes, please read Note 17, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Net Periodic Pension Cost&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-07, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Costs and Net Periodic Postretirement Benefit Cost.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; This standard requires that an employer disaggregate the service cost component from the other components of net benefit cost. This standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the statements of income and allows only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on our consolidated statements of income. We adopted this standard on January 1, 2018, using the retrospective method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As a result of the adoption of this standard, the other components of net periodic benefit cost, which we previously presented as a component of operating income, are now classified in other income (expense), net in our consolidated statements of income. For the years ended December 31, 2017 and 2016, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively, were reclassified from operating income to other income (expense), net in our consolidated statements of income to conform to our current year presentation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Debt Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In March 2017 the FASB issued ASU No. 2017-08, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. Based upon our marketable debt securities as of December 31, 2018, the adoption of this standard did not result in a significant adjustment to our marketable debt securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Derivative Instruments and Hedging Activities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2017 the FASB issued ASU No. 2017-12, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard provides guidance to better align an entity's risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. This standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We adopted this standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this standard resulted in additional disclosures and a change in the income statement classification with respect to where we recognize cash flow hedge ineffective or excluded hedge transaction gains and losses. Prior to the adoption of ASU 2017-12 on January 1, 2018, to the extent ineffective or excluded, cash flow hedge transaction gains and losses were reported in other income (expense), net. Effective January 1, 2018, we recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of any cash flow hedge ineffectiveness or excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Additionally, in October 2018 the FASB issued ASU No. 2018-16, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivatives and Hedging&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;For additional information on our derivative instruments and hedging activities, please read Note 10, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Derivative Instruments&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 the FASB issued ASU No. 2018-13, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. This standard modifies certain disclosure requirements on fair value measurements. This standard will be effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2018 the FASB issued ASU No. 2018-18, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; This standard makes targeted improvements for collaborative arrangements as follows: &lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers,&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Adds unit-of-account guidance to ASC 808, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:54px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:30px;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Requires that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting that transaction together with revenue recognized under ASC 606 is precluded if the collaborative arrangement participant is not a customer. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;This standard will be effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. We are currently evaluating the potential impact that this standard may have on our consolidated financial position and results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-B4FA992499F1B80FBC42FBB7C0B77D6F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;8.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;&amp;#160;shares of Preferred Stock authorized, of which &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.75 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are authorized as Series A, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are authorized as Series X junior participating and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5.25 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The following table describes the number of shares authorized, issued and outstanding of our common stock as of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and 2016:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="27" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:6%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;(In millions)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;221.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;"&gt;197.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;235.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;211.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1,000.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;238.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;215.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Share Repurchases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In August 2018 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.5 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2018 Share Repurchase Program). Our 2018 Share Repurchase program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;4.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock at a cost of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.4 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In July 2016 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$5.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;10.5 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;3.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$3.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$1.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the years ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In February 2011 our Board of Directors authorized a program to repurchase up to &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;20.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of our common stock (2011 Share Repurchase Program), which was completed as of March 31, 2017. Share repurchases under our 2011 Share Repurchase Program were principally used to offset common stock issuances under our share-based compensation programs. Under our 2011 Share Repurchase Program, we repurchased approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;1.2 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; shares of common stock at a cost of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$365.4 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the year ended &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Amounts paid to repurchase shares in excess of their par value are allocated between additional paid-in capital and retained earnings, with payments in excess of our additional paid-in-capital balance recorded as a reduction to retained earnings.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2018Q4YTD" id="Fact-CF714928C1273ABDBEEDFBB7C098FF15">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Skyhawk Therapeutics, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk&amp;#8217;s SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In connection with this agreement, we made an upfront payment of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$74.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; to Skyhawk. We may also pay Skyhawk up to a total of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$2.0 billion&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in additional milestone payments as well as potential royalties on net commercial sales. We expect to record research and development expense of approximately &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$35.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; in the first quarter of 2019 related to this collaboration.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2018Q4YTD" id="Fact-F2380174DA7C7036A9FBFBB7C0A86B5B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="FD2018Q4YTD" id="Fact-8B3562A2C72AD93B57B1FBB7C0F6E046">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;font-size:12pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;"&gt;Investments in Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Consolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"&gt;Neurimmune SubOne AG&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In November 2007 we entered into a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD, including aducanumab, our anti-amyloid beta antibody candidate for the treatment of AD. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&amp;#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. Under this agreement, we are also required to pay royalties on net sales of any resulting commercial products and make payments upon the achievement of certain milestone events. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;In October 2017 we amended the terms of our collaboration and license agreement with Neurimmune (as amended, the Neurimmune Agreement). Under the Neurimmune Agreement, we made a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune in exchange for a &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.&amp;#160;In May 2018 we made an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;5%&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, will now range from the high single digits to sub-teens.&amp;#160;As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interest in the fourth quarter of 2017 and the second quarter of 2018, as applicable. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, amounts reimbursed were immaterial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;Under the terms of our Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read Note 19, &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"&gt;Collaborative and Other Relationships&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, to these consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"&gt;Unconsolidated Variable Interest Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$28.7 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;$48.3 million&lt;/font&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-051310FA795F315318C8FBB7C0898552" xlink:label="Fact-051310FA795F315318C8FBB7C0898552_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-05BFB29E6FD3DB68EC18FBB7C0C7D558" xlink:label="Fact-05BFB29E6FD3DB68EC18FBB7C0C7D558_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-0BD60284F9324DDB51A7FBB7C1056BFB" xlink:label="Fact-0BD60284F9324DDB51A7FBB7C1056BFB_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-1204D9D6F3D991DFA014FBB7C0A8CF3E" xlink:label="Fact-1204D9D6F3D991DFA014FBB7C0A8CF3E_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-19A9CE3DEA75728A1A29FBB7C105AA39" xlink:label="Fact-19A9CE3DEA75728A1A29FBB7C105AA39_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-1E0C5101C3C91BD8BA87FBB7C1634532" xlink:label="Fact-1E0C5101C3C91BD8BA87FBB7C1634532_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-2103DC1E374417F9113FFBB7C163274F" xlink:label="Fact-2103DC1E374417F9113FFBB7C163274F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-3011AF50099A05D73CBFFBB7C0986916" xlink:label="Fact-3011AF50099A05D73CBFFBB7C0986916_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-3B68AEF8EDE0C25EF26BFBB7C0C7C914" xlink:label="Fact-3B68AEF8EDE0C25EF26BFBB7C0C7C914_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-40DABB1511BD3C02C3B7FBB7C0A8BD32" xlink:label="Fact-40DABB1511BD3C02C3B7FBB7C0A8BD32_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-5DEA0A52AC0E74840687FBB7C0983542" xlink:label="Fact-5DEA0A52AC0E74840687FBB7C0983542_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-63FA38D8F484DC30B585FBB7C0D73BD6" xlink:label="Fact-63FA38D8F484DC30B585FBB7C0D73BD6_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-6E4D22D3F5313590F94FFBB7C10520ED" xlink:label="Fact-6E4D22D3F5313590F94FFBB7C10520ED_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-71C8A2D372E4122CF634FBB7C089D19A" xlink:label="Fact-71C8A2D372E4122CF634FBB7C089D19A_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8247015340EB4CE7B582FBB7C182613F" xlink:label="Fact-8247015340EB4CE7B582FBB7C182613F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-833650F52D11774FBB15FBB7C134A041" xlink:label="Fact-833650F52D11774FBB15FBB7C134A041_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8D43E09D68F48CDBC68BFBB7C0892C9D" xlink:label="Fact-8D43E09D68F48CDBC68BFBB7C0892C9D_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-93A20EE668464F0801F8FBB7C0D7EF82" xlink:label="Fact-93A20EE668464F0801F8FBB7C0D7EF82_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-984625AE7C7FB99A4CF8FBB7C1059F3B" xlink:label="Fact-984625AE7C7FB99A4CF8FBB7C1059F3B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-9F11857C25DC412E1B0482341FD9B703" xlink:label="Fact-9F11857C25DC412E1B0482341FD9B703_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-9F32D086C0DBB353F404FBB7C0D70991" xlink:label="Fact-9F32D086C0DBB353F404FBB7C0D70991_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-B96F77A02B096DA3B896FBB7C0C717C4" xlink:label="Fact-B96F77A02B096DA3B896FBB7C0C717C4_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C1E948B2D1E2E57480C2FBB7C069C85F" xlink:label="Fact-C1E948B2D1E2E57480C2FBB7C069C85F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-DA9C3E6BB315A7751A38FBB7C0F6468B" xlink:label="Fact-DA9C3E6BB315A7751A38FBB7C0F6468B_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-ED3B0C68121C77143E7EFBB7C0F6D4EA" xlink:label="Fact-ED3B0C68121C77143E7EFBB7C0F6D4EA_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-051310FA795F315318C8FBB7C0898552_lbl" xlink:to="Footnote-7777C38249959CCE967CFBB7C1A1D97C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-05BFB29E6FD3DB68EC18FBB7C0C7D558_lbl" xlink:to="Footnote-067972D9AC0C0970F401FBB7C1A121F9_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-0BD60284F9324DDB51A7FBB7C1056BFB_lbl" xlink:to="Footnote-331B9F248809CA418A33FBB7C1A1E66E_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-1204D9D6F3D991DFA014FBB7C0A8CF3E_lbl" xlink:to="Footnote-331B9F248809CA418A33FBB7C1A1E66E_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-19A9CE3DEA75728A1A29FBB7C105AA39_lbl" xlink:to="Footnote-067972D9AC0C0970F401FBB7C1A121F9_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-1E0C5101C3C91BD8BA87FBB7C1634532_lbl" xlink:to="Footnote-4437EE3CC3153D72D5B0FBB7C1A14714_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-2103DC1E374417F9113FFBB7C163274F_lbl" xlink:to="Footnote-4437EE3CC3153D72D5B0FBB7C1A14714_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-3011AF50099A05D73CBFFBB7C0986916_lbl" xlink:to="Footnote-7777C38249959CCE967CFBB7C1A1D97C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-3B68AEF8EDE0C25EF26BFBB7C0C7C914_lbl" xlink:to="Footnote-067972D9AC0C0970F401FBB7C1A121F9_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-40DABB1511BD3C02C3B7FBB7C0A8BD32_lbl" xlink:to="Footnote-7777C38249959CCE967CFBB7C1A1D97C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-5DEA0A52AC0E74840687FBB7C0983542_lbl" xlink:to="Footnote-7777C38249959CCE967CFBB7C1A1D97C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-63FA38D8F484DC30B585FBB7C0D73BD6_lbl" xlink:to="Footnote-7777C38249959CCE967CFBB7C1A1D97C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6E4D22D3F5313590F94FFBB7C10520ED_lbl" xlink:to="Footnote-E5EFC1EEBF14E0FA67A2FBB7C1A1FB09_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-71C8A2D372E4122CF634FBB7C089D19A_lbl" xlink:to="Footnote-7777C38249959CCE967CFBB7C1A1D97C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8247015340EB4CE7B582FBB7C182613F_lbl" xlink:to="Footnote-4437EE3CC3153D72D5B0FBB7C1A14714_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-833650F52D11774FBB15FBB7C134A041_lbl" xlink:to="Footnote-067972D9AC0C0970F401FBB7C1A121F9_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8D43E09D68F48CDBC68BFBB7C0892C9D_lbl" xlink:to="Footnote-7777C38249959CCE967CFBB7C1A1D97C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-93A20EE668464F0801F8FBB7C0D7EF82_lbl" xlink:to="Footnote-067972D9AC0C0970F401FBB7C1A121F9_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-984625AE7C7FB99A4CF8FBB7C1059F3B_lbl" xlink:to="Footnote-067972D9AC0C0970F401FBB7C1A121F9_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-9F11857C25DC412E1B0482341FD9B703_lbl" xlink:to="Footnote-E5EFC1EEBF14E0FA67A2FBB7C1A1FB09_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-9F32D086C0DBB353F404FBB7C0D70991_lbl" xlink:to="Footnote-7777C38249959CCE967CFBB7C1A1D97C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-B96F77A02B096DA3B896FBB7C0C717C4_lbl" xlink:to="Footnote-067972D9AC0C0970F401FBB7C1A121F9_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C1E948B2D1E2E57480C2FBB7C069C85F_lbl" xlink:to="Footnote-7777C38249959CCE967CFBB7C1A1D97C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-DA9C3E6BB315A7751A38FBB7C0F6468B_lbl" xlink:to="Footnote-7777C38249959CCE967CFBB7C1A1D97C_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-ED3B0C68121C77143E7EFBB7C0F6D4EA_lbl" xlink:to="Footnote-E5EFC1EEBF14E0FA67A2FBB7C1A1FB09_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-067972D9AC0C0970F401FBB7C1A121F9_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1)</link:footnote>
		<link:footnote xlink:label="Footnote-331B9F248809CA418A33FBB7C1A1E66E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">CSPUs issued in 2018 based upon the attainment of performance criteria set for 2017 in relation to CSPUs granted in 2017.</link:footnote>
		<link:footnote xlink:label="Footnote-4437EE3CC3153D72D5B0FBB7C1A14714_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">RSUs granted in 2018 primarily represent RSUs granted in conjunction with our annual awards made in February 2018 and awards made in conjunction with the hiring of new employees. RSUs granted in 2018 also include approximately 9,000 RSUs granted to our Board of Directors.</link:footnote>
		<link:footnote xlink:label="Footnote-7777C38249959CCE967CFBB7C1A1D97C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.</link:footnote>
		<link:footnote xlink:label="Footnote-E5EFC1EEBF14E0FA67A2FBB7C1A1FB09_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">MSUs granted during 2018 include awards granted in conjunction with our annual awards made in February 2018 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2018 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2017, 2016 and 2015.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>biib-20181231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20181231" xmlns:biib="http://www.biogenidec.com/20181231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2018-01-31" schemaLocation="https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>2117100 - Disclosure - Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2417402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails1" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1">
        <link:definition>2417403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2317301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>2102100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDetailsTextual" roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual">
        <link:definition>2402401 - Disclosure - Acquisitions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships">
        <link:definition>2122100 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsAbbvieDetails2" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2">
        <link:definition>2422404 - Disclosure - Collaborative and Other Relationships - AbbVie (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1">
        <link:definition>2422403 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Eisai (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsDetailsTextual" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual">
        <link:definition>2422405 - Disclosure - Collaborative and Other Relationships (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsGenentechDetails" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails">
        <link:definition>2422402 - Disclosure - Collaborative and Other Relationships - Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAndOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables">
        <link:definition>2322301 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies">
        <link:definition>2125100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>2425402 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetailsTextual" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual">
        <link:definition>2425403 - Disclosure - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2325301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets">
        <link:definition>1003000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeCalc2" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncomeCalc2">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfEquity" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity">
        <link:definition>1005000 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfIncome" roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome">
        <link:definition>1001000 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2113100 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsCashFlowHedgesDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails">
        <link:definition>2413402 - Disclosure - Derivative Instruments Cash Flow Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1">
        <link:definition>2413403 - Disclosure - Derivative Instruments Derivative Instruments Net Investment Hedges (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails2">
        <link:definition>2413404 - Disclosure - Derivative Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual">
        <link:definition>2413405 - Disclosure - Derivative Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2313301 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.biogenidec.com/role/EarningsPerShare">
        <link:definition>2118100 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails">
        <link:definition>2418402 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.biogenidec.com/role/EarningsPerShareTables">
        <link:definition>2318301 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans">
        <link:definition>2127100 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails1" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1">
        <link:definition>2427402 - Disclosure - Employee Benefit Plans (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansEmployeeBenefitPlansDetails" roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails">
        <link:definition>2427401 - Disclosure - Employee Benefit Plans Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2116100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetails" roleURI="http://www.biogenidec.com/role/EquityDetails">
        <link:definition>2416402 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityDetailsTextual" roleURI="http://www.biogenidec.com/role/EquityDetailsTextual">
        <link:definition>2416403 - Disclosure - Equity (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>2316301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2111100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2411402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2411403 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2411404 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2411405 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2311301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2112100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2412402 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2412403 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2412404 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2412405 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1">
        <link:definition>2412406 - Disclosure - Financial Instruments (Details Textual 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2">
        <link:definition>2412407 - Disclosure - Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2312301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Guarantees" roleURI="http://www.biogenidec.com/role/Guarantees">
        <link:definition>2126100 - Disclosure - Guarantees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOff" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff">
        <link:definition>2106100 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOffDetails" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails">
        <link:definition>2406402 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual">
        <link:definition>2406403 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HemophiliaSpinOffHemophiliaSpinOffTables" roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables">
        <link:definition>2306301 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2120100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2420402 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails1" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1">
        <link:definition>2420403 - Disclosure - Income Taxes (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails2" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2">
        <link:definition>2420404 - Disclosure - Income Taxes (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails3" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3">
        <link:definition>2420405 - Disclosure - Income Taxes (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2420406 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2320301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>2115100 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2415402 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails1" roleURI="http://www.biogenidec.com/role/IndebtednessDetails1">
        <link:definition>2415403 - Disclosure - Indebtedness (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetailsTextual" roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual">
        <link:definition>2415404 - Disclosure - Indebtedness (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessTables" roleURI="http://www.biogenidec.com/role/IndebtednessTables">
        <link:definition>2315301 - Disclosure - Indebtedness (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill">
        <link:definition>2110100 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails">
        <link:definition>2410402 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1">
        <link:definition>2410403 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAndGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables">
        <link:definition>2310301 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2109100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryDetails">
        <link:definition>2409402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetailsTextual" roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual">
        <link:definition>2409403 - Disclosure - Inventory (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2309301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities">
        <link:definition>2123100 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails">
        <link:definition>2423401 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2124100 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationLitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails">
        <link:definition>2424401 - Disclosure - Litigation Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2121100 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2421402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual">
        <link:definition>2421403 - Disclosure - Other Consolidated Financial Statement Detail (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2321301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment">
        <link:definition>2114100 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2414402 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetailsTextual" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual">
        <link:definition>2414403 - Disclosure - Property, Plant and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentTables" roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables">
        <link:definition>2314301 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2129100 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetails" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails">
        <link:definition>2429402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedDetailsTextual" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual">
        <link:definition>2429403 - Disclosure - Quarterly Financial Data (Unaudited) (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2329301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuring" roleURI="http://www.biogenidec.com/role/RestructuringRestructuring">
        <link:definition>2107100 - Disclosure - Restructuring Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringRestructuringDetailsTextual" roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual">
        <link:definition>2407401 - Disclosure - Restructuring Restructuring (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>2108100 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesByProductDetails" roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails">
        <link:definition>2408402 - Disclosure - Revenues by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesDetailsTextual" roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual">
        <link:definition>2408407 - Disclosure - Revenues (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>2408406 - Disclosure - Revenues Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesForDiscountsAndAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1">
        <link:definition>2408403 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesForDiscountsAndAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2">
        <link:definition>2408404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails">
        <link:definition>2408405 - Disclosure - Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2308301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.biogenidec.com/role/SegmentInformation">
        <link:definition>2128100 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetails" roleURI="http://www.biogenidec.com/role/SegmentInformationDetails">
        <link:definition>2428402 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationDetailsTextual" roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual">
        <link:definition>2428403 - Disclosure - Segment Information (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.biogenidec.com/role/SegmentInformationTables">
        <link:definition>2328301 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.biogenidec.com/role/ShareBasedPayments">
        <link:definition>2119100 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2419402 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2419403 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails10" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10">
        <link:definition>2419412 - Disclosure - Share-Based Payments (Details 10)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails11" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11">
        <link:definition>2419413 - Disclosure - Share-Based Payments (Details 11)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails2" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2">
        <link:definition>2419404 - Disclosure - Share-Based Payments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails3" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3">
        <link:definition>2419405 - Disclosure - Share-Based Payments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails4" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4">
        <link:definition>2419406 - Disclosure - Share-Based Payments (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails5" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5">
        <link:definition>2419407 - Disclosure - Share-Based Payments (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails6" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6">
        <link:definition>2419408 - Disclosure - Share-Based Payments (Details 6)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails7" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7">
        <link:definition>2419409 - Disclosure - Share-Based Payments (Details 7)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails8" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8">
        <link:definition>2419410 - Disclosure - Share-Based Payments (Details 8)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails9" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9">
        <link:definition>2419411 - Disclosure - Share-Based Payments (Details 9)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetailsTextual" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual">
        <link:definition>2419414 - Disclosure - Share-Based Payments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2319301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsSubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents">
        <link:definition>2130100 - Disclosure - Subsequent Events Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsSubsequentEventsDetails" roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails">
        <link:definition>2430401 - Disclosure - Subsequent Events Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401403 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="biib_A2011ShareRepurchaseProgramMember" name="A2011ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2015ESPPMember" name="A2015ESPPMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2015RestructuringChargesMember" name="A2015RestructuringChargesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2016RestructuringChargesMember" name="A2016RestructuringChargesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2016ShareRepurchaseProgramMember" name="A2016ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2016ShareRepurchaseProgramYearToDateMember" name="A2016ShareRepurchaseProgramYearToDateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2017CorporateStrategyMember" name="A2017CorporateStrategyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2017OmnibusEquityPlanMember" name="A2017OmnibusEquityPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_A2018ShareRepurchaseProgramMember" name="A2018ShareRepurchaseProgramMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AGTCMember" name="AGTCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ALPROLIXMember" name="ALPROLIXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax" name="AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_AVONEXMember" name="AVONEXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AbbVieMember" name="AbbVieMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" name="AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_AcordaMember" name="AcordaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdditionalMilestonePayment" name="AdditionalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Additionalreductioninroyaltyratepayableoncommercialsales" name="Additionalreductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AducanumabMember" name="AducanumabMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AliveGenMember" name="AliveGenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_AlkermesMember" name="AlkermesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AmortizationandImpairmentofAcquiredIntangibleAssets" name="AmortizationandImpairmentofAcquiredIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" name="AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_AverageMaturityOfMarketableSecurities" name="AverageMaturityOfMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_AverageStockPriceOnGrantDateInDollarsMaximum" name="AverageStockPriceOnGrantDateInDollarsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_AverageStockPriceOnGrantDateInDollarsMinimum" name="AverageStockPriceOnGrantDateInDollarsMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BENEPALIMember" name="BENEPALIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BasicAndDilutedEarningsPerShareAbstract" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BiogenIdecInternationalNeuroscienceMember" name="BiogenIdecInternationalNeuroscienceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Biogenshareofcopromotionprofitsorlosses" name="Biogenshareofcopromotionprofitsorlosses" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BiosimilarsMember" name="BiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BioverativMember" name="BioverativMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BristolMyersSquibbMember" name="BristolMyersSquibbMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_BusinessOverviewPolicyTextBlock" name="BusinessOverviewPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_BusinessTextualAbstract" name="BusinessTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_C4TherapeuticsMember" name="C4TherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CambridgeMAMember" name="CambridgeMAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesAbstract" name="CashSettledPerformanceSharesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashSettledPerformanceSharesMember" name="CashSettledPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsoperatingexpensesMember" name="CashflowsoperatingexpensesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CashflowsrevenueMember" name="CashflowsrevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram" name="ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" name="CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CoPromotionProfitSharingFormulaAbstract" name="CoPromotionProfitSharingFormulaAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CoPromotionProfitSharingFormulaTableTextBlock" name="CoPromotionProfitSharingFormulaTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CollaborationProfitSharing" name="CollaborationProfitSharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Collaborationexpensesaccrual" name="Collaborationexpensesaccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Collaborationprofitlosssharing" name="Collaborationprofitlosssharing" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CollaborationsTextualAbstract" name="CollaborationsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CommercialMilestonesMember" name="CommercialMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CommitmentsAndContingenciesTextualAbstract" name="CommitmentsAndContingenciesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CompensationExpenseOverPurchasePeriod" name="CompensationExpenseOverPurchasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ComputerSoftwareAndHardware" name="ComputerSoftwareAndHardware" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ContractualAdjustmentsMember" name="ContractualAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ConvergencePharmaceuticalsMember" name="ConvergencePharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Copromotionprofitsandlosses" name="Copromotionprofitsandlosses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesCurrentMember" name="CorporateDebtSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CorporateDebtSecuritiesNonCurrentMember" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CumulativeSalesLevel" name="CumulativeSalesLevel" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelAxis" name="CumulativeSalesLevelAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_CumulativeSalesLevelDomain" name="CumulativeSalesLevelDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" name="DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment" name="DeferredTaxLiabilitiesDecreaseDuetoOverpayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" name="DeferredTaxLiabilitiesDepreciationAmortizationOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" name="DeferredTaxLiabilitiesTaxCreditCarryforwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_DeferredtaxliabilitiesGILTItaxcalculation" name="DeferredtaxliabilitiesGILTItaxcalculation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" name="Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DeferredtaxliabilityMember" name="DeferredtaxliabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DenominatorAbstract" name="DenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DevelopmentMilestonesMember" name="DevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DevelopmentalMilestonePayment" name="DevelopmentalMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_DirectorsPlanMember" name="DirectorsPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DiscountRateRecognizedInCompensationExpense" name="DiscountRateRecognizedInCompensationExpense" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorOneMember" name="DistributorOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DistributorTwoMember" name="DistributorTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_DueFromUnconsolidatedJointBusiness" name="DueFromUnconsolidatedJointBusiness" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ELOCTATEMember" name="ELOCTATEMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EachAdditionalOneBillionUpToTwentyBillionMember" name="EachAdditionalOneBillionUpToTwentyBillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EarningsPerShareTextualAbstract" name="EarningsPerShareTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" name="EffectiveIncomeTaxRateReconciliationManufacturingDeduction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EffectiveTaxRateReconciliationGILTItax" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EighteenbillionMember" name="EighteenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EisaiMember" name="EisaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeBenefitPlansTextualAbstract" name="EmployeeBenefitPlansTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_EquityMethodInvestmentsExpectedProfitShare" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_EstimatedUsefulLivesOfLeaseholdImprovements" name="EstimatedUsefulLivesOfLeaseholdImprovements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" name="ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" name="ExpectedLicenseFeeAndRegulatoryMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ExpenseIncurredByCollaboration" name="ExpenseIncurredByCollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Expenseincurredbythecollaboration" name="Expenseincurredbythecollaboration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Expensereflectedwithinstatementsofincome" name="Expensereflectedwithinstatementsofincome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FAMPYRAMember" name="FAMPYRAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FLIXABIMember" name="FLIXABIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FUMADERMMember" name="FUMADERMMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationAxis" name="FacilityLocationAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FacilityLocationDomain" name="FacilityLocationDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_FairValueMeasurementInputs" name="FairValueMeasurementInputs" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FifteenbillionMemberMember" name="FifteenbillionMemberMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FinancialInstrumentsTextualAbstract" name="FinancialInstrumentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ForeignSalesRequiredToTriggerMilestone" name="ForeignSalesRequiredToTriggerMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningsintheformofcashandcashequivalentsMember" name="ForeignearningsintheformofcashandcashequivalentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningstypeAxis" name="ForeignearningstypeAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ForeignearningstypeDomain" name="ForeignearningstypeDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FumapharmAgMember" name="FumapharmAgMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesAxis" name="FutureContingentMilestoneTypesAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_FutureContingentMilestoneTypesDomain" name="FutureContingentMilestoneTypesDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" name="FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" name="FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureContingentPaymentThreshold" name="FutureContingentPaymentThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" name="FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Futurepercentageofcopromotionoperatingprofits" name="Futurepercentageofcopromotionoperatingprofits" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Futureresearchanddevelopmentcommitment" name="Futureresearchanddevelopmentcommitment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_GAZYVAMember" name="GAZYVAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesCurrentMember" name="GovernmentSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_GovernmentSecuritiesNonCurrentMember" name="GovernmentSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_HemophiliaProductsMember" name="HemophiliaProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IMRALDIMember" name="IMRALDIMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IPerianMember" name="IPerianMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InLicensedPatentsMember" name="InLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IncomeTaxesTextualAbstract" name="IncomeTaxesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IncreasedCarryingAmountOfSeniorNotes" name="IncreasedCarryingAmountOfSeniorNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_IndefiniteLivedIntangibleAssetsUsefulLife" name="IndefiniteLivedIntangibleAssetsUsefulLife" nillable="true" substitutionGroup="xbrli:item" type="us-types:durationStringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" name="IntangibleAssetsAndGoodwillAdditionalTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InterestInSubsidiary" name="InterestInSubsidiary" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_InterferonMember" name="InterferonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_InventoryexpectedtobesoldtoBioverativ" name="InventoryexpectedtobesoldtoBioverativ" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Inventorynetcurrentandnoncurrent" name="Inventorynetcurrentandnoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentInVariableInterestEntitiesTextualAbstract" name="InvestmentInVariableInterestEntitiesTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Investmentincommonstocksharespurchased" name="Investmentincommonstocksharespurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_Investmentincommonstockvalue" name="Investmentincommonstockvalue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" name="InvestmentsByThirdPartyInJointVentureAsPerAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_InvestmentsInVariableInterestEntitiesAbstract" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_IonisPharmaceuticalsMember" name="IonisPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_JointVentureOwnerShipPercentageByThirdParty" name="JointVentureOwnerShipPercentageByThirdParty" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_KaryopharmMember" name="KaryopharmMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_LicenseFee" name="LicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MSProductRevenuesMember" name="MSProductRevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MajorDistributorAxis" name="MajorDistributorAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MajorDistributorDomain" name="MajorDistributorDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsActivityAbstract" name="MarketStockUnitsActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MarketStockUnitsMember" name="MarketStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumQualifyingAgeForEmployeeBenefitPlan" name="MinimumQualifyingAgeForEmployeeBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" name="MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" name="MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome" name="NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_NetMinimumLeasePayments" name="NetMinimumLeasePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsThereafter" name="NetMinimumLeasePaymentsThereafter" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFiveYear" name="NetMinimumLeasePaymentsWithInFiveYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInFourYear" name="NetMinimumLeasePaymentsWithInFourYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInOneYear" name="NetMinimumLeasePaymentsWithInOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInThreeYear" name="NetMinimumLeasePaymentsWithInThreeYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_NetMinimumLeasePaymentsWithInTwoYear" name="NetMinimumLeasePaymentsWithInTwoYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_NeurimmuneMember" name="NeurimmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NewAntiCd20Member" name="NewAntiCd20Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NineteenbillionMember" name="NineteenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Noncontrollinginterestincreasedecreaseother" name="Noncontrollinginterestincreasedecreaseother" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NotesPayableToFumedicaMember" name="NotesPayableToFumedicaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" name="NumberOfDaysForCalculationOfAverageClosingStockPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfEqualAnnualIncrements" name="NumberOfEqualAnnualIncrements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" name="NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_NumberOfSharesOfCommonStockForIssuance" name="NumberOfSharesOfCommonStockForIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_NumeratorAbstract" name="NumeratorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OCREVUSMember" name="OCREVUSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherForeignEarningsMember" name="OtherForeignEarningsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OthercorporaterevenuesMember" name="OthercorporaterevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OtherresearchanddiscoveryMember" name="OtherresearchanddiscoveryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesTableTextBlock" name="OtherrevenuesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_OutLicensedPatentsMember" name="OutLicensedPatentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PLSRMember" name="PLSRMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentTermsOfAccountsReceivable" name="PaymentTermsOfAccountsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentforTransitionTollTax" name="PaymentforTransitionTollTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" name="PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageOfMarketValuePerShareOfCommonStock" name="PercentageOfMarketValuePerShareOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfMinimumInvestmentReturn" name="PercentageOfMinimumInvestmentReturn" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageOfRoyaltiesAsPerCollaboration" name="PercentageOfRoyaltiesAsPerCollaboration" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PercentageParValueOfSeniorNotes" name="PercentageParValueOfSeniorNotes" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" name="PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinCashAbstract" name="PerformanceStockUnitsSettledinCashAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinCashMember" name="PerformanceStockUnitsSettledinCashMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PerformanceStockUnitsSettledinCashTableTextBlock" name="PerformanceStockUnitsSettledinCashTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinStockAbstract" name="PerformanceStockUnitsSettledinStockAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceStockUnitsSettledinStockMember" name="PerformanceStockUnitsSettledinStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PerformanceStockUnitsSettledinStockTableTextBlock" name="PerformanceStockUnitsSettledinStockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PerformanceUnitsMember" name="PerformanceUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PerformanceunitsactivityTableTextBlock" name="PerformanceunitsactivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PeriodOfCollaborationAgreement" name="PeriodOfCollaborationAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_PfizerMember" name="PfizerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="biib_Premiumonpurchaseofcommonstock" name="Premiumonpurchaseofcommonstock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_PrepaidtaxesMember" name="PrepaidtaxesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PretaxProfitSharingFormulaTableTextBlock" name="PretaxProfitSharingFormulaTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ProceedsFromMarketableDebtSecuritiesAbstract" name="ProceedsFromMarketableDebtSecuritiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_PurchasePriceOfCommonStockUnderEspp" name="PurchasePriceOfCommonStockUnderEspp" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Purchaseofcommonstock" name="Purchaseofcommonstock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_RatioOfNumberOfSharesReservedUnderPlan" name="RatioOfNumberOfSharesReservedUnderPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductionindeferredtaxliabilityundistributedforeignearnings" name="Reductionindeferredtaxliabilityundistributedforeignearnings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyrate" name="Reductioninroyaltyrate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Reductioninroyaltyratepayableoncommercialsales" name="Reductioninroyaltyratepayableoncommercialsales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RegulatoryMilestonesMember" name="RegulatoryMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RemedyPharmaceuticalMember" name="RemedyPharmaceuticalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetAxis" name="ResearchanddevelopmentassetAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ResearchanddevelopmentassetDomain" name="ResearchanddevelopmentassetDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ReserveforCashDiscountsMember" name="ReserveforCashDiscountsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" name="ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_ResourcesRedirectedthroughRestructuringProgram" name="ResourcesRedirectedthroughRestructuringProgram" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RestrictedStockUnitsActivityAbstract" name="RestrictedStockUnitsActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RevenuesFromUnconsolidatedJointBusinessAbstract" name="RevenuesFromUnconsolidatedJointBusinessAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" name="RevenuesInPercentageFromAntiCD20TherapeuticPrograms" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_Revenuesfromanticd20therapeuticprogramsMember" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RituxanMember" name="RituxanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_RocheGroupGenentechMember" name="RocheGroupGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_RoyaltyCostofSalesPolicyTextBlock" name="RoyaltyCostofSalesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" name="Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SOD1Member" name="SOD1Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SPINRAZAMember" name="SPINRAZAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SalesTriggerGrossSalesThreshold" name="SalesTriggerGrossSalesThreshold" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SamsungBiosimilarAgreementMember" name="SamsungBiosimilarAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" name="ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" name="ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" name="ScheduleOfDevelopmentMilestoneAndCollaborationTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" name="ScheduleOfMarketStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" name="SegmentGeographicalGroupsOfCountriesGroupOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SegmentInformationTextualAbstract" name="SegmentInformationTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" name="SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" name="SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SeriesXPreferredStockMember" name="SeriesXPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SeventeenbillionMember" name="SeventeenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ShareBasedPaymentsTextualAbstract" name="ShareBasedPaymentsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ShareOfCoPromotionProfits" name="ShareOfCoPromotionProfits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" name="SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SixteenbillionMember" name="SixteenbillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SkyhawkTherapeuticsMember" name="SkyhawkTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SobiMember" name="SobiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SolothurnMember" name="SolothurnMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionActivityAbstract" name="StockOptionActivityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StockOptionsAndEmployeeStockPurchasePlanMember" name="StockOptionsAndEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_StrategicInvestmentPortfolio" name="StrategicInvestmentPortfolio" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_StrategicInvestmentsMember" name="StrategicInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_StromedixMember" name="StromedixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" name="SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" name="SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfCommonStockTableTextBlock" name="SummaryOfCommonStockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TGNMember" name="TGNMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TMSMember" name="TMSMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" name="TaxBenefitAndCashReceivedFromStockOptionAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TaxcontingencyAbstract" name="TaxcontingencyAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TecfideraMember" name="TecfideraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Termofcollaborationagreement" name="Termofcollaborationagreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" name="ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" name="ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" name="TimeVestedRestrictedStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TimeVestedRestrictedStockUnitsMember" name="TimeVestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_Totaldeferredchargesandprepaidtaxes" name="Totaldeferredchargesandprepaidtaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_Totalpaymenttoentercollaborationagreement" name="Totalpaymenttoentercollaborationagreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="biib_TransitionTollTaxRepatriationTaxRate" name="TransitionTollTaxRepatriationTaxRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_TwentybillionMember" name="TwentybillionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_TysabriProductMember" name="TysabriProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_U.S.2017TaxActMember" name="U.S.2017TaxActMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_UniversityofPennsylvaniaMember" name="UniversityofPennsylvaniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="biib_Upfrontpaymentforcollaborationagreement" name="Upfrontpaymentforcollaborationagreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="biib_ValuationOfGrantedStockUnitsAbstract" name="ValuationOfGrantedStockUnitsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" name="WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="biib_ZINBRYTAMember" name="ZINBRYTAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>biib-20181231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20181231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20181231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20181231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20181231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncomeCalc2" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfComprehensiveIncomeCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20181231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:href="biib-20181231.xsd#DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:href="biib-20181231.xsd#DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails2" xlink:href="biib-20181231.xsd#DerivativeInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20181231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20181231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20181231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20181231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20181231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20181231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20181231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20181231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20181231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20181231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20181231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20181231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20181231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20181231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20181231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20181231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20181231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20181231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20181231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20181231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20181231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20181231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20181231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20181231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20181231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20181231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20181231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20181231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20181231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20181231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20181231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20181231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20181231.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20181231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20181231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:href="biib-20181231.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20181231.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20181231.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20181231.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20181231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20181231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20181231.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20181231.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20181231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20181231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20181231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20181231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20181231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails10" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails11" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20181231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20181231.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20181231.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="extended">
    <link:loc xlink:href="biib-20181231.xsd#biib_Copromotionprofitsandlosses" xlink:label="loc_biib_Copromotionprofitsandlosses_2483355a-fc39-4b27-7008-fbb7dc74dbd1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Copromotionprofitsandlosses_2483355a-fc39-4b27-7008-fbb7dc74dbd1" xlink:to="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Copromotionprofitsandlosses_2483355a-fc39-4b27-7008-fbb7dc74dbd1" xlink:to="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_140e4b0f-9eba-1bed-3fdc-3c30ef039ec3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:to="loc_biib_ShareOfCoPromotionProfits_140e4b0f-9eba-1bed-3fdc-3c30ef039ec3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_82fa8679-60f1-6e9b-d49f-3c30ef322da5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_82fa8679-60f1-6e9b-d49f-3c30ef322da5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_a93e93be-c9cb-1eb4-fb13-fbb7db8a78b6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_a93e93be-c9cb-1eb4-fb13-fbb7db8a78b6" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_39e76369-4fdc-9d5f-860a-45d0795e5fb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_55b5e968-aed9-5993-81a1-3f801185e617" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_a93e93be-c9cb-1eb4-fb13-fbb7db8a78b6" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_55b5e968-aed9-5993-81a1-3f801185e617" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_c856a5b8-7326-6510-a9c4-fbb7de57c364" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_c856a5b8-7326-6510-a9c4-fbb7de57c364" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_f67237f3-7c78-8a5c-b7b3-17f1eb0b017a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1ee37125-97ae-9676-6b51-158110f0eb00" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_c856a5b8-7326-6510-a9c4-fbb7de57c364" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1ee37125-97ae-9676-6b51-158110f0eb00" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_861baece-48d3-d217-cb0f-fbb7dafd8c6c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_861baece-48d3-d217-cb0f-fbb7dafd8c6c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_30d028f9-2f3a-4a0c-02f8-ea9552d875b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_680b734e-be2b-a9ae-6215-216b28f8aa8f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePayments_861baece-48d3-d217-cb0f-fbb7dafd8c6c" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_680b734e-be2b-a9ae-6215-216b28f8aa8f" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_32bc1315-87c2-c86c-da91-fbb7de47f51c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_32bc1315-87c2-c86c-da91-fbb7de47f51c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_ccaff3fc-3d87-e58a-0083-69dda0c10f9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_46feb484-9dc8-7708-8880-ab3ae4fa5724" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_32bc1315-87c2-c86c-da91-fbb7de47f51c" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_46feb484-9dc8-7708-8880-ab3ae4fa5724" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_ccca83bb-f7af-cbfd-5aa5-fbb7dace1846" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5b651b24-1278-4eab-c840-7002c6d68546" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_ccca83bb-f7af-cbfd-5aa5-fbb7dace1846" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_5b651b24-1278-4eab-c840-7002c6d68546" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_f195cc05-55eb-d65f-3b51-acb21f092efc" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_ccca83bb-f7af-cbfd-5aa5-fbb7dace1846" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_f195cc05-55eb-d65f-3b51-acb21f092efc" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_22720713-ca9c-247b-a99c-fbb7db1c1755" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36c616b1-40de-90d4-3c05-7e224ce1169a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_22720713-ca9c-247b-a99c-fbb7db1c1755" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_36c616b1-40de-90d4-3c05-7e224ce1169a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_162c926d-b086-ad25-0cf5-12fa6d69e9cc" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_22720713-ca9c-247b-a99c-fbb7db1c1755" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_162c926d-b086-ad25-0cf5-12fa6d69e9cc" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_0e6a6b77-8b3f-2437-6dc2-fbb7db0d73ef" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_0e6a6b77-8b3f-2437-6dc2-fbb7db0d73ef" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_fe404cae-7fcc-3489-844f-4d90e9776180" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7c60d6bd-e7c2-9f1e-0267-8a8e2f2cc01a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_0e6a6b77-8b3f-2437-6dc2-fbb7db0d73ef" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_7c60d6bd-e7c2-9f1e-0267-8a8e2f2cc01a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_InventoryNet_66bcd79a-a1c3-c24d-b8b4-7a0ce373714b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32f41ea9-05c6-e713-464b-586a571d1c1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_779d1d70-872c-880a-786f-5c7c2a455084" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_779d1d70-872c-880a-786f-5c7c2a455084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_928a1618-af56-709a-989c-a303706b8ca2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_18fb8fb0-a412-e54d-acd7-fbb7dbd88f22" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_18fb8fb0-a412-e54d-acd7-fbb7dbd88f22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_79aabdc0-b963-1fd1-4e81-8c0801b1ebca" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d79dcc1c-93de-0ecd-2bd5-7c1f224c9b98" xlink:to="loc_us-gaap_OtherAssetsCurrent_79aabdc0-b963-1fd1-4e81-8c0801b1ebca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_40344e31-d043-4fd3-7d85-44dbce02d758" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_40344e31-d043-4fd3-7d85-44dbce02d758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_Goodwill_831ad0b9-9dba-3997-20e6-e99a19aa28db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_5ee94de1-09b5-a281-d50f-420352002a69" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_5ee94de1-09b5-a281-d50f-420352002a69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_96dd7052-744e-d270-4e77-67944ec39152" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ddb0d184-2205-2a10-5b0e-faf2ccd717ae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_PreferredStockValue_ea289a9d-deba-2cde-21e4-3d0ae7a1f011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_CommonStockValue_aefe3f0c-abe4-5b83-9a64-da77d8e253dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6dca832a-861c-478d-b1a0-396533beb40d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_798442bf-12e1-d944-3fa1-8b797b67482e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a59bc5ae-63a0-c9bc-32f7-e2bd9f32bd26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_70b30340-b55c-aed7-73f5-36d397294f84" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6765f135-8c69-bebc-a116-d59a52a5b2f2" xlink:to="loc_us-gaap_TreasuryStockValue_70b30340-b55c-aed7-73f5-36d397294f84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_a9feabf5-0bf0-3efe-740e-f5e41a4b3194" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e0c0480e-e6f5-c4df-ce25-1ffa4a8c827a" xlink:to="loc_us-gaap_MinorityInterest_a9feabf5-0bf0-3efe-740e-f5e41a4b3194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_63817d40-f759-fa9c-45a5-8bbbb36ed5c9" xlink:to="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_AccountsPayableCurrent_c2c48170-d0ff-2c37-effc-ff5f53e30dcb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_e11f4ed8-bba4-2471-6835-a5baa4d63b38" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_TaxesPayableCurrent_e11f4ed8-bba4-2471-6835-a5baa4d63b38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_8f5a3111-d5cb-a384-b222-de3b1f0ebb53" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2dcbbde2-9146-a0ba-7f6c-c71b481e0841" xlink:to="loc_us-gaap_DebtCurrent_8f5a3111-d5cb-a384-b222-de3b1f0ebb53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_LongTermDebt_80dca0ba-44dc-8565-fb9b-c2edfc8c357d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_6b1efbc2-e859-9fbd-c572-2f4147498390" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_6b1efbc2-e859-9fbd-c572-2f4147498390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_066608da-f041-4af6-3da0-95354b640e11" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_bba08e5f-78e8-6c25-01a4-6720051135cc" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_31214f19-352c-275d-346b-0291fedc1ffa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_31214f19-352c-275d-346b-0291fedc1ffa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d4a92697-d008-996b-823a-bd9a56a04b3a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_43305c85-41ff-3d0f-c464-dc8983363bce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_dcb697a2-d8f0-57e1-08fe-44decbefa04c" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_dcb697a2-d8f0-57e1-08fe-44decbefa04c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_7d42c724-e395-d9cd-4d02-38341e761dae" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_RepaymentsOfDebt_7d42c724-e395-d9cd-4d02-38341e761dae" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_841cc99b-6221-dad6-80ee-74ba3650910b" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_841cc99b-6221-dad6-80ee-74ba3650910b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_8cec699e-eb8f-7a25-49e6-e52d81fe4f5f" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_8cec699e-eb8f-7a25-49e6-e52d81fe4f5f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_38e7f3e2-9d1a-8772-e4aa-fb2cb7d8adc0" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d8917e24-06dd-060d-a290-e426c7895e54" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_38e7f3e2-9d1a-8772-e4aa-fb2cb7d8adc0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_31214f19-352c-275d-346b-0291fedc1ffa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c4aa0718-f1b7-8481-8382-216f94e41c89" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c4aa0718-f1b7-8481-8382-216f94e41c89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_1409fb09-f174-b7de-83f3-7374f9363a4e" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_1409fb09-f174-b7de-83f3-7374f9363a4e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_9bee6818-2a16-d4ae-2725-dfdc5464a350" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_9bee6818-2a16-d4ae-2725-dfdc5464a350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_1d9f6b21-7968-bfc5-a1a6-0a5c2f012b31" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_1d9f6b21-7968-bfc5-a1a6-0a5c2f012b31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6d89f221-3ede-36b2-fcad-4a4ce1606f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1e99261d-1af1-2d77-636d-890a4a9c4511" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_1e99261d-1af1-2d77-636d-890a4a9c4511" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_93117641-f974-7fd5-be7f-b30d1cbbb2b1" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_93117641-f974-7fd5-be7f-b30d1cbbb2b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1db37fac-6ce5-5d1f-3f25-b01134e09873" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_1db37fac-6ce5-5d1f-3f25-b01134e09873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_54e087e7-dea1-4188-710c-f95dcb130e6e" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28655e34-499f-b7bf-c54f-5de0990d0c65" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_54e087e7-dea1-4188-710c-f95dcb130e6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_31214f19-352c-275d-346b-0291fedc1ffa" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b11c1cb0-596b-4c3d-0283-76cef67837c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ShareBasedCompensation_90cbc3ab-f555-6407-b3b4-b2bfa84c9f18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_29b0a481-c653-23c1-27cf-114dadcce1af" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_5f96c19e-85fe-99f6-cec0-c2c9d7470ed4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a9646808-098c-8496-e17a-df690055019e" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a9646808-098c-8496-e17a-df690055019e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_334f1d33-7cae-7fd2-9d83-bb387fc2f3dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d54a644c-3d3c-bcc1-da30-2f136651f90f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_2d76eef5-dce5-0152-632e-9bab39da698c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e69a15cf-ab4b-cbea-dc70-0b76971b08a1" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e69a15cf-ab4b-cbea-dc70-0b76971b08a1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_a039d388-4db8-a076-4618-28899f6ce801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a8656384-f7ca-f6e9-7877-ac1b97f5601a" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a8656384-f7ca-f6e9-7877-ac1b97f5601a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1bd0bd4e-4a6f-b052-029c-0ecb0c520251" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7f6d9e2c-c748-5cf7-7279-5c01f0cb27b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7f6d9e2c-c748-5cf7-7279-5c01f0cb27b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6df44786-4260-4fa4-e123-591abd5e882d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7f6d9e2c-c748-5cf7-7279-5c01f0cb27b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6df44786-4260-4fa4-e123-591abd5e882d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_5018ac42-f22a-8f01-2030-b43a520a4ea1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7f6d9e2c-c748-5cf7-7279-5c01f0cb27b7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_5018ac42-f22a-8f01-2030-b43a520a4ea1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_f44275a4-2994-4281-73e3-0fa77d53374b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_f44275a4-2994-4281-73e3-0fa77d53374b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_048ec802-2790-a30d-0e9a-5c6f3e54d390" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_f44275a4-2994-4281-73e3-0fa77d53374b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_048ec802-2790-a30d-0e9a-5c6f3e54d390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_1621a196-4a72-10b4-c544-c07605ff0ee5" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_f44275a4-2994-4281-73e3-0fa77d53374b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_1621a196-4a72-10b4-c544-c07605ff0ee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_d2c24eeb-15a0-37a7-cfdc-bd19219021be" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_d2c24eeb-15a0-37a7-cfdc-bd19219021be" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_4d113416-7c0a-683e-be37-7fe7e9060d06" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_d2c24eeb-15a0-37a7-cfdc-bd19219021be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_4d113416-7c0a-683e-be37-7fe7e9060d06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_1b551c6d-67e2-dfac-b5ad-1c70dbba0c63" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_d2c24eeb-15a0-37a7-cfdc-bd19219021be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_1b551c6d-67e2-dfac-b5ad-1c70dbba0c63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e83cd656-9fce-43ca-6f7c-1be78bef4068" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e83cd656-9fce-43ca-6f7c-1be78bef4068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_59645a08-ce25-9000-2f65-e4bfddb1182e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b087c8bb-e0f6-4c7f-883c-027f52d32745" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncomeCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_16599700E7375A6DC0519FD6EDD5FBF9_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_16599700E7375A6DC0519FD6EDD5FBF9_ff106bf5-082b-8f58-cc36-c7f91866b7d3" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_16599700E7375A6DC0519FD6EDD5FBF9_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_16599700E7375A6DC0519FD6EDD5FBF9_ff106bf5-082b-8f58-cc36-c7f91866b7d3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_16599700E7375A6DC0519FD6EDD5FBF9_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_16599700E7375A6DC0519FD6EDD5FBF9_cf605d39-9067-2f07-a6b5-7dfa6481009e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_16599700E7375A6DC0519FD6EDD5FBF9_0e67d263-6e0f-cbd4-f553-6c8cebeb68d8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_Revenues_435f940b-a471-4122-5132-a245458f6913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_5c890570-5904-7978-36d8-35b96dcf45ab" xlink:to="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_1c65a201-fd8e-32d7-dad9-c6d1d5719594" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6b6667ca-75d4-9e60-6c7f-ed168ded3470" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6b6667ca-75d4-9e60-6c7f-ed168ded3470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_693c47dd-e6fa-9c85-6a65-7baa26f76b5e" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_98B8CFD7EEEADFC847E0954C33FA5B74" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_98B8CFD7EEEADFC847E0954C33FA5B74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c85c86db-a830-0e07-1d7a-6fc2a37081a4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_db910ed0-c2ef-ba2b-b932-fbb7de764c93" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_biib_CollaborationProfitSharing_db910ed0-c2ef-ba2b-b932-fbb7de764c93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a8656384-f7ca-f6e9-7877-ac1b97f5601a" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a8656384-f7ca-f6e9-7877-ac1b97f5601a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_e04ca6ce-4142-8baf-2785-53947ccd390b" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_RestructuringCharges_e04ca6ce-4142-8baf-2785-53947ccd390b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_f6f76be7-79b0-7b7c-26ca-b40461ca94db" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_8823ccfd-55af-348e-39a2-91433072d2c9" xlink:to="loc_us-gaap_LitigationSettlementExpense_f6f76be7-79b0-7b7c-26ca-b40461ca94db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d01a4d5f-b660-27b4-db84-9a80227862fc" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8aa68cfb-2df7-9a23-d1ed-4fe33385b4a2" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d01a4d5f-b660-27b4-db84-9a80227862fc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f5ae002e-8316-7bc0-1b41-6cd171b53db3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a10eea14-f4db-3125-d183-77bb54500e95" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f5ae002e-8316-7bc0-1b41-6cd171b53db3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dd9a981-e559-d141-f1c2-4db79f71a7ef" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2dd9a981-e559-d141-f1c2-4db79f71a7ef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d342f32b-4cc6-0bef-3743-616005090121" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ce4f2f-397c-6c02-8635-7c94146a06a0" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d342f32b-4cc6-0bef-3743-616005090121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e52bef3f-d63a-d129-8b6a-48192f5d97b3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_d342f32b-4cc6-0bef-3743-616005090121" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_e52bef3f-d63a-d129-8b6a-48192f5d97b3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eed137f7-f4cf-61e8-5dd4-67d3dd178f58" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_eed137f7-f4cf-61e8-5dd4-67d3dd178f58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e0ab27ec-5a16-e4fe-975d-b94bfcaf7d5b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_6bae24fb-c89c-2c1d-91e1-c77efe1775f1" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_e0ab27ec-5a16-e4fe-975d-b94bfcaf7d5b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a97722c4-c88e-0258-6d8c-8f5c45929660" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a97722c4-c88e-0258-6d8c-8f5c45929660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ad47d869-5bf7-62ba-8427-e58f9319b050" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_ad47d869-5bf7-62ba-8427-e58f9319b050" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_a8e80998-108a-0f34-f1b4-3c30eef430a9" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f0bf2241-14f8-6ef1-e8d7-f724d52ad9c1" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_a8e80998-108a-0f34-f1b4-3c30eef430a9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_097e1b01-70b4-1050-9921-ba329e565fb9" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_a0eef5af-7e85-59ef-908d-3c30ef035fc5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_097e1b01-70b4-1050-9921-ba329e565fb9" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_a0eef5af-7e85-59ef-908d-3c30ef035fc5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bb6f3730-d49d-30bc-8e52-6eba94f7dba4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_097e1b01-70b4-1050-9921-ba329e565fb9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_bb6f3730-d49d-30bc-8e52-6eba94f7dba4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_329a232f-6b5a-4dfb-de74-33d6f53aa8f1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecurities_097e1b01-70b4-1050-9921-ba329e565fb9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_329a232f-6b5a-4dfb-de74-33d6f53aa8f1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e6f9d43e-fcd6-745d-b634-9ed4792095b2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_e6f9d43e-fcd6-745d-b634-9ed4792095b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a4e74316-f31b-80bc-a44a-3464e9dcdb33" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_19dfad62-5a43-dcc4-04a8-012732c1ed97" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a4e74316-f31b-80bc-a44a-3464e9dcdb33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b975ff9b-a11f-f2b5-e104-e0266dbbbfc6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d365c95-da3d-c3cb-6f6b-7945d285af9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bbb5a6cc-fe5e-18f1-e9f0-76884d58b714" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_816edbc5-9d4b-113c-7ce2-6c08dd555314" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bbb5a6cc-fe5e-18f1-e9f0-76884d58b714" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_97bbae57-7f84-4da9-acab-610e56204929" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_650e6c8f-1409-4de1-126f-784909f82e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_10aa09ac-60b4-bd88-6c3b-c85b3f0fbf0a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_840ca4a2-1542-fad2-992c-40136594b396" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e8a9abf2-38d3-77d1-fb6b-693fef632294" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_840ca4a2-1542-fad2-992c-40136594b396" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a38b9623-d40d-b02c-d37f-d84fb6a4eac7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_a38b9623-d40d-b02c-d37f-d84fb6a4eac7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_475c85ca-97e4-c8e8-9ee2-6c534eb18ace" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_475c85ca-97e4-c8e8-9ee2-6c534eb18ace" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7f86d0ad-9065-5c14-f7d0-2ff3cc4df692" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_7f86d0ad-9065-5c14-f7d0-2ff3cc4df692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_877d9548-0a6d-f5af-1e31-5b1edfc4107e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187bb760-9cde-c4af-d9e1-306e7a6330eb" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_187bb760-9cde-c4af-d9e1-306e7a6330eb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0cc13c2f-6b23-b741-4f28-07325c7e7169" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0cc13c2f-6b23-b741-4f28-07325c7e7169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_476b367a-1ad6-eb34-c01b-595b754b8aa8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d9af76c3-a64a-3b37-1d7d-4e9be8c70af6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_42b61cde-44f6-df44-52b0-1b84b1e28a47" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_42b61cde-44f6-df44-52b0-1b84b1e28a47" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_56DD8B4346B4B3B191E082410B4C5E71" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_56DD8B4346B4B3B191E082410B4C5E71" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:label="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_4435470A46538EA1D38B824841F561AE" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:to="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_4435470A46538EA1D38B824841F561AE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_e80a4a62-87f6-eaa2-f61c-fbb7db5b496a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_cee36967-7b64-56b0-03ea-66fbd4d14899" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_e80a4a62-87f6-eaa2-f61c-fbb7db5b496a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_51d18bf0-0823-2940-9470-e9bbca486da6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_d23dd313-f50b-59fa-fd80-0dbe24277535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2159a283-2879-8644-198d-34cde06e5374" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_2159a283-2879-8644-198d-34cde06e5374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_928f8c54-624a-8542-b4e3-59da2a4e6af6" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_928f8c54-624a-8542-b4e3-59da2a4e6af6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_8b4dec44-978c-8cf6-a303-372686bd69be" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_8b4dec44-978c-8cf6-a303-372686bd69be" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_a279d92b-35df-23ba-dc61-ed7f6f1d81e3" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_a279d92b-35df-23ba-dc61-ed7f6f1d81e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_00f37689-1982-1c68-c80b-43003f810247" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_00f37689-1982-1c68-c80b-43003f810247" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_bb3ae461-aff1-7c2a-156c-3c30eed2d304" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_bb3ae461-aff1-7c2a-156c-3c30eed2d304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7ffe16d1-cedd-985f-c95d-65ae6fa8d756" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_7ffe16d1-cedd-985f-c95d-65ae6fa8d756" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_A7FB9E41C5A89E43CA12824CBFD9A0D2" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_A7FB9E41C5A89E43CA12824CBFD9A0D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_74519641-8e05-58f3-2f6b-337cd7f7860d" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f1b8c80c-fe31-3624-3b0a-70273297561e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_74519641-8e05-58f3-2f6b-337cd7f7860d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_0809900e-b1d0-3825-d1aa-e04ba86af96c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5cb3949c-1d57-8f66-f002-a3389de7aec0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_0809900e-b1d0-3825-d1aa-e04ba86af96c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5cb3949c-1d57-8f66-f002-a3389de7aec0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_53634569-cdf7-3d1b-42b0-596cb4175c67" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_0809900e-b1d0-3825-d1aa-e04ba86af96c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_53634569-cdf7-3d1b-42b0-596cb4175c67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c4573bf7-1f66-8dfe-59b9-b6903f55406f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_0809900e-b1d0-3825-d1aa-e04ba86af96c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_c4573bf7-1f66-8dfe-59b9-b6903f55406f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e00da32d-ed06-bb21-8b28-7e7ede769972" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_0809900e-b1d0-3825-d1aa-e04ba86af96c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e00da32d-ed06-bb21-8b28-7e7ede769972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_89018c92-f86f-28e7-853c-438f4a34e1f6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_0809900e-b1d0-3825-d1aa-e04ba86af96c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_89018c92-f86f-28e7-853c-438f4a34e1f6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3b793654-c1ac-69c9-9cf3-81e6dfe102d7" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable_0809900e-b1d0-3825-d1aa-e04ba86af96c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_3b793654-c1ac-69c9-9cf3-81e6dfe102d7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99bd5160-e32a-dcfc-e4fd-38dda5d465b0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_99bd5160-e32a-dcfc-e4fd-38dda5d465b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a49df76-38f6-6baa-87dd-2e9a7efd8303" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d3bdc20c-5c58-6be6-d756-0ace6a97f212" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_7a49df76-38f6-6baa-87dd-2e9a7efd8303" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e52879aa-5fc1-863a-9bc7-07b154238ef5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_e52879aa-5fc1-863a-9bc7-07b154238ef5" xlink:type="arc" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_af012273-e8ee-655c-daa2-86b96989d377" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c9279b6a-f262-f140-7696-5ec40778343f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20181231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_90e6c96b-092c-3a0f-bace-3c30ef22b935" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2dd0840-de07-383b-bde9-fb229532490d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_90e6c96b-092c-3a0f-bace-3c30ef22b935" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_c2dd0840-de07-383b-bde9-fb229532490d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_02cb866c-0b1c-51f5-8ed3-3272dfc8c769" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_90e6c96b-092c-3a0f-bace-3c30ef22b935" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_02cb866c-0b1c-51f5-8ed3-3272dfc8c769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a979ceab-3c76-a4d5-9d1d-ca902d5e8595" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_90e6c96b-092c-3a0f-bace-3c30ef22b935" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a979ceab-3c76-a4d5-9d1d-ca902d5e8595" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5fcda05e-5b0d-7f20-111d-115dec47eebc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_InterestExpense_a56b34b7-57ab-a07c-7f03-8366849a14f0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_3589939f-ce38-3d4c-b787-38d24b24727b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_3589939f-ce38-3d4c-b787-38d24b24727b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743ecb1a-adc1-2b63-ff24-350f33c715bd" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_743ecb1a-adc1-2b63-ff24-350f33c715bd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_c5398800-6e68-ed86-a47c-16106e0730c2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_41e96f8d-e499-8de8-69a8-27f1c7d4df6e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4bcdb937-432e-7a7e-23c2-a441d7b89da5" xlink:type="locator" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_db14e221-1e49-5bf4-7e11-e421a92d7589" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:to="loc_us-gaap_Land_db14e221-1e49-5bf4-7e11-e421a92d7589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_a950b010-729f-1598-3a8b-dbb5d39fface" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_a950b010-729f-1598-3a8b-dbb5d39fface" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_1d3497d2-8d15-4825-7a03-0beb82db4fd6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_1d3497d2-8d15-4825-7a03-0beb82db4fd6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_74ff286c-49fc-4a96-3032-cc3ed93d76b0" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_74ff286c-49fc-4a96-3032-cc3ed93d76b0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_50adb9b1-a4f7-c610-0b5f-fbb7dd1ff2ce" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:to="loc_biib_ComputerSoftwareAndHardware_50adb9b1-a4f7-c610-0b5f-fbb7dd1ff2ce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_121a07b8-5bbc-6043-cf0b-e8159d4e3517" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_121a07b8-5bbc-6043-cf0b-e8159d4e3517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_ed9b6f5d-96d4-4d90-dc30-3e04f8acc5a2" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_78662f7f-2a6a-5d68-ba8a-7947ed287be5" xlink:to="loc_us-gaap_ConstructionInProgressGross_ed9b6f5d-96d4-4d90-dc30-3e04f8acc5a2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_f37ad080-c77a-efc5-c936-389b16abc420" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a08cda9-11b3-e7ac-3fc9-3a23c67d9b96" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>biib-20181231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20181231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20181231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20181231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20181231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20181231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:href="biib-20181231.xsd#DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:href="biib-20181231.xsd#DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails2" xlink:href="biib-20181231.xsd#DerivativeInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20181231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20181231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20181231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20181231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20181231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20181231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20181231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20181231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20181231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20181231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20181231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20181231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20181231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20181231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20181231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20181231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20181231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20181231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20181231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20181231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20181231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20181231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20181231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20181231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20181231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20181231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20181231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20181231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20181231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20181231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20181231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20181231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20181231.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20181231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20181231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:href="biib-20181231.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20181231.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20181231.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20181231.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20181231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20181231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20181231.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20181231.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20181231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20181231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20181231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20181231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20181231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails10" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails11" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20181231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20181231.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20181231.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9524F812A636B9EB278D9FD49DF2788C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79" xlink:to="loc_us-gaap_StatementTable_9524F812A636B9EB278D9FD49DF2788C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6DA03D1EFD5CDF5313409FD49DF232A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9524F812A636B9EB278D9FD49DF2788C" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6DA03D1EFD5CDF5313409FD49DF232A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B77093C2279D1006CB549FD49DF20919_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6DA03D1EFD5CDF5313409FD49DF232A7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B77093C2279D1006CB549FD49DF20919_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B77093C2279D1006CB549FD49DF20919" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6DA03D1EFD5CDF5313409FD49DF232A7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B77093C2279D1006CB549FD49DF20919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_9C2302D980043CC862229FD49DF2834F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B77093C2279D1006CB549FD49DF20919" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_9C2302D980043CC862229FD49DF2834F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9524F812A636B9EB278D9FD49DF2788C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9" xlink:to="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9" xlink:to="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5B67B8B69473585BE0339FD49DF2539B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5B67B8B69473585BE0339FD49DF2539B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_6F03DCDA337A766BDB659FD49DF2A7DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_6F03DCDA337A766BDB659FD49DF2A7DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8FF20788F0222BEDB9A19FD4A0A1B05D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8FF20788F0222BEDB9A19FD4A0A1B05D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4F754004E434DA28381B9FD49DF296FA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4F754004E434DA28381B9FD49DF296FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4B930120F08BD75A54FB9FD49DF27B18" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4B930120F08BD75A54FB9FD49DF27B18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_091C4BD78FD1A06FE79D9FD49DF221FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_091C4BD78FD1A06FE79D9FD49DF221FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_6E13D7E4174B7F51ACB49FD49DF2AD62" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_6E13D7E4174B7F51ACB49FD49DF2AD62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_959C3963391E191FEDCE9FD49DF224C5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_959C3963391E191FEDCE9FD49DF224C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_44D5DD9BFA59670A6A9D9FD49DF2F95C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_44D5DD9BFA59670A6A9D9FD49DF2F95C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A020D72AB1461F45A0A39FD49DF2D57F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A020D72AB1461F45A0A39FD49DF2D57F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3860BBAC596ABF1D03E99FD49DF2F0F2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3860BBAC596ABF1D03E99FD49DF2F0F2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:to="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:to="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0AF7B62009C18C596C719FD5D487DCFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0AF7B62009C18C596C719FD5D487DCFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7E319EE7ABAFB70DCA719FD5D48709D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7E319EE7ABAFB70DCA719FD5D48709D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_552F34AC139F833CD5489FD5D487162C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_552F34AC139F833CD5489FD5D487162C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8BD6FA144744EEC7E5FF9FD5D6FCEEAE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8BD6FA144744EEC7E5FF9FD5D6FCEEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_E3E5162FF35BA26803A99FD5D4877AC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_E3E5162FF35BA26803A99FD5D4877AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8AAE542D213BF16C1C3E9FD5D487EA48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8AAE542D213BF16C1C3E9FD5D487EA48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_35AB3994D1189F0CD2C49FD5D48764C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_35AB3994D1189F0CD2C49FD5D48764C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5BCA285D46E681A79D159FD5D487DADC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_Revenues_5BCA285D46E681A79D159FD5D487DADC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_EA77B1C0E46B71DF80419FD5D4879210" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_OperatingExpenses_EA77B1C0E46B71DF80419FD5D4879210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B5F47AF5606D8DF8DAA29FD5D487AC37" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_B5F47AF5606D8DF8DAA29FD5D487AC37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FF086133C61DD682A07D9FD5D4871BCD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_NetIncomeLoss_FF086133C61DD682A07D9FD5D4871BCD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_AEB60DB42B1C26955715118916E282B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A75889D2662342A10C0118916E254C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AEB60DB42B1C26955715118916E282B1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A75889D2662342A10C0118916E254C0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_DAFB299A5E683916863311A5E6E63CDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A75889D2662342A10C0118916E254C0" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_DAFB299A5E683916863311A5E6E63CDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_1986F672D55DE4363AA411A5E6EC600C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_DAFB299A5E683916863311A5E6E63CDD" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_1986F672D55DE4363AA411A5E6EC600C_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_1986F672D55DE4363AA411A5E6EC600C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_DAFB299A5E683916863311A5E6E63CDD" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_1986F672D55DE4363AA411A5E6EC600C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_1DA9C5EE497B469EBD7711A5E7FCA262" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_1986F672D55DE4363AA411A5E6EC600C" xlink:to="loc_biib_DevelopmentMilestonesMember_1DA9C5EE497B469EBD7711A5E7FCA262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3F95474917C1D7D9312E118916E2B76A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A75889D2662342A10C0118916E254C0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3F95474917C1D7D9312E118916E2B76A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3F95474917C1D7D9312E118916E2B76A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3F95474917C1D7D9312E118916E2B76A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:to="loc_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:to="loc_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TMSMember" xlink:label="loc_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:to="loc_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AliveGenMember" xlink:label="loc_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:to="loc_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:to="loc_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_AE9C9DEB922C1E15F163118916E21C6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AEB60DB42B1C26955715118916E282B1" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_AE9C9DEB922C1E15F163118916E21C6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_99EDF5CAD60A287D385B11A4E6B40429" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AEB60DB42B1C26955715118916E282B1" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_99EDF5CAD60A287D385B11A4E6B40429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_968B1D32F9438682B13511A6DF798BF1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AEB60DB42B1C26955715118916E282B1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_968B1D32F9438682B13511A6DF798BF1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E3446C6511F88F8108E19A049BB4D370" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E3446C6511F88F8108E19A049BB4D370" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2CF60E280C44F77CD7719A049BAC435A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:to="loc_srt_MajorCustomersAxis_2CF60E280C44F77CD7719A049BAC435A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_580C06347112E728D50D9A049BAC399F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2CF60E280C44F77CD7719A049BAC435A" xlink:to="loc_srt_NameOfMajorCustomerDomain_580C06347112E728D50D9A049BAC399F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_580C06347112E728D50D9A049BAC399F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2CF60E280C44F77CD7719A049BAC435A" xlink:to="loc_srt_NameOfMajorCustomerDomain_580C06347112E728D50D9A049BAC399F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_93DC2934F17888FD465D9A049BB13035" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_580C06347112E728D50D9A049BAC399F" xlink:to="loc_biib_AbbVieMember_93DC2934F17888FD465D9A049BB13035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0BA048C9AA31470657679A049BB27AA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:to="loc_srt_ProductOrServiceAxis_0BA048C9AA31470657679A049BB27AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_418E7423754F1177CD019A049BB29521_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0BA048C9AA31470657679A049BB27AA0" xlink:to="loc_srt_ProductsAndServicesDomain_418E7423754F1177CD019A049BB29521_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_418E7423754F1177CD019A049BB29521" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0BA048C9AA31470657679A049BB27AA0" xlink:to="loc_srt_ProductsAndServicesDomain_418E7423754F1177CD019A049BB29521" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_7D84725203D34F03CE019A049BB238E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_418E7423754F1177CD019A049BB29521" xlink:to="loc_us-gaap_ProductMember_7D84725203D34F03CE019A049BB238E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_18DDCC13EC0A164F90169A049BB3864B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:to="loc_srt_StatementGeographicalAxis_18DDCC13EC0A164F90169A049BB3864B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_CACC8802A873C4CCF6529A049BB34F53_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_18DDCC13EC0A164F90169A049BB3864B" xlink:to="loc_srt_SegmentGeographicalDomain_CACC8802A873C4CCF6529A049BB34F53_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_CACC8802A873C4CCF6529A049BB34F53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_18DDCC13EC0A164F90169A049BB3864B" xlink:to="loc_srt_SegmentGeographicalDomain_CACC8802A873C4CCF6529A049BB34F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_DA1567024C326D1F14419A049BB37F10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_CACC8802A873C4CCF6529A049BB34F53" xlink:to="loc_country_US_DA1567024C326D1F14419A049BB37F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9924E939A3F6468EF1BE9A049BB3BC09" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9924E939A3F6468EF1BE9A049BB3BC09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0BEA1CDB270FD7AA628B9A049BB373F1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9924E939A3F6468EF1BE9A049BB3BC09" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0BEA1CDB270FD7AA628B9A049BB373F1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0BEA1CDB270FD7AA628B9A049BB373F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9924E939A3F6468EF1BE9A049BB3BC09" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0BEA1CDB270FD7AA628B9A049BB373F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_F97CC8EEB0AB69FBEC3C9A049BB40D36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0BEA1CDB270FD7AA628B9A049BB373F1" xlink:to="loc_biib_AbbVieMember_F97CC8EEB0AB69FBEC3C9A049BB40D36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A2E4241A96C30FD24DA39A049BB4E3C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E3446C6511F88F8108E19A049BB4D370" xlink:to="loc_us-gaap_Revenues_A2E4241A96C30FD24DA39A049BB4E3C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_43C3156C9691F38749AD9A049BB4A85B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E3446C6511F88F8108E19A049BB4D370" xlink:to="loc_us-gaap_CostsAndExpenses_43C3156C9691F38749AD9A049BB4A85B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Copromotionprofitsandlosses" xlink:label="loc_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E3446C6511F88F8108E19A049BB4D370" xlink:to="loc_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_36945667EE84E8DEF28085B86A265ECA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EB7C6A1B3D1591072F9385B86A23337D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_36945667EE84E8DEF28085B86A265ECA" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EB7C6A1B3D1591072F9385B86A23337D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_CAAEA22AE06E6B67A13785B86A233D0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EB7C6A1B3D1591072F9385B86A23337D" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_CAAEA22AE06E6B67A13785B86A233D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_788BEC0AA06FCC46042985B86A232116_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CAAEA22AE06E6B67A13785B86A233D0A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_788BEC0AA06FCC46042985B86A232116_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_788BEC0AA06FCC46042985B86A232116" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CAAEA22AE06E6B67A13785B86A233D0A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_788BEC0AA06FCC46042985B86A232116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8303A9399F18F729E32285B86A23D7C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_788BEC0AA06FCC46042985B86A232116" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8303A9399F18F729E32285B86A23D7C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0BB81794DBFF46A9A67C85B86A2346B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_788BEC0AA06FCC46042985B86A232116" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0BB81794DBFF46A9A67C85B86A2346B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4F0D7EBED12009B5647485B86A23D3F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EB7C6A1B3D1591072F9385B86A23337D" xlink:to="loc_srt_ProductOrServiceAxis_4F0D7EBED12009B5647485B86A23D3F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B60B54989D19EA5B3B5E85B86A235270_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4F0D7EBED12009B5647485B86A23D3F0" xlink:to="loc_srt_ProductsAndServicesDomain_B60B54989D19EA5B3B5E85B86A235270_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B60B54989D19EA5B3B5E85B86A235270" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4F0D7EBED12009B5647485B86A23D3F0" xlink:to="loc_srt_ProductsAndServicesDomain_B60B54989D19EA5B3B5E85B86A235270" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B60B54989D19EA5B3B5E85B86A235270" xlink:to="loc_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A3F6C85DE1C9A95E7E6785B86A231C18" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EB7C6A1B3D1591072F9385B86A23337D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A3F6C85DE1C9A95E7E6785B86A231C18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01B0FAA28EF1334F256985B86A26C37B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A3F6C85DE1C9A95E7E6785B86A231C18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01B0FAA28EF1334F256985B86A26C37B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01B0FAA28EF1334F256985B86A26C37B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A3F6C85DE1C9A95E7E6785B86A231C18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01B0FAA28EF1334F256985B86A26C37B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_14888ECD3A258F8152B585B86A262A1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01B0FAA28EF1334F256985B86A26C37B" xlink:to="loc_biib_EisaiMember_14888ECD3A258F8152B585B86A262A1A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_0C5A26DA0990379A615A85B86A260979" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_36945667EE84E8DEF28085B86A265ECA" xlink:to="loc_biib_ExpenseIncurredByCollaboration_0C5A26DA0990379A615A85B86A260979" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_36945667EE84E8DEF28085B86A265ECA" xlink:to="loc_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_16BF2671370DB496C9BC85B86A26EA8F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_36945667EE84E8DEF28085B86A265ECA" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_16BF2671370DB496C9BC85B86A26EA8F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:to="loc_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:to="loc_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84" xlink:to="loc_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_42F360B32B0BEA8D16C7C42825F401C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5" xlink:to="loc_us-gaap_ScenarioForecastMember_42F360B32B0BEA8D16C7C42825F401C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4C97A430F8BF605CC47AC42825F4A429" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4C97A430F8BF605CC47AC42825F4A429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D9F213F7BC96ECA93789C42825F57DC5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4C97A430F8BF605CC47AC42825F4A429" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D9F213F7BC96ECA93789C42825F57DC5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D9F213F7BC96ECA93789C42825F57DC5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4C97A430F8BF605CC47AC42825F4A429" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D9F213F7BC96ECA93789C42825F57DC5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_EC50CBCF03B10B208151C42825F51030" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D9F213F7BC96ECA93789C42825F57DC5" xlink:to="loc_biib_InLicensedPatentsMember_EC50CBCF03B10B208151C42825F51030" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:to="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:to="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_0B9E60FC2606F89A2C7FC42825F6F977" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:to="loc_country_US_0B9E60FC2606F89A2C7FC42825F6F977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_B5FBB7D142643CB75FE4C42825F6125A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_B5FBB7D142643CB75FE4C42825F6125A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_355C148EFE12571EE5B9C42825F6AD70" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:to="loc_us-gaap_ForeignCountryMember_355C148EFE12571EE5B9C42825F6AD70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_A1491A272F841BE2282CC42825F6EAF3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:to="loc_us-gaap_EuropeanUnionMember_A1491A272F841BE2282CC42825F6EAF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_F2ED2B4AC12C1257F0A5C42825F61E5F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:to="loc_country_JP_F2ED2B4AC12C1257F0A5C42825F61E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_22E1CD6CF35B2621BE7BC42825F663A6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_22E1CD6CF35B2621BE7BC42825F663A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_188966DC9C0229841EB6C42825F7DB5D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22E1CD6CF35B2621BE7BC42825F663A6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_188966DC9C0229841EB6C42825F7DB5D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_188966DC9C0229841EB6C42825F7DB5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22E1CD6CF35B2621BE7BC42825F663A6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_188966DC9C0229841EB6C42825F7DB5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6F90A14C9B9439CCAD8FC42825F778E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_188966DC9C0229841EB6C42825F7DB5D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6F90A14C9B9439CCAD8FC42825F778E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349502A345686C9147DDC42825F79E2C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_188966DC9C0229841EB6C42825F7DB5D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349502A345686C9147DDC42825F79E2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_A9FD6596DE6ADA0DA897C42825F8954A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_srt_ProductOrServiceAxis_A9FD6596DE6ADA0DA897C42825F8954A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_A9FD6596DE6ADA0DA897C42825F8954A" xlink:to="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_A9FD6596DE6ADA0DA897C42825F8954A" xlink:to="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OCREVUSMember" xlink:label="loc_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_AF891EE1F52F340299DCC42825F91DC9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_ZINBRYTAMember_AF891EE1F52F340299DCC42825F91DC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_A8021F153C3C83F8788BC42825F9B4C4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_SPINRAZAMember_A8021F153C3C83F8788BC42825F9B4C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_C213A9A8BE0B19F8B83FC42825FA691E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_BiosimilarsMember_C213A9A8BE0B19F8B83FC42825FA691E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_18005FF1FD3AF3534D3BC42825FCB0FB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_AbbVieMember_18005FF1FD3AF3534D3BC42825FCB0FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_E3E30D0D4746C0201D2EC42825FC9A1C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_us-gaap_CollaborativeArrangementMember_E3E30D0D4746C0201D2EC42825FC9A1C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_UniversityofPennsylvaniaMember" xlink:label="loc_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_C4TherapeuticsMember" xlink:label="loc_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_0AE4398B41698A51D136C42825FD7B0C" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_0AE4398B41698A51D136C42825FD7B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_535D7244BF035AAC5491C42825FD6B9A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_srt_RangeAxis_535D7244BF035AAC5491C42825FD6B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CC4C74578600F203A654C42825FDE028_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_535D7244BF035AAC5491C42825FD6B9A" xlink:to="loc_srt_RangeMember_CC4C74578600F203A654C42825FDE028_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CC4C74578600F203A654C42825FDE028" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_535D7244BF035AAC5491C42825FD6B9A" xlink:to="loc_srt_RangeMember_CC4C74578600F203A654C42825FDE028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4A9C0D50E623F356AEACC42825FE6369" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_CC4C74578600F203A654C42825FDE028" xlink:to="loc_srt_MinimumMember_4A9C0D50E623F356AEACC42825FE6369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D5A41B160EBECF4D10D7C42825FE6853" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_CC4C74578600F203A654C42825FDE028" xlink:to="loc_srt_MaximumMember_D5A41B160EBECF4D10D7C42825FE6853" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_A4B22C422A91EF6BAB06C42826017B5D" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_A4B22C422A91EF6BAB06C42826017B5D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_59978B3CB729F061D2DAC4282602B2DC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_Revenues_59978B3CB729F061D2DAC4282602B2DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9A08DA065F079C74EA5EC42826030C54" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9A08DA065F079C74EA5EC42826030C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_BF8EBC1A08CE6760E89DC42826030C4F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_BF8EBC1A08CE6760E89DC42826030C4F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_EA576394E5580A1E7EA5C4282603F794" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_EA576394E5580A1E7EA5C4282603F794" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Upfrontpaymentforcollaborationagreement" xlink:label="loc_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Totalpaymenttoentercollaborationagreement" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_52329FF74E2BC438E185C4282605003B" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_52329FF74E2BC438E185C4282605003B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Investmentincommonstockvalue" xlink:label="loc_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_099BD1E5FE2CDC3EB4AEC4282606BE9E" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_099BD1E5FE2CDC3EB4AEC4282606BE9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Futureresearchanddevelopmentcommitment" xlink:label="loc_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_09121B4CD74A7A05FE7CC42826070EDA" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_EquityMethodInvestments_09121B4CD74A7A05FE7CC42826070EDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4E115CE8CFE8881E3A7FC42826077BED" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4E115CE8CFE8881E3A7FC42826077BED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_D50AB5E190BB7D98F44EC42826078527" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_D50AB5E190BB7D98F44EC42826078527" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1DCE4060D8FE85C9CBB1C4282607D57B" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1DCE4060D8FE85C9CBB1C4282607D57B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC" xlink:type="locator" />
    <link:definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31AB8ADDA79C4F28DC16879B8F3F28C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_746CB8FB9A1225599FB4879B8F3C7F53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31AB8ADDA79C4F28DC16879B8F3F28C8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_746CB8FB9A1225599FB4879B8F3C7F53" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_244A819C8B416B4C9732879B8F3D096D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_746CB8FB9A1225599FB4879B8F3C7F53" xlink:to="loc_srt_ProductOrServiceAxis_244A819C8B416B4C9732879B8F3D096D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_244A819C8B416B4C9732879B8F3D096D" xlink:to="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_244A819C8B416B4C9732879B8F3D096D" xlink:to="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_51684E73C53DB8A649DF879B8F3DCF4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182" xlink:to="loc_biib_GAZYVAMember_51684E73C53DB8A649DF879B8F3DCF4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_D1CD3266A1250A14E94E879B8F3D7695" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182" xlink:to="loc_biib_RituxanMember_D1CD3266A1250A14E94E879B8F3D7695" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_95FA65635F43927853E6879B8F3EBA83" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_95FA65635F43927853E6879B8F3EBA83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_169C5643FE2772991B13879B8F3E9439" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_746CB8FB9A1225599FB4879B8F3C7F53" xlink:to="loc_srt_MajorCustomersAxis_169C5643FE2772991B13879B8F3E9439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FBBC3C5E2C805C76B983879B8F3EE852_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_169C5643FE2772991B13879B8F3E9439" xlink:to="loc_srt_NameOfMajorCustomerDomain_FBBC3C5E2C805C76B983879B8F3EE852_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FBBC3C5E2C805C76B983879B8F3EE852" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_169C5643FE2772991B13879B8F3E9439" xlink:to="loc_srt_NameOfMajorCustomerDomain_FBBC3C5E2C805C76B983879B8F3EE852" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_FAFB912D22E4E4A54257879B8F3E81EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_FBBC3C5E2C805C76B983879B8F3EE852" xlink:to="loc_biib_RocheGroupGenentechMember_FAFB912D22E4E4A54257879B8F3E81EA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31AB8ADDA79C4F28DC16879B8F3F28C8" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_B199240667F4D1164976879B8F3F84F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_B199240667F4D1164976879B8F3F84F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_7A1B9C5AAC25D86FEEDC879B8F403F01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_7A1B9C5AAC25D86FEEDC879B8F403F01" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B07388263CAE8B17EA44879B8F403B05" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B07388263CAE8B17EA44879B8F403B05" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31AB8ADDA79C4F28DC16879B8F3F28C8" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_07B60DAF7F6203D86D80879B8F400204" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:to="loc_biib_ShareOfCoPromotionProfits_07B60DAF7F6203D86D80879B8F400204" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_F10531905BAD2DEC4679879B8F410A20" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_F10531905BAD2DEC4679879B8F410A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_37219C160D5D7E34ECBA879B8F419AB8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:to="loc_us-gaap_Revenues_37219C160D5D7E34ECBA879B8F419AB8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3CC54346996AC5A01C67AAF0BE32FFF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3CC54346996AC5A01C67AAF0BE32FFF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78269978E45E67E54770AAF0BE327C28_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3CC54346996AC5A01C67AAF0BE32FFF0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78269978E45E67E54770AAF0BE327C28_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78269978E45E67E54770AAF0BE327C28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3CC54346996AC5A01C67AAF0BE32FFF0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78269978E45E67E54770AAF0BE327C28" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_2645383C696129BC9889AAF0BE33F27B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78269978E45E67E54770AAF0BE327C28" xlink:to="loc_biib_IonisPharmaceuticalsMember_2645383C696129BC9889AAF0BE33F27B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E9F54A1ED70D45A8D009AAF0BE33C891" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_srt_RangeAxis_E9F54A1ED70D45A8D009AAF0BE33C891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A7C9F55A9A039E5D733AAAF0BE334BAF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_E9F54A1ED70D45A8D009AAF0BE33C891" xlink:to="loc_srt_RangeMember_A7C9F55A9A039E5D733AAAF0BE334BAF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A7C9F55A9A039E5D733AAAF0BE334BAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_E9F54A1ED70D45A8D009AAF0BE33C891" xlink:to="loc_srt_RangeMember_A7C9F55A9A039E5D733AAAF0BE334BAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C61849FCD02A5BA1EA61AAF0BE33AE76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A7C9F55A9A039E5D733AAAF0BE334BAF" xlink:to="loc_srt_MinimumMember_C61849FCD02A5BA1EA61AAF0BE33AE76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_DB174B46F0F6975D39A3AAF0BE348FCE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_A7C9F55A9A039E5D733AAAF0BE334BAF" xlink:to="loc_srt_MaximumMember_DB174B46F0F6975D39A3AAF0BE348FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_993F2FEA281716DE3CF3AAF0BE34168A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_993F2FEA281716DE3CF3AAF0BE34168A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9ACF16EC421DBF2DB14AAAF0BE346235_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_993F2FEA281716DE3CF3AAF0BE34168A" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9ACF16EC421DBF2DB14AAAF0BE346235_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9ACF16EC421DBF2DB14AAAF0BE346235" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_993F2FEA281716DE3CF3AAF0BE34168A" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9ACF16EC421DBF2DB14AAAF0BE346235" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_C9EA46374284C24E6922AAF0BE3515EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9ACF16EC421DBF2DB14AAAF0BE346235" xlink:to="loc_biib_U.S.2017TaxActMember_C9EA46374284C24E6922AAF0BE3515EF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:to="loc_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:to="loc_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:to="loc_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:to="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:to="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeventeenbillionMember" xlink:label="loc_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EighteenbillionMember" xlink:label="loc_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NineteenbillionMember" xlink:label="loc_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TwentybillionMember" xlink:label="loc_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1A5B8CCF3FC0A8D1E534AAF0BE38813C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_srt_ProductOrServiceAxis_1A5B8CCF3FC0A8D1E534AAF0BE38813C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C9D917D9D9587C8E7F5DAAF0BE38498D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1A5B8CCF3FC0A8D1E534AAF0BE38813C" xlink:to="loc_srt_ProductsAndServicesDomain_C9D917D9D9587C8E7F5DAAF0BE38498D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C9D917D9D9587C8E7F5DAAF0BE38498D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1A5B8CCF3FC0A8D1E534AAF0BE38813C" xlink:to="loc_srt_ProductsAndServicesDomain_C9D917D9D9587C8E7F5DAAF0BE38498D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_0B1669461C01F1D13BA1AAF0BE39B554" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_C9D917D9D9587C8E7F5DAAF0BE38498D" xlink:to="loc_biib_SPINRAZAMember_0B1669461C01F1D13BA1AAF0BE39B554" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_52ACCAF6D018BC605B05AAF0BE3936E2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_C9D917D9D9587C8E7F5DAAF0BE38498D" xlink:to="loc_biib_TecfideraMember_52ACCAF6D018BC605B05AAF0BE3936E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:to="loc_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:to="loc_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:to="loc_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_A94A8C1E831B0B3D9314AAF0BE3A6FD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:to="loc_biib_TysabriProductMember_A94A8C1E831B0B3D9314AAF0BE3A6FD3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:to="loc_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_A8F6E4A804E642E423CDAAF0BE3C61B5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_A8F6E4A804E642E423CDAAF0BE3C61B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_BCC8DC555DA5393CF9F1AAF0BE3CF190" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_BCC8DC555DA5393CF9F1AAF0BE3CF190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9186C404A07B9A2B3FF2AAF0BE3CC3F8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9186C404A07B9A2B3FF2AAF0BE3CC3F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_C8D79B28FD49986FB206AAF0BE3D62E0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_C8D79B28FD49986FB206AAF0BE3D62E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_721BD7B6448C22CDB262AAF0BE3D5FFA" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_721BD7B6448C22CDB262AAF0BE3D5FFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_5E237F151E04112ECB7AAAF0BE3D260C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_us-gaap_OtherCommitment_5E237F151E04112ECB7AAAF0BE3D260C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_3E439E495CA0D89E198FAAF0BE3DF5FC" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_3E439E495CA0D89E198FAAF0BE3DF5FC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment" xlink:label="loc_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_A00F65DE60517BFACC48AAF0BE3E2205" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_A00F65DE60517BFACC48AAF0BE3E2205" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_564193E18F71F1405FD4BEA935E896CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StatementTable_564193E18F71F1405FD4BEA935E896CA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_564193E18F71F1405FD4BEA935E896CA" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:to="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:to="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_A6A4CE3078804B96EFD2BEA935E815CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_A6A4CE3078804B96EFD2BEA935E815CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_40CEB1B326CF200A25D8BEA935E843A2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_40CEB1B326CF200A25D8BEA935E843A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_564193E18F71F1405FD4BEA935E896CA" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:to="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_564193E18F71F1405FD4BEA935E896CA" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147" xlink:to="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147" xlink:to="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_676448E329BA1A005448BEA935E80321" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_PreferredStockMember_676448E329BA1A005448BEA935E80321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4A6F300C0B6C754118B4BEA935E81111" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_CommonStockMember_4A6F300C0B6C754118B4BEA935E81111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_E7BE87ADEFC28AEA2BF7BEA935E83D19" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_E7BE87ADEFC28AEA2BF7BEA935E83D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2816504ECE1A0C3E7C93BEA935E81103" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2816504ECE1A0C3E7C93BEA935E81103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_315D7967BEBE0461F083BEA935E84111" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_RetainedEarningsMember_315D7967BEBE0461F083BEA935E84111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_83AA5E2DD5D0789767E0BEA935E8C267" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_TreasuryStockMember_83AA5E2DD5D0789767E0BEA935E8C267" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4072C6FA12949A504B14BEA935E876A9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4072C6FA12949A504B14BEA935E876A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_D97CE59D73B8D9DCCBD1BEA935E8AF85" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_ParentMember_D97CE59D73B8D9DCCBD1BEA935E8AF85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B3A28ABC0642BC585918BEA935E838B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B3A28ABC0642BC585918BEA935E838B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21810C9AF8789DDA346EBEA935E831D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockholdersEquity_21810C9AF8789DDA346EBEA935E831D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_C6FD245C9DA27BD1802DBEA935E879AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_MinorityInterest_C6FD245C9DA27BD1802DBEA935E879AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_D8E5C0EEA0FAF864D0E5BEA935E81561" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_SharesIssued_D8E5C0EEA0FAF864D0E5BEA935E81561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C8F097647F1A2D0CDDD9BEA935E8BF25" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_NetIncomeLoss_C8F097647F1A2D0CDDD9BEA935E8BF25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_919BC1A9374A2114B4C7BEA935E8366C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_919BC1A9374A2114B4C7BEA935E8366C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_0CB76C4329757462C18EBEA935E87F8D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_ProfitLoss_0CB76C4329757462C18EBEA935E87F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_EDEF1460C9F4FC4CDDDCBEA935E832AC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_EDEF1460C9F4FC4CDDDCBEA935E832AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_A1947E815E7759D32962BEA935E8534F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_A1947E815E7759D32962BEA935E8534F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_52C39A65D660DB860E0ABEA935E88686" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_52C39A65D660DB860E0ABEA935E88686" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1D4CDFE794E9F79C523CBEA935E8023E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1D4CDFE794E9F79C523CBEA935E8023E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_EA2036AF5B4AE50D8491BEA935E87AAD" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_EA2036AF5B4AE50D8491BEA935E87AAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_B5902399AF7A2C6AD8E4BEA935E82EEA" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_B5902399AF7A2C6AD8E4BEA935E82EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_E0715961E30054932DEDBEA935E86539" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_E0715961E30054932DEDBEA935E86539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_C64BBA340DFF5B5E5F1ABEA935E8AC38" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_C64BBA340DFF5B5E5F1ABEA935E8AC38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0450C0A497C33A1BFD87BEA935E8A137" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0450C0A497C33A1BFD87BEA935E8A137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_818FDA9F98BAA96EDD81BEA935E8A5FA" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_818FDA9F98BAA96EDD81BEA935E8A5FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_33C341D21105DAE2D569BEA935E8BD73" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_33C341D21105DAE2D569BEA935E8BD73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_23949AB60D46A31FAFE0BEA935E89A94" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_23949AB60D46A31FAFE0BEA935E89A94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32FDD7B45BC6879A0AC3BEA935E88688" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32FDD7B45BC6879A0AC3BEA935E88688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D13269CA51CC19B59FA8BEA935E83DB6" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D13269CA51CC19B59FA8BEA935E83DB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_4A61E75423D14EE35552BEA935E86755" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_4A61E75423D14EE35552BEA935E86755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B515ABE2CDC493AC442EBEA935E8D8F0" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B515ABE2CDC493AC442EBEA935E8D8F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_E99307A48167E6A1AD15BEA935E8B2B0" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockholdersEquityOther_E99307A48167E6A1AD15BEA935E8B2B0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_036B1B7979592B5E720DC427E6B9856A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_CC6E97F1214A7B2D2597C427E6A9DEB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_036B1B7979592B5E720DC427E6B9856A" xlink:to="loc_us-gaap_StatementTable_CC6E97F1214A7B2D2597C427E6A9DEB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_AEB3D162742CFD09DD47C427E6B93349" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_CC6E97F1214A7B2D2597C427E6A9DEB2" xlink:to="loc_srt_ProductOrServiceAxis_AEB3D162742CFD09DD47C427E6B93349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_AEB3D162742CFD09DD47C427E6B93349" xlink:to="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_AEB3D162742CFD09DD47C427E6B93349" xlink:to="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_0C7BB28D960696FE62DEC427E6B9E6D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB" xlink:to="loc_us-gaap_ProductMember_0C7BB28D960696FE62DEC427E6B9E6D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_A5D6A55220DA82EB604CC427E6B9D7AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_A5D6A55220DA82EB604CC427E6B9D7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_A7259BB565CFF2B20ED7C427E6B98A74" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_A7259BB565CFF2B20ED7C427E6B98A74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BD8048F51827851395F3C427E6B91413" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_036B1B7979592B5E720DC427E6B9856A" xlink:to="loc_us-gaap_Revenues_BD8048F51827851395F3C427E6B91413" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C817618481E136D6C309871CAEFC2DC7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_94CABCCFF37C2438487F871CAEEC005A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C817618481E136D6C309871CAEFC2DC7" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_94CABCCFF37C2438487F871CAEEC005A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AAF7CAC9EEB60A654C41871CAEEC97CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_94CABCCFF37C2438487F871CAEEC005A" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AAF7CAC9EEB60A654C41871CAEEC97CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_BA1B7BDA84EA7C324C14871CAEEC4813_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AAF7CAC9EEB60A654C41871CAEEC97CF" xlink:to="loc_us-gaap_HedgingRelationshipDomain_BA1B7BDA84EA7C324C14871CAEEC4813_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_BA1B7BDA84EA7C324C14871CAEEC4813" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AAF7CAC9EEB60A654C41871CAEEC97CF" xlink:to="loc_us-gaap_HedgingRelationshipDomain_BA1B7BDA84EA7C324C14871CAEEC4813" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_BA1B7BDA84EA7C324C14871CAEEC4813" xlink:to="loc_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_BA1B7BDA84EA7C324C14871CAEEC4813" xlink:to="loc_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_02839475FA8BBD1114C9871CAEEC052E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_94CABCCFF37C2438487F871CAEEC005A" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_02839475FA8BBD1114C9871CAEEC052E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_801455F14FD530CD9C95871CAEECB09F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_02839475FA8BBD1114C9871CAEEC052E" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_801455F14FD530CD9C95871CAEECB09F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_801455F14FD530CD9C95871CAEECB09F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_02839475FA8BBD1114C9871CAEEC052E" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_801455F14FD530CD9C95871CAEECB09F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_DF34A932E02F81432AD0871CAEEC7380" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_801455F14FD530CD9C95871CAEECB09F" xlink:to="loc_us-gaap_ForeignExchangeContractMember_DF34A932E02F81432AD0871CAEEC7380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_94CABCCFF37C2438487F871CAEEC005A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_C6F6570C99D47EE72D83871CAEEC7993" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:to="loc_us-gaap_SalesMember_C6F6570C99D47EE72D83871CAEEC7993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_E8B2AE9C7F24A5312967871CAEEC5290" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_E8B2AE9C7F24A5312967871CAEEC5290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_D869782E41FEB90B9C56871CAEECE589" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:to="loc_us-gaap_OperatingExpenseMember_D869782E41FEB90B9C56871CAEECE589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_93357D0A4A023B9C3069871CAEFCE4A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C817618481E136D6C309871CAEFC2DC7" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_93357D0A4A023B9C3069871CAEFCE4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_19B689CB7EF4F33B2B78871CAEFCE977" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_93357D0A4A023B9C3069871CAEFCE4A9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_19B689CB7EF4F33B2B78871CAEFCE977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_1EAEA9B2EAB4E9E9B7E1871CAEFC4351" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_93357D0A4A023B9C3069871CAEFCE4A9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_1EAEA9B2EAB4E9E9B7E1871CAEFC4351" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_208410C75C6E94305840BEA934A0A476" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_208410C75C6E94305840BEA934A0A476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8FD813BA0DD3BB8D9CF7BEA934A08DB3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_208410C75C6E94305840BEA934A0A476" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8FD813BA0DD3BB8D9CF7BEA934A08DB3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8FD813BA0DD3BB8D9CF7BEA934A08DB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_208410C75C6E94305840BEA934A0A476" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8FD813BA0DD3BB8D9CF7BEA934A08DB3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_39614066FBF97278E804BEA934A07550" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8FD813BA0DD3BB8D9CF7BEA934A08DB3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_39614066FBF97278E804BEA934A07550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B804D6C4411AF30C3E58BEA934A0B73C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B804D6C4411AF30C3E58BEA934A0B73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A9E9CCD51CE376A5359FBEA934A0BC6A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B804D6C4411AF30C3E58BEA934A0B73C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A9E9CCD51CE376A5359FBEA934A0BC6A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A9E9CCD51CE376A5359FBEA934A0BC6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B804D6C4411AF30C3E58BEA934A0B73C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A9E9CCD51CE376A5359FBEA934A0BC6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9E8404FF715FA6A72733BEA934A06183" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A9E9CCD51CE376A5359FBEA934A0BC6A" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9E8404FF715FA6A72733BEA934A06183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_AF12D11D918CBEE3C755BEA934A0EE29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_AF12D11D918CBEE3C755BEA934A0EE29" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome" xlink:label="loc_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3EB79747A7C22FCF0916BEA934A01F61" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3EB79747A7C22FCF0916BEA934A01F61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE5FB99F83081754A9D9BEA934A06CE2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE5FB99F83081754A9D9BEA934A06CE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_25BE98B32CF7FDA69D5EBEA934A08B8F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_25BE98B32CF7FDA69D5EBEA934A08B8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_E661007B628CD0A79E25BEA934A00AE3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_DerivativeTermOfContract_E661007B628CD0A79E25BEA934A00AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_7F26874ECECDAA030A9ABEA934A0A96C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_7F26874ECECDAA030A9ABEA934A0A96C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B923F97609D2307DC156BEA934A04A25" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B923F97609D2307DC156BEA934A04A25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6C4F32441DCBBD99E9C8BEA934A0D70A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6C4F32441DCBBD99E9C8BEA934A0D70A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax" xlink:label="loc_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_48F8E5239C4FF64A3A6F85B86DF5C567" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48F8E5239C4FF64A3A6F85B86DF5C567" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:to="loc_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:to="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:to="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_6E1C035303AC81FCBFE085B86DF2427B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:to="loc_currency_EUR_6E1C035303AC81FCBFE085B86DF2427B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_F267BA6DBDABB01CE10E85B86DF2AA53" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:to="loc_currency_GBP_F267BA6DBDABB01CE10E85B86DF2AA53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_B7153F14C5BDA2F4F75A85B86DF2B746" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:to="loc_currency_CHF_B7153F14C5BDA2F4F75A85B86DF2B746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_29874C30C7DB074B1E6F85B86DF27DF8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:to="loc_currency_CAD_29874C30C7DB074B1E6F85B86DF27DF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_40D6799B7FDC2EA731DE85B86DF26E5D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:to="loc_currency_JPY_40D6799B7FDC2EA731DE85B86DF26E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_A1E580399FD1869E51DC85B86DF2AD48" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_A1E580399FD1869E51DC85B86DF2AD48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_002ED51D95B9F66E896A85B86DF248AB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_A1E580399FD1869E51DC85B86DF2AD48" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_002ED51D95B9F66E896A85B86DF248AB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_002ED51D95B9F66E896A85B86DF248AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_A1E580399FD1869E51DC85B86DF2AD48" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_002ED51D95B9F66E896A85B86DF248AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ED11FFB986B7C57419E085B86DF25257" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_002ED51D95B9F66E896A85B86DF248AB" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ED11FFB986B7C57419E085B86DF25257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_182D2E2E0F26388AF8C985B86DF21243" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_182D2E2E0F26388AF8C985B86DF21243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_182D2E2E0F26388AF8C985B86DF21243" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_182D2E2E0F26388AF8C985B86DF21243" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_6A4B30954AE40BE3999B85B86DF5380B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_6A4B30954AE40BE3999B85B86DF5380B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_2C93E3F016956706679B85B86DF5C616" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:to="loc_us-gaap_OtherInvestmentsMember_2C93E3F016956706679B85B86DF5C616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_D1B3B2D001A7B6D41B9F85B86DF59FA5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_D1B3B2D001A7B6D41B9F85B86DF59FA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_02F6C9D6F379F31EE56E85B86DF5695E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_02F6C9D6F379F31EE56E85B86DF5695E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_D581A33EB830DEC5290085B86DF5EFE2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:to="loc_us-gaap_HedgingDesignationAxis_D581A33EB830DEC5290085B86DF5EFE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_257C68516AEAC586B87385B86DF50761_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_D581A33EB830DEC5290085B86DF5EFE2" xlink:to="loc_us-gaap_HedgingDesignationDomain_257C68516AEAC586B87385B86DF50761_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_257C68516AEAC586B87385B86DF50761" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_D581A33EB830DEC5290085B86DF5EFE2" xlink:to="loc_us-gaap_HedgingDesignationDomain_257C68516AEAC586B87385B86DF50761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_EB666E96A473AF47110985B86DF545D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_257C68516AEAC586B87385B86DF50761" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_EB666E96A473AF47110985B86DF545D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_69C8D6AB4E5F2E44BC4385B86DF5CC06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_257C68516AEAC586B87385B86DF50761" xlink:to="loc_us-gaap_NondesignatedMember_69C8D6AB4E5F2E44BC4385B86DF5CC06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_04AD4C1D01209168DB6185B86DF76D2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48F8E5239C4FF64A3A6F85B86DF5C567" xlink:to="loc_invest_DerivativeNotionalAmount_04AD4C1D01209168DB6185B86DF76D2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48F8E5239C4FF64A3A6F85B86DF5C567" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D3FE90E69FDDE0AEDE1485B86DF79004" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D3FE90E69FDDE0AEDE1485B86DF79004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A307498D2B92C7BB6EDC85B86DF7610A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A307498D2B92C7BB6EDC85B86DF7610A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E3233F0F7B6BD3C0C20E9528E9CD6B3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E3233F0F7B6BD3C0C20E9528E9CD6B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_76A77596DAE9134DD1EF9528E9CD0325_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E3233F0F7B6BD3C0C20E9528E9CD6B3E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_76A77596DAE9134DD1EF9528E9CD0325_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_76A77596DAE9134DD1EF9528E9CD0325" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E3233F0F7B6BD3C0C20E9528E9CD6B3E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_76A77596DAE9134DD1EF9528E9CD0325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_99474D6FA190F71B29169528E9CDE3DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_76A77596DAE9134DD1EF9528E9CD0325" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_99474D6FA190F71B29169528E9CDE3DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DC030F23841D7B02D56D9528E9CDF557" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="loc_srt_RangeAxis_DC030F23841D7B02D56D9528E9CDF557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FBCA5B7F73F5B506B3289528E9CD96B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_DC030F23841D7B02D56D9528E9CDF557" xlink:to="loc_srt_RangeMember_FBCA5B7F73F5B506B3289528E9CD96B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FBCA5B7F73F5B506B3289528E9CD96B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_DC030F23841D7B02D56D9528E9CDF557" xlink:to="loc_srt_RangeMember_FBCA5B7F73F5B506B3289528E9CD96B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4D4C3B7C23F90203DEAD9528E9CD6BFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_FBCA5B7F73F5B506B3289528E9CD96B7" xlink:to="loc_srt_MinimumMember_4D4C3B7C23F90203DEAD9528E9CD6BFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1F5AF6EBC4AA672BBB1D9528E9CD3732" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_FBCA5B7F73F5B506B3289528E9CD96B7" xlink:to="loc_srt_MaximumMember_1F5AF6EBC4AA672BBB1D9528E9CD3732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_47E6D227B8DFB7A5C8FE9528E9CDC80E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="loc_us-gaap_DebtInstrumentAxis_47E6D227B8DFB7A5C8FE9528E9CDC80E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_20718CA2424E3C4CDC819528E9CD64DD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_47E6D227B8DFB7A5C8FE9528E9CDC80E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_20718CA2424E3C4CDC819528E9CD64DD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_20718CA2424E3C4CDC819528E9CD64DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_47E6D227B8DFB7A5C8FE9528E9CDC80E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_20718CA2424E3C4CDC819528E9CD64DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E520FC9A21D1022A524D9528E9CD1835" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_20718CA2424E3C4CDC819528E9CD64DD" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E520FC9A21D1022A524D9528E9CD1835" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3348034A14D8872779769528E9CD5ADF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3348034A14D8872779769528E9CD5ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_A7DC4803D999694C26CC9528E9CD255F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3348034A14D8872779769528E9CD5ADF" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_A7DC4803D999694C26CC9528E9CD255F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_A7DC4803D999694C26CC9528E9CD255F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3348034A14D8872779769528E9CD5ADF" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_A7DC4803D999694C26CC9528E9CD255F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_9A226D5BBF247CE7BFC99528E9CD8616" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_A7DC4803D999694C26CC9528E9CD255F" xlink:to="loc_us-gaap_ForeignExchangeContractMember_9A226D5BBF247CE7BFC99528E9CD8616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_62F7D8DC7195C9FB59D09528E9CDB313" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_A7DC4803D999694C26CC9528E9CD255F" xlink:to="loc_us-gaap_InterestRateSwapMember_62F7D8DC7195C9FB59D09528E9CDB313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="loc_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:to="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:to="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_E8ADDF7A8A39AE13082D9528E9CDCA35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_E8ADDF7A8A39AE13082D9528E9CDCA35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_3059A7B811A8666D67429528E9DDE19D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:to="loc_us-gaap_NondesignatedMember_3059A7B811A8666D67429528E9DDE19D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0E882B7D6C3B4FC48F159528E9DD89EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0E882B7D6C3B4FC48F159528E9DD89EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_3ABEDB1D4363B3EB56DF9528E9DDD6B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_3ABEDB1D4363B3EB56DF9528E9DDD6B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_A310A46F5666B56A92E49528E9DDADF2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_A310A46F5666B56A92E49528E9DDADF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_9527B950AA5D5D88E6089528E9DDB6C3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="loc_invest_DerivativeNotionalAmount_9527B950AA5D5D88E6089528E9DDB6C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4A3014FAA4345F000B489528E9DD527E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4A3014FAA4345F000B489528E9DD527E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_7D82A6EE827ECF7308E51B42317A8471" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:to="loc_biib_MarketStockUnitsMember_7D82A6EE827ECF7308E51B42317A8471" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:to="loc_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4FB80642D5432BA66DDA1B42317BBBDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:to="loc_us-gaap_NetIncomeLoss_4FB80642D5432BA66DDA1B42317BBBDC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:to="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CDE9D59C1BBA940C8B371B42317CD2C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CDE9D59C1BBA940C8B371B42317CD2C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7BA198FD7F225FD026581B42317C88CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7BA198FD7F225FD026581B42317C88CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7730638B4D42DD8B239B1B42317C471F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7730638B4D42DD8B239B1B42317C471F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C0DC5601CA22E30D01B01B42317D95B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C0DC5601CA22E30D01B01B42317D95B3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6EE7D7B4EECC9966F79F85B86951B680" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6EE7D7B4EECC9966F79F85B86951B680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E41A0ED059CA45BC605285B86951CB52_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6EE7D7B4EECC9966F79F85B86951B680" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E41A0ED059CA45BC605285B86951CB52_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E41A0ED059CA45BC605285B86951CB52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6EE7D7B4EECC9966F79F85B86951B680" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E41A0ED059CA45BC605285B86951CB52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ED48F7527E18F18551B585B8695187AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E41A0ED059CA45BC605285B86951CB52" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ED48F7527E18F18551B585B8695187AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_25D9E3CB178D61BD052285B86951DDE5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_25D9E3CB178D61BD052285B86951DDE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_DB2BAEDF3B9C3F6AFDEA85B86951BEE5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_25D9E3CB178D61BD052285B86951DDE5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_DB2BAEDF3B9C3F6AFDEA85B86951BEE5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_DB2BAEDF3B9C3F6AFDEA85B86951BEE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_25D9E3CB178D61BD052285B86951DDE5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_DB2BAEDF3B9C3F6AFDEA85B86951BEE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_BCA680E5B7A5875DC7EA85B86951E847" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_DB2BAEDF3B9C3F6AFDEA85B86951BEE5" xlink:to="loc_us-gaap_ForeignPlanMember_BCA680E5B7A5875DC7EA85B86951E847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_0CAE55603C97D697870E85B86954C962" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:to="loc_srt_StatementGeographicalAxis_0CAE55603C97D697870E85B86954C962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_8A38B53000B6D834E8C585B869548ED7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0CAE55603C97D697870E85B86954C962" xlink:to="loc_srt_SegmentGeographicalDomain_8A38B53000B6D834E8C585B869548ED7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_8A38B53000B6D834E8C585B869548ED7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0CAE55603C97D697870E85B86954C962" xlink:to="loc_srt_SegmentGeographicalDomain_8A38B53000B6D834E8C585B869548ED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CH" xlink:label="loc_country_CH_2E64B705FB38519EC1D485B8695449F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8A38B53000B6D834E8C585B869548ED7" xlink:to="loc_country_CH_2E64B705FB38519EC1D485B8695449F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE_33BAC3AC326344454C8085B86954288C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8A38B53000B6D834E8C585B869548ED7" xlink:to="loc_country_DE_33BAC3AC326344454C8085B86954288C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7" xlink:to="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_EA76DB53F26E71E476F085B869542DEE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_EA76DB53F26E71E476F085B869542DEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_EFDD288999DC9B1A742785B86954014E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_EFDD288999DC9B1A742785B86954014E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_DAF7702E3593DE38B1DB85B86954B01C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:to="loc_us-gaap_PensionExpense_DAF7702E3593DE38B1DB85B86954B01C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9FF8F32787C6A241CA7C85B8695469F7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9FF8F32787C6A241CA7C85B8695469F7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:to="loc_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_F6FB18484EDF9687EB2CFBB8354A4E33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:to="loc_us-gaap_DomesticPlanMember_F6FB18484EDF9687EB2CFBB8354A4E33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_D1881BAAA9C582775BBDFBB8355A615F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_D1881BAAA9C582775BBDFBB8355A615F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_342EE3B076DB9788D770FBB8355A2827" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_342EE3B076DB9788D770FBB8355A2827" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_9FDDAD8ED5A86DFF79E6FBB8355AEC8C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_9FDDAD8ED5A86DFF79E6FBB8355AEC8C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_3BD7DCDDF7EB544114F4F08E8DAC61AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_3BD7DCDDF7EB544114F4F08E8DAC61AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3BD7DCDDF7EB544114F4F08E8DAC61AF" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3BD7DCDDF7EB544114F4F08E8DAC61AF" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_B1F1D17A3047A92BE572F08E8DAD3AFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_B1F1D17A3047A92BE572F08E8DAD3AFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_BD6A4F12A249553058E6F08E8DADD161" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_BD6A4F12A249553058E6F08E8DADD161" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_8CA9322E5C642F270813F08E8DAED220" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_8CA9322E5C642F270813F08E8DAED220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:to="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:to="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_265EA70ACE5F61B58D9CF08E8DAEFBBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_265EA70ACE5F61B58D9CF08E8DAEFBBE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:to="loc_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:to="loc_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_BD10F5F9365B2E165597F08E8DAF49A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_BD10F5F9365B2E165597F08E8DAF49A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57AF56549937017ED815F08E8DAF4125" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57AF56549937017ED815F08E8DAF4125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D13B12D16E48FBEA3E6FF08E8DAF4262" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D13B12D16E48FBEA3E6FF08E8DAF4262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8A5CA08ECF7876DB5ABDF08E8DAFB97A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8A5CA08ECF7876DB5ABDF08E8DAFB97A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_69397A0D8C4D84252910F08E8DB01213" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_69397A0D8C4D84252910F08E8DB01213" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_BF4CA95502686F6FA551856979DE57F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_BF4CA95502686F6FA551856979DE57F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_33C96FDB34BF36636531856979DE92AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_33C96FDB34BF36636531856979DE92AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DF8CDD197393BB2DA399856979DE7F7B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_DF8CDD197393BB2DA399856979DE7F7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_130A17EFBA445A59D9C2856979DEF415" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_130A17EFBA445A59D9C2856979DEF415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_63FF60E3969F05EF1A24856979DE61A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_63FF60E3969F05EF1A24856979DE61A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8241B7CEFD7D29AA8138856979DEB9FB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8241B7CEFD7D29AA8138856979DEB9FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_A0FB2246699BCE3029DC856979DEC200" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_A0FB2246699BCE3029DC856979DEC200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00BC73A33F900423B68C85989679F23E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00BC73A33F900423B68C85989679F23E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_FBFBD586A433708BC553859896791D71" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:to="loc_us-gaap_AvailableForSaleSecurities_FBFBD586A433708BC553859896791D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_71B11F052A44D12BFCD6859896790A20" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_71B11F052A44D12BFCD6859896790A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_16085048B54916CDFA8985989679B4D7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_16085048B54916CDFA8985989679B4D7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8D7611769C52AC74030585989679C120" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8D7611769C52AC74030585989679C120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3F4ECB1205CC92DA471D85989679D9F1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3F4ECB1205CC92DA471D85989679D9F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_87E98CA7A716947DBBDD85989679EAD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_87E98CA7A716947DBBDD85989679EAD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4D02AD3CE3AF6864706585989679D5B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4D02AD3CE3AF6864706585989679D5B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_08A3591744B065CD37EA859896798440" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_08A3591744B065CD37EA859896798440" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2A6067A7C02C17A51B0015EAEE277243" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_403A532001F32AE34A9F15EAEE24BDEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2A6067A7C02C17A51B0015EAEE277243" xlink:to="loc_us-gaap_DebtInstrumentTable_403A532001F32AE34A9F15EAEE24BDEA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1F3B3F2758F7BACC347E15EAEE244497" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_403A532001F32AE34A9F15EAEE24BDEA" xlink:to="loc_us-gaap_DebtInstrumentAxis_1F3B3F2758F7BACC347E15EAEE244497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1F3B3F2758F7BACC347E15EAEE244497" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1F3B3F2758F7BACC347E15EAEE244497" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_BD313C80B2887C0882A215EAEE2592A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_NotesPayableToFumedicaMember_BD313C80B2887C0882A215EAEE2592A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_12237A0908995186D1B515EAEE2638D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_12237A0908995186D1B515EAEE2638D3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_CA12EF73085A6BC179E415EAEE27E9CE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_CA12EF73085A6BC179E415EAEE27E9CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_7E3FD2505356A6FEFB2315EAEE2722C8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_7E3FD2505356A6FEFB2315EAEE2722C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_B6DB5710CCB08F32A38415EAEE27691E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_B6DB5710CCB08F32A38415EAEE27691E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_BEB9044DA01D891760F215EAEE27F44A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_BEB9044DA01D891760F215EAEE27F44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_AA27A4982560CDE6093D15EB0DF5DD9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2A6067A7C02C17A51B0015EAEE277243" xlink:to="loc_us-gaap_NotesPayable_AA27A4982560CDE6093D15EB0DF5DD9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_35CCFEC190CD0195405C15EAEE274459" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2A6067A7C02C17A51B0015EAEE277243" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_35CCFEC190CD0195405C15EAEE274459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_E3DB9CD907F742A4C82515EAEE286909" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2A6067A7C02C17A51B0015EAEE277243" xlink:to="loc_us-gaap_DebtInstrumentFairValue_E3DB9CD907F742A4C82515EAEE286909" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FFD03351B4924822000EFBB83357CE05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_B1F55CE161F222BA7D3BFBB833573531" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FFD03351B4924822000EFBB83357CE05" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_B1F55CE161F222BA7D3BFBB833573531" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3DB73607DB1235539207FBB8335741A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_B1F55CE161F222BA7D3BFBB833573531" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3DB73607DB1235539207FBB8335741A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_D8B37431A0560AE3DA2AFBB8335775B2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3DB73607DB1235539207FBB8335741A7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_D8B37431A0560AE3DA2AFBB8335775B2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_D8B37431A0560AE3DA2AFBB8335775B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3DB73607DB1235539207FBB8335741A7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_D8B37431A0560AE3DA2AFBB8335775B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_83D5705D8F713B6D4944FBB83357AD3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_D8B37431A0560AE3DA2AFBB8335775B2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_83D5705D8F713B6D4944FBB83357AD3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_C3F3680555D1EF7722A1FBB83357F701" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FFD03351B4924822000EFBB83357CE05" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_C3F3680555D1EF7722A1FBB83357F701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C65CAEE7547892987B36FBB8335759A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FFD03351B4924822000EFBB83357CE05" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C65CAEE7547892987B36FBB8335759A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E2AAEEAD128945B830E7FBB833574EF7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FFD03351B4924822000EFBB83357CE05" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E2AAEEAD128945B830E7FBB833574EF7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_A2575B97CAEB53410AF7C428287AE3F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_A2575B97CAEB53410AF7C428287AE3F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9516F6ED04EDDE400283C428287A69F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9516F6ED04EDDE400283C428287A69F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_31C856BBE0399F18CA0EC42828808937" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_31C856BBE0399F18CA0EC42828808937" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9DBF5A3D86AA038AA277C42828809A6B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:to="loc_us-gaap_DebtInstrumentAxis_9DBF5A3D86AA038AA277C42828809A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9DBF5A3D86AA038AA277C42828809A6B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9DBF5A3D86AA038AA277C42828809A6B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FFAB83D2B615E34C9B26C42828804C4B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FFAB83D2B615E34C9B26C42828804C4B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_13396646A486C10B984EC42828819B7A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_13396646A486C10B984EC42828819B7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6B90E14F3BA63F91B518C4282881A985" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6B90E14F3BA63F91B518C4282881A985" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3F82DDFFCE035DA332FBC42828810B8E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3F82DDFFCE035DA332FBC42828810B8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_80D0C42A0DB8030BE5A5C4282881946A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_80D0C42A0DB8030BE5A5C4282881946A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_22AA76EECFE757A6DAC5C4282881E3AA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_22AA76EECFE757A6DAC5C4282881E3AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22AA76EECFE757A6DAC5C4282881E3AA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22AA76EECFE757A6DAC5C4282881E3AA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6" xlink:to="loc_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs" xlink:label="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_D9F6B99D4EA5B87B08E7C4282883ED11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_D9F6B99D4EA5B87B08E7C4282883ED11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_75A683E891D32F0EC961C428288319DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_75A683E891D32F0EC961C428288319DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_27FFB555BBB297BDA7D8C428288361CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_27FFB555BBB297BDA7D8C428288361CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_547E05EA3F5DCB401D46C4282883BF8E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_547E05EA3F5DCB401D46C4282883BF8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E5C2485A0F79A69E1955C428288311C8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E5C2485A0F79A69E1955C428288311C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DE60CAC41064659E7E9FC4282883CC99" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DE60CAC41064659E7E9FC4282883CC99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D98E3419CA04DC6ED8B1C428288405B2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D98E3419CA04DC6ED8B1C428288405B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0817AE28A7926C65B7D5C42828842896" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0817AE28A7926C65B7D5C42828842896" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FairValueMeasurementInputs" xlink:label="loc_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_01BA80D7D419BE818764C428288991AA" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_01BA80D7D419BE818764C428288991AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_D467EF56530447488FC5C4693F79BFD0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_D467EF56530447488FC5C4693F79BFD0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:to="loc_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_55E5CEFBC90F8A881B6EFBB8318394D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:to="loc_us-gaap_CommercialPaperMember_55E5CEFBC90F8A881B6EFBB8318394D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_DA766CB27C0916BFF105FBB831839EA7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_DA766CB27C0916BFF105FBB831839EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8C601A1DC98AB976BD99FBB831831E37" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8C601A1DC98AB976BD99FBB831831E37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_B98401EBCF763140C03BFBB83183B5D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:to="loc_us-gaap_DebtSecuritiesMember_B98401EBCF763140C03BFBB83183B5D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_2DF9BE93E2C2BBED5EF5FBB83183AB8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_2DF9BE93E2C2BBED5EF5FBB83183AB8A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_398FB41B4EB3D0C18E75FBB8354AD187" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:to="loc_us-gaap_FinancialInstrumentAxis_398FB41B4EB3D0C18E75FBB8354AD187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_398FB41B4EB3D0C18E75FBB8354AD187" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_398FB41B4EB3D0C18E75FBB8354AD187" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_173856A12C214767B3E5FBB8354AE79C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_us-gaap_EquitySecuritiesMember_173856A12C214767B3E5FBB8354AE79C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_BAF7AD63A6A29D4B02B2FBB8354AD81B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:to="loc_us-gaap_AvailableForSaleSecurities_BAF7AD63A6A29D4B02B2FBB8354AD81B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48E33846BD45237179D8FBB8354A836D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48E33846BD45237179D8FBB8354A836D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22DE47C8A8E5383E6FD9FBB8354A73D2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22DE47C8A8E5383E6FD9FBB8354A73D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_9CCEBFA467FDA88E1CFFFBB8354A00D7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_9CCEBFA467FDA88E1CFFFBB8354A00D7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5B8A6BA7EFF603E7095EAAF0C05B3BB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5B8A6BA7EFF603E7095EAAF0C05B3BB1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5B8A6BA7EFF603E7095EAAF0C05B3BB1" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_52EEBEE6F45428030C07AAF0C05CA749" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_52EEBEE6F45428030C07AAF0C05CA749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_16713D2FFE3E777F7C3DAAF0C05CA48A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5B8A6BA7EFF603E7095EAAF0C05B3BB1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_16713D2FFE3E777F7C3DAAF0C05CA48A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D752D7309BD70554567AAF0C05C9679_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_16713D2FFE3E777F7C3DAAF0C05CA48A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D752D7309BD70554567AAF0C05C9679_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D752D7309BD70554567AAF0C05C9679" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_16713D2FFE3E777F7C3DAAF0C05CA48A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D752D7309BD70554567AAF0C05C9679" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_2A307FDD757C39D4EEABAAF0C05CBA51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D752D7309BD70554567AAF0C05C9679" xlink:to="loc_biib_IonisPharmaceuticalsMember_2A307FDD757C39D4EEABAAF0C05CBA51" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_E7EFB074148B86F9C2E3AAF0C05DB8C6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D752D7309BD70554567AAF0C05C9679" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_E7EFB074148B86F9C2E3AAF0C05DB8C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5B8A6BA7EFF603E7095EAAF0C05B3BB1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37" xlink:to="loc_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_F946AAAF88CD72F575DCAAF0C05E6148" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_Termofcollaborationagreement_F946AAAF88CD72F575DCAAF0C05E6148" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Totalpaymenttoentercollaborationagreement" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_853B3A85E9437A8FFE41AAF0C05F99B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_Totalpaymenttoentercollaborationagreement_853B3A85E9437A8FFE41AAF0C05F99B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Upfrontpaymentforcollaborationagreement" xlink:label="loc_biib_Upfrontpaymentforcollaborationagreement_3406F27D03FCA47D08A7AAF0C05F65C7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_Upfrontpaymentforcollaborationagreement_3406F27D03FCA47D08A7AAF0C05F65C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_6F2386B112A651C44B9BAAF0C05F6739" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_Investmentincommonstocksharespurchased_6F2386B112A651C44B9BAAF0C05F6739" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_C518344F9F33348EE4F0AAF0C05F8A4C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_Purchaseofcommonstock_C518344F9F33348EE4F0AAF0C05F8A4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5B9F60C99FE44BB8508EAAF0C060510D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5B9F60C99FE44BB8508EAAF0C060510D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_34ACBC6652C9EC14A0A8AAF0C060BB28" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_34ACBC6652C9EC14A0A8AAF0C060BB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_38A95D1985958FF0370DAAF0C0609EAD" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_38A95D1985958FF0370DAAF0C0609EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_36D328C47EDB9CBAE3EFAAF0C060B716" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_us-gaap_EquityMethodInvestments_36D328C47EDB9CBAE3EFAAF0C060B716" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5" xlink:to="loc_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7CE50FD6B0434A4908D85697A6AEF9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7CE50FD6B0434A4908D85697A6AEF9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_FE5D1DADF79F79920F2285697A6A11B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_FE5D1DADF79F79920F2285697A6A11B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_60CB939DE4EB8C1A580585697A6A38E7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_60CB939DE4EB8C1A580585697A6A38E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_A88447AD456F4C35F29C85697A6A50D4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_A88447AD456F4C35F29C85697A6A50D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_CE2954F6E6E0BA0CDE0885697A6A586B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_CE2954F6E6E0BA0CDE0885697A6A586B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C926F8E7BE036965D6F585697A6ADEC9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C926F8E7BE036965D6F585697A6ADEC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8CD16292C90C0E0C078E85697A6A0324" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8CD16292C90C0E0C078E85697A6A0324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6684802F4EDF72A6FAA385697A6A8AC4" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6684802F4EDF72A6FAA385697A6A8AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1F3CE75937F0EF4A9DA385697A6A18DF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1F3CE75937F0EF4A9DA385697A6A18DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_F2DD821B190719DE3EAB85697A6AC31D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_F2DD821B190719DE3EAB85697A6AC31D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1453678EC5388DE6C8FF85697A6A48B4" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1453678EC5388DE6C8FF85697A6A48B4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_55B1AD5E41F11FE8219D871CB12DC74E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_55B1AD5E41F11FE8219D871CB12DC74E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_7F13B815FE8787F63069871CB12D5CF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_55B1AD5E41F11FE8219D871CB12DC74E" xlink:to="loc_srt_MajorCustomersAxis_7F13B815FE8787F63069871CB12D5CF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_D53BA482500275E42616871CB12D549A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7F13B815FE8787F63069871CB12D5CF4" xlink:to="loc_srt_NameOfMajorCustomerDomain_D53BA482500275E42616871CB12D549A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_D53BA482500275E42616871CB12D549A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7F13B815FE8787F63069871CB12D5CF4" xlink:to="loc_srt_NameOfMajorCustomerDomain_D53BA482500275E42616871CB12D549A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_C4A1B22BEEAC725B2FCB871CB12D4162" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_D53BA482500275E42616871CB12D549A" xlink:to="loc_biib_BioverativMember_C4A1B22BEEAC725B2FCB871CB12D4162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C34448B445B79805518B871CB12DEE2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_55B1AD5E41F11FE8219D871CB12DC74E" xlink:to="loc_srt_ProductOrServiceAxis_C34448B445B79805518B871CB12DEE2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CB7056AF4F821CDD6925871CB12D2398_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_C34448B445B79805518B871CB12DEE2A" xlink:to="loc_srt_ProductsAndServicesDomain_CB7056AF4F821CDD6925871CB12D2398_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CB7056AF4F821CDD6925871CB12D2398" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_C34448B445B79805518B871CB12DEE2A" xlink:to="loc_srt_ProductsAndServicesDomain_CB7056AF4F821CDD6925871CB12D2398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_43D605A62BA6518DF127871CB12D43D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CB7056AF4F821CDD6925871CB12D2398" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_43D605A62BA6518DF127871CB12D43D3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_142BB9681B0385E8BB9D871CB12D7FFD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_CB7056AF4F821CDD6925871CB12D2398" xlink:to="loc_biib_HemophiliaProductsMember_142BB9681B0385E8BB9D871CB12D7FFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A15BDE912875DB06EF77871CB12D2054" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_55B1AD5E41F11FE8219D871CB12DC74E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A15BDE912875DB06EF77871CB12D2054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BDD0ED63A901D31B90C3871CB12D42B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A15BDE912875DB06EF77871CB12D2054" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BDD0ED63A901D31B90C3871CB12D42B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BDD0ED63A901D31B90C3871CB12D42B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A15BDE912875DB06EF77871CB12D2054" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BDD0ED63A901D31B90C3871CB12D42B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_6065BB942B60754D0AE3871CB12DF072" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BDD0ED63A901D31B90C3871CB12D42B6" xlink:to="loc_biib_BioverativMember_6065BB942B60754D0AE3871CB12DF072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_CCF77EDD5B43B9F05CFB871CB13D06A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_CCF77EDD5B43B9F05CFB871CB13D06A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_EA32FBB764986D093FD0871CB13D701B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:to="loc_us-gaap_Revenues_EA32FBB764986D093FD0871CB13D701B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8C84BDE5FA70799539BD871CB13D83F0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8C84BDE5FA70799539BD871CB13D83F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InventoryexpectedtobesoldtoBioverativ" xlink:label="loc_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:to="loc_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_B396646A14672C3F80FFA5EC432C6327" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14" xlink:to="loc_us-gaap_CostOfSalesMember_B396646A14672C3F80FFA5EC432C6327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_78193B71E6839082D3AAA5E9ED6BC460" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_srt_RangeAxis_78193B71E6839082D3AAA5E9ED6BC460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1029F2AAA886FDCD75A4A5E9ED6B059B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_78193B71E6839082D3AAA5E9ED6BC460" xlink:to="loc_srt_RangeMember_1029F2AAA886FDCD75A4A5E9ED6B059B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1029F2AAA886FDCD75A4A5E9ED6B059B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_78193B71E6839082D3AAA5E9ED6BC460" xlink:to="loc_srt_RangeMember_1029F2AAA886FDCD75A4A5E9ED6B059B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6ABC3ED31A27D36FA425A5E9ED6CE6E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1029F2AAA886FDCD75A4A5E9ED6B059B" xlink:to="loc_srt_MinimumMember_6ABC3ED31A27D36FA425A5E9ED6CE6E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_95EAD580CBCEE3803A27A5E9ED6CA8FB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1029F2AAA886FDCD75A4A5E9ED6B059B" xlink:to="loc_srt_MaximumMember_95EAD580CBCEE3803A27A5E9ED6CA8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_AC044161D81DDD9F8B19A5E9ED6D9282" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_AC044161D81DDD9F8B19A5E9ED6D9282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_A00440FDCB1C53A997A2A5E9ED6DAD93" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_srt_ProductOrServiceAxis_A00440FDCB1C53A997A2A5E9ED6DAD93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_646A73DA94B8D56CA9B9A5E9ED6DE156_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_A00440FDCB1C53A997A2A5E9ED6DAD93" xlink:to="loc_srt_ProductsAndServicesDomain_646A73DA94B8D56CA9B9A5E9ED6DE156_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_646A73DA94B8D56CA9B9A5E9ED6DE156" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_A00440FDCB1C53A997A2A5E9ED6DAD93" xlink:to="loc_srt_ProductsAndServicesDomain_646A73DA94B8D56CA9B9A5E9ED6DE156" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_5E9589DE86C3A790E408A5E9ED6DC6B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_646A73DA94B8D56CA9B9A5E9ED6DE156" xlink:to="loc_biib_ZINBRYTAMember_5E9589DE86C3A790E408A5E9ED6DC6B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:to="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:to="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:to="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:to="loc_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:to="loc_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_59369703ACF7FA085363A5E9ED6F8BC6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:to="loc_us-gaap_RetainedEarningsMember_59369703ACF7FA085363A5E9ED6F8BC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PrepaidtaxesMember" xlink:label="loc_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:to="loc_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_F4B86EE321726009CD84A5E9ED70357F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_F4B86EE321726009CD84A5E9ED70357F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_6E6D5A5C6308DC8C63DCA5E9ED706DD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:to="loc_us-gaap_GeneralBusinessMember_6E6D5A5C6308DC8C63DCA5E9ED706DD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1ED550CA893A23DD2FB1A5E9ED71920B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:to="loc_us-gaap_ResearchMember_1ED550CA893A23DD2FB1A5E9ED71920B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:to="loc_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_F5AB39C1BBEBBC01B6C3A5E9ED7231DF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:to="loc_us-gaap_DomesticCountryMember_F5AB39C1BBEBBC01B6C3A5E9ED7231DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_BF0043ED531334DD66AFA5E9ED722D37" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_BF0043ED531334DD66AFA5E9ED722D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_B3057C5874A89D519EC3A5E9ED72938F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:to="loc_us-gaap_ForeignCountryMember_B3057C5874A89D519EC3A5E9ED72938F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0C8B67501DD59E3F9E78A5EC42325DB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0C8B67501DD59E3F9E78A5EC42325DB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1BC1674FCC4DB1B0EE78A5E9ED726544" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1BC1674FCC4DB1B0EE78A5E9ED726544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1DA8C6107FB2F21D7E64A5E9ED7336BE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1DA8C6107FB2F21D7E64A5E9ED7336BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_98F6B12234B2BE8931C2A5E9ED7343AE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_98F6B12234B2BE8931C2A5E9ED7343AE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PaymentforTransitionTollTax" xlink:label="loc_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment" xlink:label="loc_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_2AC7FC7C5CA6D5ED3C19A5E9ED735FAC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_2AC7FC7C5CA6D5ED3C19A5E9ED735FAC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:label="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:label="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:label="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_C94EC303447C1C97196CA5E9ED75117A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_C94EC303447C1C97196CA5E9ED75117A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_1A40B0B65C2F84D1C163A5E9ED75821D" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_1A40B0B65C2F84D1C163A5E9ED75821D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_D24E7780F68D06C9E5DCA5E9ED75180F" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_D24E7780F68D06C9E5DCA5E9ED75180F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0944C0A48C7D1BF62509A5E9ED76E0E1" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0944C0A48C7D1BF62509A5E9ED76E0E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_69FDFAAEA318B035D31EA5E9ED760F61" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_69FDFAAEA318B035D31EA5E9ED760F61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_5A5E824947021121F4FCA5E9ED76A73D" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_5A5E824947021121F4FCA5E9ED76A73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_541481240E81EA7DDA23A5E9ED76371B" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_541481240E81EA7DDA23A5E9ED76371B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_48C15DEA76E95994E3C4A5E9ED771DEE" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_48C15DEA76E95994E3C4A5E9ED771DEE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:to="loc_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:to="loc_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_B42F1C71C08E92DBD90585697942B0AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_B42F1C71C08E92DBD90585697942B0AE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_943FA5E005CD69D3B29985697942D269" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:to="loc_us-gaap_NotesPayableCurrent_943FA5E005CD69D3B29985697942D269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_EBA91F6A9FFAA98A2EAB85697942E1DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:to="loc_us-gaap_DebtCurrent_EBA91F6A9FFAA98A2EAB85697942E1DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_3CA224CA3F7DBDC115D585697942F47C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:to="loc_us-gaap_LongTermNotesPayable_3CA224CA3F7DBDC115D585697942F47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_94F25220E633721F217385697942EFBA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:to="loc_us-gaap_LongTermDebt_94F25220E633721F217385697942EFBA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5F29F981EA13A14C5A6285B86D46E207" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_DebtInstrumentTable_5F29F981EA13A14C5A6285B86D46E207" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5F29F981EA13A14C5A6285B86D46E207" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_35AECC386FDFB5E5737B85B86D46884E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85" xlink:to="loc_us-gaap_InterestRateSwapMember_35AECC386FDFB5E5737B85B86D46884E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7A2BE33921CE70B079A085B86D460459" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5F29F981EA13A14C5A6285B86D46E207" xlink:to="loc_us-gaap_DebtInstrumentAxis_7A2BE33921CE70B079A085B86D460459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7A2BE33921CE70B079A085B86D460459" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7A2BE33921CE70B079A085B86D460459" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CA5BBA89C4A4EC101F2985B86D46B6B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CA5BBA89C4A4EC101F2985B86D46B6B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5F5F791876AB1B69631585B86D4DA684" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5F5F791876AB1B69631585B86D4DA684" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B2BBF2FDCDCA892764F385B86D4D7C76" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B2BBF2FDCDCA892764F385B86D4D7C76" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_10637F2EECAF8BE1594585B86D4D3D72" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_10637F2EECAF8BE1594585B86D4D3D72" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D93F0116252CD3806F0885B86D4D2203" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D93F0116252CD3806F0885B86D4D2203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_0FEEA980F29445F348A685B86D4D055E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_NotesPayable_0FEEA980F29445F348A685B86D4D055E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_902374E5DCACD17CA4B985B86D4DEAB9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_902374E5DCACD17CA4B985B86D4DEAB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DA424DE556FE49A929B185B86D4D92F1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DA424DE556FE49A929B185B86D4D92F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2D5D135DCD8E3A693D6B85B86D508481" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2D5D135DCD8E3A693D6B85B86D508481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C075C95500C6E496EF5585B86D50B58E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C075C95500C6E496EF5585B86D50B58E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5B9A3CD1348B6BF8EEFB85B86D50F8A5" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_5B9A3CD1348B6BF8EEFB85B86D50F8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_18F26C97A45DE472819885B86D50899C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_18F26C97A45DE472819885B86D50899C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_675D8C5DB423E14604BF85B86D504629" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_675D8C5DB423E14604BF85B86D504629" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B0048F1EF167CAD12E6785B86D50789A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B0048F1EF167CAD12E6785B86D50789A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_BB03A942DAEE494C5A0C85B86D50248B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_BB03A942DAEE494C5A0C85B86D50248B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D9F30FE03FB976950D285B86D501C86" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D9F30FE03FB976950D285B86D501C86" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PLSRMember" xlink:label="loc_biib_PLSRMember_F1BA6618196880431940C428294A3DF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:to="loc_biib_PLSRMember_F1BA6618196880431940C428294A3DF0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_2AB1441CC378E02365D8C428294A032C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:to="loc_biib_TGNMember_2AB1441CC378E02365D8C428294A032C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="loc_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:to="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:to="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5000FDEE55E475CDB45BC42829515AD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5000FDEE55E475CDB45BC42829515AD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_A37B8EA59FFE0DA246E4C42829526DC1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_A37B8EA59FFE0DA246E4C42829526DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:to="loc_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_AFAB92EB8B8A8AB26196C4282953C94D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_AFAB92EB8B8A8AB26196C4282953C94D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:to="loc_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="loc_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:to="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:to="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A26F93A18348ED50D028C4282953E6BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:to="loc_srt_MinimumMember_A26F93A18348ED50D028C4282953E6BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7A218E0B75A430870398C42829546729" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:to="loc_srt_MaximumMember_7A218E0B75A430870398C42829546729" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_33AD47A1877FDD0713AEC42829554210" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_33AD47A1877FDD0713AEC42829554210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4C257080864FE6A70786C4282955B5E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4C257080864FE6A70786C4282955B5E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5457FC74625F785D9E06C4282955F0EF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5457FC74625F785D9E06C4282955F0EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_F3204E809371F4E071F9C428295607E0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_F3204E809371F4E071F9C428295607E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0282E2A0A3206D589B69C4282956EAA4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0282E2A0A3206D589B69C4282956EAA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42D1A4C1A0451D78D0C0C428295683E3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42D1A4C1A0451D78D0C0C428295683E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_84EAB06D01FDB735ABD7C42829560E5F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_84EAB06D01FDB735ABD7C42829560E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6A2B2E2870ED431A2754C428295B682B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6A2B2E2870ED431A2754C428295B682B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_51B33855F1BF0B24C670C428295C6BD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_51B33855F1BF0B24C670C428295C6BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ED69C17952519B33DF48C428295C8484" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ED69C17952519B33DF48C428295C8484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_005E7F53763AF9A907F1C428295C2EE0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_005E7F53763AF9A907F1C428295C2EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F917D22EE162C080F141C428295C3FED" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F917D22EE162C080F141C428295C3FED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_664DCEEE816E8E71333AC428295D9025" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_664DCEEE816E8E71333AC428295D9025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D5B2E5FC001690378CAFC428295DB807" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_D5B2E5FC001690378CAFC428295DB807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_AAF356E46A3B694C4A0BC428295D487D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_AAF356E46A3B694C4A0BC428295D487D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5D02D55C823195A076AC428295D5F19" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5D02D55C823195A076AC428295D5F19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_31262007568BB8B409D9C428295D45F0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_31262007568BB8B409D9C428295D45F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7E476FFF9C91BF99F84FC428295E6A0D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7E476FFF9C91BF99F84FC428295E6A0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_889C72AA98D0C6E20C5EC428295E4CE7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_LitigationSettlementExpense_889C72AA98D0C6E20C5EC428295E4CE7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_15C5D126F9812ACBC315820F2F13FC56" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:to="loc_biib_CumulativeSalesLevelAxis_15C5D126F9812ACBC315820F2F13FC56" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_12EB130697A62FA0DE51820F2F1720C5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_15C5D126F9812ACBC315820F2F13FC56" xlink:to="loc_biib_CumulativeSalesLevelDomain_12EB130697A62FA0DE51820F2F1720C5_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_12EB130697A62FA0DE51820F2F1720C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_15C5D126F9812ACBC315820F2F13FC56" xlink:to="loc_biib_CumulativeSalesLevelDomain_12EB130697A62FA0DE51820F2F1720C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_0CB75C04C723CD8AA233820F2F48BD08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_12EB130697A62FA0DE51820F2F1720C5" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_0CB75C04C723CD8AA233820F2F48BD08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57028C9F89D916D95BFD82084AD3E595" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57028C9F89D916D95BFD82084AD3E595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_356B3A56DE029C892DC582084AD34FBF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57028C9F89D916D95BFD82084AD3E595" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_356B3A56DE029C892DC582084AD34FBF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_356B3A56DE029C892DC582084AD34FBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57028C9F89D916D95BFD82084AD3E595" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_356B3A56DE029C892DC582084AD34FBF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_3E60532D44170886D27F82084AD39F34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_356B3A56DE029C892DC582084AD34FBF" xlink:to="loc_biib_BioverativMember_3E60532D44170886D27F82084AD39F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FDA20F8CDBCB6A77DAB482084AD3F4A5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_FDA20F8CDBCB6A77DAB482084AD3F4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_647D10AB0525FD896C8782084AD34767_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FDA20F8CDBCB6A77DAB482084AD3F4A5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_647D10AB0525FD896C8782084AD34767_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_647D10AB0525FD896C8782084AD34767" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FDA20F8CDBCB6A77DAB482084AD3F4A5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_647D10AB0525FD896C8782084AD34767" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_B268AD0CA2EF7460201782084AD38C10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_647D10AB0525FD896C8782084AD34767" xlink:to="loc_biib_FumapharmAgMember_B268AD0CA2EF7460201782084AD38C10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_BA5B3FE03FCB5B027ED882084AD3C33A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:to="loc_srt_ProductOrServiceAxis_BA5B3FE03FCB5B027ED882084AD3C33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_86424F5935C8A9B3CD2982084AD34D16_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_BA5B3FE03FCB5B027ED882084AD3C33A" xlink:to="loc_srt_ProductsAndServicesDomain_86424F5935C8A9B3CD2982084AD34D16_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_86424F5935C8A9B3CD2982084AD34D16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_BA5B3FE03FCB5B027ED882084AD3C33A" xlink:to="loc_srt_ProductsAndServicesDomain_86424F5935C8A9B3CD2982084AD34D16" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_EAA8C8DF9B4F73538F1282084AD38FE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_86424F5935C8A9B3CD2982084AD34D16" xlink:to="loc_biib_TecfideraMember_EAA8C8DF9B4F73538F1282084AD38FE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_089752B4BDD61E9E304B82084AE30772" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_089752B4BDD61E9E304B82084AE30772" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_524EB03233C26F3028B4820F2ECA32ED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:to="loc_biib_CumulativeSalesLevel_524EB03233C26F3028B4820F2ECA32ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_16B0D4BA70EE71F8B4A982084AE38620" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_16B0D4BA70EE71F8B4A982084AE38620" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_B18E7EA6C5EDCD00A7B1BEA9353CECA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_B18E7EA6C5EDCD00A7B1BEA9353CECA9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D6571D529B42675C6EBEA9354CEECB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_B18E7EA6C5EDCD00A7B1BEA9353CECA9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D6571D529B42675C6EBEA9354CEECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_85BFEF0583F7664B5B56BEA9354C619A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D6571D529B42675C6EBEA9354CEECB" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_85BFEF0583F7664B5B56BEA9354C619A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_85BFEF0583F7664B5B56BEA9354C619A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D6571D529B42675C6EBEA9354CEECB" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_85BFEF0583F7664B5B56BEA9354C619A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_28E333EB1E08B86789A2BEA9354C7104" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_85BFEF0583F7664B5B56BEA9354C619A" xlink:to="loc_biib_BioverativMember_28E333EB1E08B86789A2BEA9354C7104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_78C3D8F24EEDF8395BB5BEA9354C960D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_78C3D8F24EEDF8395BB5BEA9354C960D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788" xlink:to="loc_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_95CF5A75DF02A670D877F52288ED9F91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_95CF5A75DF02A670D877F52288ED9F91" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6F1DF4BC4A1F3F3FDB54F52AEF92B0BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6F1DF4BC4A1F3F3FDB54F52AEF92B0BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_91EC81D0247F8A02CC21F52AF05E292A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6F1DF4BC4A1F3F3FDB54F52AEF92B0BD" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_91EC81D0247F8A02CC21F52AF05E292A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_91EC81D0247F8A02CC21F52AF05E292A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6F1DF4BC4A1F3F3FDB54F52AEF92B0BD" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_91EC81D0247F8A02CC21F52AF05E292A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_EDAB71E9C1424994810BF52AEF9D9494" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_91EC81D0247F8A02CC21F52AF05E292A" xlink:to="loc_country_BR_EDAB71E9C1424994810BF52AEF9D9494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="loc_us-gaap_LossContingencyDamagesSought_F27C2440F6E24D896CD1F52AEF88C8F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741" xlink:to="loc_us-gaap_LossContingencyDamagesSought_F27C2440F6E24D896CD1F52AEF88C8F9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8783859ED008347E1CD0BEA7270EE947" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_16248DF9FF59B028D2E1BEA7270ED054" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8783859ED008347E1CD0BEA7270EE947" xlink:to="loc_us-gaap_StatementTable_16248DF9FF59B028D2E1BEA7270ED054" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8C5C2257366AB9838564BEA7270E8804" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_16248DF9FF59B028D2E1BEA7270ED054" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8C5C2257366AB9838564BEA7270E8804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6AA6C42071A34D3B8FFABEA7270EE75B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8C5C2257366AB9838564BEA7270E8804" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6AA6C42071A34D3B8FFABEA7270EE75B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6AA6C42071A34D3B8FFABEA7270EE75B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8C5C2257366AB9838564BEA7270E8804" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6AA6C42071A34D3B8FFABEA7270EE75B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_EF5C97824277A8A90658BEA7270EC73D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6AA6C42071A34D3B8FFABEA7270EE75B" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_EF5C97824277A8A90658BEA7270EC73D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_A12F7C1AC6B55DDF99F5BE956ABE759A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_A12F7C1AC6B55DDF99F5BE956ABE759A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_67466BE938C4B42B4FF0BE956ABE6DED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_A12F7C1AC6B55DDF99F5BE956ABE759A" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_67466BE938C4B42B4FF0BE956ABE6DED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_67466BE938C4B42B4FF0BE956ABE6DED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_A12F7C1AC6B55DDF99F5BE956ABE759A" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_67466BE938C4B42B4FF0BE956ABE6DED" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_61FC629DF60D4BFE9A93BE956ABE9E41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_67466BE938C4B42B4FF0BE956ABE6DED" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_61FC629DF60D4BFE9A93BE956ABE9E41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F758C0881EAAD72E64CCBE956ABE3DC0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F758C0881EAAD72E64CCBE956ABE3DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7613C61007DE4A3C8817BE956ABE3097_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F758C0881EAAD72E64CCBE956ABE3DC0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7613C61007DE4A3C8817BE956ABE3097_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7613C61007DE4A3C8817BE956ABE3097" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F758C0881EAAD72E64CCBE956ABE3DC0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7613C61007DE4A3C8817BE956ABE3097" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_C800C20E11BFEB8933A2BE956ABE3B7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7613C61007DE4A3C8817BE956ABE3097" xlink:to="loc_biib_IonisPharmaceuticalsMember_C800C20E11BFEB8933A2BE956ABE3B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B6D753AF0C02BD14304CBE956ABECB4A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_srt_ProductOrServiceAxis_B6D753AF0C02BD14304CBE956ABECB4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_12505ECD71CACCA76828BE956ABEBA66_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_B6D753AF0C02BD14304CBE956ABECB4A" xlink:to="loc_srt_ProductsAndServicesDomain_12505ECD71CACCA76828BE956ABEBA66_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_12505ECD71CACCA76828BE956ABEBA66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_B6D753AF0C02BD14304CBE956ABECB4A" xlink:to="loc_srt_ProductsAndServicesDomain_12505ECD71CACCA76828BE956ABEBA66" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_502170C6155C29ECB3FBBE956ABEAAEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_12505ECD71CACCA76828BE956ABEBA66" xlink:to="loc_biib_TecfideraMember_502170C6155C29ECB3FBBE956ABEAAEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707A51F58E2DB5AC64CBE956ABE408E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707A51F58E2DB5AC64CBE956ABE408E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10AC04CA510E8E68082BBE956ABEC73D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707A51F58E2DB5AC64CBE956ABE408E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10AC04CA510E8E68082BBE956ABEC73D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10AC04CA510E8E68082BBE956ABEC73D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707A51F58E2DB5AC64CBE956ABE408E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10AC04CA510E8E68082BBE956ABEC73D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_E103B6F3616077073082BE956ABEDC50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10AC04CA510E8E68082BBE956ABEC73D" xlink:to="loc_biib_FumapharmAgMember_E103B6F3616077073082BE956ABEDC50" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_8210DDD20DCDD8B2FD1ABE956ABE752D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_biib_FacilityLocationAxis_8210DDD20DCDD8B2FD1ABE956ABE752D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_BA588E4147A3CC2566DCBE956ABE1145_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_8210DDD20DCDD8B2FD1ABE956ABE752D" xlink:to="loc_biib_FacilityLocationDomain_BA588E4147A3CC2566DCBE956ABE1145_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_BA588E4147A3CC2566DCBE956ABE1145" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_8210DDD20DCDD8B2FD1ABE956ABE752D" xlink:to="loc_biib_FacilityLocationDomain_BA588E4147A3CC2566DCBE956ABE1145" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_4F1A9239CF7229FB3F01BE956ABE483D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_BA588E4147A3CC2566DCBE956ABE1145" xlink:to="loc_biib_SolothurnMember_4F1A9239CF7229FB3F01BE956ABE483D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_9F91C3F4162DCB70E2CABE956ABEDF51" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_biib_CumulativeSalesLevelAxis_9F91C3F4162DCB70E2CABE956ABEDF51" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_CumulativeSalesLevelAxis_9F91C3F4162DCB70E2CABE956ABEDF51" xlink:to="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_CumulativeSalesLevelAxis_9F91C3F4162DCB70E2CABE956ABEDF51" xlink:to="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TwentybillionMember" xlink:label="loc_biib_TwentybillionMember_47F7652F2240FACB1CB0BE956ABE2FF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:to="loc_biib_TwentybillionMember_47F7652F2240FACB1CB0BE956ABE2FF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9B72BE618FA1F7E766C7BE956ABE861B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9B72BE618FA1F7E766C7BE956ABE861B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_3A029353DCEC138000ACBE956ABE83ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:to="loc_biib_FifteenbillionMemberMember_3A029353DCEC138000ACBE956ABE83ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_50A016E8893F16B2629FBE956ABEF832" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:to="loc_biib_SixteenbillionMember_50A016E8893F16B2629FBE956ABEF832" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2AA76283B68DFB67FA8BBE956ABE49FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2AA76283B68DFB67FA8BBE956ABE49FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_A8A15C46A020C5B88349BE956ABEC1D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_OtherAssetsCurrent_A8A15C46A020C5B88349BE956ABEC1D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E75DD31BF53092DEFC18BE956ABEA4EF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_E75DD31BF53092DEFC18BE956ABEA4EF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_CB0E240192D0ABF10684BE956ABE2395" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_biib_CumulativeSalesLevel_CB0E240192D0ABF10684BE956ABE2395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_EF4FFED25E146D08154DBE956ABEDE68" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_EF4FFED25E146D08154DBE956ABEDE68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_BE89D9EE338A42F9AB5FBE956ABED7DE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_LitigationSettlementExpense_BE89D9EE338A42F9AB5FBE956ABED7DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_A1B2B8834317805E3EDDBE956ACD25DE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_PrepaidTaxes_A1B2B8834317805E3EDDBE956ACD25DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D885BC94F1C0ED7D116CBE956ACD283D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_D885BC94F1C0ED7D116CBE956ACD283D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_A12B70BEC942EE147E73BE956ACD8772" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_A12B70BEC942EE147E73BE956ACD8772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_D6C632D0F674F77C4F81BE956ACD5287" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_EquityMethodInvestments_D6C632D0F674F77C4F81BE956ACD5287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_35A4925688D7A6F7EFDEBE956ACD9A4E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_35A4925688D7A6F7EFDEBE956ACD9A4E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A8A306B7B1918336CC999528E98FAD74" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34FDA9E5DE1B35A071DE9528E98F9B60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A8A306B7B1918336CC999528E98FAD74" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34FDA9E5DE1B35A071DE9528E98F9B60" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_47A2AE3C01A7624A3DE39528E98F8839" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34FDA9E5DE1B35A071DE9528E98F9B60" xlink:to="loc_biib_FacilityLocationAxis_47A2AE3C01A7624A3DE39528E98F8839" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_CB63936E6265CA3F70689528E98FCFE5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_47A2AE3C01A7624A3DE39528E98F8839" xlink:to="loc_biib_FacilityLocationDomain_CB63936E6265CA3F70689528E98FCFE5_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_CB63936E6265CA3F70689528E98FCFE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_47A2AE3C01A7624A3DE39528E98F8839" xlink:to="loc_biib_FacilityLocationDomain_CB63936E6265CA3F70689528E98FCFE5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_53A8827B443411F815279528E98F2BC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_CB63936E6265CA3F70689528E98FCFE5" xlink:to="loc_biib_SolothurnMember_53A8827B443411F815279528E98F2BC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1C93ECC8ADEB89126E009528E98FE28E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A8A306B7B1918336CC999528E98FAD74" xlink:to="loc_us-gaap_Depreciation_1C93ECC8ADEB89126E009528E98FE28E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_A5766B26AC2A3053D43D955D3099E367" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A8A306B7B1918336CC999528E98FAD74" xlink:to="loc_us-gaap_InterestCostsCapitalized_A5766B26AC2A3053D43D955D3099E367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_D841ED49335A16AB38BC9528E98FB15E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A8A306B7B1918336CC999528E98FAD74" xlink:to="loc_us-gaap_ConstructionInProgressGross_D841ED49335A16AB38BC9528E98FB15E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_DCAAAF59FB1E5C33115D85D6DB072393" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_DCAAAF59FB1E5C33115D85D6DB072393" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C9580D24D01781A9C43485CC9C972284" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:to="loc_srt_ProductOrServiceAxis_C9580D24D01781A9C43485CC9C972284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_C9580D24D01781A9C43485CC9C972284" xlink:to="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_C9580D24D01781A9C43485CC9C972284" xlink:to="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_A70575F6D4D28DD6920485CC9C9706CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_A70575F6D4D28DD6920485CC9C9706CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_BB8DC41AF4DE555FBFF985CC9C97FE20" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_BB8DC41AF4DE555FBFF985CC9C97FE20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_42C31F1D10E4A119B94B85CC9C974B2F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70" xlink:to="loc_us-gaap_ProductMember_42C31F1D10E4A119B94B85CC9C974B2F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8637B0BA5A770B48996BA5C6DA3EE0FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8637B0BA5A770B48996BA5C6DA3EE0FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4DE69E95DEE795F6848AA5C6DA3ECFD2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8637B0BA5A770B48996BA5C6DA3EE0FE" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4DE69E95DEE795F6848AA5C6DA3ECFD2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4DE69E95DEE795F6848AA5C6DA3ECFD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8637B0BA5A770B48996BA5C6DA3EE0FE" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4DE69E95DEE795F6848AA5C6DA3ECFD2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_0E27A9737ECB652E89A0A5C6DA4D0614" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4DE69E95DEE795F6848AA5C6DA3ECFD2" xlink:to="loc_biib_U.S.2017TaxActMember_0E27A9737ECB652E89A0A5C6DA4D0614" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_3AF4458B59011661C2D4A5C6DA4DA71E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_3AF4458B59011661C2D4A5C6DA4DA71E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_473AE2A210D9F34FE3D3A5C6DA4DF266_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_3AF4458B59011661C2D4A5C6DA4DA71E" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_473AE2A210D9F34FE3D3A5C6DA4DF266_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_473AE2A210D9F34FE3D3A5C6DA4DF266" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_3AF4458B59011661C2D4A5C6DA4DA71E" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_473AE2A210D9F34FE3D3A5C6DA4DF266" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_20EF50547B5A9B8CD1C0A5C6DA4D2B65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_473AE2A210D9F34FE3D3A5C6DA4DF266" xlink:to="loc_biib_TGNMember_20EF50547B5A9B8CD1C0A5C6DA4D2B65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F19ADD36A227A0F8A28FA5C6DA4DE92F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F19ADD36A227A0F8A28FA5C6DA4DE92F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_417A306916E8BCD82479A5C6DA4D9FE4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F19ADD36A227A0F8A28FA5C6DA4DE92F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_417A306916E8BCD82479A5C6DA4D9FE4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_417A306916E8BCD82479A5C6DA4D9FE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F19ADD36A227A0F8A28FA5C6DA4DE92F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_417A306916E8BCD82479A5C6DA4D9FE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_C6356FDAF4905A4A31C0A5C6DA4D164A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_417A306916E8BCD82479A5C6DA4D9FE4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_C6356FDAF4905A4A31C0A5C6DA4D164A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8748EB4780BB63DE5F68A5C6DA4D1BAE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8748EB4780BB63DE5F68A5C6DA4D1BAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8748EB4780BB63DE5F68A5C6DA4D1BAE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8748EB4780BB63DE5F68A5C6DA4D1BAE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_791BA242F71F7599B401A5C6DA4D7CB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:to="loc_biib_KaryopharmMember_791BA242F71F7599B401A5C6DA4D7CB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_AC9C7E697952C56E1CB6A5C6DA4DB50F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:to="loc_biib_RemedyPharmaceuticalMember_AC9C7E697952C56E1CB6A5C6DA4DB50F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_8E2FA388E4F3F2256A02A5C6DA4DD9F7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:to="loc_biib_PfizerMember_8E2FA388E4F3F2256A02A5C6DA4DD9F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AliveGenMember" xlink:label="loc_biib_AliveGenMember_E67E19131FF6938F48A5A5C6DA4D6C7F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:to="loc_biib_AliveGenMember_E67E19131FF6938F48A5A5C6DA4D6C7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_515DA5098C891D3DAAA3A5C6DA4DC044" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_srt_ProductOrServiceAxis_515DA5098C891D3DAAA3A5C6DA4DC044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_4D840E758B3DEE2B10DEA5C6DA4D76B0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_515DA5098C891D3DAAA3A5C6DA4DC044" xlink:to="loc_srt_ProductsAndServicesDomain_4D840E758B3DEE2B10DEA5C6DA4D76B0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_4D840E758B3DEE2B10DEA5C6DA4D76B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_515DA5098C891D3DAAA3A5C6DA4DC044" xlink:to="loc_srt_ProductsAndServicesDomain_4D840E758B3DEE2B10DEA5C6DA4D76B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_AD18F87B095A925FD46BA5C6DA4D60EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4D840E758B3DEE2B10DEA5C6DA4D76B0" xlink:to="loc_biib_TecfideraMember_AD18F87B095A925FD46BA5C6DA4D60EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_32C46A4C56791153CF09A5C6DA4D616C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_32C46A4C56791153CF09A5C6DA4D616C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_32C46A4C56791153CF09A5C6DA4D616C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_32C46A4C56791153CF09A5C6DA4D616C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_36D25E493F80704A2591A5C6DA4D16D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_32C46A4C56791153CF09A5C6DA4D616C" xlink:to="loc_biib_NeurimmuneMember_36D25E493F80704A2591A5C6DA4D16D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_242F5C56201AF7B11132A5C6DA4DE71E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_242F5C56201AF7B11132A5C6DA4DE71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_242F5C56201AF7B11132A5C6DA4DE71E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_242F5C56201AF7B11132A5C6DA4DE71E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_0566FECFA64A3488EDCFA5C6DA4D5FF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:to="loc_biib_BristolMyersSquibbMember_0566FECFA64A3488EDCFA5C6DA4D5FF7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_9AFE9CC85DCFE1F2FECEA5C6DA4D6DA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:to="loc_biib_IPerianMember_9AFE9CC85DCFE1F2FECEA5C6DA4D6DA0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_292F59A9FCE7050E15C9A5C6DA4DC15A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:to="loc_biib_AlkermesMember_292F59A9FCE7050E15C9A5C6DA4DC15A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_90DD79336D22C5647670A5C6DA4DC54B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:to="loc_biib_IonisPharmaceuticalsMember_90DD79336D22C5647670A5C6DA4DC54B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_02DC3C19DB8BC4D59610A5C6DA4DAC6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_02DC3C19DB8BC4D59610A5C6DA4DAC6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EDDAD5EDA7920948A1FAA5C6DA4DAFB5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_EDDAD5EDA7920948A1FAA5C6DA4DAFB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_06563D2D9809D9994389A5C6DA4D017A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_06563D2D9809D9994389A5C6DA4D017A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_03ACC83457D51B2017F6A5C6DA4D00A7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_03ACC83457D51B2017F6A5C6DA4D00A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_14DC44A823CDD5490619A5C6DA4D61A5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_14DC44A823CDD5490619A5C6DA4D61A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_374828EF76C394A36F77A5C6DA4D59BD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_374828EF76C394A36F77A5C6DA4D59BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_4097784835C1509800A4A5C6DA4DFB84" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_4097784835C1509800A4A5C6DA4DFB84" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_14C8971445251F73B5C3A5C6DA4D6CC5" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_Investmentincommonstocksharespurchased_14C8971445251F73B5C3A5C6DA4D6CC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_858B9589A7E542637399A5C6DA4DE157" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_858B9589A7E542637399A5C6DA4DE157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_74CB2CBF4E980C751554A5C6DA4D7559" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_74CB2CBF4E980C751554A5C6DA4D7559" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_4ED8A57D423429A6D3ABA5C6DA4DA4C2" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_4ED8A57D423429A6D3ABA5C6DA4DA4C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_F291BCDD15E44FE405F3A5C6DA4DEAEC" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_DevelopmentalMilestonePayment_F291BCDD15E44FE405F3A5C6DA4DEAEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_57DC3D3ACC2A8D1DC90EA5C6DA4D677B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_57DC3D3ACC2A8D1DC90EA5C6DA4D677B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_23F396DBD83E0E445B67A5C6DA4DB6EB" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_23F396DBD83E0E445B67A5C6DA4DB6EB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F01F72C724855F9BC4A5A5C6DA4D371F" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F01F72C724855F9BC4A5A5C6DA4D371F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4C4E0242449C904B9EA3A5C6DA4DF7BD" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4C4E0242449C904B9EA3A5C6DA4DF7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_AC1D7E6ECA3566D73B33A5C6DA4DAEE0" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_AC1D7E6ECA3566D73B33A5C6DA4DAEE0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_CAD95471B7EB39FD99F4C4282A6F4983" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_CAD95471B7EB39FD99F4C4282A6F4983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CCC5B54B96294EA6523CC4282A7070AC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CAD95471B7EB39FD99F4C4282A6F4983" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CCC5B54B96294EA6523CC4282A7070AC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CCC5B54B96294EA6523CC4282A7070AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CAD95471B7EB39FD99F4C4282A6F4983" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CCC5B54B96294EA6523CC4282A7070AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_5E485ACD24B325BC18B2C4282A704DF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CCC5B54B96294EA6523CC4282A7070AC" xlink:to="loc_us-gaap_RestructuringChargesMember_5E485ACD24B325BC18B2C4282A704DF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9FB6F83B0B3B353A75B2C4282A70BA3B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CCC5B54B96294EA6523CC4282A7070AC" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9FB6F83B0B3B353A75B2C4282A70BA3B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_56C512E146D0733009E2C4282A70464C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:to="loc_biib_FacilityLocationAxis_56C512E146D0733009E2C4282A70464C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_E19FE7CDA4C621566358C4282A716544_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_56C512E146D0733009E2C4282A70464C" xlink:to="loc_biib_FacilityLocationDomain_E19FE7CDA4C621566358C4282A716544_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_E19FE7CDA4C621566358C4282A716544" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_56C512E146D0733009E2C4282A70464C" xlink:to="loc_biib_FacilityLocationDomain_E19FE7CDA4C621566358C4282A716544" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_E19FE7CDA4C621566358C4282A716544" xlink:to="loc_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:to="loc_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:to="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:to="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2017CorporateStrategyMember" xlink:label="loc_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:to="loc_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2016RestructuringChargesMember" xlink:label="loc_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:to="loc_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:to="loc_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaap_OtherNonrecurringExpense_B7B7F686A15D0861BC74C4282A726440" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="loc_us-gaap_OtherNonrecurringExpense_B7B7F686A15D0861BC74C4282A726440" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResourcesRedirectedthroughRestructuringProgram" xlink:label="loc_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="loc_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram" xlink:label="loc_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="loc_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_07DE223A3880DD84BCAFC4282A73A6BC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="loc_us-gaap_RestructuringCharges_07DE223A3880DD84BCAFC4282A73A6BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_5BC02857C6B06249BD2CC4282A73C1A1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_5BC02857C6B06249BD2CC4282A73C1A1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5A1C5B0F0FB8B7C3A32D9F976593E925" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6999D2BB3DE395374F3B9F97658E3D9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5A1C5B0F0FB8B7C3A32D9F976593E925" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6999D2BB3DE395374F3B9F97658E3D9E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_9331424B6BFEA2D6C4AD9F97658EE3EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6999D2BB3DE395374F3B9F97658E3D9E" xlink:to="loc_srt_StatementGeographicalAxis_9331424B6BFEA2D6C4AD9F97658EE3EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_B7F99524ACA17DA612A69F97658F0F21_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9331424B6BFEA2D6C4AD9F97658EE3EE" xlink:to="loc_srt_SegmentGeographicalDomain_B7F99524ACA17DA612A69F97658F0F21_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_B7F99524ACA17DA612A69F97658F0F21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9331424B6BFEA2D6C4AD9F97658EE3EE" xlink:to="loc_srt_SegmentGeographicalDomain_B7F99524ACA17DA612A69F97658F0F21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_5485B7BEA7DCCDE5DF0F9F97658FF1F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_B7F99524ACA17DA612A69F97658F0F21" xlink:to="loc_country_US_5485B7BEA7DCCDE5DF0F9F97658FF1F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_7CC51C00182682F598EE9F99A43A88B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_B7F99524ACA17DA612A69F97658F0F21" xlink:to="loc_us-gaap_NonUsMember_7CC51C00182682F598EE9F99A43A88B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_3CD7E51B35F0535B805E9F97658F227E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6999D2BB3DE395374F3B9F97658E3D9E" xlink:to="loc_srt_ProductOrServiceAxis_3CD7E51B35F0535B805E9F97658F227E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3CD7E51B35F0535B805E9F97658F227E" xlink:to="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3CD7E51B35F0535B805E9F97658F227E" xlink:to="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_9B5779641286280CEEAC9F9765906BE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_TecfideraMember_9B5779641286280CEEAC9F9765906BE1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_91ACC93B3DD603BD17879F9765903A10" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_TysabriProductMember_91ACC93B3DD603BD17879F9765903A10" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_FAB5100397867B1469ED9F976591001D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_ZINBRYTAMember_FAB5100397867B1469ED9F976591001D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_B06EB6A91A602517B55A9F976591F3AD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_SPINRAZAMember_B06EB6A91A602517B55A9F976591F3AD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_CDADDF624A93D32D050E9F9765911F1F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_IMRALDIMember_CDADDF624A93D32D050E9F9765911F1F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_415325B31D2A187E77959F976591E0F0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_BiosimilarsMember_415325B31D2A187E77959F976591E0F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_4C103E1F66C26EF51D089F976593305B" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_us-gaap_ProductMember_4C103E1F66C26EF51D089F976593305B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E709C7600776D30C66069F976593D533" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5A1C5B0F0FB8B7C3A32D9F976593E925" xlink:to="loc_us-gaap_Revenues_E709C7600776D30C66069F976593D533" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7980CEB0F4B0E117B886968CB89BAB1E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_63AA93E817A6CAEE3C42968CB89910A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7980CEB0F4B0E117B886968CB89BAB1E" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_63AA93E817A6CAEE3C42968CB89910A8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_63AA93E817A6CAEE3C42968CB89910A8" xlink:to="loc_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:to="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03_default" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:to="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:to="loc_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:to="loc_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7980CEB0F4B0E117B886968CB89BAB1E" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7980CEB0F4B0E117B886968CB89BAB1E" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7980CEB0F4B0E117B886968CB89BAB1E" xlink:to="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C66EDE0C82FE2F07A1E78525C8004467" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5A2D1DE1EE7DDFD0CD788525C7FDC631" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C66EDE0C82FE2F07A1E78525C8004467" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5A2D1DE1EE7DDFD0CD788525C7FDC631" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_771BABFDC7BAA0F5B4F58525C7FD9F19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5A2D1DE1EE7DDFD0CD788525C7FDC631" xlink:to="loc_us-gaap_TypeOfArrangementAxis_771BABFDC7BAA0F5B4F58525C7FD9F19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_26ED9DCF96A61B34A8258525C7FDA1D9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_771BABFDC7BAA0F5B4F58525C7FD9F19" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_26ED9DCF96A61B34A8258525C7FDA1D9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_26ED9DCF96A61B34A8258525C7FDA1D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_771BABFDC7BAA0F5B4F58525C7FD9F19" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_26ED9DCF96A61B34A8258525C7FDA1D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_BA9545D8A394F2D8706F8525C7FE2891" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_26ED9DCF96A61B34A8258525C7FDA1D9" xlink:to="loc_us-gaap_CollaborativeArrangementMember_BA9545D8A394F2D8706F8525C7FE2891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7AB4A86A18854B92175B8525C7FEB703" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5A2D1DE1EE7DDFD0CD788525C7FDC631" xlink:to="loc_srt_ProductOrServiceAxis_7AB4A86A18854B92175B8525C7FEB703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7AB4A86A18854B92175B8525C7FEB703" xlink:to="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7AB4A86A18854B92175B8525C7FEB703" xlink:to="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_E3A9F499E105B8ED8FFC8525C7FE64E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A" xlink:to="loc_us-gaap_RoyaltyMember_E3A9F499E105B8ED8FFC8525C7FE64E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A" xlink:to="loc_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_FE3BE6FC7B951788843C8525C7FF5E63" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_FE3BE6FC7B951788843C8525C7FF5E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_3D62AF0159FBBC750B4D8525C7FFA34B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5A2D1DE1EE7DDFD0CD788525C7FDC631" xlink:to="loc_srt_MajorCustomersAxis_3D62AF0159FBBC750B4D8525C7FFA34B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3D62AF0159FBBC750B4D8525C7FFA34B" xlink:to="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3D62AF0159FBBC750B4D8525C7FFA34B" xlink:to="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_3145F14CA02A4BF536558525C800B6D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216" xlink:to="loc_biib_AbbVieMember_3145F14CA02A4BF536558525C800B6D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_9FE43081D4B7E8919CD18525C800C42B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_9FE43081D4B7E8919CD18525C800C42B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SobiMember" xlink:label="loc_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216" xlink:to="loc_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_3479AA1867F90D963D2C8525C8005532" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C66EDE0C82FE2F07A1E78525C8004467" xlink:to="loc_us-gaap_Revenues_3479AA1867F90D963D2C8525C8005532" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:to="loc_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:to="loc_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_D2CD22E8340C26F6E531968CB8B7BFF5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_D2CD22E8340C26F6E531968CB8B7BFF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_F1F19684DEA30306D059968CB8B8BB59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_F1F19684DEA30306D059968CB8B8BB59" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A319C8D4829FBD930E03121B901FB494" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_289342387B20F0DE4F2D121B901FFBB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_A319C8D4829FBD930E03121B901FB494" xlink:to="loc_us-gaap_StatementTable_289342387B20F0DE4F2D121B901FFBB0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_CCA7407BB656776270C91219ECCC0718" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_289342387B20F0DE4F2D121B901FFBB0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_CCA7407BB656776270C91219ECCC0718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_596F1322B2BBDF65EB9C1219ECCD1246_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CCA7407BB656776270C91219ECCC0718" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_596F1322B2BBDF65EB9C1219ECCD1246_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_596F1322B2BBDF65EB9C1219ECCD1246" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CCA7407BB656776270C91219ECCC0718" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_596F1322B2BBDF65EB9C1219ECCD1246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_0E23F17057ACC5C169811219ECE0759B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_596F1322B2BBDF65EB9C1219ECCD1246" xlink:to="loc_us-gaap_AccountsReceivableMember_0E23F17057ACC5C169811219ECE0759B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_660EE12B8F2B153F8E2D121A87D8414B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_596F1322B2BBDF65EB9C1219ECCD1246" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_660EE12B8F2B153F8E2D121A87D8414B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_79677E4D05C61B8A659D1219ECC1B5E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_A319C8D4829FBD930E03121B901FB494" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_79677E4D05C61B8A659D1219ECC1B5E9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_86FA3719914E1044CB669A049F9D7D84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_354DC564B61CBCFB2A299A049F9B891B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86FA3719914E1044CB669A049F9D7D84" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_354DC564B61CBCFB2A299A049F9B891B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2C572587C3A63D2A580D9A049F9B236C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_354DC564B61CBCFB2A299A049F9B891B" xlink:to="loc_srt_ProductOrServiceAxis_2C572587C3A63D2A580D9A049F9B236C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_27E6C74E8010A79E06309A049F9BBE64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2C572587C3A63D2A580D9A049F9B236C" xlink:to="loc_srt_ProductsAndServicesDomain_27E6C74E8010A79E06309A049F9BBE64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_27E6C74E8010A79E06309A049F9BBE64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2C572587C3A63D2A580D9A049F9B236C" xlink:to="loc_srt_ProductsAndServicesDomain_27E6C74E8010A79E06309A049F9BBE64" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_93BEB3F531DA48A7EA259A049F9CA0A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_27E6C74E8010A79E06309A049F9BBE64" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_93BEB3F531DA48A7EA259A049F9CA0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6403C8912603E5A125AB9A049F9C7B67" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_354DC564B61CBCFB2A299A049F9B891B" xlink:to="loc_srt_MajorCustomersAxis_6403C8912603E5A125AB9A049F9C7B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_23DCF70ED0E448D0F2529A049F9C259C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_6403C8912603E5A125AB9A049F9C7B67" xlink:to="loc_srt_NameOfMajorCustomerDomain_23DCF70ED0E448D0F2529A049F9C259C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_23DCF70ED0E448D0F2529A049F9C259C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_6403C8912603E5A125AB9A049F9C7B67" xlink:to="loc_srt_NameOfMajorCustomerDomain_23DCF70ED0E448D0F2529A049F9C259C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_EC10F1D232239E29B18D9A049F9CB6A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_23DCF70ED0E448D0F2529A049F9C259C" xlink:to="loc_biib_RocheGroupGenentechMember_EC10F1D232239E29B18D9A049F9CB6A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_08778F2C586AAB9485899A049F9DAB6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86FA3719914E1044CB669A049F9D7D84" xlink:to="loc_biib_ShareOfCoPromotionProfits_08778F2C586AAB9485899A049F9DAB6B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86FA3719914E1044CB669A049F9D7D84" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_758D9B1EC7F2EAC868619A049F9DD2BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86FA3719914E1044CB669A049F9D7D84" xlink:to="loc_us-gaap_Revenues_758D9B1EC7F2EAC868619A049F9DD2BC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_5794BC53E107E83A7FFF85CC9CAB8577" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:to="loc_srt_ProductOrServiceAxis_5794BC53E107E83A7FFF85CC9CAB8577" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5794BC53E107E83A7FFF85CC9CAB8577" xlink:to="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5794BC53E107E83A7FFF85CC9CAB8577" xlink:to="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_A1A1D98F31AED71DD96985CC9CAEC3CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_A1A1D98F31AED71DD96985CC9CAEC3CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_834084CC61A381B63BBA85EC5F431197" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467" xlink:to="loc_us-gaap_ProductMember_834084CC61A381B63BBA85EC5F431197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_F75A67902006814EF9F185CC9CAE4045" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:to="loc_srt_StatementGeographicalAxis_F75A67902006814EF9F185CC9CAE4045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_F75A67902006814EF9F185CC9CAE4045" xlink:to="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_F75A67902006814EF9F185CC9CAE4045" xlink:to="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D3DD9DF305A5A31B4E3585CC9CAE2CF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:to="loc_country_US_D3DD9DF305A5A31B4E3585CC9CAE2CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_EF04E57D20BC9FF32A7985CC9CAE80D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:to="loc_srt_EuropeMember_EF04E57D20BC9FF32A7985CC9CAE80D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_AsiaMember" xlink:label="loc_srt_AsiaMember_62AE3B768B34FE13CBF585CC9CAE13FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:to="loc_srt_AsiaMember_62AE3B768B34FE13CBF585CC9CAE13FF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_0988BF18B0B68B7FD32285CC9CAE7F03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:to="loc_us-gaap_Revenues_0988BF18B0B68B7FD32285CC9CAE7F03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_10F6E843E1B688B3365685CC9CAE2A3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432" xlink:to="loc_us-gaap_NoncurrentAssets_10F6E843E1B688B3365685CC9CAE2A3A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_0C82C275F3B87FD0AB69C428257294EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:to="loc_srt_StatementGeographicalAxis_0C82C275F3B87FD0AB69C428257294EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_99C1BB60175126CC3D4FC4282572D534_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0C82C275F3B87FD0AB69C428257294EC" xlink:to="loc_srt_SegmentGeographicalDomain_99C1BB60175126CC3D4FC4282572D534_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_99C1BB60175126CC3D4FC4282572D534" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0C82C275F3B87FD0AB69C428257294EC" xlink:to="loc_srt_SegmentGeographicalDomain_99C1BB60175126CC3D4FC4282572D534" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_B02F9FB94C15F8C04A98C4282572C326" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_99C1BB60175126CC3D4FC4282572D534" xlink:to="loc_biib_SolothurnMember_B02F9FB94C15F8C04A98C4282572C326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DK" xlink:label="loc_country_DK_2E5B90925F6CD957F36BC42825723F92" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_99C1BB60175126CC3D4FC4282572D534" xlink:to="loc_country_DK_2E5B90925F6CD957F36BC42825723F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_1F926656A1431DA70DE6C4282574D6AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F" xlink:to="loc_us-gaap_NoncurrentAssets_1F926656A1431DA70DE6C4282574D6AF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7D7D0379BC6D9664325AFBB83460D2F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7D7D0379BC6D9664325AFBB83460D2F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7D7D0379BC6D9664325AFBB83460D2F1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7D7D0379BC6D9664325AFBB83460D2F1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EA0124EEB25A0908A42FFBB83460D7A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EA0124EEB25A0908A42FFBB83460D7A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4D429B05B4F412E61357FBB834609FD5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4D429B05B4F412E61357FBB834609FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_83E1C8E96CC8602DD4E6FBB83460E28B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:to="loc_us-gaap_RestructuringChargesMember_83E1C8E96CC8602DD4E6FBB83460E28B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_36320DA5EB99718A653EFBB8346004DC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:to="loc_us-gaap_ParentMember_36320DA5EB99718A653EFBB8346004DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9F0CE78A5E4690F00B3FFBB83460189B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9F0CE78A5E4690F00B3FFBB83460189B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DA374D787DE6DD9F79B3FBB83460B67A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DA374D787DE6DD9F79B3FBB83460B67A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C58F5C0012FD697307C5FBB8346042BA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C58F5C0012FD697307C5FBB8346042BA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9352681C369C95CBF747FBB834600CA9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9352681C369C95CBF747FBB834600CA9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_499887DEC4D185E61F82F08E8D6A4355" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F3989F31CDD93510C733F08E8D696FAA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_499887DEC4D185E61F82F08E8D6A4355" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F3989F31CDD93510C733F08E8D696FAA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6BB48D4D775BFE7056DCF08E8D6921FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F3989F31CDD93510C733F08E8D696FAA" xlink:to="loc_us-gaap_PlanNameAxis_6BB48D4D775BFE7056DCF08E8D6921FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6BB48D4D775BFE7056DCF08E8D6921FC" xlink:to="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6BB48D4D775BFE7056DCF08E8D6921FC" xlink:to="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_0D148804A756E5585BF4F08E8D69B9AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_MarketStockUnitsMember_0D148804A756E5585BF4F08E8D69B9AA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_9BEC85EF2EA430C10C4DF08E8D6AC3D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_9BEC85EF2EA430C10C4DF08E8D6AC3D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_8F1E860EC69AFB3780DBF08E8D6A6EFD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_CashSettledPerformanceSharesMember_8F1E860EC69AFB3780DBF08E8D6A6EFD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_08E4D09397AB0828601DF0B32379874F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_08E4D09397AB0828601DF0B32379874F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_8872763BA965E998761AF0B34A776117" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_8872763BA965E998761AF0B34A776117" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_499887DEC4D185E61F82F08E8D6A4355" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_327E1510F01357570C0FF08E8D6B66D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_327E1510F01357570C0FF08E8D6B66D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CCE6EA81721A3F4CEB3F08E8D6B333F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CCE6EA81721A3F4CEB3F08E8D6B333F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F063094FE6FF6F54DD91F08E8D6B6489" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F063094FE6FF6F54DD91F08E8D6B6489" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_B5A759682F60FBC36C09F08E8D6B5402" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_B5A759682F60FBC36C09F08E8D6B5402" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_353197BA8206D918873E85CC9E2A0CFE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60D8AA8974AF76FE235C85CC9E277FA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_353197BA8206D918873E85CC9E2A0CFE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60D8AA8974AF76FE235C85CC9E277FA9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_12F6EAD8EA56D3B7C17485CC9E270C31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60D8AA8974AF76FE235C85CC9E277FA9" xlink:to="loc_us-gaap_AwardTypeAxis_12F6EAD8EA56D3B7C17485CC9E270C31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4143401265FCDF6700985CC9E2A4325_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_12F6EAD8EA56D3B7C17485CC9E270C31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4143401265FCDF6700985CC9E2A4325_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4143401265FCDF6700985CC9E2A4325" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_12F6EAD8EA56D3B7C17485CC9E270C31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4143401265FCDF6700985CC9E2A4325" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_D9232EA6804772BE154885CC9E2A9BE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4143401265FCDF6700985CC9E2A4325" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_D9232EA6804772BE154885CC9E2A9BE0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_353197BA8206D918873E85CC9E2A0CFE" xlink:to="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C175F3CCDAA4EDE389C785CC9E2AFCB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C175F3CCDAA4EDE389C785CC9E2AFCB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CB032796C468135464B985CC9E2A708B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CB032796C468135464B985CC9E2A708B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_746DC593DF6F36F38B1185CC9E2AD5E0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_746DC593DF6F36F38B1185CC9E2AD5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BFB335B05F9B3B0768B785CC9E2A183E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BFB335B05F9B3B0768B785CC9E2A183E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9BE211C64C47C1F1F6A185CC9E2A48C5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9BE211C64C47C1F1F6A185CC9E2A48C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_807E40643C336AD34A3985CC9E2A32F5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_807E40643C336AD34A3985CC9E2A32F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3681AFD8A42758F6152F85CC9E2C5CBF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3681AFD8A42758F6152F85CC9E2C5CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_BF988227E8D3C839D88B85CC9E2C4725" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_BF988227E8D3C839D88B85CC9E2C4725" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_640856EA7AC9DFBB54F4871CADE3AFF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:to="loc_us-gaap_PlanNameAxis_640856EA7AC9DFBB54F4871CADE3AFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7AD08147F1132212A5AF871CADE321B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_640856EA7AC9DFBB54F4871CADE3AFF6" xlink:to="loc_us-gaap_PlanNameDomain_7AD08147F1132212A5AF871CADE321B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7AD08147F1132212A5AF871CADE321B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_640856EA7AC9DFBB54F4871CADE3AFF6" xlink:to="loc_us-gaap_PlanNameDomain_7AD08147F1132212A5AF871CADE321B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7AD08147F1132212A5AF871CADE321B6" xlink:to="loc_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_F1FE1ABA889BAB3F82EE871CADE38949" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_F1FE1ABA889BAB3F82EE871CADE38949" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4E375134977D9BC8EE47871CADE3F8E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4E375134977D9BC8EE47871CADE3F8E6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:to="loc_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6" xlink:to="loc_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45" xlink:to="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A69258A77CB36963AB3C871CAE214C11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A69258A77CB36963AB3C871CAE214C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4FE6C3EE7B8D6B5D0A39871CAE2110A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4FE6C3EE7B8D6B5D0A39871CAE2110A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1B290DC65127D27F842A871CAE210642" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1B290DC65127D27F842A871CAE210642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CE98AEFF8F6B85955DFE871CAE2100BB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CE98AEFF8F6B85955DFE871CAE2100BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CACDA30051D37B507129871CAE21070E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CACDA30051D37B507129871CAE21070E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8A93CD3D48580DC61F7D871CAE21FB5E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8A93CD3D48580DC61F7D871CAE21FB5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D15571723EA24DD6BB54871CAE216A48" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D15571723EA24DD6BB54871CAE216A48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_06FF1C216BD120AA67FC871CAE21054D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_06FF1C216BD120AA67FC871CAE21054D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3AD032DBF7F4F853378FBB8348046C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC9D489ECCF7FCCC95F9FBB834802D23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3AD032DBF7F4F853378FBB8348046C4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC9D489ECCF7FCCC95F9FBB834802D23" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1137C10E0DBCFE21C356FBB834801FEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC9D489ECCF7FCCC95F9FBB834802D23" xlink:to="loc_us-gaap_AwardTypeAxis_1137C10E0DBCFE21C356FBB834801FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7DA7C5BF5491733854F1FBB834805BEC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1137C10E0DBCFE21C356FBB834801FEC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7DA7C5BF5491733854F1FBB834805BEC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7DA7C5BF5491733854F1FBB834805BEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1137C10E0DBCFE21C356FBB834801FEC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7DA7C5BF5491733854F1FBB834805BEC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_9046367906640EA750C1FBB83480D1B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7DA7C5BF5491733854F1FBB834805BEC" xlink:to="loc_biib_MarketStockUnitsMember_9046367906640EA750C1FBB83480D1B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_69EBE591A8B9A42F9E3BFBB83480CB99" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC9D489ECCF7FCCC95F9FBB834802D23" xlink:to="loc_srt_RangeAxis_69EBE591A8B9A42F9E3BFBB83480CB99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C33F33193AEFF5630C80FBB834803D12_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_69EBE591A8B9A42F9E3BFBB83480CB99" xlink:to="loc_srt_RangeMember_C33F33193AEFF5630C80FBB834803D12_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C33F33193AEFF5630C80FBB834803D12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_69EBE591A8B9A42F9E3BFBB83480CB99" xlink:to="loc_srt_RangeMember_C33F33193AEFF5630C80FBB834803D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A942F32FCB783CBB1433FBB83480F463" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_C33F33193AEFF5630C80FBB834803D12" xlink:to="loc_srt_MinimumMember_A942F32FCB783CBB1433FBB83480F463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_4468F966E378E2F4275FFBB83480A2EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_C33F33193AEFF5630C80FBB834803D12" xlink:to="loc_srt_MaximumMember_4468F966E378E2F4275FFBB83480A2EF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3AD032DBF7F4F853378FBB8348046C4" xlink:to="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D0B0CA0DFBB04EF18DECFBB834806E88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D0B0CA0DFBB04EF18DECFBB834806E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EC9C932899C708B5CEF7FBB83480DFA7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EC9C932899C708B5CEF7FBB83480DFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3B39ADCBC4F200DB70FBFBB8348F58AA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3B39ADCBC4F200DB70FBFBB8348F58AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_BE31FDDC2546DBAD8529FBB8348F3599" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_BE31FDDC2546DBAD8529FBB8348F3599" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8F99AB1D21053E7D31B9FBB8348F87C1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8F99AB1D21053E7D31B9FBB8348F87C1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8300F88801C179966D29871CAE120217" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9D960BFA82D9183D6CCF871CAE02CD02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8300F88801C179966D29871CAE120217" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9D960BFA82D9183D6CCF871CAE02CD02" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6D3CAB571AC86BEA768C871CAE12CABE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9D960BFA82D9183D6CCF871CAE02CD02" xlink:to="loc_us-gaap_AwardTypeAxis_6D3CAB571AC86BEA768C871CAE12CABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44C770035076D67C91F8871CAE12AD7C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6D3CAB571AC86BEA768C871CAE12CABE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44C770035076D67C91F8871CAE12AD7C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44C770035076D67C91F8871CAE12AD7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6D3CAB571AC86BEA768C871CAE12CABE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44C770035076D67C91F8871CAE12AD7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44C770035076D67C91F8871CAE12AD7C" xlink:to="loc_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8300F88801C179966D29871CAE120217" xlink:to="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ED7AEA17320D5CE437DB871CAE12032B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ED7AEA17320D5CE437DB871CAE12032B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5AB75D6EE2E411A9B3BD871CAE12FD72" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5AB75D6EE2E411A9B3BD871CAE12FD72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_32428BABDE38B381DC5D871CAE12ED19" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_32428BABDE38B381DC5D871CAE12ED19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4DAFCE7BF6079DBE4126871CAE1262B2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4DAFCE7BF6079DBE4126871CAE1262B2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC5583B4481C200087C8F08E8D3B965A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC5583B4481C200087C8F08E8D3B965A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7C9511A9F60582A7076BF08E8D3B64F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC5583B4481C200087C8F08E8D3B965A" xlink:to="loc_us-gaap_AwardTypeAxis_7C9511A9F60582A7076BF08E8D3B64F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48DD61CE30802EC81EC6F08E8D3B519F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7C9511A9F60582A7076BF08E8D3B64F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48DD61CE30802EC81EC6F08E8D3B519F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48DD61CE30802EC81EC6F08E8D3B519F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7C9511A9F60582A7076BF08E8D3B64F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48DD61CE30802EC81EC6F08E8D3B519F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_59425C251796DAC013FAF08E8D3B9844" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48DD61CE30802EC81EC6F08E8D3B519F" xlink:to="loc_us-gaap_PerformanceSharesMember_59425C251796DAC013FAF08E8D3B9844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40DBC404A8E106140813F08E8D3CDD79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40DBC404A8E106140813F08E8D3CDD79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CA6B6B81B4E58812C190F08E8D3DDCB7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CA6B6B81B4E58812C190F08E8D3DDCB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1D0FBF0C0114B8D934E7F08E8D3DBBF9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1D0FBF0C0114B8D934E7F08E8D3DBBF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_35BDCB99264A72A934A5F08E8D3DF872" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_35BDCB99264A72A934A5F08E8D3DF872" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_187220AC533A8585261C9A049DD60FE8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1B3B597E1CAB03DD02ED9A049DD45614" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_187220AC533A8585261C9A049DD60FE8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1B3B597E1CAB03DD02ED9A049DD45614" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1B3B597E1CAB03DD02ED9A049DD45614" xlink:to="loc_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:to="loc_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:to="loc_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_30AB71BB9D4CCF01FDF99A049DD506DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_30AB71BB9D4CCF01FDF99A049DD506DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_78703E2F9722B84A97639A049DD544C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1B3B597E1CAB03DD02ED9A049DD45614" xlink:to="loc_us-gaap_AwardTypeAxis_78703E2F9722B84A97639A049DD544C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C429AC9DA63574CCEACC9A049DD61857_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_78703E2F9722B84A97639A049DD544C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C429AC9DA63574CCEACC9A049DD61857_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C429AC9DA63574CCEACC9A049DD61857" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_78703E2F9722B84A97639A049DD544C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C429AC9DA63574CCEACC9A049DD61857" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_389B7E4C49FEFC7EF0DC9A049DD638A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C429AC9DA63574CCEACC9A049DD61857" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_389B7E4C49FEFC7EF0DC9A049DD638A5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_187220AC533A8585261C9A049DD60FE8" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83D2CF382EF03C6514589A049DD79771" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83D2CF382EF03C6514589A049DD79771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_540D20FE89DEDC2C93ED9A049DD7934B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_540D20FE89DEDC2C93ED9A049DD7934B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D91620CBC371F062044A9A049DD74C15" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D91620CBC371F062044A9A049DD74C15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89052709A0E9E06B10C09A049DD763F2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89052709A0E9E06B10C09A049DD763F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858490CE112F7E7F70B09A049DD7C4E7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858490CE112F7E7F70B09A049DD7C4E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_DA74C438EEE81BADB9F39A049DD85B68" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_DA74C438EEE81BADB9F39A049DD85B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6D0EB5F994A3003379FE9A049DD892B5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6D0EB5F994A3003379FE9A049DD892B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_49E566F8E80682E3A0A49A049DD8E71C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_49E566F8E80682E3A0A49A049DD8E71C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ACCB095C1D74110251C9A049DCA38D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4E4676488F63BB4E9A5B9A049DC8C23D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ACCB095C1D74110251C9A049DCA38D4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4E4676488F63BB4E9A5B9A049DC8C23D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_23DCAF40CB37787B05719A049DC9CCB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4E4676488F63BB4E9A5B9A049DC8C23D" xlink:to="loc_us-gaap_AwardTypeAxis_23DCAF40CB37787B05719A049DC9CCB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F0871F4E8885C0C998F69A049DC9F3FC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_23DCAF40CB37787B05719A049DC9CCB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F0871F4E8885C0C998F69A049DC9F3FC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F0871F4E8885C0C998F69A049DC9F3FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_23DCAF40CB37787B05719A049DC9CCB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F0871F4E8885C0C998F69A049DC9F3FC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_E52E76580AF24DDBA8159A049DC99B1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F0871F4E8885C0C998F69A049DC9F3FC" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_E52E76580AF24DDBA8159A049DC99B1C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ACCB095C1D74110251C9A049DCA38D4" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7F6EA1A1F469D7D9F4DA9A049DCA981B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7F6EA1A1F469D7D9F4DA9A049DCA981B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_960866D859416A299F689A049DCAB186" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_960866D859416A299F689A049DCAB186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30FFF5892D6382C3FEBA9A049DCADE73" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30FFF5892D6382C3FEBA9A049DCADE73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_594BA2C1EDD92B480ECF9A049DCBCE92" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_594BA2C1EDD92B480ECF9A049DCBCE92" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06DDE4F5280E0FB7498B871CADD36997" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06DDE4F5280E0FB7498B871CADD36997" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2AD01413A8C00F6D429E871CADD30740" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06DDE4F5280E0FB7498B871CADD36997" xlink:to="loc_us-gaap_PlanNameAxis_2AD01413A8C00F6D429E871CADD30740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3774B06E4684A5D509A1871CADD3E755_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2AD01413A8C00F6D429E871CADD30740" xlink:to="loc_us-gaap_PlanNameDomain_3774B06E4684A5D509A1871CADD3E755_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3774B06E4684A5D509A1871CADD3E755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2AD01413A8C00F6D429E871CADD30740" xlink:to="loc_us-gaap_PlanNameDomain_3774B06E4684A5D509A1871CADD3E755" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3774B06E4684A5D509A1871CADD3E755" xlink:to="loc_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3774B06E4684A5D509A1871CADD3E755" xlink:to="loc_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06DDE4F5280E0FB7498B871CADD36997" xlink:to="loc_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_8955E2C330B4A8B3E387871CADD3A9B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF" xlink:to="loc_us-gaap_DirectorMember_8955E2C330B4A8B3E387871CADD3A9B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8673CE1EDABED670D005871CADD3945A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06DDE4F5280E0FB7498B871CADD36997" xlink:to="loc_us-gaap_AwardTypeAxis_8673CE1EDABED670D005871CADD3945A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8673CE1EDABED670D005871CADD3945A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8673CE1EDABED670D005871CADD3945A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_CF9599084BD9B66BFD51871CADD33F05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_biib_MarketStockUnitsMember_CF9599084BD9B66BFD51871CADD33F05" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_DAAEFFB3ADFA33B98BB1871CADD3FF55" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_biib_CashSettledPerformanceSharesMember_DAAEFFB3ADFA33B98BB1871CADD3FF55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_63772074DD16206723BF871CADD322B5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_us-gaap_PerformanceSharesMember_63772074DD16206723BF871CADD322B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_AFC2334DCE56EE23C875871CADD32B91" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_AFC2334DCE56EE23C875871CADD32B91" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_BDACAD16830C95D2C348871CADD398E9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_BDACAD16830C95D2C348871CADD398E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F51495D85928AA2CE870871CADD3AB48" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F51495D85928AA2CE870871CADD3AB48" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B74D57A2F8FD59D32073871CADD34D26" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B74D57A2F8FD59D32073871CADD34D26" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9AAE1A2045B79846227C871CADE348AB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9AAE1A2045B79846227C871CADE348AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_4E6300CD9BE6A2D80703871CADE32BEA" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_4E6300CD9BE6A2D80703871CADE32BEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_DA3673FE2FD54AD5E2C1871CADE3F520" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_DA3673FE2FD54AD5E2C1871CADE3F520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_321DA88CB989043B32FC871CADE32054" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_321DA88CB989043B32FC871CADE32054" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:to="loc_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2AD9CE1A4722E7092DEEAAF0BC9F9984" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2AD9CE1A4722E7092DEEAAF0BC9F9984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3ACF15E75B84CC81F09AAF0BCA462CD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2AD9CE1A4722E7092DEEAAF0BC9F9984" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3ACF15E75B84CC81F09AAF0BCA462CD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3ACF15E75B84CC81F09AAF0BCA462CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2AD9CE1A4722E7092DEEAAF0BC9F9984" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3ACF15E75B84CC81F09AAF0BCA462CD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3ACF15E75B84CC81F09AAF0BCA462CD" xlink:to="loc_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_92CA66DC864BB8DF3221AAF0BCA5D29D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84" xlink:to="loc_us-gaap_SubsequentEventMember_92CA66DC864BB8DF3221AAF0BCA5D29D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_E1465013465F5D540F64AAF0BCA51AB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_E1465013465F5D540F64AAF0BCA51AB8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_F6D1D2ABF9642F311390AAF0BCA64BA8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:to="loc_biib_AdditionalMilestonePayment_F6D1D2ABF9642F311390AAF0BCA64BA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_E6FDD04313EC48801D6EAAF0BCABD2C6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_E6FDD04313EC48801D6EAAF0BCABD2C6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_9B9AEB89043A9BF5ED51BAB559A76C0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_9B9AEB89043A9BF5ED51BAB559A76C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_AD1253BA723379B236A6BAB559A7CC73_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_9B9AEB89043A9BF5ED51BAB559A76C0C" xlink:to="loc_us-gaap_AccountingGuidanceMember_AD1253BA723379B236A6BAB559A7CC73_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_AD1253BA723379B236A6BAB559A7CC73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_9B9AEB89043A9BF5ED51BAB559A76C0C" xlink:to="loc_us-gaap_AccountingGuidanceMember_AD1253BA723379B236A6BAB559A7CC73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B065DAA3F1F66AD836ECBAB559A7B53C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountingGuidanceMember_AD1253BA723379B236A6BAB559A7CC73" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_B065DAA3F1F66AD836ECBAB559A7B53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E68FA081D13CEEBF832DBAB559A73F41" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E68FA081D13CEEBF832DBAB559A73F41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E68FA081D13CEEBF832DBAB559A73F41" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E68FA081D13CEEBF832DBAB559A73F41" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_1C5500EAF721B49DAB33BAB559A71039" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43" xlink:to="loc_biib_OthercorporaterevenuesMember_1C5500EAF721B49DAB33BAB559A71039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_79588EE5F0EA7ACEB752BAB559A75A39" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43" xlink:to="loc_us-gaap_CostOfSalesMember_79588EE5F0EA7ACEB752BAB559A75A39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6D5B264E16AC232310F0BAB559A7CE5C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6D5B264E16AC232310F0BAB559A7CE5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B10CC98DA237DC727FF9BAB559A7BF22" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B10CC98DA237DC727FF9BAB559A7BF22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B10CC98DA237DC727FF9BAB559A7BF22" xlink:to="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B10CC98DA237DC727FF9BAB559A7BF22" xlink:to="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_CEA13F312AF777A61E74BAB559A726C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_CEA13F312AF777A61E74BAB559A726C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_F3DD12A48A174ECFAC03BAB559A77E1C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_F3DD12A48A174ECFAC03BAB559A77E1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_46844948A4696954CC40BAB559A79E2E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_46844948A4696954CC40BAB559A79E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201707Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201707Member_1F72E107E76AD9BF7E63BAB559A73CEF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:to="loc_us-gaap_AccountingStandardsUpdate201707Member_1F72E107E76AD9BF7E63BAB559A73CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_302C67627D9C029EC8F6BAB559A79D58" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_302C67627D9C029EC8F6BAB559A79D58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_302C67627D9C029EC8F6BAB559A79D58" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_302C67627D9C029EC8F6BAB559A79D58" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_0F08F6820158588BB5A0BAB559A7DA16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:to="loc_us-gaap_RetainedEarningsMember_0F08F6820158588BB5A0BAB559A7DA16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7F6A940E213D85A2E4F0BAB62F7A6867" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7F6A940E213D85A2E4F0BAB62F7A6867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember_6A88D0ADB4D3817A5395BAB559A7E940" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:to="loc_us-gaap_DeferredIncomeTaxChargesMember_6A88D0ADB4D3817A5395BAB559A7E940" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_E7C0C2FF93AF6E9C82C3BAB559A7B8C0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:to="loc_biib_DeferredtaxliabilityMember_E7C0C2FF93AF6E9C82C3BAB559A7B8C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_507C4C620B62D96A0914BAB559A72545" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_srt_RangeAxis_507C4C620B62D96A0914BAB559A72545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F3EC5EAA52605FD6E185BAB559A788CF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_507C4C620B62D96A0914BAB559A72545" xlink:to="loc_srt_RangeMember_F3EC5EAA52605FD6E185BAB559A788CF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F3EC5EAA52605FD6E185BAB559A788CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_507C4C620B62D96A0914BAB559A72545" xlink:to="loc_srt_RangeMember_F3EC5EAA52605FD6E185BAB559A788CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_214DDF32CFC1C8E694C1BAB559A74BB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_F3EC5EAA52605FD6E185BAB559A788CF" xlink:to="loc_srt_MinimumMember_214DDF32CFC1C8E694C1BAB559A74BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FAF1032477B54B2F05C3BAB559A7F637" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_F3EC5EAA52605FD6E185BAB559A788CF" xlink:to="loc_srt_MaximumMember_FAF1032477B54B2F05C3BAB559A7F637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_866E2FA8A5B0E992EC59BAB559B74770" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:to="loc_us-gaap_BuildingMember_866E2FA8A5B0E992EC59BAB559B74770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2719DC48BB3E0D518B82BAB559B77786" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2719DC48BB3E0D518B82BAB559B77786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6A1675B7F42F10F750CDBAB559B7F0B6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6A1675B7F42F10F750CDBAB559B7F0B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_07C8E7222458C858BEC3BAB559B7ECF8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:to="loc_us-gaap_ComputerEquipmentMember_07C8E7222458C858BEC3BAB559B7ECF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4788581F0C22F56144D6BAB559B72F41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4788581F0C22F56144D6BAB559B72F41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_7883A65E24B2899F464CBAB559B75660" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_7883A65E24B2899F464CBAB559B75660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5B9776071A8629FDFF11BAB559B71ADA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5B9776071A8629FDFF11BAB559B71ADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_B643784BD894B30B624CBAB559B7DEC8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_B643784BD894B30B624CBAB559B7DEC8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>biib-20181231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_214F39BF77EFF63BE54DC42829492134_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_214F39BF77EFF63BE54DC42829492134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_214F39BF77EFF63BE54DC42829492134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_214F39BF77EFF63BE54DC42829492134" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_214F39BF77EFF63BE54DC42829492134" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:to="lab_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:type="arc" />
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Research and development asset [Axis]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:to="lab_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:type="arc" />
    <link:label id="lab_biib_PLSRMember_F1BA6618196880431940C428294A3DF0_terseLabel_en-US" xlink:label="lab_biib_PLSRMember_F1BA6618196880431940C428294A3DF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PLSR</link:label>
    <link:label id="lab_biib_PLSRMember_F1BA6618196880431940C428294A3DF0_label_en-US" xlink:label="lab_biib_PLSRMember_F1BA6618196880431940C428294A3DF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PLSR [Member]</link:label>
    <link:label id="lab_biib_PLSRMember_F1BA6618196880431940C428294A3DF0_documentation_en-US" xlink:label="lab_biib_PLSRMember_F1BA6618196880431940C428294A3DF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PLSR [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PLSRMember" xlink:label="loc_biib_PLSRMember_F1BA6618196880431940C428294A3DF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLSRMember_F1BA6618196880431940C428294A3DF0" xlink:to="lab_biib_PLSRMember_F1BA6618196880431940C428294A3DF0" xlink:type="arc" />
    <link:label id="lab_biib_TGNMember_2AB1441CC378E02365D8C428294A032C_terseLabel_en-US" xlink:label="lab_biib_TGNMember_2AB1441CC378E02365D8C428294A032C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TGN</link:label>
    <link:label id="lab_biib_TGNMember_2AB1441CC378E02365D8C428294A032C_label_en-US" xlink:label="lab_biib_TGNMember_2AB1441CC378E02365D8C428294A032C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_2AB1441CC378E02365D8C428294A032C_documentation_en-US" xlink:label="lab_biib_TGNMember_2AB1441CC378E02365D8C428294A032C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TGN [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_2AB1441CC378E02365D8C428294A032C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember_2AB1441CC378E02365D8C428294A032C" xlink:to="lab_biib_TGNMember_2AB1441CC378E02365D8C428294A032C" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:to="lab_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="lab_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:type="arc" />
    <link:label id="lab_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585_label_en-US" xlink:label="lab_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585_documentation_en-US" xlink:label="lab_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585" xlink:to="lab_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585" xlink:type="arc" />
    <link:label id="lab_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C_label_en-US" xlink:label="lab_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C_documentation_en-US" xlink:label="lab_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C" xlink:to="lab_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C" xlink:type="arc" />
    <link:label id="lab_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6_label_en-US" xlink:label="lab_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6" xlink:to="lab_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6" xlink:type="arc" />
    <link:label id="lab_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C_label_en-US" xlink:label="lab_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C" xlink:to="lab_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C" xlink:type="arc" />
    <link:label id="lab_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E_label_en-US" xlink:label="lab_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E" xlink:to="lab_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E" xlink:type="arc" />
    <link:label id="lab_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94_terseLabel_en-US" xlink:label="lab_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94_label_en-US" xlink:label="lab_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94_documentation_en-US" xlink:label="lab_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94" xlink:to="lab_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_5000FDEE55E475CDB45BC42829515AD2_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_5000FDEE55E475CDB45BC42829515AD2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_5000FDEE55E475CDB45BC42829515AD2_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_5000FDEE55E475CDB45BC42829515AD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5000FDEE55E475CDB45BC42829515AD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_5000FDEE55E475CDB45BC42829515AD2" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_5000FDEE55E475CDB45BC42829515AD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_A37B8EA59FFE0DA246E4C42829526DC1_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_A37B8EA59FFE0DA246E4C42829526DC1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_A37B8EA59FFE0DA246E4C42829526DC1_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember_A37B8EA59FFE0DA246E4C42829526DC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_A37B8EA59FFE0DA246E4C42829526DC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember_A37B8EA59FFE0DA246E4C42829526DC1" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember_A37B8EA59FFE0DA246E4C42829526DC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:type="arc" />
    <link:label id="lab_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Out-licensed patents</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F" xlink:to="lab_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_AFAB92EB8B8A8AB26196C4282953C94D_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_AFAB92EB8B8A8AB26196C4282953C94D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_AFAB92EB8B8A8AB26196C4282953C94D_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_AFAB92EB8B8A8AB26196C4282953C94D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_AFAB92EB8B8A8AB26196C4282953C94D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_AFAB92EB8B8A8AB26196C4282953C94D" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_AFAB92EB8B8A8AB26196C4282953C94D" xlink:type="arc" />
    <link:label id="lab_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B_terseLabel_en-US" xlink:label="lab_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B_label_en-US" xlink:label="lab_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B_documentation_en-US" xlink:label="lab_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">In-licensed patents.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B" xlink:to="lab_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8_label_en-US" xlink:label="lab_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:to="lab_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248_terseLabel_en-US" xlink:label="lab_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248_label_en-US" xlink:label="lab_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:to="lab_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_A26F93A18348ED50D028C4282953E6BF_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember_A26F93A18348ED50D028C4282953E6BF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_A26F93A18348ED50D028C4282953E6BF_label_en-US" xlink:label="lab_srt_MinimumMember_A26F93A18348ED50D028C4282953E6BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A26F93A18348ED50D028C4282953E6BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_A26F93A18348ED50D028C4282953E6BF" xlink:to="lab_srt_MinimumMember_A26F93A18348ED50D028C4282953E6BF" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_7A218E0B75A430870398C42829546729_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember_7A218E0B75A430870398C42829546729" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_7A218E0B75A430870398C42829546729_label_en-US" xlink:label="lab_srt_MaximumMember_7A218E0B75A430870398C42829546729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7A218E0B75A430870398C42829546729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_7A218E0B75A430870398C42829546729" xlink:to="lab_srt_MaximumMember_7A218E0B75A430870398C42829546729" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:type="arc" />
    <link:label id="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82_terseLabel_en-US" xlink:label="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82_label_en-US" xlink:label="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82_documentation_en-US" xlink:label="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82" xlink:to="lab_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_33AD47A1877FDD0713AEC42829554210_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_33AD47A1877FDD0713AEC42829554210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_33AD47A1877FDD0713AEC42829554210_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_33AD47A1877FDD0713AEC42829554210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_33AD47A1877FDD0713AEC42829554210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_33AD47A1877FDD0713AEC42829554210" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_33AD47A1877FDD0713AEC42829554210" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4C257080864FE6A70786C4282955B5E9_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4C257080864FE6A70786C4282955B5E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated life, (In Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4C257080864FE6A70786C4282955B5E9_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4C257080864FE6A70786C4282955B5E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4C257080864FE6A70786C4282955B5E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4C257080864FE6A70786C4282955B5E9" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4C257080864FE6A70786C4282955B5E9" xlink:type="arc" />
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA_terseLabel_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA_label_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite Lived Intangible Assets Useful Life</link:label>
    <link:label id="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA_documentation_en-US" xlink:label="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Indefinite lived intangible assets useful life.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA" xlink:to="lab_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5457FC74625F785D9E06C4282955F0EF_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5457FC74625F785D9E06C4282955F0EF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5457FC74625F785D9E06C4282955F0EF_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5457FC74625F785D9E06C4282955F0EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5457FC74625F785D9E06C4282955F0EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5457FC74625F785D9E06C4282955F0EF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_5457FC74625F785D9E06C4282955F0EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_F3204E809371F4E071F9C428295607E0_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_F3204E809371F4E071F9C428295607E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_F3204E809371F4E071F9C428295607E0_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_F3204E809371F4E071F9C428295607E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_F3204E809371F4E071F9C428295607E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_F3204E809371F4E071F9C428295607E0" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_F3204E809371F4E071F9C428295607E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0282E2A0A3206D589B69C4282956EAA4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0282E2A0A3206D589B69C4282956EAA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0282E2A0A3206D589B69C4282956EAA4_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0282E2A0A3206D589B69C4282956EAA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0282E2A0A3206D589B69C4282956EAA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0282E2A0A3206D589B69C4282956EAA4" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0282E2A0A3206D589B69C4282956EAA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42D1A4C1A0451D78D0C0C428295683E3_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42D1A4C1A0451D78D0C0C428295683E3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42D1A4C1A0451D78D0C0C428295683E3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42D1A4C1A0451D78D0C0C428295683E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42D1A4C1A0451D78D0C0C428295683E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42D1A4C1A0451D78D0C0C428295683E3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42D1A4C1A0451D78D0C0C428295683E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_84EAB06D01FDB735ABD7C42829560E5F_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_84EAB06D01FDB735ABD7C42829560E5F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_84EAB06D01FDB735ABD7C42829560E5F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_84EAB06D01FDB735ABD7C42829560E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_84EAB06D01FDB735ABD7C42829560E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_84EAB06D01FDB735ABD7C42829560E5F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_84EAB06D01FDB735ABD7C42829560E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6A2B2E2870ED431A2754C428295B682B_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6A2B2E2870ED431A2754C428295B682B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6A2B2E2870ED431A2754C428295B682B_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6A2B2E2870ED431A2754C428295B682B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6A2B2E2870ED431A2754C428295B682B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6A2B2E2870ED431A2754C428295B682B" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6A2B2E2870ED431A2754C428295B682B" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill (Additional Textual)</link:label>
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4_label_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets And Goodwill (Additional Textual) [Abstract]</link:label>
    <link:label id="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets and goodwill additional.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:to="lab_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_51B33855F1BF0B24C670C428295C6BD6_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_51B33855F1BF0B24C670C428295C6BD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2019</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_51B33855F1BF0B24C670C428295C6BD6_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_51B33855F1BF0B24C670C428295C6BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_51B33855F1BF0B24C670C428295C6BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_51B33855F1BF0B24C670C428295C6BD6" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_51B33855F1BF0B24C670C428295C6BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ED69C17952519B33DF48C428295C8484_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ED69C17952519B33DF48C428295C8484" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ED69C17952519B33DF48C428295C8484_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ED69C17952519B33DF48C428295C8484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ED69C17952519B33DF48C428295C8484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ED69C17952519B33DF48C428295C8484" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ED69C17952519B33DF48C428295C8484" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_005E7F53763AF9A907F1C428295C2EE0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_005E7F53763AF9A907F1C428295C2EE0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_005E7F53763AF9A907F1C428295C2EE0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_005E7F53763AF9A907F1C428295C2EE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_005E7F53763AF9A907F1C428295C2EE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_005E7F53763AF9A907F1C428295C2EE0" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_005E7F53763AF9A907F1C428295C2EE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F917D22EE162C080F141C428295C3FED_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F917D22EE162C080F141C428295C3FED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F917D22EE162C080F141C428295C3FED_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F917D22EE162C080F141C428295C3FED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F917D22EE162C080F141C428295C3FED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F917D22EE162C080F141C428295C3FED" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F917D22EE162C080F141C428295C3FED" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_664DCEEE816E8E71333AC428295D9025_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_664DCEEE816E8E71333AC428295D9025" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_664DCEEE816E8E71333AC428295D9025_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_664DCEEE816E8E71333AC428295D9025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_664DCEEE816E8E71333AC428295D9025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_664DCEEE816E8E71333AC428295D9025" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_664DCEEE816E8E71333AC428295D9025" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_D5B2E5FC001690378CAFC428295DB807_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_D5B2E5FC001690378CAFC428295DB807" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_D5B2E5FC001690378CAFC428295DB807_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_D5B2E5FC001690378CAFC428295DB807" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D5B2E5FC001690378CAFC428295DB807" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_D5B2E5FC001690378CAFC428295DB807" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_D5B2E5FC001690378CAFC428295DB807" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_AAF356E46A3B694C4A0BC428295D487D_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_AAF356E46A3B694C4A0BC428295D487D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of out-licensed patent</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_AAF356E46A3B694C4A0BC428295D487D_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_AAF356E46A3B694C4A0BC428295D487D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_AAF356E46A3B694C4A0BC428295D487D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_AAF356E46A3B694C4A0BC428295D487D" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_AAF356E46A3B694C4A0BC428295D487D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5D02D55C823195A076AC428295D5F19_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5D02D55C823195A076AC428295D5F19" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5D02D55C823195A076AC428295D5F19_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5D02D55C823195A076AC428295D5F19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5D02D55C823195A076AC428295D5F19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5D02D55C823195A076AC428295D5F19" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5D02D55C823195A076AC428295D5F19" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_31262007568BB8B409D9C428295D45F0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_31262007568BB8B409D9C428295D45F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_31262007568BB8B409D9C428295D45F0_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_31262007568BB8B409D9C428295D45F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_31262007568BB8B409D9C428295D45F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_31262007568BB8B409D9C428295D45F0" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_31262007568BB8B409D9C428295D45F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7E476FFF9C91BF99F84FC428295E6A0D_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7E476FFF9C91BF99F84FC428295E6A0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment made to Forward Pharma</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7E476FFF9C91BF99F84FC428295E6A0D_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7E476FFF9C91BF99F84FC428295E6A0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7E476FFF9C91BF99F84FC428295E6A0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7E476FFF9C91BF99F84FC428295E6A0D" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7E476FFF9C91BF99F84FC428295E6A0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementExpense_889C72AA98D0C6E20C5EC428295E4CE7_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_889C72AA98D0C6E20C5EC428295E4CE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA litigation settlement charge</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_889C72AA98D0C6E20C5EC428295E4CE7_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_889C72AA98D0C6E20C5EC428295E4CE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_889C72AA98D0C6E20C5EC428295E4CE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense_889C72AA98D0C6E20C5EC428295E4CE7" xlink:to="lab_us-gaap_LitigationSettlementExpense_889C72AA98D0C6E20C5EC428295E4CE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D4E602D020AFC4F86E6FFBB831559FBC_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D4E602D020AFC4F86E6FFBB831559FBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D4E602D020AFC4F86E6FFBB831559FBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D4E602D020AFC4F86E6FFBB831559FBC" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D4E602D020AFC4F86E6FFBB831559FBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B150C8AC548416F7E76AFBB8315505B4_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B150C8AC548416F7E76AFBB8315505B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B150C8AC548416F7E76AFBB8315505B4_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B150C8AC548416F7E76AFBB8315505B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B150C8AC548416F7E76AFBB8315505B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B150C8AC548416F7E76AFBB8315505B4" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B150C8AC548416F7E76AFBB8315505B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_64776F61EDCEF0FFFB92856979425303_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_64776F61EDCEF0FFFB92856979425303" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_64776F61EDCEF0FFFB92856979425303" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_64776F61EDCEF0FFFB92856979425303" xlink:to="lab_us-gaap_DebtDisclosureAbstract_64776F61EDCEF0FFFB92856979425303" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:to="lab_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:to="lab_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_B42F1C71C08E92DBD90585697942B0AE_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_B42F1C71C08E92DBD90585697942B0AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Note payable to Fumedica</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_B42F1C71C08E92DBD90585697942B0AE_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_B42F1C71C08E92DBD90585697942B0AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_B42F1C71C08E92DBD90585697942B0AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember_B42F1C71C08E92DBD90585697942B0AE" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember_B42F1C71C08E92DBD90585697942B0AE" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC_label_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC_documentation_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Six Point Eight Seven Five Percent Due Twenty Eighteen.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.90% Senior Notes due 2020</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D_label_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D_documentation_en-US" xlink:label="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Two Point Nine Percent Due Twenty Twenty [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D" xlink:to="lab_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.05% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.20% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:to="lab_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:to="lab_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_943FA5E005CD69D3B29985697942D269_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_943FA5E005CD69D3B29985697942D269" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable to Fumedica AG</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_943FA5E005CD69D3B29985697942D269_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_943FA5E005CD69D3B29985697942D269" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_943FA5E005CD69D3B29985697942D269" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_943FA5E005CD69D3B29985697942D269" xlink:to="lab_us-gaap_NotesPayableCurrent_943FA5E005CD69D3B29985697942D269" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_EBA91F6A9FFAA98A2EAB85697942E1DC_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_EBA91F6A9FFAA98A2EAB85697942E1DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_EBA91F6A9FFAA98A2EAB85697942E1DC_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_EBA91F6A9FFAA98A2EAB85697942E1DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_EBA91F6A9FFAA98A2EAB85697942E1DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_EBA91F6A9FFAA98A2EAB85697942E1DC" xlink:to="lab_us-gaap_DebtCurrent_EBA91F6A9FFAA98A2EAB85697942E1DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_3CA224CA3F7DBDC115D585697942F47C_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_3CA224CA3F7DBDC115D585697942F47C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_3CA224CA3F7DBDC115D585697942F47C_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_3CA224CA3F7DBDC115D585697942F47C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_3CA224CA3F7DBDC115D585697942F47C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_3CA224CA3F7DBDC115D585697942F47C" xlink:to="lab_us-gaap_LongTermNotesPayable_3CA224CA3F7DBDC115D585697942F47C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_94F25220E633721F217385697942EFBA_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_94F25220E633721F217385697942EFBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_94F25220E633721F217385697942EFBA_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_94F25220E633721F217385697942EFBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_94F25220E633721F217385697942EFBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_94F25220E633721F217385697942EFBA" xlink:to="lab_us-gaap_LongTermDebt_94F25220E633721F217385697942EFBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20B253A01DD51100789CFBB8317438DE_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20B253A01DD51100789CFBB8317438DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20B253A01DD51100789CFBB8317438DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20B253A01DD51100789CFBB8317438DE" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20B253A01DD51100789CFBB8317438DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24A3F7295E8E6DEDA311FBB83174F3AC_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24A3F7295E8E6DEDA311FBB83174F3AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24A3F7295E8E6DEDA311FBB83174F3AC_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24A3F7295E8E6DEDA311FBB83174F3AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24A3F7295E8E6DEDA311FBB83174F3AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24A3F7295E8E6DEDA311FBB83174F3AC" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24A3F7295E8E6DEDA311FBB83174F3AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_51D0634A633639445357A5E9ED6A3501_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_51D0634A633639445357A5E9ED6A3501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_51D0634A633639445357A5E9ED6A3501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51D0634A633639445357A5E9ED6A3501" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_51D0634A633639445357A5E9ED6A3501" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesMember_B396646A14672C3F80FFA5EC432C6327_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_B396646A14672C3F80FFA5EC432C6327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_B396646A14672C3F80FFA5EC432C6327_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_B396646A14672C3F80FFA5EC432C6327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_B396646A14672C3F80FFA5EC432C6327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_B396646A14672C3F80FFA5EC432C6327" xlink:to="lab_us-gaap_CostOfSalesMember_B396646A14672C3F80FFA5EC432C6327" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C" xlink:to="lab_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_AC044161D81DDD9F8B19A5E9ED6D9282_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_AC044161D81DDD9F8B19A5E9ED6D9282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201616Member_AC044161D81DDD9F8B19A5E9ED6D9282_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201616Member_AC044161D81DDD9F8B19A5E9ED6D9282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-16 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_AC044161D81DDD9F8B19A5E9ED6D9282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201616Member_AC044161D81DDD9F8B19A5E9ED6D9282" xlink:to="lab_us-gaap_AccountingStandardsUpdate201616Member_AC044161D81DDD9F8B19A5E9ED6D9282" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F_terseLabel_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:label id="lab_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F_label_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:label id="lab_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F_documentation_en-US" xlink:label="lab_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Axis]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:to="lab_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601_terseLabel_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Domain]</link:label>
    <link:label id="lab_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601_label_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings type [Domain]</link:label>
    <link:label id="lab_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601_documentation_en-US" xlink:label="lab_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Foreign earnings type [Axis]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:to="lab_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:type="arc" />
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4_terseLabel_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings in the form of cash and cash equivalents</link:label>
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4_label_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign earnings in the form of cash and cash equivalents [Member]</link:label>
    <link:label id="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4_documentation_en-US" xlink:label="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign earnings in the form of cash and cash equivalents [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4" xlink:to="lab_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4" xlink:type="arc" />
    <link:label id="lab_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57_terseLabel_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Foreign Earnings</link:label>
    <link:label id="lab_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57_label_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Foreign Earnings [Member]</link:label>
    <link:label id="lab_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57_documentation_en-US" xlink:label="lab_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Foreign Earnings [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57" xlink:to="lab_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:type="arc" />
    <link:label id="lab_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD_label_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:label id="lab_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liability [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD" xlink:to="lab_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_59369703ACF7FA085363A5E9ED6F8BC6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_59369703ACF7FA085363A5E9ED6F8BC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_59369703ACF7FA085363A5E9ED6F8BC6_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_59369703ACF7FA085363A5E9ED6F8BC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_59369703ACF7FA085363A5E9ED6F8BC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_59369703ACF7FA085363A5E9ED6F8BC6" xlink:to="lab_us-gaap_RetainedEarningsMember_59369703ACF7FA085363A5E9ED6F8BC6" xlink:type="arc" />
    <link:label id="lab_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137_terseLabel_en-US" xlink:label="lab_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137_label_en-US" xlink:label="lab_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid taxes [Member]</link:label>
    <link:label id="lab_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137_documentation_en-US" xlink:label="lab_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid taxes [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PrepaidtaxesMember" xlink:label="loc_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137" xlink:to="lab_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_F4B86EE321726009CD84A5E9ED70357F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain_F4B86EE321726009CD84A5E9ED70357F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_F4B86EE321726009CD84A5E9ED70357F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain_F4B86EE321726009CD84A5E9ED70357F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_F4B86EE321726009CD84A5E9ED70357F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_F4B86EE321726009CD84A5E9ED70357F" xlink:to="lab_us-gaap_DeferredTaxAssetDomain_F4B86EE321726009CD84A5E9ED70357F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralBusinessMember_6E6D5A5C6308DC8C63DCA5E9ED706DD8_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember_6E6D5A5C6308DC8C63DCA5E9ED706DD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General Business</link:label>
    <link:label id="lab_us-gaap_GeneralBusinessMember_6E6D5A5C6308DC8C63DCA5E9ED706DD8_label_en-US" xlink:label="lab_us-gaap_GeneralBusinessMember_6E6D5A5C6308DC8C63DCA5E9ED706DD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Business Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_6E6D5A5C6308DC8C63DCA5E9ED706DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralBusinessMember_6E6D5A5C6308DC8C63DCA5E9ED706DD8" xlink:to="lab_us-gaap_GeneralBusinessMember_6E6D5A5C6308DC8C63DCA5E9ED706DD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_1ED550CA893A23DD2FB1A5E9ED71920B_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_1ED550CA893A23DD2FB1A5E9ED71920B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research</link:label>
    <link:label id="lab_us-gaap_ResearchMember_1ED550CA893A23DD2FB1A5E9ED71920B_label_en-US" xlink:label="lab_us-gaap_ResearchMember_1ED550CA893A23DD2FB1A5E9ED71920B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1ED550CA893A23DD2FB1A5E9ED71920B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_1ED550CA893A23DD2FB1A5E9ED71920B" xlink:to="lab_us-gaap_ResearchMember_1ED550CA893A23DD2FB1A5E9ED71920B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:type="arc" />
    <link:label id="lab_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05_terseLabel_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Tax Act</link:label>
    <link:label id="lab_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05_label_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. 2017 Tax Act [Member]</link:label>
    <link:label id="lab_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05_documentation_en-US" xlink:label="lab_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U.S. 2017 Tax Act</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05" xlink:to="lab_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_F5AB39C1BBEBBC01B6C3A5E9ED7231DF_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_F5AB39C1BBEBBC01B6C3A5E9ED7231DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Country</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_F5AB39C1BBEBBC01B6C3A5E9ED7231DF_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_F5AB39C1BBEBBC01B6C3A5E9ED7231DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_F5AB39C1BBEBBC01B6C3A5E9ED7231DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_F5AB39C1BBEBBC01B6C3A5E9ED7231DF" xlink:to="lab_us-gaap_DomesticCountryMember_F5AB39C1BBEBBC01B6C3A5E9ED7231DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_BF0043ED531334DD66AFA5E9ED722D37_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_BF0043ED531334DD66AFA5E9ED722D37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_BF0043ED531334DD66AFA5E9ED722D37_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_BF0043ED531334DD66AFA5E9ED722D37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_BF0043ED531334DD66AFA5E9ED722D37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_BF0043ED531334DD66AFA5E9ED722D37" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_BF0043ED531334DD66AFA5E9ED722D37" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_B3057C5874A89D519EC3A5E9ED72938F_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_B3057C5874A89D519EC3A5E9ED72938F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_B3057C5874A89D519EC3A5E9ED72938F_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_B3057C5874A89D519EC3A5E9ED72938F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_B3057C5874A89D519EC3A5E9ED72938F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_B3057C5874A89D519EC3A5E9ED72938F" xlink:to="lab_us-gaap_ForeignCountryMember_B3057C5874A89D519EC3A5E9ED72938F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0C8B67501DD59E3F9E78A5EC42325DB3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0C8B67501DD59E3F9E78A5EC42325DB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0C8B67501DD59E3F9E78A5EC42325DB3_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0C8B67501DD59E3F9E78A5EC42325DB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0C8B67501DD59E3F9E78A5EC42325DB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0C8B67501DD59E3F9E78A5EC42325DB3" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0C8B67501DD59E3F9E78A5EC42325DB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1BC1674FCC4DB1B0EE78A5E9ED726544_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1BC1674FCC4DB1B0EE78A5E9ED726544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1BC1674FCC4DB1B0EE78A5E9ED726544_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1BC1674FCC4DB1B0EE78A5E9ED726544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1BC1674FCC4DB1B0EE78A5E9ED726544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1BC1674FCC4DB1B0EE78A5E9ED726544" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1BC1674FCC4DB1B0EE78A5E9ED726544" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1DA8C6107FB2F21D7E64A5E9ED7336BE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1DA8C6107FB2F21D7E64A5E9ED7336BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1DA8C6107FB2F21D7E64A5E9ED7336BE_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1DA8C6107FB2F21D7E64A5E9ED7336BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1DA8C6107FB2F21D7E64A5E9ED7336BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1DA8C6107FB2F21D7E64A5E9ED7336BE" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1DA8C6107FB2F21D7E64A5E9ED7336BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_98F6B12234B2BE8931C2A5E9ED7343AE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_98F6B12234B2BE8931C2A5E9ED7343AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition toll tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_98F6B12234B2BE8931C2A5E9ED7343AE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_98F6B12234B2BE8931C2A5E9ED7343AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_98F6B12234B2BE8931C2A5E9ED7343AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_98F6B12234B2BE8931C2A5E9ED7343AE" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_98F6B12234B2BE8931C2A5E9ED7343AE" xlink:type="arc" />
    <link:label id="lab_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833_terseLabel_en-US" xlink:label="lab_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for Transition Toll Tax</link:label>
    <link:label id="lab_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833_label_en-US" xlink:label="lab_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Transition Toll Tax</link:label>
    <link:label id="lab_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833_documentation_en-US" xlink:label="lab_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment for Transition Toll Tax</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PaymentforTransitionTollTax" xlink:label="loc_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833" xlink:to="lab_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, decrease due to overpayment</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Decrease Due to Overpayment</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Decrease Due to Overpayment</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment" xlink:label="loc_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A" xlink:to="lab_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A" xlink:type="arc" />
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829_terseLabel_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transition Toll Tax repatriation tax rate</link:label>
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829_label_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transition Toll Tax Repatriation Tax Rate</link:label>
    <link:label id="lab_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829_documentation_en-US" xlink:label="lab_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transition Toll Tax Repatriation Tax Rate</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829" xlink:to="lab_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_2AC7FC7C5CA6D5ED3C19A5E9ED735FAC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_2AC7FC7C5CA6D5ED3C19A5E9ED735FAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_2AC7FC7C5CA6D5ED3C19A5E9ED735FAC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_2AC7FC7C5CA6D5ED3C19A5E9ED735FAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_2AC7FC7C5CA6D5ED3C19A5E9ED735FAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_2AC7FC7C5CA6D5ED3C19A5E9ED735FAC" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_2AC7FC7C5CA6D5ED3C19A5E9ED735FAC" xlink:type="arc" />
    <link:label id="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D_terseLabel_en-US" xlink:label="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in deferred tax liability, undistributed foreign earnings</link:label>
    <link:label id="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D_label_en-US" xlink:label="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in deferred tax liability, undistributed foreign earnings</link:label>
    <link:label id="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D_documentation_en-US" xlink:label="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in deferred tax liability, undistributed foreign earnings</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:label="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D" xlink:to="lab_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D" xlink:type="arc" />
    <link:label id="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D_terseLabel_en-US" xlink:label="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</link:label>
    <link:label id="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D_label_en-US" xlink:label="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</link:label>
    <link:label id="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D_documentation_en-US" xlink:label="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:label="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D" xlink:to="lab_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D" xlink:type="arc" />
    <link:label id="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E_terseLabel_en-US" xlink:label="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</link:label>
    <link:label id="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E_label_en-US" xlink:label="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</link:label>
    <link:label id="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E_documentation_en-US" xlink:label="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:label="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E" xlink:to="lab_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E" xlink:type="arc" />
    <link:label id="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667_terseLabel_en-US" xlink:label="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667_label_en-US" xlink:label="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, GILTI tax calculation</link:label>
    <link:label id="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667_documentation_en-US" xlink:label="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, GILTI tax calculation</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667" xlink:to="lab_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_C94EC303447C1C97196CA5E9ED75117A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit_C94EC303447C1C97196CA5E9ED75117A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherTaxExpenseBenefit_C94EC303447C1C97196CA5E9ED75117A_label_en-US" xlink:label="lab_us-gaap_OtherTaxExpenseBenefit_C94EC303447C1C97196CA5E9ED75117A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_C94EC303447C1C97196CA5E9ED75117A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherTaxExpenseBenefit_C94EC303447C1C97196CA5E9ED75117A" xlink:to="lab_us-gaap_OtherTaxExpenseBenefit_C94EC303447C1C97196CA5E9ED75117A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_1A40B0B65C2F84D1C163A5E9ED75821D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_1A40B0B65C2F84D1C163A5E9ED75821D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net impairment on certain tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_1A40B0B65C2F84D1C163A5E9ED75821D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_1A40B0B65C2F84D1C163A5E9ED75821D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_1A40B0B65C2F84D1C163A5E9ED75821D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_1A40B0B65C2F84D1C163A5E9ED75821D" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_1A40B0B65C2F84D1C163A5E9ED75821D" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_D24E7780F68D06C9E5DCA5E9ED75180F_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_D24E7780F68D06C9E5DCA5E9ED75180F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_D24E7780F68D06C9E5DCA5E9ED75180F_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_D24E7780F68D06C9E5DCA5E9ED75180F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_D24E7780F68D06C9E5DCA5E9ED75180F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_D24E7780F68D06C9E5DCA5E9ED75180F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_D24E7780F68D06C9E5DCA5E9ED75180F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_0944C0A48C7D1BF62509A5E9ED76E0E1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_0944C0A48C7D1BF62509A5E9ED76E0E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_0944C0A48C7D1BF62509A5E9ED76E0E1_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_0944C0A48C7D1BF62509A5E9ED76E0E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0944C0A48C7D1BF62509A5E9ED76E0E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_0944C0A48C7D1BF62509A5E9ED76E0E1" xlink:to="lab_us-gaap_OperatingLossCarryforwards_0944C0A48C7D1BF62509A5E9ED76E0E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_69FDFAAEA318B035D31EA5E9ED760F61_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_69FDFAAEA318B035D31EA5E9ED760F61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_69FDFAAEA318B035D31EA5E9ED760F61_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_69FDFAAEA318B035D31EA5E9ED760F61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_69FDFAAEA318B035D31EA5E9ED760F61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_69FDFAAEA318B035D31EA5E9ED760F61" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_69FDFAAEA318B035D31EA5E9ED760F61" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_5A5E824947021121F4FCA5E9ED76A73D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_5A5E824947021121F4FCA5E9ED76A73D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_5A5E824947021121F4FCA5E9ED76A73D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_5A5E824947021121F4FCA5E9ED76A73D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_5A5E824947021121F4FCA5E9ED76A73D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_5A5E824947021121F4FCA5E9ED76A73D" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_5A5E824947021121F4FCA5E9ED76A73D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_541481240E81EA7DDA23A5E9ED76371B_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_541481240E81EA7DDA23A5E9ED76371B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notice of assessment of corporate withholding tax including penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_541481240E81EA7DDA23A5E9ED76371B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_541481240E81EA7DDA23A5E9ED76371B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_541481240E81EA7DDA23A5E9ED76371B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_541481240E81EA7DDA23A5E9ED76371B" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_541481240E81EA7DDA23A5E9ED76371B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_48C15DEA76E95994E3C4A5E9ED771DEE_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_48C15DEA76E95994E3C4A5E9ED771DEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of new accounting principle in period of adoption</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_48C15DEA76E95994E3C4A5E9ED771DEE_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_48C15DEA76E95994E3C4A5E9ED771DEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_48C15DEA76E95994E3C4A5E9ED771DEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_48C15DEA76E95994E3C4A5E9ED771DEE" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_48C15DEA76E95994E3C4A5E9ED771DEE" xlink:type="arc" />
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27_verboseLabel_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual)</link:label>
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27_label_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27_documentation_en-US" xlink:label="lab_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_IncomeTaxesTextualAbstract" xlink:label="loc_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:to="lab_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:type="arc" />
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_68A4EDB10B972242201AA5E9ED7793B9_terseLabel_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_68A4EDB10B972242201AA5E9ED7793B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_68A4EDB10B972242201AA5E9ED7793B9_label_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_68A4EDB10B972242201AA5E9ED7793B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:label id="lab_biib_Totaldeferredchargesandprepaidtaxes_68A4EDB10B972242201AA5E9ED7793B9_documentation_en-US" xlink:label="lab_biib_Totaldeferredchargesandprepaidtaxes_68A4EDB10B972242201AA5E9ED7793B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total deferred charges and prepaid taxes</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_68A4EDB10B972242201AA5E9ED7793B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Totaldeferredchargesandprepaidtaxes_68A4EDB10B972242201AA5E9ED7793B9" xlink:to="lab_biib_Totaldeferredchargesandprepaidtaxes_68A4EDB10B972242201AA5E9ED7793B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_914F6D6A24921B058696A5E9ED770838_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_914F6D6A24921B058696A5E9ED770838" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_914F6D6A24921B058696A5E9ED770838_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_914F6D6A24921B058696A5E9ED770838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_914F6D6A24921B058696A5E9ED770838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_914F6D6A24921B058696A5E9ED770838" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_914F6D6A24921B058696A5E9ED770838" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_941A3E6FC67EC46C1C95A5E9ED779411_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_941A3E6FC67EC46C1C95A5E9ED779411" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_941A3E6FC67EC46C1C95A5E9ED779411_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_941A3E6FC67EC46C1C95A5E9ED779411" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_941A3E6FC67EC46C1C95A5E9ED779411" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_941A3E6FC67EC46C1C95A5E9ED779411" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_941A3E6FC67EC46C1C95A5E9ED779411" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_4CAF235BDD283F4800A7A5E9ED784F27_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_4CAF235BDD283F4800A7A5E9ED784F27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_4CAF235BDD283F4800A7A5E9ED784F27_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_4CAF235BDD283F4800A7A5E9ED784F27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_4CAF235BDD283F4800A7A5E9ED784F27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_4CAF235BDD283F4800A7A5E9ED784F27" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_4CAF235BDD283F4800A7A5E9ED784F27" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_C9F115210E946CECC13EFBB83432D69D_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_C9F115210E946CECC13EFBB83432D69D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C9F115210E946CECC13EFBB83432D69D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_C9F115210E946CECC13EFBB83432D69D" xlink:to="lab_us-gaap_EquityAbstract_C9F115210E946CECC13EFBB83432D69D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6F2D88D39C7FEA4AA00BFBB834326F32_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6F2D88D39C7FEA4AA00BFBB834326F32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6F2D88D39C7FEA4AA00BFBB834326F32_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6F2D88D39C7FEA4AA00BFBB834326F32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6F2D88D39C7FEA4AA00BFBB834326F32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6F2D88D39C7FEA4AA00BFBB834326F32" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6F2D88D39C7FEA4AA00BFBB834326F32" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27C79807347547787CFCC42825F2B28E_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27C79807347547787CFCC42825F2B28E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27C79807347547787CFCC42825F2B28E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27C79807347547787CFCC42825F2B28E" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27C79807347547787CFCC42825F2B28E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:to="lab_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84" xlink:to="lab_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3_terseLabel_en-US" xlink:label="lab_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:label id="lab_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3_label_en-US" xlink:label="lab_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AbbVie [Member]</link:label>
    <link:label id="lab_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3_documentation_en-US" xlink:label="lab_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3" xlink:to="lab_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B_label_en-US" xlink:label="lab_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:to="lab_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5_label_en-US" xlink:label="lab_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5" xlink:to="lab_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScenarioForecastMember_42F360B32B0BEA8D16C7C42825F401C1_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_42F360B32B0BEA8D16C7C42825F401C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of development expenses to be reimbursed</link:label>
    <link:label id="lab_us-gaap_ScenarioForecastMember_42F360B32B0BEA8D16C7C42825F401C1_label_en-US" xlink:label="lab_us-gaap_ScenarioForecastMember_42F360B32B0BEA8D16C7C42825F401C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_42F360B32B0BEA8D16C7C42825F401C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioForecastMember_42F360B32B0BEA8D16C7C42825F401C1" xlink:to="lab_us-gaap_ScenarioForecastMember_42F360B32B0BEA8D16C7C42825F401C1" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:to="lab_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:to="lab_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:type="arc" />
    <link:label id="lab_country_US_0B9E60FC2606F89A2C7FC42825F6F977_terseLabel_en-US" xlink:label="lab_country_US_0B9E60FC2606F89A2C7FC42825F6F977" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S</link:label>
    <link:label id="lab_country_US_0B9E60FC2606F89A2C7FC42825F6F977_label_en-US" xlink:label="lab_country_US_0B9E60FC2606F89A2C7FC42825F6F977" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_0B9E60FC2606F89A2C7FC42825F6F977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_0B9E60FC2606F89A2C7FC42825F6F977" xlink:to="lab_country_US_0B9E60FC2606F89A2C7FC42825F6F977" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_B5FBB7D142643CB75FE4C42825F6125A_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember_B5FBB7D142643CB75FE4C42825F6125A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_GeographicDistributionForeignMember_B5FBB7D142643CB75FE4C42825F6125A_label_en-US" xlink:label="lab_us-gaap_GeographicDistributionForeignMember_B5FBB7D142643CB75FE4C42825F6125A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Distribution, Foreign [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_B5FBB7D142643CB75FE4C42825F6125A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicDistributionForeignMember_B5FBB7D142643CB75FE4C42825F6125A" xlink:to="lab_us-gaap_GeographicDistributionForeignMember_B5FBB7D142643CB75FE4C42825F6125A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_355C148EFE12571EE5B9C42825F6AD70_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_355C148EFE12571EE5B9C42825F6AD70" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Outside the U.S</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_355C148EFE12571EE5B9C42825F6AD70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_355C148EFE12571EE5B9C42825F6AD70" xlink:to="lab_us-gaap_ForeignCountryMember_355C148EFE12571EE5B9C42825F6AD70" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeanUnionMember_A1491A272F841BE2282CC42825F6EAF3_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_A1491A272F841BE2282CC42825F6EAF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_A1491A272F841BE2282CC42825F6EAF3_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_A1491A272F841BE2282CC42825F6EAF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_A1491A272F841BE2282CC42825F6EAF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember_A1491A272F841BE2282CC42825F6EAF3" xlink:to="lab_us-gaap_EuropeanUnionMember_A1491A272F841BE2282CC42825F6EAF3" xlink:type="arc" />
    <link:label id="lab_country_JP_F2ED2B4AC12C1257F0A5C42825F61E5F_terseLabel_en-US" xlink:label="lab_country_JP_F2ED2B4AC12C1257F0A5C42825F61E5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_F2ED2B4AC12C1257F0A5C42825F61E5F_label_en-US" xlink:label="lab_country_JP_F2ED2B4AC12C1257F0A5C42825F61E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_F2ED2B4AC12C1257F0A5C42825F61E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_F2ED2B4AC12C1257F0A5C42825F61E5F" xlink:to="lab_country_JP_F2ED2B4AC12C1257F0A5C42825F61E5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6F90A14C9B9439CCAD8FC42825F778E3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6F90A14C9B9439CCAD8FC42825F778E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6F90A14C9B9439CCAD8FC42825F778E3_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6F90A14C9B9439CCAD8FC42825F778E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6F90A14C9B9439CCAD8FC42825F778E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6F90A14C9B9439CCAD8FC42825F778E3" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6F90A14C9B9439CCAD8FC42825F778E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349502A345686C9147DDC42825F79E2C_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349502A345686C9147DDC42825F79E2C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349502A345686C9147DDC42825F79E2C_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349502A345686C9147DDC42825F79E2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349502A345686C9147DDC42825F79E2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349502A345686C9147DDC42825F79E2C" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349502A345686C9147DDC42825F79E2C" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08_verboseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investee, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08" xlink:type="arc" />
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784" xlink:to="lab_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784" xlink:type="arc" />
    <link:label id="lab_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2_terseLabel_en-US" xlink:label="lab_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RITUXAN</link:label>
    <link:label id="lab_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2_label_en-US" xlink:label="lab_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RITUXAN [Member]</link:label>
    <link:label id="lab_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2_documentation_en-US" xlink:label="lab_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RITUXAN.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2" xlink:to="lab_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2" xlink:type="arc" />
    <link:label id="lab_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596_terseLabel_en-US" xlink:label="lab_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GAZYVA</link:label>
    <link:label id="lab_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596_label_en-US" xlink:label="lab_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:label id="lab_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596_documentation_en-US" xlink:label="lab_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596" xlink:to="lab_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596" xlink:type="arc" />
    <link:label id="lab_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83_verboseLabel_en-US" xlink:label="lab_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">New Anti-CD20</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83_label_en-US" xlink:label="lab_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Anti Cd20 [Member]</link:label>
    <link:label id="lab_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83_documentation_en-US" xlink:label="lab_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New Anti-CD20.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83" xlink:to="lab_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83" xlink:type="arc" />
    <link:label id="lab_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4_verboseLabel_en-US" xlink:label="lab_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:label id="lab_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4_label_en-US" xlink:label="lab_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCREVUS [Member]</link:label>
    <link:label id="lab_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4_documentation_en-US" xlink:label="lab_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_OCREVUSMember" xlink:label="loc_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4" xlink:to="lab_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4" xlink:type="arc" />
    <link:label id="lab_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C_terseLabel_en-US" xlink:label="lab_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SOD1</link:label>
    <link:label id="lab_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C_label_en-US" xlink:label="lab_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:label id="lab_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C_documentation_en-US" xlink:label="lab_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SOD1 [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C" xlink:to="lab_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C" xlink:type="arc" />
    <link:label id="lab_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8_label_en-US" xlink:label="lab_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8_documentation_en-US" xlink:label="lab_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8" xlink:to="lab_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:to="lab_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD_verboseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD" xlink:to="lab_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD" xlink:type="arc" />
    <link:label id="lab_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E" xlink:to="lab_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E" xlink:type="arc" />
    <link:label id="lab_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC_terseLabel_en-US" xlink:label="lab_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC_label_en-US" xlink:label="lab_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC_documentation_en-US" xlink:label="lab_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC" xlink:to="lab_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC" xlink:type="arc" />
    <link:label id="lab_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E_terseLabel_en-US" xlink:label="lab_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alkermes</link:label>
    <link:label id="lab_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E_label_en-US" xlink:label="lab_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alkermes [Member]</link:label>
    <link:label id="lab_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E_documentation_en-US" xlink:label="lab_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alkermes [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E" xlink:to="lab_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E" xlink:type="arc" />
    <link:label id="lab_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9_terseLabel_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9_label_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:label id="lab_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9_documentation_en-US" xlink:label="lab_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bristol-Myers Squibb [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9" xlink:to="lab_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9" xlink:type="arc" />
    <link:label id="lab_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6_terseLabel_en-US" xlink:label="lab_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">iPerian</link:label>
    <link:label id="lab_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6_label_en-US" xlink:label="lab_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">iPerian [Member]</link:label>
    <link:label id="lab_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6_documentation_en-US" xlink:label="lab_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">iPerian [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6" xlink:to="lab_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6" xlink:type="arc" />
    <link:label id="lab_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565_terseLabel_en-US" xlink:label="lab_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acorda</link:label>
    <link:label id="lab_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565_label_en-US" xlink:label="lab_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acorda [Member]</link:label>
    <link:label id="lab_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565_documentation_en-US" xlink:label="lab_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acorda.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565" xlink:to="lab_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565" xlink:type="arc" />
    <link:label id="lab_biib_AbbVieMember_18005FF1FD3AF3534D3BC42825FCB0FB_verboseLabel_en-US" xlink:label="lab_biib_AbbVieMember_18005FF1FD3AF3534D3BC42825FCB0FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">AbbVie</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_18005FF1FD3AF3534D3BC42825FCB0FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AbbVieMember_18005FF1FD3AF3534D3BC42825FCB0FB" xlink:to="lab_biib_AbbVieMember_18005FF1FD3AF3534D3BC42825FCB0FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_E3E30D0D4746C0201D2EC42825FC9A1C_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_E3E30D0D4746C0201D2EC42825FC9A1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_E3E30D0D4746C0201D2EC42825FC9A1C_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_E3E30D0D4746C0201D2EC42825FC9A1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_E3E30D0D4746C0201D2EC42825FC9A1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_E3E30D0D4746C0201D2EC42825FC9A1C" xlink:to="lab_us-gaap_CollaborativeArrangementMember_E3E30D0D4746C0201D2EC42825FC9A1C" xlink:type="arc" />
    <link:label id="lab_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788_terseLabel_en-US" xlink:label="lab_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGTC</link:label>
    <link:label id="lab_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788_label_en-US" xlink:label="lab_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGTC [Member]</link:label>
    <link:label id="lab_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788_documentation_en-US" xlink:label="lab_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGTC [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788" xlink:to="lab_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788" xlink:type="arc" />
    <link:label id="lab_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB_terseLabel_en-US" xlink:label="lab_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">University of Pennsylvania</link:label>
    <link:label id="lab_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB_label_en-US" xlink:label="lab_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">University of Pennsylvania [Member]</link:label>
    <link:label id="lab_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB_documentation_en-US" xlink:label="lab_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">University of Pennsylvania [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_UniversityofPennsylvaniaMember" xlink:label="loc_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB" xlink:to="lab_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB" xlink:type="arc" />
    <link:label id="lab_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB_terseLabel_en-US" xlink:label="lab_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">C4 Therapeutics</link:label>
    <link:label id="lab_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB_label_en-US" xlink:label="lab_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">C4 Therapeutics [Member]</link:label>
    <link:label id="lab_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB_documentation_en-US" xlink:label="lab_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">C4 Therapeutics [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_C4TherapeuticsMember" xlink:label="loc_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB" xlink:to="lab_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB" xlink:type="arc" />
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB" xlink:to="lab_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements and non-collaborative arrangement transactions</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:type="arc" />
    <link:label id="lab_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236_verboseLabel_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships (Textual)</link:label>
    <link:label id="lab_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236_label_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborations (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236_documentation_en-US" xlink:label="lab_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborations.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="lab_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:type="arc" />
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07_verboseLabel_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of ocrelizumab</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07_label_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Percentage To Be Received On Sale Of Product</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07_documentation_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of product.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07" xlink:to="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07" xlink:type="arc" />
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0_terseLabel_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0_label_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0_documentation_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0" xlink:to="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A_label_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A" xlink:to="lab_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A" xlink:type="arc" />
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540_verboseLabel_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Period of collaboration agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540_label_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540_documentation_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540" xlink:to="lab_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Co promotion Operating Profits first fifty million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits first fifty million.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A_label_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A_documentation_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A" xlink:to="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A" xlink:type="arc" />
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78" xlink:to="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78" xlink:type="arc" />
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales to be achieved in any twelve consecutive months under option one.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC" xlink:to="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC" xlink:type="arc" />
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90_terseLabel_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90_label_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90_documentation_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales trigger gross sales threshold.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90" xlink:to="lab_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90" xlink:type="arc" />
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82_terseLabel_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82_label_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:label id="lab_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82_documentation_en-US" xlink:label="lab_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future percentage of co-promotion operating profits</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82" xlink:to="lab_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82" xlink:type="arc" />
    <link:label id="lab_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB_verboseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB" xlink:to="lab_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB" xlink:type="arc" />
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of expense reflected within our consolidation statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D_verboseLabel_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments when certain sales threshold is met</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D_label_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Additional Milestone Payments When Meeting Certain Sales Threshold</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D_documentation_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments when meeting certain sales threshold.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D" xlink:to="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D" xlink:type="arc" />
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805_verboseLabel_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign sales required to trigger milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805_label_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Sales Required To Trigger Milestone</link:label>
    <link:label id="lab_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805_documentation_en-US" xlink:label="lab_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign sales required to trigger milestone.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805" xlink:to="lab_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_A4B22C422A91EF6BAB06C42826017B5D_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_A4B22C422A91EF6BAB06C42826017B5D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_A4B22C422A91EF6BAB06C42826017B5D_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_A4B22C422A91EF6BAB06C42826017B5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_A4B22C422A91EF6BAB06C42826017B5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_A4B22C422A91EF6BAB06C42826017B5D" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_A4B22C422A91EF6BAB06C42826017B5D" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB_verboseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Until First GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option one.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Until GAZYVA First Non-CLL FDA Approval</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option One</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option one.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After First Threshold Date and until Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option two.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6" xlink:type="arc" />
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BAN2401 and Elenbecestat R&amp;D expense incurred by collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163" xlink:to="lab_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163" xlink:type="arc" />
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743_terseLabel_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743_label_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:label id="lab_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743_documentation_en-US" xlink:label="lab_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen share of co-promotion profits or losses</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743" xlink:to="lab_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_59978B3CB729F061D2DAC4282602B2DC_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues_59978B3CB729F061D2DAC4282602B2DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_59978B3CB729F061D2DAC4282602B2DC_label_en-US" xlink:label="lab_us-gaap_Revenues_59978B3CB729F061D2DAC4282602B2DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_59978B3CB729F061D2DAC4282602B2DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_59978B3CB729F061D2DAC4282602B2DC" xlink:to="lab_us-gaap_Revenues_59978B3CB729F061D2DAC4282602B2DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9A08DA065F079C74EA5EC42826030C54_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_9A08DA065F079C74EA5EC42826030C54" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9A08DA065F079C74EA5EC42826030C54_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_9A08DA065F079C74EA5EC42826030C54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9A08DA065F079C74EA5EC42826030C54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_9A08DA065F079C74EA5EC42826030C54" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_9A08DA065F079C74EA5EC42826030C54" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Abbvie collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C" xlink:to="lab_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C" xlink:type="arc" />
    <link:label id="lab_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669_terseLabel_en-US" xlink:label="lab_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669_label_en-US" xlink:label="lab_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit sharing</link:label>
    <link:label id="lab_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669_documentation_en-US" xlink:label="lab_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669" xlink:to="lab_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153_terseLabel_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage Of Royalties As Per Collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153_label_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Royalties As Per Collaboration</link:label>
    <link:label id="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153_documentation_en-US" xlink:label="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of royalties as per collaboration.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153" xlink:to="lab_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153" xlink:type="arc" />
    <link:label id="lab_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316_terseLabel_en-US" xlink:label="lab_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316_label_en-US" xlink:label="lab_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:label id="lab_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316_documentation_en-US" xlink:label="lab_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fee</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316" xlink:to="lab_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316" xlink:type="arc" />
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD_terseLabel_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected License Fee And Regulatory Milestone Payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD_label_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected License Fee And Regulatory Milestone Payments</link:label>
    <link:label id="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD_documentation_en-US" xlink:label="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected license fee and regulatory milestone payments.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD" xlink:to="lab_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD" xlink:type="arc" />
    <link:label id="lab_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED_terseLabel_en-US" xlink:label="lab_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment for collaboration agreement</link:label>
    <link:label id="lab_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED_label_en-US" xlink:label="lab_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront payment for collaboration agreement</link:label>
    <link:label id="lab_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED_documentation_en-US" xlink:label="lab_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront payment for collaboration agreement</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Upfrontpaymentforcollaborationagreement" xlink:label="loc_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED" xlink:to="lab_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED" xlink:type="arc" />
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313_terseLabel_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313_label_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:label id="lab_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313_documentation_en-US" xlink:label="lab_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in common stock, shares purchased</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313" xlink:to="lab_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313" xlink:type="arc" />
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C" xlink:type="arc" />
    <link:label id="lab_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3" xlink:to="lab_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3" xlink:type="arc" />
    <link:label id="lab_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136" xlink:to="lab_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136" xlink:type="arc" />
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039_terseLabel_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039_label_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:label id="lab_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039_documentation_en-US" xlink:label="lab_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total payment to enter collaboration agreement</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Totalpaymenttoentercollaborationagreement" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039" xlink:to="lab_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_52329FF74E2BC438E185C4282605003B_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_52329FF74E2BC438E185C4282605003B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and discovery services</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_52329FF74E2BC438E185C4282605003B_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets_52329FF74E2BC438E185C4282605003B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_52329FF74E2BC438E185C4282605003B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets_52329FF74E2BC438E185C4282605003B" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets_52329FF74E2BC438E185C4282605003B" xlink:type="arc" />
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C" xlink:type="arc" />
    <link:label id="lab_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0_terseLabel_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:label id="lab_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0_label_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:label id="lab_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0_documentation_en-US" xlink:label="lab_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developmental Milestone Payment</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0" xlink:to="lab_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0" xlink:type="arc" />
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA_verboseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment, approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA" xlink:type="arc" />
    <link:label id="lab_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F_terseLabel_en-US" xlink:label="lab_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F_label_en-US" xlink:label="lab_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:label id="lab_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F_documentation_en-US" xlink:label="lab_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase of common stock</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F" xlink:to="lab_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F" xlink:type="arc" />
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E_terseLabel_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E_label_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:label id="lab_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E_documentation_en-US" xlink:label="lab_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premium on purchase of common stock</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E" xlink:to="lab_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E" xlink:type="arc" />
    <link:label id="lab_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA_terseLabel_en-US" xlink:label="lab_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in common stock, value</link:label>
    <link:label id="lab_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA_label_en-US" xlink:label="lab_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in common stock, value</link:label>
    <link:label id="lab_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA_documentation_en-US" xlink:label="lab_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in common stock, value</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Investmentincommonstockvalue" xlink:label="loc_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA" xlink:to="lab_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_099BD1E5FE2CDC3EB4AEC4282606BE9E_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_099BD1E5FE2CDC3EB4AEC4282606BE9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_099BD1E5FE2CDC3EB4AEC4282606BE9E_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_099BD1E5FE2CDC3EB4AEC4282606BE9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_099BD1E5FE2CDC3EB4AEC4282606BE9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_099BD1E5FE2CDC3EB4AEC4282606BE9E" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_099BD1E5FE2CDC3EB4AEC4282606BE9E" xlink:type="arc" />
    <link:label id="lab_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36_terseLabel_en-US" xlink:label="lab_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future research and development commitment</link:label>
    <link:label id="lab_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36_label_en-US" xlink:label="lab_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future research and development commitment</link:label>
    <link:label id="lab_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36_documentation_en-US" xlink:label="lab_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future research and development commitment</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Futureresearchanddevelopmentcommitment" xlink:label="loc_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36" xlink:to="lab_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB_terseLabel_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB_label_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments By Third Party In Joint Venture As Per Agreement.</link:label>
    <link:label id="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB_documentation_en-US" xlink:label="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments by third party in joint venture as per agreement</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB" xlink:to="lab_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB" xlink:type="arc" />
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A_terseLabel_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A_label_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Joint Venture Owner Ship Percentage By Third Party.</link:label>
    <link:label id="lab_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A_documentation_en-US" xlink:label="lab_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Joint venture owner ship percentage by third party.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A" xlink:to="lab_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_09121B4CD74A7A05FE7CC42826070EDA_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_09121B4CD74A7A05FE7CC42826070EDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_09121B4CD74A7A05FE7CC42826070EDA_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_09121B4CD74A7A05FE7CC42826070EDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_09121B4CD74A7A05FE7CC42826070EDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_09121B4CD74A7A05FE7CC42826070EDA" xlink:to="lab_us-gaap_EquityMethodInvestments_09121B4CD74A7A05FE7CC42826070EDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4E115CE8CFE8881E3A7FC42826077BED_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4E115CE8CFE8881E3A7FC42826077BED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4E115CE8CFE8881E3A7FC42826077BED_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4E115CE8CFE8881E3A7FC42826077BED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4E115CE8CFE8881E3A7FC42826077BED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4E115CE8CFE8881E3A7FC42826077BED" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4E115CE8CFE8881E3A7FC42826077BED" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_D50AB5E190BB7D98F44EC42826078527_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_D50AB5E190BB7D98F44EC42826078527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_D50AB5E190BB7D98F44EC42826078527_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_D50AB5E190BB7D98F44EC42826078527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_D50AB5E190BB7D98F44EC42826078527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_D50AB5E190BB7D98F44EC42826078527" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_D50AB5E190BB7D98F44EC42826078527" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1DCE4060D8FE85C9CBB1C4282607D57B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1DCE4060D8FE85C9CBB1C4282607D57B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1DCE4060D8FE85C9CBB1C4282607D57B_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1DCE4060D8FE85C9CBB1C4282607D57B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1DCE4060D8FE85C9CBB1C4282607D57B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1DCE4060D8FE85C9CBB1C4282607D57B" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_1DCE4060D8FE85C9CBB1C4282607D57B" xlink:type="arc" />
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_241B3A35973721430A9FFBB834326145_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_241B3A35973721430A9FFBB834326145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_241B3A35973721430A9FFBB834326145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_241B3A35973721430A9FFBB834326145" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_241B3A35973721430A9FFBB834326145" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_C47BC468F79DD74F1DB7FBB83432A66E_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_C47BC468F79DD74F1DB7FBB83432A66E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_C47BC468F79DD74F1DB7FBB83432A66E_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_C47BC468F79DD74F1DB7FBB83432A66E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_C47BC468F79DD74F1DB7FBB83432A66E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_C47BC468F79DD74F1DB7FBB83432A66E" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_C47BC468F79DD74F1DB7FBB83432A66E" xlink:type="arc" />
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1_verboseLabel_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option</link:label>
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1_label_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefit And Cash Received From Stock Option [Abstract]</link:label>
    <link:label id="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1_documentation_en-US" xlink:label="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" xlink:label="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1" xlink:to="lab_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_92F999F5779EAA8C8DEBFBB8355AE530_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_92F999F5779EAA8C8DEBFBB8355AE530" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit realized for stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_92F999F5779EAA8C8DEBFBB8355AE530_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_92F999F5779EAA8C8DEBFBB8355AE530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Exercise of Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_92F999F5779EAA8C8DEBFBB8355AE530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_92F999F5779EAA8C8DEBFBB8355AE530" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_92F999F5779EAA8C8DEBFBB8355AE530" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6153342425C4A401A2B0FBB8355A7F04_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_6153342425C4A401A2B0FBB8355A7F04" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_6153342425C4A401A2B0FBB8355A7F04_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_6153342425C4A401A2B0FBB8355A7F04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6153342425C4A401A2B0FBB8355A7F04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_6153342425C4A401A2B0FBB8355A7F04" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_6153342425C4A401A2B0FBB8355A7F04" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5AD09D6597189ACE473EFBB833A5BF32_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5AD09D6597189ACE473EFBB833A5BF32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5AD09D6597189ACE473EFBB833A5BF32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5AD09D6597189ACE473EFBB833A5BF32" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5AD09D6597189ACE473EFBB833A5BF32" xlink:type="arc" />
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B_terseLabel_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments (Textual)</link:label>
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B_label_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B_documentation_en-US" xlink:label="lab_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FinancialInstrumentsTextualAbstract" xlink:label="loc_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B" xlink:to="lab_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_0C397FDF19696CF25743FBB833A538CB_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_0C397FDF19696CF25743FBB833A538CB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Original maturities of commercial paper and short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentMaturityDateDescription_0C397FDF19696CF25743FBB833A538CB_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentMaturityDateDescription_0C397FDF19696CF25743FBB833A538CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date, Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_0C397FDF19696CF25743FBB833A538CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDateDescription_0C397FDF19696CF25743FBB833A538CB" xlink:to="lab_us-gaap_DebtInstrumentMaturityDateDescription_0C397FDF19696CF25743FBB833A538CB" xlink:type="arc" />
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_753CFA4A798B074067A8FBB833A5543F_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_753CFA4A798B074067A8FBB833A5543F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_753CFA4A798B074067A8FBB833A5543F_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_753CFA4A798B074067A8FBB833A5543F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_753CFA4A798B074067A8FBB833A5543F_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities_753CFA4A798B074067A8FBB833A5543F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_753CFA4A798B074067A8FBB833A5543F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities_753CFA4A798B074067A8FBB833A5543F" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities_753CFA4A798B074067A8FBB833A5543F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0CA65A8DA92001057FA09FD6EDDEB785_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0CA65A8DA92001057FA09FD6EDDEB785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0CA65A8DA92001057FA09FD6EDDEB785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0CA65A8DA92001057FA09FD6EDDEB785" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0CA65A8DA92001057FA09FD6EDDEB785" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_168ACDC732A8F92DC4179FD6EDDE006C_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_168ACDC732A8F92DC4179FD6EDDE006C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_168ACDC732A8F92DC4179FD6EDDE006C_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_168ACDC732A8F92DC4179FD6EDDE006C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_168ACDC732A8F92DC4179FD6EDDE006C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_168ACDC732A8F92DC4179FD6EDDE006C" xlink:to="lab_us-gaap_NetIncomeLoss_168ACDC732A8F92DC4179FD6EDDE006C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1839C7C60092BB4AFBBA9FD6EDDF69D3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1839C7C60092BB4AFBBA9FD6EDDF69D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1839C7C60092BB4AFBBA9FD6EDDF69D3_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1839C7C60092BB4AFBBA9FD6EDDF69D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1839C7C60092BB4AFBBA9FD6EDDF69D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1839C7C60092BB4AFBBA9FD6EDDF69D3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1839C7C60092BB4AFBBA9FD6EDDF69D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3E1A7DDA276C09CD54499FD6EDDF24B0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3E1A7DDA276C09CD54499FD6EDDF24B0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification adjustment for (gains) losses included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3E1A7DDA276C09CD54499FD6EDDF24B0_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3E1A7DDA276C09CD54499FD6EDDF24B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3E1A7DDA276C09CD54499FD6EDDF24B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3E1A7DDA276C09CD54499FD6EDDF24B0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3E1A7DDA276C09CD54499FD6EDDF24B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_306ADE9A23067DFB1FC39FD6EDDFDE0D_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_306ADE9A23067DFB1FC39FD6EDDFDE0D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_306ADE9A23067DFB1FC39FD6EDDFDE0D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_306ADE9A23067DFB1FC39FD6EDDFDE0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_306ADE9A23067DFB1FC39FD6EDDFDE0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_306ADE9A23067DFB1FC39FD6EDDFDE0D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_306ADE9A23067DFB1FC39FD6EDDFDE0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_098EB7311F93982742DA9FD6EDDF24B9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_098EB7311F93982742DA9FD6EDDF24B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) recognized during the period, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_098EB7311F93982742DA9FD6EDDF24B9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_098EB7311F93982742DA9FD6EDDF24B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_098EB7311F93982742DA9FD6EDDF24B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_098EB7311F93982742DA9FD6EDDF24B9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_098EB7311F93982742DA9FD6EDDF24B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_563A39A589D482DD4D9A9FD6EDE4281C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_563A39A589D482DD4D9A9FD6EDE4281C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: reclassification adjustment for (gains) losses included in net income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_563A39A589D482DD4D9A9FD6EDE4281C_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_563A39A589D482DD4D9A9FD6EDE4281C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_563A39A589D482DD4D9A9FD6EDE4281C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_563A39A589D482DD4D9A9FD6EDE4281C" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_563A39A589D482DD4D9A9FD6EDE4281C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_4ACA52F29AD979EA03A79FD6EDE5AA87_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_4ACA52F29AD979EA03A79FD6EDE5AA87" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_4ACA52F29AD979EA03A79FD6EDE5AA87_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_4ACA52F29AD979EA03A79FD6EDE5AA87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_4ACA52F29AD979EA03A79FD6EDE5AA87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_4ACA52F29AD979EA03A79FD6EDE5AA87" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_4ACA52F29AD979EA03A79FD6EDE5AA87" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_64675BFA52828BB6AA999FD83E995900_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_64675BFA52828BB6AA999FD83E995900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (Losses) on net investment hedge recognized during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_64675BFA52828BB6AA999FD83E995900_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_64675BFA52828BB6AA999FD83E995900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_64675BFA52828BB6AA999FD83E995900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_64675BFA52828BB6AA999FD83E995900" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_64675BFA52828BB6AA999FD83E995900" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_548377E49345C2C1CD649FD8B0361B92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_548377E49345C2C1CD649FD8B0361B92" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Reclassification of net investment hedge forward points amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_548377E49345C2C1CD649FD8B0361B92_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_548377E49345C2C1CD649FD8B0361B92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_548377E49345C2C1CD649FD8B0361B92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_548377E49345C2C1CD649FD8B0361B92" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_548377E49345C2C1CD649FD8B0361B92" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_B6C7D7453A6D264707D39FD914513F39_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_B6C7D7453A6D264707D39FD914513F39" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_B6C7D7453A6D264707D39FD914513F39_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_B6C7D7453A6D264707D39FD914513F39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), after Adjustments and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_B6C7D7453A6D264707D39FD914513F39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_B6C7D7453A6D264707D39FD914513F39" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_B6C7D7453A6D264707D39FD914513F39" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D5D3E87A4E0CE05828109FD6EDE5C258_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D5D3E87A4E0CE05828109FD6EDE5C258" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D5D3E87A4E0CE05828109FD6EDE5C258_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D5D3E87A4E0CE05828109FD6EDE5C258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D5D3E87A4E0CE05828109FD6EDE5C258" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D5D3E87A4E0CE05828109FD6EDE5C258" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D5D3E87A4E0CE05828109FD6EDE5C258" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_18DAC6CEDC483B341BB69FD6EDE5BA89_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_18DAC6CEDC483B341BB69FD6EDE5BA89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_18DAC6CEDC483B341BB69FD6EDE5BA89_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_18DAC6CEDC483B341BB69FD6EDE5BA89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_18DAC6CEDC483B341BB69FD6EDE5BA89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_18DAC6CEDC483B341BB69FD6EDE5BA89" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_18DAC6CEDC483B341BB69FD6EDE5BA89" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_AD3501C61FB5F8EC35369FD6EDE67694_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_AD3501C61FB5F8EC35369FD6EDE67694" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_AD3501C61FB5F8EC35369FD6EDE67694_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_AD3501C61FB5F8EC35369FD6EDE67694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_AD3501C61FB5F8EC35369FD6EDE67694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_AD3501C61FB5F8EC35369FD6EDE67694" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_AD3501C61FB5F8EC35369FD6EDE67694" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_13E98A29221B996036679FD6EDE66FF6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_13E98A29221B996036679FD6EDE66FF6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_13E98A29221B996036679FD6EDE66FF6_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_13E98A29221B996036679FD6EDE66FF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_13E98A29221B996036679FD6EDE66FF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_13E98A29221B996036679FD6EDE66FF6" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_13E98A29221B996036679FD6EDE66FF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_E73EBC717E132F026C359FD6EDE60CE7_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_E73EBC717E132F026C359FD6EDE60CE7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_E73EBC717E132F026C359FD6EDE60CE7_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_E73EBC717E132F026C359FD6EDE60CE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_E73EBC717E132F026C359FD6EDE60CE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_E73EBC717E132F026C359FD6EDE60CE7" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_E73EBC717E132F026C359FD6EDE60CE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B62D7CE8CBEBBFE63D4B9FD6EDE6BC28_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B62D7CE8CBEBBFE63D4B9FD6EDE6BC28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B62D7CE8CBEBBFE63D4B9FD6EDE6BC28_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B62D7CE8CBEBBFE63D4B9FD6EDE6BC28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B62D7CE8CBEBBFE63D4B9FD6EDE6BC28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B62D7CE8CBEBBFE63D4B9FD6EDE6BC28" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B62D7CE8CBEBBFE63D4B9FD6EDE6BC28" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_12B456AF41E27A2E32771689810CA41B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_12B456AF41E27A2E32771689810CA41B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_12B456AF41E27A2E32771689810CA41B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_12B456AF41E27A2E32771689810CA41B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_12B456AF41E27A2E32771689810CA41B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_12B456AF41E27A2E32771689810CA41B" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_12B456AF41E27A2E32771689810CA41B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_70C74B1C122728066A751689810C87D9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_70C74B1C122728066A751689810C87D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as cash flow hedging instruments on our consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_70C74B1C122728066A751689810C87D9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_70C74B1C122728066A751689810C87D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_70C74B1C122728066A751689810C87D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_70C74B1C122728066A751689810C87D9" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_70C74B1C122728066A751689810C87D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BDF6A2A52B21A05264341689810C342E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BDF6A2A52B21A05264341689810C342E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BDF6A2A52B21A05264341689810C342E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BDF6A2A52B21A05264341689810C342E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BDF6A2A52B21A05264341689810C342E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BDF6A2A52B21A05264341689810C342E" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BDF6A2A52B21A05264341689810C342E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3AAD0E15918A14197AE51689810CF762_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3AAD0E15918A14197AE51689810CF762" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the fair value for our outstanding derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3AAD0E15918A14197AE51689810CF762_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3AAD0E15918A14197AE51689810CF762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3AAD0E15918A14197AE51689810CF762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3AAD0E15918A14197AE51689810CF762" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3AAD0E15918A14197AE51689810CF762" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_EEF4321928087A3484C7FBB83328F4C7_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_EEF4321928087A3484C7FBB83328F4C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_EEF4321928087A3484C7FBB83328F4C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_EEF4321928087A3484C7FBB83328F4C7" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_EEF4321928087A3484C7FBB83328F4C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_AB59444DC1FEE1F38BD7FBB833281934_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_AB59444DC1FEE1F38BD7FBB833281934" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_AB59444DC1FEE1F38BD7FBB833281934_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_AB59444DC1FEE1F38BD7FBB833281934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_AB59444DC1FEE1F38BD7FBB833281934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_AB59444DC1FEE1F38BD7FBB833281934" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_AB59444DC1FEE1F38BD7FBB833281934" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B9479ADB8A7D6F8A31B0FBB8351C5CBF_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B9479ADB8A7D6F8A31B0FBB8351C5CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B9479ADB8A7D6F8A31B0FBB8351C5CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B9479ADB8A7D6F8A31B0FBB8351C5CBF" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B9479ADB8A7D6F8A31B0FBB8351C5CBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_75F9F0D466C2A01BF166FBB8351C00A0_verboseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_75F9F0D466C2A01BF166FBB8351C00A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_75F9F0D466C2A01BF166FBB8351C00A0_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_75F9F0D466C2A01BF166FBB8351C00A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_75F9F0D466C2A01BF166FBB8351C00A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_75F9F0D466C2A01BF166FBB8351C00A0" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_75F9F0D466C2A01BF166FBB8351C00A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument Risk [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract Type [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateSwapMember_35AECC386FDFB5E5737B85B86D46884E_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_35AECC386FDFB5E5737B85B86D46884E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_35AECC386FDFB5E5737B85B86D46884E_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember_35AECC386FDFB5E5737B85B86D46884E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_35AECC386FDFB5E5737B85B86D46884E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember_35AECC386FDFB5E5737B85B86D46884E" xlink:to="lab_us-gaap_InterestRateSwapMember_35AECC386FDFB5E5737B85B86D46884E" xlink:type="arc" />
    <link:label id="lab_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35_terseLabel_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable To Fumedica</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35_label_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable To Fumedica [Member]</link:label>
    <link:label id="lab_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35_documentation_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes payable.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35" xlink:to="lab_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_0FEEA980F29445F348A685B86D4D055E_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_0FEEA980F29445F348A685B86D4D055E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_0FEEA980F29445F348A685B86D4D055E_label_en-US" xlink:label="lab_us-gaap_NotesPayable_0FEEA980F29445F348A685B86D4D055E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_0FEEA980F29445F348A685B86D4D055E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_0FEEA980F29445F348A685B86D4D055E" xlink:to="lab_us-gaap_NotesPayable_0FEEA980F29445F348A685B86D4D055E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_902374E5DCACD17CA4B985B86D4DEAB9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_902374E5DCACD17CA4B985B86D4DEAB9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_902374E5DCACD17CA4B985B86D4DEAB9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_902374E5DCACD17CA4B985B86D4DEAB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_902374E5DCACD17CA4B985B86D4DEAB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_902374E5DCACD17CA4B985B86D4DEAB9" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_902374E5DCACD17CA4B985B86D4DEAB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_DA424DE556FE49A929B185B86D4D92F1_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_DA424DE556FE49A929B185B86D4D92F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_DA424DE556FE49A929B185B86D4D92F1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_DA424DE556FE49A929B185B86D4D92F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DA424DE556FE49A929B185B86D4D92F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DA424DE556FE49A929B185B86D4D92F1" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_DA424DE556FE49A929B185B86D4D92F1" xlink:type="arc" />
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388_verboseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388" xlink:to="lab_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388" xlink:type="arc" />
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02_terseLabel_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increased Carrying Amount Of Senior Notes</link:label>
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02_label_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increased Carrying Amount Of Senior Notes</link:label>
    <link:label id="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02_documentation_en-US" xlink:label="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increased carrying amount of senior notes.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02" xlink:to="lab_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2D5D135DCD8E3A693D6B85B86D508481_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2D5D135DCD8E3A693D6B85B86D508481" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net charge upon extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2D5D135DCD8E3A693D6B85B86D508481_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2D5D135DCD8E3A693D6B85B86D508481" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Gain (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2D5D135DCD8E3A693D6B85B86D508481" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2D5D135DCD8E3A693D6B85B86D508481" xlink:to="lab_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2D5D135DCD8E3A693D6B85B86D508481" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_C075C95500C6E496EF5585B86D50B58E_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_C075C95500C6E496EF5585B86D50B58E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_C075C95500C6E496EF5585B86D50B58E_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_C075C95500C6E496EF5585B86D50B58E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C075C95500C6E496EF5585B86D50B58E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C075C95500C6E496EF5585B86D50B58E" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_C075C95500C6E496EF5585B86D50B58E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_5B9A3CD1348B6BF8EEFB85B86D50F8A5_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_5B9A3CD1348B6BF8EEFB85B86D50F8A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs associated with the Senior Notes offerings</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_5B9A3CD1348B6BF8EEFB85B86D50F8A5_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts_5B9A3CD1348B6BF8EEFB85B86D50F8A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5B9A3CD1348B6BF8EEFB85B86D50F8A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts_5B9A3CD1348B6BF8EEFB85B86D50F8A5" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts_5B9A3CD1348B6BF8EEFB85B86D50F8A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_18F26C97A45DE472819885B86D50899C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_18F26C97A45DE472819885B86D50899C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemptions percentage of 2015 notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_18F26C97A45DE472819885B86D50899C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_18F26C97A45DE472819885B86D50899C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_18F26C97A45DE472819885B86D50899C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_18F26C97A45DE472819885B86D50899C" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_18F26C97A45DE472819885B86D50899C" xlink:type="arc" />
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption percentage for change in control provision on the 2015 Senior Notes</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D_label_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D_documentation_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D" xlink:to="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_675D8C5DB423E14604BF85B86D504629_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_675D8C5DB423E14604BF85B86D504629" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of the interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_675D8C5DB423E14604BF85B86D504629_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_675D8C5DB423E14604BF85B86D504629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_675D8C5DB423E14604BF85B86D504629" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_675D8C5DB423E14604BF85B86D504629" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_675D8C5DB423E14604BF85B86D504629" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B0048F1EF167CAD12E6785B86D50789A_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B0048F1EF167CAD12E6785B86D50789A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior unsecured revolving credit facility maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B0048F1EF167CAD12E6785B86D50789A_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B0048F1EF167CAD12E6785B86D50789A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B0048F1EF167CAD12E6785B86D50789A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B0048F1EF167CAD12E6785B86D50789A" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B0048F1EF167CAD12E6785B86D50789A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_BB03A942DAEE494C5A0C85B86D50248B_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_BB03A942DAEE494C5A0C85B86D50248B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_BB03A942DAEE494C5A0C85B86D50248B_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_BB03A942DAEE494C5A0C85B86D50248B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_BB03A942DAEE494C5A0C85B86D50248B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_BB03A942DAEE494C5A0C85B86D50248B" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_BB03A942DAEE494C5A0C85B86D50248B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D9F30FE03FB976950D285B86D501C86_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D9F30FE03FB976950D285B86D501C86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount outstanding under the credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D9F30FE03FB976950D285B86D501C86_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D9F30FE03FB976950D285B86D501C86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D9F30FE03FB976950D285B86D501C86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D9F30FE03FB976950D285B86D501C86" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D9F30FE03FB976950D285B86D501C86" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B5EA2F1FB349F36A641A85697A6A1C5A_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B5EA2F1FB349F36A641A85697A6A1C5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B5EA2F1FB349F36A641A85697A6A1C5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B5EA2F1FB349F36A641A85697A6A1C5A" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B5EA2F1FB349F36A641A85697A6A1C5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5" xlink:type="arc" />
    <link:label id="lab_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1_terseLabel_en-US" xlink:label="lab_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioverativ</link:label>
    <link:label id="lab_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1_label_en-US" xlink:label="lab_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:label id="lab_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1_documentation_en-US" xlink:label="lab_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioverativ [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1" xlink:to="lab_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and Liabilities Distributed to Bioverativ [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7CE50FD6B0434A4908D85697A6AEF9F_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7CE50FD6B0434A4908D85697A6AEF9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7CE50FD6B0434A4908D85697A6AEF9F_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7CE50FD6B0434A4908D85697A6AEF9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7CE50FD6B0434A4908D85697A6AEF9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7CE50FD6B0434A4908D85697A6AEF9F" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7CE50FD6B0434A4908D85697A6AEF9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_FE5D1DADF79F79920F2285697A6A11B9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_FE5D1DADF79F79920F2285697A6A11B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_FE5D1DADF79F79920F2285697A6A11B9_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_FE5D1DADF79F79920F2285697A6A11B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_FE5D1DADF79F79920F2285697A6A11B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_FE5D1DADF79F79920F2285697A6A11B9" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_FE5D1DADF79F79920F2285697A6A11B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_60CB939DE4EB8C1A580585697A6A38E7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_60CB939DE4EB8C1A580585697A6A38E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_60CB939DE4EB8C1A580585697A6A38E7_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_60CB939DE4EB8C1A580585697A6A38E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_60CB939DE4EB8C1A580585697A6A38E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_60CB939DE4EB8C1A580585697A6A38E7" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_60CB939DE4EB8C1A580585697A6A38E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_A88447AD456F4C35F29C85697A6A50D4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_A88447AD456F4C35F29C85697A6A50D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_A88447AD456F4C35F29C85697A6A50D4_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_A88447AD456F4C35F29C85697A6A50D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_A88447AD456F4C35F29C85697A6A50D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_A88447AD456F4C35F29C85697A6A50D4" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_A88447AD456F4C35F29C85697A6A50D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_CE2954F6E6E0BA0CDE0885697A6A586B_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_CE2954F6E6E0BA0CDE0885697A6A586B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_CE2954F6E6E0BA0CDE0885697A6A586B_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_CE2954F6E6E0BA0CDE0885697A6A586B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_CE2954F6E6E0BA0CDE0885697A6A586B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_CE2954F6E6E0BA0CDE0885697A6A586B" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_CE2954F6E6E0BA0CDE0885697A6A586B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C926F8E7BE036965D6F585697A6ADEC9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C926F8E7BE036965D6F585697A6ADEC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C926F8E7BE036965D6F585697A6ADEC9_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C926F8E7BE036965D6F585697A6ADEC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C926F8E7BE036965D6F585697A6ADEC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C926F8E7BE036965D6F585697A6ADEC9" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C926F8E7BE036965D6F585697A6ADEC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8CD16292C90C0E0C078E85697A6A0324_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8CD16292C90C0E0C078E85697A6A0324" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8CD16292C90C0E0C078E85697A6A0324_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8CD16292C90C0E0C078E85697A6A0324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8CD16292C90C0E0C078E85697A6A0324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8CD16292C90C0E0C078E85697A6A0324" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8CD16292C90C0E0C078E85697A6A0324" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6684802F4EDF72A6FAA385697A6A8AC4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6684802F4EDF72A6FAA385697A6A8AC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets transferred, net</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6684802F4EDF72A6FAA385697A6A8AC4_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6684802F4EDF72A6FAA385697A6A8AC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6684802F4EDF72A6FAA385697A6A8AC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6684802F4EDF72A6FAA385697A6A8AC4" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6684802F4EDF72A6FAA385697A6A8AC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1F3CE75937F0EF4A9DA385697A6A18DF_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1F3CE75937F0EF4A9DA385697A6A18DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1F3CE75937F0EF4A9DA385697A6A18DF_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1F3CE75937F0EF4A9DA385697A6A18DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1F3CE75937F0EF4A9DA385697A6A18DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1F3CE75937F0EF4A9DA385697A6A18DF" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1F3CE75937F0EF4A9DA385697A6A18DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_F2DD821B190719DE3EAB85697A6AC31D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_F2DD821B190719DE3EAB85697A6AC31D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_F2DD821B190719DE3EAB85697A6AC31D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_F2DD821B190719DE3EAB85697A6AC31D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_F2DD821B190719DE3EAB85697A6AC31D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_F2DD821B190719DE3EAB85697A6AC31D" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_F2DD821B190719DE3EAB85697A6AC31D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1453678EC5388DE6C8FF85697A6A48B4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1453678EC5388DE6C8FF85697A6A48B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities transferred, net</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1453678EC5388DE6C8FF85697A6A48B4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1453678EC5388DE6C8FF85697A6A48B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1453678EC5388DE6C8FF85697A6A48B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1453678EC5388DE6C8FF85697A6A48B4" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1453678EC5388DE6C8FF85697A6A48B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Award Type and Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:to="lab_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F" xlink:to="lab_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45" xlink:type="arc" />
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units activity</link:label>
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB_label_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units Activity [Abstract]</link:label>
    <link:label id="lab_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units activity.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="lab_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A69258A77CB36963AB3C871CAE214C11_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A69258A77CB36963AB3C871CAE214C11" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Unvested, Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A69258A77CB36963AB3C871CAE214C11_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A69258A77CB36963AB3C871CAE214C11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A69258A77CB36963AB3C871CAE214C11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A69258A77CB36963AB3C871CAE214C11" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A69258A77CB36963AB3C871CAE214C11" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4FE6C3EE7B8D6B5D0A39871CAE2110A4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4FE6C3EE7B8D6B5D0A39871CAE2110A4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4FE6C3EE7B8D6B5D0A39871CAE2110A4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4FE6C3EE7B8D6B5D0A39871CAE2110A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4FE6C3EE7B8D6B5D0A39871CAE2110A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4FE6C3EE7B8D6B5D0A39871CAE2110A4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4FE6C3EE7B8D6B5D0A39871CAE2110A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1B290DC65127D27F842A871CAE210642_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1B290DC65127D27F842A871CAE210642" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1B290DC65127D27F842A871CAE210642_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1B290DC65127D27F842A871CAE210642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1B290DC65127D27F842A871CAE210642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1B290DC65127D27F842A871CAE210642" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1B290DC65127D27F842A871CAE210642" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CE98AEFF8F6B85955DFE871CAE2100BB_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CE98AEFF8F6B85955DFE871CAE2100BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CE98AEFF8F6B85955DFE871CAE2100BB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CE98AEFF8F6B85955DFE871CAE2100BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CE98AEFF8F6B85955DFE871CAE2100BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CE98AEFF8F6B85955DFE871CAE2100BB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CE98AEFF8F6B85955DFE871CAE2100BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CACDA30051D37B507129871CAE21070E_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CACDA30051D37B507129871CAE21070E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CACDA30051D37B507129871CAE21070E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CACDA30051D37B507129871CAE21070E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CACDA30051D37B507129871CAE21070E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CACDA30051D37B507129871CAE21070E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CACDA30051D37B507129871CAE21070E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8A93CD3D48580DC61F7D871CAE21FB5E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8A93CD3D48580DC61F7D871CAE21FB5E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8A93CD3D48580DC61F7D871CAE21FB5E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8A93CD3D48580DC61F7D871CAE21FB5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8A93CD3D48580DC61F7D871CAE21FB5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8A93CD3D48580DC61F7D871CAE21FB5E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8A93CD3D48580DC61F7D871CAE21FB5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D15571723EA24DD6BB54871CAE216A48_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D15571723EA24DD6BB54871CAE216A48" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D15571723EA24DD6BB54871CAE216A48_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D15571723EA24DD6BB54871CAE216A48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D15571723EA24DD6BB54871CAE216A48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D15571723EA24DD6BB54871CAE216A48" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D15571723EA24DD6BB54871CAE216A48" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_06FF1C216BD120AA67FC871CAE21054D_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_06FF1C216BD120AA67FC871CAE21054D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_06FF1C216BD120AA67FC871CAE21054D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_06FF1C216BD120AA67FC871CAE21054D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_06FF1C216BD120AA67FC871CAE21054D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_06FF1C216BD120AA67FC871CAE21054D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_06FF1C216BD120AA67FC871CAE21054D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33246E2A0D34283E059F871CAE21ADD6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33246E2A0D34283E059F871CAE21ADD6" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Unvested, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33246E2A0D34283E059F871CAE21ADD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33246E2A0D34283E059F871CAE21ADD6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33246E2A0D34283E059F871CAE21ADD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D62567BD21D34FA33833871CAE21640B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D62567BD21D34FA33833871CAE21640B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D62567BD21D34FA33833871CAE21640B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D62567BD21D34FA33833871CAE21640B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D62567BD21D34FA33833871CAE21640B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735_label_en-US" xlink:label="lab_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:to="lab_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B_netLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:to="lab_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0AF7B62009C18C596C719FD5D487DCFA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0AF7B62009C18C596C719FD5D487DCFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains (Losses) on Securities Available for Sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0AF7B62009C18C596C719FD5D487DCFA_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0AF7B62009C18C596C719FD5D487DCFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0AF7B62009C18C596C719FD5D487DCFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0AF7B62009C18C596C719FD5D487DCFA" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0AF7B62009C18C596C719FD5D487DCFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7E319EE7ABAFB70DCA719FD5D48709D2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7E319EE7ABAFB70DCA719FD5D48709D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7E319EE7ABAFB70DCA719FD5D48709D2_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7E319EE7ABAFB70DCA719FD5D48709D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7E319EE7ABAFB70DCA719FD5D48709D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7E319EE7ABAFB70DCA719FD5D48709D2" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7E319EE7ABAFB70DCA719FD5D48709D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_552F34AC139F833CD5489FD5D487162C_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_552F34AC139F833CD5489FD5D487162C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains (Losses) on Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_552F34AC139F833CD5489FD5D487162C_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_552F34AC139F833CD5489FD5D487162C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_552F34AC139F833CD5489FD5D487162C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_552F34AC139F833CD5489FD5D487162C" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_552F34AC139F833CD5489FD5D487162C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8BD6FA144744EEC7E5FF9FD5D6FCEEAE_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8BD6FA144744EEC7E5FF9FD5D6FCEEAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8BD6FA144744EEC7E5FF9FD5D6FCEEAE_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8BD6FA144744EEC7E5FF9FD5D6FCEEAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8BD6FA144744EEC7E5FF9FD5D6FCEEAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8BD6FA144744EEC7E5FF9FD5D6FCEEAE" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8BD6FA144744EEC7E5FF9FD5D6FCEEAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_E3E5162FF35BA26803A99FD5D4877AC6_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_E3E5162FF35BA26803A99FD5D4877AC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_E3E5162FF35BA26803A99FD5D4877AC6_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_E3E5162FF35BA26803A99FD5D4877AC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_E3E5162FF35BA26803A99FD5D4877AC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_E3E5162FF35BA26803A99FD5D4877AC6" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_E3E5162FF35BA26803A99FD5D4877AC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8AAE542D213BF16C1C3E9FD5D487EA48_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_8AAE542D213BF16C1C3E9FD5D487EA48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_8AAE542D213BF16C1C3E9FD5D487EA48_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_8AAE542D213BF16C1C3E9FD5D487EA48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8AAE542D213BF16C1C3E9FD5D487EA48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_8AAE542D213BF16C1C3E9FD5D487EA48" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_8AAE542D213BF16C1C3E9FD5D487EA48" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_5BCA285D46E681A79D159FD5D487DADC_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Revenues_5BCA285D46E681A79D159FD5D487DADC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5BCA285D46E681A79D159FD5D487DADC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_5BCA285D46E681A79D159FD5D487DADC" xlink:to="lab_us-gaap_Revenues_5BCA285D46E681A79D159FD5D487DADC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_EA77B1C0E46B71DF80419FD5D4879210_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_EA77B1C0E46B71DF80419FD5D4879210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_EA77B1C0E46B71DF80419FD5D4879210_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_EA77B1C0E46B71DF80419FD5D4879210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_EA77B1C0E46B71DF80419FD5D4879210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_EA77B1C0E46B71DF80419FD5D4879210" xlink:to="lab_us-gaap_OperatingExpenses_EA77B1C0E46B71DF80419FD5D4879210" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_B5F47AF5606D8DF8DAA29FD5D487AC37_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_B5F47AF5606D8DF8DAA29FD5D487AC37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_B5F47AF5606D8DF8DAA29FD5D487AC37_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_B5F47AF5606D8DF8DAA29FD5D487AC37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B5F47AF5606D8DF8DAA29FD5D487AC37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_B5F47AF5606D8DF8DAA29FD5D487AC37" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_B5F47AF5606D8DF8DAA29FD5D487AC37" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_4A42B674AF56C82CC21285CC9CAB03C2_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_4A42B674AF56C82CC21285CC9CAB03C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_4A42B674AF56C82CC21285CC9CAB03C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_4A42B674AF56C82CC21285CC9CAB03C2" xlink:to="lab_us-gaap_SegmentReportingAbstract_4A42B674AF56C82CC21285CC9CAB03C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:type="arc" />
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_A1A1D98F31AED71DD96985CC9CAEC3CD_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_A1A1D98F31AED71DD96985CC9CAEC3CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_A1A1D98F31AED71DD96985CC9CAEC3CD_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_A1A1D98F31AED71DD96985CC9CAEC3CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_A1A1D98F31AED71DD96985CC9CAEC3CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_A1A1D98F31AED71DD96985CC9CAEC3CD" xlink:to="lab_us-gaap_ProductAndServiceOtherMember_A1A1D98F31AED71DD96985CC9CAEC3CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_834084CC61A381B63BBA85EC5F431197_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_834084CC61A381B63BBA85EC5F431197" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_834084CC61A381B63BBA85EC5F431197_label_en-US" xlink:label="lab_us-gaap_ProductMember_834084CC61A381B63BBA85EC5F431197" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_834084CC61A381B63BBA85EC5F431197" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_834084CC61A381B63BBA85EC5F431197" xlink:to="lab_us-gaap_ProductMember_834084CC61A381B63BBA85EC5F431197" xlink:type="arc" />
    <link:label id="lab_country_US_D3DD9DF305A5A31B4E3585CC9CAE2CF9_verboseLabel_en-US" xlink:label="lab_country_US_D3DD9DF305A5A31B4E3585CC9CAE2CF9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D3DD9DF305A5A31B4E3585CC9CAE2CF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_D3DD9DF305A5A31B4E3585CC9CAE2CF9" xlink:to="lab_country_US_D3DD9DF305A5A31B4E3585CC9CAE2CF9" xlink:type="arc" />
    <link:label id="lab_srt_EuropeMember_EF04E57D20BC9FF32A7985CC9CAE80D3_terseLabel_en-US" xlink:label="lab_srt_EuropeMember_EF04E57D20BC9FF32A7985CC9CAE80D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_EF04E57D20BC9FF32A7985CC9CAE80D3_label_en-US" xlink:label="lab_srt_EuropeMember_EF04E57D20BC9FF32A7985CC9CAE80D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_EF04E57D20BC9FF32A7985CC9CAE80D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember_EF04E57D20BC9FF32A7985CC9CAE80D3" xlink:to="lab_srt_EuropeMember_EF04E57D20BC9FF32A7985CC9CAE80D3" xlink:type="arc" />
    <link:label id="lab_srt_AsiaMember_62AE3B768B34FE13CBF585CC9CAE13FF_terseLabel_en-US" xlink:label="lab_srt_AsiaMember_62AE3B768B34FE13CBF585CC9CAE13FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asia</link:label>
    <link:label id="lab_srt_AsiaMember_62AE3B768B34FE13CBF585CC9CAE13FF_label_en-US" xlink:label="lab_srt_AsiaMember_62AE3B768B34FE13CBF585CC9CAE13FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asia [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_AsiaMember" xlink:label="loc_srt_AsiaMember_62AE3B768B34FE13CBF585CC9CAE13FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AsiaMember_62AE3B768B34FE13CBF585CC9CAE13FF" xlink:to="lab_srt_AsiaMember_62AE3B768B34FE13CBF585CC9CAE13FF" xlink:type="arc" />
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C_verboseLabel_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C_label_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Geographical Groups Of Countries Group Other [Member]</link:label>
    <link:label id="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C_documentation_en-US" xlink:label="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment geographical groups of countries group other.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C" xlink:to="lab_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Geographic information</link:label>
    <link:label id="lab_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432_label_en-US" xlink:label="lab_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments, Geographical Areas [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432" xlink:to="lab_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncurrentAssets_10F6E843E1B688B3365685CC9CAE2A3A_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_10F6E843E1B688B3365685CC9CAE2A3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_10F6E843E1B688B3365685CC9CAE2A3A_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_10F6E843E1B688B3365685CC9CAE2A3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_10F6E843E1B688B3365685CC9CAE2A3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_10F6E843E1B688B3365685CC9CAE2A3A" xlink:to="lab_us-gaap_NoncurrentAssets_10F6E843E1B688B3365685CC9CAE2A3A" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_9C1E73ECB406398DEC3EFBB831645918_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_9C1E73ECB406398DEC3EFBB831645918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_9C1E73ECB406398DEC3EFBB831645918_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_9C1E73ECB406398DEC3EFBB831645918" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_9C1E73ECB406398DEC3EFBB831645918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_9C1E73ECB406398DEC3EFBB831645918" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_9C1E73ECB406398DEC3EFBB831645918" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_BA9B5DDB42A09BDFB4CFFBB8316400D3_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_BA9B5DDB42A09BDFB4CFFBB8316400D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_BA9B5DDB42A09BDFB4CFFBB8316400D3_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_BA9B5DDB42A09BDFB4CFFBB8316400D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_BA9B5DDB42A09BDFB4CFFBB8316400D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_BA9B5DDB42A09BDFB4CFFBB8316400D3" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_BA9B5DDB42A09BDFB4CFFBB8316400D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_073D62851363919BACF0FBB834320AA1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_073D62851363919BACF0FBB834320AA1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_073D62851363919BACF0FBB834320AA1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_073D62851363919BACF0FBB834320AA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_073D62851363919BACF0FBB834320AA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_073D62851363919BACF0FBB834320AA1" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_073D62851363919BACF0FBB834320AA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_46468982AF80A9EA0298FBB8331946FB_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_46468982AF80A9EA0298FBB8331946FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_46468982AF80A9EA0298FBB8331946FB_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_46468982AF80A9EA0298FBB8331946FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_46468982AF80A9EA0298FBB8331946FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_46468982AF80A9EA0298FBB8331946FB" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_46468982AF80A9EA0298FBB8331946FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Land_44AD6514B96E6EA6CBA5FBB83183DFB0_terseLabel_en-US" xlink:label="lab_us-gaap_Land_44AD6514B96E6EA6CBA5FBB83183DFB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_44AD6514B96E6EA6CBA5FBB83183DFB0_label_en-US" xlink:label="lab_us-gaap_Land_44AD6514B96E6EA6CBA5FBB83183DFB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_44AD6514B96E6EA6CBA5FBB83183DFB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land_44AD6514B96E6EA6CBA5FBB83183DFB0" xlink:to="lab_us-gaap_Land_44AD6514B96E6EA6CBA5FBB83183DFB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_70EE48DB62C31F578954FBB8318345AC_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross_70EE48DB62C31F578954FBB8318345AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingsAndImprovementsGross_70EE48DB62C31F578954FBB8318345AC_label_en-US" xlink:label="lab_us-gaap_BuildingsAndImprovementsGross_70EE48DB62C31F578954FBB8318345AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Buildings and Improvements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_70EE48DB62C31F578954FBB8318345AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingsAndImprovementsGross_70EE48DB62C31F578954FBB8318345AC" xlink:to="lab_us-gaap_BuildingsAndImprovementsGross_70EE48DB62C31F578954FBB8318345AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_BB35F9E95FCE40D6D138FBB831831802_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_BB35F9E95FCE40D6D138FBB831831802" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_BB35F9E95FCE40D6D138FBB831831802_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross_BB35F9E95FCE40D6D138FBB831831802" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_BB35F9E95FCE40D6D138FBB831831802" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross_BB35F9E95FCE40D6D138FBB831831802" xlink:to="lab_us-gaap_LeaseholdImprovementsGross_BB35F9E95FCE40D6D138FBB831831802" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_4386AD649A7F237ADCA6FBB83183040D_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_4386AD649A7F237ADCA6FBB83183040D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentGross_4386AD649A7F237ADCA6FBB83183040D_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentGross_4386AD649A7F237ADCA6FBB83183040D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_4386AD649A7F237ADCA6FBB83183040D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentGross_4386AD649A7F237ADCA6FBB83183040D" xlink:to="lab_us-gaap_MachineryAndEquipmentGross_4386AD649A7F237ADCA6FBB83183040D" xlink:type="arc" />
    <link:label id="lab_biib_ComputerSoftwareAndHardware_5037454B47D1657B88D3FBB83183906E_terseLabel_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_5037454B47D1657B88D3FBB83183906E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_5037454B47D1657B88D3FBB83183906E_label_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_5037454B47D1657B88D3FBB83183906E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:label id="lab_biib_ComputerSoftwareAndHardware_5037454B47D1657B88D3FBB83183906E_documentation_en-US" xlink:label="lab_biib_ComputerSoftwareAndHardware_5037454B47D1657B88D3FBB83183906E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer software and hardware</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_5037454B47D1657B88D3FBB83183906E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ComputerSoftwareAndHardware_5037454B47D1657B88D3FBB83183906E" xlink:to="lab_biib_ComputerSoftwareAndHardware_5037454B47D1657B88D3FBB83183906E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_8E19798A82B4E238C95FFBB8318310F5_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_8E19798A82B4E238C95FFBB8318310F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesGross_8E19798A82B4E238C95FFBB8318310F5_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesGross_8E19798A82B4E238C95FFBB8318310F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_8E19798A82B4E238C95FFBB8318310F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesGross_8E19798A82B4E238C95FFBB8318310F5" xlink:to="lab_us-gaap_FurnitureAndFixturesGross_8E19798A82B4E238C95FFBB8318310F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_9007D9B4C460A33B6946FBB83183B527_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_9007D9B4C460A33B6946FBB83183B527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_9007D9B4C460A33B6946FBB83183B527_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_9007D9B4C460A33B6946FBB83183B527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_9007D9B4C460A33B6946FBB83183B527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_9007D9B4C460A33B6946FBB83183B527" xlink:to="lab_us-gaap_ConstructionInProgressGross_9007D9B4C460A33B6946FBB83183B527" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_934197C900A121F6C47AFBB8318306C1_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_934197C900A121F6C47AFBB8318306C1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_934197C900A121F6C47AFBB8318306C1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_934197C900A121F6C47AFBB8318306C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_934197C900A121F6C47AFBB8318306C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_934197C900A121F6C47AFBB8318306C1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_934197C900A121F6C47AFBB8318306C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9454B97BB36E0B692628FBB83183D75C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9454B97BB36E0B692628FBB83183D75C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9454B97BB36E0B692628FBB83183D75C_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9454B97BB36E0B692628FBB83183D75C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9454B97BB36E0B692628FBB83183D75C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9454B97BB36E0B692628FBB83183D75C" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9454B97BB36E0B692628FBB83183D75C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6D1CE72414FFA248FFDEFBB83183EFB7_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_6D1CE72414FFA248FFDEFBB83183EFB7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6D1CE72414FFA248FFDEFBB83183EFB7_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_6D1CE72414FFA248FFDEFBB83183EFB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6D1CE72414FFA248FFDEFBB83183EFB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6D1CE72414FFA248FFDEFBB83183EFB7" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_6D1CE72414FFA248FFDEFBB83183EFB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_436284466C2F06996F9CBEA935D8EF93_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_436284466C2F06996F9CBEA935D8EF93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_436284466C2F06996F9CBEA935D8EF93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_436284466C2F06996F9CBEA935D8EF93" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_436284466C2F06996F9CBEA935D8EF93" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15_terseLabel_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15_label_en-US" xlink:label="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prospective Adoption of New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:to="lab_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:label id="lab_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357_label_en-US" xlink:label="lab_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Guidance [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:to="lab_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_A6A4CE3078804B96EFD2BEA935E815CE_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_A6A4CE3078804B96EFD2BEA935E815CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_A6A4CE3078804B96EFD2BEA935E815CE_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_A6A4CE3078804B96EFD2BEA935E815CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_A6A4CE3078804B96EFD2BEA935E815CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member_A6A4CE3078804B96EFD2BEA935E815CE" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member_A6A4CE3078804B96EFD2BEA935E815CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:type="arc" />
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52_terseLabel_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52_label_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52_documentation_en-US" xlink:label="lab_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52" xlink:to="lab_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52" xlink:type="arc" />
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644_terseLabel_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644_label_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program Year To Date [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644_documentation_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program Year To Date</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644" xlink:to="lab_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644" xlink:type="arc" />
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E_terseLabel_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E_label_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E_documentation_en-US" xlink:label="lab_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2011 Share Repurchase Program</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E" xlink:to="lab_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E" xlink:type="arc" />
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F_terseLabel_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F_label_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F_documentation_en-US" xlink:label="lab_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F" xlink:to="lab_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement, Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_676448E329BA1A005448BEA935E80321_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_676448E329BA1A005448BEA935E80321" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_676448E329BA1A005448BEA935E80321_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_676448E329BA1A005448BEA935E80321" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_676448E329BA1A005448BEA935E80321" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_676448E329BA1A005448BEA935E80321" xlink:to="lab_us-gaap_PreferredStockMember_676448E329BA1A005448BEA935E80321" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_4A6F300C0B6C754118B4BEA935E81111_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_4A6F300C0B6C754118B4BEA935E81111" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_4A6F300C0B6C754118B4BEA935E81111_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_4A6F300C0B6C754118B4BEA935E81111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4A6F300C0B6C754118B4BEA935E81111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_4A6F300C0B6C754118B4BEA935E81111" xlink:to="lab_us-gaap_CommonStockMember_4A6F300C0B6C754118B4BEA935E81111" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_E7BE87ADEFC28AEA2BF7BEA935E83D19_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_E7BE87ADEFC28AEA2BF7BEA935E83D19" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_E7BE87ADEFC28AEA2BF7BEA935E83D19_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_E7BE87ADEFC28AEA2BF7BEA935E83D19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_E7BE87ADEFC28AEA2BF7BEA935E83D19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_E7BE87ADEFC28AEA2BF7BEA935E83D19" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_E7BE87ADEFC28AEA2BF7BEA935E83D19" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2816504ECE1A0C3E7C93BEA935E81103_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2816504ECE1A0C3E7C93BEA935E81103" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2816504ECE1A0C3E7C93BEA935E81103_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2816504ECE1A0C3E7C93BEA935E81103" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2816504ECE1A0C3E7C93BEA935E81103" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2816504ECE1A0C3E7C93BEA935E81103" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2816504ECE1A0C3E7C93BEA935E81103" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_315D7967BEBE0461F083BEA935E84111_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_315D7967BEBE0461F083BEA935E84111" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_315D7967BEBE0461F083BEA935E84111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_315D7967BEBE0461F083BEA935E84111" xlink:to="lab_us-gaap_RetainedEarningsMember_315D7967BEBE0461F083BEA935E84111" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_83AA5E2DD5D0789767E0BEA935E8C267_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_83AA5E2DD5D0789767E0BEA935E8C267" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_83AA5E2DD5D0789767E0BEA935E8C267_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_83AA5E2DD5D0789767E0BEA935E8C267" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_83AA5E2DD5D0789767E0BEA935E8C267" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_83AA5E2DD5D0789767E0BEA935E8C267" xlink:to="lab_us-gaap_TreasuryStockMember_83AA5E2DD5D0789767E0BEA935E8C267" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_4072C6FA12949A504B14BEA935E876A9_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_4072C6FA12949A504B14BEA935E876A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_4072C6FA12949A504B14BEA935E876A9_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_4072C6FA12949A504B14BEA935E876A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4072C6FA12949A504B14BEA935E876A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_4072C6FA12949A504B14BEA935E876A9" xlink:to="lab_us-gaap_NoncontrollingInterestMember_4072C6FA12949A504B14BEA935E876A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_D97CE59D73B8D9DCCBD1BEA935E8AF85_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_D97CE59D73B8D9DCCBD1BEA935E8AF85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_D97CE59D73B8D9DCCBD1BEA935E8AF85_label_en-US" xlink:label="lab_us-gaap_ParentMember_D97CE59D73B8D9DCCBD1BEA935E8AF85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_D97CE59D73B8D9DCCBD1BEA935E8AF85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_D97CE59D73B8D9DCCBD1BEA935E8AF85" xlink:to="lab_us-gaap_ParentMember_D97CE59D73B8D9DCCBD1BEA935E8AF85" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="lab_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B3A28ABC0642BC585918BEA935E838B6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B3A28ABC0642BC585918BEA935E838B6" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B3A28ABC0642BC585918BEA935E838B6_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B3A28ABC0642BC585918BEA935E838B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B3A28ABC0642BC585918BEA935E838B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B3A28ABC0642BC585918BEA935E838B6" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B3A28ABC0642BC585918BEA935E838B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_21810C9AF8789DDA346EBEA935E831D1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_21810C9AF8789DDA346EBEA935E831D1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_21810C9AF8789DDA346EBEA935E831D1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_21810C9AF8789DDA346EBEA935E831D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21810C9AF8789DDA346EBEA935E831D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_21810C9AF8789DDA346EBEA935E831D1" xlink:to="lab_us-gaap_StockholdersEquity_21810C9AF8789DDA346EBEA935E831D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_C6FD245C9DA27BD1802DBEA935E879AD_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_C6FD245C9DA27BD1802DBEA935E879AD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_C6FD245C9DA27BD1802DBEA935E879AD_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_C6FD245C9DA27BD1802DBEA935E879AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_C6FD245C9DA27BD1802DBEA935E879AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_C6FD245C9DA27BD1802DBEA935E879AD" xlink:to="lab_us-gaap_MinorityInterest_C6FD245C9DA27BD1802DBEA935E879AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_D8E5C0EEA0FAF864D0E5BEA935E81561_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_D8E5C0EEA0FAF864D0E5BEA935E81561" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, shares</link:label>
    <link:label id="lab_us-gaap_SharesIssued_D8E5C0EEA0FAF864D0E5BEA935E81561_label_en-US" xlink:label="lab_us-gaap_SharesIssued_D8E5C0EEA0FAF864D0E5BEA935E81561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_D8E5C0EEA0FAF864D0E5BEA935E81561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_D8E5C0EEA0FAF864D0E5BEA935E81561" xlink:to="lab_us-gaap_SharesIssued_D8E5C0EEA0FAF864D0E5BEA935E81561" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_919BC1A9374A2114B4C7BEA935E8366C_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_919BC1A9374A2114B4C7BEA935E8366C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_919BC1A9374A2114B4C7BEA935E8366C_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_919BC1A9374A2114B4C7BEA935E8366C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_919BC1A9374A2114B4C7BEA935E8366C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_919BC1A9374A2114B4C7BEA935E8366C" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_919BC1A9374A2114B4C7BEA935E8366C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_0CB76C4329757462C18EBEA935E87F8D_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_0CB76C4329757462C18EBEA935E87F8D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_0CB76C4329757462C18EBEA935E87F8D_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_0CB76C4329757462C18EBEA935E87F8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_0CB76C4329757462C18EBEA935E87F8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_0CB76C4329757462C18EBEA935E87F8D" xlink:to="lab_us-gaap_ProfitLoss_0CB76C4329757462C18EBEA935E87F8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_EDEF1460C9F4FC4CDDDCBEA935E832AC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_EDEF1460C9F4FC4CDDDCBEA935E832AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_EDEF1460C9F4FC4CDDDCBEA935E832AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_EDEF1460C9F4FC4CDDDCBEA935E832AC" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_EDEF1460C9F4FC4CDDDCBEA935E832AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_A1947E815E7759D32962BEA935E8534F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_A1947E815E7759D32962BEA935E8534F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_A1947E815E7759D32962BEA935E8534F_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_A1947E815E7759D32962BEA935E8534F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_A1947E815E7759D32962BEA935E8534F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_A1947E815E7759D32962BEA935E8534F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_A1947E815E7759D32962BEA935E8534F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_52C39A65D660DB860E0ABEA935E88686_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_52C39A65D660DB860E0ABEA935E88686" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_52C39A65D660DB860E0ABEA935E88686_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_52C39A65D660DB860E0ABEA935E88686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_52C39A65D660DB860E0ABEA935E88686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_52C39A65D660DB860E0ABEA935E88686" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_52C39A65D660DB860E0ABEA935E88686" xlink:type="arc" />
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184_terseLabel_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution by noncontrolling interest</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184_label_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:label id="lab_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184_documentation_en-US" xlink:label="lab_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, increase (decrease) other</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184" xlink:to="lab_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1D4CDFE794E9F79C523CBEA935E8023E_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1D4CDFE794E9F79C523CBEA935E8023E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1D4CDFE794E9F79C523CBEA935E8023E_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1D4CDFE794E9F79C523CBEA935E8023E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1D4CDFE794E9F79C523CBEA935E8023E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1D4CDFE794E9F79C523CBEA935E8023E" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1D4CDFE794E9F79C523CBEA935E8023E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_EA2036AF5B4AE50D8491BEA935E87AAD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_EA2036AF5B4AE50D8491BEA935E87AAD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_EA2036AF5B4AE50D8491BEA935E87AAD_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_EA2036AF5B4AE50D8491BEA935E87AAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_EA2036AF5B4AE50D8491BEA935E87AAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_EA2036AF5B4AE50D8491BEA935E87AAD" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_EA2036AF5B4AE50D8491BEA935E87AAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_B5902399AF7A2C6AD8E4BEA935E82EEA_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_B5902399AF7A2C6AD8E4BEA935E82EEA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_B5902399AF7A2C6AD8E4BEA935E82EEA_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_B5902399AF7A2C6AD8E4BEA935E82EEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_B5902399AF7A2C6AD8E4BEA935E82EEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_B5902399AF7A2C6AD8E4BEA935E82EEA" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_B5902399AF7A2C6AD8E4BEA935E82EEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_E0715961E30054932DEDBEA935E86539_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_E0715961E30054932DEDBEA935E86539" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_E0715961E30054932DEDBEA935E86539_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_E0715961E30054932DEDBEA935E86539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_E0715961E30054932DEDBEA935E86539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_E0715961E30054932DEDBEA935E86539" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_E0715961E30054932DEDBEA935E86539" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_C64BBA340DFF5B5E5F1ABEA935E8AC38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_C64BBA340DFF5B5E5F1ABEA935E8AC38" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_C64BBA340DFF5B5E5F1ABEA935E8AC38_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_C64BBA340DFF5B5E5F1ABEA935E8AC38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_C64BBA340DFF5B5E5F1ABEA935E8AC38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_C64BBA340DFF5B5E5F1ABEA935E8AC38" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_C64BBA340DFF5B5E5F1ABEA935E8AC38" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0450C0A497C33A1BFD87BEA935E8A137_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0450C0A497C33A1BFD87BEA935E8A137" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0450C0A497C33A1BFD87BEA935E8A137_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0450C0A497C33A1BFD87BEA935E8A137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0450C0A497C33A1BFD87BEA935E8A137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0450C0A497C33A1BFD87BEA935E8A137" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0450C0A497C33A1BFD87BEA935E8A137" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_818FDA9F98BAA96EDD81BEA935E8A5FA_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_818FDA9F98BAA96EDD81BEA935E8A5FA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_818FDA9F98BAA96EDD81BEA935E8A5FA_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_818FDA9F98BAA96EDD81BEA935E8A5FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_818FDA9F98BAA96EDD81BEA935E8A5FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_818FDA9F98BAA96EDD81BEA935E8A5FA" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_818FDA9F98BAA96EDD81BEA935E8A5FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_33C341D21105DAE2D569BEA935E8BD73_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_33C341D21105DAE2D569BEA935E8BD73" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_33C341D21105DAE2D569BEA935E8BD73_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_33C341D21105DAE2D569BEA935E8BD73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_33C341D21105DAE2D569BEA935E8BD73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_33C341D21105DAE2D569BEA935E8BD73" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_33C341D21105DAE2D569BEA935E8BD73" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_23949AB60D46A31FAFE0BEA935E89A94_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_23949AB60D46A31FAFE0BEA935E89A94" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_23949AB60D46A31FAFE0BEA935E89A94_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_23949AB60D46A31FAFE0BEA935E89A94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_23949AB60D46A31FAFE0BEA935E89A94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_23949AB60D46A31FAFE0BEA935E89A94" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_23949AB60D46A31FAFE0BEA935E89A94" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32FDD7B45BC6879A0AC3BEA935E88688_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32FDD7B45BC6879A0AC3BEA935E88688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32FDD7B45BC6879A0AC3BEA935E88688_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32FDD7B45BC6879A0AC3BEA935E88688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32FDD7B45BC6879A0AC3BEA935E88688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32FDD7B45BC6879A0AC3BEA935E88688" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32FDD7B45BC6879A0AC3BEA935E88688" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D13269CA51CC19B59FA8BEA935E83DB6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D13269CA51CC19B59FA8BEA935E83DB6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D13269CA51CC19B59FA8BEA935E83DB6_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D13269CA51CC19B59FA8BEA935E83DB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D13269CA51CC19B59FA8BEA935E83DB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D13269CA51CC19B59FA8BEA935E83DB6" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D13269CA51CC19B59FA8BEA935E83DB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_4A61E75423D14EE35552BEA935E86755_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_4A61E75423D14EE35552BEA935E86755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia spin-off adjustment</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_4A61E75423D14EE35552BEA935E86755_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_4A61E75423D14EE35552BEA935E86755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Spinoff Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_4A61E75423D14EE35552BEA935E86755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_4A61E75423D14EE35552BEA935E86755" xlink:to="lab_us-gaap_StockholdersEquityNoteSpinoffTransaction_4A61E75423D14EE35552BEA935E86755" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B515ABE2CDC493AC442EBEA935E8D8F0_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B515ABE2CDC493AC442EBEA935E8D8F0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from share-based payments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B515ABE2CDC493AC442EBEA935E8D8F0_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B515ABE2CDC493AC442EBEA935E8D8F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B515ABE2CDC493AC442EBEA935E8D8F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B515ABE2CDC493AC442EBEA935E8D8F0" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B515ABE2CDC493AC442EBEA935E8D8F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOther_E99307A48167E6A1AD15BEA935E8B2B0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_E99307A48167E6A1AD15BEA935E8B2B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_E99307A48167E6A1AD15BEA935E8B2B0_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_E99307A48167E6A1AD15BEA935E8B2B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_E99307A48167E6A1AD15BEA935E8B2B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther_E99307A48167E6A1AD15BEA935E8B2B0" xlink:to="lab_us-gaap_StockholdersEquityOther_E99307A48167E6A1AD15BEA935E8B2B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49AF0EB39711C18ABFF4BEA935E8C464_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49AF0EB39711C18ABFF4BEA935E8C464" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49AF0EB39711C18ABFF4BEA935E8C464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49AF0EB39711C18ABFF4BEA935E8C464" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49AF0EB39711C18ABFF4BEA935E8C464" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_E5834267931A43DBBA3FBEA935E872CB_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_E5834267931A43DBBA3FBEA935E872CB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E5834267931A43DBBA3FBEA935E872CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_E5834267931A43DBBA3FBEA935E872CB" xlink:to="lab_us-gaap_StockholdersEquity_E5834267931A43DBBA3FBEA935E872CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_F4799DB29E65E2A9ED0BBEA935E8C7CE_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_F4799DB29E65E2A9ED0BBEA935E8C7CE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_F4799DB29E65E2A9ED0BBEA935E8C7CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_F4799DB29E65E2A9ED0BBEA935E8C7CE" xlink:to="lab_us-gaap_MinorityInterest_F4799DB29E65E2A9ED0BBEA935E8C7CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_047EDA9C7681BA1CF57ABEA935E8A4B1_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_047EDA9C7681BA1CF57ABEA935E8A4B1" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_047EDA9C7681BA1CF57ABEA935E8A4B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_047EDA9C7681BA1CF57ABEA935E8A4B1" xlink:to="lab_us-gaap_SharesIssued_047EDA9C7681BA1CF57ABEA935E8A4B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:to="lab_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:to="lab_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_265EA70ACE5F61B58D9CF08E8DAEFBBE_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_265EA70ACE5F61B58D9CF08E8DAEFBBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_265EA70ACE5F61B58D9CF08E8DAEFBBE_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember_265EA70ACE5F61B58D9CF08E8DAEFBBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_265EA70ACE5F61B58D9CF08E8DAEFBBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember_265EA70ACE5F61B58D9CF08E8DAEFBBE" xlink:to="lab_us-gaap_SeriesAPreferredStockMember_265EA70ACE5F61B58D9CF08E8DAEFBBE" xlink:type="arc" />
    <link:label id="lab_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31_terseLabel_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series X junior participating</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31_label_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series X Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31_documentation_en-US" xlink:label="lab_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series X preferred stock.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31" xlink:to="lab_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31" xlink:type="arc" />
    <link:label id="lab_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32_terseLabel_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32_label_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32_documentation_en-US" xlink:label="lab_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32" xlink:to="lab_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="lab_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_BD10F5F9365B2E165597F08E8DAF49A4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_BD10F5F9365B2E165597F08E8DAF49A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_BD10F5F9365B2E165597F08E8DAF49A4_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_BD10F5F9365B2E165597F08E8DAF49A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_BD10F5F9365B2E165597F08E8DAF49A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_BD10F5F9365B2E165597F08E8DAF49A4" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_BD10F5F9365B2E165597F08E8DAF49A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57AF56549937017ED815F08E8DAF4125_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57AF56549937017ED815F08E8DAF4125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized amount of share repurchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57AF56549937017ED815F08E8DAF4125_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57AF56549937017ED815F08E8DAF4125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57AF56549937017ED815F08E8DAF4125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57AF56549937017ED815F08E8DAF4125" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57AF56549937017ED815F08E8DAF4125" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D13B12D16E48FBEA3E6FF08E8DAF4262_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D13B12D16E48FBEA3E6FF08E8DAF4262" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares authorized for repurchase</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D13B12D16E48FBEA3E6FF08E8DAF4262_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D13B12D16E48FBEA3E6FF08E8DAF4262" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D13B12D16E48FBEA3E6FF08E8DAF4262" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D13B12D16E48FBEA3E6FF08E8DAF4262" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D13B12D16E48FBEA3E6FF08E8DAF4262" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_8A5CA08ECF7876DB5ABDF08E8DAFB97A_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_8A5CA08ECF7876DB5ABDF08E8DAFB97A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8A5CA08ECF7876DB5ABDF08E8DAFB97A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_8A5CA08ECF7876DB5ABDF08E8DAFB97A" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_8A5CA08ECF7876DB5ABDF08E8DAFB97A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_69397A0D8C4D84252910F08E8DB01213_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_69397A0D8C4D84252910F08E8DB01213" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_69397A0D8C4D84252910F08E8DB01213_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_69397A0D8C4D84252910F08E8DB01213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_69397A0D8C4D84252910F08E8DB01213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_69397A0D8C4D84252910F08E8DB01213" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_69397A0D8C4D84252910F08E8DB01213" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:type="arc" />
    <link:label id="lab_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB_terseLabel_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Milestones</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB_label_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:label id="lab_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB_documentation_en-US" xlink:label="lab_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB" xlink:to="lab_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB" xlink:type="arc" />
    <link:label id="lab_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377" xlink:to="lab_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377" xlink:type="arc" />
    <link:label id="lab_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1_terseLabel_en-US" xlink:label="lab_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1_label_en-US" xlink:label="lab_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1_documentation_en-US" xlink:label="lab_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1" xlink:to="lab_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:to="lab_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA_label_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level [Domain]</link:label>
    <link:label id="lab_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Cumulative sales level [Axis]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="lab_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:type="arc" />
    <link:label id="lab_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40_terseLabel_en-US" xlink:label="lab_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fifteen billion</link:label>
    <link:label id="lab_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40_label_en-US" xlink:label="lab_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fifteen billion [Member] [Member]</link:label>
    <link:label id="lab_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40_documentation_en-US" xlink:label="lab_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fifteen billion [Member] [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40" xlink:to="lab_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40" xlink:type="arc" />
    <link:label id="lab_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605_terseLabel_en-US" xlink:label="lab_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sixteen billion</link:label>
    <link:label id="lab_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605_label_en-US" xlink:label="lab_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sixteen billion [Member]</link:label>
    <link:label id="lab_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605_documentation_en-US" xlink:label="lab_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sixteen billion [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605" xlink:to="lab_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605" xlink:type="arc" />
    <link:label id="lab_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707_terseLabel_en-US" xlink:label="lab_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Seventeen billion</link:label>
    <link:label id="lab_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707_label_en-US" xlink:label="lab_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seventeen billion [Member]</link:label>
    <link:label id="lab_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707_documentation_en-US" xlink:label="lab_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Seventeen billion [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SeventeenbillionMember" xlink:label="loc_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707" xlink:to="lab_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707" xlink:type="arc" />
    <link:label id="lab_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC_terseLabel_en-US" xlink:label="lab_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eighteen billion</link:label>
    <link:label id="lab_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC_label_en-US" xlink:label="lab_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eighteen billion [Member]</link:label>
    <link:label id="lab_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC_documentation_en-US" xlink:label="lab_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eighteen billion [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EighteenbillionMember" xlink:label="loc_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC" xlink:to="lab_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC" xlink:type="arc" />
    <link:label id="lab_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8_terseLabel_en-US" xlink:label="lab_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nineteen billion</link:label>
    <link:label id="lab_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8_label_en-US" xlink:label="lab_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nineteen billion [Member]</link:label>
    <link:label id="lab_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8_documentation_en-US" xlink:label="lab_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nineteen billion [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NineteenbillionMember" xlink:label="loc_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8" xlink:to="lab_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8" xlink:type="arc" />
    <link:label id="lab_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E_terseLabel_en-US" xlink:label="lab_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Twenty billion</link:label>
    <link:label id="lab_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E_label_en-US" xlink:label="lab_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty billion [Member]</link:label>
    <link:label id="lab_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E_documentation_en-US" xlink:label="lab_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty billion [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_TwentybillionMember" xlink:label="loc_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E" xlink:to="lab_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E" xlink:type="arc" />
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E_terseLabel_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E_label_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:label id="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E_documentation_en-US" xlink:label="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Each additional one billion up to twenty billion [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E" xlink:to="lab_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3_label_en-US" xlink:label="lab_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:to="lab_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:type="arc" />
    <link:label id="lab_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C_label_en-US" xlink:label="lab_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:to="lab_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:type="arc" />
    <link:label id="lab_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4_terseLabel_en-US" xlink:label="lab_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Solothurn</link:label>
    <link:label id="lab_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4_label_en-US" xlink:label="lab_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:label id="lab_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4_documentation_en-US" xlink:label="lab_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Solothurn [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4" xlink:to="lab_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:type="arc" />
    <link:label id="lab_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF_terseLabel_en-US" xlink:label="lab_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumapharm AG</link:label>
    <link:label id="lab_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF_label_en-US" xlink:label="lab_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:label id="lab_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF_documentation_en-US" xlink:label="lab_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumapharm AG [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF" xlink:to="lab_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales up to $2.0 billion</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27_label_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:label id="lab_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment threshold</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27" xlink:to="lab_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27" xlink:type="arc" />
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B_terseLabel_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B_label_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:label id="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B_documentation_en-US" xlink:label="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B" xlink:to="lab_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_BCC8DC555DA5393CF9F1AAF0BE3CF190_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_BCC8DC555DA5393CF9F1AAF0BE3CF190" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contingent consideration in the form of development and approval milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_BCC8DC555DA5393CF9F1AAF0BE3CF190_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_BCC8DC555DA5393CF9F1AAF0BE3CF190" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_BCC8DC555DA5393CF9F1AAF0BE3CF190" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_BCC8DC555DA5393CF9F1AAF0BE3CF190" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_BCC8DC555DA5393CF9F1AAF0BE3CF190" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_9186C404A07B9A2B3FF2AAF0BE3CC3F8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_9186C404A07B9A2B3FF2AAF0BE3CC3F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount paid in cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_9186C404A07B9A2B3FF2AAF0BE3CC3F8_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_9186C404A07B9A2B3FF2AAF0BE3CC3F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9186C404A07B9A2B3FF2AAF0BE3CC3F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_9186C404A07B9A2B3FF2AAF0BE3CC3F8" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_9186C404A07B9A2B3FF2AAF0BE3CC3F8" xlink:type="arc" />
    <link:label id="lab_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF_terseLabel_en-US" xlink:label="lab_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF_label_en-US" xlink:label="lab_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:label id="lab_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF_documentation_en-US" xlink:label="lab_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cumulative sales level</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF" xlink:to="lab_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCommitment_5E237F151E04112ECB7AAAF0BE3D260C_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment_5E237F151E04112ECB7AAAF0BE3D260C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cancellable future commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_5E237F151E04112ECB7AAAF0BE3D260C_label_en-US" xlink:label="lab_us-gaap_OtherCommitment_5E237F151E04112ECB7AAAF0BE3D260C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_5E237F151E04112ECB7AAAF0BE3D260C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment_5E237F151E04112ECB7AAAF0BE3D260C" xlink:to="lab_us-gaap_OtherCommitment_5E237F151E04112ECB7AAAF0BE3D260C" xlink:type="arc" />
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800_terseLabel_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies (Textual)</link:label>
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800_label_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800_documentation_en-US" xlink:label="lab_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800" xlink:to="lab_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800" xlink:type="arc" />
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_A0FE5E106107D9ED0061AAF0BE3E4846_verboseLabel_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_A0FE5E106107D9ED0061AAF0BE3E4846" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_A0FE5E106107D9ED0061AAF0BE3E4846_label_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_A0FE5E106107D9ED0061AAF0BE3E4846" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses On Funding Commitment Related To Clinical Research</link:label>
    <link:label id="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_A0FE5E106107D9ED0061AAF0BE3E4846_documentation_en-US" xlink:label="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_A0FE5E106107D9ED0061AAF0BE3E4846" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued expenses on funding commitment related to clinical research.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_A0FE5E106107D9ED0061AAF0BE3E4846" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_A0FE5E106107D9ED0061AAF0BE3E4846" xlink:to="lab_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_A0FE5E106107D9ED0061AAF0BE3E4846" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_BC6DE424F9F779A320E9AAF0BE3F255C_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_BC6DE424F9F779A320E9AAF0BE3F255C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities associated with uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_BC6DE424F9F779A320E9AAF0BE3F255C_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_BC6DE424F9F779A320E9AAF0BE3F255C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_BC6DE424F9F779A320E9AAF0BE3F255C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_BC6DE424F9F779A320E9AAF0BE3F255C" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsCurrent_BC6DE424F9F779A320E9AAF0BE3F255C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_385A6CBA60E07A93CA8EAAF0BE3FAE5D_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_385A6CBA60E07A93CA8EAAF0BE3FAE5D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lease rent expense which terminates at various dates through 2028</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_385A6CBA60E07A93CA8EAAF0BE3FAE5D_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_385A6CBA60E07A93CA8EAAF0BE3FAE5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_385A6CBA60E07A93CA8EAAF0BE3FAE5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_385A6CBA60E07A93CA8EAAF0BE3FAE5D" xlink:to="lab_us-gaap_LeaseAndRentalExpense_385A6CBA60E07A93CA8EAAF0BE3FAE5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_DCAAAF59FB1E5C33115D85D6DB072393_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_DCAAAF59FB1E5C33115D85D6DB072393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_DCAAAF59FB1E5C33115D85D6DB072393_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_DCAAAF59FB1E5C33115D85D6DB072393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_DCAAAF59FB1E5C33115D85D6DB072393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_DCAAAF59FB1E5C33115D85D6DB072393" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_DCAAAF59FB1E5C33115D85D6DB072393" xlink:type="arc" />
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4_terseLabel_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4_label_en-US" xlink:label="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:to="lab_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_C5AD4C0C713EBC1234E985CC9C975FE4_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_C5AD4C0C713EBC1234E985CC9C975FE4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_C5AD4C0C713EBC1234E985CC9C975FE4_label_en-US" xlink:label="lab_us-gaap_GrossProfit_C5AD4C0C713EBC1234E985CC9C975FE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_C5AD4C0C713EBC1234E985CC9C975FE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_C5AD4C0C713EBC1234E985CC9C975FE4" xlink:to="lab_us-gaap_GrossProfit_C5AD4C0C713EBC1234E985CC9C975FE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_1E8928F3A90EB49AA68285CC9C97AA27_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_1E8928F3A90EB49AA68285CC9C97AA27" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Idec Inc</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1E8928F3A90EB49AA68285CC9C97AA27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_1E8928F3A90EB49AA68285CC9C97AA27" xlink:to="lab_us-gaap_NetIncomeLoss_1E8928F3A90EB49AA68285CC9C97AA27" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9720177EFAFF441F561B85CC9C9AFDE1_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_9720177EFAFF441F561B85CC9C9AFDE1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_9720177EFAFF441F561B85CC9C9AFDE1_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_9720177EFAFF441F561B85CC9C9AFDE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_9720177EFAFF441F561B85CC9C9AFDE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_9720177EFAFF441F561B85CC9C9AFDE1" xlink:to="lab_us-gaap_EarningsPerShareBasic_9720177EFAFF441F561B85CC9C9AFDE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6DC2CED770A532B0719E85CC9C9A0611_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_6DC2CED770A532B0719E85CC9C9A0611" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6DC2CED770A532B0719E85CC9C9A0611_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_6DC2CED770A532B0719E85CC9C9A0611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6DC2CED770A532B0719E85CC9C9A0611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_6DC2CED770A532B0719E85CC9C9A0611" xlink:to="lab_us-gaap_EarningsPerShareDiluted_6DC2CED770A532B0719E85CC9C9A0611" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A877372A1A9AC6E8D1DC85CC9C9AF6C7_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A877372A1A9AC6E8D1DC85CC9C9AF6C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A877372A1A9AC6E8D1DC85CC9C9AF6C7_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A877372A1A9AC6E8D1DC85CC9C9AF6C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A877372A1A9AC6E8D1DC85CC9C9AF6C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A877372A1A9AC6E8D1DC85CC9C9AF6C7" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A877372A1A9AC6E8D1DC85CC9C9AF6C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_AEB4C7C4E0D8FD00A33785CC9C9AFC33_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_AEB4C7C4E0D8FD00A33785CC9C9AFC33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_AEB4C7C4E0D8FD00A33785CC9C9AFC33_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_AEB4C7C4E0D8FD00A33785CC9C9AFC33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_AEB4C7C4E0D8FD00A33785CC9C9AFC33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_AEB4C7C4E0D8FD00A33785CC9C9AFC33" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_AEB4C7C4E0D8FD00A33785CC9C9AFC33" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4F754004E434DA28381B9FD49DF296FA_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4F754004E434DA28381B9FD49DF296FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded Status of Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4F754004E434DA28381B9FD49DF296FA_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4F754004E434DA28381B9FD49DF296FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4F754004E434DA28381B9FD49DF296FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4F754004E434DA28381B9FD49DF296FA" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4F754004E434DA28381B9FD49DF296FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_4B930120F08BD75A54FB9FD49DF27B18_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_4B930120F08BD75A54FB9FD49DF27B18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_4B930120F08BD75A54FB9FD49DF27B18_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_4B930120F08BD75A54FB9FD49DF27B18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4B930120F08BD75A54FB9FD49DF27B18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4B930120F08BD75A54FB9FD49DF27B18" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_4B930120F08BD75A54FB9FD49DF27B18" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_091C4BD78FD1A06FE79D9FD49DF221FF_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_091C4BD78FD1A06FE79D9FD49DF221FF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_091C4BD78FD1A06FE79D9FD49DF221FF_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_091C4BD78FD1A06FE79D9FD49DF221FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_091C4BD78FD1A06FE79D9FD49DF221FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_091C4BD78FD1A06FE79D9FD49DF221FF" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_091C4BD78FD1A06FE79D9FD49DF221FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1080981A5F52B2EEC3D09FD49DF24896_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1080981A5F52B2EEC3D09FD49DF24896" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance as of January 1, 2018</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1080981A5F52B2EEC3D09FD49DF24896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1080981A5F52B2EEC3D09FD49DF24896" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1080981A5F52B2EEC3D09FD49DF24896" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_959C3963391E191FEDCE9FD49DF224C5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_959C3963391E191FEDCE9FD49DF224C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_959C3963391E191FEDCE9FD49DF224C5_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_959C3963391E191FEDCE9FD49DF224C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_959C3963391E191FEDCE9FD49DF224C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_959C3963391E191FEDCE9FD49DF224C5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_959C3963391E191FEDCE9FD49DF224C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_44D5DD9BFA59670A6A9D9FD49DF2F95C_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_44D5DD9BFA59670A6A9D9FD49DF2F95C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_44D5DD9BFA59670A6A9D9FD49DF2F95C_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_44D5DD9BFA59670A6A9D9FD49DF2F95C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_44D5DD9BFA59670A6A9D9FD49DF2F95C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_44D5DD9BFA59670A6A9D9FD49DF2F95C" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_44D5DD9BFA59670A6A9D9FD49DF2F95C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A020D72AB1461F45A0A39FD49DF2D57F_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A020D72AB1461F45A0A39FD49DF2D57F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A020D72AB1461F45A0A39FD49DF2D57F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A020D72AB1461F45A0A39FD49DF2D57F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A020D72AB1461F45A0A39FD49DF2D57F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_557FA2B994A89DC6E9749FD49DF2A130_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_557FA2B994A89DC6E9749FD49DF2A130" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_557FA2B994A89DC6E9749FD49DF2A130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_557FA2B994A89DC6E9749FD49DF2A130" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_557FA2B994A89DC6E9749FD49DF2A130" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_C099600D8D831A7BA22EFBB835C7EE93_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_C099600D8D831A7BA22EFBB835C7EE93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_C099600D8D831A7BA22EFBB835C7EE93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_C099600D8D831A7BA22EFBB835C7EE93" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_C099600D8D831A7BA22EFBB835C7EE93" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_937DED291B5FB63460ABFBB835C7F400_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_937DED291B5FB63460ABFBB835C7F400" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_937DED291B5FB63460ABFBB835C7F400_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_937DED291B5FB63460ABFBB835C7F400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_937DED291B5FB63460ABFBB835C7F400" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_937DED291B5FB63460ABFBB835C7F400" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_937DED291B5FB63460ABFBB835C7F400" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FB517FD3BD36B029E337FBB831F17791_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FB517FD3BD36B029E337FBB831F17791" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FB517FD3BD36B029E337FBB831F17791_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FB517FD3BD36B029E337FBB831F17791" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FB517FD3BD36B029E337FBB831F17791" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FB517FD3BD36B029E337FBB831F17791" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FB517FD3BD36B029E337FBB831F17791" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2228783D0DDBC0F533E6FBB833E41F6B_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2228783D0DDBC0F533E6FBB833E41F6B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2228783D0DDBC0F533E6FBB833E41F6B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2228783D0DDBC0F533E6FBB833E41F6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2228783D0DDBC0F533E6FBB833E41F6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2228783D0DDBC0F533E6FBB833E41F6B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2228783D0DDBC0F533E6FBB833E41F6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_2E96026B69852A88F23DFBB8354A4B0F_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_2E96026B69852A88F23DFBB8354A4B0F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_2E96026B69852A88F23DFBB8354A4B0F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_2E96026B69852A88F23DFBB8354A4B0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2E96026B69852A88F23DFBB8354A4B0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_2E96026B69852A88F23DFBB8354A4B0F" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_2E96026B69852A88F23DFBB8354A4B0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2E85DEE54E764EEDAC43FBB83376C18E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2E85DEE54E764EEDAC43FBB83376C18E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under non-cancelable leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2E85DEE54E764EEDAC43FBB83376C18E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2E85DEE54E764EEDAC43FBB83376C18E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2E85DEE54E764EEDAC43FBB83376C18E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2E85DEE54E764EEDAC43FBB83376C18E" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2E85DEE54E764EEDAC43FBB83376C18E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_99474D6FA190F71B29169528E9CDE3DD_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_99474D6FA190F71B29169528E9CDE3DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_99474D6FA190F71B29169528E9CDE3DD_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember_99474D6FA190F71B29169528E9CDE3DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_99474D6FA190F71B29169528E9CDE3DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember_99474D6FA190F71B29169528E9CDE3DD" xlink:to="lab_us-gaap_AccruedLiabilitiesMember_99474D6FA190F71B29169528E9CDE3DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_9A226D5BBF247CE7BFC99528E9CD8616_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_9A226D5BBF247CE7BFC99528E9CD8616" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_9A226D5BBF247CE7BFC99528E9CD8616_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_9A226D5BBF247CE7BFC99528E9CD8616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_9A226D5BBF247CE7BFC99528E9CD8616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_9A226D5BBF247CE7BFC99528E9CD8616" xlink:to="lab_us-gaap_ForeignExchangeContractMember_9A226D5BBF247CE7BFC99528E9CD8616" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:to="lab_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:to="lab_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_E8ADDF7A8A39AE13082D9528E9CDCA35_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_E8ADDF7A8A39AE13082D9528E9CDCA35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_E8ADDF7A8A39AE13082D9528E9CDCA35_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_E8ADDF7A8A39AE13082D9528E9CDCA35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_E8ADDF7A8A39AE13082D9528E9CDCA35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_E8ADDF7A8A39AE13082D9528E9CDCA35" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_E8ADDF7A8A39AE13082D9528E9CDCA35" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_3059A7B811A8666D67429528E9DDE19D_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_3059A7B811A8666D67429528E9DDE19D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_3059A7B811A8666D67429528E9DDE19D_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_3059A7B811A8666D67429528E9DDE19D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_3059A7B811A8666D67429528E9DDE19D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_3059A7B811A8666D67429528E9DDE19D" xlink:to="lab_us-gaap_NondesignatedMember_3059A7B811A8666D67429528E9DDE19D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="lab_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0E882B7D6C3B4FC48F159528E9DD89EA_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0E882B7D6C3B4FC48F159528E9DD89EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0E882B7D6C3B4FC48F159528E9DD89EA_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0E882B7D6C3B4FC48F159528E9DD89EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0E882B7D6C3B4FC48F159528E9DD89EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0E882B7D6C3B4FC48F159528E9DD89EA" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_0E882B7D6C3B4FC48F159528E9DD89EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_3ABEDB1D4363B3EB56DF9528E9DDD6B9_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_3ABEDB1D4363B3EB56DF9528E9DDD6B9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_3ABEDB1D4363B3EB56DF9528E9DDD6B9_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_3ABEDB1D4363B3EB56DF9528E9DDD6B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_3ABEDB1D4363B3EB56DF9528E9DDD6B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_3ABEDB1D4363B3EB56DF9528E9DDD6B9" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_3ABEDB1D4363B3EB56DF9528E9DDD6B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_A310A46F5666B56A92E49528E9DDADF2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_A310A46F5666B56A92E49528E9DDADF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_A310A46F5666B56A92E49528E9DDADF2_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1_A310A46F5666B56A92E49528E9DDADF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_A310A46F5666B56A92E49528E9DDADF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1_A310A46F5666B56A92E49528E9DDADF2" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1_A310A46F5666B56A92E49528E9DDADF2" xlink:type="arc" />
    <link:label id="lab_invest_DerivativeNotionalAmount_9527B950AA5D5D88E6089528E9DDB6C3_terseLabel_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_9527B950AA5D5D88E6089528E9DDB6C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate notional amount</link:label>
    <link:label id="lab_invest_DerivativeNotionalAmount_9527B950AA5D5D88E6089528E9DDB6C3_label_en-US" xlink:label="lab_invest_DerivativeNotionalAmount_9527B950AA5D5D88E6089528E9DDB6C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_9527B950AA5D5D88E6089528E9DDB6C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_DerivativeNotionalAmount_9527B950AA5D5D88E6089528E9DDB6C3" xlink:to="lab_invest_DerivativeNotionalAmount_9527B950AA5D5D88E6089528E9DDB6C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4A3014FAA4345F000B489528E9DD527E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4A3014FAA4345F000B489528E9DD527E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on senior notes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4A3014FAA4345F000B489528E9DD527E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4A3014FAA4345F000B489528E9DD527E" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_4A3014FAA4345F000B489528E9DD527E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_9EEA0B0E4DB10515E8749528E9DDF387_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_9EEA0B0E4DB10515E8749528E9DDF387" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) of other income (expense) related to foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_9EEA0B0E4DB10515E8749528E9DDF387_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_9EEA0B0E4DB10515E8749528E9DDF387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_9EEA0B0E4DB10515E8749528E9DDF387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_9EEA0B0E4DB10515E8749528E9DDF387" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_9EEA0B0E4DB10515E8749528E9DDF387" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_48C0A61F7C86760A549FFBB83569D21F_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_48C0A61F7C86760A549FFBB83569D21F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_48C0A61F7C86760A549FFBB83569D21F_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_48C0A61F7C86760A549FFBB83569D21F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_48C0A61F7C86760A549FFBB83569D21F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_48C0A61F7C86760A549FFBB83569D21F" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_48C0A61F7C86760A549FFBB83569D21F" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_5B9AC91CEB1339F147E0968CB8B6EEC2_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract_5B9AC91CEB1339F147E0968CB8B6EEC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_5B9AC91CEB1339F147E0968CB8B6EEC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_5B9AC91CEB1339F147E0968CB8B6EEC2" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract_5B9AC91CEB1339F147E0968CB8B6EEC2" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:type="arc" />
    <link:label id="lab_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE" xlink:to="lab_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE" xlink:type="arc" />
    <link:label id="lab_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D" xlink:to="lab_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_D2CD22E8340C26F6E531968CB8B7BFF5_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_D2CD22E8340C26F6E531968CB8B7BFF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_D2CD22E8340C26F6E531968CB8B7BFF5_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember_D2CD22E8340C26F6E531968CB8B7BFF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_D2CD22E8340C26F6E531968CB8B7BFF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember_D2CD22E8340C26F6E531968CB8B7BFF5" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember_D2CD22E8340C26F6E531968CB8B7BFF5" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_F1F19684DEA30306D059968CB8B8BB59_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_F1F19684DEA30306D059968CB8B8BB59" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_F1F19684DEA30306D059968CB8B8BB59_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_F1F19684DEA30306D059968CB8B8BB59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_F1F19684DEA30306D059968CB8B8BB59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_F1F19684DEA30306D059968CB8B8BB59" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_F1F19684DEA30306D059968CB8B8BB59" xlink:type="arc" />
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current provisions relating to sales in current year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2" xlink:type="arc" />
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B_negatedTerseLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Adjustments relating to prior years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A_negatedTerseLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments/returns related to sales in current year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A" xlink:type="arc" />
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2_negatedTerseLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments/returns related to sales in prior years</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_66B718C3FEF7071C7C18968CB8B9AD8D_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_66B718C3FEF7071C7C18968CB8B9AD8D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_66B718C3FEF7071C7C18968CB8B9AD8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_66B718C3FEF7071C7C18968CB8B9AD8D" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_66B718C3FEF7071C7C18968CB8B9AD8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_B58AB5584E3F1CF4D7021B4231799040_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_B58AB5584E3F1CF4D7021B4231799040" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B58AB5584E3F1CF4D7021B4231799040" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B58AB5584E3F1CF4D7021B4231799040" xlink:to="lab_us-gaap_EarningsPerShareAbstract_B58AB5584E3F1CF4D7021B4231799040" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF_verboseLabel_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF_label_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan [Member]</link:label>
    <link:label id="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF_documentation_en-US" xlink:label="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF" xlink:to="lab_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2" xlink:type="arc" />
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:type="arc" />
    <link:label id="lab_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C_verboseLabel_en-US" xlink:label="lab_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C_label_en-US" xlink:label="lab_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C_documentation_en-US" xlink:label="lab_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Numerator.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:to="lab_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:type="arc" />
    <link:label id="lab_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F_verboseLabel_en-US" xlink:label="lab_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F_label_en-US" xlink:label="lab_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F_documentation_en-US" xlink:label="lab_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denominator.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:to="lab_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CDE9D59C1BBA940C8B371B42317CD2C2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CDE9D59C1BBA940C8B371B42317CD2C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CDE9D59C1BBA940C8B371B42317CD2C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CDE9D59C1BBA940C8B371B42317CD2C2" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CDE9D59C1BBA940C8B371B42317CD2C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7BA198FD7F225FD026581B42317C88CC_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7BA198FD7F225FD026581B42317C88CC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options and employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7BA198FD7F225FD026581B42317C88CC_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7BA198FD7F225FD026581B42317C88CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7BA198FD7F225FD026581B42317C88CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7BA198FD7F225FD026581B42317C88CC" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7BA198FD7F225FD026581B42317C88CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7730638B4D42DD8B239B1B42317C471F_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7730638B4D42DD8B239B1B42317C471F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7730638B4D42DD8B239B1B42317C471F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7730638B4D42DD8B239B1B42317C471F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7730638B4D42DD8B239B1B42317C471F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7730638B4D42DD8B239B1B42317C471F" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7730638B4D42DD8B239B1B42317C471F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C0DC5601CA22E30D01B01B42317D95B3_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C0DC5601CA22E30D01B01B42317D95B3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C0DC5601CA22E30D01B01B42317D95B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C0DC5601CA22E30D01B01B42317D95B3" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C0DC5601CA22E30D01B01B42317D95B3" xlink:type="arc" />
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED_terseLabel_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share (Textual)</link:label>
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED_label_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED_documentation_en-US" xlink:label="lab_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings per share.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EarningsPerShareTextualAbstract" xlink:label="loc_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED" xlink:to="lab_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_9B8E4543E91832808A761B42317DD7FC_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_9B8E4543E91832808A761B42317DD7FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_9B8E4543E91832808A761B42317DD7FC_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_9B8E4543E91832808A761B42317DD7FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_9B8E4543E91832808A761B42317DD7FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_9B8E4543E91832808A761B42317DD7FC" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_9B8E4543E91832808A761B42317DD7FC" xlink:type="arc" />
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D_verboseLabel_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Marketable Debt Securities</link:label>
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D_label_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Marketable Debt Securities [Abstract]</link:label>
    <link:label id="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D_documentation_en-US" xlink:label="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from marketable debt securities.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ProceedsFromMarketableDebtSecuritiesAbstract" xlink:label="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D" xlink:to="lab_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D4D2913DC6B87129A4C7FBB833C4B541_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D4D2913DC6B87129A4C7FBB833C4B541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D4D2913DC6B87129A4C7FBB833C4B541_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D4D2913DC6B87129A4C7FBB833C4B541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D4D2913DC6B87129A4C7FBB833C4B541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D4D2913DC6B87129A4C7FBB833C4B541" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D4D2913DC6B87129A4C7FBB833C4B541" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_2FB933AB0A12222F56FBFBB833C4F4C7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_2FB933AB0A12222F56FBFBB833C4F4C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_2FB933AB0A12222F56FBFBB833C4F4C7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_2FB933AB0A12222F56FBFBB833C4F4C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Gains</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_2FB933AB0A12222F56FBFBB833C4F4C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_2FB933AB0A12222F56FBFBB833C4F4C7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_2FB933AB0A12222F56FBFBB833C4F4C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_545681B0F255EC468AF5FBB833C4B8CA_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_545681B0F255EC468AF5FBB833C4B8CA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_545681B0F255EC468AF5FBB833C4B8CA_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_545681B0F255EC468AF5FBB833C4B8CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Gross Realized Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_545681B0F255EC468AF5FBB833C4B8CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_545681B0F255EC468AF5FBB833C4B8CA" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_545681B0F255EC468AF5FBB833C4B8CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_D1341E5547B22F428ED49F97658E55EB_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract_D1341E5547B22F428ED49F97658E55EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_D1341E5547B22F428ED49F97658E55EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_D1341E5547B22F428ED49F97658E55EB" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract_D1341E5547B22F428ED49F97658E55EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_7CC51C00182682F598EE9F99A43A88B1_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_7CC51C00182682F598EE9F99A43A88B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of world</link:label>
    <link:label id="lab_us-gaap_NonUsMember_7CC51C00182682F598EE9F99A43A88B1_label_en-US" xlink:label="lab_us-gaap_NonUsMember_7CC51C00182682F598EE9F99A43A88B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_7CC51C00182682F598EE9F99A43A88B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_7CC51C00182682F598EE9F99A43A88B1" xlink:to="lab_us-gaap_NonUsMember_7CC51C00182682F598EE9F99A43A88B1" xlink:type="arc" />
    <link:label id="lab_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22_terseLabel_en-US" xlink:label="lab_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22_label_en-US" xlink:label="lab_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22_documentation_en-US" xlink:label="lab_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22" xlink:to="lab_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22" xlink:type="arc" />
    <link:label id="lab_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968_label_en-US" xlink:label="lab_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968" xlink:to="lab_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968" xlink:type="arc" />
    <link:label id="lab_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1" xlink:to="lab_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1" xlink:type="arc" />
    <link:label id="lab_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29_label_en-US" xlink:label="lab_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29_documentation_en-US" xlink:label="lab_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29" xlink:to="lab_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29" xlink:type="arc" />
    <link:label id="lab_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B_label_en-US" xlink:label="lab_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B_documentation_en-US" xlink:label="lab_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B" xlink:to="lab_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B" xlink:type="arc" />
    <link:label id="lab_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8_label_en-US" xlink:label="lab_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8_documentation_en-US" xlink:label="lab_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8" xlink:to="lab_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8" xlink:type="arc" />
    <link:label id="lab_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B_terseLabel_en-US" xlink:label="lab_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ELOCTATE</link:label>
    <link:label id="lab_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B_label_en-US" xlink:label="lab_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:label id="lab_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B_documentation_en-US" xlink:label="lab_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ELOCTATE [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B" xlink:to="lab_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B" xlink:type="arc" />
    <link:label id="lab_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8_terseLabel_en-US" xlink:label="lab_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPROLIX</link:label>
    <link:label id="lab_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8_label_en-US" xlink:label="lab_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:label id="lab_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8_documentation_en-US" xlink:label="lab_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPROLIX [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8" xlink:to="lab_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8" xlink:type="arc" />
    <link:label id="lab_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994_terseLabel_en-US" xlink:label="lab_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia Products</link:label>
    <link:label id="lab_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994_label_en-US" xlink:label="lab_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hemophilia Products [Member]</link:label>
    <link:label id="lab_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994_documentation_en-US" xlink:label="lab_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hemophilia Products</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994" xlink:to="lab_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_82733B16E326E77C799EFBB8325E1D14_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_82733B16E326E77C799EFBB8325E1D14" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_82733B16E326E77C799EFBB8325E1D14_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_82733B16E326E77C799EFBB8325E1D14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_82733B16E326E77C799EFBB8325E1D14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_82733B16E326E77C799EFBB8325E1D14" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_82733B16E326E77C799EFBB8325E1D14" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_3128AD5386EAF364E3E4FBB8325E9413_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_3128AD5386EAF364E3E4FBB8325E9413" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities including strategic investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_3128AD5386EAF364E3E4FBB8325E9413_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_3128AD5386EAF364E3E4FBB8325E9413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_3128AD5386EAF364E3E4FBB8325E9413" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_3128AD5386EAF364E3E4FBB8325E9413" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_3128AD5386EAF364E3E4FBB8325E9413" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DDD7C47493FDF9270974FBB8325EB595_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DDD7C47493FDF9270974FBB8325EB595" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of contractual maturities: Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DDD7C47493FDF9270974FBB8325EB595_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DDD7C47493FDF9270974FBB8325EB595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DDD7C47493FDF9270974FBB8325EB595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DDD7C47493FDF9270974FBB8325EB595" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DDD7C47493FDF9270974FBB8325EB595" xlink:type="arc" />
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F0ED673B4BE2B8A1A9D9FBB8325E6F1C_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F0ED673B4BE2B8A1A9D9FBB8325E6F1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from marketable securities, excluding strategic investments</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F0ED673B4BE2B8A1A9D9FBB8325E6F1C_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F0ED673B4BE2B8A1A9D9FBB8325E6F1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F0ED673B4BE2B8A1A9D9FBB8325E6F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F0ED673B4BE2B8A1A9D9FBB8325E6F1C" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F0ED673B4BE2B8A1A9D9FBB8325E6F1C" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_589D81382DD4ED4A49D0FBB8355A4169_terseLabel_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_589D81382DD4ED4A49D0FBB8355A4169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of common stock</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_589D81382DD4ED4A49D0FBB8355A4169_label_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_589D81382DD4ED4A49D0FBB8355A4169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Common Stock [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfCommonStockTableTextBlock_589D81382DD4ED4A49D0FBB8355A4169_documentation_en-US" xlink:label="lab_biib_SummaryOfCommonStockTableTextBlock_589D81382DD4ED4A49D0FBB8355A4169" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of common stock.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryOfCommonStockTableTextBlock" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock_589D81382DD4ED4A49D0FBB8355A4169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfCommonStockTableTextBlock_589D81382DD4ED4A49D0FBB8355A4169" xlink:to="lab_biib_SummaryOfCommonStockTableTextBlock_589D81382DD4ED4A49D0FBB8355A4169" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringChargesMember_5E485ACD24B325BC18B2C4282A704DF7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_5E485ACD24B325BC18B2C4282A704DF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_5E485ACD24B325BC18B2C4282A704DF7_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember_5E485ACD24B325BC18B2C4282A704DF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_5E485ACD24B325BC18B2C4282A704DF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember_5E485ACD24B325BC18B2C4282A704DF7" xlink:to="lab_us-gaap_RestructuringChargesMember_5E485ACD24B325BC18B2C4282A704DF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9FB6F83B0B3B353A75B2C4282A70BA3B_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9FB6F83B0B3B353A75B2C4282A70BA3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9FB6F83B0B3B353A75B2C4282A70BA3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9FB6F83B0B3B353A75B2C4282A70BA3B" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9FB6F83B0B3B353A75B2C4282A70BA3B" xlink:type="arc" />
    <link:label id="lab_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332_terseLabel_en-US" xlink:label="lab_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cambridge, MA</link:label>
    <link:label id="lab_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332_label_en-US" xlink:label="lab_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cambridge, MA [Member]</link:label>
    <link:label id="lab_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332_documentation_en-US" xlink:label="lab_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cambridge, MA [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332" xlink:to="lab_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:to="lab_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:to="lab_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:type="arc" />
    <link:label id="lab_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96_terseLabel_en-US" xlink:label="lab_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Corporate Strategy</link:label>
    <link:label id="lab_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96_label_en-US" xlink:label="lab_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Corporate Strategy [Member]</link:label>
    <link:label id="lab_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96_documentation_en-US" xlink:label="lab_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Corporate Strategy</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_A2017CorporateStrategyMember" xlink:label="loc_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96" xlink:to="lab_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96" xlink:type="arc" />
    <link:label id="lab_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE_terseLabel_en-US" xlink:label="lab_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Restructuring Charges</link:label>
    <link:label id="lab_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE_label_en-US" xlink:label="lab_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Restructuring Charges [Member]</link:label>
    <link:label id="lab_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE_documentation_en-US" xlink:label="lab_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_A2016RestructuringChargesMember" xlink:label="loc_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE" xlink:to="lab_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE" xlink:type="arc" />
    <link:label id="lab_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151_terseLabel_en-US" xlink:label="lab_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Restructuring Charges</link:label>
    <link:label id="lab_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151_label_en-US" xlink:label="lab_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 Restructuring Charges [Member]</link:label>
    <link:label id="lab_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151_documentation_en-US" xlink:label="lab_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 Restructuring Charges [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151" xlink:to="lab_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonrecurringExpense_B7B7F686A15D0861BC74C4282A726440_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonrecurringExpense_B7B7F686A15D0861BC74C4282A726440" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Nonrecurring Expense</link:label>
    <link:label id="lab_us-gaap_OtherNonrecurringExpense_B7B7F686A15D0861BC74C4282A726440_label_en-US" xlink:label="lab_us-gaap_OtherNonrecurringExpense_B7B7F686A15D0861BC74C4282A726440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonrecurring Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaap_OtherNonrecurringExpense_B7B7F686A15D0861BC74C4282A726440" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonrecurringExpense_B7B7F686A15D0861BC74C4282A726440" xlink:to="lab_us-gaap_OtherNonrecurringExpense_B7B7F686A15D0861BC74C4282A726440" xlink:type="arc" />
    <link:label id="lab_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2_terseLabel_en-US" xlink:label="lab_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Resources Redirected through Restructuring Program</link:label>
    <link:label id="lab_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2_label_en-US" xlink:label="lab_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Resources Redirected through Restructuring Program</link:label>
    <link:label id="lab_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2_documentation_en-US" xlink:label="lab_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Resources Redirected through Restructuring Program</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ResourcesRedirectedthroughRestructuringProgram" xlink:label="loc_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2" xlink:to="lab_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2" xlink:type="arc" />
    <link:label id="lab_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313_terseLabel_en-US" xlink:label="lab_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charges Recognized Under Our 2017 Corporate Strategy Restructuring Program</link:label>
    <link:label id="lab_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313_label_en-US" xlink:label="lab_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Charges Recognized Under Our 2017 Corporate Strategy Restructuring Program</link:label>
    <link:label id="lab_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313_documentation_en-US" xlink:label="lab_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Charges Recognized Under Our 2017 Corporate Strategy Restructuring Program</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram" xlink:label="loc_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313" xlink:to="lab_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_07DE223A3880DD84BCAFC4282A73A6BC_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_07DE223A3880DD84BCAFC4282A73A6BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_07DE223A3880DD84BCAFC4282A73A6BC_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_07DE223A3880DD84BCAFC4282A73A6BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_07DE223A3880DD84BCAFC4282A73A6BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_07DE223A3880DD84BCAFC4282A73A6BC" xlink:to="lab_us-gaap_RestructuringCharges_07DE223A3880DD84BCAFC4282A73A6BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_5BC02857C6B06249BD2CC4282A73C1A1_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_5BC02857C6B06249BD2CC4282A73C1A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated depreciation</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_5BC02857C6B06249BD2CC4282A73C1A1_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_5BC02857C6B06249BD2CC4282A73C1A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_5BC02857C6B06249BD2CC4282A73C1A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_5BC02857C6B06249BD2CC4282A73C1A1" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_5BC02857C6B06249BD2CC4282A73C1A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_FAE07E689A40F40909CBF08E8DB47102_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_FAE07E689A40F40909CBF08E8DB47102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_FAE07E689A40F40909CBF08E8DB47102_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_FAE07E689A40F40909CBF08E8DB47102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_FAE07E689A40F40909CBF08E8DB47102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_FAE07E689A40F40909CBF08E8DB47102" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_FAE07E689A40F40909CBF08E8DB47102" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_DAF530FEDD908E67AB7DF08E8DB4E4A0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_DAF530FEDD908E67AB7DF08E8DB4E4A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_DAF530FEDD908E67AB7DF08E8DB4E4A0_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_DAF530FEDD908E67AB7DF08E8DB4E4A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_DAF530FEDD908E67AB7DF08E8DB4E4A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_DAF530FEDD908E67AB7DF08E8DB4E4A0" xlink:to="lab_us-gaap_CommonStockSharesIssued_DAF530FEDD908E67AB7DF08E8DB4E4A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_25D94619E325C7AFC26FF08E8DB50276_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_25D94619E325C7AFC26FF08E8DB50276" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_25D94619E325C7AFC26FF08E8DB50276_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_25D94619E325C7AFC26FF08E8DB50276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_25D94619E325C7AFC26FF08E8DB50276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_25D94619E325C7AFC26FF08E8DB50276" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_25D94619E325C7AFC26FF08E8DB50276" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_333D50673374D045F3D2856979DE4FCE_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_333D50673374D045F3D2856979DE4FCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_333D50673374D045F3D2856979DE4FCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_333D50673374D045F3D2856979DE4FCE" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_333D50673374D045F3D2856979DE4FCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_BF4CA95502686F6FA551856979DE57F1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_BF4CA95502686F6FA551856979DE57F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_BF4CA95502686F6FA551856979DE57F1_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_BF4CA95502686F6FA551856979DE57F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_BF4CA95502686F6FA551856979DE57F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_BF4CA95502686F6FA551856979DE57F1" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_BF4CA95502686F6FA551856979DE57F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_33C96FDB34BF36636531856979DE92AE_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_33C96FDB34BF36636531856979DE92AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_33C96FDB34BF36636531856979DE92AE_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_33C96FDB34BF36636531856979DE92AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_33C96FDB34BF36636531856979DE92AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_33C96FDB34BF36636531856979DE92AE" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_33C96FDB34BF36636531856979DE92AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_DF8CDD197393BB2DA399856979DE7F7B_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_DF8CDD197393BB2DA399856979DE7F7B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_DF8CDD197393BB2DA399856979DE7F7B_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_DF8CDD197393BB2DA399856979DE7F7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DF8CDD197393BB2DA399856979DE7F7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_DF8CDD197393BB2DA399856979DE7F7B" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_DF8CDD197393BB2DA399856979DE7F7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_130A17EFBA445A59D9C2856979DEF415_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_130A17EFBA445A59D9C2856979DEF415" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_130A17EFBA445A59D9C2856979DEF415_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_130A17EFBA445A59D9C2856979DEF415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_130A17EFBA445A59D9C2856979DEF415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_130A17EFBA445A59D9C2856979DEF415" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_130A17EFBA445A59D9C2856979DEF415" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, by Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_63FF60E3969F05EF1A24856979DE61A0_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_63FF60E3969F05EF1A24856979DE61A0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_63FF60E3969F05EF1A24856979DE61A0_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_63FF60E3969F05EF1A24856979DE61A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_63FF60E3969F05EF1A24856979DE61A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_63FF60E3969F05EF1A24856979DE61A0" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_63FF60E3969F05EF1A24856979DE61A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_8241B7CEFD7D29AA8138856979DEB9FB_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_8241B7CEFD7D29AA8138856979DEB9FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_8241B7CEFD7D29AA8138856979DEB9FB_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_8241B7CEFD7D29AA8138856979DEB9FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8241B7CEFD7D29AA8138856979DEB9FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_8241B7CEFD7D29AA8138856979DEB9FB" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_8241B7CEFD7D29AA8138856979DEB9FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_A0FB2246699BCE3029DC856979DEC200_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_A0FB2246699BCE3029DC856979DEC200" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_A0FB2246699BCE3029DC856979DEC200_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember_A0FB2246699BCE3029DC856979DEC200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_A0FB2246699BCE3029DC856979DEC200" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember_A0FB2246699BCE3029DC856979DEC200" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember_A0FB2246699BCE3029DC856979DEC200" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_B63DF8192710F6A8022985989679ADE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00BC73A33F900423B68C85989679F23E_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00BC73A33F900423B68C85989679F23E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00BC73A33F900423B68C85989679F23E_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00BC73A33F900423B68C85989679F23E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00BC73A33F900423B68C85989679F23E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00BC73A33F900423B68C85989679F23E" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_00BC73A33F900423B68C85989679F23E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_FBFBD586A433708BC553859896791D71_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_FBFBD586A433708BC553859896791D71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_FBFBD586A433708BC553859896791D71_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_FBFBD586A433708BC553859896791D71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_FBFBD586A433708BC553859896791D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_FBFBD586A433708BC553859896791D71" xlink:to="lab_us-gaap_AvailableForSaleSecurities_FBFBD586A433708BC553859896791D71" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_71B11F052A44D12BFCD6859896790A20_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_71B11F052A44D12BFCD6859896790A20" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_71B11F052A44D12BFCD6859896790A20_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure_71B11F052A44D12BFCD6859896790A20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_71B11F052A44D12BFCD6859896790A20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure_71B11F052A44D12BFCD6859896790A20" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure_71B11F052A44D12BFCD6859896790A20" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_16085048B54916CDFA8985989679B4D7_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_16085048B54916CDFA8985989679B4D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_16085048B54916CDFA8985989679B4D7_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_16085048B54916CDFA8985989679B4D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_16085048B54916CDFA8985989679B4D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_16085048B54916CDFA8985989679B4D7" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_16085048B54916CDFA8985989679B4D7" xlink:type="arc" />
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8D7611769C52AC74030585989679C120_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8D7611769C52AC74030585989679C120" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8D7611769C52AC74030585989679C120_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8D7611769C52AC74030585989679C120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8D7611769C52AC74030585989679C120_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8D7611769C52AC74030585989679C120" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8D7611769C52AC74030585989679C120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8D7611769C52AC74030585989679C120" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8D7611769C52AC74030585989679C120" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_3F4ECB1205CC92DA471D85989679D9F1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_3F4ECB1205CC92DA471D85989679D9F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_3F4ECB1205CC92DA471D85989679D9F1_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_3F4ECB1205CC92DA471D85989679D9F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3F4ECB1205CC92DA471D85989679D9F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_3F4ECB1205CC92DA471D85989679D9F1" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_3F4ECB1205CC92DA471D85989679D9F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_7AD5CAFCDD74AFE642E0859896794D61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_87E98CA7A716947DBBDD85989679EAD0_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_87E98CA7A716947DBBDD85989679EAD0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_87E98CA7A716947DBBDD85989679EAD0_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_87E98CA7A716947DBBDD85989679EAD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_87E98CA7A716947DBBDD85989679EAD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_87E98CA7A716947DBBDD85989679EAD0" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_87E98CA7A716947DBBDD85989679EAD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4D02AD3CE3AF6864706585989679D5B2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4D02AD3CE3AF6864706585989679D5B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4D02AD3CE3AF6864706585989679D5B2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4D02AD3CE3AF6864706585989679D5B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4D02AD3CE3AF6864706585989679D5B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4D02AD3CE3AF6864706585989679D5B2" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_4D02AD3CE3AF6864706585989679D5B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_08A3591744B065CD37EA859896798440_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_08A3591744B065CD37EA859896798440" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_08A3591744B065CD37EA859896798440_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_08A3591744B065CD37EA859896798440" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_08A3591744B065CD37EA859896798440" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_08A3591744B065CD37EA859896798440" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_08A3591744B065CD37EA859896798440" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:type="arc" />
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A9B1C226D3D20623659CFBB83210CBBF_terseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A9B1C226D3D20623659CFBB83210CBBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A9B1C226D3D20623659CFBB83210CBBF_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A9B1C226D3D20623659CFBB83210CBBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_A9B1C226D3D20623659CFBB83210CBBF_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock_A9B1C226D3D20623659CFBB83210CBBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_A9B1C226D3D20623659CFBB83210CBBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock_A9B1C226D3D20623659CFBB83210CBBF" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock_A9B1C226D3D20623659CFBB83210CBBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_F195B3C42D80F680D032FBB832108703_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_F195B3C42D80F680D032FBB832108703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_F195B3C42D80F680D032FBB832108703_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_F195B3C42D80F680D032FBB832108703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_F195B3C42D80F680D032FBB832108703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_F195B3C42D80F680D032FBB832108703" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_F195B3C42D80F680D032FBB832108703" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_BF6329A1802BFC19BE02FBB83210C31A_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_BF6329A1802BFC19BE02FBB83210C31A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_BF6329A1802BFC19BE02FBB83210C31A_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_BF6329A1802BFC19BE02FBB83210C31A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_BF6329A1802BFC19BE02FBB83210C31A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_BF6329A1802BFC19BE02FBB83210C31A" xlink:to="lab_us-gaap_UseOfEstimates_BF6329A1802BFC19BE02FBB83210C31A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_86817E695E74A4B21002FBB83210B0E0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_86817E695E74A4B21002FBB83210B0E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_86817E695E74A4B21002FBB83210B0E0_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_86817E695E74A4B21002FBB83210B0E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_86817E695E74A4B21002FBB83210B0E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_86817E695E74A4B21002FBB83210B0E0" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_86817E695E74A4B21002FBB83210B0E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_06E39CAC262204B6F737FBB832100B2D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_06E39CAC262204B6F737FBB832100B2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_06E39CAC262204B6F737FBB832100B2D_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_06E39CAC262204B6F737FBB832100B2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_06E39CAC262204B6F737FBB832100B2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_06E39CAC262204B6F737FBB832100B2D" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_06E39CAC262204B6F737FBB832100B2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_36380EF5516E013F3CEBFBB83210D279_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_36380EF5516E013F3CEBFBB83210D279" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_36380EF5516E013F3CEBFBB83210D279_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_36380EF5516E013F3CEBFBB83210D279" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_36380EF5516E013F3CEBFBB83210D279" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_36380EF5516E013F3CEBFBB83210D279" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_36380EF5516E013F3CEBFBB83210D279" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_AC7353A024735E288868FBB8321048A8_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_AC7353A024735E288868FBB8321048A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_AC7353A024735E288868FBB8321048A8_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_AC7353A024735E288868FBB8321048A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_AC7353A024735E288868FBB8321048A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock_AC7353A024735E288868FBB8321048A8" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock_AC7353A024735E288868FBB8321048A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9BB54C5446898D204DBEFBB8321087F4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_9BB54C5446898D204DBEFBB8321087F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9BB54C5446898D204DBEFBB8321087F4_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_9BB54C5446898D204DBEFBB8321087F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9BB54C5446898D204DBEFBB8321087F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_9BB54C5446898D204DBEFBB8321087F4" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_9BB54C5446898D204DBEFBB8321087F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_C4BB9757060013D2752FFBB83210A7C6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_C4BB9757060013D2752FFBB83210A7C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Other Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_C4BB9757060013D2752FFBB83210A7C6_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_C4BB9757060013D2752FFBB83210A7C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_C4BB9757060013D2752FFBB83210A7C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_C4BB9757060013D2752FFBB83210A7C6" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_C4BB9757060013D2752FFBB83210A7C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_820B110C8AB00FEA2E22FBB83210EF75_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_820B110C8AB00FEA2E22FBB83210EF75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method of Accounting</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_820B110C8AB00FEA2E22FBB83210EF75_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy_820B110C8AB00FEA2E22FBB83210EF75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_820B110C8AB00FEA2E22FBB83210EF75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy_820B110C8AB00FEA2E22FBB83210EF75" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy_820B110C8AB00FEA2E22FBB83210EF75" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_27BD446810CA5C5214E0FBB83210CAEC_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_27BD446810CA5C5214E0FBB83210CAEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_27BD446810CA5C5214E0FBB83210CAEC_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_27BD446810CA5C5214E0FBB83210CAEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_27BD446810CA5C5214E0FBB83210CAEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_27BD446810CA5C5214E0FBB83210CAEC" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_27BD446810CA5C5214E0FBB83210CAEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_FA292D616606CD8E9807FBB83210CD53_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_FA292D616606CD8E9807FBB83210CD53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_FA292D616606CD8E9807FBB83210CD53_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_FA292D616606CD8E9807FBB83210CD53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_FA292D616606CD8E9807FBB83210CD53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_FA292D616606CD8E9807FBB83210CD53" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_FA292D616606CD8E9807FBB83210CD53" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_E66E3D3087B07D1529D3FBB83210A11F_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_E66E3D3087B07D1529D3FBB83210A11F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_E66E3D3087B07D1529D3FBB83210A11F_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_E66E3D3087B07D1529D3FBB83210A11F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_E66E3D3087B07D1529D3FBB83210A11F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_E66E3D3087B07D1529D3FBB83210A11F" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_E66E3D3087B07D1529D3FBB83210A11F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_B20ECD3CBECE238C808CFBB832108637_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_B20ECD3CBECE238C808CFBB832108637" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired In-process Research and Development (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_B20ECD3CBECE238C808CFBB832108637_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_B20ECD3CBECE238C808CFBB832108637" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_B20ECD3CBECE238C808CFBB832108637" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_B20ECD3CBECE238C808CFBB832108637" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_B20ECD3CBECE238C808CFBB832108637" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_9E381CAC19DF7D5ADDBDFBB8321089C3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_9E381CAC19DF7D5ADDBDFBB8321089C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_9E381CAC19DF7D5ADDBDFBB8321089C3_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_9E381CAC19DF7D5ADDBDFBB8321089C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_9E381CAC19DF7D5ADDBDFBB8321089C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_9E381CAC19DF7D5ADDBDFBB8321089C3" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_9E381CAC19DF7D5ADDBDFBB8321089C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_353C72893118E9E9909AFBB832107101_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_353C72893118E9E9909AFBB832107101" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_353C72893118E9E9909AFBB832107101_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_353C72893118E9E9909AFBB832107101" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_353C72893118E9E9909AFBB832107101" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_353C72893118E9E9909AFBB832107101" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_353C72893118E9E9909AFBB832107101" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_C8620F0D6190BA5290E9FBB832101E2E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_C8620F0D6190BA5290E9FBB832101E2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_C8620F0D6190BA5290E9FBB832101E2E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_C8620F0D6190BA5290E9FBB832101E2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_C8620F0D6190BA5290E9FBB832101E2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_C8620F0D6190BA5290E9FBB832101E2E" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_C8620F0D6190BA5290E9FBB832101E2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_C34F803F97C6C1B5AA46FBB83210FE21_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_C34F803F97C6C1B5AA46FBB83210FE21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_C34F803F97C6C1B5AA46FBB83210FE21_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_C34F803F97C6C1B5AA46FBB83210FE21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_C34F803F97C6C1B5AA46FBB83210FE21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_C34F803F97C6C1B5AA46FBB83210FE21" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_C34F803F97C6C1B5AA46FBB83210FE21" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_CFCE6770D6AFF7C50AD7FBB832101737_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_CFCE6770D6AFF7C50AD7FBB832101737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation of Foreign Currencies</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_CFCE6770D6AFF7C50AD7FBB832101737_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_CFCE6770D6AFF7C50AD7FBB832101737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_CFCE6770D6AFF7C50AD7FBB832101737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_CFCE6770D6AFF7C50AD7FBB832101737" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_CFCE6770D6AFF7C50AD7FBB832101737" xlink:type="arc" />
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B0F82B695ACC6558BA4CFBB832106A3C_terseLabel_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B0F82B695ACC6558BA4CFBB832106A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B0F82B695ACC6558BA4CFBB832106A3C_label_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B0F82B695ACC6558BA4CFBB832106A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:label id="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B0F82B695ACC6558BA4CFBB832106A3C_documentation_en-US" xlink:label="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B0F82B695ACC6558BA4CFBB832106A3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Cost of Sales [Policy Text Block]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B0F82B695ACC6558BA4CFBB832106A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B0F82B695ACC6558BA4CFBB832106A3C" xlink:to="lab_biib_RoyaltyCostofSalesPolicyTextBlock_B0F82B695ACC6558BA4CFBB832106A3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_A2F95A66F00B0214F0C0FBB83210AD9F_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_A2F95A66F00B0214F0C0FBB83210AD9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting for Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_A2F95A66F00B0214F0C0FBB83210AD9F_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_A2F95A66F00B0214F0C0FBB83210AD9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_A2F95A66F00B0214F0C0FBB83210AD9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_A2F95A66F00B0214F0C0FBB83210AD9F" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_A2F95A66F00B0214F0C0FBB83210AD9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_08AB76987518BBC9329EFBB83210CC7F_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_08AB76987518BBC9329EFBB83210CC7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_08AB76987518BBC9329EFBB83210CC7F_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_08AB76987518BBC9329EFBB83210CC7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research, Development, and Computer Software, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_08AB76987518BBC9329EFBB83210CC7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_08AB76987518BBC9329EFBB83210CC7F" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_08AB76987518BBC9329EFBB83210CC7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9ABB43076CE6C9EFDA68FBB832107C9C_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9ABB43076CE6C9EFDA68FBB832107C9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9ABB43076CE6C9EFDA68FBB832107C9C_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9ABB43076CE6C9EFDA68FBB832107C9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9ABB43076CE6C9EFDA68FBB832107C9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9ABB43076CE6C9EFDA68FBB832107C9C" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9ABB43076CE6C9EFDA68FBB832107C9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_11AF1DDD5C226E57F70AFBB83210352D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_11AF1DDD5C226E57F70AFBB83210352D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_11AF1DDD5C226E57F70AFBB83210352D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_11AF1DDD5C226E57F70AFBB83210352D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_11AF1DDD5C226E57F70AFBB83210352D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_11AF1DDD5C226E57F70AFBB83210352D" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_11AF1DDD5C226E57F70AFBB83210352D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0C87ED2156C86E1F48E0FBB832107388_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0C87ED2156C86E1F48E0FBB832107388" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0C87ED2156C86E1F48E0FBB832107388_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0C87ED2156C86E1F48E0FBB832107388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0C87ED2156C86E1F48E0FBB832107388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0C87ED2156C86E1F48E0FBB832107388" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0C87ED2156C86E1F48E0FBB832107388" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_033B6D739F87C367109BFBB832108B66_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_033B6D739F87C367109BFBB832108B66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_033B6D739F87C367109BFBB832108B66_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_033B6D739F87C367109BFBB832108B66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_033B6D739F87C367109BFBB832108B66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_033B6D739F87C367109BFBB832108B66" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_033B6D739F87C367109BFBB832108B66" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55ED2D4BA23E29ECDCB8FBB832109EB0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55ED2D4BA23E29ECDCB8FBB832109EB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55ED2D4BA23E29ECDCB8FBB832109EB0_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55ED2D4BA23E29ECDCB8FBB832109EB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55ED2D4BA23E29ECDCB8FBB832109EB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55ED2D4BA23E29ECDCB8FBB832109EB0" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55ED2D4BA23E29ECDCB8FBB832109EB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_E42E9D987D3321C773BCFBB833676D9A_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_E42E9D987D3321C773BCFBB833676D9A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_E42E9D987D3321C773BCFBB833676D9A_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_E42E9D987D3321C773BCFBB833676D9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_E42E9D987D3321C773BCFBB833676D9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_E42E9D987D3321C773BCFBB833676D9A" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_E42E9D987D3321C773BCFBB833676D9A" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E_verboseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:to="lab_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7" xlink:to="lab_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7" xlink:type="arc" />
    <link:label id="lab_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C" xlink:to="lab_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_05D41390D987F569218B9A049F9ADFF4_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_05D41390D987F569218B9A049F9ADFF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05D41390D987F569218B9A049F9ADFF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05D41390D987F569218B9A049F9ADFF4" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_05D41390D987F569218B9A049F9ADFF4" xlink:type="arc" />
    <link:label id="lab_biib_RocheGroupGenentechMember_EC10F1D232239E29B18D9A049F9CB6A7_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember_EC10F1D232239E29B18D9A049F9CB6A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_EC10F1D232239E29B18D9A049F9CB6A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember_EC10F1D232239E29B18D9A049F9CB6A7" xlink:to="lab_biib_RocheGroupGenentechMember_EC10F1D232239E29B18D9A049F9CB6A7" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_758D9B1EC7F2EAC868619A049F9DD2BC_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_758D9B1EC7F2EAC868619A049F9DD2BC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_758D9B1EC7F2EAC868619A049F9DD2BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_758D9B1EC7F2EAC868619A049F9DD2BC" xlink:to="lab_us-gaap_Revenues_758D9B1EC7F2EAC868619A049F9DD2BC" xlink:type="arc" />
    <link:label id="lab_biib_NotesPayableToFumedicaMember_BD313C80B2887C0882A215EAEE2592A7_verboseLabel_en-US" xlink:label="lab_biib_NotesPayableToFumedicaMember_BD313C80B2887C0882A215EAEE2592A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable to Fumedica</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_BD313C80B2887C0882A215EAEE2592A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableToFumedicaMember_BD313C80B2887C0882A215EAEE2592A7" xlink:to="lab_biib_NotesPayableToFumedicaMember_BD313C80B2887C0882A215EAEE2592A7" xlink:type="arc" />
    <link:label id="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_12237A0908995186D1B515EAEE2638D3_verboseLabel_en-US" xlink:label="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_12237A0908995186D1B515EAEE2638D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes due 2018</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_12237A0908995186D1B515EAEE2638D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_12237A0908995186D1B515EAEE2638D3" xlink:to="lab_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_12237A0908995186D1B515EAEE2638D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_35CCFEC190CD0195405C15EAEE274459_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_35CCFEC190CD0195405C15EAEE274459" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_35CCFEC190CD0195405C15EAEE274459_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_35CCFEC190CD0195405C15EAEE274459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_35CCFEC190CD0195405C15EAEE274459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_35CCFEC190CD0195405C15EAEE274459" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_35CCFEC190CD0195405C15EAEE274459" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_E3DB9CD907F742A4C82515EAEE286909_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_E3DB9CD907F742A4C82515EAEE286909" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_E3DB9CD907F742A4C82515EAEE286909_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue_E3DB9CD907F742A4C82515EAEE286909" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_E3DB9CD907F742A4C82515EAEE286909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue_E3DB9CD907F742A4C82515EAEE286909" xlink:to="lab_us-gaap_DebtInstrumentFairValue_E3DB9CD907F742A4C82515EAEE286909" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_43C3156C9691F38749AD9A049BB4A85B_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_43C3156C9691F38749AD9A049BB4A85B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_43C3156C9691F38749AD9A049BB4A85B_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_43C3156C9691F38749AD9A049BB4A85B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_43C3156C9691F38749AD9A049BB4A85B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_43C3156C9691F38749AD9A049BB4A85B" xlink:to="lab_us-gaap_CostsAndExpenses_43C3156C9691F38749AD9A049BB4A85B" xlink:type="arc" />
    <link:label id="lab_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F_totalLabel_en-US" xlink:label="lab_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profits and losses</link:label>
    <link:label id="lab_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F_label_en-US" xlink:label="lab_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co-promotion profits and losses</link:label>
    <link:label id="lab_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F_documentation_en-US" xlink:label="lab_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profits and losses</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Copromotionprofitsandlosses" xlink:label="loc_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F" xlink:to="lab_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_984C3F1A2238B846C6B6FBB83480B52E_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_984C3F1A2238B846C6B6FBB83480B52E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_984C3F1A2238B846C6B6FBB83480B52E_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_984C3F1A2238B846C6B6FBB83480B52E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_984C3F1A2238B846C6B6FBB83480B52E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_984C3F1A2238B846C6B6FBB83480B52E" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_984C3F1A2238B846C6B6FBB83480B52E" xlink:type="arc" />
    <link:label id="lab_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB_terseLabel_en-US" xlink:label="lab_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory expected to be sold to Bioverativ</link:label>
    <link:label id="lab_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB_label_en-US" xlink:label="lab_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory expected to be sold to Bioverativ</link:label>
    <link:label id="lab_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB_documentation_en-US" xlink:label="lab_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory expected to be sold to Bioverativ</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_InventoryexpectedtobesoldtoBioverativ" xlink:label="loc_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB" xlink:to="lab_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:to="lab_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_55E5CEFBC90F8A881B6EFBB8318394D8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_55E5CEFBC90F8A881B6EFBB8318394D8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_55E5CEFBC90F8A881B6EFBB8318394D8_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_55E5CEFBC90F8A881B6EFBB8318394D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_55E5CEFBC90F8A881B6EFBB8318394D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_55E5CEFBC90F8A881B6EFBB8318394D8" xlink:to="lab_us-gaap_CommercialPaperMember_55E5CEFBC90F8A881B6EFBB8318394D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_DA766CB27C0916BFF105FBB831839EA7_verboseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_DA766CB27C0916BFF105FBB831839EA7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Overnight Reverse Repurchase Agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_DA766CB27C0916BFF105FBB831839EA7_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember_DA766CB27C0916BFF105FBB831839EA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_DA766CB27C0916BFF105FBB831839EA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember_DA766CB27C0916BFF105FBB831839EA7" xlink:to="lab_us-gaap_RepurchaseAgreementsMember_DA766CB27C0916BFF105FBB831839EA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8C601A1DC98AB976BD99FBB831831E37_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_8C601A1DC98AB976BD99FBB831831E37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money Market Funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8C601A1DC98AB976BD99FBB831831E37_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_8C601A1DC98AB976BD99FBB831831E37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8C601A1DC98AB976BD99FBB831831E37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_8C601A1DC98AB976BD99FBB831831E37" xlink:to="lab_us-gaap_MoneyMarketFundsMember_8C601A1DC98AB976BD99FBB831831E37" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_B98401EBCF763140C03BFBB83183B5D1_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_B98401EBCF763140C03BFBB83183B5D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_B98401EBCF763140C03BFBB83183B5D1_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_B98401EBCF763140C03BFBB83183B5D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_B98401EBCF763140C03BFBB83183B5D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_B98401EBCF763140C03BFBB83183B5D1" xlink:to="lab_us-gaap_DebtSecuritiesMember_B98401EBCF763140C03BFBB83183B5D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_2DF9BE93E2C2BBED5EF5FBB83183AB8A_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_2DF9BE93E2C2BBED5EF5FBB83183AB8A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_2DF9BE93E2C2BBED5EF5FBB83183AB8A_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue_2DF9BE93E2C2BBED5EF5FBB83183AB8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_2DF9BE93E2C2BBED5EF5FBB83183AB8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue_2DF9BE93E2C2BBED5EF5FBB83183AB8A" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue_2DF9BE93E2C2BBED5EF5FBB83183AB8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="lab_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_BD8048F51827851395F3C427E6B91413_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_BD8048F51827851395F3C427E6B91413" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BD8048F51827851395F3C427E6B91413" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_BD8048F51827851395F3C427E6B91413" xlink:to="lab_us-gaap_Revenues_BD8048F51827851395F3C427E6B91413" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_0E3B38D2653E1EF06FC7C427E6B905A4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_0E3B38D2653E1EF06FC7C427E6B905A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0E3B38D2653E1EF06FC7C427E6B905A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_0E3B38D2653E1EF06FC7C427E6B905A4" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_0E3B38D2653E1EF06FC7C427E6B905A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0187858CE6AD73DC4F51C427E6B91145_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0187858CE6AD73DC4F51C427E6B91145" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0187858CE6AD73DC4F51C427E6B91145_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0187858CE6AD73DC4F51C427E6B91145" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0187858CE6AD73DC4F51C427E6B91145" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0187858CE6AD73DC4F51C427E6B91145" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0187858CE6AD73DC4F51C427E6B91145" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_3A435A850AC01E57EDB9C427E6B9E408_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_3A435A850AC01E57EDB9C427E6B9E408" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_3A435A850AC01E57EDB9C427E6B9E408_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess_3A435A850AC01E57EDB9C427E6B9E408" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3A435A850AC01E57EDB9C427E6B9E408" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess_3A435A850AC01E57EDB9C427E6B9E408" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess_3A435A850AC01E57EDB9C427E6B9E408" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BA09FFB1D2411E38CA73C427E6B9B7AE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BA09FFB1D2411E38CA73C427E6B9B7AE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BA09FFB1D2411E38CA73C427E6B9B7AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BA09FFB1D2411E38CA73C427E6B9B7AE" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BA09FFB1D2411E38CA73C427E6B9B7AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_CD28805D3A16AF856BEBC427E6B9436D_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_CD28805D3A16AF856BEBC427E6B9436D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_CD28805D3A16AF856BEBC427E6B9436D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_CD28805D3A16AF856BEBC427E6B9436D" xlink:to="lab_us-gaap_CostsAndExpenses_CD28805D3A16AF856BEBC427E6B9436D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_AA8B87DF18E7AA1EF20FC427E6B96322_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_AA8B87DF18E7AA1EF20FC427E6B96322" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_AA8B87DF18E7AA1EF20FC427E6B96322_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_AA8B87DF18E7AA1EF20FC427E6B96322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_AA8B87DF18E7AA1EF20FC427E6B96322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_AA8B87DF18E7AA1EF20FC427E6B96322" xlink:to="lab_us-gaap_OperatingIncomeLoss_AA8B87DF18E7AA1EF20FC427E6B96322" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_65AC580C1C8F27CAEE52C427E6B9EDCD_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_65AC580C1C8F27CAEE52C427E6B9EDCD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_65AC580C1C8F27CAEE52C427E6B9EDCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_65AC580C1C8F27CAEE52C427E6B9EDCD" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_65AC580C1C8F27CAEE52C427E6B9EDCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4F85A5D2D6CAD15F2415C427E6B9A746_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4F85A5D2D6CAD15F2415C427E6B9A746" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4F85A5D2D6CAD15F2415C427E6B9A746_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4F85A5D2D6CAD15F2415C427E6B9A746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4F85A5D2D6CAD15F2415C427E6B9A746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4F85A5D2D6CAD15F2415C427E6B9A746" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4F85A5D2D6CAD15F2415C427E6B9A746" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4919966F32BA328516DBC427E6C9B67A_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_4919966F32BA328516DBC427E6C9B67A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4919966F32BA328516DBC427E6C9B67A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_4919966F32BA328516DBC427E6C9B67A" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_4919966F32BA328516DBC427E6C9B67A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2943D15A30D72E6FE7D7C427E6C97D3A_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2943D15A30D72E6FE7D7C427E6C97D3A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity in loss of investee, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2943D15A30D72E6FE7D7C427E6C97D3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2943D15A30D72E6FE7D7C427E6C97D3A" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2943D15A30D72E6FE7D7C427E6C97D3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_950E78C2D97A97E933C5C427E6C9DE15_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_950E78C2D97A97E933C5C427E6C9DE15" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_950E78C2D97A97E933C5C427E6C9DE15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_950E78C2D97A97E933C5C427E6C9DE15" xlink:to="lab_us-gaap_ProfitLoss_950E78C2D97A97E933C5C427E6C9DE15" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_E6A1B9BD97DE147495E9C427E6C9C35B_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_E6A1B9BD97DE147495E9C427E6C9C35B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E6A1B9BD97DE147495E9C427E6C9C35B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_E6A1B9BD97DE147495E9C427E6C9C35B" xlink:to="lab_us-gaap_NetIncomeLoss_E6A1B9BD97DE147495E9C427E6C9C35B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_CDBE808B27ECC74CE47EC427E6C9B2BB_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_CDBE808B27ECC74CE47EC427E6C9B2BB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_CDBE808B27ECC74CE47EC427E6C9B2BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CDBE808B27ECC74CE47EC427E6C9B2BB" xlink:to="lab_us-gaap_EarningsPerShareAbstract_CDBE808B27ECC74CE47EC427E6C9B2BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AC713DD8A127D968A860C427E6C95CEE_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AC713DD8A127D968A860C427E6C95CEE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AC713DD8A127D968A860C427E6C95CEE_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AC713DD8A127D968A860C427E6C95CEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AC713DD8A127D968A860C427E6C95CEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AC713DD8A127D968A860C427E6C95CEE" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AC713DD8A127D968A860C427E6C95CEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_79ABC40524E2F132C495FBB834512AD4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_79ABC40524E2F132C495FBB834512AD4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_79ABC40524E2F132C495FBB834512AD4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_79ABC40524E2F132C495FBB834512AD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_79ABC40524E2F132C495FBB834512AD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_79ABC40524E2F132C495FBB834512AD4" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_79ABC40524E2F132C495FBB834512AD4" xlink:type="arc" />
    <link:label id="lab_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF_verboseLabel_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF_label_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Option Activity [Abstract]</link:label>
    <link:label id="lab_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF_documentation_en-US" xlink:label="lab_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock option activity.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_StockOptionActivityAbstract" xlink:label="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:to="lab_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E06B51EE9ACEE644F8D785CC9E66B915_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E06B51EE9ACEE644F8D785CC9E66B915" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Outstanding shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E06B51EE9ACEE644F8D785CC9E66B915_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E06B51EE9ACEE644F8D785CC9E66B915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E06B51EE9ACEE644F8D785CC9E66B915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E06B51EE9ACEE644F8D785CC9E66B915" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E06B51EE9ACEE644F8D785CC9E66B915" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7CDC9E8B255AA1E6F12685CC9E669AB0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7CDC9E8B255AA1E6F12685CC9E669AB0" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7CDC9E8B255AA1E6F12685CC9E669AB0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7CDC9E8B255AA1E6F12685CC9E669AB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7CDC9E8B255AA1E6F12685CC9E669AB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7CDC9E8B255AA1E6F12685CC9E669AB0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7CDC9E8B255AA1E6F12685CC9E669AB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D8F7BFD2E941041E5A3C85CC9E66510A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D8F7BFD2E941041E5A3C85CC9E66510A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D8F7BFD2E941041E5A3C85CC9E66510A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D8F7BFD2E941041E5A3C85CC9E66510A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D8F7BFD2E941041E5A3C85CC9E66510A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D8F7BFD2E941041E5A3C85CC9E66510A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D8F7BFD2E941041E5A3C85CC9E66510A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6860A6256ADFF81576D485CC9E660FEB_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6860A6256ADFF81576D485CC9E660FEB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6860A6256ADFF81576D485CC9E660FEB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6860A6256ADFF81576D485CC9E660FEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6860A6256ADFF81576D485CC9E660FEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6860A6256ADFF81576D485CC9E660FEB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6860A6256ADFF81576D485CC9E660FEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A40F3F8B1A8BBF3EB9F385CC9E660FF7_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A40F3F8B1A8BBF3EB9F385CC9E660FF7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A40F3F8B1A8BBF3EB9F385CC9E660FF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A40F3F8B1A8BBF3EB9F385CC9E660FF7" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A40F3F8B1A8BBF3EB9F385CC9E660FF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_651F4F9B9C7726A1221785CC9E660739_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_651F4F9B9C7726A1221785CC9E660739" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_651F4F9B9C7726A1221785CC9E660739_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_651F4F9B9C7726A1221785CC9E660739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_651F4F9B9C7726A1221785CC9E660739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_651F4F9B9C7726A1221785CC9E660739" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_651F4F9B9C7726A1221785CC9E660739" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_55DE9CA6D8CD164C2F9085CC9E66205A_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_55DE9CA6D8CD164C2F9085CC9E66205A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Shares, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_55DE9CA6D8CD164C2F9085CC9E66205A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_55DE9CA6D8CD164C2F9085CC9E66205A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_55DE9CA6D8CD164C2F9085CC9E66205A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_55DE9CA6D8CD164C2F9085CC9E66205A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_55DE9CA6D8CD164C2F9085CC9E66205A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_984AE97246DC2EB7A46185CC9E664C02_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_984AE97246DC2EB7A46185CC9E664C02" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Cancelled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_984AE97246DC2EB7A46185CC9E664C02_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_984AE97246DC2EB7A46185CC9E664C02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_984AE97246DC2EB7A46185CC9E664C02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_984AE97246DC2EB7A46185CC9E664C02" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_984AE97246DC2EB7A46185CC9E664C02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A92B91817C548DBE71BF85CC9E66D40B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A92B91817C548DBE71BF85CC9E66D40B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Outstanding shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A92B91817C548DBE71BF85CC9E66D40B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A92B91817C548DBE71BF85CC9E66D40B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A92B91817C548DBE71BF85CC9E66D40B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5371F98B4418377CDA8C85CC9E66E2B7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5371F98B4418377CDA8C85CC9E66E2B7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5371F98B4418377CDA8C85CC9E66E2B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5371F98B4418377CDA8C85CC9E66E2B7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5371F98B4418377CDA8C85CC9E66E2B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities by Classification of Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788_terseLabel_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788_label_en-US" xlink:label="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity, Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788" xlink:to="lab_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D_verboseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D_label_en-US" xlink:label="lab_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D" xlink:to="lab_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:to="lab_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_95CF5A75DF02A670D877F52288ED9F91_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_95CF5A75DF02A670D877F52288ED9F91" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment to Neurimmune</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_95CF5A75DF02A670D877F52288ED9F91_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_95CF5A75DF02A670D877F52288ED9F91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_95CF5A75DF02A670D877F52288ED9F91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_95CF5A75DF02A670D877F52288ED9F91" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_95CF5A75DF02A670D877F52288ED9F91" xlink:type="arc" />
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD_terseLabel_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD_label_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD_documentation_en-US" xlink:label="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD" xlink:to="lab_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD" xlink:type="arc" />
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578_label_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:label id="lab_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate payable on commercial sales</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578" xlink:to="lab_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual)</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7_label_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7_documentation_en-US" xlink:label="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in Variable Interest Entities.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:to="lab_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:type="arc" />
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_0E23F17057ACC5C169811219ECE0759B_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_0E23F17057ACC5C169811219ECE0759B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_0E23F17057ACC5C169811219ECE0759B_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_0E23F17057ACC5C169811219ECE0759B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_0E23F17057ACC5C169811219ECE0759B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_0E23F17057ACC5C169811219ECE0759B" xlink:to="lab_us-gaap_AccountsReceivableMember_0E23F17057ACC5C169811219ECE0759B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_660EE12B8F2B153F8E2D121A87D8414B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_660EE12B8F2B153F8E2D121A87D8414B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_660EE12B8F2B153F8E2D121A87D8414B_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_660EE12B8F2B153F8E2D121A87D8414B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_660EE12B8F2B153F8E2D121A87D8414B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_660EE12B8F2B153F8E2D121A87D8414B" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_660EE12B8F2B153F8E2D121A87D8414B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_79677E4D05C61B8A659D1219ECC1B5E9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_79677E4D05C61B8A659D1219ECC1B5E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_79677E4D05C61B8A659D1219ECC1B5E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_79677E4D05C61B8A659D1219ECC1B5E9" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_79677E4D05C61B8A659D1219ECC1B5E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_FFCC088D8345E800ACF0FBB835A83AE6_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_FFCC088D8345E800ACF0FBB835A83AE6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_FFCC088D8345E800ACF0FBB835A83AE6_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_FFCC088D8345E800ACF0FBB835A83AE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_FFCC088D8345E800ACF0FBB835A83AE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_FFCC088D8345E800ACF0FBB835A83AE6" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_FFCC088D8345E800ACF0FBB835A83AE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2AA76283B68DFB67FA8BBE956ABE49FF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_2AA76283B68DFB67FA8BBE956ABE49FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2AA76283B68DFB67FA8BBE956ABE49FF_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_2AA76283B68DFB67FA8BBE956ABE49FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2AA76283B68DFB67FA8BBE956ABE49FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_2AA76283B68DFB67FA8BBE956ABE49FF" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_2AA76283B68DFB67FA8BBE956ABE49FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_A8A15C46A020C5B88349BE956ABEC1D7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_A8A15C46A020C5B88349BE956ABEC1D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_A8A15C46A020C5B88349BE956ABEC1D7_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_A8A15C46A020C5B88349BE956ABEC1D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_A8A15C46A020C5B88349BE956ABEC1D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_A8A15C46A020C5B88349BE956ABEC1D7" xlink:to="lab_us-gaap_OtherAssetsCurrent_A8A15C46A020C5B88349BE956ABEC1D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_EF4FFED25E146D08154DBE956ABEDE68_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_EF4FFED25E146D08154DBE956ABEDE68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_EF4FFED25E146D08154DBE956ABEDE68_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_EF4FFED25E146D08154DBE956ABEDE68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_EF4FFED25E146D08154DBE956ABEDE68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_EF4FFED25E146D08154DBE956ABEDE68" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_EF4FFED25E146D08154DBE956ABEDE68" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidTaxes_A1B2B8834317805E3EDDBE956ACD25DE_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_A1B2B8834317805E3EDDBE956ACD25DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_A1B2B8834317805E3EDDBE956ACD25DE_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes_A1B2B8834317805E3EDDBE956ACD25DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_A1B2B8834317805E3EDDBE956ACD25DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes_A1B2B8834317805E3EDDBE956ACD25DE" xlink:to="lab_us-gaap_PrepaidTaxes_A1B2B8834317805E3EDDBE956ACD25DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_D885BC94F1C0ED7D116CBE956ACD283D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_D885BC94F1C0ED7D116CBE956ACD283D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D885BC94F1C0ED7D116CBE956ACD283D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_D885BC94F1C0ED7D116CBE956ACD283D" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_D885BC94F1C0ED7D116CBE956ACD283D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_A12B70BEC942EE147E73BE956ACD8772_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_A12B70BEC942EE147E73BE956ACD8772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_A12B70BEC942EE147E73BE956ACD8772_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent_A12B70BEC942EE147E73BE956ACD8772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_A12B70BEC942EE147E73BE956ACD8772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent_A12B70BEC942EE147E73BE956ACD8772" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent_A12B70BEC942EE147E73BE956ACD8772" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_D6C632D0F674F77C4F81BE956ACD5287_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_D6C632D0F674F77C4F81BE956ACD5287" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_D6C632D0F674F77C4F81BE956ACD5287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_D6C632D0F674F77C4F81BE956ACD5287" xlink:to="lab_us-gaap_EquityMethodInvestments_D6C632D0F674F77C4F81BE956ACD5287" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_35A4925688D7A6F7EFDEBE956ACD9A4E_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent_35A4925688D7A6F7EFDEBE956ACD9A4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Ionis</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_35A4925688D7A6F7EFDEBE956ACD9A4E_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent_35A4925688D7A6F7EFDEBE956ACD9A4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_35A4925688D7A6F7EFDEBE956ACD9A4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent_35A4925688D7A6F7EFDEBE956ACD9A4E" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent_35A4925688D7A6F7EFDEBE956ACD9A4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_A2575B97CAEB53410AF7C428287AE3F7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_A2575B97CAEB53410AF7C428287AE3F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_A2575B97CAEB53410AF7C428287AE3F7_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_A2575B97CAEB53410AF7C428287AE3F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_A2575B97CAEB53410AF7C428287AE3F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember_A2575B97CAEB53410AF7C428287AE3F7" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember_A2575B97CAEB53410AF7C428287AE3F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9516F6ED04EDDE400283C428287A69F7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9516F6ED04EDDE400283C428287A69F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9516F6ED04EDDE400283C428287A69F7_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9516F6ED04EDDE400283C428287A69F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9516F6ED04EDDE400283C428287A69F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9516F6ED04EDDE400283C428287A69F7" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9516F6ED04EDDE400283C428287A69F7" xlink:type="arc" />
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A_terseLabel_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A_label_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:label id="lab_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A_documentation_en-US" xlink:label="lab_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convergence Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A" xlink:to="lab_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A" xlink:type="arc" />
    <link:label id="lab_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F_verboseLabel_en-US" xlink:label="lab_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stromedix, Inc.</link:label>
    <link:label id="lab_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F_label_en-US" xlink:label="lab_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stromedix [Member]</link:label>
    <link:label id="lab_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F_documentation_en-US" xlink:label="lab_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stromedix.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F" xlink:to="lab_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F" xlink:type="arc" />
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E_terseLabel_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec International Neuroscience GmbH</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E_label_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biogen Idec International Neuroscience Member</link:label>
    <link:label id="lab_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E_documentation_en-US" xlink:label="lab_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biogen idec international neuroscience.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E" xlink:to="lab_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:type="arc" />
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_D9F6B99D4EA5B87B08E7C4282883ED11_terseLabel_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_D9F6B99D4EA5B87B08E7C4282883ED11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurements, changes in valuation techniques</link:label>
    <link:label id="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_D9F6B99D4EA5B87B08E7C4282883ED11_label_en-US" xlink:label="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_D9F6B99D4EA5B87B08E7C4282883ED11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servicing Asset at Fair Value, Description of Changes in Valuation Inputs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs" xlink:label="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_D9F6B99D4EA5B87B08E7C4282883ED11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_D9F6B99D4EA5B87B08E7C4282883ED11" xlink:to="lab_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_D9F6B99D4EA5B87B08E7C4282883ED11" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_27FFB555BBB297BDA7D8C428288361CC_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_27FFB555BBB297BDA7D8C428288361CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.875% Senior Notes aggregate principal amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_27FFB555BBB297BDA7D8C428288361CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_27FFB555BBB297BDA7D8C428288361CC" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_27FFB555BBB297BDA7D8C428288361CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_547E05EA3F5DCB401D46C4282883BF8E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_547E05EA3F5DCB401D46C4282883BF8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_547E05EA3F5DCB401D46C4282883BF8E_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_547E05EA3F5DCB401D46C4282883BF8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_547E05EA3F5DCB401D46C4282883BF8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_547E05EA3F5DCB401D46C4282883BF8E" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_547E05EA3F5DCB401D46C4282883BF8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E5C2485A0F79A69E1955C428288311C8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E5C2485A0F79A69E1955C428288311C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E5C2485A0F79A69E1955C428288311C8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E5C2485A0F79A69E1955C428288311C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E5C2485A0F79A69E1955C428288311C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E5C2485A0F79A69E1955C428288311C8" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E5C2485A0F79A69E1955C428288311C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DE60CAC41064659E7E9FC4282883CC99_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DE60CAC41064659E7E9FC4282883CC99" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DE60CAC41064659E7E9FC4282883CC99_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DE60CAC41064659E7E9FC4282883CC99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DE60CAC41064659E7E9FC4282883CC99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DE60CAC41064659E7E9FC4282883CC99" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DE60CAC41064659E7E9FC4282883CC99" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_D98E3419CA04DC6ED8B1C428288405B2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_D98E3419CA04DC6ED8B1C428288405B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D98E3419CA04DC6ED8B1C428288405B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D98E3419CA04DC6ED8B1C428288405B2" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_D98E3419CA04DC6ED8B1C428288405B2" xlink:type="arc" />
    <link:label id="lab_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717_terseLabel_en-US" xlink:label="lab_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement and measurement inputs, recurring and nonrecurring</link:label>
    <link:label id="lab_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717_label_en-US" xlink:label="lab_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs</link:label>
    <link:label id="lab_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717_documentation_en-US" xlink:label="lab_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_FairValueMeasurementInputs" xlink:label="loc_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717" xlink:to="lab_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_01BA80D7D419BE818764C428288991AA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_01BA80D7D419BE818764C428288991AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_01BA80D7D419BE818764C428288991AA_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_01BA80D7D419BE818764C428288991AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_01BA80D7D419BE818764C428288991AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_01BA80D7D419BE818764C428288991AA" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_01BA80D7D419BE818764C428288991AA" xlink:type="arc" />
    <link:label id="lab_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB_label_en-US" xlink:label="lab_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:to="lab_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:to="lab_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:type="arc" />
    <link:label id="lab_currency_EUR_6E1C035303AC81FCBFE085B86DF2427B_verboseLabel_en-US" xlink:label="lab_currency_EUR_6E1C035303AC81FCBFE085B86DF2427B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_6E1C035303AC81FCBFE085B86DF2427B_label_en-US" xlink:label="lab_currency_EUR_6E1C035303AC81FCBFE085B86DF2427B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_6E1C035303AC81FCBFE085B86DF2427B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_6E1C035303AC81FCBFE085B86DF2427B" xlink:to="lab_currency_EUR_6E1C035303AC81FCBFE085B86DF2427B" xlink:type="arc" />
    <link:label id="lab_currency_GBP_F267BA6DBDABB01CE10E85B86DF2AA53_terseLabel_en-US" xlink:label="lab_currency_GBP_F267BA6DBDABB01CE10E85B86DF2AA53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound sterling</link:label>
    <link:label id="lab_currency_GBP_F267BA6DBDABB01CE10E85B86DF2AA53_label_en-US" xlink:label="lab_currency_GBP_F267BA6DBDABB01CE10E85B86DF2AA53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_F267BA6DBDABB01CE10E85B86DF2AA53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP_F267BA6DBDABB01CE10E85B86DF2AA53" xlink:to="lab_currency_GBP_F267BA6DBDABB01CE10E85B86DF2AA53" xlink:type="arc" />
    <link:label id="lab_currency_CHF_B7153F14C5BDA2F4F75A85B86DF2B746_terseLabel_en-US" xlink:label="lab_currency_CHF_B7153F14C5BDA2F4F75A85B86DF2B746" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss francs</link:label>
    <link:label id="lab_currency_CHF_B7153F14C5BDA2F4F75A85B86DF2B746_label_en-US" xlink:label="lab_currency_CHF_B7153F14C5BDA2F4F75A85B86DF2B746" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_B7153F14C5BDA2F4F75A85B86DF2B746" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF_B7153F14C5BDA2F4F75A85B86DF2B746" xlink:to="lab_currency_CHF_B7153F14C5BDA2F4F75A85B86DF2B746" xlink:type="arc" />
    <link:label id="lab_currency_CAD_29874C30C7DB074B1E6F85B86DF27DF8_verboseLabel_en-US" xlink:label="lab_currency_CAD_29874C30C7DB074B1E6F85B86DF27DF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_29874C30C7DB074B1E6F85B86DF27DF8_label_en-US" xlink:label="lab_currency_CAD_29874C30C7DB074B1E6F85B86DF27DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_29874C30C7DB074B1E6F85B86DF27DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD_29874C30C7DB074B1E6F85B86DF27DF8" xlink:to="lab_currency_CAD_29874C30C7DB074B1E6F85B86DF27DF8" xlink:type="arc" />
    <link:label id="lab_currency_JPY_40D6799B7FDC2EA731DE85B86DF26E5D_terseLabel_en-US" xlink:label="lab_currency_JPY_40D6799B7FDC2EA731DE85B86DF26E5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_40D6799B7FDC2EA731DE85B86DF26E5D_label_en-US" xlink:label="lab_currency_JPY_40D6799B7FDC2EA731DE85B86DF26E5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_40D6799B7FDC2EA731DE85B86DF26E5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY_40D6799B7FDC2EA731DE85B86DF26E5D" xlink:to="lab_currency_JPY_40D6799B7FDC2EA731DE85B86DF26E5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_6A4B30954AE40BE3999B85B86DF5380B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_6A4B30954AE40BE3999B85B86DF5380B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_6A4B30954AE40BE3999B85B86DF5380B_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_6A4B30954AE40BE3999B85B86DF5380B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_6A4B30954AE40BE3999B85B86DF5380B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_6A4B30954AE40BE3999B85B86DF5380B" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_6A4B30954AE40BE3999B85B86DF5380B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherInvestmentsMember_2C93E3F016956706679B85B86DF5C616_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_2C93E3F016956706679B85B86DF5C616" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_2C93E3F016956706679B85B86DF5C616_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_2C93E3F016956706679B85B86DF5C616" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_2C93E3F016956706679B85B86DF5C616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember_2C93E3F016956706679B85B86DF5C616" xlink:to="lab_us-gaap_OtherInvestmentsMember_2C93E3F016956706679B85B86DF5C616" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_EB666E96A473AF47110985B86DF545D1_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_EB666E96A473AF47110985B86DF545D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_EB666E96A473AF47110985B86DF545D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_EB666E96A473AF47110985B86DF545D1" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_EB666E96A473AF47110985B86DF545D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Fair Value, Amount Not Offset Against Collateral [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:to="lab_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_D3FE90E69FDDE0AEDE1485B86DF79004_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_D3FE90E69FDDE0AEDE1485B86DF79004" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Asset derivatives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D3FE90E69FDDE0AEDE1485B86DF79004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D3FE90E69FDDE0AEDE1485B86DF79004" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_D3FE90E69FDDE0AEDE1485B86DF79004" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_EFEF872A0B025E17236B9A04A0467F14_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_EFEF872A0B025E17236B9A04A0467F14" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_EFEF872A0B025E17236B9A04A0467F14_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_EFEF872A0B025E17236B9A04A0467F14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_EFEF872A0B025E17236B9A04A0467F14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_EFEF872A0B025E17236B9A04A0467F14" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_EFEF872A0B025E17236B9A04A0467F14" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4406F2AFCDA848169A709A04A0471486_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_4406F2AFCDA848169A709A04A0471486" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and impairments</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4406F2AFCDA848169A709A04A0471486_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_4406F2AFCDA848169A709A04A0471486" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4406F2AFCDA848169A709A04A0471486" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_4406F2AFCDA848169A709A04A0471486" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_4406F2AFCDA848169A709A04A0471486" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_994030B338C0F5514FA79A04A048F16F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_994030B338C0F5514FA79A04A048F16F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_994030B338C0F5514FA79A04A048F16F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_994030B338C0F5514FA79A04A048F16F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_994030B338C0F5514FA79A04A048F16F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_994030B338C0F5514FA79A04A048F16F" xlink:to="lab_us-gaap_ShareBasedCompensation_994030B338C0F5514FA79A04A048F16F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_20202E279A036F6A0B549A04A0490458_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_20202E279A036F6A0B549A04A0490458" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_20202E279A036F6A0B549A04A0490458_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_20202E279A036F6A0B549A04A0490458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20202E279A036F6A0B549A04A0490458" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20202E279A036F6A0B549A04A0490458" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_20202E279A036F6A0B549A04A0490458" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_DF4D8540AFC5834E8C5F9A04A049B6BA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_DF4D8540AFC5834E8C5F9A04A049B6BA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_DF4D8540AFC5834E8C5F9A04A049B6BA_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_DF4D8540AFC5834E8C5F9A04A049B6BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_DF4D8540AFC5834E8C5F9A04A049B6BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_DF4D8540AFC5834E8C5F9A04A049B6BA" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_DF4D8540AFC5834E8C5F9A04A049B6BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_AF2166F7E492F354134E9A04A049121E_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_AF2166F7E492F354134E9A04A049121E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_AF2166F7E492F354134E9A04A049121E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_AF2166F7E492F354134E9A04A049121E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_AF2166F7E492F354134E9A04A049121E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_AF2166F7E492F354134E9A04A049121E" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_AF2166F7E492F354134E9A04A049121E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C84E53E4277272B3D58C9A04A04ABCD3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C84E53E4277272B3D58C9A04A04ABCD3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C84E53E4277272B3D58C9A04A04ABCD3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C84E53E4277272B3D58C9A04A04ABCD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C84E53E4277272B3D58C9A04A04ABCD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C84E53E4277272B3D58C9A04A04ABCD3" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C84E53E4277272B3D58C9A04A04ABCD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0DECFD3E0B0AE7B6C20F9A04A04A2C5F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0DECFD3E0B0AE7B6C20F9A04A04A2C5F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0DECFD3E0B0AE7B6C20F9A04A04A2C5F_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_0DECFD3E0B0AE7B6C20F9A04A04A2C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0DECFD3E0B0AE7B6C20F9A04A04A2C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_0DECFD3E0B0AE7B6C20F9A04A04A2C5F" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_0DECFD3E0B0AE7B6C20F9A04A04A2C5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51DB6F1EB928F350D4789A04A04A83FD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51DB6F1EB928F350D4789A04A04A83FD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51DB6F1EB928F350D4789A04A04A83FD_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51DB6F1EB928F350D4789A04A04A83FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51DB6F1EB928F350D4789A04A04A83FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51DB6F1EB928F350D4789A04A04A83FD" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51DB6F1EB928F350D4789A04A04A83FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3C08D5FB38ABE9FE1E429A04A04AD11A_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3C08D5FB38ABE9FE1E429A04A04AD11A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3C08D5FB38ABE9FE1E429A04A04AD11A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3C08D5FB38ABE9FE1E429A04A04AD11A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3C08D5FB38ABE9FE1E429A04A04AD11A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3C08D5FB38ABE9FE1E429A04A04AD11A" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3C08D5FB38ABE9FE1E429A04A04AD11A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_F2DFA91ED2BE83D8C5F39A04A04AA73D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_F2DFA91ED2BE83D8C5F39A04A04AA73D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_F2DFA91ED2BE83D8C5F39A04A04AA73D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_F2DFA91ED2BE83D8C5F39A04A04AA73D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_F2DFA91ED2BE83D8C5F39A04A04AA73D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_F2DFA91ED2BE83D8C5F39A04A04AA73D" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_F2DFA91ED2BE83D8C5F39A04A04AA73D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_900D1B358E1F5BF2C77F9A04A04B4345_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_900D1B358E1F5BF2C77F9A04A04B4345" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_900D1B358E1F5BF2C77F9A04A04B4345_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_900D1B358E1F5BF2C77F9A04A04B4345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_900D1B358E1F5BF2C77F9A04A04B4345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_900D1B358E1F5BF2C77F9A04A04B4345" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_900D1B358E1F5BF2C77F9A04A04B4345" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E4548B8C72B49F015F909A04A04B2F1A_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E4548B8C72B49F015F909A04A04B2F1A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E4548B8C72B49F015F909A04A04B2F1A_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E4548B8C72B49F015F909A04A04B2F1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E4548B8C72B49F015F909A04A04B2F1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E4548B8C72B49F015F909A04A04B2F1A" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_E4548B8C72B49F015F909A04A04B2F1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E6898CF4257A8316F2539A04A04B1B66_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E6898CF4257A8316F2539A04A04B1B66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E6898CF4257A8316F2539A04A04B1B66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E6898CF4257A8316F2539A04A04B1B66" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E6898CF4257A8316F2539A04A04B1B66" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_0356343A44E4F239B0829A04A04B84E6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_0356343A44E4F239B0829A04A04B84E6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_0356343A44E4F239B0829A04A04B84E6_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_0356343A44E4F239B0829A04A04B84E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_0356343A44E4F239B0829A04A04B84E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_0356343A44E4F239B0829A04A04B84E6" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_0356343A44E4F239B0829A04A04B84E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_CEE6765B2E4A831DAF4E9A04A04CAC62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_CEE6765B2E4A831DAF4E9A04A04CAC62" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration related to Fumapharm AG acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_CEE6765B2E4A831DAF4E9A04A04CAC62_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_CEE6765B2E4A831DAF4E9A04A04CAC62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_CEE6765B2E4A831DAF4E9A04A04CAC62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_CEE6765B2E4A831DAF4E9A04A04CAC62" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_CEE6765B2E4A831DAF4E9A04A04CAC62" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_54A47C3AEF54294322059A04A04C7EED_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_54A47C3AEF54294322059A04A04C7EED" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_54A47C3AEF54294322059A04A04C7EED_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_54A47C3AEF54294322059A04A04C7EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_54A47C3AEF54294322059A04A04C7EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_54A47C3AEF54294322059A04A04C7EED" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_54A47C3AEF54294322059A04A04C7EED" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1700FD05B74153594C9E9A04A04CB38C_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1700FD05B74153594C9E9A04A04CB38C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1700FD05B74153594C9E9A04A04CB38C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1700FD05B74153594C9E9A04A04CB38C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1700FD05B74153594C9E9A04A04CB38C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1700FD05B74153594C9E9A04A04CB38C" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1700FD05B74153594C9E9A04A04CB38C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_F1A469D6B34DA20806A69A04A04CC153_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_F1A469D6B34DA20806A69A04A04CC153" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_F1A469D6B34DA20806A69A04A04CC153_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_F1A469D6B34DA20806A69A04A04CC153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_F1A469D6B34DA20806A69A04A04CC153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_F1A469D6B34DA20806A69A04A04CC153" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_F1A469D6B34DA20806A69A04A04CC153" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_E9CC17CAD57AF94446669A04A04CA2C1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments_E9CC17CAD57AF94446669A04A04CA2C1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherInvestments_E9CC17CAD57AF94446669A04A04CA2C1_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherInvestments_E9CC17CAD57AF94446669A04A04CA2C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_E9CC17CAD57AF94446669A04A04CA2C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherInvestments_E9CC17CAD57AF94446669A04A04CA2C1" xlink:to="lab_us-gaap_PaymentsToAcquireOtherInvestments_E9CC17CAD57AF94446669A04A04CA2C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_4AB626B33F768BA9A6079A04A04C18D2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_4AB626B33F768BA9A6079A04A04C18D2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4AB626B33F768BA9A6079A04A04C18D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4AB626B33F768BA9A6079A04A04C18D2" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_4AB626B33F768BA9A6079A04A04C18D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93B46365EE5BFD1065FD9A04A04DE7B9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93B46365EE5BFD1065FD9A04A04DE7B9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93B46365EE5BFD1065FD9A04A04DE7B9_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93B46365EE5BFD1065FD9A04A04DE7B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93B46365EE5BFD1065FD9A04A04DE7B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93B46365EE5BFD1065FD9A04A04DE7B9" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93B46365EE5BFD1065FD9A04A04DE7B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5950DC0F9348913FAAD9A04A04D00A0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5950DC0F9348913FAAD9A04A04D00A0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5950DC0F9348913FAAD9A04A04D00A0_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5950DC0F9348913FAAD9A04A04D00A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5950DC0F9348913FAAD9A04A04D00A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5950DC0F9348913FAAD9A04A04D00A0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5950DC0F9348913FAAD9A04A04D00A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_AEF10AA0FE17F92DA3DA9A04A04DBCB6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_AEF10AA0FE17F92DA3DA9A04A04DBCB6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AEF10AA0FE17F92DA3DA9A04A04DBCB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AEF10AA0FE17F92DA3DA9A04A04DBCB6" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_AEF10AA0FE17F92DA3DA9A04A04DBCB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2065ECCD8898C881A3CB9A04A04D8195_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2065ECCD8898C881A3CB9A04A04D8195" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2065ECCD8898C881A3CB9A04A04D8195_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2065ECCD8898C881A3CB9A04A04D8195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2065ECCD8898C881A3CB9A04A04D8195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2065ECCD8898C881A3CB9A04A04D8195" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2065ECCD8898C881A3CB9A04A04D8195" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_EFC7A9BC6EED70C8CBC69A04A04ED3FA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_EFC7A9BC6EED70C8CBC69A04A04ED3FA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net distribution to noncontrolling interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_EFC7A9BC6EED70C8CBC69A04A04ED3FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_EFC7A9BC6EED70C8CBC69A04A04ED3FA" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_EFC7A9BC6EED70C8CBC69A04A04ED3FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfDebt_F6E28A46D34A650E1DE39A04A04E669F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_F6E28A46D34A650E1DE39A04A04E669F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_F6E28A46D34A650E1DE39A04A04E669F_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt_F6E28A46D34A650E1DE39A04A04E669F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_F6E28A46D34A650E1DE39A04A04E669F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt_F6E28A46D34A650E1DE39A04A04E669F" xlink:to="lab_us-gaap_RepaymentsOfDebt_F6E28A46D34A650E1DE39A04A04E669F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_6F02CB830E873A42BFE69A04A04E0FAD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_6F02CB830E873A42BFE69A04A04E0FAD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net cash contribution to Bioverativ, Inc.</link:label>
    <link:label id="lab_us-gaap_PaymentsOfCapitalDistribution_6F02CB830E873A42BFE69A04A04E0FAD_label_en-US" xlink:label="lab_us-gaap_PaymentsOfCapitalDistribution_6F02CB830E873A42BFE69A04A04E0FAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Capital Distribution</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_6F02CB830E873A42BFE69A04A04E0FAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfCapitalDistribution_6F02CB830E873A42BFE69A04A04E0FAD" xlink:to="lab_us-gaap_PaymentsOfCapitalDistribution_6F02CB830E873A42BFE69A04A04E0FAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_38B26D44240C413F22F79A04A04E7674_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_38B26D44240C413F22F79A04A04E7674" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration payments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_38B26D44240C413F22F79A04A04E7674_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_38B26D44240C413F22F79A04A04E7674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_38B26D44240C413F22F79A04A04E7674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets_38B26D44240C413F22F79A04A04E7674" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets_38B26D44240C413F22F79A04A04E7674" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_F33FA6E5A8C84BECB8CE9A04A04E879B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_F33FA6E5A8C84BECB8CE9A04A04E879B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_F33FA6E5A8C84BECB8CE9A04A04E879B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_F33FA6E5A8C84BECB8CE9A04A04E879B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_F33FA6E5A8C84BECB8CE9A04A04E879B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_F33FA6E5A8C84BECB8CE9A04A04E879B" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_F33FA6E5A8C84BECB8CE9A04A04E879B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_095598C3CD905623ABB39A04A04E6102_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_095598C3CD905623ABB39A04A04E6102" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flows used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_095598C3CD905623ABB39A04A04E6102_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_095598C3CD905623ABB39A04A04E6102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_095598C3CD905623ABB39A04A04E6102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_095598C3CD905623ABB39A04A04E6102" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_095598C3CD905623ABB39A04A04E6102" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_38C32A5DBD9705C03B7A9A400596AF34_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_38C32A5DBD9705C03B7A9A400596AF34" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_38C32A5DBD9705C03B7A9A400596AF34_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_38C32A5DBD9705C03B7A9A400596AF34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_38C32A5DBD9705C03B7A9A400596AF34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_38C32A5DBD9705C03B7A9A400596AF34" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_38C32A5DBD9705C03B7A9A400596AF34" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D926F5B3BAB609690A719A04A04FE973_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D926F5B3BAB609690A719A04A04FE973" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D926F5B3BAB609690A719A04A04FE973_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D926F5B3BAB609690A719A04A04FE973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D926F5B3BAB609690A719A04A04FE973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D926F5B3BAB609690A719A04A04FE973" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D926F5B3BAB609690A719A04A04FE973" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18F6DA67E4CC3E2E99F59A04A04FC75E_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18F6DA67E4CC3E2E99F59A04A04FC75E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18F6DA67E4CC3E2E99F59A04A04FC75E_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18F6DA67E4CC3E2E99F59A04A04FC75E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18F6DA67E4CC3E2E99F59A04A04FC75E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18F6DA67E4CC3E2E99F59A04A04FC75E" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_18F6DA67E4CC3E2E99F59A04A04FC75E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CE6E3B0CAB1B2F429A79A04A04F0014_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CE6E3B0CAB1B2F429A79A04A04F0014" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CE6E3B0CAB1B2F429A79A04A04F0014" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CE6E3B0CAB1B2F429A79A04A04F0014" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CE6E3B0CAB1B2F429A79A04A04F0014" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_217548D9224256B7FF731B41A429A0C0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_217548D9224256B7FF731B41A429A0C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_217548D9224256B7FF731B41A429A0C0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_217548D9224256B7FF731B41A429A0C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_217548D9224256B7FF731B41A429A0C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_217548D9224256B7FF731B41A429A0C0" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_217548D9224256B7FF731B41A429A0C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3DADFCD01403A54E89921B41A4290553_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3DADFCD01403A54E89921B41A4290553" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3DADFCD01403A54E89921B41A4290553_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3DADFCD01403A54E89921B41A4290553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3DADFCD01403A54E89921B41A4290553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3DADFCD01403A54E89921B41A4290553" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3DADFCD01403A54E89921B41A4290553" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2D803EB76839EA0905411B41A4291CCB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2D803EB76839EA0905411B41A4291CCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2D803EB76839EA0905411B41A4291CCB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2D803EB76839EA0905411B41A4291CCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2D803EB76839EA0905411B41A4291CCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2D803EB76839EA0905411B41A4291CCB" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2D803EB76839EA0905411B41A4291CCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_A91BD4566AD05EA90D811B41A42978D9_terseLabel_en-US" xlink:label="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_A91BD4566AD05EA90D811B41A42978D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit and cash received from stock option exercises</link:label>
    <link:label id="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_A91BD4566AD05EA90D811B41A42978D9_label_en-US" xlink:label="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_A91BD4566AD05EA90D811B41A42978D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Proceeds Received and Tax Benefit from Share-based Payment Awards [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:label="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_A91BD4566AD05EA90D811B41A42978D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_A91BD4566AD05EA90D811B41A42978D9" xlink:to="lab_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_A91BD4566AD05EA90D811B41A42978D9" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_FFF37ECF9AC849FFA3741B41A429685A_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_FFF37ECF9AC849FFA3741B41A429685A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market stock units activity</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_FFF37ECF9AC849FFA3741B41A429685A_label_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_FFF37ECF9AC849FFA3741B41A429685A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Market Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_FFF37ECF9AC849FFA3741B41A429685A_documentation_en-US" xlink:label="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_FFF37ECF9AC849FFA3741B41A429685A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Market Stock Units Activity.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_FFF37ECF9AC849FFA3741B41A429685A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_FFF37ECF9AC849FFA3741B41A429685A" xlink:to="lab_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_FFF37ECF9AC849FFA3741B41A429685A" xlink:type="arc" />
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_6557BF28CCD6C47C91F41B41A42970DC_terseLabel_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_6557BF28CCD6C47C91F41B41A42970DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_6557BF28CCD6C47C91F41B41A42970DC_label_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_6557BF28CCD6C47C91F41B41A42970DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions Used In Valuation Of Market Based Stock Units [Table Text Block]</link:label>
    <link:label id="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_6557BF28CCD6C47C91F41B41A42970DC_documentation_en-US" xlink:label="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_6557BF28CCD6C47C91F41B41A42970DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_6557BF28CCD6C47C91F41B41A42970DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_6557BF28CCD6C47C91F41B41A42970DC" xlink:to="lab_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_6557BF28CCD6C47C91F41B41A42970DC" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_8ED141E3ECE27E596B0D1B41A429FE1D_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_8ED141E3ECE27E596B0D1B41A429FE1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares activity</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_8ED141E3ECE27E596B0D1B41A429FE1D_label_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_8ED141E3ECE27E596B0D1B41A429FE1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_8ED141E3ECE27E596B0D1B41A429FE1D_documentation_en-US" xlink:label="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_8ED141E3ECE27E596B0D1B41A429FE1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Cash Settled Performance Shares Activity.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_8ED141E3ECE27E596B0D1B41A429FE1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_8ED141E3ECE27E596B0D1B41A429FE1D" xlink:to="lab_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_8ED141E3ECE27E596B0D1B41A429FE1D" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_DF34CD8FC19F7873CE291B41A429AFB9_terseLabel_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_DF34CD8FC19F7873CE291B41A429AFB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units activity</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_DF34CD8FC19F7873CE291B41A429AFB9_label_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_DF34CD8FC19F7873CE291B41A429AFB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceunitsactivityTableTextBlock_DF34CD8FC19F7873CE291B41A429AFB9_documentation_en-US" xlink:label="lab_biib_PerformanceunitsactivityTableTextBlock_DF34CD8FC19F7873CE291B41A429AFB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance units activity [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceunitsactivityTableTextBlock" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock_DF34CD8FC19F7873CE291B41A429AFB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceunitsactivityTableTextBlock_DF34CD8FC19F7873CE291B41A429AFB9" xlink:to="lab_biib_PerformanceunitsactivityTableTextBlock_DF34CD8FC19F7873CE291B41A429AFB9" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_B5972FEFE90FEACF5DF31B4A88228F3F_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_B5972FEFE90FEACF5DF31B4A88228F3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock activity</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_B5972FEFE90FEACF5DF31B4A88228F3F_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_B5972FEFE90FEACF5DF31B4A88228F3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_B5972FEFE90FEACF5DF31B4A88228F3F_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_B5972FEFE90FEACF5DF31B4A88228F3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockTableTextBlock" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock_B5972FEFE90FEACF5DF31B4A88228F3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock_B5972FEFE90FEACF5DF31B4A88228F3F" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockTableTextBlock_B5972FEFE90FEACF5DF31B4A88228F3F" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_ABE5FCB8A967F945F5F41B530BB7C551_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_ABE5FCB8A967F945F5F41B530BB7C551" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash activity</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_ABE5FCB8A967F945F5F41B530BB7C551_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_ABE5FCB8A967F945F5F41B530BB7C551" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Table Text Block]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_ABE5FCB8A967F945F5F41B530BB7C551_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_ABE5FCB8A967F945F5F41B530BB7C551" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashTableTextBlock" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock_ABE5FCB8A967F945F5F41B530BB7C551" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock_ABE5FCB8A967F945F5F41B530BB7C551" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashTableTextBlock_ABE5FCB8A967F945F5F41B530BB7C551" xlink:type="arc" />
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_AFCD1766AE7CAE16A47D1B41A429846D_terseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_AFCD1766AE7CAE16A47D1B41A429846D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units activity</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_AFCD1766AE7CAE16A47D1B41A429846D_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_AFCD1766AE7CAE16A47D1B41A429846D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_AFCD1766AE7CAE16A47D1B41A429846D_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_AFCD1766AE7CAE16A47D1B41A429846D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units Activity.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_AFCD1766AE7CAE16A47D1B41A429846D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_AFCD1766AE7CAE16A47D1B41A429846D" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_AFCD1766AE7CAE16A47D1B41A429846D" xlink:type="arc" />
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_1DD0A00C777FD5BF92331B41A42974CE_terseLabel_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_1DD0A00C777FD5BF92331B41A42974CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_1DD0A00C777FD5BF92331B41A42974CE_label_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_1DD0A00C777FD5BF92331B41A42974CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued Under Employee Stock Purchase Plan [Table Text Block]</link:label>
    <link:label id="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_1DD0A00C777FD5BF92331B41A42974CE_documentation_en-US" xlink:label="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_1DD0A00C777FD5BF92331B41A42974CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares issued under employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_1DD0A00C777FD5BF92331B41A42974CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_1DD0A00C777FD5BF92331B41A42974CE" xlink:to="lab_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_1DD0A00C777FD5BF92331B41A42974CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D6944E63D212E37E45CEFBB833F378BA_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D6944E63D212E37E45CEFBB833F378BA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D6944E63D212E37E45CEFBB833F378BA_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D6944E63D212E37E45CEFBB833F378BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D6944E63D212E37E45CEFBB833F378BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D6944E63D212E37E45CEFBB833F378BA" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D6944E63D212E37E45CEFBB833F378BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_83D5705D8F713B6D4944FBB83357AD3D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_83D5705D8F713B6D4944FBB83357AD3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_83D5705D8F713B6D4944FBB83357AD3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_83D5705D8F713B6D4944FBB83357AD3D" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_83D5705D8F713B6D4944FBB83357AD3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_C3F3680555D1EF7722A1FBB83357F701_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_C3F3680555D1EF7722A1FBB83357F701" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_C3F3680555D1EF7722A1FBB83357F701" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_C3F3680555D1EF7722A1FBB83357F701" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_C3F3680555D1EF7722A1FBB83357F701" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C65CAEE7547892987B36FBB8335759A8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C65CAEE7547892987B36FBB8335759A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on fair value remeasurement of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C65CAEE7547892987B36FBB8335759A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C65CAEE7547892987B36FBB8335759A8" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C65CAEE7547892987B36FBB8335759A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E2AAEEAD128945B830E7FBB833574EF7_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E2AAEEAD128945B830E7FBB833574EF7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E2AAEEAD128945B830E7FBB833574EF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E2AAEEAD128945B830E7FBB833574EF7" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E2AAEEAD128945B830E7FBB833574EF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2EFFF585FA874E216062FBB8335725F4_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2EFFF585FA874E216062FBB8335725F4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2EFFF585FA874E216062FBB8335725F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2EFFF585FA874E216062FBB8335725F4" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_2EFFF585FA874E216062FBB8335725F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyMember_E3A9F499E105B8ED8FFC8525C7FE64E7_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember_E3A9F499E105B8ED8FFC8525C7FE64E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_E3A9F499E105B8ED8FFC8525C7FE64E7_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember_E3A9F499E105B8ED8FFC8525C7FE64E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_E3A9F499E105B8ED8FFC8525C7FE64E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember_E3A9F499E105B8ED8FFC8525C7FE64E7" xlink:to="lab_us-gaap_RoyaltyMember_E3A9F499E105B8ED8FFC8525C7FE64E7" xlink:type="arc" />
    <link:label id="lab_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509" xlink:to="lab_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509" xlink:type="arc" />
    <link:label id="lab_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734_terseLabel_en-US" xlink:label="lab_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sobi</link:label>
    <link:label id="lab_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734_label_en-US" xlink:label="lab_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sobi [Member]</link:label>
    <link:label id="lab_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734_documentation_en-US" xlink:label="lab_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sobi [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SobiMember" xlink:label="loc_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734" xlink:to="lab_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_7D7A61C7E8F114F0C736118916E276F9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_7D7A61C7E8F114F0C736118916E276F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7D7A61C7E8F114F0C736118916E276F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7D7A61C7E8F114F0C736118916E276F9" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_7D7A61C7E8F114F0C736118916E276F9" xlink:type="arc" />
    <link:label id="lab_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312_terseLabel_en-US" xlink:label="lab_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Karyopharm</link:label>
    <link:label id="lab_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312_label_en-US" xlink:label="lab_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Karyopharm [Member]</link:label>
    <link:label id="lab_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312_documentation_en-US" xlink:label="lab_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Karyopharm [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312" xlink:to="lab_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312" xlink:type="arc" />
    <link:label id="lab_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D_terseLabel_en-US" xlink:label="lab_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D_label_en-US" xlink:label="lab_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D_documentation_en-US" xlink:label="lab_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D" xlink:to="lab_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D" xlink:type="arc" />
    <link:label id="lab_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A_terseLabel_en-US" xlink:label="lab_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TMS</link:label>
    <link:label id="lab_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A_label_en-US" xlink:label="lab_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TMS [Member]</link:label>
    <link:label id="lab_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A_documentation_en-US" xlink:label="lab_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TMS [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_TMSMember" xlink:label="loc_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A" xlink:to="lab_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A" xlink:type="arc" />
    <link:label id="lab_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61_terseLabel_en-US" xlink:label="lab_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AliveGen</link:label>
    <link:label id="lab_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61_label_en-US" xlink:label="lab_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AliveGen [Member]</link:label>
    <link:label id="lab_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61_documentation_en-US" xlink:label="lab_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AliveGen [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AliveGenMember" xlink:label="loc_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61" xlink:to="lab_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61" xlink:type="arc" />
    <link:label id="lab_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E_terseLabel_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical</link:label>
    <link:label id="lab_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E_label_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical [Member]</link:label>
    <link:label id="lab_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E_documentation_en-US" xlink:label="lab_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remedy Pharmaceutical [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E" xlink:to="lab_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_99EDF5CAD60A287D385B11A4E6B40429_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_99EDF5CAD60A287D385B11A4E6B40429" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_99EDF5CAD60A287D385B11A4E6B40429" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_99EDF5CAD60A287D385B11A4E6B40429" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_99EDF5CAD60A287D385B11A4E6B40429" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_968B1D32F9438682B13511A6DF798BF1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_968B1D32F9438682B13511A6DF798BF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense asset acquired</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_968B1D32F9438682B13511A6DF798BF1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_968B1D32F9438682B13511A6DF798BF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_968B1D32F9438682B13511A6DF798BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_968B1D32F9438682B13511A6DF798BF1" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_968B1D32F9438682B13511A6DF798BF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_6F3DFA9A7F8F0591F635FBB8354A54C4_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_6F3DFA9A7F8F0591F635FBB8354A54C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6F3DFA9A7F8F0591F635FBB8354A54C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6F3DFA9A7F8F0591F635FBB8354A54C4" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_6F3DFA9A7F8F0591F635FBB8354A54C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:to="lab_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:to="lab_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:to="lab_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticPlanMember_F6FB18484EDF9687EB2CFBB8354A4E33_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_F6FB18484EDF9687EB2CFBB8354A4E33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_F6FB18484EDF9687EB2CFBB8354A4E33_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_F6FB18484EDF9687EB2CFBB8354A4E33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_F6FB18484EDF9687EB2CFBB8354A4E33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember_F6FB18484EDF9687EB2CFBB8354A4E33" xlink:to="lab_us-gaap_DomesticPlanMember_F6FB18484EDF9687EB2CFBB8354A4E33" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_D1881BAAA9C582775BBDFBB8355A615F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_D1881BAAA9C582775BBDFBB8355A615F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_D1881BAAA9C582775BBDFBB8355A615F_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_D1881BAAA9C582775BBDFBB8355A615F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_D1881BAAA9C582775BBDFBB8355A615F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_D1881BAAA9C582775BBDFBB8355A615F" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_D1881BAAA9C582775BBDFBB8355A615F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:type="arc" />
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76_terseLabel_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum Qualifying Age For Employee Benefit Plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76_label_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Qualifying Age For Employee Benefit Plan</link:label>
    <link:label id="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76_documentation_en-US" xlink:label="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum qualifying age for employee benefit plan.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76" xlink:to="lab_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_342EE3B076DB9788D770FBB8355A2827_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_342EE3B076DB9788D770FBB8355A2827" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses related to savings plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_342EE3B076DB9788D770FBB8355A2827_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_342EE3B076DB9788D770FBB8355A2827" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_342EE3B076DB9788D770FBB8355A2827" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_342EE3B076DB9788D770FBB8355A2827" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_342EE3B076DB9788D770FBB8355A2827" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_9FDDAD8ED5A86DFF79E6FBB8355AEC8C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_9FDDAD8ED5A86DFF79E6FBB8355AEC8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_9FDDAD8ED5A86DFF79E6FBB8355AEC8C_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_9FDDAD8ED5A86DFF79E6FBB8355AEC8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_9FDDAD8ED5A86DFF79E6FBB8355AEC8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_9FDDAD8ED5A86DFF79E6FBB8355AEC8C" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_9FDDAD8ED5A86DFF79E6FBB8355AEC8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_59425C251796DAC013FAF08E8D3B9844_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_59425C251796DAC013FAF08E8D3B9844" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_59425C251796DAC013FAF08E8D3B9844_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_59425C251796DAC013FAF08E8D3B9844" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_59425C251796DAC013FAF08E8D3B9844" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_59425C251796DAC013FAF08E8D3B9844" xlink:to="lab_us-gaap_PerformanceSharesMember_59425C251796DAC013FAF08E8D3B9844" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7B205C1FAAA430D178E0BEA7270E4F4A_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_7B205C1FAAA430D178E0BEA7270E4F4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Paid During the Year</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_7B205C1FAAA430D178E0BEA7270E4F4A_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_7B205C1FAAA430D178E0BEA7270E4F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B205C1FAAA430D178E0BEA7270E4F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B205C1FAAA430D178E0BEA7270E4F4A" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_7B205C1FAAA430D178E0BEA7270E4F4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_A33B34CC6499C1D0684EBEA7270E7579_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_A33B34CC6499C1D0684EBEA7270E7579" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_A33B34CC6499C1D0684EBEA7270E7579_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_A33B34CC6499C1D0684EBEA7270E7579" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_A33B34CC6499C1D0684EBEA7270E7579" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_A33B34CC6499C1D0684EBEA7270E7579" xlink:to="lab_us-gaap_InterestPaidNet_A33B34CC6499C1D0684EBEA7270E7579" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_EE68EB081CBEFA51CCD5BEA7270E2E7B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_EE68EB081CBEFA51CCD5BEA7270E2E7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_EE68EB081CBEFA51CCD5BEA7270E2E7B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_EE68EB081CBEFA51CCD5BEA7270E2E7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_EE68EB081CBEFA51CCD5BEA7270E2E7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_EE68EB081CBEFA51CCD5BEA7270E2E7B" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_EE68EB081CBEFA51CCD5BEA7270E2E7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_62C6DD455D6E65F159EDBEA7270E800D_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_62C6DD455D6E65F159EDBEA7270E800D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_62C6DD455D6E65F159EDBEA7270E800D_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_62C6DD455D6E65F159EDBEA7270E800D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_62C6DD455D6E65F159EDBEA7270E800D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_62C6DD455D6E65F159EDBEA7270E800D" xlink:to="lab_us-gaap_InvestmentIncomeInterest_62C6DD455D6E65F159EDBEA7270E800D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_AF69488EBB3AA4BF8115BEA7270E6750_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_AF69488EBB3AA4BF8115BEA7270E6750" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_AF69488EBB3AA4BF8115BEA7270E6750_label_en-US" xlink:label="lab_us-gaap_InterestExpense_AF69488EBB3AA4BF8115BEA7270E6750" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_AF69488EBB3AA4BF8115BEA7270E6750" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_AF69488EBB3AA4BF8115BEA7270E6750" xlink:to="lab_us-gaap_InterestExpense_AF69488EBB3AA4BF8115BEA7270E6750" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_FE01D91A192527A38881BEA7270E96F6_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_FE01D91A192527A38881BEA7270E96F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_FE01D91A192527A38881BEA7270E96F6_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments_FE01D91A192527A38881BEA7270E96F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_FE01D91A192527A38881BEA7270E96F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments_FE01D91A192527A38881BEA7270E96F6" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments_FE01D91A192527A38881BEA7270E96F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0D477195806A0F45CC8EBEA7270E9285_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0D477195806A0F45CC8EBEA7270E9285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange gains (losses), net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0D477195806A0F45CC8EBEA7270E9285_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0D477195806A0F45CC8EBEA7270E9285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0D477195806A0F45CC8EBEA7270E9285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0D477195806A0F45CC8EBEA7270E9285" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0D477195806A0F45CC8EBEA7270E9285" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9321E29BBE39DBEE75AEBEA7270EB869_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_9321E29BBE39DBEE75AEBEA7270EB869" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9321E29BBE39DBEE75AEBEA7270EB869" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9321E29BBE39DBEE75AEBEA7270EB869" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_9321E29BBE39DBEE75AEBEA7270EB869" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_9FF0CD614471786250DDBEA7270E2305_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_9FF0CD614471786250DDBEA7270E2305" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue related reserves for discounts and allowances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9FF0CD614471786250DDBEA7270E2305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_9FF0CD614471786250DDBEA7270E2305" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_9FF0CD614471786250DDBEA7270E2305" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8F20E5A9A72E444E8070BEA7270E9EF2_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8F20E5A9A72E444E8070BEA7270E9EF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8F20E5A9A72E444E8070BEA7270E9EF2_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8F20E5A9A72E444E8070BEA7270E9EF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8F20E5A9A72E444E8070BEA7270E9EF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8F20E5A9A72E444E8070BEA7270E9EF2" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8F20E5A9A72E444E8070BEA7270E9EF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0BA312FBACF898E83FF2BEA7270EF1E6_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0BA312FBACF898E83FF2BEA7270EF1E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0BA312FBACF898E83FF2BEA7270EF1E6_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0BA312FBACF898E83FF2BEA7270EF1E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0BA312FBACF898E83FF2BEA7270EF1E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0BA312FBACF898E83FF2BEA7270EF1E6" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_0BA312FBACF898E83FF2BEA7270EF1E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_B9709B3B2C1871B826C6BEA7270EAA7A_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_B9709B3B2C1871B826C6BEA7270EAA7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_B9709B3B2C1871B826C6BEA7270EAA7A_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent_B9709B3B2C1871B826C6BEA7270EAA7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_B9709B3B2C1871B826C6BEA7270EAA7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent_B9709B3B2C1871B826C6BEA7270EAA7A" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent_B9709B3B2C1871B826C6BEA7270EAA7A" xlink:type="arc" />
    <link:label id="lab_biib_Collaborationexpensesaccrual_1FEBABF51C173E69814ABEA7270E3DDC_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_1FEBABF51C173E69814ABEA7270E3DDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expenses</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_1FEBABF51C173E69814ABEA7270E3DDC_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_1FEBABF51C173E69814ABEA7270E3DDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_1FEBABF51C173E69814ABEA7270E3DDC_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual_1FEBABF51C173E69814ABEA7270E3DDC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_1FEBABF51C173E69814ABEA7270E3DDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual_1FEBABF51C173E69814ABEA7270E3DDC" xlink:to="lab_biib_Collaborationexpensesaccrual_1FEBABF51C173E69814ABEA7270E3DDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B3D424D920278421360FBEA7270E2E71_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B3D424D920278421360FBEA7270E2E71" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B3D424D920278421360FBEA7270E2E71_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B3D424D920278421360FBEA7270E2E71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B3D424D920278421360FBEA7270E2E71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B3D424D920278421360FBEA7270E2E71" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_B3D424D920278421360FBEA7270E2E71" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_C8CFB2166EA58F2B9663BEA7270EC5C2_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_C8CFB2166EA58F2B9663BEA7270EC5C2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_C8CFB2166EA58F2B9663BEA7270EC5C2_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_C8CFB2166EA58F2B9663BEA7270EC5C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_C8CFB2166EA58F2B9663BEA7270EC5C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_C8CFB2166EA58F2B9663BEA7270EC5C2" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_C8CFB2166EA58F2B9663BEA7270EC5C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_A6871BB6A7C079853738FBB83376191A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_A6871BB6A7C079853738FBB83376191A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income tax provision and the income tax expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_A6871BB6A7C079853738FBB83376191A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_A6871BB6A7C079853738FBB83376191A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_A6871BB6A7C079853738FBB83376191A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_A6871BB6A7C079853738FBB83376191A" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_A6871BB6A7C079853738FBB83376191A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_FBFA6260691A44F83EF9FBB83376CB90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_FBFA6260691A44F83EF9FBB83376CB90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_FBFA6260691A44F83EF9FBB83376CB90_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_FBFA6260691A44F83EF9FBB83376CB90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_FBFA6260691A44F83EF9FBB83376CB90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_FBFA6260691A44F83EF9FBB83376CB90" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_FBFA6260691A44F83EF9FBB83376CB90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_68CB154E052BE00D20B6FBB833765166_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_68CB154E052BE00D20B6FBB833765166" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_68CB154E052BE00D20B6FBB833765166_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_68CB154E052BE00D20B6FBB833765166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_68CB154E052BE00D20B6FBB833765166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_68CB154E052BE00D20B6FBB833765166" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_68CB154E052BE00D20B6FBB833765166" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_856BFF02991A2893008AFBB833760C93_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_856BFF02991A2893008AFBB833760C93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of beginning and ending amount of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_856BFF02991A2893008AFBB833760C93_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_856BFF02991A2893008AFBB833760C93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_856BFF02991A2893008AFBB833760C93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_856BFF02991A2893008AFBB833760C93" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_856BFF02991A2893008AFBB833760C93" xlink:type="arc" />
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700_verboseLabel_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assumptions used in valuation of market based stock units</link:label>
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700_label_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation of Granted Stock Units [Abstract]</link:label>
    <link:label id="lab_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700_documentation_en-US" xlink:label="lab_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation of granted stock units.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="lab_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D0B0CA0DFBB04EF18DECFBB834806E88_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D0B0CA0DFBB04EF18DECFBB834806E88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D0B0CA0DFBB04EF18DECFBB834806E88_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D0B0CA0DFBB04EF18DECFBB834806E88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D0B0CA0DFBB04EF18DECFBB834806E88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D0B0CA0DFBB04EF18DECFBB834806E88" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D0B0CA0DFBB04EF18DECFBB834806E88" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EC9C932899C708B5CEF7FBB83480DFA7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EC9C932899C708B5CEF7FBB83480DFA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EC9C932899C708B5CEF7FBB83480DFA7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EC9C932899C708B5CEF7FBB83480DFA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EC9C932899C708B5CEF7FBB83480DFA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EC9C932899C708B5CEF7FBB83480DFA7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EC9C932899C708B5CEF7FBB83480DFA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3B39ADCBC4F200DB70FBFBB8348F58AA_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3B39ADCBC4F200DB70FBFBB8348F58AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3B39ADCBC4F200DB70FBFBB8348F58AA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3B39ADCBC4F200DB70FBFBB8348F58AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3B39ADCBC4F200DB70FBFBB8348F58AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3B39ADCBC4F200DB70FBFBB8348F58AA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3B39ADCBC4F200DB70FBFBB8348F58AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_BE31FDDC2546DBAD8529FBB8348F3599_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_BE31FDDC2546DBAD8529FBB8348F3599" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum range of risk-free interest rates</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_BE31FDDC2546DBAD8529FBB8348F3599_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_BE31FDDC2546DBAD8529FBB8348F3599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_BE31FDDC2546DBAD8529FBB8348F3599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_BE31FDDC2546DBAD8529FBB8348F3599" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_BE31FDDC2546DBAD8529FBB8348F3599" xlink:type="arc" />
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average stock price on grant date minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Minimum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average stock price on grant date in dollars minimum.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C" xlink:type="arc" />
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099_verboseLabel_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Average stock price on grant date maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099_label_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Average Stock Price On Grant Date In Dollars Maximum</link:label>
    <link:label id="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099_documentation_en-US" xlink:label="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average stock price on grant date in dollars maximum.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099" xlink:to="lab_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8F99AB1D21053E7D31B9FBB8348F87C1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8F99AB1D21053E7D31B9FBB8348F87C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8F99AB1D21053E7D31B9FBB8348F87C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8F99AB1D21053E7D31B9FBB8348F87C1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8F99AB1D21053E7D31B9FBB8348F87C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_E74B1C1FD985B233F49AFBB831C2060D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_E74B1C1FD985B233F49AFBB831C2060D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_E74B1C1FD985B233F49AFBB831C2060D_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_E74B1C1FD985B233F49AFBB831C2060D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_E74B1C1FD985B233F49AFBB831C2060D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_E74B1C1FD985B233F49AFBB831C2060D" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_E74B1C1FD985B233F49AFBB831C2060D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_894EB57AAA1985C62517FBB831C2578E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_894EB57AAA1985C62517FBB831C2578E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_894EB57AAA1985C62517FBB831C2578E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_894EB57AAA1985C62517FBB831C2578E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_894EB57AAA1985C62517FBB831C2578E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_894EB57AAA1985C62517FBB831C2578E" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_894EB57AAA1985C62517FBB831C2578E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_693E133819FF4B46A5D8FBB831C225A8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_693E133819FF4B46A5D8FBB831C225A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit):</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_693E133819FF4B46A5D8FBB831C225A8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_693E133819FF4B46A5D8FBB831C225A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_693E133819FF4B46A5D8FBB831C225A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_693E133819FF4B46A5D8FBB831C225A8" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_693E133819FF4B46A5D8FBB831C225A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_56B6B08234A351CF4905FBB831C2543B_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_56B6B08234A351CF4905FBB831C2543B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_56B6B08234A351CF4905FBB831C2543B_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_56B6B08234A351CF4905FBB831C2543B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_56B6B08234A351CF4905FBB831C2543B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_56B6B08234A351CF4905FBB831C2543B" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_56B6B08234A351CF4905FBB831C2543B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C00839A8B7FDC16A6375FBB831C2840C_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C00839A8B7FDC16A6375FBB831C2840C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C00839A8B7FDC16A6375FBB831C2840C_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C00839A8B7FDC16A6375FBB831C2840C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C00839A8B7FDC16A6375FBB831C2840C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C00839A8B7FDC16A6375FBB831C2840C" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C00839A8B7FDC16A6375FBB831C2840C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_069423D8B3D4E4CDCBADFBB831C2BA52_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_069423D8B3D4E4CDCBADFBB831C2BA52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_069423D8B3D4E4CDCBADFBB831C2BA52_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_069423D8B3D4E4CDCBADFBB831C2BA52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_069423D8B3D4E4CDCBADFBB831C2BA52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_069423D8B3D4E4CDCBADFBB831C2BA52" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_069423D8B3D4E4CDCBADFBB831C2BA52" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E06105AB99D6D49840A7FBB831C2ABA9_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E06105AB99D6D49840A7FBB831C2ABA9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E06105AB99D6D49840A7FBB831C2ABA9_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E06105AB99D6D49840A7FBB831C2ABA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E06105AB99D6D49840A7FBB831C2ABA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E06105AB99D6D49840A7FBB831C2ABA9" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_E06105AB99D6D49840A7FBB831C2ABA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6E1D3ED50A314E0CD4C3FBB831C29A88_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6E1D3ED50A314E0CD4C3FBB831C29A88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6E1D3ED50A314E0CD4C3FBB831C29A88_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6E1D3ED50A314E0CD4C3FBB831C29A88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6E1D3ED50A314E0CD4C3FBB831C29A88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6E1D3ED50A314E0CD4C3FBB831C29A88" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6E1D3ED50A314E0CD4C3FBB831C29A88" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_605DB4219F83D7771198FBB831C2A4AF_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_605DB4219F83D7771198FBB831C2A4AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_605DB4219F83D7771198FBB831C2A4AF_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_605DB4219F83D7771198FBB831C2A4AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_605DB4219F83D7771198FBB831C2A4AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_605DB4219F83D7771198FBB831C2A4AF" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_605DB4219F83D7771198FBB831C2A4AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10459CFEF2C6614D9997FBB831C272F0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10459CFEF2C6614D9997FBB831C272F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10459CFEF2C6614D9997FBB831C272F0_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10459CFEF2C6614D9997FBB831C272F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10459CFEF2C6614D9997FBB831C272F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10459CFEF2C6614D9997FBB831C272F0" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10459CFEF2C6614D9997FBB831C272F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_16BCB80A535D03E22490FBB831C2BEFE_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_16BCB80A535D03E22490FBB831C2BEFE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_16BCB80A535D03E22490FBB831C2BEFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_16BCB80A535D03E22490FBB831C2BEFE" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_16BCB80A535D03E22490FBB831C2BEFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_D6CCD227435D753E13E3FBB831C23B53_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_D6CCD227435D753E13E3FBB831C23B53" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D6CCD227435D753E13E3FBB831C23B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_D6CCD227435D753E13E3FBB831C23B53" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_D6CCD227435D753E13E3FBB831C23B53" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Table]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5_label_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Table]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5_documentation_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of development milestone and collaboration.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Interest Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437" xlink:to="lab_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437" xlink:type="arc" />
    <link:label id="lab_biib_NeurimmuneMember_36D25E493F80704A2591A5C6DA4D16D9_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember_36D25E493F80704A2591A5C6DA4D16D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neurimmune</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_36D25E493F80704A2591A5C6DA4D16D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember_36D25E493F80704A2591A5C6DA4D16D9" xlink:to="lab_biib_NeurimmuneMember_36D25E493F80704A2591A5C6DA4D16D9" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Line Items]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4_label_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration [Line Items]</link:label>
    <link:label id="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4_documentation_en-US" xlink:label="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Development Milestone And Collaboration.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="lab_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_02DC3C19DB8BC4D59610A5C6DA4DAC6B_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_02DC3C19DB8BC4D59610A5C6DA4DAC6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on strategic investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_02DC3C19DB8BC4D59610A5C6DA4DAC6B_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_02DC3C19DB8BC4D59610A5C6DA4DAC6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Marketable Securities, Cost Method Investments, and Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_02DC3C19DB8BC4D59610A5C6DA4DAC6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_02DC3C19DB8BC4D59610A5C6DA4DAC6B" xlink:to="lab_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_02DC3C19DB8BC4D59610A5C6DA4DAC6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_EDDAD5EDA7920948A1FAA5C6DA4DAFB5_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_EDDAD5EDA7920948A1FAA5C6DA4DAFB5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense on 2018 Ionis Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EDDAD5EDA7920948A1FAA5C6DA4DAFB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_EDDAD5EDA7920948A1FAA5C6DA4DAFB5" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_EDDAD5EDA7920948A1FAA5C6DA4DAFB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_06563D2D9809D9994389A5C6DA4D017A_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_06563D2D9809D9994389A5C6DA4D017A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_06563D2D9809D9994389A5C6DA4D017A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_06563D2D9809D9994389A5C6DA4D017A" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_06563D2D9809D9994389A5C6DA4D017A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_74CB2CBF4E980C751554A5C6DA4D7559_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders_74CB2CBF4E980C751554A5C6DA4D7559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_74CB2CBF4E980C751554A5C6DA4D7559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders_74CB2CBF4E980C751554A5C6DA4D7559" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders_74CB2CBF4E980C751554A5C6DA4D7559" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:to="lab_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2" xlink:to="lab_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Abstract]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Abstract]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_333014991CA34F723432FBB8348FBC6A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_333014991CA34F723432FBB8348FBC6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_333014991CA34F723432FBB8348FBC6A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_333014991CA34F723432FBB8348FBC6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_333014991CA34F723432FBB8348FBC6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_333014991CA34F723432FBB8348FBC6A" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_333014991CA34F723432FBB8348FBC6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4A94AD0FCEFB71FA1427FBB8348FB6F1_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4A94AD0FCEFB71FA1427FBB8348FB6F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4A94AD0FCEFB71FA1427FBB8348FB6F1_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4A94AD0FCEFB71FA1427FBB8348FB6F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4A94AD0FCEFB71FA1427FBB8348FB6F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4A94AD0FCEFB71FA1427FBB8348FB6F1" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4A94AD0FCEFB71FA1427FBB8348FB6F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3E344985807C40552B9685B8719C9CEA_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_3E344985807C40552B9685B8719C9CEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3E344985807C40552B9685B8719C9CEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3E344985807C40552B9685B8719C9CEA" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_3E344985807C40552B9685B8719C9CEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:to="lab_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:to="lab_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A7BD6DA060727869D53685B8719CF1D1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A7BD6DA060727869D53685B8719CF1D1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A7BD6DA060727869D53685B8719CF1D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A7BD6DA060727869D53685B8719CF1D1" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_A7BD6DA060727869D53685B8719CF1D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_24E715086881ACB44A1D85B8719E122F_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_24E715086881ACB44A1D85B8719E122F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_24E715086881ACB44A1D85B8719E122F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_24E715086881ACB44A1D85B8719E122F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_24E715086881ACB44A1D85B8719E122F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_24E715086881ACB44A1D85B8719E122F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_24E715086881ACB44A1D85B8719E122F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5339423C32CA942EF9BC85B8719E5DF2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_5339423C32CA942EF9BC85B8719E5DF2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5339423C32CA942EF9BC85B8719E5DF2_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_5339423C32CA942EF9BC85B8719E5DF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5339423C32CA942EF9BC85B8719E5DF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_5339423C32CA942EF9BC85B8719E5DF2" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_5339423C32CA942EF9BC85B8719E5DF2" xlink:type="arc" />
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_8E5ADE19FA6F6D1AF1F885B8719E625A_verboseLabel_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_8E5ADE19FA6F6D1AF1F885B8719E625A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_8E5ADE19FA6F6D1AF1F885B8719E625A_label_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_8E5ADE19FA6F6D1AF1F885B8719E625A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from unconsolidated joint business</link:label>
    <link:label id="lab_biib_DueFromUnconsolidatedJointBusiness_8E5ADE19FA6F6D1AF1F885B8719E625A_documentation_en-US" xlink:label="lab_biib_DueFromUnconsolidatedJointBusiness_8E5ADE19FA6F6D1AF1F885B8719E625A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_8E5ADE19FA6F6D1AF1F885B8719E625A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DueFromUnconsolidatedJointBusiness_8E5ADE19FA6F6D1AF1F885B8719E625A" xlink:to="lab_biib_DueFromUnconsolidatedJointBusiness_8E5ADE19FA6F6D1AF1F885B8719E625A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_C1559D6117E060829B1385B8719ECC16_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_C1559D6117E060829B1385B8719ECC16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_C1559D6117E060829B1385B8719ECC16_label_en-US" xlink:label="lab_us-gaap_InventoryNet_C1559D6117E060829B1385B8719ECC16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_C1559D6117E060829B1385B8719ECC16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_C1559D6117E060829B1385B8719ECC16" xlink:to="lab_us-gaap_InventoryNet_C1559D6117E060829B1385B8719ECC16" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_69735D08AA3CD27FD7D185B8719E97AB_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_69735D08AA3CD27FD7D185B8719E97AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_69735D08AA3CD27FD7D185B8719E97AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_69735D08AA3CD27FD7D185B8719E97AB" xlink:to="lab_us-gaap_OtherAssetsCurrent_69735D08AA3CD27FD7D185B8719E97AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_80F73B9E70F1E8F3305A85B8719E6B59_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_80F73B9E70F1E8F3305A85B8719E6B59" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_80F73B9E70F1E8F3305A85B8719E6B59_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_80F73B9E70F1E8F3305A85B8719E6B59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_80F73B9E70F1E8F3305A85B8719E6B59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_80F73B9E70F1E8F3305A85B8719E6B59" xlink:to="lab_us-gaap_AssetsCurrent_80F73B9E70F1E8F3305A85B8719E6B59" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_301FE99281AE4C9AC34285B8719E1B22_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_301FE99281AE4C9AC34285B8719E1B22" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_301FE99281AE4C9AC34285B8719E1B22_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_301FE99281AE4C9AC34285B8719E1B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_301FE99281AE4C9AC34285B8719E1B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_301FE99281AE4C9AC34285B8719E1B22" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_301FE99281AE4C9AC34285B8719E1B22" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_50BACAC6D9ADECF48D0985B8719E5644_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_50BACAC6D9ADECF48D0985B8719E5644" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_50BACAC6D9ADECF48D0985B8719E5644" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_50BACAC6D9ADECF48D0985B8719E5644" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_50BACAC6D9ADECF48D0985B8719E5644" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_05BD979DF61DDB2B67A285B8719EA023_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_05BD979DF61DDB2B67A285B8719EA023" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_05BD979DF61DDB2B67A285B8719EA023" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_05BD979DF61DDB2B67A285B8719EA023" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_05BD979DF61DDB2B67A285B8719EA023" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_10C95445B194BB3F84E185B8719EEFED_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_10C95445B194BB3F84E185B8719EEFED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_10C95445B194BB3F84E185B8719EEFED_label_en-US" xlink:label="lab_us-gaap_Goodwill_10C95445B194BB3F84E185B8719EEFED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_10C95445B194BB3F84E185B8719EEFED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_10C95445B194BB3F84E185B8719EEFED" xlink:to="lab_us-gaap_Goodwill_10C95445B194BB3F84E185B8719EEFED" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4A06D019B7873A61D76C85B8719E41EA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4A06D019B7873A61D76C85B8719E41EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4A06D019B7873A61D76C85B8719E41EA_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4A06D019B7873A61D76C85B8719E41EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4A06D019B7873A61D76C85B8719E41EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4A06D019B7873A61D76C85B8719E41EA" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4A06D019B7873A61D76C85B8719E41EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_17EA163A255A8F73823785B871A6844D_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_17EA163A255A8F73823785B871A6844D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_17EA163A255A8F73823785B871A6844D_label_en-US" xlink:label="lab_us-gaap_Assets_17EA163A255A8F73823785B871A6844D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17EA163A255A8F73823785B871A6844D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_17EA163A255A8F73823785B871A6844D" xlink:to="lab_us-gaap_Assets_17EA163A255A8F73823785B871A6844D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_CF6A9252D22E6355E33D85B871A6E685_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_CF6A9252D22E6355E33D85B871A6E685" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_CF6A9252D22E6355E33D85B871A6E685" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_CF6A9252D22E6355E33D85B871A6E685" xlink:to="lab_us-gaap_DebtCurrent_CF6A9252D22E6355E33D85B871A6E685" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_4447D3E6A0BE826B43F585B871A635B8_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_4447D3E6A0BE826B43F585B871A635B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_4447D3E6A0BE826B43F585B871A635B8_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_4447D3E6A0BE826B43F585B871A635B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_4447D3E6A0BE826B43F585B871A635B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_4447D3E6A0BE826B43F585B871A635B8" xlink:to="lab_us-gaap_TaxesPayableCurrent_4447D3E6A0BE826B43F585B871A635B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_23A988956D26C40EBE0485B871A6ADAB_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_23A988956D26C40EBE0485B871A6ADAB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_23A988956D26C40EBE0485B871A6ADAB_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_23A988956D26C40EBE0485B871A6ADAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_23A988956D26C40EBE0485B871A6ADAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_23A988956D26C40EBE0485B871A6ADAB" xlink:to="lab_us-gaap_AccountsPayableCurrent_23A988956D26C40EBE0485B871A6ADAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_F37B4CAF6F86B9E065A885B871A63977_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_F37B4CAF6F86B9E065A885B871A63977" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_F37B4CAF6F86B9E065A885B871A63977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_F37B4CAF6F86B9E065A885B871A63977" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_F37B4CAF6F86B9E065A885B871A63977" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_A5FE961ABB0EDC706EA085B871A64B98_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A5FE961ABB0EDC706EA085B871A64B98" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_A5FE961ABB0EDC706EA085B871A64B98_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_A5FE961ABB0EDC706EA085B871A64B98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A5FE961ABB0EDC706EA085B871A64B98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_A5FE961ABB0EDC706EA085B871A64B98" xlink:to="lab_us-gaap_LiabilitiesCurrent_A5FE961ABB0EDC706EA085B871A64B98" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_CA1F94A59EA24250B63B85B871A69690_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_CA1F94A59EA24250B63B85B871A69690" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_CA1F94A59EA24250B63B85B871A69690" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_CA1F94A59EA24250B63B85B871A69690" xlink:to="lab_us-gaap_LongTermDebt_CA1F94A59EA24250B63B85B871A69690" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_F70FC10CC564322C720085B871A648FE_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_F70FC10CC564322C720085B871A648FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_F70FC10CC564322C720085B871A648FE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_F70FC10CC564322C720085B871A648FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_F70FC10CC564322C720085B871A648FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_F70FC10CC564322C720085B871A648FE" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNoncurrent_F70FC10CC564322C720085B871A648FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_D0C18236C34229911D8985B871A844DB_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_D0C18236C34229911D8985B871A844DB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_D0C18236C34229911D8985B871A844DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_D0C18236C34229911D8985B871A844DB" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_D0C18236C34229911D8985B871A844DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_9337F834DE1B4C3F40FD85B871A8ED88_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_9337F834DE1B4C3F40FD85B871A8ED88" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_9337F834DE1B4C3F40FD85B871A8ED88_label_en-US" xlink:label="lab_us-gaap_Liabilities_9337F834DE1B4C3F40FD85B871A8ED88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_9337F834DE1B4C3F40FD85B871A8ED88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_9337F834DE1B4C3F40FD85B871A8ED88" xlink:to="lab_us-gaap_Liabilities_9337F834DE1B4C3F40FD85B871A8ED88" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5C17CE38FDC47D64E3F485B871A8E1C8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_5C17CE38FDC47D64E3F485B871A8E1C8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5C17CE38FDC47D64E3F485B871A8E1C8_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_5C17CE38FDC47D64E3F485B871A8E1C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5C17CE38FDC47D64E3F485B871A8E1C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_5C17CE38FDC47D64E3F485B871A8E1C8" xlink:to="lab_us-gaap_CommitmentsAndContingencies_5C17CE38FDC47D64E3F485B871A8E1C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:to="lab_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_B5263DC8C14AF0B4939185B871A8ECE1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_B5263DC8C14AF0B4939185B871A8ECE1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_B5263DC8C14AF0B4939185B871A8ECE1_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_B5263DC8C14AF0B4939185B871A8ECE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_B5263DC8C14AF0B4939185B871A8ECE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_B5263DC8C14AF0B4939185B871A8ECE1" xlink:to="lab_us-gaap_PreferredStockValue_B5263DC8C14AF0B4939185B871A8ECE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_332377C364D968593F1F85B871A8FFE8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_332377C364D968593F1F85B871A8FFE8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_332377C364D968593F1F85B871A8FFE8_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_332377C364D968593F1F85B871A8FFE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_332377C364D968593F1F85B871A8FFE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_332377C364D968593F1F85B871A8FFE8" xlink:to="lab_us-gaap_CommonStockValue_332377C364D968593F1F85B871A8FFE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_CF4A3E380597F40AF99D85B871A8BCE3_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_CF4A3E380597F40AF99D85B871A8BCE3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_CF4A3E380597F40AF99D85B871A8BCE3_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_CF4A3E380597F40AF99D85B871A8BCE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_CF4A3E380597F40AF99D85B871A8BCE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_CF4A3E380597F40AF99D85B871A8BCE3" xlink:to="lab_us-gaap_AdditionalPaidInCapital_CF4A3E380597F40AF99D85B871A8BCE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_693095AE9E456B1B8ED585B871A83A00_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_693095AE9E456B1B8ED585B871A83A00" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_693095AE9E456B1B8ED585B871A83A00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_693095AE9E456B1B8ED585B871A83A00" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_693095AE9E456B1B8ED585B871A83A00" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_14BC1980492C590C81F485B871A8A867_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_14BC1980492C590C81F485B871A8A867" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_14BC1980492C590C81F485B871A8A867_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_14BC1980492C590C81F485B871A8A867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14BC1980492C590C81F485B871A8A867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14BC1980492C590C81F485B871A8A867" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_14BC1980492C590C81F485B871A8A867" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_6A9DBFB964B6120D072385B871A89114_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_6A9DBFB964B6120D072385B871A89114" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_6A9DBFB964B6120D072385B871A89114_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_6A9DBFB964B6120D072385B871A89114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_6A9DBFB964B6120D072385B871A89114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_6A9DBFB964B6120D072385B871A89114" xlink:to="lab_us-gaap_TreasuryStockValue_6A9DBFB964B6120D072385B871A89114" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_710ECA4D8649B5AE58D685B871A86177_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_710ECA4D8649B5AE58D685B871A86177" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_710ECA4D8649B5AE58D685B871A86177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_710ECA4D8649B5AE58D685B871A86177" xlink:to="lab_us-gaap_StockholdersEquity_710ECA4D8649B5AE58D685B871A86177" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_ACB85E74A5F3126A801385B871AB2793_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_ACB85E74A5F3126A801385B871AB2793" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_ACB85E74A5F3126A801385B871AB2793" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_ACB85E74A5F3126A801385B871AB2793" xlink:to="lab_us-gaap_MinorityInterest_ACB85E74A5F3126A801385B871AB2793" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85C699AAB468C381704D85B871ABC616_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85C699AAB468C381704D85B871ABC616" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85C699AAB468C381704D85B871ABC616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85C699AAB468C381704D85B871ABC616" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85C699AAB468C381704D85B871ABC616" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_12352826852DB746A01285B871ABC0C5_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_12352826852DB746A01285B871ABC0C5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_12352826852DB746A01285B871ABC0C5_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_12352826852DB746A01285B871ABC0C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_12352826852DB746A01285B871ABC0C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_12352826852DB746A01285B871ABC0C5" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_12352826852DB746A01285B871ABC0C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B2EE7142C7824563345D168A367D23E8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B2EE7142C7824563345D168A367D23E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B2EE7142C7824563345D168A367D23E8_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B2EE7142C7824563345D168A367D23E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B2EE7142C7824563345D168A367D23E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B2EE7142C7824563345D168A367D23E8" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B2EE7142C7824563345D168A367D23E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_DA258196DB14F3E9A355168A367D1580_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_DA258196DB14F3E9A355168A367D1580" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_DA258196DB14F3E9A355168A367D1580_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_DA258196DB14F3E9A355168A367D1580" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_DA258196DB14F3E9A355168A367D1580" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_DA258196DB14F3E9A355168A367D1580" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_DA258196DB14F3E9A355168A367D1580" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9FF7B0AEA1C7883D960E168A367DA55E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9FF7B0AEA1C7883D960E168A367DA55E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9FF7B0AEA1C7883D960E168A367DA55E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9FF7B0AEA1C7883D960E168A367DA55E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9FF7B0AEA1C7883D960E168A367DA55E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9FF7B0AEA1C7883D960E168A367DA55E" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9FF7B0AEA1C7883D960E168A367DA55E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_D596317582270020C507168A367D300E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_D596317582270020C507168A367D300E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_D596317582270020C507168A367D300E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_D596317582270020C507168A367D300E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_D596317582270020C507168A367D300E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_D596317582270020C507168A367D300E" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_D596317582270020C507168A367D300E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8905EA63270AD77A9C5A168A367D43C5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8905EA63270AD77A9C5A168A367D43C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8905EA63270AD77A9C5A168A367D43C5_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8905EA63270AD77A9C5A168A367D43C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8905EA63270AD77A9C5A168A367D43C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8905EA63270AD77A9C5A168A367D43C5" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8905EA63270AD77A9C5A168A367D43C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_20FB192446B0BCEB462B168A367D9078_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_20FB192446B0BCEB462B168A367D9078" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 and thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_20FB192446B0BCEB462B168A367D9078_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_20FB192446B0BCEB462B168A367D9078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_20FB192446B0BCEB462B168A367D9078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_20FB192446B0BCEB462B168A367D9078" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_20FB192446B0BCEB462B168A367D9078" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_CDEC64D8FB465791BDDF168A367DBC8A_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_CDEC64D8FB465791BDDF168A367DBC8A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_CDEC64D8FB465791BDDF168A367DBC8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_CDEC64D8FB465791BDDF168A367DBC8A" xlink:to="lab_us-gaap_LongTermNotesPayable_CDEC64D8FB465791BDDF168A367DBC8A" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65_terseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance units</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65" xlink:to="lab_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65" xlink:type="arc" />
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC_verboseLabel_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash settled performance shares</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC_label_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Settled Performance Shares [Abstract]</link:label>
    <link:label id="lab_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC_documentation_en-US" xlink:label="lab_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash settled performance shares.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:to="lab_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_62714394FF4E5981BC90FBB833860D48_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_62714394FF4E5981BC90FBB833860D48" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_62714394FF4E5981BC90FBB833860D48_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_62714394FF4E5981BC90FBB833860D48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_62714394FF4E5981BC90FBB833860D48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_62714394FF4E5981BC90FBB833860D48" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_62714394FF4E5981BC90FBB833860D48" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_08626C7701C6121DCCA5FBB83386F2E9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_08626C7701C6121DCCA5FBB83386F2E9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_08626C7701C6121DCCA5FBB83386F2E9_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_08626C7701C6121DCCA5FBB83386F2E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_08626C7701C6121DCCA5FBB83386F2E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_08626C7701C6121DCCA5FBB83386F2E9" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_08626C7701C6121DCCA5FBB83386F2E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_92029F92BBE96506EF81FBB83386B179_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_92029F92BBE96506EF81FBB83386B179" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_92029F92BBE96506EF81FBB83386B179_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_92029F92BBE96506EF81FBB83386B179" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_92029F92BBE96506EF81FBB83386B179" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_92029F92BBE96506EF81FBB83386B179" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_92029F92BBE96506EF81FBB83386B179" xlink:type="arc" />
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_70E3CF6AC33E317CE954FBB833E4929B_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_70E3CF6AC33E317CE954FBB833E4929B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_70E3CF6AC33E317CE954FBB833E4929B_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_70E3CF6AC33E317CE954FBB833E4929B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_70E3CF6AC33E317CE954FBB833E4929B_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_70E3CF6AC33E317CE954FBB833E4929B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_70E3CF6AC33E317CE954FBB833E4929B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_70E3CF6AC33E317CE954FBB833E4929B" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_70E3CF6AC33E317CE954FBB833E4929B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5EBBAB4CDF3BE2ABEB31FBB833E44DB9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5EBBAB4CDF3BE2ABEB31FBB833E44DB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5EBBAB4CDF3BE2ABEB31FBB833E44DB9_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5EBBAB4CDF3BE2ABEB31FBB833E44DB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5EBBAB4CDF3BE2ABEB31FBB833E44DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5EBBAB4CDF3BE2ABEB31FBB833E44DB9" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5EBBAB4CDF3BE2ABEB31FBB833E44DB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_EBD2D7548D3AD85135D9FBB833E47507_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_EBD2D7548D3AD85135D9FBB833E47507" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_EBD2D7548D3AD85135D9FBB833E47507_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_EBD2D7548D3AD85135D9FBB833E47507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_EBD2D7548D3AD85135D9FBB833E47507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_EBD2D7548D3AD85135D9FBB833E47507" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_EBD2D7548D3AD85135D9FBB833E47507" xlink:type="arc" />
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A_verboseLabel_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under non-cancelable leases</link:label>
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A_label_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Rental Commitments Under Noncancellable Leases [Abstract]</link:label>
    <link:label id="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A_documentation_en-US" xlink:label="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum rental commitments under noncancellable leases.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" xlink:label="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="lab_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4FC8BB95EAAEFEADB6CBC42825C3C895_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4FC8BB95EAAEFEADB6CBC42825C3C895" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4FC8BB95EAAEFEADB6CBC42825C3C895_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4FC8BB95EAAEFEADB6CBC42825C3C895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4FC8BB95EAAEFEADB6CBC42825C3C895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4FC8BB95EAAEFEADB6CBC42825C3C895" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4FC8BB95EAAEFEADB6CBC42825C3C895" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_B2B1FE7F03422269A50CC42825C3DBF8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_B2B1FE7F03422269A50CC42825C3DBF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_B2B1FE7F03422269A50CC42825C3DBF8_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_B2B1FE7F03422269A50CC42825C3DBF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_B2B1FE7F03422269A50CC42825C3DBF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_B2B1FE7F03422269A50CC42825C3DBF8" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_B2B1FE7F03422269A50CC42825C3DBF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6C6224B53B90AADDCE58C42825C3EF07_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6C6224B53B90AADDCE58C42825C3EF07" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6C6224B53B90AADDCE58C42825C3EF07_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6C6224B53B90AADDCE58C42825C3EF07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6C6224B53B90AADDCE58C42825C3EF07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6C6224B53B90AADDCE58C42825C3EF07" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6C6224B53B90AADDCE58C42825C3EF07" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_28CCA43574DC41FD4618C42825C3D566_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_28CCA43574DC41FD4618C42825C3D566" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_28CCA43574DC41FD4618C42825C3D566_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_28CCA43574DC41FD4618C42825C3D566" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_28CCA43574DC41FD4618C42825C3D566" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_28CCA43574DC41FD4618C42825C3D566" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_28CCA43574DC41FD4618C42825C3D566" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635A38C5BC9A4607E336C42825C45C55_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635A38C5BC9A4607E336C42825C45C55" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, 2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635A38C5BC9A4607E336C42825C45C55_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635A38C5BC9A4607E336C42825C45C55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635A38C5BC9A4607E336C42825C45C55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635A38C5BC9A4607E336C42825C45C55" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635A38C5BC9A4607E336C42825C45C55" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_96A8A8741AE022A9BD5DC42825C4355D_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_96A8A8741AE022A9BD5DC42825C4355D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_96A8A8741AE022A9BD5DC42825C4355D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_96A8A8741AE022A9BD5DC42825C4355D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_96A8A8741AE022A9BD5DC42825C4355D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_96A8A8741AE022A9BD5DC42825C4355D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_96A8A8741AE022A9BD5DC42825C4355D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C90063C597005A194022C42825C4D9F1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C90063C597005A194022C42825C4D9F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum lease payments, Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C90063C597005A194022C42825C4D9F1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C90063C597005A194022C42825C4D9F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C90063C597005A194022C42825C4D9F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C90063C597005A194022C42825C4D9F1" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C90063C597005A194022C42825C4D9F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1A79DA138BB44D547713C42825C4F2F7_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1A79DA138BB44D547713C42825C4F2F7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2019</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1A79DA138BB44D547713C42825C4F2F7_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1A79DA138BB44D547713C42825C4F2F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1A79DA138BB44D547713C42825C4F2F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1A79DA138BB44D547713C42825C4F2F7" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1A79DA138BB44D547713C42825C4F2F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_71902520E80C0F6DEE22C42825C4DAF5_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_71902520E80C0F6DEE22C42825C4DAF5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2020</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_71902520E80C0F6DEE22C42825C4DAF5_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_71902520E80C0F6DEE22C42825C4DAF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_71902520E80C0F6DEE22C42825C4DAF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_71902520E80C0F6DEE22C42825C4DAF5" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_71902520E80C0F6DEE22C42825C4DAF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_BB7DB49DF6DFEA57090BC42825C421FA_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_BB7DB49DF6DFEA57090BC42825C421FA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2021</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_BB7DB49DF6DFEA57090BC42825C421FA_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_BB7DB49DF6DFEA57090BC42825C421FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_BB7DB49DF6DFEA57090BC42825C421FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_BB7DB49DF6DFEA57090BC42825C421FA" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_BB7DB49DF6DFEA57090BC42825C421FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_1F44ECE5251FF3D3C220C42825C4B0CB_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_1F44ECE5251FF3D3C220C42825C4B0CB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2022</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_1F44ECE5251FF3D3C220C42825C4B0CB_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_1F44ECE5251FF3D3C220C42825C4B0CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_1F44ECE5251FF3D3C220C42825C4B0CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_1F44ECE5251FF3D3C220C42825C4B0CB" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_1F44ECE5251FF3D3C220C42825C4B0CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_A2F7DD48073346C37CA3C42825C52CA8_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_A2F7DD48073346C37CA3C42825C52CA8" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, 2023</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_A2F7DD48073346C37CA3C42825C52CA8_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_A2F7DD48073346C37CA3C42825C52CA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, within Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_A2F7DD48073346C37CA3C42825C52CA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_A2F7DD48073346C37CA3C42825C52CA8" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_A2F7DD48073346C37CA3C42825C52CA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_1BE62824A77D79A2C1E7C42825C5BE1F_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_1BE62824A77D79A2C1E7C42825C5BE1F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, Thereafter</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_1BE62824A77D79A2C1E7C42825C5BE1F_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_1BE62824A77D79A2C1E7C42825C5BE1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions, Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_1BE62824A77D79A2C1E7C42825C5BE1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_1BE62824A77D79A2C1E7C42825C5BE1F" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_1BE62824A77D79A2C1E7C42825C5BE1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_99B28B24E8E2B2ED0F44C42825C57EED_negatedLabel_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_99B28B24E8E2B2ED0F44C42825C57EED" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: income from subleases, Total</link:label>
    <link:label id="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_99B28B24E8E2B2ED0F44C42825C57EED_label_en-US" xlink:label="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_99B28B24E8E2B2ED0F44C42825C57EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Minimum Sublease Rentals, Sale Leaseback Transactions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_99B28B24E8E2B2ED0F44C42825C57EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_99B28B24E8E2B2ED0F44C42825C57EED" xlink:to="lab_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_99B28B24E8E2B2ED0F44C42825C57EED" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_034BCA8A9FCCEE1771FCC42825C56082_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_034BCA8A9FCCEE1771FCC42825C56082" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2019</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_034BCA8A9FCCEE1771FCC42825C56082_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_034BCA8A9FCCEE1771FCC42825C56082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In One Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInOneYear_034BCA8A9FCCEE1771FCC42825C56082_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInOneYear_034BCA8A9FCCEE1771FCC42825C56082" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in one year.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_034BCA8A9FCCEE1771FCC42825C56082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInOneYear_034BCA8A9FCCEE1771FCC42825C56082" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInOneYear_034BCA8A9FCCEE1771FCC42825C56082" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_2B3567D0AE9AB887D346C42825C5BE3A_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_2B3567D0AE9AB887D346C42825C5BE3A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2020</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_2B3567D0AE9AB887D346C42825C5BE3A_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_2B3567D0AE9AB887D346C42825C5BE3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Two Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_2B3567D0AE9AB887D346C42825C5BE3A_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_2B3567D0AE9AB887D346C42825C5BE3A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in two year.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_2B3567D0AE9AB887D346C42825C5BE3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_2B3567D0AE9AB887D346C42825C5BE3A" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInTwoYear_2B3567D0AE9AB887D346C42825C5BE3A" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_C789CE76AA66A6FC89EBC42825C6D77A_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_C789CE76AA66A6FC89EBC42825C6D77A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2021</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_C789CE76AA66A6FC89EBC42825C6D77A_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_C789CE76AA66A6FC89EBC42825C6D77A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Three Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_C789CE76AA66A6FC89EBC42825C6D77A_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_C789CE76AA66A6FC89EBC42825C6D77A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in three year.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_C789CE76AA66A6FC89EBC42825C6D77A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_C789CE76AA66A6FC89EBC42825C6D77A" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInThreeYear_C789CE76AA66A6FC89EBC42825C6D77A" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_24846AE455F8158ED13EC42825C6502F_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_24846AE455F8158ED13EC42825C6502F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2022</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_24846AE455F8158ED13EC42825C6502F_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_24846AE455F8158ED13EC42825C6502F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Four Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFourYear_24846AE455F8158ED13EC42825C6502F_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFourYear_24846AE455F8158ED13EC42825C6502F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in four year.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_24846AE455F8158ED13EC42825C6502F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFourYear_24846AE455F8158ED13EC42825C6502F" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFourYear_24846AE455F8158ED13EC42825C6502F" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_D3D10906BD2E17B7DE82C42825C6DDAC_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_D3D10906BD2E17B7DE82C42825C6DDAC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, 2023</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_D3D10906BD2E17B7DE82C42825C6DDAC_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_D3D10906BD2E17B7DE82C42825C6DDAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments With In Five Year</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_D3D10906BD2E17B7DE82C42825C6DDAC_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_D3D10906BD2E17B7DE82C42825C6DDAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments with in five year.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_D3D10906BD2E17B7DE82C42825C6DDAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_D3D10906BD2E17B7DE82C42825C6DDAC" xlink:to="lab_biib_NetMinimumLeasePaymentsWithInFiveYear_D3D10906BD2E17B7DE82C42825C6DDAC" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_7571174975CC00D087D7C42825C68195_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_7571174975CC00D087D7C42825C68195" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_7571174975CC00D087D7C42825C68195_label_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_7571174975CC00D087D7C42825C68195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments Thereafter</link:label>
    <link:label id="lab_biib_NetMinimumLeasePaymentsThereafter_7571174975CC00D087D7C42825C68195_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePaymentsThereafter_7571174975CC00D087D7C42825C68195" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments thereafter.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_7571174975CC00D087D7C42825C68195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePaymentsThereafter_7571174975CC00D087D7C42825C68195" xlink:to="lab_biib_NetMinimumLeasePaymentsThereafter_7571174975CC00D087D7C42825C68195" xlink:type="arc" />
    <link:label id="lab_biib_NetMinimumLeasePayments_062FE3E00AACEEE59737C42825C6F27B_totalLabel_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_062FE3E00AACEEE59737C42825C6F27B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net minimum lease payments, Total</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_062FE3E00AACEEE59737C42825C6F27B_label_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_062FE3E00AACEEE59737C42825C6F27B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Minimum Lease Payments</link:label>
    <link:label id="lab_biib_NetMinimumLeasePayments_062FE3E00AACEEE59737C42825C6F27B_documentation_en-US" xlink:label="lab_biib_NetMinimumLeasePayments_062FE3E00AACEEE59737C42825C6F27B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net minimum lease payments total.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_062FE3E00AACEEE59737C42825C6F27B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetMinimumLeasePayments_062FE3E00AACEEE59737C42825C6F27B" xlink:to="lab_biib_NetMinimumLeasePayments_062FE3E00AACEEE59737C42825C6F27B" xlink:type="arc" />
    <link:label id="lab_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9_verboseLabel_en-US" xlink:label="lab_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Directors Plan</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9_label_en-US" xlink:label="lab_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Directors Plan [Member]</link:label>
    <link:label id="lab_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9_documentation_en-US" xlink:label="lab_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Directors plan.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9" xlink:to="lab_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9" xlink:type="arc" />
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4_terseLabel_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan</link:label>
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4_label_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan [Member]</link:label>
    <link:label id="lab_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4_documentation_en-US" xlink:label="lab_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Omnibus Equity Plan</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4" xlink:to="lab_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:to="lab_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF_terseLabel_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF_label_en-US" xlink:label="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF" xlink:to="lab_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DirectorMember_8955E2C330B4A8B3E387871CADD3A9B2_terseLabel_en-US" xlink:label="lab_us-gaap_DirectorMember_8955E2C330B4A8B3E387871CADD3A9B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Director</link:label>
    <link:label id="lab_us-gaap_DirectorMember_8955E2C330B4A8B3E387871CADD3A9B2_label_en-US" xlink:label="lab_us-gaap_DirectorMember_8955E2C330B4A8B3E387871CADD3A9B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_8955E2C330B4A8B3E387871CADD3A9B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DirectorMember_8955E2C330B4A8B3E387871CADD3A9B2" xlink:to="lab_us-gaap_DirectorMember_8955E2C330B4A8B3E387871CADD3A9B2" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F_verboseLabel_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total number of shares of common stock for issuance</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F_label_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Of Common Stock For Issuance</link:label>
    <link:label id="lab_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F_documentation_en-US" xlink:label="lab_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total number of shares of common stock for issuance.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F" xlink:to="lab_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F" xlink:type="arc" />
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8_verboseLabel_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8_label_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ratio Of Number Of Shares Reserved Under Plan</link:label>
    <link:label id="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8_documentation_en-US" xlink:label="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ratio of total number of shares reserved under the plan.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8" xlink:to="lab_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F51495D85928AA2CE870871CADD3AB48_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F51495D85928AA2CE870871CADD3AB48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omnibus Plan number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F51495D85928AA2CE870871CADD3AB48_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F51495D85928AA2CE870871CADD3AB48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F51495D85928AA2CE870871CADD3AB48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F51495D85928AA2CE870871CADD3AB48" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F51495D85928AA2CE870871CADD3AB48" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08_verboseLabel_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of equal annual increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08_label_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Equal Annual Increments</link:label>
    <link:label id="lab_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08_documentation_en-US" xlink:label="lab_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of equal annual increments.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08" xlink:to="lab_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08" xlink:type="arc" />
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40_verboseLabel_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40_label_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40_documentation_en-US" xlink:label="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40" xlink:to="lab_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40" xlink:type="arc" />
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B_verboseLabel_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B_label_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Target Number Of Market Stock Units Granted Based On Stock Performance In Percent</link:label>
    <link:label id="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B_documentation_en-US" xlink:label="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum target number of market stock units granted based on stock performance in percent.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B" xlink:to="lab_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B74D57A2F8FD59D32073871CADD34D26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B74D57A2F8FD59D32073871CADD34D26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B74D57A2F8FD59D32073871CADD34D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B74D57A2F8FD59D32073871CADD34D26" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B74D57A2F8FD59D32073871CADD34D26" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0_verboseLabel_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0_label_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Days For Calculation Of Average Closing Stock Price</link:label>
    <link:label id="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0_documentation_en-US" xlink:label="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of days for calculation of average closing stock price.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0" xlink:to="lab_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9AAE1A2045B79846227C871CADE348AB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9AAE1A2045B79846227C871CADE348AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of vested awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9AAE1A2045B79846227C871CADE348AB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9AAE1A2045B79846227C871CADE348AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9AAE1A2045B79846227C871CADE348AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9AAE1A2045B79846227C871CADE348AB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9AAE1A2045B79846227C871CADE348AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_4E6300CD9BE6A2D80703871CADE32BEA_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_4E6300CD9BE6A2D80703871CADE32BEA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash in settlement of CSPS awards upon vesting</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_4E6300CD9BE6A2D80703871CADE32BEA_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_4E6300CD9BE6A2D80703871CADE32BEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Cash Flow Effect, Cash Used to Settle Awards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_4E6300CD9BE6A2D80703871CADE32BEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_4E6300CD9BE6A2D80703871CADE32BEA" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_4E6300CD9BE6A2D80703871CADE32BEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_321DA88CB989043B32FC871CADE32054_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_321DA88CB989043B32FC871CADE32054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_321DA88CB989043B32FC871CADE32054_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_321DA88CB989043B32FC871CADE32054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_321DA88CB989043B32FC871CADE32054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_321DA88CB989043B32FC871CADE32054" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_321DA88CB989043B32FC871CADE32054" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611_terseLabel_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payments (Textual)</link:label>
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611_label_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payments (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611_documentation_en-US" xlink:label="lab_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Payments.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareBasedPaymentsTextualAbstract" xlink:label="loc_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:to="lab_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DABF5A02E33FF49A655E871CADE394F3_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DABF5A02E33FF49A655E871CADE394F3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to unvested share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DABF5A02E33FF49A655E871CADE394F3_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DABF5A02E33FF49A655E871CADE394F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DABF5A02E33FF49A655E871CADE394F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DABF5A02E33FF49A655E871CADE394F3" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DABF5A02E33FF49A655E871CADE394F3" xlink:type="arc" />
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_940629F42365DF14751A871CADE38E42_verboseLabel_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_940629F42365DF14751A871CADE38E42" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize the cost of unvested awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_940629F42365DF14751A871CADE38E42_label_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_940629F42365DF14751A871CADE38E42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Period To Recognize Cost Of Nonvested Awards</link:label>
    <link:label id="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_940629F42365DF14751A871CADE38E42_documentation_en-US" xlink:label="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_940629F42365DF14751A871CADE38E42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted-average period to recognize the cost of nonvested awards.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_940629F42365DF14751A871CADE38E42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_940629F42365DF14751A871CADE38E42" xlink:to="lab_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_940629F42365DF14751A871CADE38E42" xlink:type="arc" />
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_2F1C3DC50E143216F011871CADE380D7_verboseLabel_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_2F1C3DC50E143216F011871CADE380D7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_2F1C3DC50E143216F011871CADE380D7_label_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_2F1C3DC50E143216F011871CADE380D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Share Based Compensation Plans Pursuant To Which Awards Are Currently Being Made</link:label>
    <link:label id="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_2F1C3DC50E143216F011871CADE380D7_documentation_en-US" xlink:label="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_2F1C3DC50E143216F011871CADE380D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of share-based compensation plans pursuant to which awards are currently being made.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_2F1C3DC50E143216F011871CADE380D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_2F1C3DC50E143216F011871CADE380D7" xlink:to="lab_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_2F1C3DC50E143216F011871CADE380D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_CC8291DDE0BBFF6759BC871CADE346B8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_CC8291DDE0BBFF6759BC871CADE346B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares granted under stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_CC8291DDE0BBFF6759BC871CADE346B8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_CC8291DDE0BBFF6759BC871CADE346B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_CC8291DDE0BBFF6759BC871CADE346B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_CC8291DDE0BBFF6759BC871CADE346B8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_CC8291DDE0BBFF6759BC871CADE346B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35B98039714E077632E1871CADE32C17_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35B98039714E077632E1871CADE32C17" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35B98039714E077632E1871CADE32C17_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35B98039714E077632E1871CADE32C17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35B98039714E077632E1871CADE32C17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35B98039714E077632E1871CADE32C17" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35B98039714E077632E1871CADE32C17" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CDD6985C51CE1AD9E5C8871CADE37E91_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CDD6985C51CE1AD9E5C8871CADE37E91" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic values of options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CDD6985C51CE1AD9E5C8871CADE37E91_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CDD6985C51CE1AD9E5C8871CADE37E91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CDD6985C51CE1AD9E5C8871CADE37E91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CDD6985C51CE1AD9E5C8871CADE37E91" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CDD6985C51CE1AD9E5C8871CADE37E91" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE99A64B885B12EAFBBC871CADE30638_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE99A64B885B12EAFBBC871CADE30638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term for options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE99A64B885B12EAFBBC871CADE30638_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE99A64B885B12EAFBBC871CADE30638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE99A64B885B12EAFBBC871CADE30638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE99A64B885B12EAFBBC871CADE30638" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE99A64B885B12EAFBBC871CADE30638" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_9E8404FF715FA6A72733BEA934A06183_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_9E8404FF715FA6A72733BEA934A06183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_9E8404FF715FA6A72733BEA934A06183_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_9E8404FF715FA6A72733BEA934A06183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9E8404FF715FA6A72733BEA934A06183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9E8404FF715FA6A72733BEA934A06183" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_9E8404FF715FA6A72733BEA934A06183" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9" xlink:to="lab_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_AF12D11D918CBEE3C755BEA934A0EE29_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_AF12D11D918CBEE3C755BEA934A0EE29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedge</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_AF12D11D918CBEE3C755BEA934A0EE29_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_AF12D11D918CBEE3C755BEA934A0EE29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_AF12D11D918CBEE3C755BEA934A0EE29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember_AF12D11D918CBEE3C755BEA934A0EE29" xlink:to="lab_us-gaap_NetInvestmentHedgingMember_AF12D11D918CBEE3C755BEA934A0EE29" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:type="arc" />
    <link:label id="lab_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5_terseLabel_en-US" xlink:label="lab_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedge, Gain (Loss) Recognized in Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5_label_en-US" xlink:label="lab_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedge, Gain (Loss) Recognized in Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5_documentation_en-US" xlink:label="lab_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Investment Hedge, Gain (Loss) Recognized in Accumulated Other Comprehensive Income</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome" xlink:label="loc_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5" xlink:to="lab_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTermOfContract_E661007B628CD0A79E25BEA934A00AE3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_E661007B628CD0A79E25BEA934A00AE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forward contracts duration</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_E661007B628CD0A79E25BEA934A00AE3_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_E661007B628CD0A79E25BEA934A00AE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_E661007B628CD0A79E25BEA934A00AE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract_E661007B628CD0A79E25BEA934A00AE3" xlink:to="lab_us-gaap_DerivativeTermOfContract_E661007B628CD0A79E25BEA934A00AE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_7F26874ECECDAA030A9ABEA934A0A96C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_7F26874ECECDAA030A9ABEA934A0A96C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_7F26874ECECDAA030A9ABEA934A0A96C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_7F26874ECECDAA030A9ABEA934A0A96C" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_7F26874ECECDAA030A9ABEA934A0A96C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B923F97609D2307DC156BEA934A04A25_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B923F97609D2307DC156BEA934A04A25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in operating income for certain effective net investment hedge instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B923F97609D2307DC156BEA934A04A25_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B923F97609D2307DC156BEA934A04A25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B923F97609D2307DC156BEA934A04A25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B923F97609D2307DC156BEA934A04A25" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B923F97609D2307DC156BEA934A04A25" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6C4F32441DCBBD99E9C8BEA934A0D70A_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6C4F32441DCBBD99E9C8BEA934A0D70A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in net income of foreign currency forward contracts due to exclusion from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6C4F32441DCBBD99E9C8BEA934A0D70A_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6C4F32441DCBBD99E9C8BEA934A0D70A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6C4F32441DCBBD99E9C8BEA934A0D70A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6C4F32441DCBBD99E9C8BEA934A0D70A" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6C4F32441DCBBD99E9C8BEA934A0D70A" xlink:type="arc" />
    <link:label id="lab_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12_terseLabel_en-US" xlink:label="lab_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, Before Tax</link:label>
    <link:label id="lab_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12_label_en-US" xlink:label="lab_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, Before Tax</link:label>
    <link:label id="lab_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12_documentation_en-US" xlink:label="lab_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, Before Tax</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax" xlink:label="loc_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12" xlink:to="lab_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:to="lab_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_16B0D4BA70EE71F8B4A982084AE38620_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_16B0D4BA70EE71F8B4A982084AE38620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_16B0D4BA70EE71F8B4A982084AE38620_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_16B0D4BA70EE71F8B4A982084AE38620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_16B0D4BA70EE71F8B4A982084AE38620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_16B0D4BA70EE71F8B4A982084AE38620" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_16B0D4BA70EE71F8B4A982084AE38620" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:to="lab_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_81E7C4F284431DE7BC9082084AE35740_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_81E7C4F284431DE7BC9082084AE35740" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_81E7C4F284431DE7BC9082084AE35740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_81E7C4F284431DE7BC9082084AE35740" xlink:to="lab_us-gaap_Goodwill_81E7C4F284431DE7BC9082084AE35740" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_06C61055D962E96B9A2682084AE38493_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_06C61055D962E96B9A2682084AE38493" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Elimination of goodwill allocated to our hemophilia business</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_06C61055D962E96B9A2682084AE38493" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_06C61055D962E96B9A2682084AE38493" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_06C61055D962E96B9A2682084AE38493" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_A4DAF4BA14BA118D440782084AE3EFE0_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_A4DAF4BA14BA118D440782084AE3EFE0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase to goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_A4DAF4BA14BA118D440782084AE3EFE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_A4DAF4BA14BA118D440782084AE3EFE0" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_A4DAF4BA14BA118D440782084AE3EFE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_DF451E7967D5C513F17D82084AE3B017_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_DF451E7967D5C513F17D82084AE3B017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_DF451E7967D5C513F17D82084AE3B017_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_DF451E7967D5C513F17D82084AE3B017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_DF451E7967D5C513F17D82084AE3B017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_DF451E7967D5C513F17D82084AE3B017" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_DF451E7967D5C513F17D82084AE3B017" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_CBBDBC088D20E0A9292E82084AE3C68B_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_CBBDBC088D20E0A9292E82084AE3C68B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CBBDBC088D20E0A9292E82084AE3C68B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_CBBDBC088D20E0A9292E82084AE3C68B" xlink:to="lab_us-gaap_Goodwill_CBBDBC088D20E0A9292E82084AE3C68B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_036434F436533FA49555FBB832000C03_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_036434F436533FA49555FBB832000C03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_036434F436533FA49555FBB832000C03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_036434F436533FA49555FBB832000C03" xlink:to="lab_us-gaap_SubsequentEventsAbstract_036434F436533FA49555FBB832000C03" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_6B27E598F7FA63141991FBB83200250D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_6B27E598F7FA63141991FBB83200250D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_6B27E598F7FA63141991FBB83200250D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_6B27E598F7FA63141991FBB83200250D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_6B27E598F7FA63141991FBB83200250D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_6B27E598F7FA63141991FBB83200250D" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_6B27E598F7FA63141991FBB83200250D" xlink:type="arc" />
    <link:label id="lab_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5_terseLabel_en-US" xlink:label="lab_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5_label_en-US" xlink:label="lab_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:label id="lab_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5_documentation_en-US" xlink:label="lab_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aducanumab [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5" xlink:to="lab_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5" xlink:type="arc" />
    <link:label id="lab_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aducanumab expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F" xlink:to="lab_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F" xlink:type="arc" />
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_58C6FAB37DD1EC2B9812FBB83460601B_terseLabel_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_58C6FAB37DD1EC2B9812FBB83460601B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment estimated useful lives</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_58C6FAB37DD1EC2B9812FBB83460601B_label_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_58C6FAB37DD1EC2B9812FBB83460601B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment Useful Lives [Table Text Block]</link:label>
    <link:label id="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_58C6FAB37DD1EC2B9812FBB83460601B_documentation_en-US" xlink:label="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_58C6FAB37DD1EC2B9812FBB83460601B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of property plant and equipment useful lives.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_58C6FAB37DD1EC2B9812FBB83460601B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_58C6FAB37DD1EC2B9812FBB83460601B" xlink:to="lab_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_58C6FAB37DD1EC2B9812FBB83460601B" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Abstract]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Abstract]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignPlanMember_BCA680E5B7A5875DC7EA85B86951E847_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_BCA680E5B7A5875DC7EA85B86951E847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_BCA680E5B7A5875DC7EA85B86951E847_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_BCA680E5B7A5875DC7EA85B86951E847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_BCA680E5B7A5875DC7EA85B86951E847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember_BCA680E5B7A5875DC7EA85B86951E847" xlink:to="lab_us-gaap_ForeignPlanMember_BCA680E5B7A5875DC7EA85B86951E847" xlink:type="arc" />
    <link:label id="lab_country_CH_2E64B705FB38519EC1D485B8695449F8_terseLabel_en-US" xlink:label="lab_country_CH_2E64B705FB38519EC1D485B8695449F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:label id="lab_country_CH_2E64B705FB38519EC1D485B8695449F8_label_en-US" xlink:label="lab_country_CH_2E64B705FB38519EC1D485B8695449F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CH" xlink:label="loc_country_CH_2E64B705FB38519EC1D485B8695449F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH_2E64B705FB38519EC1D485B8695449F8" xlink:to="lab_country_CH_2E64B705FB38519EC1D485B8695449F8" xlink:type="arc" />
    <link:label id="lab_country_DE_33BAC3AC326344454C8085B86954288C_terseLabel_en-US" xlink:label="lab_country_DE_33BAC3AC326344454C8085B86954288C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:label id="lab_country_DE_33BAC3AC326344454C8085B86954288C_label_en-US" xlink:label="lab_country_DE_33BAC3AC326344454C8085B86954288C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE_33BAC3AC326344454C8085B86954288C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE_33BAC3AC326344454C8085B86954288C" xlink:to="lab_country_DE_33BAC3AC326344454C8085B86954288C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9_verboseLabel_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9_label_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9_documentation_en-US" xlink:label="lab_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee benefit plans.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:to="lab_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of minimum investment return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4_label_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Minimum Investment Return</link:label>
    <link:label id="lab_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4_documentation_en-US" xlink:label="lab_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of minimum investment return.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4" xlink:to="lab_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_EA76DB53F26E71E476F085B869542DEE_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_EA76DB53F26E71E476F085B869542DEE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unfunded net pension</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_EA76DB53F26E71E476F085B869542DEE_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_EA76DB53F26E71E476F085B869542DEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_EA76DB53F26E71E476F085B869542DEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_EA76DB53F26E71E476F085B869542DEE" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_EA76DB53F26E71E476F085B869542DEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_EFDD288999DC9B1A742785B86954014E_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_EFDD288999DC9B1A742785B86954014E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_EFDD288999DC9B1A742785B86954014E_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_EFDD288999DC9B1A742785B86954014E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_EFDD288999DC9B1A742785B86954014E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation_EFDD288999DC9B1A742785B86954014E" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation_EFDD288999DC9B1A742785B86954014E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionExpense_DAF7702E3593DE38B1DB85B86954B01C_terseLabel_en-US" xlink:label="lab_us-gaap_PensionExpense_DAF7702E3593DE38B1DB85B86954B01C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Cost (Reversal of Cost)</link:label>
    <link:label id="lab_us-gaap_PensionExpense_DAF7702E3593DE38B1DB85B86954B01C_label_en-US" xlink:label="lab_us-gaap_PensionExpense_DAF7702E3593DE38B1DB85B86954B01C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Cost (Reversal of Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_DAF7702E3593DE38B1DB85B86954B01C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionExpense_DAF7702E3593DE38B1DB85B86954B01C" xlink:to="lab_us-gaap_PensionExpense_DAF7702E3593DE38B1DB85B86954B01C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9FF8F32787C6A241CA7C85B8695469F7_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9FF8F32787C6A241CA7C85B8695469F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Periodic pension cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9FF8F32787C6A241CA7C85B8695469F7_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9FF8F32787C6A241CA7C85B8695469F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9FF8F32787C6A241CA7C85B8695469F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9FF8F32787C6A241CA7C85B8695469F7" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9FF8F32787C6A241CA7C85B8695469F7" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Abstract]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:to="lab_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_B199240667F4D1164976879B8F3F84F0_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_B199240667F4D1164976879B8F3F84F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Until GAZYVA First Non-CLL FDA Approval</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_B199240667F4D1164976879B8F3F84F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_B199240667F4D1164976879B8F3F84F0" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_B199240667F4D1164976879B8F3F84F0" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After First GA101 Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two [Abstract]</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_7A1B9C5AAC25D86FEEDC879B8F403F01_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_7A1B9C5AAC25D86FEEDC879B8F403F01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Until First GAZYVA Threshold Date</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_7A1B9C5AAC25D86FEEDC879B8F403F01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_7A1B9C5AAC25D86FEEDC879B8F403F01" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_7A1B9C5AAC25D86FEEDC879B8F403F01" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B07388263CAE8B17EA44879B8F403B05_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B07388263CAE8B17EA44879B8F403B05" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After First Threshold Date and until Second Threshold Date</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B07388263CAE8B17EA44879B8F403B05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B07388263CAE8B17EA44879B8F403B05" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B07388263CAE8B17EA44879B8F403B05" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option three.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C_verboseLabel_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C_label_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues From Unconsolidated Joint Business [Abstract]</link:label>
    <link:label id="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C_documentation_en-US" xlink:label="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from unconsolidated joint business.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:to="lab_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_EA0124EEB25A0908A42FFBB83460D7A5_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_EA0124EEB25A0908A42FFBB83460D7A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EA0124EEB25A0908A42FFBB83460D7A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EA0124EEB25A0908A42FFBB83460D7A5" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_EA0124EEB25A0908A42FFBB83460D7A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_36320DA5EB99718A653EFBB8346004DC_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_36320DA5EB99718A653EFBB8346004DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_36320DA5EB99718A653EFBB8346004DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_36320DA5EB99718A653EFBB8346004DC" xlink:to="lab_us-gaap_ParentMember_36320DA5EB99718A653EFBB8346004DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Allocation and Classification in Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_9F0CE78A5E4690F00B3FFBB83460189B_negatedLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_9F0CE78A5E4690F00B3FFBB83460189B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9F0CE78A5E4690F00B3FFBB83460189B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_9F0CE78A5E4690F00B3FFBB83460189B" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_9F0CE78A5E4690F00B3FFBB83460189B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DA374D787DE6DD9F79B3FBB83460B67A_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DA374D787DE6DD9F79B3FBB83460B67A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DA374D787DE6DD9F79B3FBB83460B67A_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DA374D787DE6DD9F79B3FBB83460B67A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DA374D787DE6DD9F79B3FBB83460B67A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DA374D787DE6DD9F79B3FBB83460B67A" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DA374D787DE6DD9F79B3FBB83460B67A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C58F5C0012FD697307C5FBB8346042BA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C58F5C0012FD697307C5FBB8346042BA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C58F5C0012FD697307C5FBB8346042BA_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C58F5C0012FD697307C5FBB8346042BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C58F5C0012FD697307C5FBB8346042BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C58F5C0012FD697307C5FBB8346042BA" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C58F5C0012FD697307C5FBB8346042BA" xlink:type="arc" />
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9352681C369C95CBF747FBB834600CA9_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9352681C369C95CBF747FBB834600CA9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9352681C369C95CBF747FBB834600CA9_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9352681C369C95CBF747FBB834600CA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Tax Benefit from Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9352681C369C95CBF747FBB834600CA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9352681C369C95CBF747FBB834600CA9" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9352681C369C95CBF747FBB834600CA9" xlink:type="arc" />
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_F97BB94DBD137047DC2F8512AB55B434_verboseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_F97BB94DBD137047DC2F8512AB55B434" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_F97BB94DBD137047DC2F8512AB55B434_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_F97BB94DBD137047DC2F8512AB55B434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_F97BB94DBD137047DC2F8512AB55B434_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_F97BB94DBD137047DC2F8512AB55B434" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_F97BB94DBD137047DC2F8512AB55B434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_F97BB94DBD137047DC2F8512AB55B434" xlink:to="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_F97BB94DBD137047DC2F8512AB55B434" xlink:type="arc" />
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_268645DFEEA527D106938512AB55728B_terseLabel_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_268645DFEEA527D106938512AB55728B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pretax profit sharing formula</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_268645DFEEA527D106938512AB55728B_label_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_268645DFEEA527D106938512AB55728B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_PretaxProfitSharingFormulaTableTextBlock_268645DFEEA527D106938512AB55728B_documentation_en-US" xlink:label="lab_biib_PretaxProfitSharingFormulaTableTextBlock_268645DFEEA527D106938512AB55728B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pretax Profit Sharing Formula [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_268645DFEEA527D106938512AB55728B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PretaxProfitSharingFormulaTableTextBlock_268645DFEEA527D106938512AB55728B" xlink:to="lab_biib_PretaxProfitSharingFormulaTableTextBlock_268645DFEEA527D106938512AB55728B" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_BC0E7C2EEC7E11B88F268512AB567824_verboseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_BC0E7C2EEC7E11B88F268512AB567824" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_BC0E7C2EEC7E11B88F268512AB567824_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_BC0E7C2EEC7E11B88F268512AB567824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_BC0E7C2EEC7E11B88F268512AB567824_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_BC0E7C2EEC7E11B88F268512AB567824" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_BC0E7C2EEC7E11B88F268512AB567824" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_BC0E7C2EEC7E11B88F268512AB567824" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_BC0E7C2EEC7E11B88F268512AB567824" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_9990EB1547CFBDA635F48512AB562F11_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_9990EB1547CFBDA635F48512AB562F11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to BAN2401 and Elenbecestat collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_9990EB1547CFBDA635F48512AB562F11_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_9990EB1547CFBDA635F48512AB562F11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_9990EB1547CFBDA635F48512AB562F11_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_9990EB1547CFBDA635F48512AB562F11" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_9990EB1547CFBDA635F48512AB562F11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_9990EB1547CFBDA635F48512AB562F11" xlink:to="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_9990EB1547CFBDA635F48512AB562F11" xlink:type="arc" />
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_629181B2E8276ED4E4AA8512AB55A24E_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_629181B2E8276ED4E4AA8512AB55A24E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to Aducanumab collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_629181B2E8276ED4E4AA8512AB55A24E_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_629181B2E8276ED4E4AA8512AB55A24E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_629181B2E8276ED4E4AA8512AB55A24E_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_629181B2E8276ED4E4AA8512AB55A24E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_629181B2E8276ED4E4AA8512AB55A24E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_629181B2E8276ED4E4AA8512AB55A24E" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_629181B2E8276ED4E4AA8512AB55A24E" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_EE906EC4A88E08A40D628512AB56BCFF_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_EE906EC4A88E08A40D628512AB56BCFF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to Abbvie collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_EE906EC4A88E08A40D628512AB56BCFF_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_EE906EC4A88E08A40D628512AB56BCFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration With Company Seven [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_EE906EC4A88E08A40D628512AB56BCFF_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_EE906EC4A88E08A40D628512AB56BCFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of activity related to collaboration with company seven.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_EE906EC4A88E08A40D628512AB56BCFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_EE906EC4A88E08A40D628512AB56BCFF" xlink:to="lab_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_EE906EC4A88E08A40D628512AB56BCFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022" xlink:type="arc" />
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4" xlink:type="arc" />
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797" xlink:type="arc" />
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_173856A12C214767B3E5FBB8354AE79C_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_173856A12C214767B3E5FBB8354AE79C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_173856A12C214767B3E5FBB8354AE79C_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_173856A12C214767B3E5FBB8354AE79C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_173856A12C214767B3E5FBB8354AE79C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_173856A12C214767B3E5FBB8354AE79C" xlink:to="lab_us-gaap_EquitySecuritiesMember_173856A12C214767B3E5FBB8354AE79C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Debt and Equity Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_BAF7AD63A6A29D4B02B2FBB8354AD81B_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_BAF7AD63A6A29D4B02B2FBB8354AD81B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_BAF7AD63A6A29D4B02B2FBB8354AD81B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_BAF7AD63A6A29D4B02B2FBB8354AD81B" xlink:to="lab_us-gaap_AvailableForSaleSecurities_BAF7AD63A6A29D4B02B2FBB8354AD81B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48E33846BD45237179D8FBB8354A836D_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48E33846BD45237179D8FBB8354A836D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48E33846BD45237179D8FBB8354A836D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48E33846BD45237179D8FBB8354A836D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48E33846BD45237179D8FBB8354A836D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48E33846BD45237179D8FBB8354A836D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48E33846BD45237179D8FBB8354A836D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22DE47C8A8E5383E6FD9FBB8354A73D2_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22DE47C8A8E5383E6FD9FBB8354A73D2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22DE47C8A8E5383E6FD9FBB8354A73D2_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22DE47C8A8E5383E6FD9FBB8354A73D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22DE47C8A8E5383E6FD9FBB8354A73D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22DE47C8A8E5383E6FD9FBB8354A73D2" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22DE47C8A8E5383E6FD9FBB8354A73D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_9CCEBFA467FDA88E1CFFFBB8354A00D7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_9CCEBFA467FDA88E1CFFFBB8354A00D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_9CCEBFA467FDA88E1CFFFBB8354A00D7_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_9CCEBFA467FDA88E1CFFFBB8354A00D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_9CCEBFA467FDA88E1CFFFBB8354A00D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_9CCEBFA467FDA88E1CFFFBB8354A00D7" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_9CCEBFA467FDA88E1CFFFBB8354A00D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_D0B568C81ED431C4EE3BFBB835B77A8B_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_D0B568C81ED431C4EE3BFBB835B77A8B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_D0B568C81ED431C4EE3BFBB835B77A8B_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_D0B568C81ED431C4EE3BFBB835B77A8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_D0B568C81ED431C4EE3BFBB835B77A8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_D0B568C81ED431C4EE3BFBB835B77A8B" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_D0B568C81ED431C4EE3BFBB835B77A8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1B158A5DD1269251BEF4FBB835B7B86E_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1B158A5DD1269251BEF4FBB835B7B86E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1B158A5DD1269251BEF4FBB835B7B86E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1B158A5DD1269251BEF4FBB835B7B86E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1B158A5DD1269251BEF4FBB835B7B86E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1B158A5DD1269251BEF4FBB835B7B86E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1B158A5DD1269251BEF4FBB835B7B86E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6EE1680485B32BAF6579FBB835B7E382_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6EE1680485B32BAF6579FBB835B7E382" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6EE1680485B32BAF6579FBB835B7E382_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6EE1680485B32BAF6579FBB835B7E382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6EE1680485B32BAF6579FBB835B7E382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6EE1680485B32BAF6579FBB835B7E382" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6EE1680485B32BAF6579FBB835B7E382" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_904F45BD0E5F445235E7FBB835B7F824_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_904F45BD0E5F445235E7FBB835B7F824" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after one year through five years, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_904F45BD0E5F445235E7FBB835B7F824_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_904F45BD0E5F445235E7FBB835B7F824" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_904F45BD0E5F445235E7FBB835B7F824" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_904F45BD0E5F445235E7FBB835B7F824" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_904F45BD0E5F445235E7FBB835B7F824" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F35A22F3DC80E2DF977FFBB835B7ADD3_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F35A22F3DC80E2DF977FFBB835B7ADD3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, Estimated Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F35A22F3DC80E2DF977FFBB835B7ADD3_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F35A22F3DC80E2DF977FFBB835B7ADD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F35A22F3DC80E2DF977FFBB835B7ADD3_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F35A22F3DC80E2DF977FFBB835B7ADD3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F35A22F3DC80E2DF977FFBB835B7ADD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F35A22F3DC80E2DF977FFBB835B7ADD3" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F35A22F3DC80E2DF977FFBB835B7ADD3" xlink:type="arc" />
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FE87669F5AB9D9D5A3A2FBB835B7C90A_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FE87669F5AB9D9D5A3A2FBB835B7C90A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Due after five years, Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FE87669F5AB9D9D5A3A2FBB835B7C90A_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FE87669F5AB9D9D5A3A2FBB835B7C90A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FE87669F5AB9D9D5A3A2FBB835B7C90A_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FE87669F5AB9D9D5A3A2FBB835B7C90A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FE87669F5AB9D9D5A3A2FBB835B7C90A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FE87669F5AB9D9D5A3A2FBB835B7C90A" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FE87669F5AB9D9D5A3A2FBB835B7C90A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_9C26394088CCA9A454FAFBB835B78574_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_9C26394088CCA9A454FAFBB835B78574" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_9C26394088CCA9A454FAFBB835B78574" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_9C26394088CCA9A454FAFBB835B78574" xlink:to="lab_us-gaap_AvailableForSaleSecurities_9C26394088CCA9A454FAFBB835B78574" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C95D6D83B096AC37BD16FBB835B73669_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C95D6D83B096AC37BD16FBB835B73669" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total available-for-sale securities, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C95D6D83B096AC37BD16FBB835B73669_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C95D6D83B096AC37BD16FBB835B73669" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C95D6D83B096AC37BD16FBB835B73669" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C95D6D83B096AC37BD16FBB835B73669" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C95D6D83B096AC37BD16FBB835B73669" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_85263385A36B22DBFE4611E57DFED5C0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_85263385A36B22DBFE4611E57DFED5C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_85263385A36B22DBFE4611E57DFED5C0_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_85263385A36B22DBFE4611E57DFED5C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_85263385A36B22DBFE4611E57DFED5C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_85263385A36B22DBFE4611E57DFED5C0" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_85263385A36B22DBFE4611E57DFED5C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7" xlink:to="lab_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_1750797397F7B51F5029BEA9354C68E1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_1750797397F7B51F5029BEA9354C68E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Write-downs on excess, obsolete, unmarketable or other inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_1750797397F7B51F5029BEA9354C68E1_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_1750797397F7B51F5029BEA9354C68E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_1750797397F7B51F5029BEA9354C68E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_1750797397F7B51F5029BEA9354C68E1" xlink:to="lab_us-gaap_InventoryWriteDown_1750797397F7B51F5029BEA9354C68E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the beginning and ending of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_FCB20D71E5745CEA4299A02AFCFEEB66_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_FCB20D71E5745CEA4299A02AFCFEEB66" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_FCB20D71E5745CEA4299A02AFCFEEB66_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_FCB20D71E5745CEA4299A02AFCFEEB66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_FCB20D71E5745CEA4299A02AFCFEEB66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_FCB20D71E5745CEA4299A02AFCFEEB66" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_FCB20D71E5745CEA4299A02AFCFEEB66" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_91AE4C878C0A5C7B01D1A02AFCFE28F9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_91AE4C878C0A5C7B01D1A02AFCFE28F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to the current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_91AE4C878C0A5C7B01D1A02AFCFE28F9_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_91AE4C878C0A5C7B01D1A02AFCFE28F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_91AE4C878C0A5C7B01D1A02AFCFE28F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_91AE4C878C0A5C7B01D1A02AFCFE28F9" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_91AE4C878C0A5C7B01D1A02AFCFE28F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_D5389B80809542BB9A61A02AFCFF1CAD_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_D5389B80809542BB9A61A02AFCFF1CAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_D5389B80809542BB9A61A02AFCFF1CAD_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_D5389B80809542BB9A61A02AFCFF1CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_D5389B80809542BB9A61A02AFCFF1CAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_D5389B80809542BB9A61A02AFCFF1CAD" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_D5389B80809542BB9A61A02AFCFF1CAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_87DA1618D27CB76D5627A02AFCFFA2C2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_87DA1618D27CB76D5627A02AFCFFA2C2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reductions for tax positions of prior periods</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_87DA1618D27CB76D5627A02AFCFFA2C2_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_87DA1618D27CB76D5627A02AFCFFA2C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_87DA1618D27CB76D5627A02AFCFFA2C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_87DA1618D27CB76D5627A02AFCFFA2C2" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_87DA1618D27CB76D5627A02AFCFFA2C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3B0FF5CEF9634629E564A02AFCFF3C13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3B0FF5CEF9634629E564A02AFCFF3C13" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Statute expirations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3B0FF5CEF9634629E564A02AFCFF3C13_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3B0FF5CEF9634629E564A02AFCFF3C13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3B0FF5CEF9634629E564A02AFCFF3C13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3B0FF5CEF9634629E564A02AFCFF3C13" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3B0FF5CEF9634629E564A02AFCFF3C13" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_87857308BF3FE208639FA02AFCFF0DE2_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_87857308BF3FE208639FA02AFCFF0DE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_87857308BF3FE208639FA02AFCFF0DE2_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_87857308BF3FE208639FA02AFCFF0DE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_87857308BF3FE208639FA02AFCFF0DE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_87857308BF3FE208639FA02AFCFF0DE2" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_87857308BF3FE208639FA02AFCFF0DE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_17ED71DBD74F9D0E5A67A02AFCFFB3F3_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_17ED71DBD74F9D0E5A67A02AFCFFB3F3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_17ED71DBD74F9D0E5A67A02AFCFFB3F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_17ED71DBD74F9D0E5A67A02AFCFFB3F3" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_17ED71DBD74F9D0E5A67A02AFCFFB3F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteesAbstract_82F0BFC3D67C181CB688FBB83460774E_label_en-US" xlink:label="lab_us-gaap_GuaranteesAbstract_82F0BFC3D67C181CB688FBB83460774E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="loc_us-gaap_GuaranteesAbstract_82F0BFC3D67C181CB688FBB83460774E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesAbstract_82F0BFC3D67C181CB688FBB83460774E" xlink:to="lab_us-gaap_GuaranteesAbstract_82F0BFC3D67C181CB688FBB83460774E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GuaranteesTextBlock_2FF76EFE7A9310F80F9BFBB83460E723_verboseLabel_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock_2FF76EFE7A9310F80F9BFBB83460E723" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Guarantees</link:label>
    <link:label id="lab_us-gaap_GuaranteesTextBlock_2FF76EFE7A9310F80F9BFBB83460E723_label_en-US" xlink:label="lab_us-gaap_GuaranteesTextBlock_2FF76EFE7A9310F80F9BFBB83460E723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guarantees [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:label="loc_us-gaap_GuaranteesTextBlock_2FF76EFE7A9310F80F9BFBB83460E723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteesTextBlock_2FF76EFE7A9310F80F9BFBB83460E723" xlink:to="lab_us-gaap_GuaranteesTextBlock_2FF76EFE7A9310F80F9BFBB83460E723" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E6EE122CC4BF532B65D1FBB83396F47F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E6EE122CC4BF532B65D1FBB83396F47F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E6EE122CC4BF532B65D1FBB83396F47F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E6EE122CC4BF532B65D1FBB83396F47F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E6EE122CC4BF532B65D1FBB83396F47F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E6EE122CC4BF532B65D1FBB83396F47F" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E6EE122CC4BF532B65D1FBB83396F47F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D3A617FF182184FB4D52FBB8339663D4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D3A617FF182184FB4D52FBB8339663D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D3A617FF182184FB4D52FBB8339663D4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D3A617FF182184FB4D52FBB8339663D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D3A617FF182184FB4D52FBB8339663D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D3A617FF182184FB4D52FBB8339663D4" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D3A617FF182184FB4D52FBB8339663D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_30FEA8832806A5CC5A53FBB8339673BF_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_30FEA8832806A5CC5A53FBB8339673BF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_30FEA8832806A5CC5A53FBB8339673BF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_30FEA8832806A5CC5A53FBB8339673BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_30FEA8832806A5CC5A53FBB8339673BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_30FEA8832806A5CC5A53FBB8339673BF" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_30FEA8832806A5CC5A53FBB8339673BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_BCFF9F63630D7C9FCA80FBB832AC1ADC_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_BCFF9F63630D7C9FCA80FBB832AC1ADC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_BCFF9F63630D7C9FCA80FBB832AC1ADC_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_BCFF9F63630D7C9FCA80FBB832AC1ADC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_BCFF9F63630D7C9FCA80FBB832AC1ADC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_BCFF9F63630D7C9FCA80FBB832AC1ADC" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_BCFF9F63630D7C9FCA80FBB832AC1ADC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_832BB03CA61115FBFDB0FBB83470FFAD_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_832BB03CA61115FBFDB0FBB83470FFAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_832BB03CA61115FBFDB0FBB83470FFAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_832BB03CA61115FBFDB0FBB83470FFAD" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_832BB03CA61115FBFDB0FBB83470FFAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_9515A13F5839E022A9D1FBB834703B1F_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_9515A13F5839E022A9D1FBB834703B1F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_9515A13F5839E022A9D1FBB834703B1F_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock_9515A13F5839E022A9D1FBB834703B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_9515A13F5839E022A9D1FBB834703B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock_9515A13F5839E022A9D1FBB834703B1F" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock_9515A13F5839E022A9D1FBB834703B1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6F4574D4C8E581512784FBB831743619_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6F4574D4C8E581512784FBB831743619" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6F4574D4C8E581512784FBB831743619_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6F4574D4C8E581512784FBB831743619" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6F4574D4C8E581512784FBB831743619" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6F4574D4C8E581512784FBB831743619" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_6F4574D4C8E581512784FBB831743619" xlink:type="arc" />
    <link:label id="lab_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E_terseLabel_en-US" xlink:label="lab_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Units</link:label>
    <link:label id="lab_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E_label_en-US" xlink:label="lab_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:label id="lab_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E_documentation_en-US" xlink:label="lab_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Units [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E" xlink:to="lab_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E" xlink:type="arc" />
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4" xlink:to="lab_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507_verboseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_327E1510F01357570C0FF08E8D6B66D5_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_327E1510F01357570C0FF08E8D6B66D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_327E1510F01357570C0FF08E8D6B66D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_327E1510F01357570C0FF08E8D6B66D5" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_327E1510F01357570C0FF08E8D6B66D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_DB51CD6E1072F425764781E39CA2414C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_DB51CD6E1072F425764781E39CA2414C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets and liabilities charges to equity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_DB51CD6E1072F425764781E39CA2414C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_DB51CD6E1072F425764781E39CA2414C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_DB51CD6E1072F425764781E39CA2414C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_DB51CD6E1072F425764781E39CA2414C" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_DB51CD6E1072F425764781E39CA2414C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1061BE0059A3C76A02D4120906FE28C0_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1061BE0059A3C76A02D4120906FE28C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1061BE0059A3C76A02D4120906FE28C0_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1061BE0059A3C76A02D4120906FE28C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1061BE0059A3C76A02D4120906FE28C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1061BE0059A3C76A02D4120906FE28C0" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_1061BE0059A3C76A02D4120906FE28C0" xlink:type="arc" />
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6751E3F61399C531E4DB120906FE0C78_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6751E3F61399C531E4DB120906FE0C78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of change in reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6751E3F61399C531E4DB120906FE0C78_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6751E3F61399C531E4DB120906FE0C78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6751E3F61399C531E4DB120906FE0C78_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6751E3F61399C531E4DB120906FE0C78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6751E3F61399C531E4DB120906FE0C78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6751E3F61399C531E4DB120906FE0C78" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6751E3F61399C531E4DB120906FE0C78" xlink:type="arc" />
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_119E8D55D644128E48901218C604CAE7_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_119E8D55D644128E48901218C604CAE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in consolidated balance sheet</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_119E8D55D644128E48901218C604CAE7_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_119E8D55D644128E48901218C604CAE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_119E8D55D644128E48901218C604CAE7_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_119E8D55D644128E48901218C604CAE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_119E8D55D644128E48901218C604CAE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_119E8D55D644128E48901218C604CAE7" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_119E8D55D644128E48901218C604CAE7" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_B71622827A4AAB32A06C121E92F977E7_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_B71622827A4AAB32A06C121E92F977E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_B71622827A4AAB32A06C121E92F977E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_B71622827A4AAB32A06C121E92F977E7" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_B71622827A4AAB32A06C121E92F977E7" xlink:type="arc" />
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_AC3BFE33ED8A4C46389C1227EBB0F9C4_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_AC3BFE33ED8A4C46389C1227EBB0F9C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_AC3BFE33ED8A4C46389C1227EBB0F9C4_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_AC3BFE33ED8A4C46389C1227EBB0F9C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_AC3BFE33ED8A4C46389C1227EBB0F9C4_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock_AC3BFE33ED8A4C46389C1227EBB0F9C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_AC3BFE33ED8A4C46389C1227EBB0F9C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock_AC3BFE33ED8A4C46389C1227EBB0F9C4" xlink:to="lab_biib_OtherrevenuesTableTextBlock_AC3BFE33ED8A4C46389C1227EBB0F9C4" xlink:type="arc" />
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0_verboseLabel_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0_label_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units Activity [Abstract]</link:label>
    <link:label id="lab_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0_documentation_en-US" xlink:label="lab_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted stock units activity.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="lab_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_B065DAA3F1F66AD836ECBAB559A7B53C_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_B065DAA3F1F66AD836ECBAB559A7B53C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_B065DAA3F1F66AD836ECBAB559A7B53C_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_B065DAA3F1F66AD836ECBAB559A7B53C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B065DAA3F1F66AD836ECBAB559A7B53C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_B065DAA3F1F66AD836ECBAB559A7B53C" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_B065DAA3F1F66AD836ECBAB559A7B53C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_F3DD12A48A174ECFAC03BAB559A77E1C_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_F3DD12A48A174ECFAC03BAB559A77E1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_F3DD12A48A174ECFAC03BAB559A77E1C_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_F3DD12A48A174ECFAC03BAB559A77E1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_F3DD12A48A174ECFAC03BAB559A77E1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_F3DD12A48A174ECFAC03BAB559A77E1C" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_F3DD12A48A174ECFAC03BAB559A77E1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201707Member_1F72E107E76AD9BF7E63BAB559A73CEF_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201707Member_1F72E107E76AD9BF7E63BAB559A73CEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2017-07</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201707Member_1F72E107E76AD9BF7E63BAB559A73CEF_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201707Member_1F72E107E76AD9BF7E63BAB559A73CEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2017-07 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201707Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201707Member_1F72E107E76AD9BF7E63BAB559A73CEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201707Member_1F72E107E76AD9BF7E63BAB559A73CEF" xlink:to="lab_us-gaap_AccountingStandardsUpdate201707Member_1F72E107E76AD9BF7E63BAB559A73CEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxChargesMember_6A88D0ADB4D3817A5395BAB559A7E940_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxChargesMember_6A88D0ADB4D3817A5395BAB559A7E940" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Charge</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxChargesMember_6A88D0ADB4D3817A5395BAB559A7E940_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxChargesMember_6A88D0ADB4D3817A5395BAB559A7E940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Charge [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember_6A88D0ADB4D3817A5395BAB559A7E940" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxChargesMember_6A88D0ADB4D3817A5395BAB559A7E940" xlink:to="lab_us-gaap_DeferredIncomeTaxChargesMember_6A88D0ADB4D3817A5395BAB559A7E940" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_866E2FA8A5B0E992EC59BAB559B74770_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_866E2FA8A5B0E992EC59BAB559B74770" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_866E2FA8A5B0E992EC59BAB559B74770_label_en-US" xlink:label="lab_us-gaap_BuildingMember_866E2FA8A5B0E992EC59BAB559B74770" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_866E2FA8A5B0E992EC59BAB559B74770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_866E2FA8A5B0E992EC59BAB559B74770" xlink:to="lab_us-gaap_BuildingMember_866E2FA8A5B0E992EC59BAB559B74770" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_2719DC48BB3E0D518B82BAB559B77786_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_2719DC48BB3E0D518B82BAB559B77786" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_2719DC48BB3E0D518B82BAB559B77786_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_2719DC48BB3E0D518B82BAB559B77786" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2719DC48BB3E0D518B82BAB559B77786" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_2719DC48BB3E0D518B82BAB559B77786" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_2719DC48BB3E0D518B82BAB559B77786" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_6A1675B7F42F10F750CDBAB559B7F0B6_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_6A1675B7F42F10F750CDBAB559B7F0B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_6A1675B7F42F10F750CDBAB559B7F0B6_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_6A1675B7F42F10F750CDBAB559B7F0B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6A1675B7F42F10F750CDBAB559B7F0B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_6A1675B7F42F10F750CDBAB559B7F0B6" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_6A1675B7F42F10F750CDBAB559B7F0B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_07C8E7222458C858BEC3BAB559B7ECF8_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_07C8E7222458C858BEC3BAB559B7ECF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_07C8E7222458C858BEC3BAB559B7ECF8_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_07C8E7222458C858BEC3BAB559B7ECF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_07C8E7222458C858BEC3BAB559B7ECF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_07C8E7222458C858BEC3BAB559B7ECF8" xlink:to="lab_us-gaap_ComputerEquipmentMember_07C8E7222458C858BEC3BAB559B7ECF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4788581F0C22F56144D6BAB559B72F41_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4788581F0C22F56144D6BAB559B72F41" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4788581F0C22F56144D6BAB559B72F41_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4788581F0C22F56144D6BAB559B72F41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4788581F0C22F56144D6BAB559B72F41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4788581F0C22F56144D6BAB559B72F41" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4788581F0C22F56144D6BAB559B72F41" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_7883A65E24B2899F464CBAB559B75660_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_7883A65E24B2899F464CBAB559B75660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quantification of affect of adoption of accounting guidance</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_7883A65E24B2899F464CBAB559B75660_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_7883A65E24B2899F464CBAB559B75660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_7883A65E24B2899F464CBAB559B75660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_7883A65E24B2899F464CBAB559B75660" xlink:to="lab_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_7883A65E24B2899F464CBAB559B75660" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_B643784BD894B30B624CBAB559B7DEC8_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment_B643784BD894B30B624CBAB559B7DEC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Period Reclassification Adjustment</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustment_B643784BD894B30B624CBAB559B7DEC8_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustment_B643784BD894B30B624CBAB559B7DEC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Period Reclassification Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_B643784BD894B30B624CBAB559B7DEC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustment_B643784BD894B30B624CBAB559B7DEC8" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustment_B643784BD894B30B624CBAB559B7DEC8" xlink:type="arc" />
    <link:label id="lab_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6_terseLabel_en-US" xlink:label="lab_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business (Textual)</link:label>
    <link:label id="lab_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6_label_en-US" xlink:label="lab_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6_documentation_en-US" xlink:label="lab_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_BusinessTextualAbstract" xlink:label="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:to="lab_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:type="arc" />
    <link:label id="lab_biib_InterestInSubsidiary_D6BEB35DD928B64C168FBAB559B7D44A_terseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary_D6BEB35DD928B64C168FBAB559B7D44A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_D6BEB35DD928B64C168FBAB559B7D44A_label_en-US" xlink:label="lab_biib_InterestInSubsidiary_D6BEB35DD928B64C168FBAB559B7D44A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_D6BEB35DD928B64C168FBAB559B7D44A_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary_D6BEB35DD928B64C168FBAB559B7D44A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_D6BEB35DD928B64C168FBAB559B7D44A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary_D6BEB35DD928B64C168FBAB559B7D44A" xlink:to="lab_biib_InterestInSubsidiary_D6BEB35DD928B64C168FBAB559B7D44A" xlink:type="arc" />
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_43CCB7D19FF04014CA93BAB559B7342F_verboseLabel_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_43CCB7D19FF04014CA93BAB559B7342F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment terms of accounts receivable arising from product sales</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_43CCB7D19FF04014CA93BAB559B7342F_label_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_43CCB7D19FF04014CA93BAB559B7342F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Terms Of Accounts Receivable</link:label>
    <link:label id="lab_biib_PaymentTermsOfAccountsReceivable_43CCB7D19FF04014CA93BAB559B7342F_documentation_en-US" xlink:label="lab_biib_PaymentTermsOfAccountsReceivable_43CCB7D19FF04014CA93BAB559B7342F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment  terms of accounts receivable.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_43CCB7D19FF04014CA93BAB559B7342F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentTermsOfAccountsReceivable_43CCB7D19FF04014CA93BAB559B7342F" xlink:to="lab_biib_PaymentTermsOfAccountsReceivable_43CCB7D19FF04014CA93BAB559B7342F" xlink:type="arc" />
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_C6E8BCB412ECAF0D0686BAB559B79C5C_terseLabel_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_C6E8BCB412ECAF0D0686BAB559B79C5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives of leasehold improvements</link:label>
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_C6E8BCB412ECAF0D0686BAB559B79C5C_label_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_C6E8BCB412ECAF0D0686BAB559B79C5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives Of Leasehold Improvements</link:label>
    <link:label id="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_C6E8BCB412ECAF0D0686BAB559B79C5C_documentation_en-US" xlink:label="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_C6E8BCB412ECAF0D0686BAB559B79C5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated useful lives of leasehold improvements.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EstimatedUsefulLivesOfLeaseholdImprovements" xlink:label="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_C6E8BCB412ECAF0D0686BAB559B79C5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_C6E8BCB412ECAF0D0686BAB559B79C5C" xlink:to="lab_biib_EstimatedUsefulLivesOfLeaseholdImprovements_C6E8BCB412ECAF0D0686BAB559B79C5C" xlink:type="arc" />
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_BA1523727DEEDB7A8DD2BAB559B773F7_terseLabel_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_BA1523727DEEDB7A8DD2BAB559B773F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock under ESPP</link:label>
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_BA1523727DEEDB7A8DD2BAB559B773F7_label_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_BA1523727DEEDB7A8DD2BAB559B773F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Price Of Common Stock Under ESPP</link:label>
    <link:label id="lab_biib_PurchasePriceOfCommonStockUnderEspp_BA1523727DEEDB7A8DD2BAB559B773F7_documentation_en-US" xlink:label="lab_biib_PurchasePriceOfCommonStockUnderEspp_BA1523727DEEDB7A8DD2BAB559B773F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Price Of Common Stock Under ESPP.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PurchasePriceOfCommonStockUnderEspp" xlink:label="loc_biib_PurchasePriceOfCommonStockUnderEspp_BA1523727DEEDB7A8DD2BAB559B773F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PurchasePriceOfCommonStockUnderEspp_BA1523727DEEDB7A8DD2BAB559B773F7" xlink:to="lab_biib_PurchasePriceOfCommonStockUnderEspp_BA1523727DEEDB7A8DD2BAB559B773F7" xlink:type="arc" />
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_BE84D0C32C867A4EBEF3BAB559B7E2CB_terseLabel_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_BE84D0C32C867A4EBEF3BAB559B7E2CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of market value per share of common stock</link:label>
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_BE84D0C32C867A4EBEF3BAB559B7E2CB_label_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_BE84D0C32C867A4EBEF3BAB559B7E2CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Market Value Per Share Of Common Stock</link:label>
    <link:label id="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_BE84D0C32C867A4EBEF3BAB559B7E2CB_documentation_en-US" xlink:label="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_BE84D0C32C867A4EBEF3BAB559B7E2CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of market value per share of common stock.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfMarketValuePerShareOfCommonStock" xlink:label="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_BE84D0C32C867A4EBEF3BAB559B7E2CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_BE84D0C32C867A4EBEF3BAB559B7E2CB" xlink:to="lab_biib_PercentageOfMarketValuePerShareOfCommonStock_BE84D0C32C867A4EBEF3BAB559B7E2CB" xlink:type="arc" />
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_CCEBC3A896F251D2527DBAB559B79CD1_terseLabel_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_CCEBC3A896F251D2527DBAB559B79CD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense over purchase period</link:label>
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_CCEBC3A896F251D2527DBAB559B79CD1_label_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_CCEBC3A896F251D2527DBAB559B79CD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Expense Over Purchase Period</link:label>
    <link:label id="lab_biib_CompensationExpenseOverPurchasePeriod_CCEBC3A896F251D2527DBAB559B79CD1_documentation_en-US" xlink:label="lab_biib_CompensationExpenseOverPurchasePeriod_CCEBC3A896F251D2527DBAB559B79CD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation expense over purchase period.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CompensationExpenseOverPurchasePeriod" xlink:label="loc_biib_CompensationExpenseOverPurchasePeriod_CCEBC3A896F251D2527DBAB559B79CD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CompensationExpenseOverPurchasePeriod_CCEBC3A896F251D2527DBAB559B79CD1" xlink:to="lab_biib_CompensationExpenseOverPurchasePeriod_CCEBC3A896F251D2527DBAB559B79CD1" xlink:type="arc" />
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_0DB01EB5AD5F78A92F80BAB559B7A338_terseLabel_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_0DB01EB5AD5F78A92F80BAB559B7A338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate recognized in compensation expense</link:label>
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_0DB01EB5AD5F78A92F80BAB559B7A338_label_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_0DB01EB5AD5F78A92F80BAB559B7A338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discount Rate Recognized In Compensation Expense</link:label>
    <link:label id="lab_biib_DiscountRateRecognizedInCompensationExpense_0DB01EB5AD5F78A92F80BAB559B7A338_documentation_en-US" xlink:label="lab_biib_DiscountRateRecognizedInCompensationExpense_0DB01EB5AD5F78A92F80BAB559B7A338" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Discount rate recognized in compensation expense.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DiscountRateRecognizedInCompensationExpense" xlink:label="loc_biib_DiscountRateRecognizedInCompensationExpense_0DB01EB5AD5F78A92F80BAB559B7A338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DiscountRateRecognizedInCompensationExpense_0DB01EB5AD5F78A92F80BAB559B7A338" xlink:to="lab_biib_DiscountRateRecognizedInCompensationExpense_0DB01EB5AD5F78A92F80BAB559B7A338" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_7EF2FA2F45B284AFDA5DBAB559B7D1EB_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_7EF2FA2F45B284AFDA5DBAB559B7D1EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_7EF2FA2F45B284AFDA5DBAB559B7D1EB_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_7EF2FA2F45B284AFDA5DBAB559B7D1EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_7EF2FA2F45B284AFDA5DBAB559B7D1EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_7EF2FA2F45B284AFDA5DBAB559B7D1EB" xlink:to="lab_us-gaap_AdvertisingExpense_7EF2FA2F45B284AFDA5DBAB559B7D1EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CD93CDDE547BAEAE8D48FBB833E4D403_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CD93CDDE547BAEAE8D48FBB833E4D403" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CD93CDDE547BAEAE8D48FBB833E4D403_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CD93CDDE547BAEAE8D48FBB833E4D403" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CD93CDDE547BAEAE8D48FBB833E4D403" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CD93CDDE547BAEAE8D48FBB833E4D403" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CD93CDDE547BAEAE8D48FBB833E4D403" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D" xlink:to="lab_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D" xlink:type="arc" />
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B" xlink:to="lab_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_C6F6570C99D47EE72D83871CAEEC7993_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_C6F6570C99D47EE72D83871CAEEC7993" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_C6F6570C99D47EE72D83871CAEEC7993_label_en-US" xlink:label="lab_us-gaap_SalesMember_C6F6570C99D47EE72D83871CAEEC7993" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_C6F6570C99D47EE72D83871CAEEC7993" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_C6F6570C99D47EE72D83871CAEEC7993" xlink:to="lab_us-gaap_SalesMember_C6F6570C99D47EE72D83871CAEEC7993" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenseMember_D869782E41FEB90B9C56871CAEECE589_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_D869782E41FEB90B9C56871CAEECE589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_D869782E41FEB90B9C56871CAEECE589_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember_D869782E41FEB90B9C56871CAEECE589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_D869782E41FEB90B9C56871CAEECE589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember_D869782E41FEB90B9C56871CAEECE589" xlink:to="lab_us-gaap_OperatingExpenseMember_D869782E41FEB90B9C56871CAEECE589" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_19B689CB7EF4F33B2B78871CAEFCE977_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_19B689CB7EF4F33B2B78871CAEFCE977" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net gains (losses) in operating income for the settlement of certain effective cash flow hedge instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_19B689CB7EF4F33B2B78871CAEFCE977" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_19B689CB7EF4F33B2B78871CAEFCE977" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_19B689CB7EF4F33B2B78871CAEFCE977" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_1C93ECC8ADEB89126E009528E98FE28E_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_1C93ECC8ADEB89126E009528E98FE28E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_1C93ECC8ADEB89126E009528E98FE28E_label_en-US" xlink:label="lab_us-gaap_Depreciation_1C93ECC8ADEB89126E009528E98FE28E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1C93ECC8ADEB89126E009528E98FE28E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_1C93ECC8ADEB89126E009528E98FE28E" xlink:to="lab_us-gaap_Depreciation_1C93ECC8ADEB89126E009528E98FE28E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestCostsCapitalized_A5766B26AC2A3053D43D955D3099E367_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_A5766B26AC2A3053D43D955D3099E367" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_A5766B26AC2A3053D43D955D3099E367_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_A5766B26AC2A3053D43D955D3099E367" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_A5766B26AC2A3053D43D955D3099E367" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized_A5766B26AC2A3053D43D955D3099E367" xlink:to="lab_us-gaap_InterestCostsCapitalized_A5766B26AC2A3053D43D955D3099E367" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:to="lab_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:type="arc" />
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B_terseLabel_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B_label_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:label id="lab_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B_documentation_en-US" xlink:label="lab_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Skyhawk Therapeutics [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B" xlink:to="lab_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_92CA66DC864BB8DF3221AAF0BCA5D29D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_92CA66DC864BB8DF3221AAF0BCA5D29D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_92CA66DC864BB8DF3221AAF0BCA5D29D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_92CA66DC864BB8DF3221AAF0BCA5D29D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_92CA66DC864BB8DF3221AAF0BCA5D29D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_92CA66DC864BB8DF3221AAF0BCA5D29D" xlink:to="lab_us-gaap_SubsequentEventMember_92CA66DC864BB8DF3221AAF0BCA5D29D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:to="lab_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_61020866A9DB7108D674FBB8348FA0B6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_61020866A9DB7108D674FBB8348FA0B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Indebtedness</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_61020866A9DB7108D674FBB8348FA0B6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_61020866A9DB7108D674FBB8348FA0B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_61020866A9DB7108D674FBB8348FA0B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_61020866A9DB7108D674FBB8348FA0B6" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_61020866A9DB7108D674FBB8348FA0B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0E1D97D9ACD60406E054FBB8348F0407_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0E1D97D9ACD60406E054FBB8348F0407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total debt maturities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0E1D97D9ACD60406E054FBB8348F0407_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0E1D97D9ACD60406E054FBB8348F0407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0E1D97D9ACD60406E054FBB8348F0407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0E1D97D9ACD60406E054FBB8348F0407" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0E1D97D9ACD60406E054FBB8348F0407" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_F1CAA6AFC8FC324CF62DFBB83480AD80_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_F1CAA6AFC8FC324CF62DFBB83480AD80" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_F1CAA6AFC8FC324CF62DFBB83480AD80_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_F1CAA6AFC8FC324CF62DFBB83480AD80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_F1CAA6AFC8FC324CF62DFBB83480AD80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_F1CAA6AFC8FC324CF62DFBB83480AD80" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_F1CAA6AFC8FC324CF62DFBB83480AD80" xlink:type="arc" />
    <link:label id="lab_biib_TaxcontingencyAbstract_7811BDA85F1253236C36F52AEBCFCA2D_label_en-US" xlink:label="lab_biib_TaxcontingencyAbstract_7811BDA85F1253236C36F52AEBCFCA2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax contingency [Abstract]</link:label>
    <link:label id="lab_biib_TaxcontingencyAbstract_7811BDA85F1253236C36F52AEBCFCA2D_documentation_en-US" xlink:label="lab_biib_TaxcontingencyAbstract_7811BDA85F1253236C36F52AEBCFCA2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax contingency [Abstract]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_TaxcontingencyAbstract" xlink:label="loc_biib_TaxcontingencyAbstract_7811BDA85F1253236C36F52AEBCFCA2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TaxcontingencyAbstract_7811BDA85F1253236C36F52AEBCFCA2D" xlink:to="lab_biib_TaxcontingencyAbstract_7811BDA85F1253236C36F52AEBCFCA2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:type="arc" />
    <link:label id="lab_country_BR_EDAB71E9C1424994810BF52AEF9D9494_terseLabel_en-US" xlink:label="lab_country_BR_EDAB71E9C1424994810BF52AEF9D9494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BRAZIL</link:label>
    <link:label id="lab_country_BR_EDAB71E9C1424994810BF52AEF9D9494_label_en-US" xlink:label="lab_country_BR_EDAB71E9C1424994810BF52AEF9D9494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BRAZIL</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_EDAB71E9C1424994810BF52AEF9D9494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BR_EDAB71E9C1424994810BF52AEF9D9494" xlink:to="lab_country_BR_EDAB71E9C1424994810BF52AEF9D9494" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyDamagesSought_F27C2440F6E24D896CD1F52AEF88C8F9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSought_F27C2440F6E24D896CD1F52AEF88C8F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSought_F27C2440F6E24D896CD1F52AEF88C8F9_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSought_F27C2440F6E24D896CD1F52AEF88C8F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="loc_us-gaap_LossContingencyDamagesSought_F27C2440F6E24D896CD1F52AEF88C8F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSought_F27C2440F6E24D896CD1F52AEF88C8F9" xlink:to="lab_us-gaap_LossContingencyDamagesSought_F27C2440F6E24D896CD1F52AEF88C8F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4AC7B7915AC1981320509A049CE9A47D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4AC7B7915AC1981320509A049CE9A47D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4AC7B7915AC1981320509A049CE9A47D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4AC7B7915AC1981320509A049CE9A47D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4AC7B7915AC1981320509A049CE9A47D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4AC7B7915AC1981320509A049CE9A47D" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4AC7B7915AC1981320509A049CE9A47D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_F2B3166C2068C0D03E589A049CE941FB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_F2B3166C2068C0D03E589A049CE941FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, other reserves, and accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_F2B3166C2068C0D03E589A049CE941FB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_F2B3166C2068C0D03E589A049CE941FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_F2B3166C2068C0D03E589A049CE941FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory_F2B3166C2068C0D03E589A049CE941FB" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory_F2B3166C2068C0D03E589A049CE941FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_661AC0D22D83852DCB2D9A049CE9762B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_661AC0D22D83852DCB2D9A049CE9762B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangibles, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_661AC0D22D83852DCB2D9A049CE9762B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_661AC0D22D83852DCB2D9A049CE9762B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_661AC0D22D83852DCB2D9A049CE9762B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_661AC0D22D83852DCB2D9A049CE9762B" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_661AC0D22D83852DCB2D9A049CE9762B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EA774711068CD4CE89439A049CEA35C7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EA774711068CD4CE89439A049CEA35C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EA774711068CD4CE89439A049CEA35C7_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EA774711068CD4CE89439A049CEA35C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EA774711068CD4CE89439A049CEA35C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EA774711068CD4CE89439A049CEA35C7" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EA774711068CD4CE89439A049CEA35C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_03BADDBFB7D9243EE6B69A049CEA35B5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_03BADDBFB7D9243EE6B69A049CEA35B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_03BADDBFB7D9243EE6B69A049CEA35B5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_03BADDBFB7D9243EE6B69A049CEA35B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_03BADDBFB7D9243EE6B69A049CEA35B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_03BADDBFB7D9243EE6B69A049CEA35B5" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_03BADDBFB7D9243EE6B69A049CEA35B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_40A49D0753C61F5F5BD49A049CEAF8F1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_40A49D0753C61F5F5BD49A049CEAF8F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_40A49D0753C61F5F5BD49A049CEAF8F1_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_40A49D0753C61F5F5BD49A049CEAF8F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_40A49D0753C61F5F5BD49A049CEAF8F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_40A49D0753C61F5F5BD49A049CEAF8F1" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_40A49D0753C61F5F5BD49A049CEAF8F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_888B1D78BABC5804C37E9A049CEAD5B8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_888B1D78BABC5804C37E9A049CEAD5B8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_888B1D78BABC5804C37E9A049CEAD5B8_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_888B1D78BABC5804C37E9A049CEAD5B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_888B1D78BABC5804C37E9A049CEAD5B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_888B1D78BABC5804C37E9A049CEAD5B8" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_888B1D78BABC5804C37E9A049CEAD5B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_55AADD3369A3DAAC9E249A049CEA6505_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_55AADD3369A3DAAC9E249A049CEA6505" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_55AADD3369A3DAAC9E249A049CEA6505_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_55AADD3369A3DAAC9E249A049CEA6505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_55AADD3369A3DAAC9E249A049CEA6505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_55AADD3369A3DAAC9E249A049CEA6505" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_55AADD3369A3DAAC9E249A049CEA6505" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_C0248642F44D23648C239A049CEAA83A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_C0248642F44D23648C239A049CEAA83A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_C0248642F44D23648C239A049CEAA83A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_C0248642F44D23648C239A049CEAA83A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_C0248642F44D23648C239A049CEAA83A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_C0248642F44D23648C239A049CEAA83A" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_C0248642F44D23648C239A049CEAA83A" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_F2C28C74EBF918E1969D9A049CEB1B54_terseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_F2C28C74EBF918E1969D9A049CEB1B54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Tax Credit Carryforwards</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_F2C28C74EBF918E1969D9A049CEB1B54_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_F2C28C74EBF918E1969D9A049CEB1B54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Tax Credit Carryforwards</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_F2C28C74EBF918E1969D9A049CEB1B54_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_F2C28C74EBF918E1969D9A049CEB1B54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:label="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_F2C28C74EBF918E1969D9A049CEB1B54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_F2C28C74EBF918E1969D9A049CEB1B54" xlink:to="lab_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_F2C28C74EBF918E1969D9A049CEB1B54" xlink:type="arc" />
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_51D89551724A7B1101589A049CEB65E2_negatedTerseLabel_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_51D89551724A7B1101589A049CEB65E2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, amortization and other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_51D89551724A7B1101589A049CEB65E2_label_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_51D89551724A7B1101589A049CEB65E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities Depreciation Amortization Other</link:label>
    <link:label id="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_51D89551724A7B1101589A049CEB65E2_documentation_en-US" xlink:label="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_51D89551724A7B1101589A049CEB65E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities depreciation amortization other.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_51D89551724A7B1101589A049CEB65E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_51D89551724A7B1101589A049CEB65E2" xlink:to="lab_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_51D89551724A7B1101589A049CEB65E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_35D8831CC70F2DA471049A049CEBB1EB_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_35D8831CC70F2DA471049A049CEBB1EB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_35D8831CC70F2DA471049A049CEBB1EB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_35D8831CC70F2DA471049A049CEBB1EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_35D8831CC70F2DA471049A049CEBB1EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_35D8831CC70F2DA471049A049CEBB1EB" xlink:to="lab_us-gaap_DeferredTaxLiabilities_35D8831CC70F2DA471049A049CEBB1EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_B79CA19098DBFBE664E4FBB831E1B463_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_B79CA19098DBFBE664E4FBB831E1B463" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_B79CA19098DBFBE664E4FBB831E1B463_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_B79CA19098DBFBE664E4FBB831E1B463" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_B79CA19098DBFBE664E4FBB831E1B463" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_B79CA19098DBFBE664E4FBB831E1B463" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_B79CA19098DBFBE664E4FBB831E1B463" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_73404D598CE9FA3661F9FBB831B24299_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_73404D598CE9FA3661F9FBB831B24299" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_73404D598CE9FA3661F9FBB831B24299_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_73404D598CE9FA3661F9FBB831B24299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_73404D598CE9FA3661F9FBB831B24299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_73404D598CE9FA3661F9FBB831B24299" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_73404D598CE9FA3661F9FBB831B24299" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_A755FDF34F28C1DFF355FBB831B26EA6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_A755FDF34F28C1DFF355FBB831B26EA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_A755FDF34F28C1DFF355FBB831B26EA6_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_A755FDF34F28C1DFF355FBB831B26EA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_A755FDF34F28C1DFF355FBB831B26EA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_A755FDF34F28C1DFF355FBB831B26EA6" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_A755FDF34F28C1DFF355FBB831B26EA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_90C578ECEAA42759F46BFBB831B27FB2_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_90C578ECEAA42759F46BFBB831B27FB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_90C578ECEAA42759F46BFBB831B27FB2_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_90C578ECEAA42759F46BFBB831B27FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_90C578ECEAA42759F46BFBB831B27FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_90C578ECEAA42759F46BFBB831B27FB2" xlink:to="lab_us-gaap_TreasuryStockShares_90C578ECEAA42759F46BFBB831B27FB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_C92728EA9BE08CDD9600FBB832AC4D13_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_C92728EA9BE08CDD9600FBB832AC4D13" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_C92728EA9BE08CDD9600FBB832AC4D13_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_C92728EA9BE08CDD9600FBB832AC4D13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_C92728EA9BE08CDD9600FBB832AC4D13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_C92728EA9BE08CDD9600FBB832AC4D13" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_C92728EA9BE08CDD9600FBB832AC4D13" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97662C8DB502447FE0B485697A7AF516_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97662C8DB502447FE0B485697A7AF516" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hemophilia Spin-Off</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97662C8DB502447FE0B485697A7AF516_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97662C8DB502447FE0B485697A7AF516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97662C8DB502447FE0B485697A7AF516" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97662C8DB502447FE0B485697A7AF516" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97662C8DB502447FE0B485697A7AF516" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E" xlink:to="lab_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_F9EE55C245681D5AD973FBB8353B1673_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_F9EE55C245681D5AD973FBB8353B1673" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_F9EE55C245681D5AD973FBB8353B1673_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves_F9EE55C245681D5AD973FBB8353B1673" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_F9EE55C245681D5AD973FBB8353B1673" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves_F9EE55C245681D5AD973FBB8353B1673" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves_F9EE55C245681D5AD973FBB8353B1673" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_24EC3ED2D9AC5D33001EFBB8353BD58B_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_24EC3ED2D9AC5D33001EFBB8353BD58B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_24EC3ED2D9AC5D33001EFBB8353BD58B_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_24EC3ED2D9AC5D33001EFBB8353BD58B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_24EC3ED2D9AC5D33001EFBB8353BD58B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_24EC3ED2D9AC5D33001EFBB8353BD58B" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_24EC3ED2D9AC5D33001EFBB8353BD58B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_A24F09C62BB90D499379FBB8353BC52C_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_A24F09C62BB90D499379FBB8353BC52C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_A24F09C62BB90D499379FBB8353BC52C_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_A24F09C62BB90D499379FBB8353BC52C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_A24F09C62BB90D499379FBB8353BC52C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_A24F09C62BB90D499379FBB8353BC52C" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_A24F09C62BB90D499379FBB8353BC52C" xlink:type="arc" />
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_AA0B69497A4CC5108D88FBB8353B7ABB_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_AA0B69497A4CC5108D88FBB8353B7ABB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_AA0B69497A4CC5108D88FBB8353B7ABB_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_AA0B69497A4CC5108D88FBB8353B7ABB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_AA0B69497A4CC5108D88FBB8353B7ABB_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent_AA0B69497A4CC5108D88FBB8353B7ABB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_AA0B69497A4CC5108D88FBB8353B7ABB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_AA0B69497A4CC5108D88FBB8353B7ABB" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent_AA0B69497A4CC5108D88FBB8353B7ABB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_984EFAC5CDED4B26D691FBB8353BE5B0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_984EFAC5CDED4B26D691FBB8353BE5B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_984EFAC5CDED4B26D691FBB8353BE5B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_984EFAC5CDED4B26D691FBB8353BE5B0" xlink:to="lab_us-gaap_InventoryNet_984EFAC5CDED4B26D691FBB8353BE5B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_2CEB4BDCF997823BD45FFBB8353B4AFE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_2CEB4BDCF997823BD45FFBB8353B4AFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_2CEB4BDCF997823BD45FFBB8353B4AFE_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_2CEB4BDCF997823BD45FFBB8353B4AFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_2CEB4BDCF997823BD45FFBB8353B4AFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_2CEB4BDCF997823BD45FFBB8353B4AFE" xlink:to="lab_us-gaap_InventoryNoncurrent_2CEB4BDCF997823BD45FFBB8353B4AFE" xlink:type="arc" />
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638_label_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638_documentation_en-US" xlink:label="lab_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="lab_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_62E73BEF516C5C2D058DBFA7AE0B32A9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_62E73BEF516C5C2D058DBFA7AE0B32A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_62E73BEF516C5C2D058DBFA7AE0B32A9_label_en-US" xlink:label="lab_dei_EntityRegistrantName_62E73BEF516C5C2D058DBFA7AE0B32A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_62E73BEF516C5C2D058DBFA7AE0B32A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_62E73BEF516C5C2D058DBFA7AE0B32A9" xlink:to="lab_dei_EntityRegistrantName_62E73BEF516C5C2D058DBFA7AE0B32A9" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_461BFDA3103BA76785BABFA7AE0B08DE_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_461BFDA3103BA76785BABFA7AE0B08DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_461BFDA3103BA76785BABFA7AE0B08DE_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_461BFDA3103BA76785BABFA7AE0B08DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_461BFDA3103BA76785BABFA7AE0B08DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_461BFDA3103BA76785BABFA7AE0B08DE" xlink:to="lab_dei_EntityCentralIndexKey_461BFDA3103BA76785BABFA7AE0B08DE" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_C368E2BFD371EC1276C5BFA7AE0B9794_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_C368E2BFD371EC1276C5BFA7AE0B9794" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_C368E2BFD371EC1276C5BFA7AE0B9794_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_C368E2BFD371EC1276C5BFA7AE0B9794" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_C368E2BFD371EC1276C5BFA7AE0B9794" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_C368E2BFD371EC1276C5BFA7AE0B9794" xlink:to="lab_dei_CurrentFiscalYearEndDate_C368E2BFD371EC1276C5BFA7AE0B9794" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_9F93CE9B5762E5B3012CBFA7AE0B92C3_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_9F93CE9B5762E5B3012CBFA7AE0B92C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_9F93CE9B5762E5B3012CBFA7AE0B92C3_label_en-US" xlink:label="lab_dei_EntityFilerCategory_9F93CE9B5762E5B3012CBFA7AE0B92C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_9F93CE9B5762E5B3012CBFA7AE0B92C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_9F93CE9B5762E5B3012CBFA7AE0B92C3" xlink:to="lab_dei_EntityFilerCategory_9F93CE9B5762E5B3012CBFA7AE0B92C3" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_ED28552A9644B659EC40BFA7AE0C60B4_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_ED28552A9644B659EC40BFA7AE0C60B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_ED28552A9644B659EC40BFA7AE0C60B4_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_ED28552A9644B659EC40BFA7AE0C60B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_ED28552A9644B659EC40BFA7AE0C60B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_ED28552A9644B659EC40BFA7AE0C60B4" xlink:to="lab_dei_EntitySmallBusiness_ED28552A9644B659EC40BFA7AE0C60B4" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0B979F7E59B6653678BABFA7AE0C54DF_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_0B979F7E59B6653678BABFA7AE0C54DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0B979F7E59B6653678BABFA7AE0C54DF_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_0B979F7E59B6653678BABFA7AE0C54DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_0B979F7E59B6653678BABFA7AE0C54DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_0B979F7E59B6653678BABFA7AE0C54DF" xlink:to="lab_dei_EntityEmergingGrowthCompany_0B979F7E59B6653678BABFA7AE0C54DF" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_6FF00AE76DE953109706BFA7B0034930_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_6FF00AE76DE953109706BFA7B0034930" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_6FF00AE76DE953109706BFA7B0034930_label_en-US" xlink:label="lab_dei_EntityShellCompany_6FF00AE76DE953109706BFA7B0034930" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_6FF00AE76DE953109706BFA7B0034930" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_6FF00AE76DE953109706BFA7B0034930" xlink:to="lab_dei_EntityShellCompany_6FF00AE76DE953109706BFA7B0034930" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_83CAFBCDDAD842B4BC34BFA7AE0C0B01_terseLabel_en-US" xlink:label="lab_dei_DocumentType_83CAFBCDDAD842B4BC34BFA7AE0C0B01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_83CAFBCDDAD842B4BC34BFA7AE0C0B01_label_en-US" xlink:label="lab_dei_DocumentType_83CAFBCDDAD842B4BC34BFA7AE0C0B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_83CAFBCDDAD842B4BC34BFA7AE0C0B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_83CAFBCDDAD842B4BC34BFA7AE0C0B01" xlink:to="lab_dei_DocumentType_83CAFBCDDAD842B4BC34BFA7AE0C0B01" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_69FC94A8E21DA2140B83BFA7AE0C9BB5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_69FC94A8E21DA2140B83BFA7AE0C9BB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_69FC94A8E21DA2140B83BFA7AE0C9BB5_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_69FC94A8E21DA2140B83BFA7AE0C9BB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_69FC94A8E21DA2140B83BFA7AE0C9BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_69FC94A8E21DA2140B83BFA7AE0C9BB5" xlink:to="lab_dei_DocumentPeriodEndDate_69FC94A8E21DA2140B83BFA7AE0C9BB5" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_2C74CE19A0BB0CB6E96FBFA7AE0CAE4D_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_2C74CE19A0BB0CB6E96FBFA7AE0CAE4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2C74CE19A0BB0CB6E96FBFA7AE0CAE4D_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_2C74CE19A0BB0CB6E96FBFA7AE0CAE4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_2C74CE19A0BB0CB6E96FBFA7AE0CAE4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_2C74CE19A0BB0CB6E96FBFA7AE0CAE4D" xlink:to="lab_dei_DocumentFiscalYearFocus_2C74CE19A0BB0CB6E96FBFA7AE0CAE4D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_435A0B0CA588B7E96431BFA7AE0D9808_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_435A0B0CA588B7E96431BFA7AE0D9808" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_435A0B0CA588B7E96431BFA7AE0D9808_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_435A0B0CA588B7E96431BFA7AE0D9808" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_435A0B0CA588B7E96431BFA7AE0D9808" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_435A0B0CA588B7E96431BFA7AE0D9808" xlink:to="lab_dei_DocumentFiscalPeriodFocus_435A0B0CA588B7E96431BFA7AE0D9808" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_5D6BBA69CA86065B48E7BFA7AE0D2338_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_5D6BBA69CA86065B48E7BFA7AE0D2338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_5D6BBA69CA86065B48E7BFA7AE0D2338_label_en-US" xlink:label="lab_dei_AmendmentFlag_5D6BBA69CA86065B48E7BFA7AE0D2338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_5D6BBA69CA86065B48E7BFA7AE0D2338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_5D6BBA69CA86065B48E7BFA7AE0D2338" xlink:to="lab_dei_AmendmentFlag_5D6BBA69CA86065B48E7BFA7AE0D2338" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_72D1DFB7EBAFF80BE110BFA7AE0D88A0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_72D1DFB7EBAFF80BE110BFA7AE0D88A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_72D1DFB7EBAFF80BE110BFA7AE0D88A0_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_72D1DFB7EBAFF80BE110BFA7AE0D88A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_72D1DFB7EBAFF80BE110BFA7AE0D88A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_72D1DFB7EBAFF80BE110BFA7AE0D88A0" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_72D1DFB7EBAFF80BE110BFA7AE0D88A0" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_2A3B28D69414B91F52DDBFA7AE0D4772_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_2A3B28D69414B91F52DDBFA7AE0D4772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_2A3B28D69414B91F52DDBFA7AE0D4772_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_2A3B28D69414B91F52DDBFA7AE0D4772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_2A3B28D69414B91F52DDBFA7AE0D4772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_2A3B28D69414B91F52DDBFA7AE0D4772" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_2A3B28D69414B91F52DDBFA7AE0D4772" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_BFD4526F1A9CABEC60F2BFA7AE0E801A_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_BFD4526F1A9CABEC60F2BFA7AE0E801A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_BFD4526F1A9CABEC60F2BFA7AE0E801A_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_BFD4526F1A9CABEC60F2BFA7AE0E801A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_BFD4526F1A9CABEC60F2BFA7AE0E801A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_BFD4526F1A9CABEC60F2BFA7AE0E801A" xlink:to="lab_dei_EntityVoluntaryFilers_BFD4526F1A9CABEC60F2BFA7AE0E801A" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_5AE74CD189DDD002FDE3BFA7AE0E13D5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_5AE74CD189DDD002FDE3BFA7AE0E13D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5AE74CD189DDD002FDE3BFA7AE0E13D5_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_5AE74CD189DDD002FDE3BFA7AE0E13D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_5AE74CD189DDD002FDE3BFA7AE0E13D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_5AE74CD189DDD002FDE3BFA7AE0E13D5" xlink:to="lab_dei_EntityCurrentReportingStatus_5AE74CD189DDD002FDE3BFA7AE0E13D5" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_806AD4F5AD862AD454BABFA7AE0E825D_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_806AD4F5AD862AD454BABFA7AE0E825D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_806AD4F5AD862AD454BABFA7AE0E825D_label_en-US" xlink:label="lab_dei_EntityPublicFloat_806AD4F5AD862AD454BABFA7AE0E825D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_806AD4F5AD862AD454BABFA7AE0E825D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_806AD4F5AD862AD454BABFA7AE0E825D" xlink:to="lab_dei_EntityPublicFloat_806AD4F5AD862AD454BABFA7AE0E825D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_80116DD232CD55E7FE53FBB835D7AA89_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_80116DD232CD55E7FE53FBB835D7AA89" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_80116DD232CD55E7FE53FBB835D7AA89_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_80116DD232CD55E7FE53FBB835D7AA89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_80116DD232CD55E7FE53FBB835D7AA89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_80116DD232CD55E7FE53FBB835D7AA89" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_80116DD232CD55E7FE53FBB835D7AA89" xlink:type="arc" />
    <link:label id="lab_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8_label_en-US" xlink:label="lab_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Distributor [Axis]</link:label>
    <link:label id="lab_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8_documentation_en-US" xlink:label="lab_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:to="lab_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:type="arc" />
    <link:label id="lab_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03_terseLabel_en-US" xlink:label="lab_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03_label_en-US" xlink:label="lab_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Distributor [Domain]</link:label>
    <link:label id="lab_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03_documentation_en-US" xlink:label="lab_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Major Distributor.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:to="lab_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:type="arc" />
    <link:label id="lab_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F_label_en-US" xlink:label="lab_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F_documentation_en-US" xlink:label="lab_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F" xlink:to="lab_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F" xlink:type="arc" />
    <link:label id="lab_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1_label_en-US" xlink:label="lab_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1" xlink:to="lab_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1" xlink:type="arc" />
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenue from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0" xlink:type="arc" />
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E_terseLabel_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E_label_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Receivables Of Wholesale Distributor Accounted In Consolidated Receivables</link:label>
    <link:label id="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E_documentation_en-US" xlink:label="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage receivables of wholesale distributor accounted in consolidated receivables.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E" xlink:to="lab_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E" xlink:type="arc" />
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB_terseLabel_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB_label_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:label id="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB_documentation_en-US" xlink:label="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues In Percentage From Anti-CD20 Therapeutic Programs</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB" xlink:to="lab_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_E1D9E2824A6ADD1534618208486383F6_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_E1D9E2824A6ADD1534618208486383F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_E1D9E2824A6ADD1534618208486383F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_E1D9E2824A6ADD1534618208486383F6" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_E1D9E2824A6ADD1534618208486383F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F28DDC01424B42A42CD78208486362BC_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F28DDC01424B42A42CD78208486362BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F28DDC01424B42A42CD78208486362BC_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F28DDC01424B42A42CD78208486362BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F28DDC01424B42A42CD78208486362BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F28DDC01424B42A42CD78208486362BC" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F28DDC01424B42A42CD78208486362BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7810A9594F9FEA17D1C28208486333DA_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7810A9594F9FEA17D1C28208486333DA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7810A9594F9FEA17D1C28208486333DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7810A9594F9FEA17D1C28208486333DA" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7810A9594F9FEA17D1C28208486333DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7CBA5F9C23AD93DDDE3E820848635EA3_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7CBA5F9C23AD93DDDE3E820848635EA3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7CBA5F9C23AD93DDDE3E820848635EA3_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7CBA5F9C23AD93DDDE3E820848635EA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7CBA5F9C23AD93DDDE3E820848635EA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7CBA5F9C23AD93DDDE3E820848635EA3" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7CBA5F9C23AD93DDDE3E820848635EA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_31F224D8152AF2B49776820848638472_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_31F224D8152AF2B49776820848638472" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_31F224D8152AF2B49776820848638472_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_31F224D8152AF2B49776820848638472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_31F224D8152AF2B49776820848638472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_31F224D8152AF2B49776820848638472" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_31F224D8152AF2B49776820848638472" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_CAFEC334AB659433928282084863B5DB_terseLabel_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_CAFEC334AB659433928282084863B5DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_CAFEC334AB659433928282084863B5DB_label_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_CAFEC334AB659433928282084863B5DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:label id="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_CAFEC334AB659433928282084863B5DB_documentation_en-US" xlink:label="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_CAFEC334AB659433928282084863B5DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective income tax rate reconciliation manufacturing deduction</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_CAFEC334AB659433928282084863B5DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_CAFEC334AB659433928282084863B5DB" xlink:to="lab_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_CAFEC334AB659433928282084863B5DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1F0C424BE781AF4D7C9D82084863079B_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1F0C424BE781AF4D7C9D82084863079B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Tax Act</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1F0C424BE781AF4D7C9D82084863079B_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1F0C424BE781AF4D7C9D82084863079B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1F0C424BE781AF4D7C9D82084863079B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1F0C424BE781AF4D7C9D82084863079B" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1F0C424BE781AF4D7C9D82084863079B" xlink:type="arc" />
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_83F390E0603BFE77BC2A824CCB9EE79A_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_83F390E0603BFE77BC2A824CCB9EE79A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_83F390E0603BFE77BC2A824CCB9EE79A_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_83F390E0603BFE77BC2A824CCB9EE79A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_83F390E0603BFE77BC2A824CCB9EE79A_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax_83F390E0603BFE77BC2A824CCB9EE79A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_83F390E0603BFE77BC2A824CCB9EE79A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax_83F390E0603BFE77BC2A824CCB9EE79A" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax_83F390E0603BFE77BC2A824CCB9EE79A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_55228EA6929EE5F1064682084863947E_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_55228EA6929EE5F1064682084863947E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of ZINBRYTA related tax assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_55228EA6929EE5F1064682084863947E_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_55228EA6929EE5F1064682084863947E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_55228EA6929EE5F1064682084863947E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_55228EA6929EE5F1064682084863947E" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_55228EA6929EE5F1064682084863947E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_D54E3C452AC8908BD122820848638B35_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_D54E3C452AC8908BD122820848638B35" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_D54E3C452AC8908BD122820848638B35_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_D54E3C452AC8908BD122820848638B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_D54E3C452AC8908BD122820848638B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_D54E3C452AC8908BD122820848638B35" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_D54E3C452AC8908BD122820848638B35" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3A24A534E380C5A17BB18208486360D3_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3A24A534E380C5A17BB18208486360D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3A24A534E380C5A17BB18208486360D3_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3A24A534E380C5A17BB18208486360D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3A24A534E380C5A17BB18208486360D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3A24A534E380C5A17BB18208486360D3" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3A24A534E380C5A17BB18208486360D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2271B534A596F5FA04DD82084863E1A4_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2271B534A596F5FA04DD82084863E1A4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2271B534A596F5FA04DD82084863E1A4_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2271B534A596F5FA04DD82084863E1A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2271B534A596F5FA04DD82084863E1A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2271B534A596F5FA04DD82084863E1A4" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2271B534A596F5FA04DD82084863E1A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Ownership Plan (ESOP) Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:to="lab_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:type="arc" />
    <link:label id="lab_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092_terseLabel_en-US" xlink:label="lab_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 ESPP</link:label>
    <link:label id="lab_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092_label_en-US" xlink:label="lab_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:label id="lab_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092_documentation_en-US" xlink:label="lab_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2015 ESPP [Member]</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092" xlink:to="lab_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4E375134977D9BC8EE47871CADE3F8E6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4E375134977D9BC8EE47871CADE3F8E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received under ESPP</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4E375134977D9BC8EE47871CADE3F8E6_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4E375134977D9BC8EE47871CADE3F8E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4E375134977D9BC8EE47871CADE3F8E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4E375134977D9BC8EE47871CADE3F8E6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4E375134977D9BC8EE47871CADE3F8E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:type="arc" />
    <link:label id="lab_country_DK_2E5B90925F6CD957F36BC42825723F92_terseLabel_en-US" xlink:label="lab_country_DK_2E5B90925F6CD957F36BC42825723F92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DENMARK</link:label>
    <link:label id="lab_country_DK_2E5B90925F6CD957F36BC42825723F92_label_en-US" xlink:label="lab_country_DK_2E5B90925F6CD957F36BC42825723F92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DENMARK</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DK" xlink:label="loc_country_DK_2E5B90925F6CD957F36BC42825723F92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DK_2E5B90925F6CD957F36BC42825723F92" xlink:to="lab_country_DK_2E5B90925F6CD957F36BC42825723F92" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncurrentAssets_1F926656A1431DA70DE6C4282574D6AF_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets_1F926656A1431DA70DE6C4282574D6AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets related to operations in Denmark</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_1F926656A1431DA70DE6C4282574D6AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets_1F926656A1431DA70DE6C4282574D6AF" xlink:to="lab_us-gaap_NoncurrentAssets_1F926656A1431DA70DE6C4282574D6AF" xlink:type="arc" />
    <link:label id="lab_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104_verboseLabel_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104_label_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Information (Textual) [Abstract]</link:label>
    <link:label id="lab_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104_documentation_en-US" xlink:label="lab_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Segment Information.</link:label>
    <link:loc xlink:href="biib-20181231.xsd#biib_SegmentInformationTextualAbstract" xlink:label="loc_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104" xlink:to="lab_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportableSegments_5EA0A7FB0E794E42E45FC4282575B485_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_5EA0A7FB0E794E42E45FC4282575B485" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segment</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_5EA0A7FB0E794E42E45FC4282575B485_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments_5EA0A7FB0E794E42E45FC4282575B485" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_5EA0A7FB0E794E42E45FC4282575B485" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments_5EA0A7FB0E794E42E45FC4282575B485" xlink:to="lab_us-gaap_NumberOfReportableSegments_5EA0A7FB0E794E42E45FC4282575B485" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_C4030F2C608C8D8F609E85CC9CB3A392_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_C4030F2C608C8D8F609E85CC9CB3A392" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Geographic information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_C4030F2C608C8D8F609E85CC9CB3A392_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_C4030F2C608C8D8F609E85CC9CB3A392" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_C4030F2C608C8D8F609E85CC9CB3A392" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_C4030F2C608C8D8F609E85CC9CB3A392" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_C4030F2C608C8D8F609E85CC9CB3A392" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>biib-20181231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:href="biib-20181231.xsd#AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:href="biib-20181231.xsd#Acquisitions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:href="biib-20181231.xsd#AcquisitionsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationships" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:href="biib-20181231.xsd#CollaborativeAndOtherRelationshipsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:href="biib-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:href="biib-20181231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:href="biib-20181231.xsd#CommitmentsAndContingenciesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:href="biib-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:href="biib-20181231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="biib-20181231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:href="biib-20181231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:href="biib-20181231.xsd#DerivativeInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:href="biib-20181231.xsd#DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:href="biib-20181231.xsd#DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails2" xlink:href="biib-20181231.xsd#DerivativeInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:href="biib-20181231.xsd#DerivativeInstrumentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:href="biib-20181231.xsd#DerivativeInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:href="biib-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShare" xlink:href="biib-20181231.xsd#EarningsPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:href="biib-20181231.xsd#EarningsPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:href="biib-20181231.xsd#EarningsPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:href="biib-20181231.xsd#EmployeeBenefitPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:href="biib-20181231.xsd#EmployeeBenefitPlansDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:href="biib-20181231.xsd#EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:href="biib-20181231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetails" xlink:href="biib-20181231.xsd#EquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:href="biib-20181231.xsd#EquityDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:href="biib-20181231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:href="biib-20181231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:href="biib-20181231.xsd#FairValueMeasurementsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:href="biib-20181231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:href="biib-20181231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetailsTextual1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:href="biib-20181231.xsd#FinancialInstrumentsDetailsTextual2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:href="biib-20181231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Guarantees" xlink:href="biib-20181231.xsd#Guarantees" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOff" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:href="biib-20181231.xsd#HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:href="biib-20181231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:href="biib-20181231.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:href="biib-20181231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:href="biib-20181231.xsd#IncomeTaxesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:href="biib-20181231.xsd#IncomeTaxesDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:href="biib-20181231.xsd#IncomeTaxesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:href="biib-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:href="biib-20181231.xsd#Indebtedness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:href="biib-20181231.xsd#IndebtednessDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:href="biib-20181231.xsd#IndebtednessDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:href="biib-20181231.xsd#IndebtednessDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessTables" xlink:href="biib-20181231.xsd#IndebtednessTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwillDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:href="biib-20181231.xsd#IntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:href="biib-20181231.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetails" xlink:href="biib-20181231.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:href="biib-20181231.xsd#InventoryDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:href="biib-20181231.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:href="biib-20181231.xsd#InvestmentsInVariableInterestEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:href="biib-20181231.xsd#InvestmentsInVariableInterestEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:href="biib-20181231.xsd#Litigation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:href="biib-20181231.xsd#LitigationLitigationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:href="biib-20181231.xsd#OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipmentDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:href="biib-20181231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:href="biib-20181231.xsd#QuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:href="biib-20181231.xsd#RestructuringRestructuring" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:href="biib-20181231.xsd#RestructuringRestructuringDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:href="biib-20181231.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:href="biib-20181231.xsd#RevenuesByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:href="biib-20181231.xsd#RevenuesDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:href="biib-20181231.xsd#RevenuesOtherRevenuesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:href="biib-20181231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:href="biib-20181231.xsd#RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:href="biib-20181231.xsd#RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:href="biib-20181231.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:href="biib-20181231.xsd#SegmentInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:href="biib-20181231.xsd#SegmentInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:href="biib-20181231.xsd#SegmentInformationDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:href="biib-20181231.xsd#SegmentInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPayments" xlink:href="biib-20181231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails1" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails10" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails11" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails3" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails4" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails5" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails6" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails7" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails8" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetails9" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:href="biib-20181231.xsd#ShareBasedPaymentsDetailsTextual" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:href="biib-20181231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:href="biib-20181231.xsd#SubsequentEventsSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:href="biib-20181231.xsd#SubsequentEventsSubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="biib-20181231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_C9F115210E946CECC13EFBB83432D69D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6F2D88D39C7FEA4AA00BFBB834326F32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_C9F115210E946CECC13EFBB83432D69D" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_6F2D88D39C7FEA4AA00BFBB834326F32" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DC02C5374B0A904E38B59FD49DF231F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_9524F812A636B9EB278D9FD49DF2788C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_DC02C5374B0A904E38B59FD49DF231F5" xlink:to="loc_us-gaap_StatementTable_9524F812A636B9EB278D9FD49DF2788C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6DA03D1EFD5CDF5313409FD49DF232A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9524F812A636B9EB278D9FD49DF2788C" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6DA03D1EFD5CDF5313409FD49DF232A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B77093C2279D1006CB549FD49DF20919" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_6DA03D1EFD5CDF5313409FD49DF232A7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B77093C2279D1006CB549FD49DF20919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_9C2302D980043CC862229FD49DF2834F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B77093C2279D1006CB549FD49DF20919" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_9C2302D980043CC862229FD49DF2834F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9524F812A636B9EB278D9FD49DF2788C" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0554F98147659C2089919FD49DF2ABE9" xlink:to="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5B67B8B69473585BE0339FD49DF2539B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_5B67B8B69473585BE0339FD49DF2539B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_6F03DCDA337A766BDB659FD49DF2A7DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_6F03DCDA337A766BDB659FD49DF2A7DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8FF20788F0222BEDB9A19FD4A0A1B05D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8FF20788F0222BEDB9A19FD4A0A1B05D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4F754004E434DA28381B9FD49DF296FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_4F754004E434DA28381B9FD49DF296FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4B930120F08BD75A54FB9FD49DF27B18" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E8353A62A33EBABF5BEA9FD49DF218AE" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_4B930120F08BD75A54FB9FD49DF27B18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9524F812A636B9EB278D9FD49DF2788C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6FD7C678AB2EC1D192029FD49DF2CE79" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_091C4BD78FD1A06FE79D9FD49DF221FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_091C4BD78FD1A06FE79D9FD49DF221FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_6E13D7E4174B7F51ACB49FD49DF2AD62" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_6E13D7E4174B7F51ACB49FD49DF2AD62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1080981A5F52B2EEC3D09FD49DF24896" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1080981A5F52B2EEC3D09FD49DF24896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_959C3963391E191FEDCE9FD49DF224C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_959C3963391E191FEDCE9FD49DF224C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_44D5DD9BFA59670A6A9D9FD49DF2F95C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_44D5DD9BFA59670A6A9D9FD49DF2F95C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A020D72AB1461F45A0A39FD49DF2D57F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A020D72AB1461F45A0A39FD49DF2D57F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3860BBAC596ABF1D03E99FD49DF2F0F2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_3860BBAC596ABF1D03E99FD49DF2F0F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_557FA2B994A89DC6E9749FD49DF2A130" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_857D24F47BE9D007E7CA9FD49DF2F548" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_557FA2B994A89DC6E9749FD49DF2A130" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6DBB9A2BD7A8C2F40EF99FD5D487D7C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6DBB9A2BD7A8C2F40EF99FD5D487D7C9" xlink:to="loc_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1F37EAD525385E1C651C9FD5D487464B" xlink:to="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0AF7B62009C18C596C719FD5D487DCFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_0AF7B62009C18C596C719FD5D487DCFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7E319EE7ABAFB70DCA719FD5D48709D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_7E319EE7ABAFB70DCA719FD5D48709D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_552F34AC139F833CD5489FD5D487162C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember_552F34AC139F833CD5489FD5D487162C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8BD6FA144744EEC7E5FF9FD5D6FCEEAE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_F9E17643AA19E267ADEC9FD5D487FF9C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8BD6FA144744EEC7E5FF9FD5D6FCEEAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_F9CD2A80D9981F306F3B9FD5D487B4F5" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_E3E5162FF35BA26803A99FD5D4877AC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_DF651B904B4C72139FA79FD5D487845C" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_E3E5162FF35BA26803A99FD5D4877AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3D8C2C99D0C485EDFEC69FD5D487C735" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8AAE542D213BF16C1C3E9FD5D487EA48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8AAE542D213BF16C1C3E9FD5D487EA48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_35AB3994D1189F0CD2C49FD5D48764C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_35AB3994D1189F0CD2C49FD5D48764C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_5BCA285D46E681A79D159FD5D487DADC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_Revenues_5BCA285D46E681A79D159FD5D487DADC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_EA77B1C0E46B71DF80419FD5D4879210" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_OperatingExpenses_EA77B1C0E46B71DF80419FD5D4879210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_B5F47AF5606D8DF8DAA29FD5D487AC37" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_B5F47AF5606D8DF8DAA29FD5D487AC37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_FF086133C61DD682A07D9FD5D4871BCD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_DF32D5DFF0469BF052559FD5D487A321" xlink:to="loc_us-gaap_NetIncomeLoss_FF086133C61DD682A07D9FD5D4871BCD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_CB6D35F378219170CDBBFBB8348F51D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_333014991CA34F723432FBB8348FBC6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_CB6D35F378219170CDBBFBB8348F51D4" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_333014991CA34F723432FBB8348FBC6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4A94AD0FCEFB71FA1427FBB8348FB6F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_CB6D35F378219170CDBBFBB8348F51D4" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_4A94AD0FCEFB71FA1427FBB8348FB6F1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_B71202BD0D519594F187FBB831E119E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_B79CA19098DBFBE664E4FBB831E1B463" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_B71202BD0D519594F187FBB831E119E6" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_B79CA19098DBFBE664E4FBB831E1B463" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_7D7A61C7E8F114F0C736118916E276F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A75889D2662342A10C0118916E254C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_7D7A61C7E8F114F0C736118916E276F9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A75889D2662342A10C0118916E254C0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_DAFB299A5E683916863311A5E6E63CDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A75889D2662342A10C0118916E254C0" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_DAFB299A5E683916863311A5E6E63CDD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_1986F672D55DE4363AA411A5E6EC600C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_DAFB299A5E683916863311A5E6E63CDD" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_1986F672D55DE4363AA411A5E6EC600C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_1DA9C5EE497B469EBD7711A5E7FCA262" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_1986F672D55DE4363AA411A5E6EC600C" xlink:to="loc_biib_DevelopmentMilestonesMember_1DA9C5EE497B469EBD7711A5E7FCA262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3F95474917C1D7D9312E118916E2B76A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A75889D2662342A10C0118916E254C0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3F95474917C1D7D9312E118916E2B76A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3F95474917C1D7D9312E118916E2B76A" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:to="loc_biib_KaryopharmMember_CFD0B59A11E1E9EB7FF111A47A173312" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:to="loc_biib_PfizerMember_84C982F08313B0562D6911A5389AD24D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TMSMember" xlink:label="loc_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:to="loc_biib_TMSMember_7B453CCD72B2EF436D6211A6DFBCC48A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AliveGenMember" xlink:label="loc_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:to="loc_biib_AliveGenMember_21B4CD39D2C6F8ABA26011A7FF7FFB61" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D714529B3E06B1A49B27118916E29B17" xlink:to="loc_biib_RemedyPharmaceuticalMember_DCDA7ED1B8ECC85FE5B3118916E2C03E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_AEB60DB42B1C26955715118916E282B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8A75889D2662342A10C0118916E254C0" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_AEB60DB42B1C26955715118916E282B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_AE9C9DEB922C1E15F163118916E21C6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AEB60DB42B1C26955715118916E282B1" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_AE9C9DEB922C1E15F163118916E21C6E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_99EDF5CAD60A287D385B11A4E6B40429" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AEB60DB42B1C26955715118916E282B1" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_99EDF5CAD60A287D385B11A4E6B40429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_968B1D32F9438682B13511A6DF798BF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_AEB60DB42B1C26955715118916E282B1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_968B1D32F9438682B13511A6DF798BF1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationships" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C58437C796964BE1E901FBB831743893" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6F4574D4C8E581512784FBB831743619" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C58437C796964BE1E901FBB831743893" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_6F4574D4C8E581512784FBB831743619" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D1EAF634BE53BDD189C69A049BAB5DB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D1EAF634BE53BDD189C69A049BAB5DB7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_2CF60E280C44F77CD7719A049BAC435A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:to="loc_srt_MajorCustomersAxis_2CF60E280C44F77CD7719A049BAC435A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_580C06347112E728D50D9A049BAC399F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2CF60E280C44F77CD7719A049BAC435A" xlink:to="loc_srt_NameOfMajorCustomerDomain_580C06347112E728D50D9A049BAC399F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_93DC2934F17888FD465D9A049BB13035" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_580C06347112E728D50D9A049BAC399F" xlink:to="loc_biib_AbbVieMember_93DC2934F17888FD465D9A049BB13035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0BA048C9AA31470657679A049BB27AA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:to="loc_srt_ProductOrServiceAxis_0BA048C9AA31470657679A049BB27AA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_418E7423754F1177CD019A049BB29521" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0BA048C9AA31470657679A049BB27AA0" xlink:to="loc_srt_ProductsAndServicesDomain_418E7423754F1177CD019A049BB29521" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_7D84725203D34F03CE019A049BB238E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_418E7423754F1177CD019A049BB29521" xlink:to="loc_us-gaap_ProductMember_7D84725203D34F03CE019A049BB238E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_18DDCC13EC0A164F90169A049BB3864B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:to="loc_srt_StatementGeographicalAxis_18DDCC13EC0A164F90169A049BB3864B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_CACC8802A873C4CCF6529A049BB34F53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_18DDCC13EC0A164F90169A049BB3864B" xlink:to="loc_srt_SegmentGeographicalDomain_CACC8802A873C4CCF6529A049BB34F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_DA1567024C326D1F14419A049BB37F10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_CACC8802A873C4CCF6529A049BB34F53" xlink:to="loc_country_US_DA1567024C326D1F14419A049BB37F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9924E939A3F6468EF1BE9A049BB3BC09" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9924E939A3F6468EF1BE9A049BB3BC09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0BEA1CDB270FD7AA628B9A049BB373F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9924E939A3F6468EF1BE9A049BB3BC09" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0BEA1CDB270FD7AA628B9A049BB373F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_F97CC8EEB0AB69FBEC3C9A049BB40D36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0BEA1CDB270FD7AA628B9A049BB373F1" xlink:to="loc_biib_AbbVieMember_F97CC8EEB0AB69FBEC3C9A049BB40D36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E3446C6511F88F8108E19A049BB4D370" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2952102203133319CABC9A049BAB8456" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E3446C6511F88F8108E19A049BB4D370" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_A2E4241A96C30FD24DA39A049BB4E3C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E3446C6511F88F8108E19A049BB4D370" xlink:to="loc_us-gaap_Revenues_A2E4241A96C30FD24DA39A049BB4E3C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_43C3156C9691F38749AD9A049BB4A85B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E3446C6511F88F8108E19A049BB4D370" xlink:to="loc_us-gaap_CostsAndExpenses_43C3156C9691F38749AD9A049BB4A85B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Copromotionprofitsandlosses" xlink:label="loc_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E3446C6511F88F8108E19A049BB4D370" xlink:to="loc_biib_Copromotionprofitsandlosses_2DBCFF679B715160D5589A049BB53F6F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D7F9A204A9A1C2C04B4E85B86A23A22D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EB7C6A1B3D1591072F9385B86A23337D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D7F9A204A9A1C2C04B4E85B86A23A22D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EB7C6A1B3D1591072F9385B86A23337D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_CAAEA22AE06E6B67A13785B86A233D0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EB7C6A1B3D1591072F9385B86A23337D" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_CAAEA22AE06E6B67A13785B86A233D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_788BEC0AA06FCC46042985B86A232116" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CAAEA22AE06E6B67A13785B86A233D0A" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_788BEC0AA06FCC46042985B86A232116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8303A9399F18F729E32285B86A23D7C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_788BEC0AA06FCC46042985B86A232116" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_8303A9399F18F729E32285B86A23D7C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0BB81794DBFF46A9A67C85B86A2346B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_788BEC0AA06FCC46042985B86A232116" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0BB81794DBFF46A9A67C85B86A2346B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4F0D7EBED12009B5647485B86A23D3F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EB7C6A1B3D1591072F9385B86A23337D" xlink:to="loc_srt_ProductOrServiceAxis_4F0D7EBED12009B5647485B86A23D3F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B60B54989D19EA5B3B5E85B86A235270" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4F0D7EBED12009B5647485B86A23D3F0" xlink:to="loc_srt_ProductsAndServicesDomain_B60B54989D19EA5B3B5E85B86A235270" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AducanumabMember" xlink:label="loc_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B60B54989D19EA5B3B5E85B86A235270" xlink:to="loc_biib_AducanumabMember_1670E587A793C2FEB95C85B86A23C5F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_A3F6C85DE1C9A95E7E6785B86A231C18" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EB7C6A1B3D1591072F9385B86A23337D" xlink:to="loc_us-gaap_TypeOfArrangementAxis_A3F6C85DE1C9A95E7E6785B86A231C18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01B0FAA28EF1334F256985B86A26C37B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_A3F6C85DE1C9A95E7E6785B86A231C18" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01B0FAA28EF1334F256985B86A26C37B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_14888ECD3A258F8152B585B86A262A1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_01B0FAA28EF1334F256985B86A26C37B" xlink:to="loc_biib_EisaiMember_14888ECD3A258F8152B585B86A262A1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_36945667EE84E8DEF28085B86A265ECA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EB7C6A1B3D1591072F9385B86A23337D" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_36945667EE84E8DEF28085B86A265ECA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_0C5A26DA0990379A615A85B86A260979" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_36945667EE84E8DEF28085B86A265ECA" xlink:to="loc_biib_ExpenseIncurredByCollaboration_0C5A26DA0990379A615A85B86A260979" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Expenseincurredbythecollaboration" xlink:label="loc_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_36945667EE84E8DEF28085B86A265ECA" xlink:to="loc_biib_Expenseincurredbythecollaboration_FEE05B16274820346CB685B86A26104F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_16BF2671370DB496C9BC85B86A26EA8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_36945667EE84E8DEF28085B86A265ECA" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_16BF2671370DB496C9BC85B86A26EA8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27C79807347547787CFCC42825F2B28E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27C79807347547787CFCC42825F2B28E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_222998776942B30A1340C42825F3516D" xlink:to="loc_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_267AE9EDA366CF18E782C42825F3AC84" xlink:to="loc_biib_AbbVieMember_8A9CF90447AE306782BCC42825F328D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis_65CA4926023DB634948FC42825F3857B" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="loc_us-gaap_ScenarioForecastMember_42F360B32B0BEA8D16C7C42825F401C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain_C057294A0AB56F4A5EEDC42825F4DEB5" xlink:to="loc_us-gaap_ScenarioForecastMember_42F360B32B0BEA8D16C7C42825F401C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4C97A430F8BF605CC47AC42825F4A429" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4C97A430F8BF605CC47AC42825F4A429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D9F213F7BC96ECA93789C42825F57DC5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4C97A430F8BF605CC47AC42825F4A429" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D9F213F7BC96ECA93789C42825F57DC5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_EC50CBCF03B10B208151C42825F51030" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_D9F213F7BC96ECA93789C42825F57DC5" xlink:to="loc_biib_InLicensedPatentsMember_EC50CBCF03B10B208151C42825F51030" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_03513D4D085DDF9685E8C42825F531B5" xlink:to="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_0B9E60FC2606F89A2C7FC42825F6F977" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:to="loc_country_US_0B9E60FC2606F89A2C7FC42825F6F977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeographicDistributionForeignMember" xlink:label="loc_us-gaap_GeographicDistributionForeignMember_B5FBB7D142643CB75FE4C42825F6125A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:to="loc_us-gaap_GeographicDistributionForeignMember_B5FBB7D142643CB75FE4C42825F6125A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_355C148EFE12571EE5B9C42825F6AD70" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:to="loc_us-gaap_ForeignCountryMember_355C148EFE12571EE5B9C42825F6AD70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_A1491A272F841BE2282CC42825F6EAF3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:to="loc_us-gaap_EuropeanUnionMember_A1491A272F841BE2282CC42825F6EAF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_F2ED2B4AC12C1257F0A5C42825F61E5F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3B8C42C827282AB7B913C42825F58CD9" xlink:to="loc_country_JP_F2ED2B4AC12C1257F0A5C42825F61E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_22E1CD6CF35B2621BE7BC42825F663A6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_22E1CD6CF35B2621BE7BC42825F663A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_188966DC9C0229841EB6C42825F7DB5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22E1CD6CF35B2621BE7BC42825F663A6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_188966DC9C0229841EB6C42825F7DB5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6F90A14C9B9439CCAD8FC42825F778E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_188966DC9C0229841EB6C42825F7DB5D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6F90A14C9B9439CCAD8FC42825F778E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349502A345686C9147DDC42825F79E2C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_188966DC9C0229841EB6C42825F7DB5D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_349502A345686C9147DDC42825F79E2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_6456F4949305E96116EAC42825F7BC8C" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_12B98612091170978A39C42825F89F08" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_A9FD6596DE6ADA0DA897C42825F8954A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_srt_ProductOrServiceAxis_A9FD6596DE6ADA0DA897C42825F8954A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_A9FD6596DE6ADA0DA897C42825F8954A" xlink:to="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_RituxanMember_12C41559FD8CA0AD6D28C42825F965B2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_GAZYVAMember_7D2BF92FBBB6F4C0B699C42825F94596" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NewAntiCd20Member" xlink:label="loc_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_NewAntiCd20Member_614D4E0D25B1ECBA8B5EC42825F92A83" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OCREVUSMember" xlink:label="loc_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_OCREVUSMember_D74871D266BE72AB5946C42825F9CDF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_AF891EE1F52F340299DCC42825F91DC9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_ZINBRYTAMember_AF891EE1F52F340299DCC42825F91DC9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_A8021F153C3C83F8788BC42825F9B4C4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_SPINRAZAMember_A8021F153C3C83F8788BC42825F9B4C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SOD1Member" xlink:label="loc_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_SOD1Member_773A44F12EB3AF216CF8C42825FA7A0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_C213A9A8BE0B19F8B83FC42825FA691E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_BiosimilarsMember_C213A9A8BE0B19F8B83FC42825FA691E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B4E69589D66E038CC380C42825F8BB8D" xlink:to="loc_biib_IMRALDIMember_51CCCCD88DD82DF62427C42825FA00C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2B176CBA404D7ED87C5EC42825FA13DE" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_RocheGroupGenentechMember_42B7F83888E6C681D90DC42825FBB7CD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_IonisPharmaceuticalsMember_446BF969240B76B27045C42825FBCA4E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EisaiMember" xlink:label="loc_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_EisaiMember_ABEA75263214C0F99415C42825FBBBFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_AlkermesMember_2E02DD3C1B300A1E5F0EC42825FB7E7E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_BristolMyersSquibbMember_E6365A9B0FD498E18DF1C42825FCA7E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_IPerianMember_7250583989E8F0DDFAB3C42825FC7CC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AcordaMember" xlink:label="loc_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_AcordaMember_775077EE4DF6B0EEEA04C42825FC4565" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_18005FF1FD3AF3534D3BC42825FCB0FB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_AbbVieMember_18005FF1FD3AF3534D3BC42825FCB0FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_E3E30D0D4746C0201D2EC42825FC9A1C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_us-gaap_CollaborativeArrangementMember_E3E30D0D4746C0201D2EC42825FC9A1C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AGTCMember" xlink:label="loc_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_AGTCMember_EFF2589C256BF1B47887C42825FC0788" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_UniversityofPennsylvaniaMember" xlink:label="loc_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_UniversityofPennsylvaniaMember_D78811E9FD89467B5DE7C42825FD83BB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_C4TherapeuticsMember" xlink:label="loc_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_C4TherapeuticsMember_3CD4E126B307F7325198C42825FDDBEB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherresearchanddiscoveryMember" xlink:label="loc_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_OtherresearchanddiscoveryMember_29C2242D82A634935C3FC42825FD4BDB" xlink:type="arc" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_DDAF32F2CF39B05CEBEDC42825FA97F7" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_39569A3008DD96169527C42825F89784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_535D7244BF035AAC5491C42825FD6B9A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_srt_RangeAxis_535D7244BF035AAC5491C42825FD6B9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_CC4C74578600F203A654C42825FDE028" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_535D7244BF035AAC5491C42825FD6B9A" xlink:to="loc_srt_RangeMember_CC4C74578600F203A654C42825FDE028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4A9C0D50E623F356AEACC42825FE6369" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_CC4C74578600F203A654C42825FDE028" xlink:to="loc_srt_MinimumMember_4A9C0D50E623F356AEACC42825FE6369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_D5A41B160EBECF4D10D7C42825FE6853" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_CC4C74578600F203A654C42825FDE028" xlink:to="loc_srt_MaximumMember_D5A41B160EBECF4D10D7C42825FE6853" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_71B00116B7BFC4B0CF48C42825F20B8C" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CollaborationsTextualAbstract" xlink:label="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_2F82B82BB74D6E2AD232C42825FFDE07" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_D88066D7513568392B9CC42825FFE8E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Reductioninroyaltyrate" xlink:label="loc_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_Reductioninroyaltyrate_1AC5016A36631E45680CC42825FF015A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PeriodOfCollaborationAgreement" xlink:label="loc_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_PeriodOfCollaborationAgreement_84E87F5E8FB18BF7AB0EC42825FF7540" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_255F945878CEC06E26F0C42826008A47" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_CE86568EAA7616213B31C4282600149A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_25AF3963CA88CFC06AC5C42826005B78" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_A98603DBE01BA9E4530CC428260085CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SalesTriggerGrossSalesThreshold" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_D476C35B993D6FC1D815C4282600ED90" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Futurepercentageofcopromotionoperatingprofits" xlink:label="loc_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_Futurepercentageofcopromotionoperatingprofits_9BDFF81ED0DC930B35E6C4282600FD82" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_ShareOfCoPromotionProfits_378075A351B128391A95C4282600D6AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Expensereflectedwithinstatementsofincome" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_9CDC7E49C0FF85AFAC2BC4282601F780" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_C2A75B401AD3A691F7A8C4282601B19D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignSalesRequiredToTriggerMilestone" xlink:label="loc_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_ForeignSalesRequiredToTriggerMilestone_B5C9BE87A0DDA6DCA506C4282601C805" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_A4B22C422A91EF6BAB06C42826017B5D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_A4B22C422A91EF6BAB06C42826017B5D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CollaborationsTextualAbstract_C2AE45C3D83CB73231F1C42825FFF236" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_EAE7CD5ABD28AF67F8EAC4282601D6AB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_2F644EA3270FE555F9AFC42826026E85" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_670C57447D3D3A7937A0C42826029077" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_2FA9CEE404FBB837CFCEC42826027BE6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ExpenseIncurredByCollaboration" xlink:label="loc_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_ExpenseIncurredByCollaboration_EB5FCE1DDE2E3D34E975C42826020163" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Biogenshareofcopromotionprofitsorlosses" xlink:label="loc_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Biogenshareofcopromotionprofitsorlosses_53F1CC2F284871638EBDC4282602E743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_59978B3CB729F061D2DAC4282602B2DC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_Revenues_59978B3CB729F061D2DAC4282602B2DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9A08DA065F079C74EA5EC42826030C54" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9A08DA065F079C74EA5EC42826030C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_BF8EBC1A08CE6760E89DC42826030C4F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_BF8EBC1A08CE6760E89DC42826030C4F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Collaborationprofitlosssharing" xlink:label="loc_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Collaborationprofitlosssharing_D256B6F18E148C0A7915C4282603235C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_CollaborationProfitSharing_28BAEDF88571F4223672C4282603D669" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_0B5580634F05734D0796C42826031153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_EA576394E5580A1E7EA5C4282603F794" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_EA576394E5580A1E7EA5C4282603F794" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_LicenseFee" xlink:label="loc_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_LicenseFee_6564D0AAC8A27E62DD3DC42826036316" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments" xlink:label="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments_FD77EC42F3D74F2ED528C4282604D8FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Upfrontpaymentforcollaborationagreement" xlink:label="loc_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Upfrontpaymentforcollaborationagreement_7B8516B2096815A0161EC4282604A9ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Investmentincommonstocksharespurchased_61075B598283FDEF9428C42826041313" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_2D7841008275F419C10BC4282604290C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_AdditionalMilestonePayment_F7B665E1422BA082C030C42826052FE3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Termofcollaborationagreement_3D7636CDDBF10F13EAE5C42826055136" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Totalpaymenttoentercollaborationagreement" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Totalpaymenttoentercollaborationagreement_83EBC78598E81BC82881C42826050039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_52329FF74E2BC438E185C4282605003B" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_52329FF74E2BC438E185C4282605003B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_CE2B8AA5AF72138E73FFC4282605700C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_DevelopmentalMilestonePayment_85F2E6E1D405BC9E07F0C4282605E3D0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_DD185B0E18358712E0ACC428260530BA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Purchaseofcommonstock_2F0B81492AF5A49B11FEC4282606244F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_8771E3AB8719E5A58745C4282606313E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Investmentincommonstockvalue" xlink:label="loc_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Investmentincommonstockvalue_92EC39C0E77C1FE1B0AEC42826068EAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_099BD1E5FE2CDC3EB4AEC4282606BE9E" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_099BD1E5FE2CDC3EB4AEC4282606BE9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Futureresearchanddevelopmentcommitment" xlink:label="loc_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_Futureresearchanddevelopmentcommitment_B06F82F7CD98D7FB34D9C4282606CC36" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement" xlink:label="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement_167CCD79A8BFB1CEDAD3C4282606AFEB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_JointVentureOwnerShipPercentageByThirdParty" xlink:label="loc_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_JointVentureOwnerShipPercentageByThirdParty_31CE2FA6A4E7E0C470B8C4282606CB2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_09121B4CD74A7A05FE7CC42826070EDA" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_EquityMethodInvestments_09121B4CD74A7A05FE7CC42826070EDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4E115CE8CFE8881E3A7FC42826077BED" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4E115CE8CFE8881E3A7FC42826077BED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_D50AB5E190BB7D98F44EC42826078527" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_D50AB5E190BB7D98F44EC42826078527" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_C02B811ABF22A525DFEDC428260723BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1DCE4060D8FE85C9CBB1C4282607D57B" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1DCE4060D8FE85C9CBB1C4282607D57B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EquityMethodInvestmentsExpectedProfitShare" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC" xlink:type="locator" />
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BF5A5A9737EAE1DEC829C42825FE0987" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_51A7103F4134E0303009C428260880DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31249DA71370265F3174879B8F3CEC95" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_746CB8FB9A1225599FB4879B8F3C7F53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_31249DA71370265F3174879B8F3CEC95" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_746CB8FB9A1225599FB4879B8F3C7F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_244A819C8B416B4C9732879B8F3D096D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_746CB8FB9A1225599FB4879B8F3C7F53" xlink:to="loc_srt_ProductOrServiceAxis_244A819C8B416B4C9732879B8F3D096D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_244A819C8B416B4C9732879B8F3D096D" xlink:to="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_GAZYVAMember" xlink:label="loc_biib_GAZYVAMember_51684E73C53DB8A649DF879B8F3DCF4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182" xlink:to="loc_biib_GAZYVAMember_51684E73C53DB8A649DF879B8F3DCF4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RituxanMember" xlink:label="loc_biib_RituxanMember_D1CD3266A1250A14E94E879B8F3D7695" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182" xlink:to="loc_biib_RituxanMember_D1CD3266A1250A14E94E879B8F3D7695" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_95FA65635F43927853E6879B8F3EBA83" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D124FD5CB607D0DD996D879B8F3D2182" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_95FA65635F43927853E6879B8F3EBA83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_169C5643FE2772991B13879B8F3E9439" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_746CB8FB9A1225599FB4879B8F3C7F53" xlink:to="loc_srt_MajorCustomersAxis_169C5643FE2772991B13879B8F3E9439" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_FBBC3C5E2C805C76B983879B8F3EE852" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_169C5643FE2772991B13879B8F3E9439" xlink:to="loc_srt_NameOfMajorCustomerDomain_FBBC3C5E2C805C76B983879B8F3EE852" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_FAFB912D22E4E4A54257879B8F3E81EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_FBBC3C5E2C805C76B983879B8F3EE852" xlink:to="loc_biib_RocheGroupGenentechMember_FAFB912D22E4E4A54257879B8F3E81EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31AB8ADDA79C4F28DC16879B8F3F28C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_746CB8FB9A1225599FB4879B8F3C7F53" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31AB8ADDA79C4F28DC16879B8F3F28C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CoPromotionProfitSharingFormulaAbstract" xlink:label="loc_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31AB8ADDA79C4F28DC16879B8F3F28C8" xlink:to="loc_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_B199240667F4D1164976879B8F3F84F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne_B199240667F4D1164976879B8F3F84F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CoPromotionProfitSharingFormulaAbstract_2597E2804730A2A34323879B8F3F226F" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_7A1B9C5AAC25D86FEEDC879B8F403F01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne_7A1B9C5AAC25D86FEEDC879B8F403F01" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B07388263CAE8B17EA44879B8F403B05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_B07388263CAE8B17EA44879B8F403B05" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract_E7D5666F7E6AD3650B0C879B8F3F5BE9" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_5F53CB902D5F5DD93274879B8F4024E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RevenuesFromUnconsolidatedJointBusinessAbstract" xlink:label="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31AB8ADDA79C4F28DC16879B8F3F28C8" xlink:to="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_07B60DAF7F6203D86D80879B8F400204" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:to="loc_biib_ShareOfCoPromotionProfits_07B60DAF7F6203D86D80879B8F400204" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_F10531905BAD2DEC4679879B8F410A20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_F10531905BAD2DEC4679879B8F410A20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_37219C160D5D7E34ECBA879B8F419AB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RevenuesFromUnconsolidatedJointBusinessAbstract_25BAEC91135579AF4F7C879B8F40373C" xlink:to="loc_us-gaap_Revenues_37219C160D5D7E34ECBA879B8F419AB8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC05DA3A712140B4A3198512AB55D98A" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_F97BB94DBD137047DC2F8512AB55B434" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC05DA3A712140B4A3198512AB55D98A" xlink:to="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_F97BB94DBD137047DC2F8512AB55B434" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PretaxProfitSharingFormulaTableTextBlock" xlink:label="loc_biib_PretaxProfitSharingFormulaTableTextBlock_268645DFEEA527D106938512AB55728B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC05DA3A712140B4A3198512AB55D98A" xlink:to="loc_biib_PretaxProfitSharingFormulaTableTextBlock_268645DFEEA527D106938512AB55728B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_BC0E7C2EEC7E11B88F268512AB567824" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC05DA3A712140B4A3198512AB55D98A" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_BC0E7C2EEC7E11B88F268512AB567824" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_9990EB1547CFBDA635F48512AB562F11" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC05DA3A712140B4A3198512AB55D98A" xlink:to="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock_9990EB1547CFBDA635F48512AB562F11" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_629181B2E8276ED4E4AA8512AB55A24E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC05DA3A712140B4A3198512AB55D98A" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_629181B2E8276ED4E4AA8512AB55A24E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_EE906EC4A88E08A40D628512AB56BCFF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC05DA3A712140B4A3198512AB55D98A" xlink:to="loc_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock_EE906EC4A88E08A40D628512AB56BCFF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20B253A01DD51100789CFBB8317438DE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24A3F7295E8E6DEDA311FBB83174F3AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_20B253A01DD51100789CFBB8317438DE" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_24A3F7295E8E6DEDA311FBB83174F3AC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_973ED34A07D0DF7F2EEAC42825C251C2" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract" xlink:label="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_973ED34A07D0DF7F2EEAC42825C251C2" xlink:to="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4FC8BB95EAAEFEADB6CBC42825C3C895" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4FC8BB95EAAEFEADB6CBC42825C3C895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_B2B1FE7F03422269A50CC42825C3DBF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_B2B1FE7F03422269A50CC42825C3DBF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6C6224B53B90AADDCE58C42825C3EF07" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_6C6224B53B90AADDCE58C42825C3EF07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_28CCA43574DC41FD4618C42825C3D566" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_28CCA43574DC41FD4618C42825C3D566" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635A38C5BC9A4607E336C42825C45C55" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_635A38C5BC9A4607E336C42825C45C55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_96A8A8741AE022A9BD5DC42825C4355D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_96A8A8741AE022A9BD5DC42825C4355D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C90063C597005A194022C42825C4D9F1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C90063C597005A194022C42825C4D9F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1A79DA138BB44D547713C42825C4F2F7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear_1A79DA138BB44D547713C42825C4F2F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_71902520E80C0F6DEE22C42825C4DAF5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears_71902520E80C0F6DEE22C42825C4DAF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_BB7DB49DF6DFEA57090BC42825C421FA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears_BB7DB49DF6DFEA57090BC42825C421FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_1F44ECE5251FF3D3C220C42825C4B0CB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears_1F44ECE5251FF3D3C220C42825C4B0CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_A2F7DD48073346C37CA3C42825C52CA8" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears_A2F7DD48073346C37CA3C42825C52CA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_1BE62824A77D79A2C1E7C42825C5BE1F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter_1BE62824A77D79A2C1E7C42825C5BE1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions" xlink:label="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_99B28B24E8E2B2ED0F44C42825C57EED" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions_99B28B24E8E2B2ED0F44C42825C57EED" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInOneYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInOneYear_034BCA8A9FCCEE1771FCC42825C56082" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInOneYear_034BCA8A9FCCEE1771FCC42825C56082" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInTwoYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_2B3567D0AE9AB887D346C42825C5BE3A" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInTwoYear_2B3567D0AE9AB887D346C42825C5BE3A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInThreeYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_C789CE76AA66A6FC89EBC42825C6D77A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInThreeYear_C789CE76AA66A6FC89EBC42825C6D77A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInFourYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFourYear_24846AE455F8158ED13EC42825C6502F" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFourYear_24846AE455F8158ED13EC42825C6502F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsWithInFiveYear" xlink:label="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_D3D10906BD2E17B7DE82C42825C6DDAC" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_biib_NetMinimumLeasePaymentsWithInFiveYear_D3D10906BD2E17B7DE82C42825C6DDAC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePaymentsThereafter" xlink:label="loc_biib_NetMinimumLeasePaymentsThereafter_7571174975CC00D087D7C42825C68195" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_biib_NetMinimumLeasePaymentsThereafter_7571174975CC00D087D7C42825C68195" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetMinimumLeasePayments" xlink:label="loc_biib_NetMinimumLeasePayments_062FE3E00AACEEE59737C42825C6F27B" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract_DABC6C42748A0724A4C3C42825C34B6A" xlink:to="loc_biib_NetMinimumLeasePayments_062FE3E00AACEEE59737C42825C6F27B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A239C426106B41858519AAF0BE3196E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A239C426106B41858519AAF0BE3196E5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3CC54346996AC5A01C67AAF0BE32FFF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3CC54346996AC5A01C67AAF0BE32FFF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78269978E45E67E54770AAF0BE327C28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3CC54346996AC5A01C67AAF0BE32FFF0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78269978E45E67E54770AAF0BE327C28" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_2645383C696129BC9889AAF0BE33F27B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78269978E45E67E54770AAF0BE327C28" xlink:to="loc_biib_IonisPharmaceuticalsMember_2645383C696129BC9889AAF0BE33F27B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E9F54A1ED70D45A8D009AAF0BE33C891" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_srt_RangeAxis_E9F54A1ED70D45A8D009AAF0BE33C891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_A7C9F55A9A039E5D733AAAF0BE334BAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_E9F54A1ED70D45A8D009AAF0BE33C891" xlink:to="loc_srt_RangeMember_A7C9F55A9A039E5D733AAAF0BE334BAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_C61849FCD02A5BA1EA61AAF0BE33AE76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A7C9F55A9A039E5D733AAAF0BE334BAF" xlink:to="loc_srt_MinimumMember_C61849FCD02A5BA1EA61AAF0BE33AE76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_DB174B46F0F6975D39A3AAF0BE348FCE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_A7C9F55A9A039E5D733AAAF0BE334BAF" xlink:to="loc_srt_MaximumMember_DB174B46F0F6975D39A3AAF0BE348FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_993F2FEA281716DE3CF3AAF0BE34168A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_993F2FEA281716DE3CF3AAF0BE34168A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9ACF16EC421DBF2DB14AAAF0BE346235" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_993F2FEA281716DE3CF3AAF0BE34168A" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9ACF16EC421DBF2DB14AAAF0BE346235" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_C9EA46374284C24E6922AAF0BE3515EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9ACF16EC421DBF2DB14AAAF0BE346235" xlink:to="loc_biib_U.S.2017TaxActMember_C9EA46374284C24E6922AAF0BE3515EF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesAxis" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentMilestoneTypesDomain" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_EC6DC1852F04871656A0AAF0BE354342" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DevelopmentMilestonesMember" xlink:label="loc_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:to="loc_biib_DevelopmentMilestonesMember_DF150BA01C9EC3AB09EAAAF0BE352FFB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RegulatoryMilestonesMember" xlink:label="loc_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:to="loc_biib_RegulatoryMilestonesMember_14408934B56F39EEF133AAF0BE36C377" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CommercialMilestonesMember" xlink:label="loc_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_C91C507CF61A10C56B4FAAF0BE35A950" xlink:to="loc_biib_CommercialMilestonesMember_1B2177E1CFA22A038529AAF0BE36DFE1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_13391CE38B97BA1FF03AAAF0BE369B14" xlink:to="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_FifteenbillionMemberMember_2B8D613CD456AD246EF4AAF0BE378B40" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_SixteenbillionMember_58C930DEA9FCEB532EF3AAF0BE376605" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeventeenbillionMember" xlink:label="loc_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_SeventeenbillionMember_112EBA0053B25C40CDEDAAF0BE379707" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EighteenbillionMember" xlink:label="loc_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_EighteenbillionMember_4AE511AFF5791C22EB53AAF0BE3712CC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NineteenbillionMember" xlink:label="loc_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_NineteenbillionMember_616811BD94BEB1228E2FAAF0BE3714B8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TwentybillionMember" xlink:label="loc_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_TwentybillionMember_FF5FCF675F98F46BCD39AAF0BE38291E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_E8921FF335F16A2F50C2AAF0BE3625AA" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9299471F6BA8FD76C536AAF0BE38784E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1A5B8CCF3FC0A8D1E534AAF0BE38813C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_srt_ProductOrServiceAxis_1A5B8CCF3FC0A8D1E534AAF0BE38813C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C9D917D9D9587C8E7F5DAAF0BE38498D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1A5B8CCF3FC0A8D1E534AAF0BE38813C" xlink:to="loc_srt_ProductsAndServicesDomain_C9D917D9D9587C8E7F5DAAF0BE38498D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_0B1669461C01F1D13BA1AAF0BE39B554" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_C9D917D9D9587C8E7F5DAAF0BE38498D" xlink:to="loc_biib_SPINRAZAMember_0B1669461C01F1D13BA1AAF0BE39B554" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_52ACCAF6D018BC605B05AAF0BE3936E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_C9D917D9D9587C8E7F5DAAF0BE38498D" xlink:to="loc_biib_TecfideraMember_52ACCAF6D018BC605B05AAF0BE3936E2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_139B4E793ED2A4024405AAF0BE395EC3" xlink:to="loc_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_3D312ED1923E8E79F797AAF0BE39E02C" xlink:to="loc_biib_SolothurnMember_D8499CD93CB5C0D9B579AAF0BE3AC9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FE8B87971A0E1325ED54AAF0BE3A3BA3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_A94A8C1E831B0B3D9314AAF0BE3A6FD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:to="loc_biib_TysabriProductMember_A94A8C1E831B0B3D9314AAF0BE3A6FD3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_668FDE14E32DB56A51DFAAF0BE3AD137" xlink:to="loc_biib_FumapharmAgMember_2214576B3AEA6D33260FAAF0BE3B27CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_A5D6361EB557DB25A692AAF0BE3218F6" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion_C6A986E2A576C3F67075AAF0BE3B8F33" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentPaymentThreshold" xlink:label="loc_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_FutureContingentPaymentThreshold_5D7899B30EBDE9FB122EAAF0BE3CFC27" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfRoyaltiesAsPerCollaboration" xlink:label="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_A8F6E4A804E642E423CDAAF0BE3C61B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_PercentageOfRoyaltiesAsPerCollaboration_A8F6E4A804E642E423CDAAF0BE3C61B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion" xlink:label="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion_4B6FBF470B3961375424AAF0BE3CF42B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_BCC8DC555DA5393CF9F1AAF0BE3CF190" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_BCC8DC555DA5393CF9F1AAF0BE3CF190" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9186C404A07B9A2B3FF2AAF0BE3CC3F8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9186C404A07B9A2B3FF2AAF0BE3CC3F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_C8D79B28FD49986FB206AAF0BE3D62E0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_C8D79B28FD49986FB206AAF0BE3D62E0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_CumulativeSalesLevel_BE8831156A8A4AE3BC96AAF0BE3D3AAF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_721BD7B6448C22CDB262AAF0BE3D5FFA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_721BD7B6448C22CDB262AAF0BE3D5FFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCommitment" xlink:label="loc_us-gaap_OtherCommitment_5E237F151E04112ECB7AAAF0BE3D260C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_us-gaap_OtherCommitment_5E237F151E04112ECB7AAAF0BE3D260C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_3E439E495CA0D89E198FAAF0BE3DF5FC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_3E439E495CA0D89E198FAAF0BE3DF5FC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment" xlink:label="loc_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_A00F65DE60517BFACC48AAF0BE3E2205" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2E09258D45A6EC91590EAAF0BE3B5616" xlink:to="loc_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_A00F65DE60517BFACC48AAF0BE3E2205" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A239C426106B41858519AAF0BE3196E5" xlink:to="loc_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch" xlink:label="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_A0FE5E106107D9ED0061AAF0BE3E4846" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800" xlink:to="loc_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch_A0FE5E106107D9ED0061AAF0BE3E4846" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_BC6DE424F9F779A320E9AAF0BE3F255C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsCurrent_BC6DE424F9F779A320E9AAF0BE3F255C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_385A6CBA60E07A93CA8EAAF0BE3FAE5D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CommitmentsAndContingenciesTextualAbstract_45D277C5F191EE91B5EEAAF0BE3E9800" xlink:to="loc_us-gaap_LeaseAndRentalExpense_385A6CBA60E07A93CA8EAAF0BE3FAE5D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9AAC4AD1BC334F7412F3FBB833761D44" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2E85DEE54E764EEDAC43FBB83376C18E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9AAC4AD1BC334F7412F3FBB833761D44" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_2E85DEE54E764EEDAC43FBB83376C18E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3E344985807C40552B9685B8719C9CEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3E344985807C40552B9685B8719C9CEA" xlink:to="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:to="loc_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A7BD6DA060727869D53685B8719CF1D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_A7BD6DA060727869D53685B8719CF1D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_24E715086881ACB44A1D85B8719E122F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_24E715086881ACB44A1D85B8719E122F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5339423C32CA942EF9BC85B8719E5DF2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5339423C32CA942EF9BC85B8719E5DF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DueFromUnconsolidatedJointBusiness" xlink:label="loc_biib_DueFromUnconsolidatedJointBusiness_8E5ADE19FA6F6D1AF1F885B8719E625A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:to="loc_biib_DueFromUnconsolidatedJointBusiness_8E5ADE19FA6F6D1AF1F885B8719E625A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_C1559D6117E060829B1385B8719ECC16" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:to="loc_us-gaap_InventoryNet_C1559D6117E060829B1385B8719ECC16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_69735D08AA3CD27FD7D185B8719E97AB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:to="loc_us-gaap_OtherAssetsCurrent_69735D08AA3CD27FD7D185B8719E97AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_80F73B9E70F1E8F3305A85B8719E6B59" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C8B87A819431E0583F3285B8719C8BD9" xlink:to="loc_us-gaap_AssetsCurrent_80F73B9E70F1E8F3305A85B8719E6B59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_301FE99281AE4C9AC34285B8719E1B22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_301FE99281AE4C9AC34285B8719E1B22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_50BACAC6D9ADECF48D0985B8719E5644" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_50BACAC6D9ADECF48D0985B8719E5644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_05BD979DF61DDB2B67A285B8719EA023" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_05BD979DF61DDB2B67A285B8719EA023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_10C95445B194BB3F84E185B8719EEFED" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:to="loc_us-gaap_Goodwill_10C95445B194BB3F84E185B8719EEFED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4A06D019B7873A61D76C85B8719E41EA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent_4A06D019B7873A61D76C85B8719E41EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8F5064961C8A945E018A85B871A6FB71" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8F5064961C8A945E018A85B871A6FB71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17EA163A255A8F73823785B871A6844D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_2EC66C0BB19184DF38FB85B8719CE59B" xlink:to="loc_us-gaap_Assets_17EA163A255A8F73823785B871A6844D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3E344985807C40552B9685B8719C9CEA" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_CF6A9252D22E6355E33D85B871A6E685" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:to="loc_us-gaap_DebtCurrent_CF6A9252D22E6355E33D85B871A6E685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_4447D3E6A0BE826B43F585B871A635B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:to="loc_us-gaap_TaxesPayableCurrent_4447D3E6A0BE826B43F585B871A635B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_23A988956D26C40EBE0485B871A6ADAB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:to="loc_us-gaap_AccountsPayableCurrent_23A988956D26C40EBE0485B871A6ADAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_F37B4CAF6F86B9E065A885B871A63977" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_F37B4CAF6F86B9E065A885B871A63977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_A5FE961ABB0EDC706EA085B871A64B98" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_F4FAFBAFCA2E704F369585B871A63A3F" xlink:to="loc_us-gaap_LiabilitiesCurrent_A5FE961ABB0EDC706EA085B871A64B98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_CA1F94A59EA24250B63B85B871A69690" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:to="loc_us-gaap_LongTermDebt_CA1F94A59EA24250B63B85B871A69690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_F70FC10CC564322C720085B871A648FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNoncurrent_F70FC10CC564322C720085B871A648FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_D0C18236C34229911D8985B871A844DB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_D0C18236C34229911D8985B871A844DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_9337F834DE1B4C3F40FD85B871A8ED88" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:to="loc_us-gaap_Liabilities_9337F834DE1B4C3F40FD85B871A8ED88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_5C17CE38FDC47D64E3F485B871A8E1C8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:to="loc_us-gaap_CommitmentsAndContingencies_5C17CE38FDC47D64E3F485B871A8E1C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_B5263DC8C14AF0B4939185B871A8ECE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:to="loc_us-gaap_PreferredStockValue_B5263DC8C14AF0B4939185B871A8ECE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_332377C364D968593F1F85B871A8FFE8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:to="loc_us-gaap_CommonStockValue_332377C364D968593F1F85B871A8FFE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_CF4A3E380597F40AF99D85B871A8BCE3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:to="loc_us-gaap_AdditionalPaidInCapital_CF4A3E380597F40AF99D85B871A8BCE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_693095AE9E456B1B8ED585B871A83A00" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_693095AE9E456B1B8ED585B871A83A00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14BC1980492C590C81F485B871A8A867" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_14BC1980492C590C81F485B871A8A867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_6A9DBFB964B6120D072385B871A89114" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:to="loc_us-gaap_TreasuryStockValue_6A9DBFB964B6120D072385B871A89114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_710ECA4D8649B5AE58D685B871A86177" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4948407FADB521A0663985B871A8E7AE" xlink:to="loc_us-gaap_StockholdersEquity_710ECA4D8649B5AE58D685B871A86177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_ACB85E74A5F3126A801385B871AB2793" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3" xlink:to="loc_us-gaap_MinorityInterest_ACB85E74A5F3126A801385B871AB2793" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85C699AAB468C381704D85B871ABC616" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_EEFD37EF53A82704DC0685B871A8D8C3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_85C699AAB468C381704D85B871ABC616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_12352826852DB746A01285B871ABC0C5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_79DD3F8C93EC1ACA6D2585B871A64567" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_12352826852DB746A01285B871ABC0C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0F6BB3FD486A7CD690A6FBB831A359F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_73404D598CE9FA3661F9FBB831B24299" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0F6BB3FD486A7CD690A6FBB831A359F0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_73404D598CE9FA3661F9FBB831B24299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_A755FDF34F28C1DFF355FBB831B26EA6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0F6BB3FD486A7CD690A6FBB831A359F0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_A755FDF34F28C1DFF355FBB831B26EA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_90C578ECEAA42759F46BFBB831B27FB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0F6BB3FD486A7CD690A6FBB831A359F0" xlink:to="loc_us-gaap_TreasuryStockShares_90C578ECEAA42759F46BFBB831B27FB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_EFEF872A0B025E17236B9A04A0467F14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_EFEF872A0B025E17236B9A04A0467F14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8C5DCF2F86D18B2935589A04A047EDA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_EFEF872A0B025E17236B9A04A0467F14" xlink:to="loc_us-gaap_ProfitLoss_8C5DCF2F86D18B2935589A04A047EDA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_EFEF872A0B025E17236B9A04A0467F14" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4406F2AFCDA848169A709A04A0471486" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4406F2AFCDA848169A709A04A0471486" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_4B1813D9B066A1A71D079A04A048A5B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_4B1813D9B066A1A71D079A04A048A5B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_994030B338C0F5514FA79A04A048F16F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:to="loc_us-gaap_ShareBasedCompensation_994030B338C0F5514FA79A04A048F16F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20202E279A036F6A0B549A04A0490458" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_20202E279A036F6A0B549A04A0490458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D5EB5A687F4EFE2294249A04A049CAB4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_D5EB5A687F4EFE2294249A04A049CAB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_DF4D8540AFC5834E8C5F9A04A049B6BA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_DF4D8540AFC5834E8C5F9A04A049B6BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_AF2166F7E492F354134E9A04A049121E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_AF2166F7E492F354134E9A04A049121E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C84E53E4277272B3D58C9A04A04ABCD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_C84E53E4277272B3D58C9A04A04ABCD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0DECFD3E0B0AE7B6C20F9A04A04A2C5F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0DECFD3E0B0AE7B6C20F9A04A04A2C5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51DB6F1EB928F350D4789A04A04A83FD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_51DB6F1EB928F350D4789A04A04A83FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3C08D5FB38ABE9FE1E429A04A04AD11A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3C08D5FB38ABE9FE1E429A04A04AD11A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_F2DFA91ED2BE83D8C5F39A04A04AA73D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_F2DFA91ED2BE83D8C5F39A04A04AA73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_900D1B358E1F5BF2C77F9A04A04B4345" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_70146189C3B5EEB004489A04A04927BE" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_900D1B358E1F5BF2C77F9A04A04B4345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E4548B8C72B49F015F909A04A04B2F1A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_704F7C2FD1F88BAD94949A04A04734F7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_E4548B8C72B49F015F909A04A04B2F1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E6898CF4257A8316F2539A04A04B1B66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_E6898CF4257A8316F2539A04A04B1B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_0356343A44E4F239B0829A04A04B84E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecurities_0356343A44E4F239B0829A04A04B84E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_CEE6765B2E4A831DAF4E9A04A04CAC62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_CEE6765B2E4A831DAF4E9A04A04CAC62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_54A47C3AEF54294322059A04A04C7EED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_54A47C3AEF54294322059A04A04C7EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1700FD05B74153594C9E9A04A04CB38C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1700FD05B74153594C9E9A04A04CB38C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_F1A469D6B34DA20806A69A04A04CC153" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_F1A469D6B34DA20806A69A04A04CC153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireOtherInvestments_E9CC17CAD57AF94446669A04A04CA2C1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:to="loc_us-gaap_PaymentsToAcquireOtherInvestments_E9CC17CAD57AF94446669A04A04CA2C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4AB626B33F768BA9A6079A04A04C18D2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_4AB626B33F768BA9A6079A04A04C18D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93B46365EE5BFD1065FD9A04A04DE7B9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93B46365EE5BFD1065FD9A04A04DE7B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5950DC0F9348913FAAD9A04A04D00A0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_A76C96058739E1E073589A04A04BB6B0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_B5950DC0F9348913FAAD9A04A04D00A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AEF10AA0FE17F92DA3DA9A04A04DBCB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_AEF10AA0FE17F92DA3DA9A04A04DBCB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2065ECCD8898C881A3CB9A04A04D8195" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2065ECCD8898C881A3CB9A04A04D8195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_EFC7A9BC6EED70C8CBC69A04A04ED3FA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_EFC7A9BC6EED70C8CBC69A04A04ED3FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_F6E28A46D34A650E1DE39A04A04E669F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:to="loc_us-gaap_RepaymentsOfDebt_F6E28A46D34A650E1DE39A04A04E669F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfCapitalDistribution" xlink:label="loc_us-gaap_PaymentsOfCapitalDistribution_6F02CB830E873A42BFE69A04A04E0FAD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:to="loc_us-gaap_PaymentsOfCapitalDistribution_6F02CB830E873A42BFE69A04A04E0FAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_38B26D44240C413F22F79A04A04E7674" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_38B26D44240C413F22F79A04A04E7674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_F33FA6E5A8C84BECB8CE9A04A04E879B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_F33FA6E5A8C84BECB8CE9A04A04E879B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_095598C3CD905623ABB39A04A04E6102" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_486E3C1B9ED387ED998E9A04A04DEB1D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_095598C3CD905623ABB39A04A04E6102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_38C32A5DBD9705C03B7A9A400596AF34" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_38C32A5DBD9705C03B7A9A400596AF34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D926F5B3BAB609690A719A04A04FE973" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_D926F5B3BAB609690A719A04A04FE973" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18F6DA67E4CC3E2E99F59A04A04FC75E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18F6DA67E4CC3E2E99F59A04A04FC75E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CE6E3B0CAB1B2F429A79A04A04F0014" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D16F68DF01860CC2224C9A04A046A942" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4CE6E3B0CAB1B2F429A79A04A04F0014" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0CA65A8DA92001057FA09FD6EDDEB785" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_168ACDC732A8F92DC4179FD6EDDE006C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0CA65A8DA92001057FA09FD6EDDEB785" xlink:to="loc_us-gaap_NetIncomeLoss_168ACDC732A8F92DC4179FD6EDDE006C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0CA65A8DA92001057FA09FD6EDDEB785" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1839C7C60092BB4AFBBA9FD6EDDF69D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1839C7C60092BB4AFBBA9FD6EDDF69D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3E1A7DDA276C09CD54499FD6EDDF24B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_3E1A7DDA276C09CD54499FD6EDDF24B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_306ADE9A23067DFB1FC39FD6EDDFDE0D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_306ADE9A23067DFB1FC39FD6EDDFDE0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_098EB7311F93982742DA9FD6EDDF24B9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax_098EB7311F93982742DA9FD6EDDF24B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_563A39A589D482DD4D9A9FD6EDE4281C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax_563A39A589D482DD4D9A9FD6EDE4281C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_4ACA52F29AD979EA03A79FD6EDE5AA87" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_4ACA52F29AD979EA03A79FD6EDE5AA87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_64675BFA52828BB6AA999FD83E995900" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_64675BFA52828BB6AA999FD83E995900" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_548377E49345C2C1CD649FD8B0361B92" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax_548377E49345C2C1CD649FD8B0361B92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_B6C7D7453A6D264707D39FD914513F39" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax_B6C7D7453A6D264707D39FD914513F39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D5D3E87A4E0CE05828109FD6EDE5C258" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_D5D3E87A4E0CE05828109FD6EDE5C258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_18DAC6CEDC483B341BB69FD6EDE5BA89" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_18DAC6CEDC483B341BB69FD6EDE5BA89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_AD3501C61FB5F8EC35369FD6EDE67694" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_AD3501C61FB5F8EC35369FD6EDE67694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_13E98A29221B996036679FD6EDE66FF6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_13E98A29221B996036679FD6EDE66FF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_E73EBC717E132F026C359FD6EDE60CE7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_E73EBC717E132F026C359FD6EDE60CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B62D7CE8CBEBBFE63D4B9FD6EDE6BC28" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_AAF2F89DC93FA28E923E9FD6EDDE0CF1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_B62D7CE8CBEBBFE63D4B9FD6EDE6BC28" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_436284466C2F06996F9CBEA935D8EF93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_564193E18F71F1405FD4BEA935E896CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_436284466C2F06996F9CBEA935D8EF93" xlink:to="loc_us-gaap_StatementTable_564193E18F71F1405FD4BEA935E896CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_564193E18F71F1405FD4BEA935E896CA" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_73F6C167B7D5DFD65F14BEA935E81A15" xlink:to="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_A6A4CE3078804B96EFD2BEA935E815CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_A6A4CE3078804B96EFD2BEA935E815CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_40CEB1B326CF200A25D8BEA935E843A2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_A448563B6B8E5CE0AA37BEA935E8F357" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_40CEB1B326CF200A25D8BEA935E843A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_564193E18F71F1405FD4BEA935E896CA" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_203F7B22F90008A93CF5BEA935E8D5FB" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_ECC708DFC8939B3CFB4EBEA935E87F52" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2016ShareRepurchaseProgramYearToDateMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:to="loc_biib_A2016ShareRepurchaseProgramYearToDateMember_7A0B00CE17CFC9CAA05CBEA935E8F644" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_B58CE701461DAC7FF4C1BEA935E8279E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_E835248D6426614DD458BEA935E8F4E9" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_02A26EA669DE22B9E776BEA935E85E3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_564193E18F71F1405FD4BEA935E896CA" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99D34AF3298E24FDE87ABEA935E8A147" xlink:to="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_676448E329BA1A005448BEA935E80321" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_PreferredStockMember_676448E329BA1A005448BEA935E80321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4A6F300C0B6C754118B4BEA935E81111" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_CommonStockMember_4A6F300C0B6C754118B4BEA935E81111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_E7BE87ADEFC28AEA2BF7BEA935E83D19" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_E7BE87ADEFC28AEA2BF7BEA935E83D19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2816504ECE1A0C3E7C93BEA935E81103" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2816504ECE1A0C3E7C93BEA935E81103" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_315D7967BEBE0461F083BEA935E84111" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_RetainedEarningsMember_315D7967BEBE0461F083BEA935E84111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_83AA5E2DD5D0789767E0BEA935E8C267" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_TreasuryStockMember_83AA5E2DD5D0789767E0BEA935E8C267" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_4072C6FA12949A504B14BEA935E876A9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_NoncontrollingInterestMember_4072C6FA12949A504B14BEA935E876A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_D97CE59D73B8D9DCCBD1BEA935E8AF85" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_B9545AF0F60B7EDA35F9BEA935E8E13F" xlink:to="loc_us-gaap_ParentMember_D97CE59D73B8D9DCCBD1BEA935E8AF85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_564193E18F71F1405FD4BEA935E896CA" xlink:to="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B3A28ABC0642BC585918BEA935E838B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B3A28ABC0642BC585918BEA935E838B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_21810C9AF8789DDA346EBEA935E831D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockholdersEquity_21810C9AF8789DDA346EBEA935E831D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_C6FD245C9DA27BD1802DBEA935E879AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_MinorityInterest_C6FD245C9DA27BD1802DBEA935E879AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_D8E5C0EEA0FAF864D0E5BEA935E81561" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_SharesIssued_D8E5C0EEA0FAF864D0E5BEA935E81561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_C8F097647F1A2D0CDDD9BEA935E8BF25" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_NetIncomeLoss_C8F097647F1A2D0CDDD9BEA935E8BF25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_919BC1A9374A2114B4C7BEA935E8366C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_919BC1A9374A2114B4C7BEA935E8366C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_0CB76C4329757462C18EBEA935E87F8D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_ProfitLoss_0CB76C4329757462C18EBEA935E87F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_EDEF1460C9F4FC4CDDDCBEA935E832AC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_EDEF1460C9F4FC4CDDDCBEA935E832AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_A1947E815E7759D32962BEA935E8534F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_A1947E815E7759D32962BEA935E8534F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_52C39A65D660DB860E0ABEA935E88686" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_52C39A65D660DB860E0ABEA935E88686" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Noncontrollinginterestincreasedecreaseother" xlink:label="loc_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_biib_Noncontrollinginterestincreasedecreaseother_5D324C79C9060A2CE10FBEA935E88184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1D4CDFE794E9F79C523CBEA935E8023E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_1D4CDFE794E9F79C523CBEA935E8023E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_EA2036AF5B4AE50D8491BEA935E87AAD" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_EA2036AF5B4AE50D8491BEA935E87AAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_B5902399AF7A2C6AD8E4BEA935E82EEA" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_B5902399AF7A2C6AD8E4BEA935E82EEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_E0715961E30054932DEDBEA935E86539" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_E0715961E30054932DEDBEA935E86539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_C64BBA340DFF5B5E5F1ABEA935E8AC38" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_C64BBA340DFF5B5E5F1ABEA935E8AC38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0450C0A497C33A1BFD87BEA935E8A137" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_0450C0A497C33A1BFD87BEA935E8A137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_818FDA9F98BAA96EDD81BEA935E8A5FA" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_818FDA9F98BAA96EDD81BEA935E8A5FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_33C341D21105DAE2D569BEA935E8BD73" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_33C341D21105DAE2D569BEA935E8BD73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_23949AB60D46A31FAFE0BEA935E89A94" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_23949AB60D46A31FAFE0BEA935E89A94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32FDD7B45BC6879A0AC3BEA935E88688" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_32FDD7B45BC6879A0AC3BEA935E88688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D13269CA51CC19B59FA8BEA935E83DB6" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D13269CA51CC19B59FA8BEA935E83DB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteSpinoffTransaction" xlink:label="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_4A61E75423D14EE35552BEA935E86755" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockholdersEquityNoteSpinoffTransaction_4A61E75423D14EE35552BEA935E86755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B515ABE2CDC493AC442EBEA935E8D8F0" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_B515ABE2CDC493AC442EBEA935E8D8F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_E99307A48167E6A1AD15BEA935E8B2B0" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockholdersEquityOther_E99307A48167E6A1AD15BEA935E8B2B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49AF0EB39711C18ABFF4BEA935E8C464" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49AF0EB39711C18ABFF4BEA935E8C464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_E5834267931A43DBBA3FBEA935E872CB" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_StockholdersEquity_E5834267931A43DBBA3FBEA935E872CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_F4799DB29E65E2A9ED0BBEA935E8C7CE" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_MinorityInterest_F4799DB29E65E2A9ED0BBEA935E8C7CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_047EDA9C7681BA1CF57ABEA935E8A4B1" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D139725533BE6366B8CBBEA935E8C660" xlink:to="loc_us-gaap_SharesIssued_047EDA9C7681BA1CF57ABEA935E8A4B1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_CC6E97F1214A7B2D2597C427E6A9DEB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_StatementTable_CC6E97F1214A7B2D2597C427E6A9DEB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_AEB3D162742CFD09DD47C427E6B93349" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_CC6E97F1214A7B2D2597C427E6A9DEB2" xlink:to="loc_srt_ProductOrServiceAxis_AEB3D162742CFD09DD47C427E6B93349" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_AEB3D162742CFD09DD47C427E6B93349" xlink:to="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_0C7BB28D960696FE62DEC427E6B9E6D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB" xlink:to="loc_us-gaap_ProductMember_0C7BB28D960696FE62DEC427E6B9E6D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_A5D6A55220DA82EB604CC427E6B9D7AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_A5D6A55220DA82EB604CC427E6B9D7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_A7259BB565CFF2B20ED7C427E6B98A74" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6BD8A713CCBF6AF865C9C427E6B97AAB" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_A7259BB565CFF2B20ED7C427E6B98A74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_036B1B7979592B5E720DC427E6B9856A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_CC6E97F1214A7B2D2597C427E6A9DEB2" xlink:to="loc_us-gaap_StatementLineItems_036B1B7979592B5E720DC427E6B9856A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_BD8048F51827851395F3C427E6B91413" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_036B1B7979592B5E720DC427E6B9856A" xlink:to="loc_us-gaap_Revenues_BD8048F51827851395F3C427E6B91413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_0E3B38D2653E1EF06FC7C427E6B905A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_0E3B38D2653E1EF06FC7C427E6B905A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_94ADA7E3B816D36700BCC427E6B92B89" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_94ADA7E3B816D36700BCC427E6B92B89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0187858CE6AD73DC4F51C427E6B91145" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0187858CE6AD73DC4F51C427E6B91145" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_99D0966DE5FEA72A1245C427E6B98066" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_99D0966DE5FEA72A1245C427E6B98066" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CollaborationProfitSharing" xlink:label="loc_biib_CollaborationProfitSharing_A15BBA0F4AA1AF5B7999C427E6B94A0E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:to="loc_biib_CollaborationProfitSharing_A15BBA0F4AA1AF5B7999C427E6B94A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_3A435A850AC01E57EDB9C427E6B9E408" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_3A435A850AC01E57EDB9C427E6B9E408" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_3EFB3EF48F6843E130FAC427E6B950DF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:to="loc_us-gaap_RestructuringCharges_3EFB3EF48F6843E130FAC427E6B950DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BA09FFB1D2411E38CA73C427E6B9B7AE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_BA09FFB1D2411E38CA73C427E6B9B7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_5D96469B4082487D3C6FC427E6B9E7AD" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:to="loc_us-gaap_LitigationSettlementExpense_5D96469B4082487D3C6FC427E6B9E7AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_CD28805D3A16AF856BEBC427E6B9436D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_FAE50BE45DC1FD4C27A9C427E6B926CB" xlink:to="loc_us-gaap_CostsAndExpenses_CD28805D3A16AF856BEBC427E6B9436D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_AA8B87DF18E7AA1EF20FC427E6B96322" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_OperatingIncomeLoss_AA8B87DF18E7AA1EF20FC427E6B96322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_65AC580C1C8F27CAEE52C427E6B9EDCD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_65AC580C1C8F27CAEE52C427E6B9EDCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4F85A5D2D6CAD15F2415C427E6B9A746" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4F85A5D2D6CAD15F2415C427E6B9A746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4919966F32BA328516DBC427E6C9B67A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4919966F32BA328516DBC427E6C9B67A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2943D15A30D72E6FE7D7C427E6C97D3A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2943D15A30D72E6FE7D7C427E6C97D3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_950E78C2D97A97E933C5C427E6C9DE15" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_ProfitLoss_950E78C2D97A97E933C5C427E6C9DE15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_AC517173ED3DA771E49CC427E6C9BC40" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_AC517173ED3DA771E49CC427E6C9BC40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E6A1B9BD97DE147495E9C427E6C9C35B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_NetIncomeLoss_E6A1B9BD97DE147495E9C427E6C9C35B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_CDBE808B27ECC74CE47EC427E6C9B2BB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_EarningsPerShareAbstract_CDBE808B27ECC74CE47EC427E6C9B2BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_630BEB09398BB3730D13C427E6C9594E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CDBE808B27ECC74CE47EC427E6C9B2BB" xlink:to="loc_us-gaap_EarningsPerShareBasic_630BEB09398BB3730D13C427E6C9594E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_DBE867AA9D65217261AEC427E6C983EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_CDBE808B27ECC74CE47EC427E6C9B2BB" xlink:to="loc_us-gaap_EarningsPerShareDiluted_DBE867AA9D65217261AEC427E6C983EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AC713DD8A127D968A860C427E6C95CEE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6E2F23ECD4F8E72ED89EC427E6A920B6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AC713DD8A127D968A860C427E6C95CEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6884D4C8F6C2FF6807E9C427E6C9AD5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AC713DD8A127D968A860C427E6C95CEE" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6884D4C8F6C2FF6807E9C427E6C9AD5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2906CDD8C14B610CAFD3C427E6C93205" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_AC713DD8A127D968A860C427E6C95CEE" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2906CDD8C14B610CAFD3C427E6C93205" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_241B3A35973721430A9FFBB834326145" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_C47BC468F79DD74F1DB7FBB83432A66E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_241B3A35973721430A9FFBB834326145" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_C47BC468F79DD74F1DB7FBB83432A66E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_CEBE6D82C25734A1D6CE871CAEEC3660" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_94CABCCFF37C2438487F871CAEEC005A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_CEBE6D82C25734A1D6CE871CAEEC3660" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_94CABCCFF37C2438487F871CAEEC005A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AAF7CAC9EEB60A654C41871CAEEC97CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_94CABCCFF37C2438487F871CAEEC005A" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AAF7CAC9EEB60A654C41871CAEEC97CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_BA1B7BDA84EA7C324C14871CAEEC4813" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_AAF7CAC9EEB60A654C41871CAEEC97CF" xlink:to="loc_us-gaap_HedgingRelationshipDomain_BA1B7BDA84EA7C324C14871CAEEC4813" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashflowsrevenueMember" xlink:label="loc_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_BA1B7BDA84EA7C324C14871CAEEC4813" xlink:to="loc_biib_CashflowsrevenueMember_D765EBD63E9EF5CE1AF6871CAEECBF8D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashflowsoperatingexpensesMember" xlink:label="loc_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_BA1B7BDA84EA7C324C14871CAEEC4813" xlink:to="loc_biib_CashflowsoperatingexpensesMember_3D48B8707DFE23B68840871CAEECC61B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_02839475FA8BBD1114C9871CAEEC052E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_94CABCCFF37C2438487F871CAEEC005A" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_02839475FA8BBD1114C9871CAEEC052E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_801455F14FD530CD9C95871CAEECB09F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_02839475FA8BBD1114C9871CAEEC052E" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_801455F14FD530CD9C95871CAEECB09F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_DF34A932E02F81432AD0871CAEEC7380" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_801455F14FD530CD9C95871CAEECB09F" xlink:to="loc_us-gaap_ForeignExchangeContractMember_DF34A932E02F81432AD0871CAEEC7380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_94CABCCFF37C2438487F871CAEEC005A" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FE3961C9E81791B26D2C871CAEECEF7B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_C6F6570C99D47EE72D83871CAEEC7993" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:to="loc_us-gaap_SalesMember_C6F6570C99D47EE72D83871CAEEC7993" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_E8B2AE9C7F24A5312967871CAEEC5290" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_E8B2AE9C7F24A5312967871CAEEC5290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="loc_us-gaap_OperatingExpenseMember_D869782E41FEB90B9C56871CAEECE589" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F50902F34E65739C7503871CAEECB8D4" xlink:to="loc_us-gaap_OperatingExpenseMember_D869782E41FEB90B9C56871CAEECE589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C817618481E136D6C309871CAEFC2DC7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_94CABCCFF37C2438487F871CAEEC005A" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C817618481E136D6C309871CAEFC2DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_93357D0A4A023B9C3069871CAEFCE4A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_C817618481E136D6C309871CAEFC2DC7" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_93357D0A4A023B9C3069871CAEFCE4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_19B689CB7EF4F33B2B78871CAEFCE977" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_93357D0A4A023B9C3069871CAEFCE4A9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_19B689CB7EF4F33B2B78871CAEFCE977" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_1EAEA9B2EAB4E9E9B7E1871CAEFC4351" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_93357D0A4A023B9C3069871CAEFCE4A9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_1EAEA9B2EAB4E9E9B7E1871CAEFC4351" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_67530EC3E6C78AB78BB3BEA934A07B60" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_67530EC3E6C78AB78BB3BEA934A07B60" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_208410C75C6E94305840BEA934A0A476" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_208410C75C6E94305840BEA934A0A476" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8FD813BA0DD3BB8D9CF7BEA934A08DB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_208410C75C6E94305840BEA934A0A476" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8FD813BA0DD3BB8D9CF7BEA934A08DB3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_39614066FBF97278E804BEA934A07550" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8FD813BA0DD3BB8D9CF7BEA934A08DB3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_39614066FBF97278E804BEA934A07550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B804D6C4411AF30C3E58BEA934A0B73C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B804D6C4411AF30C3E58BEA934A0B73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A9E9CCD51CE376A5359FBEA934A0BC6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B804D6C4411AF30C3E58BEA934A0B73C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A9E9CCD51CE376A5359FBEA934A0BC6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9E8404FF715FA6A72733BEA934A06183" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A9E9CCD51CE376A5359FBEA934A0BC6A" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9E8404FF715FA6A72733BEA934A06183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_D6CDEADFF19BA9776837BEA934A02FFD" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_AF12D11D918CBEE3C755BEA934A0EE29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C87F5FC47AF1A38E1DFBEA934A032A9" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_AF12D11D918CBEE3C755BEA934A0EE29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_15370097B10357DC9404BEA934A044C6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome" xlink:label="loc_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome_29267E03017B5AFB0C8EBEA934A094B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3EB79747A7C22FCF0916BEA934A01F61" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_3EB79747A7C22FCF0916BEA934A01F61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE5FB99F83081754A9D9BEA934A06CE2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BE5FB99F83081754A9D9BEA934A06CE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_25BE98B32CF7FDA69D5EBEA934A08B8F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_25BE98B32CF7FDA69D5EBEA934A08B8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_E661007B628CD0A79E25BEA934A00AE3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_DerivativeTermOfContract_E661007B628CD0A79E25BEA934A00AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_7F26874ECECDAA030A9ABEA934A0A96C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_7F26874ECECDAA030A9ABEA934A0A96C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B923F97609D2307DC156BEA934A04A25" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet_B923F97609D2307DC156BEA934A04A25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6C4F32441DCBBD99E9C8BEA934A0D70A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_6C4F32441DCBBD99E9C8BEA934A0D70A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax" xlink:label="loc_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_2194614B75388892C72EBEA934A0D971" xlink:to="loc_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax_D34053B31DDFE17057ECBEA934A0AF12" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C0A0AAE319B6FB79E24785B86DF0157C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_C0A0AAE319B6FB79E24785B86DF0157C" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:to="loc_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_B847EE56711DDB80509385B86DF026FB" xlink:to="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_6E1C035303AC81FCBFE085B86DF2427B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:to="loc_currency_EUR_6E1C035303AC81FCBFE085B86DF2427B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_GBP" xlink:label="loc_currency_GBP_F267BA6DBDABB01CE10E85B86DF2AA53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:to="loc_currency_GBP_F267BA6DBDABB01CE10E85B86DF2AA53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CHF" xlink:label="loc_currency_CHF_B7153F14C5BDA2F4F75A85B86DF2B746" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:to="loc_currency_CHF_B7153F14C5BDA2F4F75A85B86DF2B746" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_CAD" xlink:label="loc_currency_CAD_29874C30C7DB074B1E6F85B86DF27DF8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:to="loc_currency_CAD_29874C30C7DB074B1E6F85B86DF27DF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd#currency_JPY" xlink:label="loc_currency_JPY_40D6799B7FDC2EA731DE85B86DF26E5D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_B6CCD51F842D942A841F85B86DF26BD7" xlink:to="loc_currency_JPY_40D6799B7FDC2EA731DE85B86DF26E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_A1E580399FD1869E51DC85B86DF2AD48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_A1E580399FD1869E51DC85B86DF2AD48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_002ED51D95B9F66E896A85B86DF248AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_A1E580399FD1869E51DC85B86DF2AD48" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_002ED51D95B9F66E896A85B86DF248AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ED11FFB986B7C57419E085B86DF25257" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_002ED51D95B9F66E896A85B86DF248AB" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ED11FFB986B7C57419E085B86DF25257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_182D2E2E0F26388AF8C985B86DF21243" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_182D2E2E0F26388AF8C985B86DF21243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_182D2E2E0F26388AF8C985B86DF21243" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_6A4B30954AE40BE3999B85B86DF5380B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_6A4B30954AE40BE3999B85B86DF5380B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_2C93E3F016956706679B85B86DF5C616" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:to="loc_us-gaap_OtherInvestmentsMember_2C93E3F016956706679B85B86DF5C616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_D1B3B2D001A7B6D41B9F85B86DF59FA5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_D1B3B2D001A7B6D41B9F85B86DF59FA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_02F6C9D6F379F31EE56E85B86DF5695E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_EE52862F4229766DFD1C85B86DF28EAA" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_02F6C9D6F379F31EE56E85B86DF5695E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_D581A33EB830DEC5290085B86DF5EFE2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:to="loc_us-gaap_HedgingDesignationAxis_D581A33EB830DEC5290085B86DF5EFE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_257C68516AEAC586B87385B86DF50761" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_D581A33EB830DEC5290085B86DF5EFE2" xlink:to="loc_us-gaap_HedgingDesignationDomain_257C68516AEAC586B87385B86DF50761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_EB666E96A473AF47110985B86DF545D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_257C68516AEAC586B87385B86DF50761" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_EB666E96A473AF47110985B86DF545D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_69C8D6AB4E5F2E44BC4385B86DF5CC06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_257C68516AEAC586B87385B86DF50761" xlink:to="loc_us-gaap_NondesignatedMember_69C8D6AB4E5F2E44BC4385B86DF5CC06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_48F8E5239C4FF64A3A6F85B86DF5C567" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_ED7DA3E7B00968EF6C6985B86DF0EEF9" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_48F8E5239C4FF64A3A6F85B86DF5C567" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_04AD4C1D01209168DB6185B86DF76D2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48F8E5239C4FF64A3A6F85B86DF5C567" xlink:to="loc_invest_DerivativeNotionalAmount_04AD4C1D01209168DB6185B86DF76D2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeAssetFairValueNetAbstract" xlink:label="loc_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_48F8E5239C4FF64A3A6F85B86DF5C567" xlink:to="loc_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D3FE90E69FDDE0AEDE1485B86DF79004" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_D3FE90E69FDDE0AEDE1485B86DF79004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A307498D2B92C7BB6EDC85B86DF7610A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeAssetFairValueNetAbstract_C6E768BFB7216CC052A485B86DF72C5A" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_A307498D2B92C7BB6EDC85B86DF7610A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_FF237831A6C410D0C3509528E9CDE941" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_FF237831A6C410D0C3509528E9CDE941" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E3233F0F7B6BD3C0C20E9528E9CD6B3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E3233F0F7B6BD3C0C20E9528E9CD6B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_76A77596DAE9134DD1EF9528E9CD0325" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E3233F0F7B6BD3C0C20E9528E9CD6B3E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_76A77596DAE9134DD1EF9528E9CD0325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_99474D6FA190F71B29169528E9CDE3DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_76A77596DAE9134DD1EF9528E9CD0325" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_99474D6FA190F71B29169528E9CDE3DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DC030F23841D7B02D56D9528E9CDF557" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="loc_srt_RangeAxis_DC030F23841D7B02D56D9528E9CDF557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_FBCA5B7F73F5B506B3289528E9CD96B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_DC030F23841D7B02D56D9528E9CDF557" xlink:to="loc_srt_RangeMember_FBCA5B7F73F5B506B3289528E9CD96B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4D4C3B7C23F90203DEAD9528E9CD6BFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_FBCA5B7F73F5B506B3289528E9CD96B7" xlink:to="loc_srt_MinimumMember_4D4C3B7C23F90203DEAD9528E9CD6BFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1F5AF6EBC4AA672BBB1D9528E9CD3732" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_FBCA5B7F73F5B506B3289528E9CD96B7" xlink:to="loc_srt_MaximumMember_1F5AF6EBC4AA672BBB1D9528E9CD3732" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_47E6D227B8DFB7A5C8FE9528E9CDC80E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="loc_us-gaap_DebtInstrumentAxis_47E6D227B8DFB7A5C8FE9528E9CDC80E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_20718CA2424E3C4CDC819528E9CD64DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_47E6D227B8DFB7A5C8FE9528E9CDC80E" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_20718CA2424E3C4CDC819528E9CD64DD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E520FC9A21D1022A524D9528E9CD1835" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_20718CA2424E3C4CDC819528E9CD64DD" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_E520FC9A21D1022A524D9528E9CD1835" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3348034A14D8872779769528E9CD5ADF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3348034A14D8872779769528E9CD5ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_A7DC4803D999694C26CC9528E9CD255F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3348034A14D8872779769528E9CD5ADF" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_A7DC4803D999694C26CC9528E9CD255F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_9A226D5BBF247CE7BFC99528E9CD8616" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_A7DC4803D999694C26CC9528E9CD255F" xlink:to="loc_us-gaap_ForeignExchangeContractMember_9A226D5BBF247CE7BFC99528E9CD8616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_62F7D8DC7195C9FB59D09528E9CDB313" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_A7DC4803D999694C26CC9528E9CD255F" xlink:to="loc_us-gaap_InterestRateSwapMember_62F7D8DC7195C9FB59D09528E9CDB313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="loc_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_B32F198A6D7243D2CE0D9528E9CD49CD" xlink:to="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_E8ADDF7A8A39AE13082D9528E9CDCA35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_E8ADDF7A8A39AE13082D9528E9CDCA35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_3059A7B811A8666D67429528E9DDE19D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_35E46DBA5C3F7BAE5ADC9528E9CD73EB" xlink:to="loc_us-gaap_NondesignatedMember_3059A7B811A8666D67429528E9DDE19D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_BDA33AF927F1B0DFB10E9528E9CD6861" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0E882B7D6C3B4FC48F159528E9DD89EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_0E882B7D6C3B4FC48F159528E9DD89EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_3ABEDB1D4363B3EB56DF9528E9DDD6B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_3ABEDB1D4363B3EB56DF9528E9DDD6B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeRemainingMaturity1" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_A310A46F5666B56A92E49528E9DDADF2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_A310A46F5666B56A92E49528E9DDADF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_9527B950AA5D5D88E6089528E9DDB6C3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="loc_invest_DerivativeNotionalAmount_9527B950AA5D5D88E6089528E9DDB6C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4A3014FAA4345F000B489528E9DD527E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_70B0DD0977B65BCEBC059528E9DD9B59" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_4A3014FAA4345F000B489528E9DD527E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_9EEA0B0E4DB10515E8749528E9DDF387" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_FF237831A6C410D0C3509528E9CDE941" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_9EEA0B0E4DB10515E8749528E9DDF387" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35A73C913CD29C8DFF371689810CFE9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_12B456AF41E27A2E32771689810CA41B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35A73C913CD29C8DFF371689810CFE9B" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_12B456AF41E27A2E32771689810CA41B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_70C74B1C122728066A751689810C87D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35A73C913CD29C8DFF371689810CFE9B" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_70C74B1C122728066A751689810C87D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BDF6A2A52B21A05264341689810C342E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35A73C913CD29C8DFF371689810CFE9B" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_BDF6A2A52B21A05264341689810C342E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3AAD0E15918A14197AE51689810CF762" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_35A73C913CD29C8DFF371689810CFE9B" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_3AAD0E15918A14197AE51689810CF762" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="biib-20181231.xsd#biib_DocumentAndEntityInformationAbstract" xlink:label="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_62E73BEF516C5C2D058DBFA7AE0B32A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_EntityRegistrantName_62E73BEF516C5C2D058DBFA7AE0B32A9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_461BFDA3103BA76785BABFA7AE0B08DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_EntityCentralIndexKey_461BFDA3103BA76785BABFA7AE0B08DE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_C368E2BFD371EC1276C5BFA7AE0B9794" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_CurrentFiscalYearEndDate_C368E2BFD371EC1276C5BFA7AE0B9794" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_9F93CE9B5762E5B3012CBFA7AE0B92C3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_EntityFilerCategory_9F93CE9B5762E5B3012CBFA7AE0B92C3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_ED28552A9644B659EC40BFA7AE0C60B4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_EntitySmallBusiness_ED28552A9644B659EC40BFA7AE0C60B4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_0B979F7E59B6653678BABFA7AE0C54DF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_EntityEmergingGrowthCompany_0B979F7E59B6653678BABFA7AE0C54DF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_6FF00AE76DE953109706BFA7B0034930" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_EntityShellCompany_6FF00AE76DE953109706BFA7B0034930" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_83CAFBCDDAD842B4BC34BFA7AE0C0B01" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_DocumentType_83CAFBCDDAD842B4BC34BFA7AE0C0B01" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_69FC94A8E21DA2140B83BFA7AE0C9BB5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_DocumentPeriodEndDate_69FC94A8E21DA2140B83BFA7AE0C9BB5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_2C74CE19A0BB0CB6E96FBFA7AE0CAE4D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_DocumentFiscalYearFocus_2C74CE19A0BB0CB6E96FBFA7AE0CAE4D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_435A0B0CA588B7E96431BFA7AE0D9808" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_DocumentFiscalPeriodFocus_435A0B0CA588B7E96431BFA7AE0D9808" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_5D6BBA69CA86065B48E7BFA7AE0D2338" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_AmendmentFlag_5D6BBA69CA86065B48E7BFA7AE0D2338" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_72D1DFB7EBAFF80BE110BFA7AE0D88A0" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_72D1DFB7EBAFF80BE110BFA7AE0D88A0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_2A3B28D69414B91F52DDBFA7AE0D4772" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_2A3B28D69414B91F52DDBFA7AE0D4772" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_BFD4526F1A9CABEC60F2BFA7AE0E801A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_EntityVoluntaryFilers_BFD4526F1A9CABEC60F2BFA7AE0E801A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_5AE74CD189DDD002FDE3BFA7AE0E13D5" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_EntityCurrentReportingStatus_5AE74CD189DDD002FDE3BFA7AE0E13D5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_806AD4F5AD862AD454BABFA7AE0E825D" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DocumentAndEntityInformationAbstract_8BD00D2CED8D5C14D858BFA7AE0AE638" xlink:to="loc_dei_EntityPublicFloat_806AD4F5AD862AD454BABFA7AE0E825D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_554F49895EBC992824A3FBB835D75103" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_80116DD232CD55E7FE53FBB835D7AA89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_554F49895EBC992824A3FBB835D75103" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_80116DD232CD55E7FE53FBB835D7AA89" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B58AB5584E3F1CF4D7021B4231799040" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B58AB5584E3F1CF4D7021B4231799040" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_7178F30A8CEB494A3EEB1B423179AB23" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_StockOptionsAndEmployeeStockPurchasePlanMember" xlink:label="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:to="loc_biib_StockOptionsAndEmployeeStockPurchasePlanMember_34A6B550A1D227E2DFF41B42317A05AF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_ED66B76C717F7B70DE7E1B42317A1E91" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_7D82A6EE827ECF7308E51B42317A8471" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:to="loc_biib_MarketStockUnitsMember_7D82A6EE827ECF7308E51B42317A8471" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6518324B97DCA75CE0451B4231794728" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_07023B51B97D20783CBE1B42317A3E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_82D86DAF62A7A6D2F8711B4231798D29" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BasicAndDilutedEarningsPerShareAbstract" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_B739204FD8482DCE36581B42317BDBF2" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NumeratorAbstract" xlink:label="loc_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:to="loc_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_4FB80642D5432BA66DDA1B42317BBBDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_NumeratorAbstract_F71394407F2EE27F97C91B42317BA18C" xlink:to="loc_us-gaap_NetIncomeLoss_4FB80642D5432BA66DDA1B42317BBBDC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DenominatorAbstract" xlink:label="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_1D140C45B8B352E4EDAB1B42317B5B9E" xlink:to="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CDE9D59C1BBA940C8B371B42317CD2C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_CDE9D59C1BBA940C8B371B42317CD2C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7BA198FD7F225FD026581B42317C88CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7BA198FD7F225FD026581B42317C88CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7730638B4D42DD8B239B1B42317C471F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_D7F2AEE5D4E6F75C20A81B42317C1DE9" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7730638B4D42DD8B239B1B42317C471F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C0DC5601CA22E30D01B01B42317D95B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DenominatorAbstract_E854E79B7CAB26933A121B42317C0E2F" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_C0DC5601CA22E30D01B01B42317D95B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EarningsPerShareTextualAbstract" xlink:label="loc_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B58AB5584E3F1CF4D7021B4231799040" xlink:to="loc_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_9B8E4543E91832808A761B42317DD7FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EarningsPerShareTextualAbstract_891D8F71420485B07B571B42317DE1ED" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_9B8E4543E91832808A761B42317DD7FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_304FB7B45510306E4D5DFBB833E4D1CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CD93CDDE547BAEAE8D48FBB833E4D403" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_304FB7B45510306E4D5DFBB833E4D1CB" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_CD93CDDE547BAEAE8D48FBB833E4D403" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_FCEFAFBBB52EFE501B06FBB832AC3F44" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_C92728EA9BE08CDD9600FBB832AC4D13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_FCEFAFBBB52EFE501B06FBB832AC3F44" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_C92728EA9BE08CDD9600FBB832AC4D13" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_E5E5E118462722975FE285B86951C341" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_E5E5E118462722975FE285B86951C341" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6EE7D7B4EECC9966F79F85B86951B680" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6EE7D7B4EECC9966F79F85B86951B680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_E41A0ED059CA45BC605285B86951CB52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6EE7D7B4EECC9966F79F85B86951B680" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_E41A0ED059CA45BC605285B86951CB52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ED48F7527E18F18551B585B8695187AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_E41A0ED059CA45BC605285B86951CB52" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_ED48F7527E18F18551B585B8695187AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_25D9E3CB178D61BD052285B86951DDE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_25D9E3CB178D61BD052285B86951DDE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_DB2BAEDF3B9C3F6AFDEA85B86951BEE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_25D9E3CB178D61BD052285B86951DDE5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_DB2BAEDF3B9C3F6AFDEA85B86951BEE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_BCA680E5B7A5875DC7EA85B86951E847" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_DB2BAEDF3B9C3F6AFDEA85B86951BEE5" xlink:to="loc_us-gaap_ForeignPlanMember_BCA680E5B7A5875DC7EA85B86951E847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_0CAE55603C97D697870E85B86954C962" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:to="loc_srt_StatementGeographicalAxis_0CAE55603C97D697870E85B86954C962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_8A38B53000B6D834E8C585B869548ED7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0CAE55603C97D697870E85B86954C962" xlink:to="loc_srt_SegmentGeographicalDomain_8A38B53000B6D834E8C585B869548ED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CH" xlink:label="loc_country_CH_2E64B705FB38519EC1D485B8695449F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8A38B53000B6D834E8C585B869548ED7" xlink:to="loc_country_CH_2E64B705FB38519EC1D485B8695449F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="loc_country_DE_33BAC3AC326344454C8085B86954288C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8A38B53000B6D834E8C585B869548ED7" xlink:to="loc_country_DE_33BAC3AC326344454C8085B86954288C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_96E647916D414E6F6AC785B869511CD1" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EmployeeBenefitPlansTextualAbstract" xlink:label="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4EE4F967BD883360508C85B86954E8E7" xlink:to="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfMinimumInvestmentReturn" xlink:label="loc_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:to="loc_biib_PercentageOfMinimumInvestmentReturn_0028394B8BA8BBDD3CBC85B8695473A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_EA76DB53F26E71E476F085B869542DEE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_EA76DB53F26E71E476F085B869542DEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_EFDD288999DC9B1A742785B86954014E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_EFDD288999DC9B1A742785B86954014E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PensionExpense" xlink:label="loc_us-gaap_PensionExpense_DAF7702E3593DE38B1DB85B86954B01C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:to="loc_us-gaap_PensionExpense_DAF7702E3593DE38B1DB85B86954B01C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9FF8F32787C6A241CA7C85B8695469F7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_EmployeeBenefitPlansTextualAbstract_898837CF17435C570C7485B86954C3C9" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9FF8F32787C6A241CA7C85B8695469F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6F3DFA9A7F8F0591F635FBB8354A54C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6F3DFA9A7F8F0591F635FBB8354A54C4" xlink:to="loc_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_610AB85DCE5FEBA9213FFBB8354A9251" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_F6FB18484EDF9687EB2CFBB8354A4E33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:to="loc_us-gaap_DomesticPlanMember_F6FB18484EDF9687EB2CFBB8354A4E33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_D1881BAAA9C582775BBDFBB8355A615F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E4798A91F95BF2434C7FFBB8354AC288" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_D1881BAAA9C582775BBDFBB8355A615F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_28963290628052F0431FFBB8354AB5D6" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MinimumQualifyingAgeForEmployeeBenefitPlan" xlink:label="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:to="loc_biib_MinimumQualifyingAgeForEmployeeBenefitPlan_906664A595F80CDF428AFBB8355A5A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_342EE3B076DB9788D770FBB8355A2827" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_342EE3B076DB9788D770FBB8355A2827" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_9FDDAD8ED5A86DFF79E6FBB8355AEC8C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_AF9975CDBD3080AD7420FBB8355A117E" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_9FDDAD8ED5A86DFF79E6FBB8355AEC8C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6ED1B46525CB065CD132FBB83480AA3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_984C3F1A2238B846C6B6FBB83480B52E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6ED1B46525CB065CD132FBB83480AA3D" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_984C3F1A2238B846C6B6FBB83480B52E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_79A5388C8E0D81B36D29F08E8DB4FB81" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_79A5388C8E0D81B36D29F08E8DB4FB81" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_FAE07E689A40F40909CBF08E8DB47102" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_FAE07E689A40F40909CBF08E8DB47102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_DAF530FEDD908E67AB7DF08E8DB4E4A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1" xlink:to="loc_us-gaap_CommonStockSharesIssued_DAF530FEDD908E67AB7DF08E8DB4E4A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_25D94619E325C7AFC26FF08E8DB50276" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_30846214237167C7AE10F08E8DB4E5F1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_25D94619E325C7AFC26FF08E8DB50276" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_66CEA6A5F16214B00BA7F08E8DAC6B7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66CEA6A5F16214B00BA7F08E8DAC6B7A" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_3BD7DCDDF7EB544114F4F08E8DAC61AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_3BD7DCDDF7EB544114F4F08E8DAC61AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_3BD7DCDDF7EB544114F4F08E8DAC61AF" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2018ShareRepurchaseProgramMember" xlink:label="loc_biib_A2018ShareRepurchaseProgramMember_B1F1D17A3047A92BE572F08E8DAD3AFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E" xlink:to="loc_biib_A2018ShareRepurchaseProgramMember_B1F1D17A3047A92BE572F08E8DAD3AFC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2016ShareRepurchaseProgramMember" xlink:label="loc_biib_A2016ShareRepurchaseProgramMember_BD6A4F12A249553058E6F08E8DADD161" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E" xlink:to="loc_biib_A2016ShareRepurchaseProgramMember_BD6A4F12A249553058E6F08E8DADD161" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2011ShareRepurchaseProgramMember" xlink:label="loc_biib_A2011ShareRepurchaseProgramMember_8CA9322E5C642F270813F08E8DAED220" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_5203AEF4248710752C20F08E8DADF49E" xlink:to="loc_biib_A2011ShareRepurchaseProgramMember_8CA9322E5C642F270813F08E8DAED220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_EFAB304C7646D3DCDCDFF08E8DAE42C6" xlink:to="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_265EA70ACE5F61B58D9CF08E8DAEFBBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_265EA70ACE5F61B58D9CF08E8DAEFBBE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeriesXPreferredStockMember" xlink:label="loc_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:to="loc_biib_SeriesXPreferredStockMember_A9FB2359CB84E2DA7F0EF08E8DAEDD31" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_UndesignatedPreferredStockMember" xlink:label="loc_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_A637AF68C67ACDCECF8DF08E8DAE2DD3" xlink:to="loc_biib_UndesignatedPreferredStockMember_614733852FC7C3CABACDF08E8DAF6B32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5DA77CEE86312C004C38F08E8DAC919D" xlink:to="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_BD10F5F9365B2E165597F08E8DAF49A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_BD10F5F9365B2E165597F08E8DAF49A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57AF56549937017ED815F08E8DAF4125" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57AF56549937017ED815F08E8DAF4125" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D13B12D16E48FBEA3E6FF08E8DAF4262" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_D13B12D16E48FBEA3E6FF08E8DAF4262" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_8A5CA08ECF7876DB5ABDF08E8DAFB97A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_8A5CA08ECF7876DB5ABDF08E8DAFB97A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_69397A0D8C4D84252910F08E8DB01213" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_755314D10FDF63830FCBF08E8DAF3DB9" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_69397A0D8C4D84252910F08E8DB01213" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1691F4F2F3E007D28824FBB8355A2AA5" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryOfCommonStockTableTextBlock" xlink:label="loc_biib_SummaryOfCommonStockTableTextBlock_589D81382DD4ED4A49D0FBB8355A4169" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1691F4F2F3E007D28824FBB8355A2AA5" xlink:to="loc_biib_SummaryOfCommonStockTableTextBlock_589D81382DD4ED4A49D0FBB8355A4169" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3B0FA39AC452DB4B1E9EFBB8336757AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_E42E9D987D3321C773BCFBB833676D9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3B0FA39AC452DB4B1E9EFBB8336757AE" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_E42E9D987D3321C773BCFBB833676D9A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_333D50673374D045F3D2856979DE4FCE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_333D50673374D045F3D2856979DE4FCE" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_A5AF2FD765BAFA54148E856979DE1CC2" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_BF4CA95502686F6FA551856979DE57F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_BF4CA95502686F6FA551856979DE57F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_33C96FDB34BF36636531856979DE92AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_33C96FDB34BF36636531856979DE92AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_DF8CDD197393BB2DA399856979DE7F7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_19FC6A5E71C27F9F4869856979DE9096" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_DF8CDD197393BB2DA399856979DE7F7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_33FF13FF9DC43ABF44C8856979DEAA0F" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_130A17EFBA445A59D9C2856979DEF415" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_E74F1D2A8752245DD5B7856979DE4463" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_130A17EFBA445A59D9C2856979DEF415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_DE9CF97216FE06BB8631856979DE616A" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_63FF60E3969F05EF1A24856979DE61A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_63FF60E3969F05EF1A24856979DE61A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8241B7CEFD7D29AA8138856979DEB9FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8241B7CEFD7D29AA8138856979DEB9FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_A0FB2246699BCE3029DC856979DEC200" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_60BFBAEC04F2535566AB856979DE9226" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_A0FB2246699BCE3029DC856979DEC200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F96A6FED12087AC0DE0F856979DEE23F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3CBB284D04D9BFC1358B856979DED4CC" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_B147F8070CA631A2C70C856979DEADFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_B147F8070CA631A2C70C856979DEADFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1F51DC5F3E2119EDD798856979DECFEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B147F8070CA631A2C70C856979DEADFC" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_1F51DC5F3E2119EDD798856979DECFEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_C811400A8D6A4311366C856979DE6F0C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B147F8070CA631A2C70C856979DEADFC" xlink:to="loc_us-gaap_AvailableForSaleSecurities_C811400A8D6A4311366C856979DE6F0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_6B9597278496CFF9113B856979DE97EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B147F8070CA631A2C70C856979DEADFC" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_6B9597278496CFF9113B856979DE97EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_EF9D410BF08E42D4237B856979DEF13D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B147F8070CA631A2C70C856979DEADFC" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_EF9D410BF08E42D4237B856979DEF13D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_EF08249EA39046AF6E16856979DEFE7C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B147F8070CA631A2C70C856979DEADFC" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_EF08249EA39046AF6E16856979DEFE7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2FEFFD5D7334FB34882B856979DEA91E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_B147F8070CA631A2C70C856979DEADFC" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_2FEFFD5D7334FB34882B856979DEA91E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BD5E19BB50F8E842A072856979DE01F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_0ABF4472D796E3204FD385989678E7F1" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BD5E19BB50F8E842A072856979DE01F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_FB55909A77AFEF2A5C5A856979DE16BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BD5E19BB50F8E842A072856979DE01F6" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_FB55909A77AFEF2A5C5A856979DE16BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3289CB8B167516E6F95C856979DE7DC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BD5E19BB50F8E842A072856979DE01F6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3289CB8B167516E6F95C856979DE7DC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_1C445431FF1F57280DCC856979DE37E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_BD5E19BB50F8E842A072856979DE01F6" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_1C445431FF1F57280DCC856979DE37E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3B5E998D668E1A1CABF615EAEE24E615" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_403A532001F32AE34A9F15EAEE24BDEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3B5E998D668E1A1CABF615EAEE24E615" xlink:to="loc_us-gaap_DebtInstrumentTable_403A532001F32AE34A9F15EAEE24BDEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1F3B3F2758F7BACC347E15EAEE244497" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_403A532001F32AE34A9F15EAEE24BDEA" xlink:to="loc_us-gaap_DebtInstrumentAxis_1F3B3F2758F7BACC347E15EAEE244497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1F3B3F2758F7BACC347E15EAEE244497" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_BD313C80B2887C0882A215EAEE2592A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_NotesPayableToFumedicaMember_BD313C80B2887C0882A215EAEE2592A7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_12237A0908995186D1B515EAEE2638D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_12237A0908995186D1B515EAEE2638D3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_CA12EF73085A6BC179E415EAEE27E9CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_CA12EF73085A6BC179E415EAEE27E9CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_7E3FD2505356A6FEFB2315EAEE2722C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_7E3FD2505356A6FEFB2315EAEE2722C8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_B6DB5710CCB08F32A38415EAEE27691E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_B6DB5710CCB08F32A38415EAEE27691E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_BEB9044DA01D891760F215EAEE27F44A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AE4B588D66511295CA1A15EAEE2519F3" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_BEB9044DA01D891760F215EAEE27F44A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2A6067A7C02C17A51B0015EAEE277243" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_403A532001F32AE34A9F15EAEE24BDEA" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2A6067A7C02C17A51B0015EAEE277243" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_AA27A4982560CDE6093D15EB0DF5DD9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2A6067A7C02C17A51B0015EAEE277243" xlink:to="loc_us-gaap_NotesPayable_AA27A4982560CDE6093D15EB0DF5DD9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_35CCFEC190CD0195405C15EAEE274459" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2A6067A7C02C17A51B0015EAEE277243" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_35CCFEC190CD0195405C15EAEE274459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_E3DB9CD907F742A4C82515EAEE286909" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2A6067A7C02C17A51B0015EAEE277243" xlink:to="loc_us-gaap_DebtInstrumentFairValue_E3DB9CD907F742A4C82515EAEE286909" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_86FA5D431ECDE5F78B27FBB83357760B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_B1F55CE161F222BA7D3BFBB833573531" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_86FA5D431ECDE5F78B27FBB83357760B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_B1F55CE161F222BA7D3BFBB833573531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3DB73607DB1235539207FBB8335741A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_B1F55CE161F222BA7D3BFBB833573531" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3DB73607DB1235539207FBB8335741A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_D8B37431A0560AE3DA2AFBB8335775B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_3DB73607DB1235539207FBB8335741A7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_D8B37431A0560AE3DA2AFBB8335775B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_83D5705D8F713B6D4944FBB83357AD3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_D8B37431A0560AE3DA2AFBB8335775B2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_83D5705D8F713B6D4944FBB83357AD3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FFD03351B4924822000EFBB83357CE05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_B1F55CE161F222BA7D3BFBB833573531" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FFD03351B4924822000EFBB83357CE05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_C3F3680555D1EF7722A1FBB83357F701" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FFD03351B4924822000EFBB83357CE05" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_C3F3680555D1EF7722A1FBB83357F701" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C65CAEE7547892987B36FBB8335759A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FFD03351B4924822000EFBB83357CE05" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_C65CAEE7547892987B36FBB8335759A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E2AAEEAD128945B830E7FBB833574EF7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FFD03351B4924822000EFBB83357CE05" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E2AAEEAD128945B830E7FBB833574EF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2EFFF585FA874E216062FBB8335725F4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_FFD03351B4924822000EFBB83357CE05" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_2EFFF585FA874E216062FBB8335725F4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C66958383725410DF32AC42828781DAF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C66958383725410DF32AC42828781DAF" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_B6100B138A6A759C4F47C42828790CFE" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_A2575B97CAEB53410AF7C428287AE3F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_08F99B1D9246325DE2A8C428287932ED" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_A2575B97CAEB53410AF7C428287AE3F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_1CC2E7E9573C272F2CBDC428287AB376" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9516F6ED04EDDE400283C428287A69F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_9516F6ED04EDDE400283C428287A69F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesMember" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_31C856BBE0399F18CA0EC42828808937" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_AA71F7CA2A7341619539C428287A9C71" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_31C856BBE0399F18CA0EC42828808937" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9DBF5A3D86AA038AA277C42828809A6B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:to="loc_us-gaap_DebtInstrumentAxis_9DBF5A3D86AA038AA277C42828809A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9DBF5A3D86AA038AA277C42828809A6B" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FFAB83D2B615E34C9B26C42828804C4B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_FFAB83D2B615E34C9B26C42828804C4B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_13396646A486C10B984EC42828819B7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_13396646A486C10B984EC42828819B7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6B90E14F3BA63F91B518C4282881A985" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_6B90E14F3BA63F91B518C4282881A985" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3F82DDFFCE035DA332FBC42828810B8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_3F82DDFFCE035DA332FBC42828810B8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_80D0C42A0DB8030BE5A5C4282881946A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DEA2F5F9AAC5D4DF3424C4282880F116" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_80D0C42A0DB8030BE5A5C4282881946A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_22AA76EECFE757A6DAC5C4282881E3AA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_22AA76EECFE757A6DAC5C4282881E3AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_22AA76EECFE757A6DAC5C4282881E3AA" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ConvergencePharmaceuticalsMember" xlink:label="loc_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6" xlink:to="loc_biib_ConvergencePharmaceuticalsMember_DCCFD3D4CDC748434E6FC4282882588A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_StromedixMember" xlink:label="loc_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6" xlink:to="loc_biib_StromedixMember_0179F715D0CA36764AC0C4282882325F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BiogenIdecInternationalNeuroscienceMember" xlink:label="loc_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_37AAC275759D9239DE04C4282881DBE6" xlink:to="loc_biib_BiogenIdecInternationalNeuroscienceMember_DE56479104D57890E6CFC42828828C8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_7128AF3C10B21D4DE662C4282878A67F" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs" xlink:label="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_D9F6B99D4EA5B87B08E7C4282883ED11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs_D9F6B99D4EA5B87B08E7C4282883ED11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_75A683E891D32F0EC961C428288319DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_75A683E891D32F0EC961C428288319DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_27FFB555BBB297BDA7D8C428288361CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_27FFB555BBB297BDA7D8C428288361CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_547E05EA3F5DCB401D46C4282883BF8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_547E05EA3F5DCB401D46C4282883BF8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E5C2485A0F79A69E1955C428288311C8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_E5C2485A0F79A69E1955C428288311C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DE60CAC41064659E7E9FC4282883CC99" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_DE60CAC41064659E7E9FC4282883CC99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D98E3419CA04DC6ED8B1C428288405B2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_D98E3419CA04DC6ED8B1C428288405B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0817AE28A7926C65B7D5C42828842896" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_0817AE28A7926C65B7D5C42828842896" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FairValueMeasurementInputs" xlink:label="loc_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_biib_FairValueMeasurementInputs_E09FD0781D9B92188D06C42828842717" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_01BA80D7D419BE818764C428288991AA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_01BA80D7D419BE818764C428288991AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_D467EF56530447488FC5C4693F79BFD0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_C244207F59966BC4AC50C4282882AE14" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_D467EF56530447488FC5C4693F79BFD0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_BF89EB73C70C521F324DFBB83386CFEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_62714394FF4E5981BC90FBB833860D48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_BF89EB73C70C521F324DFBB83386CFEC" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_62714394FF4E5981BC90FBB833860D48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_08626C7701C6121DCCA5FBB83386F2E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_BF89EB73C70C521F324DFBB83386CFEC" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_08626C7701C6121DCCA5FBB83386F2E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_92029F92BBE96506EF81FBB83386B179" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_BF89EB73C70C521F324DFBB83386CFEC" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_92029F92BBE96506EF81FBB83386B179" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_EDE3FB48167B814A8BEAFBB835A8CB00" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_FFCC088D8345E800ACF0FBB835A83AE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_EDE3FB48167B814A8BEAFBB835A8CB00" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_FFCC088D8345E800ACF0FBB835A83AE6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_FC9FE6E0222BAF38D190FBB83183D501" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_FC9FE6E0222BAF38D190FBB83183D501" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:to="loc_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_107F9A1A4B38928FCF85FBB83183C72F" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_55E5CEFBC90F8A881B6EFBB8318394D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:to="loc_us-gaap_CommercialPaperMember_55E5CEFBC90F8A881B6EFBB8318394D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepurchaseAgreementsMember" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_DA766CB27C0916BFF105FBB831839EA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_DA766CB27C0916BFF105FBB831839EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8C601A1DC98AB976BD99FBB831831E37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8C601A1DC98AB976BD99FBB831831E37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_B98401EBCF763140C03BFBB83183B5D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_80850D5A9C594108758FFBB83183DE05" xlink:to="loc_us-gaap_DebtSecuritiesMember_B98401EBCF763140C03BFBB83183B5D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_771C0CAD3EFABC708F45FBB83183AF49" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_67F7309C13B0486E88C6FBB83183E44C" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_2DF9BE93E2C2BBED5EF5FBB83183AB8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_DA88772831A0326173D1FBB83183D5C7" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_2DF9BE93E2C2BBED5EF5FBB83183AB8A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_E19B8B11B6C9C4C5086AFBB8354A81A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_E19B8B11B6C9C4C5086AFBB8354A81A6" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_398FB41B4EB3D0C18E75FBB8354AD187" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:to="loc_us-gaap_FinancialInstrumentAxis_398FB41B4EB3D0C18E75FBB8354AD187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_398FB41B4EB3D0C18E75FBB8354AD187" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CorporateDebtSecuritiesCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_487A4FC418FF8CF4E1EEFBB8354AB022" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CorporateDebtSecuritiesNonCurrentMember" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_95529322EF7F417B7154FBB8354A65FE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_GovernmentSecuritiesCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_8C750C90B212B07E402AFBB8354AFCF4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_GovernmentSecuritiesNonCurrentMember" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_636EE6BC09086904DCCBFBB8354A1F8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_811570C474A8C45D5ECAFBB8354A7797" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_276C949D043455850DB7FBB8354A2041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_173856A12C214767B3E5FBB8354AE79C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_DF43936EAD3C74DB4A6EFBB8354AB058" xlink:to="loc_us-gaap_EquitySecuritiesMember_173856A12C214767B3E5FBB8354AE79C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_6A2F293DB304FDC82368FBB8354A2E24" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_0ED7696DBD9FF8B79269FBB8354AB680" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_BAF7AD63A6A29D4B02B2FBB8354AD81B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:to="loc_us-gaap_AvailableForSaleSecurities_BAF7AD63A6A29D4B02B2FBB8354AD81B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48E33846BD45237179D8FBB8354A836D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_48E33846BD45237179D8FBB8354A836D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22DE47C8A8E5383E6FD9FBB8354A73D2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_22DE47C8A8E5383E6FD9FBB8354A73D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_9CCEBFA467FDA88E1CFFFBB8354A00D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_E4B620B8063CCCD2BA12FBB8354A5114" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_9CCEBFA467FDA88E1CFFFBB8354A00D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_30917781C34FBD3CCD1BFBB835B7108C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_30917781C34FBD3CCD1BFBB835B7108C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_D0B568C81ED431C4EE3BFBB835B77A8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_D0B568C81ED431C4EE3BFBB835B77A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1B158A5DD1269251BEF4FBB835B7B86E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1B158A5DD1269251BEF4FBB835B7B86E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6EE1680485B32BAF6579FBB835B7E382" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6EE1680485B32BAF6579FBB835B7E382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_904F45BD0E5F445235E7FBB835B7F824" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_904F45BD0E5F445235E7FBB835B7F824" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F35A22F3DC80E2DF977FFBB835B7ADD3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_F35A22F3DC80E2DF977FFBB835B7ADD3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FE87669F5AB9D9D5A3A2FBB835B7C90A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_FE87669F5AB9D9D5A3A2FBB835B7C90A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_9C26394088CCA9A454FAFBB835B78574" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:to="loc_us-gaap_AvailableForSaleSecurities_9C26394088CCA9A454FAFBB835B78574" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C95D6D83B096AC37BD16FBB835B73669" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_5F6AA6521E4614013A1DFBB835B7AF17" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_C95D6D83B096AC37BD16FBB835B73669" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_029980B2DFE0540F90DDFBB833C48E29" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ProceedsFromMarketableDebtSecuritiesAbstract" xlink:label="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_029980B2DFE0540F90DDFBB833C48E29" xlink:to="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D4D2913DC6B87129A4C7FBB833C4B541" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_D4D2913DC6B87129A4C7FBB833C4B541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGains" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_2FB933AB0A12222F56FBFBB833C4F4C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains_2FB933AB0A12222F56FBFBB833C4F4C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_545681B0F255EC468AF5FBB833C4B8CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ProceedsFromMarketableDebtSecuritiesAbstract_632E5B71043022645DC7FBB833C4DE4D" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_545681B0F255EC468AF5FBB833C4B8CA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5AD09D6597189ACE473EFBB833A5BF32" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FinancialInstrumentsTextualAbstract" xlink:label="loc_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_5AD09D6597189ACE473EFBB833A5BF32" xlink:to="loc_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_0C397FDF19696CF25743FBB833A538CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_0C397FDF19696CF25743FBB833A538CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AverageMaturityOfMarketableSecurities" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_753CFA4A798B074067A8FBB833A5543F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FinancialInstrumentsTextualAbstract_5B1CDA21CC8BD9EED03DFBB833A5FF8B" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_753CFA4A798B074067A8FBB833A5543F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_C9ACE029E68D9369FA9CAAF0C05B43E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5B8A6BA7EFF603E7095EAAF0C05B3BB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_C9ACE029E68D9369FA9CAAF0C05B43E9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5B8A6BA7EFF603E7095EAAF0C05B3BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5B8A6BA7EFF603E7095EAAF0C05B3BB1" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_E37254E941013C3815A0AAF0C05BAF7E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_52EEBEE6F45428030C07AAF0C05CA749" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9066B6DC8251FC38142CAAF0C05BE431" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_52EEBEE6F45428030C07AAF0C05CA749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_16713D2FFE3E777F7C3DAAF0C05CA48A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5B8A6BA7EFF603E7095EAAF0C05B3BB1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_16713D2FFE3E777F7C3DAAF0C05CA48A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D752D7309BD70554567AAF0C05C9679" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_16713D2FFE3E777F7C3DAAF0C05CA48A" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D752D7309BD70554567AAF0C05C9679" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_2A307FDD757C39D4EEABAAF0C05CBA51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D752D7309BD70554567AAF0C05C9679" xlink:to="loc_biib_IonisPharmaceuticalsMember_2A307FDD757C39D4EEABAAF0C05CBA51" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5D752D7309BD70554567AAF0C05C9679" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_52EEBEE6F45428030C07AAF0C05CA749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5B8A6BA7EFF603E7095EAAF0C05B3BB1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_44AF580BB71091B354D5AAF0C05DA273" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_StrategicInvestmentsMember" xlink:label="loc_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CA1A9517E6E56672A8B4AAF0C05D1C37" xlink:to="loc_biib_StrategicInvestmentsMember_EAD5D61FE79C3FF13255AAF0C05DC0F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5B8A6BA7EFF603E7095EAAF0C05B3BB1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_StrategicInvestmentPortfolio" xlink:label="loc_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_StrategicInvestmentPortfolio_46103A57F3C40F7BDA62AAF0C05ED92C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Termofcollaborationagreement" xlink:label="loc_biib_Termofcollaborationagreement_F946AAAF88CD72F575DCAAF0C05E6148" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_Termofcollaborationagreement_F946AAAF88CD72F575DCAAF0C05E6148" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Totalpaymenttoentercollaborationagreement" xlink:label="loc_biib_Totalpaymenttoentercollaborationagreement_853B3A85E9437A8FFE41AAF0C05F99B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_Totalpaymenttoentercollaborationagreement_853B3A85E9437A8FFE41AAF0C05F99B3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Upfrontpaymentforcollaborationagreement" xlink:label="loc_biib_Upfrontpaymentforcollaborationagreement_3406F27D03FCA47D08A7AAF0C05F65C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_Upfrontpaymentforcollaborationagreement_3406F27D03FCA47D08A7AAF0C05F65C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_6F2386B112A651C44B9BAAF0C05F6739" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_Investmentincommonstocksharespurchased_6F2386B112A651C44B9BAAF0C05F6739" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Purchaseofcommonstock" xlink:label="loc_biib_Purchaseofcommonstock_C518344F9F33348EE4F0AAF0C05F8A4C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_Purchaseofcommonstock_C518344F9F33348EE4F0AAF0C05F8A4C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5B9F60C99FE44BB8508EAAF0C060510D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_5B9F60C99FE44BB8508EAAF0C060510D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_34ACBC6652C9EC14A0A8AAF0C060BB28" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_34ACBC6652C9EC14A0A8AAF0C060BB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_38A95D1985958FF0370DAAF0C0609EAD" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_38A95D1985958FF0370DAAF0C0609EAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_36D328C47EDB9CBAE3EFAAF0C060B716" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3C73C6D84BD18CD8B80BAAF0C05EEFB9" xlink:to="loc_us-gaap_EquityMethodInvestments_36D328C47EDB9CBAE3EFAAF0C060B716" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D24E2631E8CA9CE7270BFBB8325EC330" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_82733B16E326E77C799EFBB8325E1D14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D24E2631E8CA9CE7270BFBB8325EC330" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_82733B16E326E77C799EFBB8325E1D14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_3128AD5386EAF364E3E4FBB8325E9413" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D24E2631E8CA9CE7270BFBB8325EC330" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_3128AD5386EAF364E3E4FBB8325E9413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DDD7C47493FDF9270974FBB8325EB595" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D24E2631E8CA9CE7270BFBB8325EC330" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_DDD7C47493FDF9270974FBB8325EB595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F0ED673B4BE2B8A1A9D9FBB8325E6F1C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_D24E2631E8CA9CE7270BFBB8325EC330" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_F0ED673B4BE2B8A1A9D9FBB8325E6F1C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Guarantees" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GuaranteesAbstract" xlink:label="loc_us-gaap_GuaranteesAbstract_82F0BFC3D67C181CB688FBB83460774E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GuaranteesTextBlock" xlink:label="loc_us-gaap_GuaranteesTextBlock_2FF76EFE7A9310F80F9BFBB83460E723" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteesAbstract_82F0BFC3D67C181CB688FBB83460774E" xlink:to="loc_us-gaap_GuaranteesTextBlock_2FF76EFE7A9310F80F9BFBB83460E723" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_378A65EAC0A3D1E5BA9D85697A7A7381" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97662C8DB502447FE0B485697A7AF516" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_378A65EAC0A3D1E5BA9D85697A7A7381" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_97662C8DB502447FE0B485697A7AF516" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B5EA2F1FB349F36A641A85697A6A1C5A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_B5EA2F1FB349F36A641A85697A6A1C5A" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E1379B5B23FD79F97F8485697A6AEF17" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6AC2CA409422D65B57BF85697A6ABDE5" xlink:to="loc_biib_BioverativMember_92C0FC05A27E0DC58F7385697A6A6CF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_03872E9E7620B819099C85697A6ACB2D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7CE50FD6B0434A4908D85697A6AEF9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_E7CE50FD6B0434A4908D85697A6AEF9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_FE5D1DADF79F79920F2285697A6A11B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_FE5D1DADF79F79920F2285697A6A11B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_60CB939DE4EB8C1A580585697A6A38E7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_60CB939DE4EB8C1A580585697A6A38E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_A88447AD456F4C35F29C85697A6A50D4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_A88447AD456F4C35F29C85697A6A50D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_CE2954F6E6E0BA0CDE0885697A6A586B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_CE2954F6E6E0BA0CDE0885697A6A586B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C926F8E7BE036965D6F585697A6ADEC9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_C926F8E7BE036965D6F585697A6ADEC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8CD16292C90C0E0C078E85697A6A0324" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8CD16292C90C0E0C078E85697A6A0324" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6684802F4EDF72A6FAA385697A6A8AC4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_6684802F4EDF72A6FAA385697A6A8AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1F3CE75937F0EF4A9DA385697A6A18DF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_1F3CE75937F0EF4A9DA385697A6A18DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_F2DD821B190719DE3EAB85697A6AC31D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_F2DD821B190719DE3EAB85697A6AC31D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1453678EC5388DE6C8FF85697A6A48B4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_A70809B43E7DC5F3AB4785697A6AC902" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_1453678EC5388DE6C8FF85697A6A48B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_AA0355C5B16698B280A4871CB12D4EBC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_55B1AD5E41F11FE8219D871CB12DC74E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_AA0355C5B16698B280A4871CB12D4EBC" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_55B1AD5E41F11FE8219D871CB12DC74E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_7F13B815FE8787F63069871CB12D5CF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_55B1AD5E41F11FE8219D871CB12DC74E" xlink:to="loc_srt_MajorCustomersAxis_7F13B815FE8787F63069871CB12D5CF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_D53BA482500275E42616871CB12D549A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7F13B815FE8787F63069871CB12D5CF4" xlink:to="loc_srt_NameOfMajorCustomerDomain_D53BA482500275E42616871CB12D549A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_C4A1B22BEEAC725B2FCB871CB12D4162" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_D53BA482500275E42616871CB12D549A" xlink:to="loc_biib_BioverativMember_C4A1B22BEEAC725B2FCB871CB12D4162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C34448B445B79805518B871CB12DEE2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_55B1AD5E41F11FE8219D871CB12DC74E" xlink:to="loc_srt_ProductOrServiceAxis_C34448B445B79805518B871CB12DEE2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_CB7056AF4F821CDD6925871CB12D2398" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_C34448B445B79805518B871CB12DEE2A" xlink:to="loc_srt_ProductsAndServicesDomain_CB7056AF4F821CDD6925871CB12D2398" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_43D605A62BA6518DF127871CB12D43D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CB7056AF4F821CDD6925871CB12D2398" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_43D605A62BA6518DF127871CB12D43D3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_142BB9681B0385E8BB9D871CB12D7FFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_CB7056AF4F821CDD6925871CB12D2398" xlink:to="loc_biib_HemophiliaProductsMember_142BB9681B0385E8BB9D871CB12D7FFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A15BDE912875DB06EF77871CB12D2054" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_55B1AD5E41F11FE8219D871CB12DC74E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A15BDE912875DB06EF77871CB12D2054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BDD0ED63A901D31B90C3871CB12D42B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_A15BDE912875DB06EF77871CB12D2054" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BDD0ED63A901D31B90C3871CB12D42B6" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BDD0ED63A901D31B90C3871CB12D42B6" xlink:to="loc_biib_BioverativMember_C4A1B22BEEAC725B2FCB871CB12D4162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_55B1AD5E41F11FE8219D871CB12DC74E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_CCF77EDD5B43B9F05CFB871CB13D06A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_CCF77EDD5B43B9F05CFB871CB13D06A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_EA32FBB764986D093FD0871CB13D701B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:to="loc_us-gaap_Revenues_EA32FBB764986D093FD0871CB13D701B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8C84BDE5FA70799539BD871CB13D83F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8C84BDE5FA70799539BD871CB13D83F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InventoryexpectedtobesoldtoBioverativ" xlink:label="loc_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2A5C4652247A8FD80019871CB13D3753" xlink:to="loc_biib_InventoryexpectedtobesoldtoBioverativ_618689F725AEBFA1F26B871CB13D3FAB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_420544CB9371C60BD44781E39CA231CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_050095379D82EDA255F281E2F277CC97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_420544CB9371C60BD44781E39CA231CB" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_050095379D82EDA255F281E2F277CC97" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_EEE461F8BBFD294E72D5FBB8354A7D51" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2E96026B69852A88F23DFBB8354A4B0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_EEE461F8BBFD294E72D5FBB8354A7D51" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2E96026B69852A88F23DFBB8354A4B0F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_73559594DEDBE260832BFBB831C2A30A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73559594DEDBE260832BFBB831C2A30A" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_E74B1C1FD985B233F49AFBB831C2060D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_E74B1C1FD985B233F49AFBB831C2060D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_894EB57AAA1985C62517FBB831C2578E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_894EB57AAA1985C62517FBB831C2578E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_A1D7DA38320CB9C827BDFBB831C2D75E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_73C072963326A36036F2FBB831C2A305" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_A1D7DA38320CB9C827BDFBB831C2D75E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_693E133819FF4B46A5D8FBB831C225A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_693E133819FF4B46A5D8FBB831C225A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_693E133819FF4B46A5D8FBB831C225A8" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_56B6B08234A351CF4905FBB831C2543B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_56B6B08234A351CF4905FBB831C2543B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C00839A8B7FDC16A6375FBB831C2840C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_C00839A8B7FDC16A6375FBB831C2840C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_069423D8B3D4E4CDCBADFBB831C2BA52" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_069423D8B3D4E4CDCBADFBB831C2BA52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E06105AB99D6D49840A7FBB831C2ABA9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1747F4833A9AFD2968C9FBB831C2B74E" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_E06105AB99D6D49840A7FBB831C2ABA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_693E133819FF4B46A5D8FBB831C225A8" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6E1D3ED50A314E0CD4C3FBB831C29A88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6E1D3ED50A314E0CD4C3FBB831C29A88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_605DB4219F83D7771198FBB831C2A4AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_605DB4219F83D7771198FBB831C2A4AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10459CFEF2C6614D9997FBB831C272F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10459CFEF2C6614D9997FBB831C272F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_16BCB80A535D03E22490FBB831C2BEFE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_B9090A8E44210E3D2F8DFBB831C2D74E" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_16BCB80A535D03E22490FBB831C2BEFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D6CCD227435D753E13E3FBB831C23B53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAbstract_DB234A1082E91261BCFFFBB831C2A0BF" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_D6CCD227435D753E13E3FBB831C23B53" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_68E875284FC204D142639A049CE798DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_68E875284FC204D142639A049CE798DF" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4AC7B7915AC1981320509A049CE9A47D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4AC7B7915AC1981320509A049CE9A47D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_F2B3166C2068C0D03E589A049CE941FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_F2B3166C2068C0D03E589A049CE941FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_661AC0D22D83852DCB2D9A049CE9762B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_661AC0D22D83852DCB2D9A049CE9762B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EA774711068CD4CE89439A049CEA35C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EA774711068CD4CE89439A049CEA35C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_03BADDBFB7D9243EE6B69A049CEA35B5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_03BADDBFB7D9243EE6B69A049CEA35B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_40A49D0753C61F5F5BD49A049CEAF8F1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_40A49D0753C61F5F5BD49A049CEAF8F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_888B1D78BABC5804C37E9A049CEAD5B8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_888B1D78BABC5804C37E9A049CEAD5B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_55AADD3369A3DAAC9E249A049CEA6505" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_55AADD3369A3DAAC9E249A049CEA6505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_C0248642F44D23648C239A049CEAA83A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_C0248642F44D23648C239A049CEAA83A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_BA5CF9284277CAE0693A9A049CEA2134" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_BA5CF9284277CAE0693A9A049CEA2134" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredTaxLiabilitiesTaxCreditCarryforwards" xlink:label="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_F2C28C74EBF918E1969D9A049CEB1B54" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards_F2C28C74EBF918E1969D9A049CEB1B54" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredTaxLiabilitiesDepreciationAmortizationOther" xlink:label="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_51D89551724A7B1101589A049CEB65E2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther_51D89551724A7B1101589A049CEB65E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_35D8831CC70F2DA471049A049CEBB1EB" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_A386DE4669DCCFBEE8059A049CE8A071" xlink:to="loc_us-gaap_DeferredTaxLiabilities_35D8831CC70F2DA471049A049CEBB1EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_683473C831F9576EEE67820848631053" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_683473C831F9576EEE67820848631053" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_E1D9E2824A6ADD1534618208486383F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_E1D9E2824A6ADD1534618208486383F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F28DDC01424B42A42CD78208486362BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_F28DDC01424B42A42CD78208486362BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7810A9594F9FEA17D1C28208486333DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7810A9594F9FEA17D1C28208486333DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7CBA5F9C23AD93DDDE3E820848635EA3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7CBA5F9C23AD93DDDE3E820848635EA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_31F224D8152AF2B49776820848638472" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_31F224D8152AF2B49776820848638472" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction" xlink:label="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_CAFEC334AB659433928282084863B5DB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction_CAFEC334AB659433928282084863B5DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1F0C424BE781AF4D7C9D82084863079B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_1F0C424BE781AF4D7C9D82084863079B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EffectiveTaxRateReconciliationGILTItax" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_83F390E0603BFE77BC2A824CCB9EE79A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_83F390E0603BFE77BC2A824CCB9EE79A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_55228EA6929EE5F1064682084863947E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_55228EA6929EE5F1064682084863947E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_D54E3C452AC8908BD122820848638B35" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_D54E3C452AC8908BD122820848638B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3A24A534E380C5A17BB18208486360D3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_3A24A534E380C5A17BB18208486360D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2271B534A596F5FA04DD82084863E1A4" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_F7E248B82818A3D1AB8B820848632B75" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2271B534A596F5FA04DD82084863E1A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9976613264572AD39423A02AFCF9A17F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9976613264572AD39423A02AFCF9A17F" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_FCB20D71E5745CEA4299A02AFCFEEB66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_FCB20D71E5745CEA4299A02AFCFEEB66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_91AE4C878C0A5C7B01D1A02AFCFE28F9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_91AE4C878C0A5C7B01D1A02AFCFE28F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_D5389B80809542BB9A61A02AFCFF1CAD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_D5389B80809542BB9A61A02AFCFF1CAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_87DA1618D27CB76D5627A02AFCFFA2C2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_87DA1618D27CB76D5627A02AFCFFA2C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3B0FF5CEF9634629E564A02AFCFF3C13" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_3B0FF5CEF9634629E564A02AFCFF3C13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_87857308BF3FE208639FA02AFCFF0DE2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_87857308BF3FE208639FA02AFCFF0DE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_17ED71DBD74F9D0E5A67A02AFCFFB3F3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract_5CB4B8E83BACF8FB72F5A02AFCFCE55C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_17ED71DBD74F9D0E5A67A02AFCFFB3F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_51D0634A633639445357A5E9ED6A3501" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51D0634A633639445357A5E9ED6A3501" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EAD93626CE8994FEA6ABA5EB96032D95" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_B396646A14672C3F80FFA5EC432C6327" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FDAB97555FA52A5034BDA5EB96FA9E14" xlink:to="loc_us-gaap_CostOfSalesMember_B396646A14672C3F80FFA5EC432C6327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_78193B71E6839082D3AAA5E9ED6BC460" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_srt_RangeAxis_78193B71E6839082D3AAA5E9ED6BC460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1029F2AAA886FDCD75A4A5E9ED6B059B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_78193B71E6839082D3AAA5E9ED6BC460" xlink:to="loc_srt_RangeMember_1029F2AAA886FDCD75A4A5E9ED6B059B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6ABC3ED31A27D36FA425A5E9ED6CE6E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1029F2AAA886FDCD75A4A5E9ED6B059B" xlink:to="loc_srt_MinimumMember_6ABC3ED31A27D36FA425A5E9ED6CE6E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_95EAD580CBCEE3803A27A5E9ED6CA8FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1029F2AAA886FDCD75A4A5E9ED6B059B" xlink:to="loc_srt_MaximumMember_95EAD580CBCEE3803A27A5E9ED6CA8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8BB6801CE2F0C92848CBA5E9ED6CB07C" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_AC044161D81DDD9F8B19A5E9ED6D9282" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1327744FFBC68208476FA5E9ED6C857C" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_AC044161D81DDD9F8B19A5E9ED6D9282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_A00440FDCB1C53A997A2A5E9ED6DAD93" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_srt_ProductOrServiceAxis_A00440FDCB1C53A997A2A5E9ED6DAD93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_646A73DA94B8D56CA9B9A5E9ED6DE156" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_A00440FDCB1C53A997A2A5E9ED6DAD93" xlink:to="loc_srt_ProductsAndServicesDomain_646A73DA94B8D56CA9B9A5E9ED6DE156" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_5E9589DE86C3A790E408A5E9ED6DC6B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_646A73DA94B8D56CA9B9A5E9ED6DE156" xlink:to="loc_biib_ZINBRYTAMember_5E9589DE86C3A790E408A5E9ED6DC6B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignearningstypeAxis" xlink:label="loc_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignearningstypeDomain" xlink:label="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeAxis_A7E3F323BF711A3B5E2EA5E9ED6E2C2F" xlink:to="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ForeignearningsintheformofcashandcashequivalentsMember" xlink:label="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:to="loc_biib_ForeignearningsintheformofcashandcashequivalentsMember_DA2C7521C2C6F7B9303AA5E9ED6EC7A4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherForeignEarningsMember" xlink:label="loc_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ForeignearningstypeDomain_EE65F53310F56D28E94BA5E9ED6E5601" xlink:to="loc_biib_OtherForeignEarningsMember_1D31DCA03DEC1E92C416A5E9ED6E7A57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_AE95EDCEBC95C37034B3A5E9ED6F5913" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:to="loc_biib_DeferredtaxliabilityMember_66BEFDD1F784548D3F71A5E9ED6F69BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_59369703ACF7FA085363A5E9ED6F8BC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:to="loc_us-gaap_RetainedEarningsMember_59369703ACF7FA085363A5E9ED6F8BC6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PrepaidtaxesMember" xlink:label="loc_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:to="loc_biib_PrepaidtaxesMember_C20C39D4D1880C22CA57A5E9ED701137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetDomain" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_F4B86EE321726009CD84A5E9ED70357F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13490FB9469F8322DCE2A5E9ED6FB5DC" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_F4B86EE321726009CD84A5E9ED70357F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_D58421CF325A032CECEDA5E9ED70194C" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralBusinessMember" xlink:label="loc_us-gaap_GeneralBusinessMember_6E6D5A5C6308DC8C63DCA5E9ED706DD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:to="loc_us-gaap_GeneralBusinessMember_6E6D5A5C6308DC8C63DCA5E9ED706DD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1ED550CA893A23DD2FB1A5E9ED71920B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_0D8E721C2AA1C2746680A5E9ED709AE1" xlink:to="loc_us-gaap_ResearchMember_1ED550CA893A23DD2FB1A5E9ED71920B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_9F286451AB9300D71638A5E9ED7173EB" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:to="loc_biib_U.S.2017TaxActMember_76ACEF47D965530BADC4A5E9ED718C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_F5AB39C1BBEBBC01B6C3A5E9ED7231DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:to="loc_us-gaap_DomesticCountryMember_F5AB39C1BBEBBC01B6C3A5E9ED7231DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_BF0043ED531334DD66AFA5E9ED722D37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_BF0043ED531334DD66AFA5E9ED722D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_B3057C5874A89D519EC3A5E9ED72938F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_41CA3BD6950D26B97E5FA5E9ED71D085" xlink:to="loc_us-gaap_ForeignCountryMember_B3057C5874A89D519EC3A5E9ED72938F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_884E95629A0D9859D27DA5E9ED6BF1CC" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0C8B67501DD59E3F9E78A5EC42325DB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_0C8B67501DD59E3F9E78A5EC42325DB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1BC1674FCC4DB1B0EE78A5E9ED726544" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1BC1674FCC4DB1B0EE78A5E9ED726544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1DA8C6107FB2F21D7E64A5E9ED7336BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1DA8C6107FB2F21D7E64A5E9ED7336BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_98F6B12234B2BE8931C2A5E9ED7343AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_98F6B12234B2BE8931C2A5E9ED7343AE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PaymentforTransitionTollTax" xlink:label="loc_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_PaymentforTransitionTollTax_628871E874F0E96FBBEEA5E9ED733833" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment" xlink:label="loc_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment_16D9374E3ED7B0DCFD5BA5E9ED73A52A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TransitionTollTaxRepatriationTaxRate" xlink:label="loc_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_TransitionTollTaxRepatriationTaxRate_9C558817EE4BAEC64E4DA5E9ED736829" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_2AC7FC7C5CA6D5ED3C19A5E9ED735FAC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability_2AC7FC7C5CA6D5ED3C19A5E9ED735FAC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Reductionindeferredtaxliabilityundistributedforeignearnings" xlink:label="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_Reductionindeferredtaxliabilityundistributedforeignearnings_51149B71F54EEDF2AF98A5E9ED74208D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries" xlink:label="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries_C5571D5BD8F190613FC0A5E9ED74AA4D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting" xlink:label="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting_0FA21358DA21781A7C29A5E9ED74CE9E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_74D7697A6819D730C0DEA5E9ED752667" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherTaxExpenseBenefit" xlink:label="loc_us-gaap_OtherTaxExpenseBenefit_C94EC303447C1C97196CA5E9ED75117A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_OtherTaxExpenseBenefit_C94EC303447C1C97196CA5E9ED75117A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_1A40B0B65C2F84D1C163A5E9ED75821D" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses_1A40B0B65C2F84D1C163A5E9ED75821D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_D24E7780F68D06C9E5DCA5E9ED75180F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_D24E7780F68D06C9E5DCA5E9ED75180F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_0944C0A48C7D1BF62509A5E9ED76E0E1" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_OperatingLossCarryforwards_0944C0A48C7D1BF62509A5E9ED76E0E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_69FDFAAEA318B035D31EA5E9ED760F61" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_69FDFAAEA318B035D31EA5E9ED760F61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_5A5E824947021121F4FCA5E9ED76A73D" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_5A5E824947021121F4FCA5E9ED76A73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_541481240E81EA7DDA23A5E9ED76371B" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_541481240E81EA7DDA23A5E9ED76371B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_48C15DEA76E95994E3C4A5E9ED771DEE" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_B7351599FCE78BE0D8BCA5E9ED721F47" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_48C15DEA76E95994E3C4A5E9ED771DEE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IncomeTaxesTextualAbstract" xlink:label="loc_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_51D0634A633639445357A5E9ED6A3501" xlink:to="loc_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Totaldeferredchargesandprepaidtaxes" xlink:label="loc_biib_Totaldeferredchargesandprepaidtaxes_68A4EDB10B972242201AA5E9ED7793B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:to="loc_biib_Totaldeferredchargesandprepaidtaxes_68A4EDB10B972242201AA5E9ED7793B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_914F6D6A24921B058696A5E9ED770838" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_914F6D6A24921B058696A5E9ED770838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_941A3E6FC67EC46C1C95A5E9ED779411" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_941A3E6FC67EC46C1C95A5E9ED779411" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_4CAF235BDD283F4800A7A5E9ED784F27" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IncomeTaxesTextualAbstract_5BC3E2FF1A764179AE51A5E9ED77EB27" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_4CAF235BDD283F4800A7A5E9ED784F27" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5CCB9516D716AC3C635AFBB83376C17A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_A6871BB6A7C079853738FBB83376191A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5CCB9516D716AC3C635AFBB83376C17A" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_A6871BB6A7C079853738FBB83376191A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_FBFA6260691A44F83EF9FBB83376CB90" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5CCB9516D716AC3C635AFBB83376C17A" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_FBFA6260691A44F83EF9FBB83376CB90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_68CB154E052BE00D20B6FBB833765166" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5CCB9516D716AC3C635AFBB83376C17A" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_68CB154E052BE00D20B6FBB833765166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_856BFF02991A2893008AFBB833760C93" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5CCB9516D716AC3C635AFBB83376C17A" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_856BFF02991A2893008AFBB833760C93" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_FB96BCB38C758EE09DDBFBB834801E24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_F1CAA6AFC8FC324CF62DFBB83480AD80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_FB96BCB38C758EE09DDBFBB834801E24" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_F1CAA6AFC8FC324CF62DFBB83480AD80" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_64776F61EDCEF0FFFB92856979425303" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_64776F61EDCEF0FFFB92856979425303" xlink:to="loc_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:to="loc_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_140AEFB186676210920285697942EDFB" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_B42F1C71C08E92DBD90585697942B0AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_B42F1C71C08E92DBD90585697942B0AE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_68DCA65C7B695521F85685697942D5EC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_B6D715145C183A68950C856979423D3D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_0EA83E3E0BCF64D019AE856979427504" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_0AF11C119F0CA4B8532D8569794200F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52D9A7E690B07C55A948569794276D4" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_776EE19BDD0105D5835F85697942A22E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_F1F9836FD620D05CA36285697942789C" xlink:to="loc_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtCurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:to="loc_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_943FA5E005CD69D3B29985697942D269" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:to="loc_us-gaap_NotesPayableCurrent_943FA5E005CD69D3B29985697942D269" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_EBA91F6A9FFAA98A2EAB85697942E1DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtCurrentAbstract_2B823A85B0C722BEA5C9856979425FB6" xlink:to="loc_us-gaap_DebtCurrent_EBA91F6A9FFAA98A2EAB85697942E1DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_EE92FA11E274FBC06A9185697942B87A" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_3CA224CA3F7DBDC115D585697942F47C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:to="loc_us-gaap_LongTermNotesPayable_3CA224CA3F7DBDC115D585697942F47C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_94F25220E633721F217385697942EFBA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_F3AA2A9C6E1D74002B9F856979425E95" xlink:to="loc_us-gaap_LongTermDebt_94F25220E633721F217385697942EFBA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1938721814335C50DEBC168A367DEE49" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1938721814335C50DEBC168A367DEE49" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B2EE7142C7824563345D168A367D23E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_B2EE7142C7824563345D168A367D23E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_DA258196DB14F3E9A355168A367D1580" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_DA258196DB14F3E9A355168A367D1580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9FF7B0AEA1C7883D960E168A367DA55E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9FF7B0AEA1C7883D960E168A367DA55E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_D596317582270020C507168A367D300E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_D596317582270020C507168A367D300E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8905EA63270AD77A9C5A168A367D43C5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8905EA63270AD77A9C5A168A367D43C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_20FB192446B0BCEB462B168A367D9078" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_20FB192446B0BCEB462B168A367D9078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_CDEC64D8FB465791BDDF168A367DBC8A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_27BC1E06E995042DCF31168A367D89D1" xlink:to="loc_us-gaap_LongTermNotesPayable_CDEC64D8FB465791BDDF168A367DBC8A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_E0DA40C8037A9CF47FD285B86D46A334" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_5F29F981EA13A14C5A6285B86D46E207" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_E0DA40C8037A9CF47FD285B86D46A334" xlink:to="loc_us-gaap_DebtInstrumentTable_5F29F981EA13A14C5A6285B86D46E207" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5F29F981EA13A14C5A6285B86D46E207" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_E72C1FDDE444D219B8BD85B86D4654B1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_35AECC386FDFB5E5737B85B86D46884E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F3352C2F11E703DA3FE185B86D460C85" xlink:to="loc_us-gaap_InterestRateSwapMember_35AECC386FDFB5E5737B85B86D46884E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_7A2BE33921CE70B079A085B86D460459" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5F29F981EA13A14C5A6285B86D46E207" xlink:to="loc_us-gaap_DebtInstrumentAxis_7A2BE33921CE70B079A085B86D460459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7A2BE33921CE70B079A085B86D460459" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NotesPayableToFumedicaMember" xlink:label="loc_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_NotesPayableToFumedicaMember_2A125B94DDC264732F8D85B86D46CA35" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember" xlink:label="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CA5BBA89C4A4EC101F2985B86D46B6B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember_CA5BBA89C4A4EC101F2985B86D46B6B9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember" xlink:label="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5F5F791876AB1B69631585B86D4DA684" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember_5F5F791876AB1B69631585B86D4DA684" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B2BBF2FDCDCA892764F385B86D4D7C76" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_B2BBF2FDCDCA892764F385B86D4D7C76" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_10637F2EECAF8BE1594585B86D4D3D72" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_10637F2EECAF8BE1594585B86D4D3D72" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D93F0116252CD3806F0885B86D4D2203" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_4A2AF5C1FE6DC2CBA45385B86D467F84" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_D93F0116252CD3806F0885B86D4D2203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5F29F981EA13A14C5A6285B86D46E207" xlink:to="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_0FEEA980F29445F348A685B86D4D055E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_NotesPayable_0FEEA980F29445F348A685B86D4D055E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_902374E5DCACD17CA4B985B86D4DEAB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_902374E5DCACD17CA4B985B86D4DEAB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DA424DE556FE49A929B185B86D4D92F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_DA424DE556FE49A929B185B86D4D92F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageParValueOfSeniorNotes" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_D13E2C5E2B50E3C5A1A585B86D4D2388" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IncreasedCarryingAmountOfSeniorNotes" xlink:label="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_biib_IncreasedCarryingAmountOfSeniorNotes_A61940934B4A4E9DC45A85B86D4D9A02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ExtinguishmentOfDebtGainLossNetOfTax" xlink:label="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2D5D135DCD8E3A693D6B85B86D508481" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax_2D5D135DCD8E3A693D6B85B86D508481" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C075C95500C6E496EF5585B86D50B58E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_C075C95500C6E496EF5585B86D50B58E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_5B9A3CD1348B6BF8EEFB85B86D50F8A5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_5B9A3CD1348B6BF8EEFB85B86D50F8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_18F26C97A45DE472819885B86D50899C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_18F26C97A45DE472819885B86D50899C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_3596B0D64CB4D60BAC4B85B86D50AC3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_675D8C5DB423E14604BF85B86D504629" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_675D8C5DB423E14604BF85B86D504629" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B0048F1EF167CAD12E6785B86D50789A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_B0048F1EF167CAD12E6785B86D50789A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_BB03A942DAEE494C5A0C85B86D50248B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_BB03A942DAEE494C5A0C85B86D50248B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D9F30FE03FB976950D285B86D501C86" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_AE1E1920D1F90B0FE85585B86D4D2758" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_7D9F30FE03FB976950D285B86D501C86" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_B7467B0E656C87A05E41FBB8348FB4AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_61020866A9DB7108D674FBB8348FA0B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_B7467B0E656C87A05E41FBB8348FB4AC" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_61020866A9DB7108D674FBB8348FA0B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0E1D97D9ACD60406E054FBB8348F0407" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_B7467B0E656C87A05E41FBB8348FB4AC" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0E1D97D9ACD60406E054FBB8348F0407" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7EB5D9FFFC58C78BD438FBB831F14AA6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FB517FD3BD36B029E337FBB831F17791" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7EB5D9FFFC58C78BD438FBB831F14AA6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_FB517FD3BD36B029E337FBB831F17791" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_214F39BF77EFF63BE54DC42829492134" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_214F39BF77EFF63BE54DC42829492134" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_7057355FE0C76D868C3DC4282949C675" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PLSRMember" xlink:label="loc_biib_PLSRMember_F1BA6618196880431940C428294A3DF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:to="loc_biib_PLSRMember_F1BA6618196880431940C428294A3DF0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_2AB1441CC378E02365D8C428294A032C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_5C5BE29B1019917DD9D9C4282949E1D8" xlink:to="loc_biib_TGNMember_2AB1441CC378E02365D8C428294A032C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="loc_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7EE4467847140511EECCC428294AF1BF" xlink:to="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AVONEXMember" xlink:label="loc_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_AVONEXMember_E058FBFC8A0D944FA92CC428294AB585" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_TysabriProductMember_8BC8D506A57CFE926570C428294B865C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_SPINRAZAMember_0B8092AE4CF9BE6AD4E5C428295013D6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_BiosimilarsMember_B19975385982A2D6CE5AC42829505B9C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_ZINBRYTAMember_06904A855524095B8A45C42829505C8E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3CDE7CEAFBD3C54569C1C428294ABD6B" xlink:to="loc_biib_TecfideraMember_C47CE1046D5D44B54D1AC4282951EB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F4EB807CAFA9AD5F6CCCC4282951E1B4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5000FDEE55E475CDB45BC42829515AD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5000FDEE55E475CDB45BC42829515AD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_A37B8EA59FFE0DA246E4C42829526DC1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_85F5CF0092EC6E7D5D31C428295109ED" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_A37B8EA59FFE0DA246E4C42829526DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_EDB0F217133DDF1F5604C428295292FC" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OutLicensedPatentsMember" xlink:label="loc_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:to="loc_biib_OutLicensedPatentsMember_5E2939A7CAEDC78C1D3AC42829523D4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_AFAB92EB8B8A8AB26196C4282953C94D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_AFAB92EB8B8A8AB26196C4282953C94D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InLicensedPatentsMember" xlink:label="loc_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B25C7B742FD067A432FFC4282952D7AA" xlink:to="loc_biib_InLicensedPatentsMember_E35D20B21658AF789C83C4282953666B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="loc_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_157DE9DB4ABC21F90E18C428295371C8" xlink:to="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A26F93A18348ED50D028C4282953E6BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:to="loc_srt_MinimumMember_A26F93A18348ED50D028C4282953E6BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7A218E0B75A430870398C42829546729" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2F24DFA664C1CD7CB489C42829536248" xlink:to="loc_srt_MaximumMember_7A218E0B75A430870398C42829546729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_BCF10F435600BC705DB1C4282949F574" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AmortizationandImpairmentofAcquiredIntangibleAssets" xlink:label="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_biib_AmortizationandImpairmentofAcquiredIntangibleAssets_1B3E3F163A6855FECC97C42829540A82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_33AD47A1877FDD0713AEC42829554210" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_33AD47A1877FDD0713AEC42829554210" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4C257080864FE6A70786C4282955B5E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4C257080864FE6A70786C4282955B5E9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IndefiniteLivedIntangibleAssetsUsefulLife" xlink:label="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_biib_IndefiniteLivedIntangibleAssetsUsefulLife_DA43730DCB73D0579F30C428295564EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5457FC74625F785D9E06C4282955F0EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5457FC74625F785D9E06C4282955F0EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_F3204E809371F4E071F9C428295607E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_F3204E809371F4E071F9C428295607E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0282E2A0A3206D589B69C4282956EAA4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_0282E2A0A3206D589B69C4282956EAA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42D1A4C1A0451D78D0C0C428295683E3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_42D1A4C1A0451D78D0C0C428295683E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_84EAB06D01FDB735ABD7C42829560E5F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_84EAB06D01FDB735ABD7C42829560E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6A2B2E2870ED431A2754C428295B682B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_F3C9A41B177A9243C18EC42829551C8A" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6A2B2E2870ED431A2754C428295B682B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract" xlink:label="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_51B33855F1BF0B24C670C428295C6BD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_51B33855F1BF0B24C670C428295C6BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ED69C17952519B33DF48C428295C8484" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ED69C17952519B33DF48C428295C8484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_005E7F53763AF9A907F1C428295C2EE0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_005E7F53763AF9A907F1C428295C2EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F917D22EE162C080F141C428295C3FED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_F917D22EE162C080F141C428295C3FED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_664DCEEE816E8E71333AC428295D9025" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract_DF8FEF3F8638C9B68E74C428295C71A4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_664DCEEE816E8E71333AC428295D9025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_D5B2E5FC001690378CAFC428295DB807" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_D5B2E5FC001690378CAFC428295DB807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_AAF356E46A3B694C4A0BC428295D487D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_AAF356E46A3B694C4A0BC428295D487D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5D02D55C823195A076AC428295D5F19" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_A5D02D55C823195A076AC428295D5F19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_31262007568BB8B409D9C428295D45F0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_31262007568BB8B409D9C428295D45F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7E476FFF9C91BF99F84FC428295E6A0D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_7E476FFF9C91BF99F84FC428295E6A0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_889C72AA98D0C6E20C5EC428295E4CE7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_43F0DF9833F3CB4678B6C428295450F8" xlink:to="loc_us-gaap_LitigationSettlementExpense_889C72AA98D0C6E20C5EC428295E4CE7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4A503D85DF5DF83365B282084AD31E33" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4A503D85DF5DF83365B282084AD31E33" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_15C5D126F9812ACBC315820F2F13FC56" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:to="loc_biib_CumulativeSalesLevelAxis_15C5D126F9812ACBC315820F2F13FC56" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_12EB130697A62FA0DE51820F2F1720C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_15C5D126F9812ACBC315820F2F13FC56" xlink:to="loc_biib_CumulativeSalesLevelDomain_12EB130697A62FA0DE51820F2F1720C5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_0CB75C04C723CD8AA233820F2F48BD08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_12EB130697A62FA0DE51820F2F1720C5" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_0CB75C04C723CD8AA233820F2F48BD08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57028C9F89D916D95BFD82084AD3E595" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57028C9F89D916D95BFD82084AD3E595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_356B3A56DE029C892DC582084AD34FBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57028C9F89D916D95BFD82084AD3E595" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_356B3A56DE029C892DC582084AD34FBF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_3E60532D44170886D27F82084AD39F34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_356B3A56DE029C892DC582084AD34FBF" xlink:to="loc_biib_BioverativMember_3E60532D44170886D27F82084AD39F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_FDA20F8CDBCB6A77DAB482084AD3F4A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_FDA20F8CDBCB6A77DAB482084AD3F4A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_647D10AB0525FD896C8782084AD34767" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_FDA20F8CDBCB6A77DAB482084AD3F4A5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_647D10AB0525FD896C8782084AD34767" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_B268AD0CA2EF7460201782084AD38C10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_647D10AB0525FD896C8782084AD34767" xlink:to="loc_biib_FumapharmAgMember_B268AD0CA2EF7460201782084AD38C10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_BA5B3FE03FCB5B027ED882084AD3C33A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:to="loc_srt_ProductOrServiceAxis_BA5B3FE03FCB5B027ED882084AD3C33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_86424F5935C8A9B3CD2982084AD34D16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_BA5B3FE03FCB5B027ED882084AD3C33A" xlink:to="loc_srt_ProductsAndServicesDomain_86424F5935C8A9B3CD2982084AD34D16" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_EAA8C8DF9B4F73538F1282084AD38FE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_86424F5935C8A9B3CD2982084AD34D16" xlink:to="loc_biib_TecfideraMember_EAA8C8DF9B4F73538F1282084AD38FE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6986E4EA24B41B8BA47982084AD38BD0" xlink:to="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_089752B4BDD61E9E304B82084AE30772" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_089752B4BDD61E9E304B82084AE30772" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_524EB03233C26F3028B4820F2ECA32ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:to="loc_biib_CumulativeSalesLevel_524EB03233C26F3028B4820F2ECA32ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_16B0D4BA70EE71F8B4A982084AE38620" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_DA6C6771DB5FE6110B0E82084AE35B56" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_16B0D4BA70EE71F8B4A982084AE38620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4A503D85DF5DF83365B282084AD31E33" xlink:to="loc_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_81E7C4F284431DE7BC9082084AE35740" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:to="loc_us-gaap_Goodwill_81E7C4F284431DE7BC9082084AE35740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_06C61055D962E96B9A2682084AE38493" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_06C61055D962E96B9A2682084AE38493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_A4DAF4BA14BA118D440782084AE3EFE0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_A4DAF4BA14BA118D440782084AE3EFE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_DF451E7967D5C513F17D82084AE3B017" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_DF451E7967D5C513F17D82084AE3B017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CBBDBC088D20E0A9292E82084AE3C68B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6C6587FDEE65E0DA20A782084AE3E368" xlink:to="loc_us-gaap_Goodwill_CBBDBC088D20E0A9292E82084AE3C68B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A385CC89B4ECBFE1F77EFBB833E4B866" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_70E3CF6AC33E317CE954FBB833E4929B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A385CC89B4ECBFE1F77EFBB833E4B866" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_70E3CF6AC33E317CE954FBB833E4929B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5EBBAB4CDF3BE2ABEB31FBB833E44DB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A385CC89B4ECBFE1F77EFBB833E4B866" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5EBBAB4CDF3BE2ABEB31FBB833E44DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_EBD2D7548D3AD85135D9FBB833E47507" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_A385CC89B4ECBFE1F77EFBB833E4B866" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_EBD2D7548D3AD85135D9FBB833E47507" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_EEF4321928087A3484C7FBB83328F4C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_AB59444DC1FEE1F38BD7FBB833281934" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_EEF4321928087A3484C7FBB83328F4C7" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_AB59444DC1FEE1F38BD7FBB833281934" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_A7D65BA7549D422879F6FBB8353B3D20" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_A7D65BA7549D422879F6FBB8353B3D20" xlink:to="loc_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_F9EE55C245681D5AD973FBB8353B1673" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_F9EE55C245681D5AD973FBB8353B1673" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_24EC3ED2D9AC5D33001EFBB8353BD58B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_24EC3ED2D9AC5D33001EFBB8353BD58B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_A24F09C62BB90D499379FBB8353BC52C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_A24F09C62BB90D499379FBB8353BC52C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Inventorynetcurrentandnoncurrent" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_AA0B69497A4CC5108D88FBB8353B7ABB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_6C4F72DE81C56382E1D9FBB8353BD20E" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_AA0B69497A4CC5108D88FBB8353B7ABB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_984EFAC5CDED4B26D691FBB8353BE5B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_A7D65BA7549D422879F6FBB8353B3D20" xlink:to="loc_us-gaap_InventoryNet_984EFAC5CDED4B26D691FBB8353BE5B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_2CEB4BDCF997823BD45FFBB8353B4AFE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_A7D65BA7549D422879F6FBB8353B3D20" xlink:to="loc_us-gaap_InventoryNoncurrent_2CEB4BDCF997823BD45FFBB8353B4AFE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_512929E83F9E1EE5AF6BBEA9353C0645" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_B18E7EA6C5EDCD00A7B1BEA9353CECA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_512929E83F9E1EE5AF6BBEA9353C0645" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_B18E7EA6C5EDCD00A7B1BEA9353CECA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D6571D529B42675C6EBEA9354CEECB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_B18E7EA6C5EDCD00A7B1BEA9353CECA9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D6571D529B42675C6EBEA9354CEECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_85BFEF0583F7664B5B56BEA9354C619A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_C1D6571D529B42675C6EBEA9354CEECB" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_85BFEF0583F7664B5B56BEA9354C619A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BioverativMember" xlink:label="loc_biib_BioverativMember_28E333EB1E08B86789A2BEA9354C7104" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_85BFEF0583F7664B5B56BEA9354C619A" xlink:to="loc_biib_BioverativMember_28E333EB1E08B86789A2BEA9354C7104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_B18E7EA6C5EDCD00A7B1BEA9353CECA9" xlink:to="loc_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_78C3D8F24EEDF8395BB5BEA9354C960D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_C7EE21E435DE8FA478BFBEA9354C5CB7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_78C3D8F24EEDF8395BB5BEA9354C960D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_1750797397F7B51F5029BEA9354C68E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_512929E83F9E1EE5AF6BBEA9353C0645" xlink:to="loc_us-gaap_InventoryWriteDown_1750797397F7B51F5029BEA9354C68E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3B23B8F19C6B6A3EA026FBB83451F1E2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_79ABC40524E2F132C495FBB834512AD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3B23B8F19C6B6A3EA026FBB83451F1E2" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_79ABC40524E2F132C495FBB834512AD4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_9C1E73ECB406398DEC3EFBB831645918" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_BA9B5DDB42A09BDFB4CFFBB8316400D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_9C1E73ECB406398DEC3EFBB831645918" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_BA9B5DDB42A09BDFB4CFFBB8316400D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_21B219EA4A2E04ED02D2F52288E86303" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_21B219EA4A2E04ED02D2F52288E86303" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_26692509B67F422FFE21F52288EC0459" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_4B88B0092CE796A91E64F52288EC0788" xlink:to="loc_biib_NeurimmuneMember_CF933539FC18685E1936F52288ECBF0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_3B91322A110BE91B58E4F52288EAE8BA" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_95CF5A75DF02A670D877F52288ED9F91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_95CF5A75DF02A670D877F52288ED9F91" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_320653B125567A3FAFE5F526253067FD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_20D38B3920FC3744D719F52288EDA578" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentInVariableInterestEntitiesTextualAbstract" xlink:label="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_3E05F14A1D770EA292ADF52288ED9FAF" xlink:to="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentInVariableInterestEntitiesTextualAbstract_8FAFB06B49569806822AF52288EE33F7" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_ECBECD32CC95D2572ECEF52288EEE0E0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_832BB03CA61115FBFDB0FBB83470FFAD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_9515A13F5839E022A9D1FBB834703B1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_832BB03CA61115FBFDB0FBB83470FFAD" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_9515A13F5839E022A9D1FBB834703B1F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationLitigationDetails" xlink:type="extended">
    <link:loc xlink:href="biib-20181231.xsd#biib_TaxcontingencyAbstract" xlink:label="loc_biib_TaxcontingencyAbstract_7811BDA85F1253236C36F52AEBCFCA2D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxcontingencyAbstract_7811BDA85F1253236C36F52AEBCFCA2D" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_6F1DF4BC4A1F3F3FDB54F52AEF92B0BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_6F1DF4BC4A1F3F3FDB54F52AEF92B0BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_91EC81D0247F8A02CC21F52AF05E292A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_6F1DF4BC4A1F3F3FDB54F52AEF92B0BD" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_91EC81D0247F8A02CC21F52AF05E292A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_BR" xlink:label="loc_country_BR_EDAB71E9C1424994810BF52AEF9D9494" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_91EC81D0247F8A02CC21F52AF05E292A" xlink:to="loc_country_BR_EDAB71E9C1424994810BF52AEF9D9494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_2450E66B0E3314BEEABFF52AEF7F7997" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LossContingencyDamagesSought" xlink:label="loc_us-gaap_LossContingencyDamagesSought_F27C2440F6E24D896CD1F52AEF88C8F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_940F0D535B1AEBFEB53BF52AEF804741" xlink:to="loc_us-gaap_LossContingencyDamagesSought_F27C2440F6E24D896CD1F52AEF88C8F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5EE831503939F25BB0F7FBB833F3717C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D6944E63D212E37E45CEFBB833F378BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5EE831503939F25BB0F7FBB833F3717C" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_D6944E63D212E37E45CEFBB833F378BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE1655594ADEE24552FFBEA726FE34F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_16248DF9FF59B028D2E1BEA7270ED054" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE1655594ADEE24552FFBEA726FE34F2" xlink:to="loc_us-gaap_StatementTable_16248DF9FF59B028D2E1BEA7270ED054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8C5C2257366AB9838564BEA7270E8804" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_16248DF9FF59B028D2E1BEA7270ED054" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8C5C2257366AB9838564BEA7270E8804" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6AA6C42071A34D3B8FFABEA7270EE75B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8C5C2257366AB9838564BEA7270E8804" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6AA6C42071A34D3B8FFABEA7270EE75B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_EF5C97824277A8A90658BEA7270EC73D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6AA6C42071A34D3B8FFABEA7270EE75B" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_EF5C97824277A8A90658BEA7270EC73D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8783859ED008347E1CD0BEA7270EE947" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_16248DF9FF59B028D2E1BEA7270ED054" xlink:to="loc_us-gaap_StatementLineItems_8783859ED008347E1CD0BEA7270EE947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B205C1FAAA430D178E0BEA7270E4F4A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE1655594ADEE24552FFBEA726FE34F2" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B205C1FAAA430D178E0BEA7270E4F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_A33B34CC6499C1D0684EBEA7270E7579" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B205C1FAAA430D178E0BEA7270E4F4A" xlink:to="loc_us-gaap_InterestPaidNet_A33B34CC6499C1D0684EBEA7270E7579" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_EE68EB081CBEFA51CCD5BEA7270E2E7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7B205C1FAAA430D178E0BEA7270E4F4A" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_EE68EB081CBEFA51CCD5BEA7270E2E7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:type="locator" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE1655594ADEE24552FFBEA726FE34F2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_62C6DD455D6E65F159EDBEA7270E800D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:to="loc_us-gaap_InvestmentIncomeInterest_62C6DD455D6E65F159EDBEA7270E800D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_AF69488EBB3AA4BF8115BEA7270E6750" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:to="loc_us-gaap_InterestExpense_AF69488EBB3AA4BF8115BEA7270E6750" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_FE01D91A192527A38881BEA7270E96F6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_FE01D91A192527A38881BEA7270E96F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0D477195806A0F45CC8EBEA7270E9285" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0D477195806A0F45CC8EBEA7270E9285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_07B1CBF1595785CB8C40BEA7270E9F9B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_07B1CBF1595785CB8C40BEA7270E9F9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9321E29BBE39DBEE75AEBEA7270EB869" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_230CF2064D838A18A267BEA7270E9A0C" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9321E29BBE39DBEE75AEBEA7270EB869" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:type="locator" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_AE1655594ADEE24552FFBEA726FE34F2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9FF0CD614471786250DDBEA7270E2305" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9FF0CD614471786250DDBEA7270E2305" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8F20E5A9A72E444E8070BEA7270E9EF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8F20E5A9A72E444E8070BEA7270E9EF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0BA312FBACF898E83FF2BEA7270EF1E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0BA312FBACF898E83FF2BEA7270EF1E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_B9709B3B2C1871B826C6BEA7270EAA7A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_B9709B3B2C1871B826C6BEA7270EAA7A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Collaborationexpensesaccrual" xlink:label="loc_biib_Collaborationexpensesaccrual_1FEBABF51C173E69814ABEA7270E3DDC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:to="loc_biib_Collaborationexpensesaccrual_1FEBABF51C173E69814ABEA7270E3DDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_00CE69D947BEFF4B14BABEA7270E88DD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_00CE69D947BEFF4B14BABEA7270E88DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B3D424D920278421360FBEA7270E2E71" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_B3D424D920278421360FBEA7270E2E71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_C8CFB2166EA58F2B9663BEA7270EC5C2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_A27A771AF118F2151EC4BEA7270E659F" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_C8CFB2166EA58F2B9663BEA7270EC5C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35F67278C63459560DD4BE956ABEF99A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35F67278C63459560DD4BE956ABEF99A" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_A12F7C1AC6B55DDF99F5BE956ABE759A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_A12F7C1AC6B55DDF99F5BE956ABE759A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_67466BE938C4B42B4FF0BE956ABE6DED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_A12F7C1AC6B55DDF99F5BE956ABE759A" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_67466BE938C4B42B4FF0BE956ABE6DED" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_61FC629DF60D4BFE9A93BE956ABE9E41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_67466BE938C4B42B4FF0BE956ABE6DED" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_61FC629DF60D4BFE9A93BE956ABE9E41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_F758C0881EAAD72E64CCBE956ABE3DC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_us-gaap_TypeOfArrangementAxis_F758C0881EAAD72E64CCBE956ABE3DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7613C61007DE4A3C8817BE956ABE3097" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_F758C0881EAAD72E64CCBE956ABE3DC0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7613C61007DE4A3C8817BE956ABE3097" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_C800C20E11BFEB8933A2BE956ABE3B7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7613C61007DE4A3C8817BE956ABE3097" xlink:to="loc_biib_IonisPharmaceuticalsMember_C800C20E11BFEB8933A2BE956ABE3B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_B6D753AF0C02BD14304CBE956ABECB4A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_srt_ProductOrServiceAxis_B6D753AF0C02BD14304CBE956ABECB4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_12505ECD71CACCA76828BE956ABEBA66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_B6D753AF0C02BD14304CBE956ABECB4A" xlink:to="loc_srt_ProductsAndServicesDomain_12505ECD71CACCA76828BE956ABEBA66" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_502170C6155C29ECB3FBBE956ABEAAEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_12505ECD71CACCA76828BE956ABEBA66" xlink:to="loc_biib_TecfideraMember_502170C6155C29ECB3FBBE956ABEAAEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1707A51F58E2DB5AC64CBE956ABE408E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1707A51F58E2DB5AC64CBE956ABE408E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10AC04CA510E8E68082BBE956ABEC73D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1707A51F58E2DB5AC64CBE956ABE408E" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10AC04CA510E8E68082BBE956ABEC73D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FumapharmAgMember" xlink:label="loc_biib_FumapharmAgMember_E103B6F3616077073082BE956ABEDC50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10AC04CA510E8E68082BBE956ABEC73D" xlink:to="loc_biib_FumapharmAgMember_E103B6F3616077073082BE956ABEDC50" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_8210DDD20DCDD8B2FD1ABE956ABE752D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_biib_FacilityLocationAxis_8210DDD20DCDD8B2FD1ABE956ABE752D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_BA588E4147A3CC2566DCBE956ABE1145" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_8210DDD20DCDD8B2FD1ABE956ABE752D" xlink:to="loc_biib_FacilityLocationDomain_BA588E4147A3CC2566DCBE956ABE1145" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_4F1A9239CF7229FB3F01BE956ABE483D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_BA588E4147A3CC2566DCBE956ABE1145" xlink:to="loc_biib_SolothurnMember_4F1A9239CF7229FB3F01BE956ABE483D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelAxis" xlink:label="loc_biib_CumulativeSalesLevelAxis_9F91C3F4162DCB70E2CABE956ABEDF51" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_biib_CumulativeSalesLevelAxis_9F91C3F4162DCB70E2CABE956ABEDF51" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevelDomain" xlink:label="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelAxis_9F91C3F4162DCB70E2CABE956ABEDF51" xlink:to="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TwentybillionMember" xlink:label="loc_biib_TwentybillionMember_47F7652F2240FACB1CB0BE956ABE2FF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:to="loc_biib_TwentybillionMember_47F7652F2240FACB1CB0BE956ABE2FF2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EachAdditionalOneBillionUpToTwentyBillionMember" xlink:label="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9B72BE618FA1F7E766C7BE956ABE861B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:to="loc_biib_EachAdditionalOneBillionUpToTwentyBillionMember_9B72BE618FA1F7E766C7BE956ABE861B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FifteenbillionMemberMember" xlink:label="loc_biib_FifteenbillionMemberMember_3A029353DCEC138000ACBE956ABE83ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:to="loc_biib_FifteenbillionMemberMember_3A029353DCEC138000ACBE956ABE83ED" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SixteenbillionMember" xlink:label="loc_biib_SixteenbillionMember_50A016E8893F16B2629FBE956ABEF832" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CumulativeSalesLevelDomain_C4CB70617F61BE2E3681BE956ABE3537" xlink:to="loc_biib_SixteenbillionMember_50A016E8893F16B2629FBE956ABEF832" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3B2F2A3E8DA93C0BEAD2BE956ABEAC28" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2AA76283B68DFB67FA8BBE956ABE49FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2AA76283B68DFB67FA8BBE956ABE49FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_A8A15C46A020C5B88349BE956ABEC1D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_OtherAssetsCurrent_A8A15C46A020C5B88349BE956ABEC1D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_E75DD31BF53092DEFC18BE956ABEA4EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_E75DD31BF53092DEFC18BE956ABEA4EF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CumulativeSalesLevel" xlink:label="loc_biib_CumulativeSalesLevel_CB0E240192D0ABF10684BE956ABE2395" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_biib_CumulativeSalesLevel_CB0E240192D0ABF10684BE956ABE2395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_EF4FFED25E146D08154DBE956ABEDE68" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_EF4FFED25E146D08154DBE956ABEDE68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_BE89D9EE338A42F9AB5FBE956ABED7DE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_LitigationSettlementExpense_BE89D9EE338A42F9AB5FBE956ABED7DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidTaxes" xlink:label="loc_us-gaap_PrepaidTaxes_A1B2B8834317805E3EDDBE956ACD25DE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_PrepaidTaxes_A1B2B8834317805E3EDDBE956ACD25DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_D885BC94F1C0ED7D116CBE956ACD283D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_D885BC94F1C0ED7D116CBE956ACD283D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_A12B70BEC942EE147E73BE956ACD8772" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_A12B70BEC942EE147E73BE956ACD8772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_D6C632D0F674F77C4F81BE956ACD5287" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_EquityMethodInvestments_D6C632D0F674F77C4F81BE956ACD5287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_35A4925688D7A6F7EFDEBE956ACD9A4E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_82BB5953A08DD822DF40BE956ABE0268" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_35A4925688D7A6F7EFDEBE956ACD9A4E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87F8D06AC54E67A84C25FBB8339675EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E6EE122CC4BF532B65D1FBB83396F47F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87F8D06AC54E67A84C25FBB8339675EA" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_E6EE122CC4BF532B65D1FBB83396F47F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D3A617FF182184FB4D52FBB8339663D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87F8D06AC54E67A84C25FBB8339675EA" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_D3A617FF182184FB4D52FBB8339663D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_30FEA8832806A5CC5A53FBB8339673BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87F8D06AC54E67A84C25FBB8339675EA" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_30FEA8832806A5CC5A53FBB8339673BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4C7E6075057D32384037FBB833E4909D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2228783D0DDBC0F533E6FBB833E41F6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4C7E6075057D32384037FBB833E4909D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2228783D0DDBC0F533E6FBB833E41F6B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_44AD6514B96E6EA6CBA5FBB83183DFB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:to="loc_us-gaap_Land_44AD6514B96E6EA6CBA5FBB83183DFB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_70EE48DB62C31F578954FBB8318345AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_70EE48DB62C31F578954FBB8318345AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_BB35F9E95FCE40D6D138FBB831831802" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_BB35F9E95FCE40D6D138FBB831831802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_4386AD649A7F237ADCA6FBB83183040D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_4386AD649A7F237ADCA6FBB83183040D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ComputerSoftwareAndHardware" xlink:label="loc_biib_ComputerSoftwareAndHardware_5037454B47D1657B88D3FBB83183906E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:to="loc_biib_ComputerSoftwareAndHardware_5037454B47D1657B88D3FBB83183906E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_8E19798A82B4E238C95FFBB8318310F5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_8E19798A82B4E238C95FFBB8318310F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_9007D9B4C460A33B6946FBB83183B527" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:to="loc_us-gaap_ConstructionInProgressGross_9007D9B4C460A33B6946FBB83183B527" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_934197C900A121F6C47AFBB8318306C1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_934197C900A121F6C47AFBB8318306C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9454B97BB36E0B692628FBB83183D75C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9454B97BB36E0B692628FBB83183D75C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6D1CE72414FFA248FFDEFBB83183EFB7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_C064BDCF0F6E2698C061FBB8318373BB" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6D1CE72414FFA248FFDEFBB83183EFB7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_77597FA82FF7E1C40E889528E98FC3D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34FDA9E5DE1B35A071DE9528E98F9B60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_77597FA82FF7E1C40E889528E98FC3D1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34FDA9E5DE1B35A071DE9528E98F9B60" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_47A2AE3C01A7624A3DE39528E98F8839" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34FDA9E5DE1B35A071DE9528E98F9B60" xlink:to="loc_biib_FacilityLocationAxis_47A2AE3C01A7624A3DE39528E98F8839" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_CB63936E6265CA3F70689528E98FCFE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_47A2AE3C01A7624A3DE39528E98F8839" xlink:to="loc_biib_FacilityLocationDomain_CB63936E6265CA3F70689528E98FCFE5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_53A8827B443411F815279528E98F2BC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_CB63936E6265CA3F70689528E98FCFE5" xlink:to="loc_biib_SolothurnMember_53A8827B443411F815279528E98F2BC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A8A306B7B1918336CC999528E98FAD74" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_34FDA9E5DE1B35A071DE9528E98F9B60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A8A306B7B1918336CC999528E98FAD74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1C93ECC8ADEB89126E009528E98FE28E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A8A306B7B1918336CC999528E98FAD74" xlink:to="loc_us-gaap_Depreciation_1C93ECC8ADEB89126E009528E98FE28E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_A5766B26AC2A3053D43D955D3099E367" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A8A306B7B1918336CC999528E98FAD74" xlink:to="loc_us-gaap_InterestCostsCapitalized_A5766B26AC2A3053D43D955D3099E367" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_D841ED49335A16AB38BC9528E98FB15E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A8A306B7B1918336CC999528E98FAD74" xlink:to="loc_us-gaap_ConstructionInProgressGross_D841ED49335A16AB38BC9528E98FB15E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2F5086641BA96780DB79FBB83569D42C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_48C0A61F7C86760A549FFBB83569D21F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2F5086641BA96780DB79FBB83569D42C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_48C0A61F7C86760A549FFBB83569D21F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B9479ADB8A7D6F8A31B0FBB8351C5CBF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_75F9F0D466C2A01BF166FBB8351C00A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_B9479ADB8A7D6F8A31B0FBB8351C5CBF" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_75F9F0D466C2A01BF166FBB8351C00A0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_721583D76D07BC8B53B585CC9C97C595" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_721583D76D07BC8B53B585CC9C97C595" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C9580D24D01781A9C43485CC9C972284" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:to="loc_srt_ProductOrServiceAxis_C9580D24D01781A9C43485CC9C972284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_C9580D24D01781A9C43485CC9C972284" xlink:to="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_A70575F6D4D28DD6920485CC9C9706CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_A70575F6D4D28DD6920485CC9C9706CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_BB8DC41AF4DE555FBFF985CC9C97FE20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_BB8DC41AF4DE555FBFF985CC9C97FE20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_42C31F1D10E4A119B94B85CC9C974B2F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_24186B038C3C1E0827F285CC9C97BE70" xlink:to="loc_us-gaap_ProductMember_42C31F1D10E4A119B94B85CC9C974B2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_DCAAAF59FB1E5C33115D85D6DB072393" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_64F04141370B64926D6785D6DB07A7F3" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_DCAAAF59FB1E5C33115D85D6DB072393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_721583D76D07BC8B53B585CC9C97C595" xlink:to="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_2863DB3453E0A6FC367B85CC9C97F017" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:to="loc_us-gaap_Revenues_2863DB3453E0A6FC367B85CC9C97F017" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_C5AD4C0C713EBC1234E985CC9C975FE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:to="loc_us-gaap_GrossProfit_C5AD4C0C713EBC1234E985CC9C975FE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_FA8D807244136B8B0B3785CC9C9701D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:to="loc_us-gaap_ProfitLoss_FA8D807244136B8B0B3785CC9C9701D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1E8928F3A90EB49AA68285CC9C97AA27" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:to="loc_us-gaap_NetIncomeLoss_1E8928F3A90EB49AA68285CC9C97AA27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_9720177EFAFF441F561B85CC9C9AFDE1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:to="loc_us-gaap_EarningsPerShareBasic_9720177EFAFF441F561B85CC9C9AFDE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6DC2CED770A532B0719E85CC9C9A0611" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6DC2CED770A532B0719E85CC9C9A0611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A877372A1A9AC6E8D1DC85CC9C9AF6C7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_A877372A1A9AC6E8D1DC85CC9C9AF6C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_AEB4C7C4E0D8FD00A33785CC9C9AFC33" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SelectedQuarterlyFinancialInformationAbstract_E848EAA4D44010F3E10885CC9C978CD4" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_AEB4C7C4E0D8FD00A33785CC9C9AFC33" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_46C42FEE3BDE750A7896A5C6DA3E0DD0" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_46C42FEE3BDE750A7896A5C6DA3E0DD0" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8637B0BA5A770B48996BA5C6DA3EE0FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8637B0BA5A770B48996BA5C6DA3EE0FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4DE69E95DEE795F6848AA5C6DA3ECFD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8637B0BA5A770B48996BA5C6DA3EE0FE" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4DE69E95DEE795F6848AA5C6DA3ECFD2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_U.S.2017TaxActMember" xlink:label="loc_biib_U.S.2017TaxActMember_0E27A9737ECB652E89A0A5C6DA4D0614" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4DE69E95DEE795F6848AA5C6DA3ECFD2" xlink:to="loc_biib_U.S.2017TaxActMember_0E27A9737ECB652E89A0A5C6DA4D0614" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetAxis" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_3AF4458B59011661C2D4A5C6DA4DA71E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_3AF4458B59011661C2D4A5C6DA4DA71E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResearchanddevelopmentassetDomain" xlink:label="loc_biib_ResearchanddevelopmentassetDomain_473AE2A210D9F34FE3D3A5C6DA4DF266" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_3AF4458B59011661C2D4A5C6DA4DA71E" xlink:to="loc_biib_ResearchanddevelopmentassetDomain_473AE2A210D9F34FE3D3A5C6DA4DF266" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TGNMember" xlink:label="loc_biib_TGNMember_20EF50547B5A9B8CD1C0A5C6DA4D2B65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetDomain_473AE2A210D9F34FE3D3A5C6DA4DF266" xlink:to="loc_biib_TGNMember_20EF50547B5A9B8CD1C0A5C6DA4D2B65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F19ADD36A227A0F8A28FA5C6DA4DE92F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F19ADD36A227A0F8A28FA5C6DA4DE92F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_417A306916E8BCD82479A5C6DA4D9FE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_F19ADD36A227A0F8A28FA5C6DA4DE92F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_417A306916E8BCD82479A5C6DA4D9FE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_C6356FDAF4905A4A31C0A5C6DA4D164A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_417A306916E8BCD82479A5C6DA4D9FE4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_C6356FDAF4905A4A31C0A5C6DA4D164A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8748EB4780BB63DE5F68A5C6DA4D1BAE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8748EB4780BB63DE5F68A5C6DA4D1BAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8748EB4780BB63DE5F68A5C6DA4D1BAE" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_KaryopharmMember" xlink:label="loc_biib_KaryopharmMember_791BA242F71F7599B401A5C6DA4D7CB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:to="loc_biib_KaryopharmMember_791BA242F71F7599B401A5C6DA4D7CB6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RemedyPharmaceuticalMember" xlink:label="loc_biib_RemedyPharmaceuticalMember_AC9C7E697952C56E1CB6A5C6DA4DB50F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:to="loc_biib_RemedyPharmaceuticalMember_AC9C7E697952C56E1CB6A5C6DA4DB50F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PfizerMember" xlink:label="loc_biib_PfizerMember_8E2FA388E4F3F2256A02A5C6DA4DD9F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:to="loc_biib_PfizerMember_8E2FA388E4F3F2256A02A5C6DA4DD9F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AliveGenMember" xlink:label="loc_biib_AliveGenMember_E67E19131FF6938F48A5A5C6DA4D6C7F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5A9D7B41C1F95D001BD4A5C6DA4DDA18" xlink:to="loc_biib_AliveGenMember_E67E19131FF6938F48A5A5C6DA4D6C7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_515DA5098C891D3DAAA3A5C6DA4DC044" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_srt_ProductOrServiceAxis_515DA5098C891D3DAAA3A5C6DA4DC044" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_4D840E758B3DEE2B10DEA5C6DA4D76B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_515DA5098C891D3DAAA3A5C6DA4DC044" xlink:to="loc_srt_ProductsAndServicesDomain_4D840E758B3DEE2B10DEA5C6DA4D76B0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_AD18F87B095A925FD46BA5C6DA4D60EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4D840E758B3DEE2B10DEA5C6DA4D76B0" xlink:to="loc_biib_TecfideraMember_AD18F87B095A925FD46BA5C6DA4D60EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis" xlink:label="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassificationOfVariableInterestEntityDomain" xlink:label="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_32C46A4C56791153CF09A5C6DA4D616C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis_EB3A28A8C43BC6428D7EA5C6DA4D8437" xlink:to="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_32C46A4C56791153CF09A5C6DA4D616C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NeurimmuneMember" xlink:label="loc_biib_NeurimmuneMember_36D25E493F80704A2591A5C6DA4D16D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassificationOfVariableInterestEntityDomain_32C46A4C56791153CF09A5C6DA4D616C" xlink:to="loc_biib_NeurimmuneMember_36D25E493F80704A2591A5C6DA4D16D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_242F5C56201AF7B11132A5C6DA4DE71E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_us-gaap_TypeOfArrangementAxis_242F5C56201AF7B11132A5C6DA4DE71E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_242F5C56201AF7B11132A5C6DA4DE71E" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BristolMyersSquibbMember" xlink:label="loc_biib_BristolMyersSquibbMember_0566FECFA64A3488EDCFA5C6DA4D5FF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:to="loc_biib_BristolMyersSquibbMember_0566FECFA64A3488EDCFA5C6DA4D5FF7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IPerianMember" xlink:label="loc_biib_IPerianMember_9AFE9CC85DCFE1F2FECEA5C6DA4D6DA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:to="loc_biib_IPerianMember_9AFE9CC85DCFE1F2FECEA5C6DA4D6DA0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AlkermesMember" xlink:label="loc_biib_AlkermesMember_292F59A9FCE7050E15C9A5C6DA4DC15A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:to="loc_biib_AlkermesMember_292F59A9FCE7050E15C9A5C6DA4DC15A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IonisPharmaceuticalsMember" xlink:label="loc_biib_IonisPharmaceuticalsMember_90DD79336D22C5647670A5C6DA4DC54B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_36A02EC8A1D4A1787296A5C6DA4DE38A" xlink:to="loc_biib_IonisPharmaceuticalsMember_90DD79336D22C5647670A5C6DA4DC54B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems" xlink:label="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationTable_448B070A6A7392D71F1EA5C6DA3E0AD5" xlink:to="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_02DC3C19DB8BC4D59610A5C6DA4DAC6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments_02DC3C19DB8BC4D59610A5C6DA4DAC6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EDDAD5EDA7920948A1FAA5C6DA4DAFB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_EDDAD5EDA7920948A1FAA5C6DA4DAFB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_06563D2D9809D9994389A5C6DA4D017A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_06563D2D9809D9994389A5C6DA4D017A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilitiesGILTItaxcalculation" xlink:label="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_03ACC83457D51B2017F6A5C6DA4D00A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_DeferredtaxliabilitiesGILTItaxcalculation_03ACC83457D51B2017F6A5C6DA4D00A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_14DC44A823CDD5490619A5C6DA4D61A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_14DC44A823CDD5490619A5C6DA4D61A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_374828EF76C394A36F77A5C6DA4D59BD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_374828EF76C394A36F77A5C6DA4D59BD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Premiumonpurchaseofcommonstock" xlink:label="loc_biib_Premiumonpurchaseofcommonstock_4097784835C1509800A4A5C6DA4DFB84" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_Premiumonpurchaseofcommonstock_4097784835C1509800A4A5C6DA4DFB84" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Investmentincommonstocksharespurchased" xlink:label="loc_biib_Investmentincommonstocksharespurchased_14C8971445251F73B5C3A5C6DA4D6CC5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_Investmentincommonstocksharespurchased_14C8971445251F73B5C3A5C6DA4D6CC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_858B9589A7E542637399A5C6DA4DE157" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_858B9589A7E542637399A5C6DA4DE157" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToMinorityShareholders" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_74CB2CBF4E980C751554A5C6DA4D7559" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_74CB2CBF4E980C751554A5C6DA4D7559" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Additionalreductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_4ED8A57D423429A6D3ABA5C6DA4DA4C2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_Additionalreductioninroyaltyratepayableoncommercialsales_4ED8A57D423429A6D3ABA5C6DA4DA4C2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DevelopmentalMilestonePayment" xlink:label="loc_biib_DevelopmentalMilestonePayment_F291BCDD15E44FE405F3A5C6DA4DEAEC" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_DevelopmentalMilestonePayment_F291BCDD15E44FE405F3A5C6DA4DEAEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_57DC3D3ACC2A8D1DC90EA5C6DA4D677B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_57DC3D3ACC2A8D1DC90EA5C6DA4D677B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Reductioninroyaltyratepayableoncommercialsales" xlink:label="loc_biib_Reductioninroyaltyratepayableoncommercialsales_23F396DBD83E0E445B67A5C6DA4DB6EB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_Reductioninroyaltyratepayableoncommercialsales_23F396DBD83E0E445B67A5C6DA4DB6EB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F01F72C724855F9BC4A5A5C6DA4D371F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_F01F72C724855F9BC4A5A5C6DA4D371F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4C4E0242449C904B9EA3A5C6DA4DF7BD" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4C4E0242449C904B9EA3A5C6DA4DF7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_AC1D7E6ECA3566D73B33A5C6DA4DAEE0" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems_581971EF105DA7246704A5C6DA4D02F4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_AC1D7E6ECA3566D73B33A5C6DA4DAEE0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_F53700D51044A7E8F1B8FBB8343200F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_073D62851363919BACF0FBB834320AA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_F53700D51044A7E8F1B8FBB8343200F3" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_073D62851363919BACF0FBB834320AA1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuring" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_C099600D8D831A7BA22EFBB835C7EE93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_937DED291B5FB63460ABFBB835C7F400" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_C099600D8D831A7BA22EFBB835C7EE93" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_937DED291B5FB63460ABFBB835C7F400" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9E5FEA2EA6B0BC637C49C4282A6EC63F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_9E5FEA2EA6B0BC637C49C4282A6EC63F" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_CAD95471B7EB39FD99F4C4282A6F4983" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_CAD95471B7EB39FD99F4C4282A6F4983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_CCC5B54B96294EA6523CC4282A7070AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_CAD95471B7EB39FD99F4C4282A6F4983" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_CCC5B54B96294EA6523CC4282A7070AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_5E485ACD24B325BC18B2C4282A704DF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CCC5B54B96294EA6523CC4282A7070AC" xlink:to="loc_us-gaap_RestructuringChargesMember_5E485ACD24B325BC18B2C4282A704DF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9FB6F83B0B3B353A75B2C4282A70BA3B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_CCC5B54B96294EA6523CC4282A7070AC" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9FB6F83B0B3B353A75B2C4282A70BA3B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationAxis" xlink:label="loc_biib_FacilityLocationAxis_56C512E146D0733009E2C4282A70464C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:to="loc_biib_FacilityLocationAxis_56C512E146D0733009E2C4282A70464C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FacilityLocationDomain" xlink:label="loc_biib_FacilityLocationDomain_E19FE7CDA4C621566358C4282A716544" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_56C512E146D0733009E2C4282A70464C" xlink:to="loc_biib_FacilityLocationDomain_E19FE7CDA4C621566358C4282A716544" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CambridgeMAMember" xlink:label="loc_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_E19FE7CDA4C621566358C4282A716544" xlink:to="loc_biib_CambridgeMAMember_A7623D8783328C2178D4C4282A71A332" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:to="loc_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_C2C06DEFCD33AE7C0D75C4282A71BCA1" xlink:to="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2017CorporateStrategyMember" xlink:label="loc_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:to="loc_biib_A2017CorporateStrategyMember_4CCE2B3C1E1DF070A186C4282A72BC96" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2016RestructuringChargesMember" xlink:label="loc_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:to="loc_biib_A2016RestructuringChargesMember_3DE18AA7EF4407B4A87DC4282A7251EE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2015RestructuringChargesMember" xlink:label="loc_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_2AB15A0AF817F7C2135BC4282A716ECF" xlink:to="loc_biib_A2015RestructuringChargesMember_A2E753D0A55126715956C4282A728151" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_73D7FF5C82E100C96847C4282A6F7716" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonrecurringExpense" xlink:label="loc_us-gaap_OtherNonrecurringExpense_B7B7F686A15D0861BC74C4282A726440" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="loc_us-gaap_OtherNonrecurringExpense_B7B7F686A15D0861BC74C4282A726440" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ResourcesRedirectedthroughRestructuringProgram" xlink:label="loc_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="loc_biib_ResourcesRedirectedthroughRestructuringProgram_9B2D52F4B330AEEAB28FC4282A7342D2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram" xlink:label="loc_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="loc_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram_C22AE3FA0D57CB987D12C4282A734313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_07DE223A3880DD84BCAFC4282A73A6BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="loc_us-gaap_RestructuringCharges_07DE223A3880DD84BCAFC4282A73A6BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_5BC02857C6B06249BD2CC4282A73C1A1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_B5B1AEB3C145DD585D53C4282A72FF14" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_5BC02857C6B06249BD2CC4282A73C1A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_25B595E38CB2423F640D11E57C35484A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_85263385A36B22DBFE4611E57DFED5C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_25B595E38CB2423F640D11E57C35484A" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_85263385A36B22DBFE4611E57DFED5C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_D1341E5547B22F428ED49F97658E55EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_6999D2BB3DE395374F3B9F97658E3D9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_D1341E5547B22F428ED49F97658E55EB" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_6999D2BB3DE395374F3B9F97658E3D9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_9331424B6BFEA2D6C4AD9F97658EE3EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6999D2BB3DE395374F3B9F97658E3D9E" xlink:to="loc_srt_StatementGeographicalAxis_9331424B6BFEA2D6C4AD9F97658EE3EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_B7F99524ACA17DA612A69F97658F0F21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9331424B6BFEA2D6C4AD9F97658EE3EE" xlink:to="loc_srt_SegmentGeographicalDomain_B7F99524ACA17DA612A69F97658F0F21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_5485B7BEA7DCCDE5DF0F9F97658FF1F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_B7F99524ACA17DA612A69F97658F0F21" xlink:to="loc_country_US_5485B7BEA7DCCDE5DF0F9F97658FF1F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_7CC51C00182682F598EE9F99A43A88B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_B7F99524ACA17DA612A69F97658F0F21" xlink:to="loc_us-gaap_NonUsMember_7CC51C00182682F598EE9F99A43A88B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_3CD7E51B35F0535B805E9F97658F227E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6999D2BB3DE395374F3B9F97658E3D9E" xlink:to="loc_srt_ProductOrServiceAxis_3CD7E51B35F0535B805E9F97658F227E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3CD7E51B35F0535B805E9F97658F227E" xlink:to="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TecfideraMember" xlink:label="loc_biib_TecfideraMember_9B5779641286280CEEAC9F9765906BE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_TecfideraMember_9B5779641286280CEEAC9F9765906BE1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InterferonMember" xlink:label="loc_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_InterferonMember_6782EEE7AF83F5FABD8C9F9765900E22" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TysabriProductMember" xlink:label="loc_biib_TysabriProductMember_91ACC93B3DD603BD17879F9765903A10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_TysabriProductMember_91ACC93B3DD603BD17879F9765903A10" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FAMPYRAMember" xlink:label="loc_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_FAMPYRAMember_05F9C7B1AF5D9B3C975A9F9765904968" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ZINBRYTAMember" xlink:label="loc_biib_ZINBRYTAMember_FAB5100397867B1469ED9F976591001D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_ZINBRYTAMember_FAB5100397867B1469ED9F976591001D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MSProductRevenuesMember" xlink:label="loc_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_MSProductRevenuesMember_5A43AAA964DB33182B8B9F976591A0F1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SPINRAZAMember" xlink:label="loc_biib_SPINRAZAMember_B06EB6A91A602517B55A9F976591F3AD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_SPINRAZAMember_B06EB6A91A602517B55A9F976591F3AD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BENEPALIMember" xlink:label="loc_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_BENEPALIMember_216FF87EDD3306C671589F9765911F29" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FLIXABIMember" xlink:label="loc_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_FLIXABIMember_4E9A3E444E336A1EB3C19F976591849B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_IMRALDIMember" xlink:label="loc_biib_IMRALDIMember_CDADDF624A93D32D050E9F9765911F1F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_IMRALDIMember_CDADDF624A93D32D050E9F9765911F1F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BiosimilarsMember" xlink:label="loc_biib_BiosimilarsMember_415325B31D2A187E77959F976591E0F0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_BiosimilarsMember_415325B31D2A187E77959F976591E0F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_FUMADERMMember" xlink:label="loc_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_FUMADERMMember_257A7D3BC940E55BADF89F97659228E8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ELOCTATEMember" xlink:label="loc_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_ELOCTATEMember_D75059746888EB6048C39F976592DB3B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ALPROLIXMember" xlink:label="loc_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_ALPROLIXMember_D2F24CAFB9E2C30C52029F9765920CB8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_HemophiliaProductsMember" xlink:label="loc_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_biib_HemophiliaProductsMember_547A6FBBD6CA65B1A8AF9F9765927994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_4C103E1F66C26EF51D089F976593305B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_53F5C14CB999B9C8D1749F9765903354" xlink:to="loc_us-gaap_ProductMember_4C103E1F66C26EF51D089F976593305B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5A1C5B0F0FB8B7C3A32D9F976593E925" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_6999D2BB3DE395374F3B9F97658E3D9E" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5A1C5B0F0FB8B7C3A32D9F976593E925" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_E709C7600776D30C66069F976593D533" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5A1C5B0F0FB8B7C3A32D9F976593E925" xlink:to="loc_us-gaap_Revenues_E709C7600776D30C66069F976593D533" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_99E541654389F7206163968CB8992DE6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_63AA93E817A6CAEE3C42968CB89910A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_99E541654389F7206163968CB8992DE6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_63AA93E817A6CAEE3C42968CB89910A8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MajorDistributorAxis" xlink:label="loc_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_63AA93E817A6CAEE3C42968CB89910A8" xlink:to="loc_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MajorDistributorDomain" xlink:label="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorAxis_82A6240C04CE29015244968CB89A4FD8" xlink:to="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DistributorOneMember" xlink:label="loc_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:to="loc_biib_DistributorOneMember_EC8ADBEA8E3CF73EDF99968CB89AE80F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DistributorTwoMember" xlink:label="loc_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MajorDistributorDomain_906274ACF16124A9F981968CB89A5A03" xlink:to="loc_biib_DistributorTwoMember_560F3EA9883E4FA2C6E1968CB89BBFD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7980CEB0F4B0E117B886968CB89BAB1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_63AA93E817A6CAEE3C42968CB89910A8" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7980CEB0F4B0E117B886968CB89BAB1E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7980CEB0F4B0E117B886968CB89BAB1E" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_6FAD184F6757DE894737968CB89BA7F0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables" xlink:label="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7980CEB0F4B0E117B886968CB89BAB1E" xlink:to="loc_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables_50BB34E6D1741F5DB10E968CB89BB36E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms" xlink:label="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7980CEB0F4B0E117B886968CB89BAB1E" xlink:to="loc_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms_A9448C2FDE9EFD06211E968CB89BDAEB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5CA9752838C4C3EF2B9C8525C7FDEB82" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5A2D1DE1EE7DDFD0CD788525C7FDC631" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5CA9752838C4C3EF2B9C8525C7FDEB82" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5A2D1DE1EE7DDFD0CD788525C7FDC631" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_771BABFDC7BAA0F5B4F58525C7FD9F19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5A2D1DE1EE7DDFD0CD788525C7FDC631" xlink:to="loc_us-gaap_TypeOfArrangementAxis_771BABFDC7BAA0F5B4F58525C7FD9F19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_26ED9DCF96A61B34A8258525C7FDA1D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_771BABFDC7BAA0F5B4F58525C7FD9F19" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_26ED9DCF96A61B34A8258525C7FDA1D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_BA9545D8A394F2D8706F8525C7FE2891" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_26ED9DCF96A61B34A8258525C7FDA1D9" xlink:to="loc_us-gaap_CollaborativeArrangementMember_BA9545D8A394F2D8706F8525C7FE2891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7AB4A86A18854B92175B8525C7FEB703" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5A2D1DE1EE7DDFD0CD788525C7FDC631" xlink:to="loc_srt_ProductOrServiceAxis_7AB4A86A18854B92175B8525C7FEB703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7AB4A86A18854B92175B8525C7FEB703" xlink:to="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="loc_us-gaap_RoyaltyMember_E3A9F499E105B8ED8FFC8525C7FE64E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A" xlink:to="loc_us-gaap_RoyaltyMember_E3A9F499E105B8ED8FFC8525C7FE64E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A" xlink:to="loc_biib_OthercorporaterevenuesMember_7AE5EEE8292EDA0D8F3C8525C7FFC509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_FE3BE6FC7B951788843C8525C7FF5E63" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D9D1BE25F8C639964F108525C7FE344A" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_FE3BE6FC7B951788843C8525C7FF5E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_3D62AF0159FBBC750B4D8525C7FFA34B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5A2D1DE1EE7DDFD0CD788525C7FDC631" xlink:to="loc_srt_MajorCustomersAxis_3D62AF0159FBBC750B4D8525C7FFA34B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3D62AF0159FBBC750B4D8525C7FFA34B" xlink:to="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AbbVieMember" xlink:label="loc_biib_AbbVieMember_3145F14CA02A4BF536558525C800B6D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216" xlink:to="loc_biib_AbbVieMember_3145F14CA02A4BF536558525C800B6D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SamsungBiosimilarAgreementMember" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_9FE43081D4B7E8919CD18525C800C42B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_9FE43081D4B7E8919CD18525C800C42B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SobiMember" xlink:label="loc_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2644760A84B834BDB7448525C7FF8216" xlink:to="loc_biib_SobiMember_19CAE5E6BF4C3AE3A4638525C8004734" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_C66EDE0C82FE2F07A1E78525C8004467" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5A2D1DE1EE7DDFD0CD788525C7FDC631" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_C66EDE0C82FE2F07A1E78525C8004467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_3479AA1867F90D963D2C8525C8005532" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_C66EDE0C82FE2F07A1E78525C8004467" xlink:to="loc_us-gaap_Revenues_3479AA1867F90D963D2C8525C8005532" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_5B9AC91CEB1339F147E0968CB8B6EEC2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_5B9AC91CEB1339F147E0968CB8B6EEC2" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_C78C4B17548C297E7C00968CB8B66D92" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ReserveforCashDiscountsMember" xlink:label="loc_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:to="loc_biib_ReserveforCashDiscountsMember_CC19447C97B8B4690927968CB8B720CE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ContractualAdjustmentsMember" xlink:label="loc_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:to="loc_biib_ContractualAdjustmentsMember_2335625027702EC984CA968CB8B7AF8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_D2CD22E8340C26F6E531968CB8B7BFF5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_7ADF73ADE56D6FD1CE0D968CB8B7BDBB" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_D2CD22E8340C26F6E531968CB8B7BFF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_D79BAC265E4161917D1F968CB8B6D28F" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_57A85C97E85EF3B7620F968CB8B8E3B3" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_F1F19684DEA30306D059968CB8B8BB59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_F1F19684DEA30306D059968CB8B8BB59" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_4184B74282D40A10723B968CB8B8AAC2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_FB2820AF4F60270BF3D9968CB8B85C6B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_87C11A590962F1D71EA7968CB8B8B84A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_251390011194AB1D9D66968CB8B971D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_66B718C3FEF7071C7C18968CB8B9AD8D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70EB3707A4EF713C6850969F5CD23025" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_66B718C3FEF7071C7C18968CB8B9AD8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_1B1074781F6F10F0048F1219EB1C9704" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_289342387B20F0DE4F2D121B901FFBB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_1B1074781F6F10F0048F1219EB1C9704" xlink:to="loc_us-gaap_StatementTable_289342387B20F0DE4F2D121B901FFBB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_CCA7407BB656776270C91219ECCC0718" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_289342387B20F0DE4F2D121B901FFBB0" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_CCA7407BB656776270C91219ECCC0718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_596F1322B2BBDF65EB9C1219ECCD1246" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CCA7407BB656776270C91219ECCC0718" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_596F1322B2BBDF65EB9C1219ECCD1246" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_0E23F17057ACC5C169811219ECE0759B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_596F1322B2BBDF65EB9C1219ECCD1246" xlink:to="loc_us-gaap_AccountsReceivableMember_0E23F17057ACC5C169811219ECE0759B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_660EE12B8F2B153F8E2D121A87D8414B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_596F1322B2BBDF65EB9C1219ECCD1246" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_660EE12B8F2B153F8E2D121A87D8414B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_A319C8D4829FBD930E03121B901FB494" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_289342387B20F0DE4F2D121B901FFBB0" xlink:to="loc_us-gaap_StatementLineItems_A319C8D4829FBD930E03121B901FB494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_79677E4D05C61B8A659D1219ECC1B5E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_A319C8D4829FBD930E03121B901FB494" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_79677E4D05C61B8A659D1219ECC1B5E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05D41390D987F569218B9A049F9ADFF4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_354DC564B61CBCFB2A299A049F9B891B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05D41390D987F569218B9A049F9ADFF4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_354DC564B61CBCFB2A299A049F9B891B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2C572587C3A63D2A580D9A049F9B236C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_354DC564B61CBCFB2A299A049F9B891B" xlink:to="loc_srt_ProductOrServiceAxis_2C572587C3A63D2A580D9A049F9B236C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_27E6C74E8010A79E06309A049F9BBE64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2C572587C3A63D2A580D9A049F9B236C" xlink:to="loc_srt_ProductsAndServicesDomain_27E6C74E8010A79E06309A049F9BBE64" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_93BEB3F531DA48A7EA259A049F9CA0A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_27E6C74E8010A79E06309A049F9BBE64" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_93BEB3F531DA48A7EA259A049F9CA0A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_6403C8912603E5A125AB9A049F9C7B67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_354DC564B61CBCFB2A299A049F9B891B" xlink:to="loc_srt_MajorCustomersAxis_6403C8912603E5A125AB9A049F9C7B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_23DCF70ED0E448D0F2529A049F9C259C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_6403C8912603E5A125AB9A049F9C7B67" xlink:to="loc_srt_NameOfMajorCustomerDomain_23DCF70ED0E448D0F2529A049F9C259C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RocheGroupGenentechMember" xlink:label="loc_biib_RocheGroupGenentechMember_EC10F1D232239E29B18D9A049F9CB6A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_23DCF70ED0E448D0F2529A049F9C259C" xlink:to="loc_biib_RocheGroupGenentechMember_EC10F1D232239E29B18D9A049F9CB6A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_86FA3719914E1044CB669A049F9D7D84" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_354DC564B61CBCFB2A299A049F9B891B" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_86FA3719914E1044CB669A049F9D7D84" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareOfCoPromotionProfits" xlink:label="loc_biib_ShareOfCoPromotionProfits_08778F2C586AAB9485899A049F9DAB6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86FA3719914E1044CB669A049F9D7D84" xlink:to="loc_biib_ShareOfCoPromotionProfits_08778F2C586AAB9485899A049F9DAB6B" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86FA3719914E1044CB669A049F9D7D84" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_D972E2F803E99B92EE819A049F9DE795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_758D9B1EC7F2EAC868619A049F9DD2BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_86FA3719914E1044CB669A049F9D7D84" xlink:to="loc_us-gaap_Revenues_758D9B1EC7F2EAC868619A049F9DD2BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B58D5A427F6B5BF4F539120906FEC13A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1061BE0059A3C76A02D4120906FE28C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B58D5A427F6B5BF4F539120906FEC13A" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1061BE0059A3C76A02D4120906FE28C0" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6751E3F61399C531E4DB120906FE0C78" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B58D5A427F6B5BF4F539120906FEC13A" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_6751E3F61399C531E4DB120906FE0C78" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_119E8D55D644128E48901218C604CAE7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B58D5A427F6B5BF4F539120906FEC13A" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_119E8D55D644128E48901218C604CAE7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_B71622827A4AAB32A06C121E92F977E7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B58D5A427F6B5BF4F539120906FEC13A" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_B71622827A4AAB32A06C121E92F977E7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OtherrevenuesTableTextBlock" xlink:label="loc_biib_OtherrevenuesTableTextBlock_AC3BFE33ED8A4C46389C1227EBB0F9C4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B58D5A427F6B5BF4F539120906FEC13A" xlink:to="loc_biib_OtherrevenuesTableTextBlock_AC3BFE33ED8A4C46389C1227EBB0F9C4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_E99B4ADB7FA1B26A60FDFBB833199DED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_46468982AF80A9EA0298FBB8331946FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_E99B4ADB7FA1B26A60FDFBB833199DED" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_46468982AF80A9EA0298FBB8331946FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_4A42B674AF56C82CC21285CC9CAB03C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4A42B674AF56C82CC21285CC9CAB03C2" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_5794BC53E107E83A7FFF85CC9CAB8577" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:to="loc_srt_ProductOrServiceAxis_5794BC53E107E83A7FFF85CC9CAB8577" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5794BC53E107E83A7FFF85CC9CAB8577" xlink:to="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_4A5B33BF881BB14B1CFD85CC9CAEA2CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_A1A1D98F31AED71DD96985CC9CAEC3CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_A1A1D98F31AED71DD96985CC9CAEC3CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_834084CC61A381B63BBA85EC5F431197" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_22E6B1827D9365C36B3085CC9CAB1467" xlink:to="loc_us-gaap_ProductMember_834084CC61A381B63BBA85EC5F431197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_F75A67902006814EF9F185CC9CAE4045" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:to="loc_srt_StatementGeographicalAxis_F75A67902006814EF9F185CC9CAE4045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_F75A67902006814EF9F185CC9CAE4045" xlink:to="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D3DD9DF305A5A31B4E3585CC9CAE2CF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:to="loc_country_US_D3DD9DF305A5A31B4E3585CC9CAE2CF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_EF04E57D20BC9FF32A7985CC9CAE80D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:to="loc_srt_EuropeMember_EF04E57D20BC9FF32A7985CC9CAE80D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_AsiaMember" xlink:label="loc_srt_AsiaMember_62AE3B768B34FE13CBF585CC9CAE13FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:to="loc_srt_AsiaMember_62AE3B768B34FE13CBF585CC9CAE13FF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember" xlink:label="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_89C0961BA912FB696C4185CC9CAEBE3F" xlink:to="loc_biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember_1530C04403FA49FE331185CC9CAE2A2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_81DC32743147369768D585CC9CABA201" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_0988BF18B0B68B7FD32285CC9CAE7F03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:to="loc_us-gaap_Revenues_0988BF18B0B68B7FD32285CC9CAE7F03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="loc_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_3D27C2B91235F932B38E85CC9CAEFAD9" xlink:to="loc_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_10F6E843E1B688B3365685CC9CAE2A3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentsGeographicalAreasAbstract_4000871EF315EAB47E1F85CC9CAE7432" xlink:to="loc_us-gaap_NoncurrentAssets_10F6E843E1B688B3365685CC9CAE2A3A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_771024F7F2BC107CCF96C4282571ED3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_771024F7F2BC107CCF96C4282571ED3F" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_0C82C275F3B87FD0AB69C428257294EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:to="loc_srt_StatementGeographicalAxis_0C82C275F3B87FD0AB69C428257294EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_99C1BB60175126CC3D4FC4282572D534" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0C82C275F3B87FD0AB69C428257294EC" xlink:to="loc_srt_SegmentGeographicalDomain_99C1BB60175126CC3D4FC4282572D534" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SolothurnMember" xlink:label="loc_biib_SolothurnMember_B02F9FB94C15F8C04A98C4282572C326" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_99C1BB60175126CC3D4FC4282572D534" xlink:to="loc_biib_SolothurnMember_B02F9FB94C15F8C04A98C4282572C326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DK" xlink:label="loc_country_DK_2E5B90925F6CD957F36BC42825723F92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_99C1BB60175126CC3D4FC4282572D534" xlink:to="loc_country_DK_2E5B90925F6CD957F36BC42825723F92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_5835180394B261851C91C4282571811D" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="loc_us-gaap_NoncurrentAssets_1F926656A1431DA70DE6C4282574D6AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_7504B66D1ADDF9979A84C42825743E8F" xlink:to="loc_us-gaap_NoncurrentAssets_1F926656A1431DA70DE6C4282574D6AF" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SegmentInformationTextualAbstract" xlink:label="loc_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_771024F7F2BC107CCF96C4282571ED3F" xlink:to="loc_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_5EA0A7FB0E794E42E45FC4282575B485" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SegmentInformationTextualAbstract_25BC88D96D287AA98486C42825752104" xlink:to="loc_us-gaap_NumberOfReportableSegments_5EA0A7FB0E794E42E45FC4282575B485" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_95A11314D8F799C9BEAF85CC9CB3C2A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_C4030F2C608C8D8F609E85CC9CB3A392" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_95A11314D8F799C9BEAF85CC9CB3C2A0" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_C4030F2C608C8D8F609E85CC9CB3A392" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D4E602D020AFC4F86E6FFBB831559FBC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B150C8AC548416F7E76AFBB8315505B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D4E602D020AFC4F86E6FFBB831559FBC" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B150C8AC548416F7E76AFBB8315505B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3BFEF3B735BC1914B2DEFBB83460254D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3BFEF3B735BC1914B2DEFBB83460254D" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7D7D0379BC6D9664325AFBB83460D2F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7D7D0379BC6D9664325AFBB83460D2F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7D7D0379BC6D9664325AFBB83460D2F1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EA0124EEB25A0908A42FFBB83460D7A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_EA0124EEB25A0908A42FFBB83460D7A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4D429B05B4F412E61357FBB834609FD5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4D429B05B4F412E61357FBB834609FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="loc_us-gaap_RestructuringChargesMember_83E1C8E96CC8602DD4E6FBB83460E28B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:to="loc_us-gaap_RestructuringChargesMember_83E1C8E96CC8602DD4E6FBB83460E28B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_36320DA5EB99718A653EFBB8346004DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F1F76AD2404FE863FAECFBB83460E9D0" xlink:to="loc_us-gaap_ParentMember_36320DA5EB99718A653EFBB8346004DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_CC429976580461EC5252FBB834603068" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_F657EAD8944A62BE118EFBB83460107F" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9F0CE78A5E4690F00B3FFBB83460189B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9F0CE78A5E4690F00B3FFBB83460189B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DA374D787DE6DD9F79B3FBB83460B67A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_DA374D787DE6DD9F79B3FBB83460B67A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C58F5C0012FD697307C5FBB8346042BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_C58F5C0012FD697307C5FBB8346042BA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_30ED913462991CB3CF4EFBB8346084DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9352681C369C95CBF747FBB834600CA9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_71939C5B1518A1B248FEFBB8346066A2" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9352681C369C95CBF747FBB834600CA9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_831ECD7E9876EEA067C0F08E8D68E7AE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F3989F31CDD93510C733F08E8D696FAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_831ECD7E9876EEA067C0F08E8D68E7AE" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F3989F31CDD93510C733F08E8D696FAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_6BB48D4D775BFE7056DCF08E8D6921FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F3989F31CDD93510C733F08E8D696FAA" xlink:to="loc_us-gaap_PlanNameAxis_6BB48D4D775BFE7056DCF08E8D6921FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6BB48D4D775BFE7056DCF08E8D6921FC" xlink:to="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_0D148804A756E5585BF4F08E8D69B9AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_MarketStockUnitsMember_0D148804A756E5585BF4F08E8D69B9AA" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_9BEC85EF2EA430C10C4DF08E8D6AC3D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_9BEC85EF2EA430C10C4DF08E8D6AC3D1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_8F1E860EC69AFB3780DBF08E8D6A6EFD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_CashSettledPerformanceSharesMember_8F1E860EC69AFB3780DBF08E8D6A6EFD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceUnitsMember" xlink:label="loc_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_PerformanceUnitsMember_C3336374754EC4CD3A52F08E8D6AAA3E" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_08E4D09397AB0828601DF0B32379874F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_08E4D09397AB0828601DF0B32379874F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_8872763BA965E998761AF0B34A776117" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_8872763BA965E998761AF0B34A776117" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EmployeeStockPurchasePlanMember" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_F126474E17527691A531F08E8D696CFE" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_8C4CE46A75630A525DD6F08E8D6AAEC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_499887DEC4D185E61F82F08E8D6A4355" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F3989F31CDD93510C733F08E8D696FAA" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_499887DEC4D185E61F82F08E8D6A4355" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_499887DEC4D185E61F82F08E8D6A4355" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_327E1510F01357570C0FF08E8D6B66D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_327E1510F01357570C0FF08E8D6B66D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CCE6EA81721A3F4CEB3F08E8D6B333F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2CCE6EA81721A3F4CEB3F08E8D6B333F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F063094FE6FF6F54DD91F08E8D6B6489" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_F063094FE6FF6F54DD91F08E8D6B6489" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_B5A759682F60FBC36C09F08E8D6B5402" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_18E5C648B2FB3EBE0192F08E8D6A0507" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_B5A759682F60FBC36C09F08E8D6B5402" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails10" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5F50DBCF731793A737BA85CC9E27AE75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60D8AA8974AF76FE235C85CC9E277FA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5F50DBCF731793A737BA85CC9E27AE75" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60D8AA8974AF76FE235C85CC9E277FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_12F6EAD8EA56D3B7C17485CC9E270C31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60D8AA8974AF76FE235C85CC9E277FA9" xlink:to="loc_us-gaap_AwardTypeAxis_12F6EAD8EA56D3B7C17485CC9E270C31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4143401265FCDF6700985CC9E2A4325" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_12F6EAD8EA56D3B7C17485CC9E270C31" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4143401265FCDF6700985CC9E2A4325" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_D9232EA6804772BE154885CC9E2A9BE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_D4143401265FCDF6700985CC9E2A4325" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_D9232EA6804772BE154885CC9E2A9BE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_353197BA8206D918873E85CC9E2A0CFE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_60D8AA8974AF76FE235C85CC9E277FA9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_353197BA8206D918873E85CC9E2A0CFE" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RestrictedStockUnitsActivityAbstract" xlink:label="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_353197BA8206D918873E85CC9E2A0CFE" xlink:to="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C175F3CCDAA4EDE389C785CC9E2AFCB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_C175F3CCDAA4EDE389C785CC9E2AFCB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CB032796C468135464B985CC9E2A708B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_CB032796C468135464B985CC9E2A708B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_746DC593DF6F36F38B1185CC9E2AD5E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_746DC593DF6F36F38B1185CC9E2AD5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BFB335B05F9B3B0768B785CC9E2A183E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BFB335B05F9B3B0768B785CC9E2A183E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9BE211C64C47C1F1F6A185CC9E2A48C5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_9BE211C64C47C1F1F6A185CC9E2A48C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_807E40643C336AD34A3985CC9E2A32F5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_807E40643C336AD34A3985CC9E2A32F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3681AFD8A42758F6152F85CC9E2C5CBF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3681AFD8A42758F6152F85CC9E2C5CBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_BF988227E8D3C839D88B85CC9E2C4725" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_BF988227E8D3C839D88B85CC9E2C4725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7226434D19464739967385CC9E2C908A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7226434D19464739967385CC9E2C908A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_64F69C93672BF85F7AAB85CC9E2C5908" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RestrictedStockUnitsActivityAbstract_87A6772ABCA735DE50B685CC9E2A7FC0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_64F69C93672BF85F7AAB85CC9E2C5908" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails11" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CE6502C75D20E8A5D320871CADE348FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CE6502C75D20E8A5D320871CADE348FF" xlink:to="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_640856EA7AC9DFBB54F4871CADE3AFF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:to="loc_us-gaap_PlanNameAxis_640856EA7AC9DFBB54F4871CADE3AFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_7AD08147F1132212A5AF871CADE321B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_640856EA7AC9DFBB54F4871CADE3AFF6" xlink:to="loc_us-gaap_PlanNameDomain_7AD08147F1132212A5AF871CADE321B6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2015ESPPMember" xlink:label="loc_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7AD08147F1132212A5AF871CADE321B6" xlink:to="loc_biib_A2015ESPPMember_52D540614B22063BB056871CADE3E092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeStockOwnershipPlanESOPDisclosuresTable_E79BEFDF1C8BBB8B1608871CADE36AFC" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_F1FE1ABA889BAB3F82EE871CADE38949" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_F1FE1ABA889BAB3F82EE871CADE38949" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4E375134977D9BC8EE47871CADE3F8E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems_2B3CC1A51B89FE4B177F871CADE34C20" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_4E375134977D9BC8EE47871CADE3F8E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51225117B364D306440185CC9E665460" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_StockOptionActivityAbstract" xlink:label="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_51225117B364D306440185CC9E665460" xlink:to="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E06B51EE9ACEE644F8D785CC9E66B915" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E06B51EE9ACEE644F8D785CC9E66B915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7CDC9E8B255AA1E6F12685CC9E669AB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7CDC9E8B255AA1E6F12685CC9E669AB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D8F7BFD2E941041E5A3C85CC9E66510A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_D8F7BFD2E941041E5A3C85CC9E66510A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6860A6256ADFF81576D485CC9E660FEB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6860A6256ADFF81576D485CC9E660FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A40F3F8B1A8BBF3EB9F385CC9E660FF7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_A40F3F8B1A8BBF3EB9F385CC9E660FF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_651F4F9B9C7726A1221785CC9E660739" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_651F4F9B9C7726A1221785CC9E660739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_55DE9CA6D8CD164C2F9085CC9E66205A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_55DE9CA6D8CD164C2F9085CC9E66205A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_984AE97246DC2EB7A46185CC9E664C02" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_984AE97246DC2EB7A46185CC9E664C02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A92B91817C548DBE71BF85CC9E66D40B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_A92B91817C548DBE71BF85CC9E66D40B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5371F98B4418377CDA8C85CC9E66E2B7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_StockOptionActivityAbstract_F1D6F2AB2AB2E967551885CC9E6649AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5371F98B4418377CDA8C85CC9E66E2B7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails3" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DAE0DA1A878271229AE8FBB8355AEBF4" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TaxBenefitAndCashReceivedFromStockOptionAbstract" xlink:label="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_DAE0DA1A878271229AE8FBB8355AEBF4" xlink:to="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_92F999F5779EAA8C8DEBFBB8355AE530" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_92F999F5779EAA8C8DEBFBB8355AE530" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_6153342425C4A401A2B0FBB8355A7F04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract_168FF843461B2C52943AFBB8355A62C1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_6153342425C4A401A2B0FBB8355A7F04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails4" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6F64F76C0E894912A215871CAE214CA4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6F64F76C0E894912A215871CAE214CA4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:to="loc_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_40742725CD4C0A55BAA1871CAE212A47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EA263B3F441BFDA42BB6871CAE2186F6" xlink:to="loc_biib_MarketStockUnitsMember_7808C8B31E3BB9C1CE45871CAE215E7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3C7FEA2F239641AB66AE871CAE2134FD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsActivityAbstract" xlink:label="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_47EB557948D36E750B01871CAE21CD45" xlink:to="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A69258A77CB36963AB3C871CAE214C11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A69258A77CB36963AB3C871CAE214C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4FE6C3EE7B8D6B5D0A39871CAE2110A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4FE6C3EE7B8D6B5D0A39871CAE2110A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1B290DC65127D27F842A871CAE210642" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1B290DC65127D27F842A871CAE210642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CE98AEFF8F6B85955DFE871CAE2100BB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_CE98AEFF8F6B85955DFE871CAE2100BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CACDA30051D37B507129871CAE21070E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_CACDA30051D37B507129871CAE21070E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8A93CD3D48580DC61F7D871CAE21FB5E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8A93CD3D48580DC61F7D871CAE21FB5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D15571723EA24DD6BB54871CAE216A48" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D15571723EA24DD6BB54871CAE216A48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_06FF1C216BD120AA67FC871CAE21054D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_06FF1C216BD120AA67FC871CAE21054D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33246E2A0D34283E059F871CAE21ADD6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_33246E2A0D34283E059F871CAE21ADD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D62567BD21D34FA33833871CAE21640B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MarketStockUnitsActivityAbstract_D4B8B2636A8F498C1671871CAE219CCB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D62567BD21D34FA33833871CAE21640B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails5" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD16F53F220287D0B7F6FBB834801902" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC9D489ECCF7FCCC95F9FBB834802D23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FD16F53F220287D0B7F6FBB834801902" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC9D489ECCF7FCCC95F9FBB834802D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1137C10E0DBCFE21C356FBB834801FEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC9D489ECCF7FCCC95F9FBB834802D23" xlink:to="loc_us-gaap_AwardTypeAxis_1137C10E0DBCFE21C356FBB834801FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7DA7C5BF5491733854F1FBB834805BEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1137C10E0DBCFE21C356FBB834801FEC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7DA7C5BF5491733854F1FBB834805BEC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_9046367906640EA750C1FBB83480D1B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7DA7C5BF5491733854F1FBB834805BEC" xlink:to="loc_biib_MarketStockUnitsMember_9046367906640EA750C1FBB83480D1B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_69EBE591A8B9A42F9E3BFBB83480CB99" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC9D489ECCF7FCCC95F9FBB834802D23" xlink:to="loc_srt_RangeAxis_69EBE591A8B9A42F9E3BFBB83480CB99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C33F33193AEFF5630C80FBB834803D12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_69EBE591A8B9A42F9E3BFBB83480CB99" xlink:to="loc_srt_RangeMember_C33F33193AEFF5630C80FBB834803D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A942F32FCB783CBB1433FBB83480F463" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_C33F33193AEFF5630C80FBB834803D12" xlink:to="loc_srt_MinimumMember_A942F32FCB783CBB1433FBB83480F463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_4468F966E378E2F4275FFBB83480A2EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_C33F33193AEFF5630C80FBB834803D12" xlink:to="loc_srt_MaximumMember_4468F966E378E2F4275FFBB83480A2EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3AD032DBF7F4F853378FBB8348046C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC9D489ECCF7FCCC95F9FBB834802D23" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3AD032DBF7F4F853378FBB8348046C4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ValuationOfGrantedStockUnitsAbstract" xlink:label="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3AD032DBF7F4F853378FBB8348046C4" xlink:to="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D0B0CA0DFBB04EF18DECFBB834806E88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D0B0CA0DFBB04EF18DECFBB834806E88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EC9C932899C708B5CEF7FBB83480DFA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_EC9C932899C708B5CEF7FBB83480DFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3B39ADCBC4F200DB70FBFBB8348F58AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_3B39ADCBC4F200DB70FBFBB8348F58AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_BE31FDDC2546DBAD8529FBB8348F3599" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_BE31FDDC2546DBAD8529FBB8348F3599" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMinimum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMinimum_1D0C375EFF2C3E40FDEAFBB8348FFD0C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AverageStockPriceOnGrantDateInDollarsMaximum" xlink:label="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_biib_AverageStockPriceOnGrantDateInDollarsMaximum_D608DB09DADFFEE566DBFBB8348FA099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8F99AB1D21053E7D31B9FBB8348F87C1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ValuationOfGrantedStockUnitsAbstract_6F41E4C9721F0008BC78FBB834803700" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8F99AB1D21053E7D31B9FBB8348F87C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails6" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9EB2154CBE58A14252F9871CAE02D862" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9D960BFA82D9183D6CCF871CAE02CD02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9EB2154CBE58A14252F9871CAE02D862" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9D960BFA82D9183D6CCF871CAE02CD02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6D3CAB571AC86BEA768C871CAE12CABE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9D960BFA82D9183D6CCF871CAE02CD02" xlink:to="loc_us-gaap_AwardTypeAxis_6D3CAB571AC86BEA768C871CAE12CABE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44C770035076D67C91F8871CAE12AD7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6D3CAB571AC86BEA768C871CAE12CABE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44C770035076D67C91F8871CAE12AD7C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_44C770035076D67C91F8871CAE12AD7C" xlink:to="loc_biib_CashSettledPerformanceSharesMember_11C38CBFE911E7603212871CAE12EB65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8300F88801C179966D29871CAE120217" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9D960BFA82D9183D6CCF871CAE02CD02" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8300F88801C179966D29871CAE120217" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashSettledPerformanceSharesAbstract" xlink:label="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8300F88801C179966D29871CAE120217" xlink:to="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ED7AEA17320D5CE437DB871CAE12032B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ED7AEA17320D5CE437DB871CAE12032B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5AB75D6EE2E411A9B3BD871CAE12FD72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5AB75D6EE2E411A9B3BD871CAE12FD72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_32428BABDE38B381DC5D871CAE12ED19" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_32428BABDE38B381DC5D871CAE12ED19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4DAFCE7BF6079DBE4126871CAE1262B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4DAFCE7BF6079DBE4126871CAE1262B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EC09D2EED8DF8F70547871CAE12DEEA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_CashSettledPerformanceSharesAbstract_3C1F4F54DD0D766C900B871CAE128FCC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3EC09D2EED8DF8F70547871CAE12DEEA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails7" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37C309EE4D02F005900DF08E8D3B11B5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC5583B4481C200087C8F08E8D3B965A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_37C309EE4D02F005900DF08E8D3B11B5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC5583B4481C200087C8F08E8D3B965A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7C9511A9F60582A7076BF08E8D3B64F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC5583B4481C200087C8F08E8D3B965A" xlink:to="loc_us-gaap_AwardTypeAxis_7C9511A9F60582A7076BF08E8D3B64F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48DD61CE30802EC81EC6F08E8D3B519F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7C9511A9F60582A7076BF08E8D3B64F9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48DD61CE30802EC81EC6F08E8D3B519F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_59425C251796DAC013FAF08E8D3B9844" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_48DD61CE30802EC81EC6F08E8D3B519F" xlink:to="loc_us-gaap_PerformanceSharesMember_59425C251796DAC013FAF08E8D3B9844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DC5583B4481C200087C8F08E8D3B965A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40DBC404A8E106140813F08E8D3CDD79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_40DBC404A8E106140813F08E8D3CDD79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CA6B6B81B4E58812C190F08E8D3DDCB7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_CA6B6B81B4E58812C190F08E8D3DDCB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1D0FBF0C0114B8D934E7F08E8D3DBBF9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1D0FBF0C0114B8D934E7F08E8D3DBBF9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_35BDCB99264A72A934A5F08E8D3DF872" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_35BDCB99264A72A934A5F08E8D3DF872" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59B777F792F1FD5380E3F08E8D3D4568" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C3A57FD1DCB8F795EC80F08E8D3CA138" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_59B777F792F1FD5380E3F08E8D3D4568" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails8" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8A5E60B96B9E2D01E03D9A049DD41C87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1B3B597E1CAB03DD02ED9A049DD45614" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8A5E60B96B9E2D01E03D9A049DD41C87" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1B3B597E1CAB03DD02ED9A049DD45614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1B3B597E1CAB03DD02ED9A049DD45614" xlink:to="loc_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_52EC5C15A8EA4C9197AA9A049DD56C78" xlink:to="loc_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_30AB71BB9D4CCF01FDF99A049DD506DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_DD26BB7C714BCEB6FE459A049DD524F2" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_30AB71BB9D4CCF01FDF99A049DD506DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_78703E2F9722B84A97639A049DD544C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1B3B597E1CAB03DD02ED9A049DD45614" xlink:to="loc_us-gaap_AwardTypeAxis_78703E2F9722B84A97639A049DD544C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C429AC9DA63574CCEACC9A049DD61857" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_78703E2F9722B84A97639A049DD544C5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C429AC9DA63574CCEACC9A049DD61857" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C429AC9DA63574CCEACC9A049DD61857" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_30AB71BB9D4CCF01FDF99A049DD506DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_187220AC533A8585261C9A049DD60FE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1B3B597E1CAB03DD02ED9A049DD45614" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_187220AC533A8585261C9A049DD60FE8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_187220AC533A8585261C9A049DD60FE8" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83D2CF382EF03C6514589A049DD79771" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_83D2CF382EF03C6514589A049DD79771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_540D20FE89DEDC2C93ED9A049DD7934B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_540D20FE89DEDC2C93ED9A049DD7934B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D91620CBC371F062044A9A049DD74C15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_D91620CBC371F062044A9A049DD74C15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89052709A0E9E06B10C09A049DD763F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_89052709A0E9E06B10C09A049DD763F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858490CE112F7E7F70B09A049DD7C4E7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858490CE112F7E7F70B09A049DD7C4E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_DA74C438EEE81BADB9F39A049DD85B68" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_DA74C438EEE81BADB9F39A049DD85B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6D0EB5F994A3003379FE9A049DD892B5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_6D0EB5F994A3003379FE9A049DD892B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_49E566F8E80682E3A0A49A049DD8E71C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_49E566F8E80682E3A0A49A049DD8E71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BC6B91D312E6BB7210989A049DD8345D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_BC6B91D312E6BB7210989A049DD8345D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_BD34D80A0962E7DB30E49A049DD88952" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockAbstract_498FA99C524FCD1A6F5B9A049DD6D56F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_BD34D80A0962E7DB30E49A049DD88952" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails9" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52ABD70F4E2DB9F12E649A049DC8BE3A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4E4676488F63BB4E9A5B9A049DC8C23D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_52ABD70F4E2DB9F12E649A049DC8BE3A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4E4676488F63BB4E9A5B9A049DC8C23D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_23DCAF40CB37787B05719A049DC9CCB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4E4676488F63BB4E9A5B9A049DC8C23D" xlink:to="loc_us-gaap_AwardTypeAxis_23DCAF40CB37787B05719A049DC9CCB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F0871F4E8885C0C998F69A049DC9F3FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_23DCAF40CB37787B05719A049DC9CCB2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F0871F4E8885C0C998F69A049DC9F3FC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_E52E76580AF24DDBA8159A049DC99B1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F0871F4E8885C0C998F69A049DC9F3FC" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_E52E76580AF24DDBA8159A049DC99B1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ACCB095C1D74110251C9A049DCA38D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4E4676488F63BB4E9A5B9A049DC8C23D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ACCB095C1D74110251C9A049DCA38D4" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashAbstract" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9ACCB095C1D74110251C9A049DCA38D4" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7F6EA1A1F469D7D9F4DA9A049DCA981B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7F6EA1A1F469D7D9F4DA9A049DCA981B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_960866D859416A299F689A049DCAB186" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_960866D859416A299F689A049DCAB186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30FFF5892D6382C3FEBA9A049DCADE73" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_30FFF5892D6382C3FEBA9A049DCADE73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_594BA2C1EDD92B480ECF9A049DCBCE92" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_594BA2C1EDD92B480ECF9A049DCBCE92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_96C28040795B2E317B979A049DCBB380" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashAbstract_1A1FFE2D4C366DE6F02C9A049DCA98FB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_96C28040795B2E317B979A049DCBB380" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_868C74CE1B28565084C2871CADD39C1C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06DDE4F5280E0FB7498B871CADD36997" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_868C74CE1B28565084C2871CADD39C1C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06DDE4F5280E0FB7498B871CADD36997" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_2AD01413A8C00F6D429E871CADD30740" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06DDE4F5280E0FB7498B871CADD36997" xlink:to="loc_us-gaap_PlanNameAxis_2AD01413A8C00F6D429E871CADD30740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_3774B06E4684A5D509A1871CADD3E755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2AD01413A8C00F6D429E871CADD30740" xlink:to="loc_us-gaap_PlanNameDomain_3774B06E4684A5D509A1871CADD3E755" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DirectorsPlanMember" xlink:label="loc_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3774B06E4684A5D509A1871CADD3E755" xlink:to="loc_biib_DirectorsPlanMember_8378E9D8EF57F321FA2B871CADD375A9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_A2017OmnibusEquityPlanMember" xlink:label="loc_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3774B06E4684A5D509A1871CADD3E755" xlink:to="loc_biib_A2017OmnibusEquityPlanMember_286279D3355D03890620871CADD3AFD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06DDE4F5280E0FB7498B871CADD36997" xlink:to="loc_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_7F7544F002FA4A292419871CADD37B7A" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaap_DirectorMember_8955E2C330B4A8B3E387871CADD3A9B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_3F1758FB1F36E181340E871CADD31CAF" xlink:to="loc_us-gaap_DirectorMember_8955E2C330B4A8B3E387871CADD3A9B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8673CE1EDABED670D005871CADD3945A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06DDE4F5280E0FB7498B871CADD36997" xlink:to="loc_us-gaap_AwardTypeAxis_8673CE1EDABED670D005871CADD3945A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8673CE1EDABED670D005871CADD3945A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MarketStockUnitsMember" xlink:label="loc_biib_MarketStockUnitsMember_CF9599084BD9B66BFD51871CADD33F05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_biib_MarketStockUnitsMember_CF9599084BD9B66BFD51871CADD33F05" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CashSettledPerformanceSharesMember" xlink:label="loc_biib_CashSettledPerformanceSharesMember_DAAEFFB3ADFA33B98BB1871CADD3FF55" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_biib_CashSettledPerformanceSharesMember_DAAEFFB3ADFA33B98BB1871CADD3FF55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_63772074DD16206723BF871CADD322B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_us-gaap_PerformanceSharesMember_63772074DD16206723BF871CADD322B5" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_AFC2334DCE56EE23C875871CADD32B91" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_AFC2334DCE56EE23C875871CADD32B91" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashMember" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_1F392A0E62452DA1CA96871CADD3A954" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TimeVestedRestrictedStockUnitsMember" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_BDACAD16830C95D2C348871CADD398E9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9E94ABFB0C0BA0D6FDDB871CADD31531" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_BDACAD16830C95D2C348871CADD398E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06DDE4F5280E0FB7498B871CADD36997" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NumberOfSharesOfCommonStockForIssuance" xlink:label="loc_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_NumberOfSharesOfCommonStockForIssuance_7E9F928E3BCC30CECB30871CADD3075F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RatioOfNumberOfSharesReservedUnderPlan" xlink:label="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_RatioOfNumberOfSharesReservedUnderPlan_DFA408BF1F4D520BE459871CADD338E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F51495D85928AA2CE870871CADD3AB48" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_F51495D85928AA2CE870871CADD3AB48" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NumberOfEqualAnnualIncrements" xlink:label="loc_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_NumberOfEqualAnnualIncrements_9930042D4CFBD44C8760871CADD34B08" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_0B95671900E92166DCA3871CADD37D40" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent" xlink:label="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent_07172D7D45D35988F855871CADD3443B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B74D57A2F8FD59D32073871CADD34D26" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_B74D57A2F8FD59D32073871CADD34D26" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NumberOfDaysForCalculationOfAverageClosingStockPrice" xlink:label="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice_9E06712BDDF7CDD36F14871CADE38BF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9AAE1A2045B79846227C871CADE348AB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_9AAE1A2045B79846227C871CADE348AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_4E6300CD9BE6A2D80703871CADE32BEA" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards_4E6300CD9BE6A2D80703871CADE32BEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_DA3673FE2FD54AD5E2C1871CADE3F520" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_DA3673FE2FD54AD5E2C1871CADE3F520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_321DA88CB989043B32FC871CADE32054" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76C432382EED36A84C3C871CADD3BB7D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_321DA88CB989043B32FC871CADE32054" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ShareBasedPaymentsTextualAbstract" xlink:label="loc_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_868C74CE1B28565084C2871CADD39C1C" xlink:to="loc_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DABF5A02E33FF49A655E871CADE394F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_DABF5A02E33FF49A655E871CADE394F3" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards" xlink:label="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_940629F42365DF14751A871CADE38E42" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:to="loc_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards_940629F42365DF14751A871CADE38E42" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade" xlink:label="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_2F1C3DC50E143216F011871CADE380D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:to="loc_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade_2F1C3DC50E143216F011871CADE380D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_CC8291DDE0BBFF6759BC871CADE346B8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_CC8291DDE0BBFF6759BC871CADE346B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35B98039714E077632E1871CADE32C17" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_35B98039714E077632E1871CADE32C17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CDD6985C51CE1AD9E5C8871CADE37E91" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_CDD6985C51CE1AD9E5C8871CADE37E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE99A64B885B12EAFBBC871CADE30638" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ShareBasedPaymentsTextualAbstract_AC79CD646E504275C8D3871CADE3B611" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE99A64B885B12EAFBBC871CADE30638" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_217548D9224256B7FF731B41A429A0C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_217548D9224256B7FF731B41A429A0C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3DADFCD01403A54E89921B41A4290553" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_3DADFCD01403A54E89921B41A4290553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2D803EB76839EA0905411B41A4291CCB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2D803EB76839EA0905411B41A4291CCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock" xlink:label="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_A91BD4566AD05EA90D811B41A42978D9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock_A91BD4566AD05EA90D811B41A42978D9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfMarketStockUnitsActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_FFF37ECF9AC849FFA3741B41A429685A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock_FFF37ECF9AC849FFA3741B41A429685A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock" xlink:label="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_6557BF28CCD6C47C91F41B41A42970DC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock_6557BF28CCD6C47C91F41B41A42970DC" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock" xlink:label="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_8ED141E3ECE27E596B0D1B41A429FE1D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock_8ED141E3ECE27E596B0D1B41A429FE1D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceunitsactivityTableTextBlock" xlink:label="loc_biib_PerformanceunitsactivityTableTextBlock_DF34CD8FC19F7873CE291B41A429AFB9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_biib_PerformanceunitsactivityTableTextBlock_DF34CD8FC19F7873CE291B41A429AFB9" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinStockTableTextBlock" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock_B5972FEFE90FEACF5DF31B4A88228F3F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockTableTextBlock_B5972FEFE90FEACF5DF31B4A88228F3F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PerformanceStockUnitsSettledinCashTableTextBlock" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock_ABE5FCB8A967F945F5F41B530BB7C551" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashTableTextBlock_ABE5FCB8A967F945F5F41B530BB7C551" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_AFCD1766AE7CAE16A47D1B41A429846D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock_AFCD1766AE7CAE16A47D1B41A429846D" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock" xlink:label="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_1DD0A00C777FD5BF92331B41A42974CE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_515399E43FDCBEC9F9831B41A429E80E" xlink:to="loc_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock_1DD0A00C777FD5BF92331B41A42974CE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_036434F436533FA49555FBB832000C03" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_6B27E598F7FA63141991FBB83200250D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_036434F436533FA49555FBB832000C03" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_6B27E598F7FA63141991FBB83200250D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_F0589E2113D77BA21DE4AAF0BC9E1220" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_F0589E2113D77BA21DE4AAF0BC9E1220" xlink:to="loc_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2AD9CE1A4722E7092DEEAAF0BC9F9984" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2AD9CE1A4722E7092DEEAAF0BC9F9984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3ACF15E75B84CC81F09AAF0BCA462CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2AD9CE1A4722E7092DEEAAF0BC9F9984" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3ACF15E75B84CC81F09AAF0BCA462CD" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_SkyhawkTherapeuticsMember" xlink:label="loc_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_A3ACF15E75B84CC81F09AAF0BCA462CD" xlink:to="loc_biib_SkyhawkTherapeuticsMember_C5E98484C1826C95A52EAAF0BCA4D16B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_65AC3DC4FF518315CE10AAF0BCA5FAC6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_92CA66DC864BB8DF3221AAF0BCA5D29D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_C74AFF45C79C32D1ED98AAF0BCA50A84" xlink:to="loc_us-gaap_SubsequentEventMember_92CA66DC864BB8DF3221AAF0BCA5D29D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_E4AF7389B62CDD05F4FFAAF0BC9EF56F" xlink:to="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_E1465013465F5D540F64AAF0BCA51AB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_E1465013465F5D540F64AAF0BCA51AB8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_AdditionalMilestonePayment" xlink:label="loc_biib_AdditionalMilestonePayment_F6D1D2ABF9642F311390AAF0BCA64BA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:to="loc_biib_AdditionalMilestonePayment_F6D1D2ABF9642F311390AAF0BCA64BA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_E6FDD04313EC48801D6EAAF0BCABD2C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_B97436208C1362A01E03AAF0BCA562C7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_E6FDD04313EC48801D6EAAF0BCABD2C6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CCD2F19B24C0052443C6FBB832AC929D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_BCFF9F63630D7C9FCA80FBB832AC1ADC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CCD2F19B24C0052443C6FBB832AC929D" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_BCFF9F63630D7C9FCA80FBB832AC1ADC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E646BC8DC3EA041AAF04BAB559A76B87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E646BC8DC3EA041AAF04BAB559A76B87" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_9B9AEB89043A9BF5ED51BAB559A76C0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_9B9AEB89043A9BF5ED51BAB559A76C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingGuidanceMember" xlink:label="loc_us-gaap_AccountingGuidanceMember_AD1253BA723379B236A6BAB559A7CC73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis_9B9AEB89043A9BF5ED51BAB559A76C0C" xlink:to="loc_us-gaap_AccountingGuidanceMember_AD1253BA723379B236A6BAB559A7CC73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B065DAA3F1F66AD836ECBAB559A7B53C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingGuidanceMember_AD1253BA723379B236A6BAB559A7CC73" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_B065DAA3F1F66AD836ECBAB559A7B53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E68FA081D13CEEBF832DBAB559A73F41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E68FA081D13CEEBF832DBAB559A73F41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E68FA081D13CEEBF832DBAB559A73F41" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_OthercorporaterevenuesMember" xlink:label="loc_biib_OthercorporaterevenuesMember_1C5500EAF721B49DAB33BAB559A71039" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43" xlink:to="loc_biib_OthercorporaterevenuesMember_1C5500EAF721B49DAB33BAB559A71039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_79588EE5F0EA7ACEB752BAB559A75A39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43" xlink:to="loc_us-gaap_CostOfSalesMember_79588EE5F0EA7ACEB752BAB559A75A39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6D5B264E16AC232310F0BAB559A7CE5C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6CE7CE19DFA79D4E0EF7BAB559A7DE43" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6D5B264E16AC232310F0BAB559A7CE5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B10CC98DA237DC727FF9BAB559A7BF22" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B10CC98DA237DC727FF9BAB559A7BF22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B10CC98DA237DC727FF9BAB559A7BF22" xlink:to="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_CEA13F312AF777A61E74BAB559A726C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_CEA13F312AF777A61E74BAB559A726C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_F3DD12A48A174ECFAC03BAB559A77E1C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_F3DD12A48A174ECFAC03BAB559A77E1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201616Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201616Member_46844948A4696954CC40BAB559A79E2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:to="loc_us-gaap_AccountingStandardsUpdate201616Member_46844948A4696954CC40BAB559A79E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingStandardsUpdate201707Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201707Member_1F72E107E76AD9BF7E63BAB559A73CEF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_351F9D4C0502E6B64C96BAB559A708EE" xlink:to="loc_us-gaap_AccountingStandardsUpdate201707Member_1F72E107E76AD9BF7E63BAB559A73CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_302C67627D9C029EC8F6BAB559A79D58" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_302C67627D9C029EC8F6BAB559A79D58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_302C67627D9C029EC8F6BAB559A79D58" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_0F08F6820158588BB5A0BAB559A7DA16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:to="loc_us-gaap_RetainedEarningsMember_0F08F6820158588BB5A0BAB559A7DA16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7F6A940E213D85A2E4F0BAB62F7A6867" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7F6A940E213D85A2E4F0BAB62F7A6867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredIncomeTaxChargesMember" xlink:label="loc_us-gaap_DeferredIncomeTaxChargesMember_6A88D0ADB4D3817A5395BAB559A7E940" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:to="loc_us-gaap_DeferredIncomeTaxChargesMember_6A88D0ADB4D3817A5395BAB559A7E940" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DeferredtaxliabilityMember" xlink:label="loc_biib_DeferredtaxliabilityMember_E7C0C2FF93AF6E9C82C3BAB559A7B8C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_FD2CFC424E8C978B94AABAB559A7D7C7" xlink:to="loc_biib_DeferredtaxliabilityMember_E7C0C2FF93AF6E9C82C3BAB559A7B8C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_507C4C620B62D96A0914BAB559A72545" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_srt_RangeAxis_507C4C620B62D96A0914BAB559A72545" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F3EC5EAA52605FD6E185BAB559A788CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_507C4C620B62D96A0914BAB559A72545" xlink:to="loc_srt_RangeMember_F3EC5EAA52605FD6E185BAB559A788CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_214DDF32CFC1C8E694C1BAB559A74BB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_F3EC5EAA52605FD6E185BAB559A788CF" xlink:to="loc_srt_MinimumMember_214DDF32CFC1C8E694C1BAB559A74BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_FAF1032477B54B2F05C3BAB559A7F637" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_F3EC5EAA52605FD6E185BAB559A788CF" xlink:to="loc_srt_MaximumMember_FAF1032477B54B2F05C3BAB559A7F637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2C2BA7C7EDF2F83DC484BAB559A792CA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_866E2FA8A5B0E992EC59BAB559B74770" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:to="loc_us-gaap_BuildingMember_866E2FA8A5B0E992EC59BAB559B74770" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_2719DC48BB3E0D518B82BAB559B77786" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_2719DC48BB3E0D518B82BAB559B77786" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6A1675B7F42F10F750CDBAB559B7F0B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6A1675B7F42F10F750CDBAB559B7F0B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_07C8E7222458C858BEC3BAB559B7ECF8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_40C7D9A853A990690CEABAB559B7FEDC" xlink:to="loc_us-gaap_ComputerEquipmentMember_07C8E7222458C858BEC3BAB559B7ECF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0D83D266D036FBDF4D18BAB559A74C89" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4788581F0C22F56144D6BAB559B72F41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4788581F0C22F56144D6BAB559B72F41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification" xlink:label="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_7883A65E24B2899F464CBAB559B75660" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:to="loc_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification_7883A65E24B2899F464CBAB559B75660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5B9776071A8629FDFF11BAB559B71ADA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_5B9776071A8629FDFF11BAB559B71ADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustment" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustment_B643784BD894B30B624CBAB559B7DEC8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_6A5C2B7EF9BD1AF05529BAB559B73D58" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustment_B643784BD894B30B624CBAB559B7DEC8" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BusinessTextualAbstract" xlink:label="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E646BC8DC3EA041AAF04BAB559A76B87" xlink:to="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_InterestInSubsidiary" xlink:label="loc_biib_InterestInSubsidiary_D6BEB35DD928B64C168FBAB559B7D44A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:to="loc_biib_InterestInSubsidiary_D6BEB35DD928B64C168FBAB559B7D44A" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PaymentTermsOfAccountsReceivable" xlink:label="loc_biib_PaymentTermsOfAccountsReceivable_43CCB7D19FF04014CA93BAB559B7342F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:to="loc_biib_PaymentTermsOfAccountsReceivable_43CCB7D19FF04014CA93BAB559B7342F" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_EstimatedUsefulLivesOfLeaseholdImprovements" xlink:label="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_C6E8BCB412ECAF0D0686BAB559B79C5C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:to="loc_biib_EstimatedUsefulLivesOfLeaseholdImprovements_C6E8BCB412ECAF0D0686BAB559B79C5C" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PurchasePriceOfCommonStockUnderEspp" xlink:label="loc_biib_PurchasePriceOfCommonStockUnderEspp_BA1523727DEEDB7A8DD2BAB559B773F7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:to="loc_biib_PurchasePriceOfCommonStockUnderEspp_BA1523727DEEDB7A8DD2BAB559B773F7" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_PercentageOfMarketValuePerShareOfCommonStock" xlink:label="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_BE84D0C32C867A4EBEF3BAB559B7E2CB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:to="loc_biib_PercentageOfMarketValuePerShareOfCommonStock_BE84D0C32C867A4EBEF3BAB559B7E2CB" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_CompensationExpenseOverPurchasePeriod" xlink:label="loc_biib_CompensationExpenseOverPurchasePeriod_CCEBC3A896F251D2527DBAB559B79CD1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:to="loc_biib_CompensationExpenseOverPurchasePeriod_CCEBC3A896F251D2527DBAB559B79CD1" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_DiscountRateRecognizedInCompensationExpense" xlink:label="loc_biib_DiscountRateRecognizedInCompensationExpense_0DB01EB5AD5F78A92F80BAB559B7A338" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:to="loc_biib_DiscountRateRecognizedInCompensationExpense_0DB01EB5AD5F78A92F80BAB559B7A338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_7EF2FA2F45B284AFDA5DBAB559B7D1EB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BusinessTextualAbstract_BB2B3FDE7A86BE22CB3EBAB559B79BD6" xlink:to="loc_us-gaap_AdvertisingExpense_7EF2FA2F45B284AFDA5DBAB559B7D1EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_BusinessOverviewPolicyTextBlock" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_A9B1C226D3D20623659CFBB83210CBBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_A9B1C226D3D20623659CFBB83210CBBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_F195B3C42D80F680D032FBB832108703" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_F195B3C42D80F680D032FBB832108703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_BF6329A1802BFC19BE02FBB83210C31A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_UseOfEstimates_BF6329A1802BFC19BE02FBB83210C31A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_86817E695E74A4B21002FBB83210B0E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_86817E695E74A4B21002FBB83210B0E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_06E39CAC262204B6F737FBB832100B2D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_06E39CAC262204B6F737FBB832100B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_36380EF5516E013F3CEBFBB83210D279" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_36380EF5516E013F3CEBFBB83210D279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_AC7353A024735E288868FBB8321048A8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_AC7353A024735E288868FBB8321048A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9BB54C5446898D204DBEFBB8321087F4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_9BB54C5446898D204DBEFBB8321087F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_C4BB9757060013D2752FFBB83210A7C6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_C4BB9757060013D2752FFBB83210A7C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_820B110C8AB00FEA2E22FBB83210EF75" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_820B110C8AB00FEA2E22FBB83210EF75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_27BD446810CA5C5214E0FBB83210CAEC" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_27BD446810CA5C5214E0FBB83210CAEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_FA292D616606CD8E9807FBB83210CD53" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_FA292D616606CD8E9807FBB83210CD53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_E66E3D3087B07D1529D3FBB83210A11F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_E66E3D3087B07D1529D3FBB83210A11F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_B20ECD3CBECE238C808CFBB832108637" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_B20ECD3CBECE238C808CFBB832108637" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_9E381CAC19DF7D5ADDBDFBB8321089C3" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_9E381CAC19DF7D5ADDBDFBB8321089C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_353C72893118E9E9909AFBB832107101" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_353C72893118E9E9909AFBB832107101" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_C8620F0D6190BA5290E9FBB832101E2E" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_C8620F0D6190BA5290E9FBB832101E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_C34F803F97C6C1B5AA46FBB83210FE21" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_C34F803F97C6C1B5AA46FBB83210FE21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_CFCE6770D6AFF7C50AD7FBB832101737" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_CFCE6770D6AFF7C50AD7FBB832101737" xlink:type="arc" />
    <link:loc xlink:href="biib-20181231.xsd#biib_RoyaltyCostofSalesPolicyTextBlock" xlink:label="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B0F82B695ACC6558BA4CFBB832106A3C" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_biib_RoyaltyCostofSalesPolicyTextBlock_B0F82B695ACC6558BA4CFBB832106A3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_A2F95A66F00B0214F0C0FBB83210AD9F" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_A2F95A66F00B0214F0C0FBB83210AD9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_08AB76987518BBC9329EFBB83210CC7F" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_08AB76987518BBC9329EFBB83210CC7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9ABB43076CE6C9EFDA68FBB832107C9C" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_9ABB43076CE6C9EFDA68FBB832107C9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_11AF1DDD5C226E57F70AFBB83210352D" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_11AF1DDD5C226E57F70AFBB83210352D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0C87ED2156C86E1F48E0FBB832107388" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_0C87ED2156C86E1F48E0FBB832107388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_033B6D739F87C367109BFBB832108B66" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_033B6D739F87C367109BFBB832108B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55ED2D4BA23E29ECDCB8FBB832109EB0" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6BAA833AC375BC0DB6ACFBB832101666" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55ED2D4BA23E29ECDCB8FBB832109EB0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0B523A763A1C5552D50BFBB83460113F" xlink:type="locator" />
    <link:loc xlink:href="biib-20181231.xsd#biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_58C6FAB37DD1EC2B9812FBB83460601B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0B523A763A1C5552D50BFBB83460113F" xlink:to="loc_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_58C6FAB37DD1EC2B9812FBB83460601B" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>acquirediprd.jpg
<TEXT>
begin 644 acquirediprd.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 3T# 2(  A$! Q$!_\0
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M*ZNM3OH;F6Y-]JVI2N;E_D"S_P""8&F^,/A)H/P?_:'^.'B/XS>&OA[\"U^
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M3O!^M:7\:=6U:S^!7Q&\?>$+_5+GX9^&?$W@;_A!KQ-8T_4_'$=CH7TOX?\
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M-N[:V\1Z5I/B.UM-=L-.U5+FSMM6M+;4(X!=6\,L?ZQQ^&M**(3'=DE%)/\
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MJ_\ \GT ;]%8'_",Z3_SSN__  :ZO_\ )]'_  C.D_\ /.[_ /!KJ_\ \GT
M;]%8'_",Z3_SSN__  :ZO_\ )]'_  C.D_\ /.[_ /!KJ_\ \GT ;]%8'_",
MZ3_SSN__  :ZO_\ )]7['3+33O-^RK,OG;-_FW=Y<YV;MNW[5<3[/OMG9MW<
M;LX7 !H4444 %%%% !1110 4444 %%%% 'X@?\%)_P#E))_P0I_[.M_:@_\
M6.?B#7['^+?%UIX,TFTU*\M+J\BN+J&R6.T,(D5Y+>:<.WGR1KL @93@ELLO
M&,D?CA_P4G_Y22?\$*?^SK?VH/\ UCGX@U^J7QP_Y%#2_P#L-VG_ *;]0KPN
M)<=B,MR',\?A)1AB<-AG4HSE",XQGSPC=PFG&2LWHTT-:M+NT5O^%]:#_P!
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MJ^*/BI_R/WB'_KK8_P#IKL:^UZ^*/BI_R/WB'_KK8_\ IKL:^\\6/^1!@?\
ML<4?_4+'B//J***_G\ HHHH **** +VF?\A+3O\ L(6'_I9!7Z%5^>NF?\A+
M3O\ L(6'_I9!7Z%5^V>$7\+/O^OF6_\ I.-'T7J_RB%%%%?L@@HHHH ****
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M] S7O_!->_\ QNMW ]!^0HP/0?D* ,+^WXO^@9KW_@FO?_C=']OQ?] S7O\
MP37O_P ;K=P/0?D*,#T'Y"@#"_M^+_H&:]_X)KW_ .-U?L=02^\S;:W]MY6S
M/VZRGM-^_=_J_.5?,V[?GVYVY7/WA5[ ]!^0I< = !0 4444 %%%% !1110
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M?H57[9X1?PL^_P"OF6_^DXT?1>K_ "B%%%%?L@@HHHH **** "BBB@ HHHH
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MS7T9UBV589+2R@57-A?$2![:&.0D!67:6*D-DC*@U^8'_!2?_E))_P $*?\
MLZW]J#_UCGX@U^J7QP_Y%#2_^PW:?^F_4*^7XU_Y)7._^P-_^G*8X[KU7YGR
MI1117\KB"BBB@ HHHH *^IO@]97]QX0+VVKS6,8U?4%\F.SL9U+ 09??<022
M MW7=M'\(%?+-?77P2_Y$MO^PUJ7_M"OT3PP_P"2G?\ V+<7_P"GL*/H_5?J
M=_\ V7J__0Q7/_@MTK_Y%KY ^)<<L/CC7HY[AKJ59;/?</'%$TA.FV; F.%$
MB7:I"_(HR%R<L23]O5\4?%3_ )'[Q#_UUL?_ $UV-?>>+'_(@P/_ &.*/_J%
MCQ'GU%%%?S^ 4444 %%%% %S3@6U"P ;:3?60#  E2;J$!@&!4E20P!!!(P0
M02*^[CI>K$G_ (J*YZ_] W2C^OV7FOA/3/\ D):=_P!A"P_]+(*_0JOVSPB_
MA9]_U\RW_P!)QH^B]7^A@?V7J_\ T,5S_P""W2O_ )%H_LO5_P#H8KG_ ,%N
ME?\ R+6_17[((P/[+U?_ *&*Y_\ !;I7_P BT?V7J_\ T,5S_P""W2O_ )%K
M?HH P/[+U?\ Z&*Y_P#!;I7_ ,BT?V7J_P#T,5S_ ."W2O\ Y%K?HH P/[+U
M?_H8KG_P6Z5_\BT?V7J__0Q7/_@MTK_Y%K?HH P/[+U?_H8KG_P6Z5_\BU?L
M;6\MO-^U:E+J&_9L\RVM+?RMN[=C[+%'OWY7._.W:-N,G.A10 4444 %%%%
M!1110 4444 %%%% 'X@?\%)_^4DG_!"G_LZW]J#_ -8Y^(-?JE\</^10TO\
M[#=I_P"F_4*_*W_@I/\ \I)/^"%/_9UO[4'_ *QS\0:_5+XX?\BAI?\ V&[3
M_P!-^H5\OQK_ ,DKG?\ V!O_ -.4QQW7JOS/E2BBBOY7$%%%% !1110 5]=?
M!+_D2V_[#6I?^T*^1:^NO@E_R);?]AK4O_:%?HGAA_R4[_[%N+_]/84?1^J_
M*1Z]7Q1\5/\ D?O$/_76Q_\ 378U]KU\4?%3_D?O$/\ UUL?_378U]YXL?\
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M?_1YG@O_ ,-Q\?\ _P"=!7\T_P!@9]_T),X_\-F-_P#E'G^?9B/U:HK\I?\
MA^'_ ,$H_P#H\SP7_P"&X^/_ /\ .@IO_#\;_@E#NV?\-G^"-X4.8_\ A77Q
M]\P(25#F/_A4.\1LRLJR%=C.K(&+*P!_8&??]"3./_#9C?\ Y1Y_GV8'ZN45
M^4O_  _#_P""4?\ T>9X+_\ #<?'_P#^=!1_P_#_ ."4?_1YG@O_ ,-Q\?\
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M-'EKZ#_OE?\ XFGT4 ,\M?0?]\K_ /$U\NZ;\,/%]M^V9XP^+\VG0+X"U?\
M9D^'7PVL=4%_8-/+XM\/_%SXJ^+-5T]M*$QU"*&#1/%&BW2W\ELME/)<O;0S
M/<6\Z1_4F1SR..#ST(Z@^F*,C&<C'KGC\Z &^6OH/^^5_P#B:/+7T'_?*_\
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M?_B:=D'H>G!]CZ4F1C.1CUSQ^= ";1_D+_\ $T;1_D+_ /$TZB@!NT?Y"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>amortizationofintang.jpg
<TEXT>
begin 644 amortizationofintang.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MFTW1?$6F?<U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDGJ37XEEV:5<M]M[*E2J.K+#S_>\[4)X:M&M3E%0G!7335_B2;2ER.<)N_\
M7W;_ '>3ZWT1^*'Q.^%?C[7_ -EW]L&Q^(7P2^/_ .T'XR^*7Q"U+Q3\!O$?
MBKX':6/CQXI\9WWP:T'PK9^,?BE\)O EWI/@#X>6/PX&D'X<_"[QI/X3\%RW
M.F65KKUYX1TSQ9%;>-O$GK7[77@S]J#XZ:EX&^)WPM^$WA7Q+X(\.^/?V<M=
M^''P]^,&K?$OX1?%OP)XDT?]IGP1XG^+GQ"\8?#M?A=XRTZ)[CPEX7TW1[+6
MW\2PZMX,^$,7CG5='T#6-9\:76F7?ZIF-" I1"H.0"H(!]0,8S2A5 "A0 .@
M   P<C Z#!Y^O-=']N5E5HU5AZ/-0JSJ4XMU/90C.GA:4J<*<)0]C&4,)!25
M%TX-5*\(PC2J*G _K^O^#<^;/C=X@^*7BKX2?%OPO\+?"?Q%\,>/;OQEX6^#
M.G>(_L5MI,G]@>._$/P]T;X@?&SX;:C%JLT^J^#? ?@/QIXRU?2?$]U;Z-JT
M'B;P/JLD6@J^D6LM[]!:/H>A^%](TKPSX8TRVT7PSX<TVPT#PYHUF@CM-)T#
M1K6+3=&TVW0=(K'3;:VM@S%I)3&99GDFDDD;1P.>!R<G@<D8P3[C YZ\#TI:
M\J5;FI0HQA&$(U)U7RMMSE.G1IVFVW>,/92E37V'6JVTFPOT_K^O\D7M,_Y"
M6G?]A"P_]+(*_0JOSUTS_D):=_V$+#_TL@K]"J_9O"+^%GW_ %\RW_TG&AT7
MJ_RB%%%%?L@@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO++_
M ..?P5TOQ3_P@^I_%[X7Z=XU^UI8?\(???$'PC:>*#>R,$2T'A^XUF/5OM+L
M55;<V@G9F"K&2<5ZG0!^('_!2?\ Y22?\$*?^SK?VH/_ %CGX@U^J7QP_P"1
M0TO_ +#=I_Z;]0K\J/\ @I=Y_P#P\?\ ^"%GV7R//_X:L_:?\O[3YGD_\F=_
M$#=O\K]YG9NV8XW[=WR;J_43XR?VQ_PBVG?;_P"S/(_MFUV?8OMWF>9]AO\
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M>WEA<1'6+4*EKIMQ9R!_L%_AFEFU6^5D"[@4$*DL582 *5;Y?C7_ ))7._\
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M[H_UIX;_ .A]E'3_ )F&%ZV_Z>_WE^('M-%>+?\ "V]#_P"AFL/_  CM>_\
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M_!"G_LZW]J#_ -8Y^(-?JE\</^10TO\ [#=I_P"F_4*^7XU_Y)7._P#L#?\
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M.T3QC'%XF\,^'? ]UJ]S\7OB]J7B[1_ /A+Q!:>*/#7P_P#!GC?5/'-[XO\
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M\3?]>FF?^CKVOI>OZ8\.?^21RW_KYC__ %/Q(!1117W !1110 4444 %%%%
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MH#]-MZ?WE_[Z'^-&]/[R_P#?0_QKY5_X<?Z5_P!)4?\ @LQ_XFGH/_SFJ/\
MAQ_I7_25'_@LQ_XFGH/_ ,YJC_B$N;?]#3+?_ <5_P#*OZL_*X?7&F.G]I:=
M\R_\A"P_B'_/Y![U^A6]/[R_]]#_ !K\/U_X(@Z8CI(G_!5/_@LRCQNLB.O[
M:>@AD=&#HZG_ (4UD,K ,I[$ UM?\.9;W_I+7_P6H_\ $V- _P#G+U]_P3PI
MB^%X9C'%8K#XEXV6%E#ZNJJY%AXUU+G]I"/Q>V5N6_PN_2[OI;S;^^W^1^N7
MQ%=/^$&\3_,O_()N/XAZ+[U\.,Z9/S+U/\0]?K7S7-_P1?GN89;>X_X*S_\
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M?::O\1?AVFL_#SQ5I6B^)=$LO'_A:]U".,)XIB\+Q:C^WAX*A^!?P&^,>E^
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M3O!GAKQU\-O&?A+Q)\/=.U&^DN7\9:OH9/BC5M%BBT+P[KWA,WNHZG-]?T4
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*BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>anticd20.jpg
<TEXT>
begin 644 anticd20.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %N 3T# 2(  A$! Q$!_\0
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M'T'PYI^KZ=8:KX<^(^MMJ5I/K/T+HWQ<^ \LGP.U/PE\5+?^R_A]K'[4^@>
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MWJZ=IOC_ ,+6MQ=WSW&D&^EL[35]&U<:+XW\)SZKH<7C+PEX>?7M&%]0T?\
M:W^&^K?%73_A@V@_$S2(/$7CGQE\+?!7Q)U[P!JVC_"[QU\4?A[IVOZMXR\!
M>%O%%W(MW=:OI-CX1\7R66J:CHFE^$?%4WA3Q'8^"O$WB2^TBZM@ ?4M%%%
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M^QS#_P!1\0?A/TF_^3">*'_9-U+?^%F$/Y/Z***_U?/\!0HHHH **** "O[
M_P#@B#<VT/[%+":X@B)^,?Q(P)98XR<1>&B<!F!. 03]1ZBOX_*_K]_X(B:=
M87?[%3/<V5I<./C'\1P&GMH)F \GPT,!I(V(& ._8#H!C^;OI3_\FPC_ -E'
ME7W>QQWZV_$_M+Z!W_)\*O\ V1N>_P#J5E1^Q'V^Q_Y_;3_P)A_^+H^WV/\
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M<RSR_P"HCS_!B_XG7^C]:_\ K+FUN_\ JUG5NG7ZKZ_=ZV_JN^WV/_/[:?\
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MA_\ BZK?V)H__0*TW_P L_\ XS1_8FC_ /0*TW_P L__ (S7PA^J%G[?8_\
M/[:?^!,/_P 71]OL?^?VT_\  F'_ .+JBFE:#(9533M*8POY<H%E9'RWV))L
M?$/RMY<D;[6P=DB-C:ZDR#1=&(S_ &5IN.O.GV@_,& $?C0!:^WV/_/[:?\
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M7?P]_FX@_P##GA_+_J7>7X^M_KC_ (71X)_OZU_X*#_\ET?\+H\$_P!_6O\
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M_83\!_\ JJ_ M?V_-T/T/\J_A6_X*X>.?".D_P#!0_\ :.T_4M?L;.^MM4\
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M.03TR3DG R>!0/\ @K#_ ,$]USC]H721D[CCP%\4AEN!N./ W)P ,GG@4?\
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MXJU]7P-_R5N1?]AJ_P#350^+\1/^2)XC_P"Q?+_T[2/XB:***_K4_B,****
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MFTQ]9C>/RTV.EZ'0HNUAM7'H/^?7^=%% 'X@?\%)_P#E))_P0I_[.M_:@_\
M6.?B#7BG_!RK_P F2?"#_LYSPE_ZJ_XJU[7_ ,%)_P#E))_P0I_[.M_:@_\
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MK^;/$O\ Y++-/^O>7_\ JOPI_67A)_R0>3_]?<S_ /5IC HHHKX,_20HHHH
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MP7QA_P#0_#-?FOBO_P DI_W5,%_Z;Q1^L^"__)9_]TC'?^GL&?N2UWXAP?\
MB2V/0_\ ,<;T_P"P/7^>1_P6J:=O^"G7[4S7$20S'6?AQOCCF,Z*!\&OAT$*
MRF* MN0*YS$I4L4^;;N/^BJW0_0_RK_.P_X+8_\ *3_]JC_L,?#;_P!4O\.*
M_/\ PA_Y*+'_ /8EK_\ J=EY^G>.?_)+99_V/\/_ .J[,S\KZ***_HH_E@**
M** "BBB@#O\ X3EA\5?A:5 9A\4/AJ54G:&8>._#NT%L-M!. 3@X!)P<8/\
MJA_:M?#2"/2+%T$LP1SK3(742N%;:=)8KN&#M))&<$FO\K[X2_\ )5_A7_V5
M'X:?^I[X=K_5<C^Z?]^3_P!&-7X5XR?QL@_P9G^>7G]&^ W\#B;_ *^Y5_Z1
MCS\W?^"K=QK$G_!./]LM;K3+2WB_X4-XQW21ZHUPP!%F&Q%_9L&2J%W ,BAM
MNS*E@P_SB)?];+_UT?\ ]"-?Z1O_  5E_P"4;W[9G_9!O&?_ **M:_S<IO\
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M8_\ [$M?_P!3LO/T[QS_ .26RS_L?X?_ -5V9GY7T445_11_+ 4444 %%%%
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M)*G]8P>783#5O9R<7*'M:-&$^23C%RCS6DXIM-I'XK?\,/?\%A3_ ,YQ8O\
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M>_L9)!&@6XM9DFCP2C G(_,D_P#!I_\ $EB2?^"J?B?)))_XPO\ A5U)R?\
MFJ%?V345>"SG-\MISI9?FF88&E4G[2=/"8S$8>$ZEHQYY1HU(*4N6,5S--VB
ME>R1GC\BR3-:D*V9Y/EF8UJ</9TZN.P&%Q=2%/F<_9PG7I5)1AS-RY4U&[;M
MJ[_QL?\ $)]\2/\ I*GXG_\ $+_A5_\ /0H_XA/OB1_TE3\3_P#B%_PJ_P#G
MH5_9/17;_K5Q-_T4.=_^'3&__+O)?<<'^IW"7_1+\/?^&;+O_F?R_/NS^'+X
ME?\ !LM\3OA_X_\ V>/!$7_!3;Q#JL?QT^*7B;X<W&I2?L??"^T?PS%X?^!G
MQ=^,::O!:I\1ITU22[G^&$/AYK.::SCAAUJ741.\MC':W/LW_$)]\2/^DJ?B
M?_Q"_P"%7_ST*_K]U_P1X6\4:UX(\1:]H]OJ.M?#?Q%?^+/!-_-+=)+X?\0Z
MIX0\3> K_4[5()XH9IKGPCXQ\2Z(\=Y'<VZV^K3RI"EW';7$'54?ZU<3?]%#
MG?\ X=,;_P#+O)?<'^IW"7_1+\/_ /AFR_R_ZA_+\^[O_&Q_Q"??$C_I*GXG
M_P#$+_A5_P#/0H_XA/OB1_TE3\3_ /B%_P *O_GH5_9/11_K5Q-_T4.=_P#A
MTQO_ ,N\E]P?ZG<)?]$OP]_X9LN_^9_+\^[/YA_V5O\ @@U^VS^Q5JGC36OV
M<O\ @L/J7@S4?B#IVAZ5XKGU3]@'X$>+5U"Q\.7>IWVCQ0Q>(?B'>Q636USK
M&H.\EJL;SB95F++%&%_:']D#X&_MB_!I_'Y_:O\ VYD_;+3Q"/#(\"HO[,7P
MN_9T_P"%>'2_[<_X2,EOAOK.KGQ=_P )3]OT; UC[/\ V'_81^P^;_:EUL^U
MZ*\C%8O%8ZO/$XW$U\7B*BBIU\35J5ZTU"*A!2J5)2G)0A&,(IM\L8J*LDD>
MU@\%@\NP\,)@,)AL%A:;FZ>&PE"GAZ$'4FZDW"C1C"G%SG*4YN,5S3E*4KR;
M;****YSJ"BBB@ HHHH **** "BBB@ HHHH *IZAJ%CI-C>ZIJEY:Z=ING6ES
M?ZA?WT\5K965E9P27-W>7=S,R0V]K:V\4L]Q/*Z10PQO)(RHI(N5GZM+J$&E
MZE-I-C;ZGJD5A>2Z;IMY?'3+74+^.VE>SLKG419ZB;"WN[E8K>:]%A?&TBD:
MX^QW7E^1( ?(&B?M[_LYZOHOB37KS6?&_A.QT/P=HGQ&TF'QQ\*_B-X0U;X@
M_#[Q3X@TWPCX3\7?"[0M:\-V^M_$.Q\4>+M;T#PMHNE>&]/N_%$WB#Q-X2TR
MY\/VD_B[PP-7GUC]O']G#PK\,M8^)WCCQ1KO@*U\.^/K'X5^(/!/C+P7XIT3
MXIZ3\1]1M= U2U\(2_#6739?%5[J$GAOQ/H7C4WVDV.HZ GP_OU\?R:RG@Z"
M[UNW^/-'_9W_ &P?C#%XZ\=?'CX>_"_P;^T ;SX&>./ /BC3_C5<^/\ X4Z'
M/\!OCOX3^./A_P#9]\.>%].^$OA/Q+X9^&OB76_#"R^._BKJUQXI\?\ BSQ#
M+I_BB_T&+3/"/@/P%X5E^,_[-_[5GB[X3_M2:EX?^%WPKU'XO?M=^)_ UMJ7
M@^7XXZCH_@_X0>!OAEX'\(^%_#MQ)XRG^$MU/XZ\5^(;OPYJMYXC?3?".@6U
MK::UH>@Q7>KV?A1-2U  ^Z_BQ^UO\'_@WXNO/!GBR?QG=ZEX=\)Z7\0/B'?>
M$_A[XR\8:!\)_A[KFH^(M*T;QS\4=?\ #^D7NF>#/#6IWWA'Q5]ENK^>2[_L
M[PUX@UZ:QA\/:)J>K6OTT"& (.0>01T([$'N#U!'!'(XK\8?VEOV,_V@/VE_
M%US\4M=^'W@72O'_ (D^$GA;P9\/+BT_:0\>^#XOV7/&/A_Q/XC\77.K>(M,
M\$?#>7PG^U[X/N?&"^"/'MMX/^+&B7'AE+W1-1\"1^$--T'Q+XG\2ZQ^R>G0
MWEO86<&H7:7]_#:V\=[?1VRV27EVD*+<W:6:2S+:+=3B2=;99IEMQ((5ED5
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M[!;G0;_Q?#?^%]3@U?PCI^I7.O\ AXR:4?$%CIG]M:4+O\]-3_8T^-%I\/\
MXE?#3X6^ ?A7\/\ P)^U+^S#\-?V=O'_ (<U[XH>(O%%Y^S5%X.\'^.OAKK.
MK^$=43P%+<?'.UOOA[XU-QIMMJ^I> ]0D^(^C3:WKFI7MGXUUS4M%]Q\)>"?
MVE=#_;8USQ\WP4\ 6?P*O_A/X7^!UGXPC^.SWWC9=+\&>./B1XZ@^(%[X#D^
M%\27-YXDD\8V.G7FC/XS?4(+]-0U6\U.]#J)0#V_X(?M4^%_CAXT\7^ -/\
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M?,OQ._:U^#OPQU[X<>$I]5U'QKXN^*VA>+?%W@GPM\-[*W\9ZUJ_@GP-HO\
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MX3L?$OPR\8V.@106.J6T-]IMGXG^#GPUUJUM]4COA!>^%;-XBJW6I)>^W44
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MVBM+99[Z_GN;Z\F6"&,2W5Y<3W5S(&FN9I9I))&OT44 %%%% !1110 4444
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M%^E>%OB9KWA_P5^QS9:M\2?&?Q!\5^9XL^.W[<WB#0K'17UBY?P].O@CX2^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>avonex.jpg
<TEXT>
begin 644 avonex.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !5 .(# 2(  A$! Q$!_\0
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M0JJ.PJ6N&M5=27,Q-B8HI:*R$(.E+2#I6=X@U-='T.ZO6(!B0E<]V[4TFW9
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M*** $'2O./BUJVV"TTN-N7/G2 >@X'ZYKT?M7.:OX$TK6]0>\O?/:5@!Q)@
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M&JS<?$;48,7;>'[A=-)XF?()'KTQ6TJ4IPAR]@/0**Q7\5Z:GAO^V_,)M2.
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>benepalia04.jpg
<TEXT>
begin 644 benepalia04.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  2     $  0!(     0 !_^'BCVAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI
M2'IR95-Z3E1C>FMC.60B/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N-BUC,30U(#<Y
M+C$V,S0Y.2P@,C Q."\P."\Q,RTQ-CHT,#HR,B @(" @(" @(CX-"@D\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@T*"0D\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U
M=#TB(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(@
M>&UL;G,Z>&UP1TEM9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O
M:6UG+R(@>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O<U1Y<&4O4F5S;W5R8V52968C(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN
M<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O
M<B\Q+C O(B!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]T+W!G+R(@>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(@>&UL;G,Z>&UP1STB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(B!X;6QN<SIP9&8](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&1F+S$N,R\B/@T*"0D)/&1C.F9O<FUA=#YI;6%G92]J
M<&5G/"]D8SIF;W)M870^#0H)"0D\9&,Z=&ET;&4^#0H)"0D)/')D9CI!;'0^
M#0H)"0D)"3QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^4')I;G0\+W)D
M9CIL:3X-"@D)"0D\+W)D9CI!;'0^#0H)"0D\+V1C.G1I=&QE/@T*"0D)/'AM
M<#I-971A9&%T841A=&4^,C Q,RTP,RTQ.50Q-CHT,SHQ,RLP-3HS,#PO>&UP
M.DUE=&%D871A1&%T93X-"@D)"3QX;7 Z36]D:69Y1&%T93XR,#$X+3$R+3$T
M5#$S.C0P.C$U6CPO>&UP.DUO9&EF>41A=&4^#0H)"0D\>&UP.D-R96%T941A
M=&4^,C Q."TQ,BTQ-%0P.#HT,#HQ-2TP-3HP,#PO>&UP.D-R96%T941A=&4^
M#0H)"0D\>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A=&]R($-#(#(S
M+C @*$UA8VEN=&]S:"D\+WAM<#I#<F5A=&]R5&]O;#X-"@D)"3QX;7 Z5&AU
M;6)N86EL<SX-"@D)"0D\<F1F.D%L=#X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D\>&UP1TEM9SIW:61T:#XR-38\
M+WAM<$=);6<Z=VED=&@^#0H)"0D)"0D\>&UP1TEM9SIH96EG:'0^,C4V/"]X
M;7!'26UG.FAE:6=H=#X-"@D)"0D)"3QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X
M;7!'26UG.F9O<FUA=#X-"@D)"0D)"3QX;7!'26UG.FEM86=E/B\Y:B\T04%1
M4VM:2E)G04)!9T5!4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311
M:VQ.02LP04%!04%!0D%!4T%!04%!14$-"D%10DE!04%!05%!0B\K-$%$:T9K
M8C)*;$%'5$%!04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="
M9V=,1$%O2T-W;TL-"D1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B
M1WAS8TAX.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8-
M"DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF
M2'@X9DAX.&9(>#AF2'@X9B\X04%%46="04%%04%W15(-"D%!25)!44U2068O
M14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!
M06=)1$%114)!445!04%!04%!04$-"D%104-!=U%&0F=C24-1;TQ%04%#05%-
M1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-<$=H
M0GA7>%%I4$(-"E5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.55%N:S9/
M>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O4$4-"C%/
M5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T95AP-V9(,2MF
M,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5H-"G%B;DHR96XU2VIP2U=M
M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-1&)114%!:$5$0D-%
M4TU514954DYH26=:>&=:17D-"F]B2'=&34A2-%-.0T962FEC=D5Z2D121&=H
M85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:2FI:1D=I9&MD1E4S.'%/
M>G=Y9W -"C K4'IH2E-K=$U453504FQD65=6<&)81C%E6#%2;%IM9&]A5W!R
M8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\-"BM$;$I7
M5VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM<7$V>71R<2MV+V%!07=$05%!0T51
M35)!1#A!.54T<3=&6%EQ-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T8-"EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1E@-"EEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%D-"G$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T8-
M"EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@-"EEQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%D-"G$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3<-"D98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T8-"EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1E@-"EEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%D-"G$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$-"C=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T8-"EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1E@-"EEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%D-"G$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T8-
M"EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@-"EEQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%D-"G$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$-"C=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3<-"D98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T8-"EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1E@-"EEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%D-"G$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$-"C=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3<-"D9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T8-"EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1E@-"EEQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%D-"G$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E@O+S)1/3T\+WAM<$=);6<Z:6UA
M9V4^#0H)"0D)"3PO<F1F.FQI/@T*"0D)"3PO<F1F.D%L=#X-"@D)"3PO>&UP
M.E1H=6UB;F%I;',^#0H)"0D\>&UP34TZ26YS=&%N8V5)1#YU=6ED.F0Q8S W
M.&$P+3(W-#8M-#)B,BUB,&0Q+3(U865D9F8X9F(Q93PO>&UP34TZ26YS=&%N
M8V5)1#X-"@D)"3QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,6(V-CDP960M
M,CAA."UC,30Q+3DT-SDM8C9A.6-F-F)E-C4Q/"]X;7!-33I$;V-U;65N=$E$
M/@T*"0D)/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T
M.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^#0H)"0D\>&UP34TZ4F5N9&ET:6]N0VQA<W,^<')O;V8Z<&1F/"]X
M;7!-33I296YD:71I;VY#;&%S<SX-"@D)"3QX;7!-33I$97)I=F5D1G)O;2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)/'-T4F5F.FEN<W1A;F-E
M240^=75I9#HV.64V-C,Q,2TW,3<Q+69C-&4M86$Y,"TY.#(V93)D-V$P83,\
M+W-T4F5F.FEN<W1A;F-E240^#0H)"0D)/'-T4F5F.F1O8W5M96YT240^>&UP
M+F1I9#HS-&9D.#4V9BTQ.&$S+30S,38M8F,W,"TW.65C93<X9CAE,3@\+W-T
M4F5F.F1O8W5M96YT240^#0H)"0D)/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#YU=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E
M9CIO<FEG:6YA;$1O8W5M96YT240^#0H)"0D)/'-T4F5F.G)E;F1I=&EO;D-L
M87-S/G!R;V]F.G!D9CPO<W12968Z<F5N9&ET:6]N0VQA<W,^#0H)"0D\+WAM
M<$U-.D1E<FEV961&<F]M/@T*"0D)/'AM<$U-.DAI<W1O<GD^#0H)"0D)/')D
M9CI397$^#0H)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@T*"0D)"0D)/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO
M;CX-"@D)"0D)"3QS=$5V=#IP87)A;7,^9G)O;2!A<'!L:6-A=&EO;B]P9&8@
M=&\@)FQT.W5N:VYO=VXF9W0[/"]S=$5V=#IP87)A;7,^#0H)"0D)"3PO<F1F
M.FQI/@T*"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-
M"@D)"0D)"3QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX-"@D)
M"0D)"3QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1#(W1C$Q-S0P-S(P-C@Q
M,3DQ,#DY0S-"-C Q0S0U-#@\+W-T179T.FEN<W1A;F-E240^#0H)"0D)"0D\
M<W1%=G0Z=VAE;CXR,# X+3 T+3$W5#$T.C$Y.C$U*S U.C,P/"]S=$5V=#IW
M:&5N/@T*"0D)"0D)/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T
M<F%T;W(@0U,T/"]S=$5V=#IS;V9T=V%R94%G96YT/@T*"0D)"0D)/'-T179T
M.F-H86YG960^#0H)"0D)"0D)/')D9CI"86<^#0H)"0D)"0D)"3QR9&8Z;&D^
M+SPO<F1F.FQI/@T*"0D)"0D)"3PO<F1F.D)A9SX-"@D)"0D)"3PO<W1%=G0Z
M8VAA;F=E9#X-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)"3QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'-T179T.F%C=&EO;CYC;VYV
M97)T960\+W-T179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V=#IP87)A;7,^9G)O
M;2!A<'!L:6-A=&EO;B]P9&8@=&\@)FQT.W5N:VYO=VXF9W0[/"]S=$5V=#IP
M87)A;7,^#0H)"0D)"3PO<F1F.FQI/@T*"0D)"0D\<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS=$5V=#IA8W1I;VX^8V]N=F5R
M=&5D/"]S=$5V=#IA8W1I;VX^#0H)"0D)"0D\<W1%=G0Z<&%R86US/F9R;VT@
M87!P;&EC871I;VXO<&1F('1O("9L=#MU;FMN;W=N)F=T.SPO<W1%=G0Z<&%R
M86US/@T*"0D)"0D\+W)D9CIL:3X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^#0H)"0D)"0D\<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^#0H)"0D)"0D\<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.D8Y-T8Q,3<T,#<R,#8X,3$X1#1%1#(T-D(S041",4,V/"]S=$5V=#II;G-T
M86YC94E$/@T*"0D)"0D)/'-T179T.G=H96X^,C P."TP-2TQ-50Q-CHR,SHP
M-BTP-SHP,#PO<W1%=G0Z=VAE;CX-"@D)"0D)"3QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-3-#PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X-"@D)"0D)"3QS=$5V=#IC:&%N9V5D/@T*"0D)"0D)"3QR9&8Z0F%G/@T*
M"0D)"0D)"0D\<F1F.FQI/B\\+W)D9CIL:3X-"@D)"0D)"0D\+W)D9CI"86<^
M#0H)"0D)"0D\+W-T179T.F-H86YG960^#0H)"0D)"3PO<F1F.FQI/@T*"0D)
M"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z1D$W1C$Q-S0P-S(P-C@Q,3A$-$5$,C0V
M0C-!1$(Q0S8\+W-T179T.FEN<W1A;F-E240^#0H)"0D)"0D\<W1%=G0Z=VAE
M;CXR,# X+3 U+3$U5#$W.C$P.C0U+3 W.C P/"]S=$5V=#IW:&5N/@T*"0D)
M"0D)/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,T
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@T*"0D)"0D)/'-T179T.F-H86YG960^
M#0H)"0D)"0D)/')D9CI"86<^#0H)"0D)"0D)"3QR9&8Z;&D^+SPO<F1F.FQI
M/@T*"0D)"0D)"3PO<F1F.D)A9SX-"@D)"0D)"3PO<W1%=G0Z8VAA;F=E9#X-
M"@D)"0D)/"]R9&8Z;&D^#0H)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@T*"0D)"0D)/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@T*"0D)"0D)/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I%1C=&
M,3$W-# W,C V.#$Q030V0T$T-3$Y1#(T,S4V0CPO<W1%=G0Z:6YS=&%N8V5)
M1#X-"@D)"0D)"3QS=$5V=#IW:&5N/C(P,#@M,#4M,354,C(Z-3,Z,S,M,#<Z
M,# \+W-T179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!);&QU<W1R871O<B!#4S0\+W-T179T.G-O9G1W87)E06=E;G0^#0H)
M"0D)"0D\<W1%=G0Z8VAA;F=E9#X-"@D)"0D)"0D\<F1F.D)A9SX-"@D)"0D)
M"0D)/')D9CIL:3XO/"]R9&8Z;&D^#0H)"0D)"0D)/"]R9&8Z0F%G/@T*"0D)
M"0D)/"]S=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D9CIL:3X-"@D)"0D)/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D\<W1%=G0Z
M86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^#0H)"0D)"0D\<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.D8P-T8Q,3<T,#<R,#8X,3%!-#9#030U,3E$,C0S
M-39"/"]S=$5V=#II;G-T86YC94E$/@T*"0D)"0D)/'-T179T.G=H96X^,C P
M."TP-2TQ-50R,SHP-SHP-RTP-SHP,#PO<W1%=G0Z=VAE;CX-"@D)"0D)"3QS
M=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-#PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X-"@D)"0D)"3QS=$5V=#IC:&%N9V5D/@T*"0D)
M"0D)"3QR9&8Z0F%G/@T*"0D)"0D)"0D\<F1F.FQI/B\\+W)D9CIL:3X-"@D)
M"0D)"0D\+W)D9CI"86<^#0H)"0D)"0D\+W-T179T.F-H86YG960^#0H)"0D)
M"3PO<F1F.FQI/@T*"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX-"@D)"0D)"3QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX-"@D)"0D)"3QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z1C<W1C$Q-S0P
M-S(P-C@Q,4)$1$1&1#,X1#!#1C(T1$0\+W-T179T.FEN<W1A;F-E240^#0H)
M"0D)"0D\<W1%=G0Z=VAE;CXR,# X+3 U+3$V5#$P.C,U.C0S+3 W.C P/"]S
M=$5V=#IW:&5N/@T*"0D)"0D)/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M26QL=7-T<F%T;W(@0U,T/"]S=$5V=#IS;V9T=V%R94%G96YT/@T*"0D)"0D)
M/'-T179T.F-H86YG960^#0H)"0D)"0D)/')D9CI"86<^#0H)"0D)"0D)"3QR
M9&8Z;&D^+SPO<F1F.FQI/@T*"0D)"0D)"3PO<F1F.D)A9SX-"@D)"0D)"3PO
M<W1%=G0Z8VAA;F=E9#X-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)"3QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'-T179T.F%C=&EO
M;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V=#IP87)A
M;7,^9G)O;2!A<'!L:6-A=&EO;B]P9&8@=&\@)FQT.W5N:VYO=VXF9W0[/"]S
M=$5V=#IP87)A;7,^#0H)"0D)"3PO<F1F.FQI/@T*"0D)"0D\<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z1CDW1C$Q-S0P-S(P-C@Q,4)$1$1&1#,X1#!#1C(T1$0\+W-T
M179T.FEN<W1A;F-E240^#0H)"0D)"0D\<W1%=G0Z=VAE;CXR,# X+3 U+3$V
M5#$P.C0P.C4Y+3 W.C P/"]S=$5V=#IW:&5N/@T*"0D)"0D)/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,T/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@T*"0D)"0D)/'-T179T.F-H86YG960^#0H)"0D)"0D)/')D
M9CI"86<^#0H)"0D)"0D)"3QR9&8Z;&D^+SPO<F1F.FQI/@T*"0D)"0D)"3PO
M<F1F.D)A9SX-"@D)"0D)"3PO<W1%=G0Z8VAA;F=E9#X-"@D)"0D)/"]R9&8Z
M;&D^#0H)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*
M"0D)"0D)/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX-
M"@D)"0D)"3QS=$5V=#IP87)A;7,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N:6QL=7-T<F%T;W(@=&\@)FQT.W5N:VYO=VXF9W0[/"]S=$5V=#IP87)A
M;7,^#0H)"0D)"3PO<F1F.FQI/@T*"0D)"0D\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M1D$W1C$Q-S0P-S(P-C@Q,4)$1$1&1#,X1#!#1C(T1$0\+W-T179T.FEN<W1A
M;F-E240^#0H)"0D)"0D\<W1%=G0Z=VAE;CXR,# X+3 U+3$V5#$Q.C(V.C4U
M+3 W.C P/"]S=$5V=#IW:&5N/@T*"0D)"0D)/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@26QL=7-T<F%T;W(@0U,T/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@T*"0D)"0D)/'-T179T.F-H86YG960^#0H)"0D)"0D)/')D9CI"86<^#0H)
M"0D)"0D)"3QR9&8Z;&D^+SPO<F1F.FQI/@T*"0D)"0D)"3PO<F1F.D)A9SX-
M"@D)"0D)"3PO<W1%=G0Z8VAA;F=E9#X-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)
M"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@T*"0D)"0D)/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#I&0C=&,3$W-# W,C V.#$Q0D1$1$9$,SA$
M,$-&,C1$1#PO<W1%=G0Z:6YS=&%N8V5)1#X-"@D)"0D)"3QS=$5V=#IW:&5N
M/C(P,#@M,#4M,394,3$Z,CDZ,#$M,#<Z,# \+W-T179T.G=H96X^#0H)"0D)
M"0D\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S0\
M+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)"0D\<W1%=G0Z8VAA;F=E9#X-
M"@D)"0D)"0D\<F1F.D)A9SX-"@D)"0D)"0D)/')D9CIL:3XO/"]R9&8Z;&D^
M#0H)"0D)"0D)/"]R9&8Z0F%G/@T*"0D)"0D)/"]S=$5V=#IC:&%N9V5D/@T*
M"0D)"0D\+W)D9CIL:3X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^#0H)"0D)"0D\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^#0H)"0D)"0D\<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D9#-T8Q
M,3<T,#<R,#8X,3%"1$1$1D0S.$0P0T8R-$1$/"]S=$5V=#II;G-T86YC94E$
M/@T*"0D)"0D)/'-T179T.G=H96X^,C P."TP-2TQ-E0Q,3HR.3HR,"TP-SHP
M,#PO<W1%=G0Z=VAE;CX-"@D)"0D)"3QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E($EL;'5S=')A=&]R($-3-#PO<W1%=G0Z<V]F='=A<F5!9V5N=#X-"@D)
M"0D)"3QS=$5V=#IC:&%N9V5D/@T*"0D)"0D)"3QR9&8Z0F%G/@T*"0D)"0D)
M"0D\<F1F.FQI/B\\+W)D9CIL:3X-"@D)"0D)"0D\+W)D9CI"86<^#0H)"0D)
M"0D\+W-T179T.F-H86YG960^#0H)"0D)"3PO<F1F.FQI/@T*"0D)"0D\<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS=$5V=#IA
M8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z1D0W1C$Q-S0P-S(P-C@Q,4)$1$1&1#,X1#!#1C(T
M1$0\+W-T179T.FEN<W1A;F-E240^#0H)"0D)"0D\<W1%=G0Z=VAE;CXR,# X
M+3 U+3$V5#$Q.C,P.C4T+3 W.C P/"]S=$5V=#IW:&5N/@T*"0D)"0D)/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,T/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@T*"0D)"0D)/'-T179T.F-H86YG960^#0H)"0D)
M"0D)/')D9CI"86<^#0H)"0D)"0D)"3QR9&8Z;&D^+SPO<F1F.FQI/@T*"0D)
M"0D)"3PO<F1F.D)A9SX-"@D)"0D)"3PO<W1%=G0Z8VAA;F=E9#X-"@D)"0D)
M/"]R9&8Z;&D^#0H)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@T*"0D)"0D)/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N
M/@T*"0D)"0D)/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I&13=&,3$W-# W
M,C V.#$Q0D1$1$9$,SA$,$-&,C1$1#PO<W1%=G0Z:6YS=&%N8V5)1#X-"@D)
M"0D)"3QS=$5V=#IW:&5N/C(P,#@M,#4M,394,3$Z,S$Z,C(M,#<Z,# \+W-T
M179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!)
M;&QU<W1R871O<B!#4S0\+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)"0D\
M<W1%=G0Z8VAA;F=E9#X-"@D)"0D)"0D\<F1F.D)A9SX-"@D)"0D)"0D)/')D
M9CIL:3XO/"]R9&8Z;&D^#0H)"0D)"0D)/"]R9&8Z0F%G/@T*"0D)"0D)/"]S
M=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D9CIL:3X-"@D)"0D)/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D\<W1%=G0Z86-T:6]N
M/G-A=F5D/"]S=$5V=#IA8W1I;VX^#0H)"0D)"0D\<W1%=G0Z:6YS=&%N8V5)
M1#YX;7 N:6ED.D(R,S,V-CA#,38R,#8X,3%"1$1$1D0S.$0P0T8R-$1$/"]S
M=$5V=#II;G-T86YC94E$/@T*"0D)"0D)/'-T179T.G=H96X^,C P."TP-2TQ
M-E0Q,CHR,SHT-BTP-SHP,#PO<W1%=G0Z=VAE;CX-"@D)"0D)"3QS=$5V=#IS
M;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-#PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X-"@D)"0D)"3QS=$5V=#IC:&%N9V5D/@T*"0D)"0D)"3QR
M9&8Z0F%G/@T*"0D)"0D)"0D\<F1F.FQI/B\\+W)D9CIL:3X-"@D)"0D)"0D\
M+W)D9CI"86<^#0H)"0D)"0D\+W-T179T.F-H86YG960^#0H)"0D)"3PO<F1F
M.FQI/@T*"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-
M"@D)"0D)"3QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX-"@D)
M"0D)"3QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z0C,S,S8V.$,Q-C(P-C@Q
M,4)$1$1&1#,X1#!#1C(T1$0\+W-T179T.FEN<W1A;F-E240^#0H)"0D)"0D\
M<W1%=G0Z=VAE;CXR,# X+3 U+3$V5#$S.C(W.C4T+3 W.C P/"]S=$5V=#IW
M:&5N/@T*"0D)"0D)/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T
M<F%T;W(@0U,T/"]S=$5V=#IS;V9T=V%R94%G96YT/@T*"0D)"0D)/'-T179T
M.F-H86YG960^#0H)"0D)"0D)/')D9CI"86<^#0H)"0D)"0D)"3QR9&8Z;&D^
M+SPO<F1F.FQI/@T*"0D)"0D)"3PO<F1F.D)A9SX-"@D)"0D)"3PO<W1%=G0Z
M8VAA;F=E9#X-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)"3QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@T*"0D)"0D)/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#I"-#,S-C8X0S$V,C V.#$Q0D1$1$9$,SA$,$-&,C1$1#PO<W1%=G0Z
M:6YS=&%N8V5)1#X-"@D)"0D)"3QS=$5V=#IW:&5N/C(P,#@M,#4M,394,3,Z
M-#8Z,3,M,#<Z,# \+W-T179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S0\+W-T179T.G-O9G1W87)E
M06=E;G0^#0H)"0D)"0D\<W1%=G0Z8VAA;F=E9#X-"@D)"0D)"0D\<F1F.D)A
M9SX-"@D)"0D)"0D)/')D9CIL:3XO/"]R9&8Z;&D^#0H)"0D)"0D)/"]R9&8Z
M0F%G/@T*"0D)"0D)/"]S=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D9CIL:3X-
M"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)
M"0D\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^#0H)"0D)"0D\
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D8W-T8Q,3<T,#<R,#8X,3$Y-T,Q
M0D8Q-$0Q-S4Y13@S/"]S=$5V=#II;G-T86YC94E$/@T*"0D)"0D)/'-T179T
M.G=H96X^,C P."TP-2TQ-E0Q-3HT-SHU-RTP-SHP,#PO<W1%=G0Z=VAE;CX-
M"@D)"0D)"3QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R
M($-3-#PO<W1%=G0Z<V]F='=A<F5!9V5N=#X-"@D)"0D)"3QS=$5V=#IC:&%N
M9V5D/@T*"0D)"0D)"3QR9&8Z0F%G/@T*"0D)"0D)"0D\<F1F.FQI/B\\+W)D
M9CIL:3X-"@D)"0D)"0D\+W)D9CI"86<^#0H)"0D)"0D\+W-T179T.F-H86YG
M960^#0H)"0D)"3PO<F1F.FQI/@T*"0D)"0D\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS=$5V=#IA8W1I;VX^<V%V960\+W-T
M179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M1C@W1C$Q-S0P-S(P-C@Q,3DW0S%"1C$T1#$W-3E%.#,\+W-T179T.FEN<W1A
M;F-E240^#0H)"0D)"0D\<W1%=G0Z=VAE;CXR,# X+3 U+3$V5#$U.C4Q.C V
M+3 W.C P/"]S=$5V=#IW:&5N/@T*"0D)"0D)/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@26QL=7-T<F%T;W(@0U,T/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@T*"0D)"0D)/'-T179T.F-H86YG960^#0H)"0D)"0D)/')D9CI"86<^#0H)
M"0D)"0D)"3QR9&8Z;&D^+SPO<F1F.FQI/@T*"0D)"0D)"3PO<F1F.D)A9SX-
M"@D)"0D)"3PO<W1%=G0Z8VAA;F=E9#X-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)
M"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@T*"0D)"0D)/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#I&.3=&,3$W-# W,C V.#$Q.3=#,4)&,31$
M,3<U.44X,SPO<W1%=G0Z:6YS=&%N8V5)1#X-"@D)"0D)"3QS=$5V=#IW:&5N
M/C(P,#@M,#4M,394,34Z-3(Z,C(M,#<Z,# \+W-T179T.G=H96X^#0H)"0D)
M"0D\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S0\
M+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)"0D\<W1%=G0Z8VAA;F=E9#X-
M"@D)"0D)"0D\<F1F.D)A9SX-"@D)"0D)"0D)/')D9CIL:3XO/"]R9&8Z;&D^
M#0H)"0D)"0D)/"]R9&8Z0F%G/@T*"0D)"0D)/"]S=$5V=#IC:&%N9V5D/@T*
M"0D)"0D\+W)D9CIL:3X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^#0H)"0D)"0D\<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%
M=G0Z86-T:6]N/@T*"0D)"0D)/'-T179T.G!A<F%M<SYF<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YI;&QU<W1R871O<B!T;R!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N:6QL=7-T<F%T;W(\+W-T179T.G!A<F%M<SX-"@D)"0D)/"]R9&8Z
M;&D^#0H)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*
M"0D)"0D)/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@T*"0D)
M"0D)/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I&03=&,3$W-# W,C V.#$Q
M0C8R.$4S0D8R-T,X0S0Q0CPO<W1%=G0Z:6YS=&%N8V5)1#X-"@D)"0D)"3QS
M=$5V=#IW:&5N/C(P,#@M,#4M,C)4,3,Z,C@Z,#$M,#<Z,# \+W-T179T.G=H
M96X^#0H)"0D)"0D\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R
M871O<B!#4S0\+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)"0D\<W1%=G0Z
M8VAA;F=E9#X-"@D)"0D)"0D\<F1F.D)A9SX-"@D)"0D)"0D)/')D9CIL:3XO
M/"]R9&8Z;&D^#0H)"0D)"0D)/"]R9&8Z0F%G/@T*"0D)"0D)/"]S=$5V=#IC
M:&%N9V5D/@T*"0D)"0D\+W)D9CIL:3X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D\<W1%=G0Z86-T:6]N/F-O;G9E
M<G1E9#PO<W1%=G0Z86-T:6]N/@T*"0D)"0D)/'-T179T.G!A<F%M<SYF<F]M
M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YI;&QU<W1R871O<B!T;R!A<'!L:6-A
M=&EO;B]V;F0N861O8F4N:6QL=7-T<F%T;W(\+W-T179T.G!A<F%M<SX-"@D)
M"0D)/"]R9&8Z;&D^#0H)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@T*"0D)"0D)/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T
M:6]N/@T*"0D)"0D)/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I&1C=&,3$W
M-# W,C V.#$Q0C8R.$4S0D8R-T,X0S0Q0CPO<W1%=G0Z:6YS=&%N8V5)1#X-
M"@D)"0D)"3QS=$5V=#IW:&5N/C(P,#@M,#4M,C)4,38Z,C,Z-3,M,#<Z,# \
M+W-T179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B
M92!);&QU<W1R871O<B!#4S0\+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)
M"0D\<W1%=G0Z8VAA;F=E9#X-"@D)"0D)"0D\<F1F.D)A9SX-"@D)"0D)"0D)
M/')D9CIL:3XO/"]R9&8Z;&D^#0H)"0D)"0D)/"]R9&8Z0F%G/@T*"0D)"0D)
M/"]S=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D9CIL:3X-"@D)"0D)/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D\<W1%=G0Z86-T
M:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@T*"0D)"0D)/'-T179T.G!A
M<F%M<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YI;&QU<W1R871O<B!T
M;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N:6QL=7-T<F%T;W(\+W-T179T.G!A
M<F%M<SX-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@T*"0D)"0D)/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#HP-T,S0D0R-3$P,D1$1#$Q.#%"-3DT,#<P0T5".#A$.3PO<W1%=G0Z:6YS
M=&%N8V5)1#X-"@D)"0D)"3QS=$5V=#IW:&5N/C(P,#@M,#4M,CA4,38Z-#4Z
M,C8M,#<Z,# \+W-T179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S0\+W-T179T.G-O9G1W87)E06=E
M;G0^#0H)"0D)"0D\<W1%=G0Z8VAA;F=E9#X-"@D)"0D)"0D\<F1F.D)A9SX-
M"@D)"0D)"0D)/')D9CIL:3XO/"]R9&8Z;&D^#0H)"0D)"0D)/"]R9&8Z0F%G
M/@T*"0D)"0D)/"]S=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D9CIL:3X-"@D)
M"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D\
M<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@T*"0D)"0D)
M/'-T179T.G!A<F%M<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YI;&QU
M<W1R871O<B!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N:6QL=7-T<F%T;W(\
M+W-T179T.G!A<F%M<SX-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)"3QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@T*"0D)"0D)/'-T179T.FEN<W1A;F-E
M240^>&UP+FEI9#I&.#=&,3$W-# W,C V.#$Q.3 Y.$(P.3=&1$$S.4)%1CPO
M<W1%=G0Z:6YS=&%N8V5)1#X-"@D)"0D)"3QS=$5V=#IW:&5N/C(P,#@M,#8M
M,#)4,3,Z,C4Z,C4M,#<Z,# \+W-T179T.G=H96X^#0H)"0D)"0D\<W1%=G0Z
M<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S0\+W-T179T.G-O
M9G1W87)E06=E;G0^#0H)"0D)"0D\<W1%=G0Z8VAA;F=E9#X-"@D)"0D)"0D\
M<F1F.D)A9SX-"@D)"0D)"0D)/')D9CIL:3XO/"]R9&8Z;&D^#0H)"0D)"0D)
M/"]R9&8Z0F%G/@T*"0D)"0D)/"]S=$5V=#IC:&%N9V5D/@T*"0D)"0D\+W)D
M9CIL:3X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M#0H)"0D)"0D\<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^#0H)
M"0D)"0D\<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D8W-T8Q,3<T,#<R,#8X
M,3%"0C%$0D8X1C(T,D(V1C@T/"]S=$5V=#II;G-T86YC94E$/@T*"0D)"0D)
M/'-T179T.G=H96X^,C P."TP-BTP.50Q-#HU.#HS-BTP-SHP,#PO<W1%=G0Z
M=VAE;CX-"@D)"0D)"3QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S
M=')A=&]R($-3-#PO<W1%=G0Z<V]F='=A<F5!9V5N=#X-"@D)"0D)"3QS=$5V
M=#IC:&%N9V5D/@T*"0D)"0D)"3QR9&8Z0F%G/@T*"0D)"0D)"0D\<F1F.FQI
M/B\\+W)D9CIL:3X-"@D)"0D)"0D\+W)D9CI"86<^#0H)"0D)"0D\+W-T179T
M.F-H86YG960^#0H)"0D)"3PO<F1F.FQI/@T*"0D)"0D\<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z1CDW1C$Q-S0P-S(P-C@Q,4%#049".$1!.# X-31%-S8\+W-T179T
M.FEN<W1A;F-E240^#0H)"0D)"0D\<W1%=G0Z=VAE;CXR,# X+3 V+3$Q5#$T
M.C,Q.C(W+3 W.C P/"]S=$5V=#IW:&5N/@T*"0D)"0D)/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,T/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@T*"0D)"0D)/'-T179T.F-H86YG960^#0H)"0D)"0D)/')D9CI"
M86<^#0H)"0D)"0D)"3QR9&8Z;&D^+SPO<F1F.FQI/@T*"0D)"0D)"3PO<F1F
M.D)A9SX-"@D)"0D)"3PO<W1%=G0Z8VAA;F=E9#X-"@D)"0D)/"]R9&8Z;&D^
M#0H)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)
M"0D)/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@T*"0D)"0D)
M/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HP,3@P,3$W-# W,C V.#$Q.#,T
M,S@S0T0S03A$,C,P,SPO<W1%=G0Z:6YS=&%N8V5)1#X-"@D)"0D)"3QS=$5V
M=#IW:&5N/C(P,#@M,#8M,3%4,C(Z,S<Z,S4M,#<Z,# \+W-T179T.G=H96X^
M#0H)"0D)"0D\<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O
M<B!#4S0\+W-T179T.G-O9G1W87)E06=E;G0^#0H)"0D)"0D\<W1%=G0Z8VAA
M;F=E9#X-"@D)"0D)"0D\<F1F.D)A9SX-"@D)"0D)"0D)/')D9CIL:3XO/"]R
M9&8Z;&D^#0H)"0D)"0D)/"]R9&8Z0F%G/@T*"0D)"0D)/"]S=$5V=#IC:&%N
M9V5D/@T*"0D)"0D\+W)D9CIL:3X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^#0H)"0D)"0D\<W1%=G0Z86-T:6]N/G-A=F5D/"]S
M=$5V=#IA8W1I;VX^#0H)"0D)"0D\<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED
M.D8W-T8Q,3<T,#<R,#8X,3$X,3A#.#5$1C9!,4$W-4,S/"]S=$5V=#II;G-T
M86YC94E$/@T*"0D)"0D)/'-T179T.G=H96X^,C P."TP-BTR-U0Q-#HT,#HT
M,BTP-SHP,#PO<W1%=G0Z=VAE;CX-"@D)"0D)"3QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R($-3-#PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X-"@D)"0D)"3QS=$5V=#IC:&%N9V5D/@T*"0D)"0D)"3QR9&8Z0F%G/@T*
M"0D)"0D)"0D\<F1F.FQI/B\\+W)D9CIL:3X-"@D)"0D)"0D\+W)D9CI"86<^
M#0H)"0D)"0D\+W-T179T.F-H86YG960^#0H)"0D)"3PO<F1F.FQI/@T*"0D)
M"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"3QS
M=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX-"@D)"0D)"3QS=$5V
M=#II;G-T86YC94E$/GAM<"YI:60Z,#4X,#$Q-S0P-S(P-C@Q,3DQ,#DX.4,R
M038S,C5"0C4\+W-T179T.FEN<W1A;F-E240^#0H)"0D)"0D\<W1%=G0Z=VAE
M;CXR,# Y+3$Q+3(V5#$W.C(U.C,V*S U.C,P/"]S=$5V=#IW:&5N/@T*"0D)
M"0D)/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,U
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@T*"0D)"0D)/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)"3QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@T*"0D)"0D)/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#HQ8C8V.3!E9"TR.&$X+6,Q-#$M.30W.2UB-F$Y8V8V
M8F4V-3$\+W-T179T.FEN<W1A;F-E240^#0H)"0D)"0D\<W1%=G0Z=VAE;CXR
M,#$S+3 S+3$Y5#$V.C0S.C$R*S U.C,P/"]S=$5V=#IW:&5N/@T*"0D)"0D)
M/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0T,@*%=I
M;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@T*"0D)"0D)/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X-"@D)"0D)/"]R9&8Z;&D^#0H)"0D)
M/"]R9&8Z4V5Q/@T*"0D)/"]X;7!-33I(:7-T;W)Y/@T*"0D)/&EL;'5S=')A
M=&]R.E1Y<&4^1&]C=6UE;G0\+VEL;'5S=')A=&]R.E1Y<&4^#0H)"0D\:6QL
M=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^4')I;G0\+VEL;'5S=')A=&]R.E-T
M87)T=7!0<F]F:6QE/@T*"0D)/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X-"@D)"3QX;7!4
M4&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA<U9I
M<VEB;&54<F%N<W!A<F5N8WD^#0H)"0D\>&UP5%!G.DY086=E<SXQ/"]X;7!4
M4&<Z3E!A9V5S/@T*"0D)/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^#0H)"0D)/'-T1&EM.G<^-C$R+C P,# P,#PO<W1$
M:6TZ=SX-"@D)"0D\<W1$:6TZ:#XW.3(N,# P,# P/"]S=$1I;3IH/@T*"0D)
M"3QS=$1I;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X-"@D)"3PO>&UP5%!G
M.DUA>%!A9V53:7IE/@T*"0D)/'AM<%109SI3=V%T8VA'<F]U<',^#0H)"0D)
M/')D9CI397$^#0H)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@T*"0D)"0D)/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R
M;W5P/"]X;7!'.F=R;W5P3F%M93X-"@D)"0D)"3QX;7!'.F=R;W5P5'EP93XP
M/"]X;7!'.F=R;W5P5'EP93X-"@D)"0D)"3QX;7!'.D-O;&]R86YT<SX-"@D)
M"0D)"0D\<F1F.E-E<3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/E=H:71E
M/"]X;7!'.G-W871C:$YA;64^#0H)"0D)"0D)"0D\>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM
M86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX-"@D)"0D)"0D)"3QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T
M8VA.86UE/D)L86-K/"]X;7!'.G-W871C:$YA;64^#0H)"0D)"0D)"0D\>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXP+C P
M,# P,#PO>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XP+C P
M,# P,#PO>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX-"@D)"0D)"0D)"3QX;7!'.F)L86-K/C$P
M,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)"3PO<F1F.FQI/@T*"0D)
M"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)
M"0D)"3QX;7!'.G-W871C:$YA;64^0TU92R!2960\+WAM<$<Z<W=A=&-H3F%M
M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)
M"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)
M"0D\>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\
M>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X-"@D)"0D)
M"0D)"3QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX-"@D)
M"0D)"0D)"3QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@T*"0D)
M"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/D--64L@
M665L;&]W/"]X;7!'.G-W871C:$YA;64^#0H)"0D)"0D)"0D\>&UP1SIM;V1E
M/D--64L\+WAM<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXP+C P,# P,#PO
M>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XP+C P,# P,#PO
M>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W/C$P,"XP,# P
M,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,"XP,# P
M,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)"3PO<F1F.FQI/@T*"0D)"0D)"0D\
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"0D)"3QX
M;7!'.G-W871C:$YA;64^0TU92R!'<F5E;CPO>&UP1SIS=V%T8VA.86UE/@T*
M"0D)"0D)"0D)/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^#0H)"0D)"0D)
M"0D\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X-"@D)"0D)"0D)"3QX
M;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)
M/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)
M"0D)/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)
M"3PO<F1F.FQI/@T*"0D)"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX-"@D)"0D)"0D)"3QX;7!'.G-W871C:$YA;64^0TU92R!#>6%N
M/"]X;7!'.G-W871C:$YA;64^#0H)"0D)"0D)"0D\>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'
M.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'
M.FUA9V5N=&$^#0H)"0D)"0D)"0D\>&UP1SIY96QL;W<^,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM
M<$<Z8FQA8VL^#0H)"0D)"0D)"3PO<F1F.FQI/@T*"0D)"0D)"0D\<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"0D)"3QX;7!'.G-W
M871C:$YA;64^0TU92R!";'5E/"]X;7!'.G-W871C:$YA;64^#0H)"0D)"0D)
M"0D\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA
M;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E
M;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X-"@D)"0D)"0D)"3QX;7!'
M.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP
M1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX-"@D)"0D)"0D)/"]R9&8Z
M;&D^#0H)"0D)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@T*"0D)"0D)"0D)/'AM<$<Z<W=A=&-H3F%M93Y#35E+($UA9V5N=&$\+WAM
M<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^
M#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X-"@D)"0D)"0D)"3QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY
M96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB
M;&%C:SX-"@D)"0D)"0D)/"]R9&8Z;&D^#0H)"0D)"0D)"3QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)"0D)/'AM<$<Z<W=A=&-H
M3F%M93Y#/3$U($T],3 P(%D].3 @2STQ,#PO>&UP1SIS=V%T8VA.86UE/@T*
M"0D)"0D)"0D)/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^#0H)"0D)"0D)
M"0D\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X-"@D)"0D)"0D)"3QX
M;7!'.F-Y86X^,34N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP
M1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X-"@D)"0D)"0D)
M"3QX;7!'.GEE;&QO=SXY,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)
M"0D)/'AM<$<Z8FQA8VL^,3 N,# P,# P/"]X;7!'.F)L86-K/@T*"0D)"0D)
M"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/D,],"!-/3DP
M(%D].#4@2STP/"]X;7!'.G-W871C:$YA;64^#0H)"0D)"0D)"0D\>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y<&4^4%)/
M0T534SPO>&UP1SIT>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXP+C P,# P
M,#PO>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XY,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X-"@D)"0D)"0D)"3QX;7!'.GEE;&QO=SXX-2XP
M,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,"XP
M,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)"3PO<F1F.FQI/@T*"0D)"0D)
M"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"0D)
M"3QX;7!'.G-W871C:$YA;64^0STP($T].# @63TY-2!+/3 \+WAM<$<Z<W=A
M=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)
M"0D)"0D)"0D\>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)
M"0D)"0D\>&UP1SIM86=E;G1A/C@P+C P,# P,#PO>&UP1SIM86=E;G1A/@T*
M"0D)"0D)"0D)/'AM<$<Z>65L;&]W/CDU+C P,# P,#PO>&UP1SIY96QL;W<^
M#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX-
M"@D)"0D)"0D)/"]R9&8Z;&D^#0H)"0D)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E
M5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)"0D)/'AM<$<Z<W=A=&-H3F%M93Y#
M/3 @33TU,"!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)
M"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N
M/C N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A
M/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L
M;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z
M8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)"3PO<F1F.FQI
M/@T*"0D)"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-
M"@D)"0D)"0D)"3QX;7!'.G-W871C:$YA;64^0STP($T],S4@63TX-2!+/3 \
M+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y
M86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C,U+C P,# P,#PO>&UP1SIM
M86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W/C@U+C P,# P,#PO>&UP
M1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP
M1SIB;&%C:SX-"@D)"0D)"0D)/"]R9&8Z;&D^#0H)"0D)"0D)"3QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)"0D)/'AM<$<Z<W=A
M=&-H3F%M93Y#/34@33TP(%D].3 @2STP/"]X;7!'.G-W871C:$YA;64^#0H)
M"0D)"0D)"0D\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X-"@D)"0D)"0D)
M"3QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@T*"0D)"0D)"0D)/'AM
M<$<Z8WEA;CXU+C P,# P,#PO>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM<$<Z
M;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM
M<$<Z>65L;&]W/CDP+C P,# P,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\
M>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX-"@D)"0D)"0D)/"]R
M9&8Z;&D^#0H)"0D)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@T*"0D)"0D)"0D)/'AM<$<Z<W=A=&-H3F%M93Y#/3(P($T],"!9/3$P
M,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C(P+C P,# P,#PO
M>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XP+C P,# P,#PO
M>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W/C$P,"XP,# P
M,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,"XP,# P
M,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)"3PO<F1F.FQI/@T*"0D)"0D)"0D\
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"0D)"3QX
M;7!'.G-W871C:$YA;64^0STU,"!-/3 @63TQ,# @2STP/"]X;7!'.G-W871C
M:$YA;64^#0H)"0D)"0D)"0D\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X-
M"@D)"0D)"0D)"3QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@T*"0D)
M"0D)"0D)/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX-"@D)"0D)
M"0D)"3QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X-"@D)
M"0D)"0D)"3QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX-
M"@D)"0D)"0D)"3QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@T*
M"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/D,]
M-S4@33TP(%D],3 P($L],#PO>&UP1SIS=V%T8VA.86UE/@T*"0D)"0D)"0D)
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^#0H)"0D)"0D)"0D\>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X-"@D)"0D)"0D)"3QX;7!'.F-Y86X^
M-S4N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A
M/C N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)"0D)"0D)"0D\>&UP1SIY96QL
M;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB
M;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX-"@D)"0D)"0D)/"]R9&8Z;&D^
M#0H)"0D)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*
M"0D)"0D)"0D)/'AM<$<Z<W=A=&-H3F%M93Y#/3@U($T],3 @63TQ,# @2STQ
M,#PO>&UP1SIS=V%T8VA.86UE/@T*"0D)"0D)"0D)/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^#0H)"0D)"0D)"0D\>&UP1SIT>7!E/E!23T-%4U,\+WAM
M<$<Z='EP93X-"@D)"0D)"0D)"3QX;7!'.F-Y86X^.#4N,# P,# P/"]X;7!'
M.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C$P+C P,# P,#PO>&UP
M1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,3 N,# P,# P
M/"]X;7!'.F)L86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP
M1SIS=V%T8VA.86UE/D,].3 @33TS,"!9/3DU($L],S \+WAM<$<Z<W=A=&-H
M3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*
M"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)
M"0D)"0D\>&UP1SIC>6%N/CDP+C P,# P,#PO>&UP1SIC>6%N/@T*"0D)"0D)
M"0D)/'AM<$<Z;6%G96YT83XS,"XP,# P,# \+WAM<$<Z;6%G96YT83X-"@D)
M"0D)"0D)"3QX;7!'.GEE;&QO=SXY-2XP,# P,# \+WAM<$<Z>65L;&]W/@T*
M"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,S N,# P,# P/"]X;7!'.F)L86-K/@T*
M"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/D,]
M-S4@33TP(%D]-S4@2STP/"]X;7!'.G-W871C:$YA;64^#0H)"0D)"0D)"0D\
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXW
M-2XP,# P,# \+WAM<$<Z8WEA;CX-"@D)"0D)"0D)"3QX;7!'.FUA9V5N=&$^
M,"XP,# P,# \+WAM<$<Z;6%G96YT83X-"@D)"0D)"0D)"3QX;7!'.GEE;&QO
M=SXW-2XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA
M8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)"3PO<F1F.FQI/@T*
M"0D)"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)
M"0D)"0D)"3QX;7!'.G-W871C:$YA;64^0STX,"!-/3$P(%D]-#4@2STP/"]X
M;7!'.G-W871C:$YA;64^#0H)"0D)"0D)"0D\>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT
M>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXX,"XP,# P,# \+WAM<$<Z8WEA
M;CX-"@D)"0D)"0D)"3QX;7!'.FUA9V5N=&$^,3 N,# P,# P/"]X;7!'.FUA
M9V5N=&$^#0H)"0D)"0D)"0D\>&UP1SIY96QL;W<^-#4N,# P,# P/"]X;7!'
M.GEE;&QO=SX-"@D)"0D)"0D)"3QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T
M8VA.86UE/D,]-S @33TQ-2!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^#0H)
M"0D)"0D)"0D\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X-"@D)"0D)"0D)
M"3QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@T*"0D)"0D)"0D)/'AM
M<$<Z8WEA;CXW,"XP,# P,# \+WAM<$<Z8WEA;CX-"@D)"0D)"0D)"3QX;7!'
M.FUA9V5N=&$^,34N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)"0D)"0D)"0D\
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)"3PO
M<F1F.FQI/@T*"0D)"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX-"@D)"0D)"0D)"3QX;7!'.G-W871C:$YA;64^0STX-2!-/34P(%D]
M,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C@U+C P,# P,#PO
M>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XU,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X-"@D)"0D)"0D)"3QX;7!'.GEE;&QO=SXP+C P,# P
M,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX-"@D)"0D)"0D)/"]R9&8Z;&D^#0H)"0D)"0D)"3QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)"0D)/'AM
M<$<Z<W=A=&-H3F%M93Y#/3$P,"!-/3DU(%D]-2!+/3 \+WAM<$<Z<W=A=&-H
M3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*
M"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)
M"0D)"0D\>&UP1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX-"@D)"0D)
M"0D)"3QX;7!'.FUA9V5N=&$^.34N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)
M"0D)"0D)"0D\>&UP1SIY96QL;W<^-2XP,# P,# \+WAM<$<Z>65L;&]W/@T*
M"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)
M"0D)"0D)"3PO<F1F.FQI/@T*"0D)"0D)"0D\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX-"@D)"0D)"0D)"3QX;7!'.G-W871C:$YA;64^0STQ
M,# @33TQ,# @63TR-2!+/3(U/"]X;7!'.G-W871C:$YA;64^#0H)"0D)"0D)
M"0D\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA
M;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E
M;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X-"@D)"0D)"0D)"3QX;7!'
M.GEE;&QO=SXR-2XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM
M<$<Z8FQA8VL^,C4N,# P,# P/"]X;7!'.F)L86-K/@T*"0D)"0D)"0D\+W)D
M9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/D,]-S4@33TQ,# @63TP
M($L],#PO>&UP1SIS=V%T8VA.86UE/@T*"0D)"0D)"0D)/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^#0H)"0D)"0D)"0D\>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X-"@D)"0D)"0D)"3QX;7!'.F-Y86X^-S4N,# P,# P/"]X
M;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C$P,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X-"@D)"0D)"0D)"3QX;7!'.GEE;&QO=SXP+C P,# P
M,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX-"@D)"0D)"0D)/"]R9&8Z;&D^#0H)"0D)"0D)"3QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)"0D)/'AM
M<$<Z<W=A=&-H3F%M93Y#/34P($T],3 P(%D],"!+/3 \+WAM<$<Z<W=A=&-H
M3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*
M"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)
M"0D)"0D\>&UP1SIC>6%N/C4P+C P,# P,#PO>&UP1SIC>6%N/@T*"0D)"0D)
M"0D)/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)
M"0D)"0D)"0D\>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*
M"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)
M"0D)"0D)"3PO<F1F.FQI/@T*"0D)"0D)"0D\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX-"@D)"0D)"0D)"3QX;7!'.G-W871C:$YA;64^0STS
M-2!-/3$P,"!9/3,U($L],3 \+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)
M"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N
M/C,U+C P,# P,#PO>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT
M83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)"0D)"0D)"0D\>&UP1SIY
M96QL;W<^,S4N,# P,# P/"]X;7!'.GEE;&QO=SX-"@D)"0D)"0D)"3QX;7!'
M.F)L86-K/C$P+C P,# P,#PO>&UP1SIB;&%C:SX-"@D)"0D)"0D)/"]R9&8Z
M;&D^#0H)"0D)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@T*"0D)"0D)"0D)/'AM<$<Z<W=A=&-H3F%M93Y#/3$P($T],3 P(%D]-3 @
M2STP/"]X;7!'.G-W871C:$YA;64^#0H)"0D)"0D)"0D\>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXQ,"XP,# P,# \+WAM
M<$<Z8WEA;CX-"@D)"0D)"0D)"3QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO
M>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W/C4P+C P,# P
M,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXP+C P,# P
M,#PO>&UP1SIB;&%C:SX-"@D)"0D)"0D)/"]R9&8Z;&D^#0H)"0D)"0D)"3QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)"0D)/'AM
M<$<Z<W=A=&-H3F%M93Y#/3 @33TY-2!9/3(P($L],#PO>&UP1SIS=V%T8VA.
M86UE/@T*"0D)"0D)"0D)/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^#0H)
M"0D)"0D)"0D\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X-"@D)"0D)
M"0D)"3QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX-"@D)"0D)"0D)
M"3QX;7!'.FUA9V5N=&$^.34N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)"0D)
M"0D)"0D\>&UP1SIY96QL;W<^,C N,# P,# P/"]X;7!'.GEE;&QO=SX-"@D)
M"0D)"0D)"3QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@T*"0D)
M"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/D,],C4@
M33TR-2!9/30P($L],#PO>&UP1SIS=V%T8VA.86UE/@T*"0D)"0D)"0D)/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^#0H)"0D)"0D)"0D\>&UP1SIT>7!E
M/E!23T-%4U,\+WAM<$<Z='EP93X-"@D)"0D)"0D)"3QX;7!'.F-Y86X^,C4N
M,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C(U
M+C P,# P,#PO>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W
M/C0P+C P,# P,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX-"@D)"0D)"0D)/"]R9&8Z;&D^#0H)
M"0D)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)
M"0D)"0D)/'AM<$<Z<W=A=&-H3F%M93Y#/30P($T]-#4@63TU,"!+/34\+WAM
M<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP
M1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y
M<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C0P+C P,# P,#PO>&UP1SIC>6%N
M/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XT-2XP,# P,# \+WAM<$<Z;6%G
M96YT83X-"@D)"0D)"0D)"3QX;7!'.GEE;&QO=SXU,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^-2XP,# P,# \+WAM<$<Z
M8FQA8VL^#0H)"0D)"0D)"3PO<F1F.FQI/@T*"0D)"0D)"0D\<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)"0D)"3QX;7!'.G-W871C
M:$YA;64^0STU,"!-/34P(%D]-C @2STR-3PO>&UP1SIS=V%T8VA.86UE/@T*
M"0D)"0D)"0D)/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^#0H)"0D)"0D)
M"0D\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X-"@D)"0D)"0D)"3QX
M;7!'.F-Y86X^-3 N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP
M1SIM86=E;G1A/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)
M/'AM<$<Z>65L;&]W/C8P+C P,# P,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)
M"0D\>&UP1SIB;&%C:SXR-2XP,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)
M"3PO<F1F.FQI/@T*"0D)"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX-"@D)"0D)"0D)"3QX;7!'.G-W871C:$YA;64^0STU-2!-/38P
M(%D]-C4@2STT,#PO>&UP1SIS=V%T8VA.86UE/@T*"0D)"0D)"0D)/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^#0H)"0D)"0D)"0D\>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X-"@D)"0D)"0D)"3QX;7!'.F-Y86X^-34N,# P
M,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C8P+C P
M,# P,#PO>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W/C8U
M+C P,# P,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXT
M,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)"3PO<F1F.FQI/@T*"0D)
M"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX-"@D)"0D)
M"0D)"3QX;7!'.G-W871C:$YA;64^0STR-2!-/30P(%D]-C4@2STP/"]X;7!'
M.G-W871C:$YA;64^#0H)"0D)"0D)"0D\>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXR-2XP,# P,# \+WAM<$<Z8WEA;CX-
M"@D)"0D)"0D)"3QX;7!'.FUA9V5N=&$^-# N,# P,# P/"]X;7!'.FUA9V5N
M=&$^#0H)"0D)"0D)"0D\>&UP1SIY96QL;W<^-C4N,# P,# P/"]X;7!'.GEE
M;&QO=SX-"@D)"0D)"0D)"3QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L
M86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.
M86UE/D,],S @33TU,"!9/3<U($L],3 \+WAM<$<Z<W=A=&-H3F%M93X-"@D)
M"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP
M1SIC>6%N/C,P+C P,# P,#PO>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM<$<Z
M;6%G96YT83XU,"XP,# P,# \+WAM<$<Z;6%G96YT83X-"@D)"0D)"0D)"3QX
M;7!'.GEE;&QO=SXW-2XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)
M/'AM<$<Z8FQA8VL^,3 N,# P,# P/"]X;7!'.F)L86-K/@T*"0D)"0D)"0D\
M+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/D,],S4@33TV,"!9
M/3@P($L],C4\+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C,U+C P,# P
M,#PO>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XV,"XP,# P
M,# \+WAM<$<Z;6%G96YT83X-"@D)"0D)"0D)"3QX;7!'.GEE;&QO=SXX,"XP
M,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,C4N
M,# P,# P/"]X;7!'.F)L86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)
M"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D)
M"0D\>&UP1SIS=V%T8VA.86UE/D,]-# @33TV-2!9/3DP($L],S4\+WAM<$<Z
M<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C0P+C P,# P,#PO>&UP1SIC>6%N/@T*
M"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XV-2XP,# P,# \+WAM<$<Z;6%G96YT
M83X-"@D)"0D)"0D)"3QX;7!'.GEE;&QO=SXY,"XP,# P,# \+WAM<$<Z>65L
M;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,S4N,# P,# P/"]X;7!'.F)L
M86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.
M86UE/D,]-# @33TW,"!9/3$P,"!+/34P/"]X;7!'.G-W871C:$YA;64^#0H)
M"0D)"0D)"0D\>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X-"@D)"0D)"0D)
M"3QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@T*"0D)"0D)"0D)/'AM
M<$<Z8WEA;CXT,"XP,# P,# \+WAM<$<Z8WEA;CX-"@D)"0D)"0D)"3QX;7!'
M.FUA9V5N=&$^-S N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)"0D)"0D)"0D\
M>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)
M"0D\>&UP1SIB;&%C:SXU,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)
M"3PO<F1F.FQI/@T*"0D)"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX-"@D)"0D)"0D)"3QX;7!'.G-W871C:$YA;64^0STU,"!-/3<P
M(%D].# @2STW,#PO>&UP1SIS=V%T8VA.86UE/@T*"0D)"0D)"0D)/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^#0H)"0D)"0D)"0D\>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X-"@D)"0D)"0D)"3QX;7!'.F-Y86X^-3 N,# P
M,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C<P+C P
M,# P,#PO>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W/C@P
M+C P,# P,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXW
M,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)"3PO<F1F.FQI/@T*"0D)
M"0D)"3PO<F1F.E-E<3X-"@D)"0D)"3PO>&UP1SI#;VQO<F%N=',^#0H)"0D)
M"3PO<F1F.FQI/@T*"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX-"@D)"0D)"3QX;7!'.F=R;W5P3F%M93Y'<F%Y<SPO>&UP1SIG<F]U
M<$YA;64^#0H)"0D)"0D\>&UP1SIG<F]U<%1Y<&4^,3PO>&UP1SIG<F]U<%1Y
M<&4^#0H)"0D)"0D\>&UP1SI#;VQO<F%N=',^#0H)"0D)"0D)/')D9CI397$^
M#0H)"0D)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*
M"0D)"0D)"0D)/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3$P,#PO
M>&UP1SIS=V%T8VA.86UE/@T*"0D)"0D)"0D)/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^#0H)"0D)"0D)"0D\>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X-"@D)"0D)"0D)"3QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA
M;CX-"@D)"0D)"0D)"3QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X-"@D)"0D)"0D)"3QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY
M96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXQ,# N,# P,# P/"]X;7!'
M.F)L86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T
M8VA.86UE/D,],"!-/3 @63TP($L].3 \+WAM<$<Z<W=A=&-H3F%M93X-"@D)
M"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP
M1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM
M86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)"0D)"0D)"0D\>&UP
M1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM
M<$<Z8FQA8VL^.#DN.3DY-# P/"]X;7!'.F)L86-K/@T*"0D)"0D)"0D\+W)D
M9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]
M.# \+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C N,# P,# P/"]X;7!'
M.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'
M.FUA9V5N=&$^#0H)"0D)"0D)"0D\>&UP1SIY96QL;W<^,"XP,# P,# \+WAM
M<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^-SDN.3DX.# P/"]X
M;7!'.F)L86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS
M=V%T8VA.86UE/D,],"!-/3 @63TP($L]-S \+WAM<$<Z<W=A=&-H3F%M93X-
M"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)
M"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\
M>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP
M1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)"0D)"0D)"0D\
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)
M/'AM<$<Z8FQA8VL^-CDN.3DY-S P/"]X;7!'.F)L86-K/@T*"0D)"0D)"0D\
M+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP
M($L]-C \+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C N,# P,# P/"]X
M;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C N,# P,# P/"]X
M;7!'.FUA9V5N=&$^#0H)"0D)"0D)"0D\>&UP1SIY96QL;W<^,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^-3DN.3DY,3 P
M/"]X;7!'.F)L86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-3 \+WAM<$<Z<W=A=&-H3F%M
M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)
M"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)
M"0D\>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\
M>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)"0D)"0D)
M"0D\>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)
M"0D)/'AM<$<Z8FQA8VL^-3 N,# P,# P/"]X;7!'.F)L86-K/@T*"0D)"0D)
M"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @
M63TP($L]-# \+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C N,# P,# P
M/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C N,# P,# P
M/"]X;7!'.FUA9V5N=&$^#0H)"0D)"0D)"0D\>&UP1SIY96QL;W<^,"XP,# P
M,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,SDN.3DY
M-# P/"]X;7!'.F)L86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D)"0D\
M>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L],S \+WAM<$<Z<W=A=&-H
M3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*
M"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)
M"0D)"0D\>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)
M"0D\>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)"0D)
M"0D)"0D\>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)
M"0D)"0D)/'AM<$<Z8FQA8VL^,CDN.3DX.# P/"]X;7!'.F)L86-K/@T*"0D)
M"0D)"0D\+W)D9CIL:3X-"@D)"0D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^#0H)"0D)"0D)"0D\>&UP1SIS=V%T8VA.86UE/D,],"!-
M/3 @63TP($L],C \+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C N,# P
M,# P/"]X;7!'.FUA9V5N=&$^#0H)"0D)"0D)"0D\>&UP1SIY96QL;W<^,"XP
M,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)/'AM<$<Z8FQA8VL^,3DN
M.3DY-S P/"]X;7!'.F)L86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)
M"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^#0H)"0D)"0D)
M"0D\>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L],3 \+WAM<$<Z<W=A
M=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)
M"0D)"0D)"0D\>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)
M"0D)"0D\>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)
M"0D)"0D)"0D\>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*
M"0D)"0D)"0D)/'AM<$<Z8FQA8VL^.2XY.3DQ,# \+WAM<$<Z8FQA8VL^#0H)
M"0D)"0D)"3PO<F1F.FQI/@T*"0D)"0D)"0D\<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX-"@D)"0D)"0D)"3QX;7!'.G-W871C:$YA;64^0STP
M($T],"!9/3 @2STU/"]X;7!'.G-W871C:$YA;64^#0H)"0D)"0D)"0D\>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y<&4^
M4%)/0T534SPO>&UP1SIT>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXP+C P
M,# P,#PO>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XP+C P
M,# P,#PO>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W/C N
M,# P,# P/"]X;7!'.GEE;&QO=SX-"@D)"0D)"0D)"3QX;7!'.F)L86-K/C0N
M.3DX.# P/"]X;7!'.F)L86-K/@T*"0D)"0D)"0D\+W)D9CIL:3X-"@D)"0D)
M"0D\+W)D9CI397$^#0H)"0D)"0D\+WAM<$<Z0V]L;W)A;G1S/@T*"0D)"0D\
M+W)D9CIL:3X-"@D)"0D)/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^#0H)"0D)"0D\>&UP1SIG<F]U<$YA;64^0G)I9VAT<SPO>&UP1SIG<F]U
M<$YA;64^#0H)"0D)"0D\>&UP1SIG<F]U<%1Y<&4^,3PO>&UP1SIG<F]U<%1Y
M<&4^#0H)"0D)"0D\>&UP1SI#;VQO<F%N=',^#0H)"0D)"0D)/')D9CI397$^
M#0H)"0D)"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*
M"0D)"0D)"0D)/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TQ,# @63TQ,# @2STP
M/"]X;7!'.G-W871C:$YA;64^#0H)"0D)"0D)"0D\>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC
M>6%N/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'
M.FUA9V5N=&$^#0H)"0D)"0D)"0D\>&UP1SIY96QL;W<^,3 P+C P,# P,#PO
M>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXP+C P,# P,#PO
M>&UP1SIB;&%C:SX-"@D)"0D)"0D)/"]R9&8Z;&D^#0H)"0D)"0D)"3QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)"0D)/'AM<$<Z
M<W=A=&-H3F%M93Y#/3 @33TW-2!9/3$P,"!+/3 \+WAM<$<Z<W=A=&-H3F%M
M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)
M"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)
M"0D\>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\
M>&UP1SIM86=E;G1A/C<U+C P,# P,#PO>&UP1SIM86=E;G1A/@T*"0D)"0D)
M"0D)/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)
M"0D)"0D)/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)
M"0D)"3PO<F1F.FQI/@T*"0D)"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX-"@D)"0D)"0D)"3QX;7!'.G-W871C:$YA;64^0STP($T]
M,3 @63TY-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^#0H)"0D)"0D)"0D\>&UP1SIM86=E;G1A/C$P+C P
M,# P,#PO>&UP1SIM86=E;G1A/@T*"0D)"0D)"0D)/'AM<$<Z>65L;&]W/CDU
M+C P,# P,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX-"@D)"0D)"0D)/"]R9&8Z;&D^#0H)"0D)
M"0D)"3QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)
M"0D)/'AM<$<Z<W=A=&-H3F%M93Y#/3@U($T],3 @63TQ,# @2STP/"]X;7!'
M.G-W871C:$YA;64^#0H)"0D)"0D)"0D\>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X-"@D)"0D)"0D)"3QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@T*"0D)"0D)"0D)/'AM<$<Z8WEA;CXX-2XP,# P,# \+WAM<$<Z8WEA;CX-
M"@D)"0D)"0D)"3QX;7!'.FUA9V5N=&$^,3 N,# P,# P/"]X;7!'.FUA9V5N
M=&$^#0H)"0D)"0D)"0D\>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY
M96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB
M;&%C:SX-"@D)"0D)"0D)/"]R9&8Z;&D^#0H)"0D)"0D)"3QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@T*"0D)"0D)"0D)/'AM<$<Z<W=A=&-H
M3F%M93Y#/3$P,"!-/3DP(%D],"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X-"@D)
M"0D)"0D)"3QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)
M/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP
M1SIC>6%N/C$P,"XP,# P,# \+WAM<$<Z8WEA;CX-"@D)"0D)"0D)"3QX;7!'
M.FUA9V5N=&$^.3 N,# P,# P/"]X;7!'.FUA9V5N=&$^#0H)"0D)"0D)"0D\
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@T*"0D)"0D)"0D)
M/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^#0H)"0D)"0D)"3PO
M<F1F.FQI/@T*"0D)"0D)"0D\<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX-"@D)"0D)"0D)"3QX;7!'.G-W871C:$YA;64^0STV,"!-/3DP(%D]
M,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X-"@D)"0D)"0D)"3QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@T*"0D)"0D)"0D)/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^#0H)"0D)"0D)"0D\>&UP1SIC>6%N/C8P+C P,# P,#PO
M>&UP1SIC>6%N/@T*"0D)"0D)"0D)/'AM<$<Z;6%G96YT83XY,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X-"@D)"0D)"0D)"3QX;7!'.GEE;&QO=SXP+C P,S$P
M,#PO>&UP1SIY96QL;W<^#0H)"0D)"0D)"0D\>&UP1SIB;&%C:SXP+C P,S$P
M,#PO>&UP1SIB;&%C:SX-"@D)"0D)"0D)/"]R9&8Z;&D^#0H)"0D)"0D)/"]R
M9&8Z4V5Q/@T*"0D)"0D)/"]X;7!'.D-O;&]R86YT<SX-"@D)"0D)/"]R9&8Z
M;&D^#0H)"0D)/"]R9&8Z4V5Q/@T*"0D)/"]X;7!44&<Z4W=A=&-H1W)O=7!S
M/@T*"0D)/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO
M<&1F.E!R;V1U8V5R/@T*"0D\+W)D9CI$97-C<FEP=&EO;CX-"@D\+W)D9CI2
M1$8^#0H\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(#P_
M>'!A8VME="!E;F0])W<G/S[_XGT024-#7U!23T9)3$4  1( "(!P041"10(0
M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                    ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
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M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
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MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
M3['?BL\O4*W<BJP;WZO0BS %@:DD@[D  (,>@ ![.<8EE^1M5,":E9!>][L?
MDXY0 [75D?9 3[#ND.PO8:S2D0$<%:JFD L%Y*?A@_L  (,=@ ![%\6$GW5M
M1[_JG+->][I@FD=0"K4,F&9 6[ EEUTO>:P EWD<2ZFCDR$&.Z;.A#<  (,=
M@ !Z]L4&IS!M/[];H_U>_+G!H2Q0%K1AGQ1 9Z]UGEDOC:M6G-,<>*C@DT &
MAZ7KA&H  (,<@ !ZW,2=KSYM/K[AJY-?";DXJ%M0*K/,IC- A:[7I,XON:JP
MH$4<LZ@QDV<&R*5&A)8  (,<@ #F'W9P<QC0&W=+<_&Y@'@?=,RB*GCJ=:^*
M)'FR=J%Q8WI_=Z-7AGM/>)\[+WPQ>986G7TA>>CD#W2'?FC.:W6)?ANW^G9\
M?>6@RW=E?<J(W7A+?<UP+GDS?>166WH5??DZ!WKO?A(5('M4?<'B,7+PB=+,
MFG0"B&2V7W4*AQ*?1G8*A?V'?G<(A1%N\W@&A$)5/GCV@WDX^7G$@L03Q'G5
M@@O@:7&3E3C*S7*NDK^TG'/ D&R=L731CDR&$77FC'9MLG;VBL)4*G?RB2$W
M_GBRA[<2E'B+A>S>R7!UH)W),G&2G2^S G*KF>><*W/%EM6$KG3ED_AL?'8'
MD6E3(W<+COHW%7>[C/X1CW=QB3_=;&^8K W'V7"TI[JQJG'+HW^:VW+HGWJ#
M=W0/F[1K6'4UF#-2+G9!E0\V0G;ADL40M':$BTO<3F[KMXS&P7 $LENPBW$5
MK3&9OG(PJ#R"<G-=HYIJ<G2*GTQ16G64FW4UCW8EF24/_G6_BM#;;VYMPQ[%
MY6^!O16OHW"(MP28RW&;L2.!A7+)JZQII'/]IK90KW4)HGLT]'6%GK4/:G4?
MBFS:RVX;SL;%1&\IQ^2NZW AP/.7_W$GNC: NW)/L_QHZW.#KGU0"G2.JDDT
M8W3]HR@.]'2?BAS6%7\.<;;!Y7\0<LJL]'\=<\^7'W\U=-& =7]6==UH[G^(
M=O90,7_/> @TFH!9>0</6('R>3S4C'U1?'_ LGUS?'JKSGV7?'R5_GW ?(]_
M4WWS?+EGTWXW?/=/'GZ-?30SD'\2?7(.08!(?8/3 'O2AU"_!WP"AD*J07PS
MA424@7QQA&]]_GR[@[UFHGT5@R9."WUV@I@RDWWM@B4-3'[2@8/1;GJ&DAB]
M97J\D!FHH7KWCC"3#7M C&E\JGNABMUE>'P,B7)-"7QVB"$QK7S>AQX,>'V-
MA/S/\WERG.F[[WFJF@NG+7GMET&1I'H_E)A[9GJEDAQD6WLBC^=,&7N3C>$P
MW'OJC'\+PGQWA_/.LWB;I]*ZLWC4I!^E\GD5H'&0<GEJG.9Z2GG6F9%C5GI3
MEH1+/GK,D^8P(7L5DH(+*7N-AXO-KG?QLM.YL'@JKDZDZGAEJ;^/;'BYI51Y
M6GDLH31BA7FNG7%*A'HAFDLO@WI<F'(*JGK+AS;,Y'=SO?&XXW>JN*"D$'?<
MLS6.BW@GK>MX@7B;J0EAQ'DGI+=)Y7F<H6LN_'G!G4X*0GHMAO#,57<>R3ZX
M2G=1PR.C7W=WO."-RW>UML)WR'@DL2]A('BPK'M)5'DGJ/(N?7E!GV\)\'FO
MAKC&?H@8<(JS_(<S<;Z@DH9R<MJ,&X71<^YVMX5'=0M@7(3<=C5(M(2>=U4M
MQ83T>%((W(9/>6#%1H: >KBRZH6[>NJ?<X4,>QN+!X1U>U=UJH/Y>Z=?6X.<
M? E'NH-H?&DLV(.R?, (+X2J?77$$H4.A/FQJ(1<A#&>7X.S@W*)V8,L@M)T
MAX*Z@E1>48)K@?-&QX)$@9\K^X*%@6X'F(,Y@0O"K8/'CRJP,8,6C8V<R8)\
MB_>(<8( BGQS0H&HB39=-8%KB!)%U8%*AQ,K+(%XAGX'%('XA"C!5(*]F6&N
MV((-EOV;=8%ZE)V'*8$%DE%R&X"PD"U<-8"$CE1% (!HC+PJ>("$C D&HX#F
MA'W ,('MH[ZMN(% H)::5X"KG62&%( XFD5Q''_GEUI;47^VE,)$1'^ADK0I
MUW^PDA,&1'_^A#V_1(%)KC>LRX"?JDZ99( %IDN%('^.HEMP/7]$GKA:DG\8
MFX)#IG[VF2(I47[XET(%]G\_A B^D(#.N-JL$( FM#*8F7^$KV"$3G\"JI]O
M<WZWIDY9V'Z5HJE##'YWH' HWWY>FX(%MGZC@]R^%(!XP\&K@G_3OF.7['\D
MN,&#DWZ3LS5NQGY KDE917X@JG-"DWX'IS H>7WFFUX%@WXF@[JW7)%7;[&F
M-8^><.V4(8X<<A* ](S)<RYLRXN8=%17DXJ5=89 [XG@=J0F@8H[=X$#*HHD
M>;VV6(_A>5.E0XY'>9Z3'HS4>>E_^8N'>C]KUHI?>JE6JHEF>R1 "HBU>Y@E
MLHCZ>_0"VXB$?6FU28Z+@NJD#(T"@EV2 XN2@=-^UXI3@6EJS(DW@1E5NXA*
M@.,_-H>>@+HD^H?.@+@"E8<6@**T+(U-C)6BU(O+BSZ0MHIJB>A]N8DJB+1I
MO8@?AZQ4SH<^AL<^:X:8A@TD4(:VA>8"6879@9:S!8Q+EDFAPHK+E#B/G(EO
MDBU\BX@ZD#=HL(<QCFM3WX9AC.4]I86]BZ\CLX7$B[D")83*@7.R!HN%H!^@
MOHH)G5F.F(BLFH][DH=YE]IGRH9QE5M3$H68DS$\_H3WD:XC+(3LD2$!^8/E
M@5:Q-8KIJ@Z?ZXEQII:-P(@/HPUZO(;9GYUG!875G'M2:H3]F=0\=81*F#XB
MP(0PE9T!U8,G@3VPDHIRM">?0(C^L *-"8>6J[YZ H96IY=F4850H^%1QH2#
MH/0[\(/.GU\B88.4ES\!N(*-@2FP((H:OHN>O(BJN<*,;H<[M,9Y787OK^YE
MN83BJ\!11(03J.8[?X-DI3$A_X,BEOP!H((2@1FHFYKI;PB8CIAS<$&'I98\
M<6EUL)0\<HQBM9)H<[=.DI#5=.<XU(_"=?0>HY"&=H0  (IR>T6GRIF=>">7
MTI<]>("&UY4.>-UTY),->4=AZY$[><5-T(^L>E X&8Z5>LP>!H\U>PL  (C9
M?I.F[YA7@3N6T98)@,J%Z9/;@&5S[9'E@!QA!9 =?_%- 8Z8?]\W8XV!?]8=
M=XW^?_,  (=R@ "E]9<VBD"5PI3JB1^$QI+'B UR]I#-AP]@&X\3AD%,.8V6
MA94VP(Q^A1L<_(S=A68  (8[@ "E"Y8NDW&4SI/LD:.#RY'0C^)Q]H_<CC-?
M1HX6C+-+?HREBWTV*HN,BJX<CXO0BN,  (4P@ "D-)5OG,:4#9,OFE&#"I$.
ME]YQ)(\:E89>=XU:DVA*RHO?D:XUF(K%D,<<(XKRCY$  (1/@ "C@93:IBZ3
M4I*>HQF"2I!ZG_IP:(Z!G/Q=R8S#FE-*-HM&F#\U)8H6EY0;T8HLDL\  (.5
M@ "B\91IK[N2O9(QK N!JY 'J$9OQXX$I*==+8Q$H8I)IHK/GV0TM(F8G=D;
MBXF'DI\  (+]@ "BBI06N9J22)'@M5N!(X^NL/-O.(VAK+]<JHO8J5))-XI@
MIT@T4HDPHM<;-XD8DF<  (*$@ ":4J3;;H2+/*&Z;Z][69[=<-)J>YPX<?18
ME9G&<QM%;I>O=#\P<I9E=2@5_YA-=2@  (8@?FF9LJ.[=RZ*M*"D=X5ZPYW!
M=^EIY)L1>%Y7_)B;>.=$W9:">7HOZI4J>>T5II;4>=P  (4 @ "9"Z*&?\&)
MZI]]?UYZ"IR6?PUI'YGM?N!71I=Z?M!$.Y5F?MDO8I0'?N@55)5X?P@  (0$
M@ "82J%EB$J)#9YCAT1Y&)N&AE-H3IC9A816@)9SA.-#DY1DA&HNWI+_A"L5
M!Y0^A(   (,H@ "7?J!\D-V(0YU\CT)X1YJAC;UG=)?WC%A5T96!BQI"_)-[
MBC4N;)(,B=$4RI,;B4   ()L@ "6UY^PF:N'EYRYEWIWEYG?E5=FR9<ODU-5
M+Y2WD8U">Y*;D$ N#)$GD X4DI(4C48  ('.@ "61I\<HH^'&)PHG\]W%9E$
MG0UF.9:*FG14G905F$%!_Y'\ELDMM)!MEH4489$XC<@  (%+@ "5SIZQJY>&
MG9N]J$YVDIC2I/EEMI8.H==4'I.5GU%!AY&"GA M6(_IF^ 4.9"$C:P  (#@
M@ "5=9YBM/"&.YMKL2EV(IAXK49E096JJ:Y3M),JIPY!+Y$2I3HM#H]]GG84
M I ,C8<  ("+@ ",G*\T;@!^5ZM[;Q=O7:@#<"]?>:3 <4M.C*&[<F@\09\W
M<W<GS9WW="0-+Z"X<\4  ()_@ ",+*XY=D%^!JIZ=HYO *;M=O)?&J.5=VQ.
M*Z"#=_L[Z)WT>(PGA)R9>.0-.I[B>-$  ('%@ "+NJT-?EU]<ZE8??]N?*7"
M?;M>BZ)I?:)-IY]6?:@[>9S'?<8G,YM7?=X-/YTV?CL  ($A@ "+,*OJAF=\
MSZ@ZA7=MPZ2KA*)=ZZ%-@_E-$9Y#@X$[ )NT@S8FX)HU@RT-/YNU@Q$  ("3
M@ "*FZKYCH-\-*=-C0UM'J/!B[1=0:!BBH%,B9U,B8DZC9K!B.PFE)DQB/\-
M/YI<AST  ( :@ "*$*I!EL1[KJ:6E,ULF*,%DNQ<NI^AD3E,"9R%C]$Z,IG=
MCO0F6Y@_CUL-0IDGB/<  (  @ ")J*F>GR![0*7XG*ML)J)DFD9<2)[]F!A+
MH9O>EEPYXYDNE88F-I=>E-P-2I@1B/P  (  @ ")2ZDTIZ=[!:6*I+UKYZ'D
MH<Y;^)YBGR-+2ILYG3DYBIB9G*PE\Y;+F7(-2I<YB/P  (  @ ") ZCHL()Z
MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
M@ !_<KG_;6QQX;7 ;FECL;&];W%4JZWI<(!$F:I@<8TS :>3<G@>NZ;1<L$%
MO:<_<VT  (  @ !_,[D?=5!QQ[3)=8QCD;">=>E4BJRI=F)$=JD)=O RZZ8F
M=W4>Q*4P=Y(&(*4A>,4  (  @ !^^;?Q?/YQ;[.??)UC1:]G?%Y4,ZMH?%1$
M*J?"?&LRMJ35?)8>N:.U?*$&<J,V?:,  (  @ !^JK:_A))Q!;)Q@[!BQJX]
M@O%3RJHX@F9#R::6@A0R<J.D@? >I*)B@A8&MJ%_@>0  (  @ !^3+6_C#AP
MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
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MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
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M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
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MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
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MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
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MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
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M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
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M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
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M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
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M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
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M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
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MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
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M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
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M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
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M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
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M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
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M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
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M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
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M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
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M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
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M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
M>A^,'7,;:K5^O70);'EP>W3C;AU@Y76[;Z)0,G:/<1(^&G==<ETJ"W?M<T40
M/7D0<LL  (  ?;6*U7"3<[)]:W&H=,!O*7*A=:U?Z'.-=H=/3W1Z=TL]9W5/
M=_LICG6]>&D0 W;L=_   (  @ ")DVYK?*Y\4&^9?19N"W"I?5=>N'&E?7I.
M77*>?9H\BG-]?;HHW7/&?<,/H74E?9X  (  @ "(B6RDA;9[1VWCA7IM#F[_
MA0Q=QW )A()-?W$'@_\[XW';@YDH6W'_@V4/6G.A@OH  (  @ "'LFLLCKIZ
M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
M@ "'#&H"E[EYS6M8ED1KE6Q\E(%<76V)DJE,(VZ.D0\ZJF];C_8G@&\GC^P/
M '%0BB4  (  @ "&EVDDH+-Y3VI_GK1K"FN>G%%;T&RAF=Y+IVV=E](Z16Y?
MEJXG%6X)E64.IW"1B>@  (  @ "!UX&+6%UU6(%86Y=GQH%:7J%8[(%]87=(
MP8&X9!LW X(G9G$BT8,=9_@(YX2D9]\  (  >7. RWZV8.)T:'[*8U]FU'[M
M9;58%W\>9^=("W]@:?(V<'_*:[DB9X"$;,D(WX'I;)H  (  ?09_NGP-:5US
M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
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MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"__B?1!)
M0T-?4%)/1DE,10 "$H<2?;4  ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@
MA"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @    (  @ !CWH> C$59
M#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (  @    (
M@ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L
M (  @    (  @ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-
M8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K
M49@490P:4)D19;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]
M9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0
M.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (
M@ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X
M (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M
M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI
M+HZE@,X9((ZI@.L'4(P<@.   (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_F
MA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5.
M"9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (
M@ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P
M (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R
M8@<  )UL914  (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@
M$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V
M:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$
M*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (
M@ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0
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M7F"Q8&1]VF,G8S5M0F5^9>9;A&>W:'=(DFFV:N0T%VL#;0$;9VI-;B   (
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M/U,&C5]W0U9/C"MG/UE:BO)60EPKB=1$*UYNB.8PJ5\4B%(8_&!-B$D  (
M@ "3@4VXF!J%>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8
MN5\YC.T  (  @ "2]$QWH9>$[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&
ME8TOR5P3E/L865YFD'8  (  @ "16&FL4V*#GFM,5R]T\VSP6LQE&VZ07C=4
M$' C87A!K'&89( M=7*E9PD3T7/&9\<  (  <>2/RF7#7+Z"4V? 7[=SMFFA
M8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(  (  =I6.2V(J9B"
MW61R:$ERCV:,:E=BZ&B!;$-2*6I6;A= %FOK;\4L.6RE<143$FY=<0\  (
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M,5CMDR=M$5N5D8Y=[%X"C^I-OV VCGL\6V'.C7$I;V%NC4D1@F:JBF(  (
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M<&D,;S=G &JV<*%8E6Q <?)(O6VN<R(W?6[,="LD%V[A=,L+3G->=+,  (
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M,E^HF"!BVV&EEDI4A&-DE&%%*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (
M@ !X_7GN4OYM!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$
MA(#I9.T  (  >2!WLW9@6TAK]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'
M9^H<B'L%:/$$FWXI:;(  (  ?,!V?7,-8Y=JL'079=1=_'4)9_-/_'7J:>M
MN7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (  ?^]U1' %:]]I<W$Z;7U<NG)/
M;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@  (  @ !T$VU7=#=H
M2VZP=3I;HF_>=AU.!7#G=MX_/''6=XPNF7)[>!(;6''N>"($K7@9>;,  (
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M@H+-5>=52(+T62Q'RX,Y7#TXUH.A7P$GV81X82P2](:[894  (,Z9:X  (
M? -KEG^$6DY@D'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\
M ($):F(  (  ?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*
M:V<2E'^):S\  (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@V
MOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E
M<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<
M<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (
M@ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D
M (  @    (  @ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)
MAYL12W1JAL$  (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T
M"W)^C@(D+W(ACC81$7,_BO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI
M5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5
M*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (
M@ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L
M (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D
M;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\L
MP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?
M>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0
MUWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (  @    (
M@ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\
M (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9
MBS()3'LJADD  (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HD
MSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G
M7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](
MW)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (  =N0  (
M@ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0
M (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^
M;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B
M:8AH==<1XHD?=8@"1895>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4
M>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%
MB(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (  @    (
M@ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P
M (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;
M6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P9
M19ZA7-@(IY]S75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO
M7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\
MA)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (  ?8   (
M@ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\
M (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I
M<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7
M:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/
M??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z
M)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (  @    (
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M0UUA4B!V6U_]5CEF?6**6B]5@63Y7?M#/6<788\O3VA 9+$6JFEU9E0  (
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MA$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5; ?PD4AUYD?U@  (
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M2%^+6G=K8V'^7;9<>V118--,669R8\,ZS&@I9G4G0FB':)0.0VX1:/\  (
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MCDX\A'AE6U'*A!E7&%3X@[!'P%>E@UDW&5DF@RDDIEB1@T0-/&FA@Q,  (
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M%V*F8<E@263:9$Y2-V;:9J]"\6B9:.0R$&G*:LX>NFE-:_<'#705;*4  (
M?5)WDEPN9]-KFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'
M#G03<<X  (  @ !V(UB'<'AJ7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[
M==8=N&+[=CT&YW15=X0  (  @ !T\U53>2%I0EAI><=<L%LK>DY/$5V6>KQ
M5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (  @ !S_5*1@;EH8%7/@<9;X5BQ
M@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D  (  @ !S/5!#BCEG
MKU.CB;E;-E:>B/A-LUDJB"<_!UL6AX8NWEM\AT$<G5SDA\4&TW1XA)T  (
M@ !RLTYPDIIG+5'MD:):L%3UD$M-+U>"CN(^F%EAC=(NBEF4C7D<0%N>C1D&
MG733A'D  (  @ !PT7%S3>)E!G*34:18>'/-555*T74&6-X[S78M7" JYW=#
M7MD6G7@P8!8 IW[F8EH  (  >-IO#VSK5=QCNVYJ61-77V_<7"Y)Z7$V7R$[
M#7)J8= J4G-:9 ,60W0)9-< SGZD9R$  (  ?(1MEFBG7?=B4FIX8)%6-FPC
M8Q%(V&V=96DZ)F[=9X@IFF^?:3<5QW!]::T X'Z&;"H  (  ?[QL-62T9A=@
M^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (
M@ !JXV$C;D9?N&-F;Z13NV5D<.U&RF<7<A8XHVAN<R(H;6C#<^<5&VK)<]H!
M$WXN=QX  (  @ !IQ5X#=H!>R&!V=U!2YV*6=_]%]&1<>) WS66C>1$GV66J
M>7@4KFB:>6<!$GXP>_0  (  @ !HW%M+?JM=[5WC?O12&V ??PQ%-F'R?PLW
M&V,K?Q,G1V+>?R\4<6:[?V8!)'X3?_H  (  @ !H)5D#AL!=1%N[AH]1>5X+
MAA=$H%_CA8DVB6$(A2DFM&!AA284!F54A40!,'W^@,X  (  @ !GGE<MCL9<
MQ5H CC-0]UQ>C39$(EXRC"(V(%\_BVHF9UYABXD3L&0XB?,!#WXU@+@  (
M@ !DXWH,35I9W'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@
M (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG
M8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P
M^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7
M:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5
M VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (
M@ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\
M (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=
M?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,M
MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1N
MB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @    (  @ !8\X-<3&!.
MJX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (  :34  (
M?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X
M (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[
M9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHF
MB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=**752:LX_578O
M;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)
M0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (  @    (
M@ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,
M (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z
M?[ $7'BB@"<  (  @    (  @ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D
M$6UDA=L4$&ZDA;@$47BU@NL  (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#
M46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (  @ !+DXG+491"
M.(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (  <8X  (
M@ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H
M (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W
M9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;
ME8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV
M;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]
ME7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (
M@ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@
M (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU
M@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2
M>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)69
M5&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U
M.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (
M@  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8
M (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%
M:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$/
M/XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W
M<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ
M78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (
M@  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @
M (  @    (  @    /__  #__P  __\  &UF=#(     ! ,)   !
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M^27N)N,GV"C,*<$JMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH
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MQ&)_=FXOO8Y^U6"TMIQ^B%-;KW!^BT9)I_9^T3G9H!U_/"Y#E\=_]"0SCOR
MZ8DSRAJ'(GN7PVJ%H&X(O).$5V"'M96#<%,TKF&"RT8VINJ"8#GEGQ>"$BZ
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M?"B&!*SM?&"% IA2?*F$*(-E?0&#:VY<?7""PEEQ??&"&$2X?IB!<#"1?W6
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MKER#36KYJ7Z"C5XMI(N!_%%*GX.!F$2BFE:!33B;E/2!$2UOCUN \B/-B9Z
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M>IY\E#(E?+E]I-;O;AB#!<-;;[^"4:]$<52!KII[<MZ!-857=&^ UW 2=A2
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MA;J%8(TIA.&$H7R8A!Z#YVN6@W&#1%J$@MN"J4FQ@EB"#3DU@?:!:2G&@:B
ML:MCA7^._IPLA)J-E(PO@\V,"WN,@Q:*<6JM@GJ(W%F_@@.'54DC@9:%O#CF
M@4J$!"FY@1:"'*IVA)V7\9LY@\"5P(L_@O637GJO@D.0W6GH@;&.6%DB@3Z+
MTTBS@.F)/3BD@+:&;RFN@)B#7ZFV@^J@QYIV@Q6=S8I[@DB:BGGN@9>7&6DY
M@0Z3HUB8@*>0(DA9@%2,@SAO@#B(HBFE@#"$=ZDE@V2I@)G;@I6EN(G4@<.A
MBGE(@0F='&B?@(.8JE@,@"Z4*$?S?^F/ACA!?]**ERF>?]N%9:C$@P:R%YED
M@CRM?8E%@6"H57BS@)BBW&@>@ Z=8E>H?[Z7W4>H?XF2-#@2?X.,0RF8?Y:&
M*:'EE!1J3I/OD@)L/X4MD"UN&'6<CG9O[&67C,%QU55MBPESYD66B4QV'C8)
MAY=XIB=VA>E[FZ$UDIIS 9,^D+5T"(1ECNYU"W3@C3IV&63JBXUW/U3:B>9X
MA44?B#UYYC7'AI][?B>(A0A]6:!LD2E[C9))CV![Q8.&C:-[_G0!B_]\160H
MBF1\HU0\B-5]&$2JAT1]G#6,A<!^/">7A$!^]Y]ZC]N#[Y%(CAF#<H)TC&Z"
M[G,DBM*":F-DB5"!^U.EA]B!ED1#AE^!-#59A/> U2>D@Y& <IZ5CK2,6)!<
MC/^+(X&+BU^)VW) B<^(A6*UB%"'-E,9AO&%\T/DA9&$I#4LA$.#0R>P@OJ!
MR)W-C=J4OX^HC"Z2TX#:BHZ0O7&%B0".CF(%AXN,7%*0AC"**D.%A.2'ZC3]
M@ZR%@B>Z@GJ"]9TIC2^= H[\BXJ:6X MB>B7<G#>B%F48F%PANR13%(:A9F.
M*T,\A$V*\C3;@RN'B2?"@A"#^)RIC*^E'(YUBQ"AMG^=B6B=]'!2A]&9^6#M
MAF:5]5&FA2*1XD+L@]^-MC2^@L&)4R?(@;F$TYQ/C%.M$XX,BK>H['\CB0>D
M06_5AV6?3&"!A?2:45%3A+2524*M@X"0)C28@G.*UB?-@7.%AY3CG21I_8?;
MFEUKY'HME\AMOVO7E4-OGET@DK)QEDY5D!!SN#_QC5MV 3'YBIEXFR4KA\E[
MEY15F]UR,X=8F3!S/7F9EIQT3FM-E!)U<%RDD8-VKTWOCNUX$C^FC$9YDC'B
MB9=[3"5AAMM]19.WFH%Z.(:5E^MZ@GCNE5MZTVJ@DMQ[.UP0D%M[ODU\C=E\
M7#]:BT=]##',B*]]WR60A@I^T)+[F3J"%X7$EJZ!M7@-E"V!4VGKD;6 _UMP
MCTJ P$T#C-V D3\-BF& :#&UA^" 3"6YA52 .)(ZF"R)X(4)E::(VG=2DRV'
MRFDLD+V&MEKHCE"%IDR8B_F$IC[-B9&#GC&DARB"CR7;A+>!>9&:ETB1LX1G
ME-"0 W:QDEF.-&B8C^F,4%ICC8&*:TQ!BR>(BCZ9B-2&HC&5AH:$HB7YA#."
MDY$5EJ&98X/UE#"7"W8_D;*4=&@<CSJ1N5GIC-F._4OBBHN,/3YGB#B);S&&
MA?Z&@"81@\:#A)"KEB>@YH.&D[B=WW7*D32:?&>JCK*6Y%F C%*32DN$BA"/
MISXIA\2+]C%YA9"((B8D@VR$3Y!=E<ZH/X,ODUZDAG5GD-&@2V=&CD6;RUDJ
MB^"724M$B:&2P3W[AV..+3%CA4")@"8T@R6$](B IFQIIWQ1HOAK@6^CGZ5M
M76)VG$EO1U4%F,IQ4$>5E2ESA3JAD69UXBX[C7]XD",AB8![DX@2I5=Q;'O\
MH>AR<V]'GH)SC6(CFQ9TPU2\EY1V'$=?D_MWG3J$D$-Y/BY/C&]['"-YB(1]
M,8>@I IX\GMKH*IY16[,G41YJV&HF=UZ,E17EF9ZV4<7DMY[HCI@CSA\@"Y<
MBWI]AR/&AZA^K(<6HL2 2GK-GVR  &X@G!)_OV$@F+)_EE/BE4U_B$;&D=A_
MCSHWCD=_HRYEBJ!_RR0(ANF  H:%H;.'D7H\GF.&KVV+FQ"%RV",E[.$ZU-Y
ME%&$'D9WD/"#7CH0C7&"H"YLB>"!YB1 AD:!,H8%H.&.SGG"G9>-5&T5FD&+
MPV 8EN2**%,2DX.(D$8]D!R&_CGWC*^%;2YSB3B#TB1OA;R".X6BH"V5YGE<
MG.N3SVRLF921B5^SEC:/*E*\DMF,R48%CWB*93GJC *'_2Y^B*6%B"26A4N#
M'(50G[:<UWDLG'2:*6QZF0Z7(%]TE9B3Y5)ZDC:0L$7#CNF-?SF_BX6*32Z!
MB#"'""2UA.^#V842GV&CG'CNG!6@2VPTF*.<=U\KE2288E(]D;Z45T68CG.0
M4CFGBQ^,3RY^A]N(1B3.A*6$<GR^K^MI/W%+J]=K"V6+I\)LZ%E\HX)NWTU(
MGP1P_$$OFDQS236GE6-UORK.D$1XA"%7BPQ[C7QMKP-PG7$EJMAQG65HIIUR
MP5EBHD)T"TTWG;MU@4$MF0IW)36[E"QXZRL+CQ]Z[B'.B@%]'WPEK;]WK'#(
MJ9EX!64?I5AX?%D:H/QY)$T"G'UY\D$2E]QZZ#7 DP][^2L]CAI]-2(VB1E^
MBWO.K'%^A'!>J%%^362HI!E^*EC"G\1^+$RYFU5^4T#IEL9^DS6]D@U^Y2MF
MC3)_5"*/B%!_TGMPJU6%27  ISR$BF1'HPB#TUA=GK:#)TQZFDJ"F$# E<^"
M'S6WD2F!K"N'C&>!22+;AZ6 \WL9JGZ,!F^SIF6*OF/^HBR)9%@6G=B("4P[
MF6^&NT"AE/*%?36SD%Z$12NCB[:#$2,:AQ:![7K0J=>2EF]YI;N0PV/&H7J.
MP5?<G1^,K4P$F+N*HT"#E$6(HC6WCZR&I2N]BQV$IB-.AJ&"P7J?J4^8[V]+
MI2^6BF.3H.B3W5>IG(B1#$O5F"2.0D!7D[R+?#6HCR6(P"O7BIR&!2-XAD&#
M<7ITJ/F?)F]-I,F<.6./H&R8QU>.F_*5%TO#EX*1@D!6DQ^. #6SCJB*D2OI
MBD"'*2.:A?6$ '&!N:-HW&:KM01JDEO%L#%L;5#*JO]N<$70I6EPHCL-GX%S
M"S#RF5AUG">CDNEX>A_"C')[AW%$N.1OUV:KM!)PR%O4KP)Q\5#DJ:IS3D7Q
MI ATXSL]GB5VK#$UF 9XF2@*D:YZQ"!7BU=]#7$HMZ)V<V: LLIVR5NZK;!W
M3%#,J$]X$T7KHK-Y"CM.G-YZ,3%CEM)[=BA?D)5\Z"#7BF)^;7$'MD-\SV9,
ML6]\HEMYK%M\F5"CIP-\PT72H71]'SM/F[)]FS&%E;Q^+RBFCYU^Y"%%B9!_
MIW#>M12#%&8FL$*"<%M1JR^!X%!TI=N!9T7!H%.!&#M0FJ: Z#&CE,: PRCC
MCL2 MR&CB-Z NG"XM"R)4F83KT^(-EM"JC6'$5!CI.&%]46PGV"$\#M5F;>$
M!3&^D^N#*BD7C@B"7B'PB$B!IW"7LWF/8&8+KHN-R%L^J6:,"5!;I!"*046I
MGI>(C#M:F/B&Z3'9DS"%52E&C6J#TB(PA\Z";W!^LO65-V8-K?"3(5M"J+R0
MP%!9HU^.146?G>F+W#M4F%R)A3'FDJ"'0REKC.>%$B)DAVJ#%7!MLI::V687
MK7*8/5M-J"R5,5!<HL>1_$6CG5..W#M@E]"+U#'PDB>(Y2E]C(2&%R*-AQR#
MF\ZA;1AF^KOH;NQI/:BU<*UK<93J<EYMG("U=!)OSFQ6==IR%U@@=[]T?T0=
M>=]W)S#)?%EZ/LR^:K1QQ;IJ;,%RY*=@;JUT!I.^<(MU,'^D<FYV9VMB=&=W
MLU=)=GYY$D-T>,]ZFS!B>WA\8LKY:*=\?KBT:M)\@:7H;.1\C9)>;N9\MGYP
M</)\\VI<<Q=]059T=5M]ED+7=]I]^S '>JQ^;,D[9M>'#;;X:1N&"J0Y:T2%
M%I#K;6B$-7TI;YR#=FE.<>J"OU6E=%B" T)%=O^!/2^W>?> 5L>G95"1>[5Q
M9Z:/BZ*V:>6-GH]\;!Z+NWOU;F^)Z&A,<..(*%3B<W6&4T'!=D"$6B]R>5B"
M&\9?9!R;UK0R9GV9 Z%]:,:6&HY-:Q"3+WKA;7203&=D;_Z-:E0S<K**>$%+
M=9R'22\X>,^#M,5;8R:F$K,U98^B6Z!]9]R><HU1:BZ:>'G];*66AF:E;T22
MB%.?<@R.9$#J=1*)_B\(>%R%'<298G"P(+)V9-RK@9^R9R6FE(R :7>AA'DS
M:_B<>67X;JR78E,?<8F2$T"7=*",;R[@=_V&5<0:8?>YZ['T9&"T4I\99I^N
M5XO8:.BH+7B1:VNB!V5M;BF;T%*G<1657$ _=$".C"[ =["'6L""=/]F-*^/
M=?YHIIWE=O]J]8MX> %M,'B*>0YO<V5K>BYQT%)\>VET4#_$?-9W%"W3?I!Z
M2[\G<LAP>ZZ!<_]QU)SC=2-S'HJ$=D9T9W>C=W1UO62=>+YW*E'/>B5XKC]%
M>\1Z8BV.?:]\6+VO<-%ZGZSJ<B=Z\IMS<VI[0(DH=*][F79X=@5\ V.C=WE\
M?U$'>0I]!#ZZ>M-]G"U2?.1^2+PH;Q>$F:M9<(*#_IGI<=V#7H?;<SV"P750
M=+J".V*P=E.!O%!0> N!/#Y!>?N MBT=?#" &+J[;9^.>ZGX;QN-!)B-<(N+
M>H:-<@")Z'0_<Y.(7F',=5&&XD^F=RN%5#W4>3Z#J"SO>Y.!PKF2;'684ZC4
M;?R6 )=O;W63AH5[</J0^7-'<J".;&$!='&+W4\0=FN)/SUT>)V&:BS)>PV#
M0+BF:XBB"Z?H;1:>W):";I*;;(26<!^7W7)X<=B436!7<[R0KTZ3=<B,[STF
M>!6(\2RI>IV$C[?W:M>KF*<T;&>GB)7!;>&C'(/4;VV>@G&_<3"9Y5^Y<RJ5
M.4X@=4F07SSB=Z6+-BR/>D"%K[>&:F&TZ*:S:^VO[94I;5RJ?(,R;N"DSW$I
M<*6?(%\\<JJ98$VV=-J3;#R5=TJ-*2QZ>?6&GK+5?2%EI*-U?41H+),Y?8%J
MB8(<?=!LSW!P?BYO'UZ2?IUQCDSP?R%T(CN-?\]W 2L(@+IZ5;'$>PQO2Z)J
M>VEPSY(;>\=R/H$3?#)SIV^$?*UU'5W*?4!VK$Q/?>IX5#LB?L)Z+2KF?]5\
M3+"<>2AXX:$J>:MY<I$->B1Y^8 ">JMZ?FZ5>T1[%%T%>_I[O$NZ?,M\<CK#
M?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!46V%>@.! EPG>MV
MO$L5>]* =SI>?/B ,"JN?E1_VZX$=A6+H9Z/=KJ*CHYF=V")7'VD>!*(%VR5
M>.2&U5M>>>&%G$J#>O6$5CH'?#R"]BJ7?;>!:ZSZ=/B4\)V(=:B3#HUF=E:0
M^'RP=Q:.QFNX=_B,CEJP>06*4DH$>C>(!SF\>YN%C"J$?3&"T*PF=!2>'YRQ
M=,R;:XR/=7V8;'OA=D2516K^=S>2%EH:>%6.V$F=>92+?#F >Q.'YRIU?,&$
M!ZN'<VBG))P)="2CF8O==-.?JWLR=9F;A6I9=I:75EF+=\F3%4DW>1F.KCE+
M>J2* 2IH?&6%$*L?<O*O\9N.<ZZKB8M-=%2FHGJ<=1&A=6G2=@^</ED>=TN6
M]DC;>*V1@CD+>DR+S"I>?!R%[*6+A7QE.Y=_A,AGR(B-A$1J+'BV@]YL>VA1
M@X-NV%>]@S-Q5T=R@O!S_C=R@LQV]"AJ@M1Z7*2O@XAN4Y:5@Q)O[X>,@J]Q
M='?&@EQR]F=^@AATB%<-@>5V-$;J@<%W_#<C@<!Y^2AK@>A\/J.P@<!W195H
M@7!X"89_@2-XNW; @.EY;V:?@+]Z+U9:@*U[ T9H@*I[YC;;@,U\Y"AK@19^
M :*;@!B (Y1(?]^ ((53?ZZ  W7<?X=_XF7:?WI_RU7'?X9_OD8%?Z9_M3:F
M?_%_K"AK@%Y_H*%_?L*([Y-+?I:(+X19?G.'273,?EV&2F3Z?F2%354)?I*$
M6$5]?L^#639??S6"1RAK?[^!&*"6?;*1LY)<?9&0,8-Q?76.=G/T?6J,EV0Y
M?7Z*L51V?;>(QT46?@^&T38H?I.$L2AK?SB"99_9?-F:4I&>?,*8#(*U?*>5
M=G,^?*"2L6.5?,*/X%/U?0J- 43%?6N*"S7^?@F&XBAK?L>#AI]*?#2BR)$&
M?"2?NX(4? :<0W*B>_R8C&,#?"24R%-S?("0\D1J?/&- #78?9B(U"AK?FN$
M>Y[H>\"K#)"1>[.G-(&.>XVBT7(:>WF>'F*->Z&97U,7? 24CD0>?(>/GC6G
M?4**>2AK?B&%19B=CC%DZ8NIC*YG;'W=BVAIT&\ZBD%L*& =B1QND5#>A_EQ
M($'ZAM=SV3-RA<EVYB7_A-5Z89?HC&IM>8KPBR%O&GT0B?)PKFY_B--R15]Z
MA[QS[U!9AJ]UN4&8A:AWH3-&A+AYQ28A@^!\,)<7BK1UWXGUB9)VN7PQB'1W
MBFVFAVMX7U[#AFMY1D_+A7IZ1$$VA)%[53,=@\%\AR8^@P=]W98BB2-^&HCY
MB!!^1WLFAPQ^7VS9AA!^<5X2A2Y^CT]*A%M^N$#F@Y%^ZC+]@N-_)298@DE_
M9I4UA\N&5X@0ALB%TGI'A=*%*VP"A.6$;EU\A R#L4[;@U:# T">@JN"4#+@
M@A^!DR9N@:: R)1KALF.CX=CA=&-6GF@A-Z+[&M)@_:*5ES/@RF(O$Y:@GR'
M*4!'@>J%CC*Y@7F#U": @1R" )/'A?N6GX:WA0V4MGCUA!F2>FJF@S.0"EPW
M@G&-DTWC@="+&$ (@4.(D#*@@.R%W2:/@*F##)-'A5^>@88RA'F;XGAH@X&8
MTVH?@I.5?ENY@=22(4UN@4:.O#^X@,:+2C**@'B'J2:<@$N#[Y+LA.^F.H7)
MA ZBY7?O@PV>]VFE@A.:KUM3@4^69$TC@,>2%#^#@%F-M3)M@!Z)+2:F@ "$
MJ8PHEP-DK8 >E-!G('-9DM1I@V7?D.AKXU@$CNMN5TH9C.%P]CR@BLUSP"^<
MB+QVWR/,AK=Z8XN.E7ALPG^1_^)]$$E#0U]04D]&24Q%  ,2DVYN8'+!D7=O
M_659CX=QIE>2C8]S9TG"BY=U3#QGB9AW4R^5AZ%YF20.A;5\(8KFD]ITI'[$
MD?!UB7(0D 9V;V2LCB5W85<%C$!X:TE:BF%YD#PIB'UZS2^-AJ-\,B1(A--]
MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
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MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
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M5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+C'9_-B"%AXU_RFBWK)F#8U\
MJ'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!3"\9D+"!$R=!B[" YB#3ANZ
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M>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6 \3/N?1> DB<Y?G6
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M@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^*
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MNX;P@6U:A'N"@3A=_&]<@3)A7&)^@41DM54O@5YH($?.@8AKMCKA@<=O?BZ
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M?X^ 'F'[?W" (5:^?TV "DMM?SY_]$ S?U!_[S5I?X1_]2M5?]U__"*U@$V
M W:G?FB'(FQA?G.&M&&-?EN& %90?CR%(DL ?D&$1S_<?F^#>35,?K6"LRM:
M?S.!X2+<?\>!#78I?7*.%VOH?8N-#V$8?7J+HE7I?6*)^DJE?72(5S^)?;J&
MO34=?A6%+"M??J>#BR+\?UJ!['7(?+:4RVN(?->3+V"X?,J1!%60?+2.C4I@
M?,N,&S];?1V)M#4 ?8Z'52M7?CN$[B,5?P."HW!UDEY:'F:LD-I=<%QMCW-@
MRE&SC@1D-D:YC'IGQ#O/BN-KAC%ZB4UO>"?9A\MSQ1^9AG%X6F^ID#1A8&84
MCN!D#5ODC8EFQE%,C"1IDD9TBJYL?3NQB3EOES&&A\ARV2@4AG!V92 )A3YZ
M(V[VC?YH@&55C-=JDEM,BYQLK%#$BE%NV$84B/UQ'SM\AZ]SC#&!AF=V&RA"
MA3MXXB!JA#%[QFX[B_!O@F23BN9Q %J)B<ER?U WB)UT"D6EAV]UJ3LZADIW
M9#%OA2UY.2ABA"M[-2"^@TA]0&V%BBQV<&/HB3UW7EGFB#9X04^?AQ]Y($5)
MA@UZ$CK]A0][&3%<A!A\,"A]@SU]7R$%@H%^D6SDB+I]36-9A^)]KUEHANE]
M[T\MA>%^'D3LA.%^53KF@_%^HC%<@Q]^_"B7@FY_6B% @=I_MFQ:AX6#\F+4
MAL*#P%CLA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!@RBR@;V!'"%Q@5&
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MBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6>
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M6,2$#WX37(N#FF^C8%Z#%6#H9&:"D5(9:+:"&$.Z;4F!IC7K<BN!-"EY=SB
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M?;A^I2'9?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@.
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MC8U^>D,?C!)^H3O]BC5^NC3YB$5^]"XXAG5_12@XA+I_JB+=@U!__QZ.@CJ
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M;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F
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M6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6 Q"V =4R M"2A>>2
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MWRQ;@@)O."2J@K%SWAY2@W%XI6!#?!U>D%@,?.%AGD^$?9!DN4:/?BYG[#V
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M?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$
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M=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J^KX<*-;=#B/
M\!0_K/T>5YSP+6J/Y3YYAMY.@X'87XM_U&N0>M%PE'?/=)=USG>8<\UYFG+-
M>YMQS'V;<,M_G&_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N
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MV9&4GMF1E)[9D92>V9&4GMF1E)[9_Z0X*O^@14#_H4I3^Z9(8O*K2''HKTB
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M@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
MH:;._Z(V(O^?0S?_HT5'_ZI"4_ZQ05_VN$%J\<%$<^K,2WG@VE9\S]5>C<#,
M:9NSPW*HI[MYLYZU?[N7L8/"CJV%QH>KB,J!J8W-?*B6SGNHHLU[J:;->ZFF
MS7NIILU[J:;->ZFFS7NIILU[J:;->ZFFS7NIILU[J:;->ZFFS7NIILU[J:;-
M_Z,V(O^?0S?_I4-&_ZQ 4O^T/EWYO3]F[LA#;>/636_5W4Z!Q--9D;7)9I^I
MP7&KH+MYLYFV@+J4LH7 C*^&Q(:MB,> JXS)?*J2RGJKG,IYJY_*>:N?RGFK
MG\IYJY_*>:N?RGFKG\IYJY_*>:N?RGFKG\IYJY_*>:N?RGFKG\IYJY_*_Z,U
M(O^@0C?_ID%%_Z\]4/ZX.UGSQ#QAYM%#9-G?0W/(W$J%M]!7E:K'9:+_XGT0
M24-#7U!23T9)3$4 !!*@P'"LF;IYM)2V@+J1LX6^B[&&P86PB,.!KHO%?:V0
MQGJME\9ZK9K&>JV:QGJMFL9ZK9K&>JV:QGJMFL9ZK9K&>JV:QGJMFL9ZK9K&
M>JV:QGJMFL9ZK9K&_Z0T(O^A03?_J3U#_[,Y3?F^-U7JS#I9V]T[8LOE/W>[
MV4B)J\Y7F*#&9:28P'&LD[MZLY"X@;B,M82[B+.&OH6RB<"!L8O!?K"/PGNP
ME,-ZL);#>K"6PWJPEL-ZL);#>K"6PWJPEL-ZL);#>K"6PWJPEL-ZL);#>K"6
MPWJPEL-ZL);#_Z0T(O^C/C;_K3E!_[@T2/#&,TW?V390S>4V9[[D.WNMUTB,
MH,U8F9?&9Z22P7*KCKU[L(RZ@;2(N(.WA+>%N8*UB+M_M(J]?+.-OGJSD;]Z
MLY._>K.3OWJSD[]ZLY._>K.3OWJSD[]ZLY._>K.3OWJSD[]ZLY._>K.3OWJS
MD[]ZLY.__Z8R(O^F.C3_LC,]]\ N0N32+T'/Y"Y5O^\S:Z_A.WZ@UDJ-ELY;
MF9#(::&,PW.HB<![K(:^?Z^"O(&R@+N$LWVZAK5[N8BV>;B+MW>WC[AWMY"Y
M=[>0N7>WD+EWMY"Y=[>0N7>WD+EWMY"Y=[>0N7>WD+EWMY"Y=[>0N7>WD+EW
MMY"Y_Z<Q(O^L,S'_N2LVZLPF-M+A)D'![RQ:L.TS;J'A/7^5UTV,C=!>EHG+
M:YV&QW2B@\1ZIG_#?:E\P8"K>L""K'F_A*UWOH:O=;Z)L'.]C+%SO8VQ<[V-
ML7.]C;%SO8VQ<[V-L7.]C;%SO8VQ<[V-L7.]C;%SO8VQ<[V-L7.]C;%SO8VQ
M_ZDN(?^S*BORQ2(LUMX<+</M(T>R^2M=HNPV;Y7B0GV+VE*(A=1@D(+0;)9^
MS'.;>\IWGGC)>Z!VR'ZB=,> HW/&@J1QQ82E<,2'IF[$BJ=NPXNG;L.+IV[#
MBZ=NPXNG;L.+IV[#BZ=NPXNG;L.+IV[#BZ=NPXNG;L.+IV[#BZ=NPXNG_ZPJ
M(/J]'R+<V1(;Q>L:,[3Z(TJC^2Y>E>X\;8KE27F#WU:"?MIDB7K6;(YVTW&1
M<])UE''0>95OSWN7;<Y^F&S.@)EKS8*::LV$FVG,AYQHS(B<:,R(G&C,B)QH
MS(B<:,R(G&C,B)QHS(B<:,R(G&C,B)QHS(B<:,R(G&C,B)QHS(B<_[8>&.30
M#A/(Z1$@M?D;-Z7_)DN7^C1<B_%":(+J3W)\Y5MZ=^%D?W+>:H-NW'"&;-MT
MB&K9=XEHV7F+9]A\BV;7?HQEUH"-9-:"CF/5A8]BU86/8M6%CV+5A8]BU86/
M8M6%CV+5A8]BU86/8M6%CV+5A8]BU86/8M6%CV+5A8]BU86/Z<<-#,K:"P^W
M]Q(DI_\=.9C_*TF,_CI7@_9)87SP56EU[%YO;NEC=&KG:7=GY6YY9>1R>V/C
M=7QBXG=]8>)Y?F#A>W]?X7U_7^!_@%[@@H%=WX.!7=^#@5W?@X%=WX.!7=^#
M@5W?@X%=WX.!7=^#@5W?@X%=WX.!7=^#@5W?@X%=WX.!R] ) [KB"Q.H_Q0F
MFO\A-XW_,46$_T!0?/Q.6'3X5U]M]%UD9_)B9V/P:&IA[FQL7^UP;5WM<F]<
M['5O6^QW<%KK>7%:ZWIQ6>I\<ECJ?W)8ZG]S6.I_<UCJ?W-8ZG]S6.I_<UCJ
M?W-8ZG]S6.I_<UCJ?W-8ZG]S6.I_<UCJ?W-8ZG]S_YPX&O^:1BW_EU%!_YI3
M3_Z<55[UG%IL[)M?>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BW
MPH&;N<%_GKK!?:*[P'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[
M>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI33_Z<
M55[UG%IL[)M?>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BWPH&;
MN<%_GKK!?:*[P'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]
MNWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI33_Z<55[U
MG%IL[)M?>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BWPH&;N<%_
MGKK!?:*[P'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBS
MO;MXL[V[>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI33_Z<55[UG%IL
M[)M?>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BWPH&;N<%_GKK!
M?:*[P'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MX
ML[V[>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI33_Z<55[UG%IL[)M?
M>N299X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BWPH&;N<%_GKK!?:*[
MP'NFO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[
M>+.]NWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI33_Z<55[UG%IL[)M?>N29
M9X?<EG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BWPH&;N<%_GKK!?:*[P'NF
MO,!YJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]
MNWBSO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI33_Z<55[UG%IL[)M?>N299X?<
MEG&2U9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BWPH&;N<%_GKK!?:*[P'NFO,!Y
MJ[V_>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBS
MO;MXL[V[>+.]_YPX&O^:1BW_EU%!_YI33_Z<55[UG%IL[)M?>N299X?<EG&2
MU9-[G,^0A*3+CHRKR(J0L,6'E+3#A)BWPH&;N<%_GKK!?:*[P'NFO,!YJ[V_
M>+*]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MXL[V[>+.]NWBSO;MX
ML[V[>+.]_YTX&O^:12[_EU!!_YM13_^=5%WUGEAK[)U=>>2;9(;<F&Z2U95X
MG-"2@:3+CXFKQXV/L<6)D[7#A9>XPH*:NL%_GKO ?:*]OWNGOK]YK;Z[>+&^
MMGFROK9YLKZV>;*^MGFROK9YLKZV>;*^MGFROK9YLKZV>;*^MGFROK9YLKZV
M>;*^_YTX&O^:12[_F$] _YU03O^?4ESVH%5J[:!:>.6?8(7=G&J1UIASF]"5
M?:3+DH6KQX^-L<2,D;;"AY6YP8.9N[]_G;Z^?:*_O7JHP+QYK\&T>;#!L'JP
MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
MH\ULQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:B
M_XTM#O^,/AW_BDPN_Y)3._^45TC_E5Q4_9-B8/61:FOOC7)VZ8E\?^2%A(;@
M@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O H\UL
MQ:/(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:BR&[&HLANQJ+(;L:B_XTM
M#O^-/AW_C$PN_Y13._^55D?_EEM4_95A8/:2:&OOCW!UZ8MZ?^2'@X??@HJ-
MW'Z0DMEZEI?6=YN:U72@G=-RI9_2<*FAT6ZNHM!MM*/0;+JDT&S"I,INQ*3$
M;\2DQ&_$I,1OQ*3$;\2DQ&_$I,1OQ*3$;\2DQ&_$I,1OQ*3$;\2D_XXM#O^.
M/AW_CDLN_Y51.O^85$?_F%A3_IA>7_:59&KODFQUZ8YV?N2*@(??A8>.VX".
ME-A\E)C5>9J<TW:?G]%SI*+0<:JDSV^OI<YNMJ;.;;VGRF["I\-PPJ>]<<*G
MO7'"I[UQPJ>]<<*GO7'"I[UQPJ>]<<*GO7'"I[UQPJ>]<<*G_X\M#O^./A[_
MD$HM_Y=/.O^944;_FU92_II;7O>886GPE6ATZI%Q?N2.?(;?B82.VX.+E-=_
MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
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M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
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M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
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M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
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M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
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M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
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M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
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M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
MQJ$# +RI P"SL $ J[@( *2Z& "<NBD#E+DV"XRW012$M4H=?+-2)7:Q6BQP
MKV R:ZYG.&:M;CQBJW5 7JI]1%JIADA6J)%*4ZB=35&GJDY/J+I/3JC/3TZG
MZ4]-IO=/3:7_3TZD_T].I/]/3J3_3TZD_T].I/]/^G\  -B.  #)FP$ OJ4"
M +2M 0"KM0  H;\$ )O!% "4P24"C, S"(2_/A%\O4@9=;Q0(6^Z6"=JN5\M
M9;AE,F"W;#9<MG0Z6+5\/E6TA4%1M)!$3K.<1DRSJ4A*L[E(2;3.2$FSZ4A(
ML?9)2+#_2DBP_TI(L/]*2+#_2DBP_TI(L/]*XH8  ,Z4  #"H0  MJD  *NQ
M  "AN@$ F,,% )#)$ "*R2 !@\DO!7O(.PUTQT44;L9.&VC%5B%CQ%TG7L-D
M*UK":R]6P7(S4\%[-D_ A#E,P(\\2L";/D? J#]&P+A 1<#-0$7 Z#]$OO9!
M0[W_0D.\_T-#O/]#0[S_0T.\_T-#O/]#UHT  ,:;  "XI0  K:X  **V  "8
MOP( C<@& (/1"P!_TAH >=(J W+2-PALT4(/9M%+%6'04QI<SUL?6,]B(U3.
M:2=1SG$J3<YZ+4K.@S!(SHXR1<Z:-$/.J#5"SK@V0<_--4'.Z#5 S?4W/\O^
M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
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M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
M0_\> 3__)@(Z_RT"-_\S S/_.0,P_S\$+O]$!"O_2@4I_U %)_]6!B3_708B
M_V4'(/]N!QW_>0@;_X4(&O^2"1G_G@D8_Z@)%_^S"1?_MPD7_[<)%_^W"1?_
MMPD7_[<)D+H  (+%  !TT   9]P  %CC  !-\   1_\" $+_#  \_Q$ ./\8
M 33_'P$P_R4!+/\K BG_, (E_S4"(_\Z B#_/P,>_T0#'/]) QG_3P,7_U8$
M%?]>!!+_: 01_W(%#_]^!0[_B@4._Y0%#?^>!0W_H@4-_Z(%#?^B!0W_H@4-
M_Z(%_SDO O\\, /_03$#_T0T!/]$.@;_1$4(_T51#/]#71'_06D6_SYV&?\\
M@1S_.HP>_SF6(/\XGB'_-Z4C_S>K(_\VLB3_-KDE_S; )?\URB;_-=<F_S7E
M)O\U[R;_-?@F_S;_)OXV_R;\-O\F_#;_)_HV_RCZ-O\H^C;_*/HV_RCZ-O\H
M_SDO O\^+P/_1"\#_T8R!/](. ;_2$,(_TA/#?]'6Q+_1&<6_T)S&O\_?QW_
M/8H?_SR3(?\[FR/_.J(D_SFI)?\YL";_.+8F_SB^)_\XQR?_.-,H_SCC*/\X
M[2C^./<H^SC^)_DY_R?X./\I^#C_*O8X_RKV./\J]CC_*O8X_RKV./\J_SHO
M O]!+ /_1BP#_THO!/],-P7_34$(_TQ,#?]+6!+_2&07_T9P&_]#?![_08<@
M_S^0(_\^F"3_/: E_SVF)O\\K2?_/+0H_SN[*?\[Q"G_.\\I_CO@*OL[ZRKX
M._4I]CS^*?0\_RKS._\K\CO_+.\[_RWO._\M[SO_+>\[_RWO._\M_SPM O]$
M*0+_2BD#_TXL!/]1- 7_4CX(_U)*#?]051+_36$7_TIM&_](>!__18,B_T.-
M)/]"E2;_09TG_T"C*/] JBG^/[$J_3^X*_P_P2OZ/\LK]S_<+/4_Z2SQ/_0K
M[S_]+.T__RWL/O\OZS[_,.<__S#G/_\PYS__,.<__S#G/_\P_T J O]()@+_
M3B8#_U(I _]6,@7_5SP'_U='#/]541+_4ET7_U!I'/]-="#_2G\C_4B))OM'
MD2CZ1IDI^$6@*O=$IROU1*TL]$.U+?-#O2WR0\@N\$/7+NQ#YR[I1/,MYD/\
M,.1"_S'C0O\RX4+_,]Q#_S3<0_\TW$/_--Q#_S3<0_\T_T,G O]+(P+_4B("
M_U@G _]<+P3_73D'_UY##/];3A'_6%@7_E5D'/I2;R#W4'HD]$V$)_),C2GP
M2I4K[TF<+>U)HR[L2*HOZD>Q+^E'NC#G1\4PYD?2,.)(Y3#?1_(RVT?[--A&
M_S751O\VTD;_-\U(_S?-2/\WS4C_-\U(_S?-2/\W_T8D O]/( +_5A\"_UTD
M _]A+ 3_8S4&_V1 "_]B2A#Z7E06]5M?'/%8:R#N574EZU-_*.A1B"OF3Y$M
MY$Z8+^)-H##A3*<QWTRN,MU+MS/;2\(TV4K/-=5+Y#702_ VS4K[.,I*_SK(
M2O\ZQDO_.\%,_SO!3/\[P4S_.\%,_SO!3/\[_THA O]3'0+_6QP"_V(B O]G
M*0/_:3(%_VH\"?EH1@_R95 5[6%;&NA>9B#D6W$EX5A[*=Y6A"S;5(POV%*4
M,M11FS324*,UT$^J-\Y.LCC,3KPYRD[).LA.W3K$3^T[P4[Y/;Y._SV\3O\^
MND__/K90_SZV4/\^ME#_/K90_SZV4/\^_TT> O]6&@'_7QH!_V<@ O]L)@+_
M;RX$^7 X!_)O0@SK;$L2Y6E7&=]E8A_:86PEU%UV*M!;?B_-68<RRE>/-<A6
MEC?&5)TYQ%.E.\%3K3R_4K<^O5+#/[Q2TS^Y4N@_M5+V0;-2_T&Q4_]!KU/_
M0:Q4_T&L5/]!K%3_0:Q4_T&L5/]!_U < ?]:%P'_9!@!_VP= ?]Q(P+]=2H#
M\W8S!>MV/0KC<T</W&]3%]1K7A_.9F<FRF-Q*\9@>3#"7H$TOUR)-[U:D3JZ
M69@\N%B@/K97J$"T5K)"LE:]0[!5S$.M5N-$JU;S1*A7_D2G5_]$I5C_1*)8
M_T2B6/]$HEC_1*)8_T2B6/]$_U,9 ?]=% '_:!8!_W : ?]V( 'W>B8"[7PN
M ^1\. ?<>D0-TG5/%LMP6A[&;&,FP6AL++UF=3&Y8WTUMF&$.;-?C#RP790_
MKER;0:M;I$.I6JU%IUJX1J59QT>C6MY'H5KO1Y];_$>=6_]'FUS_1II<_T::
M7/]&FES_1II<_T::7/]&_U47 ?]@$@'_:Q0!_W07 /]Z' 'R?R(!YX$I MZ"
M,P33?T ,RWI,%<1V5AZ^<6 EN6YH++1K<3*Q:'DVK6: .JIDB#VG8H] I6"7
M0Z)?H$6?7JE'G5ZT29M=PDJ97=9*EU[L2I9?^DF57_])DV#_2))@_T>28/]'
MDF#_1Y)@_T>28/]'_U@5 ?]C$0'_;A( _W<5 /M^& #M@QT XH<C =:'+@/,
M@ST+Q7])%+U[4QVW=ETELG-E+*UO;3*I;74WIFI\.Z)HA#Z?9HQ!G&641)EC
MG$>78J9)E&*P2Y)AODR08=!,CV+H3(YC^$N-8_]*C&3_28MD_TF+9/])BV3_
M28MD_TF+9/])_UH3 ?]F$ #_<1$ _WH2 />"% #HAQ< W8L< -"++ /'B#L*
MOX1'$[A_41RQ>UHDK'=B*Z=T:C&C<7(VGV]Y.YMM@#^8:XA"E6F019)HF4B/
M9J)*C&:M3(IENDV(9<Q.AV;F3H9G]DR&9_]+A6C_2X1H_TJ$:/]*A&C_2H1H
M_TJ$:/]*_UP2 ?]H#P#_=!  _WT0 /.%$ #DBQ$ UH\7 ,N.*@+"C#@)NHA$
M$K.$3QNL?U@CIWQ@*Z%X:#&==6\VF7-V.Y5Q?3^2;X5"CFV-18MLEDB(:Z!+
MA6JJ38-IMTZ!:<A/@&KC3X!K]$Y_:_],?VO_2W]K_TM_:_]+?VO_2W]K_TM_
M:_]+_UX0 ?]K#@#_=@X ^X - .J(#0#;CPP T)(5 ,>2)P*^CS8(MHQ"$:Z(
M31JHA%8BHH!>*IQ]93"7>FPUDW=S.H]U>SZ,<X)"B'*+1H5PDTF";YU,?VZH
M3GUNM4][;<90>F[@4'EO\DYY;_Y->6__3'EO_TMY;_]+>6__2WEO_TMY;_]+
M_V / /]M#0#_>0P [H,+ -N+"0#4D0H S)43 ,*5)0*YDS0'L8]!$*J,2QFC
MB%0AG81<*9>!8R^2?FHUCGQQ.8IZ>#V&>(!"@W:(17]UD4E\<YM,>7*F3G9R
MLU!U<L-0<W+=4'1S\$]T<_U-='/_3'1S_TQT<_],='/_3'1S_TQT<_],_V(.
M /]O# #\>PH WH8& -6." #/E D QY@1 +Z8(P&UEC(&K9,_#Z:021B?C%(@
MF(E:*).&82Z.@V@TB8%O.85_=CV!?7Y!?7N&17IYCTEV>)E,<W>D3G%WL5!O
M=L%0;G?94&YW[T]N=_Q.;G?_36]W_TQO=_],;W?_3&]W_TQO=_],_V0- /]R
M"@#P?@8 VH@% -"0!P#*EP@ PIL0 +F;(0&QFC &J9<]#J&41Q>:D5 ?E(U8
M)XZ+7RV)B&8SA(9M.("$=#U[@GM!>("$171_C4AQ?9=+;7RB3FM\KT]I>[Y0
M:'S54&A\[4]I?/M.:7S_36I[_TQJ>_],:GO_3&I[_TQJ>_],_V8* /]U" #A
M@0( U(L% ,N3!@#$F@8 O9X. +6?'P&LGBX%I)L[#)V81166E4X>CY-6)8F0
M72R$CF0R?XMK-WJ*<CQVB'E <H:!1&^%BD=K@Y5*:(*@366!K$YC@;Q/8H'1
M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
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M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
MU'\# ,N&!0#%BP8 OHT- +6/'@"NCBT#IHPZ"9^)11&9ADX8DX-6'HZ 722)
M?F0IA7QK+8%Z<C)]>'DU>G>".7=VBSQS=94_<72?0FYSK$1L<[M%:W/.16MS
MZ41K<_A#:W/_0FQS_T%L<_] ;'/_0&QS_T!L<_] _V$% /IN 0#=>0  T(("
M ,>)! # C@0 N9$, +&2&P"IDBL#HI X")N-0P^4BDP7CHA4'8F%6R.$@V(H
M@(%I+7Q_<#%X?G<U=7Q_.'%[B#QN>I(_:WF=06AXJD-F>+A$97C,165XYT1E
M>/=#9GC_0F9X_T%F>/] 9GC_0&9X_T!F>/] _V0# .YQ  #8?   RX4" ,.,
M P"[D0, LY0) *R6& "EEB@"G90V!Y:200Z0CTH5BHU2'(2+6B)_B6 G>X=G
M+'>%;C!S@W4T;X)]-VR!ACMI?Y ^9GZ;06-^J$-A?;9$8'W)1%]]Y4-@??9"
M8'W_06%]_T!A??] 87W_0&%]_T!A??] _V<  .-T  #2?P  QX@! +Z/ @"V
ME0$ KI@& *::%0"?FB8"F)DS!I&7/PR+E4@4A9-0&G^16"!ZCU\E=HUE*G*+
M;"YNBG,R:HA[-F:'A#ECAHX\8(69/UV$ID%;A+1"6H3'0UJ$XT):@_1!6X/_
M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
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M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
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ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
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M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
M7M,  %#;  !#X   ..4  "_P   K_P  )_\( "3_#@ A_Q, 'O\9 !O_'@ 8
M_R, %?\H !/_+0 1_S( $/\X  [_/P ,_T8!"O]/ 0?_60$$_V4! ?]R 0#_
M@0$ _X\! /^; 0#_IP$ _ZD! /^I 0#_J0$ _ZD!_RPO ?\P+ '_,BP"_S,P
M O\Q-@/_,$$#_R]-!/\M6@;_*V8'_RES"/\H?@K_)X@+_R>1#/\GF0W_)I\-
M_R:E#O\FJP[_)K$/_R:X#_\FP __)LD/_R;7#_\FY@__)O /_B;Y#_LG_P_Y
M)_\/^2;_$?@F_Q'X)O\2^";_$O@F_Q+X)O\2_RXL ?\S*0'_-2H"_S8M O\V
M- +_-3\#_S-+!/\R5P;_,&0'_RYP"?\L>PK_+(4,_RN.#?\KE@[_*IT/_RJC
M#_\JJ1#_*J\0_RFV$/\IO1'_*<<1_RG3$?XIXQ'[*N\1^"KX$/8K_Q#T*O\2
M]"K_$_,J_Q3S*?\4\RG_%/,I_Q3S*?\4_S$I ?\V)@'_.28!_SHI O\[,@+_
M.ST#_SE(!?\W5 ;_-6 '_S-L"?\R=PS_,((-_S"+#O\ODP__+YH0_RZ@$?\N
MIA'_+JP2_RZS$OXNNA+]+L02^R[/$_@NX1+U+NT2\2_W$N\O_Q/N+O\5[2[_
M%NPN_Q?L+O\7["[_%^PN_Q?L+O\7_S0F ?\Y(P'_/2,!_SXF O]!+P+_03D#
M_S]%!/\]4 ;_.UP(_SEH"O\W<PW_-GX._S6'$/TTCQ'\-)82^C.=$_DSHQ/X
M,ZD4]S.P%/8SMQ3T,\ 4\S/,%/ SWA3M,^L4Z33V%><S_Q?F,_\8Y#+_&>0S
M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
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M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
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M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
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MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
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M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
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M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
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M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
MM7,) *UU%P"G=2<!H70T YMR/P>5<$D+D6Y2$(QL612):F 8A6EG&X)H;AY_
M9G4A?65])'IDA29W9(\I=6.:*W)BI2UP8K,O;V+$+VYBWB]N8_(N;F/^+6YC
M_RQN8_\K;F/_*VYC_RMN8_\K_U4  .5@  #3:0  R'   +]T  "W=P$ L'<'
M *AX%0"B>20 G'@R I9V/0:1=$<+C')/#XAP5Q.$;UX7@&UD&GUL:QUZ:W,@
M=VIZ(W1I@R9R:(TI;V>7+&UGHRYK9K$O:6;!,&EFVS!I9_ O:6?]+6EG_RQJ
M9_\K:F?_*VIG_RMJ9_\K_E@  .%C  #/;   Q',  +MX  "S>@  JWH$ *1[
M$@">?"( F'PO I)Z.P6,>$4*AW=-#H-U51)_<UP6>W)B&GAP:1UU;W @<FYX
M(V]M@29M;(LI:FR6*VAKH2YF:Z\O9&J_,&-KV#!C:^\O9&O\+61K_RUE:_\L
M96O_+&5K_RQE:_\L]%L  -UF  #+;P  P'8  +=[  "O?@  IGX! )]_$ "9
M@!\ DX M HU_.06(?4,)@WM+#7YZ4Q)Z>%H6=G=A&7-U9QQP=&X?;7-V(FIR
M?R9H<8DH97"4*V)PH"U@;ZTO7V^]+UYOU"]>;^TO7V_[+5]O_RQ@;_\L8&__
M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
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MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
M ,%[  "UA   JXP  *"0  "5E   B9<  'Z:  !WFPX <YP< &^=*0%KG#4"
M9IP_!6*;1PA?FD\+7)I6#UB97!)5F&,54YAK%U"7<QI-EGT=2I6)'T>5E2%%
ME:0C1)2S(T.4R"-#E.4C0Y+U)$.1_R1#D/\D0Y#_)$.0_R1#D/\DRG4  +N!
M  "PBP  I)$  )J5  "/F0  @YT  '2B  !NHPL :J07 &:E)0!CI3$!7Z0[
M UND1 58I$L(5:-3"U*C6@U/HF$03:)H$TJA<15'H'L81*"&&D*?DQQ GZ(=
M/I^R'CV?QAX]G^,=/9WT'CV<_Q\\F_\?/)O_(#R;_R \F_\@PGP  +6(  "I
MD   GI8  ).;  "'GP  >Z0  &^H  !CK 0 7ZT1 %RM'P!:KBL 5ZXV 52N
M0 -1K4@%3JU/!TNM5PE)K5X+1JQF#42L;@]!K'@1/ZN$$SRKD14ZJZ 6.:NP
M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
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M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
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M)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT  .57  #37P
MR&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(
M85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:
MU25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<
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M)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$  +!U  "G=P
MGG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K
M;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ
M_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D
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MA1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5>
M<QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_
M($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X
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M'0!;GBD 6)XT 56>/0)2G44#4)U-!4V=5 =+G%L)2)QC"T:<:PU#FW4/09N
M$3Z:C1,\FIL4.IJK%3F:O14YFMD5.9CO%CF7_!8XEO\7.)7_%SB5_Q<XE?\7
MNWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I   5J4, %.F%P!1
MIR, 3Z<O $RG. %*IT$!2*=) D:G4 1#IU@%0:=?!C^F: @]IG(*.J9]"SBF
MB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((
M *B,  "=D@  DI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P
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M !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@
M=:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5
MV!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@
MI  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4
M %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ(
M#>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE
MZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%
M  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82
M  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4
M />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   W
MT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^
M$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2
M  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H
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M.[P/H#O-#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]
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M%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P
MSU,  ,95  # 4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B6
M3F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*
MUAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@
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M&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90
MHV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU
M7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:
M_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4
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M&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW   (=Q!0"!<A$
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MC!-$@9H50H"I%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH
M +5U  "J?0  GX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB<
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M""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@
MC9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 X
MJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">L
ML 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D
M 'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD
M*K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<
MN< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF
M  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F
M !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D
M#\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8
MM   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1
M(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7
M  '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0
M/\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !
MWB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #E
MP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@
M "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8
M .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0
M]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6
M   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2
M  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8
M /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_
M %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L
MK #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_
M .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D
M_P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S
M ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&
M_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@
M /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X
MZPFV .@)P #F"<T Y GB .(*\ #?"_L W@S_ -P-_P#<#?\ VPW_ =L-_P';
M#?\!_Q\7 /\>$P#_&Q( _QP9 /\;(@#_&"P _Q4X /\31 #^$E  ^1%; /40
M9@#S$&\ \!!W .X0?P#L$(8 ZA", .D0D@#H$)@ Y@^> .4/I0#C#ZP X0^T
M . /O@#>#\P VA#A -41\ #2$OL SQ+_ <X3_P'-$_\!S1/_ <P3_P',$_\!
M_R(2 /\B#P#_(0\ _R(4 /\B' #_("< _QTR /@;/@#R&4L [AA6 .H78 #G
M%FH Y!9R .(6>@#@%H( WA:( -P6CP#;%I4 V1:; -86H@#4%JD TA:Q - 7
MNP#.%\D S!C> ,@9[@'%&OL!PQK_ L$;_P+ &_\"P!O_ L ;_P+ &_\"_R8.
M /\E"P#_* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4
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M!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.
MXCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K
M-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DU
MW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(
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M$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,  +A4  "Q4@
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M$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T  (U>"0"'7A,
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MC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H
M +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P
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M#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@  *]R  "D>0
MEGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB  3X8J $Z'- !,
MASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@YA9$*.(2@"S:$
ML0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X
M (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@
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M 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF
M5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >
ML#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.Q
MZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@
M $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X
M$+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (
MOO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV
M   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL
M  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(
M ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   F
MP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7
M*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>
M  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP
M$\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@
MYB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #N
MQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L
M  />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH
M /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP
M_J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\
M;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U
M /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\
M_Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#]
M ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H
MN@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48
M /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\
M\@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #?
M ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5
M$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R
M .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L
MT ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_
M& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-
M=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/
M ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@
M_Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)
M%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8
MX@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0'
M /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$
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M!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  # -P(
MNS,- +,T&0"N-B< J3<T *4W0 "B-TH GS=3 9TV6@&;-F$!F39H I<U;P*5
M-74#E#5\ Y(UA 20-8T$CS66!8TUH 6+-:L&BC6Y!H@UR@>'-N4'A3;V!X0W
M_P>#-_\'@S?_!X(W_P>"-_\']#(  .,[  #200  QD0  +U#  "W/P  L3L)
M *H[% "E/"( H#TP )T].P"9/44 ECU. 90\5@&2/%T"D#QC HX[:@.,.W$$
MBCMX!(@Z@ 6'.H@&A3J2!H,ZG >!.J@(@#JU"7X[Q@E].^$)>SSS"7L\_PEZ
M//\(>CS_"'H\_PAZ//\([C<  -U!  #+1@  OTD  +9)  "N1@  J4$$ *-!
M$0"=0AX F$,K )5#-P"10T$ CD)* 8Q"4@&)05D"AT%? X5!9@.#0&T$@4!T
M!8! >P9^/X0'?#^."'H_F0EX/Z4*=T"R"G5 PPMT0-T+<T'Q"W)!_PIR0?\*
M<D'_"7)!_PER0?\)Z3P  -5%  #%2P  NDX  +!.  "G2P  HD8  )M&#@"6
M1QH D4@G (Y(,P"*2#T AT=& 81'3@&"1E4"@$9< WY%8@1\16D$>D5P!7A$
M> 9V1($(=$2+"7)$E@IP1*(+;T2O#&Y$P QM1=D-;$7O#&M%_0MK1O\+:T;_
M"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH  )1*# "/2Q<
MBTPD (=,+P"$3#H @4Q# 7Y+2P%[2U(">4I8 W=*7P1U268%<TEM!G%)=0=O
M27X(;4B("6M(DPMJ2)\,:$BM#6=)O0UF2=0.94GM#65*_ QE2O\+94K_"V5*
M_PME2O\+X$0  ,M-  "]4@  LE8  *95  "<4@  E4X  (Y."0")3Q0 A5 @
M (%0+ !^4#< >U!  7A02 %U3T\"<TY5 W%.7 1O3F,%;4UJ!FM-<@=I37L(
M9TV%"F5-D0MD3)T,8DVK#6%-NPY@3=$.8$WL#F!-^PU@3?\,8$W_"V!-_PM@
M3?\+W$<  ,=0  "Y5@  KED  *)8  "85@  D%$  (E2!@"#4Q$ ?U,= 'M4
M*0!X5#0 =50] 7)310%P4TP";5)3 FM260-I4F $9U%G!F51;P=C47@(8E&#
M"F!1CPM>4)L-75"I#EM1N0Y;4<X/6E'J#EM1^@U;4?\,6U'_#%M1_PM;4?\+
MUDH  ,-3  "V60  JUP  )Y:  "360  BU0  (16 P!^5A  >E<: '97)@!S
M6#$ <%<Z &U70@%J5TD":%90 F965P-D5EX$8E5E!6!5;0=>578(756!"EM5
MC0M95)H-6%2G#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T
M ,!6  "S7   IUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX
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M#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@  +5@  "J9@
MFV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24 6VHO %EJ. !7
M:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX!T=HA E&:)(*1&>A"T-G
ML0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD
M (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T
M4'!% 4YP3 %,<%,"2G!: TAP8@1&;VL%1&]U!D)O@@= ;H\)/VZ>"CUNKPH]
M;L(*/&[@"CUM] H];/\*/6O_"CYK_PH^:_\*NF   *UI  "@;@  D6T  (1M
M  !X;0  ;&X  &%P  !;<@  5G0* %)U$@!0=AT 3G<G $QW,0!+>#D 27A!
M $AX20%&>% !1'=7 D)W7P- =V@#/G=S!#QV?P8Z=HT'.7:<"#=UK0@W=< (
M-G7>"#=T\@@W<_X(-W+_"#=R_P@W<O\(M68  *EO  ":<0  BW$  'YQ  !S
M<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#@#4 0H ] $&
M10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^J@8P?KT&,'[:
M!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4  'EV  !N=P
M8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3  .HDX #B)0  W
MB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&
M[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$
M %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$
M+)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@
MD/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.
M  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y"
M "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/<
M%IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \
MG   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J
M0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\
M  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP
M*ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 '
MMT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U
M]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4
M !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD
M ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@
MQ.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"
M   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X
M  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T
M>Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "
MT    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E
M-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@
M &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0
M .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P
M]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'
M&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![
M /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,,
M[ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_
M 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /,
M?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#,
M .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A
M_P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H
M '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -(
MW0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2
M /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L
MVP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#%
M .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.
M% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\
M ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D
MMPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R
M#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-
M?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z
M *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X
MV0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q
M%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;
M_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1
M ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD
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M WPQ_P-\,?\#[2\  -LW  #)/0  OCX  +,\  "L.   IS,$ *(R$0"=-!T
MF34J )4U-0"2-4  CS5) (TU4 "+-5< B35> 8<U9 &%-&L!A#1R H(T>0*
M-(("?C2+ WTTE@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W
M_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF
M (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#
M=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L
M//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5
M+0""0#< ?T!  'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$
M!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%
MW#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![
M130 >44] '9%10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#
MC09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$
M ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23
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M"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L  +E3  "K5P
MG%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"< 8E0Q &!4.0!>
M5$$ 7%1( 5I43P%95%8!5U1= E9490-45&X$4E1X!5%4A 9/5)$'3E2@"$Q4
MKPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D
M (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\
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M!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$  ']A  !T80
M:6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%
M:DP 0VI4 4)J7 % :64"/FEO CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H
M[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8
M %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D
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M B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@  $Q\  !#@
M.X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D (XQ" "*-2@ A
MC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(
M_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P
M "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T
M%9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0
ME/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::
M   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10
M  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L
MC8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7
MJ   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P
M4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD
M 'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M
M"[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2
MOE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5
M  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(
M  #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD
M ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;
MIP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0
M    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+
M  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@
M1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
MWP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T
M30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8
M /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (,
M]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G
M /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\
M'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$
M .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P
MV #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_
M "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .
MA0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U
M ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "
M\0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #.
M (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L
M_0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E
M .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($
MP "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N
M O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#
M*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:#
M +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\
MH0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@#
M##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</
MA0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_
M )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD
ML!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9
M%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<
M_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO
M *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0
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MCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(
M ,DY  "[/@  K#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4
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M UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2
MG$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F
M0D, 9$)* &-!4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#
MK0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H
M (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\
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M!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$  (%1  !W4
M;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@ 4%(_ $Y21@!-
M4DT 3%-5 $I370%)4V4!2%-O D93>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3
M[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$
M &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL
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M C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X  %)@  !,8@
M164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S
M:EL ,6IE #!J< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG
M_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L
M #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E<
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M8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X
M (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@
M&HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,
MD6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS
M  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<
M  Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(
M )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H
M>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF
M!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH
M  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA
M58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
MLP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X
M;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8
M $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@
M +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@
MR74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK
M   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P
M  #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<
M .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   D
MO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=
M    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K
M  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P
M_P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q
M (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .(
M_P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T
M /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H
MY0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1
M /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0
M.P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+
M -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\
MP0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C
M $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4
MC ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_
M +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L
MS0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U
M (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8
M_P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^
M +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D
MIP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9
M!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %
M0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF.
M )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\
M]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B
M#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1
ME "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H
M -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX
ME!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!
M&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I
M  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y!
M (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9<
M=2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W
M,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF
M1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0 ;"BA
M &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O-@
MH34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L0 !S
M+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z> 6(O
MK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH
M ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4,
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M DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0
M<ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4
M/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"
MZ ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T
M &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL
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M 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H  %E+  !43
M4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440 /U%+ #Y14P ]
M4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390
M_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(!
M $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH
M-E=C #57;P T5WP!,U>, 3%7G $P5ZT!,%?" 3!7X $P5O0!,5;_ 3%5_P$Q
M5?\!J%(  )52  "$4@  =U(  &Q2  !B4@  6%,  $]4  !)5@  1%<  $!9
M"  ]6A  .UH7 #E;(  X6R< -UPO #9<-@ U7#X -%Q& #-=3@ Q75< ,%UA
M "]=;  N77H +%V) "M=F@$J7:L!*EV_ 2E=W@$J7/(!*EO^ 2M;_P$K6O\!
MHU4  (]5  !_50  <E4  &=6  !>5@  5%<  $Q9  !%6P  /UT  #I?!  V
M8 T -&$3 #)B'  Q8B, ,&(K "]C,@ N8SH +6-" "QC2@ J9%, *61= "AD
M:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@
M (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H
M+&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?
M;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<
M  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(-
M "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X
M%75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O
M80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]
M#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X
M  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90
M868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -
MB0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)
M@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP
M %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP
M I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@
ME8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY
M   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.
M  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0
M **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   X
MBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L
M#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.
M  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0
M)IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"
MN@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$
MEP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T
M !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00
M ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@
MVYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^
M   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0   -L
M  #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\
M /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_
M $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L
ME0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_
M -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@
M] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #<
M )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L
M_P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!,
M .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )(
MR0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\
M /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -(
M4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4
M +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\
M_P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_
M %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L
MF "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P
M /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P
MK@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"<
M )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+
M  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!-
M *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D
MC@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*
M%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)
M3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB
M ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0
MKQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "(
M$$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3
MK@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,
M )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH
M?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K
M'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H
M  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+
M '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@
M82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%
M*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E
M30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK*
M %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P
M>2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?
M*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(O
MY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$
M &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT
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M 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH  & Y  !;.@
M5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$
M/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X_
M_P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX%
M $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH
M/D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y
M0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E#
M# !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A
M #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\
MID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!
M2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,
M:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<
M (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X
M.4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L
M474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*
M  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02
M #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W(
M)5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U
M3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;
M%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^
M !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40
M9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A
M8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5E
MBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8
M %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!,
M%FT: !5M(0 4;2D %&TP !-M.0#_XGT024-#7U!23T9)3$4 !Q(2;D( $6Y,
M !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\
M@ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L   =
M;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='  AW
M4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P >UT
M &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7>0
M$GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""3
M@ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(  &AB
M  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P  #88
M  B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1   CE$
M (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8
M:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(   "5
M    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7
M  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1<@
M1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B
MHP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L
M70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0
M #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P    L
M +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]4@
MO60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9
M   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP   ,
M  #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110  TE<
M -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H   :
MK@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\   #0
M    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H  .E=
M  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_ "8
M_P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K
M (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W -@
M_P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L
M /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#= '\
MVP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,< _P#&
M /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G .D
M,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_
M ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V /\
MM@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4 +0#1
M #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +<
M@ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_
M *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_ #$
MO  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G
M ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_ )@
M_P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L K0 U
M *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0": 'L
MF "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P",
M /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N )X
M-P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^
M (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\
MZ T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )( ,0"0
M #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$
MA !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14
M ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C,
M@PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R
M#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>
M  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V
M '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD
M9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?
M)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7
M. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2
M %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*
MBR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C
M'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0B
MG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+   ABT
M 'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8
M6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,
M**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3   '<O
M  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y
M %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H
M12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K
M,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM
M/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[
M #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F-0
M83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$
M,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HV
MT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P  738
M %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT
M/C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V
M.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D  %,V
M  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M"
M #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH
M,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ  !)
M.P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #-
M2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y
M "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$/P
M0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M
M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%
M_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1   .T4
M #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G2DL
M)DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B
M2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD  #)+
M   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@ (%!2
M !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\
MBD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0   H
M4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A7
M60 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D
M '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D60
M'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?50 0
M7V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.
M  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P  &6(!
M !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT
M!V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=
M4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P  $VH   ]M
M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@  <%<  '!E
M  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6  !95@
M45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<   #G,   MV!  %
M> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z
M<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P
M $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@
M (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':
MAWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI
M   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)
M  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(
M )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K
M>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=
M!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]
M  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP
M&8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
MK00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "X
MB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT
M  RB   #IP   *L   "N    L@   +8   "X    N    +H   "[    O0
M +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@
MS9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q
M    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X
M  #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(
M .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #]
M $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0
MBP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_
M ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X
M[ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0
M (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\
M_P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!"
M -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8
MO0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P
M /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,(
M10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"(
M *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\
M_P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O
M $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P
MBP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P
M .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $
MG@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"-
M (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,
M  #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!!
M (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H
M?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R
M#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (,
M0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2
M '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@
MFA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W
M!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)
MG0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@
M (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X
M; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<
M$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=
M  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_
M &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D
M4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P
M(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D7
M00!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX
M $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0
M9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0
M'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,B
MS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<
M %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D
M2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]
M*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H
M  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=#
M $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8
M."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0
M*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL
M2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W
M #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0
M1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U
M,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S
M_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(
M #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P
M+S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J
M-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV
M @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3
M "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\
MC38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R
M.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "-
M6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D
M '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004
M*D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <
M164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]
M  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<*
M "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V(
M%4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A
M00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/
M#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M
M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1
M4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 1
M5PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8
M>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@
M $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P
M"F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P
M8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,
M   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.
M  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8
M &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X
M5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q
M$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..
M  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7
M*F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@
M?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  "
MG0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH
M !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T
M (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0
MCJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\
M   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,
M  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(
M )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &
MD    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$  "J
M"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L
M  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP
M *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
MO 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(
MKP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,
M  "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+    S0
M ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@
MXJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /,
M4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3
M -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\
M_P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@
M %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8
ME@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P
M /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T
MQP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R
M )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T
M  #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!.
M +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0
MH0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>
M    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *(
M30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9
M )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
MN@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2
M $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 ((
MH "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@
M *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $<
M@P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T
M *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$
M  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!'
M '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8
M9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!
M"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L
M1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S
M %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0
M<PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A
M!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,
MQP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0
M &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44
M5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)
M$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7
M  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)'
M $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^,
M0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7
M&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $87
M2@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU
M #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@
M3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^
M'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A
M_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22
M $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP
M-R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q
M)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D
M!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3
M # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\
MC2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y
M* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL
M6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL
M '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D
M,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E
M,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O
M  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$-
M "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6,
M'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C
M,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W
M$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN
M !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0
M538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >
M/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !-
M?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD
M $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q
M%T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -
M18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\
M  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2
M !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X<
M!4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]
M/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1
M%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6
M  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@
M-$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@
M61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9
MI0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD
M "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810
M &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH
M8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3
M   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5
M  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+
M &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   6
M8   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W
M%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!
M  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P
M"V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0
MAA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'
MT0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT
M  "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#   E1
M )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP
ME]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1
M    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.
M  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L
M168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
MI0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\
M#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(
M #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@
M +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.!0
MT0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\
M  #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9
M .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$
MS "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_
M    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$
M60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F
M +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M[0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\
M %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@
MK0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP
M ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %,
MIP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6
M +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<
M @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2
M )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\
MA0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">
M  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (<
M40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z
M '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  (
MBP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X
M %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H
MR0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P &
M 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L
M:P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!>
M .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$
M"0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !,
M %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H
M4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F
M! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!
M3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M
M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04
M70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,
M"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-
M^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X(
M %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\
M1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [
M$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1
M"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4
M #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\
MCAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#
M%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #08
M6P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX
M '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P
M.QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M
M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C
M  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X.
M #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F(
M)B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C
M)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB
M$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M
M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0
M5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK
M>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP
M $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!(
M("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5
M,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N
M  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5
M !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D
M$#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^
M,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X
M&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9
M  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P
M-C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 .
M/AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_
MJ  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4
M "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D
M"$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I
M1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY
M   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<
M  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4
M $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B
M00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3
M'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*
M  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P
M%TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@
M7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:
MY   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,
M  Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP
M &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@
M9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@
M   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=
M  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P
M3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$
M'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX
M #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0
M ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@
MEB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9
M   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$
M  "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<
M *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G
M:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D
M    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8
M  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>
M%H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
MMP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5
M&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P %
M /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X
MW@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#"
M ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /,
M"P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!>
M ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,(
MK@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2
M  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$
M70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2
M )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P
MM@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"=
M %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P
MZ "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 .
M )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4
MBP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\
M /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T
M$0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4
M 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T
M;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\
M !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T
M5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X
M &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !
M;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@
M %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8
M_P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1
M &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$
M50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!,
M /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@
M$P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5
M $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\
ME0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/
M 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($
M6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA
M 'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$
M1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y
M"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5
M  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2
M #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V(
M,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D
M&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0
M%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L
M "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0
M5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P
M%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9
M>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R
M $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0
M*1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P =
M'8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B
M  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7
M "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H<
M%R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^
M)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB
M&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8
M !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@
M-B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7
M)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJ
MJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@
M "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P
M$2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )
M+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ
M   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@
M  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8
M C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F
M+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X
M)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*
M   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,
M'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0
M/B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]
MY   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8
M !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120
M $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP
M0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_
M   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH
M  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O(
M4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +
M20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7
M+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP
M $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40
M %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@
M8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_
M   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X
M  !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH
M &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U
M1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M
M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N
M  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3
M)5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2
M,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP
M !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",    C@
M )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0
MICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P
M   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP   *(
M  "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS
M +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
MB    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0   "V
M    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X
M  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$
M^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3
M &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D
M_P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6
M -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &(
MN@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E
M /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,,
M&P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A
M *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\
ME0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H
M !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ),
M8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_
M (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D
MDP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"!
M &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0
M_P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ;
M (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H
M< !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G
M /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '
M'0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!;
M &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\
MJ    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C
M !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8
M7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G
M (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D
M5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!*
M &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '
M  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ;
M $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\
M0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J
M#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0
M' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H
M #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$
M61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [
M AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'
M<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0
M $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D
M- D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G
M#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7
M  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T;
M "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0
M'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _
M&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80
M'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125
M !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P
M-AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8
MI@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T
M "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /
M'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>
M   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB
M !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4
M"R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F
M'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B
M)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'
M  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0
M(2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *
M)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $H
MX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,
M !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@
M RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX
M+/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG
M   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M
M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?
M5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2
M+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y
M,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L
M $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P
M#34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P
M0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O
M   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P
M  4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4
M $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V
M,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&
M    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\
M  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0
M+S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<
M1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD
M ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7
M %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/
M:DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$
M   620  $$T   I1   $50   %H   !=    8    &,   !F    :    &H
M  !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44
M 'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   0
M5   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![
M    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.
M  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80
M 6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
MCP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B
M60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<
M  !]    @P   (@   "-    D0   )4   "8    F@   )P   "?    H0
M *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@
MMV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/
M    E@   )L   "@    I    *@   "K    K    *\   "R    M    +8
M  "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL
M ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q
M "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D
M;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_
M )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0
MT@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q
M &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )(
M_P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G
M +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &<
MG !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P""
M /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\
M*0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H
M (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\
MU@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"(
M "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8
M:0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P
M *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0
M=0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E
M &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D
M  "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E
M &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &<
M5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\
M    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D
M)0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M
M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !-
M "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $
M=0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<
M %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "
M0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V
M ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,
M  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A
M #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T
M+0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !#
M#@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$
M(@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&,
M "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0
M.1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I
M R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'
MG0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(
M #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2
M(@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7
M#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3
M   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC
M !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+,
M$ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G
M%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80
M*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%
M  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@
M(18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1
M%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6
MW0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@
M !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H
M#!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $
M&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9
M   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO
M  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P
M6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6
M&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B
M-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T
M $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@
M$1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@
M)ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A
M   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,
M  TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D
M "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X
M)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ
M @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"
M   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P
M+2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 "
M,@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z
M3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD
M "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(
M #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P
M0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J
M   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"
M  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$
M $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;
M,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !.
M 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>
M  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.
M$3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D
M:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8
M  9*    3P   %,   !6    60   %P   !?    80   &0   !E    9P
M &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P
M<WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7
M    7    &    !D    :    &L   !N    <0   ',   !U    =P   'H
M  !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(
M (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M:P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P   "/
M    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!
M  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0
M ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
MI@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "Q
MC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4
M  ":    GP   *,   "F    J    *L   "N    L    +,   "V    N@
M +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0
MRI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .(
M-@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X
M +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\
M]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #
M #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *<
M>@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z
M -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$
MI@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1
M 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   /_B
M?1!)0T-?4%)/1DE,10 ($LT   "[    K@   *4   "?    G  ) )D #P"9
M !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0 (4
M50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_
M &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # "" !$
M@@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R
M %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_ &$
M_P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O  X ;P 2
M &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B $X
M80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4
M /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P / %\
M$P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0
M %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!* /\
MD@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %( $ !2
M !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !* $8
M4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\ A0
M '0   !G    70   %4   !/    3    $H   !(  0 1P * $< #0!& !$
M1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [
M %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?    &L
M  !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X /  1
M #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R %,
M,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%  !7
M!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  / #0
M$@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\ *0!:
M "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2"P
M2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P $  K
M !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7 "$
M9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0  0PX
M #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D 1
M) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!80 :
M 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0
M   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X '@41
M !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX
M$P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41   O
M$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)
M$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R
M  X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L$P
M)Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2
M#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/
MDP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%   )10
M "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q(
M#1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $
M$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4  !X4
M   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5
M  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@  %:,
M !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6   9
M%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83  46
M&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(  !BW
M   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8%@
M%14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@
M&QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV   ;
MT   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&   %!<#
M !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%   (1H
M "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?T0
M'^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD! !$9
M 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@  "<?
M   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0  (^X
M1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=   -
M'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<   M
M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\ 0"
M #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *)
M!B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U(
M-2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",  #(D
M   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P   2X
M   P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'   /B8
M #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G   H
M)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4    X
M    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$  $@L
M  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G*
M(B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!
M0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G  !3
M-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P  'RP
M !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,    3@
M %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B+
M83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,  !,W
M   ..P  "#\   %$    2    $P   !/    4@   %4   !8    6P   %T
M  !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0  <C0
M ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!   '
M1P   $P   !1    50   %D   !=    80   &4   !H    :P   &T   !O
M    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L  (8]
M  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.    5
M %H   !@    9    &D   !N    <@   '8   !Z    ?0   (    ""
MA0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S  "=
M1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P   &H
M  !Q    =@   'L   "     A@   (H   ".    D0   ),   "6    F0
M )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W/
MM%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P   "#
M    B0   (\   "4    F@   )\   "B    I    *<   "J    K@   +$
M  "T    N    +P   #!    QP   ,T   #4!0  V!   -4>  #3,0  T$@
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M_/[______________________________________________________P
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M______________________________________\
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M_VUF=#$      P0A   !                     0
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MQ;_4!R6ZUPE.KMH+<*#;$X>7S3F:DL-8J)&\;+*1MWJYDK2#O8ZSAK^+LH?
MB+&'P(:QB,&$L8G!@[&*P8*QB\* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
ML(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PO?
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MPH2I=,*%JG/!AZMRP8BK<L"*K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MEXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N@*+4K("CTJR
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MEZV$QI.MA,>/K(3(C*N%R8FKALJ'JX;*A:J(RH.JB<N!JHO+@*J,RX"JC,N
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M-VF%Z49T?^13>WS?8(%XW&B%=-IMB7#8<8MNUG6-;-5XCVK4>Y!ITWZ19].
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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MR)2'K,63AZ[#DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[#
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
M>9^QOWN<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO7N<LKU[G+*]>YRRO?^@$ '_
MI"0)_Z,R'/^H-"O_LR\T^;\M/.G-+T#9WB]*RN<T7[WJ.G.OWD&#H=-1D9?+
M8)V0Q&ZFC+]ZK8:[@;-_N(>X>K:-NW>UE;QUM9^\<K2HO6ZSLKYQK+*^=*>R
MOG:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO7:CLKUVH[*]=J.RO?^A$ '_I2,)
M_Z0Q'/^M+B?_N2DO[L@F,]K<)C?*YRQ/O?(R8Z_H.76AW4*$EM13D(_-8IJ*
MQW"BAL-ZJ("_@*U[O86Q=KN+M'.YDK5QN9JV<+FCM6VYJ[9JN+2X:[*VN&ZL
MMKANK+:X;JRVN&ZLMKANK+:X;JRVN&ZLMKANK+:X;JRVN/^C$ '_IR()_Z4O
M&_^S)R+TPB$FW=@=),OG(SR]\BI3K_,R9J'G.W:5WD:#C=96C8?09):$RW&<
M?\AXH7K%?J5VPH.I<L&)JV^_CZULOY:N:[Z=KFJ_IJYHOZZN9;VXL&6YN[!E
MN;NP9;F[L&6YN[!EN;NP9;F[L&6YN[!EN;NP9;F[L/^E$ '_J" (_ZPF%_R[
M'1KCT1,9S.49*;WR(D&O_2I5H?,T9I;I/W2,X4M_A=M9B(#59H]\T6^4=\YV
MF7/+?)QPR8&?;<B'H6K'C*-HQI*D9L69I63%H*5DQ:BE8\:RI&#$NZ9@Q+NF
M8,2[IF#$NZ9@Q+NF8,2[IF#$NZ9@Q+NF8,2[IO^H$ #_JAX(_[,=$>S)#@_.
MXPX5OO(8+:_^(D.A_RU5EO0Y9(SL16^$Y5%Y?N!<@'G<9X9TV6Z*<-9TCFS3
M>9%ITG^39]"$E63/BI=BSH^88,V5F5_-G)I>S:*;7<VKFUS-M)I<S;2:7,VT
MFES-M)I<S;2:7,VTFES-M)I<S;2:7,VTFO^K#P#_K1H'\L -",[3"@:^\ X:
MK_X9,*'_)$.5_S)2B_@_7H/Q2VA][%9P=^A?=G'D97ILX6Q^:=]R@6;=>(1C
MW'V&8=N"B%_:AXE=V8R+6]B2C%G7F(U8UIZ-5]:ECE;5K(Y6U:R.5M6LCE;5
MK(Y6U:R.5M6LCE;5K(Y6U:R.5M6LCO^O#0#_MPX#S<D( ;[8"0FN_1 <H?\<
M+Y7_*3^+_S=,@OY%5GSY4%YU]%ED;O%?:6CN9&UDZVIP8>IP<U_H=75=YWIW
M6^9_>%GEA'E8Y(E[5N..?%7BDWU4XIA^4N&>?E'AI7]1X:5_4>&E?U'AI7]1
MX:5_4>&E?U'AI7]1X:5_4>&E?_&T" #.P 8 O<X' :[@!PN@_Q(<E/\@*XK_
M+SB!_SU#>O])2W/_4E%L_E=79?M=6V'Y8UY>]VA@6_5M8ECT<F16\W=F5?)[
M9U/Q@&A1\(1I4/"):D_OCFM.[I-L3.Z9;4OMGVY+[9]N2^V?;DOMGVY+[9]N
M2^V?;DOMGVY+[9]N2^V?;M&Y P"\Q04 K=8# 9_X"PN3_Q88B?\D)(#_-"]Y
M_T$W</](/FC_3T-B_U5'7?]:2UG_8$U6_V504_]J45'_;E-/_W)43O]V54S^
M>U9+_7]72?V$6$C\B%E'^XU:1ON36T7ZF%Q%^IA<1?J87$7ZF%Q%^IA<1?J8
M7$7ZF%Q%^IA<1?J87+V] P"MS0$ GM\  9+_#0B'_QD2?O\I&W7_-2-L_SPJ
M9/]#+U[_2C18_U W5/]6.E'_6SQ._V ^2_]D0$K_:$%(_VQ"1O]P0T7_=$1$
M_WA%0O]]1D'_@4= _X9(/_^,23W_D4H]_Y%*/?^12CW_D4H]_Y%*/?^12CW_
MD4H]_Y%*/?^12J[%  ">UP  C_4  8;_#P1\_QL+<?\D$6?_+!=?_S4<6?\]
M(53_129/_TLI3/]2+$C_5R]&_UTP1/]A,D+_9C- _VHU/_]N-CW_<S<\_W<X
M._]\.3K_@3HX_X8Z-_^,.S;_DCPV_Y(\-O^2/#;_DCPV_Y(\-O^2/#;_DCPV
M_Y(\-O^2//^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z
M@&_N=XAWZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:Z
MD=QEP9+<9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1
MSFC2D?^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z@&_N
M=XAWZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:ZD=QE
MP9+<9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2
MD?^#$P'_A"(&_X4U%/^#1B3_?U4T_X%>0O^!9E#_?VY<^7QW9O-Z@&_N=XAW
MZG6/?>=RE8+D<)J%XVZ>B.%LHHO@:Z>-WVFKCMYHKY#=9[21W6:ZD=QEP9+<
M9<F2VV70DM)GTI'.:-*1SFC2D<YHTI'.:-*1SFC2D<YHTI'.:-*1SFC2D?^$
M$P'_A2(&_X8U%/^$1B3_@%4T_X1=0_^%95#_@VU=^(!U:/)]?G'L>H9YZ'>-
M?^5UDX7B<IB)X'"=C-]NHH[=;*:0W&NKDMMIKY3::+65VF>[E=IFPY;:9LR6
MTVC/ELQISY7(:L^6R&K/ELAJSY;(:L^6R&K/ELAJSY;(:L^6R&K/EO^%$@'_
MAR(&_X<U%/^%1B3_A%0U_XA<0_^(9%'^AVM>]X-R:?& ?'/K?85[YWJ,@N-W
MDH?@=)>,WG*<C]QPH9+;;J:4V6RJEMEJL)C8:;:9UVB]F==HQIK3:,R:S&K,
MF<9KS)K";,R:PFS,FL)LS)K";,R:PFS,FL)LS)K";,R:PFS,FO^&$@'_B"$&
M_X@U%/^&1B7_AU,U_XM;0_^,8E'^BFI>]H=Q:O"$>G3J@(-]Y7V*A.)ZD(K>
M=I:/W'2;DMIQH)78;Z68UFVKFM5KL)O5:K><U&F_G=1IR9W,:\J=QFS)G<!M
MR9V];LF=O6[)G;UNR9V];LF=O6[)G;UNR9V];LF=O6[)G?^'$@'_B2$&_XHU
M%/^(1B7_BE(U_XY:0_^/85'^CFA>]HMO:N^'>'7IA(%^Y("(AN!\CXS=>921
MVG::E=ASGYG5<*6;U&ZJGM-ML9_2:[B@TFO"H<ULQZ'&;L>AP&['H;MOQZ&X
M<,>AN'#'H;APQZ&X<,>AN'#'H;APQZ&X<,>AN'#'H?^($0'_BB$&_XLU%/^)
M1B7_C5$U_Y)80_^27E'^D&5>]HYL:^^+=7;HAWZ XX2&B-Y_C8_;>Y.4V'B9
MF=5UGIS3<J2?T7"JHM!NLJ/0;;JDSFS$I<9OQ*2_<,2ENG'$I;5QQ*6R<L2D
MLG+$I+)RQ*2R<L2DLG+$I+)RQ*2R<L2DLG+$I/^)$0'_BR$&_XPT%/^*1B7_
MD$\T_Y160_^46U'^DV%>]I%H:^Z.<';HBWN XH>#B=V#BI'9?I&7U7J7G--W
MG:#0=*2CSW&JILYOLZ?-;KVHQW#"J+YQP:FX<L&IM'/!J:]TPJBM=,*GK73"
MIZUTPJ>M=,*GK73"IZUTPJ>M=,*GK73"I_^*$0'_C"$&_XTT%/^+1B;_DTXT
M_Y930O^76%#^EEY>]I1D:NZ2;';GCW:!X8R BMR'B)+8@H^9TWV5G]!YG*/.
M=:.GS'*KJLMPM*O(<+^LOW.^K+=TOJVR=;ZLKG:_K*IVOZNH=\"JJ'? JJAW
MP*JH=\"JJ'? JJAWP*JH=\"JJ'? JO^+$0'_C2 &_XXT%/^-12;_EDTS_YE0
M0?^:54__FEI=]YA@:>^5:'7HDG" X8][BMR+A)/6AHR:TH"3H<Y[FJ;,=Z*J
MRG2KKLARN*_ =+ROMW6\L+!VO+"K=[ROJ'B]KZ5YOJVC>;ZMHWF^K:-YOJVC
M>;ZMHWF^K:-YOJVC>;ZMHWF^K?^+$ '_CB &_X\T%/^/1"7_F$HS_YM-0/^=
M44[_G5=;^)Q<:/":8W3HEVI_XI-UBMR/@)/6BHF;T820H\U^F*G)>:*NQW6M
ML<1TNK.W=KFSKWBYLZIYNK.F>KJRHWN[L:![O+"??+VNGWR]KI]\O:Z??+VN
MGWR]KI]\O:Z??+VNGWR]KO^,$ '_CR &_Y T%/^20R7_FD@R_YU*/_^?3DW_
MH%-:^:!89O&?7W+JG&5]XYAOB-R3>I+6CX2;T(B-H\N!EJO'>Z&QQ7:PM;IW
MM[:O>;>VJ'JXMJ-\N+2@?+FSGGVZLIQ^N[&;?KRPFWZ\L)M^O+";?KRPFWZ\
ML)M^O+";?KRPFWZ\L/^-$ '_CR &_Y$T%/^40R3_FT8Q_Z!(/O^B2TO_I%!8
M^J159/.D6G#KHF%[Y)]IA=Z:<Y#7E7Z9T(Z(H\J%DZS$?:"TO7BPN:]YM;FF
M>[:XH7VWMIU^N+6;?[FTF7^ZLYB NK*7@+NQEX"[L9> N[&7@+NQEX"[L9>
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M*"G_ERDH_Z J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1T0
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MB]:+=HO6BW:+UHMVB]:+=HO6B_]Y$0'_>!H"_XP9 _^>(P3_JB8&^+0E".O
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M=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?> 6$CXC5I%^)M<0OBK7D'WOE]
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M2#7_W4DT__!)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X2<FK  "VM
MJ,$  )O/  ".WP$ A_\1 7[_'01U_R<+;/\O$F3_-QA<_SX=5O]%(E#_2R5+
M_U(H1O]8*T'_7RT^_V<O._]O,3C_>#,V_X(T,_^--C'_F3<P_Z4X+_^R.B[_
MP#LN_],[+?_K/"W_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/+BP  "HO   FLD
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MCX61?8J"G(*%@*J%@7^\AH" VX6 @-V#@'_>@8!^X'^ ?>%]@'WC>X!\Y'J
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M64?0]UQ)R/=>2L'V8$N]]F!+O?9@2[WV8$N]]F!+O?9@2[WV8/^)  #9G@
MQZP! +FV @"NP0, I<X& )SD# "5[QT#C>\L"X7O.15\[T$><^]))VKN4"]B
M[E<U7.Y?.E;N:#]2[G%"3>]\1DGOB4E&\)9+0_"F34#QN4X_\MM//O#W3D+F
M^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%S_Q41<_\5.&5  #+I@  N[
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M+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8  (;3  !YX0
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M9E6D\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S9/]P#0#_A 0
MW98  ,ZC P#$K@0 N[<$ +3"!0"NS0P I\X@ I[-,0J5RSX6B\A)(X+&4BYZ
MPUHX<L%B0&O :D=DOG--7KU\4UF\B%=4NY5;4+NE74Z[N5Y-O-M=2[GW7TZQ
M]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #KC   TYL
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M1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P  *>V  ";P0
MD,P" (;9!@" \A( >?(? G'R*P9J\C8,8_,_$EWS1QA7\T\=4O-7(4WT8"1)
M]&DH1O1S*D+U?BT_]8LO//:9,3KVJ3,X][XT-OCA-3;U^34U\_\T-^S_-CGE
M_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/R   @]0
M 'GH!P!S_!(!:_T= F3])P1>_C$(6/X[#5/_0Q%-_TL52?]3&$7_6AI!_V,=
M/O]L'SO_=B$W_X(C-/^0)3+_GR<P_[ H+O_(*2W_ZBHL__\J+/__*B_Y_RHO
M^?\J+_G_*B_Y_RHO^?\J+_G_*KFF  "JK@  G+D  ([%  "!T0  ==X  &WZ
M"0!E_Q$!7O\: E?_(P-2_RP%3/\T!TC_/ I#_T0,/_],#CS_4Q X_UL2-?]C
M%#+_;!8O_W<7+/^$&2G_DQHG_Z(<)?^T'23_S!XC_^T>(O_]'R+__Q\B__\?
M(O__'R+__Q\B__\?(O__'ZRK  "=M@  C\(  (#.  !SW   9^D  %__!@!8
M_PX 4?\5 4O_'0)&_R8#0?\M!#S_-04X_SP&-/]"!S'_20@N_U )*_]7"BC_
M7PHE_VD,(_]T#2#_@@X=_Y(/&_^B$!K_LA$9_\@2&/_E$Q?_^A07__H4%__Z
M%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4  %'_ 0!*_PL
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M866)]U]GAOA>:83Y7&J"^EIK@?M::X'[6FN!^UIK@?M::X'[6O]B$ #_<@<
M^((# -N/ @#/F@4 R:,& ,.L!@"]LA  M;(D JRP-0NCK4(7FZI,(Y*F52Z*
MHUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AFE91<8I2A7U^3LF!=D\E@79/M7UZ0
M^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEEAOM998;[6?]F#0#_=P, XX<
M -.3 0#*G@0 PJ<$ +NO! "UM@T KK<A J6V,@F=LS\5E+!*((RM4RN$JELT
M?:AC/':E:D-PHW)*:J%[3V6@AE1@GI%86YV?6UB=L%U6G<==5IWK7%>:^EM:
ME?I:7)'[65Z._%A?C?Q77XW\5U^-_%=?C?Q77XW\5_]J"@#_?   W(P  ,V8
M  ##HP, NJH" +.S 0"LO H IKT= 9Z\+P:6NCP1C;A''(6U4"=]LUDP=K%@
M.&^O:#]IK7!%8ZMY2EZJA$]:J9!25:B>55*GKU=1J,974*?J5U"E_%=3G_U7
M59K]5E>6_E98E?Y56)7^55B5_E58E?Y56)7^5?]O! #F@@  TI$  ,:=  "[
MI@$ LJX  *JW 0"BP@4 G,08 )7#*@2-PCD-A<!$&'V^3B%UO%8J;KI>,FBY
M9CABMVX^7;9X0UBU@D=4M(]+4+2=3DVSKE!+M,502[/J4$JQ_U%,J_]23J7_
M4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<  +ZB  "SJ@
MJ;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C9\5<*F'$9#!<
MPVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%N?]*1[/_2TFM
M_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G  "JKP  H+@
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M+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T  ''8  !GY@8
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M!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\" "K_"@ F_P\
M(O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"!_]) @/_4P(
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MXGT024-#7U!23T9)3$4 "A*18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
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M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
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M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
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M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
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M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
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M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
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M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
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M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
M ,EV  "_?0  MX(  +"%  "HAP8 HHD7 )R**0&6B3<&D(=##(N%31.%@E49
M@(!='WQ_921X?6TI='MU+7!Z?C%M>8@T:7>4-V9VH3IC=K [87;$/&%VY3MA
M=OLY8G;_-V-U_S5C<_\T9'+_,V1R_S-D<O\S9'+_,_]8  #F9@  TG$  ,5Z
M  "[@0  LH<  *N*  "BC ( G(X4 )>/)@&1CC0%BXQ "X6*2A& B%,8>X9;
M'7:%8R)R@VHG;H)R*VJ >R]G?X8S8WZ1-F!]GCE=?*XZ6WS!.UM\XSI;?/HX
M7'O_-UU[_S5>>?\T7W?_,U]W_S-?=_\S7W?_,_Y<  #A:@  S74  ,!^  "V
MA@  KHL  *6.  ";D0  E9,1 )"4(@&+DS$#A9(]"7^12 ]ZCU$6=8U9&W&,
M8"!LBF@E:(EP*62'>2UAAH,Q786/-%J$G#97@ZPX58._.56#X3A5@ODW5H+_
M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
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M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
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M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
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M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
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M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
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M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
M0+T1 #^]'@ ^OBL /+XV #N_00 YOTL!-[]4 C7 7P(SP&H$,<!W!2_ A@8M
MP)<'*\"J""K!P@@JP.<'*;W]"BB\_PPGNO\-)[G_#B>Y_PXGN?\.)[G_#K*,
M  "EE   F9H  (VA  !_IP  <JT  &:S  !:N   3[L  $2_   ZQ ( ,,D(
M "[*$0 MRAT +,LI "O+-0 KS$  *LU* "C-5@ GSF$ )LYO 23.?P$CSY$"
M(<^E B#0O0(@S^0"'\WZ Q[+_P0>RO\%'<G_!AW)_P8=R?\&'<G_!JB4  "<
MF@  D*$  (*H  !TKP  9[8  %N\  !.P   0\,  #G'   OS   )] $ !_6
M"@ ;VA  &]L: !K;)@ :W#$ &=T\ !C=2  8WE4 %]]B !;@<@ 5X(4 %.&:
M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
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M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
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M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
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M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
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M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
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M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
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M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
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M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
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M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
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M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
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M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
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M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
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M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
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M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
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M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
M=6(N ')B.0%O8D,";&%+ VIA4P5G85H'96!B"6-@:@M@7W,-7EY]#UM>B1%9
M79825UVE$U5=MA147<X45%WN$U1=_Q%57/\055S_#E5;_PY66_\-5EO_#=Y,
M  #'5@  N%\  *UD  "@90  DV0  (EC  !_80  >6(# '5D$0!R91X ;V8K
M &QG-P%J9T "9V9) V5F401B95@&8&5@"%UD9PI;9' ,66-[#E9CAA!48I02
M4F*C$U!BM!-/8LP33V+M$D]A_Q%/8?\04&#_#E!@_PY08/\-4&#_#=E/  ##
M6@  M&,  *EI  ";:   CV<  (1G  !Y90  <V<  &]I#@!L:AL :6LH &=L
M- !D;#T!8FQ& E]K3@1=:U8%6FI=!UAJ90E6:6X+4VEX#5%HA ].:)(03&>A
M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
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M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
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M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
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M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
M07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q
M=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q
M  !<<P  47<  $IZ  !"?0, /WX. /_B?1!)0T-?4%)/1DE,10 +$CU_&  \
M?R, .X M #J -@ Y@3\ .(%( #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!
MH0,J@;8#*8'2 RE_\P,I??\#*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78
M (5U  !X=0  ;74  &%W  !7>@  3'X  $.!   [A0  -8@) #*)$0 QB1L
M,(DE "^*+P NBC@ +8M! "R+2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$B
MB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z
M  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0<
M "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX
M%9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L
M@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A
M&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+
M  NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP
M6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &
MK1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "N
MU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H
M $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10
M +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q
MO.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM
M   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84
M  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH
M ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   D
MO   &;\  !'"   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7
M$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F
M  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP
M#\H   ?.    T0   -8   #<    WP   .    #B    Y    .8#  #H"0
MZ0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #Y
MY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@
M  #=    X0   .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,
M /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP
M_]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\
M7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O
M /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\
M\ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_
M &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /<
MM #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_
M /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\
M^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H
M +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-
M$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B
M .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0
MU0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_
M# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X
M90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[
M ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@
M_PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#)
M &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0
MQP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\
M /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$
MN05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F
M"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09
M  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C
M *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X
MEQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*
M)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;
M90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q
M 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@
MM2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2
M)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K 80GNP&#*-$!@"CN 7XI
M_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4  ,$X  "T-@  JS$
M *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-+4P BRU4 (DN7 "'+F,
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M V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10  E4,  (Y   ")/
MA#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J
M07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU
M_P-=0/\#74#_ ]\Y  #(0P  N4H  *E+  ";20  D$<  (A$  "#00  ?D$&
M 'I"$0!V0QX =$4J '%%-0!O1C\ ;49' &M&3P%J1E8!:$9= F9&90)D1FT#
M8D9V!&!&@@1>1HX%7$6<!EM%K 991K\'6$;?!EA&]P571?\$5T7_!%=$_P-8
M1/\#6$3_ ]H]  #$1P  M4X  *1.  "63   BTL  (-)  !]10  >$8" '1'
M$ !P2!L ;DDG &M*,@!J2SP :$M$ &9+3 %D2U,!8DM: F!+8@)?2VH#74MT
M!%M*?P592HP%5TJ:!E5*J@=42KT'4TK<!U)*]@922O\%4DG_!%))_P-22/\#
M4TC_ ]1!  # 2P  LE$  *!0  "23P  ATX  'Y,  !X2   <DH  &Y+#0!K
M31@ :$XD &9.+P!D3SD 8D]" &%020%?4%$!75!8 EM/8 )93V@#5T]R!%5/
M?0533XH%4DZ8!E!.J =.3KL'34[9!TU.]09-3O\%34W_!$U-_P1.3/\#3DS_
M \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30  ;$\  &A0"P!E414
M8U(A &%3+ !?4S8 750_ %M41P!:5$X!6%16 59470)45&8#4E-O U!3>P1.
M4X@%3%.7!DM3IP=)4[H'2%/5!TA2\P9(4O\%2%'_!$E1_P1)4/\#25#_ \I(
M  "Y4@  JE<  )A6  "*50  ?U0  '93  !L40  9U,  &)4" !?5A( 75<>
M %M7*0!96#, 6%@\ %991 !564P!4UE3 5%96P)/6&0"35AM TM8> 1)6(8%
M1U>5!D57I09$5[@&0UC2!D-7\@9#5O\%0U7_!$15_P1$5/\#1%3_ \9,  "U
M5@  I5H  )19  "&6   >U@  '%7  !F5@  85@  %U9! !96A  5UL; %5<
M)@!373  4ETY %%>00!/7DD 35Y1 4Q>6 %*7F$"2%UK T9==@-$78,$0EV2
M!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:_P,^6?\#/UG_ \%0  "Q6@
MH5T  )!<  ""6P  =EL  &U;  !A6P  6UT  %9>  !28 T 4&$7 $YB(@!-
M8BP 3&,U $IC/@!)8T8 1V-. $9C5@%$8UX!0F-H D!C<P,^8X$#/&.0!#IB
MH00Y8K0%.&/-!3AB[P0X8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&
M (M?  !]7P  <E\  &A?  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"<
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M 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT  'ML  !O;
M96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G@A0 )H(> "6")P D
M@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#
MY@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,
M %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB<
M%XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .
MC?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^
M  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF
M  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?
M IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [
MC0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F
M*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\
M  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@
M*)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P
MLR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T
M_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P
M !:P   /M   ";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT
M ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@
MQ_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]
M   &P    ,,   #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;
M  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\
M -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)
MS    -    #5    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J
M&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T
M &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W
M .    #E    YP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@
M_!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\
M& #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M
M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\
M_0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_
M !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\
M< #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#'
M .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X
M_P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S
M '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .
MTP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P &
M /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P
MX@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#)
M .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\
M! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M
M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L
MMP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V
M  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P
M;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K
M *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!
MV@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L
M &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&
M^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T
M ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH
MGPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",
M$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1
M  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L
M )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\
M?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D
M%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>
M;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_
M '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$
ME1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![
M)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI
M_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<,
M (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\
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M =0W  # 00  KT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@
M:STD &D^+P!G/S@ 93]  &1 2 !B0$\ 84!7 %] 7@%=0&8!7$!O 5I >@)8
M0(<"5D"5 E1 I -30+8#4D#/ U% [P-00/\"4#__ E __P)1/O\!43[_ <\[
M  "]10  JD<  )E&  "+10  @40  'E"  !T/@  ;S\  &M # !G014 94(A
M &-#*P!A0S4 7T0^ %Y$10!=14T 6T54 %E%7 %8160!5D5M 51%> )2184"
M4423 T]$HP--1;0#3$7, TM%[0-+1/\"2T3_ DM#_P),0O\"3$+_ LH_  "Y
M2   IDH  )5)  "'2   ?4<  '5%  !N0@  :4,  &5$"0!B11, 7T8> %U'
M* !<2#( 6D@[ %E)0P!724H 5DE2 %1)60%326$!44EK 4])=@)-28("2TF1
M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
M3U$U $Y2/0!-4D4 3%)- $I25 !)4ET!1U)F 452<0%#4GX"05*- C]2G0,^
M4J\#/5+& SQ2Z0(\4?X"/%#_ CU/_P(]3_\"/4[_ KY+  "N4P  FE(  (E1
M  !\40  <5   &A0  !>3@  6%$  %12  !14PP 3E04 $Q5'P!+5BD 258R
M $A6.@!'5T( 1E=* $174@!#5UH 05=D 4!7;@$^5WL"/%>+ CI7FP(X5ZT"
M-U?$ C=7YP(W5OT"-U7_ C=4_P(W4_\".%/_ KI/  "I5@  E54  (54  !X
M5   ;50  &14  !85   4E8  $Y7  !*60D 1UH1 $9:&P!$6R4 0ULN $)<
M-@!!7#X /UQ& #Y=3P ]75< .UUA #I=; $X77D!-EV( 31=F0(S7:L",5W"
M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
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M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
M_^)]$$E#0U]04D]&24Q%  P2R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_
M /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L
MW0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\
M )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\
M  #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ]
M +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H
MHP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V
M    YP   -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8
M/0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ".
M (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C
MS    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1
M #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P
ME !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP
M *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #<
M?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L
M )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<
M  "-    A@   ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W
M &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8
M70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_
M @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &(
M. !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C
M %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P
M; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6
M #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@
ML@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\
M %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4
M30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^
M \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82
M  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX
M $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,<
M-0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-
M%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X/
M/  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L
M "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@
M1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V
M%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5
M_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P
M #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T
M+AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B
M&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>
M   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]#
M "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\
M'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S
M(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D
M2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_
M (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)
M*R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;
M*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E
M  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD
M "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E
M%"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J
M*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O
M   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;
M  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0
M6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7
M-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX
M90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$
M $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@(
M$#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80
M/G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T
M   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(
M  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T
M $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [
M-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)
M#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]
M  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@
M,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@
M4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4
MCP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX
M "=    @0P  &48  !-)   /3   "T\   92    5    %<"  !8!P  60L
M %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0
M7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(
M   :2P  $TX   Y2   *50   UD   !;    7@   &    !B @  8P8  &4*
M  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T
M &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   3
M50  #ED   A=   !80   &0   !G    :@   &P   !N    <    '(%  !S
M"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S
M  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80
M!F8   !J    ;P   '(   !V    >0   'P   !]    ?P   ($   "# @
MA@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(
MSP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8
M  ![    ?P   (,   "'    B@   (T   ".    D0   ),   "5    F
M )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0
MF^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-
M    D@   )8   ":    G0   )\   "A    I    *8   "H    JP   *X
M  "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(
M +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".    E    )H   "@
MI0   *H   "N    L0   +(   "U    MP   +H   "\    OP   ,,   #&
M    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO
M #=Q   I>   '8   !&)   (D0   )H   "A    IP   *T   "S    N0
M +X   #"    Q0   ,8   #)    S    ,X   #2    U0   -H   #>
MX0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\
M  #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+
M /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T
MZ0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_
M    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\
M30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B
M ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_
M_0   /H   #X    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#-
M $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$
MJ0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@
M .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4
ML0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8
M +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D
M  "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$
M )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@
M@P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F
M    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4
M0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S
M '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3
MC    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R
M $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$
MP@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?
M '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T
M8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4
M -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D
M  !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ]
M %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X
M20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;
M    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P
M/@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J
M #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0
M4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!"
M $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8
M^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T
M $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X
M.@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M
M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .
M  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM#
M #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\
M)PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y
M$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P0
M2P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_
M (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%
M,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D
M%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7
M  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8
M "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$
M'1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K
M'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;
M!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY;
M !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P
M62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @
M( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C
M9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,
M $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0<
M&28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,
M*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G
M   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+
M !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7
M!"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \
M*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ
M#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_
M   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+
M,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '
M-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   W
MD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X
M "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X
M #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP
M/:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO
M   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0
M  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0
M $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @
M-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,
M$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\
M  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/
M%3\  !!"   ,10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@
M5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5
MXP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@
M  M+   %3@   %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X
M &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0
M8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6
M    6@   %T   !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.
M  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<
M &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )6@   5\   !C
M:    &L   !O    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&
M#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__
M $9+   Z3   +D\  "-3   86   $%X   ED    :0   &\   !T    >
M 'P   "!    A    (<   "(    BP   (X   "0    DP   )8   "9!P
MG0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2
M   R50  )EH  !M@   19P  "6T   !T    >P   ($   "&    BP   )
M  "4    EP   )D   "<    GP   *$   "D    IP   *H   "M    L08
M +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K
M80  'F@  !-P   +>    (    "'    C@   )4   ":    GP   *0   "H
M    K    *T   "P    LP   +4   "X    NP   +\   ##    QP   ,L%
M  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<
M%GD   V!   !BP   ),   ";    H@   *@   "N    M    +@   "]
MP    ,(   #%    R    ,L   #.    T0   -8   #;    WP   .0   #H
M!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P
M /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4
M_ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#?
M -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P
M  #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4
M .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4
MO0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R
M    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,(
M4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#<
M *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/
MR    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F
M %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X
M\ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@
M *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H
MC@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y
M /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X
M 0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!(
M '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8
M9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X
M  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@
M2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_
M %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $
M9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8
M $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T
M_P!- /\ 30#_ *H   "4    @@   '4   !K    9    &    !=    6@ %
M %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $,
M3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!#
M /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X
M"0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!%
M $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\
M.0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$
M  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@
M20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_
M (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @
M/ $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O
M %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,
M  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@*
M #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX
M)P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M
M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +
M"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8
M " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P
M6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I
M#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D0
M9@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<
M $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L
M(A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2
M%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;
M   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18-
M !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7(
M#1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \
M'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<
M$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z
M  <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P
M,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0
M(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $B
MD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$
M "HA   F(   (B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A
M"R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP
M)J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C
M   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3
M  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0
M "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C
M)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q
M%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\
M   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@
M'"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@
M.!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   V
MY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L
M !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0
M $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP
M//P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S
M   --@  "3@   4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6
M  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P
M $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (
M/@   T$   !#    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5
M&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_
M $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2
M $H   !-    4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P
M8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\
M   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8
M  !9    7    %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4
M '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y
M/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=    80   &4   !H
M    :P   &X   !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7
M  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10
M*$@  !U,   34@  #%<   -=    8P   &@   !M    <0   '8   !Z
M?@   ($   "#    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">
M&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,
M !59   -8    V<   !N    =    'H   "     A    (H   ".    D@
M )4   "7    F@   )T   "@    HP   *<   "K    KP   +0)  "X$
MMQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI
M   %<0   'D   "!    B    (\   "4    F@   )\   "D    J    *D
M  "L    KP   +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0
M -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[
MA    (T   "5    G0   *,   "I    KP   +0   "Y    O    +X   #"
M    Q0   ,@   #,    T    -0   #:    WP   .0   #J    [@P  .T:
M  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @
M_@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V
M &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H
M_P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ )
M /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L
MU@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G
M /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .
M"P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9
M +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\
MBP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W
M  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L
M5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_
M '8 _P!S /\ <@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H
MF  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "#
M %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D
M_P!G /\ 90#_ ,P   "^    JP   )T   "3    B@   (4   ""  4 @  -
M '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\
M;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!;
M /\ 6@#_ +T   "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P
M#@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/
M %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\
M3P#_ *T   "8    A@   '@   !N    9P   &,   !@    70 % %P "P!;
M !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X
M40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_
M )\   ")    >    &P   !B    6P   %8   !3    40 " $\ " !/  T
M3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !"
M %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),
M  !^    ;@   &$   !8    40   $P   !)    1P   $4 !0!$  L 0P .
M $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %
M-P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V
M P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H
M$  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7
M "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"
M7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q
M !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8
M8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T
M $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\
M*@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 >
M 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0
M  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0
M "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L
M%@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]
M$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+
M$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^
M  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%
M,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9
M#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0
MD  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8
M "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A(
M$A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $
M%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8
M   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5
M  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$
M !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A
M&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;
M&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY
M   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P
M'!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #
M(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?
MW@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP
M !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D
M "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP
M(_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>
M   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=
M   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L
M "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0
M(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S
M(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_
M $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*
M"RH   <L   #+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0
M.R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I
M   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$
M  $T    -@   #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$
M $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X
M+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \
M    /P   $$   !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G
M  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0
M+B\  "DN   @+@  &3$  !(S   .-P  "3H   (]    0    $0   !'
M20   $P   !/    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>
M+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(
M "0S   ;-@  $SD   X]   (00   $4   !)    3    %    !3    5@
M %D   !;    70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0
M;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[
M   5/P  #D0   =)    30   %(   !6    6@   %X   !B    90   &@
M  !K    ;0   '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP
M ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /
M2P  !U$   !7    7    &(   !F    :P   &\   !T    >    'L   !^
M    @    (,   "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS
M  "720  E&(  )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@
M &$   !H    ;@   '0   !Y    ?P   (0   ")    C0   )$   "3
ME@   )D   "=    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R
M/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',
M  ![    @@   (D   ".    E    )H   "?    I    *8   "I    K0
M +    "S    MP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@
MS4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0
M    EP   )X   "D    JP   +$   "V    N@   +P   #     Q    ,@
M  #+    SP   -0   #:    X    .8   #K    \08  / 3  #N)P  [#\
M .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_
M !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$
M:@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_
M )8 _P"0 /\ C #_ /H   #R    [    .D   #I    [  % /( # #X !(
M]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#*
M &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@
M_P"# /\ @ #_ /    #E    W@   -H   #;    W    -@ !P#1  X T0 5
M -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$
MK !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V
M /\ = #_ .(   #3    R@   ,<   "\    M@   +   0"O  L K  1 *T
M& "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A
M (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\
M: #_ ,\   #!    N0   *T   "@    F    )0   "1  8 D  - )  $@"/
M !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@
M8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_
M +X   "Q    H    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0
M=P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C
M &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +
M  "?    C0   '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5
M &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P
M4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-
M    ?    &X   !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0
M%@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A
M $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_
M;P   &,   !9    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!'
M !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@
M:0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90
M %@   !/    2    $,    _    /0   #P  @ \  < .P , #L #P [ !(
M.@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M
M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"
M  !( P  0 ,  #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3
M #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X
M) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !"
M"   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@
M%0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\
M !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P
M-0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @
M !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4
MCP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T
M "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0
M&008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0
M :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/
M   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6
M !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\
M"@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A
M$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,
M&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT
M  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0
M&Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,
M$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .
MU   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(
M !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH
M"!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP
M$?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03
M 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?
M  (6)P  %S   !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<
M !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2
M$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;
M)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_
M %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00
M#Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0
M(2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9
M   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!
M  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<
M "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \
M'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?
M   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN
M   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0
M+B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E
M)P   "D    L 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V
M-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0
M "0C   ?(0  &R   !8@   1(0  #B,   HE   &*    BH    M    +P
M #(    T    -P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0
M0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E
M   ?(P  &"0  !(E   .*   "BH   4M    ,    #,    V    .    #L
M   ^    0    $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH
M $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;
M*   %"H   XM   *,   !#,    W    .@   #T   !     0P   $8   !(
M    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&
M  !76@  570  %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P
M$#(   HV   #.@   #\   !"    1@   $D   !,    3P   %(   !5
M6    %H   !=    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G
M4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT
M  )"    1P   $P   !0    5    %@   !;    7P   &(   !E    :
M &L   !N    <0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20
M>V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1
M    5@   %L   !@    90   &D   !N    <@   '8   !Y    ?    'X
M  ""    A0   (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED
M )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "5    %L   !A
M:    &X   !S    >0   'X   "#    B    (P   "/    D@   )4   "9
M    G0   *$   "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II
M  "HB   IJ@  *+1 "-(   83@  #E0   1<    9    &T   !U    ?
M (,   ")    CP   )4   ";    H    *,   "F    J0   *T   "Q
MM0   +D   "^    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%
M?   PIT  ,&] !Q5   17   !V4   !N    =P   '\   "(    D    )@
M  "?    I0   *T   "S    N    +H   "^    P@   ,8   #*    S@
M -,   #:    X    .<   #M    \P   /0.  #R'@  [S8  .Q1  #H;@
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M__________________________________________________\
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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M      ,$(0   0                    $                    !
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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M6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEO4SPH
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
MRO%15;[R6&BMYF%WGMUGA)+5;(^'SV^6?LMSG'C(=J%RQGFD;L1\IVG"@:EF
MP(:L8K^-K6&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_CZYAOX^N8;^/KF&_
MCZYAOX^N8;^/KF&_CZ[_HAT#_Z8G!_^W+PGRQS@-X=A!%-+F1BK'\$Q OOA0
M4[+U5V.BZV%PE>-G>XK=;82!V'&+>M1UD'32>9-PT'R6;,Y_F6C,@YMDRXB=
M8<J-GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@R8^?8,F/GV#)CY]@
MR8^?8,F/GV#)CY__I!T#_ZTF!?N^+0;FT#0(T^(\%L?N1BN[^4H^L/Y/3Z;Z
M5UR8\6%HC.MH<8/F;GA[XG-]==]X@7'=>X1MVW^':MJ#B6?9AHIDUXN,8=:0
MCF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.8-61CF#5D8Y@U9&.
M8-61CF#5D8[_IQP#_[4C ^[))@/5WRD'Q^P\&;KX1"NM_T@[H_]-29K_5U2-
M^6%=A/1J97SP<&IV[79N<>MZ<6WI?G1KZ()V:.:%=V;EB'ECY(QZ8>.1?&#C
MDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2?&#CDGQ@XY)\8..2
M?&#CDGS_JQL"]\ = =G<$@''ZR@*NO<[&JS_02F@_T8VE?],08W_5DN#_V%2
M>_UK5W3Z<5QO^'9?;/9[86GU?V-G](-D9?.&9F/RBF=A\8YH7_"2:5_PDVI?
M\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_PDVI?\)-J7_"3:E_P
MDVK_MQ4!UL\+ ,?J$P*Y]RD-K/\Y&I[_/B:2_T0PA_]+.8#_5$!X_V%&<O]J
M2FS_<$UI_W909O][463_?U-C_X-48?^&56#^B59>_HU77?V26%S]DUA<_9-8
M7/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUA<_9-87/V36%S]DUC6
MQ @ QM0) +CW% 2K_RD.GO\T&)#_.B&$_T$I>O]),'+_4C9L_UXZ:/]H/63_
M;T!A_W1!7_]Y0U[_?41=_X!%7/^$15O_AT9:_XI'6/^/1UC_D$A8_Y!(6/^0
M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
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MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
MCJ.+Q(BADL>#GYK)@*"GRGV:K,9]F*_!?9BOP7V8K\%]F*_!?9BOP7V8K\%]
MF*_!?9BOP7V8K\%]F*_!?9BOP7V8K\'_F!L#_Y8G"/^@+PW_K#<2_[= &_W!
M2"CVRTXY[]-43.;96F+8U&%WQ\MGBKG#;)JMO'*GH;9WL9BQ?;B/K8*^B*J)
MPX*HD,9]IYG(>J>ER7>BK,5XG[#!>)^PP7B?L,%XG[#!>)^PP7B?L,%XG[#!
M>)^PP7B?L,%XG[#!>)^PP7B?L,'_F!L#_Y<F"/^B+PS_KC<2_[D_&OG$1R?Q
MSDTXZMM32^#?66#0VE]VP=!EB;/):YFFPG"EF[UUKY&X>[:(M8"\@;*&P'NP
MC<-VKI;%<ZZAQG*MK<1RJ;# <JFPP'*IL,!RJ;# <JFPP'*IL,!RJ;# <JFP
MP'*IL,!RJ;# <JFPP'*IL,#_F1L#_Y@F"/^D+@O_L381_KT_&?3(1R7KU$TV
MY>-02=GC5U_)WUYTNM=DAJS/:9:=QVVCD<!QK(:[=;-^MWJY=[1_O7*RA;]M
ML8W!:K"7PFFQI<%LM+*];+2RO6RTLKULM+*];+2RO6RTLKULM+*];+2RO6RT
MLKULM+*];+2RO6RTLKW_FAL#_YDF"/^G+0K_M38/^<$_%^[.1B/DW$PRW>=/
M2<_H5E[ Y%URLMYD@J/4:9&5RVV<B<5PI7_ <ZQWO'>Q<+E\M6NW@;AGMH>Z
M8[60NV&UF[QCMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKECMZ:Y8[>FN6.WIKEC
MMZ:Y8[>FN6.WIKG_FQL#_YLE!_^K+0G_N34-\L<^%>751A_:XTDSS^M.2<;M
M5%VWZEQNJ.)C?9K9:8J.TFV4A,QQFWO(=:%SQ'BF;L)\J6G @:QEOH>N8KV.
ML%^]E[%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ7KR>L5Z\GK%>O)ZQ
M7KR>L5Z\GK'_G!H#_Z D!O^P+ CYP#0+Z<\]$-K?0AW.Z4DSQ/%.2+OR4EJM
M\%MIGN=C=I+@:8&'VF^)?M1SD'?1=Y5QSGN9;,Q_G&C*@YYDR8B@8<>.HE[&
ME:1<QIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;I%S&FZ1<QIND7,:;
MI%S&FZ3_GAH#_Z4C!?^W*@7PR#('W-LU#,[G0A_"\4@TN/E,1J_W456B]5MB
ME>UD;8KG:W: XG!]>=YU@G/;>H=NV7Z*:]>"C&?5AHYDU(N08=.0DE[1EI1<
MT9N57-&;E5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1FY5<T9N57-&;E5S1
MFY7_H1D"_ZTA _B_)@/BU"4#SN4S#\+P0B&V^D<SJ_Y+0J+^4$^7^UM:B_5E
M8X+P;&IZ[')P=.EX=&_G?'=LY8%Z:..$?&;BB'UCX8Q_8."1@5[?EH)<WIJ#
M7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH-<WIJ#7-Z:@US>FH/_
MHQD"_[8= >G,%P'/XQX#PO S$K7Z0"*I_T0PG?])/97_4$B+_UM0@OUE5WKY
M;5UT]G-A;_1Y9&OR?F=H\8)I9O"&:F3OBFQB[HYM8.V2;EWLEW!<ZYMQ7.N;
M<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW%<ZYMQ7.N;<5SKFW'_K!4!
M\\,0 -':"P#![Q\&M/LS$ZC_/"";_T(LD/](-H?_3S]__UI&>/]E2W'_;4]L
M_W-2:?]Y56;^?E=D_8)88OR&66'[BEI?^HY;7OJ27%SYEUU;^)M>6_B;7EOX
MFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFUY;^)M>6_B;7EOXFU[ZN0X S<L)
M ,#F#0&R_" (I_\S$YK_.1V-_S\F@O]&+GK_3C5S_U@Z;?]C/VG_;$)E_W)$
M8O]W1F#_?$=?_X%(7?^%25S_B$I;_XQ+6O^03%C_E4U7_YE-5_^935?_F4U7
M_YE-5_^935?_F4U7_YE-5_^935?_F4U7_YE-5_^935?_F4W-P08 OM ' +'V
M#@*E_R$)F?\N$HS_-!F _SL@=O]#)VW_3"QF_U0P8O]@,U[_:35<_V\W6O]T
M.%G_>3E8_WTZ5_^ .U;_A#M5_X<\5/^+/5/_D#U2_Y,^4O^3/E+_DSY2_Y,^
M4O^3/E+_DSY2_Y,^4O^3/E+_DSY2_Y,^4O^3/E+_DSZ]Q04 L-<% */_$ .9
M_R()B_\I#W[_,!5S_S@::?] 'V+_22-;_U$F5_]:*%7_8BI2_VDK4?]O+%#_
M<RU/_W<N3O]Z+D[_?2]-_X O3/^$,$O_B#!+_XLP2_^+,$O_BS!+_XLP2_^+
M,$O_BS!+_XLP2_^+,$O_BS!+_XLP2_^+,$O_BS#_BQP$_X@H"/^$- [_CSH4
M_Y="'/^>2R?_GE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A
M=*.*WW&HCMUOKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="
M'/^>2R?_GE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*
MWW&HCMUOKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>
M2R?_GE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&H
MCMUOKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;
MS&7+F\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>2R?_
MGE<T_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&HCMUO
MKI';;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+
MF\QERYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>2R?_GE<T
M_YUB0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&HCMUOKI';
M;;.4VFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QE
MRYO,9<N;S&7+F\QERYO_BQP$_X@H"/^$- [_CSH4_Y="'/^>2R?_GE<T_YUB
M0O^9;4__DWA<^(V"9_*(BW'L@I-YZ'R9@.1XGH;A=*.*WW&HCMUOKI';;;.4
MVFRYEMAKPIC5:<R:S&7+F\QERYO,9<N;S&7+F\QERYO,9<N;S&7+F\QERYO,
M9<N;S&7+F\QERYO_BQP$_XDH"/^%,P[_D#D4_YA"'/^>2R?_GU8T_YYA0O^:
M;5#_E7==]X^!:/&)BW+K@Y)[YWV8@N-XG8C@=*.,W7*HD-MOK9/:;K.6V&RZ
MF-9KPIO1:<J<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<RF;*G,IFRIS*9LJ<
MRF;*G,IFRIS_C!P#_XDG"/^(,@[_DS@4_YM!'/^B2B?_I%0T_Z)?0_^?:E']
MFG1?]91^;.V.B'CGAX^!XH"5BMU[FI#:=Z"6UG2FFM1QK)[2;[*AT&VYH\]L
MPZ;%9\.FP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'
MH<!IQZ'_C1P#_XHG"/^*,0W_EC<3_YY &_^E22?_IU,T_Z==0_^D:%/\H')B
M\II\<.J4A7WCBXN(W822D=A^F)C3>IZ?T'6DI,URJJC+;["KR6VXKL)IO+"\
M:\"JMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I;=MQ*6W;<2EMVW$I;=M
MQ*7_C1L#_XLG"/^,, W_F#<3_Z! &_^G2";_JU(T_ZM<1/^I9E3ZI7!D\)]Y
M<^>8@H'?CXB-V8B/E]*!E:#.>YNGRG:AK<=SJ+'%<*^UP6VWM[EKN+6S;KVN
ML'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:BP<,&HL'#!J+!PP:C_
MCAL#_XLF"/^., W_FC82_Z(_&O^I2";_KE$T_ZY;1/^L9%7YJFYE[Z5W=N6=
M?X7<E(62U(R,G<Z$DJ?)?9BOQ'B>M<)UI[G!=+&[N'"SN[%OMKBL<;NQJ7._
MJZESOZNI<[^KJ7._JZESOZNI<[^KJ7._JZESOZNI<[^KJ7._JZESOZO_CAL#
M_XPF"/^0+PW_FS82_Z0_&O^K1R;_L5 T_[%91/RP8U7VKFQG[:IU>..A?(C9
MF(.6T9")H\J'CZW%@I>TPG^@N+Y\J+N[>K"]L72RO:ERM+NF=+FSHW:^K:-V
MOJVC=KZMHW:^K:-VOJVC=KZMHW:^K:-VOJVC=KZMHW:^K:-VOJW_CQL#_XPF
M!_^1+@S_G382_Z8^&O^M1R7_LT\T_[181/JT85;SLFIH[*]S>N&F>HO6G8":
MS92&I\:-C:^_AY2UNH*<N;5_I+RR?:R^JWFQOZ-VLKV@>+BUGGF]KYYYO:^>
M>;VOGGF]KYYYO:^>>;VOGGF]KYYYO:^>>;VOGGF]KYYYO:__CQL#_XTF!_^3
M+@S_GC41_Z@^&?^O1B7_MDXS_K=71/>W8%;PMFAIZ+-P>]ZJ=XW0GWR=QY>#
MI[^0BJ^XBY&VLH:8NJV#H+VI@:F_I7ZPP)QYL;^:>[>WF'V[L)A]N["8?;NP
MF'V[L)A]N["8?;NPF'V[L)A]N["8?;NPF'V[L)A]N[#_D!H#_XTF!_^4+0S_
MH#41_ZD^&?^Q1B3_N$TS_+M61/6[7U;MNV=IX[5N?=:L<X_*HWJ=P9N I[B4
MA["QCXZVJXJ5NZ:'G;ZBA:7 GX2OP99^L,&4?[:XDX"[LI. N[*3@+NRDX"[
MLI. N[*3@+NRDX"[LI. N[*3@+NRDX"[LI. N[+_D!H#_XXF!_^5+0S_H341
M_ZL]&/^S1B3_NDTS^KY51/._75;JOV5JW[AK?M"O<8_%IGB<NY]^I[*8A:^K
MDXNVI8Z3NY^+FKZ;B:+!F(BLPI""K\*/@[6YCX2ZLX^$NK./A+JSCX2ZLX^$
MNK./A+JSCX2ZLX^$NK./A+JSCX2ZLX^$NK/_D!H#_XXE!_^6+ O_HC40_ZP]
M&/^U12/_O$PR^,%40_##7%;GPV-JVKMI?LRR<(_ JG:<MJ)\IZV<@J^EEXFV
MGI.0NYF/F+Z4C:#!D8RIPHN(KL**B+2ZBHBYM(J(N;2*B+FTBHBYM(J(N;2*
MB+FTBHBYM(J(N;2*B+FTBHBYM(J(N;3_D1H#_X\E!_^8+ O_I#00_ZX]&/^W
M12/_OTPR]L530^[(6U;CQF%JU+]H?L>V;HZ[K72<L:9ZIJ>@@*^?FX:UF)>.
MNY.5E;Z.DIW!BI*GPH:.KL*$C;2[A8RYM(6,N;2%C+FTA8RYM(6,N;2%C+FT
MA8RYM(6,N;2%C+FTA8RYM(6,N;3_D1H#_X\E!_^9+ O_IC0/_[ \%_^Y1"+\
MP4LQ],E20NO-657?R6!JS\)F?<*Y;(VVL7*;JZMXIJ*E?JZ9H(2UDIV+NHR:
MD[Z'F)O A)>EPH"6K\)_DK.\@)&XM8"1N+6 D;BU@)&XM8"1N+6 D;BU@)&X
MM8"1N+6 D;BU@)&XM8"1N+7_DAH#_Y E!_^;+ K_IS0/_[(\%O^[1"'YQ4LP
M\<Y10>?26%3:SEYIRL9E?+V]:XRPMG":I;!VI9RJ?*V3IH*TC*.)N8:@D+V!
MGIF_?9ZBP7N>K\%YF;.\>I>XM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU>I>XM7J7
MN+5ZE[BU>I>XM7J7N+7_DAD#_Y E!_^=*PK_JC,._[4\%?R_1"#TR$HN[=-0
M/^/85E/3TEUHQ<IC>[?":8NJNV^8G[9THY6Q>JR-K8"RA:J'MW^GCKMZII>^
M=Z:@OW2FK;]SH;2[=)ZXM72>N+5TGKBU=)ZXM72>N+5TGKBU=)ZXM72>N+5T
MGKBU=)ZXM72>N+7_DQD#_Y$D!_^?*PG_K#,-_[@[%/C#0Q[OS4HLY]I//=W>
M55'-V%MGOL]B>K#(9XFDPFV7F;QRH8^X>*F&M7ZP?[*%M7FPC+ATKY6[<*^?
MO&ZOK+QMJ[6Y;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT
M;J>YM&ZGN;3_E!D#_Y(D!_^B*@C_L#(,_KPZ$O+'0ASHTTDIX>%,.]3C4U'&
MW5IEM]5@>*G/9H>=R6N4D<5PGH?!=J9_OGRL>+R$L7*ZB[1MN9.V:KB<N&>W
MI[AGM[>V:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[
ML6BRN['_E1@#_Y4C!O^E*0?_M#$*^,$Z$.O.0AC@W4<EU>5+.\OG45"]XUEC
MK]Y?=*+898.6TVJ/BLYOF7_(<Z%UQ'BG;L%]JVF^A*YEO8NQ8;R3LE^\G;)?
MO*RQ8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_
MOJW_EA@#_YDA!?^J* ;_N3 (\,@X#>'80!/4XT4FRNM+.\'L3T^SZ%=@IN5?
M;YKB9GR.W&R&A-5QCWK0=95SS7J;;,I_GV?'A*)CQHJD7\21IES$F:=:PZ2G
M6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*?_
MF!<"_YX@!/^O)@7XP"X&YM S"-7A/!3)ZD4HO_)*.[7Q3DRI[U9;G>U?:)+J
M9W.'XVU\?MYR@G;:>(APUWV,:]2"D&;2AY)CT8R57\^2EES.F9A9SJ*96,VK
MFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-JYK_FA<"
M_Z4> _^W(P/MR28#UMXI!LGI.Q>^\T0IL_A).JCW34B?]E55E/5?8(GQ:&B
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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M?E3AN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?E3AN'[_F!,!_ZT4 ?/##P#2V L
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M ^W'+ 3?U3$&T]XY%,;81"BYT4X[K,Q63*#'75J5PF-GB[]I<8*[;WEZN':
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M'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!^FP
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M/$;_O3U%_\P]1/_F/D3_YSY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YS[+K
MN;8! *S" 0"@T ( E>4' ([_& .$_R0&>O\L"W#_-!!H_SP58?]$&5O_2QU6
M_U,@4_];(E#_8R1-_VLF2_]S)TG_>BE(_X(J1O^**T3_E"Q"_YXM0?^G+D#_
ML2X__[PO/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3"[L0  K+P
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M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
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M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
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M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
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M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
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M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
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M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
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M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
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M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
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M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
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M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
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M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
M '[,  !SU@( :>4) &3O% !?\" !6? K U3P-05/\#X'2_%&"D?Q3@Q$\5<.
M0O%?$#_R9Q(]\G 4.O)[%3CSAQ8V\Y08-?2B&3/TL1DR]<4:,?7B&C'T\1DQ
M\?X9,?'_&3'Q_QDQ\?\9,?'_&3'Q_QFRI   I:L  )BV  "+P   ?LH  ''5
M  !EW@  7O4* %G\$P!3_!X!3OPG DK], -%_3D%0?U !C[^2 <[_D\)./]7
M"C;_7@LS_V<,,?]P#2[_? XL_XD/*_^6$"G_I! H_[01)__'$2?_X1$F__(1
M)O_V$2;_]A$F__81)O_V$2;_]A&GJ0  F;,  (N^  !^R0  <-,  &3>  !8
MYP  4O\) $W_$0!'_QD!0_\B 3[_*@(Z_S(#-_\Y S/_/P0P_T8%+?]-!2O_
M5 8H_UL')O]C!R/_;0@A_WD)'_^'"1[_E0H=_Z,*'/^Q"AO_P L:_]8+&O_?
M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
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M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
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M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
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M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
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M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
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M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
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M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
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M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
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M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
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M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
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M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
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M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
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M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M4(/_'U"#_Q_>:0  R74  +R   "RB   _^)]$$E#0U]04D]&24Q%  \2J(T
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M&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P  (FA  !]I@
M<:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR1 -+L4T%2+%5!T6Q70E#
ML64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K
M_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(
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M A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP
M*=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1
M[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK
M_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$
M !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<
M _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+
MJP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z
M   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3
M  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M
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M ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT
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M";HS_PFZ,_\)NC/_";HS_PG_.1  _ST+ /] "0#_1 T _T81 /]%&0#W1",
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M_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY
M Z%<2P>=6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?
M@U&J(8%1N")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_
M2@  [E(  -Y;  #/80  QF0  +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA
M2 :67U$*DEY9#8]<81&,6V@3B5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G
M(GE6M2-W5L<D=E;D)'97]Q]W6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3
MZ58  -E?  #+90  P6@  +II  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:0
M8TX*C&)7#8EA7A"&7V43@UYL%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):
MLB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D
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M)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(  ,=K  "\<@
MLW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'>'1-"G1R50YQ
M<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5::[LF66S3)EIL
M[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL
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M&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0
M?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3
MBV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&
M_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94
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M#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@
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M !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@
MD:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5
MV@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F
M@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D
M '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP
M"_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0
M\H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ
M  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!
M  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT
M /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/
MS0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_
M    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K
M  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2<
M_Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_
M *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I
M /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP
M_P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W
M _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5
M+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ?
M /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\
M[0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@ _R A /\>*P#_
M&C< _Q=% /\440'_$EX!_Q%I ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0
MH0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_
M >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S,
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M!Z<S_P?_-P< _SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$
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M%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0
M\D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>
M3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(
MM1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L
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M'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9
MMV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ
M7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:
M[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH
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M%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P
MB',  (%S"P!\=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?
M;VH07&YS$EIN?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L
M_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@
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M$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD
M6I 4 %B0(0!6D2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM
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M!2VDEP8LI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@
MI8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  S
ML!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22Q
ME (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$
M ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T
M(KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7
MP*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>
M  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+
M !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI<
M"<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !Q
MK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9
M#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=
M  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0
M6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P
MXPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #N
MH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8
M #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04
M .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0
M_:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4
M   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@
M  #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT
M /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_
M $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\
MJ #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_
M /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_
M *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /,
M_P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5&
M /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *<
M^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I
M ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,
M3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J
M .T&L@#J!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
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M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
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M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
M (-B# !^8Q@ >F,F '9C,@!S8SP!;V)% FQA3 1J850%9V!:!V5@80AC7VD*
M85]Q#%]>>PY=7H816EZ3$EA=H!177; 55E[$%E5>XQ567O<25E[_$%=>_PY7
M7O\-5U[_#5=>_PW>4P  R%T  +MD  "P:@  IFT  )UN  "3;0  A6<  'YG
M"0!X9Q4 =&<C '%H+P!N9SD!:V=" FAF2@-E9E(%8V58!F!E7PA>9&<*7&1O
M#%IC>0Y88X0056*1$E-BGQ-28JX546+"%5!BX1518O8246+_$%)B_PY28O\-
M4F+_#5)B_PW95@  Q&   +=H  "L;@  HW$  )IS  "/<0  ?VL  'AK!0!R
M:Q( ;FP? &ML+ !H;#<!9FQ  F-K2 -@:T\$7FI6!EQJ70=9:64)5VEM"U5I
M=PU3:((/4&B/$4YGG1--9ZP42VC %$MHWA1+9_423&?_#TQG_PY-9_\-36?_
M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
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M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
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M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
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M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
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M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
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M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
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M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
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M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
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M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
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M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
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M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
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M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
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M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
M.%=1 #=86@ U6&4 -%AQ #)8@ $Q6) !+UFB 2Y9M0$M6<\!+5GO 2Y8_P$N
M5_\!+E?_ 2Y6_P&R5P  I5\  )ME  "1:0  AVH  'QJ  !Q:   8V4  %AB
M  !-7P  0UT" #Q;#0 Z7!0 .%P= #=<)@ U72X -%TV #-=/@ R748 ,5Y.
M #!>5P O7F( +5YN "Q??0 J7XX *5^@ "A?LP$G7\P )U_M 2=>_P$G7?\!
M*%W_ 2A<_P&M7   HF0  )AJ  ".;@  @V\  'EO  !N;@  8&L  %1I  !)
M9P  /V4  #5C"0 R8Q$ ,&,9 "]D(0 N9"D +60Q "QD.0 K94( *F5* "AE
M5  G95\ )F9K "1F>@ C9HL (F:= "!FL0 ?9LD 'V;K "!E_@ @9/\ (&/_
M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_XGT024-#7U!23T9)3$4 $!+_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y
M .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\
M#0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U
M /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4
MZ@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_
M  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T
M=@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D
M -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0
M_P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#:
M '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,
M[P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  '
M .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\
MPP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N
M /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\
M# #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O
M +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /(
MG0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#&
M !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *(
M;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\
M (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H
MM  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3
M V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,
M_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D-
M *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H
MA0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T
M$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/
M$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L
M '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\
M:AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%
M&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>
M< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_
M &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!(
M=R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B
M)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH
M_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9
M &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W(
M62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*
M-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M
M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z
M %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@
MMD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:
M,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LV
MA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4
M *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R(
M4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$
M.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.
M  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG
M $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$
M/D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "7
M5   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9
M+ !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@
M #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46
MBUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _
M13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)
ML0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T
M 'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX
M.4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L
M3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA
M  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R
M #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4
M)E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M
M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7
M-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE
M !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P
M76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B
M7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?
M^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X
M $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4
M&&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 0
M9O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T
M   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X
M  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\
M"6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U
M?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\
M/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_
M  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP
M(X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@
MB4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$
M_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(
M !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD
M )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+
MA@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?
M   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\
M  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0
M>)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
MK0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W
M/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@
M %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@
M +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@
MRT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F
M  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L
M  #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4
M .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   X
MM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=
M    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX
M  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !
M_P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_
M (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0
M_P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2
M /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T
M]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C
M /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\
M&0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!]
M .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\
MRP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q
M "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X
M? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_
M +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D
MVP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y
M 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4
M_P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ?
M ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4
MIP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5
M /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +,
M(P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V
M )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\
MA@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A
M "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@
M=P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_
M '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\
MD0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z
M"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T.
M_P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB
M ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'<
M;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6
M)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83
M)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^
M &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@
MO3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I
M&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?
MAP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8
M *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28
M7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/
M)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_
M  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K
M %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y
M1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "9
M10  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L
M+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&>
M $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620
MC$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!'
M,3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LV
MKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX
M (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\
M0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U
M.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0
M  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT
M #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\(
M+S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q
M4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_
M.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B
M "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P
M85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O
M13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(
M]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@
M %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL
M)TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >
M3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);
M  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%
M "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\
M&%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"
M7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A8
M10 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_
M !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@
M,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /
M84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?
M_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X
M "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T<
M!6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7
M;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV
M   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.
M  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0
MB7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0
M@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""
M50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($
M 'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@
M H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030
MD%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+
M  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T
M  "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0
M *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9
ME@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J
M    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:
M  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP
M/Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
MN    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&
M8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP
M "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&    R
M ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5
MX6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y
M   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P
M  #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP
M /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X
MB@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_
M .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "<
M_P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O
M (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D
M_P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N
M /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0
MVP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^
M /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0
M,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$
M ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\
MK #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#*
M #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\
MA0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_
M )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$
MM  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"<
M (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T
M_P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T
M *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (
MBP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N
M"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ),
M-0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$
M 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0
MS1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"#
M #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"
MBP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"
M +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#
M= @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B
M#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K
M  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R
M &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I(
M5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?
M,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5
M- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ?
M $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.
MD#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4
M'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4A
MK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T
M (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3,
M2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ]
M)\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _
M  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V
M $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\
M-RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S
M0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK
M.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'>
M #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10
M94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU
M]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4
M %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P
M,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H
M.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&
M  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI!
M "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\
M(SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*
M2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_
M2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_
M !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@
M/4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =
M14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&
M_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$
M "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P
M%4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">
M5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6
M   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4
M  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70
MD60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =
M70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;
M7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL
M (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@
M$68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@
M9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U
M  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$
M  9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0
M &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S
M?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]
M!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO
M  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P
M784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
MB08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")
M?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT
M $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP
M )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P
MF(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9
M   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4
M  "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX
M *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @
MHP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U
M    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-
M  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0
M"[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
MQP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<
MF0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L
M  "_    PP   ,8   #+    S@   -$   #1    U    -8   #9    VP
M -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB
M]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\
M00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2
M /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\
MR0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#]
M $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .<
MDP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_
M +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $
MZ0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#.
M )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T
M_P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!#
M ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X
MMP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_
M    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L
M10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1
M *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M\0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G
M $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$
ME0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP
M -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\
ME0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_
M )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-
M  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!
M (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4
M< "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M
M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '<
M0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"?
M &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P
MFQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I
M D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(
MK0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4
M (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH
M70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,
M#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I
M  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [
M %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X
M0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X
M*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6
M/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO;
M #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@
M:BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!
M'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A
M]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(
M %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T
M.2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O
M)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS
M  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9"
M #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\
M*BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.
M,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__
M "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0
M030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G
M,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R
M_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL
M #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T
M(#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C
M1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]
M   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6
M !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P
ME5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G
M0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !-
M8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8
M (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2
M&T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -
M1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@
M  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$
M !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD
M!$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z
M:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6
M"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W
M  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@
M;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #
M8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>
MAP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4
M %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL
M &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@
M:)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[
M  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-
M  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(
M '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _
M@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "#
M#0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D
M  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0
M)XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P
MD@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1
MM@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<
M !&8   )F0   )L   "<    G@   *    "@    H    *    "A    H00
M *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK
MI,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC
M    I0   *<   "I    K    *X   "N    K@   *\   "P    L0   +(
M  "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L
M +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
ML0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0   #&
M    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$
M  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@
M ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
MWP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #Q
MQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1
M /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T
M\ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_
M    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /(
M4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@
M -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M_P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#<
M %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,,
MI0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P
M /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X
MP@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L
M *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /
M  #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!.
M *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *,
MEP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/
M    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L
M3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J
M (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
MM@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P")
M $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4
MM !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0
M *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $<
M>0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E
M ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+
M  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !&
M &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P
M6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%
M#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\
M1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2
M $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&
M=1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3
M!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,
M[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL
M &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4(
M2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [
M$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=
M  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%%
M #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\
M-!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4
M'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<6
M2@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_
M "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0
M1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O
M'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@
M_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4
M #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X
M*2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F
M.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F
M P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96
M "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@
MF$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L
M* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK
M8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<
M (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8
M)"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6
M,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/
M  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+
M !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L
M$#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^
M5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X
M#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ
M  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P
M<EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0
M/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!
MB@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&
M &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX
M"$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@
M2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F
M  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1
M  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@
M $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3
M:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:
M$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K
M  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<
M/VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0
M9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@
MP0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8
M "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$
M ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO
M:^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_
M   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1
M  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H
M 'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /
MB0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-  "-
M$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO
M  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0
M )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "="P
MGA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<
M^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,
M  "E    J    *D   "I    J0   *H   "K    K    *T   "N 0  L D
M +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !D
MDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T
M    M@   +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'
M  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP
M2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
MQ@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A
M!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P
M /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L
M^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G
M +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\
M  #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !<
M .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0
MS #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_
M    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X
M7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^
M +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
MY@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V
M %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *
MRP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP
M ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4
MH@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP",
M .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4
M 0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3
M (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\
M>0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@
M  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\
M4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G
M &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
MC0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O
M %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P
M]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ %
M 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P
M8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0
M /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$
M" !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!-
M %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L
M1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A
M! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D
M3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_
M #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0,
M4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^
M"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-
M_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \&
M $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E
M- Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J
M+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1
M"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7
M "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0
MFC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U
M% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "87
M8  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H
M (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H
M+!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?
M'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!
M  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT-
M "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H
M&")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_
M1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A
M$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y
M !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@
M=$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9
M)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XK
MBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\
M &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!
M$RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (
M,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2
M  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3
M  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID
M #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;
M50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[
M%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL
M   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7
M3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0
M0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"
MPP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T
M #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@
M $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P
M2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A
M   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;
M  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(
M %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E
M:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?
M'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW
M  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<
M$V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0
M:B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D
M_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H
M  1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H
M '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^
M?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&
M    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<
M  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA
M:H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
ME0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":
M'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT
M %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I
M *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P
MKB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28
M   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0
M  "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14
M ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   I
MI@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##
M    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8
M  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $
M_P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R
M &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P
M[@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P &
M /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &,
MW !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#
M /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T
M# #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B
M ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /(
MJ@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #.
M !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P
M80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_
M )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T
MLP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7
M %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V ((
M_P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0
M )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D
MA !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P
M /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X
M$@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8
M '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\
M80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\
M !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0
M60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_
M %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !
M;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6
M %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D
M_P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1
M %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8
M20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R
M&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %,
M$P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!:
M #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(
MGR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!'
M !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$
M80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH
M ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q
M.P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K
M"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR
M  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1
M #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH
M(@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  "
M-P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0
M$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X
M !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P
M=#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08
MB0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\
M &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /
M'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"
M  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5
M !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID
M"B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<
M1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B
M&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L
M  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2
M4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,
M*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   K
MP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH
M $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL
M!2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP
M,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-
M   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@
M   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N
M #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U
M3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU
M   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50
M)5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@
M1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"
M_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH
M !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<
M $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%
M90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@
M   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM
M  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;
M>7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M:@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D
M-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<
M &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0
M '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+
M<CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^
M  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,
M  "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(
M ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+
MAP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1
M    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X
M  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D
M,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
MH    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I
M0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP
M !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O    L
M +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P
MP$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG
M    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(
M  #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL
M -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_
M !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D
M;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_
M ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4
M\P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#.
M &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0
M_P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  :
M -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@
MM@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P";
M /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T
M'@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G
M )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\
MA@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E
M "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T
M9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_
M '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L
MD  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y
M &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &<
M_P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P =
M 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$
M: !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%
M    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X
M'@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D
M %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@
MK T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!?
M !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P
M: !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10
M )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H
M40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _
M &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=
M  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P :
M $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L
M- !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$
M)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P
M&P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V
M "H B  H )P )P"P "8 R0 E .H )0'[ /_B?1!)0T-?4%)/1DE,10 1$B4!
M_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$   0PP"
M #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I!$,
M* 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?
M*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.
M!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D  ( I*
M !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0
MD#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03   M
M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y' !<.
M4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4
M (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J%0$
M(Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1
M$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\
M  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'   (!@#
M !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP
M#!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!   !W
M00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\  !<:
M"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI
M  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U10
M;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A!  /
M'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A
M>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@  :TH
M &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -) H
M"2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F=P
M)HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\  &!.
M  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H !2L.
M  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0  +(H
M "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3  !6
M40  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-   R
M$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<  #&>
M   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !55P
M25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z#P
M.1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<   W
MLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27   1%@
M #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0  0A
M $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _L0
M/M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX  #);
M   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX  $L2
M  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP  1LT
M $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB   ?
M8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40  !4
M%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H  $_O
M  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7:0
M#F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@$
M8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM  !9
M_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@  !W$
M  !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#   ;1$
M &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y
M>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T   !]
M    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P  'P2
M  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S@
M98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*
MC    (T   "-    C    (P   ",    C    (P   "-    C00  (X,  ".
M$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@  6H@
M $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9    FP
M )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B#
MHA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39   #^3
M   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@   *L
M  "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0  N0T
M +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<   C
MH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L   "Z
M    O    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$  -0/
M  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_
M_P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G
M %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"] ,L
MX #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_    _
M /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D
MRP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0 S0"R
M /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z    .
M!@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %, M !8
M +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "= .8
MFP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8  0"_
M  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1 )X
M5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -, AP#W
M (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K  <
MI0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ")
M %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K ',
M_P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  ( E  +
M )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X
M=@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B
M /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ ' ($
M#0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!.
M &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\
M5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 " ', "@!O
M  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!' %<
M3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_
M $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C  P
M7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L 2 !)
M %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_ #P
M_P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @ 50 -
M %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L
M/0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F
M%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  * $@
M#@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8 ,P!/
M #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A'
ME2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $  "P \
M  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+ "@
M50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28
M (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T  P
M,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "  4@ ?
M %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M
M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D *04-
M "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP
M%@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W
M,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP) !\)
M#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI
M  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@
M;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D."@ 5
M# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0
M>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P  :SH
M &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1$ L
M#@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03=@ #
M$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\  & ]
M  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D #!,.
M  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D
M !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"  !6
M/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-  89
M$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<  !R=
M   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !51
M2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?$
M'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;   A
ML@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420  2D8
M $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@  )1(
M "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   FL
M)<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP  $%)
M   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$  "T6
M   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP  *\L
M "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-   P
M20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04   T
M&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H  #'N
M   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J3P
M($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \&
M/"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM   W
M_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50  &5,
M !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%   11P
M $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   __P!^
M80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL   M9
M   "6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@  $\B
M  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![:0
M=&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B
M8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<  !:
M*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<   <W0
M &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M    ;0
M &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G(0
M9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z
M  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@   'H
M  !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&   =R8
M '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%
M@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B    (D   "(
M    AP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P  (DL
M  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   YB@
M*HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6
MEP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA  "=
M,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP  'I4
M !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F    IP
M *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T)P
MM#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\   6A
M    HP   *8   "I    K    *\   "S    M0   +<   "V    MP   +@
M  "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.&@  SR\
M ,](  #08@  T(   -"=  #0N                        0,$!08("0H+
M#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R,S0V-S@Y.SP]/D!!0D1%
M1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK;&YO<'%S='5W>'EZ?'U^
M@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.DIJ>HJJNLK:^PL;.TM;:X
MN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>W^#BX^3FY^CIZ^SM[O#Q
M\O3U]O?Y^OO\_O______________________________________________
M________                      $#! 4&" D*"PT.#Q$2$Q06%Q@:&QP=
M'R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y 04)$149'24I+34Y/4%)35%57
M6%E;7%U>8&%B8V5F9VEJ:VQN;W!Q<W1U=WAY>GQ]?H"!@H.%AH>(BHN,CH^0
MD9.4E9:8F9J<G9Z?H:*CI*:GJ*JKK*VOL+&SM+6VN+FZN[V^O\'"P\3&Q\C)
MR\S-S]#1TM35UM?9VMO=WM_@XN/DYN?HZ>OL[>[P\?+T]?;W^?K[_/[_____
M_________________________________________________P
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M]_CY^OO\_?[_;69T,0     # 2$   $                    !
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M________J#4          %S3____________________________?0T
M     %36___________________________N?44          $34________
M___________________\JF0O @  !"(W25C.________________________
M____Z:1K02@_8W^5I[K:_______________________________5LJRRS.3Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________ENY=W8LC_________________
M________________VYYG-@H  HS________________________________(
M?S\%     %[/_____________________________]F!.0       #RJ____
M_________________________YY,         ".0____________________
M________W&\:         !!]^?__________________________KT@
M      !O[O__________________________A!,           !DYO______
M___________________L40            !7WO______________________
M__^X%0            !(UO________________________]T%
M   XS_________________________FB6A,            CQ?__________
M_______________?FUPL           -NO__________________________
M[[%]53DB$0<! A$BLO______________________________W[^EF9B:H*R]
MVO__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____X[Z=@'S[________________________________\K>$5S . !VL____
M___________________________2BDP5      !R\___________________
M_________]9_-@        !+R?__________________________^I$^
M       OJ___________________________P%H            :E?______
M____________________C20            (A/______________________
M___G7@              =_________________________^T)0
M    :O________________________]]                6_3_________
M______________TK                3.O______________________Z4
M                /.'______________________S ,
M+=G_____________________F8IA)P              )]?_____________
M_________^V^B54G            )=S__________________________LJ=
M=EU*/#(M+# Y1][_______________________________WFW=;2T-/9Y/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________OU+O6____________________
M_____________^>XCVI++Q5O_______________________________DH6<T
M!P     \R?___________________________]:".P         2E_______
M____________________[84Q            ;_______________________
M____ID(             4.'________________________L:0
M    -\G_______________________^S+P              (K;_________
M______________]Y                $*?_______________________(T
M                 )G______________________ZD
M (S______________________T8                  '______________
M________WP                   '3_____________________EP
M             &K_____________________S@                   &/_
M_____________________RDB 0               &'_________________
M_____[FC@%<W%P           &C___________________________K3KI2&
M?'5Q<')W@93_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________V[J=@FEIT_______
M________________________R)-E/1D    =GO______________________
M_____]N.3!,         ;O__________________________VWPL
M    1=?_________________________BRH             (K3_________
M_______________"1                Y?_______________________]]
M 0               '_______________________^<V
M &K______________________YT                  %C_____________
M_________T8                  $?X____________________Z0
M             #7I____________________E@                   "7;
M____________________O                    !C.________________
M____ZP                    _"_____________________P
M          JY_____________________R<                   JU____
M_________________W                    VY____________________
M_^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38TL[,
MR\S/UN#\____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________Z].\X________________________________]*IA65(
M+!(!A?____________________________&K<3P/        3^#_________
M________________U7\U            '[+________________________C
M=1T              (G_______________________^0(P
M &?______________________]5#                 $CV____________
M_________XH                  "[=_____________________S@
M             !?(____________________O@                    2V
M____________________G                     "E________________
M____N@                    "3____________________W
M          ""_____________________P                    !T____
M_________________Q,                   !H____________________
M_T(                   !@_____________________WH
M      !=_____________________]$                   !A________
M______________\D                  !F_______________________)
MK)F)?79Q;&EG9F=K<'J,________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________XL6JD7EA=___________________________
M___=IG=0+ P     ,<3_________________________X)).$P
M (_________________________2<!T              &#_____________
M_________^YO#P               #?B_____________________Y8<
M             !3 _____________________T                    "C
M____________________K@                    ")________________
M____G@                    !R____________________O
M          !?____________________V@                    !-____
M________________^@                     [____________________
M_PX                    J^?___________________S,
M       ;Z?___________________UX                    /V_______
M_____________X\                    &T/___________________]
M                    RO____________________\K
M    R/____________________^                     R___________
M___________W%@$%!0,!       !!@T8R________________________.OA
MV,_,S<_0TM37W.+J____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________':
MQO______________________________\<:CA&A-,A@ %:O_____________
M_____________[E\1A@          ''________________________7?"\
M             #OC_____________________]]D"0                RU
M_____________________W0#                  "-________________
M____Q14                   !J____________________F0
M          !+____________________M@                     P_?__
M________________UP                     9Y___________________
M]@                     %T____________________PX
M        P?___________________R\                     K_______
M_____________U(                     GO___________________WD
M                    CO___________________Z4
M    @/___________________]@                     =/__________
M__________\V                    ;?____________________]\
M                :?_____________________7#0
M:/______________________<                   8?______________
M_________U \1DY465UA9&AL<'9^B?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____[]6[HXMS6I7___________________________B_CF1!(04      %+\
M_______________________WG588             !?!________________
M_____^5L%@                "-_____________________V,
M          !>____________________G0                     U_/__
M________________H0                     1V?__________________
MR@                      N___________________[@
M        H?___________________PP                     BO______
M_____________RT                     =O___________________TT
M                    9/___________________V\
M    4O___________________Y0                     0/__________
M_________[P                     ,/___________________^H.
M                (O____________________]$
M%?____________________^!                    "_7_____________
M_______("P                   NS_____________________7@
M             .7_____________________R1P                  -K_
M_____________________YT!              <.%\7_________________
M_______5N;S!Q\[5V^'F[?3[____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________XW\__________________
M____________[,:EB&U4.R$' #+>________________________UY)9*0
M          "@______________________^)-@                !G____
M_________________V8                    R]O__________________
ME0                     #R/__________________IP
M        H/__________________UP                      ?/______
M_____________P                      7O___________________R4
M                    0____________________T@
M    +/___________________VH                     &/__________
M_________XL                     !?/__________________Z\
M                 .'__________________]4
M ,____________________\D                     +[_____________
M______]4                     *[___________________^+
M             )_____________________+#@                   )+_
M____________________5P                   (;_________________
M____J@H                  'G______________________VT
M         &;_______________________=5                 $7_____
M____________________:B,K-3]*56!J=7Z'D9S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^C/MIV#:4ZY____
M_____________________^RR@UPZ'0(       ![____________________
M___%;2D               ! _____________________X,;
M       'R___________________D@                      F/______
M____________I                       :O__________________W0
M                    0?___________________PX
M    '?___________________SD                      .C_________
M_________V                       ,[__________________X4
M                 +?__________________Z@
M */__________________\L                      )#_____________
M_____^\6                     'W___________________\^
M             &S___________________]I                     %K_
M__________________^9                     $G_________________
M___2%@                   #G_____________________6
M         "G_____________________H@                   !G_____
M________________]58                   3_____________________
M_[LO                  #X______________________^K*0
M      #/________________________R4<     !Q,@+CY2:(3M________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]-7)____________________________^M*PDG==
M0B@,  !*________________________Q7U%%P             1V/______
M_____________\10                    G___________________H@P
M                    :/__________________E
M    -O__________________V@                      !^S_________
M_________Q4                      ,3__________________T@
M                 *+__________________W4
M (/__________________YT                      &G_____________
M_____\,                      %+__________________^</
M             #[___________________\S                     "O_
M__________________]8                     !C_________________
M__^!                      7___________________^L
M          #____________________>(@                    #R____
M________________7                     #?____________________
MGP                    #,____________________Z$H
M      "W_____________________Z 6                  "<________
M______________]Z @                !W________________________
M>@L               5,_________________________Z)7:'2 C9RKO-#G
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^WC________________________
M___2HWI8.BDC'!8.!@  G_____________________^L4@X
M    :?__________________Y$,                     -/__________
M________>0                       ./_________________S0
M                 ++__________________Q,
M (7__________________T\                      %W_____________
M_____X,                      #K__________________[(
M             !S__________________]L#                      +_
M__________________\J                      #[________________
M__]/                      #G__________________]T
M          #4__________________^;                      # ____
M_______________$!P                    "M___________________P
M,P                    ":____________________9P
M      "&____________________HP                    !R________
M____________XT0                   !<_____________________Y$&
M                  !!_____________________^M?
M   =_______________________*2P                  ____________
M____________RU<   P8)#$_3F!TBZ?'___________________________7
MY_+_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KU,W'PKZZM[.PK:FHI?___________________]U^4S\P
M(QD1"0(          -O_________________=@
M *?_________________N@                       '7_____________
M_____P<                      $;__________________TX
M             !K__________________XP                       #]
M_________________\$                       #;________________
M__$9                      "^__________________]$
M          "D__________________]K                      "-____
M______________^1                      !Y__________________^W
M                      !F___________________>(0
M      !3____________________2@                     _________
M____________=P                     K____________________K H
M                   6____________________YT4
M    _____________________XH                     ____________
M_________]9-                    _?____________________^G+@
M                U?______________________F"H           88+45@
MX/_______________________ZAC=(&/G*N[S>+Z____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^(S@$E#0U]04D]&24Q% !(2________________________________
M_______________________________GR[>IG96.B82 ?'AT<&QH99#_____
M____________O&I(+1D*                 #'__________________P
M                      /__________________T(
M      #<_________________XX                       "R________
M_________\X                       "-__________________\I
M                  !K__________________]:
M  !.__________________^&                       T____________
M______^N                       >___________________4%P
M               *___________________Z/0
M____________________90                      ________________
M____C@                      ____________________O!D
M            [___________________\4X                     V/__
M_________________XL                     O___________________
M_\Q#                    H?____________________^1&0
M        >O_____________________R= H                17_______
M________________Z'03'RPX15-B<H6;M-+U________________________
M___7Z/3_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________OW\_'N
M[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$________
M_________TLE"P                    "2_________________X@
M                  !F_________________]<
M   ]__________________\S                       8____________
M______]L                        __________________^=
M                ___________________)#
M]O_________________Q-0                      W_______________
M____6P                      R___________________@@
M            M___________________J08                     H___
M________________TR\                     C?__________________
M_UX                     =____________________Y,'
M        7O___________________\U#                    0/______
M______________^'$                   '/_____________________8
M7@                   /______________________OTX       X<+#Y2
M:H:ER/_______________________\)\C)JGML76Z/W_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^[AU\_)P[ZZMK&MJ:>F
MIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4____________
M_____]<%                        __________________\T
M                ]O________________]V
MTO________________^P                        LO______________
M___A)                       EO__________________40
M            ?/__________________>0                      9O__
M________________H                       4?__________________
MQR,                     //__________________[DL
M        )____________________W0                     $/______
M_____________Z,6                     /___________________]A,
M                     /____________________^(#P
M     /_____________________+4P                   /__________
M____________I3@           D=-$YKC/_______________________YDY
M0U%?;GV.H+7+Y?_____________________________K^?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________KS+FLH9F1BX:!?'AT<&MH9F9H
M\?________________]A13(C& X&                GO______________
M__]^                        =?_________________#
M            4O_________________[-P                      ,O__
M________________:@                      %O__________________
ME@                       /__________________OQL
M         /__________________YD(                      /______
M_____________VD                      /___________________Y "
M                     /___________________[DL
M     /3__________________^A<                     -G_________
M__________^1&                    +S____________________*4P
M                 )W_____________________F"X             $"E&
M9L3_____________________[G\=#!HH-T97:7Z5K\SN________________
M_________^>@JKG(V.G\________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________?7PZ^;B
MW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N,?__
M_______________2)1$#                     /__________________
M0@                       /__________________?0
M         /__________________L L                      /;_____
M____________W3D                      -S__________________V(
M                     ,7__________________XD
M     *___________________Z\B                     )G_________
M_________]9(                     (+___________________]R
M                 &G___________________^A*
M $[____________________37                    #/_____________
M________EBX              !4R4G?_____________________X'(3   !
M#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^>#2R,"ZM;"LJ*6B
MGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00  -3_____
M____________D@                       *W_________________S!X
M                     (O_________________^U(
M     &W__________________X                       %'_________
M_________ZD;                     #K__________________]!"
M                 "/___________________5H
M  S___________________^/%                     #_____________
M______^X/@                    #____________________E;0,
M              #_____________________GS<              ! O4'3_
M____________________W7(4      87*D%:=92VVO__________________
M_____[Q81%1D=8::K\CC_______________________________2S>'Q____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________\^_K[_?______________________[KFHG9:/BH:"?WMX=G1R
M<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_________
M_________VD                       #__________________YL*
M                  #__________________\@Y
M  #___________________!C                      #_____________
M______^*#@                    #___________________^P-
M              #____________________56P                    #_
M____________________A1H                   /L________________
M____L4D              !@Y78'_____________________Y7L>       ,
M(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?__________
M__________________^SGK3%U^O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________Z[^?A
MW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A75UE>
M97'__________________[\Q'Q80"@4               #_____________
M_____^U6                      #H__________________^"!
M              #,__________________^K+P                    "S
M___________________25P                    ";________________
M___W?!                    "%____________________HC<
M        !2N4____________________RV$"            #"Q0=I[1____
M________________]8TP       -(SM7=IF^Y?______________________
M_\-C&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G____
M_________________________________?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________=SL6_O+FV
MM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M066:A
M__________________^G)@X' @                !6________________
M___.4                      Z___________________T>0L
M           A____________________GS(                    .____
M________________Q%@                (,5J$____________________
MZ7\?           &)TMQFL+I_____________________Z=)      (7+TIH
MBJ[5_/_______________________]-U'B8X2EYUCZO+[_______________
M______________^N<H68K,+;]O__________________________________
MW^__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________O[*JIJ.AH)^?
MH:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]____
M________________GBX&                    ____________________
MPU8                  !5!____________________YWL:
M  DT8(NT_____________________Y\_          0E2G&9PNO_________
M_____________\9F#P   !,J1&*#I\WU_________________________^N.
M-2L^46B!G;S>______________________________^^=G^4J<'<^?______
M____________________________TMCS____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___V\O#O[^_Q\_C]____________________________^+"?FI>6EI:8FY^D
MK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I________
M_____________Z9! 0          !S9CC[KA_____________________\9E
M"@      !"=,<YS$[/_______________________^6(+P  $RI$8H*FS/3_
M__________________________^K4#9*87N6M-;Z____________________
M___________2AWR8L<OI____________________________________U,[M
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________M
MY>/CY.;H[?'Y______________________________VQE)*2E9F=HZFRO-#M
M__________________________^=4T=)35%68'.*K];\________________
M__________^R5@ :-5!MBZ[2]______________________________-;SY?
M>YFWU_G________________________________NGX.FPN'_____________
M________________________X\[K________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________
M
M
M          #_________________________________________________
M____________________________________________________________
M____________________________________________________________
M_P   /_; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)
M"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(
M!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( ( !*0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M6^+QC\1^)(YH/#4;_N( 2CZFPX//58P1@D<DY QR1YI^S=\'Y/CA\7--T/\
M>+99-Q?R+P8[=,%^>Q.0H/JXK]+=+TNWT33;>SLX8[>UM8UAABC7:D2*,*H'
M8  "O)\,^"J69U'F&.5Z4'91>TI;Z]TM-.K=MDT\<OPJJ/GGLANBZ)9^&]*@
ML=/M;>RLK5 D,$,82.-?0 <"K5%%?TI&,8Q48JR1[P4455U?5[/P[I%UJ&H7
M5M8V%C"]Q<W-Q*(H;>) 6=W=B JJH)))P "35>2 DOK&'4[.6WN88KBWG4I)
M%*@=)%/4$'@@^AJGX3\+6G@O1(M-T]9([&V)$$+.66!"<A%)YVCL"3@8 P
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M>I6Y*M#=EA]I4-TW+<!G*\_),F<AJ_0W]C;]M7P/_P %B/V?X?#NM75GX?\
MC#X=MS-=6:IM!884W5N"3YEN_P H= =T9.#QL=OD?%C@%Y[EL<PP"]^*YEZM
M>]%^MM^DEK9,\G$TO;1Y'\2V.T_X)C_$.*P\1^(/#,\@5M0B2^M03C<T>5D
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M;%7C8'(92.00>01SFM'Q!XZUSQ7!'%JFL:KJ4<3;T2ZNY)E0],@,3@U],_\
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M!LXI\?G,3QQS]:[<1AX5<ZIM[Q@W^+2_,MI.JO0\_P#^":W[!E]^W_\ '_\
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M &B/9G>%.%;A0>>E>CD.)HX?&QK5W9*^NKW373U.BC)*5V?D?_P3@_:^TO\
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MXQUL()?Q_P!;7[1_L2_LHV'[%7[.6B_#W3]4N-;CTF2XFDOYXA"]R\TSRD[
M6"@;@H )X7/4FOP:_P""IGB#_A)O^"AOQ<N./W?B&:TX7;_J0L/_ +3Z]ZX^
M&8TGF56=#X$G;?:ZMOJ30M[1N.Q[3_P2)_X*>^!?^"?'@WQQ8^*O#_BC5KWQ
M-<07%O)I,4#J/)1U5)#)*A )D8Y ./0YX\I_X*5?\%%-:_X*%_%:PU2;3O[
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M (-F/$C^(O+O_BOHD.D C]_!HLLERWMY;2JH[C.\^OM7TY=?\$#O@F_[.?\
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M?VSXI\4>'H;[4[W[/%;_ &F9BV6\N)4C7.!PJ@>U>^T %%%% !1110 4444
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M!?\ V!9O_2RXKC?^"'TD=WXN_;+N)IIIM4;]HWQ3#+YK,S+;I]G$ &?X0-X
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biogenbubbles.jpg
<TEXT>
begin 644 biogenbubbles.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $]!5\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3J8>,=/=<59I^??^M.V$,!B:$X5*==RU]Y2U376W;R_J_8T5\;_M(?%#Q/\
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MW4X']LW2UL_V<KVULX=MM9SVBJB#A(U<*/P' K._8E\9Z#_PJ'2/#W]L6/\
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M>@LQI8RSY8QL]K[-=_/N</\ 9E;ZC7PUUS3E=;VW3UT\CM+'_CRM_P#KFO\
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MJS8 Y))XK<KR\RQD<=B'6A&RT]7YNW4]#+L)+!4/92E?5OR7DK] HHHKRCU
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M4Y*\6D*.DD^QYY^SE_R3^7_K^D_]!2N)^,EO+X6^+&F:_+$SV<C0SA@."8R
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 444R::.WC:25UCC499W. ![F@!]%<1KGQP^'WAMBFH^--#MY5Z
MQ?;HWD'_  %23^E<S=?M:?"2SSYGC6S;_KE!-)_Z"AK>.'K2^&#?R9A*O2C\
M4TOFCUVBO'+7]K_X07F/+\9P+G_GK9W,?_H48K>TK]HKX9:U(([;QSH@=NBS
MW:PY_P"^\4WAJ\=X/[F)8BC+::^]'HM%5=.U6RUBW$]A>6][ >DEO*LB_F#5
MJL-MSHW"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1574M3L]&L)[Z_NH;*RMT+RW%Q($CC4=2S'@"ODKXP?M
M_:5H_GZ=X L1K%V,H=6OE*6R'U2/AG^IVC_>%=6'PM7$RY:4;G-7Q-+#J]1V
M/K74]4LM%L9;W4+N"PLXANDN+J58XT'J68@"OG_Q_P#MT?#GP?+);:7)=^*K
MQ>/^)<@6 'T,KXR/=0PKX!\=_$[Q5\3-1-[XFUR[U:3=N2.5\11^R1C"H/\
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MGGCM89)II%BAC4N\DC!550,DDGH *@U;5K+0=,NM1U&ZBLK&UC:6:XF8*D:
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M=TBC&^61@B*.Y/ H LV-C<:M="WMER>K,?NH/4UW6D^&;/2@&"^?/WED&3^
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M>:?;ZA$8[B%95_VAR/H>U<OX!\?7?C-KQ+WPQJWAJ6$B2)=3C4">%B=C@J2
MW'*'YE[TGQ6^(Z?"WPA<ZZ^CW^M^5TM=/0$]"2S,>$4 'D_3J:KV4^?V=M2?
M:1Y>?H4O$'AF71P;BW+36G\6>63Z^H]ZQE8,,BO1/#NM+XFT&TU'[%=6*W4>
MXVE]%Y<T?4%77UR#[&N(\1:3_8.J!$S]EGRT6?X?5?PX_.LVFG9EIW5T4Z*
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M%9>0PR*=70DHJR.=MR=V%%%%,05#=-MC-357O/\ 5'Z4GL-;GZZ?LZV2:?\
M 7X?1QJ$5M#LYB!ZO$KD_B6)_&O1*\O_ &7]6CUK]GOP!<1G*II,-L>>\0\H
M_JAKU"ORZM?VLK]V?I5'^'&W9!7A?[:7CB3P3^S_ *\;>4Q7>IE-.B93AAYA
MPQ'_  $-7NE?./[??V%?V>;XW<8>;[=;"VYP5D+]1^&<UT8&*EB:::ZHQQ;<
M</-KLS\WO!/A:X\;>+]%\/6G%QJ5W':ICMN8 G\!D_A7Z)_M$?L=V?Q ^'_A
MVR\'BWTW6O#=N+6T63Y([B'J48CHV[+!O5FSUK\]OAQXYNOAKXZT;Q-90QW%
MSIMPLXAE&5<="/;(SSVK]AO 7C33OB)X/TGQ)I3[['48%GCSU7(Y4^X.0?I7
MU&<UJ^'J4JM/1+\_/Y'S^64J-:%2G/=_E_PY\!MX'_:=T&70K*[US4K&U6\A
ML;1Y-00QJ[-A 2!EAQWS7Z*V:SI9P+<NLER(U$KH,*S8Y('89S7#_%[_ (]?
M"?\ V,FG_P#HRN^KYO%XEXF,).*6^RL>YAJ"H2DE)O;=A7G7[1=DFH? 7X@Q
MNN\+H=Y, ?5(F<'\"H/X5Z+7E_[4&K1Z+^SWX_N)#A7TF:V'UE'E#]7%<=&_
MM8V[HZJW\.5^S/R9MFW1BIJKV?\ JA]*L5^HQV/S5[A1113$%%%% 'T]\'?V
MQKSX<_!76_#-VS7&N6<8C\/2NNX*KDAE?/:+[R@]<[>@%?,UY>3ZA=SW5U,]
MQ<SNTLLTC%F=V.2Q)ZDDDYKF[R^:2\$B'B,X6MN"83PK(O1AFL*>&IT92G!:
MRU9M/$3K1C"3TCL24445N8A1110 C=#7V-_P34LTFUKXA7A4&2&&QA#=P':<
MD?CY8_*OCEONFOKC_@FOJR0^,?'>EG_6W-E;7*\]HY'4_P#HX5Y&:W^J3MY?
MFCU<LM]:A?S_ "/OFLQ/$VD2:I<Z:NIVIO[8 S6WG+YB9&1D9]/YBM.OE+XW
M?LJ^)=2U[5/$G@K7[@27]R]Y<Z9)*$)=OO;'QTP!A3Z*,X%?$8>G3JRY:D^4
M^SK3G3CS0CS'N/BWXK6&E"6ST:6VU3557YF:8+:6@_OW$O1 /[OWCT YKD_"
M:ZEJEY)J.@VK:SJ]R-L_B[6HS%;HIS\EI#][8.P& <?,37B/@6:Q\*75KIGB
M*_U'2M:A? C\6:0MROF=O+,6 Y^BMC^]7T)H-SX@\5^9'8?$;2)=J\KIME$\
ML9]&1F.WZ$5W5**PZM'[W?\ 1?UYG)"JZSN_NT_S_KR/// /B2&^AT*;3_[-
M;7+RUDUO6O%.I0 +;22[62(\@*Q615'.%5 !VIOPP^$__"9^&I)++6FT#3+:
MYN;>?1-,M8(X;B=&S$\EPH+RHAV.F3D [23@U7\%>#;/2?$VJ^#M5N[BSU*V
M.RRN8%1?M<:QHJQ,C HP>&&!U7'#I-C[M9OAVZU[P5\+].FLM3DTO4=>+1Z7
M8Q2?:;6Z>Y)YRD0$,J/(&)8Y)5L]"*Z9=52=F[?K_7EY&$>CFM%?]/Z\R?P<
MO]MC1]%UVQ*:[X5O"9IMD45K9V2KB8XBD82^9\R\C)W'=BO=/@SJ$>H_#O3S
M#.;JVM9[NPM[ACDRPV]U+!&Q]RD:G\:\2\/J/!UEX3LHM-N(O[#D:]UW4[Z&
M1)K50&#P!V&)1)E5"JS;F.?2O>_AGI%SHO@JPBO8E@OKAYK^YA7I'+<3//(@
M]E:4C\*Y,8UR_/\ S_X?^KG1AOB^7^1U%?CC\4K5=.^+7CBS1=B6^NWT*KZ!
M;AP!^E?L=7XR>.]437/B/XLU*(YCO-7N[A3G/#S.P_G7H9'?VD_1'GYS;V</
M4RJ***^R/D0HHHH *_2/]BWXY2?$_P "/H.KW'F^(M!58V=SE[FV/$<A]6&-
MK'V4GEJ_-RNV^#/Q0O/@_P#$32O$UIN>.W?9=6ZG'GV[<2)]<<C/1@I[5YN/
MPJQ5%Q7Q+;^O,]# XEX6LI/9[GZT:YK":1:[N&F;B-/ZGVKSZ:9[B5Y)&+NQ
MR6/>D;Q#'XJC@U6"436MU$LL#*>#&PRI'X'/XTVOSK;1GZ!OJ@HHHI !X%:/
M@:U%_P"()9V7<EI'D>SMP/T#5ES-MC-=#\+5WV.IS>MSY?Y*#_[-0!W%<5\7
MOA;8_&#P7-X>O[RZTX&>*ZAO+,@20S1L&1QG@X-=K7G/Q\^*T_P=^'<VOVFG
MQZG?/<P65M;S2^7&997"J7;LH[UM14W4BJ7Q7T,JO(J<O:;=3Y/U?4=3^&'Q
M.M+3XG:UXLUC3_"WB%=6TG6I+(WR7%N8-OE,RG]VQ)4XYQSQ7N$W[='PT8!+
M :YJMTP.RVL]+D9V/8<XKP6'X;:G<>/(=9\;SZCX?\3^//$IL[6Y\'>(%"6:
M>3N8L5WAQNV@*3G&?;/NR_L;07#"/4OBE\0-3LR-KVLVK[4<>AVJ":^BQ"PC
MY?;O6W3;SM9/KYGB4/K"YO8K2_7?RW:Z>1S_ ,%OA+XA^+6JV7Q%\=Z_XCCA
MM-<N-0TCPSJ$@\N! Q$3,O5",D;>/NU]55\;_!_Q!XH_9G\8V?P_U'1=-N/!
M^N>(Y[>POH-46:\B:3[F^,,2% 09W*#DGFOLBO*S#F]HFVG'[-MK'HX/EY&K
M>]UOW,[Q!IXU31[JVV[G9"4_WQROZ@5Y?I\_G0J?:O8:\9M?W.HW\/\ SRN9
M$_)B*\P[S0HHHH *Z?PKKWE,ME<-\A.(G/8_W?I7,44 >K5R?BS7#EK&!N/^
M6K#_ -!_QI(/%VS1F5CF^7Y%SW'][\/\/6N79BS$DY).230 E%%% !2.VU2:
M6H+QML+'VH Z/X<V@N+B^OV7.PB",^G=O_9:[JN5^&J_\4K%)_SUED;\F*_^
MRUT.I03W6G74-K<?9+F2)TBN-H;RG((#8/7!P<>U ')>,/B!?Z/X@MM \/\
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M>,K;IPB_U/O67110 444-TH CM[?^T]8LK+&5FD&\?[(Y;] :]950J@ 8 X
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M2YM_[,UB]LL86&0[!_LGE?T(J6IO&W[GQHP_YZ6Z/^K+_P"RU".E8FH4444
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MG\7YGT& S#V/[N?PG[(45\Y?!O\ ;J^'/Q.M;>VU:_C\&:^WRO8ZM(%A9O\
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M)=WMU(TT]Q,Q9Y'8Y9F)ZDDDU=I(T"+@4ZOMHQ459'QLI.3NPHHHJR0HHHH
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MQM\9>)(,_?L$?'^[(!_[-7E9I'FPD_E^9Z>6RY<5#Y_D?95%%%?GA]Z%%%%
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MB&Q@LX]0LIH88(Q.I2&-G50<#)..2=S8Y-<OH7[6GQ7\-:+8:3IOBK[-I]C
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M:I*W79V[&3QBFY.I33NW);JS;ONNA]KZ=\=_"VL>./C#\2K;4K.QN(-%72M
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MV5+'@C!' P6KSWXT+\(K[0=$F\#:9K'A[Q9)B/4=!D,LT%LX)#H\DQWF3<0
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M.E'E]W:FZ?R?7U/MCXA:AX&^-W[,GA&%OB#H^A:QX>TY9WTZXDC$\\\5L4:
M1O(K LRX5@&SG@'-?$]%%=%##^P<[.ZD[^ESGK5_;1@G&SBK7[KH9^M+NM5;
MT;^E8E=#J2>98R =1S^1KGJ]".QP2W"BBBK(-#15W73'T7^M;=96AI\LK^X
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MG^A7U6E1C.,G>:A=KHMGI_74^+- ^&_BWQ98-?:)X6UK6+)7,;7.GZ?-/&&
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MZ2KD?-,Q?\.@_E^M<58VK7UW% GWI&Q]/4UZ;'&L,:1H,*H"@>PH 5E#*58
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M*Q88$#" +]X-P2!MKD?#M]%\,?VY;_PUH&GV=KI?B:U22[C$9'E,MN\N8@I
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M+=_VSSC_ &J]T_93 T?]DWXG:AJ<9739?MI3S<JLH%HJG!QW;Y<CN,=JH?\
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MQQDGL!U)[ $TFU%78TG)V1]/?L1_#]K>SU?QC<QX-Q_H%GD=4!#2L/JP5?\
M@+5](^+O#_\ PE7A^ZTO[1]E\_;^]V;]N&#=,C/3UI/!OA*V\!^%M,\/VB[8
M=/@6#I@LP^\Q'JS9)]R:V:_,\97^M5I5'MT].A^BX2C]6HQ@MU^9@Z;X1@M?
M!\?A^ZD^UVXA,+R;=F[))R!DX(SZ]JRO 7PW7P3_ &@'OAJ"7BJI5H-@ &[@
M_,<YW5V=%<G5ON=72QYE=?!5HY+J/2_$-UINGW'W[0(64^Q(==P^H_.NGG\
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MN$N+K3[6YN(P DLT*NRX.1@D9'-#U5A+1W.8^$?A\Z#X/@:1"MQ>-]H<,,$
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M12PRJ59'4X92.Q!%?H>78Q8JEK\2W_S/@LPPCPM73X7M_D04445ZIY@4444
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MXC/\3/B5J_BZ.S;2)+^9)EMUG\TPE451A]JY/RYS@=:]VL_V[)[KP_I:^(_
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MWX7"74.>&'HPZ,O8^Q!/G]?KY\6OA+H/QD\)SZ%KL&5/SVUW&!YUK)CAT/\
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M7C"5NOEK]W\3WKI%41J%4!5'  & * *]CI\&FVXB@3:O<]R?4U9HHH ****
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M@JPR* /+**ZO5/!IRTEB_OY+G^1_QKF;BUFM)#'-&T;CLPQ0!%1110 4444
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M=*N#G8TBYCE [HXRKCZ$US%?3QE&:YHNZ/G)1<7RR5F%%%%42%%%% !1110
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M6X?".HR_>C2+_?<?TS7>44 <M:^!U&#<W)/^S$,?J?\ "MRQT:ST[!AA4/\
MWVY;\ZNT4 %%%% !1110 4444 %%%% !1110!!=64%ZFR>)95_VAT^A[5AW7
M@JVDR8)GA/\ =;YA_C71T4 <//X-OX\[#',/]EL']:I2>']1C.#:2'_=P?Y5
MZ+10!YK_ &/?YQ]CG_[]FI%T'47.!:2?B,?SKT:B@#A8?!^H2_?6.'_>?/\
M+-:EKX)A7!N+AI#_ '8QM'YUTU% %6STVUT]<6\*QG^]C)/XU:HHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /,/B9^S;\/_BLTL^LZ%'#J4G74]//
MD7.?5F PY_WPU?+'C_\ X)X^(=.EDG\'Z[::Q:]1:ZCFWG'L& *,?<[*^]J*
M]&AF&(P^D):=GJ<%; T,1K..O=:'Y%^,O@1\0/ )<ZYX3U*UA3K<QP^= /\
MMI'N7]:X,Y'!X-?MA6)KO@?PYXH##6= TO5MW!^W6<<V?^^E->S3SU_\O(?<
MSQZF2K_EW/[T?C517ZO7G[+_ ,*KXL9/ ^EKNZ^2C1?EM(Q66W['/P>>7S#X
M-CW>@O[H#\O-Q76L\H=8O\/\SF>2U^DE^/\ D?EK17ZMVO[+'PHL\>7X(TYL
M?\]=\G_H3&NQT'X:^$O"^TZ/X8T?2V7H]I8Q1M]<A<U$L\I?9@W_ %\RHY+4
M^U-?U]Q^4/@_X0^-?'SJ- \,:GJ2-QY\=NPA'UD;"C\37O7@7_@GSXTUJ6*7
MQ/J=AX<M#R\43?:KCZ87"#Z[S]#7Z$45YU7.J\]*:4?Q_K[CT*63T8:S;E^'
M]?>>,_#7]DCX<?#4PW$.CC6]3CP1?:P1.P;U5,!%YZ$+D>M>RTM%>'4JU*SY
MJDKL]FG2A27+35D%%%%9&H4444 %%%% !1110 4444 >)?&+]D?P-\6O.O1:
M_P#"/:])\W]I:<@7S&]98_NO]>&_VJ^._B7^Q/\ $3P%YUSI]HGBO3$Y$VE@
MF8#_ &H#\V?]W=]:_3&BO5P^98C#^ZG==F>9B,NH8C5JS[H_%2ZM9K&XD@N8
M9+>>,[7BE4JRGT(/(-15^Q_BOX>^&?'4'D^(- T[6%Q@->6R2,O^ZQ&5_ BO
M$O$W[!?PQUR226P75= =N0EC=[XP?I*KG'L"*^@I9W1E_$BU^)X53)JL?X<D
M_P #\W:*^O?B-^P9:^#[$WUGXSFE@)($,^F@L,#/WA*/_0:^?_%7PK_X1EF'
M]J?:=IQ_Q[[.^/[QKUJ.,H5U>G*_R9Y=7"5J+M./Y'!45TOA7P;_ ,),R#[9
M]FW'_GEO[D>H]*]T^&O[&2^/KH1OXO-D@7<=NF[R> <?ZT>M75Q5*BKU';[R
M*>'JUG:"N?,U%?H;X?\ ^">W@'3BCZIJVM:O(.J>;'!$WX*A;_QZO:/!?P+\
M _#WRVT'PIIMG/']VZ>+SIQ_VU?<_P"M>14SK#Q^!-_A_7W'JT\GKR^-I?B?
MF[\-?V9?B'\4FBETO09;/3G_ .8EJ6;>#'J"1N<?[@:OKCX2?L%^%O",L6H>
M+[K_ (2O4%PPM-ABLT/NN=TG_ L ]UKZEHKPL1FV(KZ1?*O+_,]K#Y70HZR]
MY^?^1#9V=OIUK%:VD$=K;0J$CAA0(B*.@ ' %3445XI[ 4444 %%%% !1110
M 4444 %5M1TVTUBQFLK^UAO;.9=DMO<1B2-U]&4C!'UJS10!\W?$G]A/P#XR
M\VYT(S^$=0;G_0_WML3[PL>/HC*/:OF;QI^PO\3/"YDDTZVLO$UJO(;3[@+)
MM]XY-IS[+NK]*J*]:CFF)HZ<UUY_U<\NMEN&K:VL_+^K'XS^(O!NO>#[HV^N
M:+J&CS XV7UL\1/TW 9_"L>OVMDC2:-HY$61&&"K#((]Q7':Y\%? /B1BVI>
M#-#NI#UE:PC$G_?0 /ZU[$,]7VZ?W,\J>2O[$_O1^0=%?JI=?LF_"2\_UG@J
MS7_KE--'_P"@N*KVW['WP@M6W)X,A8YS^\O;F0?^/2FNC^W,/_*_P_S.?^QJ
M_P#,OQ_R/RSJ2VM9KR98;>&2>9CA8XU+,?H!7ZR:;^S?\+])D62#P+HK,O3[
M1:B8?D^:[K2="TW08?)TS3K73H?^>=I L2_DH%8SSV'V(-^K_P"'-8Y+/[<U
M]W_#'Y;>#/V5?BAXX\M[3PK=6-LW/VC5,6B >N'PQ'^ZIKZ'^'/_  3OMX&C
MN?''B$W)')T_1@53Z&9QDCV"CZU]H45Y=;.,34TC[J\CTJ.4X>GK+WGYG)^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biogenlogoa04.jpg
<TEXT>
begin 644 biogenlogoa04.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _+_ ,0V3>&_'&L:>PVM8WT]N1C&TI(R
M]/PK7TC4]H7FM/\ :_\ #A\%?M+^)H=NV*^G6_C./O\ G*'8_P#?9<?A7&Z;
MJ6%ZU^N4VJU"%1=4G]Z/RVHG2K2IOHVON.\MM9PGWJ;=ZU\GWJYB+5L+UIES
MJ^5ZUE[#4T]MH6M8U7<#S7)ZU?[MU6M1U/.>:YS5;[.:[Z%*QQUJAFZM<Y)K
MGK^7)K1U&YR36-=RY->M2B>;4D59WYK$\:^+[;P1H$U]<'.T;8HP?FE?LH_S
MP,T[Q?XQLO"%EYUU)\[#]W$OWY3[#^O2O#O&?B2\\=ZQ]JNOEC3(AA!^6%?0
M>I/<]_R ,17Y%9;BHT7-W>QSM]<W'B#6+B^NFWW%U(9'/N?3V'3Z"M+3;'&.
M*DM=,P>E:]AIO/2O*C!WNST92Z$NEVG2NDTJVZ53TVQZ?+70:9:=*[:<3EJ2
M.Z^ 6@MJ_P 3M(4)N6&;[0W^R$&[/Y@?B:^K*\S_ &<OA<W@_1&U2]C,=_J"
M (C##0Q=0#[MP3]!7IE?QOXQ<24,USSV>%?-"C'DNMG*[<FO*^GG:ZT9]]P_
M@Y4,->>\G?Y=/\QR#FK4"5! N:NVR5^5P1[T2Y:1UJV472J5G'6M8Q?=XKMI
MQ-8FA80]*]&^ MCY_P 1K!L?+"LCG_OA@/U(K@M/ASBO6_V;M)\S7[V[(^6W
M@$?T+-_@IKZGAVA[3,*,5_,G]VOZ&_2Y[)1117[D2>8_M=?M,6/[(OP,U/QU
MJ6EWFKVFFS00M:VTBQR/YLJQ@@MQP6R?I7Q[_P 1#G@W_HG?B;_P.@_PKV+_
M (+6?\H]O%7_ %^Z?_Z5Q5^(-?K7 W">6YEE\L1BX-R4VMVM$HOH_,_+.-.*
M,PR['QH86:47%/9/5MKJO(_5S_B(<\&_]$[\3?\ @=!_A1_Q$.>#?^B=^)O_
M  .@_P *_*.BOLO^(=Y'_P ^W_X%+_,^1_U^SK_GXO\ P&/^1^KG_$0YX-_Z
M)WXF_P# Z#_"C_B(<\&_]$[\3?\ @=!_A7Y1T4?\0[R/_GV__ I?YA_K]G7_
M #\7_@,?\C]7/^(ASP;_ -$[\3?^!T'^%'_$0YX-_P"B=^)O_ Z#_"ORCHH_
MXAWD?_/M_P#@4O\ ,/\ 7[.O^?B_\!C_ )'ZN?\ $0YX-_Z)WXF_\#H/\*U-
M-_X.$OAE*8OMG@OQW!NQYODK:2[/IF9=WXXK\CZ*4O#K)'M3:_[>?^8X^(&<
MK>:?_;J_R/VD\(_\%T?@1XD=5O+GQ9X?#8R;_2#(%^OV=Y>GMFO</A5^W-\(
M/C9/%#X:^(GA>^N[@[8K26[%K=2'T6&;9(?P6OYZZ*\S%>%V6S7[BI.+^37W
M63_$]+#>)680?[Z$9+YI_?=K\#^FRBOP1_95_P""E?Q5_9/U&UCTK7KC7/#L
M) DT+5I&N+,IW$>3NA/)(,9 SC(8<']?/V)_V]O!?[;O@R2ZT&9M-\0:>BMJ
MFB7+#[39D\;U/22(G@.H[@$*>*_-^(N"\=E2]K+WZ?\ ,NG^)=/Q7G<_0LAX
MPP6:/V4?<J?ROKZ/K^#\CW*BBBOCSZP*X/\ ::^.]G^S+\"_$'CJ^L+G4[/P
M]#'+):P.$DE#2I'@%N!@N#SZ5WE?._\ P5A_Y1Z_$O\ Z\K?_P!*X*[\JP\*
M^-HT:GPRG%/T;29PYI7G1P=6M3^*,9->J3:/G?\ XB'/!O\ T3OQ-_X'0?X4
M?\1#G@W_ *)WXF_\#H/\*_*.BOWW_B'>1_\ /M_^!2_S/PS_ %^SK_GXO_ 8
M_P"1^KG_ !$.>#?^B=^)O_ Z#_"OM3]F7X[V?[37P+\/^.K&PN=,L_$,,DL=
MK.X>2(+*\>"5X.2A/'K7\Y]?O)_P2>_Y1Z_#3_KRN/\ TKGKXGCSA;+LLP4*
MV#@U)S2=VWI9OJ_(^RX)XFS#,<9.CBY)Q46UHEK=+HO,^B****_*3]/"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X[_ ."H7@-K35O#?BN)
M/W<T;:7<,.S*3)%^8,O_ 'R/P^6[2_P.M?I)^U1\*6^,OP,UW1X8]]^L7VJQ
MXR?/C^90/][!3Z.:_,&&]:-MK95AP0>U?IG"^)5?!^S>\';Y/5?JOD?GO$F'
M='%^T6TE?Y[/_/YG4)J>T=:CGU3*GFL-=1XZTR74>.M?0^QU/!]H7;[4<CK6
M+?WF<TV[O\*>?S-<UKWC&&S#+&&GD]ONC\?\*Z:=.QSSJ%S4+M45F9E55Y))
MQBN \8_%*.U5X=-433=#*P_=K]/7^7UJOXCU*\UUCYTA\O/$:\*/\?QK"FTG
MVK24FE9$1BKZG,:G'<:O>-<74CS3/U9SD_Y]JACT?GI73G2?:E32*YO9ZW-_
M::6,.VTK!Z5IV6F;>U:<&D\]*],^!'[+7BKX]:H(]$T]ELD<+/J%P#':P>N6
MQ\Q_V5!;V[UEB*]##4G6Q$E&*W;=D53C.K)0IJ[?1'G>C:-)=W$<,,3RS2L$
M1$7<SL3@  =23VKZN^$'[".N^%O#=OXH\262^<O[V/3/O2VR]1)*O3/?;G*\
M9YR!]%?LY?L9^%_V>;>.\5!K'B+;A]1G0?NB1@B%.0@Z\\L<\G' ]8EEK\+X
MV\1I8RC/+\I;A"2LY[2?^'LGWW?D?;93PRJ=JV+UET71>O=_AZGRO0!DUZ_\
M1_@S#K,DEYI2QV]TQ+/#]V.4^W]T_I].M>476GS:9>/#<120S1G#(XPPK^9L
M5@ZE"5I;='T/HY4W'<6 5?M8ZJP)6E:1U%-#B7+**MBPBZ50LHNE;-A%TKT*
M43:)I:?#TKW_ .!&@?V1X*6X9<27\AE_X"/E7^1/XUXOX+\.R>)-<M;*'[UP
MX4G'W1U)_ 9/X5],65G'I]G#;PKMBA01HOH ,"OTC@? .566*EM%67J]_N7Y
MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
M]^D_^*H_MK+_ /G_  _\#C_F']CX_P#Y\3_\!E_D>%T5[I_P[.^/7_1+_$__
M 'Z3_P"*H_X=G?'K_HE_B?\ [])_\51_;67_ //^'_@<?\P_L?'_ //B?_@,
MO\CPNBO=/^'9WQZ_Z)?XG_[])_\ %4?\.SOCU_T2_P 3_P#?I/\ XJC^VLO_
M .?\/_ X_P"8?V/C_P#GQ/\ \!E_D?I-_P $'-9.I_L-R0;T;^SO$E[;@+U3
M,<$N#[_O,_0BOM*OD/\ X(N? ?Q=^SW^RSKFC^--#O/#^J7GBBXOHK:Y $AA
M:UM(P^ 3P6C<?A7UY7\V<4SISS;$3I--.3=UJM?0_H;AF-2&54(U$TU%*ST9
M^#?_  5?_P"4A/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]
M'Y#_ ,BS#_\ 7N'_ *2C^?,[_P"1C7_QS_\ 2F%?:7_!!K1/[5_;CN+CRR_]
MF>&KVYR#]S,D$6?_ "+CCUKXMK[H_P"#?C_D\OQ-_P!B7=?^EUA7#Q=)QR;$
M-?RO\=#LX5BGF^'3_F1^PE%%%?R^?TH%%%% !7X7?\%C?^4CWQ&_[AG_ *:[
M2OW1K\+O^"QO_*1[XC?]PS_TUVE?I7A;_P C6I_U[?\ Z5 _._$S_D5T_P#K
MXO\ TF9\R4445^]'X>?87_!#7_D_73_^P+??^@+7[55^*O\ P0U_Y/UT_P#[
M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
MR,\/_P!?(?\ I2/Z4SO_ )%V(_P3_P#26?@W1117]7'\OA7[R?\ !)[_ )1Z
M_#3_ *\KC_TKGK\&Z_>3_@D]_P H]?AI_P!>5Q_Z5SU^9>*?_(MI?]?%_P"D
MR/T;PS_Y&-3_  /_ -*B?1%?SR_MP>&&\'?MC_%'3V4JL7BC4'C!SGRWN'=/
M_'66OZ&J_$W_ (+=?#!_A_\ MWZMJ2Q[;;Q?IEIJT6!\N0GV9Q]=UN6/^^/4
M5\IX78I0S&I1?VH:>J:_1L^H\2L.YY?3K+[,OP:?ZI'R+1117[P?B)],_P#!
M'KQ*OAK_ (*&^ 3)M$5\;VS8GJ"]E.$QR.2X4=^"?:OW3K^<?]G#XG'X+_'_
M ,%^+-S+'X>UJTOIL?QQ)*ID7_@2;A^-?T:6]Q'>01S0R)+%*H='1MRNIY!!
M'4&OPWQ4PSCCJ.(Z2A;YQ;?_ +<C]I\,L0I8*K0ZQE?Y227_ +:R2BBBORT_
M2PHHHH *_'O_ (. /$":C^U[X=T^,JW]F^%8/,]0[W5RV#_P'8?^!5^PE?@W
M_P %6_B@OQ5_;U^(%U#)OM=)NTT:$9SM^RQK#(!_VU64_C7Z)X9X=U,V=7I"
M#?WM+]6? >(V(4,K5/K*27W7?^1\[T445_0!^%%K0M&F\1:Y9Z?;C=/?3I;Q
M#&<L[!1^I%?TN65G'IUE#;PKMAMT6.-<D[5 P!GKTK\ ?^"=OPU;XL?MO?#/
M2%C,D::W#J$RXX,5KFY<'V*Q$?C7] E?B?BMB%*OA\.OLJ3^]I+_ -)9^Q>&
M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
MR2< 9) K\3_^"AW_  4^\4?ME^(;K1=)FNO#_P .K:7%KIB/LEU(*?EFNB#\
MQ) 81_<3C[S#>?I7_@X _:;NM/B\,_"?3;IHH;Z$:[K2I_RV02%+6,GT#1RN
M5/=8CV&?S#KUO#OA:E##QS3$QO.7PW^RN_J^CZ*UMSS./N)JLZ\LMP[M"/Q6
MZOMZ+JNKWV"OH#]@7_@GUXD_;J\<74-G<?V)X6T<I_:NL21>8(BWW88DR/,E
M8 G&0%'+$94-\_U^ZG_!(?P%8>!/V O S62P^=K:7&J7DL?6>:2=QECW946.
M/V$8':OIN-L^JY5E_M</\<GRI]M&V_N6GGW/G.#<CI9GC_95_@BN9KOJE;\=
M?(\K\8?\$ _A+JVCPQZ/X@\:Z-?0QA#.]Q!=1SG'+NAC7D_[+*.O'3'BGC?_
M (-X?%5G+)_PC?Q&\/ZE'U0:EI\UD>G )C,W?C./?':OU7HK\9PO'6=T=J[D
MO[R3_%J_XGZ]B."\FK;T4GY-K\G;\#\8]:_X(._'+3,^1-X)U+#;<VVJR+D?
MWOWD2<?K[5%IG_!"7XZ7Y;S5\'6.W&#-JQ.[/ILC;I[XZ]Z_:&BO3_XB7G%K
M>Y_X"_\ ,\W_ (AUE-[^_P#^!?\  /R;\%?\&\WCJ^F4>(OB!X3TN/\ B;3K
M:XU!AUZ"00=L=QU/ID_17P5_X(1?"'X>3QW7B:[U_P <W<9!,5U/]CL\CI^[
MAP_U#2,#Z=<_;5%>7C..,ZQ*Y95G%?W4H_BM?Q/2P?!>3X=\T:*D_P"\W+\'
MI^!A_#[X:^'_ (3^&H=&\,Z+I>@:5;_<M;"V6",' &2% RQQRQY/>MRBBOE)
MSE.3E)W;ZL^HC&,5RQ5D@HHHJ2C\Y?\ @XAT!KGX9?#35 ORV>J7EJ6V=#+%
M&PY[9\D\=\>U?E;7[3_\%R_AZ_C3]A.\U"./>WA76K/5&P/F",7M3^'^D GZ
M9[5^+%?T1X;XA5,EC!?8E)?CS?J?@?B%0=/.)3?VHQ?X6_0****^\/AS^CWX
M :@NK? ?P3=1AECNM L95#?> :WC(S[\UU]>&_\ !-7QU'\1/V$/A??1LK?9
M=#BTQL=FM,VI!_[\U[E7\CYC1='%U:3WC*2^YM']49?657"TZJVE&+^](***
M*XSL"BBB@ HHHH **** "BBB@#\&_P#@J_\ \I"?B7_U^V__ *205\[U]$?\
M%7_^4A/Q+_Z_;?\ ])(*^=Z_J[(?^19A_P#KW#_TE'\OYW_R,:_^.?\ Z4PK
M[H_X-^/^3R_$W_8EW7_I=85\+U]T?\&_'_)Y?B;_ +$NZ_\ 2ZPKS^,?^1+B
M/\/ZH[N$_P#D<8?_ !'["4445_,)_204444 %?A=_P %C?\ E(]\1O\ N&?^
MFNTK]T:_"[_@L;_RD>^(W_<,_P#37:5^E>%O_(UJ?]>W_P"E0/SOQ,_Y%=/_
M *^+_P!)F?,E%%%?O1^'GV%_P0U_Y/UT_P#[ M]_Z M?M57XJ_\ !#7_ )/U
MT_\ [ M]_P"@+7[55_/OB9_R-U_@C^;/W;PX_P"12_\ '+\D%%%%?GI]\%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'RC_P6L_Y1[>*O^OW3_P#TKBK\0:_;[_@M9_RCV\5?]?NG_P#I7%7X
M@U^_>%__ "*9_P#7R7_I,3\+\2?^1K'_  +\Y!1117Z,?GY^\G_!)[_E'K\-
M/^O*X_\ 2N>OHBOAO_@G#^WA\'_A1^Q1X"\/>(O'V@Z3K6FVLR75G<2,)(";
MF9@#A>ZL#^->X?\ #S/X"_\ 14/#/_?U_P#XFOYASK*<=+,:\HT9M.<[-1>J
MYGY'])9-FF"AE]",JT4U"-US+^5>9[I17A?_  \S^ O_ $5#PS_W]?\ ^)H_
MX>9_ 7_HJ'AG_OZ__P 37E_V-F'_ #XG_P" R_R/2_MC ?\ /Z'_ (%'_,]T
MHKPO_AYG\!?^BH>&?^_K_P#Q-8OBK_@K/^S[X1MV>;XBV-XP'RQV-E=73.><
M#*1D#IW('3U%5'(\RD[1P\W_ -N2_P B99UE\5>5>'_@4?\ ,^CJ^0?^"N7[
M=6G_ +,WP+U#PGI&H*?'OC&T:UM8H7_>:;:OE9;I\<K\NY8^A+G(R$;'A?[3
M'_!P!;OIEQIOPG\,W2W4JE%UG7551 >1NCMD9MQ[@NX (Y0CBOS=\?\ Q"US
MXK^,M0\0>(]4O-9UK5)?-NKRY??)*V,#Z    #       K]"X3\/\3*O'%9G
M'EA%W47NVMK]EW3U>UCX/BCCK#QH2PV72YI25G+HD][=WVMHM[F/1117[<?C
M(5]!?\$L/ ,GQ&_;Y^&]JJ[H]/U%M5E;;D(+6-YP3]6C4?5A7S[7Z8?\&^W[
M.TC7_B_XI7T#+$L8\/Z4S#AR2LMRX^F(%##/WI!Q@Y^=XLS".#RFO5;U<7%>
MLM%^=_D?0<+8&6+S2C26RDI/TCJ_RM\S]/*^=_\ @K#_ ,H]?B7_ ->5O_Z5
MP5]$5\[_ /!6'_E'K\2_^O*W_P#2N"OYSR'_ )&>'_Z^0_\ 2D?T!G?_ "+L
M1_@G_P"DL_!NBBBOZN/Y?"OWD_X)/?\ */7X:?\ 7E<?^E<]?@W7[R?\$GO^
M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biosimilarrev.jpg
<TEXT>
begin 644 biosimilarrev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  A'A'XOR>,O#?A7X(^+-"M)_P!3?^'I'[$7_17[G_PWOQ'_ /F6KQ_XV?\
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MY=F2J/+\?A,:J/*JKPN(I8CV;GS."G[*<N7FY9<O-:_+*VS"BBBN0[@HHHH
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M/FN*_P#D5?\ <S1_*H?9<"_\CQ_]@=?_ -.4#]P&Z'Z'^5?P:?\ !7V65?\
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M3NY2;E)O35MW;>BU;Z([WX82S'XF_#3,TQ_XN3\/.LLG_0ZZ#_M5_I<KT/\
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M!@]>A[GT^M?P9?\ !7[_ )2,_M*?]A7X??\ JH_ -?WG-T/T/\J_@Q_X*_\
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MJ5A>2K^T/X7=H[6\M[B147X=?$A6<I#([!59T4L1@%E!.6&?6R+_ )'&7_\
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MT+P[_AYI_CPO_I-<VJ*QO^$C\/?]!W1O_!I8_P#Q^C_A(_#W_0=T;_P:6/\
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M:^\8Z%8:3-X4N;[XBV_PH;P[XC^*?C]=#T[Q=KOA?P_I7@CP[I_B#3M5BO\
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MB=*I*E*ZISJ1LY0;C:;]UJ]G=(HHHKC/0"BBB@ HHHH **** "BBB@#\0/\
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M #!4?VEEW_0?@?\ PKP__P L\_S[,/[&S?\ Z%68_P#A%B?+_IWYH^N?A?\
M\E-^&G_92?AY_P"IMH-?Z7J]#_O/_P"AM7^5KX"_:T^ 6D>._ NKZCXPUZUT
M[2/''@O5M1N7^%?QA9+;3]+\4Z1J%_<LL?P_>1EM[.VGF98T>1EC*HK.54_W
M1#_@X?\ ^"/(R/\ AL&#[SX_XL1^T]R"Q(/'P4(Y'/!(]Z^,XMQ.'Q#P'U?$
M4*_(L3S^QJTZO+S?5^7FY)2Y;V=KVO9]F?HO >#Q>$AF2Q6%Q&&<Y85P^L4*
MM'G2C6OR^TC'FM=7M>UU>UT?7G_!3K_DP#]K3_LBOBW_ -%6]?Y_$G^LD_WV
M_P#0C7]2W[>/_!=C_@E;\7OV._VB_AE\.OVI/^$E\<>-OA;XB\/^%] MO@?^
MTE;7&K:Q?) MK917&H?!RSLHGE*MA[BYAB&T[G4<U_'0_P"U)\#B[D>*?$&"
MS$?\6L^+W0D_]2#77PIB\+0P6(C7Q.'H2EBG)1K5J5*3C[*DN9*<HMJZ:NM+
MI]F<''. QV+S'"SPN#Q6)A'!J,IT,/5K1C+VU3W7*G"24K-.S=[-/8[WXDZ5
M=ZGH,<FG:?XAO-3TZZ:YT^Y\*7VBVOB#2Y;BWDL)[FPL_$(_L;68[FSN;BRO
M=.O6&VWF^V0I*]LP7E-;DUW3]6^'&H7_ (!\0^(M>TJXU"Y\1:WX-\/>'[FS
MM].GT+QKH]AIOGC6],BCNA=:QIU]JFF:1"=&2XN;R]T^66TBM8TR_P#AJ/X'
M?]#3X@_\-9\7O_F"I/\ AJ+X''KXHU\_]TK^+W_S U[TZ^63JRK?VGA(RDJ/
MNK%83D4J,XSC.S;;F[1CS2;E&'-&+46E#YBEA<ZIT*>'_L;&RA!UWS/!XU3E
M'$4U3E3YDK1@E)RY(*,'/EG*+E&3GM:MX6\1:M87'A&&WO\ 3'/CGQ5XOB\9
MB2T.F"QUY?%<UOLV7\NK'Q!/'XAM_#&JV2Z?$(-)M+F]BOWM3IXDU[)=<@OK
M?Q(_A/6[5?#7P]MO!Y\-VTNAR7>O7YUK1;@0Z$1J[6DV@^'+>PO'TF_OK[2S
M=0ZO?K;V8D@GC?BW_:H^!,;1))XOUN-YW:.!)/AC\6HWN)%C>9HK='\"*\\J
MPQ2S-'"'=88I9F4112.LG_#4?P._Z&GQ!_X:SXO?_,#2C6RN,E)9GAEI%6^N
M82UH*/LUJ[_NVKW^*;;564XI13EA\[G'D>2XMIN3?^Q8U-RJM.L]+)>U34>5
M+EIKWJ*ISO)];I>C>)M+UY;02>(+J'_A._$GB"^U*271%\$WWAK6[[6;^*3[
M 7?53XVMH[S3M)M[R&RM-0@6Q#-?KX9D>SN/4_K7S_\ \-1_ [_H:?$'_AK/
MB]_\P5'_  U'\#O^AI\0?^&L^+W_ ,P5:T<9EM%2C',<))2ES+GQF'?*K)**
M]]:)6U=Y-W;;MISXC+\ZQ,H2EE&.BXP46X8#$QYVW=RE^[>K<EHK)*R25C^L
M?_@W-_Y*'^U5_P!B5\(?_4B^(%?U8U_"-_P1/_X*H_L'_LK^-/V@]4^/?QOO
MOAY8>,O"WPWL/#5QJ/P;^/>H+JMYH>M^,;K58(ET/X6:I)$;2WU.QD=KA8E<
M7"B(N5D"?UQ?L@?\%$_V.OV]'\?I^RA\84^*S?"X>&3XZ"> OBAX)_L(>,?[
M<_X1S)^(_@CP>-2_M'_A'-9Q_8YU VGV,_;OLOVBU\_\\XBJTJV;8FI1J4ZM
M.4,.E4I3C4@W'#THM*4&XNS33L]&FGJC]:X2HUL/D.#I8BC5H58SQ+E2K4YT
MJD5+$U91<H349+FBU)76J::T:/M>BBBO$/I HHHH **** "BBB@ HHHH 0C/
MKQZ$C\\$9_&C ]_S/^-+10 F![_F?\:,#W_,_P"-+10 F![_ )G_ !KY>TWX
M8>+[;]LKQ?\ &*6RMQX$U?\ 9G^'?PUL=1&H6K7<GBSP]\6_BIXLU2R?3!+]
MNCMX=%\4Z-<1W[Q"UFDGEMHI&FMYD7ZAR#G!!QP>1P?0^GXT9&,Y&/7(Q^?2
M@ P/?\S_ (T8'O\ F?\ &@D# ) )X ) R?0>M+0 F![_ )G_ !HP/?\ ,_XT
MM% "8'O^9_QHP/?\S_C2T4 )@>_YG_&C ]_S/^-+2$@#)( ]2<#]: &LN0,9
MX9#U/175CW]!7S/^QE\,_%OP<_96^ GPM\>64&G>,? ?PR\,^&?$EC::A:ZG
M;6NKZ9:&*[@AU"QEEL[R-'.%N+>1XI!RC$5]-$@$ D GH">3]/6ER/4=,_AZ
M_2@!,#W_ #/^-&![_F?\:171L[75L==K X^N":=0 F![_F?\:,#W_,_XTM%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF\8>$)_#$\GAO0I;2078!][4444 %%%% !1110 4444 %%%% !1110 4444
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M?9\\:FB<59\T(Z]KH*/\_ETHHKP3Z<X.T^%WPWL-#TCPU9>!/"-IX>T#Q/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>collabprofitshare.jpg
<TEXT>
begin 644 collabprofitshare.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
M@H=^S[\0_A%X5^)6KZQK'A+7-=^'?P)\=77P\E\%_$C4_%5[+^T%I^? .G?#
M'2O^$'L-?^-FG:]XDL_$'A7P_P")/AGH&NZ9KFI^&M::,VL=A=&#9\5?L6>'
M/%7C3Q9XRNO'?B6WE\6_'KX/_':[TZ+3](DM;?4?A%\(=,^$5EX<AED7SWTK
M7=/TQ-:U&[D)U"VU&5XK-EMD3'S[K7_!*SP!XL\$Z%X4\?\ Q,USXE77PQ\)
M?!7X?_ Z]^('@#X<>)-#\#^"?@5_;#>&](\8^";C1XO#?Q8N/%J:]?:?\1=1
M\0P:8^KZ9::(?"T'@O7M+;Q#>@'V1X._:T^ _P 0/&OA+X=^#O%VIZ[XT\9^
M&-6\8Z7X?MO OC^&^TSP[X?\4>*? WB*]\9B]\+VL?P]F\.>.?!VO^!_$&F>
M.W\.:KHWC.UA\*W]C#KM_8V-QY=\8OVMO$OP@^./P]^&&I_#SP)=Z!\1_'_P
M]^'OA2*?XZ>'K+XZ^.7\;ZEHVEZ_X]^&?P#MO#.JWWBGX<?"*759M0^*>K:Q
MXS\*ZYHWACP_XQ\66.@7FC:!I\OB3H_V=_V/_!W[.FM6FL^%=5M0L7PLLOAQ
M<:#H'@/P%\.O":W(^*OQ(^+FK>(=)\+?#_1="T/1)-3\0_$O5+,:=:V4A6PL
M+*[U34M;\07.K:WJ%#XN_LF:O\9?'%I>>*/C?XSD^%"_$#X<?%&X^%[>%? 4
M^H:9XJ^%?B'PCXL\-:=X&^*!T6'QKX*\&:CXE\$Z1K7BC1;9M4UV_N;[Q%;Z
M)XM\-Z;K)L;4 ZOX'?M':G\8_BA\??AWJ/PI\3?#6'X,:QX$LM'OO%^J:2^O
M>.=&\;>']4U:#Q-/X5TIKR3P78O>:-?P:-I.MZK/XBU'1_L.O:KI7AU]2BTF
M+T7XM^+OBGX8M/#-G\(_A;8_$SQ+XEU^32;B7Q'XWB^'O@7P7I4&BZKJMQXG
M\9^([?P_XS\2?89+JQLO#^DZ7X2\$>*-9U+7];TU+FWTG0H=7U[3/E?PW^RS
M^TAX0^)/[0WQ5TO]JG2K_7?C9X0N=*TS2'^ '@W1[7P?XF\-^$]?\.?";7K3
M6!XFUV748_!T^L07^LV6L:-J5GXI>R$4]MI]K/-:/Z9^TA^S[\6/CM\)O"?P
MST/]H?4?AM-!=Z2WQ5U?3_AWHFNV?QFT*ST.:QUGP7XCTM->\-:AX<\(>+-:
M>'5O$MAX.\1Z+>ZII<,O@ZYU!_"VJ:SI^H 'S59_\%'?$?B?P)X@^('@+]G\
M>(M*^$'PBN_C3^T+:77Q7TJSN= \*Z?XX^+_ ((EL/@A?:9X1UW1_C?JNKV_
MP*^(_C_P;J%]>_#7PKXK\!+X%U"VUVRU#Q[;66B_2F@?M4R>)OVBW^"^E?"[
MQ*W@N[^!.M?&GPG\7[G5]$CTWXC+HNM_#73Y]'\ ^$H9KC7-2T=K#XG:+-%X
MQUV;PY8:AK45WH.B:?JB6.I:M9^4:S^PEK'B'0'TBY^.6H^%9_'GP;TC]GC]
MH"/X9_"SP!X)\.?%#X.>%[WQU'X/T#PIX9F'B&+X,Z[X8\)_$7Q7X#T[Q-X.
MU*]=?#&L2 :5%JVC^$-2\+ZGB_\ 8]^)?B;X\V/Q,L?V@X/#'PQT[X9>(?@?
M9?!_0/@]HFFW-C\(?&4_@:\\5>'M,^*.G^,['Q7I'B&2Z\":;_PC7B[3;"WG
M\*P3RK::7=W<-M>Q@&1^QM^WSI_[6_B>Z\/Z;X9\"6;1_#NV^(6K6G@#XNI\
M3_$WP;O9_$%MX9/P?_:>\.#P+X.;X+?';^U$\10Q^ (M0\71-=> ?B18/JT7
M_")07VO_ $K\;_B1\7/ IT:'X6?"7PYX]272/%?B7Q7XJ^(/Q6L_A%\.O!FC
M>$X-,N/L.J>(XO"7Q UZ;Q+XH%_<GP_!#X07POI^G:%XCUGQ=XK\/PV&F66N
M_*WA3]@WQ?\ #:&?Q#X!^/5S9_$[P-\!?$/[//[/?BS_ (5-\+/#MI\/?"7B
M"]\&7Z:Q\0=)\.Z#%8_&3Q%HM[X%T*\TL:_:Z1X6LGD\0R:;X2T[4_$VH:JO
MKW[7'[,_Q%_:4M_ FB>'?CE'\./ OAZ_U?4_'?PTU?X5>'OB=X&^,5Q(-,/A
M>Q^(>G:IXA\+ZCJ7A?PM<6M_J3>"AJK^$O%VHWMH?&VCZ]IVCV>FN >&#_@H
MW)K7@+4OC;X.^"^H7_P/^&OPP^!'Q3^/VO>)?&</AOQ]\/M'^-_@GP]\4+C3
M/"W@:S\,>(-*\<:Q\)_A;XK\/^/_ (DPZCXT\%V\FD:G;Z?X'N/%6N+-8Q_2
M'A;]H[Q+XQ^/GQI^!%E\(=9\+W'PS^&/AOQUX1\7^//$%AHVG?$R^\0>,?B7
MX(<6&@Z-:>(M?\.>!;/6/A]$;#QIK$']J>)[75+W4=&\&G2-,TW4_$?F'B[]
MAM_'=WKX\0_&/Q%;Z#\9O#?PXT3]JWPEX=\(^&-&\/\ QVO/AMI=GHL.IZ<L
M\FJZG\*U\;^';&S\#?$*P\.:CJ\>M_#[3M)T#2+CP[K%B?$]QU&B_LV_&;3/
MVL-?_:,N?VB=/O\ PMXB\.:5X"O?A./@AX9LTC^'WAK7_'?BGPOHL'C^/Q=+
MKBZS8:YX]U&;4O$+Z4Z:Q:6EG;MH]C,);QP#<_9N^-7QJ^*7C#XT>&OBA\._
MA+X8TSX3:]H'@N'Q7\)_BQXP^).D:]X]GTDZ]XU\*-'XO^#_ ,*KFTD\":7J
MG@Z/4M4L%UBPN->\0:EX99K/6/"6N01S>+/VWOV;? 5Y\0;7QUXUUOP;%\-/
M"_COQKXCU3Q1\-?BAH6A7GA7X7ZI9:/\1]<\':]J?@VUTCXA6'@>^U*P7Q)+
MX$O/$(L8+I+U?.L4FNHO4?@=\(;3X*> IO!-MK^H^*)K[QU\5?B#JWB+5[6Q
MM-4U;7OBS\4O&/Q2UR:\CT]$MF%MJ7C"XTNT(&3IMA9JP1@47\^?$/\ P2@\
M!>)O%'Q \5ZI\5?$,NM^,_#_ .T'X5A\3MX!^'+_ !$ET#]H?7-+\2ZU:>._
MB:^DGQK\3F\!ZEI<&D_#&/Q%J=OI7A?P9#8^&GTF_ETVTUA0#ZTU+]MO]GK3
M=/FN'\3>)WUF/QKKWP^/@D?"KXN?\+%@\3>&_!^E?$+6?[2^'$?@27Q[I'AS
M3O &O^'?'-[XSU'PW!X3M_"'B/P]KQU=[77=)%Y;\,_'SQY\1OV9/@9\<_A=
M\'CXO\7?'7P+\'/&>E^!9_'.GZ%X:\&VWQ4\,Z-XJU'4_&'CZYT>ZO1X3\$:
M7J-U)J.I>'/!.O\ B;7IK>QL]!\(3WFJJEGP?B_]B]M5^+WB[XY^"?C#XN^'
M?Q'\5^-M0UY]6T[P[X2\06=CX0\4?!SX,?![QQX$32O$=G=V5U;ZU!\"_ OC
M;1_$-P@U;PWXQTU"J:MX:GU3P]JNUXN_9;\9?\,E_#C]EOX.?'_QC\'&^'G@
MGX7_  V3XHZ;X<T;Q!XPUSP-\.O#^G>&[[1KGS+[0GT.\\;:3I<%CKGB3PGJ
MFA^)M)@N;^7PGJVA:G+::I8@'D7A_P#;E^)GC^]N_A]\,OV?M#\5_&[P>?CK
M<?$GPG=?&5-'\ V=A\"OB):_#&Y'P\^)2?#G4Y?&NJ?$GQ?+J6A> [37?"'@
M:QTO6/"/C[2/B-JG@_5_"4MAJ/HG@O\ ;9TOXD_$O]F;PMX'^%OC*X^''[2_
MPCU?XL>'/B]XCO=%\/:1;Q1> _"GQ"T+PII/AJ.XU77_ !)K<FB>)9(_&6H+
M'I'A[P9JEG;Z)'JGB+6+V[L]'Y'1/V'/%?AW1/ ESX5^.\?PS^)/@KP1XI^#
M:>,/A#\%?A_X*\.7/P0\3ZQI7B"#P99?#?5+WQ?H.C>)/!>O:6VN> O'<.H7
M=SI&K:QXAEUG0O$=EKNH:?+-K'[%7CW2_B#^SGK?P>^/EG\,/AG^S!X*M?A]
M\-?A?<_!GP]XY9?"\OA7P_X+UZTU?QSJ_B[3-=O;K4O#_ARQAL;]+."XTR\D
MN+RX.K^9Y*@$W[.?[=-G^T7\3X/"WAS0/AK%X-U[0/&'B?PK<Z=\=/#NK_&"
M+PUX;UZ'2M#\4^-_@Q<>'=&FT70/'5C<VNMZ5_PA_C'Q_K7@VSU;PM:_%#2/
M!VI^)[:TL?T%KX9^$?[$6A_"7QA\.+FP^(6N:E\*O@/=_$&__9]^$@\+^#M%
MT_X;7/Q.M=:T[Q#%?^+M)TV+Q-XST_1]&\2:_H/A"PU"338K33=4-YXM?QOX
MFTW1?$6F?<U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW_@]OO\ YG*V:* ,;S_$/_0+T;_P>WW_ ,SE'G^(?^@7HW_@]OO_ )G*V:*
M,;S_ !#_ - O1O\ P>WW_P SE'G^(?\ H%Z-_P"#V^_^9RMFB@#&\_Q#_P!
MO1O_  >WW_S.4>?XA_Z!>C?^#V^_^9RMFB@#&\_Q#_T"]&_\'M]_\SE7;234
M'\S[?:V5MC;Y7V2_GO=^=V_S/.T[3_+V_+MV^;NRV=FT;KE% !1110 4444
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MPL_P%_T,EI_WYO?_ )%H_P"%G^ O^ADM/^_-[_\ (M'^L.0_]#O*/_#C@_\
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M/_RKH_MVQ_YX:S_X3GB'_P"5=;-%?L@C&_MVQ_YX:S_X3GB'_P"5=']NV/\
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M +#=I_Z;]0KY?C7_ ))7._\ L#?_ *<ICCNO5?F?*E%%%?RN(**** "BBB@
MKZZ^"7_(EM_V&M2_]H5\BU]=?!+_ )$MO^PUJ7_M"OT3PP_Y*=_]BW%_^GL*
M/H_5?E(]>KXH^*G_ "/WB'_KK8_^FNQK[7KXH^*G_(_>(?\ KK8_^FNQK[SQ
M8_Y$&!_['%'_ -0L>(\^HHHK^?P"BBB@ HHHH O:9_R$M._["%A_Z605^A5?
MGKIG_(2T[_L(6'_I9!7Z%5^V>$7\+/O^OF6_^DXT?1>K_*(4445^R""BBB@
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M_P !T_PK]L\(OX6??]?,M_\ 2<:/HO5_H;F1[_D?\*,CW_(_X5A_\(QX>_Z
M]A_X#I_A1_PC'A[_ * ]A_X#I_A7[((W,CW_ "/^%&1[_D?\*P_^$8\/?] >
MP_\  =/\*/\ A&/#W_0'L/\ P'3_  H W,CW_(_X49'O^1_PK#_X1CP]_P!
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MM.EGA1IYOKR@ HHHH **** "BBB@ HHHH **** "BBB@#\0/^"E! _X*1_\
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M._\ $)<V_P"AIEO_ (#BO_E7]6?E='U5O3^\O_?0_P :-Z?WE_[Z'^-?*O\
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M_>4XQY5[-IZWNU9-#OI;S3^Z_P#F?M?O3^\O_?0_QKXH^*CI_P )]XA^9?\
M6V/\0_Z!=C[U\8?\.9;W_I+7_P %J/\ Q-C0/_G+UE7/_!$BRO)GN;O_ (*K
M_P#!9RYN)-OF32_MJ:"TC[$6--Q_X4R,[454''"J!VKZ/C/AS$<39;A\#AL1
M0PU2CCJ>*<ZZJ.$H1H8FBXKV<92YKUHR5U:T9:WLFCZCWI_>7_OH?XT;T_O+
M_P!]#_&OE7_AQ_I7_25'_@LQ_P")IZ#_ /.:H_X<?Z5_TE1_X+,?^)IZ#_\
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M7M%*>%KM+D<(M<R7NMI7=VNGGK^EOU/TL_X7_=_]"W9_^#:3_P"0:/\ A?\
M=?\ 0MV?_@VD_P#D&OS3_P"''^E?])4?^"S'_B:>@_\ SFJ/^''^E?\ 25'_
M (+,?^)IZ#_\YJO!_L+Q$_Z*W ]/^8&C_=_ZEWE^?D!^EG_"_P"[_P"A;L__
M  ;2?_(-'_"_[O\ Z%NS_P#!M)_\@U^*GQ=_X)(7?@3XG_LL>#='_P""I?\
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M>*2_O6MX4A:[O9(8H(9+NY*&>ZDB@AB>>21HX8D*QK=HH **** "BBB@ KY
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>costofsales2018.jpg
<TEXT>
begin 644 costofsales2018.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *,@=3BOQ__;^^*WQ-\#_M]?\ !&OP-X,^('C'PKX-^+/[2_[1
M.@?%#PMX>\1:KI'A_P"(>A:!^REX[\1Z'HWC32;&Z@LO$NE:1XAMK77=.T_5
MX;NTL]8M;74X(4O;:">/Z^_;.^('C/X=_#'PYK/@GQ!>^'-5O/&FG:=<WMC'
M9R2S6,NAZ[<R6SB^M;N+RWGMK>4E8UDW1* X4L#Z.4Y;6SC,L'EE"=.G6QE9
M4:<ZSFJ49-.5YN$*DTK1:]V$G>VECR,^SG#\/9/F&=8JE6K8?+J#Q%6EAU3=
M><%*,;4U5J4J;E>2?O5(JR>M]#Z1\?>$4\>>$M7\*GQ+XL\(/JB6AM_$W@;7
M9?#GBK0[W3]0M-4L=1TC5$BNH!-;WMC T]AJ=CJ>A:S9FYT;Q#I&KZ%J&HZ9
M=_G@?^":T-O^S=K/[/VD?M+?%71K[X@S^&9?C/\ %&T\(?!J[\4?$RW\'>"?
M"_@3PQI2Z%JG@&[\&^#=+T+1/!GAJWL#X<T*+6;F/3F;7M:UN\O+R^F^3/\
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M?$>RM?#ZWVF^+/!WA?X@^*/#W@CXI^%+WPGX\\)/X3\?>&=/U*+3;W39-/\
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MWJ0Q-"4*/MJD:5+VD_9\L/:3;C#F:O9OX8S:_<>^_89\%^)/#?AG2/&?Q/\
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M_#K]H'XAZ'K7Q2U:30Q::)X!^&GAGP\VD_#:XUK6OC'XO\3>!_'W@+QIXO\
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MQ1XMOA<7^IZEJ]MBVN+#2[*U\.Z#8VUK]BAUS6)[_49)_@1K?Q-UZ+XOZ?\
M$O4=(USQ'X.^.OBSP592^%_#=UH'A^QT>T\%?#CQ'8:!H]I=S7FL7]KH]SXF
MU*WBUC7KNX\0:S$/[1U%;(RQ:;8;P\-^$YU(4U3SI.=:O04I8J@HJ="/,^:U
M%M*K!.=*T7*UU4C2E:)RU/&3CVE1J5W6X;G&GAL)BG&&"Q3FZ>+E&FE%/$*+
ME0J.-.O>2CS->QE6BW(_?<?MU_"@=-3UX#&,#X<ZB!^ 'C' /N.:7_ANSX4_
M]!/7O_#<ZC_\V%?S#:'\9_BS/\<H+75#XS7X6ZU^T+XK^$VA>,5\%>#_ /AG
M/5?#&FZ?JNFZ!X8T/QC;63?&!/CW-X_TZY\&7NH:_P#9?A%J7C#0?%'AS1M8
MN[<:!:7/WD#D \'(!R.ASZ>U+!^'/"&-59TEG$50K.C)5<51BY-1A-5*?+0E
MS4:D9*5.IHIIMI6L/,?&+Q!RR6'C7EP]4>)P\<1%T,%B*BIWE*$J-;FQ4.3$
M4I0<:U+WG3;2D^9M+]YOA'\?= ^-=WKEEX)U*0S^'[:PNM0_MGP;?Z6GE:E+
M=PVWV=CXHN?.??9S>8N$V#8<MNX]]LTU)/,_M"XL9\[?*^QV4]IMQNW^9Y]_
M>^9GY-NWR]N&SOW#;^7?_!.O_D8?BI_V!?"/_IQ\05^J5?D7&.483(L_QF6X
M%UGAJ$,+*G[>:J5+UL)0KSYIQA!/WZDK>ZK1LM;7?]!>'7$&8<4<)9=G69^P
M^NXJKCX5?JU.5*C;#8_$X:GRTY5*LD_9TH<S<W>5WI>R****^7/N HHHH **
M** "BBHIQ(891#(D4IBD\J62,S1QR;#LD>)9(3*B/AFC$L1=04$B$[P 2;ES
MMW+N_NY&?RZTM?DC\0?CCX,\)?%!/#UY\:/VP-9\6:=\1IO GBOQ;X4U#X2:
M1\.?!0TB]^!'AO7O%4GP^UG3;71M<\$:'XZ_:1^%'@FZL[#P=XP\9W.J7_B"
M:RAUS3?"FN:\?U?TJ"^MM,T^VU.^35-1M[.V@O\ 4H[--/2_O(84CN;Q;"*6
M>*S%S,KS?98II8X-_EQNR*IH _$__@I/_P I)/\ @A3_ -G6_M0?^L<_$&OL
MS_@H%_R1WPG_ -E!TK_U'?$E?&?_  4G_P"4DG_!"G_LZW]J#_UCGX@U]F?\
M% O^2.^$_P#LH.E?^H[XDKZK@C_DK,B_[#H?^D3/A?$S_D@N)_\ L6R_]/4C
M\@J***_JX_@D**** "BBB@ K]G/V"_\ DA3?]CQXJ_GIM?C'7[.?L%_\D*;_
M +'CQ5_/3:_./%/_ ))7_NIX+_TWB3]D\"_^2Y?_ &)<P_\ 3^!/M2OPA_:\
M_P"3BOB1_P!?6@?^HGH-?N]7X0_M>?\ )Q7Q(_Z^M _]1/0:^!\)/^2AQ_\
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M5WHCGK8BOB'!UZ]:NZ=.-*FZU6I5=.E&_+2INI*7)3C=\L(VC&[LE=GZ/?\
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M8-_!)'\.O!0,EQH_B:'7-8\22K>>)6M;7]N!_4_S/^?Y4 ?B#_P4G_Y22?\
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M\ 1^+OC%X,UKP)XAU+X:Z\L=KINL^*U\):7K%EXSO?"'AS4XM U-19R>(O\
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MCCB9R;24N:,;.UT_R;_X5M\0?^A*\2_^"JY_^)H_X5M\0?\ H2O$O_@JN?\
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MTC_[^)_\51O3_GI'_P!_$_\ BJ_6.2?\LO\ P%_Y'X)==U]Z'44W>G_/2/\
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M)225DG*-*FI/>7)%N[5Q%[3/^0EIW_80L/\ TL@K]"J_/73/^0EIW_80L/\
MTL@K]"J_:?"+^%GW_7S+?_2<:/HO5_E$X?XE113^ _%4,\44\4FCW*2131I-
M%(C!<J\<BLCJ>ZLI![BO@TZ)HN3_ ,271NI_YA&F^O\ UZU][?$7_D1O$_\
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MS#&RYJ$95E+$5_<J<SM%RE5ES3Y(P=1Q4(<S]VG3]ZG$^IX3_H%PW_@BE_\
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M#,J2)DKE0R@E2K#@@U]NX'H/R%?%/Q4_Y'[Q#_UUL?\ TUV-?>>+'_(@P/\
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M^U;_ /.+H_X?@_\ !+[_ *.5U7_Q'/\ :M_^<77\T_ZO9_\ ]"/.?_#7CO\
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MG&58YK1J2IX7#U<14C36$QL7.4*,)R4%*48N32BG**;NT(_2^BOR@_X?@_\
M!+[_ *.5U7_Q'/\ :M_^<71_P_!_X)??]'*ZK_XCG^U;_P#.+K\-_P!7L_\
M^A'G/_AKQW_RCS_/LQV]/O7]=?S[,_5^BOR@_P"'X/\ P2^) '[2FK$D@ #]
MG/\ :N))/   ^!>22> !R344'_!<C_@EO<PQW%M^TW?W-O,@DAN+;]GK]JBY
MMYHV^[)#<0? Z2&:-OX9(I'0X.&.#1_J]G__ $(\Y_\ #7CO_E'G^?9A;T^]
M?UU_/LS]9**_*#_A^#_P2^_Z.5U7_P 1S_:M_P#G%T?\/P?^"7W_ $<KJO\
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>fampyra.jpg
<TEXT>
begin 644 fampyra.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  C 'X# 2(  A$! Q$!_\0
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MM@''\S110T@N%I:01VT>V-1\H_EBG?8;<.7\I=Q&,_Y^@HHH458&W<<;2!@
M8EP.F.,=_P"M2A0%VXXQC%%%.PC#U#PIHMR&EDTZ'>3DE<K_ "(K.M_!VAM,
M U@I&>AD?_&BBLY15]C*45?8WK70=,LHFCM[&!$?AAMSG\34,GAS26<$V,0/
MMD#\J**)PBUJC>$G'X78M6>E65B=UM:Q1M_> Y_.KE%%:122T$VV[L****8@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>financialhighlights18.jpg
<TEXT>
begin 644 financialhighlights18.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &Q 3T# 2(  A$! Q$!_\0
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M[J^GQ6\]]I=IXS\,ZIX:N=1LH+L-:S7=C!JDEU;17*FWDFB1)@8V85\Z^/\
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M ?P\\#^$/#?QJ\">"H_$>F:%8:)I#)K<WP?OKGP9XIU3X:^(=2\':E>RZGX
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M[[Y0 3!+>VDAW$,8V4K3!X6_;3\40R+K/Q9^ OPKB9R4M_ 7PH\7_$G64C?
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M+[_D^;_@N'_V?=\,O_63?A+7[;3?ZJ7_ *YO_P"@FOQ)_P""7W_)\W_!</\
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M^'/VGM9^(%C:VOA^+24T"X\(:5JFO66D1:<_@_3KV:'2;67][1_4^GJ?3_\
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M7PLLOA?_ ,()<LRZ7/IJ1O=Z8WC32]/TA_%MQ:7$TL6G_HJ/\?YT %(2!C)
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M_P @4?V_:?\ /IK?_A/:Y_\ (% &W16)_;]I_P ^FM_^$]KG_P @4?V_:?\
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M\A2UB?V_:?\ /IK?_A/:Y_\ (%']OVG_ #Z:W_X3VN?_ "!0!MT5B?V_:?\
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M!$H0UITR2..5'BE1)(Y%9)(Y%5T='!5D=&!5E92596!# D$$$B@#\4?"*_\
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M^&7_ *R;\):_;:;_ %4O_7-__037XD_\$OO^3YO^"X?_ &?=\,O_ %DWX2T
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M"$)K"X>4G"A1A&$81:BJM514ZS<FHP****^9/M0HHHH **** "BBB@ HHHH
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M,O[$'Q?TGXK:Y\>O /[*GA33;EO /[4GP^_9T^%GC'XC>&6U#]FV\^)_PM^
M>G>'-7UOQ)X3\?*?"W@3QA\0OA]\:+_6/#_P+\;Z[KW@NX^*\7B'1A:W_B_Q
MK<^%?7?V4_V4?VA?AM\3M!U/7/#6LZ!\(])_:7\,?%KPOX7\2ZG\%M(U'P5H
M5Y^QQ^T!\)_B%-'X(^"U[?>!- GU3XJ>*O!"S:7X=UOQ9J.M6^H)XMUKQ#J>
MHIK[V*&?L\6 .#NZ9X5B/S (S[=:0,",\_\ ?+ _D1G/MC.,'H0:_);]L3]D
M/XU?&+QG^T)X[^'MQ?Z;K&K?#K]DGPS\.KR#Q/I[2ZKX=\#_ !>^(_BC]IWP
M)X=\.:[K=CX4T/Q!\4_A=JND_#_4-:\5+I6D^,=(U2#P?JOB/2O#@UJ^L_-O
MA_\ L:?M'>&;#X/VMD/$R>%/B!XJ\??"_P"/WA/Q;XM^'WA6_P#AS^S?JGCK
MPU\7_#<6@>&?A+J&H^!;2"SU'P3\1/A9I'@/P+XE\47?A'2?VH]8GL?%5QX:
M\$6UAHP!^V6X'/WN/]EN>W''S?49XYZ4H8$9&>_56!X]B ?IZ]LU_._H/[!7
M[8DFC_%/2_&6M>/]?\7^*KK3++QWXFTWQ?\ "KP#X:^,]W=?MA?!_P")MQXY
MTWQ/X,\3'XOZKJ'A/X3^%?&L/A.Y^(,?PWU7X=:-KFJ?"KPEI?BG2-0TV]TS
MW3Q#^S!^TM\-==^*Z_"/X8W.O_#_ %#3_P!MKX5_!GP#I/Q<T#PSI7@OPY^T
M5\-_V4-:\ ^,$B\2Z\(=!\#Z3\7/A1\88=9TC21?^,O"^H>._P"W_"WA&]T;
M5+^"( _:O<,XY_[Y8#\R,9[8SG/&,TH8-TS^*LO_ *$!7X3?"S]B_P#:PT#]
MH#2_&/B_6?'ZV]C;^'I=*\5>'?%'PCT?3-,^'FG_ +*FC?#1_@7J?Q!EU/Q%
M\;["TMOB7;:O?R^'_#'@B\\#GQ)<Z=\>+'QLWC:WGT)_K'_@G;\$?BS\#-,^
M(_AKQM\/[CP/X+N;3X;R>%+CQ5K?@_4?B=XD\6Z?I7B'3/B#K'C0?"OQWXK^
M%?B*&>W@\&W%A\5;#PW\+_B)\4-9NO$^K?$SP#87>G:%>W(!^E-%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M57[#9BY-X+6W%V5"&Z$,0N2@ 4(;@)YQ4* NTR8V_+C;Q5JBFFU>S:NK.SM=
M=GW7D)I.UTG9W5U>S[KLPHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **1
M@2K!6VL00K8W;21PV#P<'G!Z]*^?#\.OCWDD?M%VP!)('_"F_"9P">!G^V.<
M#C/?K0![5XCUVU\,:!K'B*^@OKBQT/3;S5;R'3;22_OWM+"![FY^R6,)\Z[G
M6".1TMX0TLNTK&K.55OD?_AOG]G?;O\ [7\5;-N_=_PANL8V;=V[.S[NWYL^
MG/2O3&^''QZ=65OVBK1E8%65O@SX396!&"&4ZQ@@C@@\$<5^;]E^QIXKD_:*
MO?A[)J\$/A[3]*A^(*>,_P#A&+632Y["XNR++3U\,O>KIV^3Q'%=:3+HIOC;
MQZ3933@-;M' P!^Q_A_6K;Q'H>D:_9P7MM9ZUIUGJEK!J5K)8W\=M?0)<VZW
MEE*?.M+CR9$:2WF EA8^7*JR*RC7KYY'PY^/8  _:+M0   !\&O"8  X  _M
MC@#L.U*?AS\?,''[1EL#V/\ PIKPF<?^5B@#Z%)P"3T R>_3V')_"OF"W_;$
M^ EU\=;G]FR#7_&C_&.S\N2Z\,'X+_&Y-/M[">YU&RMM=F\:R?#A/ 2>%[R_
MTG4].L?%;>*!X:OM3L;G3;/59[Z)K<?3<2ND<:RR>;(J(KR[!'YCA0'?8I*I
MO8%MH)"YV@X K\T/VHOV=_V@/B)\3?V@?%7PHN$T:'QI^Q[\.?A;X:U9/&TG
MA*Z\0>*?#'QV\>>.O&?P^76-)>7Q'X)'C/X<ZRWA&V^(5E:[O#4_BHZKITWV
M[176, _1B;Q)H%MK^E>%;C6-.M_$NN:1KFOZ/X?GNHHM9U30_#-WH%AXBU>P
MTV1EN[K3=#OO%7AFSU:\BB:"PNO$&BV]R\<NIV:S5-;\9>&O#FJ>#M$UO5H-
M.U3X@>(;OPIX/LIX[GS==\06/A7Q)XWN],M#' Z)/!X5\(>)-99[EX(#;:5<
M(LK7#002_A3+^P_\7M*^*NN?'OP!^RIX-TNZE\ _M2?#[]G?X5^,/B'X7:]_
M9LN_B?\ "WX":9X=UC6O$?A/QPG_  C'@7QA\0?A[\9[_6O#OP+\;:UKO@R?
MXL1^(-%6WU#Q?XXN/#'KO[*?[)_[0GPU^)^A:IKGAG6/#_PCTK]I?PQ\6_"_
MA;Q)JGP5TG4?!6AWG[''[0'PG^(<T?@CX)S3^ = N-4^*?BKP0)=+\.:OXKU
M'6K6_C\6ZWXBU348]>:P /V>+ ''/Y$@?4@8'XD4F\8)^;C_ &'S^ VY/N0#
MCO7YF?%[X!?%WQ)^U-XA\>6_@2Y\;6^M^'_A+8_ OXS1_%&'PE;?LIZCX5_X
M3<?$F[N/!RZG!KOB,^*KO5-&UYM%\-Z%K^C_ !BA8?#GXK7OA?PCX:TK49?D
M/1_V+_V@)?AAK^AWOPD\9^#;"3X:?LX^&OBAX$\.?&[X>>,M7_:(^.OPU\?:
MCXA^(OQUDM_B!J^J?#GQWX<\3:9)'8>)?#OQGU+X>^*/V@M&UF32?B)_P@EW
MX"\'7UP ?NI'XH\.2^);KP;'KFE/XLLM#L/$UYX;6^MSKEIX=U6_U'2M,URY
MTS?]L@TK4-3T?5=/LKZ6);>ZO--O[:&1Y;2=4V]PSCG/^ZV/^^L;3],]>.M?
MD-^R;^RC\0OAA^T/\/\ XV?$CX >";#Q+J_[,%Q\$KOQMX1U70I]2^%L'@/X
MT?%GQ+X*TSQ3;^(/B%XO\0K)XY^$GBOX?:-J.E?#;Q/\1_"7@WQAX=UGPEI6
MI6WP[TOPIJC^=_&[]E;]J_QW^U)XI^)WAKPA#HEI_P )I\2M.3Q-X;\4?#BP
MT'QY\#/%?[)/Q!^'7A?0]=USQ#?ZI\;Y?%MC\8M3\(WFM> +,> ?@IH(L-.\
M:Z%9^*/$=A=ZM* ?M[O&"<-P0/N/GDXX&W)'J0"!U) KD? WC[PA\2O#J^+/
M ^MVWB'P^^L>*- 74K2*[BB.L>"_%.M>"O%%AY=Y;VUR)]'\4^'=:T:YS"$:
MZT^9H'F@,4TGXV1?L1?%WP59>!]+L/A=>^._A!IO@7]B?6/C?\#8?B]!!=?'
MGXC_  _\'?M->$/C1)J6H^*/&%IHFO>*M*\2>*/V:_B'XAO_ !CKND>&_C);
M?"S3M&U76M0O-(BBE]AM?V6_VA+#_@FCK?[._A&1OAK\7[OQ5XTUR/1M$\<V
M^MW \!ZY^U?K_P 6M<^&UCX[U1A8W^H>.O@OJ6H?#S^U]>GMK%[WQ"\?B"]T
M^T:_O;8 _6'<, \\YQE6!X]B <]\8R1DC@$TFX<_>X_V6&?IQ\Q]ADU^%WAW
M]CO]I;0?"WPFN/#OAGQ./^$#^+WC+XD^(_ ?C/QA\*?"*^)?@/K.J_"VUU7]
MD'0O!WP?UVY^%W@K1O&/B3PK/^T#IFSQ-XE\,>%_%_@NR^'\WBB+P;\8O&VD
M>&?([3]EK]J3XM> ->UCX0:'XH^$.LWV@_M$Z#\3/B!??$FT_MC]J'1M7_;(
M\,^+O"'@BRT'6]6EOO#UYI_P@\%_$KPI8ZE\1]*\,:'X'@^(\/P^\%ZKJWP]
M\0^)/$&F ']%NX8!PV#_ +#YXXY&W(_$<]1Q2[AG'.?7:VWIG[V-OZ^W6OPA
MT#]@3XO:WX7M-,\7^'/%^I>'=.^#/[<L/@7P'XO\9_#GP=:_#;XD_$ZX_9=?
MX%:-I/@OX'^(S\//#5I9ZW\-/B7XZ\+1:-XC\8Z5\*O$NMW^K:;XHTF]U?2+
M#1>EUK]ES]KZ^^,FE^-/"NFZCHOQ)\3?#30/#OB7X^>/O&7@CQ;I7P]U.3]D
MV;X9ZOJ_P[U/PWXCT#XM^']:TOXNBT\27/P=U;P1\6?@3XO\0?V_\7AX@\->
M-/$-NOA\ _;C>,$X; X^X^?RVY/U Q3@<C/KSR"#^(/(^AYK^?;P'^PU^T'I
M'P-\6>&_%OA;XP:RU]X@_9^OM3^%MMXJ_9<M=,\3^(OAYI7Q"A\?^.)?!#:M
M>_#+XW6/C/4?$OAA/&2_''X@^ O%/Q<B\+^&O&FM6O@GQOX#TP>)_P!B/V5O
M#GQ'\'_L]_"GPM\6M&\.^'O'GA[PK!H^LZ+X6U?7-<T?3;?3[R]MM!M4U#Q#
MXC\8:B=0C\-QZ/\ VW9IXM\4Z9I>MG4=*T+Q)KFA6.F:I= 'T#1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4FU=V[ W8V[L#=M!)
M SUP"2<=,DFEHH **** "BBB@ HHHH **** "BBB@ HHHH * ,?_ %R3_.BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4^HZIJ>H7,NV.ULM/L+:XN[NXE*QP6\,DKD*I-?@/>?L&_M=67PE\-:)X?\
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MSX0_ '4/"IOUOK"[L/B)X[^'?Q"U4:_I%IX$\$7?@";6?#_B+4O$/B_7K2
M_=6UN[>]M[>[M9/.MKJ"*YMYE5PDL$\:2Q2*65>'C=6 (##." P(&19^*O#6
MH>(-<\)V.O:3>>)_#5CH>I^(?#]K?6\^L:+I_B7^U1X>O=3TZ-VNK*VUO^P]
M9_LJ:>-$OO[+U#[.9/LDVS\D_@]^R3^T7X7_ &W=4^+OC37?&,_AS_A:/Q \
M8VWB_2KOX,6_AK5_@_XB^'-UX:\!_ O6;MHM0^.&H:1X#O[K1HE^'G]G:/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>flixabi.jpg
<TEXT>
begin 644 flixabi.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                    ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
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M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
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MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
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MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
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MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
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MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
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M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
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MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
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MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
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MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
M )F0@    (  @ !I*;A_D?Y=%+1'D,A0/[ 8CX)"E*P;CFPS\:B;C>$CIZ8R
MCD40(J99BND  )C?@    (  @ !I#;?SF5E=%[.>E^901*]9EE5"DJM-E0@S
MY*?'E+8CG*5>D\P0/Z59BOP  )A(@    (  @ !H^K>/H.M=([,3GTE04:ZU
MG7Q"EJJ;G"4SZ:<+FVXCL:24F"(05J2#BPP  )>R@    (  @ #-4&QM9D2Y
MYVXP:'6ETV_8:I"0X'%C;)1[#G+?;HUD571/<'U,;'6D<E QK7:I<]8-QW@Q
M<[;+7&GN<52X6&OG<F>D;6VV<W>/GV]G=(9YXW$&=9=C/G*6=J5+87/Z=YLP
ML73<>%4,YG9T=^7)B&?)?&"VD6G<?%RBX6O+?%^.)FV9?'UXD6]6?*IB$G#_
M?-Y*67)O?00OQG,K?00,(73N?(/'NV7BAU"TPF@*AE"A&VH+A6",FFORA(=W
M*FW-@]-@VV^,@R])5'$%@HTNZ7&9@>L+=G.;@+C&&&1&DC2S*69\D%2?@VB-
MCGZ+#VJ#C+MUUVQNBQ=?LFY#B:)(8&_"B$$N'G KAQ\*Y')XA%+$Q6, G2&Q
MW64_FG">.&=5E[6)RFE3E0ITIFM'DH5>I6TAD#-'@FZFCBDM:6[FC,4*:'&$
MAPG#MF']J!.PU&1 I)>=*F95H/J(NVA4G6MSJ6I2FA-=R&PSEO]&QVVQE%0L
MTFW+DO,* G"YAL3"[6$\LPFP#6-_KL2<4V6-JDR'VV>%I=MRRFF$H;A<_VMM
MG@5&)&SJFOTL3VS9F%P)KW 4AHS":F"[O?ZOA6+ZN.>;LF3XLY.')6;BKDYR
M%VC:J7-<76K"I3Y%BVPWHCXKQFP G*@);7 2AE^^KW2.96"M!'6"9[Z:;'9Q
M:>^&OG=::_UR#WA";?M<6GDL;^Y%4WH/<;LK WK?<QD'@'T6<WV]1G(];_"K
MZ7-F<3N96G1U<G"%MG5V<YAQ#G9S=+U;:G=Q==]$=GA==N0J.'D%=Y &]7M;
M>!2[P' N>FNJ/G%R>K:7TW*:>OF$/W.V>T)OP73/>Y5:1'7D>^Q#<W;6?#(I
M6'=.?#\&>GG6?&RZ*6Y=A,JHFF^RA#.6,7#L@Y:"UW(;@OYN>'-/@H!9)W1X
M@@Y"A75N@9\HD76W@2X&#WB%@#&XKFS1CRFG)VXRC<.4OV]\C%"!;'"XBM]M
M1G'WB818&G,TB%)!J'0MASLGWG1$AGD%M'=D@VRW>&N6F9JE]&S_EVV3CVY-
ME2. 0V^1DMIL,'#9D*]7*7(6CK= XG,3C1(G/G+[C%8%9W;>@Z>V@FJ;I!2D
M_&P(H222DFU4G@5_26Z:FN9K1V_KE_E68'$NE59 /G(?DS@FO''>DB,%)W=*
M@WRURVG?KI>D/FM,JN>1Q6R1IOA^=FW/HP9J=V\BGV%5HW!NG#<_IG%=F?,F
M27#JEN($]'>A@UFU5FEBN22CN&K)M+>1(VO^K_A]QFTOJSYISVYZIO)5#V_%
MHV<_&'"NH0TEQW 5F8L$RG?G@SVP<'S_9*R@37T=9QV/$7U4:5=\EGV<:V=H
M_GWQ;6541'Y6;U,^$7[5<0\D '^K<B8!]X%G= &O4WK1;J"?,WLG<!.-WWMZ
M<6A[=7O5<JEG\WPZ<^-34WRO=10].'TL=ATC0WW)=I\!MG^N>'&N'7C5>)&=
MX'E->1F,OGFV>9%Z2WHF>@!FY'J<>G929GL?>NT\<'N=>TPBG'P">U0!?7XK
M?%>LN'<0@F><<W>8@B6+-W@6@<]X^GB6@7)EKGDG@2916GF\@.4[CWHZ@*,A
MYGID@%8!2WW1?[JK9G67C$";('8JBT")Y7:TBB5WL7<_B0!DG'?7A^M09GA]
MAOLZQWCZABLA27CHA<P!('X8@,.J3W1IEC*:"74#E'B(T761DI9VI'8CD*EC
MH7;!CM9/DG=CC3<Z&7??B_D@OW>8B[8 _7Y5@*NI<'-XH"^9)707G;Z'ZG2C
MFQ9UP74UF&5BS'7:E>).VW: D[$YBG;KDB@@479SD,P WWZ'@)>HRG+!JCF8
M<W-BIQ:'*W/HHZQT_W1RH#EB#G48G1-.*W7'FG@X_78LF1 ?[W5ZE/0 QWZP
M@(:H7')$M%B7\'+BL(J&CW-;K&)T6G/7J#AA<W1VI(%-I74BH; X?'6#GX8?
M=W2HE48 M'[1@'FB?X7%9!F3H(469HF#EX2<:,)R/X1':M%?N(0+;,I+\8/R
M;JPV@80@<$@<985A<.8  (!,=KJAF(.X;8.2IX-%;PF"@(+H<&UQ-8*?<;Y>
MPX)K<P1+%X):=#LUP()]=3@;R(-O=68  (  >KF@BX'9=M619H&(=XN!78$[
M>"MP$H$#>,!=P(#>>55*.(#7>>0U!8#S>D\;-X&:>BP  (  ?CJ?9H 9@"60
M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
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M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
M@ "4T8\,8Y*&\HV=9?%W\(QY:"!GGXN):B=6&XJ[;!5#/8HJ;>$N=HHI;T<3
MR(R;;Q0  (  >D"4$(TM;'J&*XOW;?YW#HKE;VAFRXGT<,!568DE<@M"D8B3
M<S\MWXA]=!X38HI]<ZP  (  ?;:3,8M?=4>%'(I-=@YV&(E(=L1EU(AD=W!4
M?8>?>!I!UX<3>+DM28;N>1\3 XA_>)H  (  @ "2+(FX??N$"XBR?B1T\H?!
M?C5DZH;B?CM3J88N?D=!+H6I?E4LRX5V?E02N8:@?@8  (  @ "1,(A,ALR#
M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
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M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
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M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
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MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
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M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
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M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
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M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
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M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
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M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
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M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
M@ !^0Y'Y769QVI"18!ID:8]Q8J95NHZ#90=%OHW#9SDT'XUR:1L?THY6:A<&
M3HZ9:A0  (  ?,M]>X_H9:AQ*HZP9Z!CLHV9:7]5&8RD:T-%-HO<;.4SM8M]
M;D4?CHPG;N &:HOV;O   (  ?]Y\KHW7;=%P.HS%;R-BY(N\<&)43HK0<8Y$
MBXH-<J,S+HFI<X8?-HHC<\P&=XF?="L  (  @ ![R8OM=>EO1(KN=JIAWHGY
M=U13A8D3=_%#UXA=>'LRHX?V>.<>W8A&>.T&?(>2>;\  (  @ !ZZ8I*?@5N
M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
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M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
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M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
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M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
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M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
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MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"__B?1!)
M0T-?4%)/1DE,10 "$H<2?;4  ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@
MA"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @    (  @ !CWH> C$59
M#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (  @    (
M@ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L
M (  @    (  @ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-
M8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K
M49@490P:4)D19;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]
M9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0
M.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (
M@ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X
M (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M
M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI
M+HZE@,X9((ZI@.L'4(P<@.   (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_F
MA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5.
M"9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (
M@ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P
M (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R
M8@<  )UL914  (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@
M$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V
M:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$
M*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (
M@ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0
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M7F"Q8&1]VF,G8S5M0F5^9>9;A&>W:'=(DFFV:N0T%VL#;0$;9VI-;B   (
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M/U,&C5]W0U9/C"MG/UE:BO)60EPKB=1$*UYNB.8PJ5\4B%(8_&!-B$D  (
M@ "3@4VXF!J%>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8
MN5\YC.T  (  @ "2]$QWH9>$[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&
ME8TOR5P3E/L865YFD'8  (  @ "16&FL4V*#GFM,5R]T\VSP6LQE&VZ07C=4
M$' C87A!K'&89( M=7*E9PD3T7/&9\<  (  <>2/RF7#7+Z"4V? 7[=SMFFA
M8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(  (  =I6.2V(J9B"
MW61R:$ERCV:,:E=BZ&B!;$-2*6I6;A= %FOK;\4L.6RE<143$FY=<0\  (
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M,5CMDR=M$5N5D8Y=[%X"C^I-OV VCGL\6V'.C7$I;V%NC4D1@F:JBF(  (
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M<&D,;S=G &JV<*%8E6Q <?)(O6VN<R(W?6[,="LD%V[A=,L+3G->=+,  (
M@ !_NF1R=H!S2&9S=V-EW&@^>")78&G=>,%'SVM:>50VI&QX>=,C;6PY>A4+
M"G&;>F4  (  @ !^H&(=?UER-V0Y?YIDW&8;?ZU6<&?0?Z-&]&E4?Y@V!FI?
M?Y@B]VG*?Z,*WW 8?\<  (  @ !]O& HB"9Q7F):A\ID#V1,AS15KF8-AH9&
M/6>8A>LU<&B3A8(BI&>DA8H*RV[/A$,  (  @ !]"EZ1D.5PLV#4C_9C9&+0
MCKM5#&24C6M%GV8>C% TU&<*BZ4B+F78B^D*LVWJASP  (  @ !\BUU7F9)P
M,E^HF"!BVV&EEDI4A&-DE&%%*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (
M@ !X_7GN4OYM!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$
MA(#I9.T  (  >2!WLW9@6TAK]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'
M9^H<B'L%:/$$FWXI:;(  (  ?,!V?7,-8Y=JL'079=1=_'4)9_-/_'7J:>M
MN7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (  ?^]U1' %:]]I<W$Z;7U<NG)/
M;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@  (  @ !T$VU7=#=H
M2VZP=3I;HF_>=AU.!7#G=MX_/''6=XPNF7)[>!(;6''N>"($K7@9>;,  (
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M@H+-5>=52(+T62Q'RX,Y7#TXUH.A7P$GV81X82P2](:[894  (,Z9:X  (
M? -KEG^$6DY@D'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\
M ($):F(  (  ?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*
M:V<2E'^):S\  (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@V
MOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E
M<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<
M<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (
M@ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D
M (  @    (  @ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)
MAYL12W1JAL$  (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T
M"W)^C@(D+W(ACC81$7,_BO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI
M5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5
M*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (
M@ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L
M (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D
M;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\L
MP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?
M>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0
MUWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (  @    (
M@ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\
M (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9
MBS()3'LJADD  (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HD
MSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G
M7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](
MW)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (  =N0  (
M@ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0
M (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^
M;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B
M:8AH==<1XHD?=8@"1895>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4
M>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%
MB(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (  @    (
M@ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P
M (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;
M6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P9
M19ZA7-@(IY]S75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO
M7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\
MA)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (  ?8   (
M@ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\
M (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I
M<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7
M:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/
M??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z
M)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (  @    (
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M0UUA4B!V6U_]5CEF?6**6B]5@63Y7?M#/6<788\O3VA 9+$6JFEU9E0  (
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MA$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5; ?PD4AUYD?U@  (
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M2%^+6G=K8V'^7;9<>V118--,669R8\,ZS&@I9G4G0FB':)0.0VX1:/\  (
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MCDX\A'AE6U'*A!E7&%3X@[!'P%>E@UDW&5DF@RDDIEB1@T0-/&FA@Q,  (
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M%V*F8<E@263:9$Y2-V;:9J]"\6B9:.0R$&G*:LX>NFE-:_<'#705;*4  (
M?5)WDEPN9]-KFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'
M#G03<<X  (  @ !V(UB'<'AJ7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[
M==8=N&+[=CT&YW15=X0  (  @ !T\U53>2%I0EAI><=<L%LK>DY/$5V6>KQ
M5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (  @ !S_5*1@;EH8%7/@<9;X5BQ
M@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D  (  @ !S/5!#BCEG
MKU.CB;E;-E:>B/A-LUDJB"<_!UL6AX8NWEM\AT$<G5SDA\4&TW1XA)T  (
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M^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (
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MQ5H CC-0]UQ>C39$(EXRC"(V(%\_BVHF9UYABXD3L&0XB?,!#WXU@+@  (
M@ !DXWH,35I9W'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@
M (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG
M8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P
M^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7
M:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5
M VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (
M@ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\
M (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=
M?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,M
MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1N
MB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @    (  @ !8\X-<3&!.
MJX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (  :34  (
M?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X
M (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[
M9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHF
MB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=**752:LX_578O
M;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)
M0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (  @    (
M@ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,
M (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z
M?[ $7'BB@"<  (  @    (  @ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D
M$6UDA=L4$&ZDA;@$47BU@NL  (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#
M46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (  @ !+DXG+491"
M.(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (  <8X  (
M@ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H
M (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W
M9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;
ME8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV
M;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]
ME7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (
M@ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@
M (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU
M@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2
M>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)69
M5&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U
M.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (
M@  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8
M (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%
M:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$/
M/XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W
M<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ
M78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (
M@  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @
M (  @    (  @    /__  #__P  __\  &UF=#(     ! ,)   !
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M^27N)N,GV"C,*<$JMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH
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MQ&)_=FXOO8Y^U6"TMIQ^B%-;KW!^BT9)I_9^T3G9H!U_/"Y#E\=_]"0SCOR
MZ8DSRAJ'(GN7PVJ%H&X(O).$5V"'M96#<%,TKF&"RT8VINJ"8#GEGQ>"$BZ
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M?"B&!*SM?&"% IA2?*F$*(-E?0&#:VY<?7""PEEQ??&"&$2X?IB!<#"1?W6
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MKER#36KYJ7Z"C5XMI(N!_%%*GX.!F$2BFE:!33B;E/2!$2UOCUN \B/-B9Z
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M>IY\E#(E?+E]I-;O;AB#!<-;;[^"4:]$<52!KII[<MZ!-857=&^ UW 2=A2
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MA;J%8(TIA.&$H7R8A!Z#YVN6@W&#1%J$@MN"J4FQ@EB"#3DU@?:!:2G&@:B
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M?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!46V%>@.! EPG>MV
MO$L5>]* =SI>?/B ,"JN?E1_VZX$=A6+H9Z/=KJ*CHYF=V")7'VD>!*(%VR5
M>.2&U5M>>>&%G$J#>O6$5CH'?#R"]BJ7?;>!:ZSZ=/B4\)V(=:B3#HUF=E:0
M^'RP=Q:.QFNX=_B,CEJP>06*4DH$>C>(!SF\>YN%C"J$?3&"T*PF=!2>'YRQ
M=,R;:XR/=7V8;'OA=D2516K^=S>2%EH:>%6.V$F=>92+?#F >Q.'YRIU?,&$
M!ZN'<VBG))P)="2CF8O==-.?JWLR=9F;A6I9=I:75EF+=\F3%4DW>1F.KCE+
M>J2* 2IH?&6%$*L?<O*O\9N.<ZZKB8M-=%2FHGJ<=1&A=6G2=@^</ED>=TN6
M]DC;>*V1@CD+>DR+S"I>?!R%[*6+A7QE.Y=_A,AGR(B-A$1J+'BV@]YL>VA1
M@X-NV%>]@S-Q5T=R@O!S_C=R@LQV]"AJ@M1Z7*2O@XAN4Y:5@Q)O[X>,@J]Q
M='?&@EQR]F=^@AATB%<-@>5V-$;J@<%W_#<C@<!Y^2AK@>A\/J.P@<!W195H
M@7!X"89_@2-XNW; @.EY;V:?@+]Z+U9:@*U[ T9H@*I[YC;;@,U\Y"AK@19^
M :*;@!B (Y1(?]^ ((53?ZZ  W7<?X=_XF7:?WI_RU7'?X9_OD8%?Z9_M3:F
M?_%_K"AK@%Y_H*%_?L*([Y-+?I:(+X19?G.'273,?EV&2F3Z?F2%354)?I*$
M6$5]?L^#639??S6"1RAK?[^!&*"6?;*1LY)<?9&0,8-Q?76.=G/T?6J,EV0Y
M?7Z*L51V?;>(QT46?@^&T38H?I.$L2AK?SB"99_9?-F:4I&>?,*8#(*U?*>5
M=G,^?*"2L6.5?,*/X%/U?0J- 43%?6N*"S7^?@F&XBAK?L>#AI]*?#2BR)$&
M?"2?NX(4? :<0W*B>_R8C&,#?"24R%-S?("0\D1J?/&- #78?9B(U"AK?FN$
M>Y[H>\"K#)"1>[.G-(&.>XVBT7(:>WF>'F*->Z&97U,7? 24CD0>?(>/GC6G
M?4**>2AK?B&%19B=CC%DZ8NIC*YG;'W=BVAIT&\ZBD%L*& =B1QND5#>A_EQ
M($'ZAM=SV3-RA<EVYB7_A-5Z89?HC&IM>8KPBR%O&GT0B?)PKFY_B--R15]Z
MA[QS[U!9AJ]UN4&8A:AWH3-&A+AYQ28A@^!\,)<7BK1UWXGUB9)VN7PQB'1W
MBFVFAVMX7U[#AFMY1D_+A7IZ1$$VA)%[53,=@\%\AR8^@P=]W98BB2-^&HCY
MB!!^1WLFAPQ^7VS9AA!^<5X2A2Y^CT]*A%M^N$#F@Y%^ZC+]@N-_)298@DE_
M9I4UA\N&5X@0ALB%TGI'A=*%*VP"A.6$;EU\A R#L4[;@U:# T">@JN"4#+@
M@A^!DR9N@:: R)1KALF.CX=CA=&-6GF@A-Z+[&M)@_:*5ES/@RF(O$Y:@GR'
M*4!'@>J%CC*Y@7F#U": @1R" )/'A?N6GX:WA0V4MGCUA!F2>FJF@S.0"EPW
M@G&-DTWC@="+&$ (@4.(D#*@@.R%W2:/@*F##)-'A5^>@88RA'F;XGAH@X&8
MTVH?@I.5?ENY@=22(4UN@4:.O#^X@,:+2C**@'B'J2:<@$N#[Y+LA.^F.H7)
MA ZBY7?O@PV>]VFE@A.:KUM3@4^69$TC@,>2%#^#@%F-M3)M@!Z)+2:F@ "$
MJ8PHEP-DK8 >E-!G('-9DM1I@V7?D.AKXU@$CNMN5TH9C.%P]CR@BLUSP"^<
MB+QVWR/,AK=Z8XN.E7ALPG^1_^)]$$E#0U]04D]&24Q%  ,2DVYN8'+!D7=O
M_659CX=QIE>2C8]S9TG"BY=U3#QGB9AW4R^5AZ%YF20.A;5\(8KFD]ITI'[$
MD?!UB7(0D 9V;V2LCB5W85<%C$!X:TE:BF%YD#PIB'UZS2^-AJ-\,B1(A--]
MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
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MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
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M5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+C'9_-B"%AXU_RFBWK)F#8U\
MJ'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!3"\9D+"!$R=!B[" YB#3ANZ
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M>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6 \3/N?1> DB<Y?G6
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M@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^*
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MNX;P@6U:A'N"@3A=_&]<@3)A7&)^@41DM54O@5YH($?.@8AKMCKA@<=O?BZ
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M?X^ 'F'[?W" (5:^?TV "DMM?SY_]$ S?U!_[S5I?X1_]2M5?]U__"*U@$V
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MAL*#P%CLA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!@RBR@;V!'"%Q@5&
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MBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6>
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M6,2$#WX37(N#FF^C8%Z#%6#H9&:"D5(9:+:"&$.Z;4F!IC7K<BN!-"EY=SB
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M?;A^I2'9?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@.
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MC8U^>D,?C!)^H3O]BC5^NC3YB$5^]"XXAG5_12@XA+I_JB+=@U!__QZ.@CJ
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M;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F
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M6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6 Q"V =4R M"2A>>2
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MWRQ;@@)O."2J@K%SWAY2@W%XI6!#?!U>D%@,?.%AGD^$?9!DN4:/?BYG[#V
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M?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$
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M=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J^KX<*-;=#B/
M\!0_K/T>5YSP+6J/Y3YYAMY.@X'87XM_U&N0>M%PE'?/=)=USG>8<\UYFG+-
M>YMQS'V;<,M_G&_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N
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MV9&4GMF1E)[9D92>V9&4GMF1E)[9_Z0X*O^@14#_H4I3^Z9(8O*K2''HKTB
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M@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
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M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
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M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
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M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
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M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
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M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
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M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
MQ&"-0\%>E4:_79Q(O%ND2[I:K4RX6;=.MEG#3[19U4^Q6NI0KEKW4*Q:_U"H
M6_]0I%S_4*1=_T^D7?]/I%W_3Z1=_T^D7?]/_U8> O]A&0+_;!H"_W4@ O]\
M)0/]@2X%\X0W">J$/P[B@4@5VWU3'=%W72?+<F<PQFYP-\)J>#R^9X!!NF6(
M1;=CD$BT89A+LE^?3:]>J$^M7;)1JUV^4JE=SE.F7>53I%[T4Z)>_U.?7_]2
MG&#_4IM@_U*;8/]2FV#_4IM@_U*;8/]2_U@< O]D%P'_<!D!_WD= ?^ (P+X
MABH#[8DR!N2*.PK<B$42T8)0',I]6B;$>&,OOG-L-[EO=#VU;'Q"LFJ$1JYG
MC$JK99--J&2;3Z5BI%*C8:Y4H6&Y59]AR%:=8>%6FV+Q59EB_5678_]4E63_
M5)1D_U.49/]3E&3_4Y1D_U.49/]3_UH: O]G%0'_<Q<!_WT; ?^$( 'SBB8"
MZ(XN!-^0-@?4C$$1RX=-&\2"5R:]?6 OMWAI-K)T<3VN<7A"JFZ 1Z9LB$JC
M:H].H&B849UGH%.:9JI5F&6U5Y5EQ%B49=M8DF;O5Y%F_%>/9_Y6CF?^58UH
M_E6-:/Y5C6C^58UH_E6-:/Y5_UP8 ?]I$P'_=A8!_X 9 ?V('0'OCB(!Y),I
M MJ4,0;.D#\/QHM+&KZ&526W@5XNL7UF-JQY;CRG=G5"HW-]1Y]PA$N<;HQ.
MF&R44I5KG522:J=7D&FR68UIP%J,:=5:BFKL68IJ^EB):_U7AVO]5H=K_E:'
M:_Y6AVO^5H=K_E:':_Y6_UX7 ?]L$@'_>!0!_X,7 /F+&@#KDAT!X)@C =.8
M+P7*E#T.P8])&;F*4R2RAELMK(%D-:9^:SRA>G)"G7=Z1YEU@4N5<XE/D7&1
M4HYOFE6+;J18B&VO6H9MO5N$;=!;@V[I6H-N^%F";_Q8@F_]5X)O_5>";_U7
M@F_]5X)O_5>";_U7_V 5 ?]N$0'_>Q, _X84 /:/%@#GEA@ VYP< ,^;+03%
MESL-O)-'&+2.42.MBEDLIX9A-*&":3N<?W!!EWQW1I-Y?DN/=X9/BW6.4HAS
MEU6$<J%8@G&L6G]QNEQ^<<Q<?7+G6WUR]EI\<OQ9?'+\5WQR_5=\<OU7?'+]
M5WQR_5=\<OU7_V(4 ?]Q$0'_?1$ _X@2 /*2$@#CFA( U9\9 ,J>*P3!FSD,
MN)=%%["23R*ICE@KHHI?,YR&9SJ7@VY DH!U18U^?$J)?(1.A7J,4H)XE59^
M=Y]8>W:J6WEUN%QW=<I<=W;E7'=W]5IW=OM9=W;\6'=V_%=W=OQ7=W;\5W=V
M_%=W=OQ7_V02 ?]S$ #_@!  _XL0 .^5#@#?G@T T*(7 ,:A*0.]GC<+M)I#
M%JR632"DDE8JG8Y>,I>+93F2B&Q C85S18B#>DJ$@(%.@'^*4GQ]DU5X?)U8
M=7NH6W-ZMEQQ>L=<<7KB7'%[\UIQ>_M9<GK\6')Z_%AR>OQ8<GK\6')Z_%AR
M>OQ8_V<1 ?]U#P#_@PX ](X- -N9"@#4H0L S*05 ,*D)P.XHC8*L)Y"%:>:
M3!^@EU0IF9-<,9.08SB-C6H_B(IQ1(.(>$E^AG]->H2(47:"D55S@9M8;X"F
M6FU_M%QK?\5<:X#?7&N \EIK@/M9;'[\6&U^_%AM?OQ8;7[\6&U^_%AM?OQ8
M_VD0 ?]X#@#_A0P XI(( -6;"0#.HPD QZ@2 +VH)0*TIC0)JZ) $Z.?2AZ;
MFU(GE)A:,(Z583>(DF@]@I!O0WZ.=DAYC'U,=8J%4'&(CE1MAYE7:H:D66>%
ML5MEA<);987<6V6%\%IFA?M99X/\6&>#_%=G@_Q79X/\5V>#_%=G@_Q7_VP.
M /][# #RB0D V94& ,^>" #)I@@ P:L0 +BK(@*OJC((IJ<^$IZD2!R6H5$E
MCYY8+HB;7S6"F68\?99M07B4=$9SDGM+;Y"#3VN/C%)GCI959(VB6&&,KUE?
MC,!:7XS965^,[EE?C/M888K]5V&)_5=AB?U788G]5V&)_5=AB?U7_V\, /]_
M"0#?C0, TI@& ,JB!@#"J08 NJ\. +*P( &IKB\&H:P\$)BI1AJ1IT\CB:16
M+(.B73-]GV0Y=YUK/W*;<41NFGE(:9B!3&67BE!AE9137I6@55N4K5=:E+U8
M69345UF4[%=9D_E66Y'^55N0_E5;D/Y56Y#^55N0_E5;D/Y5_W,) /6$! #8
MD0, S)P% ,.E!0"[K00 L[,, *NU' &CM"P%F[(Y#I*P1!>*K4T@@ZM4*7VI
M7#!WIV(V<:5I/&RD;T%HHG=%9*%_25^?B$Q<GI)/6)Z>4E:=JU-4G;Q44YW1
M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
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M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
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M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
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M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
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M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
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M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
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M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
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ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
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M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
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M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
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M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
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M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
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MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
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M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
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M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
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M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
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M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
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MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
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M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
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M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
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M)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT  .57  #37P
MR&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(
M85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:
MU25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<
M +MK  "S;   K&H$ *1K$@">;"$ F6PO 91K.@./:40&BFA-"89F50V#95P0
M@&1B$WUB:15Z8G 8>&%X&G5@@!US7XH?<%^4(6Y>H"-L7JTE:UZ\)FI>T29I
M7NPE:E_[)&I?_R-J7_\B:E__(FI?_R)J7_\B\%(  -U=  #+90  P&L  +=N
M  "O;P  IVX! *!O$ ":<!\ E' L 8]O. .*;4(&AFQ+"8)J4@Q^:5D/>VA@
M$G=F9A1U9FX7<F5U&G!D?AUM8X@?:V.2(FEBGB1G8JLE96*Z)F1BSR9D8NHF
M96+Z)&5C_R-E8_\B96/_(F5C_R)E8_\BZU4  -A@  #(:   O&X  +-Q  "K
M<P  HG$  )MR#@"5<QP D'0J 8IS-@*%<D %@7!("'UO4 MY;5<.=FQ>$7-K
M9!1P:FP7;6ES&FMI?!QH:(8?9F>0(61GG"-B9JDE8&:Y)E]FS29?9N@F8&;Y
M)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$  +!U  "G=P
MGG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K
M;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ
M_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D
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MA1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5>
M<QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_
M($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X
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M'0!;GBD 6)XT 56>/0)2G44#4)U-!4V=5 =+G%L)2)QC"T:<:PU#FW4/09N
M$3Z:C1,\FIL4.IJK%3F:O14YFMD5.9CO%CF7_!8XEO\7.)7_%SB5_Q<XE?\7
MNWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I   5J4, %.F%P!1
MIR, 3Z<O $RG. %*IT$!2*=) D:G4 1#IU@%0:=?!C^F: @]IG(*.J9]"SBF
MB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((
M *B,  "=D@  DI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P
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M !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@
M=:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5
MV!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@
MI  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4
M %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ(
M#>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE
MZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%
M  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82
M  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4
M />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   W
MT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^
M$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2
M  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H
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M.[P/H#O-#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]
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M%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P
MSU,  ,95  # 4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B6
M3F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*
MUAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@
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M&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90
MHV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU
M7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:
M_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4
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M&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW   (=Q!0"!<A$
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MC!-$@9H50H"I%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH
M +5U  "J?0  GX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB<
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M""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@
MC9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 X
MJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">L
ML 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D
M 'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD
M*K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<
MN< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF
M  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F
M !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D
M#\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8
MM   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1
M(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7
M  '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0
M/\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !
MWB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #E
MP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@
M "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8
M .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0
M]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6
M   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2
M  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8
M /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_
M %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L
MK #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_
M .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D
M_P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S
M ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&
M_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@
M /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X
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M /\E"P#_* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4
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M!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.
MXCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K
M-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DU
MW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(
M ,Y" 0#)/@8 Q#L/ +L^'0"U/RP L3\Z *T_10&I/T\!ICY8 J,]7P.A/6<$
MGSQM!9T\= :<.WL&FCN"!Y@[B@B6.Y,)E3J<"I,ZI@N1.K(+D#O #(X[U0R,
M/.P-BCS[#8D\_PV)//\,B#S_#(@\_PR(//\,_S<  .H_  #<10  SDD  ,5)
M  "_1@( ND,, +-$&0"M12< J$8U *1%00&@14L"G413 II#6P.80V(%ED)I
M!I1!< >2078(D$!^"8Y A@J-0(X+BT"8#(E H@V'0*X.A4"\#X1 SP^"0>D/
M@4'Y#X!!_P^ 0O\.@$+_#H!"_PZ 0O\.^CL  .5$  #32P  QTX  +Y/  "X
M3   LDD) *M)%0"E2R, H$LQ )Q+/0&82D<"E4E/ Y))5P202%X%CD=E!HM'
M:P>)1G()B$9Y"H9%@@N$18H-@D64#H!$GP]^1*L0?$6Y$7M%RQ%Z1>81>4;W
M$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,  +A4  "Q4@
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M$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T  (U>"0"'7A,
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MC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H
M +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P
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M#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@  *]R  "D>0
MEGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB  3X8J $Z'- !,
MASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@YA9$*.(2@"S:$
ML0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X
M (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@
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M 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF
M5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >
ML#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.Q
MZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@
M $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X
M$+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (
MOO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV
M   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL
M  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(
M ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   F
MP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7
M*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>
M  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP
M$\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@
MYB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #N
MQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L
M  />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH
M /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP
M_J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\
M;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U
M /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\
M_Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#]
M ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H
MN@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48
M /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\
M\@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #?
M ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5
M$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R
M .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L
MT ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_
M& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-
M=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/
M ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@
M_Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)
M%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8
MX@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0'
M /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$
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M!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  # -P(
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M"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH  )1*# "/2Q<
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MC0M95)H-6%2G#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T
M ,!6  "S7   IUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX
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M#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@  +5@  "J9@
MFV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24 6VHO %EJ. !7
M:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX!T=HA E&:)(*1&>A"T-G
ML0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD
M (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T
M4'!% 4YP3 %,<%,"2G!: TAP8@1&;VL%1&]U!D)O@@= ;H\)/VZ>"CUNKPH]
M;L(*/&[@"CUM] H];/\*/6O_"CYK_PH^:_\*NF   *UI  "@;@  D6T  (1M
M  !X;0  ;&X  &%P  !;<@  5G0* %)U$@!0=AT 3G<G $QW,0!+>#D 27A!
M $AX20%&>% !1'=7 D)W7P- =V@#/G=S!#QV?P8Z=HT'.7:<"#=UK0@W=< (
M-G7>"#=T\@@W<_X(-W+_"#=R_P@W<O\(M68  *EO  ":<0  BW$  'YQ  !S
M<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#@#4 0H ] $&
M10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^J@8P?KT&,'[:
M!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4  'EV  !N=P
M8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3  .HDX #B)0  W
MB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&
M[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$
M %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$
M+)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@
MD/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.
M  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y"
M "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/<
M%IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \
MG   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J
M0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\
M  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP
M*ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 '
MMT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U
M]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4
M !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD
M ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@
MQ.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"
M   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X
M  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T
M>Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "
MT    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E
M-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@
M &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0
M .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P
M]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'
M&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![
M /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,,
M[ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_
M 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /,
M?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#,
M .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A
M_P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H
M '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -(
MW0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2
M /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L
MVP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#%
M .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.
M% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\
M ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D
MMPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R
M#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-
M?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z
M *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X
MV0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q
M%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;
M_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1
M ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD
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M WPQ_P-\,?\#[2\  -LW  #)/0  OCX  +,\  "L.   IS,$ *(R$0"=-!T
MF34J )4U-0"2-4  CS5) (TU4 "+-5< B35> 8<U9 &%-&L!A#1R H(T>0*
M-(("?C2+ WTTE@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W
M_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF
M (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#
M=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L
M//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5
M+0""0#< ?T!  'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$
M!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%
MW#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![
M130 >44] '9%10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#
MC09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$
M ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23
M<TDZ '!)0@!N24D!;$A0 6I(5@%H2%T"9DAD F5(; -C2'4$84=_!6!'B@9>
M2)<'74BE"%M(M A;2,<)6DCD"%I)]@A:2?\'6DC_!EI(_P9:2/\&T44  +],
M  "R4@  HU$  )=0  "-3@  ADH  (!* 0!Z2PX =DP7 '),(P!O3"T ;4TV
M &I,/P!H3$8 9DQ- 61,4P%B3%H"84QA E],:0->3'($7$Q\!5I,B 993)4'
M5TRC"%9,L@A53,8)54SB"55,]0A53/\'54S_!U9,_P963/\&S$@  +Q0  "O
M50  H%0  )-3  ")40  @4T  'I.  !U3PP <$\5 &U0( !J4"H 9U S &50
M/ !C4$, 85!* 5]040%=4%@"7%!? EI09P-94' $5U!Z!550A@944),'4E"A
M"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L  +E3  "K5P
MG%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"< 8E0Q &!4.0!>
M5$$ 7%1( 5I43P%95%8!5U1= E9490-45&X$4E1X!5%4A 9/5)$'3E2@"$Q4
MKPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D
M (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\
M5UE& %9930%4650!4UE; E%98P)/6&P#3EAV!$Q8@@5*6(\&25B>!TA8K@A'
M6, (1UC="$=8\@A'5_\'2%?_!TA7_P9(5_\&P5$  +)9  "C7   E%L  (=;
M  !]6@  <E@  &M9  !E6@, 8%L. %U<%P!:7"$ 6%TK %9=- !47CP 4UY$
M %%>2P%07E(!3EY9 DQ>80)+76H#25UT!$==@ 5%78T&1%V<!T-=K ="7;X(
M0EW:"$)<\0="7/X'0UO_!D-;_P9#6_\&O54  *]=  "?7P  D%X  (->  !X
M70  ;5P  &5=  !?7P  6F , %=A% !58AX 4F(H %%C,0!/8SD 3F-! $QC
M2 !+8T\!26-6 4=C7@)%8V<"1&-Q T)C?01 8HL%/V*:!CYBJ@8]8KP'/&+6
M!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$  ']A  !T80
M:6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%
M:DP 0VI4 4)J7 % :64"/FEO CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H
M[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8
M %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D
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M B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@  $Q\  !#@
M.X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D (XQ" "*-2@ A
MC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(
M_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P
M "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T
M%9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0
ME/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::
M   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10
M  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L
MC8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7
MJ   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P
M4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD
M 'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M
M"[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2
MOE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5
M  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(
M  #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD
M ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;
MIP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0
M    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+
M  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@
M1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
MWP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T
M30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8
M /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (,
M]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G
M /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\
M'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$
M .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P
MV #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_
M "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .
MA0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U
M ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "
M\0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #.
M (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L
M_0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E
M .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($
MP "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N
M O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#
M*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:#
M +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\
MH0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@#
M##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</
MA0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_
M )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD
ML!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9
M%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<
M_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO
M *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0
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MCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(
M ,DY  "[/@  K#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4
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M UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2
MG$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F
M0D, 9$)* &-!4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#
MK0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H
M (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\
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M!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$  (%1  !W4
M;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@ 4%(_ $Y21@!-
M4DT 3%-5 $I370%)4V4!2%-O D93>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3
M[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$
M &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL
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M C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X  %)@  !,8@
M164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S
M:EL ,6IE #!J< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG
M_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L
M #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E<
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M8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X
M (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@
M&HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,
MD6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS
M  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<
M  Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(
M )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H
M>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF
M!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH
M  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA
M58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
MLP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X
M;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8
M $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@
M +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@
MR74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK
M   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P
M  #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<
M .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   D
MO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=
M    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K
M  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P
M_P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q
M (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .(
M_P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T
M /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H
MY0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1
M /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0
M.P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+
M -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\
MP0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C
M $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4
MC ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_
M +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L
MS0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U
M (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8
M_P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^
M +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D
MIP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9
M!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %
M0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF.
M )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\
M]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B
M#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1
ME "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H
M -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX
ME!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!
M&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I
M  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y!
M (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9<
M=2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W
M,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF
M1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0 ;"BA
M &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O-@
MH34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L0 !S
M+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z> 6(O
MK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH
M ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4,
M:C%* &@R4 !G,E< 93)= &0R90!B,FT 83-W %\S@@%>,XX!732< 5LTJ@%:
M-;L!6C72 5DU[0%9-?P!6#7_ 5@U_P%9-?\!R#@  +<^  "D/@  ECT  (L\
M  "#.@  ?3<  '@T  !T- L <#43 &TU'0!J-2< :#8P &8V. !D-C\ 8S9&
M &$V30!@-E, 7C=: %TW8@!<-VH 6CAT 5DX?P%7.(P!5CF9 54YJ )4.;D"
M4SK/ E,ZZP)3.OL!4SK_ 5,Y_P%3.?\!Q#P  +)!  "@0   DD   (8_  !^
M/0  >#H  ',X  !N.0@ :CD1 &<Y&@!D.B0 8CHL & Z- !>.CP 73M# %L[
M2@!:.U  6#M7 %<[7P!6/&< 5#QQ 5,\? %2/8D!43V7 4\]I@)./K<"3C[-
M DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0
M<ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4
M/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"
MZ ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T
M &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL
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M 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H  %E+  !43
M4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440 /U%+ #Y14P ]
M4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390
M_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(!
M $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH
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M:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@
M (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H
M+&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?
M;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<
M  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(-
M "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X
M%75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O
M80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]
M#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X
M  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90
M868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -
MB0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)
M@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP
M %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP
M I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@
ME8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY
M   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.
M  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0
M **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   X
MBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L
M#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.
M  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0
M)IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"
MN@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$
MEP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T
M !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00
M ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@
MVYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^
M   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0   -L
M  #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\
M /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_
M $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L
ME0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_
M -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@
M] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #<
M )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L
M_P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!,
M .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )(
MR0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\
M /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -(
M4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4
M +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\
M_P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_
M %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L
MF "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P
M /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P
MK@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"<
M )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+
M  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!-
M *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D
MC@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*
M%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)
M3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB
M ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0
MKQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "(
M$$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3
MK@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,
M )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH
M?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K
M'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H
M  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+
M '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@
M82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%
M*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E
M30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK*
M %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P
M>2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?
M*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(O
MY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$
M &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT
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M 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH  & Y  !;.@
M5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$
M/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X_
M_P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX%
M $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH
M/D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y
M0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E#
M# !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A
M #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\
MID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!
M2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,
M:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<
M (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X
M.4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L
M474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*
M  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02
M #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W(
M)5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U
M3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;
M%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^
M !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40
M9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A
M8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5E
MBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8
M %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!,
M%FT: !5M(0 4;2D %&TP !-M.0#_XGT024-#7U!23T9)3$4 !Q(2;D( $6Y,
M !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\
M@ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L   =
M;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='  AW
M4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P >UT
M &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7>0
M$GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""3
M@ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(  &AB
M  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P  #88
M  B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1   CE$
M (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8
M:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(   "5
M    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7
M  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1<@
M1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B
MHP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L
M70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0
M #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P    L
M +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]4@
MO60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9
M   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP   ,
M  #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110  TE<
M -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H   :
MK@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\   #0
M    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H  .E=
M  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_ "8
M_P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K
M (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W -@
M_P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L
M /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#= '\
MVP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,< _P#&
M /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G .D
M,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_
M ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V /\
MM@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4 +0#1
M #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +<
M@ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_
M *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_ #$
MO  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G
M ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_ )@
M_P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L K0 U
M *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0": 'L
MF "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P",
M /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N )X
M-P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^
M (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\
MZ T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )( ,0"0
M #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$
MA !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14
M ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C,
M@PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R
M#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>
M  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V
M '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD
M9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?
M)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7
M. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2
M %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*
MBR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C
M'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0B
MG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+   ABT
M 'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8
M6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,
M**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3   '<O
M  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y
M %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H
M12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K
M,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM
M/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[
M #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F-0
M83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$
M,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HV
MT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P  738
M %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT
M/C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V
M.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D  %,V
M  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M"
M #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH
M,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ  !)
M.P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #-
M2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y
M "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$/P
M0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M
M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%
M_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1   .T4
M #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G2DL
M)DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B
M2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD  #)+
M   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@ (%!2
M !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\
MBD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0   H
M4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A7
M60 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D
M '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D60
M'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?50 0
M7V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.
M  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P  &6(!
M !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT
M!V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=
M4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P  $VH   ]M
M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@  <%<  '!E
M  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6  !95@
M45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<   #G,   MV!  %
M> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z
M<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P
M $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@
M (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':
MAWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI
M   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)
M  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(
M )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K
M>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=
M!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]
M  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP
M&8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
MK00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "X
MB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT
M  RB   #IP   *L   "N    L@   +8   "X    N    +H   "[    O0
M +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@
MS9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q
M    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X
M  #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(
M .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #]
M $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0
MBP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_
M ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X
M[ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0
M (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\
M_P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!"
M -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8
MO0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P
M /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,(
M10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"(
M *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\
M_P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O
M $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P
MBP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P
M .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $
MG@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"-
M (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,
M  #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!!
M (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H
M?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R
M#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (,
M0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2
M '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@
MFA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W
M!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)
MG0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@
M (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X
M; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<
M$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=
M  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_
M &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D
M4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P
M(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D7
M00!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX
M $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0
M9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0
M'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,B
MS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<
M %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D
M2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]
M*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H
M  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=#
M $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8
M."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0
M*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL
M2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W
M #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0
M1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U
M,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S
M_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(
M #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P
M+S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J
M-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV
M @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3
M "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\
MC38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R
M.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "-
M6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D
M '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004
M*D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <
M164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]
M  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<*
M "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V(
M%4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A
M00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/
M#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M
M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1
M4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 1
M5PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8
M>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@
M $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P
M"F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P
M8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,
M   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.
M  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8
M &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X
M5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q
M$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..
M  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7
M*F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@
M?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  "
MG0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH
M !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T
M (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0
MCJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\
M   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,
M  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(
M )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &
MD    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$  "J
M"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L
M  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP
M *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
MO 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(
MKP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,
M  "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+    S0
M ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@
MXJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /,
M4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3
M -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\
M_P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@
M %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8
ME@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P
M /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T
MQP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R
M )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T
M  #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!.
M +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0
MH0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>
M    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *(
M30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9
M )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
MN@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2
M $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 ((
MH "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@
M *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $<
M@P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T
M *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$
M  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!'
M '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8
M9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!
M"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L
M1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S
M %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0
M<PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A
M!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,
MQP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0
M &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44
M5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)
M$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7
M  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)'
M $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^,
M0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7
M&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $87
M2@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU
M #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@
M3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^
M'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A
M_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22
M $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP
M-R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q
M)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D
M!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3
M # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\
MC2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y
M* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL
M6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL
M '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D
M,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E
M,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O
M  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$-
M "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6,
M'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C
M,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W
M$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN
M !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0
M538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >
M/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !-
M?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD
M $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q
M%T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -
M18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\
M  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2
M !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X<
M!4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]
M/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1
M%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6
M  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@
M-$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@
M61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9
MI0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD
M "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810
M &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH
M8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3
M   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5
M  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+
M &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   6
M8   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W
M%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!
M  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P
M"V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0
MAA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'
MT0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT
M  "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#   E1
M )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP
ME]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1
M    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.
M  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L
M168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
MI0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\
M#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(
M #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@
M +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.!0
MT0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\
M  #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9
M .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$
MS "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_
M    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$
M60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F
M +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M[0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\
M %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@
MK0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP
M ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %,
MIP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6
M +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<
M @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2
M )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\
MA0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">
M  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (<
M40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z
M '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  (
MBP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X
M %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H
MR0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P &
M 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L
M:P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!>
M .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$
M"0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !,
M %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H
M4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F
M! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!
M3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M
M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04
M70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,
M"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-
M^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X(
M %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\
M1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [
M$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1
M"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4
M #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\
MCAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#
M%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #08
M6P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX
M '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P
M.QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M
M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C
M  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X.
M #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F(
M)B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C
M)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB
M$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M
M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0
M5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK
M>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP
M $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!(
M("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5
M,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N
M  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5
M !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D
M$#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^
M,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X
M&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9
M  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P
M-C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 .
M/AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_
MJ  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4
M "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D
M"$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I
M1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY
M   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<
M  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4
M $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B
M00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3
M'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*
M  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P
M%TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@
M7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:
MY   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,
M  Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP
M &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@
M9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@
M   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=
M  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P
M3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$
M'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX
M #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0
M ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@
MEB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9
M   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$
M  "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<
M *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G
M:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D
M    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8
M  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>
M%H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
MMP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5
M&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P %
M /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X
MW@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#"
M ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /,
M"P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!>
M ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,(
MK@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2
M  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$
M70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2
M )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P
MM@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"=
M %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P
MZ "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 .
M )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4
MBP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\
M /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T
M$0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4
M 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T
M;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\
M !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T
M5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X
M &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !
M;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@
M %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8
M_P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1
M &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$
M50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!,
M /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@
M$P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5
M $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\
ME0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/
M 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($
M6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA
M 'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$
M1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y
M"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5
M  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2
M #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V(
M,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D
M&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0
M%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L
M "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0
M5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P
M%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9
M>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R
M $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0
M*1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P =
M'8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B
M  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7
M "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H<
M%R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^
M)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB
M&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8
M !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@
M-B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7
M)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJ
MJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@
M "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P
M$2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )
M+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ
M   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@
M  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8
M C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F
M+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X
M)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*
M   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,
M'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0
M/B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]
MY   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8
M !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120
M $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP
M0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_
M   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH
M  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O(
M4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +
M20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7
M+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP
M $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40
M %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@
M8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_
M   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X
M  !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH
M &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U
M1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M
M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N
M  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3
M)5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2
M,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP
M !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",    C@
M )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0
MICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P
M   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP   *(
M  "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS
M +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
MB    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0   "V
M    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X
M  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$
M^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3
M &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D
M_P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6
M -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &(
MN@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E
M /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,,
M&P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A
M *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\
ME0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H
M !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ),
M8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_
M (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D
MDP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"!
M &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0
M_P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ;
M (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H
M< !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G
M /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '
M'0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!;
M &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\
MJ    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C
M !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8
M7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G
M (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D
M5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!*
M &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '
M  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ;
M $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\
M0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J
M#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0
M' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H
M #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$
M61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [
M AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'
M<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0
M $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D
M- D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G
M#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7
M  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T;
M "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0
M'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _
M&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80
M'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125
M !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P
M-AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8
MI@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T
M "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /
M'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>
M   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB
M !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4
M"R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F
M'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B
M)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'
M  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0
M(2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *
M)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $H
MX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,
M !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@
M RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX
M+/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG
M   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M
M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?
M5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2
M+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y
M,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L
M $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P
M#34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P
M0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O
M   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P
M  4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4
M $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V
M,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&
M    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\
M  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0
M+S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<
M1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD
M ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7
M %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/
M:DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$
M   620  $$T   I1   $50   %H   !=    8    &,   !F    :    &H
M  !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44
M 'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   0
M5   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![
M    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.
M  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80
M 6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
MCP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B
M60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<
M  !]    @P   (@   "-    D0   )4   "8    F@   )P   "?    H0
M *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@
MMV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/
M    E@   )L   "@    I    *@   "K    K    *\   "R    M    +8
M  "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL
M ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q
M "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D
M;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_
M )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0
MT@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q
M &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )(
M_P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G
M +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &<
MG !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P""
M /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\
M*0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H
M (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\
MU@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"(
M "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8
M:0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P
M *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0
M=0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E
M &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D
M  "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E
M &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &<
M5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\
M    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D
M)0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M
M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !-
M "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $
M=0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<
M %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "
M0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V
M ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,
M  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A
M #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T
M+0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !#
M#@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$
M(@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&,
M "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0
M.1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I
M R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'
MG0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(
M #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2
M(@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7
M#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3
M   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC
M !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+,
M$ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G
M%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80
M*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%
M  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@
M(18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1
M%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6
MW0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@
M !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H
M#!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $
M&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9
M   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO
M  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P
M6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6
M&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B
M-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T
M $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@
M$1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@
M)ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A
M   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,
M  TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D
M "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X
M)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ
M @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"
M   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P
M+2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 "
M,@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z
M3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD
M "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(
M #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P
M0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J
M   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"
M  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$
M $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;
M,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !.
M 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>
M  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.
M$3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D
M:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8
M  9*    3P   %,   !6    60   %P   !?    80   &0   !E    9P
M &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P
M<WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7
M    7    &    !D    :    &L   !N    <0   ',   !U    =P   'H
M  !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(
M (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M:P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P   "/
M    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!
M  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0
M ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
MI@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "Q
MC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4
M  ":    GP   *,   "F    J    *L   "N    L    +,   "V    N@
M +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0
MRI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .(
M-@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X
M +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\
M]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #
M #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *<
M>@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z
M -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$
MI@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1
M 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   /_B
M?1!)0T-?4%)/1DE,10 ($LT   "[    K@   *4   "?    G  ) )D #P"9
M !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0 (4
M50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_
M &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # "" !$
M@@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R
M %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_ &$
M_P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O  X ;P 2
M &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B $X
M80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4
M /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P / %\
M$P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0
M %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!* /\
MD@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %( $ !2
M !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !* $8
M4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\ A0
M '0   !G    70   %4   !/    3    $H   !(  0 1P * $< #0!& !$
M1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [
M %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?    &L
M  !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X /  1
M #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R %,
M,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%  !7
M!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  / #0
M$@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\ *0!:
M "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2"P
M2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P $  K
M !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7 "$
M9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0  0PX
M #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D 1
M) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!80 :
M 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0
M   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X '@41
M !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX
M$P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41   O
M$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)
M$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R
M  X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L$P
M)Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2
M#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/
MDP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%   )10
M "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q(
M#1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $
M$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4  !X4
M   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5
M  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@  %:,
M !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6   9
M%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83  46
M&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(  !BW
M   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8%@
M%14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@
M&QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV   ;
MT   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&   %!<#
M !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%   (1H
M "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?T0
M'^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD! !$9
M 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@  "<?
M   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0  (^X
M1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=   -
M'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<   M
M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\ 0"
M #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *)
M!B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U(
M-2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",  #(D
M   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P   2X
M   P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'   /B8
M #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G   H
M)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4    X
M    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$  $@L
M  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G*
M(B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!
M0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G  !3
M-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P  'RP
M !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,    3@
M %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B+
M83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,  !,W
M   ..P  "#\   %$    2    $P   !/    4@   %4   !8    6P   %T
M  !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0  <C0
M ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!   '
M1P   $P   !1    50   %D   !=    80   &4   !H    :P   &T   !O
M    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L  (8]
M  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.    5
M %H   !@    9    &D   !N    <@   '8   !Z    ?0   (    ""
MA0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S  "=
M1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P   &H
M  !Q    =@   'L   "     A@   (H   ".    D0   ),   "6    F0
M )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W/
MM%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P   "#
M    B0   (\   "4    F@   )\   "B    I    *<   "J    K@   +$
M  "T    N    +P   #!    QP   ,T   #4!0  V!   -4>  #3,0  T$@
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M_/[______________________________________________________P
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M______________________________________\
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M_VUF=#$      P0A   !                     0
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MQ;_4!R6ZUPE.KMH+<*#;$X>7S3F:DL-8J)&\;+*1MWJYDK2#O8ZSAK^+LH?
MB+&'P(:QB,&$L8G!@[&*P8*QB\* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
ML(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PO?
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MPH2I=,*%JG/!AZMRP8BK<L"*K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MEXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N@*+4K("CTJR
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MEZV$QI.MA,>/K(3(C*N%R8FKALJ'JX;*A:J(RH.JB<N!JHO+@*J,RX"JC,N
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M-VF%Z49T?^13>WS?8(%XW&B%=-IMB7#8<8MNUG6-;-5XCVK4>Y!ITWZ19].
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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MR)2'K,63AZ[#DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[#
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
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M>[:XH7VWMIU^N+6;?[FTF7^ZLYB NK*7@+NQEX"[L9> N[&7@+NQEX"[L9>
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M*"G_ERDH_Z J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1T0
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MB]:+=HO6BW:+UHMVB]:+=HO6B_]Y$0'_>!H"_XP9 _^>(P3_JB8&^+0E".O
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M=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?> 6$CXC5I%^)M<0OBK7D'WOE]
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M2#7_W4DT__!)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X2<FK  "VM
MJ,$  )O/  ".WP$ A_\1 7[_'01U_R<+;/\O$F3_-QA<_SX=5O]%(E#_2R5+
M_U(H1O]8*T'_7RT^_V<O._]O,3C_>#,V_X(T,_^--C'_F3<P_Z4X+_^R.B[_
MP#LN_],[+?_K/"W_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/+BP  "HO   FLD
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MCX61?8J"G(*%@*J%@7^\AH" VX6 @-V#@'_>@8!^X'^ ?>%]@'WC>X!\Y'J
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M64?0]UQ)R/=>2L'V8$N]]F!+O?9@2[WV8$N]]F!+O?9@2[WV8/^)  #9G@
MQZP! +FV @"NP0, I<X& )SD# "5[QT#C>\L"X7O.15\[T$><^]))VKN4"]B
M[E<U7.Y?.E;N:#]2[G%"3>]\1DGOB4E&\)9+0_"F34#QN4X_\MM//O#W3D+F
M^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%S_Q41<_\5.&5  #+I@  N[
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M+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8  (;3  !YX0
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M9E6D\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S9/]P#0#_A 0
MW98  ,ZC P#$K@0 N[<$ +3"!0"NS0P I\X@ I[-,0J5RSX6B\A)(X+&4BYZ
MPUHX<L%B0&O :D=DOG--7KU\4UF\B%=4NY5;4+NE74Z[N5Y-O-M=2[GW7TZQ
M]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #KC   TYL
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M1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P  *>V  ";P0
MD,P" (;9!@" \A( >?(? G'R*P9J\C8,8_,_$EWS1QA7\T\=4O-7(4WT8"1)
M]&DH1O1S*D+U?BT_]8LO//:9,3KVJ3,X][XT-OCA-3;U^34U\_\T-^S_-CGE
M_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/R   @]0
M 'GH!P!S_!(!:_T= F3])P1>_C$(6/X[#5/_0Q%-_TL52?]3&$7_6AI!_V,=
M/O]L'SO_=B$W_X(C-/^0)3+_GR<P_[ H+O_(*2W_ZBHL__\J+/__*B_Y_RHO
M^?\J+_G_*B_Y_RHO^?\J+_G_*KFF  "JK@  G+D  ([%  "!T0  ==X  &WZ
M"0!E_Q$!7O\: E?_(P-2_RP%3/\T!TC_/ I#_T0,/_],#CS_4Q X_UL2-?]C
M%#+_;!8O_W<7+/^$&2G_DQHG_Z(<)?^T'23_S!XC_^T>(O_]'R+__Q\B__\?
M(O__'R+__Q\B__\?(O__'ZRK  "=M@  C\(  (#.  !SW   9^D  %__!@!8
M_PX 4?\5 4O_'0)&_R8#0?\M!#S_-04X_SP&-/]"!S'_20@N_U )*_]7"BC_
M7PHE_VD,(_]T#2#_@@X=_Y(/&_^B$!K_LA$9_\@2&/_E$Q?_^A07__H4%__Z
M%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4  %'_ 0!*_PL
M1/\0 3[_%P$Y_QX"-/\E C#_+ ,L_S($*/\X!"7_/@4B_T0%'_]*!1S_408:
M_UD&%_]C!Q3_;@<2_WP($/^," __G @._ZP)#O^["0W_TPD-_],)#?_3"0W_
MTPD-_],)#?_3"9&\  "!R0  <M<  &3D  !4ZP  2_\  $3_   ]_P0 -_\,
M #'_$ $L_Q8!*/\< 23_(@(@_R<"'/\L AG_,0,6_S8#$_\\ Q'_0@,/_TD$
M#?]1! O_6@0)_V8$!O]S!0/_@04"_Y % ?^<!0'_JP4!_ZL% ?^K!0'_JP4!
M_ZL% ?^K!?]$) +_/RX#_SPV!/] . 3_03T&_T%%"/]!40W_0%T3_S]J&/\\
M=QS_.H0@_S>1(_\VFR7_-:0G_S2L*/\TM2K_,[XK_S+(*_\RU2S_,>4M_S'Q
M+?\Q^RW_,/\M_S#_+?\S_RW_-O\L_CC_+?DZ_R[V._\N]CO_+O8[_R[V._\N
M]CO_+O]%(P+_/RX#_SXT _]"-@3_1#L&_T1#"/]%3PW_1%L3_T%H&?\_=1W_
M/((A_SJ/)/\XFB?_-Z,I_S:L*O\VM"S_-;TM_S3(+O\TUB[_,^8O_S/R+_\R
M_##_,O\P_S/_+_\V_R__.?\O^3O_,/0]_S'Q/?\Q\3W_,?$]_S'Q/?\Q\3W_
M,?]&(P+_0"T#_T$R _]&,P3_2#@&_TA "/])3 [_2%@4_T5E&O]"<A__0'\C
M_SV,)O\[F"G_.J$K_SFJ+?\XLR[_-[TO_S;',/\VU3'_-N8R_S7Q,O\U^S+_
M-?\R_S;_,O\Z_S'Z/?\S\S[_-.U _S3J0?\TZD'_-.I!_S3J0?\TZD'_-/]'
M(@+_02P#_T4O _]), 3_3#4&_TT]"/].2 [_3505_TMA&_](;B#_17LE_T*(
M*/\_E"O_/IXN_SVG+_\\KS'_/+@R_SO#,_\ZSS3_.N$U_SKN-?\Z^#7_.O\U
M_SK_-?L^_S7R0?\WZT+_..5$_SCA1?\XX47_..%%_SCA1?\XX47_./]((@+_
M0RP#_T@L _].+03_43$%_U,Y"/]510[_4U$5_U%='/].:B'_2W<F_TB#*_]%
MCR[_1)DP_T*B,_]!JS3_0;0V_T"]-_\_R3C_/]LX_S_J.?\_]3G_/_\Y^T#_
M./%#_SKH1?\\X4?_/-I(_SW52?\]U4G_/=5)_SW52?\]U4G_/?])(0+_1"H#
M_TTH _]3*03_5RT%_UDV"/]<0@[_6TX5_UA9'/]592+_4G(H_T]^+?],BC#_
M2I0S_TB>-O]'ICC_1J\Y_T6X._]%Q#S_1-(\_$3E/?A$\CWU1?X\\47_/N9(
M_T#<2O]!TDO_0<Q-_T')3?]!R4W_0<E-_T')3?]!R4W_0?]*( +_2"<"_U$E
M _]8)0/_72H$_V S!_]C/P[_8DH5_V!5'/]<82/_66TI_U5Y+O]2A#/_4(\V
M_4Z9.?M,HCOZ2ZH]^$JT/_=*OD#U2<Q \4GA0>U*\$'J2OQ"Y$K_1-A,_T7,
M3_]&QE#_1L!1_T:^4?]&OE'_1KY1_T:^4?]&OE'_1O],( +_3"0"_U4A O]=
M(0/_8R<$_V<Q!O]J/ S_:D<4_V=2&_]C7"/_7V@J^UQT,/=9?S7U5HHY\E24
M//!2G3_N4:9![%"O0^I/ND3H3L=$YD_=1>%/[D7=3OM(U$__2<A1_TK 4_]*
MNE3_2K95_TJT5O]*M%;_2K16_TJT5O]*M%;_2O]-'P+_4"$"_UH> O]B'@+_
M:24#_VTM!?]Q.0O_<402_V].&OMK6"+U9F,I\6-O,.U@>C;I7(4[YEJ//^18
MF$+A5J)$WU6K1MQ3MDC:4L-*UE+82M%3[$O,4_I-Q53_3KQ6_T^U5_]/L%C_
M3JQ9_TVJ6O]-JEK_3:I:_TVJ6O]-JEK_3?].'@+_4QX"_UX; O]G&P+_;B(#
M_W,J!/]W-0G_>$ 0^7=*&/)S5"#L;UXHYVMJ,.)G=3;>8X \V5^*0=1=DT;1
M6YU)SEFF3,M8L$[(5[Q0QE;-4<-7YE&^5_=2N%C_4[!:_U.K7/]2IUW_4J-=
M_U&B7?]0HEW_4*)=_U"B7?]0HEW_4/]/'@+_5QL"_V(7 ?]L&0+_=" "_WDG
M _]^,@?Y@#P-\7]&%>I[4!WD=ULFW7-F+M5M<#?0:7H^RV6$1,=BCDG$8)=-
MP%Z@4+U=JE.[6[95N%O%5K5;WU:R7/-7K%W]5Z9>_5:A8/Y5GF#_5)QA_U.:
M8?]3FF'_4YIA_U.:8?]3FF'_4_]0'0+_6AD!_V45 ?]P%P'_>!T!_W\D OV$
M+@7SAC@*ZH9"$>.$2QG;?U<CT7EB+\MT;#C%;W9 P&Q_1KQHB$NX9I%0M6.;
M4[%AI5:N8+!9JU^_6JE?U%NF8.];HF'Z6IUC^UF99/Q8EF3]5Y5E_E649?Y5
ME&7^591E_E649?Y5E&7^5?]0'0+_71<!_VD2 ?]T%0'_?1H!_X0A ?>)*@/M
MC30'Y(T]#=R+2!;1A50CR7]>+L)Z:#B\=7% MW%Z1[)NA$VN:XU2JFB65J=F
MH%FC9:M<H&2Y7IYDS5Z;9.I>F&;X791G^5R2:/M:D&C\68YH_5>.:/U6CFC]
M5HYH_5:.:/U6CFC]5O]2' '_7Q0!_VP1 ?]X$P'_@1<!_X@= ?*/)0+GDR\$
MWI4X"=.0117*BU$BPH5;+KN 93BT>VY!KW=W2*IT?TZE<(A3H6Z25YUKG%N9
M:J=>EFFU8)1HR&&2:>9@CVKW7XUK^%V+:_E<B6S[6HAL_%B(:_Q8B&O\6(AK
M_%B(:_Q8B&O\6/]4&@'_8A,!_V\0 ?][$@#_A10 ^HT9 .V3'P'BF2@"V)DS
M",R50A3$D$XAO(M9+;2%8C>N@6M J'QS2*)Y?$Z==H54F7..6)5QF%R1;Z1@
MC6ZQ8HMMPV.);N)BAV_V889O]U^%;_E=A&_Z6X-O^UF#;_Q8@V_\6(-O_%B#
M;_Q8@V_\6/]6& '_9!$!_W(. /]^$ #_B!$ ]9$4 .B8&0#=GB !T9XQ!\>:
M0!.^E4P@MI!6+*Z+8#>GAFA H8)P2)Q^>4Z6>X)4DGB+68UVE5V)=*!AA7.N
M8X)ROV2 <]YD@'3U8G]T]F!_<_A>?G/Y7'YR^EI^<OM9?G+[67YR^UE^<OM9
M?G+[6?]8%P'_9Q !_W4. /^!#@#_C X \940 ..=$0#6HQL RZ$O!L*>/A*Y
MF4H>L)14*ZF073:BBV8_FX=N1Y6$=DZ0@']4BWZ(689[DEV!>9YA?7BK9'IX
MO&5Y>-EE>'GT8GEX]F!Y=_A>>7;Y7'EU^EIY=?M:>77[6GEU^UIY=?M:>77[
M6O]:%0'_:0X _W@, /^$# #OD L W9H* -FB"P#0IA@ QJ4L!;VB/!"TGD@=
MJYE2*:.56S2<D6,^E8UK1H^)<TV)AGQ3A(2%6'^!D%UZ?YMA=GZH9'-]N65Q
M?M-E<7[R8W)]]F!S>_=>='KY7'1Y^EMU>?M:=7G[6G5Y^UIU>?M:=7G[6O]=
M$P'_; T _WL+ /:("0#<DP8 U9T) -&E"@#*JA4 P:DJ!+>F.@^NHD8;IIY0
M*)Z:63.6EF$\CY-I1(F/<4R#C7E2?8J#5WB(C5QSAIE@;X2F8VR$MV1JA,]D
M:H3P8FR"]F!M@/=>;W_Y7&]]^EMP?/M:<'S[6G!\^UIP?/M:<'S[6O]?$0'_
M;PH _WX( .., P#6EP4 SZ ' ,JH" #$KA, NZTG [*K-PVIIT09H*1.)IB@
M5S&1G%\ZBIEG0X.6;TI]DW=0=Y& 5G*/BEIMC99>:(NC866+M&-CB\QC8XON
M866)]U]GAOA>:83Y7&J"^EIK@?M::X'[6FN!^UIK@?M::X'[6O]B$ #_<@<
M^((# -N/ @#/F@4 R:,& ,.L!@"]LA  M;(D JRP-0NCK4(7FZI,(Y*F52Z*
MHUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AFE91<8I2A7U^3LF!=D\E@79/M7UZ0
M^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEEAOM998;[6?]F#0#_=P, XX<
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M4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<  +ZB  "SJ@
MJ;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C9\5<*F'$9#!<
MPVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%N?]*1[/_2TFM
M_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G  "JKP  H+@
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M+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T  ''8  !GY@8
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M!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\" "K_"@ F_P\
M(O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"!_]) @/_4P(
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MXGT024-#7U!23T9)3$4 "A*18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
M_'T7 .^!'@'DA"<"VX0T!="!0P_(?$\9P7A:([MS9"RU<&TSL6QV.JUJ?S^I
M9XA#I6611Z)CFTJ?8J5-G&&Q3YE@P5"78-Q0E6'S3Y-B_TZ08_],CF3_2XQD
M_TJ+9/](BV3_2(MD_TB+9/](BV3_2/]0%@'_7!  _V@- /]R#@#_>A  ]H$2
M .F&%P#>BB !THHP!,F&0 [!@DT9NGU7([1Y82RN=6HTJ7)R.J1O>T"@;(1$
MG6J-2)EHETR59Z%/DF:M49!EO5*.9=13C&;P48MG_U"(9_].AVC_3(9H_TN%
M9_])A6?_285G_TF%9_])A6?_2?]2% '_7PX _VL+ /]U# #Y?@T \(4. ..+
M$ #6CQH S(XN!,.+/0V[ATH8M(-5(JU^7BNG>V<SHG=O.IUT>$"9<H!%E6^)
M29%MDTV-;)Y0BFJJ4X=JN52%:L]4A&ON4X-L_U&";/]/@6O_38!K_TR :_]*
M@&O_2H!K_TJ :_]*@&O_2O]4$@'_80P _VX* /UX"0#H@@@ W(D) -B/"P#0
MDQ< QI,K [Z0.PRVC$@7KHA2(:>$7"NA@&0SG'QM.I=Y=4"2=WU%CG6&2HIR
MD$Z&<9M1@F^G5']OME5];\M6?&_K5'QP_U)[</]0>V__3GMO_TU[;O]+>V[_
M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
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M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
M +>=  "LI   HJL  )BS  ".NP$ A<$, ('"'0![PBT#=<$Z"6_ 11%IOT\8
M8[Y7'EZ]7R-9O&@H5;MQ+5&[>S!-NH<T2KJ5-T>ZI3E%NK@Z1+K7.4.X]3M"
MMO\]0K/_/D2N_SY%J?\^1:G_/D6I_SY%J?\^1:G_/N!]  #)C0  NYH  *ZB
M  "CJ0  F+$  (ZY  "$P0( ><D' '3+% !PS"8!:\LU!67+0 I@RDL06\I4
M%E?)71I2R64?3LAO(TO(>B9'R(8I1,B4+$+(I"Y R+@O/\G7+S_']3 ]Q/\S
M.\/_-3R^_S8]N/\W/;C_-SVX_S<]N/\W/;C_-]&&  # E0  LI\  *6G  ":
MKP  CK<  (._  !XQP, ;L\' &77#0!CV!T 8-@M EO8.@17V$8)4]A0#4_8
M61%+UV(51]=L&$37=QM!UX0>/MB3(#S8HR$[V;<B.MK5(CK6\B,WU/\G-M+_
M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
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M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
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M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
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M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
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M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
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M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
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M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
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M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
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M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
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M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
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M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
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M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
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M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
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M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
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M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
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M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
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M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
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M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
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M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
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M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
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M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
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M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
M0YDV $&:0 ! FD@!/II1 CR:6@(ZFF0#-YIO!369?08SF8P',9F=""^9L @N
MF<H(+ICM""Z6_PHME/\*+9/_"RV2_PLMDO\++9+_"[9U  "J@0  GH@  ).-
M  "&C@  >(\  &N2  !?E0  5)D  $F=  ! H   .J(- #BC%P WHR( -J0M
M #6D-P TI$$ ,Z5+ #&E5 $PI5X!+J5J 2RE> (JI8@#**6: R>EK00FI<8#
M)J3K!"6B_P4EH/\&))__!B2>_P<DGO\'))[_!Z]^  "CB   EXX  (V3  !^
ME0  <)@  &.;  !7GP  3*(  $*F   XJ0  +ZP# "JN#@ IKA@ **\C ">O
M+0 FL#< );!! "2P2P CL58 (K%C "&Q<0 ?L8( 'K*4 1RRJ0$;LL$!&['G
M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
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M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
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M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
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M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
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M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
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M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
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M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
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M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
M07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q
M=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q
M  !<<P  47<  $IZ  !"?0, /WX. /_B?1!)0T-?4%)/1DE,10 +$CU_&  \
M?R, .X M #J -@ Y@3\ .(%( #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!
MH0,J@;8#*8'2 RE_\P,I??\#*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78
M (5U  !X=0  ;74  &%W  !7>@  3'X  $.!   [A0  -8@) #*)$0 QB1L
M,(DE "^*+P NBC@ +8M! "R+2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$B
MB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z
M  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0<
M "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX
M%9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L
M@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A
M&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+
M  NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP
M6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &
MK1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "N
MU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H
M $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10
M +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q
MO.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM
M   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84
M  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH
M ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   D
MO   &;\  !'"   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7
M$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F
M  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP
M#\H   ?.    T0   -8   #<    WP   .    #B    Y    .8#  #H"0
MZ0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #Y
MY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@
M  #=    X0   .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,
M /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP
M_]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\
M7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O
M /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\
M\ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_
M &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /<
MM #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_
M /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\
M^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H
M +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-
M$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B
M .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0
MU0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_
M# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X
M90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[
M ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@
M_PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#)
M &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0
MQP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\
M /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$
MN05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F
M"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09
M  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C
M *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X
MEQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*
M)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;
M90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q
M 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@
MM2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2
M)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K 80GNP&#*-$!@"CN 7XI
M_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4  ,$X  "T-@  JS$
M *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-+4P BRU4 (DN7 "'+F,
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M V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10  E4,  (Y   ")/
MA#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J
M07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU
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M \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30  ;$\  &A0"P!E414
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M!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:_P,^6?\#/UG_ \%0  "Q6@
MH5T  )!<  ""6P  =EL  &U;  !A6P  6UT  %9>  !28 T 4&$7 $YB(@!-
M8BP 3&,U $IC/@!)8T8 1V-. $9C5@%$8UX!0F-H D!C<P,^8X$#/&.0!#IB
MH00Y8K0%.&/-!3AB[P0X8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&
M (M?  !]7P  <E\  &A?  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"<
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M 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT  'ML  !O;
M96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G@A0 )H(> "6")P D
M@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#
MY@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,
M %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB<
M%XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .
MC?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^
M  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF
M  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?
M IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [
MC0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F
M*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\
M  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@
M*)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P
MLR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T
M_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P
M !:P   /M   ";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT
M ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@
MQ_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]
M   &P    ,,   #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;
M  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\
M -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)
MS    -    #5    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J
M&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T
M &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W
M .    #E    YP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@
M_!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\
M& #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M
M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\
M_0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_
M !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\
M< #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#'
M .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X
M_P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S
M '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .
MTP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P &
M /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P
MX@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#)
M .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\
M! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M
M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L
MMP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V
M  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P
M;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K
M *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!
MV@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L
M &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&
M^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T
M ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH
MGPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",
M$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1
M  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L
M )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\
M?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D
M%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>
M;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_
M '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$
ME1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![
M)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI
M_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<,
M (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\
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M =0W  # 00  KT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@
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M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
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M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
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M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
M_^)]$$E#0U]04D]&24Q%  P2R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_
M /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L
MW0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\
M )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\
M  #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ]
M +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H
MHP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V
M    YP   -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8
M/0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ".
M (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C
MS    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1
M #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P
ME !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP
M *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #<
M?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L
M )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<
M  "-    A@   ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W
M &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8
M70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_
M @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &(
M. !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C
M %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P
M; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6
M #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@
ML@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\
M %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4
M30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^
M \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82
M  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX
M $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,<
M-0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-
M%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X/
M/  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L
M "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@
M1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V
M%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5
M_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P
M #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T
M+AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B
M&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>
M   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]#
M "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\
M'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S
M(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D
M2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_
M (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)
M*R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;
M*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E
M  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD
M "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E
M%"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J
M*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O
M   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;
M  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0
M6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7
M-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX
M90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$
M $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@(
M$#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80
M/G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T
M   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(
M  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T
M $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [
M-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)
M#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]
M  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@
M,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@
M4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4
MCP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX
M "=    @0P  &48  !-)   /3   "T\   92    5    %<"  !8!P  60L
M %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0
M7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(
M   :2P  $TX   Y2   *50   UD   !;    7@   &    !B @  8P8  &4*
M  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T
M &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   3
M50  #ED   A=   !80   &0   !G    :@   &P   !N    <    '(%  !S
M"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S
M  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80
M!F8   !J    ;P   '(   !V    >0   'P   !]    ?P   ($   "# @
MA@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(
MSP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8
M  ![    ?P   (,   "'    B@   (T   ".    D0   ),   "5    F
M )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0
MF^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-
M    D@   )8   ":    G0   )\   "A    I    *8   "H    JP   *X
M  "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(
M +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".    E    )H   "@
MI0   *H   "N    L0   +(   "U    MP   +H   "\    OP   ,,   #&
M    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO
M #=Q   I>   '8   !&)   (D0   )H   "A    IP   *T   "S    N0
M +X   #"    Q0   ,8   #)    S    ,X   #2    U0   -H   #>
MX0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\
M  #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+
M /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T
MZ0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_
M    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\
M30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B
M ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_
M_0   /H   #X    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#-
M $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$
MJ0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@
M .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4
ML0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8
M +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D
M  "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$
M )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@
M@P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F
M    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4
M0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S
M '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3
MC    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R
M $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$
MP@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?
M '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T
M8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4
M -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D
M  !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ]
M %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X
M20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;
M    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P
M/@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J
M #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0
M4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!"
M $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8
M^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T
M $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X
M.@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M
M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .
M  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM#
M #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\
M)PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y
M$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P0
M2P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_
M (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%
M,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D
M%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7
M  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8
M "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$
M'1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K
M'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;
M!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY;
M !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P
M62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @
M( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C
M9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,
M $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0<
M&28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,
M*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G
M   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+
M !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7
M!"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \
M*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ
M#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_
M   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+
M,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '
M-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   W
MD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X
M "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X
M #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP
M/:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO
M   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0
M  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0
M $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @
M-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,
M$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\
M  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/
M%3\  !!"   ,10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@
M5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5
MXP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@
M  M+   %3@   %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X
M &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0
M8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6
M    6@   %T   !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.
M  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<
M &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )6@   5\   !C
M:    &L   !O    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&
M#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__
M $9+   Z3   +D\  "-3   86   $%X   ED    :0   &\   !T    >
M 'P   "!    A    (<   "(    BP   (X   "0    DP   )8   "9!P
MG0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2
M   R50  )EH  !M@   19P  "6T   !T    >P   ($   "&    BP   )
M  "4    EP   )D   "<    GP   *$   "D    IP   *H   "M    L08
M +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K
M80  'F@  !-P   +>    (    "'    C@   )4   ":    GP   *0   "H
M    K    *T   "P    LP   +4   "X    NP   +\   ##    QP   ,L%
M  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<
M%GD   V!   !BP   ),   ";    H@   *@   "N    M    +@   "]
MP    ,(   #%    R    ,L   #.    T0   -8   #;    WP   .0   #H
M!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P
M /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4
M_ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#?
M -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P
M  #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4
M .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4
MO0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R
M    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,(
M4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#<
M *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/
MR    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F
M %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X
M\ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@
M *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H
MC@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y
M /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X
M 0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!(
M '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8
M9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X
M  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@
M2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_
M %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $
M9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8
M $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T
M_P!- /\ 30#_ *H   "4    @@   '4   !K    9    &    !=    6@ %
M %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $,
M3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!#
M /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X
M"0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!%
M $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\
M.0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$
M  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@
M20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_
M (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @
M/ $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O
M %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,
M  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@*
M #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX
M)P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M
M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +
M"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8
M " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P
M6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I
M#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D0
M9@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<
M $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L
M(A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2
M%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;
M   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18-
M !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7(
M#1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \
M'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<
M$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z
M  <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P
M,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0
M(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $B
MD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$
M "HA   F(   (B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A
M"R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP
M)J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C
M   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3
M  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0
M "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C
M)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q
M%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\
M   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@
M'"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@
M.!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   V
MY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L
M !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0
M $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP
M//P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S
M   --@  "3@   4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6
M  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P
M $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (
M/@   T$   !#    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5
M&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_
M $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2
M $H   !-    4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P
M8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\
M   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8
M  !9    7    %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4
M '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y
M/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=    80   &4   !H
M    :P   &X   !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7
M  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10
M*$@  !U,   34@  #%<   -=    8P   &@   !M    <0   '8   !Z
M?@   ($   "#    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">
M&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,
M !59   -8    V<   !N    =    'H   "     A    (H   ".    D@
M )4   "7    F@   )T   "@    HP   *<   "K    KP   +0)  "X$
MMQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI
M   %<0   'D   "!    B    (\   "4    F@   )\   "D    J    *D
M  "L    KP   +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0
M -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[
MA    (T   "5    G0   *,   "I    KP   +0   "Y    O    +X   #"
M    Q0   ,@   #,    T    -0   #:    WP   .0   #J    [@P  .T:
M  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @
M_@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V
M &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H
M_P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ )
M /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L
MU@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G
M /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .
M"P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9
M +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\
MBP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W
M  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L
M5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_
M '8 _P!S /\ <@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H
MF  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "#
M %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D
M_P!G /\ 90#_ ,P   "^    JP   )T   "3    B@   (4   ""  4 @  -
M '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\
M;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!;
M /\ 6@#_ +T   "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P
M#@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/
M %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\
M3P#_ *T   "8    A@   '@   !N    9P   &,   !@    70 % %P "P!;
M !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X
M40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_
M )\   ")    >    &P   !B    6P   %8   !3    40 " $\ " !/  T
M3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !"
M %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),
M  !^    ;@   &$   !8    40   $P   !)    1P   $4 !0!$  L 0P .
M $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %
M-P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V
M P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H
M$  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7
M "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"
M7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q
M !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8
M8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T
M $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\
M*@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 >
M 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0
M  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0
M "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L
M%@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]
M$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+
M$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^
M  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%
M,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9
M#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0
MD  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8
M "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A(
M$A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $
M%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8
M   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5
M  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$
M !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A
M&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;
M&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY
M   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P
M'!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #
M(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?
MW@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP
M !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D
M "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP
M(_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>
M   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=
M   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L
M "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0
M(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S
M(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_
M $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*
M"RH   <L   #+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0
M.R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I
M   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$
M  $T    -@   #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$
M $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X
M+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \
M    /P   $$   !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G
M  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0
M+B\  "DN   @+@  &3$  !(S   .-P  "3H   (]    0    $0   !'
M20   $P   !/    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>
M+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(
M "0S   ;-@  $SD   X]   (00   $4   !)    3    %    !3    5@
M %D   !;    70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0
M;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[
M   5/P  #D0   =)    30   %(   !6    6@   %X   !B    90   &@
M  !K    ;0   '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP
M ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /
M2P  !U$   !7    7    &(   !F    :P   &\   !T    >    'L   !^
M    @    (,   "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS
M  "720  E&(  )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@
M &$   !H    ;@   '0   !Y    ?P   (0   ")    C0   )$   "3
ME@   )D   "=    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R
M/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',
M  ![    @@   (D   ".    E    )H   "?    I    *8   "I    K0
M +    "S    MP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@
MS4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0
M    EP   )X   "D    JP   +$   "V    N@   +P   #     Q    ,@
M  #+    SP   -0   #:    X    .8   #K    \08  / 3  #N)P  [#\
M .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_
M !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$
M:@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_
M )8 _P"0 /\ C #_ /H   #R    [    .D   #I    [  % /( # #X !(
M]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#*
M &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@
M_P"# /\ @ #_ /    #E    W@   -H   #;    W    -@ !P#1  X T0 5
M -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$
MK !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V
M /\ = #_ .(   #3    R@   ,<   "\    M@   +   0"O  L K  1 *T
M& "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A
M (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\
M: #_ ,\   #!    N0   *T   "@    F    )0   "1  8 D  - )  $@"/
M !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@
M8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_
M +X   "Q    H    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0
M=P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C
M &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +
M  "?    C0   '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5
M &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P
M4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-
M    ?    &X   !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0
M%@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A
M $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_
M;P   &,   !9    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!'
M !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@
M:0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90
M %@   !/    2    $,    _    /0   #P  @ \  < .P , #L #P [ !(
M.@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M
M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"
M  !( P  0 ,  #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3
M #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X
M) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !"
M"   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@
M%0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\
M !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P
M-0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @
M !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4
MCP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T
M "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0
M&008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0
M :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/
M   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6
M !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\
M"@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A
M$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,
M&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT
M  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0
M&Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,
M$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .
MU   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(
M !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH
M"!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP
M$?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03
M 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?
M  (6)P  %S   !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<
M !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2
M$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;
M)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_
M %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00
M#Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0
M(2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9
M   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!
M  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<
M "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \
M'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?
M   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN
M   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0
M+B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E
M)P   "D    L 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V
M-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0
M "0C   ?(0  &R   !8@   1(0  #B,   HE   &*    BH    M    +P
M #(    T    -P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0
M0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E
M   ?(P  &"0  !(E   .*   "BH   4M    ,    #,    V    .    #L
M   ^    0    $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH
M $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;
M*   %"H   XM   *,   !#,    W    .@   #T   !     0P   $8   !(
M    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&
M  !76@  570  %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P
M$#(   HV   #.@   #\   !"    1@   $D   !,    3P   %(   !5
M6    %H   !=    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G
M4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT
M  )"    1P   $P   !0    5    %@   !;    7P   &(   !E    :
M &L   !N    <0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20
M>V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1
M    5@   %L   !@    90   &D   !N    <@   '8   !Y    ?    'X
M  ""    A0   (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED
M )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "5    %L   !A
M:    &X   !S    >0   'X   "#    B    (P   "/    D@   )4   "9
M    G0   *$   "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II
M  "HB   IJ@  *+1 "-(   83@  #E0   1<    9    &T   !U    ?
M (,   ")    CP   )4   ";    H    *,   "F    J0   *T   "Q
MM0   +D   "^    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%
M?   PIT  ,&] !Q5   17   !V4   !N    =P   '\   "(    D    )@
M  "?    I0   *T   "S    N    +H   "^    P@   ,8   #*    S@
M -,   #:    X    .<   #M    \P   /0.  #R'@  [S8  .Q1  #H;@
MY)   -^Q                       ! P0%!@@)"@L-#@\1$A,4%A<8&AL<
M'1\@(2(D)28H*2HK+2XO,#(S-#8W.#D[/#T^0$%"1$5&1TE*2TU.3U!24U15
M5UA96UQ=7F!A8F-E9F=I:FML;F]P<7-T=7=X>7I\?7Z @8*#A8:'B(J+C(Z/
MD)&3E)66F)F:G)V>GZ&BHZ2FIZBJJZRMK["QL[2UMKBYNKN]OK_!PL/$QL?(
MR<O,S<_0T=+4U=;7V=K;W=[?X.+CY.;GZ.GK[.WN\/'R]/7V]_GZ^_S^____
M__________________________________________________\
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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M      ,$(0   0                    $                    !
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
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M6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEO4SPH
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
ME:S'?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:
M_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'
M?)FQQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EO
ML;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA'
M)O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQ
MQ7F>M<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y
M;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA')O^N
M433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>
MM<)VH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_
MN6^QO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y8K"_^5-A+_H#X:_ZA')O^N433_
MKUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)V
MH[G =*J\O7&ROKEOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^QO[EOL;^Y;[&_N6^Q
MO[EOL;^Y;[&_N6^QO[EOL;__F1\%_Y<K"_^7-A+_H3X:_ZI&)?^P4#3_L5I%
M_[!D5_>L;6GLIW=[X9Y]BMF6@Y?1CHFBRXB.J\>"D['$?I>WP7J<N[YWHK^\
M=:K"M7&NP[-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-RK\&S<J_!LW*OP;-R
MK\&S<J_!LW*OP;-RK\'_F1\%_Y<J"O^8-1+_HST:_ZQ&)?^S3S3_M%E&_[1C
M6/:Q;&OJK75]WZ-[C=6;@9S-DH:HQXN*L<*%C[F_@)2^NWR:P[EYH<>U=JG*
MK76LQJMVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K=JW$JW:MQ*MVK<2K
M=JW$JW:MQ*MVK<3_FA\$_Y@J"O^:-!+_I3T9_ZY&)?^U3C3_MUA&_[=A6?6U
M:FSILG-_W:AXD-.??J#*EH*LQ(Z'M[Z(C+^Z@Y'%MW^8R[1\H<^K>*7/I7FJ
MR*1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&I'FLQJ1YK,:D>:S&
MI'FLQJ1YK,;_FA\$_Y@J"O^;-!'_ICT9_Z]%)?^W3C3_NE=&_[M@6?2Y:6WG
MMG&!W*QVD]"D>Z/(FG^QP).$O+N,B<6WB)#+M(:9SK*&I-&D?*31GWVIRIY]
MJLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJR)Y]JLB>?:K(GGVJ
MR)Y]JLC_FQ\$_YDJ"O^<-!'_ISP9_[%%)/^Y333_O%=&_KY?6?2]9V[GNF^"
MVK%TE<^H>:;%GWVTOI>!P+F4BL:UD9++KXV8SZJ*H=*>@J/3F8&HS)B"J<J8
M@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"J<J8@JG*F(*IRIB"
MJ<K_FQ\$_YDJ"O^=-!'_J3P8_[)%)/^[33/_OU9&_<%>6O/!9F_FOVV#V;9S
ME\VM=ZC$I7NWOJ&#P+:;B<:NE8_,J)&5SZ*.GM*9AZ+3E(:GS9.&J,N3AJC+
MDX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,N3AJC+DX:HRY.&J,O_
MFQ\$_YDJ"O^>,Q'_JCP8_[-%)/^\3#/_P55&^\1=6O/%96_EPVR$V+MQF,RR
M=:O#K7RVN:6!O[">AL:HF8S+H962T)N2F].4CJ+4CXJFSH^*J,N/BJC+CXJH
MRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,N/BJC+CXJHRX^*J,O_FQ\$
M_YHJ"O^?,Q#_JSP8_[5$(_^^3#/^PU5%^<=<6O')9&_ER&J%UL%OFLJY=*J^
ML'JVLZE_OZJBA,:BG8K+FYJ0SY67F=*/E*+4BI"FSHJ/J,R*CZC,BH^HS(J/
MJ,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,R*CZC,BH^HS(J/J,S_G!\$_YHJ
M"O^@,Q#_K#P8_[9$(_^_3#+\QE1%]LI<6N_-8G#DS6B&T\5MFL6\<ZJYM'BU
MKJU]OJ6G@L6=HHC+E9^.SX^<EM*+G*+3AI6FSH:4I\R&E*?,AI2GS(:4I\R&
ME*?,AI2GS(:4I\R&E*?,AI2GS(:4I\R&E*?,AI2GS(:4I\S_G!\$_YHI"O^B
M,Q#_K3L7_[=$(__!3#+YR5-%\\U:6NS28'#@T&:&SLALFL"_<:FTN'>UJ;%\
MOI^L@<67J(;*D*2,SHJBE=&%HJ'2@9RFSH&:I\R!FJ?,@9JGS(&:I\R!FJ?,
M@9JGS(&:I\R!FJ?,@9JGS(&:I\R!FJ?,@9JGS(&:I\S_G!X$_YLI"O^C,Q#_
MKSL7_[E$(OW#2S'VS%)$\-)96>C:7W#;U62&R<QJF;K#;ZBMNW2THK1YO9BO
M?<.0K(/(B:F)S(.GD<]^IIS0?:2FS7RBJ,M\HJC+?**HRWRBJ,M\HJC+?**H
MRWRBJ,M\HJC+?**HRWRBJ,M\HJC+?**HRWRBJ,O_G1X$_YLI"O^E,@__L3L6
M_[Q$(?K&2S'ST5%#Z]I76>/?76_3VV.%PL]IE['$;:>DO'"RF+5TNXZQ>,*&
MK7W&@*N"RGJIBLUVJ)3.=JFCS'>KJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>K
MJ,IWJZC*=ZNHRG>KJ,IWJZC*=ZNHRG>KJ,K_G1X$_YPI"O^G,@__LSL6_[Y#
M(/7*2R_NUE!"YN%65]SD6V[+WF.#NM%HE*G';*.;OFZND+AQMX:T=+U^L'C"
M=ZY\QG*L@\EMJXS*;:N9R6ZLG\=NK)_';JR?QVZLG\=NK)_';JR?QVZLG\=N
MK)_';JR?QVZLG\=NK)_';JR?QVZLG\?_GAX$_YTI"?^I,@[_MCH4^L)#'_#.
M2B[GW4] XNE25]+H6FW!X&* L=1GD:'*:YZ4PVZHB;UQL("Y=+9YMG>Z=+1[
MO6ZR@<!JL(C"9["2PV:PEL-FL);#9K"6PV:PEL-FL);#9K"6PV:PEL-FL);#
M9K"6PV:PEL-FL);#9K"6PV:PEL/_GQX$_YXI"?^M,0W_NCH3],="'>C52BO?
MY$P_U^Q15LGN66NWXV%\J-AGBYK/:Y>-R6Z@@\1QIWO =*QUO7BP<+M[LVRY
M@+9HN(:X9+>/N6.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1NF.VD;ICMI&Z8[:1
MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
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M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
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MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
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M_Z4> _^W(P/MR28#UMXI!LGI.Q>^\T0IL_A).JCW34B?]E55E/5?8(GQ:&B
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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M?E3AN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?E3AN'[_F!,!_ZT4 ?/##P#2V L
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M ^W'+ 3?U3$&T]XY%,;81"BYT4X[K,Q63*#'75J5PF-GB[]I<8*[;WEZN':
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M'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!^FP
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M/$;_O3U%_\P]1/_F/D3_YSY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YS[+K
MN;8! *S" 0"@T ( E>4' ([_& .$_R0&>O\L"W#_-!!H_SP58?]$&5O_2QU6
M_U,@4_];(E#_8R1-_VLF2_]S)TG_>BE(_X(J1O^**T3_E"Q"_YXM0?^G+D#_
ML2X__[PO/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3"[L0  K+P
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M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
MC<L  '[:  !PY@  9_\  %W_"@%4_Q !3?\5 D?_'0-!_R0$//\K!3?_,@8T
M_S@',/\]""W_0P@J_T@)*/]-"2;_4@HD_U<*(O]="R#_8PL>_VL+'/]S#!K_
M? P8_X0,%_^.#17_E0T5_Y4-%?^5#17_E0T5_Y4-%?^5#17_E0W_4B4#_TTO
M!/]1,@;_5S4'_UH\"O];10[_6D\3_UE=%_]8;1O_5GL?_U6)(O]3E27_4J G
M_U&H*?]0L2K_4+@K_T_!+/]/RBW_3M8N_T[D+O].[2__3O,O_TWX,/]-_##_
M3/\P_$S_,/E,_R_X3/\O^$S_+_A,_R_X3/\O^$S_+_A,_R__4R0#_TTO!/]4
M, 7_630'_UTZ"O]?0P[_7DX3_UU:&/];:AS_6GDA_UB&)/]6DB?_59TI_U2F
M*_]3KBW_4K8N_U*^+_]1QS#_4=(Q_U#A,O]0ZS+_3_(S_T_W,_]._#3[3O\T
M^$W_-/5._S+T3O\R]$[_,O1._S+T3O\R]$[_,O1._S+_4R0#_TXN!/]6+P7_
M7#('_V X"O]B00[_8DP3_V!8&/]?:!W_778B_UN#)O]9CRG_6)HL_U:C+O]5
MK##_5;,Q_U2[,_]3Q#3_4\XU_U+>-O]2Z3?_4?$W_U'V./M0^SCW3_\X]$__
M-_%0_S7P4/\T\%#_-/!0_S3P4/\T\%#_-/!0_S3_5",#_U M!/]9+07_7S '
M_V,V"O]F0 [_9DH3_V55&?]C91[_87,C_UZ */]<C"S_6Y<O_UFA,?]8J33_
M5[ U_U:X-_]5P3C_5<LY_U3:.O]4YSO_4_ \^U+V/?91^SWR4?\][U+_.^Q2
M_SCK4O\XZU+_..M2_SCK4O\XZU+_..M2_SC_52,#_U(K!/]<*P7_8RX'_V<T
M"O]J/@[_:T@3_VI3&?]H81__9G E_V-]*O]@B"__7I,S_UR=-O];I3C_6JTZ
M_UBU//]7O3[_5\<__U;30?Q5Y$+Y5>Y#]53V1/!3_$3L5/]!Z57_/^95_SSE
M5?\[Y57_.^55_SOE5?\[Y57_.^55_SO_5B(#_U4I!/]?* 7_9RL&_VPR"?]O
M/ W_<$83_W!0&?]N72#_:VLG_VAY+?]EA#+_8H\W_V"9._Y>H3[]7*E!^UNQ
M0_I9N47Y6,)']U?.2/56X$KQ5NQ+[E7V3.E6_$KE5_]&XEC_0]Y9_T#=6?\_
MW5G_/]U9_S_=6?\_W5G_/]U9_S__5R(#_UDG!/]C)@3_:R@&_W$P"/]T.0W_
M=4,3_W5-&?]U62'_<6<I_VUT,/UJ@#;Z9HH\^&.40/9AG$3T7J1(\ERL2_%;
MM$WO6;U0[5C)4NM7VE/G5NE5Y%?U5.%9_4_;6O]+U5O_2-!<_T3/7/]$SUS_
M1,]<_T3/7/]$SUS_1,]<_T3_6"(#_UPD _]F(P3_;R8%_W8N"/]Z-PS_>T$2
M_WM+&?][52'^=V,J^7-O,O9N>SKR:H5![V:/1^QCETSJ8)]0Z%VG5.5;KU?C
M6;A:X5?#7=]7TE[:5N9>UEGS6M)<_%7-7O]0R5[_3,5?_TG$7_](Q%__2,1?
M_TC$7_](Q%__2,1?_TC_62$"_U\B _]J(03_="0%_WLL!_]_-0O_@3X1_X)(
M&?V"4B'W?E\K\GEK->US=3[I;H!&Y6F)3>%ED53>89E9VE^B7-9=JE_37+-A
MT%N^8LY;S&/+6N)CR%SQ8,9?^EK!8/Y5O6'_4;IB_TVY8O]+N6+_2[EB_TNY
M8O]+N6+_2[EB_TO_62$"_V(@ _]N'P/_>",$_W\K!O^$,PK_ASP0_HA%%_>(
M3B'PA%LKZGYF-N1X<$'?<GI+V6V#4M-IC%C/9I5<S&2=7\EBI6+&8*YDPU^X
M9L%>Q&>_7MAHO%_K9KIC]U^V9/M9LV7^5;!E_U"O9?]/KV7_3Z]E_T^O9?]/
MKV7_3Z]E_T__6B "_V4> _]Q' /_?"(#_X0I!?^),0G_C#H.^8Y#%O&.3"#J
MBE@KXX1B-]M^;$/3>'9,S7-_4\AOAUG$:Y!>P&F88KUFH&6Z9:AHMV.R:K5B
MOFNS8LYLL&+E:Z]F]&2L9_A=J6C\6*=I_U.F:?]2IFG_4J9I_U*F:?]2IFG_
M4J9I_U+_6R "_V<< O]T&@+_?R #_X@G!/^.+P?]DC<,])1 %.R521[DD%4J
MVXI?-]&$:4/*?7),Q'A[5+]T@UJZ<8M?MFZ39+-KFV>O::1JK6>M;*IFN&ZH
M9L=OI6;?;Z5J\6BB:_9AH&SY6YYL_5:>;/Y5GFS^59YL_E6>;/Y5GFS^59YL
M_E7_7!\"_VH: O]W&0+_@Q\#_XPE!/^2+0;YES4+[YD^$N>;1AS>EE(ITI!<
M-\J)9D+#@V],O'YW5+=Y?UNR=8=@KG*/9:IPEVBF;9]LHVRI;J!KM'">:L)Q
MG&K7<9QN[FN:;_-DF6_X7I=P_%B7</U7EW#]5Y=P_5>7</U7EW#]5Y=P_5?_
M7AX"_VP9 O]Z& +_AAT"_X\C _^6*P7UFS,)ZY\[$.*@11G7FU HS)1:-L2-
M8T*\B&Q,M8)T5+!^?%NK>H1@IG>+9:)TDVF><IQMFW"E<)AOL'*5;KUSDV_0
M<Y1RZVZ3<_)FDG/V8)!S^EJ0<_M9D'/[69!S^UF0<_M9D'/[69!S^UG_7QT"
M_VX7 O]]%P+_B1P"_Y(B OV:*03QH# 'YZ0Y#=ZE0Q?1GTXGQYA8-;Z284&V
MC&E+KX=Q5*F">5ND?X!@GWR(99MYD&J7=IEMDW6B<9!SK'.-<[ITBW/+=8QV
MYW",=_!HBW?U8HIW^5R*=_I:BG?Z6HIW^EJ*=_I:BG?Z6HIW^EK_81L"_W$6
M O]_%@'_BQH!_Y4@ OF>)@/MI"X%XZDV"MBI0!;,HTPFPIQ6-+F67T"QD&=*
MJHMO4Z2'=EJ>@WY@F8"%991]C6J0>Y9NC'F?<8EXJG2&=[9UA'?'=H5ZY'*&
M>^]JA7OT9(5[^%V%>_E<A7OY7(5[^5R%>_E<A7OY7(5[^5S_8QH"_W,4 ?^!
M%0'_CAD!_YD> ?:A(P+JJ2H$X*\R!]*L/A7'IDLDO:!5,[2:7C^LE65*I9!M
M4IZ,=%F8B'M@DX6#98Z"BVJ*@)-NAGZ=<8)]IW1_?+1V?7S%=GU^X'-_?^YK
M?W_S97]^]UY_?OA=?W[X77]^^%U_?OA=?W[X77]^^%W_91@"_W43 ?^$% '_
MD1<!_YP; ?*E( 'FKB8"V[0N!LZO/13#JDDCN:13,:^>7#ZGF61)H)1K49F0
M<EF3C7E?CHJ 9(F'B&F$A9%N@(.:<7R"I71Y@;)V=X'"=G:"W71YA.UL>8/R
M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
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M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
MO<<@ K+%,@NHP4 9GKY*)Y2Z4S2+MEH^@[1A1WRQ:$]UKV]5;ZUV6FJK?5]E
MJ89C8:B09UVGFVI9IZAK5Z>X;%:GS&Q8J.EH6J?T8UNC^%Y<H_E=7*/Y75RC
M^5U<H_E=7*/Y75RC^5W_> T _XL) -^< P#2J08 R;0' ,*^!@"\S @ M<T<
M :O++PFAR#T6E\5((XW"42^$OU@Z?+Q?0W6Z9DION&U0:;=T562U?%I?M(5>
M6[./85>SFF14LJ=E4K*W9E&SS&92L^EC5++W7U6N^EM6K?M:5JW[6E:M^UI6
MK?M:5JW[6E:M^UK_?@D \I$" -:A @#*K04 P+<% +C"!0"RSPD J]07 */3
M*P:9T#H2C\Y%'X7+3BI]R58T=<==/6[%941HQ&Q)8\)S3E[!>U-9P8165<"/
M65*_FUQ/OZA=3;^X7DS S5Y,P.I<3K_Y64^\_E50NOY54+K^55"Z_E50NOY5
M4+K^55"Z_E7_A0( W9@  ,VF @#!L0, M[H# *[&!@"GTPH H-T5 )G=* 20
MVS<.AME"&7W62R1UU%0M;=)<-6?18SQAT&M!7,]R1EC/>TE4SH1-4,Z/4$W.
MFU)+SJE32<ZY5$C/SU1(SNM32<[X4$K+_TY*RO]-2LK_34K*_TU*RO]-2LK_
M34K*_TWGCP  T9\  ,.K 0"WM ( K;\# */+!@";V0H E.4: 8WE*P:$Y#4-
M>^,_%G/B2!YLX5(F9N%:+&#@8C);X&HV5^!R.E/?>SU0WX5 3=^/0TK@FT5(
MX*A&1N"X1T7AS$=%X.A'1=_V1D7>_T1%WO]$1=[_1$7>_T1%WO]$1=[_1$7>
M_T39EP  QZ8  +BP  "LN0$ HL4" )C1!@"/ZPT B>X? H#N*P9X[30,<.T]
M$VCM1AEB[4X>7>U7(UGM8"=5[6@J4NUQ+4_M>2],[8,R2NZ--$?NF#5%[J4W
M0^^S.$+PQ#A!\-\Y0>_O.$#M_3A [/\X0.S_.$#L_SA [/\X0.S_.$#L_SC+
MH   NJL  *VT  "AP   ELP! (O9!0"$^!$!?/@? G3X*09L^#(*9/@[#U[Y
M0Q-8^4L74_E3&E#Y6QU-^F0?2OIL(4CZ="-&^GXE1/N()D'[DRA ^YXI/ORK
M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
M"#/_10@P_TL)+O]1"BO_5PHI_UT+)_]D"R3_; PB_W8-(/^ #1[_C X=_Y<.
M'/^A#AO_K \;_ZX/&_^N#QO_K@\;_ZX/&_^N#QO_K@^7O   B,D  'G6  !K
MXP  7_8  %;_  !._PH 1_\0 4'_%@(\_QT"-_\D S+_*@,O_S $*_\V!2?_
M.P4E_T %(O]%!B#_2@8>_U &&_]6!QG_7 <7_V0(%?]M"!/_=P@1_X$)$/^+
M"1#_E0D/_Y@)#_^8"0__F D/_Y@)#_^8"0__F G_22<"_T0Q!/]+,03_4#0&
M_U(Z"/]20PO_44X/_T]<$_]-:Q;_3'D9_TN'&_])DQW_2)T?_TBF(/]'KB'_
M1[4B_T:](_]&QB/_1M D_T;@)/]&ZB7_1O,E_T;Z)?]&_R7_1O\E_T;_)?]&
M_R3]1O\C_4;_(_U&_R/]1O\C_4;_(_U&_R/_22<"_T8O _]-+P3_4C(&_U4Y
M"/]50@O_5$T/_U)9$_]0:!?_3W<:_TZ$'?],D1__2YLA_TJD(O]*K"/_2;,D
M_TF[)?](Q";_2,TF_TC=)_](Z"?_2/$H_TCY*/](_RC_2/\H_DC_*/M(_R?Y
M2/\F^4C_)OE(_R;Y2/\F^4C_)OE(_R;_2B<"_T@M _]0+03_53 &_U@V"/]9
M0 O_6$L/_U56$_]49AC_4G0;_U&!'O]/CB'_3I@C_TVA)?]-J2;_3+$G_TNX
M*/]+P2G_2\HJ_TK9*O]*YBO_2O K_TKX+/]*_RS]2O\L^DK_*_=*_RGU2O\H
M]4K_*/5*_RCU2O\H]4K_*/5*_RC_2R8"_TLK _]2*P3_6"X%_ULT"/]=/@O_
M74D/_UI4%/]98AC_5W$=_U5^(/]3BB/_4I4F_U&>*/]0IBK_3ZXK_TZU+/].
MO2W_3<<N_TW3+_],XS#_3.TP_$SV,?I,_C'W3/\Q]4W_+_)-_RWP3?\K\$W_
M*_!-_ROP3?\K\$W_*_!-_RO_2R8"_TXI _]6*03_7"L%_V Q!_]B.PO_8D8/
M_V!1%/]>7QG_7&T>_UIZ(_]8AB;_5I$I_U6:+/]3HB[_4JHP_U&Q,?]1N3/_
M4,,T_D_.-?M/WS;X3NLW]4[U./)._3CP3_\U[E#_,^M1_S'I4?\OZ5'_+^E1
M_R_I4?\OZ5'_+^E1_R__3"4"_U$G _]:)@/_8"@%_V4O!_]H.0K_:$,/_V=.
M%?]E6AK_8F@@_U]V)?]=@2K_6HPN_EB6,?Q7GC3[5:8V^52M./A3M3KW4KX[
M]5')/?-1VC[P4.@_[%#S0.E1_3[H4_\[YE3_..-5_S7A5?\SX57_,^%5_S/A
M5?\SX57_,^%5_S/_320"_U0D _]=(P/_924$_VHM!O]M-@K_;D ._VU+%/]K
M5AO_:&0A_F5Q*/MB?2WX7X<R]ER1-O-:F3KR6*$]\%>I0.Y5L4+L5+E$ZU/$
M1NE2TDCE4>5)XE+R2-]4_$3=5O] VUC_/=99_SK26?\XTEG_.-)9_SC26?\X
MTEG_.-)9_SC_3B0"_U@A _]A( /_:B,$_W K!?]S- G_=#X._W1(%/]R4AO[
M;U\C]FML*O)G=S'O8X(W[&"+/>E=E$'F6IQ%Y%BD2>)6K$S@5+1.W52_4-M4
MS5#74^)1TE3P3M!7^TK.6O]%S5S_0LE<_S[%7/\\Q5S_/,5<_SS%7/\\Q5S_
M/,5<_SS_3R,"_UL? O]E'0+_;B$#_W4I!?]Y,0C_>CL,_WI$$_IY3AOT=ELC
M[G%G+.EL<C7E:'P\X6.%0]U@CDC979=,U5R?3]):IU'/6;!3S5BZ5,M8QE7)
M5]I6Q5?L5<-;^4_"7O]*P%__1KU@_T*Z8/] NF#_0+I@_T"Z8/] NF#_0+I@
M_T#_4B$"_UX= O]I&@+_<Q\#_WHF!/]^+P;_@3@+^X%!$O. 2QKL?%<CYG=C
M+>!Q;3C:;7= TVF 1L]EB4O+8Y%/R&"94L5?H57"7:I7P%RS6;Y<OUJ\6\Y;
MN%OE6[=>]56W8O]/M6/_2K)D_T:P9/]#L&3_0[!D_T.P9/]#L&3_0[!D_T/_
M51\"_V$: O]M& +_=QT"_WXD _^$+ 7^AS4)]8@^$.V'2!CE@U0BWGY?+M1X
M:3C.<W- R6Y\1\1KA$S :(Q1O6645+ICG%>W8J5:M&"N7+)@N5ZP7\=>K5_?
M7ZQB\5FL9?Y3JF?_3JAG_TJF9_]&IF?_1J9G_T:F9_]&IF?_1J9G_T;_5QT"
M_V08 O]P%@+_>QP"_X,B O^)*@3YC#('[XX[#>>.1!;>BE$AU(1<+<Q^9CC%
M>&]!P'1W2+MP@$VW;8A2LVJ05K!HF%FL9J!<JF6I7Z=DM&"E8\)AHV/58J)E
M[5VB:?M7H6K_49]K_TR>:_])GFO_29YK_TF>:_])GFO_29YK_TG_61P"_V<6
M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
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M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
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M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
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M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
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M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
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M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
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M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
M '[,  !SU@( :>4) &3O% !?\" !6? K U3P-05/\#X'2_%&"D?Q3@Q$\5<.
M0O%?$#_R9Q(]\G 4.O)[%3CSAQ8V\Y08-?2B&3/TL1DR]<4:,?7B&C'T\1DQ
M\?X9,?'_&3'Q_QDQ\?\9,?'_&3'Q_QFRI   I:L  )BV  "+P   ?LH  ''5
M  !EW@  7O4* %G\$P!3_!X!3OPG DK], -%_3D%0?U !C[^2 <[_D\)./]7
M"C;_7@LS_V<,,?]P#2[_? XL_XD/*_^6$"G_I! H_[01)__'$2?_X1$F__(1
M)O_V$2;_]A$F__81)O_V$2;_]A&GJ0  F;,  (N^  !^R0  <-,  &3>  !8
MYP  4O\) $W_$0!'_QD!0_\B 3[_*@(Z_S(#-_\Y S/_/P0P_T8%+?]-!2O_
M5 8H_UL')O]C!R/_;0@A_WD)'_^'"1[_E0H=_Z,*'/^Q"AO_P L:_]8+&O_?
M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
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M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
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M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
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M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
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M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
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M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
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M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
M?;@  '&^!@!NOQ4 :K\F 6:_,P-AOC\'7;Y("UF]40]5O5D34;Q@%TZ\:!I+
MNW$=2+M['T6ZAR)"NI0D0+JB)CZZLR8]NL@F/;KH)CVX^24]M_\D/;;_(SVV
M_R,]MO\C/;;_(SVV_R/'B   N94  *R=  "AI   EJL  (JR  !_N0  <[\!
M &C&!0!@R@X 7LH= %O*+ %7RC@#5,I#!5#*3 A-R54+2LE=#D?)9A%$R6\4
M0<EY%C_(A1@\R),:.LBB&SG)LQPXR<D<.,CH'#?'^1PWQ?\<-L3_'#;$_QPV
MQ/\<-L3_'#;$_QR^D0  L)L  *2C  "8J@  C+(  ("Y  !TP   :,<  %W-
M!0!3TPH 3]<2 $W8(@!+V#  2=@\ D;81@-$V4\$0=E8!C_980@\V6L*.MEV
M##?9@@XUVI /--J@$#+:L1$QV\<1,=KG$3#8]A(PUO\3+]3_$R_4_Q,OU/\3
M+]3_$R_4_Q.SF@  IJ$  )JI  "-L0  @+H  '3!  !HR0  7,\  %+5 P!(
MW @ 1>42 $/E'@!!YBH /N8U 3OG/@$YYT<"-^=0 S3H600RZ&(%,.AM!B[I
M>0<LZ8<(*^J6"2GJIPHHZKH*)^O6"B?I\ HGY_T))N;_"B;F_PHFYO\*)N;_
M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
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M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
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M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
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M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
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M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
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M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M4(/_'U"#_Q_>:0  R74  +R   "RB   _^)]$$E#0U]04D]&24Q%  \2J(T
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M&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P  (FA  !]I@
M<:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR1 -+L4T%2+%5!T6Q70E#
ML64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K
M_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(
M %RV  !0N@$ 2;P- $B\&0!&O2< 1;TS $.]/0%!O4<!/[U0 CV]6 ,ZO6$%
M.+UK!C:]=P@TO80),KV3"C"]I LOO;<,+K[0"RZ\[@PMNOX-++G_#2RX_PXL
MN/\.++C_#BRX_PZSCP  II<  )N=  "/HP  @ZH  ':P  !JM0  7KH  %*^
M  !'P@$ /<<& #C)$  WR1L -LHG #7*,P TRST ,\M' #'+40$PRUL!+LQE
M BS,<0(JS'\#*<R0!"?,H00FS;0$)<W.!"7+[@0DR?P&(\C_!R/'_P<CQ_\'
M(\?_!R/'_P>IE@  GIT  )*C  "%JP  >+(  &NX  !?O@  4L(  $?&   ]
MR@  -,\$ "O4"0 FV0\ )=D9 "7:)0 DVC  (]L[ "/;10 BW%  (=U; "#=
M:  >WG8 '=Z' 1S?F0$:WZP!&=_$ 1C>YP$8W/@!&-O_ A?:_P(7VO\"%]K_
M A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP
M*=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1
M[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK
M_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$
M !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<
M _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+
MJP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z
M   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3
M  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M
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M ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT
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M";HS_PFZ,_\)NC/_";HS_PG_.1  _ST+ /] "0#_1 T _T81 /]%&0#W1",
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M_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY
M Z%<2P>=6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?
M@U&J(8%1N")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_
M2@  [E(  -Y;  #/80  QF0  +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA
M2 :67U$*DEY9#8]<81&,6V@3B5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G
M(GE6M2-W5L<D=E;D)'97]Q]W6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3
MZ58  -E?  #+90  P6@  +II  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:0
M8TX*C&)7#8EA7A"&7V43@UYL%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):
MLB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D
M --B  #':   O6P  +9M  "O;   IVL+ *!L&0";;"H!E6LW I!I0P6+:$P)
MAV94#(-E6Q" 8V(3?6)I%7IA<!AX87@:=6"!'7-?BQ]P7I8B;EZB)&Q>L"5K
M7L$F:5[>)FI?]"%K8/\=:V'_&VQA_QEL8?\8;&'_&&QA_QCU40  XEP  ,]E
M  ##:P  N6\  +%Q  "J<0  HF\( )MO%P"6<"< D&\U HMN0 6&;$D(@FI2
M#'YI60][:& 2=V9F%'5F;A=R978:<&1^'6UCB!]K8Y,B:6*@)&9BKB5E8K\F
M9&+:)F1C\B)E9/\>9F3_&V=D_QEG9?\89V7_&&=E_QCP4P  W5\  ,MH  "_
M;P  MG,  *YU  "F=0  G7,% )9S% "1="0 BW,R H9R/@2!<$<(?6]/"WEM
M5PYV;%X1<VMD%'!J;!=M:G,::VE\'&AHAA]F9Y$B8V>>)&%FK"5@9KTF7V?6
M)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(  ,=K  "\<@
MLW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'>'1-"G1R50YQ
M<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5::[LF66S3)EIL
M[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL
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M&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0
M?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3
MBV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&
M_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94
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M#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@
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M !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@
MD:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5
MV@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F
M@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D
M '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP
M"_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0
M\H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ
M  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!
M  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT
M /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/
MS0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_
M    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K
M  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2<
M_Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_
M *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I
M /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP
M_P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W
M _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5
M+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ?
M /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\
M[0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@ _R A /\>*P#_
M&C< _Q=% /\440'_$EX!_Q%I ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0
MH0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_
M >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S,
M_R _ /\=3 #_&U@!_!ED ?@9;@'V&'@!\QB! ?$8B0'O&) ![AB7 >P8G@'J
M&*0!Z1BL ><8M 'F&+\!Y!C- > 9XP'<&O$!V!K^ M0;_P+2&_\"T1O_ M ;
M_P+0&_\"T!O_ M ;_P+_+1( _RX/ /\N#0#_+Q  _R\7 /\N(0#_+"T _RDY
M /DF1@#T)%,![R)> >LB:0'H(7,!YB%\ >,AA 'A(8P!X"&3 =XAF@'<(:$!
MVB&I =@AL0+5(;P"TR+) M BWP+,(_ #R"/] \8D_P/$)/\#PR3_ \(D_P/!
M)/\#P23_ \$D_P/_, \ _S(+ /\S" #_-@T _S82 /\U&@#],B4 ]# R .TM
M/P#G+$P XBM8 =TK8P'9*FT!U2IV M(J?P+0*H8"SBJ. \PJE0/**IP#R2JC
M!,<JK 3%*K8$PRK#!<(JU06^*^L%NBOY!K@L_P:V+/\%M2S_!;0L_P6T+/\%
MM"S_!;0L_P7_- P _S8% /\Y P#_/ @ _SP- /T[$P#Q.!T Z#4I . T-P#9
M,T8 T312 <TS70'),V<"QC-P \0R> 3!,H $OS*'!;XRCP:\,I8&NC&>![@Q
MI@>W,; (M3*\"+,RS FQ,N4)K3/U":LS_PFJ,_\(J#/_!Z@S_P>G,_\'IS/_
M!Z<S_P?_-P< _SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$
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M%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0
M\D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>
M3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(
MM1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L
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M'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9
MMV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ
M7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:
M[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH
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M%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P
MB',  (%S"P!\=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?
M;VH07&YS$EIN?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L
M_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@
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M$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD
M6I 4 %B0(0!6D2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM
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M!2VDEP8LI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@
MI8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  S
ML!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22Q
ME (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$
M ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T
M(KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7
MP*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>
M  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+
M !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI<
M"<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !Q
MK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9
M#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=
M  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0
M6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P
MXPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #N
MH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8
M #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04
M .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0
M_:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4
M   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@
M  #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT
M /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_
M $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\
MJ #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_
M /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_
M *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /,
M_P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5&
M /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *<
M^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I
M ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,
M3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J
M .T&L@#J!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
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M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
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M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
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M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
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M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
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M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
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M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
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M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
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M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
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M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
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M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
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M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
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M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
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M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
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M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
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M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
M.%=1 #=86@ U6&4 -%AQ #)8@ $Q6) !+UFB 2Y9M0$M6<\!+5GO 2Y8_P$N
M5_\!+E?_ 2Y6_P&R5P  I5\  )ME  "1:0  AVH  'QJ  !Q:   8V4  %AB
M  !-7P  0UT" #Q;#0 Z7!0 .%P= #=<)@ U72X -%TV #-=/@ R748 ,5Y.
M #!>5P O7F( +5YN "Q??0 J7XX *5^@ "A?LP$G7\P )U_M 2=>_P$G7?\!
M*%W_ 2A<_P&M7   HF0  )AJ  ".;@  @V\  'EO  !N;@  8&L  %1I  !)
M9P  /V4  #5C"0 R8Q$ ,&,9 "]D(0 N9"D +60Q "QD.0 K94( *F5* "AE
M5  G95\ )F9K "1F>@ C9HL (F:= "!FL0 ?9LD 'V;K "!E_@ @9/\ (&/_
M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_XGT024-#7U!23T9)3$4 $!+_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y
M .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\
M#0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U
M /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4
MZ@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_
M  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T
M=@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D
M -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0
M_P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#:
M '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,
M[P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  '
M .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\
MPP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N
M /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\
M# #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O
M +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /(
MG0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#&
M !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *(
M;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\
M (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H
MM  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3
M V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,
M_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D-
M *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H
MA0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T
M$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/
M$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L
M '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\
M:AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%
M&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>
M< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_
M &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!(
M=R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B
M)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH
M_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9
M &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W(
M62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*
M-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M
M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z
M %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@
MMD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:
M,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LV
MA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4
M *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R(
M4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$
M.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.
M  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG
M $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$
M/D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "7
M5   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9
M+ !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@
M #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46
MBUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _
M13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)
ML0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T
M 'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX
M.4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L
M3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA
M  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R
M #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4
M)E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M
M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7
M-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE
M !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P
M76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B
M7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?
M^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X
M $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4
M&&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 0
M9O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T
M   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X
M  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\
M"6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U
M?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\
M/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_
M  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP
M(X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@
MB4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$
M_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(
M !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD
M )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+
MA@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?
M   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\
M  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0
M>)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
MK0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W
M/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@
M %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@
M +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@
MRT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F
M  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L
M  #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4
M .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   X
MM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=
M    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX
M  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !
M_P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_
M (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0
M_P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2
M /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T
M]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C
M /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\
M&0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!]
M .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\
MRP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q
M "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X
M? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_
M +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D
MVP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y
M 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4
M_P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ?
M ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4
MIP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5
M /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +,
M(P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V
M )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\
MA@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A
M "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@
M=P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_
M '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\
MD0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z
M"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T.
M_P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB
M ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'<
M;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6
M)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83
M)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^
M &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@
MO3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I
M&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?
MAP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8
M *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28
M7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/
M)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_
M  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K
M %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y
M1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "9
M10  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L
M+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&>
M $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620
MC$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!'
M,3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LV
MKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX
M (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\
M0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U
M.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0
M  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT
M #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\(
M+S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q
M4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_
M.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B
M "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P
M85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O
M13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(
M]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@
M %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL
M)TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >
M3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);
M  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%
M "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\
M&%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"
M7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A8
M10 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_
M !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@
M,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /
M84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?
M_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X
M "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T<
M!6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7
M;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV
M   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.
M  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0
MB7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0
M@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""
M50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($
M 'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@
M H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030
MD%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+
M  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T
M  "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0
M *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9
ME@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J
M    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:
M  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP
M/Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
MN    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&
M8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP
M "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&    R
M ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5
MX6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y
M   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P
M  #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP
M /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X
MB@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_
M .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "<
M_P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O
M (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D
M_P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N
M /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0
MVP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^
M /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0
M,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$
M ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\
MK #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#*
M #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\
MA0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_
M )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$
MM  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"<
M (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T
M_P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T
M *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (
MBP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N
M"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ),
M-0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$
M 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0
MS1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"#
M #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"
MBP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"
M +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#
M= @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B
M#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K
M  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R
M &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I(
M5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?
M,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5
M- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ?
M $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.
MD#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4
M'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4A
MK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T
M (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3,
M2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ]
M)\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _
M  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V
M $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\
M-RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S
M0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK
M.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'>
M #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10
M94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU
M]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4
M %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P
M,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H
M.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&
M  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI!
M "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\
M(SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*
M2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_
M2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_
M !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@
M/4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =
M14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&
M_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$
M "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P
M%4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">
M5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6
M   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4
M  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70
MD60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =
M70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;
M7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL
M (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@
M$68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@
M9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U
M  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$
M  9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0
M &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S
M?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]
M!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO
M  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P
M784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
MB08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")
M?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT
M $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP
M )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P
MF(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9
M   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4
M  "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX
M *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @
MHP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U
M    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-
M  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0
M"[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
MQP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<
MF0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L
M  "_    PP   ,8   #+    S@   -$   #1    U    -8   #9    VP
M -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB
M]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\
M00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2
M /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\
MR0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#]
M $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .<
MDP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_
M +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $
MZ0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#.
M )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T
M_P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!#
M ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X
MMP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_
M    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L
M10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1
M *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M\0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G
M $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$
ME0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP
M -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\
ME0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_
M )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-
M  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!
M (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4
M< "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M
M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '<
M0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"?
M &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P
MFQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I
M D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(
MK0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4
M (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH
M70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,
M#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I
M  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [
M %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X
M0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X
M*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6
M/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO;
M #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@
M:BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!
M'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A
M]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(
M %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T
M.2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O
M)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS
M  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9"
M #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\
M*BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.
M,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__
M "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0
M030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G
M,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R
M_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL
M #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T
M(#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C
M1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]
M   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6
M !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P
ME5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G
M0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !-
M8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8
M (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2
M&T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -
M1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@
M  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$
M !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD
M!$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z
M:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6
M"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W
M  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@
M;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #
M8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>
MAP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4
M %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL
M &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@
M:)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[
M  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-
M  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(
M '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _
M@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "#
M#0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D
M  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0
M)XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P
MD@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1
MM@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<
M !&8   )F0   )L   "<    G@   *    "@    H    *    "A    H00
M *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK
MI,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC
M    I0   *<   "I    K    *X   "N    K@   *\   "P    L0   +(
M  "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L
M +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
ML0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0   #&
M    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$
M  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@
M ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
MWP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #Q
MQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1
M /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T
M\ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_
M    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /(
M4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@
M -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M_P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#<
M %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,,
MI0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P
M /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X
MP@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L
M *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /
M  #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!.
M *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *,
MEP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/
M    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L
M3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J
M (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
MM@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P")
M $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4
MM !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0
M *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $<
M>0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E
M ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+
M  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !&
M &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P
M6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%
M#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\
M1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2
M $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&
M=1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3
M!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,
M[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL
M &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4(
M2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [
M$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=
M  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%%
M #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\
M-!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4
M'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<6
M2@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_
M "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0
M1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O
M'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@
M_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4
M #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X
M*2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F
M.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F
M P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96
M "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@
MF$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L
M* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK
M8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<
M (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8
M)"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6
M,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/
M  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+
M !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L
M$#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^
M5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X
M#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ
M  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P
M<EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0
M/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!
MB@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&
M &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX
M"$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@
M2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F
M  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1
M  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@
M $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3
M:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:
M$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K
M  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<
M/VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0
M9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@
MP0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8
M "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$
M ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO
M:^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_
M   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1
M  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H
M 'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /
MB0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-  "-
M$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO
M  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0
M )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "="P
MGA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<
M^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,
M  "E    J    *D   "I    J0   *H   "K    K    *T   "N 0  L D
M +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !D
MDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T
M    M@   +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'
M  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP
M2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
MQ@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A
M!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P
M /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L
M^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G
M +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\
M  #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !<
M .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0
MS #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_
M    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X
M7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^
M +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
MY@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V
M %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *
MRP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP
M ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4
MH@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP",
M .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4
M 0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3
M (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\
M>0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@
M  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\
M4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G
M &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
MC0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O
M %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P
M]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ %
M 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P
M8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0
M /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$
M" !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!-
M %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L
M1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A
M! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D
M3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_
M #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0,
M4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^
M"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-
M_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \&
M $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E
M- Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J
M+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1
M"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7
M "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0
MFC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U
M% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "87
M8  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H
M (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H
M+!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?
M'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!
M  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT-
M "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H
M&")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_
M1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A
M$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y
M !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@
M=$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9
M)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XK
MBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\
M &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!
M$RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (
M,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2
M  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3
M  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID
M #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;
M50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[
M%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL
M   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7
M3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0
M0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"
MPP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T
M #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@
M $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P
M2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A
M   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;
M  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(
M %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E
M:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?
M'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW
M  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<
M$V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0
M:B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D
M_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H
M  1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H
M '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^
M?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&
M    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<
M  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA
M:H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
ME0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":
M'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT
M %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I
M *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P
MKB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28
M   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0
M  "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14
M ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   I
MI@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##
M    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8
M  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $
M_P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R
M &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P
M[@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P &
M /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &,
MW !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#
M /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T
M# #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B
M ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /(
MJ@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #.
M !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P
M80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_
M )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T
MLP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7
M %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V ((
M_P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0
M )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D
MA !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P
M /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X
M$@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8
M '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\
M80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\
M !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0
M60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_
M %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !
M;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6
M %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D
M_P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1
M %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8
M20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R
M&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %,
M$P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!:
M #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(
MGR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!'
M !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$
M80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH
M ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q
M.P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K
M"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR
M  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1
M #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH
M(@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  "
M-P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0
M$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X
M !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P
M=#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08
MB0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\
M &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /
M'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"
M  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5
M !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID
M"B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<
M1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B
M&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L
M  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2
M4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,
M*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   K
MP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH
M $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL
M!2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP
M,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-
M   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@
M   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N
M #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U
M3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU
M   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50
M)5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@
M1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"
M_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH
M !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<
M $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%
M90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@
M   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM
M  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;
M>7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M:@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D
M-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<
M &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0
M '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+
M<CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^
M  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,
M  "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(
M ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+
MAP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1
M    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X
M  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D
M,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
MH    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I
M0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP
M !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O    L
M +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P
MP$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG
M    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(
M  #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL
M -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_
M !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D
M;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_
M ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4
M\P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#.
M &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0
M_P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  :
M -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@
MM@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P";
M /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T
M'@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G
M )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\
MA@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E
M "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T
M9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_
M '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L
MD  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y
M &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &<
M_P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P =
M 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$
M: !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%
M    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X
M'@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D
M %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@
MK T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!?
M !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P
M: !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10
M )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H
M40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _
M &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=
M  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P :
M $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L
M- !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$
M)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P
M&P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V
M "H B  H )P )P"P "8 R0 E .H )0'[ /_B?1!)0T-?4%)/1DE,10 1$B4!
M_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$   0PP"
M #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I!$,
M* 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?
M*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.
M!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D  ( I*
M !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0
MD#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03   M
M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y' !<.
M4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4
M (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J%0$
M(Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1
M$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\
M  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'   (!@#
M !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP
M#!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!   !W
M00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\  !<:
M"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI
M  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U10
M;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A!  /
M'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A
M>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@  :TH
M &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -) H
M"2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F=P
M)HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\  &!.
M  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H !2L.
M  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0  +(H
M "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3  !6
M40  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-   R
M$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<  #&>
M   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !55P
M25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z#P
M.1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<   W
MLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27   1%@
M #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0  0A
M $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _L0
M/M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX  #);
M   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX  $L2
M  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP  1LT
M $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB   ?
M8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40  !4
M%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H  $_O
M  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7:0
M#F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@$
M8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM  !9
M_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@  !W$
M  !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#   ;1$
M &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y
M>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T   !]
M    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P  'P2
M  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S@
M98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*
MC    (T   "-    C    (P   ",    C    (P   "-    C00  (X,  ".
M$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@  6H@
M $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9    FP
M )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B#
MHA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39   #^3
M   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@   *L
M  "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0  N0T
M +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<   C
MH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L   "Z
M    O    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$  -0/
M  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_
M_P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G
M %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"] ,L
MX #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_    _
M /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D
MRP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0 S0"R
M /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z    .
M!@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %, M !8
M +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "= .8
MFP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8  0"_
M  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1 )X
M5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -, AP#W
M (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K  <
MI0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ")
M %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K ',
M_P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  ( E  +
M )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X
M=@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B
M /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ ' ($
M#0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!.
M &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\
M5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 " ', "@!O
M  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!' %<
M3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_
M $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C  P
M7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L 2 !)
M %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_ #P
M_P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @ 50 -
M %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L
M/0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F
M%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  * $@
M#@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8 ,P!/
M #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A'
ME2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $  "P \
M  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+ "@
M50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28
M (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T  P
M,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "  4@ ?
M %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M
M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D *04-
M "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP
M%@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W
M,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP) !\)
M#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI
M  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@
M;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D."@ 5
M# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0
M>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P  :SH
M &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1$ L
M#@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03=@ #
M$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\  & ]
M  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D #!,.
M  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D
M !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"  !6
M/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-  89
M$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<  !R=
M   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !51
M2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?$
M'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;   A
ML@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420  2D8
M $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@  )1(
M "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   FL
M)<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP  $%)
M   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$  "T6
M   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP  *\L
M "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-   P
M20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04   T
M&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H  #'N
M   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J3P
M($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \&
M/"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM   W
M_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50  &5,
M !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%   11P
M $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   __P!^
M80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL   M9
M   "6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@  $\B
M  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![:0
M=&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B
M8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<  !:
M*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<   <W0
M &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M    ;0
M &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G(0
M9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z
M  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@   'H
M  !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&   =R8
M '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%
M@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B    (D   "(
M    AP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P  (DL
M  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   YB@
M*HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6
MEP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA  "=
M,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP  'I4
M !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F    IP
M *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T)P
MM#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\   6A
M    HP   *8   "I    K    *\   "S    M0   +<   "V    MP   +@
M  "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.&@  SR\
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M_________________________________________________P
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M]_CY^OO\_?[_;69T,0     # 2$   $                    !
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M________J#4          %S3____________________________?0T
M     %36___________________________N?44          $34________
M___________________\JF0O @  !"(W25C.________________________
M____Z:1K02@_8W^5I[K:_______________________________5LJRRS.3Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________ENY=W8LC_________________
M________________VYYG-@H  HS________________________________(
M?S\%     %[/_____________________________]F!.0       #RJ____
M_________________________YY,         ".0____________________
M________W&\:         !!]^?__________________________KT@
M      !O[O__________________________A!,           !DYO______
M___________________L40            !7WO______________________
M__^X%0            !(UO________________________]T%
M   XS_________________________FB6A,            CQ?__________
M_______________?FUPL           -NO__________________________
M[[%]53DB$0<! A$BLO______________________________W[^EF9B:H*R]
MVO__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____X[Z=@'S[________________________________\K>$5S . !VL____
M___________________________2BDP5      !R\___________________
M_________]9_-@        !+R?__________________________^I$^
M       OJ___________________________P%H            :E?______
M____________________C20            (A/______________________
M___G7@              =_________________________^T)0
M    :O________________________]]                6_3_________
M______________TK                3.O______________________Z4
M                /.'______________________S ,
M+=G_____________________F8IA)P              )]?_____________
M_________^V^B54G            )=S__________________________LJ=
M=EU*/#(M+# Y1][_______________________________WFW=;2T-/9Y/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________OU+O6____________________
M_____________^>XCVI++Q5O_______________________________DH6<T
M!P     \R?___________________________]:".P         2E_______
M____________________[84Q            ;_______________________
M____ID(             4.'________________________L:0
M    -\G_______________________^S+P              (K;_________
M______________]Y                $*?_______________________(T
M                 )G______________________ZD
M (S______________________T8                  '______________
M________WP                   '3_____________________EP
M             &K_____________________S@                   &/_
M_____________________RDB 0               &'_________________
M_____[FC@%<W%P           &C___________________________K3KI2&
M?'5Q<')W@93_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________V[J=@FEIT_______
M________________________R)-E/1D    =GO______________________
M_____]N.3!,         ;O__________________________VWPL
M    1=?_________________________BRH             (K3_________
M_______________"1                Y?_______________________]]
M 0               '_______________________^<V
M &K______________________YT                  %C_____________
M_________T8                  $?X____________________Z0
M             #7I____________________E@                   "7;
M____________________O                    !C.________________
M____ZP                    _"_____________________P
M          JY_____________________R<                   JU____
M_________________W                    VY____________________
M_^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38TL[,
MR\S/UN#\____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________Z].\X________________________________]*IA65(
M+!(!A?____________________________&K<3P/        3^#_________
M________________U7\U            '[+________________________C
M=1T              (G_______________________^0(P
M &?______________________]5#                 $CV____________
M_________XH                  "[=_____________________S@
M             !?(____________________O@                    2V
M____________________G                     "E________________
M____N@                    "3____________________W
M          ""_____________________P                    !T____
M_________________Q,                   !H____________________
M_T(                   !@_____________________WH
M      !=_____________________]$                   !A________
M______________\D                  !F_______________________)
MK)F)?79Q;&EG9F=K<'J,________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________XL6JD7EA=___________________________
M___=IG=0+ P     ,<3_________________________X)).$P
M (_________________________2<!T              &#_____________
M_________^YO#P               #?B_____________________Y8<
M             !3 _____________________T                    "C
M____________________K@                    ")________________
M____G@                    !R____________________O
M          !?____________________V@                    !-____
M________________^@                     [____________________
M_PX                    J^?___________________S,
M       ;Z?___________________UX                    /V_______
M_____________X\                    &T/___________________]
M                    RO____________________\K
M    R/____________________^                     R___________
M___________W%@$%!0,!       !!@T8R________________________.OA
MV,_,S<_0TM37W.+J____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________':
MQO______________________________\<:CA&A-,A@ %:O_____________
M_____________[E\1A@          ''________________________7?"\
M             #OC_____________________]]D"0                RU
M_____________________W0#                  "-________________
M____Q14                   !J____________________F0
M          !+____________________M@                     P_?__
M________________UP                     9Y___________________
M]@                     %T____________________PX
M        P?___________________R\                     K_______
M_____________U(                     GO___________________WD
M                    CO___________________Z4
M    @/___________________]@                     =/__________
M__________\V                    ;?____________________]\
M                :?_____________________7#0
M:/______________________<                   8?______________
M_________U \1DY465UA9&AL<'9^B?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____[]6[HXMS6I7___________________________B_CF1!(04      %+\
M_______________________WG588             !?!________________
M_____^5L%@                "-_____________________V,
M          !>____________________G0                     U_/__
M________________H0                     1V?__________________
MR@                      N___________________[@
M        H?___________________PP                     BO______
M_____________RT                     =O___________________TT
M                    9/___________________V\
M    4O___________________Y0                     0/__________
M_________[P                     ,/___________________^H.
M                (O____________________]$
M%?____________________^!                    "_7_____________
M_______("P                   NS_____________________7@
M             .7_____________________R1P                  -K_
M_____________________YT!              <.%\7_________________
M_______5N;S!Q\[5V^'F[?3[____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________XW\__________________
M____________[,:EB&U4.R$' #+>________________________UY)9*0
M          "@______________________^)-@                !G____
M_________________V8                    R]O__________________
ME0                     #R/__________________IP
M        H/__________________UP                      ?/______
M_____________P                      7O___________________R4
M                    0____________________T@
M    +/___________________VH                     &/__________
M_________XL                     !?/__________________Z\
M                 .'__________________]4
M ,____________________\D                     +[_____________
M______]4                     *[___________________^+
M             )_____________________+#@                   )+_
M____________________5P                   (;_________________
M____J@H                  'G______________________VT
M         &;_______________________=5                 $7_____
M____________________:B,K-3]*56!J=7Z'D9S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^C/MIV#:4ZY____
M_____________________^RR@UPZ'0(       ![____________________
M___%;2D               ! _____________________X,;
M       'R___________________D@                      F/______
M____________I                       :O__________________W0
M                    0?___________________PX
M    '?___________________SD                      .C_________
M_________V                       ,[__________________X4
M                 +?__________________Z@
M */__________________\L                      )#_____________
M_____^\6                     'W___________________\^
M             &S___________________]I                     %K_
M__________________^9                     $G_________________
M___2%@                   #G_____________________6
M         "G_____________________H@                   !G_____
M________________]58                   3_____________________
M_[LO                  #X______________________^K*0
M      #/________________________R4<     !Q,@+CY2:(3M________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]-7)____________________________^M*PDG==
M0B@,  !*________________________Q7U%%P             1V/______
M_____________\10                    G___________________H@P
M                    :/__________________E
M    -O__________________V@                      !^S_________
M_________Q4                      ,3__________________T@
M                 *+__________________W4
M (/__________________YT                      &G_____________
M_____\,                      %+__________________^</
M             #[___________________\S                     "O_
M__________________]8                     !C_________________
M__^!                      7___________________^L
M          #____________________>(@                    #R____
M________________7                     #?____________________
MGP                    #,____________________Z$H
M      "W_____________________Z 6                  "<________
M______________]Z @                !W________________________
M>@L               5,_________________________Z)7:'2 C9RKO-#G
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^WC________________________
M___2HWI8.BDC'!8.!@  G_____________________^L4@X
M    :?__________________Y$,                     -/__________
M________>0                       ./_________________S0
M                 ++__________________Q,
M (7__________________T\                      %W_____________
M_____X,                      #K__________________[(
M             !S__________________]L#                      +_
M__________________\J                      #[________________
M__]/                      #G__________________]T
M          #4__________________^;                      # ____
M_______________$!P                    "M___________________P
M,P                    ":____________________9P
M      "&____________________HP                    !R________
M____________XT0                   !<_____________________Y$&
M                  !!_____________________^M?
M   =_______________________*2P                  ____________
M____________RU<   P8)#$_3F!TBZ?'___________________________7
MY_+_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KU,W'PKZZM[.PK:FHI?___________________]U^4S\P
M(QD1"0(          -O_________________=@
M *?_________________N@                       '7_____________
M_____P<                      $;__________________TX
M             !K__________________XP                       #]
M_________________\$                       #;________________
M__$9                      "^__________________]$
M          "D__________________]K                      "-____
M______________^1                      !Y__________________^W
M                      !F___________________>(0
M      !3____________________2@                     _________
M____________=P                     K____________________K H
M                   6____________________YT4
M    _____________________XH                     ____________
M_________]9-                    _?____________________^G+@
M                U?______________________F"H           88+45@
MX/_______________________ZAC=(&/G*N[S>+Z____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^(S@$E#0U]04D]&24Q% !(2________________________________
M_______________________________GR[>IG96.B82 ?'AT<&QH99#_____
M____________O&I(+1D*                 #'__________________P
M                      /__________________T(
M      #<_________________XX                       "R________
M_________\X                       "-__________________\I
M                  !K__________________]:
M  !.__________________^&                       T____________
M______^N                       >___________________4%P
M               *___________________Z/0
M____________________90                      ________________
M____C@                      ____________________O!D
M            [___________________\4X                     V/__
M_________________XL                     O___________________
M_\Q#                    H?____________________^1&0
M        >O_____________________R= H                17_______
M________________Z'03'RPX15-B<H6;M-+U________________________
M___7Z/3_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________OW\_'N
M[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$________
M_________TLE"P                    "2_________________X@
M                  !F_________________]<
M   ]__________________\S                       8____________
M______]L                        __________________^=
M                ___________________)#
M]O_________________Q-0                      W_______________
M____6P                      R___________________@@
M            M___________________J08                     H___
M________________TR\                     C?__________________
M_UX                     =____________________Y,'
M        7O___________________\U#                    0/______
M______________^'$                   '/_____________________8
M7@                   /______________________OTX       X<+#Y2
M:H:ER/_______________________\)\C)JGML76Z/W_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^[AU\_)P[ZZMK&MJ:>F
MIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4____________
M_____]<%                        __________________\T
M                ]O________________]V
MTO________________^P                        LO______________
M___A)                       EO__________________40
M            ?/__________________>0                      9O__
M________________H                       4?__________________
MQR,                     //__________________[DL
M        )____________________W0                     $/______
M_____________Z,6                     /___________________]A,
M                     /____________________^(#P
M     /_____________________+4P                   /__________
M____________I3@           D=-$YKC/_______________________YDY
M0U%?;GV.H+7+Y?_____________________________K^?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________KS+FLH9F1BX:!?'AT<&MH9F9H
M\?________________]A13(C& X&                GO______________
M__]^                        =?_________________#
M            4O_________________[-P                      ,O__
M________________:@                      %O__________________
ME@                       /__________________OQL
M         /__________________YD(                      /______
M_____________VD                      /___________________Y "
M                     /___________________[DL
M     /3__________________^A<                     -G_________
M__________^1&                    +S____________________*4P
M                 )W_____________________F"X             $"E&
M9L3_____________________[G\=#!HH-T97:7Z5K\SN________________
M_________^>@JKG(V.G\________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________?7PZ^;B
MW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N,?__
M_______________2)1$#                     /__________________
M0@                       /__________________?0
M         /__________________L L                      /;_____
M____________W3D                      -S__________________V(
M                     ,7__________________XD
M     *___________________Z\B                     )G_________
M_________]9(                     (+___________________]R
M                 &G___________________^A*
M $[____________________37                    #/_____________
M________EBX              !4R4G?_____________________X'(3   !
M#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^>#2R,"ZM;"LJ*6B
MGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00  -3_____
M____________D@                       *W_________________S!X
M                     (O_________________^U(
M     &W__________________X                       %'_________
M_________ZD;                     #K__________________]!"
M                 "/___________________5H
M  S___________________^/%                     #_____________
M______^X/@                    #____________________E;0,
M              #_____________________GS<              ! O4'3_
M____________________W7(4      87*D%:=92VVO__________________
M_____[Q81%1D=8::K\CC_______________________________2S>'Q____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________\^_K[_?______________________[KFHG9:/BH:"?WMX=G1R
M<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_________
M_________VD                       #__________________YL*
M                  #__________________\@Y
M  #___________________!C                      #_____________
M______^*#@                    #___________________^P-
M              #____________________56P                    #_
M____________________A1H                   /L________________
M____L4D              !@Y78'_____________________Y7L>       ,
M(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?__________
M__________________^SGK3%U^O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________Z[^?A
MW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A75UE>
M97'__________________[\Q'Q80"@4               #_____________
M_____^U6                      #H__________________^"!
M              #,__________________^K+P                    "S
M___________________25P                    ";________________
M___W?!                    "%____________________HC<
M        !2N4____________________RV$"            #"Q0=I[1____
M________________]8TP       -(SM7=IF^Y?______________________
M_\-C&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G____
M_________________________________?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________=SL6_O+FV
MM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M066:A
M__________________^G)@X' @                !6________________
M___.4                      Z___________________T>0L
M           A____________________GS(                    .____
M________________Q%@                (,5J$____________________
MZ7\?           &)TMQFL+I_____________________Z=)      (7+TIH
MBJ[5_/_______________________]-U'B8X2EYUCZO+[_______________
M______________^N<H68K,+;]O__________________________________
MW^__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________O[*JIJ.AH)^?
MH:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]____
M________________GBX&                    ____________________
MPU8                  !5!____________________YWL:
M  DT8(NT_____________________Y\_          0E2G&9PNO_________
M_____________\9F#P   !,J1&*#I\WU_________________________^N.
M-2L^46B!G;S>______________________________^^=G^4J<'<^?______
M____________________________TMCS____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___V\O#O[^_Q\_C]____________________________^+"?FI>6EI:8FY^D
MK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I________
M_____________Z9! 0          !S9CC[KA_____________________\9E
M"@      !"=,<YS$[/_______________________^6(+P  $RI$8H*FS/3_
M__________________________^K4#9*87N6M-;Z____________________
M___________2AWR8L<OI____________________________________U,[M
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________M
MY>/CY.;H[?'Y______________________________VQE)*2E9F=HZFRO-#M
M__________________________^=4T=)35%68'.*K];\________________
M__________^R5@ :-5!MBZ[2]______________________________-;SY?
M>YFWU_G________________________________NGX.FPN'_____________
M________________________X\[K________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________
M
M
M          #_________________________________________________
M____________________________________________________________
M____________________________________________________________
M_P   /_; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)
M"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(
M!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( (<!  ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MP%H=QMW*#K$\;=CR+<'Z8+_4+_>%>\?M)_&>'X%_">_UH[&OG_T;3XFZ2W#
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MO_!-+XF^,O'W[:W@O3]0\6>)KZPWW4]Q#/J<TL3JEI,X#*S$$%@HZ=Z^U/\
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MG?Y^/>N/,*GL\+4J/I&3^Y'H910]MCJ-%?:G%??)(_#FOT1^'G_!$[P_XP\
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MKEYIUVGEW5A.]M,G]UT8JP_ @UZE^PWXK'A7]I;0-[[(=2\VQDY^]OC.P?\
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M\ T8X)X-U7K)2O9=$U;\3[JMXR8N>;0S58:-X4Y04>9M>]*+;O9:^[8^!?\
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MH_\ !7GX.>/?BS^U!I]SX?\ !7B[7M,T_0+>T6YT[2+FZ@+^=/(PW(A7</,
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MZZ>D%%%% !7P9_P6&_Y.O_8A_P"ROP_^D[5]YU\&?\%AO^3K_P!B'_LK\/\
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MR<$[6,%U)-;3Q[ASM>*1@1T/RGJ!72?LK?\ *<C]K#_L4_!O_HBZH_X+J?\
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MV"?^"5_B+_@GUX\^)_AWPAXNT&;X(>.FEU"QT>ZTZ:77=/OWMH+?+W9EV21
M1,3E-SEP21@Y**FXSA?V5O\ @E3\=/\ @F3\)M+TG]G_ .)'PZU::\M5_P"$
MIT+QMI-Y'HNJ:@A95U&UDM9#-:3/"(8I%(D1_*5\9&*];_9'_8"\>:)^U%J?
MQZ^/GCK1_'?Q2FTHZ#H5AH%E+8^'O"%@Q#S16D<C-)))*XRTLGS8RO(Z%%4(
(^MZ*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>fumaderm.jpg
<TEXT>
begin 644 fumaderm.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_P 8H^N4?YG_ . 3_P#D0^L4OYOPE_D'_"56'_3Q_P" EW_\8H^N4?YG_P"
M3_\ D0^L4OYOPE_D'_"56'_3Q_X"7?\ \8H^N4?YG_X!/_Y$/K%+^;\)?Y!_
MPE5A_P!/'_@)=_\ QBCZY1_F?_@$_P#Y$/K%+^;\)?Y!_P )58?]/'_@)=__
M !BCZY1_F?\ X!/_ .1#ZQ2_F_"7^0?\)58?]/'_ ("7?_QBCZY1_F?_ (!/
M_P"1#ZQ2_F_"7^0?\)58?]/'_@)=_P#QBCZY1_F?_@$__D0^L4OYOPE_D'_"
M56'_ $\?^ EW_P#&*/KE'^9_^ 3_ /D0^L4OYOPE_D'_  E5A_T\?^ EW_\
M&*/KE'^9_P#@$_\ Y$/K%+^;\)?Y&U:W45Y$EQ VZ.55=#@C*L RG! (R"#@
M@$=QFNV,E-*<=4TFO1ZHZ4U)*2V:NOF<9XID*W5H.PF8_P#DO<#^M>9COX</
M\:_])F<&+^!?XE^3*GFBO!/&#S10 >:* #S10 >:* #S10 >:* #S10 >:*
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MMNG%::;6;T_$SHT8U%!MN\IRCI;HFUT\B6*RLY?)*R3 7081@A,AESDMVQZ
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MT4 'V2+^Z* #[)%_=% !]DB_NB@ ^R1?W10 ?9(O[HH /LD7]T4 'V2+^Z*
C#[)%_=% !]DB_NB@ ^R1?W10 HM(O[HH O1(J#"C H __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gainlossonfvremeasurement.jpg
<TEXT>
begin 644 gainlossonfvremeasurement.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MFTW1?$6F?<U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !D>O7I[T5^0W[?/Q>^*'@']O;_@CGX"\%>/_ !9X
M6\%?&/\ :1_:'\-?%3PMH6LW6GZ%\0M \/?LL^-?%>A:1XMT^!A#K6GZ1XCL
M+36M/M;L/%;:E!%=HHFCC=?UWC)*(3R2BDGU) H =1110 4444 %%%% !111
M0 445\K?$+QYXNTCQCK6G:;K=Q:65M):+!;I!9.L8DT^TF<!I;:20[I)'<[G
M;ECC P!\_P 1\183AK!T<;C*.)KTZV*AA8QPL:4IJ<Z56KS256K1CR*-&2;4
MG+F<?=:NT'U317Q'_P +.\>?]#'=?^ VG_\ R'7D/Q$_;-\'_"7Q-X%\&_$W
MXZ^%? WBCXEW\^F^"=&\2:EHNFW6LW$%M?7!F=I;3R-(TR:33KG3;36=<FTW
M1[W7#!H-G?3ZQ<PV3?(4O%/)ZTU3I97G56;4I<E/#X2<^6$>><E&.-;M"*G*
M3M:,8N3T38'Z=45^9"?MD^$Y/B5=?!Y?CEX:'Q.LKC4+*Z\'23VD%_#JND:&
MOBC6- ;4;C28O#S^*M&\+NOB?6O!\6M2>+-'\-%O$&J:)::/'+>1O^&G[8OA
M;XR3:O;_  K^-WA_QY<:%::;J6IP: 86ECT76I;RWT/Q)91W^C6#ZWX2UVXT
M[4;?0O&>@#5?".MSV%Y#I.N7DMO*BV_$_*XP=263Y]&FH4ZDJDL)AU!4ZKM3
MJ.;QG*H5&IJG-OEFXM0<FF!^FE%?E?9_MR^"K_XHVOP6M_B_=#XGWVK^(=!T
M_P *77@+QYIAU+6/"FEW^M^(['3/$>J_#RQ\&:H^CZ/I>H:G=3:=XENK1K*U
MDGMKBX5X?-]T_P"%G^//^ACNO_ ;3_\ Y#J)^*>3TN15<JSNDYP52"J8;"TW
M.FWRJ<%/&)R@Y1FE)7BW%I-M,#[<HKXNL/B5XZFOK**3Q%=-'+>V<<BFVT_#
M1R7,4;J2+/(#(S D$$9R"#S7VC7T_#7%6!XHCC)8*ABZ"P3H1J+%1HQ<GB%5
M<>3V-:LGR^QES<SCO&U];'2_K^%O\PHHHKZ@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#\0/^"D__*23_@A3_P!G6_M0?^L<_$&OV\C_
M -7'_N+_ .@BOQ#_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\
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MO("NTDM;QX8E0& #-]NU\4?%3_D?O$/_ %UL?_378U^7^+'_ "(,#_V.*/\
MZA8\#SZBBBOY_ **** "BBB@"[IN?[1L-H!;[?9;0Q*J6^UP[0S ,54G +!6
M*@DA6(P?O+S_ !#_ - O1O\ P>WW_P SE?!VF?\ (2T[_L(6'_I9!7Z%5^V>
M$7\+/O\ KYEO_I.-'T7J_P!#&\_Q#_T"]&_\'M]_\SE'G^(?^@7HW_@]OO\
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M22V159[>XM9AC3+)3OM[J*&>,Y!($D:EEPRY5E)^W:^*/BI_R/WB'_KK8_\
MIKL:_+_%C_D08'_L<4?_ %"QX'GU%%%?S^ 4444 %%%% %W32%U&P8YPM_9,
M< LV%NX2=JJ"S-@<*H+,<!020#]Y?V[8_P#/#6?_  G/$/\ \JZ^#M,_Y"6G
M?]A"P_\ 2R"OT*K]L\(OX6??]?,M_P#2<:/HO5_H8W]NV/\ SPUG_P )SQ#_
M /*NC^W;'_GAK/\ X3GB'_Y5ULT5^R",;^W;'_GAK/\ X3GB'_Y5T?V[8_\
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MHM"\.Z]X3-[J.IS?7]% 'YC>(/V&?B'K'A[QCX6\.>._A1\+_"O[0GP*\ _
M/]I#P?X,^&&O7&A:9X6\!^&O%7@.*[_9T2\\;V,'@"\U7X9>*9?AP+3QCIGC
M'2=!LM$\(^)-)L5O-!U'1_$OI'ASX&_M)Z)^U[JWQI;Q1\ (_@[J/P]\.?!N
MV\&:?X.^)T'Q!TWX<^"O$GCGQ5X:GM_$<WCB7PFWB1[_ ,9)8ZFI\,C25L=,
M5[".&:X9$^\:* /#?@/\'Y_A!HWQ!BU378_$_B3XC?&OXO\ Q<U_7X[*:P-P
MGC[QMJ5_X1T22&XN[Z60^!?AO;>"/AW!=&X\N[M/"%M<6UO8VLD%A:^Y444
M%%%% !1110 5^;FL_LM?M"?$?]HGQ7XY^.'B[X$?$OX,ZE'X]\$^!/!__"*?
M%30O$_PI^$?CGPKJ?A'6++PI%%X]O? ]S\6_%.D:C=:?XV^+VJZ-<:S<Z!JF
MJ>$/"%EX/\)W5_H^J_I'10!^=W@;]EG]H#P(WA;Q1/\ %KX7>._'_P "/@=?
M?L^_LYS:[\-_%&A:!'X8\0:O\+KGQAXY^,G]D^/-0U?Q)\0/$FB?"7P=I#)X
M'G\'^&-,O-/UK5;72WMO%3Z+H'DG@C]@GXRZ;\*?V:])\<^*OV<_%GQ4_9'M
M/$'A+X6W5[\*_'^L?"7Q9\/O&/@_0_#GB>S^('@C7_B)<:O#XM?5M T?Q+H7
MB'1-<EL]$N='BLDTB>'4[R:W_6RB@#P_]G#X+V_[/?P7\$?"*VUN+Q GA*UU
M</J-EH=OX6T5;C7?$>L^*+O3?"OA.TO-2M?!_@G1+O7)]$\#>#K?4M2@\)>#
M].T/PY%J-^FF"[F]PHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gazyva.jpg
<TEXT>
begin 644 gazyva.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /LN@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M^_9:WC/HS\ZS#()X=.MA/?ANX]5Z=SVY'5P&4@J1D$<@CVK4^&:<79Z-=!U
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MH0!V/>L)QMJC]1R+,_:Q^IXF7O17N2;W7:YXC_9]S_SRD_[X;_"LC[?VE/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M9VKV7]HV<UJ?^6T;)^8I/:QTT*GL:L*O\LD_N/@:_MC97$ENW!B=E_)B*X]M
M#^@*<U4A"HOM13^\J*=ISZ4&OY'V?\+_ ! NMZ/$A/[VU'E..YQT;Z&NJ+NC
M\5SK"/"8J3M[M3WEVUZ'HU6?-A0 4 % &5J.B66K8^V1)*5Z%AR/QI61UT<3
M5PU_8S<;[V9F?\(7H_\ S[1_E2Y4=7]HXK_G[(0^#=&09-M& .2<4<J#^T,5
M_P _9'P)XTO ^KW7V3]W"LK*BCIA214V1[/UC$J";J.]CC6NYU/WS3LCS9XW
M%1>E61]S? +SSX=#W#,VZ5BF>R^@]JI:;'E5:DJLN>H[R[GN%,P"@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H ^1_B_X<.DZG]LC7$-V-PP.CC[V?KUKFFK.Y^OY!B_K&']A)
M^_3_ ">QY#69]<=Y\/\ Q<_A/4%D;)MY<)*O^S_>'N*N+Y6>%FF 684'%:5(
MZQ?GV/M&SO(K^%;BW8/'( 5(/K74?BE2G*C)TZBM).S3+-!D% !0 4 % 'G'
MQ.\5Q^&=)E /^DW"F.)<\_,,%OH*ENQZF"PTL345E[L=6_T/@:X!D8NW)8DD
M^YY-9GU56E;1%%;5IY%B0?,[!1]2<#^=6CPJM*US]'_ 6B?\(]H=I8L,/'$N
M_P!V/)_I5G@2WT.OH)"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?$;7=/4)#<O@>H#?SJ^9H\:IE."JN\Z6OD[%UOBKXA88-R1]%4?THYF8K),
MO^77_DS.<U#Q9JFI_P#'Q<2,/0,5'Z8I79Z-+ X;#_PJ<5ZI,YYG+G+$DGKF
MI/0VT6B[(85S03*-]#IO"7@B[\6W2PPJ5A!_>2D?*H[\^OM6D5?8^7S'$4\#
M!RFUSOX8]3[7\/Z#;>'+-+&S4*D8Y/0L>['W-="5M#\DK595YNI/=_@;5,YP
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M2^=CIHWO>]/0X]2[&;GO2T*U+J&3O2 G%(84 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 &* # H ,"@ QB@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M^A4]?TS7H+5'F[.W8^SO VO#Q!I4-P3F55"2?[X'-<$X\KL>C!W5SKZS- H
M* "@ H ^7_CC;M_:L$_\/V1$_$2SG^M=E+9KS_R.*MNGY?YG$?#RZ%IKEJ6X
M#2!2?3-:37NLSAI)'VO7GGHA0!R'B[P?:>*[8QR@+.H)CE'53[GT]JTC)P>A
MG*"DCY"USPY>Z#=-:W"-N4\$ D,.Q! [UW*2:NC@<7%V9C?9YO[C_P#?+?X5
M1-C<\-^);SPO=BYMF(P<.A^ZP[@C^1J914E9E1DX.Z/L/PMXIM?%-J+FV.&'
M$B=T;T^GH:X)1<'9GH1DI*Z.FZ5!9\C_ !8\0_VOJIMHS^ZM/W8QT+=S^M=U
M./*K]S@J2N[=CI_@MX>,LTFK2K\L7[N/(ZDC)(^E15=O=+I1^T?2-<AV'R?\
M7?#G]E:E]MB7;#=#/MO'WOSSFNVG*ZMV.&K'E=ULS6^#'B+[+=/I4IPDXW1C
M_;'7\P*56.G,BJ4K/E/IJN,[ H * *UY=QV,+W$I"I$I8D\=!G]::[">FI\1
M>+=?D\1ZC+>.?D+8C']U!T']:]",>56/-E+F=SVSX-^%?L\3:S<+AI/EA!_N
M]V'U-<]67V4=-*-O>9[U7,=04 % !0 4 >6_%C0X=2TEKEN);8AE;V[K^-;4
MW9V[F%17C?L?)=O#YTJQ=-S!<_4@?UKNV.$^Y?"VD0Z)IL-K   $!8_WF(Y/
MXUYLG=W/2BN5)(Z&I+"@ H * /"?C3H'GV\>J1+\T1V2'_9/W?R)KII.WNG+
M5CIS'BW@C6SH.K07&<1[PLGNIZ_KBNB:NFCG@^5IGT]\1=?&D:))(A^>Y41I
MZ_..OY5QPC>5NQVSERQ/D"RM7O[A((^7E<*/JQQG]<UW[:GGI7T/NG0=+71K
M&&S0 >4B@X[MCD_B:\UN[N>FERI(UZDH^4/B[XB_M/4OL41_=6GRD=B_<_D<
M5VTX\JOW.&K*[LNAJ?!CPZ;JZ?5)5_=VXV)D?QL,Y'TQ2JRLN5#I1UYCZ;KC
M.T^6?C%X=_LZ_748EQ%=#!P/XU'S9^N:[*3TMV.&K&SOW'_!SQ%]AOFTV5L1
MW(^0=A(/\0**L=+KH.E*SY>Y]1UQG:% !0 4 % 'C/QFT=KO3DO8QDVS?.?]
M@@X_(DUT4G9V.>JKJZZ'R_;3O:2K-&=KQL&!]QTKL\CBVV/M_P (Z_%XBTZ*
MZB/S!0LB]U8#!S]<9KSI1Y78]*,N971T]06% %.YT^VO"#/&DA'0L ::;6PK
M(RM0L-,TVWDNI8(@D2EC\HZ 52;>B):25['Q!J,ZW-S+*@ 5Y&( Z %CC],5
MZ"T5CS7N?1/P/L7BMKBZ/W96"C_@.<URU7JD==%639Z?XQUQ?#^ES71QOVE4
M'JS<<?3.:QBN9V-Y/E5SX@GE:>1I')+,223ZFO1VT/--FP\3:II<?D6ES+#&
M/X4.!_*I<4]T4I..B9=_X3?7/^?RX_[Z_P#K4<D>P^>7<S-2U_4-754O9Y)U
M0Y4.<X/MQ345'96)<F]V5M*OY-+NH[J(E7B<,"/;K^E#5U8$^5W1]TZ+J<>L
M64-["<K,@;\>_P"M><URNQZ2=U=&I4E!0!X/\8_%7V:)=&MVP\F&FQV7JH_'
MO732C]HY:LK>ZCQ#PGH$GB+48K-!\K,"Y[*@ZD_RKHD^57.:,>9V1]O65I'8
M0);0@+'$H50/05Y[UU/22MHBS2&% !0 4 % '$?$3_D!W/\ N_XUI#XD9S^%
MGQM8?\?,?_71/_0A7H/J><MT?>FG?\>T7^XO\J\Q[GJ+8N4AA0 4 % &3KNF
M1ZQ8S6<HRLJ$8]\9'ZU2=G=$M75CX5OK633KE[>0;7A<J1[BO16NJ/,:L['3
M^)/%\WB&TM+63(-I&5;T8\ '\!41CRMLN4N9)=CK/@_H']I:F;V09BM5S_P-
MON_EBHJ.RL:4HW=^Q]6UQ'<<]XJUI- TV:\;JB$*/5CP,?GFKBKM(B3Y4V?#
M=U</=2M,Y)9V+$GKDUZ.VAYOF:NG^)-3TJ/R;.XE@CSG:AP/Y5+BGNBE)QT3
ML7_^$WUS_G\N/^^O_K4<D>P^>7<SM1\1:CJR".]GEG13D!SD _E0HJ.RL)R;
MT;*%A>2:?<1W$1*O$P8$>HIM="4[.Z/NCP]JT>MV$-[%TE0$^QZ']:\Z2Y78
M].+NDT;-24% !0 4 4M1L(M2MI+2<;HY5*D'W_P--.VJ$U=6/B/Q5X>F\-7T
MEG," "2C=F7L1_6O1B^971YLH\KL7_!OC*Z\)7'F1?/"_$D9/!'J/<5,HJ2'
M"3@]-CZIT'QUI6OQAX9EC<]8Y"%8'OP>M<;@XG=&:EL=8)XR,AEQZY%9FAE7
M_B/3M,0O<W$:;1G&X9/T'K5*+>R)<E'=GSC\0OB7_P ) IL-.REKGYF/#2>V
M/[M=<*?+J]SCG4YM(['DUA8RZE.EM I:21@H ]2<?D.];-VU9@E?1'V_X4T)
M/#NFQ6*]5&Y_]]@"WZUY\GS.YZ45RJQX-\9_$7VNZ32XCF.W^9\'^-AC!^E=
M-*-E<YJLM>4YGX:>$(_$]ZQN@3;0KENV2>BYJYRY5IN9TX\SUV/>/^%4Z#_S
MQ/\ WT:Y?:2[G5[*/8/^%4:#_P \3_WT:/:2[A[*/8!\*=!_YXG_ +Z-'M)=
MP]E'L?./CSPU_P (QJ;VZ#$+?/%_NGMGVKKA+F5SDG'D=NAZW\%O$7FQ2:1*
M?FC_ 'D>?[O0J/QYK"K&WO(WI2^R>^5S'496MZM%HEG+>S$!8E)&>[8X'XFJ
M2N[(EOE5SX=UG5)=:O)+N8DO*Q/T&>!^ .*]%+E5D>:W=W/IKX3>%AHUC_:$
MZ@3W8!'JL?8>Q)KCJ2N[+9'92CRJ_5GKF1ZU@= 9'K0 9% "T % !0!Q'Q$_
MY =S_N_XUI#XD9S^%GQM8?\ 'S'_ -=$_P#0A7H/J><MT?>FG?\ 'M%_N+_*
MO,>YZBV+E(84 % !0 4 ?*GQAT#^SM2%]&N([L;F/;>.H_*NVD[JW8X:L;._
M<\> K<YS[)^&>@_V'H\>]=LUQ^\?Z'E1^ -<%1W9Z-./+$]#K(U/F[XT^(?-
MFCTF(_+%^\DP?XB" #].M==*/VCCJR^R<1\./":>*-0*7 /V>%=S]L^BY]ZT
MG+D6FYG3CS/78]__ .%4Z#_SQ/\ WT:Y?:2[G5[*/8/^%4:#_P \3_WT:/:2
M[A[*/84?"G01_P L3_WT:/:2[A[*/8^=OB#X7'A?4FAA!$$@WQ^P/\.?45UP
MES+S.2<>1V6QZ9\%O$7^LTB4_P#32/)Z8X*C\>:QJQ^T;4I?9/H6N4ZPH *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M/S'^\.2,>E>EBY^QKQFDG9;'S&3T'C,!4P[DX\TOBZHD_P"%=X_Y>3_WS_\
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MA^-?+SBX2<'T=C]6HU57IQK1VDDRU4'0% !0 4 % !0 4 % !0 4 % !0 4
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M_(T_'O\ R"G_ -]/YUA@?XR]&>AGW^XS_P 4?U(/ G_()/\ UTE_G5X[^/\
M)&&0_P"X?]O3.1\,?\AQ_J_\S7H8G_=H^B/G,K_Y&53U9Z?XA_Y!UQ_US/\
M2O"H?Q8>I]_F'^ZUO\#.'^&IPDX]T_\ 017JYCO#T/D>&OAK+^\CJ_%__(,E
M^E>=A?XL3Z3-O]SJ&%\/#BTD)[.:[,P_B+T/%X<TPTO\3.7\27C^(M46RM^4
M1MBCL3_$WY5W8>"PM%U9Z-JYX&95I9IC8X.CK"+Y?*_5_<>OZ=9)IUNEM$,+
M&H'^-?.5)NI)S>[9^F8>C'#4HT(*RBK'D_CGC4XCTX'_ *$M?0X+^#,_.L\T
MQE'Y'KMK_J4_W%_D*^=E\3]6?I-+^'#_  K\CQ[Q/_R'D_WHO_9J^CPW^ZR^
M9^9YG_R-8?\ ;GYB^)O^0Y']8_Y&C#?[M+YAF?\ R,Z?_;OZ'LB_<'T_I7S7
M4_3U\/R_0\8\&_\ (;?_ +;_ /H5?38S_=X_]NGY=DW_ ",JG_<3\V>D^*?^
M0;-_NUXF&_BQ]3[O-/\ =*GH>=>'[I[+1KN:/AQA1_P+BO:Q$%/$4X/8^%RZ
ML\/EV(JPT:T7ST+7@70;>_62[N5$I5MJAN@. 2?K6>.K2I-4J;LK7=CIR' T
ML3&>*KQYGS-)/[[FEX[TZVM+!6AC5&\U1D#''-88&I*56TFVK,]#/L/2HX52
MI047SI71@7?_ "+</_7<_P#H5=L/]\EZ'AUO^1+2_P ?ZG?>"O\ D%Q?4UXV
M+_C2/M<F_P!SA\S+^(4HCLHT[O)@?A@UT9>OWC?9'F\124<-&/>7Z&GX)C,>
MEQ$_Q#(K#&.]:7D>ADL7'!TV^JN<EJMU*DVI ,0$(V\]..U=]**Y:.A\]BJL
MU4QJ4GI:VNWH/O\ 23IEA!JD4KF=3&6))PP;D@C-*%7VE25"45R^];RL77PG
MU3#4L?3J2=5<C;;W3W19FU>6VO;BY!/%LA5>P9AUJ%24J<(?WW]R-IXN=*O6
MK7_Y<Q:71-K<SY+);;3UU5+AC>\2-\W7)Y7&?2M5-RJ/#N"]GJMO+<XY452P
ML<PC6?UG2;UWN]8VOV-.6YE\47<5FKM% L0DEV\%CZ5BHK"0E4M>3E:/D=\J
MD\VKT\,I.%)4U.=M&WV-#5_#D%EIEPD3.%"[^23R.WT-8TL1*=6#:6]OO.S%
MY=3H8.M&G*5DN;?JC#BT\6&A&[B=P[H#UX'TKJ<^?$>SDE9,\F&'6'RYXBG*
M7-**ZZ+T++&369K33&=EA6!9)<'EB1WJ%:A&I627-S-1\C=\^-J8? N35-4H
MSG;>5T!\SP]=RZ>CLT$T)= Q^ZW/2C3$0C5:2E&5G;J@?-EM>I@X2;I3IN44
M_LLI6VB_:-(.HM+)YZ!G0Y.%PW3KTK65;DK^Q45RNR?W'+3P?M<#]==2?M8I
MRB[[6>QZ%H%V][80SR?>92#_ ,!8K_2O'KQ5.I**V3_-)GV> JRKX:G5G\33
MO\I./Z&Q7.>D% !0!QGC;2'U*S#Q#,D!W #J01@C\J]/!552J6EM+0^7SO!O
M%X>]->_3?,EU?D<WX8\8PV%N+2]#KY7"L%+9'H?0BNW$X.52?M*.J>IX&69U
M2PU)8;&7BX:)VN_F8VL7\GB^_CAMU81K\J\'."1ECZ=ZZJ5-8*FYS?O,\S&8
MB6>8F%'#I^SB[7\GNV=3XUMQ::7# O\ RS9%'X8KS\$^:LY=[L^ASRFJ&!A2
M6T;+[C*\)^+[?3;86EVK+LR595)R#["NC$X2=6?/2U[KL>?E><4<)16'Q5XI
M:QE:]S)\0:Q)XINX[>U5O+!PH(())X+$=L"NBA16#@YU-'_6AYF88QYS7AA\
M*FX)Z>>N[[:'8^*;,:?H:VR]$"C\?_UFO,PTO:8AS[W/JLTI+#9<J*VC9'.P
M''AJ7VD/\Z[9_P"]KT/"H-?V-+_$=+\/1BR<=/WC?SKCS#2K\CV^'/\ =7;^
M9D_CW_CP'^^/YBHP'\5&_$&F#?J4O#MF;_07MAUD5E_'_(K3$2]GB5/LSGRZ
ME]9RR5%?:BT<IX4UU?#LTMO=A@C'YB 2591CI[UZ&*H/$QC4I:M(^:RK'QRJ
MI4P^*3C%O735-:;%_P 7>+(=4M_LEHK,I*LSLI7&#P,>]8X7"2HSYZFCZ([<
MVS>EC*+P^%3E&Z<IVM:W0ZCP"/\ B5[3_P ]9!^M<./TK?)'O\/ZX%+^](X5
M;D^'=;:293L#MG Y*MG!%>KR_6<.HPWM^)\BJO\ 9693J5DU!R?_ ("^J/3H
M-6M/$<,MO;%ON8.Y2O4<<&O"E1GA91E45M3[^EC*&:TZE+#R;7*T[JQYAX>U
M4^&+Z2*Y5A&<JP )(QT./3%>]7I?6J<94]UL?G^7XO\ LC$U*6)3C!MW\M=&
M;?BGQC;WMJ;6S5F\P?,S*5V@>U<F&P<Z4U.K96V7<]C,\YHXFB\/A+RON[6Y
M45-#OGTW1+B1.'+[![;N/ZUK7I^UQ,(/:U_N./ 8AX3+*U6&][+YZ&1X5U6V
MTB5[BY5WD(PN%)QZG/J:Z<51J5DH4](K<\S*L;A\#.5?$:S>WEYG>CX@6?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
8 * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>imraldi.jpg
<TEXT>
begin 644 imraldi.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M  !P<G1R0TU92TQA8B 'T  ' !H !0 I #5A8W-P05!03     !!1$)%
M                    ]M8  0    #3+4%$0D4
M                                          ID97-C    _    '1C
M<')T   !<    "MW='!T   !G    !1!,D(P   !L   H@9!,D(R   !L
MH@9!,D(Q  "CN   H@9",D$P  %%P  ".+1",D$Q  -^=  ".+1",D$R  6W
M*  ".+1G86UT  ?OW   D)%D97-C         !I5+E,N(%=E8B!#;V%T960@
M*%-73U I('8R
M                                                         '1E
M>'0     0V]P>7)I9VAT(#(P,# @061O8F4@4WES=&5M<RP@26YC+@  6%E:
M(        +5:  "\9P  DC!M9G0R      0#"0   0
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M6H)1@TB$/H4UABN'(8@7B0R* HKWB^V,XHW8CLV/PY"YD:^2I9.<E)*5B9:
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MZ*S6D"8\PZB2CVDHUZ5CD!L0!*7ABM0  (Q>@ "/Q\%0H&* 0KNUG3=P3;9
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M1<14J79F2KXHI@%6PK@]HXY&A++"HJ$U/:WXH.DB"JJ"EP0*YZE/AU\  (J
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M+X:]IFJBJH6>HHB-:(2PGMIW@H/OFV]@TX-8F%Y(^X+JE>,N!X+0E0T)48,
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MA-\;K:T=A80%$JJ;@VX  (,?@ ![6\;LD&5M9<%PCH!>_KP$C.A0 K;"BZ5
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MO*4SK2IKE:&"J<!;HYWVIKU*_YK%I/HY3I@?HL0ER)91F8P-0Y:@B/<  (
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MI+%RBN%B6ZT^B;!35:DWB*U#=*6&A_ R,:*3AYX>D*$TB"L&\9_ZA+$  (
M@ !]\+3^E 9P3["MDD!B"*QQD)=3 JABCR9#):2JCA(Q_J&=C;4>@: CC> '
M(9ZCA-(  (  @ !]G[1IF^9P"[ 2F;9AQJO)EYE2OJ>OE<1"XJ/VE((QTJ#>
ME'H>?I\NDJ<'3IUXA/$  (  @ !]:K/IH^5OV*^.H5!AD*L]GLU2AJ<;G*E"
MK*-<FW QG*!*FN(>9IY\E(T'>9QVA0X  (  @ !]-K.;K$=OT*\KJ59AA*K!
MIEU29*:"H^M"D**MHL,QE)^/G_,>=IW)E)D'H)O%A2@  (  @ !RK\5(;-YE
MI<"L;;18';PY;I])T[?L;Y4Z=;0!<($I4[$T<2T4EK'I<+@  *LI='L  (
M@ !RHL1W='!EP[^Q=(M8.KL$=-5)\;:&=4 ZEK)V=;\IC:]_=B$5%:_$=;L
M#ZGI>.<  (  @ !RH\,Z>[AEJKYR>T58)KFU>OU)UK4D>O<ZB+$#>Q(IGJWR
M>S@5;JW>>P0 HZ?3?2X  (  @ !RE<'M@MIE@+TF@?A7Y[AJ@4))J+/2@,PZ
M9J^M@)8IG*R*@) 5KZPP@,P!(:7X@,0  (  @ !R=L#2B@ME7[P'B,A7P+=%
MA[9)=;*HAMHZ4:YSAE$IGJM'ADD5[:JOAI !D:15@0\  (  @ !R4;_YD6AE
M2KL?C\M7LK9.CE1)9[&HC2(Z0:ULC%XIJ*HAC(46)ZE8BX,!\:+J@5   (
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M/XT&E)A[-XM^DL1J-8H4D/!87HC5CT9%;8?4C?$PRX<IC4T728>LC 4  (
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M2)L0<E%S/)C#<SIC)I:C=")1\)2V=0P_99,J=>DJTY)U=GH0.)3U=?(  (
M@ "/F)PA>=F!=9FZ>A)R?9=M>DUB8)53>I51/9-J>ND^RY'A>T J69$<>W$0
M!I,O>R4  (  @ ".SYK,@CV DIAN@=MQA)8M@7EAD)03@290>Y(W@.H^*I"S
M@,(IWH_B@*D/TI&2@*H  (  @ ". )FTBJA_QI=9B;EPM)4=B,=@M),'A]Y/
MUI$<APP]FX^@AGHI=X[!ACX/K9 6A7L  (  @ "-59C&DT=_%Y9XD<MP 90\
MD$!@"I(?CKI/,Y SC6 ])8Z?C&HI(HVVC%T/BX[ B9$  (  @ ",QI@8F_=^
MFI7/F?AO@I.)E]1?>I%@E;E.GH]UD_$\I8WBDLTHSXS8DL4/:8V=BFL  (
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M/Z.(>*)G(J"3>.57[YW2>3U'L)M4>: V )EG>?XAZYC,>A4(G9EG>J<  (
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MPY\;GKED?IP7G&U549DLFCA%4):5F*8T%Y2.F&$@QI-OE7\(Z)( A@8  (
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MZ:Q]?A9;=ZCS?=U--*64?<,]QZ*9?<8LT*!J?=$8YZ!:?;P"K)OZ?J\  (
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MM*B^HQE:+J3\H-!+N*%=GLD\>YXIG?,KZYN^FY,8T9KRD,@#K)6,@GP  (
M@ !J,K\#9K1=SKM : Y0X[>6:7!#([0%:L8T*K#H:_0C'Z\^;*(.(;%(:^,
M )\$<[   (  @ !I[;X];C)=S[HY;MA0];9";YQ#1;)W<&XT6Z\N<3$C<ZU*
M<9P.M:[H<.8  )W >"D  (  @ !IS;SG=61=G;C:=8!0U;3/=;A#)K#M=ADT
M4:V0=GPCD:N(=JX/'*S(=B8  )R)?"(  (  @ !IJ+MR?&M=8;=F?!Y0A[-=
M>^E"\J]W>]XT+:P4>_ CDZGR>_@/9ZKB>]@  )MH?Z$  (  @ !I>KHQ@W]=
M-;8C@MI05K(5@DM"M*XK@=<T%*JW@9HCE*B%@9X/J:DP@:X  )IL@    (
M@ !I3KD\BKM='K4<B<E01+$ B-Q"GJT-B! S_*F1AY(CG:<ZA\ /YJ>KAK@
M )F0@    (  @ !I*;A_D?Y=%+1'D,A0/[ 8CX)"E*P;CFPS\:B;C>$CIZ8R
MCD40(J99BND  )C?@    (  @ !I#;?SF5E=%[.>E^901*]9EE5"DJM-E0@S
MY*?'E+8CG*5>D\P0/Z59BOP  )A(@    (  @ !H^K>/H.M=([,3GTE04:ZU
MG7Q"EJJ;G"4SZ:<+FVXCL:24F"(05J2#BPP  )>R@    (  @ #-4&QM9D2Y
MYVXP:'6ETV_8:I"0X'%C;)1[#G+?;HUD571/<'U,;'6D<E QK7:I<]8-QW@Q
M<[;+7&GN<52X6&OG<F>D;6VV<W>/GV]G=(9YXW$&=9=C/G*6=J5+87/Z=YLP
ML73<>%4,YG9T=^7)B&?)?&"VD6G<?%RBX6O+?%^.)FV9?'UXD6]6?*IB$G#_
M?-Y*67)O?00OQG,K?00,(73N?(/'NV7BAU"TPF@*AE"A&VH+A6",FFORA(=W
M*FW-@]-@VV^,@R])5'$%@HTNZ7&9@>L+=G.;@+C&&&1&DC2S*69\D%2?@VB-
MCGZ+#VJ#C+MUUVQNBQ=?LFY#B:)(8&_"B$$N'G KAQ\*Y')XA%+$Q6, G2&Q
MW64_FG">.&=5E[6)RFE3E0ITIFM'DH5>I6TAD#-'@FZFCBDM:6[FC,4*:'&$
MAPG#MF']J!.PU&1 I)>=*F95H/J(NVA4G6MSJ6I2FA-=R&PSEO]&QVVQE%0L
MTFW+DO,* G"YAL3"[6$\LPFP#6-_KL2<4V6-JDR'VV>%I=MRRFF$H;A<_VMM
MG@5&)&SJFOTL3VS9F%P)KW 4AHS":F"[O?ZOA6+ZN.>;LF3XLY.')6;BKDYR
M%VC:J7-<76K"I3Y%BVPWHCXKQFP G*@);7 2AE^^KW2.96"M!'6"9[Z:;'9Q
M:>^&OG=::_UR#WA";?M<6GDL;^Y%4WH/<;LK WK?<QD'@'T6<WV]1G(];_"K
MZ7-F<3N96G1U<G"%MG5V<YAQ#G9S=+U;:G=Q==]$=GA==N0J.'D%=Y &]7M;
M>!2[P' N>FNJ/G%R>K:7TW*:>OF$/W.V>T)OP73/>Y5:1'7D>^Q#<W;6?#(I
M6'=.?#\&>GG6?&RZ*6Y=A,JHFF^RA#.6,7#L@Y:"UW(;@OYN>'-/@H!9)W1X
M@@Y"A75N@9\HD76W@2X&#WB%@#&XKFS1CRFG)VXRC<.4OV]\C%"!;'"XBM]M
M1G'WB818&G,TB%)!J'0MASLGWG1$AGD%M'=D@VRW>&N6F9JE]&S_EVV3CVY-
ME2. 0V^1DMIL,'#9D*]7*7(6CK= XG,3C1(G/G+[C%8%9W;>@Z>V@FJ;I!2D
M_&P(H222DFU4G@5_26Z:FN9K1V_KE_E68'$NE59 /G(?DS@FO''>DB,%)W=*
M@WRURVG?KI>D/FM,JN>1Q6R1IOA^=FW/HP9J=V\BGV%5HW!NG#<_IG%=F?,F
M27#JEN($]'>A@UFU5FEBN22CN&K)M+>1(VO^K_A]QFTOJSYISVYZIO)5#V_%
MHV<_&'"NH0TEQW 5F8L$RG?G@SVP<'S_9*R@37T=9QV/$7U4:5=\EGV<:V=H
M_GWQ;6541'Y6;U,^$7[5<0\D '^K<B8!]X%G= &O4WK1;J"?,WLG<!.-WWMZ
M<6A[=7O5<JEG\WPZ<^-34WRO=10].'TL=ATC0WW)=I\!MG^N>'&N'7C5>)&=
MX'E->1F,OGFV>9%Z2WHF>@!FY'J<>G929GL?>NT\<'N=>TPBG'P">U0!?7XK
M?%>LN'<0@F><<W>8@B6+-W@6@<]X^GB6@7)EKGDG@2916GF\@.4[CWHZ@*,A
MYGID@%8!2WW1?[JK9G67C$";('8JBT")Y7:TBB5WL7<_B0!DG'?7A^M09GA]
MAOLZQWCZABLA27CHA<P!('X8@,.J3W1IEC*:"74#E'B(T761DI9VI'8CD*EC
MH7;!CM9/DG=CC3<Z&7??B_D@OW>8B[8 _7Y5@*NI<'-XH"^9)707G;Z'ZG2C
MFQ9UP74UF&5BS'7:E>).VW: D[$YBG;KDB@@479SD,P WWZ'@)>HRG+!JCF8
M<W-BIQ:'*W/HHZQT_W1RH#EB#G48G1-.*W7'FG@X_78LF1 ?[W5ZE/0 QWZP
M@(:H7')$M%B7\'+BL(J&CW-;K&)T6G/7J#AA<W1VI(%-I74BH; X?'6#GX8?
M=W2HE48 M'[1@'FB?X7%9!F3H(469HF#EX2<:,)R/X1':M%?N(0+;,I+\8/R
M;JPV@80@<$@<985A<.8  (!,=KJAF(.X;8.2IX-%;PF"@(+H<&UQ-8*?<;Y>
MPX)K<P1+%X):=#LUP()]=3@;R(-O=68  (  >KF@BX'9=M619H&(=XN!78$[
M>"MP$H$#>,!=P(#>>55*.(#7>>0U!8#S>D\;-X&:>BP  (  ?CJ?9H 9@"60
M,W_=@"* %W^G@ -O$W]Y?]Y<VW]D?\))@']F?ZTT>']^?Y0:RG_A?U<  (
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M.7MBK&Y[_'LAJ-EJWGKDI3Q8_GK2HAU&&7K@H!HQKWK&G9\8N'GRD+<  (
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M#X=3AE=S_(9KA<-C]862A1U2]839A(% G(1<A PL6X0@@[\2=X3H@X8  (
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M:9:895EL1)3C9WA<X9-D:7),29(/:TTZ-I$@;/4EV9$X;@$+/).5;70  (
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M<H^HB^]H/XX/BO19&(R)B>M)!HLNB/TWG(HEB%LCZXG B&L*V8EGAA0  (
M@ "#)I!TE41U\8[=D_!GO(T[DF)8AHNHD,5(:XI-CV@W%(E"CI@CGHBRCL8*
MQH@=ATD  (  @ ""L8_6G<YU=HY"G 5G.HR7F>]8!(KVE\Q'ZHF3EAHVCXB,
ME6LC-(?IE!4*MH<0ASX  (  @ ""6H]DIH1U%HW.I%MFRXP7H<=7D8IGGR]'
MA(CWG5(V/(?EG' B[H<YEYX*E89&AR@  (  @ !ZD**E8G!N$Z F9)5@JYWN
M9J!2()OG:(I"6)H>:DXPXIC^:\,<@9G!;#\#WYBA;+X  (  ?]!Y_*%!:GMM
MH)[,:^)@-)Q_;4%1N9I=;I5" 9B ;](PHY=*<-0<9I?/<0<$()80<=(  (
M@ !Y:Y^B<EAL[IU"<R%?G9KT<^91(9C1=*Q!@I;R=6@P1)6Q=?X<-I8%=?L$
M4I/%=TT  (  @ !XQ)X0>AUL,IN[>F%>S9EX>IQ0?)=8>MQ [)6!>QTOTY0\
M>T\;]Y1G>S$$=)' ?$P  (  @ !X&YR_@>]KB)IR@;E>'I@U@79/R)83@2U
M:)0T@/@O9)+O@-P;M9+U@-@$CH_]@)T  (  @ !WAINZB=]J^IESB3A=DY<P
MB'5/.I4)AZT_XI,BAP<O&9&YAK$;CY&=AQ8$J(YV@R8  (  @ !W$9K=D==J
M@)B>D,1=%998CX9.NI0KCD@_;9) C4XNQ)#*C/0;AI!EC*0$QXTI@SL  (
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M.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y<[HG&YYR="X2DJ 3<Y@  )6@>#   (
M@ !LH:CJ> A@KZ8#>%-3_:,L>)Q&:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4
M )0P?&,  (  @ !L**>0?VQ@.*2O?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP
M?O(2DIR&?N,  )+H@    (  @ !KO::'AO)?V:.EAG=3):#'A>1%A9X+A5 V
MV)NKA.4F;YHHA-42DIL#A+@  )'&@    (  @ !K9*6WCGU?D:+2C:]2WY_G
MC+)%.IT>B[LVAIJ\BQLF.YDEBTH2I9FHB:$  )#;@    (  @ !K)*4/EA!?
M5*(FE/52G)\SDY]$\YQ?DEDV0)GTD;,EZ9AAD;P2@IBMC(,  ) G@    (
M@ !J\*2AG>-?5J&DG*A2F9Z8FO=$V)NBF58V,YD7F,\E_)=JEN<2JI>IC)X
M"X^*@ @  (  @ !AL[A\8(E5]+5\8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$
M9[@(7*ZD9VL  )-8<M@  (  @ !A,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8M
MY:N?;&0<\*L*;+H(\:P);&D  )(7=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R
M<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)7*FE<9T  )#A>X   (  @ !@JK1D==A5
M);$:=AE(_:W0=F$\!*JK=KHMJJ@@=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (
M@ !@:++U?-)4Z:^L?+](OJQ=?*T[N:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D
M ([!@    (  @ !@+K':@_%4QZZ!@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00
M@J *)Z/,@CD  (WC@    (  @ !?_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M
M7:0QB+8=*Z+>B2 *9:)*AH@  (TS@    (  @ !?V;!7DD94LJS+D7Y(F*E(
MD'8[A:7YCXDM2Z-!CV4=&*'LCKP*?*$?AQ<  (R<@    (  @ !?P:_=F:!4
MNZPLF+U(HZB1EX$[AZ4TEH0M4J)MEBT=,Z$!DTX*DJ BAR8  (P @    (
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M6G54:HZ% 78E;&ESBW;V;B=@[G?+;]5-(GBC<6PWPWEF<L<>*'G8<U$  (
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M/&S(ET=_%&WNE3]M\&\+DR=;[G ND31(W'$WCX@T67'%CG$;D'!=C5@  (
M@ "=Q&J6HM..BFOCH%=^6&T%G9%M-6X=FKQ;-F]"F"M(,'!2EADST7#4E1\;
M.F\UD7H  (  @ "=5&GQK)>."&L]J7)]P6Q4I?)LEVU?HFM:I6Y]GTU'M6^*
MG0,S5F__FW@:Q&Y'DAD  (  @ "84'^77EJ*27]P849[&']X8_AJEG^>9G98
MV'_7:-5%QH N:PTPY8"^;-X6M8(];30  (  =ER74WT;9YB)1GTY::1Z 7UD
M:X=ID7V<;4U7[7WC;OY$^WY!<(\P.7Z]<<D6-G^S<;L  (  >F>6.7K7<+Z(
M 7L@<@%XY7MB<R=H>'NP=#=6^GP(=3I$+WQP=BDOEWS;=M@5Q7U(=H4  (
M??.5!7C$>>>&O'DJ>G)WEWF%>MMG>7GA>SE6$'I.>XY#<7K >]PO"7L;? H5
M9GL=>Z8  (  @ "3TW<'@PZ%KG=_@O-VA'?J@K!F37A2@E)5'WC'@?M"EGE(
M@;0N5WF2@784Z7E-@5,  (  @ "2U'6DC$N$J78FBX=UA':7BI%E6'<&B8-4
M.G=^B(-!X'?VAZXMQG@PART4@7?&AJ8  (  @ "2!W2"E8F#VW4,E"-TMW5]
MDGQDD77ND,%3?79LCRE!07;BC>$M6G;\C5,4.79^BQ8  (  @ "1:G.@GLR#
M-W0PG,IT"W2>FGACYW4(F!-2UW6&E?- H78 E&8LVG8'D_X3]75WC7X  (
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M^H'%>)=LN(%X>2I=A($R>:A- ($->AX[(X$'>H$G+($R>JL-9H'1>ET  (
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M='Q@H:QI+WP3GSA9]GN\G+%)UGN'FJPX=GMKF> E)GL,ER,,BGM?B'H  (
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M>(E8?D1A&8AK?F12L(>.?FI#48;+?FTR-H9G?G<>G8:,?F,&C(7&?J\  (
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M\9GW7T)9.YA@8;1+3I;\8_L\"I7:9@<JXI5]9YX6+I>%9\<  ),-:;\  (
M?TIP]YH.9(QE9YA'9F]8M):B:$!*X94C:?@[MI/J:X,JKY-N;*L6,)47;)0
M+Y"^;K8  (  @ !P3Y@3;$)DHI9J;8Y8#I3+;LQ*/Y--;_L[-)(1<0DJ5I&"
M<<H6%9+<<84 <XYP=#,  (  @ !ODY8Q<^-CT926=*U7*Y,'=65)C9&/=A(Z
MF9!;=J@IY8_!=PD5WI#9=JT HHQK>40  (  @ !NUY2;>Y!C%Y,,>^)6<9&"
M?!U(T) )?$,Z$H[/?&<I=8XQ?'P5G(\.?#H PXJJ?:8  (  @ !N,I-;@UIB
M?)'6@SY5W)!(@OM(.X[*@J$YA(V&@E8I,(R^@C<5=HUD@F@ X(DG@)<  (
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MIJ*.9/%-DZ!M9K! ;)Y[:%8QTIS_:;\@\YS5:HH,3Y[Z:?T  (O[<LP  (
M@ !D*Z+H:G59#*"X:[A-&9Z4;/$_^)R:;AXQ?YL1;QH@T)K!;Y4,?9QL;P8
M (I[=Z(  (  @ !CG:$'<:M8:Y[B<GI,:)S)<SP_=9K1<_4Q$9E(=(T@D)C>
M=,,,CIH9=%4  (D4>^4  (  @ !C#I]N>/!7X9U3>5A+WIL[>:T^XYD_>>PP
MM)>I>B<@39<M>C$,CI@!>BH  (?1?YP  (  @ !BD)XL@%97<9P6@&%+=9GX
M@$@^?)?S@!HP599.?_H@)96B?_@,E98>@!$  (:T@    (  @ !B)ITMA[]7
M&9L8AWE+))CPAO@^*);<AF8O^I4RA@X?YI1MAD0,K)1TA0T  (7.@    (
M@ !AU9Q>CRM6S)I*CIM*TY@<C;X]V)7]C-LOKI1$C'8?BY-^C*\,B9,EB'H
M (4A@    (  @ !AE9O+ELU6OYFNEB1*Q9=LE.\]O94HDZPOJY-*DV<?L9);
MD>\,OY'LB)\  (2<@    (  @ !9([&M6F1.&J]27(U"9*T97JHUG*L88)XG
M+*GC8B,5DZMA8F@#1:FV8UH  (CG<?T  (  @ !8<+!G87U-NJWB8QM"(ZMJ
M9+DU?ZDN9CHG.J>]9V 5ZJC/9W #TJ:_:%$  (>@=K(  (  @ !8"*Z2:&A-
M2JP+:9!!T*F):K0U.*<X:\XG&*6L;)H6"J9S;'P$.:/S;7@  (9G>MT  (
M@ !7KJRG;SI,WZHF;_U!5Z>H<+DTYZ55<6TFWZ.\<>P6"J1.<:L$A*%<<OP
M (5!?HH  (  @ !74JK]=AQ,BJB"=HI!!*7_=NHTBJ.F=S,FNJ'U=VT6":)=
M=RD$PI\&>.$  (0^@    (  @ !6_ZFM?2-,4*<J?4I U:2=?4XT7J(W?3\F
MDJ!T?3,6&Z"7?18$_YSO?A8  (->@    (  @ !6NJB@A"U,*:82A!9 N:-U
M@\<T0:$"@VPF=)\T@T<6'9\M@X<%/ILA@GH  (*M@    (  @ !6A:?2BT-,
M$Z4RBOU JJ*#BF<T,I_^B<\F79XAB<H5_YX1B38%39FK@Y8  ((6@    (
M@ !68J<TDGY,#*1ZDB) IZ&ZD54T+I\CD*0F9YTOD)D6)ISVC>0%:IAP@ZD
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MU7',7&!]9W+Q7Y!LO'0;8HQ:X75$961'P79G:!,R\G=H:F 97G?-:UH  (
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M3&7?B IW)F>FAU9F]VE3AHQ5UFKMA<Q#?VQ.A2LOB&SGA+\6Z6QRA,   (
M@ "3CV)BDA*%961FD-AV1F8VCV9F(6?MC>)5#6F2C'U"UFKTBU8O%6MJBJP6
MG6LCB<<  (  @ "2WF$NFXF$LF,[F:%UCF4.EW5E;F;#E3I47FAMDSU"+VG2
MD;(NDVHND2465FH5C>4  (  @ "29F!-I/.$+F)=HF=T^V0IGX1DV676G)Q3
MV&=ZFA=!P6C9F%,N(FD8EV 5Y6E,CLX  (  @ ".?'CG6+&!)WE27 ERMWGA
M7RAB_GJ$8A-2 7LQ9-0_G7OO9UXK/'S%:5L0WGY0:6   (  =@F-4G7A8;J
M$':99$!QG'=29IMA_7@/:--1'WC/:NL^W7F5;-,JGWI';D 0B'N%;?8  (
M>A^,'7,;:K5^O70);'EP>W3C;AU@Y76[;Z)0,G:/<1(^&G==<ETJ"W?M<T40
M/7D0<LL  (  ?;6*U7"3<[)]:W&H=,!O*7*A=:U?Z'.-=H=/3W1Z=TL]9W5/
M=_LICG6]>&D0 W;L=_   (  @ ")DVYK?*Y\4&^9?19N"W"I?5=>N'&E?7I.
M77*>?9H\BG-]?;HHW7/&?<,/H74E?9X  (  @ "(B6RDA;9[1VWCA7IM#F[_
MA0Q=QW )A()-?W$'@_\[XW';@YDH6W'_@V4/6G.A@OH  (  @ "'LFLLCKIZ
M=6QYC=YL06V<C,-= FZKBY%,QF^PBGL[2'!^B:8G^G!PB6D/+G)9AW   (
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M.7Q6:REES7R7;-A7&7S<;F9',GTM;]@UOGV6<1,AYGX8<;8(Q7^&<9L  (
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MSG/[DN!A<W1SD7]3$W35D 1#HW4YCLPRRW5ZCBL?W'3@C@T(8W?.A:L  (
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MH8,(<1E9]H+'<CA,2H*,<SX]-()P=",L;8*.=,H8G(,V=+("78,*=LT  (
M@ !Q?8%"=^!EN8$=>)%9#H#J>2)+78"W>9@\F8"3>?PKZ("I>D(82(#_>A,"
M;H%$>\   (  @ !PIG^0?_)D[W]_@"-84G]5@"=*M7\A@ P\!W[X?_ KLW[I
M?^48,W[S?^@"C7^]?_@  (  @ !O]GXYB MD87XZA\97SWX-ASU**WW*AI0[
M<GV;A@LK*7U]A=07]WTJAAT"EGYV@<   (  @ !O:7TFD"1CUWTOCW)717T
MCF=)JGRUC3PZ]7Q\C& JI'Q1C#P7D'NTBUL"GWUJ@<8  (  @ !N_7Q3F$MC
M:GQ@ET)6TWPLE;]).WO6E"(ZEWN-DQ(J6WM)DO\747IUCX\"D'R@@;P  (
M@ !I Y1_5PI=T)-(6?=1KI)57,5$49&57V(U>9$E8; D<I&B8U4/3Y2,8R<
M (@):9H  (  ?M1H'9(C7JA='Y$48/U1"9 A8SA#S(]194XU%X[,9Q\D/H\<
M:%L/:9%M9_H  (8B;F0  (  @ !G48^V9C=<0([,9_U04(WG::U#'(T;:STT
MC8R1;)4CXHS";6X/7HZ";.D  (1><Z<  (  @ !F?HUQ;;Q;7HR>;O]/8HO)
M<"I"98L%<3PS[(J <B C;XJ8<IT/-XO/<@X  (*\>)H  (  @ !EKXM]=4Q:
MEHJ\=A5.FXGQ=L)!GHDN=U S9HB?=\@C XBB=_T/#(E3=Y0  (%.?.4  (
M@ !D]XGB?/!9[HDP?4M. (AG?7M!"8>??8TRWH<$?9DBV8;,?:,/"__B?1!)
M0T-?4%)/1DE,10 "$H<2?;4  ( ;@    (  @ !D6HB(A(M94H?FA'=-:(<@
MA"] =H94@] R6H6P@XHB@(58@XD/,X4A@T<  (  @    (  @ !CWH> C$59
M#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (  @    (
M@ !C?(:QE!E8K88ADWQ,RX5-DE,_X81/D08QXX-SD&XB H+MD"H.VX)=B@L
M (  @    (  @ !<X)[Q5=]20IU96)]&P)P(6T4Y^9K[7;@KB9I]7[X:29O-
M8+@&A)Q*800  (.C;4D  (  @ !<!IS=71U1K)M97U5&-YGT87DYE9C 8W(K
M49@490P:4)D19;0&WYC=9>,  ((0<C$  (  @ !;7YJ%9$-0]9D;9?Q%GY>]
M9Z(Y!9:$:28JZI7%:E8:)I:':K4'%Y6<:N0  ("7=Q0  (  @ !:MIA :UI0
M.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (  >V4  (
M@ !:#)9,<H%/DI4$<UM$,).W=!PWQI)\=+<J I&K=2T9E)(<=2$',9 J==X
M (  ?RX  (  @ !9<Y2W><A/!I-]>D-#L9(N>I4W49#I>L,IF) $>M\9<9 M
M>LP'.XWX>]$  (  @    (  @ !8\)-K@1-.EI(^@3M#3)#J@2,V[8^7@.PI
M+HZE@,X9((ZI@.L'4(P<@.   (  @    (  @ !8B))<B&!.+Y$ZB#M"YX_F
MA\0VD(Z&AS8HW(U^AP88MXUSAT<'*XJCA-D  (  @    (  @ !8-Y&.C^5.
M"9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (  @    (
M@ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@  * (8'P
M (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M8BL.QZ6R
M8@<  )UL914  (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N$:%^9GD@
M$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9:=XYI*"V
M:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.2Z(+;W%$
M*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (  @    (
M@ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX <9/:>E0
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M7F"Q8&1]VF,G8S5M0F5^9>9;A&>W:'=(DFFV:N0T%VL#;0$;9VI-;B   (
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M/U,&C5]W0U9/C"MG/UE:BO)60EPKB=1$*UYNB.8PJ5\4B%(8_&!-B$D  (
M@ "3@4VXF!J%>U%MED1VB%3%E$EFD5?;DE)5G5JWD)-#C%SZCRTP+%UXCGP8
MN5\YC.T  (  @ "2]$QWH9>$[5 WGP1U]U.3G$1F!U:KF9E5)5F(ETE#+%O&
ME8TOR5P3E/L865YFD'8  (  @ "16&FL4V*#GFM,5R]T\VSP6LQE&VZ07C=4
M$' C87A!K'&89( M=7*E9PD3T7/&9\<  (  <>2/RF7#7+Z"4V? 7[=SMFFA
M8HED VMO93=3&6TG9\! V&ZN:AHLQV^2; (387#G;%(  (  =I6.2V(J9B"
MW61R:$ERCV:,:E=BZ&B!;$-2*6I6;A= %FOK;\4L.6RE<143$FY=<0\  (
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M,5CMDR=M$5N5D8Y=[%X"C^I-OV VCGL\6V'.C7$I;V%NC4D1@F:JBF(  (
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M<&D,;S=G &JV<*%8E6Q <?)(O6VN<R(W?6[,="LD%V[A=,L+3G->=+,  (
M@ !_NF1R=H!S2&9S=V-EW&@^>")78&G=>,%'SVM:>50VI&QX>=,C;6PY>A4+
M"G&;>F4  (  @ !^H&(=?UER-V0Y?YIDW&8;?ZU6<&?0?Z-&]&E4?Y@V!FI?
M?Y@B]VG*?Z,*WW 8?\<  (  @ !]O& HB"9Q7F):A\ID#V1,AS15KF8-AH9&
M/6>8A>LU<&B3A8(BI&>DA8H*RV[/A$,  (  @ !]"EZ1D.5PLV#4C_9C9&+0
MCKM5#&24C6M%GV8>C% TU&<*BZ4B+F78B^D*LVWJASP  (  @ !\BUU7F9)P
M,E^HF"!BVV&EEDI4A&-DE&%%*63EDM8T>&6^DALAR61BD5$*:VYDAPL  (
M@ !X_7GN4OYM!'IB5H]@#7L 6?91UWNP72E"1WQH8!\P_WU!8JX<XGYL9",$
MA(#I9.T  (  >2!WLW9@6TAK]7<H7B]?#G?R8.]0_WBX8X5!E'E]9>8P='I'
M9^H<B'L%:/$$FWXI:;(  (  ?,!V?7,-8Y=JL'079=1=_'4)9_-/_'7J:>M
MN7:_:[@OQ7=];34<$'?+;=8$G'O%;KD  (  ?^]U1' %:]]I<W$Z;7U<NG)/
M;OY/$'-%<& _XG0N<9HO(73?<I8;IG2Z<N($GWFQ="@  (  @ !T$VU7=#=H
M2VZP=3I;HF_>=AU.!7#G=MX_/''6=XPNF7)[>!(;6''N>"($K7@9>;,  (
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M@H+-5>=52(+T62Q'RX,Y7#TXUH.A7P$GV81X82P2](:[894  (,Z9:X  (
M? -KEG^$6DY@D'_!72%49H '7]!'$(!58E,X0X"Y9) G=(%K9D02UX+[9E\
M ($):F(  (  ?S9JA'Q38B-?;WS+9%Y3=GTR9GQ&+GV0:&XWBWWX:B<FZGZ*
M:V<2E'^):S\  (  ;WH  (  @ !I;7EF:?A>3GH$:Z%247J%;2U%2WKW;I@V
MOWMH;\XF3'O;<*$2.7R/<$@  (  =/X  (  @ !H8W;5<=-=5'>0<O5177@E
M<_5$47BB=-$V(WD+=8TER'E@=@,1]7GX=9X  (  >>(  (  @ !G<W2@><5<
M<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (  ?@D  (
M@ !FKG+(@;-;RW.]@=M/]G1K@<5#"W3C@8PTZ74Y@6,D]W4O@601J77:@8D
M (  @    (  @ !F$G%)B9I;-')-B55/8G,!B+U"@G-TB 4T9W.[AXLD<G.)
MAYL12W1JAL$  (  @    (  @ !EF' 6D89:OG$HD.I.ZW'@C]M"$W)+CK,T
M"W)^C@(D+W(ACC81$7,_BO   (  @    (  @ !@IHQO49A6!XOM5-Q*=XNI
M5_T]G(N56N0O&HO7764>"(TI7OH)@(YJ7RD  (  :6D  (  ?G!?CXE26/Y5
M*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (  ;BD  (
M@ !>GX9!8&-4+88Q8IA(UX879*\\+X8$9I8N!88D:"D=8H;U:/T)HX=1:.L
M (  <V0  (  @ !=L(-H9\E3,H-W:7I'U8-Q:PT[9X-J;'HM58.);9P<XX0D
M;A@)AH1G;@P  (  >%L  (  @ !<QH#H;SU23H$2<'%&]($<<84ZBX$5<F\L
MP($G<RT<9X&.<V,)88'C<XH  (  ?*P  (  @ !;]'['=L11B'\*=X5&/7\?
M>!PYW7\7>(XL(W\4>.(<)7\H>/$)6G^T>9D  (  @    (  @ !;/'SP?CU0
MUWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (  @    (
M@ !:K'MYA<M0='OYA<Y%1GP;A7@Y!GOQA/TK;WNVA,,;C7M:A1L)4GQ<@]\
M (  @    (  @ !:.WI*C6Q0!7K7C2M$V7K_C&TXIWK-BY(K)WIUBT@;8GG9
MBS()3'LJADD  (  @    (  @ !4I9;<4#U*C)7Q4U4_B95/5DHS)I4"6/HD
MSY5W6Q82[YA26Z@!@I2E78T  (  ;10  (  @ !3GI/]5S])O)-$6> ^Q9*G
M7%TRB))$7ILD9Y*(8$\2V)3G8)D!U)$*8FD  (  <?@  (  @ !2RY$,7C](
MW)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (  =N0  (
M@ !2 (Y"94!(!HW(9O$]*(U+:($Q+XSI:>$C5(T!:M 22HZ3:IT"'XKP;*0
M (  >SP  (  @ !1.8O(;%5'1(MI;98\:XKW;K4P=(J/;YXBXXJ*<#T1_HN^
M;^8"+8AX<EH  (  ?P8  (  @ !0@HFK<X!&F8EG=%P[THC]=0TOZHB,=8\B
M:8AH==<1XHD?=8@"1895>$H  (  @    (  @ !/XH?B>JE&#(>X>RT[6(=4
M>W4O@(;5>Y<B!(:3>Z81J(;E>XL"<(2"?5<  (  @    (  @ !/8(9C@<1%
MB(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (  @    (
M@ !.^(4TB3-%6H5&B4 ZN83SB+TO$(0XB!0A[8.#B!H1Y(,=AR0"UX&T@>P
M (  @    (  @ !(6*)Q3E\^WZ$\44(T::!G4_8H6: H5DX9PZ%S5[\(HZ,;
M6&4  )&47^0  (  <'H  (  @ !'1Y_F5/X]^)[L5W<S>)X:6<4GCYVO6[P9
M19ZA7-@(IY]S75D  ([<9'X  (  =5$  (  @ !&FYT-6YT]-)PM7:PRPIMO
M7XXFVYKY8208PYN]8>H(EYO.8E   (Q#:5$  (  >:D  (  @ !&!YH\8CH\
MA)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (  ?8   (
M@ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\  (?&="\
M (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0 <= (DI(I
M<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D^)(!=[P7
M:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V?>TP,I%/
M??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#@)$$A,8Z
M)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (  @    (
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M0UUA4B!V6U_]5CEF?6**6B]5@63Y7?M#/6<788\O3VA 9+$6JFEU9E0  (
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MA$FX?DUO>DW$?G)@9E%V?HQ03E2_?JD^]%<=?M0K]5; ?PD4AUYD?U@  (
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M2%^+6G=K8V'^7;9<>V118--,669R8\,ZS&@I9G4G0FB':)0.0VX1:/\  (
M=FB$;EAB8$9WM%M;8M]J+5X<96-;7&"C9\5+:6+H:@,Z"V2A; TFN622;9D.
M$VN';<4  (  >HN"NU0P:6EV%U=Y:T)HE5IT;0M:%%TP;KI*/U^@<$HY%&%5
M<;0E^6#(<KT-N&EX<L\  (  ?B.!,E!K<HATJE/T<ZIG05<I=+E8U%H/=;))
M7%R?=ITX3%Y+=W$E9UV#> D-?FDQ>#H  (  @ !_ZTTA>Z=S@%#A?!=F-E1'
M?&]7WU=6?+5(>UGV?/DWLEN0?4,D]EK,?8D-4FE\?@D  (  @ !^X4I-A+1R
MCDX\A'AE6U'*A!E7&%3X@[!'P%>E@UDW&5DF@RDDIEB1@T0-/&FA@Q,  (
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M%V*F8<E@263:9$Y2-V;:9J]"\6B9:.0R$&G*:LX>NFE-:_<'#705;*4  (
M?5)WDEPN9]-KFE[::;Y>Y&%$:Y=1.V-R;5A"%V5+;NLQ;69E<$4>6&7><0$'
M#G03<<X  (  @ !V(UB'<'AJ7EMO<;U=M5X)<NU0 F!4= %!+6)!=0 PFF,[
M==8=N&+[=CT&YW15=X0  (  @ !T\U53>2%I0EAI><=<L%LK>DY/$5V6>KQ
M5%^)>R(P!V!8>X,=3V")>[L&UG1R?.H  (  @ !S_5*1@;EH8%7/@<9;X5BQ
M@:9.4%LR@7,_H%TF@4\O=5W$@4L=#%Y^@8@&V'1O@6D  (  @ !S/5!#BCEG
MKU.CB;E;-E:>B/A-LUDJB"<_!UL6AX8NWEM\AT$<G5SDA\4&TW1XA)T  (
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M^&;$:!)4XFB<:?='WFHV:[TY1FN$;4TH\&P1;H(576UN;JD \WYE<98  (
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MQ5H CC-0]UQ>C39$(EXRC"(V(%\_BVHF9UYABXD3L&0XB?,!#WXU@+@  (
M@ !DXWH,35I9W'JX4/A.!WN(5()! WQD5]TR='U,6MLAE'Z 70T,S("@77@
M (  99T  (  >[1C177"5-]8J';!6 ),_7>Z6P5 *GBD7=@QR'F"8%,A''IG
M8A$,M'RL8CT  (  :D@  (  ?O1A\7&G7(-777+N7Q=+[G0289 _+W4/8]<P
M^G7F9= @@79X9QX,?'E!9QH  (  ;U8  (  @ !@L&W59#)6&V]19C1*L'"7
M:!T^-W&L:=\P'G)^:UD?U7*S;#\,,'98;"   (  =-$  (  @ !?A&I<:^A5
M VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (  >;(  (
M@ !>=F=&<[)4!FD9=*1(OFJ<=70\:FO'=B(NSVQT=K ? VO;=OT+]'&9=Q\
M (  ?=,  (  @ !=F&23>WA32V:5>_-(&V@S?#H[TFE??&(N,VGH?(L>>FD=
M?*P+UV_"?3T  (  @    (  @ !<YV)*@S)2I&1M@T%'?68A@P<[0V=,@K,M
MJV>S@HH=[&;J@K<+BFY<@GL  (  @    (  @ !<8F!MBNQ2)F*JBJ5&_V1N
MB?4ZS&65B2TM2V78B,P=J&4FB2H+66T^AJH  (  @    (  @ !8\X-<3&!.
MJX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (  :34  (
M?AI7>'].4WQ-A'_55HI">8!@67$V+(#Q7!LH$X&Q7DD6\8,S7T,$C80(8&X
M (  ;?$  (  @ !62'M:6K-,5'P?74!!>WS)7ZHU/GU?8=<G4WX"8Y$6:W[[
M9"\$BH"V958  (  <R0  (  @ !5*W>B8?5+,7B28_U 5GE59>0T6'GW9YHF
MB'I_:.85TWKX:2\$<WW<:F\  (  >"   (  @ !4&G0Y:4=**752:LX_578O
M;#8S8G;0;6PEXG<W;E@51W>$;EX$6GMI;^,  (  ?'(  (  @ !3)G$L<*M)
M0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (  @    (
M@ !246YW> I(<V_G>*D]Q'#V>1HQ]7&6>6LDH7&;>9\4HG(F>8 $D'A*>W,
M (  @    (  @ !1IFPG?W1'[VW,?[@]6&[W?[$QJ&^)?XTD96]2?XD40G Z
M?[ $7'BB@"<  (  @    (  @ !1)6H_AO)';VP!AND\W&U!AG@Q.6W.A?,D
M$6UDA=L4$&ZDA;@$47BU@NL  (  @    (  @ !,[XV@2M=#8(UJ3C8XU8V#
M46DLO8W_5$0>58]?5E<,@)'=5O8  (F*7#0  (  ;*T  (  @ !+DXG+491"
M.(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (  <8X  (
M@ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\  (-49;H
M (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q9:L+B(2W
M9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I'H!/:E<;
ME8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP;G S_GTV
M;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&^'DQ=%T]
ME7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (  @    (
M@ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T  (  ?W@
M (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R@EL*SGBU
M@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0AJIE143L2
M>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.4=DL+)69
M5&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^09(657@U
M.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (  >70  (
M@  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH  (  ;E8
M (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT09F<"F8G%
M:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=!HE":_$/
M/XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I<"DQ](7^<.\G^(9W
M<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z?(*[=PHQ
M78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (  @    (
M@  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\  (  @
M (  @    (  @    /__  #__P  __\  &UF=#(     ! ,)   !
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M^27N)N,GV"C,*<$JMBNK+)\MDRZ'+WPP<#%D,EDS331!-38V*S<A.!8Y"SH
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MQ&)_=FXOO8Y^U6"TMIQ^B%-;KW!^BT9)I_9^T3G9H!U_/"Y#E\=_]"0SCOR
MZ8DSRAJ'(GN7PVJ%H&X(O).$5V"'M96#<%,TKF&"RT8VINJ"8#GEGQ>"$BZ
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M?"B&!*SM?&"% IA2?*F$*(-E?0&#:VY<?7""PEEQ??&"&$2X?IB!<#"1?W6
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MKER#36KYJ7Z"C5XMI(N!_%%*GX.!F$2BFE:!33B;E/2!$2UOCUN \B/-B9Z
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M>IY\E#(E?+E]I-;O;AB#!<-;;[^"4:]$<52!KII[<MZ!-857=&^ UW 2=A2
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MA;J%8(TIA.&$H7R8A!Z#YVN6@W&#1%J$@MN"J4FQ@EB"#3DU@?:!:2G&@:B
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M?<U]/RK(?PE^):]&=WJ"2Y_0>!&"!X^A>*6!KG[/>42!46V%>@.! EPG>MV
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MNXH>DE=\77WID'Q\GG$GCJ=\U6/VC-1]$E9IBPM]7DCJB49]O#OGAWY^)B^
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MG73KJ5!CZ&I/I>-F/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C
MCDAVV2 BB?AZ8G1UJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET
M;C+=D4]VO2D'C0YY3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TAT
MF"-VK3U?E"YX,#+KD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQY
MN5-6FJ)Z3T@MEMQ[!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C
MH)=_9UWPG19_3U+MF7)_.D?NE;9_03T4D>]_7C+LC@Y_A2F6BB1_OB&UAE5_
M_W+AHON&'FANGZ"%A5VCG!V$SU*CF'F$#D>OE,*#6CSXD/^"N#+LC3."("FT
MB6B!CB'WA;R!!'*2HC>,CV@OGMN+=5UJFU**'%)HEZJ(ID=VD_J'.CS9D$&%
MV3+TC':$@RG2B,:#*B(MA3V!X7)9H9F2Q6?[GCR1(ETRFJ^/)%(QEP*,]D=$
MDU2*SSRICZN(KS+EB^2&H2GPB#^$D")9A->"F7(KH3"8U6?]G<B6O5TOFB:4
M!%(<EF"0_$<[DJ:.##RTCP.+-#+VBUZ(=2H$A]J%N2)\A(6#+VH)LM=C:E_\
MKNAEJ57AJKEH#4NPIB1JFT& H2MM6#>)F^AP32X]EG1S:R6]D-EVTQZ@BUQZ
M8&F8L?)J0%_7K=)KRU76J6EMB4NZI+%O>$&<GZYQFS>YFG1S\RZ%E0]V<"8H
MCXUY*!\VBC![]6E;L(1PPE^3K&!QNU6LI_)RVTN9HS5T-T&2GCQUP3?+F15W
M>BZXD\=Y42:"CF-[5A^WB2M]9&DDKOEW"%]/JMMW@U5?IG9X&DMKH<AXWT%V
MG.%YT#?-E])ZXR[=DI]\#B;,C5Q]6R GB$M^JFCJK:)].5\<J8M]054MI2E]
M5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+C'9_-B"%AXU_RFBWK)F#8U\
MJ'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!3"\9D+"!$R=!B[" YB#3ANZ
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M>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6 \3/N?1> DB<Y?G6
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M@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F E'+E?^*
MA665?[. 7E@<?Y2 .TIM?Z" (3TY?[R "C"3?_]_]25&@%]_WXLH?QF(CW\&
M?O*']7(Z?L.'(V3I?IN&*U=L?I&%+DGP?JZ$.#SF?NB#0#!S?TR"-B5A?\N!
M((I_?AJ0;GY:??^/)7&4?=2-BV1.?;6+P5;=?;N)[DF#?>F(%SRP?C&&.3!C
M?K*$/R5W?U""-8GZ?528%GW5?4*6''$.?1B3N&/0?/B1$E9H?0B.8DD9?4R+
MJCQM?:2(ZC!5?C2&"26)?NR#'HF8?,.?A'UL?+:<W'"<?(B9I6-@?&.6'%8,
M?'.2B$C6?,&.[CPW?2V+2# W?=2'BB67?IR#WH.ED)Q?<WA:CPIB8VQGC:ME
M1E_+C%IH*5+0BOUK(47(B9IN1#D[B#=QE"T\AN5U/B*)A:]Y2X+MCJUG6'>\
MC4]IA&O'C %KK5]%BKAMWU)EB6MP)T5_B"1RE#D7AM]U)BU*A;!W_2+6A)M[
M%X(QC+YO%7;EBXMPD&L3BE1R"5Z;B2%SB5'@A^]U'D4BALAVSSCHA:9XG2U0
MA)MZFB,:@ZA\OX%@BO9VKG8(B=MWB&HOB+YX5EWTAZ!Y)U%4AH]Z D3$A8IZ
M\3BYA(Q[\BU3@Z9]$"-5@M5^08"3B7%^,'51B&A^<FF#AUQ^F5U"AE)^KE#M
MA4U^QT1ZA&M^\CB7@XY_(BU:@LQ_7".'@B!_F7_>B#F%K72FAT.%3&CAAC^$
MO5RZA3B$#5!YA$*#6$1+@VB"M3A_@JR"&"U=@@^!<B.P@8B QW],AT:-!70U
MAEZ,"FAWA5J*OUP_A$^)0$_]@V>'P4/I@J&&3CA:@>^$WRU:@7&#5R/3@0J!
MRG[8AHR4)W/!A:N2D&@"A*60A5O4@Y>.-$^<@K.+YD.+@@&)GC@@@5Z'7BU9
M@.Z% 2/O@*."HWY_A@&;%'-EA2*8Y&>?A!>6$EMU@P.2YD]/@AR/P4-7@7&,
MI3@#@.")CRU3@(B&9B0%@%&#57@SF69?*6V_ES)B"&+!E2%DZ5<ZDP5GUDMO
MD,1JWC^OCFQN%S1]C AQ?2GIB:IU/2"JAVAY4'>.E[AFGVU&E:5HQ6).DY!J
M]U;BD6UM/$LRCS-OGS^0C/%R+#1^BJ=TWRH7B&EWVB$2AD9[#7;WE>%MX6R9
MD^]O96'"D>MP\%9@C]9RD4K3C;-T2C]8BXYV*#1RB65X(RH\ATIZ4R%MA4A\
MI'9.E"!T^6OBDD%UZ6$"D%1VV%72CE9WTTIAC%%XX#\2BDMZ!S19B$1[0RI5
MADQ\HR&[A&U^$W6FDJ=\ &M D-E\86!ECOE\LU4[C0=\_4G_BQ1]5S[-B2]]
MQ#0\AT9^/2IFA6Y^R"'^@[%_6G43D7Z"_&JYC[Z"SU_IC>.">U3%B_:"$$F9
MB@Z!JCZBB"^!530KAF2!"RIUA*Z P"(U@Q2 =W2;D(:)RFI#CM2)"U]WC/V(
M#%19BQ2&YTD]B3:%PSYGAV>$JC0KA9^#FRJ(A F"@2)C@I*!:G0\C]&0;&H(
MCBF/*%\_C$J-=%0>BD^+?4D)B&^)DCXMAK>'MC0#A0:%Z2J4@X&$"R*(@BB"
M-7/RCTF6UFG!C9Z5"%[UB[F2FE/9B;F/UTC3A]B-(CX+AB6*?S/VA(:'["J;
M@QF%4B*F@=."VVU"HF]>L&-XGZ1A@%E:G-9D8T[FF=IG8D1,EJ)JASG1DT%M
MXB_UC\EQ:2;/C$MU0A\'B/)Y5&RIH/QEO6,<GC1GXED/FU!J(TZVF$1L@T0V
ME0QO"CG8D;QQP3 <CEMTGB<?BOMWOA^(A\)[ FPQGSILC6*9G(5N'5BLF:QO
MPDY>EJEQB4/^DX5S<#G%D$]U@3 QC0QWL2=AB<]Z%!_WAKE\BFNUG7QS,&(1
MFMAT.5@=F!%U3$W\E2)V=T.TDAEWOCFBCP%Y(S YB]YZH">5B,5\02!7A=5]
MZFLXG !YPV&<F6QZ2E>MEJ]ZS$V-D\M[4$-VD--[[CE^C=I\I3 YBM5]:B>]
MA]Y^12"IA1-_(FK*FM: 2V$]F$R 4E=8E9* .DU DK* %$,VC\1__#EHC--_
M_# \B>N ""?>AQ: &R#MA'" ,&IMF>F&I&#SEV:&+%<7E*J%=$T!D<F$GD+Y
MCN6#TSE&C .#&3!'B2&";B?^AFN!OR$E@^F!%6HGF2J,OV"REJR+PU;6D_"*
M:4S&D0V(WT+'CBV'7CD5BUV%ZS WB(2$CB@>A=V#*R%2@WR!U&GOF**2LF"G
MEB*125;+DUF/.TRRD&",W$+%C76*F3DJBJV(<S!0A_2&9R@VA6^$6B%V@R6"
M<&*LJ\I>&EE]J'-@UU WI.-CO4;1H/%FT#UIG*5J&30XF!UMG2NUDW=Q32/Z
MCL=U11V5BE1Y56(5JI!DP5DOIR)FX5 $HV=I,$:]GUQKKSUQFPIN8C1?EHYQ
M2RO\D?MT6B1HC6AWHQXMB19Z^&&]J-YK)%C4I71LO$_%H<!N>$:+G;AP:CU=
MF7=RAS1ME1-TU2PQD)QW0"3%C"QYV1ZPB )\<V%PIQIQ5EA]H[QR<T]IH!5S
MJ493G"-U"3T[E_IVDC1MD[5X/2Q7CU]Z 241BQ5[YA\@AQ5]Q6$CI9)W>%@X
MHD%X(4\IGJ)XTT83FKEYE#TEEJ5Z?C1LDGU[ABQVCD=\G251BB-]RA]_ADM^
M[V#=I%U]DE@*H0Y]RD\&G7%][47TF8U^$#T-E81^2C1UD6E^I"R5C5%_#B6(
MB5)_@A_/A:-_\&"CHV:#>E?JH!6#04[PG'6"T47@F)2"3SS[E):!X31UD(N!
MB2RTC'Z!126YB**!!B 0A1B RF!VHJB)*E?8GT^(@$[EFZB'>$76E\2&2CSN
MD\R%+S1HC]>$*BR\B]N#/B7@B!&"5R!$A*B!?V!9HAB.I%?3GJ^-AT[BFO^+
MX473EQ>* #SSDR&(-#1YCS>&@RS*BU"$[27UAY^#:2!NA$Z"$;=98K=:Z:;W
M95Y>6)8K9_9AN83.:HUE#7+^;3IH9V$ < UKVT]&<PUO>3W<=EMS:"UQ>@IW
MX[5R7VIE5*5^8F1GN93@94-J%X.L:!YL=7'[:Q%NVV ?;BUQ6TZ,<7AS^SU=
M=1-VX"U&>0YZ++.I7(%OI*/.7[EQ 9-Q8M5R7()69>MSQ7#3:1MU/%\K;'IV
MR$W2< IX;#SG<^UZ0"TA>"M\5;'D6>EYQJ(9759Z*Y'-8*%ZE8#Y8^M[!V^B
M9UI[C5XV:O9\(TT>;L9\Q3QY<NE]@BT =V-^6[!!5ZN#Q*"76T6#1)!@7KR"
MP7^?8B^"0&Z49<R!R5U6::2!9$Q];:V _CP9<@B G2SD=K2 -Z[E5=.-J9];
M68^,2(\]72:*UGZ38+Z)76VA9(&'Z%R<:'^&>TOT;+V%"SO%<4F#ARS,=A^!
MXZW.5$^79IY=6">5'XY36]22MWV[7X>00VS=8VV-TUO[9Y"+7TN&:_&(VCN$
M<*B&-"RY=:*#6ZS[4R&@YYV<5PN=LHV:6L::3WT-7HB6VVP\8H>3;5MM9LV/
M]DL>:U",8SM,<".(FRRI=3N$GJQS4DFJ#)T85CREV(T36?BA<WR(7;^= 6O%
M8<N8F%L-9B:4(DK*:L./ACL/;[6*K2R<=.B%K*K<:@Q:K)OZ:_U>-8QV;?%A
MGGP\;^YD\VN$<@1H4%JA=#]KRTH+=J1O=#G2>5-S=2JN?%IX *E:9O!DDYK=
M:31G'(MW:V1IDWM;;9EL FJ\;^AN>EGZ<F1Q#DF,=0]SQCF%> IVQRJ?>UIZ
M,*?,9"5N5IE!9J9OZXH-:0UQ=7H*:WIR_VF?;@9TEUD2<,)V1$C><ZYX##D?
M=NEZ!2J1>G9\/Z8W8:AW[9>Q9%EXH8B-9NYY27C2:8IY[6B.;%%ZGU@Z;TA[
M84A%<G%\,CC(=>E]'RJ%>:Q^*:2_7X&!:9938EJ!1X<_91F!#W>59]V RV>>
M:L^ CE=T;?Z 8$>[<5Z -3A]=0N #RIZ>/U_Z:.*7;R*T94Q8+.)V(8R8Y"(
MNW:<9G>'BV:_:8V&6U;/;.&%,D=&<'&$"#@\=$V"SBIR>&B!>J*47$F4#Y1(
M7UB2.X568DF0-'7094J.$V8(:(*+\E8]:_F)S4;J;ZB'G3@*<ZV%3RIK=^N"
MV*'<6RB=$9.57D6:7X2D84*7:'4H9%*44&5K9Z.1.56T:SN.'$:+;PN*ZC?>
M<RJ'C"IE=X6$!*%C6EFEO9,577RB*(0:8'J>.W2@8XZ:*63U9NR6'%58:IF2
M!T8Z;H.-UC>F<L")=2I@=S.$_IZE<9A:CI$B<LU>'X+;=!AABG/$=7=DWV0H
M=NYH/51D>(=KOT3Y>D9O<C7U?$ES@2@6?IEX&IUB;J5CVI &<"QF?H&_<:]I
M"G+)<T%KC&-2=.YN&E.X=L-PQT1[>,!SF36S>P5VM"@A?9-Z,9P::_5M%8ZY
M;;QNUX"W;W)PBG',<3-R-&* <Q)S[%,6=2%UO40/=UMWJ35_>>!YR"@K?*I\
M)YJP:8]V)HU6:X1W&G],;6=W^7"F;U-XSF%_<6UYK%),<[1ZG$."=BA[G34X
M>.1\NR@S>]U]]YEA9X!_'(P5:9E_2GX::Z)_5V^);;5_4&"M;_5_35&@<G%_
M6$,/=1A_:34!> 9_@2@Z>RQ_G9A,9<^( HL.: .'9GTF:B:&FVZF;%J%M%_C
M;KR$RE$1<5F#YD*N="V#!#31=TB"%2A >I6!%9=O9&R0O8HY9K2/57Q::.N-
MK&WJ:S:+WU\[;;B*#E".<'6(.T)B<V6&832O=J>$;2A%>AB"6Y;)8U69/(F3
M9:R7!WNS9^Z4?&U-:D:1P5ZH;-^/!5 .;[V,1$(-<LJ)=32/=B2&@2A)>;&#
M<9998HJA;HD99.F>:WLN9RR:]VS):8F73%XY;"V3H$^Z;QZ/\$'#<D:,+#1=
M=;V(12A->5^$6)*N>6%:B(9->=Q>$'DB>G]A=VLJ>SMDS%RR? MH+TX:?/5K
MNC_H??UO=C(L?T!SDB6I@,)X+Y&7=I1C1(5-=V%E\W@C>#EHBVI)>2%K'EOW
M>A]MOTV)>SYP@3^&?']S:S(&??QVGR7/?[-Z,)!X= 9KXX05=1!MQW<>=A1O
MFVE6=RAQ:%LS>%9S0TSW>:MU-S\I>R-W23'E?-EYCR7P?L-\#X]%<;1T<H+>
M<NUUE77O=!MVH6A[=55WJ%IY=K5XLTQR>#QYT3[<>>E[ S'+>]9\528,??%]
MQHX:;[U\YX';<1A]4W3P<FA]G6=T<\1]T%FS=4A^"$O.=P-^33YO>.!^FC&?
M>OE^\R8E?3U_5(TB;B&%2(#I;Y.$^G0-</R$>6:D<G6#V%C_=!>#-$M3=>Z"
MF#X@=_6!_S%_>CJ!7B8Y?*. LXQ:;,Z-?( I;E2,<G-6;\V+(67[<5J)IUAI
M<QF(*$KA=0Z&ISWE=RV%)#%K>9>#C29*?"2!Y(O!:\*5=G^0;5>3KW*];MJ1
MBF5M<'*/+U?E<D:,STIN=%F*;#V;=I*( C%7>1&%>R98>[R"YHM4:OJ=)G\=
M;)F:IG)!;A^7J&3T;[N49U>!<9>1(DHD<[R-VCU;=A"*AC$O>*R'&R9C>VF#
MNX;P@6U:A'N"@3A=_&]<@3)A7&)^@41DM54O@5YH($?.@8AKMCKA@<=O?BZ
M@C)SIB-L@L]X087Y?M!BN'JI?NAE:6Z'?PYH"V')?T%JKE2??X)M8T=F?]IP
M/3JF@$IS0"Y\@.IVCB.L@;5Z+H3^?&!JTGF7?+-LR&V@?0)NM&#S?5QPG5/S
M?<ARF4;I?E%TL3I>?O1VZ"YP?\5Y52/C@+U[]H/S>BYRRWB)>JAT%&R/>QYU
M36 N>YAV?E-+?#1WND9T?.QY"CH??;]Z;BYG?L%[]203?^1]EX+R>$1ZO7>0
M>.![66NF>75[V%]5>@]\15+(>L=\ND83>ZY].SGM?*U]R"YC?=U^9B0\?RI_
M#H(5=KR"GG;8=W&"D6L >!F"4UZI>,F!]5(F>9R!F$6I>IV!1CFJ>\. ^2Y0
M?1N JB1??HV 6(%A=7J*3G8F=D&)E6I7=O:(E%X/=[B':E&<>*.&/$5">;Z%
M$CE\>OF#ZBY(?'6"LR1[?@N!=(#5='F1P'6>=4^06VG1=@V.E5V4=M>,F%$L
M=]2*ED3?>0J(E#E >ER&DBY!>^V$?"22?:&"9(!L<[>8[W4T=)>6Y&EB=5F4
M5%TK=B61?%#7=RF.H$2D>&Z+Q3D0>=J(YRXF>X:%_"2D?4R#*7MYB<%::7#D
MB.9=S66VB#1A*5GMAXYDB$W*AN!H 4&EAC5KJ38%A91O@BL'A1)SN2%DA+=X
M3WJ;AUQB'G NAL%DSF4*AB]G>EEBA9]J+TUBA1!L_4%CA(QO\S7NA!9S$BLC
M@\)V?"&]@Y%Z*7G$A0MIMV]&A*5KO&1,A#9MOUBT@\=OQTS>@UUQYD$,@P9T
M)37)@KUVA2LU@I9Y'"(*@H][W7CA@N]Q-&Y;@JQRF&-@@E]S\E@$@A%U3DQ,
M@=)VN4"J@:5X/#6:@8EYU2L]@8][E2)-@:Y]:G@'@2)XG6V.@/IY9&*;@,=Z
M%E=%@)-ZO4O9@&Q[;4!5@&Q\+S5R@'A\_BM&@*=]X2*&@.Y^S'=&?YM_]&S=
M?X^ 'F'[?W" (5:^?TV "DMM?SY_]$ S?U!_[S5I?X1_]2M5?]U__"*U@$V
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MAL*#P%CLA=>#64Z]A-J"UD22@^R"6#JS@Q"!YC%N@D:!@RBR@;V!'"%Q@5&
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MBG!\L#7_B')]5"VPAHM^!28HA,A^OQ_]@SA_<F*"D,& Z5GBCS6! %#IC6>
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M6,2$#WX37(N#FF^C8%Z#%6#H9&:"D5(9:+:"&$.Z;4F!IC7K<BN!-"EY=SB
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M?;A^I2'9?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94>+J ]3P<>@.
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MC8U^>D,?C!)^H3O]BC5^NC3YB$5^]"XXAG5_12@XA+I_JB+=@U!__QZ.@CJ
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M;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]> 0F&H6:> -%+\7\F
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M6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6 Q"V =4R M"2A>>2
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MWRQ;@@)O."2J@K%SWAY2@W%XI6!#?!U>D%@,?.%AGD^$?9!DN4:/?BYG[#V
M?M!K0S28?XQNR2Q:@%QR=B3B@4]V81Z^@DEZ6U]4>0YE7E<B>A=GV4ZE>P-J
M7T7P>^1L^CT'?,YOLC14?=)RD2Q.?NEUCR4-@!QXNQ\<@4E[YUYP=D]L'U9.
M=YAN!DWC>,%O\T5&>=QQZCRE>P9T #07?$YV-BQ"?:-X@24P?Q%ZZA]K@&Y]
M1UVE<^1RRU67=6QT(4U'=LYU;D3">"%VP3Q!>7YX*#/Z>O1YKBQ%?(%[1B53
M?BA\Z1^M?[=^>EST<<EY1%3R<X]Z"$RW=2AZLD1.=JM[63OJ>#5\%#/0>=A\
MYBQ=>X5]RB5Y?5]^KQ_C?Q]_@%QF< )_C%2(<@=_QTQG<]%_QD09=7-_LCO'
M=QQ_NS.F>.Q_W2Q">L& %"6/?+R 0" /?J2 7%O\;I"%FE0D<+^%3$P+<K2$
MGD//='B#T3N7=CR#(S.1>"F"CRP]>B*"#R6;?$*!C" R?D*!#UB*BSI085#X
MBI14@4D:B@!8OD#=B5Y=*SAQB*=ATS RA^YFP2B=AT)KY"'8AK9Q51Q@AE%V
MV5=QA_U6UU 5A[A:@4A,AUI>14 ^AN)B+C@0AEAF2# 2A==JGBB_A69O("(U
MA1MSXASMA/%XIU:8A-5=24\[A-A@=4><A+ACLS^HA'9G$S>OA"AJG"_J@^AN
M6"C5@[ER-B*!@Z]V1AUG@[YZ3%72@=UCKTYV@AUF4T;<@C=I!S\C@C1KV#=0
M@BANSR^_@BQQ["C@@C]U)2*^@G)X@1W0@K9[QU41?REJ#4W!?ZML)D8Y?_YN
M3#Z7@#%P@C<*@&%RX2^;@*1U7RCH@/1W[B+Q@6!ZD1XI@=1]%U1??,1P6TT=
M?8IQZD6Q?A=S>CXM?GQU%3:^?MQVS2^(?TUXIRCS?])ZBR,<@'1\=!YS@1=^
M.U/%>K-V>4R4>[AW@$5"?'MX=#W9?0QY;C9[?9=Z@R]K?C)[LBD(?M9\[B-$
M?ZI^(1ZP@'M_,U-!>.=\64P6>B]\UD35>R9]+3V&>^!]@C9 ?(Q]\B\Z?5)^
M>"D#?@]_#B-O?O]_EA[A?_V  U+@=W&"'DO,>/:"%T2@>A^!OSUQ>NV!6#95
M>Z.!&B]H?'R ^"DG?6. Z".*?GZ SA\(?YB K$[8D_U/HTA*DH13TD%QD1%8
M'3H]CX5<I#+AC=EA=BN[C"-FDR5!BGIKY!^4B/9Q;QL9A[1VYTW,D/I5N4=2
MC^U9?4" CJ]=7SE]C3]A<3)LBZUEP2N6BAUJ3R5LB)]O R  AU)SY1NUAD=X
MITT4C?A;RT:,C2Q?'#_5C"EBA#CJBNAF'#(1B8EIXRMYB#%MX"60ANUQ]R!;
MA=UV+QP[A0EZ/DQXBQ%AT$7JBGQDI#\QB:]GCSA[B*QJGS')AXEMX"MEAF]Q
M1B6OA6ITP""HA)=X31RO@_A[JDO:B%YGSD53B!!J(3ZNAWMLB#@0AJAO"#&B
MA;]QN2M<A.)TBB7/A!=W8B#L@WUZ01T0@Q!\[$M!A>]MQT3&A?%OE3Y A9EQ
M;C?$A/9S7C%SA#EU<"MC@XEWI"7P@O%YVB$F@HQ\"1UA@DY^ TJ\@]!SDT1,
MA"!TW#WDA )V(C>&@XMW>S%,@O5X\BM:@FUZ@B82@?=\%R%;@<!]G!VD@:Y^
M[TI,@@!Y+T/G@I=Y\CV5@J]ZGS=6@EY[6#$M@>I\,BM%@8M]("8:@3)^%B&$
M@1E^^1W:@2Q_M$G[@'Q^I4.7@5)^VSU5@9U^YC<Q@6Q^^3$D@0]_,"M4@,I_
M?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0     #!"$
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M=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J=\*#JG?"@ZIWPH.J^KX<*-;=#B/
M\!0_K/T>5YSP+6J/Y3YYAMY.@X'87XM_U&N0>M%PE'?/=)=USG>8<\UYFG+-
M>YMQS'V;<,M_G&_+@)UORX"=;\N G6_+@)UORX"=;\N G6_+@)UORX"=;\N
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MV9&4GMF1E)[9D92>V9&4GMF1E)[9_Z0X*O^@14#_H4I3^Z9(8O*K2''HKTB
MW[-*CM:U49K0MEJDS+AEJ\J]<:[!N7NVM[* P*ZLA,BFJ(7.G:2'U)2@CMB.
MGYG;C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;GMF,FY[9C)N>V8R;
MGMF,FY[9C)N>V8R;GMF,FY[9_Z0X*O^A14#_HDE3_*='8?*M1G#ILD9_X+='
MC-F[3I?3OU>?T,5CI,7 <*VZN'FWL+* P*FMA<>@J(3-EZ6%THZAB=>'H)+9
MAZ&<V(>AG-B'H9S8AZ&<V(>AG-B'H9S8AZ&<V(>AG-B'H9S8AZ&<V(>AG-B'
MH9S8AZ&<V(>AG-B'H9S8_Z0W*O^A1$#_HTA2_*E%8?.N1&_JM4-]XKQ$B=S"
M2I/8RE29RL9BI+R];K"RMGBYJK& P:2MA<>;J83,DZ:$T(JCA]2#HH[6@J*6
MUH*BEM:"HI;6@J*6UH*BEM:"HI;6@J*6UH*BEM:"HI;6@J*6UH*BEM:"HI;6
M@J*6UH*BEM:"HI;6_Z4W*O^A1$'_I$92_:I$8/2Q0F[KN$%[Y,%"AM_,1HW3
MSU*7P<1AI[.[;;.KM7B[I;& P9^NA,:8JX3*D*B$SHBFAM&"I(S3@*22TX"D
MDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22
MTX"DDM. I)+3_Z4W*O^A1$'_I451_JQ"7_6T/VSMO#YXY\= @>#61H?)S5&:
MN,)@JJRZ;;6EM7B\H+& P9NNA,65K(3(CJJ$RX>HALZ"IXO/?Z:/T'^FC]!_
MIH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^FC]!_IH_0?Z:/T'^F
MC]!_IH_0_Z4V*O^B0T'_IT-0_ZX_7?>W/&GPPCMSYM _>=/9/XJ^RU&=K\!A
MK*6Y;K:@M7F\G+*!P)BOA,.2KH3&C*R%R(>JA\J"J8K,?ZF.S7^ICLU_J8[-
M?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_J8[-?ZF.S7^ICLU_
MJ8[-_Z8V*O^B0D'_J4!/_[([6_F].&7LRSAMW-PU>,?6/HZSR5*@I\!CK9^Y
M<+::M7J\F+*!OY2QA<*/KX7$BZZ&Q8:MA\>"K(K(?ZN-R7^KC<E_JXW)?ZN-
MR7^KC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_JXW)?ZN-R7^KC<E_JXW)
M_Z<U*O^C0D'_K#Q-_[<V5_+%,U_AUC9CS>,Q?+K3/Y&IR%2AG\!EK9FZ<K66
MMGNZE+."OI*RA<"-L8;!B;"'PX:OB,2"KHK%@*Z,Q8"NC,6 KHS%@*Z,Q8"N
MC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%_Z@T
M*O^F/C__L3=*^;XP4N?/+U71XBQHP.$P?ZW20I.@R%>AF,%GJY2\<[*2N'RW
MD+:"NHZTA;R+LX:^B+*'P(6QB<&#L8K!@;",PH&PC,*!L(S"@;",PH&PC,*!
ML(S"@;",PH&PC,*!L(S"@;",PH&PC,*!L(S"@;",PH&PC,*!L(S"_ZDR*O^K
M.#W_N"]%[L@I2-;?)5+#["ELL=\Q@J'219*7REJ?D<-IIXZ_=*V-O'RQB[J!
MM(BY@[:%N(2X@[>&N8&VA[I_M8F[?K6+O'ZUB[Q^M8N\?K6+O'ZUB[Q^M8N\
M?K6+O'ZUB[Q^M8N\?K6+O'ZUB[Q^M8N\?K6+O'ZUB[Q^M8N\_ZLP*O^Q+SCV
MPB8\W-H?.\;K(U>S["IOH]\U@I;42I"/S5V:B\AKH8G$=::&PGNJ@\!^K(&_
M@*Y_OH*P?;V#L7N\A;)ZNX>S>;N(LWF[B+-YNXBS>;N(LWF[B+-YNXBS>;N(
MLWF[B+-YNXBS>;N(LWF[B+-YNXBS>;N(LWF[B+-YNXBS_ZTN*OZ[)3#CTAHM
MR>@;0;;W(UJE["YOEN$\?XS83XN'TE^3A,ULF8'*=)Y^R'BA>\=[HWG&?:1X
MQ7^E=L2!IG7#@Z=TPX2H<\*&J7/"AJESPH:I<\*&J7/"AJESPH:I<\*&J7/"
MAJESPH:I<\*&J7/"AJESPH:I<\*&J7/"AJESPH:I_[0D)>S*%B/-Y1,LN?8;
M1J?Z)EN8[C5LC.5$>H3>4X. V6**?-5LCWC2<9-UT'65<\]XEW'.>IAPS7R9
M;\U^FF[,@)MMS(*<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<;,N$G&S+A)QL
MRX2<;,N$G&S+A)QLRX2<;,N$G&S+A)QLRX2<]<$5&='?#!B\\Q,QJO\>1YK\
M+%F.\CQGA.I+<GWE6'IYX&. =-YJA'#;;X=MVG.):]EVBFK8>(MIUWJ,:-9\
MC6?6?HYFU8".9=6!CV75@8]EU8&/9=6!CV75@8]EU8&/9=6!CV75@8]EU8&/
M9=6!CV75@8]EU8&/9=6!CV75@8]EU8&/TM(*";_H#1VM_Q4SG?\C19#_,U2%
M]T-??O%1:'?L7&]PZ6)T:^=G=VCE;7EFY'![9>-S?6/B=GUBX7A^8N%Y?V'A
M>W]@X'V 7^!_@5_@?X%?X'^!7^!_@5_@?X%?X'^!7^!_@5_@?X%?X'^!7^!_
M@5_@?X%?X'^!7^!_@5_@?X%?X'^!_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=X
MXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[
M?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5Z
MK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<
MA]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$
MNGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U
M>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<
M9Y72F7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRF
MQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&
MM7JLQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72
MF7"AS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=Z
MK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JL
MQK5ZK,:U>JS&_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"A
MS)9[J\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U
M>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5Z
MK,:U>JS&_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[
MJ\:4A+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&
MM7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U
M>JS&_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4
MA+/$DXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JL
MQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&
M_Z Y(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$
MDXNVPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5Z
MK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y
M(?^<1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNV
MPH^/NL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U
M>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^<
M1C;_FE%*_YU26?>?5&GMH%=XXY]<A]J<9Y72F7"AS)9[J\:4A+/$DXNVPH^/
MNL"+DKR^AY6_O8.8P;R!F\.[?J#$NGRFQK=ZK,:U>JS&M7JLQK5ZK,:U>JS&
MM7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&M7JLQK5ZK,:U>JS&_Z Y(?^=1C;_
MFE!*_YY16?>@4FCMH59XY*%:AMN>9)32FVZ@S)AXJL:5@;+$E8FVP9&.NK^,
MD+V]B)/ O(27P[J!F\6Y?J#'N'RGR+)[JLBP>ZK(L'NJR+![JLBP>ZK(L'NJ
MR+![JLBP>ZK(L'NJR+![JLBP>ZK(L'NJR+![JLBP>ZK(_Z X(O^=1C?_FT]*
M_Y]/6?BB4&CNHU-WY:17A=RB8)/3GFJ?S9MTJ<>8?;'$EX:VP92,NK^/CKZ\
MBI+"NH:5Q;B"FLBW?Z#+M'RGS*Q\J<JJ?:G*JGVIRJI]J<JJ?:G*JGVIRJI]
MJ<JJ?:G*JGVIRJI]J<JJ?:G*JGVIRJI]J<JJ?:G*_Z X(O^=13?_G$Y*_Z!.
M6/BC3V?OI5%VY:95A-VE79'4HF:=S9]PJ,B<>K#$FH*VP9B*NKZ2C+^[C8_$
MN(B3R+:#F<RT@*'/K'VESZ9^I\RD?ZC+I'^HRZ1_J,ND?ZC+I'^HRZ1_J,ND
M?ZC+I'^HRZ1_J,ND?ZC+I'^HRZ1_J,ND?ZC+_Z$X(O^=13?_G4U)_Z%,6/FE
M36;OIT]UYJE3@]ZH6I#5IF*<SZ-LILF@=J[%GG^UP9R'NKZ7BL"ZD(W&MHN2
MR[2(FLZRAJ31IH"DT:"!I\V?@:?,GX&GS)^!I\R?@:?,GX&GS)^!I\R?@:?,
MGX&GS)^!I\R?@:?,GX&GS)^!I\R?@:?,_Z$X(O^>13?_GDQ)_Z)+5_FF3&;P
MJ4YTYZM1@M^K5X[7JE^:T*AII,NE<ZS&HWRSPJ"$N;Z<B,"YEHS&M9&2RZ^-
MF,^JBJ'2H(2CTYN$ILZ:A*?-FH2GS9J$I\V:A*?-FH2GS9J$I\V:A*?-FH2G
MS9J$I\V:A*?-FH2GS9J$I\V:A*?-_Z$X(O^>13?_GDM)_Z-*5_JG2V7PJTQS
MZ*U/@."O5(W9KER8TJUFH<VK<*G(JGFPPZ>!M[ZAA,"UFXG&KI6/S*B1E<^B
MCI[2FHFBTY:'I<^5AZ;.E8>FSI6'ILZ5AZ;.E8>FSI6'ILZ5AZ;.E8>FSI6'
MILZ5AZ;.E8>FSI6'ILZ5AZ;._Z$W(O^>1#?_GTI)_Z1)5OJH263QK$MRZ;!-
M?^&S48O:LUJ5U+-CGL^S;J7+LWBKPZQ\M[BE@;^OGH;&J)F,RZ&5DM";DIO3
ME8ZBU)&,I="1BZ;.D8NFSI&+ILZ1BZ;.D8NFSI&+ILZ1BZ;.D8NFSI&+ILZ1
MBZ;.D8NFSI&+ILZ1BZ;._Z$W(O^>1#?_H$E(_Z5(5ONJ2&3RKDEQZK),?>*V
M3XG<N%>2UKIAFM.];:#)N'6KOK!ZMK.I?[^JHH3&HIV*RYN:D,^5EYG2D)6B
MU(V0I=",D*;/C)"FSXR0IL^,D*;/C)"FSXR0IL^,D*;/C)"FSXR0IL^,D*;/
MC)"FSXR0IL^,D*;/_Z$W(O^>1#?_H$E(_Z9'5?NK1V/SL$APZ[5*?.2Z3H;>
MOU6/VL-@E=+$;9S%NW.JN;-XMJZM?;^EIX+%G:*(RY:?CL^/G);2BYRBTXB5
MI-")E*7/B92ESXF4I<^)E*7/B92ESXF4I<^)E*7/B92ESXF4I<^)E*7/B92E
MSXF4I<^)E*7/_Z(W(O^?1#?_H4A(_Z=&5?RL16+TLD9N[+A(>N:_3(/AQU.*
MW,UBCL[(;)O OW&JM+=WM:FQ?+Z?K('%EZ>&RI"DC,Z*HI71AJ*ATH2;I="%
MFJ7/A9JESX6:I<^%FJ7/A9JESX6:I<^%FJ7/A9JESX6:I<^%FJ7/A9JESX6:
MI<^%FJ7/_Z(V(O^?0S?_HD9'_ZA$5/VN0V'UM41L[KQ&=^G$2W_CSU2$V=1E
MB,C+:YJZPG"IKKIWM*.T?+V:KX'#DJR%R(NIBLR$IY+/@*:<T("CI<^ H:;.
M@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ H:;.@*&FSH"AILZ
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K#
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M=F)4]7=C4_5Y8U/T?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MA(;@@(N-W'R1DMIYEY;8=IR9U7.@F]1QI9W3;ZF?TFZNH-)MLZ'1;+FBT6O
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MDIK4>YB>TG>>H=!TI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/
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M0$A]_TM1=?U46&WY6EUG]F!B8_-F95_R:V=<\'!I6N]T:UCN>&Q7[7QN5>R
M;U3LA'!3ZXAQ4NN,<5'JD7)0Z95S4.F5<U#IE7-0Z95S4.F5<U#IE7-0Z95S
M4.F5<U#IE7-0Z95SUKX' ,7+" "WVPD%J/\4$IO_(B&0_RXNA?\Y.GS_1$-T
M_TY*;/]44&7_6E1@_5]87?ME6EKZ:EQ7^6Y>5?AR7U3W=F!2]GEA4?9]8E#U
M@&-/](1D3O2'9$WSC&5,\Y!F3/.09DSSD&9,\Y!F3/.09DSSD&9,\Y!F3/.0
M9DSSD&9,\Y!FQ,(& +;1!P"H[0L&F_\7$Y#_)1^%_S$J?/\\-'/_1CMJ_TQ!
M8_]31E[_64E:_UY,5O]C3E3_:%!2_VQ14/]O4D__<E-._W943/]Y54O_?%5*
M_G]62?Z"5TC]AEA'_8I81_V*6$?]BEA'_8I81_V*6$?]BEA'_8I81_V*6$?]
MBEA'_8I8MLD$ *C9! &;_PX'C_\:$87_)QM[_S,D<?\\+&C_0S)A_THW6_]0
M.U;_5CU3_UQ 4/]@04[_9$-,_VA$2O]K14G_;D9(_W%&1_]T1T;_=DA%_WE(
M1/]\24/_@$E"_X-*0O^#2D+_@TI"_X-*0O^#2D+_@TI"_X-*0O^#2D+_@TI"
M_X-*_X(H"?^".1;_@4@E_XI/,?^.5CW_CUQ)_XYC5/Z*:E[XA7%H\H!Z<.Y\
M@W?J>(M]YW22@N1QF(7B;YV(X6VBB^!KIXW?::R.WFBQD-UGMY'=9KV1W&7%
MDMQES9+49M&2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2
M_X(H"?^".1;_@4@E_XI/,?^.5CW_CUQ)_XYC5/Z*:E[XA7%H\H!Z<.Y\@W?J
M>(M]YW22@N1QF(7B;YV(X6VBB^!KIXW?::R.WFBQD-UGMY'=9KV1W&7%DMQE
MS9+49M&2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2_X(H
M"?^".1;_@4@E_XI/,?^.5CW_CUQ)_XYC5/Z*:E[XA7%H\H!Z<.Y\@W?J>(M]
MYW22@N1QF(7B;YV(X6VBB^!KIXW?::R.WFBQD-UGMY'=9KV1W&7%DMQES9+4
M9M&2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2_X(H"?^"
M.1;_@4@E_XI/,?^.5CW_CUQ)_XYC5/Z*:E[XA7%H\H!Z<.Y\@W?J>(M]YW22
M@N1QF(7B;YV(X6VBB^!KIXW?::R.WFBQD-UGMY'=9KV1W&7%DMQES9+49M&2
MSVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2SVC2DL]HTI+/:-*2_X(H"?^#.1;_
M@T<E_XQ.,?^053W_D5M(_Y!A4_Z-:%[XB&]H\H-X<.U^@GCI>HI^YG:1@^1S
MEX?B<)V*X&ZBC-]KIX[=:JR0W6BRD=QGN)/;9K^3VV;'E-EFT)3/:-"3RVG0
ME,MIT)3+:="4RVG0E,MIT)3+:="4RVG0E,MIT)3+:="4_X,H"?^#.1?_AD8D
M_XY-,/^35#S_E%A'_Y)>4_^095WXC&UG\H9U<.V!?WCI?8=^Y7F/A.)UE8C@
M<IN,WF^AC]ULIY'<:ZR3VVFSE-IHNI;99\.6V6;-E]!ISI;(:LZ7Q&O-E\1K
MS9?$:\V7Q&O-E\1KS9?$:\V7Q&O-E\1KS9?$:\V7_X0H"?^$.1?_B$4D_Y%,
M,/^543O_EE9'_Y5<4O^38ESYCVIF\XIR<.V%>WCI@(1_Y7N,A>)WDXK?<YJ.
MW7"@D=MMII3::ZV6V6FTE]AHO9C89\B9T6G,F<EKS)G";,R:O6W+FKUMRYJ]
M;<N:O6W+FKUMRYJ];<N:O6W+FKUMRYJ];<N:_X4H"?^%.1?_BD0D_Y-++_^7
M3SK_F%1&_Y=94/^68%OYDF=E\XYO;^Z)>'?I@X%_Y'Z*A>%YD8O>=9B/W'&?
MD]INII;8;*Z8UVJVFM9HP9O3:<N;RFO+F\)MRIR[;LJ=N&_*G;AORIVX;\J=
MN&_*G;AORIVX;\J=N&_*G;AORIVX;\J=_X4H"?^&.1?_C$0C_Y5*+_^933K_
MFE%$_YI63_^975KZEF1D]))K;NZ-=';IAWY^Y(&'A>!\CXO==Y>0VW.>E=AO
MIIC6;*^:U6JYG-1IQIW+;,F=PVW)GKQOR)^U<,B?LG'(G[)QR)^R<<B?LG'(
MG[)QR)^R<<B?LG'(G[)QR)^R<<B?_X8G"?^&.1?_CD,C_Y=)+O^:2SG_G$]#
M_YU43O^<6EC[FF!B]99H;.^1;W7JBWE^Y86#A>!_C(S=>961V72=EM1PI9K0
M;JZ=S6RWG\MKPZ##;L>@NV_'H;5QQJ&O<L:AK'/&H:QSQJ&L<\:AK'/&H:QS
MQJ&L<\:AK'/&H:QSQJ&L<\:A_X<G"?^'.1?_D$(C_YA'+?^<23C_GTQ"_Z!1
M3/^@5U;[GEY@])ME:NV6;'/GD'9\X8J A-N$B8O3?I&2SGB9F,ETH9S&<:F?
MPG"RHL!OO:.Z<,6CLW+%I*YSQ:2I=,6CIG7%HZ9UQ:.F=<6CIG7%HZ9UQ:.F
M=<6CIG7%HZ9UQ:.F=<6C_X<G"?^(.!?_D4$B_YI%+/^>1S;_H4I _Z-02OZC
M553VHEQ=[Z!B9^B<:7#AEG1YVI!]@M&)AHO*@HV3Q7V5F<!YG9Z\=J6AN'.M
MI+5RN*6R<L.FK'3#IJ=VPZ:C=\2EH7C$I:%XQ*6A>,2EH7C$I:%XQ*6A>,2E
MH7C$I:%XQ*6A>,2E_X@G"?^(.!?_DT$B_YM$+/^@137_HTD__Z5.2/NG5%'S
MIEI;ZZ5@9..B:&W<G7-VT95Z@LF-@HO"AXJ3O(*1FK=]F9^R>J&CKW>IIJMV
MLZ>I=L"HI'?"J*%YPJ>=>L.GFWK#IIMZPZ:;>L.FFWK#IIMZPZ:;>L.FFWK#
MIIMZPZ:;>L.F_X@G"?^).!?_E4 A_YU"*_^B1#3_I4@]_ZA,1OBJ4D_OJUA7
MYZM?8."H:6G4H7!URYEX@<*2?XN[BX:4M8:.FJ^"E:"J?IVDIGNFIZ-ZL*F@
M>;RJG7K!J9I\P:F8?<*HEGW"IY9]PJ>6?<*GEGW"IY9]PJ>6?<*GEGW"IY9]
MPJ>6?<*G_XDG"?^).!?_EC\A_YY!*O^C0C/_IT8[_JM+1/6N44SLL%=4Y+%>
M7-NM:&;/I6YUQ9UU@;R6?(NUD(.4KHJ+FZB&DJ"C@IJEGH"BJ)M^K*J8?KBK
MEG[ JY1_P*J3@,&HDH#"J)* PJB2@,*HDH#"J)* PJB2@,*HDH#"J)* PJB2
M@,*H_XDG"?^*.!?_F#\@_Y\_*?^E03+_JD4Z_*Y)0?*Q3TGIM590X;=?5]6Q
M967*J&QTP*%S@+>:>HNOE(&4J(^(FZ**CZ"<AY>EEX2@J)2"J:J1@K6KCX*_
MJXZ#P*J-@\&IC8/!J(V#P:B-@\&HC8/!J(V#P:B-@\&HC8/!J(V#P:B-@\&H
M_XHG"?^+.!?_F3X@_Z$^*/^F0##_K$,X^;%(/_"U3D7GNE5+WKM>5-"T9&7%
MK&MSNZ1Q@+&>>(JIF'Z3HI.%FIN/C:"6C)6ED8F=J(V'IZN*A[*LB(>_K(B'
MP*N(AL"IB(;!J(B&P:B(AL&HB(;!J(B&P:B(AL&HB(;!J(B&P:B(AL&H_XHG
M"?^,-Q?_FST?_Z(])_^H/R__KD(V][1'/.VZ34'DP%9&V;]<4\NW8V3 KVES
MMJAO?ZRB=8JDG'R3G)B#FI64BJ"/D9*EBHZ;J(:-I*N#C*^L@8V]K(*,OZN#
MBL"I@XK!J8.*P:F#BL&I@XK!J8.*P:F#BL&I@XK!J8.*P:F#BL&I_XLG"?^.
M-Q?_G#P?_Z,[)O^J/2W_L4 S]+A%..J_3#SBQU5 T\):4L>Z86.[LV=RL*UM
M?J>G<XF>H7J2EIV F8^:B)^)EY"DA)28J'^3HJI\DJVK>I*ZK'N1P*M]C\&I
M?H[!J'Z.P:A^CL&H?H[!J'Z.P:A^CL&H?H[!J'Z.P:A^CL&H_XPG"?^/-A;_
MG3H>_Z4Z)?^M.RO\M#XP\;Q#-.?%3#;>RU(_SL994<*^8&*VN&9PJ[%L?:&L
M<HB8IWB1D*-^F(F@A9Z"G8VC?9N6IWB9GZEUF*JJ<YFWJW28P*IWE,&I>)/"
MJ'B3PJAXD\*H>)/"J'B3PJAXD\*H>)/"J'B3PJAXD\*H_XPG"?^1-1;_GS@=
M_Z<X(_^O.2CYN#PL[L)"+N7-3"W8T$\]R<E74+S#7F"PO&1OI;=J?)NR<(:2
MK7:/BJE\EH*F@YQ\I(NA=J*3I7*AG:=OH*BI;:"UJ6V@P:APF\*G<IG"IW*9
MPJ=RF<*G<IG"IW*9PJ=RF<*G<IG"IW*9PJ=RF<*G_XTF"?^4-!7_H38;_ZHV
M(?^S-B7UOCDGZLE )N#622C1U4X\P\Y63K;(7%^JPF-MG[UH>I2X;H2+M'2-
M@[%ZE'RN@9IUK(B><*N1HFNIFZ1HJ::F9JFSIF:JPZ5II,2E:Z'$I6NAQ*5K
MH<2E:Z'$I6NAQ*5KH<2E:Z'$I6NAQ*5KH<2E_XXF"?^7,Q3_HS0:_ZTS'OZX
M,B#PQ34@X],_'-C>12;*VTTZO=-43+#.6UVCR6%KF,1G=XW ;(&$O7*)?+IX
MD'6X?Y9OMH>::K60G66TFJ!BLZ6A8;2QHF"UPJ%BK\:B9*O&HF2KQJ)DJ\:B
M9*O&HF2KQJ)DJ\:B9*O&HF2KQJ)DJ\:B_Y F"?^;,1+_IC$7_[$N&O>^+1KG
MSC$7V=XY&<WC1"C"X$TXM=M32JC565J<T%]HD,QE<X;):WU]QG&%=<1WBV[#
M?I!IP8:49,"/EV# FII=P*6;6\"QFUK!P9M;O,J<7;?*G5VWRIU=M\J=7;?*
MG5VWRIU=M\J=7;?*G5VWRIU=M\J=_Y$F"?^?+Q'_JBT4_[<H%>W()A+:W"D.
MS.0V'<'F0"ZVXT@^JN!.3)[=5EF2VEUEB-9C;W[4:GAVTG!_;M!WA6C/?XEC
MSH>-7\Z0D%O-FI)9S:635\ZRDU;/PI-6R]"45\7/E5?%SY57Q<^55\7/E5?%
MSY57Q<^55\7/E5?%SY57Q<^5_Y,F"?^C+ [_L"8/]< ?#=_5&P?-Y"<3P>LT
M([7J/3.IYT5"G>5+4)'C4ER&XEAF?.!?;G3?9G5LWFUZ9MYU?V'=?8)=W(:%
M6MN/B%C9F(I6V*&+5-BLBU38MXQ3V,F+4];6BU/6UHM3UM:+4];6BU/6UHM3
MUM:+4];6BU/6UHM3UM:+_Y<D"?^I)@K^N!P)YLX1!<[C%PC [B87M/ R**CN
M.SB<[4-&D>Q+4H;L4EQ\ZUED<^M>:VKJ9'!EZ&QU8>9T>%[D?'M;XH-]6>"+
M?U;?DH%5WIJ#4]ZB@U+=JH11W;:$4=V_A%'=OX11W;^$4=V_A%'=OX11W;^$
M4=V_A%'=OX11W;^$_Y\A!O^P&P7IQ0T#T-D+ L#N& RS]B8<I_4Q+)OU.SJ0
M]41'A?5,47SU4UIS]5E@:_-?9F7P9FIA[6UM7>MT<%KJ>G-8Z(%T5N>'=E3F
MC7A3Y91Y4>2;>E#DH7M/XZI\3N.P?$[CL'Q.X[!\3N.P?$[CL'Q.X[!\3N.P
M?$[CL'Q.X[!\_Z@< NN\# '-S D P> ,!++Z&1"E_"<@FOTR+H_]/3N%_D5%
M>_]-3G+_5%5K^UI:9/A@7V#V9V)<]&UE6?)R9U?Q>&E5\'YJ4^^#;%'NB6U0
M[8]N3NR4;TWKFG!,ZZ%Q2^JF<DOJIG)+ZJ9R2^JF<DOJIG)+ZJ9R2^JF<DOJ
MIG)+ZJ9R][,- ,S#" "_T0@ L>\.!J3_&Q.9_RDACO\T+H3_/SE[_T=!<?].
M2&K_5$YC_UI27OY@5EK\9EA7^VQ:5?IQ7%/Y=EY1^'I?3_=_8$[VA&%,]8EB
M2_6.8TKTE&1)\YIE2/.>9DCSGF9(\YYF2/.>9DCSGF9(\YYF2/.>9DCSGF9(
M\YYFS;L% +W'!@"QV <!H_\0")C_'Q2-_RP@@_\W*WK_031P_T<[:/]-06'_
M5$5<_UI)6/]?2U7_94U2_VI/4/]N44[_<E),_W=32_][5$G_?U5(_H161_Z(
M5T;]C5=$_9-81/R6643\EEE$_)991/R6643\EEE$_)991/R6643\EEE$_)99
MO;\$ +#.! "BX 8"E_\3"(S_(A.#_RX=>?\X)6[_/BUF_T4R7_],-UG_4CM5
M_U@^4?]=0$__8D),_V9#2O]J1$G_;D5'_W)&1O]V1T7_>DA#_WY(0O^"24'_
MADI _XM+/_^/2S__CTL__X]+/_^/2S__CTL__X]+/_^/2S__CTL__X]+K\8"
M *+6 @"6]PH"B_\6!X+_) ]W_RT7;/\S'F/_.B1<_T(H5O])+%'_3R]._U4Q
M2_]:,TC_7C5&_V(V1/]F-T/_:3A!_VPX0/]P.3__<SH^_W<Z/?][.SS_?CPZ
M_X,\.O^&/3K_ACTZ_X8].O^&/3K_ACTZ_X8].O^&/3K_ACTZ_X8]_W4D!O]V
M-1#_=T,<_X!*)_^%4C/_AED^_X5@2/^!:%+_?&]:_'=Y8O=S@VCT;XQN\6R3
M<N]JFG7M9Z!X[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\. YU_+@>9>U8'@8-N!
MUV+>@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!_W4D!O]V-1#_
M=T,<_X!*)_^%4C/_AED^_X5@2/^!:%+_?&]:_'=Y8O=S@VCT;XQN\6R3<N]J
MFG7M9Z!X[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\. YU_+@>9>U8'@8-N!UV+>
M@=1CWX'48]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!_W4D!O]V-1#_=T,<
M_X!*)_^%4C/_AED^_X5@2/^!:%+_?&]:_'=Y8O=S@VCT;XQN\6R3<N]JFG7M
M9Z!X[&6E>NMDJGSJ8J]]Z6&U?NA@NW_H7\. YU_+@>9>U8'@8-N!UV+>@=1C
MWX'48]^!U&/?@=1CWX'48]^!U&/?@=1CWX'48]^!_W8D!O]W-1#_>4(<_X))
M)_^'43+_B%@]_X=?2/^#9E'_?FY:^WEW8O=U@FGT<8IN\6V2<^YKF7;L:)]Y
MZV:D>^IDJGWI8Z]_Z&*U@.=AO('G8,2"YE_.@N-?UX/<8=N#TF/=@\]DW8//
M9-V#SV3=@\]DW8//9-V#SV3=@\]DW8//9-V#_W<D!O]X-1#_?$$<_X5()_^*
M3S+_C%8]_XM=1_^'9%'_@FQ:^WQT8O=X?VGS=(AO\'"0=.ULEWCK:IY[Z6>D
M?NAFJH#G9+""YF*V@^5AOH3E8,>%Y6#3A=UBV8739-R%S&7;ALEEVX;)9=N&
MR67;ALEEVX;)9=N&R67;ALEEVX;)9=N&_W@D!O]X-1#_?D ;_XA')O^-3C'_
MCU4\_XY;1O^+8E#_AFE9_(!Q8O=[>VGS=H5P[W*.=>QNE7GJ:YQ]Z&FC@.=F
MJ8+E9;"$Y&.WA>1BP(?C8<N'WV+5A]5DVH?-9=F(QF?9B<1GV(G$9]B)Q&?8
MB<1GV(G$9]B)Q&?8B<1GV(G$9]B)_WDC!O]Y-!#_@#\;_XI&)O^033#_DE,[
M_Y%:1?^/8$__BF=9_(1N8?=^>&GR>8)P[W2+=NMPDWOI;9M_YVJB@N5GJ83D
M9;"&XV2YB.)BPXGB8M"*V&38BLYFV(K'9]>+P&C6C+YIUHR^:=:,OFG6C+YI
MUHR^:=:,OFG6C+YIUHR^:=:,_WDC!O]Z-!#_@SX;_XU%)?^33"__E5$Z_Y17
M1/^274[_CF58_(AK8?>"=&GR?']P[G>(=NMSD7SH;YF YFNAA.1HJ8?B9K&)
MX62[B^!CQXS<8]2,SV;6C,=HU8W :=2.NFK4CKAKU(ZX:]2.N&O4CKAKU(ZX
M:]2.N&O4CKAKU(ZX:]2._WHC!O][-!#_A3T:_X]$)/^62B[_ETXX_Y=40O^5
M6DS_DF%6_(YI7_:'<&CR@7IP[7N%=^IVCGSF<9>!XVV?AN!JJ(G=9[",VF:[
MC=9EQX[19M2/QVC3C[]JTY"Y:]*1LVS2D;)MTI&R;=*1LFW2D;)MTI&R;=*1
MLFW2D;)MTI&R;=*1_WLC!O]\-!'_B#P:_Y)#)/^82"W_FDPW_YI20?^96$K\
MEU]4]I-F7?"-;F;KAW=OYH"!=N%[BWW<=9.#UW&<A])NI(O/:ZR.S&FUD<EH
MP)+':,^3OVO1D[ALT).R;="4K6_0DZMOT9.K;]&3JV_1DZMOT9.K;]&3JV_1
MDZMOT9.K;]&3_WPC!O]]-!'_BCL9_Y1!(_^:1BS_G$LU_YU0/_^=5DCXFUU1
M\9AC6^N3:V3DC75MWH9^==B AWS1>H^#S':7B<=RGXW$;Z>1P&VPD[YLNY6[
M:\B6MFW/EK!OSI:K<,^6IG'/E:5RSY6E<L^5I7+/E:5RSY6E<L^5I7+/E:5R
MSY6E<L^5_WPC!O]]-!'_C#H9_Y= (O^<12O_GTDT_Z!.//NA5$7TH%I.[)UA
M6.69:6'>DW-JU8Q[=,Z%@WW(?XN$PGJ3BKYVFX^Z<Z.3MG&KEK-OMIBQ;\*8
MK7#-F*ARS9BD<\V8H'3.EY]TSI>?=,Z7GW3.EY]TSI>?=,Z7GW3.EY]TSI>?
M=,Z7_WTC!O]_,Q'_CCD8_YD_(?^>0RG_H4<R_Z-,.OBE4D/PI%A+Z*-?5.&?
M:%W7F'!HSI%X=,:*@'W A(B%NG^/B[5[EY"Q=Y^4K76GEZISL9FG<[V;I7/+
MFZ!URYJ==LR:FG?-F9EWS9B9=\V8F7?-F)EWS9B9=\V8F7?-F)EWS9B9=\V8
M_WXB!O^ ,A#_D#@8_YL_(/^@0BC_I$8P_J9+./2H4$#LJ5='Y*E=4-RE9EK0
MG6YHQY5U<[^.?7VYB82%LX.,C*U_DY&I?)N5I'FDF:%WK9N>=[F<G'?(G)EX
MRIR7><N;E7K,FI1ZS)F4>LR9E'K,F91ZS)F4>LR9E'K,F91ZS)F4>LR9_WXB
M!O^",A#_DC<7_YP]'_^A0"?_ID0N^ZE)-?&L3SSIKE5#X:]=2]6H9%G+H6MG
MPIES<[F3>GVRC8&%K(B)C*:$D)&A@)B6G7V@FIE\JIR6>[:=E'O$GI)\RIV1
M?<J<CWW+FX]]S)J/?<R:CWW,FH]]S)J/?<R:CWW,FH]]S)J/?<R:_W\B!O^$
M,1#_DS87_YX\'O^C/R7_J$(L^*U',N^P33GFM%0_W;-;2="L8EG&I&IFO)UQ
M<K27=WRLD7Z%IHR&C*"(C9&:A966EH*>FI* IYV/?[*>C8#!GHR R9Z+@,J=
MBH#+FXJ RYN*@,N;BH#+FXJ RYN*@,N;BH#+FXJ RYN*@,N;_W\B!O^%, __
ME386_Y\['?^E/23_JT$J];!%+^RU3#3CNE0YV+=92,NO85C!J&AFMZ%O<J^;
M=7RGE7R$H)&#BYJ-BY&4BI.6CX>;FHN%I9V(A+"?AH2^GX6%R9Z%A,F=A83*
MG(6$RYN%A,N;A83+FX6$RYN%A,N;A83+FX6$RYN%A,N;_X B!O^'+P__ES46
M_Z Z'/^G/"+^K3\G\[-$+.FZ2S#AOU(UT[I81\>S7U>\K&9ELJ5M<:F?<WNA
MFGJ$FI:!BY22B)&.CY"6B8R9FH2*HIV!BJV??XJ[GWZ*R)Y_B<F=@(C*G("(
MRYN B,N;@(C+FX"(RYN B,N;@(C+FX"(RYN B,N;_X$B!O^)+@__F345_Z(X
M&_^I.B#[L#TD\+A"*.:_2BK=PT\TSKU61L*V7E:WL&5DK:EK<*2D<7J<GWB#
ME)M^BHZ7AI"(E8Z5@I*6F7Z0H)QZCZN>>(^XGW>0R9YYCLJ=>HS+FWN,RYM[
MC,N;>XS+FWN,RYM[C,N;>XS+FWN,RYM[C,N;_X$B!O^++0[_FS04_Z0W&?^L
M.![XM#HA[;U (^3&22/7QTPSR<%51;VZ7%6RM&-CJ*YI;Y^I;WF6I7:"CJ%\
MB8>=@X^!FXN4?)B4F'>7G9MSEJB=<9:UGG"6QIURE,J<=)++FW61RYIUD<N:
M=9'+FG61RYIUD<N:=9'+FG61RYIUD<N:_X(B!O^-+ W_G303_Z8T&/^O-1OT
MN#<<Z<,^'.#-11_1RTLRQ,540[B_6U.MN6%AHK1H;9FO;G>0JW2 B*=ZAX&D
M@8U[HHF2=:"1EG">FYEMG::;:IVSG&F>PYQKG,N;;IC,FF^7S)EOE\R9;Y?,
MF6^7S)EOE\R9;Y?,F6^7S)EOE\R9_X,A!O^0*PW_H#,1_ZDR%?VS,1?POC07
MY<L[%=K4/QW+STDPOLE20K+$65&GOV!?G+IF:Y*V;'6)LG)^@:]XA7JL?XMT
MJH>0;ZB/DVJGF99GIJ289*:QF6.GP9EDI<V89Z#-F&B?S9=HG\V7:)_-EVB?
MS9=HG\V7:)_-EVB?S9=HG\V7_X0A!O^3*0O_HC /_ZTN$OBX+!+KQB\0X-4X
M"]+:/1S%U$@NN,]00*S*6$^@Q5Y=E<%D:(N]:G*#NG!Z>[=V@72U?8=NLX6+
M:+*.CV2QF))AL*.47K"PE5VQOY5=L="48*K0E&&HT)1AJ-"48:C0E&&HT)1A
MJ-"48:C0E&&HT)1AJ-"4_X8A!O^7* K_IBP-_[$H#O+ )@SCT"@'U-\R"\G?
M/AF]VT<LL=9//:315DR9S5Q9CLEB983&:&Y[Q&]V=,%U?&W ?()HOH2&8[V-
MB5^\EXQ;O**.6;ROCUB]OHY7OM2.6;;3CUJTTY!:M-.06K33D%JTTY!:M-.0
M6K33D%JTTY!:M-.0_X@A!O^<)PC_JB<*_+@A">G*&P75WB $R>4P#[[C/1VT
MX48LJ-Y..IS:54B1UEM5AM-A8'S09VETSFYP;<UU=F?+?'MBRX1^7LJ-@EK*
MEX17RJ.&5<JOAE3+OH93S-6&5,39B%7!V8E5P=F)5<'9B57!V8E5P=F)5<'9
MB57!V8E5P=F)_XT=!?^B)0;_L!\%\L(4 ]G;#@')YB 'O>@O%++G.B*GY4,Q
MF^-*/I#A4$J&WU=4?-Y>773=961LVVQJ9MMT;V':?'-<V81V6=F.>579F'M3
MVJ-\4=JP?5#;OGU0W--\4-3@?E'0X']1T.!_4=#@?U'0X']1T.!_4=#@?U'0
MX']1T.!__Y4: _^I'P/[NA("U,T+ ,GF#P*\[2 +L.TN&:7L.2>:ZT(UC^I)
M087I4$M[Z%=3<NA=6FKG8V!DYVIE7^=R:5OG>FQ7YX)N4^>+<5#GE7).Z)]T
M3.BJ=4OHM79*Y\-V2NC==DODX'5+Y.!U2^3@=4ODX'5+Y.!U2^3@=4ODX'5+
MY.!U_YT6 ?^Q$@'3PPD Q]$* +OR$02O\R$/H_,N'9GS.2J.\T(VA/-*07OS
M4DER\U=0:?-<5F/S8UI=\VE>6?-P857S=V-2\W]F3_*'9TWPCVE+[YAK2N^@
M;$GNJ6U([K-M1^W ;D;MQVY&[<=N1NW';D;MQVY&[<=N1NW';D;MQVY&[<=N
M_Z</ -.Z!P#%QP< NM8) *WZ$P:B^B(2E_HO'XW[.BN#_$,U>OU,/G']445H
M_59+8?Y;3US^8E-7_FA65/UO6%'[=5I.^GQ<3/F#74KXBE](]Y%@1_:984;V
MH&)%]:=C1/2Q9$/TM61#]+5D0_2U9$/TM61#]+5D0_2U9$/TM61#]+5DUK($
M ,2^!@"WS 8 K-P) :#_%@B5_R44B_\R'X+_/"EY_T4R;_]*.6?_3S]?_U5#
M6O];1U7_84I2_V=,3_]L3DW_<D]+_WA12?]^4D?_A%-%_XM40_^154+^F%9!
M_9Y70/VF6$#\J5A _*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E8QK@$ +;$
M! "JTP4 GO(- I3_&@F*_R@3@?\T'7?_/"5M_T(L9?]',EW_3397_U,Z4_]9
M/4__7S],_V1!2O]I0TC_;D1&_W-%1/]Y1D+_?D=!_X1(/_^*23[_D$H]_Y5+
M//^<3#S_GTP\_Y],//^?3#S_GTP\_Y],//^?3#S_GTP\_Y],M[P# *G+ @"<
MVP, DO\0 HG_'0B _RH0=?\Q&&O_.!]B_SXD6_]$*53_2BQ0_U$O3/]7,DG_
M7#-&_V U1/]E-D+_:3=!_VXX/_]S.3W_=SH\_WP[._^"/#G_ASTX_XP]-_^3
M/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^-O^5/C;_E3XV_Y4^JL0  )S2  "/YP(
MAO\1 GS_&P5Q_R0+:/\K$5__,A=7_SD;4?\_'DS_1B%(_TTC1?]2)4+_5R=
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M,:#,4C^5R5E,B\5@5X+#9F!ZP&QG<[YS;6R\>G-GNX)W8KJ*>UZYE'Y:N)^
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M5CS^S58\_LY6//[.5CS^SE8\_LY6//[.5CS^SE8\_LY6SK " +VZ! "QQP0
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MC(*6?(B GX"$?ZJ"@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^
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M8DK.\F5+R/)F2\CR9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8
MPK\& +G," "PW0P I^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%C
MX&9&7M]N2EK?=4Y6WWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??
M\%E&W/5;1MSU6T;<]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,%
M *W1" "D[1 !F^T@!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1
M5^MK0U/K<D90ZWI)3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5)
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M/#GXSSPX]^@\./?L/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP
MF,H! (S8! "$^@X ?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+
M_UHB2/]A)47_9R9"_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_
MOC(Q_] R,?_6,C'_UC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](
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M)P/UE2X%ZYDU".&<.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW>
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M=7SS9'5\\V1U?/-D_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0;
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M2T?%[4M&P_E-1<+_3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$
ML[,! *F] @"?QP4 EM() ([:$@"(VR0"@-HR"'C9/A!QV$@8:M=0'V366"5?
MU5\J6]1G+U?4;C-3TW8V4--_.4S3B#M*TY0^1].@/T74KD!$U+]!0]780$33
M[$!"TO9"0='^1$'1_D1!T?Y$0='^1$'1_D1!T?Y$T9@  ,.E  "UK@  J;@
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M)B[_XR8N_^,F+O_C)B[_XR8N_^,FK:T  )^W  "2P@  ALT  'G:  !P\@@
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M O]X* /_?#$'^'XZ"_!]0Q'I>DP8XG97']QR82C4;6LOSVET-LME?3O'8H5
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M5%.=ZU-3G/A35)K_4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@(
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M.3[+_SD^R_\Y/LO_.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@,
M@L\' 'C9"P!SWA@ ;MXF FC>,P5BWCX*7=Y(#UG>4!15WE@74=Y@&T[>9QY+
MW6\@2-YX(T;>@25#WHPG0=Z8*3_>IBH^W[4J/>#(*CW?XRH\W?$K.]S[+3K<
M_2XZW/TN.MS]+CK<_2XZW/TNP)\  +&G  "DL   F+H  (W#  "!S0( =M<'
M &[H#P!IZ!L!8^@G E[I,@58Z3L(5.E$#$_J3 ],ZE,22>I;%4;J8A=$ZVH9
M0>MR&S_K>QT\ZX8>.NR1(#CLGB$W[:PB-NV[(S7NSR,T[N8C-.OU(S3K^",T
MZ_@C-.OX(S3K^",TZ_@CLZ4  *:M  "9MP  C<$  (#+  !UU0$ :>$& &3S
M$0!>\QP!6?0F E3T, 1/]3@&2_5 "$?V1PI$]DX,0?=5#C_W7 \\]V,1.OAJ
M$S?X<Q0U^'T6,_F(%S'YE!@O^J$9+OJO&BW[OAHL^\\;*_OG&RO[ZQLK^^L;
M*_OK&RO[ZQLK^^L;J*H  )JT  "-OP  @,D  '33  !GW@  7O(( %G^$0!3
M_QH!3O\C DG_*P-%_S,$0?\Z!3[_008[_T<'./]."#7_5 DS_UH),?]A"B__
M:0LL_W(,*O]]#2C_B XF_Y4/)?^A$"3_KA$C_[H2(O_*$B+_T!(B_] 2(O_0
M$B+_T!(B_] 2G+(  (Z\  "!QP  <]$  &?=  !9XP  4_T& $W_#@!(_Q8
M0_\> 3__)@(Z_RT"-_\S S/_.0,P_S\$+O]$!"O_2@4I_U %)_]6!B3_708B
M_V4'(/]N!QW_>0@;_X4(&O^2"1G_G@D8_Z@)%_^S"1?_MPD7_[<)%_^W"1?_
MMPD7_[<)D+H  (+%  !TT   9]P  %CC  !-\   1_\" $+_#  \_Q$ ./\8
M 33_'P$P_R4!+/\K BG_, (E_S4"(_\Z B#_/P,>_T0#'/]) QG_3P,7_U8$
M%?]>!!+_: 01_W(%#_]^!0[_B@4._Y0%#?^>!0W_H@4-_Z(%#?^B!0W_H@4-
M_Z(%_SDO O\\, /_03$#_T0T!/]$.@;_1$4(_T51#/]#71'_06D6_SYV&?\\
M@1S_.HP>_SF6(/\XGB'_-Z4C_S>K(_\VLB3_-KDE_S; )?\URB;_-=<F_S7E
M)O\U[R;_-?@F_S;_)OXV_R;\-O\F_#;_)_HV_RCZ-O\H^C;_*/HV_RCZ-O\H
M_SDO O\^+P/_1"\#_T8R!/](. ;_2$,(_TA/#?]'6Q+_1&<6_T)S&O\_?QW_
M/8H?_SR3(?\[FR/_.J(D_SFI)?\YL";_.+8F_SB^)_\XQR?_.-,H_SCC*/\X
M[2C^./<H^SC^)_DY_R?X./\I^#C_*O8X_RKV./\J]CC_*O8X_RKV./\J_SHO
M O]!+ /_1BP#_THO!/],-P7_34$(_TQ,#?]+6!+_2&07_T9P&_]#?![_08<@
M_S^0(_\^F"3_/: E_SVF)O\\K2?_/+0H_SN[*?\[Q"G_.\\I_CO@*OL[ZRKX
M._4I]CS^*?0\_RKS._\K\CO_+.\[_RWO._\M[SO_+>\[_RWO._\M_SPM O]$
M*0+_2BD#_TXL!/]1- 7_4CX(_U)*#?]051+_36$7_TIM&_](>!__18,B_T.-
M)/]"E2;_09TG_T"C*/] JBG^/[$J_3^X*_P_P2OZ/\LK]S_<+/4_Z2SQ/_0K
M[S_]+.T__RWL/O\OZS[_,.<__S#G/_\PYS__,.<__S#G/_\P_T J O]()@+_
M3B8#_U(I _]6,@7_5SP'_U='#/]541+_4ET7_U!I'/]-="#_2G\C_4B))OM'
MD2CZ1IDI^$6@*O=$IROU1*TL]$.U+?-#O2WR0\@N\$/7+NQ#YR[I1/,MYD/\
M,.1"_S'C0O\RX4+_,]Q#_S3<0_\TW$/_--Q#_S3<0_\T_T,G O]+(P+_4B("
M_U@G _]<+P3_73D'_UY##/];3A'_6%@7_E5D'/I2;R#W4'HD]$V$)_),C2GP
M2I4K[TF<+>U)HR[L2*HOZD>Q+^E'NC#G1\4PYD?2,.)(Y3#?1_(RVT?[--A&
M_S751O\VTD;_-\U(_S?-2/\WS4C_-\U(_S?-2/\W_T8D O]/( +_5A\"_UTD
M _]A+ 3_8S4&_V1 "_]B2A#Z7E06]5M?'/%8:R#N574EZU-_*.A1B"OF3Y$M
MY$Z8+^)-H##A3*<QWTRN,MU+MS/;2\(TV4K/-=5+Y#702_ VS4K[.,I*_SK(
M2O\ZQDO_.\%,_SO!3/\[P4S_.\%,_SO!3/\[_THA O]3'0+_6QP"_V(B O]G
M*0/_:3(%_VH\"?EH1@_R95 5[6%;&NA>9B#D6W$EX5A[*=Y6A"S;5(POV%*4
M,M11FS324*,UT$^J-\Y.LCC,3KPYRD[).LA.W3K$3^T[P4[Y/;Y._SV\3O\^
MND__/K90_SZV4/\^ME#_/K90_SZV4/\^_TT> O]6&@'_7QH!_V<@ O]L)@+_
M;RX$^7 X!_)O0@SK;$L2Y6E7&=]E8A_:86PEU%UV*M!;?B_-68<RRE>/-<A6
MEC?&5)TYQ%.E.\%3K3R_4K<^O5+#/[Q2TS^Y4N@_M5+V0;-2_T&Q4_]!KU/_
M0:Q4_T&L5/]!K%3_0:Q4_T&L5/]!_U < ?]:%P'_9!@!_VP= ?]Q(P+]=2H#
M\W8S!>MV/0KC<T</W&]3%]1K7A_.9F<FRF-Q*\9@>3#"7H$TOUR)-[U:D3JZ
M69@\N%B@/K97J$"T5K)"LE:]0[!5S$.M5N-$JU;S1*A7_D2G5_]$I5C_1*)8
M_T2B6/]$HEC_1*)8_T2B6/]$_U,9 ?]=% '_:!8!_W : ?]V( 'W>B8"[7PN
M ^1\. ?<>D0-TG5/%LMP6A[&;&,FP6AL++UF=3&Y8WTUMF&$.;-?C#RP790_
MKER;0:M;I$.I6JU%IUJX1J59QT>C6MY'H5KO1Y];_$>=6_]'FUS_1II<_T::
M7/]&FES_1II<_T::7/]&_U47 ?]@$@'_:Q0!_W07 /]Z' 'R?R(!YX$I MZ"
M,P33?T ,RWI,%<1V5AZ^<6 EN6YH++1K<3*Q:'DVK6: .JIDB#VG8H] I6"7
M0Z)?H$6?7JE'G5ZT29M=PDJ97=9*EU[L2I9?^DF57_])DV#_2))@_T>28/]'
MDF#_1Y)@_T>28/]'_U@5 ?]C$0'_;A( _W<5 /M^& #M@QT XH<C =:'+@/,
M@ST+Q7])%+U[4QVW=ETELG-E+*UO;3*I;74WIFI\.Z)HA#Z?9HQ!G&641)EC
MG$>78J9)E&*P2Y)AODR08=!,CV+H3(YC^$N-8_]*C&3_28MD_TF+9/])BV3_
M28MD_TF+9/])_UH3 ?]F$ #_<1$ _WH2 />"% #HAQ< W8L< -"++ /'B#L*
MOX1'$[A_41RQ>UHDK'=B*Z=T:C&C<7(VGV]Y.YMM@#^8:XA"E6F019)HF4B/
M9J)*C&:M3(IENDV(9<Q.AV;F3H9G]DR&9_]+A6C_2X1H_TJ$:/]*A&C_2H1H
M_TJ$:/]*_UP2 ?]H#P#_=!  _WT0 /.%$ #DBQ$ UH\7 ,N.*@+"C#@)NHA$
M$K.$3QNL?U@CIWQ@*Z%X:#&==6\VF7-V.Y5Q?3^2;X5"CFV-18MLEDB(:Z!+
MA6JJ38-IMTZ!:<A/@&KC3X!K]$Y_:_],?VO_2W]K_TM_:_]+?VO_2W]K_TM_
M:_]+_UX0 ?]K#@#_=@X ^X - .J(#0#;CPP T)(5 ,>2)P*^CS8(MHQ"$:Z(
M31JHA%8BHH!>*IQ]93"7>FPUDW=S.H]U>SZ,<X)"B'*+1H5PDTF";YU,?VZH
M3GUNM4][;<90>F[@4'EO\DYY;_Y->6__3'EO_TMY;_]+>6__2WEO_TMY;_]+
M_V / /]M#0#_>0P [H,+ -N+"0#4D0H S)43 ,*5)0*YDS0'L8]!$*J,2QFC
MB%0AG81<*9>!8R^2?FHUCGQQ.8IZ>#V&>(!"@W:(17]UD4E\<YM,>7*F3G9R
MLU!U<L-0<W+=4'1S\$]T<_U-='/_3'1S_TQT<_],='/_3'1S_TQT<_],_V(.
M /]O# #\>PH WH8& -6." #/E D QY@1 +Z8(P&UEC(&K9,_#Z:021B?C%(@
MF(E:*).&82Z.@V@TB8%O.85_=CV!?7Y!?7N&17IYCTEV>)E,<W>D3G%WL5!O
M=L%0;G?94&YW[T]N=_Q.;G?_36]W_TQO=_],;W?_3&]W_TQO=_],_V0- /]R
M"@#P?@8 VH@% -"0!P#*EP@ PIL0 +F;(0&QFC &J9<]#J&41Q>:D5 ?E(U8
M)XZ+7RV)B&8SA(9M.("$=#U[@GM!>("$171_C4AQ?9=+;7RB3FM\KT]I>[Y0
M:'S54&A\[4]I?/M.:7S_36I[_TQJ>_],:GO_3&I[_TQJ>_],_V8* /]U" #A
M@0( U(L% ,N3!@#$F@8 O9X. +6?'P&LGBX%I)L[#)V81166E4X>CY-6)8F0
M72R$CF0R?XMK-WJ*<CQVB'E <H:!1&^%BD=K@Y5*:(*@366!K$YC@;Q/8H'1
M3V*!ZTYC@?E-8X'_3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $
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M1$N@_T1+H/]$2Z#_1$N@_T1+H/]$XWT  ,^+  #"E@  MY\  *VF  "CK0
MF;4  )"Y#@"+NAX!A+HM WVY.0EWN$,0<;9,%VNU4QUFM%HB8K-A)EZR:"M:
ML6\N5K!W,E.P@35/KXLX3*^7.DJNI#Q(KK,]1Z['/4>NXSQ&K?,]1JO^/D6K
M_S]%J_\_1:O_/T6K_S]%J_\_VH,  ,>1  "[G   KZ0  *6K  ":L@  D+H!
M (;!"0"!PA@ >\(H G7"-09OP4 ,:<!)$F2_41=?OE@<6[Y?(%>]9B14O&XG
M4;QV*DV[?RU*NXHP2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S=
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M(S?4_R,WU/\CN9P  *ND  "?K   D[4  (>^  ![Q@  <,X# &76!P!=XPX
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M<@05_W\$%/^,!1/_F@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@
M 'W"  !OS   8M@  %3?  !'Y0  /O$  #G_ 0 T_PL ,/\0 "S_%@ I_QP
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M17!OZT1P;_I#<6__07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@
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M0%N#_T!;@_\_6X/_/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF
MIYT" *"?$@"9GR,!DYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQH
MD7$P99!Y-&&.@C=>C8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)
M_SY5B?\^58G_/E6)_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(
M )FD$ "3I2 !C*0N X6C.0E_HD,/>:!,%G2?4QMOG5H@:IQA)6:::"ECF6\M
M7YAW,%N7@#18EHHW5965.5*5HCM0E+ ]3Y3#/4^4WSQ/D_(\3Y+]/$^2_SQ/
MD?\\3Y'_/$^1_SQ/D?\\Y'0  ,^!  #"C   N)8  *V<  "CH0  F*@  )"J
M#0"+JQL A:LJ GZJ-@9XJ4$,<JA)$FVG41AIIE@<9*1?(6"C9B5=HFTI6:%U
M+%:A?B]3H(@R3Y^3-4V?H#=+GJ\X2I[!.$F>W3A)G? X29S\.$F;_SE)F_\Y
M29O_.4F;_SE)F_\YVWH  ,B'  "\D@  L9H  *:@  "<I@  D:P  (>Q" "!
MLA8 ?+,F 7:R,P1QLCT):[%'#F:P3Q-BKU887JY='%JM9"!7K&LC5*QS)E"K
M?"E-JH8L2JJ2+TBIGS!&J:TR1:F_,D2JVC)$J.\R0Z?[,T.F_S-#I?\T0Z7_
M-$.E_S1#I?\TT($  ,&.  "UF   J9\  )ZE  "3K   B+(  'RY @!VNA$
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ME TPXJ,.+N*S#B[CQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*
M )RG  "/L   @[@  ';!  !JR0  7L\  %/5 0!)W 8 1>D/ $+I&0! ZB0
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M @[_E@(-_Z0"#/^P @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0
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M_QKC,O\:XS+_&N,R_QKC,O\:_S@C ?\]( '_01\!_T4C ?]'+ +_1S8#_T9
M!/]$3 ;_05@(_S]D"_L^;P[Y/'D0]CN#$?0ZBQ/S.9,4\3F9%/ XH!7N.*86
M[3BM%NPXM!;J.+T6Z3C)%N<XVQ;C.>H6X#CU&-TX_QK;-_\<V3?_'=<W_QW6
M-_\>UC?_'M8W_Q[6-_\>_SL@ ?]!' '_11H!_TL@ ?]-* '_3C("_TT\!/]*
M1P;Z2%,(]D9?"_)$:@[O0G01[$%^$^I AQ3H/XX5YCZ6%N4^G!?C/:,8XCVJ
M&. ]LAC?/;L9W3W&&=L]V!K6/>D:TCWU'<X]_A_,//\@RSS_(<D\_R')//\A
MR3S_(<D\_R')//\A_S\< ?]%%P'_2Q<!_U = ?]3) '_5"T"_U,W _=10@7Q
M3DT([$Q:"^A*90_E2&\1XD=Y%-]%@A;=1(H7VD.1&=A"F1K50I\;TT&F'-%!
MKAW/0;<>SD'!'LQ!T!_)0N4?Q4+S(<)!_B/ 0?\DOD'_)+U!_R6]0?\EO4'_
M);U!_R6]0?\E_T(8 ?])$P#_4!0 _U89 /]9( '_6B@!]UHR N]8/03H54D'
MXU-5"MY18 [93FH2U$QT%M!+?!C.280;S$B,',I'DQ[(1YH?QD:A(<1&J2+"
M1;$CP46\([]%R22]1M\EN4;O)K9&^R>T1O\HLT;_*+)&_RBQ1O\HL4;_*+%&
M_RBQ1O\H_T85 /]-$0#_51( _UL6 /]>&P#Y8",![V L >9>-@/?7$0%V%E0
M"M%76P_,5&44R%)N&,50=QO#3W\=P$Z&'[Y-CB&\3)4CNDN<)+A*I":V2JPG
MM$JV*+-)PRFQ2=8IKDKJ*JM*^"NI2O\KJ$O_*Z=+_RNG2_\KITO_*Z=+_RNG
M2_\K_TD2 /]0#@#_61  _U\2 /]C%@#R91T YV4E -YD,0'48C\%S6!+"L==
M5@_"6F 5OEAI&;M6<1RX5'D?ME.!(K-2B"2Q4) FKU"7**U/GRFK3J@KJ4ZR
M+*=.OBVF3LXNHT[F+J%/]2Z?3_\NGD__+IU/_RZ=4/\NG5#_+IU0_RZ=4/\N
M_TP0 /]4#0#_70X _V,/ /EG$0#K:14 WVH< --J+ '+:#L$Q65'";]B4@^Z
M8%P5MEUE&;);;1VO674AK%A\(ZI6@R:G58LHI523*J-3FRRA4Z,NGU*M+YU2
MN3";4LDQF5+B,9=3\C&64_\QE53_,914_S"45/\PE%3_,)14_S"45/\P_T\.
M /]8"P#_8 L ^V8, /!K#0#D;0X UFX6 ,QO* '$;3<$O6M$";=H3P^R95@5
MKF)A&JI@:1ZG7G AI%UX):%;?R>?6H<JG%F.+)I8ERZ85Z PE5:J,I-6M3.1
M5L4TD%;=-(Y7\#2-5_TSC%C_,XQ8_S*,6/\QC%C_,8Q8_S&,6/\Q_U$, /];
M"0#_8P@ ZVH' -UN" #8<0H SW(3 ,9S)0&^<C0#MW!!"+%M3 ZL:E44IV=>
M&:-E91Z@8VTBG&%T)9I@>RB77H,KE%V++9)<DS"/6YPRC5JF-(M:LC6)6L$V
MAUK6-H9;[3:%6_LUA5S_-(1<_S.$7/\SA%S_,X1<_S.$7/\S_U,* /]=!@#U
M9@0 WVT# -5R!@#0=0D R781 ,!W(@"X=C$#L70^!ZMQ20ZF;E(4H6Q;&9UI
M8AV99VHBEF9Q)9-D>"B08W\KC6&'+HI@D#"(7YDSA5^C-8->KS:!7KXX@%[1
M.']?ZC=^7_HV?F#_-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0
MVG # -!U!0#*> < PWH/ +M['P"S>B\"K'@\!Z9U1@VA<U 3G'!8&)=N8!V3
M:V<AD&IN)8UH=2B*9WPKAV:$+H1DC3&!8Y8T?V.A-GQBK3=Z8KLY>6+..7AC
MZ#AX8_@W>&3_-GAD_S5X9/\U>&3_-7AD_S5X9/\U_U<% /]B 0#A;   U',"
M ,MX! #%>P4 OGT- +9^'0"O?BP"J'PY!J%Y1 R<=TX2EW16&))R71R.<&0@
MBFYK)(=L<BB$:WHK@6J"+GYIBC%[:)0T>&>?-G9FJCAT9KDY<V;+.G)FYCER
M9_<X<F?_-W)H_S9R:/\U<FC_-7)H_S5R:/\U_UD" /9E  #=;@  SW8! ,=[
M P# ?P0 N8 , +&"&@"J@BH"HX W!9U]0@N7>TL1DGA4%XUV6QN)=&(@A7)I
M)(%Q<"=^;W<K>VY_+GAMB#%V;)(T<VN<-G!JJ#AN:K<Z;6K).FQJY#IM:_4X
M;6O_-VUK_S9M:_\V;6O_-FUK_S9M:_\V_UL  .MG  #9<0  S'D  ,-^ @"[
M@@, M(0) *V%& "FA2@!GX0U!9F"0 J3?TD0C7U2%HE[61N$>6 ?@'=G(WQU
M;B=Y='4J=G-]+G-RAC%P<9 T;7";-FMOISAI;[4Z:&_'.F=OXCIG;_0X:&__
M-VAO_S9H;_\V:&__-FAO_S9H;_\V_UX  .1J  #3=   R'P  +^! 0"WA0$
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M,U*%_S-2A?\SXVP  ,YY  #!@P  MHL  *R1  "BE0  EYD  (^;"P"*G1@
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MEQX^L*8@/+"W(#RPS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8
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M!BC=P08HW=X&)]OO!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0
M?K0  '&\  !EPP  6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ N
MYC, +>8\ "OG1  JYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWK
ML@,<[,<#'.SA QOJ\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT
M &7%  !9RP  3-   $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL
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M1V8+SD9P#LM%>!#(1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI
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M)Y-.[">13_LGD$__)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0
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M>ES_+'E<_RMZ7/\J>ES_*GI<_RIZ7/\J_U$  /);  #>9   SVH  ,=N @#
M< 0 NG , +)Q&@"K<2D!I7 W Y]N0@>:;$L,EFI4$9)H7!6.9F,8BV5I&XAC
M<!Z%8G@A@F%_)(!@B"9]7Y$I>U^<*WA>IRUV7K4N=5[&+W1>X2]T7_,N=%__
M+'1@_RMT8/\K=&#_*W1@_RMT8/\K_U,  .A>  #99P  RVT  ,-Q 0"[<P(
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M+&!O_RQ@;_\LZUX  -AI  #'<@  O'D  +-_  "K@@  H8(  )F##@"4A!T
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MF"5+BZ4G28NU*$B+RBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\
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M%SBKPQ<XJN$7-ZGS&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@
MEYL  (NA  !_I@  <ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(
MN$,"1KA+ T2X4@1!N%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*W
MP0\QM]X/,;;R$#"T_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(
M (*H  !UK0  :;,  %ZW  !3NP  1\ % $/"$ !"PAL 0,,G #_#,@ ^Q#P
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M 1/E[P$3X_H!$^/Z 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@
M2,H  #W/   STP  *MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4
M[S4 $_ ] !'P1@ 0\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GV
MV0 (]>T "/7M  CU[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](
M #'8   GW0  '^$  !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D
M"OXP  C_.  &_T$  _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP
M_\X  /_/  #_SP  _\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A
M   <Y0  %.D  !'W   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C
M  #_*@  _S(  /\\  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(
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M$ZX\\12K//T5J3S_%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H
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M((-/_Q^"4/\?@E#_'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0
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M)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U6/\A_TT  .57  #37P
MR&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG/02494<'D&1/"HQB5PV(
M85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7(71:HB-R6J\D<5J_)7!:
MU25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A^D\  .%:  #/8@  Q&<
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M)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$:P  N7$  +!U  "G=P
MGG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS3@MU<E4.<7%<$6YP8Q1K
M;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW)EIKRB9::^<E6VOW)%MJ
M_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@  MG0  *QY  "C>P  F'D
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MA1  >88> '6'*P%QAS8";88_!&F%1P=EA$\*8H-6#5^#7 ]<@F,26H%K%5>
M<QA4?WT:47^('$]^E!]-?J(@2WVQ(4I]Q")*?>$A2WST(4M[_R!+>_\@2WO_
M($M[_R!+>_\@T&<  ,!R  "T>P  JH(  *"&  "5B   AX@  'R*  !VC X
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M'0!;GBD 6)XT 56>/0)2G44#4)U-!4V=5 =+G%L)2)QC"T:<:PU#FW4/09N
M$3Z:C1,\FIL4.IJK%3F:O14YFMD5.9CO%CF7_!8XEO\7.)7_%SB5_Q<XE?\7
MNWH  *^%  "DC   F)$  (V5  "!F@  =9T  &B@  !;I   5J4, %.F%P!1
MIR, 3Z<O $RG. %*IT$!2*=) D:G4 1#IU@%0:=?!C^F: @]IG(*.J9]"SBF
MB@TVI9D.-*6I#S.ENP\SI=0/,Z3N#S*B^Q RH?\1,J'_$3*A_Q$RH?\1M((
M *B,  "=D@  DI<  (:<  !YH0  ;:4  &&I  !5K   2Z\% $>P$ !%L!P
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M !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8RO\"FYD  (^?  ""I@
M=:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C, 0 @T 8 &=4+ !;7$  5
MV!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U? !#=;0 0WGX #M^1  [@
MI  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L DI\  (6G  !WK@  :K4
M %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6V@$ $=X& !#G#0 .YQ(
M#>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K7@ #ZVX  >N   #JE
MZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<  'FO  !KMP  7KX  %'%
M  !#R0  -\T  "W1   CU@  &]L  !/?   .XP  #.X"  KV"@ ']@X !?82
M  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@  ]ET  /9N  #V@0  ]I4
M />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX  !@P   4L@  $3-   W
MT0  *]<  "'<   8X   $>0   SG   '[P  !/H   '_ P  _P@  /\-  #^
M$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL  /];  #_;   _X   /^2
M  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_&B4 _Q4G /\1+@#_$#H
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M.[P/H#O-#YX[YA";//41FCS_$9D\_Q&8//\1F#S_$9@\_Q&8//\1_SH! /]
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M%HI%W!:(1O 6AD;]%H9&_Q:%1_\5A4?_%85'_Q6%1_\5_S\  .Q(  #=3P
MSU,  ,95  # 4P, NU$, +-2&0"M4RD J%,V :-20@*?44L$G%!4!IE/7 B6
M3F,*E$UJ#)%,<0Z/2W@/C4M_$8M*AQ*)2I 4ATF:%85)I1>#2;$8@DG &(%*
MUAE_2NT8?DO\&'Y+_Q=]2_\7?4O_%GU+_Q9]2_\6_T,  .9,  #64P  R5@
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M&VI7_QIJ5_\9:U?_&6M7_QEK5_\9ZTP  -A6  #(7@  O&(  +-E  "K90
MHV(  )QB#@"68QP D60I (QC-0&(8C\#A&%(!8!@4 =]7U<)>EY="W==9 UU
M7&L0<UQR$G!;>Q1N6X07;%J/&&I:FAIH6J<<9EJV'65:R!UE6N0=95KV'&5:
M_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80  N68  +!H  "G:0  GF4
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M&E=F_QI79O\:VUD  ,=B  "Z:@  KW   *9S  ":<P  CW   (=Q!0"!<A$
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MC!-$@9H50H"I%D& NA9 @-(607_M%D%^^Q9!??\607W_%D%]_Q9!??\6PFH
M +5U  "J?0  GX(  )*#  "%A   >84  &J)  !DB@, 8(P0 %V-&P!;CB<
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M""Z@LP@NH,D(+I_G""V=]PDMG/\*+9O_"BV;_PHMF_\*KX   *.)  "7C@
MC9,  '^5  !RF   9IP  %N@  !/I   1:<  #ZI#  \JA0 .JH? #FJ*0 X
MJS( -ZL[ #6K0P TK$L ,JQ3 3&L7 $OK&8"+:QQ BNL?P,JK(X#**R>!">L
ML 0FK,4$)JOD R6I]00EJ/\%):?_!26G_P4EI_\%IXD  )N/  "1E   A)D
M 'B>  !KH@  7Z8  %.J  !(K0  /;   #2S P OM0X +;46 "RU(  KMBD
M*K8R "FW.@ HMT, )[=, ":X50 DN%\ ([AK "*X> $@N(@!'[B9 1VYJP$<
MN< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\  )25  "(FP  >Z$  &ZF
M  !BJP  5K   $JS   _M@  -;D  "R\   DOP8 '\(- !W"%  <PAX &\,F
M !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3QG\ $L:1 !''I  0Q[D
M#\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<  !^H@  <:D  &2O  !8
MM   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P& !#0"P .T1$ #=$9  W1
M(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW( !M2$  74F  $U*L  ]7
M  '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !SJP  9K$  %FX  !,O0
M/\   #3#   JQP  (<H  !G.   2T@  #=8!  G;!0 &W T !-P1  /=&  !
MWB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T  #DB   Y)L  .6N  #E
MP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP  6KL  $W!  ! Q   ,\@
M "C,   ?T   %]0  !#9   +W0  !>$   #D    Y0<  .8-  #G$0  Z!8
M .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q=@  \HH  /.<  #SK0
M]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0  $#)   SS0  )]$  !W6
M   4W   #N    CC   !Y@   .H   #N    [@   .\$  #P"@  \0X  /,2
M  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P  _W8  /^)  #_F@  _Z8
M /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)*P#_!C< _P-$ /\ 40#_
M %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6 /\ G #_ *$ _0"F /L
MK #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H [@#_ .X _P#M /\ [0#_
M .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_##0 _PI! /\'30#_!5D
M_P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"F0#Y IX ]P*D /4"J@#S
M ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_ .8%_P#F!O\ Y@;_ .8&
M_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3  _Q ] /\.20#_#%4 _PM@
M /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S"IL \0JA .\)IP#M":X
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M /\E"P#_* P _RD0 /\H%@#^)B  ]"0K .PA. #F($0 X1]0 -T?6P#9'F4
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M!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<,?\(_S   /\U  #O.
MXCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X2@&S.%0!L#== JTW9 *K
M-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@!YXUJ@B<-;8(FS7%"9DU
MW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*_S,  /8Z  #D/P  V$(
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M$7A&_Q!X1O\0>$;_#WA&_P]X1O\/\#\  -])  #-3P  P5,  +A4  "Q4@
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M$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=80  E5T  (U>"0"'7A,
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MC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\23F7_$DYE_Q).9?\2S%H
M +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q;@L ;6\4 &EP(0!F<2P
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M#CQ[LPX\>\@./'KF#CQY]PX\>/\./'C_#CUW_PX]=_\.O&@  *]R  "D>0
MEGH  (AZ  !\>@  <'P  &-_  !<@@  5X0+ %.%% !1AB  3X8J $Z'- !,
MASP!2H=$ 4B'2P)&AU,"1(9: T*&8@1 AFP&/H5V!SN%@P@YA9$*.(2@"S:$
ML0LVA,8+-H/D"S:"]@LV@?\,-H#_##: _PPV@/\,MF\  *IX  "??P  D'X
M (-_  !W@   :X(  %Z'  !5B@  3HP& $J.$ !(CQH 1X\E $60+P!$D#@
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M 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+CP  ?9$  &^4  !CF
M5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O%P AKR$ (+ I !^P,0 >
ML#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0 !6RH@ 4LK8 $[+. !.Q
MZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP  =9H  &B?  !;HP  4*@
M $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3O!4 $KP> !&])@ 1O2X
M$+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^F0 (OJP ![["  >^WP (
MOO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4  &"J  !3KP  1[,  #RV
M   QN   )[L  !^^   7P0  $<0!  S("  (R0X !\D4  ;)'  %R20 !,HL
M  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C   RY\  ,NS  #+R   S.(
M ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S  !(N   .[L  #"^   F
MP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/  #4%   U1H  -8B  #7
M*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$  -VD  #>M@  WL@  -[>
M  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \P   +\0  "3'   ;RP
M$\\   W2   'U@   -L   #>    WP,  . )  #A#@  XA(  .,7  #E'@
MYB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4  #NI0  [K0  .["  #N
MQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0  ),T  !G1   1U@  "]L
M  />    X0   .4   #H    Z0   .H   #K!@  [0L  .\/  #P$P  \AH
M /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^DP  _J(  /ZM  #^KP
M_J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!! /\ 3@#_ %H _P!E /\
M;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P ]P"B /8 IP#U *T \P"U
M /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J /\ Z@#_ .H _P#J /\
M_Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\ 2@#_ %8 _P!A /\ :P#]
M ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "? .X I #M *L [ "R .H
MN@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\ X0#_ .$ _P#A /\ _Q48
M /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_ %$ _@!< /H 9@#V &\
M\@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8 H0#D *@ XP"O .$ N #?
M ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_ -0#_P#4 _\ _Q@3 /\5
M$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P ]097 /$&80#M!FH Z05R
M .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9!J4 UP:M -0&M0#2!L
MT ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,_P#&#/\ _QL. /\9# #_
M& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2 .4-7 #A#64 W@UM -L-
M=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J, RPZK ,D.M #(#L  Q@[/
M ,,0Y@# $?4 O1+_ +P2_P"[$O\ NA+_ ;H2_P&Z$O\!_Q\* /\<! #_'P@
M_Q\- /\=$@#X&AL [A8F .84,P#@$S\ VA-+ -035@#0$U\ SA1H ,L4;P#)
M%'< QQ5] ,85A #$%8H PQ61 ,$6F # %I\ OA:G +P7L "[%[P N1?+ +<8
MX@"S&?(!L1K_ :\;_P&N&_\!KAO_ :T;_P&M&_\!_R($ /\B  #_)0( _"0'
M /<A# #L'1( X1H< -@:*@#0&S@ RQU% ,<=4 ##'EH P!YB +X>:@"\'W$
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M!8TQ_P6-,?\%C#'_!8PQ_P6,,?\%_RT  .HU  #<.@  SCT  ,8\  # -P(
MNS,- +,T&0"N-B< J3<T *4W0 "B-TH GS=3 9TV6@&;-F$!F39H I<U;P*5
M-74#E#5\ Y(UA 20-8T$CS66!8TUH 6+-:L&BC6Y!H@UR@>'-N4'A3;V!X0W
M_P>#-_\'@S?_!X(W_P>"-_\']#(  .,[  #200  QD0  +U#  "W/P  L3L)
M *H[% "E/"( H#TP )T].P"9/44 ECU. 90\5@&2/%T"D#QC HX[:@.,.W$$
MBCMX!(@Z@ 6'.H@&A3J2!H,ZG >!.J@(@#JU"7X[Q@E].^$)>SSS"7L\_PEZ
M//\(>CS_"'H\_PAZ//\([C<  -U!  #+1@  OTD  +9)  "N1@  J4$$ *-!
M$0"=0AX F$,K )5#-P"10T$ CD)* 8Q"4@&)05D"AT%? X5!9@.#0&T$@4!T
M!8! >P9^/X0'?#^."'H_F0EX/Z4*=T"R"G5 PPMT0-T+<T'Q"W)!_PIR0?\*
M<D'_"7)!_PER0?\)Z3P  -5%  #%2P  NDX  +!.  "G2P  HD8  )M&#@"6
M1QH D4@G (Y(,P"*2#T AT=& 81'3@&"1E4"@$9< WY%8@1\16D$>D5P!7A$
M> 9V1($(=$2+"7)$E@IP1*(+;T2O#&Y$P QM1=D-;$7O#&M%_0MK1O\+:T;_
M"FM&_PIK1O\*Y4   ,])  #!3P  M5(  *M2  "A3P  FTH  )1*# "/2Q<
MBTPD (=,+P"$3#H @4Q# 7Y+2P%[2U(">4I8 W=*7P1U268%<TEM!G%)=0=O
M27X(;4B("6M(DPMJ2)\,:$BM#6=)O0UF2=0.94GM#65*_ QE2O\+94K_"V5*
M_PME2O\+X$0  ,M-  "]4@  LE8  *95  "<4@  E4X  (Y."0")3Q0 A5 @
M (%0+ !^4#< >U!  7A02 %U3T\"<TY5 W%.7 1O3F,%;4UJ!FM-<@=I37L(
M9TV%"F5-D0MD3)T,8DVK#6%-NPY@3=$.8$WL#F!-^PU@3?\,8$W_"V!-_PM@
M3?\+W$<  ,=0  "Y5@  KED  *)8  "85@  D%$  (E2!@"#4Q$ ?U,= 'M4
M*0!X5#0 =50] 7)310%P4TP";5)3 FM260-I4F $9U%G!F51;P=C47@(8E&#
M"F!1CPM>4)L-75"I#EM1N0Y;4<X/6E'J#EM1^@U;4?\,6U'_#%M1_PM;4?\+
MUDH  ,-3  "V60  JUP  )Y:  "360  BU0  (16 P!^5A  >E<: '97)@!S
M6#$ <%<Z &U70@%J5TD":%90 F965P-D5EX$8E5E!6!5;0=>578(756!"EM5
MC0M95)H-6%2G#E95N ]65<P/5E7I#E95^0U65?\-5U3_#%=4_PQ75/\,T4T
M ,!6  "S7   IUX  )I=  "/7   AE@  ']9  !Y6@T =%L7 '%;(P!N6RX
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M#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)8/\+Q%@  +5@  "J9@
MFV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H&@!=:24 6VHO %EJ. !7
M:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX!T=HA E&:)(*1&>A"T-G
ML0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+OUP  +%D  "F:@  EFD
M (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7;R$ 57 K %-P-0!1<#T
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M<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C $5_+ !#@#4 0H ] $&
M10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$,G^:!3%^J@8P?KT&,'[:
M!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4=0  AG4  'EV  !N=P
M8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R()P [B3  .HDX #B)0  W
MB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7 RJ(IP,IB+H#*8C4 RF&
M[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@  @'H  '1[  !H?@  78$
M %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 QDBD ,),R "Z3.@ MDT$
M+)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3I $AD[<!()// 2&2[ $@
MD/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X   &Z"  !BA0  5XD  $V.
M  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2( ))XJ ".>,@ BGCH (9Y"
M "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7G[( %I_) !:>Z  6G/<
M%IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+  !;CP  4),  $:8   \
MG   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA !:J*0 5JC$ %*HY !.J
M0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP #*O!  RJWP ,J?( #:C\
M  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4F@  29\  #^C   UIP
M*ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV'P *MB< ";8O  BV.0 '
MMT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T  "VRP  MN4  +7Q  "U
M]P  M?< CY$  (&4  !REP  99P  %BA  !,I@  0:L  #>O   LL@  ([4
M !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P  PAX  ,(F  #"+P  PSD
M ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%O   Q-$  ,3F  #$[@
MQ.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8  "RY   BO   &;\  !'"
M   ,Q0  !L@   #+    S <  ,P-  #-$0  S18  ,X=  #/)   T"T  -(X
M  #41   U%(  -5A  #5<P  UH<  -:;  #6K0  U[\  -C.  #8W0  V-T
M>Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"   7Q@  $,D   K,   "
MT    -0   #7    V    -H%  #;"P  W X  -X3  #?&0  X2$  .,J  #E
M-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX  .JZ  #JPP  ZL, <*@
M &*O  !5M@  1[P  #G    LQ   (,@  !;,   .T   !]0   #9    W0
M .$   #C    Y    .8   #G 0  Z0<  .L,  #L$   [A4  / =  #S)P
M]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI  #[L   ^[  _PL; /\'
M&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %< _P!B /\ :P#_ ', _0![
M /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S *D \0"P .\ N #N ,,
M[ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@ _P#H /\ _PX8 /\*%0#_
M 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!> /H 9P#W &\ ]0!W /,
M?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4 Z "L .8 M #D +\ XP#,
M .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#< /\ _Q 3 /\-$0#_!A
M_P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$ 8@#N &L [ !R .H >0#H
M '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I -H L0#8 +L U0#( -(
MW0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\ _Q$/ /\.#0#_# T _PL2
M /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D &8 X0!M -\ = #= 'L
MVP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P K@#* +@ R #$ ,8 UP#%
M .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+ /\0!@#_$ D _Q . /\.
M% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&  TP1H - $;P#.!78 S 5\
M ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^!K4 O0;" +L(U "Z">D
MMPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4  #_%@, _Q0) /\1#@#R
M#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB ,0-:@#"#7$ P UW +\-
M?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0 L@_! +$0U "N$>L JQ+Z
M *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y&P  ZQD  .44!@#E$ X
MV0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<59 "U%6L M!5Q +(5> "Q
M%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB] *08SP"B&N< GQKW )T;
M_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)   W24  -0A 0#/&P@ RA<1
M ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I'V8 J!]L *8?<P"E'WD
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M WPQ_P-\,?\#[2\  -LW  #)/0  OCX  +,\  "L.   IS,$ *(R$0"=-!T
MF34J )4U-0"2-4  CS5) (TU4 "+-5< B35> 8<U9 &%-&L!A#1R H(T>0*
M-(("?C2+ WTTE@-[-:$$>36N!'@UO@5W-M0%=C;M!70W_ 5T-_\$=#?_!'0W
M_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@  GSD  )HX#@"4.AD D#HF
M (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %].F<">SIN GDZ=0)W.GX#
M=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\^@9L//\%;#S_!6P\_P5L
M//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\  )(^"P"-/Q4 B3\A (5
M+0""0#< ?T!  'U 2 ![0$\!>4!6 7<_70%U/V,"<S]J G$_<@-P/WH#;C^$
M!&P_D 5K/YP&:3^I!F@_N =G0,P'9D#H!V9 ^09E0/\&94#_!F5 _P5E0/\%
MW#X  ,=&  "Y2P  K$P  *!*  "71P  D4,  (M#" "&0Q( @D0> 'Y$*0![
M130 >44] '9%10!T1$P!<D13 7!$60%N1& ";$-G FM#;P-I0W<$9T.!!69#
MC09D0YD&8D.G!V%$M@A@1,H(8$3F"%]%^ =?1?\'8$7_!F!$_P9@1/\&UD$
M ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! " 1Q  ?$@: 'A()@!U23
M<TDZ '!)0@!N24D!;$A0 6I(5@%H2%T"9DAD F5(; -C2'4$84=_!6!'B@9>
M2)<'74BE"%M(M A;2,<)6DCD"%I)]@A:2?\'6DC_!EI(_P9:2/\&T44  +],
M  "R4@  HU$  )=0  "-3@  ADH  (!* 0!Z2PX =DP7 '),(P!O3"T ;4TV
M &I,/P!H3$8 9DQ- 61,4P%B3%H"84QA E],:0->3'($7$Q\!5I,B 993)4'
M5TRC"%9,L@A53,8)54SB"55,]0A53/\'54S_!U9,_P963/\&S$@  +Q0  "O
M50  H%0  )-3  ")40  @4T  'I.  !U3PP <$\5 &U0( !J4"H 9U S &50
M/ !C4$, 85!* 5]040%=4%@"7%!? EI09P-94' $5U!Z!550A@944),'4E"A
M"%%0L0E04,0)4%#A"5!0] A14/\'44__!U%/_P913_\&R4L  +E3  "K5P
MG%8  (]5  "%5   ?%   '51  !P4@D :U,2 &A4'0!E5"< 8E0Q &!4.0!>
M5$$ 7%1( 5I43P%95%8!5U1= E9490-45&X$4E1X!5%4A 9/5)$'3E2@"$Q4
MKPA,5,()2U3?"4Q4\PA,4_\'3%/_!TU3_P9-4_\&Q4X  +96  "G6@  F%D
M (M8  "!5P  =U0  '!5  !J5@8 9E<0 &)7&@!@6"0 75@N %M9-P!963\
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M!SUA[P8]8?T&/F#_!CY@_P8^8/\&N5D  *MA  ":80  BV$  ']A  !T80
M:6$  %]B  !99   5&8) %%G$0!.9QH 3&@D $MI+0!):38 2&D^ $9J10!%
M:DP 0VI4 4)J7 % :64"/FEO CQI>P,[:8D$.6F8!3AHJ 4W:+H%-VG3!3=H
M[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590  AF0  'IE  !O90  9&8
M %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"<#( 07 Z $!Q0@ _<4D
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M B)]_P(B??\"I7$  )-Q  "#<0  =G$  &QR  !@=0  5G@  $Q\  !#@
M.X,  #.&   MB0H *HH1 "F+&0 GBR( )HLJ "6,,0 DC#D (XQ" "*-2@ A
MC50 ((U> !^-:P =C7D '(V* !N-G  9C:X &(S$ !B,XP 9BO4 &8G_ 1F(
M_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?   4(   $:$   \B0  -(P
M "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9ES( &)@Z !>80P 6F$T
M%9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7W0 /EO( $)7\ !"4_P 0
ME/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH  $"/   VDP  +9<  "::
M   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D #J0Q  VD.@ ,I$4 "Z10
M  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #HN8  Z'S  .A^P #H?L
MC8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:   OG@  )J(  !ZE   7
MJ   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I  "P,@  L#P  +!'  "P
M4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD  *[K  "N]   KO0 AXD
M 'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   GJ@  'JX  !:Q   0M
M"[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\*   O#$  +T\  "^2
MOE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>  "]ZP  O>L ?Y(  '"5
M  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@  %;D   Z\   )OP   L(
M  #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P  RB<  ,PP  #./   SDD
M ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/VP  S]L =YP  &BA  !;
MIP  3JX  $&T   TMP  *+H  !V]   3P   #<0   ;'    R@   ,X   #0
M    T0   -("  #3"   U0P  -80  #9%0  VQP  -TD  #@+P  XCP  .-+
M  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP  Y<, ;*4  %^L  !1L@
M1+D  #6\   HP   ',0  !+(   ,RP   \\   #3    V    -P   #?
MWP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8  #N(@  \2X  /,\  #T
M30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+  _P,7 /\ %0#_ !4 _P 8
M /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#] &\ ^P!V /D ?0#X (,
M]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T LP#K +T Z@#+ .@ X0#G
M /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3 /\ $0#_ !$ _P 5 /\
M'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L \@!R /  >0#O '\ [0"$
M .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@ +D W@#& -P V@#: .P
MV #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\##@#_  T _P 2 /\ &@#_
M "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N .4 = #C 'H X@"  .
MA0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4 S@#! ,P T0#+ .< R0#U
M ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_ @H _P / /\ %0#\ "
M\0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -< ;P#4 '4 T@![ -  @ #.
M (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\ +\ RP"] ., O #R +L
M_0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04 _P8+ /\!$ #P !D Y@ E
M .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#& '  Q0!V ,, >P#! ($
MP "' +X C@"\ )0 NP"< +D I "W *X M0"Y +, R "Q -\ L 'O *\!^P"N
M O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L# /('"@#B 1$ VP(= -(#
M*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L N 5Q +<%=@"U!7P LP:#
M +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F"MT I0OP *,,_0"B#?\
MH0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/ P#6"0L S@@4 ,8*(@#
M##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK *L.<0"J#G@ J Y^ *</
MA0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X F1+Q )<3_P"6%/\ E13_
M )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$% 4 P1 . +H2&P"T$RD
ML!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6; ">%G( G!9Y )L7@ "9
M%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON (L<_0"*'/\ BAS_ (D<
M_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(   M!D+ *X:%0"H'", I!TO
M *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2'VT D1]T (\@? ".((0
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MCP%T+YL!<R^H G$OM@)P,,D";S#E FXQ]P)M,?\";3'_ FTQ_P)M,?\"WS(
M ,DY  "[/@  K#T  *$Z  ":-P  E3,  ) Q"@",,10 AS(@ (0S*P"!,S4
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M UL_KP1:/\$$6C_=!%D_\@19/_\#63__ UD__P-9/_\#S#\  +Q&  "K2
MG$<  )%&  "(1   @D   'P_  !W0 P <T 5 &]!( !L02H :D$S &A!.P!F
M0D, 9$)* &-!4 !A05< 8$)> 5Y"90%=0FX"6T)X EI"A -80I #5T*>!%9#
MK0150[\$5$/:!%1#\0140_X#5$/_ U1#_P-40_\#R$(  +A)  "G2P  F$H
M (U)  "#1P  ?4,  '9#  !Q1 H ;402 &I%'0!G12< 9$4P &)%. !@13\
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M!$9/[01&3OP$1D[_ T=._P-'3O\#O4P  *Y2  "<40  C5$  (%1  !W4
M;DP  &=.  !B3P  75 - %I0% !741X 55$G %-1, !14C@ 4%(_ $Y21@!-
M4DT 3%-5 $I370%)4V4!2%-O D93>P)%4XD#0U.7 T)3IP1!4[@$05//!$%3
M[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85   B50  'U3  !S4P  :5$
M &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,5S4 2U<\ $I71 !(5TL
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M C)@_P(R8/\"KEP  )M=  "*70  ?%T  '!=  !F70  7%X  %)@  !,8@
M164  $%F"@ ^9Q$ /&@: #MH(@ Y:2L .&DR #=J.@ V:D$ -6I) #1J4@ S
M:EL ,6IE #!J< $N:GX!+6J. 2QJGP$K:K !*FK& 2IIY0$J:/8"*V?_ BMG
M_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80  6&,  $YF  !':   0&L
M #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N<CT +7)% "QR30 K<E<
M*G)A "ER;0 G<GL )G*+ "1RG $C<JX!(W+# 2-QX@$C</0!(V__ 2-N_P$C
M;O\!H64  (YD  !_9   <F0  &AE  !>9@  5&D  $EL  !";P  .W(  #1U
M   N> H *WD1 "IY&  I>B$ )WHH "9Z,  E>S@ )'M  "-[2  B>U( (7M<
M "![:  ??'8 '7R& !Q[F  ;>ZH &GN_ !I[W@ :>?( &WC^ !MW_P$;=_\!
MF6D  (AI  !Y:0  ;6D  &-J  !9;   3V\  $5S   ]=P  -7H  "Y]   G
M@0, (H,- ""$$@ ?A!H '80B !R%*@ ;A3$ &H4Y !F%0@ 8ADP %X96 !:&
M8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\ $8+[ !*"_P 2@?\ D6X
M (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W@   +X,  ">'   AB@
M&HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1.P /D40 #I%/  V17  ,
MD6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T  B-_  (C?\ B7,  'MS
M  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@  *(X  "&1   :E0  $Y<
M  Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #G#T  IU(  "=5   G6(
M )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":]0  F?@ @GD  '9Y  !H
M>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D  !F=   2H   #J,   FF
M!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30  *D_  "I2P  J5D  *EH
M  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P  I_, ?8   &^!  !AA
M58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I   -K   !Z\   "R
MLP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U  "W0   N$X  +A=  "X
M;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H =H@  &>+  !:D   3I8
M $*<   WH@  +*<  "*K   9KP  $;,   NV   $N0   +P   "^    O@
M +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'-   R$(  ,E1  #)8@
MR74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,  &"8  !3G@  1J0  #JK
M   OL   )+4  !FX   0O   "K\   '!    Q    ,@   #*    R@   ,P
M  #- P  S@@  - -  #1$   TQ8  -8>  #:*   W30  -Y#  #?5   WV<
M .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF  !,K0  /[0  #*X   D
MO   &+\  !##   (QP   ,H   #-    T0   -4   #8    V0   -L   #=
M    WP   .$$  #C"@  Y0X  .<3  #J'   [2<  / U  #Q1@  \E@  /-K
M  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_ !$ _P 5 /\ 'P#_ "P
M_P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /< > #U 'X ] "$ /( B0#Q
M (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#% .4 VP#C .T X@#[ .(
M_P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T _P 2 /\ &P#_ "@ _P T
M /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J 'H Z0!_ .< A0#F (H
MY0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8 T #3 .@ T@#W -$ _P#1
M /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P / /\ %@#[ "( ]P O /0
M.P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4 W !Z -H @ #8 (4 U0"+
M -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#% .( Q #R ,, _@#" /\
MP0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D $0#Q !T ZP I .< -@#C
M $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U ,D >P#( (  Q@"& ,4
MC ## ), P0": +\ H@"] *L NP"V +D Q "W -H M@#M +0 ^@"T /\ M #_
M +0 _P"T /\ _P0  /\   #_    _P & .P #0#E !8 W@ B -< +P#1 #L
MS0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P =0"Z 'L N0"! +< AP"U
M (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H *@ ]P"G /\ IP#_ *8
M_P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !  S0 ; ,< )P## #, OP ^
M +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M '8 K !\ *H @@"I (D
MIP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$] ";!/\ F@7_ )H%_P"9
M!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3 +P"'P"W RP LP0W + %
M0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$ H AW )\(?@"="(4 FPF.
M )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/#O\ C@[_ (X._P"-#O\
M]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+%P"L#20 J XP *4..P"B
M#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R ),0>0"2$($ D!"* (\1
ME "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\ @Q7_ ((5_P""%?\ [1H
M -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@%!X G!4J )D5-0"6%CX
ME!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7= "&&'P A1B& (,9D "!
M&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_ '@=_P!X'?\ Y2(  - I
M  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@ D1TD (X>+P",'CD B1Y!
M (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\('@ >B"! 'DAC !W(9<
M=2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD_P!N)/\ W2D  ,@P  "W
M,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0? (0E*@"")30 @"8] 'TF
M1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0 <2=] &\HB !N*)0 ;"BA
M &LIKP%J*< !:2K; 6<J\0%G*_\!9BO_ 68J_P%F*O\!U"\  ,(V  "O-@
MH34  )8T  "0,   BBT  (<J!@"#*1  ?RH: 'PK)0!Y*R\ =RPX '4L0 !S
M+$< <2Q- ' L5 !N+%H ;2QA &LM: !J+7  :"UZ &<NA0!E+I$!9"Z> 6(O
MK %A+[T!83#5 6 P[P%?,/T!7S#_ 5\P_P%?,/\!S30  +P[  "I.@  FSH
M ) X  ")-0  @S(  '\P 0![+PX =S 6 '0P(0!Q,2L ;S$T &TQ/ !K,4,
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M DX^Z0)-/OH"3C[_ 4X]_P%./?\!P#\  *Y#  "<0P  CD,  ()"  !Z0
M<ST  &T\  !H/04 9#T. &$^%P!>/B$ 7#XI %H^,0!8/CD 5SY  %4_1@!4
M/TT 4S]5 %) 7 !00&4 3T!O 4Y!>@%-08<!2T&6 4I!I0))0K4"24++ DE"
MZ ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810  BD4  ']%  !V0P  ;T
M &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!30C8 44(] $]"0P!/0TL
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M 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J3   8$H  %E+  !43
M4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0/0! 440 /U%+ #Y14P ]
M4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$ 352X@$V4O4!-E'_ 390
M_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P  7$X  %1/  !/40  2E(!
M $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [5D$ .E9) #E740 X5UH
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M:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$ (V+] 21A_P$D8?\!G%@
M (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!8   .F,  #1F   O: H
M+&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K1@ C:T\ (FQ9 "!L90 ?
M;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\ !QH_P <:/\ E5P  (-<
M  !U7   :5T  %]=  !67@  3&$  $-D   \9P  -6H  "]M   H< 0 (W(-
M "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :=$H &714 !=U8  6=6X
M%75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q_P 3<?\ CF   'U@  !O
M80  96$  %MB  !19   2&<  #YK   W;@  ,'$  "EU   B>   ''L' !=]
M#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0 $'].  ]_6@ .?V@ #7]X
M  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +>O\ AF4  '=E  !J90
M868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^   <@0  %80  !"'"  -
MB0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(  6)5  $B6$  HEQ  &)
M@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH ?FH  '%J  !G:P  6VP
M %!P  !&=   /'@  #-]   J@0  (X4  !R(   5C   $(\   R2!@ &DPP
M I,1  "4%@  E!T  )0D  "5+   E34  )5   "53   EED  )9I  "5>@
ME8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'   &UP  !@<@  5'4  $EY
M   _?@  -8,  "R(   CC0  &Y$  !24   /EP  "IH   2= P  G@D  )\.
M  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P  HU   *-?  "C<0  HX0
M **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W  !9>P  38   $*%   X
MBP  +I   "25   ;F@  %)X   ZA   )I    J<   "J    JP0  *L*  "L
M#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48  +)5  "R9@  LGD  +*.
M  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2AP  1HT  #N3   PF0
M)IX  !RC   3IP  #:L   >N    L@   +4   "W    N    +D"  "Y"
MN@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))  ##6@  PVP  ,2"  #$
MEP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0  /YL  #.B   HJ   ':T
M !2Q   -M@  !KD   "\    OP   ,,   #$    Q0   ,8   #'    R00
M ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #830  V5\  -IS  #:B@
MVYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H  "RQ   @MP  %;L   V^
M   $P@   ,4   #)    S0   -    #2    T@   -4   #6    V0   -L
M  #>!0  X H  .(/  #E%@  Z"   .PM  #M/@  [5$  .YE  #O>@  [X\
M /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\ '0#_ "D _P U /\ 00#_
M $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_ /  A #N (D [0"/ .L
ME0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H WP#Y -T _P#= /\ W0#_
M -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_ "0 _@ Q /L /0#X $@
M] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z ., ?P#B (4 X "* -X D #<
M )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T ,L _P#+ /\ RP#_ ,L
M_P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\ \@ K .\ -P#K $( YP!,
M .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0 (  SP"% ,T BP#+ )(
MR0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T _ "\ /\ O #_ +P _P"\
M /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E -\ ,0#; #P UP!' -(
M4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H P "  +X A@"\ (T N@"4
M +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N /\ K0#_ *T _P"M /\
M_P   /\   #]    [@ ! ., # #: !0 T0 ? ,P *P#( #8 Q0!  ,( 2@"_
M %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z +  @0"N (@ K0"/ *L
MF "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X H #_ *  _P"@ /\ _P
M /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y "\ M@ Z +0 0P"Q $P
MK@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *, >P"A (( H "* )X DP"<
M )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_ ), _P"2 /\ ^04  .H+
M  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@ J@ S *< /0"D $4 H@!-
M *  4P"> %D G !? )L 9 ": &H F !P )< =@"5 'X DP"& )(!CP"0 9D
MC@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(_P"&"/\ [P\  -X4  #*
M%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L )P(-@"9"#\ EPE' )4)
M3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD B N" (<+C "%#)< @PRB
M ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![$/\ YA<  -$>  "]'0
MKQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/+P"/$#D C!!! (H02 "(
M$$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^ 'P2B !Z$I0 >!*@ '<3
MK@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\ W!\  ,8E  "S)0  I2,
M )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#%C, @1<\ ( 70P!^%TH
M?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9A !O&I  ;AJ= &P;JP!K
M'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28  +TJ  "K*@  G2H  ),H
M  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X =QXV '8>/@!T'D4 <A]+
M '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F(8T 92*: &,BJ !B([@
M82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O  "D+P  EB\  (PM  "%
M*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R &TD.@!K)4$ :B5' &@E
M30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH 72B7 %LII0!:*;4 6BK*
M %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">,P  D#,  (8R  !_+P
M>2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J-0!C*CT 8BI# & J2@!?
M*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5 %0NHP!3+[, 4R_' %(O
MY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@  BS8  ($U  !Y,P  <S$
M &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<+SD 6R]  %DO1@!8+TT
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M 4(\_P%"._\!LST  )X^  "-/@  ?SX  '4^  !L/0  9CH  & Y  !;.@
M5SH( %,[$ !1.Q@ 3CL@ $P[* !+.R\ 23PV $<\/0!'/$0 1CU+ $4]4P!$
M/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#  3U W0$]0/(!/4#_ 3X_
M_P$^/_\!KD   )I   ")00  ?$$  '%!  !H0   83P  %L]  !6/@  4CX%
M $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"04( 04%) $!!40 _0EH
M/D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$VP$Y1/$!.4/^ 3E#_P$Y
M0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74   %9   !10@  34(" $E#
M# !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\ /$9' #M&3P Z1E< .4=A
M #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T2/  -$?] #1'_P U1O\
MID0  ))%  ""1@  =48  &I&  !A10  640  %%$  !,1@  2$<  $1'"@!!
M2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$ #9+3  U2U4 -$Q? #-,
M:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\ +TS] "]+_P P2_\ H4<
M (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'2@  0DL  #],!@ [30X
M.4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!02@ O45( +E%< "U19P L
M474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\ "I0_P J3_\ G$H  (E*
M  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P  /5   #E2 @ U4PP ,U02
M #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I5D\ *%=9 "=79  F5W(
M)5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5_P D5?\ EDT  (1.  !U
M3@  :4X  %]/  !63P  35   $52   _4P  .58  #-8   O6@@ *UL/ "I;
M%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P (5U6 "!>80 ?7FX 'EY^
M !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <6_\ D%$  'Y1  !P40
M9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>   H8 , )&(, ")C$0 A
M8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651 !AE70 796H %F5Z !5E
MBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\ B50  'A5  !K50  8%8
M %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C9P  '6H' !EL#@ 8;!,
M%FT: !5M(0 4;2D %&TP !-M.0#_XGT024-#7U!23T9)3$4 !Q(2;D( $6Y,
M !!N6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\
M@ED  ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L   =
M;P  %W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='  AW
M4@ '=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P >UT
M &U=  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7>0
M$GP   U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""3
M@ED  ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(  &AB
M  !>8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P  #88
M  B)!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1   CE$
M (Y@  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8
M:0  36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(   "5
M    E@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7
M  "<:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1<@
M1G<  #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B
MHP$  *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L
M70  K'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0
M #2*   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P    L
M +$   "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]4@
MO60  +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9
M   AGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP   ,
M  #!    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110  TE<
M -)K  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H   :
MK@  $;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\   #0
M    T@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H  .E=
M  #J<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_ "8
M_P R /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K
M (0 Z0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W -@
M_P#8 /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L
M /< . #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#= '\
MVP"% -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,< _P#&
M /\ Q@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G .D
M,@#F #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_
M ,< A0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V /\
MM@#_ +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4 +0#1
M #< S@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +<
M@ "V (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_
M *< _P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_ #$
MO  [ +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G
M ($ I@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_ )@
M_P"8 /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L K0 U
M *L /@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0": 'L
MF "# )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P",
M /\ \P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N )X
M-P"< $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^
M (H B "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\
MZ T  - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )( ,0"0
M #D C@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$
MA !]!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14
M ,07  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C,
M@PL[ ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R
M#8P < V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>
M  "H'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V
M '<1/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD
M9A.6 &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?
M)   DB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7
M. !L%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2
M %P;H0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*
MBR@  ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C
M'CH 8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0B
MG@!3(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+   ABT
M 'PL  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8
M6B,] %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,
M**P 2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3   '<O
M  !O+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y
M %(I0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H
M12Z\ $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K
M,0  92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM
M/ !*+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[
M #\RTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F-0
M83(  %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$
M,4  0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HV
MT0 Z-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P  738
M %<S  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT
M/C9$ #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V
M.NP -CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D  %,V
M  !.-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M"
M #@[2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH
M,3[Z #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ  !)
M.P  13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #-
M2  R0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y
M "U!_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$/P
M0$   #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M
M14X +$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%
M_P H1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1   .T4
M #=&   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G2DL
M)DM5 "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B
M2O\ D$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD  #)+
M   N30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@ (%!2
M !]170 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\
MBD8  'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0   H
M4P( )%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A7
M60 76&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D
M '1*  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D60
M'EL' !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?50 0
M7V( #U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.
M  !B3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P  &6(!
M !-E"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT
M!V=L  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=
M4@  5%(  $Q3  !#50  .U@  #-;   K7@  )6$  !]D   99P  $VH   ]M
M!@ +< P "' 1  =P%@ %<!T !' D  -P+  "<#4  ' _  !P2@  <%<  '!E
M  !P=@  <(H  &^>  !OL@  ;L@  &WE  !M\@  ;?D <%8  &-6  !95@
M45<  $=8   ^6P  -E\  "YB   F9@  'VH  !EM   3<   #G,   MV!  %
M> L  7@/  !Y$P  >1D  'D?  !Z)@  >B\  'HY  !Z1   >E   'I?  !Z
M<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_< :EL  %];  !66P  3%P
M $)@   Y8P  ,&@  "AL   @<   &70  !-W   .>P  "7X   2! @  @@@
M (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'/   ATD  (=7  "':
MAWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96   %Q@  !180  1F0  #QI
M   R;0  *7(  "%W   9>P  $H    V#   (AP   HH   "-    C@0  (X)
M  "/#0  D!   )$4  "2&0  DR   )0I  "5,P  E4   )9.  "67P  E7(
M )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F  !*:@  /VX  #5T   K
M>0  (7\  !F$   1B0  #(T   :1    E    )@   ":    FP   )P"  "=
M!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8  *9$  "F50  IF@  *9]
M  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#=0  .'L  "V!   CAP
M&8T  !&2   +EP  !)P   "@    HP   *8   "H    J0   *H   "L
MK00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z  "W2P  N%P  +AQ  "X
MB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@  ,8D  ":0   ;EP  $IT
M  RB   #IP   *L   "N    L@   +8   "X    N    +H   "[    O0
M +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+/@  S%   ,QD  #->@
MS9$  ,VD  #-M   S<  38,  $&*   UD0  *9D  !Z@   3I@  #*P   .Q
M    M@   +H   "^    P@   ,8   #(    R    ,H   #+    S0   ,X
M  #0    T@$  -4(  #9#@  W14  .$A  #B,0  Y$,  .56  #F:P  YH(
M .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\ %@#_ "$ _P M /\ . #]
M $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T .D >@#G '\ Y@"% .0
MBP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$ TP#T -( _P#1 /\ T0#_
M ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z !T ]@ H /, ,P#P #X
M[ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D = #6 'H U !_ -( A0#0
M (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N ,$ _@#  /\ P #_ +\
M_P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@ Y@ C .( +@#@ #@ VP!"
M -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$ '0 P@!Z ,$ @ "_ (8
MO0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$ ^ "P /\ KP#_ *\ _P"P
M /\ _P   /\   #W    Z@ " .$ # #7 !, T  = ,P * #) #( Q@ \ ,(
M10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X L@!T +$ >@"O (  K0"(
M *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A /\ H #_ *  _P"A /\
M_P   /<   #H    V0   ,L " ## !  O0 8 +D (@"V "P M  V +( /P"O
M $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N *( = "@ 'H G@"" )P
MBP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L D@#_ )( _P"1 /\ ]P
M .<   #3    Q@   +L  @"S  P K0 2 *H ' "G "8 I  P *, . "@ $
MG@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ), ;@"2 '0 D !\ (\ A0"-
M (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_ (, _P"# /\ [    -,
M  #! 0  M    *P   "F  < H  . )T %@": "  EP I )4 ,@"3 #H D0!!
M (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"% &\ @P!W (( @ "  (H
M?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@ _P!X /\ W@H  ,0+  "R
M#   I@L  )T(  "9!   E0 * )$ $0". !D BP C (D + "' #0 A0 [ (,
M0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H > !R '8 >P!T (8 <P"2
M '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L _\ SA   +<1  "F$@
MFA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X")0!\ RX >@,V '@$/ !W
M!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N &L'> !J!X, : B0 &<)
MG0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\ PQ8  *T7  "=&   D!@
M (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R"R@ < PP &\,-P!M##X
M; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.=0!@#H$ 7PZ. %T/G !<
M$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L  *4=  "4'@  B!X  'X=
M  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"( 9Q$J &81,@!D$3D 8Q$_
M &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7%'T 5A2+ %05F0!3%:D
M4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB  ".(@  @2,  '<B  !P
M(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F %T6+0!<%S0 6A<[ %D7
M00!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH 3AN( $T;EP!+'*8 2ARX
M $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "()@  >R<  '$F  !J)0
M9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<*0!4'#  4QTW %$=/0!0
M'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"% $8AE !$(J0 1"*V $,B
MS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@  =BH  &TJ  !E*0  8"<
M %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-(BP 3"(S $HB.0!)(D
M2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\FD@ ^)Z, /B>T #TGR@ ]
M*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT  &@M  !A+   7"L  %@H
M  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD 128O $0F-@!#)SP 02=#
M $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y*Z$ ."RR #<LR  W+.8
M."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P  !=+P  6"X  %,K  !0
M*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL #XK,P ]*SD /"M  #LL
M2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\ ,S"Q #(PQP R,.4 ,S#W
M #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:,@  5#$  $\O  !++0
M1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O+P W+S8 -C ^ #4P1@ U
M,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P "TTQ0 M-., +C3V "\S
M_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-   430  $LR  !&,0  0C(
M #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R-#0 ,30[ # U0P P-4P
M+S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@XPP H..( *3CU "HW_P J
M-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338  $<V  !"-0  /38  #HV
M @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3( +#DY "LY00 J.DD *CI3
M "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C/.  )#ST "4[_P E._\
MC38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y   ].0  .3H  #4[   R
M.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV "8^/@ E/T< )#]0 "-
M6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X 'T#S !] _@ @/_\ B3D
M '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X/0  -#X  #!    M004
M*D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$.P ?1$0 'D5. !U%60 <
M164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q !E$_0 :1/\ A#P  ',]
M  !F/@  6S\  %(_  !*/P  1#\  #U    V00  ,4,  "Q$   G1@$ )$<*
M "%(#P @210 'DD; !U)(@ <22D &THP !I*.  92D$ &$I+ !=+50 62V(
M%4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*_  42?\ ?S\  &]   !A
M00  5T(  $Y"  !'0@  04(  #I#   R10  +4<  "A)   C2P  'DT& !M/
M#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T $5%' !%14@ 045\ #U)M
M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .3_\ >4,  &I$  !=1
M4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/   ?40  &E,  !16"0 1
M5PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#  M83@ *6%H "%AH  =8
M>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP <T8  &1'  !92   4$@
M $A(  !!20  .DH  #)-   K4   )5(  "!5   :6   %5H  !!=!@ ,8 P
M"F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@20  8%4  &!C  !@<P
M8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H  %]+  !52P  3$P  $5,
M   ]3@  -5   "Y3   G5@  (%D  !I<   57P  $&(   UE!  (9PL  V<.
M  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P  :4\  &E=  !I;0  :8
M &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/  !13P  2D\  $%1   X
M5   ,%<  "A;   A7@  &F(  !1E   0:   #&L   =N P !< D  ' -  !Q
M$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@  '-6  !S9@  <WD  '..
M  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/4P  154  #M8   R7
M*F   ")D   ;:   %&P   ]O   +<@  !G8   !Y    >@8  'H*  ![#@
M?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/  " 7P  @'$  ("&  "
MG0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@  /UT  #5A   L90  (VH
M !MO   4<P  #G<   E[   #?P   ((   "$    A@$  (8&  "("@  B0T
M (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/5@  CV@  (]^  "/E0
MCJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8  "YL   D<0  ''<  !1\
M   .@0  "(4   ")    C0   )    "2    DP   )0   "6 P  EP@  )@,
M  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3   H%X  *!T  "?C   GZ(
M )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y   =?P  %(4   V+   &
MD    )0   "8    G    )\   "A    H@   *0   "E    IP   *@$  "J
M"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0  +)I  "R@   LI@  +&L
M  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5C@  #I4   ::    GP
M *0   "H    K    *\   "Q    L0   +,   "U    M@   +@   "Z
MO 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=  #'<@  QXH  ,B?  #(
MKP  R+P 1GH  #F!   NB0  (I   !>8   /GP  !Z4   "J    KP   +,
M  "W    O    +\   #!    P@   ,0   #%    QP   ,D   #+    S0
M ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@90  X7L  .&1  #BH@
MXJT _P " /\   #_  , _P , /\ $P#_ !T _P H /X ,P#[ #X ]P!( /,
M4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D X@!_ .  A0#> (P W "3
M -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+ /\ RP#_ ,8 _P#! /\
M_P   /\   #_    _P ( /L $ #V !D \@ D .\ +@#M #D Z !" ., 2P#@
M %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y ,P ?P#* (8 R ". ,8
ME@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\ N@#_ +H _P"V /\ _P
M /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8 #, TP ] ,X 10#* $T
MQP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H >0"X (  M@"( +0 D "R
M )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_ *H _P"J /\ _P   /T
M  #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T OP W +L /P"W $< M0!.
M +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H 'H I@"! *0 B@"C )0
MH0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D _P"9 /\ _@   .X   #>
M    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P *H .0"G $$ I !( *(
M30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ', EP![ )4 A "4 (X D@"9
M )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+ /\ \    -L   #'
MN@   +    "H  H I  0 *  & "= "$ FP J )H ,P"8 #L E@!! )0 2 "2
M $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U (< ?@"% (@ @P"4 ((
MH "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\ X    ,8   "U    J@
M *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"* #0 B  [ (8 0@"% $<
M@P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H >0!X (, =@"/ '4 G !T
M *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00  +<&  "G!P  FP8  ),$
M  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X ?  V 'H / !Y $( =P!'
M '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L 'X :P"* &D F !H *8
M9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-  ";#@  CPX  (8-  "!
M"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P &\ -@!N #P ; !" &L
M1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H 8 &' %\"E0!> J, 7 .S
M %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1$P  A1,  'P2  !V$0
M<PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&,0!D!C< 8P8] &('0P!A
M!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ% %8+DP!4"Z( 4PNS %(,
MQP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&   ?1D  '08  !M%P  :A0
M &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<#3, 6PTY %H-/P!8#44
M5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0D@!,$*( 2Q"R $H1R !)
M$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX  &T=  !F'   8AH  %\7
M  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X 4Q$T %$1.P!0$D$ 3Q)'
M $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$%9\ 0Q:P $(6Q0!"%^,
M0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B  !A(0  7!\  %D<  !7
M&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P $H6-P!)%ST 1Q=# $87
M2@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT /!RN #L<PP ['.$ .QWU
M #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<)   5R,  %,@  !1'@
M3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<,P!"'#D 0!Q  #\=1P ^
M'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M #4AP0 U(=\ -2'S #8A
M_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P  4R8  $\D  !,(@  22
M $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [(38 .B$] #DA1  X(DP
M-R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # FOP O)MP ,";R # F_P Q
M)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD  $LH  !()0  1"0  $$D
M!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3, -"4Z #,F00 R)DH ,2=3
M # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J*MH *RKQ "LJ_@ L*?\
MC2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K  !#*   /R@  #PH @ Y
M* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW "XJ/P M*T< +"M1 "LL
M6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@ )B[P "8N_0 G+?\ BBL
M '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _+   .RP  #<L   T+ D
M,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO/0 H+T4 )S!. "8P60 E
M,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O "(Q_  B,?\ ABT  '4O
M  !G,   7#$  %,Q  !+,0  13$  $ P   [,   -C   #,P   P,08 +3$-
M "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C-$, (C1, "$U5P @-6,
M'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV^P =-?\ @C   '$R  !C
M,P  630  % T  !)-   0C,  #TS   W,P  ,30  "XU   K-0( *#8+ "4W
M$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4  '#E) !LZ5  :.F  &3IN
M !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8.?\ ?3(  &TT  !@-0
M538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY   F.@  (SL( " \#@ >
M/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]' !4_40 4/UX %#]L !-
M?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\ >34  &DW  !<.   4CD
M $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B/P  'D$$ !I""P 80Q
M%T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%3@ 015L #D5I  Y%>0 -
M18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D  &4Z  !8.P  3SL  $<\
M  ! /   .CP  #0\   N/@  *$   "-"   ?1   &D8  !5("  22@T $4H2
M !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *2U8 "4MD  A+=  '2X<
M!4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]  !4/@  2SX  $0^   ]
M/@  -S\  #%    J0@  )$4  !]'   :20  %4P  !%.!0 .40L "U$0  I1
M%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(  %)?  !2;P  4H$  %&6
M  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !000  2$$  $%!   [0@
M-$,  "U%   F2   ($L  !M-   64   $5,   Y5!  *6 H !E@.  )8$@
M61<  %D=  !9)0  62T  %DV  !900  64T  %I:  !::0  67P  %F0  !9
MI0  6+H  %C5  !7[   5_8 8T0  %9%  !-10  144  #]%   W1P  +TD
M "A,   B3P  &U(  !95   16   #5H   E= P $7PD  & -  !@$   810
M &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C9   8G8  &*+  !BH
M8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@  #I*   R30  *E   "-3
M   <5P  %EH  !%=   -8   "&,   -F 0  9P8  &@+  !I#@  :A$  &L5
M  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70  ;6\  &V$  !LF@  ;+
M &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51   L5   )%@  !U<   6
M8   $&0   QG   ':P   6X   !P    <@,  '('  !S"P  =0X  '81  !W
M%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@  'I\  !YE   >*H  'C!
M  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F7@  'F(  !9G   0:P
M"V\   5S    =P   'H   !\    ?@   '\"  " !@  @0H  (,-  "$$0
MAA4  (@<  "))0  BC   (H^  ")30  B5\  (ES  "(BP  B*(  (>Y  "'
MT0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0  %F\  !!T   *>0   GT
M  "!    A0   (@   "*    C    (T   "/    D 0  )((  "3#   E1
M )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9@@  FIH  )BP  "8QP
ME]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T   F#   !B    (P   "1
M    E0   )@   ":    FP   )T   "?    H    *(   "D!0  I@H  *@.
M  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P  K)   *NG  "KN@  J\L
M168  #EK   N<0  (W@  !E_   0A@  "8T   "3    F    )T   "A
MI0   *@   "K    JP   *X   "O    L0   +,   "U    MP$  +D'  "\
M#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,  ,";  #!K0  P;P /G(
M #)X   G@   '(@  !*0   *EP   )T   "C    J    *T   "R    M@
M +D   "[    O    +X   #     P@   ,0   #&    R    ,L   #.!0
MT0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,  #<GP  W*L _P   /\
M  #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D ] !# /  2P#M %( Z@!9
M .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7 (8 U ". -$ E@#/ *$
MS "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\ _P"Z /\ _P   /\   #_
M    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ] -X 10#9 $T U !3 -$
M60#. %X S !C ,H : #) &T QP!S ,4 >0## (  P0"( +\ D "] )L NP"F
M +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N /\ _P   /\   #X
M[0   .4 "P#= !$ UP : -( ) #/ "X RP W ,< 0 ## $< P !. +X 4P"\
M %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"! *T B@"K )0 J0"@ *@
MK0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\ _P   /8   #F    UP
M ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P $$ K0!( *L 3@"I %,
MIP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T @P"; (X F0"9 )< I@"6
M +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P   .0   #0    P0   +<
M @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L G !" )L 2 "9 $T EP!2
M )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0", (< B@"3 (@ H "' *\
MA0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T   "\    KP   *8   ">
M  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \ (P 0@"* $< B !, (<
M40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($ >P"- 'H F@!X *D =P"Z
M '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K    GP   )<   "0  (
MBP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T / !\ $$ >P!& 'D 2P!X
M %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"' &T E0!K *, :@"T &H
MR0!I .@ :0#Y &D _P!I /\ P    *P   "< @  D (  (@   "#    ?P &
M 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P #P ;P!! &T 1@!L $L
M:P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$ D !@ )\ 7P"O %X PP!>
M .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L  'P*  !W!P  = 0  '$
M"0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8 9  \ &, 00!B $8 8 !,
M %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6 )L 50"K %0 O@!4 -H
M4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0  !L#@  :0P  &<) P!F
M! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W %D / !8 $( 5P%' %8!
M3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D 3 6I $L%O !*!M0 2@?M
M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D$P  8!$  %X/  !=#04
M70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(. !0"#X 3PE$ $X)2@!,
M"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI $(-O !"#=4 0@WN $(-
M^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&   618  %83  !4$0  5 X(
M %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)#3H 1PY! $8.1P!%#D\
M1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1O  Z$=8 .A'P #H2_0 [
M$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL  % 8  !.%@  3!,# $P1
M"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3< 0!(] #\21  ]$DP /!-4
M #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S%M, ,Q;N #06_  T%O\
MCAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=  !(&@  1A@  $46!P!#
M%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z #@600 W%TD -1=1 #08
M6P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]  +1OL "X;^P N&_\ BAX
M '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#'@  01L  #\: P ]&@P
M.QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;/@ P'$8 +QQ/ "X=60 M
M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K "@@^@ I'_\ AB   '0C
M  !G)   7"4  %,E  !,)0  1R0  $(C   _(0  /1\  #H>   W'@D -1X.
M #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K($, *B%, "DA5@ H(F(
M)B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D^0 D(_\ @B,  '$E  !C
M)@  62<  % H  !))P  0R<  #\F   [)   ."(  #4B   R(@8 ,"(- "XB
M$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$ )"5* ",F5  B)F  (2=M
M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?)_\ ?B4  &XG  !@*0
M5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F   M)@, *R<+ "@G$  G
M)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI( !XJ4@ =*UX '"MK !LK
M>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\ >B<  &HJ  !=*P  4RP
M $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I*P  )BL( ",L#@ B+!(
M("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO4  8+UP %R]I !8P>0 5
M,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH  &<L  !:+0  4"X  $@N
M  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P  (3 % !\Q#  <,1  &S(5
M !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3-%D $C1G !$U=P 1-8D
M$#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N  !7,   33   $4P   ^
M,   .#   #,P   O,   *3$  "0R   A,P  '34" !HV"0 7-PX %3<3 !0X
M&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5< #CID  TZ=  ,.H8 ##J9
M  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3,@  2C,  $(S   [,P
M-C,  #$R   L,P  )S0  "$V   =.   &3D  !4[!@ 2/0P $#X0 ! ^%0 .
M/AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@  <_;P &/X$ !3^4  0_
MJ  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0  1S4  #\U   Y-0  -#4
M "XU   I-P  (S@  !X[   :/   %C\  !)!!  .0PH #$0.  I$$P )1!D
M"$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%:@  17P  $60  !$I
M1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@  #PX   W.   ,3@  "LY
M   E.P  (#T  !I    60@  $D0   Y'!  +20D !TH-  1+$0 !2Q8  $L<
M  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@  3'<  $N,  !+H0  2[4
M $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[   T.P  +CP  "<^   B
M00  '$,  !9&   220  #DL   M. P '4 @  E$,  !1$   4A,  %,8  !3
M'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(  %.'  !2G   4K$  %'*
M  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P0   *4(  "-$   =1P
M%TH  !)-   .4   "U,   95 @  5P<  %@+  !9#@  6A$  %H5  !;&@
M7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!  !;EP  6ZT  %K%  !:
MY   6?, 5$(  $I"  !"0@  /$(  #1#   L1@  )4D  !Y,   73P  $E,
M  Y6   *60  !5L   !>    8 0  &$(  !B#   8PX  &01  !E%@  9AP
M &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !FD0  9:@  &7   !DW@
M9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$  !A5   260  #5P   A@
M   "8P   &8   !H    :@   &L$  !L"   ;0P  &\.  !P$@  <A<  ',=
M  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@  <J$  '&X  !QU   <.P
M3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?   -9   !V@   !K
M;P   '(   !U    =@   '<   !Y @  >@8  'P*  !^#@  @!$  ((6  "$
M'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID  (&Q  " R0  @.4 2DX
M #]0   U4P  *U<  ")<   98@  $F<   QL   %<0   '4   !Y    ?0
M ($   "#    A0   (8   "(    B0   (L$  "-"   CPT  )(0  "4%@
MEB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G  "2O0  DM4 1%4  #E9
M   O70  )&,  !II   2;P  #'4   1[    @    (4   ")    C0   )$
M  "3    E    )8   "8    F@   )P   ">    H 8  *(+  "E$   J!<
M *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "FLP  I<< /EX  #)C   G
M:@  '7   !-X   ,?P   X4   "+    D0   )8   ";    GP   *(   "D
M    I0   *<   "I    JP   *T   "P    L@   +4"  "W"0  NQ   +X8
M  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0  NKD -VH  "MP   @>
M%H    V(   %CP   )8   "<    H@   *<   "L    L    +,   "V
MMP   +D   "[    O0   +\   #"    Q0   ,@   #*    S@@  -(0  #5
M&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL _P   /\   #_    _P %
M /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I $T Y@!3 .0 60#A %X
MW@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L D0#) )P Q@"G ,0 MP#"
M ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P   /\   #_    ^@ ! /,
M"P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $< S@!. ,L 5 #( %D Q@!>
M ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V )4 M "A +( KP"P ,(
MK@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\   #R    Y@   -T !P#2
M  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!( +< 3@"U %, LP!8 +$
M70"P &( K@!G *P ; "J ', J0![ *< A "E (X HP": *$ J "? +D G@#2
M )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=    S    ,$  @"Z  P
MM@ 2 +( &@"P ", KP L *T - "I #P I@!" *0 2 "B $T H !2 )X 5P"=
M %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3 )  H0". +$ C0#& (P
MZ "+ /T C #_ (P _P", /\ [0   -@   #%    MP   *P   "F  @ H0 .
M )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1 $< D !, (X 40"- %4
MBP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (  F@!_ *D ?0"\ 'P W !\
M /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I    )P   "4  , D  , (T
M$0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$ @ !& '\ 2P!] $\ ? !4
M 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P *( ;P"T &X S !N .T
M;@#^ &X _P!N /\ Q    *\   "@    E    (P   "&    @0 ( 'X #@!\
M !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!  '$ 10!P $H ;P!/ &T
M5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T 8@"M &$ P@!A .0 80#X
M &$ _P!A /\ M    *    "1    A@   'X   !Y    =0 # '$ "P!O !
M;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4 0 !D $4 8P!* &$ 3P!@
M %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H %8 NP!6 -@ 5@#Q %8
M_P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!   :0$  &< !P!D  T 8P 1
M &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9 $  6 !% %< 2P!6 %$
M50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P M@!, ,T 3 #K $P ^@!,
M /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH  %T& 0!< 0D 6@ . %@
M$P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L 3P!! $X 1P!- $T 2P!5
M $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!# ,@ 0P#F $, ]0!# /\
ME0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-  !3"@0 4P8+ %$#$ !/
M 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,] $4#0P!$ TH 0P11 $($
M6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8 .@?C #H'\P Z"/P CA
M 'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+#@  2PT& $H*# !)"!$
M1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*0  ]"D< / I/ #H+6  Y
M"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC #(-]  R#?X B!,  '<5
M  !I%P  7A@  %48  !/&   2A8  $<5  !%$P  0Q " $,." !"#0X 0 T2
M #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V#D4 -0Y- #,/5P R#V(
M,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1]@ L$?\ @Q8  '(9  !D
M&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0  #P2!  [$0H .A 0 #@0
M%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D( +A)+ "T35  K$U\ *A1L
M "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F%?\ ?AD  &X;  !@'0
M5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6   U%0< -!0- #(4$@ P
M%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9( "<74@ F&%T )!AJ ",9
M>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\ >AL  &H>  !='P  4R
M $H@  !$(   /A\  #H>   W'0  -!P  #(9   P&00 +A@+ "P8$  J&!0
M*1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;4  @'%L 'QUH !X==P =
M'8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT  &<@  !:(0  4"(  $@B
M  !!(@  .R(  #<A   S(   ,!\  "T=   K'0  *!T( "8=#@ E'1( (QT7
M "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;(5D &B%F !DA=0 8(H<
M%R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B  !7(P  320  $4E   ^
M)   .20  #0C   P(@  +"(  "DA   F(0  )"$& "(A#  @(1  'B$5 !TB
M&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5< %25D !0F<P 3)H4 $B:8
M !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4)@  2B8  $(G   \)@
M-B8  #$E   M)0  *20  "8D   B)0  'R4# !TF"@ ;)@X &2<2 !@G&  7
M)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB ! J<0 /*H, #BJ6  XJ
MJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*   2"@  $ I   Y*   -"@
M "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6*PT %"P1 !,L%@ 2+!P
M$2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO;@ ++W\ "B^2  DOI0 )
M+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L  #TK   W*P  ,2H  "TJ
M   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H $#(.  \R$P .,AD #3(@
M  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %-'L !#..  ,SH@ ",[8
M C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM   T+0  +RP  "LL   F
M+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-  HX$0 ).!8 "#@=  <X
M)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<  #F+   XGP  .+,  #C*
M   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R+P  +2\  "DO   D,
M'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^$  #/A0  #X:   ^(0
M/B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'   ^G   /K   #W'   ]
MY   /?( 6C   $XR  !$,@  /#(  #4R   P,0  *S$  "8R   @-   &S8
M !8X   2.P  #ST   P_ P (00@ !$,,  !##@  1!(  $46  !%'0  120
M $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%F   1*T  $3$  !#XP
M0_( 530  $HU  !!-0  .34  #,T   N-   *#4  "(W   =.@  %SP  !(_
M   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q   $P4  !-&0  3B   $XH
M  !.,@  33T  $Y*  !.6   36D  $U]  !,E   3*H  $O!  !+X0  2O(
M4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]   80   $T,   ]&   +
M20  !TL   ).    4 0  %$(  !2"P  4PX  %01  !5%0  5AL  %<C  !7
M+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4  %2]  !3W0  4_  2SP
M $(\   [.P  -3L  "T\   F/P  'T(  !E%   32   #DL   M/   %40
M %0   !7    6 $  %H%  !;"   7 P  %T.  !?$0  8!8  &(=  !B)@
M8C$  &(^  !A3   85T  &%P  !@B   8*   %^W  !>U   7>X 1T   #\_
M   Z/P  ,4   "E#   A1@  &DH  !-.   .40  "E4   18    6P   %X
M  !A    8P   &0!  !E!   9P@  &@+  !J#@  ;!(  &X7  !O(   ;RH
M &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !KR@  :N@ 1$0  #Y#   U
M1   *T<  "-+   ;3P  $U0   Y8   (7    F    !D    9P   &L   !M
M    ;P   '    !R    = (  '4&  !W"@  >0X  'P2  !^&   ?R(  '\N
M  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP   >=\ 0T<  #E)   O3
M)5   !Q5   46P  #F    =E    :@   &X   !R    =@   'D   !\
M?@   '\   "!    @P   (4   "' P  B@@  (P-  "/$0  DAD  )(E  "2
M,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T /4X  #)1   H5@  'EP
M !5B   .:   !VX   !T    >0   'X   ""    A@   (D   ",    C@
M )    "2    E    )8   "8    FP   )X&  "A#   I!$  *8;  "F*0
MICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<  "Q<   A8@  %VD   ]P
M   '=P   'X   "$    B@   (\   "4    F    )L   ">    GP   *(
M  "D    I@   *@   "K    K0   +    "S!   MPP  +L2  "['P  NS
M +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I   :<   $'@   F
MB    (\   "6    FP   *$   "F    J@   *X   "P    L0   +0   "V
M    N    +L   "]    P    ,,   #'    RP,  ,\,  #3%0  TB4  -(X
M  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_    _P # /\ "P#\ !$
M^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\ 5 #< %D V0!> -4 8P#3
M &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C +X L@"\ ,@ N@#J +D
M_P"X /\ L0#_ *H _P"G /\ _P   /\   #[    ]@   .T !P#G  \ X@ 6
M -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#" %, P !8 +X 70"\ &(
MN@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P J@"I +T IP#> *8 ^0"E
M /\ HP#_ )T _P"; /\ _0   /8   #K    WP   -$  P#*  P Q0 2 ,,
M&P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X K !2 *L 5P"I %P IP!A
M *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8 +0 E@#- )4 \0"4 /\
ME0#_ )  _P". /\ \P   .8   #1    P@   +@   "Q  @ K0 / *H %@"H
M !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!, )< 40"6 %4 E !: ),
M8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P A0#! (0 Y@"# /T A #_
M (, _P"! /\ Y    ,L   "Z    K    *(   "<  0 F  , )8 $0"4 !D
MDP A )( * "/ #  C0 V (L / ") $$ B !& (8 2P"% $\ A !4 (( 6@"!
M &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W '0 U !S /0 = #_ '0
M_P!T /\ RP   +8   "F    F@   )(   "*    A@ ( (, #@"! !0 @0 ;
M (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U $D = !. ', 5 !Q %H
M< !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8 QP!E .H 9@#_ &8 _P!G
M /\ N    *0   "5    B@   ($   !\    =@ $ '0 # !R !  <0 6 '
M'0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0 9P!) &4 3@!D %0 8P!;
M &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9 -\ 60#X %H _P!: /\
MJ    )4   "'    >P   ',   !N    :@ ! &< " !E  X 9  2 &, & !C
M !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$ %D 20!8 $\ 5P!6 %8
M7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -  3@#P $X _P!/ /\ G
M (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;  L 60 / %@ % !7 !D
M5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\ 1 !. $L 30!2 $L 6@!*
M &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H $0 ^@!% /\ D@0  ( '
M  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  < 4  , $\ $ !. !4 30 ;
M $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !% $8 0P!. $( 5@!! %\
M0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L ]  [ /\ B0H  '@,  !J
M#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200) $@ #0!& !$ 10 6 $0
M' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $, .P!* #H 4@ Y %P . !H
M #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S /L @@T  '$/  !D$
M61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'"P _!0X /@,2 #P"&  [
M AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5' #,%4  Q!EH , 9F "\'
M<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_< ?1   &P1  !?$P  5!0
M $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z"@P . D0 #8(%  U"!D
M- D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+3@ K"UD *0QE "@,<P G
M#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(  &@4  !;%@  41<  $@7
M  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@ ,@T- # -$0 O#18 +0T;
M "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D#UD (Q!E "$0<P @$(0
M'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06  !7&   31D  $49   _
M&0  .A@  #47   R%@  ,!4  "X3   M$00 +! * "L0#@ I$!( *! 8 "80
M'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8 '1-C !P3<0 :$X( &125
M !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4&@  2AL  $(<   \&P
M-AL  #(:   O&0  +!@  "H6   H% $ )A,' "43#  C$Q  (A,5 " 3&@ ?
M$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A !87<  5&($ %!B3 !,8
MI@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0  1QT  #\>   Y'0  -!T
M "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >%PX '!<2 !H7%P 9&!X
M&1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<;@ 1''\ $!R2 ! <I0 /
M'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\  #T@   V'P  ,1\  "T>
M   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T %QP0 !8<%0 5'!L %!TB
M !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -('P #2"/  P@H@ +(+4
M"R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA   T(0  +R$  "H@   F
M'P  (Q\  " >   ='@  &2   !8@!  4( L $B$. !$A$P 1(AD $"(?  \B
M)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@ ""2+  <DG@ ')+$ !B3'
M  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R(P  +",  "@B   D(0
M(2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG$0 -)Q8 #"<=  LG(P *
M)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'  (IFP !**\  "C%  $H
MX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0  *B0  "8D   B(P  'R,
M !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (+!0 !RP:  8L(0 %+"@
M RTP  (M.@ !+44  "U2   N8   +G$  "V$   MF0  +:T  "S"   LX
M+/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8  "0F   A)@  '28  !DG
M   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(  3(7   R'@  ,B4  #(M
M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@  ,JL  #'!   QWP  ,?
M5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H   >*0  &BH  !8L   2
M+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4   X&@  ."(  #@J   Y
M,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@  #>_   WW@  -O  42L
M $8L   \+   -"P  "XL   J*P  )2L  " L   ;+0  %R\  !,Q   0,P
M#34   DW @ %.@8  3L*   \#0  /0\  #X2   _%P  0!X  $ E  ! +P
M0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]   ]W   /?  32X  $(O
M   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@  $S4  ! W   ,.@  "3P
M  4^    000  $((  !#"P  1 T  $80  !'%   2!D  $@A  !(*@  2#4
M $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%V0  1/  2#(  #XR   V
M,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P   P_   (0@   T0   !&
M    2 (  $H%  !+"   3 L  $X.  !/$0  414  %(<  !2)0  4C   %(\
M  !12@  45H  %%M  !0A   3YT  $ZU  !-T@  3>X 0S8  #LV   T-0
M+S0  "<U   A.   &CL  !0^   000  #$0   ='   "2@   $T   !/
M40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7  !='P  72H  %TV  !<
M1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H /SD  #@Y   S.   *SD
M ",\   </P  %4,  !!'   +2@  !4X   !1    5    %<   !:    7
M %T   !?    8 0  &('  !D"P  9@X  &@2  !K&0  :R,  &HN  !J/
M:DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T  #<\   N/0  )4   !U$
M   620  $$T   I1   $50   %H   !=    8    &,   !F    :    &H
M  !K    ;0   &\"  !Q!@  = H  '8.  !Y$P  >QL  'LG  !Z-0  >44
M 'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"   H10  ($H  !=.   0
M5   "ED   )>    8P   &<   !K    ;P   '(   !U    =P   'D   ![
M    ?0   '\   ""    A ,  (<)  "*#@  CA,  (\>  ".*P  CCL  (U.
M  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B3P  &54  !!;   *80
M 6<   !M    <@   '<   ![    ?P   (,   "&    B    (H   "-
MCP   )$   "4    EP   )H!  "=!P  H0T  *44  "D(0  I#$  *-$  "B
M60  H'   )^+  "=H@  G;< ,%   "55   ;6P  $F(   MI   !<    '<
M  !]    @P   (@   "-    D0   )4   "8    F@   )P   "?    H0
M *,   "F    J0   *P   "P    M <  +@.  "Z&   NB<  +DY  "X3@
MMV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$   )Y    @0   (D   "/
M    E@   )L   "@    I    *@   "K    K    *\   "R    M    +8
M  "Y    O    ,    #$    R    ,T'  #2$   TAT  -$O  #01   SUL
M ,US  #+C0  RJ$ _P   /\   #[    ^@   /P " #X  \ ]0 7 /0 ( #Q
M "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9 -  7@#. &, RP!H ,D
M;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,, M #H +, _P"O /\ I0#_
M )X _P"; /\ _0   /<   #R    \    .<  P#A  P W  2 -@ &P#6 "0
MT@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@ 6 "V %T M0!B +, 9P"Q
M &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9 *  ^0"> /\ F #_ )(
M_P"/ /\ \P   .P   #C    TP   ,@   #!  D O0 / +L %@"Y !\ MP G
M +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C %8 H0!; )\ 80"> &<
MG !O )H > "7 (, E0"0 ), G@"1 +  D #( (X \ "- /\ B@#_ (4 _P""
M /\ YP   -T   #&    N    *X   "H  0 I0 , *$ $@"A !D H  B )\
M*0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %  C0!5 (P 6@"* &$ B !H
M (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\ /T ? #_ '@ _P!V /\
MU@   ,    "O    HP   )D   "3    CP ) (T #@"+ !0 B@ < (H (P"(
M "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/ 'L 5 !Z %H > !A '8
M:0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0 ; #_ &L _P!I /\ P
M *L   ";    CP   (<   "     ?  $ 'H # !X !$ >  7 '@ '@!W "0
M=0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L 3@!J %0 : !; &< 8P!E
M &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_ %X _P!= /\ K    )D
M  "*    ?P   '<   !Q    ;0   &H " !I  X :  2 &< & !G !\ 9P E
M &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 != $X 6P!5 %H 70!8 &<
M5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %( _P!2 /\ G0   (L   !\
M    <0   &D   !D    8    %X !0!<  L 6P / %L % !: !D 6@ ? %D
M)0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D 3P!0 $X 6 !- &( 2P!M
M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!' /\ D    'X   !P
M9@   %X   !9    5@   %,  0!2  @ 4  - $\ $ !/ !4 3@ : $X ( !-
M "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+ $0 4P!# %T 00!H $
M=0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\ AP   '4#  !H!@  70<
M %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!% !$ 10 6 $0 &P!# "
M0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H 3P Y %D . !D #< <0 V
M ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8  &T)  !@"P  5@P  $X,
M  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X /  2 #L %P [ !P .@ A
M #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q %4 , !@ "\ ;0 N 'T
M+0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,  !:#@  4 X  $D.  !#
M#@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0 #0 $P S !@ ,@ = #$
M(@ P "< +P L "X ,@ M #@ + !  "L 20 J %( *0!= "@ :P G 7H )@&,
M "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6$   3!$  $01   ^$0
M.1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%$0 L!!0 *P,9 "H#'@ I
M R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9< "$':0 @!WD 'P>+ !X'
MG0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@  2!,  $ 3   Z$P  -1(
M #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G"1$ )0@6 "0(&P C"2
M(@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,:0 :#'D & R+ !@,G@ 7
M#+  %@S% !8,X0 6"_  :1   %H2  !.%   114  #T5   W%0  ,10  "T3
M   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \ ( P3 !\,&  >#1T '0TC
M !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3$'L $A"- !$0H  1$+,
M$ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7   T%P  +Q8  "H5   G
M%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0 !D0%0 8$!L %Q A !80
M*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD #A.,  X3G@ -$[$ #1+%
M  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q&0  +!@  "@7   D%@
M(18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02$@ 3$Q@ $A,? !$3)@ 1
M%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'  H7F@ )%JT "!;!  @6
MW0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@  *AH  "49   B&   'Q@
M !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /%Q8 #A<<  X8(P -&"H
M#!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;EP $&JH  QJ_  ,9V@ $
M&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP  ",;   @&@  '1D  !H9
M   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!, "QP9  H<'P )'2< "!TO
M  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0  'JD  !Z]   =V   '>P
M6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<   >'   &QL  !@;   6
M&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7  4A'0 $(20  B(L  $B
M-0  (D   "--   C6@  (VL  "-^   CDP  (J<  "*\   AUP  (>T 51T
M $@?   ^(   -2   "X@   H(   (Q\  " >   ='0  &AT  !8=   3'@
M$1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F&@  )B$  "<I   G,@
M)ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[   FU@  )>T 42   $4A
M   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P  &"   !0@   1(@  #R,
M  TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P  +!X  "PF   M+P  +3D
M "U&   M5   +60  "UW   LC0  +*0  "NZ   KU@  *NX 32(  $$D   X
M)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,  !(D   /)@  #2@   HJ
M @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL  #,B   S*P  ,S8  #-"
M   S4   ,V   #-S   RB@  ,J$  #&X   PU@  ,.\ 224  #XF   T)P
M+2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J   -+   "BX   8P 0 "
M,@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?   Z)P  .C(  #H^   Z
M3   .EP  #IO   YA@  .)X  #BV   WU   -N\ 1"D  #HI   Q*0  *RD
M "8H   B)P  '2@  !@I   3*P  $"X   TP   ),@  !34   $W    .0(
M #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#(P  0RX  $,Y  !#1P
M0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP  #8L   O+   *BL  "4J
M   ?*P  &2T  !0O   0,@  #34   @X   $.@   #P    _    00   $,"
M  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@  32@  $TT  !,0@  3%$
M $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O   M+P  *"T  "(O   ;
M,0  %30  ! W   -.@  "#T   )     0P   $8   !(    2@   $P   !.
M 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(  %@N  !7/   5TL  %9>
M  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L,0  )3(  !TU   6.
M$3P   Q    '1    $<   !*    30   %    !3    50   %<   !9
M6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G  !F-   940  &17  !D
M:P  8H4  &&?  !@N0  7MP -3<  # U   H-P  (#H  !@]   10@  #$8
M  9*    3P   %,   !6    60   %P   !?    80   &0   !E    9P
M &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V+0  =CT  '5/  !T8P
M<WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,  !)(   ,30  !5(   !7
M    7    &    !D    :    &L   !N    <0   ',   !U    =P   'H
M  !\    ?P   (($  "&"@  B@\  (P7  "+)   BC,  (E%  "'6P  AG(
M (6+  "#I0  @KP +T   "5$   <20  $TX   U4   $6@   &$   !F
M:P   &\   !T    >0   'T   "     @P   (4   "'    B@   (P   "/
M    D@   )8   "9 @  G@D  *(0  "B&@  H2D  * [  "?4   G6<  )J!
M  ":F0  F:\ *4D  !].   55   #EL   5B    :0   '    !W    ?0
M ((   "&    BP   (\   "3    E0   )<   ":    G0   *    "C
MI@   *H   "N    L@   +<*  "[$0  NA\  +DP  "W10  M5P  +1T  "Q
MC@  KZ0 (E0  !A;   08@  !VH   !S    >P   ((   ")    D    )4
M  ":    GP   *,   "F    J    *L   "N    L    +,   "V    N@
M +T   #"    QP   ,P!  #3"P  U!4  -,F  #1.@  T%$  ,UH  #+@0
MRI8 _    /8   #R    \0   /, !0#T  P \@ 3 /  ' #M "4 Z  N .(
M-@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X Q@!C ,0 :0#! '  O@!X
M +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E /\ F@#_ )0 _P"/ /\
M]    .P   #H    YP   -\   #9  D T@ 0 ,\ %P#/ "  S  H ,8 , #
M #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!= *T 8@"K &D J0!Q *<
M>@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\ C0#_ (@ _P"$ /\ Z
M -\   #9    R0   +\   "X  0 M0 - +, $@"Q !H L  B *T *@"I #$
MI@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D 7 "7 &( E0!I ), <@"1
M 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_ 'H _P!X /\ V0   /_B
M?1!)0T-?4%)/1DE,10 ($LT   "[    K@   *4   "?    G  ) )D #P"9
M !4 F0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0 (4
M50"# %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_
M &X _P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # "" !$
M@@ 7 (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R
M %4 < !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_ &$
M_P!@ /\ M    *    "0    A0   'T   !W    <P   '  " !O  X ;P 2
M &\ & !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B $X
M80!5 %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4
M /\ H0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P / %\
M$P!? !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0
M %( 6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!* /\
MD@   (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %( $ !2
M !0 4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !* $8
M4@!% %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\ A0
M '0   !G    70   %4   !/    3    $H   !(  0 1P * $< #0!& !$
M1@ 5 $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [
M %< .@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?    &L
M  !> @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X /  1
M #P %@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R %,
M,0!> #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%  !7
M!P  30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  / #0
M$@ S !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\ *0!:
M "@ 9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2"P
M2 P  $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P $  K
M !, *@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7 "$
M9  @ ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0  0PX
M #P.   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D 1
M) $4 "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!80 :
M 7  &0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0
M   R$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X '@41
M !P%%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX
M$P>  !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41   O
M$0  *A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)
M$@ 6"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R
M  X,E  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L$P
M)Q(  ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2
M#!0 $0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/
MDP )#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%   )10
M "$3   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q(
M#1 8  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $
M$J0  Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4  !X4
M   ;%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5
M  D3&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@  %:,
M !2W   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6   9
M%0  %A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83  46
M&0 $%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(  !BW
M   7SP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8%@
M%14" !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@
M&QT  !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV   ;
MT   &NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&   %!<#
M !(6!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%   (1H
M "$B   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?T0
M'^T 2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD! !$9
M 0 .&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@  "<?
M   G)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0  (^X
M1!T  #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=   -
M'P  "B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<   M
M)   +BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\ 0"
M #8A   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *)
M!B8   (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U(
M-2H  #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",  #(D
M   J)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P   2X
M   P    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'   /B8
M #XQ   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G   H
M)@  (R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4    X
M    .@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$  $@L
M  !'.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G*
M(B<  !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!
M0P   $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G  !3
M-   4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P  'RP
M !@N   2,@  #34   @Y   "/0   $    !#    1@   $D   !,    3@
M %$   !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B+
M83P  &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,  !,W
M   ..P  "#\   %$    2    $P   !/    4@   %4   !8    6P   %T
M  !@    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0  <C0
M ')%  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!   '
M1P   $P   !1    50   %D   !=    80   &4   !H    :P   &T   !O
M    <@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L  (8]
M  "$4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.    5
M %H   !@    9    &D   !N    <@   '8   !Z    ?0   (    ""
MA0   (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S  "=
M1P  FEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P   &H
M  !Q    =@   'L   "     A@   (H   ".    D0   ),   "6    F0
M )P   "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W/
MM%(  +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P   "#
M    B0   (\   "4    F@   )\   "B    I    *<   "J    K@   +$
M  "T    N    +P   #!    QP   ,T   #4!0  V!   -4>  #3,0  T$@
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M_/[______________________________________________________P
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M______________________________________\
M 0,$!08("0H+#0X/$1(3%!87&!H;'!T?("$B)"4F*"DJ*RTN+S R,S0V-S@Y
M.SP]/D!!0D1%1D=)2DM-3D]04E-455=865M<75Y@86)C969G:6IK;&YO<'%S
M='5W>'EZ?'U^@(&"@X6&AXB*BXR.CY"1DY25EIB9FIR=GI^AHJ.DIJ>HJJNL
MK:^PL;.TM;:XN;J[O;Z_P<+#Q,;'R,G+S,W/T-'2U-76U]G:V]W>W^#BX^3F
MY^CIZ^SM[O#Q\O3U]O?Y^OO\_O__________________________________
M____________________  $" P0%!@<("0H+# T.#Q 1$A,4%187&!D:&QP=
M'A\@(2(C)"4F)R@I*BLL+2XO,#$R,S0U-C<X.3H[/#T^/T!!0D-$149'2$E*
M2TQ-3D]045)35%565UA96EM<75Y?8&%B8V1E9F=H:6IK;&UN;W!Q<G-T=79W
M>'EZ>WQ]?G^ @8*#A(6&AXB)BHN,C8Z/D)&2DY25EI>8F9J;G)V>GZ"AHJ.D
MI::GJ*FJJZRMKJ^PL;*SM+6VM[BYNKN\O;Z_P,'"P\3%QL?(R<K+S,W.S]#1
MTM/4U=;7V-G:V]S=WM_@X>+CY.7FY^CIZNOL[>[O\/'R\_3U]O?X^?K[_/W^
M_VUF=#$      P0A   !                     0
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MQ;_4!R6ZUPE.KMH+<*#;$X>7S3F:DL-8J)&\;+*1MWJYDK2#O8ZSAK^+LH?
MB+&'P(:QB,&$L8G!@[&*P8*QB\* L(S"@+",PH"PC,* L(S"@+",PH"PC,*
ML(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PH"PC,* L(S"@+",PO?
M$!7XP!8Q^;T@4^JW*'S,J$2JQJ5=M,*C<+J^HG^_O*"(P[F;B,:WF(C*M96)
MS;.2BM"QCXO2L(R-U*^*D-:NB)/8K8:8V:R%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO? $!7X
MP!8Q^;T@4^JW*'S,J$2JQJ5=M,*C<+J^HG^_O*"(P[F;B,:WF(C*M96)S;.2
MBM"QCXO2L(R-U*^*D-:NB)/8K8:8V:R%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO? $!7XP!8Q
M^;T@4^JW*'S,J$2JQJ5=M,*C<+J^HG^_O*"(P[F;B,:WF(C*M96)S;.2BM"Q
MCXO2L(R-U*^*D-:NB)/8K8:8V:R%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO? $!7XP!8Q^;T@
M4^JW*'S,J$2JQJ5=M,*C<+J^HG^_O*"(P[F;B,:WF(C*M96)S;.2BM"QCXO2
ML(R-U*^*D-:NB)/8K8:8V:R%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO? $!7XP!8Q^;T@4^JW
M*'S,J$2JQJ5=M,*C<+J^HG^_O*"(P[F;B,:WF(C*M96)S;.2BM"QCXO2L(R-
MU*^*D-:NB)/8K8:8V:R%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO? $!7XP!8Q^;T@4^JW*'S,
MJ$2JQJ5=M,*C<+J^HG^_O*"(P[F;B,:WF(C*M96)S;.2BM"QCXO2L(R-U*^*
MD-:NB)/8K8:8V:R%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VO? $!7XP!8Q^;T@4^JW*'S,J$2J
MQJ5=M,*C<+J^HG^_O*"(P[F;B,:WF(C*M96)S;.2BM"QCXO2L(R-U*^*D-:N
MB)/8K8:8V:R%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VO? $!7XP!8Q^;T@4^JW*'S,J$2JQJ5=
MM,*C<+J^HG^_O*"(P[F;B,:WF(C*M96)S;.2BM"QCXO2L(R-U*^*D-:NB)/8
MK8:8V:R%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VO? $!7XP!8Q^;T@4^JW*'S,J$2JQJ5=M,*C
M<+J^HG^_O*"(P[F;B,:WF(C*M96)S;.2BM"QCXO2L(R-U*^*D-:NB)/8K8:8
MV:R%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VO? $!7XP!8Q^;T@4^JW*'S,J$2JQJ5=M,*C<+J^
MHG^_O*"(P[F;B,:WF(C*M96)S;.2BM"QCXO2L(R-U*^*D-:NB)/8K8:8V:R%
MG=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=
MVJR%G=JLA9W:K(6=VO? $!7XP!8Q^;T@4^JW*'S,J$2JQJ5=M,*C<+J^HG^_
MO*"(P[F;B,:WF(C*M96)S;.2BM"QCXO2L(R-U*^*D-:NB)/8K8:8V:R%G=JL
MA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%
MG=JLA9W:K(6=VO? $!7XP!8Q^;T@4^JW*'S,J$2JQJ5=M,*C<+J^HG^_O*"(
MP[F;B,:WF(C*M96)S;.2BM"QCXO2L(R-U*^*D-:NB)/8K8:8V:R%G=JLA9W:
MK(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JLA9W:K(6=VJR%G=JL
MA9W:K(6=VO? #Q7XP!8P^;T@4^JX)WS,J$2KQJ5=M,*D<+J^HG^_O*"(P[F;
MB,>WF(C*M96)SK.2BM"QCXO3L(V-U:^*C]>MB)/9K8:8VJN&G=JKAIW:JX:=
MVJN&G=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:JX:=VJN&G=JKAIW:
MJX:=VO?!#Q7WP18P^+X?4^JX)GS+J4.KQJ9<M,*D;[J^HGZ_NZ"(P[F=A\BV
MFH?,LY>(S[&4B=*PDHK5KH^,UZV-CMFLBI+<JXF9W:>(G-NGB)S;IXB<VZ>(
MG-NGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<VZ>(G-NGB)S;IXB<
MV_;!#A3WP14P^+\>4^JY)7S+J4*KQJ=;L\*E;KJ^HWZ_NZ&(Q+B>A\FUG(?-
MLIF'T;"6B-2NE(G7K9*+VJN0C=RIC9+?J(V:WZ.+G-RCBYS<HXN<W*.+G-RC
MBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<W*.+G-RCBYS<HXN<W/;!
M#A3VPA4P][\>4^JZ)'S+J4&LQJ=:L\*E;;J^HWV_NZ.(Q+>@A\FTG8?.L9N'
MTZ^9B-:MEXG:JY6*W*F3C=^GDI'BI)&9X*".G-R@CIS<H(Z<W*".G-R@CIS<
MH(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<W*".G-R@CIS<H(Z<W/7"#A3U
MPA0P]L =4^JZ(WS+JD&LQJA9L\*F;;J^I'V_NJ2'Q;>AA\JSGX?/L)V'U*Z;
MB-BKF8G<J9B+WZ>8CN*EEY+FH):9X)R3F]V<DYO=G).;W9R3F]V<DYO=G).;
MW9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W9R3F]V<DYO=G).;W?3"#13UPQ0P
M]L <4^J[(GS*JD"LQJA8L\*F;+J^I'R_NJ6%Q;:CA\NSH8?0L)^'U:V=B-JJ
MG8K=IYN,X*2:CN*?F(_CG9J8X9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;W9F7
MF]V9EYO=F9>;W9F7F]V9EYO=F9>;W9F7F]V9EYO=F9>;W?+##13TPQ,P]<$;
M4^J\(7S*JS^MQJE7L\*G:[J^I7N_NJ:$Q;:EA\NRHX?1KZ&'UJN?B-JGG8G=
MI)R*WZ";B^";FHWBEYJ3X9><F]Z7G)O>EYR;WI><F]Z7G)O>EYR;WI><F]Z7
MG)O>EYR;WI><F]Z7G)O>EYR;WI><F]Z7G)O>EYR;WO###13TQ!,O]<(:4NJ]
M('S*JSZLQJI6L\*H:[J^IWF_NJB#Q;:GA\RRI8?1K**'UJB@A]FDGHC<H9V(
MW9R<B=Z7FXO@DYN/X)*=E]Z2G9?>DIV7WI*=E]Z2G9?>DIV7WI*=E]Z2G9?>
MDIV7WI*=E]Z2G9?>DIV7WI*=E]Z2G9?>DIV7WNW$#!/SQ1(O],(94NJ]'WS*
MK#RLQJM5L\*H:KF^J7>_NJJ Q;6IA\ROI8?2JJ*'UJ6@AMBAGX;:G9Z'VYF=
MA]V4G8G>D)R-WHZ=D]V.G9/=CIV3W8Z=D]V.G9/=CIV3W8Z=D]V.G9/=CIV3
MW8Z=D]V.G9/=CIV3W8Z=D]V.G9/=CIV3W>K%#!/RQ1$O\\,84NJ^'7S+K3JL
MQJQ4L\*I:;F^K'._NJU^Q;*IA\RLI8;1IZ.&U:*AA=>>H(78FJ"%VI:?AMN1
MGHC<C9Z+W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W(N>
MC]R+GH_<BYZ/W(N>C]R+GH_<BYZ/W.;%"Q/QQA$O\L074NK &WS+KSBLQJU2
MLL*K9KF_L&^^MZU^QK"IA\VJIH;1I*2%TY^CA-6;HH36EZ&%V).@A=F/H(?9
MBY^*VHB?C=J(GXW:B)^-VHB?C=J(GXW:B)^-VHB?C=J(GXW:B)^-VHB?C=J(
MGXW:B)^-VHB?C=J(GXW:B)^-VN'&"A/PQQ N\,864>K!&7S+L#6KQZ]/LL.P
M8+B\LFR_LJU^QZVIALRGIX7/H:6$TIRDA-.8HX34E*.$U9"BA=:-H8;7B:&(
MV(>AB]B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]B'H8O8AZ&+V(>AB]B'H8O8
MAZ&+V(>AB]B'H8O8AZ&+V-O'"1+NR0\N[L@44>O$%GS,LS"KQ[%,L<2X5K>V
ML6[!KJU_QZFJALNCJ(3.GJ>#SYFF@]&5I8/2D:2$TXZDA=2+HX;4B*.(U86C
MBM6%HXK5A:.*U86CBM6%HXK5A:.*U86CBM6%HXK5A:.*U86CBM6%HXK5A:.*
MU86CBM6%HXK5A:.*U=K("1+KRPTMZ\H14.O'$GS,MBJJR+=$L+JV6;JOL7#"
MJJU_QZ:KA<J@JH3,FJB#S9:H@\Z2IX//CZ:$T(RFA=&)I8;1AZ6'TH6EB=*%
MI8G2A:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2A:6)TH6EB=*%I8G2A:6)TH6E
MB=*%I8G2A:6)TMC)"1'?S0LLY\T/3^C+#GO-O"*HPKP\L;&U7KRIL7+"IJY_
MQ:*MA,><JX/)EZJ#RI.JA,N0J83,C:F$S8NHA<V(J(;.AJ>'SH2GB<^$IXG/
MA*>)SX2GB<^$IXG/A*>)SX2GB<^$IXG/A*>)SX2GB<^$IXG/A*>)SX2GB<^$
MIXG/A*>)S]7)"1#8SPHKVM,+3MC0"WK-PQ:HL[I&M:FT8KVDL73!H;!_PYZN
MA,69K83'E*R$R)"KA,F.JX3*BZJ%RXFJALN'J8?,A:F(S(.IB<R#J8G,@ZF)
MS(.IB<R#J8G,@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,@ZF)S(.IB<R#J8G,
M@ZF)S-++"0_4T0HIU=4+3-#0"GZXOR6NJ+A/N*&T9KR>LG6_G;%_P9NPA,.6
MKH3%D:Z$QHZMA<>+K(7'B:R&R(>LA\F&JX?)A*N)R8*KBLJ"JXK*@JN*RH*K
MBLJ"JXK*@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"JXK*@JN*RH*KBLJ"JXK*@JN*
MRL_,"0W0T@HHSM0*4L71"H.JPRVHGK=7N)NU:+N:M'6^F;)_OY>QA,&3L(7"
MCZ^%PXROA<2*KH;%B*Z'Q8:NB,:$K8C&@ZV*QH&MB\>!K8O'@:V+QX&MB\>!
MK8O'@:V+QX&MB\>!K8O'@:V+QX&MB\>!K8O'@:V+QX&MB\>!K8O'@:V+Q\S-
M"0S+TPHMQ]0*6;+8"X">S2N:F,%0JY:X9[>5M76\E+1^OI2SA;^0LH7 C+&&
MP8JQA\*(L(?"AK"(PH6PB<.#L(K#@J^+PX&OC,.!KXS#@:^,PX&OC,.!KXS#
M@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,PX&OC,.!KXS#@:^,P\?/"!#%
MU DTN-D*6Z+G$G:7VB6)D,]%F(['7:.-P6ZKC;UYL8RZ@;2)N(.WAK>%N82V
MAKJ#M8>[@K6(O(&TB;V M(J]?[2+OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,
MOGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OGZSC+Y^LXR^?K.,OL+1!Q:]U@@Z
MI_$.59OQ&VB1YBUXB=U A8755H^#SV>7@LMSG7[(>*%[QGRD><1_IG?#@JAU
MPH2I=,*%JG/!AZMRP8BK<L"*K'' BZQQP(NL<<"+K'' BZQQP(NL<<"+K''
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MEXG$N9.*Q[>/C,JUC([,M(F0SK.'DM"RA)72L8*9T[&!GM2N@*+4K("CTJR
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MEZV$QI.MA,>/K(3(C*N%R8FKALJ'JX;*A:J(RH.JB<N!JHO+@*J,RX"JC,N
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M-VF%Z49T?^13>WS?8(%XW&B%=-IMB7#8<8MNUG6-;-5XCVK4>Y!ITWZ19].
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
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MR)2'K,63AZ[#DH>PP)*'L,"2A[# DH>PP)*'L,"2A[# DH>PP)*'L,"2A[#
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MJ:G,<:VJS'"RJ\MPMJO+;[RKR'# J\1QP*K$<<"JQ'' JL1QP*K$<<"JQ''
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MD*'+7YV8PVVHD;UYL8NX@[B#M(B]?;&0P7FQFL%UL:7!<J^OPG6HK\%WH[#
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M>[:XH7VWMIU^N+6;?[FTF7^ZLYB NK*7@+NQEX"[L9> N[&7@+NQEX"[L9>
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M*"G_ERDH_Z J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1T0
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MB]:+=HO6BW:+UHMVB]:+=HO6B_]Y$0'_>!H"_XP9 _^>(P3_JB8&^+0E".O
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M=O9..VSV5$)D]EI(7?9B35?V:U%2]G553?> 6$CXC5I%^)M<0OBK7D'WOE]
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M2#7_W4DT__!)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X2<FK  "VM
MJ,$  )O/  ".WP$ A_\1 7[_'01U_R<+;/\O$F3_-QA<_SX=5O]%(E#_2R5+
M_U(H1O]8*T'_7RT^_V<O._]O,3C_>#,V_X(T,_^--C'_F3<P_Z4X+_^R.B[_
MP#LN_],[+?_K/"W_ZSPM_^L\+?_K/"W_ZSPM_^L\+?_K/+BP  "HO   FLD
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MCX61?8J"G(*%@*J%@7^\AH" VX6 @-V#@'_>@8!^X'^ ?>%]@'WC>X!\Y'J
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M64?0]UQ)R/=>2L'V8$N]]F!+O?9@2[WV8$N]]F!+O?9@2[WV8/^)  #9G@
MQZP! +FV @"NP0, I<X& )SD# "5[QT#C>\L"X7O.15\[T$><^]))VKN4"]B
M[E<U7.Y?.E;N:#]2[G%"3>]\1DGOB4E&\)9+0_"F34#QN4X_\MM//O#W3D+F
M^T]#W?M11-3\4T7/_%1%S_Q41<_\5$7/_%1%S_Q41<_\5.&5  #+I@  N[
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M+23__RTD__\M)/__+23__RTD__\M)/__+;&N  "CN0  E,8  (;3  !YX0
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M9E6D\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S9/]P#0#_A 0
MW98  ,ZC P#$K@0 N[<$ +3"!0"NS0P I\X@ I[-,0J5RSX6B\A)(X+&4BYZ
MPUHX<L%B0&O :D=DOG--7KU\4UF\B%=4NY5;4+NE74Z[N5Y-O-M=2[GW7TZQ
M]F!1JO9@4Z7V8%6A]F!5H?9@5:'V8%6A]F!5H?9@5:'V8/]W" #KC   TYL
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M1$#._T9 SO]&0,[_1D#._T9 SO]&0,[_1M:3  #$HP  M*P  *>V  ";P0
MD,P" (;9!@" \A( >?(? G'R*P9J\C8,8_,_$EWS1QA7\T\=4O-7(4WT8"1)
M]&DH1O1S*D+U?BT_]8LO//:9,3KVJ3,X][XT-OCA-3;U^34U\_\T-^S_-CGE
M_S@YY?\X.>7_.#GE_S@YY?\X.>7_.,B>  "VJ0  J+(  )N]  "/R   @]0
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M%!?_^A07__H4%__Z%)^S  "0OP  @,P  '+:  !DY   6/4  %'_ 0!*_PL
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M866)]U]GAOA>:83Y7&J"^EIK@?M::X'[6FN!^UIK@?M::X'[6O]B$ #_<@<
M^((# -N/ @#/F@4 R:,& ,.L!@"]LA  M;(D JRP-0NCK4(7FZI,(Y*F52Z*
MHUTX@Z!E0'V=;$=VFW1-<)E]4VN6B%AFE91<8I2A7U^3LF!=D\E@79/M7UZ0
M^%YAC/E<8XKZ6V2'^UIEAOM998;[666&^UEEAOM998;[6?]F#0#_=P, XX<
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M4E"A_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<  +ZB  "SJ@
MJ;,  *"\ @"8Q@8 D<P2 (O,)0*$RS0)?,E $G7(2AMMQU,C9\5<*F'$9#!<
MPVTV5\)V.E/"@3]/P8Y"2\&=14C!KD9'P<5&1\'J1D2^_TE%N?]*1[/_2TFM
M_TQ*J_],2JO_3$JK_TQ*J_],2JO_3.E_  #1D   PIX  +6G  "JKP  H+@
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M+#/D_RPSY/\L,^3_+,&<  "PI@  HZX  ):X  ")PP  ?<T  ''8  !GY@8
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M!8VZ  !]QP  ;=,  %_@  !0YP  0NT  #K_   U_P  +_\" "K_"@ F_P\
M(O\4 ![_&@$:_Q\!%O\C 1/_* $0_RT!#O\S 0S_.0(*_T$"!_]) @/_4P(
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MXGT024-#7U!23T9)3$4 "A*18/]'D6#_1_].& '_6A$!_V0. /]O$ #_=A,
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M2WMN_TM[;O]+>V[_2_]7$0#_8PH _W ' /!\!0#<A04 U(P( -"3"0#*EA0
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M24Z@]4E.G_])4)G_25*6_TA4DO]'5)+_1U22_T=4DO]'5)+_1_]N  #>?P
MRHT  +Z8  "SH   JJ<  *&N  "7M@  D;H0 (RZ(P&%N3(&?K@^#G>V21=Q
MM5(>:[-:)66R8BM@L6HP6[!S-5>O?3E3KHD]3ZV60$RMI4)*K;E#2:[80DBK
M]4-'JO]$2:7_1$N@_T1-G/]$39S_1$V<_T1-G/]$39S_1.IU  #2A@  PY,
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M*331_RLVRO\M-LK_+3;*_RTVRO\M-LK_+<60  "VG0  J*4  )RM  "/M@
M@[X  '?'  !LSP( 8M8' %KD#@!8Y!P 5.0I 5#D-0-,Y3\%2.5)!T7E4PI"
MYEP-/^9F#SSF<1(ZYWX4-^>,%C7GG!<SZ*X9,NG&&3+HZADQY?X9+^3_'"[D
M_QXMXO\@+>+_("WB_R MXO\@+>+_(+J:  "JHP  G:L  )"T  "#O0  =\8
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M!0[__P4.__\%#O__!96O  "&N@  =\4  &C0  !:VP  3.$  $#G   W\P
M,O\  "[_!P J_PX )O\3 "/_&@ ?_R  &_\F !C_*P$5_S(!$O\X 1#_0 $.
M_T@!#/]2 0G_70(&_VL"!/]] @+_D (!_Z," /^V @#_S0, _^P# /_L P#_
M[ , _^P# /_L XBY  !XQ   :=   %O=  !+XP  /ND  #+N   K_P  )O\
M "'_   =_P@ &O\- !;_$0 3_Q8 $/\:  [_'P +_R0 "?\J  ;_,  "_S<!
M /]  0#_2@$ _U8! /]D 0#_=0$ _X@! /^: 0#_J@$ _[L! /^[ 0#_NP$
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M,ZY-_S.J3O\RJ4[_,JE._S*I3O\RJ4[_,O]#&@'_3!, _U00 /]<$@#_81<
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M.XA?_SN(7_\[B%__._].$0#_6 H _V,' /IL!@#G<P8 W7@( -I["P#1?A<
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M1UZ![T9?@?]$8'__0F%]_T%B>_\_8WK_/V-Z_S]C>O\_8WK_/_]>  #I;0
MUGD  ,B$  "^C   MI,  *Z7  "FFP0 H)T7 )J=*0*3G#<(C)I#$(:831B
MEE4?>I1=)G6292QPD&PQ;(YU-F>-?CICBXD^7XJ505R)HT1:B;1%6(G+15B(
M[418B/]#68;_05N#_T!=@?\^78#_/EV _SY=@/\^78#_/O]B  #D<0  SWX
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M-T:@_S=(G/\W29K_-TF:_S=)FO\W29K_-^)T  #*@P  O(\  +"8  "EG@
MFZ0  )"K  "%L0  >K@$ ':Y% !RN24!;;DS!&BX/PACN$D.7K=2$UJV6AA6
MMF(<4K5K($ZT=21+M( G2+..*D6SG2Q"LZXM0;/%+D&SZ2U L/XO/Z__,3ZM
M_S) J/\R0:;_,D&F_S)!IO\R0:;_,M5\  #"B@  M98  *B=  "=HP  DJH
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M%BC:_Q8HVO\6*-K_%K.8  "EH   F:<  (NP  !^N   <<   &7(  !9S@
M3M,  $3;!  _Z0T />D7 #OJ(P YZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J
M[FL$*.YX!2;OB 8E[YH'(_"N!R+QR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J
M_PL?ZO\+'^K_"ZB?  ";I@  C:\  '^X  !QP0  9,H  %C0  !,U@  0=T
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M 82W  !TP0  9<P  %;8  !'WP  .>4  "WJ   C[@  '/T  !C_   5_P
M$?\$  __"P -_PX "?\1  ;_%0 #_QH  /\@  #_)@  _RX  /\W  #_00
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M*9U-_RF=3?\IG4W_*?]#$0#_2PP _U,( /]:"P#_7@T ^6 0 .MA%@#A8B$
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M/&UKZ3MM;/XY;6S_-VYL_S5N:_\T;FK_,FYJ_S)N:O\R;FK_,O]3  #T7P
MWFH  ,US  ##>@  NWX  +6!  "N@PD J(4: **%*P*;A#H'E8)%#I!_3Q6*
M?5@;AGM?((%Y9R5]=V\J>G9W+G9T@#)S<XLU;W*6.&QQHSII<+(\:'#&/&=P
MYSMG<?PY:''_-VAP_S5I;_\T:6[_,VEN_S-I;O\S:6[_,_]6  #K8@  V&X
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M-5:!_S18?_\S67W_,EE]_S)9??\R67W_,N]@  #;;@  QWH  +N#  "RBP
MJ)   )^3  "4E@  C9D. (F:'@"$FBX"?IDZ!WF710UTEDX3;Y56&&J37AUF
MDF4A8I%M)EZ/=BI;CH$M5XV-,%2,FC-1C*HU3XR]-4^,WC5/B_<T3XK_,U")
M_S)1AO\Q4H3_,5*$_S%2A/\Q4H3_,>IE  #2<P  PG\  +:(  "LD   HI0
M )B8  ",G   A)\* ("@&0!\H2D!=Z V!7*?00IMGDL/:)U3%&2<6QE@FV,=
M7)IK(5B9="55F'XI49>*+$Z6F"Y+EJ@P2I:\,4F6W#!)E/8P29/_,$F2_S!*
MD/\O2XW_+TN-_R]+C?\O2XW_+^)K  #*>0  O(4  +&/  "FE   FYD  )&=
M  "&H@  >J8# ':G$P!SJ"0 ;J@R VJH/09EIT<+8:90#UVE6!19I& 85:-H
M'%*C<1].HGPC2Z&()DBAEBA%H*8J1*&Z*T.AVBI#G_4K0IW_*T*<_RQ"F_\L
M1)?_*T27_RM$E_\K1)?_*]=R  ##@   MHP  *J4  "?F0  E)X  (FC  !^
MJ   <*X  &JP#@!HL1T 9;$L 6&Q. -=L$,&6;!,"E6O5 Y2KUT13JYE%4NN
M;QA(K7D;1:V&'D*LE2 _K*4B/JVY(SVMV"(]J_4C/*G_)3NG_R8[IO\F.Z3_
M)CND_R8[I/\F.Z3_)LQZ  "[B   KI(  **9  "7G@  C*0  ("J  !UKP
M:;0  %ZY!@!;NA0 6;LD %:[,0%3NST#4+M'!4V[4 =*NED*1[IB#42Z;!!!
MNG<3/KF$%3RYDQ<YN:,8.+FW&3>ZUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R
M_R SLO\@,[+_(,&#  "TD0  II@  )N>  "/I0  @JL  ':Q  !KM@  7[P
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M!:.=  "6I   B*P  'JU  !LO0  7\0  %/*  !'S@  /-,  #+:   JWP
M)>X) "/P$0 A\1D '_$B !WR*P ;\S0 &?0^ !?T2  5]5( $_9? !+V;@$1
M]X !$/B4 0_YJ@$.^<8!#OGM 0WV_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC
M  "+K   ?+4  &V^  !?Q@  4LT  $72   YV   +]X  ";B   ?Z@  '/L&
M !G_#@ 7_Q, %/\: !+_(0 0_R@ #O\P  W_.0 +_T, "?].  ;_7  $_VP
M O^   '_E@  _ZT  /_*  #_\   __\  /__  #__P  __\  /__ (VK  !]
MM0  ;K\  &#(  !2T   0]<  #?=   KX@  (N8  !GJ   5^0  $O\  !#_
M"  ._PX #/\1  G_%@ &_QP  _\B  #_*@  _S,  /\]  #_20  _U<  /]I
M  #_?@  _Y4  /^L  #_QP  _^@  /_Z  #_^@  __H  /_Z ("U  !POP
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M+GU9YBU\6OHL>UK_*GM;_RA[6_\G>UK_)GI:_R5Z6O\E>EK_)?])  #[4@
MXUP  -)C  #':   P&L  +IK @"U:PT KFT= *AN+@&C;3P%G6M("IEJ40^4
M:%H4D&9B&(UE:AR*8W(@AV)Z(X1A@R:!8(PI?E^7*WM>HRUY7K$O=UW$+W5>
MXB]U7ODM=5__*W5?_REU7_\H=5[_)G5>_R9U7O\F=5[_)O]+  #P50  WE\
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M+61L_RMD:_\I96K_*&5J_RAE:O\H96K_*/U3  #C7P  SFD  ,%Q  "W=P
MKWL  *=]  ">?0  F'X1 ). (@".@#$"B7\^!H1]2 Q_?%$1>WI9%G=Y8!IS
M=V@>;W9P(6QU>"5I=((H9G..*V-RFBY@<:@O7G&Z,%UQU#!=<?(N7G'_+%YP
M_RM?</\I8&__*&!N_RA@;O\H8&[_*/%5  #>8@  RFT  +UU  "S>P  JX
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M)DZ!_R9.@?\F3H'_)N%C  #)<   NWL  +"$  "FB@  FXX  )&1  "$DP
M>I4" '67$@!RF"( ;Y@P FJ7.P1FET4(8I9.#%^55@];E%T36)-E%U63;AI1
MDG@=3I&$($N0D2-)D*$D1Y"R)D60RB9%C^TE18W_)46,_R5&B_\D1HK_)$:*
M_R1&BO\D1HK_)-AI  ##=@  M8$  *N*  "?CP  E9,  (J6  !^F@  <)T
M &N?#@!HGQP 9J J 6*@-P)?GT$%6Y]*"%B>4@M4GEH.49UB$DZ<:Q5+G'48
M2)N!&D6;CQU"FI\?0)JP(#^:R" _F>L?/YC_(#Z6_R$^E?\A/Y3_(3^4_R$_
ME/\A/Y3_(<UP  "\?0  L(@  *2/  "9E   CI@  (.=  !WH   ::0  &"G
M" !=J!0 6ZDD %FI,0%6J3P"4ZE%!%"H3@9-J%<)2JA?#$>G: Y$IW,10:9_
M%#ZFC18\IIT7.J:O&#FFQQ@YI>H8.*/_&C>A_QLWH/\<-Y__'#>?_QPWG_\<
M-Y__',1X  "UA0  J8\  )V5  "2F@  AI\  'JC  !NJ   8JP  %6P  !0
ML@X 3K(; $VS* !+LS4 2;,_ 4:S20)$LU($0;-;!C^S9 @\LV\*.K-[##>S
MB@XULIH/,[.M$#*SQ1 RLND0,;#^$C"N_Q0OK?\5+ZS_%B^L_Q8OK/\6+ZS_
M%KN!  "NC@  H94  )::  ")H   ?:8  '&K  !EKP  6;0  $ZW  !#O 4
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M !/BL0 2X\\ $N#T !+>_P$1W?\!$=O_ A';_P(1V_\"$=O_ IZ:  "2H0
MA*D  ':Q  !HN   6[\  $[$  !"R   -\P  "W0   DU0  '-L  !7?!0 4
MZ0X $NH4 !'K'0 0ZR8 #NPP  [M.@ -[D8 "^Y3  KO8@ )\'0 "/&)  ?R
MH  %\KH !/'D  +Q_0 "[_\  ^W_  /M_P #[?\  ^W_ )6A  "&J0  >+(
M &FZ  !;P@  3<@  $#,   TT0  *M8  "';   9X   $N0   _P 0 -^0H
M"_H/  G[%0 '^QP !/PD  '\+   _#<  /Q"  #\4   _&$  /UU  #\C
M_*0  /S!  #\ZP  _/\  /W_  #]_P  _?\  /W_ (FI  !YL@  :KL  %S$
M  !.S   /]$  #+7   GW0  '>$  !7E   .Z   "O$   C]   %_P,  ?\)
M  #_#@  _Q(  /\7  #_'P  _R<  /\Q  #_/@  _TT  /]?  #_=0  _XT
M /^F  #_P@  _^<  /_\  #__P  __\  /__ 'RS  !LO   7<8  $[/   _
MU@  ,=T  "7B   :Y@  $>H   SN   %\@   /\   #_    _P   /\   #_
M!0  _PH  /\.  #_$@  _Q@  /\A  #_*P  _SD  /]*  #_70  _W,  /^,
M  #_I   _[D  /_4  #_W@  _]X  /_> /\8+ #_&2D _QDH /\5*P#_$#
M_PLX ?\#1 '_ %$!_P!> ?\ ; '_ '@!_P"" ?\ C '_ )0!_P"< /\ H@#_
M *@ _P"O /\ M@#_ +X _P#( /\ UP#_ .< _P#S /\ _0#_ /\ _P#_ /\
M_P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\;*0#_'28 _QPE /\9)P#_$RP _PXT
M /\+0 '_"$X!_P5; ?\#: '_ G0!_P)_ ?\"B '_ I$!_P*8 ?\"GP'_ :4
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M ^D3_P/I$_\#Z1/_ _\F'0#_*!@ _R@6 /\F%@#_)AT _R8H /\C- #_($
M_QU- ?\;60'_&64!_AEP ?P8>@'Y&(,!]QB, ?88DP'T&)H!\QBA ?$9J 'P
M&; "[AFZ NT9Q@+J&MD"YAKK >(;^0+@&_\#WAS_!-T<_P7<'/\%W!S_!=L<
M_P7;'/\%VQS_!?\J&0#_+1, _RT1 /\M$0#_+AD _RTB /\L+@#_*3H _R9'
M ?HD5 'V(V !\B)K >\B=0+M(GX"ZR*' NDBCP+G(I8"Y2*> N0BI0+B(JT"
MX2.W M\CPP+=(]8"V"3J ](D^07/)?\&S27_!\LE_PC*)?\(RB3_",HD_PC*
M)/\(RB3_"/\N% #_,1  _S(- /\T#@#_-10 _S4< /\S)P#Z,30 \R]! .XM
M3@'I+%H!Y2QE N(L< +?*WD"W2N" ]HKBP/8*Y($U2N:!-,KH@31*ZH%SRNS
M!<TKOP;,+,\&R"WG!\0M]PG!+?\*ORW_"[TM_PR\+?\,O"S_#+LL_PR[+/\,
MNRS_#/\Q$0#_-0P _S8' /\Z"P#_/!  _SL5 /@Y'P#O-RL YS8Y .$U1P#<
M-50!U35@ M$U:@/.-',$S#1\!<HTA0;(-(T'QC.4",0SG G",Z4)P3.N"K\S
MN0N],\@+NS3A"[<T\PVT-/\/L33_#[ T_Q"O-/\0KC3_#ZXT_P^N-/\/KC3_
M#_\U#@#_. < _SP" /] !@#_00L ^D$/ .T_%@#C/"( VCTQ -(^00#,/D\"
MR#Y: \0]9 7!/6X'OSQV"+P\?@JZ.X<+N#N/#+<[EPVU.I\.LSJI#[$ZM!"O
M.L(1KCK9$:H[[Q*G._\3I3O_%*0[_Q.C._\3HCO_$Z([_Q*B._\2HCO_$O\X
M"@#_/   _T$  /5%  #F1@( X44' .-"#0#50QD S$4L ,9'/ '!1TD"O$95
M!+E%7P:U1&@)LT-Q"[!#>0VN0H$/K$*)$*I!D1*H09H3IT"D%*5 KQ6C0+P6
MH4#0%IY!ZA><0?P7FD'_%YA!_Q>80?\6ET'_%9=!_Q670?\5ET'_%?\[!@#_
M/P  ^48  .5+  #<3@  TTT$ -%*"0#*2A0 PDTG +Q.-P&W3D4"LDU0!:],
M6@BK2V,*J$IL#:9)= ^D27P1H4B$$Y]'C!6=1Y47FT:?&)E&JAF71K@:ED;*
M&Y-&YAN11_D;CT?_&HY'_QF.1_\8C4?_&(U'_Q>-1_\7C4?_%_\^ @#_0P
MZTL  -U1  #15   RE0! ,92!0#!41$ N5,B +-5,P&N5$$"JE1,!:935@BB
M45\,GU!G#YU/;Q&:3G<4F$Y_%I9-B!B33)$9D4R;&X]+IAV-2[,>BTO%'HE+
MXAZ'3/<>ADS_'85,_QR%3?\:A4S_&85,_QF%3/\9A4S_&?]   #\1P  Y5
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M(F]:_R!P6O\><%K_'7!:_QQP6O\<<%K_'/](  #G4@  TUL  ,5B  "[9@
MLV@  *QH  "E9@4 GV<4 )II)0"5:30"D&A !(QG2@B(9E,,A&5;$(%D8A-^
M8VH6>V)R&7AA>AQV8(0><U^.(7!>FB-N7J@E;%VX)6I>SB9I7NXD:5[_(FI>
M_R!J7O\?:E[_'FI>_QUJ7O\=:E[_'?E*  #C50  SU\  ,%E  "W:@  KVP
M *=L  "?:@$ F6L1 )1M(@"0;C$!BVT]!(=L1P>#:U +?VI8#WQH8!-X9V<6
M=F=O&7-F>!QP98$>;62,(6ICF"-H8J8E9F*V)F1BS"9D8NPE9&+_(V1B_R%E
M8O\?96+_'F5B_QUE8O\=96+_'?),  #?6   RF(  +UI  "S;@  JW   *)P
M  "9;@  DW 0 (]R'P"*<BX!AG([ X)Q10=]<$X+>FY6#G9M7A)S;&45<&MM
M&&UJ=1MJ:7\>9VF*(65HEB-B9Z0E8&>T)E]GR29>9^HE7F?^(U]G_R%?9O\?
M8&;_'F!F_QY@9O\>8&;_'N]/  #:7   QF4  +IM  "P<@  IW4  )UT  "4
M<P  C70- (EV' "%=RL!@7<X WQV0P9X=4P)='14#7%S6Q%N<F,4:W%K%VAP
M<QIE;WP=8FZ'(%]ME")=;*(D6FRR)5ELQR58;.@E66S](UEK_R%::_\?6VO_
M'EMJ_QY;:O\>6VK_'NM3  #38   PFD  +9Q  "L=@  HWD  )EY  "-=P
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M$0!QB"  ;H@N 6J(.0)GAT,%8X=,"&"&4PM=A5L.6H1C$5>$:Q14@W4748*
M&DZ!C1Q+@9L>28&L'TB P2!'@.,?1W_Z'DA^_QY(??\=27S_'$E\_QQ)?/\<
M27S_'-9A  #";@  M'@  *J   "?A0  E(<  (B'  ![B0  <(P  &N.#0!H
MCQH 9H\I &*0-0%?CS\#7(](!5F.4 A6CE@+4XU@#E",:!!-C'(32HM]%DB*
MBAA%BID:0XJJ&T**OQM!BN$;08CY&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_
M&LUG  "\=   KWX  *6&  ":B@  CHP  (*-  !UD   9Y0  &&5" !>EQ0
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M""VLN DLK-D(+*KU"BNH_PLJIO\,*J7_#2JE_PTJI?\-*J7_#;6   "HBP
MG)$  )&6  "%G   >*   &NE  !?J   4ZP  $BO   ]L@  -K4+ #2U%0 S
MMB$ ,K8L #&W-P PMT$ +[A+ "ZX50 LN& !*KAM 2FY>P(GN8T");F? R2Y
MM ,CN=(#([?T!"*U_P4AM/\&(;/_!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<
M (B=  ![HP  ;J@  &&M  !5L0  2K0  #^W   TNP  *[X# "3"#  BPA0
M(L,? "'#*@ @Q#0 '\0_ ![%2@ =QE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7
MR,L %\;Q 1?$_P$6P_\"%L'_ Q;!_P,6P?\#%L'_ Z.1  "8F   BYX  'VE
M  !PJP  8K$  %:V  !*N0  /KT  #3    JQ   (L@  !G,!  3T H $=(1
M !#2&@ 0TR4 #],P  [4/  .U$@ #=56  W590 ,UG@ #-:-  O8I  *V+X
M"=GF  K6_@ +U/\ "]+_  O2_P$+TO\!"]+_ 9J8  ".GP  @*8  '*M  !D
MM   5[H  $F_   ]P@  ,L8  "C)   ?S0  %]$  !'6   ,VP4 "-X+  ;?
M$0 %WQH !. D  +A+@ !XCH  .-'  #D5@  Y&<  .5[  #FD@  YJH  .?(
M  #G\   Z/\  .C_  #H_P  Z/\  .C_ )&?  ""IP  =*\  &6W  !7O@
M2<,  #S'   PRP  )<\  !S4   4V0  #MT   GA   "Y0   .D&  #I#0
MZ1$  .H8  #K(0  [2L  .\W  #Q10  \E8  /-H  #S?@  ])<  /6P  #V
MT   ]_,  /?_  #W_P  ]_\  /?_ (6G  !VL   9K@  %C!  !*R   .\P
M "[1   CU@  &=P  !'@   ,XP  !.<   #J    ]0   /0   #U!0  ]0L
M /8/  #V%   ^!T  /HG  #\-   _T,  /]5  #_:0  _X$  /^:  #_L@
M_\\  /_M  #_^0  __D  /_Y 'BP  !HN@  6<,  $O+   [T0  +=@  "'=
M   6X@  #N8   CJ    [0   /    #X    _P   /\   #_    _P   /\&
M  #_#   _Q   /\8  #_(@  _S   /]   #_4P  _VD  /^!  #_F0  _Z\
M /_#  #_U0  _]4  /_5 /\3* #_$R4 _Q$E /\-)P#_!BT _P U /\ 00#_
M $\ _P!< /\ :0#_ '0 _P!^ /\ B #_ )  _P"7 /\ G0#_ *0 _P"J /\
ML #_ +< _P#  /\ S #_ -\ _P#L /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ _P#_ /\6)0#_%B( _Q0A /\0(P#_"B@ _P P /\ /0#_ $L
M_P!8 /\ 9 #_ '  _P!Z /\ A #_ (P _P"3 /\ F@#_ *  _P"F /\ K0#_
M +0 _P"\ /X R #] -D ^P#I /H ]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D
M_P#Y /\ ^0#_ /\:(@#_&AX _Q@= /\3'@#_#B( _PHL /\'.0#_ T8 _P!3
M /\ 8 #_ &L _P!V /\ ?P#_ (@ _P"/ /\ E@#_ )T _P"C /X J0#\ +
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M O\E$P#_)1  _R0- /\C#@#_(Q0 _R(> /\?*0#_'#4 ^1E# /083P#O%UL
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M!;$MZ@:N+OL'JR[_"*DN_PBH+O\(J"W_"*@M_PBH+?\(J"W_"/\O" #_,0
M_S4  /8W  #J-@( YS,( .0O#P#9+AL SS$L ,DS/ #$-$D P#55 ;PU7P*Z
M-6@"MS5P [4T> 2S-( %L32(!K TD :N-)D'K#2B"*LTK FI-+D)IS3*"J4U
MY0JA-?@+GS7_#)TU_PR=-?\+G#7_"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH
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M%7]'_Q1_1_\2?T?_$7]'_Q%_1_\1?T?_$?\[  #N0P  W$P  ,Q1  #!5
MN50  +11  "N30L J$\9 *-1*0">4C<!FE)# I=13@24458&D5!>"8Y/9@N,
M3FT-B4YU#X=-?A&%38<3@DR1%8!,G!9^2ZD7?$NX&'M+S1AY3.L8>$S^%W=,
M_Q5W3/\4=TS_$W=,_Q)W3/\2=TS_$O\^  #H1P  U5   ,96  "\6   M%D
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M%659_Q1E6?\495G_%.]&  #:4@  QEL  +IA  "P90  IF8  )UC  "580
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M%=U5  #%80  MVH  *QQ  "B=0  E'0  (ET  !\<P  =G4  '%W$ !O>!T
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M$CV$M1,\A,\3/(+P$CR!_Q(]@/\2/7__$CU^_Q$]?O\1/7[_$<5F  "U<0
MJGL  )^"  "2@@  A8(  'F#  !MA@  7XH  %B- 0!4C@\ 4H\; %"/)P!/
MD#, 39 ] 4N010))D$X#1I!6!$2/7P5"CV@'/X]S"3V.@ LZCH\,.(Z@#3>.
MLPXVCLP.-HWO#C6+_PXUB?\/-8C_#S:'_P\VA_\/-H?_#[YM  "P>0  I8(
M )F'  ",B   ?X@  '**  !FC0  6I$  %"5  !)EPD 1Y@3 $68( !$F2L
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M 1NO_@(:K?\"&JS_ QJK_P,:J_\#&JO_ ZB(  ";CP  D90  (2:  !VGP
M:*(  %NE  !/J0  1*T  #FP   OLP  )K8  !ZY!0 8NPX %[L6 !>\(  6
MO"H %;TU !2]0  3ODL $KY8 !*^9P 1OW@ $+^, !# H@ .P+H #L#A  ^]
M^P /O/\ $+K_ 1"Z_P$0NO\!$+K_ 9^/  "4E0  AYL  'FA  !KIP  7JP
M %*Q  !%M   .K8  "^Y   EO   ';\  !7#   /Q@4 "\H-  G*%  (RAT
M!\HG  ?*,@ &RSX !<M+  3,6@ #S&H  LQ^  ',E   S*L  ,W(  #,[0
MS/\  ,O_  '*_P !RO\  <K_ )>6  "*G   ?*,  &ZJ  !@L   4K8  $6Y
M   YO   +K\  "/#   ;Q@  $\H   W-   (T0   =0)  #4#@  U14  -8>
M  #8)P  V3$  -L^  #<2P  W5L  -YN  #>A   WYL  -^T  #>V0  W_<
M -__  #?_P  W_\  -__ (V=  !_I0  <*P  &&S  !3N@  1;\  #C"   L
MQ@  (<D  !C-   0T0  "]4   3:    W@   . !  #A"0  X@X  .03  #E
M&P  YR0  .DO  #K/   [4L  .Y=  #N<0  [XD  /"B  #PO   \.,  ._Y
M  #P_P  \/\  /#_ (&E  !RK0  8[4  %2]  !&Q   -\@  "K,   ?T
M%=4   [:   'W@   .(   #F    Z0   .H   #L    [@4  .\,  #Q$
M\Q<  /4@  #X*P  ^SD  /U*  #^7@  _W0  /^-  #_I@  _\   /_A  #_
M]0  __4  /_U '2N  !EMP  5L   $?(   XS0  *M(  !W8   3W0  #.(
M  /F    Z0   .P   #P    \P   /0   #V    ^    /H   #]!P  _PT
M /\2  #_&P  _R@  /\W  #_2@  _UX  /]V  #_CP  _Z8  /^Z  #_T0
M_]$  /_1 /\/) #_#B( _PLA /\#) #_ "D _P R /\ /@#_ $P _P!9 /\
M90#_ '  _P!Z /\ A #_ (P _P"2 /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z
M /\ Q0#_ -, _P#G /\ ] #_ /\ _@#_ /\ _P#^ /\ _@#_ /X _P#^ /\
M_@#_ /\1(0#_$!X _PT= /\''P#_ ", _P M /\ .@#_ $@ _P!5 /\ 80#_
M &P _P!V /\ ?P#_ (< _P". /\ E0#_ )L _P"A /\ IP#^ *X _0"V /P
MP #[ ,T ^0#B /@ \ #W /P ]@#_ /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_
M /\5'0#_$QH _Q 9 /\+&0#_ !T _P I /\ -@#_ $, _P!0 /\ 7 #_ &<
M_P!Q /\ >@#^ (, _ "* /H D0#Y )< ^ "= /< HP#U *H ] "R /( NP#Q
M ,@ [P#< .X [ #M /H ZP#_ .H _P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8
M&0#_%A4 _Q,3 /\.$P#_"QH _P<D /\", #_ #X _P!+ /\ 5P#_ &( _ !L
M /@ =0#U 'X \@"% /$ C #O ), [@"9 .P H #K *8 Z0"N .< MP#F ,,
MY #4 .( Z0#A /< WP#_ -T _P#= /\ W0#_ -T _P#= /\ W0#_ /\;$P#_
M&A  _Q8. /\2#@#_$A4 _P\? /\,*P#_"3@ _P9% /L#40#W EP \@)F .X"
M< #J G@ YP*  .8#AP#D XX X@.5 .$#G #?!*, W02K -L$M #8!<  U@70
M -,&YP#0"/@ S@K_ ,P+_P#+#/\ RPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L
M_QH' /\9"P#_&!$ _Q89 /\2) #Z$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>
M#7, VPU[ -D-@P#6#8H U V1 -(-F0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81
MZ0#"$OD OQ/_ +T3_P&\$_\!O!/_ ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R
M /\A!0#_'PP _QP1 /88' #L%2@ Y1,V -\20P#9$T\ TQ1: - 59 #-%FT
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M!I<O_P:6+_\&E2[_!94N_P65+O\%E2[_!?\L  #_+@  ZC4  -TY  #1.0
MRC8  ,<O!@#!+1$ NC A +0R,0"P-#X K#5* *DU5 &G-5T!I#5E J(U;0*@
M-70#GS5\!)TUA 2;-8T%FC27!I@TH0:6-*T'E#6["),UT B0->P(CC;^"(PV
M_PB+-O\(BS;_!XHU_P>*-?\'BC7_!_\O  #R-   XCP  -)!  #'0@  P$
M +LZ 0"V-@X L#D< *H[+ "F/#H HSU& )\]4 &=/5D"FCUA Y@]: 26/' %
ME#QW!I(\@ >1/(@'CSN2"(T[G0F+.ZD*B3NW"X@[R@N%/.@+@SS["X(\_PJ!
M//\*@3S_"8$\_PB!//\(@3S_"/\S  #L.@  VD,  ,I'  "_20  MT<  +%"
M  "M/@H ID 7 *)")P">0S4 FD1" 9=$3 &41%4"D4-= X]#9 6-0VL&BT)S
M!XE">PB'0H0*A4&."X-!F0R!0:4-?T&S#GY!Q@Y\0>0.>D+Y#7E"_PQX0O\+
M>$+_"WA"_PIX0?\*>$'_"O8V  #F0   T4@  ,--  "Y3@  L4T  *E)  "D
M108 GT83 )I((P"623( DDH^ 8]*2 *,2E$#BDE9!(=)8 6%26@'@TAO"(%(
M=PI_1X +?4>*#7I'E0YX1J(/=D:P$'5&PA!S1N 0<D?W#W%'_PYQ1_\-<4?_
M#'%'_PMQ1O\+<4;_"_,Y  #@1   S$P  +Y1  "T4P  JE(  *).  "=2@$
METL1 )--( "/3RX C$\Z 8A/10*%3TX#@T]6!(!.709^3F0'?$UL"7E-= MW
M3'T,=4R'#G-,D@]Q2Y\1;TNM$FU+OQ)L2]P2:TSU$6I,_P]J3/\.:DO_#6I+
M_PQJ2_\,:DO_#/ ]  #;2   QU   +I5  "P6   I58  )Q3  "73P  D5 .
M (Q2' ")5"L A50W ()40@%_5$L#?%13!'I36@9X4V((=5)I"7-2<0MQ47H-
M;E&$#VQ0D!!J4)P2:%"K$V90O!-E4-@39%#S$F10_Q!D4/\/9%#_#F5/_PUE
M3_\,94__#.Q!  #43   PU0  +99  "L7   H%H  )=7  "15   BU4, (97
M&0"#6"< @%DT 'U9/P%Z64@#=UA0!'186 9R5U\';U=F"6U6;@MK5G<-:%6!
M#V95C1%D5)H28E2I$V!4NA1?5-,47E3R$UY4_Q%?5/\/7U3_#E]3_PU?4_\-
M7U/_#>=$  #/4   OU@  +-=  "H7P  G%T  ));  "+6   A5H* (%;%@!]
M7"0 >ETQ '==/ %T748"<5U.!&]<505L7%T':EQD"6A;; ME6G4-8UI_#V%9
MBQ%>69@27%BG%%M8N!196= 465CP$UE8_Q%:6/\06EC_#EI7_PU:5_\-6E?_
M#>-(  #+4P  NUL  +!A  "D8@  EV$  (Y?  "%7   ?UX' 'M?$P!X82$
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M$DMGLA))9\D226?K$DEF_Q!*9O\/2F7_#DME_PU+9/\-2V3_#=%4  "^7@
ML6<  *9M  "7;   BFL  ']K  !S:P  ;6T  &AN# !E<!< 8G$D &!Q, !>
M<3H!7'%# EEQ2P-7<5,$57!:!E)P8@=0<&L)3F]U"TMO@@U);H\/1VZ?$$5N
ML!%$;L<10VWJ$$1L_P]$:_\.16O_#45J_PU%:O\-16K_#<M8  "Z8P  K6P
M *%Q  "2<   A6\  'IO  !N<   97,  &!U!P!==A( 6W<? %EX*P!7>#8
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M!S"%^P@P@_\(,(+_"#"!_P@P@?\(,('_"+=K  "J=@  H'\  )!^  ""?@
M=G\  &J   !>@P  4X<  $J+  !!C@( /9 . #N0&  ZD2, .9$M #B2-P W
MDD  -I)) #234@ SDUP!,9-G 2^3= (MDH,#*Y*4 RJ2IP,HDKT$*)+A R>0
M^@0GCO\%)XW_!2>,_P4GC/\%)XS_!;%T  "E?@  F84  (J$  !]A   ;X4
M &.(  !8BP  38\  $.3   ZEP  ,IH' "Z;$  MFQH +)PD "N<+@ JG3@
M*9U! "B=2P GGE4 )IYA "6>;@ CGGX!(IZ0 2">HP$?GKD!'I[= 1Z<^ (>
MFO\"'IG_ QZ7_P,>E_\#'I?_ ZI]  ">A0  DXL  (6*  !UBP  :(X  %N1
M  !0E0  1ID  #N=   RH   *J,  "*F"0 ?IQ$ 'J<: !VH)  <J"T &Z@W
M !JI00 9J4P &*E8 !>J9@ 6JG8 %:J) !2JG@ 3J[0 $JO3 !*H]0 3I_\!
M$Z7_ 1.E_P$3I/\!$Z3_ :.&  "7C   C9$  'V2  !ME0  8)@  %2<  !(
MH   /J0  #2G   JJP  (:X  !FQ   2LP< #[40  ZU%P .M2$ #;4K  VU
M-@ ,MD$ "[9.  JV7  )MFP "+9_  >VE  &MJH !;;%  :VZ@ 'M?\ "+3_
M  BS_P )LO\ ";+_ )J-  "0DP  A)@  '2<  !EH   5Z0  $NH  ! K
M-;   "JS   AM0  &+@  !&[   ,O@( !L +  + $0 !P1D  ,$B  #"*P
MPC8  ,-"  ##4   Q%\  ,1Q  #$AP  Q)T  ,2U  #$V@  Q/8  ,/_  ##
M_P  P_\  ,/_ ).4  "'F@  >*   &JF  !<K   3[$  $&U   UMP  *;H
M !^]   6P   $,,   K&   #R@   ,P%  #,#   S1$  ,X8  #.(0  T"H
M -$U  #30P  U%(  -1C  #5>   U8\  -6G  #6P@  UND  -;]  #6_P
MUO\  -;_ (J;  ![H@  ;*D  %ZP  !0M@  0KH  #2]   HP0  '<0  !3'
M   -RP  !LX   #2    UP   -D   #:!0  W L  -T0  #?%0  X1T  .,G
M  #E,P  YT(  .A4  #H9P  Z7X  .F7  #JKP  ZLX  .OO  #K_@  Z_\
M .O_ 'VC  !NJP  7[(  %&Z  !"P   -,,  "?'   ;RP  $L\   O3   "
MV    -T   #A    Y    .4   #G    Z0   .L'  #M#0  [Q$  /$9  #T
M)   ]S$  /E!  #Z50  ^FH  /N$  #[G0  _+8  /S2  #][0  _?0  /WT
M '&L  !AM0  4KT  $3$   TR0  )LT  !K2   0V   "-T   #A    Y0
M .@   #L    [P   /$   #S    ]0   /<   #Y 0  ^P@  /X.  #_%0
M_R$  /\O  #_00  _U8  /]M  #_AP  _Z   /^V  #_R@  _]0  /_4 /\+
M( #_!QX _P = /\ ( #_ "4 _P N /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V
M /\ ?P#_ (< _P". /\ E #_ )H _P"@ /\ I@#_ *T _P"U /\ O@#_ ,L
M_P#A /\ \ #^ /T _0#_ /T _P#] /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_
M"QH _P09 /\ &@#_ !\ _P J /\ -P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\
M>@#_ (( _P") /\ D #_ )8 _P"< /X H@#\ *D ^P"P /D N0#X ,8 ]@#9
M /4 ZP#T /D \P#_ /( _P#S /\ \P#_ /, _P#S /\ \P#_ /\0&0#_#A4
M_P@4 /\ % #_ !D _P E /\ ,@#_ $  _P!, /\ 60#_ &, _@!M /P =0#Z
M 'T ^0"$ /< BP#V )$ ] "7 /, G@#R *0 \ "L .X M #M ,  ZP#/ .D
MY@#H /4 Y@#_ .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ /\2% #_$!  _PP/
M /\#$ #_ !4 _P @ /\ + #_ #H _P!' /H 4P#W %X ] !G /$ < #O '@
M[0!_ .L A@#J (P Z "3 .< F0#E *  XP"G .$ L #? +H W0#) -L X #8
M /  UP#^ -4 _P#4 /\ TP#_ -, _P#3 /\ TP#_ /\5$ #_$@P _PX) /\+
M# #_"1( _P,: /\ )@#] #, ] !  .\ 30#K %@ Z !A .4 :@#B '( X !Z
M -X @ #< (< V@". -@ E0#4 )P T@"C -  K #. +8 S #$ ,H V0#( .T
MQP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$ ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_
M#PT _PP4 /P''P#Q RL YP Y .( 1@#> 5$ V@); -4"9 #2 VP SP-T ,T$
M>P#+!(( R@2) ,@%D #&!9@ Q 6@ ,(&J0#!!K0 OP;! +T(U0"[">P N O]
M +8,_P"U#?\ M W_ +0-_P"T#?\ M W_ /\;!0#_&   _Q<  /\6  #[$P8
M^A . .X,%@#C"2( V@DP -,*/@#."TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_
M#GX O0^% +P/C0"Z$)4 N!"= +<0IP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5
M_P"G%?\ IQ7_ *84_P&F%/\!IA3_ ?\?  #_'   ^AX  .L>  #C'   WQ4%
M -X.#0#3#A@ RQ$H ,43-P# %$0 O!9/ +D760"W%V$ M!AI +,9<0"Q&7@
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M X,O_P.#+_\#@R__ _LI  #K,0  V3@  ,D\  "_/   MCD  + R  "L+0L
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M!N@[  #01@  OTT  +-1  "E40  FDX  ))+  "-1P  AT@+ (-*%@!_2R0
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M#%53L U44\4-4U/F#%-3_ M34_\)5%+_"%12_PA44O\'5%+_!]I&  ##4
MM5@  *A;  "96@  C5@  (17  ![5   =E8! '%7#P!N61L ;%HH &E:,P!G
M6ST!95M% 6-;30)A6E4#7UI<!%U:9 5;66P&6%EV"%99@@E46(\+4EB>#%!8
MK@U/6,,-3ECD#$Y8^PM/5_\)3U?_"$]6_PA05O\'4%;_!]-*  # 5   LEP
M *->  "570  B5P  '];  !V60  <%H  &M<#0!H71@ 9EXD &1?, !B7SH
M8%]# 5Y?2P)<7U("6E]: UA?80557FH&4UYT!U%=?PE/78T*35V<"TM=K Q*
M7<$,25WC#$E<^@I)6_\)2EO_"$I:_PA*6O\'2EK_!\Y.  "\6   KF   )]A
M  "18   A5\  'M?  !P70  :E\  &5A"@!B8A0 8&,A %YD+0!<9#< 6F1
M 5AD2 %69% "5&17 U)D7P109&<%3F-Q!DQC?0A)8HL)1V*:"D9BJ@M$8K\+
M1&+A"T1A^0I$8/\)1&#_"$5?_P=%7_\'15__!\A2  "X7   JV0  )MD  ",
M8P  @&,  '9C  !J8@  8V0  %]F!@!;9Q$ 66@= %=I*0!6:C, 5&H\ %)J
M10%0:DP!3FI4 DQJ7 -*:F4$2&EO!49I>@=$:8@(0FB8"4!HJ0H_:+T*/FC>
M"3YG]PD^9O\(/V7_!S]E_P<_9/\'/V3_!\-7  "S80  IVD  )9H  "'9P
M>V<  '%G  !E:   7&H  %AL 0!4;@X 4F\8 %!O) !.<"X 37 X $MQ00!*
M<4D!2'%1 49Q60)$<&(#0G!L!$!P> 4^<(8&/&^5!SIOI@@X;[L(.&_;!SAN
M]@<X;?\'.&S_!CEK_P8Y:O\&.6K_!KU<  "O9@  HFT  )%L  "":P  =VL
M &QL  !A;@  5W   %!S  !,=0H 2783 $=W'P!&=RD 17@S $-X/ !">$0
M07A- 3]X50$]>%X".WAH CEX= ,W>(($-7B3!3-WI 4R=[D%,7C7!3%V]04Q
M=/\%,7/_!3%R_P4R<O\%,G+_!;=C  "J;0  G'$  (MP  !]<   <G   &=Q
M  !<<P  47<  $IZ  !"?0, /WX. /_B?1!)0T-?4%)/1DE,10 +$CU_&  \
M?R, .X M #J -@ Y@3\ .(%( #:!4  U@5H!,X%D 3&!< $O@7\"+8&/ RR!
MH0,J@;8#*8'2 RE_\P,I??\#*7S_ RE[_P,I>_\#*7O_ [%J  "E=   E78
M (5U  !X=0  ;74  &%W  !7>@  3'X  $.!   [A0  -8@) #*)$0 QB1L
M,(DE "^*+P NBC@ +8M! "R+2@ JBU0 *8M? "B+:P FBWH!)(N+ 2.+G@$B
MB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?   CWL  (!Z
M  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  DE!, (Y0<
M "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7F0 7EZX
M%9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$  'N   !L
M@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P %*$2 !2A
M&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,HZ< "J+
M  NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(  !EBP
M6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,  >M$@ &
MK1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT  *ZT  "N
MU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=E@  4)H
M $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X#@  N10
M +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI  "\Q
MO.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP  1Z@  #NM
M   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"  #%"@  Q0X  ,84
M  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-M0  SMH
M ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8  #"Y   D
MO   &;\  !'"   *Q0   LD   #,    T    -$   #2 0  TP@  -4-  #7
M$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0  Y<   .7F
M  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#   7QP
M#\H   ?.    T0   -8   #<    WP   .    #B    Y    .8#  #H"0
MZ0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T  /G&  #Y
MY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -T@  !-@
M  #=    X0   .0   #H    ZP   .T   #O    \0   /,   #V    ^ ,
M /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O  #_PP
M_]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8 _P!3 /\
M7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_ *@ _P"O
M /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0 _P#P /\
M\ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!. /\ 6@#_
M &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *, ^ "K /<
MM #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J /\ Z@#_
M /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\ 5 #^ %\
M^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F .H K@#H
M +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\ X0#_ /\-
M$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R %D [P!B
M .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L J@#8 +0
MU0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_ /\0# #_
M# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %, X0!< -X
M90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#& *\ Q "[
M ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1!0#_#@
M_PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6 ,L 7P#)
M &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L M@"W +0
MQP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_$   _P\
M /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$60"[!6$
MN05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU *@*Q0"F
M"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P  [Q@  .09
M  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O$%L K1!C
M *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3PP";%-X
MEQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,  -4E  #*
M)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58 H!I= )X;
M90"=&VP FQQS )H<>P"8'(, EQV- )4=EP"3'J( DAZO ) >OP"/']@ C"#Q
M 8D@_P&((/\!AR#_ 8<@_P&&(/\!AB#_ ?H>  #K)@  VBT  ,HP  "^+@
MM2@  + B  "N&PP J!T7 *,?)@"?(3, G"(^ )DC2 "7)%$ E219 ),E8 "2
M)6< D"9N (XF=@"-)G\ BR:( 8HGDP&()YX!AB>K 80GNP&#*-$!@"CN 7XI
M_P%]*?\!?"C_ 7PH_P%\*/\!?"C_ ?4D  #C+@  SS4  ,$X  "T-@  JS$
M *4L  "B)@8 GB83 )DH(0"5*BX DBLY (\L1 "-+4P BRU4 (DN7 "'+F,
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M V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10  E4,  (Y   ")/
MA#P* ( ]% !]/B( >C\N 'A . !U04( <T%* ')!40%P05D!;D%@ FQ!9P)J
M07 #:$%Y V=!A 1E09$%8T&?!6%!K@9@0<(&7D'B!EY!^05=0?\$74#_ UU
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M \Y$  "\3@  KE0  )Q3  ".4@  @U$  'I0  !R30  ;$\  &A0"P!E414
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M!4!=HP8_7;8&/EW0!CU<\04^6_\$/EK_!#Y:_P,^6?\#/UG_ \%0  "Q6@
MH5T  )!<  ""6P  =EL  &U;  !A6P  6UT  %9>  !28 T 4&$7 $YB(@!-
M8BP 3&,U $IC/@!)8T8 1V-. $9C5@%$8UX!0F-H D!C<P,^8X$#/&.0!#IB
MH00Y8K0%.&/-!3AB[P0X8?\$.&#_ SA?_P,Y7O\#.5[_ [Q5  "M7P  G&
M (M?  !]7P  <E\  &A?  !=8   56(  $]D  !+9@H 26<2 $=H'0!%:"<
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M 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT  'ML  !O;
M96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G@A0 )H(> "6")P D
M@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :A*D &(3! !B#
MY@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K<0  7G,
M %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-'@ 8CB<
M%XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[  V/X  .
MC?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>   6'L  $U^
M  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,FAT "YHF
M  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9SP "F?
M IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4  $6)   [
MC0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18  *8?  "F
M*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP  I>D  *7\
M  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6   RF@
M*)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#   LA$  +(7  "S'P
MLR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P  +3W  "T
M_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   JJ   (*P
M !:P   /M   ";<   &Y    O0   +X   "^!@  OPP  , 0  #!%@  PAT
M ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L  #'_@
MQ_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @MP  %KH   Z]
M   &P    ,,   #'    R0   ,H   #,    S0,  ,X)  #0#@  TA,  -0;
M  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?\P  W_\
M -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4P@  #,8   /)
MS    -    #5    V0   -H   #<    W@   .    #B!0  Y L  .<0  #J
M&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP  ]/,  /3T
M &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@   -(   #7    W
M .    #E    YP   .D   #K    [0   .\   #Q    \P   /8'  #Y#@
M_!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@  /_; /\
M& #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_ &0 _P!M
M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\ M #^ +\
M_0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_ /\ % #_
M !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &  _P!H /\
M< #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R +D \0#'
M .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#$ #_  X
M_P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C /4 :P#S
M '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +, X0#  .
MTP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_  D _P &
M /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .< 90#D &P
MX@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y ,L R0#)
M .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0  _P   /\
M! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1 &< S@!M
M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H P@"Y -L
MMP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P   /X   #V
M  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &  O@!G +P
M;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J -  J #K
M *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)  #B!
MV@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B *X : "L
M &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P G 3H )H&
M^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.$0  Q@T
M ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*8P"@"FH
MGPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J (X0_ ",
M$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0  MQ<  +,1
M  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5$V4 DQ-L
M )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8^P" &?\
M?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(  *4<  "D
M%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6  B!UG (8>
M;P"%'G< @Q^  ((?BP" 'Y< ?B"C 'T@L@![(,4 >2'D '<B^0!V(O\ =2+_
M '0A_P!T(?\ ="'_ .\A  #;*P  QS$  +8Q  "I+@  H"H  )LF  "8(0$
ME1X0 ) @&P"-(2@ B2,S (<D/0"%)$8 @R5. ($F50!_)EP ?B9C 'PG:P![
M)W, >2=\ '@HAP!V*), ="B@ 7(HKP%Q*<$!;RG@ 6TI]P%L*?\!:RG_ 6LI
M_P%K*/\!:RC_ >@H  #0,@  P#@  *XW  "A-0  F#(  )(M  ".*0  BR<,
M (<H%P"#*B, @"LO 'XL.0!\+$( >BU* '@N40!W+E@ =2Y@ ',O9P!R+V\
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M =0W  # 00  KT0  )U#  "00@  A4   'X^  !Y.P  =#H  '$Z#@!M/!@
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M TI)H0-(2;,#1TG* T9)[ -&2/\"1DC_ D='_P)'1O\"1T;_ L9#  "V3
MHDP  )%,  "$2P  >4H  '!)  !I1@  9$<  %])!@!<2A  6DL; %A,)0!6
M3"\ 54TX %--0 !234@ 44Y/ $].5P!.3E\!3$YI 4I.<P)(38 "1DV/ T5-
MGP-#3;$#0DW( T%-Z@-!3/\"04S_ D)+_P)"2O\"0DK_ L)'  "S3P  GD\
M (U.  " 3@  =4T  &Q,  !C2@  7DP  %I- @!63@X 5$\8 %)0(@!142P
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M C%<Y0(Q6_P",5K_ C%9_P(R6?\!,EC_ ;94  "D60  D%@  (!8  !S5P
M:5<  &!8  !460  3EL  $A=  !#7P0 0& . #YA%P ]82  .V(I #IB,@ Y
M8CH .&-" #=C2P V8U0 -&-= #-C:  Q8W8!+V.% 2YCE@$L8ZD!*V._ 2IC
MXP$J8OL!*F#_ 2M?_P$K7_\!*U[_ ;%9  ">7   BUP  'M;  !O6P  95L
M %Q<  !17@  26   $-B   \90  .&<* #5H$@ T:!L ,VDD #)I+0 Q:34
M+VH] "YJ1@ M:D\ +&I9 "MK90 I:W( *&N" "9KDP D:Z< (VN] ")JX  C
M:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@  "88   A6   '9?  !J7P  86   %=@
M  !-8P  1&8  #UH   V:P  ,&X$ "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W
M "5R0  D<DH (G)4 "%S8  @<VT 'G-] !USD  ;<Z, &G.Y !ESW  :<?<
M&G#_ !MO_P ;;O\!&VW_ :9F  "190  ?V0  '%D  !F9   760  %)F  !(
M:0  /VP  #=O   P<P  *78  ")Y"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\
M.0 8?$, %WQ. !9\6@ 5?&< %'UX !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_
M !%X_P 2=_\ $G?_ )YK  "*:@  >FD  &UI  !B:0  5VH  $QM  !#<
M.70  #%X   I>P  (G\  !N"   4A0D $880 !&&%P 0AQ\ $(<H  Z',0 .
MASL #8=&  R'4P +AV$ "H=Q  F'A  'AY@ !H:N  6&R0 &A>P !X3_  B#
M_P )@O\ "8+_ )5Q  "#;P  =&X  &EN  !<;P  4'(  $9U   \>0  ,GT
M "J!   BA0  &XD  !2,   /CP, "I(+  :2$0 $DA@  I(@  &2*0  DC,
M ),^  "32P  DUD  )-I  "3>P  DI   )*F  "1OP  D>4  )#Z  "/_P
MC_\  (__ (UW  !]=0  <'0  &)U  !5>   27P  #^    TA   *XD  "*-
M   :D0  $Y0   Z7   )FP   9T(  "=#@  G1,  )X:  ">(@  GRL  )\U
M  "@0@  H%   *!?  "@<0  H(<  )^=  "?M0  GMH  )WV  "=_P  G/\
M )S_ (9]  !X?   :7P  %M_  !.@P  08@  #:,   LD0  (Y8  !J:   2
MG@  #:$   :D    IP   *D#  "I"@  J@X  *L3  "L&0  K2(  *XK  "O
M-P  KT4  *]4  "O9@  KWL  *Z4  "NJP  KLD  *[O  "M_P  K?\  *W_
M (&$  !QA   88<  %.+  !&D   .98  "Z;   CH   &J0  !*H   ,K
M!*\   "R    M@   +<   "W @  N @  +D-  "Z$@  NQ@  +TA  "^*P
MP#@  ,!(  # 6@  P6X  ,&&  #!H   P;H  ,'C  # ^0  P/\  ,#_ 'F-
M  !HD   690  $N:   ]H   ,:4  "6K   :KP  $;,   NX   "NP   +X
M  #!    Q    ,4   #&    QP   ,@%  #*"P  S \  ,X5  #0'P  TRL
M -4Z  #53   UF   -AW  #8D@  V*P  -G)  #9[   V?L  -C_ '"9  !@
MG@  4:0  $.J   UL   *+8  !RZ   1O@  "<$   #%    R    ,L   #/
M    T@   -,   #6    V    -L   #=    WP<  .(-  #E$P  Z!T  .PJ
M  #M/   [5$  .YG  #O@0  [YP  /"W  #PTP  \.P  /#T &>F  !8K0
M2;0  #JZ   JO@  ',(  !#&   'R@   ,X   #2    U@   -P   #@
MXP   .0   #F    Z    .L   #M    [P   /("  #U"@  ^!$  /P<  #_
M+   _S\  /]5  #_;@  _XH  /^D  #_N@  _]$  /_A /\ % #_ !( _P 2
M /\ % #_ !D _P E /\ ,@#_ #\ _P!+ /\ 5@#_ &  _P!H /\ < #_ '@
M_P!_ /\ A0#_ (L _P"1 /\ F #_ )X _@"F /T K@#\ +D ^@#( /D X@#X
M /0 ]P#_ /8 _P#V /\ [P#_ .< _P#B /\ W@#_ /\ $0#_  X _P . /\
M#P#_ !0 _P @ /\ +0#_ #H _P!& /\ 40#_ %L _P!C /X :P#\ ', ^@!Y
M /D @ #W (8 ]@", /4 D@#S )D \@"@ /  J0#N +, [0#! .L U@#J .X
MZ0#^ .< _P#G /\ Y0#_ -T _P#5 /\ T0#_ /\ #0#_  H _P ( /\ "0#_
M !  _P ; /\ * #_ #4 _P!  /H 2P#V %4 \P!> /$ 9@#N &T [ !T .L
M>@#I (  YP"& .8 C0#D ), X@"; .  HP#> *T W "Y -H R@#7 .8 U #X
M -( _P#2 /\ T@#_ ,X _P#) /\ Q@#_ /\ " #_  , _P   /\  P#_  T
M_  6 /< (@#S "X [P Z .P 10#H $\ Y !8 .$ 8 #> &< VP!M -D = #5
M 'H TP"  -$ AP#/ (X S0"5 ,L G@#) *< QP"S ,4 P@## -P P0#Q +\
M_P"_ /\ O@#_ +X _P"] /\ NP#_ /\   #_    _P   /\   #V  @ [@ 1
M .< &P#A "< W0 S -D /@#3 $D SP!2 ,L 60#( &$ Q@!G ,0 ;0#" ',
MP !Z +\ @ "] (@ NP"0 +D F "X *( M0"M +, NP"Q ,X L #J *\ _ "M
M /\ K0#_ *X _P"N /\ K@#_ /\"  #_    _0   /(   #H    W@ , -,
M%0#, "$ R  L ,0 . #! $( O0!+ +H 4P"X %H M@!A +0 9P"R &T L !T
M *\ >@"M (( K "* *H DP"H )T I@"H *0 M0"B ,8 H0#C )\ ]@"> /\
MG@#_ )X _P"> /\ G@#_ /\&  #[    [@4  .($  #5    RP & ,, #P"]
M !D N  E +0 ,0"Q #L K@!% *P 30"I %4 IP!; *4 8@"D &@ H@!N *$
M=0"? 'P G@"% )P C@": )@ F "D )8 L "5 ,$ DP#< )( \@"1 /\ D #_
M )  _P"/ /\ CP#_ /T*  #P#@  X1$  ,X0  #"#0  NP<  +< "@"Q !(
MK  > *@ *0"E #0 H@ ^ )\ 1P"= $\ FP!6 )D!7 "7 6, E@)I )0"< "3
M W@ D0.  ) $B@".!)4 C 6A (H%K@")!KX APC8 (8)\ "$"O\ @PO_ (,+
M_P"#"_\ @PO_ /80  #F%P  TAP  , :  "S%@  K!(  *@-  "F!PT H@46
M )T'(@"9"2X E@HX )0+00"2#$H D Q1 (X-6 ",#5X BPUE (D-; "(#G0
MA@Y] (4.AP"##I, @0^? ( 0K0!^$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W
M$O\ =Q+_ .\7  #;(0  QB0  +0C  "H(   H!P  )L7  "9$00 F X0 ),0
M&P"/$2< C!(R (D3/ "'$T0 A11, (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X
M 'D7@P!X%X\ =AB< '08J@!S&;L <AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\
M;1K_ .<@  #0*0  O"L  *LJ  ">*   EB0  ) @  "-'   C!<, (@8%@"$
M&B( @1LM 'X<-P!\'4  >AU( 'D>3P!W'E4 =A]< '0?8P!S'VL <2!T ' @
M?P!N(8L ;"&8 &LAIP!I(K@ :"+/ &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_
M . F  #(+P  M#$  *,P  "6+@  C2L  (<H  "$)   @B ( 'X@$@![(AX
M>",I '4D,P!S)3P <25# ' F2P!N)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E
M*(@ 9"F5 &(II !@*;4 7RG+ %XJ[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L
M  ##-0  K34  )TT  "0,P  AC$  ( M  !\*P  >2@# '8G$ !R*1H <"HE
M &TK+P!K+#@ :BQ  &@M1P!G+4X 92Y5 &0N70!C+F4 82]N %\O> !>+X0
M7"^2 %HOH0%9+[(!6##( 58PZ0%5,/X!52__ %4O_P!5+O\ 52[_ - Q  "]
M.@  J#D  )<X  "*-P  @#8  'HR  !U,   <BX  &XN#0!K+Q8 :3 A &8Q
M*P!D,C0 8S(] &$S1 !@,TL 7S12 %TT6@!<-&( 6C1K %DU=0!7-8( 5360
M 50UGP%2-; !437& 5 UYP%/-?T!3S7_ 4\T_P%/-/\!3S/_ <LV  "X/0
MHSP  )(\  "%.P  >SH  '0W  !O-0  ;#,  &@T"@!E-1, 8C8> & W* !>
M-S$ 73@Z %LX00!:.4@ 63E0 %<Y5P!6.E\ 5#IH %,Z<P!1.G\!3SJ- 4XZ
MG0%,.JX!2SK# 4HZY0%).OP!23G_ 4DY_P%)./\!2CC_ <<Z  "S0   GC\
M (X_  "!/@  =ST  ' [  !J.   9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X
M5STW %8]/@!4/D8 4SY- %(^50!1/ET 3S]F $T_< !,/WT!2C^+ 4@_FP%'
M/ZP!13_! 40_XP%$/OL!1#[_ 40]_P%$/?\!13S_ <,^  "O0P  FD(  (I"
M  !]00  <T   &L_  !E/   8#P  %P^! !9/@\ 5S\8 %5 (@!302L 4D$T
M %!"/ !/0D, 3D)+ $U#4@!+0UH 2D-D $A#;@!'0WL!14.) 4-#F0%"0ZL!
M0$/  3]#X0$_0_D!/T+_ 3]!_P% 0?\!0$#_ ;]!  "J10  ED4  (9%  !Y
M1   ;T0  &="  !@/P  6T$  %="  !40PT 4405 $]%'P!.12@ 3$8Q $M&
M.0!*1T$ 24=( $A'4 !&1U@ 14=A $-(; !"2'@!0$B' 3Y(EP$\2*D!.TB^
M 3I(WP$Z1_@!.D;_ 3I%_P$[1?\!.T3_ ;M%  "F2   DD<  ()'  !V1P
M:T<  &-&  !;0P  5D4  %)'  !.2 H 3$D2 $I)' !(2B4 1THN $9+-@!%
M2SX 0TM& $),30!!3%8 0$Q? #Y,:@ \3'8 .TR% 3E,E0$W3*<!-DR\ 35,
MW0$U2_<!-4O_ 35*_P$V2?\!-DG_ ;A)  "B2P  CDH  'Y*  !R2@  :$H
M %])  !52   4$H  $Q+  !)3 < 1DT0 $1.&0!"3R( 04\K $!0,P _4#L
M/E!# #Q12@ [45, .E%< #A19P W47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O
M4/8!+T__ 3!._P$P3O\!,$W_ ;1-  "=30  BDT  'I-  !N30  9$T  %M-
M  !130  2T\  $90  !"4@, /U,- #U4%0 \5!X .E4G #E5+P X53< -U8_
M #961P U5E  ,U99 #)79  P5W$ +U>  "U7D0 K5Z, *E>X "E7U@ I5O4
M*57_ "I4_P$J4_\!*E+_ :]1  "840  A5$  '90  !J4   8%   %A1  !.
M4@  1U,  $%5   [6   .%D* #5:$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<
M0P M7$P +%Q6 "M=8  I76T *%U\ "9=C@ D7:$ (UVU ")=T@ B7/, (EO_
M "-:_P C6?\ )%C_ *A5  "25   @%0  '%4  !F5   7%0  %15  !*5@
M0U@  #Q;   V70  ,& % "UA#@ K814 *F(= "EB)0 H8BX )V,V "9C/@ E
M8T< (V-1 ")D7  A9&D 'V1Y !YDB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@
M_P <8/\ '%__ *%9  ",6   >U@  &U8  !B6   65@  %!9  !'6P  /EX
M #=@   Q8P  *F8  "1I"0 A:A  (&H7 !]J(  >:R@ '6LP !QK.0 ;:T(
M&FQ, !EL6  7;&4 %FQT !1LA@ 3;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3
M:/\ $V?_ )E=  "%70  =5P  &A<  !>7   55P  $M>  !"80  .60  #)G
M   K:@  )&T  !YP 0 7<PL %701 !1T&  3="$ $G4I !%U,@ 1=3L $'5&
M  ]U4@ .=5\ #75N  QU@0 +=94 "G6J  ATPP )=.< "G/]  MQ_P ,<?\
M#'#_ )%B  !_80  <&$  &1A  !:80  3V(  $5E   \:   ,VP  "MO   D
M<@  '78  !=Y   1? 0 #7\,  M_$@ *?QD "7\B  A_*@ &?S0 !7\_  1_
M2P "?U@  7]G  !_>0  ?XX  '^C  !^NP  ?>   'WW  !\_P  >_\  'O_
M (EG  !X9P  :V8  &%F  !49P  26D  #]M   U<0  +'4  "1Y   =?
M%H   !"#   ,A@( !HD*  &)#P  B10  (H;  "*(P  BRP  (LW  "+0P
MBU   (M?  "+<0  BX8  (N<  "*LP  B=,  (CS  "(_P  A_\  (?_ ()M
M  !S;   :&P  %IM  !.;P  0G,  #AW   N>P  )8   !V$   5B   $(P
M  N/   $D@   )0&  "5#   E1   )85  "7'   F"0  )@N  "9.0  F4<
M )E6  "9:   F7T  )F4  "8JP  E\@  );N  "6_P  E?\  )7_ 'MT  !O
M<P  87,  %-V  !&>@  .W\  #"$   FB   '8T  !22   .E@  "9D   &<
M    H    *$   "B!@  H@P  *00  "E%   I1P  *<D  "H+P  J#T  *E,
M  "I7@  J7(  *B)  "HH@  J+P  *?E  "F^P  IO\  *7_ '=[  !H>P
M67X  $N"   ^AP  ,HT  ">2   =EP  %)P   Z@   'I    *@   "K
MK@   *\   "P    L00  +,*  "T#@  M1,  +8;  "X)   NC$  +I   "Z
M4@  NV4  +M]  "ZEP  NK$  +K2  "Z\P  N?\  +G_ &^#  !?A@  48L
M $.0   VEP  *IT  !^B   5IP  #:P   6P    M    +<   "[    O@
M +\   #     P0   ,,!  #$!P  Q0T  ,<1  #*&0  S20  ,XS  #/1
MT%@  -!N  #1B   T*0  -#!  #1Y@  T?@  -'_ &>/  !7E   29H  #NA
M   NIP  (:T  !:S   .N   !KP   #     PP   ,8   #+    S0   ,X
M  #0    T0   -0   #6    V@(  -P)  #?#P  XQ<  .8D  #G-@  Z$D
M .E?  #J>   ZY0  .NO  #KS   [.@  .SV %^>  !0I   0JL  #2R   F
MN0  &;X   ["   $Q0   ,H   #-    T0   -@   #;    WP   .    #B
M    Y    .8   #I    ZP   .X   #Q!0  ]0T  /D6  #\)0  _3D  /Y/
M  #_9P  _X(  /^=  #_M0  _\L  /_D /\ $0#_  \ _P / /\ $0#_ !8
M_P B /\ +P#_ #L _P!' /\ 4@#_ %L _P!D /\ ; #_ ', _P!Z /\ @ #_
M (8 _P", /X DP#] )D ^P"A /H J0#X +0 ]P#" /8 V@#U /$ ] #_ /,
M_P#S /\ Z0#_ .  _P#8 /\ TP#_ /\ #@#_  L _P * /\ "P#_ !$ _P =
M /\ *@#_ #8 _P!! /\ 3 #_ %8 _@!? /L 9@#Y &T ]P!T /4 >@#T (
M\@"& /  C0#O )0 [0"; .P I #J *X Z0"Z .< S0#E .D Y #[ ., _P#B
M /\ W@#_ -$ _P#, /\ R #_ /\ "0#_  0 _P ! /\ ! #_  X _P 8 /\
M) #] #  ^P [ /< 1@#S %  [P!9 .P 8 #J &< YP!N .8 = #D 'H X@"
M .  AP#> (X W "5 -H G@#6 *@ U "S -$ PP#/ -\ S@#T ,P _P#+ /\
MRP#_ ,4 _P"_ /\ O #_ /\  @#_    _P   /\   #]  L ]P 3 /$ '@#M
M "H Z@ U .< 0 #B $H W0!2 -D 6@#5 &$ T@!G -  ;0#. ', S !Z ,H
M@ #( (< Q@"/ ,0 F #" *$ P "M +X NP"\ -  N@#M +D _@"X /\ N #_
M +< _P"S /\ L #_ /\   #_    _P   /D   #N  4 Y0 . -X & #8 ",
MT@ N ,\ .0#+ $, QP!, ,0 5 #! %L OP!A +P 9P"[ &T N0!S +< >@"U
M ($ M ") +( D@"P )L KP"G *P M "K ,8 J0#D *< ^ "F /\ I@#_ *4
M_P"E /\ I #_ /\   #_    ]0   .H   #>    T  * ,@ $@#" !T O@ H
M +L ,P"Y #T M0!& +( 30"P %4 K0!; *P 80"J &< J !M *< <P"E 'H
MI "" *( C "@ )8 GP"A )T K@"; +X F0#8 )< \0"6 /\ E@#_ )< _P"7
M /\ EP#_ /\   #U    YP$  -0   #)    P  $ +@ #@"S !8 KP A *L
M+ "H #8 I@ _ *, 1P"A $\ GP!5 )T 6P"; &$ F@!G )@ ;@"7 '4 E0!]
M )0 A@"2 )$ D "< (X J0", +@ BP#- (D ZP"( /T B #_ (@ _P"( /\
MB #_ /D&  #I#   U X  ,,,  "W"0  L (  *L "0"F !  H@ : )X )0";
M #  F  Y )8 00"4 $D D@!0 )  5@". %P C0!B (L :0"* '  B !X (<
M@0"% (P A "8 (( I0"  +0 ?@#( 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_
M /$.  #>%0  Q14  +04  "I$0  H0X  )X*  "; PP EP 3 ), '@"0 2D
MC0(S (H#/ "(!$, A@5+ (4&40"#!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z
M"8D > F6 '<*HP!U"K, <PO' '(,Y@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6
M  #0'@  N1T  *D<  "=&@  E18  ) 3  "/#@, C@H. (D+%P"&#", @PTM
M ( --@!^#CX ? Y& 'L.30!Y#U, >!!: '8080!U$&@ <Q!Q '$1>P!P$8<
M;A&4 &P1H@!K$K( :1+' &@3YP!F$_T 913_ &44_P!E$_\ 91/_ -\>  #&
M)   L"0  * C  "4(0  BQ\  (8;  "#%P  @A(( '\1$@!\$AT >10H '84
M,0!T%3H <A9! '$62 !O%T\ ;A=6 &P770!K&&0 :1AM &@9=P!F&8, 9!F0
M &,:GP!A&J\ 8!K$ %X;Y !='/L 7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@
MJ"D  )@I  ",*   @R4  'TB  !Y'P  >!L# '89#P!R&A@ ;QPC &T=+0!K
M'34 :1X] &@>1 !F'TL 91]2 &,@60!B(&$ 82!I %\A<P!=(7\ 7"&- %HB
MG !9(JP 5R+  %8CX0!5(_D 5"/_ %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX
M )(N  "%+0  ?"L  '8H  !R)@  ;R,  &TA# !J(A4 9R,? &4D*0!C)#$
M8B4Y & F00!?)D@ 729/ %PG5@!;)UT 62=F %@H< !6*'P 5"B* %,IF0!1
M*:H 4"F^ $\IW@!.*?< 32G_ $TI_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR
M  " ,0  =C   ' M  !K*P  :"D  &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV
M %DL/0!8+$0 5RU, %4M4P!4+5L 4RUC %$N;@!0+GH 3BZ( $POEP!++Z@
M22^[ $@OVP!(+_8 1R__ $<N_P!'+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![
M-0  <C0  &LR  !F+P  8BX  %\M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q
M.@!2,D( 43)) % R4 !.,U@ 33-A $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y
M $(TU@!"-/0 0C3_ $(S_P!",O\ 0C+_ , X  "G.   DS@  (,X  !W.
M;3<  &8V  !A,P  73(  %DR @!7,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,
M-S\ 2S=& $HW3@!).%8 1SA? $8X:0!$.'4 0SB# $$YDP! .:0 /CFX #TY
MTP \.?, /#C_ #TW_P ]-_\ /3;_ +L[  "B.P  CSL  '\[  !S.P  :CH
M &(Y  !=-P  6#8  %0W  !1. L 3SD3 $TY' !+.B4 2CHM $@[-0!'.SP
M1CQ$ $4\2P!$/%, 0CQ< $$]9P _/7, /CV! #P]D0 Z/:, .3VV #@]T0 W
M/?( -SS_ #@[_P X._\ .#K_ +8]  ">/@  BSX  'P^  !O/@  9CT  %X]
M  !8.P  4SH  $\[  !,/ @ 23T1 $<^&0!&/R( 1#\J $,_,@!"0#H 04!!
M $! 20 ^05$ /4%: #Q!9  Z07  .$%_ #=!CP U0J$ -$*T #)"S@ R0?
M,D#_ #- _P S/_\ -#[_ +%   ":0   AT   'A!  !L00  8D   %M   !4
M/P  3C\  $I   !&004 1$(. $)#%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%
M1@ Y14X .$98 #9&8@ U1FX ,T9\ #%&C0 P1I\ +D:S "U&S  M1N\ +47_
M "Y$_P N0_\ +D/_ *Q#  "60P  @T,  '1#  !H0P  7T,  %=#  !00P
M2$,  $1%  !!1@$ /D<, #Q($P Z2!P .4DD #A)+  V230 -4H[ #1*0P S
M2DP ,DI5 #!+7P O2VL +4MZ "Q+BP J2YT *$NQ "=+R@ G2^T )TK_ "A)
M_P H2/\ *4?_ *=&  "11@  ?T8  '!&  !E1@  6T8  %1&  !,1P  1$@
M #]*   [2P  -TP) #5-$  S3A@ ,DX@ #%/*  P3S  +T\X "Y/0  L4$@
M*U!2 "I07  H4&@ )U!W "50B  D4)L (E"O "%0R  @4.L (4__ ")._P B
M3?\ (TW_ *%)  ",20  >DD  &Q*  !A2@  6$H  %!*  !)2P  0$P  #M.
M   U4   ,5($ "U3#0 L5!0 *E0< "E5)  H52P )U4S "95/  E5D4 )%9.
M ")660 A5F4 'U9T !Y6A0 <5I@ &U:L !E6Q0 95ND &E7_ !M4_P ;4_\
M'%+_ )M-  "&30  =4T  &A-  !=30  5$T  $U.  !%3P  /%$  #93   Q
M50  *U@  "9:"0 C6Q  (EL7 "%<'P @7"< 'UPN !U<-P <74  &UU* !I=
M50 876$ %UUP !5=@0 4794 $UVJ !%=P@ 17>< $EO^ !-:_P 36O\ %%G_
M )11  " 40  <%$  &11  !940  45$  $E2  !!4P  .%8  #)9   K6P
M)5X  !]A P :8PP &&01 !=D&0 69"$ %60I !1E,0 393H $F5$ !%E4  0
M95T #V5K  YE?0 -99$ #&6E  IDO  *9.  "V/Y  QB_P -8?\ #6'_ (U5
M  !Z50  :U4  %]5  !650  3E4  $17   \60  -%P  "Q?   F8@  'V4
M !EH   3:P4 $&T-  YN$@ -;AH #&XB  QN*P +;C0 "FX^  AN2@ ';E<
M!FYE  1N=@ ";HH  &V?  !MM@  ;-8  &SS  %K_P ":O\  VK_ (5:  !T
M6@  9EH  %Q9  !360  2%H  #]=   V8   +F,  "9G   ?:@  &6T  !-Q
M   .= , "G<*  5W$  !=Q4  '<<  !W)   >"T  '@W  !X0P  >%   'A>
M  !X;P  >(0  'B9  !WL   =LT  '7P  !U_P  =/\  '3_ 'Y?  !N7P
M8EX  %E>  !-7P  0F(  #EE   P:   )VP  !]P   8=   $G<   U[   (
M?@   H (  "!#0  @1$  ((7  "#'@  @R8  (0P  "$.P  A$@  (17  "$
M:   A'P  (23  "#J@  @L4  ('K  "!_@  @/\  (#_ '=E  !I9   7V,
M %)D  !'9P  /&L  #%O   H<P  ('<  !A\   1?P  #(,   :'    B@
M (P#  ","0  C0X  (X1  "/%P  D!X  )$G  "2,@  DC\  )).  "27P
MDG,  )*+  "1H@  D;P  )#E  "/_   CO\  ([_ '%K  !F:@  6&L  $MM
M   _<0  -'8  "I[   @@   %X4  !")   +C0  !)$   "5    F    )D
M  ": P  FP@  )P-  ">$0  GQ8  * >  "B*   HC4  *-$  "C50  HVD
M **   "BF@  H;,  *#8  "@]@  G_\  )__ &YQ  !?<@  474  $1Y   W
M?@  +(0  "&*   7CP  $)0   J9   !G0   *    "D    IP   *@   "I
M    J@   *P&  "M"P  KQ   + 5  "R'@  M"D  +0Y  "T2@  M5T  +5S
M  "UC@  M:@  +3&  "S[0  LO\  ++_ &9Z  !7?0  28(  #R'   OC@
M(Y0  !B:   0GP  ":0   "I    K0   +    "T    MP   +@   "Y
MNP   +P   "^ @  P @  ,(.  #$%   QQX  ,@L  #)/0  RE   ,IF  #*
M?P  RIL  ,JX  #*W0  RO4  ,K_ %Z&  !/BP  09$  #.8   GGP  &Z4
M !&K   )L    +4   "Y    O0   ,$   #&    R    ,D   #+    S
M ,X   #0    T@   -0%  #9#   W1(  .$>  #B+@  XT(  .17  #E;P
MYHP  .:H  #EQ0  Y><  .;V %:4  !(FP  .J(  "RI   ?L   $[8   N\
M    P0   ,4   #)    S0   -(   #6    V@   -L   #>    X    .(
M  #D    YP   .D   #M    \ H  /01  #X'P  ^3(  /I(  #[7P  _'H
M /V7  #]KP  _<<  /WD /\ #@#_  T _P , /\ #@#_ !, _P > /\ *@#_
M #8 _P!" /\ 30#_ %< _P!? /\ 9P#_ &X _P!T /\ >@#_ ($ _0"' /P
MC0#Z )0 ^0"< /< I0#U *\ ] "\ /, SP#Q .P \ #^ .\ _P#O /\ XP#_
M -< _P#. /\ R@#_ /\ "@#_  8 _P $ /\ " #_ !  _P 9 /\ )0#_ #$
M_P ] /\ 1P#^ %$ ^P!9 /D 80#V &@ ] !N /, = #Q 'H [P"! .X AP#L
M (X Z@"6 .@ GP#F *D XP"U .( Q@#@ ., WP#X -T _P#= /\ U #_ ,D
M_P#" /\ O@#_ /\  P#_    _P   /\  0#_  T _P 4 /T ( #Z "L ]P V
M /, 00#O $L [ !4 .@ 6P#F &( XP!H .$ ;@#? '0 W !Z -H @0#8 (@
MU "0 -( F #/ *( S0"N ,L O #) -, QP#P ,8 _P#$ /\ Q #_ +L _P"V
M /\ LP#_ /\   #_    _P   /\   #W  @ \  0 .L &@#G "4 Y  P .$
M.P#< $4 U0!- -$ 50#. %L RP!B ,D 9P#' &T Q0!S ,, >@#! ($ OP")
M +T D@"[ )P N0"G +< M0"U ,@ LP#F +( ^P"Q /\ L #_ *X _P"J /\
MIP#_ /\   #_    _@   /$   #E  ( W  - -, % #- !\ R@ J ,< - #$
M #X P !' +P 3@"Z %4 MP!; +4 80"S &< L@!M +  <P"N 'H K "" *H
MBP"H )4 IP"@ *4 K0"C +X H0#; *  ] "? /\ G@#_ )\ _P"= /\ FP#_
M /\   #\    [@   .    #0    Q0 ( +X $ "Y !D M0 C +, +@"P #<
MK0!  *H 2 "H $\ I0!5 *, 6P"B &  H !F )\ ; "= ', FP![ )H A "8
M (X E@": )4 IP"3 +< D0#, )  [ "/ /\ C@#_ (X _P". /\ CP#_ /P
M  #O    VP   ,D   "]    M0 " *X # "I !, I0 = *( )P"@ #$ G0 Z
M )H 0@"8 $D E@!/ )0 50"3 %L D0!@ )  9P". &T C0!U (L ?@") (D
MB "5 (8 H@"% +$ @P#$ ($ Y "  /D ?P#_ (  _P"  /\ @ #_ /0"  #@
M"0  QP@  +<'  "L P  I@   *  !P";  \ F  7 )4 (0"2 "H CP S (T
M/ "+ $, B0!) (< 4 "& %4 A !; (, 80"! &@ @ !P 'X >0!\ (0 >P"0
M 'D G0!X *P =@"^ '4 W0!S /0 <P#_ ', _P!S /\ <P#_ .D-  #/$
MN1   *D0  ">#@  EPL  ),&  "0  L C  1 (D &@"& "0 @P N ($ -@!_
M #X ?0!$ 'P 2P!Z %$ >0!7 '< 70!V &0 = !L ',!=0!Q 8  ;P*- &X"
MF@!L ZH :P.[ &D$U@!H!O$ : ?_ &<'_P!G!_\ 9P?_ -\4  ##%P  KA<
M )X6  "3%0  BQ(  (80  "$# ( @P8- ( #% !\!1X >0<H '<(, !U"#@
M<PE  '()1@!P"DP ;PI3 &T+60!L"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B
M#:D 80V[ & -V !>#O, 70[_ %T._P!=#O\ 70[_ -0<  "Y'0  I!X  )4=
M  ")'   @1H  'L7  !X$P  >! & '<-#P!S#A@ < XB &X/*P!L$#, :A [
M &D00@!G$4D 9A%/ &015@!C$ET 81)F & 2;P!>$GL 7!.( %L3EP!9$Z<
M5Q2Z %84U0!5%?, 5!7_ %05_P!4%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!
M(@  >2$  ',>  !O&P  ;A<  &T3# !J%!0 9Q4> &46)P!C%B\ 81<W & 7
M/@!>&$4 71A+ %P94@!:&5H 61EB %<:; !6&G< 5!J% %(;E !1&Z0 3QNW
M $X;T !-'/$ 3!S_ $P<_P!-'/\ 31O_ ,,F  "J)P  EB<  (<H  ![)P
M<B8  &PD  !H(0  9AX  &0;" !B&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7
M'T$ 5B!( %0@3P!3(%< 42%? % A:0!.(70 32&" $LBD0!)(J( 2"*T $<B
MS0!&(^\ 12/_ $4B_P!&(O\ 1B'_ +PJ  "D*P  D2L  ((L  !V*P  ;2H
M &8I  !B)@  7R0  %TB! !;(0X 6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X
M3R9% $XF3 !,)E0 2R=< $DG9@!()W$ 1B=_ $4HCP!#**  02BR $ HRP _
M*.T /RC_ #\H_P! )_\ 0"?_ +<M  "?+@  C"\  'TO  !Q+P  :"X  &$M
M  !=*P  6B@  %<G  !4)PP 4B@3 % I' !.*24 32HL $LJ- !**SL 22M"
M $@L20!&+%$ 12Q: $0L9 !"+6\ 0"U] #\MC0 ]+9X /"VP #HMR  Z+>L
M.BW_ #HM_P Z+/\ .BS_ +(P  ";,0  B#(  'DR  !M,@  9#(  %TQ  !8
M+P  52P  %$L  !/+0D 3"T1 $HN&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q
M1P!!,4\ 0#%7 #XQ80 ],FT .S)[ #DRBP X,IP -C*O #4RQP T,ND -#+_
M #4Q_P U,?\ -3#_ *TS  "6-   A#4  '4U  !I-0  8#4  %DT  !4,P
M4#   $PQ  !),08 1S(/ $4S%@!#,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \
M-DP .C95 #DV7P W-FL -C9X #0WB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U
M_P P-?\ ,#3_ *DV  "2-@  @#<  '(X  !F.   73<  %8W  !0-@  2S0
M $<U  !$-@, 03<- #\X%  ^.!P /#DD #LY+  Z.3, .3HZ #@Z0@ V.DH
M-3I3 #0[70 R.V@ ,#MV "\[AP M.YD +#NL "H[PP I.^8 *CK] "HZ_P K
M.?\ +#C_ *0X  "..0  ?#H  &XZ  !C.@  6CH  %,Z  !-.@  1C@  $(Z
M   _.P  /#P+ #H\$0 X/1D -STA #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0
M "X_6@ M0&8 *T!T "E A  H0)< )D"J "5 P0 D0.4 )#_\ "4^_P F/?\
M)CW_ )\[  "*/   >#T  &H]  !?/0  5CT  $\]  !)/0  0CT  #P^   Y
M/P  -D$( #1!#P R0A8 ,4(> "]#)0 N0RT +4,T "Q$/  K1$0 *D1- "A$
M6  G16, )45Q "-%@@ B194 ($6H !]%OP >1., 'T3[ !]#_P @0O\ (4'_
M )H^  "%/P  =$   &=   !<0   4T   $Q   !&0   /D$  #A#   T10
M,$8# "U'#0 K2!( *D@: "E((@ H22D )TDQ "5).0 D24$ (TI* ")*50 @
M2F$ 'TIO !U*?P ;2I( &DJF !A*O0 72N  &$GZ !E(_P :1_\ &D?_ )5"
M  " 0@  <$,  &-#  !80P  4$,  $E#  !"1   .T4  #5'   P20  *TL
M "9-"0 D3A  (DX6 "%/'0 @3R4 'T\L !Y/-0 =3ST '%!' !I040 94%T
M%U!K !90?  44(\ $U"D !%0N@ 14-X $4_X !)._P 33?\ %$W_ (]%  ![
M1@  :T8  %]'  !51P  34<  $9'   _1P  -TH  #%,   K3@  )E   "!3
M P <50P &E81 !E6&  75B  %E8G !56,  45CD $U=" !)730 15UD $%=H
M  ]7>0 .5XP #5>@  M7M@ +5M0 "U;T  Q5_P -5/\ #E/_ (A)  !V2@
M9TH  %M*  !12@  2DH  $-*   [3   ,TX  "Q1   F5   (58  !M9   5
M7 < $5X- !!>$P 07AH #EXB  Y>*@ -7C, #%X]  M>2  *7E0 "%YB  =>
M<P %7H8  UZ;  )>L0 "7<P  EWN  -<_P $6_\ !5O_ (%.  !P3@  8DX
M %=.  !.3@  1TX  #Y/   V40  +E0  "=7   A6@  &UT  !5@   08P,
M#&8+  AG$  &9Q4 !6<<  1G)  "9RT  6<W  !G0@  9TX  &=<  !G;0
M9X   &:5  !FK   9<<  &7K  !D_   9/\  &/_ 'I2  !J4P  75(  %12
M  !+4@  0E,  #E5   P6   *%L  "%?   :8@  %&4  !!H   ,:P$ !FX)
M  !O#@  ;Q(  &\8  !P'P  <"<  '$P  !Q.P  <4@  '%6  !Q9@  <7D
M '&/  !PIP  ;\$  &_G  !N_   ;?\  &W_ '-8  !E5P  6E<  %%6  !&
M5P  /%H  #)=   J80  (F0  !IH   4;   #F\   IR   $=@   '@%  !X
M"P  >0X  'H3  ![&0  ?"   'TI  !],P  ?4   'U.  !]7@  ?7(  'V(
M  !\H0  ?+H  'OB  !Z^@  >?\  'C_ &U=  !@7   5UP  $M=  ! 7P
M-6,  "MG   C:P  &F\  !-S   .=P  "'L   )^    @@   (,!  "$!@
MA0L  (8/  "($P  B1D  (HA  "+*P  BS<  (Q&  "+5@  BVD  (N   "+
MF0  BK,  (G8  "(]P  B/\  (?_ &AC  !>8@  46(  $1E   X:0  +FX
M "1S   :>   $WT   V!   &A0   (D   "-    D    )(   "2    E 4
M )4*  "7#@  F!(  )H8  ";(0  G"T  )T\  "=3   G%\  )QV  ";D0
MFZL  )K)  ":\   F?\  )C_ &5I  !7:0  26P  #UQ   P=@  )7P  !N!
M   2AP  #(P   21    E0   )D   "=    H    *$   "B    I    *4!
M  "G!P  J0P  *H1  "M&   KR(  *\P  "O00  KU0  *]K  "NA0  KJ$
M *Z^  "MY@  K/P  *S_ %YQ  !/=   0GD  #5_   HA0  '8P  !.2   ,
MF    YT   "B    I@   *H   "N    L    +$   "S    M    +8   "X
M    N@0  +P*  "^$   P1<  ,,D  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O
M  #%T0  P_(  ,/_ %9\  !'@@  .H@  "R/   @E@  %)T   VC   #J0
M *X   "R    MP   +L   "_    P@   ,(   #%    Q@   ,@   #*
MS0   ,\   #2"   U0X  -L8  #=)P  WCH  -]0  #@:   X(0  .&A  #A
MO0  X>(  .#T $Z+  ! D@  ,ID  "6A   8J   #J\   6U    N@   +\
M  #$    R    ,X   #1    U    -4   #8    V@   -T   #?    X@
M .0   #G    ZP4  .\.  #T&0  ]2L  /9!  #W6   ^'(  /F0  #YJP
M^,0  /CA /\ "P#_  @ _P ) /\ # #_ !( _P : /\ )@#_ #( _P ^ /\
M2 #_ %( _P!: /\ 8@#_ &D _P!O /\ =0#^ 'L _ "! /L B #Y (\ ]P"7
M /4 H #S *H \@"W .\ R0#M .8 [ #[ .L _P#K /\ W0#_ ,X _P#& /\
MP@#_ /\ ! #_    _P   /\ !0#_  T _P 5 /\ (0#_ "P _P X /\ 0P#]
M $P ^0!4 /< 7 #T &, \@!I /  ;P#N '4 [ ![ .H @@#H (D YP"1 .0
MF@#B *0 X "P -T P #: -P V #T -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_
M /\   #_    _P   /\   #_  H _0 1 /D &P#V "< ]  R /  / #L $8
MZ !. .0 5@#A %P W@!C -P : #9 &X U0!T -( >P#0 (( S0"* ,L DP#(
M )T Q@"H ,0 MP#! ,P P #K +X _P"] /\ O0#_ +0 _P"N /\ JP#_ /\
M  #_    _P   /H   #R  4 Z@ . .4 %@#@ "$ W0 K -L -@#3 #\ S@!(
M ,H 3P#' %8 Q !< ,( 80#  &< O@!M +P <P"Z 'H N "" +8 BP"T )8
ML@"A +  KP"N ,$ K0#@ *L ]P"J /\ J0#_ *8 _P"A /\ GP#_ /\   #_
M    ]P   .@   #<    T  * ,H $0#% !L P@ E +\ +P"\ #@ N !! +4
M2 "R $\ L !5 *X 6P"L &$ J@!F *@ ; "G ', I0![ *, A "A (X GP":
M )T IP"; +@ F@#0 )D [P"8 /\ EP#_ )8 _P"4 /\ D@#_ /\   #V
MY    -(   #%    NP % +4 #@"P !4 K  ? *H *0"H #( I0 Z *( 0@"@
M $D G@!/ )P 50": %H F !@ )8 9@"5 &P DP!T )( ?0"0 (< C@"3 (P
MH0"+ +  B@#% (@ Y@"' /L A@#_ (< _P"' /\ A@#_ /@   #E    S0
M +T   "S    J@   *, "@"? !$ FP 9 )D (P"7 "P E0 T )( / "0 $,
MC@!) (P 3P"* %0 B0!: (< 8 "& &8 A !N (, =P"! ($ ?P"- 'X FP!\
M *H >P"\ 'H VP!X /4 > #_ '@ _P!X /\ > #_ .T   #1 @  NP(  *P!
M  "B    FP   )8 !0"1  T C0 4 (L '0"( "8 A@ N (0 -@"" #T @ !#
M 'X 20!] $\ ? !5 'H 6P!Y &$ =P!I '4 <0!T 'P <@"( '$ E@!O *4
M;@"V &T S@!L .X :P#_ &L _P!K /\ :P#_ -\+  #"#   K@P  )X,  "3
M"P  C <  (@"  "%  D @0 0 '\ %P!\ "  >@ H '@ , !V #@ =  ^ ',
M1 !Q $H < !0 &X 5@!M %T ; !D &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R
M &$ R0!@ .D 8 #\ &  _P!@ /\ 8 #_ - 0  "V$0  HA(  ),2  "($0
M@ \  'P-  !Y"0$ > ,+ '4 $0!S !H <  C &X!*P!L 3, :@(Y &D#0 !G
M T8 9@1, &4$4@!C!5D 8@5A & %:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'
MQ@!6">< 5@K[ %4*_P!5"O\ 5@K_ ,85  "M%P  F1@  (H8  !_%P  =A8
M '$3  !N$   ;0T% &T)#0!J"10 9PH= &4*)@!C"RX 8@PU & ,/ !?#$(
M7@U( %P-3P!;#58 60U> %@.: !6#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-
M$.H 31#] $T0_P!-$/\ 31#_ +P;  "E'   DAT  (,>  !W'0  ;QP  &D:
M  !F%P  9!0  &00" !B#Q  7Q 8 %T0(0!;$2D 6A$Q %@2. !7$CX 5A)%
M %023 !3$U, 41-; % 390!.%'  3!1] $L4C !)%)P 1Q6N $85Q0!%%>@
M11;^ $46_P!%%?\ 117_ +4?  ">(0  BR(  'PB  !Q(@  :"$  &(?  !?
M'0  7!H  %L7 @!:%0T 5Q84 %46'0!4%R4 4A@M %$8- !/&#L 3AE" $T9
M2 !+&E  2AI8 $@:8@!'&FT 11MZ $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\
M #X<_P ^&_\ /AO_ *\C  "8)   AB4  '<F  !L)@  8R4  %TD  !9(@
M5A\  %0=  !3' L 41P2 $X=&@!-'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%
M($T 0R!5 $(@7P! (6H /R%W #TAAP [(9@ .2&J #@BP  W(N, -R+[ #<B
M_P X(?\ ."'_ *HF  "4)P  @2D  ',I  !G*0  7RD  %@H  !4)@  42,
M $\B  !,(@< 2B(0 $@B%P!'(Q\ 120F $0D+@!")#0 024[ $ E0P _)4H
M/293 #PF7  Z)F< .29U #<GA  U)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R
M)O\ ,R7_ *4I  "/*@  ?2P  &\L  !D+0  6RP  %4K  !0*@  3"@  $HF
M  !')P0 1"<- $(H% !!*!P /RDC #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0
M #8K6@ U*V4 ,RMR #$K@@ P+)0 +BRG "PLO  K+-X +"SX "PK_P M*O\
M+2K_ *$L  "++0  >2X  &LO  !@+P  6"\  %$N  !,+@  2"P  $4K  !!
M*P  /RP+ #TL$0 [+1D .BXA #DN*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P
M6  P,&, +C!P "PP@  J,)( *3"E "<PN@ F,-P )C#W "<O_P H+_\ *"[_
M )PN  "',   =C$  &@R  !=,@  53(  $XQ  !(,0  1#   $ O   \,
M.C$) #<Q$  V,A8 -3(> #,S)0 R,RP ,3,S # T.P O-$, +31, "PT5@ J
M-6$ *35N "<U?@ E-9  (S6C "(UN0 A-=D (33V "(T_P C,_\ (S+_ )@Q
M  "#,P  <C0  &4T  !:-0  434  $LT  !%-   0#0  #HS   W-   -#4&
M #(V#@ P-Q, +S<; "XW(@ M."D *S@Q "HX.  I.4  *#E) "8Y4P E.5\
M(SEL "$Z?  @.HX 'CJB !PZMP ;.=4 '#GU !TX_P =./\ 'C?_ ),T  !_
M-@  ;C<  &$W  !7-P  3C<  $@W  !"-P  /#<  #4X   R.0  +SH" "P[
M"P J/!$ *3P8 "@]'P F/28 )3TN "0]-0 C/CT (CY& " ^4  ?/EP '3]I
M !L_>0 :/XP &#^@ !8_M0 5/M( %C[S !<]_P 8//\ &#S_ (XW  !Z.
M:CD  %XZ  !3.@  2SH  $4Z   _.@  .3H  #(\   N/@  *4   "9!"  D
M0@X (D(4 "%"&P @0R, 'T,J !Y#,@ <0SH &T1# !I$30 81%D %T1G !5$
M=P 31(H $D2> !%$LP 01-  $$/R !%"_P 20O\ $T'_ (D[  !V/   9CT
M %H]  !0/0  2#T  $(]   \/0  -CX  "]    J0@  )40  "%& P =2 P
M&TD1 !E)%P 821X %TDF !9)+@ 52C8 %$I  !-*2@ 12E8 $$ID  ]*=  .
M2H< #4J;  Q*L  *2LH "TGL  Q(_P -1_\ #4?_ (,^  !Q/P  8D   %9
M  !-0   14   #]    Y00  ,D(  "M%   F1P  (4D  !Q+   63@< $U .
M !)0$P 14!D $% A  ]0*0 .4#$ #5 [  U11@ +45$ "E%?  E1;P '4($
M!5"6  -0JP "4,4  T_H  -/^P %3O\ !DW_ 'U"  !K0P  740  %)$  !*
M1   0T,  #Q$   U10  +D<  "=*   A3   '$\  !=1   25 , #E<*  M8
M$  *6!4 "%@<  =8)  &6"P !5@V  -80  !6$P  %A:  !8:0  6'P  %B1
M  !7IP  5\   %;E  !6^0  5?\  %7_ '9'  !F1P  64@  $]'  !'1P
M0$<  #A(   P2@  *4T  ")0   <4P  %E4  !%8   -6P( "5X)  1?#@
M7Q(  %\8  !@'P  8"<  & P  !@.P  8$<  &!4  !@8P  8'8  &"+  !?
MH@  7[L  %_B  !>^0  7?\  %W_ &]+  !A3   54P  $Q+  !$2P  .TP
M #).   K40  (U0  !Q7   66P  $5X   U@   (8P   F8'  !G#   9P\
M &@3  !I&0  :B$  &HI  !J-   :D   &I-  !J70  :F\  &J%  !JG0
M:;8  &C=  !H]P  9_\  &;_ &E1  !<4   4E   $I/   _4   -5,  "U6
M   D60  '5T  !9@   09   #&<   9J    ;@   &\#  !P"   <0T  '(0
M  !T%   =1L  '8C  !W+   =S@  '9&  !V5@  =F@  '9^  !VEP  =;$
M '33  !S]0  <_\  '+_ &-6  !850  4%0  $15   Y6   +UL  "9?   =
M8P  %6<  !!L   *<   !',   !V    >@   'P   !\ P  ?@@  '\,  "!
M$   @A0  (0;  "%)   AB\  (8]  "&30  A5\  (5U  "%CP  A*D  (/)
M  ""\0  @?\  (#_ %];  !66@  25L  #U>   R80  )V8  !YK   5<
M#G4   EY   !?@   ($   "%    B    (H   "+    C0$  (X&  "0"P
MD0\  ),4  "5&P  ER8  )<T  "71   EU8  )9L  "5A@  E:(  )3!  "3
MZ@  DO\  )+_ %UA  !/80  0F0  #9I   J;@  'W0  !5Y   .?P  !X0
M  ")    C@   )(   "6    F    )H   ";    G0   )\   "A P  HP@
M *4-  "G$P  J1P  *HH  "J.0  JDL  *IA  "I>@  J)D  *BU  "GW0
MI_@  *;_ %9H  !(;   .G   "YV   B?0  %X0   Z*   'D    )8   ":
M    GP   *,   "G    J@   *L   "M    KP   +$   "S    M0   +@%
M  "Z#   O1(  , <  # +0  P$   +]5  "_;@  OHL  +ZH  "^R0  O>\
M +S^ $YT  ! >0  ,G\  "6'   9C@  $)4   ><    H@   *<   "L
ML    +4   "Y    O    +T   "_    P0   ,,   #&    R    ,H   #-
M @  T L  -42  #6(0  US0  -A)  #98   VGP  -J:  #;M0  V]D  -OR
M $:"   XB0  *Y   !V8   2H   "J<   "N    M    +D   "^    P@
M ,@   #+    S@   ,\   #2    U    -8   #:    W0   -\   #B
MY@   .H*  #O$P  \"4  /(Z  #S40  ]&L  /2)  #UI0  ];\  /7= /\
M!@#_  , _P % /\ "P#_ !  _P 7 /\ (@#_ "T _P Y /\ 1 #_ $T _P!5
M /\ 70#_ &0 _P!J /\ < #] '8 ^P!\ /D @P#W (H ]0"2 /, FP#P *8
M[@"S .L Q #I .0 YP#Y .8 _P#E /\ TP#_ ,< _P"_ /\ NP#_ /\   #_
M    _P   /\  @#_  L _P 2 /\ '0#_ "@ _P S /\ /@#\ $< ^ !/ /0
M5P#Q %T [@!C .P :0#J &\ Z !U .8 ? #D (, X@"+ -\ E0#< )\ V0"K
M -4 NP#2 -0 SP#R ,T _P#, /\ Q0#_ +H _P"T /\ L #_ /\   #_
M_P   /\   #_  8 ^0 / /4 %P#S "( \0 M .T -P#G $  X@!) -\ 4 #;
M %< UP!= -0 8P#1 &@ SP!N ,P =0#* 'P R "$ ,4 C0#" )@ P "D +T
ML@"[ ,8 N0#H +@ _0"W /\ M@#_ *T _P"G /\ HP#_ /\   #_    _P
M /4   #K  $ Y  , -X $P#9 !P TP F -$ , #, #H R !" ,0 2@#  %
MO0!6 +L 7 "Y &$ MP!G +4 ;0"S '0 L0!\ *\ A0"M )  J@"< *@ J@"F
M +L I0#: *, ]0"C /\ H@#_ )X _P": /\ EP#_ /\   #^    [P   -\
M  #0    QP ' ,$ #P"\ !< N0 @ +< *@"U #, L  [ *T 0P"K $D J !/
M *8 50"D %H HP!@ *$ 9@"? &T G0!T )P ?0": (@ F "4 )8 H@"4 +(
MD@#) )$ ZP"1 /\ D #_ )  _P", /\ B@#_ /P   #L    V0   ,<   "Z
M    L0 " *L # "G !( I  ; *$ ) "@ "P G@ U )L / "8 $, E@!) )0
M3P"2 %0 D !: (\ 7P"- &8 BP!M (D =@"( (  A@", (0 F@"" *H @0"^
M (  X "  /D ?P#_ '\ _P!_ /\ ?@#_ /$   #8    P@   +,   "H
MH    )D !P"5  X D@ 5 )  '@". "8 C0 N (H -@"' #T A0!# (0 20""
M $X @0!4 '\ 60!^ &  ? !G 'H ;P!Y 'H =P"& '4 E !T *, <@"U '(
MSP!Q /$ < #_ '  _P!P /\ <0#_ .$   #$    L    *(   "7    D0
M (L  @"&  L @P 1 ($ & !_ "$ ?0 I 'P , !Y #< >  ] '8 0P!T $D
M<P!. '( 5 !P %H ;P!B &T :@!K '0 :@"  &@ C@!G )T 90"O &4 Q@!D
M .@ 9 #] &, _P!C /\ 9 #_ ,\%  "V!P  HP@  )0(  ")!P  @@,  'X
M  ![  8 =P . '4 $P!R !L <0 C &\ *P!M #( ;  X &H /@!I $0 9P!)
M &8 3P!E %8 8P!= &( 90!@ &\ 7P![ %T B0!< )D 6P"J %D OP!9 .$
M6 #X %@ _P!8 /\ 60#_ ,(,  "J#0  EPX  (D.  !]#@  =@T  '$*  !O
M!@  ;0 * &L $ !I !8 9P > &4 )@!C "T 80 S &  .0!? #\ 70!% %P
M2P!; %( 6@!9 %@ 8@!7 &P 50!X %, A@!2 )8 40"G %  NP!/ =L 3@+T
M $X#_P!.!/\ 3@/_ +@0  "A$@  CA,  '\3  !T$P  ;!(  &<0  !E#@
M8PL# &,&# !A!!$ 7@,9 %P$(0!;!2@ 608O %@&-0!6!SL 50=" %0'2 !3
M"$\ 40A6 % )7P!."6D 30EV $L*A !)"I0 2 JF $<*N@!&"M@ 10OS $4,
M_P!%#/\ 10S_ + 4  "9%@  AQ@  '@9  !M&   91<  %\6  !<$P  6A$
M %H.!@!:# T 5PP4 %4,' !3#20 4@TK % -,0!/#C@ 3@X^ $T.10!+#DT
M2@Y5 $@/7@!'#V@ 10]U $,0A !!$)4 0!"F #X0NP ]$-P /1'V #T1_P ]
M$/\ /A#_ *D9  "2&P  @1P  '(=  !G'0  7QP  %D;  !5&0  4Q8  %(3
M  !2$0H 4! 0 $X1& !,$2  2A(G $D2+@!($S0 1Q,[ $430@!$$TD 0Q12
M $$46P _%&4 /A5R #P5@0 Z%9( .!6D #<5N0 U%=@ -1;U #86_P V%O\
M-Q7_ *,<  "-'@  >R   &TA  !B(0  6B$  %0?  !0'@  31L  $P9  !+
M%@8 218. $<7%0!%%QP 1!@D $(8*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:
M6  Y&F, -QMO #4;?@ S&Y  ,ANB # ;MP O&], +QSS "\;_P P&_\ ,!O_
M )T?  "((@  =R,  &DD  !>)   5B0  % C  !+(@  2"   $8=  !%' (
M0QP, $$<$@ _'1D /ATA #P>)P ['BX .A\U #D?/  W'T0 -A], #0@5@ S
M(&  ,2!M "\@?  M(8X +"&@ "HAM0 I(=  *2'R "DA_P J(/\ *R#_ )DB
M  "$)0  <R8  &4G  !;)P  4R<  $PF  !')0  1"0  $(A   _(0  /2$)
M #LA$  Y(A8 ."(> #8C)0 U(RL -"0R #,D.0 R)$$ ,"1* "\E4P M)5X
M*R5K "HE>@ H)8P )B6? "0ELP C)<X (R7P "0E_P E)/\ )23_ )0E  "
M)P  ;RD  &(J  !7*@  3RH  $DI  !$*   0"<  #TF   Z)0  -R8& #4F
M#@ T)Q0 ,B<; #$H(@ P*"D +R@P "TI-P L*3\ *RE' "DI40 H*EP )BII
M "0J>  C*HH (2J= !\JL@ >*LP 'BKO !\I_P @*?\ (2C_ ) H  !\*@
M;"L  %\L  !4+   3"P  $8L  !!*P  /"L  #@J   U*@  ,BL# # K#  N
M+!$ +2P8 "PL'P J+28 *2TM "@M-  G+CP )BY% "0N3P C+EH (2]G !\O
M=@ =+X@ '"^; !HOL  8+\H &"[M !DN_P ;+?\ &RW_ (PK  !X+0  :"X
M %LO  !1+P  22\  $,O   ^+@  .2X  #0N   P+@  +2\  "LP"@ I,1
M)S$5 "8Q'  E,B, )#(J ",R,0 A,SD (#-" !\S3  =,U< &S-D !HT=  8
M-(8 %C2: !0SK@ 3,\@ $S/L !0S_P 5,O\ %C'_ (<N  !T+P  93$  %@Q
M  !.,@  1C(  $ Q   [,0  -C$  #$Q   K,P  *#0  "4U!@ C-@T (382
M " W&0 ?-R  'C<G !TX+@ ;.#8 &C@_ !DX20 7.54 %3EB !0Y<0 2.80
M$3F8 ! YK0 ..,< #CCK ! X_P 0-_\ $3;_ (,Q  !P,@  830  %4T  !+
M-   1#0  #TT   X-   ,S0  "TU   H-P  )#D  " Z @ =.PL &SP0 !D]
M%0 8/1P %STC !8]*P 5/C, %#X\ !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5
M  L^J0 */L$ "CWD  L]^P ,//\ #3O_ 'TT  !K-@  73<  %$W  !(-P
M03<  #LW   U-P  ,#<  "HY   E.P  (#T  !P_   7008 %$,- !)#$@ 1
M0Q@ $4,? !!$)P /1"\ #D0Y  U$0P ,1$X "T1;  E$:@ '1'P !D20  1#
MI0 "0[T  T/@  -#]@ $0O\ !D'_ '@X  !G.0  63H  $XZ  !%.@  /CH
M #@Z   S.@  +3L  "<]   A0   '$(  !=$   31@, #TD*  U*#P ,2A0
M"TH;  E*(P (2BL !THT  5*/@ $2DD  DI6  !*90  2G<  $J+  !*H0
M2;D  $G=  !)]0  2/\  $C_ '(\  !B/0  53X  $H^  !"/0  /#T  #8]
M   O/@  *4   "-"   =10  %T<  !-*   /3 ( "T\)  =0#0 #41$  %$7
M  !1'@  428  %$O  !1.0  440  %)1  !28   47(  %&'  !1G0  4;4
M %#8  !0]0  3_\  $__ &Q   !=00  44$  $=!  ! 0   .4   #)!   J
M0P  )$8  !Y(   72P  $DX   Y1   +4P$ !E8'  !7#   6!   %@3  !9
M&0  6B$  %HI  !:,P  6C\  %I,  !:6@  6FP  %J!  !9F0  6;$  %C1
M  !8]   5_\  %?_ &5%  !810  344  $5$   ^1   -44  "U'   E2@
M'DT  !A0   24P  #E8   I9   $7    %X$  !?"0  8 T  &$0  !B%0
M8QL  &0C  !D+0  9#@  &1%  !D5   9&8  &1[  !CDP  8ZT  &+,  !A
M\@  8?\  &#_ %]*  !32@  2DD  $-(   Y20  +TP  "=/   ?4@  &%4
M !)9   -70  "&    )C    9@   &@!  !I!0  :@H  &L-  !M$0  ;A8
M ' =  !Q)@  <3$  ' ^  !P3@  <%\  '!S  !OC0  ;Z<  &[&  !M[P
M;/\  &S_ %I/  !03@  2$T  #U.   S40  *50  "!8   87   $6    QD
M   &:    &L   !O    <@   '0   !U    =P0  '@)  !Z#0  ?!   'T6
M  !_'@  @"@  ( U  " 10  ?U8  ']K  !_A   ?J   'V^  !\Z0  >_\
M 'K_ %94  !.4P  0E0  #=6   L6@  (E\  !AC   1:   "VT   -R
M=@   'H   !]    @    (,   "$    A@   (<"  ")!P  BPP  (T0  "0
M%@  DA\  )(L  "2.P  DDT  )%B  "1>@  CY<  (^T  ".X0  C/L  (S_
M %59  !(6@  .UT  "]A   D9@  &6P  !%R   *=P   GT   ""    A@
M (L   ".    D0   ),   "5    EP   )D   ";    G00  )\*  "B#P
MI!8  *8A  "F,0  ID,  *57  "D<   HXX  *.K  "AT   H/4  )__ $YA
M  ! 9   ,VD  "=N   ;=0  $7P   N#    B0   (X   "3    F    )T
M  "A    I    *4   "G    J0   *L   "M    L    +(   "U"   N X
M +P6  "\)0  O#<  +M,  "Z9   N8$  +>B  "WP   M^H  +?\ $9K   Y
M<   *W<  !]_   3A@  "XX   &5    FP   *$   "F    JP   +    "S
M    MP   +<   "Z    O    +\   #!    Q    ,<   #*    S04  -$.
M  #4&0  U"L  -1   #36   TW0  -.2  #2L   TM,  -+R #YY   Q@
M(X@  !>1   -F0   Z    "G    K@   +,   "X    O0   ,(   #&
MR@   ,H   #-    SP   -(   #5    V0   -T   #?    XP   .<%  #K
M#P  [!\  .TS  #N2P  [V0  .^"  #PGP  \;D  /'8 /\   #_    _P $
M /\ "0#_  X _P 5 /\ '@#_ "D _P T /\ /P#_ $@ _P!0 /\ 6 #_ %X
M_P!E /T :P#[ '$ ^0!W /@ ?@#V (4 \P"- /$ EP#N *( ZP"O .@ P #F
M .  XP#X .( _P#; /\ RP#_ ,$ _P"Y /\ M #_ /\   #_    _P   /\
M  #_  D _P 0 /\ &0#_ ", _P N /T .0#Y $( ]0!* /( 4@#N %@ ZP!>
M .D 9 #F &H Y !P .( =@#? 'T W0"& -D CP#5 )H T0"G ,X M@#+ ,X
M_^)]$$E#0U]04D]&24Q%  P2R0#P ,< _P#% /\ NP#_ +0 _P"M /\ J0#_
M /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X [  H .D ,@#C #L
MW0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^ +\ AP"\
M )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\ G #_ /\
M  #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B ,D *P#& #0 P0 ]
M +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@ ?P"F (H
MHP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_ /\   #V
M    YP   -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N "X J0 V *8
M/0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2 ($ D ".
M (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,   #C
MS    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O ), -P"1
M #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H ?@"& 'P
ME !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+    MP
M *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$ A  I (( , !_ #<
M?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_ &T C0!L
M )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X    I0   )<
M  "-    A@   ($   !\  @ >0 . '< % !V !P =  C ', *P!Q #$ ;P W
M &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &  AP!? )8
M70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,  (D$  !_
M @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P 8P R &(
M. !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4 )$ 4@"C
M %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,  !S"P
M; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M %@ ,P!6
M #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T 20"? $@
ML@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K$   8P\
M %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\ +P!. #4
M30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .< #\#KP ^
M \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%   7!,  %82
M  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'"3$ 1@DX
M $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,KP U#,<
M-0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@  % 7  !-
M%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX /PXU #X/
M/  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M$,D +1'L
M "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;  !'&@
M1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R #<3.0 V
M%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<< )A7J "<5
M_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#'0  0!P
M #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9-@ P&3T
M+AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH "$:_@ B
M&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0  /"   #D>
M   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J'CL *1]#
M "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?_0 ='_\
M'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \(P  .",  #4B   S
M(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@ (R-! "(D
M2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7(_\ &2/_
M (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E   N)
M*R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^ !TH2  ;
M*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\ %"?_ ( E
M  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J*   )BD
M "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M10 6+E
M%"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_ 'PH  !J
M*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK   F+   (BX  !\O
M   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1,TX $#-;
M  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K  !F+0
M6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(  !LS   7
M-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H "SA7  DX
M90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B,   5#$
M $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P  &S8  !<X   3.@(
M$#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2  $^80
M/G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR  !=,P  4#0  $8T
M   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H  !0]   0/P( #4$(
M  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$7   1&T
M $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@  $,X   [
M-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"   -10$ "$<'  -)
M#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P  2V@  $M]
M  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [   Y.@
M,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (3    D\%  !0"@
M4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,  %1W  !4
MCP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W/0  +SX
M "=    @0P  &48  !-)   /3   "T\   92    5    %<"  !8!P  60L
M %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ  !=B0
M7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@  *44  "%(
M   :2P  $TX   Y2   *50   UD   !;    7@   &    !B @  8P8  &4*
M  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J@@  :9T
M &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L2@  (TT  !M1   3
M50  #ED   A=   !80   &0   !G    :@   &P   !N    <    '(%  !S
M"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0  >)8  '>S
M  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<   -80
M!F8   !J    ;P   '(   !V    >0   'P   !]    ?P   ($   "# @
MA@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP  (FJ  "(
MSP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %<    '8
M  ![    ?P   (,   "'    B@   (T   ".    D0   ),   "5    F
M )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@  "=P0
MF^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[    @0   (<   "-
M    D@   )8   ":    G0   )\   "A    I    *8   "H    JP   *X
M  "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "TM0  L>(
M +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".    E    )H   "@
MI0   *H   "N    L0   +(   "U    MP   +H   "\    OP   ,,   #&
M    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP  R\L  ,OO
M #=Q   I>   '8   !&)   (D0   )H   "A    IP   *T   "S    N0
M +X   #"    Q0   ,8   #)    S    ,X   #2    U0   -H   #>
MX0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4  .O5 /\
M  #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_ $, _P!+
M /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\ D@#L )T
MZ0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_ /\   #_
M    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T \P!% .\
M30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/ )4 S "B
M ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\   #_
M_0   /H   #X    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^ -$ 1@#-
M $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T M ": +$
MJ0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y    \@
M .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +< /P"T $4
ML0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1 )H H "8
M +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L    W@   ,D
M  "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "< #X F@!$
M )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (< EP"% *@
M@P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0   +$   "F
M    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@ AP ^ (4
M0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S )\ <0"S
M '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X   "3
MC    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W '0 /0!R
M $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )< 8@"J &$
MP@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#    ?
M '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q &8 -P!D #T
M8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C %4 N0!4
M -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U    ;@   &D
M  !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8 #< 5P ]
M %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H L0!) ,X
M20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8  %X$  !;
M    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!. #, 30 X $P
M/@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!  ,4 /P#J
M #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+  !2"0
M4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T $0 .@!"
M $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X -@#C #8
M^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0  !*#@  2 T
M $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$-P [!#X
M.@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7= "X&]0 M
M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@  01   $ .
M  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U"SL ,PM#
M #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-]0 F#?\
M)PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _%0  /!0  #H2   Y
M$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H +1!" "P0
M2P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?$/\ (!#_
M (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46   T%
M,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_ "842  D
M%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\ &A3_ ((7
M  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:   O&0  +A8
M "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 91@ >&5$
M'1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_ 'T:  !K
M'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=   K'   *1L  "<;
M!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9'DX %QY;
M !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=  !G'P
M62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G(   )!\  "(@ @ @
M( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP $B-8 !$C
M9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D(@  5B,
M $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P  (",  !TD   ;)0<
M&28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6  TH9  ,
M*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)   4R8  $@G
M   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<  !DH   6*@0 %"L+
M !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M8  &+7
M!"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@  $4I   \
M*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L   3+@( $# (  XQ
M#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7   ,FP  #)_
M   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L   Y+
M,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0,@( #C0'  HW#  '
M-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X6   .&@  #A\   W
MD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V+@  ,"X
M "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8["P "/ X
M #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW   ^CP
M/:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T,0  +C   "DO
M   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %  !!"@  0@T  $,0
M  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%B@  1:0
M $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R-   +3,  "8T   @
M-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(!P  2@L  $L.  !,
M$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0  3:   $R\
M  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y   ;/
M%3\  !!"   ,10  !T@   )*    30   $\   !1!   4@<  %0+  !5#@
M5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8?P  5YH  %:W  !5
MXP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!   51   $$@
M  M+   %3@   %$   !4    5P   %D   !;    70(  %X&  !@"P  8@X
M &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q  !AW0
M8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*   03@  "E(   -6
M    6@   %T   !@    8P   &4   !G    :0   &L!  !M!0  ;PH  '(.
M  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I  !PS0  ;_<
M &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )6@   5\   !C
M:    &L   !O    <@   '4   !W    >0   'L   !]    @ ,  (,(  "&
M#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@  @?   '__
M $9+   Z3   +D\  "-3   86   $%X   ED    :0   &\   !T    >
M 'P   "!    A    (<   "(    BP   (X   "0    DP   )8   "9!P
MG0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4  )7^ #]2
M   R50  )EH  !M@   19P  "6T   !T    >P   ($   "&    BP   )
M  "4    EP   )D   "<    GP   *$   "D    IP   *H   "M    L08
M +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU #=<   K
M80  'F@  !-P   +>    (    "'    C@   )4   ":    GP   *0   "H
M    K    *T   "P    LP   +4   "X    NP   +\   ##    QP   ,L%
M  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I   C<
M%GD   V!   !BP   ),   ";    H@   *@   "N    M    +@   "]
MP    ,(   #%    R    ,L   #.    T0   -8   #;    WP   .0   #H
M!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_    _P
M /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\ 3@#_ %4
M_ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G ., N0#?
M -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_    _@   /P
M  #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I $X Y@!4
M .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,, K@#  ,4
MO0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]    /$   #R
M    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $< Q0!- ,(
M4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H +@ I@#<
M *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\   #/
MR    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!& *@ 3 "F
M %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T D #' (X
M\ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0   +\   "S    J@
M *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$ 1 "/ $H
MC@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z 'H X0!Y
M /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<   "=    E    (X
M 0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![ $, >0!(
M '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D S !H /8
M9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")    @@   'L   !X
M  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P :0!" &@
M2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9 .D 60#_
M %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y    <0   &T   !I  $
M9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \ %H 0@!8
M $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H 30#[ $T
M_P!- /\ 30#_ *H   "4    @@   '4   !K    9    &    !=    6@ %
M %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X /0!- $,
M3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q $( _P!#
M /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!  !2    4  " $X
M"0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !# #X 0@!%
M $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@ _P Y /\
M.0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,  $8 !@!$
M  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H .0!! #@
M20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O /\ , #_
M (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#   /PH  #X( @ ]! @
M/ $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^ #$ 1@ O
M %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G /\ )P#_ (8,
M  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-   V"P0 -@@*
M #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&1  I!TX
M)P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_ ( .  !M
M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0   P#P$ , T& # +
M"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C#$T (0U8
M " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1  !I$P
M6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K$@  *A # "H/"  I
M#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P &Q!8 !D0
M9@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E%0  5Q<
M $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0  )A0! "42!  C$@L
M(A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16 !049  2
M%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&   4QH  $@;
M   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<  " 6 0 >%@@ '18-
M !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 98@ .&7(
M#1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P  $4=   \
M'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:   :&P4 &!L, !8<
M$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *'FT "1Z
M  <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?   Z'P
M,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5'P( $R ) !(A#@ 0
M(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD  R)\  $B
MD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W(@  ,"$
M "HA   F(   (B   !\?   <'P  &2   !8A   2(P( $"0'  XF#  ,)A
M"R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y   GCP
M)J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T)   +B,  "@C
M   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (*PX !BL3
M  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV   LC   *Z0
M "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8  "8E   C
M)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $, X  # 1   Q
M%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R   QB0  ,:(  #"\
M   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G   A)@
M'"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/   W$@
M.!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\  #>Z   V
MY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I   >*@  &2L
M !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-   ^$   0!0
M $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW   ]XP
M//P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M   :+P  %3$  !$S
M   --@  "3@   4[    /0   $ !  !!!   0P<  $4+  !&#@  2!$  $H6
M  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&X   1?P
M $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6-0  $3@   T[   (
M/@   T$   !#    1@   $@   !*    3 0  $X'  !/"P  40X  %02  !5
M&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N  !0UP  3_L  $[_
M $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$   =$    2
M $H   !-    4    %,   !5    5P   %@"  !;!@  70L  %\.  !B$P
M8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<S   6O@  %G_ $$\
M   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL   !/    4P   %8
M  !9    7    %\   !A    8P   &4   !G 0  :@4  &T*  !P#@  <Q4
M '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_ #]    Y
M/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=    80   &4   !H
M    :P   &X   !Q    <P   '4   !X    >P   'X#  "!"@  A0\  (<7
M  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$   S10
M*$@  !U,   34@  #%<   -=    8P   &@   !M    <0   '8   !Z
M?@   ($   "#    A@   (D   "+    C@   )(   "5 0  F0D  )X0  ">
M&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L3@  (%,
M !59   -8    V<   !N    =    'H   "     A    (H   ".    D@
M )4   "7    F@   )T   "@    HP   *<   "K    KP   +0)  "X$
MMQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5   D6P  &&$   YI
M   %<0   'D   "!    B    (\   "4    F@   )\   "D    J    *D
M  "L    KP   +,   "U    N0   +T   #!    Q@   ,L   #1"@  TQ0
M -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$   =[
MA    (T   "5    G0   *,   "I    KP   +0   "Y    O    +X   #"
M    Q0   ,@   #,    T    -0   #:    WP   .0   #J    [@P  .T:
M  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_    _P   /P  0#\  @
M_@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6 /D 7 #V
M &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -  U0#V ,H
M_P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@   /,   #S    ]@ )
M /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X 50#; %L
MU@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I +8 _P"G
M /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G    Y  ! .
M"P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z %, N !9
M +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X ^P"5 /\
MBP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&    OP   +D !@"W
M  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P G0!1 )L
M5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"% /\ ? #_
M '8 _P!S /\ <@#_ .    #0    Q@   +8   "I    H0   )T  0"9  H
MF  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!* (4 4 "#
M %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\ ;@#_ &D
M_P!G /\ 90#_ ,P   "^    JP   )T   "3    B@   (4   ""  4 @  -
M '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!# '  20!O $\
M;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_ %P _P!;
M /\ 6@#_ +T   "I    EP   (D   !^    >    ',   !O  $ ;0 ) &P
M#@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!? $@ 70!/
M %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %  _P!/ /\
M3P#_ *T   "8    A@   '@   !N    9P   &,   !@    70 % %P "P!;
M !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $( 3P!) $X
M40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!% /\ 10#_
M )\   ")    >    &P   !B    6P   %8   !3    40 " $\ " !/  T
M3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$ $, 3 !"
M %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\ / #_ ),
M  !^    ;@   &$   !8    40   $P   !)    1P   $4 !0!$  L 0P .
M $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D 1P X %
M-P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_ (D   !V
M P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P  P [  @ .@ - #H
M$  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O $P +@!7
M "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$  !N"
M7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P * #( #@ Q
M !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H $D )P!4 "8
M8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H#   6@T
M $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0, +08( "P$#  K @\
M*@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1 !\!70 >
M 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@  50\  $H0
M  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F" T )0<0
M "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(7  7"&L
M%@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$  $82   ]
M$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-!P A# L ( L. !\+
M$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2#6L $ U^
M  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4   Z%
M,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\, !H.$  9
M#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L #!!\  L0
MD  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W%@  ,!8
M "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42#@ 4$A(
M$A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X  84C0 $
M%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T&   +1@  "@8
M   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0%Q  #A<5
M  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8BP  %Z$
M !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R&@  *QH  "4:   A
M&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\ "QL3  H;
M&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR   <B   '*   !NY
M   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<   ?&P
M'!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1  4@%@ #
M(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   AA@  ()X  ""X   ?
MW@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >'0  &QP
M !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E$P  )1D
M "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W   DWP
M(_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?   ='@  &AT  !8>
M   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.   K$0  +!8  "P=
M   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU   IWP  *?L
M "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <(   %R   !,A   0
M(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,  #,9   S
M(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@  +_L  "[_
M $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F   .*
M"RH   <L   #+P   #$"   S!   -0<  #<*   Y#0  .A   #L5   ['0
M.R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP  #7_ $<I
M   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H   XL   *+P  !C$
M  $T    -@   #@    [ 0  /00  #\'  !!"@  0PX  $41  !%&   12$
M $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_ $(M   X
M+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT   $-P   #H    \
M    /P   $$   !$    1@   $@#  !*!P  3 L  $X.  !0$P  4!P  % G
M  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR   U,0
M+B\  "DN   @+@  &3$  !(S   .-P  "3H   (]    0    $0   !'
M20   $P   !/    40   %,   !5 0  6 8  %H+  !=#@  7Q4  %X@  !>
M+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S-   +3(
M "0S   ;-@  $SD   X]   (00   $4   !)    3    %    !3    5@
M %D   !;    70   &    !B    90   &@%  !K"P  ;Q   &\8  !N)0
M;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P  *#D  !X[
M   5/P  #D0   =)    30   %(   !6    6@   %X   !B    90   &@
M  !K    ;0   '    !S    =@   'D   !]!   @0L  (41  "$'0  @BP
M ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$  !=&   /
M2P  !U$   !7    7    &(   !F    :P   &\   !T    >    'L   !^
M    @    (,   "&    B@   (T   "1    E@,  )L,  "=$P  FR$  )HS
M  "720  E&(  )-_  "0H   CL4  (SS #%$   E2   &DT  !!3   (6@
M &$   !H    ;@   '0   !Y    ?P   (0   ")    C0   )$   "3
ME@   )D   "=    H    *0   "H    K    +(#  "W#0  MQ<  +4H  "R
M/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL   IB    :@   ',
M  ![    @@   (D   ".    E    )H   "?    I    *8   "I    K0
M +    "S    MP   +L   #     Q0   ,L   #1!   U0X  -,=  #0,@
MS4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T    ?0   (<   "0
M    EP   )X   "D    JP   +$   "V    N@   +P   #     Q    ,@
M  #+    SP   -0   #:    X    .8   #K    \08  / 3  #N)P  [#\
M .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T  4 ]@ , /H $0#_
M !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X \P!D /$
M:@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M /\ G@#_
M )8 _P"0 /\ C #_ /H   #R    [    .D   #I    [  % /( # #X !(
M]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !< ,T 8@#*
M &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\ D #_ (@
M_P"# /\ @ #_ /    #E    W@   -H   #;    W    -@ !P#1  X T0 5
M -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +  6P"N &$
MK !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_ 'L _P!V
M /\ = #_ .(   #3    R@   ,<   "\    M@   +   0"O  L K  1 *T
M& "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3 %D D0!A
M (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T _P!J /\
M: #_ ,\   #!    N0   *T   "@    F    )0   "1  8 D  - )  $@"/
M !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %( >@!9 '@
M8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!> /\ 7 #_
M +X   "Q    H    )(   ")    @@   'P   !Z  $ >  ) '< #@!X !0
M=P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1 &0 6@!C
M &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\ 40#_ +
M  "?    C0   '\   !T    ;@   &H   !F    90 $ &, "P!C !  8P 5
M &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4 4P!3 %P
M4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_ *(   "-
M    ?    &X   !E    7@   %D   !7    50 ! %0 !P!3  T 4P 1 %0
M%@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !& %8 1 !A
M $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0   !_
M;P   &,   !9    40   $T   !*    2    $< ! !'  H 1@ . $8 $0!'
M !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %  .0!; #@
M:0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T    90
M %@   !/    2    $,    _    /0   #P  @ \  < .P , #L #P [ !(
M.@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6 "X 8P M
M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\   !L    70$  %$"
M  !( P  0 ,  #L"   W    -    #,    R  4 ,@ ) #( #0 Q !  ,0 3
M #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8 7@ E &X
M) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E!   5@8  $L'  !"
M"   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D "P I  X *0 1 "@
M%0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ > &D '0!\
M !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+   ]"P
M-0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ / "$ $@ @
M !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8 %@!X !4
MCP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y#0  ,0T
M "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$$  ;!!0
M&008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U ! "B@ 0
M :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U#P  +@\  "@/
M   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6"1( %0D6
M !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(B  +")\
M"@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$  "40   A
M$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!  $0P4 ! ,
M&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %#9T ! RT
M  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2   >$0
M&Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2  T/%P ,
M$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P   ^T   .
MU   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0  "$3   <$P  &1(
M !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2%0 )$AH
M"!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T   1UP
M$?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5   :%   %Q0  !03
M 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $%A@  Q8?
M  (6)P  %S   !<[   72   %U@  !=J   6@   %ID  !6T   5V0  %/<
M !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9%@  %A4  !,4 P 2
M$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8  !L<   ;
M)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP  &/D  !?_
M %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P  %18! !,5!0 1%00
M#Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9   @(0
M(2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H  !S_ $T9
M   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0& $ #1D!
M  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86   F'@  )R<
M "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_ $@=   \
M'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -'   "QT   @?
M   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3   N&@  +B,  "XN
M   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@   X(0
M+B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +(0  !R,   ,E
M)P   "D    L 0  +@,  # &   S"@  -0T  #81   V%P  -A\  #8I   V
M-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T)   *R0
M "0C   ?(0  &R   !8@   1(0  #B,   HE   &*    BH    M    +P
M #(    T    -P   #D#   [!@  /@H  $ .  !!$@  01H  $ E  ! ,0
M0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*   *2<  ",E
M   ?(P  &"0  !(E   .*   "BH   4M    ,    #,    V    .    #L
M   ^    0    $(   !% @  1P8  $H*  !-#@  314  $P?  !,*P  2SH
M $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD  ",G   ;
M*   %"H   XM   *,   !#,    W    .@   #T   !     0P   $8   !(
M    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9  !:)0  630  %A&
M  !76@  570  %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM   6+P
M$#(   HV   #.@   #\   !"    1@   $D   !,    3P   %(   !5
M6    %H   !=    8    &,   !G!@  :PP  &P2  !K'@  :RP  &D]  !G
M4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1.0  "CT
M  )"    1P   $P   !0    5    %@   !;    7P   &(   !E    :
M &L   !N    <0   '4   !Y    ?08  ((-  ""%@  @"0  'XU  !\20
M>V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)    +10   DL   !1
M    5@   %L   !@    90   &D   !N    <@   '8   !Y    ?    'X
M  ""    A0   (D   ".    DP   )@&  "<#@  FQH  )@K  "60   DED
M )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "5    %L   !A
M:    &X   !S    >0   'X   "#    B    (P   "/    D@   )4   "9
M    G0   *$   "E    J@   +    "W!P  N!$  +4A  "R-0  KTT  *II
M  "HB   IJ@  *+1 "-(   83@  #E0   1<    9    &T   !U    ?
M (,   ")    CP   )4   ";    H    *,   "F    J0   *T   "Q
MM0   +D   "^    Q    ,H   #2    V@H  -86  #2*0  SD$  ,I<  #%
M?   PIT  ,&] !Q5   17   !V4   !N    =P   '\   "(    D    )@
M  "?    I0   *T   "S    N    +H   "^    P@   ,8   #*    S@
M -,   #:    X    .<   #M    \P   /0.  #R'@  [S8  .Q1  #H;@
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M__________________________________________________\
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M" D*"PT.#Q$2$Q06%Q@:&QP='R A(B0E)B@I*BLM+B\P,C,T-C<X.3L\/3Y
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M      ,$(0   0                    $                    !
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M:FUO<71V>7Q^@8.&B8N.D)*5EYF;G9^AHZ6GJ*JLK:^PLK.UMK>YNKN\O;_
MP<+#Q,7&Q\C)RLO,S<W.S]#1TM+3U-76UM?8V=G:V]O<W=W>W]_@X>'BX^/D
MY>7FYN?HZ.GIZNOK[.SM[N[O[_#P\?+R\_/T]/7V]O?W^/CY^?K[^_S\_?W^
M_O__I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)T
MJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_
MI24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K
M=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&
M_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]
MIGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P
M#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"
MMZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F
M.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]
MR[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_
ML4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=
M@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C
M_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.K
MFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+
M,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!
M547^PUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^
MPUY:\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:
M\L1E<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E
M<.3";(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3"
M;(;7NG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7
MNG"9S+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67
ME>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9
MS+)TJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:E
MEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67
ME>;_I24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)T
MJL.K=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7F
MI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_
MI24&_Z0P#O^F.AC_L4,C_[M+,O_!547^PUY:\L1E<.3";(;7NG"9S+)TJL.K
M=K>]IGG"MZ%]R[&=@M.KFHG<I9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5
MYJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>:EEY7FI9>5YJ67E>;_IB4&
M_Z0P#O^G.AC_LD,B_[Q+,O_#5$7\QEU:\<AD<>/&:H?6P&^;R[ARK,*Q=+J[
MK7?$M*E[S:NC?]2BGH7;F9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:
MCN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN&9FH[AF9J.X9F:CN'_IB4&_Z4P
M#O^H.A?_LT,B_[Y+,?_%5$7YR5Q;[\UC<>/,:8C5QFV<R;]PKKVV<KJTL'7#
MJZIXRJ*E?-&9H8'8D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0
MG8G=D)V)W9"=B=V0G8G=D)V)W9"=B=V0G8G=D)V)W9"=B=W_IB4&_Z4P#O^J
M.A?_M4,B_\!+,?W(4T7VS5M;[=%A<N'09XG1RVN=PL!NK;:W<;BLL7/!HZQV
MR)JH><Z2I'[4B:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V(F@A=B)H(78
MB:"%V(F@A=B)H(78B:"%V(F@A=B)H(78B:"%V(F@A=C_IR4&_Z4P#O^K.A?_
MMD,A_\%+,?K+4D3ST5I:ZME@<M[698G+S&J<N\%MJZ^Y<+:EM'*^G*]TQ)2K
M=\J+IWO/A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U(2D@=2$I('4A*2!
MU(2D@=2$I('4A*2!U(2D@=2$I('4A*2!U(2D@=3_IR4&_Z8P#O^M.A;_N$(A
M_L1*,/?.4D3PUEA:Y^!><M;:9(C$S6F:M,-LJ*B[;[*>MG"ZEK)RP(ZN=L:&
MJGK*?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G
M?\Y_IW_.?Z=_SG^G?\Y_IW_.?Z=_SG^G?\[_J"4&_Z<P#O^N.1;_ND(@^\9*
M+_3344/KW5=:X^9<<<[;9(>]SVF8KL5KI:*^;J^8N6^VD+5QO(BQ=,&!KGC%
M>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<E[
MK'W)>ZQ]R7NL?<E[K'W)>ZQ]R7NL?<G_J"0&_Z<P#?^P.17_O4(?]\E*+^_8
M4$+FXU59W.A;<,;=8X6VT6B5I\AKH9S!;:J3O&^QBKEQMH2U=+M]LG>_=[!\
MPG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"=[!\PG>P?,)WL'S"
M=[!\PG>P?,)WL'S"=[!\PG>P?,+_J20%_Z@P#?^S.13^P$(>\\U*+>G=3T#A
MZ5-9T^I;;[_?8X*OTV>1H<MJG9;%;:6-P&^KAKUQL'^Z<[5ZMW>X=+5[NW2U
M>[MTM7N[=+5[NW2U>[MTM7N[=+5[NW2U>[MTM7N[=+5[NW2U>[MTM7N[=+5[
MNW2U>[MTM7N[=+5[NW2U>[O_JB0%_ZDO#?^V.!/YQ$$=[=))*^+C34#;[U)8
MRNU:;;?A8G^HUF>-F\]JEY');9^(Q6^E@L)QJ7N_=*UVO7>P<;M[LW&[>[-Q
MNWNS<;M[LW&[>[-QNWNS<;M[LW&[>[-QNWNS<;M[LW&[>[-QNWNS<;M[LW&[
M>[-QNWNS<;M[LW&[>[/_JR0%_ZLO#?^Z.!+SR4$;Y-I)*-CH3$#.\U%7P.]9
M:Z[D87J@W&>&E-1KD(O/;I>$S'"<?<ESH'C&=:-SQ'BF;L)\J6["?*ENPGRI
M;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["?*ENPGRI;L)\J6["?*EN
MPGRI;L)\J6["?*G_K20%_[ O"_O . _JT$$7VN)&*,SN3$'#^5!5M?-89J7I
M8727X6=^C=MKAH77;XQ_U'*1>M%UE'7/>)=QS7N:;,Q^G&S,?IQLS'Z<;,Q^
MG&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<;,Q^G&S,?IQLS'Z<
M;,Q^G&S,?IS_KR,$_[8M"?'(-@S=W#T3S>I&*L'V2T"V_T]1JO=88)OO86N/
MZ&ATA>1M>W_@<8!YWG2#==QXAG+:>XENV'Z+:]:"C6O6@HUKUH*-:]:"C6O6
M@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"C6O6@HUKUH*-:]:"
MC6O6@HW_L2,$^K\L!N/4+P?.YCL6P?-%*[3_23VH_TY,GOU76)'V86&&\6EI
M?^UO;GGJ=')UZ'=U<>=Z=V[E?7EKY(![:>.$?&GCA'QIXX1\:>.$?&GCA'QI
MXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GCA'QIXX1\:>.$?&GC
MA'S_M2(#Z\LB M#C)P?"\3H9M/Y"*J;_1CF;_TU%DO]63X;^8E9^^FI<=_=P
M8'/U=6-O\WAE;?)\9VKQ?VAH\()J9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K
M9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6MF[X5K9N^%:V;OA6OV
MPAL!U-\1 <+O)@NU_#H:I_\^)YG_1#.-_TL]A?]517S_84MU_VI/</]P4FS_
M=51J_GE6:/U\5V;\?UAD_():8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&
M6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEMC^X9;8_N&6V/[AEO4SPH
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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MNF.VD;ICMI&Z8[:1NF.VD;K_H!X$_Z$H"/^Q, O[P#D1[,Y"&=_?1RC3Z4Q
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M2%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$A8_Y!(6/^02%C_D$C$QP<
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MM*Z=A+RFF(K!H)21QIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;#
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MK\&"DJ_!@I*OP8*2K\&"DJ_!@I*OP8*2K\'_EQL#_Y4G"/^>+PW_JC@3_[5
M'/^^2"GYR$XZ\\U63>K37&+>SV)XS<=HB[^^;INRMW.HI[!YLIZK?KJ5IX3
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M_Z4> _^W(P/MR28#UMXI!LGI.Q>^\T0IL_A).JCW34B?]E55E/5?8(GQ:&B
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M;47_BWA/_X:$6?R"CF'W?99H]'B=;O%THW/N<:EW[&ZN>NILLWWI:KE_YVC
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M?E3AN'Y4X;A^5.&X?E3AN'Y4X;A^5.&X?E3AN'[_F!,!_ZT4 ?/##P#2V L
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M ^W'+ 3?U3$&T]XY%,;81"BYT4X[K,Q63*#'75J5PF-GB[]I<8*[;WEZN':
M<[9]AFVTA8MHLXZ/8[*8DF"QI)->LK&47++"E%ZRTY!?K-F)8*K:AF"JVH9@
MJMJ&8*K:AF"JVH9@JMJ&8*K:AF"JVH;_?Q<"_Y 6 O^A&@'_L1T!], @ >/1
M( '3WRP&R>([%+[?1"6RV4PXI=-429G/6U>.RV%CA,AH;'O%;G5SPW5[;,%\
M@6? A(5BOXZ)7KZ8BUJ^I(U8OK&.5[_"C5B_UXM9N-R%6;;=@UFVW8-9MMV#
M6;;=@UFVW8-9MMV#6;;=@UFVW8/_@18"_Y44 ?^G%@']N!< Z<L1 -/?%@'(
MYRP'ON8[%K/D1"6HX4LUG-U21)'965*&U6!=?--F9G31;6YLSW1T9LY\>6'-
MA7U<S(Z 6<R9@U;,I814S+.%4\W$A5/-W8-3QN!^5,/A?53#X7U4P^%]5,/A
M?53#X7U4P^%]5,/A?53#X7W_AQ,!_YP2 ?^N$0#:P@H T-(* ,?H& &\["P*
MLNL\%ZCJ0R6=Z$@SDN900(CD64M^XF!4=N%H7&_@;V)HWW=H8]Y_;%[>B'!:
MWI%S5]Z;=53>IW=2W[1X4-_$>$_@WGA/UN5U3]/G=$_3YW1/T^=T3]/G=$_3
MYW1/T^=T3]/G=$_3YW3_CP\!_Z0. -NX" #-Q0D Q=4* +KQ&@.P\BT,IO$[
M&)OP0221[T<OA^Y..G[N6$-W[6%*<.UI4&KL<55E['E98>R!7%WLBE]:[)-A
M5^V=8U7MIV52[;-F4>[ 9T_OU&A.Z^9H3>CH:$WHZ&A-Z.AH3>CH:$WHZ&A-
MZ.AH3>CH:$WHZ&C_F0L W:X$ ,R\!@#!R0< N-L* *WX' 2D^"\-F?@Y%X_X
M/R&%^$8J?/A-,G7W5SEN]V _:?=I0V3X<4=A^'E*7?B!3%KXB4]8^))15OF;
M4E/YI511^J]54/J[5D[ZRE=-^^-73/OI5TS[Z5=,^^E73/OI5TS[Z5=,^^E7
M3/OI5TS[Z5?EI0  SK0$ +^_!0"TS@8 JNL- :#_'P:7_R\-C/\V%8+_/1UX
M_T0D</],*FK_5"]E_UXS8?]G-UW_;SE:_W8\6/]^/E;_AC]3_XY!4?^70E#_
MH$-._ZE%3?^S14O_OD9*_]!'2?_<1TG_W$=)_]Q'2?_<1TG_W$=)_]Q'2?_<
M1TG_W$?1K@  O[D# ++% P"GU04 G/T/ I3_(@:)_RL,?O\R$G7_.AAL_T(=
M9?])(E__425:_UHH5_]C*U3_:RU2_W(O4/]Y,$__@#%-_X@R2_^0-$K_F#5(
M_Z$U1_^J-D;_LS=$_[\X1/_%.$3_Q3A$_\4X1/_%.$3_Q3A$_\4X1/_%.$3_
MQ3C!LP  LKX" *7, 0"9W0, D/\2 H;_'P5[_R<*<?\N#FC_-A-A_SX76O]&
M&E7_31U1_U4?3O]=($O_9"))_VLC1_]Q)$;_>"5$_W\F0_^&)T'_CBA _Y8H
M/_^>*3W_IRD\_[ J//^T*CS_M"H\_[0J//^T*CS_M"H\_[0J//^T*CS_M"JS
MN $ I<8  )?5  "+[P0!A/\3 G?_&@1M_R('9/\J"US_,@Y5_SD14/]!$TO_
M2!5(_T\71?]6&$+_7!E _V$:/O]G&CS_;1L[_W,<.?]Y'#C_@!TV_X@=-?^/
M'C3_EQXR_Z ?,O^D'S+_I!\R_Z0?,O^D'S+_I!\R_Z0?,O^D'S+_I!^FP
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M/$;_O3U%_\P]1/_F/D3_YSY$_^<^1/_G/D3_YSY$_^<^1/_G/D3_YS[+K
MN;8! *S" 0"@T ( E>4' ([_& .$_R0&>O\L"W#_-!!H_SP58?]$&5O_2QU6
M_U,@4_];(E#_8R1-_VLF2_]S)TG_>BE(_X(J1O^**T3_E"Q"_YXM0?^G+D#_
ML2X__[PO/O_-,#[_S3 ^_\TP/O_-,#[_S3 ^_\TP/O_-,#[_S3"[L0  K+P
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M<6J4[6QJE.UL:I3M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0
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M85&]]6%1O?5A4;WU85&]]6'_A@H \)H$ -2J! #(M@8 OL$% +?/"0"PXQ$
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M$B7_D!,D_YD3(_^C%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@
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M9GJ"]U]Z@OA>>H+X7GJ"^%YZ@OA>>H+X7GJ"^%[_9Q<"_W<1 ?^'$P'_E!4
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M7F*9]UYBF?=>8IGW7F*9]U[_<Q !_X4, /J6"@#;I08 T;$( ,N[" #&QPL
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M*CW\N2L[_<LK._WB*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J
MKK   *&\  "5R   B=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/
M_T<12_].$T?_5A5$_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_
MK!\S_[D?,__('S+_XB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<
M )7$  "'T   >]T  '+]"0!J_Q$!8?\9 EK_(@-4_RH%3O\R!TG_.@E%_T$+
M0?](##[_3@X[_U4/./];$#;_8A$T_VD1,O]R$B__>Q,M_X84*_^2%2K_GA4I
M_ZD6*/^S%B?_PA8G_\<6)__'%B?_QQ8G_\<6)__'%B?_QQ:DM   EL   (?,
M  !ZV@  ;>L  &3_!0!<_PX!5/\4 4W_' )(_R0$0O\L!3[_,P8Z_SD'-O]
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M ?]S%0'_?AH!_X<@ O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M
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M6(IV_U*)=O].B7;_3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0
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M4G.%_U)SA?]2<X7_4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T
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M2$;*R$A&RN9'1\GW14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0
MRYP  +VG  "QL   IKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-H
MW4T:8MQ5(%W;7298VV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<
MR#Q"V^4[0MKT.D+9_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,
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M&"S_X1@L_^\8+/_O&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S
M==D  &GD  !A_PD 6_\1 %3_&0%._R("2?\K!$3_,@5 _SH&//]!!SG_1P@V
M_TX),_]4"C'_6PLN_V(,+/]K#"G_=0TG_X .)?^-#B3_F@\C_Z80(O^S$"'_
MP1 A_] 0(?_0$"'_T! A_] 0(?_0$"'_T!"?L@  D;X  (/*  !UU@  9^(
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M/\D=_S_6'?\_Y1W_/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y
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M1()X_T2">/]$@GC_1()X_T3_7Q$!_VT, /]Z#0#_A0T \H\- .>8#0#;GPX
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M4U.?P%-2G]U259_S3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0
MX(8  ,^3  #$GP$ NJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\
MM5 B=;-8*F^R7S!JL&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJ
MP$U-JMQ-3JKR25"J_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP
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M,#_2_2\_T?\N/]#_+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0
MEKL  (O$  " S0, ==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-
MY%T62N1E&$?D;AM%Y'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC
M^B,YXO\D.>+_)#GB_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(
M '[,  !SU@( :>4) &3O% !?\" !6? K U3P-05/\#X'2_%&"D?Q3@Q$\5<.
M0O%?$#_R9Q(]\G 4.O)[%3CSAQ8V\Y08-?2B&3/TL1DR]<4:,?7B&C'T\1DQ
M\?X9,?'_&3'Q_QDQ\?\9,?'_&3'Q_QFRI   I:L  )BV  "+P   ?LH  ''5
M  !EW@  7O4* %G\$P!3_!X!3OPG DK], -%_3D%0?U !C[^2 <[_D\)./]7
M"C;_7@LS_V<,,?]P#2[_? XL_XD/*_^6$"G_I! H_[01)__'$2?_X1$F__(1
M)O_V$2;_]A$F__81)O_V$2;_]A&GJ0  F;,  (N^  !^R0  <-,  &3>  !8
MYP  4O\) $W_$0!'_QD!0_\B 3[_*@(Z_S(#-_\Y S/_/P0P_T8%+?]-!2O_
M5 8H_UL')O]C!R/_;0@A_WD)'_^'"1[_E0H=_Z,*'/^Q"AO_P L:_]8+&O_?
M"QK_WPL:_]\+&O_?"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0
M1O\% $#_#@ [_Q0 -_\; 3/_(P$O_RD"*_\P BC_-0(E_SL#(O]! Q__1P,=
M_TX#&O]5!!C_7@05_V@%$_]T!1'_@@40_Y &$/^=!@__J08._[4&#O^Z!@[_
MN@8._[H&#O^Z!@[_N@:.N@  ?\4  '#1  !BW@  5.4  $;K   __@  .?\
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M-9-J_S63:O\UDVK_-9-J_S7_5Q$!_V,- /]N# #_=PX _W\/ /"%$0#CB18
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M3V*"OT]A@MI/9(3R26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0
M]G8  -R"  #.C0  Q94" +Z< P"WH0( KZ01 *BD) *@HC0(F)] $9&<2AJ*
MF5,BA)=;*7Z58C!YDFDU=9!P.G"/=SYLC7]":(R)1F6*DTEAB9]+7HFL35V)
MO4Y<B=9-7HKP2&"+_D-BB_\_8XS_/&.,_SQCC/\\8XS_/&.,_SS_:@  YGH
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M/TVE_#Q.I/\Y3Z3_-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP
MK*4  **L  "8LP  CKL" (B]$@"#O24!?+PS!G:[/PUONDD4:KA1&F6W61]@
MMF D7+5G*5BT;RQ4LW@P4;.",TVRC39*LIHX2+&H.D:RN3I%LM$Z1K'M.4>P
M_#9'L/\T2*__,TBO_S-(K_\S2*__,TBO_S/;@@  QY   +N<  "NHP  I*H
M )FQ  "/N0  A, # 'O&#0!XQAX <\8N VW%.@AGQ$4.8L-.$UW#5AA9PEX=
M5<%F(5'!;B1.P'<H2\"!*TB_C"U%OYHO0[^H,4&_NC%!P-(Q0;[N,$&]_2]!
MO/\N0;S_+4&\_RU!O/\M0;S_+4&\_RW.B@  OY@  +&@  "FJ   F[   )"X
M  "%OP  >L<$ &_/"0!KT14 9]$F 6/1- 1>T$ (6=!*#%7/4Q!1SUL43L]C
M&$O.:QM(SG4>1<Y_($+.C") SIDD/LZH)CS.NB8\S]0F/,WO)3O,^R4[R_\E
M.\K_)3O*_R4[RO\E.\K_)3O*_R7#DP  M9X  *BF  "=K@  D;8  (6_  !Y
MQP  ;\X$ &36"0!>WA$ 6]X@ %?>+0)3WSH$4-]$!DS?3@E)WU<,1M]?#T/?
M:!%!WW$3/M]\%3S?B1<ZX)89.."E&C?@MQHVX<T:-M_L&C7>^1HTW?\;--S_
M&S3<_QLTW/\;--S_&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP
M8M8# %CA" !5ZA, 4>L@ $WK*P%)ZS4"1>P^!$+L1P4_[$\'/>U8"3KM8 HX
M[6H,-NYT#3/N@ XR[HX/,.^=$"[OK1$M\, 1+?#>$2SN\1$L[/X1+.O_$"SK
M_Q LZ_\0+.O_$"SK_Q"MH@  H*D  ).S  "&O0  ><8  &S/  !@V   5=X
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M PC_P@.*N   >\,  &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P<
M(_\. "#_$@ <_Q@ &/\= !7_(0 2_R8 $/\L 0[_,0$-_S<!"O\^ 0C_1@$%
M_T\! ?]9 0#_9@$ _W0! /^" @#_D ( _YP" /^F @#_I@( _Z8" /^F @#_
MI@+_+B\"_S,L O\W+0+_.# "_S<V _\T/P3_,4L&_R]8!_\L9@C_*G0)_RF!
M"O\HC0O_*)<+_RB?"_\HI@S_)ZT,_R>T#/\GNPS_)\0,_R?.#/\HW@O_*.D+
M_RCS"_\H^PO_*/\*_RG_"O\I_PK_*?\*_RC_"O\H_PK_*/\*_RC_"O\H_PK_
M,"T"_S8J O\Y*@+_.RX"_SHT _\X/ 3_-DD&_S-6!_\Q8PG_+W$*_RU^"_\M
MB@S_+)0,_RR<#?\LI W_+*L-_RRQ#?\LN0W_*\$-_RS+#?\LV@W_+.<-_RSQ
M#?\L^@W_+/\,_BW_#/TM_PS]+?\,_2S_"_TL_PO]+/\+_2S_"_TL_PO_,BL!
M_SDH O\]* +_/RH"_SXP _\].@3_/$8&_SE3"/\W8 G_-6T+_S-Z#/\RA@W_
M,9 ._S&9#O\QH0__,:@/_S"N#_\PM0__,+T0_S#'$/\PU!#_,.00_S'O$/XQ
M^0_[,?\/^3'_#_@Q_P[W,?\.]S'_#O8Q_P[V,?\.]C'_#O8Q_P[_-2@!_SPE
M ?] ) +_0R<"_T,L _]$-P3_0D,&_T!/"/\]7 K_.VD,_SEV#?\X@@__-XP0
M_S>5$?\VG1'_-J02_S:K$O\VLA/_-;H3_S7#$_\USQ/\->$3^3;M$_8V]Q/S
M-O\3\3;_$O V_Q+P-_\1[S?_$>\W_Q#O-_\0[S?_$.\W_Q#_.24!_T A ?]%
M( '_1R("_TDI O]*- 3_23\%_T9+"/]$6 K_0F4-_T!Q#_\^?1'_/8<2_SV1
M%/X\F17]/* 5_#NG%OH[KA?Y.[87^#N_%_8[RACT.]P8\#OJ&.T[]ACJ._\7
MZ#S_%^<\_Q;F/?\5Y3W_%.4]_Q3E/?\4Y3W_%.4]_Q3_/2(!_T0> ?])' '_
M31X!_U F O]1, /_4#L%_TY&"/]+4PO_2& ._T9L$?M%>!/X1((5]D.,%_1"
ME!CS09P9\4&C&^] JAON0+(<[3^['>L_QA[I/]4>Y3_H'^) ]![?0/X=W4'_
M&]M"_QK90O\8V$+_%]A"_Q?80O\7V$+_%]A"_Q?_0!\!_T@: ?].& '_4AL!
M_U8C O]8+ /_5S<$_U5"!_]230OY4%H.]4UG$O%,<A;N2GT8ZTB&&^E'CQWG
M1I<?Y46>(.-$IB+A1*XCX$.W)-Y#PB7<0] FUT/E)M-$\R301?XBS4;_(,Q'
M_Q[*1_\<R4C_&\E(_QO)2/\;R4C_&\E(_QO_1!L!_TP6 ?]2% '_6!@!_UT?
M ?]?* +_7C(#_5T]!O9:20KP5U4/ZE5B$^92;1CB4'<<WTZ!']Q,BB+92Y(D
MU4J:)M-)H2C12:DISTBR*LU(O"O+2,DLR$C?+,5([RO"2OPHP$O_);],_R*^
M3?\@O4W_'[U-_QZ]3?\>O4W_'KU-_Q[_1Q@!_T\3 ?]6$0#_7A4 _V(< ?]E
M) '^92T"]&0X!>UA0PGF7U$.X%Q=%-I8:!K45G(>T%1[(LQ2A";*4(PHQT^4
M*L5.FRS#3J,NP4VL+[],MC"]3,(QNTS3,KA,Z3&V3O@MM%#_*K-1_R>S4O\D
MLE+_(K)2_R*R4O\BLE+_(K)2_R+_2A4!_U,1 /];#P#_8A( _V@7 /]J'P'V
M:R@![&LR ^1I/@?<9DP-TV)8%,U?8QO(7&T@Q%IV),%8?BB^5H8KNU6.+KE3
MEC"V4IXRM%*F,[)1L#6P4;PVKE#+-ZQ0XS>J4O0SJ53_+JA6_RNH5_\HJ%?_
M):A7_R6H5_\EJ%?_):A7_R7_31, _U8. /]?#0#_9Q  _VP3 /MP&0#O<2(!
MY'$L MMP.@71;$@,R6A4%,-E7QN^8F@ANE]Q)K9=>2JS6X$ML%J),*Y8D3.K
M5YDUJ5:A-Z=6JSBE5;8ZHU7%.Z%5W3N?5O WGUC^,I]:_RZ>6_\KGES_*)Y<
M_RB>7/\HGES_*)Y<_RC_4!$ _UD, /]C# #_:PT _W 0 /5T$P#H=AH W7<E
M =%V-@3(<D0,P6Y0%+MK6QNV9V0AL65M)ZUB=2NJ8'POIU^$,J1=C#2B7)0W
MGUN=.9U:ICN:6;$]F%F_/I=9TSZ56NP[E5W[-99>_S&67_\MEF#_*I9@_RJ6
M8/\JEF#_*I9@_RK_4@\ _UP* /]F"0#_;@H ]G0, .]X#@#A>Q( U'P@ ,I[
M,P3!=T$+NG1-$[1P6!NN;&$AJ6II)Z9G<2NB97@OGV2 ,YQBB#:989 XEE^9
M.Y1>HCV17JT_CUV[0(U=S4&,7N@_C6'Y.(UB_S..9/\PCF3_+(YE_RR.9?\L
MCF7_+(YE_RS_50X _U\& /]I!@#T<@8 XG@& -M\"0#9?PP S8$= ,1_, .[
M?#\*M'A+$JUU51JH<5XAHVYF)I]L;BN;:G4OF&A],Y5GA#:298PYCV25/(QC
MGSZ)8JI AV&W0H5AR4*$8N1!A63W.X9F_S6'9_\QAVC_+H=I_RV':?\MAVG_
M+8=I_RW_5PP _V$$ /YL P#D=0$ VWL% -. " #0@PH QX4: +Z$+0.V@3P)
MKWU($JAY4AFB=EL@G7-C)IEP:RN5;G(OD6UY,XYK@3:+:8DZB&B2/(5GG#^"
M9J=!@&:T0WYFQ41\9N%#?FCU/']J_S> :_\S@6S_+X%L_R^!;/\O@6S_+X%L
M_R__60L _V,! /1O  #?>   U'\$ ,Z#!@#*AP@ PH@8 +F'*P*QA3H(JH%&
M$:-^4!B=>ED?F'=A)9-U:"J/<V\OBW%W,XAO?C:%;H8Z@FR//7]KF4!\:J5"
M>6JQ1'=JPD1V:MU$>&SS/GEN_SAZ;_\T>W#_,'QP_S!\</\P?'#_,'QP_S#_
M6P@ _V8  .=R  #:>P  SX(# ,F'!0#$B@8 O(P5 +2+* *LB3@'I85$$)Z"
M3AB8?U<>DWQ?)(YY9BJ*=VTNAG5T,H)T?#9_<H0Y?'&-/7EPET!V;Z)"<VZO
M1'%NP$5P;ME%<G#Q/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708
M_VD  .)T  #4?0  RX4" ,2*! "_C04 MX\3 +"/)@&HC34'H(I"#IJ&3!:3
M@U4=CH%=)(E^9"F%?&LM@7IR,GUX>35Z=X(Y=G:+/'-UE4!P=*!";7.M1&MS
MO45J<]5%;'3O0&YV_CIO=_\V<7C_,G%X_S%Q>/\Q<7C_,7%X_S'_7P( ]VP
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M/UR&^SI>AO\V7X?_,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C
MN9,  +"9  "HG0  GZ ) )FA&@"3H"L#C)\X"(6=0Q!_FDP7>9A4'7277")P
ME6,G:Y-J+&>2<3!DD7DS8(^"-UR.C3I9C9D]5XVF/U2-MD!3C<M 5(WI/5:-
M^CE7C?\U68[_,EF._S%9CO\Q68[_,5F._S'M;0  V7L  ,B'  "]D   M)@
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M*42J_RE$JO\I1*K_*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@
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M"B;F_PJHH   G*<  (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D
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M 07_= $#_X4! O^6 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP
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M-X)>PC> 7MPX@%_R,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8
M_UT  .=G  #;;P  T'0" ,IX!0#&>0< OGH5 +9Z* &O>#<%J'9$"Z)S3A*<
M<%<8F&U?'91K9R&0:FXEC6AU*(IG?2N'984NA&2.,8%CES1_8J(V?&*O.'IB
MOCEY8M4Y>6/O-'IE_B][9O\K?&?_*'QG_R9\9_\F?&?_)GQG_R;_50, _V
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M-VEQ^C)K<O\M;'/_*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P
MP((  +B&  "QB   J8D- ***'0"<B2X"E8<[!X^%10Z)@D\4A(!7&7]^7AY[
M?&4B>'ML)G1Y<RIQ>'LM;G>$,&MVCC-H=9HV972F.&-TM3EA=,DZ873G.&-V
M^3)E=O\N9G?_*V=W_REG=_\I9W?_*6=W_RG_7P  XVP  -!V  #%?P  O(4
M +2*  "LC   HXX* )V.&@"7CBL"D(PX!HJ*0PR$ATP2?X55&'J$7!UV@F,A
M<X!J)6]_<2EL?GDL:'V"+V5\C#)B>Y@U7WJD-UUZLSA<>L<Y7'KE-UY[^#)?
M>_\N8'S_*V%\_REA?/\I87S_*6%\_RGU8@  WF\  ,QZ  # @P  MXD  *^.
M  "FD0  G9(& )>3%P"1DR@!BY(V!86000M_CDH1>HQ2%G6*6AMQB&$?;8=H
M(VJ&;R=FA'<K8X. +F""BC%=@98T6H&C-EB LC=6@,4W5H#C-EB!]S%9@?\M
M6X+_*EN"_RE;@O\I6X+_*5N"_RGL9@  V',  ,=^  "\AP  LXX  *F2  "@
ME0  EI@! )"9$P"*F20!A9@R!'^6/@EYE$@.=)-0%&^15QEKD%X=:(YE(62-
M;25@C'4H78M^*UJ*B"Y7B90Q5(FA,U*(L#11B,,U4(CB-%*(]C!3B/\L5(C_
M*56(_RA5B/\H58C_*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@
MCIX  (>?$ "#GR  ?I\O GB=.P=SG$4,;IM-$6F9519EF%P:89=C'EZ6:B%;
ME7(E5Y1\*%23ABM1DI(N3I*@,$R2KS%+DL(Q2I'@,4R1]2U-D?\J3I#_*$Z0
M_R9.D/\F3I#_)DZ0_R;><   R7T  +R)  "RD@  IY<  )V;  "3GP  AJ0
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M&SFP_QO!A@  M),  *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@<
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M R/EH00BY;0$(>7-!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@
MF*4  (NN  !]M@  <+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K
M[A@ *>XB "?O*P E[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?T
MD@(5]*4"%/6Z A/UU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T
M '^V  !QOP  8\<  %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!,
M'OT; !S](@ 9_BD %_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*
M_Y,!"?^F 0C_N@$'_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_
M  !CR0  5M$  $C8   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3
M !'_&0 /_QX #?\D  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT
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M)9E,R":63.(FE4[U(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@
M_U   /M8  #E7@  W6(# -9C!P#480H RF(9 ,)C+ &[8CL#M&!("*]=4PRJ
M6UP1IEID%:-8;!B@5W0;G55['9M4@R"95(LBEE.3))12G2624:<GD%&S*(Y1
MPRF-4=TJC%+R)HM4_R*+5?\>BU;_'(M6_QJ+5O\:BU;_&HM6_QK_3 0 _U,
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M+75@^B=V8?\C=V+_('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0
MQ'(  +UT  "W= $ L'0. *EU'P"B="\"G'(]!9=P1PJ1;E$/C6Q9%(EJ8!>%
M:6<;@FAN'G]F=2%]97TD>F2&)W=CD"EU8YLL<F*G+G!BMB]O8LDO;F+F+F]D
M^2AP9?\D<6;_(7%F_Q]Q9O\?<6;_'W%F_Q__5   Z%\  -=I  #*<   P'4
M +EX  "R>   JW@- *1Y'0">>"T!EW<Z!9)U10J,<DX.B'!6$X1O7A> ;60:
M?6QK'7IK<R!W:GLC=&F#)G)HC2EO9YDL;&:E+FIFLR]I9L8P:&;D+VIH]REK
M:?\E;&G_(FQJ_R!L:O\@;&K_(&QJ_R#_5P  Y&(  -)L  #&<P  O7@  +5[
M  "M?   I7P* )]]&@"9?"H!DWLX!(UY0PF(=TP.@W54$G]S6Q9[<F(9>'!I
M'75O<"!R;G@C;VV!)FQLBREJ;)<L9VNC+F5KLB]D:\0P8FOA+V1L]BIF;?\F
M9FW_(V=N_R!G;O\@9V[_(&=N_R#V60  X&4  ,YO  #"=@  N7P  +%_  "I
M@   H( ' )F!%P"4@2@!CH U XA^00B#?$H-?GI2$7IX615V=V 9<W9G''!T
M;A]M<W8C:G)_)F=QB2ED<94K8G"A+6!PL"]><,(O77#?+U]Q]2I@<?\F87+_
M(V)R_R!B<O\@8G+_(&)R_R#O7   W&D  ,IR  "^>@  M8   *V$  "DA0
MFH4# )2%% ".AB4!B80S X.#/@=^@4@+>7]0$'5^5Q1Q?5X8;GME&VMZ;!YH
M>70B97A])6)WARA?=I,J7':?+%IUKBY9=< N6'7=+EEV\RI;=O\F7'?_(UQW
M_R!<=_\@7'?_(%QW_R#J8   U6P  ,5V  "Z?@  L80  *B(  "?B0  E(H
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M4(/_'U"#_Q_>:0  R74  +R   "RB   _^)]$$E#0U]04D]&24Q%  \2J(T
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M&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?EP  E9P  (FA  !]I@
M<:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR1 -+L4T%2+%5!T6Q70E#
ML64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1%#6N[Q0TK?X4-*S_%#2K
M_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0  C*,  ("H  !TK0  :+(
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M A?:_P*@G   E*,  (>K  !YLP  ;+H  %_!  !2Q@  1LH  #O.   QTP
M*=D  "'>!0 >Z X '>@5 !OI'@ 9Z2< &.HP !;J.0 5ZT, %.Q. !+L6@ 1
M[6< $.YW !#NB@ .[YX #O"S  WPS0 ,[^P #.W\  SK_P ,Z_\ #.O_  SK
M_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@  .=,  "_8   EW0  '>$
M !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +^C4 "?L_  ?[2@ $_%<
M _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\_   _/T  /S]  #\_0"+
MJP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T  "+A   9Y0  $^H  !#Z
M   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<  /\P  #_.@  _T4  /]3
M  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0  _^4  /_E  #_Y0!_M
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M ?(3_P'Q$_\"\!3_ O 4_P+P%/\"\!3_ O 4_P+_*A\ _RP< /\L&P#_*QT
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M";HS_PFZ,_\)NC/_";HS_PG_.1  _ST+ /] "0#_1 T _T81 /]%&0#W1",
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M_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4 NET1 +-?(P"L7S,!IEY
M Z%<2P>=6E0*F5E<#I989!&35FL3D%5R%HY4>AB+5((:B5.*'(=2E!Z%4IX?
M@U&J(8%1N")_4<LB?E+G(7Y3^1U^5/\:?E7_%WY5_Q9^5?\5?E7_%7Y5_Q7_
M2@  [E(  -Y;  #/80  QF0  +]E  "Z8P( LV(/ *QC( "F8S !H&(] YMA
M2 :67U$*DEY9#8]<81&,6V@3B5IO%H99=AB$6'X:@E>''']7D!]]5ILA>U:G
M(GE6M2-W5L<D=E;D)'97]Q]W6/\;=UG_&7=9_Q=W6?\6=UG_%G=9_Q;_3
MZ58  -E?  #+90  P6@  +II  "T:   K6<- *9H' "@:"T!FF<Z Y5E10:0
M8TX*C&)7#8EA7A"&7V43@UYL%H!=<QA^7'L:>UR#'7E;C1]V6I@A=%JD(W):
MLB1Q6L0E;UKA)7!;]B!Q7/\<<5W_&G%=_QAQ7?\7<5W_%W%=_Q?]3P  Y5D
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M)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL5P  V6(  ,=K  "\<@
MLW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W.P1\=44'>'1-"G1R50YQ
M<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<(UQKJB5::[LF66S3)EIL
M[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@  TF8  ,-O  "X=@  KWL
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M&DM^_QE,?O\83'[_&$Q^_QC59P  PW,  +9\  "LA   HHD  )B+  "-C0
M?(T  '6.! !OCQ( ;9 A &F0+@%ECSD"8HY"!%Z.2P=;C5(*6(Q9#%:+80]3
MBV@24(IQ%$V)>Q=*B8<92(B5&T:(HQU$B+0=0XC*'4.'ZAQ$AOL:1(;_&$6&
M_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@  G(X  )*0  "&DP  >94
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M#2^E_PVVA   JHX  )Z4  "4F0  AYX  'NC  !OJ   8ZP  %>O  !+L@
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M !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0T?\!$-'_ 1#1_P&<F@
MD:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(   MS   )-   !S5   5
MV@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"  KF3P )YUT ".=M  ;F
M@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\  .;_  #F_P"3H0  A:D
M '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   AU@  &=L  !+?   -XP
M"_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R/P  \DP  /)<  #R;0
M\H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[  #T^P"'J0  >;(  &JZ
M  !<P@  3LD  $#.   STP  *-@  ![=   5X0  #^0   KH   %\P   _T!
M  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,   _3P  /Y)  #^6@  _FT
M /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_Y ![L@  ;+L  %W$  !/
MS0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T   #T    _P   /\   #_
M    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL  /\W  #_1@  _U@  /]K
M  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_&R8 _QPD /\:) #_%2<
M_Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\ @0#_ (H _P"2 /\ F@#_
M *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#? /\ [ #_ /@ _P#_ /T
M_P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R, _Q\A /\>(0#_&2, _Q,I
M /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_ X<!_P./ /\"E@#_ IP
M_P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\ Z@#\ /8 ^ #_ /<"_P#W
M _\ ]@3_ /8$_P#V!?\ ]@7_ /8%_P#_(A\ _R(< /\A' #_'A\ _Q@D /\5
M+P#_$CP _Q!) /\.5@'_#&(!_PMN ?\+>0'_"X(!_PN+ ?\+D@'_"ID!_PJ?
M /\*I0#_"JL _PJR /\*NP#]"L8 ^PK4 /<*YP#S"O0 \ K_ .\+_P#N#/\
M[0S_ >T,_P'M#/\![0S_ >T,_P'_)1L _R88 /\E%P#_(1@ _R A /\>*P#_
M&C< _Q=% /\440'_$EX!_Q%I ?\1= '_$7T!_Q"& ?T0C@'\$)4!^A"; ?D0
MH0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?( YA'^ >02_P'C$O\!XA+_
M >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_)Q, _R@< /\G)P#_(S,
M_R _ /\=3 #_&U@!_!ED ?@9;@'V&'@!\QB! ?$8B0'O&) ![AB7 >P8G@'J
M&*0!Z1BL ><8M 'F&+\!Y!C- > 9XP'<&O$!V!K^ M0;_P+2&_\"T1O_ M ;
M_P+0&_\"T!O_ M ;_P+_+1( _RX/ /\N#0#_+Q  _R\7 /\N(0#_+"T _RDY
M /DF1@#T)%,![R)> >LB:0'H(7,!YB%\ >,AA 'A(8P!X"&3 =XAF@'<(:$!
MVB&I =@AL0+5(;P"TR+) M BWP+,(_ #R"/] \8D_P/$)/\#PR3_ \(D_P/!
M)/\#P23_ \$D_P/_, \ _S(+ /\S" #_-@T _S82 /\U&@#],B4 ]# R .TM
M/P#G+$P XBM8 =TK8P'9*FT!U2IV M(J?P+0*H8"SBJ. \PJE0/**IP#R2JC
M!,<JK 3%*K8$PRK#!<(JU06^*^L%NBOY!K@L_P:V+/\%M2S_!;0L_P6T+/\%
MM"S_!;0L_P7_- P _S8% /\Y P#_/ @ _SP- /T[$P#Q.!T Z#4I . T-P#9
M,T8 T312 <TS70'),V<"QC-P \0R> 3!,H $OS*'!;XRCP:\,I8&NC&>![@Q
MI@>W,; (M3*\"+,RS FQ,N4)K3/U":LS_PFJ,_\(J#/_!Z@S_P>G,_\'IS/_
M!Z<S_P?_-P< _SH  /\^  #Z00$ \4$& /$_#0#F/!( VSH? - [,0#*/$
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M%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(1O\-B$;_#8A&_PW_0
M\D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0(@"L43( IU$_ J)02@.>
M3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)$HI)DA2(2)P5ADBH%H5(
MM1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.@$O_#H!+_P[_0P  [$L
M -U3  #.6   Q%H  +U:  "X5P$ L50. *I6'@"E5BX GU8[ 9M51@.75% %
MDU-8")!27PJ-468,BU!M#HA/=!"&3WP2A$Z%$X).CA6 39D7?DVD&'Q-LAEZ
M3<,:>4W?&GA.]!=X3_\4>$__$GA0_Q!X4/\/>%#_#WA0_P_]1@  YT\  -97
M  #(7   OU\  +=?  "Q7   JED, *1:&@">6RH F5LX 91:0P.064P%C%A5
M"(E77 J&5F,,@U5J#H%4<1!_4WD2?5.!%'I2BQ9X4I48=E&A&711KQMS4< ;
M<5';''%2\AEQ4_\5<53_$W)4_Q%R5/\0<E3_$')4_Q#S2   XU,  -!;  #$
M8   NF,  +-C  "L80  I%X) )U?%P"87R< DU\U 8Y>0 .*74H%AEQ2!X-;
M60J 6F ,?5EG#GM8;A!X6'42=E=^%'16B!=R5I,8;U:?&FY5K!ML5;T<:U;5
M'6M6\!IK5_\7:UC_%&Q8_Q)L6/\1;%C_$6Q8_Q'Q2P  WU8  ,Q>  # 9
MMV<  *YH  "G9@  GV(& )AC% "29"0 C6,R 8EB/0*$84<$@6!/!WU?5@EZ
M7ET+=UUD#75<:Q!S7',2<%M[%&Y;A1=L6I 9:EJ<&VA9JAQF6KH=95K1'65:
M[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@  VED  ,AA  "\9P  LVH
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M%E=H_Q189_\36&?_$UAG_Q/A6   RV,  +UK  "R<@  J78  *!X  "6=P
MB',  (%S"P!\=!< >'0F '1T,@%P<ST";7-&!&IR3@=G<54)9'!<"V%P8PY?
M;VH07&YS$EIN?!57;8@756R4&5-LHQM1;+,<4&S('$]LYQM1;/H846S_%5)L
M_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@  I7L  )Q\  "1?   @G@
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M$$" _Q#&:P  MW8  *Q_  "BA0  EXD  (R+  "!C0  <XX  &6/  !=CPD
M6I 4 %B0(0!6D2T 4Y X 5&000).D$D#3)!0!$J/6 5'CV '18YI"4*.<PM
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M!2VDEP8LI*D&*Z2]!BJDW@8JHO4'*:'_!RF@_P@IG_\(*9__""F?_PBQ@@
MI8L  )J1  "0E@  @YH  ':?  !JH@  7J8  %*I  !&JP  /*T  #6O#  S
ML!4 ,K A #&P*P OL#4 +K$^ "VQ2  LL5$ *[%; "FQ9P$GL70!)K&# 22Q
ME (CL:8"(K*[ B&RVP(AK_,#(*[_ R"M_P0?K/\$'ZS_!!^L_P2JBP  G9$
M ).7  "'G   >J(  &VG  !@JP  5:\  $FQ   ^M   ,[<  "JZ P DO T
M(KT5 "&](  AO2H (+TS !^^/0 >OD< ';Y2 !R_7@ :OVP &;]\ !B_C@ 7
MP*$ %L"V !3 TP 5OO$ %;S_ 16[_P$4NO\"%+K_ A2Z_P*AD@  EI@  (J>
M  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0  *L   "'$   9QP4 $\L+
M !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -SF  #,YP  O.@P *SI<
M"<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+_P"8F   C9X  '^E  !Q
MK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H  !?-   1T0  #-8%  C9
M#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(  -YB  #><P  WH@  -^=
M  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/GP  @:8  '.N  !EM0
M6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9   )W0   ^$   #C!P
MXPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2  #L8@  [78  .Z,  #N
MH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP  =:\  &>W  !9OP  2\8
M #S*   OS@  )-(  !K8   2W   #.    7C    YP   .L   #K    [04
M .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z40  ^V,  /QW  #]C0
M_:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D  %K!  !,R@  /,\  "[4
M   BV@  %]X  !#B   )Y@   .D   #L    \    /8   #V    ]P   /@
M  #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@  _T\  /]B  #_=P  _XT
M /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2(0#_#B0 _P8J /\ ,P#_
M $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/ /\ E@#_ )P _P"B /\
MJ #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /, _@#^ /T _P#\ /\ ^P#_
M /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_$"  _PHE /\$, #_ #T
M_P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_
M *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\ /0 _P#T /\ \P#_ /,
M_P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L _PXA /\,+ #_"3D _P5&
M /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_ )0 _@"; /P H0#Z *<
M^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L _P#J /\ Z@'_ .D!_P#I
M ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8= /\3* #_$#0 _PU! /\,
M3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y  ]@:6 /,&G0#Q!J, [P:J
M .T&L@#J!KL Z ;( .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\
MW S_ -P,_P#_(Q( _R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\
M$%4 ^ ]@ /0/:@#Q#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.
MKP#@#K@ W@[% -P.V@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_
M <H2_P'_)P\ _R<, /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\
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M!*XKQ 2L*]L$J"SO!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@
M_S,  /DX  #I.0  XCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V
M,UP!LS-E K S;0*N,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z R
MO@>?,M$'G#/J!YHS^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@
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M$7M$\0]Z1?\->D;_"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5
MO54  +94  "P4   J4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'
M2V$&A4MH"(-*;PF 2G<+?DE_#'Q)B0YZ2),/>$B?$'=(K!)U2+P2=$G2$W-)
M[A%R2O\/<DK_#7)*_PMR2O\+<DK_"G)*_PKR0@  X$P  ,Y3  #!6   N%H
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M#V%7_PYA5_\-85?_#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9
MD%X  (E>#@"$7QL @%\I 'Q?-0%X7S\"=%Y' W%=3P1O7%8%;%Q<!VI;8PEH
M6VL+9EIS#61:?0]B6H@17UF4$UY9HA1<6;(56UG&%EI9Y15;6OD26UK_$%Q:
M_PY<6O\-7%K_#5Q:_PWC3P  S5D  +YA  "S9@  J6D  *!J  "7:   BV(
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M#4UG_PW26@  P&0  +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\
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M9   MVX  *MV  "B?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %>
M( !5@"L 4X$V %& /@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ(
M"SU]EPP\?:<-.GVZ#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0
MLG0  *=\  "=@0  DH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-
MB28 2XDP $F).@!(B4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'
ME0DUAZ8*-(>Y"C.'TPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H
M **"  "7AP  C8H  (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\
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M !FKR@ 9JNP!&:C] 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0
M=9X  &BB  !<I@  4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7
MMR$ %K<J !6W-  4N#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VY
MQ  -N.< #K;[  ZU_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8
M %ZK  !2KP  1K(  #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14
M"<4>  C%*  'Q3( !L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@
MQM(  ,7O  #%_   Q?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T
M  !&N   .KL  "Z^   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6
M  #1'@  TB<  -,Q  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\
M -;@  #6\P  UOX  -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   Y
MP0  +<0  "+'   9RP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?
M%   X1P  .(D  #D+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%
M  #IX@  Z?(  .GU  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@
M(,X  !;2   /U@  "-L   #?    XP   .4   #G    Z $  .H'  #K#0
M[1$  .\8  #Q(0  \RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #Z
MP@  ^MH  /K?  #ZWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H
M  W?   %XP   .8   #I    [0   .\   #Q    \P   /4   #V @  ^ D
M /H.  #]$P  _QP  /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP
M_[D  /^\  #_O #_$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\
M60#_ &4 _P!P /\ >@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P
M /\ N #_ ,( _P#. /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\
M^@#_ /H _P#_%!P _Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_
M &$ _P!L /\ =@#_ '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L
MM #Y +T ^ #) /< W #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_
M /  _P#_%Q@ _Q46 /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P
M_P!G /\ <0#_ 'H _ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P
M +@ [@## .P TP#J .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4
M_P#_&A, _Q@1 /\4$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B
M /H ; #U '4 \@!] /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0
MX@"_ .  S0#> ., W #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_
M'A  _QP- /\7"P#_%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$
M9@#J!&\ Y@-W .0$?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[
M - &R0#.!^  S CQ ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P
M_R & /\< P#_'0H _QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=
M#6D V0UQ -4->0#3#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00
MR #"$-\ OA'R +L2_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,
M /\C  #_) , _R$* /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6,
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M Y0M]022+?\#D2W_ Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0
MS#P  ,<Y  ##,04 O2X1 +4P(0"P,C  JS,] *<S20"D,U( H3-: 9\S8@&<
M,VD"FC-P IDS=P*7,G\#E3*' Y,RD 22,IH$D#*E!8XRL06-,\(&BS/<!HDT
M\@:'-/\%AC3_!88T_P2%-/\$A33_!(4T_P3\,P  ZSH  -Q!  #-1   PT0
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M"&Q%_P=L1?\';$7_!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4
MF4H" )))$0"-2A\ B4LL (5,. ""2T(!?TM* 7Q*4@)Y2E@#=TI?!'5)9@5S
M26T&<4EV!V](?PAM2(H);$B6"VI(HPQH2+(-9TC%#69)Y UF2?@+9DG_"69*
M_PAF2?\'9DG_!V9)_P?H0P  TDT  ,)3  "W6   K5D  *18  "<50  DTX
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M"%95_PC;30  Q5<  +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q(
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M"DICEPM(8Z8,1V.X#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6
MNF(  *YI  "C;@  FG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!:
M:BT 6&LV %9K/P%5:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41I
ME0I#:*4+06FW#$!ISPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8
M *IM  "@<P  EG8  (MW  " =@  <'(  &5Q  !<< < 6' 1 %9P'0!4<2@
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M!2V!R 4M@>D$+7_\!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P
MB(8  'V'  !PB   8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  V
MC#4 -(P] #.,1@ RC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,
MQ@(EB^@")8K[ R6(_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP
M ':.  !ID   7)(  %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT
M*9<V "B8/P GF$@ )IA2 "687  CF&@ (IAW ""8AP ?F)D!'9BL 1R8PP$<
ME^4!')7Z 1N4_P$;D_\"&Y/_ AN3_P*G?P  G(8  )&+  "'CP  >I(  &V5
M  !AF   59L  $F=   ]G@  ,Y\  "JA   AHPH 'Z,1 !ZC&@ =I"0 '*0M
M !ND-@ :I#\ &:1* !BD50 6I6$ %:5P !2E@0 3I90 $J6H !&EOP 0I.(
M$:+X !&A_P 1H/\!$:#_ 1&@_P&@A@  E8P  (R1  !_E0  <9H  &2>  !8
MH0  3*0  $"F   UIP  *JD  "*L   9K@  $K ) !"Q$  0L1@ #K$B  ZQ
M*P -L34 #;%   RQ2P +L5@ "K%G  BQ>  'L8L !;&@  2PM0 $L-  !+#O
M  6O_@ &KO\ !J[_  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP
M0:T  #6O   KL0  (;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@
MOBL  +XV  "^00  OTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]
M]@  O?\  +W_  "]_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8
M "JX   @NP  %[X  !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(
M ,LK  #--0  SD$  ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP
MSO@  ,[^  #._@"(FP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["
M   5Q@  #LD   C,    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?
M  #>*   X#0  .)!  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H
M .7S  #E\P!\HP  ;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,
MT0  !-4   #:    W@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M
M&@  [R0  /(Q  #T00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??
M  #WWP!PK   8;0  %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP
M .(   #E    Z0   .P   #M    \    /$   #S    ]00  /<*  #Z$
M_!8  /\A  #_+@  _T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_
MOP#_#1P _PH; /\"&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M
M /\ =P#_ '\ _P"' /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T
M_P#) /X W0#] .T _ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_
M$!D _PT7 /\&%@#_ !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\
M<@#_ 'L _P"" /\ B0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@##
M /0 T@#S .< \@#V /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0
M_P\2 /\+$@#_ !( _P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[
M '8 ^0!] /< A #U (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@
MRP#G .$ Y0#Q ., _0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$.
M /\-#0#_!P\ _P(5 /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '
M[0!X .L ?P#I (4 Z ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6
M -D U #L -( ^0#1 /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/
M!0#_#@L _PP1 /\'&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R
M -X >0#; (  V0"& -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -
MQ0#H ,, ]@#! /\ P +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_
M$P4 _Q$- /\.% #Y"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%
M<P#*!7H R 6! ,8%AP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE
M +4+]P"S#?\ L0W_ + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@
M]18% /81#0#K#A4 X@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]
M#G0 NP][ +D/@@"W$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4
M]P"E%?\ HQ7_ *(5_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$
M -P9!0#;$ P T!$9 ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X
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M G\N_P)_+O\"?B[_ GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0
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M!&!$_P3@00  RDH  +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4
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M!E-0E@=24*4(4%"W"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P
MOU0  +):  "G7@  G6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B
M5"\ 8%0X %Y40 !<5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4
ME =-5*0(2U2U"$M4S E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<
M *Y>  "D8@  FF0  )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P
M6UDV %E9/@!7648 5EE- 5195 %265L"45EC T]9; --67<$2UB$!4E8D@=(
M6*('1UFS"$99R@A%6>H(1EG]!D98_P9&6/\%1UC_!4=8_P7'4@  N%L  *MA
M  "A9@  F&@  (YI  "#9P  <F   &A>  !A70D 7%T3 %I='@!772D 5EXS
M %1>.P!27D, 45Y* 4]>4@%.7ED"3%YA DI>:@-(7G4$1EZ"!41=D 9#7J '
M05ZQ!T!>R = 7N@'0%W\!D%=_P5!7?\%05S_!4%<_P7#5@  M%\  *AF  ">
M:@  E6T  (IM  !_;   ;V<  &1D  !;8@4 5F(0 %1B&P!28R4 4&,O $YD
M. !-9$  2V1( $ID3P%(9%<!1F1? D5D: )#9',#06-_!#]CC@4]8YX&/&.P
M!CMDQ@8[9.8&.V/Z!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P
MD7(  (9R  ![<0  ;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !'
M:CT 16M$ $1K3 !":U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35J
MQ 4U:N4%-6GY!#5I_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<
M ()W  !W=P  :70  %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@
M/G)  #UR2  [<E  .G)9 3AR8P$V<FT"-')Z C-RB0,Q<IH#+W*L RYRP0,N
M<N,#+G'X RYP_P,N;_\#+F__ RYO_P.S9@  IV\  )UV  "3>@  B'P  'Y]
M  !R?0  9'P  %=[  !,>@  0GD# #QY#@ Z>A< .7HA #AZ*@ W>S, -GL[
M #1[1  S>TP ,GM5 #![7P O>VH!+7MW 2M[AP$J>Y@"*'NJ B=[OP(F>^$"
M)GKW B9X_P(F>/\")W?_ B=W_P*N;   HW8  )E\  ".?P  A((  'B#  !L
MA   7X0  %&$  !'A   /(0  #.$"0 PA!$ +X0: "V$)  LA2T *X4U "J%
M/@ IA4< *(90 ">&6@ FAF8 )(9S ".&@P AAI4 ((:G 1Z&O $>AMX 'H3U
M 1Z"_P$>@O\!'H'_ 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP
M6(P  $R-  ! C@  -HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >
MD4  '9%) !R15  :D6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2.
M_P 4C?\ %(S_ 12,_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4
M $67   YF   +ID  "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC<
M$9Y! !">3  /GE@ #IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +
MFO\ "YG_  N9_P"<A   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@
M   PH0  )J,  !VE   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX
M  *J1  !JE   *I>  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\
M *?_  "G_P"5BP  C)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   F
MJP  ':T  !2P   .L@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X
M.0  N$8  +A4  "X9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_
M  "V_P"/D@  @I<  '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@
M$[@   V[   &O@   ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@
MR#H  ,E'  #)5P  R6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(
M_0"%F0  =Y\  &BF  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,
M  /'    R@   ,T   #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT
M -TY  #>20  WEH  -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !Y
MH0  :Z@  %RO  !.M0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3
M    V0   -P   #=    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK
M  #P.@  \4L  /%>  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@
M7K$  %"Y  !!OP  ,L0  "3(   7S   #M    ;5    V@   -X   #B
MY@   .D   #J    [    .X   #P    \@   /0&  #V#   ^1(  /P<  #_
M*0  _SH  /]-  #_8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7
M /\ %P#_ !H _P A /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L
M_P"# /\ B@#_ )  _P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\
M .H ^P#X /H _P#Y /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\
M$P#_ !0 _P : /\ )P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^
M /\ A0#^ (L _0"1 /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q .,
M[P#S .X _P#M /\ [ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_
M !  _P 6 /\ (@#_ "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0
M?P#S (8 \0", .\ D@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M
M -\ ^P#> /\ W0#_ -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P
M_P 2 /\ '0#_ "D ^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E
M (  XP"& .$ C #? ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P
M]@#* /\ R@#_ ,D _P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P .
M /\ %@#W "( [P P .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H
MT "  ,X AP#, (T R@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[
M /X N0#_ +@ _P"X /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!
M$ #H !H XP H -T -@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z
M +\ @0"] (@ NP"/ +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L
MJP7_ *H&_P"I!O\ J0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #=
M Q( U ,@ ,T$+0#(!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(
M>P"O"(( K@F* *P)D@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_
M )P/_P";#_\ FP__ )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L
MQPL6 , -)0"Z#C( M@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B
M$7T H1&% )\2C@"=$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7
M_P".%_\ CA?_ (X7_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0
M +(5'@"M%BP J!<X *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W<
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M 6XO_P'H,0  TSH  ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP
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M EX]E@-=/J4#6SZV!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P
MPT<  +5,  "J4   H%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K
M03( :4$[ &=!0@!E04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"
ME -70J,$54.S!%1#R0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH
M +)0  "G4P  G50  )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X
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M!$5/PP1$4.0$1$_Y!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@
ME6   (M@  " 7@  <E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/
M4C\ 3E)& $U330!,4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4
MP00_5.($/U3X T!3_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4
M (AE  !]8@  ;EP  &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP
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M BYC_P(O8_\"+V+_ B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@
M9'   %AN  !-;   0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S
M;$D ,FQ2 #%L7  O;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J
M_P$G:O\!*&G_ BAI_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<
M %-V  !(=0  /G,  #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0
M*71- "AU5P G=6, )75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?
M<O\!(''_ 2!Q_P&I:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^
M  !#?@  .'T  "]] @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W](
M !Y_4@ =?UX '']K !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\
M%GO_ !=[_P"D<@  FGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \
MB   ,H@  "B(   @B 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*
M3  2BU@ $8ME !"+=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_
M  Z&_P"?>P  E($  (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@
M*I(  "&3   9E   $I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (
MEU  !I=>  67;@ #EH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2
M_P"8@@  CH@  (6,  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT
M !F>   2H   #:("  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@
M *16  "D90  HW<  *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1
MB@  B8X  'N2  !MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J
M   ,K   !:X   "O!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),
M  "R6P  LFP  +*!  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D
M?Y4  '&:  !CGP  5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "
MN    +L   "[    O <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##
M3P  PV   ,-T  ##BP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT
M &6C  !7J   2:T  #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0
M ,<   #(    R0   ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800
MV%,  -EF  #9?   V90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL
M  !+L@  /+<  "ZZ   AO0  %<    W$   %QP   ,H   #.    T@   -4
M  #6    V0   -L   #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,
M .Y6  #O:P  [X0  .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^
MO   +\   "#$   4R   #,P   +0    U    -D   #>    X@   .4   #F
M    Z    .D   #L    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&
M  #_6@  _W$  /^)  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !<
M_P = /\ * #_ #< _P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_
M (L _P"1 /\ EP#_ )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@
M_P#W /\ ]P#_ /< _P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7
M /\ ) #_ #( _P _ /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8
M^@", /D D@#X )@ ]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J
M /\ Z0#_ .D _P#G /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\
M'P#_ "P _P Z /\ 1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"'
M .P C0#J ), Z0": .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\
MUP#_ -4 _P#5 /\ U0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[
M "8 ]P T /0 0 #R $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P
MAP#: (T U@"4 -0 FP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_
M ,, _P## /\ PP#_ ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\
MZ@ M .8 .@#B $4 W@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#&
M (< Q ". ,( E@#  )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +(
M_P"R /\ L0#_ +$ _P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E
M -, ,@#. #X R@!) ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($
MM "( +( D "P )D K@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B
M /\ H@#_ *( _P#_$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0
M*@"_ #< NP!" +< 2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"#
M *0 BP"B )0 H "> )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\
ME G_ )0)_P#\$0  \14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R
M!BX K@@Z *H)1 "G"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,
MA@"6#)  E R: )(-I@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_
M (<1_P#V&0  YR   -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R<
MH1 S )T1/@":$4< F!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")
M%(L AQ26 (85H@"$%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9
M_P#O(0  W2D  ,HM  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM
M )$:. ".&D$ BQM) (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88
M?!Z1 'H>G@!X'ZL =Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H
M*   TC   ,(U  "W-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B
M,@"#(SP @2-$ 'XC2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:-
M &\FF0!N)J< ;2>X &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@
MRS8  +P[  "Q/0  IST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y
M*C< =RH_ '4J1P!S*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8M
ME@%E+:0!9"ZT 6,NR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P
M +=!  "L0P  HD,  )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#,
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M DX^P0)-/N$"33[X DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4
MEU$  (Y/  "$2P  >44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7
M/D  53]& %0_30!3/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"
MO@)(0MX"2$+V DA"_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50
M (M3  " 4   =4H  &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT
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M 3E._P$Y3O\!.4W_ 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@
M:5@  %]6  !44@  3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _
M44P /E)4 #Q270 [4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313
M_P$T4O\!-%+_ 312_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX
M %Q<  !16   1U4' $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD
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M 2%C_P&I8@  GFH  )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P
M.FX  #!M P I; T )VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >
M;EL '6YG !QN=@ :;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK
M_P"D:0  FG$  )!V  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@
M "MW   B=@< '78/ !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8
M$WAC !)X<@ 1>(, $'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?
M<0  E7@  (M\  ""?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"
M   <@@  %(() !&#$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=
M  F#;  (@WX !H.1  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0
MD'X  (:#  !]A0  ;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5
MC@  #X\#  J0#  &D!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/
M90  CW8  (^*  ".GP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4
M (*)  !TC   9H\  %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@
M"IL   *<"0  G X  )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7
MG6X  )R!  "<EP  G*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0
M  !JE   7)<  $^:  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@
M  "I!   J0H  *D.  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,
M *QW  "KC@  JZ0  *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?
MG   4:   $2D   VI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U
M    M0,  +8)  "W#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK
M  "]@0  O9D  +VP  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0
M1JH  #BM   JKP  'K$  !.T   ,MP   [D   "\    OP   ,(   #"
MPP   ,0   #&!@  QPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2
M<P  THL  -*D  #3NP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,
M "JV   =N0  $KP   J_    PP   ,8   #)    S0   ,\   #0    T@
M -0   #6    V0(  -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9
MZGP  .N5  #KK   Z\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W
M   1Q   "<@   #,    SP   -,   #9    W0   .    #A    XP   .4
M  #G    Z@   .P   #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH
M /^#  #_FP  _ZX  /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_
M #0 _P!! /\ 30#_ %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\
MDP#_XGT024-#7U!23T9)3$4 $!+_ )D _P"@ /\ IP#^ *\ _ "Z /H R0#Y
M .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_ .$ _P#_  \ _P - /\
M#0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %, _P!= /\ 9@#^ &T _ !U
M /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q *H [P"T .T P0#K -4
MZ@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0 _P#_  L _P ( /\ !@#_
M  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7 /0 8 #R &@ [P!O .T
M=@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0 WP"N -T N0#: ,H UP#D
M -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_  , _P   /\   #_  0
M_P - /H %@#V ", \P P /  / #M $< Z0!1 .4 6@#B &( WP!I -T ;P#:
M '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H ,< LP#% ,$ P@#8 ,
M[P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @  _P   /\   #_    ]  '
M .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #- %P R@!C ,@ :0#& &\
MPP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4 K "S +D L0#+ *\ YP"N
M /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P   /8   #N    YP   -\
M# #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4 N0!< +< 8P"U &D LP!O
M +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C +, H0## )\ W@"> /(
MG0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+  #?"@  U00  ,X !0#&
M !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6 *@ 7 "F &, I !H *(
M;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X DP"] )$ TP"0 .T CP#\
M (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-%0  Q!$  +X,  "Z @H
MM  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"5@"9 EP EP-C )4#:0"3
M V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z (4(SP"$"NL @@O\ ($,
M_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0  N!T  +$7  "L$   J D-
M *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",#5< B@U= (@-8P"'#6H
MA0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0S@!X$>P =A+_ '42_P!T
M$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@  *<C  "@'   FQ,# )8/
M$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$ ?A17 'P47@![%64 >15L
M '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M&>@ :QK\ &H;_P!J&_\
M:AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L  "7)@  D!\  (H7# "%
M&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3 '$=60!P'6  ;AUG &T>
M< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0 8B+Z &$B_P!A(O\ 82+_
M &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0+P  B"@  ( A" ![(!(
M=R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D50!F)%L 921C &,E:P!B
M)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW %DI_P!9*?\ 62G_ %DH
M_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@  @3   'DJ P!R)@\ ;B<9
M &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>*E< 72I? %PK: !:*W(
M62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O_P!2+O\ 4B[_ %(N_P#*
M-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<  '(Q  !K+ P 9RT5 &0M
M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0 5C!< %4P9 !3,6X 4C%Z
M %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,-/\ 3#/_ $PS_P#&.@
MMD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW  !D,@D 8#(2 %TR' !:
M,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19 $\U80!--6P 3#9W $LV
MA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\ 1CC_ $8W_P#!/@  LD4
M *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?-P8 6C80 %<W& !4-R(
M4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY7P!(.FD 1SIU $4[@P!$
M.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_ 4$\_P"^0@  KTD  *-.
M  "94   CU$  (50  ![3   ;T8  &5"  !:/0( 5#L. %$[%0!/.Q\ 33LG
M $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#/F< 0C]S $ _@0 _/Y$
M/D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T__P&Z10  K$P  *%1  "7
M5   C54  (-4  !X40  ;$L  &%'  !60@  3T , $P_$P!)0!P 1T D $9
M+ !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4 /4-Q #M#?P Z1(\ .42@
M #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W20  J5   )Y5  "46
MBUD  (!8  !V5@  :%   %U,  !32   2D4) $9$$0!$1!D 0D0B $%%*0 _
M13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN #9(?  U2(T -$F> #-)
ML0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3   IU0  )Q9  "27   B%T
M 'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^218 /4D> #M*)@ Z2BX
M.4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%->@ P38L +DV< "U.KP L
M3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@  )E=  "/80  AF(  'MA
M  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q, -D\; #5/(P T4"L ,U R
M #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I4H@ *%.: "=3K0 F4\4
M)E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B  "-9@  @V<  'AF  !M
M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87 "Y6'P M5B< +%8O "M7
M-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688 (5F8 "!9JP ?6<( 'UGE
M !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*:P  ?VP  '5L  !J:P
M76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=&P E7B, )%XJ "->,@ B
M7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5 !A@J0 78,  %F#B !=?
M^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<   ?'(  ')R  !F<0  6&X
M $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <9AT &V8E !IF+0 99S4
M&&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!HI@ /:+T #FC@ !!G]P 0
M9O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@  &UX  !@=P  4W8  $9T
M   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!< $G ? !%Q)P 0<2\ $'$X
M  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &<;8 !G#2  =P[P (;_\
M"6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^  !9?@  37X  $!]   U
M?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9  A\(0 '?"D !GPR  1\
M/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$  'K+  !YZP  >?H  'G_
M  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1A@  18<  #F'   MAP
M(X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(&P  B",  (DL  ")-@
MB4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$  "%Y@  A/@  (3_  "$
M_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP  /)$  #"1   DD0  &I(
M !*3   -E   !I4   "6!@  E@P  )40  "6%0  EAT  )8D  "6+@  ECD
M )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3WP  D_4  )+_  "2_P"+
MA@  @XH  '6-  !GD   690  $R7   _F0  ,IH  ":;   ;G   $IT   R?
M   $H    *(   "C 0  HP<  *,,  "C$   I!4  *0<  "E)0  IB\  *8\
M  "F2P  IEL  *9N  "EA   I9L  *2S  "CT   H^\  *+\  "B_P"&C0
M>)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE   1IP  "JD   &K
MK0   *\   "P    L    + %  "Q"P  L@\  +,4  "T&P  M20  +<P  "W
M/P  MU   +=B  "W>   MY   +:I  "VP@  MN0  +;U  "U_@![DP  ;9@
M %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )L@   +0   "W    N@
M +P   "]    O@   +X   #  @  P0@  ,(-  #$$@  QAD  ,DD  #*,@
MRT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI  #,]@!PFP  8:$  %*F
M  !$JP  -K   ">R   :M0  $+@   >[    O@   ,$   #$    R    ,L
M  #+    S0   ,X   #0    T@   -4#  #8"@  VQ   -X8  #B)   XS4
M .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #GYP!CI   5:H  $:P   X
MM0  *+D  !J\   /P   !<0   #'    RP   ,\   #4    V    -P   #=
M    WP   .$   #C    Y0   .@   #J    [08  /$.  #U%@  ^"4  /DX
M  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_  \ _P . /\ #@#_ !
M_P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\ 9@#_ &X _P!V /\ ? #_
M (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U /D PP#W -L ]@#P /0
M_P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P _P ) /\ " #_  H _P 2
M /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\ &D ^@!P /@ =P#W 'T
M]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H O #H ,T Y@#H .0 ^@#C
M /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P ! /\   #_  0 _P . /\
M&0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &, [ !J .H <0#H '< Y@!]
M .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3 ,0 T #> ,X \P#, /\
MRP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\   #_    ^P + /8 $P#Q
M "  [0 L .H . #G $, XP!- .  5@#< %T V0!D -4 :P#2 '$ T !V ,X
M? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L O0#/ +L ZP"Y /P MP#_
M +< _P"V /\ M #_ +$ _P#_    _P   /\   #V    [@ % .< #P#A !D
MVP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$ 9 "_ &H O0!P +L =@"Y
M 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#% *D X0"G /4 I@#_ *4
M_P"D /\ I #_ *0 _P#_    _    /$   #H    X    -0 "P#, !, QP ?
M ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N &0 K !I *L ;P"I '4
MIP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@ T@"7 .X E0#^ )0 _P"5
M /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S    ,4 ! "^  X N  7 +,
M(P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T G0!C )L :0": &\ F !V
M )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"( .< AP#Y (< _P"& /\
MA@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(  "Q  @ JP 1 *8 &P"A
M "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!= (X 8P", &D B@!P (@
M=P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$ >@/U 'H%_P!Y!?\ > ;_
M '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D#0  GP4, )D % "5 !\
MD0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'70!_!V, ?0AJ 'L(<@!Z
M"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV &X._P!M#O\ ;0[_ &T.
M_P#A'   RR,  +PF  "Q)@  J"0  * >  "9&   DQ " (X+#@"("Q< A PB
M ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S#UX <1!E ' 0;@!N$'<
M;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4_P!C%/\ 8A3_ &(4_P#6
M)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L  ((3" !]$1( >1(< '83
M)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED 9Q9A &46:0!D%W( 8A=^
M &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9'/\ 61S_ %D<_P#-*@
MO3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D= P!S& X ;QD8 &P:(@!I
M&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U< %P>9 !;'FX 61]Y %@?
MAP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\ 4B+_ %(B_P#(+P  N#8
M *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J( P 9B 3 &,A'0!A(28
M7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D80!3)&H 425V % E@P!/
M)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_ $LH_P##-   LSL  *<_
M  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@ 7B81 %PF&0!9)R( 5R<K
M %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,*F< 2RIS $DK@ !(*Y
M1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M_P"^.   L#\  *1#  "9
M10  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L. %4K%@!2+!\ 4"PG $\L
M+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0 12]P $,P?@!",(T 03&>
M $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[/   K4,  *%'  "620
MC$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P$P!,,!P 2C D $DQ*P!'
M,3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M #XT>P ]-8L /#:< #LV
MKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0   JD8  )Y+  "430  BDX
M (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'-1D 134A $,U* !!-2\
M0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY>0 X.8D -SJ; #4ZK0 U
M.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH  )Q.  "240  B%(  'Y0
M  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18 /SD> #XY)@ \.2T .SHT
M #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S/H< ,3Z9 # _JP O/\(
M+S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2  "/50  AE8  'Q5  !Q
M4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX; #D^(P W/BH -C\Q #4_
M.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4 +$.7 "M#J@ J0\  *43B
M "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-60  @UH  'E:  !N5P
M85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#(  R1"< ,40O #!$-@ O
M13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5 "5(J  D2+X (TC@ "1(
M]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@  @5\  '=>  !K7   7U@
M %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L220 *THK "I*,P H2CL
M)TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-I@ >3;L '4[= !Y-]@ >
M3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0  '1C  !I80  7%X  %);
M  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"  )% H "-0+P B43< (5%
M "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  64[D %5/9 !93]  74O\
M&%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I  !F9P  660  $UA  !"
M7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C !M8*P :6#, &5@\ !A8
M10 665  %5E; !19:0 36GH $EJ- !%:H0 06K< #EK5 !!9\P 06?\ $5C_
M !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B;0  56H  $AH   ^9@
M,V4  "EC   @80$ && + !5@$  48!< $V > !)@)@ 28"X $6$W !!A0  /
M84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+  AAZP )8/T "E__  M?
M_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P  3W(  $-P   X;P  +6X
M "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *:BD "6HR  AJ/  ':T<
M!6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !IYP  :?@  &C_  !H_P"7
M;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H  #UY   Q>   )W<  !UV
M   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0  '4L  !U-@  =4$  '5.
M  !U7   =6P  '5^  !TDP  =*@  '/   !SXP  <O<  '+_  !Q_P"2=0
MB7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#   I@@  'X$  !:!   0
M@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F  ""+P  @CL  ()'  ""
M50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0  'W_  !]_P"-?   A($
M 'N$  !NA@  8(@  %**  !%BP  .8P  "R,   AC   %XP  !"-   )C@
M H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0*   D#(  ) _  "030
MD%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^  "+_P"(A   @(@  '*+
M  !DC0  5I   $B3   [E0  +I8  "*6   7EP  #Y@   B9    FP   )T
M  "=    G0,  )T)  "=#0  GA$  )X7  "?'P  GRD  * U  "@0P  H%0
M *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<_P"#BP  =8X  &>2  !9
ME@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0   "F    J    *H   "J
M    J@   *L!  "K!P  K P  *T0  "N%@  KQX  +$I  "Q.   L4@  +%:
M  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!XD0  :I8  %R:  !-GP
M/Z,  #&F   CIP  %ZD   ZK   %K@   +    "R    M0   +<   "W
MN    +D   "Z    O ,  +T)  "^#@  P!0  ,,>  #%*P  Q3P  ,9.  #&
M8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0  7IX  $^D  !!J   ,JP
M "2O   6L0  #;0   .W    N@   +T   #     Q    ,8   #&    R
M ,D   #+    S    ,X   #0!@  TPT  -@3  #<'@  WBT  -]   #@5
MX6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<  $.M   TL@  );4  !>Y
M   -O    ;\   ##    QP   ,H   #/    TP   -8   #7    V@   -P
M  #?    X0   .,   #F    Z0$  .P+  #P$@  \Q\  /0Q  #V1@  ]UP
M /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\ "P#_  X _P 3 /\ 'P#_
M "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q /\ =P#_ 'X _P"$ /X
MB@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -( \P#L /$ _@#P /\ \ #_
M .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_  8 _P 0 /\ &P#_ "<
M_P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4 <@#S '@ \@!^ /  A #O
M (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C .  ]P#> /\ W0#_ -D
M_P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $ _P - /\ %@#\ "( ^0 N
M /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B '( X !W -\ ?@#= (0
MVP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D [P#' /\ Q0#_ ,0 _P"^
M /\ N #_ +4 _P#_    _P   /\   #^    ]P ) /$ $0#K !P YP H .0
M,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L R@!Q ,@ =P#& 'T Q "$
M ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S /H L0#_ +  _P"P /\
MK #_ *D _P#_    _P   /H   #Q    Z  # .  #0#8 !8 T0 B ,T +0#*
M #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J +4 < "S '8 L0!] *\
MA0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /( GP#_ )X _P"> /\ G@#_
M )P _P#_    ]P   .L   #A    U@   ,L "0#% !$ OP ; +L )@"W #$
MM  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0 :0"B '  H !V )X ?@"<
M (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\ (X _P"- /\ C #_ (T
M_P#X    Z0(  -L#  #, 0  Q    +T  @"V  T L  5 *L ( "G "H I  T
M *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3 &D D0!P (\ =P"- (
MBP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\ _P!_ /\ ?P#_ '\ _P#N
M"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0 )X & "9 ", E@ L ),
M-0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &, @P!J ($ <0!_ 'H ?0"$
M 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R /\ <0#_ '$ _P#C$0
MS1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$ $@"- !L B0 E (4 +P"#
M #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D '0!:P!R 70 < )_ &X"
MBP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\ 90G_ &4)_P#6&@  Q"
M +8C  "K(P  H2   )D;  "2%   C X! (8'#0" !!0 ? 8> 'D'* !V"#
M= @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+9P!G"W  90QZ &,,AP!B
M#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_ %L0_P#-(0  O"@  *\K
M  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\ <0T7 &X.(0!K#BH :0\R
M &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<$6L 6Q%V %D2@P!8$I(
M5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5_P#&*   MBX  *DR  "?
M,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3 &04' !A%"4 7Q4M %T5
M- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V< 4AAR % 8?P!/&8X 3AJ?
M $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!+0  L30  *4W  ":.
MD#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:& !9&R$ 5QLI %4;, !4
M'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN $D?? !''XL 1B"< $4A
MK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@  K3@  *$\  "7/@  C3T
M (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1(!T 3R$E $XA+ !,(3,
M2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D>0!!)8@ /R:9 #XFJP ]
M)\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT  )Y   "40@  BD(  ( _
M  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D 224A $<F* !%)B\ 1"8V
M $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [*H8 .2N7 #@KJ0 W++\
M-RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$  "11@  AT8  'U$  !S
M0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH> $$J)0 _*BP /BLS #TK
M.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X, -"^5 #,PIP R,+T ,3'>
M #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/2@  A4H  'M)  !P10
M94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN(@ Y+RD ."\O #<O-@ V
M,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23 "XTI@ L-;L +#7; "PU
M]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@  @TX  'E-  !N2@  8D4
M %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T,R8 ,S,M #(T-  Q-#P
M,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@XI  G.;D )CG8 "<Y]  H
M.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,  '=2  !L3P  7TD  %9&
M  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0 +C@K "TY,@ L.3D *SI!
M "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B/;< (3[4 "$^\P B/?\
M(SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56  !J4P  74\  %-,  !*
M2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH "@^+P G/C< )C\_ "0_
M2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4 &T+1 !M"\0 <0O\ '4'_
M !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G6   6U0  %%2  !(3@
M/4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$+  A1#0 ($4\ !Y%10 =
M14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C. !5'[P 61_\ %T;_ !=&
M_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@  65H  $]8  !$5   .5$
M "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :2S  &4LX !=+0@ 63$P
M%4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-[@ 03?\ $4S_ !%,_P">
M5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$  $I>   _6P  -5@  "M6
M   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP $5(T !%2/@ 04T@ #U-4
M  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *4_L "U+_  M2_P";70
MD60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D   Z8@  ,&   "9>   =
M70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP  I;.@ )6T4 !UM1  9;
M7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8  5K_  )9_P"79   CFL
M (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U:P  *FD  "%G   89@
M$68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D-0  9$   &1,  !D6@
M9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_  !A_P"3;   B7$  (!U
M  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=   (W(  !IQ   2<0  #7$
M  9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,   ;SL  &]'  !O5   ;V0
M &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K_P".<P  A7@  'U[  !S
M?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P  !-\   -?   !GT   !]
M!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0  'M   ![3@  >UX  'MO
M  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")>@  @7\  'B"  !K@P
M784  $^&  !"AP  -8@  "F'   =AP  %(<   V(   &B0   (H   "*
MB08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX  "*1@  B58  (EH  ")
M?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@  ?88  &^(  !ABP  4XT
M $6/   XD0  *Y$  !^2   4D@  #9,   24    E@   )<   "8    EP
M )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":/0  F4T  )E>  "9<P
MF(L  )BC  "7O   EN(  );W  "5_P" B0  <HP  &2/  !6DP  2)8  #J9
M   LF@  'YL  !2<   ,G@   Y\   "A    HP   *4   "E    I0   *4
M  "F @  IP@  *<-  "H$0  J1D  *LC  "K,0  JT$  *Q3  "L9P  JX
M *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8  !*G   /)\  "VB   @
MHP  $Z4   NG   !J0   *L   "N    L0   +(   "R    LP   +0   "U
M    M@   +@$  "Y"P  NQ   +T8  "_)   OS4  ,!'  # 6P  P'(  ,"-
M  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^I0  +ZD  "&K   3K0
M"[    "S    M0   +@   "\    OP   ,$   #!    PP   ,0   #&
MQP   ,D   #+    S@@  -$/  #5&   V"<  -DY  #:30  VV0  -M^  #<
MF0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP  (K(  !2U   *N    +L
M  "_    PP   ,8   #+    S@   -$   #1    U    -8   #9    VP
M -X   #@    Y    .<&  #K#@  [QD  / J  #R/P  \U4  /1M  #TB
M]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1 /\ ' #_ "@ _P T /\
M00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@ _ !^ /L A #Z (L ^0"2
M /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M /\ [ #_ .$ _P#2 /\
MR0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\ %P#_ ", _P O /\ .P#]
M $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X .P ?@#J (4 Z0", .<
MDP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\ U@#_ ,\ _P#$ /\ O0#_
M +D _P#_    _P   /\   #_    _P + /P $P#W !X ]  J /( -0#N $
MZ0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -< > #4 'X T@"% -  C0#.
M )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_ +X _P"V /\ L #_ *T
M_P#_    _P   /\   #Y    \@ & .L #P#F !D X0 D -X +P#: #D TP!#
M ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_ '< O0!^ +L A@"Y (X
MMP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H _P"H /\ HP#_ *  _P#_
M    _P   /4   #K    X0   -8 # #/ !, R@ > ,8 *0#" #, OP ] +L
M10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '  JP!W *D ?P"G (< I0"1
M *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6 /\ E@#_ ), _P#]
M\0   .4   #9    S0   ,0 !@"]  \ MP 8 +, (@"P "P K0 V *D /@"G
M $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P )@ =P"6 (  E "* )$
ME0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\ A@#_ (8 _P#S    XP
M -$   #%    O0   +8   "N  L J  2 *0 ' "@ "8 G  O )H -P"7 #\
ME0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@ <0"& 'D A "# (( CP!_
M )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_ '< _P#G!P  T0P  ,,-
M  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\ C@ H (L ,0"( #D A@!
M (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X ', =@!] '0 B !Q )4
M< "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H _P#:$   QA0  +@6  "M
M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A 'X *@![ #( >0 Y '<
M0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X :0!W &< @P!E )$ 8P"?
M &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.&   O1T  + @  "E'P
MFQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '( (P!O "L ;0$S &L!.@!I
M D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S %P&?P!:!HT 60>< %<(
MK0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P  MB4  *DH  ">*   E"4
M (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D"B4 8@HM & +- !>"SH
M70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(->P!0#HH 3PZ: $X.K !,
M#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L  *0O  "9+P  CRT  (8I
M  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\ 6! G %80+@!4$#4 4Q [
M %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !($X< 1A.7 $44J0!$%+X
M0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T  "5-0  BS0  ($Q  !X
M*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C $X5*@!,%3$ 2Q8W $D6
M/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8, /QJ4 #T:I@ \&[L .QO;
M #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1.P  ASH  'XW  !S,@
M:BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:)@!%&RT 0QLS $(;.@!!
M'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2 #<@I  V(+@ -2'6 #4A
M]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P  A3\  'L\  !P.   9S(
M %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^("D /2 P #L@-@ Z(3T
M.2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$EH@ O);8 +R;2 "\F\@ O
M)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,  'A!  !N/0  8S@  %HS
M  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8 -B0L #4E,P T)3H ,R9"
M #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J*K0 *2K/ "DK\  J*_\
M*BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%  !L0@  83T  %<X  !.
M,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I "\I,  O*C< +BH_ "TK
M2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K, )"_- "0O[@ E+_\ )2__
M "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J1P  7D(  %0]  !+.0
M030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN+@ I+C4 *2\] "@O1@ G
M,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+ !XS[0 ?,_\ (#/_ "$R
M_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3   7$8  %)#  !)/P  /SL
M #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D,S( (S0Z "(T0P A-4T
M(#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DXZP :./\ &S?_ !LW_P"C
M1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP  %!)  !'10  /4$  #,]
M   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#  'CDX !TY00 <.DL &CI6
M !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4//T %3S_ !8[_P"@2P
ME5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/  !%2P  .D<  #!#   G
M0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U !8_/@ 5/T@ %$!3 !-
M8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P $$'_ !! _P"=4   DU8
M (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!40  -DX  "Q+   C2
M&T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%.P 01D4 #T90  Y'7@ -
M1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_  M&_P":50  D%L  (=@
M  !]8@  <V,  &IB  !@80  4UX  $=:   \5P  ,E4  "A2   ?4   %TX$
M !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *34( "4U-  =.6@ &3FD
M!$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),_P"66P  C6(  (1F  !Z
M:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P  "-:   :6   $E<!  U6
M"0 )50X !U43  95&@ $52(  U4J  )5-   53X  %5*  !65P  5F4  %5W
M  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"38@  BF@  (!L  !W;@
M;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC   58@  #F$   E@"  #
M8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%  !?4P  7V$  %YR  !>
MAP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@  AF\  'UR  !U=   :G4
M %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0;   "FP   )K!@  :PL
M &H/  !J%   :AH  &HA  !I*@  :30  &E   !I3@  :5P  &EM  !H@@
M:)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8  'IY  !P>P  8GL  %5[
M  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P   W<   !W @  =P@  '8-
M  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P  =58  '5H  !T?   =)(
M '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_  !H@0  6H(  $R"   _
M@P  ,H0  "6#   :@P  $8,   J#   "@P   (0   "%    A ,  (,(  "#
M#0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\  (-@  ""=0  @HP  (&D
M  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>B   4(H  $*+   UC0
M)XT  !N-   1C@  "HX   "/    D0   )(   "2    D@   )(!  "2!P
MD@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7  "3:P  DX(  )*<  "1
MM@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D   19,  #>5   IE@  ')<
M !&8   )F0   )L   "<    G@   *    "@    H    *    "A    H00
M *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E8   I7@  *62  "DK
MI,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P  "J>   =H   $:$   BC
M    I0   *<   "I    K    *X   "N    K@   *\   "P    L0   +(
M  "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5   NVH  +J%  "YH0  N;L
M +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH   1J@  !ZP   "O
ML0   +0   "X    NP   +P   "\    O@   +\   #     P@   ,0   #&
M    R ,  ,L+  #/$@  T2   -$R  #21@  TUT  -1V  #4D@  U:L  -7$
M  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   'M0   +@   "[    O@
M ,(   #'    R@   ,P   #,    S@   -    #2    U0   -@   #;
MWP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G  #P@@  \)P  /"R  #Q
MQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0 _P P /\ / #_ $< _P!1
M /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V (4 ]0", /, E #R )T
M\ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D _P#+ /\ P@#_ +T _P#_
M    _P   /\   #_    _P , /\ % #_ "  _P K /X -P#Z $( ]@!+ /(
M4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\ XP"& .$ C@#? )8 W0"@
M -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"] /\ M@#_ +( _P#_
M_P   /\   #_    _0 ( /< $ #S !H [P F .T ,0#H #L XP!% .  30#<
M %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_ ,D AP#' )  Q0": ,,
MI0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\ J0#_ *4 _P#_    _P
M /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0 #4 RP ^ ,@ 1P#% $X
MP@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4 @ "S (@ L0"2 *X G@"L
M *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_ )@ _P#_    ^P   /
M  #E    V    ,X "0#' !$ P@ : +X ) "[ "X MP X +0 0 "Q $@ K@!.
M *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@ ($ G@"+ )P E@"9 *,
MEP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L _P#Y    ZP   -T   #/
M    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q *( .0"? $$ G0!( )L
M3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H C "# (H CP"( )P A@"J
M (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L    V@   ,D   "^
MM@   *X   "G  D H0 0 )P & "8 "( E0 J )( ,@"0 #H C0!! (L 1P")
M $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!] 'L B !X )4 =@"C '4
MM !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0  R@H  +P+  "Q"0  J 0
M *$   ";  , E  , (\ $P"* !L AP D (0 + "! #, ?P Z 'T 00![ $<
M>0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P @@!J (\ :0"= &< K@!E
M ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(  +(3  "G$@  G1   )4+
M  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T <0 T &\ .@!N $  ; !&
M &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !> (D 7 "8 %L J0!9 +P
M6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=  "?'   E1D  (T4  "%
M#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N &0 - !B #L 8 !  %\
M1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4 4@"4 % !I0!/ ;@ 3@+2
M $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9)0  CR(  (4=  !]&
M=1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$+P!7!34 5@4[ %0&00!3
M!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2 $<*HP!%"K8 1 O0 $0,
M[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+   BBH  ( F  !W(0  ;AL
M &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-#"\ 3 PV $L-/ !)#4(
M2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0H@ \$+8 .Q#1 #L1\0 [
M$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$  'PM  !R*   :2,  &$=
M  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L 0Q$Q $(1-P!!$3X 0!%%
M #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U%;, -!7- #,6[@ T%O\
M-!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T  !N+@  92H  %PD  !4
M'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M #L5-  Y%CH .!9" #<6
M2@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$ +1O* "T;[  M'/\ +AO_
M "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K-   8B\  %DJ  !0)0
M1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:,  S&C< ,AL^ #$;1P O
M'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#' "8@Z@ G(/X *"#_ "@@
M_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@  7S4  %8P  !-*P  1"4
M #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M'S0 +" [ "L@1  J(4X
M*2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$EZ  B)?T (B3_ ",D_P"F
M.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H  %,V  !*,0  02P  #@F
M P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$ )B0Y "4E00 D)4L (R96
M "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <*?L '2G_ !XH_P"C/@
MF$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[  !'-P  /C(  #4M   L
M* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV " I/P ?*DD 'BI4 !TK
M8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H &"W_ !DM_P"A00  E4<
M (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&/0  /3@  #,T   J+P8
M)"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN/  :+T8 &"]1 !<P7@ 6
M,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_ !,Q_P">10  DTL  (E/
M  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P  .S\  #$Z   G-@, 'S(+
M !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4-$0 $S1/ !(U7  1-6L
M$#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V_P";20  D4\  (=3  !^
M5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4  "Y!   D/0  '#H( !8X
M#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$ #CI,  T[60 -.V@ "SMZ
M  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"83@  CE0  (58  !\6P
M<EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'   A1   &$(# !) "P 0
M/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*  =!5@ &064 !$%V  -!
MB@ !09\  $&T  !!T  !0>X  4'\  ) _P"55   C%D  (->  !Y8   <&
M &9@  !=7@  45L  $57   Z5   +U$  "5/   <3   %$H   Y("  +1PX
M"$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(4P  2&(  $AS  !(A@
M2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6   (!C  !W90  ;F8  &5F
M  !99   3&   $!=   U6P  *ED  "!7   750  $%,   M2!P %40T  5 1
M  !0%@  4!T  % E  !0+@  4#@  %!#  !04   4%X  %!O  !0@P  3Y@
M $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI  !T;   ;&T  &%K  !3
M:0  1F<  #ID   O8P  )&$  !I?   27@  #%P   9<!@  6PL  %H/  !:
M$P  6AD  %DA  !9*0  63,  %D_  !93   65H  %EK  !8?@  6)0  %>K
M  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R<@  9W(  %IQ  !,<
M/VX  #-M   H:P  '6H  !1H   -9P  !V<   !F P  9@D  &4-  !E$0
M9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F  !C>@  8I   &&G  !@
MP0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>   8'@  %)W  !%=P  .'8
M "MV   @=   %G,   YS   '<@   '(   !R    <04  '$*  !Q#@  <!$
M ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N=   ;HL  &VB  !LO
M:^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\  $E_   \?P  +X   ")_
M   7?@  #WX   =^    ?P   '\   !_    ?@   'X%  !^"@  ?@T  'X1
M  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0  ?(0  'N<  !ZM@  >=H
M 'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(   RB0  )(D  !B)   /
MB0  !XH   "+    C    (T   "-    C    (P   ", P  C @  (T-  "-
M$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L  (R5  "+K@  BLT  (GO
M  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   FD@  &9,   Z4   &E0
M )8   "8    F@   )L   ";    FP   )L   ";    G    )T%  "="P
MGA   )\7  "@)   H#0  *!&  "@60  GW   )^*  ">I0  GL(  )WH  "<
M^0!PC   88\  %.2  !$E@  -ID  ">;   9G   #YT   6?    H0   *,
M  "E    J    *D   "I    J0   *H   "K    K    *T   "N 0  L D
M +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "SF@  L[0  +/5  "S\ !D
MDP  59<  $>;   XGP  *:(  !JD   .I@  !*@   "K    K0   +    "T
M    M@   +@   "X    N0   +H   "\    O0   +\   #     PP   ,4'
M  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP  S*@  ,S"  #,X@!8FP
M2:   #JE   LJ0  '*L   ^N   $L0   +0   "W    N@   +X   ##
MQ@   ,@   #(    R@   ,L   #-    SP   -(   #5    V0   -T   #A
M!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<  .RN  #LP@#_    _P
M /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_ $, _P!, /X 5 #[ %L
M^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\ CP#M )< ZP"A .D K0#G
M +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_ +8 _P#_    _P   /\
M  #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T \0!& .T 3P#K %8 Z !<
M .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8 )$ U "; -( I@#/ +0
MS #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L _P#_    _P   /\   #_
M    ^  % /( #@#N !< Z@ B .8 + #A #< W0!  -@ 20#3 %  T !6 ,X
M7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H O@"4 +P GP"Y *P M@"^
M +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_    _P   /D   #O
MY@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,  0@"] $H NP!0 +@ 5@"V
M %L M0!A +, 9@"Q &P L !R *X >@"L (( J0", *< F "E *4 HP"T *
MRP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_    ]@   .H   #=    SP
M ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J $, IP!) *4 3P"C %4
MH@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0 D "2 )T D "L (X OP",
M .( BP#Z (D _P") /\ A@#_ (, _P#T    Y    -0   #(    OP   +4
M 0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P E@!# )0 20"2 $X D !3
M (X 60"- %X BP!D (D :P"' ', A0!] (, B "! )4 ?P"D 'T M0![ ,\
M>0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,   "X    KP   *@   "@
M  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \ (0 0@"" $< @ !- '\
M4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X ;P"= &T K@!L ,0 :@#G
M &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K!@  H@   )L   "4
MC0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4 .P!T $$ <@!' '  3 !O
M %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7 &  IP!> +L 70#< %P
M]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$   EPT  (\(  "(    @@ %
M 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G #L 90!! &, 1@!B $P
M8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0 H@!3 +4 40#/ %  [P!0
M /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8  (<1  !_#0  =P8  '$
M" !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4 60 [ %@ 00!6 $8 50!-
M %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!( +  1P#' $8 Z0!& /L
M1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :  !W%0  ;Q   &@+  !A
M! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U $X .P!, $$ 2P!( $D
M3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T /03$ #P%Y0 \!_@ / ?_
M #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q'@  :1@  &$2  !:#0,
M4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'-@!#"#T 00A# $ (2P ^
M"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S" #,,Y  S#?D ,PW_ #0-
M_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0  9"   %P:  !4%   3 \&
M $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z#3@ . T_ #<.1P V#E
M- Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1Y0 L$?H +!'_ "T1_P"J
M+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<  %@A  !/&P  1Q8  $ 1
M"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30 ,1$[ # 10P N$DT +1)7
M "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E%OH )A;_ "85_P"F,0
MFC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H  !,(@  0QT  #L7!0 U
M% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X "D60  H%DH )Q=4 "87
M8  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@ (!K_ " :_P"C-   F#H
M (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)*   0",  #@> 0 P&0H
M+!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:/@ B&T< (1M2 " <7@ ?
M'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__ !L>_P"A.   E3T  (M!
M  "!0@  =T(  &U   !C/   63<  $\S  !&+@  /2D  #4D   M( < )QT-
M "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P ='T4 '"!/ !HA7  9(6H
M&")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C_P">/   DT$  (E$  !_
M1@  =48  &Q$  !B00  5SP  $TX  !$-   /#   #,K   J)@, (R(+ " A
M$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$( %B5- !4E60 4)F@ $R9Y
M !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<0   D44  (=(  !]2@
M=$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R   H+0  ("D) !LG#@ 9
M)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+ !$J5P 0*F8 #BMW  XK
MBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91   CTD  (5,  !\3@  <T\
M &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E-   '3 % !8M#  4+!
M$RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO50 ,,&, "C!T  DPB  (
M,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T  (-1  !Z4P  <50  &=2
M  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@  &C<! !(T"0 /,PX #C,3
M  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %-F  !#9Q  (VA   -ID
M #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6  !X6   ;UD  &58  !;
M50  45(  $=/   \3   ,4@  "=$   >00  %C\  ! \!P +.@T "3H1  @[
M%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X  #QN   \@0  /)<  #RL
M   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V70  ;5X  &-=  !:7
M3E@  $)4   W40  +4X  "-+   :20  $D8   U$!@ '0PP  T,0  !#%0
M0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K  !#?@  0Y0  $*J  !"
MPP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P  :V0  &)C  !780  25T
M #U:   R6   )U4  !Y3   540  #D\   E-!0 "30L  $P.  !,$P  2Q@
M $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*>P  2I   $FG  !)P
M2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H  %YI  !09@  0V0  #=A
M   L7P  (5T  !A;   060  "E@   -7 P  5PD  %8-  !5$   514  %0;
M  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P  4XT  %*D  !1O0  4.(
M %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N  !*;   /6L  #!I   E
M:   &F8  !%D   +8P  !&(   !B 0  808  & +  !@#@  7Q(  %\7  !?
M'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@  %R@  !;N0  6M\  %GW
M  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"<P  -7,  "AR   =<
M$V\   QN   $;@   &X   !N    ; (  &P'  !K"P  :PX  &L2  !J&0
M:B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;  !FM0  9=@  &3U  !D
M_P" =0  >GD  '![  !B>P  5'P  $9\   Y?   +'P  !][   4>@  #7H
M  1Z    >@   'H   !Z    >0   'D!  !X!@  > L  '@.  !X$P  >!H
M '@E  !X,@  =T$  '=2  !W90  =GP  '65  !TKP  <\X  '+Q  !Q_P!^
M?0  =8   &>!  !8@@  2H,  #R$   NA0  (84  !6%   -A0   X4   "&
M    AP   (@   "(    AP   (<   "'    AP0  (<)  "'#@  B!,  (@<
M  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP  A,4  (/L  ""_@!XA
M:H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0   "D0   )(   "3
ME0   )8   "6    E@   )8   "6    EP   )<   "7!P  F T  )D3  ":
M'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H  )?B  "6^ !MB@  7XT
M %"0  !!DP  ,Y8  "27   6F   #9D   &;    G0   )\   "A    I
M *4   "D    I0   *4   "F    IP   *@   "I    J@0  *P,  "N$P
MKB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-  "L[P!AD0  4Y4  $28
M   UG   )I\  !>A   -HP   *4   "G    J@   *P   "P    L@   +0
M  "S    M    +4   "W    N    +D   "[    O0   +\!  ##"P  Q14
M ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&W@!5F0  1YT  #BB   I
MI@  &:@   VK    K0   +$   "T    MP   +H   "_    P0   ,0   ##
M    Q0   ,8   #(    R@   ,T   #/    T@   -8   #;    X P  .$8
M  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_    _P   /\   #_  $
M_P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H 4 #W %< ]0!= /0 8P#R
M &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"< .0 J #B +< WP#- -P
M[@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_    _P   /\   #_    _P &
M /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E %$ X@!8 .  70#> &,
MW !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H H0#( *\ Q0#! ,( XP#
M /L P #_ +L _P"P /\ J #_ *0 _P#_    _P   /\   #[    \P ! .T
M# #H !, XP > .  * #: #( TP \ ,\ 1 #, $L R0!1 ,8 5P#$ %T P@!B
M ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R *< KP"W *T T "K /(
MJ@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0   #I    X    -4 " #.
M !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+ +$ 40"O %8 K@!; *P
M80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\ G "N )D PP"7 .< E@#_
M )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4    R    +\  P"Y  T
MLP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X 2@"= %  FP!5 )D 6@"7
M %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F (< N "% -8 A #V ((
M_P"! /\ ?@#_ 'P _P#M    W0   ,P   #!    N    *X   "G  D H@ 0
M )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+ $D B0!. (@ 4P"& %D
MA !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4 KP!S ,< <@#L '$ _P!P
M /\ < #_ &X _P#=    R0   +P   "Q    J0   *$   "9  , DP , (X
M$@"* !D AP A (0 *0"! #  ?P W 'T /0![ $( >0!( '@ 30!V %( = !8
M '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E +P 8P#A &( ^@!A /\
M80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0   "-    A@ ( ($ #@!\
M !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!! &D 1P!H $P 9@!2 &0
M60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0 5@#0 %4 \@!5 /\ 5 #_
M %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""    >P " '4 "P!P !
M;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T 00!; $8 6@!, %@ 4P!6
M %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#& $H Z@!) /X 20#_ $D
M_P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P  <0,  &L !@!E  T 80 1
M %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0 $$ 3@!' $T 3@!+ %8
M20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\ X@ _ /@ /@#_ #\ _P"R
M&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X  &((  !< 0@ 5P . %,
M$P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P 1 !" $, 20!! %$ /P!:
M #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U /0 -0#_ #4 _P"L(
MGR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0  !4# $ 3@8* $H"#P!'
M !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^ #D"10 X TT -@-6 #4$
M80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_  + C_ "P(_P"H)0  FRH
M ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/$@  2 X$ $$*"P ^!Q
M.P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)00 O"4D +@I3 "P*7@ K
M"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_ "4-_P"D*@  F"\  (TR
M  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0  0Q,  #P0!@ U#0P ,PP1
M #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G#D8 )@Y0 "0.7  C#VH
M(@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1_P"A+P  E3,  (HV  "
M-P  =C8  &TS  !C+P  62H  % E  !((   /QH  #@5   P$0@ +! . "H0
M$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4, (!). !X26@ =$V@ &Q-X
M !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">,P  DS<  (@Z  !^.P
M=#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<   M%P4 )A,, ",3$  B
M$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+ !D65P 7%V4 %A=V !08
MB0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@  D3L  (8^  !\/P  <S\
M &D]  !?.0  534  $PP  !#+   .B<  #(B   J'@$ (AD) !X7#@ <%Q(
M&A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;50 2&V, $1QT ! <AP /
M'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\  (1"  ![1   <4,  &A"
M  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0  (" & !H=#  7'!  %1P5
M !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .(&$ #2%Q  PAA0 +(ID
M"B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&  !Y2   <$@  &=&  !<
M1   4C\  $D[  ! .   .#0  "\P   G+   'B<# !8C"@ 2(0X $2$3 ! B
M&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X "29O  <F@@ &)I8 !":L
M  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X3   ;TP  &5+  !;2
M4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J!P /* T #2<1  TH%@ ,
M*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML  $K?P  *Y0  "NI   K
MP0  *^,  "OV   J_P"21@  B$L  ']/  !V40  ;5$  &-0  !:30  3TH
M $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,+PP "2X0  <N%0 &+QL
M!2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q?   ,9$  #&G   POP
M,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8  &)5  !84P  3E   $5-
M   Z20  +T4  "5"   </@  %#L   XY!0 )-PL !#8/  $V$P  -AD  #8@
M   V*0  -C(  #<]   W20  -U<  #=G   W>0  -X\  #:E   VO0  -N
M #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;  !760  3%8  $!2   U
M3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.   ^$0  /A8  #X=   ^
M)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P  #VC   \NP  /-X  #OU
M   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !47@  1UL  #I7   O50
M)5(  !M0   230  #$L   9* P  20D  $@-  !'$   1Q0  $8:  !&(@
M1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@  !$N   0]P  $+U  !"
M_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P  06$  #1>   I7   'UH
M !57   .5@  !U0   !3 0  4@8  %$+  !1#@  4!$  $\6  !/'@  3R<
M $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,M0  2]@  $KU  !*_P"%
M90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<  "UE   B9   &&(  !!@
M   )7P   %X   !>    70,  %P(  !;#   6@\  %H3  !9&0  62(  %DM
M  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@  5=(  %3T  !3_P"!;
M>7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N   :;   $6L   EJ
M:@   &D   !I    :    &<#  !F"   9@P  &8/  !E%   91P  &4G  !D
M-   9$,  &13  !D90  8WL  &*4  !AK0  8,T  %_Q  !>_P!]=   =W<
M &YY  !?>0  47D  $-Y   V>   *7@  !QW   1=@  "G4   !U    =0
M '8   !U    =    '0   !S @  <P<  ',,  !R$   <A4  '(@  !R+
M<CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM  !K_P![>P  <GX  &1^
M  !5?P  1X   #F!   K@@  'H$  !*!   *@0   ($   ""    @P   (,
M  "#    @@   ((   ""    @@   ((%  """@  @@\  ((7  ""(P  @C(
M ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\_ !V@@  :(,  %F%  !+
MAP  /(D  "Z*   @BP  $XL   J+    C    (T   "/    D0   )(   "1
M    D0   )$   "1    D0   )(   "2 @  DPD  )0/  "4&0  E"<  )0X
M  "43   DV(  )-\  "3F   DK,  )'8  "0]@!JB   7(H  $V-   _D
M,)(  "&4   4E0  "I8   "7    F0   )L   "=    GP   *    "@
MH    *    "A    H@   *,   "D    I0   *8'  "H$   J!P  *@M  "I
M0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP  4)(  $&6   SF0  (YP
M !2=   *GP   *$   "C    I@   *@   "L    K@   *\   "O    L
M +    "R    LP   +0   "V    MP   +H   "]!P  OQ   +\?  # ,P
MP$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L  #6?   FHP  %J4   NG
M    J@   *T   "P    LP   +8   "[    O0   ,    "_    P0   ,(
M  #$    Q@   ,@   #*    S    ,\   #3    V@<  -L3  #=)0  WCL
M -]3  #@;@  WXP  -VI  #=P@#_    _P   /\   #_    _P ' /\ $ #_
M !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9 .\ 7@#M &0 ZP!I .D
M;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$ U0#% -( Z #0 /\ SP#_
M ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_    _P " /L #0#W !4
M\P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@ 6 #4 %X T@!C -  :0#.
M &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z +L V0"Y /< N #_ +0
M_P"I /\ H@#_ )T _P#_    _P   /\   #V    [@   .< "@#A !$ W  :
M -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"] %@ NP!= +D 8@"X &@
MM@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8 R "D .T H@#_ *( _P";
M /\ E0#_ )$ _P#_    _    .X   #C    V    ,T !0#&  X P0 5 +T
M'@"Y "< M0 P +( . "O $  K !& *H 3 "H %$ IP!6 *4 6P"C &$ H0!G
M )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0 -\ C@#[ (X _P"+ /\
MA@#_ (, _P#X    Z0   -P   #,    P0   +@   "R  H K  1 *@ & "E
M "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0 )( 50"0 %H CP!@ (T
M9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P ? #Q 'L _P!Z /\ =P#_
M '4 _P#F    TP   ,8   "[    L0   *<   "A  4 FP - )< $P"3 !L
MD  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($ 3@!_ %, ?0!9 'L 8 !Y
M &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F &H _P!I /\ :0#_ &<
M_P#3    PP   +4   "K    HP   )L   "2    C  * (< $ "# !8 ?P =
M 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O $T ;0!3 &P 60!J &$
M: !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L ]P!; /\ 6@#_ %H _P#%
M    M@(  *D"  "?    E@   (X   "'    @  % 'H # !U !$ <0 8 &X
M'@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $< 7P!- %X 4P!< %L 6@!D
M %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!. /\ 3@#_ $T _P"["@
MK T  * -  "5#   C @  (,"  !\    =0   &X " !I  X 90 3 &( &0!?
M !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!' %$ 3@!0 %4 3@!> $P
M: !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P 0@#_ $( _P"R$0  I10
M )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?  L 6P / %< % !4 !H
M40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8 2 !% %  0P!9 $$ 8P _
M &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_ #@ _P"L%P  GQL  ),=
M  ")'   ?QD  '45  !L$   9 P  %T&  !6  8 40 , $T $ !* !4 1P :
M $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [ $L .0!4 #< 7P V &L
M- !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X _P"G'@  FB(  (\D  "$
M)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,( $4 #0!! !$ /@ 6 #P
M&P Z "$ .0 F #< +  V #( -  X #, /P Q $< , !0 "X 6P M &< *P!V
M "H B  H )P )P"P "8 R0 E .H )0'[ /_B?1!)0T-?4%)/1DE,10 1$B4!
M_P"B(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$   0PP"
M #T'"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I!$,
M* 1- "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?
M*   DRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.
M!  Q"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D  ( I*
M !\+50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0
MD#$  (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03   M
M$ 8 )@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y' !<.
M4P 6#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4
M (0X  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J%0$
M(Q$' !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1
M$E\ $!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\
M  !X/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'   (!@#
M !D4"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP
M#!=L  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!   !W
M00  ;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\  !<:
M"  2%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI
M  4<?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U10
M;$4  &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A!  /
M'0L #1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A
M>0  (8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@  :TH
M &))  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -) H
M"2,.  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F=P
M)HP  ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\  &!.
M  !72P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H !2L.
M  $J$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0  +(H
M "N@   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3  !6
M40  3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-   R
M$   ,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<  #&>
M   QM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !55P
M25,  #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z#P
M.1(  #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<   W
MLP  -](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27   1%@
M #A5   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0  0A
M $$5  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _L0
M/M   #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX  #);
M   F60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX  $L2
M  !*&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP  1LT
M $7Q  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB   ?
M8   %5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40  !4
M%   5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H  $_O
M  !._P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7:0
M#F<   9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@$
M8!<  & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM  !9
M_P![<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@  !W$
M  !Q    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#   ;1$
M &T:  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y
M>@  <'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T   !]
M    ?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P  'P2
M  !\'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S@
M98$  %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*
MC    (T   "-    C    (P   ",    C    (P   "-    C00  (X,  ".
M$P  CR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@  6H@
M $N+   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9    FP
M )P   ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B#
MHA8  *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39   #^3
M   PE@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@   *L
M  "J    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0  N0T
M +D:  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<   C
MH   $Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L   "Z
M    O    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$  -0/
M  #5'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_
M_P # /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G
M %\ Y0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"] ,L
MX #) /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_    _
M /8 "P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D
MRP!> ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0 S0"R
M /( L #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z    .
M!@#9  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %, M !8
M +( 70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "= .8
MFP#_ )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8  0"_
M  L N@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1 )X
M5@"< %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -, AP#W
M (8 _P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K  <
MI0 . *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ")
M %4 B !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K ',
M_P!S /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  ( E  +
M )  $ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X
M=@!4 '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B
M /\ 8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ ' ($
M#0!\ !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!.
M &4 5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\
M5 #_ %0 _P"^    L    *0   "9    D    (@   "!    >0 " ', "@!O
M  \ :P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!' %<
M3@!6 %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_
M $< _P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C  P
M7P 0 %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L 2 !)
M %  2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_ #P
M_P"L$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @ 50 -
M %$ $0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L
M/0!3 #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F
M%@  FAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  * $@
M#@!$ !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8 ,P!/
M #$ 60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A'
ME2   (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $  "P \
M  \ .  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+ "@
M50 F &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28
M (8H  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T  P
M,0 0 "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "  4@ ?
M %X '0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M
M  !Y+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D *04-
M "8#$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP
M%@9J !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W
M,@  ;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP) !\)
M#0 =!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI
M  X,>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@
M;#4  &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D."@ 5
M# X % P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0
M>0 ($(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P  :SH
M &$X  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1$ L
M#@X.  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03=@ #
M$XL  12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\  & ]
M  !7.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D #!,.
M  H3$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D
M !B?   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"  !6
M/P  3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-  89
M$0 $&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<  !R=
M   <LP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !51
M2T   $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?$
M'Q0  !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;   A
ML@  (<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420  2D8
M $)#   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@  )1(
M "89   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   FL
M)<P  "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP  $%)
M   U1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$  "T6
M   M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP  *\L
M "KN   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-   P
M20  )48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04   T
M&P  -"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H  #'N
M   P_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J3P
M($P  !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \&
M/"$  #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM   W
M_P"!6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50  &5,
M !!1   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%   11P
M $4G  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   __P!^
M80  =F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL   M9
M   "6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@  $\B
M  !/+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![:0
M=&P  &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B
M8@   &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<  !:
M*   6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<   <W0
M &EU  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M    ;0
M &T   !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G(0
M9R\  &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z
M  !0>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@   'H
M  !Z    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&   =R8
M '8V  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%
M@@  -H,  "B$   :A   #H,   2$    A    (4   "&    B    (D   "(
M    AP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P  (DL
M  "(/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   YB@
M*HP  !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6
MEP   )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA  "=
M,P  G4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP  'I4
M !"6   $F    )H   "<    G@   *$   "D    I@   *<   "F    IP
M *<   "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T)P
MM#T  +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\   6A
M    HP   *8   "I    K    *\   "S    M0   +<   "V    MP   +@
M  "Z    NP   +T   "_    P0   ,0   #'    RP   ,T,  #.&@  SR\
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M_________________________________________________P
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M]_CY^OO\_?[_;69T,0     # 2$   $                    !
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M________J#4          %S3____________________________?0T
M     %36___________________________N?44          $34________
M___________________\JF0O @  !"(W25C.________________________
M____Z:1K02@_8W^5I[K:_______________________________5LJRRS.3Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________ENY=W8LC_________________
M________________VYYG-@H  HS________________________________(
M?S\%     %[/_____________________________]F!.0       #RJ____
M_________________________YY,         ".0____________________
M________W&\:         !!]^?__________________________KT@
M      !O[O__________________________A!,           !DYO______
M___________________L40            !7WO______________________
M__^X%0            !(UO________________________]T%
M   XS_________________________FB6A,            CQ?__________
M_______________?FUPL           -NO__________________________
M[[%]53DB$0<! A$BLO______________________________W[^EF9B:H*R]
MVO__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____X[Z=@'S[________________________________\K>$5S . !VL____
M___________________________2BDP5      !R\___________________
M_________]9_-@        !+R?__________________________^I$^
M       OJ___________________________P%H            :E?______
M____________________C20            (A/______________________
M___G7@              =_________________________^T)0
M    :O________________________]]                6_3_________
M______________TK                3.O______________________Z4
M                /.'______________________S ,
M+=G_____________________F8IA)P              )]?_____________
M_________^V^B54G            )=S__________________________LJ=
M=EU*/#(M+# Y1][_______________________________WFW=;2T-/9Y/__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________OU+O6____________________
M_____________^>XCVI++Q5O_______________________________DH6<T
M!P     \R?___________________________]:".P         2E_______
M____________________[84Q            ;_______________________
M____ID(             4.'________________________L:0
M    -\G_______________________^S+P              (K;_________
M______________]Y                $*?_______________________(T
M                 )G______________________ZD
M (S______________________T8                  '______________
M________WP                   '3_____________________EP
M             &K_____________________S@                   &/_
M_____________________RDB 0               &'_________________
M_____[FC@%<W%P           &C___________________________K3KI2&
M?'5Q<')W@93_________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________V[J=@FEIT_______
M________________________R)-E/1D    =GO______________________
M_____]N.3!,         ;O__________________________VWPL
M    1=?_________________________BRH             (K3_________
M_______________"1                Y?_______________________]]
M 0               '_______________________^<V
M &K______________________YT                  %C_____________
M_________T8                  $?X____________________Z0
M             #7I____________________E@                   "7;
M____________________O                    !C.________________
M____ZP                    _"_____________________P
M          JY_____________________R<                   JU____
M_________________W                    VY____________________
M_^"<C'!50C,F&Q0/#0X2&B:_____________________________^>38TL[,
MR\S/UN#\____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________Z].\X________________________________]*IA65(
M+!(!A?____________________________&K<3P/        3^#_________
M________________U7\U            '[+________________________C
M=1T              (G_______________________^0(P
M &?______________________]5#                 $CV____________
M_________XH                  "[=_____________________S@
M             !?(____________________O@                    2V
M____________________G                     "E________________
M____N@                    "3____________________W
M          ""_____________________P                    !T____
M_________________Q,                   !H____________________
M_T(                   !@_____________________WH
M      !=_____________________]$                   !A________
M______________\D                  !F_______________________)
MK)F)?79Q;&EG9F=K<'J,________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________XL6JD7EA=___________________________
M___=IG=0+ P     ,<3_________________________X)).$P
M (_________________________2<!T              &#_____________
M_________^YO#P               #?B_____________________Y8<
M             !3 _____________________T                    "C
M____________________K@                    ")________________
M____G@                    !R____________________O
M          !?____________________V@                    !-____
M________________^@                     [____________________
M_PX                    J^?___________________S,
M       ;Z?___________________UX                    /V_______
M_____________X\                    &T/___________________]
M                    RO____________________\K
M    R/____________________^                     R___________
M___________W%@$%!0,!       !!@T8R________________________.OA
MV,_,S<_0TM37W.+J____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________________':
MQO______________________________\<:CA&A-,A@ %:O_____________
M_____________[E\1A@          ''________________________7?"\
M             #OC_____________________]]D"0                RU
M_____________________W0#                  "-________________
M____Q14                   !J____________________F0
M          !+____________________M@                     P_?__
M________________UP                     9Y___________________
M]@                     %T____________________PX
M        P?___________________R\                     K_______
M_____________U(                     GO___________________WD
M                    CO___________________Z4
M    @/___________________]@                     =/__________
M__________\V                    ;?____________________]\
M                :?_____________________7#0
M:/______________________<                   8?______________
M_________U \1DY465UA9&AL<'9^B?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____[]6[HXMS6I7___________________________B_CF1!(04      %+\
M_______________________WG588             !?!________________
M_____^5L%@                "-_____________________V,
M          !>____________________G0                     U_/__
M________________H0                     1V?__________________
MR@                      N___________________[@
M        H?___________________PP                     BO______
M_____________RT                     =O___________________TT
M                    9/___________________V\
M    4O___________________Y0                     0/__________
M_________[P                     ,/___________________^H.
M                (O____________________]$
M%?____________________^!                    "_7_____________
M_______("P                   NS_____________________7@
M             .7_____________________R1P                  -K_
M_____________________YT!              <.%\7_________________
M_______5N;S!Q\[5V^'F[?3[____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________XW\__________________
M____________[,:EB&U4.R$' #+>________________________UY)9*0
M          "@______________________^)-@                !G____
M_________________V8                    R]O__________________
ME0                     #R/__________________IP
M        H/__________________UP                      ?/______
M_____________P                      7O___________________R4
M                    0____________________T@
M    +/___________________VH                     &/__________
M_________XL                     !?/__________________Z\
M                 .'__________________]4
M ,____________________\D                     +[_____________
M______]4                     *[___________________^+
M             )_____________________+#@                   )+_
M____________________5P                   (;_________________
M____J@H                  'G______________________VT
M         &;_______________________=5                 $7_____
M____________________:B,K-3]*56!J=7Z'D9S_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________^C/MIV#:4ZY____
M_____________________^RR@UPZ'0(       ![____________________
M___%;2D               ! _____________________X,;
M       'R___________________D@                      F/______
M____________I                       :O__________________W0
M                    0?___________________PX
M    '?___________________SD                      .C_________
M_________V                       ,[__________________X4
M                 +?__________________Z@
M */__________________\L                      )#_____________
M_____^\6                     'W___________________\^
M             &S___________________]I                     %K_
M__________________^9                     $G_________________
M___2%@                   #G_____________________6
M         "G_____________________H@                   !G_____
M________________]58                   3_____________________
M_[LO                  #X______________________^K*0
M      #/________________________R4<     !Q,@+CY2:(3M________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________]-7)____________________________^M*PDG==
M0B@,  !*________________________Q7U%%P             1V/______
M_____________\10                    G___________________H@P
M                    :/__________________E
M    -O__________________V@                      !^S_________
M_________Q4                      ,3__________________T@
M                 *+__________________W4
M (/__________________YT                      &G_____________
M_____\,                      %+__________________^</
M             #[___________________\S                     "O_
M__________________]8                     !C_________________
M__^!                      7___________________^L
M          #____________________>(@                    #R____
M________________7                     #?____________________
MGP                    #,____________________Z$H
M      "W_____________________Z 6                  "<________
M______________]Z @                !W________________________
M>@L               5,_________________________Z)7:'2 C9RKO-#G
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________^WC________________________
M___2HWI8.BDC'!8.!@  G_____________________^L4@X
M    :?__________________Y$,                     -/__________
M________>0                       ./_________________S0
M                 ++__________________Q,
M (7__________________T\                      %W_____________
M_____X,                      #K__________________[(
M             !S__________________]L#                      +_
M__________________\J                      #[________________
M__]/                      #G__________________]T
M          #4__________________^;                      # ____
M_______________$!P                    "M___________________P
M,P                    ":____________________9P
M      "&____________________HP                    !R________
M____________XT0                   !<_____________________Y$&
M                  !!_____________________^M?
M   =_______________________*2P                  ____________
M____________RU<   P8)#$_3F!TBZ?'___________________________7
MY_+_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________KU,W'PKZZM[.PK:FHI?___________________]U^4S\P
M(QD1"0(          -O_________________=@
M *?_________________N@                       '7_____________
M_____P<                      $;__________________TX
M             !K__________________XP                       #]
M_________________\$                       #;________________
M__$9                      "^__________________]$
M          "D__________________]K                      "-____
M______________^1                      !Y__________________^W
M                      !F___________________>(0
M      !3____________________2@                     _________
M____________=P                     K____________________K H
M                   6____________________YT4
M    _____________________XH                     ____________
M_________]9-                    _?____________________^G+@
M                U?______________________F"H           88+45@
MX/_______________________ZAC=(&/G*N[S>+Z____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^(S@$E#0U]04D]&24Q% !(2________________________________
M_______________________________GR[>IG96.B82 ?'AT<&QH99#_____
M____________O&I(+1D*                 #'__________________P
M                      /__________________T(
M      #<_________________XX                       "R________
M_________\X                       "-__________________\I
M                  !K__________________]:
M  !.__________________^&                       T____________
M______^N                       >___________________4%P
M               *___________________Z/0
M____________________90                      ________________
M____C@                      ____________________O!D
M            [___________________\4X                     V/__
M_________________XL                     O___________________
M_\Q#                    H?____________________^1&0
M        >O_____________________R= H                17_______
M________________Z'03'RPX15-B<H6;M-+U________________________
M___7Z/3_____________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M______________________________________________________OW\_'N
M[.OK[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$________
M_________TLE"P                    "2_________________X@
M                  !F_________________]<
M   ]__________________\S                       8____________
M______]L                        __________________^=
M                ___________________)#
M]O_________________Q-0                      W_______________
M____6P                      R___________________@@
M            M___________________J08                     H___
M________________TR\                     C?__________________
M_UX                     =____________________Y,'
M        7O___________________\U#                    0/______
M______________^'$                   '/_____________________8
M7@                   /______________________OTX       X<+#Y2
M:H:ER/_______________________\)\C)JGML76Z/W_________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________^[AU\_)P[ZZMK&MJ:>F
MIJ>N_________________[Z&;5M,0#<O*"(<%A +!      4____________
M_____]<%                        __________________\T
M                ]O________________]V
MTO________________^P                        LO______________
M___A)                       EO__________________40
M            ?/__________________>0                      9O__
M________________H                       4?__________________
MQR,                     //__________________[DL
M        )____________________W0                     $/______
M_____________Z,6                     /___________________]A,
M                     /____________________^(#P
M     /_____________________+4P                   /__________
M____________I3@           D=-$YKC/_______________________YDY
M0U%?;GV.H+7+Y?_____________________________K^?______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________KS+FLH9F1BX:!?'AT<&MH9F9H
M\?________________]A13(C& X&                GO______________
M__]^                        =?_________________#
M            4O_________________[-P                      ,O__
M________________:@                      %O__________________
ME@                       /__________________OQL
M         /__________________YD(                      /______
M_____________VD                      /___________________Y "
M                     /___________________[DL
M     /3__________________^A<                     -G_________
M__________^1&                    +S____________________*4P
M                 )W_____________________F"X             $"E&
M9L3_____________________[G\=#!HH-T97:7Z5K\SN________________
M_________^>@JKG(V.G\________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________?7PZ^;B
MW]O8U-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N,?__
M_______________2)1$#                     /__________________
M0@                       /__________________?0
M         /__________________L L                      /;_____
M____________W3D                      -S__________________V(
M                     ,7__________________XD
M     *___________________Z\B                     )G_________
M_________]9(                     (+___________________]R
M                 &G___________________^A*
M $[____________________37                    #/_____________
M________EBX              !4R4G?_____________________X'(3   !
M#Q\O0EAPBZC([/_______________________\IO;GZ.GK##V.__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________^>#2R,"ZM;"LJ*6B
MGYV;FYR@I___________________@F162T,\-C K)R(=&!,."00  -3_____
M____________D@                       *W_________________S!X
M                     (O_________________^U(
M     &W__________________X                       %'_________
M_________ZD;                     #K__________________]!"
M                 "/___________________5H
M  S___________________^/%                     #_____________
M______^X/@                    #____________________E;0,
M              #_____________________GS<              ! O4'3_
M____________________W7(4      87*D%:=92VVO__________________
M_____[Q81%1D=8::K\CC_______________________________2S>'Q____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________\^_K[_?______________________[KFHG9:/BH:"?WMX=G1R
M<W5X?Y#_________________ZT\Z,"@A&Q40"P<"         "/_________
M_________VD                       #__________________YL*
M                  #__________________\@Y
M  #___________________!C                      #_____________
M______^*#@                    #___________________^P-
M              #____________________56P                    #_
M____________________A1H                   /L________________
M____L4D              !@Y78'_____________________Y7L>       ,
M(3A2;X^SV?_______________________[M8*3E)6FR E[#-[?__________
M__________________^SGK3%U^O_________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________Z[^?A
MW-G6U-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A75UE>
M97'__________________[\Q'Q80"@4               #_____________
M_____^U6                      #H__________________^"!
M              #,__________________^K+P                    "S
M___________________25P                    ";________________
M___W?!                    "%____________________HC<
M        !2N4____________________RV$"            #"Q0=I[1____
M________________]8TP       -(SM7=IF^Y?______________________
M_\-C&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G____
M_________________________________?__________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________=SL6_O+FV
MM+.QLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M066:A
M__________________^G)@X' @                !6________________
M___.4                      Z___________________T>0L
M           A____________________GS(                    .____
M________________Q%@                (,5J$____________________
MZ7\?           &)TMQFL+I_____________________Z=)      (7+TIH
MBJ[5_/_______________________]-U'B8X2EYUCZO+[_______________
M______________^N<H68K,+;]O__________________________________
MW^__________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________________O[*JIJ.AH)^?
MH:.FK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]____
M________________GBX&                    ____________________
MPU8                  !5!____________________YWL:
M  DT8(NT_____________________Y\_          0E2G&9PNO_________
M_____________\9F#P   !,J1&*#I\WU_________________________^N.
M-2L^46B!G;S>______________________________^^=G^4J<'<^?______
M____________________________TMCS____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___V\O#O[^_Q\_C]____________________________^+"?FI>6EI:8FY^D
MK+;"T>'N_____________________HY02D=%1$1$149'2U%::(.I________
M_____________Z9! 0          !S9CC[KA_____________________\9E
M"@      !"=,<YS$[/_______________________^6(+P  $RI$8H*FS/3_
M__________________________^K4#9*87N6M-;Z____________________
M___________2AWR8L<OI____________________________________U,[M
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________M
MY>/CY.;H[?'Y______________________________VQE)*2E9F=HZFRO-#M
M__________________________^=4T=)35%68'.*K];\________________
M__________^R5@ :-5!MBZ[2]______________________________-;SY?
M>YFWU_G________________________________NGX.FPN'_____________
M________________________X\[K________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________
M
M
M          #_________________________________________________
M____________________________________________________________
M____________________________________________________________
M_P   /_; $,  @$! @$! @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)
M"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(
M!P@,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,#/_  !$( (<!! ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MU.*E'9GI87%4L31AB*#O":4D^Z:NGKW044451T!1110 4444 %%%% !1110
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MWSFOH6OB[]I;X@ZW^RG_ ,$7]#O?#6H7&B^(M)\+^'K&UO+==LD4KM:)*W<
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M,Z;IL>WR]/M8K9=J[5PB!1@=AQTJ_117L15E9'ZPE9604444P"BBB@ HHHH
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M5$KH"P($A?#;?E]>_P"&1_VP?^CQO"__ (9:S_\ EA0,[/\ X)9_M3Q_M/\
M_!-OX7?$/4KKS+Y_#J6^N2E3N2^L@UM>%DQD$RP2-MQT88R""?$/^#>[P/#X
M]_92US]H;7+%9/B%^T%XGU;Q#JFH7"[[N*T2]EMK:R60C=]GC6 LBC"XDXXQ
MCF/^"0WAGQ-^S?\ %/\ :J_9A\4ZROB37M U<>-='U)-/&FVVJVVM6N^4P0>
M9((8TN$P4#D*TK<]<>H?\&\GBB'Q3_P1W^#+0K)')I]I?Z=<12??BE@U*ZB8
M$=L[=P!YPPH \3_X*N?LQZ;X!_X*H?LB_$WP_!%I7_";_$:RT[Q5!;Q[(]7O
M+5':PNI .#,D4U[&7/S,K("2$&/J"Y_8LUKQW_P5<;XV^+8]'U3PCX1\#Q:!
MX)M9)3+-I>HRW+RWMYY3)MCD:/9&)%8L5R"!@5YI_P %@?$5K;?M,?L4Z2TB
MB\OOC):WD2;AEHX;65'..O!GCY[9'J*Q?'?BGX@_\%(_^"E/Q6^"^C?$SQ5\
M+?A#\!M.T=?$7_")RK8ZWXIU+4HGN$C%Z09(+9(HW1A%M8LK<G<K("+_ /P7
MSU#PGHWP5^$^IWNHZ;I_Q T;XH^&[OPFXG2/4!+]OC6?R1D.4\@R%L K\JYZ
M"MG_ (*0?\I*/V&_^QL\1?\ IF>O%O\ @IC_ ,$UO@;^QK^RK8^)/"GA%/\
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M[\"_^P+-_P"EEQ0,\-\._L>>#_$7_!QOXXFNK&&70[7P'IGQ"DT-X]VGW/B
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MR]$L?!FABY0,!<3C3I99!G&"R,S*P'0!/6ONR@ HHHH **** "BBB@ HHHH
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;+6VW?-]G@10B;NY8@*"%'TM110(**** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>interferonrev.jpg
<TEXT>
begin 644 interferonrev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M^E?<- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%-=BJLRJ7(!(12H9B!D*I=D3<W1=SJNXC<RC+
M  =17Y5_LW_MZ_&+]I'3/C]'X-^#?PGOO'?PX\5^&]!\,_"M?CI-H?Q&\&#Q
M+;_#U9]/_:4\(^)_ .E>(_AQJ'@]/%'B?7/$>I>%M)\7VFJCP1XJ\%>"]/\
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M:T-[*+45U#5GU*_M+O7+Z_U:\FU+4KQRKU^#_P#PU+^T;_T6CQ[_ .#2W_\
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M/0XJ\#F.&S!5WAY-_5ZKHU%+DYE+EC--J$YN#<9J].K[.O3E>%:E3FG%9XS
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M>&4AE."I! -?U._\(_IS%F+:H2S,2?[>UT9)8D\#40!SV Q7\Z_2 _WGA?\
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M_9A_X2S0_&FGR76M>!H;G6O /B/PRTL>IZM<V>DJH\/ZC;JMOJ>CZ7<7#?\
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MF?R7_K5EO_/O%_\ @JG_ /+C]:Z*_)3_ (:W^.'_ $'M"_\ "2T7_P"-T?\
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M_P"R,>*__1=O7\"3_?;_ 'F_F:^W^C/D^$S+A7/JN(E7C.GQ!*$?93A%<O\
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M8B$8RG2RURC&=W%OV]%>\HN,FK-[23\S\F_^&C_@;_T4G0O_  'UO_Y4T?\
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MTSTYQQG^6_\ X-VQGXA?M3?]B7\(^Y'_ #,7C[TK^J#&/7\23_.O\XOI"?\
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M#_*OX2?^"NO_ "D4_:1_["?P^_\ 53> Z_#_ *+7_)>9U_V2.-_]7.1'[/\
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M! NV:2"V=]R!6;,";6)0;@H=O[NVZ'Z'^5?PD_\ !77_ )2*?M(_]A/X??\
MJIO =?B/T6O^2\SK_LD<;_ZN<B/V7Z3'_)$9/_V56$_]5&='YP!'9975698(
MUFG959E@A>>*UCFG905ABDNKBWM8Y92D;W5Q;VRL9YXHW9N7<5W+N #%<C<%
M)(#%<Y"L00K$8)# $D''ZO\ ["EM-J_P&^/7AP/H?@_3-34?\)'\4X9_@WXH
MAT33+CQ+\*['^S_CA\-?B8EGJUW\+M+LTU36]$UK1?$%E:36=]\1(-)TC6/B
M'8^%DB\,\6^#?B5J_P"PW\-=0E^$8\/Z!X1^,^N:K;:YH7@I]*.L>"=:^$?@
MFVB^)7BSQ#<^;K/B&+Q1XHD:SB\2:O=)I$$\-OHNAZ?HMK:FR']A4^+*<LUQ
M>65:&&H/#9QA,K56>80YYQQ>!J8JE7]DZ"IJK.M3]A3P<<1.O[.7MZRH-T*6
M(_DR?"\UE>$S&E7Q-;ZSE.)S-TX9?4<(/"XVEAJM%5%6=1TH4:GMIXN6'IT'
M4C[&@ZZ5:K0^$&EBC(62:*-B 0LDL:,06V A68$@N0@(!!8A1\Q I1+$7\H2
MQ&4$@Q"5#*"H#,#&&W@JI#,"N5!!. 17[,_LI>%-0\ ^!-&^'_C+PSX\L?$%
MG\=_BKI?Q4@\&3?#A?!/@1;#POH'AB'0?VX-/\37K:CXB^%UE>1R^*=%TSPS
MK'AVRM_!4WCF2PU_5/$VH6]KIEG6U\,:5^S_ &>F:IH^J^)O"'@KX*?LYWD&
MI7>J> ;7]C;XHZMX;\=^ ]:\4Z3\(PQMO'N@_'SQ]ITU[X4\1^+=?O;[S]4'
MQ;N/%/ACP[H%Y93:9YM;CVG3Q\\%2RV.)@L=A<+2Q%+,:7+7I8G%U<(L133P
M_LW/GIQJ4<-[;FQ.'JK$TZL:$95#T:7 ]2>!IXRKF$L/*6"Q.*J4*N7U;T*N
M'PM+%.A4E[=34>2I*G6Q'L>7#UZ;P]2FZ\E37XN)+%+GRI8I=N-WE2))MW9V
MYV,V-V#MSUP<9P:?N7<5W+N #%<C<%.=K%<[@K$$*2,$@@$X./U8_:F\'Z[X
MJ\#6WAK4+CQ]X[^,.N?'[QMXH^%>C>./"/P[\">)/"_P'T?X<^)O$'C7PSX;
ML?#7B_Q!9:C\-/#EW8>&YM'UVSU2P^'FJWNCWP^$VG7<"Z[//XCXR\)?$?5_
MV&OAGK,_PD_X1WPYX2^,?B37(-=T+P2=)_M7P+KGPB\!)!\2_%FO2&XU7Q"G
MBGQ+)+:Q^(=2N_['BN88-#\/6.DV5FMC7J8+BW#8RAEM9PPU)X_,%@91>/7)
M&,X8AT<1AGB,-A<1BHUJ^'GA81EA<,G7I8N,)U'ADJWFXSA;$82OF%%5,156
M"P/UU-8%N;E&>&5:AB50Q&)P^%E1H8F.*E*.*Q#5"IA93A#ZR_8_)?PTS_PL
MKX;;0"W_  L?X?[0Q*J6_P"$RT/:&8!BJDX!8*Q49(5B,'_2($_B %@NEZ0R
MAY-I.N7BDKO;!*CP^P4D<D!F /&3UK_-X^&?_)2_AK_V4CX??^IGH=?Z4"]#
M_O/_ .AM7\P?2O\ ][X(_P"O'$'_ *7DI_2/T7O]VXR_Z_Y'_P"F\T/@3_@I
M9-K+?L%?M7"ZT_3(83\&?%6^2#5[JYD4;;8$K$^BVJL0NX@&9 6 4E02R_P3
M/]]NOWCP 6).> %4%F8G@*H+,2 H)(%?WV_\%,_^3!?VL/\ LC'BO_T7;U_
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MY*?U/6<FHR>9]OM+.VQM\K[)?S7N_.[?YGG:=8>7MPNW;YN_<V=FT;OY;/\
M@W;_ .2A?M3?]B7\(_\ U(?']?U05_ _TA/^3K<1?]>,C_\ 5#EA_<O@+_R:
M_(/^PC.__5WF 4445^*'[$%%%% !1110 4444 -V)G=M7=USM&<^N<9IU%%
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M$_Y.MQ%YT,C_ /5!EA_H-X"_\FOR#_L(SO\ ]7>8!1117XH?L04444 %%%%
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MR;MH?AY17@'_  U!\%_^@WXQ_P##-_&O_P"=W1_PU!\%_P#H-^,?_#-_&O\
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M4<29!FN+_M[+*WU7+<XR['8GV5.CCE.K[#"XFK5]G!SBISY>6+E%-JZO^T^
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M./+_ *@_-?>NY]"T5X!_PU!\%_\ H-^,?_#-_&O_ .=W1_PU!\%_^@WXQ_\
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MB5+>&:X>*!9)$MX9IV40PRNDO_#4'P7_ .@WXQ_\,W\:_P#YW='_ !$#@/\
MZ+;A'_Q),F_^;0_U#XY_Z(SBO_Q'<X\O^H/S7WKN>_T5X!_PU!\%_P#H-^,?
M_#-_&O\ ^=W1_P -0?!?_H-^,?\ PS?QK_\ G=T?\1 X#_Z+;A'_ ,23)O\
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M^^W_ /BJ=10 W:/5O^^W_P#BJ-H]6_[[?_XJG44 -VCU;_OM_P#XJC:/5O\
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MBTOM/O[>6TO;.Z@D!2:VNK6:6">)P4DBD=&!5B* /Q5U?XE?'SP'IOCZ_P#
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M5=0#\\?VY_CQ^T3X3^-7Q1E^$6K?%&_^'7[/GP'\$?$'QYJ7PRUCX9Z#X>^
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MB'XT>,&L-#\:>%+3XEWOBO1K+PS>>"]'@?2;7P]XLBN6^)>E:BNBZ1K7A"U
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M6NZ+HQA&KZOI>EFX#F :CJ%G8F81;!(81=31&41F1 Y3=LWKNQN7.K7Y ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
A44 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>marketedproducts18.jpg
<TEXT>
begin 644 marketedproducts18.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '\ IH# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"TQ\3?VM->\/\ A_3O!OQ+NOV0?B9XETOP5\&/#GC7X=_$;4?&W@'3-?\
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MG:6=A;W U";PG)JD:I:Q&VBO8[60R20/-)X7I?\ P4%\'ZC_ ,%"=:_8,E\
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MQE_P39_9N_8M_P""</@VS\5/\:/!W[*7P<\$^,_VI[O]G3]HKXQ_LZ?!O0?
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MOC@/A?K1M];^%5A\7-;L-2\56'@[7=#\*^(;V"=?'/B/PQI&O>--0CD_+/\
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M'&L?$77O%FH6/P1T_P <^)?#GBO3_@AX5\<S32^&%T:QTV+30#^B#PY^T7\
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M3W&.#G(_#&#R.:6B@!,#.><XQU/3WYY]LYP>1S1@>_;G)!XZ9(.3U/4FEHH
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M_?#_ /Q-&X>C?]\/_P#$T!==U_7_  Z^\=13=P]&_P"^'_\ B:-P]&_[X?\
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M ,/I\5/_ )K:/^&L_P!JK_HYW]HO_P /I\5/_FMKY^HH^H8+_H#PO_@BE_\
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MK!7C8!D<9PZ, RL"K $$5_J4L!@<#[R=A_?6O\MC]J3_ ).<_:2_[.$^./\
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M_P#S44?\+Q^-G_1:/C'_ .':^(__ ,U%'_$',1_T/J7_ (;Y>7_49Z_UN?\
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MN(/P/QX_W#A[_L*S#_TUA#PFBBBOWD_FL**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#^S__ (-D/^3:?VDO^S@]-_\ 54>#*_IAK^9[_@V0_P"3
M:?VDO^S@]-_]51X,K^F&OY/X^_Y+#//^PBC_ .HF'/[6\-/^2'X?_P"P6K_Z
ME8@****^//NAK_<;_=;^1K_.?_X+._\ *3K]K/\ [&SP/_ZJ#X=5_HP/]QO]
MUOY&O\Y__@L[_P I.OVL_P#L;/ __JH/AU7ZQX/_ /)09C_V):O_ *GY>?BO
MCG_R3&5_]CZC_P"J_,3\P:***_H@_ED**** "BBE7AE.0.1R1D#GJ1W ].]
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MBOY+/^(H9O\ HRE__$@8_P#YTE'_ !%#-_T92_\ XD#'_P#.DKZ?_B&_&?\
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M?_6.OB%7[>1_ZN/_ '%_]!%?B'_P4H_Y21?\$*O^SK_VG?\ UCKXA5^WD?\
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M&/\ T!]0_P#![JO_ ,DT?\*%^&/_ $!]0_\ ![JO_P DU[%11]?QW_09BO\
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M7X8_] ?4/_![JO\ \DT?\*%^&/\ T!]0_P#![JO_ ,DU[%173]?QW_09BO\
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MY_\ 8U;HH_XB=X@_]%=GG_A=5\O/R_JRL?V=@?\ H%H_^ _UV_/NRI]BM_\
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M8Q)N<$AVW98$AB<FOHS_ (9L\;?]!7PS_P"!FH?_ "KH_P"&;/&W_05\,_\
M@9J'_P JZ%FN7],72U\Y>7EYK[P_LC,?^@.K]T?_ )+R7W'SN50YW(C9*L=R
M*<LG*,<@Y:,\QDY,9Y0J>: B!WD5$620 22*BB20+C:))  [A<#:'8A<< 5]
M$?\ #-GC;_H*^&?_  ,U#_Y5T?\ #-GC;_H*^&?_  ,U#_Y5T?VME_\ T%TO
MOEY>7FOZ0?V1F7_0)5_\E_\ DCYYHKZ&_P"&;/&W_05\,_\ @9J'_P JZ/\
MAFSQM_T%?#/_ (&:A_\ *NC^U<N_Z"Z7WR\O+S0?V3F7_0)5_P#)?_DCYYHK
MZ&_X9L\;?]!7PS_X&:A_\JZ/^&;/&W_05\,_^!FH?_*NC^U<N_Z"Z7WR\O+S
M0?V3F7_0)5_\E_\ DCYYHKZ&_P"&;/&W_05\,_\ @9J'_P JZ/\ AFSQM_T%
M?#/_ (&:A_\ *NC^U<N_Z"Z7WR\O+S0?V3F7_0)5_P#)?_DC[_\ ^"#<L4'_
M  4Z^!\LTD<4:^$/C:&DED2- 6^%NO@ N[*HR3@9(SVK_0+_ +6TS_H(6/\
MX&6W_P =K^%7_@B3\#_$?A/_ (*/?!K6]9N_#][IUKX4^,<<UO;RW5Q,[W/P
MUUN"$K%<Z?%"P61U9BS@JH)4$X!_NJ_LG3/^@?8_^ =M_P#&J_GKQ5Q%'$\1
MX:I0J1JP_L?#1<HWLI+%XYM.Z6J33^:/ZB\%L-7PO"F,IUZ<J4WGV+FHSM=Q
M> RQ*2LWHW%KU3#^UM,_Z"%C_P"!EK_\=J\CK(BNC*Z.H9'5@RLK#*LK*2K*
M00002".02*H_V3IG_0/L?_ .U_\ C57D18T5$541%"HBJ%55485550%50
M  !P !7YH?KHZBBB@ HHHH **** "BBB@ HHHH _$#_@I1_RDB_X(5?]G7_M
M._\ K'7Q"K]O(_\ 5Q_[B_\ H(K\0_\ @I1_RDB_X(5?]G7_ +3O_K'7Q"K]
MO(_]7'_N+_Z"* %;H/\ >3_T-:_@V^.__)<OC7_V6'XI_P#J?>(J_O);H/\
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MJXCMKO"23]CRP=L.U=5VTU3E&M%7YHM.3IR;DE)RC)1E)+GJ;)^'WP3D\%>
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M?_C+_P!D<T[_ -3G3J_IQK^C?#;3A7"V_P"@K'?^I,S]/X7_ .111_Z^U_\
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M@Y3=M(;% $U%?E=X_P#VC;KPA\0%\,ZC^U!\1CXJ'Q'N? ^LV7@_]G7P'>?
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M_P"H+S_!]@_MS)O^AKE__A9A_+_IYY_U=7\CHKUS_A1GQ*_Z ]C_ .#O2_\
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M#W_"A/B'_P ^VB?^#V#_ .,4?\*$^(?_ #[:)_X/8/\ XQ7W#11_Q)]X3?\
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MXA]_U-O_ "Q]/^HSU_#S#_6'_J#_ /+C_P"X'Y-['_YYR?\ ?M__ (FC8_\
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MC7>H_P"8D?4?],*_F ^*"[/B9\1TW.^SX@^-TWR-OD?;XIU9=\CX&^1L;G;
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MA]9A5;C4:<94??3C?5PINU6I3A/Y_HHHKUCS0HHHH **** /L?\ 8(_Y.?\
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M^KC_ -Q?_017XA_\%*/^4D7_  0J_P"SK_VG?_6.OB%7[>1_ZN/_ '%_]!%
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M* "BBB@#]*?^"8__ "5?XB_]D\L__4GLJ_:^OQ0_X)C_ /)5_B+_ -D\L_\
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M_P"@[I__ '\D_P#C=?.-%']@8?\ Y_U__*?E_<\G]_D']MXG_GW1^Z?E_?\
M)_?Y'T=_PEWA?_H.Z?\ ]_)/_C='_"7>%_\ H.Z?_P!_)/\ XW7SC11_8&'_
M .?]?_RGY?W/)_?Y!_;>)_Y]T?NGY?W_ "?W^1]'?\)=X7_Z#NG_ /?R3_XW
M1_PEWA?_ *#NG_\ ?R3_ .-U\XT4?V!A_P#G_7_\I^7]SR?W^0?VWB?^?='[
MI^7]_P G]_D?1W_"7>%_^@[I_P#W\D_^-T?\)=X7_P"@[I__ '\D_P#C=?.-
M%']@8?\ Y_U__*?E_<\G]_D']MXG_GW1^Z?E_?\ )_?Y'T=_PEWA?_H.Z?\
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M_P#8#E?_ *D8L_FOZ1W_ "+^%?\ L,S3_P!,8,\YHHHK^PC^4PHHHH ****
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MONCAF@D)*Y"[95P>2".*_I]\KQ+_ ,_FA_\ @OU'_P"6U?PU])3_ )+W+_\
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M]MG\>A1110 4444 ?5ME\)OAWJ7[.2?$#1SX@\1>+[+5XIO&6IZ!XB\.RS^
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MMW_)S?AK_LCGAC_U*?&]?N?T>/\ DXU'_L39I_Z30/QCQY_Y("K_ -C?+/\
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MGTZ6WN>*KQ-"^%FO"+XI>#_B3XN^)NB_#ZW\=W2>/;>\N_#?AOPG>:7?>%_
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MWJ7QMT=/"_CW1/AKX:M;?Q!HLVC_ -#:]!U'7KU)))S[9ZX[9Q7YE>"_@O\
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M!^0HP/0?D*/J,?\ GY+_ ,!7^?K_ $M3^T9_\^X?>_Z[_P!+7]*/^$Y\%?\
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M_P ^X?>_Z[_TM?TH_P"$Y\%?]#=X:_\ !UI__P ?H_X3GP5_T-WAK_P=:?\
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MZ#&L?^#;4O\ Y*H_MG6?^@QK'_@VU+_Y*H^HO_GXO_ 7_P#)!_:2_P"?+_\
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MX _Z'/PW_P"#2&C_ (63X _Z'/PW_P"#2&CV<_Y)_P#@+_R\U]X>UI_SP_\
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M_P!,X$\;HHHK^TS^/ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/ZRO^#>;_DW_ ./W_9<K#_U6GA.OZ#J_GQ_X-YO^3?\ X_?]ERL/_5:>$Z_H
M.K_,GQK_ .3H\7_]AV%_]5F!/]&_!O\ Y-IPI_V!5_\ U/Q84445^6GZ:(W0
M_0_RK^#G_@K'_P I#OVF_P#L9_!__JK/ =?WC-T/T/\ *OX.?^"L?_*0[]IO
M_L9_!_\ ZJSP'7],?19_Y+K//^R3Q7_JXR4_G/Z3'_)%Y+_V5&&_]5.;GYW4
M445_>!_$84444 %%%% !1110 4444 %%%% !1110 4444 %%%% '[\?\&]?_
M "<M\=_^R%Z5_P"K$TJOZX*_D?\ ^#>O_DY;X[_]D+TK_P!6)I5?UP5_G7](
MS_DZ.:_]B_)O_59AS^_OH_\ _)L\K_[&&<?^K"L%%%%?A9^U!7\<G_!??_D]
M/P9_V;QX*_\ 4Y^)=?V-U_')_P %]_\ D]/P9_V;QX*_]3GXEU^^?1M_Y.90
M_P"Q+FOY8<_"_I#_ /)NZO\ V.,L_P#2JI^(5%%%?Z&'\%A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?JA_P $6_\ E(I\'?\ L5?B_P#^JXUN
MO[B*_AW_ ."+?_*13X._]BK\7_\ U7&MU_<17\"_2@_Y.'EW_9)Y=_ZM,[/[
MF^C;_P D%F'_ &5&._\ 55DH4445_.)_004444 %%%% !1110 4444 %%%%
M'X@?\%*/^4D7_!"K_LZ_]IW_ -8Z^(5?MY'_ *N/_<7_ -!%?B'_ ,%*/^4D
M7_!"K_LZ_P#:=_\ 6.OB%7[>1_ZN/_<7_P!!% "MT'^\G_H:U_G&_M&?\G#?
M'[_LN7QA_P#5D>)Z_P!')N@_WD_]#6O\XW]HS_DX;X_?]ER^,/\ ZLCQ/7]:
M_12_Y&G&/_8!E/\ ZD8P_EKZ3_\ R+.$O^PW-O\ TS@3QNBBBO[3/X\"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH _K*_X-YO\ DW_X_?\ 9<K#
M_P!5IX3K^@ZOY\?^#>;_ )-_^/W_ &7*P_\ 5:>$Z_H.K_,GQK_Y.CQ?_P!A
MV%_]5F!/]&_!O_DVG"G_ &!5_P#U/Q84445^6GZ:(W0_0_RK^#G_ (*Q_P#*
M0[]IO_L9_!__ *JSP'7]XS=#]#_*OX.?^"L?_*0[]IO_ +&?P?\ ^JL\!U_3
M'T6?^2ZSS_LD\5_ZN,E/YS^DQ_R1>2_]E1AO_53FY^=U%%%?W@?Q&%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!^_'_  ;U_P#)RWQW_P"R%Z5_
MZL32J_K@K^1__@WK_P"3EOCO_P!D+TK_ -6)I5?UP5_G7](S_DZ.:_\ 8OR;
M_P!5F'/[^^C_ /\ )L\K_P"QAG'_ *L*P4445^%G[4%?QR?\%]_^3T_!G_9O
M'@K_ -3GXEU_8W7\<G_!??\ Y/3\&?\ 9O'@K_U.?B77[Y]&W_DYE#_L2YK^
M6'/POZ0__)NZO_8XRS_TJJ?B%1117^AA_!84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'ZH?\$6_P#E(I\'?^Q5^+__ *KC6Z_N(K^'?_@BW_RD
M4^#O_8J_%_\ ]5QK=?W$5_ OTH/^3AY=_P!DGEW_ *M,[/[F^C;_ ,D%F'_9
M48[_ -562A1117\XG]!!1110 4444 %%%% !1110 4444 ?B!_P4H_Y21?\
M!"K_ +.O_:=_]8Z^(5?MY'_JX_\ <7_T$5^'W_!2Z>&V_P""CO\ P0LFN)HH
M(4_:O_:<WRS2)%$F[]CSX@JNZ1RJ+N9E49(RQ ') K]J(_$?A[RT_P")[HWW
M%_YBECZ#_IO0!M-T'^\G_H:U_G&_M&?\G#?'[_LN7QA_]61XGK_1:;Q%X?.
M-=T8DLF -3LB3\Z]O/K_ #H_VB723]H/X]R1LKQR?'#XONCHP9'1_B/XF971
ME)5E92&5@2&!!!(-?UK]%+_D:<8_]@&4_P#J1C#^6OI/_P#(LX2_[#<V_P#3
M.!/':***_M,_CP**** "BBHYEWPS(0Y#PRH1$_ERL&C92L3D@)(<XC<E0CD,
M6 &0 ;5[H&NZ=I>A:YJ&BZK8Z+XH34I/#6KWFGW5MI?B%-&O/[.U=]%OY8EM
MM373+[%I?&SEE%M<$1R;352ZT_4+%;)[ZPO[%-2L8-4TU[VRN[-=1TRY>6.V
MU/3VNH8EO]-N9()TM]0M#-9W#PS)#.[12!?V!^+OB_X2>-?@=^SG-\</B["G
MA:+7-&;4?"7P,\=:AXZ\,?$/PMX7U34-&U.2S^"^O6^E^)O@OKFA:78Z;I.I
MWUMK&@:;H%[XB\1^'-$\+ZCC2Y[?YM_:BDTWX\#X0^(/!/Q*\/\ Q"U;PI^R
MQXH\1>.-/&AI\---\&^$O ?Q+^)VK0^&M%TG6O$NJFQN=&\,ZWINA>$OAC X
MUZ#PYI6A7=M]M77;98OB,KXMKXVIA88S*ZN"A5QN:87$XIPQ<\'A_J<L5]7Y
M<9]4CA)SFL-*GB/:UZ#I594:?L_K%2MA<)]EF7"U#!T\3/"YG2QM2G@\LQ.&
MPT986&+Q#QD<+]8OA/K<L5"$'B8U,.Z="NJM&-6HY_5Z='%8KXEC\(^+95T!
MXO"7BR1/%CM'X3DC\,:^\?BN1#AH_"TBZ<4\2R*<;DT-M0<9R5 HU_PEXL\*
M36UMXK\)^*O"MS>(\MG;>*/#6N^&[F\CB:-)9+.WUO3[":[CC>6))'MTE5'E
MB1R&E0-]W?'35/B=X0^#6KZ7XB^*^B?%CQI\2_%OPM\:^*/$WASXS_#[7?!W
MPHNO!>BZQIO@?P;\+O#/A/QG/K=MKZ6VNKIGQ"\8>&?"OA;P5X:T'2;'P)X>
M75;1=4UXYOBSXB?"_3/CYXIM/$7Q'UN^\(_L]> [KX;_ +-OB*UT/4/C/X>O
MO'FAI;6\OQ2UBTC\2VDNM0ZCXSO_ !E\8+2:UO+RT\0>+SX+TZ]4^&M)^S5O
MAN(\9B(QK4L'0Q5'DQ\E_9\L5C/;+"+ TTJ+IX;VZE/&X^&'A3JX2G4K8/#8
MG-(1A1E1H2QQ'#^#H2=&KBZV%J\^!@_KT<-A51^MO&5).LIXAT9*&#P,\1.=
M+%3ITL5B</ELG.K&K7C\&ZA8WNDW=WI^K65YI6H:?++!J%AJMI<Z;?:?/#S-
M!?V5]%;W5E/".9H;J&&6(<R(HIMU:7=C-]GOK2[LKCRK>?[/>VMQ9W'D7EO%
M>6D_D7,<4WD7=G/!=VDVSR[JTG@NH&D@FBD?[:_:8MO^$B_:H^*'Q3^%'C_P
M!\1;>\^,?A^'1=8\4:OX'A76?&6K>%8]:@U"ZT'X@:[?Z3XL\'6=UH4HUWQ[
MKCOX'?7KJTT?7&BN[R*WN^9_;936]4^-<WCC6?$WAWQC-XQ\#_"/[5XDT+X@
M^"?'T^I>)/#/P7^&OA[QJ=7G\'^(=<?3[ZU\56>IV,G]I16$5]/:W4FCBZL8
M#*G9EV?_ %VMDU&=*A0EF>2SS&K3GB)PQ>&QL(9;5> >#K8>E4?[K&UZGM*D
MJ56V%J?[,XJ<Z?'C\C^IT<VJQJUJT<MSB.7TJD*$)X7$X2<LPIK'+%T:]6FO
MWF$HP]G!5*2>*A?$<SIPG\AT445](?/A1110 4444 ?UE?\ !O-_R;_\?O\
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M'\M?2?\ ^19PE_V&YM_Z9P)XW1117]IG\>!1110 4444 ']<9]\# _(<#T'
MJ2.66)9EBEEB6XB:WN%BDDB6XMW>.5[><1LHG@>2&&1X90\320PR,A>*-ECH
MH:3T:379Z[.Z^YZ^H)M;.WH-"1@[A&@;H6"*&(]"P )]\FG?I].!^7:BB@!I
M52,%5(QC!4$8],$=#W'0X&1Q0JHN=J(N<9VJJYQP,[0,X' ST[4ZB@ HHHH
M**** "BBB@#^LK_@WF_Y-_\ C]_V7*P_]5IX3K^@ZOY\?^#>;_DW_P"/W_9<
MK#_U6GA.OZ#J_P R?&O_ ).CQ?\ ]AV%_P#59@3_ $;\&_\ DVG"G_8%7_\
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MK^QNOXY/^"^__)Z?@S_LWCP5_P"IS\2Z_?/HV_\ )S*'_8ES7\L.?A?TA_\
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M /U0_P""+?\ RD4^#O\ V*OQ?_\ 5<:W7]Q%?P[_ /!%O_E(I\'?^Q5^+_\
MZKC6Z_N(K^!?I0?\G#R[_LD\N_\ 5IG9_<WT;?\ D@LP_P"RHQW_ *JLE"BB
MBOYQ/Z""BBB@ HHHH **** "BBB@ HHHH _$#_@I1_RDB_X(5?\ 9U_[3O\
MZQU\0J_;R/\ U<?^XO\ Z"*_$'_@I6ZQ_P#!1_\ X(622,J1I^U=^TZSN[*B
M(/\ ACOX@@%G<JJY) &2,L0HRQ /[8QZC8"-!]MM.$4<75N1T'<2X/U'% %Y
MN@_WD_\ 0UK_ #C?VC/^3AOC]_V7+XP_^K(\3U_HRMJ-AC_C]M/O+_R]6_\
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M_O[%_P#%T<\/YH_?_7?\^S#DE_*_N]/\T+129']Y/^_L7_Q=&1_>3_O[%_\
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M@$\;F"(I\/\ _#@'_@CA_P!(^_@!_P""GQ+_ /-/7[#T4 ?CQ_PX!_X(X?\
M2/OX ?\ @I\2_P#S3T__ (<"?\$<?^D?7[/O_@E\0G^?B6OV$HH _'O_ (<"
M?\$<?^D?7[/O_@E\0_\ S2T?\.!/^"./_2/K]GW_ ,$OB'_YI:_82BE9=E_7
M_#+[AW?=_P!?\,ON/Q[_ .' G_!''_I'U^S[_P""7Q#_ /-+1_PX$_X(X_\
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M_P ,ON"[[O\ K_AE]Q^/?_#@3_@CC_TCZ_9]_P#!+XA_^:6C_AP)_P $<?\
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M$!/^".(&!_P3Z_9^X]=&\1$_F?$I)_$U^PM% 'X]_P##@3_@CC_TCZ_9]_\
M!+XA_P#FEH_X<"?\$<?^D?7[/O\ X)?$/_S2U^PE%*R[+^O^&7W#N^[_ *_X
M9?<?CW_PX$_X(X_](^OV??\ P2^(?_FEH_X<"?\ !''_ *1]?L^_^"7Q#_\
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M2T?\.!/^"./_ $CZ_9]_\$OB'_YI:_82BBR[+^O^&7W!=]W_ %_PR^X_'O\
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MPT[6?A_=G7+G3;:SM= \)?\ "V[CXD6_A#P=%)X+\/P67AR^U2RON/\ !/[
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MWAK3[C4]0N!MT[PUX=T+1+."&&.TTV-S/-/[)0 4444 %%%% !1110 4444
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MNB#6/$$\.EV\-?2U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXK-]5O+1;F2&-T>5("[1HZLX56!/)?\ "]?@E_T6'X6?^'"\(?\ RXK\J_\
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M\27^LZK 'M?!WAS2=/M1J?\ 9VC:18RV&D6-E%?W_P!H]QHH **** "BBB@
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M38IKJ9+:TMVN[Z:"$W-Y<R16MG;(S7%W=2Q6UM%+-(D;='7S+^U5\*+OXM>
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M+X1^$?[(/Q:\0:QJ5_\ M&^.M9NM%O/#OP=$WA[PK<?#+2U\=7?PH_:5^/\
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M+X*?#?5/ASXL\:V\?A[X:?!OQ7XJ\8WD.@6&MZW_ &E-\+/@U;1!M .OZ3*
M?JEI'C+PCK^N>*_#.A>*?#NL^(_ E_IFE>-] TK6]-U#6O!^IZUH=AXGT;3O
M%.EVES+?:!?:MX;U73-?TVTU6"UGOM%U"QU2U26RNH)WZ2OSR_9T_9X^-WPJ
M_:"\8_&+Q7K'A'4](_:"\+>*M4^*VAZ+HUKI6J^$/'>C_$F]\5?"2SNO$/\
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M>F:K?647B75=,U_6O%=F ?LRLB.I9&#J"ZDI\P#1N8Y$.W.'2161T^\KJRD
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MQPU&,HRBTU*,E!-232:::::36P4445S'6%%%% !1110 4444 %%%% !1110
M4444 %!&?\X/YCD444  &/\ .3^)/)HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>nci2018.jpg
<TEXT>
begin 644 nci2018.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MFTW1?$6F?<U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV6&PN(PWU*6'C-5W3;F\0JK7+[.4OA]C*][;JU]0Z7]?PM_F%%%%?5@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?B!_P4G_Y22?\$*?^
MSK?VH/\ UCGX@U^WD?\ JX_]Q?\ T$5^'W_!2TS+_P %'_\ @A6;>.*68?M6
M_M/;(YIG@B;_ (P[^( ;=*D%RZ87<1B%]S *=H)9?VHCG\0^6G_$KT;[B_\
M,=OO0?\ 4N4 ;E%8WG^(?^@7HW_@]OO_ )G*//\ $/\ T"]&_P#![??_ #.4
M ;-%8WG^(?\ H%Z-_P"#V^_^9RCS_$/_ $"]&_\ ![??_,Y0!LT5C>?XA_Z!
M>C?^#V^_^9RCS_$/_0+T;_P>WW_S.4 ;-%8WG^(?^@7HW_@]OO\ YG*//\0_
M] O1O_![??\ S.4 ;-?%'Q4_Y'[Q#_UUL?\ TUV-?7WG^(?^@7HW_@]OO_F<
MKX[^)C7#>.=>:ZBAAG,MEYD<$[W,*G^S+(+LGDM[5Y 5VDEK>/#$J P 9OR_
MQ8_Y$&!_['%'_P!0L>!P9W@$QLBR8/EM)'YT:O@[&EAW)YT2OM:2'>GFQAH]
MZ;MP_,7]FOX)?M _ _Q?\:]8O?A3I'_"IEU2RNO"G[-6B?'.'QY\.O'/B[2M
M.^ D?AGQC\&4^-/A_3;7X$>#/"-IX0\=6EKX>\4>(K@7KR>%/#6G>'=#C^&'
MAOQ%K?Z=T5^%X;&U,+2Q-&,*=2&*C2C4C4]JTE2J*I%QC"K3CSW3BJC3J4U)
MRHSI5+333MM_6V_=:;;=[['YU?!SPC^TKX8_9/\ A5\'/%OP(U73M3\&Z1'X
M*\?:9X%_:YT7X>_$;6=.M+E_$FD>,?A3\6_AY=VMGHT:>('_ +)\5:)XF\0^
M$/$5YI,CWVBWE[&MSI>I<98_"3]H[X7^%OV)O#.B_ #P]\4=6_9_\33>+?'W
MBOPI\7?@[X!6;P\G@?\ :-\#>$?AC:W?B_3O"FN>.-=\$6'Q;\-76M>.[S1-
M"\/^-=<C\;^-+?3['Q'XGOX+O]2**Z?[6K7K7PV$Y<17K8BK"V+4)U*\*].;
MTQG,DH8BHDHRBVU3<W/V5/E+^FG_  -?G;7YGR;X^T'XSW_Q6^&7QI\/?#'2
M=5O/@/XL^,'A+2O LOQ7\.Z3?_%7X6?%_P"'GP\MI_B#H?B'4-%70?A[XT\-
M>./"L>DKX,\52S_VGX2L_$=_#XCBN=<T/3)>_P#V;?ACKGP@^#7ACP3XIO-,
MO/%/]L?$;QIXH&@SW=UX<TWQ)\5OBCXV^+&N>'O#%S?VUE>W/AKPOJ7CBX\.
M:+>7-C82ZC9:5'JC:?IYOC96_N=%<E3%SJ8>&&]G2A3@X-."J<[5.6)G",G.
MI-<JJ8S$U-(J3E5:<G"%&%,N[6_KIU^27_#N][3/^0EIW_80L/\ TL@K]"J_
M/33<_P!HV&T M]OLMH8E5+?:X=H9@&*J3@%@K%020K$8/WEY_B'_ *!>C?\
M@]OO_F<K]B\(OX6??]?,M_\ 2<:'1>K_ $-FBL;S_$/_ $"]&_\ ![??_,Y1
MY_B'_H%Z-_X/;[_YG*_9!&S16-Y_B'_H%Z-_X/;[_P"9RCS_ !#_ - O1O\
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M G@N3QQH-OINO^,-*M?%>H6OB#QCID^J?M0.GYGICOW'KZ^^: /Q!_X*3_\
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M^OO^$;TOTOO_  <:U_\ +&C_ (1O2_2^_P#!QK7_ ,L:^0?^%G>//^ACNO\
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MTOO_  <:U_\ +&MZB@#!_P"$;TOTOO\ P<:U_P#+&K]CIMKI_FFV$X\W9O\
M.O+V[^YNV[?MES<>7]XY\O9NXW;L+B_10 4444 %%%% !1110 4AZ''7!Q_D
M\?G2TC'"D@@8!.3T''4\C@=^1]: /S5F^#_QIT[]I#XA^+)_"GQ3U_P?XJ^*
MOA+Q/H&N^$?VJ)?A1X.TSPW9:#X2TF\M-8^"?AA--TWQ+/IUYI&HW>LZKX@?
M6?$OQ!LKF'2M:NX],TS0],LOTK']3WSW_P \=NE?G7=7?Q_N_P!H/QHGB>+]
MK2;P-;_$KPJ/AG?_  @A_9CTSX'2?#J31?"IN+3Q/#XGUV^^+FI75IXG7Q3)
MXZU>>WM;F_TR[@A\&VT,-I%8V?Z*#\>IZ_7^7I[=: /Q _X*3_\ *23_ ((4
M_P#9UO[4'_K'/Q!K]4OCA_R*&E_]ANT_]-^H5^5O_!2?_E))_P $*?\ LZW]
MJ#_UCGX@U^J7QP_Y%#2_^PW:?^F_4*^7XU_Y)7._^P-_^G*8X[KU7YGRI7$_
M$?XA>&/A3X(\0?$'QE<7MOX<\-PZ<]^=,L6U/4[BXUG7-*\,Z)INF:>LULMW
MJ>L^(M<TC1M/AGN[*S^VZA ]_?Z?8)=7UOVU<;\0O#>I>,/!7B+PQI%]X9T^
M^UNQ2R27QKX(L/B3X,NK9KRUEU'1_%W@34KW3;7Q1X8\0:9%>:!KNF+J6G7G
M]FZG<7>F7UKJ=K9S+_+=%4W6I*L[4G4IJJTVFJ?.O:-.,*DD^2]FJ<VGJH3?
MNM?U_5CPC3_VL/#*_LVWW[27BWX<?%KP!IUAH*ZHGPU\3^&]-'Q%\1ZK>:9#
MJ7AWPU\/XM.UN\\*^/KSQBUS!8>%M6T+Q&="N+U-476KW08_#OB)M*7QI^U?
MX<\$^!]"^*%S\+?C-K?PQN_A?X ^,/B_XA:!X<\,3>&/AUX'^(T-C/HT^L2Z
MMXRT?4?&7B#3(+^&^\4>$_A7IOCK7M TCR=3FM9SJ>AV6J_)GPQ_X)Q>)-"^
M FA> -=^.'BCX:>+]#T[QY=^&O#/P%GTZ#X*> O$?Q ^"-A\&=972?#_ ,8?
M#?Q8U._M[^V@U[Q!J^K:)_PAKVFI?$+X@_\ "$:-X6_MV6:;O/&W[&'Q/\6_
M!+X7_ N_^('PF\:V/P_^$_P^\%>'/BY\3/ FOR?&SX*_$;PAH=EI%]\9O@AK
MWP^G\):%>^)(&TGPY<_#ZQ\2:=X/F\&W?A#0;G6M<\9PW6M:?=>_+#Y$L3:.
M*4J/UR:GIB8\F$;M:E:,E4=*,>:,Y8AN3G90Q"I1CB7I;[OQL^C]?^'V^WOB
M/XWUGP(=(LM"^%OQ*^+'B#6]2U33[70/AQ9>%PMC'HEDU]J6I>(_%/CKQ3X*
M\$^&-/V".ST<ZSXB@O?$FLW$&DZ%8WDJWT]A/\,/B-X8^+_PX\"?%7P7+J,W
MA'XB^%='\8>')-7TV?1M6_LG6K9;BWBU32;AGFT[4;=O,M;VT:6>.*Y@E^SW
M-W:F"ZG\:^+7PS^+GQ1\/ZWX6U^Q_9B^(G@F_P#&?B!9_AA\7O OCS6O"'C3
MX;M!X:NO <_C;5],O[J_L/B?X5\2:?XAU37/^$?\-WO@#Q58:KIUI:6'AK4M
M+CU4>D? KX<:G\(/@W\-/A;K/B^\\>ZGX!\)6'AFZ\6WUO<VDFK?89;E[:.U
MM+[4=9U"TT70[&>U\->&;34]9UG5;7PQHFC6^K:OJFI17=_<>54IX6."IRC4
MA+&>W2E&'M6G1<:KE*;FE!.,E148QC&RE)\]=RG'"#276_IW_P K?CY:OU>O
MKKX)?\B6W_8:U+_VA7R+7UU\$O\ D2V_[#6I?^T*^V\,/^2G?_8MQ?\ Z>PH
M='ZK\I'KU?%'Q4_Y'[Q#_P!=;'_TUV-?:]?%'Q4_Y'[Q#_UUL?\ TUV-?>>+
M'_(@P/\ V.*/_J%CQ'GU%%%?S^ 4444 %%%% %[3/^0EIW_80L/_ $L@K]"J
M_/73/^0EIW_80L/_ $L@K]"J_;/"+^%GW_7S+?\ TG&CZ+U?Y1"BBBOV0044
M44 %%%% !1110 4444 %%%% !1110 4444 %5;ZTCO[.[LI@ABO+:>UE#PV]
MRACN(7AD#6]U%/;3J4=@T-Q#-!*,I-%)&S(UJB@#\W++]AV/P]XCTNX\+?"C
M]@>P31[JRU#1_B"W[(.G6'Q T6_TR:&XTW4K;2?#_BS2O#3^(;"Y@AO+;6]/
MU'P_90ZA!%=P>'8$ MD_1/2;2\L=+T^SU#4IM9OK6SMH+S5KBVL[.?4KJ*%$
MN+Z:TT^&WL;:2[E5YW@LX(K:)I#'#&L:J*T** /P[_X*72^1_P %'_\ @A9+
MY4\^S]JS]I\^5;1^;,V?V._B OR1[ER%SN<Y^5 S<[<']1?C)J)N_"VG1'3]
M4M=FLVK>9>V7V>(XL;]=@?S9/WISD)C[H8[OEY_+_P#X*3_\I)/^"%/_ &=;
M^U!_ZQS\0:_:35= T?Q#96]GK-C%?6T4D=S'%(TJ*LZ1/$L@,,D;$A)9%P6*
MD,<C(!'C\09=6S;)LPRW#SITZV+H.E3G6<E2C+GC*\W"$YI6B_AA)^0+1I]C
MX"HK[;_X5AX"_P"A;M/^_P!>_P#R51_PK#P%_P!"W:?]_KW_ .2J_%_^(3Y]
M_P!!V4?^#<9_\Q?U9^5P^)**^V_^%8> O^A;M/\ O]>__)5'_"L/ 7_0MVG_
M '^O?_DJC_B$^??]!V4?^#<9_P#,7]6?E</B2BOMO_A6'@+_ *%NT_[_ %[_
M /)5'_"L/ 7_ $+=I_W^O?\ Y*H_XA/GW_0=E'_@W&?_ #%_5GY7#XDKZF^#
M^IFS\(M#_9^J7.=7U!_-M+/SX?F,(VB3S4RZ[?F7;QD<FNU_X5AX"_Z%NT_[
M_7O_ ,E5T^CZ'I.@6?V#1[*.QM#-)<>1&TCKYTNWS'S,\CY;:N1NVC' %?5<
M'<"9IP[G']HXS$X"M1^J5\/R8:IB)5.>K.C*+M4PU*/*E3E?WKWM9-.X^C7H
M_NO_ )E;^W3_ - ?7?\ P6G_ ./U\@?$N8W'C?79S#<6_F/8MY-U%Y$Z?\2R
MR'SQ;GVYQN7YCN0JW&<#[=P/0?D*Y'4O 7A#5[V?4=2T.VNKVY*-/</+=*TA
MCC2%"5CG1!MCC1!M4<*"<G)/TO&W#N,XERS#8+!5L-1JT<?3Q4I8J56--TXX
M?$T7&+I4JLN?FK1:3BERJ7O7231\+45]M_\ "L/ 7_0MVG_?Z]_^2J/^%8>
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M]O(_]7'_ +B_^@BOQ#_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\ U<?^XO\
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M]_P6=_\ $W;#_P"=#0!^SN]/[R_]]#_&C>G]Y?\ OH?XU^,7_#FNX_Z2O?\
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M ,(^VO\ ]M@>)"QOO[3&D:( +?[ ?. /M&BBB@ HHHH **** "BBB@ HHHH
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M#P;+-\/]?U2ZTWQ7:^&K>P\7:CIFHVL/V3PUXD\)ZE)*$\2:8L_UI0 4444
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MO)&RB]T+7-:T/48##J&C:MJ6F75K>3=E0 4444 %%%% !1110 4444 %%%%
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M^\;:E?\ A'1)(;B[OI9#X%^&]MX(^'<%T;CR[NT\(6UQ;6]C:R06%K[E110
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>ocrevus.jpg
<TEXT>
begin 644 ocrevus.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "D A\# 2(  A$! Q$!_\0
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M000I'(Z<+@ZV)J*C0BY2?1?UIZF=2I&$>:;LCZ#=UC1F8A549))X KYN^/\
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M%8G_  N/PC_T-7AO_P &</\ \53C3G)7BFQ<R6YTE%<W_P +C\(_]#5X;_\
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M3KXY_ 'PG^T=X%N/#WB[2;?4[&96\IV4">S<C EA?&8W'J.O0@@D'\3?VO\
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M^:]@')0^K+U7\1W&/4^CCX_XC(\72X5X@J.6#F^6G.3UHR;LHMO_ )=MZ:_
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MB\5&X81*JJL;$<;B6(!.-IP1F_M2_P#!&?5OV>_@EK'C#2?&G_"6-H:K/=6
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MZQ^]?YH_=;0/$%CXKT6UU+2[RUU'3[V,36]S;2K+#.AZ,K*2&!]0:N5^2?\
MP1\_:ZU;X6?'73_A]?WDDWA/QA*T,5O(V5L;TKF.1/3S"-C <$LI_AK];*_/
ML]R>>6XGV$G=-73[K_,]C"XE5X<Z^9#/8074\4LL,,DD!)C=D#-&3UP>W0=*
MFHHKQ3J"OC?_ (+4_'Y_AC^S3:^$[*8Q:EX\NC;R;3AA9P[7FP1_>8PH1W5W
M%?9%?CW_ ,%EOBTWQ#_;(O-(CF+V/@ZP@TV-0V4\UE\^5A[YE"'_ *YCTKZC
M@_ K$YE#FVA[S^6WXM'#F5;DH.W70^3Z**]6_8K^$D?QB_:&T6QNH/M&EZ66
MU74$8922*'#"-O\ 9DD,<1/_ $UK]BS3,J&7X.KC\2[4Z493D^RBFW^"/F\/
MAYUZL:-/XI-)>K=D?7'[*OP07X#_  3L8;J+R_$'B18]2U0E,/"I4^3!_P
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M$LSMU&YVQQBN,^)/Q<\5?&?7EU+Q5X@U?Q%? %8Y+ZY>8Q G.U 3A5S_  J
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MW^S_ /\ "G/V3[77+JW\O6/'DO\ :TI8?,+8#;;+_NE,R#_KN:_4>*,53R_
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M@%RH!9O=LFNCK%^(WQ$T?X3>!]2\2>(+S^S]%T>$SW=QY3R^4@(&=J*S'J.
M":/AS\1-'^+/@?3?$GA^\_M#1=8A$]I<>4\7FH21G:ZJPZ'@@&N2<:LX^VG=
MJ]KN^_:_<T3BGRK[BQXM\':1X_\ #UQI.O:5INM:3=[?/LK^V2YMYMK!UW1N
M"K89589'!4'J*Y/1_P!E3X7^'=7M=0T_X;^ ;&_L9DN+:YM_#]I%-;RHP9'1
MUC!5E8 @@@@@$5WU%$,15A'EA)I>38.,6[M!1116)1YW-^R%\)KB9I)/A?\
M#N220EF9O#=F68GJ2?+KJ/ ?PS\-_"S2Y;'PQX?T/PY93RF>6WTNQBLXI)"
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MNI-&9HX,G SNCC7OT+@GL#7TI\&OC;X7_: \#6_B/PCJUOK&DW!*>9'E7A<
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M .W_ (UY2MT/N\_I0CBO:4_AFE)/R>R^7P_(****^X/$"BBB@ HHHH ****
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M>#/$T%TB/#>:=.&,<BE2&4_,C#K@\J0>Q(KZ,/B*R_9=^,4?B#3;%M4^%WQ
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M)[<X*GAA[@$?.?AKX*_M;_LY6::%X5\7>#/'WANT416#ZTK)<V\2\*K9PPP
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ME>BVTLDEHK66Q:P\$DET=PKP']M#]@W2_P!JB73?$&F:I<>$?B!X?VG3-=M
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M 3L/(85M(^/NN>$M9_M+PG=6%XUQ)YES!%:?9)+O_KXLU)BW8'W[;!QRS9)
M_%O$SP-S'.,+*OP[BG1K2C:4)-NC57]Z+3Y)_P![EWW7,Y3/L.'.,,/A*BAC
MZ7/!.ZDOCCZ-6NO*^W6UD?HIX9^._BCPGA+;59YK=>!%=8G4#TRW(_ BNZT7
M]LN^A55U#1;6X/=K>9HOT8-_.OC/]GK]KNQ^-]V^GS:7-INJ01>8X6=)(I1T
M.P$B0GO@*V!U->MVNIV][(T<4T;R)]Y,_.GU7J/QK^&,RSCQ X(QLLJQM:I2
MG32;C)QJ12>S5^>*3Z6/VBA@LASFBL52A&2EU2<7?SM9W]3Z1M?VQM"<?O\
M2]6C]=@C?^;"DN?VQ]#7=Y.EZK)Z;_+7/Y,:^=J*V_XCWQ?R\OM87[^SC?\
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MFY;@6W[:IMT_S)J***_+3W@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH X[XY_ 3PK^T=X!N/#?B[2H=4
MTV?YXR?EFM) "!+$XY1QGJ.H)!RI(/Y6?M;?\$M/$G[,5_>ZM;KJ7BCP-RZ:
MG80A[K3%P3_I,('0?WUPAQR8\X'["4,-PP>0>"#WKWLFXAQ67.U-W@]XO;U7
M9_TTSDQ.#IUOBW[G\Y]W MM.RK(DR]G3.&'X\CZ&HZ_9#]J+_@DM\-/VA9KC
M4]+A?P/XCG)=KO3(@;6=CWEMLA3W.4*,2<DFO@GX[_\ !);XP_!B6::RT5/&
M>DQY*W6AL9I=O;=;G$N[V56 QU/&?U3+.+,OQB2Y^27:6GW/9_GY'@5\OK4]
M;77D?-\NM74\D<CSR-+"P9)3_K%(Y'S_ 'N/K7IW@W]LSQIX9M([6^FLO$EG
M'TBU6#SF _WP0Q/NQ->8:OH]YH&HRV=_:W-C=P';)!<1-')&?0JP!'XU6K3B
M#A+)<^HJCF^&A6BM8\T4W&_6,MXOSBTRL#FF,P4^?"U'!];/?U6S^9]':7^W
M3I<L2QWWA/4K5<8/]FZ_<6\8Z?=C7:%Z=C5D?MJ>&2T?F:;XXD6,8"_V_*N[
MZE6!/YU\T45^9U/H\\$RDY4Z-2-^BKU[+TO4=OE8^@CQWG"5I3B_6$/TCJ?0
MVH_MO:3''MM/ XO'QA9=8U:6_P ?A(&/XAJYKQ9^W'X\\16_D6=S8:#;XVA-
M/M@I"]AN<L1]5Q7CU%>QEO@?P1@YJJL!&I):IU93K:][5932?HCEQ'&6<58N
M/MW%/^5*'_I*1L'Q]K$NMR:E-?2WFH2#'VF[ N95.<[E:0,58'D,N".Q%9NH
MZE<:Q?275Y<375S,=TDLSF220^I8\G\:T/!G@'7/B/K*:=X?T;5-<U"3[MO8
M6KW$I_X"@)KZX_9V_P""*OQ$^),MO>^-KFU\#Z2Q#-"Q%UJ,B]>(U.Q,]/G?
M</[AZ5^@XC&9?EU-*;C325DE9:=DEK;T1X,:=:O*ZNV^O^;/CW0/#]]XKUJU
MTW2[*ZU'4+V00V]M;1-+-.YZ*JJ"6)] *_1K]A+_ ((X)I$UGXJ^+UO#<3H1
M-:>&E<21(1R&NV'#^OE*2O3<6R4'UE^S'^P_\._V3-.QX6T?S-5D39/J]\1/
M?SCN-^ $4_W4"J<<@FO7*_.L\XVJXA.C@;PCUE]I^G;\_0]K"Y7&'O5=7VZ$
M=M;1V5M'##''##"H1$1=JHH&  !P !VJ2BBO@3U@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>otherincomeexpnet.jpg
<TEXT>
begin 644 otherincomeexpnet.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
M_86TW1-9UB=OBCXCO/#HT7]LGPWX,T$^'= M9_"NA?MI>-O!/Q,\>V=UK<$A
MN/$DWA;QUX7U2^\'WEY:64Z:+KZ:+K?]J3Z-;ZO=@'MFE_M9? 36_B#IGPUT
M?QR=4U[6-0TC0].U?3_#/B^\^'USXH\0>!;7XG:!X*3XJ0: _P -%\>:W\/+
MVR\:Z5X'?Q8OBF^\,WVGZK!I30:A8_:?,?C)^V#/\&OBY+\%]9^'$NH^+?B%
MX5\-ZG^R\+7Q,EO:_'GQG=>(3X8^('P^:2?1"?!VI_"-;_PQ\1?'&H)_PDL4
M/P8UK6OB'9V<L'@/Q;I]EY)\*_\ @F%\(?A3\9O"_P 7M-O/#NN7^A2^!_$=
M[<>(_@Q\(M7\>:AX_P# _P )?#'P@M-;TSXLZCX;O?&WA3PW?Z5X2TCQ3<>$
MO#UQ:W-AXR6\N-#\4:7X9U"\\+3_ &)\3/@9H7Q.^(?P,\?ZMJ=Y:R_!#Q)X
M\\1:?I%O:V<MIX@/CWX4^+_A1J%CJ%W*%OM/AM=*\7W=_#/I4L-S+<VT5M*_
MV6692 >:Z1^W-^SAK^EZEJN@>*?%WB*.RL](U32K3P]\'OC-K6J>/=!UZ]O]
M+TGQ=\)M'L?A_+JOQ:\!WNIZ;>6D?CWX=V?B/P9"JVU]=Z[;:9J.EWU]5N/V
M^_V3+:V%])\6;<Z?'\+KOXT:EJ$?A'Q[+8^'?AM8Z[XT\)W?B#Q=<Q^%G3P?
M/!XS^'_BGP*_A[Q,-*\3GQYI\7@F/19/$]_8:7<?'OAC_@CU\(_ OA2W\*^"
MO$WAK0[/PQ+X/TKP5&G[/'P*-GK'@/P<NH0VG@OX_6]EX9TR]_:*LKV&ZTC4
M+U_&FJZ9IDGB[P-\/_'S>'Y/&7AV;6=3][^$7_!/3P7\%_A]X]^'GA+XA>($
MTSQM\([GX21SW7@;X37-IHNE3_&S]H7XU_:8/!=YX*O/AIJ-A_:'[0>M>%I?
M!NH>"'\%2>%]"L-/BT.WCO;M$ /KWP-\8? OQ \'ZGXZTJ[US0= T*XU2U\1
M?\+%\&^,?A3K'AJ?1+.'4-6'B3PY\3-!\)^(-"@LM/N(=1:^U'38-.GTN6+5
M+2[N-.ECNF\%C_;Z_9=DT72]<;QOXF@@U_7_  )X<\,Z9=_"/XQ67B;Q?>_%
M/3?&&K?"Z^\%^$;SP%;^*/%_ASXE6G@+Q:G@+Q7X;TC4_#?BJ_T._P!+TG5)
M]3A>T$WP8_8]\+?#/X(_%'X'^(_$5YXR\*?&"Y\7_P#"4:%I>DVOP^\"^&M$
M\:>"M+\ ZUX/^$_@/P_>7FG?#'PA=:3ID^M3:'HFH3POXV\0^*_%4+VUQK;6
MMMX5\%?^"9'PV^"USX%OM!\0Z)9W_@'XF?#/QO97O@SX)?!SX77GB;1_A-X,
M^*?@[PSHWCR^\ ^'-)U#Q=K>I1_%;6-8\3>*+Z\2UN-6L+67PSX6\)Q:AKT>
MJ ':_&#_ (*.? 7X?_#"3Q[X(O=4^*6KW/A30_&&E^%](\*_$73UL])U_P")
MLOPEL!\1=<3P)J=M\';^Z\=:7XI\(Z?I/Q.MO#.KWWC#PAXG\+Q6*ZGH&M)I
MWK,_[:_[-=E<^.XM2^(<FDV7P\TWX@ZMK?B#5O!WCW3/"6K6OPH\1VO@_P")
M<7@'Q??>%H/#7Q0U+P+XMOK'PGXHT?X;ZGXJU72_%-Y;^'GLY-5D%L/F_4?^
M";.G'2/$WA_P[\>/B!X9T7XDQWMK\6+.V\,^!]2D\96.G?M$?%?]H[P!#87>
MI:=-/X4G\+^(_C%XN\):S=Z:UR_C'P4=.M;N/2==L8==7'TG_@E!\#]'U?XJ
MW>F7^GZ';>.+GQSK/A'6_#7PF^$>A_%;P)XI\=?%'3OC,?$-S\8QX6O?&GCM
MO!7C[2K*?P1H_B65-';P]&/#_P 0;3XAQPV=Y: 'U;\(/VHM#^,5I^T7JNA>
M%]?TS2O@'X]C\#[?$FE^)?"7B37[A?@5\+?C-?/J_@[QGX9\-^)?!&HV,WQ(
M?PQ)H^L:?<2R+H\>NQW#6NK0VUO\Y_"W]O[6H?"WP@\:_M2_#KP-\$?!OQV^
M >H_'_P%XT\$?%+Q!\4_#FFZ3HGA+PGX[UKP+XZAU?X4_#;Q!HWC>/PCXOL]
M5\/IX<TGQ?HWBJXTG7]#LKVSU^+0--\2?3?PC_9\O_A]I7QM_P"$M^).M_$?
MQ7\?O%D7C3QSXEO?#_A_PQ%:ZM'\(/A_\&DLO#6@Z#&;'2]$MO#OPZT>YL;.
M[N-4ODO9[V2^U749)C.WQW8_\$O['Q?\(_#OP@_:)^.OB3XS>'_AQ\#X?@3\
M(H+'X<^ /A_I7@?188_ *#QMJ.@0Q>+;'QW\0VB^&7A#3FO?%,LW@X:"GB/0
M4\$I8^+_ ! +L ^H-4_;F_9MT30X=:U?Q9XLTZX;5_$FC:AX0NOA#\8D^)?A
MRX\&>'M!\7^,K[QC\+!X#;XB>#?#WA/PAXI\,>*_$'BGQ/X:TOPUIWAWQ/X8
MU9]5>T\2Z"^HV-;_ &X?V8O#E[X]MM8^)+6=C\-]"\?:]XE\4?\ "&^/9_ <
MD7PJ\*77CCXEZ/X9^(5OX7E\#^-O%W@/PE8WVO>*?!7@WQ!KOBO2;'3M7,^D
M"?0];ATWP3P;_P $Z;#X9V&A:M\(_BK;_!/XG6MW\2K37_&7P:^!'P/^'^@:
MKX2^+.G?#'3/%>A6'PZT_P ,7&@V&L:>WP;^'>N^$?&^M7OBSQ+HGB'1[E-0
MFU_P=J!\&6_+:M_P2A^#=]XA^.^K6.LZ9I<7QJT']H1!K*_!WX/ZA\5?#7C/
M]IGPUXM\/?$GQ2/C7?\ A>7XAZ[9)<>._%^N>'_#L^HZ:;*Z\07^B:GK>L^#
MDL/#5B ?20_;J_9WO-3E\,Z-XHURZ\9/KNH^#;+PYK'PZ^*'A0CQW'X+N/B%
MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MFTW1?$6F?<U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME8&EAJ>(GE.9KVDJ<53:HJ:<IXJ,UK-7E2CAH3J+>,,7AI;58W+:7NOO]/\
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MX4M%%EV7W(+ON_Z_X9?<7-,5#J6G91/^0A8'[B_\_D'M7Z&5^>NF?\A+3O\
ML(6'_I9!7Z%5^V^$*2I9]96_>9=_Z3C0>R]7^2.+^(P!\#>* 0"#I-R"",@\
M#L:^&RJ@GY$ZG^!?\*^Y/B+_ ,B-XG_[!-Q_):^'&ZGZG^=>/XLI/.<MND_^
M$SM_U%8@+NRUZO\ ]M&[5_N)_P!\+_A1M7^XG_?"_P"%+17Y59=E]R"[[O\
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M7L/[HH Q/[=/_0'UW_P6G_X_1_;I_P"@/KO_ (+3_P#'ZWL#T'Y"C ]!^0H
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M?P;XCA_LO68?,TNX7S9K#RX8^ =TLGG-L08^9L' [&OC5NI^I_G7W%\10/\
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M[_D?\*_/735#:A8*PRK7UDK#D95KN$$9!!&02,@@CL0:^[/^$8T0?\N0_P#
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MUO3AX;UB\:PM[6ZTJ>UU+RKHW4T2O;2?00TK4P !XCOL  ?\@_11T]AIP'Y
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M#^TOK/B?]G7X\_$GX^_'3QOXH\<0^#;/]FOQMI%KX;^,TOPH\,> ?!NK>"_
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MU#PW<ZK8W6G7^NWL]G>0O!<PFRTA!)$XPR[X[!77/9D96!Y!!KB?^%+>%_\
MGK=?]\6W_P 9KR^..#,TXES#!XK 5\!2IX?!_5YK%U<13FY^WJU+Q5'"UXN/
M+-*[E%WOI;5E]/1WVOO;_+YG\Q7C=O$7@/\ ;Z^,OBOX<>#];^)/Q.U+X7>/
M-=L;KQ/\.OB[X3^)?PEA/ASXNMX>\1^$/B7IUW>_![XH_LX:5KGASP_8>%O"
M/B"'3Q?/XNTS0M!L-4^)WA6XBDU_C_JW[*%Q8?"?X1OKFEZ%\8_&GP _9[N-
M%_:!\>'QI/8_LZ_#:$V7BC1_B)\']:@TR_CC^/WCC5[G6]?T[1/AS<V&IZ_X
MEFT[QA\<?$>G>"M#TG1?$?\ 2\OP6\+HXE26Z21=@614M1(HCE:>,!Q#N"QS
M.\R)G8LSO*%#NS&MH7P+\'>%](L= \-&\\/Z%ID+6VG:-HS)IVEV%NTKS&WL
M[&U6*VMX/-D=EABC6*,$1QHD:(B^7_J+Q"WAINKEL9X6A0HQ=/,\93]HZ$&J
M<JG_  D2@Z5&7+*EAO9N,VYO$5*J<X5'S*S7??1:[?K?7IT6UOP \6?$WX2>
M%?VZ/CY'H/B[QQXU^)?C+]D'QCX/;P-I'BKQ>WBV\^*FD_$W7=<\-? GX0:M
MJ.D)X$^'GBN'P^7N/ ]GI*VEM9:_K!\7ZS<:S>S27!\D_8@U;2_@9K>N:SXL
MUOP!KW@#PU^RU\-M'\:_$/X&? KXP?##1?"_C31_B#X=T"+PW^T1X2UWPWJ6
MN?%[]ICQ3<>+%NA\3= M=+UW3]$\.?$1_&OPP\#Z?XET_4;C]VOC7HEYX0^*
MG['_ (-T+Q+JUCX=^*_QR\:^!O&VDM]BGMM:\,Z/^RW^T+\2K#2T2Y@E:S6W
M\7>!/#6KF33_ +/<2+ISVLLC6-Q=P3?2#?"#07:.1]0U9Y(05AD>X#R0JPVL
ML+L"\2LORLL952ORD$<5C_J!Q!]6J85SRJ4*M#"T*LGF6*<I1PRM%Q;R6]-1
MCI2C!V@[*J\132I(NNW_  WGK;S?GM9ZGXSV?P+^$WC#]N77_$FI?!/X<Z9)
M\'/A[X>US4O'$?PV\+Z9K_C[XN?M&W7C[PUXEU?6/'MOHL&K^)HO _P>\(ZE
MH<T;ZS?06^I_%O5M0U,M?66B36WK?[*NK:OKG[-_P6U36[N\U&]N? UK';:I
MJ(?^T-7\/Z?JNK:5X+UB^:4M))=:QX'L/#6JS7$A:2\:\^VNSM<%V_2Z\^!?
M@[4;*ZTV^%Q=Z?>VEY87=E,L#6]Q9:A;O:7]J\8C $-Y;2R07"IM,L;E6/0@
MM/@7X,T^TM+"QC>RL;"UMK&QL[6VLK>UL[&R@CM;*SM;>&W2&WM;2UAAMK:W
MB1(H+>*.&)%C15'#7\->)*]"-&6+RA^S6$A3YL7CI*G##TL1&HHN67N5L17Q
M$Z[CI&G:,$Y*,7%:?+Y>7W_A??34Y#X!?\?WB;_KTTS_ -'7M?2]>>Z#\/;+
MPR]S)HFIWEB]XD27!6VTZ;S%@,C1C]_:2[=IE<_)MW9&[.!CL[&TNK;S?M.I
M3ZAOV;/.M[*#RMN[=M^QV]ONWY&?,WXVC;MRV?U/A/*,3D6183+,9.A4Q%">
M)E.>'E4G1:K8FK6CRRJ4Z,VU"HE*]-6E=*ZLVB_1117T8!1110 4444 %%%%
M !1110 4444 %%%4M2OX-*T^^U.YCNY;?3K.ZOIX["QO-3OGAM()+B5+/3M/
M@N;^_NFCC86]E96\]W=S%+>U@FGDCC8 NUE+H6B)K<WB5-'TI/$=SI=MH=QK
MZZ=9KK4^BV=Y=ZA9Z1-JHA%_+I=K?W]]?6VGO<-:07E[=W,4*SW,SO\ "_\
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M\0=4\+:-\"?">N6%Y:P?!OP?>:$+NQUOQ'J&H>*[WQSXG\0^.=1M_%;]B_\
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>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>performancegraph.jpg
<TEXT>
begin 644 performancegraph.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '@ F4# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.N:1</#::]X8UZW@LO[=\*:WH6KSZ;I-U>SZ79>X_P"?7^5>(_ /X*V7P/\
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M8^9*,DG.>E=5_P (QX>_Z ]A_P" Z?X4 ;F1[_D?\*,CW_(_X5A_\(QX>_Z
M]A_X#I_A1_PC'A[_ * ]A_X#I_A0!N9'O^1_PHR/?\C_ (5A_P#",>'O^@/8
M?^ Z?X4?\(QX>_Z ]A_X#I_A0!N9'O\ D?\ "C(]_P C_A6'_P (QX>_Z ]A
M_P" Z?X4?\(QX>_Z ]A_X#I_A0!N9'O^1_PHR/?\C_A6'_PC'A[_ * ]A_X#
MI_A1_P (QX>_Z ]A_P" Z?X4 9_B?F[\)8!_Y&NU/0]!I&N9[=JZS(]_R/\
MA7G/B3PYH4=UX4":38J)/%%K')B!1O0Z5K3%6]1N16P>X!["NJ_X1CP]_P!
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M8RY96^&7+*,K.SM)/9HW,CW_ "/^%&1[_D?\*P_^$8\/?] >P_\  =/\*/\
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MY%DU2L^2]6IEF"G4?)&,(7J2H.3Y(QC&&ONQC%*R22]!R/?\CW_"C(]_R/\
MA6'_ ,(QX>_Z ]A_X#I_A1_PC'A[_H#V'_@.G^%>(>R;F1[_ )'_  HR/?\
M(_X5A_\ ",>'O^@/8?\ @.G^%'_",>'O^@/8?^ Z?X4 ;N<^OX@C^=%4++2]
M.TWS#86=O:>=L\WR(Q'YFS=LW8Z[=S8STR:OT %%%% !1110 4444 %%%% !
M1110 4444 ?B#_P7>_Y-\_9#_P"TI7_!.C_UH31Z_;N/[I_WY/\ T8U?B)_P
M7>_Y-\_9#_[2E?\ !.C_ -:$T>OV[C^Z?]^3_P!&-0 ^BBB@ I#T_%?YBEI#
MT_%?YB@#D_ O_(I:%_UX)_Z-EKK:Y+P+_P BEH7_ %X)_P"C9:ZV@ HHHH *
M*** "BBB@ HHHH Y+Q/_ ,??A'_L:[3_ --&N5UM<EXG_P"/OPC_ -C7:?\
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M\ ?V0[?3]=T6^G_X>C_\$ZY/(M-6T^YF\N/]H31C))Y,-R\FQ REGV[5&6)
M5B/W-2YM@#_I$'WY/^6T?_/1O]K\QVZ'F@"U14'VJV_Y^(/^_P!'_P#%4?:K
M;_GX@_[_ $?_ ,50!/2'I^*_S%0_:K;_ )^(/^_T?_Q5(;JV_P"?B#J/^6T?
MJ/\ :H YKP+_ ,BEH7_7@G_HV6NMKC/ UQ;KX3T(-<0 BP0$&6/(_>2]1NKK
M/M5M_P _$'_?Z/\ ^*H GHJ#[5;?\_$'_?Z/_P"*H^U6W_/Q!_W^C_\ BJ )
MZ*@^U6W_ #\0?]_H_P#XJC[5;?\ /Q!_W^C_ /BJ )Z*@^U6W_/Q!_W^C_\
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M%[6/_3?<5T'VJV_Y^(/^_P!'_P#%5S/C2XMV\'^*5%Q 2?#VL #SH\D_8+C
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M-#_Z VE?^"VR_P#C%:]% 'GWB71-&2Z\*!-)TM1)XHM8W T^S&]#I.M,5;$
MW+N56VG(W*#C(!KJO[ T/_H#:5_X+;+_ .,5D^)_^/OPC_V-=I_Z:-<KK: ,
MC^P-#_Z VE?^"VR_^,4?V!H?_0&TK_P6V7_QBM>B@#(_L#0_^@-I7_@MLO\
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M\7RZGKGP@NW)\G1[Y-^H^*/A<TG2--/W7'B7P5"X7S/#\NK:/ 2GAR%7^BZ
M,C^P-#_Z VE?^"VR_P#C%']@:'_T!M*_\%ME_P#&*UZ* ,C^P-#_ .@-I7_@
MMLO_ (Q1_8&A_P#0&TK_ ,%ME_\ &*UZ* ,C^P-#_P"@-I7_ (+;+_XQ1_8&
MA_\ 0&TK_P %ME_\8K7HH R/[ T/_H#:5_X+;+_XQ7-^,M#T:+PCXGDCTC2T
M=- U=D==.L@RLMA.0RL( 593RK @J0""" :[NN8\;?\ (G>*O^Q>UC_TWW%
M%\:!H>!_Q)M*Z#_F&V7_ ,8I?[ T/_H#:5_X+;+_ .,5K+T'T'\J6@#(_L#0
M_P#H#:5_X+;+_P",4?V!H?\ T!M*_P#!;9?_ !BM>B@#(_L#0_\ H#:5_P""
MVR_^,4?V!H?_ $!M*_\ !;9?_&*UZ* ,<Z#H0!)T?2@!_P!0ZQ_^,?SXKY5T
MO2-+_:&^(,.N1Z5IP^!GPPUR9=#5+*T6V^*WQ'TB:2VGUQ_+B47O@?P1<^;:
MZ4A+6>O^)5GOC]HLM,A0]+\5M>UCXE^*O^% > [^[T]9;.TU+XS>,=-E\J;P
M=X)O]Y@\,:9=H?W'C3QU$DEK9A<S:-H!O=9= TEFU?0V@:#HWA;1-*\.^'].
MM=(T/1+"VTS2M-LXQ%:V-C9Q+#;V\*]=L<:@%G+22-NDE=Y'=V^;K?\ "[C9
M86.N39=72QTK7AF>8T)J4<OBVK5,%@*D5/,.5N%?&1IX"4G##YCAY^74_P"%
M"O*C_P P.%J?[0_LXO%4VI+#)_:P^&DE+$V]VI74<,VXTL52D'0-#Y)T?2O4
M_P#$MLN2?^V'))_,U\B:A:VO[2WB^Y\+^&K6UT_X!^"-9^S^-_%&F6UI;2_%
MKQ7I%S;7!\#>&[Z*U$J^"= OH OC'7+*9#K>H1?\(_IDWV6&_N7Z'XA>)-=^
M-?B[5/@;\-]5N](\+:))';?'+XDZ3,$FTBWN(TG'PQ\'W\,RX\::Y:L8_$6H
MPAQX0T:9E;_B<7D$,/TMX;\-Z%X/T'2?"_AC2K/1/#^A6,&FZ3I6GQ"&TL;*
MV0)#!$F2QP,M)+(SS3RM)/,\DTDCM^ET8QX=P]/%U8J6?8JE"ME]":4EE&%K
M14Z69UXOX<QQ%.2GE=*2YL+1E',FHU9Y?47GUK\05JN#A_R(\/4E1Q]5;9O7
MIRY:N6TG]K+Z,U*GF4U>.*JQEER<J4<=3EXI/\ /@FOBK2[,?"OP(+:;P_K]
MU+"/#M@(Y)[?4O#<4$KIY>PO%'=7"1MC<BSRJ#AR*]5T'X>^!O"]@-+\.^$?
M#FC:<)IKD6>GZ/86]OY]PP:>;RU@(WRL 7;O@>E6KG_D<]'_ .Q8\2_^G7PI
M73UXE?,<PQ4/98G'8S$4^92]G7Q-:M#F2:4N6I.4>9)M)VNKNV[/3PN493@:
MOM\%E>78.MR2I^VPN"PV'J\DFG*'M*5*$N63C%N-[-I76AD?V!H?_0&TK_P6
MV7_QBC^P-#_Z VE?^"VR_P#C%:]%<9Z)D?V!H?\ T!M*_P#!;9?_ !BC^P-#
M_P"@-I7_ (+;+_XQ6O10!D?V!H?_ $!M*_\ !;9?_&*/[ T/_H#:5_X+;+_X
MQ6O10!D?V!H?_0&TK_P6V7_QBC^P-#_Z VE?^"VR_P#C%:]% 'QK^U7\!?B#
M\9M&\.>%?AY+X%\/:#9W\NL^(IM8:[L+[4K^W3R-&M(!I6@WQ%A9B:\O9_,N
M$\Z]-D?*(M [?,?P&_8]^-7PZ\?^&OB#;ZU\-]0TO3=6U+2M?TB?4-<E;5-#
M2^N=%UZUCCF\,/;-,3:M?Z6\K*%O+6QDE,(\T+^LU<OX/_Y LG_8>\6_^I7K
M5?%9CP%D>:9[3XCQ4\Q_M2C5PM6A5I8V=.G0>#<'0C2I*+C"G&4.>4-8SG.I
M*:DZD[^#BN',NQF80S2L\3]<ISHSISA7E&--T.7V:A"SBHIQYG'52E*;DFY,
MT?[ T/\ Z ^E?^"VR_\ D>C^P-#_ .@-I7_@MLO_ (Q6O17VI[QD?V!H?_0&
MTK_P6V7_ ,8H_L#0_P#H#:5_X+;+_P",5KT4 4[73[&Q\S[%96EIYNWS/LMM
M!;^9LSLW^3&F_;N;;NSMR<8R<W*** "BBB@ HHHH **** "BBB@ HHHH ***
M* /Q!_X+O?\ )OG[(?\ VE*_X)T?^M":/7[=Q_=/^_)_Z,:OQ$_X+O?\F^?L
MA_\ :4K_ ()T?^M":/7[=Q_=/^_)_P"C&H ?1110 4AZ?BO\Q2TAZ?BO\Q0!
MR?@7_D4M"_Z\$_\ 1LM=;7)>!?\ D4M"_P"O!/\ T;+76T %%%% !1110 44
M44 %%%% ')>)_P#C[\(_]C7:?^FC7*ZVN2\3_P#'WX1_[&NT_P#31KE=;0 4
M444 %%%8WB#Q#H?A71]0\0>)-5L=$T32K=KK4-3U*YCM;.UA4A=TLTI"[G=E
MCAB7=+/,Z0P1R2NB, ;->&^(?B?J^OZQJ'@;X.V-AXC\2Z=,UEXE\7ZEYS^
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M??VDJS6M[8WL*7-I=VTJ$K+!<V\D<T4BDAT=2#5Z@ HHHH **** "N8\;?\
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MO%O_ *E>M4 =11110 4444 %%%% !1110 4444 %%%% !7YK>/?VR/B-X/\
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MZP_ UO;MX3T(M;P$FP0DF*/)_>2]3MKK/LMM_P ^\'_?F/\ ^)H S_[?T/\
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M?T/_ *#.E?\ @RLO_C]:'V6V_P"?>#_OS'_\31]EMO\ GW@_[\Q__$T 9_\
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M^@SI7_@RLO\ X_6A]EMO^?>#_OS'_P#$T?9;;_GW@_[\Q_\ Q- &?_;^A_\
M09TK_P &5E_\?KFO"6N:-'H\B2:MI:-_;OBIL-J-D#M?Q3K+HPS/RKHRNK#A
ME8,I*D$]K]EMO^?>#_OS'_\ $US'A"WMVT:0M;P$_P!O>+!DQ1]!XJUH ?=Z
M   #L!@4 :_]OZ'_ -!G2O\ P967_P ?H_M_0_\ H,Z5_P"#*R_^/UH?9;;_
M )]X/^_,?_Q-'V6V_P"?>#_OS'_\30!G_P!OZ'_T&=*_\&5E_P#'Z/[?T/\
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M'C7_ +">C_\ J-Z576UR6@_\C!XU_P"PGH__ *C>E4 =;1110 5X!\5M,O\
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M\M=/L[B_OKF"SLK*VFN[R[NI4@MK6UMHFFN+FYGE98X8((4>6:61E2.-&=B
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M%>VBV]_;[[K3+F]MHWE'(_#O]LGX,ZYJ&C^#=(D\87^O>(O%&IVFE6D?A&_
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M_)OG[(?_ &E*_P""='_K0FCU^W<?W3_OR?\ HQJ '8'O^9_QHP/?\S_C2T4
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MDX5?8S4J+^R_V7_C#XF^(7A'P[^REX6N7\$W>KZKXIO]>^(>F1PV^JV7PZ2
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M55 55 50  *?0 F![_F?\:,#W_,_XTM% "8'O^9_QHP/?\S_ (TM% ',7/\
MR.6CC)Q_PC/B4XW'&?[5\*<]?S]<#TKIL#W_ #/^-<S<_P#(YZ/_ -BQXE_]
M.OA2NGH 3 ]_S/\ C1@>_P"9_P :6B@!,#W_ #/^-&![_F?\:6B@!,#W_,_X
MT8'O^9_QI:* $P/?\S_C1@>_YG_&EHH 3 ]_S/\ C7'^!;*SL= D@LK6"S@/
MB/QI.8;6)((C-=>,=>N;F7RX@J^9/<2R32OC<\LCNQ))-=C7+^#_ /D"R?\
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MBU_<45.HG95G0C-5#,/BCXA_%XFW^'L=[\.?A[,-LWQ+U[2FC\7^([5\-O\
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M6_2'^H_F* /.?!7B#38O"VB1LUX62Q0';I.L.N?,E/#)8,C#G&58CCK74_\
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M-@=U>^U.^=?*M+2++NY+N4B1W7\J?@3\"OBE_P %#_BAX7_;*_;+\,:AX2^
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M?\(QXE..V?[5\*<UT]>&?1& ?$6E'J;[)&,C2-:!QUQD:>"/P-?-/Q:_9?\
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M^.GPQE-U^S=^UY\1]*TR-VFC^&/[3%@W[3OP[98XREMI]CXHUW6O"WQ[T&U
MQ$"GQ?UJTMXPACTF3RU0GL<LK_P<75P4W=^RQ])UJ,4K6BL9@X2J5)RUMS9=
M0IK[51;H^L9OAK*O@:.806CK9;6CAZ\F_M/ 8^I"E3A'KRYIB*CWC3;T/M/_
M (232_6^_P#!/K7_ ,KJ/^$DTOUOO_!/K7_RNKXH3]HG]JKX5@V_Q_\ V1]:
M\9Z5:QQK-\3/V0/$UM\7]'N&=LM<W_P@\8IX"^,NC[8MS2:=X6TOXH/&Z&*&
M^NR\9?UWX2_MB_LT?&[56\,_#_XN^%KKQQ#*T%[\,_$LE[X!^*^F7$:[I8-5
M^%?CVS\-?$#3Y(B"KFX\.K'E24D=1N.=7+,;3IRK*DL10@KSQ&$J4\70@M&O
M:U,-*I&@VFGR5_9S6SBFFEI1SC+ZM2%"5=X7$S?+#"XZG5P.(J2ZJC2Q<*,L
M1%/3VF'56F_LS::;]Z_X232_6^_\$^M?_*ZN;\)^(--BTB1&:\)_MSQ2^5TG
M6'!63Q1K$B\KIY&=K#*G#(<HZJZLHQ_C5\=_@_\ LZ> =2^*'QP^(?AGX9^!
M-)FMK:Z\0^*;\65O)?7K.MEIFGVT:3:CJ^KWICE^QZ/I%G?:I=B*9K>TD2&5
MD^8_V3/^"A?[&W[4^J:AX"^!OQV\,>,O'-E<^*-=?P?=67B'PGXHNM&D\0:G
M?'5-*T3QAH^A7VMV,%I<P7%[/HT=^-/BE1]06U!)$4\NQ];"U<;2P.,JX.BV
MJV+IX:M/#4FDFU4KQ@Z4&DTWS35KJ^ZOI5S3+*&+HY?6S' T<?B$I4,%5Q>'
MIXNO&3:BZ6&E45:HI--)P@T^65MG;[8_X232_6^_\$^M?_*ZC_A)-+];[_P3
MZU_\KJWJ*XSO,'_A)-+];[_P3ZU_\KJ/^$DTOUOO_!/K7_RNK>HH H6.I6NH
M>:+8SGRMF_SK.]M/O[MNW[9;6_F?=.?+W[>-VW*YOT44 %%%% !1110 4444
M %%%% !1110 4444 ?B#_P %WO\ DWS]D/\ [2E?\$Z/_6A-'K]NX_NG_?D_
M]&-7XB?\%WO^3?/V0_\ M*5_P3H_]:$T>OV[C^Z?]^3_ -&-0 ^BBB@ I#T_
M%?YBEI#T_%?YB@#D_ O_ "*6A?\ 7@G_ *-EKK:Y+P+_ ,BEH7_7@G_HV6NM
MH **** ,_5M5T[0],U'6=6O(-.TO2K&[U+4K^Z<1VUE86,$ES>7<\AX2&VMX
MI)I&/1$/>O%/A#I>H^*=1U?XW>*+2XL]7\:VD6G^"=&O4:.X\(_"^WG%UHEC
M+ PS;:UXLN OB[Q,"?-26YTC1Y>-"C%4/'9/Q9\?6OPCMOWW@OPFVD^*_B],
MO,.I2F1;_P &?#9GP5<:S<01>*/%,&./#EAI^FSXA\1XKZ) "@ 8  Q@# _
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MBJ?M*<*EWA<NPO-R2S+,G!J4,-"5XT*$7&MCZ\?J]#EC&O7P]+X$_ GXH_\
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M9_%^HWMQK6O?"M]'E\5?LJ_$G5)E,MRWBSX*17^E0>!=:U>>"U2^\??!C4_
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M?_H'Z[_X(M4_^1J/[?M_^@?KO_@BU3_Y&J2C=HK"_M^W_P"@?KO_ ((M4_\
MD:C^W[?_ *!^N_\ @BU3_P"1J -VBL+^W[?_ *!^N_\ @BU3_P"1J/[?M_\
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MOBL#SYGA/+F5&E#'TK*[J3JX".&I).^)DO>/OW ]!^0HP/0?D*^:?@_^U_\
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M>+?_ %*]:H Z? ]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:* # '0 4444 %%%%
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M3&-15HQGB,/*G5JTUH_8UI5*$K>_3DM#X"'[:GBOX4;;7]K_ /9U^(OP-LX
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M17R!]P%%%% !1110 4444 <Q<_\ (YZ/_P!BQXE_].OA2NGKF+G_ )'/1_\
ML6/$O_IU\*5T] !1110 4444 %%%% !1110 5R_@_P#Y LG_ &'O%O\ ZE>M
M5U%<OX/_ .0+)_V'O%O_ *E>M4 =11110 4444 %%%% !1110 4444 %%%%
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MU']LW/\ T+^N?]^M,_\ EM6]10!YQXDU:X>Z\*DZ%K2;/$]LX#1:=\Y&DZT
MB;=48;CN+?,57:I^;.%/4_VS<_\ 0OZY_P!^M,_^6U4/$_\ Q]^$?^QKM/\
MTT:Y76T 8/\ ;-S_ -"_KG_?K3/_ );4?VS<_P#0OZY_WZTS_P"6U;U% &#_
M &S<_P#0OZY_WZTS_P"6U']LW/\ T+^N?]^M,_\ EM6]10!@_P!LW/\ T+^N
M?]^M,_\ EM1_;-S_ -"_KG_?K3/_ );5O44 8/\ ;-S_ -"_KG_?K3/_ );4
M?VS<_P#0OZY_WZTS_P"6U;U% &#_ &S<_P#0OZY_WZTS_P"6U<MHFK7"Z[XP
M8:'K3&34M*+((M.W1[?#VEJ%?.J ;F WC:SC:RY8-E1Z/7):#_R,'C7_ +">
MC_\ J-Z50!?_ +9N?^A?US_OUIG_ ,MJ/[9N?^A?US_OUIG_ ,MJWJ* ,'^V
M;G_H7]<_[]:9_P#+:C^V;G_H7]<_[]:9_P#+:MZB@#!_MFY_Z%_7/^_6F?\
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M>_[)A]>>V>@ X !^RM%?C7_PU?\ \%G_ /I$=^SK_P"+1]"_^A+H_P"&K_\
M@L__ -(COV=?_%H^A?\ T)= '[*4AZ?BO\Q7XV?\-7_\%G_^D1W[.O\ XM'T
M+_Z$ND/[6'_!9X#G_@D=^SKU4<_\%1]"')8 =?V3!W(QZG@ G@@'ZT>!?^12
MT+_KP3_T;+76U^"OP._;J_X*Y_$WX3> _'O@;_@DW\ -1\)>*= M]5T&]O\
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MGN[K4!^RJ/L5S::KX_\ "4-A9/8R?VG%>ZC/'=0_V3+#-Z7_ ,-7_P#!9_\
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M_P @63_L/>+?_4KUJOR3_P"&K_\ @L]_TB._9U_\6CZ%_P#0EUYE\(_VX_\
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MQ?9_#VQ\2W?Z(8'(/((P022"/H<B@ #) Y/)/<_7UXX]AQTH 6BBB@ HHHH
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M;6MK#';VUM!!&L4-O;P1*L4%O!$B100QJL<42)'&JHJ@6:** "BBB@ HHHH
M*^.?VW?%7PX\#_"?0O%OQ%^!/C#]HIM"^(WAF[\!_#KPG\/?&GQ'M3\1WL=>
MM/#'B;QII/@[PSXS&B^"/"B76HZWK'C+Q%X3\2:3X2NK73M8T?0]7\>6_@W3
MKK[&HQG_ /61_*@#\"O 7PO\'>$X/ 'B_P")_P '_&G[0/P#\4_!?]JG3(?
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M *3 '0#_  SUQZ9[XZ]Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!N77V;^Q?[5_XF/_")_P!B?V5_P@OVGG_A"?\ A'_(_P!'\NOV2_X(#?\
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MG:]T[4[.UU"PO+=OB6\%W97L$=S:7,+_ ,44\$L<L;=U<5<_XRN_ZM[ZC/\
MR4OIGG\<=/>OK(YY&<8RCE6=2C)*491P*<91DDU)-5FFFFFFFTU=H]E9@FE)
M8/'M-)IK#W332:::G9IIZ->9]$5PMW\4/AK8>.M.^&%[\0?!%G\2=7L)-6TG
MX?77BWP];^-]3TJ**XFEU/3_  E-J2>(+W3XHK2ZDDO+;3I;=([>=VD"0RLG
M;KOV+Y@4R;!O"9V%\?,$W<[<YV[N<8SS7XQ?&+P%\1?#O[5VN>)OA+\*_B)X
MGUOQS^T9\"/'GBGX>?%3X!>#/B1^S_XUM?#VG?"SP#K7QX^'O[3&CP67BO\
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M+X9:OHIN;/XD>&/B]\:[GPEXV^'W[0>I:[\1/#J167CCP[XC\0>#[GQ!\)_
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M?&7X9?L':Y\>?%%K>?%[QGX0F\&>"=#U?PI^T5I7A/2O@[X@MM$\,_%S3_%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ,3Q!X;T'Q5IZZ5XCTJSUC3DO\ 2]46SOHA+"NH:)J-KJVE
MW04D?O+/4;.VN8^=K-'Y<BO$\D;[=%% !1110 4TJIZJIZ]0.YR>W<\GU/-.
MHH ;M7).U<GJ<#)SP<G'.0 /PHVKTVKC.<8'7IGIUQQ3J* *%_I>F:I'!%J6
MGV.H16U[8:E;1WUI;W:0:AI=W%?:9?0I<12K%>:?>P0WEC=1A9[2ZABN+>2*
M:-'6\54]5!XQR >/3GM[4M% "%5(P5!'H0".F._MQ].*"JGJH/ '('0'('T!
MY'H>:6B@!NU>/E7CIP..<\<<<\\=^:7 ]!^7^?04M% "%5/50>_(!YQC//MQ
M].*"JL,,H(]" 1TQW]N/IQ2T4 >3ZU\!O@?XC\77WC_Q!\'/A5KOCK4]'N_#
MVI>--9^'?@[5/%FH>'[_ $J70[[0K[Q)?:+<:S=Z/>Z+/-I-WIEQ>R65SIDL
MNGS0O9R/ WI.E:5IFA:7INB:+IUCI&C:/86>EZ3I.EV=MI^F:9IFGV\=I8:=
MIUA9Q0VEC8V5K#%;6EG:PQ6]M;Q1PP11Q(J"_10 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>plegridy.jpg
<TEXT>
begin 644 plegridy.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "6 /H# 2(  A$! Q$!_\0
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MMO#:P+%;":2<'!9L!<>W?K66FL^,[E4ECTRW2*3!''8_C5/XH_\ 'QIOT?\
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M[:>ZB/\ L28_I4I-$Q4HZ&U6?J6LV^GH06#S=HP>?Q]*GFL_.B"-<3@ 8RK
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M@>QR*W:* .-3X9:4'!>XNV4?P[@/Z5T^FZ7::3:BWL85BCZG'4GU)[U;I"<
MGTH 6BLOP_J[:WIGVIHA$?,9-H.>E:E !1165;ZPTWB6[TLQ +!$LGF9Y.<<
M8_&@#5HHHH *R-<\-6?B#ROMSS[8L[5C?:.?PJ[?:E9Z;&'O;F*!3TWMC/T]
M:K:#K*:[8-=Q1E(_-9%R>H'>@"[:6L5E:16T"[8HE"*/85-2'.#CK5+2=2_M
M*W=F3RIH9&BECSG:P/\ +O0!>HHHH *YS09/MGB;7;EN3'(ENOL%!S^M='7-
M^'D^R^)->MFX9Y5G4?[+ T 9'AW1&U_1YIKZ^NRRS.D&V4@1X[^YSZ^E,?Q'
M>?\ "#0%[@QW+7/V1[@GE5'5L^N,<T>%_$UKH^C7$5Z)%;SY&APA(E]@1WS_
M #ILFB75OX(M)FMV>:*[%Y)#MR=I/3'TP<4Q#VN=-TC5M,?0]1>;S9A%<QF8
MN'4_Q$'O5Z*U_P"$G\2:F+N>=;:P98HHXI"HW<Y;COQ4B:W9ZEJ-C!H-M!,6
M?=<N8,>2GUQPU0PWG_",>)M4%Y!.UM?,)H9(XRP+<Y7COS0!#I<EW!:>*(I[
MN6:2V^5)&;GA6P?Y4R\FNI=$\+K'=S127$J(\BMR<@?G2:5+)=6WBR62%XI)
M"3Y;#YE^5L ^^,4LL;_V5X0&QLK/'NX/'3K0!8N-/'A_Q3I/V*XN2EXSQSK+
M*6#8 Y^O-1:=HD \>7\7G76(84D!\TY)..#ZBM'Q&K-XF\/%58@2OD@=.%JO
M]MCTSXA7;78D1;N"-(6"$ACQZ?2@#-@N],URYO[G6=3>&19FCMXA,4\I1T8
M=:CGU>\N_ -O*+E_M$=ZL/G \L!T)]>"*M:5>:=X<;4+'680LJSM+"SP[O-4
M] IQST_6EUK[9<>#+62ZM4@FDNT?RHDQM7G&1ZT 6]=T5=+\):O(;F>XGN(U
M,KR-D%LCH.U5=1D&B>&M-MX+R: 7[1B29WSY:[06P>U;WC!6?PGJ"JI9C&,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>rdpercentofrev.jpg
<TEXT>
begin 644 rdpercentofrev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %D 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3\>^*/^$(\$>,/
M&7V"35?^$3\+>(O$W]F13"WEU'^P-&OM7^PQSF*80R7GV/[,DIAE$;2A_+DV
M[&_.W]G[_@H_X1\>_"[P[\5?BOKOP M]/\>Z7X<U#P7X4_94^*GQ$_; \>VM
MW=>"I?B!XTT;QWX/\!_!#1=>\,WOP_\ #$VG:CXAN++3];L+""2YDU:XTDOH
M\>K_ **>.O"T'CGP5XN\%W-Y/I]OXM\+^(?#%Q?VJ12W-E#X@T>]TB6[MXY\
MPR3VT=ZT\*2@Q/)&JR#837R=JG[&YT[PS^SU#\*?BSXA^%'Q#_9V^'-Y\)_#
MOQ#TCP=X&\0-XB\#^(?#'@7PYXQL?$GA#Q!IDWAVYU#5[OX;>"?%FE:K"(YM
M!\3>'+ -'JWANXUGPYJX![)\-OVE_@M\8/%VO^"_AAXR'CC5O"_ASPEXKUR_
M\.Z#XEO_  G9:'X^\)^%O'?@:Y7QTFCCP9=S^+_!WC+0_$OAO3;+7;C5-7T:
M2^O[2R>WTG4WM?COPW_P5+^#>MMX&UG5_ WQ<\#>"?%L7[8*WVI>,?A9\4K7
MQII5S^R)\3/AWX \27FG_#32? >K>*?$?A;5M-\:ZKXOU?Q9IL TSP#9>$=9
MT/Q.8_$-CK5AHWU/^S=^S'X-_9AT7Q+X7\!ZMKE]X:U<_#*VTC3]>>TNKO0M
M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MFTW1?$6F?<U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFO%#+Y.48Y'GDI0FJ4XJAAVX57)15*:5>\:CD^54Y)3<K)*[LBW]?=_GTO\
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M-P:M)X2F:RU&VM8?[9O08IM--V_F"&TW/YHO[;Y6!4!/*^4@G>V<#]"\,?\
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M?ZCPM_UWU?\ ]%:?7[GXA?\ )'YQZ8'_ -6>"!;_ "E^3/FZBBBOYB$%%%%
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MN(%N;>&=8;N"2UNH5FC6017%M*%EMYXPP2:"15DBD5HW 92* /Q(_P""D_\
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MSQ*_Y)3&?]A&!_\ 4NB(\8HHHK^;0"BBB@ HHHH *^MO@?\ \B9-_P!AR_\
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M5$?^Q?B__2\.![%1117]' %%%% !1110 5DZ\0-$U@F9[<#2]1)GCO+G3GA
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M4I;$K$YM>TLLPNBO>&92:>SM'GP%-MZV7,HJ^C:5V</D>H_,4M<I_P (J?\
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MOCW^T?K7P<_80?PR_P 9?B-X\^+7[-NL?&+XR>'OV<O"'P6C_:$\32Z/X$\
MRZ'\0-(L_C/I,7P6\._#*\^(?B"Y\,>,]*L1IGB?5?%/C#P'H_@:SO\ P_8>
M+K&+Z73]JS2O!/[&'PX_:5\=^)/!OB'4O%/@KX=V,&L6HU7P+\/O%/Q>\9RV
MOA:'2[JX\16.G7_@'PS;>./[13QS=Z_9Z5+X'T;0_%%Q<6=I/IEIIK];I'[%
MW[+6@^#M$\ :3\&="LO"7AF[N;SPQI:>)?B/+<>&3>Z=I6DWUAX:\07'C>;Q
M5X>\/:AIFAZ/8ZCX1T;7K'PAJ$&FV8O= GDA62O8_"GPO^'?@36#KW@GP;H7
MA+5/^$%\(?#))O#MM)I%K;_#[P!>:YJ'@OP?8Z39SQ:+IVB>&[SQ-KT^G0:?
MIUK-NU2X6ZN+F-+9(/8Q.,RJK"G&G@IKV>+G7E:C0P\J]">)KU?J\ZM.I5E3
MBJ56G2@X0:I*BH*-12A/#U=6TNG^?P_=LW\O0_*_X7?M;_%G4_@3HOQHTSXQ
M>$/VA]&^'7QF^-_PU\=ZYX2NOASH&D>//$F@?M)^*=#\%^'=9TFSTXZKIVA>
M(_@7;:9<?#AO V-=\/Q_9OB#\1+K5?#VGZOJ\GZ7_ WQ;)XO^&N@76H^)M1\
M6^*=(BCT3QUK&K>%;CP-?2^-!IVF^(=55?"-U:65QH>BRV/B32-0\'V\T+SW
M'@>_\,WM[<W>IW-_<2;UI\*_AQ8PZ9;6O@K0$M=&\4?$'QKI=I):RW5G9^+?
MBM)XFE^(_B)+.\GN+675?&3>-/%XUFXN89PT?B?7H;-+2#4[J-]?P?X)\)_#
M_1(_#?@O0;'PYH<5S<WJZ?8M=RHUY=B%;BZGNM0NKV_N[AXK>UM5EO+NX>&Q
ML['3K<PZ?865K;Y8[&8+$TZBHX18>H\3.K"4*=""]E.=22I3]FDE[)2]Q484
MH-25.4&L-2G43=_Z_IZZZ=]5O8ZBOI+X _\ 'MXI_P"OC2?_ $5?5\VU])?
M'_CV\4_]?&D_^BKZOH/#O_DK\J_PX_\ ]5V+!;2]/U1]#5\M?'G_ )&'0_\
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M-KGP3X[M;233;O79=3NEDT2YED2UM[:*!UNYKFRX7QG^T'_P6<\8:-'H[?\
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M#P5IJ:/]GM8;S9?6,"W=_P#;[B[;[86^S&"WQ$#_ (AYP?\ ]"C_ ,R&:?\
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M9HKBP_Y>XX:_!CQ?X.\._'CQ/\:?"?[-7P>^(G[/OC+P#\*?VT?!OP8N-;^
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M#4/#VI_NFO0<8]L8X[<=N,9';I0 M%%% !1110 4444 %%%% !1110 4444
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M3:;XLTTZKI:W2VHNIK0B[A6"7S8-A<[%DE&P[UVMNR><@8KS,#Q#DF9U_JV
MS/"8NOR2J>RHU8SGR1Y>:5ET7/%-]V!T-%%%>R 45Y+<_'SX&6?Q)'P:N_C-
M\*+;XO%K-!\*[CXC>#H?B06U#3X=6L / TNM)XH)O=+N;?4;11I1:YL)X;R
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MU_1[[SC9:KHNI66JZ;=BWN9K.X-K?6$]Q:W'D7=O<6LWE2OY5S!- ^V6)T4
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M@A/AO!\1O#%W8_L>Q:;-<_#/7-*\6>%KZP^.'ACP[I&N?T&8'H.N?Q&,'ZC
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MKEW\??B1K7[0]O\ %^/X;>-/"WP6M];\0>#;OP_:ZS>_&@W.@:?X5U&U\1?
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MP\'/X?T[6[K6M7FUW5M3M+K6-=M=,UG4+_2[+Z(V)C&U<<<;1CCIV[=O2G
M#   '0#@#\* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>,YM7^'GA/Q;X;TRULO"[6%ZOC'P;X2U[2@VM:WK>B:7H/@SQ=?:1YQ\3/\
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M#]GOQ+X'^)/BO3-4\77*Z1_;'ASXB>!_A]H>IZ;#K7CK6Y/#4]GI]W^A^Q,
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MPS\1_#?A;2?'=]X"\-Z5J'B_7M1_X65JNK^)O%&H7B6L^JV5O/X8\+>$DO\
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M^PSW*M[O10!^4'@O_@DQ\%_A]X;^*7AGP9K&F^$AXG\">(_!7PO\9^%O@_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
9HHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>researchanddev.jpg
<TEXT>
begin 644 researchanddev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" += 3T# 2(  A$! Q$!_\0
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M3_!C]CWPI\,O@C\4?@?XB\0WGC'PI\8+GQ<?%.A:7I-G\/O OAO1?&G@K2_
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M+M[+7/$GA/4]"\3:5;W-_)X4U;0M3FM=3L0#R'P]^W+\3/B!>WGP]^&7[/\
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MZOX5M/BAI'A#4_%%O9V'Z"U\-?"/]B+0OA+XP^'%S8?$+7=2^%?P'N_B#?\
M[/OPD'ACP;HNG?#:Y^)UKK6G>(HK[Q;I&F0^)_&>GZ1H_B37]!\(6&HRZ=%9
M:9JC7?BQ_&WB73=$\0Z9]RT %%%% !1110 4444 %%%% !1110 45Y'\=OBC
M<?!?X3>-?B=:^$=7\<3>$=,AU >'=&^TI/<)-J5AITU_J%S9:;K=]I_AW08;
MZ3Q#XLU6PT/7=0T?PKI6M:K8Z%K5W90Z7=_&GP0_:W_:!^/W[._PU^*7P[^'
M/[./B36_%<VJ/XN\=:#^T:VL_ 'P;I&A>&-&URYU"YUK2_!5W\1D\0:GJ^IW
M'A67P+>^#[>Z\%3Z/K^N^+/$*:;8:+;^* #])Z*^%=7_ &PM1N?V'-!_:XT+
MP3IOAO4_%G@WX?>(-,\+_$'6]63PSH=U\0?%WAOPA;ZIK'B3PIX=U77=7\"Z
M>WB >*;/7_#OA275?%'@^*RU/2M M[O58=/@\<\-?MS_ !&\16/P^\%:5;_L
MZ:K\8_'?BOXMZ;?3ZYXW^+7PC^&W@#3OA!X<\ >*M5\+>,+'XG_"_3/BW:_&
M#Q!HOC_2/$'A[P%/X'TT7?P[&M?%&WOKWPSX;FAU4 _4VBORTOOVT?CK\1?A
M?^SE\:/V>O!/P.U3PS^T'>^&/!6A>"?B-XT^)$/C2\^)]UX@\567CC2_#VL>
M!O VN>%M3\$>"/#7@OQAXVN/&UQ]F74/"'A'6=?BTN**YTJQN?M;XU>,?C/X
M;MO#]O\ !WX?^"/$L^HR:U>>*?&/Q.^(,O@/X??#_0M"L(KY;G66T;0?%/B[
M6-2\07$@T_3;;2=!72-&M+;6O$/B37+"'2M/TGQ$ >ZT5XO^SK\8$^/_ ,#?
MA7\:4\+ZEX,3XF>"=#\8+X:U.ZCU";2UUBU6<1VNJPV]G%K>CW Q>Z!K\=C8
M)K^@W6F:TNGV"WXLX/:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #(]>O3WHR!U.*_(7]OK
MXN_%#P%^WO\ \$<O ?@KQ_XM\*^"_C%^TE^T/X:^*GA;0M:N].T+XA:#X>_9
M9\;>*M"TCQ=IT#+!K>GZ1XCL+36M/M;P/#;:E!%>1J)XXW3ZN_;9^(_C?X9_
M"WPUKG@3Q#=^&]6O?&^FZ9=7UI!87$LUA-H6OW4MLR:C9WL(1[BTMY2R1++N
MB4"0*75@#Z;\>^$O^$[\)ZOX63Q3XN\%S:FEH;;Q3X#UL>'_ !7H=Y8:A::G
M97^DZC):ZA9EXKNRA%UIVJZ;JNA:U8-=Z+X@TC5M$U#4-.N?S4_X=A&U^$7A
M[X7:9^T]\2[>6Z\1:!XH^-FIWGP^^"NL>'/VA;WPA\//"WPV\&:#\1OAU>^"
M(_"O_"!>%=#\):3-#X-TV&.S\7ZA:VUS\4;KQ\D3PS?)_P#PUO\ M'?]%6US
M_P %OAC_ .4-><^,_P#@HIX^^'6L^%?#WCK]I*U\)ZUXVO);'PQI^MGPE93:
MG/%!=SM(S/H!BTZP)LI[2/5=6DL-*FU,PZ5%>OJ,\5JX!^UC_!'XOZC:C1M6
M_:?^(-II$'PL\+>%;:_\'>%_A=X1\01?$O0/'-QXHF^*MO\ 9_ ]_H]K->:)
M:Z)X.O\ P+/9ZI\/=9\/KJ5I?>%XGN[BXO?)]=_81L?$N@^(/[=^-GC37OB%
MXW^(>@?$CX@^/_%7PX_9Z\;VGBS5_"WA'0? WA:S7X:^-OA'XA^&WAJR\&:#
MX>L[CP;>^&/#^E^(])\12ZCKFIZ[KQUS7[+5?RQ3_@H;\19/'+_#-/VBU;Q]
M'<SV#^&#:>'UO1JEII2Z[=Z$+M_"ZZ._B:ST)EUV\\*QZF_B:ST0G6+K2(M.
M5[E<6P_X*8^)=4TGQ+KUA^U)IL^B^#X=/NO$6IE/#MO:6%EK%_-I6B:E;M=^
M%[=];TGQ!JUO/I'AO6/#J:QI/B;6(9-)\/7NIZDOV4@'[A>%_P!D[X=>#+_]
MG&7P_J?B>#2_V9O#OQ"T?P9H]]J-KJ<.N:Q\1]%T[0]<\;^+KZZL_P"T-5\:
M&W3Q)<'5[>:R2ZO/'/BR:[M9$OK>*U\Z_:#_ &0_'WQ]T8^&=3_:J^)6D>$)
M?BAKGC[4? \WP\^!WB7P7XB\-7FD:+8^&OA#XOT/6/ *MXO^&7@[5].U+Q5:
M:-XBOM0NO%6MZRUM\0KOQ;X>TG1]#M/RQ\+?MW_&#QMH4GB;PE\=;[7]$@N=
M2L;J]L=+T-9+#4=&)75]*U/3;SPM:ZQI.LZ6P"ZAHNJ:=9ZO:L\0EL5\^#S>
M4\ _\%)?'OQ/U?5- \#?'[Q#K.M:+I5IKNJ:9=> M4\,7=IH]]?S:59ZD8_&
M7PW\.">UN=1MKFRADM&N"\]M=+M MIS& ?T:^!=$UOPSX0\.Z!XD\5S^-M=T
MC2[:QU/Q9=:+H7ARXUZZ@4JVH2Z%X:M;'0=+:5=B_8])L[>RA5 (8D&176Y!
MZ'-?SY_\-;_M'?\ 15M<_P#!;X8_^4-?JW^QEX^\8?$CX.MXB\<:[<^(M;_X
M2_Q'I_\ :%W#8P2_8K/[#]FM_+T^TL[?9#YLFUO)WG<=[M@8 /K&BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /Q _X*3_\I)/^"%/_ &=;^U!_ZQS\0:^O?^"B?_)%_"/_ &4;
M2?\ U&O$]?(7_!2?_E))_P $*?\ LZW]J#_UCGX@U]>_\%$_^2+^$?\ LHVD
M_P#J->)Z /QIKXG_ &E/A_\ %;6OB)\/O%?P=\,:O#XK2&313X\TKQKX8M_"
MD<6G^%/BT^DZ'\;_ (<^--)U#3?$'PZT_6?%F^WU;PW;ZGXNN;+Q7XO\*Z8=
M U74] U"?[8HH ^!XO@G\7X[OQ%X!L-8^(6GV7B/XC?'[6];^(]SXWT&X^$M
MY\-/C+!\4;^PAT_X7Q:E+X@3XO:+K7CGP_"OB(^&].\06-WX:OM8E^(NI>%[
M^V\+W5V32OC)I/\ PAGQ"7]GR^USQ'\$O@%I'P=T#X;VOB[X<26_CGQW<>+_
M (8W]OXF\+ZG<>(38:/\,?A:GPZ/BOPWJVJ3>'_'LT^OW-GX<\*66MZ=+--]
MUT4 ?./P:'BW1=.:^UWX<?$>/QC\4OB;XA\1?%7Q)XL'PV\//IVK_P#"$:=#
M8>+HO#GAGXC>.(K;X?Q67A7PM\+?!GA_2-=\0>,+$V5GJWBK[6C:SXEN>Z^&
M.A^)[2[^)WBGQM%-%XF\;_%+Q5>6R3WZ:DUK\.?"UTW@_P"$FFP3Q33QP68\
M&Z6GB@V*M');:UXRU^6]ABU*[OE'JF!Z"B@ K]M_^"??_) V_P"Q[\6?STVO
MQ(K]M_\ @GW_ ,D#;_L>_%G\]-H ^X:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$#_@I/_RD
MD_X(4_\ 9UO[4'_K'/Q!KZ]_X*)_\D7\(_\ 91M)_P#4:\3U\>_\%+H4N/\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$#_@I/_RDD_X(4_\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$#_@I/_RDD_X(4_\
M9UO[4'_K'/Q!KZ]_X*)_\D7\(_\ 91M)_P#4:\3U\A?\%)_^4DG_  0I_P"S
MK?VH/_6.?B#7U[_P43_Y(OX1_P"RC:3_ .HUXGH _&FBBB@ HHHH **** "O
MVW_X)]_\D#;_ +'OQ9_/3:_$BOVW_P""??\ R0-O^Q[\6?STV@#[@;H?H?Y5
M^ ?[9'_)R7Q-_P"OOP]_ZB'A^OW\;H?H?Y5^ ?[9'_)R7Q-_Z^_#W_J(>'Z
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ML4B!XY8I$+))&Z,K(Z,R,I!4D&@"2BBB@ HHHH **** "BBB@ HHHH ****
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MQ)@1YY%CNO#X#W-Q-=3MGPEH#?//.\DLF,X7>[;4"H/E4  'S51110 4444
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M9;7Q;)I>D^O_ /#6_P"S!_T5'Q'TV_\ 'K\2>@_[AO7_ &OO'N:!^UQ^S"
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M?"__ &,_AS_T^6%?T]#I^+?S-?S"^%O^1I\+_P#8S^'/_3Y85_3T.GXM_,T
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M^ WU,^%8_'%Q97%PDWB(:9]H:ZN;K6%B37[F?5I+P^%_A*+P9K7@*P'B#1=
MU_7/$7B349O#_BK7]!\0_P!M>*_&UW\0M?OK+Q3I5]:Z]ITFH^)KZ\EE6ROH
M5&E7,NA+C27-J0#S35/&?Q1T'XP^"/"]SK?@77+#QUXN\10-\,]"\.Z@WB/P
M?\&](T+7)[7XQZWXXFUL3K>1^);#0M$U;2+_ ,+67A34]1\5V_A'P;J&H:]H
MUWK-Y]'#ISP>XZXKQ;0O@1X2\-_$7Q-\3](\3?%N#Q!XR\33^+/%&E3?%CQ;
M>>"M<U.2UELK6TO_  ==7$NER>'=$LY?LGACPNA30/#%M''#H5A8IYHF]IH
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MC]COX@-\DT+)*F2,-M8;D+(<JQ!_4CXQ:9#9>%M-ECN=2F9]9M5*WFJ7]]&
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M(6"$L5 +'/TG9:?%8^9Y4]_-YNS/VW4+R^V[-V/+^USS>5G<=_E[=^%W9VC
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M_P"0AXE_Z\]+_P#1]]7TI7S7\!O^0AXE_P"O/2__ $??5]*4 %%%% !1110
M4444 %9^K7$]II>HW5K'%-<VUA>7%O%.+MH)9X;:66&.86%K?7QB>1%606=E
M=W10L+:VN)S'"^A6?J\%Q=:5J5M:^3]IN-/O8+?[3+=P6_GS6TL</GSV$D5]
M##YC+YLMG)'=1Q[GMG2948 'XA7]WI_Q$^.NE:P?!GB"'PEX\^)/PF\;>._
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M_P#-OG^?9F'US!_]!>%_\**/_P GY_GV9Z)17G?_  MOX8?]#[X7_P#!DO\
M\;H_X6W\,/\ H??"_P#X,E_^-T?Z]\#?]%IPC_XDN2__ #;Y_GV8?7,'_P!!
M>%_\**/_ ,GY_GV9Z)17G?\ PMOX8?\ 0^^%_P#P9+_\;H_X6W\,/^A]\+_^
M#)?_ (W1_KWP-_T6G"/_ (DN2_\ S;Y_GV8?7,'_ -!>%_\ "BC_ /)^?Y]F
M>B5]:_!7_D3&_P"PSJ7\X*^!O^%M_##_ *'WPO\ ^#)?_C=?<7[/>OZ)XD\
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M_P#*23_@A3_V=;^U!_ZQS\0:^NO^"BW_ "17PA_V4?2/_49\45\B_P#!2?\
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M<95QV HXJLH1J5'54E34HP]RK."LI2F]HJ]Y/6^VP4445^K'I!1110 4444
M%%%% !1110!^('_!2?\ Y22?\$*?^SK?VH/_ %CGX@U]=?\ !1;_ )(KX0_[
M*/I'_J,^**^1?^"D_P#RDD_X(4_]G6_M0?\ K'/Q!K['_P""@\,<_P '/"22
MJ64?$/2F #%>1X<\2@'(YZ$U\CQYP-F_B7PAGW F05\OPV<<38+^SLOKYK6Q
M&'RZG7E6I5E+%UL)A,=B:=+EI23E1PE>?,XKD:;:^=XMS"CE7#F;YAB(U)4,
M)A75J1HQC*JXJ<(VA&<Z<6[M:.<5YGXKT5TG]GV?_/)O^_K_ .->?^,/B/\
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MVO3@N9?9A?FJ2ERQ6K:\\_X:RUCG_BBM&X)4_P#$\U'A@<%3_H?# D J<')
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M  0I_P"SK?VH/_6.?B#7V9_P4"_Y([X3_P"R@Z5_ZCOB2OC/_@I/_P I)/\
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M-/%56J5%MSQ%6?)3I0Y4Y.K4I4ZGV+_9]Y_SP;\T_P#BJ/[/O/\ G@WYI_\
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ME\2:1+IWB/6XQJ+:?R/B7X)^/_%_Q9\3>+O$'CWP#??#+Q?\+];^">O?#O\
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M#*_+_J)\_P"KJY_J#QO_ -$GQ#_X:,=Y?].//^KJ_FGAC_D9_#/_ &,GA_\
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MWB;_ *]-,_\ 1U[7TO7S1\ O^/[Q-_UZ:9_Z.O:^EZ_ICPY_Y)'+?^OF/_\
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MXXUZ)[B>Z9)+(&XN?)\Z3.F61R_V>&WA^4$(NR%/D5=VYMS-]YXL?\B# _\
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M7IP@ZLH0A5J0C&5>$*=>48QDE%UJ=.G"JTDZD*<(SO&,4NNN/B#X^N_"%O\
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M\' O_)H/PL_[.'\+_P#JN?B371?\%)_^4DG_  0I_P"SK?VH/_6.?B#7._\
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ME'R'&,IQ\AQQ\N...E+10 THA!4HA5B&92JD,PQAF!!#$8&"02,#!X%.HHH
M[;X9_P#)2_AK_P!E(^'W_J9Z'7^E O0_[S_^AM7^:_\ #/\ Y*7\-?\ LI'P
M^_\ 4ST.O]*!>A_WG_\ 0VK^,OI7_P"]\$?]>.(/_2\E/Z[^B]_NW&7_ %_R
M/_TWFA\,?\%,_P#DP7]K#_LC'BO_ -%V]?P)/]]O]YOYFO[[?^"F?_)@O[6'
M_9&/%?\ Z+MZ_@2?[[?[S?S-?6?17_Y)'B'_ +*.7_JLR\^6^DS_ ,E9D/\
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MUXKU[^Q/VL]3M-(.IZM9B:[.G6@\'7 MK,RY,$(GF\N,JADD(+L?\35\/?\
M1*9WT_YC,!;SZWT]-0_XEBSW_HJ,H_\ "/&^7GYO[O,_ "BOZC?^(7;]A'_H
MX7_@HG_XEWJG_P Q%'_$+M^PC_T<+_P43_\ $N]4_P#F(H_XFKX>_P"B4SK_
M ,+,!Y>?F_N\P_XEBSW_ **C*/\ PCQOEY^;^[S/YJ/AG_R4OX:_]E(^'W_J
M9Z'7^D^IX/7[S_PG^\?:OYOK7_@U_P#V&K&ZMKVR_:-_X*,VE[97-O>V5W;?
MM?ZM#<VEY:31W-I=VTT?@E9(;FUN8HKBWFC99(9HXY49712/IW_ARQH0Z?\
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MV_81_P"CA?\ @HG_ .)=ZI_\Q%?K7_$U?#W_ $2F=?\ A9@/+S\W]WF?EO\
MQ+%GO_1491_X1XWR\_-_=YG\N5%?T&?%_P#X-Q?V,/ WQ/\ V5/!VC_M"?\
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MWQ7_ ,% ]$^'OPR^)/BCQS\$_BO9_$GX/^.-"\!_$?X1>%XO#WC2^\/2^)-
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M HHHH **** "BBB@ HHHH **** /Y_/^"MG_  46_:5_8[^.?PV\ _!6_P#
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MO"OQ*^'_ (1M_!GQ+O/@_P"#=+TCX2_%[X&^*-&\+^%O'OQ\^(GC;PU<^+_
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M7A#P3I%Z\'BSQGI?PJLM<D\966FZ9J%K;SZ7>>']8T&\\,^)?^$@ATM/"7B
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MI=SX@TS]G'QSX_TKX">&+'P?X,LM;OM'\-> /V9O$NLV'A3P1XLU30/BW?\
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MQH^#GQ-\*^(KJU\(2ZVGB'PIXVT2TU#3=5N?!GB70=;TY+74K3[K^&WA75?
MWP[\!^"M=\8:Y\0]:\(>#?#'AC5_'WB=;1/$GC;4] T2QTJ_\6^($T^*&P36
M_$=W:2ZQJJV4,-HM]>3BWC2/:* .UHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** (WAAD(,D4<A P"Z*Q ZX!8$@9YQ3/LMM_
MS[P?]^8__B:GHI\TMKNW:[_KHB7&+WBG??3T_P D(         !@ #@  <
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M9;;_ )]X/^_,?_Q-3T5+A!N[A%M[MQ3;^;0K+LOZ_P"&7W"          8
MX  '  '04M%%4,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \-^*/CSQ#X
M5UG3K'2);)+>YTPW4HN;,7+F;[7-#E7,L>U=B+\N#SDYKS-OC)XW"L1<:5D
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M((P1_P 4]IW!!Y!]C7=T 13S1V\,UQ*VV*"*2:5L$[8XD+NV "3A5)P 2<8
MS7YCZ-_P4X\%ZK^SE\$/CI)\)_&UGXC^+GQV\$? ;6?@VVO>$;GQI\--=\1?
M$33/!WB;Q!XHU"VOFT2]\-^#O#FL:1\0VNM'FGE\2>'?$7A.WT2-M0\2Z=&?
MTVNH/M-M<6^[9]H@F@WXW;?-C:/=MR-VW=G&1G&,CK7Y96O_  3#TNPO)[ZT
M^,NL*D_@G]D71H]$F\(V<F@V'C[]G?QM\%=8^)?Q/L(!K:7T>L_'[P'^S?\
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MK&G>$?%.J:9X=\8WV@:CJMKX0UO4++3/$TVE7=S#$_AW[$_[!ND?L@M?S?\
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M8WO@O7M,\6Z?I_PH\#>$?$_@+P1<ZIXK\9Z5XQ_X3SQ/X3U#XI>-_A]9>/\
M2?LFK:-'J?P>\"_![1/$,?BKQ1K/B_P_K>IW6AIX: /N2BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH C>**0@O'&Y P"Z*Q ZX!()QGM3?L]O_SP
MA_[])_\ $U-10        8 '  '0 =@**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>reserves.jpg
<TEXT>
begin 644 reserves.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %( 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MO;NS>"XE]<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI47@;2==M?%%AX]37O$7BF_U_7O'[>*SJ&G6.A^J?\)Y\6_^BH7O_A&^"?\
MY456O?B3\3]-L[O4=2^+G]FZ=86T][?ZCJ7AKX?Z=IUA96L;375[J&H7VG6]
ME865K CSW5Y>7$%K:P))-<31Q([CL^J8;_H:X#_P3FW_ ,[/ZL_*_G_7\9_T
M(LT_\'Y%_P#/HU? W[+GQ7^%_P /O#_P3^'/[0.I^'?AIX*^#WAGPSX:U/4O
M G@[Q3XPN/B=8?$/4_%>OZ[K":I;KX>?X:ZWX;:#P'/\*])TO1;'1?"=_+IG
M@?Q#X4N-*TK4;+!\-?L(P:?X$\<^%M>^)%M=:C\4_P!H7X)_'GXAP>#_ (<:
M/X#^&EU'\&/$/PKU:'X?^#OA=::]K-IX1\/>-['X3Z1:>-=3N/$GB+7=<U+5
M];U74+N\MI+/1K7RV/\ ;&\.2?#?1?C$/VO?AHGPH\1SPVN@_$>?4/@_;^#-
M7O9UF>/3K#7KB.*RN-5$=M=2S:0L@U2T@M;JYO+.WM[6XEB]"G^-GB^V_P"$
M0^T?'G1X1\0;Q=.\ ,^F?#,)XZOVT&[\5+9^"W%H4\5W!\+6%]XF\OP^VHD>
M'K2?6SC3(S=4?5,-_P!#7 ?^"<V_^=G]6?E<^OXS_H19I_X/R+_Y]'U1XX^#
M4?CCXN_!'XHWGB:]M;7X*'XF:AIOA&.QBFTW6?%'Q!\)VO@FR\3W-XUS'+97
MWA3PW=>,M-L(H;:X2[@\:ZHLKVYAC,OE/CO]G/XJ>*_&.D_%/2?CS::!\5/
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M_ ,I\O\ J5^7XON?HZ/VA5QQ\.]>P5P,:WX0P5R3C_D+8*Y)..F232C]H<*
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M$/$4DNNWEQ&FE73/ ]EI*)*NU049X;&.5 <]8W1AU# BOCMNI^I_G0 E%%%
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M40J02J.K1G'#1<E*4*T92Q#56H[S=)1^K1<IQERRA4G"/)32F&FG7RU7XO\
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MO7H9%@IT*U6A-YO1BY4:DZ4G'ZGCGRN4)1;BVDVF[-I76@D[;'  L2 -Q)(
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M.HXS=2<:,(SE.O4DN=II0H<D56J-;K5]'LWY6W75)+5+S35C]!;3XR_">_\
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MEYM;_9%A4I%;7,!4.G[05V68F=2!Y2 @$[@<*?W195;AE5AZ, ?Y@TWR8O\
MGE'_ -\+_A7'F&!P^9X+$8#%QE+#8JFZ5:,)RIR<&T[1G%J47=+5.X+1I]C^
M='_ALK]K_P#Z0S_\%#O_  H_V2O_ )^5'_#97[7_ /TAG_X*'?\ A1_LE?\
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M23U)K^B[R8O^>4?_ 'PO^%'DQ?\ /*/_ +X7_"OF/^(:<*?] N*_\+L3Y?\
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M?_\ 2&?_ (*'?^%'^R5_\_*OZ+O)B_YY1_\ ?"_X4>3%_P \H_\ OA?\*/\
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MUK=BPN=%L(M/N9+S5X+XQRBSFTRV66^BNS%(+:2W6<QN(RI -T,#G[W SRK
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M/>%->T70-<N)[[3)97^HZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 3:,8YZ8^\<_GG(/N.1ZT;1C'S?]]-G\\Y_6EHH :5!_O?@S#\\$9^I[
M<=*=110 4444 %%%% !2$9]>/0D?G@C/XTM% ";0<=>/]IAWSR <'\<\<=*,
M#.>?S./RSC]*6B@ _P _Y_SQVHHHH **** "BBB@ I, <\^O4G]"<?ATI:*
M$"@9Z\^K,>^>,DX_#'8= *3:,8Y_[Z;/YYSCVSBG44  &!@=OQ/XD\D^I/)[
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45AZWXET/PW'
M;RZWJ$6GQW<CQ6[2I,XEDC3S'4>3%(053YB6 'H2>*Y[_A9_@+_H9+3_ +\W
MO_R+7G8C.,IPE65#%9IEV&KP47*CB,;AJ-6*DE*+E3J5(SBI1DI1NE>+4EIJ
M!WM%9VE:MIVN6,6I:5=)>64S2K%<1K(BNT,CPR@+*D;_ "2(RG*@$C(R,$Z-
M=M*K2KTX5J-2%6E5A&I3JTYQG3J4YQ4H3A.+<90E%J491;4DTTVF 444FX9Q
MSUQ]TX_/&/ISR>!S6@"T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@/Q[_Y!OAS
M_L(7W_I&*^9:^W/'7@:+QO;Z=;RZE+IPT^XGG#16R7)E\Z$1%"'EB"!0-V06
M)Z8'6O./^%!67_0S7?\ X+8/_DJOP_C3@WB+-^(L;C\OP,:^%K0PBIU'BL)2
M;=+"T:4UR5:\)JTXR7O15[75UJ-O2*[7O\V=M\'_ /D0=(_Z[ZK_ .G2\KTV
MN;\)>'$\*:%:Z''=O>I:R73BXDB6!G^TW4MR08U>0#892@(8[@N<#.!TE?K6
M0X6O@LERG!XF'L\1A<MP.'KPYHSY*M'"TJ=2/-"4H2Y9QDN:,I1=KIM-,1'+
M_JI?^N;_ /H)K^>BU?X0#XQ_'A/ 4FE)^WR__!3/PM_PB@\*'6_^%SGX3K\0
MO@P?&3>-UT;-\?V?D^ )^)__  DI\9@_#Y?#C2_V*1XQ;PUG^ANDP,YY]?O-
MCTZ9Q^&, \CFO6 _![P5^T]\6/A_X@_9>T.#Q/IV@^ _%5G\.+2+X)_#OP#X
M3L/'OB+4_'?[1GQ%\%>+=5N/ WC;POI5]XU\'P>'I/#>IW>H? OXH:3XK^",
M>E>,_B#\5_ OC'P_J?A^QO.B\-_M<_&^]^$.F^*=6^/B1^(/$7BCX&:?^TTZ
M?L^IIL/[ $_CGQ#XTL_B;H::G>Z2^A:XOA'5M&T3X9?9OBE8^+=;^'_VQ/C[
MX\O=3^&6L:;HT?[?%0?7_OIL<'/(S@^^1R.#D<4;1S][GG[S>N>#GCKSC&1P
M>.* /P3\0_MX?M#^!?A;\3]9\2^, VI:A^SY\1K[]ECQ._P=EM;OXZ>-/A[^
MTE\8? VB_$C1/#%MH=S'?WOBWX*6WP;\?ZSX8@M[3PTFB:U-\2M!TG2O ^J3
MMI%7]H'XP?MEZY\*/C=IVB_%WQC:7GQ4TK_@K+\/_ FE_#GX6>'M&\6?#D?L
MM>-/BC;? K4? _B*+0M7\0ZAXU\4^'?!UKX.U+4]16X77[36[/7? EKX<\:Z
M9:^)=6_?;:..6XX'S-^O//U.32X^O?N>_P"/Y>G;% 'XX:9^U;\0],_:@^"?
M@O2OV@8/C;\)_&EO\'?#OABS\">$O %_XQ\?:1XM\$WB^(OB]X\\-R>"? ^I
MZUX<;Q7Y>NZG\7/V<_%D_P +_A;HMC?^&_'/PC@U+2]9U&#]CU.54\\@'!&#
MR,\CG!]LG%&T9!^;C_:;''J,X/OD'/>EH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK#UOQ)H?AR
M."76]0BT^.ZD>*!I4F<221IYCJ/)BD(*H=Q+ #'0YXKGO^%G^ O^ADM/^_-[
M_P#(M '>T5G:5JVG:W8Q:EI5TEY93M*L5Q&LBJ[0RO#* LJ(XV2HZ'*C)7(R
M,$Z- !113=PSCGTSM.,^F[&WMCKUXZ\4 .HHHH **** "BBB@ HHHSV_H??O
MT[?R]10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >"?'?\ Y!OA[_L(WO\ Z1+7S57VMXY\$1>-K?3[>74I
M=.%A<37 >*V2X,OG0B$H0\L84*!N!!.3QCO7G'_"A;3_ *&>[_\ !9;_ /R5
M0!VWPB_Y$/2?^N^J?^G2[KTNN<\)^'4\*Z%::)'=O>K:O=.+F2)8&?[3<RW)
M!C1W5=AEV ACN"[C@G Z.@!&^ZWWONG[N-W3^'/&[TSQGK7XB>#KGX?:?\8O
MBO>_%#2?B+XB_;ZT_P#;"^+&H_";1/#M_P"+-*\:ZQ\'+;4M8O?@%H]EJ4>?
M#UE^R1J7P)A\-:9\3;AU?X:P>.9O&$FK1M\:D05^WE-VC.>?ID[>_P##G;WS
MTZ\]>: /P3\%_M;?M3^-E^%^B^$_C4OB@_$C6_V0K;XG^,/^%%:)I4OP$^)7
MQ:\7>-=,^-_[/=IH=SH]M;PZGX:\,Z/%?Z;I7CQ==^(7PAU71[6Z^)VK^*+#
MQMHFDGBO%WQ]_:E\(>+?&WQ,OOC]XOM?%&A?LF_MP^ /A/X*UOP'X0M?AK\5
MOC%^S!^U/\4OAYX>\<WG@VS\,1W>I_$6;X:>&O"GQ+\7Z%X0UG1;/4M/^VW'
MAG2['P1-=Z7;_P!$(4#IG\68_P R<#V'%+@>_?N>_7O^7IVQ0!^*'Q2_:E_:
M0^%7[4O@CX3^'O'FH_$>'PS\5?@/\+?'WA#QCX6\">#;[Q_H7Q?M-'?6?B?X
M0\+^$?AGKWBS5?"&@ZGXNT_0+?XK?\+&^%GPW\*>*M#U+P'K/AWQ[KFA:KJN
MO>61?'OXN_$+PK^R=\3/$7[9/C/0+;1_V@/V=O$O[3^C^&?@]X:^'OAOX):U
M\1OAG\;[+QO\!_B+XFUOP=?Z;+X0T3XAVO@KP$W@?Q6+CXG?#[6]4TOQ!\0_
M%VH7GC'X:WGA[^@+:,YYS_O-C\LX_2DV@=VY(/+N>GU;@>H'![B@#\*;C]OG
MXS6OA+0M,U?Q/JL7C_PQ\%?VE)/CU;Z!\+=*-S\,?BOX:_:S_9R^$/PYNO%5
M[XBTVW\(^!]/\+> /B)XR\2>)K[5I-7T;2?AY%=?&K6O#?C#PUH.FV^N=I^Q
MS\;/C+\:/CK\,KCXL7L7B"Y^'<_[;_P[TCQKH;/>:+X_\(6-O^Q9XN\&^+;C
M6])^'GPF\(>*9KRW\9ZKIVD^)_#7PZ\*^'=<L=+:[\/V=W$U]JM_^T6T<\MS
MU^9O7/'/'X8XXZ4H&/7\23_,F@#\2/BY^VG^TKX7_:QUWP?\)[*X\=Z/I'Q#
M^(OPON/@=XHTW0M"UN:ZT7]E+Q_\6/AUXJT/PYHOP\U+QTWA#Q]\6/"?A[PE
MH'Q>\7_&SPSX4\5GQ!?^%/#/PQN-233M?3Y]TOXR?%#7/C/IOC/P?\6(_P!H
M;Q'XL\(_LJZ)H7C+5_@UI?A.QTKXLQ_ 3_@JWXUNO!7A/0FT[2]!TWQ;X8\?
MVW@S2KNUD@N/&_AO2]6B^&_Q"U;5M32]N7_HYVC.>?IN;'3'W<[?T]^IKS[Q
M#\*O 'BOQOX$^(WB3PU9ZWXP^&/]OOX!U;4IK^Z'A6[\3Z>-(UK5=(TV2\.D
M0:W=Z.USHZ:\^GR:U9:3J&K:9I]_:6.L:K;W@!^-NM_MS_%WQGX5UG5_ /QE
M\)>&?#6@?"/]A?4_&'CO7O"*>#M,TKQW\2I_VFX_C_H>B?$7Q=\,?&GPV\"^
M,HK_ .'_ ,-]'NKCXK>%-3^''P^U2#4? ^N?\(OXV\5:=-8>7:I^TM^T:GC#
M1/BYHWQP^*OAC5/BW^R[^R/HGP\^&?Q(^$_@.P\)>(O&-S^V=JOPJ^.WC[P[
MX%TRUUI=3UO2?AQK>F>.;J_\+?$&;1]4\'^-_"_C!)!X(B\'VWAS^B/:,8RW
M_?39X]\Y^O//>EVCCKP,?>;]>>3[G)]Z /PD\4_M1?MO_#/3_&VK>'M>;XX^
M(?"_C#]NKX*^#?A]JWPATC2/^$ZU?X!?!_Q=\6O@_P".]3O?!&G:9J\OC'6=
M=T.U\&ZSI_AF/3_!/C'P](L'AOPCI7C66'4;S1^"_P"T/^UY\7=;^$/@2#XU
M>'+;PM\0/CGXO\&3?&'P19?#/XO>(YO"NC_LL^-?B/JNF2:UI7P@\$?!K3M;
MT#XGZ1X8FT74--\+>(4L-$U74/ 'CNVN_&&EF]N?W*P/?OW(Z\=C^7IU&#0%
M Z9_%F/;'<GT_/GJ30!_/1X%_:(_:/GB^+'QBU_]HRY\%^-OBC^QE^PC\5O"
MOPT\>>&]-TOX3>$FUKQ-J7A7]HKQM\.K6+X;>-M?\(W6D3E]/OO%'C.#QMX
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>restructuring2018.jpg
<TEXT>
begin 644 restructuring2018.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MFTW1?$6F?<U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*_X7WX;QN_L?6=O][.GX].OVW'7BG?\ "^?#O_0&UO\ \I__ ,F4?Z\\*?\
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M <__ ,5-_P!0/_RIT?\ %3?]0/\ \J==!10!S_\ Q4W_ % __*G1_P 5-_U
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M(8E:1\9W-M4[4#,>%-?M*FOVX1!_9^O<*HYT+5 > .H^S<'U':OQ?_X*3_\
M*2/_ ((4_P#9UO[4'_K'/Q!K]NXP/+CX'W%[#^Z* ,;^W[?_ *!^N_\ @BU3
M_P"1J/[?M_\ H'Z[_P""+5/_ )&K<P/0?D*,#T'Y"@##_M^W_P"@?KO_ ((M
M4_\ D:C^W[?_ *!^N_\ @BU3_P"1JW,#T'Y"C ]!^0H P_[?M_\ H'Z[_P""
M+5/_ )&H_M^W_P"@?KO_ ((M4_\ D:MS ]!^0HP/0?D* ,/^W[?_ *!^N_\
M@BU3_P"1J/[?M_\ H'Z[_P""+5/_ )&K<P/0?D*,#T'Y"@##_M^W_P"@?KO_
M ((M4_\ D:C^W[?_ *!^N_\ @BU3_P"1JW,#T'Y"C ]!^0H P_[?M_\ H'Z[
M_P""+5/_ )&H_M^W_P"@?KO_ ((M4_\ D:MS ]!^0HP/0?D* ,/^W[?_ *!^
MN_\ @BU3_P"1J/[?M_\ H'Z[_P""+5/_ )&K<P/0?D*,#T'Y"@##_M^W_P"@
M?KO_ ((M4_\ D:C^W[?_ *!^N_\ @BU3_P"1JW,#T'Y"C ]!^0H P_[?M_\
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MM9V<^I744*)<7TUII\-O8VTEW*KSO!9P16T32&.&-8U45H44 ?B!_P %)_\
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M_0"T;_P5V/\ \8H_X1SP]_T M&_\%=C_ /&* -FBL;_A'/#W_0"T;_P5V/\
M\8H_X1SP]_T M&_\%=C_ /&* -FBL;_A'/#W_0"T;_P5V/\ \8H_X1SP]_T
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MOV2U@MO,V;MGF>3&F_;N;;NSMW-C&37],>'/_)(Y;_U\Q_\ ZGXD"Y1117W
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MH>HP&'4-&U;4M,NK6\F[*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU_J#Q27]ZUO"D+7=[)#%!#)=W)0SW4D4$,3SR2-'#$A6-;M% !1110 4444
M%?('[7_PI_:,^,?A?POX,^!WQ)^'_@#PQ>:KJ+?&'3_%FD?$1==\>^%#8QPZ
M=X,\->.OAMXS\)>)/A[IVHWTER_C+5]#)\4:MHL46A>'=>\)F]U'4YOK^B@#
M\QO$'[#/Q#UCP]XQ\+>'/'?PH^%_A7]H3X%> ?@'^TAX/\&?##7KC0M,\+>
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( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>rituxan.jpg
<TEXT>
begin 644 rituxan.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0!<17AI9@  34T *@    @ ! ,"  (
M   6    /E$0  $    ! 0   %$1  0    !   7$E$2  0    !   7$@
M  !0:&]T;W-H;W @24-#('!R;V9I;&4 _^(,6$E#0U]04D]&24Q%  $!   ,
M2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M245#('-21T(               $  /;6  $     TRU(4" @
M                                                   18W!R=
M 5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA9
M6@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P
M9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@
M   4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P
M!#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@
M2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#
M-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                         %A9
M6B        #S40 !     1;,6%E:(                     !865H@
M    ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@
M   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                        9&5S8P         N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M           N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A
M8V4@+2!S4D="                             &1E<V,         +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y
M-C8M,BXQ                                  !V:65W       3I/X
M%%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE
M87,          0                        */     G-I9R      0U)4
M(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
M"Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-
MPPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F
M$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2
MXQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]
M%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO&-48
M^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2
M''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@
M%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P
M)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH
M/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB
M+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ
M@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R
M-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[
MZ#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J
M0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'
M>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV3
M3=Q.)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_94
M0E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU
M6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B
M26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF:
M:?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQ
ME7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6=[-X$7AN>,QY*GF)
M>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@<V"
M,(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*
MBS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1J)(1DGJ2XY--D[:4
M()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUD
MG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG
M;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[  L'6PZK%@
ML=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\
M(;R;O16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#
MQT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2
M/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6
MWAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;I
MT.I;ZN7K<.O[[(;M$>V<[BCNM.] [\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>
M]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___]L 0P (!@8'
M!@4(!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N)R B+",<'"@W*2PP
M,30T-!\G.3TX,CPN,S0R_]L 0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\  $0@
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M,"#P?4'U![BK_LZ,H7C*_P"1'UZ2E:4;'UA/J%E:S1PW%Y;PRR?<224*S=N
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MCF?;\O\ ,.5=_P RQ15?[/+_ ,_L_P#WRG_Q-'V>7_G]G_[Y3_XFCF?;\O\
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HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>rituxanhycelalogo300x87.jpg
<TEXT>
begin 644 rituxanhycelalogo300x87.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0",17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        !(     0   $@    !  .@ 0 #     0 !  "@
M @ $     0   2R@ P $     0   %<     _^T .%!H;W1O<VAO<" S+C
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M\SGP;9Q$0>4]-BQPN=N+IMXWRX'H&NCNGJ.G]L;H^'#TT)8A*5\NSH_\=S#
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M0A#R'#[J6_A;E*/#IP\U$47\.3-=[FH&\IKX9#D0KV[U<1( 2#'>6$ <@B/
M7*-<#SUG6-RS)B8D@)Y?GW80UR)SZ'/)YIGSD2I'<1*1U!,D> ZI3 [TF??N
ML(V''WVBSY.#PB>^:E0"X\/%C@>,IL9IC&T*@YBD5VS&_P#)X%R1(T0$X^7^
M:D$D)ZSYH''^'W?<_#_NK!K4,SLT/C]W^[J$;!Q\\V)B-7L?=23C!PJXP (B
M./\ \3!JCJY" =9<?YTHV9^LJXBD'')Q^5X(R"6N6'U=4D$C_*O-)Z".&#Q%
MXEJS1UP,V3Q,5*DYR</\Q%R4%244AGUM;3C1)"6GP5XW&'\$* Y)P%7D .6L
MPHHY0ND'A2A*1_2H2?%-\D D 1/$Q4(Y!PR>(>)*/_D4IA!WX68U$.(1Z(V$
M&TS$1J>KQ!\1[1^5$&9@E'FGANZ4/AAE$/,=UA(=%)X1/5%C\1<7_J9-]CCS
M<._GU>/-L@(,_>7 K@:_SNJ0E$!?$_BH>#T01\_=QF$3'_XV+%),>7"J C&%
M#J)\[>"]'":'4>UED]<0H )^U> ZDD>WY4(@@*]@IS'$=6"FL%Z!&>-IFOF0
M!#IZ*)Q)]4D'%@>$:5A[#H\=V#ARQO#(#DFK*1P"!,/W<D5:>%]#-=_B-*3^
M92SL5-Y5GC*R>[H$'X+YT8;>YY3*21UI3Z(/Y$9S2SUT[A^5"Y8I)=\/CN^S
M29\CXI>*R!+X\D^>ZL"#<=CQ?X%X^(?"!_-&5D$S$@"/U5\!X".4UKU(*ODX
MH@ @47(]9Q&15 9:N0CQ-DA& SV0_JRI(2Z"BN,9!*\?_G%EDDB0/R'/_9%C
M/CH*1,30C9/'XN_&1PR<S]WG&4DCG'=J0G2#0?Q1OL^&"-<^&L$L*?9Y_=(J
M04<F%1T')DGVYJ_ 2>IX&S71R 8BN]B:6BB=>&4J?P548Q$O@W/F\<-( ^:/
M7&V49EB^,:-2,@/:LL@BS\/7.T".H![>?'JR58SEF7 N?='G@CP\T+%P?</_
M .@@I1,'D9N,8</@*''AKB #,0.;^JPQTAXV?[[';[X=E_N] #.N1'3U5LCK
M,0T'N:V(V+.PD7E\<3RRZ_!=G@8C/8;&G7EFD$?JP+)<!F\Q<I(C\N$?B_@,
MX_PR^)7GS+-YXDA_//YH03SGKMR^R[53X9 S$OW%3X:B9D ?XHHE69G*#(D@
MWU_^R'__V@ , P$  A$#$0  $))))))))))))))))))))()!))))))))))))
M))))/'-4>-@8FNIP'?/,N))-*WC7]=Q!9'Y*8Q,')(.3KWX!ML(MM.+$QWC)
M) ( )!! (! ()8)( !))(EH0'1HNG)PAPOF Y))(((!((-  ) YXH$L)))))
M)))), !(!Y1@%())))))))))))))))))))))))))))))))))))))))/_Q  S
M$0$! 0 #  $"!04! 0 ! 0D! !$A,1!!46$@<?"1@:&QT<'A\3! 4&!P@)"@
ML,#0X/_:  @! Q$!/Q#_ /8[>X[H'YPW"^__ +=1N<ZYW_$3D#]^I_Y'."!.
M'X.\OTGL(6F;O$)TC;\ V0[!)Z ,W5XN'>'\RTS=XA_A^]_34=APKHX<Y6(!
M."Z[RST%N#'.I$#C>\W^9P.^1M+:#E'-?H1\@_.G.?58X?O<WG/WAT'EB/9#
M-H+PYQ?=?N_XMQ47>5X_8N3 'Z/OX"&JX'W@%IGE'(1'L.><>[Y!S#]_POE>
M]<A-F7[\WTY0;U\W.;]_M)>G\GF1R&.<I#T^.-^K!@04PMG.*_M$&;.N?%LN
M->O\PE%P9T?M G%7!'^\N]GC3_$PST'0G1"-Y_*Z!\1^GYV#5&+EZX[V!PPQ
M,SXT@5V"^\0Q%!? G?\ -L.3@^Q]7[PL.]&?D_U.&1@6P0U@Z.L.(=X!W\-]
MS^GYW0JAF<'=D?+^@<^,8.7@?;Y_PA,  ';\\^]P+\'[/XGXT&<9SQ]XU729
M:$2?!+.XIF8^D++F_-L78^G1#>)#'[V 0CV\\?2%Q",U-D]@]*=$"!KZ(=/7
MQGQ9=37*]?M\74W.W.['$X=W;-3Z8$LE6^XNN]6[KESK(/S#>6 ]=?:0(F@F
MDKKC-Y8#N=>99UB' ?3[R=<W\\/WQ"OA(.#!W"7[U^9?]7V7[_X3RX:"AG&=
MY*][_,/^I780 F@^-SB5CR &L'TB:%Y>T,FV=Y=_Q]O_ ,T!_E7?_P %_'\>
M['_R_J'_ /1-\_J'_P#1,\0E\B_U_P#V9__:  @! A$!/Q#_ /8X9OA+G'QQ
M_6X41N*_U&<',:X0_;)EE5H-=^+XS/0[=O!8KX+._CEX.K9U9WAM\HY9GSM@
MXMZTR"4 =J0VH/J&PF?,SAS?^TD.1OT^9!!#>N'F%'6ZT2;4,1C3 5XGPTAP
M&</J_,&0 7Y#Q\GTL)KV70?:#\,\"X@QPW;K<$50?*T_7%BL &."^ =LZ. S
M>/Z'\SZ?."0/]-RW'L2OY/KY-S:0X@:_/3TM*5CNY5[WZ'@5@*G@ ^9J^)$4
M/C73N 2"SP,U(?Q?'AIX/I^'@^X']V0)>CY#A%QCA'> Z<^\AGZ _8[_ +R_
MBVWYY=_TCL9Z >'CYB;WE+^0G!O(W^W];N3/ZO+^UR58T?V/X^L<K\73CZ'^
M;Y0L1KS]>+A88J$9_*$0/D_X-2^<<*F\/P;]8] #P_HL;G_A%_+_ )$3GD",
MWGJ#E&(N[CCS]N<@^Y?[B:=D0.!/'[-DN'^2^Q]B'_,'UKD:0&JP6%QJ8F?O
M,BQB<9CH_P &6K_BFF+#K=7HZ(M_#,_-9_KQ7IPQ?U^G^S*>1Y[!P];UP6'W
MR'V _P!_Q$8:ZN\.7^(P]Z6\"T7+A^.K!DN?F/EU( ,"8_<R1YCIR10/@XN?
M('1''GX^8,R1P&#OU<))07[+Z;QS&X S<=7.OXN#< @Z/R]=/TL3I@X\(?F,
M@/B(L?S7YM)VD!O09]OM:;P<=O@XFPH<W.W#*(X^'3+.A].+DAI<X:IW_6TC
MGTL1.?CARF;WY\4.$U/URX[,>N6?EI) -(+Y53-8P9G\D/\ 1O\ V8T([%1=
MQWY8/D9^0G]F/+7<(OKBV,6*J['Z]_G-YA@3H_67AHC,SK?\_P#SS\&?_87#
M\O\ \$OGP_ >-D]OF?@Z\SP_M>[_ /H.>']K\>?_ (F_CWS? Y/Y>;[OX-__
M &0__]H " $!  $_$/\ ]439+-4+)9__ #)/^262S9+/_)_Y)9/^S9LS_P#A
M@X<04LXDZ-5SYQO88<6/_G0UADAU)/%23V"0[">6[2$ 8S@ERK^\J-0R!08R
M$I/FH))4A$<I//-%A7IGG\$>Z^&22$3VQQ5,8BXCP#<[P.4/#"T!-2 +R)AH
MW)_Y=W3"X0Q<L\19M"A0F2[A3O[*:'F"O#$;2<"6L>M0$8<_NER@)9:T LPI
MXCCGJPJV1!!(F;&9,DD':O"U!##P Y;M<")Q**:DT"P')Z;,2NDF1_[?0H0#
M$< E[X7BRAG#M%\_!2G*04\ 7K HS0ZGVTZVADB9!4Y@&L.CK_\ "XJ05\+'
MZIL9"1$9F%F75[XI%H3Q3@BP.V>(H'R/?A!^E9!*HBGB3'.IBK"A<B!TR).,
M:BVH/4Y_&5"T\OP!GH#36!*@C"/Y-R;-L0LR)@SE_+FLU >8/R.C(IS RRK*
MMF>4.O5PMI(QU$3)V\5+HVK"*SQVM+B&:0RBYDP'FB\(+()GUB;A7)GRY_@L
M/8 *'+0+)F#(U$D+6B:CZS*FF%9X1Q]-?$@Y]O@]%U(.=Z:B?NE#FDL*!1@D
M'EDJL";%@(8*^C_C4D$#*=P!@LC\I^\+"F\9!9V\G]VG57!9C(/HNEZ"'H_[
M/_PO%.WUF1/),.9:",-QTB!/BI(E,II(,HB7/=5U%LI'/F,.QW1IYH(("1Y,
MVF$+2@0:!Y1)99DG&9!(1C&B;ZP0ZS >=IEE)TBH>17EF*7$(,+ZBLORLL9*
M'.J/Z#SYL<BR<45P0G/5!>%^'DHAY\V3?,#W4<(H8A3C%UY.">)JN*,1["9*
MF8IYAO-  U/@JQXI#TS+)+)A20DS+YK2PD#X8YHIB;1*(F9?-BS!O+27;&(O
M=!#P '/B4%D_,:"(EQQXL%"01(A_7_'".J Q> A?[O !\!_%"8HJH9F0Z^*
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>Q5X9LX" 0E6/-E!(M0E%Z#W<0B< C(X&_P#[(?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>royaltyandcorprev.jpg
<TEXT>
begin 644 royaltyandcorprev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M1_PC.D?\\;G_ ,&>J_\ R=0!OT5@?\(SI'_/&Y_\&>J__)U'_",Z1_SQN?\
MP9ZK_P#)U &_16!_PC.D?\\;G_P9ZK_\G4?\(SI'_/&Y_P#!GJO_ ,G4 ;]%
M8'_",Z1_SQN?_!GJO_R=1_PC.D?\\;G_ ,&>J_\ R=0!OT5@?\(SI'_/&Y_\
M&>J__)U'_",Z1_SQN?\ P9ZK_P#)U &_16!_PC.D?\\;G_P9ZK_\G4?\(SI'
M_/&Y_P#!GJO_ ,G4 ;]%8'_",Z1_SQN?_!GJO_R=1_PC.D?\\;G_ ,&>J_\
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M8RG1IU5"FXJ,</.$J'LO>M!4X4X4HQ7N."YG%U6ZC+[Z;_@%?77P2_Y$MO\
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MIEBQG=YK+IQ$6W!)\PK@ DX . #<HK#3Q%ILAVQ&^E8#)6+2-9E8#U*QZ>S
M9P,D8R0,Y(IK>)-*4E6DNT8'#*^EZNK*1U#*U@&4CH00"#P10!O45@?\)-I'
M_/:Y_P#!9JO_ ,@T?\)-I'_/:Y_\%FJ__(- &_16!_PDVD?\]KG_ ,%FJ_\
MR#1_PDVD?\]KG_P6:K_\@T ;]%8'_"3:1_SVN?\ P6:K_P#(-'_"3:1_SVN?
M_!9JO_R#0!OT5@?\)-I'_/:Y_P#!9JO_ ,@T?\)-I'_/:Y_\%FJ__(- &_16
M!_PDVD?\]KG_ ,%FJ_\ R#1_PDVD?\]KG_P6:K_\@T ;]%8'_"3:1_SVN?\
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MBM\K,0&!!(/\UO[(^N^!=%U/]MGP/\3/$'CCQYX"U#4]/O?B7^T'8>(?VM?
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MJ7]HGXTZM\?O DV@?!+PU\:_!FN:%:^&_@EXTT_XP^ O''PKMM4@^&$.NO\
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MEU9/!["RL=/N(?[8U$E[K5+BSE#GR-R^5%I-ZFT?POYV6YRB]_E:OKKX)?\
M(EM_V&M2_P#:%?HGAA_R4[_[%N+_ /3V%'T?JOU/1/M'B'_H%:/_ .#Z\_\
MF=KX\^)C7#>.=>:ZBAAG,MEYD<$[W,2D:;9!=D\EO:O("NUB6MX]K$J P4,W
MV[7Q1\5/^1^\0_\ 76Q_]-=C7WGBQ_R(,#_V.*/_ *A8\1Y]1117\_@%%%%
M!1110!=TXL-0L"H#,+ZR*JS%06%W#M!8*Q4%L L%8J"6"L1M/WC]H\0_] K1
M_P#P?7G_ ,SM?!^F?\A+3O\ L(6'_I9!7Z%5^V>$7\+/O^OF7?\ I.-'T7J_
MRB>;>/IM;;P9XD6YT[2X8#I=QYDD.L75Q*B_+DQPOHENDC#LK3Q ]W%?&)ZG
MZG^=?<?Q%_Y$;Q/_ -@FX_DM?#C=3]3_ #KR/%G_ )'.6_\ 8L_]VL0'1>K_
M $/SM_X*8>(/$6@_ &S/AWXIZ5\.7O?$DL>I:)J/Q7U3X"WGQ2L+;29I8?!W
MA[XU:7I6IMX*UO1]3DL/&JZ5<RZ1;>.--T#4=$FU:WMK6ZCF\?\ &OQ,T?XF
M^$?AM)\.?VAOC'I7[1_CWX<^$;SX/^#_ !3\=/"OAG3?@SI^C?$/7= \3_M&
M_'J3P??Z%\._BOX1\7RZ=?Z99:UXRTKQAIG[0.@Z)H&B? WPH&\6>*?$^F_J
MMXE\,^'/&6@ZGX6\7:#HWBGPSK44$.L>'O$.FVFL:)JD5M=0WUM'?Z9?136E
MTMO>VUO=P>=$QAN(8YHRKJ#7*^*?@]\(/'.L+XA\;_"+X3>-?$"164":]XQ^
M%_@#Q7KD<&FF0Z;;QZQXA\.:EJ45MIGFRC3;:.Z2WTX2.MC%;J[ _"X3,Z%#
M"X:A/#R=3#XC$5O;1]DU4514G&E.$H)RIRE!*NO:1J5*,/8.JZ%7V5$3MV_7
MUUNO+\;7LS\V/VA?B=XJ\#_&FP\8_ 7XAZS\0-6UGQG\>_"*Z';?M$W/CK4M
M0^)^@_ _XTWGA/\ 9IN_V,38Z/X9\(?#WP5\0O"7A/6[KXJ:=+K7Q$T6_P!.
M1M;CUW0O&>K>*H_2?@#\2?"GA;X@^'#H?[0>H_$;X.^)?V.O!_QE^,/CGXF_
M&=?&VC^#?C!K?Q \%^&?"'BJYUWQ/KEWIWPQU3XSV/B+Q_:ZI\,;*]\,^&+:
M_P#A_I"^'O!NB7-I<K??H-'X7\+P^)+GQG#X7\,0^,[VQCTN]\90^'-#A\8W
MNEP[/*TR\\61:>GB*[TV(1QB/3[G4Y;-%CC5(0L<86FG@7P-'I^N:3'X'\$Q
MZ3XHU-];\3Z3%X.\,Q:5XGUN2XM[N36O$NFQZ4MCXBUF2ZM+2Z?5M:M[[47N
MK6VN&NC-;PR(I9EAIX:&'>%G>-"%&=3VD'*JE4G+FJ7I.\J$9_[-R.E",XJ]
M-4[4XMM>?3TTMTZ]4M4^[=]/S)\"?$SQ[-^T?:Z]X_UO5[;5]6_;/^+_ .SK
M%\.]*_:4UN'Q7H'AC1/^$YL?AY::E^RA_8=Y\/+WX)#P-X>\._$[Q%XW:YTS
MXT?VGXAA^+B^)XO!I_X12Y_5Y3E0>>0#SP>1W X!]<=ZQ_\ A'/#G_"12^,/
M^$<\._\ "83Z8-%G\8?V!H__  ET^BB7SAHT_BK[%_PD$VCB;]Z-)EU)M.$@
M#BV# &MFN/'8JGBY494Z"H>SHQIRBIRE'24FE!2ORP@I<D4G:R3LFVB?Z_+^
MOZ=_=?@<]^E[XB-A;6ERQM=-\P7=]-9!1YUWM*-#I]^9"3NW!EB"@#!?<0OT
MM9R:C)YGV^TL[;&WROLE_->[\[M_F>=IUAY>W"[=OF[]S9V;1N^=?@%_Q_>)
MO^O33/\ T=>U]+U_17AS_P DCEO_ %\Q_P#ZGXD HHHK[@ HHHH **** "@G
M )]!FBJM\EQ)9W<=I(T-S);7"6\J&$/%.T+K#(IN(+J#<DI1E\ZVN(L@>;!-
M'NC8 ^+O^&J]:U+XU^.OA7HVC_ O2(/A]\0_#7@/5XOB9^TC'X(^*.JIKN@>
M%O$*^)/#GPHTOX9^+Q<Z-JEOXDFL? RZKXPTF]\9:EHNI1O;Z%;>3<-]M_\
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M'/\ R2.6_P#7S'_^I^) OT445]P 4444 %%%% !1110 4444 ?B!_P %)_\
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M FT>K?\ ?;__ !5&T>K?]]O_ /%4I(! ) ). "0"3Z#U/TI: &[1ZM_WV_\
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M+W*MJ_VK7M:\2^/+S3=%TQ/$WB&]U>/P^UWI.GP^%_"6@6MMJ$NL^]C]E_\
M9U,7PQBE^"/PNN5^"]M:67PH>]\$Z#?S?#ZSL+B&\L;7PI<WUE<7&D6]E?VM
MGJ5G#;2K':ZI966J6ZQZC9VMU#BV7['W[+VF_&"7]H"P^ _PQL_C9<:M=ZY/
M\4[?PK81^.9M4OH[R.[NY?$*H+^1IEU&_+1O(8!)>W4RQ++/*[ '@O[%WA3Q
M&GCW]H;Q6GQK^/'Q'^&7AWQU=_ CP+H_Q@\>0^-TN_$/PCO[K3_BU\0+:5M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+5Q-%X?T6'PAX%TOPU\0O$OB#X/7_C?QEXJAAT?Q]\/O$^EVG@KQA]FU1M!
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M1] 7Q1X?UK]F[5/A%X?E\<Z_'XBFU?Q:EKXUT[QNUU>:_P"%8O#:? #]LO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>sellinggeneralandadmin.jpg
<TEXT>
begin 644 sellinggeneralandadmin.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MFTW1?$6F?<U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME>^5M\W[)=07/E[]VSS/)D?9NVMMW8W;6QG!H N4444 %%%% !1110 4444
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M>(/B;HL%U>^)0_[IC@8],^_<\GIR>I]\\GK7XL:9I4ND_'>U\)>'+W6/$I\
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M7^7I[=: /Q _X*3_ /*23_@A3_V=;^U!_P"L<_$&OU2^.'_(H:7_ -ANT_\
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M/] USQGX2E\#^(&37]2\(^+=MO>^&KF\TQEM+:SG^SWU["UP\%U+"WR/>?\
M!%?^T(EAOO\ @K#_ ,%HKN%7$JQS_MK: R"1595< ?!@?,%=U!]&->1GV75,
MWR?'Y;1J0I5,90=*%2JI.G!N<97DH)RM:/1-^0T[-/L[GTQO3^\O_?0_QHWI
M_>7_ +Z'^-?*O_#C_2O^DJ/_  68_P#$T]!_^<U1_P ./]*_Z2H_\%F/_$T]
M!_\ G-5^._\ $)<V_P"AIEO_ (#BO_E7]6?E='U5O3^\O_?0_P :-Z?WE_[Z
M'^-?*O\ PX_TK_I*C_P68_\ $T]!_P#G-5\W:=_P2<OKO]K?Q7\"I/\ @J5_
MP5^'A'0_V=/ /Q8M)T_;*T@>(6\2>*/BE\3/!6HQ7%X?A*;=]&32_!VER6=J
MMA')%>O?2O=S"9(H3_B$N;?]#3+O_ <5_P#*@/T[WI_>7_OH?XT;T_O+_P!]
M#_&OE7_AQ_I7_25'_@LQ_P")IZ#_ /.:H_X<?Z5_TE1_X+,?^)IZ#_\ .:H_
MXA+FW_0TRW_P'%?_ "K^K/RN'U5O3^\O_?0_QKZZ^"3I_P (6WS+_P AK4OX
MA_TP]Z_)O_AQ_I7_ $E1_P""S'_B:>@__.:K3M/^"++6$(M[+_@K'_P6CM8
MS.(8?VU] 5 [G<[ 'X,'!8\GGD\U]1PCP%C^'<W_ +1Q..P>(I_5*V']G0C7
M4^:K.C-2_>4XQY5[-IZWNU9-#OI;S3^Z_P#F?M?O3^\O_?0_QKXH^*CI_P )
M]XA^9?\ 6V/\0_Z!=C[U\8?\.9;W_I+7_P %J/\ Q-C0/_G+UE7/_!$BRO)G
MN;O_ (*K_P#!9RYN)-OF32_MJ:"TC[$6--Q_X4R,[454''"J!VKZ/C/AS$<3
M9;A\#AL10PU2CCJ>*<ZZJ.$H1H8FBXKV<92YKUHR5U:T9:WLFCZCWI_>7_OH
M?XT;T_O+_P!]#_&OE7_AQ_I7_25'_@LQ_P")IZ#_ /.:H_X<?Z5_TE1_X+,?
M^)IZ#_\ .:K\T_XA+FW_ $-,M_\  <5_\J_JS\KA]5;T_O+_ -]#_&C>G]Y?
M^^A_C7RHW_!$#2@ ?^'J'_!9@_,@_P"3T]!'WF"]O@SGOVY]"#S7SI^R-_P2
M8OOCM^S+\#_C%XO_ ."I?_!7^#Q/\1_AQX<\6Z[#X>_;*T>ST./4M7M?.N4T
MNTG^$E]-;V:N/W,4EY<LJD!IG.6)_P 0ES;_ *&F7?\ @.*_^5 ?IMO3^\O_
M 'T/\:-Z?WE_[Z'^-?*O_#C_ $K_ *2H_P#!9C_Q-/0?_G-4?\./]*_Z2H_\
M%F/_ !-/0?\ YS5'_$)<V_Z&F6_^ XK_ .5?U9^5P^N-,=/[2T[YE_Y"%A_$
M/^?R#WK]"MZ?WE_[Z'^-?A^O_!$'3$=)$_X*I_\ !9E'C=9$=?VT]!#(Z,'1
MU/\ PIK(96 93V(!K:_X<RWO_26O_@M1_P")L:!_\Y>OO^">%,7PO#,8XK%8
M?$O&RPLH?5U57(L/&NI<_M(1^+VRMRW^%WZ7=]+>;?WV_P C]<OB*Z?\(-XG
M^9?^03<?Q#T7WKX<9TR?F7J?XAZ_6OFN;_@B_/<PRV]Q_P %9_\ @M--!,C1
M31/^VQH!22-P5=' ^# RK*2&&>02#Q61_P ./]*_Z2H_\%F/_$T]!_\ G-5Q
M<:<%8WB?'X3%X;&87#0P^$^KRCB%6<I2]M4J<T?9PDN6TTM;.Z?D'1+S?XV_
MR/JK>G]Y?^^A_C1O3^\O_?0_QKY5_P"''^E?])4?^"S'_B:>@_\ SFJ/^''^
ME?\ 25'_ (+,?^)IZ#_\YJOC?^(2YM_T-,M_\!Q7_P J_JS\KH^JMZ?WE_[Z
M'^-&]/[R_P#?0_QK\UOB[_P20N_ GQ/_ &6/!NC_ /!4O_@L%)IGQJ^,WB[X
M?>*WU']LK1I[Z'1-"_9Q^.GQ;M)-!EC^$<"6>I-XE^&N@0W$\\5[&^C2:K:K
M;)+<Q7EK[_\ \./]*_Z2H_\ !9C_ ,33T'_YS5'_ !"7-O\ H:9;_P" XK_Y
M5_5GY7#ZJWI_>7_OH?XT;T_O+_WT/\:^5?\ AQ_I7_25'_@LQ_XFGH/_ ,YJ
MC_AQ_I7_ $E1_P""S'_B:>@__.:H_P"(2YM_T-,M_P# <5_\J_JS\KA^E?P"
M=/MWB;YE_P"/33/XA_SVO?>OI@$'H0?H0?Y5^)-E_P $48M.,IT__@J]_P %
MH+,S!!,8/VUM 3S!'O,>_/P8.=GF/M]-[>M?<7[(/[&,_P"R0WCYIOVM_P!M
M7]J/_A/!X:55_:^^-NG_ !A7P5_PC9UPEO (L?!7A#^P#X@_ML#Q,93?_P!I
MC1]#V"U^PMY_ZSPOD];(<DPF5UZU*O5P\L1*52BIJG+VV)JUXJ/.HR]V-11=
MTO>3M=68'VK1117T !1110 4444 %%%% !1110 4444 %%%4M2OX-*T^^U.Y
MCNY;?3K.ZOIX["QO-3OGAM()+B5+/3M/@N;^_NFCC86]E96\]W=S%+>U@FGD
MCC8 NUE+H6B)K<WB5-'TI/$=SI=MH=QKZZ=9KK4^BV=Y=ZA9Z1-JHA%_+I=K
M?W]]?6VGO<-:07E[=W,4*SW,SO\ "_\ PWUH.A#5++XF_ GXY_"_Q5=>#/!_
MC[X;>!/$.F>!M3\8?$_1OB#\2_"7P<\'^'M,T_PYXWU6T\&?$:]^)WC[P-X2
MU;P5\1]0\*/H%UXMTV\OM7:QTKQA/X8;XI_X*">"_ 'PT^(7B[QY\)/C%H_C
MWX4^.-&^'_Q ^#FBZ-H'C3Q3X>U/7M \*>,=.\47?BKPMX@U#X;6OPUE\$>,
M-,\6MX\U;Q=I.GFWM]4\+16DOQ%L?^$+E /O^BOB/X]?MP>#O@3\1-8^'U]X
M"\9>*Y_!/PWT'XO_ !(U;1]6^'NAQ>&_A]XEU_Q?X9TF]\+Z+XT\9>&_$OQ;
M\1MJW@G64O/!OPNTCQ+KUF9O#^EM%)XH\8>#_#FO?;2L'4,N<,,C((.#TR#R
M#[$ CH0""  .HHHH **** "BBO$_C!\6/$GPXD\+Z5X-^#7Q(^,WBCQ;<ZJM
MGI/@A?#&CZ-HNGZ%;6EUJ6J>+O'/CO7_  QX.\-QW!O;/2_#NF76JRZ[XHUN
M\CMM)TR33-.\1ZQH0![9_G\NE9>B:'HOAG2-/T#PYI&EZ!H6D6L5CI6BZ+I]
MII6DZ990+M@L]/TVPAM[*RM85^6*WMH(H8UX1 *^!+C_ (*.?#*[\)6/Q(\(
M?#CXK^,_AGHWP>\$_'GXS>+],T_PGI[? KX9^/3XI&EZGXQ\.ZUXLL->\2:O
MH=IX(\7^(_&7A_X=6GBV^T#P;X=N?$L#ZK%K7@^S\3>]>$?VF_"_CKXW?%'X
M%^&_"/C]]=^%_@31/&L_B?6O#S>&?!OC%]9\3^,?",FB^ ]1UZ:QU'Q(VBZU
MX-NK75O%-OI2>!I9M0M+;0?$NN7-EKT6D 'TK17R7\ _VB_'_P 6OB%\2OAW
MXV_9^\2?"._^&6E^$KK6]7OOB1\+?B#HIUOQA%>:C8>#99OA_K^J76F^*[7P
MU;V'B[4=,U&UA^R>&O$GA/4I)0GB33%G^M* "BBB@ HHHH **0G )P3@$X R
M3CL!W/H*^/-;_; TOPE\2M-\*>.?A'\5? GPZU[X@^)?A1X<^-OBVT\*:1X.
MUGQWX4\)>,O&^IM%X9E\3M\2;+P%=:'X \6IH7Q+O_!]OX6UR\T2:ZM9E\+Z
MAH/B?5P#ZQOM%T?4[S1]0U'2M-O[_P .W\^JZ!>WMA:W=WH>IW.E:CH5SJ.C
MW,\4DVF7UQHFKZKH\]Y9/!<2Z7J>H:?)(UG>W,,NG7PQX(_;K\)>)(HKCQ/\
M)?C1X B\4_"NW^.7P?@U#PK8^,M;^,GPKN];\'>'(M3\)>%OAGJWC+Q/IGB^
MTU?XB_#M-9^'GBK2M%\2Z)9>/_"U[J$<83Q3%X7BU']O#P5#\"_@-\8]+\!>
M,+S5?VB?"X\7>"OAOK&N?#GP?K/A[0K+PXOB?Q1JOQ)\9>)_&6G_  S\%Z/X
M,M9M.T?Q!K$OB[4;&;Q5KOAWPYX>?7;[7+!I #[LHKC?A[XP;Q]X+\-^,9/#
M'B?P7)X@TN#49?"OC.VTNU\3:#-*7273=830]6U[0IKJWDC91>Z%KFM:'J,!
MAU#1M6U+3+JUO)NRH **** "BBB@ HHHH **** "BBB@ HHHH **** "L[5U
MU5]*U)-#FL+?6FL+Q=)GU6WN;K3(=3-M*+"34;:SN;.[N+%+LPM>06MW:W,M
ML)8X+F"9DE31HH _*3P9^Q1^T=X@T;XA2_'_ .*_P:\0_%OQ7JWPB^(&E_'G
MP/X#^(R^)[/XF? CXI:5\5?A1ITG@KQI\0=4\+:-\"?">N6%Y:P?!OP?>:$+
MNQUOQ'J&H>*[WQSXG\0^.=1M_%;]B_\ :(\<?"OX\:9I/Q)^!<?QA_:E\1>%
M;CXN>)]:^'7Q&'@3PYX.^'WA/P]X9\">$_AQX;TGXCIXC9])?0+C6M3U?Q7X
MFOFU;6_%'B*ZM[+2M/\ [)TBP_5"B@#\E_CK_P $^OB5^T9K$_C+XE>+/@#J
MWCSQ5\/=!\%R>)M<^$/C#Q7K7[,WB#0-2US51\3?V+O$EU\2-%U[X3^-=3U2
MY\*^*;O4;^XGU;_A// _ACQ'=>(-3TO1])\,6'ZMZ=9MI]A96+WEWJ#V=I;V
MK7^H/%)?WK6\*0M=WLD,4$,EW<E#/=2100Q//)(T<,2%8UNT4 %%%% !1110
M 5\@?M?_  I_:,^,?A?POX,^!WQ)^'_@#PQ>:KJ+?&'3_%FD?$1==\>^%#8Q
MPZ=X,\->.OAMXS\)>)/A[IVHWTER_C+5]#)\4:MHL46A>'=>\)F]U'4YOK^B
M@#\QO$'[#/Q#UCP]XQ\+>'/'?PH^%_A7]H3X%> ?@'^TAX/\&?##7KC0M,\+
M> _#7BKP'%=_LZ)>>-[&#P!>:K\,O%,OPX%IXQTSQCI.@V6B>$?$FDV*WF@Z
MCH_B7TCPY\#?VD]$_:]U;XTMXH^ $?P=U'X>^'/@W;>#-/\ !WQ.@^(.F_#G
MP5XD\<^*O#4]OXCF\<2^$V\2/?\ C)+'4U/AD:2MCIBO81PS7#(GWC10!X;\
M!_@_/\(-&^(,6J:['XG\2?$;XU_%_P"+FOZ_'936!N$\?>-M2O\ PCHDD-Q=
MWTLA\"_#>V\$?#N"Z-QY=W:>$+:XMK>QM9(+"U]RHHH **** "BBB@ K\W-9
M_9:_:$^(_P"T3XK\<_'#Q=\"/B7\&=2C\>^"? G@_P#X13XJ:%XG^%/PC\<^
M%=3\(ZQ9>%(HO'M[X'N?BWXITC4;K3_&WQ>U71KC6;G0-4U3PAX0LO!_A.ZO
M]'U7](Z* /SN\#?LL_M >!&\+>*)_BU\+O'?C_X$? Z^_9]_9SFUWX;^*-"T
M"/PQX@U?X77/C#QS\9/[)\>:AJ_B3X@>)-$^$O@[2&3P//X/\,:9>:?K6JVN
MEO;>*GT70/)/!'[!/QETWX4_LUZ3XY\5?LY^+/BI^R/:>(/"7PMNKWX5^/\
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>spinrazalogonewa01.jpg
<TEXT>
begin 644 spinrazalogonewa01.jpg
M_]C_X  02D9)1@ ! 0$ 2 !(  #_[@ .061O8F4 9      !_^$0C$5X:68
M $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    )    '(!,@ "    %    ):':0 $
M 0   *H   $N  K\@   )Q  "OR    G$$%D;V)E(%!H;W1O<VAO<"!#0R R
M,#$U("A-86-I;G1O<V@I #(P,38Z,3 Z,C@@,#@Z-# Z-#,   >0 P "
M%    020!  "    %    1B2D0 "     S P  "2D@ "     S P  "@ 0 #
M     0 !  "@ @ $     0   >"@ P $     0   /      ,C Q-CHQ,#HR
M." P.#HT,#HP,  R,#$V.C$P.C(X(# X.C0P.C P      8! P #     0 &
M   !&@ %     0   7P!&P %     0   80!*  #     0 "   " 0 $
M 0   8P" @ $     0  #O<         2     $   !(     ?_8_^T #$%D
M;V)E7T--  '_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5
M#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !0 * # 2(  A$! Q$!_]T
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M[1AB4&AO=&]S:&]P(#,N,  X0DE-!"4      !
M.$))300Z      $+    $     $       MP<FEN=$]U='!U=     4
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M8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M     $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"
M<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M  !2<VQT56YT1B-0>&Q 4@            IV96-T;W)$871A8F]O; $
M4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M         %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O
M='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!2
M96-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#
M[0      $ !(     0 ! $@    !  $X0DE-!"8       X
M/X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M   )           ! #A"24TG$       "@ !          $X0DE- _4
M $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $
M6@    8       $ -0    $ +0    8       $X0DE- _@      '   /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z   .$))300        "   X0DE-! (       (
M #A"24T$,        0$ .$))300M       &  $    ".$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      U<
M   &              #P   !X    !$ 4P!0 $D 3@!2 $$ 6@!! %\ ; !O
M &< ;P!? &X 90!W     0                         !
M  '@    \                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG    \     !29VAT;&]N9P   >     &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   /      4F=H
M=&QO;F<   '@     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 4 "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M300A      !=     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
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M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\
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M>W/Z>QY[ZC_D+;5_TL4_ZLS]9(_W9'_3[>>/_%1N/^[EM?5.'\I_CY-[T_\
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M 2B#$3.B_I#GW+?L/S-#[.>UUCR1>V;7V\Q7-U*9(B$@;QYGD05D/B JK!6
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MYD_Y[I?^/=?3U]WG_IQ?LQ_XKMA_U:7K:(_EL?\ ,H?C7_X@7$?^X-'[Q_\
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M\BYID<ZQ2HH/*M;'O[O-CO'NU]Y;:N:ELVCL;.Y>_G\Q!;PQ-#:Q,PQK:0Q
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MK(6=_EZ]S^4;?EC>9_H!_B1N9XOD'AD9"1Z!U :G &M,4 )5_.@_[=_=F?\
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M2]0K -)FV*$#[$&3%WWBYQ_>E]_5C;Y0=OM7K,0?CF'X/]+#Y^LF*=F>V?\
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M2/\ [^+97O/+WC_Y4+<O^:]M_P!I$?4T_P!WO_XE'R=_TKMW_P"[5=]:R?\
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M,;JWCL[>VR]MY#:RMM2HPE/3;IP53D8\O0T68.7Q.19:K!UK51H9$>.-!7U
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M]1-!-63N7UL"3<RCN/-G*NQ1".]WBUB5!I$:,'84'PB./45]!4 #UZQAY?\
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MIIV9HB8G4 %0205!^*F:4X'UQY]<?DIOW([GVW\+_DG+U+WCB]B==?),;V[
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M\KAG;^6I\!6=F=S\./CCJ9F+,3_HCVI]6:Y/MCFT4YIYB X?73?]7&ZMM/\
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M3PTE'3P4M+31)#3TU-%'!3P0QJ%CBAAB58XHHU%@J@ #Z>VB2Q)8U)ZL
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..[KW7O?NO=>]^Z]U__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>spinrazarev.jpg
<TEXT>
begin 644 spinrazarev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3\>^*/^$(\$>,/
M&7V!]4_X13PMXB\2_P!F1S?9Y-0_L#1K[5_L,<_E3^2]W]C^SK+Y,OEM*'\J
M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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MO ^D_%'QO%\'O'&G^._#=CXJO/!_A/PWX4ETN^O+2\T75],TCPII%H/#NO\
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MW32C&4:M-I5G1FW.--1=5^S/J2OTX_9'_P"23G_L:O$/_H5E7YCU^G'[(_\
MR2<_]C5XA_\ 0K*OU7P%_P"2\?\ V),Q_P#3^!/LO#C_ )*-_P#8NQ?_ *<P
MQ]04445_:Y^]A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (1KP[_T M(_\%UI_P#&J/\ A&O#O_0"TC_P76G_ ,:K^US][-HG SC/^?\
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M9?XL2_$*/X1'2(?A_/%>Q"+Q=)XFGUPW'A5?"RZYIFLV^G+XA_;X\.Z+\/\
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M@U.]D(X2TTZ:*_N6Q!9RQW,D3KJTC?=;KT/0X/3L>Q]Z /P\\(_"&7PO\3/
MEK=0ZQ<3V7B?X?ZD;C2OV+_^"FL>C^7?W&@ZW;J_C'6OVJ?$7@?1)K>WO88-
M9O/%-CJVD>$M3BU"U\9:5/\ V/K.F5^X8_J>Q'<^O\^AZCBOQ'U%_AY)^VI\
M7X_&)_9A;Q+#\?\ X;MX?'QY\1^+O$_QH6!_!_PU33&^&QT,_P#",>%_#!OX
M)(_AUX*!DN-'\30ZYK'B25;SQ*UK:_MP/ZG^9_S_ "H _$'_ (*3_P#*23_@
MA3_V=;^U!_ZQS\0:^PO^"AOQ3\'_  D^#/A+Q#XTN-1MM,O?B)I6CV[Z9I<V
MJSF^G\->)KN-7MX'1TB\BSG9IB2JL$0C+@CX]_X*3_\ *23_ ((4_P#9UO[4
M'_K'/Q!KIO\ @MM_R:[\.?\ LN/A[_U _'M?)<>86GC>$,_PM9R5.O@7";@U
M&:3JTW[K:DD].J?H>)Q'2C7R3,J,[\E3#N,N5V=G.&S::3^3/@W_ (;8^ ?_
M $%O%O\ X1FH?_)%'_#;'P#_ .@MXM_\(S4/_DBOQJHK^._]4,I_FQG_ (.I
M^7_3CR?W^1^(_P!A8+^:O_X,C_\ *S]E?^&V/@'_ -!;Q;_X1FH?_)%'_#;'
MP#_Z"WBW_P (S4/_ )(K\:J*/]4,I_FQG_@ZGY?]./)_?Y!_86"_FK_^#(__
M "L_97_AMCX!_P#06\6_^$9J'_R11_PVQ\ _^@MXM_\ ",U#_P"2*_&JBC_5
M#*?YL9_X.I^7_3CR?W^0?V%@OYJ__@R/_P K/V5_X;8^ ?\ T%O%O_A&:A_\
MD5^UW[ 'Q*\*_%7X"MXH\'SW]QI \=>+-,\S4M.FTNY^UV+:;]H7[-.SN8U\
MY-DH;;)DX'RFOXO*_JZ_X(Q_\F=2?]E>^(_\]!K]/\(^'\!EO%OUG#O$.I_9
M6,I_O:D)0Y9U<)?2-.#O>*:?-9:IIGUO!668?"9W[6DZKE]2Q$??E&2M*="^
MBC'71:W/UFKX%^,7[0OQ)\%_$CQ-X8T.YT--*TN;3DM$N]%6ZN MSH^GWLOF
M3F[C,A,]S*5.Q=J%5YVY/WU7Y*_M'?\ ):?&_P#U\:/_ .HYH]?=^.6<YMD?
M"V6XK)\QQF6XFIG^&H5*^"KU,/5G1EE^95)4I3IRC)TW.G3FXMV<H1EO%-?0
M>(..QF7Y/A:V"Q5?"U99C2IRJ4*DZ4I4WA\5)P<H--Q<HQE:]KQ3W2.D_P"&
MKOB]_P _GAO_ ,)Y?_DZA/VKOB_*TB177AV22&?[+-''X<$DD-U]G@O/LLJ)
M?,\5S]DNK6[^SR*LWV2ZMKKR_L]Q!))\V[BA#A'D*?.(XRBR2%?F$<;2$1K+
M(0$C:0B-9&4R$(&(_#WX,WOPI^&EE^UA:_%K1/%OB+X.:=-I=U\3OB5%\/OV
M@/A]\6]>US2T^ 3:)\*OCMX&NKJ^T+XC?$7XD:OJMY%K&H^"]41]5L]*^(-M
MXV7P]\(O'NF35_.V2\3\<9M1Q]1<8\31J8+ZC[.AAJ^*Q-3$?6L5##S47+&8
M>G&K!->PP[J>UQE:<*%!<UW'\QP&;<08VGB9K.\V4J'L.6G2J5ZTJOM:T*34
M6Z]**FKKV=/FYZ\Y*G35UI_2G_PU?\7?*\_[;X:\@Q+.)_\ A'X_(-NY"QW'
MG_;_ "?L\C,J1S[_ "7=E5'+,H+S^U5\8E<1M<>'UD:4P*C>&MKM.$>4VZHU
MZ&:X$<<DA@4&81QR2% D;LO\]MCX^_93\+_"67QMXUTKP#XT\-^.?VA/$6K_
M  M_9I\.W>JWWP$^'WC"\^&'AS1E\'^.)CX;;X8:?9Z7H-A>?%#Q_P")9O#M
MU\.O"OCOQQK;_"+P]XL\7?V+<>(_.M5\+2Z-H6COJWB/P)\:],T/X ?"=/V6
M9]5^&GQD^(</Q?\ %&G>(_B-K'C_ .&/P0\2:5K.C>*/@QK]GXS;PMX9T+X@
MK?7/Q:L? 6D?#'5=7E3P9X.\3)?^O1S/C>HVI\;\4T$JWL8>UCC7]8DIQI5H
M83V>835>6$J2@J\W*&%E3ABL1A\37PV!Q-:GVPQ>?R;4L_S>G::IKG6(_>23
M49QH\N*E[1T9<OM)7C1<56J4JM2EAJLX_P!)\W[6_P 5;9%DN=5\(VL;':LE
MUH]K;1LV"VU7N-2C1FV@MM5BVT%L8!(D3]K'XMR*KQW_ (7DC<922+08I8W'
MJDD>H,CK_M*Q![&ORW_:7O? WQ(^$WQ%TZV\">$?B=XT\'^/_#WPJT33?'?P
MULO'&F> ?C%\1]4\#>$K;Q)!8>+/#DVAZM'X)T?XG6'BS4/$GAU;WPU=V6G7
M>FR:L88M6L[7Z,\!^ ?"/PK\%>%?AKX!TJWT3P5X$T+3_"OA?2[:*.&.UT;1
MXOLUJSI$D<9N[LB2_P!0E2-%N-1N[NYV(9BH^9K<;<;4,#1Q-3B[B.&(K8FK
M06'GC,3&*IT:-"M*M[7ZUSVG'%87V*]@HU5*K*,XJC'VGDSS_/J>'IU99UFB
MJSJSIJE*O62Y:<*51SY_;<UFJM'D7LTIWFU)*$>;[,TO]J;XMW>J:7:37?AS
MR;K4].M9@OA]5<PW-[!!*$;[<=KF.1MK8.TX;!Q@_IN.?S/Z$BOP]T+_ )#N
MA_\ 8;T;_P!.EI7[A#I^+?S-?OO@-Q!G>>T.)GG.:X[,WAJN5+#O&XFKB'15
M6&/]HJ;JRDX*I[.'.HV3Y(W6B/TCPYS+'YC2S9X[&8C%NE/!*D\15G5<%..)
MYU'G;Y>;DC>UKV7966BBBOZ"/TL**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "@G )]!FBJM\EQ)9W<=I(T-S);7"6\J&$/%.T+K#(IN(+J#<DI1E\ZVN
M(L@>;!-'NC8 ^+O^&J]:U+XU^.OA7HVC_ O2(/A]\0_#7@/5XOB9^TC'X(^*
M.JIKN@>%O$*^)/#GPHTOX9^+Q<Z-JEOXDFL? RZKXPTF]\9:EHNI1O;Z%;>3
M<-]M_P#U_?O_ )SZ'BOR'3P)X_MOB+I6K^*I?VIO%WCNS\0Z)JUW97?[)/[%
MVIVGB-])O+*X"3_&G1_AW9>%K"VO([9+=-9;X@>'-=TZW<75JFD7ULBVOZTZ
M5<7MWIFGW6I6']E:A<V5M<7VE_:H;[^SKN:%)+BQ-[;JMO=M:2LUNUS /)G:
M,R1%HV5B ?B?_P %)_\ E))_P0I_[.M_:@_]8Y^(-=-_P6V_Y-=^'/\ V7'P
M]_Z@?CVN9_X*3_\ *23_ ((4_P#9UO[4'_K'/Q!KIO\ @MM_R:[\.?\ LN/A
M[_U _'M?-<8_\DQG/_8(_P#TY3/)SW_D48[_ *\_^WP/Y>****_EP_)0HHHH
M **** "OZNO^",?_ "9U)_V5[XC_ ,]!K^46OZNO^",?_)G4G_97OB/_ #T&
MOT'PS_Y*;_NG8K_T[A3Z7A/_ )&S_P"P2O\ ^ET3]9NE?B#^U?\ '#X0>$_V
M@?B)X>\2_$7PSHFMZ==:"M]I=_<727=JUQX4T*ZA$R1V<J RVT\,R;7;*2*3
M@Y _;UNA^A_E7\;'_!3XD?MT_'K!/_(1\$]_^J9^"Z^H\:,LHYKPSEV'KU*M
M.$,\H5DZ3@I.4<!F,$GSQFK6FWHD[I:VNGZO'>#AC<JPU*I*<%',*<[PY;MK
M#XI6?,I*WO7[Z'W'_P -)? 3_HK/@[_P+O?_ ) I\?[2WP(A?S8/B]X2@ER6
M\V"_U"&7<T:0LWF16*/N:&**%FW;FABBA),4<:+^$63ZG\S1D^I_,U_,W^IF
M7Z_[5C-='[U'5=G^Y/RC^P,-_P _J_WT_P#Y _>7_AJ+X*;S+_PNKP]YI4(9
M?[9UCS2BL65#)]EWE%8EE0MM5F9@ 228S^TY\#29F/QC\,%KD8N6.IZH6N1C
M&+@FSS.,<8E+C'&,5^#V3ZG\S1D^I_,TO]2\O_Z"<9]]#IM_RY\E]PO]7\+_
M ,_:W_E/_P"0/W=_X:6^!!VY^+WA([$,29O]0.R([MT29L?DB;>^Z-<(=[Y4
M[VRS_AI+X"?]%9\'?^!=[_\ (%?A+D^I_,T9/J?S-/\ U,R__H*QGWT/_E(_
M[ PW_/ZO]]/_ .0/WS\.?M&? FY\1^'+:W^*OA":>Y\1:!;01)=WF^6>XUBR
MA@B3-B!OEE=(TR0-S#) YK^BL=/Q;^9K^!#X>D_\+ \ <G_D??!'<_\ 0V:/
M7]]R]#_O/_Z&U?T!X(9/A\HH\1QH5:U3V]3+')U7!V]G'')<O)"&_.[WOLK'
MZ5P!@*>!IYHJ<YS56>$;Y^73DCB+6Y8Q_FUO<=1117[P?H84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% #=B9W;5W=<[1G/KG&:=110!^'G_  4M
M\W_AY!_P0J\CR_,_X:O_ &G,>;OV;/\ ACWQ_P"9G9\V[R]^SMOV[OES6O\
M\%J/[7_X9@^'?]HG3O*_X7=H&W[&+L/O_P"$%\=;=WV@E=FWS,XYW;<<;JS/
M^"D__*23_@A3_P!G6_M0?^L<_$&NF_X+;?\ )KOPY_[+CX>_]0/Q[7S7&/\
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M)_\ E))_P0I_[.M_:@_]8Y^(-=-_P6V_Y-=^'/\ V7'P]_Z@?CVN9_X*3_\
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M12$@8!(!/ SWH 6BDR,@9&3D@9Y(&,D#OC(SZ9%!95QN8#)P,D#)]!GJ?84
M+1110 4444 %%%% !1110 4444 %%%% !1110!^('_!2?_E))_P0I_[.M_:@
M_P#6.?B#73?\%MO^37?AS_V7'P]_Z@?CVO"O^"S'QD^'O[.'[7O_  1K_:$^
M,>K:GX7^#_PJ_:?_ &B-2^(/C*Q\)>,?&4/AFPU[]ECQAX8TBYO=(\#:!XE\
M03)?:[JUAI\*V6DW4GF3F9T6VM[F>'XN_P""IO\ P6?_ .";G[0WP$\%>#?@
M[\?]>\:>)-)^*VC>(]0TRU_9Z_:>TZ2WT6U\)>+M-GOC-K7P7TVU=([[4[&
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M /AMQO\ \I#^S<Q_Z ,;_P"$M?\ ^5GUA17RI_PVQ^S;_P!#EXM_\,E\>/\
MYV5'_#;'[-O_ $.7BW_PR7QX_P#G94?ZOY]_T),W_P##;C?_ )2']FYC_P!
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M6+'XZ^(?'$7PX;PI-;>-KSXA^+K?5/%?C'Q#X:TOX4KHNBV/ZEU\TZ-^QO\
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M6=E9V\-M;01I#!$D:*HUJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M37>EZ+IGC"Q\/>-[N<7WAB$V?Q$NO#G@Q-<\.ZU=76D^%/"^OV%H\OL>@?\
M!1OXL>)O%'Q='AS]FGQ'JWA/PS%^U/HOP\EUB#Q1\/+75/&'[,>M^(O"EI!X
MI^*GCK1=)^$0TSXP>*?"VKZ7I,7A76=2U+X;2R:!%XP&I?VUJ$_AP _7>BOE
MC]E'X[ZW\</"?C'_ (3*#0-*\?\ P\\<2^#?%OA[2O#OQ4\$ZKI+W?ACPUXQ
MT)_$O@+XQ^$?"GC+PCJFHZ'XGM+JWM(Y?%WAS5M+%CK^@>,M2MM4ET[2/J>@
M JE>:EIVGF,7U_961E#&(7=U;VQD";=Y03R1[PNY=VW.W<N<9&;M?!'[:JHU
M[\.]R(V+7Q/C<BMC,VA9QN!QG SCT%?)\<<2SX0X9S'B"GA(XZ>!E@DL+.L\
M/&JL5C\-@W>LJ59PY%7=1?NY<SBH^[?F7C<09K+),IQ69QH+$RP[H)495'24
MO;8BE0=YJ%1KE51R7NN[5M+W7V[_ ,))X?\ ^@YH_P#X-+#_ .2*U89H;F*.
M>WECG@E4/%-#(DL4B-R'CDC+(ZGLRL0>QK\*A%$2/W474?\ +)/_ (FOV%^!
MP ^$7P[   'A32<   #]R>@& /PKXCPV\4Z_'N9X_+ZN2TLLC@L!]<56GCYX
MMU'[>A0]FX2PF'45^]<N92EM;EUNOG^%>,*G$>+Q.&G@(818?#>WYXXB59R?
MM84^7E=&E9>^W>[V6FNGJM%%-8X'_ E'YL ?TK]C/N0#HQ(5E)'4!@2.W(!R
M.>*=7\W'PV_:]^.7PFFOOC5XJ;]ISQ/I>C:%_P %%_C7X[TOXE?$+X8^(/A)
M\=?AI^S=\0_B+X2\,?#[]FOPKH-]XP\<> _'_AGQ!J7PIU.23Q%H/PYM++X4
MZ%\0M3U'3O&<UO%'9?:T'[=7[2EWX'OHX?V=KJU\>Z9\4M(\(7NJ:GX"^-]C
MI#^%=5^%^M_$.7Q%H'P6F\+I^T;XTDT/Q'I5G\-=>3P=X1UL6MCKVF?&"UL[
MWPE!K'AS2P#]<:*_.7]CW]HCXQ_'OXX?M#7VM^(/ACK'P!M/!/[+_C+X(6O@
MNU\07&KVL'Q@^#>E^/-?GNO$^M:3X;F\3>'[O4[B_P#[*U'4/"^@ZP$@@6XT
M/P^ZWVBVWSQ\:?V]_C\?AK\4M;^&_AGX9>$4\9^$?VY-%^ &N:EK6N^(?'/@
MGQO^QFOC.Q\2>(OB[X'DT:TTN#2_$B^"/$=YI-GI-S>/X#\2S?#[PYXQM_$S
M>,+]-" /V@!! (((/0@Y!^A%+7YT_%?XW?$7]BW]GWX#R:[:VWQ:U[6=.F^%
M^JZSXF\:^([O5_$WQ]\2^ M=U#X*^'+?Q#JVGW&I7MG\7/C'8:9\)[*^U>U2
M_P!/U+QEX3CBMWQ)#7EVA_\ !0;XC?%2Q\+0?"#P3\)H-7\4Z)\9/$\&I?$_
MQ_KGAWP;:0_LQ^#?@POQZ\&S:OI6BWM[+XOT3XU_%76?A*LT-F=-\+V7PO\
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ME^(H_ WAJ/6_'^@ZM!%:ZMHWC#5$TU;WQ%IFJVUO:PZI9:I-<P:E':6BWZ7
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M/#WAF^U=K[49-8O!J-SHVGV<UVMQJLLVI21S.\9OII;H(LTLCMZI10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>taxexpense.jpg
<TEXT>
begin 644 taxexpense.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %2 3T# 2(  A$! Q$!_\0
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M9=1 /I?4_P!NG]G#1M MM=U7Q'XUL+B36O$VA:AX/N/@Y\8Q\3/#5SX)\/\
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M74]#\4:3;75_-X2UC0=4EM=3L@#QSP_^W'\4OB!<S^!/AC\ /#_BOXU>$?\
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M$5CHNOZ7]PT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P &>J__ "=0!OT5@?\ ",Z1_P \;G_P9ZK_ /)U'_",Z1_SQN?_  9ZK_\
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M4J:I>S5,NNU_-]OE;\_+NW_.U\9_%_B#Q%X8\$>(1IWP@^$4'A']D*RC\!>
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M#_Q[>*?^OC2?_15]7S;7TE\ ?^/;Q3_U\:3_ .BKZO<\/9SJ<8Y9.I)SG/\
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MN7_Y)K\7-4U+Q[XU^-?[-A\ _M'_ !"ATSXD^!])_:!\=>$?"EE\*KKX+/\
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M /*23_@A3_V=;^U!_P"L<_$&OU:^-G_(D6O_ &&=._\ 2:\KYKC'_DE\\_[
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M0WNM#7]80KN.J%F;/.?'N-(K7PG'&BI''+JJ(B*%1$6'3E5$50%154 *J@*
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M/XZ]>=DZE>M*=6H]9SD]3ZDKYX^/W^H\+?\ 7?5__16GU]#U\\?'[_4>%O\
MKOJ__HK3Z_9O$+_DC\X],#_ZL\$=*W^4OR9\W4445_,0@HHHH **** "OI+X
M _\ 'MXI_P"OC2?_ $5?5\VU])? '_CV\4_]?&D_^BKZOMO#O_DK\J_PX_\
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MGK8C+\%7JSM&//5K8:E4J2Y8J,8\TY-\L8J*O:*2205];? __D3)O^PY?_\
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M\(:3HGASPSJOBBZ\1:]>:=;76N>([$6FFQ6.F>'_  =;MJOB'5=6TPG4M T
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M41^T]]H\CS/*\_R/^%)^=Y'F_NO/V>3YO[K?YGRT?ZOY]_T(\XU_ZEF-\O\
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MEK=SO#<+%]*U^_ %%%% !1110 4444 %%%% "$9]>/0D?G@C/XT8'O\ F?\
M&EHH 3 ]_P S_C1@>_YG_&EHH 3 ]_S/^-?+7Q;^%OC#Q9^T7^RI\1-$LK>X
M\+?"O4/C?<>,KN74;6VN+&+QM\+CX7\/FVLII%N=1-SK&(9EM$D-I'_I$^R+
MYJ^I<@D@$$CJ,C(STR.HS0"#D@@@9!((.".H/T[T &![_F?\:,#W_,_XT%E
MR2 #T)( .>G/O2T )@>_YG_&C ]_S/\ C2T4 )@>_P"9_P :,#W_ #/^-+10
M F![_F?\:,#W_,_XTM% "8'O^9_QKY:'PM\8?\-G/\9?L5O_ ,($?V9(_AF-
M0_M&U^U_\):OQ?E\7FS_ +,\S[;]G_L-A<?;_+^R^;_HV\S#:/J7(.<$''!Y
M'!]#Z?C1D8SD8]<C'Y]* # ]_P S_C1@>_YG_&D9T4X9U4GD!F ./7DBG4 )
M@>_YG_&C ]_S/^-+10 F![_F?\:,#W_,_P"-+10 F![_ )G_ !HP/?\ ,_XT
MM% "8'O^9_QKY;^$7PN\8>$OVB/VKOB'K=E;V_A?XJZM\%+OP9=Q:C:W-Q?0
M>"OA1:>%-?:ZLH9&N=.-MK,3P0K=I&UW$!<P;X2&KZDW+C.X8'4Y&!CKSTXH
MR.#D8.,'/7/3'U[4 &![_F?\:,#W_,_XT9&0,C)Z#/)QUP/:EH 3 ]_S/^-&
M![_F?\:6B@ QC_\ 63_.BBB@ HHHH **** "BBB@ HHHH **** "D/UQTZ^F
M>?3J,C/;KSTI:" >O/(/X@Y'Y$9H _&CXP_%+]HKX-ZS\>/'?PM^-GB[X\W'
MP@^#/[4'Q#^.]KK_ ((\/6OP ^'WB70_!NI^)/@!\,OA[8Z)I$6LVWQ'\)ZF
M^E2>,O"]CX_\7ZG/\,=)\2:_\6SI_C#QA\+1<=-JOB/]H#P7JG[1OP5^'7[2
M_B7QS':?L?\ A#]HG0/CCX]\,>!?'WB#X=^)=;USXJ:!KH\-VGAS3?!/A>2W
M^)NC>$+?QA\)K'Q'8>*O"_@?7-!\3W)T+Q-X+?2_!L7VI\/OV+_V4_A1XVE^
M(OPV^ 7PP\#^-9[GQ=>3>(/#/ABSTF\DO/'UW>ZAXVNW2VVVK7/BS4-2U'4/
M$,YMS+J]_?7E[>O-<W,TKV)OV./V5I?A_P"(_A2/V??A);?#CQ?K5EXB\4^"
MM/\ !&B:9X=\0:QIA4:;>:OINFVMI#?'38D2UT^"</:V%@B:?9V\%BBVP /S
MI^,OQK_:9\2^$?V,_#WPA;XQ?$WQGXM_9/U'XW_%;X?_  -\7?!SX6_%?5]4
M7PC\+(_!/Q'OOB#\;=)/P^G\'1^/-6U[PSKOPXT:73O$_B#7/%FC>(?[*\0>
M#O"?B#0)?T^_9K^(7_"V/V?/@E\2F\46?C:X\<?"OP'XEOO%^G>'[_PG8^)=
M3U7PSIMSJVM6GA?5;>TU+PY!J&J->7$>A7]M!=Z2'^PSPQ/ 47B+;]B3]D:U
M\"Z!\,HOV<?@\W@#PKJNIZUX:\)7'@;1+O1/#^H:VFGQ:T^C6EW;3C3+?6+?
M2M-M-5L+-X=.U*SL+.SO;2>UMH84^E=+TO3=#TS3]&T;3['2=(TBQM-,TK2M
M,M+>PT[3=-L+>.TL=/T^QM(X;6RLK*UABMK2TMH8K>VMXHX8(XXD1  7Z***
M "BBB@ J"Z%PUO.+26&"Z,,HMIKF"2YMXK@HP@DGMXKBUEN(4E*-+!'<V\DR
M!HTGA=A*D]5KRSMM0M+FQO8([FSO+>>TNK>90\4]M<Q/!/#*AX:.6*1XW4\,
MK$=Z /Q3\5?%+]H+X8:=\3]6\!_M)>./BM\/-)\/_"OX:_%/]H#XA^$/ MOX
M$\)?M"?$O]I/X4?"CQ5XQ_9^M-+\)Z=HS^&?@_\ #7Q+\3/$GQ$T":Z\??"W
MP3XET;X=^&[C6=7\5Z#\8;>:]\:/B-^TM\-OA+_P4 ^'WPY^/WB.8_LM6WP^
M\<>&/C)XR\+^%_&WQ/30_%WPHF\=>(?@TFM0Z?H'A<>*])U^Q\/ZXGC3Q'X-
M\5:MIGPP^)EKI$=E/XACT#Q9H_Z"_"_]B?\ 9+^"L.M6GPI_9X^$W@/3O$7@
MJY^&^MZ1X=\':99Z'J?P_O6A:[\%7>A-'+HTGA6Y^SQ)-H/V :;)$IA:W,+N
MC/U_]BO]DWQ3\-=/^#FO_L\?"35/A7IFO7GBBU^']SX+TC_A%/\ A(M0LYM/
MO]:N=&BACM+_ %*^L;B6TN[O4$NYKFW*0S.\<4*Q@'A?[:OA;Q-XG\9_ 7PS
MX!^._P =/A5\0OB]X\M_AEH=C\-/'^E^&?"^D^&/#-AXF^*?Q0^)&M>'M3\)
M>((==US1/ 'A;5/#^@I=SKIMWXDUWP=9W]JUB;IYOT14850>P Y)8\>K,2S'
MU8G+'D\FO+?"/P/^$7@/3? &D>$/AUX2T&P^%=MXAM/AQ#8Z/;!O!-MXL,G_
M  DT/AN>42W.E1Z\)I%U86TR_;D8I/O0!1ZI0 4444 %%%% !7$_$FU\0WW@
M#QG9^$_&UA\-O$EUX9UFWT;X@ZGH=AXELO!-]+83+%XKFT'5K_3-(U7^P 6U
M..SUB\31Y)K:,ZK'<:<MS:S=M7'_ !!^'W@?XK^"?%/PV^)7A30/'7@#QOH>
MH>&?&'@[Q3IEKK7ASQ-X>U:!K;4]$US2;U);/4M+U"V9K>]LKJ.2WN87:*9'
MC9E(!^1NF?$'XV3:GX=\%>'/CU\6;C]FSX[?M*?#/X0?#?\ :"^(-CX5M?BU
MJ.E+\$_C=\2/BIJGPT\1CP+X?L9/AU\3/'O@/X;_  V^$7C[7/!T]U?:AXG^
M(&K?#&_F\&W_ ,(=8CTT^,'[2A\&_#DV?QFO)/#OPM_X*1Z?^S'XH\4W/@SP
MU?>,_P!H+X=1?'?PYX#TF'6O%%M!8^&M!M_#^E:YXB\#_$Z\\+> ],U[Q;X]
M\!I?Z=KOA/3F\0:5KWWSX8_8X_9;\&^$/&W@#PW\!_AGIG@KXC-HDGCCPLOA
MBRNM#\32^&G:7P[/JNGWXNX)KC09F%QHMRBQW&E744%U82V]S;V\L5'QW^Q+
M^R3\3=!\"^%O'G[.WPD\3>&?AE8S:=\/?#^H>#=+_L7P9:3WEOJ,B>&]+MHK
M>RTF3^T+2WU!+FU@CNHK^(7L<RW3/,P!\*^./CQ\;T_:3^)OBS4=;^+OA/X,
M? ?]J3X&?L_7]CX5U;X0VWA6/1OB3X=^!-Y::QXE^&WBCPYJ?CCXL6GQ,\3?
M&B/3-6\1:!XN\'ZQ\//#<'ARX^%&B>*O%FD^.;+5/V-!R/S'X@X/IZ5XJ?V;
MO@$WBOP3XZD^#GPVG\:?#C1M'\/^!?%=QX/T2Y\0^%M'\.VSV?AZRT;5[BTE
MOK1/#]K+<P:%()VN-&BO+Y=,FM/MUX9_:^G2@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H)K
MFVM]OVBX@@WYV>=+'%NVXW;=[+NVY&<9QD9ZBIZ^<?C\ 6\+$JI.-8'*@]],
M]0:\/B3.)9#DV,S6&'CBI85X=*A*JZ*G[?%4<.[U%"HX\JJN:]QW<>72]T'T
M#_:6G?\ /_9?^!4'_P <JU'(DJ+)$Z21N-R/&P=&4]"K*2K ^H)%?G4%4D?(
MG4?P+_A7W)\.0!X&\+@  #2;? ' '#=J^9X0XXJ\48[$X.>6T\$L/A'B54AB
MI8AS:K4J7(XO#T>5?O.;FYGM:VMQM*UT^_2VUO-]SM***:QP/^!*/S8 _I7Z
M$(<"#R"".>1ST.#^1X/O17X<>$?V_P#X]^$O"'CVXF\)>$_B5I7P=\*_'7XZ
M?$/Q1XP\7ZGH'B34/ GAG]NC]I/X+V/@'PE8:)X<O]-.M:5\/?AG9/X=U?66
MATJ.;1[?2]:25=3.L:?]":S^W-\5-+TCQ+XTC^'/PF?P?XF^+GBSX#_!73-2
M^*NK:+XWC\>>$?VKO#O[(LOB'XMZ5=>#Y;?2?A]=>,M>D\6Z_J?@W^VM1\ Z
M1#X;\,:Q;ZMXB\=:7/I@!^H=%?CQXN_X*(?&[PK!\2M*C^$GPLUCQ1^SSX _
M:E^('QGEM_B#XHM_"WB+3_V4M<^!%[K^G_"K48_"NHWK:KX[\"_&;;:6_BNV
MBM_ 'Q$T#5/"GB&]U[3[&36;NUX__P""B'QA\#>*=0^#EQ\$]-U?XOCXQZ]X
M-T^\\#:=\7_BIX+M_ VG? /P#^T'8:IJFA?#SP%JWQ(D\57.G?$/1_A_=V>F
MZ)+X=L]0L]6\>2ZNFCVB^%I0#]?:*_.7]H+]H7]H&?\ 9E_9?^+OP0T+PY\,
M/'?QC^-7[(VB^+_"'QBL+_5_^$9\(_&KQUX8\/>+?"-V^A1I(NM07'B"WT:3
M688[9H].-]J&F"RU9M/$/E/B#_@HGX[L_BQXP\#^'_ O@;6?"^H>&?VI;_X1
M?$"\U#QWX:^'NH^(?V37@?QCI/B[XC^*O#GA_0KVSUA8-<TK6]=\ Z1KGAWX
M:>(]'NK&;7O']A#=ZC;@'ZX45^>ES^W6EI^PAK'[;\/PZU;6+"\TN[UWP;\+
M;(7\'C:W35_B#!\//"7@SXC64=CJE_X5^(NA:U?6FG_&3PQIVEZU?_#OQ%8>
M*?"UK9^(=4\.YU'Q*[_X**_%'PQX;\'W?CCX.:9X:O\ Q+\=;O\ 9M75?%MM
M\3/A=ITGBGQ+X:\#^)OAY\8KCPC\1_"6D^/?"_P/TJ7Q#J_A'XM:AXET^+6O
M#/B,>#[[09M;\.^+8-0M@#]>**_(#XJ?\%+O&OP9M/'/CWQ'\(_"OB_X:Z3X
MK_; ^&OA/2/A_P".=3U;XI7GCS]E:X\974$OB?0QX<NM*TCPQXWTWPI-9:I-
M8S7^M> K^YT:_NM/\0V?B**PT?3\/?MQ_M+^+-9\%?#32?@3X9T+XD>*O'7Q
M8\'QZ_\ $^T^,?PI\$WFG?#[X)^&OC!:>*-+\)>,_!&G_%5;5]1\0GX>ZK8:
MEH4 ENH+;QEH.I:AHM\--@ /ULHK\KO W_!0?QCXP\8?!'5-7^%NB> ?@W\8
MO ?P/U[2->UG4?'OBC4M6\3?&_X36_Q)L/">E>+O O@/7OAKX6\9:+KM_H_P
M^T3X<_%_5/AQXB^*-UK%AXG\%ZFMIJ/A[1O$/8_L.?MN>/?VKKN.Y\4? _Q1
M\.?#7B[X3>$?C;X$UV_\,_$30=/M- \9WBQV'@76-3^(7A7PI9>,O$]IH]WH
M^O\ _"9?#(:UX U..[U?3+:XM9="M+[Q$ ?I!1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>2_%#P+K'C,Z*=*FL(?[.&H>
M?]NFGBW?:OL?E^7Y-M<;L>0^_=LQE<;LG'K5%>=FV5X7.<!7RW&JH\-B'2=1
M4Y^SF_8UJ=>%II-KWZ4;Z:JZZ@?)P^!OB\$'[9H/!S_Q]WO_ ,KJ^D/">E7.
MA^&]&TB\:%[K3[&*VG:W9WA:1,Y,;O'$[(<\%HT/JHKH:*\C(N$,GX>Q%;%9
M='$*K7H_5YNM7=6/LW.%1VBXJSYZ:=[[70[]/ZZ?Y!1_G\NE%%?4"/(_^% _
M _[!XCTO_A47PW_LWQ?H&K^%O%5A_P (;H/V3Q'X:U_Q5XC\<:YH.MV_V'RM
M3T?5_&7C#Q7XJU+3KM);6]\0>(];U:>-[[4[R:7/N?V;?V?+S5/B+K=W\$?A
M/=:Q\7M.FTCXI:E<_#[PK/>_$/2[F2":ZT_QE/-I;R>(K2[FM;2>\@U,W$=Y
M<VEI<W0FN;2VEB]LHH \=L?V>O@3IGAR'PAIWP=^&EEX6@\"^+OAE%X>M?!7
MA^#1U^'GQ U"VU?QWX*_L^*P6V?PUXTU:TMM5\6:0\;6GB+4X4U#5X[R\!F+
M?&W[._P&^)-EKFG?$#X-_#+QI8^)?$&A^+/$%KXH\$^'M;AUGQ/X9T"+PGX?
M\0ZBNH:?/]JUG1O"L*>&=/U*0F[MO#IDT..4:7--:R>R44 <'XI^%OPV\;?#
M^Z^%'B[P'X0\2?#.]TG3]"N? .L>'=*OO"#Z/I#V<FCZ<OAZ:U.EPVFCS:?I
M\^D0P6T2Z5<6%C/I_P!FFL[:2+S]?V5_V:TUS7_$Z? 7X0KXC\4WEUJ'B771
M\//"PU?7;V_6T34KG5=1&F"ZOI=5^P6CZN;B60:O-!'/J2W4^Z1O?** .&B^
M&/PZAT3QEX:C\"^$1X<^(FH^(]6\>^'SX=TF30_&>I>,(5M_%E[XHTB2T?3M
M=N/$\*[/$,FI6UP=:#RMJ0N6FE9^$T;]F+]G;P[X5NO VA?!#X5Z1X.O?#OC
M#PE>^&-/\"^'+70KSPU\06T5_'6BWFFQ:>MK=V'C%_#?AYO$\-S'+_;AT+1Q
MJ)N%TNQ%O[I10!\[^#?V4O@%X*UGQSXFLOAGX/U?Q;\2;WXER^-/%_B/PMX8
MU;Q1K^C?%CQ?JOC/Q?X.U367T6*[U+P9=:CJK6":!J+7=O/HMAI6G:J^IK80
MR#I/ _[._P !_AG;:#:?#SX.?#/P3;>%[[Q#JGAZ+PMX)\/:&-&U+Q;IEGHO
MB?4=.;3["![:^U_1=-T[1]7NT;[1?:3IUAID\CV-E:P1>R44 >':=^S+^SMI
M'BKPAXYTKX&_"?3?&/P_\/:)X3\$>*+'P!X7M=>\*>&_#6EKHGAK1- U2'3$
MO-+T[PYHH;2/#\%K+&-$TN6?3]*-I:7$\,N[\._@;\&OA'J'B?5OA=\*OAY\
M.]4\:7HU'Q;J'@KP=X?\,WOB.\6XNKM)M8N='L+.:_V7E_J%['%.[01WVHZC
M>QQ+=:A>S3^J44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !116-XAUN#PYHNHZY<V6K:C!IMNUS)9:%I=YK6KW*JRJ8[#2K".6
M\OK@E@5@MXWD90S!2%-5"$ZDX4X1<IU)1A"*U<IR:C&*75MM)>;(J5(4:=2K
M5DH4Z4)5*DY.T80A%RG*3Z*,4VWV1LT$X]?R)_E7@O\ PT%H'_0@?&S_ ,,[
MXX_^5E?$_P"VI\5(_%GAWP'#HND_$CPM)9^(-7EGG\1^%?%/@B&\1](2-8;6
MYOX;%-0FB9O-DMXGD>&/$SHJE6/T^3\)9GFF987 5J5; T\1*:EBIT'4C24*
M,ZJ;AST^;F<5!>_&SE?6UG\3Q%Q]DF1Y-CLUH5\/F=;"0I2A@*6)5&IB'4Q%
M&BXQJ^RK<G)&JZC?LIW4&M+J1^J.1[_D?\*6OYHI-=UXQR@:]K@)BD )UO5@
M 2C#)/VS@#.2>W7M7[<^!OCQHMEX*\'V<_@CXRW<]KX6\.V\UU;?"CQK?VUS
M+#HUDCW%O?1Z>\=Y!.RF6&[C=TN8W6='=)%<^WQ+X>8W(:6$J8;%2S5XFI5A
M.%+!N@Z*IQIM2D_K%;F4W-I*T;<KU9\UP9XNY;Q57QU'&8&&11P=*A4IU*^8
M+$K$2K3G&4(Q6$PW(Z?(I-\T[\R22M=_4E%>,:+\;M%US5]-T:#P5\6[*;4[
MR*RBO-7^%GB_2M+MGFSB;4-2O-/CM;&U3!\VZN'2&/(+L,BO96/ (_O+^18
M_I7PF*P>*P4HPQ5"I0E.//"-2/*Y1O:Z[I/1^9^HX',<#F4)U<#B:6*ITYJ$
MY4I<RC-Q4N5OORM/T8!T)*AU+#.5# D8ZY&<C'?TI0RGHRG@'@@\'H>.Q['H
M:_GX\(^+_P!K1OV?/VSOVCM"\0_''2O'/@_3?VUG^%?Q ^*OQI\.>,OV=]0E
M\%?M _%/P=H0\,_ GPU>W'B3PWJ/@?P)X2MH_!\WB31(-*@U;2HGU.VU6WO;
MR.]T_#G[07[5_P"S3XY\:^#_ ![J.J?'+Q=XA^-V@_LP_"6VT&'XZ_%7PQX&
M\,_#+]F'P_\ M#>-?&?C'PCH&D:Q\0O'OCGQ3-XB:R77M-4:UJ5QJ=])JNHZ
M=X-\$:3I!YCM/WUHR,XR,XSCOCUQZ<&OS!^'G[:7QK^,FLV,7A;X:?#'X6V.
MF^'/@II7CC0/C;X^U/1?'NG?$[X^_#JZ\:^&[?PKH^GZ;;:?XE\-^&+J71+"
M'3)KW3/%OQ-\[Q1::%#X1UKPD--U_P ,^ W[:WQJT;X2? CXM?M 7GA;Q%K&
MM?LT?L8?$OX]^(-"U?4O#/P[\.^#/C_\5/B?X(UKXEZ7X2N;![31]?\ !+#P
M5XA^)&JR:C:^'W\+VWB==.T[2=.\,:9)=@'[8T5^0?@/_@H[\5O''QHT+P-:
M_L[Z^/":^,_@UX/\6:C8Z#X_U)["V_:!T31/'WA'Q8OCB#0O^%9>'K+P%\._
M'7P\O_&?AGQ3K-MXF\3ZS=^-+/PC%:MX8T>T\6>D_'O]IKXR_!?]JOQC9W7B
M/X56/[.7@O\ 8D\1?&B]T7Q98^*K+Q#>_%:P^)W_  ANC8\3^%]$\5:K'H=]
M+?:%HYTS1?"?B;6;@W[1Z3X=U'7;S3@0#],Z*_&&7_@IC\3O#/ASQ!)XY^%'
MA_0O$?@O]HS2/V:/%;>(V\3?#ZRT_6OBI\'_  3\4_A1\5M3T+7;C7-=\*_"
MSPD?&*1_'FZURZEU3P7X"LY_B=9[=/M[[0+7[G^.WQ[\9_##XJ? _P"'OA_1
MO L^B^/=$^+_ (T^(OC7QMX@U/0-,\#^"/@MI_@76O$6IV5KI]KJ$FH7FI67
MB>ZLK>*ZF@M=)D$.L7US=65A=V%\ ?6]%?A+K/\ P4'_ &J/'\>F>%/AMX:^
M'?@'QA+\4?V#?%MCXJ\5>%/B.O@KQA^S_P#M8?&KQ=\+;C2]%TKQ?:>'_&]S
M<I?>$(OLOQ#O/#W@M=<\/:U<W.D>$?"FO6-LTGU1^S[^W5X^^-GQ]U'P')\#
M/%NA_"[4/&7[0'@7PYXRO/"OCK2WTB__ &>_&>L>![S6_$?BKQ!HNF?#SQ+9
M_$75O#?B!M*T'X?:IJ>O> Y(=$LO%"ZF^LW]SX= /TRHK\W/'W[:WCOPK\6/
M&.FV'@3P5/\ "GP%^T#X0_99UPZCXIUFW^+NH?$CQY\(_#?Q4T;QOHGA)-(3
M19?A]I@\8^'].OM,GU/_ (2+5/"]KXQ^(^GWMII7AJRT/Q%U'['O[5?Q,^.F
MH:7H_P 5? ?@KP=JGC#]F/\ 9S_:F\*)X%\2ZWXBMM/\+?'>'Q9I]QX,\33:
M[I.E,_B3POKG@R\N%U;1EDT?5=,UFWM1;6MUH\E]K0!]]T5^.FN_\%&OC%X<
M\)WWC6;X2_#'Q#IGBOX<_M$>,/A3I?A[XAZZVJ#7/V:OVA_ _P "O$N@?$:Y
MN-!DTO1K3QE)\0=)O=,U32)[F3P7XBTR^\)>(K+5;J]M+JWZ#PW_ ,%"_BPW
MQK\1_#WQ#^SWXOUWPE\//B5KOP.\=Z_\,_AY\6?$MS)XY\+?"R+XDZYXV\(:
MI-H"^$-?\*R:G=6O@O0OAO!J\_Q8UNSEC\?VMI]AE/A>  _6NBOQZM/VR/VD
M;'QU^TNMW;>![W0K_P"-_P  _AG^RW\.];^'/Q6L_BOI0^(_[,7ASX\^*-#\
M7>"/#FF7&M^(O%VCZ*/$.NZCX;U74/ ]MH+Z9XRN-?\ '/AW0/#-AIEST7P+
M_P""C7B/XR>-/V6_"=Q\/?#?A/\ X:7\'^(?$-O/J7B&[EN/!6N_"+QA\3_"
M'Q8\&:]:P+*L7B#QI+X'M=7^ %I)<02^,=+\/?&]M42.3X/7?_"0@'ZQY&<9
M&<9QWQZX].#17YV_M"?M'?$'X4_'JV\$^ - L?$^N>,?^&2O 6F6/B[QAJFE
M^!=)F^-_C[]J/2]3\5G1M+T:ZNX=4\/V?PHM;R_FM;R6?Q7IXLM 6/2)-/M]
M5EXOX8_MN_&#XG^)]'\-6G@3X+^&9OA]_8]O\>[OQ9\4-;T.SU6]U;]JWXT_
MLELOP4N;WPS#%=QQ>(_@3XI\7V$?C3RKK6;OQ!X'^%EM%;^(]<N?$VG@'ZC4
M5^.-U_P4C^+%MX8\*>-8?A/\--0T?XY>'(?&WP.T6#XA>((_$OA_0]._:J^
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>tecfidera.jpg
<TEXT>
begin 644 tecfidera.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !2 7(# 2(  A$! Q$!_\0
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M.BJO:4XJ75HYW5]=U/Q7JBF>1W:1]L,(.%3/8"NMM/A',]INNM2BCG(SL7D
M^YKS^VBDGN8XH2!([ *2<<_6NM_X0#Q9_='_ '_JI^[9)V+J^ZDHR43%UK1K
M_P )ZLL,DNV0?/%-$W##U%>K?#SQ9)XBTV2"\8&\M<!C_?7L:\_D^''BB4@R
M0(Y'3,V:ZGX>>$=8\/ZU-/?Q)'"\6WY7SD]JSJN,H:O4PQ#ISI:R3:/-=9_Y
M#=]_U\2?^A&MW1?!&N>)X$NB^RW(VK+,V<@=,#TK"UG_ )#=]_U\2?\ H1KV
M_P  ?\B7I_\ N556;A%-&F(JRI4TXG*>&OA?<:=X@BN=3DBFMH/G0)_$W;(]
M*B\2?#G6-3\222V]SYEI-\WF2R9,?MCO7I6H7T6FZ?/=SG$<*EC7B&M^/=:U
MRY/EW$EM 3^[AA./S/>LJ<JDWS'/0G6JRYDSH1\(75/GU:#?[+@5QGB'P_<^
M&]2^R7$D<F5W))$>&']*VHOA]XIU"%9Y(0-W.)90&'U!K%U_P_>^';N.WU#9
MYCIO 5LX'^16T&[V<KG52D^:SFF>D_"KQ!<ZC93Z?=RF5K8 QLW79Z5Z#7DO
MP=_Y"VH?]<!_Z%7I]_J=KIJJUU*$WG"CUKEKJTW8\W%Q4:KL6Z*AM;N&]@6:
MW</&W0BIJQ.8**** "BBB@ K&O\ 20"TMNO'4H/Z5LT54)N+NB*E-35F8.E7
M8MYS#(<(YXSV-:D^FV=U)YD]M%(_]YE!-5M2T@7*F2W(2;K[&G:;?%[9TNOW
M<L'W]W''K6E6,:BYE\S&E>#]G+Y#-8OX=$TLF)51C\D2*,<UQMAILVK7!$8R
M2<NYZ"K[VEYXOU<SX:#3825C<_QX/) _STKKK&Q@T^V6&W7:HZGN3ZFDFH*R
MW/1NJ4;=2'2M(M])@V0KES]YR.6J_1163=S!MMW84444"/GGQ:K'Q;JI"DC[
M5)V_VC7J?PL!'@\9&/W[=?H*Z*73](EO&26ULWN7^<AHU+'WJY;VT-I'Y=O$
MD29SM10!6\ZRE'EL=E;$JI34+'.>.?"(\4::OD,J7L',3-T;U4UXX$U?POJH
M?9/:7<1X.#@C^HKZ+J&YL[>\CV74$4R?W9%##]:5.LXJSU0J&*=-<K5T>16_
MQ>U>*()-;6LS@??;()_ 5$_Q'\2ZE=1+:1A 7'[J*/.[GIG%>HGPIH9;=_95
MG]/*&/RJ]:Z=9V*D6EK# #VC0+_*J]K3Z1*>(HK6,#,U;24\6>&1;W<36\DJ
M!P&',3_YS7B>K^'=5\-WH6ZAD0JV8YHP=K8[@U]$4R6*.>,QRHKHW56&0:FG
M6<-.A%#$NEI;0\:T_P"*VM6, BN(X+HJ,!Y 0?THOOB?X@U%?+M(X[;=Q^Y4
ML?S/2O4G\+:)(VYM*L\^T0%6K32-/L#FTL;> ^L<8!JO:T]^4T>(H;J&I3\/
MW]WJ/AR&>_MY(+DQXD5QC)QU'L:\!U!&_M&Z^5O]:_;W-?2O7BJ3:)IC,6;3
M[4DG))B7G]*5.JH-NVY%#$JDV[;E'P5_R)NE_P#7 52^(X)\%W@ STKIHHD@
MC6.)%1%&%51@"DG@BN8C'/&DD9ZJXR#^%9J7O<Q@JEJG/YW/GCPVK#Q-I>5(
M_P!+B[?[8KUKQ[X*/B6!+FS*K?0C"AN!(/0UTB:+IL3J\=A:JZG(81*"#^57
M:TG6;DI(Z*N*<IJ<=+'SK'_;'A75!(B3VEU'ZJ<$>_J*Z:#XNZQ%%LEM[65P
M.7;(/Y"O7KBTM[N/9<P1S)_==0P_6LYO"FANV3I5IGVB JG6A+XHEO%4Y_Q(
M:G@FJZC/K>J3WTL8$DS;BJ D"O5OAYI2WO@&XLKV)ECN)GX88."JX(KK+?0=
M*M&#6^G6L;#H5B4'\ZO@8&!TI5*W,K)$UL4IQ48JQX#XD\&ZEX<NGWQ/):[O
MW<Z#@^GXU?TCXF:WI$"6\ACNHT&U1,,$#Z]37M[*KJ58 J>H(K,E\,:+.Q:3
M2[0L>I\H FG[=25IJY2QD9QM5C<\NNOBQK=U&5M;>W@;^]&I;]#FNZ^'^KZG
MJNBL=6AE$JN=LSK@2*>?TK;MM!TJT8-;Z=:QL/XEB7/YU?Z5$YQ:M%&-6M3E
M'EA&Q\WZRK'6K[Y6_P"/B3M_M&O;O  (\&:?D8^2M%-,T>[+R)9V<IW$,PC4
M\]\U>CBAM85CB1(HUX"J  *=2KSQM8JOB55@HI%/7=-_M?1+NQS@S)@'WZC]
M17S[?:=?:'J!ANHGBGA;AL<'!X(]J^D<@#.>/6J]U8V>HQA;NWAN$["1 P_6
ME2J\F@L/B71NFKH\FMOB]JT<"1R6EK-(!@N<@M^5<YX@U35?$,RZEJ$+!!^Z
M1E3"COBO<(_"^B1-N32K3/J8@<5>ELK:> 0S6\3Q#D(R @?A5JM"+O&)JL52
M@[P@>6?!\[=8U!6^4F 8![_-7=^(M'FU$1M& ZC <'[W'/%:EOIMA:S;[:UM
MXI .J( <?A5NLJD^>7,<U>HJL^8S="L9;#3RD^/,>1I"!T7/:M*FLRKC<P&>
MF33JS,0HHHH **** "BBB@ J"XLX+G_71ANWU'H?:IZ*$[ -5510J@*HX  X
M%.HHH **** "BBB@#D_#D*WGB35;VXR\T<GE(3_"OM6]K-R]KI-S-"P61$RI
MK#\+MLO];;KMG)_2L5;"?6-)U+59KZ=621E6,'Y<#L?P(JNI)T$<^LW_ (=T
MZXL)4^T.H:9F P1CW]ZZ.N&N;B6#PKH)AE>/<0#M.,C%6M4MY]2\9_81>3P0
MF#<PC;&>E*P[G7Y&,Y&*6N T[1[O4+^^TV74[@169/ED-U)QC/MS4MKK-Y'X
M*F;S295F$"2$\@$X!HL%SN00>AK+CUAG\1R:9Y8VI$'W]^<_X5S7D3>'M0TJ
M>.^FG%TP69';(R<?X_I2QZ(C^-9[?[5<@"(/O#_-SGC/IQ18+FUI&I7-QXBU
M2VFD!A@V[!CIR:WZX2+2&U?Q5JL?VJ6!$P3Y9P6/.,^U57NK[_A&9C]JE,EC
M=8+[N2IR/\*=A7/1:Y_PUJ5U?WFII<R;UAF*H,8P,M_A576;V2]O]%M[::1%
MG(D8H<94_P#U\4>#_P#D(:S_ -?!_P#0FI6T'?4T_$VJR:3I#S0 &9F")GH"
M3UJ;1(KZ*P!U*=9IW^;*C  QTK"\>V0>PBN3+("LBKL!^7DCG'K4>J02:2NC
MPP75PRRRDL6?DC"\?2CH'4[*D) ZUS=[/*OCRPA$KB)HF)0'@_*W:LF#3KC6
MM0U?S-0N8DMY#Y:JW ./Y46"YW60.]%>=6UG>7_AN759-2N!-;G;&H;C Q_C
M6[/%JFOZ1IOE3>5#(H:XD5L-Z<46"YU (/2C.*Y'2/.TKQ%=:4+F2XMS#YBE
MSDJ<9_K5?PYIUUJLDMW<7]QY4%R2D0;[Q#=_;@46"YVV1G&>:R]>U=M'MX)%
MC#^9*L9![9KG;_1=26ROM4OM0DBNH]TD21/\H Z#]*@U]&U+0]+OYI9!)(R1
M,H/R]2-V/6BP7.\5MR!O49I3AU(X(/!KD-;CELK73M*M[N91=2@/,S?, >,?
MRI^DI)HOBG^SA=R7%M/#O7><D,/_ -9HL%QV@I]@\7:G8Q$B!E\T+Z'(_P 3
M3/%>HW<AN+.&*/R(/+=W)YY(Z?G4NG?\E O_ /KA_5:?KFA7]Y?3O:/&8KE4
M#ANJ[2.GUQ3ZBZ%9O$\LES);>7"+4L]OG=\X(7KCTID&LWFF>&[&6WB@,?E%
MG,KX/!Z =S5F'PU<Q:G+@6QM9':0RF,&3D8VC/3FJ4OA/4C#%&3;2B.-HEW#
M[H)R&'O1H&I<;Q9< O&MO&9C)'Y:DGYHW&?S%0Q^,K@/*TL,)C*2-$$.6!4\
M;AVI(M.CD\56$8(=K:U F*\@..!G\*<GANY#7%JS6:HR/Y;!!YCYZ9/7BC0-
M1=#U%TU>_N=6:*!VCC)"GY0#TJS=^(;R.^N_LT<,MG;1K(7SR0PXQ^-2:+HE
MS%<SS:HD$GF(J8 R/EZ'FI)=#DEN-5(*I'=11I'CMM%+0>IAW6MSZG]FBNDB
M62.[B(,+$@AA6G'XGG?6&MQ#$T'GM N&^?('7Z&H%\-7SV0W"UBGBD1XDC0!
M3M]3U.:E@\.7D.IS.#;+#)(TOF[ 9.1]W/8 ]Z>@M2-_%=[;M=QW%M"98H?-
M58WSCYMN#4LGB2^CL;=FBM?-GEV(X?,97&<YJKIWAG4[.21U>WB<6YA#*H(<
M[@<L#ZC/Z4+X4NUM1+LMC.+CSOLQ'[H<8Q_6C0-2-/B&@C7S+1M^!NQTSW[T
M5<3PK=E%+W5HK$<@649P?RHHT#4ZFBBBI*"BBB@ HHHH **** "BBB@#D_#7
M_'WKO_79OY53T>1!X+U12P#"9\@GGL/Z5LZ;I%WIOB*\EC*M8W/SG)Y#>G^?
M:HY_!.GSW<TWF3HDQ+/$K#:3Z]/6JN38Q+[_ )%3P_\ [R_^@UK?\U%_[=3_
M $K2E\.6DUA:6C-)Y=J04((STQS5C^R8/[9_M++>=L\O';''^%*X[&+H/_(T
MZW_O#^0KG44-X(N0?NB\4D^@SS7>6FDP6=_=7<9;S+DY<'IVZ?E4%KX>LK73
M9K'#203$E@QYYIW"QAC1=#LFT^6:67S92K1#=GGC^I%68W6/XA3AV"EK9<9/
M7K5G3O!]EI]XEQYLT[1_ZL2$$+].*M:KX>LM7FCFG5EFCZ.AP<>E*X6,O0?^
M1OUK_@/\S5+1K7[;H^O0XR6=B![@L1_*NGM-(@L]0N;R,L9+C&\'IQ5>*WT_
MPW!<323%$F8LV\]3R<#]:+A8YGP>\FI:U$[CY;"V$0S^7\Q6EX0=5U368V(#
M^>3M/7[S4>!+4+97-WMP)Y3L/^R/_KUK/X>LSK*:FH9+A>3M/#<8YIL2,_QU
M_P @1/\ KLG\Z@\4D"70B3@>9W^BUOZKI<.KVH@N"P0,&^7U%1ZKHEMJ]DMM
M<;@$^XZGE:28[&->LK?$+3\$']TW3_=:F^'O^/[7_P#KJW\JOZ=X2L]-OHKM
M)9Y)H\_,[ YR".?SJ[9Z-;V4MW)&7)NF+/D^V.*+A8Y;2/\ DGU[_O'_ -EI
MKRRSV/A_3?M#007";G9#@G!QC]:Z:W\/VMMI$NG(TGDR'))//;_"HKSPM97F
MGVUJS2)]F&(Y%(W"G<5C#L+.&P\;3P02,ZK;')9LGH*O>#I#%H]\X&2MQ(<>
MO)J[IWA:TTV[-S'),\K(49G;.[/4U>TS2H-*@DB@+%9'+G=ZFDV-(XI;4:KX
M>U'5+V\E><;P(]^ N#P,5-J!"^"M)=N%6=23Z?,?\*V)? ^GR32L)9TBE.3$
MK#:#Z]*U/[$M#I"Z;(ADMP,#<>?\\T[BL<[XLBBNKS1ED;$#R!6<'I^/TJ[8
M:3H^FZ\D<$DCW@0L 6S@<?\ UJLMX3L6T<:>QD,:N71R1N4^U/TGPW;:/++/
M"\DUPZXWRG)^G%*X[&?IW_)0+_\ ZX?U6KEW?ZG)K;VNGI%LMU5G$AQOSCC/
M;%-T'2+J#4KW4M0VBXG;:JKT"\?X"GW^C7TNJO=65X(%F55E^7)P/3\J *;Z
M]?0ZV;>1[8H[2(L2')0*,AB??TJJ?$NJ6T$DDR1RF2#S80B_=^;'/T'-3CPS
M<VMW)<M<1M#&\LP&SYVW*>"?:HM*T._NK(7+78B?R#'  O*?-SGUIZ"U+%AJ
MUUMMG;[+(;F<QF6+JP SD\<'J*@M]4EFU)+Z107CLYFVCH=K''\JEC\+WD40
MECN8ENOM!GP$P@XQTJ6+PM<11P 7J[A#)#,=GWPWIZ=:- U*$?BR^6TNF/E3
M.$2160'$>XX(/'..M=#H-W<7E@9+IX9"&PDD)R'7 Y]C[5FVWA[4H;.2/[?&
MKA%2/9'@<?WO7-:&@:2^DVLJRNK232F1@@PHSV I.PU<U:***0PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N>\8HKV%L&
M4,//'!&>QHHIK<3V-JRC2*SB2-%10HP%&!4]%%(84444 %%%% !1110 4444
M %%%% !1110 4444 (1D8/2@ *,  #T%%% "T444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>tecfiderarev.jpg
<TEXT>
begin 644 tecfiderarev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M;R75_$$ME;ZWJGA;P_\ VAXALP#ZRHIJ-N!.,?,Z_P#?+LH/XXS3J "BBB@
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MEO\ BI_PT?\ M ?]%J^)_P#X66L?_)%'_#1_[0'_ $6KXG_^%EK'_P D4?\
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M4?<_V<?A7\3_ (6>$/%WP_\ 'GPH\4^)O!G[3/[0?C%=1T?X@?%C3OB/\5/
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MXN?V%OVG?'UIX8U?6=0^).@3_L[?#_X=>#/A7X3\>_&WX8:KJ?BVU\#?M"_
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MI=,6VDM[F< ^TZ*** "BBB@ HHHH **** "BBB@ HHHH _$#_@I/_P I)/\
M@A3_ -G6_M0?^L<_$&OJ7_@I;_R0WP;_ -E,T?\ ]1?Q57RU_P %)_\ E))_
MP0I_[.M_:@_]8Y^(-?4O_!2W_DAO@W_LIFC_ /J+^*J^W\-_^2YX:_[&,?\
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M-64?:QKXBLL1&-6*A@YT:>'Q&(K4X1\9LOAUX]U&/79;'P=XBN5\,W-W9^(
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M_(*ER1T)%?*G_#8_P;]?&7_A,+_\M*/^&Q_@WZ^,O_"87_Y:5_>_]DYG_P!
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MH_X;GM_^B97/_A60_P#R@I?ZOYM_T!_^5L-Y?]/O3\/(/]8,H_Z"U_X(Q/\
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M6]O>PP:S>>*;'5M(\):G%J%KXRTJ?^Q]9TROW#']3V([GU_GT/4<5^(^HO\
M#R3]M3XOQ^,3^S"WB6'X_P#PW;P^/CSXC\7>)_C0L#^#_AJFF-\-CH9_X1CP
MOX8-_!)'\.O!0,EQH_B:'7-8\22K>>)6M;7]N!_4_P S_G^5 'X@_P#!2?\
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MDQ_R1&3_ /9583_U49T?F]11Z#N20!W) +$#U(4%B!D[03T!-'<C(R "1GD
MG )'4 G@$\$Y Z5_>1_$(44=P,C+$A1GEB!DA1W(') R0.3Q1D9QD9 !(SR
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MG%*"J3LI/]MVZ'Z'^5?PD_\ !77_ )2*?M(_]A/X??\ JIO =?W+-IVMX/\
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M46MY]C;_ (0KX2@M]FBN<D^(_'1!VRLH&%608Z'S,GE%S_4[8V]]!YOVR_\
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MZ*\ _P"&H/@O_P!!OQC_ .&;^-?_ ,[NC_AJ#X+_ /0;\8_^&;^-?_SNZ/\
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MX<U7_A%M)M]1N]8MM+TI]2L+N6+3+;6+^[UBVTZ5YK*WU:>34X(([YC<5]'
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M>QT[3K&UBBMK.RL[>&VMH(TA@B2-%4:U !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A( ))  !)).
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K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>teclitigation.jpg
<TEXT>
begin 644 teclitigation.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #P 3T# 2(  A$! Q$!_\0
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M*^%OP/\ AC\#=$LCJ=O!;S:O/>Z+\,=/UO4]0O88YYM7U34$BCALTM8H_&]
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MX8\(:_JGB+P38:9X0U+XC>#[?_A(_AB_B:XTV'XCZ(ZW_@=M?#1Q2<I\*O\
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MFTW1?$6F?<U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-'_",:+_ ,^0_P# B\_^2: -[(]_R/\ A1D>_P"1_P *P?\ A&-%_P"?(?\
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M/.>,?TQX<_\ )(Y;_P!?,?\ ^I^) T****^X **** "BBB@ HHHH **\LO\
MXY_!72_%/_"#ZG\7OA?IWC7[6EA_PA]]\0?"-IXH-[(P1+0>'[C68]6^TNQ5
M5MS:"=F8*L9)Q7J= 'X@?\%)_P#E))_P0I_[.M_:@_\ 6.?B#7[>1_ZN/_<7
M_P!!%?B'_P %)_\ E))_P0I_[.M_:@_]8Y^(-?MY'_JX_P#<7_T$4 /HHHH
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M??\ 0N:S_P!__#W_ ,O:/[4OO^A<UG_O_P"'O_E[6S10!C?VI??]"YK/_?\
M\/?_ "]H_M2^_P"A<UG_ +_^'O\ Y>ULT4 8W]J7W_0N:S_W_P##W_R]H_M2
M^_Z%S6?^_P#X>_\ E[6S10!C?VI??]"YK/\ W_\ #W_R]H_M2^_Z%S6?^_\
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M/_=K$#Z+U?Z"4445^5""BBB@ HHHH ]V^!US-;7OB(PZ?>7Y>UTT,MH]@AB
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M_6O$FC77B?X+BZT\Z]#>MI/C'6_[+L=!O](/Q#MM.BN=4MH_VG']3Z^I]?\
M]7IQB@#\0?\ @I/_ ,I)/^"%/_9UO[4'_K'/Q!K]O(_]7'_N+_Z"*_$/_@I/
M_P I(_\ @A3_ -G6_M0?^L<_$&OV[C(\N/D?<7N/[HH DHI,CU'YBC(]1^8H
M 6BDR/4?F*,CU'YB@!:*3(]1^8HR/4?F* %HI,CU'YBC(]1^8H 6BDR/4?F*
M,CU'YB@!:*3(]1^8HR/4?F* %HI,CU'YBC(]1^8H 6BDR/4?F*,CU'YB@!:*
M3(]1^8HR/4?F* .,^(O_ "(WB?\ [!-Q_):^'&ZGZG^=?<7Q%(_X0?Q/R/\
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MI^T\GU/>OQ?_ ."D_P#RDD_X(4_]G6_M0?\ K'/Q!K]O(_\ 5Q_[B_\ H(H
MQ?[ M_\ H(:[_P"#W5/_ ))H_L"W_P"@AKO_ (/=4_\ DFMVB@#"_L"W_P"@
MAKO_ (/=4_\ DFC^P+?_ *"&N_\ @]U3_P"2:W:* ,+^P+?_ *"&N_\ @]U3
M_P"2:/[ M_\ H(:[_P"#W5/_ ))K=HH PO[ M_\ H(:[_P"#W5/_ ))H_L"W
M_P"@AKO_ (/=4_\ DFMVB@#"_L"W_P"@AKO_ (/=4_\ DFC^P+?_ *"&N_\
M@]U3_P"2:W:* ,+^P+?_ *"&N_\ @]U3_P"2:/[ M_\ H(:[_P"#W5/_ ))K
M=HH PO[ M_\ H(:[_P"#W5/_ ))H_L"W_P"@AKO_ (/=4_\ DFMVB@#"_L"W
M_P"@AKO_ (/=4_\ DFC^P+?_ *"&N_\ @]U3_P"2:W:* ,+^P+?_ *"&N_\
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MS;J?J?YU^">+/_(YRW_L6?\ NUB!]%ZO]/\ (2BBBORH04444 %%%% 'T#\
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M'^-&]/[R_P#?0_QK\6?^',M[_P!):_\ @M1_XFQH'_SEZ/\ AS+>_P#26O\
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MF5UZU*O5P\L1*52BIJG+VV)JUXJ/.HR]V-11=TO>3M=68'VK1117T !1110
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MKD^B>!O!UOJ6I0>$O!^G:'X<BU&_33!=S>X444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>tysabri.jpg
<TEXT>
begin 644 tysabri.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !W -@# 2(  A$! Q$!_\0
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M)T!2444 +2444 +2444 +2444 +1110 E+110 E+110 4E%% !1110 M%%%
M!4%X\J6<S6Z!Y@AV*3C)[444UN)['/>!M->ST^>XG&)KB0YYS@+D?SS1116E
..>3E4DV8X:"IT8Q78_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>tysabrirev.jpg
<TEXT>
begin 644 tysabrirev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
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M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M^E?<- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_\ B+O!?_05CO\ PWXCR\O/\'V/1OCI^Q[\</VH]%MK_P 1>&_AY\*=8_:
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M0?\ H0Q_\.F3_P#SP\_S[,/^(J<"_P#0ZG_X;,W_ /F'S_/LQ-2_9V_:3O\
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MM_T4.+_\$X'R_P"H7R_JRM^E_P#P\Z^)_P#T3/P%_P"#7Q)_\51_P\Z^)_\
MT3/P%_X-?$G_ ,57YH44?\0QX"_Z)O!_^#\?_P#-?DON#_B(G&W_ $4.+_\
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MQ2@MH8K>".\\.;(8(TBB3=X-\.LVR.-51=S,S' &6))Y)-?*^ W_ "5N9_\
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M@QP "2< X !)/ !) K^IL^)-*1F5I;D,KNI']F:KP0Q!'%B1P1V)'O7\]_2
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M +.M_:@_]8Y^(-?4O_!2W_DAO@W_ +*9H_\ ZB_BJOM_#?\ Y+GAK_L8Q_\
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MZ/\ ^9^C_ANB+_HF$O\ X5T?_P S]'^K^<?] 4O_  ?AO_EW]6?E<_UAR?\
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M:/\ A:7PR_Z*+X&_\*O0_P#Y-K\.-B?W5_[Y'^%&Q/[J_P#?(_PH_P!4</\
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MU_Y2*?M(_P#83^'W_JIO =?W*M_PD^#QH70]]3]/I7\,G_!6W[1_P\._:/\
MM7D^?_:G@'?Y'F>5C_A5/@79M\S#Y\O;NSQOW;?EQ7XY]%K_ )+S.O\ LD<;
M_P"KG(C];^DQ_P D1D__ &56$_\ 51G1^<E%%%?WD?Q"%%%% !1110!VWPS_
M .2E_#7_ +*1\/O_ %,]#K_2@7H?]Y__ $-J_P U[X:[O^%D_#?9C?\ \+&^
M'^S=G;O_ .$RT/;NQSMW8W8YQG'-?Z0;?\))OD\L:)Y?FR^7O.I;]GF-LW[1
MMW;<;MORYSCC%?QE]*__ 'O@C_KQQ!_Z7DI_7?T7O]UXS_Z_Y'_Z;S0^-O\
M@IG_ ,F"_M8?]D8\5_\ HNWK^!)_OM_O-_,U_>K_ ,%*?[=_X8+_ &K_ +8-
M)\G_ (4QXIS]F-]YO_+INQYP"?ZOS-O^WLS\NZOX*G^^W^\W\S7UGT5_^21X
MB_[*.7_JLR\^6^DU_P E9D/_ &3Z_P#5CC1M%%%?U"?S:%%%% !1110!_1Q_
MP;M_\E"_:F_[$OX1_P#J0^/Z_J@K^5+_ (-Z/[0_X3_]J7[!]CW_ /"%?"7/
MVLW 7/\ PD?CK;C[."<;?-SGG/EXXWU_4[8?VI^]_M+[!_!Y/V(W1_O>9YGV
MD#_8V;/]K=VK_.+Z0G_)UN(O^O&1_P#J@RP_T&\!?^37Y!_V$9W_ .KO,#0H
MHHK\4/V(**** "BBB@ H)P"?09HJK?)<26=W':2-#<R6UPEO*AA#Q3M"ZPR*
M;B"Z@W)*49?.MKB+('FP31[HV /B[_AJO6M2^-?CKX5Z-H_P+TB#X??$/PUX
M#U>+XF?M(Q^"/BCJJ:[H'A;Q"OB3PY\*-+^&?B\7.C:I;^))K'P,NJ^,-)O?
M&6I:+J4;V^A6WDW#?;?_ -?W[_YSZ'BOR'3P)X_MOB+I6K^*I?VIO%WCNS\0
MZ)JUW97?[)/[%VIVGB-])O+*X"3_ !IT?X=V7A:PMKR.V2W366^('AS7=.MW
M%U:II%];(MK^M.E7%[=Z9I]UJ5A_96H7-E;7%]I?VJ&^_LZ[FA22XL3>VZK;
MW;6DK-;M<P#R9VC,D1:-E8@'XG_\%)_^4DG_  0I_P"SK?VH/_6.?B#7._\
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M0FTFRO\ ]AIY+E9V9?C?\5,>5>WULHR?#2D[+:ZA0DA%R2N3CUR3_/OTE_\
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M4X(((."<%2&!Y!! -?Z0A\.:7(SR.EV6>25V/]J:L,LTC,QPM^%&23P  .P
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M)O\ YM#_ %#XY_Z(SBS_ ,1W./\ YC\U]Y[_ %_9G_P0:_Y,7D_[+?\ %/\
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M*\=CZ5.K]?Q<_95*F%H580J<DHRY)24N6496M)-^_45X!_PU!\%_^@WXQ_\
M#-_&O_YW='_#4'P7_P"@WXQ_\,W\:_\ YW=?T=_Q$#@/_HMN$?\ Q),F_P#F
MT_G[_4/CG_HC.+/_ !'<X_\ F/S7WGO]%?/<G[4WP0B>".7Q%XJBDN9&AMHY
M?A#\9HI+F9(9+AX;:.3X?*]Q*EO#-</% LDB6\,T[*(89727_AJ#X+_]!OQC
M_P"&;^-?_P [NC_B(' ?_1;<(_\ B29-_P#-H?ZA\<_]$9Q7_P"([G'E_P!0
M?FOO7<]_HKP#_AJ#X+_]!OQC_P"&;^-?_P [NC_AJ#X+_P#0;\8_^&;^-?\
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MGTH 3:/5O^^W_P#BJ-H]6_[[?_XJG44 -VCU;_OM_P#XJE  Z9_$D_S)I:*
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MQ9W?FVQ:,@'Y/>+OB]^UII7PU^-OB/XK?&#6OA7\;?V-/V,?@C\9T\%Z%;^
M8O"7Q8^+7B;PY\4_$WB>3XF:?%H&HZ?XQT+QAK?@/2O@8FC^ M6T+0=-\81>
M.]:\"&VU?4_!-WH/V]\//$WQHO/VS?C'X&\>?$*>]\#:S^S3\,_'_@CX?Z)X
M;T_PY:?"^?7?B=\7?"]RK:O]JU[6O$OCR\TW1=,3Q-XAO=7C\/M=Z3I\/A?P
MEH%K;:A+K/O8_9?_ &=3%\,8I?@C\+KE?@O;6EE\*'O?!.@W\WP^L["XAO+&
MU\*7-]97%QI%O97]K9ZE9PVTJQVNJ65EJENL>HV=K=0XME^Q]^R]IOQ@E_:
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M$R:996C:H+75Y;C5K>.=S#!JEY?ZC%&MYJ%[-<8.@?L5_LE>%_AQ?_"#P_\
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MOY*E@@R/W$'4?\L8O7_<K^EG]E$!?V;_ (+!0%4?#WP\ J@*H'V7H%   '8
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M>:_/=>)]:TGPW-XF\/W>IW%__96HZAX7T'6 D$"W&A^'W6^T6V^>/C3^WO\
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MC6-?\2^*+/1[[2I["VU[Q'K7B+Q!J?B#5(8$N];O==UF?5);MM4OO/\ 9J*
M.+D^&_P_FFN;B7P3X4EGO?%VB^/KN:30-+:2Z\<>&]+T;0_#_B^=S;9E\2Z'
MHWAW0=*TG6G)U#3M.T72K.TGBM["UCCY_P  _ WX,?"O4M8UCX:?"CX=?#_5
MO$#W<FN:EX,\&>'O#-]J[7VHR:Q>#4;G1M/LYKM;C599M2DCF=XS?32W019I
M9';U2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>zinbrytarev.jpg
<TEXT>
begin 644 zinbrytarev.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 3T# 2(  A$! Q$!_\0
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M3;L;\Y/V>?\ @I)X4^('PK\/?%;XK:]\ &LO'>D^&+_P9X1_9*^)OQ%_:_\
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M'>?\+0+V(^%=U\:=1OHO!OCZ:R\._#BRUWQIX3NM;\6W,/A=T\)WL7C3X?\
MBGP+_P (UXA&G>*9?'=A%X,M]%F\1WUCIT_R/X;_ ."0/P@\$^%8?"_@WQ%X
M8T&W\.R^"M+\(F#]G3]G^.VUOP)X(DU/[!X,^/L&G>#=,N_VC+2[2_TV[O)_
M'6IV5FWBCP1\/O'PT8^//#=QXBU?W7X1?\$]/ OP7^'GCGX<^#O'OB.VTSQE
M\'[CX.Q7;^#_ (6S1Z'HEQ\9?C_\93/9^$KSP9>_#>\LSJ/Q_P!;\-2^$;[P
M3)X*E\,Z)IVG)H,$%S=0H ?7'@3XQ>!OB#X,U3QYIMQKWAWP_H-QK%IXC_X6
M3X.\7_"C6/#,V@6T=[K!\1^'_B5H?A76]%M;*PECU$ZC?V,6F7&F21ZG:7MQ
M8.MR? X?V_/V89M$T[71XO\ %T,.N>(O ?AGPSIEW\'_ (Q6/B;QA>?%73/&
M&K?"W4/!GA.]\!VWB;Q9X:^)5IX!\7KX#\5Z!I6H>'/$][H-_INFZG)J,36P
MO?!7]D#PC\+O@E\3O@AKFMS^+?"OQ=OO&$WBC0](T33OASX&\.Z/XU\&:7X$
MUGPA\*O 'A6=M'^&/@^?2=,FUB31-!NI4D\9Z_XI\5">.\UR2"#POX*?\$RO
MAA\%9_!%WH6M:%:WO@'XC_##QIIMWX-^"/P5^%-SKVD?"+P;\4?!WA31O&]W
M\-_">@7WC#6;V'XJ:SK'B3Q1JMVT-SK-E:W/ASPUX4CO=9AU$ Z[XP?\%&_@
M9\/_ (7R>//!$^L_$W6KGP?H/C72_"NG>$?B1IR66E>(/BE_PJ"QB^(VN1^
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MT^XFDCT>+7$G-OJL5I;_ #K\+/V_-=M_"OP>\;?M4_#[P#\%/!GQW^ 6J?M
M> _&G@;XG>)/BAH&F:5H?A3P=XZUCP'XXM=8^%7P\U_2_&J^$_&EGJ/AS_A&
MM-\7:3XKO-(U[0;6?3]?7PYIOB;Z=^$'[/5W\.](^-0\5_$;6_B/XL^/OBX>
M-_'WBB_T+0?#*)K1^$O@+X0&V\.Z%H4?V'2=$M_#WP]T>:PL;B?4KV&YEN6O
M=5U*21KA_D&R_P""8.E>+OA+H7P@_:&^-_B;XT>&OA]\#%^ GPELX?A]\/O
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MJC:_KS7J>"GUB&^UFQUC1=3L?%MQ9J;FTT^TEGL)?3?VCOV?/BI\=OA/X/\
MAKH_[0FJ?#B6TOM(E^*FJZ?\/?#VO6?QHT&ST"XT_6? _BG2FU;P_=:%X,\6
MZW+#K'BC3?!^N:)=ZQIML_@VZOW\)ZKK>EZD ?,UC_P4;\4>*_ &N_$7X??
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M^E?<- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBL!*A&M]=I4*3D\0JKA[/V&)Q/,E[&?-S<EKQM>[LM%%%?&GUP4444 %%%%
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MH^P6/_/E:?\ @-#_ /$5;HH J?8+'_GRM/\ P&A_^(H^P6/_ #Y6G_@-#_\
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M*T_\!H?_ (BC[!8_\^5I_P" T/\ \15NB@"I]@L?^?*T_P# :'_XBC[!8_\
M/E:?^ T/_P 15NB@"I]@L?\ GRM/_ :'_P"(H^P6/_/E:?\ @-#_ /$5;HH
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M/I ?[SPO_P!>LW_]*RP_H3P-_A<2?]?,K_\ 2<>+1117\['[X%%%% !1110
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M16)_9>H?]#)J_P#X#>'_ /Y24?V7J'_0R:O_ . WA_\ ^4E &W16)_9>H?\
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M))5O/$K6MK^W _J?YG_/\J /Q!_X*3_\I)/^"%/_ &=;^U!_ZQS\0:_;R/\
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MS1_:.N?]  ?^#BR_^,UT-% '/?VCKG_0 '_@XLO_ (S1_:.N?]  ?^#BR_\
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M7D-WYN[=O_U*)Y>S"_>SNW<8VFM"B@ HHHH **** "BBB@ HHHH **** /Q
M_P""D_\ RDD_X(4_]G6_M0?^L<_$&OV\C_U<?^XO_H(K\0_^"D__ "DD_P""
M%/\ V=;^U!_ZQS\0:_;R/_5Q_P"XO_H(H ?1102 "2< <DGH!ZF@ HKYCL_V
MNO@SJ/Q_O?V<-/OO%E_XZTZSE>^UVQ\!>,+SX8V>O6R2W%YX(N_BA;:/+X)M
M?&UC8Q?;;W0+G5X7M3)'I<MPOB!_['':?!3]H+X2_M$:9XUUSX/>+(/&N@>
M_'^J?#76?$&GV6HPZ#>^)=(T/PWXBNY/#.KWEK;V7BSP]+I7BO1KG3/%OAV7
M4?#.MQW#S:+JNH6T?VA@#VBBO$O$O[0GPO\ "GQO^&_[/&K:U=CXI?%/PWXQ
M\6>&-$L]'U*_M8M#\$VT5UJ5WK^L6L#Z9X<?48O[0/AFVU>XMKKQ.=!\2?V+
M#=IX?U9[7VV@ HHHH 1NA^A_E7\Z7[;?_)T/Q4_Z_/#7_J&>'*_HM;H?H?Y5
M_.E^VW_R=#\5/^OSPU_ZAGAROV[P&_Y*W,_^R=Q/_JSRH_'/&S_DF<M_['M#
M_P!5^8GRK1117]9'\Q!1110 4444 =!X2_Y&WPG_ -C5X9_]/NGU_5N.GXM_
M,U_*1X2_Y&WPG_V-7AG_ -/NGU_5N.GXM_,U_-'T@/\ >>%_^O6;_P#I66']
M">!O\+B3_KYE?_I./%I,CU'YBO$/VE/$&M^%?@-\5?$7AS4[O1==T?P;JM]I
M>JV+I'>6%Y"L9BN;=W21%EC).TLC#D\5^"[?M5?M'Y./C/XYZG_E^LO7_L'U
M^>\&>&V9\:X'%8_ YAE^$IX7%O"3IXOZS[24U1I5G./L*%6/)RU8QUDI<R>E
MK7^\XM\0LMX0QN&P.,P..Q53$X98J,\+]7Y(P=6=+EE[:O2ES7IR>B:LUK?0
M_I7R/4?F*,CU'YBOYI_^&JOVC_\ HL_CG_P.LO\ Y7UYKXX_X*%_$/X;:KX;
MT3QS^TOXG\.ZGXLN6MM&M;JY>X)18-0G.I:K+8:'=P>']"WZ7>68U_7I=-T8
MZ@GV(7IE2X\CZNOX%YSA:;K8GB'A_#T5*$75KU,92IJ52<80BYSPD8ISG)1B
MF]9225WO\S0\9\IQ-14L/D.>UZK4I*G1IX2K4<81YYM0IXJ4FHQ4I2:344FW
MHKO^J+(]1^8HR/4?F*_E2;_@HC\4X_B!9_#&?XU?&JT\7:CJ^IZ%IL=]\/OB
M%8^'-2U31])N]=U*#3O'-Y\/X/ U]#::387EZ]]:^(Y=/=+=HXKJ2=HXGO\
MB[_@H-\2O FJ0Z+XK_:-\;:9J3Z6FO75O#:ZMK*:'X=DNKJQB\3>*[O0/"VJ
MV7@[PQ+>V%]:1>(O%=SHVCR3V&H;+QH].U"2UR?@EF485*DN)^&8TZ-7V%:H
M\3B5"E6M&3HU)/#<M.KRRC+V<VIVE%VLU?1>,672G3@N'.(I3K4U6I0CA\,Y
MU:3ER^UIQ6)<IT^92CSP4HWBU>ZU_J>R/4?F*,CU'YBOYI_^&JOVC_\ HM'C
M@CJ"NH6+*0>A5EL"K*1RK*2K @J2"#1_PU5^T?\ ]%G\<_\ @=9?_*^NO_B
M?$/_ $.LD_\ +_\ ^8_7^EKS?\1OR+_H3YQ_Y8^7_47Z_P!;_P!+.0>A!HK\
MNO\ @GK\7/B=\2_$'Q0MO'_CC7_%UOI&C>$Y],AUFX@F2QFO-0UZ.ZEMQ#;0
M%6N([>!)=Q<%84P!@Y_46ORCBGAW$\*YUBLDQ=>AB:^$CAI3K8;VGL9+$X6C
MBH\OM84Y^[&M&,KP7O)VNK-_IW#>?8?B;)\-G.%HU\/1Q,L1&-+$>S]K%X?$
M5<//F]E.I"TI4G*-IOW6KZW"BBBOGCW0HHHH **** "BBB@ HHHH _$#_@I/
M_P I)/\ @A3_ -G6_M0?^L<_$&OV\C_U<?\ N+_Z"*_GT_X+,?&3X>_LX?M>
M_P#!&O\ :$^,>K:GX7^#_P *OVG_ -HC4OB#XRL?"7C'QE#X9L->_98\8>&-
M(N;W2/ V@>)?$$R7VNZM8:?"MEI-U)YDYF=%MK>YGAO?%O\ X.0/^":/A7PU
MIU[\*?C7>?$KQ#+JUO:7VB7/P(_:O\/I9Z2UE>23ZFMY/\!625H;N&SM?LZC
M+"Z,@.(S73@\+4QN)HX6E/#TZE>?)&>*Q.'P>'B[-WJXK%5*.'HQLOCJU81O
M97NT<^*Q-/!X>KB:L*\Z=&/-*&&P]?%UY*Z5J6&PU.K7K2N_@I4YRM=VLF?T
M 4AY! QD@]1D?B.X]17\O'_$3Y^RC_=7_P -M^U+_P#."H_XB?/V4?[J_P#A
MMOVI?_G!5]+_ *F9G_T,>%O_ !,.%_\ Y[>O]/3YW_6_+?\ H!XDZ?\ -*\2
M=>7_ *E?][\#]+[_ /9.^/2?M_7'Q^\)67@3X?\ @&ZT[3[WQ5XX\$?$#QUH
M]Q\5]&M9M9AOOAC\3/V>[JWU+X<>)/%VMV4N@Z==_&J\U<7NE:7H6DZWH&EV
M6OPRZ(O8? 33/VT/ =_^U9K>L_LY?!S1]0^*7Q"/Q@^&NE1_M,7NHZ3)JR?#
MGX(_"B#P%XEO].^!45UX<MHM,^'.N>)8O$NF:5X@MHQ+I6A#1R\\]]9?E!_Q
M$^?LH_W5_P##;?M2_P#S@JC_ .(H+]DLS&V$EN;A85N&MQ\//VH#<+;O(\*7
M#6X^ OGK;O-')"EPT8A>:.2%)&DC=%/]3,S_ .ACPM_XF'"__P ]O7^GH+B_
M+7_S <2=/^:4XD_N_P#4K_O?@?IS>_L/_M 67[:'PR_:)TK]H;2->\ V'QG^
M,GQ-\?>%_$?PS\/6OBN+P[XT^%MM\./!?P^T+Q1IMV9=3T3PKH=C9>&-'N[F
MSTJ]T731J&N3+K>NZUK%Q??JF.G/)[GIFOY=_P#B)\_91_NK_P"&V_:E_P#G
M!4?\1/G[*/\ =7_PVW[4O_S@J/\ 4S,_^ACPM_XF'"__ ,]O7^GH?ZWY;_T
M\2=/^:5XDZ\O_4K_ +WX']1%%?R[_P#$3Y^RC_=7_P -M^U+_P#."KZ5^%'_
M  <>?\$Q_$WA4ZE\4?CG>_#KQ/\ VI?VP\/6_P !/VL->C.F0>3]AU#[=!\!
ME3=>;YMT&,Q&+DG=7GYEP[C<KPWUJOB\DK4_:0I\F7\09)F6(YIJ34OJV Q^
M)Q'LURM2J>S]G!N*E).44^[+^(,'F6(^K4,+G%*?LY5.?'9%G&7T.6/)=?6,
M=@L/0YVYKEA[3GDDW&+2=OWR;H?H?Y5_.E^VW_R=#\5/^OSPU_ZAGAROH4_\
M'#G_  2"(/\ QE=JG0_\VU?M;?\ SAZ_%K]J;_@KA_P3\^(GQZ^('C'P?\;_
M !!K/AO6KG0Y-,U*/]G_ /:8MTNDM/#&B:?<,L-Y\&[>Y3R[NTN(2)84),99
M=R%6/Z'X*9EEV5\3YC7S/'X++J$\AQ%&%;'8JAA*4ZLLPRR:I1J8BI3A*HX4
MYS4%)R<83DE:+:^#\8,OQ^8\.Y?1R_ XS'UH9U0J3I8+#5L54A36!Q\'4E3H
M0J2C!3G"+FTHJ4HIN\E?W:BO@C_AYW^Q%_T5SQ'_ .&%_:/_ /G14?\ #SO]
MB+_HKGB/_P ,+^T?_P#.BK^G?];^$_\ HJ.'?_#WEO\ \TG\Z?ZK\3?]$YGW
M_AGS'R_ZAO-'WO17P1_P\[_8B) 'Q<\2$D@ #X"?M'DDG@  ?"'))/  Y)J*
M#_@J%^PW<PQ7%M\8]<N;>9!)#<6WP+_:)N;>>-ONR07$'PEDAFC;^&2*1T;G
M#'%'^M_"?_14<._^'O+?_FD/]5^)O^B<S[_PSYCY?]0WFC[\HKX(_P"'G?[$
M7_17/$?_ (87]H__ .=%1_P\[_8B_P"BN>(__#"_M'__ #HJ/];^$_\ HJ.'
M?_#WEO\ \TA_JOQ-_P!$YGW_ (9\Q\O^H;S1^B_A+_D;?"?_ &-7AG_T^Z?7
M]6XZ?BW\S7\)/AW_ (*B_L-V/B+P]?77Q@\116MCX@T*]NI3\!/VD"(K6SU:
MSN;F4A?A"S,(X(I'*JI9MN%!8@'^@\?\'#G_  2"&?\ C*[5.I_YMJ_:V]3Z
M? <U_/7CCFV59K7X<EE>9Y?F4:-+-56> QN&QBHNI++O9JJ\/5J*FY\D^13L
MY<DN6_*[?NO@UE>9Y;2X@68Y=CLO=:>6NBL;A,1A'54(XWG=-5Z=-SY.>/-R
MWY>:-[75_P!(/VM/^3;?C/\ ]B'K/_H,5?S8-U/U/\Z^R/VB/^"^7_!)_P <
M?!#XG>$O"_[3^KZIX@U_PCJ>FZ1IT?[-_P"U= ]Y?7"QB&!9KKX&06\9<@_/
M+*B#'+"OQ /_  4\_8A)/_%W?$?4_P#-!?VC_P#YT5>[X)YYDN5Y#FM+,\XR
MO+JM3-Y5*=+'YAA,)4G3>#PD?:0AB*U.4H<T91YXIQYHM7NFCQO&#)LWS'/,
MMJY?E698^E#*U3G4P6!Q6*IPJ?6\0^24Z%*I&,[2B^5M.TD[6:9][5\A?M%?
M#CXI>*/&7P^\2_"72;C3/$^G22:=%\2-!^)<G@Z\\."+PW\3!I\'Q%\(:GX?
M\0^&?B'\-['7/$EC?1:>NG:CXD\W5?%GAJQATNW\6_VU!PO_  \[_8B_Z*YX
MC_\ #"_M'_\ SHJ/^'G?[$/_ $5SQ'_X87]H_P#^=%7ZSF6?\&YGA7A:W%F1
M4HNI1JJK0SS*8UH3HU(U(RISJ5:JIRO&RJ1BJD+\U.<)I27YAE^2<59?B%B:
M7#&<U9>SJTG3KY-FKI3A6ING*-2%.E2<XVFFZ<I.G/:I"<;Q?U78>&]?N/C!
MKOC#71;MH&D?#OPKX.\!2Q3JXCO];UG7-?\ BQJHTL32SZ9+?2Z7\.M(A:9G
MEN=*T46T%Q/$+HM\L_%_X2?%7XJ:A=^+'\%>*?#FO>*/A%H_@S3=%\&?&WPA
MX9TWPQX@M]9\2Z[J.A_M!(UK+HOQX^&RZK/H5SI^CV>F^+M)@T#4_'OAF+PC
M!=^*]1U2_K/_ ,%0OV&XGACE^,>NQ27,C16T<OP+_:*BDN94BDG>*VCD^$BO
M<2I!#-.\4"R2+!#-.RB&&5TD_P"'G?[$7_17/$?_ (87]H__ .=%7-C<TX)Q
M^&GA:_%V3JE4KU\14Y,]R5SJ5:SERN<ZKJMK#TI>PPR_Y=THTV^:K1H5:6^$
MRWB_!UX8FEPQFSJTZ-"A3YLFS=1A3HJ%U&-*-)1=>I%5L0UK4JSJ6Y*5:M2G
M]X6BW*6EHEZ]K+>I:6B7LMC ]K8RWJ6T2WLEA:R,\EK8270F>QM9)))+:T:&
M"221XV=IZ^"/^'G?[$7_ $5SQ'_X87]H_P#^=%1_P\[_ &(O^BN>(_\ PPO[
M1_\ \Z*O77%_"227^M'#SLDM<[RUO3NWBKM]V]6>6^%^)F[_ .KF?:N^F3Y@
MEK;9?5K):K3H?TB_\$O?^1F^,/\ V ?!7_IS\25^Q5?R6_L%_P#!:+_@FQ\'
M-=^)5Y\1_P!H+7/#=OKVD>%[;2I)_P!GC]J&\%W/I]_K<UY&HT[X*WC1F&.[
MMV)E"!O, 0L0VW]_/V0?^"B/['W[>3^/T_94^+%U\3F^%X\,GQR+GX:?%SX>
M?V*/&']M_P#".[#\4O 7@D:M_:'_  CFL[O[$.I&R^R#^T/LGVJS^T?R1XK8
MW!YAQQFV*P&+PV.PM2GEJIXG!UZ6)H3<,KP5.:A6HSG3DX5(RA)1D^6<91=F
MFE_4OAEA,7@>#,LPV-PN(P>(A5S%SP^*H5</7@IYCBIP<Z5:,*D5.$HSBY17
M-&2DKIIGVM1117YR??!1110 4444 %%%% !1110 A .,YX]&8?G@C/XTFT>K
M?]]O_P#%4ZB@!NT>K?\ ?;__ !5&T>K?]]O_ /%4ZB@!NT>K?]]O_P#%5\PZ
M;\+_ !=;?MC^+_C%+:6X\":O^S1\._AI8WPU&W:]D\6>'OBU\4_%NJ6KZ:'^
MV16T6B^*='GCOW46\\LTMM&QEMY5'T^"#G!!P<'!!P1U!]"/>@,I&X$%>N01
MC'KGI0 FT>K?]]O_ /%4;1ZM_P!]O_\ %4I(! ) ). "0"3Z#U/TI: &[1ZM
M_P!]O_\ %4;1ZM_WV_\ \53J* &[1ZM_WV__ ,51M'JW_?;_ /Q5.HH ;M'J
MW_?;_P#Q5&T>K?\ ?;__ !5.I"0HR2 /4D ?F: &,F0,;LAD/+MT5U8]3@\#
MIWKYI_8U^&/BOX-_LL? 7X6^.[6WL?&'@/X9>&?#/B.SLM1@U.UMM6TVU,5W
M%!J%F[VMY$DAPMQ S1N.4. *^F20" 2 3P 2 2>N!Z\>E+D>HZ9_#U^E #=H
M]6_[[?\ ^*HVCU;_ +[?_P"*H5T;.UU;'7:P./K@FG4 -VCU;_OM_P#XJC:/
M5O\ OM__ (JG44 -VCU;_OM__BJ-H]6_[[?_ .*IU% #=H]6_P"^W_\ BJ-H
M]6_[[?\ ^*IU)D9VY&<9QD9QZXZX]Z /G/XR_#CQ/XR^*W[)/BK0K6"?1OA)
M\;_&?C?QK--?PVTUEX?UK]F/X^_#*PN+2WF<2ZE/)XM\?>&[1[2T#SQ6US<7
M[*+:SN'7Z+VCU;_OM_\ XJE!!S@@X.#@YP?0^AH+*!N) 'J2,?GTH 3:/5O^
M^W_^*HVCU;_OM_\ XJG44 -VCU;_ +[?_P"*I0 .F?Q)/\R:6B@ HHHH ***
M* "BBB@ HHHH **** "BBB@ JEJ4=_+I]]%I=U;6.I26=S'I]Y>V4FI6=I?/
M!(MG<W6GPWNG2WUM!<F*:>SBU"QDNHD>W2\MFD$\=VJ&J:7IVMZ9J&C:O96V
MI:5JUC=Z9J>GWL*7%I?:??V\MI>V=U!("DUM=6LTL$\3@I)%(Z,"K$4 ?BKJ
M_P 2OCYX#TWQ]?\ @7]I/XB_$CX/W5]^SG\&_&?[1_Q"\-> UT71OCA\5/VF
M? GPJ^*GQ!_9\-IX1TCPV/!GP_\ AOXA\1S>(DFB\9_![PE\1V\#:+X?O=5O
MO"7QBM1<^+?Q*_:2\!_"#]MKP?X ^/'B?[%^RS\3OA7)H/Q8\4^'O#7C;XF:
MSX8\8^ /A?X]UWX+R^)_LFC:!!X@\.:YXE>/5O&NM>#/%'B;_A6/C+1M"ADM
M?&D,/CRP_0WX;?L4_LE?!ZQU_2OAA^SI\'_ ^C^*O!R_#OQ%HGA[P-HEEH6L
M> E"(G@N_P!#^S2:3<>%4CC2%- :R_LM;=5MUM1 /+I_B3]BW]DSQA\/-"^$
MOB?]G3X/:W\,?#>L7_B#1? 5_P" ]"E\)V.NZHDD>IZPNABU2QGU/41+(U_?
M745Q=7DC>;<2R2JKJ ?GC^W/\>/VB?"?QJ^*,OPBU;XHW_PZ_9\^ _@CX@^/
M-2^&6L?#/0?#WP!\3:OXE\<ZSK7Q$^.7@_Q]I%UXN_:,\#7OPGT5_%-M\./@
M]<WVO:3I/P^\3Z+_ &''XT\?>#?$.F?L]IM_:ZKI]EJ=C.MS9:A:6U]9W**Z
M)<6MY"ES;3HDBK(B302QR*LBAU5@KC>&KY^G_9 _9:N[+P-I]_\ L^?!_4[/
MX::=%I'@.'5? 'AS5?\ A%M)M]1N]8MM+TI]2L+N6+3+;6+^[UBVTZ5YK*WU
M:>34X(([YC<5]' 8Z?Y_SWH **** "BBB@ KY%_:[N7TKPKX;UW5/CG\2OA'
MX2L=5U"TO?#'P3\/Z7JWQF^,7B_4[!(O G@3X?7%UH_BK6)]2COX=3UA_"OA
M;PK=ZIXJFM;$ZUK.C>!]%\6V^L?75>(?&3]FOX!?M"OX5E^-_P (/A_\4KCP
M-<:U=>#+KQKX;T_7+SPK<>([&#3/$$WA^\NHS=:2^N:9;0:=JYLIH?[1L(Q9
MW?FVQ:,@'Y/>+OB]^UII7PU^-OB/XK?&#6OA7\;?V-/V,?@C\9T\%Z%;^ 8O
M"7Q8^+7B;PY\4_$WB>3XF:?%H&HZ?XQT+QAK?@/2O@8FC^ M6T+0=-\81>.]
M:\"&VU?4_!-WH/V]\//$WQHO/VS?C'X&\>?$*>]\#:S^S3\,_'_@CX?Z)X;T
M_P .6GPOGUWXG?%WPO<JVK_:M>UKQ+X\O--T73$\3>(;W5X_#[7>DZ?#X7\)
M:!:VVH2ZS[V/V7_V=3%\,8I?@C\+KE?@O;6EE\*'O?!.@W\WP^L["XAO+&U\
M*7-]97%QI%O97]K9ZE9PVTJQVNJ65EJENL>HV=K=0XME^Q]^R]IOQ@E_: L/
M@/\ #&S^-EQJUWKD_P 4[?PK81^.9M4OH[R.[NY?$*H+^1IEU&_+1O(8!)>W
M4RQ++/*[ '@O[%WA3Q&GCW]H;Q6GQK^/'Q'^&7AWQU=_ CP+H_Q@\>0^-TN_
M$/PCO[K3_BU\0+:5M TNYTZYNOB-=ZQ\,K+3XKF:R_LOX9R:VT2WOB2>*S_0
MNL/P[X8\.^$=/FTGPOH>E>'M,N-9\1>(9]/T:PMM.LYM=\6Z_J7BKQ1K$MO:
MQQ1/J7B'Q+K.K:]K-ZRF?4=7U*^U"Z>2YN9I&W* "BBB@ HHHH 0]#SC@\^G
MO^%?EK\2O%7QP\#_ +05Y>_"WXL_$CX[>(_#.H?$GQ]\9/A'8^'/"UE\#?AQ
M\#K3X5^-]8^&7PNF-GH\^L6/QU\0^.(OAPWA2:V\;7GQ#\76^J>*_&/B'PUI
M?PI71=%L?U+KYIT;]C?]ECP[\4KKXV:!\ OA9HGQ9OO%VM^/[[X@:3X1TW3_
M !/>^-_$L$MMXA\77FI6L<4EWXDUNWGDAU;6;A9+^_CV)<SR+%$$ /ASX&>-
M_C[JGB#X'^&O#'[2D_Q%U7]JK]BZ_P#VB=?\2^._#'AKQ?X>^$OCW3_$OP$M
MH?%G@#PMX9'P_NM-\!>.M'^+OC70O"?@36=8U32;'6?ASX>U &[:V^(;>(N"
MM?C;^TGX[_9[_P"";W@'0?$OQ U_QY^T=\,/%/B3XA_$+1?$/@OX;>+?&FO_
M  V^'.E:Y;Z!JOQ$O/!FNZ)\.AXWN]7U'QEX@U/P+\.=0\0W%CX'U#1/"6BZ
M3I-_JD]E^FR_LI_LUQZ!\1?"]M\"OA58^'_BY<6UU\3=)TSP1H.E6?CJ>SU%
M]8M'\3)IEE:-J@M=7EN-6MXYW,,&J7E_J,4:WFH7LUQ@Z!^Q7^R5X7^'%_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ?O!13(R2I).3OE'X"1P!^  %/H **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832854272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 01, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,708,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,267,511,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833439072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
<td class="nump">$ 11,448.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">1,816.3<span></span>
</td>
<td class="nump">1,630.0<span></span>
</td>
<td class="nump">1,478.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">2,597.2<span></span>
</td>
<td class="nump">2,253.6<span></span>
</td>
<td class="nump">1,973.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,106.3<span></span>
</td>
<td class="nump">1,933.9<span></span>
</td>
<td class="nump">1,946.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">747.3<span></span>
</td>
<td class="nump">814.7<span></span>
</td>
<td class="nump">385.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">185.0<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">112.5<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">33.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(12.3)<span></span>
</td>
<td class="nump">62.7<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement charge</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">454.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expenses</a></td>
<td class="nump">7,564.3<span></span>
</td>
<td class="nump">6,928.1<span></span>
</td>
<td class="nump">6,297.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">5,888.6<span></span>
</td>
<td class="nump">5,345.8<span></span>
</td>
<td class="nump">5,151.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="num">(217.0)<span></span>
</td>
<td class="num">(218.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">5,899.6<span></span>
</td>
<td class="nump">5,128.8<span></span>
</td>
<td class="nump">4,933.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">1,425.6<span></span>
</td>
<td class="nump">2,458.7<span></span>
</td>
<td class="nump">1,237.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,474.0<span></span>
</td>
<td class="nump">2,670.1<span></span>
</td>
<td class="nump">3,695.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">43.3<span></span>
</td>
<td class="nump">131.0<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 4,430.7<span></span>
</td>
<td class="nump">$ 2,539.1<span></span>
</td>
<td class="nump">$ 3,702.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 21.63<span></span>
</td>
<td class="nump">$ 11.94<span></span>
</td>
<td class="nump">$ 16.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 21.58<span></span>
</td>
<td class="nump">$ 11.92<span></span>
</td>
<td class="nump">$ 16.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">204.9<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">205.3<span></span>
</td>
<td class="nump">213.0<span></span>
</td>
<td class="nump">218.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">$ 10,886.8<span></span>
</td>
<td class="nump">$ 10,354.7<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">1,980.2<span></span>
</td>
<td class="nump">1,559.2<span></span>
</td>
<td class="nump">1,314.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">$ 585.9<span></span>
</td>
<td class="nump">$ 360.0<span></span>
</td>
<td class="nump">$ 316.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationandImpairmentofAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813619040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 4,430.7<span></span>
</td>
<td class="nump">$ 2,539.1<span></span>
</td>
<td class="nump">$ 3,702.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) recognized during the period, net of tax</a></td>
<td class="num">(10.6)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Less: reclassification adjustment for (gains) losses included in net income, net of tax</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(3.9)<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="num">(10.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) recognized during the period, net of tax</a></td>
<td class="nump">97.4<span></span>
</td>
<td class="num">(193.8)<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax', window );">Less: reclassification adjustment for (gains) losses included in net income, net of tax</a></td>
<td class="nump">41.8<span></span>
</td>
<td class="nump">31.5<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">139.2<span></span>
</td>
<td class="num">(162.3)<span></span>
</td>
<td class="nump">47.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Gains (Losses) on net investment hedge recognized during period</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax', window );">Less: Reclassification of net investment hedge forward points amortization</a></td>
<td class="num">(1.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax', window );">Gains (losses) on net investment hedges</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="num">(4.1)<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(67.8)<span></span>
</td>
<td class="nump">158.7<span></span>
</td>
<td class="num">(138.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">76.5<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(95.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Biogen Inc.</a></td>
<td class="nump">4,507.2<span></span>
</td>
<td class="nump">2,540.6<span></span>
</td>
<td class="nump">3,606.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(42.9)<span></span>
</td>
<td class="num">(131.0)<span></span>
</td>
<td class="nump">7.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 4,550.1<span></span>
</td>
<td class="nump">$ 2,671.6<span></span>
</td>
<td class="nump">$ 3,599.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109240241&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph c<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL34724391-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109978405&amp;loc=d3e80720-113993<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832712992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,224.6<span></span>
</td>
<td class="nump">$ 1,573.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">2,313.4<span></span>
</td>
<td class="nump">2,115.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,958.5<span></span>
</td>
<td class="nump">1,787.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DueFromUnconsolidatedJointBusiness', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">526.9<span></span>
</td>
<td class="nump">532.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">929.9<span></span>
</td>
<td class="nump">902.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">687.6<span></span>
</td>
<td class="nump">962.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">7,640.9<span></span>
</td>
<td class="nump">7,873.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">1,375.9<span></span>
</td>
<td class="nump">3,057.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,601.2<span></span>
</td>
<td class="nump">3,182.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,120.0<span></span>
</td>
<td class="nump">3,879.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,706.4<span></span>
</td>
<td class="nump">4,632.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent', window );">Deferred tax asset</a></td>
<td class="nump">2,153.9<span></span>
</td>
<td class="nump">595.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,690.6<span></span>
</td>
<td class="nump">431.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">25,288.9<span></span>
</td>
<td class="nump">23,652.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">63.5<span></span>
</td>
<td class="nump">68.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">370.5<span></span>
</td>
<td class="nump">395.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,861.2<span></span>
</td>
<td class="nump">2,901.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,295.2<span></span>
</td>
<td class="nump">3,368.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">5,936.5<span></span>
</td>
<td class="nump">5,935.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">1,636.2<span></span>
</td>
<td class="nump">122.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,389.4<span></span>
</td>
<td class="nump">1,628.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,257.3<span></span>
</td>
<td class="nump">11,054.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">97.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(240.4)<span></span>
</td>
<td class="num">(318.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">16,257.0<span></span>
</td>
<td class="nump">15,810.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 23.8 million and 23.8 million shares, respectively</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">13,039.6<span></span>
</td>
<td class="nump">12,612.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">13,031.6<span></span>
</td>
<td class="nump">12,598.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 25,288.9<span></span>
</td>
<td class="nump">$ 23,652.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DueFromUnconsolidatedJointBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivable from unconsolidated joint business for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DueFromUnconsolidatedJointBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31958-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6716268112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="nump">$ 0.0005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock at cost, shares</a></td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832616512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 4,474.0<span></span>
</td>
<td class="nump">$ 2,670.1<span></span>
</td>
<td class="nump">$ 3,695.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, amortization and impairments</a></td>
<td class="nump">1,016.6<span></span>
</td>
<td class="nump">1,081.0<span></span>
</td>
<td class="nump">682.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">112.5<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">157.5<span></span>
</td>
<td class="nump">128.0<span></span>
</td>
<td class="nump">154.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">108.3<span></span>
</td>
<td class="nump">91.7<span></span>
</td>
<td class="num">(175.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(12.3)<span></span>
</td>
<td class="nump">62.7<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(69.1)<span></span>
</td>
<td class="nump">162.1<span></span>
</td>
<td class="nump">89.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(205.2)<span></span>
</td>
<td class="num">(435.6)<span></span>
</td>
<td class="num">(241.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">5.7<span></span>
</td>
<td class="num">(232.0)<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(52.1)<span></span>
</td>
<td class="num">(94.5)<span></span>
</td>
<td class="num">(165.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(119.1)<span></span>
</td>
<td class="num">(76.6)<span></span>
</td>
<td class="nump">59.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">465.5<span></span>
</td>
<td class="num">(227.4)<span></span>
</td>
<td class="nump">622.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="nump">321.7<span></span>
</td>
<td class="nump">1,303.9<span></span>
</td>
<td class="num">(232.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(16.3)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="nump">69.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows provided by operating activities</a></td>
<td class="nump">6,187.7<span></span>
</td>
<td class="nump">4,551.0<span></span>
</td>
<td class="nump">4,587.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">9,173.7<span></span>
</td>
<td class="nump">5,565.9<span></span>
</td>
<td class="nump">7,378.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(7,694.8)<span></span>
</td>
<td class="num">(5,355.2)<span></span>
</td>
<td class="num">(7,913.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Contingent consideration related to Fumapharm AG acquisition</a></td>
<td class="num">(1,500.0)<span></span>
</td>
<td class="num">(1,200.0)<span></span>
</td>
<td class="num">(1,200.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Payments to Acquire in Process Research and Development</a></td>
<td class="num">(112.5)<span></span>
</td>
<td class="num">(120.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(770.6)<span></span>
</td>
<td class="num">(867.4)<span></span>
</td>
<td class="num">(616.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(975.4)<span></span>
</td>
<td class="num">(111.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Payments to Acquire Other Investments</a></td>
<td class="num">(462.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="num">(676.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
<td class="num">(22.8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(2,046.3)<span></span>
</td>
<td class="num">(2,963.1)<span></span>
</td>
<td class="num">(2,484.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(4,352.6)<span></span>
</td>
<td class="num">(1,365.4)<span></span>
</td>
<td class="num">(1,000.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(5.3)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Net distribution to noncontrolling interest</a></td>
<td class="num">(36.4)<span></span>
</td>
<td class="num">(134.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(560.9)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfCapitalDistribution', window );">Net cash contribution to Bioverativ, Inc.</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(302.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Contingent consideration payments</a></td>
<td class="num">(58.2)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(38.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(19.5)<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows used in financing activities</a></td>
<td class="num">(4,472.0)<span></span>
</td>
<td class="num">(2,380.0)<span></span>
</td>
<td class="num">(1,052.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(330.6)<span></span>
</td>
<td class="num">(792.1)<span></span>
</td>
<td class="nump">1,049.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(18.6)<span></span>
</td>
<td class="nump">39.4<span></span>
</td>
<td class="num">(31.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of the year</a></td>
<td class="nump">1,573.8<span></span>
</td>
<td class="nump">2,326.5<span></span>
</td>
<td class="nump">1,308.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of the year</a></td>
<td class="nump">$ 1,224.6<span></span>
</td>
<td class="nump">$ 1,573.8<span></span>
</td>
<td class="nump">$ 2,326.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfCapitalDistribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow to owners or shareholders, excluding ordinary dividends. Includes special dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfCapitalDistribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=107668666&amp;loc=SL79513924-113897<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6904970144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Noncontrolling interests</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>2018 Share Repurchase Program</div></th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2018 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2016 Share Repurchase Program</div></th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2011 Share Repurchase Program</div></th>
<th class="th">
<div>2011 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th"><div>2016 Share Repurchase Program</div></th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2016 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>Accounting Standards Update 2016-01 </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>Accounting Standards Update 2016-16 </div>
<div>Retained earnings</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2015</a></td>
<td class="nump">$ 9,374,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (224,000,000)<span></span>
</td>
<td class="nump">$ 12,208,400,000<span></span>
</td>
<td class="nump">$ 2,611,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2015</a></td>
<td class="nump">9,372,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning Balance at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning Balance, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(241,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">3,702,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,702,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(7,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">3,695,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(95,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(95,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquisition of noncontrolling interest</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of noncontrolling interest</a></td>
<td class="num">(7,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="num">(1,000,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(164,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(835,100,000)<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">43,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(52,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(47,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">169,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation', window );">Tax benefit from share-based payments</a></td>
<td class="num">(600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="nump">12,128,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(319,900,000)<span></span>
</td>
<td class="nump">15,071,600,000<span></span>
</td>
<td class="num">$ (2,611,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="nump">12,140,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(238,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">2,539,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,539,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">131,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,670,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">15,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interest</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000,000,000)<span></span>
</td>
<td class="num">$ (1,000,000,000)<span></span>
</td>
<td class="num">$ (365,400,000)<span></span>
</td>
<td class="num">$ (365,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,700,000)<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="num">(3,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(36,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(964,000,000)<span></span>
</td>
<td class="num">$ (1,000,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">40,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">40,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(45,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(44,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="num">(138,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(138,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSpinoffTransaction', window );">Hemophilia spin-off adjustment</a></td>
<td class="num">(852,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(852,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Tax benefit</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="nump">12,598,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">97,800,000<span></span>
</td>
<td class="num">(318,400,000)<span></span>
</td>
<td class="nump">15,810,400,000<span></span>
</td>
<td class="num">$ (2,977,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="nump">12,612,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2017</a></td>
<td class="num">(14,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(235,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">4,430,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,430,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">43,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">4,474,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">76,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">76,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Noncontrollinginterestincreasedecreaseother', window );">Capital contribution by noncontrolling interest</a></td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interest</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,352,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,352,600,000)<span></span>
</td>
<td class="num">$ (3,000,000,000)<span></span>
</td>
<td class="num">$ (3,000,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (92,800,000)<span></span>
</td>
<td class="num">$ (1,259,800,000)<span></span>
</td>
<td class="num">$ (1,352,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (171,100,000)<span></span>
</td>
<td class="num">$ (2,828,900,000)<span></span>
</td>
<td class="num">$ (3,000,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to the 2016 Share Repurchase Program, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">41,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">41,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">$ (43,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(43,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="num">$ (168,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(168,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Tax benefit</a></td>
<td class="nump">106,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 104,600,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="nump">13,031,600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (240,400,000)<span></span>
</td>
<td class="nump">$ 16,257,000,000<span></span>
</td>
<td class="num">$ (2,977,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="nump">13,039,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending Balance at Dec. 31, 2018</a></td>
<td class="num">$ (8,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(221,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Noncontrollinginterestincreasedecreaseother">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling interest, increase (decrease) other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Noncontrollinginterestincreasedecreaseother</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from a tax benefit associated with share-based compensation plan other than an employee stock ownership plan (ESOP). Includes, but is not limited to, excess tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109245112&amp;loc=d3e23524-113945<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of treasury stock (units) reissued during the period, excluding reissuance of shares (units) held in treasury used to satisfy equity-based compensation obligations exercised by the holders of such rights. Upon reissuance of shares (units) from treasury, either the common or preferred stock (unit) reissued is outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSpinoffTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 60<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6406278&amp;loc=d3e26268-112671<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSpinoffTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823609056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&#8217;s disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), Parkinson's disease, ALS, stroke, epilepsy, cognitive impairment associated with schizophrenia (CIAS) and pain.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilar products through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ Inc. (Bioverativ), as an independent, publicly traded company. Our consolidated results of operations and financial position included in these audited consolidated financial statements reflect the financial results of our hemophilia business for all periods through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the spin-off of our hemophilia business, please read Note 3,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2014-09 that have the same effective date and transition date: ASU No. 2016-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; and ASU No. 2016-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not change our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon adoption. However, the adoption of the new revenue standards will result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under ASU 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the new revenue standards, other corporate revenue was higher by&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;and cost of sales, excluding amortization and impairment of acquired intangible assets was higher by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the year ended December 31, 2018, compared to what would have been reported under the previous revenue guidance, primarily due to the earlier recognition of revenue associated with our contract manufacturing agreements. Under the previous revenue guidance, these amounts would have been recognized in future periods upon shipment. The adoption of the new revenue standards did not have a material impact on any other balances within our consolidated financial statements as of and for the&#160;year ended&#160;December 31, 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the United States (U.S.), we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates, non-US pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration with Genentech is within the scope of Accounting Standards Codification (ASC) 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Agreements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech, the Roche Group and us. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates that are based on information received from Genentech. These estimates are subject to change and actual results may differ. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Genentech, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with AbbVie Inc. (AbbVie), Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with AbbVie, Genentech and Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Corporate Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We provide reserves against trade receivables for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of the new revenue standards did not change our historical accounting methods for our accounts receivable.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Marketable Securities and Other Investments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities and Venture Capital Funds</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Equity Method of Accounting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also includes our U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired In-process Research and Development (IPR&amp;D)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&#160;25, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions of a business completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cash Flow and Fair Value Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Translation of Foreign Currencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Royalty Cost of Sales</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Share-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense, net of forfeitures, for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of PSUs that settle in stock are based upon the stock price on the date of grant and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes valuation model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> discount is recognized as compensation expense over the 90-day purchase period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. In December 2018 we elected to recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfers of assets other than inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset is transferred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Earnings per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">New Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued ASU 2014-09, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. For additional information on the adoption of the new revenue standards, please read the section titled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue Recognition </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">above, and Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, and recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> net increase to retained earnings as well as a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase to accumulated other comprehensive income reflecting the cumulative impact for the accounting changes made upon adoption. The adoption of this standard resulted in a change in the income statement classification with respect to where we recognize changes in fair value related to certain equity security investments. Prior to the adoption of ASU 2016-01, we recognized changes in fair value in accumulated other comprehensive income (loss), net. Upon the adoption of ASU 2016-01, we recognize changes in fair value in other income (expense), net. During the year ended December 31, 2018, we recognized net gains resulting from changes in fair value related to our equity security investments in other income (expense), net totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under this standard that would not have been recognized in other income (expense), net under the previous standard. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Leasing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This standard became effective for us on January 1, 2019. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB has subsequently issued the following amendments to ASU 2016-02, which have the same effective date and transition date of January 1, 2019, and which we collectively refer to as the new leasing standards: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-01,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that exist or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which amends certain narrow aspects of the guidance issued in ASU 2016-02.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvements for Lessors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which contains certain narrow scope improvements to the guidance issued in ASU 2016-02.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards on January 1, 2019, using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019. We have reviewed our existing lease contracts and the impact of the new leasing standards on our consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards, we expect to recognize a lease liability and related right-of-use asset on our consolidated balance sheet of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The impact of adoption of the new leasing standards will have an immaterial impact to our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Credit Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard will be effective for us on January 1, 2020. We are currently evaluating the potential impact that this standard may have on our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, offset by a corresponding net increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> with a corresponding reduction to our retained earnings as these differences are related to inter-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our income taxes, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Periodic Pension Cost</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Costs and Net Periodic Postretirement Benefit Cost.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> This standard requires that an employer disaggregate the service cost component from the other components of net benefit cost. This standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the statements of income and allows only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on our consolidated statements of income. We adopted this standard on January 1, 2018, using the retrospective method. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the adoption of this standard, the other components of net periodic benefit cost, which we previously presented as a component of operating income, are now classified in other income (expense), net in our consolidated statements of income. For the years ended December 31, 2017 and 2016, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reclassified from operating income to other income (expense), net in our consolidated statements of income to conform to our current year presentation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Debt Securities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. Based upon our marketable debt securities as of December 31, 2018, the adoption of this standard did not result in a significant adjustment to our marketable debt securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard provides guidance to better align an entity's risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. This standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this standard resulted in additional disclosures and a change in the income statement classification with respect to where we recognize cash flow hedge ineffective or excluded hedge transaction gains and losses. Prior to the adoption of ASU 2017-12 on January 1, 2018, to the extent ineffective or excluded, cash flow hedge transaction gains and losses were reported in other income (expense), net. Effective January 1, 2018, we recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of any cash flow hedge ineffectiveness or excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, in October 2018 the FASB issued ASU No. 2018-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will be effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> This standard makes targeted improvements for collaborative arrangements as follows: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Requires that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting that transaction together with revenue recognized under ASC 606 is precluded if the collaborative arrangement participant is not a customer. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will be effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. We are currently evaluating the potential impact that this standard may have on our consolidated financial position and results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973075968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Acquisitions</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB100 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2018 we acquired BIIB100 (formerly known as KPT-350) from Karyopharm Therapeutics Inc. (Karyopharm). BIIB100 is a Phase 1 ready investigational oral compound for the treatment of certain neurological and neurodegenerative diseases, primarily in ALS. BIIB100 is a novel therapeutic candidate that works by inhibiting a protein known as XPO1, with the goal of reducing inflammation and neurotoxicity, along with increasing neuroprotective responses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Karyopharm, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB100 has not yet reached technological feasibility. We may also pay Karyopharm up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$207.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as tiered royalties on potential net commercial sales in the mid-single digit to low-teen percentages. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB104 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we acquired BIIB104 (formerly known as PF-04958242) from Pfizer Inc. (Pfizer). BIIB104 is a first-in-class, Phase 2b ready AMPA receptor potentiator for CIAS, representing our first program in neurocognitive disorders. AMPA receptors mediate fast excitatory synaptic transmission in the central nervous system, a process which can be disrupted in a number of neurological and psychiatric diseases, including schizophrenia. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Pfizer, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB104 has not yet reached technological feasibility. We may also pay Pfizer up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$515.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the low to mid-teen percentages. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2018 we accrued a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment related to the Phase 2b trial for BIIB104, which is included in research and development expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">TMS Co., Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we entered into an exclusive option agreement with TMS Co., Ltd. (TMS) granting us the option to acquire TMS-007, a plasminogen activator with a novel mechanism of action associated with breaking down blood clots, which is in Phase 2 development in Japan, and backup compounds for the treatment of stroke. In exchange for the purchase option, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment to TMS, which was recorded as research and development expense in our consolidated statements of income as TMS-007 has not yet reached technological feasibility. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we exercise the purchase option, we will make an additional payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon closing of the asset acquisition, which will be recorded as acquired IPR&amp;D expense in our consolidated statements of income as TMS-007 will not have reached technological feasibility at that time. In addition, we may pay TMS up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$335.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and commercialization milestone payments as well as tiered royalties on potential net commercial sales in the high-single digit to low-teen percentages. If we exercise the purchase option, consummation of the asset acquisition may be subject to the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB110 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we acquired BIIB110 (formerly known as ALG-801) (Phase 1a) and ALG-802 (preclinical) from AliveGen Inc. (AliveGen).&#160;BIIB110 and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 in multiple neuromuscular indications, including SMA and ALS. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as the value being acquired primarily relates to a single asset. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to AliveGen, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB110 has not yet reached technological feasibility. We may also pay AliveGen up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$535.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and commercialization milestones.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">BIIB093 Acquisition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2017 we acquired BIIB093 (glibencamide IV) (formerly known as CIRARA) from Remedy Pharmaceuticals Inc. (Remedy). BIIB093 is a Phase 3 ready candidate for large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The U.S. Food and Drug Administration (FDA) granted BIIB093 orphan drug designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted BIIB093 Fast Track designation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are responsible for the future development and commercialization of BIIB093 and Remedy will share in the cost of development for the target indication for BIIB093 in LHI stroke.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We accounted for this transaction as an asset acquisition as we did not acquire any employees from Remedy nor did we acquire any significant processes required in the development of BIIB093. In connection with the closing of this transaction, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Remedy, which was recorded as acquired IPR&amp;D in our consolidated statements of income as BIIB093 has not yet reached technological feasibility. We may also pay Remedy certain development and sales based milestone payments that are substantially payable upon or after regulatory approval, as well as royalties on potential net commercial sales.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823611232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin-Off Hemophilia Spin-Off<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Hemophilia Spin-Off</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Hemophilia Spin-Off</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On February 1, 2017, we completed the spin-off of our hemophilia business, Bioverativ, as an independent, publicly traded company, which was acquired by Sanofi in March 2018. In connection with the spin-off, each Biogen shareholder received one share of Bioverativ common stock for every two shares of Biogen common stock they owned. The separation and distribution was structured to be tax-free for shareholders for federal income tax purposes. Bioverativ assumed all of our rights and obligations under our collaboration agreement with Swedish Orphan Biovitrum AB (Sobi) and our collaboration and license agreement with Sangamo Biosciences Inc.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen and Bioverativ entered into a separation agreement and various other agreements, including a manufacturing and supply agreement, which govern the separation and distribution and the relationship between the two companies going forward. Under the separation agreement, Bioverativ is obligated to indemnify us for liabilities that may exist relating to its business activities, whether incurred prior to or after the distribution, including any pending or future litigation.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the distribution we made a net cash contribution to Bioverativ, during the first quarter of 2017, totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$302.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The following table summarizes the assets and liabilities that were charged against equity as a result of the spin-off of our hemophilia business:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to the terms of our agreements with Bioverativ, upon completion of the spin-off, we distributed ALPROLIX and ELOCTATE on behalf of Bioverativ until Bioverativ obtained appropriate regulatory authorizations in certain countries, including a Biologics License Application transfer in the U.S., which was received in September 2017. Accordingly, commencing October 2017, we ceased distribution of ALPROLIX and ELOCTATE on behalf of Bioverativ under this arrangement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the manufacturing and supply agreement, we manufacture and supply certain products and materials to Bioverativ. The manufacturing and supply agreement has an initial term of five years, with a five-year extension at Bioverativ's sole discretion and a further five-year extension with Bioverativ's and our consent. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$206.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues in relation to contract manufacturing services provided to Bioverativ, which is reflected as a component of other royalty and corporate revenues in our consolidated statements of income. We also recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$180.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as cost of sales in relation to these services during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Additionally, pursuant to the terms of the manufacture and supply agreement, we expect to sell substantially all remaining hemophilia related inventory to Bioverativ during the first quarter of 2019, when Bioverativ will assume full control over its manufacturing processes. Hemophilia related inventory on hand as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totals approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$180.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts earned under the non-manufacturing and supply related transaction service agreements are recorded as a reduction of costs and expenses in their respective expense line items. These amounts, which were primarily reflected as a reduction to selling, general and administrative expenses in our consolidated statements of income, were not significant for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Hemophilia related product revenues reflected in our consolidated statements of income for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$846.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Results for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, only reflect hemophilia-related product revenues through January 31, 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538335;font-style:italic;">Patents</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to the spin-off of our hemophilia business, we were awarded various methods of treatment and composition of matter patents related to ELOCTATE and ALPROLIX. Upon completion of the spin-off, these patents were transferred to the patent portfolio of Bioverativ.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973099824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Restructuring, Business Transformation and Other Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2017 Corporate Strategy</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017, in connection with creating a leaner and simpler operating model, we approved a corporate restructuring program intended to streamline our operations and reallocate resources. We expect to make total non-recurring operating and capital expenditures of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$135.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in connection with this program and our goal is to redirect resources of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$400.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> annually by 2020 to prioritized research and development and other value creation opportunities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to this effort, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are reflected as restructuring charges and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are included in selling, general and administrative expenses in our consolidated statements of income. These restructuring charges were primarily related to severance.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges incurred to date under this program have been substantially paid in cash as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2016 Organizational Changes and Cost Saving Initiatives</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2016 Restructuring Charges</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we initiated cost saving measures primarily intended to realign our organizational structure due to the changes in roles and workforce resulting from our decision to spin-off our hemophilia business, and to achieve further targeted cost reductions. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to this effort. These amounts, which were substantially incurred and paid by the end of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were primarily related to severance and are reflected in restructuring charges in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cambridge, MA Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 following an evaluation of our current and future manufacturing capabilities and capacity needs, we decided to cease manufacturing and vacate our 67,000 square foot small-scale biologics manufacturing facility in Cambridge, MA and close and vacate our 46,000 square foot warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December&#160;2016 we subleased our rights to the Cambridge, MA manufacturing facility to Brammer Bio MA,&#160;LLC (Brammer). Brammer also purchased from us certain manufacturing equipment, leasehold improvements and other assets in exchange for shares of Brammer common LLC interests and assumed manufacturing operations effective January 1, 2017. In December 2016 we closed and vacated our warehouse space in Somerville, MA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our departure from these facilities shortened the expected useful lives of certain leasehold improvements and other assets at these facilities. As a result, we recorded additional depreciation expense to reflect the assets' new shorter useful lives. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of this additional depreciation, which was recorded as cost of sales in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2016 we also recognized charges totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for severance costs related to certain employees separated from Biogen in connection with our departure from these facilities. These amounts were substantially incurred and paid by the end of first quarter of 2017 and are reflected in restructuring charges in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2015 Restructuring Charges</font></div><div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, include </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of expense related to our 2015 restructuring program.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823612032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,253.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,020.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">4,274.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,294.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">920.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4,214.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,169.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">798.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,968.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,668.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">694.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,363.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,889.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">756.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,645.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,980.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">814.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,795.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,025.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">839.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,864.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,113.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">859.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,973.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,182.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">780.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,963.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">92.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">92.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">91.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">91.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS Product Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">5,946.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,648.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">8,595.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,296.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,680.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,977.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,332.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,487.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,819.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">854.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">870.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,724.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">657.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">226.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">883.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">485.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">485.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">370.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">370.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">43.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">43.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">545.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">545.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">379.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">379.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">22.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">22.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">39.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">39.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">42.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">48.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">445.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">68.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">513.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">21.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">26.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">268.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">65.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">333.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Hemophilia product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">63.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">74.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">713.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">133.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">846.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">6,800.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">4,086.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7,017.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,337.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">10,354.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7,050.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognized revenues from two wholesalers accounting for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">34%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of gross product revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, two wholesale distributors individually accounted for approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">27.7%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.6%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net accounts receivable associated with our product sales, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">19.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">109.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">606.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">761.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">679.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,686.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">23.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,389.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(12.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(551.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,887.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,440.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(109.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(506.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(646.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">127.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">888.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">482.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,307.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,917.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(475.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,756.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,232.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(69.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(442.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(534.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">109.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">606.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">592.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,044.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,668.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(522.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,576.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,099.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(536.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(609.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">482.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">176.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">874.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,431.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,316.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our total revenues in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, are derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2472b9;font-style:italic;">Other Revenues</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">96.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Sobi and royalties from Sobi on sales of ELOCTA and ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">459.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">253.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">585.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with AbbVie and Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For additional information on our contract manufacturing agreements with Bioverativ, please read Note 3,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823662672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">196.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">162.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">606.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">133.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">157.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">929.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">902.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the table above is hemophilia related inventory totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$180.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of December 31, 2018, which is expected to be sold to Bioverativ in the first quarter of 2019. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-term inventory, which primarily consists of work in process, is included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory amounts written down as a result of excess, obsolescence, unmarketability or other reasons are charged to cost of sales, and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$76.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823612032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(542.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(535.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,734.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">270.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,689.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">476.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">476.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,638.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,330.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,308.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,971.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,160.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,811.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,727.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,607.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,120.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,264.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,385.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,879.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$747.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$814.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$385.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes the impact of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$176.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge related to our intangible asset associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below. Amortization and impairment of acquired intangible assets for 2018 also reflects the impact of impairment charges related to certain IPR&amp;D assets associated with our vixotrigine (BIIB074) program totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$189.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes the impact of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$328.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge related to our intangible assets associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. Amortization and impairment of acquired intangible assets for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> also includes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge related to our acquired and in-licensed rights and patents intangible asset associated with ZINBRYTA after the initiation of an European Medicines Agency (EMA) review (referred to as an Article 20 Procedure) of ZINBRYTA following the report of a case of fatal fulminant liver failure, as well as four cases of serious liver injury. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization and impairments of acquired intangible assets for the year ended December 31, 2016, included impairment charges of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;related to two of our IPR&amp;D intangible assets resulting from the termination of our collaboration agreements with Rodin Therapeutics, Inc. and Ataxion Inc.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amortization of acquired intangible assets, excluding impairment charges, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$381.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$455.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$373.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Out-licensed Patents</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents to third-parties primarily relate to patents acquired in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Developed Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. The net book value of this asset, as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$265.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">IPR&amp;D represents the fair value assigned to research and development assets that we acquired and had not reached technological feasibility at the date of acquisition. Upon commercialization, we will determine the estimated useful life and amortize these amounts based upon an economic consumption method. The carrying value associated with our IPR&amp;D assets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, relates to the various IPR&amp;D programs we acquired in connection with our acquisitions of Convergence Pharmaceuticals (Convergence), Stromedix Inc. (Stromedix) and Biogen International Neuroscience GmbH (BIN) in 2015, 2012 and 2010, respectively. IPR&amp;D balances include adjustments related to foreign currency exchange rate fluctuations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of anticipated lifetime revenues and anticipated development costs is performed annually during our long-range planning cycle, which was most recently updated in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.&#160;This analysis is based upon certain assumptions that we evaluate on a periodic basis, including anticipated future product sales, the expected impact of changes in the amount of development costs and the probabilities of our programs succeeding, the introduction of new products by our competitors and changes in our commercial and pipeline product candidates.&#160;&#160;</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Vixotrigine</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints; therefore, we discontinued development of vixotrigine for the treatment of PLSR and we recognized an impairment charge of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the related IPR&amp;D intangible asset to zero. In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the treatment of TGN as we awaited the outcome of ongoing interactions with the FDA regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the treatment of PLSR and insights from the Phase 2 study of vixotrigine for the treatment of small fiber neuropathy. We reassessed the fair value of our vixotrigine program for the treatment of TGN using reduced expected lifetime revenues, higher expected clinical development costs and lower cumulative probabilities of success, and, as a result of that assessment, we recognized an impairment charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$129.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the third quarter of 2018 to reduce the fair value of the IPR&amp;D intangible asset associated with our vixotrigine program for the treatment of TGN to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$41.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In late December 2018 we received feedback from the FDA regarding the design of the Phase 3 vixotrigine program for the treatment of TGN. Following this feedback, we are now planning to initiate the Phase 3 vixotrigine program for the treatment of TGN.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The IPR&amp;D impairment charges that resulted from the developments in our vixotrigine program for the treatment of TGN, as discussed above, were included in amortization and impairment of acquired intangible assets. The fair value of the intangible assets were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues, costs and probabilities of success.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may recognize additional impairment charges in the future depending upon our ability to advance vixotrigine for the treatment of TGN or other indications. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Acquired and In-licensed Rights and Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan. Acquired and in-licensed rights and patents also includes our U.S and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, as discussed below, and other amounts related to our other marketed products and other programs acquired through business combinations. The net book value of the TYSABRI asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2,027.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">TECFIDERA License Rights</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017. Pursuant to this agreement, we obtained U.S. and rest of world licenses to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA. In exchange, we paid Forward Pharma&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.25 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;in cash, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$795.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded within intangible assets in the first quarter of 2017. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have two intellectual property disputes with Forward Pharma, one in the U.S. and one in the E.U., concerning intellectual property related to TECFIDERA. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the U.S. intellectual property dispute was decided in our favor. Forward Pharma appealed to the U.S. Court of Appeals for the Federal Circuit. We evaluated the recoverability of the U.S. asset acquired from Forward Pharma and recorded a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$328.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge in the first quarter of 2017 to adjust the carrying value of the acquired U.S. asset to fair value reflecting the impact of the developments in the U.S. legal dispute and continued to amortize the remaining net book value of the U.S. intangible asset in our consolidated statements of income utilizing an economic consumption model. The U.S. Court of Appeals for the Federal Circuit upheld the U.S. Patent and Trademark Office&#8217;s (USPTO) March 2017 ruling and in January 2019 denied Forward Pharma's petition for rehearing. We evaluated the recoverability of the U.S. asset based upon these most recent developments recorded a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$176.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> impairment charge in the fourth quarter of 2018 to reduce the remaining net book value of the U.S. asset to zero.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the European Patent Office (EPO) revoked Forward Pharma&#8217;s European Patent No. 2 801 355. Forward Pharma has filed an appeal to the Technical Board of Appeal of the EPO and the appeal is pending. Based upon our assessment of this ruling, we continue to amortize the remaining net book value of the rest of world intangible asset in our consolidated statements of income utilizing an economic consumption model. The remaining net book value of the TECFIDERA intangible asset as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$71.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on these disputes, please read Note 21, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Litigation,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Estimated Future Amortization of Intangible Assets</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#679acb;font-style:italic;"> </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant intangible assets are related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products and other programs acquired through business combinations. Annually, during our long-range planning cycle, we perform an analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products. This analysis is also updated whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of any of these products. Impairments are recorded in the period in which they are incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our most recent long-range planning cycle was completed in the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">270.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">290.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,632.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,669.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(314.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,080.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,267.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,706.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,632.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The elimination of goodwill represents an allocation based upon the relative enterprise fair value of our hemophilia business as of February 1, 2017. For additional information on the spin-off of our hemophilia business, please read Note 3, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The increase to goodwill during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was related to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent milestones achieved (exclusive of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$119.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$232.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in tax benefits), respectively, and payable to the former shareholders of Fumapharm AG and holders of their rights. In the fourth quarter of 2018 we achieved the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales level threshold and accrued our last </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment related to FUMADERM and TECFIDERA (together, the Fumapharm Products), which will be paid in the first quarter of 2019. For additional information on contingent payments to the former shareholders of Fumapharm AG and holders of their rights, please read Note 22, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other includes changes related to foreign currency exchange rate fluctuations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> accumulated impairment losses related to goodwill.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823687888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,459.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,459.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">969.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">969.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">615.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">563.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,102.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,050.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">434.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,444.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,433.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">There have been </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> changes in valuation techniques or transfers between fair value measurement levels during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The fair value of Level 2 instruments classified as cash equivalents, marketable debt securities and our marketable equity security investment in Ionis Pharmaceuticals, Inc. (Ionis) were determined through third-party pricing services or an option pricing valuation model. For additional information on our new agreement with Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,489.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,517.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,745.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,851.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,802.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,077.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,037.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica AG, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs that were payable to Fumedica AG in varying amounts from June 2008 through June 2018. In June 2018 we redeemed our remaining note payable to Fumedica AG.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our notes payable to Fumedica AG, as of December 31, 2017, was estimated using market observable inputs, including current interest and foreign currency exchange rates. The fair value for each series of our Senior Notes was determined through market, observable and corroborated sources. For additional information on our debt instruments, please read Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and BIN in 2015, 2012 and 2010, respectively, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(12.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(101.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$265.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$279.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our consolidated balance sheets with the remaining balance reflected as a component of accrued expenses and other. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations were primarily due to delays in the expected timing of achievement of milestones related to our vixotrigine program for the treatment of TGN and an increase in discount rates used to revalue our contingent consideration liabilities, partially offset by the passage of time. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, payments and other reflects a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment made to the former shareholders of Stromedix, as discussed below. For additional information on our IPR&amp;D intangible asset related to our vixotrigine program for the treatment of TGN, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, changes in the fair value of our contingent consideration obligations are primarily due to changes in the expected timing and probabilities of success related to the achievement of certain development milestones and changes in the discount rate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of the intangible assets and contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs including estimated revenues and probabilities of success. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Convergence Pharmaceuticals Ltd.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence in February 2015 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$274.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This valuation was based on probability weighted net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$450.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was the estimated cost of debt financing for market participants. This liability reflected the revised estimate from the date of acquisition for our initial clinical development plans, resulting probabilities of success and the timing of certain milestone payments. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$246.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$259.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash flow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$400.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in our contingent consideration obligation was primarily due to delays in the expected timing of achievement of milestones related to our vixotrigine program for the treatment of TGN and an increase in discount rates used to revalue our contingent consideration liabilities, partially offset by the passage of time. Accrued expenses and other in our consolidated balance sheets include </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$144.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as we expect to make the payment within one year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Stromedix Inc.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Stromedix in March 2012 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$122.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$83.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$162.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$306.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in our contingent consideration obligation was primarily due to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone paid to the former shareholders of Stromedix as we dosed our first patient in the Phase 2b study of BG00011 (STX-100) in idiopathic pulmonary fibrosis in September 2018, changes in the expected timing related to the achievement of certain remaining developmental milestones and an increase in discount rates, partially offset by the passage of time. No amounts are reflected as a current liability in our consolidated balance sheets as we do not expect to make a payment in the next year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Biogen Idec International Neuroscience GmbH</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of BIN in December 2010 we recorded a contingent consideration obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$81.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the fair value of this contingent consideration obligation was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$102.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our most recent valuation was determined based upon net cash outflow projections of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$335.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, probability weighted and discounted using a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.8%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which is a measure of the credit risk associated with settling the liability. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the net decrease in our contingent consideration obligation was primarily due to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> development milestone paid in the first quarter of 2018 as we dosed our first patient in our Phase 2 SPARK study of BIIB054 (&#945;-synuclein mAb) in Parkinson's disease in January 2018 and an increase in discount rates, partially offset by the passage of time. No amounts are reflected as a current liability in our consolidated balance sheets as we do not expect to make a payment in the next year.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acquired IPR&amp;D</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisition of Convergence, we also allocated </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$424.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the total purchase price to acquired IPR&amp;D, which was capitalized as an intangible asset. The amount allocated to acquired IPR&amp;D was based on significant inputs not observable in the market and thus represented a Level 3 fair value measurement. These assets will be tested for impairment annually until commercialization, after which time the acquired IPR&amp;D will be amortized over its estimated useful life using the economic consumption method. During the third quarter of 2018 we recognized impairment charges related to certain IPR&amp;D assets associated with our vixotrigine program totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$189.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our IPR&amp;D intangible assets related to our vixotrigine program, including a discussion of our most significant assumptions, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823612032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">279.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">948.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">194.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">247.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and our short-term debt securities approximate fair value due to their short-term maturities. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon the adoption of ASU 2016-01, our marketable equity securities gains (losses) are recorded in other income (expense), net in our consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available for sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,607.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,608.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">851.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">854.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">706.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">263.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">264.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">615.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">127.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">496.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,570.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,569.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">845.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Contractual Maturities: Available-for-Sale Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,313.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,314.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,115.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,116.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,232.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,235.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The average maturity of our marketable debt securities available-for-sale as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;months and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">17</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> months, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Proceeds from Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,173.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,565.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,378.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to impairments recognized on certain of our available-for-sale marketable debt securities, sales of agency mortgage-backed securities, corporate bonds and government securities. Realized losses for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Strategic Investments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our strategic investment portfolio was comprised of investments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which are included in investments and other assets in our consolidated balance sheets. The increase in our strategic investment portfolio is primarily a result of our investment in Ionis' common stock, as discussed below. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies and venture capital funds where the underlying investments are in equity securities of certain biotechnology companies. Our investments in equity securities of certain publicly-traded biotechnology companies are regularly measured and carried at fair value and classified as Level 1 marketable equity securities within our disclosures included in Note 8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Ionis Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we closed a new </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year exclusive agreement with Ionis to develop novel antisense oligonucleotide (ASO) drug candidates for a broad range of neurological diseases (the 2018 Ionis Agreement) for a total payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and the purchase of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Ionis' common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$625.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Ionis' common stock is remeasured each reporting period and carried at fair value as a Level 2 marketable equity security due to certain holding period restrictions. The effect of these holding period restrictions are estimated using an option pricing valuation model. The most significant assumptions within the model are the term of the restrictions and the stock price volatility, which is based upon historical volatility of similar companies. We also use a constant maturity risk-free interest rate to match the remaining term of the restrictions on our investment in Ionis' common stock and a dividend yield of zero based upon the fact that Ionis and similar companies generally have not historically granted cash dividends.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on the 2018 Ionis Agreement, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we exercised our option under our joint venture agreement with Samsung BioLogics to increase our ownership percentage in Samsung Bioepis from approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), which is classified as a component of investments and other assets within our consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -URI http://asc.fasb.org/topic&amp;trid=2122426<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823609056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Derivative Instruments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU 2017-12. We adopted this standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this standard resulted in additional disclosures and a change in the income statement classification with respect to where we recognize cash flow hedge ineffective or excluded hedge transaction gains and losses. For additional information on this standard, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies - New Accounting Pronouncements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due to the global nature of our operations, portions of our revenues and operating expenses are recorded in currencies other than the U.S.&#160;dollar. The value of revenues and operating expenses measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, we use foreign currency forward contracts to lock in exchange rates associated with a portion of our forecasted international revenues and operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign currency forward contracts in effect, as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenues when the sale of product in the currency being hedged is recognized and in operating expenses when the expense in the currency being hedged is recorded. Prior to the adoption of ASU 2017-12 on January 1, 2018, to the extent ineffective or excluded, cash flow hedge transaction gains and losses were reported in other income (expense), net. Effective January 1, 2018, we recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of any cash flow hedge ineffectiveness or excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,701.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,875.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">131.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">98.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,239.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,198.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$113.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$49.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We expect the net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to be settled over the next </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenues or operating expenses. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, credit risk did not change the fair value of our foreign currency forward contracts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Year&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized Directly into Net Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Interest Rate Contracts - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have entered into interest rate lock contracts or interest rate swap contracts on certain borrowing transactions to manage our exposure to interest rate changes and to reduce our overall cost of borrowing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interest Rate Swap Contracts</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the issuance of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes, as described in Note 12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Indebtedness</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements, we entered into interest rate swaps with an aggregate notional amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$675.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which expire on September 15, 2020. The interest rate swap contracts are designated as hedges of the fair value changes in our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes attributable to changes in interest rates. Since the specific terms and notional amount of the swaps match the debt being hedged, it is assumed to be a highly effective hedge and all changes in the fair value of the swaps are recorded as a component of our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes with no net impact recorded in income. Any net interest payments made or received on the interest rate swap contracts are recorded as a component of interest expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Net Investment Hedges - Hedging Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis is exposed to the currency fluctuations in the South Korean won. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In order to mitigate these currency fluctuations between the U.S. dollar and South Korean won, we have entered into foreign currency forward contracts. Foreign currency forward contracts in effect as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, had remaining durations of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10 months</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. These contracts have been designated as net investment hedges. Since the critical terms of the investment and the foreign currency forward contracts match, these contracts are assumed to be highly effective. We recognize changes in the spot exchange rate in accumulated other comprehensive income (loss) (referred to as AOCI in the table below). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We exclude fair value changes related to the forward rate from our hedging relationship and will amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedge in our consolidated financial statements:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">For the Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net Gains/(Losses) Recognized in AOCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (Losses) on Net Investment Hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net Gains/(Losses) Reclassified from AOCI into Net Income </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Foreign Currency Forward Contracts - Other Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The aggregate notional amount of these outstanding foreign currency contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$735.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$564.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net gains of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and net losses of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to these contracts were recorded as a component of other income (expense), net, for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Summary of Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823612032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Property, Plant and Equipment</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">144.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">141.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,282.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,213.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">94.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,258.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,207.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">798.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">767.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,758.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,276.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,398.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,741.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,797.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,601.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,182.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation expense totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$269.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$266.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$309.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we capitalized interest costs related to construction in progress totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$54.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The increase in capitalized interest costs is primarily due to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, as discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. Upon completion, the facility will include 393,000&#160;square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.6 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, capitalized as construction in progress related to this facility.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823576000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Indebtedness</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,480.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,482.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">995.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">994.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,737.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,736.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,722.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,722.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,935.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">6.875% Senior Notes due March 1, 2018</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">On March 4, 2008, we issued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$550.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.875%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due March 1, 2018, at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">99.184%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par. These notes were senior unsecured obligations. We also entered into interest rate swap contracts where we received a fixed rate and paid a variable rate. These contracts were terminated in December 2008. Upon termination of these interest rate swap contracts, the carrying amount of these Senior Notes increased by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$62.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, with this amount being amortized using the effective interest rate method over the remaining life of the Senior Notes and recognized as a reduction of interest expense.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we redeemed these Senior Notes prior to their maturity and recognized a net charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the extinguishment of these Senior Notes. This charge, which was recognized in interest expense in other income (expense), net in our consolidated statements of income for the year ended December 31, 2017, reflects the payment of a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> early call premium and the write-off of remaining unamortized original debt issuance costs and discount balances, partially offset by a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> gain related to the remaining unamortized balance of the interest rate swap liability discussed above.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Notes payable to Fumedica AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our 2006 distribution agreement with Fumedica AG, we issued notes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">61.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Swiss Francs that were payable to Fumedica AG in varying amounts from June 2008 through June 2018. In June 2018 we redeemed our remaining note payable to Fumedica AG.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">2015 Senior Notes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following is a summary of our principal indebtedness as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2020, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.792%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">3.625%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2022, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.920%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">4.05%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15, 2025, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.764%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1.75 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5.20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes due September 15,&#160;2045, valued at </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">99.294%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of par.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The costs associated with these offerings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$47.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> have been recorded as a reduction to the carrying amount of the debt in our consolidated balance sheet. These costs along with the discounts will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These notes are senior unsecured obligations. These Senior Notes may be redeemed at our option at any time at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued interest and a specified make-whole amount. These Senior Notes contain a change of control provision that may require us to purchase the notes at a price equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">101%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes offering due in 2020, we entered into interest rate swap contracts. The carrying value of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.90%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Senior Notes as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to changes in the fair value of these contracts. For additional information on our interest rate contracts, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2015 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">five</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> outstanding borrowings and were in compliance with all covenants under this facility.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Debt Maturity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments due under our debt arrangements are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,000.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair value of our debt is disclosed in Note&#160;8, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurements,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823599088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Equity</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares of Preferred Stock authorized, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.75 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series A, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are authorized as Series X junior participating and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.25 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares are undesignated. Shares may be issued without a vote or action of shareholders from time to time in classes or series with the designations, powers, preferences, and the relative, participating, optional or other special rights of the shares of each such class or series and any qualifications, limitations or restrictions thereon as set forth in the instruments governing such shares. Any such Preferred Stock may rank prior to common stock as to dividend rights, liquidation preference or both, and may have full or limited voting rights and may be convertible into shares of common stock. No shares of Preferred Stock were issued and outstanding during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and 2016:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">221.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">197.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share Repurchases</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2018 Share Repurchase Program). Our 2018 Share Repurchase program does not have an expiration date. All share repurchases under our 2018 Share Repurchase Program will be retired. Under our 2018 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of our common stock (2016 Share Repurchase Program), which was completed as of June 30, 2018. All share repurchases under our 2016 Share Repurchase Program were retired. Under our 2016 Share Repurchase Program, we repurchased and retired approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2011 our Board of Directors authorized a program to repurchase up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock (2011 Share Repurchase Program), which was completed as of March 31, 2017. Share repurchases under our 2011 Share Repurchase Program were principally used to offset common stock issuances under our share-based compensation programs. Under our 2011 Share Repurchase Program, we repurchased approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$365.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We did not repurchase any shares of common stock under our 2011 Share Repurchase Program during the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts paid to repurchase shares in excess of their par value are allocated between additional paid-in capital and retained earnings, with payments in excess of our additional paid-in-capital balance recorded as a reduction to retained earnings.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973109232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Accumulated Other Comprehensive Income (Loss)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(318.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU 2016-01</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(316.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">97.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(67.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">29.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">41.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">139.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(67.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">76.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(243.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(240.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(193.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(162.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(104.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(318.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(92.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973075968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Earnings&#160;per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,430.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">205.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Earnings per share for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, reflects, on a weighted average basis, the repurchase of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of our common stock, respectively, under our 2018, 2016 and 2011 Share Repurchase Programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adjustments related to the spin-off of our hemophilia business did not have a material impact on the potentially dilutive securities to be considered in the calculation of diluted earnings per share of common stock.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973047888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Share-Based Payments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">105.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">121.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">181.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(27.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">142.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">117.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">135.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">126.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">107.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">181.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, unrecognized compensation cost related to unvested share-based compensation was approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$188.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, net of estimated forfeitures. We expect to recognize the cost of these unvested awards over a weighted-average period of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Spin-off Related Equity Adjustments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pursuant to an employee matters agreement entered into in connection with the spin-off of our hemophilia business and the provisions of our existing share-based compensation arrangements, we made certain adjustments to the number and terms of our outstanding stock options, RSUs, CSPUs and other share-based awards to preserve the intrinsic value of the awards immediately before and after the spin-off. For purposes of the vesting of these equity awards, continued employment or service with Biogen or with Bioverativ was treated as continued employment for purposes of both Biogen's and Bioverativ's equity awards with the outstanding awards continuing to vest over their respective original vesting periods. Outstanding equity awards for employees transferring to Bioverativ were converted to unvested Bioverativ equity awards.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments to the number of our share-based compensation awards were made using an adjustment ratio based upon the weighted-average closing price of our common stock for the 10 calendar days prior to the effective date of the spin-off and the volume-weighted average prices for the 10 calendar days of our common stock following the effective date of the spin-off. For stock options, the exercise prices of the awards were modified to maintain the pre-spin intrinsic value of the awards in relation to the post-spin stock price of Biogen. The difference between the fair value of the awards based upon the adjustment ratio and the opening price on the distribution date was not material.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Share-Based Compensation Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share-based compensation plans pursuant to which awards are currently being made: (i)&#160;the Biogen Inc. 2006 Non-Employee Directors Equity Plan (2006&#160;Directors Plan); (ii)&#160;the Biogen Inc. 2017 Omnibus Equity Plan (2017 Omnibus Equity Plan); and (iii)&#160;the Biogen Inc. 2015 Employee Stock Purchase Plan (2015 ESPP). </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Directors Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2006 our shareholders approved the 2006&#160;Directors Plan for share-based awards to our directors. Awards granted from the 2006&#160;Directors Plan may include stock options, shares of restricted stock, RSUs, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. We have reserved a total of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of common stock for issuance under the 2006&#160;Directors Plan. The 2006&#160;Directors Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares reserved under the plan in a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ratio. In June 2015 our shareholders approved an amendment to extend the term of the 2006 Directors Plan until June 2025.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Omnibus Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 our shareholders approved the 2017 Omnibus Equity Plan for share-based awards to our employees. Awards granted from the 2017 Omnibus Equity Plan may include stock options, shares of restricted stock, RSUs, performance shares, stock appreciation rights and other awards in such amounts and with such terms and conditions as may be determined by a committee of our Board of Directors, subject to the provisions of the plan. Shares of common stock available for grant under the 2017 Omnibus Equity Plan consist of&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;shares reserved for this purpose, plus shares of common stock that remained available for grant under our 2008 Omnibus Equity Plan as of June 7, 2017, or that could again become available for grant if outstanding awards under the 2008 Omnibus Equity Plan as of June 7, 2017, are cancelled, surrendered or terminated in whole or in part. The 2017 Omnibus Equity Plan provides that awards other than stock options and stock appreciation rights will be counted against the total number of shares available under the plan in a&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5-to-1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;ratio.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have not made any awards pursuant to the 2008 Omnibus Equity Plan since our shareholders approved the 2017 Omnibus Equity Plan, and do not intend to make any awards pursuant to the 2008 Omnibus Equity Plan in the future, except that unused shares under the 2008 Omnibus Equity Plan have been carried over for use under the 2017 Omnibus Equity Plan.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We currently do not grant stock options to our employees or directors. Outstanding stock options previously granted to our employees and directors generally have a 10-year term and vest over a period of between one and four years, provided the individual continues to serve at Biogen through the vesting dates. Options granted under all plans are exercisable at a price per share not less than the fair market value of the underlying common stock on the date of grant. The estimated fair value of options, including the effect of estimated forfeitures, is recognized over the options&#8217; vesting periods. The fair value of the stock options granted in 2010 was estimated as of the date of grant using a Black-Scholes option valuation model. There were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">no</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> grants of stock options made in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, all outstanding options were exercisable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The expected life of options granted is derived using assumed exercise rates based on historical exercise patterns and represents the period of time that options granted are expected to be outstanding. Expected stock price volatility is based upon implied volatility for our exchange-traded options and other factors, including historical volatility. After assessing all available information on either historical volatility, implied volatility or both, we have concluded that a combination of both historical and implied volatility provides the best estimate of expected volatility. The risk-free interest rate used is determined by the market yield curve based upon risk-free interest rates established by the Federal Reserve, or non-coupon bonds that have maturities equal to the expected term. The dividend yield of zero is based upon the fact that we have not historically granted cash dividends, and do not expect to issue dividends in the foreseeable future. Stock options granted prior to January&#160;1, 2006, were valued based on the grant date fair value of those awards, using the Black-Scholes option pricing model, as previously calculated for pro-forma disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">42,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.82</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total intrinsic values of options exercised in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. The aggregate intrinsic values of options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$6.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The weighted average remaining contractual term for options outstanding as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;years. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Market Stock Units (MSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees prior to 2014 vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">four</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">MSUs awarded to employees in 2014 and thereafter vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date, and participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on actual stock performance. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs earned is calculated at each annual anniversary from the date of grant over the respective vesting periods, resulting in multiple performance periods. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">171,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">370.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">129,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">378.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(91,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">365.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(29,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">376.51</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">180,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">371.32</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">MSUs granted during 2018 include awards granted in conjunction with our annual awards made in February 2018 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2018 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2017, 2016 and 2015.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We value grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price on the date of grant for MSUs, expected volatility of our stock price, risk-free rates of return and expected dividend yield.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assumptions used in our valuation are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.5% - 32.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.0% - 35.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.2% - 40.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.9% - 2.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9% - 1.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6% - 0.9%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$279.47 - $346.76</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$263.18 - $267.88</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.67 - $304.86</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$378.85</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.59</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$328.03</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of MSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Cash Settled Performance Units (CSPUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">CSPUs awarded to employees vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment with such awards settled in cash. The number of CSPUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December&#160;31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional CSPUs may be issued or currently outstanding CSPUs may be cancelled upon final determination of the number of units earned. CSPUs are classified as liability awards and will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date, once the actual vested and earned number of units is known. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">105,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(51,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">These shares reflect the CSPUs issued in 2018 based upon the attainment of performance criteria set for 2017 in relation to CSPUs granted in 2017.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The cash paid in settlement of CSPUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance-vested Restricted Stock Units (PUs)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">PUs are granted to certain employees in the form of RSUs that may be settled in cash or shares of our common stock at the sole discretion of the Compensation and Management Development Committee of our Board of Directors. These awards are structured and accounted for the same way as the CSPUs, and vest in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equal annual increments beginning on the first anniversary of the grant date. The number of PUs granted represents the target number of units that are eligible to be earned based on the attainment of certain performance measures established at the beginning of the performance period, which ends on December 31 of each year. Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of units granted based on the degree of actual performance metric achievement. Accordingly, additional PUs may be issued or currently outstanding PUs may be cancelled upon final determination of the number of units earned. PUs settling in cash are based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through each vesting date once the actual vested and earned number of units is known. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(52,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">These shares reflect the PUs issued in 2018 based upon the attainment of performance criteria set for 2017 in relation to PUs granted in 2017.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">All PUs that vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> were settled in cash totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Performance Stock Units (PSUs)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018 we began granting awards for performance-vested RSUs that will settle in stock. PSUs awarded to employees have a three-year performance period and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of cumulative three-year performance measures established at the beginning of the performance period, which ends on December 31 of the third year of the performance period. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in stock activity:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">317.09</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">315.70</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">317.26</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PSUs settled in stock granted in 2018 include awards granted in conjunction with our annual awards made in February 2018 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#00823b;font-style:italic;">PSUs Settled in Cash</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the first quarter of 2018 we began granting awards for performance-vested restricted stock units that will settle in cash. PSUs awarded to employees have three performance periods and vest on the third anniversary of the grant date. The vesting of these awards is subject to the respective employee&#8217;s continued employment. The number of PSUs granted represents the target number of units that are eligible to be earned based on the achievement of three annual performance measures established when the performance objectives are defined, which will be at the beginning of each year and will end on December 31 of such year. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Participants may ultimately earn between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">200%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the target number of PSUs granted based on the degree of achievement of the applicable performance metric. Accordingly, additional PSUs may be issued or currently outstanding PSUs may be cancelled upon final determination of the number of units earned. PSUs are classified as liability awards and will be settled in cash based on the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> calendar day average closing stock price through the vesting date, once the actual vested and earned number of PSUs is determined. Since no shares are issued, these awards do not dilute equity. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in cash activity:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">45,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">PSUs settled in cash granted in 2018 include awards granted in conjunction with our annual awards made in February 2018 and PSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Time-Vested Restricted Stock Units (RSUs)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs awarded to employees generally vest no sooner than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one-third per year over three years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on the anniversary of the date of grant, or upon the third anniversary of the date of the grant, provided the employee remains continuously employed with us, except as otherwise provided in the plan. Shares of our common stock will be delivered to the employee upon vesting, subject to payment of applicable withholding taxes. RSUs awarded to directors for service on our Board of Directors vest on the first anniversary of the date of grant, provided in each case that the director continues to serve on our Board of Directors through the vesting date. Shares of our common stock will be delivered to the director upon vesting and are not subject to any withholding taxes. The fair value of all RSUs is based on the market value of our stock on the date of grant. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">832,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">291.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">581,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.32</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(376,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">299.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(134,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">298.81</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">903,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">303.18</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">RSUs granted in 2018 primarily represent RSUs granted in conjunction with our annual awards made in February 2018 and awards made in conjunction with the hiring of new employees. RSUs granted in 2018 also include approximately </font><font style="font-family:Franklin Gothic Book;font-size:9pt;">9,000</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"> RSUs granted to our Board of Directors.</font></div></td></tr></table><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">RSUs granted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> had weighted average grant date fair values of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$293.41</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$268.52</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of RSUs vested in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$104.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.&#160; </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan (ESPP)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2015 our shareholders approved the 2015 ESPP. The 2015 ESPP, which became effective on July 1, 2015, replaced the Biogen Idec Inc. 1995 ESPP, which expired on June&#160;30, 2015. The maximum aggregate number of shares of our common stock that may be purchased under the 2015 ESPP is </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">167,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">190,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973121808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Income Taxes</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Income Tax Expense</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,877.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,540.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,655.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,022.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,588.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,277.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,899.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,128.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,933.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,131.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,201.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,304.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">45.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">140.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">108.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,317.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,367.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,412.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(62.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">241.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">177.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(159.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(45.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">108.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,425.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,458.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,237.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">2017 Tax Act</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Tax Cuts and Jobs Act of 2017 (2017 Tax Act) resulted in significant changes to the U.S. corporate income tax system. These changes include a federal statutory rate reduction from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the elimination or reduction of certain domestic deductions and credits and limitations on the deductibility of interest expense and executive compensation. The 2017 Tax Act also transitions international taxation from a worldwide system to a modified territorial system, which has the effect of subjecting certain earnings of our foreign subsidiaries to U.S. taxation as GILTI, and includes base erosion prevention measures on non-U.S. earnings. These changes became effective in 2018. During the fourth quarter of 2018 we elected to recognize deferred taxes for basis differences expected to reverse as GILTI is incurred and have established initial deferred tax balances, as of the enactment date of the 2017 Tax Act.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the fourth quarter of 2017 we recognized within our provision for income taxes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> provisional estimate pursuant to the U.S. Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 118. Our provisional estimate included an amount of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> associated with a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax), as discussed below, and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$184.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the impact of remeasuring our deferred tax balances to reflect the new federal statutory rate and other changes to U.S. tax law. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the year ended December 31, 2018, we recognized a net reduction of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our estimated Transition Toll Tax, an expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to remeasure our deferred tax balances, an expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$135.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to establishing deferred taxes for GILTI and an expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$11.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect other aspects of the 2017 Tax Act.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Transition Toll Tax</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The 2017 Tax Act eliminated the deferral of U.S. income tax on the historical unrepatriated earnings by imposing the Transition Toll Tax. The Transition Toll Tax was assessed on our share of our foreign corporations' accumulated foreign earnings that were not previously taxed. Earnings in the form of cash and cash equivalents were taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and all other earnings were taxed at a rate of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.0%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, under the Transition Toll Tax. The decrease in this liability is primarily attributed to our 2018 Transition Toll Tax payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$85.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the application by the U.S. Internal Revenue Service (IRS) of an approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> overpayment against the accrual and the impact of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> net reduction described above. Of the amounts accrued as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to the overpayment discussed above. The Transition Toll Tax will be paid in installments over an eight--year period, which started in 2018, and will not accrue interest.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Status of our Assessment</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The final determination of the Transition Toll Tax and the remeasurement of our deferred assets and liabilities was completed during the fourth quarter of 2018 under SEC Staff Accounting Bulletin No. 118. Throughout 2018 proposed regulations were issued by the IRS, which are expected to be finalized in 2019 and may have an impact on our income tax provision. We will assess the impact of any additional guidance when it is issued.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Unremitted Earnings</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">At </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we considered none of our earnings to be permanently reinvested outside the U.S. and therefore recorded deferred tax liabilities associated with an estimate of the total withholding taxes expected as a result of our repatriation of earnings. Other than for earnings, we are permanently reinvested for book/tax basis differences related to foreign subsidiaries. These differences are estimated to total approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and primarily arose through the impacts of purchase accounting. These basis differences could reverse through sales of the foreign subsidiaries, as well as various other events, none of which are considered probable as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The residual U.S. tax liability, if these differences would reverse, would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.3 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Article 20 Procedure of ZINBRYTA</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the Article 20 Procedure of ZINBRYTA, for the year ended December 31, 2017, we recognized a net impairment charge on certain tax assets related to ZINBRYTA reflected within income tax expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This charge reflected the write-off of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$142.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to prepaid taxes, which was partially offset by the recognition of an unrecorded deferred tax benefit of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. For additional information on our collaboration arrangement with AbbVie, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Tax Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">102.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">163.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,298.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">378.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">209.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,823.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">831.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(232.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(250.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(544.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,425.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(102.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(107.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,305.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(358.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to deferred tax assets and liabilities, we have recorded prepaid tax and deferred charges related to intra-entity transactions. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the total deferred charges and prepaid taxes were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$239.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$617.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU 2016-16. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date.&#160;Upon adoption, we recognized additional deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> offset by a corresponding increase to deferred tax liabilities, related to an expected reduction in future U.S. foreign tax credits of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and an increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> with a corresponding reduction to our retained earnings as these differences are related to inter-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 Tax Act</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment of ZINBRYTA related tax assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Changes in Tax Rate</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the decrease in our effective tax rate was primarily due to the enactment of the 2017 Tax Act. The effects of an overall reduction in the federal statutory rate in the U.S. were partially offset by the elimination of the manufacturing deduction, the imposition of the GILTI tax on international earnings, our recording of deferred taxes on GILTI in 2018, limits on the deductibility of certain benefits on executive compensation and a reduction in the tax benefit associated with the Orphan Drug Credit, all resulting from the 2017 Tax Act, and a change in accounting rules related to recording the tax impacts of intra-entity transactions. Included in taxes on foreign earnings in the above rate reconciliation for 2018 was an increase of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">350</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> basis points related to the sale of inventory, the tax effect of which had been included within prepaid taxes at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at a higher effective tax rate. The effective tax rate for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, also reflected the impact of a favorable settlement related to a state tax matter in 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, as compared to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the most significant factors contributing to the increase in our effective tax rate was the effect of the enactment of the 2017 Tax Act and the impairment of certain ZINBRYTA related tax assets, both of which are discussed above. Excluding the effect of these items, our income tax rate would have decreased due to a lower percentage of our earnings being recognized in the U.S., a higher tax jurisdiction. The geographic split of our earnings was affected by milestone and upfront payments in the current year and the spin-off of our hemophilia business, partially offset by growth from the U.S. launch of SPINRAZA and increases in our revenues from anti-CD20 therapeutic programs in the U.S. In addition, in 2017 we earned a lower benefit from the Orphan Drug Credit due to the FDA's approval of SPINRAZA.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Tax Attributes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had net operating losses and general business credit carry forwards for federal income tax purposes of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which begin to expire in 2022. Additionally, for state income tax purposes, we had net operating loss carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that begin to expire in 2020. For state income tax purposes, we also had research and investment credit carry forwards of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$133.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> that begin to expire in 2019. For foreign income tax purposes, we had </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.2 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of net operating loss carryforwards that begin to expire in 2024.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In assessing the realizability of our deferred tax assets, we have considered whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. In making this determination, under the applicable financial reporting standards, we are allowed to consider the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies. Our estimates of future taxable income take into consideration, among other items, our estimates of future income tax deductions related to the exercise of stock options. Based upon the level of historical taxable income and income tax liability and projections for future taxable income over the periods in which the deferred tax assets are utilizable, we believe it is more likely than not that we will realize the net benefits of the deferred tax assets of our wholly owned subsidiaries. In the event that actual results differ from our estimates or we adjust our estimates in future periods, we may need to establish a valuation allowance, which could materially impact our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accounting for Uncertainty in Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">58.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement refund (payment)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(64.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">114.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our 2017 activity above reflects a refund received from a state, related to the settlement of an uncertain tax position.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2013 or state, local or non-U.S. income tax examinations for years before 2010.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Included in the balance of unrecognized tax benefits as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, are </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> (net of the federal benefit on state issues), respectively, of unrecognized tax benefits that, if recognized, would affect the effective income tax rate in future periods. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize potential interest and penalties accrued related to unrecognized tax benefits in income tax expense. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, 2017 and 2016 we recognized a net interest expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$9.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We have accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$13.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the payment of interest and penalties as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">International Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have made payments totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to the Danish Tax Authority (SKAT) for assessments received for 2009, 2011 and 2013 regarding withholding taxes and the treatment of certain intercompany transactions involving a Danish affiliate and another of our affiliates. We continue to dispute the assessments for all of these periods and believe that the positions taken in our historical filings are valid. It is reasonably possible that we will adjust the value of our uncertain tax positions related to Danish withholding taxes based on potential European court decisions expected in 2019 on similar matters.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Federal and State Uncertain Tax Positions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823665904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Other Consolidated Financial Statement Detail</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Supplemental Cash Flow Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">243.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,007.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,066.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,642.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-cash Operating, Investing and Financing Activity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the fourth quarter of 2018 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of the Fumapharm Products, which will be paid in the first quarter of 2019. In the fourth quarter of 2017 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$600.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon reaching </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total cumulative sales of the Fumapharm Products, which was paid in the first quarter of 2018. These amounts, net of tax benefit, were accounted for as increases to goodwill in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. For additional information on the contingent payments to the former shareholders of Fumapharm AG and holders of their rights, please read Note 22, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Commitments and Contingencies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland, we accrued charges related to processing equipment and engineering services of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated balance sheets as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. For additional information on the construction of our manufacturing facility in Solothurn, Switzerland, please read Note 11,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Property, Plant and Equipment,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2016 we accrued </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$454.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the settlement and license agreement with Forward Pharma. For additional information on the settlement and license agreement with Forward Pharma, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Income (Expense), Net</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">112.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(200.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(250.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(260.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">119.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(18.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(217.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(218.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, gain (loss) on investments, net, as reflected in the table above, substantially relate to marketable equity securities held at </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Current Assets</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$687.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$962.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and include prepaid taxes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$271.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$657.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Investments and other assets</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,690.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$563.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to our investments in Samsung Bioepis and Ionis, respectively. For additional information on our collaboration arrangements with Samsung Bioepis and Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Accrued Expenses and Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">874.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">444.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">320.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">297.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">224.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">206.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">125.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">159.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">261.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">609.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">636.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,861.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Long-term Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,389.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,628.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and include accrued income taxes totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$791.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$979.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973264512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our business strategy, we have entered into various collaboration agreements that provide us with rights to develop, produce and market products using certain know-how, technology and patent rights maintained by our collaborative partners. Terms of the various collaboration agreements may require us to make milestone payments upon the achievement of certain product research and development objectives and pay royalties on future sales, if any, of commercial products resulting from the collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depending on the collaborative arrangement, we may record funding receivable or payable balances with our partners, based on the nature of the cost-sharing mechanism and activity within the collaboration. Our significant collaboration arrangements are discussed below.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Genentech, Inc. (Roche Group)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of PPMS and RMS and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration arrangements will continue in effect until we mutually agree to terminate the collaboration, except that if we undergo a change in control, as defined in our collaboration agreement, Genentech has the right to present an offer to buy the rights to RITUXAN and we must either accept Genentech&#8217;s offer or purchase Genentech&#8217;s rights on the same terms as its offer. Genentech will also be deemed concurrently to have purchased our rights to any other anti-CD20 products in development in exchange for a royalty and our rights to GAZYVA in exchange for the compensation described in the table below. Our collaboration with Genentech was created through a contractual arrangement and not through a joint venture or other legal entity.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">RITUXAN</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN, as well as all development and commercialization activities as follows:</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">U.S.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Canada</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">GAZYVA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. We recognize our share of the development and commercialization expenses of GAZYVA as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercialization of GAZYVA impacts our percentage of the co-promotion profits for RITUXAN, as summarized in the table below.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">OCREVUS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FDA approved OCREVUS for the treatment of RMS and PPMS. Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and increasing up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">24%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if annual net sales exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$900.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. There will be a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction to these royalties if a biosimilar to OCREVUS is approved in the U.S. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we receive a gross </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11 years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the first commercial sale of OCREVUS on a country-by-country basis. OCREVUS has been approved for the treatment of RMS and PPMS in the E.U. and certain other countries. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis. OCREVUS royalty revenues were based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenues will be adjusted for in the period in which they become known, which is expected to be the following quarter.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Profit-sharing Formulas</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">RITUXAN Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax co-promotion profit-sharing formula for RITUXAN provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of co-promotion operating profits earned each calendar year. Our share of annual co-promotion profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of RITUXAN pre-tax profits in the U.S. decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">40%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in February 2016 when GAZYVA was approved by the FDA as a new treatment for follicular lymphoma and further decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12-month period exceeded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, should the FDA approve an anti-CD20 product other than OCREVUS or GAZYVA that is acquired or developed by Genentech and subject to the collaboration agreement, our share of the co-promotion operating profits would be between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on certain events.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">GAZYVA Profit Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our current pretax profit-sharing formula for GAZYVA provides for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share on the first </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of operating profits earned each calendar year. Our share of annual profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> GAZYVA profit-sharing threshold was met during the third quarter. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> our share of operating profits on GAZYVA was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 the FDA approved GAZYVA in combination with chemotherapy, followed by GAZYVA alone, for people with previously untreated advanced follicular lymphoma.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,431.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,316.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> RITUXAN profit-sharing threshold was met during the first quarter. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> profit-sharing threshold was met during the first quarter and further decreased to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">37.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2017 as gross sales of GAZYVA in the U.S. for the preceding 12-month period exceeded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> profit-sharing threshold was met during the first quarter.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we record our share of the expenses incurred by the collaboration for the development of anti-CD20 products in research and development expense in our consolidated statements of income. After an anti-CD20 product is approved, we record our share of the development expenses related to that product as a reduction of our share of pre-tax profits in revenues from anti-CD20 therapeutic programs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Ionis Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Collaborations </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2012 we entered into an exclusive worldwide option and collaboration agreement with Ionis to develop and commercialize SPINRAZA for the treatment of SMA. SPINRAZA was approved for the treatment of SMA in the U.S., E.U. and Japan in December 2016, June 2017 and July 2017, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized product revenues of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,724.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$883.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, on our sales of SPINRAZA. Under our agreement with Ionis, we make royalty payments to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recognized in cost of sales within our consolidated statements of income. Royalty cost of sales related to sales of SPINRAZA for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$238.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$112.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During the third quarter of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, upon the exercise of our option to develop and commercialize SPINRAZA, we paid a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee to Ionis, which was recorded as research and development expense in our consolidated statements of income. In addition, during </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we made milestone payments to Ionis totaling&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;related to the marketing approvals discussed above, which were capitalized in intangible assets, net in our consolidated balance sheets.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> no clinical trial payments were made to Ionis due to the completion of study activities. During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we made clinical trial payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the advancement of the program, which were recorded in investments and other assets in our consolidated balance sheets as they represented prepaid research and development expenditures. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, these prepaid research and development amounts were fully expensed as the services were provided.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$285.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$234.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$257.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reflected in total costs and expenses in our consolidated statements of income related to the advancement and commercialization of the program. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Antisense Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2012 we entered into an agreement with Ionis for the development and commercialization of up to three therapeutic targets. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, Ionis is responsible for global development of any product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. We have an option to license the product candidate</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">until completion of the Phase 2 trial. If we exercise our option, we will pay a license fee of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis and assume global development, regulatory and commercialization responsibilities. Ionis is eligible to receive up to another </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in milestone payments upon the achievement of certain regulatory milestones as well as royalties on future sales</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt"> </sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis and agreed to make potential additional payments, prior to licensing, of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> based on the development of the selected product candidate as well as a mark-up of the cost estimate of the Phase 1 and Phase 2 trials. During 2015 we recognized this </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone upon the selection of BIIB080 (also known as IONIS-MAPT</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), which is currently in Phase 1 development for the treatment of AD. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Research Collaborations</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">2018 Ionis Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2018 we closed the 2018 Ionis Agreement, which is a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year exclusive agreement with Ionis to develop novel ASO drug candidates for a broad range of neurological diseases for a total payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, consisting of an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and the purchase of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Ionis' common stock at a cost of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$625.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon closing, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$375.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment as prepaid services in our consolidated balance sheets and recognized the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$324.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as research and development expense in our consolidated statements of income. The amount recorded as prepaid services represented the value of the employee resources committed to the arrangement to provide research and discovery services over the term of the agreement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Ionis' common stock were purchased at a premium to their fair value at the transaction closing date. The premium consisted of acquiring the shares at a price above the fair value based on the trailing 10-day weighted-average close price prior to entering into the 2018 Ionis Agreement in April 2018 and the effect of certain holding period restrictions. We recorded an asset of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$462.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in investments and other assets in our consolidated balance sheets reflecting the fair value of the common stock as of the purchase date and a charge of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$162.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to research and development expense in our consolidated statements of income in the second quarter of 2018 reflecting the premium paid for the common stock. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investment in Ionis' common stock is remeasured each reporting period. Changes in the fair value of our investment in Ionis' common stock, including the effect of the holding period restrictions, are reflected in other income (expense), net in our consolidated statements of income. For additional information on the fair value of our investment in Ionis' common stock, please read Note 9, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have the option to license therapies arising out of this agreement and will be responsible for the development and commercialization of such therapies. We may pay development milestones to Ionis of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$125.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$270.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for each program, depending on the indication plus an annual license fee, as well as royalties on potential net commercial sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">2017 SMA Collaboration Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2017 we entered into a new collaboration agreement with Ionis to identify new ASO drug candidates for the treatment of SMA. Under this agreement, we have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization of these therapies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment to Ionis and we may pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional development and regulatory milestone payments if new drug candidates advance to marketing approval. Upon commercialization, we may also pay Ionis up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$800.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">2013 Long-term Strategic Research Agreement</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2013 we entered into a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">six</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">-year research collaboration agreement with Ionis under which both companies collaborate to perform discovery level research and subsequent development and commercialization activities of antisense or other therapeutics for the treatment of neurological diseases.&#160;Under this agreement, Ionis performs research on a set of neurological targets identified within the agreement. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ionis is eligible to receive milestone payments, license fees and royalty payments for all product candidates developed through this collaboration, with the specific amount dependent upon the modality of the product candidate advanced by us under the terms of the 2013 agreement. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For non-ALS antisense product candidates, Ionis will be responsible for global development through the completion of a Phase 2 trial and we will provide advice on the clinical trial design and regulatory strategy. For ALS antisense product candidates, we are responsible for global development, clinical trial design and regulatory strategy. We have an option to license a product candidate until completion of the Phase 2 trial. If we exercise our option, we will pay Ionis up to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> license fee and assume global development, regulatory and commercialization responsibilities. Ionis could receive additional milestone payments upon the achievement of certain regulatory milestones of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$130.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, plus additional amounts related to the cost of clinical trials conducted by Ionis under the collaboration, and royalties on future sales if we successfully develop the product candidate after option exercise. </font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB067 (IONIS-SOD1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:pt">Rx</sub></font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), an investigational treatment for ALS with superoxide dismutase 1 (SOD1) mutations. In connection with the option exercise, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis. Future payments may include potential post-licensing milestone payments of up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$55.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and royalties in the low to mid-teen percentages on potential annual worldwide net sales. We are solely responsible for the costs and expenses related to the development, manufacturing and commercialization of BIIB067 following the option exercise. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we incurred milestones of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$53.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to the advancement of BIIB067 and other neurological targets identified.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Eisai Co., Ltd. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">BAN2401 and Elenbecestat Collaboration</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize BAN2401, a monoclonal antibody that targets amyloid beta aggregates, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the treatment of AD (the BAN2401 and Elenbecestat Collaboration). Eisai serves as the global operational and regulatory lead for BAN2401 and elenbecestat and all costs, including research, development, sales and marketing expenses, are shared equally between us and Eisai; and, if applicable, upon marketing approval in major markets, such as the U.S., the E.U. and Japan, we and Eisai will co-promote BAN2401 and elenbecestat and share profits equally. In smaller markets, Eisai will distribute these products and pay us a royalty. In addition, the BAN2401 and Elenbecestat Collaboration provides both parties with certain rights and obligations in the event of a change in control of either party.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The BAN2401 and Elenbecestat Collaboration also provided Eisai with an option to jointly develop and commercialize aducanumab, our anti-amyloid beta antibody candidate for the treatment of AD (Aducanumab Option), and an option to jointly develop and commercialize one of our anti-tau monoclonal antibodies (Anti-Tau Option). Upon exercise of each of the Aducanumab Option and the Anti-Tau Option, a separate collaboration agreement would be entered into with Eisai on terms and conditions that mirror the BAN2401 and Elenbecestat Collaboration agreement. Eisai has not yet exercised its Anti-Tau Option.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 Eisai exercised its Aducanumab Option and we entered into a new collaboration agreement for the joint development and commercialization of aducanumab (Aducanumab Collaboration Agreement).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the Aducanumab Collaboration Agreement, the two companies will continue to jointly develop BAN2401 and elenbecestat in accordance with the BAN2401 and Elenbecestat Collaboration; however, we are no longer required to pay Eisai any milestone payments for products containing BAN2401 and we are no longer entitled to any potential development and commercial milestone payments from Eisai in relation to aducanumab. The two companies will co-promote aducanumab with a region-based profit split and we will continue to lead the ongoing Phase 3 development of aducanumab.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, sales and marketing expenses related to the BAN2401 and Elenbecestat Collaboration were immaterial. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">232.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">146.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">116.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, during the fourth quarter of 2016 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment related to the initiation of a Phase 3 trial for elenbecestat, which is included in research and development expense in our consolidated statements of income. We could pay Eisai up to an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$625.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under the BAN2401 and Elenbecestat Collaboration based on the future achievement of certain development, regulatory and commercial milestones.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Aducanumab Collaboration Agreement</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the period through March 31, 2018, we were responsible for 100% of development costs incurred by the collaboration for the advancement of aducanumab (aducanumab development expense). For the period April 1, 2018 through December 31, 2018, Eisai reimbursed us for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of aducanumab development expense incurred and beginning January 1, 2019, is reimbursing us for </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">45%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of aducanumab development expense incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon commercialization, both companies will co-promote aducanumab with a region-based profit split. We will receive a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in the U.S., a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">68.5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in the E.U. and a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the potential profits (losses) in Japan and Asia, excluding China and South Korea. The two companies will continue to share equally in the potential profits (losses) in rest of world markets. Sales and marketing expense incurred before commercialization are shared in proportion to the same region-based profit split that will be utilized to co-promote aducanumab.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">264.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">268.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">209.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">268.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">209.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">27.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Anti-Tau Option</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Eisai may exercise the Anti-Tau Option after completion of the Phase 1 clinical trial of such anti-tau monoclonal antibody. If Eisai exercises its Anti-Tau Option, we will receive an upfront payment from Eisai and will be entitled to additional development and commercial milestone payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Alkermes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 we entered into an exclusive license and collaboration agreement with Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc (Alkermes), for diroximel fumarate (BIIB098), a novel fumarate in Phase 3 development for the treatment of RMS. In December 2018 Alkermes submitted a New Drug Application (NDA) to the FDA for diroximel fumarate. Alkermes is seeking approval of diroximel fumarate under the 505(b)(2) regulatory pathway. If approved, we intend to market diroximel fumarate under the brand name VUMERITY. This name has been conditionally accepted by the FDA and will be confirmed upon approval.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received an exclusive, worldwide license to develop and commercialize diroximel fumarate and will pay Alkermes a mid-teens percentage royalty on potential worldwide net commercial sales of diroximel fumarate. Royalties payable on net commercial sales of diroximel fumarate are subject, under certain circumstances, to tiered minimum payment requirements for a period of five years following FDA approval. Alkermes is eligible to receive royalties in the high-single digits to sub-teen double digits of annual net commercial sales upon successful development and commercialization of new product candidates other than diroximel fumarate, developed under the exclusive license from Alkermes. Alkermes will maintain responsibility for regulatory interactions with the FDA through the potential approval of the NDA for diroximel fumarate. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment to Alkermes representing our share of diroximel fumarate development costs already incurred in 2017. Beginning in 2018 we became responsible for all development expenses related to diroximel fumarate. In December 2017 we also recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> expense, which was paid to Alkermes in 2018, enabling the continuation of the agreement to develop diroximel fumarate. Both the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> continuation payment were recorded as research and development expense in our consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may also pay Alkermes an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> milestone payment upon a regulatory achievement related to diroximel fumarate under this agreement. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$80.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in research and development expense in our consolidated statements of income related to this collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the license and collaboration agreement, we may also enter into a supply agreement with Alkermes for the commercial supply of diroximel fumarate and other products developed under the license and collaboration agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Bristol-Myers Squibb Company</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2017 we completed an exclusive license agreement with Bristol-Myers Squibb Company (BMS) for the development and potential commercialization of BIIB092, a Phase 2 investigational therapy with potential in AD and PSP. BIIB092 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain associated with AD and other neurodegenerative tauopathies such as PSP. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we received worldwide rights to BIIB092 and are responsible for the full development and potential commercialization of BIIB092 in AD and PSP. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to BMS and we may pay BMS up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$410.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments, and potential royalties. We also assumed all remaining obligations to the former shareholders of iPierian, Inc. (iPierian) related to BMS&#8217;s acquisition of iPierian in 2014. In June 2017 we recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 study of BIIB092 for PSP and we may pay the former shareholders of iPierian up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$490.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestone payments as well as potential royalties on net commercial sales. Both the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> developmental milestone payment were recorded as research and development expense in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$97.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in research and development expense in our consolidated statements of income related to this collaboration.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Acorda Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2009 we entered into a collaboration and license agreement with Acorda Therapeutics, Inc. (Acorda) to develop and commercialize products containing fampridine, such as FAMPYRA, in markets outside the U.S.&#160;We are responsible for all regulatory activities and the future clinical development of related products in those markets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we pay tiered royalties based on the level of ex-U.S. net sales and we may pay potential milestone payments based on the successful achievement of certain regulatory and commercial milestones, which would be capitalized as intangible assets upon achievement of the milestones and amortized utilizing an economic consumption model. The next expected milestone would be </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, due if ex-U.S. net sales reach </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$100.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> over a period of four consecutive quarters. Royalty payments are recognized in cost of sales within our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we also entered into a supply agreement with Acorda for the commercial supply of FAMPYRA. This agreement is a sublicense arrangement of an existing agreement between Acorda and Alkermes, who acquired Elan Drug Technologies, the original party to the license with Acorda. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, total cost of sales related to royalties and commercial supply of FAMPYRA reflected in our consolidated statements of income were </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$36.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$34.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$31.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">AbbVie Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration agreement with AbbVie for the development and commercialization of ZINBRYTA, which was approved for the treatment of RMS in the U.S. in May 2016 and in the E.U. in July 2016. In March 2018 we and AbbVie announced the voluntary worldwide withdrawal of ZINBRYTA for RMS.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under this agreement, we and AbbVie conducted ZINBRYTA co-promotion activities in the U.S., E.U. and Canadian territories (Collaboration Territory), where development and commercialization costs and profits were shared equally. Outside of the Collaboration Territory, we were solely responsible for development and commercialization of ZINBRYTA and paid a tiered royalty to AbbVie as a percentage of net sales in the low to high teens.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We were responsible for manufacturing and research and development activities in both the Collaboration Territory and outside the Collaboration Territory and recorded these activities within their respective lines in our consolidated statements of income, net of any reimbursement of research and development expenditures received from AbbVie.&#160;For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the collaboration incurred </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$32.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for research and development activities, respectively, for which we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$24.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expense recognized in our consolidated statements of income for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, includes a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> charge recognized in the first quarter of 2018 related to the termination of research and development contracts and clinical trials as a result of the voluntary worldwide withdrawal of ZINBRYTA. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Prior to regulatory approval, we also recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of pre-commercialization expenses within our selling, general and administrative expense, which represented </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the collaboration's pre-commercialization costs for 2016. After ZINBRYTA was approved by the FDA and the EMA in 2016, we began to recognize our share of the collaboration activities within the Collaboration Territories as described below under </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Co-promotion Profits and Losses.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Co-promotion Profits and Losses</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the U.S., AbbVie recognized revenues on sales to third parties and we recognized our </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the co-promotion profits or losses as a component of total revenues in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The collaboration began selling ZINBRYTA in the U.S. in the third quarter of 2016 and ceased selling ZINBRYTA in the U.S. in March 2018 in connection with the voluntary worldwide withdrawal of ZINBRYTA for RMS. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net reduction in revenues from collaborative and other relationships, a component of other revenues, of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$8.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$21.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect our share of the overall net losses within the collaboration for each of those years.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a summary of the U.S. collaboration and our share of the co-promotion losses on ZINBRYTA in the U.S.:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the E.U. and Canada, we recognized revenues on sales to third parties in product revenues, net in our consolidated statements of income. We began to recognize net product revenues on sales of ZINBRYTA in the E.U. and Canada in the third quarter of 2016 and first quarter of 2017, respectively, and ceased selling ZINBRYTA in the E.U. and Canada in March 2018 in connection with the voluntary worldwide withdrawal of ZINBRYTA for RMS. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net product revenues on the sales of ZINBRYTA in the E.U. and Canada of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$52.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. We also recorded the related cost of revenues and sales and marketing expenses to their respective line items in our consolidated statements of income as these costs were incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reimbursed AbbVie for their </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> share of the co-promotion profits or losses in the E.U. and Canada. This reimbursement was recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized net profit-sharing income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to reflect AbbVie's </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration losses in the E.U. and Canada, as compared to net profit-sharing expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, and net profit-sharing income of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.9 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the year ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Research and Discovery Arrangements </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">C4 Therapeutics</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we entered into a collaborative research and license agreement with C4 Therapeutics (C4T) to investigate the use of C4T&#8217;s novel protein degradation platform to discover and develop potential new treatments for neurological diseases, such as AD and Parkinson&#8217;s disease.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the agreement, C4T will provide expertise and research services in targeted protein degradation and we will provide neuroscience expertise and drug development capabilities. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to C4T, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as research and development expense in our consolidated statements of income and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> was recorded as prepaid research and development expenditures within investments and other assets in our consolidated balance sheets. We may also pay C4T up to a total of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$370.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as potential royalties on net commercial sales.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">University of Pennsylvania</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and alliance with the University of Pennsylvania (UPenn) to advance gene therapy and gene editing technologies. In December 2018 we notified UPenn that we will be terminating certain programs under our collaboration and alliance with UPenn, including the development of therapeutic approaches that target the eye, skeletal muscle and central nervous system and research and validation of next generation gene transfer technology using adeno-associated virus (AAV) gene delivery vectors and exploring the expanded use of genome editing technology as a potential therapeutic platform. The termination of these programs will be effective in May 2019. This termination did not impact our collaboration with UPenn for the development of BIIB089 for the treatment of SMA.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into this agreement we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to UPenn, which was recorded as research and development expense in our consolidated statements of income, and made prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which was recorded in investments and other assets in our consolidated balance sheets. During 2017 we made additional prepaid research and development expenditures to UPenn of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$29.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the advancement of the programs under this agreement. These prepaid research and development amounts were expensed as the services were provided, of which no amounts remain as a prepaid asset as of December 31, 2018. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We may be required to make future payments of over </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$137.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in research funding, options and milestone payments in relation to the BIIB089 program if we are successful and exercise our related options under this agreement. UPenn is also eligible to receive royalties in the mid-single digit percentages of annual net commercial sales upon successful development and commercialization of BIIB089. UPenn is no longer entitled to any potential future research funding, options and milestone payments from us in relation to the development of programs other than BIIB089.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$33.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in research and development expense in our consolidated statements of income related to this collaboration.  </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Applied Genetic Technologies Corporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases with Applied Genetic Technologies Corporation (AGTC). This collaboration focused on the development of BIIB087, an investigational AAV-based gene therapy for the treatment of X-linked Retinoschisis (XLRS), and BIIB088, an investigational AAV-based gene therapy for the treatment of X-Linked Retinitis Pigmentosa (XLRP). This collaboration also provided us with options to early stage discovery programs in two ophthalmic diseases and one non-ophthalmic condition.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2018 we notified AGTC of the termination of our collaboration agreement with AGTC. The termination of this collaboration agreement will be effective in March 2019 and we will have no further involvement in the development of any of the programs under this collaboration. Accordingly, AGTC is no longer entitled to any potential development, regulatory and commercial milestone payments from us in relation to the development of these programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with the collaboration and license agreement, we also received a manufacturing license under which we received an exclusive license to use AGTC&#8217;s proprietary technology platform to make AAV vectors for up to six genes, three of which are in AGTC&#8217;s discretion, in exchange for payment of milestones and royalties. Our termination of the collaboration agreement does not impact our rights under the manufacturing license.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Upon entering into the collaboration agreement we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to AGTC. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$124.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upfront payment reflected a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$30.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equity investment in AGTC, including a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> premium on our equity investment, prepaid research and development expenditures of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and total licensing and other fees of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in total licensing and other fees and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$7.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> premium on our equity investment were recorded as a charge to research and development expense in our consolidated statements of income. The remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$22.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> equity investment and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$58.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of prepaid research and development expenditures were recorded in investments and other assets in our consolidated balance sheets. These prepaid research and development amounts were expensed as the services were provided. No amounts remain as a prepaid asset as of December 31, 2018. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recorded </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$39.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$26.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, which were reflected in research and development expense in our consolidated statements of income related to this collaboration. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we entered into several research, discovery and other related arrangements that resulted in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$10.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, recorded as research and development expense in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Samsung Bioepis Co., Ltd.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Joint Venture Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2012 we entered into a joint venture agreement with Samsung BioLogics, establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&#160;Samsung BioLogics contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">280.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$250.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for an </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> stake in Samsung Bioepis and we contributed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) for the remaining </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> ownership interest.&#160;In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which reflected the effect of previous equity financings in which we did not participate, to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The share purchase transaction was completed in November 2018 and, upon closing, we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$676.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">) to Samsung BioLogics.&#160;As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, our ownership percentage remains approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">49.9%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity become available, which is reflected as equity in income (loss) of investee, net of tax in our consolidated statements of income. During 2015, as our share of losses exceeded the carrying value of our initial investment, we suspended recognizing additional losses. In the first quarter of 2019, depending on the results of Samsung Bioepis, we expect to restart recognizing our share of Samsung Bioepis' income (losses) and we will begin recognizing the amortization of certain basis differences resulting from our November 2018 investment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investment in Samsung Bioepis totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">759.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> South Korean won (</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$680.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">), which is classified as a component of investments and other assets within our consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:6px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Commercial Agreement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In December 2013 pursuant to our rights under the joint venture agreement with Samsung BioLogics, we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, 3 anti-tumor necrosis factor (TNF) biosimilar product candidates in Europe and in the case of BENEPALI, Japan.&#160;Under this agreement, we have made upfront and clinical development milestone payments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$46.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which were recorded as research and development expense in our consolidated statements of income as the programs they relate to had not achieved regulatory approval. We also agreed to make additional milestone payments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon regulatory approval in the E.U. for each of the three anti-TNF biosimilar product candidates. IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, received regulatory approval in the E.U. in August 2017, May 2016 and January 2016, respectively, and we capitalized the related milestone payments totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as intangible assets, net in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2018 we and Samsung Bioepis announced an agreement with AbbVie related to the commercialization of IMRALDI. Under the terms of the agreement, AbbVie granted us and Samsung Bioepis patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and we make royalty payments to AbbVie on behalf of Samsung Bioepis. We began to recognize revenues on sales of IMRALDI to third parties in the E.U. in the fourth quarter of 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We reflect revenues on sales of IMRALDI, FLIXABI and BENEPALI to third parties in product revenues, net in our consolidated statements of income and record the related cost of revenues and sales and marketing expenses in our consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We share </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our consolidated statements of income. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized a net profit-sharing expense of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$187.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, to reflect Samsung Bioepis' </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> sharing of the net collaboration profits. </font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement, a technical development services agreement and a manufacturing agreement with Samsung Bioepis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we will receive single digit royalties on all biosimilar products developed and commercialized by Samsung Bioepis. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the technical development services agreement, we provide Samsung Bioepis technical development and technology transfer services, which include, but are not limited to, cell culture development, purification process development, formulation development and analytical development. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under our manufacturing agreement, we manufacture clinical and commercial quantities of bulk drug substance of biosimilar products for Samsung Bioepis pursuant to contractual terms.&#160;Under limited circumstances, we may also supply Samsung Bioepis with quantities of drug product of biosimilar products for use in clinical trials through arrangements with third-party contract manufacturers. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$96.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, in revenues under our license, technical development services and manufacturing agreements, which is reflected in revenues from collaborative and other relationships, as a component of other revenues in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720247104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Investments in Variable Interest Entities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Consolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Neurimmune SubOne AG</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2007 we entered into a collaboration and license agreement with Neurimmune SubOne AG (Neurimmune) for the development and commercialization of antibodies for the treatment of AD, including aducanumab, our anti-amyloid beta antibody candidate for the treatment of AD. We are responsible for the development, manufacturing and commercialization of all collaboration products. This agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of any product using such a licensed compound. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100% of the research and development costs incurred in support of the collaboration. Under this agreement, we are also required to pay royalties on net sales of any resulting commercial products and make payments upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2017 we amended the terms of our collaboration and license agreement with Neurimmune (as amended, the Neurimmune Agreement). Under the Neurimmune Agreement, we made a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.&#160;In May 2018 we made an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> payment to Neurimmune to further reduce the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab, by an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Our royalty rates payable on products developed under the Neurimmune Agreement, including royalty rates payable on potential commercial sales of aducanumab, will now range from the high single digits to sub-teens.&#160;As we consolidate the results of Neurimmune, we treated these payments as distributions and recognized them as charges to noncontrolling interest in the fourth quarter of 2017 and the second quarter of 2018, as applicable. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development costs for which we reimburse Neurimmune are reflected in research and development expense in our consolidated statements of income. During the years ending </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, amounts reimbursed were immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The assets and liabilities of Neurimmune are not significant to our consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than previously contractually required amounts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the terms of our Aducanumab Collaboration Agreement, Eisai had an option to share in the benefit and cost associated with the royalty reductions discussed above; however, Eisai did not elect to share in the benefit and cost with respect to either the October 2017 or May 2018 royalty reductions, which will impact the amount of profits (losses) on potential commercial sales of aducanumab to be shared with Eisai. For additional information on our collaboration arrangements with Eisai, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Unconsolidated Variable Interest Entities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have relationships with variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$28.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previously contractually required amounts.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973264512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:5px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read Note 1, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Summary of Significant Accounting Policies,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes, and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Loss Contingencies </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">IMRALDI Patent Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis UK Limited that Biogen has commercialized in Europe, infringes the French counterpart of European Patent No. 3 148 510 (the '510 Patent), which was issued in June 2018 and expires in March 2035. In October 2018 Fresenius Kabi commenced preliminary injunction proceedings against Biogen (Denmark) Manufacturing ApS and Biogen Denmark A/S in Denmark's Maritime and Commercial High Court alleging infringement of Danish Utility Models. In November 2018 Fresenius Kabi commenced infringement proceedings for damages and injunctive relief against Biogen Italia S.R.L. in the District Court of Milan relating to the Italian counterpart of the &#8216;510 Patent, and against Biogen GmbH in the Dusseldorf Regional Court relating to the German counterpart of the &#8216;510 Patent. No hearing has yet been set in these proceedings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 Biogen Idec Ltd. (Biogen UK) and Samsung Bioepis UK Limited filed an action in the United Kingdom Patents Court to revoke the United Kingdom counterpart of the '510 Patent. Fresenius Kabi has filed a counterclaim asserting infringement of the '510 Patent and seeking damages and an injunction to restrain infringement if the patent is found valid and infringed. A trial has been set for July 2019.&#160;In December 2018 Biogen B.V. and Samsung Bioepis UK Limited filed an action in the District Court of the Hague, Netherlands to revoke the Dutch counterpart of the &#8216;510 Patent.&#160;A trial has been set for October 2019. An estimate of the possible loss or range of loss in the above matters cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2018 Gedeon Richter PLC asserted to Biogen and Samsung Bioepis UK Limited that IMRALDI infringes European Patent No. 3 212 667, which was issued in September 2018 and expires in October 2035.&#160;We dispute the assertion. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Qui Tam Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2015 a qui tam action filed by Michael Bawduniak on behalf of the U.S. and certain states was unsealed by the U.S. District Court for the District of Massachusetts. The action alleges sales and promotional activities in violation of the federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys&#8217; fees and costs. Our motion to dismiss was denied in part. No trial date has been set. The U.S. has not made an intervention decision. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2018 we were served with a qui tam action filed by SMSF, LLC on behalf of the U.S. and certain states in the U.S. District Court for the District of Massachusetts alleging activities by nurse-educators in violation of the federal False Claims Act and state law counterparts. The government declined to intervene, and we, other defendants and the U.S. moved to dismiss. In December 2018 the court dismissed the case with prejudice against the relator and without prejudice as to the U.S. and states. The period for an appeal has lapsed and we consider the matter closed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 we and certain other drug manufacturers and pharmacy benefit managers were served with a qui tam action filed by John Borzilleri on behalf of the U.S. and certain states in the U.S. District Court for the District of Rhode Island. The case alleges agreements with pharmacy benefit managers in violation of the Federal False Claims Act and state law counterparts and seeks single and treble damages, civil penalties, interest, attorneys' fees and costs. We, the other defendants and the U.S. have moved to dismiss the case and the motions are pending. No trial date has been set. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Securities Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We and certain current and former officers are defendants in an action filed by a shareholder in October 2016 in the U.S. District Court for the District of Massachusetts alleging violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seeking a declaration of the action as a class action and an award of damages, interest and attorneys' fees. In March 2018 the court dismissed the complaint with prejudice. The plaintiff's appeal is pending. An estimate of the possible loss or range of loss cannot be made at this time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Hatch-Waxman Act Litigation relating to TECFIDERA Orange-Book Listed Patents</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June and July 2017, January, March, April, August and December 2018 and January 2019 we initiated patent infringement proceedings against multiple parties pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act, in the U.S. District Courts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Patent infringement proceedings pursuant to the Hatch-Waxman Act are pending against Accord Healthcare Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma U.S.A., Inc., Banner Life Sciences LLC, Caribe Holdings (Cayman) Co. Ltd.&#160;DBA Puracap&#160;Caribe, Cipla Limited, Glenmark Pharmaceuticals Ltd., Graviti Pharmaceuticals Pvt. Ltd., Hetero USA, Inc.,&#160;Lupin Atlantis Holdings SA, Macleods Pharmaceuticals, Ltd., MSN Laboratories Pvt. Ltd., Pharmathen S.A., Prinston Pharmaceutical Inc., Sandoz Inc., Sawai USA, Inc., Shipla Medicare Limited, Slayback Pharma LLC, Sun Pharma Global FZE, Torrent Pharmaceuticals Ltd., TWi Pharmaceuticals, Inc., Windlas Healthcare Pvt. Ltd. and Zydus Pharmaceuticals (USA) Inc. in the U.S. District Court for the District of Delaware and against Mylan Pharmaceuticals Inc. in the U.S. District Court for the Northern District of West Virginia.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A trial has been set for December 2019 in the Delaware actions, and a trial date has been set for February 2020 in the West Virginia action. A trial date has not been set in the case against Banner Life Sciences LLC or the case against Hetero USA Inc. that was filed in January 2019.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Petition for Inter Partes Review filed by Mylan Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2018 Mylan Pharmaceuticals, Inc. filed a petition with the U.S. Patent Trial and Appeal Board seeking </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of our U.S. Patent No. 8,399,514 (the '514 Patent). The '514 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate per day as provided for in our TECFIDERA label. The petition is pending. February 6, 2019, the U.S. Patent Trial and Appeal Board instituted </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">inter partes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> review of the '514 Patent.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Interference Proceeding with Forward Pharma</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In April 2015 the USPTO declared an interference between Forward Pharma&#8217;s U.S. Patent Application No. 11,576,871 and the '514 Patent. The U.S. Court of Appeals for the Federal Circuit affirmed the March 2017 ruling of the USPTO in favor of Biogen and in January 2019 denied Forward Pharma's petition for rehearing. For additional information regarding this matter, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">European Patent Office Oppositions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2016 the EPO revoked our European patent number 2 137 537 (the '537 Patent). We have appealed to the Technical Boards of Appeal of the EPO and the appeal is pending. The '537 Patent includes claims covering the treatment of MS with 480 mg of dimethyl fumarate as provided for in our TECFIDERA label. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2018 the EPO revoked Forward Pharma&#8217;s European Patent No. 2 801 355, which was issued in May 2015 and expires in October 2025. Forward Pharma has filed an appeal to the Technical Boards of Appeal of the EPO and the appeal is pending. The settlement and license agreement that we entered into with Forward Pharma in January 2017 did not resolve the issues pending in this proceeding and we and Forward Pharma intend to permit the Technical Boards of Appeal and the Enlarged Board of Appeal, if applicable, to make a final determination. For additional information regarding this matter, please read Note 7, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Intangible Assets and Goodwill,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI Patent Revocation Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2017 Bioeq GMBH, affiliated with the Polpharma Group, brought an action to the Polish Patent Office seeking to revoke Polish Patent Number 215263 (the Polish '263 Patent), the Polish patent corresponding to our European Patent Number 1 485 127 (the EU '127 Patent) ("Administration of agents to treat inflammation"). The Polish '263 Patent concerns administration of natalizumab (TYSABRI) to treat MS. The Polish '263 Patent was issued in 2013 and expires in February 2023. Swiss Pharma International AG, also affiliated with the Polpharma Group, filed actions in the District Court of The Hague (January 2016), the German Patents Court (March 2016) and the Commercial Court of Rome (November 2017) seeking to invalidate the Dutch, German and Italian counterparts of the EU '127 Patent, which was issued in 2011 and also concerns administration of natalizumab (TYSABRI) to treat MS. The EU '127 Patent expires in February 2023. The Dutch and German counterparts were ruled invalid and we have appealed. No date for a hearing on the merits has been set in the Polish and Italian actions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">'755 Patent Litigation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May&#160;2010 Biogen MA Inc. (formerly Biogen Idec MA Inc.) filed a complaint in the U.S.&#160;District Court for the District of New Jersey alleging infringement by Bayer Healthcare Pharmaceuticals Inc. (Bayer) (manufacturer, marketer and seller of BETASERON and manufacturer of EXTAVIA), EMD Serono, Inc. (EMD Serono) (manufacturer, marketer and seller of REBIF), Pfizer (co-marketer of REBIF) and Novartis Pharmaceuticals Corp. (Novartis) (marketer and seller of EXTAVIA) of our U.S. Patent No. 7,588,755 ('755 Patent), which claims the use of interferon beta for immunomodulation or treating a viral condition, viral disease, cancers or tumors. The complaint seeks monetary damages, including lost profits and royalties. Bayer had previously filed a complaint against us in the same court, on May 27, 2010, seeking a declaratory judgment that it does not infringe the '755 Patent and that the '755 Patent is invalid, and seeking monetary relief in the form of attorneys' fees, costs and expenses. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Bayer, Pfizer, Novartis and EMD Serono all filed counterclaims seeking declaratory judgments of patent invalidity and non-infringement, and seeking monetary relief in the form of costs and attorneys' fees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In September 2018, following a trial against EMD Serono and Pfizer, the court granted Biogen's motion for judgment as a matter of law that the '755 Patent is infringed and valid and ordered a new trial on all damages issues. The court has not yet scheduled the trial on damages or a trial against Bayer and Novartis. In October 2018 EMD Serono and Pfizer filed an appeal from the judgment in the U.S. Court of Appeals for the Federal Circuit, which is pending.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Government Matters</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have learned that state and federal governmental authorities are investigating our sales and promotional practices and have received related subpoenas. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have received subpoenas and other requests from the federal government for documents and information relating to our relationship with non-profit organizations that assist patients taking drugs sold by Biogen and Biogen's co-pay assistance programs. We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2016 we received civil investigative demands from the federal government for documents and information relating to our treatment of certain service agreements with wholesalers when calculating and reporting Average Manufacturer Prices in connection with the Medicaid Drug Rebate Program.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In July 2017 we learned that the Prosecution Office of Milan is investigating our interactions with certain healthcare providers in Italy.&#160;We are cooperating with the government.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Matter</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the second quarter of 2018 the State Treasury of Goias, Brazil issued tax assessments for the period 2013 through February 2018 relating to tax on the circulation of goods and totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$70.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> including interest and penalties. We dispute the assessments and have filed defenses with the Administrative Court of Appeals for the State of Goias, which are pending. We have not formed an opinion that an unfavorable outcome of the dispute is either probable or remote.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Product Liability and Other Legal Proceedings</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823529792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Payments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">TYSABRI</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2013 we acquired from Elan full ownership of all remaining rights to TYSABRI that we did not already own or control. Under the acquisition agreement, we are obligated to make contingent payments to Elan of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales up to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> on annual worldwide net sales that exceed </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Royalty payments to Elan and other third parties are recorded as cost of sales in our consolidated statements of income. Elan was acquired by Perrigo Company plc (Perrigo) in December 2013, and Perrigo subsequently sold its rights to these payments to a third-party effective January 2017.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">SPINRAZA</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the third quarter of 2016 we exercised our option to develop and commercialize SPINRAZA from Ionis. Under our agreement with Ionis, we make royalty payment to Ionis on annual worldwide net sales of SPINRAZA using a tiered royalty rate between </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which are recorded as cost of sales in our consolidated statements of income. For additional information on our collaboration arrangements with Ionis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Consideration related to Business Combinations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with our acquisitions of Convergence, Stromedix and BIN, we agreed to make additional payments based upon the achievement of certain milestone events. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As the acquisitions of Convergence, Stromedix and BIN occurred after January&#160;1, 2009, we recognized the contingent consideration liabilities associated with these transactions at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in remaining milestones related to these acquisitions.</font></div><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fumapharm AG</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In 2006 we acquired Fumapharm AG. As part of this acquisition we acquired the Fumapharm Products. We paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$220.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon closing of the transaction and agreed to pay an additional </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> if a Fumapharm Product was approved for MS in the U.S.&#160;or E.U. In the second quarter of 2013 TECFIDERA was approved in the U.S. for MS by the FDA and we made the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment. We are also required to make additional contingent payments to former shareholders of Fumapharm AG and holders of their rights based on the attainment of certain cumulative sales levels of Fumapharm Products and the level of total net sales of Fumapharm Products in the prior 12-month period, as defined in the acquisition agreement, until such time as the cumulative sales level reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, at which time no further contingent payments are due. These payments are accounted for as an increase to goodwill as incurred, in accordance with the accounting standard applicable to business combinations when we acquired Fumapharm AG. Any portion of the payment that is tax deductible was recorded as a reduction to goodwill. Payments are due within 60&#160;days following the end of the quarter in which the applicable cumulative sales level was reached. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">During </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> we paid </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in contingent payments as we reached the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$16.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales levels related to the Fumapharm Products in the fourth quarter of 2017 and the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$17.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$18.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$19.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales levels related to the Fumapharm Products in the first, second and third quarters of 2018, respectively. In the fourth quarter of 2018 we achieved the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$20.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> cumulative sales level threshold and accrued our last </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> contingent payment related to the Fumapharm Products, which will be paid in the first quarter of 2019.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Contingent Development, Regulatory and Commercial Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based on our development plans as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we could make potential future milestone payments to third parties of up to approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, including approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.7 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in development milestones, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.8 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in regulatory milestones and approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory approval or commercial milestones. </font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other Funding Commitments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expenses of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$27.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in our consolidated balance sheet for expenditures incurred by CROs as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We have approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$655.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in cancellable future commitments based on existing CRO contracts as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Tax Related Obligations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we have </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$117.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of liabilities associated with uncertain tax positions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and 2017, we have accrued income tax liabilities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$697.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, under the Transition Toll Tax. Of the amounts accrued as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, no amounts are expected to be paid within one year due to a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> overpayment of taxes in the current year. The Transition Toll Tax will be paid over an eight-year period, which started in 2018, and will not accrue interest. For additional information on the Transition Toll Tax, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Solothurn, Switzerland Manufacturing Facility</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. We expect this facility to be operational by the end of 2020. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we had contractual commitments of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$111.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the construction of this facility.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We rent laboratory and office space and certain equipment under non-cancelable operating leases. These lease agreements contain various clauses for renewal at our option and, in certain cases, escalation clauses typically linked to rates of inflation. Rental expense, net of sublease income under these leases, which terminate at various dates through 2028, amounted to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$64.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$65.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$68.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In addition to rent, the leases may require us to pay additional amounts for taxes, insurance, maintenance and other operating expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">87.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">601.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(26.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(25.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(58.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(182.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">156.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">418.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">Represents sublease income expected to be received for the vacated manufacturing facility in Cambridge, MA, the vacated portion of our Weston, MA facility and other facilities throughout the world. </font></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under certain of our lease agreements, we are contractually obligated to return leased space to its original condition upon termination of the lease agreement. At the inception of a lease with such conditions, we record an asset retirement obligation liability and a corresponding capital asset in an amount equal to the estimated fair value of the obligation. In subsequent periods, for each such lease, we record interest expense to accrete the asset retirement obligation liability to full value and depreciate each capitalized asset retirement obligation asset, both over the term of the associated lease agreement. Our asset retirement obligations were not significant as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973040688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Guarantees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesAbstract', window );"><strong>Guarantees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteesTextBlock', window );">Guarantees</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Guarantees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we did not have significant liabilities recorded for guarantees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, clinical sites and customers. Under these provisions, we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. However, to date we have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for each guarantee obligation, or each group of similar guarantee obligations, including (a) the nature of the guarantee, including its term, how it arose, and the events or circumstances that would require the guarantor to perform under the guarantee; (b) the maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee; (c) the current carrying amount of the liability, if any, for the guarantor's obligations under the guarantee; and (d) the nature of any recourse provisions under the guarantee, and any assets held either as collateral or by third parties, and any relevant related party disclosure. Excludes disclosures about product warranties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI http://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823519936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Employee Benefit Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We sponsor various retirement and pension plans. Our estimates of liabilities and expenses for these plans incorporate a number of assumptions, including expected rates of return on plan assets and interest rates used to discount future benefits.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">401(k) Savings Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a 401(k) Savings Plan, which is available to substantially all regular employees in the U.S. over the age of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">21</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Participants may make voluntary contributions. We make matching contributions according to the 401(k) Savings Plan&#8217;s matching formula. All matching contributions and participant contributions vest immediately. The 401(k) Savings Plan also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The expense related to our 401(k) Savings Plan primarily consists of our matching contributions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expense related to our 401(k) Savings Plan totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Deferred Compensation Plan</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We maintain a non-qualified deferred compensation plan, known as the Supplemental Savings Plan (SSP), which allows a select group of management employees in the U.S. to defer a portion of their compensation. The SSP also provides certain credits to highly compensated U.S. employees that are paid by the company. These credits are known as the Restoration Match. The deferred compensation amounts are accrued when earned. Such deferred compensation is distributable in cash in accordance with the rules of the SSP. Deferred compensation amounts under such plan as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, totaled approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$109.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and are included in other long-term liabilities in our consolidated balance sheets. The SSP also holds certain transition contributions on behalf of participants who previously participated in the Biogen, Inc. Retirement Plan. The Restoration Match and participant contributions vest immediately. Distributions to participants can be either in one lump sum payment or annual installments as elected by the participants.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Pension Plans</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our retiree benefit plans include defined benefit plans for employees in our affiliates in Switzerland and Germany as well as other insignificant defined benefit plans in certain other countries where we maintain an operating presence.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our Swiss plan is a government-mandated retirement fund that provides employees with a minimum investment return. The minimum investment return is determined annually by the Swiss government and was </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.00%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.25%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. Under the Swiss plan, both we and certain of our employees with annual earnings in excess of government determined amounts are required to make contributions into a fund managed by an independent investment fiduciary. Employer contributions must be in an amount at least equal to the employee&#8217;s contribution. Minimum employee contributions are based on the respective employee&#8217;s age, salary and gender. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, the Swiss plan had an unfunded net pension obligation of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$48.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, and plan assets that totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$93.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$83.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. In </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, we recognized expense totaling </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$14.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$12.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$15.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, related to our Swiss plan, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, was included in other income (expense), net.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The obligations under the German plans are unfunded and totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$45.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$43.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively. Net periodic pension cost related to the German plans totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$5.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$4.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of which </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, was included in other income (expense), net.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823612032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We operate as </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">one</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Our Chief Executive Officer (CEO), as the chief operating decision-maker, manages and allocates resources to the operations of our company on a total company basis. Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. The company is also supported by corporate staff functions. Managing and allocating resources on a total company basis enables our CEO to assess the overall level of resources available and how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. Consistent with this decision-making process, our CEO uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Enterprise-wide disclosures about product revenues, other revenues and long-lived assets by geographic area are presented below. Revenues are primarily attributed to individual countries based on location of the customer or licensee.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Geographic Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,800.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,370.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">281.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">434.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,903.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">76.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">457.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">96.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">585.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,152.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,442.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,601.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,017.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,844.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">332.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,475.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,226.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,948.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,182.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,050.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,237.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">313.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">224.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,272.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,221.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Other</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,748.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1,215.7 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$545.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to the construction of our large-scale biologics manufacturing facility in Solothurn, Switzerland.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$646.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$707.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$643.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of our long-lived assets were related to our manufacturing facilities in Denmark.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our large-scale biologics manufacturing facility in Solothurn, Switzerland, please read Note 11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Property, Plant and Equipment,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823519936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">&#160;&#160;&#160;&#160;Quarterly Financial Data (Unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b) (c) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b) (e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (f) (g) (h) (i)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,523.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,757.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,780.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,825.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">443.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">490.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">511.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">534.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">164.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">108.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">147.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">165.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">585.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,131.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,356.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,439.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,526.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13,452.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,685.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,935.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,978.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,037.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,636.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,171.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">915.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,442.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">944.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,474.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,172.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">866.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,444.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">946.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,430.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.55</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.18</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.17</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.74</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.63</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.54</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.18</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.15</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.73</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.58</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">201.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">199.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">201.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">200.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">205.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(j) (k) (l)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(m) (n) (o) (p)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,380.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,639.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,622.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,712.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">340.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">397.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">406.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">415.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">179.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,810.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,078.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,077.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,307.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,273.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,426.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,712.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,707.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,797.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,643.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">862.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,226.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(166.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,670.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">862.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,226.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(297.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.07</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.07</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the first, second, third and fourth quarters of 2018 includes pre-tax charges related to (losses) gains recorded in relation to changes in the fair value of our strategic investments of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$(6.4) million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$5.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$141.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$(12.2) million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the first, second and third quarters of 2018 include pre-tax charges to acquired IPR&amp;D of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$27.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, for upfront payments to Karyopharm, Pfizer and AliveGen, respectively, upon closing of the asset purchase transactions for BIIB100, BIIB104 and BIIB110, respectively, as the underlying assets had not yet reached technological feasibility.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2018 includes pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$486.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the closing of the 2018 Ionis Agreement. Included in this amount was a charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$162.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflecting the premium paid above fair value for the purchase of approximately </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Ionis' common stock upon the closing of the 2018 Ionis Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. for the second quarter of 2018 includes a pre-tax charge to noncontrolling interest of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2018 includes the impact of impairment charges totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$189.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to certain IPR&amp;D assets associated with our vixotrigine program and an adjustment to the value of our contingent consideration obligations related to our vixotrigine program for the treatment of TGN to reflect the lower cumulative probabilities of success, which resulted in a gain of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$89.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2018. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In late December 2018 we received feedback from the FDA regarding the design of the Phase 3 vixotrigine program for the treatment of TGN. Following this feedback, we are now planning to initiate the Phase 3 vixotrigine program for the treatment of TGN and, as a result, we adjusted the fair value of our contingent consideration obligations related to our vixotrigine program for the treatment of TGN to reflect the increased probabilities of success and recognized a loss of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$80.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the fourth quarter of 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 and the first quarter of 2017 includes </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$176.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$328.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of impairment charges related to our intangible asset associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 includes a net increase to income tax expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$135.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflecting the impact of electing to record deferred taxes on GILTI.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 includes an upfront payment of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis, as we exercised our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB067.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(j)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment made to BMS upon entering into our agreement to exclusively license BIIB092.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(k)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to acquired IPR&amp;D of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment to Remedy upon closing of the asset purchase transaction for BIIB093.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(l)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a developmental milestone that became payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 study of BIIB092 for PSP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(m)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to noncontrolling interest of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a payment made to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(n)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment and a continuation payment, respectively, to Alkermes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(o)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment to Ionis upon entering into a new collaboration agreement to identify new ASO drug candidates for the treatment of SMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(p)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the provisions of the 2017 Tax Act, including a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> expense under the Transition Toll Tax.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our acquisitions of BIIB100, BIIB104, BIIB110 and BIIB093, please read Note 2, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Acquisitions</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For additional information on our collaboration arrangements with Ionis, BMS and Alkermes, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For additional information on our collaboration arrangement with Neurimmune, please read Note 20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Investments in Variable Interest Entities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For additional information on the amortization and impairment of acquired intangible assets, including our IPR&amp;D intangible asset related to our vixotrigine program for the treatment of TGN and our TECFIDERA settlement and license agreement, please read Note 7,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Intangible Assets and Goodwill</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For additional information on the 2017 Tax Act, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720247104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:12pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:12pt;color:#578196;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;">Skyhawk Therapeutics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2019 we entered into a collaboration and research and development services agreement with Skyhawk Therapeutics, Inc. (Skyhawk) pursuant to which the companies will leverage Skyhawk&#8217;s SkySTAR technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases, including MS and SMA. We will be responsible for the development and potential commercialization of any therapies resulting from this collaboration. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In connection with this agreement, we made an upfront payment of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$74.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Skyhawk. We may also pay Skyhawk up to a total of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.0 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in additional milestone payments as well as potential royalties on net commercial sales. We expect to record research and development expense of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the first quarter of 2019 related to this collaboration.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833431536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Business Overview</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases, including in our core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer&#8217;s disease (AD) and dementia, movement disorders, including Parkinson's disease, and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). We are also focused on discovering, developing and delivering worldwide innovative therapies in our emerging growth areas of acute neurology, neurocognitive disorders, pain and ophthalmology. In addition, we are employing innovative technologies to discover potential treatments for rare and genetic disorders, including new ways of treating diseases through gene therapy in our core and emerging growth areas. We also manufacture and commercialize biosimilars of advanced biologics.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketed products include TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA and FUMADERM for the treatment of severe plaque psoriasis. We also have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL, GAZYVA for the treatment of CLL and follicular lymphoma, OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS) and other potential anti-CD20 therapies pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities. For over two decades we have led in the research and development of new therapies to treat MS, resulting in our leading portfolio of MS treatments. Now our research is focused on additional improvements in the treatment of MS, such as the development of next generation therapies for MS, with a goal to reverse or possibly repair damage caused by the disease. We are also applying our scientific expertise to solve some of the most challenging and complex diseases, including AD, progressive supranuclear palsy (PSP), Parkinson's disease, ALS, stroke, epilepsy, cognitive impairment associated with schizophrenia (CIAS) and pain.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our innovative drug development and commercialization activities are complemented by our biosimilar products that expand access to medicines and reduce the cost burden for healthcare systems. We are leveraging our manufacturing capabilities and know-how to develop, manufacture and market biosimilar products through Samsung Bioepis Co., Ltd. (Samsung Bioepis), our joint venture with Samsung BioLogics Co., Ltd. (Samsung BioLogics). Under our commercial agreement, we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, FLIXABI, an infliximab biosimilar referencing REMICADE, and IMRALDI, an adalimumab biosimilar referencing HUMIRA, in the European Union (E.U.). For additional information on our collaboration arrangement with Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">100%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the economics, we record net income (loss) attributable to noncontrolling interests in our consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In determining whether we are the primary beneficiary of an entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. These considerations impact the way we account for our existing collaborative relationships and other arrangements. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The preparation of our consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. Actual results may differ from these estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenues when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB subsequently issued the following amendments to ASU 2014-09 that have the same effective date and transition date: ASU No. 2016-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; ASU No. 2016-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">; and ASU No. 2016-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. We adopted these amendments with ASU 2014-09 (collectively, the new revenue standards).</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The new revenue standards became effective for us on January 1, 2018, and were adopted using the modified retrospective method. The adoption of the new revenue standards as of January 1, 2018, did not change our revenue recognition as the majority of our revenues continue to be recognized when the customer takes control of our product. As we did not identify any accounting changes that impacted the amount of reported revenues with respect to our product revenues, revenues from anti-CD20 therapeutic programs or other revenues, no adjustment to retained earnings was required upon adoption. However, the adoption of the new revenue standards will result in a change in the timing of revenue recognition related to certain of our contract manufacturing activities based upon the terms of the underlying agreements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Under the new revenue standards, we recognize revenues when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. We recognize revenues following the five-step model prescribed under ASU 2014-09: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the new revenue standards, other corporate revenue was higher by&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;and cost of sales, excluding amortization and impairment of acquired intangible assets was higher by </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$42.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for the year ended December 31, 2018, compared to what would have been reported under the previous revenue guidance, primarily due to the earlier recognition of revenue associated with our contract manufacturing agreements. Under the previous revenue guidance, these amounts would have been recognized in future periods upon shipment. The adoption of the new revenue standards did not have a material impact on any other balances within our consolidated financial statements as of and for the&#160;year ended&#160;December 31, 2018.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Product Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In the United States (U.S.), we sell our products primarily to wholesale distributors and specialty pharmacy providers. In other countries, we sell our products primarily to wholesale distributors, hospitals, pharmacies and other third-party distribution partners. These customers subsequently resell our products to health care providers and patients. In addition, we enter into arrangements with health care providers and payors that provide for government-mandated or privately-negotiated discounts and allowances related to our products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recognized when the customer obtains control of our product, which occurs at a point in time, typically upon delivery to the customer. We expense incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Reserves for Discounts and Allowances</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from product sales are recorded net of reserves established for applicable discounts and allowances that are offered within contracts with our customers, health care providers or payors, including those associated with the implementation of pricing actions in certain of the international markets in which we operate. Our process for estimating reserves established for these variable consideration components do not differ materially from our historical practices.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenue reserves, which are classified as a reduction in product revenues, are generally characterized in the following categories: discounts, contractual adjustments and returns.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). Our estimates of reserves established for variable consideration are calculated based upon a consistent application of our methodology utilizing the expected value method. These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discounts include trade term discounts and wholesaler incentives. Trade term discounts and wholesaler incentives primarily relate to estimated obligations for credits to be granted to wholesalers for remitting payment on their purchases within established incentive periods and credits to be granted to wholesalers for compliance with various contractually-defined inventory management practices, respectively. We determine these reserves based on our historical experience, including the timing of customer payments.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contractual adjustments primarily relate to Medicaid and managed care rebates, co-payment (copay) assistance, Veterans Administration (VA) and Public Health Service (PHS) discounts, specialty pharmacy program fees and other governmental rebates or applicable allowances.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Medicaid rebates relate to our estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in other current liabilities. Our liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Governmental rebates or chargebacks, including VA and PHS discounts, represent our estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices we charge to wholesalers which provide those products. The wholesaler charges us for the difference between what the wholesaler pays for the products and the ultimate selling price to the qualified healthcare providers. Rebate and chargeback reserves are established in the same period as the related revenue is recognized, resulting in a reduction in product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider from the wholesaler, and we generally issue credits for such amounts within a few weeks of the wholesaler notifying us about the resale. Our reserves for VA, PHS and chargebacks consist of amounts that we expect to issue for inventory that exists at the wholesalers that we expect will be sold to qualified healthcare providers and chargebacks that wholesalers have claimed for which we have not issued a credit.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Managed care rebates represent our estimated obligations to third parties, primarily pharmacy benefit managers. Rebate accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability which is included in accrued expenses and other current liabilities. These rebates result from performance-based goals, formulary position and price increase limit allowances (price protection). The calculation of the accrual for these rebates is based on an estimate of the customer&#8217;s buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Copay assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The calculation of the accrual for copay is based on an estimate of claims and the cost per claim that we expect to receive associated with inventory that exists in the distribution channel at period end.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other governmental rebates, non-US pharmaceutical taxes or applicable allowances primarily relate to mandatory rebates and discounts in international markets where government-sponsored healthcare systems are the primary payors for healthcare.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product returns are established for returns expected to be made by wholesalers and are recorded in the period the related revenue is recognized, resulting in a reduction to product revenues. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Expired product return reserves are estimated through a comparison of historical return data to their related sales on a production lot basis. Historical rates of return are determined for each product and are adjusted for known or expected changes in the marketplace specific to each product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition to discounts, rebates and product returns, we also maintain certain customer service contracts with distributors and other customers in the distribution channel that provide us with inventory management, data and distribution services, which are generally reflected as a reduction of revenues. To the extent we can demonstrate a separable benefit and fair value for these services we classify these payments in selling, general and administrative expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenues from Anti-CD20 Therapeutic Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our collaboration with Genentech is within the scope of Accounting Standards Codification (ASC) 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Agreements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which provides guidance on the presentation and disclosure of collaborative arrangements. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> Our share of the pre-tax co-promotion profits on RITUXAN and GAZYVA and royalty revenues on the sale of OCREVUS resulted from an exchange of a license. As we do not have future performance obligations under the license or collaboration agreement, revenues are recognized as the underlying sales occur.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs consist of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">our share of pre-tax profits and losses in the U.S. for RITUXAN and GAZYVA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(ii)&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">other revenues from anti-CD20 therapeutic programs, which primarily consist of our share of pre-tax co-promotion profits on RITUXAN in Canada and royalty revenues on sales of OCREVUS.  </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Pre-tax co-promotion profits on RITUXAN and GAZYVA are calculated and paid to us by Genentech in the U.S. Pre-tax co-promotion profits on RITUXAN are calculated and paid to us by the Roche Group in Canada. Pre-tax co-promotion profits consist of U.S. and Canadian net sales to third-party customers less applicable costs to manufacture, third-party royalty expenses, distribution, selling and marketing expenses and joint development expenses incurred by Genentech, the Roche Group and us. Our share of the pre-tax profits on RITUXAN and GAZYVA in the U.S. and pre-tax co-promotion profits on RITUXAN in Canada include estimates that are based on information received from Genentech. These estimates are subject to change and actual results may differ. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our relationship with Genentech, please read Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have a number of significant collaborative and other third-party relationships for revenues and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. Where we are the principal on sales transactions with third parties, we recognize revenues, cost of sales and operating expenses on a gross basis in their respective lines in our consolidated statements of income. Where we are not the principal on sales transactions with third parties, we record our share of the revenues, cost of sales and operating expenses on a net basis in collaborative and other relationships included in other revenues in our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our development and commercialization arrangements with AbbVie Inc. (AbbVie), Genentech and Samsung Bioepis represent collaborative arrangements as each party is an active participant in one or more joint operating activities and is exposed to significant risks and rewards of these arrangements. These arrangements resulted from an exchange of a license and utilize the sales and usage based royalty exception. Therefore, revenues relating to royalties or profit-sharing amounts received are recognized as the underlying sales occur.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with AbbVie, Genentech and Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Royalty Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We receive royalty revenues on sales by our licensees of other products covered under patents that we own. We do not have future performance obligations under these license arrangements. We record these revenues based on estimates of the sales that occurred during the relevant period as a component of other revenues. The relevant period estimates of sales are based on interim data provided by licensees and analysis of historical royalties that have been paid to us, adjusted for any changes in facts and circumstances, as appropriate. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known, typically the following quarter. Historically, adjustments have not been material when compared to actual amounts paid by licensees. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Corporate Revenues</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We record other corporate revenues primarily from amounts earned under contract manufacturing agreements. Revenues under contract manufacturing agreements are recognized when the customer obtains control of the product, which may occur at a point in time or over time depending on the terms and conditions of the agreement.</font></div><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We have certain financial assets and liabilities recorded at fair value which have been classified as Level&#160;1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;1</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined utilizing quoted prices (unadjusted) in active markets for identical assets or liabilities that we have the ability to access;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;2</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Fair values are determined by utilizing quoted prices for identical or similar assets and liabilities in active markets or other market observable inputs such as interest rates, yield curves, foreign currency spot rates and option pricing valuation models;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Level&#160;3</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;&#8212; Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our financial assets have been classified as Level&#160;2. Our financial assets (which include our cash equivalents, marketable debt securities and certain of our marketable equity securities, derivative contracts and plan assets for deferred compensation) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third-party pricing services or option pricing valuation models. The pricing services utilize industry standard valuation models, including both income and market-based approaches and observable market inputs to determine value. These observable market inputs include reportable trades, benchmark yields, credit spreads, broker/dealer quotes, bids, offers, current spot rates and other industry and economic events.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We validate the prices provided by our third-party pricing services by understanding the models used, obtaining market values from other pricing sources and analyzing pricing data in certain instances. The option pricing valuation models use assumptions within the model, including the term, stock price volatility, constant maturity risk-free interest rate and dividend yield. After completing our validation procedures, we did not adjust or override any fair value measurements provided by our pricing services as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Other Assets and Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The carrying amounts reflected in our consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expenses and other, approximate fair value due to their short-term maturities.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We consider only those investments that are highly liquid, readily convertible to cash and that mature within three months from date of purchase to be cash equivalents. As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, cash equivalents were comprised of money market funds, commercial paper, overnight reverse repurchase agreements and other debt securities with maturities less than 90 days from the date of purchase.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The majority of our accounts receivable arise from product sales and primarily represent amounts due from our wholesale and other third-party distributors, public hospitals, pharmacies and other government entities and have standard payment terms that generally require payment within </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 to 90 days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We do not adjust our receivables for the effects of a significant financing component at contract inception if we expect to collect the receivables in one year or less from the time of sale.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In countries where we have experienced a pattern of payments extending beyond our contractual payment term and we expect to collect receivables greater than one year from the time of sale, we have assessed whether the customer has a significant financing component and discounted our receivables and reduced related revenues over the period of time that we estimate those amounts will be paid using the country&#8217;s market-based borrowing rate for such period. The related receivables are classified at the time of sale as non-current assets. We accrete interest income on these receivables, which is recorded as a component of other income (expense), net in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We provide reserves against trade receivables for estimated losses that may result from a customer's inability to pay. Amounts determined to be uncollectible are charged or written-off against the reserve.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The adoption of the new revenue standards did not change our historical accounting methods for our accounts receivable.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments as previously defined by us. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Concentrations of credit risk with respect to receivables, which are typically unsecured, are somewhat mitigated due to the wide variety of customers and markets using our products, as well as their dispersion across many different geographic areas. We monitor the financial performance and creditworthiness of our customers so that we can properly assess and respond to changes in their credit profile. We continue to monitor these conditions and assess their possible impact on our business. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Marketable Securities and Other Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Debt Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Available-for-sale marketable debt securities are recorded at fair market value and unrealized gains and losses are included in accumulated other comprehensive income (loss) in equity, net of related tax effects, unless the security has experienced a credit loss, we have determined that we have the intent to sell the security or we have determined that it is more likely than not that we will have to sell the security before its expected recovery. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Marketable Equity Securities and Venture Capital Funds</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our marketable equity securities are recorded at fair market value and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, unrealized gains and losses were included in accumulated other comprehensive income (loss) in equity, net of related tax effects. Our marketable equity securities represent investments in publicly traded equity securities and are included in investments and other assets in our consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our investments in venture capital funds are recorded at net asset value, which approximates fair value, and, beginning January 1, 2018, unrealized gains and losses are included in other income (expense), net in our consolidated statements of income. Prior to January 1, 2018, these investments were accounted for under the cost method of accounting. The underlying investments of the venture capital funds in which we invest are in equity securities of certain biotechnology companies and are included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Non-Marketable Equity Securities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We also invest in equity securities of companies whose securities are not publicly traded and where fair value is not readily available. These investments are recorded using either the equity method of accounting or the cost minus impairment adjusted for changes in observable prices, depending on our ownership percentage and other factors that suggest we have significant influence. We monitor these investments to evaluate whether any increase or decline in their value has occurred, based on the implied value of recent company financings, public market prices of comparable companies and general market conditions. These investments are included in investments and other assets in our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Evaluating Investments for Other-than-Temporary Impairments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We conduct periodic reviews to identify and evaluate each investment that has an unrealized loss, in accordance with the meaning of other-than-temporary impairment and its application to certain investments. An unrealized loss exists when the current fair value of an individual security is less than its amortized cost basis. Unrealized losses on available-for-sale debt securities that are determined to be temporary, and not related to credit loss, are recorded, net of tax, in accumulated other comprehensive income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For available-for-sale debt securities with unrealized losses, management performs an analysis to assess whether we intend to sell or whether we would more likely than not be required to sell the security before the expected recovery of the amortized cost basis. Where we intend to sell a security, or may be required to do so, the security&#8217;s decline in fair value is deemed to be other-than-temporary and the full amount of the unrealized loss is reflected in earnings as an impairment loss.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Regardless of our intent to sell a security, we perform additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified where we do not expect to receive cash flows sufficient to recover the amortized cost basis of a security.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method of Accounting</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In circumstances where we have the ability to exercise significant influence over the operating and financial policies of a company in which we have an investment, we utilize the equity method of accounting for recording investment activity.&#160;In assessing whether we exercise significant influence, we consider the nature and magnitude of our investment, the voting and protective rights we hold, any participation in the governance of the other company and other relevant factors such as the presence of a collaborative or other business relationship.&#160;Under the equity method of accounting, we record in our results of operations our share of income or loss of the other company. If our share of losses exceeds the carrying value of our investment, we will suspend recognizing additional losses and will continue to do so unless we commit to providing additional funding. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value with cost based on the first-in, first-out method. We classify our inventory costs as long-term when we expect to utilize the inventory beyond our normal operating cycle and include these costs in investments and other assets in our consolidated balance sheets. Inventory that can be used in either the production of clinical or commercial products is expensed as research and development costs when identified for use in a clinical manufacturing campaign.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Capitalization of Inventory Costs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We capitalize inventory costs associated with our products prior to regulatory approval, when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. We consider numerous attributes in evaluating whether the costs to manufacture a particular product should be capitalized as an asset. We assess the regulatory approval process and where the particular product stands in relation to that approval process, including any known safety or efficacy concerns, potential labeling restrictions and other impediments to approval. We evaluate our anticipated research and development initiatives and constraints relating to the product and the indication in which it will be used. We consider our manufacturing environment including our supply chain in determining logistical constraints that could hamper approval or commercialization. We consider the shelf life of the product in relation to the expected timeline for approval and we consider patent related or contract issues that may prevent or delay commercialization. We also base our judgment on the viability of commercialization, trends in the marketplace and market acceptance criteria. Finally, we consider the reimbursement strategies that may prevail with respect to the product and assess the economic benefit that we are likely to realize. We expense previously capitalized costs related to pre-approval inventory upon a change in such judgment, due to, among other potential factors, a denial or significant delay of approval by necessary regulatory bodies.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Obsolescence and Unmarketable Inventory</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We periodically review our inventories for excess or obsolescence and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. If the actual net realizable value is less than that estimated by us, or if it is determined that inventory utilization will further diminish based on estimates of demand, additional inventory write-downs may be required. Additionally, our products are subject to strict quality control and monitoring that we perform throughout the manufacturing process. In the event that certain batches or units of product no longer meet quality specifications, we will record a charge to cost of sales to write-down any unmarketable inventory to its estimated net realizable value. In all cases, product inventory is carried at the lower of cost or its estimated net realizable value. Amounts written-down due to unmarketable inventory are charged to cost of sales.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment are carried at cost, subject to review for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. The cost of normal, recurring, or periodic repairs and maintenance activities related to property, plant and equipment are expensed as incurred. The cost for planned major maintenance activities, including the related acquisition or construction of assets, is capitalized if the repair will result in future economic benefits.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest costs incurred during the construction of major capital projects are capitalized until the underlying asset is ready for its intended use, at which point the interest costs are amortized as depreciation expense over the life of the underlying asset. We also capitalize certain direct and incremental costs associated with the validation effort required for licensing by regulatory agencies of new manufacturing equipment for the production of a commercially approved drug. These costs primarily include direct labor and material and are incurred in preparing the equipment for its intended use. The validation costs are either amortized over the life of the related equipment or expensed as cost of sales when the product produced in the validation process is sold.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In addition, we capitalize certain internal use computer software development costs. If the software is an integral part of production assets, these costs are included in machinery and equipment and are amortized on a straight-line basis over the estimated useful lives of the related software, which generally range from </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">three to five years</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We generally depreciate or amortize the cost of our property, plant and equipment using the straight-line method over the estimated useful lives of the respective assets, which are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When we dispose of property, plant and equipment, we remove the associated cost and accumulated depreciation from the related accounts in our consolidated balance sheets and include any resulting gain or loss in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our intangible assets consist of acquired and in-licensed rights and patents, developed technology, out-licensed patents, in-process research and development acquired after January&#160;1, 2009, trademarks and trade names. Our intangible assets are recorded at fair value at the time of their acquisition and are stated in our consolidated balance sheets net of accumulated amortization and impairments, if applicable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to acquired and in-licensed rights and patents, developed technology and out-licensed patents are amortized over their estimated useful lives using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when revenues cannot be reasonably estimated. Amortization is recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents primarily relate to our acquisition of all remaining rights to TYSABRI from Elan Pharma International, Ltd. (Elan), an affiliate of Elan Corporation, plc. Acquired and in-licensed rights and patents also includes our U.S. and rest of world licenses to Forward Pharma A/S' (Forward Pharma) intellectual property, including Forward Pharma's intellectual property related to TECFIDERA, and other amounts related to our other marketed products and other programs acquired through business combinations. Developed technology primarily relates to our AVONEX product, which was recorded in connection with the merger of Biogen, Inc. and IDEC Pharmaceuticals Corporation in 2003. We amortize the intangible assets related to our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products using the economic consumption method based on revenues generated from the products underlying the related intangible assets. An analysis of the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products is performed annually during our long-range planning cycle and whenever events or changes in circumstances would significantly affect the anticipated lifetime revenues of our TYSABRI, AVONEX, SPINRAZA and TECFIDERA products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets related to trademarks, trade names and in-process research and development prior to commercialization are not amortized because they have indefinite lives; however, they are subject to review for impairment. We review our intangible assets with indefinite lives for impairment annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-process Research and Development (IPR&amp;D)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired IPR&amp;D represents the fair value assigned to research and development assets that have not reached technological feasibility. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenues from the projects and discounting the net cash flows to present value. The revenues and costs projections used to value acquired IPR&amp;D are, as applicable, reduced based on the probability of success of developing a new drug. Additionally, the projections consider the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by us and our competitors. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections. Upon the acquisition of IPR&amp;D, we complete an assessment of whether our acquisition constitutes the purchase of a single asset or a group of assets. We consider multiple factors in this assessment, including the nature of the technology acquired, the presence or absence of separate cash flows, the development process and stage of completion, quantitative significance and our rationale for entering into the transaction.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">If we acquire a business as defined under applicable accounting standards, then the acquired IPR&amp;D is capitalized as an intangible asset. If we acquire an asset or group of assets that do not meet the definition of a business under applicable accounting standards, then the acquired IPR&amp;D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">When performing our impairment assessment, we calculate the fair value using the same methodology as described above. If the carrying value of our acquired IPR&amp;D exceeds its fair value, then the intangible asset is written-down to its fair value. Changes in estimates and assumptions used in determining the fair value of our acquired IPR&amp;D could result in an impairment. Impairments are recorded within amortization and impairment of acquired intangible assets in our consolidated statements of income. Assets that have been previously impaired, including our vixotrigine (BIIB074) program for the treatment of neuropathic pain, such as trigeminal neuralgia (TGN), could become further impaired in the future.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets when accounted for using the purchase method of accounting. Goodwill is not amortized, but reviewed for impairment. Goodwill is reviewed annually, as of October&#160;31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We compare the fair value of our reporting unit to its carrying value. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we would record an impairment loss equal to the difference. As described in Note&#160;25, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Segment Information,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements, we operate in one operating segment, which is our only reporting unit.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets to be held and used, including property, plant and equipment, and definite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets or asset group may not be recoverable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written-down to their fair values. Long-lived assets to be disposed of are carried at fair value less costs to sell.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Contingent Consideration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The consideration for our acquisitions often includes future payments that are contingent upon the occurrence of a particular event or events. For acquisitions completed before January 1, 2009, we record contingent consideration resulting from a business combination when the contingency is resolved. For acquisitions of a business completed after January&#160;1, 2009, we record an obligation for such contingent payments at fair value on the acquisition date. We estimate the fair value of contingent consideration obligations through valuation models that incorporate probability-adjusted assumptions related to the achievement of the milestones and thus likelihood of making related payments. We revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations are recognized in our consolidated statements of income. Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows and reserves associated with products upon commercialization, changes in the assumed achievement or timing of any cumulative sales-based and development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Discount rates in our valuation models represent a measure of the credit risk associated with settling the liability. The period over which we discount our contingent obligations is based on the current development stage of the product candidates, our specific development plan for that product candidate adjusted for the probability of completing the development step and when the contingent payments would be triggered. In estimating the probability of success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments and Hedging Activities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Cash Flow and Fair Value Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We recognize all derivative instruments as either assets or liabilities at fair value in our consolidated balance sheets. Changes in the fair value of our derivative instruments are recognized each period in current earnings or accumulated other comprehensive income (loss), depending on whether the derivative instrument is designated as part of a hedge transaction and, if so, the type of hedge transaction. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items. We do not hold or issue derivative instruments for trading or speculative purposes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We assess at inception and on an ongoing basis, whether the derivative instruments that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. We exclude the forward points portion of the derivative instruments used in a hedging transaction from the effectiveness test and record the fair value gain or loss related to this portion each period in our consolidated statements of income in the same line as the underlying hedged item. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting for the affected portion of the hedge instrument, and any related unrealized gain or loss on the contract is recognized in current earnings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Investment Derivative Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are exposed to the impact of foreign exchange fluctuations on our investment in the equity of Samsung Bioepis, which is denominated in a currency other than the U.S. dollar, and could adversely impact the U.S. dollar value of this investment. Using derivative instruments, we have hedged our net investment position to mitigate the effects of foreign exchange fluctuations. We recognize these designated net investment hedges as either assets or liabilities, at fair value, in our consolidated balance sheets. We hedge the changes in the spot exchange rate in accumulated other comprehensive income (loss) and exclude changes to the forward rate and amortize the forward points in other income (expense), net in our consolidated statements of income over the term of the contract. We classify the cash flows from these instruments in the same category as the cash flows from the hedged items.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Translation of Foreign Currencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The functional currency for most of our foreign subsidiaries is their local currency. For our non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign currency exchange rates for the period. Adjustments resulting from the translation of the financial statements of our foreign operations into U.S.&#160;dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of equity. For subsidiaries where the functional currency of the assets and liabilities differ from the local currency, non-monetary assets and liabilities are translated at the rate of exchange in effect on the date assets were acquired while monetary assets and liabilities are translated at current rates of exchange as of the balance sheet date. Income and expense items are translated at the average foreign currency rates for the period. Translation adjustments of these subsidiaries are included in other income (expense), net in our consolidated statements of income.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RoyaltyCostofSalesPolicyTextBlock', window );">Royalty Cost of Sales</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We make royalty payments to a number of third parties under license or purchase agreements associated with our acquisition of intellectual property. These royalty payments are typically calculated as a percentage (royalty rate) of the sales of our products in a particular year.&#160;That royalty rate may remain constant, increase or decrease within each year based on the total amount of sales during the annual period. Each quarterly period, we estimate our total royalty obligation for the full year and recognize the proportional amount as cost of sales based on actual quarterly sales as a percentage of full year estimated sales. For example, if the level of net sales in any calendar year increases the royalty rate within the year, we will record our cost of sales at an even rate over the year, based on the estimated blended royalty rate.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Accounting for Share-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share-based compensation programs grant awards that have included stock options, restricted stock units that vest based on stock performance known as market stock units (MSUs), performance-vested restricted stock units that settle in cash (CSPUs), time-vested restricted stock units (RSUs), performance-vested restricted stock units that can be settled in cash or shares of our common stock (PUs) at the sole discretion of the Compensation and Management Development Committee of our Board of Directors, performance-vested stock units that settle in stock or cash (PSUs) and shares issued under our employee stock purchase plan (ESPP). We charge the estimated fair value of awards against income over the requisite service period, which is generally the vesting period. Where awards are made with non-substantive vesting periods (for instance, where a portion of the award vests upon retirement eligibility), we estimate and recognize expense based on the period from the grant date to the date the employee becomes retirement eligible.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our stock option grants are estimated as of the date of grant using a Black-Scholes option valuation model. The estimated fair values of the stock options are then expensed over the options&#8217; vesting periods.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our MSUs are estimated using a lattice model with a Monte Carlo simulation. We apply an accelerated attribution method to recognize share-based compensation expense over the applicable service period, net of estimated forfeitures when accounting for our MSUs. The probability of actual shares expected to be earned is considered in the grant date valuation, therefore the expense is not adjusted to reflect the actual units earned.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our RSUs are based on the market value of our stock on the date of grant. Compensation expense, net of forfeitures, for RSUs is recognized straight-line over the applicable service period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We apply an accelerated attribution method to recognize share-based compensation expense when accounting for our CSPUs, PUs and PSUs that settle in cash, and the fair value of the liability is remeasured at the end of each reporting period through expected settlement. Compensation expense associated with CSPUs, PUs and PSUs that settle in cash are based upon the stock price and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of PSUs that settle in stock are based upon the stock price on the date of grant and the number of units expected to be earned after assessing the probability that certain performance criteria will be met and the associated targeted payout level that is forecasted will be achieved, net of estimated forfeitures. Cumulative adjustments are recorded each quarter to reflect the estimated outcome of the performance-related conditions until the date results are determined and settled.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The purchase price of common stock under our ESPP is equal to </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">85%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> of the lesser of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date. The fair value of the discounted purchases made under our ESPP is calculated using the Black-Scholes valuation model. The fair value of the look-back provision plus the </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> discount is recognized as compensation expense over the 90-day purchase period. </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development expenses consist of upfront fees and milestones paid to collaborators and expenses incurred in performing research and development activities, which include compensation and benefits, facilities and overhead expenses, clinical trial expenses and fees paid to contract research organizations (CROs), clinical supply and manufacturing expenses, write-offs of inventory that was previously capitalized in anticipation of product launch and determined to no longer be realizable and other outside expenses. Research and development expenses are expensed as incurred. Payments we make for research and development services prior to the services being rendered are recorded as prepaid assets in our consolidated balance sheets and are expensed as the services are provided. We also accrue the costs of ongoing clinical trials associated with programs that have been terminated or discontinued for which there is no future economic benefit at the time the decision is made to terminate or discontinue the program.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, we enter into development agreements in which we share expenses with a collaborative partner. We record payments received from our collaborative partners for their share of the development costs as a reduction of research and development expense, except as discussed in Note&#160;19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to these consolidated financial statements. Because an initial indication has been approved for both RITUXAN and GAZYVA, expenses incurred by Genentech in the ongoing development of RITUXAN and GAZYVA are not recorded as research and development expense, but rather reduce our share of profits recorded as a component of revenues from anti-CD20 therapeutic programs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For collaborations with commercialized products, if we are the principal, we record revenues and the corresponding operating costs in their respective line items in our consolidated statements of income. If we are not the principal, we record operating costs as a reduction of revenue.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, General and Administrative Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative expenses are primarily comprised of compensation and benefits associated with sales and marketing, finance, human resources, legal, information technology and other administrative personnel, outside marketing, advertising and legal expenses and other general and administrative costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Advertising costs are expensed as incurred. For the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, advertising costs totaled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$90.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$75.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$106.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The provision for income taxes includes federal, state, local and foreign taxes. Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences of temporary differences between the financial statement carrying amounts and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which the temporary differences are expected to be recovered or settled. We evaluate the realizability of our deferred tax assets and establish a valuation allowance when it is more likely than not that all or a portion of deferred tax assets will not be realized. In December 2018 we elected to recognize deferred taxes associated with our global intangible low-taxed income (GILTI) tax calculations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfers of assets other than inventory within our consolidated group, both current and deferred, are recorded as a prepaid tax or deferred charge and recognized through our consolidated statements of income when the asset is transferred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We account for uncertain tax positions using a &#8220;more-likely-than-not&#8221; threshold for recognizing and resolving uncertain tax positions. We evaluate uncertain tax positions on a quarterly basis and consider various factors including, but not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, information obtained during in process audit activities and changes in facts or circumstances related to a tax position. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We are currently involved in various claims and legal proceedings. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management&#8217;s best estimate of probable loss. Disclosure also is provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. On a quarterly basis, we review the status of each significant matter and assess its potential financial exposure.&#160;Significant judgment is required in both the determination of probability and the determination as to whether an exposure is reasonably estimable. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to pending claims and litigation and may change our estimates. These changes in the estimates of the potential liabilities could have a material impact on our consolidated results of operations and financial position.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share is computed by dividing undistributed net income attributable to Biogen Inc. by the weighted-average number of common shares outstanding during the period. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have or may have a material impact on our consolidated financial statements or disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Revenue recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In May 2014 the FASB issued ASU 2014-09, which supersedes all existing revenue recognition requirements, including most industry specific guidance. This standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. For additional information on the adoption of the new revenue standards, please read the section titled </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue Recognition </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">above, and Note 5, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenues</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In January 2016 the FASB issued ASU No. 2016-01, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in a company's results of operations. This standard does not apply to investments accounted for under the equity method of accounting or those investments that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in other comprehensive income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, and recognized a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> net increase to retained earnings as well as a </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$1.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> increase to accumulated other comprehensive income reflecting the cumulative impact for the accounting changes made upon adoption. The adoption of this standard resulted in a change in the income statement classification with respect to where we recognize changes in fair value related to certain equity security investments. Prior to the adoption of ASU 2016-01, we recognized changes in fair value in accumulated other comprehensive income (loss), net. Upon the adoption of ASU 2016-01, we recognize changes in fair value in other income (expense), net. During the year ended December 31, 2018, we recognized net gains resulting from changes in fair value related to our equity security investments in other income (expense), net totaling approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$128.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> under this standard that would not have been recognized in other income (expense), net under the previous standard. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Leasing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In February 2016 the FASB issued ASU No. 2016-02, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard established a right-of-use model that requires all lessees to recognize right-of-use assets and liabilities on their balance sheet that arise from leases with terms longer than 12 months as well as provide disclosures with respect to certain qualitative and quantitative information related to their leasing arrangements. This standard became effective for us on January 1, 2019. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The FASB has subsequently issued the following amendments to ASU 2016-02, which have the same effective date and transition date of January 1, 2019, and which we collectively refer to as the new leasing standards: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-01,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;"> Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">which permits an entity to elect an optional transition practical expedient to not evaluate under Topic 842 land easements that exist or expired prior to adoption of Topic 842 and that were not previously accounted for as leases under the prior standard, ASC 840, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Codification Improvements to Topic 842, Leases</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which amends certain narrow aspects of the guidance issued in ASU 2016-02.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-11, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842): Targeted Improvements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which allows for a transition approach to initially apply ASU 2016-02 at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption as well as an additional practical expedient for lessors to not separate non-lease components from the associated lease component.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">ASU No. 2018-20, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Narrow-Scope Improvements for Lessors</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, which contains certain narrow scope improvements to the guidance issued in ASU 2016-02.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted the new leasing standards on January 1, 2019, using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019. We have reviewed our existing lease contracts and the impact of the new leasing standards on our consolidated results of operations, financial position and disclosures. Upon adoption of the new leasing standards, we expect to recognize a lease liability and related right-of-use asset on our consolidated balance sheet of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The impact of adoption of the new leasing standards will have an immaterial impact to our consolidated statements of income. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Credit Losses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In June 2016 the FASB issued ASU No. 2016-13, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard will be effective for us on January 1, 2020. We are currently evaluating the potential impact that this standard may have on our consolidated financial position and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In October 2016 the FASB issued ASU No. 2016-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other Than Inventory</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard eliminates the deferral of the tax effects of intra-entity asset transfers other than inventory. As a result, the income tax consequences from the intra-entity transfer of an asset other than inventory and associated changes to deferred taxes will be recognized when the transfer occurs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, through a cumulative-effect adjustment to retained earnings as of that date. Upon adoption, we recognized additional net deferred tax assets of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, offset by a corresponding net increase to retained earnings of approximately </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.5 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. In the fourth quarter of 2018, when we elected to begin recognizing deferred taxes on the GILTI tax calculation, we recorded an additional deferred tax liability of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$0.4 billion</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> with a corresponding reduction to our retained earnings as these differences are related to inter-entity transactions. We will recognize incremental deferred income tax expense thereafter as these deferred tax assets and liabilities are utilized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our income taxes, please read Note 17, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income Taxes</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Net Periodic Pension Cost</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-07, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Costs and Net Periodic Postretirement Benefit Cost.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> This standard requires that an employer disaggregate the service cost component from the other components of net benefit cost. This standard also provides explicit guidance on how to present the service cost component and the other components of net benefit cost in the statements of income and allows only the service cost component of net benefit cost to be eligible for capitalization. The other components of the net periodic benefit cost must be presented separately from the line items that include service cost and outside of any subtotal of operating income on our consolidated statements of income. We adopted this standard on January 1, 2018, using the retrospective method. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As a result of the adoption of this standard, the other components of net periodic benefit cost, which we previously presented as a component of operating income, are now classified in other income (expense), net in our consolidated statements of income. For the years ended December 31, 2017 and 2016, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$2.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$3.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, were reclassified from operating income to other income (expense), net in our consolidated statements of income to conform to our current year presentation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Debt Securities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In March 2017 the FASB issued ASU No. 2017-08, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Receivables - Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard amends the amortization period for certain purchased callable debt securities held at a premium by shortening the amortization period to the earliest call date. This standard became effective for us on January 1, 2019, and was adopted using a modified retrospective transition approach. Based upon our marketable debt securities as of December 31, 2018, the adoption of this standard did not result in a significant adjustment to our marketable debt securities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Derivative Instruments and Hedging Activities</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2017 the FASB issued ASU No. 2017-12, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard provides guidance to better align an entity's risk management activities and financial reporting for hedging relationships through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results. This standard expands and refines hedge accounting for both non-financial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">We adopted this standard on January 1, 2018, using the modified retrospective method, which did not have an impact on our financial position or results of operations; however, the adoption of this standard resulted in additional disclosures and a change in the income statement classification with respect to where we recognize cash flow hedge ineffective or excluded hedge transaction gains and losses. Prior to the adoption of ASU 2017-12 on January 1, 2018, to the extent ineffective or excluded, cash flow hedge transaction gains and losses were reported in other income (expense), net. Effective January 1, 2018, we recognize all cash flow hedge reclassifications from accumulated other comprehensive income and fair value changes of any cash flow hedge ineffectiveness or excluded portions in the same line item in our consolidated statements of income that has been impacted by the hedged item.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additionally, in October 2018 the FASB issued ASU No. 2018-16, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging (Topic 815): Inclusion of the Secured Overnight Financing Rate (SOFR) Overnight Index Swap (OIS) Rate as a Benchmark Interest Rate for Hedge Accounting Purposes. </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard permits use of the OIS rate based on the SOFR as a U.S. benchmark interest rate for hedge accounting purposes under ASC 815, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our derivative instruments and hedging activities, please read Note 10, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Derivative Instruments</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In August 2018 the FASB issued ASU No. 2018-13, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. This standard modifies certain disclosure requirements on fair value measurements. This standard will be effective for us on January 1, 2020. We do not expect that the adoption of this standard will have a material impact on our disclosures.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#538235;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In November 2018 the FASB issued ASU No. 2018-18, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> This standard makes targeted improvements for collaborative arrangements as follows: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers,</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> when the collaborative arrangement participant is a customer in the context of a unit of account. In those situations, all the guidance in ASC 606 should be applied, including recognition, measurement, presentation and disclosure requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adds unit-of-account guidance to ASC 808, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative Arrangements</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to align with the guidance in ASC 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of ASC 606; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Requires that in a transaction with a collaborative arrangement participant that is not directly related to sales to third parties, presenting that transaction together with revenue recognized under ASC 606 is precluded if the collaborative arrangement participant is not a customer. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">This standard will be effective for us on January 1, 2020; however, early adoption is permitted. A retrospective transition approach is required for either all contracts or only for contracts that are not completed at the date of initial application of ASC 606, with a cumulative adjustment to opening retained earnings. We are currently evaluating the potential impact that this standard may have on our consolidated financial position and results of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RoyaltyCostofSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Cost of Sales [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RoyaltyCostofSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=SL94080555-108585<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109236672&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2,12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e4975-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 50<br> -Section 25<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=16397303&amp;loc=d3e19347-109286<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 40<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6389767&amp;loc=d3e17916-109280<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823688864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Property, plant and equipment estimated useful lives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset Category</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;text-decoration:underline;">Useful Lives</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Land</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Not depreciated</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Buildings</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">15 to 40&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Leasehold Improvements</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Lesser of the useful life or the term of the respective lease</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Furniture and Fixtures</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 7&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Machinery and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5 to 20&#160;years</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Computer&#160;Software&#160;and&#160;Hardware</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3 to 5&#160;years</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of property plant and equipment useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973276960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin-Off Hemophilia Spin-Off (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Assets and liabilities charges to equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">302.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">144.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">116.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Property, plant and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">20.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">56.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">314.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">53.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Assets transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1,008.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other current liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">87.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">67.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liabilities transferred, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">155.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823534576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenue by product</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues by product are summarized as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="36" rowspan="1"></td></tr><tr><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">United</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Rest of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">World</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Multiple Sclerosis (MS):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TECFIDERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">3,253.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,020.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">4,274.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,294.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">920.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4,214.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,169.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">798.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,968.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Interferon*</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,668.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">694.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,363.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,889.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">756.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,645.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,980.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">814.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,795.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">TYSABRI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,025.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">839.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,864.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,113.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">859.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,973.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,182.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">780.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">1,963.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FAMPYRA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">92.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">92.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">91.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">91.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">84.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ZINBRYTA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">52.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: MS Product Revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">5,946.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">2,648.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">8,595.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,296.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,680.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,977.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6,332.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,487.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">8,819.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Spinal Muscular Atrophy:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">SPINRAZA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">854.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">870.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">1,724.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">657.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">226.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">883.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">4.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Biosimilars:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">BENEPALI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">485.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">485.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">370.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">370.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FLIXABI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">43.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">43.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">IMRALDI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">16.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Biosimilar product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">545.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">545.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">379.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">379.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">100.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Other:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">FUMADERM</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">22.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">22.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">39.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">39.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">45.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Hemophilia:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ELOCTATE</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">42.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">6.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">48.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">445.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">68.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">513.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">21.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">5.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">26.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">268.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">65.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">333.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Subtotal: Hemophilia product revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">63.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">11.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">74.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">713.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">133.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">846.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">Total product revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">6,800.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">4,086.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7,017.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">3,337.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">10,354.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">7,050.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">2,767.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">9,817.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">*Interferon includes AVONEX and PLEGRIDY.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change in reserves</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">An analysis of the change in reserves for discounts and allowances is summarized as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">109.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">606.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">761.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">679.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,686.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">23.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,389.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(12.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(551.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,887.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,440.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(109.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(506.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(646.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">127.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">888.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">482.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">583.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,307.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,917.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(8.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(475.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,756.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,232.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(69.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(442.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(23.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(534.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">109.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">606.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Discounts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Returns</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">56.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">548.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">662.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current provisions relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">592.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,044.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,668.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Adjustments relating to prior years</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(522.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,576.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,099.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments/returns relating to sales in prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(53.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(536.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(609.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">482.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheet</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reduction of accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">176.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.6</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Component of accrued expenses and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">874.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenue-related reserves</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,051.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">761.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,431.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,316.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,431.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,316.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues are summarized as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from collaborative and other relationships:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(8.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under our technical development agreement, manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">96.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Sobi and royalties from Sobi on sales of ELOCTA and ALPROLIX</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other royalty and corporate revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalty</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">38.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">69.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">46.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">459.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">253.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">230.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">585.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic partners, including Bioverativ.</font></div><div style="line-height:120%;padding-top:12px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">For additional information on our collaboration arrangements with AbbVie and Samsung Bioepis, please read Note 19, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Collaborative and Other Relationships</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, to these consolidated financial statements. For additional information on our contract manufacturing agreements with Bioverativ, please read Note 3,&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hemophilia Spin-Off</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">,&#160;to these consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833961424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The components of inventory are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">196.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">162.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">606.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">605.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">133.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">157.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet Classification:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">929.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">902.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total inventory</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">925.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813664064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated Life</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Out-licensed patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">13-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">543.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(542.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">543.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(535.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">15-23 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,005.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,734.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">270.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,005.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2,689.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In-process research and development</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite until commercialization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">476.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">476.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">680.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Indefinite</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">64.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">64.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Acquired and in-licensed rights and patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4-18 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,638.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,330.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,308.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,971.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,160.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,811.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7,727.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4,607.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,120.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8,264.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4,385.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,879.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization of intangible assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">270.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">290.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">250.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">230.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the changes in our goodwill balance:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,632.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,669.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Elimination of goodwill allocated to our hemophilia business</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(314.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Increase to goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,080.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,267.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Goodwill, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,706.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,632.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813408688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices in</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,459.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,459.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">969.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">969.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">615.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">563.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,102.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">51.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,050.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">434.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quoted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">in&#160;Active</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Observable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(Level 3)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable debt securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,609.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,919.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">643.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Plan assets for deferred compensation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">28.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,444.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,433.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Derivative contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">634.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">111.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The fair values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,489.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,517.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,032.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,745.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,851.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,802.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,077.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,037.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6,483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table provides a roll forward of the fair values of our contingent consideration obligations, which includes Level 3 measurements:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">523.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">467.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Changes in fair value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(12.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">62.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Payments and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(101.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Fair value, end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">409.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">523.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6962960144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our financial assets with maturities of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">less than 90&#160;days</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> from the date of purchase included in cash and cash equivalents in our consolidated balance sheets:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Commercial paper</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">231.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Overnight reverse repurchase agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Money market funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">279.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">948.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Short-term debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">194.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">247.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,229.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Marketable securities including strategic investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize our marketable debt and equity securities, classified as available for sale:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,607.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,608.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">851.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">854.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">705.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">706.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">263.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">264.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">260.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(6.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">615.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">127.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">496.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,039.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,570.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,569.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Government securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,075.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">845.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Mortgage and other asset backed securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">642.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total marketable debt securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(2.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Marketable equity securities, non-current</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">14.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: Available-for-sale securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The estimated fair value and amortized cost of our marketable debt securities available-for-sale by contractual maturity are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair&#160; Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Cost</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,313.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,314.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,115.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,116.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after one year through five years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,232.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,235.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,730.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Due after five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">143.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">327.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total available-for-sale securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,689.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,694.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,172.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,173.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable securities, excluding strategic investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Proceeds from maturities and sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">9,173.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,565.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,378.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Realized losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720565504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The notional value of foreign currency forward contracts that were entered into to hedge forecasted revenues and operating expenses is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Notional Amount</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Foreign Currency: (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,701.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,875.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">British pound sterling</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">150.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Swiss francs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">131.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">88.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Japanese yen</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">98.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Canadian dollar</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total foreign currency forward contracts</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,239.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,198.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of derivatives designated as cash flow hedging instruments on our consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our consolidated statements of income:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Year&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;font-style:italic;">&#160;</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(in millions)</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized in Operating Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19" rowspan="1"></td></tr><tr><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:24%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Reclassified from AOCI into Operating Income (in millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Net Gains/(Losses)</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Recognized Directly into Net Income (in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">8.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the effect of our net investment hedge in our consolidated financial statements:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:43%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">For the Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net Gains/(Losses) Recognized in AOCI</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (Losses) on Net Investment Hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">(3.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net Gains/(Losses) Reclassified from AOCI into Net Income </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of the fair value for our outstanding derivatives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the fair value and presentation in our consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance&#160;Sheet&#160;Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">65.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">14.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:33%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Balance Sheet Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value<br clear="none"/>As of December 31, 2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Hedging Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Investments and other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other long-term liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Other Derivative Instruments:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Asset derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other current assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Liability derivative instruments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued&#160;expenses&#160;and&#160;other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6972966944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of property, plant and equipment, net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of property, plant and equipment, net are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Land</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">144.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">141.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Buildings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,282.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,213.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">94.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">80.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Machinery and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,258.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,207.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Computer software and hardware</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">798.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">767.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">61.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,758.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,276.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total cost</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,398.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,741.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,797.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1,559.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total property, plant and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,601.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,182.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6957994208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Indebtedness</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our indebtedness is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Notes payable to Fumedica AG</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of notes payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Non-current portion:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.900% Senior Notes due September 15, 2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,480.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,482.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.625% Senior Notes due September 15, 2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">995.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">994.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.050% Senior Notes due September 15, 2025</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,737.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,736.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.200% Senior Notes due September 15, 2045</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,722.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,722.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Non-current portion of notes payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,936.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,935.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Total debt maturities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The total gross payments due under our debt arrangements are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,500.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2024 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,500.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,000.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973102224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfCommonStockTableTextBlock', window );">Summary of common stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table describes the number of shares authorized, issued and outstanding of our common stock as of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and 2016:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="27" rowspan="1"></td></tr><tr><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">As of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Outstanding</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Common stock</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,000.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">221.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">197.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">235.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,000.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">238.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6972936208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of accumulated other comprehensive income (loss)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the changes in accumulated other comprehensive income (loss), net of tax by component:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(318.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified, net of tax, upon adoption of ASU 2016-01</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, January 1, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(104.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(36.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(175.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(316.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">97.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(67.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">29.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">41.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">139.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(67.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">76.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">34.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(31.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(243.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(240.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(193.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">31.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(162.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">158.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(104.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(318.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Securities Available for Sale, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unrealized Gains (Losses) on Cash Flow Hedges, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Gains (Losses) on Net Investment Hedge, Net of Tax</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Unfunded Status of Postretirement Benefit Plans, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Currency Translation Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(37.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(195.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(224.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other comprehensive income (loss) before reclassifications</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">51.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(92.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Amounts reclassified from accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(4.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net current period other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(138.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(95.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance, December 31, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(10.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(334.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(319.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of accumulated other comprehensive income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amounts reclassified from accumulated other comprehensive income:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td rowspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Income Statement Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Amounts Reclassified from</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Accumulated Other Comprehensive Income</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on securities available for sale</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(8.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(19.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(42.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(32.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Operating expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gains (losses) on net investment hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other Income (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax benefit (expense)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total reclassifications, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(47.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(44.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6972911024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic and diluted earnings per share are calculated as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,430.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,702.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted average number of common shares outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Stock options and employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares used in calculating diluted earnings per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">205.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">218.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831007200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in consolidated statements of income</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense included in our consolidated statements of income:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">84.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">105.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">121.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">181.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income tax effect</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(27.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(42.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(54.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">142.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">117.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">135.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Market stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Time-vested restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">126.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">107.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">120.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash settled performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">16.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance units</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in stock</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Performance stock units settled in cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee stock purchase plan</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Subtotal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">181.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">169.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">204.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Capitalized share-based compensation costs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(11.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation expense included in total cost and expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">189.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock option activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our stock option activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Price</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">42,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(15,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.82</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock', window );">Tax benefit and cash received from stock option exercises</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes the amount of tax benefit realized for stock options and cash received from the exercise of stock options:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax benefit realized for stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received from the exercise of stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock', window );">Market stock units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our MSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">171,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">370.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">129,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">378.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(91,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">365.83</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(29,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">376.51</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">180,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">371.32</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock', window );">Assumptions used in valuation of market based stock units</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">he assumptions used in our valuation are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of expected stock price volatility</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">27.5% - 32.4%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">33.0% - 35.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">38.2% - 40.7%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Range of risk-free interest rates</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.9% - 2.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9% - 1.6%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6% - 0.9%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">30 calendar day average stock price on grant date</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$279.47 - $346.76</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$263.18 - $267.88</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$260.67 - $304.86</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average per share grant date fair value</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$378.85</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$382.59</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$328.03</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock', window );">Cash settled performance shares activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our CSPU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">105,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">12,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(51,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(16,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceunitsactivityTableTextBlock', window );">Performance units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">91,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(52,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">48,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceStockUnitsSettledinStockTableTextBlock', window );">Performance stock units settled in stock activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in stock activity:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">67,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">317.09</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">315.70</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">317.26</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceStockUnitsSettledinCashTableTextBlock', window );">Performance stock units settled in cash activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our PSUs that settle in cash activity:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">45,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(5,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock', window );">Time-vested restricted stock units activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our RSU activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Grant&#160;Date</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">832,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">291.85</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Granted (a)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">581,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">316.32</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(376,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">299.94</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(134,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">298.81</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Unvested at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">903,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">303.18</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock', window );">Shares issued under employee stock purchase plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following table summarizes our ESPP activity:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Shares issued under the 2015 ESPP</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">170,000</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">167,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">190,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash received under the 2015 ESPP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">39.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in valuation of market based stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AssumptionsUsedInValuationOfMarketBasedStockUnitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceStockUnitsSettledinCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Stock Units Settled in Cash [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceStockUnitsSettledinCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceStockUnitsSettledinStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Stock Units Settled in Stock [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceStockUnitsSettledinStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceunitsactivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance units activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceunitsactivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Cash Settled Performance Shares Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfCashSettledPerformanceSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfMarketStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Market Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfMarketStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SharesIssuedUnderEmployeeStockPurchasePlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Time Vested Restricted Stock Units Activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TimeVestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash received from exercise of stock options and similar instruments granted under share-based payment arrangements and tax benefit from exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProceedsReceivedAndTaxBenefitFromShareBasedPaymentAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813525616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Income before income tax provision and the income tax expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income before income tax provision and the income tax expense consist of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income before income taxes (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,877.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,540.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,655.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,022.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,588.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,277.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5,899.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5,128.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4,933.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Income tax expense (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,131.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,201.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,304.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">45.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">57.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">55.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">140.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">108.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">52.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,317.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,367.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,412.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(62.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">241.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(125.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(7.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(3.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">177.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(159.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(45.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">108.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">91.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(175.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total income tax expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,425.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,458.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,237.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of deferred tax assets and liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Significant components of our deferred tax assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As&#160;of&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">102.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">60.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Inventory, other reserves and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">163.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">147.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Intangibles, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,298.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">378.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net operating loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">213.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">209.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">38.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(20.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(16.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,823.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">831.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-style:italic;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(232.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(250.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(544.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1,425.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Depreciation, amortization and other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(102.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(107.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2,305.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(358.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statutory rate</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">35.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">State taxes</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Taxes on foreign earnings</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(1.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(11.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Credits and net operating loss utilization</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(0.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(0.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Purchased intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Manufacturing deduction</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other permanent items</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017 Tax Act</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">22.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">GILTI</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Impairment of ZINBRYTA related tax assets</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Effective tax rate</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">24.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">47.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#160;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of beginning and ending amount of unrecognized tax benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A reconciliation of the beginning and ending amount of our unrecognized tax benefits is summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at January&#160;1,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">66.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.9</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions based on tax positions related to the current period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Additions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">58.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">36.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Reductions for tax positions of prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(13.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(21.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(13.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Statute expirations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(2.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Settlement refund (payment)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">44.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(64.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Balance at December&#160;31,</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">114.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">66.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">32.4</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=109238393&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973098816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental cash flow information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Supplemental disclosure of cash flow information for the years ended </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2017</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2016</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:51%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Cash paid during the year for:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">243.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">281.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,007.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,066.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,642.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Components of other income (expense), net, are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">112.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">78.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(200.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(250.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(260.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gain (loss) on investments, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">119.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(36.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Foreign exchange gains (losses), net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(9.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(9.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(10.5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(14.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(18.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total other income (expense), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(217.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(218.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Accrued expenses and other consists of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">As of December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenue-related reserves for discounts and allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">874.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">572.0</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Current portion of contingent consideration obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">444.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">844.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Employee compensation and benefits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">320.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">297.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Royalties and licensing fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">224.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">206.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">125.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">159.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Collaboration expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">261.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">183.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">609.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">636.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total accrued expenses and other</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,861.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,901.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823677584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaTableTextBlock', window );">Co-promotion profit sharing formula</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of annual co-promotion profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until GAZYVA First Non-CLL FDA Approval</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">40.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First Non-CLL GAZYVA FDA Approval</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the FDA&#8217;s first approval of GAZYVA in an indication other than CLL.</font></div><div style="line-height:120%;padding-top:12px;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">First GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the earlier of (i)&#160;the date of the First Non-CLL GAZYVA FDA approval if U.S. gross sales of GAZYVA for the preceding consecutive 12-month period were at least </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> or (ii)&#160;the first day of the calendar quarter after the date of the First Non-CLL GAZYVA FDA Approval that U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;text-decoration:underline;">Second GAZYVA Threshold Date</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> means the first day of the calendar quarter after U.S. gross sales of GAZYVA within any consecutive 12-month period have reached </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$500.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">. The Second GAZYVA Threshold Date can be achieved regardless of whether GAZYVA has been approved in a non-CLL indication.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PretaxProfitSharingFormulaTableTextBlock', window );">Pretax profit sharing formula</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Our share of annual profits in excess of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> varies, as summarized in the table below, upon the following events:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:82%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">Until First GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After First GAZYVA Threshold Date until Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">37.5</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">After Second GAZYVA Threshold Date</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">35.0</font></div></td><td style="vertical-align:top;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,431.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,316.4</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs are summarized as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For&#160;the&#160;Years&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,431.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,316.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from anti-CD20 therapeutic programs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">548.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">242.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">65.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock', window );">Summary of activity related to BAN2401 and Elenbecestat collaboration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development expenses related to the BAN2401 and Elenbecestat Collaboration is as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total development expense incurred by the collaboration related to the advancement of BAN2401 and Elenbecestat</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">232.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">146.2</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">95.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of BAN2401 and Elenbecestat development expense reflected in research and development expense in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">116.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">74.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">50.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of activity related to Aducanumab collaboration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">A summary of development and sales and marketing expenses related to the Aducanumab Collaboration Agreement is as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Years Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#257acb;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab development expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">264.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">268.7</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">209.5</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">234.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">268.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">209.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total aducanumab sales and marketing expense incurred by the collaboration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">50.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#257acb;">27.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">23.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">18.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock', window );">Summary of activity related to Abbvie collaboration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">For the Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">53.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6.1</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">25.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">92.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">50.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">17.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">39.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">43.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Biogen's share of co-promotion losses in the U.S.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">8.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">16.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PretaxProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pretax Profit Sharing Formula [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PretaxProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of activity related to collaboration with company seven.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToCollaborationWithCompanySevenTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823606848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Minimum rental commitments under non-cancelable leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">As of </font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, minimum rental commitments under non-cancelable leases, net of income from subleases, for each of the next five years and total thereafter were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">2023</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Minimum lease payments </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">87.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">80.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">75.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">71.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">215.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">601.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Less: income from subleases (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(26.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(25.6</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(23.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(24.3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(58.4</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">(182.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net minimum lease payments</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">60.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">55.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">52.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">47.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">46.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">156.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">418.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;"></font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6720221360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Geographic information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">The following tables contain certain financial information by geographic area:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;color:#2573ba;font-weight:bold;">December 31, 2018 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">6,800.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,370.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">281.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">434.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,903.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">76.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">457.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">32.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">96.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">585.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,152.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,442.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,601.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2017 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,017.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,844.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">160.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">332.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,475.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">83.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">249.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">67.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">42.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,226.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,948.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,182.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">December 31, 2016 (In millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Europe</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Asia</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7,050.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,237.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">217.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">313.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">9,817.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,249.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">63.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,314.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues from external customers</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">224.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">71.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">20.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">316.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Long-lived assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,272.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,221.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,501.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823611232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2018</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b) (c) (d)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (b) (e)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(a) (f) (g) (h) (i)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,523.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,757.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,780.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,825.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">10,886.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">443.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">490.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">511.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">534.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,980.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">164.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">108.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">147.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">165.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">585.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,131.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,356.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,439.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,526.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">13,452.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,685.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,935.5</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">2,978.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">3,037.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">11,636.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,171.2</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">915.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,442.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">944.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,474.0</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,172.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">866.6</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">1,444.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">946.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4,430.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.55</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.18</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.17</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.74</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.63</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">5.54</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.18</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">7.15</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">4.73</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">$</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">21.58</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.1</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">201.4</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">199.8</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">204.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">211.7</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">207.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">201.9</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">200.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;color:#2573ba;">205.3</font></div></td><td style="vertical-align:bottom;background-color:#dddddd;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(In millions, except per share amounts)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">First</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Second</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Third</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Fourth</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">Year</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(g)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(j) (k) (l)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;font-weight:bold;">(m) (n) (o) (p)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Product revenues, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,380.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,639.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,622.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,712.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,354.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Revenues from anti-CD20 therapeutic programs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">340.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">397.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">406.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">415.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,559.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Other revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">90.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">41.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">48.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">179.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">360.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,810.7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,078.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,077.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3,307.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">12,273.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Gross profit (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,426.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,712.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,707.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,797.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">10,643.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">862.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,226.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(166.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,670.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">747.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">862.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">1,226.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(297.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">2,539.1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income per share:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.07</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.41</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">3.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">4.07</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">5.79</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(1.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">11.92</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Weighted-average shares used in calculating:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Basic earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Diluted earnings per share attributable to Biogen Inc.</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">215.9</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">211.8</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">212.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">213.0</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:9pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:9pt;">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the first, second, third and fourth quarters of 2018 includes pre-tax charges related to (losses) gains recorded in relation to changes in the fair value of our strategic investments of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$(6.4) million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$5.4 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$141.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$(12.2) million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the first, second and third quarters of 2018 include pre-tax charges to acquired IPR&amp;D of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$10.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$75.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$27.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, for upfront payments to Karyopharm, Pfizer and AliveGen, respectively, upon closing of the asset purchase transactions for BIIB100, BIIB104 and BIIB110, respectively, as the underlying assets had not yet reached technological feasibility.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2018 includes pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$486.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> upon the closing of the 2018 Ionis Agreement. Included in this amount was a charge of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$162.1 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflecting the premium paid above fair value for the purchase of approximately </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">11.5 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> shares of Ionis' common stock upon the closing of the 2018 Ionis Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. for the second quarter of 2018 includes a pre-tax charge to noncontrolling interest of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a payment to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">5%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(e)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the third quarter of 2018 includes the impact of impairment charges totaling </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$189.3 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to certain IPR&amp;D assets associated with our vixotrigine program and an adjustment to the value of our contingent consideration obligations related to our vixotrigine program for the treatment of TGN to reflect the lower cumulative probabilities of success, which resulted in a gain of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$89.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the third quarter of 2018. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(f)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">In late December 2018 we received feedback from the FDA regarding the design of the Phase 3 vixotrigine program for the treatment of TGN. Following this feedback, we are now planning to initiate the Phase 3 vixotrigine program for the treatment of TGN and, as a result, we adjusted the fair value of our contingent consideration obligations related to our vixotrigine program for the treatment of TGN to reflect the increased probabilities of success and recognized a loss of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$80.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> in the fourth quarter of 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(g)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 and the first quarter of 2017 includes </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$176.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$328.2 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">, respectively, of impairment charges related to our intangible asset associated with our U.S. license to Forward Pharma's intellectual property, including Forward Pharma's intellectual property related to TECFIDERA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(h)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 includes a net increase to income tax expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$135.8 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reflecting the impact of electing to record deferred taxes on GILTI.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(i)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2018 includes an upfront payment of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$35.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> to Ionis, as we exercised our option to obtain a worldwide, exclusive, royalty-bearing license from Ionis to develop and commercialize BIIB067.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(j)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$300.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment made to BMS upon entering into our agreement to exclusively license BIIB092.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(k)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to acquired IPR&amp;D of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$120.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment to Remedy upon closing of the asset purchase transaction for BIIB093.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(l)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the second quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$60.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a developmental milestone that became payable to the former shareholders of iPierian upon dosing of the first patient in the Phase 2 study of BIIB092 for PSP.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(m)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to noncontrolling interest of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$150.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for a payment made to Neurimmune in exchange for a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">15%</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> reduction in the previously negotiated royalty rates payable on products developed under the Neurimmune Agreement, including royalties payable on potential commercial sales of aducanumab.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(n)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes pre-tax charges to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$28.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> and </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$50.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment and a continuation payment, respectively, to Alkermes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(o)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes a pre-tax charge to research and development expense of </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$25.0 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> for an upfront payment to Ionis upon entering into a new collaboration agreement to identify new ASO drug candidates for the treatment of SMA.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:6px;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">(p)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;">Net income and net income attributable to Biogen Inc. for the fourth quarter of 2017 includes </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$1,173.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> related to the provisions of the 2017 Tax Act, including a </font><font style="font-family:Franklin Gothic Book;font-size:10pt;">$989.6 million</font><font style="font-family:Franklin Gothic Book,sans-serif;font-size:10pt;"> expense under the Transition Toll Tax.</font></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109225645&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834589520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_BusinessTextualAbstract', window );"><strong>Business (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentTermsOfAccountsReceivable', window );">Payment terms of accounts receivable arising from product sales</a></td>
<td class="text">30 to 90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedUsefulLivesOfLeaseholdImprovements', window );">Estimated useful lives of leasehold improvements</a></td>
<td class="text">Lesser of the useful life or the term of the respective lease<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PurchasePriceOfCommonStockUnderEspp', window );">Purchase price of common stock under ESPP</a></td>
<td class="text">85% of the lower of (i)&#160;the fair market value per share of the common stock on the first business day of an offering period and (ii)&#160;the fair market value per share of the common stock on the purchase date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfMarketValuePerShareOfCommonStock', window );">Percentage of market value per share of common stock</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CompensationExpenseOverPurchasePeriod', window );">Compensation expense over purchase period</a></td>
<td class="text">The fair value of the look-back provision plus the 15% discount<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DiscountRateRecognizedInCompensationExpense', window );">Discount rate recognized in compensation expense</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="nump">$ 90.2<span></span>
</td>
<td class="nump">$ 75.2<span></span>
</td>
<td class="nump">$ 106.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification', window );">Quantification of affect of adoption of accounting guidance</a></td>
<td class="nump">$ 128.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Accumulated other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Deferred Income Tax Charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="nump">400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues | Accounting Standards Update 2014-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification', window );">Quantification of affect of adoption of accounting guidance</a></td>
<td class="nump">75.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales | Accounting Standards Update 2014-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification', window );">Quantification of affect of adoption of accounting guidance</a></td>
<td class="nump">42.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Accounting Standards Update 2017-07</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustment', window );">Prior Period Reclassification Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification', window );">Quantification of affect of adoption of accounting guidance</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CompensationExpenseOverPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation expense over purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CompensationExpenseOverPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DiscountRateRecognizedInCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate recognized in compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DiscountRateRecognizedInCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedUsefulLivesOfLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated useful lives of leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedUsefulLivesOfLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentTermsOfAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment  terms of accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentTermsOfAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfMarketValuePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of market value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfMarketValuePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PurchasePriceOfCommonStockUnderEspp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase Price Of Common Stock Under ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PurchasePriceOfCommonStockUnderEspp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of a reclassification adjustment made to prior period financial statement amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredIncomeTaxChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredIncomeTaxChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_DeferredtaxliabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_DeferredtaxliabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201707Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201707Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProspectiveAdoptionOfNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6832683248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112.5<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember', window );">Karyopharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TMSMember', window );">TMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense asset acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember', window );">AliveGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 535.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember', window );">Remedy Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember', window );">Development Milestones | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814061584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Hemophilia Spin-Off Hemophilia Spin-Off (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">314.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets transferred, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,008.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities transferred, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 314.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814989920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hemophilia Spin-Off Hemophilia Spin-Off (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 3,307.0<span></span>
</td>
<td class="nump">$ 3,077.8<span></span>
</td>
<td class="nump">$ 3,078.4<span></span>
</td>
<td class="nump">$ 2,810.7<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
<td class="nump">$ 11,448.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,816.3<span></span>
</td>
<td class="nump">1,630.0<span></span>
</td>
<td class="nump">1,478.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 302.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180.4<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">165.7<span></span>
</td>
<td class="nump">$ 147.2<span></span>
</td>
<td class="nump">$ 108.6<span></span>
</td>
<td class="nump">$ 164.4<span></span>
</td>
<td class="nump">$ 179.6<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
<td class="nump">316.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue | Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206.7<span></span>
</td>
<td class="nump">64.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_HemophiliaProductsMember', window );">Hemophilia Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 74.4<span></span>
</td>
<td class="nump">$ 846.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Assets and Liabilities Distributed to Bioverativ [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InventoryexpectedtobesoldtoBioverativ', window );">Inventory expected to be sold to Bioverativ</a></td>
<td class="nump">$ 180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryexpectedtobesoldtoBioverativ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory expected to be sold to Bioverativ</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryexpectedtobesoldtoBioverativ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_HemophiliaProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_HemophiliaProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833158528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Restructuring (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 33.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2017CorporateStrategyMember', window );">2017 Corporate Strategy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonrecurringExpense', window );">Other Nonrecurring Expense</a></td>
<td class="nump">$ 135.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResourcesRedirectedthroughRestructuringProgram', window );">Resources Redirected through Restructuring Program</a></td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram', window );">Charges Recognized Under Our 2017 Corporate Strategy Restructuring Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.9<span></span>
</td>
<td class="nump">19.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2016RestructuringChargesMember', window );">2016 Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember', window );">2015 Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_CambridgeMAMember', window );">Cambridge, MA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_CambridgeMAMember', window );">Cambridge, MA | 2016 Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges | 2017 Corporate Strategy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member] | 2017 Corporate Strategy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.9<span></span>
</td>
<td class="nump">$ 18.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges Recognized Under Our 2017 Corporate Strategy Restructuring Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ChargesRecognizedUnderOur2017CorporateStrategyRestructuringProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResourcesRedirectedthroughRestructuringProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Resources Redirected through Restructuring Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResourcesRedirectedthroughRestructuringProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=114868883&amp;loc=SL114871943-224233<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2017CorporateStrategyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2017CorporateStrategyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2016RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2016RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2015RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_CambridgeMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_CambridgeMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905642016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues by Product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 3,307.0<span></span>
</td>
<td class="nump">$ 3,077.8<span></span>
</td>
<td class="nump">$ 3,078.4<span></span>
</td>
<td class="nump">$ 2,810.7<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
<td class="nump">$ 11,448.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,274.1<span></span>
</td>
<td class="nump">4,214.0<span></span>
</td>
<td class="nump">3,968.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,363.0<span></span>
</td>
<td class="nump">2,645.8<span></span>
</td>
<td class="nump">2,795.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,864.0<span></span>
</td>
<td class="nump">1,973.1<span></span>
</td>
<td class="nump">1,963.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.7<span></span>
</td>
<td class="nump">91.6<span></span>
</td>
<td class="nump">84.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,595.2<span></span>
</td>
<td class="nump">8,977.2<span></span>
</td>
<td class="nump">8,819.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,724.2<span></span>
</td>
<td class="nump">883.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485.2<span></span>
</td>
<td class="nump">370.8<span></span>
</td>
<td class="nump">100.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.2<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545.1<span></span>
</td>
<td class="nump">379.8<span></span>
</td>
<td class="nump">100.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ELOCTATEMember', window );">ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">48.4<span></span>
</td>
<td class="nump">513.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ALPROLIXMember', window );">ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="nump">333.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_HemophiliaProductsMember', window );">Hemophilia Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">74.4<span></span>
</td>
<td class="nump">846.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 2,825.7<span></span>
</td>
<td class="nump">$ 2,780.1<span></span>
</td>
<td class="nump">$ 2,757.5<span></span>
</td>
<td class="nump">$ 2,523.5<span></span>
</td>
<td class="nump">$ 2,712.4<span></span>
</td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,639.7<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="nump">10,886.8<span></span>
</td>
<td class="nump">10,354.7<span></span>
</td>
<td class="nump">9,817.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,253.2<span></span>
</td>
<td class="nump">3,294.0<span></span>
</td>
<td class="nump">3,169.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,668.3<span></span>
</td>
<td class="nump">1,889.1<span></span>
</td>
<td class="nump">1,980.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,025.0<span></span>
</td>
<td class="nump">1,113.8<span></span>
</td>
<td class="nump">1,182.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,946.5<span></span>
</td>
<td class="nump">6,296.9<span></span>
</td>
<td class="nump">6,332.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854.0<span></span>
</td>
<td class="nump">657.0<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">42.2<span></span>
</td>
<td class="nump">445.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">268.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Hemophilia Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">63.2<span></span>
</td>
<td class="nump">713.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800.5<span></span>
</td>
<td class="nump">7,017.1<span></span>
</td>
<td class="nump">7,050.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020.9<span></span>
</td>
<td class="nump">920.0<span></span>
</td>
<td class="nump">798.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">694.7<span></span>
</td>
<td class="nump">756.7<span></span>
</td>
<td class="nump">814.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839.0<span></span>
</td>
<td class="nump">859.3<span></span>
</td>
<td class="nump">780.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.7<span></span>
</td>
<td class="nump">91.6<span></span>
</td>
<td class="nump">84.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,648.7<span></span>
</td>
<td class="nump">2,680.3<span></span>
</td>
<td class="nump">2,487.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">870.2<span></span>
</td>
<td class="nump">226.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485.2<span></span>
</td>
<td class="nump">370.8<span></span>
</td>
<td class="nump">100.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.2<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545.1<span></span>
</td>
<td class="nump">379.8<span></span>
</td>
<td class="nump">100.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">45.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | ELOCTATE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">68.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | ALPROLIX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Hemophilia Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">11.2<span></span>
</td>
<td class="nump">133.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Rest of world | Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,086.3<span></span>
</td>
<td class="nump">$ 3,337.6<span></span>
</td>
<td class="nump">$ 2,767.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ELOCTATEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ELOCTATEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ALPROLIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ALPROLIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_HemophiliaProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_HemophiliaProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905681856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 761.6<span></span>
</td>
<td class="nump">$ 605.5<span></span>
</td>
<td class="nump">$ 662.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">3,389.1<span></span>
</td>
<td class="nump">2,917.3<span></span>
</td>
<td class="nump">2,668.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(12.1)<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="num">(16.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns related to sales in current year</a></td>
<td class="num">(2,440.4)<span></span>
</td>
<td class="num">(2,232.8)<span></span>
</td>
<td class="num">(2,099.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns related to sales in prior years</a></td>
<td class="num">(646.9)<span></span>
</td>
<td class="num">(534.4)<span></span>
</td>
<td class="num">(609.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">1,051.3<span></span>
</td>
<td class="nump">761.6<span></span>
</td>
<td class="nump">605.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
<td class="nump">56.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">679.3<span></span>
</td>
<td class="nump">583.0<span></span>
</td>
<td class="nump">592.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns related to sales in current year</a></td>
<td class="num">(551.7)<span></span>
</td>
<td class="num">(475.8)<span></span>
</td>
<td class="num">(522.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns related to sales in prior years</a></td>
<td class="num">(109.1)<span></span>
</td>
<td class="num">(69.1)<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">127.8<span></span>
</td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">606.0<span></span>
</td>
<td class="nump">482.7<span></span>
</td>
<td class="nump">548.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">2,686.7<span></span>
</td>
<td class="nump">2,307.4<span></span>
</td>
<td class="nump">2,044.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(10.0)<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns related to sales in current year</a></td>
<td class="num">(1,887.6)<span></span>
</td>
<td class="num">(1,756.9)<span></span>
</td>
<td class="num">(1,576.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns related to sales in prior years</a></td>
<td class="num">(506.3)<span></span>
</td>
<td class="num">(442.2)<span></span>
</td>
<td class="num">(536.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">888.8<span></span>
</td>
<td class="nump">606.0<span></span>
</td>
<td class="nump">482.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">46.0<span></span>
</td>
<td class="nump">51.2<span></span>
</td>
<td class="nump">57.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current provisions relating to sales in current year</a></td>
<td class="nump">23.1<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
<td class="nump">30.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments relating to prior years</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(8.9)<span></span>
</td>
<td class="num">(16.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/returns related to sales in current year</a></td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/returns related to sales in prior years</a></td>
<td class="num">(31.5)<span></span>
</td>
<td class="num">(23.1)<span></span>
</td>
<td class="num">(19.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 34.7<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="nump">$ 51.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6907185824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,051.3<span></span>
</td>
<td class="nump">$ 761.6<span></span>
</td>
<td class="nump">$ 605.5<span></span>
</td>
<td class="nump">$ 662.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">176.6<span></span>
</td>
<td class="nump">189.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 874.7<span></span>
</td>
<td class="nump">$ 572.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816416320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-cd20 therapeutic programs</a></td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 3,307.0<span></span>
</td>
<td class="nump">$ 3,077.8<span></span>
</td>
<td class="nump">$ 3,078.4<span></span>
</td>
<td class="nump">$ 2,810.7<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
<td class="nump">$ 11,448.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,431.9<span></span>
</td>
<td class="nump">1,316.4<span></span>
</td>
<td class="nump">1,249.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548.3<span></span>
</td>
<td class="nump">242.8<span></span>
</td>
<td class="nump">65.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-cd20 therapeutic programs</a></td>
<td class="nump">$ 534.9<span></span>
</td>
<td class="nump">$ 511.7<span></span>
</td>
<td class="nump">$ 490.4<span></span>
</td>
<td class="nump">$ 443.2<span></span>
</td>
<td class="nump">$ 415.0<span></span>
</td>
<td class="nump">$ 406.5<span></span>
</td>
<td class="nump">$ 397.1<span></span>
</td>
<td class="nump">$ 340.6<span></span>
</td>
<td class="nump">$ 1,980.2<span></span>
</td>
<td class="nump">$ 1,559.2<span></span>
</td>
<td class="nump">$ 1,314.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814867952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 3,307.0<span></span>
</td>
<td class="nump">$ 3,077.8<span></span>
</td>
<td class="nump">$ 3,078.4<span></span>
</td>
<td class="nump">$ 2,810.7<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
<td class="nump">$ 11,448.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="nump">69.8<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459.4<span></span>
</td>
<td class="nump">253.7<span></span>
</td>
<td class="nump">230.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="nump">$ 165.7<span></span>
</td>
<td class="nump">$ 147.2<span></span>
</td>
<td class="nump">$ 108.6<span></span>
</td>
<td class="nump">$ 164.4<span></span>
</td>
<td class="nump">$ 179.6<span></span>
</td>
<td class="nump">$ 48.8<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
<td class="nump">$ 90.0<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
<td class="nump">316.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(16.9)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.4<span></span>
</td>
<td class="nump">42.7<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Sobi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 10.7<span></span>
</td>
<td class="nump">$ 41.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_SobiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_SobiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973155008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Details Textual)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms', window );">Revenues In Percentage From Anti-CD20 Therapeutic Programs</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenue from major distributors</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">27.70%<span></span>
</td>
<td class="nump">26.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MajorDistributorAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenue from major distributors</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables', window );">Percentage receivables of wholesale distributor accounted in consolidated receivables</a></td>
<td class="nump">15.60%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage receivables of wholesale distributor accounted in consolidated receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageReceivablesOfWholesaleDistributorAccountedInConsolidatedReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues In Percentage From Anti-CD20 Therapeutic Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesInPercentageFromAntiCD20TherapeuticPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MajorDistributorAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MajorDistributorAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6962960144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Components of inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 196.3<span></span>
</td>
<td class="nump">$ 162.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">606.7<span></span>
</td>
<td class="nump">605.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">133.5<span></span>
</td>
<td class="nump">157.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">936.5<span></span>
</td>
<td class="nump">925.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">929.9<span></span>
</td>
<td class="nump">902.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="nump">$ 22.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815517120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs on excess, obsolete, unmarketable or other inventory</a></td>
<td class="nump">$ 41.9<span></span>
</td>
<td class="nump">$ 76.9<span></span>
</td>
<td class="nump">$ 48.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093879-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1C<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=SL66093883-108312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66092785&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834738384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747.3<span></span>
</td>
<td class="nump">$ 814.7<span></span>
</td>
<td class="nump">$ 385.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080.1<span></span>
</td>
<td class="nump">1,267.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">$ 7,727.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,264.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,727.3<span></span>
</td>
<td class="nump">8,264.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,607.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,385.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,607.3)<span></span>
</td>
<td class="num">(4,385.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,879.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120.0<span></span>
</td>
<td class="nump">3,879.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2019</a></td>
<td class="nump">270.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">290.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381.2<span></span>
</td>
<td class="nump">455.3<span></span>
</td>
<td class="nump">373.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of out-licensed patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="num">(62.7)<span></span>
</td>
<td class="num">(14.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Payment made to Forward Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 454.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="nump">543.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(542.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(535.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(542.3)<span></span>
</td>
<td class="num">(535.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Out-licensed patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,005.3<span></span>
</td>
<td class="nump">3,005.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,734.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,689.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,734.8)<span></span>
</td>
<td class="num">(2,689.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">270.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270.5<span></span>
</td>
<td class="nump">316.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">23 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">3,638.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,971.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,638.7<span></span>
</td>
<td class="nump">3,971.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,330.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,160.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,330.2)<span></span>
</td>
<td class="num">(1,160.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,308.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,811.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,308.5<span></span>
</td>
<td class="nump">2,811.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life, (In Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">476.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 476.0<span></span>
</td>
<td class="nump">680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of out-licensed patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife', window );">Indefinite lived intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Indefinite<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Developed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">265.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">2,027.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,027.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of out-licensed patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">176.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of out-licensed patent</a></td>
<td class="nump">176.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">795.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">176.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_PLSRMember', window );">PLSR | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent Consideration</a></td>
<td class="nump">$ 80.6<span></span>
</td>
<td class="nump">89.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract', window );"><strong>Intangible Assets and Goodwill (Additional Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationandImpairmentofAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationandImpairmentofAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IndefiniteLivedIntangibleAssetsUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IndefiniteLivedIntangibleAssetsUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible assets and goodwill additional.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsAndGoodwillAdditionalTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_PLSRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_PLSRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6835422176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Feb. 01, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">$ 1,425.6<span></span>
</td>
<td class="nump">$ 2,458.7<span></span>
</td>
<td class="nump">$ 1,237.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">4,632.5<span></span>
</td>
<td class="nump">3,669.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Elimination of goodwill allocated to our hemophilia business</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (314.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">1,080.1<span></span>
</td>
<td class="nump">1,267.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(6.2)<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">5,706.4<span></span>
</td>
<td class="nump">4,632.5<span></span>
</td>
<td class="nump">$ 3,669.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="nump">119.9<span></span>
</td>
<td class="nump">232.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">1,200.0<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember', window );">Bioverativ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Elimination of goodwill allocated to our hemophilia business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (314.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember', window );">Each additional one billion up to twenty billion | Fumapharm AG | TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">$ 20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_BioverativMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816262768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 3,689.3<span></span>
</td>
<td class="nump">$ 5,172.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">705.5<span></span>
</td>
<td class="nump">1,229.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">615.4<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">66.9<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">25.4<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,102.5<span></span>
</td>
<td class="nump">6,444.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">111.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">409.8<span></span>
</td>
<td class="nump">523.6<span></span>
</td>
<td class="nump">$ 467.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">434.4<span></span>
</td>
<td class="nump">634.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,459.2<span></span>
</td>
<td class="nump">2,609.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">969.6<span></span>
</td>
<td class="nump">1,919.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">260.5<span></span>
</td>
<td class="nump">643.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">51.7<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">51.7<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">705.5<span></span>
</td>
<td class="nump">1,229.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">563.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">66.9<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">25.4<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,050.8<span></span>
</td>
<td class="nump">6,433.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">111.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">111.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">2,459.2<span></span>
</td>
<td class="nump">2,609.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">969.6<span></span>
</td>
<td class="nump">1,919.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">260.5<span></span>
</td>
<td class="nump">643.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">409.8<span></span>
</td>
<td class="nump">523.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">409.8<span></span>
</td>
<td class="nump">523.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814270480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1)<br> SFr in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2006 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value</a></td>
<td class="nump">$ 6,037.6<span></span>
</td>
<td class="nump">$ 6,483.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember', window );">Notes Payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 61.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,489.5<span></span>
</td>
<td class="nump">1,517.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,000.4<span></span>
</td>
<td class="nump">1,032.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">1,745.1<span></span>
</td>
<td class="nump">1,851.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,802.6<span></span>
</td>
<td class="nump">$ 2,077.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814206640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="num">$ (62.7)<span></span>
</td>
<td class="num">$ (14.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(101.5)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">523.6<span></span>
</td>
<td class="nump">467.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 409.8<span></span>
</td>
<td class="nump">$ 523.6<span></span>
</td>
<td class="nump">$ 467.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6838393216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2015</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 12, 2015</div></th>
<th class="th"><div>Mar. 04, 2008</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs', window );">Fair value measurements, changes in valuation techniques</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101.5<span></span>
</td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of out-licensed patent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember', window );">Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="nump">$ 274.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246.6<span></span>
</td>
<td class="nump">259.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 424.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember', window );">Stromedix, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
<td class="nump">162.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueMeasurementInputs', window );">Fair value measurement and measurement inputs, recurring and nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember', window );">Biogen Idec International Neuroscience GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.2<span></span>
</td>
<td class="nump">102.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueMeasurementInputs', window );">Fair value measurement and measurement inputs, recurring and nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">6.875% Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">6.875% Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">6.875% Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">6.875% Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">6.875% Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265.0<span></span>
</td>
<td class="nump">$ 279.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount rate | Convergence Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FairValueMeasurementInputs', window );">Fair value measurement and measurement inputs, recurring and nonrecurring</a></td>
<td class="text">0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FairValueMeasurementInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurement Inputs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FairValueMeasurementInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the changes to the valuation model inputs that led to changes in fair value of the servicing assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=68078379&amp;loc=d3e122625-111746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingAssetAtFairValueDescriptionOfChangesInValuationInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ConvergencePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_StromedixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_StromedixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_BiogenIdecInternationalNeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833578320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 705.5<span></span>
</td>
<td class="nump">$ 1,229.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">231.2<span></span>
</td>
<td class="nump">30.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight Reverse Repurchase Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">279.5<span></span>
</td>
<td class="nump">948.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 194.8<span></span>
</td>
<td class="nump">$ 247.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6831005312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">$ 3,689.3<span></span>
</td>
<td class="nump">$ 5,172.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6.0)<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">3,694.0<span></span>
</td>
<td class="nump">5,173.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">1,607.5<span></span>
</td>
<td class="nump">1,039.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">1,608.4<span></span>
</td>
<td class="nump">1,039.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">851.7<span></span>
</td>
<td class="nump">1,570.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(3.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">854.9<span></span>
</td>
<td class="nump">1,569.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">705.8<span></span>
</td>
<td class="nump">1,075.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">706.1<span></span>
</td>
<td class="nump">1,075.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">263.8<span></span>
</td>
<td class="nump">844.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">264.0<span></span>
</td>
<td class="nump">845.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">260.4<span></span>
</td>
<td class="nump">642.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">260.5<span></span>
</td>
<td class="nump">642.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Marketable equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable Debt and Equity Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Fair Value</a></td>
<td class="nump">615.4<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">127.7<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 496.2<span></span>
</td>
<td class="nump">$ 14.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6722323040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, Estimated Fair Value</a></td>
<td class="nump">$ 2,313.4<span></span>
</td>
<td class="nump">$ 2,115.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, Amortized Cost</a></td>
<td class="nump">2,314.6<span></span>
</td>
<td class="nump">2,116.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Estimated Fair Value</a></td>
<td class="nump">1,232.7<span></span>
</td>
<td class="nump">2,730.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">1,235.9<span></span>
</td>
<td class="nump">2,730.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, Estimated Fair Value</a></td>
<td class="nump">143.2<span></span>
</td>
<td class="nump">327.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, Amortized Cost</a></td>
<td class="nump">143.5<span></span>
</td>
<td class="nump">327.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Total available-for-sale securities, Fair Value</a></td>
<td class="nump">3,689.3<span></span>
</td>
<td class="nump">5,172.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total available-for-sale securities, Amortized Cost</a></td>
<td class="nump">$ 3,694.0<span></span>
</td>
<td class="nump">$ 5,173.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973038864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ProceedsFromMarketableDebtSecuritiesAbstract', window );"><strong>Proceeds from Marketable Debt Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 9,173.7<span></span>
</td>
<td class="nump">$ 5,565.9<span></span>
</td>
<td class="nump">$ 7,378.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains', window );">Realized gains</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses</a></td>
<td class="num">$ (11.7)<span></span>
</td>
<td class="num">$ (22.4)<span></span>
</td>
<td class="num">$ (4.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ProceedsFromMarketableDebtSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from marketable debt securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ProceedsFromMarketableDebtSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross profit realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109979856&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813907728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FinancialInstrumentsTextualAbstract', window );"><strong>Financial Instruments (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Original maturities of commercial paper and short-term debt securities</a></td>
<td class="text">less than 90&#160;days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">17 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FinancialInstrumentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FinancialInstrumentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6835990032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual 2)<br> shares in Millions, $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember', window );">Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 676.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.3<span></span>
</td>
<td class="nump">$ 85.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Totalpaymenttoentercollaborationagreement', window );">Total payment to enter collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Upfrontpaymentforcollaborationagreement', window );">Upfront payment for collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Purchaseofcommonstock', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstocksharespurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, shares purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstocksharespurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Purchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Purchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Totalpaymenttoentercollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total payment to enter collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Totalpaymenttoentercollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Upfrontpaymentforcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment for collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Upfrontpaymentforcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815605136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments Cash Flow Hedges (Details) - Foreign Exchange Contract - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember', window );">Cash flows, revenue | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in operating income for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="num">$ (42.5)<span></span>
</td>
<td class="num">$ (32.5)<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts due to exclusion from effectiveness testing</a></td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember', window );">Cash flows, revenue | Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts due to exclusion from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember', window );">Cash flows, operating expenses | Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts due to exclusion from effectiveness testing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember', window );">Cash flows, operating expenses | Operating Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in operating income for the settlement of certain effective cash flow hedge instruments</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="num">$ (1.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Net gains (losses) in net income of foreign currency forward contracts due to exclusion from effectiveness testing</a></td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109977999&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814788768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments Derivative Instruments Net Investment Hedges (Details 1)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 29, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
<td class="num">$ (113.0)<span></span>
</td>
<td class="nump">$ 49.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome', window );">Net Investment Hedge, Gain (Loss) Recognized in Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Forward contracts duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax', window );">AOCI, Derivative Qualifying as Hedge, Excluded Component, Before Tax</a></td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet', window );">Net gains (losses) in operating income for certain effective net investment hedge instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>AOCI, Derivative Qualifying as Hedge, Excluded Component, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AOCIDerivativeQualifyingasHedgeExcludedComponentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Investment Hedge, Gain (Loss) Recognized in Accumulated Other Comprehensive Income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetInvestmentHedgeGainLossRecognizedinAccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624177-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833193472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 2,239.1<span></span>
</td>
<td class="nump">$ 2,198.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">735.1<span></span>
</td>
<td class="nump">564.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other current assets | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">65.8<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other current assets | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Investments and other assets | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Accrued expenses and other | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">84.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Accrued expenses and other | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract | Other long-term liabilities | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueNetAbstract', window );"><strong>Summary of the effect of derivatives designated as hedging instruments on the consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">14.5<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">1,701.4<span></span>
</td>
<td class="nump">1,875.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound sterling | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">215.3<span></span>
</td>
<td class="nump">150.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss francs | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">131.4<span></span>
</td>
<td class="nump">88.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">92.2<span></span>
</td>
<td class="nump">83.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 98.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109247956&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109247956&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814061312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="num">$ (27.3)<span></span>
</td>
<td class="nump">$ 113.0<span></span>
</td>
<td class="num">$ (49.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Net gains (losses) of other income (expense) related to foreign currency forward contracts</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">$ 29.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">2,239.1<span></span>
</td>
<td class="nump">2,198.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="nump">$ 735.1<span></span>
</td>
<td class="nump">$ 564.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Aggregate notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">21 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Foreign Exchange Contract | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="nump">$ 84.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Foreign Exchange Contract | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability derivatives</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Article 12<br> -Section 13<br> -Sentence Column B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109247956&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814699456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">$ 144.5<span></span>
</td>
<td class="nump">$ 141.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Buildings</a></td>
<td class="nump">1,282.8<span></span>
</td>
<td class="nump">1,213.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">94.4<span></span>
</td>
<td class="nump">80.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">1,258.1<span></span>
</td>
<td class="nump">1,207.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ComputerSoftwareAndHardware', window );">Computer software and hardware</a></td>
<td class="nump">798.7<span></span>
</td>
<td class="nump">767.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">61.6<span></span>
</td>
<td class="nump">55.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,758.5<span></span>
</td>
<td class="nump">1,276.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">5,398.6<span></span>
</td>
<td class="nump">4,741.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(1,797.4)<span></span>
</td>
<td class="num">(1,559.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">$ 3,601.2<span></span>
</td>
<td class="nump">$ 3,182.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ComputerSoftwareAndHardware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Computer software and hardware</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ComputerSoftwareAndHardware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6976970848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 269.4<span></span>
</td>
<td class="nump">$ 266.3<span></span>
</td>
<td class="nump">$ 309.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest Costs Capitalized</a></td>
<td class="nump">54.0<span></span>
</td>
<td class="nump">30.7<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">1,758.5<span></span>
</td>
<td class="nump">1,276.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">$ 1,600.0<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817892176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">6,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Non-current portion of notes payable</a></td>
<td class="nump">5,936.5<span></span>
</td>
<td class="nump">5,935.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Note payable to Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrentAbstract', window );"><strong>Current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable to Fumedica AG</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">1,480.8<span></span>
</td>
<td class="nump">1,482.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">995.5<span></span>
</td>
<td class="nump">994.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">1,737.8<span></span>
</td>
<td class="nump">1,736.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Non-current notes payable</a></td>
<td class="nump">$ 1,722.4<span></span>
</td>
<td class="nump">$ 1,722.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973274992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indebtedness (Details 1)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Total debt maturities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2019</a></td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2020</a></td>
<td class="nump">1,500.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2021</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2022</a></td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">2024 and thereafter</a></td>
<td class="nump">3,500.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Total</a></td>
<td class="nump">$ 6,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6903225392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details Textual)<br> SFr in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2008 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 04, 2008 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2006 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Costs associated with the Senior Notes offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemptions percentage of 2015 notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage', window );">Redemption percentage for change in control provision on the 2015 Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Senior unsecured revolving credit facility maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding', window );">Amount outstanding under the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember', window );">Notes Payable To Fumedica</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes Payable | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 61.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember', window );">6.875% Senior Notes due 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.184%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncreasedCarryingAmountOfSeniorNotes', window );">Increased Carrying Amount Of Senior Notes</a></td>
<td class="nump">$ 62,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax', window );">Net charge upon extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment for Debt Extinguishment or Debt Prepayment Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember', window );">2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.792%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.05% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.764%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.20% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Senior Notes aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Redemption percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.294%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax', window );">Net charge upon extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap | 2.90% Senior Notes due 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value of the interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100,000<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Make Whole Provision Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncreasedCarryingAmountOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increased carrying amount of senior notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncreasedCarryingAmountOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109247956&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001942&amp;loc=d3e12317-112629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the amount outstanding under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NotesPayableToFumedicaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesSixPointEightSevenFivePercentDueTwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesTwoPointNinePercentDueTwentyTwentyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823522976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000.0<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">221.0<span></span>
</td>
<td class="nump">235.3<span></span>
</td>
<td class="nump">238.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">197.2<span></span>
</td>
<td class="nump">211.5<span></span>
</td>
<td class="nump">215.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834193888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details Textual) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 4,352.6<span></span>
</td>
<td class="nump">$ 1,365.4<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember', window );">Series X junior participating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember', window );">Undesignated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember', window );">2018 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 1,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember', window );">2016 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 3,000.0<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember', window );">2011 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock shares authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_SeriesXPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=biib_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2018ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2016ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2011ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6836023680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">$ (318,400,000)<span></span>
</td>
<td class="num">$ (319,900,000)<span></span>
</td>
<td class="num">$ (224,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance as of January 1, 2018</a></td>
<td class="num">(318,400,000)<span></span>
</td>
<td class="num">(319,900,000)<span></span>
</td>
<td class="num">(224,000,000)<span></span>
</td>
<td class="num">$ (316,900,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="nump">29,500,000<span></span>
</td>
<td class="num">(42,700,000)<span></span>
</td>
<td class="num">(92,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">47,000,000<span></span>
</td>
<td class="nump">44,200,000<span></span>
</td>
<td class="num">(3,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">76,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="num">(95,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">76,100,000<span></span>
</td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="num">(95,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(240,400,000)<span></span>
</td>
<td class="num">(318,400,000)<span></span>
</td>
<td class="num">(319,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Securities Available for Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="num">(10,800,000)<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance as of January 1, 2018</a></td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="num">(10,800,000)<span></span>
</td>
<td class="num">(800,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(10,600,000)<span></span>
</td>
<td class="num">(3,500,000)<span></span>
</td>
<td class="num">(10,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">6,700,000<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(3,900,000)<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="num">(10,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="num">(1,600,000)<span></span>
</td>
<td class="num">(10,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="nump">57,800,000<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance as of January 1, 2018</a></td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="nump">57,800,000<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="nump">97,400,000<span></span>
</td>
<td class="num">(193,800,000)<span></span>
</td>
<td class="nump">51,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">41,800,000<span></span>
</td>
<td class="nump">31,500,000<span></span>
</td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">139,200,000<span></span>
</td>
<td class="num">(162,300,000)<span></span>
</td>
<td class="nump">47,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">34,700,000<span></span>
</td>
<td class="num">(104,500,000)<span></span>
</td>
<td class="nump">57,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance as of January 1, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="num">(1,500,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded Status of Postretirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="num">(32,700,000)<span></span>
</td>
<td class="num">(37,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance as of January 1, 2018</a></td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="num">(32,700,000)<span></span>
</td>
<td class="num">(37,800,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="num">(4,100,000)<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="num">(4,100,000)<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(31,300,000)<span></span>
</td>
<td class="num">(36,800,000)<span></span>
</td>
<td class="num">(32,700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="num">(175,500,000)<span></span>
</td>
<td class="num">(334,200,000)<span></span>
</td>
<td class="num">(195,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance as of January 1, 2018</a></td>
<td class="num">(175,500,000)<span></span>
</td>
<td class="num">(334,200,000)<span></span>
</td>
<td class="num">(195,600,000)<span></span>
</td>
<td class="num">(175,500,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications</a></td>
<td class="num">(67,800,000)<span></span>
</td>
<td class="nump">158,700,000<span></span>
</td>
<td class="num">(138,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(67,800,000)<span></span>
</td>
<td class="nump">158,700,000<span></span>
</td>
<td class="num">(138,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (243,300,000)<span></span>
</td>
<td class="num">$ (175,500,000)<span></span>
</td>
<td class="num">$ (334,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unrealized Gains (Losses) on Securities Available for Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unrealized Gains (Losses) on Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Unfunded Status of Postretirement Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 | Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109228884&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815767280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10.5)<span></span>
</td>
<td class="num">$ (14.7)<span></span>
</td>
<td class="num">$ (18.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,425.6<span></span>
</td>
<td class="nump">2,458.7<span></span>
</td>
<td class="nump">1,237.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="num">$ (3,526.3)<span></span>
</td>
<td class="num">$ (3,439.0)<span></span>
</td>
<td class="num">$ (3,356.5)<span></span>
</td>
<td class="num">$ (3,131.1)<span></span>
</td>
<td class="num">$ (3,307.0)<span></span>
</td>
<td class="num">$ (3,077.8)<span></span>
</td>
<td class="num">$ (3,078.4)<span></span>
</td>
<td class="num">$ (2,810.7)<span></span>
</td>
<td class="num">(13,452.9)<span></span>
</td>
<td class="num">(12,273.9)<span></span>
</td>
<td class="num">(11,448.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="num">(217.0)<span></span>
</td>
<td class="num">(218.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 946.8<span></span>
</td>
<td class="nump">$ 1,444.4<span></span>
</td>
<td class="nump">$ 866.6<span></span>
</td>
<td class="nump">$ 1,172.9<span></span>
</td>
<td class="num">$ (297.4)<span></span>
</td>
<td class="nump">$ 1,226.1<span></span>
</td>
<td class="nump">$ 862.8<span></span>
</td>
<td class="nump">$ 747.6<span></span>
</td>
<td class="nump">4,430.7<span></span>
</td>
<td class="nump">2,539.1<span></span>
</td>
<td class="nump">3,702.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47.0)<span></span>
</td>
<td class="num">(44.2)<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains (Losses) on Securities Available for Sale | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="num">(19.5)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42.5)<span></span>
</td>
<td class="num">(32.5)<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember', window );">Unrealized Gains (Losses) on Cash Flow Hedges | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815947568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Idec Inc</a></td>
<td class="nump">$ 946.8<span></span>
</td>
<td class="nump">$ 1,444.4<span></span>
</td>
<td class="nump">$ 866.6<span></span>
</td>
<td class="nump">$ 1,172.9<span></span>
</td>
<td class="num">$ (297.4)<span></span>
</td>
<td class="nump">$ 1,226.1<span></span>
</td>
<td class="nump">$ 862.8<span></span>
</td>
<td class="nump">$ 747.6<span></span>
</td>
<td class="nump">$ 4,430.7<span></span>
</td>
<td class="nump">$ 2,539.1<span></span>
</td>
<td class="nump">$ 3,702.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">199.8<span></span>
</td>
<td class="nump">201.4<span></span>
</td>
<td class="nump">207.1<span></span>
</td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">211.5<span></span>
</td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">211.9<span></span>
</td>
<td class="nump">215.6<span></span>
</td>
<td class="nump">204.9<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">200.3<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
<td class="nump">211.7<span></span>
</td>
<td class="nump">212.0<span></span>
</td>
<td class="nump">211.8<span></span>
</td>
<td class="nump">212.2<span></span>
</td>
<td class="nump">215.9<span></span>
</td>
<td class="nump">205.3<span></span>
</td>
<td class="nump">213.0<span></span>
</td>
<td class="nump">218.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EarningsPerShareTextualAbstract', window );"><strong>Earnings per share (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EarningsPerShareTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EarningsPerShareTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_StockOptionsAndEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817303296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (168.7)<span></span>
</td>
<td class="num">$ (138.1)<span></span>
</td>
<td class="nump">$ 169.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">181.6<span></span>
</td>
<td class="nump">169.7<span></span>
</td>
<td class="nump">204.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(11.5)<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="num">(14.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">170.1<span></span>
</td>
<td class="nump">160.1<span></span>
</td>
<td class="nump">189.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(27.5)<span></span>
</td>
<td class="num">(42.8)<span></span>
</td>
<td class="num">(54.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(75.8)<span></span>
</td>
<td class="num">(74.0)<span></span>
</td>
<td class="num">(84.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">(105.8)<span></span>
</td>
<td class="num">(95.7)<span></span>
</td>
<td class="num">(121.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (142.6)<span></span>
</td>
<td class="num">$ (117.3)<span></span>
</td>
<td class="num">$ (135.8)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total recognized tax benefit related to compensation cost for equity-based payment arrangements recognized in income during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815951072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 168.7<span></span>
</td>
<td class="nump">$ 138.1<span></span>
</td>
<td class="num">$ (169.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">181.6<span></span>
</td>
<td class="nump">169.7<span></span>
</td>
<td class="nump">204.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(11.5)<span></span>
</td>
<td class="num">(9.6)<span></span>
</td>
<td class="num">(14.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">170.1<span></span>
</td>
<td class="nump">160.1<span></span>
</td>
<td class="nump">189.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">27.2<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
<td class="nump">38.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">126.6<span></span>
</td>
<td class="nump">107.3<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">18.4<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_PerformanceUnitsMember', window );">Performance Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense, net of income tax, recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_PerformanceUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_PerformanceUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814137488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 2)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_StockOptionActivityAbstract', window );"><strong>Stock Option Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance, Outstanding shares | shares</a></td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 53.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised | shares</a></td>
<td class="num">(15,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">$ 53.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Cancelled | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance, Outstanding shares | shares</a></td>
<td class="nump">27,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance, Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 53.82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock option activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973200416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract', window );"><strong>Tax benefit and cash received from stock option</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefit realized for stock options</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from the exercise of stock options</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TaxBenefitAndCashReceivedFromStockOptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax benefit and cash received from stock option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TaxBenefitAndCashReceivedFromStockOptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815555232">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 4) - Market stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MarketStockUnitsActivityAbstract', window );"><strong>Market stock units activity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">171,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 370.83<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">129,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 378.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 382.59<span></span>
</td>
<td class="nump">$ 328.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(91,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 365.83<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(29,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 376.51<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">180,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 371.32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 370.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted during 2018 include awards granted in conjunction with our annual awards made in February 2018 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2018 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2017, 2016 and 2015.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MarketStockUnitsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market stock units activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MarketStockUnitsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812749024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 5) - Market stock units - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Minimum range of risk-free interest rates</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Maximum range of risk-free interest rates</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum', window );">Average stock price on grant date minimum</a></td>
<td class="nump">$ 279.47<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 263.18<span></span>
</td>
<td class="nump">$ 260.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum', window );">Average stock price on grant date maximum</a></td>
<td class="nump">$ 346.76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 267.88<span></span>
</td>
<td class="nump">$ 304.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 378.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 382.59<span></span>
</td>
<td class="nump">$ 328.03<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">27.50%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">38.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ValuationOfGrantedStockUnitsAbstract', window );"><strong>Assumptions used in valuation of market based stock units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Range of expected stock price volatility</a></td>
<td class="nump">32.40%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35.60%<span></span>
</td>
<td class="nump">40.70%<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted during 2018 include awards granted in conjunction with our annual awards made in February 2018 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2018 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2017, 2016 and 2015.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageStockPriceOnGrantDateInDollarsMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average stock price on grant date in dollars minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageStockPriceOnGrantDateInDollarsMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ValuationOfGrantedStockUnitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation of granted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ValuationOfGrantedStockUnitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823670720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 6) - Cash settled performance units<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CashSettledPerformanceSharesAbstract', window );"><strong>Cash settled performance shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">105,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(51,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(16,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">CSPUs issued in 2018 based upon the attainment of performance criteria set for 2017 in relation to CSPUs granted in 2017.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CashSettledPerformanceSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash settled performance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CashSettledPerformanceSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814028576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 7) - Performance units<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">91,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="num">(52,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">48,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">CSPUs issued in 2018 based upon the attainment of performance criteria set for 2017 in relation to CSPUs granted in 2017.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6722123664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 8) - Performance stock units settled in stock<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceStockUnitsSettledinStockAbstract', window );"><strong>Performance stock units settled in stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted | shares</a></td>
<td class="nump">67,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="nump">$ 317.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited | shares</a></td>
<td class="num">(7,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">$ 315.70<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares | shares</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value | $ / shares</a></td>
<td class="nump">$ 317.26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted during 2018 include awards granted in conjunction with our annual awards made in February 2018 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2018 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2017, 2016 and 2015.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceStockUnitsSettledinStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Stock Units Settled in Stock [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceStockUnitsSettledinStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6963267968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 9) - Performance stock units settled in cash<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PerformanceStockUnitsSettledinCashAbstract', window );"><strong>Performance stock units settled in cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="nump">45,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PerformanceStockUnitsSettledinCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Performance Stock Units Settled in Cash [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PerformanceStockUnitsSettledinCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814867120">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 10) - Time-vested restricted stock units - $ / shares<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RestrictedStockUnitsActivityAbstract', window );"><strong>Time-vested restricted stock units</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">832,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 291.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">581,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 316.32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 293.41<span></span>
</td>
<td class="nump">$ 268.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(376,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 299.94<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Shares, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(134,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 298.81<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance, Unvested, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">903,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance, Weighted Average Grant Date Fair Value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 303.18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 291.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">RSUs granted in 2018 primarily represent RSUs granted in conjunction with our annual awards made in February 2018 and awards made in conjunction with the hiring of new employees. RSUs granted in 2018 also include approximately 9,000 RSUs granted to our Board of Directors.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestrictedStockUnitsActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted stock units activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestrictedStockUnitsActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6813457360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 11) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember', window );">2015 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems', window );"><strong>Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="nump">170,000<span></span>
</td>
<td class="nump">167,000<span></span>
</td>
<td class="nump">190,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Cash received under ESPP</a></td>
<td class="nump">$ 40.5<span></span>
</td>
<td class="nump">$ 39.8<span></span>
</td>
<td class="nump">$ 41.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2015ESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2015ESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819006464">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details Textual)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th" colspan="2">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Plan </div>
<div>Increment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>Increment</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under ESPP</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareBasedPaymentsTextualAbstract', window );"><strong>Share-Based Payments (Textual)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to unvested share-based compensation | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 188.5<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards', window );">Weighted-average period to recognize the cost of unvested awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1 year 11 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade', window );">Number of share-based compensation plans pursuant to which awards are currently being made | Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares granted under stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic values of options outstanding | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term for options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">8 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">129,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 26.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 31.4<span></span>
</td>
<td class="nump">$ 39.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 378.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 382.59<span></span>
</td>
<td class="nump">$ 328.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember', window );">Cash settled performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash in settlement of CSPS awards upon vesting | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 16.6<span></span>
</td>
<td class="nump">$ 31.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfEqualAnnualIncrements', window );">Number of equal annual increments | Increment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards', window );">Cash in settlement of CSPS awards upon vesting | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 17.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">11.5<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">67,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 317.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Minimum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent', window );">Percentage of earnings of the target number of units granted based on actual stock performance (Maximum)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice', window );">Number of days for calculation of average closing stock price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">30 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">581,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of vested awards | $</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 111.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 104.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 316.32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 293.41<span></span>
</td>
<td class="nump">$ 268.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember', window );">Director | Time-vested restricted stock units</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">9,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_DirectorsPlanMember', window );">Directors Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NumberOfSharesOfCommonStockForIssuance', window );">Total number of shares of common stock for issuance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,600,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1.5-to-1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember', window );">2017 Omnibus Equity Plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RatioOfNumberOfSharesReservedUnderPlan', window );">Ratio of total number of shares reserved under the plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">1.5-to-1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Omnibus Plan number of shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">MSUs granted during 2018 include awards granted in conjunction with our annual awards made in February 2018 and MSUs granted in conjunction with the hiring of employees. These grants reflect the target number of shares eligible to be earned at the time of grant. MSUs granted in 2018 also reflect an adjustment based upon the final performance multiplier in relation to shares granted in 2017, 2016 and 2015.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">CSPUs issued in 2018 based upon the attainment of performance criteria set for 2017 in relation to CSPUs granted in 2017.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">RSUs granted in 2018 primarily represent RSUs granted in conjunction with our annual awards made in February 2018 and awards made in conjunction with the hiring of new employees. RSUs granted in 2018 also include approximately 9,000 RSUs granted to our Board of Directors.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MaximumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum target number of market stock units granted based on stock performance in percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumTargetNumberOfMarketStockUnitsGrantedBasedOnStockPerformanceInPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfDaysForCalculationOfAverageClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days for calculation of average closing stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfDaysForCalculationOfAverageClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfEqualAnnualIncrements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal annual increments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfEqualAnnualIncrements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share-based compensation plans pursuant to which awards are currently being made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfShareBasedCompensationPlansPursuantToWhichAwardsAreCurrentlyBeingMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSharesOfCommonStockForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of common stock for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSharesOfCommonStockForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RatioOfNumberOfSharesReservedUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of total number of shares reserved under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RatioOfNumberOfSharesReservedUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedPaymentsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedPaymentsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period to recognize the cost of nonvested awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_WeightedAveragePeriodToRecognizeCostOfNonvestedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_CashSettledPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_DirectorsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_DirectorsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=biib_A2017OmnibusEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819787536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Income before income taxes (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 3,877.0<span></span>
</td>
<td class="nump">$ 3,540.4<span></span>
</td>
<td class="nump">$ 3,655.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">2,022.6<span></span>
</td>
<td class="nump">1,588.4<span></span>
</td>
<td class="nump">1,277.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">5,899.6<span></span>
</td>
<td class="nump">5,128.8<span></span>
</td>
<td class="nump">4,933.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">1,131.8<span></span>
</td>
<td class="nump">2,201.4<span></span>
</td>
<td class="nump">1,304.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">45.5<span></span>
</td>
<td class="nump">57.0<span></span>
</td>
<td class="nump">55.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">140.0<span></span>
</td>
<td class="nump">108.6<span></span>
</td>
<td class="nump">52.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">1,317.3<span></span>
</td>
<td class="nump">2,367.0<span></span>
</td>
<td class="nump">1,412.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(62.0)<span></span>
</td>
<td class="nump">241.0<span></span>
</td>
<td class="num">(125.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(7.4)<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
<td class="num">(3.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">177.7<span></span>
</td>
<td class="num">(159.2)<span></span>
</td>
<td class="num">(45.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">108.3<span></span>
</td>
<td class="nump">91.7<span></span>
</td>
<td class="num">(175.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense</a></td>
<td class="nump">$ 1,425.6<span></span>
</td>
<td class="nump">$ 2,458.7<span></span>
</td>
<td class="nump">$ 1,237.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6973291408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components of deferred tax assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">$ 102.8<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory, other reserves, and accruals</a></td>
<td class="nump">163.9<span></span>
</td>
<td class="nump">147.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles, net</a></td>
<td class="nump">2,298.6<span></span>
</td>
<td class="nump">378.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">213.1<span></span>
</td>
<td class="nump">209.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">25.8<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">38.9<span></span>
</td>
<td class="nump">25.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(20.0)<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">2,823.1<span></span>
</td>
<td class="nump">831.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Purchased intangible assets</a></td>
<td class="num">(232.8)<span></span>
</td>
<td class="num">(250.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="num">(544.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards', window );">Deferred Tax Liabilities, Tax Credit Carryforwards</a></td>
<td class="num">(1,425.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther', window );">Depreciation, amortization and other</a></td>
<td class="num">(102.3)<span></span>
</td>
<td class="num">(107.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">$ 2,305.4<span></span>
</td>
<td class="nump">$ 358.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesDepreciationAmortizationOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation amortization other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesDepreciationAmortizationOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Tax Credit Carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredtaxliabilitiesGILTItaxcalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, GILTI tax calculation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredtaxliabilitiesGILTItaxcalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819457024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 2)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(11.10%)<span></span>
</td>
<td class="num">(9.60%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(0.90%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction', window );">Manufacturing deduction</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">2017 Tax Act</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">22.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Impairment of ZINBRYTA related tax assets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Permanent items</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">24.20%<span></span>
</td>
<td class="nump">47.90%<span></span>
</td>
<td class="nump">25.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation manufacturing deduction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveIncomeTaxRateReconciliationManufacturingDeduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815476224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract', window );"><strong>Reconciliation of the beginning and ending of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 66.8<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
<td class="nump">$ 67.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current period</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior periods</a></td>
<td class="nump">58.7<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">36.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior periods</a></td>
<td class="num">(13.6)<span></span>
</td>
<td class="num">(21.8)<span></span>
</td>
<td class="num">(13.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Statute expirations</a></td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="nump">44.6<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 114.2<span></span>
</td>
<td class="nump">$ 66.8<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6834830032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(11.10%)<span></span>
</td>
<td class="num">(9.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,425.6<span></span>
</td>
<td class="nump">$ 2,458.7<span></span>
</td>
<td class="nump">$ 1,237.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries', window );">Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(544.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Net impairment on certain tax assets</a></td>
<td class="nump">48.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_IncomeTaxesTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Totaldeferredchargesandprepaidtaxes', window );">Total deferred charges and prepaid taxes</a></td>
<td class="nump">617.7<span></span>
</td>
<td class="nump">239.2<span></span>
</td>
<td class="nump">617.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefit</a></td>
<td class="nump">64.3<span></span>
</td>
<td class="nump">109.1<span></span>
</td>
<td class="nump">64.3<span></span>
</td>
<td class="nump">26.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Net interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</a></td>
<td class="nump">16.1<span></span>
</td>
<td class="nump">$ 13.8<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember', window );">2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,173.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Transition toll tax liabilities</a></td>
<td class="nump">989.6<span></span>
</td>
<td class="nump">$ 697.0<span></span>
</td>
<td class="nump">989.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PaymentforTransitionTollTax', window );">Payment for Transition Toll Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment', window );">Deferred tax liabilities, decrease due to overpayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Income tax expense (benefit)</a></td>
<td class="nump">184.0<span></span>
</td>
<td class="nump">12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductionindeferredtaxliabilityundistributedforeignearnings', window );">Reduction in deferred tax liability, undistributed foreign earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherTaxExpenseBenefit', window );">Other tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Notice of assessment of corporate withholding tax including penalties and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Domestic Country</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember', window );">General Business | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=biib_PrepaidtaxesMember', window );">Prepaid taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses', window );">Net impairment on certain tax assets</a></td>
<td class="nump">$ 142.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember', window );">Earnings in the form of cash and cash equivalents | 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TransitionTollTaxRepatriationTaxRate', window );">Transition Toll Tax repatriation tax rate</a></td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember', window );">Other Foreign Earnings | 2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_TransitionTollTaxRepatriationTaxRate', window );">Transition Toll Tax repatriation tax rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecorded tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Retained Earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member', window );">Accounting Standards Update 2016-16 | Deferred Tax Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of new accounting principle in period of adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting', window );">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting', window );">Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Decrease Due to Overpayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredtaxliabilitiesGILTItaxcalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, GILTI tax calculation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredtaxliabilitiesGILTItaxcalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, temporary differences, purchase accounting, foreign subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Deferredtaxliabilitiestemporarydifferencespurchaseaccountingforeignsubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeTaxesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeTaxesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentforTransitionTollTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for Transition Toll Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentforTransitionTollTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductionindeferredtaxliabilityundistributedforeignearnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in deferred tax liability, undistributed foreign earnings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductionindeferredtaxliabilityundistributedforeignearnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Residual U.S. tax liability on reversal of deferred tax liabilities on foreign subsidiaries purchase accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResidualU.S.taxliabilityonreversalofdeferredtaxliabilitiesonforeignsubsidiariespurchaseaccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Totaldeferredchargesandprepaidtaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total deferred charges and prepaid taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Totaldeferredchargesandprepaidtaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TransitionTollTaxRepatriationTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transition Toll Tax Repatriation Tax Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TransitionTollTaxRepatriationTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiaries and other recognized entities not within the country of domicile of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_GeneralBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_PrepaidtaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_PrepaidtaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignearningstypeAxis=biib_ForeignearningsintheformofcashandcashequivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignearningstypeAxis=biib_OtherForeignEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201616Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=biib_DeferredtaxliabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=biib_DeferredtaxliabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredTaxAssetDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_DeferredTaxAssetDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6838255808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash Paid During the Year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">$ 243.2<span></span>
</td>
<td class="nump">$ 281.7<span></span>
</td>
<td class="nump">$ 281.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,007.1<span></span>
</td>
<td class="nump">1,066.4<span></span>
</td>
<td class="nump">1,642.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other Nonoperating Income (Expense) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">112.5<span></span>
</td>
<td class="nump">78.5<span></span>
</td>
<td class="nump">63.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">200.6<span></span>
</td>
<td class="nump">250.8<span></span>
</td>
<td class="nump">260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain (loss) on investments, net</a></td>
<td class="nump">119.5<span></span>
</td>
<td class="num">(36.3)<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses), net</a></td>
<td class="num">(9.9)<span></span>
</td>
<td class="nump">6.3<span></span>
</td>
<td class="num">(9.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(10.5)<span></span>
</td>
<td class="num">(14.7)<span></span>
</td>
<td class="num">(18.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="num">(217.0)<span></span>
</td>
<td class="num">(218.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue related reserves for discounts and allowances</a></td>
<td class="nump">1,051.3<span></span>
</td>
<td class="nump">761.6<span></span>
</td>
<td class="nump">$ 605.5<span></span>
</td>
<td class="nump">$ 662.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration obligations</a></td>
<td class="nump">444.8<span></span>
</td>
<td class="nump">844.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">320.9<span></span>
</td>
<td class="nump">297.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">224.7<span></span>
</td>
<td class="nump">206.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expenses</a></td>
<td class="nump">261.6<span></span>
</td>
<td class="nump">183.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="nump">125.2<span></span>
</td>
<td class="nump">159.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">609.3<span></span>
</td>
<td class="nump">636.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">2,861.2<span></span>
</td>
<td class="nump">2,901.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue related reserves for discounts and allowances</a></td>
<td class="nump">$ 874.7<span></span>
</td>
<td class="nump">$ 572.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833884672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details Textual)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other Liabilities, Noncurrent</a></td>
<td class="nump">$ 1,389.4<span></span>
</td>
<td class="nump">$ 1,628.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,389.4<span></span>
</td>
<td class="nump">$ 1,628.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other Assets, Current</a></td>
<td class="nump">687.6<span></span>
</td>
<td class="nump">962.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687.6<span></span>
</td>
<td class="nump">962.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080.1<span></span>
</td>
<td class="nump">1,267.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="nump">125.2<span></span>
</td>
<td class="nump">159.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.2<span></span>
</td>
<td class="nump">159.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">TECFIDERA litigation settlement charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 454.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">271.2<span></span>
</td>
<td class="nump">657.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271.2<span></span>
</td>
<td class="nump">657.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,690.6<span></span>
</td>
<td class="nump">431.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,690.6<span></span>
</td>
<td class="nump">431.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued Income Taxes, Noncurrent</a></td>
<td class="nump">791.4<span></span>
</td>
<td class="nump">979.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">791.4<span></span>
</td>
<td class="nump">979.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Accrued construction in progress</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG | Twenty billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG | Each additional one billion up to twenty billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG | Fifteen billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG | Sixteen billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Investment in Ionis</a></td>
<td class="nump">563.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_TwentybillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_TwentybillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6836758864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Genentech (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-cd20 therapeutic programs</a></td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 3,307.0<span></span>
</td>
<td class="nump">$ 3,077.8<span></span>
</td>
<td class="nump">$ 3,078.4<span></span>
</td>
<td class="nump">$ 2,810.7<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
<td class="nump">$ 11,448.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,431.9<span></span>
</td>
<td class="nump">1,316.4<span></span>
</td>
<td class="nump">1,249.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 548.3<span></span>
</td>
<td class="nump">$ 242.8<span></span>
</td>
<td class="nump">$ 65.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaAbstract', window );"><strong>Co-promotion profit sharing formula</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne', window );">Until GAZYVA First Non-CLL FDA Approval</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract', window );"><strong>After First GA101 Threshold Date</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract', window );"><strong>Revenues from unconsolidated joint business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-cd20 therapeutic programs</a></td>
<td class="nump">$ 534.9<span></span>
</td>
<td class="nump">$ 511.7<span></span>
</td>
<td class="nump">$ 490.4<span></span>
</td>
<td class="nump">$ 443.2<span></span>
</td>
<td class="nump">$ 415.0<span></span>
</td>
<td class="nump">$ 406.5<span></span>
</td>
<td class="nump">$ 397.1<span></span>
</td>
<td class="nump">$ 340.6<span></span>
</td>
<td class="nump">$ 1,980.2<span></span>
</td>
<td class="nump">$ 1,559.2<span></span>
</td>
<td class="nump">$ 1,314.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesFromUnconsolidatedJointBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues from unconsolidated joint business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesFromUnconsolidatedJointBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815354288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Collaborative and Other Relationships - Eisai (Details 1) - Eisai - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">BAN2401 and Elenbecestat R&amp;D expense incurred by collaboration</a></td>
<td class="nump">$ 232.0<span></span>
</td>
<td class="nump">$ 146.2<span></span>
</td>
<td class="nump">$ 95.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="nump">116.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
<td class="nump">50.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Aducanumab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Aducanumab expense incurred by the collaboration</a></td>
<td class="nump">264.8<span></span>
</td>
<td class="nump">268.7<span></span>
</td>
<td class="nump">209.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="nump">234.6<span></span>
</td>
<td class="nump">268.7<span></span>
</td>
<td class="nump">209.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member] | Aducanumab [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Aducanumab expense incurred by the collaboration</a></td>
<td class="nump">50.6<span></span>
</td>
<td class="nump">23.6<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="nump">$ 27.3<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
<td class="nump">$ 18.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AducanumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AducanumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817199472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - AbbVie (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 3,307.0<span></span>
</td>
<td class="nump">$ 3,077.8<span></span>
</td>
<td class="nump">$ 3,078.4<span></span>
</td>
<td class="nump">$ 2,810.7<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
<td class="nump">$ 11,448.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,564.3<span></span>
</td>
<td class="nump">6,928.1<span></span>
</td>
<td class="nump">6,297.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Copromotionprofitsandlosses', window );">Co-promotion profits and losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.8<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
<td class="nump">43.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(16.9)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="nump">92.6<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 2,825.7<span></span>
</td>
<td class="nump">$ 2,780.1<span></span>
</td>
<td class="nump">$ 2,757.5<span></span>
</td>
<td class="nump">$ 2,523.5<span></span>
</td>
<td class="nump">$ 2,712.4<span></span>
</td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,639.7<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="nump">10,886.8<span></span>
</td>
<td class="nump">10,354.7<span></span>
</td>
<td class="nump">9,817.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800.5<span></span>
</td>
<td class="nump">7,017.1<span></span>
</td>
<td class="nump">7,050.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 53.1<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Copromotionprofitsandlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profits and losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Copromotionprofitsandlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6930824656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Details Textual)<br> shares in Millions, $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="15">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2013</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2012 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,597.2<span></span>
</td>
<td class="nump">$ 2,253.6<span></span>
</td>
<td class="nump">$ 1,973.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 3,307.0<span></span>
</td>
<td class="nump">$ 3,077.8<span></span>
</td>
<td class="nump">$ 3,078.4<span></span>
</td>
<td class="nump">$ 2,810.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,452.9<span></span>
</td>
<td class="nump">12,273.9<span></span>
</td>
<td class="nump">11,448.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,816.3<span></span>
</td>
<td class="nump">1,630.0<span></span>
</td>
<td class="nump">1,478.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185.0<span></span>
</td>
<td class="nump">112.3<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="nump">5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,690.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,690.6<span></span>
</td>
<td class="nump">1,690.6<span></span>
</td>
<td class="nump">431.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">676.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of investee, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold', window );">Expected additional milestone payments when certain sales threshold is met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800.0<span></span>
</td>
<td class="nump">800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 324.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments', window );">Expected License Fee And Regulatory Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Upfrontpaymentforcollaborationagreement', window );">Upfront payment for collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Totalpaymenttoentercollaborationagreement', window );">Total payment to enter collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Purchaseofcommonstock', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Premiumonpurchaseofcommonstock', window );">Premium on purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstockvalue', window );">Investment in common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
<td class="nump">50.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">BAN2401 and Elenbecestat R&amp;D expense incurred by collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232.0<span></span>
</td>
<td class="nump">146.2<span></span>
</td>
<td class="nump">95.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625.0<span></span>
</td>
<td class="nump">625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember', window );">Alkermes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.7<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember', window );">Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410.0<span></span>
</td>
<td class="nump">410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember', window );">iPerian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490.0<span></span>
</td>
<td class="nump">490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DevelopmentalMilestonePayment', window );">Developmental Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AcordaMember', window );">Acorda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
<td class="nump">34.0<span></span>
</td>
<td class="nump">31.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold', window );">Expected additional milestone payments when certain sales threshold is met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ForeignSalesRequiredToTriggerMilestone', window );">Foreign sales required to trigger milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember', window );">AGTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.5<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and discovery services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Purchaseofcommonstock', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Premiumonpurchaseofcommonstock', window );">Premium on purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstockvalue', window );">Investment in common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_UniversityofPennsylvaniaMember', window );">University of Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="nump">33.0<span></span>
</td>
<td class="nump">27.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futureresearchanddevelopmentcommitment', window );">Future research and development commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
<td class="nump">137.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_C4TherapeuticsMember', window );">C4 Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Upfrontpaymentforcollaborationagreement', window );">Upfront payment for collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.0<span></span>
</td>
<td class="nump">370.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationProfitSharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187.4<span></span>
</td>
<td class="nump">$ 111.0<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Equity Method Investments, Expected Profit Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of Co promotion Operating Profits first fifty million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne', window );">Until GAZYVA First Non-CLL FDA Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of Co promotion Operating Profits first fifty million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment', window );">Co-promotion operating profit threshold for Rituxan in U S and Canada to determine share of co promotion operating profit prior to amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SalesTriggerGrossSalesThreshold', window );">Sales Trigger Gross Sales Threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne', window );">Until First GAZYVA Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After First Threshold Date and until Second Threshold Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti-CD20 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_NewAntiCd20Member', window );">New Anti-CD20 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Futurepercentageofcopromotionoperatingprofits', window );">Future percentage of co-promotion operating profits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage', window );">Royalty operating profit threshold for highest royalty rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyrate', window );">Reduction in royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PeriodOfCollaborationAgreement', window );">Period of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">OCREVUS | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 52.7<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Unrecorded tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember', window );">ZINBRYTA | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">19.9<span></span>
</td>
<td class="nump">24.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,724.2<span></span>
</td>
<td class="nump">883.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285.0<span></span>
</td>
<td class="nump">234.5<span></span>
</td>
<td class="nump">257.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238.0<span></span>
</td>
<td class="nump">112.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_LicenseFee', window );">License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Ionis Pharmaceuticals | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SOD1Member', window );">SOD1 | Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.0<span></span>
</td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545.1<span></span>
</td>
<td class="nump">379.8<span></span>
</td>
<td class="nump">100.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement', window );">Investments By Third Party In Joint Venture As Per Agreement.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 280.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_JointVentureOwnerShipPercentageByThirdParty', window );">Joint Venture Owner Ship Percentage By Third Party.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="nump">$ 680.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 49.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to Acquire Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96.4<span></span>
</td>
<td class="nump">42.7<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">BAN2401 and Elenbecestat R&amp;D expense incurred by collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.4<span></span>
</td>
<td class="nump">39.9<span></span>
</td>
<td class="nump">48.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | ZINBRYTA | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Biogen's share of expense reflected within our consolidation statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.6)<span></span>
</td>
<td class="num">(16.9)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">854.0<span></span>
</td>
<td class="nump">657.0<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | SPINRAZA | Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,724.2<span></span>
</td>
<td class="nump">883.7<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S | IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember', window );">Foreign | AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">52.7<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Abbvie collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember', window );">Outside the U.S | OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Future royalties percentage to be received on sale of ocrelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">European Union | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">JAPAN | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Biogenshareofcopromotionprofitsorlosses', window );">Biogen share of co-promotion profits or losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember', window );">Acquired and in-licensed rights and patents | Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Net change in acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Percentage of development expenses to be reimbursed | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_AbbVieMember', window );">AbbVie | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.6)<span></span>
</td>
<td class="num">(16.9)<span></span>
</td>
<td class="num">(21.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_AbbVieMember', window );">AbbVie | U.S | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CollaborationsTextualAbstract', window );"><strong>Collaborative and Other Relationships (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8.6)<span></span>
</td>
<td class="num">$ (16.9)<span></span>
</td>
<td class="num">$ (21.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Biogenshareofcopromotionprofitsorlosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Biogen share of co-promotion profits or losses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Biogenshareofcopromotionprofitsorlosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationProfitSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationProfitSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DevelopmentalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Developmental Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DevelopmentalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected additional milestone payments when meeting certain sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected license fee and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedLicenseFeeAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignSalesRequiredToTriggerMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign sales required to trigger milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignSalesRequiredToTriggerMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future royalties percentage to be received on sale of product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Futurepercentageofcopromotionoperatingprofits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future percentage of co-promotion operating profits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Futurepercentageofcopromotionoperatingprofits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Futureresearchanddevelopmentcommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future research and development commitment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Futureresearchanddevelopmentcommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstocksharespurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, shares purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstocksharespurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstockvalue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstockvalue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments by third party in joint venture as per agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsByThirdPartyInJointVentureAsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_JointVentureOwnerShipPercentageByThirdParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint venture owner ship percentage by third party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_JointVentureOwnerShipPercentageByThirdParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits first fifty million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRoyaltiesAsPerCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRoyaltiesAsPerCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period Of Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Premiumonpurchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Premiumonpurchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Purchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Purchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyrate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyrate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty operating profit threshold for highest royalty rate percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SalesTriggerGrossSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales trigger gross sales threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SalesTriggerGrossSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales to be achieved in any twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Totalpaymenttoentercollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total payment to enter collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Totalpaymenttoentercollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Upfrontpaymentforcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment for collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Upfrontpaymentforcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AlkermesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IPerianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AcordaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AcordaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AGTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AGTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UniversityofPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UniversityofPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_C4TherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_C4TherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_NewAntiCd20Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_NewAntiCd20Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SOD1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SOD1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_GeographicDistributionForeignMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_InLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814225920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payment to Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.4<span></span>
</td>
<td class="nump">$ 134.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract', window );"><strong>Investment in Variable Interest Entities (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.7<span></span>
</td>
<td class="nump">$ 48.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payment to Neurimmune</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInVariableInterestEntitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInVariableInterestEntitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6823480480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation Litigation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_BR', window );">BRAZIL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSought', window );">Loss Contingency, Damages Sought</a></td>
<td class="text">70.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSought">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the form and magnitude of the award the plaintiff seeks in the legal matter, which may include an unspecified amount of money.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSought</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817279360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract', window );"><strong>Minimum rental commitments under non-cancelable leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">Minimum lease payments, 2019</a></td>
<td class="nump">$ 87.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">Minimum lease payments, 2020</a></td>
<td class="nump">80.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">Minimum lease payments, 2021</a></td>
<td class="nump">75.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">Minimum lease payments, 2022</a></td>
<td class="nump">71.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">Minimum lease payments, 2023</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Minimum lease payments, Thereafter</a></td>
<td class="nump">215.3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Minimum lease payments, Total</a></td>
<td class="nump">601.6<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear', window );">Less: income from subleases, 2019</a></td>
<td class="num">(26.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears', window );">Less: income from subleases, 2020</a></td>
<td class="num">(25.6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears', window );">Less: income from subleases, 2021</a></td>
<td class="num">(23.7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears', window );">Less: income from subleases, 2022</a></td>
<td class="num">(24.0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears', window );">Less: income from subleases, 2023</a></td>
<td class="num">(24.3)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter', window );">Less: income from subleases, Thereafter</a></td>
<td class="num">(58.4)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions', window );">Less: income from subleases, Total</a></td>
<td class="num">(182.8)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInOneYear', window );">Net minimum lease payments, 2019</a></td>
<td class="nump">60.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInTwoYear', window );">Net minimum lease payments, 2020</a></td>
<td class="nump">55.1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInThreeYear', window );">Net minimum lease payments, 2021</a></td>
<td class="nump">52.2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFourYear', window );">Net minimum lease payments, 2022</a></td>
<td class="nump">47.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsWithInFiveYear', window );">Net minimum lease payments, 2023</a></td>
<td class="nump">46.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePaymentsThereafter', window );">Net minimum lease payments, Thereafter</a></td>
<td class="nump">156.9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_NetMinimumLeasePayments', window );">Net minimum lease payments, Total</a></td>
<td class="nump">$ 418.8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1)</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum rental commitments under noncancellable leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumRentalCommitmentsUnderNoncancellableLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFiveYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in five year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFiveYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInFourYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in four year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInFourYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInThreeYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in three year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInThreeYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NetMinimumLeasePaymentsWithInTwoYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net minimum lease payments with in two year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NetMinimumLeasePaymentsWithInTwoYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals to be received by the seller-lessee for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum sublease rentals for sale-leaseback transactions accounted for using the deposit method or as a financing to be received by the seller-lessee in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77914019&amp;loc=d3e50824-112756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FutureMinimumSubleaseRentalsSaleLeasebackTransactionsWithinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816303632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2006</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Apr. 02, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080.1<span></span>
</td>
<td class="nump">$ 1,267.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Cancellable future commitments</a></td>
<td class="nump">655.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">655.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments And Contingencies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch', window );">Accrued expenses</a></td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Liabilities associated with uncertain tax positions</a></td>
<td class="nump">117.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease rent expense which terminates at various dates through 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.5<span></span>
</td>
<td class="nump">65.3<span></span>
</td>
<td class="nump">$ 68.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion', window );">Future contingent payment for annual worldwide net sales up to $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentThreshold', window );">Future contingent payment threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion', window );">Future contingent payment for annual worldwide net sales that exceed $2.0 billion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember', window );">Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Amount paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Cancellable future commitments</a></td>
<td class="nump">111.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Maximum contingent consideration in the form of development and approval milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200.0<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember', window );">Fifteen billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember', window );">Sixteen billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_SeventeenbillionMember', window );">Seventeen billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EighteenbillionMember', window );">Eighteen billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_NineteenbillionMember', window );">Nineteen billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_TwentybillionMember', window );">Twenty billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Increase to goodwill</a></td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember', window );">Each additional one billion up to twenty billion | TECFIDERA | Fumapharm AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_CumulativeSalesLevel', window );">Cumulative sales level</a></td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember', window );">Development Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember', window );">Regulatory Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember', window );">Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment, approximately</a></td>
<td class="nump">2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember', window );">2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Transition toll tax liabilities</a></td>
<td class="nump">$ 697.0<span></span>
</td>
<td class="nump">$ 989.6<span></span>
</td>
<td class="nump">697.0<span></span>
</td>
<td class="nump">$ 989.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment', window );">Deferred tax liabilities, decrease due to overpayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Minimum | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals | Maximum | SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfRoyaltiesAsPerCollaboration', window );">Percentage Of Royalties As Per Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses on funding commitment related to clinical research.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedExpensesOnFundingCommitmentRelatedToClinicalResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CommitmentsAndContingenciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CommitmentsAndContingenciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevel">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative sales level</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevel</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Decrease Due to Overpayment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredTaxLiabilitiesDecreaseDuetoOverpayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales that exceed $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesThatExceed20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment for annual worldwide net sales up to $2.0 billion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentForAnnualWorldwideNetSalesUpTo20Billion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent payment threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfRoyaltiesAsPerCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfRoyaltiesAsPerCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiaries and other recognized entities not within the country of domicile of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_FumapharmAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_FifteenbillionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SixteenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_SeventeenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_SeventeenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EighteenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EighteenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_NineteenbillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_NineteenbillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_TwentybillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_TwentybillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CumulativeSalesLevelAxis=biib_EachAdditionalOneBillionUpToTwentyBillionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_DevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6969940832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember', window );">Domestic Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan', window );">Minimum Qualifying Age For Employee Benefit Plan</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expenses related to savings plan</a></td>
<td class="nump">$ 42.2<span></span>
</td>
<td class="nump">$ 42.6<span></span>
</td>
<td class="nump">$ 45.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Deferred Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation liability</a></td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="nump">$ 109.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_MinimumQualifyingAgeForEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum qualifying age for employee benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_MinimumQualifyingAgeForEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_DomesticPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6907558352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details 1) - Foreign Plan - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_ForeignPlanMember', window );">SWITZERLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_PercentageOfMinimumInvestmentReturn', window );">Percentage of minimum investment return</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Unfunded net pension</a></td>
<td class="nump">$ 48.6<span></span>
</td>
<td class="nump">$ 48.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee Benefit Plan obligations</a></td>
<td class="nump">93.1<span></span>
</td>
<td class="nump">83.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Pension Cost (Reversal of Cost)</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="nump">$ 15.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_ForeignPlanMember', window );">GERMANY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Employee Benefit Plan obligations</a></td>
<td class="nump">45.3<span></span>
</td>
<td class="nump">43.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Periodic pension cost</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | SWITZERLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionExpense', window );">Pension Cost (Reversal of Cost)</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | GERMANY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_EmployeeBenefitPlansTextualAbstract', window );"><strong>Employee Benefit Plans (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Periodic pension cost</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EmployeeBenefitPlansTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EmployeeBenefitPlansTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfMinimumInvestmentReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum investment return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfMinimumInvestmentReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=112275985&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=108410482&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension benefits. Excludes other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820588432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 3,307.0<span></span>
</td>
<td class="nump">$ 3,077.8<span></span>
</td>
<td class="nump">$ 3,078.4<span></span>
</td>
<td class="nump">$ 2,810.7<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
<td class="nump">$ 11,448.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">3,601.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,182.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,601.2<span></span>
</td>
<td class="nump">3,182.4<span></span>
</td>
<td class="nump">2,501.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">1,152.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,226.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,152.7<span></span>
</td>
<td class="nump">1,226.9<span></span>
</td>
<td class="nump">1,272.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">2,442.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,948.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,442.8<span></span>
</td>
<td class="nump">1,948.2<span></span>
</td>
<td class="nump">1,221.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_AsiaMember', window );">Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Geographic information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">534.9<span></span>
</td>
<td class="nump">511.7<span></span>
</td>
<td class="nump">490.4<span></span>
</td>
<td class="nump">443.2<span></span>
</td>
<td class="nump">415.0<span></span>
</td>
<td class="nump">406.5<span></span>
</td>
<td class="nump">397.1<span></span>
</td>
<td class="nump">340.6<span></span>
</td>
<td class="nump">1,980.2<span></span>
</td>
<td class="nump">1,559.2<span></span>
</td>
<td class="nump">1,314.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,903.4<span></span>
</td>
<td class="nump">1,475.6<span></span>
</td>
<td class="nump">1,249.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.6<span></span>
</td>
<td class="nump">83.0<span></span>
</td>
<td class="nump">63.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">165.7<span></span>
</td>
<td class="nump">147.2<span></span>
</td>
<td class="nump">108.6<span></span>
</td>
<td class="nump">164.4<span></span>
</td>
<td class="nump">179.6<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
<td class="nump">316.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">457.0<span></span>
</td>
<td class="nump">249.5<span></span>
</td>
<td class="nump">224.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.7<span></span>
</td>
<td class="nump">67.8<span></span>
</td>
<td class="nump">71.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.2<span></span>
</td>
<td class="nump">42.7<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="nump">$ 2,825.7<span></span>
</td>
<td class="nump">$ 2,780.1<span></span>
</td>
<td class="nump">$ 2,757.5<span></span>
</td>
<td class="nump">$ 2,523.5<span></span>
</td>
<td class="nump">$ 2,712.4<span></span>
</td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,639.7<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="nump">10,886.8<span></span>
</td>
<td class="nump">10,354.7<span></span>
</td>
<td class="nump">9,817.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800.5<span></span>
</td>
<td class="nump">7,017.1<span></span>
</td>
<td class="nump">7,050.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,370.3<span></span>
</td>
<td class="nump">2,844.8<span></span>
</td>
<td class="nump">2,237.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Asia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281.2<span></span>
</td>
<td class="nump">160.1<span></span>
</td>
<td class="nump">217.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 434.8<span></span>
</td>
<td class="nump">$ 332.7<span></span>
</td>
<td class="nump">$ 313.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=biib_SegmentGeographicalGroupsOfCountriesGroupOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6905133824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 3,601.2<span></span>
</td>
<td class="nump">$ 3,182.4<span></span>
</td>
<td class="nump">$ 2,501.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_SegmentInformationTextualAbstract', window );"><strong>Segment Information (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=biib_SolothurnMember', window );">Solothurn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 1,748.5<span></span>
</td>
<td class="nump">1,215.7<span></span>
</td>
<td class="nump">545.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DK', window );">DENMARK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets related to operations in Denmark</a></td>
<td class="nump">$ 646.5<span></span>
</td>
<td class="nump">$ 707.1<span></span>
</td>
<td class="nump">$ 643.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SegmentInformationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Segment Information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SegmentInformationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=biib_SolothurnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=biib_SolothurnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816723808">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,526.3<span></span>
</td>
<td class="nump">$ 3,439.0<span></span>
</td>
<td class="nump">$ 3,356.5<span></span>
</td>
<td class="nump">$ 3,131.1<span></span>
</td>
<td class="nump">$ 3,307.0<span></span>
</td>
<td class="nump">$ 3,077.8<span></span>
</td>
<td class="nump">$ 3,078.4<span></span>
</td>
<td class="nump">$ 2,810.7<span></span>
</td>
<td class="nump">$ 13,452.9<span></span>
</td>
<td class="nump">$ 12,273.9<span></span>
</td>
<td class="nump">$ 11,448.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,037.8<span></span>
</td>
<td class="nump">2,978.2<span></span>
</td>
<td class="nump">2,935.5<span></span>
</td>
<td class="nump">2,685.1<span></span>
</td>
<td class="nump">2,797.8<span></span>
</td>
<td class="nump">2,707.8<span></span>
</td>
<td class="nump">2,712.2<span></span>
</td>
<td class="nump">2,426.1<span></span>
</td>
<td class="nump">11,636.6<span></span>
</td>
<td class="nump">10,643.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">944.9<span></span>
</td>
<td class="nump">1,442.9<span></span>
</td>
<td class="nump">915.0<span></span>
</td>
<td class="nump">1,171.2<span></span>
</td>
<td class="num">(166.3)<span></span>
</td>
<td class="nump">1,226.1<span></span>
</td>
<td class="nump">862.8<span></span>
</td>
<td class="nump">747.5<span></span>
</td>
<td class="nump">4,474.0<span></span>
</td>
<td class="nump">2,670.1<span></span>
</td>
<td class="nump">3,695.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Idec Inc</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 946.8<span></span>
</td>
<td class="nump">$ 1,444.4<span></span>
</td>
<td class="nump">$ 866.6<span></span>
</td>
<td class="nump">$ 1,172.9<span></span>
</td>
<td class="num">$ (297.4)<span></span>
</td>
<td class="nump">$ 1,226.1<span></span>
</td>
<td class="nump">$ 862.8<span></span>
</td>
<td class="nump">$ 747.6<span></span>
</td>
<td class="nump">$ 4,430.7<span></span>
</td>
<td class="nump">$ 2,539.1<span></span>
</td>
<td class="nump">$ 3,702.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="nump">$ 7.17<span></span>
</td>
<td class="nump">$ 4.18<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
<td class="num">$ (1.41)<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="nump">$ 3.47<span></span>
</td>
<td class="nump">$ 21.63<span></span>
</td>
<td class="nump">$ 11.94<span></span>
</td>
<td class="nump">$ 16.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4.73<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
<td class="nump">$ 4.18<span></span>
</td>
<td class="nump">$ 5.54<span></span>
</td>
<td class="num">$ (1.40)<span></span>
</td>
<td class="nump">$ 5.79<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
<td class="nump">$ 21.58<span></span>
</td>
<td class="nump">$ 11.92<span></span>
</td>
<td class="nump">$ 16.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">199.8<span></span>
</td>
<td class="nump">201.4<span></span>
</td>
<td class="nump">207.1<span></span>
</td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">211.5<span></span>
</td>
<td class="nump">211.4<span></span>
</td>
<td class="nump">211.9<span></span>
</td>
<td class="nump">215.6<span></span>
</td>
<td class="nump">204.9<span></span>
</td>
<td class="nump">212.6<span></span>
</td>
<td class="nump">218.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">200.3<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
<td class="nump">207.3<span></span>
</td>
<td class="nump">211.7<span></span>
</td>
<td class="nump">212.0<span></span>
</td>
<td class="nump">211.8<span></span>
</td>
<td class="nump">212.2<span></span>
</td>
<td class="nump">215.9<span></span>
</td>
<td class="nump">205.3<span></span>
</td>
<td class="nump">213.0<span></span>
</td>
<td class="nump">218.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenues from anti-cd20 therapeutic programs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 534.9<span></span>
</td>
<td class="nump">$ 511.7<span></span>
</td>
<td class="nump">$ 490.4<span></span>
</td>
<td class="nump">$ 443.2<span></span>
</td>
<td class="nump">$ 415.0<span></span>
</td>
<td class="nump">$ 406.5<span></span>
</td>
<td class="nump">$ 397.1<span></span>
</td>
<td class="nump">$ 340.6<span></span>
</td>
<td class="nump">$ 1,980.2<span></span>
</td>
<td class="nump">$ 1,559.2<span></span>
</td>
<td class="nump">$ 1,314.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">165.7<span></span>
</td>
<td class="nump">147.2<span></span>
</td>
<td class="nump">108.6<span></span>
</td>
<td class="nump">164.4<span></span>
</td>
<td class="nump">179.6<span></span>
</td>
<td class="nump">48.8<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">90.0<span></span>
</td>
<td class="nump">585.9<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
<td class="nump">316.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,825.7<span></span>
</td>
<td class="nump">$ 2,780.1<span></span>
</td>
<td class="nump">$ 2,757.5<span></span>
</td>
<td class="nump">$ 2,523.5<span></span>
</td>
<td class="nump">$ 2,712.4<span></span>
</td>
<td class="nump">$ 2,622.5<span></span>
</td>
<td class="nump">$ 2,639.7<span></span>
</td>
<td class="nump">$ 2,380.1<span></span>
</td>
<td class="nump">$ 10,886.8<span></span>
</td>
<td class="nump">$ 10,354.7<span></span>
</td>
<td class="nump">$ 9,817.9<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization and impairment of acquired intangible assets.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=109256448&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6833071216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details Textual) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 05, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments', window );">Unrealized gain (loss) on strategic investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12.2)<span></span>
</td>
<td class="nump">$ 141.2<span></span>
</td>
<td class="nump">$ 5.4<span></span>
</td>
<td class="num">$ (6.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 381.2<span></span>
</td>
<td class="nump">$ 455.3<span></span>
</td>
<td class="nump">$ 373.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(544.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(544.6)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.3<span></span>
</td>
<td class="num">(62.7)<span></span>
</td>
<td class="num">(14.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,597.2<span></span>
</td>
<td class="nump">2,253.6<span></span>
</td>
<td class="nump">1,973.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112.5<span></span>
</td>
<td class="nump">120.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.4<span></span>
</td>
<td class="nump">134.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
<td class="nump">131.0<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,425.6<span></span>
</td>
<td class="nump">2,458.7<span></span>
</td>
<td class="nump">$ 1,237.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember', window );">Bristol-Myers Squibb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember', window );">iPerian</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DevelopmentalMilestonePayment', window );">Developmental Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember', window );">Alkermes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.7<span></span>
</td>
<td class="nump">80.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember', window );">Ionis Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense on 2018 Ionis Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Premiumonpurchaseofcommonstock', window );">Premium on purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Investmentincommonstocksharespurchased', window );">Investment in common stock, shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Payments to Noncontrolling Interests</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales', window );">Additional reduction in royalty rate payable on commercial sales</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_Reductioninroyaltyratepayableoncommercialsales', window );">Reduction in royalty rate payable on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TecfideraMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember', window );">Karyopharm</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember', window );">Remedy Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember', window );">AliveGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Loss (gain) on fair value remeasurement of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.6<span></span>
</td>
<td class="nump">89.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember', window );">2017 Tax Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems', window );"><strong>Schedule Of Development Milestone And Collaboration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_DeferredtaxliabilitiesGILTItaxcalculation', window );">GILTI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,173.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Transition toll tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 989.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 697.0<span></span>
</td>
<td class="nump">$ 989.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Additionalreductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Additionalreductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DeferredtaxliabilitiesGILTItaxcalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, GILTI tax calculation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DeferredtaxliabilitiesGILTItaxcalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DevelopmentalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Developmental Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DevelopmentalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Investmentincommonstocksharespurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in common stock, shares purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Investmentincommonstocksharespurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Premiumonpurchaseofcommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Premiumonpurchaseofcommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyratepayableoncommercialsales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate payable on commercial sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyratepayableoncommercialsales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Development Milestone And Collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ScheduleOfDevelopmentMilestoneAndCollaborationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiaries and other recognized entities not within the country of domicile of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate net change in the difference between the fair value and the carrying value, or in the comparative fair values, of marketable securities categorized as trading held at each balance sheet date, that was included in earnings for the period, which may have arisen from (a) securities classified as trading, (b) the unrealized holding gain (loss) on held-to-maturity securities transferred to the trading security category, and (c) the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) on available-for-sale securities transferred to trading securities during the period and/or any unrealized gains or losses on investments that are separately or otherwise not categorized as trading or available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_BristolMyersSquibbMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IPerianMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IPerianMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_AlkermesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_AlkermesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntitiesByClassificationOfEntityAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TecfideraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TecfideraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_KaryopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_RemedyPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_AliveGenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=biib_U.S.2017TaxActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.10.0.1</span><table class="report" border="0" cellspacing="2" id="idp6968755984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events Subsequent events (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,690.6<span></span>
</td>
<td class="nump">$ 431.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember', window );">Skyhawk Therapeutics | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront And Milestone Payments Made To Collaborative Partner</a></td>
<td class="nump">$ 74.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid research and development</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SkyhawkTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>184
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_RNPFXP=F__L?%%4';PZR[D%U!+ P04    " #NBD9.F5R<(Q &  "<)P
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MSPT]G]%+YXA\1 4+%*! X=%K1V!$% ;1CXBJ2/- &B6H4GHJ"T?%1Z 45JA
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MIO/XTM6GJ:$>7[KZR_\!4$L#!!0    ( .Z*1DY"PU@QI ,  +H/   8
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MO%C1B^5>HLG?6-9+:0U+7\N6R)6);'&B$\>=1'UL''-BRD*Q:1%D-NRD!!=
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M\=,508@E8#*?9*R2@%6("3:)YHMW9V,_G*AW4*0@3S)/2: @Q&4F\5."88J
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MS45VUZT20H,1)!NC6)L':"P85-I.]V8N_6?H"RVZX87!XS.7_0-02P,$%
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MHSB?_L@4=!OC<Y"OX2B;=GR6!S* 4_Z](3#UA#H!3]B&02?DLA-8=P+%+I*
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M2Q "$B@,1IUT)'UK5<@S)AL!LEE)-D+$\M6DK+Z0+DLT%9 N\5->J-['/"/
M,RMY1KIXNI(S*P&8Y:G3MH'.&!-B F&:$:"9*AX)X,?Z-;1<:I,NR=00N229
M&\80(P Q*R%&@$Y)J@MTTM66,GQ),M^#P?QBP"]5V+ F3BR?^(8UO/P3%WY!
M)+\6"A5CC-'%H!A3)22#8HQBJ]<*4)@GK&HP*+19L)1D3$T&A9@-@)<#.V<
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MNDIR["OGVRDCTQKE?%JY0>7G.@;I1%6+!MC<)!%Q-2#B#FV7&8"&$B-\/9<
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M*M TIB#&09?,E![2E8!T^2)S*JT662>A)E1ZV%0"-J4.9Q+Q(&W37'<>NI*
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M96/_&T0'7DIRXT>H\Q]L-10T+AS?^[.9QVPV' [+#V+K-RY_ 5!+ P04
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M7RQ:;&&II(;.2=,1"W5.'Y+3.0WQ,>"[A-&MSB14<C7F)1B?JISN@B!04/K
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M[[4:"AH?CN_P;.<AFPUOAN7_L/43EW\ 4$L#!!0    ( .Z*1DY$3:.LLP$
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M\?'X-ISM-&:3X;&??Q!;OG'Y"U!+ P04    " #NBD9.J%*SY+0!  #2 P
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M.-MIS";#8S__(+9\X_(74$L#!!0    ( .Z*1DZ\>TY7M0$  -(#   9
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M=V]R:W-H965T<R]S:&5E=#$W+GAM;'U3VV[;, S]%4$?4#E*U@6!;:#I,*S
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M/K/V^*( XP)>IW]?P([KME9>@!GFG#DS#/F$YMEV (Z\**EM03OGAB-CMNI
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M^+*Q_[4Q'E!*<H4CU.('6PP)M0_'SWBVTYA-AC?]_(/8\HV+WU!+ P04
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M P[W,-7S@9*I^&]P!>7#@Q*?HT!EXTJ*WCK4$XN7HL7KN,LV[L-XLT\FV#J
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M^.T"]Z!4(/(R7F=.NJ0,P/7YG?U3K-W7<A86[E$]R\JU.;VEI():#,H]X?@
M<SW7E,S%?X8+*!\>E/@<)2H;5U(.UJ&>6;P4+=ZF779Q'Z>;-)UAVP ^ _@"
MN(UYV)0H*O\HG"@R@R,Q4^][$9YX=^"^-V5PQE;$.R_>>N^EX-=)QBZ!:(XY
M3C%\%;-;(IAG7U+PK11'_A><;\/3385IA*>_*?Q'_OTFP3X2[/];XE;,GRK9
MJJ<:3!.GR9(2ARY.\LJ[#.P=CV_R*WR:]B_"-+*SY(S.OVSL?XWHP$M)KOP(
MM?Z#+8:"VH7C!W\VTYA-AL-^_D%L^<;%3U!+ P04    " #NBD9.G-S4?[$!
M  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q]4V%OFS 0_2N6
M?T"=.*2K(D!J6E6;M$E1IVV?'3C JHVI;4+[[W<VA+$.[0N^.^Z]>W<^IX.Q
M+ZX!\.1-J]9EM/&^.S#FB@:T<#>F@Q;_5,9JX=&U-7.=!5%&D%:,;S:W3 O9
MTCR-L9/-4]-[)5LX6>)ZK85]/X(R0T:W]!IXEG7C0X#E:2=J^ [^1W>RZ+&9
MI90:6B=-2RQ4&;W?'HY)R(\)/R4,;F&3T,G9F)?@?"DSN@F"0$'A X/ XP(/
MH%0@0AFO$R>=2P;@TKZR/\7>L9>S</!@U"]9^B:C=Y244(E>^6<S?(:IGSTE
M4_-?X0(*TX,2K%$8Y>*7%+WS1D\L*$6+M_&4;3R'B?\*6P?P"< _ -A8*"I_
M%%[DJ34#L>/L.Q&N>'O@.)LB!.,HXC\4[S!ZR?E^E[)+()IRCF,.7^1LYPR&
M[',)OE;BR/^!\W7X;E7A+L)W?RE,U@F258(D$B3_;7$M9_^A"%O,5(.MXS8Y
M4IB^C9N\B,X+>\_CG?Q)'[?]F["U;!TY&X\W&^=?&>,!I6QN<(4:?&"SHZ#R
MP?R$MAW7;'2\Z:87Q.9GG/\&4$L#!!0    ( .Z*1DZKRU-FL0$  -(#   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;'U3;6^<, S^*U%^0'.7HR\Z
M 5*O4]5*FW3JM.US#@Q$33!-PM'^^R6!8ZQ#^T)LX^?Q8\=)!S2OM@%PY%VK
MUF:T<:[;,V:+!K2P5]A!Z_]4:+1PWC4ULYT!44:05HQO-C=,"]G2/(VQH\E3
M[)V2+1P-L;W6PGP<0.&0T2V]!%YDW;@08'G:B1J^@_O1'8WWV,Q22@VME=@2
M U5&[[?[0Q+R8\)/"8-=V"1T<D)\#<YSF=%-$ 0*"A<8A#_.\ !*!2(OXVWB
MI'/) %S:%_;'V+OOY20L/*#Z)4O79/2.DA(JT2OW@L,33/U<4S(U_Q7.H'QZ
M4.)K%*AL_)*BMP[UQ.*E:/$^GK*-YS#Q7V#K #X!^"< &PM%Y5^$$WEJ<"!F
MG'TGPA5O]]S/I@C!.(KXSXNW/GK.^?5-RLZ!:,HYC#E\D;.=,YAGGTOPM1('
M_@^<K\-WJPIW$;[[2V&R3I"L$B21(/EOBVLYMY^*L,5,-9@Z;I,E!?9MW.1%
M=%[8>Q[OY$_ZN.W?A*EE:\D)G;_9./\*T8&7LKGR*]3X!S8["BH7S%MOFW'-
M1L=A-[T@-C_C_#=02P,$%     @ [HI&3H+S3$:V 0  T@,  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL?5-A;]L@$/TKB!]0')*T661;:CI-F]1*
M4:=MGXE]ME'!YP&.VW\_P*[G;=:^ '?<>_?N.-(!S8MM !QYU:JU&6V<ZXZ,
MV:(!+>P-=M#ZFPJ-%LZ;IF:V,R#*"-**\22Y95K(EN9I])U-GF+OE&SA;(CM
MM1;F[00*AXQNZ+OC6=:-"PZ6IYVHX2NX;]W9>(O-+*74T%J)+3%09?1^<SSM
M0GP,^"YAL(LS"95<$%^"\:7,:!($@8+"!0;AMRL\@%*!R,OX.7'2.64 +L_O
M[)]B[;Z6B[#P@.J'+%V3T0,E)52B5^X9A\\PU;.G9"K^$:Z@?'A0XG,4J&Q<
M2=%;AWIB\5*T>!UWV<9]&&_VVPFV#N 3@,^ 0\S#QD11^4?A1)X:'(@9>]^)
M\,2;(_>]*8(SMB+>>?'6>Z\YWQ]2=@U$4\QIC.&+F,T<P3S[G(*OI3CQ?^!\
M';Y=5;B-\.T?"C^L$^Q6"7:18/??$E=B;I._DK!%3S68.DZ3)07V;9SDA7<>
MV'L>W^1W^#CM3\+4LK7D@LZ_;.Q_A>C 2TEN_ @U_H/-AH+*A>.=/YMQS$;#
M83?](#9_X_P74$L#!!0    ( .Z*1D[@*G6.M $  -(#   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;'U3VV[;, S]%4$?4"5*EA6!;:#I,&S !@0=
MMCTK-FT+U<63Y+C[^U&RZWJ;VQ=)I'@.#RDJ&ZQ[]"U ($]:&9_3-H3NR)@O
M6]#"W]@.#-[4UFD1T'0-\YT#42605HQO-@>FA32TR)+O[(K,]D%) V='?*^U
M<+]/H.R0TRU]=CS(I@W1P8JL$PU\@_"].SNTV,Q220W&2VN(@SJG=]OC:1_C
M4\ /"8-?G$FLY&+M8S0^5SG=1$&@H R10>!VA7M0*A*AC%\3)YU31N#R_,S^
M,=6.M5R$AWNK?LHJM#F]I:2"6O0J/-CA$TSUO*-D*OX+7$%A>%2".4JK?%I)
MV?M@]<2"4K1X&G=ITCZ,-X?#!%L'\ G 9\!MRL/&1$GY!Q%$D3D[$#?VOA/Q
MB;='CKTIHS.U(MVA>(_>:\$/VXQ=(]$4<QIC^"+F)8(A^YR"KZ4X\?_@?!V^
M6U6X2_#=7PI?(=BO$NP3P?[-$M=B=O\D88N>:G!-FB9/2MN;-,D+[SRP=SR]
MR4OX..U?A6ND\>1B [YLZG]M;0"4LKG!$6KQ@\V&@CK$XWL\NW',1B/8;OI!
M;/[&Q1]02P,$%     @ [HI&3A\)%AJU 0  T@,  !D   !X;"]W;W)K<VAE
M971S+W-H965T,CDN>&UL?5/;;MLP#/T501]0)8J3%8%MH.DP;, *!!VV/BLV
M?4%U\20Y;O]^E.QZ;F?L11(IGL-#BDH'8Y]= ^#)BY+:9;3QOCLRYHH&E' W
MI@.--Y6Q2G@T;<U<9T&4$:0DXYO-@2G1:IJGT7>V>6IZ+UL-9TM<KY2PKR>0
M9LCHEKXY'MNZ\<'!\K03-?P _[,[6[38S%*V"K1KC286JHS>;8^G),3'@%\M
M#&YQ)J&2BS'/P?A69G03!(&$P@<&@=L5[D'*0(0R?D^<=$X9@,OS&_N76#O6
M<A$.[HU\:DO?9/26DA(JT4O_:(:O,-6SIV0J_CM<06)X4((Y"B-=7$G1.V_4
MQ()2E'@9]U;'?1AO]GR"K0/X!. SX#;F86.BJ/RS\")/K1F('7O?B?#$VR/'
MWA3!&5L1[U"\0^\UYX<D9== -,6<QAB^B-G.$0S9YQ1\+<6)_P/GZ_#=JL)=
MA._>*=RO$R2K!$DD2/Y;XEK,X4,2MNBI EO':7*D,+V.D[SPS@-[%Q^1_0T?
MI_U!V+K5CER,QY>-_:^,\8!2-C<X0@U^L-F04/EP_(1G.X[9:'C333^(S=\X
M_P-02P,$%     @ [HI&3FZ?6,ZU 0  T@,  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL?5/;;MLP#/T501]0)4K69H%MH.DP;, &!!VV/2LV;0O5
MQ9/DN/O[4;+K>:VQ%TFD> X/*2H;K'OR+4 @SUH9G],VA.[(F"];T,+?V X,
MWM36:1'0= WSG0-1)9!6C&\VMTP+:6B1)=_9%9GM@Y(&SH[X7FOA?I] V2&G
M6_KB>)1-&Z*#%5DG&O@&X7MW=FBQF:62&HR7UA '=4[OM\?3/L:G@!\2!K\X
MDUC)Q=JG:'RN<KJ)@D!!&2*#P.T*#Z!4)$(9OR9..J>,P.7YA?UCJAUKN0@/
M#U;]E%5H<WJ@I():]"H\VN$33/6\HV0J_@M<06%X5((Y2JM\6DG9^V#UQ()2
MM'@>=VG2/HPWG$^P=0"? 'P&'%(>-B9*RC^(((K,V8&XL?>=B$^\/7+L31F=
MJ17I#L5[]%X+?GN7L6LDFF).8PQ?Q&SG"(;L<PJ^EN+$W\#Y.GRWJG"7X+M_
M%![6"?:K!/M$L/]OB6LQ[U\E88N>:G!-FB9/2MN;-,D+[SRP]^D1V=_P<=J_
M"M=(X\G%!GS9U/_:V@ H97.#(]3B!YL-!76(QSL\NW',1B/8;OI!;/[&Q1]0
M2P,$%     @ [HI&3N)&HXNS 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL?5-A;]P@#/TKB!]0$N[65J<D4J_3M$F;=.JT]3.7. DJQ"F0
M2_?O!R3-TB[;%\#&[_G9F&Q$\V1; $=>M.IL3EOG^@-CMFQ!"WN%/73^ID:C
MA?.F:9CM#8@J@K1B/$FNF1:RHT46?2=39#@X)3LX&6('K87Y=02%8TY3^NIX
MD$WK@H,562\:^ [N1W\RWF(+2R4U=%9B1PS4.;U+#\=]B(\!/R6,=G4FH9(S
MXE,POE0Y38(@4%"ZP"#\=H%[4"H0>1G/,R==4@;@^OS*_BG6[FLY"POWJ!YE
MY=J<WE)202T&Y1YP_ QS/1\HF8O_"A=0/CPH\3E*5#:NI!RL0SVS>"E:O$R[
M[.(^3C>[=(9M _@,X O@-N9A4Z*H_*-PHL@,CL1,O>]%>.+TP'UORN",K8AW
M7KSUWDO!;Y*,70+1''.<8O@J)ETBF&=?4O"M%$?^%YQOPW>;"G<1OGNC\!_Y
M]YL$^TBP_V^)6S'O5;)53S68)DZ3)24.79SDE7<9V#L>W^1/^#3MWX1I9&?)
M&9U_V=C_&M&!EY)<^1%J_0=;# 6U"\<;?S;3F$V&PW[^06SYQL5O4$L#!!0
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M9,;/,-=S2\E<_%>X@L3PH 1SE$:ZN))R<-ZHF06E*/$R[9V.^SC=[.YFV#:
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MR:T#" K5 ;8# DHGKPX0*%0'V X(*-T[22$H5 ?8#@@<^9FW;\ .*& [A.V
M@-3)M1T("M@.83\@</"GWKX!/Z! O0GL!P)(7;C[!D%NO24WG_2U; ^VF>FB
MK3HWMI.Z&9T:I@>R+<$_^-!M?2_:0]ETT:O2IK&PG_][I;0T<V%WIB:/IL&;
M'BJYU_WMW-RW0Y<S/&AU&CNX9&HCUW\!4$L#!!0    ( .Z*1DY=6LJ@M@$
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M\QXM 8-*VVUB]G*:RBG0HI\?'+*\>OD?4$L#!!0    ( .Z*1DYIHP"EW0$
M  $%   9    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;'54VX[;(!#]%<0'
M+ Y.XC2R+6VVJEJIE:*MVCX3>WS1@G&!Q-N_+V#'=;WL2V#&YS)#&-)!JA?=
M !CT*GBG,]P8TQ\)T44#@ND'V4-GOU12"69LJ&JB>P6L]"3!"8VB/1&L[7">
M^MQ9Y:F\&MYV<%9(7X5@ZL\)N!PRO,'WQ'-;-\8E2)[VK(;O8'[T9V4C,JN4
MK8!.M[)#"JH,/VZ.I\3A/>!G"X->[)'KY"+EBPN^E!F.7$' H3!.@=GE!D_
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MW:MQ*L? R'YZ<,C\ZN5_ 5!+ P04    " #NBD9.B5A(,[<!  #2 P  &0
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M?S;3F$V&PW[^06SYQN5?4$L#!!0    ( .Z*1D[D:>'PQ@$  #<$   9
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M\R\;^]\B.O!2DAL_0KW_8*LAH77A>.?/9AZSV7 X+#^(K=^X^@M02P,$%
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M9A#<=:V$T&!*">[,J3;F/5H"!I6VVX/9RVDJIT"+?GYPR/+JY7\ 4$L#!!0
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M    >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;'54;6^;,!#^*\@_H$YXR9L
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MSS@^P5Q/2LE<_%>X@O+PD(F/4:*R<27E8!WJ6<6GHL7KM,LN[N-TDZ8S;9O
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M5[9J U0LU#,"/@;'F6?&0:\C(@0> 9@[!'!!]0*/ 0P /H_M>P=$44CDP<,
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M"V.2*DD0J=AOZL]B&M3T(O5CKI[Y<+P. \FZ\=<AGOY?RC]02P,$%     @
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MMY&\Y\T1H'D0K-3'&[<]8RW^ U!+ P04    " #NBD9.C-DS,%T*  "G1@
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MW1T<H"S)4)9Q( 8@#ZD+D@S(0S+W#FF233I!G=23Y-XXQ7FODDG*P/0$33!
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M@(4J=ITJ""L^B4]HW0B:'<ITK%D!(IP,(F;0"!<HY2I PDY#W&FXX(V@<%Z
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M#8 1%O=J;A!V!(<= 6$'5MC1J".N4V3-DZ<Q11BQRW'34KQ'!>\$',,!Q^.
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M:LW[2==O)&N'*>Z-?R6*_U!+ P04    " #NBD9.\8?JLBH"  "2!@  &0
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M=,2\A:!4.YBS%,@@7:I23Y3JO%9/>XMY0:%LC=*>XO&ILHQE&].>N)D"-3O
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MPG6.9;G8VG)SV=C;E[;_VM=4?7Y#Z;S15J?Q[:OT\@K8^G]02P,$%     @
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MY)J9$6XV@K;][>0/5V3^%U!+ P04    " #NBD9.?:AE'@L%  !#&P  &0
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M)OUQ,[U(GTZZ^C+_DR"\_:=B]S]02P,$%     @ [XI&3HZ=H*%? @  M <
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M(-8"\8- ,&N4P60:TVG,.L@B+_/'SXRQ6S*2)$V\V0GLE[ LRE83V$,!B;6
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M5V(<JYF&AA!B72*-)R# %+#&%)#&%=!_V +2^ ("C$']2"U D'(&6)J 5E^
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ME@DE[N./$C6;-06Q_7Y3W\C@>3 O2476-/N=[MAQ84:FL2/[Y)RQ9WK]0E1
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M5!@1&"8'87( )@BS'C3E- PI"2H#&DB&,U3 .!3$H0!.$>#069PJ1WDZN7!
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M:VLZ$'P6:IO*/3/#VQP$[<=["4R7X_8?4$L#!!0    ( .^*1DY/O! VK0(
M &L*   9    >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;)56[8Z;,!!\%<0#
M +;Y/"61FE15*[52=%6OOWV)DZ #3&TGN;Y];>-#'"P5]R=@F!W/;'82K^Y<
MO,@+8\I[K:M&KOV+4NU#&,K#A=54!KQEC7YSXJ*F2B_%.92M8/1HB^HJQ%&4
MAC4M&W^SLL_V8K/B5U65#=L+3U[KFHJ_6U;Q^]I'_MN#Q_)\4>9!N%FU],Q^
M,O6KW0N]"GN68UFS1I:\\00[K?U/Z&&';8%%/)7L+@?WGK'RS/F+67P[KOW(
M*&(5.RA#0?7EQG:LJ@R3UO''D?K]GJ9P>/_&_L6:UV:>J60[7OTNC^JR]G/?
M.[(3O5;JD=^_,F<H\3WG_CN[L4K#C1*]QX%7TGYZAZM4O'8L6DI-7[MKV=CK
MO7L39ZX,+L"N /<%*/YO 7$%9%00=LJLU<]4T<U*\+LGNF^KI68HT /1S3R8
MA[9W]IUV*_73VR8O\E5X,T0.L^TP>(#![Q&[*8*0'A)J ;T*#*K MIZ\4U'
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M=?>H^GQ\3\:!9/WT5*+YO<[_ 5!+ P04    " #OBD9.4UHHIQ,$  "1%0
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ME*IE4VAXTW3=0:;;RTDF=W5[*)KCLM\D[$]J==(;H,%E%W;]/U!+ P04
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MIOND^V*\0\:!XOUT/:+YCB[^ E!+ P04    " #OBD9.',(P,EH#  #I#@
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MFM #P3$N.#8$AUI0%K$1E(1%>HBO3$HN'],C?&UB<13I>_4&<4:X$=U;$YM
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MD?)TY?X+R1'@+DO>@F!S09"[+#@J@E]WE-ZN&89?>.S=H-D FO\5"__2__U
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MMM=.X@2T!E/;"=NWKVU8RI*)NC?XP,S_S3#8DW=2/>N2<Q.\U*+1Z[ TIGU
M2!]*7C.]D"UO[)N35#4S=JG.2+>*LZ-WJ@6B&*>H9E43%KG?VZDBEQ<CJH;O
M5* O=<W4GRT7LEN')'S=>*K.I7$;J,A;=N;?N?G1[I1=H5'E6-6\T95L L5/
MZW!#'K8D<@[>XF?%.SV9!RZ5O93/;O'EN ZQBX@+?C!.@MGARA^Y$$[)QO%[
M$ U'IG.<SE_5/_GD;3)[IOFC%+^JHRG7818&1WYB%V&>9/>9#PDE83!D_Y5?
MN;#F+A++.$BA_3,X7+21]:!B0ZG92S]6C1^[_DT:#VZP QT<Z.@0>0[J03[R
MC\RP(E>R"U3_\5OF:DP>J/TV![?I/X5_9X/7=O=:$(RC'%V=TF"T[8WHU&BT
M0%9^9%"(L:6W[AC'L$($1AEYA>BM0@(KQ*!"[!7BMPKI+,_>*/%&C3>*[?^-
M84X"<A*(LYQQ>J/5A)-$BRR".2G(22%.-N.D-_G<R64),I808S5C]$;I_QD9
MR,@ !L$S1G:3QP>2W"W,"@2M(!"9@59@8>[\: 3#)PI#)#H_4OB]M2%W#BZ!
M,#<GE[RW/ 0\NQM"(4P\Q]";;.CR;H$(?,A)!*&2.2H":T1G*#2Y &NNSO[J
MU\%!7AK?=R:[8WO94'^!_C/O>],WILY5HX.]-/8:]I?E24K#;31X85,N;3L<
M%X*?C)LN[5SU/:%?&-D._0Z-3;?X"U!+ P04    " #OBD9.LA6S-PH"  ")
M!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Y."YX;6Q]5-N.FS 4_!7$!\1<
MDVT$2)M$U59JI6BKML\.'"Y:&[.V$[9_7U]8E@#=%VP?9L8SQIRD9_Q%U #2
M>:.D%:E;2]GM$1)Y#12+#>N@56]*QBF6:LDK)#H.N# D2E#@>5M$<=.Z66)J
M9YXE["I)T\*9.^)**>9_#T!8G[J^^UYX;JI:Z@+*D@Y7\!/DK^[,U0J-*D5#
MH14-:QT.9>H^^OM3K/$&\+N!7DSFCDYR8>Q%+[X5J>MI0T @EUH!J^$&1R!$
M"RD;KX.F.VZIB=/YN_I7DUUEN6 !1T;^-(6L4_?!=0HH\97(9]8_P9 G=ITA
M_'>X 5%P[43MD3,BS-/)KT(R.J@H*Q2_V;%IS=C;-_%NH*T3@H$0C 1_^RDA
M' CA!R'ZE! -A&A&0#:*.9L3ECA+..L=;K]NA_4E\O>1.OU<%\UAFW?J>(2J
MWC+?\[<)NFFE 72PH& *&A%(R8][!&M['((%/;C?X+A$A.$]Y+0"B=9-A*M!
M0\,/[X/NUA6B587(*$3W"@^SH[*@G0&U-NMFGG:)"3?1+*[%;">8_Z2-5[W&
M:UZ_S+S&"Q_>9I;GN(;9S;PN,=/,UBV:7$@*O#(_NW!R=FVE_JR3ZMA/'@-]
MH6?U@^HSMBU\R-@F]0/SJFF%<V%2_2[F4I>,25 6O8WR6*N^."X(E%)/=VK.
M;7>P"\FZH?&AL?MF_P!02P,$%     @ [XI&3ML1N!3; @  <@H  !D   !X
M;"]W;W)K<VAE971S+W-H965T.3DN>&UL?59M;]HP$/XK4;XOL9UW!$B%MMJD
M3:HZ;?MLP$#4),YL ]V_G^VD:7 .OI#8?IY[[B['^>87+M[DD3'EO==5(Q?^
M4:EV%H9R>V0UE0%O6:-/]ES45.FE.(2R%8SN+*FN0H)0&M:T;/SEW.Z]B.6<
MGU15-NQ%>/)4UU3\6[&*7Q8^]C\V7LO#49F-<#EOZ8']9.I7^R+T*ARL[,J:
M-;+DC2?8?N$_X-DS3@S!(GZ7[")'[YX)9</YFUE\VRU\9#QB%=LJ8X+JQYFM
M65492]J/O[U1?] TQ/'[A_5G&[P.9D,E6_/J3[E3QX6?^]Z.[>FI4J_\\I7U
M 26^UT?_G9U9I>'&$ZVQY96TO][V)!6O>RO:E9J^=\^RL<]+=Y)F/0TFD)Y
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M]YPKI@-&@0[XJ ? 85&QO3*OF7X7W134+11O^PDO',;,Y7]02P,$%     @
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M-T2J)3\BT7$@>Q/44!1BG*"&U*V?9\:VY7G&3I+6+6RY)TY-0_C?#5#6K_S
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M,L-4CT775+N)XDU_80B&6\OZ+U!+ P04    " #OBD9.$,=+M_H!  !R!0
M&@   'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&ULC931CILP$$5_!?'>M8%
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MME98%1I;V+;RFDW33/K;(:DNCBWL<'G5A@BI@@15F /*=W@6.A%3V.#JEA6
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M%(-#S/<&[S^+JR@UW"C18^QDV79/;W=IE:P&%BVERO_T[Z+NWK?^#T\&,]R
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MUX/88";*HIF&VO2H<("*J;;JVTF>DM][4FA1,RT*:-%05P0%L2"?^3.D!6.
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MU@>4^%X?_7=V896&&R=ZCAVOI/WW=F>I>-VK:"LU?>F>96.?UU[_E083<$_
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M^1W@)@+<1'##6@EQ$R'FA99&B]"(%XQ<6YH0C?0UL#(AOYL7/8\CW.,(\WC
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M&'[ =0^XQP?:NO<]X+L'_.,#V]ZD#X3N@9#[0.P>B+D/E-T#9>X#5?= E?M
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MRYTB,^*_CI">LZ37CI6."YTE+,<J(HSE+&.U%3G=>1TLQZ$<X37G0>>IBEY
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MJ8>)&O/V'FPGDC7='>_U'QK9/U!+ P04    " #OBD9.ODF=4<0!   6!
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M?!FZY7#19O3KD""0%<BZ+7U)."&8%2.8%02S C(+YLQ*0!HUV6/J91_2",?
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ME3G-]+EH9[EVH7CCYM2X&Y:7_P%02P,$%     @ [XI&3J>O(EG*!@  ^28
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MB.]UV7]G-U9HN'&B8V2\D/;I95>I>-FI:"LE?6G'O+)CT[XAJ*.Y":@CH)Z
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ME)DF>B[:/M0N%*^['@OZ1K_Z#U!+ P04    " #OBD9.+]7,:@P&  "\'@
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MHG^'*25T$/:9&654GYAS7J(^LZ",E'UDR;@1R,T=PP :VA7#2,2L/QV:^/.
M-PRB>($D7RFR=B#[E3*@L>)=J-J%ZB4+J-8:QM;,H8E3"^.A=*8-9KJ8DDB
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M-Z_P@VO)^0K(^<$=@\F(+'\K#E,!76*8[CL* YQ!S'%:1YC;<)P$U<FBK_A
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MJ9 ! -)E!@ 4    >&PO<VAA<F5D4W1R:6YG<RYX;6SLO6ESX\BU(/IYWJ]
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M9$D4!FL !Y%Z>";+T?ZKUP0R^*\)G$OZ>SM(Z"9=;PL,=<B;W\5;#0"P#T5
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M-R755TS>/XY?J0&@8QL1+^1KU@.X58HP:5CI.1:1138/<,]4JR*B#'H2*1)
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MC3BMOQ">HYW=9.I_PIPF]G\EU.T)JU:2$VM.SN8U@MRD$J'(A,H'M75RG8)
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MM2??^.%!UHZ+KYC^1Q+Q8U,MM5 <5:NJ4$T 4&)VNFXHXR)[,L5/WGZ:)J3
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M0C"Z'*,M"+[JCMC V@LGW:Y5,Y,J4I,39=P;\UD-PE%G+,?8#[OB&)Z$O=&
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M[Q/@!5D/0N;CC^^E=&B$5:]E[&Q;<G,H0/>4R[Q1RA<7\RB<\("567/J%F>
MPC586Y:$97"I<1]P0A#P.0P6=0MY'- Z<H+O%V"H/>@D+5A;JH[VC,$H_3!8
M)L@)N1<0XK@$\G(S,X&7?\I5)=^H]JT'P.U<&6L6CF[5J'Y(%=3CW#UB:GRW
M$#!0O:@B&9E>T6E8HV9$P"1/-ZS7>HM*Z=IF2^<<<7U !]*6BZ^^,7MNRB'[
MRD'04TV"KC*0T:4C+4#G)4YDZUQ!; DD']LX..0Z]AX\9VWHG'7*,W!1,RT7
MFZ!:,D^.=5,914X8_XHI/_KPKNNXA!.,(B8TI_0K EM.]IR9*T8]$V)7:X'^
MI=89*9%8PZVZ!DYSV@[!D;HRNW/;+=E$>.,5-/TBX;?5?"M5L/A*OT6HP!FH
M>25]W[G_DG2S+0LEW3B]P-U[=Z7;;K M0FPOJ.?7KQ^D\7J:6MBFWB67%T;9
MW#6@C!:/Y($\BIU85Z*JYG_A>R&NE57KUEFUC-K^'(]%D_)>T2P(,[RB7BY3
MV^2&$2*_AKMT\:S9?5.?F"^E;@L[3)\HGT[&*/Y3&,M#[79>F\A1SP;)7[*+
M.%XX$=:]Z"(S#;A,W25;D'6NNBFVFPAB>P:&I.\W%(2=WEC5HKM0R8BF+*2@
MU+77;W%<[SX$ FA9KES9W7J17P /A^6@+GGWE,"N_.H*J$2&S<KF3]F*3@\;
M%X65,V3!7U0A6\F*[5%:_7*9\PR6:FGKBTHUT*2H5+JS13C)K/Z?"#&]UD;<
M11C3H"M@.NE>](;!3!4C FJKB^APAJ=!!L_>A0(!A5M4*?R>>(\QD5'NP?N4
MM6P'6RYLT01"(H>_XI#J<>M81KHR[K/7%Y\NJ'4-G'YJ!.MG@,P6#Q^[*?8N
MDX!B2G$(9UY&CUE^4</)S28F(ZZ8=FCL*\S(1^A,Z5MG)G\C=;ROL(]Q4G)-
M*E'@31EI:IAL0TR6"BBN?T%NQ(B&&^(J"QQV-NT[5>9AR+LY%+76LI:L 68U
M:H5HPW&\6WR#1L1S=H4F"<CN=05RX<J>!H=2&D46UZ6,?8I%-9-*<]R^%'QT
MLC_W<S957QH-B%C-3/4".?;X06QXB%<+MTCFY;1=&\H0?$ U/[;=ST\_W=U\
M_'"F<3K?VD#YQ"/?EP#@%#MXUV@.&5.,(P'[UT=(F;\$'Y69BBVOROKEGZ]&
MS$,.]F1/:8NJ\G/4^=>-!*ZC -,8X]"30V"P!Z>O;SZ0-R_[M09'>R;5=]_#
M#+U@TND&_>&P1C*P*O"2%'EL2D(H8JC'1QN _3+#-RP.F;W :JR535XEFR6)
MH1?!2W<8),]9-=1Z%AA73(MPVROZ61?*YX;_H)MU:%%.HFE0>/=*1^.NYT79
M']W+.&ZX64/8;@]&?VN+WC\OL-C%B;UA#:/J:ZR'PF'U'D_!LRWV"J>0D66W
M";YU;;!!"<0IZ%+[W>9K<0EYS2LO0FHHGK;0U40@$F=/[%N(RE.QUH?'FNMC
M8^JG:UA)4M[O2!![U7.WUV#D)UW(> BPTC'6W\&N(W13<FWGGB/36&,]''2B
M/&7;U4*?".:#D^![W/JQ6P/OM8C5 J^5Y]^K-2P$6;K[P5\L2Y;8]T32^:@X
MCT(7X0&M9T"WSUG7#_A'7FH^DWA.%@O1L.(C%#T].MIC;SEU&G\N59WVAICH
M]D3TMEA18L@G%#+9X<J=O4OYM1OTAO)KS_W:I\2/CHN$)7-,I6.%5$4G(V2V
M6IG6(GZVO34OW9NAQ!OWK&!\LXX0]F\R;^%=BOW (A&C?H_BV/OA:(3&S->K
M1 =AV+E-<59+)QJ*(-IPS%-N/7&&'LN<:"V\9(?JAIU)ATK/]$88ILC)':<C
M"KWL:N"%IDR4+'<8CCN<,6@6CM"-6Y:LW.A(+7@#^) O_DB^UZ,HS9L\*9H,
MW4W[;=-5#[*CXXHQ_R;I)02RI.E<A ;[?G#6-"V'0#W5JJE<<?7"UUM)0+G'
M&^[:'9JJF(O@5+5!1@-Z][(:0H_9[BY2%0E,]!EP-XTQ1_6LECY)-BKN%R;R
M&+=$]/LQX2EMU]$&A;E@^B.'0KCO2BZV3M:4_27:I'&I[ 8?.Z&H7@,!Y8+@
M1+0564:!#\8%%=<C?[9D)1.WPZY^)WVO6K""84/;:ULEQV=8IV5V3[V F*"Z
M[4H5)82=W_?7%(5MTR8O#R%R?9W%-SJ$)AFMAXEAZW6B,DJNS +F"<=F'7\+
M/HCE5BR:AN1^<4Q#N[@:2]"-E^>@!#A)$54SFQM92_YX@U3I9Z)*[Y1Y?<]C
M+L-C7Y'REG&Y)@#>K8(-JH'IE:L1(9IEV]*J+FV=EU@PP9XXV*U4G -\'=!*
M@0HO/*5#G4@S)L,Z:SA\D\3857&@P7W,436TRJXK],KYL7_;4O%E45\8S"Y*
MJ=C"M7##M:>.^%R6<P#^_VV&YW:3)QPHPW7A8]15?T5PG+)SI'L6W"E9G/'O
MPPSS:8AZ7;-[1)[N^4]_2K.V)_NFY]0+;CJ%)5%A%W1^)\&8:CN<6,Y<_^2=
MI$=AU:)X5F*LPC:G@WNA*LI7OL**:I0F;\MA5?[^D1JQ$7ZKMRY'NG*7_]<[
MD/?NHWN=B&V,%7-4X_7D(TQ@L5-[?ZGM2%\O]>*H.P3I@>KH#$=]50KM%6;@
M,]DV::#P-*9WV0P3_<?-RK0FE3I()F"80E[2@C&O-U0E[[P_&'%0GNEV6/RB
M->$'6(!KHHY'=<IZT;Q,D$XYF\2=<>6#*T>G*7]O$9N.X*JYX*"CJ[/9O!WZ
MU*QW0%5C&F;BQXY+K/H7N#4@F?8N*SNM?_:E-V?D0;KZ=_/-Z8:7W4M5!Z_Z
M]S-NSVC05ZCH_[7W]G0Q?(!^5+&D$2]U>4?]^Y&79Z*ON/[#(.,H' P&7$BD
M2U<&/NCWJ9+0<RY/M\N%7=1)5SXYZOH,>WU%S%RAR[XM @ +[/-ZZU/)<]09
MV]7P!YE!J8*-+ U57^F&4M@.ELU>>&:@7]*EJBFF0"X<QA]A;U&Z.'/)NHZY
M0G+E7H7!NO7",-IN<_V(CX [E4Z,T+C.4M#O*Z&S$M)]2E^><82#Y?+.&N6B
MXBG0?.X5I$")%]MK$*3-MP[V8MT\7$X (R(K351I6?_HF@<8H#//DXU.JX#M
MX(N\0TEG\2303>YW;Z.BS7N 9HYO/]B:MAX&=Y2]2Y*;)MY35QGR!O:)$GYP
M'K1)JL\#S"O$OFN%N3Y^6V,A8:G"<%T+RUP )>E^JYI7")E"J[5OL.P\@ 6U
M)DT^L !8[^*RT_E=<!>G6!J,7\6V%Z[U(\=[][ "\&""99:ZX9"Z1@#-Z0V/
M>;5'O4$Q 1;^[6.YX,%%9WC4K#C;F(K!=L/)$!/HAQ>]HQ8\P%<G':GD-AYK
M0@JKX.*E0/,G?4I:;@R[AYE&E=:__I54D"55+2D*U,S3K-0EUT==E<;#T1%O
ML.*Z[BK;<EQ$N-D):T)0R DL'2HZ$TN53,\*;I9M_^* O 4N6KHO.*<*WJ#F
M>9M(-E&E/:C5EKLR9I^+3N.@_BQ$J@,E8G&$EXZ;,(7P3!\%(A3[%>MZ!!OU
M],;NX)@)YRZGAT#L^Z]1>EYCJ!<I)7[RC(@MBD:FU]1AFEZG!W6"U@LI;WT&
M0[,5[SF$28D:5YZH\4&)&BVXOB?%1">14,[(]?NC4D$X !-OS,+VWU(0LD:?
MBD%5[&/&/65;=QA[H/A*FKLY'["--U#I^1'RF:V38@P^)F)1ARD^BTB_L0MI
M-JVS2(<%-)%273DY3F$VEH/%Z@!4Z=)4@%0B_&FW8TJQ4O5)/:=O&6<%S,S:
M9KY0V4V5T'\_+8T-L>-+]5$5,6K'84Z#Z^ =<R9B6S[4_[6YC?3A^C$N>-]1
M3//$OEG;:T8>U7T$;7Z5])LZD(X#C]]E27I946J$'=HYN- '<L_K]VZ?LL)7
M/+W/BA_G/"SG.(#Y36PPDVU,[I.\1-GJOGUZ4A/% U+65K9<DM+*/4(VH$Y$
M'&J/OM"CP;^IWR1;[2#"6ABJ_8LC2L;43JWL]YNQ+35M+M%PF)'LB?3_BD-J
M8$?C\%"EGN>K% =.8/S-+D#4A/^5H:L78%_HN)>FWLZG=(J)]F'Y*6P4"J=O
M0%5NL7$)#6$7-C9N_]7XSQBC?R X_[#KL]&.H2:W)OJD^KS@CL/,9H?#UZJ9
MSQ;96C-Y,2+Z"'&M(JWAQJU/F1H!>1VUCKD[Y%S%UC1#'3^.(1@.FLA]+6HI
MQ(+9T >'6E!<,D9EVW+)[I_LK_'<2I@G@V''$Q$4)C+.1>PK0W\B]AS0$=]^
MU(<INT82M@!:>D*(GD%, L-C4AN48\Y<-[EF?O^8X+[,\"I[IY[-3G-PU19,
M*EHUIYIA%$P1JJH5K33&1/HYAER7?PV#:O<;*DFM3D IEN88+.!$@L%(U7EB
MT6[8+MK5@X%\E%%:EA+[+:HTXTG'QY-&;*,R!NT(U,>.&*K<862HEXV:P7Z\
ML.BD^+66+D?Y#\;J:=&&J17!V^N4X>".VUK$3N0YDG41H/Z?Y*8DMVE[(?8C
M)'G;/*T[&*@09,[GK?:'?G"BG#B+\<JAP')1K:5P'&EV+R4J KGWA52YV].%
M<_XA%(#:7/AMDJD4ZV]" -IX1;\S\EHS_]]) _:I'\GB6+5#,'^1F8ZL'+ZS
M@8G%/5(VII6__+'3Z72[P>G=Q[^<=SL=*@B2+!)*^,9:T-O5&L0V$#N6R8S[
MX&'S46N8Y8JS!R3PXX1LIY,K-@M,MR)P[R5<SZ _[S-K?JTU&(^LF=()%$<0
M)7,&5/6A0H0B2X($2!2;RC3(Y- !3AVLVG(<@1)SGL[C[GPA=?**6OUCB%-'
MS<C$J=/S*FO](XA3?_@-!)3)OSYQZGDE0)H4X8-A@Y/#U D_-&4J[FZFMW]2
M) KK1 X'P>F__??+P?"'\V*7;N>K&,7GZ8SHU0WH PE<2^QE L=A=JY2J";_
M54F'S=A65<.>JUV&MLFP"^D^&5 <C]<2V70#,JVXV2?,+>ZKJ]!ZW3S:).@V
M$_]G5$],94.)U"3RXLKK(_M:JI_,0M8"A*#G@J*EB\[(NMBV<*'@1 SW6T)L
M5V,IDR#1LH TIFN?"MZT]:9:RB"'4H]2,B\PHZ/4*9AJHS*/R>J"#5.]Q[)H
M*:#&]*<U3<A42#NF7)*J=?(;U7\]5/7UZXRFQRA(7ETM8[-55J5:MI0JW/7;
M&U9K$;GV(16FT-090HJQA<$4IN20$=W28$_,;],,C1XY&]!0-)O?Z,#AJ$PL
M#P!TA9:0$N3$X+(3+%#KK9E@+%W194^(27-,<"4H[S!5?9;W[LH5']M$FQA=
M:+T^MT/K8SCI!PS"0[Y/=L^<CMZN6-4AM7UI@7R^ ^ZX,Z1GN4T718 ^M&%P
M.<#.<W?8SYX=6=7HI^XEJK4]*MIM8AQ,G*Z)._Q8R^=6#E!_,QZJB^)M// A
MD94CMA;"C:CMQ\3Y%.U[48Y%36!%Q. @?_6ZPQLI*TGD<9'9>*7IW2<JA'K>
M@>/<&R*&L]\#=2J"4XZI/ZNEPQF+ Z6RGHHQXHP[$1R; MOHME;]3JN+)  A
MX&JK#2L1<]%CE*SH'>0RF#]R;"2Z"HOZD3K:?DJ!5#$3_I% 4OOX+:<=3"V[
MH?X%[7&KIA$C8B16M?>CRD\[TK *O\2.RN^S]-S(1A.*;L:62Z=]>@R[:U^V
M1+J:>1#_)]3)^I0K[V/J5]<;MT>]RN41]*/WJ _ ,V)AS60=U:Q:-]+V9\-U
MX/^G'7+*<^ YW]<]H8V46T?,#GLY4%^ D2WY/Z*F\?O";@$YU2).)(:=>[".
MN6G8D 8;7&(&W7$QV/]@?.GT+RLQMJ?<:,%\.?0@C7TR$;0=%7(/GU&ZP'ZD
M@='&0VF ?MJAF G^:.PCY #[N>,2I(/NA"+4O@AQZM'0^)F>;33 &+8N+PD;
M<(RHM\<1B#,,NV/.#^@QXG C6/ZB_TS$D2AI_GG*[5_A3_Q%^<9T*]=WEC8#
M'3*TZ1QHT_D=-KF^<TO]Z*?P^ED\3J(U7IXF"JE9B#<7-=2>[6S0]I:@5G)0
M\#^@_8NZ*Q7D/^:95UO6R\4$C>'%)!QAB_5^MR_-UC%?=D2_=;M#DD+P-R03
M^#ZK$'8($]RF4IV[(:=-XK]#ZG8[IBQD\Z\;1;\TH+;R VRRU:>6)?C3M#9I
M.(06HF:HF,97@Z"DZ6$MDOO8'=H78< 1%9O)6][MH>!2/K"P I_S7U4S$I7Q
MCQ<BF*I[1+'!%=3>> \K41>GL T'#X2W.]^AI:DLK7 !2Z*NOUGGRYO#.S@)
M+NG0. ]I..(.A>.P/\;>UK?^FCGV&']2^T+  _N ;(4(#H[5ZW'&=L,S1_9\
M:2I]9Z'NVB7.,A!10>'FE@YK(>;G=>)=(>_U)RZ^9*7CEI7JQ@Q*T<Y<B6BY
M#PU(WXY2H8/ P0V'52 1!.Z;..D7[7STSSFC.]O#4FN\1YBL_0:8*J\$FW;
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M97) PBJGKD] AJ6&_&LO<,,ZZPO7U)D*"\BM$IG?^9,EI-L7F<3PM%<3XY=
M-"!?MPSEK]BSQ1V5L'$R[@]5GW,*HAZ.!JHO6-5+^-XWC%:+&^FJ=\84JQA!
M[U)5%_$INL>=Q>W3KO:TD^K0BYIO[[ @%F.!R*BV414TT(:K#PG0O$HBP<(]
MJZU\D>_NAG42-M2C>.KFV%#5JY!R&6J2EKY/QT:N*]MT1>J0CIDXZXS63I&+
M7+5CD0!EY^+BIB_UH071B?+RC^(=E4AK*2'!%.^(*A\F3D)=E^:3T?G:Y4-6
M-!DF*B;;*B]Z*5/?$4%PG,F%;S>HJ2^X;D$;OC"1- F$ M.38(0)#F]MN9.6
ME_<4?(,AT")8MA=WIK3$X5XJ_65KQR3,KULZICW]TT"/&:W7^P+]V#S]=3N<
M#&"6_:=#1<9_B]/Y6L3J7W2J 7DWV.8[1TL)-AYBM>TU")Y4UNA9#^^)^MO_
MGOMV8[^-[;>^Q4H'+I,%F&7_;.D)V0NL9X-Q00EJ_E>&+142P]$^&X_V;=J4
MO"5N&V!-1BI4,<#Z&2^W"<7<4T[J!/.5X=\NXLM;% "I!V:RQB+_PG$N,0&9
M8E[?8:FX- 9^YP,(!AA.N%]L!W/><;M;%,V*;%D^16+:>@!!C/X8DW]Z/!K#
M*V^V>9I8Z]<R^5Q2P.&H"],-T76!718 M>:&IE.Q&+1U=\/Q<$*]4GKCD4V*
M)9/\,.S#%*-@$(X'*"R_A>=?M!Y/< I#78XIW1I^'0XOR4W$XQUQ5I1?VY'2
M)&%W@MF4K_3XQI)I0HQ/>J-+K[@C?%#+4NMW=/6=I:DR=D@@>=/VX%/L%7ZR
M9E8$F%]!J W@-JFNTIE@./!L_[!RU1Z6Z\7U]LB*'RNI<7M6F3241!/-V2U9
MF/H*2R.=%W/*34\X2:A0YE:2C:.YK0AV!X^4#X"-(89PE'^/\Q79()O2Z)J?
MA>NA!W]C!D=M!8N$R[T#*?7;K,V/1D #K7F%354V_!/06 )ZI"4%.V"HF(N8
M8!,T($HVAQ350UN(*>O:O^QC>Z&@P-)4\%#LE\%_WHY"[-!=&PZ6]43%-+=%
M''*)<9?^O-V@&20H-M&<"<6PVS1 M%@G:4()CM3?%Q\_*DI 6L!6$!MI4*63
M<D]EB?F)HY6J:JVWR--GU*'5 N2U8Z\>PSXKCXMV]]R#;/%6'[3'4SVG4I-(
M"6*I>O&\[EB5MRFKSWN_^H(NW&&G?&:/K0YQO0&1ZF?TV+J\Q(I/EY>8*?^\
M_EK],<TX[B.=?U9_K3%EY_._G:;--T%L&%[V1U+FX9(J9XXN)N.F77*U9',E
M/ICRR8.06E_ICELG0Z^6O#-# $E.L>R[MD,<-5V(PM0E<-O)X'<D%TD$>1'+
MAD@=+'B,;4I)AVB_U"% GBFHW9&MK08J#X&]EA'*';%8B4F/1#=3A&W!$@*H
M;1Y1-S]P,=-(?%BJP&MG8LIER1->6/.^%59RF*K&'0^FAG%2R.;)J.=EMDN
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MXU*90<2*,:267?!'5W]C&H'3-WW]S<!(^8#Z5&BR+T.HGMW\=V->C(C[IBR
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MNTB>M:M)=E'_]W+*_[X%WW,+!H0=0]N;=#"!6N_\R.[\9"!GU.T2LWH&CC^
M@Y?W08%;*^F-\9/6A,!SGNL&P/N8R39=@58/">K;V'_2P;&- &E<T !9QX]A
M2 ?HB.EW[F2H$K*2>FG!AVU5CYQ939'M88KO7GBHH''3.[^A)1@_-6VR;,/(
M'3!*TB?0T+O\1$T;>6:H)_-M=%\$C6*(719[-7.IX+!:C"C!U!*D*,2)JH)
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MK%$?"M*;*NK?Z /]WA**IED!_#675AS_'+TVOS7B>HJ0Q./1"&$K>_$ 6UW
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MW(A!?_CY8TZ39Z^F Q:V'8U8M?O<OFRK[LAJDN6CD1L+VRK>-D*RG9!Y+P&
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MXXC)#3?*4^2KVS8 ?"WSR[C.1,I<9=JB]=6-@F62*Q!KT.Y%2KSH%LGWV&L
MZ8'4X ,/0L5SI60:NV8!Y5-C!</W(7D$4K:4!<R]OD0SA'XMX)!.O]!HJFZ3
M#7B7,Z'J:YR[W2@?L&=824KN(A<#1*<O"60Y$.+'TSOS^GDFP25B1\V^%4/
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MO/<NFV/,%'F<9=UV8;0W&%/5,411<<S)@DF4<:H&#PIUV0!+DJT17G@CW3G
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MIJ!!0YWA3.7I5"XA#9\8MC"(DBXSLS>?HY_@/SQZU/K3J4)+X-K#6S2<86W
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M";+[!DLD\NJ]4UH1@3$@P";5L7+:>.T2J)L.*BL==<$@@9TE$(ZQ=!!\=8>
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M;\;LVE2<%N7/U:92$ZH=-'\E\%<7$W>QQ3@/<85C?N U$<E8%?@H&H- ,O^
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MBY46A2 ?YG F6XKLLVO5,=[#OJ$G9R$0V^C[^R%;KT0@#VC1\11XA]9,DMY
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M.8.$L<S8S\BO:3Z<^_OJX^S2YBH\.#+'XI6FT!F5<3?9+C:1I;R'P/G[PNG
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M9[L-90^/OH/9,=J4/^]JJA9VEC=JD$<^Q.!I=4UJ)$M3-2.(-"Y*#:X);GZ
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MGQ$/2FF#V$H)\8'&G89+9049.[<@?JX5F^8!!UH'?,=K#E;HQHN0W:GDT69
MDB=L<].A1W _R23 >!,>9C@P-PG&WPCHDJIQ($JWH\FMQ0+!VQJ*"$8?K5"J
MNP>%7D,#EUJW!7L2!/,*9_U$?.Q,\)/C[S^2W]^]K];<"B-HX+?H^"FYI @B
MWRE*<]+Z^W9QR[;2U<("+A-EH(D62ZCSL6>(&@'6*V[4BV2@-!.L0K-!-<-
MB2C^LRB7T)*')4$^[F,I#8BS:=I)?@2IR'7="-@&? ^$LY(1139-\-Y15;%@
M Q 2WS4&LX?0U:O670Z@FFA<1)DZS[2LBB^)P^0<K]D7.)A+J(7'N(.I$XNI
MPANS3@!U\6ABZ&F ;V@N<*H8E,:,_5I*8S@Q<HVB/\:@-NT K3=N@D9;>ISW
MVET!0',,390!PMXO<H"VUSC?TM!.A80YA=#)&RS@5T6$<X H17_1@,*&E6*-
M[?J*J^V6K5<%!%"VW\RN7ATY%:X$8-O:!S\]()A\>W;UZ<@)1"?8PS%4*9=!
MX0Q.HWI\"NS0_E@\N,MPU!D=M;3HUO8!%#4,KE@N+?>@%M=^FG+(6(#Q^A,J
M7/EJX3IRS JN3%33;K<YPNH"QW4[KN6%]:RF:E=G_P,&\OI]0W3??$,<ZP9F
M %6 &1:?/6D0%Z\3#" HD4I9#F,@M"!NF= 6#405^4)*>_6020FDKTK/!&\%
MFV:*BD"-!=K 30#+D[HU6VC:D=L_V3H:!=Z^&-4&H609<B+4]Z3VNT'=A<]>
M8A-, :/CSN09%/"R=>'4+X"H7;9 5]]"-@IPI-/P8OPY[ NREI[1USF'QZ G
MP -$!94,8:)OM7YJW&_O6?V^=WS$:9-7<\!O.;=6$.CM AI ]@<HY0MR7_Y,
M<1NV<XAY^ @V=7SV%(K4S/V8@V8AP%GZ/W3$I"<OB@>.OH?P $\P^+ EF3;<
MMR8$ZRY#RY*<6#EGH(U^;/I.PA8]K6&.'-X*XN]F%!*NPX>%JGB,VU(BH^^+
M!<&@.UEZ7:BT3!<0]8\O&72K^O&0DZ32M11VX7!!LG95.1-;K>[3OT/]R$>1
M&Y23L.Q%]<P#.%3D,1L+NK5QL@,CTQ9+:8F-"PC58NK-:-07@BQ[GJWR&-8Z
M1]$RJUY/+&5X?A?9\$W')O4]Q._9D\,.LNO&)J=3A<@@ TC5($T2II+G'$I#
MU8874J+5US8Y>&_1M^^ES%1V4PR1H!;=FAL[NG0J"5 F(P7.4V1/,KH((:QI
M'AXH/JJ@U-6.L75TZN<2HNE&5Q4.2K';,)X^("2W*_<8>5^Y3)*G75U<6SQR
MW^.-%0?7-MY>O]7.PR#)H1?_<W9<;K('..?9$L'OYDZ%U]A:PY9>8KZ#'@C9
MG+;3^]DV+$OSLWO2/LJZN]X)-J%(RHUR:_BJ>U>56+9D^S!SIS[-,WCL\Y&"
MF=8_9,P&AW6-NJQKMFG[VV N@>G"/;[)RYU3"\KS[#P^B?K;!"Q3'H%C"A4:
MW)?7CY@4':81??^,^[C+0<^DG5OXX2;TX82D+08H_X**!.KO9("@8N#,%WU(
MJ82"Z\Q%M$P,XB*7L47S0+IVFLDZX".&O=1E0C4QDUK6L&,\<GV3XEB=FUX\
M@,IH 3$Y[!BT=4H(/OSN#*J?I;ZNE*0MK?!Z(BI2$Y54 3Y(O>80AM7BH$T^
M4< 6Q5LYYSHE*X"E I4&-- VI)\=(4M%0[BY[TJSL4@HA2-AP M3I-N"2VJB
MNH$I 1RS\RAU ]9HGHMK%SR_NZ3E>"G6Z /;-'4F2BAU@NFFQU0 S4+R>H.(
M&)]4]@MT!W#DQ0.#*BSH66G-"6&4Y\9>(HJYJ\:&9+Z@7=7]NZO!1UA86WZ!
MRN75U&P 0\\Z_XQ18,<F14.J3GE$Z2]$<E%@K0<*#F%Y%-P84RW(N+!#7JNY
M:$WKHN<6\_D6YKC!ZC@Y9]CD]YFMPT=9.13R\ZC ?]R1QLNM2LY.Y80@*M\&
MW5Y+R?74\Q.& "9=5DJ_Y6PDE1)? 4/VM=,WFE(E)A?#4"PO*7TU;\",Q6H1
M:RMOYF#A%,8 "XXH<F2&>1WLU\SOUR';LI:2",A?N=6L!!M_7@).!29;/#PL
MW1)?TX&J)PY%0"ZXS" SJ'FH-5D9"TYD+26C"?*Q"(.72!**>?^&TCNY,)/P
M6A 01)8LHE(HM"TA(C:Y]/ YE<T87YX1Q EXF6JXD&V)88[K5XRN$37YAN(?
M7*'%"H_SHD#.SP8LV6!'RKAEL%C&QO= ZBY(?Q&BE@Y$JU"ML>9@69)VQ[GB
M)D.KJI? *[YJ(^3G@-:SELLN-(B 6'9; #]^Z4G"%[P$ YU74L24"A5<E(7J
MT@5E08+*?)[^2RX2A:<"54 LJ)B94B+$FIBX5XN:%=#Y<SP?TS%)WKA-[?PF
M.G0F+=!2[A&ZUDQYV)UOIEQ34RZ9-%0UCFJ*$C825@-)X6P]A)-1G%*I](;6
M:CK(UC;O;<V.?V[<;/Y;M ?E;H0C8&P"UL :N$IK#=*.+(!K2HDG(8\5^02W
M6"P^-$VJ"9*JC;'#/?NLM+1QS2V0.[#1<@' F2S?(&!YYJNKMJZWCQ)&(D'?
M[N*%\\]6P(INH942)0.K8=D;\\R;V&2"]FIP<&VO_\ZJ'R'30B$FDN7#PALD
M-@K;)LVG6"WU>@, 8%$Y"<J+\!:6G-^:1H%68"NDD/70G$%7I8)XJ&ID[VZP
M P"[PLN83 &!#*S&>3FU,%F(B^)0<VNG#YP93OZ!$QD8]MV2/QI@B]BP+ULT
M]S=JNF)[&'(24X")U3B^E3UC.C%WIX28NIU8<#WF<!-5J,0R*!GBV /]/.EY
M(Z<2RT*7G]9UM?HKG'93RN\:0L'3U48T+VF<XW^S^YPP]C6M :>=KS6;6U4&
MRU(\(K]H,:AX'MHMAB;EOO:>^)R"(N?'4IX,0-!6>-Q-+42]U&) L]^RT$Q@
M[PR]+W8P'2LY6".5L@7)OSA1RVY\;=5MUCN(IT+PJ94OP34G<>J:"'->',LN
MM.>%^_4(Q)8<%#X8V*\P*R@2-%M M( 6-&G_RL'P%UNW/?/67T@VNB*33ZM]
M\9>K(WO9UFM.E-^6!7J-E_[Q?%W3+1/(=9Y%G2!0>&_TLY^JO.)7P9[>D&PA
MI(_40]+_+;6ML_S^&@II4_!;X&&_Q#ZH,J33T$(!E<\PNE?X(-M;7Z2@W+*K
M*"C3RC]DRPL$*'$_ZG#5F&)N>2V?6ZV,)%=<Z 2&0%!]&T,MXR6U95C]G8IG
MBTI&"Q.'-24.C,YQT>.E7T[52>2U&]+NW$^%[_.N*K1EF&K2Q5K$1I -/Q=
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ML]"9QNF\>$UO,;?,'':SA ?WM*]Y:-$ !OAI[^G#+*]6?L87 ;'4^Y!$>>1
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M]^*T(#^)!5!JZI@<+D:^P3!9^%-#&)WJDRY$=J;[7]PF-[5+E98M4\)3<OA
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M2R](@.2$4Z-YW0HJ +17Q9'6:GH##Q .7#BK%C",&[,!<L#?":,"W&!DZ,U
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MML).#4(?3F45\K6 /U9#4.)KL#*:E=_,:"N)E7,P*GKA:"'Q^E1KLT[F^\Q
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M!X#3&-Z?@-OR_TL?TA7$93QF3@>9F,OM-%VEB]QI)@N(1EE#UEFO->FK '3
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M_<B8Q%D V=,^$'9C']]"W[NK''$JH9.K32@P5)^CRH;DB!G!2LZXAD;)UC0
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MPSUV^L03NMT$K.8CFY^-;'=,E\FT.V3> ^P7R]USQ<.!8U<#1C@Z+.\1ZU?
MJY.17"3@:1A@HR,./Z/D;].HDN++%B6SUR6P[^S8S1X%X!-$1W+L&\6-D_&
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MO6=V29)"1R;9(Y9@D&1I7NVE-PZ/751*WW9C2JS./0K,.!+/&F%160^<N4&
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M60#). LUY2>OA,0DWF$R4[66UHC4_E;]^<I(D/-D"L5"A=C+6DW,2CJEI73
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M-P/?.#!Z<W'8-V6+$0+KJ"&GYI*3=7OMF*TK?57_%@V>Q9A <#OBH=N!/(\
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M@_?H$?<X&!V'4\_WYH>N>NC:MF;XVTZT#;\Q()(C#2*IX0;;^Z,N17^'8TA
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MGTUDZ]6@L)%\GB5B/T-KZK.B9BC"1-8B00.Y!SFQ$M4!L2<-PU<J41UM>D*
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M,A?1YGC)J_)2L>'/?;5,!LVM^JHZ-<>^-E]:/AP?OV._<^?[_P!02P,$%
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M0]V-_XKR<YH.+_M'RX;V]C=02P$"% ,4    " #NBD9.'R// \     3 @
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M2P$"% ,4    " #NBD9.0L-8,:0#  "Z#P  &               @ $<$0
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ [HI&3@2*?:NI
M!   [!8  !@              ( !]A0  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( .Z*1DZMH9:0X0$  /($   8              "
M =49  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #NBD9.
M#>DJ=Q8&  "_'P  &               @ 'L&P  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ [HI&3LUS4G@G"0  ;CL  !@
M     ( !."(  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M .Z*1D[+;&]=M $  -(#   8              "  94K  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " #NBD9.-J6PB+4!  #2 P  &
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M970Q,RYX;6Q02P$"% ,4    " #NBD9.1$VCK+,!  #2 P  &0
M    @ $=-P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M .Z*1DZH4K/DM $  -(#   9              "  0<Y  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ [HI&3KQ[3E>U 0  T@,  !D
M             ( !\CH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " #NBD9.X<YL9;0!  #2 P  &0              @ '>/   >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .Z*1DZ.W=\TM $
M -(#   9              "  <D^  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ [HI&3K"*A^BU 0  T@,  !D              ( !
MM$   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #NBD9.
MY$R%9;,!  #2 P  &0              @ &@0@  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( .Z*1D[&&:,MM $  -(#   9
M      "  8I$  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ [HI&3I*D/#.T 0  T@,  !D              ( !=48  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #NBD9.=?EU"[4!  #2 P
M&0              @ %@2   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( .Z*1D[7@4CDLP$  -(#   9              "  4Q*  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ [HI&3IS<U'^Q
M 0  T@,  !D              ( !-DP  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " #NBD9.J\M39K$!  #2 P  &0
M@ $>3@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .Z*
M1DZ"\TQ&M@$  -(#   9              "  090  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ [HI&3N J=8ZT 0  T@,  !D
M         ( !\U$  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " #NBD9.'PD6&K4!  #2 P  &0              @ '>4P  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .Z*1DYNGUC.M0$  -(#
M   9              "  <I5  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ [HI&3N)&HXNS 0  T@,  !D              ( !ME<
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #NBD9.0[P1
M)[4!  #2 P  &0              @ &@60  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( .Z*1DYK8/L9M0$  -(#   9
M  "  8Q;  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M[HI&3OSXDU2W 0  T@,  !D              ( !>%T  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " #NBD9.Z5K $Q@#  !2#@  &0
M            @ %F7P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( .Z*1DY=6LJ@M@$  -(#   9              "  ;5B  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ [HI&3E+RRCBX 0
MT@,  !D              ( !HF0  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " #NBD9.3$*X+>P!  !F!0  &0              @ &1
M9@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( .Z*1DXC
M[-^SM@$  -(#   9              "  ;1H  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ [HI&3IK(S'_1 0  G 0  !D
M     ( !H6H  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .Z*1D[D:>'PQ@$  #<$   9              "
M <=T  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ [HI&
M3L=(63ZV 0  T@,  !D              ( !Q'8  'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " #NBD9.6<:-*<4!   W!   &0
M        @ &Q>   >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( .Z*1DXP[?V4M@$  -(#   9              "  :UZ  !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ [HI&3H2%'M!( @  / @
M !D              ( !FGP  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    " #NBD9.1BP/:=T!   !!0  &0              @ $9?P
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( .Z*1DZ4&+?V
MT $  )H$   9              "  2V!  !X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ [HI&3C&I<3;U 0  RP4  !D
M ( !-(,  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #N
MBD9.>AJH:;8!  #2 P  &0              @ %@A0  >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( .Z*1DY_E_N]N $  -(#   9
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M970U."YX;6Q02P$"% ,4    " #NBD9.HIF6V.@#  !R$0  &0
M    @ $4E@  >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M .Z*1DY=I:C]*0,  &\-   9              "  3.:  !X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ [HI&3HS9,S!="@  IT8  !D
M             ( !DYT  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    " #NBD9.7"=,H[X$  #S%@  &0              @ $GJ   >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( .Z*1DZLZF_G%P(
M ",&   9              "  1RM  !X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ [HI&3E\BH8=8 P  9PT  !D              ( !
M:J\  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    " #NBD9.
M^?M;(.\#  "D$0  &0              @ 'YL@  >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( .Z*1DXZJ4_#6@(  %8(   9
M      "  1^W  !X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ [HI&3O&'ZK(J @  D@8  !D              ( !L+D  'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " #NBD9.'!N@ZQ<"  "E!0
M&0              @ $1O   >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+
M 0(4 Q0    ( .Z*1DXDJ<:VU <   TP   9              "  5^^  !X
M;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ [HI&3AM%1'XN
M P  EPP  !D              ( !:L8  'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6Q02P$"% ,4    " #NBD9.^Z:Z4+8%   .)@  &0
M@ '/R0  >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( .Z*
M1DZ>!W;GGP(  /\)   9              "  ;S/  !X;"]W;W)K<VAE971S
M+W-H965T-S(N>&UL4$L! A0#%     @ [HI&3H%<M-M3 @  +@<  !D
M         ( !DM(  'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
M    " #NBD9.?:AE'@L%  !#&P  &0              @ $<U0  >&PO=V]R
M:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( .Z*1DZX?EYV40(  !D(
M   9              "  5[:  !X;"]W;W)K<VAE971S+W-H965T-S4N>&UL
M4$L! A0#%     @ [XI&3K&V*2U^!   M1@  !D              ( !YMP
M 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " #OBD9.CIV@
MH5\"  "T!P  &0              @ &;X0  >&PO=V]R:W-H965T<R]S:&5E
M=#<W+GAM;%!+ 0(4 Q0    ( .^*1D[_B4BE. (  $L&   9
M  "  3'D  !X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @
M[XI&3B07JS[C 0  QP0  !D              ( !H.8  'AL+W=O<FMS:&5E
M=',O<VAE970W.2YX;6Q02P$"% ,4    " #OBD9.TUP[L8<#   ;$   &0
M            @ &ZZ   >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4
M Q0    ( .^*1DYSY4?AE@(  $<)   9              "  7CL  !X;"]W
M;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ [XI&3F?4I]<- P
M3PP  !D              ( !1>\  'AL+W=O<FMS:&5E=',O<VAE970X,BYX
M;6Q02P$"% ,4    " #OBD9.,R8%$G<#  #?$   &0              @ &)
M\@  >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( .^*1DXQ
ML\1.60,  +D.   9              "  3?V  !X;"]W;W)K<VAE971S+W-H
M965T.#0N>&UL4$L! A0#%     @ [XI&3H4O?=B> @  ^ @  !D
M     ( !Q_D  'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .^*1DY=@NAV  (  *\%   9              "
M 84( 0!X;"]W;W)K<VAE971S+W-H965T.3 N>&UL4$L! A0#%     @ [XI&
M3AS",#): P  Z0X  !D              ( !O H! 'AL+W=O<FMS:&5E=',O
M<VAE970Y,2YX;6Q02P$"% ,4    " #OBD9.0=$%DVD&   F*0  &0
M        @ %-#@$ >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0
M   ( .^*1D[[BPM#D 0   06   9              "  >T4 0!X;"]W;W)K
M<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @ [XI&3JD///0:!   TQ,
M !D              ( !M!D! 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q0
M2P$"% ,4    " #OBD9.(N<@<"$#  "8#   &0              @ $%'@$
M>&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4 Q0    ( .^*1D['DUZ.
M? ,  )0/   9              "  5TA 0!X;"]W;W)K<VAE971S+W-H965T
M.38N>&UL4$L! A0#%     @ [XI&3C^MV)Y, @  @ <  !D
M ( !$"4! 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6Q02P$"% ,4    " #O
MBD9.LA6S-PH"  ")!0  &0              @ &3)P$ >&PO=V]R:W-H965T
M<R]S:&5E=#DX+GAM;%!+ 0(4 Q0    ( .^*1D[;$;@4VP(  '(*   9
M          "  =0I 0!X;"]W;W)K<VAE971S+W-H965T.3DN>&UL4$L! A0#
M%     @ [XI&3EV0^1OY @  " P  !H              ( !YBP! 'AL+W=O
M<FMS:&5E=',O<VAE970Q,# N>&UL4$L! A0#%     @ [XI&3D\C1@H^ @
MRP8  !H              ( !%S ! 'AL+W=O<FMS:&5E=',O<VAE970Q,#$N
M>&UL4$L! A0#%     @ [XI&3HU3X?T\ @  R08  !H              ( !
MC3(! 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL4$L! A0#%     @ [XI&
M3B+59**# @  P0@  !H              ( ! 34! 'AL+W=O<FMS:&5E=',O
M<VAE970Q,#,N>&UL4$L! A0#%     @ [XI&3A#'2[?Z 0  <@4  !H
M         ( !O#<! 'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&UL4$L! A0#
M%     @ [XI&3OJ8M/;B @  = H  !H              ( ![CD! 'AL+W=O
M<FMS:&5E=',O<VAE970Q,#4N>&UL4$L! A0#%     @ [XI&3F';%$\P @
MA08  !H              ( !"#T! 'AL+W=O<FMS:&5E=',O<VAE970Q,#8N
M>&UL4$L! A0#%     @ [XI&3HWZK43L!0  \B$  !H              ( !
M<#\! 'AL+W=O<FMS:&5E=',O<VAE970Q,#<N>&UL4$L! A0#%     @ [XI&
M3IQ-9/!A P  00T  !H              ( !E$4! 'AL+W=O<FMS:&5E=',O
M<VAE970Q,#@N>&UL4$L! A0#%     @ [XI&3NWE.]/0 @  C@H  !H
M         ( !+4D! 'AL+W=O<FMS:&5E=',O<VAE970Q,#DN>&UL4$L! A0#
M%     @ [XI&3EC=VF+K @  E0P  !H              ( !-4P! 'AL+W=O
M<FMS:&5E=',O<VAE970Q,3 N>&UL4$L! A0#%     @ [XI&3K-,JBNA @
M& D  !H              ( !6$\! 'AL+W=O<FMS:&5E=',O<VAE970Q,3$N
M>&UL4$L! A0#%     @ [XI&3G1AQ3"D!0  Q!\  !H              ( !
M,5(! 'AL+W=O<FMS:&5E=',O<VAE970Q,3(N>&UL4$L! A0#%     @ [XI&
M3D>3^YC- P  L!   !H              ( !#5@! 'AL+W=O<FMS:&5E=',O
M<VAE970Q,3,N>&UL4$L! A0#%     @ [XI&3L-PJ\B !   Z!8  !H
M         ( !$EP! 'AL+W=O<FMS:&5E=',O<VAE970Q,30N>&UL4$L! A0#
M%     @ [XI&3EDM;XT[!   E10  !H              ( !RF ! 'AL+W=O
M<FMS:&5E=',O<VAE970Q,34N>&UL4$L! A0#%     @ [XI&3MMM1\"E @
M?@D  !H              ( !/64! 'AL+W=O<FMS:&5E=',O<VAE970Q,38N
M>&UL4$L! A0#%     @ [XI&3EYZ"P0&!    A(  !H              ( !
M&F@! 'AL+W=O<FMS:&5E=',O<VAE970Q,3<N>&UL4$L! A0#%     @ [XI&
M3AZPP_PJ$   XG$  !H              ( !6&P! 'AL+W=O<FMS:&5E=',O
M<VAE970Q,3@N>&UL4$L! A0#%     @ [XI&3D/0QPN" @  = @  !H
M         ( !NGP! 'AL+W=O<FMS:&5E=',O<VAE970Q,3DN>&UL4$L! A0#
M%     @ [XI&3KY)G5'$ 0  %@0  !H              ( !='\! 'AL+W=O
M<FMS:&5E=',O<VAE970Q,C N>&UL4$L! A0#%     @ [XI&3FMRA]E0 P
MU@T  !H              ( !<($! 'AL+W=O<FMS:&5E=',O<VAE970Q,C$N
M>&UL4$L! A0#%     @ [XI&3NT_!UV'!0  JQ\  !H              ( !
M^(0! 'AL+W=O<FMS:&5E=',O<VAE970Q,C(N>&UL4$L! A0#%     @ [XI&
M3C\&;3DN @  FP8  !H              ( !MXH! 'AL+W=O<FMS:&5E=',O
M<VAE970Q,C,N>&UL4$L! A0#%     @ [XI&3I%1S"/3 @  . L  !H
M         ( !'8T! 'AL+W=O<FMS:&5E=',O<VAE970Q,C0N>&UL4$L! A0#
M%     @ [XI&3J>O(EG*!@  ^28  !H              ( !*) ! 'AL+W=O
M<FMS:&5E=',O<VAE970Q,C4N>&UL4$L! A0#%     @ [XI&3N'I#UMP @
M] <  !H              ( !*I<! 'AL+W=O<FMS:&5E=',O<VAE970Q,C8N
M>&UL4$L! A0#%     @ [XI&3B_5S&H,!@  O!X  !H              ( !
MTID! 'AL+W=O<FMS:&5E=',O<VAE970Q,C<N>&UL4$L! A0#%     @ [XI&
M3M58[3M%!@  (2(  !H              ( !%J ! 'AL+W=O<FMS:&5E=',O
M<VAE970Q,C@N>&UL4$L! A0#%     @ [XI&3CFK^\4M @  7P8  !H
M         ( !DZ8! 'AL+W=O<FMS:&5E=',O<VAE970Q,CDN>&UL4$L! A0#
M%     @ [XI&3E9&&W2ID $ TF4& !0              ( !^*@! 'AL+W-H
M87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ [XI&3D)?>E.7 @  1A    T
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8;6Q02P4&     (H B@ 6)@  I$L#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.10.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>923</ContextCount>
  <ElementCount>617</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>231</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedStatementsOfEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff</Role>
      <ShortName>Hemophilia Spin-Off Hemophilia Spin-Off</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Restructuring Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuring</Role>
      <ShortName>Restructuring Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2123100 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Guarantees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Guarantees</Role>
      <ShortName>Guarantees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2127100 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2128100 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2129100 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2130100 - Disclosure - Subsequent Events Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents</Role>
      <ShortName>Subsequent Events Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables</Role>
      <ShortName>Hemophilia Spin-Off Hemophilia Spin-Off (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOff</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwill</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Indebtedness (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessTables</Role>
      <ShortName>Indebtedness (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2316301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShare</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2320301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2322301 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationships</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2328301 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformation</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2329301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Acquisitions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsDetailsTextual</Role>
      <ShortName>Acquisitions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Acquisitions</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetails</Role>
      <ShortName>Hemophilia Spin-Off Hemophilia Spin-Off (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Hemophilia Spin-Off Hemophilia Spin-Off (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffDetailsTextual</Role>
      <ShortName>Hemophilia Spin-Off Hemophilia Spin-Off (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/HemophiliaSpinOffHemophiliaSpinOffTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2407401 - Disclosure - Restructuring Restructuring (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringRestructuringDetailsTextual</Role>
      <ShortName>Restructuring Restructuring (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringRestructuring</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Revenues by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesByProductDetails</Role>
      <ShortName>Revenues by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesForDiscountsAndAllowancesDetails2</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesFromAntiCd20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2408406 - Disclosure - Revenues Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2408407 - Disclosure - Revenues (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesDetailsTextual</Role>
      <ShortName>Revenues (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RevenuesTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Inventory (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryDetailsTextual</Role>
      <ShortName>Inventory (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InventoryTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsAndGoodwillTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Financial Instruments (Details Textual 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual1</Role>
      <ShortName>Financial Instruments (Details Textual 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Derivative Instruments Cash Flow Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsCashFlowHedgesDetails</Role>
      <ShortName>Derivative Instruments Cash Flow Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Derivative Instruments Derivative Instruments Net Investment Hedges (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDerivativeInstrumentsNetInvestmentHedgesDetails1</Role>
      <ShortName>Derivative Instruments Derivative Instruments Net Investment Hedges (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Derivative Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails2</Role>
      <ShortName>Derivative Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Derivative Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetailsTextual</Role>
      <ShortName>Derivative Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Property, Plant and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantAndEquipmentDetailsTextual</Role>
      <ShortName>Property, Plant and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Indebtedness (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails1</Role>
      <ShortName>Indebtedness (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2415404 - Disclosure - Indebtedness (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetailsTextual</Role>
      <ShortName>Indebtedness (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IndebtednessTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2416402 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2416403 - Disclosure - Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityDetailsTextual</Role>
      <ShortName>Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EquityTables</ParentRole>
      <Position>91</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2417403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails1</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsPerShareTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Share-Based Payments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails2</Role>
      <ShortName>Share-Based Payments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2419405 - Disclosure - Share-Based Payments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails3</Role>
      <ShortName>Share-Based Payments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2419406 - Disclosure - Share-Based Payments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails4</Role>
      <ShortName>Share-Based Payments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2419407 - Disclosure - Share-Based Payments (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails5</Role>
      <ShortName>Share-Based Payments (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Share-Based Payments (Details 6)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails6</Role>
      <ShortName>Share-Based Payments (Details 6)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Share-Based Payments (Details 7)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails7</Role>
      <ShortName>Share-Based Payments (Details 7)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Share-Based Payments (Details 8)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails8</Role>
      <ShortName>Share-Based Payments (Details 8)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Share-Based Payments (Details 9)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails9</Role>
      <ShortName>Share-Based Payments (Details 9)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>2419412 - Disclosure - Share-Based Payments (Details 10)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails10</Role>
      <ShortName>Share-Based Payments (Details 10)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>2419413 - Disclosure - Share-Based Payments (Details 11)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails11</Role>
      <ShortName>Share-Based Payments (Details 11)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>2419414 - Disclosure - Share-Based Payments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetailsTextual</Role>
      <ShortName>Share-Based Payments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>2420402 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>108</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>2420403 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>109</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>2420404 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>110</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>2420405 - Disclosure - Income Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails3</Role>
      <ShortName>Income Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>111</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>2420406 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>112</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>113</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Other Consolidated Financial Statement Detail (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>2422402 - Disclosure - Collaborative and Other Relationships - Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsGenentechDetails</Role>
      <ShortName>Collaborative and Other Relationships - Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>2422403 - Disclosure - Collaborative and Other Relationships Collaborative and Other Relationships - Eisai (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsCollaborativeAndOtherRelationshipsEisaiDetails1</Role>
      <ShortName>Collaborative and Other Relationships Collaborative and Other Relationships - Eisai (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>2422404 - Disclosure - Collaborative and Other Relationships - AbbVie (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsAbbvieDetails2</Role>
      <ShortName>Collaborative and Other Relationships - AbbVie (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>2422405 - Disclosure - Collaborative and Other Relationships (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsDetailsTextual</Role>
      <ShortName>Collaborative and Other Relationships (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeAndOtherRelationshipsTables</ParentRole>
      <Position>118</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>2423401 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsInVariableInterestEntities</ParentRole>
      <Position>119</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>2424401 - Disclosure - Litigation Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationLitigationDetails</Role>
      <ShortName>Litigation Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>121</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>2425403 - Disclosure - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CommitmentsAndContingenciesDetailsTextual</Role>
      <ShortName>Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>122</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>2427401 - Disclosure - Employee Benefit Plans Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlansEmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>2427402 - Disclosure - Employee Benefit Plans (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EmployeeBenefitPlansDetails1</Role>
      <ShortName>Employee Benefit Plans (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>2428402 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>125</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>2428403 - Disclosure - Segment Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationDetailsTextual</Role>
      <ShortName>Segment Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformationTables</ParentRole>
      <Position>126</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>2429402 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>127</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>2429403 - Disclosure - Quarterly Financial Data (Unaudited) (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedDetailsTextual</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>128</Position>
    </Report>
    <Report instance="biib-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>2430401 - Disclosure - Subsequent Events Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SubsequentEventsSubsequentEvents</ParentRole>
      <Position>129</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>biib-20181231.xml</File>
    <File>biib-20181231.xsd</File>
    <File>biib-20181231_cal.xml</File>
    <File>biib-20181231_def.xml</File>
    <File>biib-20181231_lab.xml</File>
    <File>biib-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>190
<FILENAME>0000875045-19-000006-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-19-000006-xbrl.zip
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M]47\F%[[V(=@-COX*+[AP..@(<=?L;[IR&O2;'K\-7#3@=<<?47#X\D$4-G
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MCM9T<P =!M -Z%Y$23K:$2-ETD8,@Q;.1JN_Z7<4)/<Q_B3*\-'&[;2D>23
M6<>D'8T'_'H>1W=9//F3,H2TLR 5^OI#0Y^1]\G.X19E01BAJ1<D41@]45*
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M/H@<C\B$YR?/#&"ND:H1&:H6@1\7/JO15 LOQ87/N-GGV_X(WO9'E+O8WT?
M-X>1O#FL]VTDW& 0:##Z/JKE-*?!MPH3,*=H:/?QQIB#>Y"+>!"B('.BR^'F
M9O#)!+U%'[DMR/,Z%Q_/$CXLLSC96HG2+Z\C2G8UYMI>1]+:$-311*<02RZ
MRW%,AGQ_$"X7_$BJC-W-]OWWF#FI;VBBUVQWUEXN1S:T5^?:>U'M[7- +/>]
M8UODZ2QXKL!L"+YSFL4%3W^:U=U?<SM/G+_&0E3Y,BO)1?*2^-4>DRU>]J:B
M[$U4RG8Z?/A"_6"=/4.#YD27PPW.X.ML!+D?'H ,M$I/J?7@_F:@QK!>;$:K
MN7C_OOIBW_Y^OSX1,K]Y<[#M1Q0_)<'B.9R )N$G<KXDKW]\NR,=!T?F]>Q2
M?4C$+?]6(\_>_[IFVB_?[D94ZVHU$.H*'DH>41)'XT+?/MV,X6]HY]<>?Y]O
MK4_N52OP%9[T2QQ]H\07'D-AF?I^(5AXY1+S1H3%5F/B.1:9Q^+02Q&ML>A_
MNOJ795\Q@:P=6KB@=P5]=W/UY=;Z-R7GVQ^1]"XQ(Q)UJUC'__;9<KW;S^.*
MM'>IYG'V,-CC9H8%4;?R*/=H\@A22 (F9+U'S8A\2JO:X:XJC"YI:6\):,Y:
M2*@FMIT\O+XX/CP6\-AA $?D<(BLK6_3BZ_.96O&Q-TN]GE-@X<D'*T16H5,
M-4Q@U1!1$ZC9WA?OQOK4KKK,3/*_2S5CR3\U5I$[059,S4GB'HNQ87Q-GP3\
MM:HU=NIG8B_\NF1C$U_5/[[J8GV^^?V6C<+W#BW<[)S>OL&.S[M<UP9?7.,-
MO*-IX"4!>ZW<F_?IVKFW[KUQ86^7:L:P1X+'/0%[HX$48Z)NY>*V)]*QD:15
MZ!F17VDE<*[;HQ'U;B!'N:C;1Z6,B;K5*M3?T#R&V&86!NM[TI$6Z9H8P6JY
MCH2UJE8(M3[=W%Y_NOK7N/*97:H9RV>HP1YOT.?8&R"7YJV38VJ=I";EYPMG
M]"<%W04])KO3#1HT&QT2L-@J!.NTG,$>&"^YKL&34;YK<A2B;N4$>=V!N=R/
M!*?7+@ K#\@8"_1:3P7AR.L/>75;A2C'5=?=3V,4^^>[];5;](*B)2TCB8](
MOH&J$0F_5=<.%_XXBWJGE)E9B#8&J"[S@*/E<)K1%7@ZC+.AN<)# AY;.</=
M!)AR<+7/YAES?2=,6AR=Y1G'J"02T-AN, W?K<96"$9"I?OD&3F4XVK F@\)
M!J>5V$]L_67&]@S3\3O*S6.M'&"W3) 9&%XT 1RE$VS7ZLM[GECO>:(&BWQ>
MS@CFY5"#QIT<C7)HM<XWQRAH/B>>#6&_9=%W+%'W":O#%$;?U.1^E>D+HPMZ
M.LV?X''/)>*>;E-3V8/D9<>G<D3R1JT!&K6H$?[NY'3*9=Y^##QCHFXW6XL?
M#<!:)$Y-_Q/OQQM%/QXUF>%I=0KV<#E(P6+<,?G9SXAGQE6SW+9%C67D_3NC
MZ-\AP1+VZ*F9@>,X5A2H06.7?AYF,'C!-IY1(N_\U1OV$I5+EG'X?C:^OW><
M^WM)R%+.?QP->]9P'//;2$!C]R/A*(?6$+V,-+B]4\]]9\'U#73<^RC=W_G'
MES*#0*9/8R,A$3UAE,58L,?T!$L2[%Z[0Y8[3+!D+^J_X"C+<0?]?33R,F,)
M+]N_.TH_W&Y?5?=<A#V3>/FDA#>OG-Q"0#G63ND,8,PQM@O2=@[ZHESH[4\M
M8TS4[2;*<U&/I?39::PA,\'N):<9CC+M?\L<^=%%NR/KUJ;&-O*N,&X9J9BS
MSY1)'-5QKB38PG8=LOR0*;9L(0EEIQ.VLH_)$HZH0Y8:-.Z8!,JAU=J\,2;H
M5L%_I[&:S'B\2T[3Y.$_+\J-IBA'0J!_\IF>HPNZQK3^3 (RNP]/H!Q@0[3C
MD^#^6@FZZWQ/9CS@A<=ZCC( Z_.T&_8<X3!C,\;=IMHJ3.O4KL\>+B_9MS_N
MT.R$C4N48ZO]?J0QUL7XH.N1#+JFQA7R6<<L^)EV._+W=(]R87<Q)8R)^^S[
M IDI K#<=$""3VE7@N)-!^PW'9" QK.?]LX>&"\X/WC<#3#MU@?YP<OL^642
M(L(3=J:-SA2VW\M&LRTD 8V]+%2R!\C1'$1(0JQX_MXQ]@!YR2:R<5O('K=X
M,A,UCF/,/S5HY(>@C.(0%!+P>/XJ(S,H9/KH1A+BQ+-O;F<O3+S@+O=QYRPG
MV$'*H37("CX)HCYYO"'E N^Z682Q58/S3Y=FS]V,HUV5!"/4KF.,UVW'4K>E
M)A?LM++%3"YXR06M4>:"[595^: SMI!'@M4[81L3Y8AJ'^6-4=3\<"-N9H:J
M.O#T<P3I)S7%D-TA2Y1CJ_W$*,8BZ[Y.<V'&]8W@9$D23$Z[L87\1(?1B+J<
MU](NZ;8Y.F.";A5&\.,31GE\ CVQ3Z>=0NSA\J);AL:==O6RZL=,(,[Z6#EJ
MRE!\]]H(=J^18 ]/V[U&.;PZF3G& K)VR[S\F'76CUFGP16><L(5"['8  =;
M\8(H;SQ@6=3=W1[EDA[BR!X:? H/:,>HV9U:BMB+:"_96S3ND/;\)X:QA\9+
M'ATV[M67OLYQ8B')&DOG"356D=>\1U#S)L$JMD(CGU[)H"TD 7VGS$X=#Z@8
M<WPGG54P.M<WEH-22$!D][/+1P?'4:S_D5"Z:X5%O@>&!5'W.761/0LTML,T
MJ7&,O#.4T<Y0$FQD*P1VFMK-#/PN.:Q[=-B[RK$G=BR(%5[7#Z,P0Y_"%S2%
M/"Z(GL*'&;+2%&6I_?HY^$^<.+,@3<OI[B=X<92BZ0U\=Y2QX;+/6S@K7'$'
MYFYRZ5KN]@?E, + PE,K(,LE9!97WERM_=JY6LO!R<%94_T5A:&KOZ>@>3S@
M8TS8X%1!V!<3W\7BCQTK?Y[X _1BA7UG.5_.@@R,RETP0^DG]()FI3ZN8/)L
M3:=A!L +9M<1LL/9#/[];7$?WW\'PE_7ORB%Q]V]AKU,PPB!Y9K\M0S3_(^5
M:J/+.82+03*WGNA0SUP)F]A:-(AUX^L9 O"+>ZL&H18UWWVI7B1@VK,Z;P^8
M"E4ZTM+^V_47[U]O")6*9UP,HWB!IB"RYRB>Q4^OM^'3,R-14YE-0X1,Q4-'
MN$PG4E?!D(R#H1R3MRA%03)Y#J+I=$4O_N  LZ9DL#]^V4/M531%CR<@]RH"
MP4_ '!1_UP(WMOV[=. W1^D1QA4VM>#<F8#<D>];,+=B_.7:0?1.,:)@?I"%
M<R<$'77@YM/=+5>"DY1@RSJN!61IP2I3XFDQ>;7FGG(]7LXC+D&BH)S7?T!Z
M0F<PFU6#<>?HQ'4-K^O&+4IDJW+- R^#G5 &J^$=+W6=3XU(J,AS \^1^>:@
MN+>U(AX7DX=9"N)BHE*\4E6+%ZAXL>B\Q:*6]8.Z+>W<6/:]]9TBB]G_(JS,
MU[7XNM;%C/0.GG=L[GDJ8WJ;OC6^5>OML5NG'+F75G#L7KD98LTF]-1H=')0
M=;W,J(RJ3H]QFBBF%P#ZB0!@I'V,^J8NG210T)QJT9GX]"+^-SD%+G[:7<*I
MXN<N@0R70%2<P -%1IR"SE-*YE+*WJ.'4X%RGP13- ^2/U/@3?[#EV".*+,:
M)P/D(/5LN! .##J!<7:+L=>R>0N<6%6C\4^?@4GSY?P-BW^,Q*2XSKUAS?M?
M\8\[O!EBT6_PD)?$!L^^<$QS:DTB> GH\2$;L<&/<R"6UL2O#K)EC@P&V<OG
ME:/#+$-6E@C(<BN[1BROGC!0/2$57+T%G2RY<"*B3N["SV40>3%H@&(0J6#J
M(QYDN'HT=&C(JT<'5UB#,/DMF"T1, X%Z3+)YQS["?IKB:+)ZPXX-_>6[H3@
M:+),DC"B9"/C!D+'Z=Y"IPWA=!;%KU:G+7 X4 D'K?>F' X'BN#0?X_6EBV;
M?_X-.(Z3X]?M9(G*[5?18IFMYB?(^T$21]@!5M: K,K+<P55'/-',)]'F-68
MW8F319Q 6.:BA^P.\R#,PB(].J?NB%QW]I&Z*Y(M/@_*Y/P*<[(*BUR%25#A
M_-=V,/D33?M48(DK<%L%/B 1@M17XNI+1=3)%8]CGE;,-[BL;W?W2<Z%5RN:
M?HQ?4!)M5R6Y[@SBM [*A+LMKL(#J3 ONC"GPKSV0T?DR6LVO%A"*^;/4RP9
M*\R)J&QP9!-8!N3A&)G*PH,QNM7W8OD4#^J8RZ=X;$F$"E_( W,%9LP#<_4E
M0GT[>V"N;8.Z2XYN(AN]>(+(7*,73Q'I5&&N;X/J&T<WD0Z*]X20JC"\)X0T
M%6[8;<E+%WQ!F03,]S_6G[L;DC#/[?QE,<]#->)TAX=J7(5I4F%>#F1.A7DY
MD @5YJV,]*P-<V3S01R$YE3<FA-AS7GW >\^8!?=O#6.-'7AK7%<??MS3CRP
M8\W?\?B2;A7F4Z)(4V Z/#"OUQ.AOKSWCZ[B.D<WD:M1/$$D56%XBDBW"O.1
M;N2I,"TI(H\QB5!A/D&$- 6F(T7D%1XBU)=/$"%/@6GQP#R([DF%RWO@<")U
M!6]-EOA#<[7(SPZ]0U$8)U_B#*7WSPE"-W$897?AC_OOL1^^H!N43.!^=XGN
MO\/_OA;_C>G2EBKUZY,^WT;^1:#1^]ZJ)FCD7+D)7H.'&;J/?;@Z#2<!(X(_
M1-QH--Z/ETF.^'^CY #>\15&Q/X6XNG5]JZPP,S G %#M\\4/TZ8!41[LMF&
M C?\3(JU'.L PC'2OX11@]EC1-HGT$PO"-H$=1P$Y("@][H-]_6T^'H2H,#S
M?R+S?Q*@P1-%XA+%WNL'#EP,HR?X*OA7"EQ/@@QX9[_>OR[03EW].GM&P*H(
METWA]D]A\!#.2LM%M(#A*,7;PO$QDJD,(@$!@L;SPV'S0T$[LU1=0(KZ5=Q(
MU5ZF$/RFJ37Y:QFF(4;X5K0 _!>4@ I,T,USD,R#"5IF0/^,,E5N('(MXV-4
M]B=GD&62N4&&L/ZJ'P3I@["1]/9:Z0$437=NEXSM7YL6-Y_)XA]$AAW&P+"K
M*9I<P2N2*#>-P>P+6B9Q.@DQ+UF"2&MRJ;3TOKL2_>_W+I<^F=+?L10&F(D.
MEF(/+F^W%%WA<I<E,7:</U@"Q1Y1(Q']?K;(TP+2TX*S9X8K[1>_<F?!IK,0
MY+-;C-9A)4\XZ TB.PF:AP0DBU'G8KRP&'OQTE('+\TE>3:/*W7SN%(?'K>U
M!O/H;,!"3N^K-F\*MDY(\JS))%FB*;7)77]Q6S\99A._Z0P]L,\2OBH\LR36
M=NWX.>$#_+_V?DXX<RWJK"M9F[>4MO[DFY(J)F[_!C=,)_$RRFZ!&);0=B%C
MU\3OK8T[SO!Q+-!=K?!>D0NOK!!66<D%+TK#+<]Q8\>-'6L+3=RXD6'<^I\N
M$$9!- F#65VO6<,D*&>UP$:7L!L(W0C[.*4C$/CG.,F>@B=D1=-\-;5V#,F7
M.&(0 2>1SC8DBNL>F,?L=7\.#?5B+VZH)X]MT1XR[VSJ=TMB1R#V[30:IEWZ
M43)'*FHVU;L-I2,0>*LHAD'Q=Z>;7C 8/'TC-GWKO<V+!W0D!G3#BIU[^?$(
MG.?DS(J65^!(K<!1 (FQXF%L8.#%&YI%O6HMD,HM=WA1^OK12I(@>D*[LKZ*
MHS"E>H6UEKBUB)NIN]R:N])MJY;V01;.MN:^4GLI9\,DGLV"AWC5><JA,00T
M=M0>)"VH UGXNPPGM4_AY"IZ06F&+U(FVL.FO9D^.FUZ(=PTR?ZX \9/ES,
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M8TC XU=*X]<QNG]N;1FRMF,,%WB1B_HB%PE!PJ7M+@\2* T22+"QEXYH>8V
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MBII<_;CZ,:I^)!1-^U<_'F@2I'1C#31)4+56@>;=M2NV5PIZ]WL?T9$M&RX
MQR'VE1,7A[5?/<N'*"5K0Q)$TVF83N(71-O@N$.(.$+BB++C5O'!W<W5EUOK
MWQ8W7+_LLF(,QHL$UUI"Z>?@/W'B+-,,@J$DK5\"/E=/3''5B6>SX"%>)2ZE
MF^A!=)5K'5>:Z6F1*2X?%MHXE:>UB6][6"9W 6=0F@L<TLD]3+=>(S^,P@Q]
M LLQO8HR8%KX,$/Y41FI_;HRIK,@+;F?J^@3H 22[.D-?$QU?""3BK*9P=R>
M6P7FZMDU!K0/G0Q>Y<F@>,0?W(;9\D<0T8'#(P9[AY;^I%P:"@29G=SK"7('
MS,FW"/0P2>%KX\<;%$7IZ^PEB,* #E&V4>'#%%Y$P#V-19.Y5O8J-,'\( OG
M$UKKZ!J?F0&?ZDPEH3G INVTJ@.RK=#;0Y1\F<.Q2 I4,=RDKZ*/'E8%#A#]
M=#D#,^G]M<P/-,F>8PC 7M#JL);J;Q'Z$LS+25\P3Y?1DQW&:3@/9T%B/26(
MLLK&6[A0)'1'V' A=$D?!*D#NO+;);.W6D%S_:P(0KQE$B]0$($_KH[Z9V:E
M]T!)JPA6:AC!5UE[/.2ZS8Z@29Q,&8IYR_1<)%CJY7@C8_=XHP/R<Y3[9P3:
MEJ?HE)5##LFQCJZ+:6^G(9-]U:*_\AX)WB-!'CK+QPCS!)PNGW(\ ;]V;KW?
MOMTQ(;<=6D82^76<*,B#/X8$WD&S6R:N-)Z'>BZC<+ZL][(GK]*)SIJVBG/-
MZF$W[CUW?P4!34FDQ-ADU&\.Z\Q'Z]^__V8Q >4R*71&V*MN 9X6]=LMT%]:
MU"9:GOV)DCFBQ'FTBI=W*!J)<=T;*\'[I'F?-#U]TB1LA=%:+TY0M())YD(B
M(0?'<5O);25]MG+H!N+S=KV5-SO0@/J!N][:[@UA++"5O\HM?3.]93$J2DCR
M!T'O  9YM^7V7&!H&ZC1WN#8!A*$="_*W4(Z>;"IBKR[9(3=)23DE^TK<MQL
MC2:XZ=#2:B<AY%JSSZ^0;=W]M0P?'MA!0Q-M]"Z:2.V$2J]_(=7NEP0K]2%8
MXZO$!3NP8,%J:WWMY.-;; ?<8DN4;VZ?4O#Y6..=CT50:L$37Y[X$FA#VY_C
MQ1WK14!!Q@J2>'PGV+^OOMBWO]^ST0RX2PRI^K\SN*:7T;,7'"I.X[F %,WY
M'NFYE&IK?T9O$$5%<*-V X-*2H+(MX'P;2 \8^4Q 8\)F,EQ.VRW^'COT(6^
M@^+>4#,B86M=IF1M+[CX\*OP88E5=[UYEDVSU7(#<0O.L&FP"'+ YPQ%*=H6
M05(\.,XY;BK?5-KK$KG:QZ;2]H=(\4K^:#R)SE,YGLJ="<]#KTQU:,?D$RII
M:,-4O\H\*>\]U#CS7/W580CMVBQOX-6T!(FMJL-E@BXB/KW'9DH^Z8?=+*YS
M%>'O-^.L(OS]AE<1AMTZP[-1&N.W5:]%VXW?/(1[:R]%EXW=ZIDW=F-9FU_%
MC: W9O5N@J( WK13/RA^B=<*)D&:M2\94.1="IC4LF);*ZCG!9,>Q^SF<?+;
MSW]T8JN\A'N<"W@<;;#,I3IUFMW#W,X]6IH?Y-:Q8X1O_&86",6YKGPEM,_Z
M5B^[P-MM[^?E22+32KWU""EZ^ZNIZ$76NXV-ZF4K6OO]B7PP#U\)Y@/4Z3'S
M[6-L;N:9CK/?<F#/@<R>;61=>H/6J84!KB1GCX7XU@:^M8'*L*VUH=^=QL B
M3,\RBH)>)!)F3?GT,#X]C'Q[R7T^]_E46MH2A@\<,,*^<3WUO!!6["D)6&PU
M$H;'GXS'GX1LS6O;/<EKV.-;SN)"9S*&!_%,ES/@D??7$@CYC++G>'H5O: T
MPZ16?XO0EV!>SDB/+ &.YHC#M[#R#,NI;U<*H@XNI#TV:[.S_0[-9F'T]!%%
M*($$,9I:TWD8X7PP9_UZ"W?*H[YS ;_5?OI.4N'A: _AZ.I('/'.E2[DHVC0
ME8'=R]EZ-Z0/@O1!,L_;NZ%?,J+A:!E;P-QJ:887:1@OTA"$Q#;@FL3)E*$M
M9&5Z1B3P]EV)U]DS2I+U,*@@FD[#=!*_H.25'0P<(7%4J:E\_$04WBPPXF8!
MK=L>?:V/P]?;CX#D QEH3MC/N!>ZO 9-.A0&W@O==KF>,=?7(03F1H7V\%?C
M2U7L58<86ZHBP?F>TCS,3Y;B)TN-N)NYPZ9="@>!#3Z,ZT+;=4>_Z9)OA"0F
M)>%1*H]2B8U2!W:W*Y/=:APB][9O-XG*T"91^RJU[";GTR\OE:5V <7>N,Q+
ME^[X8N8XW$+'92+:6[,HFJE%1E6KK1/A8T_[M!!='(?>A^/HL)#,VYXHU_QU
MH+ 1]F]!$@8/,W0%MX"[S#Q,3HA2^]69!6D*0EAU\4.:F!.ZQ<(7M$S"^7P9
M4=)C6>#A%(K7<-DG^6(VHNM61J&'Y')+/ </1>"!=%7ME*["[3VW6:XV"MT'
M/ZQE]APG!3"*-3'[EA8TU!.R76JR;\=1I@49"WM!A+U,PPBEJ36!F J2\V)W
M7J[]_G(>+'!5VWJB2_T;J%IK>(6LRTA?Z!92"'UL*)._2G<MA7__F@8/2;A>
M%69)_G64760)4,Z3".E\2X"KU5MQ?;SN<KZ<Y=7UNV"&TD_X&.12T0!^A"=1
M]!#.9L"/4OM#<Z_$/9H\@F"28&_1A2VKL3K$MX%[13VBEGUGZ(0XT'6QQ_TS
M+=,08QMWUL8%^>P'3H"MX_#F*-LQO^<]_*IHGEGC(ELFR('K8?2$ZY0AF)$L
MCA N;*1;_)2.I]_<0DFGQ5IVQ^A<"_D H1<R*KV<8B.W\;9? /S<V9[J;&NY
MQWWMV7SM^<^>[VP%;]$31D"<O+)M!)OII-D&2FULH!<^/7,;>*H-K.4>MX%G
MLX$$1()./)^C9!(&,[9M8#.==-K 4JF<AX(\%*3,#)*T(%'9W7AT(Y;K;93A
M%F5ADM]],PLB;'1V6K_78^3Q-3K4H>6^*-<[$R+K^;=MV*XP<!R=%SLG#'-
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MX U0V\&;GX,_T3^?XQG:O/T63=%\L6I;""=XN6L"]P5/J(WYV^T"=?#"M>%
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M>]B;SUE#RKH:>1\D3RC[DB/Z^O$S9,DHN\/>YAN\+_T(7P^AEXUCBNLH_SV
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M1QAY^ ]X[R5_7R8/?='TD.$D<\P^>B]5$BX+;[O.(7REX/(>PWA:AG==5:O
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M$0OP9$3?#B9SM?'XD. N-K_#C.#Y1. R<8GTZ=L'DX'IT-)_Z V;(&&E0;L
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MFU)4+LV'\VN]]^/W'X>3R[>#R>R+N[F9C/\@7F;-]9?-PY3,BM]IA%,\>.#
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MPUJ)/AV$9R)+%WB!>_?KX'(\[XY6QO,\GK?!4P;Z!.T%8XQWI2%VL;@LF6%
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MIF"#)-FY7T'VUPCGUML4 B:!0!:TDB9P;XSN!ND:HZIM^C5J[CV-/B>89%Y
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MKPV;,)'R<,XE+@Q8FYWA[22Q0&MHZ][F?'L9<ES&-NQ#&2QMK2B"0@B0C(K
M6YEA5&!UCO;V]M'>C/TT'EWLX];R7#KF)2&]"H(9,+FM03(VD):O1874VV_
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M5->J0RM7MU#F56O]9V;E4(O(O$"!,BA$0$;K&*5H,]6<J9M POK3MS7G4U*
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MCK[.U]&_AI+UI/_27#8WB\^\FXTOFG47HK]J]R2((_"MC%<]Q2*S-4RRKOY
M$SH]I\'7\;&6K,><+!_&J66HF<R?+.&]'LWGXZMQ,P@2\> -=[S<[D(-N_T[
M7]]-D<+N<P_[>Q^W_ Z-[YC""<@9O:RB%C);\GUU(H4Z-Z]73N_,_)$E9Y])
M<K1G+^.-T9AS2GJD72%^H>0,U.5-E%R=&1]!<JOWT6,]86&DBI>$UMG)R)2W
M&A/'MN2=BJD: EYQH>HL>AO2CL',P$.$$1)-;$$5]S* *Y:);N<1AM[5>YR
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MEB4DI;BVU80;46*N5]8A2QOH74?7X7P,Z /W*2ZFXHSPZ&@T5[+C ]U._7K
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M.:--%E&H7(0.;183,2*O%,U6 P*'D7LPYX2(-5X@I-. QJ[GC><LE,]H+=
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MGD[K!1L43N\8P)+6U!E&,$=1D4&1!1B#>I56A;"WY;FO@5'%)([I+5!4'_Z
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M&Q9;S#6P473=V]6L( ]U'FON/LU67)*S#\/>T\G,H6&_M@+*$NBL9;4"M.
M@VTA8+_>K4<.V@-WPES\N_[E'Q__//OG/SZEAFY^OYK]OQO)#?W%?PC+]RST
M@\\_M/"/2VCQBS804XJI:,\*PX,*+L0 Y(+S+G@PJ<1.3+"E[LB7[]^?#^A1
MFUW3: PK\"Q^.Z%%@)B7&)($T"<8W6H"/_W^34F[E2P3(W;T8P\8M^Y\F8U)
MLT_"-ET/:3B.,-L2_C#W$PZZ;_=<@Y-5_7/TU]GYNZ&X<CD7"+1/.WP_87K]
M.+O^Z2W[CANG\+*5?9NNF&+Y?)QMI,(2(#OV.<9O=.\>[HGVX\AC(E<('$YJ
M#ID!=&U@E</61BC<HFOG<L0NZ?JBI#&U5<F: #F;HH/2H!SDL,R<*M7'XM]T
MTV_'%D>:<6PR>U@#N-KZ?6A?,,>A@A5C81^HCN-_@P+K]QU$TY6PMB?WP%QO
M7^PHL[<")9XX%GU[?OWJW=G%G3.;*FM0S8D*:' .9 C1+*!>6.5XW>]8Z'H3
M/D>!'J#V&MD#-S5XCNZ*;I%C"S7>W!JP&UQUJ_WUST_.OUW,9RS1_Y;=6K+8
M;9BJ7<A^"I"A@FY*>6NDW3IZ#N[;<E-N[KU2MI9?@E!/N/L_RM1S+4%RR$;+
MF@:?-=KHJ!F3^AV.G_E)_<I1Q]6[6Q=X77V-'L!S^)NAD:YL ZV.XR((5N&]
M"=30UR5/4)83GJ"6<0KB&R/JTA<3;%INQ@NF-U/?V ["X'2Y?A[+[SG2R"F%
MK/C:N.B336FYL[U OV?"O@33OZM$]V_Z5221+QDPE3Q[6\[JL09*)7?)H6\X
MI.T:'CY/2>]@_&U&*"JD)'L/=(46QY9#_D!U_;X?> F1P*XR/6';SS8^*4_5
M8$:'.6CV@P7V)YKD*L>U+\SV[WI2V]A^"?==\ Y+K;IJTP"76Y34BD46VG5
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M\OR?1WI770BU?3.+XI#5A^BKM:8:F6\;]WQ7KU?LK+:KVZEWH?G  IAX5ZS
M^2H(X &_(F3.!7EKT7I"*JPH9?IN/\^IBV"JI2MG,,F&%#5HW:R/GU)$+:Q
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MGO?M;NS-)VHXHFZA-F=C;&0,XF(#N^8SYPATA5NXR5#1&B0?@?OGZ;+1H&I
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MSQK1%?:XO3(> RQ5:.X1E31T,$&'HWVJ6S[5:CA>*$HPW%2*K"&7U?5J^KX
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M9;KDQ]D_Z?7@E<H0^)S]]9N+U\/UZ4;C%U_$VO?BS=G\S=5O']ZP'I8S4OC
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M30O&F1*LLGR9J@FM$J31MT7?H\U^\<+FGSP"P MA9=EH]=/\[S=G[\[??A3
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MP;"546BB;)1DB7@2=Z;?-ZGZLO.^!7+Y^_DQ6 \MF>JS-S#L"'/&I10,^YM
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M5U*G5%VU'-MJ<BG)8=UR2JT9WR_I.,Z1KHF-U[)L"*L<(6FM#"M&9_U@JD%
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M_&G/U@QSXFIR,6#*.87E_#*F?M@O[#CL>721K1,S5YL*.T;-N::C-8*!.<J
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M:QDH^%:'+_$@;R7]7"-11D5/8$H$KX(BG: N:W?.W-L/NDS\'3$1>U\X+^5
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M8!9P'LKZ^A'\X$8>%[C'6ATOUFW?ONKE!@ZR%U[,1YC%B$?*6,52)UYJ*AH
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M;$N4FAF 3QK)0XKR!C;VEQC;>.@&;#L.9T^PQK$F5)AH43P$&K3IH<_;]!V
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MYB-._< TKRL>Y[SLFRZ++A\?TG$RLA\">ZKN,1;]<9N.RW1KN=$Q$28T@6_
M )'&!^?3KX.L-@>]D=#_.##\@L7N;,]K1 )I\"<UU6$<2!2;  E"%RF8DC2P
MDVVH00ZZYW7Z BPU"D9<@+4,%0.+GRXBR,(TS>)6PW^G>VX1FGFSD@Z,)Y]J
MY8=8$]LK6BG%([48YFX;,#S>OMQ\^]NL>Q^46,/\5"H[:9C@ '%*B(EXX->P
M%P=1PY;G&\)>#RFQ1B14X&LPH7E@ H6(1E+@1?^) .R)!B7Z18BN_ H<!X*%
M&EP(FUYBJ/*U7CK,K&$@ '*\A!#/MR1?2(8U<N&'%'2@M@73L:#:5*WZYW(A
M0M)PKUHOM?M/A34R$7*"?<P#(8B0)I*^G;I6,T/<3&;CZD7P\!(RS%3,^_%"
M ]GTOD$Q?9SYN.YR(^ H!G$7),**<40BA,+:&@"WJGEIV&CA^(PE=K[#59<B
M,K3U;SY3DLD0SLL(K&K=STGSH@FW!A>ZW^'LX&O.J.WF)Q-:RF)BVRX.IX/)
M^^)C6GS-!NDRL/O?[W[Q+W[[9-;EF4@<^HS[W-9.D%B"I8^Q#P(N>$1TV !]
MO2DMVC>S 14N4KLCR_8/1..GY+9,WU^9V]M1-JCN5B?)9#J!EW[*;K))\CRP
MCWW -SASK9"M/,-8&U3K/+ -F_61&UXYOF03>Z?1.@N)$Q7:J5X*' 45$8KJ
M>@C*D,1-<3E%&JW1$['R;>F>;S-T8ZIEH/0BI3A"<<-M)!M>LN^81I^ND\D_
M\^EH^.[F%K8175W-6KC"6RZ224M:]:K[^]@.9-;&*()B;4(9<;;(3U:D"25$
M;$B$-:O<Q3Y7*DBJI!2!C+ ?(,1B:4?CS?=I<-3PG3:^6CO /E>I2=MI.U!<
M4!;R4$0Q#L-%96;(HV:;1K3I9<@6&[4I/14[F]$H_Y:,!Y5#;?NN%E_3TD]&
M]J7M(F)P8LKP&,2:<FSKM\';J?>%XN:H']O![=&^-EI5-]M8)%&L?L2GN]M[
MRC^P3?=AK]-D9(;_,YW'%M>E8T5!+)!"0@%H@=T?1U36=*&8-ZZ,.6L8NWVG
MR_S5J[P(DO(ZS,JJ[_3:OMN^P8A&8!KXME.9T$HOFLY'+2W8><,B[C%=%NE]
MR<@Z(Y-I,;;O6WYH71ZX9CB.).(\- '%)O(EK34?C6G30VK$E_=%G%6Z2T4T
M\B-KZ/N10K$(E,"+^S!*FVV/8;^'V\;^,"$,.?<U!\)H&JK(^+P^72" E@U=
MQ]3!L/*Y='D>)MB>23HRG*$H()P $K!@,2HI;D:?FQ.&>TR7EV)"B"1HU(@'
MX%1%&CQ*'>NZ@EJ YFU@0B/M:%_$65G("&R/6> '/,0<@;(CH5_G=3+=;%,M
MQ<'.^/YLQ/F;/EZGZ<1VN*^>UC)M 0YVD&9?K?>PKKT"G"2H-*F!(C+T183K
MGO"@"%73L,>VT/,("#$;WC>[B/XI2RZS415Z7#N%0V&L.(D1PB0T41RQ1?]Y
M)H(6A3=C[@-38^>J0C,C X, _%B,I!^&/E[T[@F9::1B"M3H=-QWNCQ/52 =
M$ZE-)+0!) FM>\QKVT*#$]GB1_5!?/:D*Q@%MU)IQ;%1,0F1P6+A=6#=G$C%
M#L8UJWQE@0UCX#R"S6OS;:GQT6+P$0&<;)XQ;TQ%V>,^=J@L L:I#AFQB=D\
MPG%LH;*N4@^CIK*0XE#<OA4AGJ<L(A(1$4H>Q4$4B$@J17!=J<B9;("B#4GT
M@!J[]RLBZR?@V&:CZ8#[OL]T;5($OFQPB1UV=61T>>9= WRC=:.5B0,<ZHA@
MNFC3%P6LI6&C/"+"O%A9L)@C"C 260\4$>*'B][3B*%F7]^72],_T^S+]20=
MFJ]ID7Q)?YG:!8;9: JOS9JHO)].2CNVS":P+01@ZTA4:+@ *T'Z*-!VE+N@
M**@[XG,_;&V2\VAOSUSJ3G:[)J8$?@3H/PUN(@N$K=U1C-7&8L ?:(ECV.VZ
ML8@F)H#L6I@ (9N<SD-6GRV6LJW%W[YV^_[JJ8=LS<$"D<CX%#Q$<)8QHRR*
M<)TK8<0#Z%HT[\0-6-]RE9UN4*ZIQ?-CBF@HE)V7JH21(D +I<6"L'6#_/%U
MYV$WN+*:3H*GHFS5I:VX(52Q>-[:'VD5D-8FI*19$G78#:XLB,,ADYH8KJF(
M2( 9$29:S-A@0K9NL%$P<=@-KJQHB\#/M!UJ- A@'$:QB514LZ@?/!@\?N\$
M'WM4!][@2C7I1TH;+ .M0NY30%2E%HZ6CEH[!#=KS ^YP34%OY%M9N5KB0-L
M""A&REA4RZ")'O0VN<>BC\V<PVYP)<B0,!0^]KD"71@;Y0<*+S9HJS':-H@:
MV86'W>!JD)$1(LA(S'@0PKL-KO,#?&EG5K=N$/=)3:PIF\6:T0 TA>$! <5'
M8H--?8)1H%IE$*%^G>#JW%=PSD''HR@$6UQ) ?OS:Z]=@%ILW2#?_09GG[DW
M3.'C]/)_TL'D4[YLWO(>W$UP84:S5@Q;&W&4A5*02!DC!"<L$C'GB[A6NQNR
M(?9LO_@]461=(C1ATE"FI/*59B'GH= U14Q@V@"YT0[XV$BR3CZ$D!:Q0O@G
M$$PI39;!3QVUF5&X432T?YK<$S8_*;/!UL+! P/[$Z'Q!>-,<E+/M42!U#IJ
MMZ[41J[<4VOL<'-KO!LX4Q9I(6P6&QC'1@;1_.)6:"+BMD;\X-T\OKL]W.96
M&AT,$Q/:.'1LF&"4*DYQO3F-:+MONJE.WL/F5AH<@H?$(&&4340(!0FYT8OD
M%1.WNVV-+-W#;6ZEL>$'L".C!0K!U*=!Z/,ZW&IA.#+MFWN<G'/ S:VLN<7,
MV&X781QJ3L#C5O-.ZUC0D++VS35ZH!UJ<VL\&1%)YN- 2QGY6BA0&$8L/!D1
M/N')](4MUW@QH8DU@&7 ):@"Q22<7U!O+D;M)X<:7:0/M[F5@!)Q;7A,PU J
M%K&8Q((M[J(I#5I/#O7HY%8"BF)4(*8B#MJ<*AD+4>LYK126;2>'=:,UWP$W
MMPI0& 5QTU&(@SB2G&E"_(5EQB+4-FR (/9B/6<#7M^;<3*Z*[/R_=5L?!7\
M.QX&U\GX2_IN/"]4NDB_IN-IN@@,V8#R)]B@/P)+[^G=+F\H#58\E(2:6)"
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M(A_ ?W\$>+@]]V+8: UCL+)L?&6+E*OOS,?;+@24F=5&0+.A]POLUL/ZS&N
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MPK,+L9WCP/G.QE=V_$W51\[^;UK<;Q$+KR0%?,F7^]2:M9*K\FP?E?F?>;?
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MXCA797D(FC%T[IIL.A.B,Q.B<_KT&(*Z!9TCQY99QI(^[^R*WX&& PT'&J\
M-!CNS@0Y%=!X<?;F,Q,OEYF;5=+@W?NKNOO#13JRA9F?\L"FP5W.:Y3_F4VN
M;?IP,KZ++,,\?-KV29V81T3+* R#($"&A@+S65*G)&&@R"L=Y6SF.9QWMD)J
MF'Y-1WF5@.NE?]RFXQ)V7<Q.QR8,6Z_2-[\0AO"LDF&4CB_!\2PGR<1[<'A>
M5GI).<\7+9NIH$>:RHD1ZE_RICAL"A\YZ@1$M_ECV;Q+WG3)F_M.WJPT7I6J
MZ549FIY+S.Q=8N8IIF!V%=!R^9DOI_"QW7CT+'/NF%CY2>;M66:G8U['O ?/
M">VAA;W#XM=\DHS:[D>\;#R8%@68AI=WE;4X>' -\NCR)!E^3<:#JBV0O6]Y
MZB[ED&C3_WS)$XGFG]+T;D+)N<O8=3&](XWI]8:Q^A[P.UK,FB5=,G'>7=?W
MOO", Z/3 B.'-T>48*#Y>6>3KDX%-)P;^22[^%G^)1W_>SEO(K#"!6SU-8OT
M:I0.K#^96=>RA ,:7%<?;?=,JZ9,@WQ<*:?*#[6/GG6EM5\.OFM^TUFK-9<>
M?EB'LL]@V5;GB<4>?,93 =7^X:>SQ ZM39PE=N]YDIUW-D3=@88##0<:KP T
M>(<E:J<"&B_.#^\^O?L%J>,?P3':O@-P%.#0A$$4H-!@I)GQ#5*<,L-#22(6
M[#Q9?%,&<7G4W>51Z\-FTQYW+K#;_+%L_NBOYUP>]?'F4;LT:I=&[=*H71IU
M_R\&7";JKEG9)54[5CX15G9M=U]X$?>AR(?3P<0K['7--"W/O'':SS3H'E/2
M!:8[H9ET;<L.&D%Q$:;3S%;>)3R=<NYR"]TX[2[ML#?LY'#*X93#J9/"*>%@
MRK6X[L ]#/)R4E:)SG5;LN=<?ZP=P[+/V^J^M:5OJ^KDW:74/9NVIR+:S@+9
MGZ">J#QJ<K[Q1>-+Y=&)G1,[)W9UDFC7@UI.7NR./LEHE[;LV]LBO\FK_C"C
MO+0]=N$)-D/F\_G'\]UP&@5.&^93F]/Y$FGM?VN.'OGZ:T_ =8^95P+*[D8[
M/)_HO6%A9P[U]QYT-ZC:%\X[)O!\91A)=8=1Z;48V1>&=%#HH-!!H8/"AW,%
MZ;EV4.B\];UXZ\V./8,3]]];OJK'AW0*#GQW%#\4)*M=!2:>Z< ?F(>=V?IZ
MS58'GSNR6X\?);$XC.'JT-"AH4-#AX;]0D."'1H>?>NFEO9*S69-\-Z;?%R-
M!]ZZ$Q-7VL0Q,P'GOA"^"EB$J[&]R"BA(K[7L;WBMB=3>S]=I_/9NK T;]:K
M:9B6@R*[A W;JXCQU/;7L/<5U<5%Z273R75>P&.&9UY6#6^N\FGSZ:2<P _V
M.?#F6<-@>URP5'M"2=4HN,& 76ZFM1F(U]KKH,NO/=OMKEH+W+O\@NKX;.UQ
M<[KR?1%?Q=L;R,,#_?^:NHH1V4E7,4Q?UMQ)'7-GJP-/IG[9QP_<#LZQS7$N
MWK'-H3XNCWGQ^V6;HP_X];,'H#K2 K.^=-(QE;-1^P/>DVZ NPP\.*N> $=N
MPX,]ZU7F>/"D>? Q]^UV@K-KC;J+UJB'**9;0_6^LKM97$TZE.T>91TC;LR(
M[ZI[<<>$C@D/R(3OEQ$9QXF.$YU>=HSXVAG1Z67'A =G0J>77P$G'E-O^N-2
MVJ]@O()CX=-5]XY]'?ONSE!P?5^?ZI6U3$7M"@\Z#;*?4ET]/H-%=]CJSC5:
MVA<7GIA/L#_"'9F$$H+W()].!)T(.A%\2DEJ>4Z<"/;*-SM=23LU@=J%G>ED
MQ<G*R<H*H1W.X'"2XB3E="4%X^XZI#I)<9+R7/H<[97@3BX!W5V?DS(G94VS
M3G7>SMO)F),Q)V/W#4+>>8.ITY:QSMI'/=GPJ=D;ZD.1#Z>#R87M(S5-+U(X
MSZ]I^6X\&$V'Z?#=.,C'%;%M&RH_&27C0?KQ.DTGY=:=I**8A+'R!4,8(R:#
M +$0$ZP"P00+*-IK)RELY6ME*RG;-V<?8F);24WR23+RBCGQO>02L.W,^P:/
MN/9LU^ML?ARVS_6L0]3R4+S+V:EX974L9]4'RNIX;1*:;2 UZU15NCY%\SY%
M6I\KQ)%0A C8G^+==2U2G30M$@=NI<&.N9/'<6W>=0+922<0Z4K;J]\V:*_P
M#.O$U;8?MK:=]JG/3>_+23;I?./:W.PFI_FEG'J2#/DD"V[<Y<;E*[<[4Q>I
M=6;M8"!0<LE@ ! W*<&Q&J39U\JA/N1M3N_S<?O4K=V-YIV%@Z3H<+1/[SG0
MW6"[&^P^0%NW8';*F#5#*:4['T!V>)[IS\3'UV/ V;$60$QXX,R *^R<A/2/
MVW1LQSQ6 Q,F<"K/<45>6EYYJ.:P!YLI*-EY9VTWGTW<4Q%X9WWL3U)/02"K
MYW%).D\%>Y)JIR)I+U2M^&1UZZ=YE+F*]+\M9J.E%E'GW;#9KN<F]YCF.[T>
MV>5DY#Z[&^UE\QQW5Z3Q?-*>"H Z4Z6'"-ACH-LSM!TY@E7/DP+O<6+[J0!3
M9_F1'24]/LZFS!_/[9SD!KXG&4]ODLO@_@3/K9,G)?8CB1BG7(5Q$!F%A(JQ
M5I'P1:P%>:7)DV:>Z7AGKXN&<)RC_/;&WA[9FZ(R&<WOC. =OZ<36/[R*JDV
M?R=Y-:YS>4[>@X/RS)<B3:M'9F4GN92/Z;8V<7*#TSJFY,M.AT1BTDF^)3_P
MT+CC3IATFS^6S1])LFGOS/WE<G&_KR8/E[T4YT6E2'\#VZ[THK&M5F@=++V;
M:SR7;OIZTTV/J6/I\OXJ&5P>32[J*VB^VX]$U6-BY2>9MV>S&AWS.N;=G'EW
M.^JQ9QQ]N"ADLKQON7]M,[^>.22 ]#])]MDA,VMRN#3M71"4"';>F<W6?PYT
MT<?^1A]=FK9+TWZJ(XM0G6=T'IYG'!@Y,')@='Q@A+1KP;;#Q-8>M@K9'3/Y
M6?XE'?][Z977MOV1K1U9Z6!Z17HU2@>364LEFP*;%+;7TGC8^NZVMDOE!/ZQ
M[ZH::F3C07[33[^UQV?75]>TS^#9YGU2MH<BX5.!T?XAYNG;=#W&H+V;;7T&
ME^[=1(<:#C4<:KP&U.C2GSL5U#@2E^TQE,PSA?DSLK@/&.0^;%.[/M/0L5OW
M[.:XRG&5XZJ.274D^K(7>3,KRIOL=>2T*&QS^+LJ*WMPOZ;)W5*Z6\H#T(PC
M=TEY0NKUX#K573>\ZNL&VAV:.-!PH.% XQ6 !E9NF+-SN;K)*EGE?CW(+BG3
M$7SOES,/GI46UH>#SR3#FVR<E1/KD7U-7:*)<^%ZAYAMB2:RPSYK?6 C9XTY
M:\Q98\Z%<Z#A0,.!QC& AG/A5KIP+^F+^-SVA8LVB+;_VZ]I"9^\@/\6F?6
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M3GK=7OFB2]A%V$781=A5%,TNJNC#ORU_Y1'R1+SWE&0L CX"/@*^&CB;D_:
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MI+5*P:XVQ#I;+4$<1QQ''%=GPM6&6,1QKX'CZ&"!DM8HHED?1XPT ,5""A=
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M<8&MQILB5Z2/25:V[M=I3TE.2$Y(3BBD1/)"\E*D#3::MD<D*X7Z-HUU;7Y
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MRXQ9^6M]">_CP8,3 P9PT@J1930?_OHG()S''9,5+H6GYD$R 8Y6/>-AA2:
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MP$R;*4;"VT><A,99I!K5?8"O3'&&XEH/W,AY.[&>],W4NTK94J^:Q&%RWAE
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M\W9WG46^28*9HZGC!=,!IK!5*LL+EKFR,"P!+\P,[2<79'E:7K+=C@#;K>D
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M>+^SR\)GT0FWN6!*BA)C=JZTF=@N/P3CU/V&*A*,6CL,9*+^!=+UK8:?55;
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MN.B2X:_D[/5R%SKH5K90,^-<;A_[MC:D(PZ1BR&XP@P!  OQH(>)LVD,'(N
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MEM_GJ;)>NC(*DD.9S'DD&-840,>XCE36N4G\ =!>QAG8RS_?GG^^NI&5QMP
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M_X*UXYB^Y\%RR8)[3!K)7BM;)QDF6HP*U(#\R]M?/'663@3I,",/?Y 7)8I
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M'ME&!, :1. )B 3$W8&X);63@%IZB0<!F8!,&K4.0"4@$A )B 1$ B(!\?B
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M Z6U EN<TWG29.64V".*Q!F)LVTQEP([=FXE& 562"Z17"*Y5(<MGQ,63Z7
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M)S3O:2WBU8IX]:T&RY3K?SRX($0-].@=]^-_&?*?RBM:#\_RX?R[@U%ORC<
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M+*MZ2I&,6M$)&.H<H25_CN;#2UZS47M4S9K![*UGABWX\<2IA1DLPL,Z0"$
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M'<]4I278JM<++-4'WED*5Y7\_I7-G2=,4%;G3,@!QV=3I >M[E82+56^8L0
M\L)ZV+"J-2R&"3O.QV@'Q< ]#R:H\Z1 ,:RL09F1/H]#M<)G.O?F#$]>8W.
M+SXRJ?B&:8EO,F/;"'_U854]KJH?L2.Y&A8,46:"OUQ\DYEQ7KE-Y;+[+FFC
M>P><+^D&[SO79=D\LLQ7D*TZ2#)V)F5*^A?7L>%O7>0#L4A8M H3]_N+A"CU
M>5C7U&?@.?C*9I?R3%7]&9GP"2%UZ42'QYRQ4#,5+CIKDR5]%8BH//O!<J;
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M.?RE-S[H.1+]XSY[9E"+4S!V*1FD1I[I(//[&SI>@%K*UH$3J:5L??MY;CT
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M[T;C'(N2,MZM[LW_3 WHMUU?VL R1 /64!<SW7*PW6G]L,+=Y!)8)RM]MAS
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MS-3<7<PLVY)B$OI $-\G=RE>"^CS:/G81CV^6GVS0&B=A]VX)3V8X@.-QV^
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M JQ_RCQU]<4XZIBK<8X@#E/E>='+LB0 [L:AH'VZID<S5ZT\O"2X+,]\VBE
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MIA)Z)[^^;BR10W,:XKEM XPO0RT"+22A$_KQX?9>(DV4F:"WTI">AWY3.EY
ML A]M0?LU\^ .]312)CS2:-0O4RZ?V7=:A'_:A6R"KWK]AE"?,9_\&G7@2+Z
MY!\M-_3A\;$IM_$LDIUD#_&@'.5)&VX@SI6BW;K XWF][\!KTS,RF0E B'WR
MKJ//%J?X$CK7;\1ZQHQ.*F&9+#.D#!9]TD<3U&>9(&*1#RZ8>6[X,%LY@$1/
M/,XWFET\)2U$,.C(CXDJ,SK)(/6"RBWR[R_BXU2BM8UGPJ3JDJ.$N?2^JF#U
M1(&>;R]Q!"OV1GQ8$)VPT'"TRLT$@*R<3R0VL3:55T]K=D:.P.6^R 3@Q >4
M\>.2DKG#OVR>3G[9>DBRRB8Q(8%[ 89:=-B1CD0F5NW*3.-C-G%E2^/KQ;V!
MQH<?/9/>I@V$N6LJF\;A*7V$5*BR==QB-_(T=Z+(*@U)\\&S"GU[":%>18]_
MLQ90KLN#V%/T%#:31?-\ 6R^:QQ)B"B=W1S%XD/ D 'MNAG)I!4H^ \0U;:F
M6760XJ\O0--8Y ;5X.K[X1PC8>)S>0\U8'2V#=@*6V/0VAC1G#FZI^BI:,/F
M*0H3HJ"*639@$,!=:9-V?1!:>T8C!<4\68F;:8J/\6_9P_I'%X_T;31:K96S
M=POL#+1Z,Q>@[:M#KHP91E1=!)Y$ZR"[T=2[T*F,_"VINLS,.'TDB R%,@&Y
M0*,3X8#-TOVEY9![B=01YM1:]/2MCVIL&S$,& ..*.J+S"*P7*)T7+UU1KM@
M@OMP>D,4GI1Y/DYIRW,S&W#<)(!=%6M=L@5B0F<GBGSD6?[7BZFG*.Q+H5.-
M^$+0UH1X*.O2PF='5LW24K:))B?N2=(UVO$\L@& ?I8_2Y]THTRT#\5G[:(A
MWXCC.A>P[\='35S'C/P)1"B82^A9@:4H)@ONBP-D$@:#D<8!'D@+()0>)1#@
M/\ISU]A)VVE&M!M[RNP\4VIGC%WL I0\V%_9)Z:1N'B6DK[>3[9_+DJ.TKX=
MV@HVHU/@=8E)0G_^(9U0>LL45 E36X.&AC>RP,Q4>O$MVI0BPVK=2G-]E838
M:3B@(^IMUA8*(1W*HZW50(LM8_D#28S0CHU*9+H+$@>,<L& )PI.KB'<9B*B
M:!$!2D$.X#I?^QDR:RDD!DN!@+U_-1UVS2ISSTK"4RLF540:_)Q]J(-+9*^2
M%Z])'JPGA7[!Z)J_?=?ZCC[["VG$G[?0\PM OR]^54_BLSN7&VED3Y89S-Z/
MQ\U1J]\:C#J= <QOU/\ASH*!7;PM%[YZ'_^QL>+I$+,U'I+,F.'6*B#[5XG0
M QP,?W@Y]69K$I"^O]U_X_TG?7NOU-<?5O:#\RLW1":O6CWYE.8Q*!P_,\U1
MOC".C]OA"R2_ZP$49 [;D\.Z1Z@&]0(MJ\J$_XK"M?<U%2HQZ$L=6GY28_X8
M;6E/:M!WN!_>5P*Y#.UV\SU[H@'[O-A;)2(G5?$M2=]<W*YB2?-;:B?U.@T
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M=$4+&]/#Q9,%H]=U'C(7SRSE2<^8+>,R"/BU'EZ@C)EC_8$YZ&F)#*H?8ZI
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MRK=K=VO!4;Z6PR@N-/.DM<C$M4W]_$M?N%/Q01EJ/E&>Z+8;HM-J#\6[6T?
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M_UJ>>;&0'CQUX5D&LB+,_M$R-#=+1[@+XO+XUY3OYZZI[*:XP<L >? [:<.
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MV/L=][\-J@\2H):9RR D_,3RFQ=33ZE56S8J2XH4A3^(;YOBDBI)(>[8BJ"
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MEF26Y"-P7V?8:O99F;+A6KJDU4&@BK!(65985FHK*V X#D;C_.(1ZF8?\DD
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MA!/S$.M&;W)EM*V.MN2F6L#F &E)&W]RP47.98Q.-!_1I;6?R0C?N[B[@#?
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M!K_3AD<JO3*7@?DJ]3=1I;-+>F3V53.CO%S&!FT8SO-)V9I'19S5P6,I\H0
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MA#?LF^!^S0VQ,L/5SB6;(N%P3JO7:C5^0@U]R!KZ$'?Z$'1M_G7S)R2Z3#!
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M9C%)FH?PDXC9FOL_^@T)0Z^"H4&,1L] D<XA'W/Z)*26R'/Y,_,12-'IY[]
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M@=*^-:?2T $7Q'6&%B R_QNFBPD'E:-R+K/P@?ZMKTX_?,IB4R&P]#U:)=2
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M3$:24[I:(1H2KAQ"_ 6!))0_M5^PJ1/@I#M8H*<PKB5NK"O%P _H+XJW14J
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MS,&N%\SRE3,E6<I,IP0X"I_"'UMDA>W'.\N=^__-?.=&C)TMY,E?BO6UMNR
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MOP1(%PTPQ/F_BYIS$[$/5TW%FZ]S%-1O_PJ\  Z+R5WY0DD5_-^]E\T1R3F
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MJCN))Q$=L LGS"CEB\%YDF3CB8K%B^ Z;_D4ZS?!Q+*83FAQ0/.:=^GTGLH
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MND[M(N]?'WSGI_?A\@L2.ODN- &;[NY,<MYD_J_<Z(S;.8J))?>AJKVM:UY
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MJ+[RQGR7OO+@.G!=43+K=CL%=LJI@Q[!0X.'!M8Z<M8:M0KLE5,'/0)K@;7
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MA(9'CR[*HT;H!MR\0 N_"--U)@ .@ /@[*2%MS/+ VZ &^!F1T?-#;U@!N
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M"+P!W@!O@#=V;)+:[R*1BD3JEOKRDP@TRS'=N0#%@&*V$L:@.T!;,C@F<$S
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M7<P>WYU =F+OR*V-L YVC0X:!XV#QM59<#5WY/8NGYI[;WN7#_0'^@/]@?Y
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M/;0A 0 !0 #P&  (G)W<WD'LM 5:@)9MT=(9M)I#X 0X 4Z $^ $.('W!;0
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M3SWE _V!_D!_H#_0GQK*!T?[K,UP?OCYQXOK]Y]_?(F:X5 #G.V#!C%[9WO
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MI=\?XL0=Q#\XQ+02^9WIQ?6A6]6>(\A-H1$DS-DK>ITA/@).@),MS% ?9WC
M#@%?)>*KL$6ET\870C$<?EH)9'OM=G'>XVEC%C81 %MC$QN]08&=%0$Q0 P0
M6\XN EZ %^!5$KS:C=9H!"<1@5T- CL<?EI4W-?!V8HPJH=F5$\)GZ6UXP=
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M>UU:KEA8Y31F.HW&2XGS/RJRS6,=8G%L2JQ'(O,YH!T#GN3]NNUF8:OE  J
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M_E$MM0UZS6%\!&NI3TH'I'I.^%),LAU9@Q$;)3B( +S ^B-*I].5; HM3[5
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M 9"W7=A.P)?W1N:0.S8.0K:2V.VD_1KS-&G$=M[V<*"J?<445EQX \?D#=0
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MRTA,?GV.>]/[D+&I"&[OL_)XM\)3YAI8M>K-#9Y%$<FSVT38%-C"A9"'MR;
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M3K-6$GGQ>C&%DLBJ@Y%@2)1$%DAOS>W(>,M)S.%LYL91E5A4(F]&I3W3XVG
MJ&L&4HQA"!5V%!3F(+FL4W-R2<_7U9"(!N]G1V6Y]A_XZCP(GUJ$?XF%)&3\
MX >6;8]1QPD3ZN5QC)!GO<W*=\UV'U8>5E[Z<O=XLJP[$FOQFH(4F+:MIBVF
M_KU[Y[&H17P6PX@=;L2,EM&WVUV8,9@QF+&].]3T;)@QF+%=2X583((9"VG,
MKYMX0835F Q#IIMM'68,9@QF;.]>HEH?9@QF;-?\_ D-V<<[&K%1FI_/_(B*
MLE<8,PG&S,+^(6P9;-D!MJPK+S;?%*# E&U1EB]BHPQVZW"[9=K8$8/=@MTZ
MP&Y9\J(830$*[-869?D?ZB7IFHM04==,?2=/CZ'=K5B9E5*JH7*#E3LU)"9D
M'2S<I;K6.^]O@Z#SU/W!E):$]B: .H.QWI6X\;VCU)J"UGSX1-O ;;4J04R]
M3<U,BM'+HGL%*BSNVK8#5#D]?6-"D6W(W(G=6[1-6?W MU&0 14FNI*IK>8,
MEI[/-G6)^VWO2:PIQ(3^"GOU5UCI4(<F"U4;!QA/-%E Z'D/D_DU"9U)FOOC
M/E=E2%ZZ8F5:X"9JS=VVC5%YLXRN"TT+Y"'L7B_O0V%5DDM=-6>H.2=96GOG
MAG6[2J0IU%/J'D)S7;'?KC_=7N_C\"-[[84'874Z)93"-@W&\"#*69\?30Y<
M)B;;T UIGA9BK@TW@OLU?80IW&8*]5;'L.2YKC"&,(8PAC"&,(9EZ,P%FX7,
M<=/4\!:A4S&/]C_S1'%_E/4%+,1*(E'\A175C+8IS88B4QPV5B4;>T29XEI/
M8F$C4L6+,^I'E2J^DDI4C'(B7QSYXD7[2$;+U*QV1QW9-H5WX285ZB8AZ1Q)
MYP<YE:8EL_'NKB)K"KOM[57*F!.?8_[[MA'RH?M 8_>!7?M1'"93,=O\-^KZ
MGX(HNO9O8AHS\=F7\97K4]]QJ?>5\Y^8%NX[^8;+7VB6==D=ZD/KRM3ZE\/!
M>3\;+G_9-8VA7>IP^33DIL1T^=L)FT^#Y]=&4I6(EL/B2<S_S,9CYL1BX#R7
M.[\AGS@)?^R^\R0^>*3A*!5_R*4<<;\\XD?PIY;.F>>/^5Z<UUT^7/XZ'5S/
MOY(N]])#H\5S3N?:N[X33-GKHH 5Z:Z9#<6'R^N:)F^<O*Y+F2=O&IC(7M77
M3;/.5U^R[+=I\QH@2H_.Y2_G4&)J\%6P,LV=4_ORS9^,KOSIDO/HZ/]Y-0F>
M2!@ __S<NGALNSXVT2A=^$31CZ?"+6+OS(%7[?*_,<>C4>2.76[IQV$P)8,O
MPVM1+Q.0+\_]WZ]3H__JQ@JZL.S/XK1K!8IO+("+E- I_SH_F>=RGRA/:.(9
M3!; =#Q@"NY]?HPH.'L%'[*7)N7;:JA.I?9>>)?V=#X%3M[>WP@O[LAQ[]9[
MEYET\5K(\Y]/%Y>O?ELQ9ER/B&]691%#@1I7$24'EX)+P:7'RJ5[.6,J$41Q
ML>IO[('YB;P<#S""?/EL98;=,:V6YJG:E:((>5:6^](QVE9I0LVU\]L@M472
MB\*\>8@3I);FP5371.5@JF&J<PM4UTKH+:6, JI3M7=4"[WEM@;[+N9IPH[4
MTHXHK&:JFHJ:60.M;10NM:;P/:BI;O*!Z8-^P?3!]&V.66H2A[N@%"_7>FFW
MTI6WBC%6[OM?212[XZ==:CJ.M^J@+Z7JP*AWYKM6ZZL_YILW:ETP4F_9U^OF
MWZ\WZ2/76DZ]251NP0F>VQ'ER.]<<+)?QCS6VN_*![@[1MPM:E,NW) YL?>4
M@4[<%PI4D%3=;*([-*GZB(C.T'3ITV"@@JJH8)W2][?JI[2.1-!/%702=OK8
ME5 QDJP+#\).-U8%C\M.(]\2V?J*N#Q[I9JHDA.M^C#4VF;;9VDEIL12N+W2
M1VJM:(C@@\) 8=52F"5]U$_U&H/$\&914?U\]"]B6-F\-3(YG2>'P]PIK&/*
MD!?,79&2LJ5/Q*I>8V#N0$6@HMI1D0$J0@F^)'<3=8@UXG?5M:E,"E>>I35Y
MTZZ:0L3@#' &../-R<L5[PJIKBV(A"E,-35T?Q%MK9F.J:Y1,&>KYDQBXRB8
M,U -J 94LW6U+:U-3U-6VY*'0$N9X)QC//26DP:1*RHFKJ@;_@_UDES#H;N#
MX=7%Y4"_&ER>=P?:^="TKK+AT%?=<],88CCT8CCT<C9TE Z''G-QDP<A;T+]
M$9F%+.*7F-:N;)ST?$<]\=Q)-&$LF_8L#@F2.(KY]\7/C)Z?^>K8Z)9PQKTD
M/2*>!!%[?]+TZP'2NW:'VN$)KMF-8VH%U9/2":I3;4.>FH]@[BO1$F>7_4-4
M]:W->;U&KQ'4EZI1.G6>&>*EO&^$15Z^106JNN5_!8_?4ZSTS]EAPI[P^DGJ
M]F];' U29W.ULQ@I;BP?%[=2%JZ0)4+V5IQF;8;Z?\\]\>M=/7&02(TW9R"?
MFLEG=R-4K9%12W 'TK_>1/X_R<QJQ.(M,1N@MJFL5MV6O).$(=<M0H7>0<,4
MUC#,QCC:V1A=JX0A@0W<C8-KL7J^3RZ]<STW?H)[43ORKY^V#1PG3%:;T#_7
MO3Q_0OV5/P?"':FOB)NO@DH8#O@?E?@?$NL@5= B==P/\!7D4TOY5!>Q\ )Q
M7RR<$F_NT+HHIE59T92@?#@.5<A,[\@KLU-"C=3Q'(YY2SPS!,MD9NR-U\04
M0#Y')1_LC>\C. 2PL3<.5E-@I8F]\;IHF!)K RPQ*UEBRJM'54*+%%YA-M>S
MP-9X?;F_?MJ&K?&&J: 2A@/N1Q4R,^4UWE%"BRKODX&> .@)@)X NQ&&RI78
MZ EP1$Z3TII8>4\ DK8"(.@ H&X'@'+VF910RGU+^W<>7%U5'H,R(S90]U\#
MZBA!/M(4\AB%5VOY[&R7D-^0VSXT=Q<"^0W'2%[(;X"&%1041X?L:CID[[Q4
M.L(.V2B* ]$V53Y54.^U_\"B./41TX[A:;( 3+KRFJ:Z7L&DKYET:;O\QVG2
MCV@5CUS"^I)R_;0-N80-4T'5%0Y^P<KY[ [6^ECK*\HDD$_3C#T:X-12T517
M*YCTE?,99KL+DRYUK=]$/L[>ODK:0F>:FG(TY'-4\D&"%D*[2-!24?G4DP\2
MM*!A6.(U:(FGRYNF@A5>PTT^=G/K2\KUTS;LYC9,!557./@%*^<SVQK\@JU^
MP?:6+9M>__QC$GV\IW1V=N-,V"CQV)?Q,BRZ$A6]]F]B&C/Q^LOXRO6I[[C4
M^QI$KJB5%\7*::WR+1?2N1<X?_WZ][_]O.'4;C0+(NK]%@;)C)_3\1*A?OQC
MA]^DZW-2_3)C85I_+_X<3-GSS\ZK]-,B_8$_&G#%%8=13WS;"Z(D9-'SSQ-Q
M/O[F&QO_<G)U(4:>_]'Y\_;BA+@C_@%UXH]FS^KV+_I7IJE?770N[8$UM&S]
M8CCH7@S-8;=W\NL+!5A]F.\TF]FD/ZM=<'1#^[#+=]:X3/'6.OU^V]8LK6L;
M1I??GVW):[33D=)HQZZX54T/K6J.JE5-S;I>J.7EU20]J;+P=IX5+?K[5Z.!
MS0VW#&DTJ7*]ID0/QKV[4E+G3O*RKOF=/)]E9FJ&O&1>)?1(G8#Q<9'8P''X
MDX\C$C*'\16O6#;O852-,HUJCM9E50%4[TC,M@= CQB@HF;:CX/P";"4 $N]
MBQ$<@*4$6'X-@QF__Z<6F7E4I+WX(\+^G;@S$:5M$9_%P.OA>#4D%K,#KD<,
MUVL_IOZ]*T+_68(:("H)HE977H82('K$$/TM"$:/KN<!E!+B0WH'?BY0*2NY
MNSAC^<ZFW['AUC(E1HWVE2U@?22[IR3F7XW&+ S9*"_$<ZB>R55O%"3"]SYD
M,W^KOM9UED*A>V'O/8%#-LN*$'AE$<&6IMEMLWJY*Z/%H.17.1CSW$)#)!)*
M%6>Q<X342F111X@UT<(J2XCR=>FIJTK670V;N^R<%Q>114W12KOH1:&Q(@VE
ME%A&J>1Y'D\6EMU#Z!ML)RO(=G"O/$3=]L1QMX>HFT(X;RS,5YQKA-Z:ZP A
M]+9CZ,VRVE;U4E=&A^M3&UU6 ?/F^NE+&OK\YZ*O++R9T)"=T\AU^+DN7"^)
MV>A6W%Z>&NA+3;NTNQ?VX')HV!W3O+!T^^K\O#?4.YU!W^@77@.]BOONHKYY
M19%6ZYU-8X_PV3[&*I5JNNP>97(E;"YWPI\MB83DB?C'H>@D'A5'T(B, \_C
MB'F[?R@*PF44A.N&E(IPRZRV(KSBG\?-'\G-UWYA4D"MOX1=*%VOH+ _1U#!
MX4:!A<6*,7WWJF7"51"2>,+(G]QP1N22FZ<1N6 .F]ZQ<"ES4V\5NK1&-PL5
MNUE4O!%6,CZ6BS_SCFYY),(SE[48K#YCH$99 DKT75&"L+D*2HL#0P6A@ONI
MX,X373#I9-=))Y^3J0A'<1M4B/HBJ06\6(1B07^@/] ?S(.1$L__S&+BIGLQ
MA,9QZ-XE6> [#LBY&]PSGUS[3EL63,O=AE98]NM+WQKM--=C,_E9J)U6Q]2*
M2N/)(]JF[!C#$"O(@ H37<G45G,&RQ;[+<OL2ZS3?T]FH"90$Z@)U+3+>)%6
M3S,D5C<<"S4A)KMK3/:"^<'4]1&55<$BP&(BJ@;]@?X@*ENR5_J_Z0:P2)WF
M,J#WC/B)2 \CP9A?['0:^%FB=42")(YBZHO;VT<IT2!O/5QH:)UV7YIWBU@@
MZ']7I#4!4!F$=*.]<Z[*L<R@!%* E U(L=L=( 61DEV4Y7(\9DXL',"T[DZ,
M<(^8DX1IV3@B)5CI5BX?K'2A/] ?1$K*M8LWL:CF#V9I4X%LW,YTY@5/C-O'
M]$^S)'0F-&+I0![$2 Z/D63*:_-UGC3V0Z0$]']\ZS]-7HX/< *< "?'@Q.X
M@UMT133?^?C (K%W%O+_"UU'O,Q<P<1WXV(Z9QZ9"ZA)G(P UP\F[0A-FK3Y
MI< )< *<' ].X/IMT97?:?@7B^'JR7;U,# 4)@PF#-$+X 0X 4[@ZBG@ZGWE
M:!7]NWV'K?I[)&)Q[+$1X6=+/R[$ <24G,*W@X]]6 X,9'EX;0(LJP(B\ :\
M 6_ &Y+\Y:C4Q2*U?Q;$S(]=ZJV7>\*?+2/@*:TF!WXL["KL:OY 4&D !,Z
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MQBP,F8#?=,;\B"\F@[?G<N^+VG>&71X;J@V9VY'[RK8I<(?=+</N L&%VV4
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M;KZK&:5U-5UBBP05]$CA5IV-38[YQ*+H;',)/#G5]ZI[.K2GKE0#HEJSW0U
M/C6Z[=<M$@IJO?NN<)>J6QQE5F1E\F@S7)P]71S0P-XT8)77@1LT !H #:A)
M Z;$+2S0 &@ -%!+&NA(W+T!#8 &0 ,UI8&"&C2#!D #H(&:T(!EMSN@ =
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M1(#?4ZH+_X>SQ'3*-2:* ^>O?,H#(P8CMFK$1C!B,JP6?6&WQ'G\@)_?C\.
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M\*EO5F S7@"GVSU:7E.;36$T03T)?"/PC;E\X\W!20C\!KX1^$;@&P_8C,/
M,P+/"#PC\(R'I'D$P)# ,P+/"#SC(>[3SMY)=^<@\(T_XD!],LSDZ?3F"'U,
M0G^<0%>/OE>!K@)=!;H*=/5<]BK05:"KT"?NH?;2H_6).PI]XD*?N.?J^ HD
M&/K$!2)\AD08^L0%$GQD$@Q]X@(-/C8-ACYQ2XA_A3YQ(:"ZU,TX[NP>[H:
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M2IE1C/YHC-<DY;?M8:&4K\M*K27N*/R#Z'8G.AU62AHH2#Y57>BSD(S>OAJ
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M*EV?MU1B2HXRVE,J<]%P^)LH07S,I=OD>UX5R37ZC+?>75R\VST^>*T=6*9
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M*%U#)O NU)!0)]O'UX72P:]&8+0%Z:85O44'U::F1-=H,I9NNJ;DB4OH\)[
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M+R-1LAH0\%OT,:?N K8K@;%)&LF*4H1K*9.@YB1N,^&O,!Q((6'I.M,_=0C
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MT/C-O7Q@$-<P56*0<U*5+EOF!AQ8%&(,%\YZ_YI1PS0:]BXIE9.&U5-I?L=
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MKUC42.VNW4C]R*#ADKQX<M!]O=XT1)V[2^I-0="#^7 ;0]2,ORD6C'9O@DI
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M_LN\4<$O;O(4[F#)#20QP&0=TN8E;?I<JN%?7IV_1W_9_Q[\_<O[5U$R@%_
M3FR_.S@_??.F>_#FS?G>NY/=\W=G!]WS=^^.SW;?'1^_/SI_]=^-.S5/>LZZ
M+ ^ZDLX@W27?N*[C:ST^V7MSQ'^\X^GT8$?Y<[RI&^=?[AX>[_?B%N6V?1<^
M%[J$F@AN*=OQ9,H_-8#@2A7W=?5*8P5J[VCWI_(F+CB)J'%Z45Q7-WF!TAL1
M)B3A;:6SVMLY7E,=DZP:98!=)CK2KN =^,/IBBNV]M;5$^^^A?XM^@?8S2"<
MC9)E&D&O=&*'.]WU'S4JH9PYC#K.%?]!>B%+I AUBKQ&!?,64S#^?WO/VN0F
MDN3W^Q6$UWMA1ZC5/ 5X=B<"@=CPQGJ\88_O/EX@B>YFC$ #HMO:7W^96542
M2*C5M!H]VOB#;4E4D965[\K*1,=U(@P/FHEK47Y'-6(WN>A?@(NR^\*<>\^K
MRFT;.<MH2X,5EC&;6M2]Z*T2=5F*\GW8JVY*;]TV!JTJ,K:HQ3 E$H/P7"4!
MKWDZ1$,M+[#^+8)6 HR21),E3Y$6^8@]":L^+7AR(DM67601CU=3U0Q6V!OK
MS8!-!XN+-OL>Y])M2BEA6#,37\W  :.2;N;"%YN2!K< MW;=J@9LPAF\*&>"
MB-5JBC 5/>'U2PG2/PO1)GN-1XGG73-TKFRTFR(FM-'RX,6PNV0:,KR)1\<4
M^R4'$>,%5%!VC<PR4'WIM_)/FRNBE%).4N)^,MJ-5%2&M0UME>K1<&LYPM0V
M_&:[8J%U"8?W?EM]P>M+9VAH;KJ,'U^AK?E[I0NBN/&63[)HS,OQ)05E.PBM
ME%>LM1V"!YU.\E.KLK7M,E3B8N#:YA0W!#L)M4]"H1#Y\&S:?H)W70G8RH+^
M.;WCY_*D"6:XQE7Q48GQ-@JS-X@+L+BY(L.:QEA@+;NB:.$\#S^(_VPQ;GT@
M?A7;5<U*T+=Y()W#I/VU:2B_,MXZ;+ARTN&#2P;>OF3@.[+IR.9G(QOSDH$_
M+MDT.P,&=WF1SJIGMVCIEO5\^3-[OO(5^='T39.CU$V5O=;ZULM:UM9VW//Q
M,Y?*3JP68;UY'(/<-N'X4>8_)#H0DOXBTY]?QL'D^VV6%LGTBGL\4_KS+-37
MFB_UR)U0AYQVT5OCPFTY;$Y]H9 &6W%F!(QQ+KQR^^$NFH+%W-@WC)([0.6B
M?MQ)2?454&03&MQVY3H:[&BP+1K<I+[M..'^%):GZ_4VT'Q!>K]^"]Y]3,3Q
M4_[^.<2MGH"X]V#]7,G=684F.RG[\E*V(\0G$^)'BHMW1-@1X0F)\//Z1*:C
MQ(X2.[W<$>+/3HB=7NZ(\.1$V.GEGX 2^5LH<V'K%1=!IN>JM)^.V8Z$?W(2
M/D=UWY%O1[[M&0J-[V2?55"^Q2(YI534EY('+WK(_F)BH81=VI[C9E2S.T<]
M +HOMX[G-G#V+(I\5)3"N'$F3>(PR/[^)DF3\,WU"@GG1H6OS"<X'N(NC$-5
M53D"?W8LV+%@QX*[E*1M]M6.!<_*-WN]G/;:&*H-.[/CE8Y77BVOJ)K1USI.
MZ3BEXY1]G*(H?:/CE(Y33LTI%QL2;"4(V,7Z.B[KN&S;K+->3EEU/-;Q6,=C
M-0:AT;<['FO 8SL+()>?/QI@/T&!*JHP*'T)YT4VN0ORFN;M!U6I.G&?/JPE
M-4RID?:-Y%$A\33+*V4FL8'\;1;,L'Y?MD*#5,SQBRUDO"2L;[6^(8V/45^R
MKJK6.T+0YO9+_V;8>-^7/A>\4]G6,P)CTS3,*ZW%PQ_SB!6,I@+9?<F)8U;\
MJX1:T5@VW3D_AV%5-#P+%UC!NR]]>]I WN5:?#WE9:UI$E8;_$>$K?CB9;L;
MK/>UH]8/K2V>1H7HTYSU!SK>VM\J??TXQ,UK56+%N24(=RE,L&)_J^\\4;FX
MEZZF> +A_,\"" ^ODY^Y:#;Z\FE%\V"W:.[Q.M</05YN3$#\_\\B"25-9L3X
M)/F[^T6L0FR]\-T]ZER$KR+WCU.]N>4BCEK?/(X2:;W:K'9\=7@>JE [DC!I
MF1+?*L<2BJV3XO&6LF&=Y*_8/'D5U6S;7D*[];9[6 R?-T2*EZ_ 7O3#<4;-
MH0!URGG;C*I\Y(89NTQ'Y7FFXZ< 'EX5&^.])W;;C;O?PNS&.<@]; L1@WHM
M<M:V+;VYP:8,%8BQ$#CV?"Q/3PN\&I/YB&"&22YZ*- ;\@UK=#<LV];H$2W0
MOGH^]D[+%L[  '?_*(L])W>_77U$+>"FT91";"59ABU1=FSY4SGTG)!X61TH
MCJT#G1DVS\NE>1!--W0:IX$(XZX@/T5KG8@:)4G8+)!U$ 01G$ZHXY]HYHXK
MXVUZ<-XK; L4S/&<0'CKU6:$O(_A/%BRYCF55R*U;4]X)28<!S&U],5&F]F4
M:9L /DT+T9:SIOGAX\=%TZUN@T_M'5AI.%B,\_#/ A8TNL=5-6DPZ/JFHMNJ
MY2JJJ3E#;S@:>:S!H&WYOF(<M\'@QN'2J1H,KA$J,8S^]&=KWY=WP<-WZ?>[
M, OF8;&()L!*'Y/)RPBELVD%\W'=PQ68Q4:3BVX^8^-<;$]5Z?J[[C(:DL&)
M'Z8AN"OIG)JB\I;>("1NLY UUR7ALQN9TCO^VWL)9"-:D]1:E5FZK&WO;!XD
MK-59'$LQ-I<-;D,QY7_S3LV*^4N.WWW]W?DB+<+)70*[?KN4YG&PN$FS6:E/
M>8H-SFZP'_D$<S!0ET9)DMZS%J_Y#!O,SM(XG!0Q-J8-@P43G#?4Q6X1T0>:
M+@F+#%^#Y_TX7XB6=@]FP\[#..^GKX2BKY\<L@?69V+Y/$URZ@&&L[+^;6LT
MXIAUAU@T$L(,V[!%_UDUJ44[8D'81-2PMJ_X1M8V#OO(5K9M3Q?C2Z1:$/1)
M6&I/38M>T1WY#K-@2D>;Q1S0DBR$#FS?I#;U8[F3P"N<$XC"L,E<$.<I+G7%
M=<Q_#N"O!2/]8\9/U6,%ZZ**:03SA&!6)^':\ ';Y2$$!H1_U\R5I<L@QO[C
MV&4YX?XMXS;6J)S0&O[ N PS=] 2VBT!\<DD#X\>I3:.17"\'>--E(%O^B?H
MC05K$T;*H]3EO48&-34,=]EX94/P6QY^OAGE"T)S_@3KSU<U"YP_W7-,UY2U
M@6/[0V;].=9@: R/:OV=+-4&&\#-P1T)LI5&>:3%>+Z +Q@3\8[L.;9_AUV>
M!=^!.P3Z>](?Q?26<QOV_\SS8C87O3V#!1-/U$6>-R*=IQD%L;BCA%R3YR'K
MOAF V(B0-7M22'X!!DB!$@K>792S6LY-$D9YTY7?P/QKZEU..I7FI6=+4_>E
MSVC2 //?IJ@^QT$>Y60#L7[M(:%EYP)GX>(NG9()P"4%QKVJ8U"P "\LTHS,
M!(0ZBZB3*/7/2\#9RZ(4T,DZKF[A#( 9AW$4WC.'$.R1'"0<F X]CL-5QW=F
M-)&U@[^PM:!] ;N$BRO!/L8>M&1>!5FVQ!_)Y=RU PS?M FK+K)LSW! [:[T
M)6>R*%#"<@!Q[Z<1;'XFC!20H6LT-94.5<8OBX3_ 7PB?CZ2&9LO1D #B^7S
MFM%;0\T8J([JFJKCV=K0,(<*DQ;^8"3K@Y^R&?W'Y![0NHHF"'Q+ N$283QZ
MH73$"_8AW;(X;1E-9V.:?WZ2'F$^4LAM"?% 29C="W1% ETA1Q?2'#\)82)Q
M0<H,!$&&'9:3\":"R;)E7ZJV.<5'Z8 "\$,=J6'-N]_24NSQB,1J:):J&37$
M2N_[#7S7:#;#E",PM#[#/\X_CL.OQW02?P,/GSJAJ+)L/BFV 0@B WXC@E&'
M+NG=^MOW.QWY'>[[(AJG4Z1F,6X5:<#?':\<1@BF!5!K,0O&/1:QA=%7P6P9
MIQ'%A0,QWQ+T>3(EOMLU+UDIS)!X- C1 X6=%#>@!-EQP^ZEQ/$&&L'MP0!Q
MC@Q8]LDE^!"2]8>!%O'.&&POYD(0!,7:(IV$&<:6,>C";<^8&M4S;Y9OU%2\
M#KNO*RI/U! 6!O=3-IPZ$4 1(XL\$KWD2_-BY EKJ[Q0[.1\^.)_P[* WK0B
M2Y1.'C,0!;#,C&+\PB!]1.IN3#$.)T$![ 2#*-&<1J4/(>Y]EA:W(LA7IA_8
MWBGE!S [$\F%"7[F0^"A:$F&@V\=S>8!?YK$][(2%02//4EG@!LPO-$X#H3M
M_2 8@5P:\EIO8+\E[ ,LZ'&GHX]GLZ3&BHS)$Z"?.;HS8N1&_(V=>=<$J=@I
M3YY6X,#PS59H@N(1@G;7(;\2<0O.8\X)^F:KZ$<Q3Q..SSMT)H1$$$RV#IB$
MY&V_.JH';?!YLDB9,E!(&00S=G9*8A)HO)26T5PMO,.S,38A\\Q*OSEBU/LU
M(=0_4(I;MIU%9QPMYT7$78&P2VMF!Y%W 8A_4@8M+U@Q_MKN*M?'HCQ&-@?'
M&#U[D%!)>)LN(C*'&5L# U-P %!#]F=);0HQ \\6>VAE;2*LA45YQIHSA)(4
M65D5_?6Y/G#)IV#)KNB4(NBER&J[5'EJHB0=D%$DAO8SO*R=[$GCY3'WJV6>
M8A?9VL1SW:Q/QC6=YR7I \Q!0DP8G7>@"R6T*6/, ;J-%A0KS8OQU2($+5)B
M-X<LK"=98Z09R)AG&BNO'FU,HWR11>."10Y92'22@I7T'_;X#!\":9O=A@1-
MDB88_LI T[$34.[_BOA^BERP$> W5\&_'(VJZ<;/5H_R0^9S4):(S%=G0GQY
MW!A$);8*3&1A-!L765XA1&9NWL1@VS*;<>\Y$CRS%9@OA5$ \4#1Z0QP[=4D
MJ^,77;9ZEZW>RA:(0YL5I4]9\C#0.M!G!E+SI6-HI^9_C"?6GR-M.LZ !DS\
M+(<:,85Z=VATGN81BWMD9?$/.HTY(23C(PJA!+NE1IK=!@F/S5"@AWQN4)/W
M$?HY22K>R((H)8C9X1,XV$G9V"$-$= Y3KQ<.ZA\YU_;]JX]LXHSZ*PTON16
M_,*263&*\B ";$_I,'$NPACL^B97J2Q((H*".1U)IA-F2JZRDU96B7 F2+-/
MBISRW\?I??B+=)<^8!:4>*O(,@YCGJ/P^%OI5?RF"3X=1GSKPZI_#(2X\@2V
MH5I=1D 3J!1_69\* M7=H.7S+DX!^/Q]$],*X1KS)%F.'%IK7_+32L)JE%!$
MAW%.4N>[9V2;S=9)6S113YK'F*V%QZE3"1-.)<5N3ZOLB,&7R.F>A:0^TUY\
MH4 G8/DNFF^?#KVL%*=4#30F]Y[9'(G=S_<X[ULR^1D/](0:R<I4R7CID4,Z
M$2J>IB2<RBX."RO'P>1[.1S\:-!W=[Q7!'?S8E+*H\_#]4$>'@/FF^"+\\>H
M>I8MHJ'C*"TED:YS4"O9KQN21FB#UQ<Z=?+64R9/Y$@<Q1!OUY?HU>3Q"-.E
M(75GX1R)FW*F2KJZJ,J]QY@>,TS;OHST5K5>35F%M[IUI,(*&[>+*; V"WY$
MLV*&P0:6,@="&*VU:AXG"L_'LC%R<(1FT?KQ_;3XVAP'H2'I&*^28;!75S ]
M*ACS$30_W*%OO>O(4DQ023Y8Z5"A NM_E9BW0/KP98-2J.F!();B#714^@2_
M="_-O;RWNIU@^.0T0LP]!(+Y_N$F31=@ZX3_@@_2#_HJ2Y&^[A:+^8?KZX>'
MA_Z/<1;WP4V_5F59N\:?K_'!-_SYQ7(.S\/,=([X!J;F<\.+^"-W&:8K_H72
M$V5#T139=TS;\#7%T!3+M5AZHF5;AJ&*:8'TPIBG-.X;\W_Q.*Z"0S<0T^R-
M=+T?GJ$_5.W1P/<T;SBP1J["YW9-SS"L>G@>'W,0/$-O(*N6[MN:JGO>T% <
MD^969&, KZV%9\^80^ !&:9[MC?P-<^V%<]W9$47R>>NKXWJX-DWYB!X;,=V
M1YHW<DS#5"U'<51;K-5Q-+L6GCUC#H)G)+N&(BNNYMK*T+.&CL5Q/]!T0ZNE
MYWUC#H%'563-<Y619NJZ8OJVHFB^F%LU=;\.GGUC#H%'DQ7%\0U9MFU'-CQ3
M<X>^N+HZL)5!'3S[QAP$#_"K,_*MD0>;H!HC7QT,!>_";NBU\.P9<P@\NNPY
MPZ%B*$ (FBNKKC8T!:_ -[7TLV_,(? 8P"6R8ZB.*X],W=+E :=-P+UFZ+7P
M[!MS"#P#S7<TR[-\F-=S-7EH6 :;&^@"Y%X=//O&' 3/2/=4U=-\4$.:8<N^
MK?M"EJCRR*N%9\^80^ Q%==R8&Y3'>F*JKH^B!"A&ST0?'7P[!MS"#R6JILR
MZ&A='@UU=V0"[E6V5DL=@%RI@V??F(/@T;2!(?N&ZBF*:>(R%48+BJ8[LJ[4
MPK-GS$'P>+HVDD$Y(G6ZWM =6$.!>]6U:^EGWYA#X+$U!TAP-!A8^D#W94M6
M?$OP"HB\6G[?-^8@>&!.U7!&I@LB!.2_[O*Y@5=L7ZNU?_:-.0@>7U$LPP2Q
M[[G +"-E*.N6JNF*[]E#4]9JX=DSYC!X--63K0'@>CC4#,W795W@'O1E+3WO
M&W,(/$-[X)NF(ZM#V1YXCC:TX NN&Q73K=6G^\8< @^8,;9N#8%U1^K( &T$
M&IO-/;!=4 -U\.P;<P@\'IB>VF@ >%<,QS3!--<L<1U+!SZN@V??F$/@&7G:
M4 8!HJB*:YH*"!9@63ZWIX]J]<6^,4^#1_B:3C:1J+< ]0Y@H\!WW^-W\B>N
M,;W_2DPEAF,:TW-\Q10&\:FN3/CC:J"*;-NP77=D#TR7"1%'\6S3W5XD@'22
M!39P/LL+E >F;:J>#58:&&:F#%) $0M4%;_&"SK1 IMXL^4%:IHRM'U5MRS9
M=AU=L1Q-$PL$957C=IYF@8W<XXM<8!-_^Q))M)$#7UZ@KFOF:*2Y+HHF#Y9J
M#&6Q0-VL\R1/L\!&$8%+7&"C$,,EJHE&,8M+Y,%&09!+W,%&495+7&"C,,U%
M+K!)W*>\P!'P*TC?T=!7]!$8LP/34<4"?7":SF6!C0))E[B#C2)3EZ@'&X6Z
M+E%--(J=72*)-@K&7>(.-HKN7>0"FX0++U%--(H_7B(/-@IH7B*)-HJ07N(.
M-@JY7N("&\5PVQ$R&Y'EY_# 4Y*3-I' @,K"/"VR"7X[BP&&Y/;O;\+DZMO7
M-[^^4][_[;H"Z9-A;Q*1:P5V]^N_O^74U((EPM'=%];)8ET^8X&)=J)Z1KFD
MR"2+Z-J;A&TR\"XH7:.A?+IX5=B$O>(V"Y+%ZAUF_[D8:V(8MX*Q+U^W5F/Q
MJC 1Y>#QA&)I\\%)FOQ1)*7RO:RN48(5 X.'()OFK/9 5&TC8[&ZDM4'MN9B
M=[#I.BSL41(^2.%L'J?+$%,A:T&FS$UQ)Z!:N-7NR;)<'<6O\FUWLWGV1C81
M?&VQK?2/#'-_V;TM3.N=!/&D8(G  <_M7M=ZC/&RA6A00E>X>EC.0U2LFJ79
M0A2)PBW#*QM1)M@FF/#<S"A9 !14@XI=K'PV!IM(UE8P^*E,(;Q'!]'6BJP8
MU;X4$WS:QU%5+BAQ $L&IJ&YN([.KCUB=8"%E!14,@WWE76I"..([1&[EH>=
M'I F^*!H1CG>-%]_"ZPU>XDW47F*/PJ6"[XI7C$/.*Z(U1F6.9K'49AMRE(.
MW88P97U)"$7P'Z.&H#:^^1=\^/6__G:-1!!]P+]__7]02P,$%     @ [XI&
M3N9YE)$\)P  __4! !$   !B:6EB+3(P,3@Q,C,Q+GAS9.U=67/C.))^GU^A
M]=-LQ+IMV75'5V_(5[5V;<MKJZIZYF4#(B$)6Q2@!DG;FE^_"? F09"@5"-X
MZ(B.+IE$)C/S Y")*_'K?SZOO,$CYCYA]//!\)?C@P&F#G,)77P^^/IP.'HX
M'X\/_O.WO_SZ;X>'?YS=7P\NF!.N, T&YQRC +N#)Q(L!]]=[/\8S#E;#;XS
M_H,\HL/#B&@@?SS[[B??6>(5&J @X&06!OB*\=4%GJ/0"SX?A/3/$'ED3K +
M(GA8?*)0(/<Z0'R!@UNTPOX:.?CSP3((UI^.CIZ>GGZ9$;; E+C8^<5AJZ.3
MX^&'X<GI\&  BE+_TXR0F4EYC] ?A?+/,^[]PO@"2AZ?'HG7,^3CI#AEE(8K
M-8$;\*-@L\9'4.@02F%.G)2NF:A($/J'XK&?4LV1/Y,4R1NIRN'Q\#!31G!U
M@Y0DK\K;H^AEOBC1*$ZH'R#JI(H_5PSU="I+#S]^_'@DWZ9%?5=5$-@.C_ZX
MN7Z0M>3@M[\,!K+6D-6:\6! *VBG&OL\*"@;U;-KYJ! UNJ\NA6B(^P%OOCK
M,&/Q"WSW8'!D( (8?8'0VER,/&$D2OQD6W$X\TIUH+L\DM>V E4K97>!)*\N
M NDJ<HTX51+QUV%"=R@>'0Y/MI,BZT?,I$CH=B'%QR/$'0$UP.8$A_AY[2&*
M L8W5_!W.\D\S@M<+C,F0L2/0L3ANRU$E)PI7@C/TUZD/-5.Y3 P2T*Q]??5
M?J2-&'G*VXAPA])TDZ2[&&KWU;+]) 3BPV_-/NE#J+!@CT<."VG -Z)G>M^F
M2U/1)7\<9DPZ"A-R#H%;!VGRA.E?6\OC8M+8U_MU1.)'E]Z]P P_.TMS$5(J
M^6MK(0A]Q+X,-$Y-0,F1Q;\/,Q;=)*&(.+YQ[<BHHI];UPN?.(+=T$2(A$;\
M.,R(.PH0K+EYM4BIY"]-M4"4LD!R$H^2A^LUH7,6/8%GPFM_2ESW/9X/9'S\
M*7:<^BCZ:,W9&O. 0#"5&WU(!DN.YY\/Q!#G,!G'_*^#O%\@[DZ*5#Y0#"JD
MDP(2)_2D$M>9D D'T6U_/O#!VAZ.-?^G*^7BN:E20$(HL5@G#\U,=0(2[%FJ
MSIIC4W6 Q(=1?Z>*)QA,H<" P.!RY#CA2M1@[$Z")>;G; 6\EYCZY!&/*8SS
M\37S_8.!H/IZ/]9-"$C)VC),9$JDRBK=;R?#X?OA\?'@<'!!?,=C?L@Q_)'C
M/)"L!P7>@XCYX*^"_;__>E3F6OI>Z(. ]#?YNVS-F#@NHB$L-?_6=,46IB2+
M'R9@;0_A!0X0\7:/9,)7!^B;X?LWQR=; 3KX:_RA5VCK(!C^+&R'S>">[@;<
MP? 5W@H*4S3S\.X;;LQ6!^WI\/WI\7!+:*/O] O7/T/B2VY&L.6HM.[Q^$3I
M'C/RGMHZ[D2F^#D(D=?-\B4>VH[O&/Y3M(Z,6=:OQ?SZU K.F0=1-^,@QB,>
MT:@ONL>16/Z2K W:1@M>VA9SHFHQ!:8#1)/>K,#W%;"<,4:SV2/!<9T^V25\
M)<[:9G<"S>Y-)S!%\YS-OA&<-<R3UR:9MU!SB4OB(V(><>[^TXUUI!*3MJLC
M;6N2E*:GD6LS5EU]L3'GQFKPMELU>'7=.A"^8 KJ86=I/*W0@7<CQ)6IA;9M
M./U4+Z<7FJ$P'7JVYJ@==9Z<*$:=+5MM_T:;,/A>D4!L O/!XN>,!H0", XQ
M ZZ>B3ZR?JN,K%-N$JD"OU=HA!4Z])N-O/3]Y%ME/ZD!JJ=]8I.9.X0T;5DV
M J@(:=L V,\8IM;JYEZMB97>G;U5NC,M<'UT8]1G'G'%M/(9\L2&P8<EQH$1
M3G4L-/B ^SH]EB[L 4PG-U-+>#)6@YC7(&+VBDG@WR$.6BUQ0!RSGK 5OP:T
MWLK6U!*MP5\+O/O:HE)K^9/Y.?*75QY[ZMBRU*STF+UI:&$9SP&;#P37@63[
MBM9<L7JW ]P43/4(GI@AJ%@0?,529?9SD-=H)MV0\RNJ/QW5RS]#$FRVQS#F
MHT?LK1%B$<M7C.:[ZCA;]95#(XQZUXXN,">/<AIO3/V RR.2!K&(FEP[234\
M54Q297P&.49]QR&)Z'['[J+#+)4!3^UDQ_!4,5NE1BP+%P?1!WHY;Z4TO/+A
M+0[&\J"$^*L B<%R[FX^UU@%*O-=-56@YC%\>Y!]O%P]^K5D6X.8Z58./9M&
M0"O[-FJ0Z^?^#)UQC:>=VS!KQ*NR>-Z$5P]GFI6&-IUCUC'1SBX/3Q6SRW4H
M]6]:.<G!,:+N)0U@,#2F<\974BH#='1<-/ <IX.!-!=([J>8]X_8#7+\>@3.
M)>*4T(5_A_G#$G&#\5F%4A__?U#$_PF+P1KS@6328\L;!_IU#/0>Y8,BJJ_B
MT,L OFQ04P=20Z_W'1\4OD.%1__\QN5J[;$-QF>8 MO@SD,F9SF4U/I]-*HC
MCPF;0<QG(!GU' 7SP:J6BW[/A>K<HAJ5G@XK5;;5V'L[T'2,&W&L=G1J'!O@
M[16XABL;S2L8$(N]4W5T?5NGB!0V;Q0%,GVL]4[5=4GZ'M?EKI,I2NI&^U>F
M+TOV[^-L260"X^@V3Z6/:=^I8MK8[OV+8Z\0X=^0%^(;C(0Q#!?;U.3Z#GZH
MZ. %GX%D-,ASZCL0Q@Y RT7?'PT5_J &EEXZ")UI#08;>C:-$%5<1A-$_1IN
MZ*QKL(JE9],(4F45JQ&D7BUCZ:QK''FU8=8(6&49JQ&P'D9F2DN;!FHZ)OJX
M;:B(VVIAZF$@1RBB#D%>ITU32FI]&*=*F9&RZ>F6*949S6,X#1-]3Z8ZZJR$
MI)\!7+U=3>(W'9=&>*KAFQ:>G@5O]:8UB=UT7!H!JH9N>H#Z%;C5F_9T)P"=
M-@-4#=7T )V^ I2/A7?3TZ7,&N%Z9PA7S/FUXRM:>C?]7\JL$;;W'6'K?7=H
M/!ZJYZ$?#JERH-2 U+_!T)<0<40#;()$CD:_$T.U0)D1]\C*O^,56R^)1]##
MFM#)?%YYT-[Z+7AI43E6H9+Q& @FA\!%]>P5LMP#X^%J>Y9:KW.L6H]N"6 O
MA[.M[6X\I6K,N1'8RK#7%-@^SK<VPV :;+3FJ T]CE4KZ*T![5\P$AW@G:)G
M$ZCR1/IPY%CA^.(4ZY*\GY8V=F,*6FVW=G*L\%=YN_?2*56M:##AH")NQ*#B
M6I08]&L^H6I(@_D#%7$C"I5I4S4*O9H>J!K28))41=R(0F5N5(U"KZ9$JX8T
MCH?K630B4IG^5"/2P^@V9U33,+9*JHU73XX5\6H1ASX&I2Z>!=BEV.3VM@*5
M?GN *N]OGKRGMNX0EU:)]=/WJD2^>2X]#4PK9C2*3!74C2@H0E,%"GT+32N6
M[."/:WDT8J((5%68]-(A9X8P]\@56OWJE2KE<1&)/KKD -$% ;5'OH]E+NDO
MC+E/Q#-J&_5,] Y;/8^4<!M$[&1.BH3A*S;""AT\>B,O?3>FGGG2(=53E]]D
M9Z,(H)E9(VJ*@* 5:GT+$6I-;>Z7FECIW91ZY*C'K(^.ZQ&$9]S@)'A&HE_5
M_ZAT2C%M'TW<P=N4*/6+M1^5OB5FT5,W4C1@A^&*FD$C$ IW40:BGP.5V KF
MWJ!(J%_E_JCL^U, ^MG-1YE2_3']AC@1%@!OB$&K0.:I,[I2K!T[_=JW*F]S
MCN^ T$'">9"P'B2\7Z$KVKJ3:VG-5;]4<JK(O],:R%ZZI6M@M#!,4YFCT;>K
M-XIVE1'WTLK9+^-VHF.B;Q9O%,TBXY'_V<<F("_XS-^<D.Y_3V]0B*S2'JKV
M+/4-2)7C)+J/M'#30[9A/[L,(N+_"F/5YL8-SYBSOC6J,J08@?K:2EN 8#R^
MZOJ!1K KXZ]N8/=QC-8:$],QG"EC_<X054X)0Y#[-PZ\XVR->; 1>2]EQO,_
M0[(6-FF/8CT+_1J5*BY->/V'3,099TU/^+W"DK0'@S;6R$F_T/%&X2:U(/72
M+389V=@-MF78"%[%[;4#KX]NKM;FIFZMB9%^F>J-PHTU@-8_M_4_(>(!YMXF
M]>87*$!?*0I= DZ^/59-C/0C0]6*5LHQ%VD(GH._IEQ?D4I-8>S/6O+3CP=4
M"V-M<.NE<VMG<6,79\:V$<^*HS/"LX_^K@$ 4Z_7CIU^"*=:IFN'8_]<X#T6
M64&<(.2$+@I_M,=,PT._E4-U@4F!OOC7*RSP1]>.LC5'_1X$U:T8&LAZW37>
MXT=,0Y/>+Z70MQO5W60):0_M>[:!D8T+5<XX#*SEH&\$JCO)$E:#V680,^ME
MG)?8H7L_I:1O!*22GBP%Y+4+PKZ<P2Z9UAP3)9=&9"H'7E-DHGGU"E!]! B\
M)N:/V+]B7-B*A51N31YY'GN"<+5+[@1SUHU05H9'*7;)1P9SQ@?I9^044_:A
MGNY>-P7"(#.#.>M&C"O'X;IBW*O,#AD0T;]7G*U&-"#G[LGQ%'HYM,9A0!R(
M#!8<K;IWP8;\&]&NY(?(H1W_F,.G!N);A^<7)\>#W-<&R>=ZW76;3G&4Z+1S
M&<>JZU8SA]F_^8H'O!"K%9VNY%;0ZB?F5>.LF$E/K]^NFM"X)ZMGH9^=50VZ
M%&#TLBNJM:GQ\*N14R-(E1A1!U(?QV15$YMZD%H.^GEQE2]1@M-#MR(N+3]#
M0'V'-H87Y2AHM6YEJ%KOE4P.9X++(&'3:_N;^Y5:%OKM+:I5W B-LP(:_70L
M=48UF(?0\&A$INI,=,CT:UJAWJ['NP#GN!&=H5F[&0R/7^$1EMU)VVEN/$/3
MQO/:>@QGWS0\&GNVRC2;'IQ>3:;5VM4@6ZJ&1R,VE4DQ/3:]2IY::]<W.\#F
M33,VE=4D/39O7K$!,[S= 39OF[&IK,'JL7G[B@V8X=T.L'G7C,T',VS>O6(#
M9GB_ VS>-V/ST0R;]Z_8@!D^[ ";#\U!=,U,31TV'UZQ 3-\W $V'YNQJ<YF
M:K'Y^(I-IR6!)DZ-.!F.=?JX)E"QL?&:0!T'[9K 4+577HU.#Q<%PIF/_PQ!
M@4N1X\LO_VT 3A,G[8+!J2H/;\9B$/&H/GF%*OW;?#6A)4-MWW=ZK-@MKP4.
M/_9WJ2%<K1#?3.8/9$')G#CBV*LC]Y@1NKAC'G&,DLFUY*=M><>JI#TQXP&;
M#W*L!QGO0<+\%;V2M3LT0Q.VVL9XK$K?TA[+US99:_Z?U39;M=&38W'?X3:X
M)K]>@2T#8!R#FG#5QJ7'$/145Q<-0/V7CE9_/7KVW4]HO29TSL2C^ &E+))>
M/A./L!>E)D(S/^#("3X?!#S$![(.S B9_>\(&L]0!OSW>!UR9PE1?[RK]P:O
M9I@?#"A:X<\';0H2SQ-F3S[B0UP3D" 4$GWA+%Q_/GB><8]\(@%>'0P"T.?S
M 664AJM/+ELA0L?P0JAY,(@*KC$GS)W*@F[(X_V>1V;JO;U\N+NK*E-\;*GH
MA<.4YV#]!?85JFB+V:G:NW:JZ8M9JEK;]M14\$6I]S>,^)1=H "W5E1!8J?*
M[\\97S,@Q@^!^/]B4]514\92I28K2F:A+U( 16F&%$K5E[%3J0]MVUY300O5
M^S(]+^F1?V*AP-=W]Y/K\1\EH<M/]R9X)NCD?'P!1(]0]!'_3X@\,M^ NT'^
M[]A=X,MGQPM=[)ZSU9I1H#S#<\;%;:.I3ELPZ*)^]&0%O ((B,OZSY GCN*!
M\GA& I55"/4#)+(SFJ#Y;7)[6<:R^,S"*CB;?2-EAU1\9D'U<QSXM'OYO,;4
MQ_Z$7H74%=$.6ZV(S'9_CSV1=73*SF$T *,>3QS%1-!QI3IMQ>(G5D&'8]>X
M#N8LP[B+2O 5GUD G^O*,1SR;@B,.0,P2;QJDHJL*V&O\5.I@0U$X/"34,XV
MR LV(L!9HXT0G(EKDU>8BY1*/I+S!66MC>D[@0J(@HJ..!BS/:3_%\;W3$Q9
MG,TC/G69'(*6[0E:V)0]"*''] Z^P45$FS/ EESVX1JZ=;.@&@( T*S45JO/
M+?01'OCL+[@<_9:?VBCX#\Q7E5%S^:D%/>2*\8#\0Q9$U!VOUHAP483-1PZ,
M+*!_*%_+EVK3B=2VAI-9 GK#C4_\R1P4"VD _U+W? GR8]'V55V$G,D46R+.
M/.;\2.VR T9;5(P@8;-]W?#]<+46Q?ROO@#S&_)"23:9WR#^ P=R(\)# !_[
M2DE09X^MV=AAC4=$I!A7C N/\("=D)/HTJ19<(."^*_1/,#\"GHHZ2KB1B(&
M&'X6=.R$E66CDRT-=06=AZ@8>#LCY=G8:R#,T0+'*FR25B!DS93,S-"N<'=E
MD]J_@Q8B194-&8(E!T_@TV ,,8LXIA<,).3^#7HFJW!54J\MC;W>HY4>,+PS
MUCVEL4WWVN#G[/+V\FYT/2X&/Y6G]D5MX(>( \[Z@G@A#,@O$8=AT<*_PUS.
M2(YBNE2CUL6[0P<L@.?63?-,+@F/7>S(^_AH%+1YMSCDS'<(AEI00LN 8/]1
M;"2M+ZS.Y@Y;<[9B@@A^S"&@8-QC$'_Z1>7:%-_3:+>^AA+FDQ61'4,9K\H+
M"QL88:+/"\AC1?KR<PN%Y\0/F'>SP=Q_@/'-K#2BUKRWH(6$/J'8]R=@YT>"
MG^1VC$TE5F\NML]8O!Z:6.QX>WJEHZY]O:^.N5:3\S>Y)&ZE-E[SSKZ6<HY6
M,TY<B%I')0T4+VP4WU\^X"#PL N^7";? 7<G?;I?KEHMR]I7SS1RES%K4=).
M$.<>>_+%Q3IR(A?'*S!5]1K*6:P<C^:1:E0JO]V_&XIW"=UCARVHF,OX2EW,
M)R%7[M(H;#"*=P&D2NZ"DVU#JLQ.8E$B"DHG2;V\D]'I= GM;LD\=\HN,$3F
M*_!LLC%.YO5$<NEBRD;P$3>_^O7S/V/;$EI]D\JTBI01VH)F5]#AA1ZJ]/NM
MB^]][-<@JGK2UI3(BBG:<S%E,F-1R8+8F5J:$A;W!CFI$_>$Q+X"<5A4H5FU
MC&WM4*U;-  7HV]?@YNJE&W8:?J9G"9U Y:F0O:%D^D^@70;13G.TI6P,,)*
M=^>(9.WG3!YBP%0>DJC#S(#" J>P$EV$+!AO31)C_KMDRZ7DEU.M56$KM HA
M6GE@\^!)3,%2]W?$7?$SKTM]$<N6C#35D\H7HE9E6UG*+4Y;QL8V1Z%6B3:#
M[Z!C7R%'SG0@KZI84SD+1CJ5:65$W>(TM+[("_)H\6!+K,MF:Y+G(>= 5X:N
M55D;ZZ92\%M&3?14%+>@IH8K>4+N$<N-;M?X$6=1I?J=;=%D/6P*^4?/Q-?I
M%[]OIZ,;?'()R.#'"^C_G&A+(?6%K PZO=(2-E0YV0A@ /9(?!GBMMV$&5.*
MO1Z9KKMAMI=*W<I<HA,94S&#)9[?H!_X^Y)Y.-7X'KLXVF$EMQ'<18N/:)$&
M/=LPV/>&WPL\QP"3.T7/UP3-B!?O 0*;0NQY$>* B6!T7=S7;4QEF[MMU'_-
M,8RF!'E^(Z:\MZW)"'I2VSKW!DO 7^>2[3GB?#-G'$)YU]>;H);&LOB_HGJ
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M=AL&N@*AD,AUIU:EWAKM22T836#AS?ZXX_&"C&)#N+Z(C2B*&^'JDA?6OK4
M"V5.L\MG\5,DA_9"-SHDY<L;,>,7V0BF,_G+F15*54S3+]<$-"T*[GTU)3V
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M)5@U&IQ::CA&!A0B N_$><NU#/;DLYO[@LOD%,1=RAML,KK-B2H[?<8V9*M
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MYE_M-%?T_XN=AOSCMCRM'4TJ@2WXF(Z 4YD4\N"8 [!%6CUJ$P@,J\WV428
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M0:BD:5,)\Y8;QH72R!EHH40 26^)M!X9QU\8U9,R/WPQVZBG6U2V(36KV?]
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M]?9XD?1XRM7(1ECUQ9'/V>JQS%^R:39+)T%^-;X+ZI@OU@MPY8,XRI:3VDF
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M7!9\6BBAT(3_8X6P5B#K&2);EYX"P#1W>\L+4%0;*/HZYX_SA@G2D+-@NA)
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M='6=TG!CFI^51O=#][M,M@"I^00["MBE1Z;7)V42SBG@W#EB/=/ .:= E5[
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M=1&,NL<,9!N'U!-X]D:.1_Q&8@#2 D*E/4**(FJ]JZ+F.<*ZQ>3VAKW)9]1
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MRBN)!73-(X8Z,:TC(%]T $MC1;YZ9G:32M07L[OE)*T>^MJGUIK5$T0E=T@
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MR"8/>_<\[9M..(+:<LT($08A8S5BU:1FJ??-KW3*RZ%'_SCVM3BL7G)Z%/_
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M= S.>7C0]IT6!1T5 $OI+11,.@JMV:X+EC0?IQW?4QW0EK4#G/MG5+Q7-P!
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M+/9. L>DM]8!Y:R#VYX'^ZO7)^'CO3186Y][N1(-LH&0I7*V/#0GS+:)1&'
MB106Z?)>L-;,;8-0PJ+<XI;]69^G[(@T36$[\QWGJ^S[8IE.GLMT\3>=.=#
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MN=HNX:^F4'7Q7^N'DLVG+ES'>PR<8\"PT,1&P\P*C;"L[0)#.!R1N3,@S_*
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M;5,"G,M&W+MHOA;CZ,G32?T$*+UABCH.354FW1/!9(V%!)*-^U0RM<(/\6E
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M@%9(R!GPM<W&/2'=O5>#G;,/1Y3!8,NU=7UJG3=L5Y\^%I1"7!$I$&7 6,>
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MWBF*_U;5J_PPWVJU^#C[6?VXBJR?[=J>-H,--8H H%8"6&[C@J&=@(*S^J!
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M[-D2KEW\UWI;S-*7BT_%G]N<WK/YU9=%.8]_G6Y,N&,QL"?U$X363 !H'/+
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MW%U>%I&7/XL="%\C<;\6TW(^K5+'5CK8BO/L"3N+#1?%?#5[3-JYAR$IN@_
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M"'AS9M2]+0(0DE.DB;:602<=!D37<2B \Q$F64X72Y,&DZ0'[:<<L0>*B-,
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M2,W#'<2@\ IZ[CACIG6:BX#<B(%IIR#XL'#%ZS#3FU59SE\PX@&CT<X1!58
MU4TTK7$&8@$ 4*U0*7"/V./DU6('(7$R9.)5FNE?/\U@IU[SQK,%!0I YH20
MV$.F$:O%^NT\O<#QIW+RFJZ#4# !)J,FO#Y+Q_Q8S:\.-HW;/:A 2G&&!-9,
M6%_W3E"BM9(2Z3.,VAHD32X90J/R@5HNR]7R<-/ GQ\NE%"0&L+" 04,U4)@
M(EOK.+3Q@O1@U=^'HWL?9,:B]V]5=?V/<#YMG1S7=KV8SK]_+A?3ZGH/Y?<-
M*QRGUF*H/<5 (NOJAABMN8"X^+T_6)7W07@@(49)E>1CU.,BZ PNZ \PS!$H
M[2%@@K1*!);Q]N3!JK(GI64J8,;:SG6A@M7BL;G Y\=^ MOSYS$0^?"=WO$-
MA?/$>V<1=9 P"P2DQ+9F!M>M)D BO^ I-_DP<(W%+D]ER+^6J]5C+KW[Z[Z<
M+_=52M@SJ@CZA[2RKBPO%$%>*DU;Z=9R&Q\3=KQ-_)1LD0ZBL5CA\Z*\GTRO
MOTW^>K,7PUN/%0IJM!%D,.0"4!<TSRU3F\#I/8C-SXK8/3 Y@5C?7;-[_7QA
MA:#:2.*A 36K0LA,N[8^ODIQ5O1. <YHZ7E75XMU>=V6?NVHV>\;5F?):QZ0
M"HM%+MQGW''<K%1P'F_5D6?%!@DQ&HL;WBZ)L.^\WS&BL,PP'$1?SSCQG!OB
M&WN8L12)'@XS<%9,D :?L>C_8;+XLUS50NK7,G!J=TO?_H$%IHI(1)D0EBOF
MN?/6-:N509V-YX;S,O<EA>F)*4Y?W&X3![*K#'6:FMB?%]5]N5@]?)Y--LI3
MO;/N[YZQY;A?W5]Y>YR/G[J6X,[YM3MEKZ9P:'!M$L6 ::ZAA )C9HR4,IR.
M3@JO+.]4,GF8E3^%2.U<1O=Z@OM?46#BK9(NZ 90AQ,"<&A=@X+4;,P@^;UU
M!%,2=&<UP:1838:I(CA4J#WA"BF'#8"U9X@H;!UN%A<TRC$[2D3&$Z:BWL$0
M^^.@.FU(MM$,2\P<0XP:A3T'3#1S-=Z=78A]9^P[Q&;'89,W/?.+%3PY&5/%
MH\2%V <Y7@C$-2&80!@4,8IX,SND34:=F9)@O"_$_C@HQE)+;7F_*(/6L7IV
MS;PA43U_K(!&8F>,4+8N<0,1<P T*W&H1_+Y8!KG@/)3#V3&HG'3!-A4R]72
M3.ZGJ\EL^L]R7Y#!KB&%HIS5D5/*H( 7Q99@*RFU&$CI,,LPR&1 VB="Z10>
MZG?S@,OW,/GE;XMJN4^9W#.JL() 9XG$0:2$3&DLM&F TY#&GP2#A9L,R WI
M@!K!_+1?71C6]O(?Z\DB;)S90VORLI/5Y/?Y9'T]73T=2Z?X]JF;OMGI<O(]
M\,VC _O3S9?R1SE?EUV,/H>&%M8HI3R5@>$<-1A#2*V@EED-. KRS>E,/CNF
M?LC,LV]8P8@'!!*(.=",2,0LX\UJ%?>=5CN&:2<=V5X+)NG0&<B8<[KBAN'L
M%< B8@'D BII@DPN:#CHC>0(B6P;QJ6AZ:%"AL>A$RF]C%S/#A$HF 98&&R@
M T$1\ZA9DW8<Y&D)ZD^B3H7MXL"Y#,)G93+*A-Z);$;;TVE9KR](F=.K:P1J
MK^?D?E,U][Z6D"=W!\H3'_620G% .?7,$HN$M4PBT.($F#F;(HB=*52-!-5X
ML9 ;2)X0V?C)#Q8PWS>LT%I80Z#RQ#I*J=?>RV:EWJ$Q&RF,RA0#@#,R&W2E
M>Y-VC0R&'EH('%$02BV);M9"-,HH^V500D>A,8+-H9ON'1]YL<MUT?I(;9T^
M4FW,'!^FLW*YJN9E0-]4L\!:U6+R(A)IIXLC[G4%%5!RZ#P$U"J.".. *&J8
M5>%61SXJXB+)BG>IV;&O*@@10>4 BBF.);(\,*%[7"EV0-DQO71OJM[CD+$:
M%<4Q5?0(!\0V3E>M5[?58KIZ.%#V^.T!A6"8:Z 553SHN$1(R70#B0-^3,=3
M)[5]>-K_Y)!(@-MX;JG7DSU8OW;7D"((+TPZ2:US7 :A5A"AFA4:;U&>ZGTJ
MLAWD@EXH72(_9*7UY\8&B=3_W__MZ[^%G_)Z!GM$^9W/%L AKB3'W!G-*')"
M*M!>M0QF%#R2#O(J+2@];#?+,@R^G<ROKY^NK4F=>;4ON/+ L ('/9-0H:D$
M$#(&#;*M]*2"6#6B*I[7#3X >D/0?G_4WL&!!>%8.:3J$K/28^(=MKA9@4>Y
M]A-*2YR.%.^%V#G2/JL[.6>2)R+UM]\^'BCVV#Q0(. \!91P3974PEAHVDL'
MA6LHGYLX-<15 CS&$Z"W&)?OIS_J[-C59/Y]&FZCQX1I_?!A\M_5PLP"$ ?U
M[Z/>5'@HE;68*12$$^"%0L(W>#@YJN$UKVM]'$ S8;"G-3SU_8YGLK?>5A#(
MZ^ \65?QT\8*1+AL<)'>D3SEA\&YX#AN2XCL+\YK\,E*>KD$ACL5HWU>5%?E
M<MG($.$>>'X]'')(=AI?&(8I\S:(CQ)0111^)C] UJ.Y[H"6C0$I_!,WI<=P
M+/Y)U^)1<"*<)EP K1FVKK8:M>O3*KL6CZ/+5&F .R5CI&O;%]00RS6!!GI)
M+0!0/VFB5D&1MUS4FY)']^^+P^M?@U>RE&3R8Y%$5IA_GRP>JDU_POW&F-?/
M%5R&]2&"?#@P.952$P";^7&C1S6GI6KPV!GS*ATR/4RE=^7UP^?ZPY.K383E
M9'8HEG77B$(9:;ACLDX)-I0Y&.;9S%E3$&]!&;-X=PIJ)L,HFJZ?;Z;_/-0Z
MX_DSA7#(*UPW8?/8(T3K.N/M.J6/SXD=L^AV"MKU0"6:6FH6])'?R@-U"5X^
M53C&'9000^^9Q,*3<&<T<V.&Q^^V,4MKIZ!8+UQ&2 ")SO"BD%I%@11&2&BQ
M54JU!GX#2+RY9J#>N:-I3XD0.X_D'V(% 8Y3H8-HZ)"&P+I6$F#ZW+*^.I.H
M4Q90'#B70?BL=)Q,Z)W*K5Q>W4P#5I,#SN67CQ7*0N$%UT"&BPQ1;TD3Y1:N
M'M"C<\G(F5N=4:Z2@3&66>)OD\6TOG.:LB=NOMJ46=4/&\OO]&9ZM<U+WOSF
M4)!WS.L*I[%"0@E#L#:,(&%Y"Z\@/;J%#M3X=W2KZ BHCL5OKR?\YM(.!PD?
M\YH"H[I/% GJ)9<04FP\:'T6##*3I\0P#O%?U[L9'M=_94[+2D0Y?P9+)-U\
M+->+Z=W=>E[N%V]>/U=@5G<@(A)[ >J4,41E:Y2$S(Y98;:CR6$8^*MT((UU
M.GP+7_MTHQ:+R?S[)GON@&#SYO-%;9"F 9_P$>6YAA#BUA[F^H2^']^Q)T_)
M)05L8['$LUDN'[N-39Y^\BW\;3G9U(';7=PB\DUABRB G!$*6J(@%QS)U@CN
ML%!Y"R@]:?RZ#<PHV/WBJ2Q%D;Q9*9&XH1?3<-+./CR4B^77_UE/__ACO]BQ
MZ_D"4,:\,UXQHC 1PEG31O91W\-'-9CX,1A%JO1X1=/W7=V3=G+ >?7BH4(J
M[Z0Q@H89.>A1F&4K38<_,JIF,RHE^X#4P_GX9[FX*P^4L'KY5(%D.**DDMXX
M#BAPD)I65#:0QI^V@[F+1R%@+Y3B-V UGRY?1AL<H.;N$84$UG*):RVF#E @
MG/$V)-50HO-S*X^S-5,A-I8D]OM\43Y6\OXM@/B^6BX_S=_J+U;7_?ZI_UR
M<5-?JUN3O]2?*@"R!ALHK1;:A+M*,M@BJ@R+Y\%A4O7&*L.3"=YC<?#;D?.'
M^TOO'5<X:X/^[@+@$@%)PBG@5;M6K^/30).+'B?AK93@C:9TWE6+U?2?6Q/?
MZ[2.?3KFWH$%8)1ABZP40%HI)<&BO;X!Y!D).2=AE:3H10L_MKPI%XOR>C4)
M#T_^J%O?A*/OMW?OO[T+/PK7]-5ZMJLSS'$O* !601S'A')+H:ZKFOA6< !
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M2(TL19YHC(%R3FDD_'9MF" ;KY6/<\*GXH'AH8LWN3R>2G51AN_SNC[6[_,
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M#+;$-VNR%&><59Z 3IULQ'$(70;US\@Q,"[14UFYJEFUNETOYH?:1[]XK-
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M 1= &*$Q=%AK::!QA#9SI8['!\><5PYL9Y)U:))P'*3)R-\UX_70N,(2+72
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M!#2HC@O@1FQQU)+1^+#9_!R)G5EFP')$QX!]@8Y$;B2M!>UP\E*!% ><Z08
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M;.ZJQV/.5XMWR^6ZYNE=K-)M=,&=]!()A[4Q83G.:-QZ>P&GE]DWX]@@Q^$
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M^BR"3LVO/U;SR=-/OH6_+2=7&]GO8-S[D6\J%%;&0^HXU4$$, )Z(+<;D=2
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MZ#'%,T B=L14(AH%B&+5<W[V7/N_H<X*U W>U29M+A'W  \U*'?'>5F<G2>
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M#K?X@H@\,]#4.&0>(U&1;<4875K!6-[=YVU838[1///B10Z)"#9U?0!!)S?
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M'JP0K@B$\LS^8(^G[&VTPBY@*Z+,@'M8>#FYL1;5%#-J0:,.-=J]]'X+?)U
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MKABG=T.VV17+Q_37LM@\-R?X\CI=/O:-64;@QI[I>5[DA(ZG$U\;&@L"-R2
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M0WSP=G:+&?6@V_L.&MA<1TQE^8(A5Y[4#4 !_!UZ@.NT[P2>D''L5]PCT /
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MWT&F/C/S(>=L"#3RFME0>[D@ZBX7/!B'PG<DB1-Z<M8THJ]F$&9'-;>8:$Q
M0G9_VJ-9LM\>!%D8L19XNN4;.+:QY0>Z'@_'!AW#LF+VJB#7YU67_GI0W9:2
MW9DFB.+RT<82_Y0S!HQHDY$%"3C*2>,,(5#R&,/!,7-/"KP0-W.0;#$#"FG]
M!"*K9?J4;6@+ST=;]%Q7CTP<4!'W(QM3,;>&E1_'U,V(75_%VE&_9-R@:^Y3
M?I8@(X*<LHCO>'2"%XMGQ"1$F<=CE%.B!9AE5.NS%)R4;3G$S4&_)5E2R.]6
MXM=>?$O6FW3A&U%H^J$6N6Y(@X<>:'@;0;P(8]'++MA:4:SFYRX#: &*7[K
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MCMW/!&/7C_KAX?0,:!*EPK!0XPK=0^O9\/Q8_G6?W79/6)E8JS,:[^DY<?%
M:\N&?VN=^KO%W>+9\"8[U"V@?Y*,.]&GNY%=)JL<^TT(DF+NFZ-9K#_KS<*"
M1+Z;+RHZ,AW+BS2[/>!C4:2'[>-U40-+ME7K0//=_MGNF+,CXP3B %."ZU$J
M\H"#4-"#13"*]=UI91"DC/RI/:36@;:J$\ZSO9/Z<IC)2$Y/82L)H?;Q7.>7
M-83YS+-VE'86]O,,ML8-*^I!4LQ@,[2*]2>P.4B0R%^SQ62F.Q@WD'B^[>#
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MUJ*4R;NT0&4^&BM8M9K!R7S6%JYZC\9P0_+Y_<JP+--J$X0^B;!/$' ]ZH#
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M)]*,REQF:4QT-'"[$@W2X<ES2=+&COA@KDYV?'*\L=39A=^S<D,91%YM)0Q
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MU 15GCTQ07W5WTN".HV<%0CJ1 =R;0U%0E"O_Z@;R^-3,[5@,\R"T&=QQ$"
M,/'ZG6:1&SM"CY@J?[AA,6TA*4BI$E$"0FJ:(SD9?4J/BH@J\20AH:;Y4A-0
M6=[$Y/,57R^)YQ1:5B"=D^#GFIJ'S, ^V=[!W:ZYJBC9?SRDJ+7XV\-UWD)
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MHI$3.RF"Q*3,%#-R0B5$B1$%.O-_1%]46%J'>B@ASZ>W$;F>_R&MVH6=]_R
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MR4)V&J."M>AL5$J6DY<X7$B81GD:J^^T\+L.B=+DR_,J2R-#HF+ULBQKGOI
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M/>;U)9G6PM0*5%J/'[GN-B3YL%ZR3\O/:74L#KR*/Y7TG57B8N*Z-/* C=V
M!=3WG*&.9TSJ+L"IM@SK=8=,\F6[J?R)31?,29WD3 %'9G70FMF L\F!9>[,
M>H.LD:D 732O8Q9 FS?/GWO3RI+.%?OWPXTY?@@COZYG:>13YJ$P<.U^=2NB
M'A(Z'6?&\OI7[M_+WM9E*$3ZEO#-1&?V97R1P,R^EO]^Y/XOLS'Z<=;T%7Q3
M6-=795"T5OPU_Y:VAYW&IX _Y_L]:T^Y;$*;(B^T0P@H"QT/!Y%OQT',_#I%
M>+8K53^:L+^$&O=^6-E!9$V%NV-U_DBN:!F)F%C%NG2P-(BSD3@9J7@5R!ZI
M@DV&;AV5L5$/\_DZ@LX=!MTSEAOF,%ZM T*A9WMV0&P_[G,'XI>J/J1%EN^^
M5$E1Z=AH(&I7IO,_ARBL RB]S0[-M2U?6U@Z=Q (,ZQC"X$)6N?80W UX:(*
M4UL(.BZ5]Q#(QF(=(JG9)ZE=!&J,B2U,-8<BJT]%_BTK^2U8UWG]]>ZXK3ZG
MW]+#,1T$F1_BKJ7@.F\F/-YUQRFK_Y,FQ08X$4 A<".7 !LZ=NAZJ <&(1;:
MP#HC'--+72T4?GBQ\Z(] L^%M,JMLIDCS/I#\)7U6&.66<29)V0B"V:KBY;D
MREH7@),#UG5N=2Y8G0^GFK;W@O]2.]'[KC\)7UG_9Y5!E%FR6UTP%=?V7O:^
MNM,]=$$MNJ 6?5#?[)F3%P5U\'IQ]7#6H*UAF7%>A_/%.HA$#C];'16&]*D>
M$A0<4+EAJ 9C0P988+NAC9A'AJK"QP'J;VR^%LSAAN$(*<C3>YNO%2[;.]MH
M<2X1#QQHHPLR6U=,1T@@5Z\A*DI)^CP2TMFY\:#)S6L*ET167E'8U-+Q>?BD
M\_!9;YN:AJ<1>2G_SA2>%23>N3S-YV_\$JGV4_+8P.G7^Q\>]EFZ@\U5:-5;
M",_+@"C$C@/]V(X#ESDD="@,AZ%\!*!LTIT-V#SIMW?G/XIN*\W9'7)3Q\_S
MQ5 @+:\K;FJ7"74N#-N>.B>LS@NQE*TXCIXOF!))>Y5!54O?0T>T^IZ8=-%-
MNN@*972= VI=[%[*Z;-';P79?7Z?\R7[RUP9?RA&-J[O>+%M.X[S_[/WKLUQ
MXUJVX%_AESM3%:$ZP_>CYQ->K/8=N^2Q7=VWHSYD4)F4Q%NII$Z2<EG]ZP=@
MDIF4E$EA@P#).C'G$98E.??:"\#"WGAL)#["#DUH&+;(DLBA[J3SO3RL!<WV
M:IGW5,UG>JK7W&0S3O2GE'R!S3C5)&^F.6>=XD_C<]8)_LBLD>D=WFY_]\E=
MP6-M4[LJVWJ/ (4ACIR8>"E+(SMR"(\QXLXVHC%MCP"QG>2;AGJLP@\ =0"E
MA8'_ YFS/W_C(RBR)/^=CJ!(^Z1T! 7&F.Q 9-E>'#.K/N?[K_?9/C^6N\1!
MC' 0Q#[S4H>D/HULU\$^GRZB)+%]6_)PF/+GFPNF.D@6QV0UH'35=06/M4OL
M# ROT80N8T2-=Z/4W-& ]U7; X77MVA7%YMB^R3*VG_-U^(-MB*OV(_U]FF3
M;U+NN2BL_G0(#:]O7^,\%$&,71J'%*6ABR(44C>-(Z<#&5,W 5UOG1::Z9L+
MK3>B)GW?'^ODD-5Y9(E^9O5\$O_HW'"'U(2=J\7E]'7!C0U3Y3G:V<RM7ZTM
M,C 3S-3TRY@_YG+^]17D.=M =JX:"0T_G_^ I@9EY$1QZMDH)@S[/$/T&,,=
M8H1=J?O-2\!I>!;3I&A7ULWS1754J<X[:]>0F^'^+KT">+9*K1&-S%@&&1Z8
MOI;0KLN8RQ;!1+F\4:=CEOLM>\C;4J!AX,2>Z^,DH@1% 6&V'W1F_<B-QT]5
M &/SS#=7EH"H6)9X/,%C!-\0MUI46Y;6"=7[1!=8@A687K*.JK@C)8;*/$F=
M?OA:E^L_KQ^%O(K58/;PN"V?\[SY]F?>/>^S*A>OA[6UCCP?A3@(;.10UXV8
M2]/4;Q$@.T"IW*NY)BQ#1J/2B[@-,*L\ #Z\4]A"MJKF1X\MZ.8E0\#6M^XF
MD#BI,"/WP.4:$.DJ%3-ULP\X8#!C*Z@=)("UQMA3 C!Z+IT&,$3R G;]37E6
MFN^B@ GJ6_&0_T=>U;G8J:SWQ9I_U9C_?5<<BX4R*K8M0\)#_C3"D4U9Q#J[
M#DL<P+2DQ9[QR4B@_.5[ U,<UFEQMJ/P22 %2* >BB6FG<FYA4TV IYUP&>=
M %H'U6L@JDPP>M@%3"N3LZPVF31L#W;AL1.(#!&7I@VM)"Y@LM#K3VFJNT'.
M;>?[VW+_( ZMG,Q]S>MZFV^*7?.MUK@=V:Z'>:;$\R;7CF*/X*-QCWFV=/$2
M?28-K\OT@/8'E%4=L(K3ULVW(0=T]=$M,5/,PS1LNNB3W)\COIY(/GQ;8=+0
MR#;DQ/,LK"L>:M;&ON2995EN+AY+UD[N J85 TZ51CODI%O:'X\5:G'D):[M
MIS3V8Y<2YH5!W,+#%*>@!V G _7WV*R>="<:T**3;#N;:4P]>\S@8U0?-=7[
MGGIG^N- 2?#9VGG)>R4FW=:[P:S*NU0&@[.J6*/=A@I\^>;BT6*'.KY-_ #'
MV M<YC.*NHUL'."$ 5:W=)DTOL#5 &V6F#<'J%;>*<8C5XQ*7OGU4BV1N\S!
M,4RQ#^1RB%:+\:P<OW]9P2#/@*QE#K[5<A:93CUVT4N2C4M9BFXR%Y"C:'>I
M--CY -/';[P'[@6M1R.B>'KB^W:4NHRY49I$).F,("<F@(D"_N'&IX0CI'\#
M")("21(2;Y8=F)@?L:@IM@)! &TV2Y2:"A\QC97:-\Y=$E5U%A8@GR/ EUIZ
M D 2:;XK'XK="S,L#GP6)3@B"+MAXGG(Z2[F$9NYD"-+*A]O7!9[H"#"J$25
MA#2:Y@@FCCTT:O*H1!- ($W3I2:1/51C1?*,@Y=D<@P7"Q#*4?!+37T"MK[]
MGWEQ=\_#5L25)[O+N4;?Y/OKVR9TK:Z?ZJK.FA(1392[(I0E-$B(@S%*>#3+
M0]FHPT!=N4<@S%@VO%+=@;6R UIKU\ 5ZYCK\N&AW!U2M\HJ3\"G7<$$T3FP
M3&FF69:Q%FG(MW**C@T;UO3MA9A.1RB/MA!C ?59F$8!<6W4+6,2AX.1BX8T
M&#(>%[';VWQ=BS%ZW)RHCC E(R4=A,KM TW$)#!Z.G<'I>-U9QV6LQ94Y^0R
MB0.2IX'Y9>B;#D=*[;T2IEP?=NM]\WQ@MB7-S'K03537^^+FJ1:WU[^5AZM_
M695OVN)C:+_GW;;Y=]5*)(])G I\;I!2VSUMU) X)I*+8!,",JZ$)FZN3-E@
M<@JZL):"*6T/O'5 ?Y#2RNKC%U48CYI\FM^:W_SE1GAEM6Y9?;^F%>'Q[3 @
MUA,V\C)$?4J'R]D&E(:LM=V >1-GGYZ86$619X=>C'WJNY3&V/62;@^&^)&3
MKNJ2^SHB?]6  93)'N'"([K'LN9P"BXW+S)8F/@;:P@YQ5]"&\!D_KB0T$*V
M#IB/V_"MYO=@6R?<"UA1>)]<Z-J"QN9:AF ;]U)FO4$[JR,7%"_A61&;DB"T
M'8)<EWDVM1ULMRAH$F!OM"2/L&U8BMNQ_E0=#JNOL^WZJ2VVK7#D:<I5Q4N,
MPM<51[?-@L>\#N_DUA8UL2BUP_JFH%S^HW[*ML=E@3AQ:)Q&CN_:?AQ@.\)!
MMZ!)F<.H]%VKL88,;PFP-T/3^JF%^#-@>W$TG1([LE,R"0N'SBP='DE4VZX=
MS2=@ZW9*7M6V<=]VTK&[N>_X?&EG5Q=5"]CEU>9*:: K:=S];5-^L3[X]>GF
M?^?K^EOY)>]6"J_W1%S*VFX/XR3!,?,#WV.)*% 4VS&*P@X?3_Z)MIUAK:@,
M3Q$G7/V-8OEKMS,TTXB\>_86TI.)=\NIU=5Q';99(F]]$2NP_7;=6WU_%A&=
MPYM!]3R D:9>=$1OTF_(.0*#S,O57MB7ZSS?5.+^U*=L_V?>K ;3_*8^LU,8
M>BX+<.38OF>[;N@'E$0IQK'G$9\RGP(.8&JU:WS?K4-[N !YPFL)P+T]=4A=
M *W$2R0/LS$.DW-9JM6R"KVL0PHRS,6^8DV&%ZWP<&J%C6B%T^F;T>_' 6BY
ME)(8H78!^8D9OTK3G1*6N?0AB&?AT6[S*:N%[>?K6_0]*[8"4EKNQ0]/J%;4
MIV[B>)2$.(X<-T'^"0T.? >2IYC"8#@K>3U&ZTX9Q;F0YBU66'9BK"GD<I$E
MM,*8J4K :JCO4(L,Y-6D=64='?GEMMS_(EIIVE1#D>6!Q,)TNRTCC3#N93GM
M: !6S[EH\-=]655?\FQ;_'>^^54\%;IR4RQN-6 ;.2[_3QJ$*>X@I!P.[-B>
M5M/&$X4.CM6\F@HL:*.59#G1G8U=F-*^5<T7HMI@M8[<_SK(O9FZ,P >![34
M2',L0T#-N/:Z1HPY_C1+Y4?^-9?KP _"V,%VZ@8!(WX8HS0XRG5,T&J7WV5U
M+OE<L5[;4L,Y.0SG/DRX6&X;0$;44I9GK7*ID^ )]/+C,/US"N8!VGC%!+;(
MWTHRH;ZI::82@_+7W*KL[FXO1*0IWM4^,W^ZHN)XOL."P(\P%VK?C1GUDS2)
MPB#FWV58^FK6.#/F!NQ+9")S;+'-> -KD*N!(:F+Y64,0FW>O+F0I9,EV8'V
M6[G[O:OD'1$2.,3FS>^&,0]_DI@Q;H&GC!Z*8PQ:0H-\KO'-^JJY2_-7N=]N
M8#$%B!TYR3%%#$Q>. K^)[B LAXEZ5$PH!HJ1"U#(920E^.["6"7]\..#Z3;
M?%]VS[N$4>PRQB*4QAZ?P!&F,3FH2V+;S)4J *'VR89'_PD/8%<03L_PX#?/
M#&SXGZ"H5+"'LP/8%S7*DMK>IT07DMO<?.W;I0U,90X6L$FICKW4T0L &IBB
M3Y__ZPOJJLP':4(B[/#TA2;8(TD4H,Z GX12;[LJ?*QA]6O!  8WD!4)W3-'
M"$ST6APJB@<D!2!WYLA1TSIIDN04[X5[E^1.C8,%:)TB\')T^P-4[M/7S_MR
M\[2NVWRR"RH#$3TBE(0^Q9['0TL<X]:4@^Q4*MD;9<"P\GWZ:K6XNI43R&$\
M9=8D]' *PF#*>(8K%954)@V@EU.0IZ:<2B3*J>@%IR_IZ5B.%J"LHUTH-?89
MR+L/[#?V&7W\T%IPG3!-XXA1ZGEV2,+(">+.@I.ZB;3( C_7L+9V:""O!P")
MD=!1@YS Y+,#HJ*94%X@CR>8XT?QC01IGB3?0WCAX"4U5*1A 2*HBKP<WPD@
M:?3'#_\+X<Z SQ+D,=_WF>>%R&$\B'4Z [&?8/DT&O2QIM/H QA(Q@AC12:-
M-D8(,(T^X%!*HV&D0-)H8^0HIM&R)$FFT7WW+J;12APL0.<4@9>CVQ^B<K]_
M0I1]^=3I:!"AB'J8)+[-@@ CFG8ZZKHQ ZP6PC[7M,ZU:"!C&DB,C-*9XP0H
M=2T0):T#\@(1.W/\**J=-$^2<O?"P8MZIT;#$@1/$7DYOA- Z@%]O";?T#?6
M6J!18 =)Y(=Q'#,<VGY,O,X"SY_E(SO@YQJ6O X-I!(-D!@)R3/("4SR.B J
MD@?E!5*0QQP_BO5WI'F2K+[SPL%+DJ=(PP(D3Q5Y.;X3 "0/??S\Y9J'DIT%
M-W5]@E*<,)=X-@E<V^TLV 3+1WG SS4L>1T:P-"&$B,A>08Y@4E>!T1%\J"\
M "3/(#]JDB?/DYSDO73PDN0ITK  R5-%7H[O! #)^_?\H7R\+[9%UFZ2''='
M_ B%*<8T)"@,L(-BE':VHB3QI<5/V8)A&3SAZC;N(#O$ZKQ):.,DE,%4\@Q;
M*H*I3AM .B>A3TU$(9U.3D8O.7M)4$>3LP!I'>]#J;.[P*Y<?%W?YYNG;7Y]
M2[+J'NTVX@_VSZ?B>[853RM\:YY?R'_4F/O[YRIV(\_#3L@\-V111+AAUERP
M<@,FGIZ&W9[7;!PR8-0>N'EZ>,CV3>F,VV*7[=;B78.LJG(N/W\5]7V_S G_
MG6U>559]G^VLQ+8VV7-E%;OU]FF3;YK?;HIQ5_=-58[FB_SD.>QFB.Y&')X4
M%M!ZL-FB RK:A'2,-U_TT%I_-'@M =AJ$$]\$05&YQE!-=PNR[C.8LJY<I*^
MK>NR_LFRY[@QHH$7APRE7N@SC_F=Y<1W/%WE3.0M&E?A7M6]4ZFW5EK%JP;B
MBF*=WQ5K_KWO^>$9"FW7]P',RZGHU)0#ER.&KNK/+ID2W WHI$[FER&.6CV2
MOHBORI;\6XW'44RV/-HJ;HM\@Y])N6ON(C]EVZ[V%.7C_I4R4TK%.S-^XJ4T
MY8&RG41'2#A( N@KC0:A3!F^KD^(>T'KOYTI -?36.B+C2:;34Y<%]->,-7M
MP;9.N*V;9ZN'_%3)3V"?78O'4#T@TI.TX#+4>QI7WSR^.!F_LGK?KX,EZKI<
M[WH@7R%(;4;#R,,^9BZ.D8,2FG0(PM0!/L*KT[)Q-;]8!+GJU5+*?VB,BK4V
MC)R S]4B,+U^4=O/^DD _5D\7-[7\;GU&<#D@!R;:(]EJ*\1STKSO1FPN];&
M?]>WO6<=7ED-XH3&CA>[E/J,^LA/J-U8#0+D.Z'\'2$-M@SON+V(AJ%OYFCC
M4V+_;6(J@6NK+8O7MR_?L0'(G1EB 3MT$Q.LME=WH;N.?>+@?=\O;=UI9&T!
MFW@ZO2G-]"W5C3U1<FS_M!91_.X.[39?\JVHADK*JIUT5I%'HS0-2.PRQ[9)
M$L8^C^O=V$5A&D5."*FUIM.NZ1F@MR_T FRS0=3"M1J\K9Y)BIB1-H!NRDU+
MO_J.W%CF#6_&O4NCU$Z<OL981K1LQ+.+>W"ZV9-?B>C9)??9_NYT79_Y<8 (
M=7W,(W),G!B[!X.1[=,T@DCF"#.&%?+EV%P?H$$7#=0YE%TCF(0^Z)) G[D6
MU4PE+B\3-)CICV9U&5*EPY$W>;PF;J2#N7S+?WKW:[[+]]F6*R#:/!2[HEG3
M*[[G[,=COJN.&)(4AVGL81M[V L\% 4G#!C)78XR8]ET0'< >V6U<)MHXB5@
MJT,\TU@$\3D46AAIEV6,6$.^O0XO##(HM1Q'LH>;?;&YRS]U%==0%+H>C:/8
M\]R8N$X44[\UXB#^/>G5-_A'&QZ91T!7UB=( 4@%CB16U,S2 PL47C"C<HA=
M@2+ VIA9JM26PH"4R2V$O7'TTKJ7.B,+6.8: ;[4TBM&)&"?>2= /XIJ15QB
MAY2EA'H>8A&Q:11TMC!!H*<!U"Q,FG8)5-8? A=P^4F1/86LRPAQ8Q(N&<[,
MYUH=+;)I%IC&9<1K(WT82JX4&5'6%UH^9,5NY2+L!,A&:>Q$:<3ES..I7&LM
M9"0=I3"2-F;0F .RL2HCRZ&BSAB@;[S2O,?<-%IS0 %1&R"9"]4;J!?O*8X2
M*W(U'7A31J3</Y;B--;7PYFLYZY2&"',%>7!F$-3.[*1$X>M/1>31&H;;KP5
MP[HCH%E';%8'#E+F8!2'$NGA9/3!=.<"<TJ5(D91"*D;,165:IDDM#-*UI(8
M</I25JF%J 4DF'K\*'5W(:!$AP,K_!YE3HQ0Q%+?MR/LHSBBG<G 80RDTF,,
MF1?J\-7F/(%L .HA4U*NI^(1K-@7*%05[5%< G5[*DZ5I5N96WD9'^!@2,EU
M4+<0,=?BRFL]U\>/M*0' R:1RZ+ HS8* L<59<B3X#B+Q$X@__S,6$/F)3W0
M(NFCR)24]*EX!$OZ!0I5)7T4ET!)GXI394E7YE9>T@<X&))T'=0M1-*UN/):
MTO7QHW8ZKZSJYF1@E>^_YQ^+7?ZASA^J%1:5DIJ:ZWY :1 '-/ ZTVGJ2!6.
MTVIPTF5= ;(]4MO M/X00*T&Z9AE7F6V%=9\IR!ZS *P&L<3'/0[SYOTD;^1
MM"]PJ7BT2X/' +7P):M]U_5]OO^MW.W%75]AOCVNM,(1CM(P#I$34#L.'4RB
M;A_>#7E #=$[92.&-:[!9?6!=:?Z8)*F3J*<C$W"'TRZ%*@SHE27J!E0I]%L
M+D.1QKM1:NYE@$3Z2]NSJB_YIN &ZWQ3W^_+I[O[EWMH^_)NGSVL$NS2P$U]
M['DV8@QA-TY;!)[O4OGSC)KMFH_!#FBM$URKQ?LJOVD1 U)&W4T@D8W/R#XX
M,/O[$ ](W6=L +5,7F-#R"7V,(8NY?F&>%Y VF_*L])\+X6<J#^L.GS)U^7=
M3A3:^'W'2;U^VI_=0CR+BK@N8EZ*;!I$!"=Q1!WWB,IS//DC^.:Q&)[&NK6W
MDPM6XX/%G; N'488J[)3-*'$E+>PUH--@_^R#0>YM["L!E2\Z&"^(24O1XQF
M\]*4.V$[+6 :GM+;<I[1,/Z&_<J.*'-=#WEQ;%,:^YB@8V2 0DS&WJU_U\"D
M:_3:;M6_SYO*ZKL!RD:MMK_#UF07Z*77T8$$+F.5:IP+$M?E@7PHZ4F[%H_6
MZWR;"VG;T/R1)R;%(7X(,+'=F*M9B.W0]1-,7=(A(,Z(:V0C[1I6GQXL:]/#
M-4* QA*MH$L3<CQ&KEZ7,[JR^O13&?K-*]HPE[)"IZE%%JA_NCP;DD6M[,FJ
M9:\FW6]/XJ3&]>U7+L]Y]3G;_T>V?<K1;M-L+]"B6F_+ZHG_"-U4367HE6?'
M?N@ZONM%3AB1"#''3NV8Q13[+$A!\FD4B&$]'55'=)J6D-/7Q30"<+6C5W;T
MRCH@%XUQP'YE<?16 [\1X\,&:,\#ZX_.AXD/:XRA>T"3)VG%98CT-*Z6,XP2
M91D_0$%/]7VY%WG^*D7,CE@8)\BW4]].[(3@SF+DV%);L#KLF%ZK[BGOE54U
MZ*SL"$]9C.%\@K76*)5CI/0 S$+OLVA:'U]3)"=_RL0N3MW4/;DL7B/94=:F
M#U7UQ*U1E :>G3)*$VXCC!".Z%$)?00ZIZ9J8PY-*AIH(_5(ED-%+3) WW@=
MNK(^#%,WC0@=0$ $",CF0L4'ZL5[PJ/$BK+H7#_55<W#?YYHK]R )G[H),QS
M QZ!I<0-T]9D8+L1J-CY*$-SR$]YPC=2@T"4*@J1*39UJ-&U!)/32%(/"427
M5,A=J#@IN?*>0JGS(RM3:58<4L:SJ:+GT< .(\^+?&K[0>I1-P[")$HH\U/R
MWLUX+3;,C2D!JUV56<):S!!+ V-*"[G+&%-Z7"D-=#[%,86J*J\KM-M\++*;
M8MN\A_<ISP2&S?7N2W=8GO]"_^P\SJJB?5(@34(4\LC$<>TX0L2FS$X[?,SU
M0#7@ID-E.*@XC=LKZ^!+LZK:\\;JW!$/X!T=:G[KQ;63QB>U9U4F;&.@R"ZJ
M>945N47<O$IW-=2&LSS-HHUL&6&?K$$7-@M,Y_>E*6-BYL'S"WX^?OGO1;[G
M__[^^6/^G3>4*%>* I2Z*8W" *,4!;[C\V"Q->X0 EIVUV1RLIG!.H([* ;Z
M#Z7JQ;J8!DKX="0KZS.87[,Z/,B8C,CJH7QA"JK)J4ORJ),SL/;U X2W,-KJ
MJ4Z2DA %+'*(&Z5)ZL=ATF%(;+EJIF8L3Q@COPRESHYAM:K+FML"*)*3-X-.
MK9RE5C.(.AG1U-H$"]-.O;Y=DE ##(*5],/N\:FN&N%VVF))./4)2H+ =L,X
M3,-4%$WJ+ 91ZJR^Y_N;$JR<"I8@ [0/2GJ<_K]/I3@&^WE?B*O"Q<Y"Z^:-
MKD_9_D^QM/!3 ]=R?E;41A5V@4IHF%95W;NR#L"NK);"F9X[&^!)1N1&L+LP
M21OCR24!&\W.&+ERNW*='DG"E&+/QZD7AEX8>$>+B8O8>+F2M61<KKX6=[OB
MMEAGN[H]1WI](TYM-R_='P!WDN5JD"QIAM4ERP2UNB3+79!DN4J2!65WN9(%
M]D1"LM38&2-97FN1IC&AU$DB+_$P=BGRDF-,%Z41'B]9LI8FE:S?=^4EN?(T
MR)4TN^IR98)677+E+4BN/"6Y@K*[7+D">R(A5VKL*&PK]-+2=)__\RG?K9^;
M13W/2U.'_S^AQ/<0C_1\$G>6$;+5-J1'V)MN0^'FN;^09AUACMU74*<:O*DP
M"<LP+5.BU/16PB6>Y/811K.\,$W3X='E'01-;(W9/CC:;9?;6.2G#G51' 6N
MVQ3,Q='Q4) ?2I7?TFEOGJV"_G#4MCL IEI]3\ DR^KQFB+!DVT'O&(-N F@
MROG"%$^'1Q(+_N/8&K5A>CRZT@:4CF<C)V(I1KX?H""A"3F>@TQ])U#,1L>8
M-)Z67MXB/4+5L!T*9GK$+JA)BK5(WHN3?#.GJ@/$0;<^57E?KNRINR2ST3F.
M+X5TMCG'1[99536A)64)29/(=<*4V2'&<7A:[0N=$"DFL4 KDZ:N#3:K 3<V
M8862"4Y3#?((4S$ ::93TI><R"6BBCPN3)74_;B<=(YB1O$6R)ESP\U!X?Z*
M>+/4)PID[M;%]E!UJ0^VC1-#&W.I9,3V4S?P@B ,$3YM5KAJA]JF!CEA4MO>
M$3E_)Z1Q[^K,OH3UTL6K-RHZ+BF>O%, 97C)_6&$BL^;:&LF568:F*L=%S:+
MS$;#\-62N=I%OHA!6Y:9YC?U5P&QO0/3Q.VAEZ:AS;PD3%([8*F#7/\T;R(;
MMFHPSI;QY8)3E?,-QV=51X#0&@:C&)53\>FHA$GQB4,!S#HAFVDQ8)"G 775
MP^\R)%*3+V\J&>AC2%:L?O_Z;=_HZ3/:;7XM^2C?B>6&UF;L^@Z."$MI1-T$
MH=CQCOM).$F!!V[&V3(N5B=$RD(UDDTYH9J.1IA0_?[5ZH U=S9Z?,ZC5(-$
M#2B5'H*7H52:?"E-=$&84C71&\[6?^:;-]J([!2[KA^&28()\VPWH:2S2#AM
M,)T:8\FX2GTJ]_5==G<HBELVAYFS)EF[:0 K2]<H>N6$:RI>%5+=7UKV9H^N
M!C@:4"P=S"Y#K[1X4NKO=],7L_EX?(G:(QB[L:BU0Q.<$L<+XF.:2GT">E9G
M6F33+UB.*VKS4>(!^"4TN-*ZY(+:6GUC?+)F7FP)G&.+R*]D3M3RRYA!9O+=
M0#D<U1:8<I8Z5H6SF^.FD4NC)&2>:_LI]>(@B9,PBIGZ[><IH!F/V7LOC60G
M_=KV](LC%P-C8V6U=2OD[KMP?OHY2+XYIYN"C+3CS#/0W.4R-32'X>D'W.K_
M.K,/W'4#DX\B_Z#5G%/UCE.=T:-=''HTC9W$C1P[#5%LNV[2VDT09<#CM>/M
M&9\E#A#_36'99AR/@,6;R0A46,)Y6:;IA&\VL7V7L?<6=+2PO0Q9U.C/N<4=
MC4Q)[_)GU3W73?$'^^=3P>.U%^6(3CA6MHU)Y"'/2Q/;]ET/AS'I[*>N!RRT
MH<^N^=U_CM'*3R"!F_[Z")8\ # +L\## ()2$50V7_1@7A"_B8\&R#(X=$Q
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M7\22F* (14Z8^!'%F![5ER$*W( R N'ONW@[DOI1*[C3<:YI&5<\A-%!7D0
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MDR)SZ*R8UL98AO9I]NE2J5&-C(TKP?=:?[W0BVV6!H$3,MOQ4H\PW-FF;I2
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MF0&Y&4GE,J1FK!.EUNX%O_KT-5\_[8NZR#M3.(E]VV&8I%'H.;Y-; ]WIG!
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MQ9C1@*6G4U8X1CHE]5UCYO?[#.K<^U3JT#>M'&K7M26)F;*(25/\=Q O>6=
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MB)O&GV[$U]F/+L ^!-N'UP^*7;LT<,N_%![D>2,)XAO\GT!+O"V'8] !TF5
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M0!CP#67MYHV/M@[Q+]D!\F&\5=93U1Q(MM;9=OVT;393@!<T]3>%W +VK&T
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M2HF-H?KY4U[?EYO>3+>B(0D]E]II&/EI%!$_C9W.6N#&DO=PQUHQOJ?]\E[
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MKVI%DS3$24)]A@(<1]B.67NX*_88=4 '$0Q#,:S4 JWU7<"U'DZ'XJHK:WT
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ML8L\E/J1X]A)9]D/J .[B:O#HO&EB1-(+C]6"],ZX9RZ=->[E V,,9V$+V/
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M\ 8=OVFY[Q^<Z:G'RP/,B8?]T L#Q@*<4L<.@Y2V*"B+<#)B&.N",,UH5BA
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M!17[!I^,$"-QK7*0T67/\U5IEG_+UJA8WRR_IUF1W>4[D5+_8PC[<[E=5Z\
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M+//B4UE5EVV-^,N"+K=B%%0+'(4841J'09Q #R9QZD<=_A"B9&@8GP:UY;F
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M]JD4#\EOLV]9L<^JMKT8T9!2FGC0HP0YO#V_:X_AT)&O1C"H%<OBT!Q>]^!
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M&$<;=',*>YX2SQ\6X22U7*%^)4H\]<_3@&$B(;#G,OG@OPC7J07Z5P+U;=T
M/<\:BNRJM+X1Q:U[:SD1V[ZIKT3GB?BU5!.XYN6,9\ H39V(X@ F">47.#HD
M\L84 >$LDZB&3P/(>G7\K<A\<_.U+":<Z2MYS<K<WK:[IIK-]W9,/757<J/5
MR;IM=^I-S\\,OR?C#GSC;ET/;FVY/=I'+$S0:&ZNK>.CY<3JJ0S6FT_K<RW_
MM ;\FI=;WF16-]?YMK@NUKNF[,IBN.0\@E[FI3Y!OA-D!">>'R7]_M\P@![U
M K7G,G1;M3TW/GD#X0#U/<O=W[<,+#BBU7W/0IO]RV%V7N(EHZDQSBT_(O$&
MA1>.09AWPS)..EBPZ^P##F:9$SROT#QRL2Y(<=,=V\.[YN3:[2")89#AP$VR
M+.'GYUQ*QW:1XPG>"FJNO0E.)PPHP8;!9+G/87P.0*4VR)M@6&#*,3FU<AIX
MY)3C.]6\ 2'X?8]1[O2!"7*E#AU,3++J68,W.K#^28.W>3A_P, @APO(P\W:
M4]OJ;?I1X;>Z>MIT&H8L'GD>S>(L<&,4NV$P-AV%&=4/#-)-SA@;&-;W:U/Q
M09YK]1!AE6134>(W_@2 \4@A3[-^L+!*MVZ\N$"[I9CQG [)L*',YG(CA[I)
M L%#DR^A^/%+S:2UXMWP7-!*<!PZ.'60YWK(B6G@>'!L-&-!3")RZ#=F/68<
M(>K-)0SP*A EIB54+CZ<,&EF!F& 4HF(,"VU:K'@8F?5C0%O$G!._<TQMP#=
M-VA,;:5W:6K]BQ@3^1&E$<+\'<,HY4^U832VZV:)S$3!2'LS*;[:#,$,PXK"
M;Y5:$]I_PJDI_9<G5S,$6"59.PK8F0V(\" 3#)0Y7&@\4+?GK9"@R9105/BU
M;KJ[_*Z U>8C/]0%V[;H4+[^H]B<C4VN&\8.#N( )C@(24CQ(3;%<1I+Q @+
MK5N/&"/F_MQ3S5&#G,,&-SUNO8F##7<(!)29_2 77@X.X)>_]G!!CQ?L 1N:
M;]CPA$3TF=DC:K%(?FCH!B=YFLZ%*HN$+R!PV;2NGJ;;F@YJ+Z*K%T<X#5+B
M!'X0ADGH$!0?5NV=P#4=UZ0!+"FTJ<V0+#G&5(2SZA%K04YSP<623TS'.JN^
MT0QW4CZ:).2)3M#L4O^S!#YU Z5CGR:7PM>>_W-7=C^.S0Z-N;&?A!%T/>RY
M01S%R*?AV!B-4RSW+J!B(_;#6-[\473]N8:BAW@2N"1O*%>D\7) FI _N:"S
M!_1DF^M;\<3.7>"O$G-A4ZLFD\O8P:IKQ/.[MTUP8G(O_X>R*JZZXJ%=.93$
M41H11-(L2U"<>E%ZV D5)8[I_?SB+<N,+84]_<\V;;Q[;9/Y[QPMZ.%:V-(O
MX00Q$9N/?SEM,T;];#O[#RQ>$$([WEB&/EJR36&7ORJ#PJ\]GVWY\ 8\#5#D
M.2AQ(A]C3#S$%'UL.'1=P7TY!AN<,JOKQW)_[=CSA$7RR6<#/(NIY,0$6Y#&
M$>?$PO@V<1?4T"#KRY! DP8]?Z[9-%?Z8K=",(LAB7P802\E 7(\=&B0)"XR
M)7)O-F1=W+*\;,#?\NUNXE>7SG.B-*R$B5SZ<!(W1'@827)C(%=8KW?\"O*N
MV/S2U&W[UZHI]@_3_I*7%2J8MA?\Y?4@H;Z?!!$B0>CYL1NGY'!:,?$C8BR5
M,(3'_IXPC@X<X0&.SUQJ8<HMVIG'#/Z02TPN'L%F:<K1 /"JS]Z!F]X*_M[=
M4G15D'6UK,:P1Y>NTL;M%<^)K#!M4_,_L.^.N#R/T"#&"4QHZ"<^C3)RF+?&
M/O'DWC.UCT=(8W2>,GVA'QR?P?FD*;_8$WT+#IE<]+D-/Y?H/V'=L.BK>?3G
M%7U%>PV(O@[3!D3_H6XZ#H._J;U*,:8H@T$49X1?V.3B+!M;=QP2RRRNF&K3
M\K+* 0S@:(QIMARMVLILC5&S^ON$:X#RMA1^^<6ZS)Y2J":F2DY8O&2J624N
MC!JLZ<L?+U__FG?/JY5A%D$8A9Y+@\@-'->'+MG#0#',7,%C"M::MU[%.+E"
M$M=5#VJ7;\$1ZO]Z5N>_?CK43<FHJGMT]70"OQ@5UGX5Y@AX@2LNKS.JI+.:
MSEFZX.J:)ZR\1G@T+<'\-M&R^E@5_U7D#5_9Z!<V5L1!893@Q*4D\%T<4.JC
M$50,$V.K.4; 6)=GLBM 68&Z*L /AHSU5K M^.R5MEWYT$]O!1:%9O&3666>
MP$%R.BVP'/YN%.H?[+?;7H>8O_B.A.NRNF/"/OX:$/:;=_T-S<S9S$C K7PG
MXMI9Q?UUIQB0>DUO_US"KVNL8A@PPK'5H/!TPN B-TQ@2(CK1:D7NHAFP0@,
M)9'@I1,3 IHO.-BI=)CSE,708,]%RPL/@FY>3HC0K[P8]_Q/'"H4#381+G2X
M-E[*N>V*AN'Z<M_4N[O[K/S:0VR/(2VBU(T2)TA"Y'L(9E$8IR,^ZB>"%UY/
MCVN2 ))SF,<8TNW1@EL&M__)I',- [XT7!":U(FSAYA]9^ 19C 8<(O[<-,N
M?SKRIK-,%*&,=8B?*_(8M%NU;&68^:GBT+-E#R?(@A 1AX99P'?[A#0>,6:)
M9^Q$A@UL2XE'4TQO#'ESFFADSXT+CT@_PPQ(R&D6(Y-:Y_C7B$Z*MAN.4#H>
M$+K)2 K@*X$S\T/H>9E/<.)0CV1I'&>'A2!"?(D[C6Q#F3 &F9D"3>.@RW%F
M<9Z1"RL'Y"#C;U(_>V/M^8IXC_\D2BS48Q(W'RW)<VIW('VY+UM0=L4#:(I'
M]G?L UJ6VA7@EOOF*T?)=Z \>X+E'?AV7Z[O0=X4H/C^6*R'=TT?N,4O1RG@
M\:/_U)N<M;XN0'M?%!W8\(<P>(9Q_#2>==S539\Y5$4YW&$&[HOMYGU7OW\8
M<Y"*];>NR3<L-3G!I7LWDZ8_7\D5)NTF"[BO:3)3ZQF&H?7 _S0?R6@21U&:
MA1"E)"4A]*$WPL*I ZT'?SDX,R4 *G/.Z5QD+?S;\\VD*<"RO6<]%;#G18/I
MP(O@GW=@S?"^8Q&ZZY\XW_QCUW8/_1\_Y!N6/+"ND*_73<$;9W^_MS+??]=?
M3/J^N\^K]ZPA_G12\P.4#X],CON/>->G!/?%YHX%]W>@9)]?_?C_&<?9;F,V
MZU#KD3]MYJ%HKG[VH<.S@:LY4NQ%?AHX28(Q3&$0!AD<&TS".%AU=9=O=6O=
M;S8C=;#H@$A<SO@_ ?G+C=NG:K:\Q3.EFJ,PUTLO((H;(GYWAQPWJN/KZ0.
M3T9X?\YJA=.01"3QD9-&$/LQ(FXTPO#9^-<9==J-+V$LFEQ TO>&VAK1I(ZP
ML RTI*6;M[B44$IC;EFF?IHS[PU5-<RCJ-9^+KX6U:[(&!'C<3B^\0VSB4?]
M4#1?BN\=8OS\L4I")O5^PE*H"'D>01D_0^/2,"89)2&6NIS66*-2VBI_@'K
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MP_4CU_=%T<%J,UZZ_O1PU_$  0I=3"+J.K&7!5X81T&<N-1/,?0"-Y#;G;I
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M]P!Q+%3);+W6IU1&C*=@4UV67Q*II=#*C*IH]13,ZJNV"L.2 GZ&B#>E7)?
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M4?>Y\&C8.W#J]B=_QJV;OZ*IZQ_)\N=DW6&AX612"@0*JQ/[0SV#YZ7(5>#
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MS$(WDCI:;AN,Y63R?Q</]>-]N2US</U85N\_WMY*+L):]X;@<NV2'"&YL#M
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MV88."^+2</V0;[?C'7TK2KPD#-E<)PH"%(4IQ8$SM((C!PFG&2J?/8TT])C
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M2_PL,A%*S"*R'D8.N"['@ F%1(I :1&QXYXE"X@EBX7$PR;;)H6# RI@M?G
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M><44<=P!0WCYUF8UP32*>B7KQT' #NAUIYR^+#GWCV6V>/@]7=R6.>+;B73
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M!@'CL[XISA74P>54RB!J!?/.V8V\", >P(M:C<^+N%Z>%C]-G\/"_SE>8=:
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MQWH9 ,PZTDAKR<9[+*QZ<&LT6*++NIX&.6>X@U +X0/O:TX9%RAFD1M4!&H
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M._KI+Q__$G[+2PK&B\..Z*ZVB9%.$88Y08(81%R8+=5TH9"Z"[$EVU-7WJY
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M9NJHAX^W$@W.2H'<_'C@@M?!'E >-"+F\5;[C9K?[ 1X6K-Z.U2.Q<HT?$T
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M%D;Q>I=/YYW9-8_I'/I*8>?T'JN^AAHS'V>KV=U&HF_%:G5?//&B#[#\0*M
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M.*[C5%[)*O)N\8[*P^]6\:W2G[2#>"@Z?9C'H5LL5U\GJ^+;7Y.?1WGT=H/
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MUHLXL&"CF?!ULZ P!(HP3Z,=$L54$CE22:JLSXFB&6'41-^S7S; EY/7(,K
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M[5$99PKB/W/EFRYC^#$@7G--:+IS 9@CEMK-I0D<?X1F%#5K7L4//M_V.Z%
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ME50\:@U0"3W#=%LBA*C(B#,&K^\89\KY]II\%&9S;'8DN/10LX"$9!A)P)
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M^\IG;#7'#'"K(<*48HE C3N!PQ[$#5F]?B"VG)+-N)5&!F=B;]F,K="8QPE
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MRH>'8I&,D2^3G\7B*(G>?#Y0ZJAQ?K/5)9004#-7R2:)O;IMR"[5_2H)=#[
M0Y'G:_%S%^NF[A;%]M#B*(/V-PI6<<:,1MP "9GV'H)Z]$GWLK;\Y6\<]DBC
MSE >BDN_E_/BU]:9\^OYS7$>O=T@",, 5- :*926G&DK924==%E9GD=XN:='
M!G6"[Y#7PQ[]_Z/<>>OQD%(J NBT\9QA2( !N^+=43)-;<[EV-;W;BY\]ND
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M\W_9>]<EMW$F3?B.9G$^1.P?''O]A=OVVNYYOYD_"'45JZQIE5BC@]V>JU]
M$E5'411!4BRY8W;?MLL$"OGD R"12&1JPQA%1CH#B0)*5!AHC7*.:J?GWWA;
MA.P;[,%>WV_MO^77<@/+HGA=H-KG]@V["%@H22V4@DH:CQ\ <V K!*13.>N?
M_$7HUA/6YUW>ZLAU4#YF,1*&<&>U-%HY[/Q^-G'(<IR/X!<A4S?8GO'AS\8I
MOWPZG M\[V,1<8AAZ(11TCB..-BF(4#4&8P;E6+L^[V/F2R_J?EU^D^BU??)
M;*^@]"Y+SUX_F[7K* C$,=:0.8R8X]QP*5V%"+275RBP:Z(<?.W3 _KG3XO1
MA( -6@<,D5"68L&<\IB1N"Z22FY)8(ZK>E2/3P=B7?>0#T6U1RB8V62YG-Y,
MBVO]TY3S#2+KR>SQ2^S&BV!.M\%:RU/5=HF]]3+J0/(]4CH:@4/>HUP .0?4
MQ5"L?9S;*"65^3A_)&1CDI[02_# 6<:Q)MHA+5)0SJX07<2!>9CC7AUEDOB>
M.=D?] /9\+^M)XO)?%6<T69_&$(#^_SEQ]'V\5%9!D=P#130:":V21$( YR3
M1J]Y^Y:LR31^Y>N O.?,><>5Q!!X ;S4E6R1I3GVS2BMZASUEEW#.= 4_#_%
M77D?89E.OMQ/YQ]O;E[\X&Q3TTZ75V6Z6EP7UQ_OB^U%=(H'C?]P7RXGL]\6
MY?J^R;P]L:> N5",.F6 PA8ZJN-J*2B37,7_PZ+1 Z'>,'DTX'?SJ]GZ>CJ_
M?5W ]--9N5PO&FWDN5T'R1E#1EA- 2*$>P<TJ5#S-,\%-SX/7&^<>I[1:5BU
MC&;9V27Q^057'QU9@CST&A,9S[B*$:BV"F,*&MKH[71?Y]RHP.)+5/DF%DA/
M9I/Y5?'E6U&LHC@/]ZL/-%SJGR<1^%@6H(%&$  6'#GI^*9.,I1 2E/IP&@T
M:$[R\:UEC1GZXA ]1NT-YR7J6_HC+RJ'&4!P$'.IJ4;86RZ]Y%Z0"GTW<%7E
M(1)OC8S3@\^Y%DH?+'OI*7+4)EK*[#%$)2&C") $(<NHIES["A]M78X[]I><
M%*>1+L>F;JW$UH&,>EI^W_SV[_6/19]_%R0RP!M %>(.6$.%CR>+W?B8\1>6
MV*)W+9;=87TY-L;[!D]*!QQ%4!P((%/R2AZUX+'2A._W10ERZBR/\'G9/]9&
M6\V?Q>2HE^7UX(JFQD>;OH/CQE'@+=. 8**(!,(^[)@R)U_V"'>(4;*QSA89
M0*<CG ?JZJI<1TD^E*LB>1W>EY/Y\G-Q5401XV+TH3CB7>ON]P3OJ(5661_-
M22XE AZAO6<#9N4[^"5WDT'G1^?Z'>%<23?\\\BYGV:]6+S^;+:#7@,#1DLL
MK2-."P,5%8!6.&'A<GPX(WR%?6'S(%.;(V3]IT49_[CZ^2DJ)JDD;7_W!UZ-
M=]E]4$(0PI4EE'EB,/7HP0ZFP.8$%H_P5?F%S8.NU#K""?$N\FE^.XV[FEHN
MBZX.#<][#<8A28EGCCF@%3#6 ;''2;"<NDPC?"!_8?3/U.8(6?];65[_F,X>
MB@CFT7W?73 2,1\W0NT 9I)1R_Q^@[3.Y)C](WSW?V$\;ZO&$1)\$R+<Y8K^
MJ,,@C(4,211A-\"EM,#"5>@ C')LF1&F&[@PDK=7Y&#OK3:#^WAS@E!U[Z].
M[RTP)H@ R!,7S_=(,:_4_DI&*)-#\!&F+W@+!.]?BR-<Q-75U2+^_?UT\N=T
MMGF_UJFOYF#W 7IL'*<2<P^<)TK:!^2@L#G._1'F4W@+_#^#6D<X(39[UX=R
M?K45Z)&('1HYK_8?/+)6(*BA!!Q*Z[!3>J\X#+/B.$>8%N+"YD1GBAUJ4CP:
M85>&4-LN R04LV@9&HJ%L(X9X?=A+D3HK)P(_]SUMJ+^0+H<VQN.72'F7_ I
MAXKG,4H-U9 Q*302(*J+0Z,ALL3I1@^>WVJ@V%B><M"(OK+4$>@A]"YN&M)6
M.C -7^B^G9"7WAAZIJ<<IVFOY3[?J#;O[Y/_*A=FO5Q%N1>'GEJ\_F'@'F(M
M((T"<,$]PR""O9."&C]H?J)+V(I/Y$;9H7+ZI%@*4OYX\V2(M96?#WX?+,4Z
M3F1$ 4 \(H089'N9B,RIOSHBPN4JM.P>RN&#_@U14".DG5.&(ZJ1-WJ_@D.6
M$P ],E5WH*/:D/[3D.QS(?BT**_75ZN/BVWIJZ)FMWGMTV P(>E<0*CF4@!*
MH=A+XARZL/++8]YO.E#/ $1[J+)6'"Z*6/M],)H#RI0G/N)BK&42T4HFA&5.
M[NB1+4-Y*GW)C6PP!\L-O1WOPW W_KFCY;OKF@6"+0-4,:13;0AA/41\O^9B
M.VB.H4%HDZ/MY\F?NP.VM=GRX/.IY*LW7PY]'R!!6DLFH 984"?B7_:+*_<^
MQU,_HBVK6R)TB>CEO% <1Q8$!:FV3D(D.+4:,.?Y?OXA0'.._+]D!'T[$VS4
M2O_ULB!H:U,>2JPD@!9#+8'!^TT)Z0M+$38VTG64!>$T);XD^=M18.\(G=\=
M,<+]^_W(,@P@10UA%"&2JF1: 0#<N1.C&<UISA'EEWP#-/:=O*WF1QAY=88,
M \;$[<=92S7!6GI C=<59H"I?[;X_MG8>8:!TW0Z7/[Z[T4<?1V=JT^"4QAY
MK3DC4C +4B)^4$G  <QYR#8B[\);8F5+U0Q%+E,N5Q]OTM.BQWZ:+^4#[*_0
M[7"C($PJQ^6H5QQP*2F6VE92"NP;U6QZ6^4XQD_!SM35VGNZ?ZE?_'U?7*V*
MZU7Y9[&, UB5#\>!0Z[41HT#@X()Z>,!0CGM%?2([==N[%7.RO=+6J_M:=>;
MTD83[WGF^GOGB_,DR<]"4I*-J"0&M"6$"^BP-"K.=]-HDO6#R4,IMY-8WF(>
MG5;6;[#1!$ !B LXC\=+Y*Q"E'H4=8,\XMP8>6'IB'MC[L$2@6/5Y$"KXE:B
MKY._SUIX=#>&!]@:51L]V"HXYPB#7FCM+9+$<63IIE8-)8I;>L8***^,NEDM
MO</- G*2@;C%,BDH4D)XA&TE+=%@T*R(PQGGF9I_U2_7"<##S]QS%QOI?@)S
M3*FDDEAGM4,,"(RVQ::@00J#LQ<12?7J?"2FV>X1<<-XM%LU%;U))\%JA(F"
M(.X9$B(&M?%^CP30%YGR-),3KT[M'L >]LZJ3@!=W)2+XM&*\/MT7J9JGN_F
M46?%,EDG3WLY4"R]$^YV/IJH>@,XD@QCQ!1F #./'JG^(LL/=$O8D^?$N94X
MXLEEXQ^6J^E5MY.DZC4X3C0TT-MH;43U8D^DJG "#%Q8\:91,S%_UK34ZHC9
M[^-?I[=UX57M.PTBFNR:<J44C#@9ABCD%4J4BYS7KJ.]Z+I8[K=3ZHBIWQ;\
M<5A304'+4_(=C%)"92,0U[;2@^4T9W*='M-;KB:S?R;7Z%DP[&R,DKF_[XOY
MLM#%O+B9KK+.UR?U%IC$#F(LH/2>:,(4M:+"!5&5\P+L36X]'9TQ^E3"8-$4
MVP1.W7*T?:<!<L(]$1BK:$/:N-X((RN4],7E!.F51\]C*H92RL#4]474[F3V
M0J+C_#S4,E"FF8Z+0EP;,(4FGF< W5MU!.=$9HR0A$,0XW4N=J2 @0FWN2/=
M%+&Y:D6[^O;! ""P5$)S;PUDBF&^EUT0T"@SU=O9K,]'OD[5,/2:MSU^MEGS
M#K0,@$F"L!4:6^*(L4:KO>VL%<U)5C+"5Y%G7/.Z4< X[,/6-F!P@$% E9;2
M,DMDG%%J[SA16N74=3@]^+'W _OYZ-8-_H,]H-FIK=OC2$:O04L@@1*.$ 2!
MPQ9Y\<BED'4>&>%N/.1Y9#BM#,W>G5E[^IK9K(/ '+3860H4AL0!8XG!E?31
M8KF0A#Z#\N0 -SM5Q- T?&+@MB=CDVX" ]3J"++T EO..81ROP@HHG)">4:X
M3)Z3DCVH8_#U<6L"9ZR/M1T$" B5QCN/#&.06"GEWK;A:-@779=-QDX5,1(C
ML[TA&2#31@N@**868(<0D6!OJSN?8RR.\%!S3N)UHX$SWP">?LL7+#/&(L1)
ME(_39'B[O<6!=5;&BS=YS]W73=Z)0)\M+O[9<X\W'1C/A!.<(D&\08!82!##
M4@$BC>.R89&LGIQ@Y=U].4\A!A]OJA4HRK"MH99LL8?J(4UN1T_O+2@LF'6$
M,6F-\=HY >@.&Z$ ;_3JY^T<^3IAR8LGY7VC/K3]LA]]_(.)?X];[F2Q^'E3
M+GY,%M>UN62:]1"(,EQS":DR\0 !,0(4[.27BO +"]?ME2$'[)AN-7 V!N[?
MSI]"NGVCX)'&D+$4+2P,2(8;%964!/H+RP%S5IZU!?ULU*IJ2&^" )^633^%
M;#7=A'@V51$!A*S @B)K-+(5$IRA'/J-T%]P5OIUIX:S$7)W^)C?IG-)ZQWW
M<"_!*<X)AS#-2TLBPI)4%H["U.2D11AA7IBSTK$S+9S3]JM^MCO!)D#C?[>J
MGU_O#K3++]^B.O1D65P__B E6CK14,S]=0%@K:S57G,K$<'.I=?G>V1USHM'
M^@^_SZRN\RW+J<+"22MP:A (4$1:P"DV#'KJJ;:DDLX+GW.P9O^0,1OPL]'I
MWR>S]5:ALUGY(Z7".85;+UL'(82&E@NMM*$"$(.YJ^2V5.=<VO/&1)-;HLV+
MV\DJ#O>R^9:MA+.1[T-QTJ8</P^4JKA*8QR79FR5,M*A_;1B-"N-@!C?Q<!9
M>74ZW&<@TB,$:LY<[4[4[?H.!B B&$&>$(LP(\*@O46M!,XI?2?_60'/H*+6
MR56K@:XF\>.'@;Y[__5=_-'59':UGFU4_ H?3^L@:$6-ETB0E(E..<!D"J3=
M2H0@SJKO"WY- Z]7#61SZBGY&U^-G-Q'\,@@D>HA:"^A<%!&_'9R::BSRDC!
M7_1VI&\E=$PN6T0E74VWVKLK%ZOI_VS^?.@HVK:K0*$5DE+($5%<0PC@WE6O
M&759A82;7Y!<XM8YD$K.:P">;-4%3*U(H2Z& X^L(AR"RKS5&KJL![ CC#,Z
MOY%V(N)GBS=ZQNLW'F^$"<<FHNXEY<PYQ[A 0$0+&$/0+):N'UG=S4UQM9I^
M?TB*\CDNN:_%O^W^Z7-Q5<ZO4K[WS6P[CDM'OR%X'@^^0@LDH(@G8:AT^LL6
M0Z3YH-D+SYV?MS&?RC'H8J@MZ77IGHE090)(CQO6*3KAR<<G\_BDWH.#5CHD
MXD;.E+608L)@A9O ?M"Z6$-P>'"^->)[GSH;$]=??[]3:Z3E=!M/2,): R!!
M1!.D"#)VORHQI =-)_$/NSM5UIAH_?PE4/K"3F/#I+/I9)9)[V/=!RX@4"F%
MMI?>*<AM2M.Q0PYCF^-<'F45K[= \XZ5-B:Z[]U1N>OV0T>!&ZVHEP9A926V
MUCKL*C2H4\-4LWWJY/GE*=Q:/6,BZX<RG='7\;,_9\4N#NB)=VM^_=C!E<GH
M$W];B,<EA(@5D"+ED2:2<[8WY0C/<6Z>' [VS\H]A Y;N^&;#/WWR7Q]$_%9
M+U*IJZT0AR\2V_<8C/+.8$R49G$'PUC&K:N265.;XR,=8>38N5@[K);&M&J;
M;Y/Y;?S S2>I&F4WOI#7.PW0 Y/.'"Y:9,H3RTVJY+9%"7"9P^7FP6D7S^7!
M%96_T+XZMNJ6_^BB6MLZ".RQ! XP@+5WG&N#E$#$&"V=XS+GR'9ZR-K%DJX_
MC8QIL7S-8'EW=S^9+E)F^/2Z(]O#UN17!$H1$DXQB2)BU$/ R-X0DH3G9 !I
M'N-V\9P^L]K&3OQC3R&R^@V6$H<-B9:^$1((;2':6U1"XZPKOY,CZOXYL'6K
MKC%1>S-^=?U?Z^.E9MIT%[!"1%$<X1' 4 6YUOL[) 9LCK_M] "^?XC<B9;.
MR]_7H.PD"",@Q*&.*"@JF:=> 6+W=K^#*BO8]/04";T'9(V3J1UHYFR!6\_F
MR9L.W)*2,P8Q8H1RI"Q.>=,50,H;+^,"<<9$47_,%Y&(M_/I_VR.[-7KVKTP
MGXKY9+8)(]P\QMA4M]KMU@TPZ:#W0(TF6CB!M3)>>,V1ISOLC*,T)QQ@A$'K
MG;"H/+<6AMK4#DAV.B.#-QH!RZ&CG%#C%$%2[N1S3K-!0ZKB4CTM4]K<Q:I7
MK@W*BV:</%$/9^991&I13.)Q_'.Q7,]25HY-UL=M'8-/&RTF&,OE])AAU<TO
M"!(J1XS@P@!%#=< 1@MBAQX2/J=&Q0C34HV0O_TJ;)1T_Q2%6O1']@/=!TNQ
MD%H  20E2&NI6(6<AT;E9/H;80JL-T/U;M1U9J+;HE>BG]1]$-PJR*"PB!O-
MF:4,\0HYA4Q.M$G;(*O^7]*-D.]]:NW,?/]<!1\\E>W]Y'Y9?+Q1]_>SZ=7D
MSUFQ#6V//WH_O9NNCGJ+>OAM 6O@?30,O628,"0=9:3"%1N8XP)M'GOUSVP8
M4HFCW R^%*O5K-@X?/\U77V+W\=_4.O5MU0'O/X%:Z>_)RXT@G(,A/8XFHP@
M7?_Y"DM@LUY:CS"H:X0S81"]O3V'"N0N'N.MMIQX:8&CBNTW0(U]SD)]<H#6
MUJ'BYOU&AX^0FR=JX6R^_J_%WZOUPY.;"_#X4VA!W-P4PS@%9!"**5?426>9
MPA0TRM+8CZQ?7\M+\C7MU36B'FX4A"!.1O-6*F"EH#):O'8GJ8Y'NU_(/]]8
MYV5/X ZU2VQ!V+P)W(8D76TU]_>T;J>H:15<>J'"$$M9BR7Q3C&EHYQ:,H"1
ME8.^RN^?1%TH_-6J0%V >V82V?)N,JU[T5/;+GBKM.244J\H4A1@HNU65J^D
M@UEA!^,C4B=:;\:D5O@.Q:64]OGCS9?)K%C^7MS]61M+^.+;H+%DC# %">/(
M8"_BZ33*9 A&AF&4D[[^[7#F5/V^*%:4AVI+IBP7JT<LB7][SI#XH_ Y/4PX
ML#D]^??TO%=BS:%C DL@D,5*5:NO(2RG#N<([\\ZW(9R8.Q=]0>7A&=?! B0
M]"B.50CFK;&<*E*-&]"L1T4C6@A:ZNJYIEMAUJ>N?Y_.IW?KNUIM/_DFQ!W1
M8&<Q5)'>.*YP!-'=V(UC;M"RY'V&T[;66=D-<KUJ??+W<:T__B9(FE*G"V"T
M<2E&%T<9JK$K,6SMKM%K/0.YH8R_1['7OEQ\*'ZHJZMRG0)?;S\MRGG\X]76
M$7OD?'I2/T%HS02 QB$/3$H6+%*VA2T6&O <M\<(XP]Z.+'V"?=0U/L:?]O'
M&W5=WF\>=!\[>KSV>8#1%N:$>*_-]@479[Z23- L(HW(Z.A9Z\\]:OE #[9Z
M[>6/1[+Y=<H1_<?]=3R<Q>\99$<YU:A]4 80$O]N!;362B\TE#O9;4HP<%DD
MRU/_\W6J!X#[-(CB-$I7\Q\77XK%]^E5W<'WM4^# E$2$ T$#0W%2DJN4"5)
M<BD-$F_T%C>VCA =@!OI!G(WP.5!?VOM]R%Y=CBV2A(M+(WFG]1[OCM(!XV7
M[_>HG*?2E]S(!K-UCHS_?/=!?_Z/K^K@GO+*5R$.@PIIG6 &*RZ!(T!48S,L
MJ_;A.!6=HY^R*QQ;ZWB7P;"8+.9QQUJFW@YL '6?!\4=]AAA[3F$"FOJD-N-
MUB&#&CU8>SL5+SO<!#I$M4L.'%SEZQL$YQCU%&,(/&46"1>G0#5BRIJ%,8Q_
M]G>CM",,:(5H5QR8SE??BDCLN_+F:K+\%NW8])_BO]?3[Y-9.F[5[PGM>@M6
M(<,I@@89YKF6&.#*M^P,SWL#/G[VG*KP&O[T WAK<FU2'NR&Z'9#K"?0X18!
M6@RM40!;9Z"3R,1C5#5FKFC.[>N([MSZ($EGH [EZ]"362IJ^N5;430-&CK4
M)*BX+3MKG#:2&LS3137>2>BIS'H(,,*XYQ[\KQTA>T[N'(T5.MPH0$PD\%H2
M)KW "$6!JQ.<U]1>F-LU7]D-V-,*V=:;T"OU''_6;T*'6P3&M//60L\%H418
M'(V]:LQ,ZIS7I&^$#:<J[TAIS7; #K68?$YAY_/B^JCQ4M\@4(F9C)-&&<^]
M H)BMI\]0IL<+]B(;)<>:-,IKJV7D$^+XGXR3;2MB1L\\&4P"!@L+;%0"& 0
M,JJ*]N8 0IQCMX[P KCK)2,;T*&6BN?5%8_:'*\W")YHP9S#"'+$ )#&"E))
MAVFS%%!OYUJEAZ6B$UP'"PQXS5X_<M0YV"98*D@\U'N,:#S2(>.,L_N9(4F.
MK3K"9.<]G'6Z@O:L]/DPN3OLQVW8,@ K'$\.(J7B_W#"F "5O%*Y"W'H=JCW
M)DQJC>]0?/JMF*?2A'J]C,;6\KBY^^KW@3EFJ:*&82"L$?&_UE2R,6L'#9<]
M$W?::+KL'MOASDG+(OZN;PW.1X\_#-!92H%10F*%L+7(Z]VICT.)P* AMF^7
M*5F@#ON,+QEEN^0&/QL] WW>($B/!",4JG1KD3( ,BPJZ3C.*N ^PMH:O;T
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MV %M/",60*G<'F0*<HRM$7I(^^-:[]!W03M?KA>;0?YGL:@98OJ7QJ0[N<\
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M;8+;31;S^%FMXVFH,01%+4"6QK,DPE!2!3C;;RC4PYPPQY,OA][\$CM6M8W
M:-W&M$=)%A&:PA;;_[:S5U_O*V"(6&0$ITQH+30!^]H?<3FA675N3K][>MLK
M>-_@#T7(]]%JO]TH\TNQ6LTV$W);F5S]F$357G\M/ZZ^%8M/D\7J9PT93^HG
M<$<X\]Y+(Z'V4GI!*E/*,05R3 GYBQ&Q3^#/2<+=N>Y$RNU:!2&DX4@IF2)7
MF$/ T.HJV1'C<LY%Z5G1+\^P=C@_\.G,Q62?I32\^&JR1%& K:#6Q_\7"<#B
M458@((BR&#K<**RN'SP>GC]7$C4O'?ND16!2Q).24XAH N,&JPB7E8Q"VPLI
MXM>S_@_6B<W!NG4PC=G&)L9E[<MD5BS?IW19==5@#WT?(#74PI1'(_X&9;3!
MD,;Q>N0A]H8.&F<P9$J!EEHKN\>T4P[45WD]W") Y#3$@$FN&/+1WG$4[L;,
MT]YU&3SH2&_'6- *T]8\<).K;P^7#!_GA8Z\CG_^X_YK^?5'1./G[@?UR>M.
M["8 HSDU@$0K!QLKE$(8;Z4C:<I<2)JJSG1<#@;U<#'!T:XLOD3M;0Q?/9E-
MYE?%EV]%L8I[[X-\#[ON4O^,?[DOEY/9;XMR?;_S3DWGM^F;<KZ:SM?%]<?[
M8K%AQ/&B)D,,(%">TDK% Z&T$C(KJ?:VVAP<E3E+XPA?X':U18Y:24--D9/D
M:)0LNV6/ 5.FL:+,.H"D$1)90RM\B!\VR=P0S]G&1;KGV6T'46)K@T)/R^^;
MW_[]:''!)]\%[!B@&%E"( =",(NXK\8G/<Z)_QPAR7K78MD=UD,M>'J]G,Z+
MY7*3E&BYF65'-O$#+8*W*EHXPEAM-%.<6Z5))9^/I_8A8S/?WJ[;#:KG9,TV
MJ]7Q#?%HV\ (MQ H#2BB<7V6S B^GV^<97F\Q\>D;,TW8%(.OJUW);^^F]Q_
MFRSNU&W]MO3BPZ 1$\H"HY#SG# 0.]^/4)BLK'-OA $M-59V"&O+Q:11^MU=
M=="/BUUMT)JTZZ]]&K2B&GL'L#>::H"XLZ*2Q&"<DV1IU/6-\C:;CN <@!@O
MR\;6L^.5,K."$40\E9@:H:3&QJ(].,3""W&4YZOT)3>RP6R]9;2LJNR4$D98
M+S7Q'%,L/-S?"0GO+N08TY&&ZJHJGP;D4-9FM>B];Y"6^\6WP2IF&.?0:NH=
M@Q!HX+8R.4QUUH79B!XU]'4NR<5S6-_VU\G?NW .7<R+FVE]4MI76P0@)*=(
M$VTM@TXZ#(BNY .<7UA>[0S]ONHWSL6ST\O54ZY5 T7$:8 1Q@8QCP$2F_.6
M1\XHC++>ZHWPUB!?[UTA.?0NLGVP4%P_RA?U\(;A?7U"SL9]!,@TL$0K#ISC
MT$<$E*S0% P-^E+Y+;"I;X2'9MGG<C;SY2+%K3;@TZ.O0\2-"IY*93.ZJ6$,
M%*_D<ICE7-./*B?#L.%?^4@/S: &M D".FZ(1X(0#*WCVDBPGV6<#.HGN]^\
M%?BRFBQ6@_"EE28/L.)$(,]R&UU_7U5) FMHTZ:[ "*V$%!J)4-.,BT58OME
MELB<-);-EZ.G:2R_#K:?=<&Q 5 ?>FGJLL",(E;YN(W#]/^AL(2 !UC]Y:1T
MZ7/YZ@#8H2FT><ASP@O!VG;!>D+C"BX9M]10B#WDMI)5 YAS8SC"ZX ^*-0%
MKF.TD(S65AL@A$7  2611/MSB&$B)T?IR=Z_K87DYOWF8>[%/CH-QO,_CMHX
M/9=/1W7Q3Z,4%M08(35Q1GL'/>?.:QU/28YHP1IYNAMZVXX6(]@H(.7/T;''
MOPXYXD[L)L2S/C:>*1-%PI ;)RFI)(R<S)G-HTJRV;/^ZU+#=JN"H;:$ZMJC
MK"L]ZM>K!-?+C$M'R=K'KPG4::TT,=9C[9#23F-8(4FL'K2@\-A>^9U*Y1$H
M:&BJ/[KA.X&YK[0*3EMD.27"8F5%-//BL;.2D].LS%NC/H(-0\5\Q <SI[ZG
MJK>+GV<SF_8C.,E(JFD5G/,$(RB1 ((K3 0Q? LT$C[^N8U)U)NL3>9Q7;.@
M-)4D+DT&>A>)FB[V]])".6PX_S!EN#K0_(MK[,X 'GK>[C)"7-#T5=PRJE5<
M*:4E" DN/=O@3;'&MMDM:L^R?BA6IPCYZ/-X*B>>(^L$-)1A@1S<[0)1NG3.
M_I6F:V--'YJN[8$=+D1I-]3/DQ^_3Z+%/9W,4H&7CS>?BY0PKJA_.GNL<?#2
M.4H-(I0):*FRDN-*:LAXSDW-N.G42O6'>-05OH.SZE_EXJ]W\T^+\JI8GDZK
MPZT#BH8O=M%@E<I0BS$ T.TAI5DNU%$&)/3#J\X 'IQ8Z22]C&>9=(PYG5B'
M6P>%B ?2,*2U!)9(B?D>4T.1N;1S9S_$Z@S@UJ&7^Z',BU7*;9KT,;^>E_/=
M7PY[?^O;!:5 RA4LN2+&4 B$%:(:/U<Z9^4Y_5IO@ )S'="C#V '7W'J*V ^
M_BQ(09R/RZ:QSA*-F&425I(XJG/"!T;H1.W;@CX1SN&)4;>FU'P=D'$I MUX
M*;E <>H0ZBNYB/(Y1ZT1AN/V2Y.VJ)[)';(KXG%!7A$*D432"1Q/)#">291G
M6CLE(^P&,-(HTT*?KW#Z3.-R+*7F0",(&@K'G6*&.FLL (IK6.G &95S>3?"
M5T*=L''P/%-M-/5/+K9N,RX9&+<;#BU%4A/$.#7,;=$GQCDS:,3&):2Q.I'3
MY\GM=IK2?[W<;H)J[SR@<<WDC!&='D15^# H<[)7_)*3XC32=93;[30E#I_;
M#0F',78:.B"T8%Q(A:KQ<0@N)"G"8%JLS>UV&M:#'YO?-TB<\/+C8+AS"#J"
MJ77"*\*%]I54U.B<N*!1^E;&OG=G*FB$K];V,IFC7IV,7@,7!EOA$7$N/1J5
M5,=YOL-)LJP:/2-<"G.(TO[M6B;HPU^7+J:KN G\J+/O7GX<8 K/DQQ+[KFF
MT%,0S8UJOQ .#KDFGCMFH_W)/Q/6H3V)9WY-TKT'$6N$M?!0&J:9PDX!M'4"
MDX@]=(URW/0=W?Q\03DY2/]8%X%+I0T!*5U)JAB!#)&T0@$I^TN%2S9FQ,$H
MYT[!'G"&+U?)W(NVV[]/%M-MT<ZX1\<?N[C%K::MYGW-1?G17U<SM4_O)$@#
M'<?Q^$L PU+8%&FR@1W&!5K"1ME$^IGIKP[]Q&CHQGT$K:2FUFJ"%)#:>DV,
MKW  P%Y,<%R?%"F' 7],<[]]2/5XE@ $-8+2*:*0 \2E6L+(4X2$<()A,(J*
M>8>$:%Y!K[:'N+W)N.<@E1)1.0DU%8[L,%!.Z OQN/9)CH/[?I? #W4*/#1F
M_=/,)LOE]&9ZM5'SQYOMHG;D+JU-=P$Q)A&-ZR'CGB#D?3RA[Y Q("Z\E[(C
M]<:8)MM1MTH8BI[/!WQ@ISUV/75*-X%H(30 $IF4[T-)Z!C9(\'%A52'&X8L
MY6!Z:'VM]*%8+Z9W=^MY47^M]/R[8+S$F&+I#11,4 <E9M7XM!_6ESK$LM6/
M\LKN(#[KGMGH:NE(RX =H!X2!2WGP"DDD;([>:WT*J?4V0COF<ZR#[9&>RAV
M?9K\W)BL7\O?I_-R$4?\Y5N$\ULYBWJL(U=]PR"I\51Q:CU BG%@!></TLH<
M?_THEZO.M%_V"'/K7>OA%C9BOKY*?YS.%^7/R6SU<S%9%?>3GTGX,EWEWA6+
MJ_2(;S)[]:%25G\!(\#2LS]$*>,*1^ <C?(R1#&(UL&%)0OOFE1#8M^::Y\[
M8=AIO00$4CD&+!'P!G-"+(>R0E)1GF.%C_"=0B^\ZA7QK#=R6Z_,8:?,[J5"
M<^]?XZZ"B&AIP#21E$D!F(B&Q4Y*A[$?-$'F6]P&!P*^$WKI:;DJKK[-RUEY
M^].4=_>3>1K8M\E*+0I;Q/'>11RNOY:Z^"-.A_FRG$VO4U[E8Q=@=43L_)>&
M>-9QQF)DC*0648Z<<15R#F0E!AZ5Y=8_M0YQ^-PZ&^BBYWT<V^VFY=DB.%+!
M"K,)F8JCN_KY;GY3+NZVK/RS7*\>1OC[9)6VW0;A'6V[# (CK0$VBD$(J=?>
M:K"]B.? >]7(=.T)I>)V,JN&.[]^D&Y'_F.WP8W:QZ,*I IB3P66#L0Y(RVL
MY(]6Y:"%U8?8"OLG2MF_&@9?*A[^U/D5\-?)WU</^CAF[;W^=> "0FV5B%9,
M//<@S,S&1ZB<-MXH=,99O*\#]HATS5YMOM(F($*!8TR#N*5!HIU3VF_D]-QS
M*2^D%G0GFCY4CRT3TV%?1,;QJO7JV\;#U.@%X_,&@7EH/=$F&O<>Q_^SFI*M
M=!)IH"\NV#M;RX=XDP/K^4AS]%;T4),@H3,"6H (]T*!:,1NKO>4!]2E ^*%
M$J>EFH^RIA6JI_%F&??NV_+[_[HJU_/5XF>B#:_^DAC#'S%F]^.@/[_"C8=_
M#,XJS:&3!A)$I"0" KT#P$HB+^S97+[:RDP$!U\I'BV432XO:]L%28 'EF*J
M8=R0O=,4[V05@' RZ'.0-[W9=(#N4$QZ=J"RD[O);;'\4JYOOYUP8'_2+'C$
M#2)17.80L4(R8^%.4F&$O[AT(IUH_?FYLSN !SIN;HHNF4>.-3^=3^;I;F+_
M#'5[^CR;X^KCXG8RWQ5)>!AH(MC\^M,CR3_>O!QZ$R]6)_T'ZIS D (LL?2(
M:@W\+BVWQQSR1HDD^\'OX9)S/_Y'#IC3'CN<W%>P3!+B&+8((H>Y(]2X/2X#
M1ST/X>H:F$WEL/H9VZ)T[G3S;V-M4@XR2JDDRKJX]5"*?'IZS1'S#A-_SJ>6
MU6"//K)X\F& #!%AO8P&GM0 "8L<W$C$@;. 7M@):6 6/']FD0/]4 ;QXU09
M[\MMH.P1W]VA)D$8:A"B'#.FM!184$8J"86XM*PU;=5;]H+F.?ERU&UWN%%@
M2C%#$.!086+3,V:O*BD=IQ>68RY?V0W8TPK9H?BSM5"VK\S?3R=_3F>;Z(.#
M#QD:M0O.4Y/2V!+$N1)* D9%):OA^,+N#;I0>MD?O$-1:;\ -W$%OOPX")[F
MF8RK,T@WUPX:"_9827)A*;(ZVJZR<1R,'>O[^]EFI).9F2R_^5GYXTG\Q-$S
M1,,> M<(4 .]4HI@8"$7;B\_\23GI#Y"'IW9INY%)\/=8VQC[CY-IM?'ZB0\
M^3(HC#4FQC BI8$6,$%<)0^G_,)\S)UK^<7-10ZZ@]]Z%<LFA'G^<7".":>!
M@$8[KR@TQM)**N3XH+6?+H$SF0 /:F%_*.?E-KO?_'8[\EV9Y":^LT8=!(2!
M\0@P8N/VKZ!0B/%*>JE 9@6H2]R\>@%VR.2+5?!Y&G6UAM:N2:\W"0P99FT$
MSC+'J(?)>-R?=L&EY?3L6NVO9&3L .6A;:"=^ ULH-V707DFB8@KKL9Q[=9>
M0+A?;AFG%U8NJG?6Y( [%%E^FTSG*33@X_S+I,I3N,N/5$.<FE;!.P"MA I*
M1!%76 BQ/_=*YEG>KO6+D:@[H(<BE"\7Q?1VOO5T7?W\NIC,EY/-B]-*%EU$
MFS'9>34$.Z&7 "SA'$HJ %/ $VJ,V)\M)!*-"CYU5@?QK1.N/^#'89VWMLH#
MX#H>0](F3[F@1@M#]L<:Z67.88_^<C3K%.NAF-6&5(=EE!A!AZ36#LMH-3I.
MU7[V:,%R'$YL?.5;>^935S /125U=;581^4\7 3MKH8:> ^.M@TJF@-Q958>
M0N$1I-"9_5TGHS+G$2?IC2!G=1QTC>EP:<=FZRU*LUGY(]U9ID>E58GKW35F
M#9<:M0_2>V L@X1PR 5#%-C].3?.V!P+:Y21DAVRX47ZL>[Q'BPP9;V<SHL4
M17[W9YR"NXFZ#2A?I2D[O=Y5.ZF :U"XIGVG(0(/'%4RXN(((4X _F DN&:Q
M@V^IV$A_K!Q,"4-1U=W=S\J?1?&YF*48W9>0U3#R:-L M,(0>:V,%U*D"B\>
M53)[Z ;U<+QMXG6-]<#FV^=-!JU&K#K0(FC)@=18(P,%AUH@9E@EGU(\)[1A
ME*FG^N-2-PBWSC%EREE4>[E=)HOMX6,Y26-ZJ*[^/'M%79L O=-*>PH-Y-@Q
M*2#9!YIA:W-N_T;H;^B>%UTC/-3:DO;;U6*;I._3-B]?!<7\.IYSKXZN-0U[
M" "8*+65)!ZQO2<:$KV77PB;<TEXN@?B#3*L7[P']9<>!.>8O_1@PZ"Q)8A8
MB0#B@B"(&?"/8C=R'G_S7VMGZQ3H06EU.I]>D<\(XS6"C#E%(VY:,H;WL='4
MY)SSQ/@<I3W3*!O?D;ZSW*5_?#K6?YY;/G./8NI9U*LP#!,J*0/61NK$/\1]
MR,OG5=E?GTH]!9/O\_Y7S@AU]=_KZ7+S9GBI?S[Z6_.J5\VZ2M4=/5+8":LD
M-LE]85&%BC+HPHJ[#,RD@Y6Q>E%.R]UMN5@]HFK\VW.:QA\]&KJ+8US]_+U8
M?2NO'R(R7OZT*#Y,[HH#CSUSNPP*(L\-5/$X2ZFU$75/*V0X;3:9WY)7OC_J
ME&?12)]</33,@P])CS<*C!/&HCA81'N#($V\!Y5TS+H+B2D=C@1E3\BW=F%]
MF=PMU_-;/2V7T[OI;+)0MXMBL^[75\$ZUBXPZ U#TOJX31#MG8SSL1J_=%EY
MP$;&G*X46?8'[U 'P*_QMWV\48O%9'Z[&>V1I >O?A\\I\( (:!3RG+D&#&F
MD@U;<V$AR;UO<5V"/=AER\,HEUN'VN3A)X\"%(\_<3^QI\ 9Q(9! +AU1&$3
MD>%[/,"EI%?NB!//KV-ZQ;KU'O>NG$^7G[Y-%G>3JV*]FEY-9H=Y<Z1%, (
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M?^T4SUJ()W^'"(!QC$!I#U.UC+TK ,L+2VC;*0^Z O7RDGTX3[QW%E$'";-
M0$KLWDGILDSE$=[?]K*X] /U4%1['U&XW:CN2[%:;0NY',]?6],J:">DE<YA
M+!1!7BI-]^=,RVU.V-D(+X=ZH51W\ Y%HT^+XGXRO=Z4Z:GAS>//@H(:;0PW
M#+D U&%G=Q/"Q%F21901'M-[(4H&GF<X/C4_?3__/E@AJ#:2>&A HCF$S.QE
MRPLT.#W;R]OD2A? #O:X;YONYE'MKT;<J6N67F#KE(4T"HM<W(.YX[B25'">
MXT^6OPB%.L1W*":]_E2_;H\ZT")89AB.QP3/./&<&^(K3[RQ%(FLF 8PQLP:
MO5"H&W2'8L_OD\5?Q2J9]%^*R//F/N3ZA@%3122B3 C+%?/<>>LJ::4B.:8/
M_%4<R9U"_$"H<>0OV]S4+)^.\9^\9<^R30GNA051H90XQI4@!L6SD!882\9I
MLY=P_>#W<"=7E41]7";53I=7LW*YCH)N])RRU.DXD+]J$&O98W L[L4(&4.2
M@Q-I1BVL,/+DTAZC#\RK@UG,^M314'O?@S3U57I:4/B4#H/%*H4_>"@0%,1K
M$NV!"AV&+<E@\"@+.HR%PSTJ:7@*O\R?VH*VQSH)&'BGA, HU;ZCQE!%\1YT
MK >]JON5J-JQ8@8R!C\MTM1:_?PTFVSN"M+1Z/[NT;EB<+/OX(@:F'1'VP9B
MN&. 4T"YQ0@+ C#?*L$1"60C'][ <C_LV4U6BE.Z"0C%4ZW -A5Q,B#N^]BQ
M"@WH64[L\RCS=';(CQ=.\-Y@/_=*L$MC?:$+@@&,:&L\\,PA)D7\^];NA0+'
M5;G1%.CI5G0RKXO72?\<"%&644BT9-& 5\QH1:O16Z\O[.5[A]I\?MEY.IC#
M!2='3*+EFS+0O+N[7Y3?MZ;+;XMR61^=7-,N<. <$58S9##TE M)224KH2JG
MA,\( P+[(TZ7* \6;E%,EL6W<G82G0XW"EICZJ63U!M'@&468E%)"07(N=0:
M87!@CXM05Q /=S,1L9H7BY^/83A&I,.- L&"Q2682,4]PEQ9HU@E)8AB7U9T
M87]$Z@SB]H&FY=W].D+XI;Q9_8AHQ('\G\GB.OWQ8+SIX2:!1BN<4*()MY!1
MKH6PN!JU!"SGJFJ$$8+=$Z-C@(=:7_QZ,9^NUINA^NG?Z4]']ZF#;8)P4'(I
ME$":N'BT,W$UW:^A\11V63&!_:TN72%\CD#F=_.(RVT<\%$>U;0*,B4.EIH8
MPH#"6#-)]HNHIB@G"F.$08/],:D[C(<+,3V Q3$ZU3<,$I,X=4P46D$$/3.$
MJ_VVS$Q.,IL1%I+KCU&=PCQ@H.'V64AQ;8NHJZOI-KE3<3\K=A<9ZJY<K':7
M'$==]J\')7;R*X),5H+D\3S"'(B3$C&T/XA83G/\!LT#&.66J//B-@GT]0VO
M@&?2R]F7RP]%*Z]M;!;BV=<XC@@DWBM$A/?659+&/PP; GF1:^7I*(_DBN+<
ME3;[O:G@G,KT'!UYSQTT)%5FEA0))X4WV#:R$?H.<3@H1?/*F/5=!$R\5=)1
MZZ#&5 $.K:M0D)K]<C<>C5EQ,'"A4\#;)VW*S0(<33FD'#8 I@0.1&'K<#5.
M(;"\+&)TK[ZCV7]/ [@S(K3*_FLTPS*:0@PQ:A3V'+"'6>'=Q6?_;:RK!ME_
M3\.R?:ZN=ME_*59"(*X)B6<[Z 6DB%>C0]KD1&:.7=.GZJ<N^^]I,)[]_/"^
M07JNXXU3 I=X[M=<0QGM6LR,D;*26ED^:%CO&]XS>D-\*)X]/GO7,.KQ9P$:
MB9TQ0ME4\0VB>.X&E20.956V&='"TX=JR\Y0'8H?[^81X6*Y,N5RM323^VD\
M]4__IZ@+SSK4)"C*6<I\J R*>%%L";:24HN!E ZS"TO%U2-O.D+X[5Y#64&@
MLT3BN$9#IC06VE3 :4AS5J"W%'>3SZ3N0#ZW(^S,3S;[=8 A3X%@C$"M).,"
M6,WEQB=)F;0$-;I[&%CNK(C]AX!Q(@Q0#'IN!.,,*)HR45:2(WAA#R@[9$)3
M [4MU /-]_^[GBPB[K.?^R=,=K*:_#&?K*^GJP<S9/#Y_G)<[^8WY>)N>SS=
MOWQH,/M/["EH2;A45@O%+?-QW8<:;-4$#37-7KF= 9,FZT&S#@*G7GI@"6/1
MS %0>\A8A0  :E!'^!!O=WIC2#D _.-8)\[]DN=\RP5'D*:+<&8!UT9HBC45
M--J'1G)#F^4M[<GU,%U.;J.]>;M[I/JY^%[,U\6Q^[*Z9H$1#P@D$'.@&9&(
MV;A)4LNL!EQQCR_+7.B-"\_]%-U!WO+,>4H]]R>UR5\ATL$RYO%T$PTJ1"R
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MDWF*.0"60D"(XDYXJ(776F""(S5]J[9^P\CDD>D'Y[1%KNHNIV]?OW-,^EX
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MAA&A4?1)G'8 RD8R@(*4+3K+HZ&S,:O,!,*\8BC3XWLQX@Y&U>)!E6I'.3#
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MLA+8(N.Q0,X#;!B%A(H=!EQRGE)//+O0P.$(>K:KJ=/@F] 2RK.:?_OA!4J
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M2<!=_M+)-1(RJBZMD('.6HDT$< 9O\-!&R<G4Z;[\A=0*G:7OX9R]'TD,T@
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MS^NY6D<FMB?V@GH[)G62;^>K@>W)XE6Y_%[=3!3+XD>QV!1'XJT.O1.@H10
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M@'>R1^F[%$3Y6@&JUB0H_AGH6RB [2^J?_Y.RO3?__H_4$L! A0#%     @
M[XI&3C6&U+3^SP0 #-%5 !$              ( !     &)I:6(M,C Q.#$R
M,S$N>&UL4$L! A0#%     @ [XI&3N9YE)$\)P  __4! !$
M ( !+= $ &)I:6(M,C Q.#$R,S$N>'-D4$L! A0#%     @ [XI&3NCO3"ZB
M-0  MV8" !4              ( !F/<$ &)I:6(M,C Q.#$R,S%?8V%L+GAM
M;%!+ 0(4 Q0    ( .^*1DZMP1^3ZN\  )D:#  5              "  6TM
M!0!B:6EB+3(P,3@Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #OBD9.DU4MQAC6
M 0"SO1@ %0              @ &*'08 8FEI8BTR,#$X,3(S,5]L86(N>&UL
M4$L! A0#%     @ [XI&3D.-46]@4@$ >& 1 !4              ( !U?,'
L &)I:6(M,C Q.#$R,S%?<')E+GAM;%!+!08     !@ & (H!  !H1@D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
